<SEC-DOCUMENT>0000200406-23-000016.txt : 20230216
<SEC-HEADER>0000200406-23-000016.hdr.sgml : 20230216
<ACCEPTANCE-DATETIME>20230216160153
ACCESSION NUMBER:		0000200406-23-000016
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		134
CONFORMED PERIOD OF REPORT:	20230101
FILED AS OF DATE:		20230216
DATE AS OF CHANGE:		20230216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			JOHNSON & JOHNSON
		CENTRAL INDEX KEY:			0000200406
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				221024240
		STATE OF INCORPORATION:			NJ
		FISCAL YEAR END:			0101

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03215
		FILM NUMBER:		23638460

	BUSINESS ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
		BUSINESS PHONE:		732-524-2455

	MAIL ADDRESS:	
		STREET 1:		ONE JOHNSON & JOHNSON PLZ
		CITY:			NEW BRUNSWICK
		STATE:			NJ
		ZIP:			08933
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>jnj-20230101.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2023 Workiva--><!--r:18208529-7e82-4728-be6a-fd0bc0acc451,g:1f111954-4d05-432b-a89f-49b08039c9af,d:51a46167ef364951bf70ae9d6493776c--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:jnj="http://www.jnj.com/20230101" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:xbrli="http://www.xbrl.org/2003/instance" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>jnj-20230101</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y180L2ZyYWc6ZDYzNDRlYTJkNzExNDU3Nzg3YzU1Y2MzY2E0YzI2Y2IvdGFibGU6Yjk3Y2Q3MTVmOWRjNDljOWE3YTQ2NjhlYWFiNWRjZmIvdGFibGVyYW5nZTpiOTdjZDcxNWY5ZGM0OWM5YTdhNDY2OGVhYWI1ZGNmYl8yLTEtMS0xLTg0NDQ0_17befa4f-030d-4ecb-b014-bbf7de1eb8f9">0000200406</ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y180L2ZyYWc6ZDYzNDRlYTJkNzExNDU3Nzg3YzU1Y2MzY2E0YzI2Y2IvdGFibGU6Yjk3Y2Q3MTVmOWRjNDljOWE3YTQ2NjhlYWFiNWRjZmIvdGFibGVyYW5nZTpiOTdjZDcxNWY5ZGM0OWM5YTdhNDY2OGVhYWI1ZGNmYl8zLTEtMS0xLTg0NDQ0_68d7cae4-aa1d-45b2-b405-6d97b9d102f6">2022</ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y180L2ZyYWc6ZDYzNDRlYTJkNzExNDU3Nzg3YzU1Y2MzY2E0YzI2Y2IvdGFibGU6Yjk3Y2Q3MTVmOWRjNDljOWE3YTQ2NjhlYWFiNWRjZmIvdGFibGVyYW5nZTpiOTdjZDcxNWY5ZGM0OWM5YTdhNDY2OGVhYWI1ZGNmYl80LTEtMS0xLTg0NDQ0_1d1b238f-90d9-4557-abde-158d499f82a2">FY</ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y180L2ZyYWc6ZDYzNDRlYTJkNzExNDU3Nzg3YzU1Y2MzY2E0YzI2Y2IvdGFibGU6Yjk3Y2Q3MTVmOWRjNDljOWE3YTQ2NjhlYWFiNWRjZmIvdGFibGVyYW5nZTpiOTdjZDcxNWY5ZGM0OWM5YTdhNDY2OGVhYWI1ZGNmYl81LTEtMS0xLTg0NDQ0_fc0e1e1a-a073-4c14-acda-c3e356741cec">false</ix:nonNumeric><ix:nonNumeric contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODEw_97635a41-161e-48cc-9741-d517f85ec4b3">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" name="us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODEw_df08f0e2-160d-4a75-87a1-87cfb24da89c">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzMx_e32a30e6-d584-47b7-845d-23d4e433bc41">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzQ4_870a3311-5ffc-4b2b-8721-b5d7ead81c4b">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzU3_21dc535a-a5b3-4717-bcb6-281e2bef1694">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" name="us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzU3_b32467a4-74d9-403d-8502-48e5120b86ad">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItMi0xLTEtMTA5MzI3_baf92b4c-2473-4ad1-9202-3d7157cbead6">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</ix:nonNumeric><ix:nonNumeric contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" name="us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItMi0xLTEtMTA5MzI3_d20882e0-6ef3-4436-8245-6610c60bdc82">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="jnj-20230101.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c37a522bee54a7797e1e6cb838f251b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24117e0479bb43b39fee8a31afe69358_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88ae5583fd7b47fd87a649c4e0bfef49_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1602ec71af1c48e8a8514b07a9371e2d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibfdad04f19eb4b2788c13457aacbc7d5_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a6f74ddd04b42a7beb1b698b449e828_I20220703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="id42e890d27894b429fe640211353b83a_I20230210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i5b376816a5e84e09b89d79bed596a4a7_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibe67d998d2674637a9c218fa218dce7d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic330177c89fd42f9a9a64f7236279ef9_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie0d81a2faf2847ea921dc2fc7b6a23ce_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9807f0aec4641a1ac4bec134b355aad_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86826cf58c434c3ea3d165935690175b_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c5dd290ffc74ea1be26c69d111518e6_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2730b868c9a489d915184459e52ff91_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib7e50ef6296740dda9036c6c59bae7a8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9a2bd92352194bcdb8a871945d2b04b6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie485eb6b64444292b2444b1661ce61de_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i81bc749533a9432f82631e2ec08fb7c4_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i011816d4a7074b90ad92edd54a14570a_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22968ecd8b144767bf02c951d4deb7ae_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i646e87c85036437b9c9703c88ff78a63_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ica40f5d5420a42c4baf327e28f3ff166_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieade5efd55fc4e7f9b55b76ad9b270a0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec1f1ce9d602483b960c5f739d33f211_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icec2276dbd2e4d76878d45adc66f315e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ef1d9f1b2874c9dadea9df7caa69641_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2339bc2da5948afb7331d7646e12408_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b341fec469b4745a481f3935cfdc814_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bd8a9ce6ebc4c33ba835359ee340f7a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb64fb4e20f1404cbc6e31613ca7eef9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id693fb46504d40baa0ff184c359c60c3_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8ed0029b3204669a3f2d23dad442d8e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e876c735af9409796c44f0d4a41a05a_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4b74a9312aa14cef802c651c6aca0f51_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="employee"><xbrli:measure>jnj:Employee</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>jnj:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i4f6dd96b61df4014b63f77ec38d4f931_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc105f8c066041479b85014a44b4f246_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if67355a8e31e4d4e89a2d4cc2404fd2a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a7641e1bba746ceacabd5c374aae1d9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bd05c5ccad24c3e9251efadcad9b101_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c19938fb98647cb9ab6821478e99ec4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe54a493eb1a41b6b7d5520bdcfdcbf9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f076cad0e094616a814262376cb5191_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4852527980040579d16cf952b6a58ff_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic46c5718fa2f417e8d7f7298244c427b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6908986b3f7946f8bf4a62d5cf5b646c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i220866b1cfb44cf7905eb75b0089e1a7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02fac9589cc2476b800ec305e2b17a61_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cdccdf73d6c4a2d8ad6277d9b89cbc6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd8fd68737c9443dac923965cbcebb07_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2ba832f9031d440b8709fc80396eb47d_D20170102-20171231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-02</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f986503ddc443e8b150a30eb4915336_D20180101-20181230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf53a7687af04964921188585c336575_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85c32c30caff4e45bdfc303e877e94fe_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6bca58ccfae247149a00663f0e2670b1_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id6f10e7ae95e4d70a2beba21fbda5a78_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8467c8ec68cf4654bf1cfcdfa1fe2c5a_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i67038bc29ba6469cb0cb5ca65068f855_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i632070131d164fd8a05baaff80e0d485_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icacfc2ccbd7d4914be4e26893f91b754_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib93e73399a1d41008b08bfb56335dc30_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i00843ad11c494c3fb53ae75e01995264_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i519faf5a8e3a4305a459c43d43018179_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic073077c7dc4462981e17199faf38094_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i82c0433d6c4941c9b80bb52a13ddf638_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a78016e63d142e2be872b5982def0bd_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i257e8511898a47d39e8a99ec93263f31_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id9c9e2118e3a44a88a2ba07a0b756864_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib4c98dc571d344a8a06b677c3e8a1699_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if181e914ddc64a03888d0ef1285d38d7_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3ce066abcfe8429094c975b988b24365_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i75b15a0f49774cf698bedb20449bca68_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29a1acc3c1844b598aadafb03da80979_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if115c6f434d64fca899b4e6a5f072637_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifedc4ec86cd34c35b9afcab55baa12c2_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b40c1d088ec4a9789ae9b2483d16368_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id891cac7e84b467ea4fcc3186ec8542e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib504a49900c149668603de87c85be222_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibacac16e36314568b61aff5d3e80baea_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01d8e5a2c62c4ce184e8d87099bffb41_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9e0ee8b5a704aaca8a9274822576332_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9408b29849f4c0b9380a8d9f61c6f3e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i282196aad12c47c99220e44da280b8d8_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i247541d8f154426a91d3065202f7ea83_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifdfd1b47f49946eca78fbf8f06e72987_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i626b5e4c6aef4b478b14fa53c5ad89bf_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i406e87a2fe59450390cb44ac1a234e33_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4d2228f7987c44149e5a689a665fe7f0_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e228c02951e4d53a756f82e5d074c5e_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib43d5a9a7c574ba0a893b62c4b1938a6_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie439be9218914ee6b4279a8133fe851b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib42b110678ca4863806a1d2bf6bd1bcc_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5629ac5f2c33469584439760fbeaa46e_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f72a14eea6547cebb097d81ee48e0d6_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c6099acc42a42639c659499eeee550a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4784eb1517047d9af150653b71eabfe_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i85328680ec914e0d9a276b4db4c66dcd_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia324deef03f5433486883e8775658b95_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie72473fe7392450db0865cca43131db3_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0fe95ef042a2429798d99a69cf874da9_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1379957dc92040fdaa4530fe7c7b94a4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie385825a1c3f41b6b5d0e02f82243bb4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7a29114e911461faec7fe4e8a9d1d04_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9ea9658839544de90b002aa4a145255_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc88406d872445a3ad6785a8573a5a24_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5e54799bc7f7459f8e4524bc93b31c2b_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iab47b85ba2e7444aa7e1fb2845fe47bd_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c2143b059d34074a2a1c452daf27abc_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia2bd3f4828754f62ad5a5f11c2503d8f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife931fffad564c719966395e598010a2_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ab96c6a2a554d78b428a02174937f21_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e6a3d10477946979e7db7037955a625_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b66c56f1d944b9798daa8b8b05d751a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id306832042b14bc3bb6e213608544feb_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie74a64d7fcd74669819570ee01cfe012_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iead1aa87d38f45fead8c4b6118f2e9cd_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6e3bf19e86414044b7432eb058f5401e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i862297e326264912a68191b181c4f8ba_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i328303dfcaed4235be1c6fb645ddafa7_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i639b622f74424cdebe2c37fde791f0dd_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fc528ec58784d3da8a3590dbabf6c70_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if363846d56154bcfaaaf3101bca3794f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28d922839a92453babec3a62e5dd77d0_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i73a1657c370b446a9a91aeb39ed80cb3_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b9d25facfe14e558d8538281e17e27f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7eda7450d4d9456b9e83912cf600f6da_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98e6ade62ef44067805f023366e22a49_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81d9971dcb124172ad9892da8f77ed8f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c15d323b29d4f51a3b0277a6efe9fcb_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i260cec3db7e141a7bab9fbc38d51513a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5af51b0799c94e2f99fb3ffe042cf726_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i82dcae20ab7f46d58205e38411c02bc4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic45912abb9de446ab846fa3d96ef734b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56073f5e045041e085b3b01d323734e9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6e64db864e94433959e07e907b7df1d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic55999a6bc9a460e938066f5c6f50247_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4b7dae6e9bb14eb495b8a03281389def_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44cb3ddc5bc04bb699e468e1eb79f066_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e4545ac2dc1439cbf7c13f15c6f32af_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dc946cef90d46caaddb4f18c8fd5893_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa09240ffe5c45a493822e57c2dc3858_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb9f80f9c820492780c7f8c91535919c_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14cee3a2fdc941089f344ca72308f0f0_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a01ed372cd4e95abefcdf0e51356aa_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8143a538b2e94972a97a82b7e6ec6c68_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b5eb91944ab42f6bd12eae5c9d5ae5d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb690af5f3694f69b7b889d872aeaf05_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic136e45ed1b94c44a821b42b608d5c9d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7980b23189f4bc7b2e93c0103862863_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef91f5dac5a431b8628840f5ad90267_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia55d14fcbb70445388964f5f5d173a93_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i237858b83a9d4cf297ac85f26bb8ae97_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab7309c98649499d9713793656af22d7_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83f081c66b1b450a84f5571770ed1022_D20221003-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12f4dde8b4404aef8dca3c97bf241db1_D20211004-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2e7e250084ad46a6a9cbab407dbeb7ab_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c81dca775704665a78c37783de6d091_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8d53c59ceef44b389961dad508f831b_D20221003-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-10-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ae9179932924168b60062ab11671493_D20211004-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6534a66bb873492c8df03d6fc07250d9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i828e3ede8e3549dc9f5058a9b4b0483e_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bb50a86cda447408f1cd7369b0d9418_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia3e4435e5d9a4e60aa7205751e72f33b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f2f9ac2b4014e1fbb1ff7315cbbb47a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5db883efd7e1433a90d82a1129bb778b_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3133d52c339b4153b25eed2e42d701a3_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0a9dbd90e4e4b16b09008c309918698_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9771bb6b36dc4c2eb9a95f16e382664c_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5daa381fed7742f0a17f958e3f55f3d0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7375a9453abe472696f28e9901817945_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id2864e7cf41c41f3a7a0337f807e5568_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3bc84e4de9ae423e8fd3d6a2ad33e500_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14578454fa464922b37380e635487d56_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0310802ba8b84af0ab17442fe8266124_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia39659278be5497eb0de37bcacef7e1c_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic3d82bd1550d4cf091ae15cb452ce838_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7c9291dfb5a14a27898df7a62b8d588a_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29258a2318d3469e9984174d5a29a387_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie48b117336c44afdb375a11b9255f3b1_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ef2c7f6b53641888829b0aa74f1baba_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10c2690afca047d8a831e4a7983bda38_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iff70c34dd9b948dca087b12faaa08430_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i38d00501bab6464fa7c7be34c6d914c9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id7cd5b6c455d48de8f7bf42de3895a90_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fa9b7b2390c4ef88b1b4a20e07ca293_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i853d7b4b73e148b18f6b3d77f487972d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4535c102f78246f28d354501ec8be219_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9da5b69b8f28444dbde29713e7b26de9_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i141ff0a4da5940ae95c9e2df4dd982b2_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33c7604b66f44fbc8b00fe1f4ef4b6eb_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia68fbb4c6ced466380b79a6a0e444ecc_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3935ca62623944f3a9d651e98ee70890_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd838f2728344154a7eaa225122dffc9_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="ib4be09c6f2a742c2872a7b5200cf5855_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1be16c858d742f980612d02fd786f2f_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.25Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4adc99f2fb284c778be3f71c61bc0de9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.25Notesdue2022Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ed0d053a547493695781065ce302590_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c69578754b841ad8feb98ac1c3242b2_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9b6971f2c45b4b4bbe271ae191423bff_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie38e52b1bfe842649d2000136af597c5_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5182d9f822204a00a480cc34f4ec92a0_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fe3adfe765241a28bf93429cd742b69_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34b79ae775034104a023060dd2d5ec9f_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie437d7bfb45f4c6995ab0a136f5c1320_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5971a213eabf4160b6e3f25559619b06_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="gbp"><xbrli:measure>iso4217:GBP</xbrli:measure></xbrli:unit><xbrli:context id="i12619cfbbd3b4411975c686625cd4ee8_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id160170994a44083bc75890cadbe9623_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4b486d1b1024bb589a658274877269a_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie9afa533d623446aaad16fd946291ca1_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic5bb2d0484d64d079887869bc2c1d3d7_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia73e0d2b294240f09389800e85e374d4_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id09ef46ccfc64f829b503e8d23112272_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8e41ec0707864b1b9019a8e24ae75a97_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i168bd65ad6a0451d816d411b7f64f62d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibeb93d53afa248caa20093bc023648b7_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22bff2ba3f0e400a90a0044c29f13928_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia496b34d6cb74a168adcb5bf7122133e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92f030712061450fa2980a5ce6c8142a_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7258a1e04b8c4f889adafc8d5386fd96_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i602d89dbe75f4f748c2295cd5de57aec_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i423501f49ac54505aa65ac29a7fd6d80_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26d49418e0d74c1189e8912cc7d7675f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaa0326f0db384917ad2a786fa145a98a_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf8bfdbb53ca42e3af2e559cf8fb62c2_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie15d3b834f6345ec822ccb7085d7c0ff_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8db5ee980d1342e793d3791eedfbef40_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i65b796c75e3b43b6bda7c9efb4daa55f_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad65bba4399943f9b1454685a4155820_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0dd231a0bb104e1684521862f1414b9f_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfedf7be284043c98fd18f790c2086ec_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd6fe30488d441739d3babad588015ad_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8a23940668d946ea8954481965daba62_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6ba6c50490e34f12bda5adb99407a82b_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd4cdb4f57b84232a93db6b02e61c82d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if509cd02d4494abc9bae248548e9fe2b_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie8dfee6b2b9f486783bc9cb6cab9a4dd_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26b8da89821f4ac284bd3d5d3cabf51e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1cf6df4972c749909f6092392e43369e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i696b5a358a7a4568935c7e93c24e7f41_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd634615b6a848fa8f9569f674e894e6_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7967ec234e94809b83f6d22fbf9ce9d_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia97fbaf7b43e485e95cf7e8916d74a96_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if61dc0cc1b304eaa99917f19dad110d2_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i83fdb88fdea44eacb07ca88b7b8ca7dd_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9293aa9d30342248d3d85c512c81764_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i565be597706647e888d0c0ea676ef094_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i26f202863bc94082a97d142a46e8d1b2_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if67ac9c2c837491fa49ff3662e87bfe1_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib10ffb3abaf54da0b43cea2e2ceb7e08_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1902162eea4549f78cee91e0c0156868_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91feec6def3047ae92ab21665e29fbe4_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iefcd48741e0b49cebaf892a4bad31d22_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f24fb8b890841428b85dac4bce5953f_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86d445ff094d4648b596d34b86e80355_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1fad250982dc47abbb5a254928d9895f_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e53361c290b43718ffeb7cd8f9afc2d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i46a29376f79d4b30a03d32aff4ccdfe8_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id01a95b64b3942d1a96051a89d5e3413_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80f90c4157e04d8cb1fd3fca5f4ecb65_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbebb1875a3d44ca9658f3fde18446f9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac989accfda349e1b99a6c9cdcdcaa17_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f53b7ce48b043d2944b5ea32ee20998_I20221130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i608e0e39b1eb42ac87ce9ad42b7316e9_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9d8b8a1c1b90452cb498943d7fbd6cdd_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2821f9be6044964b18bd8dd41179df6_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">jnj:ConsumerHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i93cff80013cb4ca0867d9c8d85521e22_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic658f5e90fb74521b314a6664d0b97c5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5117957d990a4c01bf764aa9f770ef81_D20211004-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fb809688a744a4ea19a1ad0f2b4bf9c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifaf8a0dc444a439691c1ba9c0fc72e52_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9abf5a6f4dd843c6bdff0c9b78680b08_D20211004-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic88fac17377d4247a40066aad9de7fc4_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id39169ea988c4eadb476790566c83233_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic89e3ab0d07149d68abf9f2332bddb1e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OpiodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id40d1a3a2e954c59984259c6a56987f8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OpiodsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6823d2e54e284392b4c4cc465f125c28_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie38c867d387040219eb10b7ae2cf8194_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i381b1781da63498caf01563beb9220f8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i160fee01a45e4e15969651172a1b8a52_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i703d5232b81a4b55936dd90e0dad0606_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c7ef14eeaff45dba385c284096876e5_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iee7e142ff6024167983180ffabb98005_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfb66bf1fb1c43f6b51ba191f9fdbc89_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i568e2ee4449d4f8280ec25b22561b13b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf25c935e9904a50a945cc29fc06d712_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1330068050ee43c89fd0edf712d3cd33_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89994b04ef5a4989828cbb2641ea63d2_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i02d251447a4644728a4ec4ab07eeee7e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2f5c5ef2ccbe491e8eae45d4c1b715f8_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifbef14fca11e481c8e30ad28994f26d9_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4ee98d3d2af347e6aa674a643b6056df_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6f2b519c9234298b0417a7077818079_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c2557ba884340dcb35175f91b95b324_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9ef98128abe4aedb0a5007195b08de1_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i92a0708b59e24d4ea0866aa54072a7da_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c0a56ded60c4a9bb35be25cde1c1637_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6a1005463744b0db3476c6fa293b2a7_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b5854265567407d8c334a909d643d48_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i22e0ddcdbf4c44c2a8e38032719cfecb_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i065c9f2a0f964ee285c2b8a25d0a06ec_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2b6a8806889b4e03a0a58daf7c2e8756_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dd0d8c6503a45b587ecfb92769cc43c_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74650ae05ec94371b9d6bc18a602bdba_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id57112356ae147f6acddb2fa2ef3c2c2_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i91b00037a81c40799e88359b6a3d230a_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id4e0173b76424c5f8b69bc8e9ad909f3_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11c5835ef6d041e0a21935aa096c3e34_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i89fe4d1a68ff41478d904f10e0e0ae0e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6e4971765ee45178f66de2094bb223b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib2558baea70f43d6a6cf9affe1cb228c_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaaa2fb24fe7f4913b81bd9b6e6a69211_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia65b35d656b7404cad2cded1a7f84257_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i13253a658c83423ba8e9c1af10e40f9f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idfffbb437b674ebbad4375b66a624388_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia30472b13c2c42c698c7f0512ec7426c_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6f96d2d3087247fea72a69f7464a8ffe_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic562463a901d4f7d98741278df63a71e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i040ae04cd8d34049b557c7754b4d1903_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0a4136d235304b9ca96dc52ca2bae31f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3aca2e86db254efcb60046d3b1959e83_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i629d668c721f43fa9a69ae248da4c767_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27927d8dc21840e0886a91b302a75133_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72431f66c0344014974314a2d6fcebee_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6053a0abc1f746509f25b60b89e316da_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie1c3b856e495487fb9397d837ce7430d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6a93ad27dcc346cb8ed7ba5d19476117_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34cf66c98020432c86dbfab2c8bc0591_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i907758fcc942478385fb4e997c7b28e4_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if460c561b88c46f197e086c2eb780175_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if667a81b90034bb89345e0e86dc1c837_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie873bd0c000344438fb4154226263234_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i14706b8e4e9b45fa8ad2b00f7b025b13_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i08e5d2a42732496faba5e2998478e99f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c63ed9d635548eda5b40167be502d34_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5c17edc19d844447920bcf55fcb965c9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9464afb4525c4171b9f7c85f564ca383_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i678ae776bb3e4394807bdb4118962522_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idbdd72723de74d5ab22897210e1d235d_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id16f7d3ae47a40419613a4e6ebcdf931_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94f0cc6d1b0143a7ad0de6a6b7171527_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1489b8c66a064c22a4d320bbc28a949e_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5684bd25916640ce8a21cd76052a6a5c_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id5175417cdaa471eb56e2f0adbf22f49_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4522e617517843a2883f058c7048bf98_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7f898d8c94c649a4bcd40d0903b33a8b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6d78a014cb7b4600b9b987e0c8d3ef4e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if9eedf365257482e9a59a6c5f27d0a37_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i409919d7e88f41b790a753d01b52083e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5db77b85a6024162854cd564cb20a41d_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9e09026399524065bc97affeb43c546d_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i199aa9d6185f445c8a0e845551e8cd3b_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44bda01bf133404387afaead8b97a718_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccce90dd21004e5daf45ef5005ed0551_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idd19fe4f42064eab8bbfb528aac6c080_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i74f4b70efeba4325a8712247faf7b3ff_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ifc3e95d2480f4b09a43e8526cb530ec0_D20230103-20230103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-03</xbrli:startDate><xbrli:endDate>2023-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aaa8d30ebdd4b799164c6d64da029ec_I20220914"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">jnj:December172018ShareRepurchaseProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-09-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie95b18f0bb224ce39159e2cece26a7de_D20220914-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-14</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i998292a4720542fb97323e8a21027018_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i11d2f866128a4c0bbd34f29e255e2e5e_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2e5b348e871404cb444f06edd6e8a44_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i72f9f2cb97f549a783317a29d6bcb3a6_I20191229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4bdd796b17934806b83c05e06ce34090_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdc62ce8bcb249e58d2e978447347cbf_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd018d59093549458cb4f3761ccbb821_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b330b391c664593bf5ce01ca6a9e387_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1263a8933f94cd2b1db256f5159e8c1_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i86541415a18745ad9fad6d5a9da21dab_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56cfe48a1389431abade9bcff2c63177_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5a4b14144c8b45d7b5c9ed3c00162124_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic08350f7471944cfb12cf9ffa56a221c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i503c1b32967d4343a8eb327c8c6be661_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i602c299adc484e92a89fdcbd8f6fc8cc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief3f111fd6524bf78a21c828a283c3d5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0b83f8ef9bf4d359fa8bb52b6dc3fcf_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaba6b6f0ecea42ebb8ac410bf2612423_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id1d1b96425db42a181eb410f603a9c9c_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43fcad8870384544ab9df6081f406c7f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i71c7679daebf4d0db0b277193d8ac50e_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76d61a4fb2f4474181a28e27ff866f5d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fd635367c6c4ca58981a78d2275f2cb_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4d00a4d2722e40608c24963350b6de0a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icf4d10f59ddd4ab8bd56434bad43ae20_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5800e1082b6146cea9073bcfbb7f02fd_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6e067c6346f74a20b1c0fe95515d8e9c_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4ddbcdadcf848e69b32b80c8a7d34f4_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="stockbasedcompensationplans"><xbrli:measure>jnj:StockBasedCompensationPlans</xbrli:measure></xbrli:unit><xbrli:context id="i4a0e319fb645457cbe71977be1f29fdb_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">jnj:A2022LongTermIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33dbc6eb904844ee90275f3f8b7ed3ab_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ef74a38473e44019ba37eeec97c7385_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i847f3b4e40ed4892b6cd1c9603a89184_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14d568c675ed410f94bed5ff0929c46a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a71324ab9d241068eb20d3f9cd41ba3_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad9b5fbc5ef141b588c3ee79455a9741_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07803580a3e146b98a24a385beff349a_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i34afa7b8b8a04ccb830c793de735eb10_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b1e92a43acd42e993eb03a79e248489_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i215808acd76647669f725a762f3598d8_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i354df684ca7745c6aa4c8a3b46276a9b_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4c10dbb3a1594a2d8da6daba7890426e_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf5256f81d8e4f98b3cca09bfe121aef_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ife13ff98e4674d7694f59286307e1d2d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bc3aa29768f417584ae7a6a6eda8f3f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie2cad4d651314028b720522ec64631ba_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb399cca07bf4bf1a81d45b257cf9c08_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i71da035cf1914f3b9868aecc174233de_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bc0d59a1f134f84a89b363a070d1183_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iec99756e458a459cb8bef3fdab17c001_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1ec1e614eeb4b98a73fb86f9046cd7d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab9745c050214279b0fa340682e40433_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i69db6ec00d174b129e0e5cb215633ec0_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf40cc2fafb74f6c9d2be93eeff661c6_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec1fd52e3482447ea1b11486ef26a9be_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2198f462491444aca0da61923b632a27_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ce09bf2900145f1a937004d1c00046f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9f84b91d4aae4af0a05f5090f62c6609_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i58914e95bbb84bc5a9ea2cb7385bd869_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8a784927c1c4189af0712f9727df3f0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id4e29289044343a48f06844e7131ac18_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3ee2aa1541c4993ab5a6731b5086c7d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2433209091f4b3d9ccc6502e13af23d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5735f3b990b141e4a4be776a1cc02da1_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i62fff57daefb4ad48862e19671a6dc9a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i439805017432405eb34a20668de55a4a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcef65e498e74c66bbc548320bf01eda_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56cc8799267a4d1bb446fc871370346d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id06a8fbb2c854362baef8d48b3e539ec_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i305f2baf4f5040bfa89c742f613cb693_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bcd6c0066854e439a15990c5325aea0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife8ad7f9de9f40939e7def44ca83e3cb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i575246cb13cb4e958a9cd5c6a9682cc2_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia568e79890ed43dca885e271433dca1d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6438bc69468141788dc7dd15c2e6f0b1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i740d75bd86104d0c94afefc9b87d51ef_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8aff1a3d834643a8840f76c325a3a99f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b07581a92b746fc9cdb03ab06449ec2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6514fba7e78484d8e9d6a382b648d8f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieef3ea0559af465c8780f85fc9c95f1d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i187c9f9d5d5349338afe50224cc27c1e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaf17bd3c525a4b3bb0011ec89a64ff51_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i193f625c1b214c7793df54d141c36d73_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i042187f7809d42bc81ee957ee586ef6b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5671c06ac22418998bf233fa3ac24ff_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1f0e48a118f4e0f8d62b1d1fbf833aa_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cebe4ddd2e04f1cb5a741a9533d0a67_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4fb8ac4e52c9497b82e8cd22bd29d272_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i015e212fa198442b8d18e922914d6075_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81bd67b3b0634ce4b563b42531da6b02_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i001c88dc32694c0aa767413204814f97_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb68778688b84eec8b98dc05b1c73823_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ee93092fc834bb3890c0d900445063e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3aa6061cdfda45b48d4a19e23fa32015_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c2531fa73d44239a380b2362f5e121d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8578159027f24dcf86568156693183a5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id93ba1dabe3f4b5da204b1077b4518d0_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bfbe7c9fccc4c64b09c41d52ad70175_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i263452e9213e47c886650ce7cb371065_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d7ed3b7665e416388b6a9aa612a4869_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4896b102e9542ca93ed851ae014915e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1269622a495a4e64ad8c2c22a7e91280_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fb3b41722c44fb497e08d86ff98bf18_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1082a9661ae476683c756bbaca58883_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if02a3937e37448db80bbb8a99ffff4dc_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2292a22d2f6a4e18acba13c92c14b1c3_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib87733bbde604e8f9bd05fb51223e407_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34a442a0814740f1a1e5b57d6e051977_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3285a500e83d4e938ed7a18bb07f562d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3c3b87812e3421384238aff93cefacf_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc2c65b893a44bd3a5dff496a5a117bc_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id1ee80a6d40c46f0b266441ca6963f33_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43d7081e6eac4175b0632049d45aea0b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb2956c17ea2404b80a4eb00815a6af4_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88289ceda63741c295f461bebbc818d7_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie47ee78762394fc48eeb03bbee8192b3_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id69b428176aa4a3cbe479f87f86f7bbd_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieabc073d9ebf4111b8a8d92bdd0b8b7d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e88cbad6cbe49bd8e825a7ed41c9c3a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4e22bab2b8ce4579a43a60a12cd1a9c5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec93cf328ce84ef3a066a9fa498ab413_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i986b4a68a2bf4fb0ab3a4d6b014ad0b4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if74c6a56a65d42e393222e70b8ee3b45_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7849117524e141089fc6dba149013836_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i397c0bcfffa744e1afc241f015ce8b04_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if478f7362b5f45038c0ff48e4dd32d76_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i002e689e81af4469875bf4167de1a9f3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i12bc3574823a42a18c54341c7e48ccfd_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i72281ed8b429494f9436d47de34888bf_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i39cd91fc937e48888264b49955721321_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i912cb26a60ad460497cb59430e03bcd6_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4af108e7bc8424987da6ec7762b48a7_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe204b8f9621439b9d7201393c46acc4_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b9e7de8698c4e4b8582e62338b3a308_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1893a467cc624e79a62e62fec246d121_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50aef40f53704f639eeb4ead4f673ed0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i150c9d621d58436592cfc84eadbbd8de_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cd61c709b4f4822b6b0abb800e70ce2_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i07927d37d35247c4ab9e64a048a34675_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idce1aa757100453fbf226e404cf449c5_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad404b1e843448c5a861fc281c54f700_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00d6f86395074f92b284bee5e41b9c56_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie59a2dae302645e09d149c7d7a174a78_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafa5cf4ed7ac4030baf40b5dbd7736bf_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i692eee4c082846c498f4462756e57681_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3834f86e6904624bfc14ea56990f87f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i203194712a9c4ff294ad81780e8d8a52_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bc9b8fea3634731bf270a2f122b7d2d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia865193fbf2a4050bbe5db56a5edfd29_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ab664701a68493eb072fd6ca439c0a5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16dc654ea1db4b339475642249680907_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i80dcf3087ead4df5aeb6e738124670d9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3d161ddece944bf8ad540a6a199f574_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6fdb567ab044e4fa2b02db9f1115bc1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaf99c2470714a549d4827198b5e4306_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42f4fa8e366c4d2b8cfaed938a637eae_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i61655eb3ec9a40bf900bfa9966b2388f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75ed4bc48a164740854aa44ff42c7c43_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d721f0119c44c98b11f757b023c30a6_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic03f559a7b2b4eb3ad1bd1999053ca64_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i476d6bdc170f480880b6f349fe1d02a4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i655fec7a57304dc5b69e3c08e261ce49_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie6870ec4af934c098b1c08e0fcc5d5ea_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ebfb3cbb91849ffa928740c09fb6845_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7187388ca7ef477bb2a513ddc7d152a5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib767315f9702455d885f117ae21d3c8b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iedf85e7c05384372a344804b1789a29f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iacae22ebe7674dd6b631866883fc36a3_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide93fb67d26b41bcba491ed0c9028795_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5952a4c02d1407ab7d93feadb356126_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d48aee7697b440ebfe16cb49fadabe5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68ae8a2a744646ef8a4dd8027eff0ee1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cf92bdfac4a45ff8d99efa6eaed94c6_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a36def101eb47b484d4ee34dde2f395_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i111650d10ac748e7a9e029ffdde290cd_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i735de00a843942b69ff5f4e4395b0611_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i494446ad1b9140cebb18afa776b08b68_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib33427d3662a40198bb45dcf433c1468_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if823818df08f47e38c8e54ee1da81441_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9098882055048acb56f0a7daff7b6cc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9abfdce0d16e405883d49726c32f1acb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddcc1f0bfd31441da630d17bcd07bdd5_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2117a45f239d496da7c89c744b4799cf_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic396314e70cc4e8aa30c901f000516c6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice5729f779d5409483631d4dc721f7d2_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7789339e6baa4ad0abaa2c19f511a483_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92e52543ccad4142906214832c2a1522_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i133db46d59e84bdab73a70f71326e38f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2853f108a89e46679d84a145dc7f721b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i739fdbf5c9b249b5bb242066485fd13b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5e252aba7cdd4ec2a540688ab64830b1_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d36aaa849d34410912a18791f8c1fdc_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65e91319a96348ee87ae160ca65edaff_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i681b21f0446d4385936cb77eb4b9dca1_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib410879725f24ae8ba0999c6d06366a5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeb843593c464cb18a4c3dacc904ae00_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35f94389fa524ab289f01a52a921cf7c_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffe39ec345a94ec18338abc237e01452_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie433d85e7b6448d19d8075af0de26e2d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6bc2c48e4eca4c58b9de0abae4adff22_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib44093e5c3a0432f8560133ae4395d30_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf0b6c7689e44b268e1b721f04f9848b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b87d067ef004f5aafaed64f58162f4d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41fb3351d90d4979bd4aade9045ceba1_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19991ad08c1340cb8a9f12dfc8fbf112_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i186ad1cd9a1e4945a51acd1fbe039a6c_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2534504edb8d464f8ee62a5593a78d54_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20f893fb187e464aa1a397a82dad33e8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iffa2c64baab1439f89e0e380d54cb895_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33b8737e36dc40e891fd7257c424ab9b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if08b714b754d43ffa7a441ceafdc12db_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafa49f8cb28444c08b3e7691d9289fd0_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b32cf9f39464d33a7bac9a57081607b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifce1d8aac6f64a9e8d3edf11466fbeb0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a6257c648ce4c319ca04351b1ac19ca_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd0f4a707d5c4611ba64f2bd6e1a1cbb_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae286eb23a9649dab05aa0c949e37a1e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d8e4c1f3ded4e2683fd1b1d3d7f2f3c_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4a46b60d378740ab9a53a2c913e6fa9b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6008938b9b8142ec828a603dc31c9ad2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cd9ba3232ba45e7b1a6b4629a8020a2_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i531f3041cd70490aa0a614493a0966a5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c2c03afbcdc4c75bc0ae9b17f75089b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i402fca2f518340d8af0930c93c070ab6_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e268daebe694083b67a5bd25ccebbaf_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ed046d3cd9f404a967c40585336ae5e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6d6c31d76c79411d9f1e91f496118539_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i89359ce197324e7d8e9b12c16f4d715a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie38900d6ebb345d29c6d1b684d8bc793_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ief7ad9c3131d41be987d8486d4ad049b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idcc6f1927b774f8d96f04fe0a712fb86_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if22f8c6bf53748f190098078cc426ff1_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6610d754863471e9d5a6fed947d250a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i388399bd3edd4e449f4d93d8915eb54c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia806a9dc2927417fa00d06260663112c_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie4a41b434b5643ac9706b30fd05f05cc_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c01b12144ba4292808074086604f6b9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icfaa8480658d47aeb19114550474ae8e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e93fc3771554eaea942a7d80a2a5191_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5235c523a314775ab067969dfd06501_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib3d7ae90ffe640d1b0883b71099f3c5c_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i03c54db2a9f24834a5cd8e9430746ef9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia1925b3bd72f49578ec926bb8b286ea4_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifec5634cbb6c4bc397afe138e65efc43_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26dc3482b6c144828d2d9c88adc29ae9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia24bd46b2fd04893b597d1d6c0898eb7_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic7228601370344a3b7c098e83bbcb756_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8cc6bf38d4874b188bd7a4fbd673a97a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6698df7c52e241f69da5dfaf96df667e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8692c4c3b564eeaabf2e1b6e509764f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb475dbd9dd64c05bd7d3314c41d69fe_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe678f07567c458196735fc6dbe00d17_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i605fa23baf2f4ea78746871328fb7ead_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iae81ec5366b14326a0b7f0c13fb74817_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9404055d94a45daba90f61bf0fb4da5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6f2a17cebf7348ba8a85d601ef95950d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b4e7b35d9e54a27b148b95717e09f65_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i46565c94f13f45f4b15ef2dfc93ac248_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i269786122e034c9a8fd09281eddd8ce6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie53f9949f4d84aa5a52762670bfefd4b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i324b80e3c3ce440d9637c080549788f0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i84e21a76b60c423bb70648b1c526109e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i531753cbd8df46a191a33e3a9070c38f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26f47936bebf4e8e931a42d37ff16544_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iff8d6fee31d84079a124b85f43dd7a5d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i258d249f5434470bb702dca877dce7cc_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1bf95a45f3b7410cb1201a2856109d72_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i262b23b4cfa3413ea822c90957dc8c6b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i24b8ea85287e48b5ab16ce511107e30d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d14d3af658b449da07dc0be4f9a9b0d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7520de6a9d0449ffb1547564cab682ed_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i68e64b453d6c408381dbb9d6a4335a90_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5c85d4146adf40d590c1b983de215889_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab4f46984eb74afe9365b8352076078e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i42467f46f4f94427ab2e63069eef5ae8_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ffac75e48304352a8dfea6d5c6ab3f6_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i646423bb9a524219bf440e4800663ed3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if600a19a06ac46f1afe1fb53208669c2_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddfa392c8b99451a919767258d532fe5_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic353f059b15e42808dfe31fbfa26b20b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56d81c1fa8cd49908a0537e36e44cae0_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic0bfc95e5f50496095f0e7adbac02fae_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i081324fa191f4ecfb64d5fd21e4897f8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic5a747f1894746c18acebe55fcee36be_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia9952f78ff604ce98857b34e7d2d4ee4_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i56304f6c91134b9ea995c8c26f92fcf8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1170f44e3e784c13a897d1f33b657d36_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1aab7e608c8647bfae8078c104427a5e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98cb0d95137a4c3e932962b28dfea7fd_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7df5c5bd36f4c42bc5a42a86e4787fd_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib995e35deab1419bb10080c3e8bbe15f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i008fe96bbc464d418ec59e61164bd16f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e40224a7adc43c8a51c165cb1091d51_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0e1bf9204c548b1a2ba79c5c9f86b69_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1d65c31f1e1e4231a4590f52e12e147f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8696093b3c14612a5e87f253f041390_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i013ed648148d4e64a510c4039f176525_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0ee4b03f8ff435d8d7e8b5936462ff2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1bef826f6694533ac45bf2390d238f4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d1ab414424746e7be5d469d0581e83d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i98d58d05f93b4a88bda30ee75b9bd330_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf89a91e03874addb0a5a3f057b8bf3b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic89356ecf07b40f0a9a2da3ade617700_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idea1ec1749cd4cabbe3791c077d397a5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee811815defd442b9a2cc33fcd46a0d9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie657f643b4d84751a89bb88a4ad2046b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0fc87b939f80405381cdf5826af23b5e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b389620244e4707b32be2326487bc32_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iefecdd362bfa4d2db19e395e947a0d65_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id84af39344ca4fa5a66b03352afc5e18_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b76b01e302941c287997d97c3f61777_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6936c2410a964df4898165a8dde602da_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie7bd843dd374433190aa473e3d8f6192_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76995ebc9d3b42ce851ae92a54711982_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36a27cd0e7ed41e68d19c477b421f3c0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7001035b825b4a55830f9093152ea514_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba577ca1802747c39cfd14db4de2c73e_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i59a17dd172ff4c2481abf0f956446b82_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9d1cfe8125bf4f15bb0a5e1a59589712_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1fe446820d2747f094272bcdc9f800bf_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b8757a22a8743e3ac6b47bb33abf088_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6d1cb780cac40c392f1b55b06665d46_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a13564b2ced4d028a7c3601115a89a0_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e26b9b503db42389ed14ff2087d196d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i374baaf3b488452d89425765aac44db0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77a7e09f6f90410eb6663244cbe7e73d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cfc4b069b214a88b076bd5e9211de36_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idf16b29572b6423cbbce71268561dc2f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5463962cffff4346b6f757fb352376bf_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4508e19a81e14913a4c1c511d2086478_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0255ba511594a8bbe1f7b35cf65502f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i22de2e9856b44e04a06ccf411d64efe4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0dc14570d9244e2aa7a97f84bbea32ad_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icce2f7bceb104ba68129e1d88ba12479_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id6137d6c2ae845578e96f2f9558e743f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9b1ade7237d24dd7ab77638d8c40a4e7_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95b5c4f0629a4cc4aecab891a4bc05f0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb55d931932c4dbfabf0ea3d29fbb324_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5becc7177bbb4f019eb9d2832933f156_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic28b731dc2294261b6dbf518da9544b6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b6cf0ef3640429391dcd90960832aa6_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a56ab7b9ca24f89852d9e93dffafe9f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8e2a5ed832e47a9b4b8c86beaaf4733_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5eb95d7922c64ca28dea90d41bac3081_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if85629f30c724cee9d887e6dd896ce8d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b8655d882ea44638ed3ff1d03bd0dbe_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i30916c73190f498bb12adcd4eee7e812_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b7c39109744471db0921f5a010a74fd_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3cf850e2559a44ccb6fb87628e4893d5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6c76de98f2c417a87e983700d3295da_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5500ee09e8148309c05055c79c1eab2_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iccddf880ad6748c5b0f867362c1aac4d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i799adb7b649a470ab60c3ff073dc1386_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9059956b7ebd4ef9aa0ca0715ffea91e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36786c954f1b44aabdb08b417155a2f2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8f249bd22be4ccc99f79b41ee68c3cb_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaea127e21314435ea7a422bda430700d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i79f7eca78939441fa15ec6298a45d1ef_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i32cf8ca571194576b3812f9911ec7c96_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c3d4326ed9749e08f9f55e523f5ee30_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb734ded22cc4f09a1e7aa403217a9eb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i475da8e727be45c3b387f78b1fea2e7e_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b6d20e6fbcf404989fa7f5435ba4ba6_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic976412b06ed475dbb01665551f97bd7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2de02b1a13d4d139855d845acf40789_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if5e8976d4e1a4b71a27811336c8ab1f8_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id7c26f3cd65d4c5d8f2b5bd56c02ed3d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3f077fb9d5034effb52f4a2b5f9eef57_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33a26b2938054f1184c11ed6cf4b88f0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a88b4bdd8c94764a0107e43c486dc09_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie8d8278156114626afb74c2ac5266a22_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5bd8ff0a20174e8aa35746d67cdc6c5a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4cddddd8de4b47ea9ad8c08d1dbcfde7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ea11b9899164f17b368e2e8e1fd6646_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13c3371fdeb14d998c863d3e43e1fc97_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieafb2d92ce5b42eba36f9dd9ad33d3a5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieaf051fa36294b75bbdb2a6a108964d0_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id73e900fdc57444dbbceb802f1d0608b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib07d526f34e8412e9d6ac51ac9f427f2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81eec297555347958006226c1ad5a577_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iafbedc70de804139afe4d7945d4cb53d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcc31dc5500e46db949b0cb3ef157084_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a2ef424a8a8474cac5b9126f26ba070_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d05b9c8081748e2a9f6313aa40cc11b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if79c42dff8224bcd8bda45cfd70678a7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2555de19982c4c1c919234a3b7833ea2_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e55884aa128493da77727ae7c6d1253_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23a8d86b9d8a4084b1e6ddcc45ead16a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i76a0c1c8ef9849838870a39529fcdb16_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie5e0a45bdcbf45c7b2fdde90c75f5932_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50af60fd4c5f4255ac6d02be0a13ae03_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45a0926568d6467b9669368002f75388_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17d037573a5d4222b17c5284accac4ec_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f866a6e7b4747ab9df0359131844149_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ac1d092bd684cfe97e775dae9a43281_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b6d9f05d93342c9ac54a0fd0e292ec8_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1ddc948c59f44ab9aeceef6ea85eea1b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i45c63832601e43b1ad4c8f083610e7c3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i850b26f85bd14a8598514f4059d09199_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id55db4e038a84957890427287eb9ab56_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92374c3d2722492fa34458de0e14064c_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i599608cf1f684eed8b209bd530f295e9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i422216cc59db4c0c941301f559702000_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20e19e67050949db82566d3868c92ad7_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if9afb09ccee54d4abc14d8bb45e5e1bb_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia20a5ce5890e4d60b4948961eba84c76_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i00419766ad6e4ea89e37292413d0efab_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa1c27da4bbd4f5bb7644fd70f60b7ff_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6abe4cf6499f44b8864302dc6a141046_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib44237838e71484c841e5e53a3a8c7bb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4be2e62190a748c1a9f9858019ad5f2c_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7280243f94ec4714a8ecd07ad5de6b9b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7bb69c6ba5614a0da3881621e639aaba_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie95a799c54a94247a4f4738e17ef6bdd_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78fa9c5783f54e208617e980cb82b18c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c722ac2a4a64faa8604869f789d2250_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c379bb07b1f423494b9602d42fcbda1_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i599b25cf3d4a4566a4fb6560ac142a99_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa4a315b27d540e6a99eb9f14f0a2b22_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba96a050bfaa4084a8d2900a2e3a04d5_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i74464a7622714b598ec7ac59bb92daa9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia431b44bdbc04745b1da9bc7e6129763_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1c3fa299f6ba45c4b222ae1e49bcebb9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i386d38aa8c394c4f935a4311fd4ef278_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib5940e0037084662b3d6936dc73b3ee8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i16a080af195245c883230bee9c30e225_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia55cc74e40ab4d0592d91514f04f2608_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91aa6b32077b4d2497b10c0c7a56e179_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib6a9e1c6f9634d72a1c5c2e943619a42_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i97e2595ac4db46c4bddda29dbd79cb53_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icacd0f9bc97a476d9227cb9d73c43f17_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i555d0de63ee2467baa26c01abdb6a217_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0158c50e3f843b98737f71038b73b04_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7ad2240e53ec400db99843a0627fa101_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id93d92b03daf447eb4bf22985d9d8c14_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i523f9716669b47d5b297828fd6724f6a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id3648561601548a8b97f7f711182c5f0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2a8043dcb8a040d7adcd300412045ab4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i223e6d03e08f4f5a90b7a1f6a8ac3d0a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i346d453f53cc4ecea306f279831549f3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if03efae791104d9aa1b01944645a6b01_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e3094a2457647888f8c0f56ba3fed56_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9250e1cbda2047ae9863cef248995cf3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4122251b77234594bcddabafeb5af123_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie544b42a603147f09a40781c6c42143e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd6437ba34c148db8aeccaa67fa06cf2_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida0bc11d3c5748e98275291ec923ccc5_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9347c56f2a1444a78a4fc62e6b386a5a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i01517169bf524cb6924cf818325d7fdc_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2160f5b0fbab41038676a89c226cb367_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23c7667c458748c8904119e1c5445a7e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id5c1850237ad45cda71fcf02b4cf082e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e62ffa3592b449586bbb8ca2c4d6213_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib476cbca912b416981dd09c3a83db02e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1dc2f5c56a204d2d8e644eb8886f841e_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i28c6713f2ac548cc8106299c4be563a8_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id895d721db2044efbb2aef35407c5f24_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9db4f8d31fdc492993044895704613be_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96bb599ebb2d4c758610207a98846d97_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2c19ae7f1d1548cf9a2a61003b3d3900_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1b8a7dbc6dbd43db9aab7933e394d7d5_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0b2a0ef2af13440cbfde1878f560a53e_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8a93418c3f9348089a17785066c9ecc3_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e5b37a473aa4e9684ab211e4fae10e6_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96d0bb9e034b4b778811c7e9a7a32561_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i660f2a9622b542f29df16b4d0065c995_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i31bd9ea308664465abdeee40896776b0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69a0f6c8007a466aa040c51aae63e17b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib47ac25eee8d470cb19fc3f3bad77acb_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4ee222c80d4f45629294aa4cee852d97_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92b401eaaab44d8a91db95e7fd4cfaea_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c79a9ae4055493892121d39b7f040e9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5659d078f59d475b8e7b8881e5f8c8cc_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e13a27025ab49258fc3f28523703d4b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0797cce295e84999983ff7d4951ae7d4_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8ad838c4d37450791faf447300dcf25_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i882f781054b24565afcf9d67c24e9a56_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ce0c967e6d044a2b3a5bc24c3067d09_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f2fdf8254144adc9c79f0edf1186108_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0bc0508a06e84d47a8eff2b1d5c74e86_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i728978b4bbb44796bdeddaa130466c9e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ae8b4447dde420f8505681fa323ea4a_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f8b318c15894833b1cf92df3f7a9fb5_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8df5c7b107134f5abf47b44faecc645b_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5419094e757b46019b8bd5f8d7e871b4_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0940ba1ce2fb4e058d1eb84ccb6c5e03_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06e2030e683e436aa4324bd6a5a14b69_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1d0785d36d044d6b08df217279ef868_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i488b67a47d294aabab33cbdf59e13a0e_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic31b2338c66b49679900818d0ee6a39c_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i656cbb2cc38042e38ca323806c588d5d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if2f17244bd1447cf9c736ae386f8dee8_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8e7770d83fdd4f678c448c98a7ec4ec9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3fe4b910600f4a8d98db1f5f0c7b5c53_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf869d6b3a56497f82172be314aa1d7a_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7cb2f6bb944c47db8946085e687244f3_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb6de0174c394ad7878f8b8ab48c1760_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i69e5be1f408d42a6a28f913328b3aa23_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6a6d1bdd3da5427197bae916d67ef765_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id0aac6fcbd0b4218a1df93bffd709deb_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i780835081b4f4f33ad0a3bec79b6575e_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i20f1c099cf014d2396f6e27e3f282b73_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3240822529b343708c19d857074c3efe_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icd9e83bd141f43718f07eebf8ae9d726_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i686d5e925e204bfb9c56b7dc9949c828_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i94d99e94b59a4dc786f934bdf8f8ad28_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i02394e8a5d34408f80dba10b20b2294e_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id12b26c88eb041a5b128765f1710cfff_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c5ab80c014e4ab6bf12909c673b5286_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice2505dd78c947788c029470885cbb84_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i26073ee7b24f444ea78dd572e1428c7f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie04e4e86c1b24d1889b9660122ff5c0b_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia05a6854e4e147f5a99bd5f6979dc765_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3420461825204a15b06642c0e8effdc3_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic25e0a35046d4798afe7f6c61ccd2212_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iddce33c475c74ebcb63073bdefd18fc8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f735f0bd8754f549f6a3d8505541990_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia7f7ca8fc4824ad1b05a99c0f85ecbd9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i21ae89a5e6e44a19bda3cea2a2a46a91_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11096dc41162493598fbde3c3328208f_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:CONSUMERHEALTHAndPHARMACEUTICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44f421d84e9d4a00bd90e95f56e2755d_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:CONSUMERHEALTHAndPHARMACEUTICALMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i65f83a7c98be45a5b6124322b7bd487f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if7d4fcfbaed948f7b96ddd9e7c955350_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0db9c12fbc594fa39ecdd6ab21950596_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i41b31e63f2ca46a3845da852aec0b900_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i716a54942efa46028603ae4da3c07d56_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia03e77d7325e4d73b78a0c69bf6f9c96_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie279ec7ee04446a18580684b9417ccef_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeb973b453fb448c977acc62f23cfbf9_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia41cb8ba083c40d8bb8e8e5a75a886d3_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56d29c41cf14436b8bd0387c90fdcc9c_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1a7ed898049b448889443be8ec36feff_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b06ba1df96b4a3e9332405eed4144c7_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife9ff28d3f5c4f9f823666db103add14_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44bfea2a30414fd2acc71a28c1a9338c_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2bd8eb466f7641b58a738548f55f05ca_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i765d240ac3504d22b02095e7b50f9664_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3c6e97913c1e42e8a73e24fdcddbb0f0_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic546e27439c549a5930ca85efae9f793_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibaa94ed145ab44e893b1141cd2f4b6d2_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2194cc52a1204b8bb062f0829cc720a3_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia637975db75f4d6ca976d19b81d5d23b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5a13137501ef420499797d78d356afa9_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i50227f06e5f04961b0e6a7aea3926827_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iea8f7496466a454890b32615eb14ec08_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:ConsumerHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3d62e4d77ba942f7bd7bc31625c7c643_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:ConsumerHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iec21bae1ba8f4a4b9e8a25cbda75c2c4_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i12f90c84177a4ab0ac0f09d5f702e4e9_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3baea8052de54dbf99a582b503fe5ae9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i365b842e2df647adb11480f7f5a63d9f_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44e23d74806e4408bdef269ad289b155_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i35f2772fa1fb464686fdad7eba530bc2_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iad4ae67402be4d30bf0509f57bdf82a4_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4662aafc35c84c71a32e5811a0481ac0_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf6f3d4d30c44652ac9e77a021f74bc7_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i901d71842aaf4089b7b7a4d97fdc8942_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id907daafbe5d44ec927b1cf4e8fcfb0d_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8bd1a077b7d6414e8935bd70e97c8cf2_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68257c001b354a5a98508e8a0ac0e82a_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96a3daea3f49408e971870669b0f5512_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fa7b3a6c25c4eada02b8646ac415062_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1cdb9152618c42eea5013297dbf2e4c3_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i200f93e3b77244a583b1ad4b7a71d3a1_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib112e058fb6b447dbc3310478fc97587_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="icafa0a8044c04de497b6f3dfe30d2a58_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i43130bad99db457ba44ec22f2c697510_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9c2fc3c8e9594706a561854ef8052a58_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id2d96b411f4d40debdac91b9aabb935f_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01fde314497149c6b70e4d076fa6dd4f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i20c9f4592a754d2cb500873c6ed0be54_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if1a5151945ca4ac086f58deeeb720914_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i44509d3ef3cb4581b00a5c4862521e64_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ebf98b5fa324cbaa9bfaebdca053ff4_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i29d342791cfc4b03a1713eb39bf942d5_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d276957b87d4834ba1ee537b68aa89e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0daf7a509a1742c0af022ecd6a711956_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fea49b8326e4a0bbb7c8f8cfee7b454_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibb0265bad6f240a28a737ed052560826_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie500d8c896d44983b9c33f2ac1ef9710_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ae4ff8713334360a336393c7dac68d5_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if853701b34c2430d8f37795599100d52_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic1cb58176e324fddab800e715c7039c3_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i40efe68b209843249746ea7032375b47_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i196d06199bcb47afb512e58c6c6cce33_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib97ee1e8d98d45f78eea6e86d0d96a02_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4dc7c4601c144f7091a2700b230221f8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i648dd03c46344752a321bbba8fc97340_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1a210155919049c2bd43c936b49f1ee6_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0675e6e915374fb5b095d7fd0834c9be_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i903579018dfc4744b7b1bc7085ee9dea_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6272b36311854ffb8459a6a826a10495_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4498e185f42a4d2c931df62d565c61fc_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic6bb87c09ab1449d8ac694d344eae356_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib9836117d3a94830a8233450377a1deb_D20221222-20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-22</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i92d127c3ca8d4ec2976b3e3c568fecc2_D20221222-20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-22</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i81a39d36d1174514a434b80d6c743dc6_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8b185cbc0eed49e1bf2b12aead1c396f_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84406520b58240c49988945086079984_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ImpellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7342e69dce654189845f736621bb11ac_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ClassIRecommendationForImpellaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4f147e1dd45545d3abb1795f5f7086da_D20221222-20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-12-22</xbrli:startDate><xbrli:endDate>2022-12-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3ea49ac2e6aa4de69e5169b63d21cc06_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1690230576734ba492365e566a8b6b5e_I20221222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-22</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3fbf2d6d15164f949f7d00b550a2d80f_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:A2020AcquisitionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c96d667b7284485a85bb50fece53ad0_D20210104-20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2021-04-04</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia24eda47473543d58b1d6c2d349bdfc5_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="idf3a369e46f249199404ae4a686a3719_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i829e1cea7f8840eabf95f9902ac2836e_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic25eb0c4ceda4b8ca2e1719553bd3d9f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icc8a7af544c348f792fe38f31e341481_I20210404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:VerbSurgicalIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i96285e2125c044239562f06c5a49708f_D20201001-20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3825927182464ac79b6e43df181cccf8_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i27aa2a498bdb4d7fb75719ee6d31b90f_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if2ea1b03a3be4ff59976cf8545ab6d21_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6535353e93a14112b8d587f589b7bd9f_I20201001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i07c8b24309d443688602562848d8298e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie3dd034235f641b9a1484d7974551ed8_D20191230-20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2021-01-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="chf"><xbrli:measure>iso4217:CHF</xbrli:measure></xbrli:unit><xbrli:context id="i1aee0cedf1f94f5a8d36040886e87e0f_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5282653c940b42ef862b668ed6921a2d_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0e37979e6ad844279246c3dd8ff74a38_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i647eea070e4240cca28f6b76979c3a28_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claimant"><xbrli:measure>jnj:claimant</xbrli:measure></xbrli:unit><xbrli:context id="i34154fc7f1e24a8cb5c558996d6b6896_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i255cda4840fb4aa88fa64590ce872e72_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6cf165cbbd74fdfbb1fa0b952e8bff6_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2c9a481d368148b0929cadc2b0a5af97_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie47bff957cb84bb49f3b161a5860618a_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibc66bcf7171d418a86ecd62a2404c17e_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ElmironMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i03778e924ff348b5a3f45913272ec65a_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iddc88969213c48ea97060082ffa73825_I20210531"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="cases"><xbrli:measure>jnj:cases</xbrli:measure></xbrli:unit><xbrli:context id="ia897c0714e5c4774b0c045831789f7f2_I20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf6a73a559664e0ebb512a48d328ad5e_D20210901-20210930"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac21980ceda94b21a50b291a322d153b_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3682b642e54048a5b5181c77d2d45dd4_D20191001-20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-10-01</xbrli:startDate><xbrli:endDate>2019-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5dcee1a6065d4ba0abd1619dd17fb039_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i595e23088c2c4b02bebb9612c8ab2a93_D20180701-20180731"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i33aa324aaa9d42f4a185c9928408a20c_D20200601-20200630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i748cd779f212410081567ad7ca01f948_D20210601-20210630"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2391578fa34543b695b3fb891576fdee_D20211001-20211031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if6878b220b444ed8b48a88bc1bfe70dc_D20220301-20220322"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jnj:RasmussenInstrumentsLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibe39ec7be3e24f578dd104058f18f8a3_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8fe1e7bec0cc453594ea48b53c12aae3_D20191230-20200927"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-30</xbrli:startDate><xbrli:endDate>2020-09-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i78a211fb9da44857b52720a3523178e1_I20191031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibd40d3a12acb4dcfbf80471e318ded84_I20201031"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="claim"><xbrli:measure>jnj:claim</xbrli:measure></xbrli:unit><xbrli:context id="ie97127abe6644e81b414d38b27b36e32_D20200101-20200131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3b4964f990444943801868a6dd79fc6b_D20220401-20220430"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-04-01</xbrli:startDate><xbrli:endDate>2022-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2474e48849f1407492b006d664c27c42_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie567e5eb9dcb41d0a398be109e77b0d9_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iaa15521dd2654667b094254ebe535fc4_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i49c2401f8f3d4163afe6adbe4293302d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i95e5b2037fbd445ea91d492ad3152fe5_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32d057f69df94f2280959b742aaf5e0b_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i628034b976194b3c95eee1d092e53459_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i31117717375a483aba04eca1e392ee44_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if41a7f60706e4d6c8d7278663011a8e6_I20210103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib3e13d3f1dcb4123ab1494c07d04692a_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib8895b2c96ae49d9ab87668b6e4d972e_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icbf00d9c7c2c47b2a38a0e33043c8e05_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3dbe54c0baea4b92b0175ecdc2c32d60_D20210104-20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-04</xbrli:startDate><xbrli:endDate>2022-01-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i346e675961384d10af15a172a233f844_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i224a56e9b03f475f8ef466ec18c2e508_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9413ac0768844d14a4e88ef98209b2be_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7ccc395680a1473f92468bceaec711ec_I20220102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i78a5f0207ed948bbab5f326ccad7f02d_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0a124d2841f84a198ab499b74262070b_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia22ff0765200405d8456d1b39ac5257f_D20220103-20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-03</xbrli:startDate><xbrli:endDate>2023-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i105785393ea04c2ba49bcb40429c6955_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6235e13b21004a43a0daa993991daa3a_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2ba4d95af9e4e4fa22e3ffb45143679_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i1f013b59c3b14695b75acec1bdb16def_I20230101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000200406</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i51a46167ef364951bf70ae9d6493776c_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:2pt;text-align:center"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington,&#160;D.C. 20549</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQw_9949bbd9-7111-445c-9b3f-53a295ce3443">10-K</ix:nonNumeric> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6ZGNjYTdhYjJiM2FjNGJiMWFiNjljODA4NzU5NDUxZWIvdGFibGVyYW5nZTpkY2NhN2FiMmIzYWM0YmIxYWI2OWM4MDg3NTk0NTFlYl8wLTAtMS0xLTg0NDQ0_aa8f2684-2fd7-438a-aaf8-1a1e9ce820fe">&#9745;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18xMTU_cb4d87b1-bc35-4b0a-8c42-434fda7d3ecc"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18xMTU_d1f5c0f5-0bed-4037-b2ca-22f4c365a3f6">January 1</ix:nonNumeric>, 2023</ix:nonNumeric> </span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">or</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.713%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6ZjQ0MjdjY2Y3NTA4NDkzNTlmNDc3OWJhYmM4M2FmNTYvdGFibGVyYW5nZTpmNDQyN2NjZjc1MDg0OTM1OWY0Nzc5YmFiYzgzYWY1Nl8wLTAtMS0xLTg0NDQ0_629ff729-23ca-4b63-9b7f-e5b5598de3b3">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934<br/>for the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commission file number <ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQ1_a7ae1332-5acd-47f3-94bc-26ecc3cb1391">1-3215</ix:nonNumeric> </span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODM1_73f3365b-77c6-430e-8e1b-c79664f016eb">JOHNSON &amp; JOHNSON</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:47.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.489%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6MDIyYjYyOWMyNDhmNGI3NTk0OTkxYjE0OTViNWViNTQvdGFibGVyYW5nZTowMjJiNjI5YzI0OGY0Yjc1OTQ5OTFiMTQ5NWI1ZWI1NF8wLTAtMS0xLTg0NDQ0_bd7d6b1d-3947-448b-89f9-48dc8203ed2c">New Jersey</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6MDIyYjYyOWMyNDhmNGI3NTk0OTkxYjE0OTViNWViNTQvdGFibGVyYW5nZTowMjJiNjI5YzI0OGY0Yjc1OTQ5OTFiMTQ5NWI1ZWI1NF8wLTItMS0xLTg0NDQ0_54fa01ce-f990-4251-bda1-1541f00663e4">22-1024240</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State of incorporation)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">One Johnson&#160;&amp; Johnson Plaza<br/>New Brunswick, New Jersey</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">08933</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Zip Code)</span></td></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQx_71473352-8f9e-4394-b885-d2115cf41532">One Johnson &amp; Johnson Plaza</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQ2_1ffa9611-7495-4a24-8109-fde340590413">New Brunswick</ix:nonNumeric>, <ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQ3_dcc810bb-8f27-4b09-ac3f-82f974e6d6c5">New Jersey</ix:nonNumeric> <ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQ4_0eb9468c-88be-4ab8-9279-7355217f7406">08933</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Address of principal executive offices)</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODM2_09942029-5ac3-4317-bc05-06b4faf58e73">732</ix:nonNumeric>)&#160;<ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODM4_13e57c8a-ca62-4535-824a-6cfc1492bd75">524-0400</ix:nonNumeric> </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECURITIES REGISTERED PURSUANT TO SECTION&#160;12(b) OF THE ACT</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.005%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.543%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c37a522bee54a7797e1e6cb838f251b_D20220103-20230101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8xLTAtMS0xLTg0NDQ0_428a1a85-5515-4987-98c3-e16062a40f65">Common Stock, Par Value $1.00</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c37a522bee54a7797e1e6cb838f251b_D20220103-20230101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8xLTEtMS0xLTg0NDQ0_085d79b4-2e69-46c4-87a3-52479fbfa5a2">JNJ</ix:nonNumeric></span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0c37a522bee54a7797e1e6cb838f251b_D20220103-20230101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8xLTItMS0xLTg0NDQ0_07af4003-d65c-48b1-b77e-73e8686c8d99">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i24117e0479bb43b39fee8a31afe69358_D20220103-20230101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8yLTAtMS0xLTg0NDQ0_38e5ee08-a0ed-47b1-b622-1da79992e7e6">0.650% Notes Due May 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i24117e0479bb43b39fee8a31afe69358_D20220103-20230101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8yLTEtMS0xLTg0NDQ0_5c943417-0fbd-44ad-8b93-7c6faffb5b96">JNJ24C</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i24117e0479bb43b39fee8a31afe69358_D20220103-20230101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8yLTItMS0xLTg0NDQ0_2a78b9b8-5975-4b1e-b472-b850886e85d7">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88ae5583fd7b47fd87a649c4e0bfef49_D20220103-20230101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8zLTAtMS0xLTg0NDQ0_cb024ad3-bf93-4d1e-a3a8-9de1e8083be7">5.50% Notes Due November 2024</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88ae5583fd7b47fd87a649c4e0bfef49_D20220103-20230101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8zLTEtMS0xLTg0NDQ0_c2787abf-a444-4133-956d-67a5190e1848">JNJ24BP</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i88ae5583fd7b47fd87a649c4e0bfef49_D20220103-20230101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8zLTItMS0xLTg0NDQ0_a249bfb0-588c-469f-a89a-5755b832918c">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1602ec71af1c48e8a8514b07a9371e2d_D20220103-20230101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl80LTAtMS0xLTg0NDQ0_6af65028-0c27-4739-87ae-6a7c4f1ea34c">1.150% Notes Due November 2028</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1602ec71af1c48e8a8514b07a9371e2d_D20220103-20230101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl80LTEtMS0xLTg0NDQ0_aa9f70ac-5251-476f-8e98-2483ca34ef95">JNJ28</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1602ec71af1c48e8a8514b07a9371e2d_D20220103-20230101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl80LTItMS0xLTg0NDQ0_5138aadf-a382-4ae6-85db-11c816bf2f8b">New York Stock Exchange</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibfdad04f19eb4b2788c13457aacbc7d5_D20220103-20230101" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl81LTAtMS0xLTg0NDQ0_8b4793d1-70da-4b58-8f22-312e2c55c80b">1.650% Notes Due May 2035</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibfdad04f19eb4b2788c13457aacbc7d5_D20220103-20230101" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl81LTEtMS0xLTg0NDQ0_ffcf771e-419e-436c-aea0-deeaafb84dea">JNJ35</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ibfdad04f19eb4b2788c13457aacbc7d5_D20220103-20230101" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl81LTItMS0xLTg0NDQ0_bdbb616d-ee28-43af-8d7b-b154c5148b90">New York Stock Exchange</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;<ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityWellKnownSeasonedIssuer" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQy_37390e7e-cbb0-430f-b60b-87b571fbbce0">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act.&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityVoluntaryFilers" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQz_e21c011b-c911-4eba-8153-10744f65c878">No</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Exchange Act during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;<ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODM3_9cb0a540-ad17-4f71-8d0c-acaf1792fb55">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation&#160;S-T during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;<ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODM5_1ea012d7-7096-433e-9226-7893b1329853">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"></td><td style="width:7.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.518%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.861%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.883%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.248%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6Zjk2NThlYmUyM2U0NDBmYzg1ZWY2YzMxNjFhNDExZjMvdGFibGVyYW5nZTpmOTY1OGViZTIzZTQ0MGZjODVlZjZjMzE2MWE0MTFmM18wLTEtMS0xLTg0NDQ0_a4e4afa7-7b6b-47aa-b9b7-56b609005fbb">Large accelerated filer</ix:nonNumeric> </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9745;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-accelerated filer </span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6Zjk2NThlYmUyM2U0NDBmYzg1ZWY2YzMxNjFhNDExZjMvdGFibGVyYW5nZTpmOTY1OGViZTIzZTQ0MGZjODVlZjZjMzE2MWE0MTFmM18xLTQtMS0xLTg0NDQ0_462983a6-90e0-4584-987e-ccbbff784a83">&#9744;</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6Zjk2NThlYmUyM2U0NDBmYzg1ZWY2YzMxNjFhNDExZjMvdGFibGVyYW5nZTpmOTY1OGViZTIzZTQ0MGZjODVlZjZjMzE2MWE0MTFmM18yLTItMS0xLTg0NDQ0_70314669-7ffe-4e33-bb7c-677d9588fa46">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes&#160;<ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQ5_d9c64b2d-aa40-4476-acc5-982ac5a9ed44">&#9745;</ix:nonNumeric>&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;Yes&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:EntityShellCompany" format="ixt:fixed-false" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQ0_67fd5f98-8a3f-43ce-a9a1-bf49eda4c42d">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#254;</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate market value of the Common Stock held by non-affiliates computed by reference to the price at which the Common Stock was last sold as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was approximately $<ix:nonFraction unitRef="usd" contextRef="i2a6f74ddd04b42a7beb1b698b449e828_I20220703" decimals="-9" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yNzIz_5ca87861-6b3a-4381-b87a-822fa68bbd91">472</ix:nonFraction> billion.</span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 10, 2023, there were <ix:nonFraction unitRef="shares" contextRef="id42e890d27894b429fe640211353b83a_I20230210" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yNzYw_431770ac-0da1-42d5-9a06-1e9489b00817">2,604,286,303</ix:nonFraction> shares of Common Stock outstanding.</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.830%"><tr><td style="width:1.0%"></td><td style="width:6.740%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.060%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Parts I and III:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portions of registrant&#8217;s proxy statement for its 2023 annual meeting of shareholders filed within 120&#160;days after the close of the registrant&#8217;s fiscal year (the &#8220;Proxy Statement&#8221;), are incorporated by reference to this report on Form 10-K (this &#8220;Report&#8221;).</span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_7"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:5.195%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.109%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.396%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Item</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr style="height:11pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_13">PART&#160;I</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_16">Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_16">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_19">General</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_19">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_22">Segments of Business</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_22">1</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_25">Geographic Areas</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_25">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_28">Raw Materials</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_28">2</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_31">Patents</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_31">2</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_34">Trademarks</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_37">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_37">Seasonality</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_37">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_40">Competition</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_40">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_43">Environment</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_43">3</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_46">Regulation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_46">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_49">Employees and Human Capital Management</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_49">5</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6.75pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_52">Available Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_52">7</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_55">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_55">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_58">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_58">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_61">Properties</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_61">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_64">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_64">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_67">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_67">16</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_70">Executive Officers of the Registrant</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_70">17</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_73">PART&#160;II</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_76">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_76">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_79">(Reserved)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_79">20</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_85">Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_85">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_106">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_106">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_109">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_109">39</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_244">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_244">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_247">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_247">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9B.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_250">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_250">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9C.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_253">Disclosures Regarding Foreign Jurisdictions That Prevent Inspections</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_253">108</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_256">PART&#160;III</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_259">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_259">108</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_262">Executive Compensation</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_262">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_265">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_265">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_268">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_268">109</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_271">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_271">109</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_274">PART&#160;IV</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_277">Exhibits and Financial Statement Schedules</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_277">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_280">Form 10-K Summary</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_280">110</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_283">Signatures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_283">111</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_286">Exhibit&#160;Index</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_286">113</a></span></div></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_10"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS </span></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K </span><span style="color:#212121;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Johnson &amp; Johnson&#8217;s other publicly available documents contain &#8220;forward-looking statements&#8221; within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Management and representatives of Johnson &amp; Johnson and its subsidiaries (the Company) also may from time to time make forward-looking statements. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forward-looking statements do not relate strictly to historical or current facts and reflect management&#8217;s assumptions, views, plans, objectives and projections about the future. Forward-looking statements may be identified by the use of words such as &#8220;plans,&#8221; &#8220;expects,&#8221; &#8220;will,&#8221; &#8220;anticipates,&#8221; &#8220;estimates&#8221; and other words of similar meaning in conjunction with, among other things: discussions of future operations; expected operating results and financial performance; impact of planned acquisitions and dispositions; impact and timing of restructuring initiatives, including associated cost savings and other benefits; the planned separation of the Company&#8217;s Consumer Health business; the Company&#8217;s strategy for growth; product development activities; regulatory approvals; market position and expenditures.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because forward-looking statements are based on current beliefs, expectations and assumptions regarding future events, they are subject to uncertainties, risks and changes that are difficult to predict and many of which are outside of the Company&#8217;s control. Investors should realize that if underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, the Company&#8217;s actual results and financial condition could vary materially from expectations and projections expressed or implied in its forward-looking statements. Investors are therefore cautioned not to rely on these forward-looking statements. Risks and uncertainties include, but are not limited to:</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Development, Market Success and Competition</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges and uncertainties inherent in innovation and development of new and improved products and technologies on which the Company&#8217;s continued growth and success depend, including uncertainty of clinical outcomes, additional analysis of existing clinical data, obtaining regulatory approvals, health plan coverage and customer access, and initial and continued commercial success;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges to the Company&#8217;s ability to obtain and protect adequate patent and other intellectual property rights for new and existing products and technologies in the United States and other important markets;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of patent expirations, typically followed by the introduction of competing generic, biosimilar or other products and resulting revenue and market share losses;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Increasingly aggressive and frequent challenges to the Company&#8217;s patents by competitors and others seeking to launch competing generic, biosimilar or other products and increased receptivity of courts, the United States Patent and Trademark Office and other decision makers to such challenges, potentially resulting in loss of market exclusivity and rapid decline in sales for the relevant product sooner than expected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition in research and development of new and improved products, processes and technologies, which can result in product and process obsolescence;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition to reach agreement with third parties for collaboration, licensing, development and marketing agreements for products and technologies;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Competition based on cost-effectiveness, product performance, technological advances and patents attained by competitors; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Allegations that the Company&#8217;s products infringe the patents and other intellectual property rights of third parties, which could adversely affect the Company&#8217;s ability to sell the products in question and require the payment of money damages and future royalties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Product Liability, Litigation and Regulatory Activity</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Product efficacy or safety concerns, whether or not based on scientific evidence, potentially resulting in product withdrawals, recalls, regulatory action on the part of the United States Food and Drug Administration (or international counterparts), declining sales, reputational damage, increased litigation expense and share price impact;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact, including declining sales and reputational damage, of significant litigation or government action adverse to the Company, including product liability claims and allegations related to pharmaceutical marketing practices and contracting strategies;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of an adverse judgment or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, product liability, personal injury claims, securities class actions, government investigations, employment and other legal proceedings;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Increased scrutiny of the healthcare industry by government agencies and state attorneys general resulting in investigations and prosecutions, which carry the risk of significant civil and criminal penalties, including, but not limited to, debarment from government business; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Failure to meet compliance obligations in compliance agreements with governments or government agencies, which could result in significant sanctions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Potential changes to applicable laws and regulations affecting United States and international operations, including relating to: approval of new products; licensing and patent rights; sales and promotion of healthcare products; access to, and reimbursement and pricing for, healthcare products and services; environmental protection; and sourcing of raw materials;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Compliance with local regulations and laws that may restrict the Company&#8217;s ability to manufacture or sell its products in relevant markets, including requirements to comply with medical device reporting regulations and other requirements such as the European Union&#8217;s Medical Devices Regulation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Changes in domestic and international tax laws and regulations, increasing audit scrutiny by tax authorities around the world and exposures to additional tax liabilities potentially in excess of existing reserves; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The issuance of new or revised accounting standards by the Financial Accounting Standards Board and regulations by the Securities and Exchange Commission.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to the Company&#8217;s Strategic Initiatives, Healthcare Market Trends and the Planned Separation of the Company&#8217;s Consumer Health Business</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Pricing pressures resulting from trends toward healthcare cost containment, including the continued consolidation among healthcare providers and other market participants, trends toward managed care, the shift toward governments increasingly becoming the primary payers of healthcare expenses, significant new entrants to the healthcare markets seeking to reduce costs and government pressure on companies to voluntarily reduce costs and price increases;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Restricted spending patterns of individual, institutional and governmental purchasers of healthcare products and services due to economic hardship and budgetary constraints; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Challenges to the Company&#8217;s ability to realize its strategy for growth including through externally sourced innovations, such as development collaborations, strategic acquisitions, licensing and marketing agreements, and the potential heightened costs of any such external arrangements due to competitive pressures;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected strategic benefits and opportunities from any planned or completed acquisition or divestiture by the Company may not be realized or may take longer to realize than expected; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected benefits and opportunities related to past and ongoing restructuring actions may not be realized or may take longer to realize than expected;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company&#8217;s ability to consummate the planned separation of the Company&#8217;s Consumer Health business on a timely basis or at all;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Company&#8217;s ability to successfully separate the Company&#8217;s Consumer Health business and realize the anticipated benefits from the planned separation; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The New Consumer Health Company&#8217;s ability to succeed as a standalone publicly traded company.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Economic Conditions, Financial Markets and Operating Internationally</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The risks associated with global operations on the Company and its customers and suppliers, including foreign governments in countries in which the Company operates;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of inflation and fluctuations in interest rates and currency exchange rates and the potential effect of such fluctuations on revenues, expenses and resulting margins;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Potential changes in export/import and trade laws, regulations and policies of the United States and other countries, including any increased trade restrictions or tariffs and potential drug reimportation legislation;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact on international operations from financial instability in international economies, sovereign risk, possible imposition of governmental controls and restrictive economic policies, and unstable international governments and legal systems; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of global public health crises and pandemics, including the novel coronavirus (COVID-19) pandemic;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Changes to global climate, extreme weather and natural disasters that could affect demand for the Company&#8217;s products and services, cause disruptions in manufacturing and distribution networks, alter the availability of goods and services within the supply chain, and affect the overall design and integrity of the Company&#8217;s products and operations; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The impact of armed conflicts and terrorist attacks in the United States and other parts of the world, including social and economic disruptions and instability of financial and other markets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks Related to Supply Chain and Operations </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Difficulties and delays in manufacturing, internally, through third-party providers or otherwise within the supply chain, that may lead to voluntary or involuntary business interruptions or shutdowns, product shortages, withdrawals or suspensions of products from the market, and potential regulatory action;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Interruptions and breaches of the Company&#8217;s information technology systems or those of the Company&#8217;s vendors, which could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Reliance on global supply chains and production and distribution processes that are complex and subject to increasing regulatory requirements that may adversely affect supply, sourcing and pricing of materials used in the Company&#8217;s products; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">The potential that the expected benefits and opportunities related to restructuring actions contemplated for the global supply chain may not be realized or may take longer to realize than expected, including due to any required approvals from applicable regulatory authorities. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors also should carefully read the Risk Factors described in Item 1A of this Annual Report on Form 10-K for a description of certain risks that could, among other things, cause the Company&#8217;s actual results to differ materially from those expressed in its forward-looking statements. Investors should understand that it is not possible to predict or identify all such factors and should not consider the risks described above and in Item 1A to be a complete statement of all potential risks and uncertainties. The Company does not undertake to publicly update any forward-looking statement that may be made from time to time, whether as a result of new information or future events or developments.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_13"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;I</span></div><div id="i51a46167ef364951bf70ae9d6493776c_16"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">BUSINESS</span></div><div id="i51a46167ef364951bf70ae9d6493776c_19"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Johnson&#160;&amp; Johnson and its subsidiaries (the Company) have approximately 152,700&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. Johnson&#160;&amp; Johnson is a holding company, with operating companies conducting business in virtually all countries of the world. The Company&#8217;s primary focus is products related to human health and well-being. Johnson&#160;&amp; Johnson was incorporated in the State of New Jersey in 1887.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Executive Committee of Johnson&#160;&amp; Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Company's three business segments: Consumer Health, Pharmaceutical and MedTech (previously referred to as Medical Devices). Within the strategic parameters provided by the Committee, senior management groups at U.S. and international operating companies are each responsible for their own strategic plans and the day-to-day operations of those companies. Each subsidiary within the business segments is, with limited exceptions, managed by residents of the country where located.</span></div><div id="i51a46167ef364951bf70ae9d6493776c_22"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segments of Business</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is organized into three business segments: Consumer Health, Pharmaceutical and MedTech. Additional information required by this item is incorporated herein by reference to the narrative and tabular descriptions of segments and operating results under: &#8220;Item 7. Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition&#8221; of this Report; and Note&#160;17 &#8220;Segments of Business and Geographic Areas&#8221; of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consumer Health</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;The Consumer Health segment includes a broad range of products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women&#8217;s Health and Wound Care markets. Major brands in Skin Health/Beauty include the AVEENO; CLEAN&#160;&amp; CLEAR; DR. CI:LABO; NEUTROGENA and OGX product lines. Over-the-Counter (OTC) medicines include the broad family of TYLENOL acetaminophen products; SUDAFED cold, flu and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products outside the U.S.; ZARBEE&#8217;S products, inspired by nature, and the PEPCID line of acid reflux products. Baby Care includes the JOHNSON&#8217;S and AVEENO Baby line of products. Oral Care includes the LISTERINE product line. Major brands in Women&#8217;s Health outside of North America are STAYFREE and CAREFREE sanitary pads and o.b. tampon brands. Wound Care brands include the BAND-AID Brand Adhesive Bandages and NEOSPORIN First Aid product lines. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">              In November 2021, the Company announced its intention to separate the Company&#8217;s Consumer Health business (Kenvue as the name for the planned New Consumer Health Company), with the intention to create a new, publicly traded company by the end of the fiscal year 2023. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pharmaceutical</span></div><div style="text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">The Pharmaceutical segment is focused on the following therapeutic areas: Immunology (e.g., rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease and psoriasis), Infectious Diseases (e.g., HIV/AIDS), Neuroscience (e.g., mood disorders, neurodegenerative disorders and schizophrenia), Oncology (e.g., prostate cancer, hematologic malignancies, lung cancer and bladder cancer), Cardiovascular and Metabolism (e.g., thrombosis, diabetes and macular degeneration) and Pulmonary Hypertension (e.g., Pulmonary Arterial Hypertension). Medicines in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. Key products in the Pharmaceutical segment include: REMICADE (infliximab), a treatment for a number of immune-mediated inflammatory diseases; SIMPONI (golimumab), a subcutaneous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis and moderately active to severely active ulcerative colitis; SIMPONI ARIA (golimumab), an intravenous treatment for adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis and active ankylosing spondylitis and active polyarticular juvenile idiopathic arthritis (pJIA) in people 2 years of age and older; STELARA (ustekinumab), a treatment for adults and children with moderate to severe plaque psoriasis, for adults with active psoriatic arthritis, for adults with moderately to severely active Crohn's disease and treatment of moderately to severely active ulcerative colitis; TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:105%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%"> (guselkumab), a treatment for adults with moderate to severe plaque psoriasis and active psoriatic arthritis; EDURANT (rilpivirine), PREZISTA (darunavir) and PREZCOBIX/REZOLSTA (darunavir/cobicistat), antiretroviral medicines for the treatment of human immunodeficiency virus (HIV-1) in combination with other antiretroviral products and SYMTUZA (darunavir/cobicistat/emtricitabine/tenofovir alafenamide), a once-daily single tablet regimen for the treatment of HIV; CONCERTA (methylphenidate HCl) extended-release tablets CII, a treatment for attention deficit hyperactivity disorder; INVEGA SUSTENNA/XEPLION (paliperidone palmitate), for the treatment of schizophrenia and schizoaffective disorder in adults; INVEGA TRINZA/TREVICTA (paliperidone palmitate), for the treatment of schizophrenia in patients after they have been adequately treated with INVEGA SUSTENNA for at least four months; RISPERDAL CONSTA (risperidone long-acting injection), for the treatment of schizophrenia and the maintenance treatment of Bipolar 1 Disorder in adults; ZYTIGA </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:105%">(abiraterone acetate), a treatment for patients with prostate cancer; ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer; IMBRUVICA (ibrutinib), a treatment for certain B-cell malignancies, or blood cancers and chronic graft versus host disease; DARZALEX (daratumumab), a treatment for multiple myeloma; DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), a treatment for multiple myeloma and light chain (AL) Amyloidosis; XARELTO (rivaroxaban), an oral anticoagulant for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism (PE) in patients undergoing hip or knee replacement surgery, to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation, and for the treatment and reduction of risk of recurrence of DVT and PE to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD) and peripheral artery disease (PAD), for the treatment and secondary prevention of thromboembolism in pediatric patients, and for thromboprophylaxis in pediatric patients following the Fontan procedure; INVOKANA (canagliflozin), for the treatment of adults with type 2 diabetes; INVOKAMET/VOKANAMET (canagliflozin/metformin HCl), a combination therapy of fixed doses of canagliflozin and metformin hydrochloride for the treatment of adults with type 2 diabetes; and INVOKAMET XR (canagliflozin/metformin hydrochloride extended-release), a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release, for the treatment of adults with type 2 diabetes; OPSUMIT (macitentan) as monotherapy or in combination, indicated for the long-term treatment of pulmonary arterial hypertension (PAH); UPTRAVI (selexipag), the only approved oral and intravenous, selective IP receptor agonist targeting a prostacyclin pathway in PAH. Many of these medicines were developed in collaboration with strategic partners or are licensed from other companies and maintain active lifecycle development programs.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MedTech </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:111%">&#160;&#160;&#160;&#160;The MedTech (previously referred to as Medical Devices) segment includes a broad portfolio of products used in the Interventional Solutions, Orthopaedics, Surgery and Vision categories. Interventional Solutions include Electrophysiology products (Biosense Webster) to treat cardiovascular diseases, Neurovascular care (Cerenovus) that treats hemorrhagic and ischemic stroke and the Heart Recovery portfolio (Abiomed) which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock. The Orthopaedics portfolio (DePuy Synthes) comprises products in support of Hips, Knees, Trauma, and Spine, Sports &amp; Other. The Surgery portfolios include advanced and general surgery offerings (Ethicon), solutions that focus on Breast Aesthetics (Mentor), and Ear, Nose and Throat (Acclarent) procedures.  Johnson &amp; Johnson Vision products include ACUVUE Brand contact lenses and ophthalmic technologies related to cataract and laser refractive surgery. These products are distributed to wholesalers, hospitals and retailers, and used predominantly in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics.</span></div><div><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_25"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Geographic Areas</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Johnson&#160;&amp; Johnson and its subsidiaries (the Company) have approximately 152,700&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world with the primary focus on products related to human health and well-being.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The products made and sold in the international business include many of those described above under &#8220;&#8211;&#160;Segments of Business&#160;&#8211; Consumer Health,&#8221; &#8220;&#8211;&#160;Pharmaceutical&#8221; and &#8220;&#8211;&#160;MedTech.&#8221; However, the principal markets, products and methods of distribution in the international business vary with the country and the culture. The products sold in international business include those developed in the U.S. and by subsidiaries abroad.</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments and activities in some countries outside the U.S. are subject to higher risks than comparable U.S.&#160;activities because the investment and commercial climate may be influenced by financial instability in international economies, restrictive economic policies and political and legal system uncertainties.</span></div><div id="i51a46167ef364951bf70ae9d6493776c_28"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Raw Materials</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Raw materials essential to the Company's business are generally readily available from multiple sources.  Where there are exceptions, the temporary unavailability of those raw materials would not likely have a material adverse effect on the financial results of the Company.</span></div><div id="i51a46167ef364951bf70ae9d6493776c_31"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patents </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's subsidiaries have made a practice of obtaining patent protection on their products and processes where possible. They own, or are licensed under, a significant number of patents in the U.S. and other countries relating to their products, product uses, formulations and manufacturing processes, which in the aggregate are believed to be of material importance to the Company in the operation of its businesses. The Company&#8217;s subsidiaries face patent challenges from third parties, including challenges seeking to manufacture and market generic and biosimilar versions of the Company's key pharmaceutical products prior to expiration of the applicable patents covering those products. Significant legal proceedings and claims involving the Company's patent and other intellectual property are described in Note 19, &#8220;Legal Proceedings&#8212;</span><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intellectual Property&#8221; of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">              Sales of the Company&#8217;s largest product, STELARA (ustekinumab), accounted for approximately 10.2% of the Company's total revenues for fiscal 2022. Accordingly, the patents related to this product are believed to be material to the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#2c2c2c;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Company.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Janssen Biotech, Inc., a wholly-owned subsidiary of Johnson &amp; Johnson, owns patents specifically related to STELARA</span><span style="color:#000000;font-family:'Palatino Linotype',sans-serif;font-size:12pt;font-weight:400;line-height:107%">.</span><span style="color:#000000;font-family:'Palatino Linotype',sans-serif;font-size:7.8pt;font-weight:400;line-height:107%;position:relative;top:-4.2pt;vertical-align:baseline">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The latest expiring United States composition of matter patent expires in 2023. The latest expiring European composition of matter patent expires in 2024. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Sales of the Company&#8217;s second largest product, collectively DARZALEX (daratumumab) and DARZALEX FASPRO (daratumumab and hyaluronidase-fihj), accounted for approximately 8.4% of the Company's total revenues for fiscal 2022. Accordingly, the patents related to this product are believed to be material to the Company.  Genmab A/S owns two patent families related to DARZALEX, and Janssen Biotech, Inc. has an exclusive license to those patent families. The two patent families both expire in the United States in 2029. The latest expiring licensed European patent expires in 2032. Janssen Biotech, Inc. owns a separate patent portfolio related to DARZALEX FASPRO.</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> </span></div><div id="i51a46167ef364951bf70ae9d6493776c_34"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company&#8217;s subsidiaries have made a practice of selling their products under trademarks and of obtaining protection for these trademarks by all available means. These trademarks are protected by registration in the U.S. and other countries where such products are marketed. The Company considers these trademarks in the aggregate to be of material importance in the operation of its businesses.</span></div><div id="i51a46167ef364951bf70ae9d6493776c_37"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Seasonality</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Worldwide sales do not reflect any significant degree of seasonality; however, spending has typically been heavier in the fourth quarter of each year than in other quarters. This reflects increased spending decisions, principally for advertising and research and development activity.</span></div><div id="i51a46167ef364951bf70ae9d6493776c_40"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Competition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In all of their product lines, the Company's subsidiaries compete with companies both locally and globally. Competition exists in all product lines without regard to the number and size of the competing companies involved. Competition in research, both internally and externally sourced, involving the development and the improvement of new and existing products and processes, is particularly significant. The development of new and innovative products, as well as protecting the underlying intellectual property of the Company&#8217;s product portfolio, is important to the Company's success in all areas of its business. The competitive environment requires substantial investments in continuing research. In addition, the development and maintenance of customer demand for the Company&#8217;s consumer products involve significant expenditures for advertising and promotion.</span></div><div id="i51a46167ef364951bf70ae9d6493776c_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Environment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is subject to a variety of U.S.&#160;and international environmental protection measures. The Company believes that its operations comply in all material respects with applicable environmental laws and regulations. The Company&#8217;s compliance with these requirements is not expected to have a material effect upon its capital expenditures, cash flows, earnings or competitive position.</span></div><div id="i51a46167ef364951bf70ae9d6493776c_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160; The Company&#8217;s businesses are subject to varying degrees of governmental regulation in the countries in which operations are conducted, and the general trend is toward increasingly stringent regulation and enforcement. The Company is subject to costly and complex U.S. and foreign laws and governmental regulations and any adverse regulatory action may materially adversely affect the Company's financial condition and business operations. In the U.S., the drug, device and cosmetic industries have long been subject to regulation by various federal and state agencies, primarily as to product safety, efficacy, manufacturing, advertising, labeling and safety reporting. The exercise of broad regulatory powers by the U.S. Food and Drug Administration (the U.S. FDA) continues to result in increases in the amounts of testing and documentation required for U.S. FDA approval of new drugs and devices and a corresponding increase in the expense of product introduction. Similar trends are also evident in major markets outside of the U.S.  The new medical device regulatory framework and the evolving privacy, data localization, and emerging cyber security laws and regulations around the world are examples of such increased regulation. Five U.S. States (California, Connecticut, Colorado, Utah and Virginia) now have comprehensive privacy laws in place and China introduced broad personal information protection and data security regulations in 2022. With other jurisdictions enacting similar privacy laws, local data protection authorities will force greater accountability on the collection, access and use of personal data in the healthcare industry.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">               </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory agencies under whose purview the Company operates have administrative powers that may subject it to actions such as product withdrawals, recalls, seizure of products and other civil and criminal sanctions. In some cases, the Company&#8217;s subsidiaries may deem it advisable to initiate product recalls regardless of whether it has been required or directed to.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">               The U.S. FDA and regulatory agencies around the globe are also increasing their enforcement activities. If the U.S. FDA were to conclude that we are not in compliance with applicable laws or regulations, or that any of our drugs or medical </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">devices are ineffective or pose an unreasonable health risk, the U.S. FDA could ban such products, detain or seize adulterated or misbranded products, order a recall, repair, replacement, or refund of such products, refuse to grant pending applications for marketing authorization or require certificates of foreign governments for exports, and/or require us to notify health professionals and others that the products present unreasonable risks of substantial harm to the public health. The U.S. FDA may also assess civil or criminal penalties against us, our officers or employees and impose operating restrictions on a company-wide basis, or enjoin and/or restrain certain conduct resulting in violations of applicable law. The U.S. FDA may also recommend prosecution to the U.S. Department of Justice. Any adverse regulatory action, depending on its magnitude, may restrict us from effectively marketing and selling our products and limit our ability to obtain future clearances or approvals, and could result in a substantial modification to our business practices and operations. Equivalent enforcement mechanisms exist in different countries in which we conduct business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The costs of human healthcare have been and continue to be a subject of study, investigation and regulation by governmental agencies and legislative bodies around the world. In the U.S., attention has been focused by states, regulatory agencies and Congress on prices, profits, overutilization and the quality and costs of healthcare generally. Laws and regulations have been enacted to require adherence to strict compliance standards and prevent fraud and abuse in the healthcare industry. There is increased focus on interactions and financial relationships between healthcare companies and healthcare providers. Various transparency laws and regulations require disclosures of payments and other transfers of value made to physicians and teaching hospitals and, beginning with disclosures in 2022, to certain non-physician practitioners. Federal and foreign laws governing international business practices require strict compliance with anti-bribery standards and certain prohibitions with respect to payments to any foreign government official. Payers and Pharmacy Benefit Managers (PBMs) have become a more potent force in the market place and increased attention is being paid to drug pricing and appropriate drug and medical device utilization.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our business has been and continues to be affected by federal and state legislation that alters the pricing, coverage, and reimbursement landscape.  At the federal level, in August 2022, President Biden signed into law the Inflation Reduction Act (IRA), which includes provisions that effectively authorize the government to establish prices for certain high-spend single-source drugs and biologics reimbursed by the Medicare program, starting in 2026 for Medicare Part D drugs and 2028 for Medicare Part B drugs.  It is not yet certain which products the federal government will select and subject to government-established prices, or how the federal government will establish prices for selected products, as the IRA specifies a ceiling price but not a minimum price. One or more of our products could be selected and subject to the government-established price.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">The IRA also contains provisions that impose rebates if certain prices increase at a rate that outpaces the rate of inflation, beginning October 1, 2022, for Medicare Part D drugs and January 1, 2023, for Medicare Part B drugs. Separate IRA provisions redesign the Medicare Part D benefit in various ways, including by shifting a greater portion of costs to manufacturers within certain coverage phases and replacing the Part D coverage gap discount program with a new manufacturer discounting program. Failure to comply with IRA provisions may subject manufacturers to various penalties, including civil monetary penalties. The impact of the IRA on our business and the broader pharmaceutical industry remains uncertain, as the federal government has yet to make various IRA implementation decisions.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">Additionally, we expect continued scrutiny on drug pricing and government price reporting from Congress, agencies, and other bodies at the federal and state levels. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:133%">There are a number of additional bills pending in Congress and healthcare reform proposals at the state level that would affect drug pricing, including in the Medicare and Medicaid programs. This changing legal landscape has both positive and negative impacts on the U.S. healthcare industry with much remaining uncertain as to how various provisions of federal and state law, and potential modification or repeal of these laws, will ultimately affect the industry. The IRA and any other federal or state legislative change could affect the pricing and market conditions for our products.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">               </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, business practices in the healthcare industry have come under increased scrutiny, particularly in the U.S., by government agencies and state attorneys general, and resulting investigations and prosecutions carry the risk of significant civil and criminal penalties. Of note is the increased enforcement activity by data protection authorities in various jurisdictions, particularly in the European Union, where significant fines have been levied on companies for data breaches, violations of privacy requirements, and unlawful cross-border data transfers.  In the U.S., the Federal Trade Commission has stepped up enforcement of data privacy with several significant settlements and there have been a material increase in class-action lawsuits linked to the collection and use of biometric data.   </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">               Further, the Company relies on global supply chains, and production and distribution processes, that are complex, are subject to increasing regulatory requirements, and may be faced with unexpected changes such as those resulting from the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 pandemic and Brexit that may affect sourcing, supply and pricing of materials used in the Company's products.  These processes also are subject to complex and lengthy regulatory approvals.</span></div><div><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_49"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employees and Human Capital Management </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of January&#160;1, 2023, and January&#160;2, 2022, the number of employees were approximately:</span></div><div style="padding-left:56.25pt;padding-right:56.25pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:72.368%"><tr><td style="width:1.0%"></td><td style="width:52.031%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.334%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.335%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employees</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">1</span></div></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155,800&#160;</span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144,300&#160;</span></td><td style="border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Full-time equivalent (FTE) positions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">2</span></div></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">152,700&#160;</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,700&#160;</span></td><td style="border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:112.5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:112%;position:relative;top:-2.8pt;vertical-align:baseline">1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8220;Employee&#8221; is defined as an individual working full-time or part-time, excluding fixed term employees, interns and co-op employees. Employee data may not include full population from more recently acquired companies and individuals on long-term disability are excluded. Contingent workers, contractors and subcontractors are also excluded. Abiomed headcount has been included in the above table.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:107%;position:relative;top:-2.8pt;vertical-align:baseline">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%"> FTE represents the total number of full-time equivalent positions and does not reflect the total number of individual employees as some work part-time.</span></div><div style="text-indent:30.35pt"><span><br/></span></div><div style="text-indent:126pt"><img src="jnj-20230101_g1.jpg" alt="jnj-20230101_g1.jpg" style="height:269px;margin-bottom:5pt;vertical-align:text-bottom;width:341px"/></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Strategy </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company believes that its employees are critical to its continued success and are an essential element of its long-term strategy. Management is responsible for ensuring that its policies and processes reflect and reinforce the Company's desired corporate culture, including policies and processes related to strategy, risk management, and ethics and compliance. The Company&#8217;s human capital management strategy is built on three fundamental focus areas:</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Attracting and recruiting the best talent </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Developing and retaining talent </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Empowering and inspiring talent</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Underpinning these focus areas are ongoing efforts to cultivate and foster a culture built on diversity, equity and inclusion (DEI), innovation, health, well-being and safety, where the Company's employees are encouraged to succeed both professionally and personally while helping the Company achieve its business goals.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Culture and Employee Engagement </span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">At the Company, employees are guided by Our Credo which sets forth the Company's responsibilities to patients, consumers, customers, healthcare professionals, employees, communities and shareholders. Employees worldwide must adhere to the Company&#8217;s Code of Business Conduct which </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">sets basic requirements and serves as a foundation for the Company policies, procedures and guidelines, all of which provide additional guidance on expected employee behaviors </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in every market where it operates. The Company c</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">onducts global surveys that offer its employees the ability to provide feedback and valuable insight to help address potential human resources risks and identify opportunities to improve. In 2022, 92% of global employees across 77 countries participated in Our Credo Survey which was offered in 36 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">languages</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="margin-top:6pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Growth and Development </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To continue to lead in the changing healthcare landscape, it is crucial that the Company continue to attract and retain top talent. The Company believes that its employees must be equipped with the right knowledge and skills and be provided with opportunities to grow and develop in their careers. Accordingly, professional development programs and educational resources</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">are available to all employees. The Company's objective is to foster a learning culture that helps shape each person&#8217;s unique career path while creating a robust pipeline of talent to deliver on the Company&#8217;s long-term strategies. In furtherance of this objective, the Company deploys a global approach to ensure development is for everyone, regardless of where they are on their career journey. In 2022, 46.2% of employees in Manager and above job categories who had movements (including upward promotions or lateral transfers) took advantage of career opportunities by moving across functions, country or business segment lines (excluding employees in the research and development organizations). The Company's voluntary turnover rate was 9%.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Diversity, Equity, and Inclusion (DEI)</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is committed to workplace diversity and to cultivating, fostering, and advancing a culture of equity and inclusion. In 2022, Johnson &amp; Johnson introduced the Company&#8217;s evolved enterprise Diversity, Equity and Inclusion strategy, which recognizes how DEI accelerates the Company&#8217;s ability to meet the changing needs of the communities the Company serves to deliver Our Purpose to profoundly change the trajectory of health for humanity. The Company&#8217;s DEI vision is: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Be yourself, change the world.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> The Company&#8217;s DEI Mission is: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Make diversity, equity and inclusion how we work everyday</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Our evolved enterprise DEI Strategy is aligned to our DEI Vision and Mission and rests on four core pillars: </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Accelerate our global culture of inclusion where every individual belongs </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Build a workforce that reflects the diversity of our communities</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Transform talent and business processes to achieve equitable access and outcomes for all</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drive innovation and growth with our business to serve diverse markets around the world </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s DEI strategy is guided by internal and external insights, global best practices and continual employee feedback which remind the Company that while diversity changes by location, inclusion is the same everywhere. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation and Benefits </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of the Company's total rewards philosophy, the Company offers competitive compensation and benefits to attract and retain top talent. The Company is committed to fairness and equitable treatment in its compensation and benefits for employees at all levels. The Company observes legal minimum wage provisions and exceeds them where possible. The Company's total rewards offerings include an array of programs to support its employees' well-being, including annual performance incentive opportunities, pension and retirement savings programs, health and welfare benefits, paid time off, leave programs, flexible work schedules and employee assistance programs. In recognition of the Company&#8217;s commitment to help employees balance their personal and professional responsibilities, the Company extended its paid parental leave benefit globally from 8 to 12 weeks for all eligible employees. In the U.S., the benefit was effective on January 1, 2022, with retroactive coverage for new family additions as of July 1, 2021.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Health, Wellness and Safety </span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company&#8217;s investment in employee health, well-being and safety is built on its conviction that advancing health for humanity starts with advancing the health of its employees. With the right awareness, focus, practices and tools, the Company ensures that all its employees around the world, as well as temporary contractors and visitors to the Company's sites, can work safely. The Company has continuously expanded health and well-being programs throughout the Company and across the globe, incorporating new thinking and technologies to keep its offerings best-in-class and to help employees achieve their personal health goals. The programs and practices the Company advances for total health&#8212;physical, mental, emotional and financial&#8212;ensure employee health protection for emerging health risks. Protecting and supporting our employees as the COVID-19 pandemic has evolved continues to be a top priority and the Company&#8217;s approach includes: ensuring the health and safety of our employees in the workplace through robust layers of protection; enhanced cleaning and access to cleaning supplies and personal protective equipment; supporting employees with benefits and well-being tools. The Company continues to address our employees needs through J&amp;J Flex, a hybrid model that empowers the Company&#8217;s office-based employees to find the right productivity and balance of in-person and remote work.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Available Information </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company&#8217;s main corporate website address is </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.jnj.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. All of the Company&#8217;s SEC filings are also available on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.investor.jnj.com/sec.cfm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as soon as reasonably practicable after having been electronically filed or furnished to the SEC. All SEC filings are also available at the SEC&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.sec.gov</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.  </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investors and the public should note that the Company also announces information at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.factsaboutourprescriptionopioids.com,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.factsabouttalc.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.LTLManagementInformation.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use these websites to communicate with investors and the public about our products, litigation and other matters. It is possible that the information we post to these websites could be deemed to be material information. Therefore, we encourage investors and others interested in the Company to review the information posted to these websites in conjunction with www.jnj.com, the Company's SEC filings, press releases, public conference calls and webcasts.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, the Amended and Restated Certificate of Incorporation, By-Laws, the written charters of the Audit Committee, the Compensation&#160;&amp; Benefits Committee, the Nominating&#160;&amp; Corporate Governance Committee, the Regulatory Compliance &amp; Sustainability Committee, the Science &amp; Technology Committee and any special committee of the Board of Directors and the Company&#8217;s Principles of Corporate Governance, Code of Business Conduct (for employees), Code of Business Conduct&#160;&amp; Ethics for Members of the Board of Directors and Executive Officers, and other corporate governance materials, are available at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">www.investor.jnj.com/gov.cfm </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">on the Company's website and will be provided without charge to any shareholder submitting a written request, as provided above. The information on </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">www.jnj.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">www.factsaboutourprescriptionopioids.com,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">www.factsabouttalc.com </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">www.LTLManagementInformation.com </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">is not, and will not be deemed, a part of this Report or incorporated into any other filings the Company makes with the SEC.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.&#160;&#160;&#160;&#160;RISK FACTORS</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investment in the Company&#8217;s common stock or debt securities involves risks and uncertainties. The Company seeks to identify, manage and mitigate risks to our business, but uncertainties and risks are difficult to predict and many are outside of the Company&#8217;s control and cannot therefore be eliminated. In addition to the other information in this report and the Company&#8217;s other filings with the SEC, investors should consider carefully the factors set forth below. Investors should be aware that it is not possible to predict or identify all such factors and that the following is not meant to be a complete discussion of all potential risks or uncertainties. If known or unknown risks or uncertainties materialize, the Company&#8217;s business, results of operations or financial condition could be adversely affected, potentially in a material way.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Business, Industry and Operations </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company&#8217;s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company&#8217;s earnings.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company faces substantial competition in all three operating segments and in all geographic markets. The Company&#8217;s businesses compete with companies of all sizes on the basis of cost-effectiveness, technological innovations, intellectual property rights, product performance, real or perceived product advantages, pricing and availability and rate of reimbursement. The Company also competes with other market participants in securing rights to acquisitions, collaborations and licensing agreements with third parties. Competition for rights to product candidates and technologies may result in significant investment and acquisition costs and onerous agreement terms for the Company. Competitors&#8217; development of more effective or less costly products, and/or their ability to secure patent and other intellectual property rights and successfully market products ahead of the Company, could negatively impact sales of the Company&#8217;s existing products as well as its ability to bring new products to market despite significant prior investment in the related product development. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the Company&#8217;s Pharmaceutical businesses, loss of patent exclusivity for a product often is followed by a substantial reduction in sales as competitors gain regulatory approval for generic and other competing products and enter the market. Similar competition can be triggered by the loss of exclusivity for a biological product. For the Company&#8217;s MedTech businesses, technological innovation, product quality, reputation and customer service are especially important to competitiveness. Development by other companies of new or improved products, processes and technologies could threaten to make the Company&#8217;s products or technologies less desirable, less economical or obsolete. The Company&#8217;s Consumer Health businesses face intense competition from other branded products and retailers&#8217; private-label brands. If the Company fails to sufficiently differentiate and market its brand name consumer products, this could adversely affect revenues and profitability of those products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interruptions and delays in manufacturing operations could adversely affect the Company&#8217;s business, sales and reputation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s manufacture of products requires the timely delivery of sufficient amounts of complex, high-quality components and materials. The Company&#8217;s subsidiaries operate 89 manufacturing facilities as well as sourcing from thousands of suppliers around the world. The Company has in the past, and may in the future, face unanticipated interruptions and delays in manufacturing through its internal or external supply chain. Manufacturing disruptions can occur for many reasons including regulatory action, production quality deviations or safety issues, labor disputes, labor shortages, site-specific incidents (such as fires), natural disasters such as hurricanes and other severe weather events, raw material shortages, political unrest, terrorist attacks and epidemics or pandemics. Such delays and difficulties in manufacturing can result in product shortages, declines in sales and reputational impact as well as significant remediation and related costs associated with addressing the shortage. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company relies on third parties to manufacture certain of our products. Any failure by or loss of a third-party manufacturer could result in delays and increased costs, which may adversely affect our business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company relies on third parties to manufacture certain of our products. We depend on these third-party manufacturers to allocate to us a portion of their manufacturing capacity sufficient to meet our needs, to produce products of acceptable quality and at acceptable manufacturing yields and to deliver those products to us on a timely basis and at acceptable prices. However, we cannot guarantee that these third-party manufacturers will be able to meet our near-term or long-term manufacturing requirements, which could result in lost sales and have an adverse effect on our business. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks associated with our reliance on third parties to manufacture these products include reliance on the third party for regulatory compliance and quality assurance, misappropriation of the Company&#8217;s intellectual property, limited ability to manage our inventory, possible breach of the manufacturing agreement by the third party and the possible termination or nonrenewal of the manufacturing agreement by the third party at a time that is costly or inconvenient for us. Moreover, if any of our third-party manufacturers suffers any damage to facilities, loses benefits under material agreements, experiences power outages, encounters financial difficulties, is unable to secure necessary raw materials from its suppliers or suffers any other reduction in efficiency, the Company may experience significant business disruption. In the event of any such disruption, the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company would need to seek and source other qualified third-party manufacturers, likely resulting in further delays and increased costs which could affect our business adversely.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our industry continues to be challenged by the vulnerability of distribution channels to illegal counterfeiting and the presence of counterfeit products in a growing number of markets and over the Internet. Third parties may illegally distribute and sell counterfeit versions of our products, which do not meet our rigorous manufacturing and testing standards. To distributors and patients, counterfeit products may be visually indistinguishable from the authentic version. Counterfeit medicines pose a risk to patient health and safety because of the conditions under which they are manufactured </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">&#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">often in unregulated, unlicensed, uninspected and unsanitary sites </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10.5pt;font-weight:400;line-height:115%">&#8211; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">as well as the lack of regulation of their contents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The industry&#8217;s failure to mitigate the threat of counterfeit medicines could adversely impact our business and reputation by impacting patient confidence in our authentic products, potentially resulting in lost sales, product recalls, and an increased threat of litigation. In addition, diversion of our products from their authorized market into other channels may result in reduced revenues and negatively affect our profitability.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Global health crises, pandemics, epidemics, or other outbreaks could adversely disrupt or impact certain aspects of the Company&#8217;s business, results of operations and financial condition.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We are subject to risks associated with global health crises, epidemics, pandemics and other outbreaks (such incident(s), a health crisis or health crises), including the global outbreak of coronavirus and its variants (COVID-19). The COVID-19 pandemic has adversely impacted, and may continue to adversely impact, certain aspects of the Company&#8217;s business, results of operations and financial condition, including lower sales and reduced customer demand and usage of certain of our products. The continued spread of COVID-19 or other health crises may cause the Company to modify its business practices, and take further actions as may be required by government authorities or as the Company determines are in the best interests of our patients, customers, employees and business partners. While the Company has robust business continuity plans in place across our global supply chain network to help mitigate the impact of health crises, these efforts may not completely prevent our business from being adversely affected and future impacts remain uncertain. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While the U.S. and other countries have substantially reopened their economies, the extent to which COVID-19, or other health crises, could impact the Company&#8217;s future operations will depend on many factors which cannot be predicted with confidence, including the duration of an outbreak and impact of variants. A surge in COVID-19 or other health crises could result in the imposition of new mandates and prolonged restrictive measures implemented in order to control the spread of disease. The global spread of COVID-19 or other health crises could adversely impact the Company&#8217;s operations, including, among other things, our manufacturing operations, supply chain, third-party suppliers, sales and marketing, and clinical trial operations. Any of these factors could adversely affect the Company&#8217;s business, financial results, and global economic conditions generally.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We also face uncertainties related to our vaccine development programs, including uncertainties related to the risk that our continued development programs may not be successful, commercially viable or receive approval from regulatory authorities; risks associated with clinical trial and real-world data, including further analyses of its efficacy, safety and durability; the risk that continued evolution and mutation of disease and the duration of a particular outbreak may impede our ability to conduct trials within a specified time frame; the risk that data are subject to differing interpretations and assessments, including during the peer review/publication process, in the scientific community generally, and by national immunization technical advisory groups (NITAGs) and regulatory authorities; disruptions in the relationships between us, our third-party suppliers, external manufacturers, and other third parties with whom we engage; the risk that other companies may produce superior or competitive products; the risk that demand for any products we may develop may no longer exist; risks related to the availability of raw materials to manufacture any such products; the risk that we may not be able to recoup costs associated with our R&amp;D and manufacturing efforts and risks associated with any changes in the way we approach or provide additional research funding for potential drug development; the risk that we may not be able to create or scale up manufacturing capacity on a timely basis, that we may continue to experience manufacturing delays once a manufacturing site is activated, or have access to logistics or supply channels commensurate with global demand for any potential approved vaccine or product candidate, which would negatively impact our ability to supply the estimated numbers of doses of our vaccine within the projected time periods indicated, and other challenges and risks associated with the pace of our vaccine development program; and pricing and access challenges for such products, including in the U.S.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Government Regulation and Legal Proceedings</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global sales in the Company&#8217;s Pharmaceutical and MedTech segments may be negatively impacted by healthcare reforms and increasing pricing pressures.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of the Company&#8217;s Pharmaceutical and MedTech products are significantly affected by reimbursements by third-party payers such as government healthcare programs, private insurance plans and managed care organizations. As part of various efforts to contain healthcare costs, these payers are putting downward pressure on prices at which products will be reimbursed. In the U.S., increased purchasing power of entities that negotiate on behalf of Medicare, Medicaid, and private sector beneficiaries, in part due to continued consolidation among healthcare providers, could result in further pricing pressures. In addition, recent legislation and ongoing political scrutiny or pricing, coverage and reimbursement could result in additional pricing pressures. Specifically, the Inflation Reduction Act of 2022 (IRA) may subject certain products to government-established pricing, potentially impose rebates, and subject manufacturers who fail to adhere to the government's interpretations of the law to penalties. Outside the U.S., numerous major markets, including the EU, United Kingdom, Japan and China, have pervasive government involvement in funding healthcare and, in that regard, directly or indirectly impose price controls, limit access to, or reimbursement for, the Company&#8217;s products, or reduce the value of its intellectual property protection.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the ordinary course of business, Johnson &amp; Johnson and its subsidiaries are subject to numerous claims and lawsuits involving various issues such as product liability, patent disputes and claims that their product sales, marketing and pricing practices violate various antitrust, unfair trade practices and/or consumer protection laws. The Company&#8217;s more significant legal proceedings are described in Note 19, &#8220;Legal Proceedings&#8221; under Notes to the Consolidated Financial Statements included in Item 8 of this Report. Litigation, in general, and securities, derivative action, class action and multi-district litigation, in particular, can be expensive and disruptive. Some of these matters may include thousands of plaintiffs, may involve parties seeking large and/or indeterminate amounts, including punitive or exemplary damages, and may remain unresolved for several years. For example, the Company is a defendant in numerous lawsuits arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S Baby Powder, and the Company&#8217;s sale, manufacturing and marketing of opioids.</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">While the Company believes it has substantial defenses in these matters, it is not feasible to predict the ultimate outcome of litigation. The Company could in the future be required to pay significant amounts as a result of settlements or judgments in these matters, potentially in excess of accruals, including matters where the Company could be held jointly and severally liable among other defendants. The resolution of, or increase in accruals for, one or more of these matters in any reporting period could have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period. The Company does not purchase third-party product liability insurance; however, the Company utilizes a wholly owned captive insurance company subject to certain limits.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concerns about product safety, whether raised internally or by litigants, regulators or consumer advocates, and whether or not based on scientific evidence, can result in safety alerts, product recalls, governmental investigations, regulatory action on the part of the U.S. Food and Drug Administration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(or its counterpart in other countries), private claims and lawsuits, payment of fines and settlements, declining sales and reputational damage. These circumstances can also result in damage to brand image, brand equity and consumer trust in the Company&#8217;s products. Product recalls have in the past, and could in the future, prompt government investigations and inspections, the shutdown of manufacturing facilities, continued product shortages and related sales declines, significant remediation costs, reputational damage, possible civil penalties and criminal prosecution. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company faces significant regulatory scrutiny, which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Like other companies in the healthcare industry, the Company is subject to extensive regulation, investigations and legal action by national, state and local government agencies in the U.S. and other countries in which it operates. Regulatory issues regarding compliance with current Good Manufacturing Practices (cGMP) (and comparable quality regulations in foreign countries) by manufacturers of drugs, devices and consumer products can lead to fines and penalties, product recalls, product shortages, interruptions in production, delays in new product approvals and litigation. In addition, the marketing, pricing and sale of the Company&#8217;s products are subject to regulation, investigations and legal actions including under the Federal Food, Drug, and Cosmetic Act, the Medicaid Rebate Program, federal and state false claims acts, state unfair trade practices acts and consumer protection laws. Scrutiny of healthcare industry business practices by government agencies and state attorneys general in the U.S., and any resulting investigations and prosecutions, carry risk of significant civil and criminal penalties including, but not limited to, debarment from participation in government healthcare programs. Any such debarment could have a material adverse effect on the Company&#8217;s business and results of operations. The most significant current investigations and litigation brought by government agencies are described in Note 19, &#8220;Legal Proceedings&#8212;Government Proceedings&#8221; under Notes to the Consolidated Financial Statements included in Item 8 of this Report. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company&#8217;s operating results.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in tax laws or regulations around the world, including in the U.S. and as led by the Organization for Economic Cooperation and Development, such as the recent adoption by the EU, enactment by South Korea and the anticipated enactment </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by additional countries of a global minimum tax, could negatively impact the Company&#8217;s effective tax rate and results of operations. A change in statutory tax rate or certain international tax provisions in any country would result in the revaluation of the Company&#8217;s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted. This change would result in an expense or benefit recorded to the Company&#8217;s Consolidated Statement of Earnings. The Company closely monitors these proposals as they arise in the countries where it operates. Changes to tax laws or regulations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 8, &#8220;Income Taxes&#8221; under Notes to the Consolidated Financial Statements included in Item 8 of this Report for additional information. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company conducts business and files tax returns in numerous countries and is addressing tax audits and disputes with many tax authorities. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. The Company regularly assesses the likely outcomes of its tax audits and disputes to determine the appropriateness of its tax reserves. However, any tax authority could take a position on tax treatment that is contrary to the Company&#8217;s expectations, which could result in tax liabilities in excess of reserves.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Our Intellectual Property </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company faces increased challenges to intellectual property rights central to its business.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company owns or licenses a significant number of patents and other proprietary rights relating to its products and manufacturing processes. These rights are essential to the Company&#8217;s businesses and materially important to the Company&#8217;s results of operations. Public policy, both within and outside the U.S., has become increasingly unfavorable toward intellectual property rights. The Company cannot be certain that it will obtain adequate patent protection for new products and technologies in the United States and other important markets or that such protections, once granted, will last as long as originally anticipated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Competitors routinely challenge the validity or extent of the Company&#8217;s owned or licensed patents and proprietary rights through litigation, interferences, oppositions and other proceedings, such as inter partes review (IPR) proceedings before the United States Patent &amp; Trademark Office (USPTO). These proceedings absorb resources and can be protracted as well as unpredictable. In addition, challenges that the Company&#8217;s products infringe the patents of third parties could result in an injunction and/or the need to pay past damages and future royalties and adversely affect the competitive position and sales of the products in question. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company has faced increasing patent challenges from third parties seeking to manufacture and market generic and biosimilar versions of the Company&#8217;s key pharmaceutical products prior to expiration of the applicable patents covering those products. In the U.S., manufacturers of generic versions of innovative human pharmaceutical products may challenge the validity, or claim non-infringement, of innovator products through the Abbreviated New Drug Application, or ANDA, process with the U.S. FDA and related ANDA litigation. The Biologics Price Competition and Innovation Act (BPCIA), enacted in 2010, which created a new regulatory pathway for the approval by the U.S. FDA of biosimilar alternatives to innovator-developed biological products, also created mechanisms for biosimilar applicants to challenge the patents on the innovator biologics. The IPR process with the USPTO is also being used by competitors to challenge patents asserted in litigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the event the Company is not successful in defending its patents against such challenges, or upon the &#8220;at-risk&#8221; launch by the generic or biosimilar firm of its product, the Company can lose a major portion of revenues for the referenced product in a very short period of time. Current legal proceedings involving the Company&#8217;s patents and other intellectual property rights are described in Note 19, &#8220;Legal Proceedings&#8212;Intellectual Property&#8221; under Notes to the Consolidated Financial Statements included in Item 8 of this Report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Product Development, Regulatory Approval and Commercialization</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Significant challenges or delays in the Company&#8217;s innovation and development of new products, technologies and indications could have an adverse impact on the Company&#8217;s long-term success.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s continued growth and success depends on its ability to innovate and develop new and differentiated products and services that address the evolving healthcare needs of patients, providers and consumers. Development of successful products and technologies is also necessary to offset revenue losses when the Company&#8217;s existing products lose market share due to various factors such as competition and loss of patent exclusivity. New products introduced within the past five years </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounted for approximately 25% of 2022 sales. The Company cannot be certain when or whether it will be able to develop, license or otherwise acquire companies, products and technologies, whether particular product candidates will be granted regulatory approval, and, if approved, whether the products will be commercially successful.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company pursues product development through internal research and development as well as through collaborations, acquisitions, joint ventures and licensing or other arrangements with third parties. In all of these contexts, developing new products, particularly pharmaceutical and biotechnology products and medical devices, requires significant investment of resources over many years. Only a very few biopharmaceutical research and development programs result in commercially viable products. The process depends on many factors including the ability to: discern patients&#8217; and healthcare providers&#8217; future needs; develop promising new compounds, strategies and technologies; achieve successful clinical trial results; secure effective intellectual property protection; obtain regulatory approvals on a timely basis; and, if and when they reach the market, successfully differentiate the Company&#8217;s products from competing products and approaches to treatment. New products or enhancements to existing products may not be accepted quickly or significantly in the marketplace due to product and price competition, changes in customer preferences or healthcare purchasing patterns, resistance by healthcare providers or uncertainty over third-party reimbursement. Even following initial regulatory approval, the success of a product can be adversely impacted by safety and efficacy findings in larger real-world patient populations, as well as market entry of competitive products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Risks Related to Financial and Economic Market Conditions</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The Company faces a variety of financial, economic, legal, social and political risks associated with conducting business internationally</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s extensive operations and business activity throughout the world are accompanied by certain financial, economic, legal, social and political risks, including those listed below. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Exchange</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In fiscal 2022, approximately 49% of the Company&#8217;s sales occurred outside of the U.S., with approximately 25% in Europe, 6% in the Western Hemisphere, excluding the U.S., and 18%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the Asia-Pacific and Africa region. Changes in non-U.S. currencies relative to the U.S. dollar impact the Company&#8217;s revenues and expenses. While the Company uses financial instruments to mitigate the impact of fluctuations in currency exchange rates on its cash flows, unhedged exposures continue to be subject to currency fluctuations. In addition, the weakening or strengthening of the U.S. dollar may result in significant favorable or unfavorable translation effects when the operating results of the Company&#8217;s non-U.S. business activity are translated into U.S. dollars. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inflation and Currency Devaluation Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company faces challenges in maintaining profitability of operations in economies experiencing high inflation rates. Specifically, the Company has accounted for operations in Argentina, Turkey and Venezuela as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. While the Company strives to maintain profit margins in these areas through cost reduction programs, productivity improvements and periodic price increases, it might experience operating losses as a result of continued inflation. In addition, the impact of currency devaluations in countries experiencing high inflation rates or significant currency exchange fluctuations could negatively impact the Company&#8217;s operating results. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Illegal Importation of Pharmaceutical Products</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The illegal importation of pharmaceutical products from countries where government price controls or other market dynamics result in lower prices may adversely affect the Company&#8217;s sales and profitability in the U.S. and other countries in which the Company operates. With the exception of limited quantities of prescription drugs for personal use, foreign imports of pharmaceutical products are illegal under current U.S. law. However, the volume of illegal imports continues to rise as the ability of patients and other customers to obtain the lower-priced imports has grown significantly.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Anti-Bribery and Other Regulations: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to various federal and foreign laws that govern its international business practices with respect to payments to government officials. Those laws include the U.S. Foreign Corrupt Practices Act (FCPA), which prohibits U.S. publicly traded companies from promising, offering, or giving anything of value to foreign officials with the corrupt intent of influencing the foreign official for the purpose of helping the Company obtain or retain business or gain any improper advantage. The Company&#8217;s business is heavily regulated and therefore involves significant interaction with foreign officials. Also, in many countries outside the U.S., the healthcare providers who prescribe human pharmaceuticals are employed by the government and the purchasers of human pharmaceuticals are government entities; therefore, the Company&#8217;s interactions with these prescribers and purchasers are subject to regulation under the FCPA. In addition to the U.S. application and enforcement of the FCPA, various jurisdictions in which the Company operates have laws </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and regulations, including the U.K. Bribery Act 2010, aimed at preventing and penalizing corrupt and anticompetitive behavior. Enforcement activities under these laws could subject the Company to additional administrative and legal proceedings and actions, which could include claims for civil penalties, criminal sanctions, and administrative remedies, including exclusion from healthcare programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Financial, Economic, Legal, Social and Political Risks</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Other risks inherent in conducting business globally include:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">local and regional economic environments and policies in the markets that we serve, including interest rates, monetary policy, inflation, economic growth, recession, commodity prices, and currency controls or other limitations on the ability to expatriate cash; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">protective economic policies taken by governments, such as trade protection measures and import/export licensing requirements; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">compliance with local regulations and laws including, in some countries, regulatory requirements restricting the Company&#8217;s ability to manufacture or sell its products in the relevant market; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">diminished protection of intellectual property and contractual rights in certain jurisdictions;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">potential nationalization or expropriation of the Company&#8217;s foreign assets; </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">political or social upheavals, economic instability, repression, or human rights issues; and </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">geopolitical events, including natural disasters, disruptions to markets due to war, armed conflict, terrorism, epidemics or pandemics.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to maintain a satisfactory credit rating could adversely affect our liquidity, capital position, borrowing costs and access to capital markets.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently maintain investment grade credit ratings with Moody&#8217;s Investors Service and Standard &amp; Poor&#8217;s Ratings Services. Rating agencies routinely evaluate us, and their ratings of our long-term and short-term debt are based on a number of factors. Any downgrade of our credit ratings by a credit rating agency, whether as a result of our actions or factors which are beyond our control, can increase the cost of borrowing under any indebtedness we may incur, reduce market capacity for our commercial paper or require the posting of additional collateral under our derivative contracts. There can be no assurance that we will be able to maintain our credit ratings, and any additional actual or anticipated changes or downgrades in our credit ratings, including any announcement that our ratings are under review for a downgrade, may have a negative impact on our liquidity, capital position and access to capital markets. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The Russia-Ukraine War, and actions taken in response to the Russia-Ukraine War, could adversely affect our business, results of operations or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2022, Russia launched a military invasion of Ukraine. The ongoing Russia-Ukraine War has provoked strong reactions from the United States, the United Kingdom, the European Union and various other countries and economic and political organizations around the world. We have been monitoring the geopolitical situation in Russia since the start of the Russia-Ukraine War and have suspended additional investment, enrollment of clinical trials, and supply of our personal care products in Russia. We continue to monitor the need for humanitarian relief in the region and continue to supply our medicines, medical devices and equipment in the region in compliance with the applicable sanctions. We will continue to monitor the geopolitical situation in Russia and to evaluate our activities and future operations in Russia. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Actions taken in response to the Russia-Ukraine War include the imposition of export controls and broad financial and economic sanctions against Russia, Belarus and specific areas of Ukraine. Additional sanctions or other measures may be imposed by the global community, including but not limited to limitations on our ability to file, prosecute and maintain patents, trademarks and other intellectual property rights. Furthermore, the Russian government has already taken action allowing Russian companies and individuals to exploit inventions owned by patent holders from the United States and many other countries without consent or compensation and we may not be able to prevent third parties from practicing our inventions in Russia or from selling or importing products in and into Russia.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have experienced, and expect to continue to experience, other risks related to the broad economic consequences of the Russia-Ukraine War, including foreign currency volatility, decreased demand for our products in countries affected by the Russia-Ukraine War and challenges to our global supply chain related to increased costs of materials and other inputs for our products and suppliers operating in Russia and Ukraine. We also continue to monitor the various sanctions and export controls imposed in response to the Russia-Ukraine War.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The full impact of the Russia-Ukraine War, and actions taken in response to the ongoing conflict, on the global economy and geopolitical relations, in general, and on our business in particular, remain uncertain. Any or all of the foregoing risks could </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">have an adverse effect on our business, results of operations or financial condition, particularly as the conflict continues for an indefinite period of time. Given that developments concerning the Russia-Ukraine War are ongoing and have been constantly evolving, additional impacts and risks may arise that are not presently known to us. The Russia-Ukraine War may also have the effect of heightening many of the other risks described in this &#8220;Risk Factors&#8221; section.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to the Planned Separation of our Consumer Health Business</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">The planned separation of the Company&#8217;s Consumer Health business may not be completed on the terms or timeline currently contemplated, if at all, and may not achieve the expected results.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In November 2021, the Company announced its intention to separate the Company&#8217;s Consumer Health business, with the intention to create a standalone publicly traded company, which was subsequently named Kenvue, Inc. ("Kenvue"). The planned separation is intended to qualify as a tax-free transaction for U.S. federal income tax purposes. The Company is targeting completion of the planned separation in 2023. Completion of the planned separation will be subject to the satisfaction of certain conditions, including, among others, consultations with works councils and other employee representative bodies, as required, final approval by the Company&#8217;s Board of Directors, the continuing effectiveness and validity of the Company's private letter ruling from the Internal Revenue Service (&#8220;IRS&#8221;) and receipt of favorable opinions of the Company's U.S. tax advisors with respect to the tax-free nature of the transaction, and the receipt of other regulatory approvals. There can be no assurance regarding the ultimate timing of the planned separation or that such separation will be completed. Unanticipated developments could delay, prevent or otherwise adversely affect the planned separation, including but not limited to disruptions in general or financial market conditions or potential problems or delays in obtaining various regulatory and tax approvals or clearances.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The costs to complete the planned separation will be significant. In addition, the Company may be unable to achieve some or all of the strategic and financial benefits that it expects to achieve from the planned separation of the Company&#8217;s Consumer Health business.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has incurred, and is expected to incur, significant expenses in connection with the planned separation. In addition, the Company may not be able to achieve the full strategic and financial benefits that are expected to result from the planned separation. The anticipated benefits of the planned separation are based on a number of assumptions, some of which may prove incorrect.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Following the planned separation, the price of shares of the Company&#8217;s common stock may fluctuate significantly.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company cannot predict the effect of the planned separation on the trading price of shares of its common stock, and the market value of shares of its common stock may be less than, equal to or greater than the market value of shares of its common stock prior to the planned separation. In addition, the price of the Company&#8217;s common stock may be more volatile around the time of the planned separation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">The planned separation could result in substantial tax liability.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has received a private letter ruling from the IRS as to the tax-free nature of the planned separation under the U.S. Internal Revenue Code of 1986, as amended. The planned separation is conditioned on, among other things, the continuing effectiveness and validity of the Company's private letter ruling from the IRS and receipt of favorable opinions of the Company's U.S. tax advisors. The private letter ruling and opinions will be based on, among other things, various facts, assumptions, representations and undertakings from the Company and Kenvue regarding the past and future conduct of the companies&#8217; respective businesses and other matters. If any of these facts, assumptions, representations or undertakings are incorrect or not otherwise satisfied, the Company and its shareholders may not be able to rely on the ruling or the opinions of tax advisors. Notwithstanding the private letter ruling and opinions of tax advisors, if subsequent to the planned separation the IRS determines that certain steps of the transaction do not qualify for tax-free treatment for U.S. federal income tax purposes, the resulting tax liability to the Company and its shareholders could be substantial.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The planned separation may also not qualify for tax-free treatment in other countries around the world, and as a result may trigger substantial tax liability to the Company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Risks </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business depends on our ability to recruit and retain talented, highly skilled employees and a diverse workforce. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our continued growth requires us to recruit and retain talented employees representing diverse backgrounds, experiences, and skill sets. The market for highly skilled workers and leaders in our industry is extremely competitive and our ability to compete depends on our ability to hire, develop and motivate highly skilled personnel in all areas of our organization. Maintaining our brand and reputation, as well as a diverse, equitable and inclusive work environment enables us to attract top talent. If we are less successful in our recruiting efforts, or if we cannot retain highly skilled workers and key leaders, our ability to develop and deliver successful products and services may be adversely affected. In addition, effective succession planning is important to our long-term success. Any unsuccessful implementation of our succession plans or failure to ensure effective transfer of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">knowledge and smooth transitions involving key employees could</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">adversely affect our business, financial condition, or results of operations.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Climate change or legal, regulatory or market measures to address climate change may negatively affect our business and results of operations.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Climate change resulting from increased concentrations of carbon dioxide and other greenhouse gases in the atmosphere could present risks to our operations, including an adverse impact on global temperatures, weather patterns and the frequency and severity of extreme weather and natural disasters. Natural disasters and extreme weather conditions, such as a hurricane, tornado, earthquake, wildfire or flooding, may pose physical risks to our facilities and disrupt the operation of our supply chain. The impacts of the changing climate on water resources may result in water scarcity, limiting our ability to access sufficient high-quality water in certain locations, which may increase operational costs. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concern over climate change may also result in new or additional legal or regulatory requirements designed to reduce greenhouse gas emissions and/or mitigate the effects of climate change on the environment. If such laws or regulations are more stringent than current legal or regulatory obligations, we may experience disruption in, or an increase in the costs associated with sourcing, manufacturing and distribution of our products, which may adversely affect our business, results of operations or financial condition. Further, the impacts of climate change have an influence on customer preferences, and failure to provide climate-friendly products could potentially result in loss of market share.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">An information security incident, including a cybersecurity breach, could have a negative impact to the Company&#8217;s business or reputation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To meet business objectives, the Company relies on both internal information technology (IT) systems and networks, and those of third parties and their vendors, to process and store sensitive data, including confidential research, business plans, financial information, intellectual property, and personal data that may be subject to legal protection, and ensure the continuity of the Company&#8217;s supply chain. The extensive information security and cybersecurity threats, which affect companies globally, pose a risk to the security and availability of these systems and networks, and the confidentiality, integrity, and availability of the Company&#8217;s sensitive data. The Company continually assesses these threats and makes investments to increase internal protection, detection, and response capabilities, as well as ensure the Company&#8217;s third-party providers have required capabilities and controls, to address this risk</span><span style="color:#00b050;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not experienced any material impact to the business or operations resulting from information or cybersecurity attacks; however, because of the frequently changing attack techniques, along with the increased volume and sophistication of the attacks, there is the potential for the Company to be adversely impacted. This impact could result in reputational, competitive, operational or other business harm as well as financial costs and regulatory action. The Company maintains cybersecurity insurance in the event of an information security or cyber incident; however, the coverage may not be sufficient to cover all financial, legal, business or reputational losses.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As a result of the Russia-Ukraine War, there has been, and we expect there will continue to be, an increased risk of information security or cybersecurity incidents, including cyberattacks perpetrated by Russia or others at its direction. Although we have taken steps to enhance our protections against these attacks, we may not be able to address the threat of information security or cybersecurity incidents proactively or implement adequate preventative measures and we may not be able to detect and address any such disruption or security breach promptly, or at all, which could adversely affect our business, results of operations or financial condition. Moreover, we are aware of incidents in which our third-party partners have been the target of information security or cybersecurity incidents as a result of the Russia-Ukraine War. Although, to date, our IT Systems have not been compromised by these incidents, it is possible that future information security or cybersecurity incidents involving our customers, manufacturers, suppliers or other third-party partners could successfully compromise our IT Systems, which could adversely affect our business, results of operations or financial condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">A breach of privacy laws or unauthorized access, loss or misuse of personal data could have a negative impact to the Company&#8217;s business or reputation.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company is subject to privacy and data protection laws across the globe that impose broad compliance obligations on the collection, use, storage, access, transfer and protection of personal data. Breach of such requirements could result in substantial fines, penalties, private right of actions, claims and damage to our reputation and business. New privacy laws are expected in other territories, together with greater privacy enforcement by governmental authorities globally, particularly on data localization requirements and international data flows. The Company has established privacy compliance programs and controls that our businesses worldwide are required to comply with, but with many technology and data-driven initiatives being prioritized across the Company and involving multiple vendors and third parties, there are potential risks of controls imposed on cross border data flows, unauthorized access, and loss of personal data through internal and external threats that could impact our business operations and research activities. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:10pt;margin-top:6pt;padding-left:36pt;text-indent:18pt"><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_58"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.36pt">UNRESOLVED STAFF COMMENTS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Not applicable.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.02pt">PROPERTIES</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's subsidiaries operate 89 manufacturing facilities occupying approximately 14.9&#160;million square feet of floor space. The manufacturing facilities are used by the industry segments of the Company&#8217;s business approximately as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:81.916%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.152%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt;text-indent:-4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Segment</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Square Feet<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,562&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,948&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Within the U.S., four facilities are used by the Consumer Health segment, five by the Pharmaceutical segment and 19 by the MedTech segment. Outside of the U.S., 23 facilities are used by the Consumer Health segment, 13 by the Pharmaceutical segment and 25 by the MedTech segment. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The locations of the manufacturing facilities by major geographic areas of the world are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Geographic Area</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Facilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Square Feet<br/>(in thousands)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,169&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,016&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere, excluding U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Africa, Asia and Pacific</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,030&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,948&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition to the manufacturing facilities discussed above, the Company maintains numerous office and warehouse facilities throughout the world. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company's subsidiaries generally seek to own, rather than lease, their manufacturing facilities, although some, principally in non-U.S. locations, are leased. Office and warehouse facilities are often leased. The Company also engages contract manufacturers.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company is committed to maintaining all of its properties in good operating condition.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;&#160;&#160;&#160;Segment information on additions to property, plant and equipment is contained in Note&#160;17 &#8220;Segments of Business and Geographic Areas&#8221; of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div id="i51a46167ef364951bf70ae9d6493776c_64"></div><div style="margin-top:9pt;padding-left:54pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">LEGAL PROCEEDINGS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the information set forth in Note&#160;19 &#8220;Legal Proceedings&#8221; of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div id="i51a46167ef364951bf70ae9d6493776c_67"></div><div style="padding-left:54pt"><span><br/></span></div><div style="padding-left:54pt;text-indent:-58.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:28.52pt">MINE SAFETY DISCLOSURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_70"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE OFFICERS OF THE REGISTRANT</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Listed below are the executive officers of the Company. There are no family relationships between any of the executive officers, and there is no arrangement or understanding between any executive officer and any other person pursuant to which the executive officer was selected. At the annual meeting of the Board of Directors, the executive officers are elected by the Board to hold office for one year and until their respective successors are elected and qualified, or until earlier resignation or removal.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Information with regard to the directors of the Company is incorporated herein by reference to the material captioned &#8220;Item 1. Election of Directors&#8221; in the Proxy Statement.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:33.701%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.158%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:58.373%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Position</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Vanessa Broadhurst</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Global Corporate Affairs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board; Chief Executive Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(b)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter M. Fasolo, Ph.D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Chief Human Resources Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(c)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Elizabeth Forminard</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, General Counsel</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(d)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">William N. Hait, M.D., Ph. D.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Chief External Innovation and Medical Safety Officer; Interim Head Janssen R&amp;D</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(e)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ashley McEvoy</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Worldwide Chairman, MedTech</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(f)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thibaut Mongon</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee, Executive Vice President, Worldwide Chairman, Consumer Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(g)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">James Swanson</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Chief Information Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(h)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Jennifer L. Taubert</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Worldwide Chairman, Pharmaceuticals</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(i)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Kathryn E. Wengel</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Chief Technical Operations &amp; Risk Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(j)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Member, Executive Committee; Executive Vice President, Chief Financial Officer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(k)</span></div></td></tr></table></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Ms. V. Broadhurst joined the Company in 2005 as Worldwide Vice President, Anemia &amp; Oncology Supportive Care. She then went on to become Vice President of the Cardiovascular &amp; Institutional Franchise in 2008, and President of Janssen Therapeutics in 2011 before becoming U.S. President, Internal Medicine in 2012. From 2013 to 2017, she held General Manager roles at Amgen in Inflammation &amp; Cardiovascular, and Cardiovascular &amp; Bone. In 2017, Ms. Broadhurst rejoined Johnson &amp; Johnson as U.S. President, Cardiovascular &amp; Metabolism and a member of the Janssen Americas Leadership Team. In this role she also provided operational oversight of the full portfolio of Janssen medicines in Puerto Rico and Canada. In 2018, she was appointed Company Group Chairman, Global Commercial Strategy Organization. In 2022, Ms. Broadhurst was named Executive Vice President, Global Corporate Affairs and a member of the Executive Committee, leading the Company's global marketing, communication, Global Public Health and philanthropy functions.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Mr. J. Duato became Chairman of the Board of Directors in January 2023 subsequent to his appointment as Chief Executive Officer and a Director in January 2022. He joined the Company in 1989 with Janssen-Farmaceutica S.A. (Spain), a subsidiary of the Company, and held executive positions of increasing responsibility in all business sectors and across multiple geographies and functions. In 2009, he was named Company Group Chairman, Pharmaceuticals, and in 2011, he was named Worldwide Chairman, Pharmaceuticals. In 2016, Mr. Duato became a member of the Executive Committee and was named Executive Vice President, Worldwide Chairman, Pharmaceuticals. In July 2018, Mr. Duato was promoted to Vice Chairman of the Executive Committee, where he provided strategic direction for the Pharmaceutical and Consumer Health sectors and oversaw both the Global Supply Chain, Information Technology and Health &amp; Wellness teams. As a dual citizen of Spain and the United States, Mr. Duato's international perspective and global lens gives him a deep appreciation of diverse thoughts and opinions.  </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Dr.&#160;P. M. Fasolo joined the Company in 2004 as Worldwide Vice President, Human Resources in the MedTech segment, and subsequently served as the Company&#8217;s Chief Talent Officer. He left Johnson &amp; Johnson in 2007 to join Kohlberg Kravis Roberts &amp; Co. as Chief Talent Officer. Dr. Fasolo returned to the Company in 2010 as the Vice President, Global Human Resources, and in 2011, he became a member of the Executive Committee. In April 2016, he was named Executive Vice President, Chief Human Resources Officer. Dr. Fasolo has responsibility for global talent, recruiting, diversity, compensation, benefits, employee relations and all aspects of the human resources agenda for the Company. He also serves on the Boards of the Human Resources Policy Association, Tufts University and Save the Children and was named a Fellow of the National Academy of Human Resources in 2017.  </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:24.34pt">Ms. Elizabeth Forminard joined the Company in 2006 as Vice President, Law, Consumer Healthcare Global Business Unit and continued to serve in roles of increasing responsibility. In 2012, she was promoted to General Counsel, Medical Devices &amp; Diagnostics and became General Counsel, Consumer Group &amp; Supply Chain in 2013. She was appointed Worldwide Vice President, Corporate Governance in 2016. From 2019 to 2022, she served as General Counsel, Pharmaceuticals. In October 2022, she was named Executive Vice President, General Counsel and became a member of the Executive Committee. Ms. Forminard has worldwide responsibility for the legal and privacy functions, and leads the development and execution of the Company's environment, social and governance strategy.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.91pt">Dr. W. Hait joined the Company in 2007 as Senior Vice President, Worldwide Head of Oncology Research. He then served as the first Global Therapeutic Area Head for Oncology from 2009 to 2011, and then as Global Head, Janssen Research &amp; Development from 2011 through 2018. From 2018 to 2022, he was Global Head, Johnson &amp; Johnson Global External Innovation. In 2022, he became Executive Vice President, Chief External Innovation, Medical Safety and Global Public Health Officer, and a member of the Executive Committee. He is responsible for leading external sourcing and creation of transformational innovation to help Johnson &amp; Johnson achieve its mission to improve human health utilizing the Company&#8217;s excellence in pharmaceuticals, medical devices and consumer products. He also has oversight over Global Public Health and the Office of the Chief Medical Officer. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As Interim Head of Janssen R&amp;D, Dr. Hait's mission is to focus the best research and development teams in the world at the intersection of unmet medical need and breakthroughs in science and technology to make medicines with benefit for patients worldwide. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.01pt">Ms. A. McEvoy joined the Company in 1996 as Assistant Brand Manager of McNeil Consumer Health, a subsidiary of the Company, advancing through positions of increasing responsibilities until she was appointed Company Group Chairman, Vision Care in 2012, followed by Company Group Chairman, Consumer Medical Devices in 2014. In July 2018, Ms. McEvoy was promoted to Executive Vice President, Worldwide Chairman, MedTech, and became a member of the Executive Committee. Ms. McEvoy has responsibility for the surgery, orthopaedics, interventional solutions and eye health businesses across Ethicon, DePuy Synthes, Biosense Webster, Abiomed, and Johnson &amp; Johnson Vision.</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(g)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.18pt">Mr. T. Mongon joined the Company in 2000 as Director of Marketing for the Vision Care group in France and subsequently held positions of increasing responsibility until he transitioned to the Pharmaceutical sector in 2012, as the Global Commercial Strategy Leader for the Neuroscience therapeutic area. In 2014, he joined the Consumer Health sector as Company Group Chairman Asia-Pacific. In 2019, he was promoted to Executive Vice President and Worldwide Chairman, Consumer Health, and became a member of the Executive Committee. Mr. Mongon has responsibility for  the global development of Johnson &amp; Johnson&#8217;s health and wellness products and solutions in beauty, OTC, oral care, baby care, women&#8217;s health, and wound care.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Mr. J. Swanson rejoined the Company in 2019 as Chief Information Officer of Johnson &amp; Johnson from Bayer Crop Science, where he served as a member of the Executive Leadership Team and as CIO and Head of Digital Transformation. From 1996 to 2005, Mr. Swanson held positions of increasing responsibility at the Company, including Project Manager, Director IT, Sr. Director IT and Vice President, Chief Information Officer. Mr. Swanson is responsible for enhancing Johnson &amp; Johnson&#8217;s business impact and shaping its direction through the strategic use of technology. Mr. Swanson, Executive Vice President, Enterprise Chief Information Officer, joined the Executive Committee effective January 3, 2022.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:26.57pt">Ms. J. L. Taubert joined the Company in 2005 as Worldwide Vice President, and she held several executive positions of increasing responsibility in the Pharmaceutical sector. In 2012, she was appointed Company Group Chairman, North America Pharmaceuticals, and in 2015 became Company Group Chairman, The Americas, Pharmaceuticals. In July 2018, Ms. Taubert was promoted to Executive Vice President, Worldwide Chairman, Pharmaceuticals, and became a member of the Executive Committee. Ms. Taubert is responsible for the Pharmaceutical sector globally, including shaping the company&#8217;s strategy of transformational medical innovation and for successfully bringing to market critical new medicines that significantly improve the lives of patients living with cancer, immune-related diseases, cardiovascular disease, infectious diseases, pulmonary hypertension and serious mental illness. </span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(j)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:26.57pt">Ms. K. E. Wengel joined the Company in 1988 as Project Engineer and Engineering Supervisor at Janssen, a subsidiary of the Company. During her tenure with the Company, she has held a variety of strategic leadership and executive positions, including in roles within operations, quality, engineering, new products, information technology, and other technical and business functions. In 2018, she was named Executive Vice President, Chief Global Supply </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Chain Officer, and became a member of the Executive Committee. In January 2023, she was appointed Executive Vice President, Chief Technical Operations &amp; Risk Officer. Ms. Wengel has enterprise-wide responsibilities for key technical operations functions, including Procurement, Engineering &amp; Property Services, Sustainability and cross-sector Supply Chain teams focused on standards, services, strategic programs and data science, and serves as Chair of the Company&#8217;s Supply Chain Management Committee. She also oversees critical risk functions, including Quality &amp; Compliance, Health Care Compliance, Environmental Health &amp; Safety, Global Security and Global Brand Protection. </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(k)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Mr. J. J. Wolk joined the Company in 1998 as Finance Manager, Business Development for Ortho-McNeil, a subsidiary of the Company, and through the years held a variety of senior leadership roles in several segments and functions across the Company's subsidiaries, in Pharmaceuticals, Medical Devices and Supply Chain. From 2014 to 2016, he served as Vice President, Finance and Chief Financial Officer of the Janssen Pharmaceutical Companies of Johnson &amp; Johnson. In 2016, Mr. Wolk became the Vice President, Investor Relations. In July 2018, he was appointed Executive Vice President, Chief Financial Officer and became a member of the Executive Committee. Mr. Wolk plays a strategic role in the overall management of the Company, and leads the development and execution of the Company's global long-term financial strategy.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;II</span></div><div id="i51a46167ef364951bf70ae9d6493776c_76"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">MARKET FOR REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;As of February 10, 2023, there were 124,211 record holders of common stock of the Company. Additional information called for by this item is incorporated herein by reference to the following sections of this Report: Note&#160;16 &#8220;Common Stock, Stock Option Plans and Stock Compensation Agreements&#8221; of the Notes to Consolidated Financial Statements included in Item 8; and Item&#160;12 &#8220;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#160;&#8211; Equity Compensation Plan Information.&#8221;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's Common Stock. Share repurchases may be made at management&#8217;s discretion from time to time on the open market or through privately negotiated transactions.  The repurchase program has no time limit and may be suspended for periods or discontinued at any time. </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information with respect to common stock purchases by the Company during the fiscal fourth quarter of 2022. Common stock purchases on the open market are made as part of a systematic plan to meet the needs of the Company&#8217;s compensation programs. The repurchases below also include the stock-for-stock option exercises that settled in the fiscal fourth quarter.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:42.304%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.096%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.936%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.158%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%;text-decoration:underline">Fiscal Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Shares Purchased</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Avg. Price<br/>Paid Per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 3, 2022 through October 30, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,921,949&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.29&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179,491</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">October 31, 2022 through November 27, 2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,444,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173.26&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">November 28, 2022 through January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,379,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178.18&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,745,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,179,491</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,876,567&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;During the fiscal fourth quarter of 2022, the Company repurchased an aggregate of 7,745,055 shares of Johnson &amp; Johnson Common Stock in open-market transactions, of which 3,179,491 shares were purchased pursuant to the repurchase program that was publicly announced on September 14, 2022, and of which 4,565,564 shares were purchased as part of a systematic plan to meet the needs of the Company&#8217;s compensation programs. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2023, an aggregate of 15,411,776 shares were purchased for a total of $2.5 billion since the inception of the repurchase program announced on September 14, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3) &#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2023, the maximum number of shares that may yet be purchased under the plan is 13,876,567 based on the closing price of Johnson &amp; Johnson Common Stock on the New York Stock Exchange on December 30, 2022 of $176.65 per share.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_79"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Reserved</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_85"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL CONDITION</span></div><div id="i51a46167ef364951bf70ae9d6493776c_88"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization and Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Description of the Company and Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson&#160;&amp; Johnson and its subsidiaries (the Company) have approximately 152,700&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world with the primary focus on products related to human health and well-being.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is organized into three business segments: Consumer Health, Pharmaceutical and MedTech. The Consumer Health segment includes a broad range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-Counter pharmaceutical, Women&#8217;s Health and Wound Care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on the following therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular) and Vision fields.  These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Executive Committee of Johnson&#160;&amp; Johnson is the principal management group responsible for the strategic operations and allocation of the resources of the Company. This Committee oversees and coordinates the activities of the Consumer Health, Pharmaceutical and MedTech business segments.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In all of its product lines, the Company competes with other companies both locally and globally, throughout the world. Competition exists in all product lines without regard to the number and size of the competing companies involved. Competition in research, involving the development and the improvement of new and existing products and processes, is particularly significant. The development of new and innovative products, as well as protecting the underlying intellectual property of the Company's product portfolio, is important to the Company&#8217;s success in all areas of its business. The competitive environment requires substantial investments in continuing research. In addition, the development and maintenance of customer demand for the Company&#8217;s consumer products involves significant expenditures for advertising and promotion.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Objectives </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With &#8220;Our Credo&#8221; as the foundation, the Company&#8217;s purpose is to blend heart, science and ingenuity to profoundly change the trajectory of health for humanity. The Company is committed to bringing its full breadth and depth to ensure health for people today and for future generations. United around this common ambition, the Company is poised to fulfill its purpose and successfully meet the demands of the rapidly evolving markets in which it competes. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is broadly based in human healthcare, and is committed to creating value by developing accessible, high quality, innovative products and services. New products introduced within the past five years accounted for approximately 25% of 2022 sales. In 2022, $14.6 billion was invested in research and development reflecting management&#8217;s commitment to create life-enhancing innovations and to create value through partnerships that will profoundly change the trajectory of health for humanity. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A critical driver of the Company&#8217;s success is the diversity of its 152,700 employees worldwide. Employees are empowered and inspired to lead with Our Credo and purpose as guides. This allows every employee to use the Company&#8217;s reach and size to advance the Company&#8217;s purpose, and to also lead with agility and urgency. Leveraging the extensive resources across the enterprise enables the Company to innovate and execute with excellence. This ensures the Company can remain focused on addressing the unmet needs of society every day and invest for an enduring impact, ultimately delivering value to its patients, consumers and healthcare professionals, employees, communities and shareholders.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-align:center"><img src="jnj-20230101_g2.jpg" alt="jnj-20230101_g2.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><img src="jnj-20230101_g3.jpg" alt="jnj-20230101_g3.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:180px"/><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><img src="jnj-20230101_g4.jpg" alt="jnj-20230101_g4.jpg" style="height:184px;margin-bottom:5pt;vertical-align:text-bottom;width:181px"/></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Consolidated Sales</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For discussion on results of operations and financial condition pertaining to the fiscal years 2021 and 2020 see the Company&#8217;s Annual Report on Form 10-K for the fiscal year ended January&#160;2, 2022, Item 7. Management's Discussion and Analysis of Results of Operations and Financial Condition.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, worldwide sales increased 1.3% to $94.9&#160;billion as compared to an increase of 13.6% in 2021. These sales changes consisted of the following:</span></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:74.269%"><tr><td style="width:1.0%"></td><td style="width:62.679%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.028%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sales increase/(decrease) due to:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Volume</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Price</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The net impact of acquisitions and divestitures on the worldwide sales growth was a negative impact of 0.1% in 2022 and a negative impact of 0.6% in 2021. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales by U.S.&#160;companies were $48.6&#160;billion in 2022 and $47.2&#160;billion in 2021. This represents increases of 3.0% in 2022 and 9.3% in 2021. Sales by international companies were $46.4&#160;billion in 2022 and $46.6&#160;billion in 2021. This represents a decrease of 0.6% in 2022 and an increase of 18.2% in 2021.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The five-year compound annual growth rates for worldwide, U.S.&#160;and international sales were 4.4%, 4.0% and 4.9%, respectively. The ten-year compound annual growth rates for worldwide, U.S.&#160;and international sales were 3.5%, 5.0% and 2.2%, respectively.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, sales by companies in Europe experienced a decline of 0.6% as compared to the prior year, which included operational growth  of 11.0% and a negative currency impact of 11.6%. Sales by companies in the Western Hemisphere, excluding the U.S., achieved growth of 6.5% as compared to the prior year, which included operational growth of 10.2%, and a negative currency impact of 3.7%. Sales by companies in the Asia-Pacific, Africa region experienced a decline of 2.8% as compared to the prior year, including operational growth of 6.2% and a negative currency impact of 9.0%.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In 2022, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.5%, 13.0% and 12.0% of the total consolidated revenues. In 2021, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. </span></div><div style="text-align:center;text-indent:18pt"><span><br/></span></div><div style="text-align:center"><img src="jnj-20230101_g5.jpg" alt="jnj-20230101_g5.jpg" style="height:269px;margin-bottom:5pt;vertical-align:text-bottom;width:356px"/><img src="jnj-20230101_g6.jpg" alt="jnj-20230101_g6.jpg" style="height:269px;margin-bottom:5pt;vertical-align:text-bottom;width:320px"/></div><div><span><br/></span></div><div style="padding-left:180pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Note: values may have been rounded</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_94"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                                               </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Sales by Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consumer Health segment sales in 2022 were $15.0 billion, a decrease of 0.5% from 2021, which included 3.6% operational growth and a negative currency impact of 4.1%.  U.S.&#160;Consumer Health segment sales were $6.6 billion, an increase of 1.3%. International sales were $8.4 billion, a decrease of 1.9%, which included 5.3% operational growth and a negative currency impact of 7.2%. In 2022, acquisitions and divestitures had a net negative impact of 0.3% on the operational sales growth of the worldwide Consumer Health segment. </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Consumer Health Franchise Sales*:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:29.841%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.605%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.904%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">OTC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,031&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,627&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,541&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Women&#8217;s Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Consumer Health  Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,953</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,035</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.6</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal 2021 reflects approximately $0.4 billion of certain international OTC products, primarily in China, which were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The OTC franchise sales of $6.0 billion increased 7.2% as compared to the prior year. Operational growth was primarily attributable to  increased Cough/Cold/Flu, adult and pediatric incidences, price actions primarily in the U.S. and increased consumption in China due to easing of COVID-19 restrictions. Growth was partially offset by supply constraints.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Skin Health/Beauty franchise sales of $4.4 billion declined 4.2% as compared to the prior year. The operational decline was driven by supply constraints in the U.S. partially offset by price actions and strong new product performance in the Asia Pacific and Latin America region.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Oral Care franchise sales of $1.5 billion declined 8.5% as compared to the prior year. The operational decline was due to portfolio simplification in the U.S., competitive pressures in EMEA and China, category decline and pricing pressures in EMEA, as well as suspension of personal care sales in Russia and negative COVID-19 impacts in China. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Baby Care franchise sales of $1.5 billion declined 6.7% as compared to the prior year. The operational decline was driven by category deceleration and competitive pressures in the U.S., suspension of personal care sales in Russia and weakness in India.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Women&#8217;s Health franchise sales of $0.9 billion declined 1.5% as compared to the prior year. Operational growth driven by lapping prior year supply constraints in EMEA, strength in India, and price actions in LATAM was partially offset by suspension of personal care sales in Russia and negative currency impacts.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Wound Care/Other franchise sales of $0.7 billion declined 5.3% as compared to the prior year. The operational decline was driven by lapping strong prior year consumption, competitive pressure in the U.S., and decreased consumption in China. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Company announced its intention to separate the Company&#8217;s Consumer Health business (Kenvue as the name for the planned New Consumer Health Company), with the intention to create a new, publicly traded company by the end of the fiscal year 2023.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical segment sales in 2022 were $52.6 billion, an increase of 1.7% from 2021, which included operational growth of 6.7% and a negative currency impact of 5.0%.  U.S.&#160;sales were $28.6 billion, an increase of 2.3%. International sales were $24.0 billion, an increase of 1.0%, which included 11.9% operational growth and a negative currency impact of 10.9%. In 2022, acquisitions and divestitures had a net negative impact of 0.1% on the operational sales growth of the worldwide Pharmaceutical segment. Adjustments to previous sales reserve estimates were approximately $0.1 billion and $0.7 billion in fiscal years 2022 and 2021, respectively.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major Pharmaceutical Therapeutic Area Sales*:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:39.400%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.240%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.356%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.534%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.244%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Immunology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,935</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,750</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.1</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;SIMPONI/SIMPONI ARIA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,276&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;STELARA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;TREMFYA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Infectious Diseases</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,449</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5,825</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;COVID-19 VACCINE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,385&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;EDURANT/rilpivirine</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PREZISTA/ PREZCOBIX/REZOLSTA/                                                    SYMTUZA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,083&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Infectious Diseases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Neuroscience</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,893</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,988</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;CONCERTA/methylphenidate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVEGA SUSTENNA/XEPLION/<br/>&#160;&#160;&#160;&#160;&#160;INVEGA TRINZA/TREVICTA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;RISPERDAL CONSTA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Neuroscience</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Oncology</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">15,983</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,548</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16.9</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;DARZALEX</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,977&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ERLEADA</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;IMBRUVICA</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;ZYTIGA /abiraterone acetate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Pulmonary Hypertension </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,417</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,450</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;OPSUMIT</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;UPTRAVI</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,887</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,119</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;XARELTO</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;INVOKANA/ INVOKAMET</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1,2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total Pharmaceutical Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">52,563</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">51,680</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fiscal 2021 reflects approximately $0.4 billion of certain international OTC products, primarily in China, which were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Immunology products achieved sales of $16.9 billion in 2022, representing an increase of 1.1% as compared to the prior year. Operational growth was driven by strong uptake of STELARA (ustekinumab) in Crohn's disease and Ulcerative Colitis and strength of TREMFYA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(guselkumab) in Psoriasis and uptake in Psoriatic Arthritis. This was partially offset by lower sales of REMICADE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(infliximab) due to biosimilar competition. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Biosimilar versions of REMICADE have been introduced in the United States and certain markets outside the United States and additional competitors continue to enter the market. Continued infliximab biosimilar competition will result in a further reduction in sales of REMICADE. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The latest expiring United States patent for STELARA (ustekinumab) will expire in September 2023. STELARA (ustekinumab) U.S. sales in fiscal 2022 were approximately $6.4 billion and the expiration of this product patent or loss of market exclusivity will result in a reduction in sales.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Infectious disease products sales were $5.4 billion in 2022, representing a decline of 6.5% as compared to the prior year.  Operational growth was driven by the COVID-19 vaccine outside the U.S partially offset by lower sales of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and PREZCOBIX/REZOLSTA (darunavir/cobicistat) due to increased competition and loss of exclusivity of PREZISTA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in certain countries outside the U.S.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neuroscience products sales were $6.9 billion, in 2022, representing a decline of 1.4% as compared to the prior year. The operational sales growth of INVEGA SUSTENNA/XEPLION (paliperidone palmitate) and INVEGA TRINZA/TREVICTA from new patient starts and persistence as well as the launch of INVEGA HAFYERA was offset by negative currency impacts and lower sales of RISPERDAL CONSTA. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Oncology products achieved sales of $16.0 billion in 2022, representing an increase of 9.9% as compared to the prior year. Contributions to operational growth were strong sales of DARZALEX (daratumumab) driven by share gains in all regions, continued strong market growth, and uptake of the subcutaneous formulation as well as the continued global launch uptake of ERLEADA (apalutamide). This was partially offset by declining sales of IMBRUVICA (ibrutinib) due to competitive pressures and market suppression and ZYTIGA due to loss of exclusivity in the European Union in the second half of 2022. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pulmonary Hypertension products sales were $3.4 billion, a decline of 1.0% as compared to the prior year. The operational sales growth of OPSUMIT (macitentan) and UPTRAVI (selexipag) due to continued share gains and market growth was offset by COVID-19 related impacts and continued declines in Other Pulmonary Hypertension.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cardiovascular/Metabolism/Other products sales were $3.9 billion, a decline of 5.6% as compared to the prior year. The operational decline was primarily attributable to lower sales of INVOKANA/INVOKAMET (canagliflozin) due to share erosion and PROCRIT/ EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(epoetin alfa) due to biosimilar competition.  </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:110%">The Company updated its policy so that no end customer will be permitted direct delivery of product to a location other than the billing location. The policy impacts contract pharmacy transactions involving non-grantee 340B covered entities for most of the Company&#8217;s drugs, subject to multiple exceptions. Both grantee and non-grantee covered entities can maintain certain contract pharmacy arrangements under policy exceptions. The Company has been and will continue to offer 340B discounts to covered entities on all of its covered outpatient drugs, and it believes its policy will improve its ability to identify inappropriate duplicate discounts and diversion prohibited by the 340B statute. The 340B Drug Pricing Program is a U.S. federal government program requiring drug manufacturers to provide significant discounts on covered outpatient drugs to covered entities. This policy update had discount implications which positively impacted sales to customers in 2022.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2022, the Company advanced its pipeline with several regulatory submissions and approvals for new drugs and additional indications for existing drugs as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:19.660%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.110%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.478%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.774%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Product Name          (Chemical Name)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Indication</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US  Approval</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EU  Approval</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US Filing</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">EU Filing</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">aprocitentan</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment for difficult to treat hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABENUVA (rilpivirine and cabotegravir)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">HIV treatment for adolescents</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CARVYKTI (ciltacabtagene autoleucel)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment for patients with relapsed or refractory Multiple Myeloma</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ERLEADA <br/>(apalutamide)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tablet reduction</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">IMBRUVICA  (ibrutinib)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment for Pediatric Patients with Chronic Graft-Versus-Host Disease</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment for Frontline Chronic Lymphocytic Leukemia (I + V fixed duration) (GLOW)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">niraparib</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of L1 Prostate cancer metastatic castration-resistant in combination with abiraterone acetate and Prednisone</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">STELARA (ustekinumab)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of Pediatric Patients with Juvenile Psoriatic Arthritis</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Talquetamab</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of Patients with Relapsed Refractory Multiple Myeloma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">teclistamab<br/>(BCMA/CD3)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Treatment of Patients with Relapsed Refractory Multiple Myeloma</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:11pt;font-weight:700;line-height:100%">&#8226;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech Segment**</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MedTech segment sales in 2022 were $27.4 billion, an increase of 1.4% from 2021, which included operational growth of 6.2% and a negative currency impact of 4.8%. U.S.&#160;sales were $13.4 billion, an increase of 5.4% as compared to the prior year. International sales were $14.1 billion, a decrease of 2.3% as compared to the prior year, which included operational growth of 6.9% and a negative currency impact of 9.2%. In 2022, the net impact of acquisitions and divestitures on the MedTech segment worldwide operational sales growth was a positive 0.1%. </span></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Major MedTech Franchise Sales*:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.122%"><tr><td style="width:1.0%"></td><td style="width:31.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.731%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.389%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.537%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.738%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currency</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,690</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,812</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.8</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.0)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Advanced</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,569&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;General</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,587</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,588</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">0.0</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Hips</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Knees</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Trauma</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Spine, Sports &amp; Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,849</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,688</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9.5</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(6.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Contact Lenses/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,440&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Surgical</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,300</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,971</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8.3</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13.7</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total MedTech Sales</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,427</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">27,060</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1.4</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6.2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**Previously referred to as Medical Devices</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Surgery franchise sales were $9.7 billion in 2022, representing a decline of 1.2% from 2021. The operational growth in Advanced Surgery was primarily driven by the following: Endocutter market recovery and new products partially offset by competitive pressures in the U.S.; Biosurgery market recovery and the success of new products partially offset by strong U.S. market demand in the prior year for infection prevention products; and Energy products driven by market recovery and new product penetration coupled with competitive supply challenges. The operational growth in General Surgery was primarily driven by market recovery and technology penetration.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Orthopaedics franchise sales were $8.6 billion in 2022, which was flat to the prior year. The Orthopaedics franchise  included operational sales growth of 3.7% offset by a negative currency impact of 3.7%. The operational growth in hips reflects the market recovery combined with continued strength of the portfolio including the ACTIS stem and enabling technologies &#8211; KINCISE and VELYS Hip Navigation. This growth was partially offset by impacts of volume-based procurement in China and the timing of tenders outside the U.S. The operational growth in knees was primarily driven by procedure recovery, strength of the ATTUNE portfolio and pull through related to the VELYS Robotic assisted solution. This growth was partially offset by impacts of volume-based procurement in China and timing of tenders outside the U.S. The operational growth in Trauma was driven by global market recovery and uptake of new products. The operational growth in Spine, Sports &amp; Other was primarily driven by procedure recovery and new product introductions. This growth was partially offset by competitive pressures in Spine and impacts of volume-based procurement in China.    </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Vision franchise achieved sales of $4.8 billion in 2022, representing an increase of 3.4% from 2021. The Contact Lenses/Other operational growth was due to market recovery, price actions, commercial execution and benefits from new products. Surgical Vision operational growth was primarily due to market recovery and the success of new products and was partially offset by a higher prior year U.S. Refractory market.   </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Interventional Solutions franchise achieved sales of $4.3 billion in 2022, representing an increase of 8.3% from 2021. Operational growth was driven by market recovery and success of new products and commercial strategies. Interventional solutions also includes sales from Abiomed, Inc. (Abiomed) which were reflected as of  December 22, 2022. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_97"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Analysis of Consolidated Earnings Before Provision for Taxes on Income</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated earnings before provision for taxes on income was $21.7 billion and $22.8 billion for the years 2022 and 2021, respectively. As a percent to sales, consolidated earnings before provision for taxes on income was 22.9% and 24.3%, in 2022 and 2021, respectively.</span></div><div><span><br/></span></div><div style="text-align:center"><img src="jnj-20230101_g7.jpg" alt="jnj-20230101_g7.jpg" style="height:300px;margin-bottom:5pt;vertical-align:text-bottom;width:350px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div style="text-align:center"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cost of Products Sold and Selling, Marketing and Administrative Expenses:</span></div><div><span><br/></span></div><div style="text-align:center"><img src="jnj-20230101_g8.jpg" alt="jnj-20230101_g8.jpg" style="height:201px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/><img src="jnj-20230101_g9.jpg" alt="jnj-20230101_g9.jpg" style="height:200px;margin-bottom:5pt;vertical-align:text-bottom;width:300px"/></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(Dollars in billions. Percentages in chart are as a percent to total sales)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold increased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">One-time COVID-19 vaccine manufacturing exit related costs</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Currency impacts in the Pharmaceutical segment</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Commodity inflation in the MedTech and Consumer Health segments</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Supply chain benefits in the Consumer Health segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The intangible asset amortization expense included in cost of products sold was $4.3 billion and  $4.7 billion for the fiscal years 2022 and 2021, respectively.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, Marketing and Administrative Expenses decreased as a percent to sales driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Reduction of brand marketing expenses in the Pharmaceutical and Consumer Health businesses</span></div><div style="padding-left:36pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Research and Development Expense: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expense by segment of business was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.836%"><tr><td style="width:1.0%"></td><td style="width:47.246%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.711%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.868%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.025%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.587%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.502%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Sales*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">% of Sales*</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,878&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,488&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,603&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,714&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Percent increase/(decrease) over the prior year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">*As a percent to segment sales </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities represent a significant part of the Company's business. These expenditures relate to the processes of discovering, testing and developing new products, upfront payments and developmental milestones, improving existing products, as well as ensuring product efficacy and regulatory compliance prior to launch. The Company remains committed to investing in research and development with the aim of delivering high quality and innovative products. </span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development decreased as a percent to sales primarily driven by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Lower milestone payments in the Pharmaceutical business</span></div><div style="padding-left:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">In-Process Research and Development (IPR&amp;D): </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the fiscal year 2022, the Company recorded an intangible asset impairment charge of approximately $0.8 billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS). Additional information regarding efficacy of the AD indication and HS indication became available which led the Company to the decision to terminate the development of bermekimab for both AD and HS. The Company acquired all rights to bermekimab from XBiotech, Inc. in the fiscal year 2020. In fiscal year 2021, the Company recorded a partial IPR&amp;D charge of $0.9 billion primarily related to expected development delays in the general surgery digital robotics platform (Ottava) acquired with the Auris Health acquisition in 2019. The impairment charge was calculated based on revisions to the discounted cash flow valuation model reflecting a delay of first in human procedures of approximately two years from the initial acquisition model assumption of the second half of 2022. The Company will continue to monitor the remaining $1.5 billion Ottava platform intangible asset as development program activities are ongoing. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Other (Income) Expense, Net:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;Other (income) expense, net is the account where the Company records gains and losses related to the sale and write-down of certain investments in equity securities held by Johnson &amp; Johnson Innovation - JJDC, Inc. (JJDC), changes in the fair value of securities, investment (income)/loss related to employee benefit programs, gains and losses on divestitures, certain transactional currency gains and losses, acquisition and divestiture related costs, litigation accruals and settlements, as well as royalty income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other (income)&#160;expense, net for the fiscal year 2022 was unfavorable by $1.4 billion as compared to the prior year primarily due to the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:49.862%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.529%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.318%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.978%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">(Dollars in Billions)(Income)/Expense</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health separation costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Litigation related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in the fair value of securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">One-time COVID-19 vaccine manufacturing exit related costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Acquisition, Integration and Divestiture related</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring related</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee benefit plan related</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Other (Income) Expense, Net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2022 was primarily related to pelvic mesh and 2021 was primarily related to talc and Risperdal Gynecomastia </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2022 was primarily costs related to the acquisition of Abiomed.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">2021</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was p</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">rimarily related to divestiture gains of two pharmaceutical brands outside the U.S. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Interest (Income) Expense:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;Interest (income) expense in the fiscal of 2022 was net interest income of $214 million as compared to interest expense of $130 million in the fiscal year 2021 primarily due to higher rates of interest earned on cash balances. Cash, cash equivalents and marketable securities totaled $23.5&#160;billion at the end of 2022, and averaged $27.6&#160;billion as compared to the cash, cash equivalents and marketable securities total of $31.6&#160;billion and $28.4&#160;billion average cash balance in 2021. The total debt balance at the end of 2022 was $39.7&#160;billion with an average debt balance of $36.7&#160;billion as compared to $33.8&#160;billion at the end of 2021 and an average debt balance of $34.5 billion. The lower average cash, cash equivalents and marketable securities and higher average debt balance were primarily due to the acquisition of Abiomed in late December of 2022. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Before Tax by Segment</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income (loss) before tax by segment of business were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:38.212%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.018%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.317%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.018%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.547%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.321%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Income Before Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Segment Sales</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent of Segment Sales</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,953&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,035&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segment earnings before tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,915&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,943&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,775&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.7&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expenses not allocated to segments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide income before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,725&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,776&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,943&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,775&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">See Note&#160;17 to the Consolidated Financial Statements for more details.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%;padding-left:11.2pt">Prior year income before tax of approximately $0.2 billion has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Consumer Health segment income before tax as a percent of sales was 19.6% versus 10.5% in 2021. The increase in the income before tax as a percent of sales was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Lower litigation expense of $0.2 billion in 2022 versus $1.6 billion (primarily talc related) in 2021</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">Reduction in brand marketing expenses in 2022 versus 2021</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Supply chain benefits in 2022</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Commodity inflation in 2022</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment: </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Pharmaceutical segment income before tax as a percent to sales was 30.3% versus 34.8% in 2021.&#160;The decrease in the income before tax as a percent of sales was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">One-time COVID-19 vaccine manufacturing exit related costs of $1.5 billion in 2022</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Unfavorable changes in the fair value of securities ($0.7 billion loss in 2022 vs. $0.5 billion gain in 2021)</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An IPR&amp;D charge of $0.8 billion in 2022 related to bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Lower divestiture gains of $0.1 billion in 2022 versus $0.6 billion related to two pharmaceutical brands outside the U.S. in fiscal 2021</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Currency impacts in Cost of Products Sold</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Lower litigation related expense of $0.1 billion in 2022 versus $0.6 billion (primarily related to Risperdal Gynecomastia) in 2021</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Lower Research &amp; Development milestone payments in 2022</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Lower brand marketing expenses in 2022 versus 2021 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal 2020 and 2021, the Company entered into a series of contract manufacturing arrangements for vaccine production with third party contract manufacturing organizations. These arrangements provided the Company with supplemental commercial capacity for vaccine production and potentially transferable rights to such production if capacity is not required. The Company continues to evaluate and monitor both its internal and external supply arrangements. In fiscal 2022, the COVID-19 Vaccine related costs (mentioned above) included the remaining commitments and obligations, including external manufacturing network exit and related inventory costs and required clinical trial expenses, associated with the Company's modification of its </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">COVID-19 vaccine research program and manufacturing capacity to levels that meet all remaining customer contractual requirements. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech Segment:&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the MedTech segment income before tax as a percent to sales was 16.8% versus 16.2% in 2021. The increase in the income before tax as a percent to sales was primarily driven by the following:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:11pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.15pt">An IPR&amp;D charge of $0.9 billion in 2021 related to the general surgery offering in digital robotics (Ottava) acquired with the Auris Health acquisition in 2019</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">partially offset by:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Higher litigation related expense of  $0.6 billion in 2022, primarily related to pelvic mesh costs versus $0.1 billion in 2021</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Acquisition related costs of $0.3 billion in 2022 related to the Abiomed acquisition versus $0.1 billion in 2021 </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Restructuring:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#160;In the fiscal second quarter of 2018, the Company announced plans to implement actions across its Global Supply Chain that are intended to enable the Company to focus resources and increase investments in critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio of the future, enhance agility and drive growth. The Global Supply Chain actions included expanding its use of strategic collaborations, and bolstering its initiatives to reduce complexity, improving cost-competitiveness, enhancing capabilities and optimizing its supply chain network.&#160;The Company has achieved approximately $0.8 billion in annual pre-tax cost savings as outlined in the restructuring actions. In 2022, the Company recorded a pre-tax charge of $0.5 billion, which is included on the following lines of the Consolidated Statement of Earnings, $0.3 billion in restructuring, $0.1 billion in other (income) expense and $0.1 billion in cost of products sold. Total project costs of approximately $2.2 billion have been recorded since the restructuring was announced. The program was completed in the fiscal fourth quarter of 2022. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;20 to the Consolidated Financial Statements for additional details related to the restructuring programs.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Provision for Taxes on Income:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The worldwide effective income tax rate was 17.4% in 2022 and 8.3% in 2021. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In the fiscal 2022, the Company incurred approximately $0.5 billion net incremental international tax cost related to the legal separation of the Consumer Health business, and may continue to incur additional cost in fiscal 2023. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">     On December 15, 2022, the European Union (EU) Member States formally adopted the EU&#8217;s Pillar Two Directive, which generally provides for a minimum effective tax rate of 15%, as established by the Organization for Economic Co-operation and Development (OECD) Pillar Two Framework that was supported by over 130 countries worldwide. The EU effective dates are January 1, 2024, and January 1, 2025, for different aspects of the directive. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">    </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A significant number of other countries are expected to also implement similar legislation, including South Korea which approved legislation on December 23, 2022 with a full effective date of January 1, 2024. The Company is continuing to evaluate the potential impact on future periods of the Pillar Two Framework, pending legislative adoption by additional individual countries, including those within the European Union.    </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> For discussion related to the fiscal 2022 provision for taxes refer to Note&#160;8 to the Consolidated Financial Statements. </span></div><div style="margin-bottom:8pt;margin-top:2.7pt;text-indent:18pt"><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_100"></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity&#160;&amp; Cash Flows</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash and cash equivalents were $14.1&#160;billion at the end of 2022 as compared to $14.5&#160;billion at the end of 2021. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The primary sources and uses of cash that contributed to the $0.4&#160;billion decrease were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.713%"><tr><td style="width:1.0%"></td><td style="width:21.364%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:76.436%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q4 2021 Cash and cash equivalents balance</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">cash generated from operating activities</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash used by investing activities</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net cash used by financing activities</span></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">effect of exchange rate and rounding</span></td></tr><tr><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Q4 2022 Cash and cash equivalents balance</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company had $9.4 billion in marketable securities at the end of fiscal year 2022 and $17.1 billion at the end of fiscal year 2021. See Note&#160;1 to the Consolidated Financial Statements for additional details on cash, cash equivalents and marketable securities.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow from operations of $21.2&#160;billion was the result of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net Earnings</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">non-cash expenses and other adjustments primarily for depreciation and amortization, stock-based compensation and asset write-downs partially offset by the deferred tax provision, net gain on sale of assets/businesses and credit losses and accounts receivable allowances</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a decrease in current and non-current liabilities</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">a decrease in other current and non-current assets</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase in accounts payable and accrued liabilities </span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">an increase in accounts receivable and inventories </span></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash Flow from operations</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investing activities use of $12.4 billion of cash was primarily used for:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">additions to property, plant and equipment</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">acquisitions</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from the disposal of assets/businesses, net</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net sales of investments</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">other (primarily licenses and milestones) and rounding</span></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.4)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for investing activities</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financing activities use of $8.9 billion of cash was primarily used for: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.736%"><tr><td style="width:1.0%"></td><td style="width:19.424%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.376%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Dollars In Billions)</span></td><td colspan="3" style="border-right:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">dividends to shareholders </span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">repurchase of common stock</span></td></tr><tr><td colspan="2" style="background-color:#cceeff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">net proceeds from short and long term debt</span></td></tr><tr><td colspan="2" style="background-color:#ffffff;border-left:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-right:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">proceeds from stock options exercised/employee withholding tax on stock awards, net</span></td></tr><tr><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used for financing activities</span></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">As of January 1, 2023, the Company's notes payable and long-term debt was in excess of cash, cash equivalents and marketable securities. As of January 1, 2023, the net debt position was $16.1 billion as compared to the prior year of $2.1 billion. The increase was primarily due to the acquisition of Abiomed, Inc. in December 2022. The debt balance at the end of 2022 was $39.7 billion as compared to $33.8 billion in 2021. Considering recent market conditions, the Company has re-evaluated its operating cash flows and liquidity profile and does not foresee any significant incremental risk. The Company anticipates that operating cash flows, the ability to raise funds from external sources, borrowing capacity from existing committed credit facilities and access to the commercial paper markets will continue to provide sufficient resources to fund operating needs, including the Company's remaining balance to be paid on the agreement to settle opioid litigation for approximately $2.7 billion and the establishment of the $2.0 billion trust for talc related liabilities (See Note 19 to the Consolidated Financial Statements for additional details). In addition, the Company monitors the global capital markets on an ongoing basis and from time to time may raise capital when market conditions are favorable. Effective beginning in fiscal 2022, the U.S. Tax Cuts and Job Act of 2017 (TCJA) requires the Company to deduct U.S. and international research and development expenditures for tax purposes over 5 to 15 years, instead of in the current fiscal year. As a result, in fiscal 2022, the Company experienced an increase in annual cash tax payments of approximately $1.2 billion above what otherwise would have been remitted to the U.S Treasury. The Company concurrently records a deferred tax benefit for the future amortization of the research and development (R&amp;D) for tax purposes. The requirement to expense R&amp;D as incurred is unchanged for U.S. GAAP purposes and the impact to pre-tax R&amp;D expense is not affected by this provision.  </span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's Common Stock. Share repurchases may be made at management&#8217;s discretion from time to time on the open market or through privately negotiated transactions.  The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Any shares acquired will be available </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">for general corporate purposes. The Company intends to finance the share repurchase program through available cash. Through January&#160;1, 2023, approximately $2.5 billion has been repurchased under the program.</span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the Company&#8217;s material contractual obligations and their aggregate maturities as of January&#160;1, 2023: To satisfy these obligations, the Company intends to use cash from operations.  </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:28.281%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.002%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.002%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.914%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Tax Legislation (TCJA)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Debt Obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest on<br/>Debt Obligations</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,029&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,536&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">789&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,992&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">744&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,740&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">736&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,007&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">After 2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,562&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,772&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,087</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,439</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,777</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">47,303</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">For tax matters, see Note&#160;8 to the Consolidated Financial Statements. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financing and Market Risk</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses financial instruments to manage the impact of foreign exchange rate changes on cash flows. Accordingly, the Company enters into forward foreign exchange contracts to protect the value of certain foreign currency assets and liabilities and to hedge future foreign currency transactions primarily related to product costs. Gains or losses on these contracts are offset by the gains or losses on the underlying transactions. A 10% appreciation of the U.S.&#160;Dollar from the January&#160;1, 2023 market rates would increase the unrealized value of the Company&#8217;s forward contracts by $0.1 billion.  Conversely, a 10% depreciation of the U.S.&#160;Dollar from the January&#160;1, 2023 market rates would decrease the unrealized value of the Company&#8217;s forward contracts by $0.1&#160;billion. In either scenario, the gain or loss on the forward contract would be offset by the gain or loss on the underlying transaction, and therefore, would have no impact on future anticipated earnings and cash flows.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company hedges the exposure to fluctuations in currency exchange rates, and the effect on certain assets and liabilities in foreign currency, by entering into currency swap contracts. A 1% change in the spread between U.S.&#160;and foreign interest rates on the Company&#8217;s interest rate sensitive financial instruments would either increase or decrease the unrealized value of the Company&#8217;s swap contracts by approximately $1.7 billion. In either scenario, at maturity, the gain or loss on the swap contract would be offset by the gain or loss on the underlying transaction, and therefore, would have no impact on future anticipated cash flows.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not enter into financial instruments for trading or speculative purposes. Further, the Company has a policy of only entering into contracts with parties that have at least an investment grade credit rating. The counterparties to these contracts are major financial institutions and there is no significant concentration of exposure with any one counterparty. Management believes the risk of loss is remote. The Company entered into credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. See Note&#160;6 to the Consolidated Financial Statements for additional details on credit support agreements.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests in both fixed rate and floating rate interest earning securities which carry a degree of interest rate risk. The fair market value of fixed rate securities may be adversely impacted due to a rise in interest rates, while floating rate securities may produce less income than predicted if interest rates fall. A 1% (100 basis points) change in spread on the Company&#8217;s interest rate sensitive investments would either increase or decrease the unrealized value of cash equivalents and current marketable securities by less than $0.1 billion. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has access to substantial sources of funds at numerous banks worldwide. In September 2022, the Company secured a new 364-day Credit Facility of $10&#160;billion, which expires on September&#160;7, 2023. In November 2022, the Company secured an additional 364-day revolving Credit Facility of $10 billion, which has an expiration of November 21, 2023. Interest charged on borrowings under the credit line agreement is based on either Secured Overnight Financing Rate (SOFR) Reference Rate or other applicable market rate as allowed plus applicable margins. Commitment fees under the agreement are not material.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total borrowings at the end of 2022 and 2021 were $39.7&#160;billion and $33.8&#160;billion, respectively. The increase in borrowings was due to the acquisition of Abiomed, Inc. In 2022, net debt (cash and current marketable securities, net of debt) was $16.1&#160;billion compared to net debt of $2.1 billion in 2021. Total debt represented 34.1% of total capital (shareholders&#8217; equity and total debt) in 2022 and 31.3% of total capital in 2021. Shareholders&#8217; equity per share at the end of 2022 was $29.39 compared to $28.16 at year-end 2021.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of borrowings can be found in Note&#160;7 to the Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company increased its dividend in 2022 for the 60th&#160;consecutive year. Cash dividends paid were $4.45 per share in 2022 and $4.19 per share in 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2023, the Board of Directors declared a regular cash dividend of $1.13 per share, payable on March 7, 2023 to shareholders of record as of February 21, 2023.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i51a46167ef364951bf70ae9d6493776c_103"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Information</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management&#8217;s discussion and analysis of results of operations and financial condition are based on the Company&#8217;s consolidated financial statements that have been prepared in accordance with accounting principles generally accepted in the U.S.&#160;(GAAP). The preparation of these financial statements requires that management make estimates and assumptions that affect the amounts reported for revenues, expenses, assets, liabilities and other related disclosures. Actual results may or may not differ from these estimates. The Company believes that the understanding of certain key accounting policies and estimates are essential in achieving more insight into the Company&#8217;s operating results and financial condition.  These key accounting policies include revenue recognition, income taxes, legal and self-insurance contingencies, valuation of long-lived assets, assumptions used to determine the amounts recorded for pensions and other employee benefit plans and accounting for stock based awards.</span></div><div style="margin-top:3pt;text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during the fiscal years&#160;2022, 2021 and 2020.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements of certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in fiscal year 2022 and less than 3.0%  of the total revenues in fiscal years 2021 and 2020 and are included in sales to customers.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company enters into collaboration arrangements that contain multiple revenue generating activities.   Amounts due from collaborative partners for these arrangements are recognized as each activity is performed or delivered, based on the relative selling price. Upfront fees received as part of these arrangements are deferred and recognized over the performance period. See Note&#160;1 to the Consolidated Financial Statements for additional disclosures on collaborations.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Reasonably likely changes to assumptions used to calculate the accruals for rebates, returns and promotions are not anticipated to have a material effect on the financial statements. The Company currently discloses the impact of changes to assumptions in the quarterly or annual filing in which there is a material financial statement impact. </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Below are tables that show the progression of accrued rebates, returns, promotions, reserve for doubtful accounts and reserve for cash discounts by segment of business for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consumer Health Segment</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:46.268%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.930%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.982%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.381%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.935%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments/Credits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>End of     Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(948)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">391&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(88)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,077&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,008)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,212&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,044)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(208)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,427&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,255)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(895)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,999)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,987&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,030)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">750&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">213&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(210)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">844&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,200&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,247)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">797&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes reserve for customer rebates of $82&#160;million at January&#160;1, 2023 and $80&#160;million at January&#160;2, 2022, recorded as a contra asset.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Segment</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:45.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.806%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments/Credits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>End of       Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,068)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(315)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,854&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,475&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41,390)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,939&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,281&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,265)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,998&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,756&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(42,661)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,093&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,428)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">460&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">345&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,303&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,280&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37,729)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,854&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,139)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,425&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,461&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38,888)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,998&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes reserve for customer rebates of $203&#160;million at January&#160;1, 2023 and $218&#160;million at January&#160;2, 2022, recorded as a contra asset. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes prior period adjustments</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:13pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">MedTech Segment</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:45.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.492%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.540%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.906%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accruals</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Payments/Credits</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance at<br/>End of       Period</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,107)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,470&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">531&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(531)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,764&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,751)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,647&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(100)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,869&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,880)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,942&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,670)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued returns</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">559&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(563)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued promotions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(138)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,364&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,641&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,371)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,634&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for doubtful accounts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve for cash discounts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,575&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,749&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,532)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,792&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes reserve for customer rebates of $802&#160;million at January&#160;1, 2023 and $845&#160;million at January&#160;2, 2022, recorded as a contra asset.</span></div><div style="margin-top:3pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP, which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately  $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 1 and Note 8 to the Consolidated Financial Statements for further information regarding income taxes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal and Self Insurance Contingencies:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company records accruals for various contingencies, including legal proceedings and product liability claims as these arise in the normal course of business. The accruals are based on management&#8217;s judgment as to the probability of losses and, where applicable, actuarially determined estimates. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. </span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. </span></div><div style="text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes 1 and 19 to the Consolidated Financial Statements for further information regarding product liability and legal proceedings.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Long-Lived and Intangible Assets:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company assesses changes, both qualitatively and quantitatively, in economic conditions and makes assumptions regarding estimated future cash flows in evaluating the value of the Company&#8217;s property, plant and equipment, goodwill and intangible assets.  As these assumptions and estimates may change over time, it may or may not be necessary for the Company to record impairment charges.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employee Benefit Plans:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. These plans are based on assumptions for the discount rate, expected return on plan assets, mortality rates, expected salary increases, healthcare cost trend rates and attrition rates. See Note&#160;10 to the Consolidated Financial Statements for further details on these rates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Based Compensation:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The Company recognizes compensation expense associated with the issuance of equity instruments to employees for their services. Based on the type of equity instrument, the fair value is estimated on the date of grant using either the Black-Scholes option valuation model or a combination of both the Black-Scholes option valuation model and Monte Carlo valuation model, and is expensed in the financial statements over the service period. The input assumptions used in determining fair value are the expected life, expected volatility, risk-free rate and expected dividend yield. For performance share units, the fair market value is calculated for the two component goals at the date of grant: adjusted operational earnings per share and relative total shareholder return. The fair values for the earnings per share goal of each performance share unit was estimated on the date of grant using the fair market value of the shares at the time of the award, discounted for dividends, which are not paid on the performance share units during the vesting period.&#160;The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model. See Note&#160;16 to the Consolidated Financial Statements for additional information.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Refer to Note&#160;1 to the Consolidated Financial Statements for recently adopted accounting pronouncements and recently issued accounting pronouncements not yet adopted as of January&#160;1, 2023.</span></div><div style="margin-top:9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Economic and Market Factors</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company is aware that its products are used in an environment where, for more than a decade, policymakers, consumers and businesses have expressed concerns about the rising cost of healthcare.  In response to these concerns, the Company has a long-standing policy of pricing products responsibly. For the period 2012&#160;- 2022, in the U.S., the weighted average compound annual growth rate of the Company&#8217;s net price increases for healthcare products (prescription and over-the-counter drugs, hospital and professional products) was below the U.S.&#160;Consumer Price Index (CPI).</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company operates in certain countries where the economic conditions continue to present significant challenges. The Company continues to monitor these situations and take appropriate actions. Inflation rates continue to have an effect on worldwide economies and, consequently, on the way companies operate. The Company has accounted for operations in Argentina and Venezuela as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. Beginning in the fiscal second quarter of 2022, the Company accounted for operations in Turkey as highly inflationary, as the prior three-year cumulative inflation rate surpassed 100%. This did not have a material impact to the Company's results in the period. In the face of increasing costs, the Company strives to maintain its profit margins through cost reduction programs, productivity improvements and periodic price increases.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Russia-Ukraine War</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the long-term implications of Russia&#8217;s invasion of Ukraine are difficult to predict at this time, the financial impact of the conflict in the fiscal 2022, including accounts receivable or inventory reserves, was not material. As of both the fiscal years ending January 1, 2023 and January 2, 2022, the business of the Company&#8217;s Ukraine subsidiaries represented less than 1% of the Company&#8217;s consolidated assets and revenues. As of both the fiscal years ending January 1, 2023 and January 2, 2022, the business of the Company&#8217;s Russian subsidiaries represented less than 1% of the Company&#8217;s consolidated assets and represented 1% of revenues.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">       In early March, the Company took steps to suspend all advertising, enrollment in clinical trials, and any additional investment in Russia. Additionally, at the end of March, the Company made the decision to suspend supply of personal care products in Russia. The Company continues to supply its other products as patients rely on many of the products for healthcare purposes.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company is exposed to fluctuations in currency exchange rates. A 1% change in the value of the U.S.&#160;Dollar as compared to all foreign currencies in which the Company had sales, income or expense in 2022 would have increased or decreased the translation of foreign sales by approximately $0.5&#160;billion and net income by approximately $0.1&#160;billion.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Governments around the world consider various proposals to make changes to tax laws, which may include increasing or decreasing existing statutory tax rates. In connection with various government initiatives, companies are required to disclose more information to tax authorities on operations around the world, which may lead to greater audit scrutiny of profits earned in other countries. A change in statutory tax rate in any country would result in the revaluation of the Company&#8217;s deferred tax assets and liabilities related to that particular jurisdiction in the period in which the new tax law is enacted.&#160; This change would result in an expense or benefit recorded to the Company&#8217;s Consolidated Statement of Earnings.&#160; The Company closely monitors these proposals as they arise in the countries where it operates. Changes to the statutory tax rate may occur at any time, and any related expense or benefit recorded may be material to the fiscal quarter and year in which the law change is enacted. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company faces various worldwide healthcare changes that may continue to result in pricing pressures that include healthcare cost containment and government legislation relating to sales, promotions, pricing and reimbursement of healthcare products.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the behavior and spending patterns of purchasers of healthcare products and services, including delaying medical procedures, rationing prescription medications, reducing the frequency of physician visits and foregoing healthcare insurance coverage, as a result of the current global economic downturn, may continue to impact the Company&#8217;s businesses.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also operates in an environment increasingly hostile to intellectual property rights. Firms have filed Abbreviated New Drug Applications or Biosimilar Biological Product Applications with the U.S. FDA or otherwise challenged the coverage and/or validity of the Company's patents, seeking to market generic or biosimilar forms of many of the Company&#8217;s key pharmaceutical products prior to expiration of the applicable patents covering those products. In the event the Company is not successful in defending the patent claims challenged in the resulting lawsuits, generic or biosimilar versions of the products at issue will be introduced to the market, resulting in the potential for substantial market share and revenue losses for those products, and which may result in a non-cash impairment charge in any associated intangible asset. There is also a risk that one or more competitors could launch a generic or biosimilar version of the product at issue following regulatory approval even though one or more valid patents are in place.  </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Legal Proceedings</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability, intellectual property, commercial, employment, indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of business.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. As of January&#160;1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company's opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company's balance sheet, is not expected to have a material adverse effect on the Company's financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company's results of operations and cash flows for that period.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;19 to the Consolidated Financial Statements included in Item 8 of this report for further information regarding legal proceedings.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s Common Stock is listed on the New York Stock Exchange under the symbol JNJ. As of February 10, 2023, there were 124,211 record holders of Common Stock of the Company. </span></div><div style="text-align:center"><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_106"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.8pt">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to &#8220;Item 7. Management&#8217;s Discussion and Analysis of Results of Operations and Financial Condition&#160;- Liquidity and Capital Resources - Financing and Market Risk&#8221; of this Report; and Note&#160;1 &#8220;Summary of Significant Accounting Policies&#160;- Financial Instruments&#8221; of the Notes to Consolidated Financial Statements included in Item 8 of this Report.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_109"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. &#160;&#160;&#160;&#160;FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:7.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:90.224%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Index to Audited Consolidated Financial Statements</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_115">40</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_115">Consolidated Balance Sheets</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_121">41</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_121">Consolidated Statements of Earnings</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_124">42</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_124">Consolidated Statements of Comprehensive Income </a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_130">43</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_130">Consolidated Statements of Equity</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_136">44</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_136">Consolidated Statements of Cash Flows</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_139">46</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_139">Notes to Consolidated Financial Statements</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_232">103</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_232">Report of Independent Registered Public Accounting Firm</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> (PCAOB ID <ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:AuditorFirmId" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMDkvZnJhZzpjMDc4YjM4ODIyYjY0NWZkYTEzNzYwYzgyNmVjZDcyNy90YWJsZTplMTgzMzdjMWU4ZjE0NDdkYjA2NDI2OTE0NjE4YzIzYy90YWJsZXJhbmdlOmUxODMzN2MxZThmMTQ0N2RiMDY0MjY5MTQ2MThjMjNjXzctMS0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo0Y2RiNjVjZTYyZGU0YmE5YTUxYzUxMThjZTYzNzVkYV83MA_83c125e3-a9c4-4922-b790-50c61591bdbc">238</ix:nonNumeric>)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_235">106</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i51a46167ef364951bf70ae9d6493776c_235">Management&#8217;s Report on Internal Control Over Financial Reporting</a></span></div></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOHNSON&#160;&amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONSOLIDATED BALANCE SHEETS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">At January&#160;1, 2023 and January&#160;2, 2022 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Millions Except Share and Per Share Amounts) (Note&#160;1)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:72.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current assets</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents (Notes&#160;1 and 2)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMtMS0xLTEtODQ0NDQ_fbb64bd0-345f-4c50-96e8-3167148fce33">14,127</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMtMy0xLTEtODQ0NDQ_b5d750f8-4cc1-465c-9333-2b72ad4b11c5">14,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities (Notes&#160;1 and 2)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzQtMS0xLTEtODQ0NDQ_acc91843-d42c-402a-8d32-2f04154db5c3">9,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzQtMy0xLTEtODQ0NDQ_9e2ddf38-29a3-40d8-966a-58c3a67c47bf">17,121</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable trade, less allowances for doubtful accounts $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzUtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjowYjIxZTU2YjgyOWU0MWEyYWJiMDQ1OWIxZmFmZTQxNF83MA_475e2fb9-fa05-43e0-8691-34c258a1ef15">203</ix:nonFraction> (2021, $<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzUtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjowYjIxZTU2YjgyOWU0MWEyYWJiMDQ1OWIxZmFmZTQxNF84MQ_2a0de18e-f69d-442d-81bc-1b845ebe34a0">230</ix:nonFraction>)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzUtMS0xLTEtODQ0NDQ_611614be-82fe-4313-bf7d-ec2cdfff4ba4">16,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzUtMy0xLTEtODQ0NDQ_54aa754c-416f-401a-b2a4-ffd075fcf297">15,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories (Notes&#160;1 and 3)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzYtMS0xLTEtODQ0NDQ_08087429-322f-4665-acfc-1d2bab78fc78">12,483</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzYtMy0xLTEtODQ0NDQ_b17f26b2-5252-4fb3-9bd6-7b2575a520a0">10,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzgtMS0xLTEtODQ0NDQ_49003c05-6be9-4791-a616-9e46b58e79b3">3,132</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzgtMy0xLTEtODQ0NDQ_e792b737-d139-42ce-9570-6712330d2599">3,701</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzktMS0xLTEtODQ0NDQ_ac4372f8-1958-47aa-9087-2e0f1599ffbe">55,294</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzktMy0xLTEtODQ0NDQ_4647ed63-5ee0-4d38-bf9d-ceb4b1889243">60,979</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, plant and equipment, net (Notes&#160;1 and 4)</span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzEwLTEtMS0xLTg0NDQ0_9bbe30e9-4067-48bf-a02e-7eba8d11f771">19,803</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzEwLTMtMS0xLTg0NDQ0_2c29a255-5506-4dcb-9aad-d40e610c23dd">18,962</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net (Notes&#160;1 and 5)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzExLTEtMS0xLTg0NDQ0_035eed1a-a10c-4142-a3ab-8bbff1434e1b">48,325</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzExLTMtMS0xLTg0NDQ0_6d03a377-b6c4-4605-9798-2b046af9a2af">46,392</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill (Notes&#160;1 and 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzEyLTEtMS0xLTg0NDQ0_8ed7a150-1cce-496f-895f-853d53c8e356">45,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzEyLTMtMS0xLTg0NDQ0_61b9abc2-f8f7-4bf6-be38-877fbe7e52f8">35,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzEzLTEtMS0xLTg0NDQ0_f4655cf3-9a1a-4af2-98a6-2bd196ea8f40">9,123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DeferredIncomeTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzEzLTMtMS0xLTg0NDQ0_6905f6d7-4652-42ca-8f50-f15ba0b2f7c8">10,223</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzE0LTEtMS0xLTg0NDQ0_e88f1c4a-f46b-4b9d-88e2-edda2f5513cf">9,602</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzE0LTMtMS0xLTg0NDQ0_1aa8c73b-9033-4f2b-8e22-f26c07b14cec">10,216</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzE1LTEtMS0xLTg0NDQ0_79d810e3-4696-4b98-8b05-2b57b3ea958c">187,378</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzE1LTMtMS0xLTg0NDQ0_84c47b87-1f9b-4883-8244-cfa07452e409">182,018</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and Shareholders&#8217; Equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loans and notes payable (Note&#160;7)</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzE4LTEtMS0xLTg0NDQ0_da816bf0-5649-4e65-8df7-f8acec8d2977">12,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzE4LTMtMS0xLTg0NDQ0_cb3e0c53-9745-4728-8f4c-6d29ce89433e">3,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzE5LTEtMS0xLTg0NDQ0_f72b003b-4d64-426f-843a-5bfdaf6aff7c">11,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzE5LTMtMS0xLTg0NDQ0_e0c9f3ff-8bca-4c50-aa6d-ec9cca1ac61e">11,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzIwLTEtMS0xLTg0NDQ0_d40e8934-2062-4af1-85fd-9c5d597c668f">11,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzIwLTMtMS0xLTg0NDQ0_63f8ca0d-b9f7-43aa-be0b-10d4a58e8a63">13,612</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued rebates, returns and promotions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzIxLTEtMS0xLTg0NDQ0_6e05c87c-a513-42d9-ab7f-e846bbec21c1">14,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzIxLTMtMS0xLTg0NDQ0_ac9cfa13-8ca1-4258-8f28-f7d7fb77f41a">12,095</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and employee related obligations</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzIyLTEtMS0xLTg0NDQ0_665dcdda-6ccc-4e3f-9d3c-c57fe0c60f88">3,328</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzIyLTMtMS0xLTg0NDQ0_840e3ffc-0468-400e-9a08-af76f12e0fb9">3,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued taxes on income (Note 8)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzIzLTEtMS0xLTg0NDQ0_084e2e62-e993-4adc-b16c-129e5acbf34a">2,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:AccruedIncomeTaxesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzIzLTMtMS0xLTg0NDQ0_82960655-5cad-4e2f-94b6-096be981085c">1,112</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI0LTEtMS0xLTg0NDQ0_ac329c67-118e-4ca0-8c5a-13000c4107ff">55,802</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI0LTMtMS0xLTg0NDQ0_fab8d9be-85bc-4bb4-811a-dd7351cb424c">45,226</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term debt (Note&#160;7)</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI1LTEtMS0xLTg0NDQ0_87616c63-c216-454e-a400-b7b540f2b7fd">26,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI1LTMtMS0xLTg0NDQ0_6b189b11-12f6-4ca1-99fc-ab93a5b2dfd7">29,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes on income (Note 8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI2LTEtMS0xLTg0NDQ0_afe517dd-9ca5-43a8-a90e-d1fe2ff5eab9">6,374</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI2LTMtMS0xLTg0NDQ0_dc5bbe40-128a-4718-80af-f458d556d1bd">7,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations (Notes&#160;9 and 10)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI3LTEtMS0xLTg0NDQ0_211f4918-49bd-49ba-806c-dcc2a6fa3b15">6,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI3LTMtMS0xLTg0NDQ0_7396a5d0-ab9b-4116-9dc5-a408f894cd3e">8,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term taxes payable (Note 1)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI4LTEtMS0xLTg0NDQ0_41dec7f4-26e8-429a-a695-0b2635a8bfdc">4,306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:AccruedIncomeTaxesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI4LTMtMS0xLTg0NDQ0_a350672e-3656-48dc-a73e-cab5cb7d584a">5,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI5LTEtMS0xLTg0NDQ0_246082cf-8762-42d6-8582-72cf58f523ee">10,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI5LTMtMS0xLTg0NDQ0_ab962a5a-6a74-4a15-9d8a-a5902d85a0c7">10,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMwLTEtMS0xLTg0NDQ0_7dff3486-d453-47f0-b1fe-872d3b8c9a99">110,574</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMwLTMtMS0xLTg0NDQ0_6378e7e8-ff5a-4c28-aac9-27f9417bbb3e">107,995</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and Contingencies (Note 19)</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMxLTEtMS0xLTg0NDQ0_4ae2fa2d-9b96-4a02-b658-7a1bfe9a0419"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMxLTMtMS0xLTg0NDQ0_02bb4b34-1f2b-4873-8c1e-22b8faa085f2"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock&#160;&#8212; without par value (authorized and unissued <ix:nonFraction unitRef="shares" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMzLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NzIyNjZmMzZiMDdiNDI4ODg2ZmEwYWRiNTYyYWVjZjZfNjU_ab223652-d8ce-47d2-a3d3-60afacb5a996"><ix:nonFraction unitRef="shares" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMzLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NzIyNjZmMzZiMDdiNDI4ODg2ZmEwYWRiNTYyYWVjZjZfNjU_e20be93d-274c-45b0-9ba4-36f9e8a809f3">2,000,000</ix:nonFraction></ix:nonFraction>&#160;shares)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMzLTEtMS0xLTg0NDQ0_c7df43d0-0984-4c83-b204-dbfdffdda2e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMzLTMtMS0xLTg0NDQ0_2ca4dea6-acc7-4120-9c40-80fdfa02c452">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock&#160;&#8212; par value $<ix:nonFraction unitRef="usdPerShare" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NTM0OTI3MWU5YTU2NDYyNmE0ODVlODc1MWJkZmVlOWJfMzA_fb3d4939-df3c-47fe-b850-5057ef934006"><ix:nonFraction unitRef="usdPerShare" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NTM0OTI3MWU5YTU2NDYyNmE0ODVlODc1MWJkZmVlOWJfMzA_fcac3872-bbbb-43ae-b27c-ce457c448013">1.00</ix:nonFraction></ix:nonFraction> per share (Note&#160;12) (authorized <ix:nonFraction unitRef="shares" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NTM0OTI3MWU5YTU2NDYyNmE0ODVlODc1MWJkZmVlOWJfNjU_1815a034-c23f-4e82-8184-633d10f8e5db"><ix:nonFraction unitRef="shares" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NTM0OTI3MWU5YTU2NDYyNmE0ODVlODc1MWJkZmVlOWJfNjU_47d9e290-db1e-46b8-9cac-50ff762f844d">4,320,000,000</ix:nonFraction></ix:nonFraction>&#160;shares; issued <ix:nonFraction unitRef="shares" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NTM0OTI3MWU5YTU2NDYyNmE0ODVlODc1MWJkZmVlOWJfODM_7c271d0b-847a-4583-83c4-316855b74c13"><ix:nonFraction unitRef="shares" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NTM0OTI3MWU5YTU2NDYyNmE0ODVlODc1MWJkZmVlOWJfODM_f9298fb7-cb87-4553-87f0-c262c307c708">3,119,843,000</ix:nonFraction></ix:nonFraction>&#160;shares)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM0LTEtMS0xLTg0NDQ0_503a2d89-633d-446c-9638-36b81fbb8957">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:CommonStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM0LTMtMS0xLTg0NDQ0_a0590f76-a4a4-4eae-9318-15b7aa7b81b1">3,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income (loss) (Note&#160;13)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM1LTEtMS0xLTg0NDQ0_4a1955bc-bbd9-4b38-af7f-ba5cd336bf8f">12,967</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM1LTMtMS0xLTg0NDQ0_db7a0226-191e-477b-b98d-b2cae5346fd2">13,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM2LTEtMS0xLTg0NDQ0_7838f67b-d499-4603-8fa7-ec0fa2efed54">128,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM2LTMtMS0xLTg0NDQ0_257bbb45-86d7-4506-87c2-9d988e6e1a1f">123,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:StockholdersEquityBeforeTreasuryStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM3LTEtMS0xLTg0NDQ0_f7dabcb2-61da-43a8-9945-e64695105940">118,498</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:StockholdersEquityBeforeTreasuryStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM3LTMtMS0xLTg0NDQ0_5541dc06-7ddc-44f0-ad17-edbf2947c8e8">113,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: common stock held in treasury, at cost (Note&#160;12) (<ix:nonFraction unitRef="shares" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM4LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MzNhZjEzOWMzYmU5NDM1MjlmZmE4ZTA0NzFlNjA2ZGFfNjA_2fa090bf-3c4c-46ea-8b14-871f558c871b">506,246,000</ix:nonFraction>&#160;shares and <ix:nonFraction unitRef="shares" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM4LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MzNhZjEzOWMzYmU5NDM1MjlmZmE4ZTA0NzFlNjA2ZGFfNzQ_7c9222b0-aac5-4656-89f0-285667cb1028">490,878,000</ix:nonFraction>&#160;shares)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM4LTEtMS0xLTg0NDQ0_dd44f222-690f-4ce1-adce-31a819de9678">41,694</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM4LTMtMS0xLTg0NDQ0_c40ab317-163c-4c94-a708-f5bd4fffcdf8">39,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM5LTEtMS0xLTg0NDQ0_6fbb84d7-8e89-405a-beea-4718e9169de2">76,804</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM5LTMtMS0xLTg0NDQ0_f0d3d781-180e-40c1-9e7f-dda6672ba577">74,023</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzQwLTEtMS0xLTg0NDQ0_16ca264a-6ef8-448b-8701-4f0bf4532b0f">187,378</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzQwLTMtMS0xLTg0NDQ0_d272ebb9-8f17-4f82-8554-fe6d312af002">182,018</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_121"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOHNSON&#160;&amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EARNINGS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars and Shares in Millions Except Per Share Amounts) (Note&#160;1)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:63.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.210%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to customers</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEtMS0xLTEtODQ0NDQ_1b298ec4-2b9f-42ba-bf0c-ad96c91f21bf">94,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEtMy0xLTEtODQ0NDQ_b4485073-b6b3-4159-be94-3bc7f54ff08a">93,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEtNS0xLTEtODQ0NDQ_5452f4f1-f02e-41ad-9276-35352577008f">82,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzItMS0xLTEtODQ0NDQ_3bca784a-1bef-49b6-8a94-0fa429cc20e3">31,089</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzItMy0xLTEtODQ0NDQ_51a64f33-0125-43e8-97c8-77f1a0b75d07">29,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzItNS0xLTEtODQ0NDQ_7c09199d-eb8d-48fe-832e-6c4583fc187f">28,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzMtMS0xLTEtODQ0NDQ_4d11d416-abc6-4c0b-8f24-1547e40070ca">63,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzMtMy0xLTEtODQ0NDQ_4e286ffe-788b-4357-aee8-3ea60e970cab">63,920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzMtNS0xLTEtODQ0NDQ_dec2ceaa-4ea5-41a2-b300-1865209ae488">54,157</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, marketing and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzQtMS0xLTEtODQ0NDQ_84f5489a-0de4-464f-a03c-3b861b52970c">24,765</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzQtMy0xLTEtODQ0NDQ_7384e88b-afad-499e-b17b-c57f0fc75ed3">24,659</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzQtNS0xLTEtODQ0NDQ_62f10b71-b69a-4cd2-a1b0-565415949998">22,084</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzUtMS0xLTEtODQ0NDQ_78e74110-8485-4890-8d18-2c6dd6f721fd">14,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzUtMy0xLTEtODQ0NDQ_384d48a4-b5bd-41e9-978b-76ca273e55cc">14,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzUtNS0xLTEtODQ0NDQ_ede4a6f5-a0ea-4b8a-837b-1545876f432c">12,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">In-process research and development (Note 5)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzYtMS0xLTEtODQ0NDQ_7876b10f-86ea-43bc-82c7-621e28ca12de">783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzYtMy0xLTEtODQ0NDQ_1f53a315-68d1-4abd-a9f7-72ad763db397">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:ResearchAndDevelopmentInProcess" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzYtNS0xLTEtODQ0NDQ_98812f38-2f8c-4044-bf56-bf51ea6c4395">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzctMS0xLTEtODQ0NDQ_877b3759-d97a-46fd-b2b9-af8743e3a1b7">490</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzctMy0xLTEtODQ0NDQ_ddae7bfd-48f8-4b10-b39c-52bfe719eb0c">53</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:InvestmentIncomeInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzctNS0xLTEtODQ0NDQ_f26241eb-18a7-4ae4-bff1-884efeed5d25">111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest expense, net of portion capitalized (Note&#160;4)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzgtMS0xLTEtODQ0NDQ_18a94d2b-997b-4860-be8f-b34e40ebd21d">276</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzgtMy0xLTEtODQ0NDQ_d9c42465-fa41-461a-9ad4-ff2ac8ea2740">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:InterestExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzgtNS0xLTEtODQ0NDQ_ffa12976-7e19-4016-b172-552f689c17ad">201</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (income) expense, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzktMS0xLTEtODQ0NDQ_9256bf28-c31b-49b1-ae81-5c1d03116217">1,871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzktMy0xLTEtODQ0NDQ_4bfbeb90-f378-43dd-84bb-4595d5726e27">489</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzktNS0xLTEtODQ0NDQ_ee3d9dbb-3b17-4970-b6c0-7e736cd34c93">2,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restructuring (Note 20)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEwLTEtMS0xLTg0NDQ0_c0d2ea83-d513-4e39-8ea5-4e22f476783a">321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEwLTMtMS0xLTg0NDQ0_973d996d-5011-47b4-ae2b-588ba3fb8e7f">252</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEwLTUtMS0xLTg0NDQ0_b49187b8-a3e4-40e1-8c36-50ffc89900e9">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before provision for taxes on income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzExLTEtMS0xLTg0NDQ0_90e86feb-8571-4591-89a1-006d16e3dbbb">21,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzExLTMtMS0xLTg0NDQ0_98d83c3f-3246-436f-a96a-cd635eb53e2e">22,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzExLTUtMS0xLTg0NDQ0_f36ce766-4be4-4eca-bbb5-a7b5eadeec25">16,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for taxes on income (Note&#160;8)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEyLTEtMS0xLTg0NDQ0_78b1e5bc-9e1d-4cd7-be27-3f622f2598f9">3,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEyLTMtMS0xLTg0NDQ0_acd8b251-0ad5-4d87-b047-bff723e19629">1,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEyLTUtMS0xLTg0NDQ0_a1d70552-7f10-41af-9c69-5748551e94c3">1,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net earnings</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEzLTEtMS0xLTg0NDQ0_68cdabd3-ae47-43d1-9e64-fb9c05c4cc05">17,941</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEzLTMtMS0xLTg0NDQ0_5ae68e1e-a4d4-490b-81cb-324255e5e3eb">20,878</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEzLTUtMS0xLTg0NDQ0_0822c701-4635-47aa-b99d-95ff548a27b5">14,714</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net earnings per share (Notes 1 and 15)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Basic</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE2LTEtMS0xLTg0NDQ0_db19d8bb-a87b-4a30-9ef7-09df8adbfbaa">6.83</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE2LTMtMS0xLTg0NDQ0_0cc0e8a6-d0fe-42e5-a23c-4a50a071e8ae">7.93</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE2LTUtMS0xLTg0NDQ0_67877b5b-ad4f-426c-b4ff-8351e0696267">5.59</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Diluted </span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE3LTEtMS0xLTg0NDQ0_77082265-00f3-4ec6-83d4-985bb8d48649">6.73</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE3LTMtMS0xLTg0NDQ0_966b2012-44af-41ed-9006-a834bbed5abc">7.81</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE3LTUtMS0xLTg0NDQ0_05e51390-9a55-497a-91b8-a5db15881660">5.51</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average shares outstanding (Notes 1 and 15)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Basic</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE5LTEtMS0xLTg0NDQ0_0556ff91-622a-4e0b-aff5-3c07992b1715">2,625.2</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE5LTMtMS0xLTg0NDQ0_516c2766-7ca6-41cf-9d09-c2aba174d3ee">2,632.1</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE5LTUtMS0xLTg0NDQ0_f907dc28-2dac-435c-a00b-a9bb38b615bd">2,632.8</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Diluted</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzIwLTEtMS0xLTg0NDQ0_e3fc8241-28c0-4a49-af63-98b64d562a23">2,663.9</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzIwLTMtMS0xLTg0NDQ0_09917441-094c-40df-bef6-a268f83c7101">2,674.0</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzIwLTUtMS0xLTg0NDQ0_aefc54e2-fde0-4794-8761-85d3c52f24eb">2,670.7</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_124"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Millions) (Note&#160;1)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.935%"><tr><td style="width:1.0%"></td><td style="width:56.295%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.600%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.761%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.890%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.764%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net earnings </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEtMS0xLTEtODQ0NDQ_08afc636-efd6-40e1-810e-ca59ea9b698a">17,941</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEtMy0xLTEtODQ0NDQ_7d3b46aa-c7c7-41df-83ed-1ffc85fd4100">20,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEtNS0xLTEtODQ0NDQ_3806501f-f373-4fc1-8a6e-583c19c62eca">14,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Foreign currency translation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzQtMS0xLTEtODQ0NDQ_5128ca8e-954a-4dcb-8c3b-445c62e4a91e">1,796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzQtMy0xLTEtODQ0NDQ_78169503-a001-484c-afe9-fef89058116e">1,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzQtNS0xLTEtODQ0NDQ_07f9fde7-174d-4245-8d6c-dcaa88a2a4f7">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Securities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unrealized holding gain (loss) arising during period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzctMS0xLTEtODQ0NDQ_ab54c967-c02c-421d-a6bc-41e5f0c818ce">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzctMy0xLTEtODQ0NDQ_c734ee8c-11e4-4e37-91e7-93309ed28381">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzctNS0xLTEtODQ0NDQ_d00c6dc1-ef75-47bb-8aa6-89f0362b4fc3">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzgtMS0xLTEtODQ0NDQ_e08ca63e-74e2-4201-9215-30b65f8b0a3e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzgtMy0xLTEtODQ0NDQ_ed7dae72-2640-4211-bd5c-feb7e87f31d5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzgtNS0xLTEtODQ0NDQ_d8cfbce6-994f-4846-9d7e-e996e6e5364a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzktMS0xLTEtODQ0NDQ_c84ddeaa-27fc-4a67-944e-058dc87a42c2">24</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzktMy0xLTEtODQ0NDQ_f9953042-fcd0-432a-9c71-c04e25d45024">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzktNS0xLTEtODQ0NDQ_cdeee152-ad69-46dc-8be5-60303d5f3cd0">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Employee benefit plans:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Prior service credit (cost), net of amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEyLTEtMS0xLTg0NDQ0_903e26f2-ea6b-4aa8-b538-4092cce4cf92">160</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEyLTMtMS0xLTg0NDQ0_04501413-bb7d-4208-932b-a5cb5c253d72">169</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEyLTUtMS0xLTg0NDQ0_368607ca-29b5-412c-837f-38a23def5582">1,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Gain (loss), net of amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEzLTEtMS0xLTg0NDQ0_da1230e9-a721-46e4-97f6-2d6c6ccd6af8">1,854</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEzLTMtMS0xLTg0NDQ0_ab994eb5-2dd4-42ef-806e-29cef6b51621">4,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEzLTUtMS0xLTg0NDQ0_60f0e16c-74c3-4076-938b-8677e5f97d8f">1,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Effect of exchange rates</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE0LTEtMS0xLTg0NDQ0_6f9d74ae-598e-4964-b5ad-18a9cba6d959">111</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE0LTMtMS0xLTg0NDQ0_6c76037d-3c76-41c6-b67f-5e2244bb218b">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE0LTUtMS0xLTg0NDQ0_3acba7e7-8117-41fa-85aa-9e84a1657abc">229</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE1LTEtMS0xLTg0NDQ0_24220a1b-ac82-4351-b41d-6c3d824fcc66">1,805</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE1LTMtMS0xLTg0NDQ0_24246945-816b-40db-8744-e95f838d912a">4,255</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE1LTUtMS0xLTg0NDQ0_04bd9213-51f0-4343-9ae5-edd8ab4cca6b">66</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;Derivatives &amp; hedges:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Unrealized gain (loss) arising during period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE4LTEtMS0xLTg0NDQ0_d3136d1f-f94c-48f5-b7b9-74a605aece51">454</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE4LTMtMS0xLTg0NDQ0_1087d1c6-2eb5-4cd8-84ac-e489f9cdb765">199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE4LTUtMS0xLTg0NDQ0_1f235593-635a-4448-8b23-3298f165b3d9">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Reclassifications to earnings</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE5LTEtMS0xLTg0NDQ0_d3e6190a-9834-4e50-bb95-4889b5208578">348</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE5LTMtMS0xLTg0NDQ0_5fa88afe-d6c3-48ef-9f60-b6d3eb350a3c">789</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE5LTUtMS0xLTg0NDQ0_800d03fe-83eb-44b8-be80-8bc4bdb6c858">53</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Net change</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzIwLTEtMS0xLTg0NDQ0_93de580e-ce59-45da-969f-59c04a01de0b">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzIwLTMtMS0xLTg0NDQ0_29775933-51ff-4ef8-862b-4498ec83643f">988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzIwLTUtMS0xLTg0NDQ0_3ca3e296-e76c-4419-ae34-723891b5a44e">947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss)</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzIyLTEtMS0xLTg0NDQ0_257512ec-f5fb-4af3-8709-1aaa97c0ccb8">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzIyLTMtMS0xLTg0NDQ0_3af5b411-9072-4fe8-96f0-3d46f08d0754">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzIyLTUtMS0xLTg0NDQ0_d90c20c8-48cd-4f6e-bd6b-cf766f7bfb68">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income </span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzI0LTEtMS0xLTg0NDQ0_ed661d29-dd99-4615-a2b0-7e33c174f4a3">18,032</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzI0LTMtMS0xLTg0NDQ0_facc923f-7944-4e35-8cc5-fe160f7eacc6">23,062</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzI0LTUtMS0xLTg0NDQ0_d1f94148-b8d6-4146-9fd5-55cabdf5b832">15,363</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The tax effects in other comprehensive income for the fiscal years 2022, 2021 and 2020 respectively: Foreign Currency Translation; $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8xMzY_a6850446-75bc-4486-a8f6-2587a4602a91">460</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8xNDk_9bf6e8c8-53ed-4ba0-8498-3cfdebe4d201">346</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8xNjU_d98b6f68-9af2-4a6f-ae36-eb7fa71c98ac">536</ix:nonFraction> million; Securities: $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8xOTA_69d20e77-c7d0-4171-bd76-d593fe0a5d3b">6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF82NTk3MDY5NzY3MDI0_3d176449-85ee-479e-93e1-7e066f0626b9">1</ix:nonFraction> million in 2022 and 2021, Employee Benefit Plans: $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8yMzU_b717d770-a409-465c-a8b0-d8dbc6b530a6">461</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8yNDg_278b4007-f759-4aa3-837c-dd713a0ae745">1,198</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8yNjQ_81985f53-da51-42cb-a81f-c8a086751dda">21</ix:nonFraction> million, Derivatives &amp; Hedges: $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8yOTk_5988ba7b-ceec-4356-b0eb-f6b47debfdba">30</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8zMTI_1fe4c543-d307-48b5-852c-595b48f75963">263</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8zMjg_a40397d9-59b8-4fb8-a505-5bc055fe01ac">252</ix:nonFraction> million.</span></div></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_130"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOHNSON&#160;&amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Millions) (Note&#160;1)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.807%"><tr><td style="width:1.0%"></td><td style="width:34.624%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.512%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.444%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.662%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.341%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.053%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.593%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.110%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.743%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.518%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retained<br/>Earnings</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Other<br/>Comprehensive<br/>Income (Loss)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock<br/>Issued Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury<br/>Stock<br/>Amount</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, December 29, 2019</span></td><td style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEtMS0xLTEtODQ0NDQ_88abda68-2597-4e79-895a-137e3ba5897c">59,471</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie0d81a2faf2847ea921dc2fc7b6a23ce_I20191229" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEtMy0xLTEtODQ0NDQ_4f64efc2-d16a-4be2-bf1b-fc39156ab48a">110,659</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9807f0aec4641a1ac4bec134b355aad_I20191229" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEtNS0xLTEtODQ0NDQ_a989a7ee-24cb-4c1d-a5fe-f3302c8c4aa8">15,891</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86826cf58c434c3ea3d165935690175b_I20191229" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEtNy0xLTEtODQ0NDQ_11e458bd-962a-47e9-a9e6-72c4be702067">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6c5dd290ffc74ea1be26c69d111518e6_I20191229" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEtOS0xLTEtODQ0NDQ_1332b001-e7a5-4fce-a05d-605f39785d2e">38,417</ix:nonFraction>)</span></td><td style="border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net earnings </span></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzMtMS0xLTEtODQ0NDQ_8804d56f-d7c3-4337-bb78-86c8db98c162">14,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2730b868c9a489d915184459e52ff91_D20191230-20210103" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzMtMy0xLTEtODQ0NDQ_d052d1c4-bbb7-4a56-9732-54b56881412e">14,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzQtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjowM2QyZTMxN2E2ZjM0YzIwODhkMmUyYTQyN2FjNjAzYl8yNg_bf8e3695-1c6a-4336-ba4f-fa350303dd19">3.98</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzQtMS0xLTEtODQ0NDQ_3743828c-ff96-4acc-b0b5-a6564fd59b9f">10,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2730b868c9a489d915184459e52ff91_D20191230-20210103" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzQtMy0xLTEtODQ0NDQ_96e0900c-c3d8-4152-834f-ed1a22f48d43">10,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzUtMS0xLTEtODQ0NDQ_b5745ccf-7799-4f7f-beda-d55b2efbf613">2,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2730b868c9a489d915184459e52ff91_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzUtMy0xLTEtODQ0NDQ_207be59a-2b32-4934-8049-e86d68caeb76">931</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e50ef6296740dda9036c6c59bae7a8_D20191230-20210103" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzUtOS0xLTEtODQ0NDQ_8f7bd354-f7f6-4e8f-847b-0567dd10573b">3,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzYtMS0xLTEtODQ0NDQ_0384a122-85bb-4930-b370-69c3ecef7748">3,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib7e50ef6296740dda9036c6c59bae7a8_D20191230-20210103" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzYtOS0xLTEtODQ0NDQ_a7b5fc9f-d502-4d4c-977c-d0be063d8091">3,221</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzctMS0xLTEtODQ0NDQ_e510074a-9dea-4d67-a78e-413de1e5a297">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if2730b868c9a489d915184459e52ff91_D20191230-20210103" decimals="-6" name="us-gaap:StockholdersEquityOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzctMy0xLTEtODQ0NDQ_3a9396f3-5739-4656-b2cf-89290de23598">71</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzgtMS0xLTEtODQ0NDQ_45ca41a5-46c6-431a-b206-c95cf0f6509b">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a2bd92352194bcdb8a871945d2b04b6_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzgtNS0xLTEtODQ0NDQ_c1e647f2-9957-492e-9405-864fa71e5086">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 3, 2021</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzktMS0xLTEtODQ0NDQ_da3d3f47-da31-4021-8818-b05ab1e62002">63,278</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie485eb6b64444292b2444b1661ce61de_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzktMy0xLTEtODQ0NDQ_a5a66e46-6dce-4c7b-90fd-8dd0a897a93c">113,890</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81bc749533a9432f82631e2ec08fb7c4_I20210103" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzktNS0xLTEtODQ0NDQ_cb288cbb-5ba9-41e6-9d72-ee860936bb73">15,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i011816d4a7074b90ad92edd54a14570a_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzktNy0xLTEtODQ0NDQ_74c97513-4360-4908-841e-bf8d4bc0204c">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i22968ecd8b144767bf02c951d4deb7ae_I20210103" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzktOS0xLTEtODQ0NDQ_04b69fc3-2040-4e75-bd2f-cb55dc2d52ca">38,490</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net earnings</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzExLTEtMS0xLTg0NDQ0_ec95f51b-7793-475b-ba73-951a2eaa4500">20,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646e87c85036437b9c9703c88ff78a63_D20210104-20220102" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzExLTMtMS0xLTg0NDQ0_3fe8842c-4d38-4a18-aaea-26f49dc2a27e">20,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEyLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246M2ExZmQ5NmU3MTU2NDZkODkyMTM3NzllOTJmOTNhNDVfMjY_45ff67a9-b8cf-4525-93b6-12af065f781e">4.19</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEyLTEtMS0xLTg0NDQ0_4cc5c305-2bec-4afe-be1c-eea6789f8920">11,032</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646e87c85036437b9c9703c88ff78a63_D20210104-20220102" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEyLTMtMS0xLTg0NDQ0_58e31ad0-1619-47b0-a5d2-6a9495ca0ced">11,032</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEzLTEtMS0xLTg0NDQ0_a0d08a00-d3c4-455c-b26e-70bf90e713df">2,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i646e87c85036437b9c9703c88ff78a63_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEzLTMtMS0xLTg0NDQ0_075224d2-d77f-42b4-9ab7-3913a0b9e5cc">676</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica40f5d5420a42c4baf327e28f3ff166_D20210104-20220102" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEzLTktMS0xLTg0NDQ0_8f00cd52-b66e-4141-b556-fc0b993fa27d">2,847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE0LTEtMS0xLTg0NDQ0_35ff5675-4503-4ff7-9ec8-df6a6b4b3cc8">3,456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ica40f5d5420a42c4baf327e28f3ff166_D20210104-20220102" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE0LTktMS0xLTg0NDQ0_7781383f-475c-4336-afe8-be8447d5f5a8">3,456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE2LTEtMS0xLTg0NDQ0_1c66e6f3-6f87-4fe3-85d8-ea142057c213">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieade5efd55fc4e7f9b55b76ad9b270a0_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE2LTUtMS0xLTg0NDQ0_b5181394-fc58-4f98-b472-399dc833e5ee">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 2, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE3LTEtMS0xLTg0NDQ0_cade66b0-2049-4878-8076-3cc56a939d17">74,023</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec1f1ce9d602483b960c5f739d33f211_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE3LTMtMS0xLTg0NDQ0_5dabeb4e-3195-41e3-af24-6e095aedd727">123,060</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icec2276dbd2e4d76878d45adc66f315e_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE3LTUtMS0xLTg0NDQ0_19c6bf87-baba-400f-a487-f1ff29fbbcb9">13,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ef1d9f1b2874c9dadea9df7caa69641_I20220102" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE3LTctMS0xLTg0NDQ0_f76c8f1c-6ee3-4de5-a64f-1c08c9e0c438">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia2339bc2da5948afb7331d7646e12408_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE3LTktMS0xLTg0NDQ0_4b2c8c81-32e2-450d-ab57-6e4033ace196">39,099</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net earnings </span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE5LTEtMS0xLTg0NDQ0_5ed4e766-29e4-4a6e-a05e-8f1aca9d592f">17,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b341fec469b4745a481f3935cfdc814_D20220103-20230101" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE5LTMtMS0xLTg0NDQ0_8d8c7eb2-3f82-40e8-b7c9-6bef70d7e1c1">17,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash dividends paid ($<ix:nonFraction unitRef="usdPerShare" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="INF" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzIwLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MzkzYWQ2ZmYyNTBjNGIxMGIxOThkNjY2Yzg3NTc2MDZfMjY_39d44a4d-3db0-4969-b3a1-4e6ac2fcaf17">4.45</ix:nonFraction> per share)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzIwLTEtMS0xLTg0NDQ0_630e5431-0a39-4641-b7f8-5d5d68dae3ef">11,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b341fec469b4745a481f3935cfdc814_D20220103-20230101" decimals="-6" name="us-gaap:DividendsCommonStockCash" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzIwLTMtMS0xLTg0NDQ0_6a723d08-e7cd-49ef-a390-94822b1aaf69">11,682</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzIxLTEtMS0xLTg0NDQ0_632fad99-8672-48e0-a386-1d2497492aa4">2,466</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9b341fec469b4745a481f3935cfdc814_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzIxLTMtMS0xLTg0NDQ0_92bec0cc-8d30-4559-8eb5-c3ac0abb042d">974</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd8a9ce6ebc4c33ba835359ee340f7a_D20220103-20230101" decimals="-6" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzIxLTktMS0xLTg0NDQ0_69fe56e3-786c-4435-8ead-d1882fc89ca9">3,440</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzIyLTEtMS0xLTg0NDQ0_9d81d158-5178-4ac1-9680-7789607d8734">6,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0bd8a9ce6ebc4c33ba835359ee340f7a_D20220103-20230101" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzIyLTktMS0xLTg0NDQ0_064b54e4-b7e3-4172-b1ec-f8807e86a574">6,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive income (loss), net of tax</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzI0LTEtMS0xLTg0NDQ0_ff842e70-f846-47bc-9fbc-e71fadb950df">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb64fb4e20f1404cbc6e31613ca7eef9_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzI0LTUtMS0xLTg0NDQ0_82a43447-1e9f-431f-a8b5-56a6e925a866">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, January 1, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzI1LTEtMS0xLTg0NDQ0_6c6e583f-36bc-4f11-bfb5-0d618a0770f0">76,804</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id693fb46504d40baa0ff184c359c60c3_I20230101" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzI1LTMtMS0xLTg0NDQ0_08ac406f-f86a-446e-90eb-e86ef4004d5d">128,345</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8ed0029b3204669a3f2d23dad442d8e_I20230101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzI1LTUtMS0xLTg0NDQ0_89f76fcd-76ed-4428-993d-85c8c64f99e6">12,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e876c735af9409796c44f0d4a41a05a_I20230101" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzI1LTctMS0xLTg0NDQ0_ba21c56b-4b47-4245-b1f9-387db5b0a0b6">3,120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4b74a9312aa14cef802c651c6aca0f51_I20230101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzI1LTktMS0xLTg0NDQ0_16bf592d-aac7-4919-be3b-2fd387af6147">41,694</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt"><span><br/></span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_136"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">JOHNSON &amp; JOHNSON AND SUBSIDIARIES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Dollars in Millions) (Note 1)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:61.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.851%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net earnings</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzItMS0xLTEtODQ0NDQ_af3b81ad-0f72-445e-baaf-1b58c7c97da1">17,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzItMy0xLTEtODQ0NDQ_ec824388-ea80-4c05-becd-935b34e3136e">20,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzItNS0xLTEtODQ0NDQ_b2d5df67-58df-4b48-ae2d-84ab73bb0b30">14,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net earnings to cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization of property and intangibles</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQtMS0xLTEtODQ0NDQ_016787ff-b5b7-450d-9b40-8af9d649aa35">6,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQtMy0xLTEtODQ0NDQ_f7e5c810-ff12-4833-bbb7-bd4e49ad5390">7,390</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQtNS0xLTEtODQ0NDQ_e5942dbc-3e06-41ac-bc7a-51d7ee104878">7,231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUtMS0xLTEtODQ0NDQ_79c71fe3-b701-4c7a-bd30-b4aa58ea2da4">1,138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUtMy0xLTEtODQ0NDQ_ca8acb0b-4198-4da6-a14a-dde9e22ac0f5">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUtNS0xLTEtODQ0NDQ_33117aa5-a50b-4b29-bb9f-d258aa4ef36f">1,005</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asset write-downs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzctMS0xLTEtODQ0NDQ_2c27add5-ed58-42e2-abbe-d3c7f03dcae0">1,216</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzctMy0xLTEtODQ0NDQ_30bcf894-f624-4637-acac-db648232d8b6">989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:AssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzctNS0xLTEtODQ0NDQ_472a20e1-e5f6-4b14-846f-bdd3150fb3af">233</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Contingent consideration reversal</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzgtMS0xLTEtODQ0NDQ_7d93c7ca-2da0-46e4-b570-02cc7ba33e55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzgtMy0xLTEtODQ0NDQ_28276b36-c5c2-4075-88be-3f1343e449bb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzgtNS0xLTEtODQ0NDQ_b1ef7937-ae57-4781-84a3-2b106caa7dfd">1,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net gain on sale of assets/businesses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzktMS0xLTEtODQ0NDQ_b866d479-06d5-4ff2-9fd1-d02760095e46">380</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzktMy0xLTEtODQ0NDQ_2ddb6564-551c-4b5a-bf6f-14538c87c070">617</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzktNS0xLTEtODQ0NDQ_236ace0e-0954-4ac8-9c50-07acabe4f768">111</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax provision</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzExLTEtMS0xLTg0NDQ0_5d8e0994-a5e6-4f1d-95c0-6502e0fc8d5d">1,663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzExLTMtMS0xLTg0NDQ0_3eccca0e-c076-4eb8-8128-30b63e9fab73">2,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzExLTUtMS0xLTg0NDQ0_acd67ad8-d7cf-4495-ac17-46a0edb6d2fd">1,141</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit losses and accounts receivable allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzEyLTEtMS0xLTg0NDQ0_d2aa60f4-cae3-49d4-91d7-29452aa9f4c6">17</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzEyLTMtMS0xLTg0NDQ0_1d700ff5-e09b-479e-bc44-643b95310621">48</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:ProvisionForDoubtfulAccounts" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzEyLTUtMS0xLTg0NDQ0_19cea028-b168-42a2-9fe9-d51715c2da2b">63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Increase)/Decrease in accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE0LTEtMS0xLTg0NDQ0_e02a946d-53d4-48e1-8cef-bfe9aeaaae46">1,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE0LTMtMS0xLTg0NDQ0_fa883095-5b78-4123-8658-272e80825ab9">2,402</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE0LTUtMS0xLTg0NDQ0_0e06b377-813b-4e9d-80bc-3f22005b8a06">774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in inventories</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE1LTEtMS0xLTg0NDQ0_30e8ac7f-68df-46cc-8850-de5258c71474">2,527</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE1LTMtMS0xLTg0NDQ0_54465125-c7d4-4cf7-82a2-6acdc9f6a58b">1,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:IncreaseDecreaseInInventories" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE1LTUtMS0xLTg0NDQ0_1e586a51-efa0-4a56-9b50-f18b5fb43b2b">265</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increase in accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE2LTEtMS0xLTg0NDQ0_543333d8-a69f-451e-9aab-036326019440">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE2LTMtMS0xLTg0NDQ0_5250da0b-59b7-43a2-a821-62314090e185">2,437</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE2LTUtMS0xLTg0NDQ0_d36fbbd0-e475-4d47-b2a0-403b655ebabe">5,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Decrease/(Increase) in other current and non-current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE3LTEtMS0xLTg0NDQ0_122f6f6b-d1b3-48ca-8ab5-71652b6fdcdb">687</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE3LTMtMS0xLTg0NDQ0_180395c1-8736-4fc0-960e-e09a515ed1b9">1,964</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE3LTUtMS0xLTg0NDQ0_d62de0ef-a0a8-460e-a2d5-123067624bcd">3,704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Decrease)/Increase in other current and non-current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE4LTEtMS0xLTg0NDQ0_d29288cd-a453-4370-b4e5-0d7fb9c7464b">1,979</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE4LTMtMS0xLTg0NDQ0_dbb1d6a1-144f-4f95-849f-b26b75e75746">1,061</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE4LTUtMS0xLTg0NDQ0_b1192422-d33e-4b6f-b88a-52b1bb812e72">744</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash flows from operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE5LTEtMS0xLTg0NDQ0_1a932995-2730-4ca2-b2da-ebc92ee773f6">21,194</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE5LTMtMS0xLTg0NDQ0_f2ce4fb8-1236-4535-b76a-ab82fc7dda31">23,410</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE5LTUtMS0xLTg0NDQ0_f0751f94-3226-463d-bef4-d874df6b639c">23,536</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additions to property, plant and equipment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIxLTEtMS0xLTg0NDQ0_24733dd6-ac4d-4201-b439-dcd73e197221">4,009</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIxLTMtMS0xLTg0NDQ0_3fa00997-3260-4a0e-8ecf-008200c7182d">3,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIxLTUtMS0xLTg0NDQ0_5ba10700-a899-4998-be05-25f4fec6cf37">3,347</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the disposal of assets/businesses, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIyLTEtMS0xLTg0NDQ0_02f87a88-baae-4786-9544-0f9faee6c3ef">543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIyLTMtMS0xLTg0NDQ0_4868e587-f7b5-4fe3-bcbd-5bfab688e3a0">711</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:ProceedsFromSaleOfProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIyLTUtMS0xLTg0NDQ0_208b51e4-6530-4935-9c64-26093fb4e8c2">305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acquisitions, net of cash acquired (Note&#160;18)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIzLTEtMS0xLTg0NDQ0_e9b6d926-ffaa-4d56-b638-428064461517">17,652</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIzLTMtMS0xLTg0NDQ0_71f0a3ba-7654-4142-ace5-22b299e9c6ff">60</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIzLTUtMS0xLTg0NDQ0_122bb212-2a85-4311-97db-808544a3c276">7,323</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI0LTEtMS0xLTg0NDQ0_770aec0b-fd54-4b9e-923c-ae03ed44b2c0">32,384</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI0LTMtMS0xLTg0NDQ0_82664ef9-04f6-442a-85a1-e0db6f677d8e">30,394</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:PaymentsToAcquireInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI0LTUtMS0xLTg0NDQ0_7bbfa543-8ef1-4347-b8aa-97d04cc7053d">21,089</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI1LTEtMS0xLTg0NDQ0_b4b635d3-9c98-4c18-930e-1dac8f22f9aa">41,609</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI1LTMtMS0xLTg0NDQ0_7585a807-f2a1-4ef2-8e38-f29d6fd80019">25,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI1LTUtMS0xLTg0NDQ0_203b629b-1f89-43be-ba8b-8cb16b9f5441">12,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI2LTEtMS0xLTg0NDQ0_4c683fd0-7706-4085-b4fa-665ee3ffc3c8">249</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI2LTMtMS0xLTg0NDQ0_1fc483e0-cf1a-4af3-93f0-d5ff83d9dfab">214</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI2LTUtMS0xLTg0NDQ0_d7f74caf-1921-479b-b891-446fb16fae21">987</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other (primarily licenses and milestones)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI3LTEtMS0xLTg0NDQ0_12f19723-787b-4658-bf79-c1c638e5b16a">229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI3LTMtMS0xLTg0NDQ0_1bae97ff-e3dc-4d7b-8d7f-6f562e869ed0">508</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI3LTUtMS0xLTg0NDQ0_cb13b61e-c3d8-4290-a4a6-53b949e29c7c">521</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash used by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI4LTEtMS0xLTg0NDQ0_23927a9a-8ce4-40c2-9a9c-2b0d0b93a962">12,371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI4LTMtMS0xLTg0NDQ0_a39eddb2-aff0-4fc0-84bf-df368eae132d">8,683</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI4LTUtMS0xLTg0NDQ0_c004f2f6-a245-4424-bdbe-a8af50503b10">20,825</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dividends to shareholders</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMwLTEtMS0xLTg0NDQ0_11a5ca8c-27a3-491f-8022-a4da73f658a4">11,682</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMwLTMtMS0xLTg0NDQ0_40e860ec-d2d7-45cc-b576-445fac9f8268">11,032</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:PaymentsOfOrdinaryDividends" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMwLTUtMS0xLTg0NDQ0_038a966c-cbed-4c1e-ac1a-474591f01b1f">10,481</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMxLTEtMS0xLTg0NDQ0_e13e4702-c2b8-4457-805a-0b232f8845cf">6,035</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMxLTMtMS0xLTg0NDQ0_55d48d78-ee86-482d-a2c4-0422fc12f8db">3,456</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMxLTUtMS0xLTg0NDQ0_5c14527f-941e-4b27-a05e-0b02c423247f">3,221</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from short-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMyLTEtMS0xLTg0NDQ0_fa3a1180-d7be-44f3-a26a-0c02a9a8e401">16,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMyLTMtMS0xLTg0NDQ0_08ce970c-6b54-4073-b696-cde5fbea35d4">1,997</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:ProceedsFromShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMyLTUtMS0xLTg0NDQ0_339f9e47-9402-4fd1-88d3-e8a815dcdc0c">3,391</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of short-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMzLTEtMS0xLTg0NDQ0_51b92db4-86e4-4172-92a9-d03928a31c9d">6,550</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMzLTMtMS0xLTg0NDQ0_690569fe-efcb-4d7b-b09e-67cd6ebe9736">1,190</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:RepaymentsOfShortTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMzLTUtMS0xLTg0NDQ0_78d6ebce-92b0-4a06-9efb-29200b8c1379">2,663</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from long-term debt, net of issuance costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM0LTEtMS0xLTg0NDQ0_4b11f41d-c4a4-4ac6-8638-828db8dca99f">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM0LTMtMS0xLTg0NDQ0_fce24748-c94d-4bbc-9f6d-77d0ed45045d">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM0LTUtMS0xLTg0NDQ0_322fb33a-0d06-4121-9a7d-1966a3624d6e">7,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Repayment of long-term debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM1LTEtMS0xLTg0NDQ0_8f02e467-994e-46f4-bd7a-6cc3ff889425">2,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM1LTMtMS0xLTg0NDQ0_eaf33c37-f5d8-4108-af0b-5f36f33f4f24">1,802</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM1LTUtMS0xLTg0NDQ0_c971e27f-75e6-4423-bc7b-5761247ad77a">1,064</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM2LTEtMS0xLTg0NDQ0_380a5b3f-8731-4e8c-bb4d-46090787e6f0">1,329</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM2LTMtMS0xLTg0NDQ0_95e5e173-84a7-49ba-aaba-66d78cef6cf7">1,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM2LTUtMS0xLTg0NDQ0_2da6dfa9-3790-4515-b2a3-164b2a8c34cd">1,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Credit support agreements activity, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM3LTEtMS0xLTg0NDQ0_98e578aa-3858-490b-addf-99f72f0bb2b4">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM3LTMtMS0xLTg0NDQ0_e9bb7116-19ca-48c3-b506-b07ae0788103">281</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM3LTUtMS0xLTg0NDQ0_3cffb60a-a19b-46ac-8100-3a7af5a21670">333</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM4LTEtMS0xLTg0NDQ0_9b1b449a-5de0-4227-9b21-9cbd6b9fcc3e">93</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM4LTMtMS0xLTg0NDQ0_83bb0594-7d9f-4e72-84f0-7c504d063c4c">114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM4LTUtMS0xLTg0NDQ0_dabe8505-6a27-463a-8f61-5d0e00d440b6">294</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net cash used by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM5LTEtMS0xLTg0NDQ0_b2c13166-c384-46dc-a4c4-84bd953a2fd8">8,871</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM5LTMtMS0xLTg0NDQ0_fa67e404-2a7f-474f-a63f-a0364010ca30">14,047</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM5LTUtMS0xLTg0NDQ0_95210754-3e2a-4e7a-9f24-0b3b83fb179f">6,120</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of exchange rate changes on cash and cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQwLTEtMS0xLTg0NDQ0_11efbafe-03d2-49ba-8cc1-f3cbc3bb192e">312</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQwLTMtMS0xLTg0NDQ0_98d815dc-01b6-4a0b-a366-d1521e997aab">178</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQwLTUtMS0xLTg0NDQ0_7002d7db-14a5-4781-8b37-834872991802">89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(Decrease)/Increase in cash and cash equivalents</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQxLTEtMS0xLTg0NDQ0_47406562-397f-40c3-99b5-e4a4f3c2b439">360</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQxLTMtMS0xLTg0NDQ0_b6565be4-ca33-49b8-9b83-ae3b70e5aea1">502</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQxLTUtMS0xLTg0NDQ0_355e2df3-02b3-4b88-9e32-3528b3148a80">3,320</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents, beginning of year (Note&#160;1)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQyLTEtMS0xLTg0NDQ0_3e63211e-ef39-4b45-9dde-adc00461b835">14,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQyLTMtMS0xLTg0NDQ0_033c4b90-1e6d-4211-a864-ece19ae3bc72">13,985</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQyLTUtMS0xLTg0NDQ0_cb281bd8-eca0-4702-9afd-339c8b5e6740">17,305</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash and cash equivalents, end of year (Note&#160;1)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQzLTEtMS0xLTg0NDQ0_ad4b4d4f-a0ec-4d25-917d-e89eb6de74b2">14,127</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQzLTMtMS0xLTg0NDQ0_d997b868-b35b-4a93-a10c-0dec55ab94ea">14,487</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="-6" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQzLTUtMS0xLTg0NDQ0_abd7b143-c476-44ce-a83b-5ffc4cad3524">13,985</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental cash flow data</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash paid during the year for:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ3LTEtMS0xLTg0NDQ0_3368bd88-a47b-492a-b3cd-64207ae302a9">982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ3LTMtMS0xLTg0NDQ0_1fd22f11-5634-44de-86e0-f550ca56dc72">990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:InterestPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ3LTUtMS0xLTg0NDQ0_5568dbab-eea7-478a-a09a-377eb0840a6b">904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest, net of amount capitalized</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ4LTEtMS0xLTg0NDQ0_273b7357-7de4-43ba-bd35-810c8f14e8ae">933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ4LTMtMS0xLTg0NDQ0_0da598b5-1423-4d63-a925-5d43dd12a6cf">941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:InterestPaidNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ4LTUtMS0xLTg0NDQ0_e42ff6e0-2e2b-4e3b-8c46-dde7be2f00ca">841</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ5LTEtMS0xLTg0NDQ0_c1fb193f-f83e-4827-8cb9-d8b9e63d2166">5,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ5LTMtMS0xLTg0NDQ0_3b61e12d-a926-4b80-84fc-ee4a606846de">4,768</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:IncomeTaxesPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ5LTUtMS0xLTg0NDQ0_71285da1-2af9-4c12-a2ac-28458df2f3a2">4,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.982%"><tr><td style="width:1.0%"></td><td style="width:61.793%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.692%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.586%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.851%"></td><td style="width:0.1%"></td></tr><tr style="height:38pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Supplemental schedule of non-cash investing and financing activities</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUyLTEtMS0xLTg0NDQ0_5102e0c2-f56b-43fa-aa1b-c7952e9c6720">2,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUyLTMtMS0xLTg0NDQ0_2125c33f-fd82-4f17-800f-3fedef65eb97">1,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUyLTUtMS0xLTg0NDQ0_9ce20aa2-b677-4579-b372-c38cdbb54b58">1,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conversion of debt</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUzLTEtMS0xLTg0NDQ0_836ef4a5-3e02-46eb-8a04-6ffd1bb7e70a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUzLTMtMS0xLTg0NDQ0_96a9a66c-dd04-4df0-a7e3-b2c4814821ff">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:DebtConversionConvertedInstrumentAmount1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUzLTUtMS0xLTg0NDQ0_d73787c0-ebf2-4e89-918e-dd4592b36b05">27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Acquisitions</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of assets acquired</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU2LTEtMS0xLTg0NDQ0_baf3eb62-cc58-432e-81fe-864c2fe0e66e">18,710</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU2LTMtMS0xLTg0NDQ0_a518cd3d-d56b-4c44-85f9-4bd6e4bc9d25">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU2LTUtMS0xLTg0NDQ0_c1ea5787-64b9-4eca-8bd2-37643f7c058d">7,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Fair value of liabilities assumed</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU3LTEtMS0xLTg0NDQ0_12a46762-8d1d-4b65-8777-a238bf2f6d2e">1,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU3LTMtMS0xLTg0NDQ0_8d968fde-fe64-47b5-ac91-59b210526969">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU3LTUtMS0xLTg0NDQ0_644865bc-c604-4c28-a795-4cc75387763f">432</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash paid for acquisitions (Note 18)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU4LTEtMS0xLTg0NDQ0_dc6b50af-fe6d-4c4e-ac3f-eceb70054e0f">17,652</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU4LTMtMS0xLTg0NDQ0_36c906a3-f3ea-4e81-95c5-27cb52a7f914">60</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU4LTUtMS0xLTg0NDQ0_84c20786-e239-4d50-b67c-e1fb22fba43a">7,323</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See Notes to Consolidated Financial Statements</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_139"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="margin-top:7pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_142"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzQ5_1b3ddae5-8081-4199-b8c8-9d489c5b3388" continuedAt="i393a88b3bfe749c798f23ff93f2a8005" escape="true">Summary of Significant Accounting Policies</ix:nonNumeric></span></div><ix:continuation id="i393a88b3bfe749c798f23ff93f2a8005" continuedAt="id426de1f23ad42d1ba0c0e08831213ff"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzIy_5416d2a9-aa54-43f8-a6b4-0a395bde0263" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Johnson&#160;&amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODIz_5dd2d0b6-1db0-4906-951c-a64feffe8f60" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of the Company and Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately <ix:nonFraction unitRef="employee" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-2" name="jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzQ1NA_1998cb8f-ed43-4ba5-988b-0e64e8921d69">152,700</ix:nonFraction>&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is organized into <ix:nonFraction unitRef="segment" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzc3MA_984d5d56-ff3f-4a84-8cd3-907a6e3a561d">three</ix:nonFraction> business segments: Consumer Health, Pharmaceutical and MedTech. The Consumer Health segment includes a broad range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-Counter pharmaceutical, Women&#8217;s Health and Wound Care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on the following therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2021, the Company announced its intention to separate the Company&#8217;s Consumer Health business (Kenvue as the name for the planned New Consumer Health Company), with the intention to create a new, publicly traded company by the end of the fiscal year 2023.</span></div></ix:nonNumeric><div style="margin-top:3pt"><span><br/></span></div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODMy_029588fb-92af-470e-a50a-79e6de8e8335" escape="true"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in fiscal 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Adopted as of January 1, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50) &#8211; Disclosure of Supplier Finance Program Obligations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This update requires that a buyer in a supplier finance program disclose additional information about the program to allow financial statement users to better understand the effect of the programs on an entity&#8217;s working capital, liquidity, and cash flows. This update will be effective for the Company for fiscal years beginning after December 15, 2022, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently assessing the impact of this update on its disclosures and will adopt this standard in the fiscal first quarter of 2023.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzMw_41e68ad7-9f96-40ca-9646-196d9b3e11db" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.  The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than <ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="INF" name="jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzUwMzE_a2e3d338-4f68-4763-9a5e-322e411115eb">102</ix:nonFraction>% of their value.  The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at <ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="INF" name="jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzU0MDQ_73427cfe-7912-42d5-b9a3-1b96e443e4cd">102</ix:nonFraction>% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:InvestmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODI1_52bebfe5-a4ab-4e70-853f-41bdf44d7c58" continuedAt="i9eff685f360147c8bbba8c14643debf5" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id426de1f23ad42d1ba0c0e08831213ff" continuedAt="i490f9a8ecb884c529d18f14ae37a672e"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9eff685f360147c8bbba8c14643debf5">losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.</ix:continuation>&#160;</span></div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODM4_475c8eec-e420-4339-b657-2eee5d336d83" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment and Depreciation</span></div><div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="jnj:EstimatedUsefulLivesOfAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2Nzg5_fb2fbb56-aad0-4a08-b1fe-5d41be05c63f" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"></td><td style="width:86.011%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.789%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4f6dd96b61df4014b63f77ec38d4f931_D20220103-20230101" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90YWJsZTowOTZkMjk2YTNkNDk0YTRlYWFkY2QxYTlhNTVhZWIwZS90YWJsZXJhbmdlOjA5NmQyOTZhM2Q0OTRhNGVhYWRjZDFhOWE1NWFlYjBlXzAtMS0xLTEtODQ0NDQvdGV4dHJlZ2lvbjphMmYxMWJlNWRjZDQ0NDFlOGI5ZTk5MmZhZWM5YjkxMV85_53fab3cb-7b8e-46b1-8a03-94cffffec916">30</ix:nonNumeric>&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="icc105f8c066041479b85014a44b4f246_D20220103-20230101" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90YWJsZTowOTZkMjk2YTNkNDk0YTRlYWFkY2QxYTlhNTVhZWIwZS90YWJsZXJhbmdlOjA5NmQyOTZhM2Q0OTRhNGVhYWRjZDFhOWE1NWFlYjBlXzEtMS0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo4YTk1MWUyMGQ1Y2M0ZGQzOWUwZTBlYzJhMzIwYWRiMF80_1423d52b-4061-468d-89cf-a607c6597426">10</ix:nonNumeric>&#160;- <ix:nonNumeric contextRef="if67355a8e31e4d4e89a2d4cc2404fd2a_D20220103-20230101" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90YWJsZTowOTZkMjk2YTNkNDk0YTRlYWFkY2QxYTlhNTVhZWIwZS90YWJsZXJhbmdlOjA5NmQyOTZhM2Q0OTRhNGVhYWRjZDFhOWE1NWFlYjBlXzEtMS0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo4YTk1MWUyMGQ1Y2M0ZGQzOWUwZTBlYzJhMzIwYWRiMF85_93b365a0-8c77-4cf0-99bf-d77505600d38">20</ix:nonNumeric>&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i1a7641e1bba746ceacabd5c374aae1d9_D20220103-20230101" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90YWJsZTowOTZkMjk2YTNkNDk0YTRlYWFkY2QxYTlhNTVhZWIwZS90YWJsZXJhbmdlOjA5NmQyOTZhM2Q0OTRhNGVhYWRjZDFhOWE1NWFlYjBlXzItMS0xLTEtODQ0NDQvdGV4dHJlZ2lvbjoxOWQ2NGI3NGI1NzM0ODJiODkxYmI3M2JlZTIzMzRiNF80_48f0b324-1e12-4fe2-ab0f-5b1b41d6efdc">2</ix:nonNumeric>&#160;- <ix:nonNumeric contextRef="i5bd05c5ccad24c3e9251efadcad9b101_D20220103-20230101" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90YWJsZTowOTZkMjk2YTNkNDk0YTRlYWFkY2QxYTlhNTVhZWIwZS90YWJsZXJhbmdlOjA5NmQyOTZhM2Q0OTRhNGVhYWRjZDFhOWE1NWFlYjBlXzItMS0xLTEtODQ0NDQvdGV4dHJlZ2lvbjoxOWQ2NGI3NGI1NzM0ODJiODkxYmI3M2JlZTIzMzRiNF85_7a6dc7a3-2ea3-4434-b86a-d48789071cba">13</ix:nonNumeric>&#160;years</span></div></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from <ix:nonNumeric contextRef="i1c19938fb98647cb9ab6821478e99ec4_D20220103-20230101" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzY5MDk_ce2f2f7e-7a76-4d39-bf05-7fca535f7645">3</ix:nonNumeric> to <ix:nonNumeric contextRef="ibe54a493eb1a41b6b7d5520bdcfdcbf9_D20220103-20230101" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzY5MTU_9cdd1959-3e8c-413d-be77-d849a2f5181c">8</ix:nonNumeric>&#160;years.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODA4_50268a46-9e56-4b07-a637-f77562c5677e" continuedAt="i2cd90a9eef4447dcbb585c48a2273401" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Managed Care, Medicare and Medicaid programs, which amounted to $<ix:nonFraction unitRef="usd" contextRef="i6f076cad0e094616a814262376cb5191_I20230101" decimals="-8" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzg3MDE_44f08c75-971d-487b-a099-8cd58213dcb7">9.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ia4852527980040579d16cf952b6a58ff_I20220102" decimals="-8" name="jnj:AccruedRebatesReturnsAndPromotions" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzg3MDg_ded2507c-cf02-4670-8fcd-493ef50cb447">7.7</ix:nonFraction> billion as of January&#160;1, 2023 and January&#160;2, 2022, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately <ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="3" name="jnj:SalesReturnReserve" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzEwMjQ0_85a86da4-3fce-4582-bdf8-a81b2624303b"><ix:nonFraction unitRef="number" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="3" name="jnj:SalesReturnReserve" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzEwMjQ0_b9bd6ce9-d1b2-431d-b543-30e0cc4aef60"><ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="3" name="jnj:SalesReturnReserve" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzEwMjQ0_cbccea22-199e-4236-8177-92762fcb8f51">1.0</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of annual net trade sales during each of the fiscal years&#160;2022,&#160;2021&#160;and&#160;2020.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. Profit-share payments were less than <ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="3" name="jnj:ProfitLossPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzc2OTY1ODE0NDA0Mjk_be2f80f9-c7c2-4b7c-b616-62b8baf3d567">2.0</ix:nonFraction>% of the total revenues in fiscal year 2022 and less than <ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="3" name="jnj:ProfitLossPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzExMTM0_b9c0af23-98cf-4eb0-8341-68bc993b5b33"><ix:nonFraction unitRef="number" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="3" name="jnj:ProfitLossPercentToSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzExMTM0_f41214bf-f36d-4c69-b211-fd47920dd550">3.0</ix:nonFraction></ix:nonFraction>% of the total revenues in fiscal years 2021 and 2020 and are included in sales to customers.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i490f9a8ecb884c529d18f14ae37a672e" continuedAt="i854406b8c5af46a2bcf33586dc7207ef"><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i2cd90a9eef4447dcbb585c48a2273401">See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.</ix:continuation></span></div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ShippingAndHandlingCostPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODIy_6de65b11-9c14-4e63-b18c-94994eb87ceb" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred were $<ix:nonFraction unitRef="usd" contextRef="ic46c5718fa2f417e8d7f7298244c427b_D20220103-20230101" decimals="-8" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzExMzU1_54005ab2-b8ec-4c05-94a7-1edb708e9be9">1.1</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i6908986b3f7946f8bf4a62d5cf5b646c_D20210104-20220102" decimals="-8" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzExMzU5_29a518c7-1112-4683-8509-7433a86eab61">1.1</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i220866b1cfb44cf7905eb75b0089e1a7_D20191230-20210103" decimals="-8" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzExMzY2_53f41cce-f9f5-4e5a-90da-8b6711abd614">1.0</ix:nonFraction> billion in fiscal years 2022, 2021 and 2020, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than <ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="3" name="jnj:ShippingandHandlingCostsasaPercentofSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzExNTUx_a9f7f5e8-d00c-4cfd-854d-21bf6c0745e0"><ix:nonFraction unitRef="number" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="3" name="jnj:ShippingandHandlingCostsasaPercentofSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzExNTUx_f5df1a23-3d2d-4ced-b55c-018e5c086f01"><ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="3" name="jnj:ShippingandHandlingCostsasaPercentofSales" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzExNTUx_ff78cca8-9d0f-4217-ab0d-49b057275be9">1.0</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of sales to customers for all periods presented.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:InventoryPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzI0_7ccfe0fc-5401-4b35-9f72-386f7a48b2d5" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2Nzc0_cbf214d3-043e-45bb-8fa9-d0b5ecf10d34" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2022 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset. If warranted the purchased in-process research and development could be written off or partially impaired depending on the underlying program.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions.  See Note&#160;5 for further details on Intangible Assets and Goodwill.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2Nzgz_80f6b297-a071-41ce-a2f7-c4ec6a7b8f41" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#8217;s impact on the Company&#8217;s financial performance; (2)&#160;protect the Company&#8217;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.</span></div></ix:nonNumeric><div><span><br/></span></div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:LesseeLeasesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODUx_21d1634e-b22b-4d68-80ad-53bd90baa086" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODEw_97635a41-161e-48cc-9741-d517f85ec4b3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODEw_df08f0e2-160d-4a75-87a1-87cfb24da89c">Other assets</span></span>, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzMx_e32a30e6-d584-47b7-845d-23d4e433bc41"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzQ4_870a3311-5ffc-4b2b-8721-b5d7ead81c4b">Accrued liabilities</span></span>, and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzU3_21dc535a-a5b3-4717-bcb6-281e2bef1694"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzU3_b32467a4-74d9-403d-8502-48e5120b86ad">Other liabilities</span></span> on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-8" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE1OTE4_3e6756b6-df97-489d-8636-84c53b29c29c">1.1</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-8" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE1OTI1_fdc19ce4-e1b5-419e-adc0-0227cd93c0a7">0.9</ix:nonFraction>&#160;billion in fiscal years 2022 and 2021, respectively. The lease liability was $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-8" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE1OTg0_c61fbfd4-da1b-481a-9341-e4a1c4c9cf34">1.3</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-8" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE1OTkx_06fa972d-d5ce-417e-8482-735c51e8996a">1.0</ix:nonFraction>&#160;billion in fiscal years 2022 and 2021, respectively. The operating lease costs were $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-8" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE2MDU2_1800c38e-d585-4bf6-adeb-334729d72991"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-8" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE2MDU2_1bb5cf57-f774-4d1d-afe6-6184e32bc66f"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-8" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE2MDU2_2c6dba9f-3e20-4722-b654-4349d4e51f77">0.3</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;billion in fiscal years 2022, 2021 and 2020, respectively. Cash paid for amounts included in the measurement of lease liabilities were $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-8" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE2MTg0_8ae55af8-ed15-4229-8e1f-4dd14aa65066"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-8" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE2MTg0_9a16dd4a-58b8-4e03-b034-c8408f2d1f32"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-8" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE2MTg0_cad53d10-4498-4614-b1c9-bea4f31dcb01">0.3</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;billion in fiscal years 2022, 2021 and 2020, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="jnj:ProductLiabilityPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzM4_00addaf2-e1bb-4c67-a49a-e7f4ce7ba901" continuedAt="i5782137ac1334dbca85ff6ca5e748a9f" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product Liability</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i854406b8c5af46a2bcf33586dc7207ef" continuedAt="i7fb97af286b54c4fb76ec8ca8320bd77"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i5782137ac1334dbca85ff6ca5e748a9f" continuedAt="i03804a3bf47744ba902228298d439256">accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</ix:continuation></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i03804a3bf47744ba902228298d439256"> The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.</ix:continuation> </span></div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzM5_44835a2d-ba73-4ccb-8288-b92d47080401" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development.  Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product.  Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#8217;s operations. In general, the income statement presentation for these collaborations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.535%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Collaboration</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Earnings Presentation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third-party sale of product &amp; profit share payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties/milestones paid to collaborative partner (post-regulatory approval)*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties received from collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payments&#160;&amp; milestones paid to collaborative partner (pre-regulatory approval)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments to collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments received from collaborative partner or government entity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"></td><td style="width:1.706%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all years presented, there was no individual project that represented greater than <ix:nonFraction unitRef="number" contextRef="i02fac9589cc2476b800ec305e2b17a61_D20210104-20220102" decimals="INF" name="jnj:ConcentrationRiskThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE4OTY1_65028e99-b8d8-4433-974a-852337309754"><ix:nonFraction unitRef="number" contextRef="i2cdccdf73d6c4a2d8ad6277d9b89cbc6_D20191230-20210103" decimals="INF" name="jnj:ConcentrationRiskThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE4OTY1_99303881-54aa-4f50-aec7-61170a0d1bf1"><ix:nonFraction unitRef="number" contextRef="ibd8fd68737c9443dac923965cbcebb07_D20220103-20230101" decimals="INF" name="jnj:ConcentrationRiskThresholdPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE4OTY1_fcedf5fb-409c-45b0-b941-bf52e1225b71">5</ix:nonFraction></ix:nonFraction></ix:nonFraction>% of the total annual consolidated research and development expense.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG and IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.</span></div></ix:nonNumeric><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODUy_43d90c53-5feb-4a54-9494-19665bb26947" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE5Njk0_d0dbae8e-c60d-4e03-9e2d-e40814d497b7">2.1</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE5Njk4_6397eb0b-568f-483a-85a4-6f948ed27452">2.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-8" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE5NzA1_1bed4461-dece-483e-b122-8d6da25e1d97">2.1</ix:nonFraction> billion in fiscal years 2022, 2021 and 2020, respectively.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:IncomeTaxPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2Nzg2_442747ab-9e0a-4e78-a714-3c20172caaa8" continuedAt="i5e5852ce53e34904a0cdeeea282a2de3" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from <ix:nonFraction unitRef="number" contextRef="i2ba832f9031d440b8709fc80396eb47d_D20170102-20171231" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzIwOTEz_79a91e8b-f0dc-499f-8bc9-8ca2cb403f88">35</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i6f986503ddc443e8b150a30eb4915336_D20180101-20181230" decimals="INF" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzIwOTE5_121092f0-a92b-4f18-9602-f63255262445">21</ix:nonFraction>%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7fb97af286b54c4fb76ec8ca8320bd77"><ix:continuation id="i5e5852ce53e34904a0cdeeea282a2de3"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of  <ix:nonFraction unitRef="number" contextRef="i6f986503ddc443e8b150a30eb4915336_D20180101-20181230" decimals="3" name="jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzIxMTc0_8782142f-cb7e-4157-8e45-9bfa3c35692a">15.5</ix:nonFraction>% and all other earnings were taxed at a rate of <ix:nonFraction unitRef="number" contextRef="i6f986503ddc443e8b150a30eb4915336_D20180101-20181230" decimals="3" name="jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzIxMjI0_d9901cc1-0c19-4279-a43b-3cbee39fcb13">8.0</ix:nonFraction>%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2022 was approximately  $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-8" name="jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzIxNDE1_cc342a71-2932-4539-b013-c7c885324210">6.1</ix:nonFraction>&#160;billion, of which $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-8" name="jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzIxNDI4_b3be4dc6-a65a-4e14-ad48-2653d5998f95">4.6</ix:nonFraction>&#160;billion is classified as noncurrent and reflected as &#8220;Long-term taxes payable&#8221; on the Company&#8217;s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder&#8217;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#8220;period cost&#8221;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., &#8220;deferred method&#8221;). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-8" name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzIzMjM5_f1dd7fab-239a-4ee5-9428-ed624e4cb54e">0.5</ix:nonFraction> billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">See Note 8 to the Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">for further information regarding income taxes.</span></div></ix:continuation><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:EarningsPerSharePolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzMz_1f7cbd27-4680-4167-a0f7-40f9c10ef8de" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Earnings Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODA0_04e4f102-ab76-42d8-89ec-a4ca641aafa5" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="jnj:FiscalPeriodPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODIx_e3f53a12-b473-4981-8265-53939c69157a" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Closing Date</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzIx_71cf50c0-ed51-4efd-926c-4a4d73a883bb" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">50</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_148"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90ZXh0cmVnaW9uOjkxNjM1MTczMDllMTQzOTc4ZWQ2ZTU5NWRiNWE2Mjk2XzEwMDY_d0c5f1a0-af13-4621-bfad-57989186b0b1" continuedAt="id3adb4673eff455bb41ec4593c91faaf" escape="true">Cash, Cash Equivalents and Current Marketable Securities</ix:nonNumeric></span></div><ix:continuation id="id3adb4673eff455bb41ec4593c91faaf" continuedAt="i839a690ccdf54143be56a9beffaa107e"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90ZXh0cmVnaW9uOjkxNjM1MTczMDllMTQzOTc4ZWQ2ZTU5NWRiNWE2Mjk2XzEwMDE_5e68d9b9-3784-4a04-a8bc-c8c0f4214637" escape="true"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the fiscal year 2022 and 2021, cash, cash equivalents and current marketable securities were comprised of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.615%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.056%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Loss</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf53a7687af04964921188585c336575_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzItMi0xLTEtODQ0NDQ_68fbae21-e639-46be-ba22-785c28f04c85">4,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf53a7687af04964921188585c336575_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzItNi0xLTEtODQ0NDQ_947b79cd-08bf-4335-9f55-a1514e9b884b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf53a7687af04964921188585c336575_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzItOC0xLTEtODQ0NDQ_f9611d0e-be26-4a72-9915-f705cde46e03">4,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf53a7687af04964921188585c336575_I20230101" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzItMTAtMS0xLTg0NDQ0_1be685ad-9615-464a-9671-9382b56cd34c">4,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf53a7687af04964921188585c336575_I20230101" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzItMTItMS0xLTg0NDQ0_c5318322-497b-4161-9bdf-e3356c102ee0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c32c30caff4e45bdfc303e877e94fe_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzUtMi0xLTEtODQ0NDQ_d87f6e62-6c32-49b9-be3a-3fc974b98eb1">1,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c32c30caff4e45bdfc303e877e94fe_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzUtNi0xLTEtODQ0NDQ_725941c8-2ebc-481b-a719-c8fc90cc9daa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c32c30caff4e45bdfc303e877e94fe_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzUtOC0xLTEtODQ0NDQ_444a6f72-2029-4c72-a758-5587999bf280">1,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c32c30caff4e45bdfc303e877e94fe_I20230101" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzUtMTAtMS0xLTg0NDQ0_8ae07efd-9f92-4a0f-8e00-3603cea7a7c7">1,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85c32c30caff4e45bdfc303e877e94fe_I20230101" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzUtMTItMS0xLTg0NDQ0_aeab5d5e-3512-4495-ab7a-ecc144666ceb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bca58ccfae247149a00663f0e2670b1_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzctMi0xLTEtODQ0NDQ_4820c970-d9b2-48a0-ae52-73a92c33fe6b">873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6bca58ccfae247149a00663f0e2670b1_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzctNi0xLTEtODQ0NDQ_3699a4b8-48ac-45ea-a7e2-3505f8888397">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bca58ccfae247149a00663f0e2670b1_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzctOC0xLTEtODQ0NDQ_eb97a084-56c9-49be-a0ca-5a0d9ce4196d">872</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bca58ccfae247149a00663f0e2670b1_I20230101" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzctMTAtMS0xLTg0NDQ0_942d9843-b351-4c86-986d-9028b5cca91d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bca58ccfae247149a00663f0e2670b1_I20230101" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzctMTItMS0xLTg0NDQ0_8e641af2-3f55-44ec-922e-15b7d9a602c2">873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f10e7ae95e4d70a2beba21fbda5a78_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzgtMi0xLTEtODQ0NDQ_eecd84e0-9bc2-460f-adad-5650a4a63598">5,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f10e7ae95e4d70a2beba21fbda5a78_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzgtNi0xLTEtODQ0NDQ_6b284023-8386-4fa1-b8a0-b84c00277a09">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f10e7ae95e4d70a2beba21fbda5a78_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzgtOC0xLTEtODQ0NDQ_bd89853f-bbba-4834-9257-15e7192ca002">5,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f10e7ae95e4d70a2beba21fbda5a78_I20230101" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzgtMTAtMS0xLTg0NDQ0_83804ae8-5c99-42b1-a999-9db575fca0dc">5,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6f10e7ae95e4d70a2beba21fbda5a78_I20230101" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzgtMTItMS0xLTg0NDQ0_73be0bee-d169-47ed-9f45-08871db51f92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8467c8ec68cf4654bf1cfcdfa1fe2c5a_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzktMi0xLTEtODQ0NDQ_9c48d46a-721e-4218-b2bf-581ed260e58e">446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8467c8ec68cf4654bf1cfcdfa1fe2c5a_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzktNi0xLTEtODQ0NDQ_bfb0e769-1d6c-41c3-9389-20df0f81c52a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8467c8ec68cf4654bf1cfcdfa1fe2c5a_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzktOC0xLTEtODQ0NDQ_f0818cf1-6f23-40be-8fdc-3c9653afa98a">446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8467c8ec68cf4654bf1cfcdfa1fe2c5a_I20230101" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzktMTAtMS0xLTg0NDQ0_f2b69077-c7b8-43ed-b20f-6c720e4b0f1a">446</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8467c8ec68cf4654bf1cfcdfa1fe2c5a_I20230101" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzktMTItMS0xLTg0NDQ0_8e872f27-a338-4201-b19b-b948ecf80261">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67038bc29ba6469cb0cb5ca65068f855_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEwLTItMS0xLTg0NDQ0_0e23ac88-9b2e-48d4-97ac-24fc5b4baf49">13,032</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i67038bc29ba6469cb0cb5ca65068f855_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEwLTYtMS0xLTg0NDQ0_58d1b27c-cc94-4225-a3a2-c53e38b2b0bc">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67038bc29ba6469cb0cb5ca65068f855_I20230101" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEwLTgtMS0xLTg0NDQ0_fb584749-4976-4ec0-b8d9-e98dd4eef6bf">13,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67038bc29ba6469cb0cb5ca65068f855_I20230101" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEwLTEwLTEtMS04NDQ0NA_56c181fa-32c5-462e-a99f-f366d1fb71d5">12,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i67038bc29ba6469cb0cb5ca65068f855_I20230101" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEwLTEyLTEtMS04NDQ0NA_d80ea656-2a5f-4317-b20e-70b8f9900117">873</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632070131d164fd8a05baaff80e0d485_I20230101" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEyLTItMS0xLTg0NDQ0_5f40b467-fa5e-4563-90dd-895935d82034">9,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i632070131d164fd8a05baaff80e0d485_I20230101" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEyLTYtMS0xLTg0NDQ0_8036673c-69a3-43b1-aca1-53c88404aca9">28</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632070131d164fd8a05baaff80e0d485_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEyLTgtMS0xLTg0NDQ0_be36f0c8-498f-43ec-a8f5-a1c2512d5fd4">9,931</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632070131d164fd8a05baaff80e0d485_I20230101" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEyLTEwLTEtMS04NDQ0NA_020ff0ee-1861-429a-9e4d-e1b343785a14">1,922</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i632070131d164fd8a05baaff80e0d485_I20230101" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEyLTEyLTEtMS04NDQ0NA_f31b4930-87aa-41b9-8102-63d0e19ad5da">8,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't Agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacfc2ccbd7d4914be4e26893f91b754_I20230101" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEzLTItMS0xLTk4MDY3_993a7799-2d2c-40d5-b82f-afe6e986c088">210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icacfc2ccbd7d4914be4e26893f91b754_I20230101" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEzLTYtMS0xLTk4MDc2_43199ffb-2a31-495a-ae57-bc12059b2c8d">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacfc2ccbd7d4914be4e26893f91b754_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEzLTgtMS0xLTk4MDg0_4c4933e3-ebf8-4737-82e9-a62c9762a6e5">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacfc2ccbd7d4914be4e26893f91b754_I20230101" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEzLTEwLTEtMS05ODA5NA_40fc1437-9c7a-4941-af06-9383d8296e23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacfc2ccbd7d4914be4e26893f91b754_I20230101" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEzLTEyLTEtMS05ODEwMg_51a90182-06ea-4ad7-9024-b78e983e9277">205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and other debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib93e73399a1d41008b08bfb56335dc30_I20230101" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE0LTItMS0xLTg0NDQ0_2dde3af0-a33e-42b4-8418-c63bf66b83f2">352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib93e73399a1d41008b08bfb56335dc30_I20230101" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE0LTYtMS0xLTg0NDQ0_d29e8b1f-be76-4627-8e43-3511953bb5e6">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib93e73399a1d41008b08bfb56335dc30_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE0LTgtMS0xLTg0NDQ0_db830a19-772b-4f94-9ac4-3395030a4e67">351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib93e73399a1d41008b08bfb56335dc30_I20230101" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE0LTEwLTEtMS04NDQ0NA_b9f73cdb-dc52-4a6b-b5a4-4f5ca6988821">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib93e73399a1d41008b08bfb56335dc30_I20230101" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE0LTEyLTEtMS04NDQ0NA_24a8eb2b-2f7d-49df-a2c2-ecc69d8e7edf">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00843ad11c494c3fb53ae75e01995264_I20230101" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE2LTItMS0xLTg0NDQ0_89f070df-3b9f-4ff8-b38f-af771e1577a4">10,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i00843ad11c494c3fb53ae75e01995264_I20230101" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE2LTYtMS0xLTg0NDQ0_9b253df2-a977-4871-8c6d-1aa06133682e">34</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00843ad11c494c3fb53ae75e01995264_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE2LTgtMS0xLTg0NDQ0_b1ed767f-7d73-4828-8b7f-e4a3c54baa03">10,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00843ad11c494c3fb53ae75e01995264_I20230101" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE2LTEwLTEtMS04NDQ0NA_1f9776c7-9b22-42b2-ae8f-b330c20f3577">1,968</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00843ad11c494c3fb53ae75e01995264_I20230101" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE2LTEyLTEtMS04NDQ0NA_00aa0b71-1668-4bbc-bd00-b5975c577391">8,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE4LTEwLTEtMS04NDQ0NA_26a6523a-494f-4a60-801d-49356c843fa4">14,127</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE4LTEyLTEtMS04NDQ0NA_66f77046-fa89-4487-891d-12db7efa8926">9,392</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.615%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.056%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:11.690%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.219%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.382%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.526%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Loss</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i519faf5a8e3a4305a459c43d43018179_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzItMi0xLTEtOTg5Mjg_42605bfe-59b0-4c0c-bf89-6e2d0fec36e9">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i519faf5a8e3a4305a459c43d43018179_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzItNi0xLTEtOTkwMTI_71daab92-f62a-41b2-bd42-69d691a43bca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i519faf5a8e3a4305a459c43d43018179_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzItOC0xLTEtOTk0NjE_713b4913-cf57-4cde-93e9-b0cb2d01fb6b">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i519faf5a8e3a4305a459c43d43018179_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzItMTAtMS0xLTk5NDk3_4c528feb-904a-4855-a71a-1893e37a0fcb">2,936</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i519faf5a8e3a4305a459c43d43018179_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzItMTItMS0xLTk5NTAz_0421abca-15c0-4c8f-a028-b64422f92a76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic073077c7dc4462981e17199faf38094_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzQtMi0xLTEtOTg5Njk_8e374d35-caf3-4090-be45-88e15f17278a">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic073077c7dc4462981e17199faf38094_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzQtNi0xLTEtOTk0MDE_3dc28bfb-3d4d-44ab-a6b9-5637890aed44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic073077c7dc4462981e17199faf38094_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzQtOC0xLTEtOTk0Njc_238b6a2f-3d1c-4fa2-8ff5-ab4043cd23f1">1,006</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic073077c7dc4462981e17199faf38094_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzQtMTAtMS0xLTk5NTA5_ddcc6370-fa8a-4e4a-8e48-f7972b303717">90</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic073077c7dc4462981e17199faf38094_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzQtMTItMS0xLTk5NTE1_5b2799c6-027b-40e3-a5fe-9337b4055ea2">916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c0433d6c4941c9b80bb52a13ddf638_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzUtMi0xLTEtOTg5Njk_9b2d4f46-2cb9-4123-b7b1-2b22dbd26648">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c0433d6c4941c9b80bb52a13ddf638_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzUtNi0xLTEtOTk0MDE_de0fde40-0033-45b8-86df-391d6c499fd0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c0433d6c4941c9b80bb52a13ddf638_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzUtOC0xLTEtOTk0Njc_dd2562dc-4eaa-4fad-a69e-76dd5868c6a5">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c0433d6c4941c9b80bb52a13ddf638_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzUtMTAtMS0xLTk5NTA5_e83900a2-ac2e-4225-b244-7a395ce425e0">1,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82c0433d6c4941c9b80bb52a13ddf638_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzUtMTItMS0xLTk5NTE1_9f06815c-337a-45f3-9015-0a0b9fb5efe6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a78016e63d142e2be872b5982def0bd_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzctMi0xLTEtOTg5NzU_d18ce3e2-bdfd-4212-a118-b9be7b919048">3,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a78016e63d142e2be872b5982def0bd_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzctNi0xLTEtOTk0MTA_13054dc6-bd87-4f70-90c8-a14295367481">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a78016e63d142e2be872b5982def0bd_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzctOC0xLTEtOTk0NzM_e861e908-0394-4bce-8336-592a483000ea">3,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a78016e63d142e2be872b5982def0bd_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzctMTAtMS0xLTk5NTIx_820080d0-1f16-4383-9159-5ec91d7991c3">200</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a78016e63d142e2be872b5982def0bd_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzctMTItMS0xLTk5NTI3_cd8a1086-c60e-40d5-883f-28ef81af72e6">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i257e8511898a47d39e8a99ec93263f31_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzgtMi0xLTEtOTg5NzU_957deda2-49db-4229-be16-2aa8524bedd0">1,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i257e8511898a47d39e8a99ec93263f31_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzgtNi0xLTEtOTk0MTA_45bd5cd5-64c2-45a7-a8b9-6a497031ca92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i257e8511898a47d39e8a99ec93263f31_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzgtOC0xLTEtOTk0NzM_aab4d988-9125-488c-9a3b-cc4b34b0694b">1,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i257e8511898a47d39e8a99ec93263f31_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzgtMTAtMS0xLTk5NTIx_d5b37d0d-7873-45a3-8ce0-508542e1a154">1,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i257e8511898a47d39e8a99ec93263f31_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzgtMTItMS0xLTk5NTI3_5fc903d1-4e47-485f-8941-ac4a32e09e8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c9e2118e3a44a88a2ba07a0b756864_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzktMi0xLTEtOTg5NzU_dcadd982-9edb-42ea-94eb-13843e306ca0">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c9e2118e3a44a88a2ba07a0b756864_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzktNi0xLTEtOTk0MTA_77ae4946-c19c-4bce-ba13-f0134c915a44">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c9e2118e3a44a88a2ba07a0b756864_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzktOC0xLTEtOTk0NzM_d497b89e-db7e-4180-9a83-815412899458">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c9e2118e3a44a88a2ba07a0b756864_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzktMTAtMS0xLTk5NTIx_f7b157db-8d36-4080-a150-e9a6990c4b43">900</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9c9e2118e3a44a88a2ba07a0b756864_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzktMTItMS0xLTk5NTI3_2b994915-0ab0-4cd2-8e65-1a2d0d91ef07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4c98dc571d344a8a06b677c3e8a1699_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEwLTItMS0xLTk4OTc1_f923a00b-0a7a-43dc-9018-15e813680b08">11,881</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib4c98dc571d344a8a06b677c3e8a1699_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEwLTYtMS0xLTk5NDMy_0be38d9c-30d6-4807-8e11-85f3ccc10a34">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4c98dc571d344a8a06b677c3e8a1699_I20220102" decimals="-6" name="us-gaap:HeldToMaturitySecuritiesFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEwLTgtMS0xLTk5NDcz_34e9e09f-6f34-41c1-a29b-d0d753c2ef45">11,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4c98dc571d344a8a06b677c3e8a1699_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEwLTEwLTEtMS05OTUyMQ_1c612221-f233-4715-9389-19932e433ccd">7,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4c98dc571d344a8a06b677c3e8a1699_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEwLTEyLTEtMS05OTUyNw_77830cf1-d121-4b68-899d-a4090fd961d6">4,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if181e914ddc64a03888d0ef1285d38d7_I20220102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEyLTItMS0xLTk4OTg2_4b6a8345-8ed8-4f03-bc9f-f9f64da739e1">19,485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if181e914ddc64a03888d0ef1285d38d7_I20220102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEyLTYtMS0xLTk5NDM4_81f12a75-b7b0-4bdb-a008-fa56718be431">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if181e914ddc64a03888d0ef1285d38d7_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEyLTgtMS0xLTk5NDc5_7bfd1165-9dab-4adf-973c-2402e8311d5a">19,481</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if181e914ddc64a03888d0ef1285d38d7_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEyLTEwLTEtMS05OTUzMw_1e304218-d434-409d-87b1-dd98c3abd575">6,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if181e914ddc64a03888d0ef1285d38d7_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEyLTEyLTEtMS05OTU1MQ_7e4b6059-7638-4842-8a1f-71409525d0f6">12,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and other debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce066abcfe8429094c975b988b24365_I20220102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE0LTItMS0xLTk4OTk0_7d63b8a0-aa1d-40ec-b715-eeff4a9b9dd4">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce066abcfe8429094c975b988b24365_I20220102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE0LTYtMS0xLTk5NDQ5_3df11e1d-b321-4983-97af-90942e42cc90">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce066abcfe8429094c975b988b24365_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE0LTgtMS0xLTk5NDg1_faa7d0f7-9528-405f-9f05-71e1269f4e01">246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce066abcfe8429094c975b988b24365_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE0LTEwLTEtMS05OTUzOQ_29a9cc83-ea55-42a5-997a-c914ee0cc03f">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ce066abcfe8429094c975b988b24365_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE0LTEyLTEtMS05OTU1Nw_d62ddd23-b164-48fb-aeb9-c75c42e09436">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b15a0f49774cf698bedb20449bca68_I20220102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE2LTItMS0xLTk5MDAx_8e5f4799-4672-408c-b910-d224c0155ed7">19,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i75b15a0f49774cf698bedb20449bca68_I20220102" decimals="-6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE2LTYtMS0xLTk5NDU1_833a9cd1-aef5-4585-94c2-fdbe3074bb00">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b15a0f49774cf698bedb20449bca68_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE2LTgtMS0xLTk5NDkx_bca6f088-731c-47fa-9be6-7413788f44c0">19,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b15a0f49774cf698bedb20449bca68_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE2LTEwLTEtMS05OTU0NQ_bbe0ccb1-cec6-4886-9074-3816edb3083d">6,801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75b15a0f49774cf698bedb20449bca68_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE2LTEyLTEtMS05OTU2Mw_60629a9d-ef05-4356-816c-85e971482719">12,926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE4LTEwLTEtMS05OTU2OQ_e00b8151-5864-4a33-8831-d303660ae63d">14,487</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE4LTEyLTEtMS05OTU3NQ_55d36fc2-3c35-462f-b6ca-858a01f7e89b">17,121</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i839a690ccdf54143be56a9beffaa107e"><div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90ZXh0cmVnaW9uOjkxNjM1MTczMDllMTQzOTc4ZWQ2ZTU5NWRiNWE2Mjk2XzEwMDM_a2bdde92-1092-48a4-9803-1031107425c2" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale debt securities at January&#160;1, 2023 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"></td><td style="width:43.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.117%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.377%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:22.119%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTpiZjExYzhmN2FiZTc0MjE0YjdmNTM2YTkxYmRiZmU2NS90YWJsZXJhbmdlOmJmMTFjOGY3YWJlNzQyMTRiN2Y1MzZhOTFiZGJmZTY1XzEtMi0xLTEtODQ0NDQ_694b5c29-ac51-4787-8d7b-e7ac902a06e4">10,430</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTpiZjExYzhmN2FiZTc0MjE0YjdmNTM2YTkxYmRiZmU2NS90YWJsZXJhbmdlOmJmMTFjOGY3YWJlNzQyMTRiN2Y1MzZhOTFiZGJmZTY1XzEtNC0xLTEtODQ0NDQ_add7a15e-f1a7-4b17-9839-26037caccffc">10,399</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTpiZjExYzhmN2FiZTc0MjE0YjdmNTM2YTkxYmRiZmU2NS90YWJsZXJhbmdlOmJmMTFjOGY3YWJlNzQyMTRiN2Y1MzZhOTFiZGJmZTY1XzItMi0xLTEtODQ0NDQ_c57e72cc-6733-499b-9449-06037e2c9a3c">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTpiZjExYzhmN2FiZTc0MjE0YjdmNTM2YTkxYmRiZmU2NS90YWJsZXJhbmdlOmJmMTFjOGY3YWJlNzQyMTRiN2Y1MzZhOTFiZGJmZTY1XzItNC0xLTEtODQ0NDQ_0222e6e1-ab06-49c5-b84e-bc75f4d9539e">88</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTpiZjExYzhmN2FiZTc0MjE0YjdmNTM2YTkxYmRiZmU2NS90YWJsZXJhbmdlOmJmMTFjOGY3YWJlNzQyMTRiN2Y1MzZhOTFiZGJmZTY1XzMtMi0xLTEtODQ0NDQ_1549dc78-69ba-4ce6-a9d7-039d1b03ee5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTpiZjExYzhmN2FiZTc0MjE0YjdmNTM2YTkxYmRiZmU2NS90YWJsZXJhbmdlOmJmMTFjOGY3YWJlNzQyMTRiN2Y1MzZhOTFiZGJmZTY1XzMtNC0xLTEtODQ0NDQ_47500c47-df51-451a-bfbf-1cab32d92618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTpiZjExYzhmN2FiZTc0MjE0YjdmNTM2YTkxYmRiZmU2NS90YWJsZXJhbmdlOmJmMTFjOGY3YWJlNzQyMTRiN2Y1MzZhOTFiZGJmZTY1XzQtMi0xLTEtODQ0NDQ_883eb41a-3097-4330-8717-ae07f8116efb">10,521</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTpiZjExYzhmN2FiZTc0MjE0YjdmNTM2YTkxYmRiZmU2NS90YWJsZXJhbmdlOmJmMTFjOGY3YWJlNzQyMTRiN2Y1MzZhOTFiZGJmZTY1XzQtNC0xLTEtODQ0NDQ_61e5873e-d5d8-4d5e-b6bb-96c64f385a4b">10,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.</span></div></ix:continuation><div><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_151"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">3.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90ZXh0cmVnaW9uOjdiNWVkMzUyMmVmMzQ2NWZhNmM1NzA0NGJkOTJmMDE3Xzk1_b0c0635c-fe4c-47b6-aaec-6ed593a8187d" continuedAt="iebb24dfc8dc548738213c6e5f3986757" escape="true">Inventories</ix:nonNumeric></span></div><div><ix:continuation id="iebb24dfc8dc548738213c6e5f3986757"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90ZXh0cmVnaW9uOjdiNWVkMzUyMmVmMzQ2NWZhNmM1NzA0NGJkOTJmMDE3Xzk5_000d8ee5-e246-484e-96a4-1eeef7ece73e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2022 and 2021, inventories were comprised of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"></td><td style="width:66.000%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.614%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.645%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.072%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90YWJsZTo5MTVmYTA3MjY0NmE0OGJmOGNiMzQ2ZmNjYjljZDliNy90YWJsZXJhbmdlOjkxNWZhMDcyNjQ2YTQ4YmY4Y2IzNDZmY2NiOWNkOWI3XzEtMi0xLTEtODQ0NDQ_ff41ea3f-a3f4-4ea5-b28c-6f1b6858d7fc">2,070</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90YWJsZTo5MTVmYTA3MjY0NmE0OGJmOGNiMzQ2ZmNjYjljZDliNy90YWJsZXJhbmdlOjkxNWZhMDcyNjQ2YTQ4YmY4Y2IzNDZmY2NiOWNkOWI3XzEtNC0xLTEtODQ0NDQ_bc4b03f1-12cc-4774-b428-3796956c594a">1,592</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90YWJsZTo5MTVmYTA3MjY0NmE0OGJmOGNiMzQ2ZmNjYjljZDliNy90YWJsZXJhbmdlOjkxNWZhMDcyNjQ2YTQ4YmY4Y2IzNDZmY2NiOWNkOWI3XzItMi0xLTEtODQ0NDQ_869dc377-04d3-4652-995d-2d8de9b47e97">1,700</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90YWJsZTo5MTVmYTA3MjY0NmE0OGJmOGNiMzQ2ZmNjYjljZDliNy90YWJsZXJhbmdlOjkxNWZhMDcyNjQ2YTQ4YmY4Y2IzNDZmY2NiOWNkOWI3XzItNC0xLTEtODQ0NDQ_f345314b-d4ee-405c-b827-3f49a193d98d">2,287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90YWJsZTo5MTVmYTA3MjY0NmE0OGJmOGNiMzQ2ZmNjYjljZDliNy90YWJsZXJhbmdlOjkxNWZhMDcyNjQ2YTQ4YmY4Y2IzNDZmY2NiOWNkOWI3XzMtMi0xLTEtODQ0NDQ_6151129a-6267-4948-ab25-e5737db15f55">8,713</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90YWJsZTo5MTVmYTA3MjY0NmE0OGJmOGNiMzQ2ZmNjYjljZDliNy90YWJsZXJhbmdlOjkxNWZhMDcyNjQ2YTQ4YmY4Y2IzNDZmY2NiOWNkOWI3XzMtNC0xLTEtODQ0NDQ_45ba55fa-0d7d-4cee-9940-65b022e3b11b">6,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90YWJsZTo5MTVmYTA3MjY0NmE0OGJmOGNiMzQ2ZmNjYjljZDliNy90YWJsZXJhbmdlOjkxNWZhMDcyNjQ2YTQ4YmY4Y2IzNDZmY2NiOWNkOWI3XzQtMi0xLTEtODQ0NDQ_aaeae968-d4e6-469f-bd95-65430398b902">12,483</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90YWJsZTo5MTVmYTA3MjY0NmE0OGJmOGNiMzQ2ZmNjYjljZDliNy90YWJsZXJhbmdlOjkxNWZhMDcyNjQ2YTQ4YmY4Y2IzNDZmY2NiOWNkOWI3XzQtNC0xLTEtODQ0NDQ_33104ebe-68da-4846-8288-a7eba38b66f1">10,387</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_154"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90ZXh0cmVnaW9uOjI5ZTBlM2JiMWE5ZTQyYWJhOGU5MmM5OTJhMzY1YzIzXzgxMQ_ca1d3323-45e2-4345-87b3-e26b7a39aee5" continuedAt="ib611d0e5388f4f03ba5bd29f76f63339" escape="true">Property, Plant and Equipment</ix:nonNumeric></span></div><ix:continuation id="ib611d0e5388f4f03ba5bd29f76f63339"><div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90ZXh0cmVnaW9uOjI5ZTBlM2JiMWE5ZTQyYWJhOGU5MmM5OTJhMzY1YzIzXzgxNA_5396a86d-766d-408e-b6cd-af6f1d7ee508" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2022 and 2021, property, plant and equipment at cost and accumulated depreciation were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"></td><td style="width:67.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.570%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.443%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.307%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29a1acc3c1844b598aadafb03da80979_I20230101" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzEtMi0xLTEtODQ0NDQ_7dfe818e-43bf-4254-9d87-128710e678e2">859</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if115c6f434d64fca899b4e6a5f072637_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzEtNC0xLTEtODQ0NDQ_2eb31cf1-bc3b-43d2-be1b-76bc2ba7fe19">884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifedc4ec86cd34c35b9afcab55baa12c2_I20230101" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzItMi0xLTEtODQ0NDQ_095ab3b9-7891-49bd-96e3-dac66b53506c">12,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b40c1d088ec4a9789ae9b2483d16368_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzItNC0xLTEtODQ0NDQ_c51c485d-2269-429c-a96a-1519d1bc9d57">12,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id891cac7e84b467ea4fcc3186ec8542e_I20230101" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzMtMi0xLTEtODQ0NDQ_c74d150e-691f-4226-8519-cd4c31fd7f79">30,431</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib504a49900c149668603de87c85be222_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzMtNC0xLTEtODQ0NDQ_5413b41b-91df-486a-bb4e-d977bef121df">29,774</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibacac16e36314568b61aff5d3e80baea_I20230101" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzQtMi0xLTEtODQ0NDQ_f6dfa518-6eaa-46a7-a08a-4d23cf443965">4,974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01d8e5a2c62c4ce184e8d87099bffb41_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzQtNC0xLTEtODQ0NDQ_9b7beb1b-593e-4308-84a2-0637803dd37c">4,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzUtMi0xLTEtODQ0NDQ_f7c92d7f-7e52-4ed8-8945-4b9ab68175c1">49,253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzUtNC0xLTEtODQ0NDQ_02364566-85d9-490c-9607-ed2dd423388f">47,679</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzYtMi0xLTEtODQ0NDQ_e6565b91-2ae1-4fca-9a27-730d58f5dac2">29,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzYtNC0xLTEtODQ0NDQ_5216a3e0-a459-4b15-9be8-dd60911d378b">28,717</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzctMi0xLTEtODQ0NDQ_49b0abd6-bd2e-40a3-b939-97946248c017">19,803</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzctNC0xLTEtODQ0NDQ_4505ea5e-5c3f-4057-8cbe-9ad1b0bb2f41">18,962</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90ZXh0cmVnaW9uOjI5ZTBlM2JiMWE5ZTQyYWJhOGU5MmM5OTJhMzY1YzIzXzMxOA_2dbb07b2-22cf-4958-80e7-a41c56c5cdd7">49</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90ZXh0cmVnaW9uOjI5ZTBlM2JiMWE5ZTQyYWJhOGU5MmM5OTJhMzY1YzIzXzMyMg_e94874d7-d3d2-4fed-ad35-d34f4fa190a6">49</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:InterestCostsCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90ZXh0cmVnaW9uOjI5ZTBlM2JiMWE5ZTQyYWJhOGU5MmM5OTJhMzY1YzIzXzMyOQ_2474af8c-140e-4235-9699-c4ee03dc5f2b">63</ix:nonFraction> million, respectively.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense, including the amortization of capitalized interest in fiscal years 2022, 2021 and 2020 was $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-8" name="jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90ZXh0cmVnaW9uOjI5ZTBlM2JiMWE5ZTQyYWJhOGU5MmM5OTJhMzY1YzIzXzQ1NA_5c3546d7-9fd8-451d-a057-fb2f35f13fc3">2.7</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-8" name="jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90ZXh0cmVnaW9uOjI5ZTBlM2JiMWE5ZTQyYWJhOGU5MmM5OTJhMzY1YzIzXzQ1OA_d2be2fae-b09b-42e1-a3c5-cf4c68086d23">2.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-8" name="jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90ZXh0cmVnaW9uOjI5ZTBlM2JiMWE5ZTQyYWJhOGU5MmM5OTJhMzY1YzIzXzQ2NQ_c859cbae-58ce-4e94-b853-42703c8d70f7">2.6</ix:nonFraction> billion, respectively. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_157"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzE1NDA_1ce80390-acca-4e87-a524-10aec8c8acab" continuedAt="i2af2edf4f2f64361b12e0c4725c44d29" escape="true">Intangible Assets and Goodwill</ix:nonNumeric></span></div><ix:continuation id="i2af2edf4f2f64361b12e0c4725c44d29"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzE1NDk_f88f5b53-9294-47e1-a5f2-6e755959691a" continuedAt="ifc1d0989802c487992856a36a26647ca" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2022 and 2021, the gross and net amounts of intangible assets were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e0ee8b5a704aaca8a9274822576332_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzItMi0xLTEtODQ0NDQ_99432cf7-4b0f-4bf5-9951-4fde42a9dd29">44,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9408b29849f4c0b9380a8d9f61c6f3e_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzItNC0xLTEtODQ0NDQ_e49a20f8-06ee-4b50-96ae-f47c130a444d">38,572</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9e0ee8b5a704aaca8a9274822576332_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzMtMi0xLTEtODQ0NDQ_b9de4925-d6f3-4eec-ba5c-2c7e3d291a2c">22,266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib9408b29849f4c0b9380a8d9f61c6f3e_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzMtNC0xLTEtODQ0NDQ_58144203-232b-405e-85d5-f516933c50d6">20,088</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9e0ee8b5a704aaca8a9274822576332_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzQtMi0xLTEtODQ0NDQ_7c6e2929-5dd5-4285-bb2e-6b0606c512dc">21,746</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9408b29849f4c0b9380a8d9f61c6f3e_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzQtNC0xLTEtODQ0NDQ_8632a54c-0f44-42b6-b1da-10b6b0e27f70">18,484</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282196aad12c47c99220e44da280b8d8_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzUtMi0xLTEtODQ0NDQ_862f2a39-4c0e-4f9d-86e9-8643167d1173">22,987</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i247541d8f154426a91d3065202f7ea83_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsGross" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzUtNC0xLTEtODQ0NDQ_d3ef6fd2-d339-4219-aba8-f6df66972073">23,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i282196aad12c47c99220e44da280b8d8_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzYtMi0xLTEtODQ0NDQ_81a260a6-82a5-4abb-abcb-cc69753ad149">12,901</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i247541d8f154426a91d3065202f7ea83_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzYtNC0xLTEtODQ0NDQ_35a59f00-5907-4d21-9521-db6629086898">11,925</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i282196aad12c47c99220e44da280b8d8_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzctMi0xLTEtODQ0NDQ_dadbe387-c190-475e-9b0e-d2f7c233ebac">10,086</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i247541d8f154426a91d3065202f7ea83_I20220102" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzctNC0xLTEtODQ0NDQ_c2703bd5-c998-4fa1-8fd9-26efda698d92">11,086</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifdfd1b47f49946eca78fbf8f06e72987_I20230101" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzktMi0xLTEtODQ0NDQ_a0aa6607-e812-4491-bb4a-045dc0ad2751">6,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i626b5e4c6aef4b478b14fa53c5ad89bf_I20220102" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzktNC0xLTEtODQ0NDQ_7297e42c-9049-4c34-b37b-60ce3a657e90">6,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i406e87a2fe59450390cb44ac1a234e33_I20230101" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzEwLTItMS0xLTg0NDQ0_d4595ae1-cba5-4882-b192-fc439d815c73">9,686</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d2228f7987c44149e5a689a665fe7f0_I20220102" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzEwLTQtMS0xLTg0NDQ0_d32cf866-09da-4d8b-aa9f-f932f11c781a">9,837</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzExLTItMS0xLTg0NDQ0_29ee15fc-9488-4460-8580-8907197b44a2">16,493</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzExLTQtMS0xLTg0NDQ0_6db4381f-23af-46c7-8d05-695095965fcb">16,822</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets&#160;&#8212; net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzEyLTItMS0xLTg0NDQ0_fed66578-27ce-4c56-b7db-0e54a4a8e713">48,325</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzEyLTQtMS0xLTg0NDQ0_c7b62a74-1931-4732-89e8-d540081833e8">46,392</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change was primarily related to the intangible assets acquired with the acquisition of Abiomed, Inc. which was partially offset by amortization expense of previously existing intangible assets and the result of currency translation effects.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority is comprised of customer relationships</span></div></ix:nonNumeric><div><ix:continuation id="ifc1d0989802c487992856a36a26647ca" continuedAt="ibc197076a2314718bf6dfebf3d37089c"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The reduction was primarily related to an intangible asset impairment charge of approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:continuation id="ibc197076a2314718bf6dfebf3d37089c">$<ix:nonFraction unitRef="usd" contextRef="i0e228c02951e4d53a756f82e5d074c5e_D20220103-20230101" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzU0OTc1NTgxNjIwMQ_2882df41-158a-4433-89ce-bcd63dee8b7a">0.8</ix:nonFraction>&#160;billion recorded in the fiscal year 2022 related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS. An additional reduction of $<ix:nonFraction unitRef="usd" contextRef="ib43d5a9a7c574ba0a893b62c4b1938a6_D20220103-20230101" decimals="-8" sign="-" name="us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzU0OTc1NTgxOTQxNg_23248519-ac76-4891-8ede-59098c19ac52">0.7</ix:nonFraction>&#160;billion was driven by Monarch assets that reached commercialization and are now classified as having definite lives. This was partially offset by approximately $<ix:nonFraction unitRef="usd" contextRef="ie439be9218914ee6b4279a8133fe851b_D20220103-20230101" decimals="-8" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzU0OTc1NTgxOTIyNA_de3ff367-555c-4baf-a65c-6168057d5427">1.1</ix:nonFraction>&#160;billion of IPR&amp;D acquired with Abiomed, Inc.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfGoodwillTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzE1NTY_184cd824-292a-4a9a-9afc-52c14b844419" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of January&#160;1, 2023 and January&#160;2, 2022, as allocated by segment of business, was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:33.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.253%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.777%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.407%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.249%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MedTech</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42b110678ca4863806a1d2bf6bd1bcc_I20210103" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzEtMi0xLTEtODQ0NDQ_8094be31-5206-4aa8-a0f6-cf9f8486750e">10,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5629ac5f2c33469584439760fbeaa46e_I20210103" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzEtNC0xLTEtODQ0NDQ_14c549e1-a341-4c0b-ac76-53ad1e6c1bfb">11,009</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f72a14eea6547cebb097d81ee48e0d6_I20210103" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzEtNi0xLTEtODQ0NDQ_665aa453-2dd6-4177-823e-f668b9f02f52">15,048</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzEtOC0xLTEtODQ0NDQ_182cfff9-8683-431d-a245-420d392bfad5">36,393</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6099acc42a42639c659499eeee550a_D20210104-20220102" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzItMi0xLTEtODQ0NDQ_06b3b81f-af67-46ba-b0ad-40b9bef4e6ef">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzItNC0xLTEtODQ0NDQ_a7b3bffd-e0f8-4c99-9ea2-28138374fd88">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzItNi0xLTEtODQ0NDQ_7022917c-5b64-4087-829c-396a95104ca0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzItOC0xLTEtODQ0NDQ_bb35d41c-c598-4699-911b-ec005e695c19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to divestitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6099acc42a42639c659499eeee550a_D20210104-20220102" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzMtMi0xLTEtODQ0NDQ_b6b91360-c977-4e4b-9072-dcc64f97915e">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzMtNC0xLTEtODQ0NDQ_b483e00d-435b-47c1-ba60-8f30ef3ac65f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzMtNi0xLTEtODQ0NDQ_2cac1594-d399-4eee-9873-95f4eb5d81e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzMtOC0xLTEtOTg0MTA_5c0d2173-2060-465c-acad-d8b7a1c8dc9a">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c6099acc42a42639c659499eeee550a_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzQtMi0xLTEtODQ0NDQ_a830a442-2c23-46de-9c95-eb6e03d7e3df">517</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzQtNC0xLTEtODQ0NDQ_1bd1ac77-eef5-4382-a1d6-59b6fd5afc7e">429</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzQtNi0xLTEtODQ0NDQ_176d454a-9c06-42f1-8427-7c3d98c5ab3c">192</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzQtOC0xLTEtODQ0NDQ_0aadde63-4dfc-46ca-a043-178a5278ec9b">1,138</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4784eb1517047d9af150653b71eabfe_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzUtMi0xLTEtODQ0NDQ_66dc7731-a12a-4ba6-aece-53d2bfa0b17b">9,810</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4852527980040579d16cf952b6a58ff_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzUtNC0xLTEtODQ0NDQ_14d1a187-a278-4db8-a188-9a7e87897177">10,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85328680ec914e0d9a276b4db4c66dcd_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzUtNi0xLTEtODQ0NDQ_4b962222-0e07-43c9-a1f8-825af5547c52">14,856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzUtOC0xLTEtODQ0NDQ_685f0010-1949-4f8c-9ff8-e50420cb9512">35,246</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia324deef03f5433486883e8775658b95_D20220103-20230101" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzYtMi0xLTEtODQ0NDQ_b877f7d6-9ac3-4d54-9f1e-9fd124e3a082">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzYtNC0xLTEtODQ0NDQ_e100d89f-0957-4a7e-bce0-efda661ddcaa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzYtNi0xLTEtODQ0NDQ_512ddead-5f4e-4141-82e6-d472dc0d4ab1">11,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzYtOC0xLTEtODQ0NDQ_78c706ef-e675-4d49-acbd-a2d443cc03b8">11,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to divestitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia324deef03f5433486883e8775658b95_D20220103-20230101" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzctMi0xLTEtODQ0NDQ_1987ee81-4357-49e0-ade4-d7b614ca4a61">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzctNC0xLTEtODQ0NDQ_dbfe6472-ceb5-4b7b-aa08-81cb979c295c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzctNi0xLTEtODQ0NDQ_7a36c5bd-4285-4fed-9f99-660676b7a699">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzctOC0xLTEtODQ0NDQ_4639be48-6814-461c-af5a-c96a52efaa4d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia324deef03f5433486883e8775658b95_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzgtMi0xLTEtODQ0NDQ_c7d1030a-809e-4e62-b8d3-a916901ad36a">626</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzgtNC0xLTEtODQ0NDQ_dd66a7c3-4565-4a41-bd3c-684eedeb72b0">396</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzgtNi0xLTEtODQ0NDQ_ab692542-7ebb-4c5a-a797-4a8b4f4b0e5e">49</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:GoodwillOtherIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzgtOC0xLTEtODQ0NDQ_7430df1c-00f5-4128-8020-8f8b6a675506">1,071</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie72473fe7392450db0865cca43131db3_I20230101" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzktMi0xLTEtODQ0NDQ_e20f965f-ecf3-420a-a94c-24b7e99a2044">9,184</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f076cad0e094616a814262376cb5191_I20230101" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzktNC0xLTEtODQ0NDQ_4d338f33-5701-432c-a31a-5a055ac6c488">10,184</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fe95ef042a2429798d99a69cf874da9_I20230101" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzktNi0xLTEtODQ0NDQ_6bca1791-ff3c-4f47-ad39-aa14b86bc29b">25,863</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzktOC0xLTEtODQ0NDQ_78657f7b-c1b2-43c2-bd96-62db328bac18">45,231</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is <ix:nonNumeric contextRef="i1379957dc92040fdaa4530fe7c7b94a4_D20220103-20230101" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1Xzk1Mg_07ee9421-929c-42c2-8dc7-990a0f8597fb">12</ix:nonNumeric> years. The weighted average amortization period for customer relationships and other intangible assets is <ix:nonNumeric contextRef="ie385825a1c3f41b6b5d0e02f82243bb4_D20220103-20230101" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzEwNTU_90fe0214-4828-4620-a0ad-0b76134da38f">21</ix:nonNumeric> years. The amortization expense of amortizable assets included in Cost of products sold was $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzExNDQ_128ffcf8-ba72-42f5-8864-f0a287bf9d1e">4.3</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzExNDg_5e03a6cc-d5f7-461e-a905-9d57628cfe9c">4.7</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-8" name="us-gaap:AmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzExNTU_09b8107d-a064-4ccd-be1f-43ba52e4ca74">4.7</ix:nonFraction> billion before tax, for the fiscal years ended January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net.</span></div><div><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzE1NDY_4aa70e5a-53c6-444a-bfc4-2e4895b449e8" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"></td><td style="width:18.528%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.114%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.833%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTplMzJlMmY3Yzk2NjU0ODBhYmUyYmVlOWM5NWM0M2YyMC90YWJsZXJhbmdlOmUzMmUyZjdjOTY2NTQ4MGFiZTJiZWU5Yzk1YzQzZjIwXzItMC0xLTEtODQ0NDQ_1cc549be-3749-450f-9afd-58a313deaae0">4,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTplMzJlMmY3Yzk2NjU0ODBhYmUyYmVlOWM5NWM0M2YyMC90YWJsZXJhbmdlOmUzMmUyZjdjOTY2NTQ4MGFiZTJiZWU5Yzk1YzQzZjIwXzItMi0xLTEtODQ0NDQ_9cf3b78f-3974-48a9-b98b-31e7d709f980">4,400</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTplMzJlMmY3Yzk2NjU0ODBhYmUyYmVlOWM5NWM0M2YyMC90YWJsZXJhbmdlOmUzMmUyZjdjOTY2NTQ4MGFiZTJiZWU5Yzk1YzQzZjIwXzItNC0xLTEtODQ0NDQ_07b4cb90-8fbd-43f4-9edd-cacde1e27d14">3,600</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTplMzJlMmY3Yzk2NjU0ODBhYmUyYmVlOWM5NWM0M2YyMC90YWJsZXJhbmdlOmUzMmUyZjdjOTY2NTQ4MGFiZTJiZWU5Yzk1YzQzZjIwXzItNi0xLTEtODQ0NDQ_8eb2a7d3-b411-46df-b43b-8d8eb120994c">3,000</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTplMzJlMmY3Yzk2NjU0ODBhYmUyYmVlOWM5NWM0M2YyMC90YWJsZXJhbmdlOmUzMmUyZjdjOTY2NTQ4MGFiZTJiZWU5Yzk1YzQzZjIwXzItOC0xLTEtODQ0NDQ_ced8b47a-e889-4ce2-9dc1-4f6faee74b53">2,400</ix:nonFraction></span></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_160"></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzEwMDE4_c47775dc-1f50-4781-acf8-c7b57ce44629" continuedAt="i4303c44ff73f48dcb3a088dd761a820d" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><ix:continuation id="i4303c44ff73f48dcb3a088dd761a820d" continuedAt="i4bcdd6494932474a9501fde3da811291"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company primarily uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> In the fiscal fourth quarter of 2022, the Company entered into forward starting interest rate swaps with notional amounts totaling $<ix:nonFraction unitRef="usd" contextRef="ie7a29114e911461faec7fe4e8a9d1d04_I20230101" decimals="-8" name="us-gaap:DerivativeAssetsCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzI3NDg3NzkwODMxOTI_ed244edc-c0b3-4f37-9dba-4dfe4d185535">2.4</ix:nonFraction>&#160;billion in contemplation of hedging interest rate risk associated with long-term financing for the Consumer Health segment separation. These forward starting interest rate swaps are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings. At the end of the fiscal year 2022, the changes in fair value was not material and therefore not included in the table below.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of January&#160;1, 2023, the total amount of cash collateral paid by the Company under the CSA amounted to $<ix:nonFraction unitRef="usd" contextRef="ie9ea9658839544de90b002aa4a145255_I20230101" decimals="-8" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzE2NDE_a6104cee-dd5a-4b48-9a8e-c4f5d73e0b48">0.8</ix:nonFraction> billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of January&#160;1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="ie9ea9658839544de90b002aa4a145255_I20230101" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzIzMDU_99a5308d-9804-4fd2-bf36-39df5ac2ce84">43.3</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ibc88406d872445a3ad6785a8573a5a24_I20230101" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzIzMDk_afb7ef2e-4e57-4041-9d43-6039c6a2e1dd">36.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i5e54799bc7f7459f8e4524bc93b31c2b_I20230101" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzIzMTY_5141a324-4fac-4c74-ad74-1f4d052653f5">12.4</ix:nonFraction> billion, respectively. As of January&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $<ix:nonFraction unitRef="usd" contextRef="iab47b85ba2e7444aa7e1fb2845fe47bd_I20220102" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzY1OTcwNjk3NzY4MjE_3982c205-0cbb-464d-b47a-e2e4247e01c0">45.8</ix:nonFraction> billion,  $<ix:nonFraction unitRef="usd" contextRef="i6c2143b059d34074a2a1c452daf27abc_I20220102" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzY1OTcwNjk3NzY4MjU_04ff72d4-d9f4-4874-a10d-a9a93f870350">37.4</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ia2bd3f4828754f62ad5a5f11c2503d8f_I20220102" decimals="-8" name="us-gaap:DerivativeNotionalAmount" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzY1OTcwNjk3NzY4MTU_4d586e5b-6677-48f8-91bb-3826b5e707f8">10.0</ix:nonFraction> billion, respectively.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings.&#160;Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted through the currency translation account within accumulated other comprehensive income.&#160;The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of January&#160;1, 2023, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" sign="-" name="us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzQ2MDA_3d192573-2862-464a-a3c2-7f1121dbd730">230</ix:nonFraction> million&#160;after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note&#160;13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the <ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzQ4NTk_1231d22c-5da6-480e-a867-0e8c1d25835d">next 12 months</ix:nonNumeric> as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is <ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzUwMjA_dfaa8e5e-15ac-4cb8-8622-d9c5dea6dea6">18</ix:nonNumeric> months, excluding interest rate contracts and net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4bcdd6494932474a9501fde3da811291" continuedAt="if7e69bcefaa2430f85e07d4226d1307d"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzEwMDQ0_6202a4c3-4703-4ff6-813e-a04939d2d0b9" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022, net of tax:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.771%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.356%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.087%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.648%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.239%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife931fffad564c719966395e598010a2_D20220103-20230101" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtMS0xLTEtODQ0NDQ_f83e71e5-fb26-4e9c-97cf-32e38daaec9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab96c6a2a554d78b428a02174937f21_D20220103-20230101" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtMi0xLTEtODQ0NDQ_c6db5343-4517-4a06-8674-ecc2b48af2cd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e6a3d10477946979e7db7037955a625_D20220103-20230101" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtMy0xLTEtODQ0NDQ_3b18bd2a-fef3-480a-be66-9555f8495567">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8b66c56f1d944b9798daa8b8b05d751a_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtNC0xLTEtODQ0NDQ_fee8e747-b21b-4db2-8cb2-4015f2fb8b57">1,098</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id306832042b14bc3bb6e213608544feb_D20220103-20230101" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtNS0xLTEtODQ0NDQ_1c7a3e46-dd9f-4dd9-bb0d-a8a372dde4f0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie74a64d7fcd74669819570ee01cfe012_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtNi0xLTEtODQ0NDQ_60209cea-57a7-4fae-9c03-b8d2d26b73d2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead1aa87d38f45fead8c4b6118f2e9cd_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtNy0xLTEtODQ0NDQ_e1b8ff90-0db0-4c2f-9965-a7e3d94007c9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3bf19e86414044b7432eb058f5401e_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtOC0xLTEtODQ0NDQ_efb54f59-0fca-431a-8e2c-ac896864bcad">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i862297e326264912a68191b181c4f8ba_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtOS0xLTEtODQ0NDQ_11097348-6f50-4fbf-8c28-31d03e82edb8">109</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i328303dfcaed4235be1c6fb645ddafa7_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtMTAtMS0xLTg0NDQ0_f27294ca-3aeb-4ab8-b72d-5d59d27c7829">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife931fffad564c719966395e598010a2_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktMS0xLTEtODQ0NDQ_e977f7e7-cfe8-4339-ae0d-8adbda281a43">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ab96c6a2a554d78b428a02174937f21_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktMi0xLTEtODQ0NDQ_b9141de6-507a-4440-8357-2d63ecd6bb7b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e6a3d10477946979e7db7037955a625_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktMy0xLTEtODQ0NDQ_3f55f406-faf4-4d79-a1d0-54557249a8cf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b66c56f1d944b9798daa8b8b05d751a_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktNC0xLTEtODQ0NDQ_f4ad432c-ab25-470d-a2b1-29ac4dcf4151">1,098</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id306832042b14bc3bb6e213608544feb_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktNS0xLTEtODQ0NDQ_6a58cf5b-13c3-43ec-92f4-7a45c3e599fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie74a64d7fcd74669819570ee01cfe012_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktNi0xLTEtODQ0NDQ_a5ad898f-dba3-48f1-97b6-0479a0721080">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iead1aa87d38f45fead8c4b6118f2e9cd_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktNy0xLTEtODQ0NDQ_89cb9e2b-13fb-491e-9212-476034747238">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6e3bf19e86414044b7432eb058f5401e_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktOC0xLTEtODQ0NDQ_0b6ddb64-1d3b-4731-ac7a-a429c268b7a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i862297e326264912a68191b181c4f8ba_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktOS0xLTEtODQ0NDQ_674104a2-1fbf-4c28-b066-86501cdd1f88">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i328303dfcaed4235be1c6fb645ddafa7_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktMTAtMS0xLTg0NDQ0_5ed23394-1c06-48ff-bb51-5f95101a65ac">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i639b622f74424cdebe2c37fde791f0dd_D20220103-20230101" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTEtMS0xLTg0NDQ0_0acdc26d-81cb-48f3-b156-b7d80b515cb4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fc528ec58784d3da8a3590dbabf6c70_D20220103-20230101" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTItMS0xLTg0NDQ0_bf94295c-e25b-4607-ae48-13b03552df6f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if363846d56154bcfaaaf3101bca3794f_D20220103-20230101" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTMtMS0xLTg0NDQ0_07a80547-caa6-4cbd-aff1-a2a479977a23">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d922839a92453babec3a62e5dd77d0_D20220103-20230101" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTQtMS0xLTg0NDQ0_fa34d219-8778-4432-8c05-e490cc5ec3c0">140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a1657c370b446a9a91aeb39ed80cb3_D20220103-20230101" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTUtMS0xLTg0NDQ0_2f9e73fd-18ba-4b8e-a0cb-85a41cc43f07">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b9d25facfe14e558d8538281e17e27f_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTYtMS0xLTg0NDQ0_d887727a-ddf3-44bb-9f2e-ce700c3da9db">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eda7450d4d9456b9e83912cf600f6da_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTctMS0xLTg0NDQ0_a4bc68a5-064e-4b5e-aa8a-12b6761d882f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98e6ade62ef44067805f023366e22a49_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTgtMS0xLTg0NDQ0_2422e571-8ec4-4a9e-8dde-56bca7e7dc85">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d9971dcb124172ad9892da8f77ed8f_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTktMS0xLTg0NDQ0_b8aa7f23-4098-4135-abfd-44f51ca6383b">174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c15d323b29d4f51a3b0277a6efe9fcb_D20210104-20220102" decimals="-6" name="us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTEwLTEtMS04NDQ0NA_e3a70196-bb1f-4045-b423-28541b6897a6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i639b622f74424cdebe2c37fde791f0dd_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTEtMS0xLTg0NDQ0_331b01ec-77a7-4fdf-b9c4-90c719c0e618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fc528ec58784d3da8a3590dbabf6c70_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTItMS0xLTg0NDQ0_2354e08d-d995-4ef9-b332-4a3ff8e8a5ca">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if363846d56154bcfaaaf3101bca3794f_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTMtMS0xLTg0NDQ0_e0295132-7712-46cd-9c5b-16be5923aab8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28d922839a92453babec3a62e5dd77d0_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTQtMS0xLTg0NDQ0_7bb23438-43d5-4a8b-84a8-b14a1ab14ca7">140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i73a1657c370b446a9a91aeb39ed80cb3_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTUtMS0xLTg0NDQ0_c3c5ec18-e515-4ad1-abad-09f3ddee4f83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b9d25facfe14e558d8538281e17e27f_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTYtMS0xLTg0NDQ0_77566fa5-5278-4b71-b996-8368c8d2b1e6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7eda7450d4d9456b9e83912cf600f6da_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTctMS0xLTg0NDQ0_21c4be7d-f69d-4804-b005-886ae101040f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98e6ade62ef44067805f023366e22a49_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTgtMS0xLTg0NDQ0_07845ae5-b197-4cb0-9e0f-90db3c22b863">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81d9971dcb124172ad9892da8f77ed8f_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTktMS0xLTg0NDQ0_cf9d1c03-c1dd-44bd-b3ff-503a5db83cb8">174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c15d323b29d4f51a3b0277a6efe9fcb_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTEwLTEtMS04NDQ0NA_6f6f3226-3237-4585-a955-a4ef1883a9a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i260cec3db7e141a7bab9fbc38d51513a_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTEtMS0xLTg0NDQ0_5c64c76c-cdd6-43bb-b558-69874be6eec2">72</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5af51b0799c94e2f99fb3ffe042cf726_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTItMS0xLTg0NDQ0_39afad0c-c6c6-4305-9e87-4dc0931bdec5">271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dcae20ab7f46d58205e38411c02bc4_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTMtMS0xLTg0NDQ0_cb7bd621-2d2c-4fb9-9267-ef7c3a005b42">149</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic45912abb9de446ab846fa3d96ef734b_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTQtMS0xLTg0NDQ0_4fd70dff-73a8-4457-9374-955fd05291e2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56073f5e045041e085b3b01d323734e9_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTUtMS0xLTg0NDQ0_6a623588-e80d-416f-9d19-3ffef361d7e8">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6e64db864e94433959e07e907b7df1d_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTYtMS0xLTg0NDQ0_6f658a9c-66a2-44cc-ba86-011e1e051c5a">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55999a6bc9a460e938066f5c6f50247_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTctMS0xLTg0NDQ0_4e168105-087c-4c6f-9e33-0a25c2df0760">119</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b7dae6e9bb14eb495b8a03281389def_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTgtMS0xLTg0NDQ0_5d6765a6-372b-4cd8-bbba-768d5057284c">30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cb3ddc5bc04bb699e468e1eb79f066_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTktMS0xLTg0NDQ0_a6ca2d4d-549d-4be4-9343-7beb759defd1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4545ac2dc1439cbf7c13f15c6f32af_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTEwLTEtMS04NDQ0NA_0368cae0-f144-473c-ad41-b970a6256356">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i260cec3db7e141a7bab9fbc38d51513a_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTEtMS0xLTg0NDQ0_5981181a-9f62-4549-97ca-6180958b16e0">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5af51b0799c94e2f99fb3ffe042cf726_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTItMS0xLTg0NDQ0_d11cbbdb-ddb4-43a2-8136-8626764e1ac1">319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i82dcae20ab7f46d58205e38411c02bc4_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTMtMS0xLTg0NDQ0_12485b3e-4b46-4705-91f6-130bed3bc93c">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic45912abb9de446ab846fa3d96ef734b_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTQtMS0xLTg0NDQ0_229effad-9df1-471f-8290-7425b444ea67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56073f5e045041e085b3b01d323734e9_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTUtMS0xLTg0NDQ0_ac4c5b3a-cd67-4698-a1b6-3a5ec5e8d0a8">113</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib6e64db864e94433959e07e907b7df1d_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTYtMS0xLTg0NDQ0_e2636f0f-46a0-4211-8806-520ffc1c6c0a">94</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic55999a6bc9a460e938066f5c6f50247_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTctMS0xLTg0NDQ0_f4682aac-89a9-4cdc-b758-0e527d6af345">557</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4b7dae6e9bb14eb495b8a03281389def_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTgtMS0xLTg0NDQ0_d70104c8-5c17-4ddc-9d0b-d6e22a721803">123</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44cb3ddc5bc04bb699e468e1eb79f066_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTktMS0xLTg0NDQ0_5d2de4f3-282f-4c01-8fe1-b8686398651d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e4545ac2dc1439cbf7c13f15c6f32af_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTEwLTEtMS04NDQ0NA_b1c4cae4-d0c1-4b7c-b13e-ef810aacd063">146</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc946cef90d46caaddb4f18c8fd5893_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTEtMS0xLTg0NDQ0_cb669226-8079-4383-a162-4ad48454e9ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa09240ffe5c45a493822e57c2dc3858_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTItMS0xLTg0NDQ0_29e744fd-0edc-4311-8c8f-dc6788a35e28">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9f80f9c820492780c7f8c91535919c_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTMtMS0xLTg0NDQ0_0a73b410-3bc2-4840-a5c4-b6596b6cf887">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14cee3a2fdc941089f344ca72308f0f0_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTQtMS0xLTg0NDQ0_2bcfca5d-4ddb-41d6-97c2-d3bb1d74fad1">425</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59a01ed372cd4e95abefcdf0e51356aa_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTUtMS0xLTg0NDQ0_79cb5dfb-76e5-4a27-a15d-479fe0f001b3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8143a538b2e94972a97a82b7e6ec6c68_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTYtMS0xLTg0NDQ0_667caa4c-5c08-4fa3-81e9-50f2bea3b253">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5eb91944ab42f6bd12eae5c9d5ae5d_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTctMS0xLTg0NDQ0_c293291d-e506-4e8a-b874-bcbf3b7302da">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb690af5f3694f69b7b889d872aeaf05_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTgtMS0xLTg0NDQ0_24f0d79a-04b6-4ff3-835e-83fbd10702a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic136e45ed1b94c44a821b42b608d5c9d_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTktMS0xLTg0NDQ0_710077b6-b347-4e06-9637-8258ecc96459">402</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7980b23189f4bc7b2e93c0103862863_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTEwLTEtMS04NDQ0NA_33c0bdc9-8b4b-4a73-a777-be61422a8f2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3dc946cef90d46caaddb4f18c8fd5893_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTEtMS0xLTg0NDQ0_a58d06fa-5b1d-4569-ab33-40376dfc5396">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa09240ffe5c45a493822e57c2dc3858_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTItMS0xLTg0NDQ0_50d25e97-f7e0-44d1-968b-537c7cd9f25a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb9f80f9c820492780c7f8c91535919c_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTMtMS0xLTg0NDQ0_7d155e11-fdca-4810-83a0-82413bdfd98d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14cee3a2fdc941089f344ca72308f0f0_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTQtMS0xLTg0NDQ0_b388d642-fadf-4f7a-8171-dcce0d5dcf1a">42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59a01ed372cd4e95abefcdf0e51356aa_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTUtMS0xLTg0NDQ0_21601079-01c9-408c-ac46-d43b98a07c76">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8143a538b2e94972a97a82b7e6ec6c68_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTYtMS0xLTg0NDQ0_5d0b328e-5b6a-4874-9445-8e01202b2ac3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b5eb91944ab42f6bd12eae5c9d5ae5d_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTctMS0xLTg0NDQ0_1d08c458-343e-460e-9bb3-af1df0616bf4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb690af5f3694f69b7b889d872aeaf05_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTgtMS0xLTg0NDQ0_cc5af963-231e-49b9-97e1-b81771daddab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic136e45ed1b94c44a821b42b608d5c9d_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTktMS0xLTg0NDQ0_316d66b9-9e29-40ec-a353-b30e26b64628">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7980b23189f4bc7b2e93c0103862863_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTEwLTEtMS04NDQ0NA_19367c50-65fb-4a32-863a-27c4389c97eb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January&#160;1, 2023 and January&#160;2, 2022, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"></td><td style="width:30.328%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ef91f5dac5a431b8628840f5ad90267_I20230101" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpiYmY5MjgzM2E3ZTA0MTVlYWRjZmE3ZjE0Mjc5MThkZS90YWJsZXJhbmdlOmJiZjkyODMzYTdlMDQxNWVhZGNmYTdmMTQyNzkxOGRlXzQtMi0xLTEtODQ0NDQ_eece80f5-224f-4816-be5a-7a0f3e0431a6">8,665</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia55d14fcbb70445388964f5f5d173a93_I20220102" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpiYmY5MjgzM2E3ZTA0MTVlYWRjZmE3ZjE0Mjc5MThkZS90YWJsZXJhbmdlOmJiZjkyODMzYTdlMDQxNWVhZGNmYTdmMTQyNzkxOGRlXzQtNC0xLTEtODQ0NDQ_c3b4159c-fb00-4b0c-b9c6-e4f1b0237673">9,793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8ef91f5dac5a431b8628840f5ad90267_I20230101" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpiYmY5MjgzM2E3ZTA0MTVlYWRjZmE3ZjE0Mjc5MThkZS90YWJsZXJhbmdlOmJiZjkyODMzYTdlMDQxNWVhZGNmYTdmMTQyNzkxOGRlXzQtNi0xLTEtODQ0NDQ_663cad9f-992b-4389-b694-e9409a693a5b">1,435</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia55d14fcbb70445388964f5f5d173a93_I20220102" decimals="-6" sign="-" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpiYmY5MjgzM2E3ZTA0MTVlYWRjZmE3ZjE0Mjc5MThkZS90YWJsZXJhbmdlOmJiZjkyODMzYTdlMDQxNWVhZGNmYTdmMTQyNzkxOGRlXzQtOC0xLTEtODQ0NDQ_b35885cb-f179-400a-9ada-42ae59c70a09">142</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if7e69bcefaa2430f85e07d4226d1307d" continuedAt="i6e4aa579693e4d6f8690548c3b7bc6c9"><div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzEwMDQy_8e4819b1-5f9c-4361-aac3-a711d20f3dea" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"></td><td style="width:37.594%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.510%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.012%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.469%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.532%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItMi0xLTEtMTA5MzI3_baf92b4c-2473-4ad1-9202-3d7157cbead6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItMi0xLTEtMTA5MzI3_d20882e0-6ef3-4436-8245-6610c60bdc82">Other (income) expense</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i237858b83a9d4cf297ac85f26bb8ae97_D20220103-20230101" decimals="-6" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItNC0xLTEtODQ0NDQ_79c28af2-4837-4157-a751-4fff3c15c517">94</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab7309c98649499d9713793656af22d7_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DerivativeGainLossOnDerivativeNet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItNi0xLTEtODQ0NDQ_f2b5789b-ac41-4271-9261-6e3516691de8">70</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzEwMDU3_142aa5f1-8e87-4492-add4-c150fb08b382" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of net investment hedges for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:20.422%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.621%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.027%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)           Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo5YmVmMzM0YTRjNWU0MmM1YTg0YWIwNDA0NTQ4MTM1MS90YWJsZXJhbmdlOjliZWYzMzRhNGM1ZTQyYzVhODRhYjA0MDQ1NDgxMzUxXzItMi0xLTEtODQ0NDQ_46f185f6-b149-4cd3-9ab5-6098db1bc908">197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo5YmVmMzM0YTRjNWU0MmM1YTg0YWIwNDA0NTQ4MTM1MS90YWJsZXJhbmdlOjliZWYzMzRhNGM1ZTQyYzVhODRhYjA0MDQ1NDgxMzUxXzItNC0xLTEtODQ0NDQ_e73c6666-2560-4e62-b308-852a2e0e3c2a">387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense<br/></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83f081c66b1b450a84f5571770ed1022_D20221003-20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo5YmVmMzM0YTRjNWU0MmM1YTg0YWIwNDA0NTQ4MTM1MS90YWJsZXJhbmdlOjliZWYzMzRhNGM1ZTQyYzVhODRhYjA0MDQ1NDgxMzUxXzItOC0xLTEtODQ0NDQ_7ebe2411-e224-47fc-8ceb-72d77500159a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f4dde8b4404aef8dca3c97bf241db1_D20211004-20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo5YmVmMzM0YTRjNWU0MmM1YTg0YWIwNDA0NTQ4MTM1MS90YWJsZXJhbmdlOjliZWYzMzRhNGM1ZTQyYzVhODRhYjA0MDQ1NDgxMzUxXzItMTAtMS0xLTg0NDQ0_312fe63a-67b2-47d2-aa41-fa3cbfb3e706">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2e7e250084ad46a6a9cbab407dbeb7ab_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo5YmVmMzM0YTRjNWU0MmM1YTg0YWIwNDA0NTQ4MTM1MS90YWJsZXJhbmdlOjliZWYzMzRhNGM1ZTQyYzVhODRhYjA0MDQ1NDgxMzUxXzMtMi0xLTEtODQ0NDQ_ad07dc5f-68f0-4dcf-8401-18cb401be35f">766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c81dca775704665a78c37783de6d091_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo5YmVmMzM0YTRjNWU0MmM1YTg0YWIwNDA0NTQ4MTM1MS90YWJsZXJhbmdlOjliZWYzMzRhNGM1ZTQyYzVhODRhYjA0MDQ1NDgxMzUxXzMtNC0xLTEtODQ0NDQ_79ab5c2e-19ef-4455-aba6-c6990f27043a">548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8d53c59ceef44b389961dad508f831b_D20221003-20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo5YmVmMzM0YTRjNWU0MmM1YTg0YWIwNDA0NTQ4MTM1MS90YWJsZXJhbmdlOjliZWYzMzRhNGM1ZTQyYzVhODRhYjA0MDQ1NDgxMzUxXzMtOC0xLTEtODQ0NDQ_f5a082db-99e8-40c8-9531-b01d807185e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ae9179932924168b60062ab11671493_D20211004-20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo5YmVmMzM0YTRjNWU0MmM1YTg0YWIwNDA0NTQ4MTM1MS90YWJsZXJhbmdlOjliZWYzMzRhNGM1ZTQyYzVhODRhYjA0MDQ1NDgxMzUxXzMtMTAtMS0xLTg0NDQ0_25e779f1-6ddf-4e3c-a557-d6439cfdd554">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzEwMDI0_a7b2a79b-a5ac-41a7-85f3-a2ec23631714" escape="true"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:25.772%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.143%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.504%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6534a66bb873492c8df03d6fc07250d9_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzItMi0xLTEtODQ0NDQ_3ca6ec34-a233-42fa-8647-22eb5bfbf515">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828e3ede8e3549dc9f5058a9b4b0483e_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzItNC0xLTEtODQ0NDQ_89f3afe0-1229-45fd-b020-ed0f68e18281">538</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i828e3ede8e3549dc9f5058a9b4b0483e_D20220103-20230101" decimals="-6" sign="-" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzItNi0xLTEtODQ0NDQ_a1404d0a-bfaa-4ae0-86c1-1a47744209a3">770</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb50a86cda447408f1cd7369b0d9418_I20230101" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzItOC0xLTEtODQ0NDQ_5b02cf3e-6452-4a32-9ba7-7caeb3753e4d">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bb50a86cda447408f1cd7369b0d9418_I20230101" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzItMTAtMS0xLTg0NDQ0_dcc4f92a-a6d9-464c-8b76-0bb8308ee7cd">576</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e4435e5d9a4e60aa7205751e72f33b_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzQtMi0xLTEtODQ0NDQ_8ed5774c-c346-4a29-ae27-79cbfdb943ca">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2f9ac2b4014e1fbb1ff7315cbbb47a_D20220103-20230101" decimals="-6" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzQtNC0xLTEtODQ0NDQ_1c0cd83b-f2d6-4613-8d9e-2433b63297a9">91</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f2f9ac2b4014e1fbb1ff7315cbbb47a_D20220103-20230101" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzQtNi0xLTEtODQ0NDQ_af48782a-e305-4378-9d62-925126485418">107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db883efd7e1433a90d82a1129bb778b_I20230101" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzQtOC0xLTEtODQ0NDQ_28334f8e-3b49-4c20-90fd-730e6a4b9873">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db883efd7e1433a90d82a1129bb778b_I20230101" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzQtMTAtMS0xLTg0NDQ0_817cb85b-fd9a-4c79-a6e3-bb63be076957">698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:25.478%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.143%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.827%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.318%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.505%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3133d52c339b4153b25eed2e42d701a3_I20210103" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzItMi0xLTEtODQ0NDQ_4108960d-450e-4518-b2d6-00581b819f3a">1,481</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a9dbd90e4e4b16b09008c309918698_D20210104-20220102" decimals="-6" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzItNC0xLTEtODQ0NDQ_ea61684f-f915-4a6d-a7db-47f430baf4e4">198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a9dbd90e4e4b16b09008c309918698_D20210104-20220102" decimals="-6" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzItNi0xLTEtODQ0NDQ_28ddfa38-afe4-424e-89c6-68ee7ef9586b">205</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6534a66bb873492c8df03d6fc07250d9_I20220102" decimals="-6" name="us-gaap:MarketableSecuritiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzItOC0xLTEtODQ0NDQ_129ff40b-6dce-49a6-be2c-b70416cc551b">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6534a66bb873492c8df03d6fc07250d9_I20220102" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzItMTAtMS0xLTg0NDQ0_67dcfd84-9bcc-42a4-a4ad-139bbd5f9117">1,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9771bb6b36dc4c2eb9a95f16e382664c_I20210103" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzQtMi0xLTEtODQ0NDQ_ba7aca6f-814a-4d17-ba03-a192e411cb86">738</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5daa381fed7742f0a17f958e3f55f3d0_D20210104-20220102" decimals="-6" name="us-gaap:EquityFairValueAdjustment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzQtNC0xLTEtODQ0NDQ_d9165270-1f1d-4825-9019-56bb0ee22ff3">394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5daa381fed7742f0a17f958e3f55f3d0_D20210104-20220102" decimals="-6" sign="-" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzQtNi0xLTEtODQ0NDQ_a00372d2-cb20-4626-92ed-9d71b2813021">632</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e4435e5d9a4e60aa7205751e72f33b_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzQtOC0xLTEtODQ0NDQ_eae32a8a-3b88-4a5c-b394-baf8d083c69b">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia3e4435e5d9a4e60aa7205751e72f33b_I20220102" decimals="-6" name="us-gaap:OtherAssetsNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzQtMTAtMS0xLTg0NDQ0_a90c1e15-e787-43a1-9c91-ebd2be7e4a0b">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i6e4aa579693e4d6f8690548c3b7bc6c9" continuedAt="i8174e1638bd34cb68c3abeacfef15909"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022 for equity investments without readily determinable market values, $<ix:nonFraction unitRef="usd" contextRef="i1f2f9ac2b4014e1fbb1ff7315cbbb47a_D20220103-20230101" decimals="-6" sign="-" name="jnj:EquityFairValueAdjustmentImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzY1NDE_7cf3e3cc-cc3b-45d0-8ef2-fd8983876118">51</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5daa381fed7742f0a17f958e3f55f3d0_D20210104-20220102" decimals="-6" sign="-" name="jnj:EquityFairValueAdjustmentImpairmentLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzY1NDg_dc0d566b-394e-4834-816b-0ad94fa292d9">28</ix:nonFraction> million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were offsetting impacts of $<ix:nonFraction unitRef="usd" contextRef="i1f2f9ac2b4014e1fbb1ff7315cbbb47a_D20220103-20230101" decimals="-6" name="jnj:EquityFairValueAdjustmentChangeinObservablePrices" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzY1OTcwNjk3ODA4OTE_bf43b4a9-44d8-4062-9835-3485511ddc9d">142</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i5daa381fed7742f0a17f958e3f55f3d0_D20210104-20220102" decimals="-6" name="jnj:EquityFairValueAdjustmentChangeinObservablePrices" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzY2OTI_8ba2f27b-8b26-4046-a9be-1d27a92b5ae9">422</ix:nonFraction> million, respectively, of changes in the fair value reflected in net income due to changes in observable prices and gains on the disposal of investments. The impact in fiscal year 2021, was driven by the gain on disposal of the Grail investment. In fiscal year 2022, the Company sold all of its equity investments in argenx SE for proceeds of $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-8" name="jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzc2OTY1ODE0MDc5NTk_911183bb-ee83-4af3-a98f-0e653369100e">0.6</ix:nonFraction>&#160;billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability.  In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S.&#160;Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level&#160;1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#160;&#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#160;&#8212; Significant other observable inputs.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#160;&#8212; Significant unobservable inputs.</span></div></ix:continuation><div style="margin-top:7pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i8174e1638bd34cb68c3abeacfef15909" continuedAt="i757c5a69d5ad4ad18f17b1624f3d16cb"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzEwMDQz_768f8d21-d317-4495-9ddf-48f0f69d6a8b" continuedAt="ic9a76c58ed0042fdb21137625cf82779" escape="true"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of the fiscal year ended January&#160;1, 2023 and January&#160;2, 2022 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:42.218%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7375a9453abe472696f28e9901817945_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzQtMi0xLTEtODQ0NDQ_452c6678-2337-49cc-bb67-5c17f9202b92">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2864e7cf41c41f3a7a0337f807e5568_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzQtNC0xLTEtODQ0NDQ_db3a4862-bbf0-4914-bcc1-1d074308e3e9">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bc84e4de9ae423e8fd3d6a2ad33e500_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzQtNi0xLTEtODQ0NDQ_6f778ff4-18f4-4eb1-98d0-3d04f85c5e6b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ea9658839544de90b002aa4a145255_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzQtOC0xLTEtODQ0NDQ_1ce1dbaf-a313-4dbe-8f88-3f401f46f41a">629</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14578454fa464922b37380e635487d56_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzQtMTAtMS0xLTg0NDQ0_3da23963-1bc6-4383-a2f6-09a2e7ea9172">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0310802ba8b84af0ab17442fe8266124_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzUtMi0xLTEtODQ0NDQ_e8392417-2c1b-4636-94e6-1ecf9d8d7ccb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39659278be5497eb0de37bcacef7e1c_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzUtNC0xLTEtODQ0NDQ_a7023a3c-e8d0-46f6-a7e1-3fff7cdc1201">1,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d82bd1550d4cf091ae15cb452ce838_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzUtNi0xLTEtODQ0NDQ_7177f208-7b4d-4031-bafa-5845bbf40263">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9291dfb5a14a27898df7a62b8d588a_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzUtOC0xLTEtODQ0NDQ_ad38a963-fdd2-4554-97f9-82d7fa9810f5">1,534</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29258a2318d3469e9984174d5a29a387_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzUtMTAtMS0xLTg0NDQ0_5ad82e16-ef8b-4f1a-8fc2-c0e9b636d04d">796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48b117336c44afdb375a11b9255f3b1_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzctMi0xLTEtODQ0NDQ_73464291-cdad-4160-bc9f-e4cdbcc0c8b4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef2c7f6b53641888829b0aa74f1baba_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzctNC0xLTEtODQ0NDQ_7b90899a-b627-4f85-979f-a3b71a80243c">2,163</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c2690afca047d8a831e4a7983bda38_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzctNi0xLTEtODQ0NDQ_02b7c543-ef2e-466f-9c80-d290490ce722">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzctOC0xLTEtODQ0NDQ_6384f838-e67b-422d-b494-745e033ff48d">2,163</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff70c34dd9b948dca087b12faaa08430_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzctMTAtMS0xLTg0NDQ0_526a6312-e7a4-44cd-8b98-0ae89a46e9ce">1,336</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7375a9453abe472696f28e9901817945_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzktMi0xLTEtODQ0NDQ_78482d42-15e4-4f01-ab48-e1ac3779bb9f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2864e7cf41c41f3a7a0337f807e5568_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzktNC0xLTEtODQ0NDQ_af0a996c-3904-4258-93f4-6443405bc782">511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bc84e4de9ae423e8fd3d6a2ad33e500_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzktNi0xLTEtODQ0NDQ_dc54ef1c-7794-4178-a7bf-b3e0ef2e7a1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ea9658839544de90b002aa4a145255_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzktOC0xLTEtODQ0NDQ_6f87f1d7-c541-4bd2-82b8-cb22c4d4a630">511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14578454fa464922b37380e635487d56_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzktMTAtMS0xLTg0NDQ0_558430e6-1c22-4684-8dce-daa9873c972f">881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0310802ba8b84af0ab17442fe8266124_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEwLTItMS0xLTg0NDQ0_3ba87914-1e94-43c3-a844-0184d3a3c767">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia39659278be5497eb0de37bcacef7e1c_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEwLTQtMS0xLTg0NDQ0_bce477ac-cfce-4d7b-84ac-78a1cc59eee0">2,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3d82bd1550d4cf091ae15cb452ce838_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEwLTYtMS0xLTg0NDQ0_0b1dc01f-93a1-49fb-859d-a9fe48455648">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c9291dfb5a14a27898df7a62b8d588a_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEwLTgtMS0xLTg0NDQ0_72cf72d8-4f14-4625-9879-cf76e4237488">2,778</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29258a2318d3469e9984174d5a29a387_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEwLTEwLTEtMS04NDQ0NA_abe8caef-f1a8-4dc6-8a7a-711ba6283e46">979</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48b117336c44afdb375a11b9255f3b1_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEzLTItMS0xLTg0NDQ0_1f0107a6-3fe5-437e-a2b4-63e3b09f7cc6">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef2c7f6b53641888829b0aa74f1baba_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEzLTQtMS0xLTg0NDQ0_37a162b7-422b-4e0b-b6b5-4dca2e5367cf">3,289</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c2690afca047d8a831e4a7983bda38_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEzLTYtMS0xLTg0NDQ0_e6023c90-dc2b-412d-b5cc-1f9c919bafb8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEzLTgtMS0xLTg0NDQ0_92e31ca6-8abf-4581-8ca7-ecdf7fe570cd">3,289</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff70c34dd9b948dca087b12faaa08430_I20220102" decimals="-6" name="us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEzLTEwLTEtMS04NDQ0NA_3b50f329-1afc-4b5c-b39e-6830dfc437de">1,860</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7375a9453abe472696f28e9901817945_I20230101" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE2LTItMS0xLTg0NDQ0_50c44b9f-3ba1-4451-8074-13e43184ea6a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2864e7cf41c41f3a7a0337f807e5568_I20230101" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE2LTQtMS0xLTg0NDQ0_78dd48f7-abcc-47ec-b022-9c6473090e51">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bc84e4de9ae423e8fd3d6a2ad33e500_I20230101" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE2LTYtMS0xLTg0NDQ0_0dbd67d1-eca7-4691-85ed-87178ed610fb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ea9658839544de90b002aa4a145255_I20230101" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE2LTgtMS0xLTg0NDQ0_7020e0eb-0bf9-41ca-9d09-15d2383a87aa">38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14578454fa464922b37380e635487d56_I20220102" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE2LTEwLTEtMS04NDQ0NA_b6153214-f96b-4481-a9be-b72abdff992e">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7375a9453abe472696f28e9901817945_I20230101" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE4LTItMS0xLTg0NDQ0_d6bc396c-cee8-41d7-90a9-5a2e6f1b5985">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2864e7cf41c41f3a7a0337f807e5568_I20230101" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE4LTQtMS0xLTg0NDQ0_a78d9401-c28c-4720-bb91-ea1caae150bc">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bc84e4de9ae423e8fd3d6a2ad33e500_I20230101" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE4LTYtMS0xLTg0NDQ0_8924b5bd-8624-4146-a55e-56ee59e87c66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9ea9658839544de90b002aa4a145255_I20230101" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE4LTgtMS0xLTg0NDQ0_8d54d460-d112-43ac-b4bf-624f84c15b8e">68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14578454fa464922b37380e635487d56_I20220102" decimals="-6" name="us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE4LTEwLTEtMS04NDQ0NA_651456d6-2fe9-4f8f-90f2-093c02930e26">28</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Available For Sale Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48b117336c44afdb375a11b9255f3b1_I20230101" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIwLTItMS0xLTg0NDQ0_35b6d3be-2971-4a3b-8708-c2526549b2f7">576</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef2c7f6b53641888829b0aa74f1baba_I20230101" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIwLTQtMS0xLTg0NDQ0_0dd33ea2-eeba-443b-8f22-560b1e446b97">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c2690afca047d8a831e4a7983bda38_I20230101" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIwLTYtMS0xLTg0NDQ0_b9f8854c-a49b-4aa1-88be-7ff7e5b4eb1c">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIwLTgtMS0xLTg0NDQ0_e934dd01-599c-4a7a-ba40-60694316a5ac">576</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIwLTEwLTEtMS04NDQ0NA_b415d7a6-2f95-4b09-af1e-78c21a4d19e0">1,884</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie48b117336c44afdb375a11b9255f3b1_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIxLTItMS0xLTg0NDQ0_b4677d29-b342-4315-9f4c-a287c01a9da7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ef2c7f6b53641888829b0aa74f1baba_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIxLTQtMS0xLTg0NDQ0_f89fb4fd-9c5a-47bf-8081-03794034ac27">10,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c2690afca047d8a831e4a7983bda38_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIxLTYtMS0xLTg0NDQ0_82d31a22-1c92-45b4-aa4c-6e7efdbf56c1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIxLTgtMS0xLTg0NDQ0_cf773796-4525-40f4-9c6f-3fd6a21a086c">10,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIxLTEwLTEtMS04NDQ0NA_cfb6828d-279f-4e83-a647-5645d0624682">19,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10c2690afca047d8a831e4a7983bda38_I20230101" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIzLTYtMS0xLTg0NDQ0_431a76bd-566b-47f6-9b9e-a4115ab0b9a9">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIzLTgtMS0xLTg0NDQ0_f9f7cb14-9117-4579-aaef-570832fc89df">1,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIzLTEwLTEtMS04NDQ0NA_d000a022-c727-412e-ad22-664012a0743e">533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.409%"><tr><td style="width:1.0%"></td><td style="width:53.627%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.263%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.527%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.356%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzItMi0xLTEtODQ0NDQ_3c4522a5-9def-4ebe-acef-38565579d522">2,201</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzItNC0xLTEtODQ0NDQ_6a97bbc5-5d5a-409f-9c7b-21c219441e27">1,360</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzMtMi0xLTEtODQ0NDQ_67a9023e-bc8d-4d92-b3c0-ef58e6adf2c5">2,176</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DerivativeAssetFairValueGrossLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzMtNC0xLTEtODQ0NDQ_56845f4c-cb45-4a5b-b0cd-3f2f65cb896a">1,285</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" name="jnj:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzQtMC0xLTEtODQ0NDQ_4966d4e1-530d-4c61-924d-57de650e9cb3"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="jnj:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzQtMC0xLTEtODQ0NDQ_9607f038-69b7-42a6-bd6e-71e943c248fb">Total Net Asset</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzQtMi0xLTEtODQ0NDQ_6f485f54-a8c4-4dcd-be02-2b632460f93c">25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DerivativeAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzQtNC0xLTEtODQ0NDQ_0fc0dd44-ae06-448c-9c43-1482893a65d0">75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzYtMi0xLTEtODQ0NDQ_97a59b83-ca51-4002-aceb-7fef51d19906">3,357</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DerivativeFairValueOfDerivativeLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzYtNC0xLTEtODQ0NDQ_f393dccf-7fac-42b0-a35d-9d974aca2a9d">1,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzctMi0xLTEtODQ0NDQ_21e70c65-a27b-496b-8ef7-6fde7a5f67bb">3,023</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DerivativeLiabilityFairValueGrossAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzctNC0xLTEtODQ0NDQ_59d3de29-a9c7-4d13-9a18-eb43e38b319a">1,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="jnj:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzgtMC0xLTEtODQ0NDQ_3e8d0ab9-c9f2-4465-beaa-3506b5e362e8"><ix:nonNumeric contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" name="jnj:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzgtMC0xLTEtODQ0NDQ_ddba4376-7665-4b75-b536-8046a2692df3">Total Net Liabilities</ix:nonNumeric></ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzgtMi0xLTEtODQ0NDQ_c2970802-c0be-4b82-937d-ca7a0e427033">334</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DerivativeLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzgtNC0xLTEtODQ0NDQ_8e617ebb-cb18-4459-add6-3bc8671d13f0">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzItMy0xLTEtODQ0NDQ_cf3a30b0-fd6e-4ad6-84fb-4117c6b59651">533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzItNC0xLTEtODQ0NDQ_3c841210-a1df-4d4e-960f-7440e80ba827">633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzItNS0xLTEtODQ0NDQ_51757283-9e5e-4881-8533-82910823e943">1,715</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzMtMy0xLTEtODQ0NDQ_b13c6da7-c80d-4bad-b916-1a14da9a898a">194</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzMtNC0xLTEtODQ0NDQ_f803537b-5abf-46c3-b3dc-3de9c4b4aad1">52</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzMtNS0xLTEtODQ0NDQ_0399cf00-0e50-45a2-aacd-4f22f6feb065">1,089</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzQtMy0xLTEtODQ0NDQ_af2136f2-29de-43e6-a95a-ce6ecdf5567f">792</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzQtNC0xLTEtODQ0NDQ_4f13c8ac-3df6-4f33-8a58-297e30c033ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzQtNS0xLTEtODQ0NDQ_ebe8bf44-d439-4e9c-8700-24515c30f08f">106</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzUtMy0xLTEtODQ0NDQ_7aab4537-3fa5-4842-a4e5-6a4ba58054c2">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzUtNC0xLTEtODQ0NDQ_07fff26c-da0c-4fd6-80ff-1fd4fea65d10">48</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzUtNS0xLTEtODQ0NDQ_6d477839-ea21-40bf-befb-b84a19f56663">99</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzYtMy0xLTEtODQ0NDQ_c5748e11-e129-416d-87a8-32fe98271d52">1,120</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzYtNC0xLTEtODQ0NDQ_0d3dc1fc-0aba-45a2-9a88-6ff5a076f18d">533</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="-6" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzYtNS0xLTEtODQ0NDQ_f8ce9779-0ac3-4b2a-be95-fe22e0126657">633</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2021 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $<ix:nonFraction unitRef="usd" contextRef="i38d00501bab6464fa7c7be34c6d914c9_I20220102" decimals="-6" name="us-gaap:EquitySecuritiesFvNi" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzkwNzQ_545636f0-90f9-43a2-89cb-61672c0b3e27">1,884</ix:nonFraction> million, which are classified as Level&#160;1 and contingent consideration of $<ix:nonFraction unitRef="usd" contextRef="id7cd5b6c455d48de8f7bf42de3895a90_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzkxNDI_a3f69d02-2538-4629-bbfe-7c4bb04f3f97">533</ix:nonFraction> million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes cross currency interest rate swaps and interest rate swaps.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i757c5a69d5ad4ad18f17b1624f3d16cb"><ix:continuation id="ic9a76c58ed0042fdb21137625cf82779"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as non-current other assets.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes $<ix:nonFraction unitRef="usd" contextRef="i1fa9b7b2390c4ef88b1b4a20e07ca293_I20230101" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzkzNTU_7befa2b4-bf19-4c5d-bffc-2d6bc2061418">1,116</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i853d7b4b73e148b18f6b3d77f487972d_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzkzNTk_d8f4c5f3-0b38-4957-9a15-7bcf43bc751b">520</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i4535c102f78246f28d354501ec8be219_I20210103" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzkzNjY_6fdcef03-c744-4488-83ea-ed48e29d0fec">594</ix:nonFraction> million, classified as non-current other liabilities as of January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, respectively. Includes $<ix:nonFraction unitRef="usd" contextRef="i9da5b69b8f28444dbde29713e7b26de9_I20230101" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzk0NTg_e5f17ccd-bb46-4465-84b9-673ccfea8b87">4</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i141ff0a4da5940ae95c9e2df4dd982b2_I20220102" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzk0NjI_eebcfce3-65b4-4985-9380-e80bb6fbc73d">13</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="i33c7604b66f44fbc8b00fe1f4ef4b6eb_I20210103" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzk0Njk_c242b62d-afc6-40bc-b0da-0c80aa4949bb">39</ix:nonFraction>&#160;million classified as current liabilities as of January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, respectively.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt">Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense.  The Company recorded a contingent consideration reversal of $<ix:nonFraction unitRef="usd" contextRef="ia68fbb4c6ced466380b79a6a0e444ecc_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzk3MDA_f3bfa59d-14f4-4d43-9ff5-dfd9879b9f88">1,148</ix:nonFraction>&#160;million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt">In fiscal year 2022, the Company recorded $<ix:nonFraction unitRef="usd" contextRef="i3935ca62623944f3a9d651e98ee70890_I20230101" decimals="-6" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzc2OTY1ODE0MDc3ODk_8acf27d5-d199-4bdb-88a7-f64616fadad9">704</ix:nonFraction>&#160;million of contingent consideration related to Abiomed.</span></div></ix:continuation><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes&#160;2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_166"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">7.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:DebtDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzE2Njc_1dd1466d-25c6-458b-b3bd-99fc4b966a70" continuedAt="id9a7c0d389a44006a135042daba57143" escape="true">Borrowings</ix:nonNumeric></span></div><ix:continuation id="id9a7c0d389a44006a135042daba57143" continuedAt="ibf9b03ff6d2e4106a76dc5fc27eb26d8"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzE2NzA_3bb23fcb-18ce-4014-a949-dfe42e94945f" continuedAt="i75ade58041b3455494d354c1dc1ef025" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term debt are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.122%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.572%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.280%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.285%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.426%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.289%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd838f2728344154a7eaa225122dffc9_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo0Njg1M2VhODY0ZTA0NTVmOWQ2NDhkNjc1YWVjZTgzN180_945193cf-7328-4e64-ba17-ef666b363763">0.250</ix:nonFraction>% Notes due 2022                                                        (<ix:nonFraction unitRef="eur" contextRef="idd838f2728344154a7eaa225122dffc9_I20230101" decimals="-9" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo0Njg1M2VhODY0ZTA0NTVmOWQ2NDhkNjc1YWVjZTgzN183OA_239c6220-1dd6-4636-96ee-048cbc47ca7b">1</ix:nonFraction>B Euro <ix:nonFraction unitRef="number" contextRef="idd838f2728344154a7eaa225122dffc9_I20230101" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo0Njg1M2VhODY0ZTA0NTVmOWQ2NDhkNjc1YWVjZTgzN184Nw_361feba9-8fea-4792-b092-b0ff27540597">1.1311</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd838f2728344154a7eaa225122dffc9_I20230101" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQtMi0xLTEtODQ0NDQ_cb1970f9-0758-47c3-9b5c-a54ae512ffe4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd838f2728344154a7eaa225122dffc9_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQtNC0xLTEtODQ0NDQ_95f4c482-0ebb-4271-85ae-e8d9d1204555">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4be09c6f2a742c2872a7b5200cf5855_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQtNi0xLTEtODQ0NDQ_486d1b92-5a66-4d5a-9206-7ac88693231a">1,131</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4be09c6f2a742c2872a7b5200cf5855_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQtOC0xLTEtODQ0NDQ_63dc0f15-6522-4038-90de-a5e62e8205bc">0.26</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1be16c858d742f980612d02fd786f2f_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzUtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo5OWM0YzUzMTI1NDg0YzMwODgwMGRlOWFjZDk3YmYxNF80_057c1f7a-72bd-43e8-ab1d-46ec8e033209">2.25</ix:nonFraction>% Notes due 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1be16c858d742f980612d02fd786f2f_I20230101" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzUtMi0xLTEtODQ0NDQ_cfad07e2-a530-4361-8cc0-2bb23fc8f070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1be16c858d742f980612d02fd786f2f_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzUtNC0xLTEtODQ0NDQ_f3492b31-fbaf-4751-9330-55a93fc185ee">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4adc99f2fb284c778be3f71c61bc0de9_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzUtNi0xLTEtODQ0NDQ_37af4b58-8a6b-44b0-847a-51914d54e304">1,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4adc99f2fb284c778be3f71c61bc0de9_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzUtOC0xLTEtODQ0NDQ_ad0ca292-64bc-43a8-8d12-6bbd4aa7f4cd">2.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ed0d053a547493695781065ce302590_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzYtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjpiNjk4MmVkY2QyY2E0ZmY1YmE1YWRjN2IwMWM1NTdhMV80_9eb47f47-97ea-4cad-9cb4-84ce88b0664b">6.73</ix:nonFraction>%&#160;Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ed0d053a547493695781065ce302590_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzYtMi0xLTEtODQ0NDQ_5aaae5e7-0311-4bb1-9f29-37e14d9868b7">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ed0d053a547493695781065ce302590_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzYtNC0xLTEtODQ0NDQ_63b1b986-f70a-4604-95f9-0b4df0d572a8">6.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c69578754b841ad8feb98ac1c3242b2_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzYtNi0xLTEtODQ0NDQ_43cb3f7b-abe4-4103-9c54-81d714f338c2">250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c69578754b841ad8feb98ac1c3242b2_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzYtOC0xLTEtODQ0NDQ_4fdcf679-ea90-44b6-9c97-f66ba573c034">6.73</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b6971f2c45b4b4bbe271ae191423bff_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzctMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NDc5ZmZhNGFjYjI0ODFmODY2YzgzZjcwMThiZWExMV80_14c9ad3f-da41-400c-b9fc-96b2be35a829">3.375</ix:nonFraction>% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b6971f2c45b4b4bbe271ae191423bff_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzctMi0xLTEtODQ0NDQ_b13724ab-2763-4abd-b421-18088391c5bb">801</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b6971f2c45b4b4bbe271ae191423bff_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzctNC0xLTEtODQ0NDQ_b0d0f685-91c3-4364-8269-f5fc7b54492a">3.17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38e52b1bfe842649d2000136af597c5_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzctNi0xLTEtODQ0NDQ_26d04231-a4d7-484e-8324-c8cac8157c8c">802</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie38e52b1bfe842649d2000136af597c5_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzctOC0xLTEtODQ0NDQ_9aa40caa-6287-4abf-b359-833a61aa027e">3.18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5182d9f822204a00a480cc34f4ec92a0_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzgtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjphOTBkNzUwMDczMzQ0NjYwYTU4ODcxODdmY2Q4NzBlM180_bacf4d4a-79c1-4093-acc0-80e4bc89317d">2.05</ix:nonFraction>% Notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5182d9f822204a00a480cc34f4ec92a0_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzgtMi0xLTEtODQ0NDQ_6be8af63-2f04-4582-8102-f97fa3d7b2fa">500</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5182d9f822204a00a480cc34f4ec92a0_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzgtNC0xLTEtODQ0NDQ_4f65a715-f9e4-4f61-8df4-d63cdf6b502c">2.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8fe3adfe765241a28bf93429cd742b69_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzgtNi0xLTEtODQ0NDQ_eff9bc60-3031-4fd5-a088-61bf68e54fd2">499</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8fe3adfe765241a28bf93429cd742b69_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzgtOC0xLTEtODQ0NDQ_34929271-12b3-428e-bc01-cb147178f2c8">2.09</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34b79ae775034104a023060dd2d5ec9f_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjpiYzA4NWRhODJiZGY0MzRhODNlMzQxZThmODEzZWUyM180_49e21be1-b0d7-404a-82ff-01154eb3f309">0.650</ix:nonFraction>% Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="eur" contextRef="i34b79ae775034104a023060dd2d5ec9f_I20230101" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjpiYzA4NWRhODJiZGY0MzRhODNlMzQxZThmODEzZWUyM18yNA_30082295-5fef-4751-8cf2-ecff0a7e967c">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="i34b79ae775034104a023060dd2d5ec9f_I20230101" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjpiYzA4NWRhODJiZGY0MzRhODNlMzQxZThmODEzZWUyM18zNA_ba897b28-4c1c-4f0b-b125-e9946e173e19">1.0651</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(<ix:nonFraction unitRef="eur" contextRef="ie437d7bfb45f4c6995ab0a136f5c1320_I20220102" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjpiYzA4NWRhODJiZGY0MzRhODNlMzQxZThmODEzZWUyM180Mg_9d1e3ba4-9096-400f-9282-6ce549af2af9">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="ie437d7bfb45f4c6995ab0a136f5c1320_I20220102" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjpiYzA4NWRhODJiZGY0MzRhODNlMzQxZThmODEzZWUyM181Mg_14e2c310-4a6e-41a5-99fe-fb82eecbbe2c">1.1311</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34b79ae775034104a023060dd2d5ec9f_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktMi0xLTEtODQ0NDQ_560659b7-f206-44c6-bfcd-14a0471264a5">792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i34b79ae775034104a023060dd2d5ec9f_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktNC0xLTEtODQ0NDQ_bdcc4f3e-51bc-4a61-a303-6b0acf1eae64">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie437d7bfb45f4c6995ab0a136f5c1320_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktNi0xLTEtODQ0NDQ_1c04a905-9f61-4776-b3f8-30a83c4c55f0">847</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie437d7bfb45f4c6995ab0a136f5c1320_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktOC0xLTEtODQ0NDQ_1b3a8222-ef2f-48df-ae09-d2055a8e44ef">0.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5971a213eabf4160b6e3f25559619b06_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246Y2IwZmU2Y2ZhOWI0NGY1NDk1ODJjMTQ3MGQwZWU0NzhfNA_ff0519a3-a5f9-4f13-8521-5b1e46fb0983">5.50</ix:nonFraction>%&#160;Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="gbp" contextRef="i5971a213eabf4160b6e3f25559619b06_I20230101" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246Y2IwZmU2Y2ZhOWI0NGY1NDk1ODJjMTQ3MGQwZWU0NzhfMjQ_1757cdbe-d2ff-4067-9a39-0cd17029004b">500</ix:nonFraction>MM <ix:nonFraction unitRef="number" contextRef="i5971a213eabf4160b6e3f25559619b06_I20230101" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246Y2IwZmU2Y2ZhOWI0NGY1NDk1ODJjMTQ3MGQwZWU0NzhfMjk_34c31510-f544-4120-b290-f5bbc0a75617">1.2037</ix:nonFraction> GBP )</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(<ix:nonFraction unitRef="gbp" contextRef="i12619cfbbd3b4411975c686625cd4ee8_I20220102" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246Y2IwZmU2Y2ZhOWI0NGY1NDk1ODJjMTQ3MGQwZWU0NzhfNDI_3bebcc29-3d70-4c43-859f-b1a53034971f">500</ix:nonFraction>MM GBP <ix:nonFraction unitRef="number" contextRef="i12619cfbbd3b4411975c686625cd4ee8_I20220102" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246Y2IwZmU2Y2ZhOWI0NGY1NDk1ODJjMTQ3MGQwZWU0NzhfNTE_422f3de6-b96d-4ebe-ad22-1c13dcb56732">1.3485</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5971a213eabf4160b6e3f25559619b06_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTItMS0xLTg0NDQ0_163d0cee-a7ae-4c0a-a1d2-5e8512a001d3">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5971a213eabf4160b6e3f25559619b06_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTQtMS0xLTg0NDQ0_f6f25d1a-589f-41fb-8559-a0526164e1c1">6.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12619cfbbd3b4411975c686625cd4ee8_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTYtMS0xLTg0NDQ0_d82a7dbe-18dc-40cc-a35c-134fc0ec9d5b">672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i12619cfbbd3b4411975c686625cd4ee8_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTgtMS0xLTg0NDQ0_47a0c2e0-8868-4072-8257-09e749293aac">6.75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id160170994a44083bc75890cadbe9623_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzExLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246YTJiYzg1MjI4ODY3NDQzODljYzA3YmU4YzYwMzA2YTRfNA_9eaeb031-cb00-41ad-b814-ac042a6940ed">2.625</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id160170994a44083bc75890cadbe9623_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzExLTItMS0xLTg0NDQ0_dccc3302-1a0d-4311-9c1a-7bd8f35fcc14">749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id160170994a44083bc75890cadbe9623_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzExLTQtMS0xLTg0NDQ0_5c2e6d0a-2f2a-4ff1-adad-a9cfc34cb5b1">2.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4b486d1b1024bb589a658274877269a_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzExLTYtMS0xLTg0NDQ0_dd4b8c97-35d5-4cca-9dd6-8c52c4754319">749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id4b486d1b1024bb589a658274877269a_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzExLTgtMS0xLTg0NDQ0_dd79acb2-99ef-4cb5-87d4-38ab9a091b4f">2.63</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie9afa533d623446aaad16fd946291ca1_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEyLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ODZkMjlkMGI2NjY3NDY1MWE3ODFiYTgyMDI0NTU2MjJfNA_ee458ea3-01a8-4dcb-846e-3a0330403589">0.55</ix:nonFraction>% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie9afa533d623446aaad16fd946291ca1_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEyLTItMS0xLTg0NDQ0_6a9d0c04-aa7e-4283-9023-08fd1817c553">918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie9afa533d623446aaad16fd946291ca1_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEyLTQtMS0xLTg0NDQ0_8352e70b-6c67-414d-973d-6baad2924cba">0.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5bb2d0484d64d079887869bc2c1d3d7_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEyLTYtMS0xLTg0NDQ0_9fbb72f1-9e8d-4872-bb41-69af977000d4">983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5bb2d0484d64d079887869bc2c1d3d7_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEyLTgtMS0xLTg0NDQ0_44d28ab5-f9a6-4e2d-8fd1-66ba4669b5fc">0.57</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia73e0d2b294240f09389800e85e374d4_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEzLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ZjAxNjZmNjc1MDE3NGU2OThhMzAyMWQ5NDQ5ZThkYTRfNA_6827772a-3fec-406d-a9cc-8163709ce9bb">2.45</ix:nonFraction>% Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia73e0d2b294240f09389800e85e374d4_I20230101" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEzLTItMS0xLTg0NDQ0_e2c664b2-533c-4082-917d-9969224a2beb">1,996</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia73e0d2b294240f09389800e85e374d4_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEzLTQtMS0xLTg0NDQ0_2533045f-dc8c-440a-be0b-9126278f8268">2.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id09ef46ccfc64f829b503e8d23112272_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEzLTYtMS0xLTg0NDQ0_0a53983f-ff22-46a4-a3f2-8092c37c9a42">1,995</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id09ef46ccfc64f829b503e8d23112272_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEzLTgtMS0xLTg0NDQ0_55c7f7ff-b17f-43b5-ab46-9c5a13575aff">2.47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8e41ec0707864b1b9019a8e24ae75a97_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246Mzc3MWZlZGFkNjEwNDFhODliODNjMWFlMmI2MDViYWFfNA_6955e516-e8b7-46db-bab8-386ba157c8bc">2.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e41ec0707864b1b9019a8e24ae75a97_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE0LTItMS0xLTg0NDQ0_42c7ce90-12f9-4e3c-bddf-8b4f556a2292">877</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8e41ec0707864b1b9019a8e24ae75a97_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE0LTQtMS0xLTg0NDQ0_88f2808f-d0e4-4f3e-9f2a-2f9718688f96">2.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i168bd65ad6a0451d816d411b7f64f62d_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE0LTYtMS0xLTg0NDQ0_0880bb30-7a96-4976-9d49-195974131ba0">978</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i168bd65ad6a0451d816d411b7f64f62d_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE0LTgtMS0xLTg0NDQ0_ea504ce1-c8e9-4f68-bd65-0bd3b4d76c3f">2.96</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibeb93d53afa248caa20093bc023648b7_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE1LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NzE4NDIyNjE5MWRmNDM3Y2I1Mjc4MWUwNzhkMzdhMWZfNA_08b5c632-c6bf-4cec-97bd-8d2b2b856805">0.95</ix:nonFraction>% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibeb93d53afa248caa20093bc023648b7_I20230101" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE1LTItMS0xLTg0NDQ0_73f29ec7-e95e-48f0-a590-d4beee737111">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibeb93d53afa248caa20093bc023648b7_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE1LTQtMS0xLTg0NDQ0_1ac40928-405d-4893-a5e3-1307867d02d9">0.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22bff2ba3f0e400a90a0044c29f13928_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE1LTYtMS0xLTg0NDQ0_bb463b05-a560-4155-be59-1ea23f8d5f12">1,478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i22bff2ba3f0e400a90a0044c29f13928_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE1LTgtMS0xLTg0NDQ0_c1455b2c-cec2-4b74-8a0b-1b2df93c638f">0.96</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia496b34d6cb74a168adcb5bf7122133e_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ZDcwOWM0NmMzY2M0NDExNTlhOWRmMzQ1NGJkZjhiNzdfNA_8fec346a-65eb-4230-a862-2c8a88038d3d">1.150</ix:nonFraction>% Notes due 2028                                                (<ix:nonFraction unitRef="eur" contextRef="ia496b34d6cb74a168adcb5bf7122133e_I20230101" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ZDcwOWM0NmMzY2M0NDExNTlhOWRmMzQ1NGJkZjhiNzdfNzA_7ba510e5-c49d-4c76-b479-63ea66b68764">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="ia496b34d6cb74a168adcb5bf7122133e_I20230101" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ZDcwOWM0NmMzY2M0NDExNTlhOWRmMzQ1NGJkZjhiNzdfODA_9021ab78-9f44-4fd5-b5c1-34f16b8d32d2">1.0651</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(<ix:nonFraction unitRef="eur" contextRef="i92f030712061450fa2980a5ce6c8142a_I20220102" decimals="-6" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ZDcwOWM0NmMzY2M0NDExNTlhOWRmMzQ1NGJkZjhiNzdfODg_18b6551d-485d-4aea-800c-1a99b9321dce">750</ix:nonFraction>MM Euro <ix:nonFraction unitRef="number" contextRef="i92f030712061450fa2980a5ce6c8142a_I20220102" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ZDcwOWM0NmMzY2M0NDExNTlhOWRmMzQ1NGJkZjhiNzdfOTg_e3cfcaaf-62b2-442b-a539-98d77495d0c5">1.1311</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia496b34d6cb74a168adcb5bf7122133e_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTItMS0xLTg0NDQ0_9d8075ab-0717-447a-9077-40044326f5bf">794</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia496b34d6cb74a168adcb5bf7122133e_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTQtMS0xLTg0NDQ0_e0edbe5a-f9c8-4761-a6d2-571b05a82a87">1.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92f030712061450fa2980a5ce6c8142a_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTYtMS0xLTg0NDQ0_587b8e49-5f29-4e99-860f-23520c021fd8">843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i92f030712061450fa2980a5ce6c8142a_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTgtMS0xLTg0NDQ0_dddff9ab-147f-4277-baf4-62191d083b4f">1.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7258a1e04b8c4f889adafc8d5386fd96_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE3LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ZTc4OWM3NTY0YWZjNGYyMTkxNTdlNjYwODQ2NjMzN2ZfNA_02f88a26-3e05-4ae5-900c-fd3c04bf4242">2.90</ix:nonFraction>%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7258a1e04b8c4f889adafc8d5386fd96_I20230101" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE3LTItMS0xLTg0NDQ0_bf8ab000-b687-4a84-98e5-693571c164ea">1,496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7258a1e04b8c4f889adafc8d5386fd96_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE3LTQtMS0xLTg0NDQ0_15e4a8bd-cd93-495b-861f-022b27ec8686">2.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602d89dbe75f4f748c2295cd5de57aec_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE3LTYtMS0xLTg0NDQ0_a7c82e0a-483a-436b-a3c5-9002efd04370">1,495</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i602d89dbe75f4f748c2295cd5de57aec_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE3LTgtMS0xLTg0NDQ0_9b439ab1-5f93-4ea0-9140-6c614f586196">2.91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i423501f49ac54505aa65ac29a7fd6d80_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE4LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MDc0NjVkNDBiZjk0NGRkYjllMTAzYmYyNGE0YzU4ZmZfNA_0cc7ee77-931e-4334-b2de-9dc09c9b3af4">6.95</ix:nonFraction>%&#160;Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i423501f49ac54505aa65ac29a7fd6d80_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE4LTItMS0xLTg0NDQ0_f6484ec9-cd7d-4c30-b001-3cf8e29d95f2">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i423501f49ac54505aa65ac29a7fd6d80_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE4LTQtMS0xLTg0NDQ0_7f2016b7-0a41-454d-ba54-734910aed7b7">7.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26d49418e0d74c1189e8912cc7d7675f_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE4LTYtMS0xLTg0NDQ0_def57efb-8248-460f-9d0f-22577e12d1fc">298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26d49418e0d74c1189e8912cc7d7675f_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE4LTgtMS0xLTg0NDQ0_be5346c8-d48d-4e52-9a32-d0b9cfb7c5f0">7.14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa0326f0db384917ad2a786fa145a98a_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE5LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NDM2YTQ5MDI2YmEyNDExOGIxNTgwOWYzMzg1MzAwNWRfNA_fc688e87-5af9-4b47-968a-7807495325e3">1.30</ix:nonFraction>% Notes due 2030</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa0326f0db384917ad2a786fa145a98a_I20230101" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE5LTItMS0xLTg0NDQ0_51dfb279-eac9-473a-8077-9dc40ef483a1">1,607</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa0326f0db384917ad2a786fa145a98a_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE5LTQtMS0xLTg0NDQ0_f61cc5ad-0111-4629-a289-52192022bfef">1.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf8bfdbb53ca42e3af2e559cf8fb62c2_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE5LTYtMS0xLTg0NDQ0_ec83439f-895f-4b4b-8cad-d2a1354ed41b">1,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaf8bfdbb53ca42e3af2e559cf8fb62c2_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE5LTgtMS0xLTg0NDQ0_1c08db45-2091-4ebe-88f3-0571f97d729b">1.30</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie15d3b834f6345ec822ccb7085d7c0ff_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIwLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246Nzc5MTc3OWYxZTY4NDgwNjgzNzQwOTczNGE2YTczZmZfNA_df556ff2-6ba4-47bf-a4f1-49c7674857c0">4.95</ix:nonFraction>%&#160;Debentures due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie15d3b834f6345ec822ccb7085d7c0ff_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIwLTItMS0xLTg0NDQ0_c113fe5b-c7b0-422e-99ef-ec6a78b54dab">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie15d3b834f6345ec822ccb7085d7c0ff_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIwLTQtMS0xLTg0NDQ0_a16a6c2d-5b90-492c-b9ed-1e6a32cf0b6d">4.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8db5ee980d1342e793d3791eedfbef40_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIwLTYtMS0xLTg0NDQ0_74e716a4-315e-4e3a-bb02-301ff52bc581">498</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8db5ee980d1342e793d3791eedfbef40_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIwLTgtMS0xLTg0NDQ0_faefc765-3dfd-42f0-aedc-7623865b2c6d">4.95</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i65b796c75e3b43b6bda7c9efb4daa55f_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIxLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NWE4NDlhYTZhMGNkNGVhN2ExYjZjYWMwNTBkYTQ2NjZfNA_af05148e-624b-475a-b270-69dae07d242f">4.375</ix:nonFraction>% Notes due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65b796c75e3b43b6bda7c9efb4daa55f_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIxLTItMS0xLTg0NDQ0_63464434-5b69-431f-8a3d-2951e3c1e8d0">854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i65b796c75e3b43b6bda7c9efb4daa55f_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIxLTQtMS0xLTg0NDQ0_3633f65d-f3e3-4d29-a1db-b7082373e497">4.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad65bba4399943f9b1454685a4155820_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIxLTYtMS0xLTg0NDQ0_78cb5108-d801-46dd-8879-a68644cb5e9e">854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iad65bba4399943f9b1454685a4155820_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIxLTgtMS0xLTg0NDQ0_7ef98e9f-1876-42fa-9669-0dae1f64cb21">4.24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dd231a0bb104e1684521862f1414b9f_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NDY1NTE3YjllNGMwNDhlZjhiN2RhZWE3ZWI0NzA1NTJfNA_5cdc1b32-474c-4e7b-bdf9-b147416dbfd4">1.650</ix:nonFraction>% Notes due 2035                                                     (<ix:nonFraction unitRef="eur" contextRef="i0dd231a0bb104e1684521862f1414b9f_I20230101" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NDY1NTE3YjllNGMwNDhlZjhiN2RhZWE3ZWI0NzA1NTJfNzU_465fb86f-79c4-426f-bbe1-ae4c609fb920">1.5</ix:nonFraction>B Euro <ix:nonFraction unitRef="number" contextRef="i0dd231a0bb104e1684521862f1414b9f_I20230101" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NDY1NTE3YjllNGMwNDhlZjhiN2RhZWE3ZWI0NzA1NTJfODQ_ea7becfc-bc5c-4648-85c4-8f8f4b18653c">1.0651</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(<ix:nonFraction unitRef="eur" contextRef="idfedf7be284043c98fd18f790c2086ec_I20220102" decimals="-8" name="us-gaap:DebtInstrumentFaceAmount" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NDY1NTE3YjllNGMwNDhlZjhiN2RhZWE3ZWI0NzA1NTJfOTI_d26ae8df-20d0-428a-a4b5-42add9f25fd5">1.5</ix:nonFraction>B Euro <ix:nonFraction unitRef="number" contextRef="idfedf7be284043c98fd18f790c2086ec_I20220102" decimals="INF" name="us-gaap:ForeignCurrencyExchangeRateTranslation1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NDY1NTE3YjllNGMwNDhlZjhiN2RhZWE3ZWI0NzA1NTJfMTAx_78fad006-3cde-46ff-98e7-c076c6ef5acd">1.1311</ix:nonFraction>)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dd231a0bb104e1684521862f1414b9f_I20230101" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTItMS0xLTg0NDQ0_d1b54bd1-2afd-44c6-b579-e1994cea960e">1,591</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dd231a0bb104e1684521862f1414b9f_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTQtMS0xLTg0NDQ0_46bb21a6-2a0b-49f5-95dd-1034cdb08e16">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfedf7be284043c98fd18f790c2086ec_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTYtMS0xLTg0NDQ0_48e665ed-a902-402d-9df0-85c6687614a4">1,683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idfedf7be284043c98fd18f790c2086ec_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTgtMS0xLTg0NDQ0_1f94b952-1eec-4501-8357-6cf3e38257ad">1.68</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd6fe30488d441739d3babad588015ad_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIzLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MTM2ZGQ3ZDBlZTY4NDM0OTkzZmIzYjVjOGFmNzkyZDhfNA_e6c3c0da-ede1-40b1-be74-449e6ab4ec15">3.55</ix:nonFraction>% Notes due 2036</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd6fe30488d441739d3babad588015ad_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIzLTItMS0xLTg0NDQ0_0fd60ea9-f3ae-4c2c-ac56-293bb36702c8">842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd6fe30488d441739d3babad588015ad_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIzLTQtMS0xLTg0NDQ0_e4998880-d510-4d87-9726-52069af8ee93">3.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a23940668d946ea8954481965daba62_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIzLTYtMS0xLTg0NDQ0_d30f84e0-9944-4387-9504-fb8a6424849c">974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a23940668d946ea8954481965daba62_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIzLTgtMS0xLTg0NDQ0_45a52b6b-3648-4aed-b5be-5b561b3fe047">3.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ba6c50490e34f12bda5adb99407a82b_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246N2Q4YzUzZTRkZTVjNDhiZThkYmE0ZDEzMWNmYzEyYjRfNA_f29d0058-5aca-4b6d-843c-defa7af3dc86">5.95</ix:nonFraction>%&#160;Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ba6c50490e34f12bda5adb99407a82b_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI0LTItMS0xLTg0NDQ0_8d821269-a4ac-4cb2-8fa3-1ac0e19d1615">993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ba6c50490e34f12bda5adb99407a82b_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI0LTQtMS0xLTg0NDQ0_e34fddf3-94c2-477f-8afb-5d17b4617997">5.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd4cdb4f57b84232a93db6b02e61c82d_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI0LTYtMS0xLTg0NDQ0_e2dc2d75-cb42-454d-a777-75058c5fcbfc">993</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd4cdb4f57b84232a93db6b02e61c82d_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI0LTgtMS0xLTg0NDQ0_877254ed-3ef0-4fed-ae89-c3b2b97ffe01">5.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if509cd02d4494abc9bae248548e9fe2b_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI1LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246OGU3ODBiMTkwZGYyNDkwYTg3OTdkZjY0YzNlN2RhNTFfNA_66b91aaf-c625-4058-a04b-8733443f582b">3.625</ix:nonFraction>% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if509cd02d4494abc9bae248548e9fe2b_I20230101" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI1LTItMS0xLTg0NDQ0_e2a61a6a-b38c-4aef-a79a-b346f62d4fb6">1,336</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if509cd02d4494abc9bae248548e9fe2b_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI1LTQtMS0xLTg0NDQ0_24837d1c-2bb0-4442-84fd-de9abfe26581">3.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8dfee6b2b9f486783bc9cb6cab9a4dd_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI1LTYtMS0xLTg0NDQ0_900ff0bd-d680-4624-8bc7-3dd2f6fda9eb">1,475</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie8dfee6b2b9f486783bc9cb6cab9a4dd_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI1LTgtMS0xLTg0NDQ0_d1ed4b4a-45d9-41c2-a9b7-fb1d0b3061d5">3.64</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26b8da89821f4ac284bd3d5d3cabf51e_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI2LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MmUwOWU1Yzg4NDExNDM3Mjg2OTczZDRmZjQ3NjA0OTlfNA_ef07f509-2c79-417a-94c1-5d8c5c1d4b02">5.85</ix:nonFraction>%&#160;Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26b8da89821f4ac284bd3d5d3cabf51e_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI2LTItMS0xLTg0NDQ0_a544a9b4-dfdd-43bf-b6d3-9b4c89e9ec70">697</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26b8da89821f4ac284bd3d5d3cabf51e_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI2LTQtMS0xLTg0NDQ0_7f663e27-ecba-4d1a-94ae-cea4870e41c5">5.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cf6df4972c749909f6092392e43369e_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI2LTYtMS0xLTg0NDQ0_ffb84435-c39f-45cb-b1ca-62272657d599">696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1cf6df4972c749909f6092392e43369e_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI2LTgtMS0xLTg0NDQ0_0af0ec13-f501-4c94-9643-335e6abef016">5.85</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i696b5a358a7a4568935c7e93c24e7f41_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI3LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MTI5NDhmZTJhNmVmNDY4YzliYmJiMmFmNjQwNTc5YWRfNA_ce3ca7a4-96c9-4e20-a95e-976af0d3f75a">3.400</ix:nonFraction>%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i696b5a358a7a4568935c7e93c24e7f41_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI3LTItMS0xLTg0NDQ0_483e69ed-6e02-4ccf-8428-4bafc8486266">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i696b5a358a7a4568935c7e93c24e7f41_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI3LTQtMS0xLTg0NDQ0_85f82136-60b3-4976-a0a0-8a309500f360">3.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idd634615b6a848fa8f9569f674e894e6_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI3LTYtMS0xLTg0NDQ0_fbd35910-df61-4e14-b6ff-9611090d89e9">992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd634615b6a848fa8f9569f674e894e6_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI3LTgtMS0xLTg0NDQ0_88523ae7-87c2-4b5a-bd65-539b4c08237f">3.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7967ec234e94809b83f6d22fbf9ce9d_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI4LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246YzQ3OTZiMDE2MDdkNGMzNDk3MmMyYzI4NWI3NmI2YzlfNA_c12a7184-6489-4e01-bd79-766ebd5cb122">4.50</ix:nonFraction>%&#160;Debentures due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7967ec234e94809b83f6d22fbf9ce9d_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI4LTItMS0xLTg0NDQ0_8e74deaa-a46c-4829-9edf-c12e2a1f1612">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7967ec234e94809b83f6d22fbf9ce9d_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI4LTQtMS0xLTg0NDQ0_0542055a-c5bf-43a8-95e0-e434cc962715">4.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia97fbaf7b43e485e95cf7e8916d74a96_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI4LTYtMS0xLTg0NDQ0_be92f16f-df49-4ff6-80d4-c6fac4bcde62">540</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia97fbaf7b43e485e95cf7e8916d74a96_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI4LTgtMS0xLTg0NDQ0_683e2317-71f8-4513-822b-e6ed9c3974b5">4.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if61dc0cc1b304eaa99917f19dad110d2_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI5LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NTk5NTk1MjMwMzdjNDRjYzg4Mzc2OGE2NDQxODY1NjNfNA_86cc87e9-fc19-48b9-8e1f-825eb4ed887f">2.10</ix:nonFraction>% Notes due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if61dc0cc1b304eaa99917f19dad110d2_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI5LTItMS0xLTg0NDQ0_10453bc5-eed9-4333-ab65-f6af7a4e0736">828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if61dc0cc1b304eaa99917f19dad110d2_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI5LTQtMS0xLTg0NDQ0_bb0b245b-8f1f-4f5f-ba38-8f13a2dbf5e6">2.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83fdb88fdea44eacb07ca88b7b8ca7dd_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI5LTYtMS0xLTg0NDQ0_007dc76e-bb45-4a71-b858-a2f3384c92ba">974</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i83fdb88fdea44eacb07ca88b7b8ca7dd_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI5LTgtMS0xLTg0NDQ0_43ae8cb8-d109-4978-8d1d-ec173b44915f">2.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib9293aa9d30342248d3d85c512c81764_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMwLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NTc5ZGQ4NThhNzJkNGNhMWFlYTJiYzBmOTZhNmM3ZjhfNA_1d7865a8-4770-4d64-946f-7ae302afd0bf">4.85</ix:nonFraction>% Notes due 2041</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib9293aa9d30342248d3d85c512c81764_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMwLTItMS0xLTg0NDQ0_ba4dacb2-42a6-4eb8-9d25-1e79cb067661">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib9293aa9d30342248d3d85c512c81764_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMwLTQtMS0xLTg0NDQ0_1911ceec-aa8a-446a-b9aa-3d25be06518a">4.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i565be597706647e888d0c0ea676ef094_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMwLTYtMS0xLTg0NDQ0_74066004-564c-454c-a443-c097a5b31def">297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i565be597706647e888d0c0ea676ef094_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMwLTgtMS0xLTg0NDQ0_2fb4f5ca-7289-4d6d-a7ae-e5ad9f1352d3">4.89</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26f202863bc94082a97d142a46e8d1b2_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMxLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246YmNlMjgwNTFhYWY0NDZhMGI5MmFlZDNmMjVhZThmODdfNA_554e582a-59cb-4b07-baac-b12f50e96c87">4.50</ix:nonFraction>% Notes due 2043</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f202863bc94082a97d142a46e8d1b2_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMxLTItMS0xLTg0NDQ0_acd9b273-d138-4b80-890c-07ce0b22db97">496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26f202863bc94082a97d142a46e8d1b2_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMxLTQtMS0xLTg0NDQ0_af6ab844-3d6a-4ebb-909c-b3d56e6147ff">4.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if67ac9c2c837491fa49ff3662e87bfe1_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMxLTYtMS0xLTg0NDQ0_03835f07-1753-4aa9-a2ab-4d16caaf7327">496</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if67ac9c2c837491fa49ff3662e87bfe1_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMxLTgtMS0xLTg0NDQ0_10f72c59-bcc3-413d-a1a0-e9649b533427">4.52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib10ffb3abaf54da0b43cea2e2ceb7e08_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMyLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246YTNhMDZiYjhiOWU2NDQwZGFlN2VlZjE5Y2ZmM2ExODBfNA_e4a89cd7-e214-433c-993f-65393786f08c">3.70</ix:nonFraction>% Notes due 2046</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib10ffb3abaf54da0b43cea2e2ceb7e08_I20230101" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMyLTItMS0xLTg0NDQ0_4846ef3b-0d82-4fbc-a7a1-b7c6de382ead">1,976</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib10ffb3abaf54da0b43cea2e2ceb7e08_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMyLTQtMS0xLTg0NDQ0_072549ba-23a8-4088-bf9b-8323c9bb1301">3.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1902162eea4549f78cee91e0c0156868_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMyLTYtMS0xLTg0NDQ0_91352346-84cf-42d4-a509-7cbbe362b1b1">1,975</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1902162eea4549f78cee91e0c0156868_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMyLTgtMS0xLTg0NDQ0_40353370-979d-43d1-beaa-a49f811e0171">3.74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i91feec6def3047ae92ab21665e29fbe4_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMzLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MmRiZWQxZjBiY2UwNDYzMTlkMzI0MWU2YjBiZWE3ZGRfNA_ddae6e8f-2943-4a4a-aa0f-9612062d78fc">3.75</ix:nonFraction>% Notes due 2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91feec6def3047ae92ab21665e29fbe4_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMzLTItMS0xLTg0NDQ0_83afa388-2bcb-4e63-841f-0448e80472f4">812</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i91feec6def3047ae92ab21665e29fbe4_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMzLTQtMS0xLTg0NDQ0_436a964f-d8e6-418c-9388-2e7f395c7f18">3.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefcd48741e0b49cebaf892a4bad31d22_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMzLTYtMS0xLTg0NDQ0_c1d99e9a-faaf-491d-8eec-9d999d579e67">971</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iefcd48741e0b49cebaf892a4bad31d22_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMzLTgtMS0xLTg0NDQ0_708a3906-dbc1-4962-b2b8-7cb3790d62bd">3.76</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4f24fb8b890841428b85dac4bce5953f_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MThiYTMwZDUzNmU0NDNkZTljY2FlMmVmMDZmYTNhMGRfNA_b87c49cf-ecb4-4403-9251-ba7c80505701">3.500</ix:nonFraction>% Notes due 2048</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f24fb8b890841428b85dac4bce5953f_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM0LTItMS0xLTg0NDQ0_d973d1e9-6093-4363-b949-5a1776ac7e4e">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4f24fb8b890841428b85dac4bce5953f_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM0LTQtMS0xLTg0NDQ0_726083da-a24a-41ff-9ec3-f914dce5a005">3.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86d445ff094d4648b596d34b86e80355_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM0LTYtMS0xLTg0NDQ0_cf5dd344-0b2b-4493-86e6-a5c40625e262">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i86d445ff094d4648b596d34b86e80355_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM0LTgtMS0xLTg0NDQ0_1ad2c13a-1739-40e0-adfe-b7f4f9bf68ff">3.52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1fad250982dc47abbb5a254928d9895f_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM1LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ZGY0YmRmMmVmMjdhNGIzMDk3Mzk4ZGJkYTRlZTc5ZDhfNA_f2e787ba-0780-4abe-863f-6a05285ae268">2.250</ix:nonFraction>% Notes due 2050</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fad250982dc47abbb5a254928d9895f_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM1LTItMS0xLTg0NDQ0_c65c65ce-4df0-474d-94c0-ef0505fb02a8">808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1fad250982dc47abbb5a254928d9895f_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM1LTQtMS0xLTg0NDQ0_b9406cc4-9b22-43b5-8dc7-6fe0a10514be">2.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e53361c290b43718ffeb7cd8f9afc2d_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM1LTYtMS0xLTg0NDQ0_17b7b9a2-6edf-41c7-b090-50877dd5b786">983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e53361c290b43718ffeb7cd8f9afc2d_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM1LTgtMS0xLTg0NDQ0_a0b697f8-dc94-4897-8a8d-c99ef2be2db4">2.29</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46a29376f79d4b30a03d32aff4ccdfe8_I20230101" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM2LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246Y2M1YTIzM2VhYmZhNDc5YjgwMWJkNmVkMDkyNDI3NDZfNA_df355b8e-3e98-4a0a-89a5-8e2d2e405fc0">2.450</ix:nonFraction>% Notes due 2060</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46a29376f79d4b30a03d32aff4ccdfe8_I20230101" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM2LTItMS0xLTg0NDQ0_adddfdfa-77a6-4a46-be07-6735cead4b9e">1,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46a29376f79d4b30a03d32aff4ccdfe8_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM2LTQtMS0xLTg0NDQ0_77c47578-a94f-4ec4-8b42-b6ecd084d215">2.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id01a95b64b3942d1a96051a89d5e3413_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM2LTYtMS0xLTg0NDQ0_124f4583-03cc-4667-ae50-98f2de591e6c">1,222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id01a95b64b3942d1a96051a89d5e3413_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM2LTgtMS0xLTg0NDQ0_af01f2aa-b81c-4649-b025-9414cb87d853">2.49</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80f90c4157e04d8cb1fd3fca5f4ecb65_I20230101" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM3LTItMS0xLTg0NDQ0_42ef7f83-5828-488c-824b-c54c3d9e2f65">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80f90c4157e04d8cb1fd3fca5f4ecb65_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM3LTQtMS0xLTg0NDQ0_3d4cf62b-de02-4e0d-ae6c-13ca32acb759">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbebb1875a3d44ca9658f3fde18446f9_I20220102" decimals="-6" name="us-gaap:LongTermDebt" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM3LTYtMS0xLTg0NDQ0_4102d121-6d00-4c17-becf-889bc1f25272">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifbebb1875a3d44ca9658f3fde18446f9_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM3LTgtMS0xLTg0NDQ0_66330cbd-3c36-41ca-92fb-df62b6e79abd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM4LTItMS0xLTg0NDQ0_e63d9247-def1-49d3-91a3-f3a449905212">28,439</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM4LTQtMS0xLTg0NDQ0_cc84c5e1-b436-4e88-95d6-97363b70c9b2">3.04</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM4LTYtMS0xLTg0NDQ0_cac23772-cb1e-4020-8d94-107be2ea324c">32,116</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="4" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM4LTgtMS0xLTg0NDQ0_fc1f2bc0-6144-4705-a0c7-3cf9a827a9a9">2.89</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM5LTItMS0xLTg0NDQ0_2daf5732-8db6-4790-95ee-75bbb8984ed6">1,551</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM5LTYtMS0xLTg0NDQ0_1fa9a09a-67e6-42eb-a4bb-3e0b8691fbb2">2,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQwLTItMS0xLTg0NDQ0_e0faf598-4a64-476e-b2b2-24c8e51df88c">26,888</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQwLTYtMS0xLTg0NDQ0_b88aac3b-782c-4dd5-8ce4-779546dba489">29,985</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Weighted average effective rate.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at January&#160;1, 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at January&#160;2, 2022.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ibf9b03ff6d2e4106a76dc5fc27eb26d8"><div style="padding-left:18pt;text-indent:-18pt"><ix:continuation id="i75ade58041b3455494d354c1dc1ef025"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The excess of the carrying value over the fair value of debt was $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-8" name="jnj:ExcessOfCarryingValueOverFairValueOfDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzIxNQ_86b1a0c4-15d8-445c-bd80-2b6ae889cead">1.6</ix:nonFraction> billion at the end of fiscal year 2022 and the excess of the fair value over the carrying value of debt was $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-8" name="jnj:ExcessOfFairValueOverCarryingValueOfDebt" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzI1MQ_fa78d064-3621-4e9d-8573-9e36c93dd12e">3.2</ix:nonFraction> billion at the end of fiscal year 2021.</span></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has access to substantial sources of funds at numerous banks worldwide. In September 2022, the Company secured a new 364-day Credit Facility of  $<ix:nonFraction unitRef="usd" contextRef="iac989accfda349e1b99a6c9cdcdcaa17_I20210930" decimals="-9" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzYzNQ_d35f0301-52e6-468f-b029-9600d9bebbf0">10</ix:nonFraction> billion, which expires on September&#160;7, 2023. In November 2022, the Company secured an additional 364-day Credit Facility of $<ix:nonFraction unitRef="usd" contextRef="i4f53b7ce48b043d2944b5ea32ee20998_I20221130" decimals="-9" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzU0OTc1NTgxNzAxNg_828cd0a6-6ce9-4325-a613-fdf8daac0990">10</ix:nonFraction>&#160;billion, which expires on November 21, 2023. Interest charged on borrowings under the credit line agreement is based on either the Term SOFR Reference Rate or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreements are not material.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Throughout fiscal years 2022 and 2021, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-8" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzExNjA_36734269-07c7-4f59-91a5-8efffeb58550">12.8</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-8" name="us-gaap:DebtCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzExNjc_b22698c9-7d86-44d6-994f-d51e2d6d6744">3.8</ix:nonFraction> billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> at the end of fiscal years 2022 and 2021, respectively. The current portion of the long term debt was $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-8" name="us-gaap:LongTermCommercialPaperCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzEyNzA_27a4e649-0e09-49f2-a402-5180662ef49b">1.6</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-8" name="us-gaap:LongTermCommercialPaperCurrent" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzEyNzc_f0042990-16dc-4565-a82b-e8ed453fb693">2.1</ix:nonFraction> billion in 2022 and 2021, respectively, and the remainder is commercial paper and local borrowing by international subsi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">diaries. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The current debt balance as of January&#160;1, 2023 includes $<ix:nonFraction unitRef="usd" contextRef="i608e0e39b1eb42ac87ce9ad42b7316e9_I20230101" decimals="-8" name="us-gaap:ShortTermBorrowings" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzE0NDU_9fcd704a-322e-4737-948a-8190ff956e94">11.2</ix:nonFraction>&#160;billion of commercial paper which has a weighted average interest rate of <ix:nonFraction unitRef="number" contextRef="i608e0e39b1eb42ac87ce9ad42b7316e9_I20230101" decimals="4" name="us-gaap:DebtWeightedAverageInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzE1MTQ_cf781839-7f8b-47fc-a79f-30798bbaa179">4.23</ix:nonFraction>% and a weighted average maturity of approximately <ix:nonNumeric contextRef="i9d8b8a1c1b90452cb498943d7fbd6cdd_D20220103-20230101" name="us-gaap:DebtInstrumentTerm" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzE1NjY_8b923cc9-9405-4011-9796-c47810b851f4">two months</ix:nonNumeric>.</span></div><div style="text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzE2NDk_1dcc12f1-abac-4258-9529-f8d9cfa3ffac" escape="true"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate maturities of long-term debt obligations commencing in 2023 are:</span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"></td><td style="width:15.223%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.879%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.707%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.659%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.882%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">After 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo1YzBlMTgyMjJkN2U0NDM3OTEzODJhMzQ1NmZlMjczNi90YWJsZXJhbmdlOjVjMGUxODIyMmQ3ZTQ0Mzc5MTM4MmEzNDU2ZmUyNzM2XzItMC0xLTEtODQ0NDQ_86459d6b-d9f8-4973-936f-b72cb1976b88">1,551</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo1YzBlMTgyMjJkN2U0NDM3OTEzODJhMzQ1NmZlMjczNi90YWJsZXJhbmdlOjVjMGUxODIyMmQ3ZTQ0Mzc5MTM4MmEzNDU2ZmUyNzM2XzItMi0xLTEtODQ0NDQ_77f38e95-c234-47dd-b8f1-a2d2195741ea">1,392</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo1YzBlMTgyMjJkN2U0NDM3OTEzODJhMzQ1NmZlMjczNi90YWJsZXJhbmdlOjVjMGUxODIyMmQ3ZTQ0Mzc5MTM4MmEzNDU2ZmUyNzM2XzItNC0xLTEtODQ0NDQ_031225dd-a770-4420-8d24-33d827678a84">1,667</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo1YzBlMTgyMjJkN2U0NDM3OTEzODJhMzQ1NmZlMjczNi90YWJsZXJhbmdlOjVjMGUxODIyMmQ3ZTQ0Mzc5MTM4MmEzNDU2ZmUyNzM2XzItNi0xLTEtODQ0NDQ_df6c3ab6-93d8-4472-b50d-c9e931f2e9be">1,996</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo1YzBlMTgyMjJkN2U0NDM3OTEzODJhMzQ1NmZlMjczNi90YWJsZXJhbmdlOjVjMGUxODIyMmQ3ZTQ0Mzc5MTM4MmEzNDU2ZmUyNzM2XzItOC0xLTEtODQ0NDQ_2792054b-5fe7-42b3-b994-075d9f9fa436">2,271</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo1YzBlMTgyMjJkN2U0NDM3OTEzODJhMzQ1NmZlMjczNi90YWJsZXJhbmdlOjVjMGUxODIyMmQ3ZTQ0Mzc5MTM4MmEzNDU2ZmUyNzM2XzItMTAtMS0xLTg0NDQ0_03c94055-f171-428a-bee3-513c95c34ab7">19,562</ix:nonFraction></span></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_172"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">8.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMzY2_e4249d3f-6bba-4103-b3e2-3d2815624f70" continuedAt="i0f1a0cfa6b594532ae48421c7e500e40" escape="true">Income Taxes</ix:nonNumeric></span></div><div style="margin-top:4pt;padding-left:18pt;text-indent:-18pt"><ix:continuation id="i0f1a0cfa6b594532ae48421c7e500e40" continuedAt="i1bc784574bee49acad1b0f72e9865b93"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMzc2_56b35758-bfe4-4507-b465-82aa56e613f1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for taxes on income consists of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"></td><td style="width:50.115%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.000%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.141%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.003%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currently payable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzItMS0xLTEtODQ0NDQ_0f1fb76e-da8a-4070-ab5c-78613c859d8d">2,378</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzItMy0xLTEtODQ0NDQ_8fe232d7-6742-42a7-b6aa-46e509e5930d">1,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzItNS0xLTEtODQ0NDQ_6bc490ca-7c29-465d-b2b0-786241fb45bf">1,026</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzQtMS0xLTEtODQ0NDQ_198d561b-7edc-4de7-b5e1-dfe950cdb66d">3,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzQtMy0xLTEtODQ0NDQ_c6a7b41d-b005-4784-84a6-6a5d305ef2fd">2,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:CurrentForeignTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzQtNS0xLTEtODQ0NDQ_f26f5a20-0d95-46ee-b7bd-b1a7005ab887">1,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total currently payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzUtMS0xLTEtODQ0NDQ_f45f0ea8-2c17-4171-933f-b07d43b0b24e">5,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzUtMy0xLTEtODQ0NDQ_152284e6-8305-4f59-af14-0840ad25dd68">3,977</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzUtNS0xLTEtODQ0NDQ_e8a99b89-a611-4cd5-b318-db861174f08a">2,924</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzctMS0xLTEtODQ0NDQ_dba8d283-b116-4551-99b2-a0c223725cfc">2,081</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzctMy0xLTEtODQ0NDQ_39ff6f73-5481-4ada-b02c-2f7d7ed8827c">583</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzctNS0xLTEtODQ0NDQ_cb1b6299-ecef-4af0-a401-9c4c20218948">76</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzktMS0xLTEtODQ0NDQ_cf0bdacc-5d60-4b90-ae41-9a9ca530fad7">418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzktMy0xLTEtODQ0NDQ_05684e9a-155f-46f0-8f07-405b46188875">2,662</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzktNS0xLTEtODQ0NDQ_3cc20fe1-0d97-4c90-a609-b25dea3c6735">1,065</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzEwLTEtMS0xLTg0NDQ0_32008ec0-acde-418d-a824-80fb2c7c2e58">1,663</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzEwLTMtMS0xLTg0NDQ0_06ca2a0c-6ad9-4325-86cc-8a5bf12ecbfe">2,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzEwLTUtMS0xLTg0NDQ0_53a2f968-0aa4-4bcc-9956-0bebfda73394">1,141</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Provision for taxes on income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzExLTEtMS0xLTg0NDQ0_4ad3a14e-c50f-402b-97cc-581b6b39c953">3,784</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzExLTMtMS0xLTg0NDQ0_4d7babb7-2c1b-4f6e-ae5d-843374cdbf7c">1,898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzExLTUtMS0xLTg0NDQ0_a662c53d-f24d-4f96-8c4b-a7138c89440a">1,783</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></ix:nonNumeric></ix:continuation></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i1bc784574bee49acad1b0f72e9865b93" continuedAt="if9551312d8d844f0a982fd9950c0fde9"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMzc3_8f9a3abc-494b-47ca-b743-fef89b716c2a" escape="true"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A comparison of income tax expense at the U.S.&#160;statutory rate of <ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzNA_31a5ec66-7be6-4e2a-95d0-a40353b082ee"><ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="2" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzNA_91efaa80-119a-4a1b-80e9-dd322df5f681">21</ix:nonFraction></ix:nonFraction>% in fiscal years 2022, 2021 and 2020, to the Company&#8217;s effective tax rate is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"></td><td style="width:48.820%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.597%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.930%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.089%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.297%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:1.933%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEtMi0xLTEtODQ0NDQ_8003a496-dc1c-4357-812d-efae47b62f28">5,369</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEtNC0xLTEtODQ0NDQ_1f8fbf23-321e-4020-aa19-3c8ac7e71255">6,110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEtNi0xLTEtODQ0NDQ_40493403-c35e-4dd1-8dc0-8ffc9e38ca2b">4,312</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzItMi0xLTEtODQ0NDQ_576ea995-5068-4bb9-95f6-05b92a5d4f3d">16,356</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzItNC0xLTEtODQ0NDQ_81560cce-533f-4915-862f-41951a4c1400">16,666</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzItNi0xLTEtODQ0NDQ_72a68e0f-1c96-45c8-9715-c8eba28c9a56">12,185</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes on income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzMtMi0xLTEtODQ0NDQ_191e5964-0883-4d37-9eb8-3502fce6459e">21,725</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzMtNC0xLTEtODQ0NDQ_6b46b956-eeb6-4f9f-979d-aa6bd8f497e7">22,776</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzMtNi0xLTEtODQ0NDQ_935c0b38-5d1e-4544-abdd-8cdf67a8637e">16,497</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rates:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzUtMi0xLTEtODQ0NDQ_ae08110f-1221-4a93-82d3-c378b7774d80">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzUtNC0xLTEtODQ0NDQ_216226ed-5ad1-4be3-ab8f-c90cd0f30746">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzUtNi0xLTEtODQ0NDQ_38bcfa87-2a93-4760-b1a6-a2f9c84da09d">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzYtMi0xLTEtODQ0NDQ_c23e7645-ecdc-4c5d-8051-b36e587e321c">4.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzYtNC0xLTEtODQ0NDQ_eafbb6e7-82f5-46e5-abb5-714a37e71c57">16.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzYtNi0xLTEtODQ0NDQ_67c9f892-ba60-4f29-b018-45cb01dfc41b">9.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer health separation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEwLTItMS0xLTEwNTUzNw_5be77885-1907-4a5e-ab54-5307d686f4c4">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEwLTQtMS0xLTEwNTU0NQ_ab5806ea-ee5d-4aee-82a9-42483ae114a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEwLTYtMS0xLTEwNTU1Mw_246d267d-35c4-40db-9e03-aa278be7093d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes on international income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEwLTItMS0xLTg0NDQ0_8936d546-3dc8-4fe7-be9f-5838e8a1a0b7">1.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEwLTQtMS0xLTg0NDQ0_13a35a59-755d-4452-ae58-10f5ef34b929">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEwLTYtMS0xLTg0NDQ0_27c8514d-8e35-4ffa-b986-46935f12e62e">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits from loss on capital assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzExLTQtMS0xLTg0NDQ0_8c3adabc-9893-46b8-99e0-653250f541c4">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzExLTYtMS0xLTg0NDQ0_26dc73fc-9e4a-452a-9858-0e78946aaeb2">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits on share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEyLTItMS0xLTg0NDQ0_35f8d486-cdf0-4e5e-8e09-f6aa43de1635">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEyLTQtMS0xLTg0NDQ0_7f280d3e-8f2e-4d71-b05c-1e737f4be0c3">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEyLTYtMS0xLTg0NDQ0_45cf084e-68e8-47b2-8174-7c140e70f137">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzE1LTItMS0xLTg0NDQ0_db66c510-a148-454a-9bb1-cbb714f1cfda">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzE1LTQtMS0xLTg0NDQ0_49edad65-1fcc-4a7a-a78a-c0a73f8360a3">0.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzE1LTYtMS0xLTg0NDQ0_5f5fe9af-b141-49a6-881d-9b231870e200">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzE2LTItMS0xLTg0NDQ0_382e0dca-bc10-4cda-8df9-e8608bde2581">17.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzE2LTQtMS0xLTg0NDQ0_65dd7090-92b3-4a41-b0c9-4ac83a304ad7">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzE2LTYtMS0xLTg0NDQ0_96180031-56e8-4e50-97ae-1b668c237c40">10.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)       </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflect the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2021 amounts include the reorganization of international subsidiaries; the 2020 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. The 2022 amount includes the impact of certain provisions of the 2017 TCJA that became effective in fiscal 2022. The 2021 amounts include the reorganization of international subsidiaries; the 2020 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">    Certain prior year amounts have been reclassified to conform to current year presentation.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The fiscal year 2022 effective tax rate increased <ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3Xzk4OTU2MDQ2ODk4NjM_33ffa58c-8945-4bb6-b467-bac515c2530e">9.1</ix:nonFraction>% as compared to the fiscal year 2021 effective tax rate. As part of the planned separation of the Company&#8217;s Consumer Health business, the Company has recognized approximately $<ix:nonFraction unitRef="usd" contextRef="id2821f9be6044964b18bd8dd41179df6_D20220103-20230101" decimals="-8" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3Xzk4OTU2MDQ2ODk4NjU_7fd90379-45a4-4c41-b6ea-9ea087e2dbeb">0.5</ix:nonFraction>&#160;billion in net incremental tax costs in fiscal year 2022, which increased the 2022 effective tax rate by approximately <ix:nonFraction unitRef="number" contextRef="id2821f9be6044964b18bd8dd41179df6_D20220103-20230101" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3Xzk4OTU2MDQ2ODk4Nzk_f5912c20-66ad-4af7-b77d-d0dc47cbcdab">2.2</ix:nonFraction>%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, the Company recorded certain non-recurring favorable tax items in fiscal year 2021 which resulted in an unfavorable impact to the Company&#8217;s fiscal 2022 effective tax rate when compared to the prior fiscal year. These items are described below. The Company&#8217;s 2022 tax rate also benefited from certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in fiscal 2022, the impairment of bermekimab for AD and HS IPR&amp;D (for further information see Note 5 of the 2022 10-K Consolidated Financial Statements) and changes in the fair value of securities in the Company&#8217;s investment portfolio, both recorded at the U.S. statutory rate. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fiscal year 2021 tax rate decreased by <ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="3" sign="-" name="jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzOTg_fbcfcd53-ba80-4e48-bfdd-130e2628484a">2.5</ix:nonFraction>% compared to the fiscal year 2020 tax rate, which was primarily driven by the following items. In fiscal year 2021, the Company reorganized the ownership structure of certain wholly-owned international subsidiaries. As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with applicable local regulations. The net impact of this restructuring was approximately $<ix:nonFraction unitRef="usd" contextRef="i93cff80013cb4ca0867d9c8d85521e22_I20220102" decimals="-6" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzE4MjA_374969b1-2296-403d-bea3-46cd472a3c18">0.6</ix:nonFraction>&#160;billion net benefit or <ix:nonFraction unitRef="number" contextRef="ic658f5e90fb74521b314a6664d0b97c5_D20210104-20220102" decimals="3" name="jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzE4Mzg_d3165753-ed07-466a-8814-72ab6a81974b">2.7</ix:nonFraction>% benefit to the Company&#8217;s annual effective tax rate, comprised of the following items: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzE5NDM_66e7ba35-1f69-45f3-8e6c-960379a353bb">2.3</ix:nonFraction>&#160;billion of local deferred tax assets to record the remeasurement of the tax basis of these assets to fair value, this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzIxNzk_2994f492-fff5-4649-b5a4-a4542b219e45">1.7</ix:nonFraction>&#160;billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of these deferred tax assets. This expense has been reflected as &#8220;U.S. tax on international income&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Also, in the fiscal fourth quarter of 2021, the Company recognized a loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2021 tax rate by approximately <ix:nonFraction unitRef="number" contextRef="i5117957d990a4c01bf764aa9f770ef81_D20211004-20220102" decimals="3" sign="-" name="jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzI2NjI_8e56c7af-48ba-4194-bb08-a964fcee7db0">1.3</ix:nonFraction>% which is reflected as a &#8220;Tax benefits from loss on capital assets&#8221; on the effective tax rate reconciliation. Additionally other fiscal 2021 impacts to the rate were primarily driven by litigation and acquisition related items as follows:</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="if9551312d8d844f0a982fd9950c0fde9" continuedAt="i7bf7837c642e4363b7de701e6d733267"><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company accrued additional legal expenses, of approximately $<ix:nonFraction unitRef="usd" contextRef="i9fb809688a744a4ea19a1ad0f2b4bf9c_D20210104-20220102" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzI5Njg_f6187d15-0d44-48cb-bdeb-cef1a45ccf7e">1.6</ix:nonFraction>&#160;billion for talc at an effective tax rate of <ix:nonFraction unitRef="number" contextRef="i9fb809688a744a4ea19a1ad0f2b4bf9c_D20210104-20220102" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzMwMDg_28930f4c-5ee9-41cf-84da-05bd6b16b9ec">23.5</ix:nonFraction>% and $<ix:nonFraction unitRef="usd" contextRef="ifaf8a0dc444a439691c1ba9c0fc72e52_D20210104-20220102" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzMwMTU_c090f77b-47f1-4448-b004-65539f5e3b42">0.8</ix:nonFraction>&#160;billion for Risperdal Gynecomastia settlements at an effective tax rate of <ix:nonFraction unitRef="number" contextRef="ifaf8a0dc444a439691c1ba9c0fc72e52_D20210104-20220102" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzMwNzI_0039b848-deb8-4de8-a640-ead197a5afb1">16.4</ix:nonFraction>% (See Note 19 to the Consolidated Financial Statements for more details).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company recorded a partial IPR&amp;D charge of $<ix:nonFraction unitRef="usd" contextRef="i9abf5a6f4dd843c6bdff0c9b78680b08_D20211004-20220102" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzMxOTU_b510ed0f-0cd9-4713-894f-3c807732273b">0.9</ix:nonFraction>&#160;billion for the Ottava intangible asset (acquired with the Auris Health acquisition in 2019) at an effective rate of <ix:nonFraction unitRef="number" contextRef="i9abf5a6f4dd843c6bdff0c9b78680b08_D20211004-20220102" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzMzMDc_117ab197-5c82-4361-9391-f8446b1fb3d8">22.4</ix:nonFraction>%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal year 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF) and became effective for fiscal year 2020. The Federal transitional provisions of TRAF allow companies, under certain conditions, to adjust the tax basis in certain assets to fair value (i.e., &#8220;step-up&#8221;) to be depreciated and amortized resulting in an incremental Swiss tax deduction over the transitional period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TRAF also provides for parameters which enable the Swiss cantons to establish localized tax rates and regulations for companies. The new cantonal tax parameters include favorable tax benefits for patents and additional research and development tax deductions. The cantonal transitional provisions of TRAF allowed companies to elect either 1) tax basis step-up similar to the Federal transition benefit or 2) alternative statutory tax rate for a period not to exceed 5 years. The Company has operations located in various Swiss cantons. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the fiscal year 2020, the final canton where the Company maintains significant operations enacted TRAF legislation. Additionally, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company revising its estimate on the tax basis adjustment (i.e., &#8220;step-up&#8221;) for its assets and as a result, the Company recorded additional deferred tax benefits in 2020. The Company recognized a net benefit in the fiscal year 2020 for Swiss Tax Reform of approximately $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="jnj:FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzUyMjU_96240a7c-969f-4454-9d6f-328bc10c3dca">0.4</ix:nonFraction>&#160;billion or <ix:nonFraction unitRef="number" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="3" name="jnj:EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzUyMzE_b8caecbd-f9e4-4b58-a786-90c27ecdaa47">2.6</ix:nonFraction>% benefit to the Company&#8217;s annual effective tax rate, comprised of the following items: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-8" name="jnj:FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzUzMzc_48b6b268-67ce-403b-a37d-0723f68c76b8">0.3</ix:nonFraction> billion tax benefit relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred in the fiscal year 2020; this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzU2NDg_a8f3dd67-4424-49e4-be13-5b295cd54d3e">450</ix:nonFraction> million deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company&#8217;s Swiss subsidiaries&#8217; assets as described above; this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-8" name="jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzU5MjU_2093399a-eea8-4e5b-ac4f-188ca06f510a">0.3</ix:nonFraction> billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities in the fiscal year 2020. This benefit has been reflected as &#8220;U.S. tax on international income&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company does not expect to receive future rulings regarding the transitional provisions of TRAF. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Also, in the fiscal year 2020, the Company recognized a capital loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2020 tax rate by approximately <ix:nonFraction unitRef="number" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationDeductions" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzY1NTA_48598cf7-eed9-4c09-95b7-621c73207379">1.2</ix:nonFraction>% which is reflected as a &#8220;Tax benefits from loss on capital assets&#8221; on the effective tax rate reconciliation. In addition, in the fiscal year 2020, the Company had lower income in higher tax jurisdictions, primarily driven by:       </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the accrual of litigation costs related to talc for $<ix:nonFraction unitRef="usd" contextRef="ic88fac17377d4247a40066aad9de7fc4_D20191230-20210103" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzY4NTM_c1c9d7e6-e52a-4709-86f7-f253150c4600">4.0</ix:nonFraction>&#160;billion which reduced the U.S. earnings before taxes at an effective tax rate of <ix:nonFraction unitRef="number" contextRef="id39169ea988c4eadb476790566c83233_D20191230-20210103" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzY5Mjk_6564f0ca-7698-46e0-a406-2c1118a21d09">23.5</ix:nonFraction>%;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accrual of additional legal costs, including an additional $<ix:nonFraction unitRef="usd" contextRef="ic89e3ab0d07149d68abf9f2332bddb1e_D20191230-20210103" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzY5OTY_696ec326-fa63-4615-9860-9e9cc8241a4e">1.0</ix:nonFraction>&#160;billion associated with a revised agreement in principle to settle opioid litigation at an effective tax rate of <ix:nonFraction unitRef="number" contextRef="id40d1a3a2e954c59984259c6a56987f8_D20191230-20210103" decimals="3" name="jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzcxMDQ_e8baf793-e3cd-48cd-a6f3-fafa685140a4">21.4</ix:nonFraction>% </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also reduced the contingent consideration liability related to the Auris Health acquisition in 2019 and reversed some of its unrecognized tax benefits due to the completion of several years of tax examinations in certain jurisdictions during the fiscal year 2020. </span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="padding-right:4.5pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7bf7837c642e4363b7de701e6d733267"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMzY4_1e24750f-91fe-42cb-8c23-22969651236b" continuedAt="i9697711ecf85477fad7e327cd8765938" escape="true"><div style="margin-bottom:9.9pt;margin-top:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Temporary differences and carryforwards at the end of fiscal years 2022 and 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:38.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.723%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.408%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.729%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 Deferred Tax</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Deferred Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzItMi0xLTEtODQ0NDQ_378c9874-8b00-48d9-9000-9bebeb11f55d">725</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzItNi0xLTEtODQ0NDQ_d1807e94-0069-4f88-b560-e508070b83f6">1,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzMtMi0xLTEtODQ0NDQ_3f267a27-b770-4f51-a9f0-97a6dbd8ad30">687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzMtNi0xLTEtODQ0NDQ_bbc5c9ce-9307-4b17-9bb5-d348b1fa8eeb">679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation of property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzQtNC0xLTEtODQ0NDQ_b8560e39-770e-46ef-bf4e-e25a2f88cf91">858</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzQtOC0xLTEtODQ0NDQ_908088f9-ec4a-49e3-b836-88209ef9ca62">876</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzUtNC0xLTEtODQ0NDQ_babc1ad4-9cdb-4d1a-a7fd-2c0728e968f4">4,271</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzUtOC0xLTEtODQ0NDQ_53ab1509-41d3-447a-8803-7b88bafd8b4e">2,659</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D capitalized for tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzYtMi0xLTEtODQ0NDQ_26e92178-0680-45d1-bcb6-bd22eb12ece0">2,611</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzYtNi0xLTEtODQ0NDQ_91481e24-0cce-44fc-953f-1f78fd77a56f">1,664</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves&#160;&amp; liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzctMi0xLTEtODQ0NDQ_d0da2357-c241-419d-bda1-a03c95a73930">2,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzctNi0xLTEtODQ0NDQ_b4410a80-987f-445e-83fb-652869ebf5a9">2,882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income reported for tax purposes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzgtMi0xLTEtODQ0NDQ_955ea45b-b7f6-4e0b-9f9f-93364dc2fb63">2,045</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DeferredTaxAssetsDeferredIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzgtNi0xLTEtODQ0NDQ_85e7e6e1-c93e-4e45-bfe5-49fc449266fc">2,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realizable operating loss carryforwards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzktMi0xLTEtODQ0NDQ_53804d7c-7090-466c-a777-db7e68bace00">1,260</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzktNi0xLTEtODQ0NDQ_ef5462da-61eb-4432-9b81-7db29ea4a424">1,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undistributed foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="jnj:DeferredTaxAssetsUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEwLTItMS0xLTg0NDQ0_6b60edad-d993-4d20-a52f-5a8f9444ae17">1,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEwLTQtMS0xLTg0NDQ0_f78639a5-cd98-42c4-bb18-b24c7a973b00">1,693</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="jnj:DeferredTaxAssetsUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEwLTYtMS0xLTg0NDQ0_e2aa4cf7-c7b6-4f3e-a6f3-1b70cdf69939">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEwLTgtMS0xLTg0NDQ0_101b0e3d-722a-48c8-acbf-1d6eb28c09d9">1,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzExLTQtMS0xLTg0NDQ0_9cf7e67c-6ca8-4fd4-961b-c9ad4ffc12bd">3,547</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzExLTgtMS0xLTg0NDQ0_d9ce67b0-4f3f-4496-956a-7a8536d0661d">4,853</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous international</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEyLTItMS0xLTg0NDQ0_a59d5897-903a-4288-ad91-937abb3f654c">1,053</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEyLTQtMS0xLTg0NDQ0_71cae9d9-eaaa-45d1-bc1f-fa5e36cb79c3">65</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEyLTYtMS0xLTg0NDQ0_1febcad7-ea69-4167-bd7c-8b8e677147a9">870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DeferredTaxLiabilitiesOther" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEyLTgtMS0xLTg0NDQ0_d91260a9-5233-41d7-80dc-9449da349e03">39</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="jnj:DeferredTaxAssetsOtherDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEzLTItMS0xLTg0NDQ0_cecf4a6c-d93c-459c-a50f-b0e784f71b25">476</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="jnj:DeferredTaxLiabilitiesOtherDomestic" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEzLTgtMS0xLTg0NDQ0_1a8437fc-9b46-40fc-b0b1-b82a1bd2223b">16</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzE0LTItMS0xLTg0NDQ0_0ead31e5-4744-4ea9-a9d4-4ed659275a30">13,183</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzE0LTQtMS0xLTg0NDQ0_0624d3eb-fa52-40ec-a122-74ceff1808ab">10,434</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DeferredTaxAssetsNet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzE0LTYtMS0xLTg0NDQ0_ee3fccc6-6464-4f7a-8b43-72574f2632e5">12,640</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzE0LTgtMS0xLTg0NDQ0_2635d7a0-0a25-4aca-93d7-08ca9acefb1d">9,904</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Amount is inclusive of the $<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-8" name="jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzExMDc2_c6885af5-7729-4ee9-96c9-6410360eeaf1">2.3</ix:nonFraction>&#160;billion deferred tax asset established as part of the reorganized ownership structure of   certain wholly-owned international subsidiaries, as previously described. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Amount is inclusive of the $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzU0OTc1NTg2Nzg2Mw_3f9fa05b-da68-4501-9353-891bf1aa998a">1.8</ix:nonFraction>&#160;billion deferred tax liability due to the acquisition of Abiomed.</span></div></ix:nonNumeric><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"><ix:continuation id="i9697711ecf85477fad7e327cd8765938" continuedAt="i9ec0a1828d16421baeeda7628416ccb7">(4) </ix:continuation></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9ec0a1828d16421baeeda7628416ccb7">   Net of valuation allowances of $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-8" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzU0OTc1NTg2Nzg3Nw_057d0b09-c1ab-41e8-9a91-e6df45d2e967"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-8" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzU0OTc1NTg2Nzg3Nw_34560cbe-986f-49cb-bc2d-5965cd583676">0.9</ix:nonFraction></ix:nonFraction>&#160;billion in both 2022 and 2021.</ix:continuation> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to utilize these deferred tax assets. However, in certain jurisdictions, valuation allowances have been recorded against deferred tax assets for loss carryforwards that are not more likely than not to be realized. </span></div><div style="margin-top:4pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:SummaryOfIncomeTaxContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMzg2_9770f9cd-ea7c-41ee-9bf6-476f611c2e1e" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to unrecognized tax benefits:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"></td><td style="width:50.775%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.581%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.456%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.025%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.556%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzEtMi0xLTEtODQ0NDQ_0fc4c6f0-b714-404d-9888-18805d98bd92">3,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzEtNC0xLTEtODQ0NDQ_2cb499c6-228d-475a-84c0-ed157b8f657f">3,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzEtNi0xLTEtODQ0NDQ_24f8da13-fd22-4e54-9c5e-5bebf976fa81">3,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzItMi0xLTEtODQ0NDQ_2813d89b-cb6a-4684-a280-9e968208c3f1">523</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzItNC0xLTEtODQ0NDQ_7b9917f2-05f9-417a-a623-f0dd68ab7648">242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzItNi0xLTEtODQ0NDQ_5ad27aeb-2f57-4214-86a1-fa475ec8adef">265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to prior period tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzMtMi0xLTEtODQ0NDQ_6f46bfbe-2171-489b-a467-d3b95b189752">143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzMtNC0xLTEtODQ0NDQ_2fa6178b-89f6-4bbc-b1ee-25dc3ba4b9ff">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzMtNi0xLTEtODQ0NDQ_643c0ca1-c62a-4bf1-8477-742305890dbd">668</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to prior period tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzQtMi0xLTEtODQ0NDQ_a891de05-c987-4e87-b797-1e4d78ddd035">148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzQtNC0xLTEtODQ0NDQ_3b1eba04-0cc7-4d41-9939-85e2e8e8473c">128</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzQtNi0xLTEtODQ0NDQ_56776f10-53b5-4cb2-95b5-a6470cea82b6">551</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzUtMi0xLTEtODQ0NDQ_8018b02b-7326-4728-b36e-e32b341e65d6">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzUtNC0xLTEtODQ0NDQ_2cee6463-5c74-4c52-acd7-c350afd8abd3">187</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzUtNi0xLTEtODQ0NDQ_29079255-8872-48e0-8f83-fecac31989bb">839</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzYtMi0xLTEtODQ0NDQ_e746887d-9570-42e7-85bb-651eb8592633">11</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzYtNC0xLTEtODQ0NDQ_06ff4a77-eb45-446f-9a51-5367b4d6957e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzYtNi0xLTEtODQ0NDQ_fd9934b7-5436-417c-b740-7e7a11053683">23</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzctMi0xLTEtODQ0NDQ_7131898b-b813-4296-807f-95617a5fb43d">3,829</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzctNC0xLTEtODQ0NDQ_d9508fb4-920b-45f2-82fb-4e833b6b4e7d">3,323</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzctNi0xLTEtODQ0NDQ_dc0d67aa-a2d3-4a10-8097-6848a05408a3">3,373</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The unrecognized tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-8" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzExODI1_e603bbb3-7900-4be4-9622-ade6038ccd91">3.8</ix:nonFraction> billion at January&#160;1, 2023, if recognized, would affect the Company&#8217;s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. In the fiscal year 2020, the Company made its final payments for approximately $<ix:nonFraction unitRef="usd" contextRef="i6823d2e54e284392b4c4cc465f125c28_D20191230-20210103" decimals="-8" name="jnj:UnrecognizedTaxBenefitLiabilityPayment" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEyMjg0_4f2ad854-a7da-4097-a997-5edb4de2d5f6">0.7</ix:nonFraction> billion to the U.S. Treasury related to the final settlement of 2010-2012 tax audit liability.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:96%">In other major jurisdictions where the Company conducts business, the years that remain open to tax audits go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions, including in the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments or change in uncertain tax positions, if any. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMjEx_d7c3c32f-c789-4c11-a293-4e4e0e029a4d">139</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMjE1_4d38134f-87b4-4102-b962-c822da867b4d">44</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMjIy_fc98546e-30ea-4e2f-9378-8401e5f050af">32</ix:nonFraction> million in fiscal years 2022, 2021 and 2020, respectively. The total amount of accrued interest was $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMzEx_47896a03-45ce-4a62-a248-967cedcfaad3">651</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMzE4_b1f10098-c3a3-4bb8-aef9-b2b7e706e1bb">512</ix:nonFraction> million in fiscal years 2022 and 2021, respectively.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_178"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.5pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:CompensationRelatedCostsGeneralTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90ZXh0cmVnaW9uOjdiMGNjNzI1M2Y5YzRkYzRhYmIxODU3NjdlYzA1OGE3XzMwNA_26a9fe4c-5531-433b-a46e-b2cfee088fbc" continuedAt="i65f0330618404ae98871ff508a99094e" escape="true">Employee Related Obligations</ix:nonNumeric></span></div><ix:continuation id="i65f0330618404ae98871ff508a99094e"><div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="jnj:EmployeeRelatedObligationsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90ZXh0cmVnaW9uOjdiMGNjNzI1M2Y5YzRkYzRhYmIxODU3NjdlYzA1OGE3XzMwMg_76d43370-3e4b-4441-927f-6960f5b27064" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal 2022 and fiscal 2021, employee related obligations recorded on the Consolidated Balance Sheets were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzEtMi0xLTEtODQ0NDQ_508a7d7a-508d-4c7b-aa64-a97a5344c1f5">2,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzEtNC0xLTEtODQ0NDQ_bfb36b2a-163c-4023-9276-fd3a1f76349b">4,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzItMi0xLTEtODQ0NDQ_20857b36-4f45-4dd9-ae38-69d51488d120">1,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzItNC0xLTEtODQ0NDQ_f1821273-ec0e-4e12-839f-435bd52aa265">2,069</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postemployment benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzMtMi0xLTEtODQ0NDQ_b6640edc-b3f5-4c94-8aff-05fd02f151f0">2,832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzMtNC0xLTEtODQ0NDQ_753a44f5-cbed-45d5-9994-193ea6dbc4ac">3,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzQtMi0xLTEtODQ0NDQ_cfdd2c69-0c61-40fa-9fb0-c9ee79467a23">100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzQtNC0xLTEtODQ0NDQ_cbdf6f1d-c7a7-4fbd-bde8-23a503bacb5b">181</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total employee obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="jnj:EmployeeObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzUtMi0xLTEtODQ0NDQ_68262424-fdc7-42af-9fc1-b1df31474131">7,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="jnj:EmployeeObligations" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzUtNC0xLTEtODQ0NDQ_5fd627e5-049d-4aa3-a2f6-c92c8c59f2fc">9,455</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current benefits payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzYtMi0xLTEtODQ0NDQ_88717380-3f4d-4557-b9af-f07b2d06b911">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzYtNC0xLTEtODQ0NDQ_6989d24c-942a-4e79-84f3-f43afee4eb6a">557</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations&#160;&#8212; non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzctMi0xLTEtODQ0NDQ_bb10e6d6-6016-4761-8c79-8435f160b380">6,767</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzctNC0xLTEtODQ0NDQ_d4cfbddb-455c-47b0-9112-7cc01874ac15">8,898</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid employee related obligations of $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90ZXh0cmVnaW9uOjdiMGNjNzI1M2Y5YzRkYzRhYmIxODU3NjdlYzA1OGE3XzE5NA_8625080b-4ef9-49f2-bb0e-34d84b71113b">4,581</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90ZXh0cmVnaW9uOjdiMGNjNzI1M2Y5YzRkYzRhYmIxODU3NjdlYzA1OGE3XzIwMQ_b08d4049-49aa-4049-9547-95b1c23f7ef4">4,436</ix:nonFraction> million for 2022 and 2021, respectively, are included in Other assets on the Consolidated Balance Sheets.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_181"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjU2_4cd59238-8340-4efc-9edc-251bdc468340" continuedAt="i262f9ddefd194dcf989536dcdf125d36" escape="true">Pensions and Other Benefit Plans</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i262f9ddefd194dcf989536dcdf125d36" continuedAt="i5693b3b0e5fb4c4fa5849b92b890d982"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily healthcare, to all eligible U.S.&#160;retired employees and their dependents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S, non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee&#8217;s compensation during the last <ix:nonNumeric contextRef="ie38c867d387040219eb10b7ae2cf8194_D20220103-20230101" name="jnj:EmployeeCompensationPeriod" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzYyNg_9b638475-05d3-4e43-92c6-f61682b1a06e">five years</ix:nonNumeric> before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula).</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrued under the Final Average Pay formula for service before January 1, 2026. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not fund retiree healthcare benefits in advance and has the right to modify these plans in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022 and 2021 the Company used December 31, 2022 and December 31, 2021, respectively, as the measurement date for all U.S.&#160;and international retirement and other benefit plans.</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfNetBenefitCostsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjE4_588446bc-3dc1-46c7-abcc-08a4a1766bf4" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans for 2022, 2021 and 2020 include the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzItMi0xLTEtODQ0NDQ_71622c25-f2b6-4bbd-9919-8e6b0167f126">1,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzItNC0xLTEtODQ0NDQ_1fa6a2fb-02ac-4cb5-9b1e-e50032045e43">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzItNi0xLTEtODQ0NDQ_052b5d96-c4ab-433e-9292-0142242de20e">1,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzItOC0xLTEtODQ0NDQ_8124ecc0-e2ce-4b1d-9ac0-c8dd99dfad8b">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzItMTAtMS0xLTg0NDQ0_fc240bc1-d6d9-4e13-9117-8eb2c35eb402">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzItMTItMS0xLTg0NDQ0_170c6f62-8d10-4539-bd27-0a8c56659d27">287</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzMtMi0xLTEtODQ0NDQ_bd03cea6-bf6e-46db-8974-292b2b91d383">911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzMtNC0xLTEtODQ0NDQ_55b2aeab-e326-4d5e-82a0-c3906bec2711">770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzMtNi0xLTEtODQ0NDQ_c6e7f197-3966-490a-8ef0-e1b0f986cb98">955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzMtOC0xLTEtODQ0NDQ_dc3d5346-d5db-465b-ba66-c298c5d5a8c6">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzMtMTAtMS0xLTg0NDQ0_6dd00e56-789b-460a-8f7a-b71d3de5d129">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzMtMTItMS0xLTg0NDQ0_ba82ebbb-e7a2-47fc-8c09-5d3ace475b77">133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzQtMi0xLTEtODQ0NDQ_c3b97161-d546-44dc-96d4-372a4696e6ae">2,757</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzQtNC0xLTEtODQ0NDQ_87c36c2e-ab62-48f7-babd-53c03956638f">2,645</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzQtNi0xLTEtODQ0NDQ_af21a01e-b27a-40f7-918a-3ddc7a6ab3fd">2,461</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzQtOC0xLTEtODQ0NDQ_5f97b2ca-2bb0-485a-aae9-9c3cd2b78b48">8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzQtMTAtMS0xLTg0NDQ0_1074cba2-735b-4867-8ca7-107e01273095">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzQtMTItMS0xLTg0NDQ0_e6639802-f90b-4023-9897-c61259bfaca8">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzUtMi0xLTEtODQ0NDQ_3d8de1cb-22c8-4436-9c3b-53b24be8db17">184</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzUtNC0xLTEtODQ0NDQ_afe355ac-fd17-48c1-ac6f-50028122db09">181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzUtNi0xLTEtODQ0NDQ_9b3bc58c-0ce6-42cb-889b-030aad39b2bb">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzUtOC0xLTEtODQ0NDQ_8bf2f11e-c17a-430d-a438-b2f3a4b92e48">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzUtMTAtMS0xLTg0NDQ0_be960196-996a-4d97-9761-337b921b3c23">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzUtMTItMS0xLTg0NDQ0_428bbde3-41b1-4488-8953-5054cefdd526">31</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzctMi0xLTEtODQ0NDQ_cb95e8b4-682c-431f-8e07-f7bba83bb280">655</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzctNC0xLTEtODQ0NDQ_092ab5b9-3e08-445e-8db6-c68fa2e00b4e">1,257</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzctNi0xLTEtODQ0NDQ_de08670e-8e0d-41fb-8fb0-a0760b2d28da">891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzctOC0xLTEtODQ0NDQ_8b40ded8-b522-4c4a-b920-13018dfd7eb9">121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzctMTAtMS0xLTg0NDQ0_2ae2ddaf-e87a-4fac-8249-04be52df6139">151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzctMTItMS0xLTg0NDQ0_a27aea24-f6ba-4447-bace-27df78198766">142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzgtMi0xLTEtODQ0NDQ_72637888-744a-4b56-8114-27f867a228bb">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzgtNC0xLTEtODQ0NDQ_62774e59-36ef-4c8b-b7c6-6fd4017a5ebe">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzgtNi0xLTEtODQ0NDQ_1f32c764-5887-4874-8354-b3d6927aa567">23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzgtOC0xLTEtODQ0NDQ_f857cc0b-9373-4831-9476-fa4864d88ce1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzgtMTAtMS0xLTg0NDQ0_9b618248-3bcb-40b5-b133-fbc5bc0694a8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzgtMTItMS0xLTg0NDQ0_42d7b879-af67-4ab1-ad8b-abd36837ca9a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzktMi0xLTEtODQ0NDQ_2886fb44-dae0-4b0b-a1bd-792c1c7d2369">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzktNC0xLTEtODQ0NDQ_2a90762a-2037-4e82-a9cb-e0976d40e883">623</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzktNi0xLTEtODQ0NDQ_97b04d75-1b34-4879-a9d1-ab310be9b31d">790</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzktOC0xLTEtODQ0NDQ_6f10f85e-de75-4aa7-b797-f748d58404e9">533</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzktMTAtMS0xLTg0NDQ0_298aab2f-b342-40ce-a0ab-eaae913359b8">503</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzktMTItMS0xLTg0NDQ0_f5aed802-eced-4a56-8063-4c147b7e26f6">524</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i5693b3b0e5fb4c4fa5849b92b890d982" continuedAt="i5a74a67eee0b4bffa49283678f0df48f"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized gains and losses for the U.S.&#160;pension plans are amortized over the average remaining future service for each plan.  For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S.&#160;benefit plans is determined by using a <ix:nonFraction unitRef="number" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="2" name="jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzI3NjY_06422818-403c-4363-9092-69cdea2ff041">10</ix:nonFraction>% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior service costs/benefits for the U.S.&#160;pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S.&#160;benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjY0_fcf199be-ac51-4b27-966d-2be39ac17672" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average actuarial assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"></td><td style="width:39.358%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.060%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.563%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.064%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Periodic Benefit Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzMtMi0xLTEtODQ0NDQ_a877bcc0-e4bb-4a1e-b325-1b616d173681">2.46</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzMtNC0xLTEtODQ0NDQ_f9971243-3b25-4a43-b527-5f983573ce13">2.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzMtNi0xLTEtODQ0NDQ_730bb690-4fcd-4c69-9bd2-71bcb8ba0445">2.82</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzMtOC0xLTEtODQ0NDQ_9b6663f0-7759-45e5-bdce-009ddfa87d30">2.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzMtMTAtMS0xLTg0NDQ0_4eb966fe-c8df-4bdd-8499-ceed20722b84">2.09</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzMtMTItMS0xLTg0NDQ0_b80cd946-fe89-4a3b-8f2b-39296efe3688">3.04</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzQtMi0xLTEtODQ0NDQ_54618d1b-78b3-43fe-a56d-96601d0b0f9c">2.80</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzQtNC0xLTEtODQ0NDQ_25d6581b-e820-4531-94ac-236f3ab609e0">2.34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzQtNi0xLTEtODQ0NDQ_b9f86773-a601-4cf4-8329-b16c499d63d8">3.13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzQtOC0xLTEtODQ0NDQ_ed7006d6-8572-46ab-b43c-dbe223ed3696">2.64</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzQtMTAtMS0xLTg0NDQ0_6a79b2b5-794a-425a-a062-24d5313871a0">2.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103" decimals="4" name="jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzQtMTItMS0xLTg0NDQ0_d0b268fd-2532-4b42-bc8e-56021144ce41">3.08</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzUtMi0xLTEtODQ0NDQ_4e739540-adbc-45ae-a9c2-5e07a8c048e6">4.02</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzUtNC0xLTEtODQ0NDQ_8baf55b4-587b-43dc-b8ea-edc87479ea16">4.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzUtNi0xLTEtODQ0NDQ_a57c065e-bf0a-425e-a4b6-9af8f7f83f94">4.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzUtOC0xLTEtODQ0NDQ_6661685e-86a2-4721-8ae5-473f16007cb2">4.21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzUtMTAtMS0xLTg0NDQ0_42e5ce49-a9ff-4713-8968-d00992d07700">4.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzUtMTItMS0xLTg0NDQ0_1c18aaaa-66e9-4ab5-8cb8-6abf9ed36971">4.25</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzYtMi0xLTEtODQ0NDQ_23080b2b-f808-4fb7-96fe-dcc96c0b6d92">7.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzYtNC0xLTEtODQ0NDQ_3e73f179-aa9f-46b3-b4d1-9977390db12d">7.71</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzYtNi0xLTEtODQ0NDQ_207bece0-5ebf-4f6a-9e24-28aef5bd8f7a">8.12</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzktMi0xLTEtODQ0NDQ_459fa37c-b30c-411e-94fe-68a0c20aeac4">5.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzktNC0xLTEtODQ0NDQ_c31d3457-4e6c-4aa1-9531-e438a57023c7">2.49</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i703d5232b81a4b55936dd90e0dad0606_I20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzktNi0xLTEtODQ0NDQ_894c9b21-84ab-4917-a3d1-f8555b8eacc0">2.14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzktOC0xLTEtODQ0NDQ_83519883-997d-4a10-b8cd-1cfc6280bdc6">5.42</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee7e142ff6024167983180ffabb98005_I20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzktMTAtMS0xLTg0NDQ0_56d5f7b6-f8a2-46f1-bc7c-bf8a8e9ae322">2.68</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idfb66bf1fb1c43f6b51ba191f9fdbc89_I20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzktMTItMS0xLTg0NDQ0_31b0aa02-f531-4368-8388-d4dd765b5cef">2.23</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzEwLTItMS0xLTg0NDQ0_6f360d03-bda0-4c93-8c8c-237e19e81938">4.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzEwLTQtMS0xLTg0NDQ0_4610460b-88f7-4eeb-9702-7fc96b0a4de3">4.01</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i703d5232b81a4b55936dd90e0dad0606_I20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzEwLTYtMS0xLTg0NDQ0_b437de13-a233-4d09-bf60-2d980001d9db">4.00</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzEwLTgtMS0xLTg0NDQ0_9236066e-9c87-4ce1-8547-239bada51ced">4.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iee7e142ff6024167983180ffabb98005_I20220102" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzEwLTEwLTEtMS04NDQ0NA_3bf739b9-96cb-42dc-8b82-4e4be2122243">4.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idfb66bf1fb1c43f6b51ba191f9fdbc89_I20210103" decimals="4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzEwLTEyLTEtMS04NDQ0NA_e7f2a4a5-03ed-4148-93f2-98af958f7f04">4.27</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. </span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjMz_38447870-eb47-4093-a0de-24021beaa3eb" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the assumed healthcare cost trend rates, for all individuals:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"></td><td style="width:71.313%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.943%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.549%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.946%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Healthcare Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare cost trend rate assumed for next year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="4" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyMjFhY2FjZTI1ZTc0MDMxOGMxMmE4MjAwYzFlMjdhZS90YWJsZXJhbmdlOjIyMWFjYWNlMjVlNzQwMzE4YzEyYTgyMDBjMWUyN2FlXzEtMi0xLTEtODQ0NDQ_9008992f-47d3-42e4-851c-cd35a8cb3421">5.99</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="4" name="us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyMjFhY2FjZTI1ZTc0MDMxOGMxMmE4MjAwYzFlMjdhZS90YWJsZXJhbmdlOjIyMWFjYWNlMjVlNzQwMzE4YzEyYTgyMDBjMWUyN2FlXzEtNC0xLTEtODQ0NDQ_dabac546-6dfe-4fdf-94f2-8aa81aab420c">5.33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline (ultimate trend)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="4" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyMjFhY2FjZTI1ZTc0MDMxOGMxMmE4MjAwYzFlMjdhZS90YWJsZXJhbmdlOjIyMWFjYWNlMjVlNzQwMzE4YzEyYTgyMDBjMWUyN2FlXzItMi0xLTEtODQ0NDQ_bd65d97c-0359-40c1-8cdf-09e21e807f5b">4.01</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="4" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyMjFhY2FjZTI1ZTc0MDMxOGMxMmE4MjAwYzFlMjdhZS90YWJsZXJhbmdlOjIyMWFjYWNlMjVlNzQwMzE4YzEyYTgyMDBjMWUyN2FlXzItNC0xLTEtODQ0NDQ_619076a9-af8b-4a54-ab27-a3a647b6420d">3.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year the rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyMjFhY2FjZTI1ZTc0MDMxOGMxMmE4MjAwYzFlMjdhZS90YWJsZXJhbmdlOjIyMWFjYWNlMjVlNzQwMzE4YzEyYTgyMDBjMWUyN2FlXzMtMi0xLTEtODQ0NDQ_90d0329a-d75e-44fc-9575-4604b0995995">2047</ix:nonNumeric>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" name="us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyMjFhY2FjZTI1ZTc0MDMxOGMxMmE4MjAwYzFlMjdhZS90YWJsZXJhbmdlOjIyMWFjYWNlMjVlNzQwMzE4YzEyYTgyMDBjMWUyN2FlXzMtNC0xLTEtODQ0NDQ_a2c57b40-585b-4c07-8f62-32c7913ea8ce">2046</ix:nonNumeric>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="margin-top:3pt"><ix:continuation id="i5a74a67eee0b4bffa49283678f0df48f" continuedAt="ieaa43db0ef5046fcb7ee4f912770e61f"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfNetFundedStatusTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjQ1_9615c4aa-ec94-4f8a-94b8-358a414a580b" continuedAt="i26f7e930660944929ae3cae5a1ec31a6" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2022 and 2021 for the Company&#8217;s defined benefit retirement plans and other post-retirement plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMtMi0xLTEtODQ0NDQ_473fb4b3-8261-4683-8c3a-018cdc8df9d5">41,582</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i703d5232b81a4b55936dd90e0dad0606_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMtNC0xLTEtODQ0NDQ_d200d84c-ea79-4641-bd93-f3b63f619aa4">43,300</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee7e142ff6024167983180ffabb98005_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMtNi0xLTEtODQ0NDQ_a79afbd4-816d-4cef-a8e9-98887acd6c77">4,878</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb66bf1fb1c43f6b51ba191f9fdbc89_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMtOC0xLTEtODQ0NDQ_f48bb8a9-4460-44fc-b0e6-40f96babd94a">5,028</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQtMi0xLTEtODQ0NDQ_fabeff50-4c1d-4e28-951d-6e56aeff9a7c">1,327</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQtNC0xLTEtODQ0NDQ_cb3d091e-4463-43d6-afe5-b422099eb240">1,421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQtNi0xLTEtODQ0NDQ_bfd33933-2311-456e-a104-fe97e5bd18f0">320</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanServiceCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQtOC0xLTEtODQ0NDQ_8e105a2e-97c7-44e6-ad90-bab5521200ca">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzUtMi0xLTEtODQ0NDQ_8cafe36a-91ec-4330-ae3e-ae41c7782b8d">911</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzUtNC0xLTEtODQ0NDQ_e8ea4e98-a2ab-47cc-940e-44ffe67a1ef0">770</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzUtNi0xLTEtODQ0NDQ_dbdbf72b-2023-43e3-aaec-0308926dc8d4">105</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanInterestCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzUtOC0xLTEtODQ0NDQ_e85eb711-c505-42b7-b3d7-7eeb3be3593d">81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzYtMi0xLTEtODQ0NDQ_ff42f78c-0758-43ee-8430-d3e8b67f3dc9">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzYtNC0xLTEtODQ0NDQ_3e14a544-6abe-468b-8d18-91a4de95f1ce">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzYtNi0xLTEtODQ0NDQ_fe397b96-1402-4a8c-a231-6ff106e972a1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzYtOC0xLTEtODQ0NDQ_9971b4df-809e-4999-a7bc-f06e2e548924">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzctMi0xLTEtODQ0NDQ_3db19da7-7d1e-42ad-ae2f-e3a1651b97a7">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzctNC0xLTEtODQ0NDQ_200a24df-e686-4260-8122-c6178edd7143">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzctNi0xLTEtODQ0NDQ_33748b03-f53e-452c-a2e5-18f788fdf92b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAmendments" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzctOC0xLTEtODQ0NDQ_82eb406b-d290-4787-ab84-d566b0f091a5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains) losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzgtMi0xLTEtODQ0NDQ_6893ac25-915a-4c16-ac33-9e9ded51d1cb">12,213</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzgtNC0xLTEtODQ0NDQ_37ce9db6-b131-4b73-a01d-3cf897bf94ab">2,132</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzgtNi0xLTEtODQ0NDQ_d04a5468-fa3a-40f1-8066-684ee972aeaf">704</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzgtOC0xLTEtODQ0NDQ_e9d41afb-4b1c-44d2-acf3-8bafd0837375">188</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzktMi0xLTEtODQ0NDQ_acd773b7-ab1a-4d80-b8a5-4421f2291e8f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzktNC0xLTEtODQ0NDQ_5aad43dc-031d-4b7e-a9d1-0f3d538630d4">2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzktNi0xLTEtODQ0NDQ_5f50ea22-99a4-4342-87e0-487ba6719adf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzktOC0xLTEtODQ0NDQ_482a21b5-c1d8-441e-a8de-e914c058c3af">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments, settlements&#160;&amp; restructuring</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="jnj:CurtailmentsAndSettlementsAndRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEwLTItMS0xLTg0NDQ0_030d98dd-70e4-430f-b397-d71b295b39ad">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="jnj:CurtailmentsAndSettlementsAndRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEwLTQtMS0xLTg0NDQ0_fcd8ffbc-8b79-4456-ac03-294ade0b4935">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="jnj:CurtailmentsAndSettlementsAndRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEwLTYtMS0xLTg0NDQ0_b0e8cbd1-4485-4df6-b704-09b537179384">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="jnj:CurtailmentsAndSettlementsAndRestructuring" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEwLTgtMS0xLTg0NDQ0_77270dd1-011f-4d64-98a9-063a5277a1aa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzExLTItMS0xLTg0NDQ0_64fa331e-1e92-4900-acdc-da76023a1c46">1,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzExLTQtMS0xLTg0NDQ0_4bfc11b8-83ff-49d4-b75a-b02355910cb4">1,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzExLTYtMS0xLTg0NDQ0_1eaba255-75cc-4d04-b5da-4398e8f62b3c">393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzExLTgtMS0xLTg0NDQ0_6de93f95-9c6d-44e2-b8e8-a944b8146575">348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEyLTItMS0xLTg0NDQ0_725f2ab8-d81e-45d9-94b5-099203d2801d">815</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEyLTQtMS0xLTg0NDQ0_394cf338-3a5f-4132-8e1f-d5476174dc6b">683</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEyLTYtMS0xLTg0NDQ0_72a03404-21ee-4124-8f2a-3f270533f245">9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEyLTgtMS0xLTg0NDQ0_c8ec18c6-e46b-4228-95b3-d1ef959e9661">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEzLTItMS0xLTg0NDQ0_da503f03-315f-471d-aa15-eba2e06f0c9a">29,631</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEzLTQtMS0xLTg0NDQ0_3ad0312e-8fb8-4192-9912-cbb3636b58aa">41,582</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEzLTYtMS0xLTg0NDQ0_2101129e-b151-499b-a823-93b731fe1ba7">4,197</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee7e142ff6024167983180ffabb98005_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEzLTgtMS0xLTg0NDQ0_70cee68c-c15f-4be3-93da-2a648077a2ee">4,878</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE1LTItMS0xLTg0NDQ0_0e4de76c-742f-47a7-a561-9876bbcebf81">41,930</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i703d5232b81a4b55936dd90e0dad0606_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE1LTQtMS0xLTg0NDQ0_c11e0fcf-5c7c-425c-856d-b30f77aa1d3d">38,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee7e142ff6024167983180ffabb98005_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE1LTYtMS0xLTg0NDQ0_c03cecef-9eba-4b39-b20a-f390194ac763">102</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfb66bf1fb1c43f6b51ba191f9fdbc89_I20210103" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE1LTgtMS0xLTg0NDQ0_9081cde1-321b-48cd-a7f8-6a0cb8498d2b">90</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return (loss) on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE2LTItMS0xLTg0NDQ0_f8022463-d023-4067-870b-36bbb623377d">8,665</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE2LTQtMS0xLTg0NDQ0_0f62e600-0360-40d1-a82c-506c480f779a">4,439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE2LTYtMS0xLTg0NDQ0_9f213db9-72be-4200-9bca-b00bfbf1fd2e">17</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE2LTgtMS0xLTg0NDQ0_2c6a1fdd-f52f-406b-baf0-6905223feee8">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE3LTItMS0xLTg0NDQ0_50ef24b8-4aee-4611-b532-a01ed5ed3f2d">270</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE3LTQtMS0xLTg0NDQ0_694f947b-cb7b-4dfc-af88-d4e9b437deea">969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE3LTYtMS0xLTg0NDQ0_d3272346-8e14-4dd7-ab6c-fad1f8aeb3d2">386</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE3LTgtMS0xLTg0NDQ0_236b3ada-57c3-4c7c-b411-19a3692b851b">343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE4LTItMS0xLTg0NDQ0_d243b9cb-8025-487f-8d5c-8aaa4aba4cc9">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE4LTQtMS0xLTg0NDQ0_f496987b-dac6-400b-81c0-067e486fa3ab">67</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE4LTYtMS0xLTg0NDQ0_0483e35b-8503-4e31-ae67-e4e75e85bafb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE4LTgtMS0xLTg0NDQ0_9bef777e-88ad-4967-9ff4-4962a8940e2c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE5LTItMS0xLTg0NDQ0_e527d8e7-23b2-452a-bbf5-60a8fbba2f8f">5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE5LTQtMS0xLTg0NDQ0_c927f081-02fb-4868-91e9-1aeab89581df">7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE5LTYtMS0xLTg0NDQ0_90e3f8b8-cd20-4201-b740-0d4d21ecff04">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE5LTgtMS0xLTg0NDQ0_a393a0b2-dfba-421d-83a3-f35d053c910f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIwLTItMS0xLTg0NDQ0_17304df4-4ace-49d4-92c8-370c51f0105e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIwLTQtMS0xLTg0NDQ0_80ffb3f2-7bfe-4b9f-83dd-10dc5f88965d">2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIwLTYtMS0xLTg0NDQ0_2cc510ec-f616-4b66-8dd8-8a43dfb50a4b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIwLTgtMS0xLTg0NDQ0_60b85f68-e295-49db-a3de-4c7640c36933">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIxLTItMS0xLTg0NDQ0_19483fb0-1281-4ad1-a952-588941088ef1">1,228</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIxLTQtMS0xLTg0NDQ0_8a3807ed-9bee-490a-b4ba-0c2122940f54">1,157</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIxLTYtMS0xLTg0NDQ0_02fd5247-ec43-4833-b5af-b02b6cd9b825">393</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIxLTgtMS0xLTg0NDQ0_597484f6-26ac-4581-8f5b-6de973919008">348</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIyLTItMS0xLTg0NDQ0_5164f845-65be-44a8-9e2a-48999dae4cfd">855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIyLTQtMS0xLTg0NDQ0_6512028d-2c96-48ee-a460-14e9c947b6c5">574</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIyLTYtMS0xLTg0NDQ0_f9746164-e961-448f-822b-50074b52081a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIyLTgtMS0xLTg0NDQ0_35681fd2-85fc-4a13-8246-3839e8f32720">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIzLTItMS0xLTg0NDQ0_d46f5020-9ab7-4ffd-8d63-393ae31c9ead">31,514</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIzLTQtMS0xLTg0NDQ0_8a8be5b5-9388-4769-9e69-852e95e33eb9">41,930</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIzLTYtMS0xLTg0NDQ0_fbfc3426-9072-4db3-b379-e7ea94da90d0">78</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee7e142ff6024167983180ffabb98005_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIzLTgtMS0xLTg0NDQ0_96aa787c-7275-473d-adb1-02fabc5bba88">102</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status &#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI0LTItMS0xLTg0NDQ0_8bfd7b61-3ca5-4cd8-a4ae-2b662509cb4f">1,883</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI0LTQtMS0xLTg0NDQ0_6e8dcd7f-09f3-49fc-b793-c6dba46574e0">348</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI0LTYtMS0xLTg0NDQ0_8ecca1a7-5ba5-4043-a772-d1d32f4e83f9">4,119</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee7e142ff6024167983180ffabb98005_I20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI0LTgtMS0xLTg0NDQ0_eb549ccc-6b3a-4692-9f16-6e53166bc7cf">4,776</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI2LTItMS0xLTg0NDQ0_2cba5de2-8cec-4648-8a77-11f17a47eae7">4,581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI2LTQtMS0xLTg0NDQ0_84def377-7a75-4e71-a477-3bbb9ece7ce2">4,436</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI2LTYtMS0xLTg0NDQ0_41cc7eed-5922-4e6f-99ba-cf8339974ecd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee7e142ff6024167983180ffabb98005_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI2LTgtMS0xLTg0NDQ0_1439e151-247b-42d7-9d76-52ea48456502">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI3LTItMS0xLTg0NDQ0_f7d39b59-e820-43ff-8996-4448c31cd82b">132</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI3LTQtMS0xLTg0NDQ0_8744a260-e155-43ec-8da8-837aebc1bb80">115</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI3LTYtMS0xLTg0NDQ0_bf0adca3-fd2d-463b-b875-509380422f2f">461</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee7e142ff6024167983180ffabb98005_I20220102" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI3LTgtMS0xLTg0NDQ0_ba5ab444-39b2-4186-b858-84dd2b78b536">438</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI4LTItMS0xLTg0NDQ0_8a4278c7-8ffe-4d92-820e-b8e82241f959">2,566</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI4LTQtMS0xLTg0NDQ0_532f4dd7-2d76-4123-bf93-e00402420831">3,973</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI4LTYtMS0xLTg0NDQ0_4eef1581-eb0f-461b-b589-75ca829f0eca">3,658</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee7e142ff6024167983180ffabb98005_I20220102" decimals="-6" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI4LTgtMS0xLTg0NDQ0_f61c72e5-157b-4d27-b250-493780c1f4b1">4,338</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI5LTItMS0xLTg0NDQ0_6b80510c-492c-4b99-a3ea-2856512751ad">1,883</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI5LTQtMS0xLTg0NDQ0_a14c2683-b5e4-4acc-a79a-f041091b7c28">348</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI5LTYtMS0xLTg0NDQ0_ee75baa3-33d7-4fe8-8160-2f98d1067bf5">4,119</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee7e142ff6024167983180ffabb98005_I20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI5LTgtMS0xLTg0NDQ0_a6c901c6-20bb-4326-8482-cf9d262dbb4e">4,776</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMxLTItMS0xLTg0NDQ0_ef9fbcfa-e8c7-4563-834c-105759729bf1">3,948</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMxLTQtMS0xLTg0NDQ0_b219de41-b15e-43ba-8906-2427bba70bf3">5,539</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMxLTYtMS0xLTg0NDQ0_1e92bb08-3192-4c76-aff8-7abff1da1c6e">239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee7e142ff6024167983180ffabb98005_I20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMxLTgtMS0xLTg0NDQ0_286198e9-30b5-46b8-a10b-46e1399b77b6">1,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMyLTItMS0xLTg0NDQ0_2f83077b-e655-491e-99bd-470f207b5ec3">1,417</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMyLTQtMS0xLTg0NDQ0_91021db7-b8bf-4882-b805-773a9e078da4">1,610</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMyLTYtMS0xLTg0NDQ0_3dc26ee4-8ab8-431d-bd87-8db36ad1ae85">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iee7e142ff6024167983180ffabb98005_I20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMyLTgtMS0xLTg0NDQ0_0aed8263-5bbe-4068-93ad-23b08231be9c">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net transition obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMzLTItMS0xLTg0NDQ0_6a483cf1-130a-4aeb-b799-be63060ad9b8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMzLTQtMS0xLTg0NDQ0_15c208e6-40e8-4546-9502-ab35cca94dcd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMzLTYtMS0xLTg0NDQ0_f10b57a2-5419-43bf-a611-d3727a4f8416">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee7e142ff6024167983180ffabb98005_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMzLTgtMS0xLTg0NDQ0_d98c8feb-3158-4b45-b7ff-c0d5ee72027b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzM0LTItMS0xLTg0NDQ0_16c161f0-e727-4996-bb9d-272942ce4715">2,531</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzM0LTQtMS0xLTg0NDQ0_e8f48450-e17a-4f7e-a7cc-70020110d155">3,929</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzM0LTYtMS0xLTg0NDQ0_f4ef3d23-555b-4c93-813a-535b3f74b3e3">232</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee7e142ff6024167983180ffabb98005_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzM0LTgtMS0xLTg0NDQ0_ac4c8aeb-0a56-48e3-a2e1-94e9465a5449">1,100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligations&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzM2LTItMS0xLTg0NDQ0_bcd8ad07-60d7-41ae-a034-254f8e949d07">28,023</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzM2LTQtMS0xLTg0NDQ0_3ea98c33-d0c2-498c-8951-77af297d2320">39,049</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The actuarial gain for retirement plans in 2022 and 2021 was primarily related to increases in discount rates.</span></div></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ieaa43db0ef5046fcb7ee4f912770e61f" continuedAt="i256a6fea46a24513aa80412991fbb2b9"><div style="margin-top:3pt"><ix:continuation id="i26f7e930660944929ae3cae5a1ec31a6"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.139%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.619%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.624%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQyLTItMS0xLTg0NDQ0_506cbb4a-b798-4c26-afe3-d89d4341e562">47</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQyLTQtMS0xLTg0NDQ0_35353d8f-121f-4617-a40e-cd1591f49a1d">623</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQyLTYtMS0xLTg0NDQ0_bb9c4d74-4707-4c2f-8d05-fa1ca306c48f">533</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQyLTgtMS0xLTg0NDQ0_94735e95-fe61-4811-a28c-967746a602a9">503</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (gain) loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQzLTItMS0xLTg0NDQ0_4e9fda09-d32c-4000-a429-5862661c1938">793</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQzLTQtMS0xLTg0NDQ0_387b4320-cb0f-4f35-9647-d02116e5a465">3,927</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQzLTYtMS0xLTg0NDQ0_a2d0d0e1-0d03-4eb0-828d-cdd46079a7d9">751</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQzLTgtMS0xLTg0NDQ0_25b676cf-717a-4213-a899-9062fcd331df">199</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ0LTItMS0xLTg0NDQ0_7528022e-de86-415d-8463-23d95d3dd1f4">655</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ0LTQtMS0xLTg0NDQ0_621252c5-1f16-409a-833f-682815563d25">1,257</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ0LTYtMS0xLTg0NDQ0_50a56dc5-2dbb-4c24-b6e9-ee172fdc56a6">121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ0LTgtMS0xLTg0NDQ0_58aaa291-916e-4dde-9097-ff2f9573c000">151</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ1LTItMS0xLTg0NDQ0_2047fe58-a89b-4aea-a6a1-b928148cb314">7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ1LTQtMS0xLTg0NDQ0_b0e4ebca-720e-4abb-86d5-66e580a73d45">5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ1LTYtMS0xLTg0NDQ0_c63bdead-84cb-4802-ad15-6739f492fbab">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ1LTgtMS0xLTg0NDQ0_7ddb9b93-b9bb-4502-a15f-775a006e161c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (cost) credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ2LTItMS0xLTg0NDQ0_f1ea9fb3-affe-4234-a0ba-8519c0a394c3">183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ2LTQtMS0xLTg0NDQ0_12794e4e-7d3f-4827-9b0a-181724ebd10c">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ2LTYtMS0xLTg0NDQ0_a73af249-db78-41f5-989d-ef3883e6c3de">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ2LTgtMS0xLTg0NDQ0_5570b72b-7d48-4a67-ad6b-3c0c2ee5be3e">31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" sign="-" name="jnj:EffectOfExchangeRates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ3LTItMS0xLTg0NDQ0_caf51e98-7333-4378-9cab-614f4c05bedd">140</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" sign="-" name="jnj:EffectOfExchangeRates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ3LTQtMS0xLTg0NDQ0_e73b5455-67bc-4f6e-8ef6-d47bccaae451">136</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" sign="-" name="jnj:EffectOfExchangeRates" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ3LTYtMS0xLTg0NDQ0_94bb3bce-2f89-495e-8768-1b2419b7afdc">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="jnj:EffectOfExchangeRates" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ3LTgtMS0xLTg0NDQ0_90c3ff4e-4511-4322-a21e-e2d0b8e6a58d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total loss/(income) recognized in other comprehensive income, before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ4LTItMS0xLTg0NDQ0_619f115c-b509-432b-af34-57b16d66837c">1,398</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ4LTQtMS0xLTg0NDQ0_00fbbc63-96aa-42d7-a997-4eb84756b299">5,134</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ4LTYtMS0xLTg0NDQ0_c096e5cd-0c18-4f2c-9587-ed9793a02a27">868</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ4LTgtMS0xLTg0NDQ0_3b03e9de-29e3-42a4-95cf-3161e2897a3f">319</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ5LTItMS0xLTg0NDQ0_6ac2ca5e-ea50-4e36-80ca-4c047531555e">1,445</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ5LTQtMS0xLTg0NDQ0_7cdd785a-5ae3-46eb-a480-4131243f1932">4,511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ5LTYtMS0xLTg0NDQ0_9b4afbfa-a917-4095-8495-42e9ca9d6dad">335</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102" decimals="-6" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ5LTgtMS0xLTg0NDQ0_ed98e8e6-6872-4500-9f69-1fa2ffb57ae7">184</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company contributed $<ix:nonFraction unitRef="usd" contextRef="i568e2ee4449d4f8280ec25b22561b13b_D20220103-20230101" decimals="-6" name="us-gaap:PensionContributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzQ5OTQ_8fd56f20-6389-4938-ae3a-8818d5bfd3f1">119</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="idf25c935e9904a50a945cc29fc06d712_D20220103-20230101" decimals="-6" name="us-gaap:PensionContributions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzUwMDE_9ec8dad8-9351-4b0d-9981-0e0c7e8ef4c5">151</ix:nonFraction> million to its U.S.&#160;and international pension plans, respectively.</span></div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjI4_b719f076-7e24-4e75-b022-083579a1b429" escape="true"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the funded status of the Company's U.S. Qualified &amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2022 and December&#160;31, 2021, respectively:</span></div><div style="margin-top:7pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:25.879%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.697%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.844%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.137%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.288%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unfunded Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1330068050ee43c89fd0edf712d3cd33_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzMtMS0xLTEtODQ0NDQ_bcd532e0-4ab7-4310-a4b6-72e9d2228413">20,937</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89994b04ef5a4989828cbb2641ea63d2_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzMtMi0xLTEtODQ0NDQ_f35e5879-4d70-4dc4-96cc-2d4274c4d26c">27,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02d251447a4644728a4ec4ab07eeee7e_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzMtMy0xLTEtODQ0NDQ_0fdbe8a5-302f-4875-965a-ac3b5d4d2a9c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5c5ef2ccbe491e8eae45d4c1b715f8_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzMtNC0xLTEtODQ0NDQ_e074b952-070d-410a-8346-796bd46cb8cb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbef14fca11e481c8e30ad28994f26d9_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzMtNS0xLTEtODQ0NDQ_9d3ded6f-4189-4c4e-adbc-789204b19560">10,577</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee98d3d2af347e6aa674a643b6056df_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzMtNi0xLTEtODQ0NDQ_493728d3-4db8-411a-b4c4-8ab641dd9916">13,986</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6f2b519c9234298b0417a7077818079_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzMtNy0xLTEtODQ0NDQ_d3673580-fa4a-4df0-91dd-695598127dcb">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c2557ba884340dcb35175f91b95b324_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzMtOC0xLTEtODQ0NDQ_fd54bc80-5fb0-4b7e-b9ae-efe43e882bfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1330068050ee43c89fd0edf712d3cd33_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzQtMS0xLTEtODQ0NDQ_27f0f5ea-1ef6-4f8a-8577-7ace7fcf64cc">18,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89994b04ef5a4989828cbb2641ea63d2_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzQtMi0xLTEtODQ0NDQ_a34216a5-c441-44e1-9c2f-1bd6f6a55163">25,041</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02d251447a4644728a4ec4ab07eeee7e_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzQtMy0xLTEtODQ0NDQ_5f2f0af0-20b4-4b61-92d1-226e1185ca64">1,937</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5c5ef2ccbe491e8eae45d4c1b715f8_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzQtNC0xLTEtODQ0NDQ_f1d1aec0-3434-4876-aa5b-a5e4a6c95c85">2,703</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbef14fca11e481c8e30ad28994f26d9_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzQtNS0xLTEtODQ0NDQ_34c011fa-5dc5-419a-b11d-032c01eb5efe">9,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee98d3d2af347e6aa674a643b6056df_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzQtNi0xLTEtODQ0NDQ_4e183134-3bf9-45c1-9c38-f28804e6b0cf">13,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6f2b519c9234298b0417a7077818079_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzQtNy0xLTEtODQ0NDQ_521045fd-4694-4b82-aee6-694cfe12064d">276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c2557ba884340dcb35175f91b95b324_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzQtOC0xLTEtODQ0NDQ_5447bb2f-180e-4c94-bb49-78eefeaff34e">410</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1330068050ee43c89fd0edf712d3cd33_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzUtMS0xLTEtODQ0NDQ_893896b9-6fe6-4c5b-8a97-6c583d483ad8">17,696</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89994b04ef5a4989828cbb2641ea63d2_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzUtMi0xLTEtODQ0NDQ_359e6a13-e227-4d84-99d8-d4c0515f80cd">23,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02d251447a4644728a4ec4ab07eeee7e_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzUtMy0xLTEtODQ0NDQ_151c9e1d-6e2c-4781-88b5-4d24f9530a9a">1,872</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f5c5ef2ccbe491e8eae45d4c1b715f8_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzUtNC0xLTEtODQ0NDQ_7f663e1a-546a-4bc2-900f-c631138652f4">2,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbef14fca11e481c8e30ad28994f26d9_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzUtNS0xLTEtODQ0NDQ_b36b4a44-165c-48fb-84a4-4de069df82aa">8,202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee98d3d2af347e6aa674a643b6056df_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzUtNi0xLTEtODQ0NDQ_c094d172-a698-4e60-a409-03b89f9f0afe">12,212</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6f2b519c9234298b0417a7077818079_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzUtNy0xLTEtODQ0NDQ_a4d28b6b-5872-43fe-8517-0adaa8480b41">253</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c2557ba884340dcb35175f91b95b324_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzUtOC0xLTEtODQ0NDQ_6020afd8-8bf1-4458-b4d4-d4ac7214605f">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over (Under) Funded Status</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1330068050ee43c89fd0edf712d3cd33_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzctMS0xLTEtODQ0NDQ_3e2d4f0a-2c04-4fac-b81c-439ae64f3eaf">2,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89994b04ef5a4989828cbb2641ea63d2_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzctMi0xLTEtODQ0NDQ_97baa712-211a-4c35-8690-8b8acdfb3bb0">2,903</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02d251447a4644728a4ec4ab07eeee7e_I20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzctMy0xLTEtODQ0NDQ_8a161a5f-b68a-4179-8dc1-b0e66a91dad0">1,937</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f5c5ef2ccbe491e8eae45d4c1b715f8_I20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzctNC0xLTEtODQ0NDQ_13c036c8-ca30-4a9e-be9a-a68309e05165">2,703</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbef14fca11e481c8e30ad28994f26d9_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzctNS0xLTEtODQ0NDQ_adf03891-ec7c-453a-9baa-12feeb6610ba">1,553</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee98d3d2af347e6aa674a643b6056df_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzctNi0xLTEtODQ0NDQ_5c718eb2-90ef-4862-a00f-f99c536f5d9a">558</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6f2b519c9234298b0417a7077818079_I20230101" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzctNy0xLTEtODQ0NDQ_b50c968c-a513-4121-af69-85793fd2e17f">276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c2557ba884340dcb35175f91b95b324_I20220102" decimals="-6" sign="-" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzctOC0xLTEtODQ0NDQ_f3e4a854-7c79-456b-bfeb-a175caa2a087">410</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1330068050ee43c89fd0edf712d3cd33_I20230101" decimals="-6" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzgtMS0xLTEtODQ0NDQ_41bcc91e-f65e-4311-bf33-15eff4ca3ceb">3,241</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89994b04ef5a4989828cbb2641ea63d2_I20220102" decimals="-6" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzgtMi0xLTEtODQ0NDQ_41706110-4652-4352-84fd-11612901fe68">3,959</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i02d251447a4644728a4ec4ab07eeee7e_I20230101" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzgtMy0xLTEtODQ0NDQ_3a0c9e5d-0c90-47d2-bf3b-536a89c6764f">1,872</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2f5c5ef2ccbe491e8eae45d4c1b715f8_I20220102" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzgtNC0xLTEtODQ0NDQ_87ab44c8-d093-4544-9379-a3dffae64868">2,479</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifbef14fca11e481c8e30ad28994f26d9_I20230101" decimals="-6" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzgtNS0xLTEtODQ0NDQ_182f199d-c8e4-4c73-ad8d-aff5f688fc44">2,375</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee98d3d2af347e6aa674a643b6056df_I20220102" decimals="-6" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzgtNi0xLTEtODQ0NDQ_fc224df2-f958-4dad-9a46-25b3e0d59a08">1,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie6f2b519c9234298b0417a7077818079_I20230101" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzgtNy0xLTEtODQ0NDQ_73d32c74-1be7-43ed-ab77-e1492e99fc2b">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2c2557ba884340dcb35175f91b95b324_I20220102" decimals="-6" sign="-" name="jnj:DefinedBenefitPlanOverUnderFundedStatusABO" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzgtOC0xLTEtODQ0NDQ_eb6477f3-b223-4410-9021-4cfb25a66f6c">373</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzU0NDA_497e7bb0-a07c-4373-be99-b67e8416d924">2.9</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzU0NDQ_51a1de96-e9ca-4b12-bd9a-7e6ff81eaa24">2.9</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzU0NTE_84e76f5d-2176-45c1-8a32-fd9af1a58647">0.3</ix:nonFraction> billion, respectively, at the end of 2022, and $<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzU0OTE_ccd38d6b-d478-4d21-85b2-435c6706cd1d">3.9</ix:nonFraction> billion, $<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzU0OTU_0075cb8c-588e-4a6e-8fac-a2e532af4160">4.2</ix:nonFraction> billion and $<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-8" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzU1MDI_5510a48f-81fa-44b7-88bb-575fc4cfe6c3">0.3</ix:nonFraction> billion, respectively, at the end of 2021.</span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjI5_eda555a2-ce6d-4f55-8f8c-bd9311b045b7" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future benefit payments from the Company&#8217;s retirement and other benefit plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:35.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2028-2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future benefit payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzItMi0xLTEtODQ0NDQ_abe6750d-e525-43c3-aca0-2d86136814ac">1,445</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzItNC0xLTEtODQ0NDQ_a1882bf1-808f-4fa1-986a-c52a62009e7a">1,457</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzItNi0xLTEtODQ0NDQ_b2c8f2da-41f0-48ab-8158-a5e795c25788">1,532</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzItOC0xLTEtODQ0NDQ_2129db0c-96e9-423f-966a-6814478d93e5">1,609</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzItMTAtMS0xLTg0NDQ0_de7d5b6d-ca49-4146-8204-93dc4bbfb93d">1,708</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzItMTItMS0xLTg0NDQ0_b60f0020-98a0-4cb7-90ca-3a6bcc7d8017">10,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other benefit plans&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzUtMi0xLTEtODQ0NDQ_6c32a70f-a528-4add-a729-aac5ade21638">471</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzUtNC0xLTEtODQ0NDQ_a38613c8-38f8-4730-970b-39f4cac0a0e1">485</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzUtNi0xLTEtODQ0NDQ_ac786eae-4519-4227-8f37-f0bac2c9057a">433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzUtOC0xLTEtODQ0NDQ_58a133c7-eae3-4319-8558-7c2dac71e3f9">447</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzUtMTAtMS0xLTg0NDQ0_e082cee5-aa74-4315-be87-6d6b004b33d0">462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzUtMTItMS0xLTg0NDQ0_f682f2db-ace3-4062-abcb-39c3387f7455">2,539</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjA1_10f88ae5-84aa-4c97-9562-066bbb7d3773" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future minimum contributions to the unfunded retirement plans.  These amounts do not include any discretionary contributions that the Company may elect to make in the future.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:35.089%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.796%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.803%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2028-2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyZDViYjk3MzlhNmI0ZmVmOGJlNjk1MzlmOTY2OGQzOC90YWJsZXJhbmdlOjJkNWJiOTczOWE2YjRmZWY4YmU2OTUzOWY5NjY4ZDM4XzEtMi0xLTEtODQ0NDQ_e1dedf8f-0216-4501-8c56-c91efd53d996">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyZDViYjk3MzlhNmI0ZmVmOGJlNjk1MzlmOTY2OGQzOC90YWJsZXJhbmdlOjJkNWJiOTczOWE2YjRmZWY4YmU2OTUzOWY5NjY4ZDM4XzEtNC0xLTEtODQ0NDQ_870e2661-bca7-4705-9ea4-b6c63db2521c">128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyZDViYjk3MzlhNmI0ZmVmOGJlNjk1MzlmOTY2OGQzOC90YWJsZXJhbmdlOjJkNWJiOTczOWE2YjRmZWY4YmU2OTUzOWY5NjY4ZDM4XzEtNi0xLTEtODQ0NDQ_d76f16c4-768a-4d60-8c67-57dba918b793">136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyZDViYjk3MzlhNmI0ZmVmOGJlNjk1MzlmOTY2OGQzOC90YWJsZXJhbmdlOjJkNWJiOTczOWE2YjRmZWY4YmU2OTUzOWY5NjY4ZDM4XzEtOC0xLTEtODQ0NDQ_c8517aed-a98b-4fd1-8e56-9f5a34f95291">141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyZDViYjk3MzlhNmI0ZmVmOGJlNjk1MzlmOTY2OGQzOC90YWJsZXJhbmdlOjJkNWJiOTczOWE2YjRmZWY4YmU2OTUzOWY5NjY4ZDM4XzEtMTAtMS0xLTg0NDQ0_b0487641-1cad-49d9-8ac9-58f73efb25a9">146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyZDViYjk3MzlhNmI0ZmVmOGJlNjk1MzlmOTY2OGQzOC90YWJsZXJhbmdlOjJkNWJiOTczOWE2YjRmZWY4YmU2OTUzOWY5NjY4ZDM4XzEtMTItMS0xLTg0NDQ0_860cf11d-ebef-4dfb-aecb-34f582938c9b">816</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i256a6fea46a24513aa80412991fbb2b9" continuedAt="ie936cdb056254d2bb52bafe0b107d011"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company&#8217;s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds.  </span></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjQ5_ec0ed06a-2af5-4cc5-acd1-7552b2b8604d" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s retirement plan asset allocation at the end of 2022 and 2021 and target allocations for 2023 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:58.131%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.750%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.538%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.755%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent of<br/>Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Target<br/>Allocation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib9ef98128abe4aedb0a5007195b08de1_I20230101" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzMtMi0xLTEtODQ0NDQ_b6341672-0c17-454a-8948-ff50977501e2">62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i92a0708b59e24d4ea0866aa54072a7da_I20220102" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzMtNC0xLTEtODQ0NDQ_ad4d9ac4-0145-4347-81c7-6eb1d24d723e">65</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib9ef98128abe4aedb0a5007195b08de1_I20230101" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzMtNi0xLTEtODQ0NDQ_2dde57c4-f493-46be-9edb-11550014dce6">61</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c0a56ded60c4a9bb35be25cde1c1637_I20230101" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzQtMi0xLTEtODQ0NDQ_1e971be1-6611-4eb5-a426-23c40623d49f">38</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie6a1005463744b0db3476c6fa293b2a7_I20220102" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzQtNC0xLTEtODQ0NDQ_77877b65-4d34-4da6-a276-f56023b11577">35</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c0a56ded60c4a9bb35be25cde1c1637_I20230101" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzQtNi0xLTEtODQ0NDQ_4cc155c3-bc3e-4b06-b275-4cd08938d943">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzUtMi0xLTEtODQ0NDQ_9062ed3f-5749-4c60-a11e-7d57fc36bc42">100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzUtNC0xLTEtODQ0NDQ_d7d6c3c2-cfe3-437b-9c82-c24bd0e69663">100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzUtNi0xLTEtODQ0NDQ_3ef4c765-f0f8-4fdc-9a44-eb2d2d0a1541">100</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Determination of Fair Value of Plan Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan has an established and well-documented process for determining fair values.  Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation Hierarchy</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a description of the valuation methodologies used for the investments measured at fair value.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Short-term investment funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level&#160;2.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Government and agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level&#160;1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level&#160;2.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Debt instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level&#160;1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level&#160;2. Level&#160;3 debt instruments are priced based on unobservable inputs.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level&#160;1 of the valuation hierarchy.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commingled funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level&#160;2 category have a quoted market price.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie936cdb056254d2bb52bafe0b107d011" continuedAt="ie7a5c917f0104a7ab0266ccb8bacf3eb"><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level&#160;1, while inactively traded assets are classified as Level&#160;2. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjA4_bcd46648-514b-4ab6-826c-cd660c1d8a30" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2022 and December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"></td><td style="width:18.235%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.754%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.150%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.555%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b5854265567407d8c334a909d643d48_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzMtMi0xLTEtODQ0NDQ_e750d0eb-ce6a-48ca-b291-38f0de585aa4">33</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22e0ddcdbf4c44c2a8e38032719cfecb_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzMtNC0xLTEtODQ0NDQ_22cec668-1119-4e2a-89b2-3c4f944e1d41">102</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i065c9f2a0f964ee285c2b8a25d0a06ec_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzMtNi0xLTEtODQ0NDQ_ed881a45-bf3f-4abe-9cdc-98c24ed69159">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b6a8806889b4e03a0a58daf7c2e8756_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzMtOC0xLTEtODQ0NDQ_80cc0b21-89bd-4608-8e65-ea7b9920cf6f">1,033</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dd0d8c6503a45b587ecfb92769cc43c_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzMtMTAtMS0xLTg0NDQ0_1fded3ae-b93b-4663-bc49-6fdbc1bfdbfe">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74650ae05ec94371b9d6bc18a602bdba_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzMtMTItMS0xLTg0NDQ0_d21049aa-833a-4047-9e9f-2dec2915a2e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id57112356ae147f6acddb2fa2ef3c2c2_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzMtMTgtMS0xLTg0NDQ0_abaf0b66-a93c-4708-a856-92a881be54cc">46</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91b00037a81c40799e88359b6a3d230a_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzMtMjAtMS0xLTg0NDQ0_8bdaa25a-5b74-48c0-b117-9f8480b82896">1,135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government and agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4e0173b76424c5f8b69bc8e9ad909f3_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzQtMi0xLTEtODQ0NDQ_ac8d7813-307c-4e46-97b1-93a6bbdab43e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11c5835ef6d041e0a21935aa096c3e34_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzQtNC0xLTEtODQ0NDQ_d2b4f154-ff0f-4dba-8b03-18f0e7f17a72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89fe4d1a68ff41478d904f10e0e0ae0e_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzQtNi0xLTEtODQ0NDQ_1240c4af-ae62-4a24-89f2-68fe14b60d7c">5,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6e4971765ee45178f66de2094bb223b_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzQtOC0xLTEtODQ0NDQ_d5d9772b-5ec6-4cb4-bdb0-fb4cd10a5578">7,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2558baea70f43d6a6cf9affe1cb228c_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzQtMTAtMS0xLTg0NDQ0_1a8b8981-5b28-499c-8dcf-8a589d1b36c4">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaaa2fb24fe7f4913b81bd9b6e6a69211_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzQtMTItMS0xLTg0NDQ0_600ab1f2-3434-4de4-9a71-62cffa097383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia65b35d656b7404cad2cded1a7f84257_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzQtMTgtMS0xLTg0NDQ0_90c284dd-87c4-4e83-bbcc-024ea209546a">5,863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13253a658c83423ba8e9c1af10e40f9f_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzQtMjAtMS0xLTg0NDQ0_87496e5c-001b-49a6-b041-8df906131700">7,016</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idfffbb437b674ebbad4375b66a624388_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzUtMi0xLTEtODQ0NDQ_833e7ee0-11f8-4373-ac87-8c1e26cabe4f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia30472b13c2c42c698c7f0512ec7426c_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzUtNC0xLTEtODQ0NDQ_6300aa8c-a4e1-4458-918f-3bbb5f358a14">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f96d2d3087247fea72a69f7464a8ffe_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzUtNi0xLTEtODQ0NDQ_d667c75f-fd5f-4bf0-9115-71ddb5685731">3,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic562463a901d4f7d98741278df63a71e_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzUtOC0xLTEtODQ0NDQ_16df4ac7-82cb-423e-b983-e8059e606bdc">3,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i040ae04cd8d34049b557c7754b4d1903_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzUtMTAtMS0xLTg0NDQ0_64251114-991e-487f-b779-18695c0c9d1d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a4136d235304b9ca96dc52ca2bae31f_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzUtMTItMS0xLTg0NDQ0_00d0adc0-086c-482f-ace6-6b99e1d997f1">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aca2e86db254efcb60046d3b1959e83_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzUtMTgtMS0xLTg0NDQ0_c3e233ee-8582-46cd-88d3-52497c3286d3">3,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i629d668c721f43fa9a69ae248da4c767_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzUtMjAtMS0xLTg0NDQ0_8bcbc8aa-da2a-43a2-83b1-ff799f8eaf83">3,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i27927d8dc21840e0886a91b302a75133_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzYtMi0xLTEtODQ0NDQ_32f6d034-e3b3-4e2f-a3c0-e229bea47bdb">8,846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72431f66c0344014974314a2d6fcebee_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzYtNC0xLTEtODQ0NDQ_a1183dce-dc6e-44f8-963f-c1ade03e0a27">14,107</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6053a0abc1f746509f25b60b89e316da_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzYtNi0xLTEtODQ0NDQ_6def09bc-1233-4b37-9548-a61fed4d5bd8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1c3b856e495487fb9397d837ce7430d_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzYtOC0xLTEtODQ0NDQ_58a07694-8065-499f-b26b-985b822413ba">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a93ad27dcc346cb8ed7ba5d19476117_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzYtMTAtMS0xLTg0NDQ0_600a34ae-c1a3-4d00-8fdd-0da3a36fa3c0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34cf66c98020432c86dbfab2c8bc0591_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzYtMTItMS0xLTg0NDQ0_26a9cb00-141a-4d21-9aa0-018179f18f60">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i907758fcc942478385fb4e997c7b28e4_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzYtMTgtMS0xLTg0NDQ0_883481ad-2253-4453-b902-018e16e29339">8,848</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if460c561b88c46f197e086c2eb780175_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzYtMjAtMS0xLTg0NDQ0_584fdc73-f20f-4e7f-b9f9-d1313a6d7d03">14,109</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if667a81b90034bb89345e0e86dc1c837_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctMi0xLTEtODQ0NDQ_3be200a1-5aaf-4c48-b97c-10b984299b7f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie873bd0c000344438fb4154226263234_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctNC0xLTEtODQ0NDQ_242ed8e5-c76c-4fd9-942a-f7b96e678650">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i14706b8e4e9b45fa8ad2b00f7b025b13_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctNi0xLTEtODQ0NDQ_1a54c188-cda6-4afa-9257-3dd4381761f1">4,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i08e5d2a42732496faba5e2998478e99f_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctOC0xLTEtODQ0NDQ_ebcd1984-fa8c-4ec2-b5a9-f7439e8edc66">5,496</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4c63ed9d635548eda5b40167be502d34_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctMTAtMS0xLTg0NDQ0_441cd29d-f2c7-4b4f-a7b0-cc29fabebd6a">56</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c17edc19d844447920bcf55fcb965c9_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctMTItMS0xLTg0NDQ0_5ceb9aaf-a160-4e96-bc91-a51daf219035">105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9464afb4525c4171b9f7c85f564ca383_I20230101" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctMTQtMS0xLTg0NDQ0_cad97ca6-5809-425c-9a1a-182010682bff">6,106</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678ae776bb3e4394807bdb4118962522_I20220102" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctMTYtMS0xLTg0NDQ0_204bfa7c-d958-4db9-a7fc-9c1605105c06">8,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9464afb4525c4171b9f7c85f564ca383_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctMTgtMS0xLTg0NDQ0_2edc7f6d-cf32-411d-9823-c05bb917ae8e">10,524</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i678ae776bb3e4394807bdb4118962522_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctMjAtMS0xLTg0NDQ0_709047d5-6f16-4ed8-b898-bcf62f1845e4">14,309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idbdd72723de74d5ab22897210e1d235d_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktMi0xLTEtODQ0NDQ_0d68204f-de37-43d4-968e-759953e9040f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id16f7d3ae47a40419613a4e6ebcdf931_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktNC0xLTEtODQ0NDQ_3f267763-1321-4e58-9a46-0ab2016cfe2f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94f0cc6d1b0143a7ad0de6a6b7171527_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktNi0xLTEtODQ0NDQ_cb8de841-220c-49dd-99f0-0c85ffe851e4">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1489b8c66a064c22a4d320bbc28a949e_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktOC0xLTEtODQ0NDQ_33c24f34-857f-4b46-8ff7-f18395ea1fe1">34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5684bd25916640ce8a21cd76052a6a5c_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktMTAtMS0xLTg0NDQ0_9307cf0c-32c0-48ea-a821-f8a7876c18c3">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5175417cdaa471eb56e2f0adbf22f49_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktMTItMS0xLTg0NDQ0_8642e849-fbb7-4775-b06f-03de0f8ef39d">15</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4522e617517843a2883f058c7048bf98_I20230101" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktMTQtMS0xLTg0NDQ0_e2a12272-e58b-427e-b9bc-a1f2836c283f">2,506</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f898d8c94c649a4bcd40d0903b33a8b_I20220102" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktMTYtMS0xLTg0NDQ0_77772839-dea1-4a2c-a247-b4c47d1a7674">1,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4522e617517843a2883f058c7048bf98_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktMTgtMS0xLTg0NDQ0_29d980e5-ea2a-4e86-bac5-0efc97139be8">2,552</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7f898d8c94c649a4bcd40d0903b33a8b_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktMjAtMS0xLTg0NDQ0_0273064f-4092-42b6-bb7d-981fb0d46593">1,856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d78a014cb7b4600b9b987e0c8d3ef4e_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTItMS0xLTg0NDQ0_ecb42b98-34c3-42f0-a22b-7acef3a0aab0">8,879</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9eedf365257482e9a59a6c5f27d0a37_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTQtMS0xLTg0NDQ0_7ef7b07c-6c32-41dd-8349-1428646c5914">14,209</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i409919d7e88f41b790a753d01b52083e_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTYtMS0xLTg0NDQ0_3da7c555-36ce-49a6-a537-3ce57c63926d">13,954</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5db77b85a6024162854cd564cb20a41d_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTgtMS0xLTg0NDQ0_9789bd71-2ff4-490a-a9db-402d3c85c327">17,086</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e09026399524065bc97affeb43c546d_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTEwLTEtMS04NDQ0NA_079de2c8-b218-4413-9f28-2a3b5d143e60">69</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i199aa9d6185f445c8a0e845551e8cd3b_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTEyLTEtMS04NDQ0NA_1d89b92a-91d1-4d65-bfa7-e36fa45796cb">120</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44bda01bf133404387afaead8b97a718_I20230101" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTE0LTEtMS04NDQ0NA_026a9a6f-423d-42ab-84de-686143ff4d8c">8,612</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccce90dd21004e5daf45ef5005ed0551_I20220102" decimals="-6" name="jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTE2LTEtMS04NDQ0NA_0e8771c9-9535-4655-947e-6c41a153fe18">10,515</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44bda01bf133404387afaead8b97a718_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTE4LTEtMS04NDQ0NA_aae97caf-955f-4827-b48c-cdb04e0c4358">31,514</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccce90dd21004e5daf45ef5005ed0551_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTIwLTEtMS04NDQ0NA_eafc2abf-142d-4540-8873-6e85ad30a51d">41,930</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The activity for the Level 3 assets is not significant for all years presented.</span></div></ix:nonNumeric><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Other Benefit Plans are unfunded except for U.S.&#160;commingled funds (Level 2) of $<ix:nonFraction unitRef="usd" contextRef="idd19fe4f42064eab8bbfb528aac6c080_I20230101" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzEwOTQ4_03794fb3-2bd0-4e95-91e4-b1443b4e1409">78</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i74f4b70efeba4325a8712247faf7b3ff_I20220102" decimals="-6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzEwOTU1_434c2041-1dc6-4986-9bc4-617f8e6d0795">102</ix:nonFraction> million at December&#160;31, 2022 and December&#160;31, 2021, respectively. </span></div></ix:continuation><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie7a5c917f0104a7ab0266ccb8bacf3eb">The fair value of Johnson&#160;&amp; Johnson Common Stock directly held in plan assets was $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMDk5_72c091d2-763c-4a97-9f63-40df7860704d">21</ix:nonFraction> million (<ix:nonFraction unitRef="number" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="3" name="jnj:PercentageOfCompanysCommonStockToPlanAsset" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMTAz_f80fd5c9-7a6e-4d4f-891d-bc689f50138b">0.1</ix:nonFraction>% of total plan assets) at December&#160;31, 2022 and $<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMTUz_262c5fb2-5042-4bf1-b667-5da8f60084fa">385</ix:nonFraction> million (<ix:nonFraction unitRef="number" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="3" name="jnj:PercentageOfCompanysCommonStockToPlanAsset" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMTU3_b115e194-2b7d-4399-96fa-93dc2a91009f">0.9</ix:nonFraction>% of total plan assets) at December&#160;31, 2021.</ix:continuation> </span></div><div><span><br/></span></div><div><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_187"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="jnj:SavingsPlanTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODcvZnJhZzplOTk1MWU2OTkzODY0ZmRlOTI5ZjFjYmY3YWYwMjhkZS90ZXh0cmVnaW9uOmU5OTUxZTY5OTM4NjRmZGU5MjlmMWNiZjdhZjAyOGRlXzQwNA_a287b6b3-9408-4287-b3c2-66833f750c50" continuedAt="i1fb5e497085a4da7b030d94fd8903f34" escape="true">Savings Plan</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i1fb5e497085a4da7b030d94fd8903f34">The Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee&#8217;s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODcvZnJhZzplOTk1MWU2OTkzODY0ZmRlOTI5ZjFjYmY3YWYwMjhkZS90ZXh0cmVnaW9uOmU5OTUxZTY5OTM4NjRmZGU5MjlmMWNiZjdhZjAyOGRlXzM0Mg_75a5fef2-9caf-4876-b404-f4d8e5c6ac89">275</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODcvZnJhZzplOTk1MWU2OTkzODY0ZmRlOTI5ZjFjYmY3YWYwMjhkZS90ZXh0cmVnaW9uOmU5OTUxZTY5OTM4NjRmZGU5MjlmMWNiZjdhZjAyOGRlXzM0Ng_0cfdf53a-6785-45e8-8dcf-00296e6deeec">256</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:DefinedContributionPlanCostRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODcvZnJhZzplOTk1MWU2OTkzODY0ZmRlOTI5ZjFjYmY3YWYwMjhkZS90ZXh0cmVnaW9uOmU5OTUxZTY5OTM4NjRmZGU5MjlmMWNiZjdhZjAyOGRlXzM1Mw_e1b05ede-3880-4a98-9754-50605141d6c2">243</ix:nonFraction> million in fiscal years 2022, 2021 and 2020, respectively.</ix:continuation></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:TreasuryStockTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzc2OA_0a3b1cbc-2bfc-4b99-a19d-dfdfb1a0c7ba" continuedAt="iefc63b348a63403a9043f2ae06c5d56f" escape="true">Capital and Treasury Stock</ix:nonNumeric></span></div><ix:continuation id="iefc63b348a63403a9043f2ae06c5d56f"><div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="jnj:ChangesInTreasuryStockTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzc3Nw_75e793c2-c7f0-4695-940d-e89278050573" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in treasury stock were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:71.960%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in Millions Except Treasury Stock Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzItMi0xLTEtODQ0NDQ_4f11a4b3-3e4f-4c73-8056-a8c6d135fd34">487,336</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzItNC0xLTEtODQ0NDQ_b8ac3f15-2811-4c6f-8f18-7dd949921567">38,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzMtMi0xLTEtODQ0NDQ_582a3cb6-2ea7-4810-bcf7-bf01c7ccae09">21,765</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzMtNC0xLTEtODQ0NDQ_c53264ee-4e0f-4792-a601-b6740746037a">3,148</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib7e50ef6296740dda9036c6c59bae7a8_D20191230-20210103" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzQtMi0xLTEtODQ0NDQ_9894848f-2ce8-429d-8503-86627bdd8728">21,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib7e50ef6296740dda9036c6c59bae7a8_D20191230-20210103" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzQtNC0xLTEtODQ0NDQ_339f841f-382f-427c-941a-87663b66bea8">3,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzUtMi0xLTEtODQ0NDQ_2ba6b19f-dfd9-482e-83dc-6b2b1cc82723">487,331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzUtNC0xLTEtODQ0NDQ_723a8553-082f-49e5-9f33-4dcff5d7cc77">38,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzYtMi0xLTEtODQ0NDQ_a51057e8-3e60-4c69-b01c-2cfe08ada420">17,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzYtNC0xLTEtODQ0NDQ_4ff786ed-86f6-459f-91bc-e81701bd1bfa">2,847</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ica40f5d5420a42c4baf327e28f3ff166_D20210104-20220102" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzctMi0xLTEtODQ0NDQ_7b665ec7-61be-4d87-a183-8ef402f8f1e8">20,946</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ica40f5d5420a42c4baf327e28f3ff166_D20210104-20220102" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzctNC0xLTEtODQ0NDQ_4763b800-a994-41e9-886c-4c006522b782">3,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzgtMi0xLTEtODQ0NDQ_bd6d0365-ac6d-4264-ba9c-848595f9b2d0">490,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzgtNC0xLTEtODQ0NDQ_7aa15b59-da1f-4c62-9d65-77faa3b5cb03">39,099</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzktMi0xLTEtODQ0NDQ_02f1ec4b-58ae-4179-9737-08cab7325a53">20,007</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzktNC0xLTEtODQ0NDQ_95213481-6046-4aae-8bc3-0e8b15b3f263">3,440</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0bd8a9ce6ebc4c33ba835359ee340f7a_D20220103-20230101" decimals="-3" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzEwLTItMS0xLTg0NDQ0_3c873471-51b5-43a3-92f6-d2fddf2ca2e2">35,375</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bd8a9ce6ebc4c33ba835359ee340f7a_D20220103-20230101" decimals="-6" name="us-gaap:TreasuryStockValueAcquiredCostMethod" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzEwLTQtMS0xLTg0NDQ0_3246bb94-9849-421a-908d-519e749a45d0">6,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-3" name="us-gaap:TreasuryStockShares" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzExLTItMS0xLTg0NDQ0_caea7d19-3783-40a7-8262-1ffd908276ae">506,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:TreasuryStockValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzExLTQtMS0xLTg0NDQ0_f502b170-db08-4e00-9d4c-9957bd52587c">41,694</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate shares of common stock issued were approximately <ix:nonFraction unitRef="shares" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzEyNg_1a6b39b0-e1b5-43a7-a747-6f9056da7e0d"><ix:nonFraction unitRef="shares" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzEyNg_7a6beb44-33cb-4032-a105-12f8c2616393"><ix:nonFraction unitRef="shares" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzEyNg_e532dde2-e844-443e-9dfb-38d899294517">3,119,843,000</ix:nonFraction></ix:nonFraction></ix:nonFraction>&#160;shares at the end of fiscal years 2022, 2021 and 2020.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash dividends paid were $<ix:nonFraction unitRef="usdPerShare" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzIwNA_bab0f4cb-8b84-42d5-b47d-83d9d4e0f30b">4.45</ix:nonFraction> per share in fiscal year 2022, compared with dividends of $<ix:nonFraction unitRef="usdPerShare" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzI2Mw_26dfeab5-c715-4bf2-9f65-83e5f76b87a9">4.19</ix:nonFraction> per share in fiscal year 2021, and $<ix:nonFraction unitRef="usdPerShare" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="2" name="us-gaap:CommonStockDividendsPerShareCashPaid" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzI5OQ_849c079b-c3a5-4805-80c1-4d8cfe3049b3">3.98</ix:nonFraction> per share in fiscal year 2020. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2023, the Board of Directors declared a regular cash dividend of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifc3e95d2480f4b09a43e8526cb530ec0_D20230103-20230103" decimals="INF" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzQxMQ_0d55da42-59de-48bc-a264-5045b4341029">1.13</ix:nonFraction> per share, payable on March 7, 2023 to shareholders of record as of February 21, 2023.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $<ix:nonFraction unitRef="usd" contextRef="i3aaa8d30ebdd4b799164c6d64da029ec_I20220914" decimals="-8" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzY1Mg_da55cd89-e37b-4711-8587-c9e69072cc6f">5.0</ix:nonFraction> billion of the Company's shares of common stock. Share repurchases may be made at management&#8217;s discretion from time to time on the open market or through privately negotiated transactions.  The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Through January&#160;1, 2023, approximately $<ix:nonFraction unitRef="usd" contextRef="ie95b18f0bb224ce39159e2cece26a7de_D20220914-20230101" decimals="-8" name="us-gaap:StockRepurchasedDuringPeriodValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzU0OTc1NTgxNjMyOQ_6c28ce5e-f07e-4217-85aa-ef2499566470">2.5</ix:nonFraction>&#160;billion has been repurchased under the program.</span></div></ix:continuation><div style="text-indent:18pt"><span><br/></span></div><div><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_196"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90ZXh0cmVnaW9uOjZhNTQwMDFhMjBiODQwYTk4Y2Y0MzkzZjhjMTVmZjNkXzkxNw_cfcd7135-8be5-406e-9e2a-05050c4011b7" continuedAt="i653dd4573d1b4b6d970ca060f53f5443" escape="true">Accumulated Other Comprehensive Income (Loss)</ix:nonNumeric></span></div><ix:continuation id="i653dd4573d1b4b6d970ca060f53f5443"><div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90ZXh0cmVnaW9uOjZhNTQwMDFhMjBiODQwYTk4Y2Y0MzkzZjhjMTVmZjNkXzkyNA_8f95d921-8ab4-459c-9b1e-630310e54785" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:35.117%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.897%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.457%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.292%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.483%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.630%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.392%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>Currency Translation</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss) On Securities</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/<br/>(Loss) On<br/>Derivatives &amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i998292a4720542fb97323e8a21027018_I20191229" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEtMi0xLTEtODQ0NDQ_a62906d5-10f6-46e5-aa2d-dd57574af9f3">8,705</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i11d2f866128a4c0bbd34f29e255e2e5e_I20191229" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEtNC0xLTEtODQ0NDQ_acd3f84d-0b61-4eaa-972b-c84e40d05e5a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic2e5b348e871404cb444f06edd6e8a44_I20191229" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEtNi0xLTEtODQ0NDQ_3414eb07-904e-4a1c-a1b3-d864532ea869">6,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i72f9f2cb97f549a783317a29d6bcb3a6_I20191229" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEtOC0xLTEtODQ0NDQ_f1b53d91-c8a2-4457-a566-3bac32e07256">295</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ie9807f0aec4641a1ac4bec134b355aad_I20191229" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEtMTAtMS0xLTg0NDQ0_a43e5291-3007-4f96-9a7e-2c4b7da9da85">15,891</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2020 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i4bdd796b17934806b83c05e06ce34090_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzMtMi0xLTEtODQ0NDQ_c25bda50-c63c-4089-b1bd-1b9f6ae2d1e8">233</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibdc62ce8bcb249e58d2e978447347cbf_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzMtNC0xLTEtODQ0NDQ_bc85cd39-b42f-4108-b18f-f6064034dfce">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="idd018d59093549458cb4f3761ccbb821_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzMtNi0xLTEtODQ0NDQ_9cf754da-7e7c-4195-a23b-115444a7567c">66</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b330b391c664593bf5ce01ca6a9e387_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzMtOC0xLTEtODQ0NDQ_4c3a0cc4-100e-4fbb-ab8b-a4fa240bfcae">947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9a2bd92352194bcdb8a871945d2b04b6_D20191230-20210103" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzMtMTAtMS0xLTg0NDQ0_b65bd112-1e46-4f62-bd78-c9e6c096571a">649</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib1263a8933f94cd2b1db256f5159e8c1_I20210103" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzQtMi0xLTEtODQ0NDQ_6fa8430a-0757-4af2-a0a8-aa8a9e640cc6">8,938</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i86541415a18745ad9fad6d5a9da21dab_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzQtNC0xLTEtODQ0NDQ_285ea4c6-f9b1-4323-8a52-8bfaf854ddf9">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i56cfe48a1389431abade9bcff2c63177_I20210103" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzQtNi0xLTEtODQ0NDQ_a9cc2f7e-2a40-4898-a5ae-b395bd6b5460">6,957</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a4b14144c8b45d7b5c9ed3c00162124_I20210103" decimals="-6" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzQtOC0xLTEtODQ0NDQ_e62695b7-5ed0-44d6-9eca-ad9fe54da408">652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i81bc749533a9432f82631e2ec08fb7c4_I20210103" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzQtMTAtMS0xLTg0NDQ0_9ab6fa3c-5c4f-48ec-88bf-057ace4c6843">15,242</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2021 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic08350f7471944cfb12cf9ffa56a221c_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzYtMi0xLTEtODQ0NDQ_aba72bab-04c8-4a3f-a741-3e7e048829f7">1,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i503c1b32967d4343a8eb327c8c6be661_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzYtNC0xLTEtODQ0NDQ_26ccbe58-f7ee-42d7-9cb6-5872914751a8">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602c299adc484e92a89fdcbd8f6fc8cc_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzYtNi0xLTEtODQ0NDQ_b232ae5c-00e2-4aec-9f29-db0bbe75996f">4,255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief3f111fd6524bf78a21c828a283c3d5_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzYtOC0xLTEtODQ0NDQ_e95ab340-c0ec-46b3-89fc-9728c20b33c0">988</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieade5efd55fc4e7f9b55b76ad9b270a0_D20210104-20220102" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzYtMTAtMS0xLTg0NDQ0_f5b4fbe3-9d94-488c-a376-48e107046bfb">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id0b83f8ef9bf4d359fa8bb52b6dc3fcf_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzctMi0xLTEtODQ0NDQ_0f8988d7-d838-4d9a-bbea-5a4623981f27">10,017</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iaba6b6f0ecea42ebb8ac410bf2612423_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzctNC0xLTEtODQ0NDQ_9b6cc221-e7c5-4a86-98a3-bfd9aa54452b">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id1d1b96425db42a181eb410f603a9c9c_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzctNi0xLTEtODQ0NDQ_81ea932e-7d22-4b9f-a8bc-1572967718ac">2,702</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i43fcad8870384544ab9df6081f406c7f_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzctOC0xLTEtODQ0NDQ_25a3ab19-09dc-4345-822f-38bc4fde56cc">336</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icec2276dbd2e4d76878d45adc66f315e_I20220102" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzctMTAtMS0xLTg0NDQ0_9b67f811-456a-497a-a822-7fc8c3e2ae7d">13,058</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2022 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i71c7679daebf4d0db0b277193d8ac50e_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzktMi0xLTEtODQ0NDQ_7ce15834-790b-4750-ab7e-f5d93aabb8d6">1,796</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i76d61a4fb2f4474181a28e27ff866f5d_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzktNC0xLTEtODQ0NDQ_6122157d-6d24-4979-a0bd-b6ddd27962ca">24</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fd635367c6c4ca58981a78d2275f2cb_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzktNi0xLTEtODQ0NDQ_9389ea23-9779-4ed0-a2e4-be2a611f2f33">1,805</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4d00a4d2722e40608c24963350b6de0a_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzktOC0xLTEtODQ0NDQ_00e1e7d4-95a3-4f9c-bdd0-4426c1614252">106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb64fb4e20f1404cbc6e31613ca7eef9_D20220103-20230101" decimals="-6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzktMTAtMS0xLTg0NDQ0_9da12b8c-1619-4bae-8794-241c082c8f8b">91</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="icf4d10f59ddd4ab8bd56434bad43ae20_I20230101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEwLTItMS0xLTg0NDQ0_8738afe9-c28f-457a-a266-4e78aaa389d1">11,813</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5800e1082b6146cea9073bcfbb7f02fd_I20230101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEwLTQtMS0xLTg0NDQ0_bd1b8735-142e-42f3-bad7-46dc272f9e30">27</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6e067c6346f74a20b1c0fe95515d8e9c_I20230101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEwLTYtMS0xLTg0NDQ0_06631886-0d21-4248-9388-42740ac2fdbf">897</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4ddbcdadcf848e69b32b80c8a7d34f4_I20230101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEwLTgtMS0xLTg0NDQ0_fb188f46-5588-483d-bfeb-7cff5ef6e3c8">230</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia8ed0029b3204669a3f2d23dad442d8e_I20230101" decimals="-6" sign="-" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEwLTEwLTEtMS04NDQ0NA_498cc8fc-de11-4225-97b1-20d0a830e399">12,967</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details.</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction.  See Note 6 for additional details.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_199"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ForeignCurrencyDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTkvZnJhZzowNjg5MTMxZTY5ZmQ0MTk3YTUzNTIxMGUwMGYxMTJmNC90ZXh0cmVnaW9uOjA2ODkxMzFlNjlmZDQxOTdhNTM1MjEwZTAwZjExMmY0XzE1MTg_00044bef-a82d-446f-84b6-d1341b0dfcf1" continuedAt="i217e562aff3c4b23bd8423733b49ee21" escape="true">International Currency Translation</ix:nonNumeric></span></div><ix:continuation id="i217e562aff3c4b23bd8423733b49ee21"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For translation of its subsidiaries operating in non-U.S.&#160;Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non-current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies, (Argentina and Venezuela). Beginning in the fiscal second quarter of 2022, the Company also accounted for operations in Turkey as highly inflationary. The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the changes during fiscal years 2022, 2021 and 2020 for foreign currency translation adjustments is included in Note&#160;13. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net currency transaction gains and losses included in Other (income) expense were losses of $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTkvZnJhZzowNjg5MTMxZTY5ZmQ0MTk3YTUzNTIxMGUwMGYxMTJmNC90ZXh0cmVnaW9uOjA2ODkxMzFlNjlmZDQxOTdhNTM1MjEwZTAwZjExMmY0XzE0NTc_a155dc93-d560-4e78-8bed-79c570b6e46a">328</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTkvZnJhZzowNjg5MTMxZTY5ZmQ0MTk3YTUzNTIxMGUwMGYxMTJmNC90ZXh0cmVnaW9uOjA2ODkxMzFlNjlmZDQxOTdhNTM1MjEwZTAwZjExMmY0XzE0NjE_dcf5189c-11ee-41b1-ba91-a72529c44411">236</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:ForeignCurrencyTransactionGainLossBeforeTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTkvZnJhZzowNjg5MTMxZTY5ZmQ0MTk3YTUzNTIxMGUwMGYxMTJmNC90ZXh0cmVnaW9uOjA2ODkxMzFlNjlmZDQxOTdhNTM1MjEwZTAwZjExMmY0XzE0Njg_98c0ff48-bc7c-4f5c-95c5-7339f69cae79">209</ix:nonFraction> million in fiscal years 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_202"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90ZXh0cmVnaW9uOjA5NGYyNjc5NzAxOTRiNGE5ZTNlYTNjNmIxYzFiNTgwXzExODI_f56d8c3f-4b9f-46f8-8ab8-c02a10c324f6" continuedAt="ie4afcad983bb41788843bfb62cddbb1c" escape="true">Earnings Per Share</ix:nonNumeric></span></div><ix:continuation id="ie4afcad983bb41788843bfb62cddbb1c" continuedAt="i9f4dbffb462d4c75a338dcdf86d7045b"><div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90ZXh0cmVnaW9uOjA5NGYyNjc5NzAxOTRiNGE5ZTNlYTNjNmIxYzFiNTgwXzExODQ_eb651b23-f055-44fe-ade2-27167ca212ad" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.637%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions Except Per Share Amounts)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzEtMi0xLTEtODQ0NDQ_4e536b8c-faf2-49ce-9709-969fdd59d4ae">6.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzEtNC0xLTEtODQ0NDQ_7bb2998e-ed2f-40a6-83a0-35faf1faa3d4">7.93</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzEtNi0xLTEtODQ0NDQ_2bb151d4-33e1-4512-babc-a6e81cda7062">5.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding&#160;&#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzItMi0xLTEtODQ0NDQ_ac37d4e3-53fc-498c-88ea-684d0a93876c">2,625.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzItNC0xLTEtODQ0NDQ_40576d52-970d-4fdf-a7cb-c95382347c47">2,632.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzItNi0xLTEtODQ0NDQ_19fb08bf-a159-47f1-9f6e-79449ff2db0f">2,632.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-5" name="jnj:PotentialSharesExercisableUnderStockOptionPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzMtMi0xLTEtODQ0NDQ_ea67103c-5070-4751-8175-314e00178a6d">140.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-5" name="jnj:PotentialSharesExercisableUnderStockOptionPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzMtNC0xLTEtODQ0NDQ_b0f3975f-cba2-41f8-b3ca-3f6ec9a4f161">138.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-5" name="jnj:PotentialSharesExercisableUnderStockOptionPlans" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzMtNi0xLTEtODQ0NDQ_749717a5-2c95-4618-91d7-8096bc913707">118.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzQtMi0xLTEtODQ0NDQ_215cc636-a158-45fd-812e-80081b690a73">101.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzQtNC0xLTEtODQ0NDQ_61af70a7-45e0-48a7-b9bd-4a790100d200">96.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-5" name="jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzQtNi0xLTEtODQ0NDQ_b8d3aaba-de18-469d-930b-3b4d485ffef4">80.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted average shares outstanding&#160;&#8212; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzYtMi0xLTEtODQ0NDQ_241f081f-e948-4865-9858-e02b19d43d49">2,663.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzYtNC0xLTEtODQ0NDQ_54825b19-492c-4987-ab15-62d568b9db71">2,674.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzYtNi0xLTEtODQ0NDQ_f72b67f2-14b0-4d66-a23d-9e53b9ee35ba">2,670.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzctMi0xLTEtODQ0NDQ_b41fa438-ab51-4a43-b03b-f12842cab51c">6.73</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzctNC0xLTEtODQ0NDQ_dbcd3206-a584-410e-8fd5-921924d0ab32">7.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzctNi0xLTEtODQ0NDQ_0bb5b024-6345-427e-ba59-d8c93ca69c3b">5.51</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diluted net earnings per share calculation for the fiscal years 2022 and 2021 included all shares related to stock options, as the exercise price of these options was less than the average market value of the Company's stock. </span></div></ix:continuation><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9f4dbffb462d4c75a338dcdf86d7045b">The diluted net earnings per share calculation for fiscal year 2020 excluded <ix:nonFraction unitRef="shares" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90ZXh0cmVnaW9uOjA5NGYyNjc5NzAxOTRiNGE5ZTNlYTNjNmIxYzFiNTgwXzUzMA_79a4c7a8-234f-42a8-b708-f8f393f974a0">18</ix:nonFraction> million shares related to stock options, as the exercise price of these options was greater than the average market value of the Company's stock.</ix:continuation> </span></div><div style="text-indent:18pt"><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_208"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">16.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzYwMzc_2f21aba2-60b7-4cdd-8185-9e038a40c431" continuedAt="i43f62ae4d7b54cdba04aa3ac30674269" escape="true">Common Stock, Stock Option Plans and Stock Compensation Agreements</ix:nonNumeric></span></div><ix:continuation id="i43f62ae4d7b54cdba04aa3ac30674269" continuedAt="i4fad988ee32145eb8b1cfdea421bead8"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At January&#160;1, 2023, the Company had <ix:nonFraction unitRef="stockbasedcompensationplans" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="0" name="jnj:NumberOfStockBasedCompensationPlans" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzk2_87aeba63-70b7-480e-85b5-a88776562c03">one</ix:nonFraction> stock-based compensation plan. The shares outstanding are for contracts under the Company's 2012 Long-Term Incentive Plan and the 2022 Long-Term Incentive Plan. The 2012 Long-Term Incentive Plan expired on April 26, 2022. All awards (stock options, restricted shares units and performance share units) granted subsequent to that date were under the 2022 Long-Term Incentive Plan. Under the 2022 Long-Term Incentive Plan, the Company may issue up to <ix:nonFraction unitRef="shares" contextRef="i4a0e319fb645457cbe71977be1f29fdb_I20230101" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzU0OTc1NTgyMzI4OA_c3338055-e699-4474-afc5-0949d64f636c">150</ix:nonFraction>&#160;million shares of common stock, of which up to <ix:nonFraction unitRef="shares" contextRef="i4a0e319fb645457cbe71977be1f29fdb_I20230101" decimals="-6" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzU0OTc1NTgyMzgwMg_3015beef-ae9a-438b-96b6-01ea192e02af">110</ix:nonFraction>&#160;million shares of common stock may be issued subject to stock options or stock appreciation rights and up to <ix:nonFraction unitRef="shares" contextRef="i4a0e319fb645457cbe71977be1f29fdb_I20230101" decimals="-6" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzU0OTc1NTgyMzgxNQ_6ee4045e-71a1-43ca-92a1-e6a3726f2055">40</ix:nonFraction>&#160;million shares of common stock may be issued subject to full value awards. Awards will generally be counted on a 1-for-1 basis against the share reserve, provided that if more than <ix:nonFraction unitRef="shares" contextRef="i4a0e319fb645457cbe71977be1f29fdb_I20230101" decimals="-6" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzU0OTc1NTgyMzgyNw_7866b8af-795f-4c40-959d-66c0a32a2513">40</ix:nonFraction>&#160;million full value awards are granted, each full value award in excess of <ix:nonFraction unitRef="shares" contextRef="i4a0e319fb645457cbe71977be1f29fdb_I20230101" decimals="-6" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzU0OTc1NTgyMzgzOQ_e40005fc-76da-4613-918f-7464e0215e7b">40</ix:nonFraction>&#160;million will be counted on a 5-for-1 basis against the share reserve. Shares available for future grants under the 2022 Long-Term Incentive Plan were <ix:nonFraction unitRef="shares" contextRef="i4a0e319fb645457cbe71977be1f29fdb_I20230101" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzczNg_ba9f3780-8f75-4d7b-a262-c8cbb6b6fbac">150</ix:nonFraction> million at the end of fiscal year 2022.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation cost that has been charged against income for these plans was $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzg0OA_84ba1cfe-1ad3-434e-b682-afb017a73802">1,138</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzg1Mg_26d2eda3-9456-4f09-99e1-c1585ae77ea5">1,135</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzg1OQ_1e0fac7c-83a7-4c8e-ac47-85f0e884bbfb">1,005</ix:nonFraction> million for fiscal years 2022, 2021 and 2020, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzEwMTE_3bc68a22-321b-41a9-8602-900821bb4e12">196</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzEwMTU_4ca13973-ec45-440b-85d1-cf2b288d2737">218</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzEwMjI_edacefcf-751e-4592-acc9-8b0d84febf59">210</ix:nonFraction> million for fiscal years 2022, 2021 and 2020, respectively. The Company also recognized additional income tax benefits of $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzExMzM_a4c1773f-33f6-46b0-9cc6-6d911498daaf">282</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzExMzc_e13beef7-b55f-4388-bc23-4538a3b2567d">223</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzExNDQ_ba0cab5b-96ac-44b6-81ff-7fb1b670e3d9">248</ix:nonFraction>&#160;million for fiscal years 2022, 2021 and 2020, respectively, for which options were exercised or restricted shares were vested. The total unrecognized compensation cost was $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzEzMTE_de7219fd-4149-4912-b8e4-0fc928ecac32">939</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzEzMTU_b208b91f-27fe-48fe-bb9f-1f812cbebdcc">862</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="-6" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzEzMjI_01592390-78e7-425b-a929-3bae987885b0">804</ix:nonFraction> million for fiscal years 2022, 2021 and 2020, respectively.  The weighted average period for this cost to be recognized was <ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzE0MzU_44613f99-33e4-49b2-bfca-4b6105aceca4">1.80</ix:nonNumeric>&#160;years, <ix:nonNumeric contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzE0NDU_f5a7c330-1b84-4462-945c-0d20cdeda391">1.78</ix:nonNumeric>&#160;years and <ix:nonNumeric contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzE0NTg_0077ef56-fc12-4935-841b-3c3f30b002d6">1.76</ix:nonNumeric>&#160;years for fiscal years 2022, 2021, and 2020, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i4fad988ee32145eb8b1cfdea421bead8" continuedAt="i85912a5faf8f46ee826e451ba76499ae"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options expire <ix:nonNumeric contextRef="i33dbc6eb904844ee90275f3f8b7ed3ab_D20220103-20230101" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzE4Nzc_07d50dcf-1b06-4481-90dc-8896c92f0322">10</ix:nonNumeric>&#160;years from the date of grant and vest over service periods that range from <ix:nonNumeric contextRef="i8ef74a38473e44019ba37eeec97c7385_D20220103-20230101" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzE5NTU_7da6a409-13b5-43cc-a9bd-f682d8ec81dd">6</ix:nonNumeric> months to <ix:nonNumeric contextRef="i847f3b4e40ed4892b6cd1c9603a89184_D20220103-20230101" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzE5NjE_a417d36e-d982-4529-91d6-ea6ee0e68148">4</ix:nonNumeric> years.  All options are granted at the average of the high and low prices of the Company&#8217;s Common Stock on the New York Stock Exchange on the date of grant. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2022, 2021, and 2020 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson&#160;&amp; Johnson options with a life of 2&#160;years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S.&#160;Treasury yield curve in effect at the time of grant.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzYwNTI_6c61339c-8e84-4350-b3b8-7fe595ac47c5" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average fair value of options granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzI3NzM_a891d4d2-cb18-4bae-a97b-625ba50c3598">23.23</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzI3Nzc_a7f06c1a-8cda-44bf-898f-8436dcf7c163">20.86</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzI3ODQ_d2fe85e9-9c1f-446d-a79f-dbb154a6094a">16.42</ix:nonFraction>, in fiscal years 2022, 2021 and 2020, respectively.  The fair value was estimated based on the weighted average assumptions of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"></td><td style="width:56.819%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.409%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.576%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.411%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzEtMS0xLTEtODQ0NDQ_89f28300-8865-4a2f-b0a1-5d09a71663e1">1.98</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzEtMy0xLTEtODQ0NDQ_76cf1fac-d55c-4c5a-b268-969bd3d6aafb">0.83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzEtNS0xLTEtODQ0NDQ_0bfc741c-c3a6-4c5e-86cb-eaf09cf21c1a">1.47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzItMS0xLTEtODQ0NDQ_18abb125-9c14-4404-8085-791f4620b130">18.00</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzItMy0xLTEtODQ0NDQ_d06a2da0-7862-4133-9596-f916c4bae56f">18.59</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzItNS0xLTEtODQ0NDQ_43b16a54-6f16-4d3c-8926-9432301fac4c">15.33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzMtMS0xLTEtODQ0NDQ_ae4e84ac-9d22-4835-a593-21718f511e8f">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzMtMy0xLTEtODQ0NDQ_6a688712-12dd-4c91-beef-cd5bfb7ccae8">7.0</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzMtNS0xLTEtODQ0NDQ_9993da22-2a9d-431d-8e31-efe9a1d5621a">7.0</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzQtMS0xLTEtODQ0NDQ_8ea7c69c-efe9-4c67-a5fe-60d80ef7695b">2.70</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzQtMy0xLTEtODQ0NDQ_6222c96a-6bdd-4a8a-9e76-97e56bdb96b3">2.50</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzQtNS0xLTEtODQ0NDQ_d6740b70-3726-48bf-9a42-634c0200bec3">2.60</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzYwNTU_eb16a124-ee68-482d-90a4-c9b3777009a1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Plan as of January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, and changes during the years ending on those dates is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"></td><td style="width:47.322%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.672%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.588%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.570%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(Dollars in Millions) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEtMi0xLTEtODQ0NDQ_6a80bb3c-3ffe-46fc-82f2-33c3024bb786">111,637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEtNC0xLTEtODQ0NDQ_4fb26731-23ee-44f1-8117-a620c6b0180a">105.63</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEtNi0xLTEtODQ0NDQ_db9c2102-09f1-4169-a02d-1986b5277f92">4,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzItMi0xLTEtODQ0NDQ_35eb7cad-53b0-4db8-9d68-12c0f259e92f">20,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzItNC0xLTEtODQ0NDQ_6e855043-ec09-4828-9411-a5e7a6d01d93">151.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzMtMi0xLTEtODQ0NDQ_8b4596cd-40ac-4a79-b2e0-ba0665072374">16,275</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzMtNC0xLTEtODQ0NDQ_52e57a84-d22e-4373-b4bb-cb7488aa0e1c">86.05</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzQtMi0xLTEtODQ0NDQ_348a5dcb-4452-468e-b36d-5495191970a6">1,835</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzQtNC0xLTEtODQ0NDQ_00d6618f-7f32-4934-9ed0-de521438ac63">137.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzUtMi0xLTEtODQ0NDQ_7d4fcec3-892a-4991-9916-6f0b949d5e86">114,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzUtNC0xLTEtODQ0NDQ_da9849e8-98b1-4738-b1b0-c6ddc923901d">116.22</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzUtNi0xLTEtODQ0NDQ_f2e03809-161a-463e-9b70-3d931015bb98">4,703</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzYtMi0xLTEtODQ0NDQ_9196606e-b327-40b4-998f-f6db351cb85e">18,525</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzYtNC0xLTEtODQ0NDQ_aa875bcb-bc7a-4007-a038-006e09578147">164.62</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzctMi0xLTEtODQ0NDQ_f55ef7b7-de0f-4aec-a366-7d77d7974b30">13,248</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzctNC0xLTEtODQ0NDQ_7008a009-b9b2-468c-877c-9875fde72138">97.48</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzgtMi0xLTEtODQ0NDQ_c02947f6-84b8-45de-bbc3-689450deaaa4">2,166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzgtNC0xLTEtODQ0NDQ_351d5c19-2854-459b-83bd-e29cbbb5164d">149.75</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzktMi0xLTEtODQ0NDQ_7adc014b-498d-495e-91f9-dd9b5fa3a05b">117,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzktNC0xLTEtODQ0NDQ_dde023aa-0334-4ba9-9e54-f9fe6aa4d727">125.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzktNi0xLTEtODQ0NDQ_f23dd7c2-7543-4a85-8601-59380293da2e">5,364</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEwLTItMS0xLTg0NDQ0_2daca3db-bac1-44a8-acc9-d6daf4534888">19,809</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEwLTQtMS0xLTg0NDQ0_da56fa10-156a-4a46-9312-d8e34ba246cb">165.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzExLTItMS0xLTg0NDQ0_9442366d-51a3-4c99-992d-537cb1571e17">16,310</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzExLTQtMS0xLTg0NDQ0_f3d875ab-fdff-45df-bd32-fb8b9c36fc2f">100.15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEyLTItMS0xLTg0NDQ0_9733e1e7-19f1-4f3a-a2ac-7a149f1f0793">2,188</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEyLTQtMS0xLTg0NDQ0_8f74c00e-1848-4dc5-ba5f-8ff1e218648f">160.56</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEzLTItMS0xLTg0NDQ0_5b2b5743-f6c0-4784-8548-b39db0ca89c4">118,672</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEzLTQtMS0xLTg0NDQ0_ed0d89f0-9853-48b5-806d-d69910f2d9d9">134.95</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEzLTYtMS0xLTg0NDQ0_25673495-9e82-4829-a602-47affa3a8cf3">4,949</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:nonNumeric></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzMxMDA_0f43d1f4-ed6c-4a5f-8002-f35fde716e13">1,228</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzMxMDQ_746fbe1b-faae-4e53-bf33-13a2b1b8826b">919</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzMxMTE_92d54ce2-aebc-4c31-a31e-c87117fb77a1">1,021</ix:nonFraction> million in fiscal years 2022, 2021 and 2020, respectively.</span></div></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">73</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i85912a5faf8f46ee826e451ba76499ae" continuedAt="i179e03501b1b446fb401b467ff353fce"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzYwNjA_55d6a1e9-b5a5-4b60-a06d-5f504d342aa5" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock options outstanding and exercisable at January&#160;1, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"></td><td style="width:29.132%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.163%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.628%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.217%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.575%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.168%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price Range</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i14d568c675ed410f94bed5ff0929c46a_D20220103-20230101" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo0YjZiNzExZDc0OTc0Mjg0YTJkYTU5MDAxYjYxOWFhZl81_e9d6ad9d-3f7f-4d77-a257-5e76074c26e3">72.54</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i14d568c675ed410f94bed5ff0929c46a_D20220103-20230101" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo0YjZiNzExZDc0OTc0Mjg0YTJkYTU5MDAxYjYxOWFhZl85_d0c0ccc9-c164-4402-9bb7-17fca80440ff">100.48</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a71324ab9d241068eb20d3f9cd41ba3_I20230101" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzItMi0xLTEtODQ0NDQ_d644cc65-8b09-4d00-84ce-2c97242ceeea">17,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i14d568c675ed410f94bed5ff0929c46a_D20220103-20230101" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzItNC0xLTEtODQ0NDQ_75d27d1f-421a-4618-b242-4956ee014c10">1.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1a71324ab9d241068eb20d3f9cd41ba3_I20230101" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzItNi0xLTEtODQ0NDQ_088700f0-45df-4d9e-a8b1-90486187fe72">93.07</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1a71324ab9d241068eb20d3f9cd41ba3_I20230101" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzItOC0xLTEtODQ0NDQ_39fd4c40-9c77-404a-b16e-7e50d05b8dca">17,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1a71324ab9d241068eb20d3f9cd41ba3_I20230101" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzItMTAtMS0xLTg0NDQ0_aed5bd22-c2da-4b3d-b878-bd04f8f28db7">93.07</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="iad9b5fbc5ef141b588c3ee79455a9741_D20220103-20230101" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzMtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjozZjQ0MGNhOTQ0MDg0NjA0OGYxYjc5YmJkYzhhMWJjN181_c7b171dc-536d-4af2-b2fb-38913e719685">101.87</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="iad9b5fbc5ef141b588c3ee79455a9741_D20220103-20230101" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzMtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjozZjQ0MGNhOTQ0MDg0NjA0OGYxYjc5YmJkYzhhMWJjN185_720a495d-6a09-40c8-a61d-e49b6b2df7e3">115.67</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07803580a3e146b98a24a385beff349a_I20230101" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzMtMi0xLTEtODQ0NDQ_0dc2d6fd-822f-434d-bd8e-f044e5bfacb6">22,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="iad9b5fbc5ef141b588c3ee79455a9741_D20220103-20230101" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzMtNC0xLTEtODQ0NDQ_518385b5-acad-466b-9e04-981cfb7d3882">3.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i07803580a3e146b98a24a385beff349a_I20230101" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzMtNi0xLTEtODQ0NDQ_84d23636-d2b3-4e6e-8958-4d40240e48fa">108.78</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i07803580a3e146b98a24a385beff349a_I20230101" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzMtOC0xLTEtODQ0NDQ_99574068-5b90-492d-a10f-1fbe7238197a">22,039</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i07803580a3e146b98a24a385beff349a_I20230101" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzMtMTAtMS0xLTg0NDQ0_2a5d3630-181a-4d1c-be1b-60d8ba408e63">108.78</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i34afa7b8b8a04ccb830c793de735eb10_D20220103-20230101" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzQtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjowY2VhODJjNTRiYzE0MWQ4YmQzYWViMmEwZThkNmNlYV81_39c1f36e-5244-4187-b6a0-fd06f0a1b48a">129.51</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i34afa7b8b8a04ccb830c793de735eb10_D20220103-20230101" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzQtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjowY2VhODJjNTRiYzE0MWQ4YmQzYWViMmEwZThkNmNlYV85_cc47d449-47b9-4618-b18a-af684cac84ca">141.06</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b1e92a43acd42e993eb03a79e248489_I20230101" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzQtMi0xLTEtODQ0NDQ_7bdc8977-7a4d-4588-bce9-26deea76b5e1">24,870</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i34afa7b8b8a04ccb830c793de735eb10_D20220103-20230101" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzQtNC0xLTEtODQ0NDQ_371f7608-5ca2-4877-bdaf-924b7001ad6c">5.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1b1e92a43acd42e993eb03a79e248489_I20230101" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzQtNi0xLTEtODQ0NDQ_5153c216-3850-446a-99f9-1d4b258b29d8">130.88</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i1b1e92a43acd42e993eb03a79e248489_I20230101" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzQtOC0xLTEtODQ0NDQ_72f524d9-f36c-439e-a6bd-f2a219f564d6">24,228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i1b1e92a43acd42e993eb03a79e248489_I20230101" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzQtMTAtMS0xLTg0NDQ0_a3452764-cd47-4e38-b7b3-44d673ac43fe">130.85</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i215808acd76647669f725a762f3598d8_D20220103-20230101" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzUtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjpmNDBlOTc3ZWY3YTc0MDQ3YTBjMTY3OGRjNzg5NjZmOF81_9538f3c7-a6d6-4bb1-84e7-c6fb51ae3304">151.41</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i215808acd76647669f725a762f3598d8_D20220103-20230101" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzUtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjpmNDBlOTc3ZWY3YTc0MDQ3YTBjMTY3OGRjNzg5NjZmOF85_a430832c-5280-435a-9d69-e3f60504d008">164.62</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i354df684ca7745c6aa4c8a3b46276a9b_I20230101" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzUtMi0xLTEtODQ0NDQ_2b55c592-eaef-413a-8d7b-ef280994930a">35,465</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i215808acd76647669f725a762f3598d8_D20220103-20230101" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzUtNC0xLTEtODQ0NDQ_c7e56f0a-53d3-4216-880e-e793a6abdbd1">7.6</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i354df684ca7745c6aa4c8a3b46276a9b_I20230101" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzUtNi0xLTEtODQ0NDQ_c46bff0b-73be-47ea-b648-899ab97535c8">157.75</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i354df684ca7745c6aa4c8a3b46276a9b_I20230101" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzUtOC0xLTEtODQ0NDQ_4eae8ff0-7e39-4745-9839-9e3aec9af1c9">150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i354df684ca7745c6aa4c8a3b46276a9b_I20230101" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzUtMTAtMS0xLTg0NDQ0_667295c3-025f-4193-8a6d-965f94e1c350">156.21</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i4c10dbb3a1594a2d8da6daba7890426e_D20220103-20230101" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzYtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjowNDI4MWI1YWRmZGQ0M2I3OWE2MTVjMWE4Y2MyMzQ5M181_cd5048eb-31bd-4c6c-a356-fe3130695b93">164.63</ix:nonFraction>-$<ix:nonFraction unitRef="usdPerShare" contextRef="i4c10dbb3a1594a2d8da6daba7890426e_D20220103-20230101" decimals="2" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzYtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjowNDI4MWI1YWRmZGQ0M2I3OWE2MTVjMWE4Y2MyMzQ5M185_da30de7b-898f-4d02-8ae1-0798dda183dd">165.89</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf5256f81d8e4f98b3cca09bfe121aef_I20230101" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzYtMi0xLTEtODQ0NDQ_5020bc68-2337-4c71-9a51-8271498e8f93">19,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i4c10dbb3a1594a2d8da6daba7890426e_D20220103-20230101" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzYtNC0xLTEtODQ0NDQ_d0fe8b5d-6664-4d03-924d-1e488f223a5d">9.1</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="idf5256f81d8e4f98b3cca09bfe121aef_I20230101" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzYtNi0xLTEtODQ0NDQ_f113e5f2-b01c-415a-a04b-1d4c26da1473">165.89</ix:nonFraction></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idf5256f81d8e4f98b3cca09bfe121aef_I20230101" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzYtOC0xLTEtODQ0NDQ_4a2f38a7-6a75-4bf0-926b-69606f0ce6ee">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="idf5256f81d8e4f98b3cca09bfe121aef_I20230101" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzYtMTAtMS0xLTg0NDQ0_c51e2d2c-477c-4c78-a94d-58c763d20552">165.89</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzctMi0xLTEtODQ0NDQ_72eb277a-21d1-41ac-a203-f66312e144bc">118,672</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzctNC0xLTEtODQ0NDQ_9ca0a8c8-abcc-4f6b-9d92-25bcff8a994a">5.8</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzctNi0xLTEtODQ0NDQ_71fe86e4-ee6b-43bc-8583-87a349011769">134.95</ix:nonFraction></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzctOC0xLTEtODQ0NDQ_5e61ab88-df33-468a-a0b8-bc0512c5c561">63,661</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="2" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzctMTAtMS0xLTg0NDQ0_8f3ac40f-5b50-4dc4-ae5f-c35da5eb121f">113.06</ix:nonFraction></span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Average contractual life remaining in years.</span></div></ix:nonNumeric><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding at January&#160;2, 2022 and January&#160;3, 2021 were <ix:nonFraction unitRef="shares" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzMzMzY_14d19325-9ed2-4d2e-b3ee-2007f00d5623">117,361</ix:nonFraction> and an average life of <ix:nonNumeric contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzMzNjI_97a3bdd6-64c0-4eab-8675-4d67d35850fe">5.8</ix:nonNumeric> years and <ix:nonFraction unitRef="shares" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="-3" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzMzNzU_26f737eb-4a12-485a-b87a-c9d7f8e01deb">114,250</ix:nonFraction> and an average life of <ix:nonNumeric contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" name="us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzM0MDE_7d88842a-6496-442e-91fc-c0bbd70f07fc">6.0</ix:nonNumeric>&#160;years, respectively. Stock options exercisable at January&#160;2, 2022 and January&#160;3, 2021 were <ix:nonFraction unitRef="shares" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzM0Njk_bf653133-fa8f-4cbd-aca9-361bc807dbd2">62,742</ix:nonFraction> at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzM0OTU_37c37134-9cc6-4a93-95ab-f2e4db656f00">104.42</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzM1MDI_59a0d134-201c-46af-bfdf-db64f1749519">61,289</ix:nonFraction> at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzM1Mjg_19c07c21-3531-4aa7-9205-631023bcdb6a">96.97</ix:nonFraction>, respectively. </span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Share Units and Performance Share Units</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company grants restricted share units which vest over service periods that range from <ix:nonNumeric contextRef="ife13ff98e4674d7694f59286307e1d2d_D20220103-20230101" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durmonth" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzM2ODg_4bee08f0-83e8-4358-adc3-9b49c4ff1ade">6</ix:nonNumeric> months to <ix:nonNumeric contextRef="i3bc3aa29768f417584ae7a6a6eda8f3f_D20220103-20230101" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzM2OTQ_bf5d98e1-445f-49aa-97f6-0afe6f322127">3</ix:nonNumeric> years. The Company also grants performance share units, which are paid in shares of Johnson &amp; Johnson Common Stock after the end of a <ix:nonNumeric contextRef="ie2cad4d651314028b720522ec64631ba_D20220103-20230101" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzYwMzk_5e156df5-82bc-496f-8d2b-5c043fa0c366">three-year</ix:nonNumeric> performance period. Performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The number of shares actually earned at the end of the <ix:nonNumeric contextRef="ie2cad4d651314028b720522ec64631ba_D20220103-20230101" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzYwMzU_3ea33c25-79f8-4750-b6a8-6434268c3a24">three-year</ix:nonNumeric> period will vary, based only on actual performance, from <ix:nonFraction unitRef="number" contextRef="ifb399cca07bf4bf1a81d45b257cf9c08_D20220103-20230101" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzQ2MTA_7630b589-27da-4a90-80fa-396870e8208b">0</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i71da035cf1914f3b9868aecc174233de_D20220103-20230101" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzQ2MTY_ed34259b-8437-4aa9-a357-d577fcc24d5f">200</ix:nonFraction>% of the target number of performance share units granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">. </span></div><div><span><br/></span></div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzYwMzA_c3ba136d-e442-4550-8458-41c719742d43" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted share units and performance share units activity under the Plans as of January&#160;1, 2023 is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"></td><td style="width:55.231%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.611%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.081%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.445%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.032%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Performance Share Units</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i6bc0d59a1f134f84a89b363a070d1183_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzktMi0xLTEtODQ0NDQ_bf926f7c-a410-4e23-b4f0-7ee4ed522fd2">14,122</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iec99756e458a459cb8bef3fdab17c001_I20220102" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzktNC0xLTEtODQ0NDQ_9091b28a-1d9a-4c12-af34-f4c0ab078716">2,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1ec1e614eeb4b98a73fb86f9046cd7d_D20220103-20230101" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzEwLTItMS0xLTg0NDQ0_0c3a2aee-e34d-47d1-8334-bfc94201ee95">5,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ie2cad4d651314028b720522ec64631ba_D20220103-20230101" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzEwLTQtMS0xLTg0NDQ0_3982665a-a380-4a10-887e-489f4740f768">753</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib1ec1e614eeb4b98a73fb86f9046cd7d_D20220103-20230101" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzExLTItMS0xLTg0NDQ0_35fad04f-af0e-416a-8e2a-07cafde36123">4,866</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie2cad4d651314028b720522ec64631ba_D20220103-20230101" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzExLTQtMS0xLTg0NDQ0_1f6ad5d8-55d6-414f-bacb-6d985a7ee755">637</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited/adjusted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ib1ec1e614eeb4b98a73fb86f9046cd7d_D20220103-20230101" decimals="-3" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzEyLTItMS0xLTg0NDQ0_d6703de9-f989-4b93-b6f9-70b33c765e4d">794</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="ie2cad4d651314028b720522ec64631ba_D20220103-20230101" decimals="-3" sign="-" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzEyLTQtMS0xLTg0NDQ0_916302fe-1262-4b84-8b4e-c3b57885dc21">71</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="iab9745c050214279b0fa340682e40433_I20230101" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzEzLTItMS0xLTg0NDQ0_1d8f4745-3c53-42e2-ad03-28c94c849b97">13,616</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i69db6ec00d174b129e0e5cb215633ec0_I20230101" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzEzLTQtMS0xLTg0NDQ0_562ef4a6-5e67-4d27-95b1-d6e76cda1c4c">2,357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average fair value of the restricted share units granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="ib1ec1e614eeb4b98a73fb86f9046cd7d_D20220103-20230101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzQ4Njc_0ea79a1f-a61f-472a-9721-d5ef45aadc99">153.67</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="ibf40cc2fafb74f6c9d2be93eeff661c6_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzQ4NzE_ccc6982a-b5bf-474e-99d3-051d475e901f">152.62</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="iec1fd52e3482447ea1b11486ef26a9be_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzQ4Nzg_34b6bcd3-16c8-4041-a91b-0fc158b49ec2">139.58</ix:nonFraction> in fiscal years 2022, 2021 and 2020, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $<ix:nonFraction unitRef="usd" contextRef="ib1ec1e614eeb4b98a73fb86f9046cd7d_D20220103-20230101" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzUxNzU_36700c93-6a9d-434b-aea7-fbd901e93659">591</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="ibf40cc2fafb74f6c9d2be93eeff661c6_D20210104-20220102" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzUxNzk_44e87d8d-e147-42f8-8acc-9873a5843c2e">611</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="iec1fd52e3482447ea1b11486ef26a9be_D20191230-20210103" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzUxODY_c182ffd0-71a1-4822-9c50-669c40ea5ed9">650</ix:nonFraction> million in 2022, 2021 and 2020, respectively.</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of the performance share units granted was $<ix:nonFraction unitRef="usdPerShare" contextRef="ie2cad4d651314028b720522ec64631ba_D20220103-20230101" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzUyOTY_e5836cce-df5f-4406-9138-eb54d536244b">170.46</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="i2198f462491444aca0da61923b632a27_D20210104-20220102" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzUzMDA_6076a895-db6e-485a-864e-36dc66cbd441">179.35</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="i6ce09bf2900145f1a937004d1c00046f_D20191230-20210103" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzUzMDc_c5d6c04e-9585-4cf9-9eb2-1f5a8b839c0f">160.54</ix:nonFraction> in fiscal years 2022, 2021 and 2020, calculated using the weighted average fair market value for each of the component goals at the date of grant.&#160; </span></div></ix:continuation><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i179e03501b1b446fb401b467ff353fce">The fair values for the sales and earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period.&#160;The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model.&#160;The fair value of performance share units issued was $<ix:nonFraction unitRef="usd" contextRef="ie2cad4d651314028b720522ec64631ba_D20220103-20230101" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzU5Njk_a70dd030-fbac-4686-99d3-3632905dff84">94</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="i2198f462491444aca0da61923b632a27_D20210104-20220102" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzU5NzM_98ff4035-83cf-4ae5-9e30-d3d4cf9ffe54">83</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i6ce09bf2900145f1a937004d1c00046f_D20191230-20210103" decimals="-6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzU5ODA_bbd98027-4105-4649-8bd4-a85e42381460">91</ix:nonFraction> million in fiscal years 2022, 2021 and 2020, respectively.</ix:continuation> </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_214"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">17.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" name="us-gaap:SegmentReportingDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzMyMjM_2a1bbaba-a801-460a-8126-ed52b985d596" continuedAt="i6b95f0f1ebb44baca94e514cca68b4e3" escape="true">Segments of Business* and Geographic Areas</ix:nonNumeric></span></div><div><ix:continuation id="i6b95f0f1ebb44baca94e514cca68b4e3" continuedAt="i3641fb9157e8491eba7a0cccf187463d"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="jnj:SalesBySegmentOfBusinessTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzMyMzc_38a642dc-e217-4226-9862-adaeb09ecba1" continuedAt="iff0b9a0030414a79b276c74be6b33d7b" escape="true"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;22 vs. &#8217;21</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;21 vs. &#8217;20</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSUMER HEALTH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9f84b91d4aae4af0a05f5090f62c6609_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUtMi0xLTEtODQ0NDQ_c799dec2-f446-4b32-82fb-8b250f6126aa">2,782</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i58914e95bbb84bc5a9ea2cb7385bd869_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUtNC0xLTEtODQ0NDQ_f4c0a499-897f-4be3-9b08-48a477a3024e">2,594</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8a784927c1c4189af0712f9727df3f0_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUtNi0xLTEtODQ0NDQ_a43ed9d4-1511-43c6-bc41-268b35af2d5b">2,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9f84b91d4aae4af0a05f5090f62c6609_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUtOC0xLTEtODQ0NDQ_da3fb9bc-aa5c-4525-adc3-2d0f4bd634cb">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i58914e95bbb84bc5a9ea2cb7385bd869_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUtMTAtMS0xLTg0NDQ0_b8550b55-7d48-412c-91c9-553b6a55d0a8">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id4e29289044343a48f06844e7131ac18_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYtMi0xLTEtODQ0NDQ_bb4864bf-d7a1-47b2-bce8-56c9dc500a20">3,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3ee2aa1541c4993ab5a6731b5086c7d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYtNC0xLTEtODQ0NDQ_d46c0e62-bdbc-4d09-816a-8ac82e660f4c">3,034</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2433209091f4b3d9ccc6502e13af23d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYtNi0xLTEtODQ0NDQ_182d8a10-3920-4349-9bcc-b1cbf65602d6">2,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id4e29289044343a48f06844e7131ac18_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYtOC0xLTEtODQ0NDQ_f3bc3a88-65b6-4c02-8a81-c68957f1c846">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3ee2aa1541c4993ab5a6731b5086c7d_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYtMTAtMS0xLTg0NDQ0_bbaf4b0a-deba-4443-a17e-3b1a415370c7">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5735f3b990b141e4a4be776a1cc02da1_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzctMi0xLTEtODQ0NDQ_e132d1c4-ea68-43c9-be45-8932831d882d">6,031</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i62fff57daefb4ad48862e19671a6dc9a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzctNC0xLTEtODQ0NDQ_5ef430cc-90fd-4814-9197-a5b58acf8ce9">5,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i439805017432405eb34a20668de55a4a_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzctNi0xLTEtODQ0NDQ_fdaae01d-5dd3-4388-acf6-fcf7ec12472a">5,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5735f3b990b141e4a4be776a1cc02da1_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzctOC0xLTEtODQ0NDQ_b172b4ae-1505-45a4-b0cc-785e0562e0d3">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i62fff57daefb4ad48862e19671a6dc9a_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzctMTAtMS0xLTg0NDQ0_b004f7bc-e16d-4b70-9edb-524877bc7fe7">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcef65e498e74c66bbc548320bf01eda_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzktMi0xLTEtODQ0NDQ_5291e177-bf92-43c5-bf01-572a48b7414d">2,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56cc8799267a4d1bb446fc871370346d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzktNC0xLTEtODQ0NDQ_0f407ba5-d101-42a2-827a-d4ff30072642">2,400</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id06a8fbb2c854362baef8d48b3e539ec_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzktNi0xLTEtODQ0NDQ_ed3c668b-9efa-4a49-b55f-9ebdfc28aff0">2,350</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifcef65e498e74c66bbc548320bf01eda_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzktOC0xLTEtODQ0NDQ_08b535c7-de9b-4842-972e-6485f130db27">2.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56cc8799267a4d1bb446fc871370346d_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzktMTAtMS0xLTg0NDQ0_69fd76e7-c299-4abe-90ec-87fa80770fc9">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i305f2baf4f5040bfa89c742f613cb693_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwLTItMS0xLTg0NDQ0_45fb07f9-03f7-44b3-9ae8-11ba21b3fbd7">2,015</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bcd6c0066854e439a15990c5325aea0_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwLTQtMS0xLTg0NDQ0_193eb547-a63f-4caa-8fe1-231684bb69c1">2,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife8ad7f9de9f40939e7def44ca83e3cb_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwLTYtMS0xLTg0NDQ0_91327612-de4a-4622-8c97-5248af9c6b15">2,100</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i305f2baf4f5040bfa89c742f613cb693_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwLTgtMS0xLTg0NDQ0_04f95bc7-8684-49a7-b545-e7b57b185831">5.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1bcd6c0066854e439a15990c5325aea0_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwLTEwLTEtMS04NDQ0NA_a018f781-f4aa-401a-b98e-0dfb00bdbac8">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i575246cb13cb4e958a9cd5c6a9682cc2_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExLTItMS0xLTg0NDQ0_55e53e5c-7d0e-4e01-ae7b-dc8f97533222">4,352</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia568e79890ed43dca885e271433dca1d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExLTQtMS0xLTg0NDQ0_78baf9fa-8d7f-4418-b52f-0d794acca6cc">4,541</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6438bc69468141788dc7dd15c2e6f0b1_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExLTYtMS0xLTg0NDQ0_ab49690a-5a63-4f6d-a6ea-3717b0692828">4,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i575246cb13cb4e958a9cd5c6a9682cc2_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExLTgtMS0xLTg0NDQ0_76a882e5-c7b1-479f-a0b2-310117b19809">4.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia568e79890ed43dca885e271433dca1d_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExLTEwLTEtMS04NDQ0NA_85797f68-c7cb-4d3c-a169-1be9f1d948e4">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i740d75bd86104d0c94afefc9b87d51ef_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzLTItMS0xLTg0NDQ0_32ed8c8a-e85b-44e9-8da0-1feeb3c8e8b0">635</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8aff1a3d834643a8840f76c325a3a99f_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzLTQtMS0xLTg0NDQ0_87c072dd-acc4-40ee-8b54-ca2c6e0c4eb7">637</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b07581a92b746fc9cdb03ab06449ec2_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzLTYtMS0xLTg0NDQ0_6008b6d7-4bbb-49be-b1d8-dcfc945d1005">683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i740d75bd86104d0c94afefc9b87d51ef_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzLTgtMS0xLTg0NDQ0_f67a8c98-a9eb-44bc-b576-3eff9726d128">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8aff1a3d834643a8840f76c325a3a99f_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzLTEwLTEtMS04NDQ0NA_f08edfe4-9c09-42ef-a60b-3872964997a7">6.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6514fba7e78484d8e9d6a382b648d8f_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0LTItMS0xLTg0NDQ0_a859fe83-ef29-46c9-afd9-b4bc34b204d8">871</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieef3ea0559af465c8780f85fc9c95f1d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0LTQtMS0xLTg0NDQ0_008ac16d-63d1-418d-974a-b35ad2c62e06">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i187c9f9d5d5349338afe50224cc27c1e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0LTYtMS0xLTg0NDQ0_a8e0213e-adfd-4efb-b0d0-bec30618e7a2">958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id6514fba7e78484d8e9d6a382b648d8f_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0LTgtMS0xLTg0NDQ0_42062e6f-1b7e-49a9-a589-a82082770bba">13.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieef3ea0559af465c8780f85fc9c95f1d_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0LTEwLTEtMS04NDQ0NA_c7887a4b-696d-4663-97c3-a5779a6b6f96">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf17bd3c525a4b3bb0011ec89a64ff51_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1LTItMS0xLTg0NDQ0_f6d74e7a-d974-485d-a118-33f36ac40c4f">1,505</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i193f625c1b214c7793df54d141c36d73_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1LTQtMS0xLTg0NDQ0_8da7b9a6-91b0-4245-a19a-1f6e926e8066">1,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i042187f7809d42bc81ee957ee586ef6b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1LTYtMS0xLTg0NDQ0_87f78c28-b51b-4c41-95be-216e363e8150">1,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaf17bd3c525a4b3bb0011ec89a64ff51_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1LTgtMS0xLTg0NDQ0_3ca3e163-59da-4ed3-9768-d4727c466427">8.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i193f625c1b214c7793df54d141c36d73_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1LTEwLTEtMS04NDQ0NA_30ca8492-f254-4259-a070-9d29dd4438c1">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5671c06ac22418998bf233fa3ac24ff_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3LTItMS0xLTg0NDQ0_e39e2d7f-f3c1-4578-a93b-073c551201c9">357</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f0e48a118f4e0f8d62b1d1fbf833aa_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3LTQtMS0xLTg0NDQ0_ebd99454-b6d8-44a7-bc72-176346ff59a6">378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cebe4ddd2e04f1cb5a741a9533d0a67_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3LTYtMS0xLTg0NDQ0_a66c728c-b8c4-4b0a-b265-66d73f306b8a">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib5671c06ac22418998bf233fa3ac24ff_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3LTgtMS0xLTg0NDQ0_d22acd7f-a13d-49cf-9cf1-19121d2cc21f">5.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie1f0e48a118f4e0f8d62b1d1fbf833aa_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3LTEwLTEtMS04NDQ0NA_a3b770e0-eb43-47e4-96e3-288a139a6bf3">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4fb8ac4e52c9497b82e8cd22bd29d272_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4LTItMS0xLTg0NDQ0_18abe64d-dbf3-4cf9-a276-f7f29c762db5">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i015e212fa198442b8d18e922914d6075_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4LTQtMS0xLTg0NDQ0_bd693f2f-c1ec-47ac-ae11-a0b55a58561a">1,188</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81bd67b3b0634ce4b563b42531da6b02_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4LTYtMS0xLTg0NDQ0_eec68993-5704-43bd-a5c6-fea9db4e3b11">1,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4fb8ac4e52c9497b82e8cd22bd29d272_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4LTgtMS0xLTg0NDQ0_2056ba2d-ef6d-4655-81af-2b6faff09842">7.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i015e212fa198442b8d18e922914d6075_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4LTEwLTEtMS04NDQ0NA_d2122229-b709-4112-ac6e-96451ef90717">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i001c88dc32694c0aa767413204814f97_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5LTItMS0xLTg0NDQ0_aa327ad3-cfd8-4373-8b63-3c6d7c889c40">1,461</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb68778688b84eec8b98dc05b1c73823_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5LTQtMS0xLTg0NDQ0_8d533fa3-e449-410d-8895-b9a82720cc14">1,566</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ee93092fc834bb3890c0d900445063e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5LTYtMS0xLTg0NDQ0_33e395be-d974-498d-9f6f-e1bfc2501e26">1,517</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i001c88dc32694c0aa767413204814f97_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5LTgtMS0xLTg0NDQ0_5e98a1e8-43d6-4390-b758-1e716e612d44">6.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb68778688b84eec8b98dc05b1c73823_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5LTEwLTEtMS04NDQ0NA_d69f9036-7a4f-4536-88bf-08564a799306">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3aa6061cdfda45b48d4a19e23fa32015_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxLTItMS0xLTg0NDQ0_2a698b92-a89f-4fcf-bccf-0c2eb5d3aaf6">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c2531fa73d44239a380b2362f5e121d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxLTQtMS0xLTg0NDQ0_726067d5-2825-44f4-96c9-639839008688">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8578159027f24dcf86568156693183a5_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxLTYtMS0xLTg0NDQ0_8a23477e-1263-4f55-bffa-0295409dd4c7">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3aa6061cdfda45b48d4a19e23fa32015_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxLTgtMS0xLTg0NDQ0_26a30e2f-0dc0-4e30-ad53-d1bab96fd926">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1c2531fa73d44239a380b2362f5e121d_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxLTEwLTEtMS04NDQ0NA_ff9177f4-5d41-4468-bfc9-7c74c695376d">1.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id93ba1dabe3f4b5da204b1077b4518d0_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyLTItMS0xLTg0NDQ0_ad45c121-ea21-4251-a838-51ff053a0d7f">891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bfbe7c9fccc4c64b09c41d52ad70175_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyLTQtMS0xLTg0NDQ0_5ec4d758-4cb6-4848-a1ee-66a1ec6dd7aa">905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i263452e9213e47c886650ce7cb371065_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyLTYtMS0xLTg0NDQ0_136ea39e-a15f-4bfe-8398-f5ef1ed3571d">888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id93ba1dabe3f4b5da204b1077b4518d0_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyLTgtMS0xLTg0NDQ0_ead46394-7870-4f5b-98ff-4538a521a775">1.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3bfbe7c9fccc4c64b09c41d52ad70175_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyLTEwLTEtMS04NDQ0NA_5f682e06-ec83-4a4f-9435-a4f8c1e024a1">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d7ed3b7665e416388b6a9aa612a4869_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzLTItMS0xLTg0NDQ0_ad3fb3b7-3005-46dc-8f50-4dba76a89d32">904</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4896b102e9542ca93ed851ae014915e_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzLTQtMS0xLTg0NDQ0_6ef0940b-b8e5-461a-9254-216c7e6f9b01">917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1269622a495a4e64ad8c2c22a7e91280_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzLTYtMS0xLTg0NDQ0_050e4ebc-67fc-40a1-9825-a299aa3affc9">901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9d7ed3b7665e416388b6a9aa612a4869_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzLTgtMS0xLTg0NDQ0_e9f37236-ce24-47a9-987c-0d96d261a8d0">1.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib4896b102e9542ca93ed851ae014915e_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzLTEwLTEtMS04NDQ0NA_68549e81-36e1-4d95-96ae-84c0b580458e">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fb3b41722c44fb497e08d86ff98bf18_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI1LTItMS0xLTg0NDQ0_5c39e375-d3d7-416e-8b29-e03c46e9b063">475</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1082a9661ae476683c756bbaca58883_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI1LTQtMS0xLTg0NDQ0_f2d67a5f-9a94-4827-954a-103708ff66a4">495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if02a3937e37448db80bbb8a99ffff4dc_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI1LTYtMS0xLTg0NDQ0_161fe8cf-195d-4203-a300-f08fc3123776">480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1fb3b41722c44fb497e08d86ff98bf18_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI1LTgtMS0xLTg0NDQ0_10b6faa0-f7da-4437-9446-b323e4f244f0">4.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib1082a9661ae476683c756bbaca58883_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI1LTEwLTEtMS04NDQ0NA_a52212d9-0378-4c5d-8275-ef219725d0b3">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2292a22d2f6a4e18acba13c92c14b1c3_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI2LTItMS0xLTg0NDQ0_1b371e03-de4e-44c5-b9ef-08df7f63e371">224</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib87733bbde604e8f9bd05fb51223e407_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI2LTQtMS0xLTg0NDQ0_1f71554f-00ea-4d93-af39-50c9e8249eff">243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34a442a0814740f1a1e5b57d6e051977_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI2LTYtMS0xLTg0NDQ0_9b8049c8-9824-4a2e-8bd6-c4a470186801">240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2292a22d2f6a4e18acba13c92c14b1c3_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI2LTgtMS0xLTg0NDQ0_e31a41b3-1a30-4b88-8e7c-0de0ef1f359d">8.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib87733bbde604e8f9bd05fb51223e407_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI2LTEwLTEtMS04NDQ0NA_1ec5c1ef-7cf2-4813-b6c1-fb64722c10fe">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3285a500e83d4e938ed7a18bb07f562d_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI3LTItMS0xLTg0NDQ0_a3986bf0-4553-401f-8aed-9dad9afc14cb">700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3c3b87812e3421384238aff93cefacf_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI3LTQtMS0xLTg0NDQ0_a8760383-9aea-4998-926e-5eaf70fe335d">739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc2c65b893a44bd3a5dff496a5a117bc_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI3LTYtMS0xLTg0NDQ0_5659ac13-3fdb-4238-8628-48dc71a66784">720</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3285a500e83d4e938ed7a18bb07f562d_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI3LTgtMS0xLTg0NDQ0_807ae26c-5ed5-4915-b866-41bb6ad63eb9">5.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3c3b87812e3421384238aff93cefacf_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI3LTEwLTEtMS04NDQ0NA_16bc79bb-194d-4a81-9c3b-4e2de27696d3">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id1ee80a6d40c46f0b266441ca6963f33_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI5LTItMS0xLTg0NDQ0_d055f133-9048-476f-9a93-c12cba364c8f">6,599</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43d7081e6eac4175b0632049d45aea0b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI5LTQtMS0xLTg0NDQ0_3f24d8a0-026c-472c-a5d0-f90854aa3a00">6,516</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb2956c17ea2404b80a4eb00815a6af4_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI5LTYtMS0xLTg0NDQ0_28370584-c663-4583-8aab-92537ef3d282">6,362</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id1ee80a6d40c46f0b266441ca6963f33_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI5LTgtMS0xLTg0NDQ0_2f8b1f86-fb1f-4cb3-99fc-9d60c687fcf5">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i43d7081e6eac4175b0632049d45aea0b_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI5LTEwLTEtMS04NDQ0NA_cce948b3-e05c-45ad-b3f9-6f850a236307">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i88289ceda63741c295f461bebbc818d7_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMwLTItMS0xLTg0NDQ0_580b388b-b870-491c-bf9e-8f3010bd1761">8,354</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie47ee78762394fc48eeb03bbee8192b3_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMwLTQtMS0xLTg0NDQ0_d17e8718-e9c0-472a-83a2-09bb0fe46378">8,519</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id69b428176aa4a3cbe479f87f86f7bbd_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMwLTYtMS0xLTg0NDQ0_04059dd4-26ef-4688-a0ce-b4a337301250">8,088</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i88289ceda63741c295f461bebbc818d7_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMwLTgtMS0xLTg0NDQ0_e6f457cc-caa3-4586-900a-9c23312ed35b">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie47ee78762394fc48eeb03bbee8192b3_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMwLTEwLTEtMS04NDQ0NA_90f13b97-7e8a-4b8b-833e-0f32e4156048">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia324deef03f5433486883e8775658b95_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMxLTItMS0xLTg0NDQ0_93ce1f95-5376-4880-a0ed-f96d24b43a9f">14,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c6099acc42a42639c659499eeee550a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMxLTQtMS0xLTg0NDQ0_0c9d231e-2486-4017-ac68-93974d4fbf8e">15,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieabc073d9ebf4111b8a8d92bdd0b8b7d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMxLTYtMS0xLTg0NDQ0_99f2ca6e-125a-4831-8df9-79bc05123355">14,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ia324deef03f5433486883e8775658b95_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMxLTgtMS0xLTg0NDQ0_430ea938-5a2b-4742-a2a9-9111c44adba6">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c6099acc42a42639c659499eeee550a_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMxLTEwLTEtMS04NDQ0NA_48d27c13-8499-4aad-ba88-9f93b0dbb550">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:189pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:nonNumeric></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><ix:continuation id="i3641fb9157e8491eba7a0cccf187463d" continuedAt="i2522aa280ffc401fb5b39387e7abc63f"><ix:continuation id="iff0b9a0030414a79b276c74be6b33d7b" continuedAt="i6b0ac609e91f4f2e8b47ba802fe63c8e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e88cbad6cbe49bd8e825a7ed41c9c3a_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM1LTItMS0xLTg0NDQ0_4013b410-89d4-412a-9656-7ff119b49bf4">11,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e22bab2b8ce4579a43a60a12cd1a9c5_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM1LTQtMS0xLTg0NDQ0_205c5753-67f7-432f-b2b1-03e17b320726">10,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec93cf328ce84ef3a066a9fa498ab413_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM1LTYtMS0xLTg0NDQ0_017e0967-f36c-4f9d-8022-5885098ce6b3">10,175</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5e88cbad6cbe49bd8e825a7ed41c9c3a_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM1LTgtMS0xLTg0NDQ0_8eb1f59a-b407-4ff7-b835-6557a2325ad5">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4e22bab2b8ce4579a43a60a12cd1a9c5_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM1LTEwLTEtMS04NDQ0NA_b6b4e428-a87a-4f51-9dae-4fb068f09636">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i986b4a68a2bf4fb0ab3a4d6b014ad0b4_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM2LTItMS0xLTg0NDQ0_912790d5-6943-4f1f-83cc-6128fbf6ec5b">5,899</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if74c6a56a65d42e393222e70b8ee3b45_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM2LTQtMS0xLTg0NDQ0_bfade3eb-a9fa-49ed-8842-ddd5423889b8">5,907</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7849117524e141089fc6dba149013836_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM2LTYtMS0xLTg0NDQ0_30f801dd-3777-47a8-87e6-1ff5d5d39bba">4,880</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i986b4a68a2bf4fb0ab3a4d6b014ad0b4_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM2LTgtMS0xLTg0NDQ0_f601dffb-7284-4bc4-acc3-f77fab2b378d">0.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if74c6a56a65d42e393222e70b8ee3b45_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM2LTEwLTEtMS04NDQ0NA_306f79be-5903-4155-bb0c-235c5b874b10">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i397c0bcfffa744e1afc241f015ce8b04_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM3LTItMS0xLTg0NDQ0_fb1404ab-c9da-4571-9151-e248df8bcba8">16,935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if478f7362b5f45038c0ff48e4dd32d76_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM3LTQtMS0xLTg0NDQ0_3405e8bc-60b2-4b4a-8bef-e25732b25428">16,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i002e689e81af4469875bf4167de1a9f3_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM3LTYtMS0xLTg0NDQ0_7db6a9dc-a72c-4b98-a655-94178c6497b1">15,055</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i397c0bcfffa744e1afc241f015ce8b04_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM3LTgtMS0xLTg0NDQ0_bcfaa126-0e3a-4661-ab73-405642a1ebb4">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if478f7362b5f45038c0ff48e4dd32d76_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM3LTEwLTEtMS04NDQ0NA_cb3d00fa-6e84-4ed0-8046-f39941b37a0e">11.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12bc3574823a42a18c54341c7e48ccfd_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM5LTItMS0xLTg0NDQ0_5e496427-d3a9-4384-8c19-1dd6d96da496">1,417</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i72281ed8b429494f9436d47de34888bf_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM5LTQtMS0xLTg0NDQ0_c4476c8b-1dac-48dc-be84-a7680626156f">2,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i39cd91fc937e48888264b49955721321_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM5LTYtMS0xLTg0NDQ0_a7fde4f2-73cc-4c44-bf7a-adb064cb71da">2,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i12bc3574823a42a18c54341c7e48ccfd_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM5LTgtMS0xLTg0NDQ0_fb3f96e0-795b-4ac7-ac79-a69df347a5b1">29.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i72281ed8b429494f9436d47de34888bf_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM5LTEwLTEtMS04NDQ0NA_d4acf813-b693-4730-a9c0-9bbfeb336bb0">19.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i912cb26a60ad460497cb59430e03bcd6_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQwLTItMS0xLTg0NDQ0_a9dcdbff-637d-4056-991c-ad0c4fb04c87">204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4af108e7bc8424987da6ec7762b48a7_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQwLTQtMS0xLTg0NDQ0_1b90b0c9-0ae3-41d8-86ce-97166ebb0413">236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe204b8f9621439b9d7201393c46acc4_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQwLTYtMS0xLTg0NDQ0_0588613e-25d1-4791-82a4-fab1a8ad54a8">346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i912cb26a60ad460497cb59430e03bcd6_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQwLTgtMS0xLTg0NDQ0_2f439b93-0de2-4727-b82a-36005e8a6e55">13.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie4af108e7bc8424987da6ec7762b48a7_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQwLTEwLTEtMS04NDQ0NA_9156d077-384a-426b-8342-291a94757282">31.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b9e7de8698c4e4b8582e62338b3a308_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQxLTItMS0xLTg0NDQ0_3469d887-c0eb-4771-842f-ab21cf631c97">722</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1893a467cc624e79a62e62fec246d121_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQxLTQtMS0xLTg0NDQ0_f05aeaa4-4e2c-41bd-ae2a-37bb63043f2e">935</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50aef40f53704f639eeb4ead4f673ed0_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQxLTYtMS0xLTg0NDQ0_df37f8c4-8866-4de1-867e-f61fecad30ca">893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3b9e7de8698c4e4b8582e62338b3a308_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQxLTgtMS0xLTg0NDQ0_232e9a9c-d5bd-48ae-9a7c-948e4cfd1cb3">22.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1893a467cc624e79a62e62fec246d121_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQxLTEwLTEtMS04NDQ0NA_d7eb8900-3cb5-48e1-bbae-508eab946c06">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i150c9d621d58436592cfc84eadbbd8de_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQyLTItMS0xLTg0NDQ0_d9a3e7ad-f292-4f95-b896-96ea12885cf5">2,343</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cd61c709b4f4822b6b0abb800e70ce2_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQyLTQtMS0xLTg0NDQ0_5a91d3ff-eed8-4380-adf3-e78b8369a32f">3,190</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i07927d37d35247c4ab9e64a048a34675_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQyLTYtMS0xLTg0NDQ0_b921a57a-155c-46bf-911c-cefc1af70f63">3,747</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i150c9d621d58436592cfc84eadbbd8de_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQyLTgtMS0xLTg0NDQ0_3ae462f4-1727-4114-84ac-f7cebdb17fcb">26.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1cd61c709b4f4822b6b0abb800e70ce2_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQyLTEwLTEtMS04NDQ0NA_4b58653b-b986-482b-b872-e89b82d48aeb">14.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idce1aa757100453fbf226e404cf449c5_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ0LTItMS0xLTg0NDQ0_5f308e02-5aab-494e-8eca-5be7b05441ef">1,166</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad404b1e843448c5a861fc281c54f700_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ0LTQtMS0xLTg0NDQ0_274a5a3e-cbd5-4f97-85d3-53f17dd4053b">1,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00d6f86395074f92b284bee5e41b9c56_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ0LTYtMS0xLTg0NDQ0_e9eafd0e-888a-46f0-89de-89484ec8da50">1,155</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idce1aa757100453fbf226e404cf449c5_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ0LTgtMS0xLTg0NDQ0_e56d13b3-679e-4954-895b-c20db3fc93dd">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iad404b1e843448c5a861fc281c54f700_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ0LTEwLTEtMS04NDQ0NA_3a313eaf-f5a2-4d23-9ec3-b755ac04ad09">2.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie59a2dae302645e09d149c7d7a174a78_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ1LTItMS0xLTg0NDQ0_730a83df-500b-4893-b673-b2551bc5693e">1,017</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafa5cf4ed7ac4030baf40b5dbd7736bf_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ1LTQtMS0xLTg0NDQ0_96d81bb3-3971-4629-9570-4f9fb3a5f05d">1,148</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i692eee4c082846c498f4462756e57681_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ1LTYtMS0xLTg0NDQ0_67e7d022-045c-4464-b5b7-c8f10f42d821">1,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie59a2dae302645e09d149c7d7a174a78_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ1LTgtMS0xLTg0NDQ0_58baacc8-b627-4299-a430-789e55bd8229">11.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iafa5cf4ed7ac4030baf40b5dbd7736bf_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ1LTEwLTEtMS04NDQ0NA_d8a9b14e-0d63-4728-b862-a56fa1e2568c">5.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic3834f86e6904624bfc14ea56990f87f_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ2LTItMS0xLTg0NDQ0_662b8181-0eb2-4bc8-98cf-4a79ec3906b0">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i203194712a9c4ff294ad81780e8d8a52_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ2LTQtMS0xLTg0NDQ0_2070d55c-755f-4ac4-9543-4afe39354cfc">2,276</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc9b8fea3634731bf270a2f122b7d2d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ2LTYtMS0xLTg0NDQ0_ffde87e1-1f6b-4ace-bb6c-7e80f1cb2b21">2,243</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic3834f86e6904624bfc14ea56990f87f_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ2LTgtMS0xLTg0NDQ0_87dd9c18-8f92-4efe-96b8-d5e1268371ab">4.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i203194712a9c4ff294ad81780e8d8a52_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ2LTEwLTEtMS04NDQ0NA_633ae063-a28e-4cc8-b299-92320e86e284">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia865193fbf2a4050bbe5db56a5edfd29_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ4LTItMS0xLTg0NDQ0_565cf582-1f34-43bf-b11a-93ed533cff3d">6,388</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ab664701a68493eb072fd6ca439c0a5_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ4LTQtMS0xLTg0NDQ0_18255d32-fa4e-40d2-9fd1-6039a8839da4">5,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16dc654ea1db4b339475642249680907_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ4LTYtMS0xLTg0NDQ0_1a99264e-96ef-405c-8de3-a0a1f9c2bba8">5,240</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia865193fbf2a4050bbe5db56a5edfd29_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ4LTgtMS0xLTg0NDQ0_1b02d0ce-58e2-4d6e-a00f-5df852d5911c">7.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4ab664701a68493eb072fd6ca439c0a5_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ4LTEwLTEtMS04NDQ0NA_7c779d89-81b4-4214-8a68-0f875529f2f1">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80dcf3087ead4df5aeb6e738124670d9_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ5LTItMS0xLTg0NDQ0_15183c46-63df-4dc4-ae92-8e46510465c0">3,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3d161ddece944bf8ad540a6a199f574_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ5LTQtMS0xLTg0NDQ0_7c52724b-d22b-4006-917c-27b49a74b2ab">3,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6fdb567ab044e4fa2b02db9f1115bc1_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ5LTYtMS0xLTg0NDQ0_ef5bf8ef-a842-4470-861e-7774a183e7a1">2,467</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i80dcf3087ead4df5aeb6e738124670d9_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ5LTgtMS0xLTg0NDQ0_dee6d34b-1775-46a4-aa2b-10ec99b2f019">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id3d161ddece944bf8ad540a6a199f574_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ5LTEwLTEtMS04NDQ0NA_d49073a2-8eef-4535-9eae-da5660fcbcf2">29.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaf99c2470714a549d4827198b5e4306_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUwLTItMS0xLTg0NDQ0_7173492d-03e5-4c5f-87b7-f9b4728a116b">9,723</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42f4fa8e366c4d2b8cfaed938a637eae_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUwLTQtMS0xLTg0NDQ0_2e8e1773-1e9d-44ca-a4c7-7f19387cee39">9,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i61655eb3ec9a40bf900bfa9966b2388f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUwLTYtMS0xLTg0NDQ0_21560dcd-5ddb-483a-b8cc-f82d2adeecd2">7,707</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibaf99c2470714a549d4827198b5e4306_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUwLTgtMS0xLTg0NDQ0_25423867-5fbb-4005-b586-8cf0564665f8">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42f4fa8e366c4d2b8cfaed938a637eae_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUwLTEwLTEtMS04NDQ0NA_4caeae10-d638-40b7-9b5a-3368519f57f5">18.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75ed4bc48a164740854aa44ff42c7c43_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUyLTItMS0xLTg0NDQ0_99b1428d-8a27-4093-97b8-53606308d956">1,844</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d721f0119c44c98b11f757b023c30a6_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUyLTQtMS0xLTg0NDQ0_8df390f2-f3d4-4e27-a14d-b3a00c99c3df">1,503</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic03f559a7b2b4eb3ad1bd1999053ca64_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUyLTYtMS0xLTg0NDQ0_5945470a-4164-484d-aa35-31c38029f52c">926</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i75ed4bc48a164740854aa44ff42c7c43_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUyLTgtMS0xLTg0NDQ0_acdb1250-566e-46c5-bf54-63be6fac7676">22.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6d721f0119c44c98b11f757b023c30a6_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUyLTEwLTEtMS04NDQ0NA_dfd851ff-f344-4508-bc71-c3024d4f8a03">62.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i476d6bdc170f480880b6f349fe1d02a4_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUzLTItMS0xLTg0NDQ0_e631ae5a-e14c-4059-8be0-99b79f94448c">824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i655fec7a57304dc5b69e3c08e261ce49_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUzLTQtMS0xLTg0NDQ0_eabda62f-7b83-43f9-b505-309f2246cd29">624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6870ec4af934c098b1c08e0fcc5d5ea_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUzLTYtMS0xLTg0NDQ0_698d46e5-1427-4186-bb8e-10560b9e5510">421</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i476d6bdc170f480880b6f349fe1d02a4_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUzLTgtMS0xLTg0NDQ0_fe0cb30c-ffb1-468f-a69f-a545a3617c3f">32.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i655fec7a57304dc5b69e3c08e261ce49_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUzLTEwLTEtMS04NDQ0NA_e092783d-9c57-46d4-af97-17c8d08a335a">48.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ebfb3cbb91849ffa928740c09fb6845_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU0LTItMS0xLTg0NDQ0_4a4566bb-7cb3-4ab0-806c-def7e0b98a03">2,668</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7187388ca7ef477bb2a513ddc7d152a5_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU0LTQtMS0xLTg0NDQ0_d0159c11-31db-4714-a96f-715942fa376b">2,127</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib767315f9702455d885f117ae21d3c8b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU0LTYtMS0xLTg0NDQ0_01e3c06d-87fa-4085-af73-2dccfefbae47">1,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ebfb3cbb91849ffa928740c09fb6845_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU0LTgtMS0xLTg0NDQ0_e0a65009-0d29-4882-98b0-6304e081d68f">25.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7187388ca7ef477bb2a513ddc7d152a5_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU0LTEwLTEtMS04NDQ0NA_2846118c-243e-4013-9162-003628c203e5">57.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedf85e7c05384372a344804b1789a29f_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU2LTItMS0xLTg0NDQ0_aa02cb44-29cb-4369-b7e1-0f25a45fa1be">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iacae22ebe7674dd6b631866883fc36a3_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU2LTQtMS0xLTg0NDQ0_b7bb4936-aead-487d-be1f-f1baccdeffc7">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide93fb67d26b41bcba491ed0c9028795_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU2LTYtMS0xLTg0NDQ0_aaa288a5-91a7-492d-bea9-c765beed40a9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iedf85e7c05384372a344804b1789a29f_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU2LTgtMS0xLTg0NDQ0_c4a22b17-31d3-4e6a-8af6-b7225d68eb76">18.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5952a4c02d1407ab7d93feadb356126_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU3LTItMS0xLTg0NDQ0_48accda8-6b4c-4fbc-b624-eae09fbccb4d">0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d48aee7697b440ebfe16cb49fadabe5_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU3LTQtMS0xLTg0NDQ0_38fcc9ea-5935-445a-862e-c48c26b70b4d">3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68ae8a2a744646ef8a4dd8027eff0ee1_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU3LTYtMS0xLTg0NDQ0_0f9b34cc-7e6b-41ac-a4ac-adf10c4ab693">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0d48aee7697b440ebfe16cb49fadabe5_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU3LTEwLTEtMS04NDQ0NA_8d7ba171-732d-44c3-b6e7-d9d0be83ee4b">73.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf92bdfac4a45ff8d99efa6eaed94c6_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU4LTItMS0xLTg0NDQ0_d4617a7a-38b6-4ed1-8c8c-98416af42651">17</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a36def101eb47b484d4ee34dde2f395_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU4LTQtMS0xLTg0NDQ0_d434091e-5dd5-434b-a2ba-e3214c818d89">24</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i111650d10ac748e7a9e029ffdde290cd_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU4LTYtMS0xLTg0NDQ0_8622ba87-df5e-4586-84b1-7272ebecef8c">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6cf92bdfac4a45ff8d99efa6eaed94c6_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU4LTgtMS0xLTg0NDQ0_acb3394c-6c89-4dd1-a46c-0e561be5e7c2">28.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i735de00a843942b69ff5f4e4395b0611_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYxLTItMS0xLTg0NDQ0_c0cd2425-9caf-4931-a940-81df1290fc4c">1,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i494446ad1b9140cebb18afa776b08b68_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYxLTQtMS0xLTg0NDQ0_51de5e17-9f14-4c95-86b8-5652db77aac9">2,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib33427d3662a40198bb45dcf433c1468_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYxLTYtMS0xLTg0NDQ0_25e4d5c3-dbc1-48a5-9ee4-384afd71242b">1,735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i735de00a843942b69ff5f4e4395b0611_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYxLTgtMS0xLTg0NDQ0_2f4109d9-6981-4364-8e85-03d5b0548a61">25.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i494446ad1b9140cebb18afa776b08b68_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYxLTEwLTEtMS04NDQ0NA_a21f66cd-0830-4d04-b07e-475c08683a13">29.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if823818df08f47e38c8e54ee1da81441_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYyLTItMS0xLTg0NDQ0_e7b5f17e-3c9a-4483-a542-1b104c7f7cf9">3,769</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9098882055048acb56f0a7daff7b6cc_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYyLTQtMS0xLTg0NDQ0_c48599cf-fc3f-48bd-8754-f4fde25c6e12">3,576</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9abfdce0d16e405883d49726c32f1acb_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYyLTYtMS0xLTg0NDQ0_42e941e5-1b65-46ca-9510-afa5509f9677">1,808</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if823818df08f47e38c8e54ee1da81441_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYyLTgtMS0xLTg0NDQ0_0ff22930-22aa-444c-b7f6-55166406258e">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9098882055048acb56f0a7daff7b6cc_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYyLTEwLTEtMS04NDQ0NA_fa302353-b478-4b4f-bba2-02f24de462cc">97.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddcc1f0bfd31441da630d17bcd07bdd5_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYzLTItMS0xLTg0NDQ0_9642a27c-2971-49ad-9db0-6ff2036de3e1">5,449</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2117a45f239d496da7c89c744b4799cf_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYzLTQtMS0xLTg0NDQ0_70279e3c-b6d0-4d5f-b94f-954ba3eacb9e">5,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic396314e70cc4e8aa30c901f000516c6_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYzLTYtMS0xLTg0NDQ0_b1b3a21b-ed0f-4119-9aeb-76e986106304">3,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iddcc1f0bfd31441da630d17bcd07bdd5_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYzLTgtMS0xLTg0NDQ0_a123dac6-769b-4b5f-928b-9073b482c058">6.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2117a45f239d496da7c89c744b4799cf_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYzLTEwLTEtMS04NDQ0NA_f4429d3a-35dc-43da-95e7-1b24fe919f02">64.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice5729f779d5409483631d4dc721f7d2_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY1LTItMS0xLTg0NDQ0_93b4999d-2263-46e2-8bf6-a4e710c3e79b">120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7789339e6baa4ad0abaa2c19f511a483_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY1LTQtMS0xLTg0NDQ0_431168b8-00a2-4918-9cb4-e7e80fa7d653">634</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92e52543ccad4142906214832c2a1522_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY1LTYtMS0xLTg0NDQ0_b48f4c95-d134-4c64-b4a2-5b43ce58b69a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ice5729f779d5409483631d4dc721f7d2_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY1LTgtMS0xLTg0NDQ0_cd963629-ee3a-408d-aa7e-17a6146062c5">81.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i133db46d59e84bdab73a70f71326e38f_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY2LTItMS0xLTg0NDQ0_e81944e9-a2e2-4fb1-b43d-586b92baa8b3">2,059</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2853f108a89e46679d84a145dc7f721b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY2LTQtMS0xLTg0NDQ0_5eda7096-7bf6-4e9a-a5e0-ebcd0238b5ec">1,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i739fdbf5c9b249b5bb242066485fd13b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY2LTYtMS0xLTg0NDQ0_c764f554-41a2-4e5d-806b-1b11f24330f7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i133db46d59e84bdab73a70f71326e38f_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY2LTgtMS0xLTg0NDQ0_cbb15647-4a5a-43e9-90e8-e97985f0096a">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5e252aba7cdd4ec2a540688ab64830b1_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY3LTItMS0xLTg0NDQ0_a0f89d1e-1e51-46bb-9a4a-d8ec73bbc2c1">2,179</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d36aaa849d34410912a18791f8c1fdc_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY3LTQtMS0xLTg0NDQ0_c0a17d12-b9d2-456d-8789-6b78b89e5c0f">2,385</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65e91319a96348ee87ae160ca65edaff_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY3LTYtMS0xLTg0NDQ0_222d3939-fb16-47da-9654-01acbea90d0e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5e252aba7cdd4ec2a540688ab64830b1_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY3LTgtMS0xLTg0NDQ0_7de9e680-cf46-4eca-a1dc-592ff3a5f8fa">8.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT / rilpivirine</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i681b21f0446d4385936cb77eb4b9dca1_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY5LTItMS0xLTg0NDQ0_4e237308-5ad7-46fb-8ca7-5499c9268a1e">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib410879725f24ae8ba0999c6d06366a5_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY5LTQtMS0xLTg0NDQ0_81d58d74-812a-47f4-90ef-adf3f727f4be">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb843593c464cb18a4c3dacc904ae00_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY5LTYtMS0xLTg0NDQ0_7d2d2aee-dd39-4ea7-bcbf-334b2be67c72">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i681b21f0446d4385936cb77eb4b9dca1_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY5LTgtMS0xLTg0NDQ0_84091358-cff6-4122-84f9-91b9d8ce259d">10.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib410879725f24ae8ba0999c6d06366a5_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY5LTEwLTEtMS04NDQ0NA_9cfcf6e1-3664-446d-8ea6-a3045ead845b">7.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35f94389fa524ab289f01a52a921cf7c_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcwLTItMS0xLTg0NDQ0_02c23b90-7f78-4d8f-843b-980e577c8e53">972</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffe39ec345a94ec18338abc237e01452_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcwLTQtMS0xLTg0NDQ0_0eae857a-6328-427c-8123-64d3addae8d7">953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie433d85e7b6448d19d8075af0de26e2d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcwLTYtMS0xLTg0NDQ0_7269cd01-90c5-4fa1-84bb-106f4e0ae472">920</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i35f94389fa524ab289f01a52a921cf7c_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcwLTgtMS0xLTg0NDQ0_55b8572d-d7ab-4198-9583-1bdba662fe79">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iffe39ec345a94ec18338abc237e01452_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcwLTEwLTEtMS04NDQ0NA_4f6c6006-8fcb-4586-aacd-616dd414f87d">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6bc2c48e4eca4c58b9de0abae4adff22_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcxLTItMS0xLTg0NDQ0_af9867da-728b-4555-b7f7-08bfd28e343f">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44093e5c3a0432f8560133ae4395d30_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcxLTQtMS0xLTg0NDQ0_ca5e1efd-824a-4a3c-9961-e7d4a47ff321">994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf0b6c7689e44b268e1b721f04f9848b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcxLTYtMS0xLTg0NDQ0_04a6563d-dad1-4607-9480-1ac5cfa476b3">964</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6bc2c48e4eca4c58b9de0abae4adff22_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcxLTgtMS0xLTg0NDQ0_2b929410-2aed-4506-8825-6993ff68b807">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib44093e5c3a0432f8560133ae4395d30_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcxLTEwLTEtMS04NDQ0NA_e60a16db-22b8-49ea-bdf4-1326321aae4d">3.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA / PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> /                                              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b87d067ef004f5aafaed64f58162f4d_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzczLTItMS0xLTg0NDQ0_915ee996-cf8d-4283-84a0-fbd6d9346d04">1,494</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41fb3351d90d4979bd4aade9045ceba1_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzczLTQtMS0xLTg0NDQ0_4f4ad68b-ec7c-485d-ac02-56db9082c5a4">1,508</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19991ad08c1340cb8a9f12dfc8fbf112_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzczLTYtMS0xLTg0NDQ0_a3e05de0-d668-4625-b28e-e4af42cdd3b0">1,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5b87d067ef004f5aafaed64f58162f4d_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzczLTgtMS0xLTg0NDQ0_ce05a81c-8006-458d-8dd0-aa0d3498e4f0">1.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i41fb3351d90d4979bd4aade9045ceba1_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzczLTEwLTEtMS04NDQ0NA_a848bfe6-3045-465a-a795-b7fc64f3e2f8">4.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i186ad1cd9a1e4945a51acd1fbe039a6c_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc0LTItMS0xLTg0NDQ0_0e62432f-4040-4af0-b472-6b291507bc0b">449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2534504edb8d464f8ee62a5593a78d54_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc0LTQtMS0xLTg0NDQ0_cbbc3cbb-8f5e-42df-a495-b903a2a934b2">575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f893fb187e464aa1a397a82dad33e8_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc0LTYtMS0xLTg0NDQ0_4bce929a-d034-4b3a-aa46-5663102bdd89">597</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i186ad1cd9a1e4945a51acd1fbe039a6c_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc0LTgtMS0xLTg0NDQ0_1fa04e00-f85f-4290-914a-9bbc7e40657f">21.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2534504edb8d464f8ee62a5593a78d54_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc0LTEwLTEtMS04NDQ0NA_3cba7695-e644-4e9d-b70e-729d015e7b98">3.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffa2c64baab1439f89e0e380d54cb895_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc1LTItMS0xLTg0NDQ0_4388de6c-43e3-4053-b7f5-8ffae6c2829d">1,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33b8737e36dc40e891fd7257c424ab9b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc1LTQtMS0xLTg0NDQ0_fa8e3043-82e4-47a4-93e3-1aa37d8c9352">2,083</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if08b714b754d43ffa7a441ceafdc12db_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc1LTYtMS0xLTg0NDQ0_330b3816-5276-42f7-b306-de5da2340794">2,184</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iffa2c64baab1439f89e0e380d54cb895_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc1LTgtMS0xLTg0NDQ0_1a2c9c3d-df99-409c-b6d9-49333853adb3">6.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i33b8737e36dc40e891fd7257c424ab9b_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc1LTEwLTEtMS04NDQ0NA_7dcc1cb7-ad9c-4bd6-a4ca-b2a7c61e907d">4.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafa49f8cb28444c08b3e7691d9289fd0_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc3LTItMS0xLTg0NDQ0_9ab52602-16a9-40ec-bbcd-20fd4ae7091a">30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b32cf9f39464d33a7bac9a57081607b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc3LTQtMS0xLTg0NDQ0_80a059b4-18a6-4c01-b452-c8b0be075178">66</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifce1d8aac6f64a9e8d3edf11466fbeb0_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc3LTYtMS0xLTg0NDQ0_391c5337-097b-4ef8-a7e3-abf58a7973b2">104</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iafa49f8cb28444c08b3e7691d9289fd0_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc3LTgtMS0xLTg0NDQ0_28eeb197-935f-4da7-92be-07bf03a0f46a">55.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5b32cf9f39464d33a7bac9a57081607b_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc3LTEwLTEtMS04NDQ0NA_83c11b7d-8239-4deb-8673-f0f95036f026">36.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a6257c648ce4c319ca04351b1ac19ca_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc4LTItMS0xLTg0NDQ0_f7bd6155-92d8-4ec3-8d26-6a8a3b329b88">289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd0f4a707d5c4611ba64f2bd6e1a1cbb_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc4LTQtMS0xLTg0NDQ0_fdb664c0-450d-4b4a-84c6-ba191bedb3de">297</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae286eb23a9649dab05aa0c949e37a1e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc4LTYtMS0xLTg0NDQ0_b68e6432-a59a-40c3-93da-98b80254e718">292</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6a6257c648ce4c319ca04351b1ac19ca_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc4LTgtMS0xLTg0NDQ0_21a2ca65-ff1c-4b44-995f-52a5a696838c">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifd0f4a707d5c4611ba64f2bd6e1a1cbb_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc4LTEwLTEtMS04NDQ0NA_0a3035d4-da05-40de-8ad6-83b963d77e99">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d8e4c1f3ded4e2683fd1b1d3d7f2f3c_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc5LTItMS0xLTg0NDQ0_e25c31a3-4b30-478d-bd58-d983a43b32d4">318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4a46b60d378740ab9a53a2c913e6fa9b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc5LTQtMS0xLTg0NDQ0_3c1a7391-37fb-469c-a19d-a9da1a1883e1">363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6008938b9b8142ec828a603dc31c9ad2_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc5LTYtMS0xLTg0NDQ0_902a9cc5-ffd5-4c74-a219-8943bdedf8e7">396</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3d8e4c1f3ded4e2683fd1b1d3d7f2f3c_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc5LTgtMS0xLTg0NDQ0_a4e8e268-bd20-4a49-ac8b-8ae40656ded7">12.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4a46b60d378740ab9a53a2c913e6fa9b_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc5LTEwLTEtMS04NDQ0NA_af8b414f-2621-4efa-87c8-9c75e2de175b">8.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><ix:continuation id="i2522aa280ffc401fb5b39387e7abc63f" continuedAt="i7a76a5db602846c0bc2f555a33cd7478"><ix:continuation id="i6b0ac609e91f4f2e8b47ba802fe63c8e" continuedAt="i5e00ba099ce14e2598362ae958e1822f"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cd9ba3232ba45e7b1a6b4629a8020a2_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgyLTItMS0xLTg0NDQ0_7e1745e2-45df-446d-a2ab-b616c1fb5f90">3,570</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531f3041cd70490aa0a614493a0966a5_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgyLTQtMS0xLTg0NDQ0_1c60584b-00dc-4d2a-a751-48d12be6a031">3,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2c03afbcdc4c75bc0ae9b17f75089b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgyLTYtMS0xLTg0NDQ0_562383ac-1328-402c-a6a9-01084a3c39a6">3,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2cd9ba3232ba45e7b1a6b4629a8020a2_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgyLTgtMS0xLTg0NDQ0_3d623e2a-1796-4532-926d-2b5b51d3ac67">6.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i531f3041cd70490aa0a614493a0966a5_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgyLTEwLTEtMS04NDQ0NA_441eaa8b-92d2-4dc4-9967-70a73205c5e3">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i402fca2f518340d8af0930c93c070ab6_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgzLTItMS0xLTg0NDQ0_61de4603-fb5b-4932-9c4c-3dad3240734b">3,323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e268daebe694083b67a5bd25ccebbaf_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgzLTQtMS0xLTg0NDQ0_f9093954-066a-44d0-bc5d-3b21faed7d79">3,641</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ed046d3cd9f404a967c40585336ae5e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgzLTYtMS0xLTg0NDQ0_3f640f08-d5f9-4977-98b8-a02ac881d494">3,435</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i402fca2f518340d8af0930c93c070ab6_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgzLTgtMS0xLTg0NDQ0_af745640-cefa-4b62-92e2-3865f295a5eb">8.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e268daebe694083b67a5bd25ccebbaf_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgzLTEwLTEtMS04NDQ0NA_1601398b-8820-41b0-87b4-f86d9c12036c">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6d6c31d76c79411d9f1e91f496118539_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg0LTItMS0xLTg0NDQ0_6eb1ef24-6311-40d2-93ce-e126854f6390">6,893</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i89359ce197324e7d8e9b12c16f4d715a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg0LTQtMS0xLTg0NDQ0_5456c2d9-9ed9-4bee-b036-1fba14d822db">6,988</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie38900d6ebb345d29c6d1b684d8bc793_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg0LTYtMS0xLTg0NDQ0_6d9804e6-397c-4e81-846c-6e1f659e56bc">6,526</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6d6c31d76c79411d9f1e91f496118539_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg0LTgtMS0xLTg0NDQ0_00c4fd6e-89d6-4f9c-80b5-e3410fffe461">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i89359ce197324e7d8e9b12c16f4d715a_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg0LTEwLTEtMS04NDQ0NA_394cc3ec-b1bc-4ab3-b7ec-c33f4e31b1a4">7.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA / methylphenidate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ief7ad9c3131d41be987d8486d4ad049b_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg2LTItMS0xLTg0NDQ0_220cba1f-719d-4f11-88d2-55b2be95d434">151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idcc6f1927b774f8d96f04fe0a712fb86_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg2LTQtMS0xLTg0NDQ0_19b2a137-d700-43e4-ba78-abb899ee129c">172</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if22f8c6bf53748f190098078cc426ff1_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg2LTYtMS0xLTg0NDQ0_67b593be-b742-4afb-808d-28e4e76b6bb6">183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ief7ad9c3131d41be987d8486d4ad049b_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg2LTgtMS0xLTg0NDQ0_0701af91-bc97-400c-834d-2647fa9e247b">12.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idcc6f1927b774f8d96f04fe0a712fb86_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg2LTEwLTEtMS04NDQ0NA_27c979fd-925c-41dc-83fc-b914d497f799">5.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6610d754863471e9d5a6fed947d250a_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg3LTItMS0xLTg0NDQ0_06ec4ced-dffe-4fd5-8769-dd8e283b54b6">493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i388399bd3edd4e449f4d93d8915eb54c_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg3LTQtMS0xLTg0NDQ0_c4852a38-0c9a-4223-a66d-86ceda91ba78">495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia806a9dc2927417fa00d06260663112c_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg3LTYtMS0xLTg0NDQ0_8046c0d0-a914-4162-9ed7-849c90e01232">439</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic6610d754863471e9d5a6fed947d250a_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg3LTgtMS0xLTg0NDQ0_71eff16f-00cb-4f9b-9562-4203337d460e">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i388399bd3edd4e449f4d93d8915eb54c_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg3LTEwLTEtMS04NDQ0NA_308b3cfe-894c-4413-b4fc-4df026285862">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie4a41b434b5643ac9706b30fd05f05cc_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg4LTItMS0xLTg0NDQ0_63444b59-9ea4-4d6a-883f-c26db710028b">644</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c01b12144ba4292808074086604f6b9_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg4LTQtMS0xLTg0NDQ0_188a75f4-e700-4dc7-8f34-ad8d67f924ad">667</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icfaa8480658d47aeb19114550474ae8e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg4LTYtMS0xLTg0NDQ0_8ef9cfe5-2656-4938-8c46-f43f2b52d03f">622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie4a41b434b5643ac9706b30fd05f05cc_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg4LTgtMS0xLTg0NDQ0_6b3125c0-002a-4cd1-a412-21bfc2ebbc75">3.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c01b12144ba4292808074086604f6b9_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg4LTEwLTEtMS04NDQ0NA_b41a817f-ca47-405d-ac46-94ad0fa42695">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e93fc3771554eaea942a7d80a2a5191_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkwLTItMS0xLTg0NDQ0_ce55caaf-74ef-4f04-b1cd-59f828e0382a">2,714</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5235c523a314775ab067969dfd06501_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkwLTQtMS0xLTg0NDQ0_de191f51-ca21-43e3-b18d-b10119ebeac3">2,550</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib3d7ae90ffe640d1b0883b71099f3c5c_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkwLTYtMS0xLTg0NDQ0_4eeea559-706f-4c9b-947a-755e9bb014eb">2,314</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e93fc3771554eaea942a7d80a2a5191_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkwLTgtMS0xLTg0NDQ0_34d03487-ef26-44e3-89c8-d153c34a7c46">6.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie5235c523a314775ab067969dfd06501_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkwLTEwLTEtMS04NDQ0NA_8ef11315-85ea-4b21-ace3-f9e0497d0efa">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i03c54db2a9f24834a5cd8e9430746ef9_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkxLTItMS0xLTg0NDQ0_fa2901ba-c79b-4f5d-acc5-aa0b66ed50ce">1,426</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia1925b3bd72f49578ec926bb8b286ea4_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkxLTQtMS0xLTg0NDQ0_2528f8a0-518e-4466-86bb-b5fb0b2b5753">1,472</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifec5634cbb6c4bc397afe138e65efc43_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkxLTYtMS0xLTg0NDQ0_e90e66fb-3541-41d7-8236-5b45091ca667">1,339</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i03c54db2a9f24834a5cd8e9430746ef9_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkxLTgtMS0xLTg0NDQ0_3c5c541e-b4b1-4e0b-915a-f392b8ab8a58">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia1925b3bd72f49578ec926bb8b286ea4_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkxLTEwLTEtMS04NDQ0NA_bc6526f5-2233-42c4-903f-14dc76139b8f">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26dc3482b6c144828d2d9c88adc29ae9_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkyLTItMS0xLTg0NDQ0_d6cc3c18-277c-480e-936c-c78d573d4ef0">4,140</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia24bd46b2fd04893b597d1d6c0898eb7_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkyLTQtMS0xLTg0NDQ0_837fd93c-c1af-43ad-8db6-2f1ab3a0f637">4,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic7228601370344a3b7c098e83bbcb756_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkyLTYtMS0xLTg0NDQ0_79915ddb-c699-409a-bd86-648e29d71f54">3,653</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26dc3482b6c144828d2d9c88adc29ae9_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkyLTgtMS0xLTg0NDQ0_9b742b5d-19e2-494a-adbd-1058501eacd5">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia24bd46b2fd04893b597d1d6c0898eb7_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkyLTEwLTEtMS04NDQ0NA_b1dd6d8e-957a-476f-add8-a0710e24f0da">10.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8cc6bf38d4874b188bd7a4fbd673a97a_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk0LTItMS0xLTg0NDQ0_e7b2e066-24a4-4ec1-868d-b218572004f1">257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6698df7c52e241f69da5dfaf96df667e_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk0LTQtMS0xLTg0NDQ0_6bd96698-ac94-4a69-b3eb-7014a24384d4">287</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8692c4c3b564eeaabf2e1b6e509764f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk0LTYtMS0xLTg0NDQ0_86442588-6cc1-47b4-829f-35b9df1b9312">296</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8cc6bf38d4874b188bd7a4fbd673a97a_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk0LTgtMS0xLTg0NDQ0_b6927beb-4c55-4105-9e5b-d06af961ddb4">10.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i6698df7c52e241f69da5dfaf96df667e_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk0LTEwLTEtMS04NDQ0NA_a5e87fa5-e0ef-47b2-95f7-c2e7283f1e27">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb475dbd9dd64c05bd7d3314c41d69fe_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk1LTItMS0xLTg0NDQ0_fb937fbe-d899-4c0a-ba94-7566757ce4a4">228</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe678f07567c458196735fc6dbe00d17_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk1LTQtMS0xLTg0NDQ0_37a5f5e9-ac40-4922-8f14-9ec57c010c14">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i605fa23baf2f4ea78746871328fb7ead_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk1LTYtMS0xLTg0NDQ0_31239aef-05db-4c2d-a1f8-be8a1d93c99a">346</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ifb475dbd9dd64c05bd7d3314c41d69fe_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk1LTgtMS0xLTg0NDQ0_fbbfcaeb-6773-48bf-8d59-bf36b0a029e7">25.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ibe678f07567c458196735fc6dbe00d17_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk1LTEwLTEtMS04NDQ0NA_bba8d681-ff42-4368-ba2e-4eccafc934c8">11.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae81ec5366b14326a0b7f0c13fb74817_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk2LTItMS0xLTg0NDQ0_86189178-6c72-49e6-a901-98de9a3c85bc">485</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9404055d94a45daba90f61bf0fb4da5_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk2LTQtMS0xLTg0NDQ0_ff4a030c-f2bf-4455-882c-c93dbe5db8f4">592</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6f2a17cebf7348ba8a85d601ef95950d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk2LTYtMS0xLTg0NDQ0_ff2fbf26-9281-4230-8619-3a3788b45e0f">642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iae81ec5366b14326a0b7f0c13fb74817_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk2LTgtMS0xLTg0NDQ0_bf6e09bc-8f7a-4b90-af8b-387dcb79dcb7">18.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic9404055d94a45daba90f61bf0fb4da5_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk2LTEwLTEtMS04NDQ0NA_802b0e41-d5d3-4bff-8626-1067f6da762a">7.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b4e7b35d9e54a27b148b95717e09f65_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk4LTItMS0xLTg0NDQ0_f1a84b94-3e7a-4800-a798-19beda89564f">447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i46565c94f13f45f4b15ef2dfc93ac248_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk4LTQtMS0xLTg0NDQ0_724836aa-9e4c-4745-81f2-48575b4c510d">338</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i269786122e034c9a8fd09281eddd8ce6_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk4LTYtMS0xLTg0NDQ0_d0972c94-97f4-4e43-a6c8-b69f054e53b8">298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b4e7b35d9e54a27b148b95717e09f65_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk4LTgtMS0xLTg0NDQ0_769ae52c-6444-43c6-a3bf-346c71815bf0">32.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i46565c94f13f45f4b15ef2dfc93ac248_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk4LTEwLTEtMS04NDQ0NA_3a84efb3-e8b7-4813-ab90-8be30a068b71">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie53f9949f4d84aa5a52762670bfefd4b_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk5LTItMS0xLTg0NDQ0_0810b9ae-6968-4711-bf50-0710f4079ae6">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i324b80e3c3ce440d9637c080549788f0_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk5LTQtMS0xLTg0NDQ0_247cfedb-9f77-4ee8-be5b-3a228dd560fa">1,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84e21a76b60c423bb70648b1c526109e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk5LTYtMS0xLTg0NDQ0_80c22b0c-a691-407d-9be2-1996df98c5d6">1,312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie53f9949f4d84aa5a52762670bfefd4b_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk5LTgtMS0xLTg0NDQ0_54e2a233-a1d7-4371-b124-4a2def17fadf">14.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i324b80e3c3ce440d9637c080549788f0_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk5LTEwLTEtMS04NDQ0NA_ed7138d7-89b3-448c-a8e0-d22dd748e6b6">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i531753cbd8df46a191a33e3a9070c38f_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMC0yLTEtMS04NDQ0NA_38639408-e9f5-4118-bab3-cbb4b777a86a">1,623</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26f47936bebf4e8e931a42d37ff16544_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMC00LTEtMS04NDQ0NA_98ea4761-fb2e-4edc-91c7-367ddf812850">1,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iff8d6fee31d84079a124b85f43dd7a5d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMC02LTEtMS04NDQ0NA_342efb66-fde1-4042-9d13-a73f335b52b9">1,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i531753cbd8df46a191a33e3a9070c38f_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMC04LTEtMS04NDQ0NA_7be8f142-04a0-41a5-a08c-2eb672b9c697">4.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26f47936bebf4e8e931a42d37ff16544_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMC0xMC0xLTEtODQ0NDQ_ed617c49-4ad7-4c65-895b-54762a60a313">6.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i258d249f5434470bb702dca877dce7cc_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMy0yLTEtMS04NDQ0NA_79fd5d2e-b687-49f7-8957-3e09928572e3">6,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1bf95a45f3b7410cb1201a2856109d72_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMy00LTEtMS04NDQ0NA_af26c20a-c505-4dab-aa2d-0810f1a4c81d">5,958</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i262b23b4cfa3413ea822c90957dc8c6b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMy02LTEtMS04NDQ0NA_f8a66ede-c8d8-495a-a183-afdccdf6da0b">5,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i258d249f5434470bb702dca877dce7cc_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMy04LTEtMS04NDQ0NA_5b4e397e-54ad-4f55-b18f-d417d6cf5674">16.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1bf95a45f3b7410cb1201a2856109d72_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMy0xMC0xLTEtODQ0NDQ_b024d80b-a7f9-4c2d-996c-cbd6152d50b4">17.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i24b8ea85287e48b5ab16ce511107e30d_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNC0yLTEtMS04NDQ0NA_a443a8ff-e613-4855-b5eb-fe57871b9699">9,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0d14d3af658b449da07dc0be4f9a9b0d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNC00LTEtMS04NDQ0NA_e77719be-0642-4e8f-9fd5-d7276d1a22eb">8,590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7520de6a9d0449ffb1547564cab682ed_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNC02LTEtMS04NDQ0NA_45cabbb7-2727-4a79-a7e1-8767b4dafbf1">7,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i24b8ea85287e48b5ab16ce511107e30d_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNC04LTEtMS04NDQ0NA_bef3e543-0a9c-4873-b24b-232259d4a0ce">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0d14d3af658b449da07dc0be4f9a9b0d_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNC0xMC0xLTEtODQ0NDQ_a7cde4b8-bb6a-4ce7-8e22-f9ae84a02667">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68e64b453d6c408381dbb9d6a4335a90_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNS0yLTEtMS04NDQ0NA_cad25694-a5d7-4981-86e9-550671d4aed7">15,983</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5c85d4146adf40d590c1b983de215889_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNS00LTEtMS04NDQ0NA_906b86ca-0802-4197-bb99-f5546526c3e7">14,548</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab4f46984eb74afe9365b8352076078e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNS02LTEtMS04NDQ0NA_a6d971f6-d426-4503-8b4a-b6c2fa782a36">12,367</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i68e64b453d6c408381dbb9d6a4335a90_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNS04LTEtMS04NDQ0NA_a65f318f-b141-464f-a14e-bfc70332beba">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5c85d4146adf40d590c1b983de215889_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNS0xMC0xLTEtODQ0NDQ_4a6f3b75-25a1-48ad-a362-09afec6d20dc">17.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i42467f46f4f94427ab2e63069eef5ae8_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNy0yLTEtMS04NDQ0NA_104e9a46-9db8-4997-a773-16684f35bce7">4,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ffac75e48304352a8dfea6d5c6ab3f6_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNy00LTEtMS04NDQ0NA_e7a201cb-2dfb-4f38-ba60-ccab2351b1fd">3,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i646423bb9a524219bf440e4800663ed3_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNy02LTEtMS04NDQ0NA_54eec778-21e6-4061-9631-b7073a5def35">2,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i42467f46f4f94427ab2e63069eef5ae8_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNy04LTEtMS04NDQ0NA_bb2b83e5-2365-46bb-97f4-f6211455faa9">32.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6ffac75e48304352a8dfea6d5c6ab3f6_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNy0xMC0xLTEtODQ0NDQ_dab98830-b831-44e4-8417-48ffb927071f">42.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if600a19a06ac46f1afe1fb53208669c2_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOC0yLTEtMS04NDQ0NA_3038d85e-7f65-416d-9c28-d9462cd763f7">3,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddfa392c8b99451a919767258d532fe5_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOC00LTEtMS04NDQ0NA_147d5390-5404-4e77-99a6-d8195db3efff">2,854</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic353f059b15e42808dfe31fbfa26b20b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOC02LTEtMS04NDQ0NA_879bab56-035d-4d87-ae71-0ee02a42d047">1,958</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if600a19a06ac46f1afe1fb53208669c2_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOC04LTEtMS04NDQ0NA_e9170898-ebcb-4a0d-9979-10bfcbd0eb23">32.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iddfa392c8b99451a919767258d532fe5_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOC0xMC0xLTEtODQ0NDQ_e9194080-00a6-4a4c-9931-1e78284ebb0f">45.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56d81c1fa8cd49908a0537e36e44cae0_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOS0yLTEtMS04NDQ0NA_714ce710-e75d-49c3-ad35-6e7fedcba5d8">7,977</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic0bfc95e5f50496095f0e7adbac02fae_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOS00LTEtMS04NDQ0NA_4b05fd5d-0e8e-4e58-9204-8689670454f8">6,023</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i081324fa191f4ecfb64d5fd21e4897f8_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOS02LTEtMS04NDQ0NA_d2512c5c-6e02-4c0e-908d-aa5c03a44958">4,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i56d81c1fa8cd49908a0537e36e44cae0_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOS04LTEtMS04NDQ0NA_ea997b4e-c34f-44cc-8184-9b5096dfaf5a">32.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic0bfc95e5f50496095f0e7adbac02fae_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOS0xMC0xLTEtODQ0NDQ_cb7f77ca-2cb6-478d-b9f4-b53c9684f19d">43.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic5a747f1894746c18acebe55fcee36be_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMS0yLTEtMS04NDQ0NA_7a932d7b-7559-4d2c-907c-c5f5efc2b80a">968</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia9952f78ff604ce98857b34e7d2d4ee4_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMS00LTEtMS04NDQ0NA_a5f9528b-141d-4daf-bb82-d7e15aae2ac2">813</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56304f6c91134b9ea995c8c26f92fcf8_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMS02LTEtMS04NDQ0NA_08dffd3b-c886-4123-bcb4-c4220845d7eb">583</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic5a747f1894746c18acebe55fcee36be_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMS04LTEtMS04NDQ0NA_a52ecf38-ada1-41ae-93a7-75cf54d09ca1">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia9952f78ff604ce98857b34e7d2d4ee4_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMS0xMC0xLTEtODQ0NDQ_1ba7ec8a-b0f3-4b52-8856-7044f2f152d6">39.3</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1170f44e3e784c13a897d1f33b657d36_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMi0yLTEtMS04NDQ0NA_db11ec2b-92bf-41ed-bac7-543501f967c0">913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1aab7e608c8647bfae8078c104427a5e_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMi00LTEtMS04NDQ0NA_e90d1e6d-13cd-4fec-9b06-d810c03a0613">478</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98cb0d95137a4c3e932962b28dfea7fd_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMi02LTEtMS04NDQ0NA_da3c2120-0386-43d5-9530-e6e58e895d48">176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* *</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7df5c5bd36f4c42bc5a42a86e4787fd_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMy0yLTEtMS04NDQ0NA_73bcde1e-0fcb-4e26-8a5c-26f1d831bef7">1,881</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib995e35deab1419bb10080c3e8bbe15f_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMy00LTEtMS04NDQ0NA_1ebe85ab-6613-424d-aa1a-75e021e90d53">1,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i008fe96bbc464d418ec59e61164bd16f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMy02LTEtMS04NDQ0NA_c6d46e71-10d9-4e49-b5db-f021b9b6c4d7">760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7df5c5bd36f4c42bc5a42a86e4787fd_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMy04LTEtMS04NDQ0NA_509efd45-513c-4f33-bbf2-ccf14cef038c">45.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib995e35deab1419bb10080c3e8bbe15f_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMy0xMC0xLTEtODQ0NDQ_66d22a5a-40c7-45a6-95b6-f919a032a966">70.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e40224a7adc43c8a51c165cb1091d51_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNS0yLTEtMS04NDQ0NA_1ebdb71e-5dbf-448a-a875-1d76ea6e7d5c">1,390</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0e1bf9204c548b1a2ba79c5c9f86b69_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNS00LTEtMS04NDQ0NA_e01eb4bb-4911-4343-9f2f-e296a76b3401">1,747</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1d65c31f1e1e4231a4590f52e12e147f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNS02LTEtMS04NDQ0NA_81a5c4b0-0802-47a7-bbda-c68d48515992">1,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i3e40224a7adc43c8a51c165cb1091d51_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNS04LTEtMS04NDQ0NA_3c61eacb-667d-4d4c-a343-805fe5822a3d">20.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id0e1bf9204c548b1a2ba79c5c9f86b69_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNS0xMC0xLTEtODQ0NDQ_6e747843-46d1-42fe-92d5-6018abf55b2b">4.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8696093b3c14612a5e87f253f041390_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNi0yLTEtMS04NDQ0NA_14bd3573-caad-465d-8eda-c1b71aa351fb">2,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i013ed648148d4e64a510c4039f176525_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNi00LTEtMS04NDQ0NA_a51927a5-839b-4d21-a66c-e61761400339">2,622</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0ee4b03f8ff435d8d7e8b5936462ff2_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNi02LTEtMS04NDQ0NA_4fa878d5-4f24-44fd-a97d-5c2b9d77f664">2,307</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib8696093b3c14612a5e87f253f041390_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNi04LTEtMS04NDQ0NA_b5d020c8-8bcc-44e2-bbc4-78ca799d8410">8.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i013ed648148d4e64a510c4039f176525_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNi0xMC0xLTEtODQ0NDQ_414a996d-ebd9-4422-b048-f14e8cb29354">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1bef826f6694533ac45bf2390d238f4_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNy0yLTEtMS04NDQ0NA_d9a6e5ec-bf54-44f3-90e9-59be854e063f">3,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d1ab414424746e7be5d469d0581e83d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNy00LTEtMS04NDQ0NA_a03e2b5f-dd8b-4049-8e40-aaf26d041b3f">4,369</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98d58d05f93b4a88bda30ee75b9bd330_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNy02LTEtMS04NDQ0NA_a38e5ec3-c2c5-4d8b-b570-138f20711a33">4,128</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie1bef826f6694533ac45bf2390d238f4_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNy04LTEtMS04NDQ0NA_02ab001c-4a25-42b3-8f11-fb54d3b501c2">13.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9d1ab414424746e7be5d469d0581e83d_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNy0xMC0xLTEtODQ0NDQ_bc8d7465-462e-4c1e-bf96-cc6fdb58fe5f">5.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf89a91e03874addb0a5a3f057b8bf3b_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyMy0yLTEtMS04NDQ0NA_51e13b43-9881-4af2-97fb-75f5469cba76">74</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic89356ecf07b40f0a9a2da3ade617700_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyMy00LTEtMS04NDQ0NA_cac887a0-73a2-4278-b67c-1b0c0e72120c">119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idea1ec1749cd4cabbe3791c077d397a5_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyMy02LTEtMS04NDQ0NA_d144c198-f73c-4209-8c94-44c29df81a42">373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="idf89a91e03874addb0a5a3f057b8bf3b_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyMy04LTEtMS04NDQ0NA_9b62340f-5851-44cb-9847-e6b4c7719328">37.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ic89356ecf07b40f0a9a2da3ade617700_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyMy0xMC0xLTEtODQ0NDQ_acc2462d-7af6-4450-a0dc-1fe2cae0debc">68.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee811815defd442b9a2cc33fcd46a0d9_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNC0yLTEtMS04NDQ0NA_8042428b-cc42-4dd3-9df6-5731cac153b4">1,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie657f643b4d84751a89bb88a4ad2046b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNC00LTEtMS04NDQ0NA_0de79e64-ab03-4fe7-89c1-6b05b38ced6f">2,178</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0fc87b939f80405381cdf5826af23b5e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNC02LTEtMS04NDQ0NA_601cb9be-6e1b-4456-a6e0-e0afa2f9c32f">2,097</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iee811815defd442b9a2cc33fcd46a0d9_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNC04LTEtMS04NDQ0NA_ef2bddf9-f871-4cd9-853d-161156d93fdf">22.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie657f643b4d84751a89bb88a4ad2046b_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNC0xMC0xLTEtODQ0NDQ_b9b9f531-4c8e-4600-9b63-5962b1e6cb99">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b389620244e4707b32be2326487bc32_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNS0yLTEtMS04NDQ0NA_20b0bf9e-98c7-4960-b898-6977f72f75cd">1,770</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iefecdd362bfa4d2db19e395e947a0d65_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNS00LTEtMS04NDQ0NA_a1371306-98de-4f8a-86eb-9eb02383d3c9">2,297</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id84af39344ca4fa5a66b03352afc5e18_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNS02LTEtMS04NDQ0NA_3566838f-071c-44b3-b252-390f1240942f">2,470</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7b389620244e4707b32be2326487bc32_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNS04LTEtMS04NDQ0NA_6369267a-dece-46d8-9b0d-8dd74a55ab3c">22.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iefecdd362bfa4d2db19e395e947a0d65_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNS0xMC0xLTEtODQ0NDQ_b71be8da-8cb6-49a2-8e0e-d23a5b6410eb">7.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b76b01e302941c287997d97c3f61777_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNy0yLTEtMS04NDQ0NA_a62e8176-d320-4b03-be4e-393fa7cdc1f9">289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6936c2410a964df4898165a8dde602da_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNy00LTEtMS04NDQ0NA_9e7a7717-4a58-4dff-b250-ca3e42b1ab02">110</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie7bd843dd374433190aa473e3d8f6192_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNy02LTEtMS04NDQ0NA_ae9ecf81-4ec1-4df3-8e97-bb0316b80a8e">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6936c2410a964df4898165a8dde602da_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNy0xMC0xLTEtODQ0NDQ_c29020e7-780f-4086-ba61-c58f74e11445">31.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76995ebc9d3b42ce851ae92a54711982_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOC0yLTEtMS04NDQ0NA_fe7d90a8-1741-4552-8204-051d1b4afd59">283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36a27cd0e7ed41e68d19c477b421f3c0_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOC00LTEtMS04NDQ0NA_75b03d09-3624-49c9-a0c0-9632a26be54d">458</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7001035b825b4a55830f9093152ea514_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOC02LTEtMS04NDQ0NA_e9077542-8f76-4846-a7c9-442f5401e8c3">738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i76995ebc9d3b42ce851ae92a54711982_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOC04LTEtMS04NDQ0NA_f3d1b03d-858e-4a9a-aaa9-7db535e26821">38.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i36a27cd0e7ed41e68d19c477b421f3c0_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOC0xMC0xLTEtODQ0NDQ_6fd61b5f-f60e-4045-bb63-f19097223434">37.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba577ca1802747c39cfd14db4de2c73e_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOS0yLTEtMS04NDQ0NA_927c786e-1028-4965-85f5-e68a89b1347d">571</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59a17dd172ff4c2481abf0f956446b82_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOS00LTEtMS04NDQ0NA_8adcfc51-2ad3-4821-b74e-82ebfe4b33c7">568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9d1cfe8125bf4f15bb0a5e1a59589712_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOS02LTEtMS04NDQ0NA_43da5e3a-4386-4808-9246-65e194753206">821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iba577ca1802747c39cfd14db4de2c73e_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOS04LTEtMS04NDQ0NA_82d8eff2-d704-4d09-8cc9-b61c710df0a1">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i59a17dd172ff4c2481abf0f956446b82_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOS0xMC0xLTEtODQ0NDQ_1443ca14-04ee-4b4b-93ee-e48c3e717990">30.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">77</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><ix:continuation id="i7a76a5db602846c0bc2f555a33cd7478" continuedAt="ia4f0032f4c054590a8200c2b5e4707cb"><ix:continuation id="i5e00ba099ce14e2598362ae958e1822f" continuedAt="i85eb53fb3f0749aba9f0e9e8f2f3ca90"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1fe446820d2747f094272bcdc9f800bf_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMi0yLTEtMS04NDQ0NA_26d0e450-da64-46d9-a657-60b7da539834">2,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b8757a22a8743e3ac6b47bb33abf088_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMi00LTEtMS04NDQ0NA_3fdf9c51-88da-4379-b0d3-aa8372cf9ea1">2,365</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if6d1cb780cac40c392f1b55b06665d46_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMi02LTEtMS04NDQ0NA_6c35d249-7fdc-4096-97d9-e6719afaf6ee">2,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1fe446820d2747f094272bcdc9f800bf_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMi04LTEtMS04NDQ0NA_3ba4df86-2f30-45c6-8bfa-b354011ea18c">0.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b8757a22a8743e3ac6b47bb33abf088_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMi0xMC0xLTEtODQ0NDQ_d57f1648-e67d-49eb-bb9e-c191149ab4fc">10.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a13564b2ced4d028a7c3601115a89a0_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMy0yLTEtMS04NDQ0NA_6b8640d2-1660-4f03-95f2-7f79549fcfe6">1,071</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e26b9b503db42389ed14ff2087d196d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMy00LTEtMS04NDQ0NA_1e337c30-94b2-406c-9f04-eebbef8bcd28">1,085</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i374baaf3b488452d89425765aac44db0_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMy02LTEtMS04NDQ0NA_99c51a07-19de-42b7-bf8e-74d0884593d5">1,015</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0a13564b2ced4d028a7c3601115a89a0_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMy04LTEtMS04NDQ0NA_1ef24e3a-c3da-48a5-ae5b-d91fe296124a">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8e26b9b503db42389ed14ff2087d196d_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMy0xMC0xLTEtODQ0NDQ_8acc573e-af48-4632-90a8-7abf83f4dda9">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77a7e09f6f90410eb6663244cbe7e73d_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNC0yLTEtMS04NDQ0NA_b6f68b10-eaae-4178-8899-65262c504d63">3,417</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cfc4b069b214a88b076bd5e9211de36_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNC00LTEtMS04NDQ0NA_74925cf0-73ac-49f2-bbc4-09812b1c3a03">3,450</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idf16b29572b6423cbbce71268561dc2f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNC02LTEtMS04NDQ0NA_f0ae5502-e09d-46ed-b767-a2e5ce38f045">3,148</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i77a7e09f6f90410eb6663244cbe7e73d_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNC04LTEtMS04NDQ0NA_8b8a010d-0da7-476e-b722-94c0325938cf">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2cfc4b069b214a88b076bd5e9211de36_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNC0xMC0xLTEtODQ0NDQ_bea8d3a2-4910-4b28-82c3-f64639db4c2e">9.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5463962cffff4346b6f757fb352376bf_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNi0yLTEtMS04NDQ0NA_8ca30ed2-f3c5-417b-b83c-7e2580649855">1,132</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4508e19a81e14913a4c1c511d2086478_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNi00LTEtMS04NDQ0NA_20975fa5-1d7f-4bf4-9b98-dc4692df1cfa">1,147</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0255ba511594a8bbe1f7b35cf65502f_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNi02LTEtMS04NDQ0NA_cda0b04f-b91f-4ee3-8fcd-b1c41462b3f5">1,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5463962cffff4346b6f757fb352376bf_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNi04LTEtMS04NDQ0NA_330fe26a-1362-4665-aa90-24e65b8808ea">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4508e19a81e14913a4c1c511d2086478_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNi0xMC0xLTEtODQ0NDQ_71d5f01a-316b-44f3-9458-151936489b05">13.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i22de2e9856b44e04a06ccf411d64efe4_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNy0yLTEtMS04NDQ0NA_5591949e-7866-49e7-b2bd-ff96e4fd376f">651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0dc14570d9244e2aa7a97f84bbea32ad_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNy00LTEtMS04NDQ0NA_44124c28-3f0b-43fc-9776-75b4515375f3">672</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icce2f7bceb104ba68129e1d88ba12479_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNy02LTEtMS04NDQ0NA_39518a41-4b4e-46fc-a3ed-828c894386cc">631</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i22de2e9856b44e04a06ccf411d64efe4_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNy04LTEtMS04NDQ0NA_ca300d1c-4a9a-41c4-83af-8a4fa742b8ac">3.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0dc14570d9244e2aa7a97f84bbea32ad_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNy0xMC0xLTEtODQ0NDQ_9ba69358-7572-43a9-98e9-a78b49323a04">6.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id6137d6c2ae845578e96f2f9558e743f_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzOC0yLTEtMS04NDQ0NA_e0d85bda-0013-44f3-9f05-50210ff5a87f">1,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9b1ade7237d24dd7ab77638d8c40a4e7_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzOC00LTEtMS04NDQ0NA_15c5f165-2e95-4d1d-8132-0f82aaaa5c9e">1,819</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i95b5c4f0629a4cc4aecab891a4bc05f0_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzOC02LTEtMS04NDQ0NA_17ac631d-cf39-499a-9da3-f16cdc51b303">1,639</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="id6137d6c2ae845578e96f2f9558e743f_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzOC04LTEtMS04NDQ0NA_8190bb9a-5fb3-45d0-8427-1f50d061897e">2.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9b1ade7237d24dd7ab77638d8c40a4e7_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzOC0xMC0xLTEtODQ0NDQ_158f9e70-b652-45b7-ac3f-cec62f1efd4d">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb55d931932c4dbfabf0ea3d29fbb324_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MC0yLTEtMS04NDQ0NA_e21022b2-0dfa-4355-b042-cfa2a99dd9b6">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5becc7177bbb4f019eb9d2832933f156_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MC00LTEtMS04NDQ0NA_785078ca-4c88-475c-b786-78c3b8890275">1,056</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic28b731dc2294261b6dbf518da9544b6_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MC02LTEtMS04NDQ0NA_02463ff0-e786-43f8-a9db-cca5b7470bad">955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icb55d931932c4dbfabf0ea3d29fbb324_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MC04LTEtMS04NDQ0NA_8877ae78-3b7c-47d7-8178-1d3fe9a357ce">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5becc7177bbb4f019eb9d2832933f156_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MC0xMC0xLTEtODQ0NDQ_0bc20a98-766a-4284-b5bc-2154a3ee383e">10.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b6cf0ef3640429391dcd90960832aa6_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MS0yLTEtMS04NDQ0NA_e0d493d8-0da4-4dc2-9576-a84665fb5182">218</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a56ab7b9ca24f89852d9e93dffafe9f_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MS00LTEtMS04NDQ0NA_31270250-b7dc-4f36-9ff1-6dadb2be6976">181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8e2a5ed832e47a9b4b8c86beaaf4733_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MS02LTEtMS04NDQ0NA_a8bbfe2e-7ded-45e0-a149-f9bb1f9445bf">138</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2b6cf0ef3640429391dcd90960832aa6_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MS04LTEtMS04NDQ0NA_077fb067-193d-4698-8b5b-ab71ce7d46d6">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0a56ab7b9ca24f89852d9e93dffafe9f_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MS0xMC0xLTEtODQ0NDQ_b6b7db2f-41d6-4aaa-a240-3a514cd370f3">31.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5eb95d7922c64ca28dea90d41bac3081_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Mi0yLTEtMS04NDQ0NA_a5e12cb3-8ce3-4b05-a0ef-ae89c92afc30">1,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if85629f30c724cee9d887e6dd896ce8d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Mi00LTEtMS04NDQ0NA_dc3faf20-801f-457a-8c9c-5ae62e7ba6ff">1,237</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b8655d882ea44638ed3ff1d03bd0dbe_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Mi02LTEtMS04NDQ0NA_a0dcca4a-f0bd-4838-be15-c39cff7750fd">1,093</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5eb95d7922c64ca28dea90d41bac3081_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Mi04LTEtMS04NDQ0NA_b31948ce-e753-469f-ab93-8719364fb8d6">6.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if85629f30c724cee9d887e6dd896ce8d_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Mi0xMC0xLTEtODQ0NDQ_63828be5-c95f-403f-aaca-d90b194a0cf7">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i30916c73190f498bb12adcd4eee7e812_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NC0yLTEtMS04NDQ0NA_283e7928-80e9-4028-8db1-8e82e2fc0526">110</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7b7c39109744471db0921f5a010a74fd_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NC00LTEtMS04NDQ0NA_301ad34c-152a-4d36-bad5-8f6f288d4cbe">163</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3cf850e2559a44ccb6fb87628e4893d5_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NC02LTEtMS04NDQ0NA_d02a0dc8-4230-400c-a3b0-da988b8b829a">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i30916c73190f498bb12adcd4eee7e812_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NC04LTEtMS04NDQ0NA_d34f8360-3378-4e22-ad1e-5f9ca7612da5">32.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i7b7c39109744471db0921f5a010a74fd_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NC0xMC0xLTEtODQ0NDQ_4ca31234-328c-45e7-86e9-7b40056192ab">3.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6c76de98f2c417a87e983700d3295da_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NS0yLTEtMS04NDQ0NA_9a0c23d1-5bca-45e8-be1c-53363aa6d858">202</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5500ee09e8148309c05055c79c1eab2_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NS00LTEtMS04NDQ0NA_bd50f67f-a905-4abe-ae43-559a2a8f7312">232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccddf880ad6748c5b0f867362c1aac4d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NS02LTEtMS04NDQ0NA_cec4a48c-8301-4ffc-80f9-60bb816ecc0c">247</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib6c76de98f2c417a87e983700d3295da_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NS04LTEtMS04NDQ0NA_f3dd1cb4-123d-43a2-a1b2-a2340de43522">12.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib5500ee09e8148309c05055c79c1eab2_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NS0xMC0xLTEtODQ0NDQ_2fad40e6-3faa-4a6c-b7e3-b6e78bdc57fb">5.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i799adb7b649a470ab60c3ff073dc1386_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Ni0yLTEtMS04NDQ0NA_6235179b-ce9c-48c6-b080-7b180d360f60">313</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9059956b7ebd4ef9aa0ca0715ffea91e_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Ni00LTEtMS04NDQ0NA_f171e29f-8913-4f8e-a8fc-09d85bc8c99e">395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36786c954f1b44aabdb08b417155a2f2_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Ni02LTEtMS04NDQ0NA_9eb86da5-8067-44c6-8658-cfef73c7763c">416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i799adb7b649a470ab60c3ff073dc1386_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Ni04LTEtMS04NDQ0NA_cb665933-83d2-4575-acc4-7cc2fd634c5a">20.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i9059956b7ebd4ef9aa0ca0715ffea91e_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Ni0xMC0xLTEtODQ0NDQ_11bcacba-31bd-4cce-8b68-4de5bf997174">5.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8f249bd22be4ccc99f79b41ee68c3cb_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0OS0yLTEtMS04NDQ0NA_245374d7-8b88-417b-aca9-a7cbdec2c604">3,042</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaea127e21314435ea7a422bda430700d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0OS00LTEtMS04NDQ0NA_b0f51bc9-3e1d-4988-96b2-4c721d878236">3,192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i79f7eca78939441fa15ec6298a45d1ef_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0OS02LTEtMS04NDQ0NA_7c390970-08c7-4250-b4bf-408e8ff16e03">3,509</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib8f249bd22be4ccc99f79b41ee68c3cb_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0OS04LTEtMS04NDQ0NA_00eb1ffe-bb65-46b2-8c7f-a088f6ce7440">4.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iaea127e21314435ea7a422bda430700d_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0OS0xMC0xLTEtODQ0NDQ_e77384d1-2a10-4eb5-bc37-9947380dd856">9.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32cf8ca571194576b3812f9911ec7c96_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MC0yLTEtMS04NDQ0NA_dff5179d-ed01-46ef-a20d-5d6c37601bbc">845</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c3d4326ed9749e08f9f55e523f5ee30_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MC00LTEtMS04NDQ0NA_dbb3c444-d5df-4ec7-87af-2c44433ffdae">927</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb734ded22cc4f09a1e7aa403217a9eb_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MC02LTEtMS04NDQ0NA_6e2ab469-5dae-477e-a6f0-3ffcb5786c45">1,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i32cf8ca571194576b3812f9911ec7c96_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MC04LTEtMS04NDQ0NA_bae208d2-7aba-428a-9a02-feff8083ce4f">8.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2c3d4326ed9749e08f9f55e523f5ee30_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MC0xMC0xLTEtODQ0NDQ_0ecfdb3f-e2e8-466b-8b14-54c586ecb045">9.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i475da8e727be45c3b387f78b1fea2e7e_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MS0yLTEtMS04NDQ0NA_8af61a32-5430-42ee-8564-dd3796e53134">3,887</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b6d20e6fbcf404989fa7f5435ba4ba6_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MS00LTEtMS04NDQ0NA_da936132-f6f1-478d-8fc3-28de2bf15279">4,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic976412b06ed475dbb01665551f97bd7_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MS02LTEtMS04NDQ0NA_2e27a1ab-454d-4cb8-8349-e44b94103610">4,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i475da8e727be45c3b387f78b1fea2e7e_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MS04LTEtMS04NDQ0NA_f0b2e58b-9655-43c1-bd6b-11506c394cc6">5.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8b6d20e6fbcf404989fa7f5435ba4ba6_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MS0xMC0xLTEtODQ0NDQ_b97b66e4-481b-49a4-8b85-9ef74e8511e5">9.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib2de02b1a13d4d139855d845acf40789_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1My0yLTEtMS04NDQ0NA_9807407f-30d6-4f33-ae29-b7a50e828a00">2,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if5e8976d4e1a4b71a27811336c8ab1f8_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1My00LTEtMS04NDQ0NA_9112c67c-b03d-4e44-9d56-083f1b7ef987">2,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id7c26f3cd65d4c5d8f2b5bd56c02ed3d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1My02LTEtMS04NDQ0NA_f59791c2-2f0c-4fb2-8f1a-53310b84fa5e">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2de02b1a13d4d139855d845acf40789_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1My04LTEtMS04NDQ0NA_0ff73d2b-17f2-4b5c-8825-8ed603c656f7">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if5e8976d4e1a4b71a27811336c8ab1f8_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1My0xMC0xLTEtODQ0NDQ_7c1b6520-a0ee-4759-9178-7f6de8bdc240">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3f077fb9d5034effb52f4a2b5f9eef57_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NC0yLTEtMS04NDQ0NA_b46552ea-4ca1-4ba8-83e5-bcde695cbf72">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33a26b2938054f1184c11ed6cf4b88f0_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NC00LTEtMS04NDQ0NA_c0a2aab6-40c9-4b92-b495-a2dfe0fbd064">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a88b4bdd8c94764a0107e43c486dc09_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NC02LTEtMS04NDQ0NA_0c63a432-b9ac-4460-a14e-8d6e32055c9d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3f077fb9d5034effb52f4a2b5f9eef57_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NC04LTEtMS04NDQ0NA_a3570819-9a9d-4082-b8cf-6e47165ef665">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i33a26b2938054f1184c11ed6cf4b88f0_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" format="ixt:fixed-zero" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NC0xMC0xLTEtODQ0NDQ_0b84643d-4eb9-4de8-922f-479dcf4a95ce">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie8d8278156114626afb74c2ac5266a22_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NS0yLTEtMS04NDQ0NA_208332fb-2c33-4806-b5ae-f6b85402f11d">2,473</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd8ff0a20174e8aa35746d67cdc6c5a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NS00LTEtMS04NDQ0NA_7e7fe6bf-d72f-4157-be50-ae8173f3b440">2,438</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4cddddd8de4b47ea9ad8c08d1dbcfde7_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NS02LTEtMS04NDQ0NA_bac875d4-a244-4690-857d-74d576453761">2,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie8d8278156114626afb74c2ac5266a22_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NS04LTEtMS04NDQ0NA_6e5dc74b-5c31-4703-8e7f-c671ab51aec7">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5bd8ff0a20174e8aa35746d67cdc6c5a_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NS0xMC0xLTEtODQ0NDQ_4786b29b-b3e3-43f3-be77-dc37939ce06d">4.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA/ INVOKAMET</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ea11b9899164f17b368e2e8e1fd6646_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1Ny0yLTEtMS04NDQ0NA_ea4b8949-69a9-42f7-90a9-58d32ea5f50a">193</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i13c3371fdeb14d998c863d3e43e1fc97_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1Ny00LTEtMS04NDQ0NA_b00d006e-f4b6-4dfb-9853-8167894c3710">308</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieafb2d92ce5b42eba36f9dd9ad33d3a5_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1Ny02LTEtMS04NDQ0NA_76ecff55-3733-43f2-8d05-4d3c509a5e11">564</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8ea11b9899164f17b368e2e8e1fd6646_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1Ny04LTEtMS04NDQ0NA_7e2e21eb-0c6d-4ee7-a059-65743b4e1955">37.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i13c3371fdeb14d998c863d3e43e1fc97_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1Ny0xMC0xLTEtODQ0NDQ_bf0eb0bb-4ca0-4b24-87a5-b58633ac7774">45.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieaf051fa36294b75bbdb2a6a108964d0_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OC0yLTEtMS04NDQ0NA_5efdf70e-7e58-49b6-912a-631d0d4ccf22">255</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id73e900fdc57444dbbceb802f1d0608b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OC00LTEtMS04NDQ0NA_9eaa1907-0520-4b2b-b889-0c334fc226af">254</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib07d526f34e8412e9d6ac51ac9f427f2_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OC02LTEtMS04NDQ0NA_bf6f4743-0f71-4ed6-84d3-791693839565">231</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieaf051fa36294b75bbdb2a6a108964d0_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OC04LTEtMS04NDQ0NA_909ce4b1-bf13-40ab-93b1-95f1ef71d009">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id73e900fdc57444dbbceb802f1d0608b_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OC0xMC0xLTEtODQ0NDQ_d81b1336-ecf2-4774-94d8-22b2b1990936">9.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i81eec297555347958006226c1ad5a577_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OS0yLTEtMS04NDQ0NA_1cef35c1-ac0d-4929-a428-95002a4fc130">448</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iafbedc70de804139afe4d7945d4cb53d_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OS00LTEtMS04NDQ0NA_d7b87782-f3c7-439c-8cfd-1d7270805881">563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcc31dc5500e46db949b0cb3ef157084_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OS02LTEtMS04NDQ0NA_052f55b3-e105-4c03-b40a-470a09fbf6cf">795</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i81eec297555347958006226c1ad5a577_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OS04LTEtMS04NDQ0NA_409856e1-0ac9-4dfa-809b-6c7b387238cf">20.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iafbedc70de804139afe4d7945d4cb53d_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OS0xMC0xLTEtODQ0NDQ_638c9114-d813-4229-8662-e583f2fc42c2">29.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a2ef424a8a8474cac5b9126f26ba070_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2NS0yLTEtMS04NDQ0NA_93811f87-c1c8-4d9e-91ea-1d431d7208e1">376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2d05b9c8081748e2a9f6313aa40cc11b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2NS00LTEtMS04NDQ0NA_02a3f7c4-525e-429b-9f66-d9b41337c2bd">446</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if79c42dff8224bcd8bda45cfd70678a7_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2NS02LTEtMS04NDQ0NA_592fcfb1-01ae-48ca-be14-01814e86a540">600</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i5a2ef424a8a8474cac5b9126f26ba070_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2NS04LTEtMS04NDQ0NA_f1f2f06d-1b70-473f-8f45-69d6ecf1e6cd">15.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2d05b9c8081748e2a9f6313aa40cc11b_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2NS0xMC0xLTEtODQ0NDQ_5eedeaaf-2501-4d24-b4be-e52e770be5b6">25.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2555de19982c4c1c919234a3b7833ea2_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ni0yLTEtMS04NDQ0NA_57f6fdd1-f6ac-456b-865f-ef977266e37d">590</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e55884aa128493da77727ae7c6d1253_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ni00LTEtMS04NDQ0NA_6968b2fe-769c-46ef-bb7a-8ca7e8b6806f">673</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23a8d86b9d8a4084b1e6ddcc45ead16a_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ni02LTEtMS04NDQ0NA_7b74bd8a-12b2-44e0-8c32-2ed6888f2c03">794</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2555de19982c4c1c919234a3b7833ea2_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ni04LTEtMS04NDQ0NA_13a927f4-591b-49c0-b96c-43a4ee8f30cc">12.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i1e55884aa128493da77727ae7c6d1253_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ni0xMC0xLTEtODQ0NDQ_105296fe-69bc-4f2a-a6c1-ca608cf90832">15.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i76a0c1c8ef9849838870a39529fcdb16_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ny0yLTEtMS04NDQ0NA_3b0ec23c-b791-460d-ab4f-071614128d87">966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie5e0a45bdcbf45c7b2fdde90c75f5932_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ny00LTEtMS04NDQ0NA_968b25c7-b492-42e1-93ca-42aed2ba730e">1,119</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50af60fd4c5f4255ac6d02be0a13ae03_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ny02LTEtMS04NDQ0NA_bb46e887-9906-416d-9229-2d20fb306fa2">1,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i76a0c1c8ef9849838870a39529fcdb16_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ny04LTEtMS04NDQ0NA_b60f65ea-4b29-40ca-b34d-80eb1cef0c0a">13.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ie5e0a45bdcbf45c7b2fdde90c75f5932_D20210104-20220102" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ny0xMC0xLTEtODQ0NDQ_8135cd9a-8b2b-4d0c-93eb-16e5f997f318">19.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45a0926568d6467b9669368002f75388_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MC0yLTEtMS04NDQ0NA_23339909-4c7d-4409-810f-3b64853d808d">28,604</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17d037573a5d4222b17c5284accac4ec_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MC00LTEtMS04NDQ0NA_68e275fe-9f71-4439-a8cc-e205f2ac5670">27,954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f866a6e7b4747ab9df0359131844149_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MC02LTEtMS04NDQ0NA_f57129bf-36fc-4f27-90f6-a2f2c48d96c5">25,735</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i45a0926568d6467b9669368002f75388_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MC04LTEtMS04NDQ0NA_1734561e-5340-437c-91e4-88b9e625f46e">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i17d037573a5d4222b17c5284accac4ec_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MC0xMC0xLTEtODQ0NDQ_a442a951-1aef-4b2d-911b-e500f08ac416">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3ac1d092bd684cfe97e775dae9a43281_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MS0yLTEtMS04NDQ0NA_a569ae20-23ee-44c0-a84b-09a07d409d26">23,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3b6d9f05d93342c9ac54a0fd0e292ec8_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MS00LTEtMS04NDQ0NA_e833255f-1fdf-4cbe-8802-628dc7354bb2">23,726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1ddc948c59f44ab9aeceef6ea85eea1b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MS02LTEtMS04NDQ0NA_01b88777-4e28-4ab2-a2e1-01d7c00ba65c">19,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3ac1d092bd684cfe97e775dae9a43281_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MS04LTEtMS04NDQ0NA_b97f7aec-42fe-4ae0-9323-fc9c2965d43c">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3b6d9f05d93342c9ac54a0fd0e292ec8_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MS0xMC0xLTEtODQ0NDQ_43dbea11-b987-450e-a4d3-3081032b3051">22.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3Mi0yLTEtMS04NDQ0NA_54840670-469c-4bf7-b296-4693cdee9f23">52,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3Mi00LTEtMS04NDQ0NA_7d4135db-78aa-4ffe-a64e-41e32c220730">51,680</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i45c63832601e43b1ad4c8f083610e7c3_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3Mi02LTEtMS04NDQ0NA_8962a27f-fbd4-496c-a501-394a28c5ea5e">45,175</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3Mi04LTEtMS04NDQ0NA_a73df45e-5638-49a3-904f-10a2342add11">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3Mi0xMC0xLTEtODQ0NDQ_85a185d4-0bea-4f1e-858a-c1b9197ce52d">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:113pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">78</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><ix:continuation id="ia4f0032f4c054590a8200c2b5e4707cb" continuedAt="i0ba3e61fc8424c5db43e0c252bdfe0b3"><ix:continuation id="i85eb53fb3f0749aba9f0e9e8f2f3ca90" continuedAt="i64cdd9152891449fbaed6f69a1bac82e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MEDTECH*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i850b26f85bd14a8598514f4059d09199_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4NS0yLTEtMS04NDQ0NA_61e39050-ab60-4cf1-9759-681827e32319">2,169</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id55db4e038a84957890427287eb9ab56_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4NS00LTEtMS04NDQ0NA_d1064d66-d585-428e-bdbc-6754ab8483bb">1,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92374c3d2722492fa34458de0e14064c_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4NS02LTEtMS04NDQ0NA_535b2d07-3f33-4ffa-a82a-811fcb1c8e74">1,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i850b26f85bd14a8598514f4059d09199_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4NS04LTEtMS04NDQ0NA_b430fe0a-6b87-4675-8806-a10b4c7e5cef">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id55db4e038a84957890427287eb9ab56_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4NS0xMC0xLTEtODQ0NDQ_a398320b-f908-4d1a-a06f-5598c35e1fc8">26.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i599608cf1f684eed8b209bd530f295e9_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ni0yLTEtMS04NDQ0NA_71fa344a-f286-4c13-80c3-4f6575a86c18">2,131</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i422216cc59db4c0c941301f559702000_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ni00LTEtMS04NDQ0NA_180b8cf9-3887-43e5-984d-2c107f6cd24b">2,135</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20e19e67050949db82566d3868c92ad7_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ni02LTEtMS04NDQ0NA_2fbd5417-c189-4dae-9bdc-38045be0c53f">1,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i599608cf1f684eed8b209bd530f295e9_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ni04LTEtMS04NDQ0NA_3c8408ae-d0ab-4f24-8d10-798937321a37">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i422216cc59db4c0c941301f559702000_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ni0xMC0xLTEtODQ0NDQ_89c485dc-a0dd-4b86-b40c-11c9bc6f6d10">34.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if9afb09ccee54d4abc14d8bb45e5e1bb_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ny0yLTEtMS04NDQ0NA_be2aabd7-56ca-46e2-bc45-c65116899d89">4,300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia20a5ce5890e4d60b4948961eba84c76_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ny00LTEtMS04NDQ0NA_e6db09ce-2995-459f-ac3f-28cd2796713a">3,971</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i00419766ad6e4ea89e37292413d0efab_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ny02LTEtMS04NDQ0NA_9c2d9b33-c5d3-4118-baac-b8409737f349">3,046</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if9afb09ccee54d4abc14d8bb45e5e1bb_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ny04LTEtMS04NDQ0NA_5d9db4c7-c44a-4362-a2f1-4cecf3879b7d">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia20a5ce5890e4d60b4948961eba84c76_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ny0xMC0xLTEtODQ0NDQ_8cee9330-3e9c-4746-9732-a18d981e62a6">30.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa1c27da4bbd4f5bb7644fd70f60b7ff_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4OS0yLTEtMS04NDQ0NA_e24b69b1-a0c8-4ad2-968c-521e1dd8182c">5,321</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6abe4cf6499f44b8864302dc6a141046_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4OS00LTEtMS04NDQ0NA_2e3226a9-64be-41d8-ac1a-7bb6b1be2ad8">5,126</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib44237838e71484c841e5e53a3a8c7bb_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4OS02LTEtMS04NDQ0NA_50f9f73f-7e24-41f3-a7c2-40a06a0e12a7">4,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="iaa1c27da4bbd4f5bb7644fd70f60b7ff_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4OS04LTEtMS04NDQ0NA_b4bd5942-57ba-473e-9265-4843cc3052db">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6abe4cf6499f44b8864302dc6a141046_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4OS0xMC0xLTEtODQ0NDQ_75aa0996-cf11-4094-be8b-f8477acde8a5">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4be2e62190a748c1a9f9858019ad5f2c_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MC0yLTEtMS04NDQ0NA_47815d2b-e874-4f11-b84b-3d47674b8d4a">3,267</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7280243f94ec4714a8ecd07ad5de6b9b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MC00LTEtMS04NDQ0NA_52a04285-8623-4dfa-971d-9c44a268d6b3">3,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bb69c6ba5614a0da3881621e639aaba_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MC02LTEtMS04NDQ0NA_2e06a221-a1e6-4e76-ae72-1b977bcfaa96">2,984</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i4be2e62190a748c1a9f9858019ad5f2c_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MC04LTEtMS04NDQ0NA_1ae22274-4a6c-42a1-a7b7-23b80d540b61">5.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7280243f94ec4714a8ecd07ad5de6b9b_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MC0xMC0xLTEtODQ0NDQ_5f967af4-7644-4a46-ab9a-9d452ba98629">16.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie95a799c54a94247a4f4738e17ef6bdd_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MS0yLTEtMS04NDQ0NA_1337eb46-02df-46a3-82cc-b53ecb3c925a">8,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78fa9c5783f54e208617e980cb82b18c_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MS00LTEtMS04NDQ0NA_7144e5b5-b66e-4aee-9a71-27e40e750550">8,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c722ac2a4a64faa8604869f789d2250_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MS02LTEtMS04NDQ0NA_fe495f6c-2826-44b8-9550-eba8c7482b21">7,763</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie95a799c54a94247a4f4738e17ef6bdd_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MS04LTEtMS04NDQ0NA_354f665b-1ddf-44af-af61-1ad849306d6f">0.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i78fa9c5783f54e208617e980cb82b18c_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MS0xMC0xLTEtODQ0NDQ_9684fa8a-65b8-4393-b1cd-208c902bf3cd">10.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c379bb07b1f423494b9602d42fcbda1_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5My0yLTEtMS04NDQ0NA_c8ec4e9b-0fe0-4feb-b561-fff9995079b5">943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i599b25cf3d4a4566a4fb6560ac142a99_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5My00LTEtMS04NDQ0NA_038e74dc-9d3e-4e04-a87c-7aee0c254605">878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaa4a315b27d540e6a99eb9f14f0a2b22_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5My02LTEtMS04NDQ0NA_688a4d70-b2e5-49f3-b841-cc1c4d5ac8bd">793</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c379bb07b1f423494b9602d42fcbda1_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5My04LTEtMS04NDQ0NA_14e2c9fc-5a52-4bc4-80d6-6d20cd9fb794">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i599b25cf3d4a4566a4fb6560ac142a99_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5My0xMC0xLTEtODQ0NDQ_0349cf47-f4d4-42fd-992f-c4edfdbcc3e6">10.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba96a050bfaa4084a8d2900a2e3a04d5_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NC0yLTEtMS04NDQ0NA_97884a8b-d9a4-48a7-996d-8e87690913f9">571</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i74464a7622714b598ec7ac59bb92daa9_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NC00LTEtMS04NDQ0NA_d50d3019-c886-4785-830e-e4cf4cf6683a">602</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia431b44bdbc04745b1da9bc7e6129763_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NC02LTEtMS04NDQ0NA_a6217f37-10b6-4c8e-a3d5-98b9a9a88f2e">487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="iba96a050bfaa4084a8d2900a2e3a04d5_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NC04LTEtMS04NDQ0NA_cadad67e-71c3-44a0-b6a5-17a4b4042193">5.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i74464a7622714b598ec7ac59bb92daa9_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NC0xMC0xLTEtODQ0NDQ_b2b7039c-a3d3-49ec-90ef-e905ef85b6f7">23.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1c3fa299f6ba45c4b222ae1e49bcebb9_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NS0yLTEtMS04NDQ0NA_a8987f88-be62-43f8-a2ed-211cfc620aee">1,514</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i386d38aa8c394c4f935a4311fd4ef278_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NS00LTEtMS04NDQ0NA_206141f7-1566-4452-bec8-23d82f78108a">1,480</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib5940e0037084662b3d6936dc73b3ee8_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NS02LTEtMS04NDQ0NA_3cbd4b5b-e693-4fcb-9134-81e95a3e111a">1,280</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i1c3fa299f6ba45c4b222ae1e49bcebb9_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NS04LTEtMS04NDQ0NA_56be5386-d91f-4ae6-b9a7-8a7b50164134">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i386d38aa8c394c4f935a4311fd4ef278_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NS0xMC0xLTEtODQ0NDQ_7e7c5df7-5ba5-48bf-afc1-c89e48fba77b">15.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i16a080af195245c883230bee9c30e225_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5Ny0yLTEtMS04NDQ0NA_7b32d3f4-cfd7-4532-b370-b982e42b59da">851</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia55cc74e40ab4d0592d91514f04f2608_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5Ny00LTEtMS04NDQ0NA_6c12aafd-a5dd-4fdc-95a8-af52cb718690">787</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91aa6b32077b4d2497b10c0c7a56e179_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5Ny02LTEtMS04NDQ0NA_1644790f-b1da-4cae-ab8d-076990d42cd9">743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i16a080af195245c883230bee9c30e225_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5Ny04LTEtMS04NDQ0NA_19afbd8c-d3c1-48c3-b6f0-0bac8216b5a1">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia55cc74e40ab4d0592d91514f04f2608_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5Ny0xMC0xLTEtODQ0NDQ_eb989772-6654-4750-9470-582881321e85">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib6a9e1c6f9634d72a1c5c2e943619a42_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OC0yLTEtMS04NDQ0NA_f118f3e4-b93e-480f-a588-b9c76746b089">508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i97e2595ac4db46c4bddda29dbd79cb53_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OC00LTEtMS04NDQ0NA_cc2e8f8f-2256-483a-ad48-377f8c9bb991">538</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icacd0f9bc97a476d9227cb9d73c43f17_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OC02LTEtMS04NDQ0NA_0bc457ba-8d80-420d-b7d9-6009e1c62f98">427</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ib6a9e1c6f9634d72a1c5c2e943619a42_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OC04LTEtMS04NDQ0NA_17cd93e8-8490-47b8-b58a-be258059956b">5.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i97e2595ac4db46c4bddda29dbd79cb53_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OC0xMC0xLTEtODQ0NDQ_03769658-a1a0-4fc9-baf4-8e60790d3b88">26.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i555d0de63ee2467baa26c01abdb6a217_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OS0yLTEtMS04NDQ0NA_be5e423e-6382-4be7-8fca-f6942ef50684">1,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0158c50e3f843b98737f71038b73b04_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OS00LTEtMS04NDQ0NA_21600fe1-2166-4ecf-855f-b3e89f906fc1">1,325</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ad2240e53ec400db99843a0627fa101_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OS02LTEtMS04NDQ0NA_87d22911-6319-4af0-9115-40ee166118af">1,170</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i555d0de63ee2467baa26c01abdb6a217_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OS04LTEtMS04NDQ0NA_edf7fe50-2df5-449e-9c6e-b966ad4f1431">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if0158c50e3f843b98737f71038b73b04_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OS0xMC0xLTEtODQ0NDQ_c91a9552-f8e1-4a4c-bdb1-b8881669127a">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id93d92b03daf447eb4bf22985d9d8c14_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMS0yLTEtMS04NDQ0NA_6998b8e7-09b5-4c24-9fbe-3a3fb22d1b9d">1,882</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i523f9716669b47d5b297828fd6724f6a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMS00LTEtMS04NDQ0NA_c3108c91-a056-4f4d-ae2e-8ca3530880b8">1,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id3648561601548a8b97f7f711182c5f0_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMS02LTEtMS04NDQ0NA_9e9458ff-b7d2-462a-b1a9-bd5e70f895fd">1,648</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id93d92b03daf447eb4bf22985d9d8c14_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMS04LTEtMS04NDQ0NA_a50c179e-645d-49a7-84f7-ef306da79f76">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i523f9716669b47d5b297828fd6724f6a_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMS0xMC0xLTEtODQ0NDQ_81fd7d5c-db13-4e37-bda7-6ca11e09a162">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2a8043dcb8a040d7adcd300412045ab4_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMi0yLTEtMS04NDQ0NA_189c94d2-484a-448b-9a58-fc6f1647cb3e">989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i223e6d03e08f4f5a90b7a1f6a8ac3d0a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMi00LTEtMS04NDQ0NA_39c16baa-282f-4d9f-a670-bf295f048096">1,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i346d453f53cc4ecea306f279831549f3_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMi02LTEtMS04NDQ0NA_4d3ab4cb-a3a0-4fc1-b61d-69a827422093">966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2a8043dcb8a040d7adcd300412045ab4_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMi04LTEtMS04NDQ0NA_cb51fa86-fda5-4721-a6e8-b6a449f240d4">7.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i223e6d03e08f4f5a90b7a1f6a8ac3d0a_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMi0xMC0xLTEtODQ0NDQ_c8b01806-41f1-4bc2-8ea1-afdb18d6b5ff">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if03efae791104d9aa1b01944645a6b01_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMy0yLTEtMS04NDQ0NA_f6e7c514-f05e-47d2-9f48-1343a9ede93b">2,871</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e3094a2457647888f8c0f56ba3fed56_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMy00LTEtMS04NDQ0NA_12c749d4-a6ea-4e72-aa7c-cb1a3d7cc343">2,885</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9250e1cbda2047ae9863cef248995cf3_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMy02LTEtMS04NDQ0NA_e519df2e-ef10-453c-b417-954b43f5de16">2,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if03efae791104d9aa1b01944645a6b01_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMy04LTEtMS04NDQ0NA_1f997a77-cc4b-4425-9d56-44847794f7ec">0.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e3094a2457647888f8c0f56ba3fed56_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMy0xMC0xLTEtODQ0NDQ_d51761e9-b120-4481-b8f6-d7315a90944d">10.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4122251b77234594bcddabafeb5af123_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNS0yLTEtMS04NDQ0NA_76a102ef-7e12-4101-bb7a-0fef426c12a0">1,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie544b42a603147f09a40781c6c42143e_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNS00LTEtMS04NDQ0NA_18927996-6f27-4d3f-843f-97d44b166cfd">1,642</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibd6437ba34c148db8aeccaa67fa06cf2_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNS02LTEtMS04NDQ0NA_74597f9b-227a-48fd-a330-503802a20e42">1,595</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i4122251b77234594bcddabafeb5af123_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNS04LTEtMS04NDQ0NA_d3f10c6e-2038-444c-a6f2-cac144c870d3">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ie544b42a603147f09a40781c6c42143e_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNS0xMC0xLTEtODQ0NDQ_0ffa1d1d-babf-4336-ac5f-9c9d2d7150d3">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida0bc11d3c5748e98275291ec923ccc5_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNi0yLTEtMS04NDQ0NA_795a3c5f-7067-4ccb-97e5-21d6f374026b">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9347c56f2a1444a78a4fc62e6b386a5a_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNi00LTEtMS04NDQ0NA_03dd6511-f1bb-4bbb-af8a-7c9377ca8551">1,256</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01517169bf524cb6924cf818325d7fdc_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNi02LTEtMS04NDQ0NA_03eb7935-5987-4d94-8203-9836b5433122">1,104</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ida0bc11d3c5748e98275291ec923ccc5_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNi04LTEtMS04NDQ0NA_1804fdbe-b85a-4380-b209-1a2fd3d72dcc">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i9347c56f2a1444a78a4fc62e6b386a5a_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNi0xMC0xLTEtODQ0NDQ_a47318d6-82ad-41dd-99f4-b21fb82be0e7">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2160f5b0fbab41038676a89c226cb367_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNy0yLTEtMS04NDQ0NA_763f3480-8d28-4b8f-95fe-7add5442bc4b">2,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23c7667c458748c8904119e1c5445a7e_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNy00LTEtMS04NDQ0NA_9f218403-b52f-453f-9c48-6bd29d9848c7">2,898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id5c1850237ad45cda71fcf02b4cf082e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNy02LTEtMS04NDQ0NA_1cb81f1d-d797-4401-bda0-76e046c585ff">2,699</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i2160f5b0fbab41038676a89c226cb367_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNy04LTEtMS04NDQ0NA_6ae95150-ec75-4e9d-a361-3aa4a9772ca4">1.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i23c7667c458748c8904119e1c5445a7e_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNy0xMC0xLTEtODQ0NDQ_52e565f8-432b-499e-a1cc-6abd7a7b23a9">7.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e62ffa3592b449586bbb8ca2c4d6213_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwOS0yLTEtMS04NDQ0NA_5ce57618-fd5d-47f3-8896-e5d461c58134">3,897</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib476cbca912b416981dd09c3a83db02e_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwOS00LTEtMS04NDQ0NA_e7dcc98a-a220-4a22-b7b0-8d8cb65e3104">3,867</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1dc2f5c56a204d2d8e644eb8886f841e_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwOS02LTEtMS04NDQ0NA_8ced3489-eb56-453c-ad9f-4d4cc9ed5d3e">3,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3e62ffa3592b449586bbb8ca2c4d6213_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwOS04LTEtMS04NDQ0NA_bf44df96-11f2-4efd-aa56-c05fa9264166">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib476cbca912b416981dd09c3a83db02e_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwOS0xMC0xLTEtODQ0NDQ_0878421b-6cfb-40e3-9138-32cb5a157cef">19.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i28c6713f2ac548cc8106299c4be563a8_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMC0yLTEtMS04NDQ0NA_d01068b1-bce1-400c-8899-a988ad7e76bd">5,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id895d721db2044efbb2aef35407c5f24_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMC00LTEtMS04NDQ0NA_b670afee-388c-475f-afeb-7d2a447cc83a">5,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9db4f8d31fdc492993044895704613be_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMC02LTEtMS04NDQ0NA_5d56b4b2-b564-44f2-819c-4b9f50dda634">4,983</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i28c6713f2ac548cc8106299c4be563a8_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMC04LTEtMS04NDQ0NA_c6970919-0b43-4048-b3c2-9d41b6d0a132">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id895d721db2044efbb2aef35407c5f24_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMC0xMC0xLTEtODQ0NDQ_02322258-e637-411a-b125-cfc18cd8ba23">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96bb599ebb2d4c758610207a98846d97_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMS0yLTEtMS04NDQ0NA_ab7feb22-f4b0-4060-8a30-13ccb0e4a5e4">9,690</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2c19ae7f1d1548cf9a2a61003b3d3900_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMS00LTEtMS04NDQ0NA_7e9a51dd-62b7-42e0-8689-19751a636990">9,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1b8a7dbc6dbd43db9aab7933e394d7d5_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMS02LTEtMS04NDQ0NA_f01129b7-1a03-497e-844b-609abfe05726">8,232</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i96bb599ebb2d4c758610207a98846d97_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMS04LTEtMS04NDQ0NA_23fa031e-c987-48f1-9e66-8273a6128ca3">1.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c19ae7f1d1548cf9a2a61003b3d3900_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMS0xMC0xLTEtODQ0NDQ_8abb8fb2-e66f-4237-9243-104f956e3e68">19.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0b2a0ef2af13440cbfde1878f560a53e_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMy0yLTEtMS04NDQ0NA_7b4749ef-c175-4571-b0bc-d1da7f0f6067">1,784</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8a93418c3f9348089a17785066c9ecc3_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMy00LTEtMS04NDQ0NA_c77f1a0b-7df0-4766-880b-0d2483ca8669">1,761</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e5b37a473aa4e9684ab211e4fae10e6_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMy02LTEtMS04NDQ0NA_8bb4c8d8-2f24-49a6-8b19-481b0949e4cd">1,535</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0b2a0ef2af13440cbfde1878f560a53e_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMy04LTEtMS04NDQ0NA_7e927bc0-98ca-45a0-9e8c-5fe37c65c36b">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8a93418c3f9348089a17785066c9ecc3_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMy0xMC0xLTEtODQ0NDQ_f117d601-4fe4-4e11-8d44-11c79306a8ac">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96d0bb9e034b4b778811c7e9a7a32561_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNC0yLTEtMS04NDQ0NA_cfd30496-6abf-4451-a633-6ceb8da5e30d">2,785</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i660f2a9622b542f29df16b4d0065c995_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNC00LTEtMS04NDQ0NA_cce05a1d-8e73-4a94-aaab-55f2ee443f94">2,861</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31bd9ea308664465abdeee40896776b0_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNC02LTEtMS04NDQ0NA_a5bf8ef5-b735-4d48-8435-a344560810ba">2,304</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i96d0bb9e034b4b778811c7e9a7a32561_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNC04LTEtMS04NDQ0NA_37225464-5769-4f83-ac17-389ae33033e8">2.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i660f2a9622b542f29df16b4d0065c995_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNC0xMC0xLTEtODQ0NDQ_d330f37b-5d47-4eca-b064-fc7fe39e6599">24.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69a0f6c8007a466aa040c51aae63e17b_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNS0yLTEtMS04NDQ0NA_fad3962b-e186-4cab-b2c8-0c04902a5b29">4,569</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib47ac25eee8d470cb19fc3f3bad77acb_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNS00LTEtMS04NDQ0NA_dc5877c1-4fd9-4359-9fbb-70afdbe14efd">4,622</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4ee222c80d4f45629294aa4cee852d97_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNS02LTEtMS04NDQ0NA_fdeaaa9f-fdbf-448b-bdab-c35f3e068415">3,839</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i69a0f6c8007a466aa040c51aae63e17b_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNS04LTEtMS04NDQ0NA_f62307fe-f6cb-40a7-a103-f789ce947d90">1.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib47ac25eee8d470cb19fc3f3bad77acb_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNS0xMC0xLTEtODQ0NDQ_e1da4e61-f49b-4758-ad4d-d9e9926f4685">20.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i92b401eaaab44d8a91db95e7fd4cfaea_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNy0yLTEtMS04NDQ0NA_34ae1b15-d841-44a1-9e2a-da21a45e8942">2,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c79a9ae4055493892121d39b7f040e9_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNy00LTEtMS04NDQ0NA_a92d6e88-0b78-4bcf-9494-8c7ba95056f5">2,105</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5659d078f59d475b8e7b8881e5f8c8cc_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNy02LTEtMS04NDQ0NA_a6120208-bbf0-42bc-b8e6-656a94cb82c2">1,714</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i92b401eaaab44d8a91db95e7fd4cfaea_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNy04LTEtMS04NDQ0NA_121d42f0-911b-4693-8127-3f96c8a4974b">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7c79a9ae4055493892121d39b7f040e9_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNy0xMC0xLTEtODQ0NDQ_56005955-7426-4d48-82cd-1a3406ca6c47">22.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e13a27025ab49258fc3f28523703d4b_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOC0yLTEtMS04NDQ0NA_9a2ed0a5-c9ae-4142-8fff-970beefa1e61">3,008</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0797cce295e84999983ff7d4951ae7d4_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOC00LTEtMS04NDQ0NA_defd3451-c48d-43d3-bde1-a0d42dd5431a">3,085</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8ad838c4d37450791faf447300dcf25_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOC02LTEtMS04NDQ0NA_346c6635-04bd-4b5f-98ae-a649b873e26d">2,679</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i0e13a27025ab49258fc3f28523703d4b_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOC04LTEtMS04NDQ0NA_c9656e7a-0429-4593-a423-d8625a588a29">2.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0797cce295e84999983ff7d4951ae7d4_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOC0xMC0xLTEtODQ0NDQ_8887f6e1-0bec-4a3a-abaf-ea59f1a4774a">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i882f781054b24565afcf9d67c24e9a56_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOS0yLTEtMS04NDQ0NA_55523554-ea3d-46c6-a8d9-36e70aa66264">5,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ce0c967e6d044a2b3a5bc24c3067d09_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOS00LTEtMS04NDQ0NA_0ac9607c-8a8e-4082-90de-6d9b150709c3">5,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2fdf8254144adc9c79f0edf1186108_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOS02LTEtMS04NDQ0NA_a3a68850-ff89-405c-af07-35d5650e90b0">4,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i882f781054b24565afcf9d67c24e9a56_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOS04LTEtMS04NDQ0NA_4e425760-6e94-4d5b-b7b5-4d98e0ef7357">1.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5ce0c967e6d044a2b3a5bc24c3067d09_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOS0xMC0xLTEtODQ0NDQ_05c9e961-edc5-44d2-8905-67104c6809ee">18.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0bc0508a06e84d47a8eff2b1d5c74e86_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMS0yLTEtMS04NDQ0NA_262f87a6-c9f3-4be7-a02a-64f99c07f19f">1,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i728978b4bbb44796bdeddaa130466c9e_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMS00LTEtMS04NDQ0NA_5c5364a5-2b31-4630-8a4b-3578412ccbef">1,857</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ae8b4447dde420f8505681fa323ea4a_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMS02LTEtMS04NDQ0NA_c54428b8-8086-47e9-b4bd-85094812040c">1,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0bc0508a06e84d47a8eff2b1d5c74e86_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMS04LTEtMS04NDQ0NA_169d3446-0ba5-45dd-b51f-1c347d7c6904">7.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i728978b4bbb44796bdeddaa130466c9e_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMS0xMC0xLTEtODQ0NDQ_34338550-e50d-4fb8-8fe1-c21cc7b0ad5e">19.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2f8b318c15894833b1cf92df3f7a9fb5_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMi0yLTEtMS04NDQ0NA_b144bbfe-8b01-4aaa-bde9-7e0dfcfd29a2">2,859</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8df5c7b107134f5abf47b44faecc645b_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMi00LTEtMS04NDQ0NA_f0fe4286-7718-4bce-9f02-b93ba21290b6">2,831</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5419094e757b46019b8bd5f8d7e871b4_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMi02LTEtMS04NDQ0NA_f55e155a-30c7-4574-8395-33f77ca2a652">2,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f8b318c15894833b1cf92df3f7a9fb5_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMi04LTEtMS04NDQ0NA_d2e90a63-41d7-4843-ae75-85f79a6b4217">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8df5c7b107134f5abf47b44faecc645b_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMi0xMC0xLTEtODQ0NDQ_94490e01-2285-46a3-90ac-fee5db6f6c82">19.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0940ba1ce2fb4e058d1eb84ccb6c5e03_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMy0yLTEtMS04NDQ0NA_5baa8d6a-d7fc-4b12-8c7a-335234889ae5">4,849</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i06e2030e683e436aa4324bd6a5a14b69_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMy00LTEtMS04NDQ0NA_af034a50-e8f2-44ea-8193-605df3d4addc">4,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic1d0785d36d044d6b08df217279ef868_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMy02LTEtMS04NDQ0NA_0da17c34-1904-4a2b-a65e-21067d4114cf">3,919</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0940ba1ce2fb4e058d1eb84ccb6c5e03_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMy04LTEtMS04NDQ0NA_f22138dc-dd7e-41f1-ab35-1dd549ad871e">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i06e2030e683e436aa4324bd6a5a14b69_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMy0xMC0xLTEtODQ0NDQ_748b9479-ce02-4a5b-a2bb-acb9954aa789">19.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i488b67a47d294aabab33cbdf59e13a0e_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNS0yLTEtMS04NDQ0NA_dff164cc-03e5-4989-a6ea-ab453c1b68f1">1,522</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic31b2338c66b49679900818d0ee6a39c_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNS00LTEtMS04NDQ0NA_0f71eed9-ea8a-4541-a864-4bfe9bc71cd9">1,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i656cbb2cc38042e38ca323806c588d5d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNS02LTEtMS04NDQ0NA_163d51e9-b4d5-48f5-aff0-ea5bd995b8c9">1,213</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i488b67a47d294aabab33cbdf59e13a0e_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNS04LTEtMS04NDQ0NA_7196707b-e630-4d1b-bd1e-c09cbf013f91">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic31b2338c66b49679900818d0ee6a39c_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNS0xMC0xLTEtODQ0NDQ_77423263-83d4-4747-9d15-b40e7cbd7b10">15.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if2f17244bd1447cf9c736ae386f8dee8_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNi0yLTEtMS04NDQ0NA_b3f3f6f3-44a9-4db5-b2a9-c6f4dea69512">2,022</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8e7770d83fdd4f678c448c98a7ec4ec9_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNi00LTEtMS04NDQ0NA_4efe6ee1-fb27-4455-ac89-934d368d0833">2,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fe4b910600f4a8d98db1f5f0c7b5c53_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNi02LTEtMS04NDQ0NA_b46235d9-a85d-4ad8-bb36-28f7659442cb">1,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="if2f17244bd1447cf9c736ae386f8dee8_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNi04LTEtMS04NDQ0NA_66223b31-58d2-48ba-b2c1-5ffb3c7d7ef1">1.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8e7770d83fdd4f678c448c98a7ec4ec9_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNi0xMC0xLTEtODQ0NDQ_db6cdf90-7614-46c9-ba99-6daddeddf01e">14.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf869d6b3a56497f82172be314aa1d7a_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNy0yLTEtMS04NDQ0NA_6bda994e-bf4d-4943-a5a1-cdc88052d5b3">3,543</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7cb2f6bb944c47db8946085e687244f3_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNy00LTEtMS04NDQ0NA_b0c82ba7-c6fb-4867-a6dc-1dcc22a80926">3,440</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb6de0174c394ad7878f8b8ab48c1760_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNy02LTEtMS04NDQ0NA_0e86d2f3-2891-405f-8242-565a59a12bbe">2,994</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibf869d6b3a56497f82172be314aa1d7a_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNy04LTEtMS04NDQ0NA_b34e22e7-cc20-4341-ba3c-e340d4ca9384">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7cb2f6bb944c47db8946085e687244f3_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNy0xMC0xLTEtODQ0NDQ_fa964d2f-184f-44c1-824d-232e95619d0d">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></ix:continuation></ix:continuation></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">79</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i0ba3e61fc8424c5db43e0c252bdfe0b3" continuedAt="id346198f77214a088d208946cbacdab3"><ix:continuation id="i64cdd9152891449fbaed6f69a1bac82e"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"></td><td style="width:34.374%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.285%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.564%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.290%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i69e5be1f408d42a6a28f913328b3aa23_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMC0yLTEtMS04NDQ0NA_fcc0f317-c7d7-44ae-a247-1d0cc02109d2">468</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6a6d1bdd3da5427197bae916d67ef765_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMC00LTEtMS04NDQ0NA_6ae34435-74f8-4e66-8f5d-fb4ecfdaec3a">459</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id0aac6fcbd0b4218a1df93bffd709deb_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMC02LTEtMS04NDQ0NA_9e7848ef-f03e-4da1-8e87-566304c51e48">344</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i69e5be1f408d42a6a28f913328b3aa23_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMC04LTEtMS04NDQ0NA_643571a0-4124-4d68-a014-c6943fe37615">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6a6d1bdd3da5427197bae916d67ef765_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMC0xMC0xLTEtODQ0NDQ_8ac8496d-a157-44f0-9d63-b38d749ea448">33.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i780835081b4f4f33ad0a3bec79b6575e_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMS0yLTEtMS04NDQ0NA_8e3723aa-236e-47d1-8447-9b9d8a44f902">837</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20f1c099cf014d2396f6e27e3f282b73_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMS00LTEtMS04NDQ0NA_82467810-36af-4ea5-a205-ab64b6ccefe1">788</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3240822529b343708c19d857074c3efe_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMS02LTEtMS04NDQ0NA_47282e41-0e7e-4b4d-aafa-f215d78043bb">581</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i780835081b4f4f33ad0a3bec79b6575e_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMS04LTEtMS04NDQ0NA_d65723cb-7827-4bb1-a2e7-5a868fad9d03">6.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i20f1c099cf014d2396f6e27e3f282b73_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMS0xMC0xLTEtODQ0NDQ_0c9fb1a6-2908-40ac-a712-97c984b22719">35.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icd9e83bd141f43718f07eebf8ae9d726_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMi0yLTEtMS04NDQ0NA_3a642a0e-d6c8-4c72-8e84-e3947f08a184">1,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i686d5e925e204bfb9c56b7dc9949c828_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMi00LTEtMS04NDQ0NA_db3fceb8-6639-4cd4-8576-f690238d2f01">1,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94d99e94b59a4dc786f934bdf8f8ad28_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMi02LTEtMS04NDQ0NA_bcfe3ffa-503b-4ac2-a036-f0b185259e8d">925</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="icd9e83bd141f43718f07eebf8ae9d726_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMi04LTEtMS04NDQ0NA_52e3bca4-7da3-4e96-bf75-221f84894da7">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i686d5e925e204bfb9c56b7dc9949c828_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMi0xMC0xLTEtODQ0NDQ_e879d0cc-6e25-4b5b-8ce8-bd5a8498f84e">34.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i02394e8a5d34408f80dba10b20b2294e_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNS0yLTEtMS04NDQ0NA_52ec605f-b297-4be9-9864-668f022d653a">13,377</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id12b26c88eb041a5b128765f1710cfff_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNS00LTEtMS04NDQ0NA_0a42de61-f292-4e30-bdfb-baf3f92f3d2f">12,686</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c5ab80c014e4ab6bf12909c673b5286_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNS02LTEtMS04NDQ0NA_0ad6cbac-ea76-4272-b1ea-441a08b21697">11,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i02394e8a5d34408f80dba10b20b2294e_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNS04LTEtMS04NDQ0NA_e1825e82-3a41-4c47-bd6b-690c4c155a2e">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id12b26c88eb041a5b128765f1710cfff_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNS0xMC0xLTEtODQ0NDQ_2a655e25-8e4a-48df-bee3-4400d2338e6c">14.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ice2505dd78c947788c029470885cbb84_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNi0yLTEtMS04NDQ0NA_de48a12c-b7f0-4ef6-bce2-e39c0a024353">14,050</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i26073ee7b24f444ea78dd572e1428c7f_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNi00LTEtMS04NDQ0NA_8360f75c-86b4-4b5b-83b9-38b0daa9259d">14,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie04e4e86c1b24d1889b9660122ff5c0b_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNi02LTEtMS04NDQ0NA_1f758417-1689-4489-836b-3b775b35bbe9">11,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="ice2505dd78c947788c029470885cbb84_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNi04LTEtMS04NDQ0NA_27db489b-36bf-4a72-92ef-2d72cce1a935">2.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i26073ee7b24f444ea78dd572e1428c7f_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNi0xMC0xLTEtODQ0NDQ_f3b802c9-a611-4619-8e10-6cb6482c6048">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNy0yLTEtMS04NDQ0NA_1c501217-18f2-4593-a420-e4160507b08b">27,427</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNy00LTEtMS04NDQ0NA_533e59f0-e2a8-4764-9de5-7c15946b7089">27,060</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia05a6854e4e147f5a99bd5f6979dc765_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNy02LTEtMS04NDQ0NA_825a0fd0-c464-4dfc-9c2a-c7192be9a11e">22,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNy04LTEtMS04NDQ0NA_94e13d1e-23c2-484a-af3f-11962f37cd3d">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNy0xMC0xLTEtODQ0NDQ_9f1924b7-be02-4c0b-97ef-4fc755fc9ab1">17.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3420461825204a15b06642c0e8effdc3_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MC0yLTEtMS04NDQ0NA_5bac1b71-c105-486f-84ed-4de11e9c417f">48,580</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic25e0a35046d4798afe7f6c61ccd2212_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MC00LTEtMS04NDQ0NA_da966ee3-e3c9-4779-8407-a8466b3f81d4">47,156</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iddce33c475c74ebcb63073bdefd18fc8_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MC02LTEtMS04NDQ0NA_c765e07f-b76e-4860-88ed-ee8955a10b68">43,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3420461825204a15b06642c0e8effdc3_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MC04LTEtMS04NDQ0NA_c9b69034-5fd5-4f8d-bf42-c17ecc50835d">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic25e0a35046d4798afe7f6c61ccd2212_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MC0xMC0xLTEtODQ0NDQ_633510bf-daca-49da-98cc-17e0d578e1de">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f735f0bd8754f549f6a3d8505541990_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MS0yLTEtMS04NDQ0NA_b2ba0d29-2970-4d6d-ac59-71cfc86dc6fa">46,363</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f7ca8fc4824ad1b05a99c0f85ecbd9_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MS00LTEtMS04NDQ0NA_34050583-3d6a-434d-a8f4-970dee85cc49">46,619</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i21ae89a5e6e44a19bda3cea2a2a46a91_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MS02LTEtMS04NDQ0NA_3cb3fa4d-d74a-46dc-a819-677ed3bc888a">39,451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="i8f735f0bd8754f549f6a3d8505541990_D20220103-20230101" decimals="3" sign="-" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MS04LTEtMS04NDQ0NA_43f277a8-9310-4a44-8219-028fcbc7c9ca">0.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia7f7ca8fc4824ad1b05a99c0f85ecbd9_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MS0xMC0xLTEtODQ0NDQ_6cb3571c-1514-4616-b6e6-a0a7bb167b08">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0Mi0yLTEtMS04NDQ0NA_75b37740-e530-459e-a13f-6a898e4b4d66">94,943</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0Mi00LTEtMS04NDQ0NA_a9ae6546-e476-42f6-8219-818c02bad5f1">93,775</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0Mi02LTEtMS04NDQ0NA_66827f79-0677-49a8-bc8e-cd30430a0424">82,584</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0Mi04LTEtMS04NDQ0NA_42358740-24b3-42c0-b612-644d45e18bc5">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="3" name="jnj:PercentageChangeInSalesBySegmentOfBusiness" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0Mi0xMC0xLTEtODQ0NDQ_1f8c611b-cf49-4bc9-839e-4131867f2347">13.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Approximately $<ix:nonFraction unitRef="usd" contextRef="i11096dc41162493598fbde3c3328208f_D20191230-20210103" decimals="-8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgxNzUyOQ_2f328ba7-6e69-4cfb-96af-8c5cc71a29a4"><ix:nonFraction unitRef="usd" contextRef="i44f421d84e9d4a00bd90e95f56e2755d_D20210104-20220102" decimals="-8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgxNzUyOQ_e7487fca-74d7-4d4c-8d72-3b3e90e966c9">0.4</ix:nonFraction></ix:nonFraction>&#160;billion in both the fiscal 2021 and 2020, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pr</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">eviously referred to as Medical Devices</span></div></ix:continuation><div><span><br/></span></div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzMyMTk_f72ef568-7372-4392-9ac3-5fff81a92df3" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.295%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.446%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (Loss) Before Tax*</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f83a7c98be45a5b6124322b7bd487f_D20220103-20230101" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzItMi0xLTEtODQ0NDQ_d796984a-8027-4354-9dce-1b2221716290">2,930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d4fcfbaed948f7b96ddd9e7c955350_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzItNC0xLTEtODQ0NDQ_ac018646-49d3-44a6-a7cd-31978d92f349">1,573</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0db9c12fbc594fa39ecdd6ab21950596_D20191230-20210103" decimals="-6" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzItNi0xLTEtODQ0NDQ_82e507bc-0ad5-48fe-84f2-bccaa1e3c420">852</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i41b31e63f2ca46a3845da852aec0b900_I20230101" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzItOC0xLTEtODQ0NDQ_099c0e3a-ba1a-4842-8374-ac99009b200d">24,068</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i716a54942efa46028603ae4da3c07d56_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzItMTAtMS0xLTg0NDQ0_018bc0e7-7d05-45ed-a0fa-af902563bc5e">25,081</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia03e77d7325e4d73b78a0c69bf6f9c96_D20220103-20230101" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzMtMi0xLTEtODQ0NDQ_21824062-c6a3-49de-8bd6-461a7dd35058">15,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie279ec7ee04446a18580684b9417ccef_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzMtNC0xLTEtODQ0NDQ_dbec410d-a185-4da8-8a78-0eb832c273df">17,969</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb973b453fb448c977acc62f23cfbf9_D20191230-20210103" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzMtNi0xLTEtODQ0NDQ_e7bea324-4703-4fe2-894d-5bac1c7ecfe2">15,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia41cb8ba083c40d8bb8e8e5a75a886d3_I20230101" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzMtOC0xLTEtODQ0NDQ_4b6fbdba-a13b-4a83-a74c-655cbddd3c92">58,436</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56d29c41cf14436b8bd0387c90fdcc9c_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzMtMTAtMS0xLTg0NDQ0_e49a58ce-f130-4fac-9dfd-a0d3c5c86bb3">64,376</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a7ed898049b448889443be8ec36feff_D20220103-20230101" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzQtMi0xLTEtODQ0NDQ_1ad6fbac-975d-4566-8e09-a223acedc9ec">4,607</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06ba1df96b4a3e9332405eed4144c7_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzQtNC0xLTEtODQ0NDQ_6ee06c95-3847-46bd-a448-abf4cd3c0362">4,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9ff28d3f5c4f9f823666db103add14_D20191230-20210103" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzQtNi0xLTEtODQ0NDQ_2445347e-9fac-43d2-a86d-b99a0ec462e1">3,044</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44bfea2a30414fd2acc71a28c1a9338c_I20230101" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzQtOC0xLTEtODQ0NDQ_ebd9563d-2519-4821-9acf-7a5518a769ea">70,956</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2bd8eb466f7641b58a738548f55f05ca_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzQtMTAtMS0xLTg0NDQ0_57fc0a5f-3d6b-4ca1-b62b-34dee7101cb4">53,372</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i765d240ac3504d22b02095e7b50f9664_D20220103-20230101" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzUtMi0xLTEtODQ0NDQ_2634c5b7-e85f-4a74-9e3f-c3d9f6025a88">23,438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c6e97913c1e42e8a73e24fdcddbb0f0_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzUtNC0xLTEtODQ0NDQ_2b72659d-0d5f-4505-b91a-37cc0c9b486e">23,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic546e27439c549a5930ca85efae9f793_D20191230-20210103" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzUtNi0xLTEtODQ0NDQ_47eff7f1-1a6c-410e-a84a-2c57b14ba550">17,442</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibaa94ed145ab44e893b1141cd2f4b6d2_I20230101" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzUtOC0xLTEtODQ0NDQ_5a0fd95f-835a-4959-904c-a191bb49f5a5">153,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2194cc52a1204b8bb062f0829cc720a3_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzUtMTAtMS0xLTg0NDQ0_b419f039-f833-4472-a676-0cc7941bb165">142,829</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia637975db75f4d6ca976d19b81d5d23b_D20220103-20230101" decimals="-6" name="jnj:ExpenseNotAllocatedToSegments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzYtMi0xLTEtODQ0NDQ_3f5a4241-e0d8-401d-bc3b-017b0f813692">624</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5a13137501ef420499797d78d356afa9_D20210104-20220102" decimals="-6" name="jnj:ExpenseNotAllocatedToSegments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzYtNC0xLTEtODQ0NDQ_c239e753-a44c-46c8-a8b5-431490831812">1,072</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i50227f06e5f04961b0e6a7aea3926827_D20191230-20210103" decimals="-6" name="jnj:ExpenseNotAllocatedToSegments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzYtNi0xLTEtODQ0NDQ_48709f4c-0269-4b5c-8322-39ddd2413368">945</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iea8f7496466a454890b32615eb14ec08_D20220103-20230101" decimals="-6" name="jnj:ExpenseNotAllocatedToSegments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzctMi0xLTEtOTQxMDk_ac50867b-a4f5-4cb5-b146-41c6af48d8ef">1,089</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3d62e4d77ba942f7bd7bc31625c7c643_D20210104-20220102" decimals="-6" name="jnj:ExpenseNotAllocatedToSegments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzctNC0xLTEtOTQxMjI_d552beaa-ca05-48aa-970a-be4478e313fb">67</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec21bae1ba8f4a4b9e8a25cbda75c2c4_I20230101" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzctOC0xLTEtODQ0NDQ_4f21aef0-6af4-442e-b2be-98ec86847797">33,918</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f90c84177a4ab0ac0f09d5f702e4e9_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzctMTAtMS0xLTg0NDQ0_d7395fd4-fee0-4f9e-99ba-dc9fd28a8257">39,189</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzgtMi0xLTEtODQ0NDQ_a309fd21-80ae-4a32-bf3f-99796f4c66b4">21,725</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzgtNC0xLTEtODQ0NDQ_d0355860-028f-458e-8ffc-464a24ecbd20">22,776</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzgtNi0xLTEtODQ0NDQ_41f982be-355b-46ce-a8ee-bdcabe29c5e0">16,497</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzgtOC0xLTEtODQ0NDQ_5fd3964e-1a32-4bd5-ac3c-52159632ab3d">187,378</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzgtMTAtMS0xLTg0NDQ0_075947f6-cef0-427b-a024-e5ef6c85bfb4">182,018</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*Income before tax of approximately $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-8" name="us-gaap:ResultsOfOperationsIncomeBeforeIncomeTaxes" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzI3NDg3NzkwODI1Njc_dba99a4b-0c3e-429c-ab3c-8526b8295591">0.2</ix:nonFraction>&#160;billion and $<ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-8" name="us-gaap:ResultsOfOperationsIncomeBeforeIncomeTaxes" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzI3NDg3NzkwODI1ODE_e6ddfb62-89eb-4d1d-bfc6-d12cc0e4b5bb">0.2</ix:nonFraction>&#160;billion in the fiscal years 2021 and 2020, respectively, has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions to Property,<br/>Plant &amp; Equipment</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation and<br/>Amortization</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f83a7c98be45a5b6124322b7bd487f_D20220103-20230101" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzItMi0xLTEtODQ0NDQ_29ecb0e6-b4f6-40c3-9e43-94a61a6eddb0">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d4fcfbaed948f7b96ddd9e7c955350_D20210104-20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzItNC0xLTEtODQ0NDQ_e40a1fb1-6eb5-4e7c-96e5-89dcb4fa52c7">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db9c12fbc594fa39ecdd6ab21950596_D20191230-20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzItNi0xLTEtODQ0NDQ_7ec2072c-969c-4ec8-9976-a86e77682c20">248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i65f83a7c98be45a5b6124322b7bd487f_D20220103-20230101" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzItOC0xLTEtODQ0NDQ_938554c7-f98e-4f9f-8140-2b801b9db78e">658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if7d4fcfbaed948f7b96ddd9e7c955350_D20210104-20220102" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzItMTAtMS0xLTg0NDQ0_c38700e9-8109-4227-bcf2-08ac5402f977">759</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0db9c12fbc594fa39ecdd6ab21950596_D20191230-20210103" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzItMTItMS0xLTg0NDQ0_a32f538f-9898-4846-8d90-c6d0b34fa51d">785</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia03e77d7325e4d73b78a0c69bf6f9c96_D20220103-20230101" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzMtMi0xLTEtODQ0NDQ_63877649-9799-423f-851a-3e224572c9d0">1,374</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie279ec7ee04446a18580684b9417ccef_D20210104-20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzMtNC0xLTEtODQ0NDQ_e42451c6-afb0-449a-9601-9ea06978d8b1">1,198</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb973b453fb448c977acc62f23cfbf9_D20191230-20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzMtNi0xLTEtODQ0NDQ_f92e8ef6-e67b-40b6-a467-1371948ab3f3">863</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia03e77d7325e4d73b78a0c69bf6f9c96_D20220103-20230101" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzMtOC0xLTEtODQ0NDQ_82d2c800-8133-475d-89df-e1a45c104067">3,687</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie279ec7ee04446a18580684b9417ccef_D20210104-20220102" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzMtMTAtMS0xLTg0NDQ0_8928811e-f753-4035-a2b5-5499b8e86165">4,029</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifeb973b453fb448c977acc62f23cfbf9_D20191230-20210103" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzMtMTItMS0xLTg0NDQ0_281057bb-95c2-4855-be15-ca91464868fb">4,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a7ed898049b448889443be8ec36feff_D20220103-20230101" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzQtMi0xLTEtODQ0NDQ_ae188a31-dc09-457e-8294-c9f8886b59be">2,120</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06ba1df96b4a3e9332405eed4144c7_D20210104-20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzQtNC0xLTEtODQ0NDQ_008b3470-f9c0-4a06-8d5d-9476197c65ac">1,933</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9ff28d3f5c4f9f823666db103add14_D20191230-20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzQtNi0xLTEtODQ0NDQ_07ad01ba-4904-4d70-96ac-45b8396830e6">1,980</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1a7ed898049b448889443be8ec36feff_D20220103-20230101" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzQtOC0xLTEtODQ0NDQ_20dc46d1-a300-419d-b8db-4ea5ec09dc8f">2,302</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b06ba1df96b4a3e9332405eed4144c7_D20210104-20220102" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzQtMTAtMS0xLTg0NDQ0_0490ec09-c792-4845-8ad8-17eed307aaa1">2,286</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife9ff28d3f5c4f9f823666db103add14_D20191230-20210103" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzQtMTItMS0xLTg0NDQ0_4ace5a95-3371-4f63-8e7a-4c0426df04b0">2,140</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3baea8052de54dbf99a582b503fe5ae9_D20220103-20230101" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzUtMi0xLTEtODQ0NDQ_49794c68-3475-43aa-936a-48722d55a40e">3,817</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i365b842e2df647adb11480f7f5a63d9f_D20210104-20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzUtNC0xLTEtODQ0NDQ_5fbb879f-8e3c-4d49-b5c4-e60f3056e961">3,462</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e23d74806e4408bdef269ad289b155_D20191230-20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzUtNi0xLTEtODQ0NDQ_4381830a-652e-4b5b-8b10-4fa717c6610c">3,091</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3baea8052de54dbf99a582b503fe5ae9_D20220103-20230101" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzUtOC0xLTEtODQ0NDQ_577f5bff-adf5-4781-acdd-2120f6ab6d88">6,647</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i365b842e2df647adb11480f7f5a63d9f_D20210104-20220102" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzUtMTAtMS0xLTg0NDQ0_b675d0fc-6731-4c40-9b91-1171e4d3dcb4">7,074</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44e23d74806e4408bdef269ad289b155_D20191230-20210103" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzUtMTItMS0xLTg0NDQ0_be59271d-d144-455b-a97c-c75d7d15a247">6,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35f2772fa1fb464686fdad7eba530bc2_D20220103-20230101" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzYtMi0xLTEtODQ0NDQ_7f7662e5-eba2-41e6-8d3b-a8f7b8451f3d">192</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4ae67402be4d30bf0509f57bdf82a4_D20210104-20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzYtNC0xLTEtODQ0NDQ_d4cb0541-02dc-4e8b-a42f-82c5d99eb16c">190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4662aafc35c84c71a32e5811a0481ac0_D20191230-20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzYtNi0xLTEtODQ0NDQ_31f6e966-90c6-4105-b7cf-389f1ada6c91">256</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i35f2772fa1fb464686fdad7eba530bc2_D20220103-20230101" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzYtOC0xLTEtODQ0NDQ_a8fce9c8-9d25-4149-aac7-523196ccb5f6">323</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4ae67402be4d30bf0509f57bdf82a4_D20210104-20220102" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzYtMTAtMS0xLTg0NDQ0_44fe23f1-7e96-4294-9e08-82be664a2257">316</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4662aafc35c84c71a32e5811a0481ac0_D20191230-20210103" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzYtMTItMS0xLTg0NDQ0_48441730-526b-40ce-92cc-5801db5462ab">300</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzctMi0xLTEtODQ0NDQ_664b08f9-0cee-4035-a058-81de5527d181">4,009</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzctNC0xLTEtODQ0NDQ_7d9b26f0-8bcb-4d5e-9a5b-0fb4e6082a4a">3,652</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:PropertyPlantAndEquipmentAdditions" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzctNi0xLTEtODQ0NDQ_e985fc6b-61d1-4ab0-a718-89a6a6570dc6">3,347</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzctOC0xLTEtODQ0NDQ_d5492a74-9996-4080-afe4-691f066be96a">6,970</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzctMTAtMS0xLTg0NDQ0_cd8e2a0f-5744-484a-bebf-d8bca23a61fe">7,390</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:DepreciationDepletionAndAmortization" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzctMTItMS0xLTg0NDQ0_5abc732f-ddcd-4d1b-9b0f-b72474c73c7f">7,231</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id346198f77214a088d208946cbacdab3" continuedAt="ide3ddefe3b804702bed406a870b039f1"><ix:nonNumeric contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" name="us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzMyMTI_bc503088-12ee-4670-b6c2-d7b0bd1c181b" continuedAt="i49330f89e09e4d03bd2a1ec16a130e39" escape="true"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:44.580%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.824%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.300%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-Lived Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf6f3d4d30c44652ac9e77a021f74bc7_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzItMi0xLTEtODQ0NDQ_1d15abc5-2edb-4723-be47-9eaccf4f3ef3">48,580</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i901d71842aaf4089b7b7a4d97fdc8942_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzItNC0xLTEtODQ0NDQ_4c3c1179-c99a-48d8-8ce2-7b3cc1af9605">47,156</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id907daafbe5d44ec927b1cf4e8fcfb0d_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzItNi0xLTEtODQ0NDQ_36058287-d252-45ae-81dc-ff1c323cbc3f">43,133</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8bd1a077b7d6414e8935bd70e97c8cf2_I20230101" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzItOC0xLTEtODQ0NDQ_6e8bfbfe-bda0-44f5-8d54-bf3dcdae9385">66,283</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68257c001b354a5a98508e8a0ac0e82a_I20220102" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzItMTAtMS0xLTg0NDQ0_e8491590-3bb8-46ed-af1c-9e8f1b7ac79b">48,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96a3daea3f49408e971870669b0f5512_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzMtMi0xLTEtODQ0NDQ_31149c12-9f9f-4aeb-abc9-926d9c9d813a">23,449</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fa7b3a6c25c4eada02b8646ac415062_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzMtNC0xLTEtODQ0NDQ_a10cd7a2-e0a0-49f0-a527-b82a3b455647">23,594</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1cdb9152618c42eea5013297dbf2e4c3_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzMtNi0xLTEtODQ0NDQ_cb7f2309-88e4-46cf-b667-e029447d5eba">18,980</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i200f93e3b77244a583b1ad4b7a71d3a1_I20230101" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzMtOC0xLTEtODQ0NDQ_7be39930-b862-47f1-a502-d015bbb2c9cc">38,774</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib112e058fb6b447dbc3310478fc97587_I20220102" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzMtMTAtMS0xLTg0NDQ0_ee4ee891-93f7-426f-8e53-5456b8695d74">43,257</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere excluding U.S.&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icafa0a8044c04de497b6f3dfe30d2a58_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzQtMi0xLTEtODQ0NDQ_464fecdf-17ab-46d9-89c8-72e1fc1acb29">6,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43130bad99db457ba44ec22f2c697510_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzQtNC0xLTEtODQ0NDQ_126fb0b1-05d5-4d77-88ae-9672d2948677">5,750</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9c2fc3c8e9594706a561854ef8052a58_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzQtNi0xLTEtODQ0NDQ_dc08f969-8f6d-4a05-8a6b-ba5ce1b441a3">5,335</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id2d96b411f4d40debdac91b9aabb935f_I20230101" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzQtOC0xLTEtODQ0NDQ_58bb6367-c91e-4b72-a0b3-b69183a6a6f6">2,737</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01fde314497149c6b70e4d076fa6dd4f_I20220102" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzQtMTAtMS0xLTg0NDQ0_1d4fdc36-2c97-4ff2-b741-19d6d8aaf4e7">2,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i20c9f4592a754d2cb500873c6ed0be54_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzUtMi0xLTEtODQ0NDQ_5a4c9140-88db-4bf8-893c-c524f5864479">16,789</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if1a5151945ca4ac086f58deeeb720914_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzUtNC0xLTEtODQ0NDQ_84bc0e01-aa84-4236-87d4-6067b3ae60a6">17,275</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44509d3ef3cb4581b00a5c4862521e64_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzUtNi0xLTEtODQ0NDQ_ee4f73ab-1c6e-4b05-af8b-1c243e935ad7">15,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8ebf98b5fa324cbaa9bfaebdca053ff4_I20230101" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzUtOC0xLTEtODQ0NDQ_c8e0f2ea-9266-46be-b53d-f405069ba74d">4,431</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i29d342791cfc4b03a1713eb39bf942d5_I20220102" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzUtMTAtMS0xLTg0NDQ0_4dac11c4-5caa-4241-b6b5-6ff73f6ce569">5,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i765d240ac3504d22b02095e7b50f9664_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzYtMi0xLTEtODQ0NDQ_c042694e-25e4-4b3d-b191-44902ca45501">94,943</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3c6e97913c1e42e8a73e24fdcddbb0f0_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzYtNC0xLTEtODQ0NDQ_42aa22d8-2506-4348-ad69-69f6b185c116">93,775</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic546e27439c549a5930ca85efae9f793_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzYtNi0xLTEtODQ0NDQ_d8e3a81b-eb02-4cb0-8cf2-71c43687a330">82,584</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d276957b87d4834ba1ee537b68aa89e_I20230101" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzYtOC0xLTEtODQ0NDQ_17509e78-1f01-4bf6-a520-34d91c61ee2a">112,225</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0daf7a509a1742c0af022ecd6a711956_I20220102" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzYtMTAtMS0xLTg0NDQ0_93b352cb-daa8-4b10-b97c-10a028835893">99,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iec21bae1ba8f4a4b9e8a25cbda75c2c4_I20230101" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzctOC0xLTEtODQ0NDQ_4761d5c2-0d5e-4061-b16a-a9f2586c64fd">1,134</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i12f90c84177a4ab0ac0f09d5f702e4e9_I20220102" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzctMTAtMS0xLTg0NDQ0_7df4d23d-69c9-4007-a225-aaaf9918b145">1,014</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non long-lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3fea49b8326e4a0bbb7c8f8cfee7b454_I20230101" decimals="-6" name="jnj:OtherNonLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzgtOC0xLTEtODQ0NDQ_1cc90142-8dcd-4e1b-a624-91151bcd3350">74,019</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibb0265bad6f240a28a737ed052560826_I20220102" decimals="-6" name="jnj:OtherNonLongLivedAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzgtMTAtMS0xLTg0NDQ0_2464a274-baaf-4c5f-9132-f6f38ee1df3f">81,418</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzktMi0xLTEtODQ0NDQ_243ab64f-e9c1-4417-8a37-3da4f51ab7ac">94,943</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzktNC0xLTEtODQ0NDQ_ba8eb4e9-5f81-4978-9155-e20ee30118b7">93,775</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="-6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzktNi0xLTEtODQ0NDQ_49e191b3-6c86-4a82-87d8-aa1706428776">82,584</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzktOC0xLTEtODQ0NDQ_02962e6d-5ffb-4566-b23a-5504769a7bde">187,378</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-6" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzktMTAtMS0xLTg0NDQ0_e5428880-e941-4181-bb24-c038d54e456a">182,018</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;1 for a description of the segments in which the Company operates. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Export sales are not significant. In fiscal year 2022, the Company utilized three wholesalers distributing products for all <ix:nonFraction unitRef="segment" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNzE3NA_1c0d91f1-8489-4b7f-9d29-88f8f704f776"><ix:nonFraction unitRef="segment" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNzE3NA_535e325a-ca53-47f4-8162-979275a2add7">three</ix:nonFraction></ix:nonFraction> segments that represented approximately <ix:nonFraction unitRef="number" contextRef="ie500d8c896d44983b9c33f2ac1ef9710_D20220103-20230101" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzQ0Mw_5e95631e-7eef-4ad4-8365-e07756b67fa6">16.5</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i3ae4ff8713334360a336393c7dac68d5_D20220103-20230101" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzQ0Nw_0420bd06-8d3c-445c-9a66-921d13dc684b">13.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="if853701b34c2430d8f37795599100d52_D20220103-20230101" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzQ1NA_d75d0cfd-d075-48e6-8fb2-282ccaaccd83">12.0</ix:nonFraction>% of the total consolidated revenues. In fiscal year 2021, the Company had three wholesalers distributing products for all <ix:nonFraction unitRef="segment" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU3Ng_e6189f47-5ac8-4658-8019-c4730028a7bd">three</ix:nonFraction> segments that represented approximately <ix:nonFraction unitRef="number" contextRef="ic1cb58176e324fddab800e715c7039c3_D20210104-20220102" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzYxOQ_fc198ae2-be92-4988-8cdd-81624d24cc09">14.0</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i40efe68b209843249746ea7032375b47_D20210104-20220102" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzYyMw_491165c1-b574-42b1-919b-57cd41222901">11.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i196d06199bcb47afb512e58c6c6cce33_D20210104-20220102" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzYzMA_033efe1b-d498-4a21-a692-5c078219525a">11.0</ix:nonFraction>% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all <ix:nonFraction unitRef="segment" contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc1Mg_b861c310-b3a7-46e6-aeba-5ff1b786132b">three</ix:nonFraction> segments that represented approximately <ix:nonFraction unitRef="number" contextRef="ib97ee1e8d98d45f78eea6e86d0d96a02_D20191230-20210103" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc5NQ_bc5638b0-319f-47ee-b9ae-469cd49ec4a3">16.0</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="i4dc7c4601c144f7091a2700b230221f8_D20191230-20210103" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc5OQ_b79a6f03-088b-4d77-87a4-82a1ef47b6e8">12.0</ix:nonFraction>%, and <ix:nonFraction unitRef="number" contextRef="i648dd03c46344752a321bbba8fc97340_D20191230-20210103" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzgwNw_3a73cae3-df02-4e88-a430-93fb6ffdd8b0">12.0</ix:nonFraction>% of the total consolidated revenues. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">General corporate includes cash, cash equivalents and marketable securities.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i1a210155919049c2bd43c936b49f1ee6_D20220103-20230101" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzI3NDg3NzkwODI1OTc_cbec6075-caef-46c9-a5ed-b02868a8b282">0.2</ix:nonFraction>&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i1a210155919049c2bd43c936b49f1ee6_D20220103-20230101" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzI3NDg3NzkwODI2MTE_ce5b5c77-2f1b-4bf8-8c4b-f2c106ae3144">0.1</ix:nonFraction>&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.44pt">One-time COVID-19 Vaccine manufacturing exit related costs of $<ix:nonFraction unitRef="usd" contextRef="ia03e77d7325e4d73b78a0c69bf6f9c96_D20220103-20230101" decimals="-8" name="us-gaap:SuppliesExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNDk1Mg_91a87a8b-4580-46c8-8184-568a3e25d6f1">1.5</ix:nonFraction>&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An intangible asset impairment charge of approximately $<ix:nonFraction unitRef="usd" contextRef="i0e228c02951e4d53a756f82e5d074c5e_D20220103-20230101" decimals="-8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyMzY1NQ_495b4d72-a1ed-4788-97fe-3de143358cce">0.8</ix:nonFraction>&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNDk4NQ_4111f69e-4e21-40a6-ac9e-7b1fa55a2590">0.1</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of $<ix:nonFraction unitRef="usd" contextRef="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101" decimals="-8" sign="-" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNDk3MA_65c2ffd9-8c52-4f6b-b6d3-fa75b61a179a">0.7</ix:nonFraction>&#160;billion related to the change in the fair value of securities </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="ia324deef03f5433486883e8775658b95_D20220103-20230101" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNTAxNA_e528c0f7-616e-4ec2-af76-9ffcf0e23896">0.1</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MedTech includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNTQyNA_86956e80-43e5-4cde-860f-6548d1021f20">0.6</ix:nonFraction>&#160;billion primarily for pelvic mesh related costs</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNTQxMA_0712a165-020f-4e1b-9d6c-ed23ffa1fc4f">0.3</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquisition and integration related costs of $<ix:nonFraction unitRef="usd" contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101" decimals="-8" name="us-gaap:AcquisitionCosts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNTQzNw_b684bc3a-848d-4fd1-b19c-47d15d43e749">0.3</ix:nonFraction>&#160;billion primarily related to the acquisition of Abiomed</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Medical Device Regulation charge of $<ix:nonFraction unitRef="usd" contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101" decimals="-8" name="jnj:RegulationCharge" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNTQzOQ_fe18afde-62d3-454c-8898-f5324bad3ef8">0.3</ix:nonFraction>&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i2c6099acc42a42639c659499eeee550a_D20210104-20220102" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc4NDI_8e63eb00-cbdc-4e7f-b814-db28b9186f67">1.6</ix:nonFraction>&#160;billion, primarily talc related costs</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i2c6099acc42a42639c659499eeee550a_D20210104-20220102" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc4NTA_828e4506-d979-4409-9d92-f1fb479c31f5">0.1</ix:nonFraction>&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc4NTg_19ecf231-292f-4fc2-9d4c-63c1bd5b9abd">0.6</ix:nonFraction>&#160;billion, primarily related to Risperdal Gynecomastia</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Divestiture gains of $<ix:nonFraction unitRef="usd" contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102" decimals="-8" name="us-gaap:GainLossOnSaleOfBusiness" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc4NjY_b35d3649-c159-4fbc-bc98-4fbd6f9e380f">0.6</ix:nonFraction>&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Gains of  $<ix:nonFraction unitRef="usd" contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102" decimals="-8" name="us-gaap:MarketableSecuritiesRealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc4NzQ_71e7e4f1-3293-4cfa-82a0-d168a72dd199">0.5</ix:nonFraction>&#160;billion related to the change in the fair value of securities</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc4ODI_e9676f98-13bc-48f7-88b7-931d67c5429a">0.1</ix:nonFraction>&#160;billion </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ide3ddefe3b804702bed406a870b039f1"><ix:continuation id="i49330f89e09e4d03bd2a1ec16a130e39"><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MedTech includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc4OTA_0f0da4c8-d213-4536-9dc6-3608d789e3e0">0.3</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $<ix:nonFraction unitRef="usd" contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102" decimals="-8" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc4OTg_7e7ebf0c-5b47-403a-9ad0-6f172d338073">0.9</ix:nonFraction>&#160;billion related to Ottava</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A Medical Device Regulation charge of $<ix:nonFraction unitRef="usd" contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102" decimals="-8" name="jnj:RegulationCharge" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc5MDY_cabf04e2-c48b-4ad0-aff0-286bab0886a3">0.2</ix:nonFraction>&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc5MTQ_0d16b5eb-0f05-4488-b5e1-7dee6f2f7a8a">0.1</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="ieabc073d9ebf4111b8a8d92bdd0b8b7d_D20191230-20210103" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzE1NzM_483f918c-7c9c-45ed-b6f7-d191b95d70c7">3.9</ix:nonFraction>&#160;billion, primarily talc related costs and certain settlements.</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="i45c63832601e43b1ad4c8f083610e7c3_D20191230-20210103" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzE2ODE_231d7335-6fe6-4260-abc5-329212658b49">0.8</ix:nonFraction>&#160;billion, primarily related to the agreement in principle to settle opioid litigation </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $<ix:nonFraction unitRef="usd" contextRef="ifeb973b453fb448c977acc62f23cfbf9_D20191230-20210103" decimals="-8" name="us-gaap:MarketableSecuritiesUnrealizedGainLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzE3OTg_af435078-49d4-43f2-8015-2db2756d1b88">0.5</ix:nonFraction>&#160;billion related to the change in the fair value of securities</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="i45c63832601e43b1ad4c8f083610e7c3_D20191230-20210103" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzE4MzY_d3fb99b2-4d02-45aa-b64f-19a9adf46bf4">0.1</ix:nonFraction>&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MedTech includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A contingent consideration reversal of $<ix:nonFraction unitRef="usd" contextRef="i0675e6e915374fb5b095d7fd0834c9be_D20191230-20210103" decimals="-8" sign="-" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzE5MDQ_33446bab-3e37-4355-abb4-679ee4e80a18">1.1</ix:nonFraction>&#160;billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $<ix:nonFraction unitRef="usd" contextRef="ia05a6854e4e147f5a99bd5f6979dc765_D20191230-20210103" decimals="-8" name="us-gaap:LitigationSettlementExpense" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzIwMzQ_a816c650-57ba-40af-9f9d-9d8f72fc649e">0.3</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $<ix:nonFraction unitRef="usd" contextRef="ia05a6854e4e147f5a99bd5f6979dc765_D20191230-20210103" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzIwNzI_9fc419cd-e8ef-4413-bdfa-a6f32c500c93">0.3</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $<ix:nonFraction unitRef="usd" contextRef="ia05a6854e4e147f5a99bd5f6979dc765_D20191230-20210103" decimals="-8" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzIxMjY_867abdd1-ea82-4287-a445-a8cc11f8e9df">0.2</ix:nonFraction>&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A Medical Device Regulation charge of $<ix:nonFraction unitRef="usd" contextRef="ia05a6854e4e147f5a99bd5f6979dc765_D20191230-20210103" decimals="-8" name="jnj:RegulationCharge" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzIxNjg_3969a44b-69b9-4a81-bbbc-ffa19a2a1531">0.1</ix:nonFraction>&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Long-lived assets include property, plant and equipment, net for fiscal years 2022, and 2021 of $<ix:nonFraction unitRef="usd" contextRef="i903579018dfc4744b7b1bc7085ee9dea_I20230101" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzMwODM_a4923c20-9570-49c3-8d9c-6411537dfba3">19,803</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="i6272b36311854ffb8459a6a826a10495_I20220102" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzMwOTA_39da22e7-422e-4d37-be2f-0ab37ca2d0b3">18,962</ix:nonFraction>, respectively, and intangible assets and goodwill, net for fiscal years 2022 and 2021 of $<ix:nonFraction unitRef="usd" contextRef="i4498e185f42a4d2c931df62d565c61fc_I20230101" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzMxNzg_682a3b37-3d78-48ac-bd79-8f4596babecc">93,556</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="ic6bb87c09ab1449d8ac694d344eae356_I20220102" decimals="-6" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzMxODU_c1dca1da-ef09-47b3-984b-ea2cc64e2d9d">81,638</ix:nonFraction>, respectively.</span></div></ix:continuation></ix:continuation><div><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_217"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" name="us-gaap:BusinessCombinationDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzEwMDI5_fc0ac1b7-99e4-4eeb-864d-e427fb683d45" continuedAt="i758b47cbdcb347689b5996f48be90525" escape="true">Acquisitions and Divestitures</ix:nonNumeric></span></div><ix:continuation id="i758b47cbdcb347689b5996f48be90525" continuedAt="i7c3b18c9e3264d35a292cd99f7feb1e5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the fiscal year 2022, certain businesses were acquired for $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-8" name="us-gaap:PaymentsToAcquireBusinessesGross" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTEzMzQ_e4886f35-056d-43f5-b480-54b9764c88ea">17.7</ix:nonFraction>&#160;billion in cash and $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTEzNDk_883728b1-d1f8-41d1-93db-971cb8aced83">1.1</ix:nonFraction>&#160;billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.   </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $<ix:nonFraction unitRef="usd" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="-8" name="jnj:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTEzNjM_d392a9e6-085d-4ed2-83b5-421d2544f37e">17.3</ix:nonFraction>&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fiscal year 2022 acquisitions primarily included Abiomed, Inc. (Abiomed). The remaining acquisitions were not material.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Company&#8217;s position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcare&#8217;s largest areas of unmet need. The transaction was accounted for as a business combination and the results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $<ix:nonFraction unitRef="usdPerShare" contextRef="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222" decimals="2" name="us-gaap:BusinessAcquisitionSharePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTEzNzg_bcc39731-8a29-4aae-96a6-af6f275dd9a6">380.00</ix:nonFraction> per share in cash, amounting to $<ix:nonFraction unitRef="usd" contextRef="ib9836117d3a94830a8233450377a1deb_D20221222-20221222" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTE0MjY_eea4b5e3-0daf-427d-be49-9b398e99eff1">17.1</ix:nonFraction>&#160;billion, net of cash acquired, as well as a non-tradeable contingent value right (&#8220;CVR&#8221;) entitling the holder to receive up to $<ix:nonFraction unitRef="usdPerShare" contextRef="i92d127c3ca8d4ec2976b3e3c568fecc2_D20221222-20221222" decimals="2" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1ODg1MQ_c50a31fd-fdd1-4d12-80e9-0b1ee37a434c">35.00</ix:nonFraction> per share in cash (which with respect to the CVRs total approximately $<ix:nonFraction unitRef="usd" contextRef="i92d127c3ca8d4ec2976b3e3c568fecc2_D20221222-20221222" decimals="-8" name="jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1OTIxMQ_1e1fa0a7-12c9-47bc-8da2-987d4ffb39b4">1.6</ix:nonFraction>&#160;billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $<ix:nonFraction unitRef="usd" contextRef="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1OTE5Ng_a41d9bb9-4a2b-4fc5-9365-858c98b5cdf0">16.5</ix:nonFraction>&#160;billion includes cash, cash equivalents and marketable securities acquired. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The milestones of the CVR consist of:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">$<ix:nonFraction unitRef="usdPerShare" contextRef="i81a39d36d1174514a434b80d6c743dc6_I20221222" decimals="2" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTE0NDE_c290a436-d1dc-41d2-b448-ad0c9871a06c">17.50</ix:nonFraction> per share, payable if net sales for Abiomed products exceeds $<ix:nonFraction unitRef="usd" contextRef="i92d127c3ca8d4ec2976b3e3c568fecc2_D20221222-20221222" decimals="-8" name="jnj:RevenuesContingentConsideration" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTE0NDk_ee953fee-594d-4d25-84fe-590a8a1ccd53">3.7</ix:nonFraction>&#160;billion during Johnson &amp; Johnson&#8217;s fiscal second quarter of 2027 through fiscal first quarter of 2028, or if this threshold is not met during this period and is subsequently met during any rolling four quarter period up to the end of Johnson &amp; Johnson&#8217;s fiscal first quarter of 2029, $<ix:nonFraction unitRef="usdPerShare" contextRef="i8b185cbc0eed49e1bf2b12aead1c396f_I20221222" decimals="2" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTE0NjM_59d51420-de2f-4c26-b250-100b3674e481">8.75</ix:nonFraction> per share;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">$<ix:nonFraction unitRef="usdPerShare" contextRef="i84406520b58240c49988945086079984_I20221222" decimals="2" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTE0NzA_86de3f4f-6ff3-4458-ac76-b954a5236040">7.50</ix:nonFraction> per share payable upon FDA premarket application approval of the use of Impella</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> products in ST-elevated myocardial infarction (STEMI) patients without cardiogenic shock by January 1, 2028; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">$<ix:nonFraction unitRef="usdPerShare" contextRef="i7342e69dce654189845f736621bb11ac_I20221222" decimals="2" name="us-gaap:DividendsPayableAmountPerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTE0Nzc_f5216cc3-d4a9-49d0-b575-819e270fc243">10.00</ix:nonFraction> per share payable upon the first publication of a Class I recommendation for the use of Impella</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> products in high risk PCI or STEMI with or without cardiogenic shock within four years from their respective clinical endpoint publication dates, but in all cases no later than December 31, 2029.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the acquisition was allocated to assets acquired of $<ix:nonFraction unitRef="usd" contextRef="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTQ0MA_2ff4b549-e0e5-49e7-b593-696b7d0e06b2">19.9</ix:nonFraction>&#160;billion (net of $<ix:nonFraction unitRef="usd" contextRef="ib9836117d3a94830a8233450377a1deb_D20221222-20221222" decimals="-8" name="us-gaap:CashAcquiredFromAcquisition" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTQ4Mw_72ebd972-bca6-40cd-8fb7-e3b55fc51eba">0.3</ix:nonFraction>&#160;billion cash acquired), primarily to goodwill for $<ix:nonFraction unitRef="usd" contextRef="ib9836117d3a94830a8233450377a1deb_D20221222-20221222" decimals="-8" name="us-gaap:GoodwillAcquiredDuringPeriod" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTQ5Nw_486bdf73-5d73-429c-a77b-4d040a201f5d">10.9</ix:nonFraction>&#160;billion, amortizable intangible assets for $<ix:nonFraction unitRef="usd" contextRef="ib9836117d3a94830a8233450377a1deb_D20221222-20221222" decimals="-8" name="us-gaap:FinitelivedIntangibleAssetsAcquired1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTQ1NQ_106216e6-f173-4731-a39c-4a13a4385f30">6.6</ix:nonFraction>&#160;billion, IPR&amp;D for $<ix:nonFraction unitRef="usd" contextRef="ib9836117d3a94830a8233450377a1deb_D20221222-20221222" decimals="-8" name="us-gaap:ResearchAndDevelopmentInProcess" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTQ2OQ_a6171530-2763-43b9-89bd-dab3387102d9">1.1</ix:nonFraction>&#160;billion, marketable </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7c3b18c9e3264d35a292cd99f7feb1e5" continuedAt="ie9b7440a44a043808d095d95fbaae3cc"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">securities of $<ix:nonFraction unitRef="usd" contextRef="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTUxMg_02934db0-dec2-4ef0-9244-1258d7a0c6de">0.6</ix:nonFraction>&#160;billion and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTUyNg_9ccd5d10-e080-4eae-898b-6cea20c499a8">2.8</ix:nonFraction>&#160;billion, which includes the fair value of the contingent consideration mentioned above for $<ix:nonFraction unitRef="usd" contextRef="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222" decimals="-8" name="us-gaap:BusinessCombinationContingentConsiderationLiability" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTU0MA_70bc7e38-e294-4cda-8503-831d8ab69b8d">0.7</ix:nonFraction>&#160;billion and deferred taxes of $<ix:nonFraction unitRef="usd" contextRef="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTU1NA_24fb1034-7509-4c34-a852-3320ba17fb68">1.8</ix:nonFraction>&#160;billion. The goodwill is primarily attributable to the commercial acceleration and expansion of the portfolio and is not expected to be deductible for tax purposes. The contingent consideration was recorded in Other Liabilities on the Consolidated Balance Sheet.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the acquisition occurred in December 2022, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. To assist management in the allocation, the Company engaged valuation specialists to prepare appraisals. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortizable intangible assets were primarily comprised of already in-market products of the Impella</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform with an average weighted life of <ix:nonNumeric contextRef="i4f147e1dd45545d3abb1795f5f7086da_D20221222-20221222" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" format="ixt-sec:duryear" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTE0OTU_8074e455-424a-4da1-8766-50c21f0a1f51">14</ix:nonNumeric> years. The IPR&amp;D assets were valued for technology programs for unapproved products. The value of the IPR&amp;D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from <ix:nonFraction unitRef="number" contextRef="i3ea49ac2e6aa4de69e5169b63d21cc06_I20221222" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTM4OA_a97a93f5-6862-453d-ae31-410ec965e932">52</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i1690230576734ba492365e566a8b6b5e_I20221222" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTM5Mw_ec870e86-1468-4a2a-9349-d0eca9ff6f34">70</ix:nonFraction>%. The discount rate applied was <ix:nonFraction unitRef="number" contextRef="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222" decimals="3" name="jnj:BusinessAcquisitionDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTM5OA_df460b60-5108-4c04-8c88-94ea740e6092">9.5</ix:nonFraction>%.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2022, the Company recorded acquisition related costs before tax of approximately $<ix:nonFraction unitRef="usd" contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" decimals="-8" name="us-gaap:BusinessCombinationAcquisitionRelatedCosts" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg0NDk1NQ_0d7ea0fd-32a3-4f96-b4b0-01accbc59a08">0.3</ix:nonFraction>&#160;billion, which was recorded in Other (income)/expense. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During fiscal year 2021, the Company did not make any material acquisitions. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During fiscal year 2020, certain businesses were acquired for $<ix:nonFraction unitRef="usd" contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzE3Nw_bd60ff1d-6f53-415f-a128-6efbc189c7db">7.3</ix:nonFraction>&#160;billion in cash and $<ix:nonFraction unitRef="usd" contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzE5Mg_d3b81c88-7e06-4f81-b452-0be1ec8adb7c">0.4</ix:nonFraction>&#160;billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $<ix:nonFraction unitRef="usd" contextRef="i3fbf2d6d15164f949f7d00b550a2d80f_I20220102" decimals="-8" name="us-gaap:IntangibleAssetsNetIncludingGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzUxNg_c67651e9-4df5-42d4-ba6d-d66be6c9312e">7.5</ix:nonFraction>&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fiscal year 2020 acquisitions primarily included: all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc. (XBiotech), Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases and the outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $<ix:nonFraction unitRef="usd" contextRef="i6c96d667b7284485a85bb50fece53ad0_D20210104-20210404" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzEzMzI_a179da65-5826-4ce3-aa92-e9afa81fa345">0.8</ix:nonFraction>&#160;billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $<ix:nonFraction unitRef="usd" contextRef="ia24eda47473543d58b1d6c2d349bdfc5_I20210404" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzE0NTM_00bcb283-61c1-4925-a4cb-0e0ca7f28e13">0.8</ix:nonFraction>&#160;billion applying a probability of success factor that ranged from <ix:nonFraction unitRef="number" contextRef="idf3a369e46f249199404ae4a686a3719_I20210404" decimals="1" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzE1MTQ_72817e28-2d80-4b66-a412-262dc370a84e">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i829e1cea7f8840eabf95f9902ac2836e_I20210404" decimals="1" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzE1MjE_f2391e20-2f89-4c45-a1be-20a72e39135b">60</ix:nonFraction>% to reflect inherent development, regulatory and commercial risk for the different indications. The discount rate applied was approximately <ix:nonFraction unitRef="number" contextRef="ia24eda47473543d58b1d6c2d349bdfc5_I20210404" decimals="2" name="jnj:BusinessAcquisitionDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzE2NjM_25813adb-7611-4dd4-a33c-e535a729eef7">16</ix:nonFraction>%. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. In fiscal 2022, the Company recorded an intangible asset impairment charge of approximately $<ix:nonFraction unitRef="usd" contextRef="ic25eb0c4ceda4b8ca2e1719553bd3d9f_D20220103-20230101" decimals="-8" name="us-gaap:AssetImpairmentCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MjIzNQ_d7731409-5f97-44cb-b252-ec414a94bea2">0.8</ix:nonFraction>&#160;billion related to this in-process research and development asset.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in the fiscal first quarter of 2020, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the MedTech segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $<ix:nonFraction unitRef="usd" contextRef="icc8a7af544c348f792fe38f31e341481_I20210404" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzMwODk_2f770c3b-384e-43cb-a2da-78e6fd87b1a1">0.4</ix:nonFraction>&#160;billion, goodwill for $<ix:nonFraction unitRef="usd" contextRef="icc8a7af544c348f792fe38f31e341481_I20210404" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzMxMDY_41dfde46-995f-4ee4-b951-3d82d8faf1b4">0.2</ix:nonFraction>&#160;billion, other assets of $<ix:nonFraction unitRef="usd" contextRef="icc8a7af544c348f792fe38f31e341481_I20210404" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzMxMjY_8a9eb47c-acf6-4962-b156-3a29bbed7c92">0.2</ix:nonFraction>&#160;billion and liabilities assumed of $<ix:nonFraction unitRef="usd" contextRef="icc8a7af544c348f792fe38f31e341481_I20210404" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzMxNTY_b4829f98-2141-4f49-a7c3-711a34ca8d68">0.3</ix:nonFraction>&#160;billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $<ix:nonFraction unitRef="usd" contextRef="icc8a7af544c348f792fe38f31e341481_I20210404" decimals="-8" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzMyNTI_792e1123-736e-438b-855d-f11f61c2f7d2">0.4</ix:nonFraction>&#160;billion. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 1, 2020, the Company completed the acquisition of Momenta for a purchase price of approximately $<ix:nonFraction unitRef="usd" contextRef="i96285e2125c044239562f06c5a49708f_D20201001-20201001" decimals="-8" name="us-gaap:BusinessCombinationConsiderationTransferred1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzMzNjQ_83c38976-f99c-4b43-98d9-891a1423e9dd">6.1</ix:nonFraction>&#160;billion, net of cash acquired. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets (IPR&amp;D) of $<ix:nonFraction unitRef="usd" contextRef="i3825927182464ac79b6e43df181cccf8_I20201001" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzM0OTY_e236552c-02d3-4f2f-acc2-7d72df00bd42">6.0</ix:nonFraction>&#160;billion, goodwill of $<ix:nonFraction unitRef="usd" contextRef="i27aa2a498bdb4d7fb75719ee6d31b90f_I20201001" decimals="-8" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzM1MTI_42a6f067-e961-485d-a0b2-22312b123daa">1.2</ix:nonFraction>&#160;billion, other assets of $<ix:nonFraction unitRef="usd" contextRef="i27aa2a498bdb4d7fb75719ee6d31b90f_I20201001" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzM1MzI_2287dcb5-bba5-4269-a67f-c35eeea40876">0.5</ix:nonFraction>&#160;billion and liabilities of $<ix:nonFraction unitRef="usd" contextRef="i27aa2a498bdb4d7fb75719ee6d31b90f_I20201001" decimals="-8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzM1NTQ_0f600db2-448b-4dbc-a002-fdbff7e36ee8">1.6</ix:nonFraction>&#160;billion. The assets acquired are intended to address substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Depending on the asset, probability of success factors ranging from <ix:nonFraction unitRef="number" contextRef="if2ea1b03a3be4ff59976cf8545ab6d21_I20201001" decimals="1" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzM4MTM_086b0705-bcfb-4fcb-acc5-bff75d7e002b">20</ix:nonFraction>% to <ix:nonFraction unitRef="number" contextRef="i6535353e93a14112b8d587f589b7bd9f_I20201001" decimals="2" name="jnj:BusinessCombinationProbabilityOfSuccessFactor" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzM4MTk_cf9b3513-97ca-4f91-ae09-fbc88c2a236d">77</ix:nonFraction>% were used in the fair value calculation to reflect inherent development and regulatory risk of the IPR&amp;D. The discount rate applied was approximately <ix:nonFraction unitRef="number" contextRef="i27aa2a498bdb4d7fb75719ee6d31b90f_I20201001" decimals="2" name="jnj:BusinessAcquisitionDiscountRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzM5NzI_92f7accb-6f8f-4274-8bc5-19d6ac5d2e85">13</ix:nonFraction>%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. The transaction was accounted for as a business combination and included in the Pharmaceutical segment.                   </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with U.S.&#160;GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2022, 2021 and 2020 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company&#8217;s results of operations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During fiscal year 2022, the Company did not make any material divestitures. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During fiscal year 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $<ix:nonFraction unitRef="usd" contextRef="i07c8b24309d443688602562848d8298e_D20210104-20220102" decimals="-7" name="us-gaap:ProceedsFromDivestitureOfBusinesses" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzkwMDk_c4c7ffb4-a5ce-4c2c-82aa-1c64531b6d8d">0.6</ix:nonFraction>&#160;billion. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="ie9b7440a44a043808d095d95fbaae3cc">During fiscal year 2020, the Company sold <ix:nonFraction unitRef="shares" contextRef="ie3dd034235f641b9a1484d7974551ed8_D20191230-20210103" decimals="-5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzkwNTY_6be3daa8-92cc-4893-a48e-b1c34ea3bb7a">11.8</ix:nonFraction>&#160;million shares of Idorsia LTD (Idorsia), or its <ix:nonFraction unitRef="number" contextRef="ie3dd034235f641b9a1484d7974551ed8_D20191230-20210103" decimals="3" name="us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzkwOTk_5831718d-23e4-461d-b035-49b2ed52179d">8.3</ix:nonFraction>% ownership in the company at that time. The transaction resulted in gross proceeds of approximately CHF <ix:nonFraction unitRef="chf" contextRef="ie3dd034235f641b9a1484d7974551ed8_D20191230-20210103" decimals="-6" name="us-gaap:ProceedsFromSaleOfInterestInCorporateUnit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzkyMDU_75630753-54fb-428c-9070-ad0e4970f2b5">337</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="ie3dd034235f641b9a1484d7974551ed8_D20191230-20210103" decimals="-6" name="us-gaap:ProceedsFromSaleOfInterestInCorporateUnit" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzkyMDk_955cc9ce-ec87-4945-8639-6418850653e9">357</ix:nonFraction>&#160;million) based on a sales price of CHF <ix:nonFraction unitRef="usdPerShare" contextRef="i1aee0cedf1f94f5a8d36040886e87e0f_I20210103" decimals="2" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzkyNDM_e1a86d60-0eca-4db4-9f26-a91cfc2bc62e">28.55</ix:nonFraction>/share and resulted in an immaterial net loss. At the end of fiscal 2020, the Company had rights to approximately <ix:nonFraction unitRef="shares" contextRef="ie3dd034235f641b9a1484d7974551ed8_D20191230-20210103" decimals="-5" name="jnj:ConvertibleNoteEquityInterestNumberOfShares" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzkzNTk_13ef837d-c996-4a5c-a9a2-c8f6ae095b3c">38.7</ix:nonFraction>&#160;million shares through a convertible loan with a principal amount of CHF <ix:nonFraction unitRef="chf" contextRef="i5282653c940b42ef862b668ed6921a2d_I20210103" decimals="-5" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzk0Mjc_be39fed6-3518-4e60-b4ca-2644fca3bf78">445</ix:nonFraction>&#160;million (due June 2027). During fiscal year 2021, the Company converted CHF <ix:nonFraction unitRef="chf" contextRef="i0e37979e6ad844279246c3dd8ff74a38_D20210104-20220102" decimals="-6" name="jnj:DebtInstrumentConvertibleAmountOfLoanConverted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzk0OTg_13fdacf4-0570-42e4-8f1d-3f655bab357b">110</ix:nonFraction>&#160;million ($<ix:nonFraction unitRef="usd" contextRef="i0e37979e6ad844279246c3dd8ff74a38_D20210104-20220102" decimals="-6" name="jnj:DebtInstrumentConvertibleAmountOfLoanConverted" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzk1MDI_677bdbec-877c-4677-963e-3fd8612ac533">120</ix:nonFraction>&#160;million) of this loan into approximately <ix:nonFraction unitRef="shares" contextRef="i0e37979e6ad844279246c3dd8ff74a38_D20210104-20220102" decimals="-5" name="us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzk1Mzg_d6328b62-9dde-475d-8ac6-21bd45368111">9.6</ix:nonFraction>&#160;million shares of Idorsia which were reflected at fair value as of January 2, 2022. During the fiscal third quarter of 2021, the Company's undrawn credit facility with Idorsia was terminated.</ix:continuation> </span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i51a46167ef364951bf70ae9d6493776c_220"></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">19.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:LegalMattersAndContingenciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzI3NDg3NzkzNzc1ODE_96d1f226-4d4a-4278-b9bb-3e4036e94804" continuedAt="i9810d188c63d4a7ab7b423ae7ef2b24b" escape="true">Legal Proceedings</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="i9810d188c63d4a7ab7b423ae7ef2b24b" continuedAt="i02afcddca9b34481b68c56c0452d2922"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of January 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company&#8217;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#8217;s balance sheet, is not expected to have a material adverse effect on the Company&#8217;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant of these cases include: the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; the PINNACLE Acetabular Cup System; pelvic meshes; RISPERDAL; body powders containing talc, primarily JOHNSON'S Baby Powder; ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Flexible Composite Mesh; ELMIRON; and TYLENOL. As of January&#160;1, 2023, in the United States there were approximately <ix:nonFraction unitRef="claimant" contextRef="i647eea070e4240cca28f6b76979c3a28_I20230101" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzQ1OTY_735aa8dd-694f-425a-9591-d002dd074005">170</ix:nonFraction> plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; <ix:nonFraction unitRef="claimant" contextRef="i34154fc7f1e24a8cb5c558996d6b6896_I20230101" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzQ3NjA_d54c13c2-c98d-4ed5-bc8c-fbce7e656888">1,400</ix:nonFraction> with respect to the PINNACLE Acetabular Cup System; <ix:nonFraction unitRef="claimant" contextRef="i255cda4840fb4aa88fa64590ce872e72_I20230101" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzQ4MTY_b09239b2-4f72-45d6-a0dc-ad9d3a7621db">9,000</ix:nonFraction> with respect to pelvic meshes; <ix:nonFraction unitRef="claimant" contextRef="ie6cf165cbbd74fdfbb1fa0b952e8bff6_I20230101" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzQ4NTA_bef6c590-24f4-4dda-8bd0-95a31b187b8e">1,100</ix:nonFraction> with respect to RISPERDAL; <ix:nonFraction unitRef="claimant" contextRef="i2c9a481d368148b0929cadc2b0a5af97_I20230101" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzQ5MTA_c1131f39-c051-438c-b27f-29f9a0f53ee4">40,300</ix:nonFraction> with respect to body powders containing talc;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="claimant" contextRef="ie47bff957cb84bb49f3b161a5860618a_I20230101" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzQ5OTM_041cc840-8ead-4e53-981f-f9dc6930ceca">2,100</ix:nonFraction> with respect to ETHICON PHYSIOMESH Flexible Composite Mesh; <ix:nonFraction unitRef="claimant" contextRef="ibc66bcf7171d418a86ecd62a2404c17e_I20230101" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTkwOTAyMg_b3b4e0cb-9e47-41af-a97c-72bf87ec7ae6">2,000</ix:nonFraction> with respect to ELMIRON; and 170 with respect to TYLENOL. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">84</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><ix:continuation id="i02afcddca9b34481b68c56c0452d2922" continuedAt="i9d236d98e2e44f998555658073b8612b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than <ix:nonFraction unitRef="claimant" contextRef="i03778e924ff348b5a3f45913272ec65a_I20230101" decimals="0" name="jnj:Numberofpatientsinsettlement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTkyMjE1MQ_c8d59fd7-79b1-4c0f-9417-b57e3f17c612">10,000</ix:nonFraction> claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. Prior to 2019, several adverse verdicts had been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon&#8217;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#8217;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#8217;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia, Canada and South Africa. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In September 2022, after exhausting its appeals, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia, pending Federal Court approval. In November 2022, the application for approval of the settlement was filed, and a hearing on the settlement has been scheduled for the end of February 2023. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicon&#8217;s pelvic mesh products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">85</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9d236d98e2e44f998555658073b8612b" continuedAt="ib7a0b1692ecc4e4f8d21f1484ba59f5e"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately <ix:nonFraction unitRef="cases" contextRef="iddc88969213c48ea97060082ffa73825_I20210531" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTk0OTMzOQ_aea7c0c9-3aff-4dd9-8265-c088606ac9f0">3,600</ix:nonFraction> Physiomesh cases (covering approximately <ix:nonFraction unitRef="claimant" contextRef="iddc88969213c48ea97060082ffa73825_I20210531" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTk0OTM0NQ_44dc0025-e45c-4362-92a4-8d4a91b03dd5">4,300</ix:nonFraction> plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes <ix:nonFraction unitRef="cases" contextRef="ia897c0714e5c4774b0c045831789f7f2_I20210930" decimals="0" name="jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTk0OTM0Nw_4e9df01c-bdcc-4d6f-b452-82bab96c8176">3,729</ix:nonFraction> cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, <ix:nonFraction unitRef="cases" contextRef="iaf6a73a559664e0ebb512a48d328ad5e_D20210901-20210930" decimals="0" name="us-gaap:LossContingencyClaimsDismissedNumber" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTk0OTM1NA_910bcd34-e37c-4177-802b-b058792e49fb">2,236</ix:nonFraction> have been dismissed with prejudice. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of January 2023, there are approximately <ix:nonFraction unitRef="cases" contextRef="iac21980ceda94b21a50b291a322d153b_I20230101" decimals="0" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTk0OTM2MQ_a8899a5f-ef0f-479b-beaa-68cc30942e8a">208</ix:nonFraction> active cases subject to these orders which are being reviewed and evaluated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products.  All litigation activities in the two New Jersey MCLs are stayed pending resolution of the proposed settlement.  Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $<ix:nonFraction unitRef="usd" contextRef="i3682b642e54048a5b5181c77d2d45dd4_D20191001-20191031" decimals="-9" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTk1MDM2OA_9629d525-2217-463a-8d0f-dd4a5031e717">8.0</ix:nonFraction>&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $<ix:nonFraction unitRef="usd" contextRef="i5dcee1a6065d4ba0abd1619dd17fb039_D20200101-20200131" decimals="-5" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTk1MDM4Mg_6cbad731-80fc-4966-a24e-07987fa849a3">6.8</ix:nonFraction>&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury arising out of the use of XARELTO, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); the Company; and JPI&#8217;s collaboration partner for XARELTO, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases were filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and the Company announced an agreement in principle to settle the XARELTO cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp; Johnson Consumer Inc. and the Company arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $<ix:nonFraction unitRef="usd" contextRef="i595e23088c2c4b02bebb9612c8ab2a93_D20180701-20180731" decimals="-8" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyODkyNg_aec7027a-096b-4c12-81e1-1c2fce9cf5e7">4.7</ix:nonFraction>&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ingham v. Johnson &amp; Johnson, et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No. ED 207476 (Mo. App.), reducing the overall award to $<ix:nonFraction unitRef="usd" contextRef="i33aa324aaa9d42f4a185c9928408a20c_D20200601-20200630" decimals="-6" name="us-gaap:LossContingencyDamagesSoughtValue" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyODk0MA_1f97808c-d690-4fdb-b66a-370467e5422b">2.1</ix:nonFraction>&#160;billion. An application for transfer of the case to the Missouri Supreme Court </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ib7a0b1692ecc4e4f8d21f1484ba59f5e" continuedAt="i238011d40d5a4b1f8a6e36569aa23276"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $<ix:nonFraction unitRef="usd" contextRef="i748cd779f212410081567ad7ca01f948_D20210601-20210630" decimals="-6" name="us-gaap:PaymentsForLegalSettlements" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyODk1NA_614af2d9-4419-45e0-a93d-1e20e4bab885">2.5</ix:nonFraction>&#160;billion. The facts and circumstances, including the terms of the award, were unique to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#8217;s direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#8217;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#8217; compensation statute or act (the Talc-Related Liabilities). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, notwithstanding the Company&#8217;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the North Carolina Bankruptcy Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties). The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court extended the PI through the end of February 2022. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions by order issued in March 2022. The New Jersey Bankruptcy Court simultaneously issued another order extending the stay as to the Protected Parties. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss and the extension of the stay. In May 2022, the Third Circuit Court of Appeals granted the petitions to appeal. The briefing and oral argument on the appeal were completed in September 2022. On January 30, 2023, the Third Circuit reversed the Bankruptcy Court&#8217;s ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy.  LTL filed a petition for rehearing on the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the New Jersey Bankruptcy Court&#8217;s order effectively stays all of the Company&#8217;s talc-related personal injury litigation, LTL has agreed to lift the stay on a small number of appeals where appeal bonds have been filed.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $<ix:nonFraction unitRef="usd" contextRef="i2391578fa34543b695b3fb891576fdee_D20211001-20211031" decimals="-9" name="jnj:LossContingencyReserveEstablishedWithinTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyODk2OA_489d0efd-5782-400e-89fd-7d1ef9be368e">2</ix:nonFraction>&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $<ix:nonFraction unitRef="usd" contextRef="i2391578fa34543b695b3fb891576fdee_D20211001-20211031" decimals="-9" name="jnj:LossContingencyReserveEstablishedWithinTrust" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyODk4MA_b19facd9-58b2-4e5a-b110-40a0487c8d91">2</ix:nonFraction>&#160;billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action). The Edley Class Action asserts, among other things, that the Company fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by the Company&#8217;s then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter. The Company removed the Edley Class Action to federal court in the District of New Jersey. In July 2022, Imerys filed a motion in the Imerys Bankruptcy to stay the Edley Class Action, which was denied in August 2022.  In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds.  In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#8217; Committee (TCC), and the Future Claimants&#8217; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">87</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i238011d40d5a4b1f8a6e36569aa23276" continuedAt="ie79f7c4a2dde45099330db1f4adf783d"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#8217;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, certain of Imerys&#8217;s insurers, and certain parties in the Cyprus Mines chapter 11 case (described below) (collectively the Mediation Parties) agreed to engage in mediation. The most recent term of the mediation ended on December 31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys Adversary Proceeding). The Imerys Adversary Proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#8217;s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys Adversary Proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Cyprus Mines Corporation and its parent, Cyprus Amax Minerals Company (CAMC) (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus Adversary Proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain protected parties. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus Adversary Proceeding. In June 2022, Cyprus commenced an Adversary Proceeding in its chapter 11 case seeking an order enforcing the automatic stay by enjoining parties from commencing or continuing &#8220;talc-related claims&#8221; against CAMC. In June 2022, the court entered a preliminary injunction order enjoining claimants from pursuing talc-related claims against CAMC through January 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, several of the Company&#8217;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action. In March 2022, the New Jersey Bankruptcy Court ruled that the LTL automatic stay applied to the Coverage Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder, and that purchasers of the Company&#8217;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiff&#8217;s motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff&#8217;s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. In April 2022, Defendants filed a second motion to supplement the class certification record.  In May 2022, the New Jersey Bankruptcy Court entered an order staying the securities class action. Plaintiff has appealed the Bankruptcy Court&#8217;s order.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ie79f7c4a2dde45099330db1f4adf783d" continuedAt="i7cc7d367349e4cee95d394aa6a7bc170"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#8217;S Baby Powder. In that lawsuit, the plaintiffs allege that the Company violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. In October 2021, Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit. A bankruptcy stay was imposed in December 2021, and the Court held the reply deadline in abeyance. In February 2022, the Bankruptcy Court issued an order extending the stay. The appeal continues to be held in abeyance, with the Company being required to file periodic status updates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of INVOKANA, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against Johnson and Johnson Consumer Inc. (JJCI), arising out of the use of TYLENOL, an over-the-counter pain medication, alleging that prenatal exposure to acetaminophen is associated with the development of autism spectrum disorder and/or attention-deficit/hyperactivity disorder. In October 2022, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the Southern District of New York.  In addition, lawsuits have been filed in Canada.  Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with TYLENOL related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i7cc7d367349e4cee95d394aa6a7bc170" continuedAt="i9181e9eada684dde9c546907b5b1db76"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">MedTech</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos.  6,522,906 (&#8217;906); 6,800,056 (&#8217;056); 8,142,447 (&#8217;447); and 9,452,276 (&#8217;276) based on Auris&#8217; MONARCH Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the &#8217;056, &#8217;447, &#8217;276 and &#8217;906 patents.  In December 2019, the USPTO denied review of the &#8217;056 patent. In February and March 2020, the USPTO instituted review of the &#8217;447, and &#8217;906 patents and denied review of the &#8217;276 patent. In March 2021, the USPTO ruled that the challenged claims of the &#8217;447 and &#8217;906 patents are not invalid. Auris appealed, and in April 2022, the United States Court of Appeals for the Federal Circuit vacated the decision that the &#8217;447 patent was not invalid and remanded the decision to the USPTO for further review.  In May 2022, the United States Court of Appeals for the Federal Circuit confirmed the ruling that claim 53 of the &#8217;906 patent was not invalid, vacated the decision that the remaining claims of the &#8217;906 patent were not invalid and remanded the decision to the USPTO for further review. Auris filed a request for reexamination of the &#8217;276 patent in November 2021, and in January 2022, the USPTO granted the reexamination request. Trial is scheduled to begin in September 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in the United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of U.S. Patent Nos. 6,984,234 (&#8217;234) and 9,713,537 (&#8217;537) by one or more of the following products:  ZERO-P-VA Spacer, ZERO-P Spacer, ZERO-P NATURAL Plate, SYNFIX LR Spacer and SYNFIX Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. In June 2022, DePuy filed potentially dispositive summary judgment motions that the &#8217;234 patent is invalid as anticipated and the &#8217;537 patent is not infringed.  In November 2022, the Court granted DePuy&#8217;s summary judgment motion that the &#8217;234 patent is invalid as anticipated and denied DePuy&#8217;s motion that the &#8217;537 patent is not infringed.  In December 2022, the Court conducted a jury trial on the &#8217;537 patent where the jury found that the &#8217;537 patent was not literally infringed, but that DePuy infringed under the doctrine of equivalents (DOE).  The jury awarded RSB $12 million in damages subject to post-trial motions and appeals.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Rasmussen Instruments, LLC (Rasmussen) filed a patent infringement suit against DePuy Synthes Products, Inc., DePuy Synthes Sales, Inc. and Medical Device Business Services, Inc. (collectively, DePuy) in the United States District Court for the District of Massachusetts. Rasmussen alleges that DePuy willfully infringes U.S. Patent Nos. 9,492,180 (&#8217;180) and 10,517,583 (&#8217;583) by making and selling the Attune Balanced Sizer. In April 2021, Rasmussen sought permission to amend its infringement contentions to allege that DePuy also willfully infringes the &#8217;583 patent by making and selling the Attune Balancing Blocks. Rasmussen seeks treble damages for willful infringement. Trial concluded in March 2022, with the jury returning a verdict in favor of Rasmussen, finding willful infringement of the &#8217;180 patent, and awarding damages in the amount of $<ix:nonFraction unitRef="usd" contextRef="if6878b220b444ed8b48a88bc1bfe70dc_D20220301-20220322" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyODk5Mg_7f531309-b384-47a0-b236-4da7cb731b86">20</ix:nonFraction>&#160;million. DePuy challenged the verdict in its post-trial motions. In July 2022, a hearing was held on the post-trial motions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes lawsuits the Company&#8217;s subsidiaries have brought against generic companies that have filed ANDAs with the U.S. FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents. In the event the Company&#8217;s subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the U.S. FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#8217;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. </span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i9181e9eada684dde9c546907b5b1db76" continuedAt="i857419e9a7914debaf90b246668ada92"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYTIGA </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in January 2019, Janssen Inc., Janssen Oncology, Inc., and BTG International Ltd. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy&#8217;s Laboratories Ltd. and Dr. Reddy&#8217;s Laboratories, Inc. (collectively, DRL) in response to those parties&#8217; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA before the expiration of the Canadian Patent No. 2,661,422 (&#8217;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#8217;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision. The appeal hearing took place in September 2022. In November 2022, Janssen's appeal was dismissed.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, July 2021 and April 2022, respectively, Apotex, DRL and Pharmascience initiated Statements of Claim under Section 8 of the Patented Medicines (Notice of Compliance) Regulations against Janssen seeking damages in respect of those parties generic Zytiga tablets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Trials against Apotex and DRL are scheduled for June 2023. A trial date for the Pharmascience action has not been set.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XARELTO</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO (2.5 mg) before expiration of U.S. Patent No. 10,828,310 (&#8217;310). The following generic drug companies are named defendants:  Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories, Ltd.; Lupin Limited and Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc.; and Teva Pharmaceuticals USA, Inc. In October 2021, the court consolidated the Delaware lawsuits for all purposes, including trial. Trial for the consolidated Delaware lawsuits is scheduled to begin in May 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan) which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#8217;310 patent. In August 2021, JPI and Bayer filed a motion before the United States Judicial Panel on Multidistrict Litigation (the MDL panel) to transfer this lawsuit to the United States District Court for the District of Delaware for coordinated and consolidated pretrial proceedings. In December 2021, the MDL panel granted the motion. In August 2022, after receiving a second notice letter from Mylan regarding the same ANDA, JPI and Bayer filed a second patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan. In September 2022, Mylan moved to dismiss the second lawsuit. In September 2022, the MDL panel transferred the second lawsuit to the District of Delaware. No trial date has been set for these two lawsuits. In October 2022, Mylan voluntarily withdrew its motion to dismiss.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent. In January 2023, the court issued an order staying the lawsuits until after a final written decision is issued in the Inter Partes Review proceedings on the &#8217;310 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Mylan Pharmaceuticals Inc. filed a Petition for Inter Partes Review (IPR) with the United States Patent and Trademark Office (USPTO), seeking to invalidate the &#8217;310 patent. In August 2022, the Patent Trial and Appeal Board (PTAB) issued a decision instituting IPR.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, InvaGen Pharmaceuticals, Inc. filed a Petition for IPR with the USPTO seeking to invalidate the &#8217;310 patent. Also in September 2022, Teva Pharmaceuticals USA, Inc. filed a Petition for IPR with the USPTO seeking to invalidate the &#8217;310 patent. In October 2022, the PTAB issued decisions instituting IPR in both proceedings and joining them with the earlier IPR proceeding filed by Mylan Pharmaceuticals Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, JPI, Bayer, and Bayer Intellectual Property GmbH (BIP) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against USV Private Limited (USV), who filed an ANDA seeking approval to market generic versions of XARELTO (2.5 mg, 10 mg, 15 mg, and 20 mg) before the expiration of the '310 patent and U.S. Patent No. 9,539,218 (&#8217;218). JPI, Bayer, and BIP are seeking an order enjoining USV from marketing its generic version of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent, and its generic versions of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#8217;218 patent. In November 2022, the MDL panel transferred this lawsuit to the United States District Court for the District of Delaware.</span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i857419e9a7914debaf90b246668ada92" continuedAt="ic614405bcfaf490e83acec79db6921f5"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, JPI, Bayer AG, and BIP </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mankind Pharma Limited (Mankind), who filed an ANDA seeking approval to market generic versions of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#8217;218 patent. JPI, Bayer AG, and BIP are seeking an order enjoining Mankind from marketing its generic versions of XARELTO before the expiration of the &#8217;218 patent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, JPI, Bayer, and BIP initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Epic Pharma, LLC (Epic), who filed an ANDA seeking approval to market generic versions of XARELTO (2.5 mg, 10 mg, 15 mg, and 20 mg) before the expiration of the &#8217;310 patent and the &#8217;218 patent. JPI, Bayer, and BIP are seeking an order enjoining Epic from marketing its generic version of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent, and its generic versions of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#8217;218 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, JPI and Bayer initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Apotex Inc. and Apotex Corp. (collectively, Apotex), who filed an ANDA seeking approval to market generic versions of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent. JPI and Bayer are seeking an order enjoining Apotex from marketing its generic version of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSUMIT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen Inc. (Janssen) and Actelion Pharmaceuticals Ltd (Actelion) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of Canadian Patent No. 2,659,770 (&#8217;770). Sandoz stipulated to infringement of the &#8217;770 patent.  Trial against Sandoz on the issue of validity concluded in February 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Sandoz appealed the decision. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the &#8217;770 patent. Apotex stipulated to validity of the &#8217;770 patent.  Trial against Apotex on the issue of infringement concluded in March 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Apotex appealed the decision.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#404a52;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Generic Medical Partners Inc. (GMP) in Canada in response to GMP&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT 10 mg, before the expiration of Canadian Patent Nos. 2,659,770 and 2,621,273.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. (collectively, Actelion) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Sun Pharmaceutical Industries Limited and Sun Pharmaceutical Industries, Inc. (collectively, Sun) who filed an ANDA seeking approval to market a generic version of OPSUMIT before the expiration of U.S. Patent Nos. 7,094,781 (&#8217;781) and 10,946,015 (&#8217;015).  Actelion is seeking an order enjoining Sun from marketing their generic versions of OPSUMIT before the expiration of the &#8217;781 and &#8217;015 patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA SUSTENNA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of U.S. Patent No. 9,439,906 (&#8217;906). Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen&#8217;s favor. Teva has appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent. Pursuant to an agreement by the parties, judgment in favor of Janssen was entered in December 2021. Mylan appealed. </span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic614405bcfaf490e83acec79db6921f5" continuedAt="i1924357b5f6d4dab8c2a3cc661895c28"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Tolmar, Inc., Tolmar Therapeutics, Inc., Tolmar Pharmaceuticals, Inc. and Tolmar Holding, Inc. (collectively, Tolmar), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent. A trial is scheduled to begin in October 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Accord Healthcare, Inc., Accord Healthcare, Ltd. and Intas Pharmaceuticals, Ltd. (collectively, Accord), who filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of Canadian Patent Nos. 2,309,629 (&#8217;629) and 2,655,335 (&#8217;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#8217;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#8217;s generic version of INVEGA SUSTENNA, if approved, would infringe certain claims of the &#8217;335 patent and that the claims of the &#8217;335 patent are not invalid. Teva Canada appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in November 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Pharmascience filed an appeal. In March 2022, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience in response to Pharmascience&#8217;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. The action has been consolidated with the November 2020 action for trial, which took place in July 2022. In August 2022, the Court issued a decision finding the claims of the&#8217;335 patent are not invalid. Pharmascience appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex&#8217;s filing of an ANDS (original ANDS) seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in December 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Apotex appealed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Janssen Canada initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex in response to Apotex&#8217;s Notice of Allegation of invalidity with respect to the original ANDS and in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A trial is scheduled to begin in March 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA TRINZA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LLC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (546 mg) before expiration of U.S. Patent No. 10,143,693 (&#8217;693) relating to INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(546 mg).  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(819 mg) before expiration of the &#8217;693 patent.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="i1924357b5f6d4dab8c2a3cc661895c28" continuedAt="idc5793c5388643d295f7611b41c5476a"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (273 mg and 410 mg) before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the court consolidated the three cases into the case filed in September 2020. In each of these consolidated cases, Janssen is seeking an order enjoining Mylan from marketing its generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before expiration of the &#8217;693 patent. Trial was conducted in November and December 2022, and post-trial briefing is proceeding. Closing arguments will be held in March 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMBRUVICA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA tablets, asserting infringement of U.S. Patent Nos. 7,514,444; 8,003,309; 8,476,284; 8,497,277; 8,697,711; 8,753,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of U.S. Patent No. 10,213,386. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trial against Alvogen took place in October 2020. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. In November 2022, the United States Court of Appeals for the Federal Circuit affirmed the District Court&#8217;s decision.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#8217;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capsules before the expiration of Canadian Patent Nos. 2,663,116 (&#8217;116); 2,928,721 (&#8217;721); 2,800,913 (&#8217;913); 3,007,787 (&#8217;787); 3,007,788 (&#8217;788); 2,875,986 (&#8217;986); and 3,022,256 (&#8217;256). In this lawsuit, Pharmacyclics and Janssen Canada are seeking an order enjoining Natco from marketing its generic version of IMBRUVICA before the expiration of the relevant patents. Trial is scheduled to begin in July 2023.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Pharmacyclics and Janssen Canada initiated a second Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco in response to Natco&#8217;s filing of an ANDS seeking approval to market a generic version of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capsules before the expiration of the &#8217;116, &#8217;721, &#8217;913, &#8217;787, and &#8217;788 patents and Canadian Patent No. 2,851,808. In this lawsuit, Pharmacyclics and Janssen Canada are seeking an order enjoining Natco from marketing its generic version of IMBRUVICA capsules before the expiration of the relevant patents. Trial in this second action is scheduled to begin in August 2024. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, Pharmacyclics and Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capsules before the expiration of the &#8217;116, &#8217;913, &#8217;787, and &#8217;788 patents. Also in February 2023, Pharmacyclics and Janssen initiated a Statement of Claim under Section 8.2 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz asserting the &#8217;721 and &#8217;256 patents, which are also listed in Health Canada&#8217;s Patent Register for IMBRUVICA. In these lawsuits, Pharmacyclics and Janssen Canada are seeking an order enjoining Sandoz from marketing its generic version of IMBRUVICA capsules before the expiration of the relevant patents. A trial date for these actions has not been set. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SYMTUZA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited, Lupin Pharmaceuticals, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., and MSN Pharmaceuticals Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of SYMTUZA before the expiration of U.S. Patent Nos. 10,039,718 (&#8217;718) and 10,786,518 (&#8217;518). The trial is scheduled to begin in October 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Apotex Inc. and Apotex Corp. (collectively, Apotex), which filed an ANDA seeking approval to market a generic version of SYMTUZA before the expiration of the &#8217;718 and &#8217;518 patents. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="idc5793c5388643d295f7611b41c5476a" continuedAt="id361e289793e4df2917a407f7bcb42bc"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of SYMTUZA before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ERLEADA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. (collectively, Janssen) and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of U.S. Patent No. 9,481,663 (&#8217;663). In August 2022, Janssen and SKI filed a first amended complaint against Lupin adding U.S. Patent Nos. 9,884,054 (&#8217;054), 10,052,314 (&#8217;314), 10,702,508 (&#8217;508) and 10,849,888 (&#8217;888) to the suit. Janssen and SKI are seeking an order enjoining Lupin from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents. In August 2022, Janssen and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Janssen and SKI initiated a patent infringement lawsuit in United States District Court for the District of New Jersey against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA), Inc., and Zydus Lifesciences Limited (collectively, Zydus), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents. Janssen and SKI are seeking an order enjoining Zydus from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Janssen, The Regents of the University of California (UC), and SKI initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Sandoz Inc. (Sandoz), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663 patent and U.S. Patent Nos. 8,445,507 (&#8217;507), 8,802,689 (&#8217;689), 9,338,159 (&#8217;159), and 9,987,261 (&#8217;261).  In August 2022, Janssen, UC, and SKI filed a first amended complaint against Sandoz adding the &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents to the suit. In August 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint.  In December 2022, Janssen, UC, and SKI filed a second amended complaint against Sandoz withdrawing the &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents from the suit without prejudice.  Janssen, UC, and SKI are seeking an order enjoining Sandoz from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507, &#8217;689, &#8217;159, and &#8217;261 patents.  The New Jersey action is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Janssen, UC, and SKI initiated patent infringement lawsuits in United States  District Court for the Districts of New Jersey and Delaware against Eugia Pharma Specialities Limited, Aurobindo Pharma USA, Inc., and Auromedics Pharma LLC (collectively, Eugia), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of  the &#8217;663, &#8217;507, &#8217;689, &#8217;159 and &#8217;261 patents. In September 2022, Janssen, UC, and SKI filed a first amended complaint against Eugia adding U.S. Patent Nos. 9,884,054 (&#8217;054), 10,052,314 (&#8217;314), 10,702,508 (&#8217;508) and 10,849,888 (&#8217;888) to the suit. In September 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint. Janssen, UC, and SKI are seeking an order enjoining Eugia from marketing its generic version of ERLEADA before the expiration of the &#8217;663,&#8217;507, &#8217;689, &#8217;159, &#8217;261, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents. The New Jersey action is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Janssen, UC, and SKI initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Hetero Labs Limited Unit V and Hetero USA, Inc. (collectively, Hetero), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507,&#8217;054, &#8217;314,&#8217;508, and &#8217;888 patents. Janssen, UC, and SKI are seeking an order enjoining Hetero from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507, &#8217;054, &#8217;314, &#8217;508 and &#8217;888 patents.  In August 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UPTRAVI </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Actelion Pharmaceuticals Ltd, and Janssen Inc. (collectively, Janssen) and Nippon Shinyaku Co. (Nippon Shinyaku) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. in response to Sandoz&#8217;s filing of an ANDS seeking approval to market generic versions of UPTRAVI tablets before the expiration of Canadian Patent Nos. 2,731,370 and 2,764,475. In this lawsuit, Janssen and Nippon Shinyaku are seeking an order enjoining Sandoz from marketing its generic version of UPTRAVI before the expiration of the relevant patents. A trial is scheduled to begin in May 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Actelion Pharmaceuticals US Inc. and Actelion Pharmaceuticals Ltd (collectively, Actelion) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals Inc. (collectively, Alembic) who filed an </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="id361e289793e4df2917a407f7bcb42bc" continuedAt="ib25d6f198a714bfbaedd8d7250cf12a0"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANDA seeking approval to market generic versions of UPTRAVI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">injection for intravenous use before expiration of U.S. Patent Nos. 8,791,122 (&#8217;122) and 9,284,280 (&#8217;280) relating to UPTRAVI. In this lawsuit, Actelion and Nippon Shinyaku are seeking an order enjoining Alembic from marketing a generic version of UPTRAVI before the expiration of the relevant patents. A trial date has not been set. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2023, Actelion and Nippon Shinyaku initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Ltd. and Lupin Pharmaceuticals, Inc. (collectively, Lupin) who filed an ANDA seeking approval to market generic versions of UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">injection for intravenous use before expiration of the &#8217;122 and &#8217;280 patents relating to UPTRAVI. In this lawsuit, Actelion and Nippon Shinyaku are seeking an order enjoining Lupin from marketing a generic version of UPTRAVI before the expiration of the relevant patents. A trial date has not been set.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Litigation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Janssen Pharmaceutica N.V. (Janssen) provided to Alkermes Pharma Ireland Limited, Elan Pharma International Limited, and Elan Drug Delivery, Inc. three-months&#8217; notice of termination of a License Agreement by and among Elan Pharmaceutical Research Corp., d/b/a Nanosystems, Elan Pharma International Limited and Janssen, executed in March, 1999. In November 2021, Janssen also provided to Alkermes Pharma Ireland Limited three-months&#8217; notice of termination of a License Agreement between Elan Pharma International Limited and Janssen executed in July 2003. In April 2022, in response to these notices, Alkermes Pharma Ireland Limited (Alkermes) initiated arbitration in the International Institute for Conflict Prevention and Resolution. The parties exchanged opening briefs in July 2022 and responsive briefs in September 2022.  In December 2022, the Arbitration Tribunal issued an Interim Decision finding that Janssen may terminate the agreements, but it may not continue to sell products developed during the term of the agreements without continuing to pay royalties to Alkermes.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the pharmaceutical, consumer health and medical devices industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Average Wholesale Price (AWP) Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), the Company and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opioid Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to <ix:nonFraction unitRef="claimant" contextRef="ibe39ec7be3e24f578dd104058f18f8a3_I20230101" decimals="0" name="jnj:ProductLiabilityContingencyNumberOfClaimant" format="ixt:num-dot-decimal" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTAwNQ_52b02c02-df32-452c-8148-6f8a47f6b752">3,500</ix:nonFraction> lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including the Company and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in every state but Alaska. The Government of Puerto Rico filed suit in Superior Court of San Juan. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="ib25d6f198a714bfbaedd8d7250cf12a0" continuedAt="i47f6cc7f535343178c0f1cabdedf336b"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, JPI and other pharmaceutical companies had also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, the Company and JPI were contacted by the Texas and Colorado Attorney General&#8217;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against the Company and JPI in the amount of $<ix:nonFraction unitRef="usd" contextRef="i8fe1e7bec0cc453594ea48b53c12aae3_D20191230-20200927" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTAxNA_6d06a682-c2fc-40bb-83ca-43b72c072992">465</ix:nonFraction>&#160;million. The Company and JPI appealed the judgment, and in November 2021, the Oklahoma Supreme Court reversed the trial court&#8217;s judgment and directed entry of judgment for Defendants. In October 2019 the Company and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against the Company and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021, and in December 2021, the Court entered a final trial judgment in favor of Defendants on all claims. In February 2022, Plaintiffs&#8217; motion to set aside and vacate the judgment was denied. Plaintiffs appealed the judgment, but later filed a request to dismiss the appeal after electing to participate in the national settlement agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $<ix:nonFraction unitRef="usd" contextRef="i78a211fb9da44857b52720a3523178e1_I20191031" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTAyOA_f227ef1c-14e5-4fed-9ab9-ca91c0262f09">4</ix:nonFraction>&#160;billion as settlement of these matters that had not been tried or settled. In October 2020, the Company agreed to contribute up to an additional $<ix:nonFraction unitRef="usd" contextRef="ibd40d3a12acb4dcfbf80471e318ded84_I20201031" decimals="-9" name="jnj:LossContingencyEstimateOfAdditionalPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTA0MA_7d71b7b4-9b45-4d4d-b435-c29ce87f0cae">1</ix:nonFraction>&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $<ix:nonFraction unitRef="usd" contextRef="ibd40d3a12acb4dcfbf80471e318ded84_I20201031" decimals="-6" name="us-gaap:LossContingencyEstimateOfPossibleLoss" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTA1Mg_44a29709-efce-46e7-b2b5-9dc28ae97d88">5</ix:nonFraction>&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately half of the all-in settlement was expected to be paid by the end of fiscal year 2022, depending upon the level of participation by the states and their subdivisions. The terms provided a period of time for states to elect to participate in the agreement and, thereafter, a period for the subdivisions of the participating states to opt-in. Based on expected participation, the Company committed in advance to proceed with the settlement in five of the participating states (New York, Texas, Florida, Nevada, and New Mexico) and with tribal governments. By late February 2022, 45 states, five territories, the District of Columbia, and the vast majority of eligible subdivisions had elected to participate in the settlement, and the Company confirmed that the level of participation was sufficient to proceed with the agreement as to all participants. The agreement was effective in April 2022. Also in April 2022, the Company entered into settlement agreements with the states of Alabama and West Virginia and their participating subdivisions. In July 2022, the Company reached a settlement agreement with all litigating Oklahoma subdivisions, and in September 2022, the Company settled with the State of New Hampshire and its participating subdivisions. Consequently, by the end of the fiscal year 2022, the Company had settled the opioid claims advanced by all states except Washington.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are approximately <ix:nonFraction unitRef="claim" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="INF" name="us-gaap:LossContingencyPendingClaimsNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTA2OA_daaefb99-6737-4031-b805-a04223ae5075">60</ix:nonFraction> cases remaining post-settlement in various state courts. There are approximately <ix:nonFraction unitRef="claim" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="INF" name="jnj:LossContingencyPendingClaimsNumberRemaining" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTA2NA_5fe8c546-21fc-4edd-9179-2351eb590d82">570</ix:nonFraction> remaining federal cases against the Company and JPI coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio, and approximately <ix:nonFraction unitRef="claim" contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101" decimals="INF" name="jnj:LossContingencyPendingClaimsNumberAdditional" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTA3MA_96afde91-32a8-4c2a-98d2-79d0641c0504">20</ix:nonFraction> additional cases pending against the Company and JPI in other federal courts. In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an antitrust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i47f6cc7f535343178c0f1cabdedf336b" continuedAt="i99ab5b24cd464614931cad5d9a68df79"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020. By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted the Company&#8217;s motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state court&#8217;s dismissal order.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#8217;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#8217; second amended complaint; the District Court denied DePuy&#8217;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#8217;s July 2021 ruling. In November 2021, the District Court granted DePuy&#8217;s motion for reconsideration and dismissed the case with prejudice. The District Court&#8217;s order was unsealed in December 2021. The relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration, which the District Court denied. Following the District Court&#8217;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#8217; fees and costs, which the District Court denied except as to costs. The Relators have appealed the District Court&#8217;s dismissal of the case to the First Circuit. The briefing on the appeal is complete, the First Circuit held oral argument on December 6, 2022, and the First Circuit&#8217;s decision remains pending.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2012, the Company was contacted by the California Attorney General&#8217;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by the Company&#8217;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against the Company, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, the Company and Ethicon settled the Washington case. In October 2019, the Company and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon. In November 2020, the Company settled with the Attorney General of Mississippi. Trial in the Kentucky matter is scheduled for June 2023. The California case started trial in July 2019 and concluded in September 2019. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $<ix:nonFraction unitRef="usd" contextRef="ie97127abe6644e81b414d38b27b36e32_D20200101-20200131" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTA3NQ_b5a5f870-4d12-47ca-896b-dfaafb02fd9c">344</ix:nonFraction>&#160;million. In April 2020, the Court in California denied the Company&#8217;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $<ix:nonFraction unitRef="usd" contextRef="ie97127abe6644e81b414d38b27b36e32_D20200101-20200131" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTA4OQ_9fa41753-cd17-4a82-bc24-0d88a3785aaa">344</ix:nonFraction>&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company appealed the penalty judgment. In April 2022, the Court of Appeals reduced the judgment to $<ix:nonFraction unitRef="usd" contextRef="i3b4964f990444943801868a6dd79fc6b_D20220401-20220430" decimals="-6" name="us-gaap:LossContingencyDamagesAwardedValue" format="ixt:num-dot-decimal" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTEwMw_4c44fa84-f6a0-4c24-99aa-20e5c6790100">302</ix:nonFraction>&#160;million, but otherwise denied the appeal. In July 2022, the Supreme Court of California denied the Company&#8217;s petition to review the Court of Appeals decision, and the Company recorded a charge to reflect the judgment in the second quarter of 2022. In November 2022, the Company petitioned the United States Supreme Court for review.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against the Company and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#8217; use of talc contained in JOHNSON&#8217;S Baby Powder and JOHNSON&#8217;S Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. The Company and JJCI moved for summary judgment on the grounds that the State&#8217;s claim was barred by preemption, which the trial court denied. The Mississippi Supreme Court granted the Company and JJCI&#8217;s request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing and oral argument were completed. Thereafter, the Court </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i99ab5b24cd464614931cad5d9a68df79" continuedAt="ia9007a49e4154963a2bcfffcf068def6"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rejected the interlocutory appeal in April 2021 and remanded the matter to the trial court. In August 2021, JJCI filed a Petition for Writ of Certiorari in the United States Supreme Court as to the Mississippi Supreme Court&#8217;s ruling of April 2021. In December 2021 the United States Supreme Court denied the Petition for Writ of Certiorari. After the Mississippi Supreme Court remanded the matter to the trial court, the State moved for a trial setting. JJCI objected to any trial setting as barred by the stay arising from the LTL Bankruptcy Case, referenced above, while the State argued that the stay did not apply. In January 2022, the Court granted the State&#8217;s motion for trial setting and directed the parties to consult with the Court administrator to secure a trial date. In February 2022, the trial court set the case for trial to begin in February 2023. However, given the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a temporary stay of discovery until May 2022. The temporary stay expired in May 2022. LTL thereafter moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. The State filed an appeal to the Third Circuit concerning the stay order.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. In March 2022, the New Mexico court denied the Company&#8217;s motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Company&#8217;s request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexico&#8217;s discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. In December 2022, the State filed an appeal to the Third Circuit concerning the stay order. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexico&#8217;s discovery obligations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty-two states and the District of Columbia have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states (including Mississippi and New Mexico) agreed to mediation of their claims in the LTL Bankruptcy Case. In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court. LTL moved the New Jersey Bankruptcy Court for an order staying further proceedings in those two actions, which the Bankruptcy Court granted in October 2022.  In December 2022, the Bankruptcy Court allowed New Mexico and Mississippi to file a direct appeal of its stay.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April and September 2017, the Company received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX, OLYSIO, REMICADE, SIMPONI, STELARA and ZYTIGA. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div></ix:continuation><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ia9007a49e4154963a2bcfffcf068def6" continuedAt="ic3d48a2b6ed94cd181428b2a69ff4036"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, the Company received a subpoena from the United States Attorney&#8217;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. (DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals.  The Company and DePuy fully cooperated with the government&#8217;s investigation. In January 2023, the Company, DePuy Synthes, Inc., and DePuy Synthes Sales Inc. entered into a settlement agreement with the United States resolving the matter for an immaterial amount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE against the Company and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re REMICADE Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in United States District Court for the Eastern District of Pennsylvania. This case was settled in February 2022.  The final approval hearing is scheduled for February 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#8217;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands.  Janssen is in ongoing discussions with the FTC staff regarding the inquiry. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc. seeking milestones and an extended royalty term for Darzalex FASPRO. Janssen filed its Notice of Defense in July 2022. Genmab and Janssen have cross-moved for early disposition of the arbitration.  Argument was had in January 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#8217;s decision. In February 2022, defendants petitioned for rehearing en banc. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In October 2019, the Court granted Actelion&#8217;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="ic3d48a2b6ed94cd181428b2a69ff4036" continuedAt="i97292f8b669b497991908b23a07c5630"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#8217; motions to dismiss. Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint. In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. In December 2021, several insurance companies and other payers filed individual &#8220;Opt-Out&#8221; complaints containing allegations similar to the original complaint. In September 2022, the Court granted in part and denied in part plaintiff&#8217;s motion for class certification. In January 2023, the Court granted in part and denied in part defendants&#8217; motion for summary judgment.  Trial is scheduled for May 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#8217;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#8217;s motion to dismiss. In December 2021, BWI filed a motion for summary judgment. In March 2022, the Court granted BWI&#8217;s motion for summary judgment. In April 2022, Innovative appealed this ruling to the United States Court of Appeals for the Ninth Circuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company received a demand for indemnification from Pfizer Inc. (Pfizer), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson Inc. received notice reserving rights to claim indemnification from Sanofi Consumer Health, Inc. (Sanofi), pursuant to the 2016 Asset Purchase Agreement between Johnson &amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim), pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. In November 2022, Johnson &amp; Johnson received a demand for indemnification from GlaxoSmithKline LLC (GSK), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer, and certain 1993, 1998, and 2002 agreements between Glaxo Wellcome and Warner-Lambert entities. The notices seek indemnification for legal claims related to over-the-counter ZANTAC (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief. The Company and Johnson &amp; Johnson Inc. have also been named in putative class actions filed in Canada with similar allegations regarding ZANTAC or ranitidine use. Johnson &amp; Johnson Inc. was also named as a defendant along with other manufacturers in various personal injury actions in Canada related to ZANTAC products. Johnson &amp; Johnson Inc. has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Asset Purchase Agreement related to the class actions and personal injury actions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#8217; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for January 2024.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Emergent Biosolutions Inc. et al (&#8220;EBSI&#8221;) with the American Arbitration Association, alleging that EBSI breached the parties&#8217; Manufacturing Services Agreement for the Company&#8217;s COVID-19 vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In July 2022, Emergent filed its answering statement and counterclaims.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Merck Sharp &amp; Dohme Corp. with the American Arbitration Association pursuant to the Parties&#8217; agreements relating to production of drug substance and drug product for the Company&#8217;s COVID-19 vaccine. Also in October 2022, Merck filed its answer and counterclaims.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in May 2021, multiple putative class actions were filed in state and federal courts (California, Florida, New York, and New Jersey) against various Johnson &amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products and the affirmative promotion of those products as &#8220;safe&#8221;; and, in at least one case, alleging a strict liability manufacturing defect and failure to warn claims, asserting that the named plaintiffs suffered unspecified injuries as a result of alleged exposure to benzene. The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. In December 2021, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">101</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="i97292f8b669b497991908b23a07c5630"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiffs in the consolidated actions filed a motion for preliminary approval of a nationwide class settlement. The settlement was preliminarily approved by the court in March 2022.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company (subsequently substituted by Johnson &amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:10pt"><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_223"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">20. <ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90ZXh0cmVnaW9uOmVkOWRkOWM2NzhjMDRhNmU4ZDZiMTUzZjYxMGFlYTY2XzIzODc_1a170e40-7f85-4017-849e-5d2c535f4b27" continuedAt="i05836f7bca7d4176a1d5ec3a7d083912" escape="true">Restructuring</ix:nonNumeric></span></div><ix:continuation id="i05836f7bca7d4176a1d5ec3a7d083912"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2018, the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In fiscal year 2022, the Company recorded a pre-tax charge of $<ix:nonFraction unitRef="usd" contextRef="i2474e48849f1407492b006d664c27c42_D20220103-20230101" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90ZXh0cmVnaW9uOmVkOWRkOWM2NzhjMDRhNmU4ZDZiMTUzZjYxMGFlYTY2XzY1Mg_bcdcf1df-9a28-47c2-b485-2a21b23af93e">0.5</ix:nonFraction> billion, which is included on the following lines of the Consolidated Statement of Earnings, $<ix:nonFraction unitRef="usd" contextRef="ie567e5eb9dcb41d0a398be109e77b0d9_D20220103-20230101" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90ZXh0cmVnaW9uOmVkOWRkOWM2NzhjMDRhNmU4ZDZiMTUzZjYxMGFlYTY2Xzc0MA_ce0bb41b-a749-47b7-9f5e-128dfec927ca">0.3</ix:nonFraction> billion in restructuring, $<ix:nonFraction unitRef="usd" contextRef="iaa15521dd2654667b094254ebe535fc4_D20220103-20230101" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90ZXh0cmVnaW9uOmVkOWRkOWM2NzhjMDRhNmU4ZDZiMTUzZjYxMGFlYTY2Xzc2MQ_d7875348-8284-49b3-9b5a-14d4d3ebf597">0.1</ix:nonFraction> billion in other (income) expense and $<ix:nonFraction unitRef="usd" contextRef="i49c2401f8f3d4163afe6adbe4293302d_D20220103-20230101" decimals="-8" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90ZXh0cmVnaW9uOmVkOWRkOWM2NzhjMDRhNmU4ZDZiMTUzZjYxMGFlYTY2Xzc5NA_e68c18f2-8461-429f-ab6a-adc7b719c354">0.1</ix:nonFraction> billion in cost of products sold. Total project costs of approximately $<ix:nonFraction unitRef="usd" contextRef="i95e5b2037fbd445ea91d492ad3152fe5_I20230101" decimals="-8" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" format="ixt:num-dot-decimal" scale="9" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90ZXh0cmVnaW9uOmVkOWRkOWM2NzhjMDRhNmU4ZDZiMTUzZjYxMGFlYTY2Xzg2MA_48f009a7-8742-4879-a057-11ae4bed0749">2.2</ix:nonFraction> billion have been recorded since the restructuring was announced. The program was completed in the fiscal fourth quarter of 2022. </span></div><div style="text-indent:18pt"><span><br/></span></div><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90ZXh0cmVnaW9uOmVkOWRkOWM2NzhjMDRhNmU4ZDZiMTUzZjYxMGFlYTY2XzIzOTE_c89ded33-5cb5-4844-bf16-14e9e8d6494d" escape="true"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2022: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:31.986%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.291%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.517%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.173%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.885%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.767%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.481%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;3, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i32d057f69df94f2280959b742aaf5e0b_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzE4LTEtMS0xLTg0NDQ0_55c94eb8-6a50-4b64-a2b1-43060f5a3e06">135</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i628034b976194b3c95eee1d092e53459_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzE4LTItMS0xLTg0NDQ0_3ef16716-a872-427e-9e45-05228915c070">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i31117717375a483aba04eca1e392ee44_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzE4LTQtMS0xLTg0NDQ0_6295348a-2235-4849-9947-90f87672d39f">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if41a7f60706e4d6c8d7278663011a8e6_I20210103" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzE4LTYtMS0xLTg0NDQ0_a0b8a96f-22df-4c9e-81ee-45905883b733">144</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib3e13d3f1dcb4123ab1494c07d04692a_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzIwLTEtMS0xLTg0NDQ0_14518385-1910-4c53-8eda-024456f5b685">23</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib8895b2c96ae49d9ab87668b6e4d972e_D20210104-20220102" decimals="-6" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzIwLTItMS0xLTg0NDQ0_279761ac-dc1c-4e74-aeae-56125d368fb5">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icbf00d9c7c2c47b2a38a0e33043c8e05_D20210104-20220102" decimals="-6" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzIwLTQtMS0xLTg0NDQ0_2b348a05-6cbf-4882-8ed5-0a7ec81b696f">16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3dbe54c0baea4b92b0175ecdc2c32d60_D20210104-20220102" decimals="-6" sign="-" name="us-gaap:RestructuringReservePeriodIncreaseDecrease" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzIwLTYtMS0xLTg0NDQ0_e6289b84-43ff-4d80-981d-0c6cac2abf62">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;2, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i346e675961384d10af15a172a233f844_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzIyLTEtMS0xLTg0NDQ0_38a76f27-384d-4e5e-88c4-5b3f58ec51e7">112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i224a56e9b03f475f8ef466ec18c2e508_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzIyLTItMS0xLTg0NDQ0_5149a2d9-fe68-47d4-b499-417acee0630f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9413ac0768844d14a4e88ef98209b2be_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzIyLTQtMS0xLTg0NDQ0_fe95750b-9286-4f36-aa34-b61e0250e04c">25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7ccc395680a1473f92468bceaec711ec_I20220102" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzIyLTYtMS0xLTg0NDQ0_5b0653a0-b02e-4761-ba3c-ee2b795fac37">137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a5f0207ed948bbab5f326ccad7f02d_D20220103-20230101" decimals="-6" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI1LTEtMS0xLTg0NDQ0_6a631f60-0690-409c-b19e-0fcaa2cf76e3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a124d2841f84a198ab499b74262070b_D20220103-20230101" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI1LTItMS0xLTg0NDQ0_9dde2058-31f6-4e0f-a4c7-fe32c85019d9">15</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia22ff0765200405d8456d1b39ac5257f_D20220103-20230101" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI1LTQtMS0xLTg0NDQ0_e9d17736-2092-4cd9-b8f8-e5289db0ae6d">448</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2474e48849f1407492b006d664c27c42_D20220103-20230101" decimals="-6" name="us-gaap:RestructuringCharges" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI1LTYtMS0xLTg0NDQ0_517b7285-140a-418b-969c-31541d31e985">463</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i78a5f0207ed948bbab5f326ccad7f02d_D20220103-20230101" decimals="-6" name="jnj:GainOnSaleOfAnAssetPaymentForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI2LTEtMS0xLTg0NDQ0_22df7135-76f1-4dd0-b5a4-a3fe5067d30a">37</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0a124d2841f84a198ab499b74262070b_D20220103-20230101" decimals="-6" sign="-" name="jnj:GainOnSaleOfAnAssetPaymentForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI2LTItMS0xLTg0NDQ0_27988681-bee6-4861-a189-cc63d05d8f02">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ia22ff0765200405d8456d1b39ac5257f_D20220103-20230101" decimals="-6" name="jnj:GainOnSaleOfAnAssetPaymentForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI2LTQtMS0xLTg0NDQ0_b075f12b-38bd-457c-980c-e5edc5771b65">439</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2474e48849f1407492b006d664c27c42_D20220103-20230101" decimals="-6" name="jnj:GainOnSaleOfAnAssetPaymentForRestructuring" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI2LTYtMS0xLTg0NDQ0_3e7f90aa-42ef-474b-9c0f-2944e3e3ba9e">432</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78a5f0207ed948bbab5f326ccad7f02d_D20220103-20230101" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI3LTEtMS0xLTg0NDQ0_ea545280-0579-479a-a26f-08e455e75001">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0a124d2841f84a198ab499b74262070b_D20220103-20230101" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI3LTItMS0xLTg0NDQ0_77d90328-2ab2-44c7-add1-526c76703952">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="ia22ff0765200405d8456d1b39ac5257f_D20220103-20230101" sign="-" xsi:nil="true" name="us-gaap:RestructuringReserveSettledWithoutCash2" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI3LTQtMS0xLTg0NDQ0_b21a97b5-b54c-4277-b725-7d0c12373218"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i2474e48849f1407492b006d664c27c42_D20220103-20230101" decimals="-6" name="us-gaap:RestructuringReserveSettledWithoutCash2" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI3LTYtMS0xLTg0NDQ0_13c02774-5656-4b4a-997d-65d4a614aeb6">59</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;1, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i105785393ea04c2ba49bcb40429c6955_I20230101" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI4LTEtMS0xLTg0NDQ0_4b4e6748-5823-48ce-84f0-d7223dcaf9ae">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6235e13b21004a43a0daa993991daa3a_I20230101" decimals="-6" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI4LTItMS0xLTg0NDQ0_f1d3d77e-d799-4fc0-ab6e-449e610a4b1f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2ba4d95af9e4e4fa22e3ffb45143679_I20230101" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI4LTQtMS0xLTg0NDQ0_043ccaaa-7b50-499a-bdaf-51d4cf2d795b">34</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1f013b59c3b14695b75acec1bdb16def_I20230101" decimals="-6" name="us-gaap:RestructuringReserve" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI4LTYtMS0xLTg0NDQ0_8717f772-c8fe-4995-8650-8cb451a77cf3">109</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Although the restructuring program has been completed in the fiscal year 2022, the Company expects that severance charges will continue beyond that date. The reserve balance as of January 1, 2023 is recorded in the Employee Related Obligation account in the Consolidated Balance Sheet.   </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents gain on sale of assets</span></div></ix:nonNumeric></ix:continuation><div><span><br/></span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_232"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Report of Independent Registered Public Accounting Firm</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the Board of Directors and Shareholders of Johnson &amp; Johnson</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Opinions on the Financial Statements and Internal Control over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the accompanying consolidated balance sheets of Johnson &amp; Johnson and its subsidiaries (the &#8220;Company&#8221;) as of January 1, 2023 and January 2, 2022, and the related consolidated statements of earnings, of comprehensive income, of equity and of cash flows for each of the three fiscal years in the period ended January 1, 2023, including the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). We also have audited the Company's internal control over financial reporting as of January 1, 2023, based on criteria established in Internal Control - Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of January 1, 2023 and January 2, 2022, and the results of its operations and its cash flows for each of the three fiscal years in the period ended January 1, 2023 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of January 1, 2023, based on criteria established in Internal Control - Integrated Framework (2013) issued by the COSO.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Basis for Opinions</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company's management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express opinions on the Company&#8217;s consolidated financial statements and on the Company's internal control over financial reporting based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Management&#8217;s Report on Internal Control Over Financial Reporting, management has excluded Abiomed, Inc., (&#8220;Abiomed&#8221;) from its assessment of internal control over financial reporting as of January 1, 2023, because it was acquired by the Company in a business combination during 2022. We have also excluded Abiomed from our audit of internal control over financial reporting. Abiomed is a wholly-owned subsidiary whose total assets and total sales excluded from management&#8217;s assessment and our audit of internal control over financial reporting represent less than 1% of each of the related consolidated financial statement amounts as of and for the fiscal year ended January 1, 2023.</span></div><div style="text-indent:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">103</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-indent:5pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Critical Audit Matters</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that (i) relate to accounts or disclosures that are material to the consolidated financial statements and (ii) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">U.S. Pharmaceutical Rebate Reserves &#8211; Managed Care, Medicare and Medicaid</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Note 1 to the consolidated financial statements, the Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied. Rebates and discounts provided to customers are accounted for as variable consideration and recorded as a reduction in sales. The liability for such rebates and discounts is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet. A significant portion of the liability related to rebates is from the sale of pharmaceutical goods within the U.S., primarily the Managed Care, Medicare and Medicaid programs, which amounted to $9.6 billion as of January 1, 2023. For significant rebate programs, which include the U.S. Managed Care, Medicare and Medicaid rebate programs, rebates and discounts estimated by management are based on contractual terms, historical experience, patient outcomes, trend analysis, and projected market conditions in the U.S. pharmaceutical market. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The principal considerations for our determination that performing procedures relating to U.S. pharmaceutical rebate reserves - Managed Care, Medicare and Medicaid is a critical audit matter are the significant judgment by management due to the significant measurement uncertainty involved in developing these reserves and the high degree of auditor judgment, subjectivity and audit effort in performing procedures and evaluating the assumptions related to contractual terms, historical experience, patient outcomes, trend analysis, and projected market conditions in the U.S. pharmaceutical market. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to U.S. pharmaceutical rebate reserves - Managed Care, Medicare and Medicaid, including controls over the assumptions used to estimate these rebates. These procedures also included, among others, (i) developing an independent estimate of the rebates by utilizing third party information on price and market conditions in the U.S. pharmaceutical market, the terms of the specific rebate programs, and the historical experience and trend analysis of actual rebate claims paid; (ii) testing rebate claims processed by the Company, including evaluating those claims for consistency with the contractual and mandated terms of the Company&#8217;s rebate arrangements; and (iii) comparing the independent estimates to management&#8217;s estimates.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Litigation Contingencies &#8211; Talc</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Notes 1 and 19 to the consolidated financial statements, the Company records accruals for loss contingencies associated with legal matters, including talc, when it is probable that a liability will be incurred and the amount of the loss can be reasonably estimated. To the extent adverse awards, judgments, or verdicts have been rendered against the Company, management does not record an accrual until a loss is determined to be probable and can be reasonably estimated. For these matters, management is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors, including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. Management continues to believe that the Company has strong legal grounds to contest the talc verdicts it has appealed. Notwithstanding management&#8217;s confidence in the safety of the Company&#8217;s talc products, in certain circumstances the Company has settled cases. In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI), a wholly-owned subsidiary of Johnson &amp; Johnson, implemented a corporate restructuring and created a subsidiary, LTL Management LLC (LTL), which became solely responsible for the talc-related liabilities, and another subsidiary, New JJCI, which became responsible for the remaining business of Old JJCI. LTL filed a voluntary petition, seeking relief under chapter 11 of the Bankruptcy Code. As a result of the LTL bankruptcy case, the Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, Johnson &amp; Johnson, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties. The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court extended the PI through the end of </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 2022. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions by order issued in March 2022. The New Jersey Bankruptcy Court simultaneously issued another order extending the stay as to the Protected Parties. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss and the extension of the stay. In May 2022,the Third Circuit Court of Appeals granted the petitions to appeal. The briefing and oral argument on the appeal were completed in September 2022. On January 30, 2023, the Third Circuit reversed the Bankruptcy Court&#8217;s ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy. LTL has filed a petition for rehearing on the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The principal considerations for our determination that performing procedures relating to the talc litigation is a critical audit matter are the significant judgment by management when assessing the likelihood of a loss being incurred and when determining whether a reasonable estimate of the loss or range of loss for the future and existing talc claims can be made, which in turn led to a high degree of auditor judgment, subjectivity and effort in performing procedures and evaluating management&#8217;s assessment of the loss contingencies associated with this litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements. These procedures included testing the effectiveness of controls relating to management&#8217;s evaluation of the talc litigation, including controls over determining whether a loss is probable and whether the amount of loss can be reasonably estimated, as well as financial statement disclosures. These procedures also included, among others, (i) gaining an understanding of the Company&#8217;s process around the accounting and reporting for the talc litigation; (ii) discussing the status of significant known actual and potential litigation and the ongoing LTL bankruptcy proceedings with the Company&#8217;s in-house legal counsel, as well as external counsel when deemed necessary; (iii) obtaining and evaluating the letters of audit inquiry with internal and external legal counsel for significant litigation; (iv) evaluating the reasonableness of management&#8217;s assessment regarding whether an unfavorable outcome is reasonably possible or probable and reasonably estimable; and (v) evaluating the sufficiency of the Company&#8217;s litigation contingencies disclosures.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">/s/ <ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:AuditorName" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMzIvZnJhZzplOWU3ZDg2NWZlMDU0NjBlYTIzZmEwYThmOTBhZGVjZS90ZXh0cmVnaW9uOmU5ZTdkODY1ZmUwNTQ2MGVhMjNmYTBhOGY5MGFkZWNlXzE4Njcx_661c3e2d-1c2f-446f-bee3-102e56adc6c9">PricewaterhouseCoopers LLP</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101" name="dei:AuditorLocation" id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMzIvZnJhZzplOWU3ZDg2NWZlMDU0NjBlYTIzZmEwYThmOTBhZGVjZS90ZXh0cmVnaW9uOmU5ZTdkODY1ZmUwNTQ2MGVhMjNmYTBhOGY5MGFkZWNlXzE4Njcz_e103e102-1da4-4d77-bcd8-d86779038e5a">Florham Park, New Jersey</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">February 16, 2023</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We have served as the Company&#8217;s auditor since at least 1920. We have not been able to determine the specific year we began serving as auditor of the Company.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_235"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section&#160;404 of the Sarbanes-Oxley Act of 2002, management is required to assess the effectiveness of the Company&#8217;s internal control over financial reporting as of the end of each fiscal year and report, based on that assessment, whether the Company&#8217;s internal control over financial reporting is effective.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting.  The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance as to the reliability of the Company&#8217;s financial reporting and the preparation of external financial statements in accordance with generally accepted accounting principles.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Internal controls over financial reporting, no matter how well designed, have inherent limitations.  Therefore, internal control over financial reporting determined to be effective can provide only reasonable assurance with respect to financial statement preparation and may not prevent or detect all misstatements.  Moreover, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management has assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of  January&#160;1, 2023.  In making this assessment, the Company used the criteria established by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in &#8220;Internal Control-Integrated Framework (2013).&#8221;  These criteria are in the areas of control environment, risk assessment, control activities, information and communication, and monitoring.  The Company&#8217;s assessment included extensive documenting, evaluating and testing the design and operating effectiveness of its internal controls over financial reporting.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company acquired Abiomed, Inc. (Abiomed), in a business combination in December 2022. Abiomed's total assets, excluding intangible assets and goodwill, and total sales represented less than</span><span style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1% of each of the related consolidated financial statement amounts as of and for the fiscal year ended January 1, 2023. As the acquisition occurred in the fiscal year 2022, the scope of the Company's assessment of the design and effectiveness of internal control over financial reporting for the fiscal year 2022 excluded the above mentioned acquisition. This exclusion is in accordance with the SEC's general guidance that an assessment of a recently acquired business may be omitted from the scope in the year of acquisition.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the Company&#8217;s processes and assessment, as described above, management has concluded that, as of  January&#160;1, 2023, the Company&#8217;s internal control over financial reporting was effective.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effectiveness of the Company&#8217;s internal control over financial reporting as of  January&#160;1, 2023 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report, which appears herein.</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:47.948%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.192%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/&#160;&#160;J. Duato</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">/s/ Joseph J. Wolk</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman, Board of Directors</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President, Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_241"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shareholder Return Performance Graphs </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Set forth below are line graphs comparing the cumulative total shareholder return on the Company&#8217;s Common Stock for periods of five years and ten years ending January&#160;1, 2023, against the cumulative total return of the Standard&#160;&amp; Poor&#8217;s 500 Stock Index, the Standard&#160;&amp; Poor&#8217;s Pharmaceutical Index and the Standard&#160;&amp; Poor&#8217;s Healthcare Equipment Index. The graphs and tables assume that $100 was invested on December&#160;31, 2017 and December&#160;31, 2012 in each of the Company&#8217;s Common Stock, the Standard&#160;&amp; Poor&#8217;s 500 Stock Index, the Standard&#160;&amp; Poor&#8217;s Pharmaceutical Index and the Standard&#160;&amp; Poor&#8217;s Healthcare Equipment Index and that all dividends were reinvested.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5 Year Shareholder Return Performance J&amp;J vs. Indices</span></div><div style="margin-top:9pt"><img src="jnj-20230101_g10.jpg" alt="jnj-20230101_g10.jpg" style="height:238px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="margin-top:9pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:28.621%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.614%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$94.86</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$110.24</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$122.20</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$136.19</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$144.32</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P 500 Index</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$95.61</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$125.70</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$148.81</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$191.48</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$156.77</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P Pharmaceutical Index</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$108.09</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$124.40</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$133.76</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$168.21</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$182.43</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P Healthcare Equipment Index</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$116.24</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$150.32</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$176.83</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$211.05</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$171.25</span></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10 Year Shareholder Return Performance J&amp;J vs. Indices</span></div><div style="margin-top:18pt"><img src="jnj-20230101_g11.jpg" alt="jnj-20230101_g11.jpg" style="height:239px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.425%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.761%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.765%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2012</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2013</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2014</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2015</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2016</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2017</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2018</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2019</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Johnson &amp; Johnson</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$134.62</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$157.95</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$159.78</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$184.26</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$229.23</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$217.46</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$252.71</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$280.13</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$312.20</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$330.83</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P 500 Index</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$132.37</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$150.47</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$152.53</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$170.76</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$208.02</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$198.87</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$261.47</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$309.54</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$398.32</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$326.12</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P Pharmaceutical Index</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$135.23</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$165.27</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$174.84</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$172.10</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$193.74</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$209.41</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$241.01</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$259.15</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$325.89</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$353.44</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">S&amp;P Healthcare Equipment Index</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$100.00</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$127.69</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$161.24</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$170.87</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$181.95</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$238.17</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$276.85</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$358.03</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$421.16</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$502.66</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$407.86</span></td></tr></table></div><div style="margin-top:3pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_244"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:24.02pt">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Not applicable.</span></div><div id="i51a46167ef364951bf70ae9d6493776c_247"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:16.8pt">CONTROLS AND PROCEDURES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Disclosure Controls and Procedures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;At the end of the period covered by this Report, the Company evaluated the effectiveness of the design and operation of its disclosure controls and procedures. The Company&#8217;s disclosure controls and procedures are designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Joaquin Duato, Chairman and Chief Executive Officer, and Joseph J. Wolk, Executive Vice President, Chief Financial Officer, reviewed and participated in this evaluation. Based on this evaluation, Messrs.&#160;Duato and Wolk concluded that, as of the end of the period covered by this Report, the Company&#8217;s disclosure controls and procedures were effective.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Reports on Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;The information called for by this item is incorporated herein by reference to &#8220;Management&#8217;s Report on Internal Control Over Financial Reporting&#8221;, and the attestation regarding internal controls over financial reporting included in the &#8220;Report of Independent Registered Public Accounting Firm&#8221; included in Item 8 of this Report.</span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Changes in Internal Control Over Financial Reporting.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;During the fiscal quarter ended January&#160;1, 2023, there were no changes in the Company&#8217;s internal control over financial reporting identified in connection with the evaluation required under Rules&#160;13a-15 and 15d-15 under the Exchange Act that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. The Company continues to monitor and assess the effectiveness of the design and operation of its disclosure controls and procedures. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is implementing a multi-year, enterprise-wide initiative to integrate, simplify and standardize processes and systems for the human resources, information technology, procurement, supply chain and finance functions. These are enhancements to support the growth of the Company&#8217;s financial shared service capabilities and standardize financial systems. This initiative is not in response to any identified deficiency or weakness in the Company&#8217;s internal control over financial reporting. In response to this initiative, the Company has and will continue to align and streamline the design and operation of its financial control environment.</span></div><div id="i51a46167ef364951bf70ae9d6493776c_250"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:17.36pt">OTHER INFORMATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Not applicable.</span></div><div style="margin-top:6pt"><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_253"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C.       DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">              Not applicable.</span></div><div id="i51a46167ef364951bf70ae9d6493776c_256"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;III</span></div><div id="i51a46167ef364951bf70ae9d6493776c_259"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the discussion of the Audit Committee under the caption &#8220;Item 1. Election of Directors - Board Committees&#8221;; and the material under the captions &#8220;Item 1. Election of Directors&#8221; and, if applicable, &#8220;Stock Ownership and Section 16 Compliance &#8211; Delinquent Section&#160;16(a) Reports&#8221; in the Proxy Statement; and the material under the caption &#8220;Executive Officers of the Registrant&#8221; in Part&#160;I of this Report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The Company&#8217;s Code of Business Conduct, which covers all employees (including the Chief Executive Officer, Chief Financial Officer and Controller), meets the requirements of the SEC rules promulgated under Section&#160;406 of the Sarbanes-Oxley Act of 2002. The Code of Business Conduct is available on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.jnj.com/code-of-business-conduct</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and copies are available to shareholders without charge upon written request to the Secretary at the Company&#8217;s principal executive offices. Any substantive amendment to the Code of Business Conduct or any waiver of the Code granted to the Chief Executive Officer, the Chief Financial Officer or the Controller will be posted on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.investor.jnj.com/gov.cfm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within five business days (and retained on the website for at least one year).</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;In addition, the Company has adopted a Code of Business Conduct&#160;&amp; Ethics for Members of the Board of Directors and Executive Officers. The Code of Business Conduct&#160;&amp; Ethics for Members of the Board of Directors and Executive Officers </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is available on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.investor.jnj.com/gov/boardconduct.cfm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and copies are available to shareholders without charge upon written request to the Secretary at the Company&#8217;s principal executive offices. Any substantive amendment to the Code or any waiver of the Code granted to any member of the Board of Directors or any executive officer will be posted on the Company&#8217;s website at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">www.investor.jnj.com/gov.cfm</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> within five business days (and retained on the website for at least one year).</span></div><div id="i51a46167ef364951bf70ae9d6493776c_262"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">EXECUTIVE COMPENSATION</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the material under the captions &#8220;Item 1. Election of Directors &#8211; Director Compensation,&#8221; and &#8220;Item 2. Compensation &amp; Benefits Committee Report,&#8221; &#8220;Compensation Discussion and Analysis&#8221; and &#8220;Executive Compensation Tables&#8221; in the Proxy Statement.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The material incorporated herein by reference to the material under the caption &#8220;Compensation &amp; Benefits Committee Report&#8221; in the Proxy Statement shall be deemed furnished, and not filed, in this Report and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, as a result of this furnishing, except to the extent that the Company specifically incorporates it by reference.</span></div><div id="i51a46167ef364951bf70ae9d6493776c_265"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the material under the caption &#8220;Item 1. Stock Ownership and Section&#160;16 Compliance&#8221; in the Proxy Statement; and Note&#160;16 &#8220;Common Stock, Stock Option Plans and Stock Compensation Agreements&#8221; of the Notes to Consolidated Financial Statements in Item 8 of this Report.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The following table provides certain information as of January 1, 2023 concerning the shares of the Company&#8217;s Common Stock that may be issued under existing equity compensation plans.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:52.633%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.466%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.613%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Plan Category</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Securities to<br/>be Issued Upon Exercise of<br/>Outstanding Options and  Rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price of<br/>Outstanding Options and Rights</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Number of Securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Remaining Available for</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Future Issuance Under Equity Compensation Plans</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:700;line-height:100%;position:relative;top:-2.8pt;vertical-align:baseline">(2)(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Compensation Plans Approved by Security Holders</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,644,525&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$118.94&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,652,710&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Compensation Plans Not Approved by Security Holders</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">134,644,525&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$118.94&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,652,710&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div><span><br/></span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Included in this category are the following equity compensation plans which have been approved by the Company&#8217;s shareholders: 2012 Long-Term Incentive Plan and 2022 Long-Term Incentive Plan.</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">This column excludes shares reflected under the column &#8220;Number of Securities to be Issued Upon Exercise of Outstanding Options and Rights.&#8221;</span></div><div style="margin-top:5pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The 2012 Long-Term Incentive Plan expired April 26, 2022.  All options and restricted shares granted subsequent to that date were under the 2022 Long-Term Incentive Plan.</span></div><div id="i51a46167ef364951bf70ae9d6493776c_268"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the material under the captions &#8220;Item 1. Election of Directors&#160;- Director Independence&#8221; and &#8220;Related Person Transactions&#8221; in the Proxy Statement.</span></div><div id="i51a46167ef364951bf70ae9d6493776c_271"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">PRINCIPAL ACCOUNTANT FEES AND SERVICES</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The information called for by this item is incorporated herein by reference to the material under the caption &#8220;Item 3. Ratification of Appointment of Independent Registered Public Accounting Firm&#8221; in the Proxy Statement.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_274"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART&#160;IV</span></div><div id="i51a46167ef364951bf70ae9d6493776c_277"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:19.02pt">EXHIBITS&#160;AND FINANCIAL STATEMENT SCHEDULES</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following documents are filed as part of this report:</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financial Statements</span></div><div style="margin-top:5pt;text-indent:54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consolidated Balance Sheets at end of Fiscal Years 2022 and 2021</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consolidated Statements of Earnings for Fiscal Years 2022, 2021 and 2020&#160;&#160;&#160;&#160;</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consolidated Statements of Comprehensive Income for Fiscal Years 2022, 2021 and 2020</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consolidated Statements of Equity for Fiscal Years 2022, 2021 and 2020</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Consolidated Statements of Cash Flows for Fiscal Years 2022, 2021 and 2020</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notes to Consolidated Financial Statements</span></div><div style="margin-top:5pt;text-indent:49.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Report of Independent Registered Public Accounting Firm</span></div><div style="margin-top:9pt;padding-left:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All schedules are omitted because they are not applicable or the required information is included in the financial statements or notes.</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Exhibits&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Required</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> to be Filed by Item&#160;60l of Regulation&#160;S-K</span></div><div style="margin-top:5pt;text-indent:45pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information called for by this item is incorporated herein by reference to the Exhibit&#160;Index in this Report.</span></div><div style="margin-top:5pt;text-indent:45pt"><span><br/></span></div><div id="i51a46167ef364951bf70ae9d6493776c_280"></div><div style="margin-top:9pt;padding-left:54pt;text-indent:-54pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16.    FORM 10-K SUMMARY</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">                 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Registrants may voluntarily include a summary of information required by Form 10-K under this Item 16. The Company has elected not to include such summary information.</span></div><div style="padding-left:54pt;text-indent:-54pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_283"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:19pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section&#160;13 of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date:   February&#160;16, 2023                                                        </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.192%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">JOHNSON&#160;&amp; JOHNSON</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Registrant)</span></td></tr></table></div><div style="text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:52.631%"><tr><td style="width:1.0%"></td><td style="width:6.400%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:91.400%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;J. Duato</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Duato, Chairman of the Board<br/>and Chief Executive Officer</span></td></tr></table></div><div style="text-align:center;text-indent:324pt"><span><br/></span></div><div style="margin-top:7pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"></td><td style="width:34.942%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:42.918%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.308%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;J. Duato</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chairman of the Board</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. Duato</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer <br/>(Principal Executive Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;J. J. Wolk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. J. Wolk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Financial Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;R. J. Decker Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Controller and Chief Accounting Officer</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R. J. Decker Jr.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Principal Accounting Officer)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/D. Adamczyk</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D. Adamczyk</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ M. C. Beckerle</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M. C. Beckerle</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;D. S. Davis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">D. S. Davis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;I. E. L. Davis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I. E. L. Davis</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;J. A. Doudna</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">J. A. Doudna</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:36.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:41.337%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:17.844%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Signature</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ M. A. Hewson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M. A. Hewson</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ H. Joly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">H. Joly</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ M. B. McClellan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M. B. McClellan</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;A. M. Mulcahy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. M. Mulcahy</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;A. E. Washington</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">A. E. Washington</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;&#160;M. A. Weinberger</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">M. A. Weinberger</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ N.Y. West</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">February 16, 2023</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">N. Y. West</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112</span></div></td></tr></table></div></div></div><div id="i51a46167ef364951bf70ae9d6493776c_286"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;margin-top:19pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;INDEX</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reg. S-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Table</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Item No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Exhibit</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/200406/000119312522274491/d395813dex21.htm">2(i)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Agreement and Plan of Merger, dated as of October 31, 2022, by and among Johnson &amp; Johnson, Athos Merger Sub, Inc. and ABIOMED, Inc. &#8211; Incorporated herein by reference to Exhibit 2.1 of the Registrant&#8217;s Form 8-K Current Report filed November 1, 2022.&#8224;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040616000071/exhibit3i-restatedcertific.htm">3(i)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restated Certificate of Incorporation effective February 19, 2016&#160;&#8212; Incorporated herein by reference to Exhibit 3(i) of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended January 3, 2016.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040620000034/ex31amendmenttocoi.htm">3(ii)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificate of Amendment to the Certificate of Incorporation of Johnson &amp; Johnson effective April 30, 2020 &#160;&#8212; Incorporated herein by reference to Exhibit 3.1 of the Registrant's Form 8-K Current Report filed April 29, 2020.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040620000039/ex31amendmenttoby-laws.htm">3(iii)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By-Laws of the Company, as amended effective June 9, 2020&#160;&#8212; Incorporated herein by reference to Exhibit 3.1 of the Registrant&#8217;s Form 8-K Current Report filed June 10, 2020.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upon the request of the Securities and Exchange Commission, the Registrant will furnish a copy of all instruments defining the rights of holders of long-term debt of the Registrant.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040620000052/aug12exhibit41.htm">4(b)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Description of Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934 &#160;&#8212; Incorporated herein by reference to Exhibit 4.1 of the Registrant&#8217;s Form 8-K Current Report filed August 12, 2020.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040605000088/ltipexhibitfour.txt">10(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2005 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Exhibit 4 of the Registrant&#8217;s S-8 Registration Statement filed on May 10, 2005 (file no. 333-124785).*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040612000006/tenoneformofcertificatesto.htm">10(b)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Option Certificate under the 2005 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Form 8-K Current Report filed January 13, 2012.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040617000015/a2017jnjproxy.htm">10(c)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2012 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Appendix A of the Registrant&#8217;s Proxy Statement filed on March 15, 2017.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040612000081/0000200406-12-000081-index.htm">10(d)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Form of Stock Option Certificate, Restricted Share Unit Certificate and Performance Share Unit Certificate under the 2012 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Exhibits 10.2, 10.3 and 10.4 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended April 1, 2012.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040618000019/0000200406-18-000019-index.htm">10(e)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global NonQualified Stock Option Award Agreement, Global Restricted Share Unit Award Agreement and Global Performance Share Unit Award Agreement under the 2012 Long-Term Incentive Plan&#160;&#8212; Incorporated herein by reference to Exhibits 10.1, 10.2 and 10.3 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended April 1, 2018.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040619000033/a201910-q1qexhibit10ajjexe.htm">10(f)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Johnson &amp; Johnson Executive Incentive Plan (Amended as of November 28, 2018)&#160;&#8212; Incorporated herein by reference to Exhibit 10(a) of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended March 31, 2019.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000095012304003155/y94471exv10wg.txt">10(g)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Domestic Deferred Compensation (Certificate of Extra Compensation) Plan&#160;&#8212; Incorporated herein by reference to Exhibit 10(g) of the Registrant&#8217;s Form 10-K Annual Report for the year ended December 28, 2003.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000095012309003187/y74152exv10wj.htm">10(h)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendments to the Certificate of Extra Compensation Plan effective as of January 1, 2009&#160;&#8212; Incorporated herein by reference to Exhibit 10(j) of the Registrant&#8217;s Form 10-K Annual Report for the year ended December 28, 2008.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000095012309057624/y79425exv10w1.htm">10(i)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2009 Certificates of Long-Term Performance Plan&#160;&#8212; Incorporated herein by reference to Exhibit&#160;10.1 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended September 27, 2009.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex21-subsidiariesxform10xk.htm">10(j)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amended and Restated Deferred Fee Plan for Directors&#160;(Amended as of January 17, 2012) &#8212; Incorporated herein by reference to Exhibit 10(k) of the Registrant's Form 10-K Annual Report for the fiscal year ended January 1, 2012.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040612000140/exhibit101.htm">10(k)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Johnson &amp; Johnson Executive Income Deferral Plan Amended and Restated Effective January 1, 2010&#160;&#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended September 30, 2012.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex101-jjexcessplanx2022res.htm">10(l)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The Johnson &amp; Johnson Excess Savings Plan (amended and restated as of January 1, 2022) &#8212; Filed with this document.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/200406/000020040621000008/ex31-jjexcessplanx2020rest.htm">10(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/200406/000020040621000008/ex31-jjexcessplanx2020rest.htm">m</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/200406/000020040621000008/ex31-jjexcessplanx2020rest.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Excess Benefit Plan of Johnson &amp; Johnson and Affiliated Companies (amended and restated as of January 1, 2020)&#8212; incorporated by reference to Exhibit 10(n) of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended January 3, 2021.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10(n)**</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Life Plan Agreement&#160;&#8212; Incorporated herein by reference to Exhibit 10(i) of the Registrant&#8217;s Form 10-K Annual Report for the fiscal year ended January 3, 1993.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040615000019/a201510-q1qexhibit101execu.htm">10(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040615000019/a201510-q1qexhibit101execu.htm">o</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040615000019/a201510-q1qexhibit101execu.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Life Plan Agreement&#160;Closure Letter &#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Form 10-Q Quarterly Report for the quarter ended March 29, 2015.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/200406/000020040622000026/a2022jnjproxy.htm">10(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/200406/000020040622000026/a2022jnjproxy.htm">p</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/200406/000020040622000026/a2022jnjproxy.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2022 Long-Term Incentive Plan &#8212; Incorporated by reference to Appendix A of the Registrant&#8217;s Proxy Statement filed on March 16, 2022.*</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:86.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Reg. S-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exhibit Table</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Description</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Item No.</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">of Exhibit</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040614000097/a201410-q3qexhibit101sever.htm">10(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040614000097/a201410-q3qexhibit101sever.htm">q</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040614000097/a201410-q3qexhibit101sever.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Severance Pay Plan of Johnson &amp; Johnson and U.S. Affiliated Companies, Amended and Restated as of October 1, 2014 &#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant's Form 10-Q Quarterly Report for the quarter ended September 28, 2014.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040615000044/exhibit101severancepayplan.htm">10(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040615000044/exhibit101severancepayplan.htm">r</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040615000044/exhibit101severancepayplan.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">First Amendment to the Severance Pay Plan of Johnson &amp; Johnson and U.S. Affiliated Companies (as amended and restated effective October 1, 2014) &#8212; Incorporated herein by reference to Exhibit 10.1 of the Registrant's Form 10-Q Quarterly Report for the quarter ended June 28, 2015.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040616000071/exhibit10x-secondamendment.htm">10(</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040616000071/exhibit10x-secondamendment.htm">s</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="http://www.sec.gov/Archives/edgar/data/200406/000020040616000071/exhibit10x-secondamendment.htm">)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Second Amendment to the Severance Pay Plan of Johnson &amp; Johnson and U.S. Affiliated Companies (as amended and restated effective October 1, 2014) &#8212; Incorporated herein by reference to Exhibit 10(x) of the Registrant's Form 10-K Annual Report for the fiscal year ended January 3, 2016.*</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/200406/000119312522311072/d428734dex101.htm">10(t)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Value Rights Agreement, dated as of December 22, 2022, by and between Johnson &amp; Johnson and American Stock Transfer &amp; Trust Company, LLC &#8211; Incorporated herein by reference to Exhibit 10.1 of the Registrant&#8217;s Form 8-K Current Report filed December 22, 2022.&#8224;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex21-subsidiariesxform10xk.htm">21</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subsidiaries &#8212; Filed with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex23-pwcconsentxform10xkx2.htm">23</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consent of Independent Registered Public Accounting Firm&#160;&#8212; Filed with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex311-302certofceoxform10x.htm">31.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act&#160;&#8212; Filed with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex312-302certofcfoxform10x.htm">31.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act&#160;&#8212; Filed with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex321-906certofceoxform10x.htm">32.1</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act&#160;&#8212; Furnished with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="ex322-906certofcfoxform10x.htm">32.2</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certification of Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act&#160;&#8212; Furnished with this document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 101:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Instance Document - the instance document does not appear in the Interactive Data File because its                XBRL tags are embedded within the Inline XBRL document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Label Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">EX-101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Document</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exhibit 104:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File&#8211;&#8211;the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"></td><td style="width:2.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:94.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Management contract or compensatory plan.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Paper filing.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8224;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certain exhibits and schedules have been omitted pursuant to Item 601(b)(2)(ii) or 601(b)(10)(iv) of Regulation S-K, as applicable.</span></td></tr></table></div><div style="margin-top:4pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A copy of any of the Exhibits listed above will be provided without charge to any shareholder submitting a written request specifying the desired exhibit(s) to the Secretary at the principal executive offices of the Company. Pursuant to Item 601(b)(4)(iii)(A) of Regulation S-K, the Company has not filed as exhibits to this Form 10-K certain long-term debt instruments, including indentures, under which the total amount of securities authorized does not exceed 10% of the total assets of the Company and its subsidiaries on a consolidated basis. The Company hereby agrees to furnish a copy of any such instrument to the SEC upon request.</span></div><div style="margin-top:4pt;text-indent:24.75pt"><span><br/></span></div><div style="margin-top:4pt;text-indent:18pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">      </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.430%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:31.840%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114</span></div></td></tr></table></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>ex101-jjexcessplanx2022res.htm
<DESCRIPTION>EX-10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i7de6dbc8f6234da0b846a365c751c6b5_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Exhibit 10.1</font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION OF AMENDMENT AND RESTATEMENT OF THE</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXCESS BENEFIT PLAN OF</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JOHNSON &#38; JOHNSON AND AFFILIATED COMPANIES </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">(2022 Restatement)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This restatement of the Excess Benefit Plan of Johnson &#38; Johnson and Affiliated Companies, effective January 1, 2022, except as otherwise provided, incorporates all amendments adopted since January 1, 1983, and includes certain other changes and clarifications. This restatement has been approved by the Pension and Benefits Committee of Johnson &#38; Johnson.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:45.305%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:52.495%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ON BEHALF OF THE<br>PENSION AND BENEFITS COMMITTEE OF<br>JOHNSON &#38; JOHNSON</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dated&#58;  02&#47;16&#47;2023</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Warren Luther</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">WARREN LUTHER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Member</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><div id="i7de6dbc8f6234da0b846a365c751c6b5_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXCESS BENEFIT PLAN OF</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="margin-bottom:0.12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">JOHNSON &#38; JOHNSON AND AFFILIATED COMPANIES</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(Amended and restated effective January 1, 2022, except as otherwise provided)</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div><font><br></font></div><div id="i7de6dbc8f6234da0b846a365c751c6b5_7"></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">THE JOHNSON &#38; JOHNSON</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">EXCESS SAVINGS PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">(2022 Restatement)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">TABLE OF CONTENTS</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Page</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.076%"><tr><td style="width:1.0%"></td><td style="width:92.690%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.110%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE I - PURPOSE</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7de6dbc8f6234da0b846a365c751c6b5_10" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">1</a></font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE II - DEFINITIONS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7de6dbc8f6234da0b846a365c751c6b5_247" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">2</a></font></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE III - ELIGIBILITY</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7de6dbc8f6234da0b846a365c751c6b5_274" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">3</a></font></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE IV - AMOUNT AND METHOD OF PAYMENT OF BENEFITS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7de6dbc8f6234da0b846a365c751c6b5_302" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">4</a></font></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE V -  PLAN ADMINISTRATION</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7de6dbc8f6234da0b846a365c751c6b5_335" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">7</a></font></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE VI - AMENDMENT AND TERMINATION</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7de6dbc8f6234da0b846a365c751c6b5_361" style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">10</a></font></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ARTICLE VII - MISCELLANEOUS</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline"><a href="#i7de6dbc8f6234da0b846a365c751c6b5_393" style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">11</a></font></div></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div><div><font><br></font></div></div></div><div id="i7de6dbc8f6234da0b846a365c751c6b5_10"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">THE JOHNSON &#38; JOHNSON</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">EXCESS SAVINGS PLAN</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">(2022 Restatement)</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">ARTICLE I - PURPOSE</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">1.1   The purpose of the Plan, which is intended to constitute an unfunded deferred compensation plan, is to provide its Members certain benefits that cannot be provided under the Johnson &#38; Johnson Savings Plan by reason of the limitations of Section 401(a)(17) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;). Participation in the Plan is limited to a select group of management and highly compensated employees of Johnson &#38; Johnson and its affiliates, within the meaning of ERISA Sections 201(2), 301(a)(3), and 401(a)(1).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        1.2    The Plan has been in effect since January 1, 1996, and was amended in 2008 to comply with the requirements of Section 409A of the Code. This restatement of the Plan, effective January 1, 2022, except as otherwise provided, incorporates all amendments adopted since January 1, 1996, and includes certain changes and clarifications.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><div id="i7de6dbc8f6234da0b846a365c751c6b5_247"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE II - DEFINITIONS</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Whenever used herein, the following defined terms have the following meanings&#58;</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Account&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means a bookkeeping account used to record a Member&#8217;s benefit that accumulates under the Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Beneficiary&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means, for a Member, the Member&#8217;s Beneficiary under the Qualified Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Code&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Internal Revenue Code of 1986, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Controlled Group&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> has the same meaning as under the Qualified Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Employee&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means any person who is employed by the Employer and is an eligible Employee under the Qualified Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Employer&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means Johnson &#38; Johnson and the affiliated companies that are participating employers under the Qualified Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;ERISA&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Employee Retirement Income Security Act of 1974, as amended.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Member&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means a person who is designated to participate in the Plan in the manner described in Article III and has an account under the Plan that has not been paid in full or forfeited.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Pension Committee&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Committee designated to administer and supervise the Qualified Plan (currently Johnson &#38; Johnson&#8217;s Pension and Benefits Committee) or its designee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Plan&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Johnson &#38; Johnson Excess Savings Plan as set forth herein and as may be amended and restated from time to time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Plan Administrator&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Pension Committee.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Plan Year&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the 12 month period beginning on January first.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Qualified Plan&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Johnson &#38; Johnson Savings Plan as in effect and amended from time to time.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Separation from Service&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means, for a Member, the Member&#8217;s &#8220;separation from service&#8221; under Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Specified Employee&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means a specified employee described in Section 409A(a)(2)(B)(i) of the Code, as determined by Johnson &#38; Johnson in accordance with Treasury Regulations Section 1.409A-1(i).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><div id="i7de6dbc8f6234da0b846a365c751c6b5_274"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">ARTICLE III - ELIGIBILITY</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.1       An Employee will automatically become a Member under the Plan if he is eligible to be a member of the Qualified Plan (determined under the terms of the Qualified Plan) and his eligible compensation under the Qualified Plan exceeds the Code Section 401(a)(17) limitation on compensation, unless the Plan Administrator determines that he is not a part of a select group of management or highly compensated employees.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.2       Any change in a Member&#8217;s eligibility to participate under the Plan will not affect Plan benefits previously credited to the Member&#8217;s Account.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">3.3      Any Employee who is ineligible or becomes ineligible to receive contributions under the Qualified Plan (whether or not he continues to maintain an account balance under the Qualified Plan) is ineligible to participate in this Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><div id="i7de6dbc8f6234da0b846a365c751c6b5_302"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">ARTICLE IV &#8211; AMOUNT AND METHOD OF PAYMENT OF BENEFITS</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.1    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Plan Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. If the employer contributions to a Member&#8217;s account under the Qualified Plan are or could be reduced or limited in any year because of the limitation imposed by Section 401(a)(17) of the Code, and assuming for these purposes that the Member participates in the Qualified Plan and contributes the maximum amount eligible to be matched by the Employer, then a benefit may accrue under this Plan in favor of the Member.  Such benefit shall be credited to the Member&#8217;s Account.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.2     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Amount of Benefit</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. The amount of the benefit credited to a Member&#8217;s account for a pay period equals the excess of (a) over (b) where&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)   is the maximum Employer Matching Contribution (as defined under the Qualified Plan) that would be allocated to the Member&#8217;s account under the Qualified Plan for such pay period if the Member had contributed to the Qualified Plan for such pay period the maximum amount eligible to be matched by the Employer and the provisions of the Qualified Plan were administered without regard to the limitations imposed by Section 401(a)(17) of the Code, and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)    is the maximum Employer Matching Contribution that could be allocated to the Member&#8217;s account under the Qualified Plan for such pay period if the Member contributed to the Qualified Plan the maximum amount eligible to be matched by the Employer for such pay period, after giving effect to the limitations imposed by Section 401(a)(17) of the Code.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                     </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.3     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">No Employee Contribution Required or Permitted</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. A Member will be entitled to a benefit under this Plan without regard to whether the Employee made any employee contributions (including any salary reduction contributions) under the Qualified Plan. No Member contribution is required or permitted under the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.4    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Earnings on Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Amounts credited to a Member&#8217;s Account will be adjusted for deemed investment gains and losses, as if the balance of the Account were invested in an investment fund designated by the Pension Committee (without regard to the Member&#8217;s investment elections under the Qualified Plan). No Member is entitled to earnings on his Account for service prior to the date of the Member&#8217;s participation in the Plan or for any period before the applicable amount has been credited to the Member&#8217;s Account. The Pension Committee reserves the right to designate a different rate of earnings for amounts credited or to be credited under this Plan, provided that any new rate shall apply on a prospective basis only.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                     </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.5    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Vesting of Account</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. The benefits provided under this Plan will vest in the same manner and at the same time as Employer Matching Contributions made under the Qualified Plan.  A Member&#8217;s vested percentage on any date shall be the same as his vested percentage under the Qualified Plan.  If a Member terminates employment with Employer and its Controlled Group before his benefits are fully vested, the unvested portion (i.e., the Member&#8217;s Account balance times one minus his vested percentage) shall be forfeited.  If the Member is rehired within five years after the forfeiture event (the Member&#8217;s termination date), the forfeited amount shall be reinstated (without any adjustment for investment earnings or losses), subject to the Plan&#8217;s rules on vesting and time and form of payment.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                      </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> &#160;&#160;&#160;&#160;4.6      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Time and Form of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(1)    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Payment Events</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Subject to Section 4.10, below (Delayed Payment Rules for Specified Employees) and paragraph (2) (Grandfathered Payment Elections), a Member&#8217;s vested Account balance (if any) shall be paid in a lump sum within 90 days after the first to occur of the following events (each, a &#8220;Payment Event&#8221;)&#58;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(a)    The Member&#8217;s Separation from Service with the Employer and its                               Controlled Group&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                   </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(b)          The Member&#8217;s death&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                                   </font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(c)  The Member&#8217;s disability within the meaning of Section                                         409A(a)(2)(C) of the Code.</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">With respect to a Member who is on an approved absence due to long-term disability, the Employer shall determine whether a Separation from Service has occurred and whether a disability has occurred, based on the facts and circumstances.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">(2)    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Grandfathered Payment Elections</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. If the Member has an Effective Grandfathered Payment Election in place and his Payment Event occurs after the Member attains age 55, the vested balance of the of the Member&#8217;s Account shall be paid in the form and at the time prescribed by the Effective Grandfathered Payment Election (subject to Section 4.10, below) (Delayed Payment Rules for Specified Employees), to the extent applicable.  For this purpose, an &#8220;Effective Grandfathered Payment Election&#8221; is a binding payment election that (i) was submitted on or before December 15, 2008, (ii) was made in accordance with the Plan&#8217;s rules and procedures in place at the time of such election, including the form and timing of such election, and (iii) was made at least 12 months before the Member&#8217;s Payment Event. The Plan Administrator shall have the sole and discretionary authority to determine whether a Member has made an Effective Grandfathered Payment Election, including the effective date of such election. A Member&#8217;s Effective Grandfathered Payment Election shall be irrevocable as of December 15, 2008, and shall apply to the total value of the Member&#8217;s Account, but shall be disregarded if the Member&#8217;s Payment Event occurs before the Member attains age 55.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">In all cases, the time of payment within a window prescribed hereunder shall be determined by the Plan Administrator in its sole discretion.  In no event shall a Member have any influence on any determination as to the time of payment within the applicable window.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.7     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Payment to Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Notwithstanding any other provision of the Plan, including any election made by the Member, if a Member dies prior to or following the commencement of payments to him under the Plan, his entire remaining Account balance, to the extent vested, shall be paid to his Beneficiary as soon as administratively practicable following the Member&#8217;s death (and, in any event, no later than December 31</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">st</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> of the first calendar year that starts after the Member&#8217;s death).</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.8     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Not &#8220;Compensation&#8221; for Other Purposes</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Any benefits payable under this Plan will not be considered compensation to the Member for purposes of the Qualified Plan or any other qualified retirement plan maintained by the Employer.</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.9    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">No Deferral of Payment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Except as provided in Section 4.6(2) with respect to a Member&#8217;s Effective Grandfathered Payment Election, a Member may not elect to defer receipt of any portion of his benefit under the Plan.  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                  </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.10  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Delayed Payment Rules for Specified Employees</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Notwithstanding any other provision of the Plan, no portion of a Specified Employee&#8217;s Account that accrued or became vested after December 31, 2004 (including earnings thereon) and is payable upon Separation from Service shall be paid before the earlier of the date that is six months after the Member&#8217;s Separation from Service with the Employer and its Controlled Group or the Member&#8217;s death.  Any amount that would have been paid to a Specified Employee but for the six-month delay imposed by this Section 4.10 shall be paid to the Member in a single lump sum (adjusted for investment gains and losses up to the final valuation date before payment) within 30 days after the end of the required delay period.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">4.11  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Designated Payment Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. A payment shall be treated as being made on the designated payment date if it is actually made on the designated payment date or on a later date that is either in the same calendar year as the designated payment date or, if later, by the 15</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> day of the third calendar month following the designated payment date. In addition, a payment shall be treated as made on the designated payment date if it is made no more than 30 days before the designated payment date.  For the avoidance of doubt, no Member shall be permitted, either directly or indirectly, to designate the taxable year of a payment under this Plan.</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div><div id="i7de6dbc8f6234da0b846a365c751c6b5_335"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">ARTICLE V &#8211; PLAN ADMINISTRATION</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5.1    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Plan Administrator&#8217;s Powers</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. The Plan Administrator shall have all powers as may be necessary to carry out the provisions of the Plan. Without limiting the generality of the foregoing, the Plan Administrator shall have discretionary authority to determine eligibility for Plan benefits and the amount and payment terms thereof, to construe and interpret the Plan, and to determine all questions arising in the administration of the Plan, and the Plan Administrator may from time to time establish rules for the administration of the Plan. Actions by the Plan Administrator shall be final, conclusive and binding on all Members, Beneficiaries, and others making claims under the Plan.  Individuals serving in the capacity of the Plan Administrator shall not be subject to individual liability with respect to this Plan.</font></div><div style="text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">           &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5.2    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Delegation of Administrative Authority</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. To the extent permitted by applicable law, the Plan Administrator may designate persons to assist in carrying out its duties, and may allocate responsibilities to one or more persons as &#8220;designated administrators.&#8221; All references to the Plan Administrator shall include the Plan Administrator&#8217;s designee, unless the contrary is clearly indicated.</font></div><div style="text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">          &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; 5.3    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Engaging Third Parties to Assist with Plan Administration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Johnson &#38; Johnson and the Plan Administrator may employ or engage such agents, accountants, actuaries, counsel, other experts and other persons as it deems necessary or desirable in connection with the interpretation and administration of this Plan.  None of the Plan Administrator, Johnson &#38; Johnson, or any of its committees, officers, directors and employees shall be liable for any action taken, suffered or omitted by them in good faith in reliance upon the advice or opinion of any such agent, accountant, actuary, counsel or other expert. All action so taken, suffered or omitted shall be conclusive upon each of them and upon all other persons interested in this Plan.</font></div><div style="text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">           &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5.4    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Privilege</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. To the extent that the Plan Administrator or Johnson &#38; Johnson or an affiliate, committee, employee, member, affiliate or representative consults with legal counsel in connection with the design or administration of the Plan, the attorney-client relationship shall be exclusively between such counsel and the party engaging counsel.  No employee, former employee, Member, Beneficiary, or other individual shall be a party to such attorney-client relationship (other than to the extent such individual was involved in engaging counsel).  Except as determined by the Plan Administrator or Johnson &#38; Johnson, the party engaging counsel shall preserve all rights to maintain the confidentiality of their communications with advisers, including the attorney-client privilege, to the full extent permitted by law.</font></div><div style="text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            &#160;&#160;&#160;&#160;  5.5    </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Proof of Right to Receive Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. The Plan Administrator may require proof of death or disability of any Member, former Member or Beneficiary and evidence of the right of any person to receive any Plan benefit.</font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                      </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   5.6   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Johnson &#38; Johnson may withhold (or cause to be withheld) from benefits under this Plan any taxes or other amounts that Johnson &#38; Johnson determines are required by law to be withheld.  Johnson &#38; Johnson may deduct (or cause to be deducted) from the unpaid portion of a Member&#8217;s (or Beneficiary&#8217;s) benefit any tax that Johnson &#38; Johnson reasonably determines to be due with respect to the benefit, and an amount sufficient to pay applicable withholding on imputed income. Alternatively, Johnson &#38; Johnson may require the Member or Beneficiary to remit to Johnson &#38; Johnson or its designee an amount sufficient to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">satisfy any applicable federal, state, and local income and employment tax with respect to the Member&#8217;s benefit, or Johnson &#38; Johnson may withhold such amount from other compensation. Regardless of the amount withheld or reported, the Member or Beneficiary shall remain responsible at all times for paying all federal, state, local, and foreign income and employment taxes with respect to benefits under this Plan (including taxes on imputed income) except for the employer&#8217;s portion of employment taxes. In no event shall Johnson &#38; Johnson or any employee or agent of Johnson &#38; Johnson be liable for any interest or penalty that a Member or Beneficiary incurs by failing to make timely payments of tax.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">        &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;5.7   </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Claims Procedures</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. A Member or Beneficiary (or his duly authorized representative) who believes that he is being denied a benefit to which he is entitled under the Plan (referred to in this Section 5.7 as a &#8220;Claimant&#8221;) may file a written request with the claims administrator designated by the Plan Administrator (the &#8220;Claims Administrator&#8221;) setting forth the claim.  The Claims Administrator shall consider and resolve the claim as set forth below.</font></div><div style="text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                        (a)       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Time for Response</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. The Claims Administrator shall render a decision within 90 days after receiving the claim&#59; provided that if the Claims Administrator needs additional time, the period may be extended by up to 90 additional days.  The Claims Administrator shall notify the Claimant of any extension and the expected response date.</font></div><div style="text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">           &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(b)      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Denial</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. If the claim is denied in whole or part, the Claims Administrator shall notify the Claimant of its decision in writing, setting forth (i) the reason(s) for such denial, (ii) reference to relevant provision(s) of this Plan on which such denial is based, (iii) a description and explanation of any additional material or information necessary for the Claimant to perfect the claim, and (iv) a description of the Plan&#8217;s review procedures and the time limits applicable to such procedures, including a statement of the Claimant&#8217;s right to bring a civil action under ERISA Section 502(a) following an adverse benefit determination on review.</font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                    </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">   (c)      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Request for Review</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Within 60 days after receiving notice of a claim denial, the Claimant may request in writing that an appeals administrator designated by the Plan Administrator (the &#8220;Appeals Administrator&#8221;) review the determination.  The Claimant may, but need not, submit written comments, documents, records, and other information relating to the claim.  Upon request (and free of charge), the Claimant shall be provided reasonable access to, and copies of, all documents, records, and other information relevant to the benefit determination.  If the Claimant does not request a review of the initial determination within such 60-day period, the Claimant shall be barred from challenging the determination.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                         (d)      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Time to Respond to Request for Review</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. The Appeals Administrator shall render a decision within 60 days after receiving the request for review&#59; provided that if the Appeals Administrator needs additional time, the period may be extended by up to 60 additional days.  The Appeals Administrator shall notify the Claimant of any extension, the reason therefor, and the expected response date.  If the Appeals Administrator needs additional information, the period for reviewing the benefit determination shall be tolled until the Claimant responds to the request for additional information (or, if the Claimant fails to respond, until the Claimant&#8217;s response is due).</font></div><div style="text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                         (e)       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Full and Fair Review</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. The Appeals Administrator&#8217;s review shall take into account all comments, documents, records, and other information submitted by the Claimant relating to </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">8</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">the request for review, without regard to whether such information was submitted or considered in the initial benefit determination.</font></div><div style="text-align:justify;text-indent:-36pt"><font><br></font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                       (f)       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Decision on Review</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. All decisions on review shall be final and binding with respect to all concerned parties.  If the appeal is denied, the Appeals Administrator shall notify the Claimant of its decision in writing, setting forth (i) the reason(s) for the decision, (ii) reference to relevant Plan provision(s) upon which the adverse determination is based, (iii) a statement that the Claimant is entitled to receive, upon request and free of charge, reasonable access to and copies of all documents, records, and other information, relevant to the Claimant&#8217;s claim for benefits, and (iv) a statement of the Claimant&#8217;s right to bring a civil action under ERISA Section 502(a).</font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            &#160;&#160;&#160;&#160;</font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">5.8      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Limitations and Forum Selection</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. The limitations period prescribed by the Qualified Plan (generally two years after a claim is repudiated) and the forum selection provisions of the Qualified Plan shall apply with respect to all claims under this Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                     5.9          </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">No Plan Assets</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Benefits provided under this Plan are unfunded obligations of Johnson &#38; Johnson.  Nothing contained in this Plan shall require the Employer to segregate any monies from its general funds, to create any trust, to make any special deposits, or to purchase any policies of insurance with respect to such obligations.  If Johnson &#38; Johnson elects to purchase individual policies of insurance on one or more of the Members to help finance its obligations under this Plan, such individual policies and the proceeds of the policies shall at all times remain the sole property of Johnson &#38; Johnson and neither the Members whose lives are insured nor their Beneficiaries shall have any ownership rights in such policies of insurance.</font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                       </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> 5.10         </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Non-Duplication of Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. If a Member participates in another non-qualified plan which is sponsored by the Employer or a member of the Controlled Group, benefits payable under the other non-qualified plan that are attributable to the Section 401(a)(17) limits under the Qualified Plan for periods with respect to which amounts have been credited to the Member&#8217;s Account under this Plan will be reduced by the amount credited for such period (adjusted for deemed investment gains and losses) under this Plan.  The decision of the Pension Committee as to duplication of benefits otherwise payable under this Plan will be final.  For this purpose, if the other plan(s) have as their purpose the intent to recompense its eligible participants for amounts affected by the Code Section 401(a)(17) limits, it will be deemed a non-qualified plan regardless of the terminology employed.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">9</font></div></div></div><div id="i7de6dbc8f6234da0b846a365c751c6b5_361"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">ARTICLE VI&#8212;AMENDMENT AND TERMINATION</font></div><div style="margin-bottom:0.12pt;text-align:center"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                        6.1       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Amendment and Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Johnson &#38; Johnson, through the Pension Committee, reserves the right, at any time and from time to time, including retroactively if deemed necessary or appropriate,  to amend or terminate in whole or in part any or all provisions of the Plan&#59; provided that (i) no amendment or termination shall reduce a Member&#8217;s or Beneficiary&#8217;s accrued benefit under this Plan (it being understood that a reduction under this Plan that is caused by a corresponding increase in the amount payable under the Qualified Plan shall not be treated as an impermissible reduction), and (ii) no amendment or termination shall change the time or form of payment of benefits under the Plan in a manner that results in a tax under Code Section 409A.</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                        An amendment to, or termination of, the Qualified Plan shall not be deemed to be an amendment to this Plan, and shall not be subject to the restrictions under this Section 6.1, even if such amendment or termination affects the benefit provided under this Plan.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">                        6.2       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Payment Upon Plan Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. To the extent permitted by Code Section 409A, benefits accrued under the Plan shall be paid upon termination of the Plan.  Payments shall be made in a manner that is reasonably designed to avoid tax under Code Section 409A.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">10</font></div></div></div><div id="i7de6dbc8f6234da0b846a365c751c6b5_393"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">ARTICLE VII&#8212;MISCELLANEOUS</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.1  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Rules of Construction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">For purposes of the Plan, unless the contrary is clearly indicated by the context&#58;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)    The use of the masculine gender shall also include within its             meaning the feminine and vice versa&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)    The use of the singular shall also include within its meaning the            plural and vice versa&#59;</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)    The word &#8220;include&#8221; shall mean to include, but not be limited to&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)    The reference to a statute or section of a statue shall further be a           reference to any successor or amended statute or section, and any regulations or other          guidance of general applicability issued thereunder.</font></div><div style="text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">            </font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11.5pt;font-weight:400;line-height:112%">7.2</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">No Alienation or Transfer of Benefits</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. No amount payable under this Plan shall be subject in any manner to alienation, sale, transfer, assignment, pledge or encumbrance of any kind.  Any attempt to alienate, sell, transfer, assign, pledge or otherwise encumber any such benefit, whether presently or subsequently payable, shall be void. Except as required by law, no benefit payable under this Plan shall in any manner be subject to garnishment, attachment, execution or other legal process, or be liable for or subject to the debts or liability of any Member or Beneficiary.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.3       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Section 409A Compliance</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. The Plan is intended to comply with the requirements of Code Section 409A, to avoid tax thereunder, and shall be administered, construed, and interpreted consistently with such intent.  None of the Employer or its affiliates warrants that the Plan will comply with Code Section 409A with respect to any Member or with respect to any payment.  Notwithstanding anything to the contrary in the Plan, the Pension Committee reserves the right to revise the Plan as it deems necessary or advisable, in its sole discretion, to comply with Section 409A or to otherwise avoid imposition of any additional tax or income recognition under Section 409A.  In no event shall any Controlled Group member or any director, officer, or employee of a Controlled Group member (other than the Member) be liable for any additional tax, interest, or penalty incurred by a Member or Beneficiary as a result of the Plan&#8217;s failure to satisfy the requirements of Code Section 409A, or as a result of the Plan&#8217;s failure to satisfy any other requirements of applicable tax laws.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.4       </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Scrivener&#8217;s Error</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  An individual&#8217;s right to any benefit under the Plan shall be determined in accordance with the terms of this document&#59; provided, however, that this document shall be applied and interpreted without regard to any scrivener&#8217;s error (as described in the next following sentence) in this document or any other document of the Plan. The determination of whether a scrivener&#8217;s error has occurred shall be made by the Pension Committee, in the exercise of its best judgment and sole discretion, based on its intent as settlor of the Plan (or, if applicable, its understanding of Johnson &#38; Johnson&#8217;s intent as Plan sponsor), and taking into account such evidence, written or oral, as it deems appropriate or helpful. The Pension Committee is authorized to correct any scrivener&#8217;s error that it discovers in this document or in any other document of the Plan.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">11</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.5      </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Return of Overpayment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. If the Plan Administrator determines that an overpayment or incorrect payment or distribution has been made to a Member, spouse, Beneficiary or other person, the Plan Administrator shall take such steps as it deem appropriate under the relevant facts and circumstances to recover such payments with interest.  Without limiting the generality of the foregoing, and subject to the requirements under Code Section 409A, overpayments that are not repaid, and associated interest, may be recovered by an offset against subsequent payments otherwise becoming due under the Plan.  The remedies under this Section 7.5 shall not be exclusive.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.6  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Address Records</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">. Each Member and alternate payee shall keep the Plan Administrator informed of their post office address and the post office address of their spouse or other Beneficiary. Any communication, statement or notice from the Plan Administrator or its designee addressed to a Member, spouse, Beneficiary or alternate payee at their last post office address filed with the Plan Administrator, or if no address is filed with the Plan Administrator, at the last post office address shown on the Employer&#8217;s or a member of the Controlled Group&#8217;s records, shall be binding on the Member, spouse, Beneficiary or alternate payee (as applicable) for all purposes of the Plan.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.7     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">Controlling State Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Except to the extent preempted by ERISA, this Plan shall be construed in accordance with the laws of the State of New Jersey, without regard to conflict of law provisions that might otherwise point to the law of a different jurisdiction.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">7.8     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%;text-decoration:underline">No Right to Employment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">.  Nothing contained in this Plan shall be construed as a contract of employment between any Employer and any individual, or to suggest or create a right in any employee to be continued in employment, or as a limit of the employer&#8217;s right to discharge any employee at any time and for any reason, with or without cause.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">12</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%">EXHIBIT A</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">TRANSFER OF LIABILITIES TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:174%">THE KENVUE EXCESS SAVINGS PLAN</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">Effective on a date within the first quarter of 2023, as determined by the Johnson &#38; Johnson Pension and Benefits Committee (the &#8220;Transfer Date&#8221;), all liabilities under this Plan for active employees whose accounts under the Qualified Plan are transferred to the Kenvue Savings Plan (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, active employees of the Controlled Group&#8217;s Consumer Health Care Business (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">i.e.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">, Kenvue Inc. and its affiliates that are part of the Consumer Health Care business)) (the &#8220;J&#38;J Transferring Members&#8221;) shall be transferred directly to the a new plan maintained by Kenvue Inc. (the &#8220;Kenvue Excess Savings Plan&#8221;). All amounts transferred from this Plan pursuant to such transfer (&#8220;J&#38;J Transferred Amounts&#8221;) shall thereafter be subject to the terms of the Kenvue Excess Savings Plan and the J&#38;J Transferring Members shall have no further rights whatsoever under or with respect to this Plan. As a result of this transfer, the J&#38;J Transferring Members shall not be entitled to any payments under this Plan and shall have no claims or rights for benefits hereunder. Nor shall they have any claims against Johnson &#38; Johnson or any of its affiliates (other than the affiliates that are part of the Consumer Health Care business for so long as they are affiliates of Johnson &#38; Johnson) in respect of benefits under this Plan. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">The transfer described in this Exhibit A shall not be treated as a separation from service. No change shall be made to the time or form of payment of any J&#38;J Transferred Amount unless such change is permitted by the terms of the Kenvue Excess Savings Plan and satisfies the requirements to avoid tax under Code Section 409A.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">All J&#38;J Transferred Amounts that are vested under the Plan immediately before the Transfer Date shall be fully vested under the Kenvue Excess Savings Plan. All service credited under this Plan shall count for purposes of vesting and eligibility under the Kenvue Excess Savings Plan.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:112%;text-decoration:underline">Subsequent Liability Transfers</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">If an active employee&#8217;s accounts under the Qualified Plan are transferred after the Transfer Date to the Kenvue Savings Plan (pursuant to the provisions under the Qualified Plan for subsequent plan-to-plan transfers), then all liabilities under this Plan for such employee shall be transferred to the Kenvue Excess Savings Plan at the same time as the transfer of such employee&#8217;s accounts from the Qualified Plan to the Kenvue Savings Plan, in accordance with the principles of this Exhibit A. Such employee shall be treated as a J&#38;J Transferring Member and such liabilities shall be treated as J&#38;J Transferred Amounts, and all of the provisions described above with respect to the J&#38;J Transferring Members&#8217; rights and the J&#38;J Transferred Amounts shall apply.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">13</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>3
<FILENAME>ex21-subsidiariesxform10xk.htm
<DESCRIPTION>EX-21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="if4ad043b051242d9b9a3d0d4239e61e4_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;21</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUBSIDIARIES</font></div><div style="margin-top:9pt;text-indent:24.75pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson&#160;&#38; Johnson, a New Jersey corporation, had the U.S. and international subsidiaries shown below as of January&#160;1,&#160;2023. Johnson &#38; Johnson is not a subsidiary of any other entity. </font></div><div><font><br></font></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Subsidiaries&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABD Holding Company, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABIOMED R&#38;D, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ABIOMED, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Acclarent, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Pharmaceuticals US, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Albany Street LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ALZA Corporation</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Alza Land Management, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Development, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Manufacturing USA, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Nominee Holdings, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Sales and Service, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Spain Holdings, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anakuria Therapeutics, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AorTx, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Aragon Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Asia Pacific Holdings, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Atrionix, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AUB Holdings LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Auris Health, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BeneVir BioPharm, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">BioMedical Enterprises, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biosense Webster, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">California</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Breethe, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Centocor Biologics, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Centocor Research &#38; Development, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cerenovus, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Coherex Medical, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Consumer Test Entity (TEST PURPOSE ONLY)</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CoTherix Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CRES Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CrossRoads Extremity Systems, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tennessee</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">CSATS, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Washington</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Mitek, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Orthopaedics, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Products, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Spine, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Synthes Institute, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Synthes Products, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Synthes Sales, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Massachusetts</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Synthes, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dutch Holding LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ECL7, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Endo-Surgery, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ohio</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Endo-Surgery, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon US, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Texas</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hansen Medical International, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hansen Medical, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">I.D. Acquisition Corp.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen BioPharma, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Biotech, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Global Services, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Oncology, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Ortho LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Products, LP</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Research &#38; Development, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Scientific Affairs, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Supply Group, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Manufacturing, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jevco Holding, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJHC, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ International Investment LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL (APAC) HoldCo 2 LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL (APAC) HoldCo LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL (Japan) HoldCo Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL (Middle East) HoldCo LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL (Thailand) HoldCo LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (Services) LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL HoldCo 2 LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL HoldCo 3 LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL HoldCo 4 LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL HoldCo 5 LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL HoldCo 6 LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL HoldCo 7 LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL HoldCo 8 LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL HoldCo LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Holdings 2, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Holdings 3, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Holdings, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Middle East) Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Singapore) Holdco LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nevada</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Enterprise Innovation Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Finance Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Gateway, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Health and Wellness Solutions, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Michigan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Health Care Systems Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Innovation - JJDC, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Innovation LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson International</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Devices &#38; Diagnostics Group - Latin America, L.L.C.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson S.E., Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Services, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Surgical Vision, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Urban Renewal Associates</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Vision Care, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JOM Pharmaceutical Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kenvue Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">LTL Management LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Consumer Pharmaceuticals Co.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Healthcare LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil LA LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNEIL MMP, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Nutritionals, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Device Business Services, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indiana</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices &#38; Diagnostics Global Services, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medical Devices International LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">MegaDyne Medical Products, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Utah</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Partnership Holding Company I, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Texas GP LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Texas L.P.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Worldwide LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Middlesex Assurance Company Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vermont</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Momenta Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NeoStrata Company, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands Holding Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NeuWave Medical, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Novira Therapeutics, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NuVera Medical, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OMJ Pharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Omrix Biopharmaceuticals, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ortho Biologics LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ortho Biotech Holding LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Patriot Pharmaceuticals, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pennsylvania</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peninsula Pharmaceuticals, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Percivia LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">preCARDIA, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Princeton Laboratories, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prosidyan, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pulsar Vascular, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Regency Urban Renewal Associates</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty A&#38;M LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">North Carolina</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rutan Realty LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Jersey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Scios LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SterilMed, Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Minnesota</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes USA Products, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes USA, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TARIS Biomedical LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TearScience, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Anspach Effort, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Vision Care Institute, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Florida</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tibotec, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Torax Medical, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Verb Surgical Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vogue International LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">WH4110 Development Company, L.L.C.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Georgia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zarbee's, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Subsidiaries&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3Dintegrated ApS</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Pharmaceuticals Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Pharmaceuticals Trading (Shanghai) Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Actelion Treasury Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO (Hangzhou) Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO (Shanghai) Medical Devices Trading Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO ASIA LIMITED</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Australia Pty Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Canada Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Denmark ApS</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO France</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Germany GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Groningen B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO International Holdings Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Ireland</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Italy SRL</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Japan K.K.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Netherlands BV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Norway AS</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Puerto Rico Manufacturing, Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cayman Islands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Singapore Pte. Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Switzerland GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO United Kingdom, Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">AMO Uppsala AB</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Apsis</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Backsvalan 6 Handelsbolag</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beijing Dabao Cosmetics Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Berna Rhein B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Biosense Webster (Israel) Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">C Consumer Products Denmark ApS</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carlo Erba OTC S.r.l.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ChromaGenics B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ci&#58;z. Labo Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag AG</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag GmbH International</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag Holding AG</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag Holding Treasury Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cilag-Biotech, S.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">ColBar LifeScience Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cordis de Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Corimmun GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Debs-Vogue Corporation (Proprietary) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Hellas SA</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy International Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Ireland Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">DePuy Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EES Holdings de Mexico, S. de R.L. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EES, S.A. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EIT Emerging Implant Technologies GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Endo-Surgery (Europe) GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Sarl</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethicon Women's Health &#38; Urology Sarl</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethnor (Proprietary) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethnor del Istmo S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ethnor Farmaceutica, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venezuela, Bolivarian Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury (Development) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury (Instruments) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury Medical Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury Orthopaedics International Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finsbury Orthopaedics Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">FMS Future Medical System SA</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GATT Technologies B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GH Biotech Holdings Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Global Investment Participation B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">GMED Healthcare BV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Guangzhou Bioseal Biotech Co., Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hansen Medical Deutschland GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hansen Medical UK Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Healthcare Services (Shanghai) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Innomedic Gesellschaft f&#252;r innovative Medizintechnik und Informatik mbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J &#38; J Company West Africa Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nigeria</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J&#38;J Argentina S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J&#38;J Pension Trustees Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J&#38;J Productos Medicos &#38; Farmaceuticos del Peru S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peru</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J.C. General Services BV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Biologics (Ireland) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Biologics B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Cilag Farmaceutica S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Cilag S.p.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Cilag SPA</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Algeria</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Cilag, C.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venezuela, Bolivarian Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Development Finance Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Egypt LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Farmaceutica Portugal Lda</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen France Treasury Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Holding GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Irish Finance Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Japan Treasury Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Korea Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Mexico Treasury Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutica (Proprietary) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutica NV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutica S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peru</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutical K.K.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutical Sciences Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Pharmaceutical Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen R&#38;D Ireland Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Sciences Ireland Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Vaccines &#38; Prevention B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen Vaccines Corp.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag (New Zealand) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag A&#47;S</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag AG</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Aktiebolag</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag AS</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag d.o.o. Beograd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Serbia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag de Mexico S. de R.L. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Farmaceutica Lda.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Farmaceutica Ltda.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag International NV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Kft.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag NV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag OY</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Pharma GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Pharmaceutical S.A.C.I.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Polska, Sp. z o.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag Pty Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag s.r.o.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Cilag, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Janssen-Pharma, S.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">J-C Health Care Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJ Surgical Vision Spain, S.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJC Acquisition Company B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV Belgium BV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV Manufacturing Malaysia SDN. BHD.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV Norden AB</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JJSV Produtos Oticos Ltda.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ Global Business Services s.r.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNJ Holding EMEA B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL (APAC) HoldCo 3 Pte. Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL (APAC) HoldCo Pte. Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL (Malaysia) Sdn. Bhd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL (Puerto Rico) HoldCo GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL (Shanghai) Investment Co., Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL (Switzerland) HoldCo GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL (UK) HoldCo Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (Vietnam) Co. Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vietnam</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (Belgium) BV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (Brazil) Ltda.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (Czech Republic) s.r.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (Dominican Republic), S.A.S.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dominican Republic</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (Finland) Oy</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (France) SAS</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (Hungary) Kft</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (India)&#160;Private Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (New Zealand) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (Norway) AS</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Norway</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (Philippines) Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (Poland) sp. z o.o.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (Portugal) Limitada</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (Slovakia), s.r.o.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Slovakia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (Spain), S.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health (Taiwan) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taiwan (Province of China)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health General Services BV</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health I (Ireland) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health I (Switzerland) GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health II (Switzerland) GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health Mexico, S. de R.L. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Consumer Health Middle East FZ-LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Holdings B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Ireland HoldCo 2 B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Netherlands HoldCo B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">JNTL Turkey T&#252;ketici Sa&#287;l&#305;&#287;&#305; Limited &#350;irketi</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson - Societa' Per Azioni</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Angola), Limitada</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Angola</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Australia) Pty Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Canada) Inc.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (China) Investment Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Ecuador) S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ecuador</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Egypt) S.A.E.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Hong Kong) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Ireland) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Jamaica) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jamaica</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Kenya) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kenya</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Mozambique), Limitada</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mozambique</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Namibia) (Proprietary) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Namibia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (New Zealand) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New Zealand</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Philippines), Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Private) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Zimbabwe</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Thailand) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Trinidad) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Trinidad and Tobago</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson (Vietnam) Co., Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vietnam</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson AB</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson AG</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Bulgaria EOOD</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bulgaria</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson China Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer (Hong Kong) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hong Kong</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer (Thailand) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer Holdings France</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer NV</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer Saudi Arabia Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Consumer Services EAME Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson d.o.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Slovenia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Argentina S.A.C. e. I.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Chile S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Colombia S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Uruguay S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Uruguay</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson de Venezuela, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venezuela, Bolivarian Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson del Ecuador, S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ecuador</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Del Paraguay, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Paraguay</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson del Peru S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peru</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson do Brasil Industria E Comercio de Produtos Para Saude Ltda.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Dominicana, S.A.S.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dominican Republic</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson European Treasury Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Finance Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Financial Services GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson for Export and Import LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Egypt</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Gesellschaft m.b.H.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson GT, Sociedad An&#243;nima</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Guatemala</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Guatemala, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Guatemala</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Hellas Commercial and Industrial S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Hellas Consumer Products Commercial Societe Anonyme</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Hemisferica S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Puerto Rico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Holding GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Holdings (Austria) GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Inc.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Industrial Ltda.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Brazil</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Innovation Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson International (Singapore) Pte. Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson International Financial Services Unlimited Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Irish Finance Company Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson K.K.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Japan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Kft.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Hungary</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Korea Selling &#38; Distribution LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Korea, Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russian Federation</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Luxembourg Finance Company Sarl</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Luxembourg</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Management Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical (China) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical (Proprietary) Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical (Shanghai) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical (Suzhou) Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical B.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Greece Single Member S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greece</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Korea Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical NV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Products GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Austria</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Pty Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Argentina</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical S.p.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Italy</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical SAS</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Saudi Arabia Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Saudi Arabia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical Taiwan Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taiwan (Province of China)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medical, S.C.S.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Venezuela, Bolivarian Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medikal Sanayi ve Ticaret Limited Sirketi</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson MedTech (Thailand) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thailand</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Medtech Colombia S.A.S.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Colombia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Middle East FZ-LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Morocco Societe Anonyme</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Morocco</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Nordic AB</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Pacific Pty Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Pakistan (Private) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pakistan</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Panama, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Personal Care (Chile) S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chile</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Pharmaceutical Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Poland Sp. z o.o.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Poland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Private Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Pte. Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Singapore</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Pty. Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Romania S.R.L.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Romania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson S.E. d.o.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Croatia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Sante Beaute France</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson SDN. BHD.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Malaysia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Surgical Vision India Private Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">India</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Taiwan Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Taiwan (Province of China)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson UK Treasury Company Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Ukraine LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ukraine</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Vision Care (Australia) Pty Ltd</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Australia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Vision Care (Shanghai) Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Vision Care Ireland Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson Vision Korea, Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Korea, Republic of</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson, Lda</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Portugal</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson, s.r.o.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Slovakia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson &#38; Johnson, s.r.o.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Czech Republic</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson and Johnson (Proprietary) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson and Johnson Sihhi Malzeme Sanayi Ve Ticaret Limited Sirketi</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Turkey</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Johnson Y Johnson de Costa Rica, S.A.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costa Rica</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">La Concha Land Investment Corporation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Philippines</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil AB</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Denmark ApS</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Denmark</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Healthcare (Ireland) Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Healthcare (UK) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Iberica S.L.U.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spain</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Panama, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Panama</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Products Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">McNeil Sweden AB</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sweden</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medos International Sarl</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Medos Sarl</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Menlo Care De Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Deutschland GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mentor Medical Systems B.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Netherlands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Momenta Ireland Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">NeoStrata UG (haftungsbeschr&#228;nkt)</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Neuravi Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Obtech Medical Mexico, S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OBTECH Medical Sarl</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OGX Beauty Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">OMJ Holding GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Omrix Biopharmaceuticals Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Omrix Biopharmaceuticals NV</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orthospin Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Israel</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orthotaxy</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmadirect Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Canada</font></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.045%"><tr><td style="width:1.0%"></td><td style="width:77.888%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.912%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pharmedica Laboratories (Proprietary) Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Productos de Cuidado Personal y de La Salud de Bolivia S.R.L.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Bolivia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proleader S.A.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Uruguay</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PT Integrated Healthcare Indonesia</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indonesia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PT Johnson &#38; Johnson Indonesia</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indonesia</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">PT Johnson and Johnson Indonesia Two</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Indonesia</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">RespiVert Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Review Manager Test Entity 2</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Serhum S.A. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shanghai Elsker Mother &#38; Baby Co., Ltd</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shanghai Johnson &#38; Johnson Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shanghai Johnson &#38; Johnson Pharmaceuticals Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sodiac ESV</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Belgium</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spectrum Vision Limited Liability Company</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Russian Federation</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spectrum Vision Limited Liability Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ukraine</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Spectrum Vision Limited Liability Partnership</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Kazakhstan</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Surgical Process Institute Deutschland GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Costa Rica S.C.R., Limitada</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Costa Rica</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SYNTHES GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Holding AG</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Holding Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">SYNTHES Medical Immobilien GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Medical Surgical Equipment &#38; Instruments Trading LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Arab Emirates</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Produktions GmbH</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Switzerland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Proprietary Limited</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">South Africa</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes S.M.P., S. de R.L. de C.V.</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mexico</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Synthes Tuttlingen GmbH</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Germany</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">UAB &#34;Johnson &#38; Johnson&#34;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Lithuania</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vania Expansion</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vision Care Finance Unlimited Company</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Xian Janssen Pharmaceutical Ltd.</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">China</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">XO1 Limited</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">United Kingdom</font></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>4
<FILENAME>ex23-pwcconsentxform10xkx2.htm
<DESCRIPTION>EX-23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="idbe0cfcdb1144a7d9e8a584b3c4bb973_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXHIBIT&#160;23</font></div><div style="margin-top:19pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div style="margin-top:7pt"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-264596, 333-211250, 333-181092, 333-163857, 333-129542, and 333-124785) and Form S-3 (No. 333-236499) of Johnson &#38; Johnson of our report dated February 16, 2023 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.</font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#47;s&#47;PricewaterhouseCoopers LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Florham Park, NJ </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">February 16, 2023</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>ex311-302certofceoxform10x.htm
<DESCRIPTION>EX-31.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i1fe8dab761d443b1880acf2df1139e96_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit&#160;31.1</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joaquin Duato, certify that&#58;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;I have reviewed this Annual Report on Form 10-K for the fiscal year ended January&#160;1, 2023 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#8220;Company&#8221;)&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;The Company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the Company and have&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(c) Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(d) Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company&#8217;s most recent fiscal quarter (the Company&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;The Company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joaquin Duato</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;16, 2023</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>ex312-302certofcfoxform10x.htm
<DESCRIPTION>EX-31.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i3f1afa5283824f6e89d96b8f41402f07_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exhibit 31.2</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Joseph J. Wolk certify that&#58;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;I have reviewed this Annual Report on Form 10-K for the fiscal year ended January&#160;1, 2023 (the &#8220;report&#8221;) of Johnson &#38; Johnson (the &#8220;Company&#8221;)&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the Company as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;The Company&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules&#160;13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules&#160;13a-15(f) and 15d-15(f)) for the Company and have&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the Company, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(c) Evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(d) Disclosed in this report any change in the Company&#8217;s internal control over financial reporting that occurred during the Company&#8217;s most recent fiscal quarter (the Company&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:6pt;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;The Company&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the Company&#8217;s auditors and the audit committee of the Company&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(a)&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the Company&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:6pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;(b)&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#8217;s internal control over financial reporting.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph J. Wolk</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;16, 2023 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>ex321-906certofceoxform10x.htm
<DESCRIPTION>EX-32.1 CEO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i4b08c3cfc22b40afa351f88c04e5bf4a_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit&#160;32.1</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned, Joaquin Duato, the Chief Executive Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2023 (the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joaquin Duato</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joaquin Duato</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Executive Officer&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February 16, 2023</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is being furnished to the SEC with this Report on Form 10-K pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.</font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div style="margin-top:18pt;text-align:center"><font><br></font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>8
<FILENAME>ex322-906certofcfoxform10x.htm
<DESCRIPTION>EX-32.2 CFO
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2023 Workiva -->
<title>Document</title></head><body><div id="i413bbc6879234119b26e2d3340cb6494_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="margin-top:18pt;text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF CHIEF FINANCIAL OFFICER</font></div><div style="margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The undersigned, Joseph J. Wolk, the Chief Financial Officer of Johnson &#38; Johnson, a New Jersey corporation (the &#8220;Company&#8221;), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge&#58;</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the Company's Annual Report on Form 10-K for the fiscal year ended January 1, 2023 (the &#8220;Report&#34;) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934&#59; and</font></div><div style="padding-left:36pt"><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.680%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:49.120%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Joseph J. Wolk</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Joseph J. Wolk&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Chief Financial Officer&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dated&#58; February 16, 2023</font></div><div style="margin-top:6pt;text-indent:15.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This certification is being furnished to the SEC with this Report on Form 10-K pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section&#160;18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liability of that section.</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>jnj-20230101.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:18208529-7e82-4728-be6a-fd0bc0acc451,g:1f111954-4d05-432b-a89f-49b08039c9af-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:jnj="http://www.jnj.com/20230101" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.jnj.com/20230101">
  <xs:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20230101_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20230101_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20230101_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="jnj-20230101_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.jnj.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.jnj.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets">
        <link:definition>0000003 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEarnings" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings">
        <link:definition>0000005 - Statement - Consolidated Statements of Earnings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome">
        <link:definition>0000006 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>0000007 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquity" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity">
        <link:definition>0000008 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofEquityParenthetical" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical">
        <link:definition>0000009 - Statement - Consolidated Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>0000010 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>0000011 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandCurrentMarketableSecurities" roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities">
        <link:definition>0000012 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.jnj.com/role/Inventories">
        <link:definition>0000013 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipment" roleURI="http://www.jnj.com/role/PropertyPlantandEquipment">
        <link:definition>0000014 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwill" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill">
        <link:definition>0000015 - Disclosure - Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.jnj.com/role/FairValueMeasurements">
        <link:definition>0000016 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Borrowings" roleURI="http://www.jnj.com/role/Borrowings">
        <link:definition>0000017 - Disclosure - Borrowings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.jnj.com/role/IncomeTaxes">
        <link:definition>0000018 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRelatedObligations" roleURI="http://www.jnj.com/role/EmployeeRelatedObligations">
        <link:definition>0000019 - Disclosure - Employee Related Obligations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlans" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans">
        <link:definition>0000020 - Disclosure - Pensions and Other Benefit Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SavingsPlan" roleURI="http://www.jnj.com/role/SavingsPlan">
        <link:definition>0000021 - Disclosure - Savings Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalandTreasuryStock" roleURI="http://www.jnj.com/role/CapitalandTreasuryStock">
        <link:definition>0000022 - Disclosure - Capital and Treasury Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLoss" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss">
        <link:definition>0000023 - Disclosure - Accumulated Other Comprehensive Income (Loss)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InternationalCurrencyTranslation" roleURI="http://www.jnj.com/role/InternationalCurrencyTranslation">
        <link:definition>0000024 - Disclosure - International Currency Translation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShare" roleURI="http://www.jnj.com/role/EarningsPerShare">
        <link:definition>0000025 - Disclosure - Earnings Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreements" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements">
        <link:definition>0000026 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreas" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas">
        <link:definition>0000027 - Disclosure - Segments of Business and Geographic Areas</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestitures" roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures">
        <link:definition>0000028 - Disclosure - Acquisitions and Divestitures</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedings" roleURI="http://www.jnj.com/role/LegalProceedings">
        <link:definition>0000029 - Disclosure - Legal Proceedings</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Restructuring" roleURI="http://www.jnj.com/role/Restructuring">
        <link:definition>0000030 - Disclosure - Restructuring</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>0000031 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>0000032 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandCurrentMarketableSecuritiesTables" roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables">
        <link:definition>0000033 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.jnj.com/role/InventoriesTables">
        <link:definition>0000034 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentTables" roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentTables">
        <link:definition>0000035 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillTables" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables">
        <link:definition>0000036 - Disclosure - Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.jnj.com/role/FairValueMeasurementsTables">
        <link:definition>0000037 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsTables" roleURI="http://www.jnj.com/role/BorrowingsTables">
        <link:definition>0000038 - Disclosure - Borrowings (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.jnj.com/role/IncomeTaxesTables">
        <link:definition>0000039 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRelatedObligationsTables" roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsTables">
        <link:definition>0000040 - Disclosure - Employee Related Obligations (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansTables" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables">
        <link:definition>0000041 - Disclosure - Pensions and Other Benefit Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalandTreasuryStockTables" roleURI="http://www.jnj.com/role/CapitalandTreasuryStockTables">
        <link:definition>0000042 - Disclosure - Capital and Treasury Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossTables" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables">
        <link:definition>0000043 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareTables" roleURI="http://www.jnj.com/role/EarningsPerShareTables">
        <link:definition>0000044 - Disclosure - Earnings Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsTables" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables">
        <link:definition>0000045 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasTables" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables">
        <link:definition>0000046 - Disclosure - Segments of Business and Geographic Areas (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringTables" roleURI="http://www.jnj.com/role/RestructuringTables">
        <link:definition>0000047 - Disclosure - Restructuring (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>0000048 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails">
        <link:definition>0000049 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails">
        <link:definition>0000050 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails">
        <link:definition>0000051 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.jnj.com/role/InventoriesDetails">
        <link:definition>0000052 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails">
        <link:definition>0000053 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantandEquipmentNarrativeDetails" roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails">
        <link:definition>0000054 - Disclosure - Property, Plant and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails">
        <link:definition>0000055 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillGoodwillDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails">
        <link:definition>0000056 - Disclosure - Intangible Assets and Goodwill - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillNarrativeDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails">
        <link:definition>0000057 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails" roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails">
        <link:definition>0000058 - Disclosure - Intangible Assets and Goodwill - Estimated Amortization of Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativeDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails">
        <link:definition>0000059 - Disclosure - Fair Value Measurements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofDerivativeActivityDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails">
        <link:definition>0000060 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails">
        <link:definition>0000061 - Disclosure - Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
        <link:definition>0000062 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
        <link:definition>0000063 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
        <link:definition>0000064 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
        <link:definition>0000065 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsScheduleofLongtermDebtInstrumentsDetails" roleURI="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails">
        <link:definition>0000066 - Disclosure - Borrowings - Schedule of Long-term Debt Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsNarrativeDetails" roleURI="http://www.jnj.com/role/BorrowingsNarrativeDetails">
        <link:definition>0000067 - Disclosure - Borrowings - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BorrowingsAggregateMaturitiesofLongTermObligationsDetails" roleURI="http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails">
        <link:definition>0000068 - Disclosure - Borrowings - Aggregate Maturities of Long Term Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesProvisionforIncomeTaxesDetails" roleURI="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails">
        <link:definition>0000069 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" roleURI="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails">
        <link:definition>0000070 - Disclosure - Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesNarrativeDetails" roleURI="http://www.jnj.com/role/IncomeTaxesNarrativeDetails">
        <link:definition>0000071 - Disclosure - Income Taxes - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" roleURI="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails">
        <link:definition>0000072 - Disclosure - Income Taxes - Temporary Differences and Carryforwards (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" roleURI="http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails">
        <link:definition>0000073 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails">
        <link:definition>0000074 - Disclosure - Employee Related Obligations - Employee Related Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1" roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1">
        <link:definition>0000074 - Disclosure - Employee Related Obligations - Employee Related Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EmployeeRelatedObligationsNarrativeDetails" roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails">
        <link:definition>0000075 - Disclosure - Employee Related Obligations - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansNarrativeDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails">
        <link:definition>0000076 - Disclosure - Pensions and Other Benefit Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
        <link:definition>0000077 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails">
        <link:definition>0000078 - Disclosure - Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails">
        <link:definition>0000079 - Disclosure - Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails">
        <link:definition>0000080 - Disclosure - Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails">
        <link:definition>0000081 - Disclosure - Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails">
        <link:definition>0000082 - Disclosure - Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails">
        <link:definition>0000083 - Disclosure - Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails">
        <link:definition>0000084 - Disclosure - Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails">
        <link:definition>0000085 - Disclosure - Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SavingsPlanNarrativeDetails" roleURI="http://www.jnj.com/role/SavingsPlanNarrativeDetails">
        <link:definition>0000086 - Disclosure - Savings Plan - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalandTreasuryStockChangesinTreasuryStockDetails" roleURI="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails">
        <link:definition>0000087 - Disclosure - Capital and Treasury Stock - Changes in Treasury Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalandTreasuryStockNarrativeDetails" roleURI="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails">
        <link:definition>0000088 - Disclosure - Capital and Treasury Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveIncomeLossDetails" roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails">
        <link:definition>0000089 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InternationalCurrencyTranslationNarrativeDetails" roleURI="http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails">
        <link:definition>0000090 - Disclosure - International Currency Translation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" roleURI="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails">
        <link:definition>0000091 - Disclosure - Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerShareNarrativeDetails" roleURI="http://www.jnj.com/role/EarningsPerShareNarrativeDetails">
        <link:definition>0000092 - Disclosure - Earnings Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails">
        <link:definition>0000093 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails">
        <link:definition>0000094 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails">
        <link:definition>0000095 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails">
        <link:definition>0000096 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails">
        <link:definition>0000097 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails">
        <link:definition>0000098 - Disclosure - Segments of Business and Geographic Areas - Sales by Segment of Business (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails">
        <link:definition>0000099 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsandDivestituresNarrativeDetails" roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails">
        <link:definition>0000100 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LegalProceedingsDetails" roleURI="http://www.jnj.com/role/LegalProceedingsDetails">
        <link:definition>0000101 - Disclosure - Legal Proceedings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringNarrativeDetails" roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails">
        <link:definition>0000102 - Disclosure - Restructuring - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" roleURI="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails">
        <link:definition>0000103 - Disclosure - Restructuring - Summary of Severance Charges and Associated Spending (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="jnj_AuditorInformationAbstract" abstract="true" name="AuditorInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" abstract="false" name="FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_LossContingencyReserveEstablishedWithinTrust" abstract="false" name="LossContingencyReserveEstablishedWithinTrust" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_RisperdalMember" abstract="true" name="RisperdalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2020AcquisitionsMember" abstract="true" name="A2020AcquisitionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ConcentrationOfCreditRiskTable" abstract="true" name="ConcentrationOfCreditRiskTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_A2.45Notesdue2026Member" abstract="true" name="A2.45Notesdue2026Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_EquityInvestmentRollForward" abstract="true" name="EquityInvestmentRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithoutReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BabyPowderMember" abstract="true" name="BabyPowderMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A1.150NotesDue2028Member" abstract="true" name="A1.150NotesDue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A055NotesDue2025Member" abstract="true" name="A055NotesDue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" abstract="false" name="LossContingencyNumberOfClaimsWithinSettlementAgreement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_PurchasedInProcessResearchAndDevelopmentMember" abstract="true" name="PurchasedInProcessResearchAndDevelopmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A095NotesDue2027Member" abstract="true" name="A095NotesDue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" abstract="false" name="DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A3.55Notesdue2036Member" abstract="true" name="A3.55Notesdue2036Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ChangesInTreasuryStockTableTextBlock" abstract="false" name="ChangesInTreasuryStockTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_Wholesaler1Member" abstract="true" name="Wholesaler1Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A1.650NotesDue2035Member" abstract="true" name="A1.650NotesDue2035Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_AsrMember" abstract="false" name="AsrMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RemicadeMember" abstract="true" name="RemicadeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" abstract="false" name="TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ExercisePriceRangeTwoMember" abstract="true" name="ExercisePriceRangeTwoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" abstract="false" name="TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DeferredTaxAssetsUndistributedForeignEarnings" abstract="false" name="DeferredTaxAssetsUndistributedForeignEarnings" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" abstract="false" name="DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ChangesInTreasuryStockRollForward" abstract="true" name="ChangesInTreasuryStockRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_OncologyMember" abstract="true" name="OncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ChangesinTreasuryStockSharesOutstandingRollForward" abstract="true" name="ChangesinTreasuryStockSharesOutstandingRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_CashPaidDuringTheYearAbstract" abstract="true" name="CashPaidDuringTheYearAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_PhysiomeshMember" abstract="true" name="PhysiomeshMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" abstract="false" name="FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_InterestIncomeExpenseNetMember" abstract="true" name="InterestIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.70Notesdue2046Member" abstract="true" name="A3.70Notesdue2046Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_UnfundedPlansMember" abstract="true" name="UnfundedPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PercentageOfCompanysCommonStockToPlanAsset" abstract="false" name="PercentageOfCompanysCommonStockToPlanAsset" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_StelaraMember" abstract="true" name="StelaraMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" abstract="true" name="PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" abstract="true" name="CONSUMERHEALTHAndPHARMACEUTICALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BusinessCombinationProbabilityOfSuccessFactor" abstract="false" name="BusinessCombinationProbabilityOfSuccessFactor" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_UPTRAVIMember" abstract="true" name="UPTRAVIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_PatentsAndTrademarksMember" abstract="true" name="PatentsAndTrademarksMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" abstract="false" name="EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_OpioidMember" abstract="true" name="OpioidMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" abstract="true" name="FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_InterventionalSolutionsMember" abstract="true" name="InterventionalSolutionsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RegulationCharge" abstract="false" name="RegulationCharge" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_WoundCareandOtherMember" abstract="true" name="WoundCareandOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" abstract="false" name="SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" abstract="false" name="DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" abstract="false" name="TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" abstract="false" name="EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" abstract="false" name="EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A3.625Notesdue2037Member" abstract="true" name="A3.625Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" abstract="false" name="IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_SURGICALMember" abstract="true" name="SURGICALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_VisionMember" abstract="true" name="VisionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SurgeryMember" abstract="true" name="SurgeryMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ExcessOfFairValueOverCarryingValueOfDebt" abstract="false" name="ExcessOfFairValueOverCarryingValueOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_BusinessAcquisitionDiscountRate" abstract="false" name="BusinessAcquisitionDiscountRate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_OPSUMITMember" abstract="true" name="OPSUMITMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EDURANTrilpivirineMember" abstract="true" name="EDURANTrilpivirineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ImpellaMember" abstract="true" name="ImpellaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EvraAndDoxilMember" abstract="true" name="EvraAndDoxilMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.95Notesdue2027Member" abstract="true" name="A2.95Notesdue2027Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesAxis" abstract="true" name="LitigationSettlementByCompaniesAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_DARZALEXMember" abstract="true" name="DARZALEXMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.25Notesdue2022Member" abstract="true" name="A2.25Notesdue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_GENERALMember" abstract="true" name="GENERALMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" abstract="false" name="TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_CurtailmentsAndSettlementsAndRestructuring" abstract="false" name="CurtailmentsAndSettlementsAndRestructuring" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_UNITEDSTATESExportsMember" abstract="true" name="UNITEDSTATESExportsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ImmunologyMember" abstract="true" name="ImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AsiaPacificAfricaMember" abstract="true" name="AsiaPacificAfricaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.375Notesdue2033Member" abstract="true" name="A4.375Notesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.75Notesdue2047Member" abstract="true" name="A3.75Notesdue2047Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EffectOfExchangeRates" abstract="false" name="EffectOfExchangeRates" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_SimponiSimponiAriaMember" abstract="true" name="SimponiSimponiAriaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_NeuroscienceMember" abstract="true" name="NeuroscienceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ElmironMember" abstract="true" name="ElmironMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_WesternHemisphereExcludingUSMember" abstract="true" name="WesternHemisphereExcludingUSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_DebtInstrumentConvertibleAmountOfLoanConverted" abstract="false" name="DebtInstrumentConvertibleAmountOfLoanConverted" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" abstract="false" name="EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_InfectiousDiseasesMember" abstract="true" name="InfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SurgicalMeshProductsMarketingMember" abstract="true" name="SurgicalMeshProductsMarketingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A130NotesDue2030Member" abstract="true" name="A130NotesDue2030Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ConsumerMember" abstract="true" name="ConsumerMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" abstract="true" name="ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_SkinHealthBeautyMember" abstract="true" name="SkinHealthBeautyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_WholesalerConcentrationRiskMember" abstract="true" name="WholesalerConcentrationRiskMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_WomensHealthMember" abstract="true" name="WomensHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityInvestmentswithReadilyDeterminableValueMember" abstract="true" name="EquityInvestmentswithReadilyDeterminableValueMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" abstract="false" name="DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_QualifiedPlansMember" abstract="true" name="QualifiedPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_BabyCareMember" abstract="true" name="BabyCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherOncologyMember" abstract="true" name="OtherOncologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PinnacleAcetabularCupSystemMember" abstract="false" name="PinnacleAcetabularCupSystemMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" abstract="false" name="DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" abstract="false" name="NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_SegmentsTotalMember" abstract="true" name="SegmentsTotalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" abstract="false" name="TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A4.95Debenturesdue2033Member" abstract="true" name="A4.95Debenturesdue2033Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" abstract="false" name="FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OrthopaedicsMember" abstract="true" name="OrthopaedicsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ExercisePriceRangeThreeMember" abstract="true" name="ExercisePriceRangeThreeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A5.50NotesDue2024Member" abstract="true" name="A5.50NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ConvertibleNoteEquityInterestNumberOfShares" abstract="false" name="ConvertibleNoteEquityInterestNumberOfShares" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_EmployeeRelatedObligationsTableTextBlock" abstract="false" name="EmployeeRelatedObligationsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_OtherImmunologyMember" abstract="true" name="OtherImmunologyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A6.95Notesdue2029Member" abstract="true" name="A6.95Notesdue2029Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EquityFairValueAdjustmentImpairmentLoss" abstract="false" name="EquityFairValueAdjustmentImpairmentLoss" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A3.400Notesdue2038Member" abstract="true" name="A3.400Notesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.625Notesdue2025Member" abstract="true" name="A2.625Notesdue2025Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_OpiodsMember" abstract="true" name="OpiodsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_MedTechMember" abstract="true" name="MedTechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ConsumerHealthMember" abstract="true" name="ConsumerHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CONTACTLENSESOTHERMember" abstract="true" name="CONTACTLENSESOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" abstract="false" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" abstract="false" name="MinimumCollateralValueasaPercentReverseRepurchaseAgreement" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_SalesReturnReserve" abstract="false" name="SalesReturnReserve" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_AurisHealthMember" abstract="true" name="AurisHealthMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" abstract="false" name="DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ProfitLossPercentToSales" abstract="false" name="ProfitLossPercentToSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_A5.85Debenturesdue2038Member" abstract="true" name="A5.85Debenturesdue2038Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" abstract="false" name="EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="jnj_OtherIncomeExpenseNetMember" abstract="true" name="OtherIncomeExpenseNetMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" abstract="false" name="ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_EmployeeObligations" abstract="false" name="EmployeeObligations" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ShortTermInvestmentFundsMember" abstract="true" name="ShortTermInvestmentFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ExercisePriceRangeFiveMember" abstract="true" name="ExercisePriceRangeFiveMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LegalProceedingTextualsAbstract" abstract="true" name="LegalProceedingTextualsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_ExercisePriceRangeFourMember" abstract="true" name="ExercisePriceRangeFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EmployeeCompensationPeriod" abstract="false" name="EmployeeCompensationPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="jnj_A0.650NotesDue2024Member" abstract="true" name="A0.650NotesDue2024Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_IdorsiaMember" abstract="true" name="IdorsiaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" abstract="false" name="FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" abstract="false" name="InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_NonQualifiedPlansMember" abstract="true" name="NonQualifiedPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_IMBRUVICAMember" abstract="true" name="IMBRUVICAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ZYTIGAMember" abstract="true" name="ZYTIGAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" abstract="false" name="DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" abstract="false" name="ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OTCMember" abstract="true" name="OTCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OralCareMember" abstract="true" name="OralCareMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.900Notesdue2028Member" abstract="true" name="A2.900Notesdue2028Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.85Notesdue2041Member" abstract="true" name="A4.85Notesdue2041Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ExcessOfCarryingValueOverFairValueOfDebt" abstract="false" name="ExcessOfCarryingValueOverFairValueOfDebt" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OTHERNEUROSCIENCEMember" abstract="true" name="OTHERNEUROSCIENCEMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FundedPlansMember" abstract="true" name="FundedPlansMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanOverUnderFundedStatusABO" abstract="false" name="DefinedBenefitPlanOverUnderFundedStatusABO" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_SPINESPORTSOTHERMember" abstract="true" name="SPINESPORTSOTHERMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A4.50Notesdue2043Member" abstract="true" name="A4.50Notesdue2043Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RevenuesContingentConsideration" abstract="false" name="RevenuesContingentConsideration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_A4.50Debenturesdue2040Member" abstract="true" name="A4.50Debenturesdue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_BermekimabMember" abstract="true" name="BermekimabMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" abstract="false" name="EffectiveIncomeTaxRateReconciliationCapitalLoss" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_LossContingencyEstimateOfAdditionalPossibleLoss" abstract="false" name="LossContingencyEstimateOfAdditionalPossibleLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ExpenseNotAllocatedToSegments" abstract="false" name="ExpenseNotAllocatedToSegments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_TRAUMAMember" abstract="true" name="TRAUMAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProductLiabilityPolicyTextBlock" abstract="false" name="ProductLiabilityPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_CommingledFundsMember" abstract="true" name="CommingledFundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" abstract="false" name="PercentageOfCorridorOfGreaterOfMarketValueOfAssets" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_DeferredTaxAssetsOtherDomestic" abstract="false" name="DeferredTaxAssetsOtherDomestic" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_SupplyChainMember" abstract="true" name="SupplyChainMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_RasmussenInstrumentsLLCMember" abstract="true" name="RasmussenInstrumentsLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherNonLongLivedAssets" abstract="false" name="OtherNonLongLivedAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_OtherInfectiousDiseasesMember" abstract="true" name="OtherInfectiousDiseasesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SavingsPlanAbstract" abstract="true" name="SavingsPlanAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_GainOnSaleOfAnAssetPaymentForRestructuring" abstract="false" name="GainOnSaleOfAnAssetPaymentForRestructuring" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_Numberofpatientsinsettlement" abstract="false" name="Numberofpatientsinsettlement" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_A6.73Debenturesdue2023Member" abstract="true" name="A6.73Debenturesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" abstract="false" name="DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_CardiovascularMetabolismOtherMember" abstract="true" name="CardiovascularMetabolismOtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TalcMember" abstract="true" name="TalcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_TremfyaMember" abstract="true" name="TremfyaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ConcentrationRiskThresholdPercentage" abstract="false" name="ConcentrationRiskThresholdPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="jnj_XareltoMember" abstract="true" name="XareltoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" abstract="false" name="DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_LandAndLeaseholdImprovementsMember" abstract="true" name="LandAndLeaseholdImprovementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FiscalPeriodPolicyTextBlock" abstract="false" name="FiscalPeriodPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" abstract="true" name="OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" abstract="false" name="ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_A0.250NotesDue2022Member" abstract="true" name="A0.250NotesDue2022Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2450NotesDue2060Member" abstract="true" name="A2450NotesDue2060Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" abstract="true" name="ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_KNEESMember" abstract="true" name="KNEESMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" abstract="false" name="FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_PelvicMeshesMember" abstract="false" name="PelvicMeshesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_NumberOfStockBasedCompensationPlans" abstract="false" name="NumberOfStockBasedCompensationPlans" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_PotentialSharesExercisableUnderStockOptionPlans" abstract="false" name="PotentialSharesExercisableUnderStockOptionPlans" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" abstract="false" name="FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_VerbSurgicalIncMember" abstract="true" name="VerbSurgicalIncMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherMember" abstract="true" name="OtherMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_CONCERTAMethylphenidateMember" abstract="true" name="CONCERTAMethylphenidateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" abstract="false" name="ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DeferredTaxLiabilitiesOtherDomestic" abstract="false" name="DeferredTaxLiabilitiesOtherDomestic" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_MomentaMember" abstract="true" name="MomentaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_INVOKANAINVOKAMETMember" abstract="true" name="INVOKANAINVOKAMETMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A210NotesDue2040Member" abstract="true" name="A210NotesDue2040Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_AccruedRebatesReturnsAndPromotions" abstract="false" name="AccruedRebatesReturnsAndPromotions" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_December172018ShareRepurchaseProgramMember" abstract="true" name="December172018ShareRepurchaseProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ConcentrationOfCreditRiskLineItems" abstract="true" name="ConcentrationOfCreditRiskLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="jnj_LossContingencyPendingClaimsNumberAdditional" abstract="false" name="LossContingencyPendingClaimsNumberAdditional" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_PulmonaryHypertensionMember" abstract="true" name="PulmonaryHypertensionMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" abstract="false" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_RISPERDALCONSTAMember" abstract="true" name="RISPERDALCONSTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_Wholesaler3Member" abstract="true" name="Wholesaler3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_Wholesaler2Member" abstract="true" name="Wholesaler2Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_COVID19Member" abstract="true" name="COVID19Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A3.375Notesdue2023Member" abstract="true" name="A3.375Notesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ADVANCEDMember" abstract="true" name="ADVANCEDMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A5.95Notesdue2037Member" abstract="true" name="A5.95Notesdue2037Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" abstract="true" name="INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" abstract="false" name="EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" abstract="false" name="OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DePuyASRU.S.Member" abstract="true" name="DePuyASRU.S.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_GeneralCorporateMember" abstract="true" name="GeneralCorporateMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_UnrecognizedTaxBenefitLiabilityPayment" abstract="false" name="UnrecognizedTaxBenefitLiabilityPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_AbiomedMember" abstract="true" name="AbiomedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ProductLiabilityContingencyNumberOfClaimant" abstract="false" name="ProductLiabilityContingencyNumberOfClaimant" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_EquityFairValueAdjustmentChangeinObservablePrices" abstract="false" name="EquityFairValueAdjustmentChangeinObservablePrices" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_SavingsPlanTextBlock" abstract="false" name="SavingsPlanTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_A3.500Notesdue2048Member" abstract="true" name="A3.500Notesdue2048Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" abstract="true" name="ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="jnj_NonTradeableContingentValueRightMember" abstract="true" name="NonTradeableContingentValueRightMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_PercentageChangeInSalesBySegmentOfBusiness" abstract="false" name="PercentageChangeInSalesBySegmentOfBusiness" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" abstract="false" name="DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_AssetWriteoffMember" abstract="true" name="AssetWriteoffMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LossContingencyPendingClaimsNumberRemaining" abstract="false" name="LossContingencyPendingClaimsNumberRemaining" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="jnj_A2022LongTermIncentivePlanMember" abstract="true" name="A2022LongTermIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" abstract="false" name="EstimatedUsefulLivesOfAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_ClassIRecommendationForImpellaMember" abstract="true" name="ClassIRecommendationForImpellaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_ShippingandHandlingCostsasaPercentofSales" abstract="false" name="ShippingandHandlingCostsasaPercentofSales" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="jnj_ErleadaMember" abstract="true" name="ErleadaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_SalesBySegmentOfBusinessTableTextBlock" abstract="false" name="SalesBySegmentOfBusinessTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="jnj_HIPSMember" abstract="true" name="HIPSMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_PharmaceuticalMember" abstract="true" name="PharmaceuticalMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2250NotesDue2050Member" abstract="true" name="A2250NotesDue2050Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_A2.05Notesdue2023Member" abstract="true" name="A2.05Notesdue2023Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_LitigationSettlementByCompaniesDomain" abstract="true" name="LitigationSettlementByCompaniesDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" abstract="false" name="OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="jnj_ExercisePriceRangeOneMember" abstract="true" name="ExercisePriceRangeOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" abstract="false" name="DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>jnj-20230101_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:18208529-7e82-4728-be6a-fd0bc0acc451,g:1f111954-4d05-432b-a89f-49b08039c9af-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20230101.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f7d90965-63c2-4fe7-a4cc-c4f02c962f08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_888cd434-3dcf-4da2-adf8-1a766d8608d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7d90965-63c2-4fe7-a4cc-c4f02c962f08" xlink:to="loc_us-gaap_AssetsCurrent_888cd434-3dcf-4da2-adf8-1a766d8608d8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_b1175062-e71f-4ade-aec3-3f03c28ab9dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7d90965-63c2-4fe7-a4cc-c4f02c962f08" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_b1175062-e71f-4ade-aec3-3f03c28ab9dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b2dd10ee-3cf8-4f55-87fd-3b83be9d12b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7d90965-63c2-4fe7-a4cc-c4f02c962f08" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b2dd10ee-3cf8-4f55-87fd-3b83be9d12b0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_b40cca55-a4ad-4400-9a35-64344a342538" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7d90965-63c2-4fe7-a4cc-c4f02c962f08" xlink:to="loc_us-gaap_Goodwill_b40cca55-a4ad-4400-9a35-64344a342538" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_04578544-a04b-489b-a3c8-9b9ab5148ad1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7d90965-63c2-4fe7-a4cc-c4f02c962f08" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_04578544-a04b-489b-a3c8-9b9ab5148ad1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_caa26e9a-b867-4ce7-8ccd-ea3be47e4e95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_f7d90965-63c2-4fe7-a4cc-c4f02c962f08" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_caa26e9a-b867-4ce7-8ccd-ea3be47e4e95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b494d518-a34a-47df-a37f-f4288da4c876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_283fc1d0-d54c-4437-8a1f-4a073255b509" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b494d518-a34a-47df-a37f-f4288da4c876" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_283fc1d0-d54c-4437-8a1f-4a073255b509" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_131f1c9d-8cbf-4b57-bf37-062d6aa944dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b494d518-a34a-47df-a37f-f4288da4c876" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_131f1c9d-8cbf-4b57-bf37-062d6aa944dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_788f166c-7d80-4e68-aa7f-e2df173200ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b494d518-a34a-47df-a37f-f4288da4c876" xlink:to="loc_us-gaap_CommonStockValue_788f166c-7d80-4e68-aa7f-e2df173200ee" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_e2614491-cba7-4c1a-9d30-31768d44889c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b494d518-a34a-47df-a37f-f4288da4c876" xlink:to="loc_us-gaap_TreasuryStockValue_e2614491-cba7-4c1a-9d30-31768d44889c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_a14d99ed-78b1-43c0-8f1c-cdbf8ee2065b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2ae17311-bbaf-44e0-b035-5a64de9783c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a14d99ed-78b1-43c0-8f1c-cdbf8ee2065b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_2ae17311-bbaf-44e0-b035-5a64de9783c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_32a34d41-f436-4096-91ce-461ff14b6ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a14d99ed-78b1-43c0-8f1c-cdbf8ee2065b" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_32a34d41-f436-4096-91ce-461ff14b6ffe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_43ea06f7-188a-435a-8109-36ecb019a74e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a14d99ed-78b1-43c0-8f1c-cdbf8ee2065b" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_43ea06f7-188a-435a-8109-36ecb019a74e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_39f15f4c-ad28-4b0e-975b-3586bbf2b50c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a14d99ed-78b1-43c0-8f1c-cdbf8ee2065b" xlink:to="loc_us-gaap_InventoryNet_39f15f4c-ad28-4b0e-975b-3586bbf2b50c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b7ecc6b5-5faa-4583-becb-9b1302202a9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_a14d99ed-78b1-43c0-8f1c-cdbf8ee2065b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b7ecc6b5-5faa-4583-becb-9b1302202a9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_3726f2b0-a925-46d2-9b63-7b2a7012f10c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4948c0cb-18df-4d27-9e0c-156aed172cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_3726f2b0-a925-46d2-9b63-7b2a7012f10c" xlink:to="loc_us-gaap_PreferredStockValue_4948c0cb-18df-4d27-9e0c-156aed172cc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a5274d25-5491-4445-baa3-903efc405723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_3726f2b0-a925-46d2-9b63-7b2a7012f10c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_a5274d25-5491-4445-baa3-903efc405723" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0d911660-fea7-4162-a143-d41cba7df734" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_3726f2b0-a925-46d2-9b63-7b2a7012f10c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_0d911660-fea7-4162-a143-d41cba7df734" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_23721ace-b4cb-4e1c-80b4-2dcf18b66e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_3726f2b0-a925-46d2-9b63-7b2a7012f10c" xlink:to="loc_us-gaap_CommonStockValue_23721ace-b4cb-4e1c-80b4-2dcf18b66e23" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e5675a5f-e88e-4991-b03f-fd910fb8547e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_0a455a29-13cf-407f-98f5-69b2bf2876de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5675a5f-e88e-4991-b03f-fd910fb8547e" xlink:to="loc_us-gaap_LiabilitiesCurrent_0a455a29-13cf-407f-98f5-69b2bf2876de" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_01b06103-65f1-4355-90da-9e48f77c25e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5675a5f-e88e-4991-b03f-fd910fb8547e" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_01b06103-65f1-4355-90da-9e48f77c25e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c4f6ef49-8bd5-4003-bbe0-dae8d722d454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5675a5f-e88e-4991-b03f-fd910fb8547e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_c4f6ef49-8bd5-4003-bbe0-dae8d722d454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_cc51d6d0-165c-4925-b583-adb4d5b7ee82" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5675a5f-e88e-4991-b03f-fd910fb8547e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_cc51d6d0-165c-4925-b583-adb4d5b7ee82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_f6c1decf-da2d-4e69-8f95-d94869f138bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5675a5f-e88e-4991-b03f-fd910fb8547e" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_f6c1decf-da2d-4e69-8f95-d94869f138bd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8f9900f6-888f-4002-be48-3465f600b8e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_e5675a5f-e88e-4991-b03f-fd910fb8547e" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8f9900f6-888f-4002-be48-3465f600b8e4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_53a37ce8-5a4b-4d1b-938a-77a83fff4909" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_58269e5a-69c2-4247-a85c-ccac2c1f9acd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_53a37ce8-5a4b-4d1b-938a-77a83fff4909" xlink:to="loc_us-gaap_ShortTermBorrowings_58269e5a-69c2-4247-a85c-ccac2c1f9acd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9e2836ed-7d52-4d35-be15-8c2ea430ae2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_53a37ce8-5a4b-4d1b-938a-77a83fff4909" xlink:to="loc_us-gaap_AccountsPayableCurrent_9e2836ed-7d52-4d35-be15-8c2ea430ae2b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_7487c968-1f22-4b1a-84c0-939719fe85c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_53a37ce8-5a4b-4d1b-938a-77a83fff4909" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_7487c968-1f22-4b1a-84c0-939719fe85c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_53c84f64-4b82-4a2f-bdbf-c591d4d8cd63" xlink:href="jnj-20230101.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_53a37ce8-5a4b-4d1b-938a-77a83fff4909" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_53c84f64-4b82-4a2f-bdbf-c591d4d8cd63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_821996f1-3cab-4861-a07a-102938acac11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_53a37ce8-5a4b-4d1b-938a-77a83fff4909" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_821996f1-3cab-4861-a07a-102938acac11" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_f250a011-89c4-44ec-a308-90a6452776dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_53a37ce8-5a4b-4d1b-938a-77a83fff4909" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_f250a011-89c4-44ec-a308-90a6452776dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f65f5c31-118f-4aa7-b86b-0f087f23bfc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_fde89bc5-cd6c-49b7-b792-3892bf894f39" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f65f5c31-118f-4aa7-b86b-0f087f23bfc8" xlink:to="loc_us-gaap_Liabilities_fde89bc5-cd6c-49b7-b792-3892bf894f39" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cc450f34-11a6-4208-a22a-0f0371111ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f65f5c31-118f-4aa7-b86b-0f087f23bfc8" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_cc450f34-11a6-4208-a22a-0f0371111ad9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_e870770d-cf51-4ad8-bbff-82392473881d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_f65f5c31-118f-4aa7-b86b-0f087f23bfc8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_e870770d-cf51-4ad8-bbff-82392473881d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20230101.xsd#ConsolidatedStatementsofEarnings"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8bf7c768-b90e-4b93-a087-f14d1544b939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0a4293d8-2ce1-42fa-966a-c113ff9b965c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8bf7c768-b90e-4b93-a087-f14d1544b939" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_0a4293d8-2ce1-42fa-966a-c113ff9b965c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_ada83769-ab61-477b-bd73-779b8c6b2aff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8bf7c768-b90e-4b93-a087-f14d1544b939" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_ada83769-ab61-477b-bd73-779b8c6b2aff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_890f4826-c1f6-4789-b879-27eceafd7efc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_82091292-a461-4651-beff-b1331f709920" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_890f4826-c1f6-4789-b879-27eceafd7efc" xlink:to="loc_us-gaap_GrossProfit_82091292-a461-4651-beff-b1331f709920" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c2508ebe-d173-48ad-98c9-e1f54616c997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_890f4826-c1f6-4789-b879-27eceafd7efc" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_c2508ebe-d173-48ad-98c9-e1f54616c997" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ba989bd9-5739-4705-ba53-9054ecdfa343" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_890f4826-c1f6-4789-b879-27eceafd7efc" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_ba989bd9-5739-4705-ba53-9054ecdfa343" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_8fd13ad5-bcf8-4278-85e1-1aca7d8132c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_890f4826-c1f6-4789-b879-27eceafd7efc" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_8fd13ad5-bcf8-4278-85e1-1aca7d8132c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_5e54cc0c-b425-415e-8387-6f3bd4a72115" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_890f4826-c1f6-4789-b879-27eceafd7efc" xlink:to="loc_us-gaap_InvestmentIncomeInterest_5e54cc0c-b425-415e-8387-6f3bd4a72115" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_f84d3cbf-732b-4b83-b3df-a481ff3bc548" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_890f4826-c1f6-4789-b879-27eceafd7efc" xlink:to="loc_us-gaap_InterestExpense_f84d3cbf-732b-4b83-b3df-a481ff3bc548" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_d49fda3c-6a64-4d33-973c-447c7f8b51eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_890f4826-c1f6-4789-b879-27eceafd7efc" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_d49fda3c-6a64-4d33-973c-447c7f8b51eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_d4263b22-b77d-4151-ae2f-8a382b9f68bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_890f4826-c1f6-4789-b879-27eceafd7efc" xlink:to="loc_us-gaap_RestructuringCharges_d4263b22-b77d-4151-ae2f-8a382b9f68bf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_c80b759c-bc3a-414b-923c-8c4f1cb89eb3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_991db94f-af2a-424e-a3c0-c1e379a2e0a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_c80b759c-bc3a-414b-923c-8c4f1cb89eb3" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_991db94f-af2a-424e-a3c0-c1e379a2e0a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_e7e2f575-c611-414c-9a1a-37f4cf61a7d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_c80b759c-bc3a-414b-923c-8c4f1cb89eb3" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_e7e2f575-c611-414c-9a1a-37f4cf61a7d6" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20230101.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8e75d20f-f48b-43cd-8cd3-2c637e624cf4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4510c8e4-5a04-4244-ba3a-8c16234477dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8e75d20f-f48b-43cd-8cd3-2c637e624cf4" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4510c8e4-5a04-4244-ba3a-8c16234477dd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_b17af6e9-fd49-4653-8e28-d779c2f04901" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_8e75d20f-f48b-43cd-8cd3-2c637e624cf4" xlink:to="loc_us-gaap_NetIncomeLoss_b17af6e9-fd49-4653-8e28-d779c2f04901" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6585532b-bed7-4383-a364-c468d5913978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_65df73a1-2340-4522-afc8-0285e5a01d03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6585532b-bed7-4383-a364-c468d5913978" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_65df73a1-2340-4522-afc8-0285e5a01d03" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_4494460c-367d-403c-98d3-68b36980fd51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6585532b-bed7-4383-a364-c468d5913978" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_4494460c-367d-403c-98d3-68b36980fd51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_352fdf06-168a-44f9-976c-416150a64899" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6585532b-bed7-4383-a364-c468d5913978" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_352fdf06-168a-44f9-976c-416150a64899" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_3bfed7f1-39f7-443a-9f07-bb2039bfebfe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6585532b-bed7-4383-a364-c468d5913978" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_3bfed7f1-39f7-443a-9f07-bb2039bfebfe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2183b29f-235f-4548-8e13-5a1c8dac82e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_1c6adda3-c1f4-4dad-bb93-93e784e2e008" xlink:href="jnj-20230101.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2183b29f-235f-4548-8e13-5a1c8dac82e2" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_1c6adda3-c1f4-4dad-bb93-93e784e2e008" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_b304e116-91b6-464b-b313-6f9e2bd3e0ca" xlink:href="jnj-20230101.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2183b29f-235f-4548-8e13-5a1c8dac82e2" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_b304e116-91b6-464b-b313-6f9e2bd3e0ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_ee2eb3c6-4f78-4d88-83a1-05368a9b00d6" xlink:href="jnj-20230101.xsd#jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_2183b29f-235f-4548-8e13-5a1c8dac82e2" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_ee2eb3c6-4f78-4d88-83a1-05368a9b00d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4f0bd206-49d6-4be1-8e1a-090b70dedd5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_957ca6f1-044e-4994-8ca9-a196412e0140" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4f0bd206-49d6-4be1-8e1a-090b70dedd5e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_957ca6f1-044e-4994-8ca9-a196412e0140" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c7d5cbd8-e5a0-421b-9ea0-052edde59b65" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_4f0bd206-49d6-4be1-8e1a-090b70dedd5e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_c7d5cbd8-e5a0-421b-9ea0-052edde59b65" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_fdd55ffd-bdc8-4ce5-a4e6-2bbc880e01e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_0077bc77-0bff-49d6-840e-be3f0f14790f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_fdd55ffd-bdc8-4ce5-a4e6-2bbc880e01e6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_0077bc77-0bff-49d6-840e-be3f0f14790f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_a619f8fa-61b2-4572-94ec-fa3eb2ba2e0f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_fdd55ffd-bdc8-4ce5-a4e6-2bbc880e01e6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_a619f8fa-61b2-4572-94ec-fa3eb2ba2e0f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20230101.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_92338b68-7efb-4bf8-bd77-f389e9ae4c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_d051070c-2868-49d8-b006-088d96ae5b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_92338b68-7efb-4bf8-bd77-f389e9ae4c8b" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_d051070c-2868-49d8-b006-088d96ae5b8d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_1134b581-3613-4e6b-b20b-8e4a04fa164f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_92338b68-7efb-4bf8-bd77-f389e9ae4c8b" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_1134b581-3613-4e6b-b20b-8e4a04fa164f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_049b97a9-fbe9-40c3-8be1-8aa0bfc45a66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416899a5-91e4-42e2-a1f8-51fee306e552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_049b97a9-fbe9-40c3-8be1-8aa0bfc45a66" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_416899a5-91e4-42e2-a1f8-51fee306e552" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ab2b8923-5a31-4f4f-b213-e24a3eb07669" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_049b97a9-fbe9-40c3-8be1-8aa0bfc45a66" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_ab2b8923-5a31-4f4f-b213-e24a3eb07669" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23c17cd4-cd8f-4d34-90ab-7eadc5ecc1c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_049b97a9-fbe9-40c3-8be1-8aa0bfc45a66" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_23c17cd4-cd8f-4d34-90ab-7eadc5ecc1c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49dadead-2c6c-4005-bbec-e273943f712f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_049b97a9-fbe9-40c3-8be1-8aa0bfc45a66" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_49dadead-2c6c-4005-bbec-e273943f712f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64f76930-0314-4a8b-a6bb-aa76bbd8702f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4cb9d007-731e-4168-a9e3-824d49afe34a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64f76930-0314-4a8b-a6bb-aa76bbd8702f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_4cb9d007-731e-4168-a9e3-824d49afe34a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_950e2e0a-515d-472a-8265-d4af2c41c985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64f76930-0314-4a8b-a6bb-aa76bbd8702f" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_950e2e0a-515d-472a-8265-d4af2c41c985" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_75f500ef-7fbd-4863-bf15-20eec57d09fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64f76930-0314-4a8b-a6bb-aa76bbd8702f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_75f500ef-7fbd-4863-bf15-20eec57d09fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_b4814c0d-9dd2-4020-9055-8eb08d1f47ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64f76930-0314-4a8b-a6bb-aa76bbd8702f" xlink:to="loc_us-gaap_ShareBasedCompensation_b4814c0d-9dd2-4020-9055-8eb08d1f47ff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_8124869f-5098-42c2-978d-03e235368708" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64f76930-0314-4a8b-a6bb-aa76bbd8702f" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_8124869f-5098-42c2-978d-03e235368708" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1ba35cd6-5227-4cb8-a1ca-7099b0a62f62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64f76930-0314-4a8b-a6bb-aa76bbd8702f" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1ba35cd6-5227-4cb8-a1ca-7099b0a62f62" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_74e66fe8-3646-44a1-8e63-6567d0c794a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64f76930-0314-4a8b-a6bb-aa76bbd8702f" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_74e66fe8-3646-44a1-8e63-6567d0c794a3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_48b98ab7-22f9-4d7b-af3c-c4601df994f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64f76930-0314-4a8b-a6bb-aa76bbd8702f" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_48b98ab7-22f9-4d7b-af3c-c4601df994f4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0f4b8116-7bf2-4a9e-8644-232ea25af0d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64f76930-0314-4a8b-a6bb-aa76bbd8702f" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0f4b8116-7bf2-4a9e-8644-232ea25af0d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e5ed86d3-e52a-419e-aab5-ff2984f8466a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64f76930-0314-4a8b-a6bb-aa76bbd8702f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_e5ed86d3-e52a-419e-aab5-ff2984f8466a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1a612c57-0de9-4b6e-bc93-55d06a406506" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64f76930-0314-4a8b-a6bb-aa76bbd8702f" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_1a612c57-0de9-4b6e-bc93-55d06a406506" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_e4edb3cc-f7a1-4a62-b89e-23692c7fdc02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64f76930-0314-4a8b-a6bb-aa76bbd8702f" xlink:to="loc_us-gaap_NetIncomeLoss_e4edb3cc-f7a1-4a62-b89e-23692c7fdc02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_8bfb3149-44fe-4874-a72f-8ea660186f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_64f76930-0314-4a8b-a6bb-aa76bbd8702f" xlink:to="loc_us-gaap_AssetImpairmentCharges_8bfb3149-44fe-4874-a72f-8ea660186f9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f714eaad-d801-44fe-a6f4-5fb4e2f8a475" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_100e42c3-c131-4270-86df-73d356c9bd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f714eaad-d801-44fe-a6f4-5fb4e2f8a475" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_100e42c3-c131-4270-86df-73d356c9bd0b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_27abceb1-a5f0-4ccc-80f0-f0fe95ca54a1" xlink:href="jnj-20230101.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f714eaad-d801-44fe-a6f4-5fb4e2f8a475" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_27abceb1-a5f0-4ccc-80f0-f0fe95ca54a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_2f29abb4-bf13-4903-bce8-1b5ea5a353d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f714eaad-d801-44fe-a6f4-5fb4e2f8a475" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_2f29abb4-bf13-4903-bce8-1b5ea5a353d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_8df8499e-4a43-42d2-b89f-8ea4274ff514" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f714eaad-d801-44fe-a6f4-5fb4e2f8a475" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_8df8499e-4a43-42d2-b89f-8ea4274ff514" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_9b5f90f3-e7b6-4689-8784-42bb6c2c74dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f714eaad-d801-44fe-a6f4-5fb4e2f8a475" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_9b5f90f3-e7b6-4689-8784-42bb6c2c74dc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0c28bc76-8ce3-4691-89dc-fb504848d2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f714eaad-d801-44fe-a6f4-5fb4e2f8a475" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_0c28bc76-8ce3-4691-89dc-fb504848d2fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_66cf3548-eb23-4b9a-992f-20f2b9956f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f714eaad-d801-44fe-a6f4-5fb4e2f8a475" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_66cf3548-eb23-4b9a-992f-20f2b9956f21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1b57e496-bbc8-43b2-b6ac-77533d63002c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f714eaad-d801-44fe-a6f4-5fb4e2f8a475" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_1b57e496-bbc8-43b2-b6ac-77533d63002c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_3e4b5300-65c6-42a8-92bb-6895e0ed1bf0" xlink:href="jnj-20230101.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_f714eaad-d801-44fe-a6f4-5fb4e2f8a475" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_3e4b5300-65c6-42a8-92bb-6895e0ed1bf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4aac06a2-c664-42a7-a0eb-ba4758ec5c01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b150da5f-f721-4816-96b5-745521c2609f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4aac06a2-c664-42a7-a0eb-ba4758ec5c01" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_b150da5f-f721-4816-96b5-745521c2609f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_ed08638d-301f-4496-be57-988f53e6486d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4aac06a2-c664-42a7-a0eb-ba4758ec5c01" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_ed08638d-301f-4496-be57-988f53e6486d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_140d2ce5-02e4-4f91-b481-a3f8a109aa9d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4aac06a2-c664-42a7-a0eb-ba4758ec5c01" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_140d2ce5-02e4-4f91-b481-a3f8a109aa9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b3a87ebd-0789-4ba9-86d1-5894c985a0fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4aac06a2-c664-42a7-a0eb-ba4758ec5c01" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_b3a87ebd-0789-4ba9-86d1-5894c985a0fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_768f7a1e-59a2-436d-baf9-07d5e4c60ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4aac06a2-c664-42a7-a0eb-ba4758ec5c01" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_768f7a1e-59a2-436d-baf9-07d5e4c60ebe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0e649a73-5d0d-401a-8e72-178e201f3962" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4aac06a2-c664-42a7-a0eb-ba4758ec5c01" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0e649a73-5d0d-401a-8e72-178e201f3962" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_6683ec94-f575-4ef7-9e0b-151704eb45dd" xlink:href="jnj-20230101.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4aac06a2-c664-42a7-a0eb-ba4758ec5c01" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_6683ec94-f575-4ef7-9e0b-151704eb45dd" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_4f4dc1e9-c150-4eff-883b-53a20df0021e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_52a4d1e0-b1c7-4b31-a8bc-b549ab623a02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_4f4dc1e9-c150-4eff-883b-53a20df0021e" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_52a4d1e0-b1c7-4b31-a8bc-b549ab623a02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3775da63-f66e-443e-ac33-c90864d2a1e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_4f4dc1e9-c150-4eff-883b-53a20df0021e" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_3775da63-f66e-443e-ac33-c90864d2a1e1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b82bef6a-ba7c-4d23-90ed-0dfd37fa9f21" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_4f4dc1e9-c150-4eff-883b-53a20df0021e" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_b82bef6a-ba7c-4d23-90ed-0dfd37fa9f21" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_46ab5993-a077-4fa0-8802-d228c90c33de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_a461b901-9c03-473c-a3c0-303e9b013838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_46ab5993-a077-4fa0-8802-d228c90c33de" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_a461b901-9c03-473c-a3c0-303e9b013838" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f96cbe90-a262-4f4d-b70d-051ee6c35679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_46ab5993-a077-4fa0-8802-d228c90c33de" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_f96cbe90-a262-4f4d-b70d-051ee6c35679" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2b0e8f88-60a7-42e3-8cf2-caf78eb9c558" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_538ac180-778d-4ca0-a7e9-f99b495b9d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2b0e8f88-60a7-42e3-8cf2-caf78eb9c558" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_538ac180-778d-4ca0-a7e9-f99b495b9d55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a2d9e1ba-3120-4214-bafa-2a125b0bffce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_2b0e8f88-60a7-42e3-8cf2-caf78eb9c558" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_a2d9e1ba-3120-4214-bafa-2a125b0bffce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c6b56369-9361-4e9e-8285-a9eb4cde7793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6817fde5-6711-4434-a29b-e46c94c01d35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c6b56369-9361-4e9e-8285-a9eb4cde7793" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6817fde5-6711-4434-a29b-e46c94c01d35" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f7319875-f985-4b0a-b12e-4dbba17f717f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_c6b56369-9361-4e9e-8285-a9eb4cde7793" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_f7319875-f985-4b0a-b12e-4dbba17f717f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_8148bf28-491e-40b2-a177-299e1f3c76cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7b6a16d1-0970-4229-a0b2-82e547146cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_8148bf28-491e-40b2-a177-299e1f3c76cb" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_7b6a16d1-0970-4229-a0b2-82e547146cf0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_a2440eb9-f48b-45d6-b4b4-1aad3bb93eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeAssets_8148bf28-491e-40b2-a177-299e1f3c76cb" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_a2440eb9-f48b-45d6-b4b4-1aad3bb93eac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_eb9f58a1-0a20-41dd-9ebf-0d9cf351526b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_e901877d-a6fc-4df3-8a99-2ad68fce1179" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_eb9f58a1-0a20-41dd-9ebf-0d9cf351526b" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_e901877d-a6fc-4df3-8a99-2ad68fce1179" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_570d08d7-6c34-4afb-ae0d-e7c999ff7f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_eb9f58a1-0a20-41dd-9ebf-0d9cf351526b" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_570d08d7-6c34-4afb-ae0d-e7c999ff7f4e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#BorrowingsScheduleofLongtermDebtInstrumentsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_9386c95d-6f2e-413f-8540-6b4a460e62ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_1572889f-b7e3-4f80-b15c-27726d3aadf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9386c95d-6f2e-413f-8540-6b4a460e62ee" xlink:to="loc_us-gaap_LongTermDebtCurrent_1572889f-b7e3-4f80-b15c-27726d3aadf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_a8704f70-02f5-4950-b784-ac415ae3d5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_9386c95d-6f2e-413f-8540-6b4a460e62ee" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_a8704f70-02f5-4950-b784-ac415ae3d5ad" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6df2ae0e-ac0e-41d1-8fbb-f11c7cf10f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ff6ae3b6-31e7-4466-b507-3fb6493ec1fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6df2ae0e-ac0e-41d1-8fbb-f11c7cf10f36" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_ff6ae3b6-31e7-4466-b507-3fb6493ec1fa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2e5f9b03-641f-44d2-a60f-6e64a356c7ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_6df2ae0e-ac0e-41d1-8fbb-f11c7cf10f36" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2e5f9b03-641f-44d2-a60f-6e64a356c7ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a7114d19-287f-4532-8eaa-973738db23ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_fc4fdd6c-b837-4b93-96f9-62a1e9e19dd6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a7114d19-287f-4532-8eaa-973738db23ae" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_fc4fdd6c-b837-4b93-96f9-62a1e9e19dd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_f958818c-834f-4886-934a-77a4d4dd5573" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a7114d19-287f-4532-8eaa-973738db23ae" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_f958818c-834f-4886-934a-77a4d4dd5573" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_60a0339b-ef26-4696-aa4e-543d0ae8e30f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0244bdc4-f542-41b1-839f-416acad8412b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_60a0339b-ef26-4696-aa4e-543d0ae8e30f" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0244bdc4-f542-41b1-839f-416acad8412b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_25a29d1b-d261-4349-beed-655e547da395" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_60a0339b-ef26-4696-aa4e-543d0ae8e30f" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_25a29d1b-d261-4349-beed-655e547da395" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1a1b2568-69ea-4559-824a-369b6e08f621" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0159c6f7-29b5-4705-93bc-617262da7ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1a1b2568-69ea-4559-824a-369b6e08f621" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_0159c6f7-29b5-4705-93bc-617262da7ee2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4d6fefe3-eca7-4aa1-b081-a4545d7c45c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1a1b2568-69ea-4559-824a-369b6e08f621" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4d6fefe3-eca7-4aa1-b081-a4545d7c45c8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fa69939b-46fc-426b-84a8-b9d8cca6978e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ad7be0ec-57a0-4cde-8e55-9e11eb4add9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fa69939b-46fc-426b-84a8-b9d8cca6978e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ad7be0ec-57a0-4cde-8e55-9e11eb4add9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_97c52409-112f-4749-96cf-f832382b3436" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fa69939b-46fc-426b-84a8-b9d8cca6978e" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_97c52409-112f-4749-96cf-f832382b3436" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e35c9b19-1b84-4457-a1b3-d1ef36811ffa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fa69939b-46fc-426b-84a8-b9d8cca6978e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_e35c9b19-1b84-4457-a1b3-d1ef36811ffa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_b0e10fea-7215-434a-90a1-efb2e6dc4dfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fa69939b-46fc-426b-84a8-b9d8cca6978e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_b0e10fea-7215-434a-90a1-efb2e6dc4dfd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cf4620a6-1e93-4882-8b1a-b1881a1bf378" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fa69939b-46fc-426b-84a8-b9d8cca6978e" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cf4620a6-1e93-4882-8b1a-b1881a1bf378" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_0da4ae2f-1b76-4af9-bad0-8cf293bbbdaf" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fa69939b-46fc-426b-84a8-b9d8cca6978e" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_0da4ae2f-1b76-4af9-bad0-8cf293bbbdaf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation_9e1317db-5eaa-4173-9140-4563f5438f33" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_fa69939b-46fc-426b-84a8-b9d8cca6978e" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation_9e1317db-5eaa-4173-9140-4563f5438f33" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_1edf3dcb-b001-4a5d-8f2f-7d083c0735ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_085ae981-9481-4180-ae0d-832b321c6c6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_1edf3dcb-b001-4a5d-8f2f-7d083c0735ab" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_085ae981-9481-4180-ae0d-832b321c6c6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_7aa63235-8578-4972-bf99-7e954c8de3b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_1edf3dcb-b001-4a5d-8f2f-7d083c0735ab" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_7aa63235-8578-4972-bf99-7e954c8de3b7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2e54a972-1e4b-4d3c-821e-2f64ab84cdf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_1edf3dcb-b001-4a5d-8f2f-7d083c0735ab" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_2e54a972-1e4b-4d3c-821e-2f64ab84cdf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_fe795d45-35e7-417d-8a4f-b0498cc394c3" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_1edf3dcb-b001-4a5d-8f2f-7d083c0735ab" xlink:to="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_fe795d45-35e7-417d-8a4f-b0498cc394c3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_ca995588-ecaa-431b-bdf6-e9de34904490" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_1edf3dcb-b001-4a5d-8f2f-7d083c0735ab" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_ca995588-ecaa-431b-bdf6-e9de34904490" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilitiesOtherDomestic_853fe598-882f-4fa3-8531-7409b8260b9c" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxLiabilitiesOtherDomestic"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_1edf3dcb-b001-4a5d-8f2f-7d083c0735ab" xlink:to="loc_jnj_DeferredTaxLiabilitiesOtherDomestic_853fe598-882f-4fa3-8531-7409b8260b9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_279223ce-1889-4b72-acdf-b8551f77c4c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a859768c-7efe-430e-a68a-1df80b87a105" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_279223ce-1889-4b72-acdf-b8551f77c4c4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_a859768c-7efe-430e-a68a-1df80b87a105" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_3c35711d-75a9-4214-911f-246a0f37025d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_279223ce-1889-4b72-acdf-b8551f77c4c4" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_3c35711d-75a9-4214-911f-246a0f37025d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_6c203944-0895-4c01-9d67-be7b29bd9457" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_279223ce-1889-4b72-acdf-b8551f77c4c4" xlink:to="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_6c203944-0895-4c01-9d67-be7b29bd9457" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_5a66b8eb-5f73-44b8-b368-c112199e345e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_279223ce-1889-4b72-acdf-b8551f77c4c4" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_5a66b8eb-5f73-44b8-b368-c112199e345e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_817dff5a-e995-4dc0-a461-16bcab1fd2d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_279223ce-1889-4b72-acdf-b8551f77c4c4" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_817dff5a-e995-4dc0-a461-16bcab1fd2d2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_b5289b4d-0fa6-455a-aafb-f2c4ab0b0c1f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_279223ce-1889-4b72-acdf-b8551f77c4c4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_b5289b4d-0fa6-455a-aafb-f2c4ab0b0c1f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings_130b2359-33b7-4584-9194-22175660df51" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxAssetsUndistributedForeignEarnings"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_279223ce-1889-4b72-acdf-b8551f77c4c4" xlink:to="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings_130b2359-33b7-4584-9194-22175660df51" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_0a8a136e-57d4-400b-b1fa-6a35d193ff31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_279223ce-1889-4b72-acdf-b8551f77c4c4" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_0a8a136e-57d4-400b-b1fa-6a35d193ff31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsOtherDomestic_fa05ffc9-16bd-49c5-a0ba-f3d43468aacb" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxAssetsOtherDomestic"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_279223ce-1889-4b72-acdf-b8551f77c4c4" xlink:to="loc_jnj_DeferredTaxAssetsOtherDomestic_fa05ffc9-16bd-49c5-a0ba-f3d43468aacb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeObligations_02a40398-4160-4e4f-9160-5e654709585e" xlink:href="jnj-20230101.xsd#jnj_EmployeeObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_1063a80c-8a8f-4bd1-81f3-383e7f023098" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_02a40398-4160-4e4f-9160-5e654709585e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_1063a80c-8a8f-4bd1-81f3-383e7f023098" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_2f2180f4-1865-46a2-bc4d-f02e831bf353" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_02a40398-4160-4e4f-9160-5e654709585e" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_2f2180f4-1865-46a2-bc4d-f02e831bf353" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1" xlink:type="simple" xlink:href="jnj-20230101.xsd#EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeObligations_29c18d34-7f3a-4f58-9aaa-3196b67a56c4" xlink:href="jnj-20230101.xsd#jnj_EmployeeObligations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_c754a247-1748-442a-a5dc-34a43acdcbbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_29c18d34-7f3a-4f58-9aaa-3196b67a56c4" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_c754a247-1748-442a-a5dc-34a43acdcbbc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_3898c108-e051-4de5-a791-c538ee9f1e9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_29c18d34-7f3a-4f58-9aaa-3196b67a56c4" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_3898c108-e051-4de5-a791-c538ee9f1e9f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_a70a25e6-057d-4129-9670-90e5fc23e608" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_29c18d34-7f3a-4f58-9aaa-3196b67a56c4" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_a70a25e6-057d-4129-9670-90e5fc23e608" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_0261de9f-c2da-4c79-8d7c-7fcf1dfe05e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_jnj_EmployeeObligations_29c18d34-7f3a-4f58-9aaa-3196b67a56c4" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_0261de9f-c2da-4c79-8d7c-7fcf1dfe05e3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9003ee99-288c-4257-978e-2b957e6b715f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_0ca34977-ffa1-45c3-bb36-c85818c3ba6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9003ee99-288c-4257-978e-2b957e6b715f" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_0ca34977-ffa1-45c3-bb36-c85818c3ba6d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_5a991567-6dee-4da4-94a4-94703273dcf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9003ee99-288c-4257-978e-2b957e6b715f" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_5a991567-6dee-4da4-94a4-94703273dcf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_5e010208-a0db-4709-a4d6-22b8c84225c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9003ee99-288c-4257-978e-2b957e6b715f" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_5e010208-a0db-4709-a4d6-22b8c84225c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_65e7e826-ba2a-4015-8524-72fa980126e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9003ee99-288c-4257-978e-2b957e6b715f" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_65e7e826-ba2a-4015-8524-72fa980126e5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6dc8efc5-a4ae-4844-a9fa-73e3c6303d76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9003ee99-288c-4257-978e-2b957e6b715f" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6dc8efc5-a4ae-4844-a9fa-73e3c6303d76" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_80cc95f6-a6d5-489f-acf3-b7b6bb184384" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_9003ee99-288c-4257-978e-2b957e6b715f" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_80cc95f6-a6d5-489f-acf3-b7b6bb184384" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_363e253e-ef6c-4b9d-afa1-85f2df3d4977" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_01a15bf6-686d-4f00-aab2-658c46a17ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_363e253e-ef6c-4b9d-afa1-85f2df3d4977" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_01a15bf6-686d-4f00-aab2-658c46a17ed0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_69bd49a1-ecbf-4290-b19c-36fda10b1da3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_363e253e-ef6c-4b9d-afa1-85f2df3d4977" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_69bd49a1-ecbf-4290-b19c-36fda10b1da3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_c53e9bdc-fc85-4b89-a021-0fa9d521e927" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_363e253e-ef6c-4b9d-afa1-85f2df3d4977" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_c53e9bdc-fc85-4b89-a021-0fa9d521e927" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_560bc738-475e-4614-9c26-a2df2f7ed8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_6bfc6d1f-ed9e-4f58-9713-dbd1f8666fa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_560bc738-475e-4614-9c26-a2df2f7ed8d3" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_6bfc6d1f-ed9e-4f58-9713-dbd1f8666fa0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2366c89c-999f-44bf-aa1f-7c6ed66d5b84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_560bc738-475e-4614-9c26-a2df2f7ed8d3" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_2366c89c-999f-44bf-aa1f-7c6ed66d5b84" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_c4f8cbdf-da09-44f3-b753-f5c6aafeef62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_012de680-37a5-42e0-a63b-55027dbd8303" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_c4f8cbdf-da09-44f3-b753-f5c6aafeef62" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_012de680-37a5-42e0-a63b-55027dbd8303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_575183eb-c3f8-4d9b-b065-6ef4cfa0b363" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_c4f8cbdf-da09-44f3-b753-f5c6aafeef62" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_575183eb-c3f8-4d9b-b065-6ef4cfa0b363" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_45ee9d4b-ce26-4d48-a48d-12d9f285f6a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_c4f8cbdf-da09-44f3-b753-f5c6aafeef62" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_45ee9d4b-ce26-4d48-a48d-12d9f285f6a3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"/>
  <link:calculationLink xlink:role="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3e7eb9ce-51aa-432c-8836-0caafd536f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5e2af0e1-4bfb-40d1-8500-8923afa4c23a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3e7eb9ce-51aa-432c-8836-0caafd536f9c" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5e2af0e1-4bfb-40d1-8500-8923afa4c23a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_2e10993f-228e-4b61-8fc4-aa086f974f3a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3e7eb9ce-51aa-432c-8836-0caafd536f9c" xlink:to="loc_us-gaap_EarningsPerShareBasic_2e10993f-228e-4b61-8fc4-aa086f974f3a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans_d5942f19-ae6a-40bc-8690-cbf568f3eb30" xlink:href="jnj-20230101.xsd#jnj_PotentialSharesExercisableUnderStockOptionPlans"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3e7eb9ce-51aa-432c-8836-0caafd536f9c" xlink:to="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans_d5942f19-ae6a-40bc-8690-cbf568f3eb30" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_75598a22-6905-452f-9292-9de79de3d498" xlink:href="jnj-20230101.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_3e7eb9ce-51aa-432c-8836-0caafd536f9c" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_75598a22-6905-452f-9292-9de79de3d498" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>jnj-20230101_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:18208529-7e82-4728-be6a-fd0bc0acc451,g:1f111954-4d05-432b-a89f-49b08039c9af-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.jnj.com/role/CoverPage" xlink:type="simple" xlink:href="jnj-20230101.xsd#CoverPage"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CoverPage" xlink:type="extended" id="i2b665476d5e343fab05ca5daf63b4c19_CoverPage">
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1c2a87ac-9dec-4d3d-a592-c2a6de1dcb8f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_DocumentType_1c2a87ac-9dec-4d3d-a592-c2a6de1dcb8f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_878c34fd-478f-4c4a-add4-1bf45f6c62b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_DocumentAnnualReport_878c34fd-478f-4c4a-add4-1bf45f6c62b1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_82ab7898-d4c3-439e-8b35-3a612ac0e332" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_DocumentPeriodEndDate_82ab7898-d4c3-439e-8b35-3a612ac0e332" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_acdc3a42-2e2f-4ebe-ba55-d906d85d423d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_DocumentTransitionReport_acdc3a42-2e2f-4ebe-ba55-d906d85d423d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b81426be-94f8-4c46-8aff-6760116c4562" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityFileNumber_b81426be-94f8-4c46-8aff-6760116c4562" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7ed6f628-b52e-4907-a5cb-2214dd0d0804" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityRegistrantName_7ed6f628-b52e-4907-a5cb-2214dd0d0804" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_114f740e-8704-446a-98d4-033464733e5c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityIncorporationStateCountryCode_114f740e-8704-446a-98d4-033464733e5c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_97385b16-09e4-4ee2-b9a8-8456bb837e6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityTaxIdentificationNumber_97385b16-09e4-4ee2-b9a8-8456bb837e6f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_77b6df96-d26d-4286-ae3b-8ea8b334aca0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityAddressAddressLine1_77b6df96-d26d-4286-ae3b-8ea8b334aca0" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0395fc7e-fe52-41a8-a2b4-84e2ea88a2ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityAddressCityOrTown_0395fc7e-fe52-41a8-a2b4-84e2ea88a2ac" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5cbddc8a-e4a7-486a-8a26-ea4c94b9d641" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityAddressStateOrProvince_5cbddc8a-e4a7-486a-8a26-ea4c94b9d641" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3e537705-f18f-45d3-9cac-3e7c8a30427e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityAddressPostalZipCode_3e537705-f18f-45d3-9cac-3e7c8a30427e" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fa406ecc-4f45-4318-b0ee-434d591981db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_CityAreaCode_fa406ecc-4f45-4318-b0ee-434d591981db" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_80e4d4ba-59ff-40dc-a238-e6a1234aae57" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_LocalPhoneNumber_80e4d4ba-59ff-40dc-a238-e6a1234aae57" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_dd0c0cdc-8e85-497e-924b-77ff386ff915" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_Security12bTitle_dd0c0cdc-8e85-497e-924b-77ff386ff915" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ac537387-1352-4f2b-8cc1-000e8dda823a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_TradingSymbol_ac537387-1352-4f2b-8cc1-000e8dda823a" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9f72fcc7-9530-4400-a58b-62920024d2a0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_SecurityExchangeName_9f72fcc7-9530-4400-a58b-62920024d2a0" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_f5ce46dc-33e7-40d8-adaa-0891450b6f0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_f5ce46dc-33e7-40d8-adaa-0891450b6f0e" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_72c01f63-a768-4fbc-966f-cb93213e0841" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityVoluntaryFilers_72c01f63-a768-4fbc-966f-cb93213e0841" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_74bcb2d2-8899-4ccf-b0bd-5334a6f3ad64" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityCurrentReportingStatus_74bcb2d2-8899-4ccf-b0bd-5334a6f3ad64" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4a9f3401-cad9-46c0-89d3-af2f5189fd7f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityInteractiveDataCurrent_4a9f3401-cad9-46c0-89d3-af2f5189fd7f" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_26cab73a-5351-4fad-beef-dbdc5eb55107" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityFilerCategory_26cab73a-5351-4fad-beef-dbdc5eb55107" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_35c089ae-2d8c-4f37-9e2f-34482cc78584" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityEmergingGrowthCompany_35c089ae-2d8c-4f37-9e2f-34482cc78584" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5bba94c2-823c-4bff-afe4-e105d0c2c199" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntitySmallBusiness_5bba94c2-823c-4bff-afe4-e105d0c2c199" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_045f09fd-a367-4141-9563-96dd657de860" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_IcfrAuditorAttestationFlag_045f09fd-a367-4141-9563-96dd657de860" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a6c4ff5a-a330-4264-a1e1-123e1d354cb6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityShellCompany_a6c4ff5a-a330-4264-a1e1-123e1d354cb6" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f7a9db68-147a-4309-9af5-4fada9c9803e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityPublicFloat_f7a9db68-147a-4309-9af5-4fada9c9803e" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f3a545ee-769e-4a2f-b121-49d5bebce051" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f3a545ee-769e-4a2f-b121-49d5bebce051" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7dca2e04-38de-4ee6-b841-3fc8c4a4c464" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityCentralIndexKey_7dca2e04-38de-4ee6-b841-3fc8c4a4c464" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ab96a725-9b2a-4538-9e3b-ed5e7c929097" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_CurrentFiscalYearEndDate_ab96a725-9b2a-4538-9e3b-ed5e7c929097" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_dc3d1a5a-5505-488b-b460-3a2152268da5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_DocumentFiscalYearFocus_dc3d1a5a-5505-488b-b460-3a2152268da5" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_be092b5d-8d84-49ce-a8d7-e3d9d83917bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_DocumentFiscalPeriodFocus_be092b5d-8d84-49ce-a8d7-e3d9d83917bd" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e58761e5-c210-4369-8212-cf94b78e3b91" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_AmendmentFlag_e58761e5-c210-4369-8212-cf94b78e3b91" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_30a618b0-b925-4acf-969d-ce7f6473a2a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_DocumentInformationTable_30a618b0-b925-4acf-969d-ce7f6473a2a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_455e14f9-038c-48a3-83cd-fe9f3566989d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_DocumentInformationTable_30a618b0-b925-4acf-969d-ce7f6473a2a9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_455e14f9-038c-48a3-83cd-fe9f3566989d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_455e14f9-038c-48a3-83cd-fe9f3566989d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_455e14f9-038c-48a3-83cd-fe9f3566989d" xlink:to="loc_us-gaap_ClassOfStockDomain_455e14f9-038c-48a3-83cd-fe9f3566989d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_31a8f509-efa9-4637-9795-bf339968387e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_455e14f9-038c-48a3-83cd-fe9f3566989d" xlink:to="loc_us-gaap_ClassOfStockDomain_31a8f509-efa9-4637-9795-bf339968387e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9b217a2f-a2b3-406a-b80e-1a86b84481c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_31a8f509-efa9-4637-9795-bf339968387e" xlink:to="loc_us-gaap_CommonStockMember_9b217a2f-a2b3-406a-b80e-1a86b84481c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_6d58c0ce-ac37-434d-8610-936d55fe59ae" xlink:href="jnj-20230101.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_31a8f509-efa9-4637-9795-bf339968387e" xlink:to="loc_jnj_A0.650NotesDue2024Member_6d58c0ce-ac37-434d-8610-936d55fe59ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_ac0f9aab-34d5-49a1-81fe-36cb70fbd57c" xlink:href="jnj-20230101.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_31a8f509-efa9-4637-9795-bf339968387e" xlink:to="loc_jnj_A5.50NotesDue2024Member_ac0f9aab-34d5-49a1-81fe-36cb70fbd57c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_5e997ce5-39d5-4187-8e70-e62b69f7addf" xlink:href="jnj-20230101.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_31a8f509-efa9-4637-9795-bf339968387e" xlink:to="loc_jnj_A1.150NotesDue2028Member_5e997ce5-39d5-4187-8e70-e62b69f7addf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_2367d4fc-2227-40c5-b46c-373fd3cbf5ee" xlink:href="jnj-20230101.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_31a8f509-efa9-4637-9795-bf339968387e" xlink:to="loc_jnj_A1.650NotesDue2035Member_2367d4fc-2227-40c5-b46c-373fd3cbf5ee" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20230101.xsd#ConsolidatedStatementsofEquity"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended" id="icde60d7ad84443dc9da9cf621948de6e_ConsolidatedStatementsofEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_35bd789e-8b39-4ff0-b217-1d1b1f768165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_35bd789e-8b39-4ff0-b217-1d1b1f768165" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2615de94-ef3c-45d0-a326-d2a952461dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:to="loc_us-gaap_NetIncomeLoss_2615de94-ef3c-45d0-a326-d2a952461dc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_2e7b6073-b62a-4930-8ebd-5e630a9c11ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:to="loc_us-gaap_DividendsCommonStockCash_2e7b6073-b62a-4930-8ebd-5e630a9c11ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0f86c791-5e0d-4309-bc97-e7d9c0cb68cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0f86c791-5e0d-4309-bc97-e7d9c0cb68cb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0c11ca3d-6a45-4fba-ac49-83132cd3ca64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0c11ca3d-6a45-4fba-ac49-83132cd3ca64" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_2c1d2193-85d3-4e8f-b589-7d5b0dacf530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:to="loc_us-gaap_StockholdersEquityOther_2c1d2193-85d3-4e8f-b589-7d5b0dacf530" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c3ff3e37-fe54-48b0-8ab1-bb5d176d329a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c3ff3e37-fe54-48b0-8ab1-bb5d176d329a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49caeff5-13f3-4e43-bf82-a18d22b8e075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f0d2860d-76ef-4aba-a040-41444a1ec918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:to="loc_us-gaap_StatementTable_f0d2860d-76ef-4aba-a040-41444a1ec918" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6b9769d9-a1db-4aaf-821e-0faf86a174c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f0d2860d-76ef-4aba-a040-41444a1ec918" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6b9769d9-a1db-4aaf-821e-0faf86a174c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6b9769d9-a1db-4aaf-821e-0faf86a174c9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6b9769d9-a1db-4aaf-821e-0faf86a174c9" xlink:to="loc_us-gaap_EquityComponentDomain_6b9769d9-a1db-4aaf-821e-0faf86a174c9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4b8439f6-3ecc-41cc-9fbe-4cd712e1c59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6b9769d9-a1db-4aaf-821e-0faf86a174c9" xlink:to="loc_us-gaap_EquityComponentDomain_4b8439f6-3ecc-41cc-9fbe-4cd712e1c59c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d9e898ad-081b-46a5-9a20-aa178fd1405b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4b8439f6-3ecc-41cc-9fbe-4cd712e1c59c" xlink:to="loc_us-gaap_RetainedEarningsMember_d9e898ad-081b-46a5-9a20-aa178fd1405b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ec09a25-2f86-4618-809e-5c1ca7ca269e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4b8439f6-3ecc-41cc-9fbe-4cd712e1c59c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ec09a25-2f86-4618-809e-5c1ca7ca269e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_09cdeffc-2098-42d0-a9e0-0ea17ca5141b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4b8439f6-3ecc-41cc-9fbe-4cd712e1c59c" xlink:to="loc_us-gaap_CommonStockMember_09cdeffc-2098-42d0-a9e0-0ea17ca5141b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2189413b-c8b9-4572-9648-785278cd6bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4b8439f6-3ecc-41cc-9fbe-4cd712e1c59c" xlink:to="loc_us-gaap_TreasuryStockMember_2189413b-c8b9-4572-9648-785278cd6bc4" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" id="i75d65fb185d14fcba078d078ba1496c8_SummaryofSignificantAccountingPoliciesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:href="jnj-20230101.xsd#jnj_ConcentrationOfCreditRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_1e735507-6b3b-4954-ba54-7a8c6b52ae66" xlink:href="jnj-20230101.xsd#jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_1e735507-6b3b-4954-ba54-7a8c6b52ae66" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_21117138-608b-4918-8c75-0760be97bc84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_NumberOfReportableSegments_21117138-608b-4918-8c75-0760be97bc84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_bf88671a-0863-439a-af51-6553ce5e9e86" xlink:href="jnj-20230101.xsd#jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_bf88671a-0863-439a-af51-6553ce5e9e86" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c8526352-e002-4ad1-b42c-053633f3a5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c8526352-e002-4ad1-b42c-053633f3a5e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_b245901b-810e-4393-9d68-4dbf443e670d" xlink:href="jnj-20230101.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_b245901b-810e-4393-9d68-4dbf443e670d" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesReturnReserve_92892d8b-eea2-49b8-b199-a45d63b9f163" xlink:href="jnj-20230101.xsd#jnj_SalesReturnReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_SalesReturnReserve_92892d8b-eea2-49b8-b199-a45d63b9f163" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProfitLossPercentToSales_94cfcc28-35e2-4eb6-adef-1a2d0c179f92" xlink:href="jnj-20230101.xsd#jnj_ProfitLossPercentToSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_ProfitLossPercentToSales_94cfcc28-35e2-4eb6-adef-1a2d0c179f92" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9f7cfada-ac76-45f9-a7f5-8cbb25fd06a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9f7cfada-ac76-45f9-a7f5-8cbb25fd06a8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShippingandHandlingCostsasaPercentofSales_458d1d4e-b508-4d51-8dc2-494c72b95666" xlink:href="jnj-20230101.xsd#jnj_ShippingandHandlingCostsasaPercentofSales"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_ShippingandHandlingCostsasaPercentofSales_458d1d4e-b508-4d51-8dc2-494c72b95666" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_450602bd-ee38-4209-a245-7eb9a52c2dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_450602bd-ee38-4209-a245-7eb9a52c2dcc" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_960b0da1-2363-460d-8e02-0e63b68b9d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_960b0da1-2363-460d-8e02-0e63b68b9d4e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_6d66a91c-b388-4318-858c-10887a16cf28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_6d66a91c-b388-4318-858c-10887a16cf28" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_19dcf999-c10c-451d-a27c-f4b9192d3772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_19dcf999-c10c-451d-a27c-f4b9192d3772" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_dd65b6c5-d89c-40ba-9ab0-591d1f95c7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_OperatingLeaseLiability_dd65b6c5-d89c-40ba-9ab0-591d1f95c7a4" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_78df5c50-3045-401e-af31-19c9be10d6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_OperatingLeaseCost_78df5c50-3045-401e-af31-19c9be10d6b9" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5e6777ce-4024-4d71-854f-e379c02954f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_OperatingLeasePayments_5e6777ce-4024-4d71-854f-e379c02954f5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationRiskThresholdPercentage_e0c2e58d-7a1e-4ab3-8d45-4261ad3df887" xlink:href="jnj-20230101.xsd#jnj_ConcentrationRiskThresholdPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_ConcentrationRiskThresholdPercentage_e0c2e58d-7a1e-4ab3-8d45-4261ad3df887" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_bfae84e7-ec6c-4911-9da5-114edc30e096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_AdvertisingExpense_bfae84e7-ec6c-4911-9da5-114edc30e096" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_081251a9-1857-4e80-8db1-d7bacc665af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_081251a9-1857-4e80-8db1-d7bacc665af7" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_418ed7db-6fa2-44bc-ad8a-272e3212b50b" xlink:href="jnj-20230101.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_418ed7db-6fa2-44bc-ad8a-272e3212b50b" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_3d89f955-a380-479f-aa70-190aa42980eb" xlink:href="jnj-20230101.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_3d89f955-a380-479f-aa70-190aa42980eb" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_32d8da64-0697-47e0-8e77-19d57e2edcd8" xlink:href="jnj-20230101.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_32d8da64-0697-47e0-8e77-19d57e2edcd8" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_780da594-9ea1-4f6b-b349-fb7a8a493b8d" xlink:href="jnj-20230101.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_780da594-9ea1-4f6b-b349-fb7a8a493b8d" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_eca12767-8264-4e40-b04d-32f7bda384a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_eca12767-8264-4e40-b04d-32f7bda384a1" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:href="jnj-20230101.xsd#jnj_ConcentrationOfCreditRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d41237f0-30d9-46d7-85e0-6be344969c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d41237f0-30d9-46d7-85e0-6be344969c7d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_d41237f0-30d9-46d7-85e0-6be344969c7d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d41237f0-30d9-46d7-85e0-6be344969c7d" xlink:to="loc_us-gaap_SegmentDomain_d41237f0-30d9-46d7-85e0-6be344969c7d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_70ea591e-8560-44e5-9bb1-129c5eae8fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d41237f0-30d9-46d7-85e0-6be344969c7d" xlink:to="loc_us-gaap_SegmentDomain_70ea591e-8560-44e5-9bb1-129c5eae8fc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_efefe774-853f-403c-bb6d-0ceee17313eb" xlink:href="jnj-20230101.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_70ea591e-8560-44e5-9bb1-129c5eae8fc6" xlink:to="loc_jnj_PharmaceuticalMember_efefe774-853f-403c-bb6d-0ceee17313eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_991886a8-4eae-46af-9764-e8d649662b1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:to="loc_srt_ProductOrServiceAxis_991886a8-4eae-46af-9764-e8d649662b1b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_991886a8-4eae-46af-9764-e8d649662b1b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_991886a8-4eae-46af-9764-e8d649662b1b" xlink:to="loc_srt_ProductsAndServicesDomain_991886a8-4eae-46af-9764-e8d649662b1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b7ec4102-29db-4a15-bb29-3064aa67520c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_991886a8-4eae-46af-9764-e8d649662b1b" xlink:to="loc_srt_ProductsAndServicesDomain_b7ec4102-29db-4a15-bb29-3064aa67520c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_ea5f11fd-7803-4225-bdfc-6edaec4747c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b7ec4102-29db-4a15-bb29-3064aa67520c" xlink:to="loc_us-gaap_ShippingAndHandlingMember_ea5f11fd-7803-4225-bdfc-6edaec4747c0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2f0a3cc-5bc2-41ce-953e-9971a5b85c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2f0a3cc-5bc2-41ce-953e-9971a5b85c4d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2f0a3cc-5bc2-41ce-953e-9971a5b85c4d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2f0a3cc-5bc2-41ce-953e-9971a5b85c4d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d2f0a3cc-5bc2-41ce-953e-9971a5b85c4d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d4039c51-91e4-44e6-bb54-4a252ac87d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2f0a3cc-5bc2-41ce-953e-9971a5b85c4d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d4039c51-91e4-44e6-bb54-4a252ac87d8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a9a73753-babf-4501-bae9-dbf5d56d4f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d4039c51-91e4-44e6-bb54-4a252ac87d8f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a9a73753-babf-4501-bae9-dbf5d56d4f98" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4230f33c-0c27-4682-9c2e-5254f230ccba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:to="loc_srt_RangeAxis_4230f33c-0c27-4682-9c2e-5254f230ccba" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4230f33c-0c27-4682-9c2e-5254f230ccba_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_4230f33c-0c27-4682-9c2e-5254f230ccba" xlink:to="loc_srt_RangeMember_4230f33c-0c27-4682-9c2e-5254f230ccba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e1611e23-d1bc-4c47-90e7-af9a241c7334" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_4230f33c-0c27-4682-9c2e-5254f230ccba" xlink:to="loc_srt_RangeMember_e1611e23-d1bc-4c47-90e7-af9a241c7334" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3a6d7335-6ea0-4b31-8f7b-e3d8c225c0a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e1611e23-d1bc-4c47-90e7-af9a241c7334" xlink:to="loc_srt_MinimumMember_3a6d7335-6ea0-4b31-8f7b-e3d8c225c0a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_70a61bbb-8b9d-4443-889f-ec9b4b084c39" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e1611e23-d1bc-4c47-90e7-af9a241c7334" xlink:to="loc_srt_MaximumMember_70a61bbb-8b9d-4443-889f-ec9b4b084c39" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c534bf6-5187-44ff-9d71-9959346fe84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c534bf6-5187-44ff-9d71-9959346fe84c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8c534bf6-5187-44ff-9d71-9959346fe84c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c534bf6-5187-44ff-9d71-9959346fe84c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8c534bf6-5187-44ff-9d71-9959346fe84c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b04490d3-7a84-4898-b108-58b6bd12cbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c534bf6-5187-44ff-9d71-9959346fe84c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b04490d3-7a84-4898-b108-58b6bd12cbfa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_df29fa94-9629-4d33-80b4-44f86f557df6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b04490d3-7a84-4898-b108-58b6bd12cbfa" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_df29fa94-9629-4d33-80b4-44f86f557df6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d3fc33a2-de56-4402-baf7-12411230d149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d3fc33a2-de56-4402-baf7-12411230d149" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_d3fc33a2-de56-4402-baf7-12411230d149_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d3fc33a2-de56-4402-baf7-12411230d149" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_d3fc33a2-de56-4402-baf7-12411230d149_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c43551d4-5787-4c84-933f-493dc3865a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d3fc33a2-de56-4402-baf7-12411230d149" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c43551d4-5787-4c84-933f-493dc3865a9b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_e58b9799-3219-4f06-b7d8-07aec978156e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c43551d4-5787-4c84-933f-493dc3865a9b" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_e58b9799-3219-4f06-b7d8-07aec978156e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="extended" id="ieeedbdca0e5148d381e14988a1527101_SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0275639-aed6-4685-b823-c5e5eef8b903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_34ec15c5-f1c3-4418-8c85-48f2d490490f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0275639-aed6-4685-b823-c5e5eef8b903" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_34ec15c5-f1c3-4418-8c85-48f2d490490f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a28a172-b1ef-44bf-9001-a60fda827bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0275639-aed6-4685-b823-c5e5eef8b903" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a28a172-b1ef-44bf-9001-a60fda827bfa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_592443d6-a809-4721-9205-3228dce3618d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a28a172-b1ef-44bf-9001-a60fda827bfa" xlink:to="loc_srt_RangeAxis_592443d6-a809-4721-9205-3228dce3618d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_592443d6-a809-4721-9205-3228dce3618d_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_592443d6-a809-4721-9205-3228dce3618d" xlink:to="loc_srt_RangeMember_592443d6-a809-4721-9205-3228dce3618d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cbed1495-e8ce-4992-9a76-f6879374e9c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_592443d6-a809-4721-9205-3228dce3618d" xlink:to="loc_srt_RangeMember_cbed1495-e8ce-4992-9a76-f6879374e9c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7ec69327-ef60-4357-8f5e-c0bf1ca17f63" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cbed1495-e8ce-4992-9a76-f6879374e9c4" xlink:to="loc_srt_MinimumMember_7ec69327-ef60-4357-8f5e-c0bf1ca17f63" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5c2d00e7-3738-410f-bec6-ac37eb6baceb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cbed1495-e8ce-4992-9a76-f6879374e9c4" xlink:to="loc_srt_MaximumMember_5c2d00e7-3738-410f-bec6-ac37eb6baceb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08d04065-c632-4e9e-8c62-b180aef3a5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a28a172-b1ef-44bf-9001-a60fda827bfa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08d04065-c632-4e9e-8c62-b180aef3a5d4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_08d04065-c632-4e9e-8c62-b180aef3a5d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08d04065-c632-4e9e-8c62-b180aef3a5d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_08d04065-c632-4e9e-8c62-b180aef3a5d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e97abd9d-22e6-49c2-acb9-dd2b6365278d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08d04065-c632-4e9e-8c62-b180aef3a5d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e97abd9d-22e6-49c2-acb9-dd2b6365278d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_ada6a193-1114-4107-abb7-15b7240e992a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e97abd9d-22e6-49c2-acb9-dd2b6365278d" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_ada6a193-1114-4107-abb7-15b7240e992a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember_383dc888-2895-4408-b7bd-66a3e4d9cd8c" xlink:href="jnj-20230101.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e97abd9d-22e6-49c2-acb9-dd2b6365278d" xlink:to="loc_jnj_LandAndLeaseholdImprovementsMember_383dc888-2895-4408-b7bd-66a3e4d9cd8c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_2a3f1b31-e085-4cde-9598-db25adca84ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e97abd9d-22e6-49c2-acb9-dd2b6365278d" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_2a3f1b31-e085-4cde-9598-db25adca84ec" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" xlink:type="extended" id="i1a1c9693dc7e4050aad60c119da77e25_CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_993791f0-0c62-44bf-85c7-5b8625414928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_993791f0-0c62-44bf-85c7-5b8625414928" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_196b7e64-d4ad-420f-8553-49011cae5d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:to="loc_us-gaap_HeldToMaturitySecurities_196b7e64-d4ad-420f-8553-49011cae5d1d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_59abe047-ef0b-44a1-9dae-5db70c2f1799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_59abe047-ef0b-44a1-9dae-5db70c2f1799" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_a24d37a8-ff7a-43be-9216-ef2bdd68a69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_a24d37a8-ff7a-43be-9216-ef2bdd68a69f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b9cf88b-4004-470d-89b7-413d39eacfd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b9cf88b-4004-470d-89b7-413d39eacfd7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e1f78f02-71e3-4db2-956e-a7190ec4640a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e1f78f02-71e3-4db2-956e-a7190ec4640a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2fbfceb6-3979-4693-bd03-74b4f0105529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2fbfceb6-3979-4693-bd03-74b4f0105529" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_f50beb50-362d-4dae-bf56-37e74056a793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_f50beb50-362d-4dae-bf56-37e74056a793" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3cf0e53c-4991-45ce-811f-f0a956e4cc30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3cf0e53c-4991-45ce-811f-f0a956e4cc30" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4e155fee-6f4f-4096-b4df-d1bc5d0b2381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_993791f0-0c62-44bf-85c7-5b8625414928" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4e155fee-6f4f-4096-b4df-d1bc5d0b2381" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_f9197bcd-e6f2-4ea1-a553-005901c079d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4e155fee-6f4f-4096-b4df-d1bc5d0b2381" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_f9197bcd-e6f2-4ea1-a553-005901c079d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_f9197bcd-e6f2-4ea1-a553-005901c079d4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_f9197bcd-e6f2-4ea1-a553-005901c079d4" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_f9197bcd-e6f2-4ea1-a553-005901c079d4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_1793976d-3168-4e2e-969a-139c3860534d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_f9197bcd-e6f2-4ea1-a553-005901c079d4" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_1793976d-3168-4e2e-969a-139c3860534d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_30181078-fabd-4a86-9703-ce468376604a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_1793976d-3168-4e2e-969a-139c3860534d" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_30181078-fabd-4a86-9703-ce468376604a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_9a74f441-faf2-4526-978d-0cf89bdd0a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_1793976d-3168-4e2e-969a-139c3860534d" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_9a74f441-faf2-4526-978d-0cf89bdd0a52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7dcfb641-2605-4540-b5ee-b423b2484b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4e155fee-6f4f-4096-b4df-d1bc5d0b2381" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7dcfb641-2605-4540-b5ee-b423b2484b01" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7dcfb641-2605-4540-b5ee-b423b2484b01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7dcfb641-2605-4540-b5ee-b423b2484b01" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7dcfb641-2605-4540-b5ee-b423b2484b01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7dcfb641-2605-4540-b5ee-b423b2484b01" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_2fb54bfc-6399-4bd4-8a71-a4155917cf3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:to="loc_us-gaap_CashMember_2fb54bfc-6399-4bd4-8a71-a4155917cf3d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_54ef8211-69f5-438b-9ad5-c174937d2856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_54ef8211-69f5-438b-9ad5-c174937d2856" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_244dde98-b425-4863-b8c7-e1d8c49833d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_244dde98-b425-4863-b8c7-e1d8c49833d8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8d832643-2535-4454-a1d9-d6b93b00d8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8d832643-2535-4454-a1d9-d6b93b00d8e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_de1da924-705f-4b3c-93e2-770edfdb3365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:to="loc_us-gaap_MoneyMarketFundsMember_de1da924-705f-4b3c-93e2-770edfdb3365" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_ceb3164d-ffe7-4003-a3c7-b3dfbe898168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:to="loc_us-gaap_BankTimeDepositsMember_ceb3164d-ffe7-4003-a3c7-b3dfbe898168" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_89922868-7520-48cf-b5fd-d4e32e8e614f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_89922868-7520-48cf-b5fd-d4e32e8e614f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0cfe74b9-6991-4d49-a4a9-34c31366388f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0cfe74b9-6991-4d49-a4a9-34c31366388f" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="extended" id="i30c9bd99d04c4f21a644c11b193ad9be_PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b16b79-fa16-445d-91a6-aedb51df4c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_93df4320-89b5-4dc4-80d3-a69f39aeeaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b16b79-fa16-445d-91a6-aedb51df4c29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_93df4320-89b5-4dc4-80d3-a69f39aeeaeb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4cba74d7-abc5-455d-b04e-0d96c72aa786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b16b79-fa16-445d-91a6-aedb51df4c29" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4cba74d7-abc5-455d-b04e-0d96c72aa786" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4f8f6446-9568-4005-aa2c-4fa7c69088c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b16b79-fa16-445d-91a6-aedb51df4c29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4f8f6446-9568-4005-aa2c-4fa7c69088c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_67df00d5-50a7-415c-8abb-41715f99ec03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b16b79-fa16-445d-91a6-aedb51df4c29" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_67df00d5-50a7-415c-8abb-41715f99ec03" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b56fb25e-6585-459e-88b3-f5d76b340f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_67df00d5-50a7-415c-8abb-41715f99ec03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b56fb25e-6585-459e-88b3-f5d76b340f63" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b56fb25e-6585-459e-88b3-f5d76b340f63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b56fb25e-6585-459e-88b3-f5d76b340f63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b56fb25e-6585-459e-88b3-f5d76b340f63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d38bfc60-d02b-4ada-8a5f-acf9d1941bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b56fb25e-6585-459e-88b3-f5d76b340f63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d38bfc60-d02b-4ada-8a5f-acf9d1941bee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember_e34b0cd3-ae9e-43f8-a513-c02e57874c1d" xlink:href="jnj-20230101.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d38bfc60-d02b-4ada-8a5f-acf9d1941bee" xlink:to="loc_jnj_LandAndLeaseholdImprovementsMember_e34b0cd3-ae9e-43f8-a513-c02e57874c1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_f47a2a7a-4802-4fdb-b4f8-f18739f42c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d38bfc60-d02b-4ada-8a5f-acf9d1941bee" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_f47a2a7a-4802-4fdb-b4f8-f18739f42c5e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_53b720b3-97a2-45ad-a006-9bdfbd91ea4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d38bfc60-d02b-4ada-8a5f-acf9d1941bee" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_53b720b3-97a2-45ad-a006-9bdfbd91ea4c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_6d63eb65-ee51-490f-946c-e3322784f581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d38bfc60-d02b-4ada-8a5f-acf9d1941bee" xlink:to="loc_us-gaap_ConstructionInProgressMember_6d63eb65-ee51-490f-946c-e3322784f581" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="extended" id="ie1722739c5f742beaa1ef99dbee39f46_IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_b8f23a29-f426-4e5e-aa80-3052f28391f2" xlink:href="jnj-20230101.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cb26ad3d-baf7-4e54-bced-e4bb88378f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_b8f23a29-f426-4e5e-aa80-3052f28391f2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cb26ad3d-baf7-4e54-bced-e4bb88378f31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cf8ea545-52b9-4561-aea1-d539fb357ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cb26ad3d-baf7-4e54-bced-e4bb88378f31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cf8ea545-52b9-4561-aea1-d539fb357ada" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5d28c50f-2b93-429f-ad9f-9ce59edd2700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cf8ea545-52b9-4561-aea1-d539fb357ada" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5d28c50f-2b93-429f-ad9f-9ce59edd2700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2203ee26-6f2f-4fb5-91d9-350b15540bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cf8ea545-52b9-4561-aea1-d539fb357ada" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2203ee26-6f2f-4fb5-91d9-350b15540bc8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_87f22fde-d525-4704-af01-18ddaff7ad3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cf8ea545-52b9-4561-aea1-d539fb357ada" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_87f22fde-d525-4704-af01-18ddaff7ad3d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_51ae2426-42e3-4fda-b6f6-cc9b1885dc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cb26ad3d-baf7-4e54-bced-e4bb88378f31" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_51ae2426-42e3-4fda-b6f6-cc9b1885dc8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2a332a20-baba-41b6-80d2-eb67d8aa0157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_51ae2426-42e3-4fda-b6f6-cc9b1885dc8a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2a332a20-baba-41b6-80d2-eb67d8aa0157" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b407a0fb-2b29-46d4-ae94-5714e2b9d255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_51ae2426-42e3-4fda-b6f6-cc9b1885dc8a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b407a0fb-2b29-46d4-ae94-5714e2b9d255" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4a38f201-de61-4e90-a71f-ba7b76df40d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_b8f23a29-f426-4e5e-aa80-3052f28391f2" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4a38f201-de61-4e90-a71f-ba7b76df40d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_4e924eb6-79f3-4392-9982-df41345062fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_b8f23a29-f426-4e5e-aa80-3052f28391f2" xlink:to="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_4e924eb6-79f3-4392-9982-df41345062fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_eabbb843-359d-4ba4-81ca-4c4ec31a9183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_b8f23a29-f426-4e5e-aa80-3052f28391f2" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_eabbb843-359d-4ba4-81ca-4c4ec31a9183" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_92e5048f-7145-4a67-bb76-27cfe10182ca" xlink:href="jnj-20230101.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_b8f23a29-f426-4e5e-aa80-3052f28391f2" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_92e5048f-7145-4a67-bb76-27cfe10182ca" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2f54ef7c-8735-4225-8f65-0628fcead7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_92e5048f-7145-4a67-bb76-27cfe10182ca" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2f54ef7c-8735-4225-8f65-0628fcead7f3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f54ef7c-8735-4225-8f65-0628fcead7f3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2f54ef7c-8735-4225-8f65-0628fcead7f3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2f54ef7c-8735-4225-8f65-0628fcead7f3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2da97125-0c9b-4753-9379-d5b4ca1724cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2f54ef7c-8735-4225-8f65-0628fcead7f3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2da97125-0c9b-4753-9379-d5b4ca1724cc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember_d90048f8-b334-4b1e-a13f-07c42434ecba" xlink:href="jnj-20230101.xsd#jnj_AbiomedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2da97125-0c9b-4753-9379-d5b4ca1724cc" xlink:to="loc_jnj_AbiomedMember_d90048f8-b334-4b1e-a13f-07c42434ecba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_58b339c4-8bfd-42c6-9a76-ac4fabd43fd3" xlink:href="jnj-20230101.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2da97125-0c9b-4753-9379-d5b4ca1724cc" xlink:to="loc_jnj_BermekimabMember_58b339c4-8bfd-42c6-9a76-ac4fabd43fd3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bfeff74b-de72-4554-8f99-c31fba3b4502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_92e5048f-7145-4a67-bb76-27cfe10182ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bfeff74b-de72-4554-8f99-c31fba3b4502" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bfeff74b-de72-4554-8f99-c31fba3b4502_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bfeff74b-de72-4554-8f99-c31fba3b4502" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_bfeff74b-de72-4554-8f99-c31fba3b4502_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e163f01-1bc3-48e2-ac76-b9e28ee48e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bfeff74b-de72-4554-8f99-c31fba3b4502" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e163f01-1bc3-48e2-ac76-b9e28ee48e6a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_0701570e-e045-4662-b66c-e4fc50d75647" xlink:href="jnj-20230101.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e163f01-1bc3-48e2-ac76-b9e28ee48e6a" xlink:to="loc_jnj_PatentsAndTrademarksMember_0701570e-e045-4662-b66c-e4fc50d75647" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_9b73bdc2-981e-49ef-b9dd-1f34b7f97dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e163f01-1bc3-48e2-ac76-b9e28ee48e6a" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_9b73bdc2-981e-49ef-b9dd-1f34b7f97dbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_29b3cf78-f036-4234-8a1d-b9e12f7b48c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e163f01-1bc3-48e2-ac76-b9e28ee48e6a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_29b3cf78-f036-4234-8a1d-b9e12f7b48c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_18c7258f-680d-467a-938d-03ea39607e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_92e5048f-7145-4a67-bb76-27cfe10182ca" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_18c7258f-680d-467a-938d-03ea39607e64" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_18c7258f-680d-467a-938d-03ea39607e64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_18c7258f-680d-467a-938d-03ea39607e64" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_18c7258f-680d-467a-938d-03ea39607e64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f309f60-f854-4b59-9ad4-c303e993c249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_18c7258f-680d-467a-938d-03ea39607e64" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f309f60-f854-4b59-9ad4-c303e993c249" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_3e52a8db-e5b2-49d8-9e4d-5ccf41545944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f309f60-f854-4b59-9ad4-c303e993c249" xlink:to="loc_us-gaap_TrademarksMember_3e52a8db-e5b2-49d8-9e4d-5ccf41545944" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_25c3d735-d927-4126-a3df-0fc41a060d28" xlink:href="jnj-20230101.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f309f60-f854-4b59-9ad4-c303e993c249" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_25c3d735-d927-4126-a3df-0fc41a060d28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e93a0eba-af9f-4de3-b431-fcb61b84791e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f309f60-f854-4b59-9ad4-c303e993c249" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e93a0eba-af9f-4de3-b431-fcb61b84791e" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IntangibleAssetsandGoodwillGoodwillDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails" xlink:type="extended" id="i3dbaea34d35745a5b918f674e5b045d7_IntangibleAssetsandGoodwillGoodwillDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_9e85730b-3172-4964-9090-f0c8633a05d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_ab1812c5-d835-4881-847e-befa67688091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_9e85730b-3172-4964-9090-f0c8633a05d2" xlink:to="loc_us-gaap_GoodwillRollForward_ab1812c5-d835-4881-847e-befa67688091" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bfeffd3c-8963-4d84-836a-943a597b5212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ab1812c5-d835-4881-847e-befa67688091" xlink:to="loc_us-gaap_Goodwill_bfeffd3c-8963-4d84-836a-943a597b5212" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_c40e02d9-6bfc-44b8-bff2-f5d4f0d469c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ab1812c5-d835-4881-847e-befa67688091" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_c40e02d9-6bfc-44b8-bff2-f5d4f0d469c6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_aad307f2-64de-49db-8132-9f117428a7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ab1812c5-d835-4881-847e-befa67688091" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_aad307f2-64de-49db-8132-9f117428a7ad" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_3b620cb1-98f1-4062-a81a-b1c26b17d7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_ab1812c5-d835-4881-847e-befa67688091" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_3b620cb1-98f1-4062-a81a-b1c26b17d7a8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_445e5fe1-ec8e-4bfc-a833-5db9db4bea97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_22a73c53-af1c-4540-ae05-4a99324e95be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_9e85730b-3172-4964-9090-f0c8633a05d2" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_22a73c53-af1c-4540-ae05-4a99324e95be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f37c9b48-7dae-4ab6-9b75-0aef263323bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_22a73c53-af1c-4540-ae05-4a99324e95be" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f37c9b48-7dae-4ab6-9b75-0aef263323bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_f37c9b48-7dae-4ab6-9b75-0aef263323bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f37c9b48-7dae-4ab6-9b75-0aef263323bd" xlink:to="loc_us-gaap_SegmentDomain_f37c9b48-7dae-4ab6-9b75-0aef263323bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_185bd64c-9770-4ae2-885b-3587db88975f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f37c9b48-7dae-4ab6-9b75-0aef263323bd" xlink:to="loc_us-gaap_SegmentDomain_185bd64c-9770-4ae2-885b-3587db88975f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_75a1543e-8ea4-4126-bdb7-e0a30330dbcc" xlink:href="jnj-20230101.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_185bd64c-9770-4ae2-885b-3587db88975f" xlink:to="loc_jnj_ConsumerMember_75a1543e-8ea4-4126-bdb7-e0a30330dbcc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_1406eee3-8fc7-4a18-a9b0-dd5831568112" xlink:href="jnj-20230101.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_185bd64c-9770-4ae2-885b-3587db88975f" xlink:to="loc_jnj_PharmaceuticalMember_1406eee3-8fc7-4a18-a9b0-dd5831568112" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_ae8c3901-38c8-43ee-87ec-d6723ae3f3d7" xlink:href="jnj-20230101.xsd#jnj_MedTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_185bd64c-9770-4ae2-885b-3587db88975f" xlink:to="loc_jnj_MedTechMember_ae8c3901-38c8-43ee-87ec-d6723ae3f3d7" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended" id="i196967e7bad14f87bd5cbc5f68e4667c_IntangibleAssetsandGoodwillNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aecc7d0e-393d-4ba7-9aad-6da250ecf425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f95a1070-1fbd-446e-941d-59e4ab93d9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aecc7d0e-393d-4ba7-9aad-6da250ecf425" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f95a1070-1fbd-446e-941d-59e4ab93d9f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1edbbe0b-ea16-4a47-b207-06e5f81e7d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aecc7d0e-393d-4ba7-9aad-6da250ecf425" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1edbbe0b-ea16-4a47-b207-06e5f81e7d5c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9e705082-8c6f-4d3b-aa49-7121fb9de552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aecc7d0e-393d-4ba7-9aad-6da250ecf425" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9e705082-8c6f-4d3b-aa49-7121fb9de552" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ee0c61ae-4751-4bd1-9f0b-422e26a9955f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aecc7d0e-393d-4ba7-9aad-6da250ecf425" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ee0c61ae-4751-4bd1-9f0b-422e26a9955f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9d0097c9-c104-4f4d-8595-916c70dea8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ee0c61ae-4751-4bd1-9f0b-422e26a9955f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9d0097c9-c104-4f4d-8595-916c70dea8c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9d0097c9-c104-4f4d-8595-916c70dea8c2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9d0097c9-c104-4f4d-8595-916c70dea8c2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_9d0097c9-c104-4f4d-8595-916c70dea8c2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1ffd8af4-9c42-46c1-92cf-e8585c26bcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9d0097c9-c104-4f4d-8595-916c70dea8c2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1ffd8af4-9c42-46c1-92cf-e8585c26bcbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_0daf7cbb-d9be-4bb0-8ed6-349b298fe05b" xlink:href="jnj-20230101.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1ffd8af4-9c42-46c1-92cf-e8585c26bcbc" xlink:to="loc_jnj_PatentsAndTrademarksMember_0daf7cbb-d9be-4bb0-8ed6-349b298fe05b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_ce24ae55-35b6-4627-a24b-875a911fc9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1ffd8af4-9c42-46c1-92cf-e8585c26bcbc" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_ce24ae55-35b6-4627-a24b-875a911fc9d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_26ffcac8-10d9-4b4a-b5bb-60dce7278f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1ffd8af4-9c42-46c1-92cf-e8585c26bcbc" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_26ffcac8-10d9-4b4a-b5bb-60dce7278f20" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_76d14b55-5367-436f-9e46-16b2a27482e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ee0c61ae-4751-4bd1-9f0b-422e26a9955f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_76d14b55-5367-436f-9e46-16b2a27482e0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76d14b55-5367-436f-9e46-16b2a27482e0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_76d14b55-5367-436f-9e46-16b2a27482e0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_76d14b55-5367-436f-9e46-16b2a27482e0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bfad5321-47ed-44bd-bdec-e54393ff5404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_76d14b55-5367-436f-9e46-16b2a27482e0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bfad5321-47ed-44bd-bdec-e54393ff5404" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_a862d7e8-4731-4f32-ae9a-24e31e50d04e" xlink:href="jnj-20230101.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bfad5321-47ed-44bd-bdec-e54393ff5404" xlink:to="loc_jnj_BermekimabMember_a862d7e8-4731-4f32-ae9a-24e31e50d04e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended" id="if613b3e70ec54d96a88914d91e8304dc_FairValueMeasurementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_eb2e5618-ee76-4ef2-99c1-375d0faa73e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_eb2e5618-ee76-4ef2-99c1-375d0faa73e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_ce0139d2-864e-4ac3-a12c-856b055aee74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_us-gaap_DerivativeNotionalAmount_ce0139d2-864e-4ac3-a12c-856b055aee74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_78a29257-6414-47e2-aa48-892d6599b809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_78a29257-6414-47e2-aa48-892d6599b809" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_cd2e8530-09e1-425b-813d-296cf36e2283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_cd2e8530-09e1-425b-813d-296cf36e2283" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_919537f0-e106-4fb7-8a8d-8c069cf01e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_919537f0-e106-4fb7-8a8d-8c069cf01e49" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_65da9c0a-762e-4899-aad4-728a08bc0082" xlink:href="jnj-20230101.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_65da9c0a-762e-4899-aad4-728a08bc0082" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices_e41f6848-6dca-40a9-a15f-82442e1bc2dd" xlink:href="jnj-20230101.xsd#jnj_EquityFairValueAdjustmentChangeinObservablePrices"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices_e41f6848-6dca-40a9-a15f-82442e1bc2dd" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_74b0c844-32a7-49b9-a85e-8f798c6a8c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_74b0c844-32a7-49b9-a85e-8f798c6a8c57" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_1914cd98-9125-44a8-a6f4-a4ef203b800b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_1914cd98-9125-44a8-a6f4-a4ef203b800b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_48923a18-c9dc-48e2-abf6-bd882b4ee7ff" xlink:href="jnj-20230101.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_48923a18-c9dc-48e2-abf6-bd882b4ee7ff" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_374bb587-1cf7-444b-ad31-eddf3b57357a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_us-gaap_DerivativeTable_374bb587-1cf7-444b-ad31-eddf3b57357a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_e6c46cf6-b252-459a-a7e9-d40bed5e5732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_374bb587-1cf7-444b-ad31-eddf3b57357a" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_e6c46cf6-b252-459a-a7e9-d40bed5e5732" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e6c46cf6-b252-459a-a7e9-d40bed5e5732_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e6c46cf6-b252-459a-a7e9-d40bed5e5732" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_e6c46cf6-b252-459a-a7e9-d40bed5e5732_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_701b19e5-15e1-4770-85e9-91ddfbb4d48f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e6c46cf6-b252-459a-a7e9-d40bed5e5732" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_701b19e5-15e1-4770-85e9-91ddfbb4d48f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_7c923cab-582a-4274-bca4-430c6c115d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_701b19e5-15e1-4770-85e9-91ddfbb4d48f" xlink:to="loc_us-gaap_EquitySecuritiesMember_7c923cab-582a-4274-bca4-430c6c115d92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_3313af3e-c7a7-4c34-8122-43a00aed0adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_374bb587-1cf7-444b-ad31-eddf3b57357a" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_3313af3e-c7a7-4c34-8122-43a00aed0adf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_3313af3e-c7a7-4c34-8122-43a00aed0adf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_3313af3e-c7a7-4c34-8122-43a00aed0adf" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_3313af3e-c7a7-4c34-8122-43a00aed0adf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_1b22ec9b-65fc-4e54-8462-cd962b15dbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_3313af3e-c7a7-4c34-8122-43a00aed0adf" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_1b22ec9b-65fc-4e54-8462-cd962b15dbbd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_b3119ae7-0363-4608-92a0-b66e25ba93fc" xlink:href="jnj-20230101.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_1b22ec9b-65fc-4e54-8462-cd962b15dbbd" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_b3119ae7-0363-4608-92a0-b66e25ba93fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3f7cde78-52c0-4d83-98d3-9fd3fc8c29c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_374bb587-1cf7-444b-ad31-eddf3b57357a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3f7cde78-52c0-4d83-98d3-9fd3fc8c29c1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_3f7cde78-52c0-4d83-98d3-9fd3fc8c29c1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3f7cde78-52c0-4d83-98d3-9fd3fc8c29c1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_3f7cde78-52c0-4d83-98d3-9fd3fc8c29c1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f0c1abc1-03cd-4eeb-a506-ce8ce41d077a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3f7cde78-52c0-4d83-98d3-9fd3fc8c29c1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f0c1abc1-03cd-4eeb-a506-ce8ce41d077a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d42e88d3-8255-40f4-9007-f6bf0bfe4e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f0c1abc1-03cd-4eeb-a506-ce8ce41d077a" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d42e88d3-8255-40f4-9007-f6bf0bfe4e20" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_825a5bb4-7bf4-4065-9c18-9832585152b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f0c1abc1-03cd-4eeb-a506-ce8ce41d077a" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_825a5bb4-7bf4-4065-9c18-9832585152b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_1661017a-808b-4bcd-a23c-5c7b1481b30a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f0c1abc1-03cd-4eeb-a506-ce8ce41d077a" xlink:to="loc_us-gaap_InterestRateSwapMember_1661017a-808b-4bcd-a23c-5c7b1481b30a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ac7cafe5-19f3-4bb8-8900-43a47886bc09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_374bb587-1cf7-444b-ad31-eddf3b57357a" xlink:to="loc_us-gaap_HedgingDesignationAxis_ac7cafe5-19f3-4bb8-8900-43a47886bc09" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_ac7cafe5-19f3-4bb8-8900-43a47886bc09_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_ac7cafe5-19f3-4bb8-8900-43a47886bc09" xlink:to="loc_us-gaap_HedgingDesignationDomain_ac7cafe5-19f3-4bb8-8900-43a47886bc09_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bb670ec4-590e-4267-aed9-adb3f63728af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_ac7cafe5-19f3-4bb8-8900-43a47886bc09" xlink:to="loc_us-gaap_HedgingDesignationDomain_bb670ec4-590e-4267-aed9-adb3f63728af" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3312eebb-b5fa-4478-88c4-baf132863f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_bb670ec4-590e-4267-aed9-adb3f63728af" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3312eebb-b5fa-4478-88c4-baf132863f8f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended" id="i91c6b9240d864185b958c22d97e07c6f_FairValueMeasurementsSummaryofDerivativeActivityDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_63b4e30c-e34f-4d16-a1f5-9dfcad9dd29b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_0f6d0db0-74d3-432e-8972-fe8803fc519e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_63b4e30c-e34f-4d16-a1f5-9dfcad9dd29b" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_0f6d0db0-74d3-432e-8972-fe8803fc519e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_e3c2ce3f-e24d-48e9-a6c3-1a2bae12e61a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_63b4e30c-e34f-4d16-a1f5-9dfcad9dd29b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_e3c2ce3f-e24d-48e9-a6c3-1a2bae12e61a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_33b0096c-8496-4981-ab71-016508c893cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_63b4e30c-e34f-4d16-a1f5-9dfcad9dd29b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_33b0096c-8496-4981-ab71-016508c893cd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_6a3f55a0-c4f3-4a55-b174-df512d208242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_63b4e30c-e34f-4d16-a1f5-9dfcad9dd29b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_6a3f55a0-c4f3-4a55-b174-df512d208242" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fb11cee8-c82d-4197-bb8d-5403629121a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_63b4e30c-e34f-4d16-a1f5-9dfcad9dd29b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fb11cee8-c82d-4197-bb8d-5403629121a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cbf0e817-9778-4130-a6a8-870dbbe3e4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fb11cee8-c82d-4197-bb8d-5403629121a6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cbf0e817-9778-4130-a6a8-870dbbe3e4d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_cbf0e817-9778-4130-a6a8-870dbbe3e4d1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cbf0e817-9778-4130-a6a8-870dbbe3e4d1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_cbf0e817-9778-4130-a6a8-870dbbe3e4d1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9b9049b5-a184-4198-8e8c-021be6c2e66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cbf0e817-9778-4130-a6a8-870dbbe3e4d1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9b9049b5-a184-4198-8e8c-021be6c2e66f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_5e70453a-80a6-4272-b282-374e9025ff49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b9049b5-a184-4198-8e8c-021be6c2e66f" xlink:to="loc_us-gaap_SalesMember_5e70453a-80a6-4272-b282-374e9025ff49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_b07c1134-011d-4209-9264-f74a5a93cf16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b9049b5-a184-4198-8e8c-021be6c2e66f" xlink:to="loc_us-gaap_CostOfSalesMember_b07c1134-011d-4209-9264-f74a5a93cf16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cb2bd923-6d11-4c30-ac69-70fea55b173e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b9049b5-a184-4198-8e8c-021be6c2e66f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cb2bd923-6d11-4c30-ac69-70fea55b173e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_45433e34-83ca-4a86-9ffa-b9dd49c21630" xlink:href="jnj-20230101.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b9049b5-a184-4198-8e8c-021be6c2e66f" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_45433e34-83ca-4a86-9ffa-b9dd49c21630" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_1605fe08-c76d-4f04-8622-1f48226000e2" xlink:href="jnj-20230101.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b9049b5-a184-4198-8e8c-021be6c2e66f" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_1605fe08-c76d-4f04-8622-1f48226000e2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_381f783b-a5dd-42e5-9c9a-cb8e2cdbce74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fb11cee8-c82d-4197-bb8d-5403629121a6" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_381f783b-a5dd-42e5-9c9a-cb8e2cdbce74" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_381f783b-a5dd-42e5-9c9a-cb8e2cdbce74_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_381f783b-a5dd-42e5-9c9a-cb8e2cdbce74" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_381f783b-a5dd-42e5-9c9a-cb8e2cdbce74_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9bff47f9-1cdd-4bc9-a646-ece924396adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_381f783b-a5dd-42e5-9c9a-cb8e2cdbce74" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9bff47f9-1cdd-4bc9-a646-ece924396adc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_44782bd1-adbb-4c01-8f90-8d986f25edb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9bff47f9-1cdd-4bc9-a646-ece924396adc" xlink:to="loc_us-gaap_InterestRateSwapMember_44782bd1-adbb-4c01-8f90-8d986f25edb2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_6732e39e-12bd-4325-b835-1a03f04d1fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9bff47f9-1cdd-4bc9-a646-ece924396adc" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_6732e39e-12bd-4325-b835-1a03f04d1fd9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_94b17330-1858-4283-9fd6-25d801903171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9bff47f9-1cdd-4bc9-a646-ece924396adc" xlink:to="loc_us-gaap_ForeignExchangeContractMember_94b17330-1858-4283-9fd6-25d801903171" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_97140366-19b3-4e6a-97a0-93c418ac58e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fb11cee8-c82d-4197-bb8d-5403629121a6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_97140366-19b3-4e6a-97a0-93c418ac58e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_97140366-19b3-4e6a-97a0-93c418ac58e8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_97140366-19b3-4e6a-97a0-93c418ac58e8" xlink:to="loc_us-gaap_HedgingRelationshipDomain_97140366-19b3-4e6a-97a0-93c418ac58e8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d52b99d6-57c3-4e6e-b216-b70c555bd1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_97140366-19b3-4e6a-97a0-93c418ac58e8" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d52b99d6-57c3-4e6e-b216-b70c555bd1c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_22a69ecf-1b0b-4220-a7dd-bd278f438433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d52b99d6-57c3-4e6e-b216-b70c555bd1c3" xlink:to="loc_us-gaap_FairValueHedgingMember_22a69ecf-1b0b-4220-a7dd-bd278f438433" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_22c50a73-7e4b-4176-ba3a-83b311b8d48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d52b99d6-57c3-4e6e-b216-b70c555bd1c3" xlink:to="loc_us-gaap_CashFlowHedgingMember_22c50a73-7e4b-4176-ba3a-83b311b8d48c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" xlink:type="extended" id="i68b4010ee75d40a78d6a31b796017e97_FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a8d68d26-1021-4326-8419-f8f36f8da1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a011a2a5-d322-46b2-ae4c-5450621b8c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a8d68d26-1021-4326-8419-f8f36f8da1ec" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a011a2a5-d322-46b2-ae4c-5450621b8c02" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_95db6146-3421-4e18-8b56-4515ce6cd6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a8d68d26-1021-4326-8419-f8f36f8da1ec" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_95db6146-3421-4e18-8b56-4515ce6cd6bf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a22c8aa3-7aa5-435e-bad9-a49554c4416e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a8d68d26-1021-4326-8419-f8f36f8da1ec" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a22c8aa3-7aa5-435e-bad9-a49554c4416e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d06fafcc-5262-4f4b-b649-78554f44d6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a22c8aa3-7aa5-435e-bad9-a49554c4416e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d06fafcc-5262-4f4b-b649-78554f44d6a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_d06fafcc-5262-4f4b-b649-78554f44d6a1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d06fafcc-5262-4f4b-b649-78554f44d6a1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_d06fafcc-5262-4f4b-b649-78554f44d6a1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f3415f7e-d453-49af-9f9e-7f4ee35e460f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d06fafcc-5262-4f4b-b649-78554f44d6a1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f3415f7e-d453-49af-9f9e-7f4ee35e460f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_0277632b-a020-4d01-94b1-a2c78c3e35a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f3415f7e-d453-49af-9f9e-7f4ee35e460f" xlink:to="loc_us-gaap_LongTermDebtMember_0277632b-a020-4d01-94b1-a2c78c3e35a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_690dd601-138a-432f-97a2-6fa17afcfe7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a22c8aa3-7aa5-435e-bad9-a49554c4416e" xlink:to="loc_us-gaap_HedgingDesignationAxis_690dd601-138a-432f-97a2-6fa17afcfe7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_690dd601-138a-432f-97a2-6fa17afcfe7b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_690dd601-138a-432f-97a2-6fa17afcfe7b" xlink:to="loc_us-gaap_HedgingDesignationDomain_690dd601-138a-432f-97a2-6fa17afcfe7b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6cf747fc-d749-489d-a04f-6a16c46acf34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_690dd601-138a-432f-97a2-6fa17afcfe7b" xlink:to="loc_us-gaap_HedgingDesignationDomain_6cf747fc-d749-489d-a04f-6a16c46acf34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f1dc54c6-b5be-4e7c-96eb-e3fa5dfd6a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_6cf747fc-d749-489d-a04f-6a16c46acf34" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f1dc54c6-b5be-4e7c-96eb-e3fa5dfd6a88" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended" id="i1ef745fe6167492e9ca6ad6e0928975d_FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_40f93da8-a3de-4f8e-832a-c1bdff10e97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c95b0324-b37b-4832-834d-5814ce72ce93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_40f93da8-a3de-4f8e-832a-c1bdff10e97e" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c95b0324-b37b-4832-834d-5814ce72ce93" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_b791e512-7161-4a8b-ba30-409dc424c276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_40f93da8-a3de-4f8e-832a-c1bdff10e97e" xlink:to="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_b791e512-7161-4a8b-ba30-409dc424c276" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f9026de9-1e32-4534-9645-ec996600521b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_40f93da8-a3de-4f8e-832a-c1bdff10e97e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f9026de9-1e32-4534-9645-ec996600521b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_73682a79-63ae-47af-a442-7597b9c47fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f9026de9-1e32-4534-9645-ec996600521b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_73682a79-63ae-47af-a442-7597b9c47fd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_73682a79-63ae-47af-a442-7597b9c47fd2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_73682a79-63ae-47af-a442-7597b9c47fd2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_73682a79-63ae-47af-a442-7597b9c47fd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_14b5ed0b-6df5-4aa8-bc85-400a8baa49d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_73682a79-63ae-47af-a442-7597b9c47fd2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_14b5ed0b-6df5-4aa8-bc85-400a8baa49d1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_58c3f246-52cd-4c07-b37b-1c7304e86abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_14b5ed0b-6df5-4aa8-bc85-400a8baa49d1" xlink:to="loc_us-gaap_ForeignExchangeContractMember_58c3f246-52cd-4c07-b37b-1c7304e86abd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_85cf6ef3-e6e8-4e4c-938a-0fe1529c2bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f9026de9-1e32-4534-9645-ec996600521b" xlink:to="loc_us-gaap_HedgingDesignationAxis_85cf6ef3-e6e8-4e4c-938a-0fe1529c2bba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_85cf6ef3-e6e8-4e4c-938a-0fe1529c2bba_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_85cf6ef3-e6e8-4e4c-938a-0fe1529c2bba" xlink:to="loc_us-gaap_HedgingDesignationDomain_85cf6ef3-e6e8-4e4c-938a-0fe1529c2bba_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_193f8b46-2304-4e2b-8c2b-2211b17d4be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_85cf6ef3-e6e8-4e4c-938a-0fe1529c2bba" xlink:to="loc_us-gaap_HedgingDesignationDomain_193f8b46-2304-4e2b-8c2b-2211b17d4be8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_bc4eb59e-c366-4e59-919f-8dbf37a8360c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_193f8b46-2304-4e2b-8c2b-2211b17d4be8" xlink:to="loc_us-gaap_NondesignatedMember_bc4eb59e-c366-4e59-919f-8dbf37a8360c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_da9dab34-2840-4e83-b544-de947e3b73d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f9026de9-1e32-4534-9645-ec996600521b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_da9dab34-2840-4e83-b544-de947e3b73d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_da9dab34-2840-4e83-b544-de947e3b73d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_da9dab34-2840-4e83-b544-de947e3b73d3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_da9dab34-2840-4e83-b544-de947e3b73d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_eb7e69d1-6e4e-4840-888c-d4412a0b5838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_da9dab34-2840-4e83-b544-de947e3b73d3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_eb7e69d1-6e4e-4840-888c-d4412a0b5838" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_4908befe-eb55-4cb8-9921-37634e73d711" xlink:href="jnj-20230101.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_eb7e69d1-6e4e-4840-888c-d4412a0b5838" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_4908befe-eb55-4cb8-9921-37634e73d711" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended" id="i24b27ad08046455eabf78db5d1e6233b_FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0c422a98-5e75-4c68-bc30-4f9a06d15068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_ada891ac-b42c-4100-a496-859f21bf9212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0c422a98-5e75-4c68-bc30-4f9a06d15068" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_ada891ac-b42c-4100-a496-859f21bf9212" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_9045706c-d91e-4ce9-a13b-dd8e1710c1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0c422a98-5e75-4c68-bc30-4f9a06d15068" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_9045706c-d91e-4ce9-a13b-dd8e1710c1aa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_65fe016f-a166-4ab3-ac4d-fa7257a66cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0c422a98-5e75-4c68-bc30-4f9a06d15068" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_65fe016f-a166-4ab3-ac4d-fa7257a66cf0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f5c6d026-eeb2-4a7e-b5a7-b6793b6b53d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_65fe016f-a166-4ab3-ac4d-fa7257a66cf0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f5c6d026-eeb2-4a7e-b5a7-b6793b6b53d7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_f5c6d026-eeb2-4a7e-b5a7-b6793b6b53d7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f5c6d026-eeb2-4a7e-b5a7-b6793b6b53d7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_f5c6d026-eeb2-4a7e-b5a7-b6793b6b53d7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_815141e2-178b-408e-aefb-571b58a5949c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f5c6d026-eeb2-4a7e-b5a7-b6793b6b53d7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_815141e2-178b-408e-aefb-571b58a5949c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_8c0144fc-2ad6-43c8-9a76-bfc9285763fd" xlink:href="jnj-20230101.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_815141e2-178b-408e-aefb-571b58a5949c" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_8c0144fc-2ad6-43c8-9a76-bfc9285763fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_204846f8-395b-4d4a-873b-7220b86a1e84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_65fe016f-a166-4ab3-ac4d-fa7257a66cf0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_204846f8-395b-4d4a-873b-7220b86a1e84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_204846f8-395b-4d4a-873b-7220b86a1e84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_204846f8-395b-4d4a-873b-7220b86a1e84" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_204846f8-395b-4d4a-873b-7220b86a1e84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_39c568d7-51b2-4c42-aff5-3a66c2b66b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_204846f8-395b-4d4a-873b-7220b86a1e84" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_39c568d7-51b2-4c42-aff5-3a66c2b66b53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_c397ab86-0ba5-40ab-9b5e-5b631a3e9b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_39c568d7-51b2-4c42-aff5-3a66c2b66b53" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_c397ab86-0ba5-40ab-9b5e-5b631a3e9b63" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended" id="i4ce028927f3644928d9c78cc55648cfd_FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_00f6aa1c-423c-4b2e-9232-3053924d49e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_00effc79-05fa-439d-9be8-6ba50f89bfff" xlink:href="jnj-20230101.xsd#jnj_EquityInvestmentRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_00f6aa1c-423c-4b2e-9232-3053924d49e1" xlink:to="loc_jnj_EquityInvestmentRollForward_00effc79-05fa-439d-9be8-6ba50f89bfff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_5d5dd93f-de42-4e0d-987d-5a7d3bc182ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_00effc79-05fa-439d-9be8-6ba50f89bfff" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_5d5dd93f-de42-4e0d-987d-5a7d3bc182ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_311d3dca-6ba7-49ee-aed9-a09f07a0641c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_00effc79-05fa-439d-9be8-6ba50f89bfff" xlink:to="loc_us-gaap_EquityFairValueAdjustment_311d3dca-6ba7-49ee-aed9-a09f07a0641c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_bce1eb4e-2e3f-4ccb-8665-80addd79c1e3" xlink:href="jnj-20230101.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_00effc79-05fa-439d-9be8-6ba50f89bfff" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_bce1eb4e-2e3f-4ccb-8665-80addd79c1e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_33fa821d-5478-473f-9c31-0392658a6e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_00effc79-05fa-439d-9be8-6ba50f89bfff" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_33fa821d-5478-473f-9c31-0392658a6e18" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b44d27dd-e2ea-4496-89ff-e1c771617887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_EquityInvestmentRollForward_00effc79-05fa-439d-9be8-6ba50f89bfff" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b44d27dd-e2ea-4496-89ff-e1c771617887" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_c9053dfe-520f-420d-be58-cfca24051ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_00f6aa1c-423c-4b2e-9232-3053924d49e1" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_c9053dfe-520f-420d-be58-cfca24051ec8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_ffb1681a-f9de-48ec-95f2-6aa7847a6f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_c9053dfe-520f-420d-be58-cfca24051ec8" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_ffb1681a-f9de-48ec-95f2-6aa7847a6f84" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ffb1681a-f9de-48ec-95f2-6aa7847a6f84_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_ffb1681a-f9de-48ec-95f2-6aa7847a6f84" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_ffb1681a-f9de-48ec-95f2-6aa7847a6f84_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8130aac5-d60e-4305-af12-dbc380064ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_ffb1681a-f9de-48ec-95f2-6aa7847a6f84" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8130aac5-d60e-4305-af12-dbc380064ae1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_3be3485a-a694-4c7c-8a40-3d49a063e254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8130aac5-d60e-4305-af12-dbc380064ae1" xlink:to="loc_us-gaap_EquitySecuritiesMember_3be3485a-a694-4c7c-8a40-3d49a063e254" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_265f05b1-9855-4d92-9d8c-bbefa351a454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_c9053dfe-520f-420d-be58-cfca24051ec8" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_265f05b1-9855-4d92-9d8c-bbefa351a454" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_265f05b1-9855-4d92-9d8c-bbefa351a454_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_265f05b1-9855-4d92-9d8c-bbefa351a454" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_265f05b1-9855-4d92-9d8c-bbefa351a454_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9ab5a8d7-7052-443a-bb4c-52e5ae718bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_265f05b1-9855-4d92-9d8c-bbefa351a454" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9ab5a8d7-7052-443a-bb4c-52e5ae718bd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_49599187-1587-4618-8bb2-a9dc605c0d5d" xlink:href="jnj-20230101.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9ab5a8d7-7052-443a-bb4c-52e5ae718bd4" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_49599187-1587-4618-8bb2-a9dc605c0d5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_dbc5719b-fea0-4339-b50a-95ef188b51a1" xlink:href="jnj-20230101.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9ab5a8d7-7052-443a-bb4c-52e5ae718bd4" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_dbc5719b-fea0-4339-b50a-95ef188b51a1" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended" id="i3142223b69db406c9b662b20baf28091_FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_931f837c-7b3d-45e1-9ef7-c163d187e802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_931f837c-7b3d-45e1-9ef7-c163d187e802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_acae41c2-7ee8-4849-901f-fce0e177c825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_acae41c2-7ee8-4849-901f-fce0e177c825" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_556b6676-0d67-4fef-bec5-5bc6d05e4162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_556b6676-0d67-4fef-bec5-5bc6d05e4162" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_185128a6-83e9-42aa-aea3-cbe9cfee2f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_185128a6-83e9-42aa-aea3-cbe9cfee2f9e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_81d72d47-dc8b-4c57-a5d9-413297804f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_81d72d47-dc8b-4c57-a5d9-413297804f6d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_39f1fc69-7cea-4c36-9991-aacbc446f43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_39f1fc69-7cea-4c36-9991-aacbc446f43d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_80ad288b-6e5b-4b56-b5cd-1a94f81725b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_80ad288b-6e5b-4b56-b5cd-1a94f81725b7" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c31b72b3-0fb5-453a-ad5c-ecfa3eeffc54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c31b72b3-0fb5-453a-ad5c-ecfa3eeffc54" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_bbf01e3c-b126-4d61-a23a-bb490b9fc770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_bbf01e3c-b126-4d61-a23a-bb490b9fc770" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_32a59a92-1556-4d9e-ae55-fe1084fa6739" xlink:href="jnj-20230101.xsd#jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_32a59a92-1556-4d9e-ae55-fe1084fa6739" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_9a54a764-34fd-4017-bb02-c75482b45abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_DerivativeAssets_9a54a764-34fd-4017-bb02-c75482b45abf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_5b0a2a29-4f47-48b9-ae6a-848fbbd6befe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_5b0a2a29-4f47-48b9-ae6a-848fbbd6befe" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_740b3331-7a27-46c8-b99c-48855ce0c627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_740b3331-7a27-46c8-b99c-48855ce0c627" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_bfdc534b-acf4-4007-90f6-d0a6385feb32" xlink:href="jnj-20230101.xsd#jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_bfdc534b-acf4-4007-90f6-d0a6385feb32" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_8bfeb71b-a26e-45b0-bbea-7dc2a603ac0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_DerivativeLiabilities_8bfeb71b-a26e-45b0-bbea-7dc2a603ac0b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eea3a443-f555-4dad-9161-92bf42b0ff4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eea3a443-f555-4dad-9161-92bf42b0ff4a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_46cecd93-6782-4079-b34e-77b4734b524a" xlink:href="jnj-20230101.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_46cecd93-6782-4079-b34e-77b4734b524a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_e37ff994-f8fa-4df0-9ab9-24c31a7a8492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_e37ff994-f8fa-4df0-9ab9-24c31a7a8492" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_5fced0ab-6678-477c-b3e1-5408cf662b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_5fced0ab-6678-477c-b3e1-5408cf662b59" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_30abd258-108d-45bf-9d48-8f6320e85d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_092ce934-1b31-4cdb-abb0-580da17269a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_092ce934-1b31-4cdb-abb0-580da17269a7" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c3816fe7-a434-4c1f-b4d1-b7ad494ddbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:to="loc_us-gaap_HedgingDesignationAxis_c3816fe7-a434-4c1f-b4d1-b7ad494ddbc6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_c3816fe7-a434-4c1f-b4d1-b7ad494ddbc6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_c3816fe7-a434-4c1f-b4d1-b7ad494ddbc6" xlink:to="loc_us-gaap_HedgingDesignationDomain_c3816fe7-a434-4c1f-b4d1-b7ad494ddbc6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7ad9509f-3388-4783-b2c0-8ff6c925e313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_c3816fe7-a434-4c1f-b4d1-b7ad494ddbc6" xlink:to="loc_us-gaap_HedgingDesignationDomain_7ad9509f-3388-4783-b2c0-8ff6c925e313" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_178af82c-809d-417f-ae26-175f26c95427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_7ad9509f-3388-4783-b2c0-8ff6c925e313" xlink:to="loc_us-gaap_NondesignatedMember_178af82c-809d-417f-ae26-175f26c95427" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c5f4c1da-5851-4d01-8701-8fa2449db5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c5f4c1da-5851-4d01-8701-8fa2449db5cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_c5f4c1da-5851-4d01-8701-8fa2449db5cb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c5f4c1da-5851-4d01-8701-8fa2449db5cb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_c5f4c1da-5851-4d01-8701-8fa2449db5cb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7b488b8a-c258-4e8e-a861-a036e5953fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c5f4c1da-5851-4d01-8701-8fa2449db5cb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7b488b8a-c258-4e8e-a861-a036e5953fbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_9e8ce47f-4429-44db-8a23-1737847c21f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7b488b8a-c258-4e8e-a861-a036e5953fbf" xlink:to="loc_us-gaap_InterestRateContractMember_9e8ce47f-4429-44db-8a23-1737847c21f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ae4f3eef-8055-4fe6-bcef-24b9223cd7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7b488b8a-c258-4e8e-a861-a036e5953fbf" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ae4f3eef-8055-4fe6-bcef-24b9223cd7fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b68ccf99-ecef-432b-b3f7-816378ab0c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b68ccf99-ecef-432b-b3f7-816378ab0c87" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b68ccf99-ecef-432b-b3f7-816378ab0c87_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b68ccf99-ecef-432b-b3f7-816378ab0c87" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b68ccf99-ecef-432b-b3f7-816378ab0c87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc176a0b-8d97-4087-9963-415e4aa15f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b68ccf99-ecef-432b-b3f7-816378ab0c87" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc176a0b-8d97-4087-9963-415e4aa15f9f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5ddb59cb-1d1e-4ec0-9096-42138f95ee92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc176a0b-8d97-4087-9963-415e4aa15f9f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5ddb59cb-1d1e-4ec0-9096-42138f95ee92" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fa8bfe10-0212-49ff-8f62-92443c74f8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc176a0b-8d97-4087-9963-415e4aa15f9f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fa8bfe10-0212-49ff-8f62-92443c74f8b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ad4079df-a55d-4714-bd73-932015c584ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc176a0b-8d97-4087-9963-415e4aa15f9f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ad4079df-a55d-4714-bd73-932015c584ee" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_9d086630-32cd-4695-a9ef-11252526c8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:to="loc_us-gaap_InvestmentTypeAxis_9d086630-32cd-4695-a9ef-11252526c8b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_9d086630-32cd-4695-a9ef-11252526c8b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_9d086630-32cd-4695-a9ef-11252526c8b1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_9d086630-32cd-4695-a9ef-11252526c8b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_639f9eea-e7aa-4a7a-9b8f-38999d0a651f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_9d086630-32cd-4695-a9ef-11252526c8b1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_639f9eea-e7aa-4a7a-9b8f-38999d0a651f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_c85165fb-36a8-4f06-9a26-430f7aa8434b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_639f9eea-e7aa-4a7a-9b8f-38999d0a651f" xlink:to="loc_us-gaap_EquitySecuritiesMember_c85165fb-36a8-4f06-9a26-430f7aa8434b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e950cac3-f87b-4986-b15a-37d980b05ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e950cac3-f87b-4986-b15a-37d980b05ad9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e950cac3-f87b-4986-b15a-37d980b05ad9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e950cac3-f87b-4986-b15a-37d980b05ad9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e950cac3-f87b-4986-b15a-37d980b05ad9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65e57abb-6478-48fb-bb07-9d4846373f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e950cac3-f87b-4986-b15a-37d980b05ad9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65e57abb-6478-48fb-bb07-9d4846373f9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_f705fe2c-182a-47df-82fd-9b6ad4e70384" xlink:href="jnj-20230101.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65e57abb-6478-48fb-bb07-9d4846373f9c" xlink:to="loc_jnj_AurisHealthMember_f705fe2c-182a-47df-82fd-9b6ad4e70384" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember_f6628e36-9564-4f1c-a700-3a85a9438531" xlink:href="jnj-20230101.xsd#jnj_AbiomedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65e57abb-6478-48fb-bb07-9d4846373f9c" xlink:to="loc_jnj_AbiomedMember_f6628e36-9564-4f1c-a700-3a85a9438531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_fb86a40a-cee0-4611-a7a0-dd14b75e6e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_fb86a40a-cee0-4611-a7a0-dd14b75e6e75" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_fb86a40a-cee0-4611-a7a0-dd14b75e6e75_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fb86a40a-cee0-4611-a7a0-dd14b75e6e75" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_fb86a40a-cee0-4611-a7a0-dd14b75e6e75_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b218d6e4-9c8b-4058-ac33-881be0e34f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fb86a40a-cee0-4611-a7a0-dd14b75e6e75" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b218d6e4-9c8b-4058-ac33-881be0e34f35" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_14984517-f67a-4bf9-922f-24190fc08d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b218d6e4-9c8b-4058-ac33-881be0e34f35" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_14984517-f67a-4bf9-922f-24190fc08d28" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_9c6e972e-b361-4f5a-8908-ef3f2a33a655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b218d6e4-9c8b-4058-ac33-881be0e34f35" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_9c6e972e-b361-4f5a-8908-ef3f2a33a655" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#BorrowingsScheduleofLongtermDebtInstrumentsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="extended" id="i4ed1823e26324fcdb041cdf96be5206b_BorrowingsScheduleofLongtermDebtInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_41097a8c-1fdd-4f83-a62f-9b7f1b179ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_41097a8c-1fdd-4f83-a62f-9b7f1b179ef9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_276d8990-2346-423d-b6e9-f0dc7ea7cf22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_us-gaap_LongTermDebt_276d8990-2346-423d-b6e9-f0dc7ea7cf22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_922ea187-bec2-4922-abf2-9f49279c124b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_us-gaap_LongTermDebtCurrent_922ea187-bec2-4922-abf2-9f49279c124b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d8872255-b700-4b23-9d50-44199b3a98e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d8872255-b700-4b23-9d50-44199b3a98e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6b4b99a2-c9a2-4796-b21b-124494cdff40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6b4b99a2-c9a2-4796-b21b-124494cdff40" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_29840a2a-9a75-49c2-a573-019920084d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_29840a2a-9a75-49c2-a573-019920084d4c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_e1810638-e891-423e-b591-86f667c2a1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_e1810638-e891-423e-b591-86f667c2a1d2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt_ec3cd8cb-a21f-4166-846c-3af703b60f62" xlink:href="jnj-20230101.xsd#jnj_ExcessOfCarryingValueOverFairValueOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt_ec3cd8cb-a21f-4166-846c-3af703b60f62" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_f10ff941-1d04-457b-8dac-9bd25994e8a7" xlink:href="jnj-20230101.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_f10ff941-1d04-457b-8dac-9bd25994e8a7" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b679b360-ca73-44f0-b07a-292c715698a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_us-gaap_DebtInstrumentTable_b679b360-ca73-44f0-b07a-292c715698a6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_af1a7cfd-bcf7-4215-9f17-fc21fd7c72a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b679b360-ca73-44f0-b07a-292c715698a6" xlink:to="loc_us-gaap_DebtInstrumentAxis_af1a7cfd-bcf7-4215-9f17-fc21fd7c72a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_af1a7cfd-bcf7-4215-9f17-fc21fd7c72a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_af1a7cfd-bcf7-4215-9f17-fc21fd7c72a4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_af1a7cfd-bcf7-4215-9f17-fc21fd7c72a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_af1a7cfd-bcf7-4215-9f17-fc21fd7c72a4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member_737f17cf-4a91-4dc0-be3e-08ad5611370a" xlink:href="jnj-20230101.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A0.250NotesDue2022Member_737f17cf-4a91-4dc0-be3e-08ad5611370a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.25Notesdue2022Member_c2177346-3ec1-4906-98dd-426460955348" xlink:href="jnj-20230101.xsd#jnj_A2.25Notesdue2022Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A2.25Notesdue2022Member_c2177346-3ec1-4906-98dd-426460955348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member_f9bdcca4-823f-42df-baad-868f50709c8e" xlink:href="jnj-20230101.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A6.73Debenturesdue2023Member_f9bdcca4-823f-42df-baad-868f50709c8e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member_c674763a-6f1f-40ac-91a1-64662625cadd" xlink:href="jnj-20230101.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A3.375Notesdue2023Member_c674763a-6f1f-40ac-91a1-64662625cadd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.05Notesdue2023Member_5737bab4-6607-4e74-a001-6031f80a5d9b" xlink:href="jnj-20230101.xsd#jnj_A2.05Notesdue2023Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A2.05Notesdue2023Member_5737bab4-6607-4e74-a001-6031f80a5d9b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_d7c6dfed-5ffa-4075-aef1-1bee8aa0c374" xlink:href="jnj-20230101.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A0.650NotesDue2024Member_d7c6dfed-5ffa-4075-aef1-1bee8aa0c374" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_077f1244-cc83-4e1e-b848-307c285bdf8e" xlink:href="jnj-20230101.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A5.50NotesDue2024Member_077f1244-cc83-4e1e-b848-307c285bdf8e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_a64f26c1-d470-4fbe-bc1d-75380eb59d7a" xlink:href="jnj-20230101.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A2.625Notesdue2025Member_a64f26c1-d470-4fbe-bc1d-75380eb59d7a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A055NotesDue2025Member_9ed8d169-2ade-4f22-8010-417bc77f094e" xlink:href="jnj-20230101.xsd#jnj_A055NotesDue2025Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A055NotesDue2025Member_9ed8d169-2ade-4f22-8010-417bc77f094e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_e3988c1d-233c-4c8f-96f1-aa246c311480" xlink:href="jnj-20230101.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A2.45Notesdue2026Member_e3988c1d-233c-4c8f-96f1-aa246c311480" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_84f917fa-12eb-45cf-998f-518130444c9e" xlink:href="jnj-20230101.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A2.95Notesdue2027Member_84f917fa-12eb-45cf-998f-518130444c9e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_ae844c93-e644-4a07-9e42-38d37d9c0180" xlink:href="jnj-20230101.xsd#jnj_A095NotesDue2027Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A095NotesDue2027Member_ae844c93-e644-4a07-9e42-38d37d9c0180" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_1dd7c475-892e-4ab6-8e74-2c342fdcba05" xlink:href="jnj-20230101.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A1.150NotesDue2028Member_1dd7c475-892e-4ab6-8e74-2c342fdcba05" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_1d5d8c4b-9ef5-42aa-9a6b-1103294a4974" xlink:href="jnj-20230101.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A2.900Notesdue2028Member_1d5d8c4b-9ef5-42aa-9a6b-1103294a4974" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_dcba9a06-3e50-4ae8-99bc-3dbbb94c628e" xlink:href="jnj-20230101.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A6.95Notesdue2029Member_dcba9a06-3e50-4ae8-99bc-3dbbb94c628e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A130NotesDue2030Member_15e5228c-213f-4796-b16d-ef35ba3b57f3" xlink:href="jnj-20230101.xsd#jnj_A130NotesDue2030Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A130NotesDue2030Member_15e5228c-213f-4796-b16d-ef35ba3b57f3" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_83f09009-90f0-4cdc-a4fa-242b0ce7bfcf" xlink:href="jnj-20230101.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_83f09009-90f0-4cdc-a4fa-242b0ce7bfcf" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_3d2e6078-02a9-4f08-9ec2-5aa86382ed7b" xlink:href="jnj-20230101.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A4.375Notesdue2033Member_3d2e6078-02a9-4f08-9ec2-5aa86382ed7b" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_67b66885-36c3-4924-87ee-d311699b1970" xlink:href="jnj-20230101.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A1.650NotesDue2035Member_67b66885-36c3-4924-87ee-d311699b1970" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_5c63101d-2e53-43c0-a5e4-7098416c83a0" xlink:href="jnj-20230101.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A3.55Notesdue2036Member_5c63101d-2e53-43c0-a5e4-7098416c83a0" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_84067f9c-d1dc-44c8-869b-2ee1efe4ce97" xlink:href="jnj-20230101.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A5.95Notesdue2037Member_84067f9c-d1dc-44c8-869b-2ee1efe4ce97" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_d6f2dce2-54cc-4720-9f19-4f71ba1b1416" xlink:href="jnj-20230101.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A3.625Notesdue2037Member_d6f2dce2-54cc-4720-9f19-4f71ba1b1416" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_6ceb943e-1340-42d6-bde6-9da8216cf575" xlink:href="jnj-20230101.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_6ceb943e-1340-42d6-bde6-9da8216cf575" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_a8e9ba37-fa2c-4904-b758-5e863ae2b5c0" xlink:href="jnj-20230101.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A3.400Notesdue2038Member_a8e9ba37-fa2c-4904-b758-5e863ae2b5c0" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_c2f0a571-58dd-4a19-86c1-9691d536d87e" xlink:href="jnj-20230101.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_c2f0a571-58dd-4a19-86c1-9691d536d87e" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_c3f739b3-c205-4a2f-b93c-b0eddbb5b2e8" xlink:href="jnj-20230101.xsd#jnj_A210NotesDue2040Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A210NotesDue2040Member_c3f739b3-c205-4a2f-b93c-b0eddbb5b2e8" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_a56b16ff-1521-48da-acba-7d141ce5015d" xlink:href="jnj-20230101.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A4.85Notesdue2041Member_a56b16ff-1521-48da-acba-7d141ce5015d" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_d466be21-24b5-4022-a529-a0c0fb47335c" xlink:href="jnj-20230101.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A4.50Notesdue2043Member_d466be21-24b5-4022-a529-a0c0fb47335c" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_ac2deefc-62e3-4d2e-a04f-5e939a38aac3" xlink:href="jnj-20230101.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A3.70Notesdue2046Member_ac2deefc-62e3-4d2e-a04f-5e939a38aac3" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_31421ec8-6431-4f35-a307-db45e02095fe" xlink:href="jnj-20230101.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A3.75Notesdue2047Member_31421ec8-6431-4f35-a307-db45e02095fe" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_ee95960b-594b-4981-826c-65874f158899" xlink:href="jnj-20230101.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A3.500Notesdue2048Member_ee95960b-594b-4981-826c-65874f158899" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_4221ecb8-10a0-41ca-828f-fe97fc6bfc7d" xlink:href="jnj-20230101.xsd#jnj_A2250NotesDue2050Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A2250NotesDue2050Member_4221ecb8-10a0-41ca-828f-fe97fc6bfc7d" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_d306935b-42be-4049-b2c9-6fb48ef17e1e" xlink:href="jnj-20230101.xsd#jnj_A2450NotesDue2060Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A2450NotesDue2060Member_d306935b-42be-4049-b2c9-6fb48ef17e1e" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_f799c57e-c254-4521-a715-f2c45a6df194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_f799c57e-c254-4521-a715-f2c45a6df194" xlink:type="arc" order="33"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#BorrowingsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="extended" id="i5758e2985533443da4026d04403c6c8b_BorrowingsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_5c0bd090-67e8-43a3-bce4-d532621b9ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_d89c4231-1572-4a3b-a15c-95354cf71f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_5c0bd090-67e8-43a3-bce4-d532621b9ee9" xlink:to="loc_us-gaap_ShortTermBorrowings_d89c4231-1572-4a3b-a15c-95354cf71f09" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_c849b727-c3ae-498c-83d9-86ed6e73316b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_5c0bd090-67e8-43a3-bce4-d532621b9ee9" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_c849b727-c3ae-498c-83d9-86ed6e73316b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_7b5a8274-154d-4b06-9246-a00fc9f73523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_5c0bd090-67e8-43a3-bce4-d532621b9ee9" xlink:to="loc_us-gaap_DebtInstrumentTerm_7b5a8274-154d-4b06-9246-a00fc9f73523" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_aa893b33-1042-451a-93c3-3640abfbeb72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_5c0bd090-67e8-43a3-bce4-d532621b9ee9" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_aa893b33-1042-451a-93c3-3640abfbeb72" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_c442091f-d510-4fc2-a824-d6b32349136e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_aa893b33-1042-451a-93c3-3640abfbeb72" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_c442091f-d510-4fc2-a824-d6b32349136e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_c442091f-d510-4fc2-a824-d6b32349136e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_c442091f-d510-4fc2-a824-d6b32349136e" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_c442091f-d510-4fc2-a824-d6b32349136e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_183291b2-0670-4b1b-9ebe-25c86b6899a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_c442091f-d510-4fc2-a824-d6b32349136e" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_183291b2-0670-4b1b-9ebe-25c86b6899a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7192c043-1863-4d9d-9434-4b0992c436c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_183291b2-0670-4b1b-9ebe-25c86b6899a9" xlink:to="loc_us-gaap_CommercialPaperMember_7192c043-1863-4d9d-9434-4b0992c436c7" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IncomeTaxesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended" id="i6ce39a12aa0e41d0977b6b7f182cc121_IncomeTaxesNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_c8fe616a-ee22-4c6d-a939-1b03f8433b31" xlink:href="jnj-20230101.xsd#jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_c8fe616a-ee22-4c6d-a939-1b03f8433b31" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e9dfbb90-8bc6-4476-a3ba-95ce6c1f58a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e9dfbb90-8bc6-4476-a3ba-95ce6c1f58a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_194e3e9b-b84b-4baf-b3b7-d298eaad1dd4" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_194e3e9b-b84b-4baf-b3b7-d298eaad1dd4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_d8acb2da-4924-4d83-8b1d-04ec1f6206d7" xlink:href="jnj-20230101.xsd#jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_d8acb2da-4924-4d83-8b1d-04ec1f6206d7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_cbae67f9-7594-43b5-9eb4-84d59ed66603" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_cbae67f9-7594-43b5-9eb4-84d59ed66603" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_d0fb2cbf-84a9-40d7-8e8d-37399928e022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_LitigationSettlementExpense_d0fb2cbf-84a9-40d7-8e8d-37399928e022" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_65c9361f-5afd-42b8-9b7f-09f61af89465" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_65c9361f-5afd-42b8-9b7f-09f61af89465" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_dbe9686b-3592-491f-9634-7b2cf962c116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_dbe9686b-3592-491f-9634-7b2cf962c116" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_22d9d827-bf1c-4091-a492-adb9acc55d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_22d9d827-bf1c-4091-a492-adb9acc55d0b" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_cf524ae1-50a0-43e3-8ea5-24dbdfdd5f07" xlink:href="jnj-20230101.xsd#jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_cf524ae1-50a0-43e3-8ea5-24dbdfdd5f07" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_6b007861-b5dc-4e4e-8bc6-2a17c3d9a2c6" xlink:href="jnj-20230101.xsd#jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_6b007861-b5dc-4e4e-8bc6-2a17c3d9a2c6" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_17a7fe5f-646a-464f-aaf1-b1d3f333777d" xlink:href="jnj-20230101.xsd#jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_17a7fe5f-646a-464f-aaf1-b1d3f333777d" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_ac313925-6074-4de2-b3cc-2771a0cd332b" xlink:href="jnj-20230101.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_ac313925-6074-4de2-b3cc-2771a0cd332b" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_679904b6-9708-4914-b3cf-be170a57c8ab" xlink:href="jnj-20230101.xsd#jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_679904b6-9708-4914-b3cf-be170a57c8ab" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_8642deb4-b0bf-4979-bdc1-7d60cc4ec370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_8642deb4-b0bf-4979-bdc1-7d60cc4ec370" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f6249fb5-82ee-4588-b3b2-1cbfb1ae024d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f6249fb5-82ee-4588-b3b2-1cbfb1ae024d" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment_0ca195fa-2db8-48b5-8f7c-990121ee454e" xlink:href="jnj-20230101.xsd#jnj_UnrecognizedTaxBenefitLiabilityPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment_0ca195fa-2db8-48b5-8f7c-990121ee454e" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_92b9e78b-3a1c-4cc2-8109-c5e69209f1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_92b9e78b-3a1c-4cc2-8109-c5e69209f1e0" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_56ee3136-d78e-4ff8-a4aa-c942dea1f7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_56ee3136-d78e-4ff8-a4aa-c942dea1f7d5" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_a6538431-5f44-4c1e-823a-8ec2a0934923" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_a6538431-5f44-4c1e-823a-8ec2a0934923" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5a7ee8de-3fd9-47ad-8fb4-4af51d6ba6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5a7ee8de-3fd9-47ad-8fb4-4af51d6ba6a8" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_25c8fa88-f356-45c5-aa8f-1ab48fb88348" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:to="loc_srt_LitigationCaseAxis_25c8fa88-f356-45c5-aa8f-1ab48fb88348" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_25c8fa88-f356-45c5-aa8f-1ab48fb88348_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_25c8fa88-f356-45c5-aa8f-1ab48fb88348" xlink:to="loc_srt_LitigationCaseTypeDomain_25c8fa88-f356-45c5-aa8f-1ab48fb88348_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4f2b6fc1-d425-4df8-b073-62e62a8bc38e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_25c8fa88-f356-45c5-aa8f-1ab48fb88348" xlink:to="loc_srt_LitigationCaseTypeDomain_4f2b6fc1-d425-4df8-b073-62e62a8bc38e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_60a894b5-1eb5-418e-8dfc-a40cbe1611e2" xlink:href="jnj-20230101.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4f2b6fc1-d425-4df8-b073-62e62a8bc38e" xlink:to="loc_jnj_TalcMember_60a894b5-1eb5-418e-8dfc-a40cbe1611e2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_6c5b724e-355f-4fe3-86ca-c6f132f71d95" xlink:href="jnj-20230101.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4f2b6fc1-d425-4df8-b073-62e62a8bc38e" xlink:to="loc_jnj_RisperdalMember_6c5b724e-355f-4fe3-86ca-c6f132f71d95" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpiodsMember_7f069afa-02be-4a1d-9039-1e345b79af25" xlink:href="jnj-20230101.xsd#jnj_OpiodsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_4f2b6fc1-d425-4df8-b073-62e62a8bc38e" xlink:to="loc_jnj_OpiodsMember_7f069afa-02be-4a1d-9039-1e345b79af25" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_dc47bc4e-9687-4277-b0df-112824dbfa6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_dc47bc4e-9687-4277-b0df-112824dbfa6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_dc47bc4e-9687-4277-b0df-112824dbfa6b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_dc47bc4e-9687-4277-b0df-112824dbfa6b" xlink:to="loc_us-gaap_SegmentDomain_dc47bc4e-9687-4277-b0df-112824dbfa6b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c69d1c2f-dc8b-4ad4-a8eb-b79b59e09122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_dc47bc4e-9687-4277-b0df-112824dbfa6b" xlink:to="loc_us-gaap_SegmentDomain_c69d1c2f-dc8b-4ad4-a8eb-b79b59e09122" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_a47e0e7f-874c-4403-959d-8712a5b941c2" xlink:href="jnj-20230101.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c69d1c2f-dc8b-4ad4-a8eb-b79b59e09122" xlink:to="loc_jnj_ConsumerMember_a47e0e7f-874c-4403-959d-8712a5b941c2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_ea4bd3b8-86b0-47ff-99d4-66444dc4b5f8" xlink:href="jnj-20230101.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_c69d1c2f-dc8b-4ad4-a8eb-b79b59e09122" xlink:to="loc_jnj_PharmaceuticalMember_ea4bd3b8-86b0-47ff-99d4-66444dc4b5f8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_88e910b2-b6fd-46f5-9375-c4953e6dfa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_88e910b2-b6fd-46f5-9375-c4953e6dfa1b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_88e910b2-b6fd-46f5-9375-c4953e6dfa1b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_88e910b2-b6fd-46f5-9375-c4953e6dfa1b" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_88e910b2-b6fd-46f5-9375-c4953e6dfa1b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_16ae5d92-505a-43b7-880b-583433eb0ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_88e910b2-b6fd-46f5-9375-c4953e6dfa1b" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_16ae5d92-505a-43b7-880b-583433eb0ac0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_cd52743c-4203-4073-93e0-5a060bdcb63e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_16ae5d92-505a-43b7-880b-583433eb0ac0" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_cd52743c-4203-4073-93e0-5a060bdcb63e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7ec69d83-c96a-4baf-abaf-b6b9021afe14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7ec69d83-c96a-4baf-abaf-b6b9021afe14" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ec69d83-c96a-4baf-abaf-b6b9021afe14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7ec69d83-c96a-4baf-abaf-b6b9021afe14" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7ec69d83-c96a-4baf-abaf-b6b9021afe14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e4c2fcf-0608-455b-a950-8a345b213f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7ec69d83-c96a-4baf-abaf-b6b9021afe14" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e4c2fcf-0608-455b-a950-8a345b213f9a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_dc505705-43be-4d6f-bcb4-d73fd45b2ef1" xlink:href="jnj-20230101.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e4c2fcf-0608-455b-a950-8a345b213f9a" xlink:to="loc_jnj_AurisHealthMember_dc505705-43be-4d6f-bcb4-d73fd45b2ef1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1a589da6-01ac-469c-a124-cabb05632598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1a589da6-01ac-469c-a124-cabb05632598" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a589da6-01ac-469c-a124-cabb05632598_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1a589da6-01ac-469c-a124-cabb05632598" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1a589da6-01ac-469c-a124-cabb05632598_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6f6dee2-de0a-4c9a-82f4-8e8e38fc4099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1a589da6-01ac-469c-a124-cabb05632598" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6f6dee2-de0a-4c9a-82f4-8e8e38fc4099" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_cb81de51-2d23-4133-9854-cca5a3c0b503" xlink:href="jnj-20230101.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6f6dee2-de0a-4c9a-82f4-8e8e38fc4099" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_cb81de51-2d23-4133-9854-cca5a3c0b503" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_db39327b-06f0-46af-aa15-50e0cc96f03c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_db39327b-06f0-46af-aa15-50e0cc96f03c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_db39327b-06f0-46af-aa15-50e0cc96f03c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_db39327b-06f0-46af-aa15-50e0cc96f03c" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_db39327b-06f0-46af-aa15-50e0cc96f03c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f77e018e-329d-4eda-a37f-ca4311ab9e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_db39327b-06f0-46af-aa15-50e0cc96f03c" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f77e018e-329d-4eda-a37f-ca4311ab9e7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_ab8ff02d-5a98-4b8c-80bf-02e9b5f62f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f77e018e-329d-4eda-a37f-ca4311ab9e7f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_ab8ff02d-5a98-4b8c-80bf-02e9b5f62f69" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c7f687a8-90b2-47db-8b47-2d2421e2df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c7f687a8-90b2-47db-8b47-2d2421e2df0b" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_c7f687a8-90b2-47db-8b47-2d2421e2df0b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c7f687a8-90b2-47db-8b47-2d2421e2df0b" xlink:to="loc_us-gaap_RelatedPartyDomain_c7f687a8-90b2-47db-8b47-2d2421e2df0b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_153259ad-81f2-4505-98cd-8b57e8d391cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c7f687a8-90b2-47db-8b47-2d2421e2df0b" xlink:to="loc_us-gaap_RelatedPartyDomain_153259ad-81f2-4505-98cd-8b57e8d391cb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerHealthMember_dc8a87e5-bd90-4ef2-a939-d7fd475daa85" xlink:href="jnj-20230101.xsd#jnj_ConsumerHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RelatedPartyDomain_153259ad-81f2-4505-98cd-8b57e8d391cb" xlink:to="loc_jnj_ConsumerHealthMember_dc8a87e5-bd90-4ef2-a939-d7fd475daa85" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails" xlink:type="extended" id="i14191d2d6d7f4dd6bb16f8d672132441_PensionsandOtherBenefitPlansNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeCompensationPeriod_e3198abe-2cc4-484f-8e7f-d25f98d54ab8" xlink:href="jnj-20230101.xsd#jnj_EmployeeCompensationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_jnj_EmployeeCompensationPeriod_e3198abe-2cc4-484f-8e7f-d25f98d54ab8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_da55f905-8fff-48ba-b5a6-a023c6ec31a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_da55f905-8fff-48ba-b5a6-a023c6ec31a8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_d418bba9-354b-48b8-93ee-4ee28befbdd1" xlink:href="jnj-20230101.xsd#jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_d418bba9-354b-48b8-93ee-4ee28befbdd1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_cdacb069-2f46-41d7-8abb-1f610c3cfc01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_us-gaap_PensionContributions_cdacb069-2f46-41d7-8abb-1f610c3cfc01" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_b53e2857-7873-40e6-abbe-a054c0b15e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_b53e2857-7873-40e6-abbe-a054c0b15e81" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_7b11de74-7ff9-4bd2-b41c-6249de1657d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_7b11de74-7ff9-4bd2-b41c-6249de1657d1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_e413f3f5-3623-4e73-845b-0ff6b9d78802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_e413f3f5-3623-4e73-845b-0ff6b9d78802" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e04ddf86-52c6-4600-b120-e30f0598fff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e04ddf86-52c6-4600-b120-e30f0598fff9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_4d37f946-0b2f-45b7-90bd-aa61cba0ec8d" xlink:href="jnj-20230101.xsd#jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_4d37f946-0b2f-45b7-90bd-aa61cba0ec8d" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset_cd7c761d-ef71-4b1d-828a-459ff6db76fa" xlink:href="jnj-20230101.xsd#jnj_PercentageOfCompanysCommonStockToPlanAsset"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset_cd7c761d-ef71-4b1d-828a-459ff6db76fa" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca652616-b751-4e30-855b-7efcbb4ce337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca652616-b751-4e30-855b-7efcbb4ce337" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd355bfe-61c8-4fcb-99cc-8b538dfba370" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca652616-b751-4e30-855b-7efcbb4ce337" xlink:to="loc_srt_RangeAxis_fd355bfe-61c8-4fcb-99cc-8b538dfba370" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_fd355bfe-61c8-4fcb-99cc-8b538dfba370_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_fd355bfe-61c8-4fcb-99cc-8b538dfba370" xlink:to="loc_srt_RangeMember_fd355bfe-61c8-4fcb-99cc-8b538dfba370_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb5e02fd-1f73-412f-91fe-801d4aeb1165" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_fd355bfe-61c8-4fcb-99cc-8b538dfba370" xlink:to="loc_srt_RangeMember_cb5e02fd-1f73-412f-91fe-801d4aeb1165" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3f23d7d4-4efa-401e-8ddb-688fca0964c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_cb5e02fd-1f73-412f-91fe-801d4aeb1165" xlink:to="loc_srt_MaximumMember_3f23d7d4-4efa-401e-8ddb-688fca0964c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_aa3fc720-f9af-401e-aeb6-94fefd461e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca652616-b751-4e30-855b-7efcbb4ce337" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_aa3fc720-f9af-401e-aeb6-94fefd461e23" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_aa3fc720-f9af-401e-aeb6-94fefd461e23_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_aa3fc720-f9af-401e-aeb6-94fefd461e23" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_aa3fc720-f9af-401e-aeb6-94fefd461e23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_16d04e1b-34d6-4300-8220-6b1ef2adca56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_aa3fc720-f9af-401e-aeb6-94fefd461e23" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_16d04e1b-34d6-4300-8220-6b1ef2adca56" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember_e9771496-5bb6-4fd5-b83d-3f799f457b59" xlink:href="jnj-20230101.xsd#jnj_CommingledFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_16d04e1b-34d6-4300-8220-6b1ef2adca56" xlink:to="loc_jnj_CommingledFundsMember_e9771496-5bb6-4fd5-b83d-3f799f457b59" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d983be8f-c7cf-4442-8e73-615c223ea3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca652616-b751-4e30-855b-7efcbb4ce337" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d983be8f-c7cf-4442-8e73-615c223ea3a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d983be8f-c7cf-4442-8e73-615c223ea3a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d983be8f-c7cf-4442-8e73-615c223ea3a9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d983be8f-c7cf-4442-8e73-615c223ea3a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63d863c9-c4d0-4cf2-81b8-b7d3f4231cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d983be8f-c7cf-4442-8e73-615c223ea3a9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63d863c9-c4d0-4cf2-81b8-b7d3f4231cdf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d8cd30ea-5e35-46c6-8246-c425c4b49fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63d863c9-c4d0-4cf2-81b8-b7d3f4231cdf" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d8cd30ea-5e35-46c6-8246-c425c4b49fcf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_2a27d34c-4ecf-4143-b389-1b365561d499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca652616-b751-4e30-855b-7efcbb4ce337" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_2a27d34c-4ecf-4143-b389-1b365561d499" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_2a27d34c-4ecf-4143-b389-1b365561d499_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_2a27d34c-4ecf-4143-b389-1b365561d499" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_2a27d34c-4ecf-4143-b389-1b365561d499_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_e882928b-be1b-4ea3-8154-cb30478c7534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_2a27d34c-4ecf-4143-b389-1b365561d499" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_e882928b-be1b-4ea3-8154-cb30478c7534" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_f543377e-f119-437b-8f95-e7f2827d6b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_e882928b-be1b-4ea3-8154-cb30478c7534" xlink:to="loc_us-gaap_DomesticPlanMember_f543377e-f119-437b-8f95-e7f2827d6b8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_84f88194-f9c0-4ccc-a45f-70183f51a025" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_f543377e-f119-437b-8f95-e7f2827d6b8d" xlink:to="loc_country_US_84f88194-f9c0-4ccc-a45f-70183f51a025" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_0070fb4e-9485-47b1-b12e-41599d36d9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_e882928b-be1b-4ea3-8154-cb30478c7534" xlink:to="loc_us-gaap_ForeignPlanMember_0070fb4e-9485-47b1-b12e-41599d36d9a7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2bf3a819-a4e6-4f73-8726-501c111395ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca652616-b751-4e30-855b-7efcbb4ce337" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2bf3a819-a4e6-4f73-8726-501c111395ec" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2bf3a819-a4e6-4f73-8726-501c111395ec_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2bf3a819-a4e6-4f73-8726-501c111395ec" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2bf3a819-a4e6-4f73-8726-501c111395ec_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_fecee48c-86b7-4e9e-aa0a-5f463f6ff3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2bf3a819-a4e6-4f73-8726-501c111395ec" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_fecee48c-86b7-4e9e-aa0a-5f463f6ff3cd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_c33dd345-7df1-407a-8f39-21dcd284af86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_fecee48c-86b7-4e9e-aa0a-5f463f6ff3cd" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_c33dd345-7df1-407a-8f39-21dcd284af86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c7e701a6-d553-4dc4-a8f6-d52eb50e1178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_fecee48c-86b7-4e9e-aa0a-5f463f6ff3cd" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c7e701a6-d553-4dc4-a8f6-d52eb50e1178" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended" id="i4bb513949a254ad08662c0e789e5ebfa_PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_856df280-a4bd-4d31-94d4-1ff4caab6aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_856df280-a4bd-4d31-94d4-1ff4caab6aa3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_cc70943e-1735-4381-89cb-d80621d7d254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_cc70943e-1735-4381-89cb-d80621d7d254" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2dc00d48-ea4c-44b7-8346-fc7f9603f9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2dc00d48-ea4c-44b7-8346-fc7f9603f9fd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_c52a8d9e-57b5-45a0-8348-156097a707e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_c52a8d9e-57b5-45a0-8348-156097a707e7" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_e461ff3b-e721-49c8-8201-ce76ff1ba58e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_e461ff3b-e721-49c8-8201-ce76ff1ba58e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_c36f4e28-8f1a-4ae5-aa92-ca85258cd192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_c36f4e28-8f1a-4ae5-aa92-ca85258cd192" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_145972cb-a7c8-44c3-82d0-bc4e059d16dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_145972cb-a7c8-44c3-82d0-bc4e059d16dc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9072b58a-dea6-4a42-b7c3-15ff0d31461c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9072b58a-dea6-4a42-b7c3-15ff0d31461c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_f2526f0e-c13e-4b2a-98da-e2f18f6c483a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9072b58a-dea6-4a42-b7c3-15ff0d31461c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_f2526f0e-c13e-4b2a-98da-e2f18f6c483a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_f2526f0e-c13e-4b2a-98da-e2f18f6c483a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_f2526f0e-c13e-4b2a-98da-e2f18f6c483a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_f2526f0e-c13e-4b2a-98da-e2f18f6c483a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_389a6bad-4dfb-4525-ac5b-f06050b712ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_f2526f0e-c13e-4b2a-98da-e2f18f6c483a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_389a6bad-4dfb-4525-ac5b-f06050b712ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_af4a44a8-e4b9-4a73-91c3-000af497f5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_389a6bad-4dfb-4525-ac5b-f06050b712ad" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_af4a44a8-e4b9-4a73-91c3-000af497f5b8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_9f2fd408-dac4-478e-8c07-b2b427904b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_389a6bad-4dfb-4525-ac5b-f06050b712ad" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_9f2fd408-dac4-478e-8c07-b2b427904b44" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="extended" id="ied7d530b55ac464a915c78a17f71c5f9_PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7ab8d90a-b471-44e5-b10a-8e246d5d0f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_bcb0ed63-444f-4859-b84a-acfcbb01140c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7ab8d90a-b471-44e5-b10a-8e246d5d0f74" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_bcb0ed63-444f-4859-b84a-acfcbb01140c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_a8a6ca34-3bfe-480f-aa1c-fb523cc6e49a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_bcb0ed63-444f-4859-b84a-acfcbb01140c" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_a8a6ca34-3bfe-480f-aa1c-fb523cc6e49a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_c503f281-baeb-4e6b-8767-351c2fae3a7f" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_bcb0ed63-444f-4859-b84a-acfcbb01140c" xlink:to="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_c503f281-baeb-4e6b-8767-351c2fae3a7f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_49f69806-016e-4c9f-849c-37a302d7f298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_bcb0ed63-444f-4859-b84a-acfcbb01140c" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_49f69806-016e-4c9f-849c-37a302d7f298" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_469b8860-406d-4ac0-b5f5-9896505709da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_bcb0ed63-444f-4859-b84a-acfcbb01140c" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_469b8860-406d-4ac0-b5f5-9896505709da" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_ba90e794-aae0-469a-ae7c-1ee51023a269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7ab8d90a-b471-44e5-b10a-8e246d5d0f74" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_ba90e794-aae0-469a-ae7c-1ee51023a269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_1dfa9f82-e61b-4dcd-abfc-5a3be3c97995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_ba90e794-aae0-469a-ae7c-1ee51023a269" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_1dfa9f82-e61b-4dcd-abfc-5a3be3c97995" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_18bf83c7-246a-47b1-b126-e689fe7bcef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_ba90e794-aae0-469a-ae7c-1ee51023a269" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_18bf83c7-246a-47b1-b126-e689fe7bcef6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55ec1611-2562-4113-9068-19bc4e2a5b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7ab8d90a-b471-44e5-b10a-8e246d5d0f74" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55ec1611-2562-4113-9068-19bc4e2a5b54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_f19d6696-3404-4ac4-b0b0-ebc2f622afe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55ec1611-2562-4113-9068-19bc4e2a5b54" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_f19d6696-3404-4ac4-b0b0-ebc2f622afe8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_f19d6696-3404-4ac4-b0b0-ebc2f622afe8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_f19d6696-3404-4ac4-b0b0-ebc2f622afe8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_f19d6696-3404-4ac4-b0b0-ebc2f622afe8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_d7581e0c-5b15-4e73-bef9-e76d8e95980e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_f19d6696-3404-4ac4-b0b0-ebc2f622afe8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_d7581e0c-5b15-4e73-bef9-e76d8e95980e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_12b92fa6-9ed1-4fc8-bb96-770216fbe5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d7581e0c-5b15-4e73-bef9-e76d8e95980e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_12b92fa6-9ed1-4fc8-bb96-770216fbe5ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c3b5f30d-3ee9-453e-93f7-cbdef45454a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d7581e0c-5b15-4e73-bef9-e76d8e95980e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c3b5f30d-3ee9-453e-93f7-cbdef45454a7" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="extended" id="ida4ec5858600428388f710d75f612d46_PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9bce677d-3f9b-4280-a8ae-36a87b71bc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9bce677d-3f9b-4280-a8ae-36a87b71bc93" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_36be6cc5-38b2-4968-becc-bc24f20f5549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_36be6cc5-38b2-4968-becc-bc24f20f5549" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_bba03bc9-ccf8-4103-8d0e-6974d37aaa85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_bba03bc9-ccf8-4103-8d0e-6974d37aaa85" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_233953f0-227f-41ae-bf8b-8f10782babb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_233953f0-227f-41ae-bf8b-8f10782babb0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_564c8a0b-2ce0-414b-989e-cbedc4030146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_564c8a0b-2ce0-414b-989e-cbedc4030146" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_5d179322-4b19-4b50-8d25-6d8b107ffee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_5d179322-4b19-4b50-8d25-6d8b107ffee0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_b3e50a68-05f3-49ae-84e2-75b6a853910d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_b3e50a68-05f3-49ae-84e2-75b6a853910d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_57c81944-8c2c-4ff5-8235-9b379aaaef41" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_57c81944-8c2c-4ff5-8235-9b379aaaef41" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CurtailmentsAndSettlementsAndRestructuring_a50f095b-3496-4d8c-b1e0-263284451d54" xlink:href="jnj-20230101.xsd#jnj_CurtailmentsAndSettlementsAndRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_jnj_CurtailmentsAndSettlementsAndRestructuring_a50f095b-3496-4d8c-b1e0-263284451d54" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_7f2939e8-abc3-4c90-bf64-c4e4c89afa40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_7f2939e8-abc3-4c90-bf64-c4e4c89afa40" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_8aabc484-2e1a-45ea-b00f-1e52540efc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_8aabc484-2e1a-45ea-b00f-1e52540efc62" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_eb65a370-f9ce-434c-b158-198880851fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9bce677d-3f9b-4280-a8ae-36a87b71bc93" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_762d5855-8620-498e-8580-6238bcf8f911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_762d5855-8620-498e-8580-6238bcf8f911" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_c967cfd3-0a43-4471-9a31-24a3a9cab67d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_c967cfd3-0a43-4471-9a31-24a3a9cab67d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_f932fc3e-0802-4705-927b-df4d5a0ebb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_f932fc3e-0802-4705-927b-df4d5a0ebb28" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_eb2696f2-f4aa-4141-8aec-13690121ae73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_eb2696f2-f4aa-4141-8aec-13690121ae73" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_7bf0d331-3fb4-4a22-bf0a-50e9c8bf0a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_7bf0d331-3fb4-4a22-bf0a-50e9c8bf0a6c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_0f8cb6f6-ca7e-4b30-8b2e-99fd25380308" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_0f8cb6f6-ca7e-4b30-8b2e-99fd25380308" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_85647183-2024-40bd-83b1-db135028b97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_85647183-2024-40bd-83b1-db135028b97f" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_3573c4f0-36ec-4202-a65e-90695bddb2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_3573c4f0-36ec-4202-a65e-90695bddb2ff" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_81ad63ad-98ce-41e6-bae8-34a016d4f375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ef02e84e-6e07-44ba-a16d-5dc1c6380535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ef02e84e-6e07-44ba-a16d-5dc1c6380535" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3f682c99-0d26-42c1-8d37-ca5002b12267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9bce677d-3f9b-4280-a8ae-36a87b71bc93" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3f682c99-0d26-42c1-8d37-ca5002b12267" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1cb0d623-34dd-49bd-b0dd-c9459a426dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3f682c99-0d26-42c1-8d37-ca5002b12267" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1cb0d623-34dd-49bd-b0dd-c9459a426dc0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_ca59a72b-27c1-438b-872b-dea35671784b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3f682c99-0d26-42c1-8d37-ca5002b12267" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_ca59a72b-27c1-438b-872b-dea35671784b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3d46fa9d-bcd5-4ebe-b951-9a755c14df50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3f682c99-0d26-42c1-8d37-ca5002b12267" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3d46fa9d-bcd5-4ebe-b951-9a755c14df50" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_a13408e6-4c07-4971-b4b7-acd302473092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3f682c99-0d26-42c1-8d37-ca5002b12267" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_a13408e6-4c07-4971-b4b7-acd302473092" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f5ddfbd6-8428-4169-b44e-4f26c1507c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9bce677d-3f9b-4280-a8ae-36a87b71bc93" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f5ddfbd6-8428-4169-b44e-4f26c1507c93" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_14e6edbb-0b56-41aa-8639-526b2a8427ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f5ddfbd6-8428-4169-b44e-4f26c1507c93" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_14e6edbb-0b56-41aa-8639-526b2a8427ee" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_d0af8dcf-8995-4311-88e8-1cfd4b3108cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f5ddfbd6-8428-4169-b44e-4f26c1507c93" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_d0af8dcf-8995-4311-88e8-1cfd4b3108cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_9b25548d-a854-473d-9bc7-279b4af2f9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f5ddfbd6-8428-4169-b44e-4f26c1507c93" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_9b25548d-a854-473d-9bc7-279b4af2f9ae" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_4b87e8f5-b7d4-427e-a335-3e027aece428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f5ddfbd6-8428-4169-b44e-4f26c1507c93" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_4b87e8f5-b7d4-427e-a335-3e027aece428" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_bdafbf4f-d76d-4bd3-886f-776a33131a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f5ddfbd6-8428-4169-b44e-4f26c1507c93" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_bdafbf4f-d76d-4bd3-886f-776a33131a96" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_e0997dcf-c5a5-49bd-8961-afde638d3ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f5ddfbd6-8428-4169-b44e-4f26c1507c93" xlink:to="loc_us-gaap_PensionContributions_e0997dcf-c5a5-49bd-8961-afde638d3ec7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9bce677d-3f9b-4280-a8ae-36a87b71bc93" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_73444d59-53a9-4cb1-84df-c53a84640b13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_73444d59-53a9-4cb1-84df-c53a84640b13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_1aae0649-4982-4661-9b3d-a6a21a2557d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_1aae0649-4982-4661-9b3d-a6a21a2557d1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_9181b254-adf4-417e-a784-9144b91cd01f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_9181b254-adf4-417e-a784-9144b91cd01f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_687485ae-0339-476a-a290-bd69102ef655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_687485ae-0339-476a-a290-bd69102ef655" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_8555cfc6-e4d7-4833-90c0-804127df4fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_8555cfc6-e4d7-4833-90c0-804127df4fc0" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectOfExchangeRates_706ca5cb-6aab-429a-b094-eeb717a9efd7" xlink:href="jnj-20230101.xsd#jnj_EffectOfExchangeRates"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:to="loc_jnj_EffectOfExchangeRates_706ca5cb-6aab-429a-b094-eeb717a9efd7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_0a617405-c7d0-4de8-bf9e-046bd696d8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_0a617405-c7d0-4de8-bf9e-046bd696d8d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_6196e424-4ce6-4254-9178-79de34417c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_6196e424-4ce6-4254-9178-79de34417c83" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1b8becba-aa95-4340-b5a2-6af8d95b51df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9bce677d-3f9b-4280-a8ae-36a87b71bc93" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1b8becba-aa95-4340-b5a2-6af8d95b51df" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7609a063-d273-485a-b2de-38ec77231642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1b8becba-aa95-4340-b5a2-6af8d95b51df" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7609a063-d273-485a-b2de-38ec77231642" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_7609a063-d273-485a-b2de-38ec77231642_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7609a063-d273-485a-b2de-38ec77231642" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_7609a063-d273-485a-b2de-38ec77231642_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2fb80f33-c8d5-4d26-8710-b277ad31f2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7609a063-d273-485a-b2de-38ec77231642" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2fb80f33-c8d5-4d26-8710-b277ad31f2b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_d8605ec8-d993-4cbb-8aa9-5dfdedbe1508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2fb80f33-c8d5-4d26-8710-b277ad31f2b8" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_d8605ec8-d993-4cbb-8aa9-5dfdedbe1508" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_78852f48-fca4-452c-83f0-789d08cc0d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2fb80f33-c8d5-4d26-8710-b277ad31f2b8" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_78852f48-fca4-452c-83f0-789d08cc0d8c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="extended" id="ic8ccecf9d0a74c7cbc690503570ae0ab_PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71ea8b86-0170-45c8-8507-607966badfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_340ed514-a32f-4d42-9d8a-0007f5b5ad8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71ea8b86-0170-45c8-8507-607966badfa4" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_340ed514-a32f-4d42-9d8a-0007f5b5ad8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_c23be965-cfe1-457a-b985-45b43e6d28ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71ea8b86-0170-45c8-8507-607966badfa4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_c23be965-cfe1-457a-b985-45b43e6d28ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_46628085-1bb7-4f7c-ba83-20468269bb34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71ea8b86-0170-45c8-8507-607966badfa4" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_46628085-1bb7-4f7c-ba83-20468269bb34" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_77d91d8d-9454-45db-927d-b13145ae3ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71ea8b86-0170-45c8-8507-607966badfa4" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_77d91d8d-9454-45db-927d-b13145ae3ce9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_c7dd94e4-b22e-4ae0-b383-87742440e8b3" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanOverUnderFundedStatusABO"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71ea8b86-0170-45c8-8507-607966badfa4" xlink:to="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_c7dd94e4-b22e-4ae0-b383-87742440e8b3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3b46d2ac-4e87-43b2-b5c9-c58ab8f9fa1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71ea8b86-0170-45c8-8507-607966badfa4" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3b46d2ac-4e87-43b2-b5c9-c58ab8f9fa1d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d9bc16ad-b5a1-467f-b1b5-aa5e91308de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3b46d2ac-4e87-43b2-b5c9-c58ab8f9fa1d" xlink:to="loc_us-gaap_PlanNameAxis_d9bc16ad-b5a1-467f-b1b5-aa5e91308de0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d9bc16ad-b5a1-467f-b1b5-aa5e91308de0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d9bc16ad-b5a1-467f-b1b5-aa5e91308de0" xlink:to="loc_us-gaap_PlanNameDomain_d9bc16ad-b5a1-467f-b1b5-aa5e91308de0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_845d2178-6f5d-4f33-a6a0-bd111044cad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d9bc16ad-b5a1-467f-b1b5-aa5e91308de0" xlink:to="loc_us-gaap_PlanNameDomain_845d2178-6f5d-4f33-a6a0-bd111044cad2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_QualifiedPlansMember_5d449316-60c9-487d-8797-565d0ced2952" xlink:href="jnj-20230101.xsd#jnj_QualifiedPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_845d2178-6f5d-4f33-a6a0-bd111044cad2" xlink:to="loc_jnj_QualifiedPlansMember_5d449316-60c9-487d-8797-565d0ced2952" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonQualifiedPlansMember_971dcba0-a340-4979-9942-d8f8bc025c66" xlink:href="jnj-20230101.xsd#jnj_NonQualifiedPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_845d2178-6f5d-4f33-a6a0-bd111044cad2" xlink:to="loc_jnj_NonQualifiedPlansMember_971dcba0-a340-4979-9942-d8f8bc025c66" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FundedPlansMember_7c2c8b8e-877c-4d26-9c39-7b3b09664e95" xlink:href="jnj-20230101.xsd#jnj_FundedPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_845d2178-6f5d-4f33-a6a0-bd111044cad2" xlink:to="loc_jnj_FundedPlansMember_7c2c8b8e-877c-4d26-9c39-7b3b09664e95" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnfundedPlansMember_ae9d5da0-f030-4887-8905-467c9445bb42" xlink:href="jnj-20230101.xsd#jnj_UnfundedPlansMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_845d2178-6f5d-4f33-a6a0-bd111044cad2" xlink:to="loc_jnj_UnfundedPlansMember_ae9d5da0-f030-4887-8905-467c9445bb42" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_4649c967-9e3d-4704-8b71-583d353c15ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3b46d2ac-4e87-43b2-b5c9-c58ab8f9fa1d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_4649c967-9e3d-4704-8b71-583d353c15ea" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_4649c967-9e3d-4704-8b71-583d353c15ea_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_4649c967-9e3d-4704-8b71-583d353c15ea" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_4649c967-9e3d-4704-8b71-583d353c15ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_46c0b21f-9989-447e-bba2-ac2a52796ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_4649c967-9e3d-4704-8b71-583d353c15ea" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_46c0b21f-9989-447e-bba2-ac2a52796ee1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_e5b5bc43-39e6-4b76-9ade-506489f087ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_46c0b21f-9989-447e-bba2-ac2a52796ee1" xlink:to="loc_us-gaap_DomesticPlanMember_e5b5bc43-39e6-4b76-9ade-506489f087ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c13eca65-3ef4-4bb4-afdf-a06bf945f7c8" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_e5b5bc43-39e6-4b76-9ade-506489f087ab" xlink:to="loc_country_US_c13eca65-3ef4-4bb4-afdf-a06bf945f7c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_783c63ff-c606-4a99-8f32-cbffdc4bd249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_46c0b21f-9989-447e-bba2-ac2a52796ee1" xlink:to="loc_us-gaap_ForeignPlanMember_783c63ff-c606-4a99-8f32-cbffdc4bd249" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="extended" id="i22e8d079f9a5440fbca4017a13dd56dc_PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_040dcd8a-0f3d-44c1-9380-27d9a5ff2d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_1aedf611-b9dd-4bd4-96fc-2d4ad9ea4251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_040dcd8a-0f3d-44c1-9380-27d9a5ff2d50" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_1aedf611-b9dd-4bd4-96fc-2d4ad9ea4251" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_44c25ece-ca04-46b8-bbb2-06ed6fb927fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_040dcd8a-0f3d-44c1-9380-27d9a5ff2d50" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_44c25ece-ca04-46b8-bbb2-06ed6fb927fd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_10f41a82-fb8a-4d96-9a24-486653820703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_040dcd8a-0f3d-44c1-9380-27d9a5ff2d50" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_10f41a82-fb8a-4d96-9a24-486653820703" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_2608c413-f8a3-43fe-952e-859f07fdab7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_040dcd8a-0f3d-44c1-9380-27d9a5ff2d50" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_2608c413-f8a3-43fe-952e-859f07fdab7c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_c0c2a5f5-4793-4c99-a26d-06fd890f6e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_040dcd8a-0f3d-44c1-9380-27d9a5ff2d50" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_c0c2a5f5-4793-4c99-a26d-06fd890f6e99" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_5108275e-956a-44d8-91d8-7bedd8599df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_040dcd8a-0f3d-44c1-9380-27d9a5ff2d50" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_5108275e-956a-44d8-91d8-7bedd8599df1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1c3e66bb-e915-4567-8ff7-14f2321e56c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_040dcd8a-0f3d-44c1-9380-27d9a5ff2d50" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1c3e66bb-e915-4567-8ff7-14f2321e56c8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_82340b60-311c-4742-afb5-dfcac585cf06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1c3e66bb-e915-4567-8ff7-14f2321e56c8" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_82340b60-311c-4742-afb5-dfcac585cf06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_82340b60-311c-4742-afb5-dfcac585cf06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_82340b60-311c-4742-afb5-dfcac585cf06" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_82340b60-311c-4742-afb5-dfcac585cf06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e8417f82-1415-4801-b8b2-ec6733f58c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_82340b60-311c-4742-afb5-dfcac585cf06" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e8417f82-1415-4801-b8b2-ec6733f58c00" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_fd3fa528-d303-4b12-8f1c-048dcd2c62b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e8417f82-1415-4801-b8b2-ec6733f58c00" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_fd3fa528-d303-4b12-8f1c-048dcd2c62b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_d232b011-2d8d-4817-9a63-b172cf539a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e8417f82-1415-4801-b8b2-ec6733f58c00" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_d232b011-2d8d-4817-9a63-b172cf539a0d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="extended" id="i59d1b6292fcd4bf5b3dd655d16a8444c_PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74c79cb8-dd6a-4418-8de3-15d6c5eed4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_b082b41a-0367-43fc-9f8a-fa02a3346db1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74c79cb8-dd6a-4418-8de3-15d6c5eed4ef" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_b082b41a-0367-43fc-9f8a-fa02a3346db1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_7111b77e-dbbb-41a6-ad72-a3c96da1a1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74c79cb8-dd6a-4418-8de3-15d6c5eed4ef" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_7111b77e-dbbb-41a6-ad72-a3c96da1a1bd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_13a9ede5-5753-4bee-b501-741764005662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74c79cb8-dd6a-4418-8de3-15d6c5eed4ef" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_13a9ede5-5753-4bee-b501-741764005662" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_db430c24-f714-4ad0-94a3-4669a632fad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_13a9ede5-5753-4bee-b501-741764005662" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_db430c24-f714-4ad0-94a3-4669a632fad3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_db430c24-f714-4ad0-94a3-4669a632fad3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_db430c24-f714-4ad0-94a3-4669a632fad3" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_db430c24-f714-4ad0-94a3-4669a632fad3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_c8a93fad-bae9-4f5e-8e83-ffee97c8fe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_db430c24-f714-4ad0-94a3-4669a632fad3" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_c8a93fad-bae9-4f5e-8e83-ffee97c8fe5b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_3b46ab9d-2b11-4358-94a9-440fa8ef8b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c8a93fad-bae9-4f5e-8e83-ffee97c8fe5b" xlink:to="loc_us-gaap_EquitySecuritiesMember_3b46ab9d-2b11-4358-94a9-440fa8ef8b4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_27681674-f903-4515-ae8f-9bdf9f368e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c8a93fad-bae9-4f5e-8e83-ffee97c8fe5b" xlink:to="loc_us-gaap_DebtSecuritiesMember_27681674-f903-4515-ae8f-9bdf9f368e23" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="extended" id="ib36678dd5318465ba0f24d106a00b90d_PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4beb6fbe-f65b-4469-817e-da38801f3a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_07b836aa-0d0b-479b-9882-bf71114b8af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4beb6fbe-f65b-4469-817e-da38801f3a19" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_07b836aa-0d0b-479b-9882-bf71114b8af9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_8509e7f3-a82a-4b87-a560-07faeae1ce3f" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4beb6fbe-f65b-4469-817e-da38801f3a19" xlink:to="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_8509e7f3-a82a-4b87-a560-07faeae1ce3f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bfbb30fc-a5c4-4b3d-bba6-22b4c1e3e96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4beb6fbe-f65b-4469-817e-da38801f3a19" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bfbb30fc-a5c4-4b3d-bba6-22b4c1e3e96a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b3b0bc9a-0570-442a-bdcd-0fd46b301033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bfbb30fc-a5c4-4b3d-bba6-22b4c1e3e96a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b3b0bc9a-0570-442a-bdcd-0fd46b301033" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_b3b0bc9a-0570-442a-bdcd-0fd46b301033_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b3b0bc9a-0570-442a-bdcd-0fd46b301033" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_b3b0bc9a-0570-442a-bdcd-0fd46b301033_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3a8aff8a-b4c6-4453-a402-0ca2a47d0cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b3b0bc9a-0570-442a-bdcd-0fd46b301033" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3a8aff8a-b4c6-4453-a402-0ca2a47d0cf1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0ec4d7df-1b3f-4589-968a-a8761c5a6cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3a8aff8a-b4c6-4453-a402-0ca2a47d0cf1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0ec4d7df-1b3f-4589-968a-a8761c5a6cd0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2d1809ab-24e7-445a-9890-b7cef46c83fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bfbb30fc-a5c4-4b3d-bba6-22b4c1e3e96a" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2d1809ab-24e7-445a-9890-b7cef46c83fc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2d1809ab-24e7-445a-9890-b7cef46c83fc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2d1809ab-24e7-445a-9890-b7cef46c83fc" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2d1809ab-24e7-445a-9890-b7cef46c83fc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2ea1333d-4578-4666-8605-0e620293d50d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2d1809ab-24e7-445a-9890-b7cef46c83fc" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2ea1333d-4578-4666-8605-0e620293d50d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_5bcb84fb-2ae9-4922-9761-1895daed358e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2ea1333d-4578-4666-8605-0e620293d50d" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_5bcb84fb-2ae9-4922-9761-1895daed358e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_c38c089f-a394-48b6-8b20-ce8a7d460819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bfbb30fc-a5c4-4b3d-bba6-22b4c1e3e96a" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_c38c089f-a394-48b6-8b20-ce8a7d460819" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_c38c089f-a394-48b6-8b20-ce8a7d460819_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_c38c089f-a394-48b6-8b20-ce8a7d460819" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_c38c089f-a394-48b6-8b20-ce8a7d460819_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_53f3d9a3-9a53-49a7-89ac-379018b55999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_c38c089f-a394-48b6-8b20-ce8a7d460819" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_53f3d9a3-9a53-49a7-89ac-379018b55999" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShortTermInvestmentFundsMember_e4d968b6-8946-434f-8e76-64c7d6181057" xlink:href="jnj-20230101.xsd#jnj_ShortTermInvestmentFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_53f3d9a3-9a53-49a7-89ac-379018b55999" xlink:to="loc_jnj_ShortTermInvestmentFundsMember_e4d968b6-8946-434f-8e76-64c7d6181057" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_83f36528-bee8-4979-bf9d-18cb67311292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_53f3d9a3-9a53-49a7-89ac-379018b55999" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_83f36528-bee8-4979-bf9d-18cb67311292" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_4062d9c8-46cb-400f-806e-ed79be0d5067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_53f3d9a3-9a53-49a7-89ac-379018b55999" xlink:to="loc_us-gaap_DebtSecuritiesMember_4062d9c8-46cb-400f-806e-ed79be0d5067" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_023a5423-a12d-45eb-82b1-e6288a671055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_53f3d9a3-9a53-49a7-89ac-379018b55999" xlink:to="loc_us-gaap_EquitySecuritiesMember_023a5423-a12d-45eb-82b1-e6288a671055" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember_5a06b3fa-f766-44cf-89fd-4d9dc81e5d24" xlink:href="jnj-20230101.xsd#jnj_CommingledFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_53f3d9a3-9a53-49a7-89ac-379018b55999" xlink:to="loc_jnj_CommingledFundsMember_5a06b3fa-f766-44cf-89fd-4d9dc81e5d24" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_3e54d382-dee5-4994-a010-d877ad1ac5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_53f3d9a3-9a53-49a7-89ac-379018b55999" xlink:to="loc_us-gaap_OtherAssetsMember_3e54d382-dee5-4994-a010-d877ad1ac5f4" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5967e5d-512c-4e1f-8e5d-b66cff3e7d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bfbb30fc-a5c4-4b3d-bba6-22b4c1e3e96a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5967e5d-512c-4e1f-8e5d-b66cff3e7d36" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5967e5d-512c-4e1f-8e5d-b66cff3e7d36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5967e5d-512c-4e1f-8e5d-b66cff3e7d36" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_a5967e5d-512c-4e1f-8e5d-b66cff3e7d36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1be73a7-cf0a-47fc-99fc-b630eaf3494b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5967e5d-512c-4e1f-8e5d-b66cff3e7d36" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1be73a7-cf0a-47fc-99fc-b630eaf3494b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_259e6c83-5aa5-4852-9aa0-2021af0e37ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1be73a7-cf0a-47fc-99fc-b630eaf3494b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_259e6c83-5aa5-4852-9aa0-2021af0e37ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_784f288f-c577-4b40-94ed-dca129966770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1be73a7-cf0a-47fc-99fc-b630eaf3494b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_784f288f-c577-4b40-94ed-dca129966770" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c11a2bb4-f962-4034-b86b-877197cfc6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1be73a7-cf0a-47fc-99fc-b630eaf3494b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c11a2bb4-f962-4034-b86b-877197cfc6ed" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#CapitalandTreasuryStockChangesinTreasuryStockDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails" xlink:type="extended" id="i3f83eb53f39a4fdbaf85b8775583e0cc_CapitalandTreasuryStockChangesinTreasuryStockDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cab602a6-98f5-46a7-a98e-d74766a6bb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_7dc39afc-8947-4e99-849c-353f7a4166c3" xlink:href="jnj-20230101.xsd#jnj_ChangesinTreasuryStockSharesOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cab602a6-98f5-46a7-a98e-d74766a6bb3f" xlink:to="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_7dc39afc-8947-4e99-849c-353f7a4166c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_732bebf0-7661-4b68-a0c6-3ace2a7d1e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_7dc39afc-8947-4e99-849c-353f7a4166c3" xlink:to="loc_us-gaap_TreasuryStockShares_732bebf0-7661-4b68-a0c6-3ace2a7d1e12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_c8b89725-1462-4ebc-941b-3bae1b937a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_7dc39afc-8947-4e99-849c-353f7a4166c3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_c8b89725-1462-4ebc-941b-3bae1b937a84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_7af4139f-d079-4bf0-9451-9b5aeb43a043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_7dc39afc-8947-4e99-849c-353f7a4166c3" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_7af4139f-d079-4bf0-9451-9b5aeb43a043" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_5158792b-9af2-428a-bb47-e19f7104001b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockRollForward_33ccd548-07be-4cb6-a507-04d53f483746" xlink:href="jnj-20230101.xsd#jnj_ChangesInTreasuryStockRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cab602a6-98f5-46a7-a98e-d74766a6bb3f" xlink:to="loc_jnj_ChangesInTreasuryStockRollForward_33ccd548-07be-4cb6-a507-04d53f483746" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_c58cf7dd-79e4-4bee-b0b5-4c440e10eee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_33ccd548-07be-4cb6-a507-04d53f483746" xlink:to="loc_us-gaap_TreasuryStockValue_c58cf7dd-79e4-4bee-b0b5-4c440e10eee3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_1e2a6774-a056-4e17-b500-f8d9e1202ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_33ccd548-07be-4cb6-a507-04d53f483746" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_1e2a6774-a056-4e17-b500-f8d9e1202ebf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6aca0fb3-59dd-4c96-8203-45acf878b11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_33ccd548-07be-4cb6-a507-04d53f483746" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6aca0fb3-59dd-4c96-8203-45acf878b11a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b833177d-7bda-4da4-a469-92d4927f7b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_2d0ff6b9-a46c-4aeb-8ae9-751b8a04575e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cab602a6-98f5-46a7-a98e-d74766a6bb3f" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_2d0ff6b9-a46c-4aeb-8ae9-751b8a04575e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9252d6c4-448e-4f47-9204-781d15b3f6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_2d0ff6b9-a46c-4aeb-8ae9-751b8a04575e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9252d6c4-448e-4f47-9204-781d15b3f6a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9252d6c4-448e-4f47-9204-781d15b3f6a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9252d6c4-448e-4f47-9204-781d15b3f6a9" xlink:to="loc_us-gaap_EquityComponentDomain_9252d6c4-448e-4f47-9204-781d15b3f6a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_76f66cc5-e601-4cfc-9515-f716d722e2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9252d6c4-448e-4f47-9204-781d15b3f6a9" xlink:to="loc_us-gaap_EquityComponentDomain_76f66cc5-e601-4cfc-9515-f716d722e2fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_92e47fcc-f2be-4ff6-9f60-afe59adc2e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_76f66cc5-e601-4cfc-9515-f716d722e2fe" xlink:to="loc_us-gaap_TreasuryStockMember_92e47fcc-f2be-4ff6-9f60-afe59adc2e97" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#CapitalandTreasuryStockNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails" xlink:type="extended" id="idc5d401ee7654deb90c4e8b169e5ba34_CapitalandTreasuryStockNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7f78a0-e6e7-4c29-9949-38501db32296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_23697ae0-e9ff-44a8-9dd7-a13366657c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7f78a0-e6e7-4c29-9949-38501db32296" xlink:to="loc_us-gaap_CommonStockSharesIssued_23697ae0-e9ff-44a8-9dd7-a13366657c8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_c7605ffd-4ae6-4d5f-b010-97ee6a26656d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7f78a0-e6e7-4c29-9949-38501db32296" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_c7605ffd-4ae6-4d5f-b010-97ee6a26656d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_e1180111-d0fa-4513-9aa0-062bbd00c213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7f78a0-e6e7-4c29-9949-38501db32296" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_e1180111-d0fa-4513-9aa0-062bbd00c213" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_50d6499b-6035-4744-a478-496fc4bb81ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7f78a0-e6e7-4c29-9949-38501db32296" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_50d6499b-6035-4744-a478-496fc4bb81ca" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_5833d589-70c4-4132-b274-a383d6148c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7f78a0-e6e7-4c29-9949-38501db32296" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_5833d589-70c4-4132-b274-a383d6148c91" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_9136b0a0-d030-43f1-b7d1-0cbfc339a6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7f78a0-e6e7-4c29-9949-38501db32296" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_9136b0a0-d030-43f1-b7d1-0cbfc339a6b1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_1f47d28e-b6d0-4460-9c07-074d13c5946c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_9136b0a0-d030-43f1-b7d1-0cbfc339a6b1" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_1f47d28e-b6d0-4460-9c07-074d13c5946c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_1f47d28e-b6d0-4460-9c07-074d13c5946c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1f47d28e-b6d0-4460-9c07-074d13c5946c" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_1f47d28e-b6d0-4460-9c07-074d13c5946c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_098d2a83-fde6-4773-918a-731501f9e193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1f47d28e-b6d0-4460-9c07-074d13c5946c" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_098d2a83-fde6-4773-918a-731501f9e193" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_December172018ShareRepurchaseProgramMember_847cd10a-cfd1-429b-8289-744dfacfe705" xlink:href="jnj-20230101.xsd#jnj_December172018ShareRepurchaseProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_098d2a83-fde6-4773-918a-731501f9e193" xlink:to="loc_jnj_December172018ShareRepurchaseProgramMember_847cd10a-cfd1-429b-8289-744dfacfe705" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a5da3614-7adb-44b2-af98-daa8a3cfaf2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_9136b0a0-d030-43f1-b7d1-0cbfc339a6b1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a5da3614-7adb-44b2-af98-daa8a3cfaf2b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_a5da3614-7adb-44b2-af98-daa8a3cfaf2b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a5da3614-7adb-44b2-af98-daa8a3cfaf2b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_a5da3614-7adb-44b2-af98-daa8a3cfaf2b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7b28188a-9954-4ff6-9169-962888090200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a5da3614-7adb-44b2-af98-daa8a3cfaf2b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7b28188a-9954-4ff6-9169-962888090200" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d184cc0c-4fe3-4573-85c8-9f2d63c75159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7b28188a-9954-4ff6-9169-962888090200" xlink:to="loc_us-gaap_SubsequentEventMember_d184cc0c-4fe3-4573-85c8-9f2d63c75159" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended" id="icc293ea7c2cd412984908f849813e776_AccumulatedOtherComprehensiveIncomeLossDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ccdc28c2-dc5c-4f96-bbf9-3a36bed51bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3789822d-4077-4c9a-b8b3-a70694f832a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ccdc28c2-dc5c-4f96-bbf9-3a36bed51bc5" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3789822d-4077-4c9a-b8b3-a70694f832a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_805c9314-6693-4db9-8e5f-b21505006c86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3789822d-4077-4c9a-b8b3-a70694f832a5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_805c9314-6693-4db9-8e5f-b21505006c86" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6901308a-020a-4dbf-8e2a-4e29bf25ee29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3789822d-4077-4c9a-b8b3-a70694f832a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6901308a-020a-4dbf-8e2a-4e29bf25ee29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7114ff28-4962-49d3-928b-f2599daefcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_fe838da1-a083-450e-82bd-fef42a04bfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ccdc28c2-dc5c-4f96-bbf9-3a36bed51bc5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_fe838da1-a083-450e-82bd-fef42a04bfbb" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d36d2c64-c756-4d97-8e89-63c32d8c5191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_fe838da1-a083-450e-82bd-fef42a04bfbb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d36d2c64-c756-4d97-8e89-63c32d8c5191" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_d36d2c64-c756-4d97-8e89-63c32d8c5191_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d36d2c64-c756-4d97-8e89-63c32d8c5191" xlink:to="loc_us-gaap_EquityComponentDomain_d36d2c64-c756-4d97-8e89-63c32d8c5191_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5050efc3-07cf-4bab-b047-26e614891655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d36d2c64-c756-4d97-8e89-63c32d8c5191" xlink:to="loc_us-gaap_EquityComponentDomain_5050efc3-07cf-4bab-b047-26e614891655" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5a049ee5-4913-4101-b597-a48eaba6beaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5050efc3-07cf-4bab-b047-26e614891655" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5a049ee5-4913-4101-b597-a48eaba6beaa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_9917f636-89cb-43d5-bbf6-c858252c8f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5050efc3-07cf-4bab-b047-26e614891655" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_9917f636-89cb-43d5-bbf6-c858252c8f20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_31f2a1cc-06d8-4b99-be21-df15d96074ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5050efc3-07cf-4bab-b047-26e614891655" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_31f2a1cc-06d8-4b99-be21-df15d96074ce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_95c9f36a-ec96-4e89-a728-3e5e3cb62fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5050efc3-07cf-4bab-b047-26e614891655" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_95c9f36a-ec96-4e89-a728-3e5e3cb62fdf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_16cc3eef-55da-4f09-867f-599627e227f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5050efc3-07cf-4bab-b047-26e614891655" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_16cc3eef-55da-4f09-867f-599627e227f3" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" xlink:type="extended" id="i8403d46bb25c44d0922d1ca89c78aec3_CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfStockBasedCompensationPlans_a658ecdc-ff4b-4cc3-8e8e-58c9bbbe11a7" xlink:href="jnj-20230101.xsd#jnj_NumberOfStockBasedCompensationPlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_jnj_NumberOfStockBasedCompensationPlans_a658ecdc-ff4b-4cc3-8e8e-58c9bbbe11a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a1a497be-9d57-476f-be56-2f10a9a3d18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a1a497be-9d57-476f-be56-2f10a9a3d18d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4765f961-8290-46f6-b638-1c838bfc19a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4765f961-8290-46f6-b638-1c838bfc19a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bd0dcf08-a76d-4208-9043-38b74e4eb94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bd0dcf08-a76d-4208-9043-38b74e4eb94f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_bc30e831-f23d-4b5e-8674-1d785758dd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_bc30e831-f23d-4b5e-8674-1d785758dd0b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_dfcb28d1-37bf-4b47-91ca-91589724c3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_dfcb28d1-37bf-4b47-91ca-91589724c3d8" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f2d22e36-b51c-4930-a633-c6fc4b33d952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f2d22e36-b51c-4930-a633-c6fc4b33d952" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ea7b3d59-0e3e-4f87-bb34-212ff2a4f127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ea7b3d59-0e3e-4f87-bb34-212ff2a4f127" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a08af434-5734-45dc-b913-b3a0e75693fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a08af434-5734-45dc-b913-b3a0e75693fb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_91859087-df85-4972-84e2-e26369ac37e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_91859087-df85-4972-84e2-e26369ac37e2" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fb4a41fd-8c40-4598-932e-4d8a6d5fa7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fb4a41fd-8c40-4598-932e-4d8a6d5fa7b2" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_558bb20e-599e-46c1-8e3a-6c0e087c0715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_558bb20e-599e-46c1-8e3a-6c0e087c0715" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_580fc611-faf2-4630-a63c-b6f6669c754c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_580fc611-faf2-4630-a63c-b6f6669c754c" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_fb009c72-f3dc-4ba8-96f6-b2848ca3ebaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_fb009c72-f3dc-4ba8-96f6-b2848ca3ebaf" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0bb65baf-2b8b-47d6-9e2d-d95697a29613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0bb65baf-2b8b-47d6-9e2d-d95697a29613" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c3e326fb-5302-4a61-94da-b97a00e62335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c3e326fb-5302-4a61-94da-b97a00e62335" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cc83a16b-fe7b-4317-a8eb-3dc8115f087b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cc83a16b-fe7b-4317-a8eb-3dc8115f087b" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3d1122ee-afe8-42ac-bab1-7ba292235ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3d1122ee-afe8-42ac-bab1-7ba292235ed2" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_bdb69806-604b-4775-8919-ad8bd4cf501e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_bdb69806-604b-4775-8919-ad8bd4cf501e" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights_b0fdad7d-44bb-407e-abe6-02424036a020" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights_b0fdad7d-44bb-407e-abe6-02424036a020" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards_f2368f15-b906-48ca-a35e-a327a4c86fae" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards_f2368f15-b906-48ca-a35e-a327a4c86fae" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess_be3422c6-a8fc-4e46-8e1c-54153cc12d49" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess_be3422c6-a8fc-4e46-8e1c-54153cc12d49" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b134651a-bb00-4c58-8731-2d658ff6d0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b134651a-bb00-4c58-8731-2d658ff6d0ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_56af3790-db74-4792-9d0c-2879cffe843f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b134651a-bb00-4c58-8731-2d658ff6d0ac" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_56af3790-db74-4792-9d0c-2879cffe843f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_56af3790-db74-4792-9d0c-2879cffe843f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_56af3790-db74-4792-9d0c-2879cffe843f" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_56af3790-db74-4792-9d0c-2879cffe843f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_45ecc114-56d6-46bb-ab14-0d044ad200b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_56af3790-db74-4792-9d0c-2879cffe843f" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_45ecc114-56d6-46bb-ab14-0d044ad200b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2022LongTermIncentivePlanMember_88086dfd-b9e1-43ac-8bad-93ad221e0c2a" xlink:href="jnj-20230101.xsd#jnj_A2022LongTermIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_45ecc114-56d6-46bb-ab14-0d044ad200b2" xlink:to="loc_jnj_A2022LongTermIncentivePlanMember_88086dfd-b9e1-43ac-8bad-93ad221e0c2a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_02046bfc-f628-4bca-8f28-04be11b3860a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b134651a-bb00-4c58-8731-2d658ff6d0ac" xlink:to="loc_srt_RangeAxis_02046bfc-f628-4bca-8f28-04be11b3860a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_02046bfc-f628-4bca-8f28-04be11b3860a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_02046bfc-f628-4bca-8f28-04be11b3860a" xlink:to="loc_srt_RangeMember_02046bfc-f628-4bca-8f28-04be11b3860a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5eaed84-7887-480f-b3ad-e22baef3b2dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_02046bfc-f628-4bca-8f28-04be11b3860a" xlink:to="loc_srt_RangeMember_e5eaed84-7887-480f-b3ad-e22baef3b2dd" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9ada5123-635a-47c1-b23f-7bcf37003e46" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e5eaed84-7887-480f-b3ad-e22baef3b2dd" xlink:to="loc_srt_MinimumMember_9ada5123-635a-47c1-b23f-7bcf37003e46" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e668cc6e-1519-4cc4-85aa-2a254b82f787" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_e5eaed84-7887-480f-b3ad-e22baef3b2dd" xlink:to="loc_srt_MaximumMember_e668cc6e-1519-4cc4-85aa-2a254b82f787" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5c1bf716-a176-407d-986c-4942608e9823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b134651a-bb00-4c58-8731-2d658ff6d0ac" xlink:to="loc_us-gaap_AwardTypeAxis_5c1bf716-a176-407d-986c-4942608e9823" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c1bf716-a176-407d-986c-4942608e9823_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5c1bf716-a176-407d-986c-4942608e9823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5c1bf716-a176-407d-986c-4942608e9823_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e4e3ff4-8766-4fb3-b317-9dd57d74f1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5c1bf716-a176-407d-986c-4942608e9823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e4e3ff4-8766-4fb3-b317-9dd57d74f1f0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f1fb1373-39a7-4281-99cf-db6f95a48e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e4e3ff4-8766-4fb3-b317-9dd57d74f1f0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f1fb1373-39a7-4281-99cf-db6f95a48e78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3b78da55-c20e-45ee-91a8-ef16adb4d17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e4e3ff4-8766-4fb3-b317-9dd57d74f1f0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3b78da55-c20e-45ee-91a8-ef16adb4d17c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_8eba68e7-56bc-45d8-ad6e-d7c81a7e2759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e4e3ff4-8766-4fb3-b317-9dd57d74f1f0" xlink:to="loc_us-gaap_PerformanceSharesMember_8eba68e7-56bc-45d8-ad6e-d7c81a7e2759" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" xlink:type="extended" id="ibbb80626a50d417496269beb2c1abe24_CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_be72d516-4b2c-485f-9016-0e7e013c6f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_be72d516-4b2c-485f-9016-0e7e013c6f05" xlink:to="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_9fc199c2-4af7-41cc-a871-76aac837cead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_9fc199c2-4af7-41cc-a871-76aac837cead" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_20b4843e-5ac0-4ff5-a491-80f6b66fb750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_20b4843e-5ac0-4ff5-a491-80f6b66fb750" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c5f90280-8df3-4943-9dca-e191a3cb89d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c5f90280-8df3-4943-9dca-e191a3cb89d9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_15576e39-76bc-4b1e-be89-633b4d638861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_15576e39-76bc-4b1e-be89-633b4d638861" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_da94d42d-17b2-4703-8a5b-935540cc15e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_da94d42d-17b2-4703-8a5b-935540cc15e1" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_abff9a6d-e7fe-460e-b06c-692ce3c744c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_abff9a6d-e7fe-460e-b06c-692ce3c744c4" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_8c65dcb4-2477-407b-91bc-7a6ab2bd6f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_8c65dcb4-2477-407b-91bc-7a6ab2bd6f34" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_d731bf1f-f340-4253-8786-9510dcb69010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_be72d516-4b2c-485f-9016-0e7e013c6f05" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_d731bf1f-f340-4253-8786-9510dcb69010" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1e3ed78f-4984-4dd2-bc3c-3a34a8b06700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_d731bf1f-f340-4253-8786-9510dcb69010" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1e3ed78f-4984-4dd2-bc3c-3a34a8b06700" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1e3ed78f-4984-4dd2-bc3c-3a34a8b06700_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1e3ed78f-4984-4dd2-bc3c-3a34a8b06700" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_1e3ed78f-4984-4dd2-bc3c-3a34a8b06700_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_dd24c06c-8193-4193-b207-9f9166de2267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1e3ed78f-4984-4dd2-bc3c-3a34a8b06700" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_dd24c06c-8193-4193-b207-9f9166de2267" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeOneMember_cc4cc786-7ae6-4700-96de-e398120ba002" xlink:href="jnj-20230101.xsd#jnj_ExercisePriceRangeOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_dd24c06c-8193-4193-b207-9f9166de2267" xlink:to="loc_jnj_ExercisePriceRangeOneMember_cc4cc786-7ae6-4700-96de-e398120ba002" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeTwoMember_1cdfd2ca-fb7c-4197-9f07-7adc4b839c0d" xlink:href="jnj-20230101.xsd#jnj_ExercisePriceRangeTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_dd24c06c-8193-4193-b207-9f9166de2267" xlink:to="loc_jnj_ExercisePriceRangeTwoMember_1cdfd2ca-fb7c-4197-9f07-7adc4b839c0d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeThreeMember_85a8fd4c-e718-43ec-9b3a-f1a23e54c904" xlink:href="jnj-20230101.xsd#jnj_ExercisePriceRangeThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_dd24c06c-8193-4193-b207-9f9166de2267" xlink:to="loc_jnj_ExercisePriceRangeThreeMember_85a8fd4c-e718-43ec-9b3a-f1a23e54c904" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFourMember_b22632ab-c7d2-4153-a985-82e49ae0fb11" xlink:href="jnj-20230101.xsd#jnj_ExercisePriceRangeFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_dd24c06c-8193-4193-b207-9f9166de2267" xlink:to="loc_jnj_ExercisePriceRangeFourMember_b22632ab-c7d2-4153-a985-82e49ae0fb11" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFiveMember_22d66dd5-3baa-4726-932d-bbb87b5b287b" xlink:href="jnj-20230101.xsd#jnj_ExercisePriceRangeFiveMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_dd24c06c-8193-4193-b207-9f9166de2267" xlink:to="loc_jnj_ExercisePriceRangeFiveMember_22d66dd5-3baa-4726-932d-bbb87b5b287b" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" xlink:type="extended" id="i3c421983aadc47e0869be266372ccb05_CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc4e0c83-5570-4520-8448-ffc09c6f66e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_110a498d-ad82-47cb-8b92-c6757e21cd2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc4e0c83-5570-4520-8448-ffc09c6f66e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_110a498d-ad82-47cb-8b92-c6757e21cd2f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_eb673aee-dbb5-41da-bb2f-171907215cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_110a498d-ad82-47cb-8b92-c6757e21cd2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_eb673aee-dbb5-41da-bb2f-171907215cd2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_15027bd0-bd12-4a91-bd44-56cff746aa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_eb673aee-dbb5-41da-bb2f-171907215cd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_15027bd0-bd12-4a91-bd44-56cff746aa28" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_910117ed-d57d-4eb2-9b5b-896fa5028436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_eb673aee-dbb5-41da-bb2f-171907215cd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_910117ed-d57d-4eb2-9b5b-896fa5028436" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_64ff2ce4-925a-497d-9f7b-753c2151d742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_eb673aee-dbb5-41da-bb2f-171907215cd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_64ff2ce4-925a-497d-9f7b-753c2151d742" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_1ff4a39a-0878-4c71-b337-c2a77f0c4d6e" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_eb673aee-dbb5-41da-bb2f-171907215cd2" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_1ff4a39a-0878-4c71-b337-c2a77f0c4d6e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c8d62c6a-adb7-4d7a-8e36-e9294f9af4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2133c436-9511-4a4b-b0af-d411603698c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc4e0c83-5570-4520-8448-ffc09c6f66e7" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2133c436-9511-4a4b-b0af-d411603698c0" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_075cd106-1344-4f11-b43f-1f64b8a11f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2133c436-9511-4a4b-b0af-d411603698c0" xlink:to="loc_us-gaap_AwardTypeAxis_075cd106-1344-4f11-b43f-1f64b8a11f77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_075cd106-1344-4f11-b43f-1f64b8a11f77_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_075cd106-1344-4f11-b43f-1f64b8a11f77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_075cd106-1344-4f11-b43f-1f64b8a11f77_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c136687d-1e51-4e7e-ac5a-62c4213e05bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_075cd106-1344-4f11-b43f-1f64b8a11f77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c136687d-1e51-4e7e-ac5a-62c4213e05bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8065cd5f-d3ec-49c3-af44-e02d06d05398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c136687d-1e51-4e7e-ac5a-62c4213e05bb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8065cd5f-d3ec-49c3-af44-e02d06d05398" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_91a75989-fe78-404b-93ae-287e9b755c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c136687d-1e51-4e7e-ac5a-62c4213e05bb" xlink:to="loc_us-gaap_PerformanceSharesMember_91a75989-fe78-404b-93ae-287e9b755c2d" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="extended" id="ibc4a585444284cc297c19fdd01c6cf1b_SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d86a8ef5-d973-43b2-80e4-5e87be6bbbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a195b86-105a-4005-b34b-8148a4521834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d86a8ef5-d973-43b2-80e4-5e87be6bbbf6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a195b86-105a-4005-b34b-8148a4521834" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_3e836788-b229-4a9c-a6f1-41855e62159d" xlink:href="jnj-20230101.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d86a8ef5-d973-43b2-80e4-5e87be6bbbf6" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_3e836788-b229-4a9c-a6f1-41855e62159d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d86a8ef5-d973-43b2-80e4-5e87be6bbbf6" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2df5f751-73a8-4890-a6ea-7d63ff4d5049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2df5f751-73a8-4890-a6ea-7d63ff4d5049" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2df5f751-73a8-4890-a6ea-7d63ff4d5049_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2df5f751-73a8-4890-a6ea-7d63ff4d5049" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2df5f751-73a8-4890-a6ea-7d63ff4d5049_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc2ae324-1a68-4848-a2b0-60e581adb359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2df5f751-73a8-4890-a6ea-7d63ff4d5049" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc2ae324-1a68-4848-a2b0-60e581adb359" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_522a9ba1-70d4-4d32-9eba-5a2d2ea034ac" xlink:href="jnj-20230101.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc2ae324-1a68-4848-a2b0-60e581adb359" xlink:to="loc_jnj_AurisHealthMember_522a9ba1-70d4-4d32-9eba-5a2d2ea034ac" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_38d24875-a347-4e31-9cf1-0dfcbd017b19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:to="loc_srt_StatementGeographicalAxis_38d24875-a347-4e31-9cf1-0dfcbd017b19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_38d24875-a347-4e31-9cf1-0dfcbd017b19_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_38d24875-a347-4e31-9cf1-0dfcbd017b19" xlink:to="loc_srt_SegmentGeographicalDomain_38d24875-a347-4e31-9cf1-0dfcbd017b19_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b0227ebd-c8ed-445e-9397-969d11386c4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_38d24875-a347-4e31-9cf1-0dfcbd017b19" xlink:to="loc_srt_SegmentGeographicalDomain_b0227ebd-c8ed-445e-9397-969d11386c4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_af760f8a-c0f1-4380-9e0c-51b35583bb51" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b0227ebd-c8ed-445e-9397-969d11386c4e" xlink:to="loc_country_US_af760f8a-c0f1-4380-9e0c-51b35583bb51" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_ad3ab2a0-7ad8-4cab-8863-71fee3f13422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b0227ebd-c8ed-445e-9397-969d11386c4e" xlink:to="loc_us-gaap_NonUsMember_ad3ab2a0-7ad8-4cab-8863-71fee3f13422" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_6c359b75-4535-4dff-bec6-e7e17a8c6cc4" xlink:href="jnj-20230101.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b0227ebd-c8ed-445e-9397-969d11386c4e" xlink:to="loc_jnj_UNITEDSTATESExportsMember_6c359b75-4535-4dff-bec6-e7e17a8c6cc4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_f774ff9d-5188-4e44-b8b4-c503222295d3" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_b0227ebd-c8ed-445e-9397-969d11386c4e" xlink:to="loc_country_CN_f774ff9d-5188-4e44-b8b4-c503222295d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0232b9ca-a64e-403d-a361-869887e3dbaf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:to="loc_srt_ProductOrServiceAxis_0232b9ca-a64e-403d-a361-869887e3dbaf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0232b9ca-a64e-403d-a361-869887e3dbaf_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0232b9ca-a64e-403d-a361-869887e3dbaf" xlink:to="loc_srt_ProductsAndServicesDomain_0232b9ca-a64e-403d-a361-869887e3dbaf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0232b9ca-a64e-403d-a361-869887e3dbaf" xlink:to="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_214f34bb-2c87-4598-9248-71568cebe4c4" xlink:href="jnj-20230101.xsd#jnj_OTCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_OTCMember_214f34bb-2c87-4598-9248-71568cebe4c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SkinHealthBeautyMember_f32f9723-5029-4740-a496-4cf77a3b288f" xlink:href="jnj-20230101.xsd#jnj_SkinHealthBeautyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_SkinHealthBeautyMember_f32f9723-5029-4740-a496-4cf77a3b288f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_3e8c48a4-777b-4f3f-ad2d-fff1dcb70891" xlink:href="jnj-20230101.xsd#jnj_OralCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_OralCareMember_3e8c48a4-777b-4f3f-ad2d-fff1dcb70891" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_4896157e-1051-470e-83d8-9322954d3ecf" xlink:href="jnj-20230101.xsd#jnj_BabyCareMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_BabyCareMember_4896157e-1051-470e-83d8-9322954d3ecf" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_f6fcc7a7-4fd7-4311-b65b-0f256fef1d01" xlink:href="jnj-20230101.xsd#jnj_WomensHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_WomensHealthMember_f6fcc7a7-4fd7-4311-b65b-0f256fef1d01" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_24e418e4-f4c9-4927-877f-58cbd365faa5" xlink:href="jnj-20230101.xsd#jnj_WoundCareandOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_WoundCareandOtherMember_24e418e4-f4c9-4927-877f-58cbd365faa5" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_d46dacde-45ef-4021-b9f5-65bd01c1181e" xlink:href="jnj-20230101.xsd#jnj_RemicadeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_RemicadeMember_d46dacde-45ef-4021-b9f5-65bd01c1181e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_a23c30c3-f883-407a-b7a8-3b2469d5bd10" xlink:href="jnj-20230101.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_SimponiSimponiAriaMember_a23c30c3-f883-407a-b7a8-3b2469d5bd10" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_546f08bc-1790-419e-85a2-c4ba61081981" xlink:href="jnj-20230101.xsd#jnj_StelaraMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_StelaraMember_546f08bc-1790-419e-85a2-c4ba61081981" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_674e274d-dbff-48d1-a01f-74d085a73458" xlink:href="jnj-20230101.xsd#jnj_TremfyaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_TremfyaMember_674e274d-dbff-48d1-a01f-74d085a73458" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_f3236e6f-0d7c-4829-93f0-fa7472eadf16" xlink:href="jnj-20230101.xsd#jnj_OtherImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_OtherImmunologyMember_f3236e6f-0d7c-4829-93f0-fa7472eadf16" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_e060c45a-ca34-4d1b-8ecb-a612f41e7d4c" xlink:href="jnj-20230101.xsd#jnj_COVID19Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_COVID19Member_e060c45a-ca34-4d1b-8ecb-a612f41e7d4c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_c76a6659-c0c9-4fa4-b2fb-b736c84244a8" xlink:href="jnj-20230101.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_EDURANTrilpivirineMember_c76a6659-c0c9-4fa4-b2fb-b736c84244a8" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_b25eba9b-db2c-4754-8c8f-b284f83ad7fd" xlink:href="jnj-20230101.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_b25eba9b-db2c-4754-8c8f-b284f83ad7fd" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_0d68ee1d-f0a1-4d17-a6b7-3d9bb9932b09" xlink:href="jnj-20230101.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_0d68ee1d-f0a1-4d17-a6b7-3d9bb9932b09" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_7c6d5167-8c72-47ea-9839-0484fbf11ff6" xlink:href="jnj-20230101.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_7c6d5167-8c72-47ea-9839-0484fbf11ff6" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_b0b00b7e-9c6c-4ee3-a60d-3b71176538f4" xlink:href="jnj-20230101.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_b0b00b7e-9c6c-4ee3-a60d-3b71176538f4" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember_78c97495-3a6a-40e4-8c56-8affd2373c7d" xlink:href="jnj-20230101.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_RISPERDALCONSTAMember_78c97495-3a6a-40e4-8c56-8affd2373c7d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_dff5df5a-da85-4d06-8b3a-5e27765fdd4b" xlink:href="jnj-20230101.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_dff5df5a-da85-4d06-8b3a-5e27765fdd4b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_db124e4a-4a88-49ed-b7b4-7c8c7a611ffb" xlink:href="jnj-20230101.xsd#jnj_DARZALEXMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_DARZALEXMember_db124e4a-4a88-49ed-b7b4-7c8c7a611ffb" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ErleadaMember_79496b3b-be81-4d9a-a012-7fae91bf5a0b" xlink:href="jnj-20230101.xsd#jnj_ErleadaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_ErleadaMember_79496b3b-be81-4d9a-a012-7fae91bf5a0b" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_9536616a-ba8e-4323-bd54-aa6b0c62e918" xlink:href="jnj-20230101.xsd#jnj_IMBRUVICAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_IMBRUVICAMember_9536616a-ba8e-4323-bd54-aa6b0c62e918" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_52ed6fa1-0a29-4a40-bd29-f224271aca68" xlink:href="jnj-20230101.xsd#jnj_ZYTIGAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_ZYTIGAMember_52ed6fa1-0a29-4a40-bd29-f224271aca68" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_98edd5f2-a5d7-402e-8d02-561e2d80cb46" xlink:href="jnj-20230101.xsd#jnj_OtherOncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_OtherOncologyMember_98edd5f2-a5d7-402e-8d02-561e2d80cb46" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_cb1b726e-aa2a-4496-9c47-38fe11e98a4d" xlink:href="jnj-20230101.xsd#jnj_OPSUMITMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_OPSUMITMember_cb1b726e-aa2a-4496-9c47-38fe11e98a4d" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_0010f04d-a3d7-4aa1-adcf-479cedee549e" xlink:href="jnj-20230101.xsd#jnj_UPTRAVIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_UPTRAVIMember_0010f04d-a3d7-4aa1-adcf-479cedee549e" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_73bbe2f9-85a1-4936-b9c8-0c488d81db33" xlink:href="jnj-20230101.xsd#jnj_OtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_OtherMember_73bbe2f9-85a1-4936-b9c8-0c488d81db33" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_a2712902-95d2-44fd-99d7-a79639626e7c" xlink:href="jnj-20230101.xsd#jnj_XareltoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_XareltoMember_a2712902-95d2-44fd-99d7-a79639626e7c" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember_93ffcb97-6a92-4ffc-8941-f9d775aec5fd" xlink:href="jnj-20230101.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_INVOKANAINVOKAMETMember_93ffcb97-6a92-4ffc-8941-f9d775aec5fd" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_6dc9820e-86ad-4a97-b4c0-5c0f4f4c6495" xlink:href="jnj-20230101.xsd#jnj_HIPSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_HIPSMember_6dc9820e-86ad-4a97-b4c0-5c0f4f4c6495" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_7ac11a0a-fa16-44b4-8f1d-658d226b5b90" xlink:href="jnj-20230101.xsd#jnj_KNEESMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_KNEESMember_7ac11a0a-fa16-44b4-8f1d-658d226b5b90" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_6ff8d5d0-116c-4ca9-b35f-947304c660da" xlink:href="jnj-20230101.xsd#jnj_TRAUMAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_TRAUMAMember_6ff8d5d0-116c-4ca9-b35f-947304c660da" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINESPORTSOTHERMember_496cb117-3d3c-43f0-88bb-7cd8dac2a418" xlink:href="jnj-20230101.xsd#jnj_SPINESPORTSOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_SPINESPORTSOTHERMember_496cb117-3d3c-43f0-88bb-7cd8dac2a418" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_dc08e367-95ec-4012-91b6-4b07788ccc3a" xlink:href="jnj-20230101.xsd#jnj_ADVANCEDMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_ADVANCEDMember_dc08e367-95ec-4012-91b6-4b07788ccc3a" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_da1a01db-08b1-4e76-8778-14542fac3105" xlink:href="jnj-20230101.xsd#jnj_GENERALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_GENERALMember_da1a01db-08b1-4e76-8778-14542fac3105" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_a028ec00-19bf-40d5-bede-f2cbf0371227" xlink:href="jnj-20230101.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_a028ec00-19bf-40d5-bede-f2cbf0371227" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_cef1bb3c-4476-4590-9b75-324952708862" xlink:href="jnj-20230101.xsd#jnj_SURGICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_SURGICALMember_cef1bb3c-4476-4590-9b75-324952708862" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e780fb6c-67da-4c28-88e0-ad9b0e092efc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:to="loc_srt_ConsolidationItemsAxis_e780fb6c-67da-4c28-88e0-ad9b0e092efc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_e780fb6c-67da-4c28-88e0-ad9b0e092efc_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_e780fb6c-67da-4c28-88e0-ad9b0e092efc" xlink:to="loc_srt_ConsolidationItemsDomain_e780fb6c-67da-4c28-88e0-ad9b0e092efc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c87f5ff9-ba39-4e20-8466-13cf1b990dc3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_e780fb6c-67da-4c28-88e0-ad9b0e092efc" xlink:to="loc_srt_ConsolidationItemsDomain_c87f5ff9-ba39-4e20-8466-13cf1b990dc3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a0dd469c-d307-4c8f-8baa-5fe8a17be051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a0dd469c-d307-4c8f-8baa-5fe8a17be051" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a0dd469c-d307-4c8f-8baa-5fe8a17be051_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a0dd469c-d307-4c8f-8baa-5fe8a17be051" xlink:to="loc_us-gaap_SegmentDomain_a0dd469c-d307-4c8f-8baa-5fe8a17be051_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a59366cf-191b-4cd9-837d-0a416930bca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a0dd469c-d307-4c8f-8baa-5fe8a17be051" xlink:to="loc_us-gaap_SegmentDomain_a59366cf-191b-4cd9-837d-0a416930bca1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_7517bae9-bfae-4e91-a9a2-88584dd853e6" xlink:href="jnj-20230101.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a59366cf-191b-4cd9-837d-0a416930bca1" xlink:to="loc_jnj_ConsumerMember_7517bae9-bfae-4e91-a9a2-88584dd853e6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_03cfa8cf-57d7-4e07-b92d-ee7f403f8716" xlink:href="jnj-20230101.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a59366cf-191b-4cd9-837d-0a416930bca1" xlink:to="loc_jnj_PharmaceuticalMember_03cfa8cf-57d7-4e07-b92d-ee7f403f8716" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_f4554c81-2382-4bfa-8a7e-a04309ab72a8" xlink:href="jnj-20230101.xsd#jnj_MedTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a59366cf-191b-4cd9-837d-0a416930bca1" xlink:to="loc_jnj_MedTechMember_f4554c81-2382-4bfa-8a7e-a04309ab72a8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_6d767617-ee5e-466a-a36c-676bef0b31bd" xlink:href="jnj-20230101.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_a59366cf-191b-4cd9-837d-0a416930bca1" xlink:to="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_6d767617-ee5e-466a-a36c-676bef0b31bd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_c0831582-0c4c-468b-a655-b9181225daae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:to="loc_us-gaap_SubsegmentsAxis_c0831582-0c4c-468b-a655-b9181225daae" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_c0831582-0c4c-468b-a655-b9181225daae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_c0831582-0c4c-468b-a655-b9181225daae" xlink:to="loc_us-gaap_SubsegmentsDomain_c0831582-0c4c-468b-a655-b9181225daae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_c0831582-0c4c-468b-a655-b9181225daae" xlink:to="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_705d4ad7-68fa-4fb7-8489-763caa50d5a9" xlink:href="jnj-20230101.xsd#jnj_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_ImmunologyMember_705d4ad7-68fa-4fb7-8489-763caa50d5a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_22970320-431c-4c51-8fd0-1cf016a2e28a" xlink:href="jnj-20230101.xsd#jnj_InfectiousDiseasesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_InfectiousDiseasesMember_22970320-431c-4c51-8fd0-1cf016a2e28a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_100903c6-a25f-4663-b60c-c3ba86a2f51c" xlink:href="jnj-20230101.xsd#jnj_NeuroscienceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_NeuroscienceMember_100903c6-a25f-4663-b60c-c3ba86a2f51c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_356494d4-c82a-409c-a795-5b525b87e412" xlink:href="jnj-20230101.xsd#jnj_OncologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_OncologyMember_356494d4-c82a-409c-a795-5b525b87e412" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_5a271c4b-2415-43f8-baa0-0fcd5c0ec56e" xlink:href="jnj-20230101.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_PulmonaryHypertensionMember_5a271c4b-2415-43f8-baa0-0fcd5c0ec56e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_cfc8de4a-77c7-4880-a760-092bfa60841a" xlink:href="jnj-20230101.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_cfc8de4a-77c7-4880-a760-092bfa60841a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_8732ff32-3efc-45f5-8ae7-795d3a4c9d0d" xlink:href="jnj-20230101.xsd#jnj_InterventionalSolutionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_InterventionalSolutionsMember_8732ff32-3efc-45f5-8ae7-795d3a4c9d0d" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_2e4e2859-7d31-40e1-beb8-885d9494e6e9" xlink:href="jnj-20230101.xsd#jnj_OrthopaedicsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_OrthopaedicsMember_2e4e2859-7d31-40e1-beb8-885d9494e6e9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_e2e0797e-27ac-46fd-8a38-537cb7b0748f" xlink:href="jnj-20230101.xsd#jnj_SurgeryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_SurgeryMember_e2e0797e-27ac-46fd-8a38-537cb7b0748f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_cd8aeb84-ac19-4b48-ab97-a3f33ed7eb81" xlink:href="jnj-20230101.xsd#jnj_VisionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_VisionMember_cd8aeb84-ac19-4b48-ab97-a3f33ed7eb81" xlink:type="arc" order="9"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="extended" id="i9ecf4116da59424fb8e8f09293e688b0_SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_346b48f0-81c7-4b92-876a-972d44be40fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_346b48f0-81c7-4b92-876a-972d44be40fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExpenseNotAllocatedToSegments_e166291d-3a55-462c-9816-4355349aa397" xlink:href="jnj-20230101.xsd#jnj_ExpenseNotAllocatedToSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_jnj_ExpenseNotAllocatedToSegments_e166291d-3a55-462c-9816-4355349aa397" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_856a075f-013f-41f0-b0fb-1f0f7e230dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_Assets_856a075f-013f-41f0-b0fb-1f0f7e230dfa" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes_8768330b-2aee-4276-8046-e5d3389557e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes_8768330b-2aee-4276-8046-e5d3389557e3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_fceb0ed2-8021-42dd-b2f8-f5e613264d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_fceb0ed2-8021-42dd-b2f8-f5e613264d90" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_971ad391-3283-4eb7-a0f7-459796370ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_971ad391-3283-4eb7-a0f7-459796370ea6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4221784c-81c6-4c1f-aca4-9a74e83a7610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4221784c-81c6-4c1f-aca4-9a74e83a7610" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_03e7ee68-e1a4-438c-849e-801db78cf563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_NoncurrentAssets_03e7ee68-e1a4-438c-849e-801db78cf563" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonLongLivedAssets_4cce7ae2-c3b9-4f1e-a496-1605d6775d89" xlink:href="jnj-20230101.xsd#jnj_OtherNonLongLivedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_jnj_OtherNonLongLivedAssets_4cce7ae2-c3b9-4f1e-a496-1605d6775d89" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_4e96df6b-8724-48f8-8088-e0899408b7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_4e96df6b-8724-48f8-8088-e0899408b7c8" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d25371fe-2f55-41ba-a347-1e138b2ae35f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d25371fe-2f55-41ba-a347-1e138b2ae35f" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_261c4bf4-471f-44e7-9e96-e2c0ff41ff4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_LitigationSettlementExpense_261c4bf4-471f-44e7-9e96-e2c0ff41ff4c" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_fe8509b6-b631-452b-b981-dfb891e4dade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_RestructuringCharges_fe8509b6-b631-452b-b981-dfb891e4dade" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_3dd3ff05-1320-45f8-9dba-9cdf16b42744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_3dd3ff05-1320-45f8-9dba-9cdf16b42744" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_01f60312-bb7b-4c76-8392-b7f8d6b2be46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_01f60312-bb7b-4c76-8392-b7f8d6b2be46" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ddfe10c8-7382-4edf-a871-46dda8192e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ddfe10c8-7382-4edf-a871-46dda8192e53" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RegulationCharge_bbbe1843-0ed8-47ab-8188-cb2a233c42d1" xlink:href="jnj-20230101.xsd#jnj_RegulationCharge"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_jnj_RegulationCharge_bbbe1843-0ed8-47ab-8188-cb2a233c42d1" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_cb719da8-70bf-41ff-ae23-87ef8fe4fcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_cb719da8-70bf-41ff-ae23-87ef8fe4fcdc" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9eb74955-0dc6-46ca-9915-b50c436451df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9eb74955-0dc6-46ca-9915-b50c436451df" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_22276695-1814-4f26-9c1e-48cffb9dc679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_22276695-1814-4f26-9c1e-48cffb9dc679" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_470502e4-84d8-4fe6-9f15-da51c9e59938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_SuppliesExpense_470502e4-84d8-4fe6-9f15-da51c9e59938" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionCosts_f362cd9a-418d-4d03-93c7-f459ea5a96ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquisitionCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_AcquisitionCosts_f362cd9a-418d-4d03-93c7-f459ea5a96ed" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_e802a13b-7e7e-4300-8812-123e6928b9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_SubsegmentsAxis_e802a13b-7e7e-4300-8812-123e6928b9ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_e802a13b-7e7e-4300-8812-123e6928b9ad_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_e802a13b-7e7e-4300-8812-123e6928b9ad" xlink:to="loc_us-gaap_SubsegmentsDomain_e802a13b-7e7e-4300-8812-123e6928b9ad_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_6ffc3b7c-9667-4541-91c4-54302364a00e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_e802a13b-7e7e-4300-8812-123e6928b9ad" xlink:to="loc_us-gaap_SubsegmentsDomain_6ffc3b7c-9667-4541-91c4-54302364a00e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_fa059485-52cf-4c13-b840-9bd5300a1acd" xlink:href="jnj-20230101.xsd#jnj_ImmunologyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_6ffc3b7c-9667-4541-91c4-54302364a00e" xlink:to="loc_jnj_ImmunologyMember_fa059485-52cf-4c13-b840-9bd5300a1acd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_d9f838e5-0099-4f2f-bcb5-c3145c71af8b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_srt_ConsolidationItemsAxis_d9f838e5-0099-4f2f-bcb5-c3145c71af8b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_d9f838e5-0099-4f2f-bcb5-c3145c71af8b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_d9f838e5-0099-4f2f-bcb5-c3145c71af8b" xlink:to="loc_srt_ConsolidationItemsDomain_d9f838e5-0099-4f2f-bcb5-c3145c71af8b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b04c5d07-f40c-4023-8f41-88f0fb0e6c16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_d9f838e5-0099-4f2f-bcb5-c3145c71af8b" xlink:to="loc_srt_ConsolidationItemsDomain_b04c5d07-f40c-4023-8f41-88f0fb0e6c16" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_74935910-a41c-4492-8e00-d60eb8f22d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_b04c5d07-f40c-4023-8f41-88f0fb0e6c16" xlink:to="loc_us-gaap_CorporateNonSegmentMember_74935910-a41c-4492-8e00-d60eb8f22d8a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2d117469-1373-405e-aaf8-afe1e97ae11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_b04c5d07-f40c-4023-8f41-88f0fb0e6c16" xlink:to="loc_us-gaap_OperatingSegmentsMember_2d117469-1373-405e-aaf8-afe1e97ae11c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8127abc2-fff1-461d-8eab-e9047fc687da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8127abc2-fff1-461d-8eab-e9047fc687da" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_8127abc2-fff1-461d-8eab-e9047fc687da_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8127abc2-fff1-461d-8eab-e9047fc687da" xlink:to="loc_us-gaap_SegmentDomain_8127abc2-fff1-461d-8eab-e9047fc687da_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_36ceea9b-0b08-41c7-88e0-a2cb4f783416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8127abc2-fff1-461d-8eab-e9047fc687da" xlink:to="loc_us-gaap_SegmentDomain_36ceea9b-0b08-41c7-88e0-a2cb4f783416" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GeneralCorporateMember_4da0e986-36a3-4aac-a125-cd89168391a9" xlink:href="jnj-20230101.xsd#jnj_GeneralCorporateMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_36ceea9b-0b08-41c7-88e0-a2cb4f783416" xlink:to="loc_jnj_GeneralCorporateMember_4da0e986-36a3-4aac-a125-cd89168391a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_ad613a21-e44d-458a-8b8a-079d09b03d27" xlink:href="jnj-20230101.xsd#jnj_ConsumerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_36ceea9b-0b08-41c7-88e0-a2cb4f783416" xlink:to="loc_jnj_ConsumerMember_ad613a21-e44d-458a-8b8a-079d09b03d27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_1d187781-b323-461a-8b38-485cfebd9ce3" xlink:href="jnj-20230101.xsd#jnj_PharmaceuticalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_36ceea9b-0b08-41c7-88e0-a2cb4f783416" xlink:to="loc_jnj_PharmaceuticalMember_1d187781-b323-461a-8b38-485cfebd9ce3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_f3602a31-3f72-492b-a2a0-5d1302377dc1" xlink:href="jnj-20230101.xsd#jnj_MedTechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_36ceea9b-0b08-41c7-88e0-a2cb4f783416" xlink:to="loc_jnj_MedTechMember_f3602a31-3f72-492b-a2a0-5d1302377dc1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SegmentsTotalMember_eaf64d3f-e26e-4233-8119-bf2bcd0daf39" xlink:href="jnj-20230101.xsd#jnj_SegmentsTotalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_36ceea9b-0b08-41c7-88e0-a2cb4f783416" xlink:to="loc_jnj_SegmentsTotalMember_eaf64d3f-e26e-4233-8119-bf2bcd0daf39" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerHealthMember_c6144439-d8ce-4a02-ac0d-201aa75aad10" xlink:href="jnj-20230101.xsd#jnj_ConsumerHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_36ceea9b-0b08-41c7-88e0-a2cb4f783416" xlink:to="loc_jnj_ConsumerHealthMember_c6144439-d8ce-4a02-ac0d-201aa75aad10" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3df16a30-257a-44b9-a755-d5ce9c3d950b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_srt_StatementGeographicalAxis_3df16a30-257a-44b9-a755-d5ce9c3d950b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_3df16a30-257a-44b9-a755-d5ce9c3d950b_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_3df16a30-257a-44b9-a755-d5ce9c3d950b" xlink:to="loc_srt_SegmentGeographicalDomain_3df16a30-257a-44b9-a755-d5ce9c3d950b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_954b5720-7f3c-441d-9234-db81de5ac32c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_3df16a30-257a-44b9-a755-d5ce9c3d950b" xlink:to="loc_srt_SegmentGeographicalDomain_954b5720-7f3c-441d-9234-db81de5ac32c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7c43068f-80a1-43d0-a704-f7ab55b796d4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_954b5720-7f3c-441d-9234-db81de5ac32c" xlink:to="loc_country_US_7c43068f-80a1-43d0-a704-f7ab55b796d4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_883d0321-4ed0-40c0-a13e-3d8685186894" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_954b5720-7f3c-441d-9234-db81de5ac32c" xlink:to="loc_srt_EuropeMember_883d0321-4ed0-40c0-a13e-3d8685186894" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_d4ee9d8d-b249-48e2-96ee-934e59dd0b18" xlink:href="jnj-20230101.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_954b5720-7f3c-441d-9234-db81de5ac32c" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_d4ee9d8d-b249-48e2-96ee-934e59dd0b18" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_f14c9613-09b1-443c-a2a5-5b8b3b7113aa" xlink:href="jnj-20230101.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_954b5720-7f3c-441d-9234-db81de5ac32c" xlink:to="loc_jnj_AsiaPacificAfricaMember_f14c9613-09b1-443c-a2a5-5b8b3b7113aa" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_cae81cbe-df20-4998-aaac-e0cd92bf007a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_srt_MajorCustomersAxis_cae81cbe-df20-4998-aaac-e0cd92bf007a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_cae81cbe-df20-4998-aaac-e0cd92bf007a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_cae81cbe-df20-4998-aaac-e0cd92bf007a" xlink:to="loc_srt_NameOfMajorCustomerDomain_cae81cbe-df20-4998-aaac-e0cd92bf007a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e8146009-4087-4fc8-82a1-6243e4671566" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_cae81cbe-df20-4998-aaac-e0cd92bf007a" xlink:to="loc_srt_NameOfMajorCustomerDomain_e8146009-4087-4fc8-82a1-6243e4671566" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler1Member_e7bc6e37-a2ce-42c1-b223-4041e80680ab" xlink:href="jnj-20230101.xsd#jnj_Wholesaler1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8146009-4087-4fc8-82a1-6243e4671566" xlink:to="loc_jnj_Wholesaler1Member_e7bc6e37-a2ce-42c1-b223-4041e80680ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler2Member_507e1ae7-6257-428a-bc28-24b1f39d0470" xlink:href="jnj-20230101.xsd#jnj_Wholesaler2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8146009-4087-4fc8-82a1-6243e4671566" xlink:to="loc_jnj_Wholesaler2Member_507e1ae7-6257-428a-bc28-24b1f39d0470" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler3Member_87195715-2c95-469e-bc12-0365816f3be4" xlink:href="jnj-20230101.xsd#jnj_Wholesaler3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8146009-4087-4fc8-82a1-6243e4671566" xlink:to="loc_jnj_Wholesaler3Member_87195715-2c95-469e-bc12-0365816f3be4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0982be30-bc5f-4ecd-95d7-3b647fb662f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0982be30-bc5f-4ecd-95d7-3b647fb662f6" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0982be30-bc5f-4ecd-95d7-3b647fb662f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0982be30-bc5f-4ecd-95d7-3b647fb662f6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_0982be30-bc5f-4ecd-95d7-3b647fb662f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca8e3f82-44a6-4e69-a806-ca3f47fcfbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0982be30-bc5f-4ecd-95d7-3b647fb662f6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca8e3f82-44a6-4e69-a806-ca3f47fcfbed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_4177e4b1-6752-4bd6-8534-f29f0fe12436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca8e3f82-44a6-4e69-a806-ca3f47fcfbed" xlink:to="loc_us-gaap_SalesRevenueNetMember_4177e4b1-6752-4bd6-8534-f29f0fe12436" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f4b814b5-c018-4da6-8a48-44bbf3ca6dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f4b814b5-c018-4da6-8a48-44bbf3ca6dc0" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4b814b5-c018-4da6-8a48-44bbf3ca6dc0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f4b814b5-c018-4da6-8a48-44bbf3ca6dc0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_f4b814b5-c018-4da6-8a48-44bbf3ca6dc0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e946d1fa-2556-411a-b40d-97b59fe6ab03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f4b814b5-c018-4da6-8a48-44bbf3ca6dc0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e946d1fa-2556-411a-b40d-97b59fe6ab03" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_2e8b5cb5-25b2-4880-85a5-adcf03d9a010" xlink:href="jnj-20230101.xsd#jnj_AurisHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e946d1fa-2556-411a-b40d-97b59fe6ab03" xlink:to="loc_jnj_AurisHealthMember_2e8b5cb5-25b2-4880-85a5-adcf03d9a010" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_c347eeaf-48df-411a-8900-750c5a602b4c" xlink:href="jnj-20230101.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e946d1fa-2556-411a-b40d-97b59fe6ab03" xlink:to="loc_jnj_BermekimabMember_c347eeaf-48df-411a-8900-750c5a602b4c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e8391998-c4bb-406e-aded-d5642eaa7ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e8391998-c4bb-406e-aded-d5642eaa7ee6" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_e8391998-c4bb-406e-aded-d5642eaa7ee6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e8391998-c4bb-406e-aded-d5642eaa7ee6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_e8391998-c4bb-406e-aded-d5642eaa7ee6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d204b2b1-363f-40de-9ae7-bdc6ace1a744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e8391998-c4bb-406e-aded-d5642eaa7ee6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d204b2b1-363f-40de-9ae7-bdc6ace1a744" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember_468f03d8-7f35-424e-8a43-77cb55e34b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d204b2b1-363f-40de-9ae7-bdc6ace1a744" xlink:to="loc_us-gaap_OtherIncomeMember_468f03d8-7f35-424e-8a43-77cb55e34b3c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4a43417-2988-41a0-b728-4688778e4b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4a43417-2988-41a0-b728-4688778e4b36" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a4a43417-2988-41a0-b728-4688778e4b36_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4a43417-2988-41a0-b728-4688778e4b36" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a4a43417-2988-41a0-b728-4688778e4b36_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_611097a4-85da-4345-af56-1c345fb55057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4a43417-2988-41a0-b728-4688778e4b36" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_611097a4-85da-4345-af56-1c345fb55057" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_553aece3-283f-43ce-a9ab-6cb4fa2679b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_611097a4-85da-4345-af56-1c345fb55057" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_553aece3-283f-43ce-a9ab-6cb4fa2679b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_55cf1193-9c6f-4275-8228-6c670d98dbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_611097a4-85da-4345-af56-1c345fb55057" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_55cf1193-9c6f-4275-8228-6c670d98dbbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_95237b8a-f260-48d1-9a69-57019329f21e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_95237b8a-f260-48d1-9a69-57019329f21e" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_95237b8a-f260-48d1-9a69-57019329f21e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_95237b8a-f260-48d1-9a69-57019329f21e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_95237b8a-f260-48d1-9a69-57019329f21e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1d6c7118-1699-4b2a-967f-9c18459f8d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_95237b8a-f260-48d1-9a69-57019329f21e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1d6c7118-1699-4b2a-967f-9c18459f8d2b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerHealthMember_8a7ce98e-90ac-48e8-b805-f07c4dd01bfa" xlink:href="jnj-20230101.xsd#jnj_ConsumerHealthMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1d6c7118-1699-4b2a-967f-9c18459f8d2b" xlink:to="loc_jnj_ConsumerHealthMember_8a7ce98e-90ac-48e8-b805-f07c4dd01bfa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2858d4c7-6e25-43b1-8665-160cd7bb045b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2858d4c7-6e25-43b1-8665-160cd7bb045b" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_2858d4c7-6e25-43b1-8665-160cd7bb045b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2858d4c7-6e25-43b1-8665-160cd7bb045b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_2858d4c7-6e25-43b1-8665-160cd7bb045b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e96f715e-5fad-49d7-897e-46fc6723bd20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2858d4c7-6e25-43b1-8665-160cd7bb045b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e96f715e-5fad-49d7-897e-46fc6723bd20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WholesalerConcentrationRiskMember_a09787a5-52ef-439b-97a0-ce80af68c38c" xlink:href="jnj-20230101.xsd#jnj_WholesalerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e96f715e-5fad-49d7-897e-46fc6723bd20" xlink:to="loc_jnj_WholesalerConcentrationRiskMember_a09787a5-52ef-439b-97a0-ce80af68c38c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ff0cd47c-3256-43e4-885a-f335cc08489f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ff0cd47c-3256-43e4-885a-f335cc08489f" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ff0cd47c-3256-43e4-885a-f335cc08489f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ff0cd47c-3256-43e4-885a-f335cc08489f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_ff0cd47c-3256-43e4-885a-f335cc08489f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40c0fe78-8a17-4a33-8e1a-9a164eb4913a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ff0cd47c-3256-43e4-885a-f335cc08489f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40c0fe78-8a17-4a33-8e1a-9a164eb4913a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2bf36dbf-d2bf-4b82-9ddd-14fe1342007e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40c0fe78-8a17-4a33-8e1a-9a164eb4913a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2bf36dbf-d2bf-4b82-9ddd-14fe1342007e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended" id="i0e89513a9e734d92bb246b9af7a80b4b_AcquisitionsandDivestituresNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d6473a96-326e-4816-bf31-16e950eef2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d6473a96-326e-4816-bf31-16e950eef2de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_65a40597-898d-4932-94dd-2477ce72603e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_65a40597-898d-4932-94dd-2477ce72603e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_23e7fd02-6b6e-468a-8eee-7da3260138df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_23e7fd02-6b6e-468a-8eee-7da3260138df" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_460755f7-b795-4f54-b73d-7e58c4b84d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_460755f7-b795-4f54-b73d-7e58c4b84d7e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_8dea54ba-6e23-46db-8c14-e867a06499d0" xlink:href="jnj-20230101.xsd#jnj_BusinessCombinationProbabilityOfSuccessFactor"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_8dea54ba-6e23-46db-8c14-e867a06499d0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessAcquisitionDiscountRate_49c411e6-8b8f-4dfb-8e11-52bce6f8739a" xlink:href="jnj-20230101.xsd#jnj_BusinessAcquisitionDiscountRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_jnj_BusinessAcquisitionDiscountRate_49c411e6-8b8f-4dfb-8e11-52bce6f8739a" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_455d2f1f-ee5c-4e08-802b-ac9daf27904e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_Goodwill_455d2f1f-ee5c-4e08-802b-ac9daf27904e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a22398fe-f9a5-444c-9974-a4224d546fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a22398fe-f9a5-444c-9974-a4224d546fa1" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_2249d130-ed7a-42ca-bac8-a2315bb1bebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_2249d130-ed7a-42ca-bac8-a2315bb1bebf" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_49bc09bc-90bd-49fe-a23c-35b1fe1d3007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_49bc09bc-90bd-49fe-a23c-35b1fe1d3007" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_dc089da9-89a5-4272-bcd2-d7384774f1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_dc089da9-89a5-4272-bcd2-d7384774f1ca" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_357f9e85-a383-4587-b8ab-31634ee863e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_357f9e85-a383-4587-b8ab-31634ee863e3" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_f73178da-b983-4ffb-9be7-4dd1fa544cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_f73178da-b983-4ffb-9be7-4dd1fa544cba" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_3123e5cb-bff5-4d94-a701-f68b948eb35d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfInterestInCorporateUnit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_3123e5cb-bff5-4d94-a701-f68b948eb35d" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_bae7cd20-01bf-4615-b5f6-9046d7a6471e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_bae7cd20-01bf-4615-b5f6-9046d7a6471e" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares_f22f1656-92bf-4b27-9d67-260df90a5a8c" xlink:href="jnj-20230101.xsd#jnj_ConvertibleNoteEquityInterestNumberOfShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares_f22f1656-92bf-4b27-9d67-260df90a5a8c" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_654404e2-0e9b-4c41-a130-cf39ad278226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_LongTermDebt_654404e2-0e9b-4c41-a130-cf39ad278226" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DebtInstrumentConvertibleAmountOfLoanConverted_2d6dad7b-1fcd-4ffd-aff7-d83394ce74fa" xlink:href="jnj-20230101.xsd#jnj_DebtInstrumentConvertibleAmountOfLoanConverted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_jnj_DebtInstrumentConvertibleAmountOfLoanConverted_2d6dad7b-1fcd-4ffd-aff7-d83394ce74fa" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_38532a72-e800-4b9c-ac31-e07cbba5ae0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_38532a72-e800-4b9c-ac31-e07cbba5ae0b" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3b2310bd-9265-4427-a6b0-baa5ed859cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_AssetImpairmentCharges_3b2310bd-9265-4427-a6b0-baa5ed859cb1" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ec9cdbd5-12ae-4c7b-a01f-65619585caa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ec9cdbd5-12ae-4c7b-a01f-65619585caa5" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b039e380-1faa-4fb2-969e-9b9e2d1020b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b039e380-1faa-4fb2-969e-9b9e2d1020b0" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_d7d80e1e-4e20-4ebf-abbb-b31aac11104c" xlink:href="jnj-20230101.xsd#jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_d7d80e1e-4e20-4ebf-abbb-b31aac11104c" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_29fc984c-447a-4ee2-bc41-989b0b431665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_29fc984c-447a-4ee2-bc41-989b0b431665" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a901492a-4661-41b4-8b42-1081f2e060d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a901492a-4661-41b4-8b42-1081f2e060d4" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6b9c3e48-f075-4348-96ed-cdd24de999a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6b9c3e48-f075-4348-96ed-cdd24de999a1" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_270bb43e-248a-4693-94bc-086159856205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_270bb43e-248a-4693-94bc-086159856205" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_155f454a-3c01-47d8-baa8-5dc4a9f36360" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_155f454a-3c01-47d8-baa8-5dc4a9f36360" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_e84dba83-c9a5-4880-8d32-84a41115972e" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_e84dba83-c9a5-4880-8d32-84a41115972e" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare_c0a1e9c7-610b-44a1-b1c2-ffbd8a9e47c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_DividendsPayableAmountPerShare_c0a1e9c7-610b-44a1-b1c2-ffbd8a9e47c0" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RevenuesContingentConsideration_752a1886-aea8-402b-b96e-7d99ba22fe49" xlink:href="jnj-20230101.xsd#jnj_RevenuesContingentConsideration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_jnj_RevenuesContingentConsideration_752a1886-aea8-402b-b96e-7d99ba22fe49" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3cb77ff3-a867-4eeb-af18-c8845268411d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3cb77ff3-a867-4eeb-af18-c8845268411d" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1f623cbd-40d1-429c-8cb7-ae65ebcbe76f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1f623cbd-40d1-429c-8cb7-ae65ebcbe76f" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_155dee59-023b-4f03-ade6-414e14583859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_155dee59-023b-4f03-ade6-414e14583859" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_aad3c229-8755-47a9-ba77-770ef940aa53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_aad3c229-8755-47a9-ba77-770ef940aa53" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_61313219-ff13-4db6-a76b-da586eb8d7de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_61313219-ff13-4db6-a76b-da586eb8d7de" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_7e1b8061-ce6e-4e30-8362-9b5a5bd199c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_7e1b8061-ce6e-4e30-8362-9b5a5bd199c6" xlink:type="arc" order="36"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c07375b6-85f0-437c-bd46-ebe4a2a08ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c07375b6-85f0-437c-bd46-ebe4a2a08ebf" xlink:type="arc" order="37"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a4acad78-f486-4ced-bfa7-e223252d870f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a4acad78-f486-4ced-bfa7-e223252d870f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a4acad78-f486-4ced-bfa7-e223252d870f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a4acad78-f486-4ced-bfa7-e223252d870f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_a4acad78-f486-4ced-bfa7-e223252d870f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_671020f9-04b1-4057-9cc6-63366f142df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a4acad78-f486-4ced-bfa7-e223252d870f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_671020f9-04b1-4057-9cc6-63366f142df9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember_36ca6b91-6e13-4e61-937f-914466dcc13c" xlink:href="jnj-20230101.xsd#jnj_EvraAndDoxilMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_671020f9-04b1-4057-9cc6-63366f142df9" xlink:to="loc_jnj_EvraAndDoxilMember_36ca6b91-6e13-4e61-937f-914466dcc13c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5ec027b3-08ee-43be-a2ff-6add3d60cc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5ec027b3-08ee-43be-a2ff-6add3d60cc8a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_5ec027b3-08ee-43be-a2ff-6add3d60cc8a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5ec027b3-08ee-43be-a2ff-6add3d60cc8a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_5ec027b3-08ee-43be-a2ff-6add3d60cc8a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e22cbb4e-8800-4fa1-8cf6-efcaadd04c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5ec027b3-08ee-43be-a2ff-6add3d60cc8a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e22cbb4e-8800-4fa1-8cf6-efcaadd04c09" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_8536a024-cb9d-4368-9748-c940ac200958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e22cbb4e-8800-4fa1-8cf6-efcaadd04c09" xlink:to="loc_us-gaap_ConvertibleDebtMember_8536a024-cb9d-4368-9748-c940ac200958" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7d01e691-4373-4bf5-8ef3-4ae11455a877" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:to="loc_srt_RangeAxis_7d01e691-4373-4bf5-8ef3-4ae11455a877" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7d01e691-4373-4bf5-8ef3-4ae11455a877_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7d01e691-4373-4bf5-8ef3-4ae11455a877" xlink:to="loc_srt_RangeMember_7d01e691-4373-4bf5-8ef3-4ae11455a877_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7afb1f0f-87c4-482c-8a31-145ed3fe5aae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7d01e691-4373-4bf5-8ef3-4ae11455a877" xlink:to="loc_srt_RangeMember_7afb1f0f-87c4-482c-8a31-145ed3fe5aae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7b51f41b-169b-405c-9883-238ac0edf3f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7afb1f0f-87c4-482c-8a31-145ed3fe5aae" xlink:to="loc_srt_MaximumMember_7b51f41b-169b-405c-9883-238ac0edf3f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a4e525ee-d204-4dca-86f5-8c334e36d0c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_7afb1f0f-87c4-482c-8a31-145ed3fe5aae" xlink:to="loc_srt_MinimumMember_a4e525ee-d204-4dca-86f5-8c334e36d0c4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_88f6d291-6fb7-419c-b9f1-ad823f732284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_88f6d291-6fb7-419c-b9f1-ad823f732284" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88f6d291-6fb7-419c-b9f1-ad823f732284_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_88f6d291-6fb7-419c-b9f1-ad823f732284" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_88f6d291-6fb7-419c-b9f1-ad823f732284_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2719f4e4-bf8e-452b-9813-347c4a67891f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_88f6d291-6fb7-419c-b9f1-ad823f732284" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2719f4e4-bf8e-452b-9813-347c4a67891f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IdorsiaMember_a1fe0ec4-75fc-4cc9-91e1-d0961f0ae56d" xlink:href="jnj-20230101.xsd#jnj_IdorsiaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2719f4e4-bf8e-452b-9813-347c4a67891f" xlink:to="loc_jnj_IdorsiaMember_a1fe0ec4-75fc-4cc9-91e1-d0961f0ae56d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MomentaMember_436faffa-a3d4-48e2-b2de-db9d6dee2785" xlink:href="jnj-20230101.xsd#jnj_MomentaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2719f4e4-bf8e-452b-9813-347c4a67891f" xlink:to="loc_jnj_MomentaMember_436faffa-a3d4-48e2-b2de-db9d6dee2785" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2020AcquisitionsMember_00f7e64e-11ea-485e-93a9-8e1b5f6e2d6a" xlink:href="jnj-20230101.xsd#jnj_A2020AcquisitionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2719f4e4-bf8e-452b-9813-347c4a67891f" xlink:to="loc_jnj_A2020AcquisitionsMember_00f7e64e-11ea-485e-93a9-8e1b5f6e2d6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_67ab77ea-e178-4da1-a7a7-8b191c2308d6" xlink:href="jnj-20230101.xsd#jnj_BermekimabMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2719f4e4-bf8e-452b-9813-347c4a67891f" xlink:to="loc_jnj_BermekimabMember_67ab77ea-e178-4da1-a7a7-8b191c2308d6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalIncMember_6483c453-040b-40fb-9265-ea64c10699d6" xlink:href="jnj-20230101.xsd#jnj_VerbSurgicalIncMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2719f4e4-bf8e-452b-9813-347c4a67891f" xlink:to="loc_jnj_VerbSurgicalIncMember_6483c453-040b-40fb-9265-ea64c10699d6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember_ac943bea-3f3f-4718-b75a-8e7d4e396b23" xlink:href="jnj-20230101.xsd#jnj_AbiomedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2719f4e4-bf8e-452b-9813-347c4a67891f" xlink:to="loc_jnj_AbiomedMember_ac943bea-3f3f-4718-b75a-8e7d4e396b23" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f69bf16c-5521-45ad-af63-b696f3017313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f69bf16c-5521-45ad-af63-b696f3017313" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f69bf16c-5521-45ad-af63-b696f3017313_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f69bf16c-5521-45ad-af63-b696f3017313" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_f69bf16c-5521-45ad-af63-b696f3017313_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54b8e481-f660-4f64-bf46-cdc5ed2e5c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f69bf16c-5521-45ad-af63-b696f3017313" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54b8e481-f660-4f64-bf46-cdc5ed2e5c11" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_28fb66ec-e924-4295-9bc6-67e259203a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54b8e481-f660-4f64-bf46-cdc5ed2e5c11" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_28fb66ec-e924-4295-9bc6-67e259203a40" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fc07c793-1019-48f6-8b5d-4dc0fa9775b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:to="loc_us-gaap_AwardTypeAxis_fc07c793-1019-48f6-8b5d-4dc0fa9775b0" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc07c793-1019-48f6-8b5d-4dc0fa9775b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_fc07c793-1019-48f6-8b5d-4dc0fa9775b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fc07c793-1019-48f6-8b5d-4dc0fa9775b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7741fb02-c80d-4643-8bfc-c87600bc56d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_fc07c793-1019-48f6-8b5d-4dc0fa9775b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7741fb02-c80d-4643-8bfc-c87600bc56d9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonTradeableContingentValueRightMember_43971272-33f0-41b0-a2d9-589f0e7b039a" xlink:href="jnj-20230101.xsd#jnj_NonTradeableContingentValueRightMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7741fb02-c80d-4643-8bfc-c87600bc56d9" xlink:to="loc_jnj_NonTradeableContingentValueRightMember_43971272-33f0-41b0-a2d9-589f0e7b039a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_97aebeb3-4d5c-4774-b463-d0ac6aae1ba9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:to="loc_srt_ProductOrServiceAxis_97aebeb3-4d5c-4774-b463-d0ac6aae1ba9" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_97aebeb3-4d5c-4774-b463-d0ac6aae1ba9_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_97aebeb3-4d5c-4774-b463-d0ac6aae1ba9" xlink:to="loc_srt_ProductsAndServicesDomain_97aebeb3-4d5c-4774-b463-d0ac6aae1ba9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_315fe530-1a0a-4b1a-8049-325e34a316cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_97aebeb3-4d5c-4774-b463-d0ac6aae1ba9" xlink:to="loc_srt_ProductsAndServicesDomain_315fe530-1a0a-4b1a-8049-325e34a316cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImpellaMember_9f3c1277-d085-4ac6-a2de-a596a4cdf810" xlink:href="jnj-20230101.xsd#jnj_ImpellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_315fe530-1a0a-4b1a-8049-325e34a316cf" xlink:to="loc_jnj_ImpellaMember_9f3c1277-d085-4ac6-a2de-a596a4cdf810" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ClassIRecommendationForImpellaMember_cf22d9dd-bcc9-4972-ba80-d7ca010a5f20" xlink:href="jnj-20230101.xsd#jnj_ClassIRecommendationForImpellaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_315fe530-1a0a-4b1a-8049-325e34a316cf" xlink:to="loc_jnj_ClassIRecommendationForImpellaMember_cf22d9dd-bcc9-4972-ba80-d7ca010a5f20" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#LegalProceedingsDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended" id="i8a209124524c41c3ba054e08d6ce9bdb_LegalProceedingsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c9da4494-085f-4879-859d-d46310bb0678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:href="jnj-20230101.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c9da4494-085f-4879-859d-d46310bb0678" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_b32d2906-9215-4b8a-9433-280d1a8c5309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_b32d2906-9215-4b8a-9433-280d1a8c5309" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_4dbb30ad-34f1-4f39-994c-28967e472947" xlink:href="jnj-20230101.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_4dbb30ad-34f1-4f39-994c-28967e472947" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_577855a4-ceb7-4777-b6a1-6f2e6aff3c29" xlink:href="jnj-20230101.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_577855a4-ceb7-4777-b6a1-6f2e6aff3c29" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_d69b115d-7bde-4e80-95d5-0961bd6557bf" xlink:href="jnj-20230101.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_jnj_Numberofpatientsinsettlement_d69b115d-7bde-4e80-95d5-0961bd6557bf" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_84a6de1e-2417-4444-9775-632ca7d05110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_84a6de1e-2417-4444-9775-632ca7d05110" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_8623d0a3-759d-45f5-98e9-1643e66cc79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_8623d0a3-759d-45f5-98e9-1643e66cc79e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_66710e12-e7a9-4284-be68-875fa4977085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_66710e12-e7a9-4284-be68-875fa4977085" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust_3b2fc1f9-1d98-44a0-921e-e1eca63737db" xlink:href="jnj-20230101.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrust_3b2fc1f9-1d98-44a0-921e-e1eca63737db" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_c7903c1f-af0b-43ba-8683-5a2e3995d530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_c7903c1f-af0b-43ba-8683-5a2e3995d530" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_182c3d4e-10bd-46de-b8eb-e5bcc24c42bc" xlink:href="jnj-20230101.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_182c3d4e-10bd-46de-b8eb-e5bcc24c42bc" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyPendingClaimsNumberAdditional_76fa3f1a-35a2-4f79-8495-48c2c46394c3" xlink:href="jnj-20230101.xsd#jnj_LossContingencyPendingClaimsNumberAdditional"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c9da4494-085f-4879-859d-d46310bb0678" xlink:to="loc_jnj_LossContingencyPendingClaimsNumberAdditional_76fa3f1a-35a2-4f79-8495-48c2c46394c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_de8f8f7f-9739-4424-9455-6d784da034bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c9da4494-085f-4879-859d-d46310bb0678" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_de8f8f7f-9739-4424-9455-6d784da034bb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyPendingClaimsNumberRemaining_12462377-806d-4f22-ae76-9cb7ebc260ab" xlink:href="jnj-20230101.xsd#jnj_LossContingencyPendingClaimsNumberRemaining"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_c9da4494-085f-4879-859d-d46310bb0678" xlink:to="loc_jnj_LossContingencyPendingClaimsNumberRemaining_12462377-806d-4f22-ae76-9cb7ebc260ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_c9da4494-085f-4879-859d-d46310bb0678" xlink:to="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9707f016-4e14-42cd-b72a-ccdffb661ece" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:to="loc_srt_LitigationCaseAxis_9707f016-4e14-42cd-b72a-ccdffb661ece" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_9707f016-4e14-42cd-b72a-ccdffb661ece_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_9707f016-4e14-42cd-b72a-ccdffb661ece" xlink:to="loc_srt_LitigationCaseTypeDomain_9707f016-4e14-42cd-b72a-ccdffb661ece_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ae1bdcb2-7731-45cd-bb21-25af84e010fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_9707f016-4e14-42cd-b72a-ccdffb661ece" xlink:to="loc_srt_LitigationCaseTypeDomain_ae1bdcb2-7731-45cd-bb21-25af84e010fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_33375db1-f835-4cf2-b6dd-079396a98b13" xlink:href="jnj-20230101.xsd#jnj_DePuyASRU.S.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ae1bdcb2-7731-45cd-bb21-25af84e010fe" xlink:to="loc_jnj_DePuyASRU.S.Member_33375db1-f835-4cf2-b6dd-079396a98b13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_1cbfa188-8467-454b-b192-57286729a281" xlink:href="jnj-20230101.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ae1bdcb2-7731-45cd-bb21-25af84e010fe" xlink:to="loc_jnj_RisperdalMember_1cbfa188-8467-454b-b192-57286729a281" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_40336d9b-2196-49bc-813c-c7ad93236f10" xlink:href="jnj-20230101.xsd#jnj_BabyPowderMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ae1bdcb2-7731-45cd-bb21-25af84e010fe" xlink:to="loc_jnj_BabyPowderMember_40336d9b-2196-49bc-813c-c7ad93236f10" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_f7e76b0f-2df1-4133-9d87-e02a3884625a" xlink:href="jnj-20230101.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ae1bdcb2-7731-45cd-bb21-25af84e010fe" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_f7e76b0f-2df1-4133-9d87-e02a3884625a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember_3ce420ca-c0be-47f6-aab4-4fc03b4ea5c0" xlink:href="jnj-20230101.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_ae1bdcb2-7731-45cd-bb21-25af84e010fe" xlink:to="loc_jnj_SurgicalMeshProductsMarketingMember_3ce420ca-c0be-47f6-aab4-4fc03b4ea5c0" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_e7c0b3d9-be6f-42b7-b5da-ee2e16bf07bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:to="loc_us-gaap_LitigationStatusAxis_e7c0b3d9-be6f-42b7-b5da-ee2e16bf07bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_e7c0b3d9-be6f-42b7-b5da-ee2e16bf07bd_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_e7c0b3d9-be6f-42b7-b5da-ee2e16bf07bd" xlink:to="loc_us-gaap_LitigationStatusDomain_e7c0b3d9-be6f-42b7-b5da-ee2e16bf07bd_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_3a04dd4c-996c-4616-ab44-3e7cb1e60e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_e7c0b3d9-be6f-42b7-b5da-ee2e16bf07bd" xlink:to="loc_us-gaap_LitigationStatusDomain_3a04dd4c-996c-4616-ab44-3e7cb1e60e05" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_811e5807-9106-4177-93b6-3436dfca45cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_3a04dd4c-996c-4616-ab44-3e7cb1e60e05" xlink:to="loc_us-gaap_SettledLitigationMember_811e5807-9106-4177-93b6-3436dfca45cd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_0b16ef48-7595-46c5-abed-c1410582ee6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_JudicialRulingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_3a04dd4c-996c-4616-ab44-3e7cb1e60e05" xlink:to="loc_us-gaap_JudicialRulingMember_0b16ef48-7595-46c5-abed-c1410582ee6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_c83a2d8e-3bc5-4308-8f8d-a5aa222fb4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_3a04dd4c-996c-4616-ab44-3e7cb1e60e05" xlink:to="loc_us-gaap_PendingLitigationMember_c83a2d8e-3bc5-4308-8f8d-a5aa222fb4a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73bedc8a-a0b4-40db-bfda-a96fac579b15" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:to="loc_srt_ProductOrServiceAxis_73bedc8a-a0b4-40db-bfda-a96fac579b15" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_73bedc8a-a0b4-40db-bfda-a96fac579b15_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_73bedc8a-a0b4-40db-bfda-a96fac579b15" xlink:to="loc_srt_ProductsAndServicesDomain_73bedc8a-a0b4-40db-bfda-a96fac579b15_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_73bedc8a-a0b4-40db-bfda-a96fac579b15" xlink:to="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_bbacd058-69a0-45c8-812d-7f5f799a5e72" xlink:href="jnj-20230101.xsd#jnj_AsrMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:to="loc_jnj_AsrMember_bbacd058-69a0-45c8-812d-7f5f799a5e72" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_dc050cc3-88b5-479e-9e53-de9f448049b4" xlink:href="jnj-20230101.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_dc050cc3-88b5-479e-9e53-de9f448049b4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_22892aa6-0608-46e1-896f-c2220548f9f1" xlink:href="jnj-20230101.xsd#jnj_PelvicMeshesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:to="loc_jnj_PelvicMeshesMember_22892aa6-0608-46e1-896f-c2220548f9f1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_32dd6b55-9bc9-4de3-8869-8fbbbeac13e8" xlink:href="jnj-20230101.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:to="loc_jnj_RisperdalMember_32dd6b55-9bc9-4de3-8869-8fbbbeac13e8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_dd770e2f-c792-4c49-9882-6b3fabbe33a4" xlink:href="jnj-20230101.xsd#jnj_TalcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:to="loc_jnj_TalcMember_dd770e2f-c792-4c49-9882-6b3fabbe33a4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_5c0274a1-fe55-4bca-9dcf-e8a437f1e6d7" xlink:href="jnj-20230101.xsd#jnj_PhysiomeshMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:to="loc_jnj_PhysiomeshMember_5c0274a1-fe55-4bca-9dcf-e8a437f1e6d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_3631cd22-5786-42b8-b199-837a6018401b" xlink:href="jnj-20230101.xsd#jnj_OpioidMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:to="loc_jnj_OpioidMember_3631cd22-5786-42b8-b199-837a6018401b" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElmironMember_587a0fb8-3287-4c62-b5e8-a50af757d1a2" xlink:href="jnj-20230101.xsd#jnj_ElmironMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:to="loc_jnj_ElmironMember_587a0fb8-3287-4c62-b5e8-a50af757d1a2" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_54ebbb46-40e0-4d31-973b-bb77eb07fc95" xlink:href="jnj-20230101.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_54ebbb46-40e0-4d31-973b-bb77eb07fc95" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_54ebbb46-40e0-4d31-973b-bb77eb07fc95_default" xlink:href="jnj-20230101.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_54ebbb46-40e0-4d31-973b-bb77eb07fc95" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_54ebbb46-40e0-4d31-973b-bb77eb07fc95_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_dd7191bd-794c-4aa0-a5a2-0bfc0307ec30" xlink:href="jnj-20230101.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_54ebbb46-40e0-4d31-973b-bb77eb07fc95" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_dd7191bd-794c-4aa0-a5a2-0bfc0307ec30" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_70ffc84d-36ac-40cd-a963-8959417197ad" xlink:href="jnj-20230101.xsd#jnj_RisperdalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_dd7191bd-794c-4aa0-a5a2-0bfc0307ec30" xlink:to="loc_jnj_RisperdalMember_70ffc84d-36ac-40cd-a963-8959417197ad" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_7c6b5e8e-1b1f-4ed5-80b3-2e68a353c30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_7c6b5e8e-1b1f-4ed5-80b3-2e68a353c30d" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_7c6b5e8e-1b1f-4ed5-80b3-2e68a353c30d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_7c6b5e8e-1b1f-4ed5-80b3-2e68a353c30d" xlink:to="loc_us-gaap_LossContingencyNatureDomain_7c6b5e8e-1b1f-4ed5-80b3-2e68a353c30d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_c375ad84-12c9-47d6-a7f6-c76edc5417eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_7c6b5e8e-1b1f-4ed5-80b3-2e68a353c30d" xlink:to="loc_us-gaap_LossContingencyNatureDomain_c375ad84-12c9-47d6-a7f6-c76edc5417eb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_fc0c43ba-0ca8-45b4-ad19-d19cf222980e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_c375ad84-12c9-47d6-a7f6-c76edc5417eb" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_fc0c43ba-0ca8-45b4-ad19-d19cf222980e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_26b573f6-3d42-4eb7-985b-fe6f4c77608a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:to="loc_srt_CounterpartyNameAxis_26b573f6-3d42-4eb7-985b-fe6f4c77608a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26b573f6-3d42-4eb7-985b-fe6f4c77608a_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_26b573f6-3d42-4eb7-985b-fe6f4c77608a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_26b573f6-3d42-4eb7-985b-fe6f4c77608a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b6506c2-460c-47c0-a3fb-d0d166f85c51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_26b573f6-3d42-4eb7-985b-fe6f4c77608a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b6506c2-460c-47c0-a3fb-d0d166f85c51" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RasmussenInstrumentsLLCMember_761c193d-183e-4cb3-8b6b-1cb35f8a517b" xlink:href="jnj-20230101.xsd#jnj_RasmussenInstrumentsLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b6506c2-460c-47c0-a3fb-d0d166f85c51" xlink:to="loc_jnj_RasmussenInstrumentsLLCMember_761c193d-183e-4cb3-8b6b-1cb35f8a517b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#RestructuringNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended" id="i909474b1b5a64044b0dea90fbfd5dc2b_RestructuringNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_29d6113c-95ec-499b-a15e-50c3c59dd94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_5e34b431-e695-4f86-9e2c-22e5f4b1694f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_29d6113c-95ec-499b-a15e-50c3c59dd94a" xlink:to="loc_us-gaap_RestructuringCharges_5e34b431-e695-4f86-9e2c-22e5f4b1694f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_4b7a0a69-ae39-4a63-905d-8f548085d29d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_29d6113c-95ec-499b-a15e-50c3c59dd94a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_4b7a0a69-ae39-4a63-905d-8f548085d29d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_627d8565-6397-4823-b2b8-ffbd385b7fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_29d6113c-95ec-499b-a15e-50c3c59dd94a" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_627d8565-6397-4823-b2b8-ffbd385b7fcd" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a86d33d5-c22a-40b2-80a4-bc3920565985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_627d8565-6397-4823-b2b8-ffbd385b7fcd" xlink:to="loc_us-gaap_RestructuringPlanAxis_a86d33d5-c22a-40b2-80a4-bc3920565985" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_a86d33d5-c22a-40b2-80a4-bc3920565985_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_a86d33d5-c22a-40b2-80a4-bc3920565985" xlink:to="loc_us-gaap_RestructuringPlanDomain_a86d33d5-c22a-40b2-80a4-bc3920565985_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_11ca8db0-75af-4ffc-9314-2cdcfa3469ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_a86d33d5-c22a-40b2-80a4-bc3920565985" xlink:to="loc_us-gaap_RestructuringPlanDomain_11ca8db0-75af-4ffc-9314-2cdcfa3469ad" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_a34193ec-d973-4175-bebd-3efe9316cf5e" xlink:href="jnj-20230101.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_11ca8db0-75af-4ffc-9314-2cdcfa3469ad" xlink:to="loc_jnj_SupplyChainMember_a34193ec-d973-4175-bebd-3efe9316cf5e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_05e47c64-d585-4ee6-a43d-2809187790a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_627d8565-6397-4823-b2b8-ffbd385b7fcd" xlink:to="loc_srt_RangeAxis_05e47c64-d585-4ee6-a43d-2809187790a6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_05e47c64-d585-4ee6-a43d-2809187790a6_default" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_05e47c64-d585-4ee6-a43d-2809187790a6" xlink:to="loc_srt_RangeMember_05e47c64-d585-4ee6-a43d-2809187790a6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82905f87-1213-479a-ae5a-de774a273d08" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_05e47c64-d585-4ee6-a43d-2809187790a6" xlink:to="loc_srt_RangeMember_82905f87-1213-479a-ae5a-de774a273d08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5a135c43-52df-4220-82b5-fc9b56a5f745" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_82905f87-1213-479a-ae5a-de774a273d08" xlink:to="loc_srt_MinimumMember_5a135c43-52df-4220-82b5-fc9b56a5f745" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_936e6a3a-8f82-4ea8-8003-9091a3a69917" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_82905f87-1213-479a-ae5a-de774a273d08" xlink:to="loc_srt_MaximumMember_936e6a3a-8f82-4ea8-8003-9091a3a69917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_83ee8897-1f8f-46a3-821c-adad257806ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_627d8565-6397-4823-b2b8-ffbd385b7fcd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_83ee8897-1f8f-46a3-821c-adad257806ce" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_83ee8897-1f8f-46a3-821c-adad257806ce_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_83ee8897-1f8f-46a3-821c-adad257806ce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_83ee8897-1f8f-46a3-821c-adad257806ce_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_03ed1080-7be9-4232-951e-488b2139fd12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_83ee8897-1f8f-46a3-821c-adad257806ce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_03ed1080-7be9-4232-951e-488b2139fd12" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_1d132cd0-7469-4904-8815-0637fc6e19e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_03ed1080-7be9-4232-951e-488b2139fd12" xlink:to="loc_us-gaap_RestructuringChargesMember_1d132cd0-7469-4904-8815-0637fc6e19e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_04a75dda-7987-4ab6-99bc-9f6623b0fa8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_03ed1080-7be9-4232-951e-488b2139fd12" xlink:to="loc_us-gaap_CostOfSalesMember_04a75dda-7987-4ab6-99bc-9f6623b0fa8f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_e7f965c1-e536-447d-a911-2fc33168658d" xlink:href="jnj-20230101.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_03ed1080-7be9-4232-951e-488b2139fd12" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_e7f965c1-e536-447d-a911-2fc33168658d" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"/>
  <link:definitionLink xlink:role="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" xlink:type="extended" id="i28defde4a06b48ca9ecca4e5667a14a9_RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_d9e21e12-5cff-431a-b0f5-013095380759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_b1cfce26-5d75-43f3-b4ef-e3575b146d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d9e21e12-5cff-431a-b0f5-013095380759" xlink:to="loc_us-gaap_RestructuringReserveRollForward_b1cfce26-5d75-43f3-b4ef-e3575b146d6d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_75368aee-7ab7-4d82-abba-3bad70843867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b1cfce26-5d75-43f3-b4ef-e3575b146d6d" xlink:to="loc_us-gaap_RestructuringReserve_75368aee-7ab7-4d82-abba-3bad70843867" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_8e988aa4-f452-400e-b153-d098e48d8875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b1cfce26-5d75-43f3-b4ef-e3575b146d6d" xlink:to="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_8e988aa4-f452-400e-b153-d098e48d8875" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_aacc6973-9fba-4cfb-9e7e-730751243368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b1cfce26-5d75-43f3-b4ef-e3575b146d6d" xlink:to="loc_us-gaap_RestructuringCharges_aacc6973-9fba-4cfb-9e7e-730751243368" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_a5c505ac-a6f4-4fc8-b41c-eb6c59136337" xlink:href="jnj-20230101.xsd#jnj_GainOnSaleOfAnAssetPaymentForRestructuring"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b1cfce26-5d75-43f3-b4ef-e3575b146d6d" xlink:to="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_a5c505ac-a6f4-4fc8-b41c-eb6c59136337" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_5750faf2-d33b-491f-bb6f-fcfaa41cd936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b1cfce26-5d75-43f3-b4ef-e3575b146d6d" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_5750faf2-d33b-491f-bb6f-fcfaa41cd936" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_263abcb1-c25a-4e30-a520-df5c038d0ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fffac13-fca0-40ce-bc1b-a4693c9f595c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d9e21e12-5cff-431a-b0f5-013095380759" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fffac13-fca0-40ce-bc1b-a4693c9f595c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_8b18abc2-d217-4a26-8ec5-72e65fb1be9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fffac13-fca0-40ce-bc1b-a4693c9f595c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_8b18abc2-d217-4a26-8ec5-72e65fb1be9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_8b18abc2-d217-4a26-8ec5-72e65fb1be9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8b18abc2-d217-4a26-8ec5-72e65fb1be9c" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_8b18abc2-d217-4a26-8ec5-72e65fb1be9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4626811b-11dd-490b-b56c-a0eeb9598046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8b18abc2-d217-4a26-8ec5-72e65fb1be9c" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4626811b-11dd-490b-b56c-a0eeb9598046" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_2d2c6922-276c-4b6c-bd63-990cb4e340f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4626811b-11dd-490b-b56c-a0eeb9598046" xlink:to="loc_us-gaap_EmployeeSeveranceMember_2d2c6922-276c-4b6c-bd63-990cb4e340f9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_652874ab-78d1-4a01-bdb7-0e71963b20d0" xlink:href="jnj-20230101.xsd#jnj_AssetWriteoffMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4626811b-11dd-490b-b56c-a0eeb9598046" xlink:to="loc_jnj_AssetWriteoffMember_652874ab-78d1-4a01-bdb7-0e71963b20d0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_833d6591-c79b-4450-b2cf-22ba4f7834cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4626811b-11dd-490b-b56c-a0eeb9598046" xlink:to="loc_us-gaap_OtherRestructuringMember_833d6591-c79b-4450-b2cf-22ba4f7834cb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_59855e0b-dfb2-4d41-9dbc-87551349f274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fffac13-fca0-40ce-bc1b-a4693c9f595c" xlink:to="loc_us-gaap_RestructuringPlanAxis_59855e0b-dfb2-4d41-9dbc-87551349f274" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_59855e0b-dfb2-4d41-9dbc-87551349f274_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_59855e0b-dfb2-4d41-9dbc-87551349f274" xlink:to="loc_us-gaap_RestructuringPlanDomain_59855e0b-dfb2-4d41-9dbc-87551349f274_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_7b088fc0-0f79-41db-b52d-b259d79349c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_59855e0b-dfb2-4d41-9dbc-87551349f274" xlink:to="loc_us-gaap_RestructuringPlanDomain_7b088fc0-0f79-41db-b52d-b259d79349c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_55e787c0-6a08-4846-9fd9-e7332d9422de" xlink:href="jnj-20230101.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_7b088fc0-0f79-41db-b52d-b259d79349c6" xlink:to="loc_jnj_SupplyChainMember_55e787c0-6a08-4846-9fd9-e7332d9422de" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_42fc314b-9593-4d86-8fae-0014d60e290e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fffac13-fca0-40ce-bc1b-a4693c9f595c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_42fc314b-9593-4d86-8fae-0014d60e290e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_42fc314b-9593-4d86-8fae-0014d60e290e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_42fc314b-9593-4d86-8fae-0014d60e290e" xlink:to="loc_us-gaap_SegmentDomain_42fc314b-9593-4d86-8fae-0014d60e290e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_06950da0-3142-41e6-abce-4696d132cd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_42fc314b-9593-4d86-8fae-0014d60e290e" xlink:to="loc_us-gaap_SegmentDomain_06950da0-3142-41e6-abce-4696d132cd6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_73b5ce3d-5968-41e9-9ad2-cdf96c1a750f" xlink:href="jnj-20230101.xsd#jnj_SupplyChainMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_06950da0-3142-41e6-abce-4696d132cd6f" xlink:to="loc_jnj_SupplyChainMember_73b5ce3d-5968-41e9-9ad2-cdf96c1a750f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="loc_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>jnj-20230101_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:18208529-7e82-4728-be6a-fd0bc0acc451,g:1f111954-4d05-432b-a89f-49b08039c9af-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_e6fd91fd-be0f-4f45-9fa7-f462dfa9ff0f_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_3ab2933a-e833-4a7a-a89e-8b53afc7db3e_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International taxes</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_d365f81d-40f6-4762-bee8-d8baae83417d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of pending claims</link:label>
    <link:label id="lab_us-gaap_LossContingencyPendingClaimsNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPendingClaimsNumber" xlink:to="lab_us-gaap_LossContingencyPendingClaimsNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_51263d5e-6460-4666-b562-c58969dadeda_verboseLabel_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit losses and accounts receivable allowances</link:label>
    <link:label id="lab_us-gaap_ProvisionForDoubtfulAccounts_label_en-US" xlink:label="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Credit Loss Expense (Reversal)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProvisionForDoubtfulAccounts" xlink:to="lab_us-gaap_ProvisionForDoubtfulAccounts" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_41221708-e339-45c8-804e-cf2757a992e7_terseLabel_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_label_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:label id="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_documentation_en-US" xlink:label="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:href="jnj-20230101.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:to="lab_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyPowderMember_9877921d-2ba8-4f27-adb1-aed2d8d121af_terseLabel_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder</link:label>
    <link:label id="lab_jnj_BabyPowderMember_label_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:label id="lab_jnj_BabyPowderMember_documentation_en-US" xlink:label="lab_jnj_BabyPowderMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Powder [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember" xlink:href="jnj-20230101.xsd#jnj_BabyPowderMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyPowderMember" xlink:to="lab_jnj_BabyPowderMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_27bd351e-110e-4dda-b89d-06b616a1812a_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note&#160;8)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings_9080332f-9dca-47f2-8703-b01690110000_terseLabel_en-US" xlink:label="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed foreign earnings</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings_label_en-US" xlink:label="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Undistributed Foreign Earnings</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings_documentation_en-US" xlink:label="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxAssetsUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:to="lab_jnj_DeferredTaxAssetsUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConsumerMember_d6848ac1-7e77-472b-80b3-a8bd1b02b1e3_terseLabel_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Health</link:label>
    <link:label id="lab_jnj_ConsumerMember_label_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer [Member]</link:label>
    <link:label id="lab_jnj_ConsumerMember_documentation_en-US" xlink:label="lab_jnj_ConsumerMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember" xlink:href="jnj-20230101.xsd#jnj_ConsumerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConsumerMember" xlink:to="lab_jnj_ConsumerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeFiveMember_d8c35253-0b1e-4829-b0a7-c8388611c0f4_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$164.63-$165.89</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeFiveMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Five [Member]</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeFiveMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeFiveMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFiveMember" xlink:href="jnj-20230101.xsd#jnj_ExercisePriceRangeFiveMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeFiveMember" xlink:to="lab_jnj_ExercisePriceRangeFiveMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_ed3550ee-56e4-442a-9ef9-ddf73c614fd4_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_a15c2e71-1c22-471a-8b75-aee91177430f_terseLabel_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]</link:label>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_label_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:to="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_87b3f52e-856a-4c13-a29c-0cc868ec8482_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_ec0eb6b6-9ecd-4ecd-86c1-5359fb270527_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense recorded related to TRAF</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:href="jnj-20230101.xsd#jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ADVANCEDMember_064d3d32-8d71-4f59-b612-1c5e2cfd1d3f_terseLabel_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_label_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:label id="lab_jnj_ADVANCEDMember_documentation_en-US" xlink:label="lab_jnj_ADVANCEDMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ADVANCED [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember" xlink:href="jnj-20230101.xsd#jnj_ADVANCEDMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ADVANCEDMember" xlink:to="lab_jnj_ADVANCEDMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_f108b072-0bc5-4b67-92c6-f52101a1f204_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_83bee7c7-a307-45b5-bb17-219c6be0dece_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment, gross</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_f184cfd6-4abd-4e9c-958b-bec298640944_terseLabel_en-US" xlink:label="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of company's common stock directly held in plan assets</link:label>
    <link:label id="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_label_en-US" xlink:label="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Of Company's Common Stock Directly Held In Plan Assets</link:label>
    <link:label id="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_documentation_en-US" xlink:label="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of company's common stock directly held in plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:href="jnj-20230101.xsd#jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:to="lab_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_37b5a706-ae54-4e7c-b1da-1f1ec911a967_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation, nondeductible expense, impairment losses, percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_c14a2951-6479-4a90-a1bb-1bcbba8628d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_43048ccf-8d84-4ebc-bdbe-87a285e1638d_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to Property, Plant &amp; Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAdditions_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNetAbstract_ddfe28ed-aa82-4033-b81d-57658136ddfb_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNetAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNetAbstract" xlink:to="lab_us-gaap_InventoryNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_33afdb1c-af32-47ad-9796-d94f943cade2_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign exchange contracts</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_415772e9-cf0f-4bf7-8260-cb5adebdb5ba_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Forward foreign exchange contracts:</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember" xlink:to="lab_us-gaap_ForeignExchangeContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_732a888e-2094-4a97-9e0d-bfdac531b7e0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2020AcquisitionsMember_6fc1ddda-4559-4410-a51b-9a6c55316de5_terseLabel_en-US" xlink:label="lab_jnj_A2020AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Acquisitions</link:label>
    <link:label id="lab_jnj_A2020AcquisitionsMember_label_en-US" xlink:label="lab_jnj_A2020AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Acquisitions [Member]</link:label>
    <link:label id="lab_jnj_A2020AcquisitionsMember_documentation_en-US" xlink:label="lab_jnj_A2020AcquisitionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2020 Acquisitions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2020AcquisitionsMember" xlink:href="jnj-20230101.xsd#jnj_A2020AcquisitionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2020AcquisitionsMember" xlink:to="lab_jnj_A2020AcquisitionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_35fccc3e-4300-4507-97eb-f6c8312b4afd_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_3fc72fa8-2405-4e64-9330-b52ede4e583e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_a9f51eb3-8902-4d0e-92a7-5e58af52940b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_1bbebbfb-174b-4c9b-86df-c86d924516bd_terseLabel_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_label_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:label id="lab_jnj_CONTACTLENSESOTHERMember_documentation_en-US" xlink:label="lab_jnj_CONTACTLENSESOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONTACT LENSES/OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember" xlink:href="jnj-20230101.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONTACTLENSESOTHERMember" xlink:to="lab_jnj_CONTACTLENSESOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_84f8c52f-c077-4fcd-baae-ed670112e532_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stated interest rate (as a percent)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_c3c845e8-61dd-4d4f-b558-619cd30c17f6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_6de2051d-2871-47ad-be04-fa9dd260d2d1_terseLabel_en-US" xlink:label="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D capitalized for tax</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_label_en-US" xlink:label="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets International Research And Development Capitalized</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_documentation_en-US" xlink:label="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets international research and development capitalized.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:to="lab_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_3cd12d5c-2489-4293-9f31-5384df38396b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Derivative Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_5f7a9a39-0d27-4c1f-8e51-4cc1ced2d3f5_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures&#160;&amp; acquisitions</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:to="lab_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_5ee9786d-f87d-469e-b0f9-b3a91bfb56f9_verboseLabel_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceedings</link:label>
    <link:label id="lab_us-gaap_LegalMattersAndContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Matters and Contingencies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:to="lab_us-gaap_LegalMattersAndContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_4e8047ff-4943-491d-b1b1-ef6a7a7556af_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SkinHealthBeautyMember_9f03eb3d-b56e-4f9b-bc5a-20f4dd937878_terseLabel_en-US" xlink:label="lab_jnj_SkinHealthBeautyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skin health/Beauty</link:label>
    <link:label id="lab_jnj_SkinHealthBeautyMember_label_en-US" xlink:label="lab_jnj_SkinHealthBeautyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skin health/Beauty [Member]</link:label>
    <link:label id="lab_jnj_SkinHealthBeautyMember_documentation_en-US" xlink:label="lab_jnj_SkinHealthBeautyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Skin health/Beauty</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SkinHealthBeautyMember" xlink:href="jnj-20230101.xsd#jnj_SkinHealthBeautyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SkinHealthBeautyMember" xlink:to="lab_jnj_SkinHealthBeautyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_HIPSMember_ebcaf7e5-e3b1-4da7-947e-fd82fb34f50f_terseLabel_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS</link:label>
    <link:label id="lab_jnj_HIPSMember_label_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:label id="lab_jnj_HIPSMember_documentation_en-US" xlink:label="lab_jnj_HIPSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">HIPS [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember" xlink:href="jnj-20230101.xsd#jnj_HIPSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_HIPSMember" xlink:to="lab_jnj_HIPSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UnfundedPlansMember_56661847-ee54-47eb-b197-697331d1ee44_terseLabel_en-US" xlink:label="lab_jnj_UnfundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded Plans</link:label>
    <link:label id="lab_jnj_UnfundedPlansMember_label_en-US" xlink:label="lab_jnj_UnfundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded Plans [Member]</link:label>
    <link:label id="lab_jnj_UnfundedPlansMember_documentation_en-US" xlink:label="lab_jnj_UnfundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unfunded plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnfundedPlansMember" xlink:href="jnj-20230101.xsd#jnj_UnfundedPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UnfundedPlansMember" xlink:to="lab_jnj_UnfundedPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_71d46e69-9a71-418b-b378-b58c360c9b4a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaid_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaid" xlink:to="lab_us-gaap_IncomeTaxesPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_0ecfa0f7-7d28-4bd8-92d9-c9c977d37745_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_d0a1473d-1372-42d4-9a11-c1a9e0820e75_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskTable_a5cb6fd6-1de2-40ab-9926-1067ef40e7b9_terseLabel_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk [Table]</link:label>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskTable_label_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk [Table]</link:label>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskTable_documentation_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskTable" xlink:href="jnj-20230101.xsd#jnj_ConcentrationOfCreditRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable" xlink:to="lab_jnj_ConcentrationOfCreditRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationLineItems_03644d27-1e4c-4570-98e5-5999626dce05_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:label id="lab_dei_DocumentInformationLineItems_label_en-US" xlink:label="lab_dei_DocumentInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationLineItems" xlink:to="lab_dei_DocumentInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_cd92f802-10c0-4afb-ba01-f5d479f0b9b7_verboseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due May 2035</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_d2f29027-fb7f-4b6a-a959-043c076710b6_terseLabel_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes due 2035 (1.5B Euro 1.0651)(2)/(1.5B Euro 1.1311)(3)</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_label_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:label id="lab_jnj_A1.650NotesDue2035Member_documentation_en-US" xlink:label="lab_jnj_A1.650NotesDue2035Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.650% Notes Due 2035 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member" xlink:href="jnj-20230101.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.650NotesDue2035Member" xlink:to="lab_jnj_A1.650NotesDue2035Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NonTradeableContingentValueRightMember_7c941004-61eb-4bb5-81d9-36f02f228127_terseLabel_en-US" xlink:label="lab_jnj_NonTradeableContingentValueRightMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Tradeable Contingent Value Right</link:label>
    <link:label id="lab_jnj_NonTradeableContingentValueRightMember_label_en-US" xlink:label="lab_jnj_NonTradeableContingentValueRightMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Tradeable Contingent Value Right [Member]</link:label>
    <link:label id="lab_jnj_NonTradeableContingentValueRightMember_documentation_en-US" xlink:label="lab_jnj_NonTradeableContingentValueRightMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Tradeable Contingent Value Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonTradeableContingentValueRightMember" xlink:href="jnj-20230101.xsd#jnj_NonTradeableContingentValueRightMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NonTradeableContingentValueRightMember" xlink:to="lab_jnj_NonTradeableContingentValueRightMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_d14028ba-4355-43dd-9fb6-d49ecdebceab_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_292503b8-03e0-4b0f-81c4-27098b4deaeb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WholesalerConcentrationRiskMember_b714f629-bc40-4510-aafc-3742852e9974_terseLabel_en-US" xlink:label="lab_jnj_WholesalerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler Concentration Risk</link:label>
    <link:label id="lab_jnj_WholesalerConcentrationRiskMember_label_en-US" xlink:label="lab_jnj_WholesalerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler Concentration Risk [Member]</link:label>
    <link:label id="lab_jnj_WholesalerConcentrationRiskMember_documentation_en-US" xlink:label="lab_jnj_WholesalerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler Concentration Risk</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WholesalerConcentrationRiskMember" xlink:href="jnj-20230101.xsd#jnj_WholesalerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WholesalerConcentrationRiskMember" xlink:to="lab_jnj_WholesalerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_13428f83-8e67-4f0a-9e9c-a43aeb4d2c4d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">All other (3)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_32a73fa0-cef4-4502-8955-c93668e73255_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:to="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_1f3c6a0f-355d-4025-8ebb-6b5f9a87b7cc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Options Outstanding</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_94f15bde-8c40-4226-955c-643fe3dc11b6_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:href="jnj-20230101.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_2b754722-c251-41f9-b7d7-f0ec8670c16f_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_60a23c50-2178-43e0-8064-9171e60b2d43_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of claims within settlement agreement</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_label_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Claims within Settlement Agreement</link:label>
    <link:label id="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_documentation_en-US" xlink:label="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Number of Claims within Settlement Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:href="jnj-20230101.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:to="lab_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_81f8ece8-c87f-42ea-9937-751a02694987_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_us-gaap_SubsequentEventTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentRollForward_fe5231d9-5ffe-4821-9fbd-83ed7eba0444_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_label_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:label id="lab_jnj_EquityInvestmentRollForward_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investment [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward" xlink:href="jnj-20230101.xsd#jnj_EquityInvestmentRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentRollForward" xlink:to="lab_jnj_EquityInvestmentRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_edff33d0-4e1c-4d81-8a83-ffdc6d60cb1f_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of basic net earnings per share to diluted net earnings per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_3bcba75a-e35b-4c46-9716-513bcac12d2b_terseLabel_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_label_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:label id="lab_jnj_OTHERNEUROSCIENCEMember_documentation_en-US" xlink:label="lab_jnj_OTHERNEUROSCIENCEMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTHER NEUROSCIENCE [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember" xlink:href="jnj-20230101.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTHERNEUROSCIENCEMember" xlink:to="lab_jnj_OTHERNEUROSCIENCEMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_4cd3ae34-ba65-48a8-9a9e-be3a5217dcdd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c921109e-8a39-4514-8ce1-6b03c84bb826_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding number of Options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_0c8bf093-1c2b-44cb-9b07-3eb609739e1d_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to current year tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_c86c46d3-4c19-4e56-b466-7a14c4f223a4_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, estimate of possible loss</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_cae953f8-7624-47bd-8dd3-79cf4f684247_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_0f7ee3e2-25c4-4411-9088-8d7e5f49b467_terseLabel_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Income Tax Contingencies [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:to="lab_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_369b5cbc-c7cb-49c6-ab82-a2cb6c68f2c7_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax rates:</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyDomain_2dbce3d6-ca4b-4db5-8fcd-0bc2b293f731_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyDomain_label_en-US" xlink:label="lab_us-gaap_RelatedPartyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyDomain" xlink:to="lab_us-gaap_RelatedPartyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PhysiomeshMember_f3df262d-b392-406d-8770-2ba1c1e99a64_terseLabel_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_label_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:label id="lab_jnj_PhysiomeshMember_documentation_en-US" xlink:label="lab_jnj_PhysiomeshMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Physiomesh [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember" xlink:href="jnj-20230101.xsd#jnj_PhysiomeshMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PhysiomeshMember" xlink:to="lab_jnj_PhysiomeshMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A055NotesDue2025Member_6ad519ee-2777-4c77-98e2-49744297b41c_terseLabel_en-US" xlink:label="lab_jnj_A055NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.55% Notes due 2025</link:label>
    <link:label id="lab_jnj_A055NotesDue2025Member_label_en-US" xlink:label="lab_jnj_A055NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.55% Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A055NotesDue2025Member_documentation_en-US" xlink:label="lab_jnj_A055NotesDue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.55% Notes due 2025</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A055NotesDue2025Member" xlink:href="jnj-20230101.xsd#jnj_A055NotesDue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A055NotesDue2025Member" xlink:to="lab_jnj_A055NotesDue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_081c8e3b-804c-4a9b-abe6-3b99f6afc331_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4646153b-3197-44eb-8050-aa787f5c3481_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1fbb1cf2-31ae-4c8e-bac0-6274b416eae0_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_9e504b8f-05fc-4299-8f32-5208bf3a936b_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain" xlink:to="lab_us-gaap_HedgingDesignationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_af74b3bf-8b72-440b-829b-e3069d3810a4_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_4960eb64-b67a-4f65-970a-5fc0fb3264a1_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets at fair value&#160;&#8212; beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_82892f19-e4ae-4ddd-aad2-f4fd9d4091be_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan assets at fair value&#160;- End of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_9868270d-ee47-446c-bfb1-8dd3c8d850f7_terseLabel_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95%&#160;Notes due 2029</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_label_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:label id="lab_jnj_A6.95Notesdue2029Member_documentation_en-US" xlink:label="lab_jnj_A6.95Notesdue2029Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.95% Notes due 2029 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member" xlink:href="jnj-20230101.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.95Notesdue2029Member" xlink:to="lab_jnj_A6.95Notesdue2029Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_28ac7cf0-df5b-4c45-806d-7f07faf9550c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_b159bdfa-815a-4eb9-ba6a-0ec85fd33646_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow data</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_baf4c9f2-519d-4932-b0f8-da3f36606dc4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled/forfeited, average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_2951f146-a7e9-4509-a17f-ab6225939837_negatedLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of liabilities assumed</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_5c2a4726-362d-435c-8cc7-491fb1af991d_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt_4cda2621-a0a9-4e5c-b8f1-29d4ab3be9be_terseLabel_en-US" xlink:label="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of carrying value over fair value of debt</link:label>
    <link:label id="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt_label_en-US" xlink:label="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Of Carrying Value Over Fair Value Of Debt</link:label>
    <link:label id="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt_documentation_en-US" xlink:label="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Of Carrying Value Over Fair Value Of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:href="jnj-20230101.xsd#jnj_ExcessOfCarryingValueOverFairValueOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:to="lab_jnj_ExcessOfCarryingValueOverFairValueOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_daa982aa-f06d-42b3-87fb-aed9853b65ca_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments with Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:href="jnj-20230101.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_72b9a5d7-8917-49c3-bf85-743534266f70_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_7e27fa1d-a301-4453-8cf4-38a570705b85_terseLabel_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere excluding U.S.&#160;</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_label_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:label id="lab_jnj_WesternHemisphereExcludingUSMember_documentation_en-US" xlink:label="lab_jnj_WesternHemisphereExcludingUSMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Western Hemisphere, excluding U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember" xlink:href="jnj-20230101.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WesternHemisphereExcludingUSMember" xlink:to="lab_jnj_WesternHemisphereExcludingUSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_8520979e-f41f-4a87-b83c-5c0488640afb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Undistributed foreign earnings</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_abe77a7f-bcae-4ee3-9942-2894e0bbf672_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_788e291e-d134-40eb-b316-022f7f57ddb2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ErleadaMember_9a9165c4-f910-437d-9384-e148bd21ce79_terseLabel_en-US" xlink:label="lab_jnj_ErleadaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ERLEADA</link:label>
    <link:label id="lab_jnj_ErleadaMember_label_en-US" xlink:label="lab_jnj_ErleadaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erleada [Member]</link:label>
    <link:label id="lab_jnj_ErleadaMember_documentation_en-US" xlink:label="lab_jnj_ErleadaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Erleada</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ErleadaMember" xlink:href="jnj-20230101.xsd#jnj_ErleadaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ErleadaMember" xlink:to="lab_jnj_ErleadaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_a5ff9f83-bf95-4830-a3fd-f2fa21f0b306_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actuarial (gains) losses(1)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_47f42508-ffe1-4689-bc51-41f5b7a64afe_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_f06b31f9-151f-4482-b63c-c8bb677ddf18_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_442d1ac2-ee37-4579-9c1b-d5361a28f13b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total loss/(income) recognized in other comprehensive income, before tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_5b4c5dd2-ef16-4213-b158-b3b718b259b1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_fbb5745d-1d83-41c8-97ee-cb2230e2f737_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from divestiture of brands</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_5f6e5d7f-a637-48f5-99d8-bd7ec583d6d1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits on share-based compensation</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_5068642e-23e5-4d73-9ae3-942cca8bbc6c_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits from loss on capital assets</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_de22e565-ad67-432f-a86e-8a682e039298_negatedTerseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax benefits from loss on capital assets</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Capital Loss</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Capital Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_05e000b4-dfb6-4401-a0ec-70c9728fd28c_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt (Note&#160;7)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_68c4e199-2997-4894-a499-ffbbb95ec436_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyPendingClaimsNumberRemaining_2469f61f-ff31-4375-b511-9bb0c6b22a30_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyPendingClaimsNumberRemaining" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number, Remaining</link:label>
    <link:label id="lab_jnj_LossContingencyPendingClaimsNumberRemaining_label_en-US" xlink:label="lab_jnj_LossContingencyPendingClaimsNumberRemaining" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number, Remaining</link:label>
    <link:label id="lab_jnj_LossContingencyPendingClaimsNumberRemaining_documentation_en-US" xlink:label="lab_jnj_LossContingencyPendingClaimsNumberRemaining" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Pending Claims, Number, Remaining</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyPendingClaimsNumberRemaining" xlink:href="jnj-20230101.xsd#jnj_LossContingencyPendingClaimsNumberRemaining"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyPendingClaimsNumberRemaining" xlink:to="lab_jnj_LossContingencyPendingClaimsNumberRemaining" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_9002149c-12a1-42cd-b213-6c2481b9df06_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_7ed2cf5e-ba2e-46f7-8125-953b89ea04d6_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_3827f509-9ec0-4adc-9b78-8e470e6eb53b_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Time deposits</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember" xlink:to="lab_us-gaap_BankTimeDepositsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_71a0bb9c-54cf-488c-bb43-e652d0ab70e9_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the disposal of assets/businesses, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfProductiveAssets_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:to="lab_us-gaap_ProceedsFromSaleOfProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_31c41bbb-8841-4ac8-b339-bf5dee7defad_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_0f24fae6-cee4-4b40-8d01-d6a3dce2b31d_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_09195f9c-6a57-49b7-8daa-6059b0ab37b1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_e5b65b9d-638b-4c78-ba79-5c30c3af74a9_terseLabel_en-US" xlink:label="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONSUMER HEALTH and PHARMACEUTICAL</link:label>
    <link:label id="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_label_en-US" xlink:label="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONSUMER HEALTH and PHARMACEUTICAL [Member]</link:label>
    <link:label id="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_documentation_en-US" xlink:label="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONSUMER HEALTH and PHARMACEUTICAL</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:href="jnj-20230101.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:to="lab_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_febc6bb7-2e85-4263-9b0c-1c617fc27152_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service cost (credit)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_118ccab9-3479-4307-a2b5-da57dec493b2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_235bca5b-be7f-4cb2-83fa-2fcff31cbf54_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_aa509547-4f84-4cf8-b89b-b3f00e4c2120_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeOneMember_c35182b5-a91b-4aba-85d5-e6def62811c5_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$72.54-$100.48</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeOneMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range One Member</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeOneMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise price range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeOneMember" xlink:href="jnj-20230101.xsd#jnj_ExercisePriceRangeOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeOneMember" xlink:to="lab_jnj_ExercisePriceRangeOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_775cf250-d4cc-41cd-81b2-733d9dd672ed_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) On Securities</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_a1ba4aa9-771c-4981-b6f0-211f1d378ef1_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currently payable:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_2dd78255-9788-4269-9f03-b4c17cb3e6de_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_f6ef75f7-1023-4ee6-bf56-1471b7b06c48_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, percentage of ownership before transaction</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Percentage of Ownership before Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:to="lab_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DePuyASRU.S.Member_fafa34ab-f956-4c7c-9b09-635c45b741cc_terseLabel_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S.</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_label_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:label id="lab_jnj_DePuyASRU.S.Member_documentation_en-US" xlink:label="lab_jnj_DePuyASRU.S.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DePuy ASR U.S. [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member" xlink:href="jnj-20230101.xsd#jnj_DePuyASRU.S.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DePuyASRU.S.Member" xlink:to="lab_jnj_DePuyASRU.S.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_e7e0eba9-1d89-4655-8655-1ced4f829e5a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A095NotesDue2027Member_71c6df67-f2c5-48c1-9b2c-4b1d5e853090_terseLabel_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_label_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A095NotesDue2027Member_documentation_en-US" xlink:label="lab_jnj_A095NotesDue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.95% Notes due 2027</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member" xlink:href="jnj-20230101.xsd#jnj_A095NotesDue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A095NotesDue2027Member" xlink:to="lab_jnj_A095NotesDue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_8fb00b7d-1365-4849-8720-b919c34aea83_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of the assets</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_c757b430-f1da-480f-9a01-b4c4ca874605_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity, unrecognized loss</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_66c87b32-a792-4ecd-93de-2a5539bc0406_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SupplyChainMember_6543a357-55db-41d3-8b27-4d77dea3e398_terseLabel_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain</link:label>
    <link:label id="lab_jnj_SupplyChainMember_label_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain [Member]</link:label>
    <link:label id="lab_jnj_SupplyChainMember_documentation_en-US" xlink:label="lab_jnj_SupplyChainMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supply Chain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember" xlink:href="jnj-20230101.xsd#jnj_SupplyChainMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SupplyChainMember" xlink:to="lab_jnj_SupplyChainMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_ea37045f-6642-45b2-93e2-7d04fadcc71f_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax provision</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_a0e4ff8d-bd1e-4bf5-80c2-e4eb0373e767_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_143a649e-d5ac-4c70-9228-3fa9fc1310d5_terseLabel_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.375Notesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.375Notesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.375% Notes due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member" xlink:href="jnj-20230101.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.375Notesdue2033Member" xlink:to="lab_jnj_A4.375Notesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_d78191c1-8449-4ceb-b71c-dea1ce1fff2c_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid employee related obligations</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_33cfecd6-105c-44d0-8ad6-c1b89d8b8a97_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_45f1de65-2d5a-4a79-87e4-a8710d055842_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_482283c1-8480-46d7-8d71-9c7eabad4881_terseLabel_en-US" xlink:label="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans</link:label>
    <link:label id="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_label_en-US" xlink:label="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Estimated Future Employer Contributions [Table Text Block]</link:label>
    <link:label id="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of estimated future employer contributions.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:href="jnj-20230101.xsd#jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:to="lab_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesReturnReserve_c48c25fa-158b-4109-9a9c-124d996829e2_terseLabel_en-US" xlink:label="lab_jnj_SalesReturnReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return reserve (as a percent)</link:label>
    <link:label id="lab_jnj_SalesReturnReserve_label_en-US" xlink:label="lab_jnj_SalesReturnReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Return Reserve</link:label>
    <link:label id="lab_jnj_SalesReturnReserve_documentation_en-US" xlink:label="lab_jnj_SalesReturnReserve" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales return reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesReturnReserve" xlink:href="jnj-20230101.xsd#jnj_SalesReturnReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesReturnReserve" xlink:to="lab_jnj_SalesReturnReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_1443585e-9bc6-4014-b516-9f133714d98a_terseLabel_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing</link:label>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_label_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing [Member]</link:label>
    <link:label id="lab_jnj_SurgicalMeshProductsMarketingMember_documentation_en-US" xlink:label="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgical Mesh Products Marketing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember" xlink:href="jnj-20230101.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgicalMeshProductsMarketingMember" xlink:to="lab_jnj_SurgicalMeshProductsMarketingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_866aead3-d375-4956-9e1d-bc8d6e73af38_terseLabel_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, fair value adjustment</link:label>
    <link:label id="lab_us-gaap_EquityFairValueAdjustment_label_en-US" xlink:label="lab_us-gaap_EquityFairValueAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityFairValueAdjustment" xlink:to="lab_us-gaap_EquityFairValueAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_de468be6-a849-4e72-a6f3-f6d012dc6f21_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_ff509efd-834d-4495-b93d-fda443c216fd_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_7a4b57c6-2c3a-431c-8869-bab32318b229_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_930e9715-deb5-493a-906c-a52a0b501263_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_cd624af1-24a0-47b2-9f96-436ffbca9fbc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefit plans:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_58c27340-8d57-4fad-96f4-4a0f28d5f9f7_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights_e946e572-69f5-4c37-b3e6-25c52058fe29_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued subject to stock options or stock appreciation rights (in shares)</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Stock Options Or Stock Appreciation Rights</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Stock Options Or Stock Appreciation Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" xlink:to="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_1a0c8672-41aa-4f7d-bc88-2e6d034465f2_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_77093dad-a88b-44be-a549-94539a30dc51_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion of long term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_c1fe4ede-8bcc-44d8-b60c-d478348744fc_terseLabel_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-lived Intangible Assets Acquired</link:label>
    <link:label id="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1_label_en-US" xlink:label="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:to="lab_us-gaap_FinitelivedIntangibleAssetsAcquired1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_a476c116-38fc-425a-89cc-db3fdb136fd1_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_952eda78-6e92-4102-81bf-1aab889224bb_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_dbe39ac0-206d-4dd4-b659-5f1e769df588_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss) on divestiture</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfBusiness_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Disposition of Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfBusiness" xlink:to="lab_us-gaap_GainLossOnSaleOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_74419543-7fd3-40f7-9606-35e423b69005_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan with accumulated benefit obligation in excess of plan assets, plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LandAndLeaseholdImprovementsMember_c68ea876-32f6-44e7-a480-02e9bd576ca3_terseLabel_en-US" xlink:label="lab_jnj_LandAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and leasehold improvements</link:label>
    <link:label id="lab_jnj_LandAndLeaseholdImprovementsMember_label_en-US" xlink:label="lab_jnj_LandAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land And Leasehold Improvements [Member]</link:label>
    <link:label id="lab_jnj_LandAndLeaseholdImprovementsMember_documentation_en-US" xlink:label="lab_jnj_LandAndLeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Land and leasehold improvements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember" xlink:href="jnj-20230101.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LandAndLeaseholdImprovementsMember" xlink:to="lab_jnj_LandAndLeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_4c05d0e1-1222-47a8-9a8d-7c2b63e55837_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_85e97b03-0b76-43e4-9379-893bb7586495_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other receivables</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_3bd96c8b-67fa-4f04-934d-1ced0bc6b0c7_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year Two</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year two.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_33821884-cc91-4e8b-8a25-21b95aed5658_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_33a3567b-a903-4781-a2b8-b76f3ad8a2d2_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, held-to-maturity</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities" xlink:to="lab_us-gaap_HeldToMaturitySecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_bf7fc50a-cdc6-4f8a-97cf-0877a0731157_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_01d420f3-b7c8-4098-b2e8-2848a46b958a_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_2c1c33d6-1b32-47b6-ac0b-622521f7d38e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_b44cc0bc-fc91-43da-ba84-c99582ce2345_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_4fc2fad5-a4ef-4b42-b61c-4e143ee2ef48_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_63395245-b5fb-4e28-95a1-a35a677aef69_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_66f3ab0a-824b-4d8c-9929-d8f1f85fbe39_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service credit (cost), net of amortization</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:href="jnj-20230101.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_648eb443-a6ba-4375-a35d-48be9d7c46ba_terseLabel_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_label_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:label id="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_documentation_en-US" xlink:label="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:href="jnj-20230101.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:to="lab_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_7ed7ba75-9205-4c30-9a34-e4b1c12fc50d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_1c6e65ab-b08e-45dd-a034-b8445a75f7b9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for Income Taxes</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_fc5029cf-5a38-4765-98ee-d1fdde73dbca_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Assets and Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_94fff1fc-200c-4cbb-8a8f-35ef1c83249a_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average period for total compensation cost not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_27332091-8b38-400a-b2f7-c3653e3285ce_terseLabel_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_label_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular Cup System [Member]</link:label>
    <link:label id="lab_jnj_PinnacleAcetabularCupSystemMember_documentation_en-US" xlink:label="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pinnacle Acetabular cup system.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:href="jnj-20230101.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PinnacleAcetabularCupSystemMember" xlink:to="lab_jnj_PinnacleAcetabularCupSystemMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_af5f20e5-579e-4089-ad38-5a8cf799ae18_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain" xlink:to="lab_us-gaap_RestructuringPlanDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_b92f6b7a-4aa1-4cb9-bdd9-fe814f625cfd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled non cash</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveSettledWithoutCash2_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Settled without Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:to="lab_us-gaap_RestructuringReserveSettledWithoutCash2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_58c504f1-b917-4610-bc2f-b04b3742ed94_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_ac903258-fe34-4d16-97b5-526e8ab296e6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_1323445d-c40a-4cd9-b140-eb62defd4cd2_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_848cc87d-5a83-4341-b903-0d4f882363fc_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_1bb415d6-21fd-4126-8660-914132ce520d_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TCJA, provisional liability</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:href="jnj-20230101.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_34bc81dd-a8db-4a4c-b9d8-d2df0906a719_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_7986ce20-3d23-408d-8585-045b4d768064_terseLabel_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50%&#160;Debentures due 2040</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_label_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Debenturesdue2040Member_documentation_en-US" xlink:label="lab_jnj_A4.50Debenturesdue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Debentures due 2040 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member" xlink:href="jnj-20230101.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Debenturesdue2040Member" xlink:to="lab_jnj_A4.50Debenturesdue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_2237646f-5afd-45ea-b53a-342078ffabcc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_304842e0-d719-4ca4-8936-3c8df9e35800_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Range, Maximum (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_97d558f3-c070-4ea9-93c7-90e8bb7b6e45_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid from plan</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_476bd91f-ee6d-49e6-8cb3-2d66b4c9b4f8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in intangible assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Intangible Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:to="lab_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Wholesaler3Member_fba0180e-5df2-4794-8f00-47070ba9ca3d_terseLabel_en-US" xlink:label="lab_jnj_Wholesaler3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 3</link:label>
    <link:label id="lab_jnj_Wholesaler3Member_label_en-US" xlink:label="lab_jnj_Wholesaler3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 3 [Member]</link:label>
    <link:label id="lab_jnj_Wholesaler3Member_documentation_en-US" xlink:label="lab_jnj_Wholesaler3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler3Member" xlink:href="jnj-20230101.xsd#jnj_Wholesaler3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Wholesaler3Member" xlink:to="lab_jnj_Wholesaler3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_fed160f2-3d76-40ae-aa69-3a54c5963722_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pensions and Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_8f6a1ad4-94f2-4083-8c8e-58c01d30c310_terseLabel_en-US" xlink:label="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, tax basis increase of certain assets due to reorganization</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_label_en-US" xlink:label="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_documentation_en-US" xlink:label="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:to="lab_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsAxis_90bed933-fcd0-4cdf-b3d2-4922591efbfe_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis" xlink:to="lab_us-gaap_SubsegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_64e7f554-09eb-4e53-82a8-47e4fb22f251_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_552d43a6-5894-4050-bde3-b190aa522651_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_161dc636-6ca5-4ed0-aeaa-cacfc383d6e5_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShippingandHandlingCostsasaPercentofSales_2fc43283-5490-4108-b2fe-75338ecaa9fe_terseLabel_en-US" xlink:label="lab_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and handling costs as a percent of sales</link:label>
    <link:label id="lab_jnj_ShippingandHandlingCostsasaPercentofSales_label_en-US" xlink:label="lab_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling Costs as a Percent of Sales</link:label>
    <link:label id="lab_jnj_ShippingandHandlingCostsasaPercentofSales_documentation_en-US" xlink:label="lab_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling Costs as a Percent of Sales</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:href="jnj-20230101.xsd#jnj_ShippingandHandlingCostsasaPercentofSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:to="lab_jnj_ShippingandHandlingCostsasaPercentofSales" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_7ba3cc24-2eb2-4e4c-9429-23676b2aad56_terseLabel_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_label_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:label id="lab_jnj_SimponiSimponiAriaMember_documentation_en-US" xlink:label="lab_jnj_SimponiSimponiAriaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Simponi/Simponi Aria [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember" xlink:href="jnj-20230101.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SimponiSimponiAriaMember" xlink:to="lab_jnj_SimponiSimponiAriaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_9d5429c1-531a-4d04-8f89-4e4610aa8ef9_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Principles of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_4e4d517d-77f7-48a2-b75d-57abc7b776e2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_35569f76-dc9a-49f6-816b-a2ee77ae0863_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital and Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockTextBlock_label_en-US" xlink:label="lab_us-gaap_TreasuryStockTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockTextBlock" xlink:to="lab_us-gaap_TreasuryStockTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_e661e36d-02ab-4e5d-af81-f7f90e37f4a8_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_4a525028-e99e-4983-b6bf-219c82a6db89_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2f1e5ab3-ec7d-40cb-b17a-c91ece910ad6_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_07198cec-6018-4e80-8580-466416a1e022_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, par value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_XareltoMember_d80d7155-4f77-4c4c-a404-e793c50c20dd_terseLabel_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">XARELTO</link:label>
    <link:label id="lab_jnj_XareltoMember_label_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:label id="lab_jnj_XareltoMember_documentation_en-US" xlink:label="lab_jnj_XareltoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Xarelto [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember" xlink:href="jnj-20230101.xsd#jnj_XareltoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_XareltoMember" xlink:to="lab_jnj_XareltoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_29e7827a-b484-4272-91d3-585e0ee9c044_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_88cbc295-3ef5-4cac-95ee-9e77c16a6658_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_d3b5d362-0beb-49c7-bad8-c7a8552929c2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_58aae5e7-c6db-4205-a90d-87c681d500e0_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_df33a133-8ded-4f4b-aa3e-321ba758ffb7_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_7eecec61-ab44-41a5-8d75-b5ac0ae4490c_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year Three</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year three.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_86dcace2-87cd-4ab9-86f4-3566b9fe399f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_46e07963-8be8-432c-a45b-9b3c326d88c9_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_b454aab0-7b11-458a-8ba1-187d471e5241_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_f40dbf4d-650d-429b-a96f-582faacd2337_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_83b8d7d5-921a-4fac-afeb-f8e51ec590e2_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_56917cec-7a0a-459b-91bd-1847adbf09d5_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock option average life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_1793bda8-d0a3-4168-870b-b92bd1fad882_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding, Average Life</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RasmussenInstrumentsLLCMember_db6376ed-7a59-4884-af98-b40c7a714b03_terseLabel_en-US" xlink:label="lab_jnj_RasmussenInstrumentsLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rasmussen Instruments, LLC</link:label>
    <link:label id="lab_jnj_RasmussenInstrumentsLLCMember_label_en-US" xlink:label="lab_jnj_RasmussenInstrumentsLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rasmussen Instruments, LLC [Member]</link:label>
    <link:label id="lab_jnj_RasmussenInstrumentsLLCMember_documentation_en-US" xlink:label="lab_jnj_RasmussenInstrumentsLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rasmussen Instruments, LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RasmussenInstrumentsLLCMember" xlink:href="jnj-20230101.xsd#jnj_RasmussenInstrumentsLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RasmussenInstrumentsLLCMember" xlink:to="lab_jnj_RasmussenInstrumentsLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_bef95061-b785-44c5-a94f-f4fdc7951a84_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International taxes</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_eba22e6e-4ddd-4e36-948d-4236afbe3009_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_71c68c28-7307-4296-8b38-572136cc3f87_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_9b85a24d-70be-4da2-a949-0e4abce9664a_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_27dbe7c2-02e4-4463-902d-a15b24f10e66_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_8cdde313-cec1-478a-967f-af725a9c4784_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_6f747f73-caf8-4c77-8072-b83055baba4d_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions and Divestitures</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ZYTIGAMember_d973df3f-106b-497f-8a22-df6e898bb302_terseLabel_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA/abiraterone acetate</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_label_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:label id="lab_jnj_ZYTIGAMember_documentation_en-US" xlink:label="lab_jnj_ZYTIGAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ZYTIGA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember" xlink:href="jnj-20230101.xsd#jnj_ZYTIGAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ZYTIGAMember" xlink:to="lab_jnj_ZYTIGAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_d6a3091c-876e-4e60-b050-439a634b3205_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_29b985e2-f7f3-4cbf-90d7-e11d5a04a789_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending Balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_30a78522-a77d-4078-8238-aa5d15013989_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk (as a percent)</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_974e7268-d679-4a5e-b31a-4f6d5f8bedc5_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring costs incurred since announced</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_f91d9989-b5ea-42a3-bf88-dff747e1063b_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions (7)</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Liabilities Incurred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_33571974-a345-4875-ab11-c53bdabbd3f3_verboseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Intangible Assets and Goodwill</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:href="jnj-20230101.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:to="lab_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_0213c0d4-39da-4a75-9966-9431e2efc29e_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_68c39a8e-5233-4624-b52c-e47c21390811_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_ffecc0ef-9f52-422d-a3ba-90e7b963a68b_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_d4c4092e-ca19-485b-85ea-8fcc3e9690f6_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherNonLongLivedAssets_f2e940fe-4dbf-431d-b1a8-9cce55bc965d_terseLabel_en-US" xlink:label="lab_jnj_OtherNonLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non Long Lived Assets</link:label>
    <link:label id="lab_jnj_OtherNonLongLivedAssets_label_en-US" xlink:label="lab_jnj_OtherNonLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Non Long Lived Assets</link:label>
    <link:label id="lab_jnj_OtherNonLongLivedAssets_documentation_en-US" xlink:label="lab_jnj_OtherNonLongLivedAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other non long lived assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonLongLivedAssets" xlink:href="jnj-20230101.xsd#jnj_OtherNonLongLivedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherNonLongLivedAssets" xlink:to="lab_jnj_OtherNonLongLivedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_af773f76-c324-40f0-98d4-9171702742fc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assumed Health Care Cost Trend Rates</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Health Care Cost Trend Rates [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_8e215fe7-1973-427f-ae54-8db3761103e6_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_16598c8a-1d62-49c8-b465-34fce8546eaf_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic net earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_710c6ef5-56bf-455f-869e-9912a534a0ae_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without readily determinable value</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_label_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:label id="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments without Readily Determinable Value [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:href="jnj-20230101.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:to="lab_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_8cbf4be4-abe5-4fd4-aa25-b73f2c068eae_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:to="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_b928226c-1c36-4108-bf28-992241f85f84_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value of RSU or PSU units settled</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_f756ae3c-21f2-450e-b03f-86911ee7f64c_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember" xlink:to="lab_us-gaap_CorporateNonSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_000fb4fd-d59b-40a6-bb24-67a763c74026_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred compensation</link:label>
    <link:label id="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Compensation Liability, Current and Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_2be453b7-a090-4184-af1e-7160c690d37d_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation contingency</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesSoughtValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Sought, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesSoughtValue" xlink:to="lab_us-gaap_LossContingencyDamagesSoughtValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_74518841-2ecc-49b8-bbe6-78fb7d417efb_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_ff66a4e4-f24c-407a-b3a8-6640a0c38ae1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after five years through ten years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_95527b5c-302c-4fba-b9b7-100a43cd0c38_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net actuarial (gain) loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VerbSurgicalIncMember_0d1485da-02fd-48a1-bd22-a1a4f0f38df2_terseLabel_en-US" xlink:label="lab_jnj_VerbSurgicalIncMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verb Surgical Inc.</link:label>
    <link:label id="lab_jnj_VerbSurgicalIncMember_label_en-US" xlink:label="lab_jnj_VerbSurgicalIncMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verb Surgical Inc. [Member]</link:label>
    <link:label id="lab_jnj_VerbSurgicalIncMember_documentation_en-US" xlink:label="lab_jnj_VerbSurgicalIncMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Verb Surgical Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalIncMember" xlink:href="jnj-20230101.xsd#jnj_VerbSurgicalIncMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VerbSurgicalIncMember" xlink:to="lab_jnj_VerbSurgicalIncMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SurgeryMember_bf2ea432-cc22-4f9f-b9b4-0a0439ebe2a4_terseLabel_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery</link:label>
    <link:label id="lab_jnj_SurgeryMember_label_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:label id="lab_jnj_SurgeryMember_documentation_en-US" xlink:label="lab_jnj_SurgeryMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Surgery [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember" xlink:href="jnj-20230101.xsd#jnj_SurgeryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SurgeryMember" xlink:to="lab_jnj_SurgeryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_113f09d6-a239-4c0b-89c4-e5e60a57a5cb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_1b3a8031-c8bb-4b96-963d-4b0716a61d82_terseLabel_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_HeldtomaturitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Held-to-Maturity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldtomaturitySecuritiesMember" xlink:to="lab_us-gaap_HeldtomaturitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_59c07c92-be16-4a56-b767-e500635804f3_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_00b9645a-68e4-4977-b504-af8ead2c71ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_ab549d61-23bc-4498-a864-f1d969951c36_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in assets and liabilities, net of effects from acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_2df4a674-c4a8-4b7a-ade1-9a621eb68224_terseLabel_en-US" xlink:label="lab_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:label id="lab_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_label_en-US" xlink:label="lab_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:label id="lab_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_documentation_en-US" xlink:label="lab_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:href="jnj-20230101.xsd#jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="lab_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EmployeeCompensationPeriod_2b039a54-f9cb-420b-b705-09154ac7aa52_terseLabel_en-US" xlink:label="lab_jnj_EmployeeCompensationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement plan benefits Employee compensation Period</link:label>
    <link:label id="lab_jnj_EmployeeCompensationPeriod_label_en-US" xlink:label="lab_jnj_EmployeeCompensationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Compensation Period</link:label>
    <link:label id="lab_jnj_EmployeeCompensationPeriod_documentation_en-US" xlink:label="lab_jnj_EmployeeCompensationPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Compensation Period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeCompensationPeriod" xlink:href="jnj-20230101.xsd#jnj_EmployeeCompensationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EmployeeCompensationPeriod" xlink:to="lab_jnj_EmployeeCompensationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_36ea002b-7c56-48b6-b098-427b1b776ed0_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_d5476c5a-802b-401c-bc93-8e009117a903_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_AvailableforsaleSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-Sale Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableforsaleSecuritiesMember" xlink:to="lab_us-gaap_AvailableforsaleSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_1e63b08a-ab9c-4e4c-aa6a-111eae1f361c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsLineItems_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems" xlink:to="lab_us-gaap_CashAndCashEquivalentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ElmironMember_c6bb3a72-53e8-42ee-9dac-2ab69394bdc1_terseLabel_en-US" xlink:label="lab_jnj_ElmironMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elmiron</link:label>
    <link:label id="lab_jnj_ElmironMember_label_en-US" xlink:label="lab_jnj_ElmironMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elmiron [Member]</link:label>
    <link:label id="lab_jnj_ElmironMember_documentation_en-US" xlink:label="lab_jnj_ElmironMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Elmiron</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElmironMember" xlink:href="jnj-20230101.xsd#jnj_ElmironMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ElmironMember" xlink:to="lab_jnj_ElmironMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusDomain_de6a1b30-9320-46ea-86a9-68d894ad44ec_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain" xlink:to="lab_us-gaap_LitigationStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_606bc2b8-c5de-433f-af42-304fa33e0da4_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, realized gain (loss)</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_1ef3bd0f-188f-456e-9926-92bd8aa1ce76_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_34add476-f168-47ae-9ffd-ef737306bb31_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_eb6be1ad-0c5d-4489-8aca-4025401ace4a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">After 2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, after Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_be1f56ca-cb26-4cdd-b1f3-827ab2e77e99_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_6d3776e9-912a-4bae-8e8f-292a329a4505_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_ee615f1e-8dab-4b68-b3a4-6f7186af0a56_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities, noncurrent</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesNoncurrent" xlink:to="lab_us-gaap_MarketableSecuritiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_dc70e749-5832-4510-b8b3-94ba378d11cc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_351bb164-dfc7-4ee9-9e34-510d90e15f97_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_ab6e4a3a-b247-485a-a3e2-b68fec833ecb_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_d877ddbe-e5cb-445b-8440-6b13403c3bab_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDisclosureTextBlock_c7328c8e-30f9-449f-8030-a50014eb53ca_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Currency Transalation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:to="lab_us-gaap_ForeignCurrencyDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_3630c6c2-4f17-40ef-afa2-1f6367efde3b_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets by Major Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_VisionMember_b657d1c3-fc7d-4285-b092-5b63d201c180_terseLabel_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision</link:label>
    <link:label id="lab_jnj_VisionMember_label_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision [Member]</link:label>
    <link:label id="lab_jnj_VisionMember_documentation_en-US" xlink:label="lab_jnj_VisionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vision[Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember" xlink:href="jnj-20230101.xsd#jnj_VisionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_VisionMember" xlink:to="lab_jnj_VisionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TrademarksMember_8ceed5ab-2c76-43b5-bc24-04658e75f151_terseLabel_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks</link:label>
    <link:label id="lab_us-gaap_TrademarksMember_label_en-US" xlink:label="lab_us-gaap_TrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TrademarksMember" xlink:to="lab_us-gaap_TrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_3f40ca1c-8882-405d-9964-7715fe72dcd3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_ee6358f1-794f-4635-bf5b-d848f8359efc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options average price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2022LongTermIncentivePlanMember_7bf6837a-eb25-4d26-a6da-83d427c7212f_terseLabel_en-US" xlink:label="lab_jnj_A2022LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Long-Term Incentive Plan</link:label>
    <link:label id="lab_jnj_A2022LongTermIncentivePlanMember_label_en-US" xlink:label="lab_jnj_A2022LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Long-Term Incentive Plan [Member]</link:label>
    <link:label id="lab_jnj_A2022LongTermIncentivePlanMember_documentation_en-US" xlink:label="lab_jnj_A2022LongTermIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022 Long-Term Incentive Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2022LongTermIncentivePlanMember" xlink:href="jnj-20230101.xsd#jnj_A2022LongTermIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2022LongTermIncentivePlanMember" xlink:to="lab_jnj_A2022LongTermIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_adab18b8-8782-4db5-b494-409cd1cc20a2_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year Four</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year four.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_e0a23e40-9d75-4b23-80bb-61d8a2216c46_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignPlanMember_0bebb837-9c80-43b6-a2b0-89c87d73f06a_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International Plans</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember" xlink:to="lab_us-gaap_ForeignPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_1cb84b05-064d-44c0-8d35-5e5fdb737644_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Asset Amortization Expense</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_22cf78c3-b6a0-4ad0-a5cc-941639fdad01_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_4e353924-86b6-4fbf-8b37-eef7996b2726_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_d874c856-4ec7-4963-8f7d-700137449828_terseLabel_en-US" xlink:label="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (decrease) in deferred tax liabilities, global intangible low-taxed income (GILTI)</link:label>
    <link:label id="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_label_en-US" xlink:label="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)</link:label>
    <link:label id="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_documentation_en-US" xlink:label="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:href="jnj-20230101.xsd#jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:to="lab_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GENERALMember_049a38f0-cf08-4ded-8f85-f3a778205c6c_terseLabel_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL</link:label>
    <link:label id="lab_jnj_GENERALMember_label_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:label id="lab_jnj_GENERALMember_documentation_en-US" xlink:label="lab_jnj_GENERALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GENERAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember" xlink:href="jnj-20230101.xsd#jnj_GENERALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GENERALMember" xlink:to="lab_jnj_GENERALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_394e4468-ea30-4d94-847b-870ca3a57f03_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_b8dcdd1c-ccfb-478e-a1a3-b96b848dfd6f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesTable_9e908bd5-8687-486e-bd4e-53e44fad5c40_verboseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable" xlink:to="lab_us-gaap_LossContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_dfe6bd1d-a1b9-434c-814d-9d996b9fb1af_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total currently payable</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_ab4c8d34-889e-43c5-ab98-416697706a60_terseLabel_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_label_en-US" xlink:label="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="lab_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShortTermInvestmentFundsMember_dc693561-35f8-4644-ae90-fe4944803019_terseLabel_en-US" xlink:label="lab_jnj_ShortTermInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investment funds</link:label>
    <link:label id="lab_jnj_ShortTermInvestmentFundsMember_label_en-US" xlink:label="lab_jnj_ShortTermInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short Term Investment Funds [Member]</link:label>
    <link:label id="lab_jnj_ShortTermInvestmentFundsMember_documentation_en-US" xlink:label="lab_jnj_ShortTermInvestmentFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short term investment funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShortTermInvestmentFundsMember" xlink:href="jnj-20230101.xsd#jnj_ShortTermInvestmentFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShortTermInvestmentFundsMember" xlink:to="lab_jnj_ShortTermInvestmentFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_d4539cd6-d006-4f2b-9851-ce6674c18626_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Conversion of debt</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_9e787afb-407b-4fd2-ba74-8aca95441377_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Restricted Share Units</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_ee9e6b89-d936-4a0e-a807-cc3502ab10c7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase in inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationStatusAxis_a7541f00-cfff-4f3a-b6bc-2152f2203b0d_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis" xlink:to="lab_us-gaap_LitigationStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_f6ba0230-0217-4d21-b1cc-34fac1cf6ab0_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_e3a31793-cdc4-47fa-9b09-e09715846ef4_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities without readily determinable fair value, amount</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentInformationTable_cc4286f5-1224-48da-bcad-eb14a27d18f8_terseLabel_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:label id="lab_dei_DocumentInformationTable_label_en-US" xlink:label="lab_dei_DocumentInformationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Information [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentInformationTable" xlink:to="lab_dei_DocumentInformationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_13d224ad-47a0-49e8-812a-3ab7c6aa8890_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill (Notes&#160;1 and 5)</link:label>
    <link:label id="lab_us-gaap_Goodwill_b5e6a88a-3c72-4911-b855-434b5568e2b6_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill beginning of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_864a165d-464f-49bd-909c-3bb435cd518a_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill end of period</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_5f76b9fe-b3f9-45df-bf8f-071bec51e2cc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EmployeeObligations_2e6140a7-9830-4b8d-ab02-842e861f4df2_totalLabel_en-US" xlink:label="lab_jnj_EmployeeObligations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total employee obligations</link:label>
    <link:label id="lab_jnj_EmployeeObligations_label_en-US" xlink:label="lab_jnj_EmployeeObligations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Obligations</link:label>
    <link:label id="lab_jnj_EmployeeObligations_documentation_en-US" xlink:label="lab_jnj_EmployeeObligations" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total employee obligations current and non current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeObligations" xlink:href="jnj-20230101.xsd#jnj_EmployeeObligations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EmployeeObligations" xlink:to="lab_jnj_EmployeeObligations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockShares_787ba3f8-e865-4f25-abc0-97bd2048d11b_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock, shares</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_c30c1863-7af0-4740-91a1-bb4e09209a74_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, beginning balance (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_d1701d8d-774e-4526-aa2e-3d85fdb65100_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, ending balance (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares" xlink:to="lab_us-gaap_TreasuryStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2a8381ad-0dac-45c1-bc69-5f9d6d9a2ccc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_7071e673-8200-40b5-b965-e7d10a30b223_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Actual return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_55e60d73-c71e-4ba8-988d-e50e07a2b596_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income (Note&#160;8)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c596826d-6788-430a-b266-0c8f9c3865ff_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_832f192a-e850-40e5-89d6-d8dc743e5cf6_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Incremental tax costs</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_f5754e98-719c-4d4f-8c80-96142b61e1c9_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_732f6493-49b5-46c6-9ca1-a0586d37e2ec_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes on income (Note 8)</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_fb2f4668-4d19-477e-9e18-8757e416c623_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_b6d8e757-5af2-469d-986f-deee28aa3389_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AcquisitionCosts_abbabca8-678e-49ae-8070-5f715cbe1aac_terseLabel_en-US" xlink:label="lab_us-gaap_AcquisitionCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Costs, Period Cost</link:label>
    <link:label id="lab_us-gaap_AcquisitionCosts_label_en-US" xlink:label="lab_us-gaap_AcquisitionCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition Costs, Period Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquisitionCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquisitionCosts" xlink:to="lab_us-gaap_AcquisitionCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_c031ea1b-e4ba-4f2d-aa57-21bdebe7d00c_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ImmunologyMember_920d706e-c021-43f4-9934-592de5b38655_terseLabel_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology</link:label>
    <link:label id="lab_jnj_ImmunologyMember_label_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:label id="lab_jnj_ImmunologyMember_documentation_en-US" xlink:label="lab_jnj_ImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember" xlink:href="jnj-20230101.xsd#jnj_ImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ImmunologyMember" xlink:to="lab_jnj_ImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_f0b83a5e-c53b-4b59-81d8-df2f30735166_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilities_9c3424e0-6df1-475e-bc07-f254e1efebb7_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities" xlink:to="lab_us-gaap_DerivativeLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0e977caa-1e9a-412b-8037-3afb4d20cb9a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes_d89e3117-1dce-4f3f-8fe1-b1cd213c64db_terseLabel_en-US" xlink:label="lab_us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Results of Operations, Income before Income Taxes</link:label>
    <link:label id="lab_us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Results of Operations, Income before Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes" xlink:to="lab_us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_3788cafa-3362-4e7f-b481-078339dd186a_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount of the Hedged Liability</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_f27c3f27-4848-4459-b2c8-a3c151e3a6bf_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gross Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_5fc7c912-cba7-4298-b98a-084c4f182af0_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems" xlink:to="lab_us-gaap_LossContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_2e497803-8f9f-477d-8775-fb541bbd8e4c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_cdd54e2b-a5a3-4621-874a-5e56078e6e1d_terseLabel_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_documentation_en-US" xlink:label="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:href="jnj-20230101.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:to="lab_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_c6189e10-78ff-480d-933f-303cc91a476e_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock&#160;&#8212; par value $1.00 per share (Note&#160;12) (authorized 4,320,000,000&#160;shares; issued 3,119,843,000&#160;shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringChargesMember_f0836c94-fd1d-4798-96d6-01b21ab4a972_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesMember_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesMember" xlink:to="lab_us-gaap_RestructuringChargesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_2cfdc0f4-88d2-4460-a9f8-ba85ce59a78a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_49a5cc9e-2e78-48ca-b9c5-f6573362fda4_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProfitLossPercentToSales_4c7e2001-6963-4ac7-b879-93f6da377cc4_terseLabel_en-US" xlink:label="lab_jnj_ProfitLossPercentToSales" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of profit share payments (less than)</link:label>
    <link:label id="lab_jnj_ProfitLossPercentToSales_label_en-US" xlink:label="lab_jnj_ProfitLossPercentToSales" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit Loss Percent To Sales</link:label>
    <link:label id="lab_jnj_ProfitLossPercentToSales_documentation_en-US" xlink:label="lab_jnj_ProfitLossPercentToSales" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profit loss percent to sales.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProfitLossPercentToSales" xlink:href="jnj-20230101.xsd#jnj_ProfitLossPercentToSales"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProfitLossPercentToSales" xlink:to="lab_jnj_ProfitLossPercentToSales" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeFourMember_6db71065-0ff3-4c76-ae0d-9093c7a77336_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$151.41-$164.62</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeFourMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Four [Member]</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeFourMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFourMember" xlink:href="jnj-20230101.xsd#jnj_ExercisePriceRangeFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeFourMember" xlink:to="lab_jnj_ExercisePriceRangeFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_232f4c5e-01ca-4712-8558-8aa9500cdd4e_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less current benefits payable</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_a48932a0-1592-4376-8a57-6dfcde106376_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_9471e8b4-da55-4ee9-8080-cb27c1f4a94c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated benefit obligation unfunded plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_d0ad4b6c-f2f1-435a-bb37-d20280a4178d_verboseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due May 2024</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_f5b60cc8-c841-41c2-ad43-211e08b83161_terseLabel_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes due 2024 (750MM Euro 1.0651)(2)/(750MM Euro 1.1311)(3)</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A0.650NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A0.650NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.650% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member" xlink:href="jnj-20230101.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0.650NotesDue2024Member" xlink:to="lab_jnj_A0.650NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_34b34460-5100-4d70-8553-b76313ddbaa3_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, beginning of year (Note&#160;1)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9ff7dbc1-a5eb-4ba9-ae4b-b2e47a685f8a_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents, end of year (Note&#160;1)</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_c7707a2b-c619-47ec-a52e-e7c0e763ee66_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WomensHealthMember_e2df9df5-3cf2-4f16-bc0a-b715c880b94f_terseLabel_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health</link:label>
    <link:label id="lab_jnj_WomensHealthMember_label_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:label id="lab_jnj_WomensHealthMember_documentation_en-US" xlink:label="lab_jnj_WomensHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Women's Health [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember" xlink:href="jnj-20230101.xsd#jnj_WomensHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WomensHealthMember" xlink:to="lab_jnj_WomensHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_71659ae5-48aa-4445-b3d6-b7b404363ea9_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor_e865f347-e2e9-4e6c-a8d1-08a566c53606_terseLabel_en-US" xlink:label="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Probability of success factor</link:label>
    <link:label id="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor_label_en-US" xlink:label="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Probability Of Success Factor</link:label>
    <link:label id="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor_documentation_en-US" xlink:label="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Probability Of Success Factor</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:href="jnj-20230101.xsd#jnj_BusinessCombinationProbabilityOfSuccessFactor"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:to="lab_jnj_BusinessCombinationProbabilityOfSuccessFactor" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_0d703f0e-d0bc-4920-bc1e-3c44785e8afc_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_us-gaap_RetirementPlanTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_f9d715d8-b077-4400-b4c8-47ef39d601c5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4997e2d7-3363-415d-87e4-f9c9b41841ef_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options outstanding and exercisable</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Abstract]</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share based compensation shares authorized under stock option plans by exercise price range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:to="lab_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_d4b2c238-f128-4685-a9a9-59312f6f57c6_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_1bd85935-e59f-4969-8d57-5791d65b61dc_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_0c5aeb68-455b-4e92-b6d9-0c66b546a064_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueHedgingMember_8fbbed27-07ca-4ae2-80c7-d170e6519880_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging</link:label>
    <link:label id="lab_us-gaap_FairValueHedgingMember_label_en-US" xlink:label="lab_us-gaap_FairValueHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueHedgingMember" xlink:to="lab_us-gaap_FairValueHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_6a3f656a-6096-4aab-a33f-dc148fe2e498_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_d19d9b77-42bc-4a3c-9bdf-ad6e92c5cbe6_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis" xlink:to="lab_us-gaap_InvestmentTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4daee117-5ff0-444e-885b-d09482673c53_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_d48ab7d4-c218-4969-a9af-5dbf12e82137_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_bac8e923-53e5-4ae9-8449-481df0d5e9b1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_bfb1a63a-579e-4a82-b715-b36a8071587f_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, related to acquisitions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OPSUMITMember_6349498f-278c-43eb-ad80-d10484232c60_terseLabel_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT</link:label>
    <link:label id="lab_jnj_OPSUMITMember_label_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:label id="lab_jnj_OPSUMITMember_documentation_en-US" xlink:label="lab_jnj_OPSUMITMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OPSUMIT [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember" xlink:href="jnj-20230101.xsd#jnj_OPSUMITMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OPSUMITMember" xlink:to="lab_jnj_OPSUMITMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_77711e2c-7dcb-4144-ab01-22abbb6ff5c9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_1fa9ae71-9ab7-4f4a-b4f4-1b228ec61625_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in progress</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember" xlink:to="lab_us-gaap_ConstructionInProgressMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_04e90f88-2c39-4eef-8c28-58d03e8b2d10_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_2b92c7a6-381d-4237-b48e-a0bb0f187fcc_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax liability, acquisition</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_6d147148-f46b-48d6-a886-498767b7051f_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_e37488ed-8a47-464f-9d8e-0a6cdc93ec88_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets, noncurrent</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_847ce1db-c017-47e8-9fd7-061cd442f445_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_569ad33b-bb1d-4320-953b-0ffdcdae3dfe_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of option activity under the Plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_9c71f3e8-18cc-4f5d-813c-aed01d199568_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options exercisable</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A0.250NotesDue2022Member_7c7380b0-fc82-4194-8761-2ca08aef85bd_terseLabel_en-US" xlink:label="lab_jnj_A0.250NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes due 2022 (1B Euro 1.1311)(3)</link:label>
    <link:label id="lab_jnj_A0.250NotesDue2022Member_label_en-US" xlink:label="lab_jnj_A0.250NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes Due 2022 [Member]</link:label>
    <link:label id="lab_jnj_A0.250NotesDue2022Member_documentation_en-US" xlink:label="lab_jnj_A0.250NotesDue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">0.250% Notes Due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member" xlink:href="jnj-20230101.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A0.250NotesDue2022Member" xlink:to="lab_jnj_A0.250NotesDue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_11882024-6e79-4a68-84f3-fed70aebba5e_verboseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and amortization of property and intangibles</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8e2970cb-578e-49e2-8ee2-e24cd7bea9e5_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_eaa37b38-c981-43a0-9317-08e4cd7cc63b_terseLabel_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.90%&#160;Notes due 2028</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_label_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A2.900Notesdue2028Member_documentation_en-US" xlink:label="lab_jnj_A2.900Notesdue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.900% Notes due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member" xlink:href="jnj-20230101.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.900Notesdue2028Member" xlink:to="lab_jnj_A2.900Notesdue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_ae8fa833-2b1f-4c1d-b542-59423de6a6a0_terseLabel_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_label_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:label id="lab_jnj_UNITEDSTATESExportsMember_documentation_en-US" xlink:label="lab_jnj_UNITEDSTATESExportsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES Exports [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember" xlink:href="jnj-20230101.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UNITEDSTATESExportsMember" xlink:to="lab_jnj_UNITEDSTATESExportsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_1482464c-c530-4674-9428-3b8a8a0b5d6c_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_b0740b8e-c15f-49e3-be97-a7a33cd6bc5d_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. taxes on international income</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation Related To Domestic Tax On International Income</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation related to domestic tax on international income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_d8e8de28-d6d8-48a9-bd5e-fef022b07fc6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_529c8194-f646-4d1c-b805-9b2ddc87092f_terseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchase price over fair value of assets acquired</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Including Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetIncludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_c2de055c-bf44-4431-897a-dc4b5b26d94b_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_a815e9c0-f849-4f3a-87e0-5e6659711d42_terseLabel_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of fair value over carrying value of debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_label_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess Of Fair Value Over Carrying Value Of Debt</link:label>
    <link:label id="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt_documentation_en-US" xlink:label="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Excess of fair value over carrying value of debt.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:href="jnj-20230101.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:to="lab_jnj_ExcessOfFairValueOverCarryingValueOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_1ddd41c8-1aa5-4f8f-a3d4-723c0480ca9d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_949571d6-a9fa-42ae-b306-a75a60fb86dc_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_05e6db6d-7445-4a6e-9764-3e6bc9595a32_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid for operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_175096d4-2c62-4bc3-aeba-7d3db3b6f3f1_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_1c9eee59-c103-40a3-bc71-296bf1a4206a_terseLabel_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95%&#160;Debentures due 2033</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_label_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:label id="lab_jnj_A4.95Debenturesdue2033Member_documentation_en-US" xlink:label="lab_jnj_A4.95Debenturesdue2033Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.95% Debentures due 2033 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member" xlink:href="jnj-20230101.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.95Debenturesdue2033Member" xlink:to="lab_jnj_A4.95Debenturesdue2033Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_KNEESMember_fd0b24d1-e442-47f7-a930-d73669b43961_terseLabel_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES</link:label>
    <link:label id="lab_jnj_KNEESMember_label_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:label id="lab_jnj_KNEESMember_documentation_en-US" xlink:label="lab_jnj_KNEESMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">KNEES [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember" xlink:href="jnj-20230101.xsd#jnj_KNEESMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_KNEESMember" xlink:to="lab_jnj_KNEESMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_b5701dd8-cd35-4537-8faa-4dcebef48c48_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_513e853a-51cf-4f8d-8473-7269d6c932c9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticPlanMember_f0bed169-c033-404a-980e-6a534f1d9c00_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember" xlink:to="lab_us-gaap_DomesticPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValue_66e3382d-fd16-4bdb-942b-0b5530819375_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: common stock held in treasury, at cost (Note&#160;12) (506,246,000&#160;shares and 490,878,000&#160;shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_27ce179b-e575-4eee-8af0-2337b658333b_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Balance</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_a8f6a63c-0081-4851-ad23-2b06479bcd37_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Ending Balance</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue" xlink:to="lab_us-gaap_TreasuryStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMember_3f720c39-ff4f-4ad4-aabb-8740cf718731_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember" xlink:to="lab_us-gaap_LongTermDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_899d0e03-b4dc-4697-90f4-bdf75bb1ea43_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_1895a860-53ac-42ae-bd6a-fe1c3ede06c7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_8ba81d67-f18e-4c9a-b550-0b55db215ebb_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Assets, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_1f5500a9-a4f8-4ada-8b0a-d9ec7e12fb04_verboseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowances for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_1a1e1bf7-3734-429a-ac9f-cd8b522804eb_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Benefit Obligation</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Over (Under) Funded Status ABO</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan over (under) funded status ABO</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanOverUnderFundedStatusABO"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:to="lab_jnj_DefinedBenefitPlanOverUnderFundedStatusABO" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_217d281c-3ece-40da-abc2-0781ec1697b0_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_dd0f52c2-d936-462c-8cc8-5d0a36516e84_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_64388542-8fdf-4472-b59e-773eda60303c_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_83b1a29e-4e06-42d2-9de9-fe4aaa87f7dd_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued taxes on income (Note 8)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_2816891d-7f42-4a8b-963f-f3640040ad7c_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_65050111-5980-477d-8af9-c625cbd32407_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_9dfd73ce-71fb-4d78-9a3c-18ecbc4a4068_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Derivatives not Designated as Hedging Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives Not Designated as Hedging Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_a7b31ee7-b156-4232-bc5b-be8d2c521015_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents (Notes&#160;1 and 2)</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_da19677a-2d7f-4fbf-9674-f096f8b60118_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_ab34a5ae-450a-4c70-bbe5-fb97a4271491_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_419fc6ff-0444-4320-9ddd-a522b915a956_terseLabel_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency, number of claimants</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_label_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability Contingency Number Of Claimant</link:label>
    <link:label id="lab_jnj_ProductLiabilityContingencyNumberOfClaimant_documentation_en-US" xlink:label="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability contingency number of claimant.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:href="jnj-20230101.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:to="lab_jnj_ProductLiabilityContingencyNumberOfClaimant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_4edfd9a1-c68e-4f0b-989f-174d1f1c1dc9_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_cd548692-8c5b-4c80-864d-63455b9c4b1a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_87d8ca65-16e2-4dad-9422-8ec41ff0ae8c_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Currency translation/other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_6997eb89-f314-4d8c-91b0-56103ecdaaa1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_3272f7ff-f807-41f0-a0d4-de2f6e0f4fbc_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_92b442c6-11c1-4f9d-844b-b8d6a4502ed0_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Benefit Costs [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTranslationAbstract_1aed3950-1bb0-456f-9f2d-54fbd7f3149d_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTranslationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation [Abstract]</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTranslationAbstract_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTranslationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTranslationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTranslationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTranslationAbstract" xlink:to="lab_us-gaap_ForeignCurrencyTranslationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_a1c7151d-3f39-4a4e-9adf-13d845b205bc_terseLabel_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET</link:label>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_label_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET [Member]</link:label>
    <link:label id="lab_jnj_INVOKANAINVOKAMETMember_documentation_en-US" xlink:label="lab_jnj_INVOKANAINVOKAMETMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVOKANA/INVOKAMET [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember" xlink:href="jnj-20230101.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_INVOKANAINVOKAMETMember" xlink:to="lab_jnj_INVOKANAINVOKAMETMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_47cc890b-d19b-412b-801e-fd87b06cdf04_terseLabel_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400%&#160;Notes due 2038</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_label_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A3.400Notesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A3.400Notesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.400% Notes due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member" xlink:href="jnj-20230101.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.400Notesdue2038Member" xlink:to="lab_jnj_A3.400Notesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_b2234fba-b7f0-41db-94ac-c4604b037f1e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of Plan Assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_2c555df8-1824-4f55-9855-aa8a65734aa0_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax expense related to TRAF</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:href="jnj-20230101.xsd#jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_bd496f2b-f95b-4b5d-986e-c0886601fe05_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total income tax benefit recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_0bc3a91c-d4d5-43c0-a106-0b22920bf9f7_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Increase)/Decrease in accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermBorrowings_3a331dfa-d19a-4c74-8fbb-26722e1bd0e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans and notes payable (Note&#160;7)</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_7531d151-2fd1-4c8f-ba48-5622a625e6cd_verboseLabel_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loans and notes payable</link:label>
    <link:label id="lab_us-gaap_ShortTermBorrowings_label_en-US" xlink:label="lab_us-gaap_ShortTermBorrowings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermBorrowings" xlink:to="lab_us-gaap_ShortTermBorrowings" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_31066276-a3e4-4d39-a967-aba4608335b3_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_0e982d38-c078-4850-85e6-c397569d9637_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_16e77d5c-51a5-43d1-a4bb-b0f34b786cf0_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_ae712f60-6d8c-42e2-b49f-f62908448af2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_4d76a7ea-5356-4fa9-ac70-e51e9a1a9f87_verboseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments of Business and Geographic Areas</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_f6ebc068-feb3-493f-9cf5-2c41957db11a_terseLabel_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:label id="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis_label_en-US" xlink:label="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Security Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="lab_us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_09f69837-c97f-488b-911e-49eddd830e25_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_cef98fe7-5f16-487b-917f-4548f9c0b01d_verboseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due November 2024</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_b9c9b8a5-afbe-4a4e-b819-44bcfa6a12cc_terseLabel_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50%&#160;Notes due 2024 (500MM 1.2037 GBP )(2)/(500MM GBP 1.3485)(3)</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_label_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:label id="lab_jnj_A5.50NotesDue2024Member_documentation_en-US" xlink:label="lab_jnj_A5.50NotesDue2024Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.50% Notes Due 2024 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member" xlink:href="jnj-20230101.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.50NotesDue2024Member" xlink:to="lab_jnj_A5.50NotesDue2024Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_d1015b54-eb8c-4718-b13a-19b4910385f4_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RisperdalMember_1863daee-deb1-4597-ab7c-479ec2d4b2f1_terseLabel_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal</link:label>
    <link:label id="lab_jnj_RisperdalMember_label_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal [Member]</link:label>
    <link:label id="lab_jnj_RisperdalMember_documentation_en-US" xlink:label="lab_jnj_RisperdalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risperdal.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember" xlink:href="jnj-20230101.xsd#jnj_RisperdalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RisperdalMember" xlink:to="lab_jnj_RisperdalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_261e6d09-0d32-479a-a979-29bd48cf927b_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Current Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_3cd57db3-9ad7-48a5-9314-c9d7eb0c5643_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding (Notes 1 and 15)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_2054eb7e-fccc-4d3b-9aaa-eb4e89a34519_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories (Notes&#160;1 and 3)</link:label>
    <link:label id="lab_us-gaap_InventoryNet_6c84f2d4-9ce1-4e76-8ad6-8196ae383911_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_63ea5032-5da2-4fb6-82d3-b31c2627317e_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_26966dcb-3e86-434f-904f-4ba03cb99578_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherOncologyMember_131571c1-6331-4fdb-9717-5f88281b7c60_terseLabel_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_label_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:label id="lab_jnj_OtherOncologyMember_documentation_en-US" xlink:label="lab_jnj_OtherOncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember" xlink:href="jnj-20230101.xsd#jnj_OtherOncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherOncologyMember" xlink:to="lab_jnj_OtherOncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9feb8722-84ce-4e49-8d84-a6b54258b259_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_76b5c235-30a3-433b-9c70-9dbcfcc14828_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding&#160;&#8212; basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_77259f1a-7edb-43c0-817e-ce8a965875bd_terseLabel_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73%&#160;Debentures due 2023</link:label>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_label_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A6.73Debenturesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A6.73Debenturesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">6.73% Debentures due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member" xlink:href="jnj-20230101.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A6.73Debenturesdue2023Member" xlink:to="lab_jnj_A6.73Debenturesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_cb78006f-20e8-4183-a761-070abce2ec72_terseLabel_en-US" xlink:label="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense, including the amortization of capitalized interest</link:label>
    <link:label id="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_label_en-US" xlink:label="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation Expense Including Amortization Of Capitalized Interest</link:label>
    <link:label id="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_documentation_en-US" xlink:label="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation expense including the amortization of capitalized interest.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:href="jnj-20230101.xsd#jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:to="lab_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_c1b4f544-fefe-4520-aa5d-640b08c619dc_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_8690ce96-9370-4e3c-a28c-17861cfc8417_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with indefinite lives:</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_b77ee3af-b972-44f8-8341-8d761f0d5630_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Target Allocation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_fe37cd99-c874-40ea-932e-b22506bcfed3_negatedTerseLabel_en-US" xlink:label="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Global intangible low-taxed income</link:label>
    <link:label id="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_label_en-US" xlink:label="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Global Intangible Low-Taxed Income</link:label>
    <link:label id="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_documentation_en-US" xlink:label="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liability, Global Intangible Low-Taxed Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:to="lab_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_5a7d052b-9eef-4cb7-94af-45846275e9c6_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_8de5213a-9db0-41a0-ac30-0b4cd04b3829_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock&#160;&#8212; without par value (authorized and unissued 2,000,000&#160;shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_e9ee5e33-628a-402f-9e6b-83723f04b65b_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Healthcare cost trend rate assumed for next year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:to="lab_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_76d7827d-85db-443f-9eea-957398a86dc2_terseLabel_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA</link:label>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_label_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA [Member]</link:label>
    <link:label id="lab_jnj_RISPERDALCONSTAMember_documentation_en-US" xlink:label="lab_jnj_RISPERDALCONSTAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">RISPERDAL CONSTA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember" xlink:href="jnj-20230101.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RISPERDALCONSTAMember" xlink:to="lab_jnj_RISPERDALCONSTAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BermekimabMember_17080148-af58-4442-96d0-e03efcb18de9_terseLabel_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab</link:label>
    <link:label id="lab_jnj_BermekimabMember_label_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab [Member]</link:label>
    <link:label id="lab_jnj_BermekimabMember_documentation_en-US" xlink:label="lab_jnj_BermekimabMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">bermekimab</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember" xlink:href="jnj-20230101.xsd#jnj_BermekimabMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BermekimabMember" xlink:to="lab_jnj_BermekimabMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_1cec3e37-4505-4190-8b0c-91ac5c6ebb44_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_1afd8274-bc5f-439e-a3f2-6ee0ebffacb4_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_6444e000-9777-4e07-95c9-d689963c0843_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtCurrent_02e77e0d-fba0-4de4-ac56-0295af4da6ab_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term borrowings and the current portion of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_label_en-US" xlink:label="lab_us-gaap_DebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent" xlink:to="lab_us-gaap_DebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PendingLitigationMember_f05e1948-7171-4450-8020-e85db7052849_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember" xlink:to="lab_us-gaap_PendingLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_acfeac6b-ac44-4279-ad15-b81d3bbe85a4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_9e877449-5b26-446a-a87e-6b215d721c5a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_a3804116-ede4-4160-a73c-63025d1be62d_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_9bcd41ae-8518-4e34-b080-cd05b58546f0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable number of Options (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_709c0a1f-d957-47b4-977f-b38b53944844_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_31afdd4e-235f-4f41-9eee-f6555aebb572_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Stock Option Plans and Stock Compensation Agreements</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_6aa1eff1-d041-4d6e-af16-867249c89437_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_0cabe146-0b25-4f43-8c69-c794699a4f0d_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goods in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_fdcff290-d510-41aa-9604-2cd27d9be285_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value, held-to-maturity</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Held-to-Maturity, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ChangesInTreasuryStockRollForward_75cd01ea-8893-4c7d-893b-7e7ac63fb1e5_terseLabel_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in treasury stock</link:label>
    <link:label id="lab_jnj_ChangesInTreasuryStockRollForward_label_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Treasury Stock [Roll Forward]</link:label>
    <link:label id="lab_jnj_ChangesInTreasuryStockRollForward_documentation_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in treasury stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockRollForward" xlink:href="jnj-20230101.xsd#jnj_ChangesInTreasuryStockRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward" xlink:to="lab_jnj_ChangesInTreasuryStockRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermCommercialPaperCurrent_b6482b90-d02c-40e6-b894-23d5868499be_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermCommercialPaperCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowed under the commercial paper program</link:label>
    <link:label id="lab_us-gaap_LongTermCommercialPaperCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermCommercialPaperCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Commercial Paper, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermCommercialPaperCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermCommercialPaperCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermCommercialPaperCurrent" xlink:to="lab_us-gaap_LongTermCommercialPaperCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_b2c485cb-d446-47d5-9163-03d68a18286d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, related to divestitures</link:label>
    <link:label id="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_label_en-US" xlink:label="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill, Written off Related to Sale of Business Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:to="lab_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeTwoMember_d21d7dea-c1ab-4ccd-8ee6-f4d524739369_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$101.87-$115.67</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeTwoMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Two [Member]</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeTwoMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeTwoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeTwoMember" xlink:href="jnj-20230101.xsd#jnj_ExercisePriceRangeTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeTwoMember" xlink:to="lab_jnj_ExercisePriceRangeTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_93238d53-a0e5-4a36-953c-eedb36455be3_terseLabel_en-US" xlink:label="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives of Assets</link:label>
    <link:label id="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_label_en-US" xlink:label="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated Useful Lives Of Assets [Table Text Block]</link:label>
    <link:label id="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Estimated useful lives of the assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:href="jnj-20230101.xsd#jnj_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:to="lab_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_bd609497-6da8-446c-8bbe-f316e83d8cfe_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instrument, term</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm" xlink:to="lab_us-gaap_DebtInstrumentTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_2f4c8222-626d-4d9a-8344-26ec31314bcf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Temporary Differences and Carryforwards</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_3058e4d7-e15e-4f87-a69c-0bc0e217ae6a_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_8a4d7a70-32bb-41f4-9075-f66907bb23e7_terseLabel_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:label id="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_label_en-US" xlink:label="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Related Party [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="lab_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillRollForward_a6d71a8f-6859-4d39-9474-b01f67067d17_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward" xlink:to="lab_us-gaap_GoodwillRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_27dd71b9-2398-49ea-b3f6-dc01c9f44c35_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NonQualifiedPlansMember_ecba935e-747e-4bf2-82a9-072d4e881911_terseLabel_en-US" xlink:label="lab_jnj_NonQualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-Qualified Plans</link:label>
    <link:label id="lab_jnj_NonQualifiedPlansMember_label_en-US" xlink:label="lab_jnj_NonQualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non Qualified Plans [Member]</link:label>
    <link:label id="lab_jnj_NonQualifiedPlansMember_documentation_en-US" xlink:label="lab_jnj_NonQualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non qualified plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonQualifiedPlansMember" xlink:href="jnj-20230101.xsd#jnj_NonQualifiedPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NonQualifiedPlansMember" xlink:to="lab_jnj_NonQualifiedPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_06e5de69-daa6-4b7b-96d4-9ce4921f6eb2_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions, net of cash acquired (Note&#160;18)</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_8ccf71d8-fadf-4c70-aa17-9e01cf79c3bf_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year Five</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year five.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_032c553b-698d-41a2-9044-994d17118904_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_d0893b53-1675-47a4-b3f0-d80ddcee7489_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_eb802366-c0a0-4b75-b21b-fef8124d16d7_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities (Notes&#160;1 and 2)</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_408d47c7-fed5-40ce-9077-59b0c413ffd6_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_b8206668-c48e-4a36-b28d-7f14864b30f5_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_ef776d56-ac95-415e-b6af-0a029be3209e_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets, net (Notes&#160;1 and 5)</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_55c1eac9-c9c9-463b-99b7-a00375a2e49e_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intangible assets - net</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GeneralCorporateMember_cba21147-0548-4121-96e1-e42300bc6ddb_terseLabel_en-US" xlink:label="lab_jnj_GeneralCorporateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Corporate</link:label>
    <link:label id="lab_jnj_GeneralCorporateMember_label_en-US" xlink:label="lab_jnj_GeneralCorporateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General Corporate [Member]</link:label>
    <link:label id="lab_jnj_GeneralCorporateMember_documentation_en-US" xlink:label="lab_jnj_GeneralCorporateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">General corporate member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GeneralCorporateMember" xlink:href="jnj-20230101.xsd#jnj_GeneralCorporateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GeneralCorporateMember" xlink:to="lab_jnj_GeneralCorporateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_8aef9bd2-659b-4491-830e-f9863883d1b0_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest on income tax expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_9ed19ee3-c289-4f2b-be7c-2d6336e9fc48_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt, number of equity instruments (in shares)</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="lab_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_26fee11c-369b-40ac-a8aa-23f9f8660159_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and stock option plans</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_2c50041f-11d5-4ba5-8efb-5e1c5dbee931_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan participant contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_ddf2cdce-8e15-4aa9-9a67-24857015a66f_terseLabel_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_label_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:label id="lab_jnj_A4.85Notesdue2041Member_documentation_en-US" xlink:label="lab_jnj_A4.85Notesdue2041Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.85% Notes due 2041 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member" xlink:href="jnj-20230101.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.85Notesdue2041Member" xlink:to="lab_jnj_A4.85Notesdue2041Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_d362e8dc-6ac4-4fb7-975f-05e5f3c8338e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_f7d1ab37-90e9-41c5-9850-95ab45172fdd_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_b85b7b98-1fa4-4069-8257-c07917cf0ff0_terseLabel_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective tax rate reconciliation, net increase (decrease) in tax rate, percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_label_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_documentation_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:href="jnj-20230101.xsd#jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:to="lab_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherRestructuringMember_1a0329eb-d875-4423-aec5-9f20659dba37_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember" xlink:to="lab_us-gaap_OtherRestructuringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans_8e37b969-8f38-4d28-bd78-193f7eddc8cf_terseLabel_en-US" xlink:label="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential shares exercisable under stock option plans (in shares)</link:label>
    <link:label id="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans_label_en-US" xlink:label="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Shares Exercisable Under Stock Option Plans</link:label>
    <link:label id="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans_documentation_en-US" xlink:label="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Potential Shares Exercisable Under Stock Option Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:href="jnj-20230101.xsd#jnj_PotentialSharesExercisableUnderStockOptionPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:to="lab_jnj_PotentialSharesExercisableUnderStockOptionPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_7bc93ebd-01ad-409b-a148-990669068215_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term taxes payable (Note 1)</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesNoncurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Income Taxes, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_4d2cfdbf-eeab-47ee-aea3-3444adf4079b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_74755398-9dce-486c-836d-8e6fad3c32c0_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TRAUMAMember_8a89e776-e8f7-4a58-8eb6-2b46094b1a84_terseLabel_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA</link:label>
    <link:label id="lab_jnj_TRAUMAMember_label_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:label id="lab_jnj_TRAUMAMember_documentation_en-US" xlink:label="lab_jnj_TRAUMAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAUMA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember" xlink:href="jnj-20230101.xsd#jnj_TRAUMAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TRAUMAMember" xlink:to="lab_jnj_TRAUMAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_d46641dd-05e9-4412-8392-c0b93aa119d8_terseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (Income) Expense</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_cf1437f6-38a2-4b6f-9705-0f48e479c1d1_verboseLabel_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:label id="lab_jnj_OtherIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_OtherIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income Expense Net [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember" xlink:href="jnj-20230101.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherIncomeExpenseNetMember" xlink:to="lab_jnj_OtherIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_4c1886e5-4f9e-4d6b-8e0a-d45f4a9a5d1f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Price Range, Minimum (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_2f684b87-ea56-402b-a96f-7dcf7011237b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_99b9cf0a-39ac-4e31-95eb-6db1e7e38e40_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral paid</link:label>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_label_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:to="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_78f74c10-9c70-45db-936d-465041880452_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_c8435d34-ce35-400e-9c65-781d266b0cea_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FundedPlansMember_b6d77f30-ea41-483f-b5ae-cdb9b7cfaa73_terseLabel_en-US" xlink:label="lab_jnj_FundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded Plans</link:label>
    <link:label id="lab_jnj_FundedPlansMember_label_en-US" xlink:label="lab_jnj_FundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded Plans [Member]</link:label>
    <link:label id="lab_jnj_FundedPlansMember_documentation_en-US" xlink:label="lab_jnj_FundedPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FundedPlansMember" xlink:href="jnj-20230101.xsd#jnj_FundedPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FundedPlansMember" xlink:to="lab_jnj_FundedPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_5b534fa0-b00c-4427-b85b-f429c66404c6_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial assets and liabilities at fair value</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentDetailAbstract_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument Detail [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract" xlink:to="lab_us-gaap_DerivativeInstrumentDetailAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_5f656ea3-6be5-4f34-816c-da2337b0f611_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_6ea94fba-c930-4284-9b36-056d833db518_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_label_en-US" xlink:label="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Excluded Component, Gain (Loss), Recognized in Earnings</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:to="lab_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OTCMember_2340dfcb-9504-4026-b605-5b611b020826_terseLabel_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC</link:label>
    <link:label id="lab_jnj_OTCMember_label_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:label id="lab_jnj_OTCMember_documentation_en-US" xlink:label="lab_jnj_OTCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OTC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember" xlink:href="jnj-20230101.xsd#jnj_OTCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OTCMember" xlink:to="lab_jnj_OTCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_066921f1-8540-4af8-bd93-f18a29c6f992_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_3e4a0159-697e-46f4-a14a-3073f7271e7a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Pension Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:to="lab_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_a47f10c2-cc4a-4ac0-8c10-65ba65c1ad27_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Reclassified From Accumulated OCI Into Income</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_efcd4a2f-f437-4a1f-92ea-19f5248d00f9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized holding gain (loss) arising during period</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ImpellaMember_6d8d918c-700e-4047-86d8-656139acc33a_terseLabel_en-US" xlink:label="lab_jnj_ImpellaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impella</link:label>
    <link:label id="lab_jnj_ImpellaMember_label_en-US" xlink:label="lab_jnj_ImpellaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impella [Member]</link:label>
    <link:label id="lab_jnj_ImpellaMember_documentation_en-US" xlink:label="lab_jnj_ImpellaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impella</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImpellaMember" xlink:href="jnj-20230101.xsd#jnj_ImpellaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ImpellaMember" xlink:to="lab_jnj_ImpellaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_eac2ff4e-9430-497f-a81f-64342715ef64_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Government and agency securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Corporations and Agencies Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_d786147a-283e-44c2-86d5-a3e96d665cbb_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized gain (loss) on securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConsumerHealthMember_7f64824b-dd64-4007-b8ae-0550cbc80ec0_terseLabel_en-US" xlink:label="lab_jnj_ConsumerHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Health Business</link:label>
    <link:label id="lab_jnj_ConsumerHealthMember_label_en-US" xlink:label="lab_jnj_ConsumerHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Health [Member]</link:label>
    <link:label id="lab_jnj_ConsumerHealthMember_documentation_en-US" xlink:label="lab_jnj_ConsumerHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerHealthMember" xlink:href="jnj-20230101.xsd#jnj_ConsumerHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConsumerHealthMember" xlink:to="lab_jnj_ConsumerHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_53186231-c595-4c65-8cc2-98a3cf14e716_terseLabel_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_15ae6a18-1dda-4e15-afb8-c9cb623112af_terseLabel_en-US" xlink:label="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of corridor of greater of market value of assets</link:label>
    <link:label id="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_label_en-US" xlink:label="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Corridor Of Greater Of Market Value Of Assets</link:label>
    <link:label id="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_documentation_en-US" xlink:label="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of corridor of greater of market value of assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:href="jnj-20230101.xsd#jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:to="lab_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_8b01b1ca-a819-4524-8a2c-7c1c25518c19_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issued (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment_89e240be-5cea-480b-8329-c31c84ad63f2_terseLabel_en-US" xlink:label="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment on unrecognized tax benefit liability</link:label>
    <link:label id="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment_label_en-US" xlink:label="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefit Liability, Payment</link:label>
    <link:label id="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment_documentation_en-US" xlink:label="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefit Liability, Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:href="jnj-20230101.xsd#jnj_UnrecognizedTaxBenefitLiabilityPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:to="lab_jnj_UnrecognizedTaxBenefitLiabilityPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_6158c32d-9cba-46f5-9f13-b6321bb99422_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_73414d19-49ab-45dc-82d7-858fc0f82ee4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares authorized for issuance under long-term incentive plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_401374bc-53c7-4fe0-9230-7c3db29d9fbf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativesFairValueLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativesFairValueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Fair Value [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesFairValueLineItems" xlink:to="lab_us-gaap_DerivativesFairValueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_7f0d09c8-0685-4523-9084-7ed57e099d04_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax asset recorded related to TRAF</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:href="jnj-20230101.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_52f4310f-fe94-4679-b6b9-7e97aeccbf7a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Short-Term Debt [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_b311b18e-6408-4502-b916-ec74a16f5311_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_925ac455-271d-49e9-91d0-da10b01c131d_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Domain]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesDomain_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:href="jnj-20230101.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain" xlink:to="lab_jnj_LitigationSettlementByCompaniesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_9f8697f3-6492-4957-85e2-379da7e5aef8_terseLabel_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_label_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:label id="lab_jnj_CONCERTAMethylphenidateMember_documentation_en-US" xlink:label="lab_jnj_CONCERTAMethylphenidateMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CONCERTA/Methylphenidate [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember" xlink:href="jnj-20230101.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CONCERTAMethylphenidateMember" xlink:to="lab_jnj_CONCERTAMethylphenidateMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_5c51ab3b-baf3-4edf-95b3-7d58f6cb0b5b_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and stock option plans (shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8bfb135b-7093-4a6b-9c48-6aeea7626348_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_StelaraMember_9b89b509-7eca-4702-8978-04b7a5a2a1ad_terseLabel_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara</link:label>
    <link:label id="lab_jnj_StelaraMember_label_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:label id="lab_jnj_StelaraMember_documentation_en-US" xlink:label="lab_jnj_StelaraMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stelara [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember" xlink:href="jnj-20230101.xsd#jnj_StelaraMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_StelaraMember" xlink:to="lab_jnj_StelaraMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_aa19445b-8406-46ca-9f9b-2dc9fa4c1c96_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net actuarial loss</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_21923cb5-379d-4ff5-8065-05a2ffcd5f8b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments and settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_a5c87402-871b-46f5-9d71-4bb4b57d795c_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense" xlink:to="lab_us-gaap_LitigationSettlementExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_fcaa0757-fcad-4bb6-aa15-f318bd8c0fd5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_db2cf35e-2d75-45d4-ab87-cc683be68dae_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease)/Increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OrthopaedicsMember_c3040d9e-97a9-4715-b6de-82cc94978fb5_terseLabel_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_label_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:label id="lab_jnj_OrthopaedicsMember_documentation_en-US" xlink:label="lab_jnj_OrthopaedicsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Orthopaedics [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember" xlink:href="jnj-20230101.xsd#jnj_OrthopaedicsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OrthopaedicsMember" xlink:to="lab_jnj_OrthopaedicsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_ccabfd00-def3-43c6-a420-0646518fb578_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_e8af21a4-f90e-4207-aea4-00602e4e6309_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_dd48fb0d-003a-4922-bd7a-16aa78c9dc60_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_ff393bf3-db36-427e-8b04-96aed321b831_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_b825d7be-090a-41a6-8f99-f7038e04c677_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CurtailmentsAndSettlementsAndRestructuring_976c8027-ea86-445e-8055-7443298afab8_negatedTerseLabel_en-US" xlink:label="lab_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments, settlements&#160;&amp; restructuring</link:label>
    <link:label id="lab_jnj_CurtailmentsAndSettlementsAndRestructuring_label_en-US" xlink:label="lab_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Curtailments And Settlements And Restructuring</link:label>
    <link:label id="lab_jnj_CurtailmentsAndSettlementsAndRestructuring_documentation_en-US" xlink:label="lab_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">The amount of increase or decrease related to curtailments, settlements and restructuring.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:href="jnj-20230101.xsd#jnj_CurtailmentsAndSettlementsAndRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:to="lab_jnj_CurtailmentsAndSettlementsAndRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_87e4876e-edef-48cc-9b19-60540f98821e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_029fd572-740e-43e6-b74b-eb97c3e7548b_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease_6822965c-0f05-411f-a148-d441298c1a4e_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Activity during the period</link:label>
    <link:label id="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:to="lab_us-gaap_RestructuringReservePeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_28f603a6-bb48-4459-a84d-df6bbd4f5b98_totalLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash paid for acquisitions (Note 18)</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_b0587b87-87db-4f49-8669-e24e97034f17_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_09a152cd-fc18-4a0e-a70c-290957648893_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByAssetClassAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByAssetClassAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByAssetClassAxis" xlink:to="lab_us-gaap_FairValueByAssetClassAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_0e919f8a-e852-433d-ba94-24af961ab601_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_JudicialRulingMember_ab85f800-fdb9-4d24-8e35-fcfb38f221ff_terseLabel_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling</link:label>
    <link:label id="lab_us-gaap_JudicialRulingMember_label_en-US" xlink:label="lab_us-gaap_JudicialRulingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_JudicialRulingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JudicialRulingMember" xlink:to="lab_us-gaap_JudicialRulingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_4ede7c59-886d-4926-8d24-46d86d1d49dd_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from sale of equity interests</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale of Interest in Corporate Unit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfInterestInCorporateUnit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:to="lab_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_ae80f816-b9aa-482c-9c3c-8a095a4d0d54_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_135760ac-6bea-42d9-aff0-b88702d2416e_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental schedule of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_41bfd528-d87e-4245-bfc2-6373240c1d81_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayment of short-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repayments of Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_04cd31e4-2ea4-487f-a9bf-9cc4ed20ef7f_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_a0371c2b-cb16-4623-b6d6-bae4c003a112_terseLabel_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_label_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:label id="lab_jnj_AsiaPacificAfricaMember_documentation_en-US" xlink:label="lab_jnj_AsiaPacificAfricaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asia-Pacific, Africa [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember" xlink:href="jnj-20230101.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsiaPacificAfricaMember" xlink:to="lab_jnj_AsiaPacificAfricaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_7e8a857c-46e4-42e2-8527-df2ab0a783c6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average fair value of option granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_d8a70e27-d87d-4ed9-901e-f0d26bac1e15_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee compensation and stock option plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_234b4b16-b70f-4509-bf9b-7e343018de1d_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateContractMember_1078c94c-100a-4559-b96c-6b799adba878_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest rate swaps contracts:</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember" xlink:to="lab_us-gaap_InterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_ab46e846-4892-4b0d-8e4a-5d4887c46571_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">(Decrease)/Increase in other current and non-current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a771dc5a-c867-4cb2-beb8-ce9ff0326a0a_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additions to property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_dc502a3f-5ea6-4197-a428-74ef5878ddac_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_5b78e3ae-c900-4068-833b-8591d5b0e896_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation - beginning of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_bc7e7d3b-e693-4d71-8339-e271c318ff1f_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation - end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_2df62d68-fea6-4e3c-8e18-6f0ed1366034_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_9422adce-3bd1-453a-9637-ff541630484b_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SegmentsTotalMember_3a1a7024-216f-4cce-82a0-421120dc4757_terseLabel_en-US" xlink:label="lab_jnj_SegmentsTotalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments Total</link:label>
    <link:label id="lab_jnj_SegmentsTotalMember_label_en-US" xlink:label="lab_jnj_SegmentsTotalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments Total [Member]</link:label>
    <link:label id="lab_jnj_SegmentsTotalMember_documentation_en-US" xlink:label="lab_jnj_SegmentsTotalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments Total</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SegmentsTotalMember" xlink:href="jnj-20230101.xsd#jnj_SegmentsTotalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SegmentsTotalMember" xlink:to="lab_jnj_SegmentsTotalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_8b56f852-87ba-46c9-b6e9-84662619164e_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_64e07485-b13c-4551-9502-3d53b81e8ed0_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Benefit Plans</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_f9eabbca-c94a-4ce0-8b33-53dc25039540_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other benefit plans&#160;</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_248c23b0-2509-4349-a7ea-7f4b8c8e4d34_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due within one year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_af0dc5bb-4400-4935-89a4-d7af22f7cbef_negatedTerseLabel_en-US" xlink:label="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash settlements</link:label>
    <link:label id="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_label_en-US" xlink:label="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Sale of an Asset (Payment) for Restructuring</link:label>
    <link:label id="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_documentation_en-US" xlink:label="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Sale of an Asset (Payment) for Restructuring</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:href="jnj-20230101.xsd#jnj_GainOnSaleOfAnAssetPaymentForRestructuring"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:to="lab_jnj_GainOnSaleOfAnAssetPaymentForRestructuring" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_5e488b86-b2c2-4bd7-ac40-a127180f0038_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of increase in compensation levels</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_baf1f19c-b7f8-4d64-a607-5513dc143db7_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_2216d763-dd4f-41c7-a6b1-c186b37477d6_terseLabel_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in estimated fair value</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_label_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:label id="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_documentation_en-US" xlink:label="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:href="jnj-20230101.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:to="lab_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DARZALEXMember_8360d0e7-37a3-48f7-a367-9709fab09f68_terseLabel_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX</link:label>
    <link:label id="lab_jnj_DARZALEXMember_label_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:label id="lab_jnj_DARZALEXMember_documentation_en-US" xlink:label="lab_jnj_DARZALEXMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">DARZALEX [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember" xlink:href="jnj-20230101.xsd#jnj_DARZALEXMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DARZALEXMember" xlink:to="lab_jnj_DARZALEXMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_1ee152e8-78f2-4a9d-810d-17c17382b17d_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_28262dd1-8c6e-4fbc-8fb0-4d6c1ae28754_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_9320d9f2-a179-4f3d-a624-1842406ab84c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAmendments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_5f396417-ff6e-44a0-99da-fc102c4a8c02_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowing capacity under credit facility</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_2dffb545-4057-4939-98ce-f8a8869af755_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_6bdaf8eb-48af-403b-aa55-8488f40aa230_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_f088cdcb-9d13-4785-b511-67d241c11aa3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalent Composition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_3a1b321d-50dd-4102-9311-802c976bf496_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve balance beginning</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_9aa6bd1c-b995-4845-b7af-9c85a3e2fb9f_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve balance ending</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_fa052743-798b-4e7c-82e3-fc73f62cf1ef_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages awarded</link:label>
    <link:label id="lab_us-gaap_LossContingencyDamagesAwardedValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Damages Awarded, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyDamagesAwardedValue" xlink:to="lab_us-gaap_LossContingencyDamagesAwardedValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_ae04ec32-ba33-434b-abac-7efd536d60ff_terseLabel_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total recognized in net periodic benefit cost and other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:to="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SuppliesExpense_40f8ad67-5cc8-4061-b640-dab8bfd815c0_terseLabel_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Expense</link:label>
    <link:label id="lab_us-gaap_SuppliesExpense_label_en-US" xlink:label="lab_us-gaap_SuppliesExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplies Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SuppliesExpense" xlink:to="lab_us-gaap_SuppliesExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_5743e359-a9bb-4f72-8951-306da7771bf5_terseLabel_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_label_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:label id="lab_jnj_A3.75Notesdue2047Member_documentation_en-US" xlink:label="lab_jnj_A3.75Notesdue2047Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.75% Notes due 2047 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member" xlink:href="jnj-20230101.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.75Notesdue2047Member" xlink:to="lab_jnj_A3.75Notesdue2047Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_6384a028-a4f9-4388-aa95-7203d6b87f79_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (primarily licenses and milestones)</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_837cbe59-8811-46e0-ad7e-93a22c8c8f2c_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_06ebefe8-d7db-45b2-8c74-d3ccd498232d_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionContributions_07021ca2-53c1-41ce-9b99-71b9b425776f_terseLabel_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contribution to pension plans</link:label>
    <link:label id="lab_us-gaap_PensionContributions_label_en-US" xlink:label="lab_us-gaap_PensionContributions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment for Pension Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionContributions" xlink:to="lab_us-gaap_PensionContributions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_ed1e0228-ca36-40a7-af42-1a1552f19e42_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_9a4ac16f-d472-4064-9187-83cbb886fda2_terseLabel_en-US" xlink:label="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information Related to the Benefit Obligation and the Fair Value of Plan Assets</link:label>
    <link:label id="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information Related To Benefit Obligation And Fair Value Of Plan Assets [Table Text Block]</link:label>
    <link:label id="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Information related to the benefit obligation and the fair value of plan assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:href="jnj-20230101.xsd#jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:to="lab_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9818a777-628a-405c-91de-ba13a87c0b31_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_0785df99-59ba-4e22-ab1c-353d3c5c7be5_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Lapse of statute of limitations</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_16f8fca1-8767-4319-a579-d182f92050cb_negatedTerseLabel_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: shares repurchased under treasury stock method (in shares)</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_label_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Which Could Be Repurchased Under Treasury Stock Method</link:label>
    <link:label id="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_documentation_en-US" xlink:label="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:href="jnj-20230101.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:to="lab_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_f5c1c3c4-3ede-48a9-b24c-b6b2b3211929_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_a7a2b63d-96ba-421b-92c4-1ffb873009fc_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost (credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_09dd088e-6e17-457e-bd05-88b2376aceda_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net periodic benefit cost (credit)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_aeee4522-0e87-4087-bf29-9af552fe0e85_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_a389bf8b-cc01-47c5-9b7c-e4d9c7999592_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_7396ec54-13a9-4d2e-a0b6-37e424590a69_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency exchange rate, translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Exchange Rate, Translation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:to="lab_us-gaap_ForeignCurrencyExchangeRateTranslation1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_f4da5ba6-5800-4dff-b74e-ae71d428c2a1_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_056ad9c0-f750-4524-8547-899ddb928daf_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_12abc699-3c4b-4023-b262-22564228e62f_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_1e7ffc0b-6193-43f4-b7c8-c9bb751ddd3a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Due after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_893acfa1-e439-467c-a8be-b16334f4307a_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_47285079-808a-434f-87cf-eaff48d4daa8_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt instruments</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember" xlink:to="lab_us-gaap_DebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_dd44bac2-ce0d-434a-b285-27ffbf137547_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer relationships and other intangible assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_7d52e9dc-4f37-4bd0-a13d-21c4748c44a7_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets</link:label>
    <link:label id="lab_us-gaap_OtherIntangibleAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherIntangibleAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Intangible Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIntangibleAssetsMember" xlink:to="lab_us-gaap_OtherIntangibleAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_314c2f78-2b1f-405a-a070-53a10ebeab75_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate Maturities of Long Term Obligations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_c7a914c3-54b0-49c4-b52c-9b264385741c_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_us-gaap_SubsequentEventTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_448bcea2-d7e4-4ef8-83de-a794e14a377d_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_0e23fc68-e7ac-4a16-9fe0-6e61c8d8df00_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate of increase in compensation levels</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_448aa5bb-04d1-4343-9ddd-36b1c26794da_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis" xlink:to="lab_us-gaap_RestructuringPlanAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A130NotesDue2030Member_9b623ed7-5a9f-492b-bc92-34631f9a9adb_terseLabel_en-US" xlink:label="lab_jnj_A130NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes due 2030</link:label>
    <link:label id="lab_jnj_A130NotesDue2030Member_label_en-US" xlink:label="lab_jnj_A130NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes due 2030 [Member]</link:label>
    <link:label id="lab_jnj_A130NotesDue2030Member_documentation_en-US" xlink:label="lab_jnj_A130NotesDue2030Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.30% Notes due 2030</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A130NotesDue2030Member" xlink:href="jnj-20230101.xsd#jnj_A130NotesDue2030Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A130NotesDue2030Member" xlink:to="lab_jnj_A130NotesDue2030Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_98d06033-fffd-44ac-9834-4a1b69625fd0_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_December172018ShareRepurchaseProgramMember_0c976f3a-7408-4a56-b791-f167edb1b126_terseLabel_en-US" xlink:label="lab_jnj_December172018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 17, 2018 Share Repurchase Program</link:label>
    <link:label id="lab_jnj_December172018ShareRepurchaseProgramMember_label_en-US" xlink:label="lab_jnj_December172018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 17, 2018 Share Repurchase Program [Member]</link:label>
    <link:label id="lab_jnj_December172018ShareRepurchaseProgramMember_documentation_en-US" xlink:label="lab_jnj_December172018ShareRepurchaseProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">December 17, 2018 Share Repurchase Program [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_December172018ShareRepurchaseProgramMember" xlink:href="jnj-20230101.xsd#jnj_December172018ShareRepurchaseProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_December172018ShareRepurchaseProgramMember" xlink:to="lab_jnj_December172018ShareRepurchaseProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_95d9f708-3020-40c0-bd83-fbdfa1e2a231_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_582f10f5-299b-4a47-81a1-6a8566c91ef7_terseLabel_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_label_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:label id="lab_jnj_Numberofpatientsinsettlement_documentation_en-US" xlink:label="lab_jnj_Numberofpatientsinsettlement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of patients in settlement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement" xlink:href="jnj-20230101.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Numberofpatientsinsettlement" xlink:to="lab_jnj_Numberofpatientsinsettlement" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ChangesInTreasuryStockTableTextBlock_08be1bb1-dd5a-4f37-96e1-6bdc11b58c09_terseLabel_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Treasury Stock</link:label>
    <link:label id="lab_jnj_ChangesInTreasuryStockTableTextBlock_label_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes In Treasury Stock [Table Text Block]</link:label>
    <link:label id="lab_jnj_ChangesInTreasuryStockTableTextBlock_documentation_en-US" xlink:label="lab_jnj_ChangesInTreasuryStockTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in treasury stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockTableTextBlock" xlink:href="jnj-20230101.xsd#jnj_ChangesInTreasuryStockTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ChangesInTreasuryStockTableTextBlock" xlink:to="lab_jnj_ChangesInTreasuryStockTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_ba02c993-c129-4c4f-bc47-30dd864a8208_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible assets with definite lives:</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_05f14f36-e3a2-4c95-9356-b063e0853942_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_7616de51-efd0-4377-83a9-38c8eed52550_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments : Assets</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_5385f101-e2cf-4266-8cab-6666c1baebc2_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AbiomedMember_639d2a71-d46e-4278-8685-15536d25dc52_terseLabel_en-US" xlink:label="lab_jnj_AbiomedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abiomed</link:label>
    <link:label id="lab_jnj_AbiomedMember_label_en-US" xlink:label="lab_jnj_AbiomedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abiomed [Member]</link:label>
    <link:label id="lab_jnj_AbiomedMember_documentation_en-US" xlink:label="lab_jnj_AbiomedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Abiomed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember" xlink:href="jnj-20230101.xsd#jnj_AbiomedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AbiomedMember" xlink:to="lab_jnj_AbiomedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillLineItems_183d9be4-2484-4c2f-89ad-ba9e7ab45462_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems" xlink:to="lab_us-gaap_GoodwillLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_e24381a8-307d-4de5-a4b5-61f350fba902_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_36fc1638-cc35-4713-b70c-40a8dbcc921b_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectOfExchangeRates_36bd62a1-f686-4092-84ea-246ebf7e2188_terseLabel_en-US" xlink:label="lab_jnj_EffectOfExchangeRates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_jnj_EffectOfExchangeRates_label_en-US" xlink:label="lab_jnj_EffectOfExchangeRates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect Of Exchange Rates</link:label>
    <link:label id="lab_jnj_EffectOfExchangeRates_documentation_en-US" xlink:label="lab_jnj_EffectOfExchangeRates" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect Of Exchange Rates.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectOfExchangeRates" xlink:href="jnj-20230101.xsd#jnj_EffectOfExchangeRates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectOfExchangeRates" xlink:to="lab_jnj_EffectOfExchangeRates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_4808582b-39c5-4033-8703-88f659119c39_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior service cost (credit)(1)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_27bda8fe-f1dc-45dd-9f15-766b6a5f3af6_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash flows from operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_cf3281ae-bad4-4a47-b3b0-f0b4b7c51cff_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repatriation of foreign earnings amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:to="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExpenseNotAllocatedToSegments_21c9a9eb-f26f-40cc-bcd0-32c51f63bc34_terseLabel_en-US" xlink:label="lab_jnj_ExpenseNotAllocatedToSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less: Expense not allocated to segments</link:label>
    <link:label id="lab_jnj_ExpenseNotAllocatedToSegments_label_en-US" xlink:label="lab_jnj_ExpenseNotAllocatedToSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense Not Allocated To Segments</link:label>
    <link:label id="lab_jnj_ExpenseNotAllocatedToSegments_documentation_en-US" xlink:label="lab_jnj_ExpenseNotAllocatedToSegments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expense not allocated to segments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExpenseNotAllocatedToSegments" xlink:href="jnj-20230101.xsd#jnj_ExpenseNotAllocatedToSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExpenseNotAllocatedToSegments" xlink:to="lab_jnj_ExpenseNotAllocatedToSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssets_429e40cb-26de-4123-a858-cdbb94d3b478_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Net Asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets" xlink:to="lab_us-gaap_DerivativeAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_fd299009-f5cd-455b-b125-f607852a4c60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contractual Maturities of Available for Sale Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_e3896a08-9096-425e-9a70-5cd2df439229_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_9657d804-b98b-414d-8a05-71b8eaa11ae7_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_37f7704a-0388-41da-a3bf-3107378ec9e7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentMember" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_cd646da2-b248-4d54-b263-b2d255e9e784_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options canceled/forfeited</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_6d1d27b0-432b-4882-bc4a-f5dd60f7c638_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_41a87483-3727-4714-878b-6717cd3b0fd5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_COVID19Member_08db04d2-a9b2-463b-ae1e-068b7a193a33_terseLabel_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:label id="lab_jnj_COVID19Member_label_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19 [Member]</link:label>
    <link:label id="lab_jnj_COVID19Member_documentation_en-US" xlink:label="lab_jnj_COVID19Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COVID-19</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member" xlink:href="jnj-20230101.xsd#jnj_COVID19Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_COVID19Member" xlink:to="lab_jnj_COVID19Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_a2a6f8b9-b48b-4840-a5f2-52b0bc53d5d4_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_bb2cf9d0-ab16-419f-9209-f7edd676c13b_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations (Notes&#160;9 and 10)</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_ab7d6e83-17fc-4479-ba7a-1a37dcb62032_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations&#160;&#8212; non-current</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_84857686-e2c2-448e-974e-7cb4753ea0e9_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_082cb263-f476-4930-9b4b-b5b13c566584_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.25Notesdue2022Member_068db506-8827-49cf-a550-82aaa6986377_terseLabel_en-US" xlink:label="lab_jnj_A2.25Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes due 2022</link:label>
    <link:label id="lab_jnj_A2.25Notesdue2022Member_label_en-US" xlink:label="lab_jnj_A2.25Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes due 2022 [Member]</link:label>
    <link:label id="lab_jnj_A2.25Notesdue2022Member_documentation_en-US" xlink:label="lab_jnj_A2.25Notesdue2022Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.25% Notes due 2022 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.25Notesdue2022Member" xlink:href="jnj-20230101.xsd#jnj_A2.25Notesdue2022Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.25Notesdue2022Member" xlink:to="lab_jnj_A2.25Notesdue2022Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_8e7ffce9-2456-44c2-a464-a38f6987d699_terseLabel_en-US" xlink:label="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards</link:label>
    <link:label id="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_label_en-US" xlink:label="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Issued For Employee Compensation And Stock Option Plans Net Of Cash Proceeds</link:label>
    <link:label id="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_documentation_en-US" xlink:label="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury stock issued for employee compensation and stock option plans, net of cash proceeds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:href="jnj-20230101.xsd#jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:to="lab_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_d77bbc34-2721-4bce-a44f-1ea2c95ec4ba_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_d65e59d0-e230-4b02-b21a-9b906bfecdce_terseLabel_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023</link:label>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_label_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A3.375Notesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A3.375Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.375% Notes due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member" xlink:href="jnj-20230101.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.375Notesdue2023Member" xlink:to="lab_jnj_A3.375Notesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_3c3ca170-ddd3-4cbd-9697-302bfe33c24e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment at Cost and Accumulated Depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_432866ca-0f10-4f0c-a14e-cb3ff79131f4_terseLabel_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_label_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:label id="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_documentation_en-US" xlink:label="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:href="jnj-20230101.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:to="lab_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsAbstract_19b86b25-dde1-4fcf-a52d-7828e42b7f73_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract" xlink:to="lab_us-gaap_CompensationRelatedCostsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_3033fa0f-3304-49b0-b795-aa9a2d9eac42_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_1bfb2feb-4ff7-4f5c-bbef-98d80a04df6e_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_861ed295-cc6b-4d7c-8a45-f7ac7db78d44_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_8e2f533b-048a-47e8-91f3-516c8f81a3b6_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_673ba402-19bf-4954-b025-ad246fb21ec4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_f4c316da-b0b2-4bbe-a616-c4651d818728_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Borrowings</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_44fcd3f1-40b5-4ee5-968c-9e4429edb0cd_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_3fc07506-0671-4b02-971e-b0865f57ce99_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_6dd37df9-4e1f-4a98-8509-22e13b804df4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decreases related to prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_3a41b2af-fa75-4a1a-85d1-dec35b0821bc_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Company' Retirement Plan Asset Allocation and Target Allocations</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_5857e428-0297-4c42-9b05-e2e124536c16_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_333ee109-2465-43f0-b145-1e20b8a7d8f9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_43b26905-dc65-45b1-9615-e7016da410be_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_4119e7e3-b34d-405f-81c7-ae526f04ee23_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TCJA, undistributed foreign earnings percent related to cash and cash equivalents</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:href="jnj-20230101.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Wholesaler1Member_55043cc8-40c1-45c1-b84a-645820df1c94_terseLabel_en-US" xlink:label="lab_jnj_Wholesaler1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 1</link:label>
    <link:label id="lab_jnj_Wholesaler1Member_label_en-US" xlink:label="lab_jnj_Wholesaler1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 1 [Member]</link:label>
    <link:label id="lab_jnj_Wholesaler1Member_documentation_en-US" xlink:label="lab_jnj_Wholesaler1Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler1Member" xlink:href="jnj-20230101.xsd#jnj_Wholesaler1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Wholesaler1Member" xlink:to="lab_jnj_Wholesaler1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_aa24e9d8-c46e-44a5-a2cd-7c84c700da79_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales Revenue, Net</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsDomain_9e1c0e75-73d0-411f-a561-426c4ccd5e1a_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain" xlink:to="lab_srt_ConsolidationItemsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsequentEventMember_5a28bc31-54eb-434a-bc22-424cdc28fdb2_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember" xlink:to="lab_us-gaap_SubsequentEventMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NumberOfStockBasedCompensationPlans_19cb5009-7aab-49e1-82f7-fc53396af1f7_terseLabel_en-US" xlink:label="lab_jnj_NumberOfStockBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock-based compensation plans</link:label>
    <link:label id="lab_jnj_NumberOfStockBasedCompensationPlans_label_en-US" xlink:label="lab_jnj_NumberOfStockBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Stock Based Compensation Plans</link:label>
    <link:label id="lab_jnj_NumberOfStockBasedCompensationPlans_documentation_en-US" xlink:label="lab_jnj_NumberOfStockBasedCompensationPlans" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of stock-based compensation plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfStockBasedCompensationPlans" xlink:href="jnj-20230101.xsd#jnj_NumberOfStockBasedCompensationPlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NumberOfStockBasedCompensationPlans" xlink:to="lab_jnj_NumberOfStockBasedCompensationPlans" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5969349c-6b3c-43a5-b200-3cbbac32f689_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_6e6e0450-1e69-4e41-94ea-04f77fe7806a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_ccb12cc2-793c-41ea-a462-5638f65fba43_terseLabel_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-U.S. Sovereign Securities</link:label>
    <link:label id="lab_us-gaap_SovereignDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sovereign Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SovereignDebtSecuritiesMember" xlink:to="lab_us-gaap_SovereignDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_0a8d3ab9-ea75-44a6-9040-9209ef5986cf_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of prior service (cost) credit</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_ea3d47cd-cc86-47b3-8a21-dabab94808eb_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Accumulated Other Comprehensive Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_39456d06-d5a6-4164-8628-ddd1082cb7b6_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_2fd2e714-423b-4cda-ac7f-94da71abcd1c_verboseLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Identifiable Assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_eda80d00-60cb-474e-ae97-c8a14032f5d0_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net earnings per share (Notes 1 and 15)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_8a273c63-6464-4c36-9970-2a69ad21edd4_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_777dd3eb-42e6-4f6f-85c0-4e2f2d62c437_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average assumptions of fair value of options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BusinessAcquisitionDiscountRate_5b92688f-fc62-49ce-a7df-dceeffc9f6cf_terseLabel_en-US" xlink:label="lab_jnj_BusinessAcquisitionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_jnj_BusinessAcquisitionDiscountRate_label_en-US" xlink:label="lab_jnj_BusinessAcquisitionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Discount Rate</link:label>
    <link:label id="lab_jnj_BusinessAcquisitionDiscountRate_documentation_en-US" xlink:label="lab_jnj_BusinessAcquisitionDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Acquisition, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessAcquisitionDiscountRate" xlink:href="jnj-20230101.xsd#jnj_BusinessAcquisitionDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BusinessAcquisitionDiscountRate" xlink:to="lab_jnj_BusinessAcquisitionDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_7d482a92-5e49-4144-bdd0-00e951835dbe_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_8e7e20c1-2c94-4a16-92eb-2785ddea854c_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities, FV-NI, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi" xlink:to="lab_us-gaap_EquitySecuritiesFvNi" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestRateSwapMember_8f2f4d12-aaf5-417e-b0d7-38ce7ef1d0e8_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap</link:label>
    <link:label id="lab_us-gaap_InterestRateSwapMember_label_en-US" xlink:label="lab_us-gaap_InterestRateSwapMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Rate Swap [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateSwapMember" xlink:to="lab_us-gaap_InterestRateSwapMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_1fe13e9a-f715-4837-8a9a-fa3bc540d9c4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_42ea2200-6d81-4242-b98c-fcb7d28b66c1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercised, average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_dd5548bb-3cbe-4935-b7d4-0a91f814f5e7_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock repurchase program, authorized amount</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_e863988b-f240-4d26-9c13-b2b3fc95c8aa_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and employee related obligations</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_ebe45873-bbf3-49be-845f-1145e9889d25_terseLabel_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_label_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:label id="lab_jnj_CardiovascularMetabolismOtherMember_documentation_en-US" xlink:label="lab_jnj_CardiovascularMetabolismOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cardiovascular/Metabolism/Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember" xlink:href="jnj-20230101.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CardiovascularMetabolismOtherMember" xlink:to="lab_jnj_CardiovascularMetabolismOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_4289daa7-3428-4654-ab95-d09237e67cb8_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_e6e1c600-da89-4740-acf7-3b999101b34e_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings before provision for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_fbd8a55c-acfa-4cbf-aa1a-3e5d313601f8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_c8bcce7b-e348-434a-aa5a-2e4241e6431e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OpiodsMember_79d33f54-3e20-4603-b72a-4756b31499b7_terseLabel_en-US" xlink:label="lab_jnj_OpiodsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opiods</link:label>
    <link:label id="lab_jnj_OpiodsMember_label_en-US" xlink:label="lab_jnj_OpiodsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opiods [Member]</link:label>
    <link:label id="lab_jnj_OpiodsMember_documentation_en-US" xlink:label="lab_jnj_OpiodsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opiods [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpiodsMember" xlink:href="jnj-20230101.xsd#jnj_OpiodsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OpiodsMember" xlink:to="lab_jnj_OpiodsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_0d9325ef-813f-49af-98bc-5f50a172e968_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_37b79681-5ff6-4981-b724-43656bbbb006_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous international</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaid_6030e00e-0830-4469-a26d-0468342e057d_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaid_label_en-US" xlink:label="lab_us-gaap_InterestPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Including Capitalized Interest, Operating and Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid" xlink:to="lab_us-gaap_InterestPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_c602c595-86e9-42b4-924a-22004ca48f5a_terseLabel_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding (Textuals)</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_label_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding (Textuals) [Abstract]</link:label>
    <link:label id="lab_jnj_LegalProceedingTextualsAbstract_documentation_en-US" xlink:label="lab_jnj_LegalProceedingTextualsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Legal Proceeding Textuals Abstract.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract" xlink:href="jnj-20230101.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LegalProceedingTextualsAbstract" xlink:to="lab_jnj_LegalProceedingTextualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_2ecf19d4-32e3-45c6-bb32-074712f21748_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_f97daf1d-530b-4d47-be30-0f8281b484fc_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_9bd6d7e6-81b3-42bb-b2bc-5210538e2995_verboseLabel_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued rebates, returns and promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_b07de0ec-e50a-4c2c-ae18-438858602fd6_terseLabel_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates Returns And Promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_label_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Rebates Returns And Promotions</link:label>
    <link:label id="lab_jnj_AccruedRebatesReturnsAndPromotions_documentation_en-US" xlink:label="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:href="jnj-20230101.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AccruedRebatesReturnsAndPromotions" xlink:to="lab_jnj_AccruedRebatesReturnsAndPromotions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_78f30ea9-9ef4-4196-bd21-3fa504023572_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instruments in Hedges, Liabilities, at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:to="lab_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08a9ef86-1b63-48b9-8b40-2e890038f1eb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_26678389-507b-48f1-94f8-abc890440c62_verboseLabel_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased in-process research and development</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_c4bb54e8-bebe-4acf-a03e-11c7eaa39263_terseLabel_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased in-process research and development(1)</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_label_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:label id="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember_documentation_en-US" xlink:label="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchased In-Process Research And Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:href="jnj-20230101.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:to="lab_jnj_PurchasedInProcessResearchAndDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BabyCareMember_b185bae8-4def-4529-8a7e-ffe763535865_terseLabel_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care</link:label>
    <link:label id="lab_jnj_BabyCareMember_label_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:label id="lab_jnj_BabyCareMember_documentation_en-US" xlink:label="lab_jnj_BabyCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Baby Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember" xlink:href="jnj-20230101.xsd#jnj_BabyCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BabyCareMember" xlink:to="lab_jnj_BabyCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_1cef4143-e4ce-4313-95de-f84d91a1dd77_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Effect of Net Investment Hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_21c92715-4323-4bfb-b1c3-35f73dfec7a6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_e1bcbf7e-a240-4385-86a8-3a3aea347105_terseLabel_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment benefits</link:label>
    <link:label id="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postemployment Benefits Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:to="lab_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_e3b0b493-3528-42c9-9b3c-4601ded50fac_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardLineItems_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_us-gaap_TaxCreditCarryforwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_country_CN_73885cfc-1ec1-4a75-ac22-e15c9f48a0b6_terseLabel_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:label id="lab_country_CN_label_en-US" xlink:label="lab_country_CN" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN" xlink:to="lab_country_CN" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_f6d54d03-8346-4ce1-a569-23933f8f8e78_terseLabel_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_label_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:label id="lab_jnj_A3.55Notesdue2036Member_documentation_en-US" xlink:label="lab_jnj_A3.55Notesdue2036Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.55% Notes due 2036 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member" xlink:href="jnj-20230101.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.55Notesdue2036Member" xlink:to="lab_jnj_A3.55Notesdue2036Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_e60becc2-8930-4fd9-9051-88097e858b2e_terseLabel_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred net losses (gains) on derivatives included in accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_label_en-US" xlink:label="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:to="lab_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_465c153e-4ee7-4b5d-b39f-7dd6ea2f938b_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2022</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Year One</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in year one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_3d1be6cd-58fa-40f8-9c70-552b8e9356a0_terseLabel_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development</link:label>
    <link:label id="lab_us-gaap_SoftwareDevelopmentMember_label_en-US" xlink:label="lab_us-gaap_SoftwareDevelopmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Software Development [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SoftwareDevelopmentMember" xlink:to="lab_us-gaap_SoftwareDevelopmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_6883ab1a-e6cc-4ecc-9349-7e44703c56e6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward" xlink:to="lab_us-gaap_RestructuringReserveRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TalcMember_4b36b2c9-e447-4fce-957e-589e73a4feff_terseLabel_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc</link:label>
    <link:label id="lab_jnj_TalcMember_label_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:label id="lab_jnj_TalcMember_documentation_en-US" xlink:label="lab_jnj_TalcMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Talc [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember" xlink:href="jnj-20230101.xsd#jnj_TalcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TalcMember" xlink:to="lab_jnj_TalcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_77a07f08-f3e9-4e19-b09f-769be43c009a_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_daac272f-50e3-4938-9669-f5daaabdd329_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Postretirement benefits</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability, Other Postretirement Defined Benefit Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:to="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_290e7805-0eb1-4984-8a81-f5bfb552dd40_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_91416325-edec-424a-8e6b-295db958ac6e_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest cost discount rate</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:to="lab_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_6d1cd501-9965-452e-a159-0bab4903b708_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/ (Loss) On Derivatives &amp; Hedges</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_a5c44dda-fcd0-4ffe-9d64-7f8585f4ac4c_terseLabel_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85%&#160;Debentures due 2038</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_label_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:label id="lab_jnj_A5.85Debenturesdue2038Member_documentation_en-US" xlink:label="lab_jnj_A5.85Debenturesdue2038Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.85% Debentures due 2038 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member" xlink:href="jnj-20230101.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.85Debenturesdue2038Member" xlink:to="lab_jnj_A5.85Debenturesdue2038Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_b531b076-d539-4f79-9386-6270cd8ec7e3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PelvicMeshesMember_4f6ffa0b-ff86-48c5-88e8-68dabd8188e4_terseLabel_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_label_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic Meshes [Member]</link:label>
    <link:label id="lab_jnj_PelvicMeshesMember_documentation_en-US" xlink:label="lab_jnj_PelvicMeshesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pelvic meshes.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember" xlink:href="jnj-20230101.xsd#jnj_PelvicMeshesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PelvicMeshesMember" xlink:to="lab_jnj_PelvicMeshesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_d93f28a2-3c32-4cdd-b22a-44b283ea44e4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027-2031</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_e8ef9717-8436-46e1-88e2-ceda7090477f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_1d7e5a00-4e7c-4b6f-a00e-4ae7c0236cdc_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits, interest on income taxes accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares_f9b2b860-90f8-4b7a-8507-fb7f3030e0d4_terseLabel_en-US" xlink:label="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible note, equity Interest (in shares)</link:label>
    <link:label id="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares_label_en-US" xlink:label="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note, Equity Interest, number of shares</link:label>
    <link:label id="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares_documentation_en-US" xlink:label="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Note, Equity Interest, number of shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:href="jnj-20230101.xsd#jnj_ConvertibleNoteEquityInterestNumberOfShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:to="lab_jnj_ConvertibleNoteEquityInterestNumberOfShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_b318c1c0-9c5c-47e0-9c9a-b5e56c3021f6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net realizable operating loss carryforwards(4)</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards, Foreign</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_f8f02209-74a5-4893-ad20-e7b569995966_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_5927bcf3-468b-41a9-b842-c05530546b8d_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_5a097ed6-4172-4721-a054-0ce4e997c6e7_verboseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_6cde6c1e-8d07-4aac-8d78-e0463186b89b_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement plans</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_102822cd-2f55-46d6-8d80-0eeb70448576_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_label_en-US" xlink:label="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:to="lab_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EmployeeRelatedObligationsTableTextBlock_78b7d3ed-3490-422a-9eae-3b2a35b5a88a_terseLabel_en-US" xlink:label="lab_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Related Obligations</link:label>
    <link:label id="lab_jnj_EmployeeRelatedObligationsTableTextBlock_label_en-US" xlink:label="lab_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Related Obligations [Table Text Block]</link:label>
    <link:label id="lab_jnj_EmployeeRelatedObligationsTableTextBlock_documentation_en-US" xlink:label="lab_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:href="jnj-20230101.xsd#jnj_EmployeeRelatedObligationsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:to="lab_jnj_EmployeeRelatedObligationsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_1f42189d-3dac-49d6-ae4c-858e46c38c46_terseLabel_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_label_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:label id="lab_jnj_A2.45Notesdue2026Member_documentation_en-US" xlink:label="lab_jnj_A2.45Notesdue2026Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.45% Notes due 2026 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member" xlink:href="jnj-20230101.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.45Notesdue2026Member" xlink:to="lab_jnj_A2.45Notesdue2026Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyPendingClaimsNumberAdditional_ca5a8a2d-f345-4b65-a3df-5dcfe9c3bf7c_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyPendingClaimsNumberAdditional" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Pending Claims, Number, Additional</link:label>
    <link:label id="lab_jnj_LossContingencyPendingClaimsNumberAdditional_label_en-US" xlink:label="lab_jnj_LossContingencyPendingClaimsNumberAdditional" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Pending Claims, Number, Additional</link:label>
    <link:label id="lab_jnj_LossContingencyPendingClaimsNumberAdditional_documentation_en-US" xlink:label="lab_jnj_LossContingencyPendingClaimsNumberAdditional" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Pending Claims, Number, Additional</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyPendingClaimsNumberAdditional" xlink:href="jnj-20230101.xsd#jnj_LossContingencyPendingClaimsNumberAdditional"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyPendingClaimsNumberAdditional" xlink:to="lab_jnj_LossContingencyPendingClaimsNumberAdditional" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_ac02f383-448e-4afd-92fd-ce4e45fc1274_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increases related to prior period tax positions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_6e0a58c8-7ed5-490b-bc06-0649fc2e8d50_terseLabel_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_label_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:label id="lab_jnj_A4.50Notesdue2043Member_documentation_en-US" xlink:label="lab_jnj_A4.50Notesdue2043Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">4.50% Notes due 2043 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member" xlink:href="jnj-20230101.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A4.50Notesdue2043Member" xlink:to="lab_jnj_A4.50Notesdue2043Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_a40552b9-d744-43dc-92f1-12bb2eaf8c22_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs)</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_94ad73b7-f532-4fe7-b7ca-75ec01b0e169_terseLabel_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity investments, increase (decrease) from acquisition (sale) during period</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_label_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:label id="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_documentation_en-US" xlink:label="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:href="jnj-20230101.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:to="lab_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RegulationCharge_90c181ac-18b5-4add-ad12-589e63089bdd_terseLabel_en-US" xlink:label="lab_jnj_RegulationCharge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulation charge</link:label>
    <link:label id="lab_jnj_RegulationCharge_label_en-US" xlink:label="lab_jnj_RegulationCharge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulation charge</link:label>
    <link:label id="lab_jnj_RegulationCharge_documentation_en-US" xlink:label="lab_jnj_RegulationCharge" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Regulation charge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RegulationCharge" xlink:href="jnj-20230101.xsd#jnj_RegulationCharge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RegulationCharge" xlink:to="lab_jnj_RegulationCharge" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_adfaba13-f847-43f5-aa83-90a4b1df51a7_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_9eb1bd95-8452-48b6-9140-3efc1bc55247_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net change</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_843fb1e3-b149-4936-8828-711f23714efb_verboseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization expense of amortizable intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_8e8d4b33-5a02-41aa-a020-0764391f1e39_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_2dd3a16d-8095-4b15-8598-a12421f1db89_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_ad0d7945-db00-4df4-abcb-60912e90b4c1_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest, net of amount capitalized</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_ee1a0006-4f96-4704-bd22-266228438871_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_af4384ef-5228-48a4-8ffc-c68619e8c0c1_terseLabel_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_label_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Settlement By Companies [Axis]</link:label>
    <link:label id="lab_jnj_LitigationSettlementByCompaniesAxis_documentation_en-US" xlink:label="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation settlement by companies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:href="jnj-20230101.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis" xlink:to="lab_jnj_LitigationSettlementByCompaniesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsMember_b0dbc631-b5f1-413c-a188-af0f60b7b217_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsMember_label_en-US" xlink:label="lab_us-gaap_OtherAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsMember" xlink:to="lab_us-gaap_OtherAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PharmaceuticalMember_bf024af5-91f2-402b-a48b-30372f7a6189_verboseLabel_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_3b9a60c0-62e5-4b86-bbde-586d66878e66_terseLabel_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_label_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical [Member]</link:label>
    <link:label id="lab_jnj_PharmaceuticalMember_documentation_en-US" xlink:label="lab_jnj_PharmaceuticalMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pharmaceutical.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember" xlink:href="jnj-20230101.xsd#jnj_PharmaceuticalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PharmaceuticalMember" xlink:to="lab_jnj_PharmaceuticalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_5f3343e8-20e1-4b4f-afa3-9684c8f5e6a5_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Benefit Plans</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_a772d24d-c040-4a0d-b7c8-2fdb33333d55_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_d6b9cd9c-9c44-489f-83d9-9add0599056e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_7ac50ec8-0d79-4867-ac7d-bd288a5e8490_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockMember_d1dc2c42-0fa1-4bb3-b2c8-3ceef830e089_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock Amount</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_1757b063-7159-40f0-abcc-009ff9f0efc8_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember" xlink:to="lab_us-gaap_TreasuryStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_8cbbd366-3e6e-4914-acea-b267f66f7a3d_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Reverse repurchase agreements</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementsMember_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase Agreements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementsMember" xlink:to="lab_us-gaap_RepurchaseAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SavingsPlanTextBlock_258028a8-0469-4bc4-9acc-8f43b3ed780e_terseLabel_en-US" xlink:label="lab_jnj_SavingsPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan</link:label>
    <link:label id="lab_jnj_SavingsPlanTextBlock_label_en-US" xlink:label="lab_jnj_SavingsPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan [Text Block]</link:label>
    <link:label id="lab_jnj_SavingsPlanTextBlock_documentation_en-US" xlink:label="lab_jnj_SavingsPlanTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanTextBlock" xlink:href="jnj-20230101.xsd#jnj_SavingsPlanTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SavingsPlanTextBlock" xlink:to="lab_jnj_SavingsPlanTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_12d3b07f-7a0d-4d4f-94ed-2a8f2b3a4bad_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous international</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SPINESPORTSOTHERMember_b52a6be8-9dd5-4224-9829-3f79c0b4a0ca_terseLabel_en-US" xlink:label="lab_jnj_SPINESPORTSOTHERMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE,SPORTS &amp; OTHER</link:label>
    <link:label id="lab_jnj_SPINESPORTSOTHERMember_label_en-US" xlink:label="lab_jnj_SPINESPORTSOTHERMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE, SPORTS &amp; OTHER [Member]</link:label>
    <link:label id="lab_jnj_SPINESPORTSOTHERMember_documentation_en-US" xlink:label="lab_jnj_SPINESPORTSOTHERMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SPINE &amp; OTHER [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINESPORTSOTHERMember" xlink:href="jnj-20230101.xsd#jnj_SPINESPORTSOTHERMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SPINESPORTSOTHERMember" xlink:to="lab_jnj_SPINESPORTSOTHERMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_d90c4683-4039-4603-8080-d0e3e91f7927_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock, number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_6283c07d-4e79-44bd-9d4d-6692a26abe36_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Less accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RemicadeMember_13cfe4ad-1c9f-4050-a133-90a6ad7bfd60_terseLabel_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade</link:label>
    <link:label id="lab_jnj_RemicadeMember_label_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:label id="lab_jnj_RemicadeMember_documentation_en-US" xlink:label="lab_jnj_RemicadeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remicade [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember" xlink:href="jnj-20230101.xsd#jnj_RemicadeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RemicadeMember" xlink:to="lab_jnj_RemicadeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_ac542861-d0e3-4270-9e5f-9dc7dbaeafa1_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_eb867e1b-1966-49a0-ba00-d002963dd53c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; hedges:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_143f4e16-1bb3-4a62-8ac9-2c6d9c813856_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_ccf71796-5a6e-46a0-bdf8-47d697d0e4af_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum length of time for hedging transaction exposure</link:label>
    <link:label id="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_label_en-US" xlink:label="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum Length of Time, Foreign Currency Cash Flow Hedge</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:to="lab_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TremfyaMember_39349763-4fbd-4b9b-9336-53e0525e5276_terseLabel_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya</link:label>
    <link:label id="lab_jnj_TremfyaMember_label_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfya [Member]</link:label>
    <link:label id="lab_jnj_TremfyaMember_documentation_en-US" xlink:label="lab_jnj_TremfyaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tremfaya</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember" xlink:href="jnj-20230101.xsd#jnj_TremfyaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TremfyaMember" xlink:to="lab_jnj_TremfyaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_70049951-03ee-4ee9-bdb2-7d934397b943_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_28054f3d-f513-480f-9edb-138f23393178_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_222c35ae-9e7d-4f9d-a2f8-d796c2540f1b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash" xlink:to="lab_us-gaap_DividendsCommonStockCash" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_4f6a1a0f-12fd-4545-a3b0-1591e0ce5f36_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par Value $1.00</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_143c2a59-56a8-4713-95cb-2116cb8b94a6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock Issued Amount</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NeuroscienceMember_3692db47-6f03-4c05-b0e1-262c3f9ac18d_terseLabel_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_label_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:label id="lab_jnj_NeuroscienceMember_documentation_en-US" xlink:label="lab_jnj_NeuroscienceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Neuroscience [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember" xlink:href="jnj-20230101.xsd#jnj_NeuroscienceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NeuroscienceMember" xlink:to="lab_jnj_NeuroscienceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_b6584bb3-12d7-4fa7-8de8-67630d1a30ed_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_665228e9-5e14-41c7-801d-a8dff3819699_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares available for future grants under long-term incentive plan</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_6b6ae61a-104f-44d9-83c2-885e553b86ab_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration liability</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_d02d43f9-aafc-46b2-ae2d-98abbd7845f0_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_40ecaade-fd44-4141-8fc1-ce4bfef1350a_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ExercisePriceRangeThreeMember_d248ca28-2c65-48a9-b65d-8260e819e6fc_terseLabel_en-US" xlink:label="lab_jnj_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">$129.51-$141.06</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeThreeMember_label_en-US" xlink:label="lab_jnj_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range Three [Member]</link:label>
    <link:label id="lab_jnj_ExercisePriceRangeThreeMember_documentation_en-US" xlink:label="lab_jnj_ExercisePriceRangeThreeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeThreeMember" xlink:href="jnj-20230101.xsd#jnj_ExercisePriceRangeThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ExercisePriceRangeThreeMember" xlink:to="lab_jnj_ExercisePriceRangeThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_19552901-8eb7-4d9e-a6b5-b73078673c2b_terseLabel_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income tax expense related to change in tax rate from TRAF</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Change In Tax Rate, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Federal Act On Tax Reform And AHV Financing, Change In Tax Rate, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:href="jnj-20230101.xsd#jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:to="lab_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_d8e03032-768d-41a1-b45d-7ce761edcd92_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_6587b944-f8bb-43db-a3b7-f153b9171bd6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Matching contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation_38a7d22a-b7d5-4e8a-8bba-4e1c4ab5e973_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consumer health separation</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Consumer Health Separation</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Consumer Health Separation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_b2b83a1a-361e-4071-9f5a-df57e8912a4b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Accumulated OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_7817c8ac-4bb8-466f-80e6-de00cb333e0a_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_1a3c55e9-8e41-4ee2-86bb-124047a43dd9_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Repurchase of common stock (shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_413c1c73-156f-49b1-90f2-8d9d342d6a0a_verboseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Indefinite-Lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_2ae67f5a-27de-4b17-b4a6-4bc8ecb02167_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation, litigation settlement, percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Litigation Settlement, Percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Litigation Settlement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_a65002ef-cfdc-4ad8-a687-aaf4ffb352ad_terseLabel_en-US" xlink:label="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum reverse repurchase agreement collateral (as a percent)</link:label>
    <link:label id="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_label_en-US" xlink:label="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Collateral Value as a Percent, Reverse Repurchase Agreement</link:label>
    <link:label id="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_documentation_en-US" xlink:label="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Minimum Collateral Value as a Percent, Reverse Repurchase Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:href="jnj-20230101.xsd#jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:to="lab_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_d904ef73-4d2a-4fd3-aef7-cdd3a3b88616_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_1c27bdb2-842e-4523-a088-8358e75b5530_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts receivable trade, less allowances for doubtful accounts $203 (2021, $230)</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_7ec51039-ef23-49c7-89cd-a0db020add30_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Gov't Securities</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4e05c59b-6be1-4494-a117-d7293a773be3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_4f396751-b77a-45e5-8668-c8bc3a136f5f_verboseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_d01ade16-a973-492f-8507-7a0e0698683e_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case Type [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_e8cf7d00-31e7-4b68-bf15-68eec4774030_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of the Company And Business Segments</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AuditorInformationAbstract_label_en-US" xlink:label="lab_jnj_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information [Abstract]</link:label>
    <link:label id="lab_jnj_AuditorInformationAbstract_documentation_en-US" xlink:label="lab_jnj_AuditorInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AuditorInformationAbstract" xlink:href="jnj-20230101.xsd#jnj_AuditorInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AuditorInformationAbstract" xlink:to="lab_jnj_AuditorInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_4571e2a1-e85a-4dc6-9f11-f509391a20aa_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_d18f23dd-186e-4b4c-a452-ad563bd0cada_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net gain on sale of assets/businesses</link:label>
    <link:label id="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (Loss) on Sale of Assets and Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:to="lab_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_141f33b3-d419-40bb-a116-7bc3c05bbcf5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_84020427-a9e9-4b7d-b566-e57e46ef017e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_f1016015-eea3-4477-86fb-5a19ee3780e7_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets gross</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_f159db61-bde1-4785-81b3-516128800e5e_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, marketing and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_0d901096-569a-4fe5-bc57-457bac21505a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contingent consideration reversal</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_689e6232-faa0-450f-b16b-0b8459be716c_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate reconciliation, deduction</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7b62bc6f-0903-4aef-80e6-cd1bd33b5c7d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Available-for-sale, unrecognized loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_251332a2-ffec-4d03-9ee5-bb9d84834528_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease, right-of-use asset</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_48d336fa-a5ce-4842-a12c-59628263bb2c_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stocks repurchased</link:label>
    <link:label id="lab_us-gaap_StockRepurchasedDuringPeriodValue_label_en-US" xlink:label="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock Repurchased During Period, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchasedDuringPeriodValue" xlink:to="lab_us-gaap_StockRepurchasedDuringPeriodValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_8ef07fde-a33f-4eb4-81dc-55580c3239fb_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_50e9955c-0eca-439f-95c0-9a302a5b1959_terseLabel_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_label_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:label id="lab_jnj_A3.500Notesdue2048Member_documentation_en-US" xlink:label="lab_jnj_A3.500Notesdue2048Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.500% Notes due 2048 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member" xlink:href="jnj-20230101.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.500Notesdue2048Member" xlink:to="lab_jnj_A3.500Notesdue2048Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_d63f08a3-7791-457b-8587-4c2cc30b8ee0_verboseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_329e63b4-fba3-4a7b-9a70-08702b76d3b1_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_383d31d1-2b76-4f01-9360-025b1e40476d_terseLabel_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, fair value adjustment, impairment loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_label_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentImpairmentLoss_documentation_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:href="jnj-20230101.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:to="lab_jnj_EquityFairValueAdjustmentImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_dcca8eb0-50f5-413f-a237-3df17139f93b_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_60cb945a-492e-41b2-b741-59fa26d69358_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_04f98410-6cbe-49a2-8fd4-714f1b291c1c_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_7c07a5e4-23ae-4932-a287-f662c1ffc355_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IdorsiaMember_6c35f4eb-89e9-41b6-ac5f-7c54d9b333b7_terseLabel_en-US" xlink:label="lab_jnj_IdorsiaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia</link:label>
    <link:label id="lab_jnj_IdorsiaMember_label_en-US" xlink:label="lab_jnj_IdorsiaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia [Member]</link:label>
    <link:label id="lab_jnj_IdorsiaMember_documentation_en-US" xlink:label="lab_jnj_IdorsiaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Idorsia [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IdorsiaMember" xlink:href="jnj-20230101.xsd#jnj_IdorsiaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IdorsiaMember" xlink:to="lab_jnj_IdorsiaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_9604e694-9638-4130-a572-ac6edd6bfc53_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_6e366957-eb24-484d-a52c-c1319b73d357_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingMember_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingMember" xlink:to="lab_us-gaap_ShippingAndHandlingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_e302600d-f770-4f6b-8148-5a4ce3729dc0_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives not designated as hedging instruments : Liabilities</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:to="lab_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_3095d928-9517-4d8d-b19e-446522e45ac3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_3339bdef-3174-48c0-840e-afc310ff4378_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027-2031</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan Expected Future Benefit Contribution In Five Fiscal Years Thereafter</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined benefit plan expected future benefit contribution in five fiscal years thereafter.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:to="lab_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_6fb767c4-f897-4be2-b50c-6548b5a22cfb_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_322e86ba-e849-49b6-a21a-fbe2f101a43b_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_6afae89c-ea8a-4e1d-9163-893644f94020_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortization of net actuarial loss</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_93245b27-e049-4562-8854-7ebf97e996a9_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain (loss), net of amortization</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:href="jnj-20230101.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_a9c92145-eec5-4257-a04d-6bf042a4fec1_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net earnings to cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_cff4a6df-96c1-4c49-85cf-6c43689ecbd3_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_78f51a3c-1cfd-49bf-81f6-7dfcec3844aa_terseLabel_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TRAF effect on tax rate</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_label_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Federal Act On Tax Reform And AHV Financing, Percent</link:label>
    <link:label id="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_documentation_en-US" xlink:label="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Tax Rate Reconciliation, Federal Act On Tax Reform And AHV Financing, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:href="jnj-20230101.xsd#jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:to="lab_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_55076bd0-7d4b-4adc-936e-4553b5e96495_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment and Depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_5df91a94-3f4f-4670-a04c-199cbee7f830_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from short-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Short-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_7b80488a-30ea-491c-a5f0-7a2396f7bd9c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4b2fe708-a0da-4430-a71c-56730e39c2ad_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. taxes</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_7f58bbcd-7395-44fe-8f0b-0562c5ad5991_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_a3d27cd6-0549-4ed9-8c2f-7f538c202631_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLineItems_013201da-83a5-4034-9614-fcdec5b0f767_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems" xlink:to="lab_us-gaap_DerivativeLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_6a9a245d-5ece-4319-8194-b4b9d8a8053e_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_ad23b41d-11ae-43ff-aec5-59d89ea0d532_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_dbe75731-4adc-41a5-abd9-20eeff7f27bf_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain" xlink:to="lab_us-gaap_LossContingencyNatureDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_8f014d66-6e9f-48af-93d2-b583923df851_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c9abae54-2f49-436b-adde-bfb81bfbfa04_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_21809323-4a15-4016-8fbb-a98d31de8f9d_terseLabel_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of reclassification of cash flow hedge gain (loss)</link:label>
    <link:label id="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_label_en-US" xlink:label="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Description of Reclassification of Cash Flow Hedge Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:to="lab_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_d7ce8801-7569-41e3-bb9e-9a9a2b749567_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and building equipment</link:label>
    <link:label id="lab_us-gaap_BuildingAndBuildingImprovementsMember_label_en-US" xlink:label="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Building and Building Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingAndBuildingImprovementsMember" xlink:to="lab_us-gaap_BuildingAndBuildingImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_dc2b0cd6-5766-46ee-a61d-7a6d08d8fd21_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Activity Related to Equity Investments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_0508468e-292a-43d8-89ec-9e9140921ecc_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividends paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareCashPaid_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Cash Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:to="lab_us-gaap_CommonStockDividendsPerShareCashPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_7ada9801-7415-4ff6-9d80-8f84421bf267_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_d64bed65-1b2f-47cc-80e7-b71ca06c3588_terseLabel_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit support agreements activity, net</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_label_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:label id="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_documentation_en-US" xlink:label="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:href="jnj-20230101.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:to="lab_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_e8cabcb1-b6a6-4de1-8b43-2851fbde34d6_verboseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due November 2028</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_8776f694-bcc6-495a-9944-912fda5da671_terseLabel_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes due 2028 (750MM Euro 1.0651)(2)/(750MM Euro 1.1311)(3)</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_label_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:label id="lab_jnj_A1.150NotesDue2028Member_documentation_en-US" xlink:label="lab_jnj_A1.150NotesDue2028Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">1.150% Notes Due 2028 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member" xlink:href="jnj-20230101.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A1.150NotesDue2028Member" xlink:to="lab_jnj_A1.150NotesDue2028Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_845a08af-b594-4584-9f7d-b4bbcbe4f0d0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_342cfe5e-af9f-4829-9969-9fec2732afbb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Average fair value of RSU's and PSU's granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_9f4d2e61-ce41-4099-9d29-c15193719cd1_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-Term Debt [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems" xlink:to="lab_us-gaap_ShortTermDebtLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_335ba6a3-e3ab-4cff-ad4e-7e69c35749e6_terseLabel_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_label_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:label id="lab_jnj_EDURANTrilpivirineMember_documentation_en-US" xlink:label="lab_jnj_EDURANTrilpivirineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">EDURANT/rilpivirine [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember" xlink:href="jnj-20230101.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EDURANTrilpivirineMember" xlink:to="lab_jnj_EDURANTrilpivirineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_d38c5be3-a175-41a3-b163-477fcb020864_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtMember_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible Debt [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtMember" xlink:to="lab_us-gaap_ConvertibleDebtMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_fac6964b-f376-48c2-9266-d8614ae94b87_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember" xlink:to="lab_us-gaap_OperatingSegmentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_c372fb08-dbc7-43ee-86c0-05584cd6bbea_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss contingency, estimate of additional possible loss</link:label>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_label_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Additional Possible Loss</link:label>
    <link:label id="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_documentation_en-US" xlink:label="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Estimate of Additional Possible Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:href="jnj-20230101.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:to="lab_jnj_LossContingencyEstimateOfAdditionalPossibleLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_1ccdc102-d126-4233-bf24-e336fed66785_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_8e3ba9c3-13a6-459b-9ca7-f989800d5f1e_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Project Concentration Risk</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember" xlink:to="lab_us-gaap_ProductConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_541db57e-95ec-405a-950c-b52930325dd5_terseLabel_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_label_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</link:label>
    <link:label id="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_documentation_en-US" xlink:label="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:to="lab_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_339cfe5c-a3fe-433c-910b-6349f8c8f66e_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:href="jnj-20230101.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_caeff266-5511-4056-a128-3093cdf84880_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from long-term debt, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherIncomeMember_a3f31e0d-1792-4736-b707-1a4f6879be6d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income</link:label>
    <link:label id="lab_us-gaap_OtherIncomeMember_label_en-US" xlink:label="lab_us-gaap_OtherIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Income [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeMember" xlink:to="lab_us-gaap_OtherIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_4a52f260-56d5-4f56-95cd-9650978e3fba_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_IMBRUVICAMember_dd67ac4a-bfb9-4eb3-bad3-70e7112e2643_terseLabel_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_label_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:label id="lab_jnj_IMBRUVICAMember_documentation_en-US" xlink:label="lab_jnj_IMBRUVICAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">IMBRUVICA [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember" xlink:href="jnj-20230101.xsd#jnj_IMBRUVICAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_IMBRUVICAMember" xlink:to="lab_jnj_IMBRUVICAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_2d3f77cb-e9c9-472e-84fc-7720c438602e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives &amp; hedges</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2250NotesDue2050Member_46916f32-d4c6-4334-9130-ed95a5224cba_terseLabel_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_label_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050 [Member]</link:label>
    <link:label id="lab_jnj_A2250NotesDue2050Member_documentation_en-US" xlink:label="lab_jnj_A2250NotesDue2050Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.250% Notes due 2050</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member" xlink:href="jnj-20230101.xsd#jnj_A2250NotesDue2050Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2250NotesDue2050Member" xlink:to="lab_jnj_A2250NotesDue2050Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_ba865d0e-7e38-4b35-abf1-67b1b9e54303_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency transaction gain (loss), before tax</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_ce99fcce-5cd8-466b-8aeb-af057fa25c90_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisition related costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Acquisition Related Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="lab_us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_d986a32d-a1af-4b08-b33e-edf1a5fcffea_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember" xlink:to="lab_us-gaap_CashFlowHedgingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_9cb30422-5381-4865-9d72-d2b6b0279da5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash used by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_f9a8562e-4a1a-4b51-9d73-22076dfe4277_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee related obligations</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_05ef9b57-052c-49b1-a849-83963b90cf9d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_5ea3ad6b-909e-4ee4-9903-2fb9a796e289_terseLabel_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS)</link:label>
    <link:label id="lab_us-gaap_InternalRevenueServiceIRSMember_label_en-US" xlink:label="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_us-gaap_InternalRevenueServiceIRSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_2b2cd447-8364-469a-b44c-d4c129ab1add_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity method investments, fair value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_28e8544d-3594-4d10-883c-55da0d6c6938_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OralCareMember_580109c6-6ece-4d37-9c30-5452c217da6d_terseLabel_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care</link:label>
    <link:label id="lab_jnj_OralCareMember_label_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:label id="lab_jnj_OralCareMember_documentation_en-US" xlink:label="lab_jnj_OralCareMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oral Care [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember" xlink:href="jnj-20230101.xsd#jnj_OralCareMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OralCareMember" xlink:to="lab_jnj_OralCareMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_03df95f0-ebaa-42b3-93e2-034b13235ec5_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_cee3d2de-e9de-4a9c-89c2-dc878e79b19c_terseLabel_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_label_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:label id="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_documentation_en-US" xlink:label="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:href="jnj-20230101.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:to="lab_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_66dd4d91-4137-4b6c-9d6c-0535912899bf_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_ab2f4f7f-02e8-4d69-864c-a7169b16cf7b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee benefits</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_062697fd-d382-41bd-8f37-d917c024c206_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_ebcc4a61-bd33-494a-95c0-452f0f72f41d_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate maturities of long-term obligations</link:label>
    <link:label id="lab_us-gaap_LongTermDebtByMaturityAbstract_label_en-US" xlink:label="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract" xlink:to="lab_us-gaap_LongTermDebtByMaturityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_383caab1-6c64-431c-b9da-f68ab090b3fb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Funded Status</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Net Funded Status [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetFundedStatusTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfNetFundedStatusTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_207baf84-ce60-490d-8924-6e6b30eccb3e_verboseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross currency interest rate swaps</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_e5238147-307b-4305-807a-21b2790d83b6_terseLabel_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross currency interest rate swaps contracts:</link:label>
    <link:label id="lab_us-gaap_CrossCurrencyInterestRateContractMember_label_en-US" xlink:label="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cross Currency Interest Rate Contract [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CrossCurrencyInterestRateContractMember" xlink:to="lab_us-gaap_CrossCurrencyInterestRateContractMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_bea820c8-2ec2-4d6e-bdc5-70cdd9a0dc95_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6c202633-6c09-4147-a6cc-ab4c9063627f_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. statutory rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DividendsPayableAmountPerShare_e4087dea-1b98-4fe2-906f-59bfc4c30a5f_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Amount Per Share</link:label>
    <link:label id="lab_us-gaap_DividendsPayableAmountPerShare_label_en-US" xlink:label="lab_us-gaap_DividendsPayableAmountPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends Payable, Amount Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableAmountPerShare" xlink:to="lab_us-gaap_DividendsPayableAmountPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AssetWriteoffMember_d663580a-4f36-4dd8-b309-567ce1677174_terseLabel_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-offs/Sales</link:label>
    <link:label id="lab_jnj_AssetWriteoffMember_label_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off [Member]</link:label>
    <link:label id="lab_jnj_AssetWriteoffMember_documentation_en-US" xlink:label="lab_jnj_AssetWriteoffMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Write-off [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember" xlink:href="jnj-20230101.xsd#jnj_AssetWriteoffMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AssetWriteoffMember" xlink:to="lab_jnj_AssetWriteoffMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess_0c09e553-2018-43ea-bbc2-e7fdc71da07a_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares subject to full value award, excess (in shares)</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards, Excess</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards, Excess</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" xlink:to="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTable_c030a2ae-a125-47f1-9708-665e53b1eea3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_label_en-US" xlink:label="lab_us-gaap_DerivativeTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable" xlink:to="lab_us-gaap_DerivativeTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_Wholesaler2Member_17f93076-7f39-4f22-9643-fb78474f9c01_terseLabel_en-US" xlink:label="lab_jnj_Wholesaler2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 2</link:label>
    <link:label id="lab_jnj_Wholesaler2Member_label_en-US" xlink:label="lab_jnj_Wholesaler2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 2 [Member]</link:label>
    <link:label id="lab_jnj_Wholesaler2Member_documentation_en-US" xlink:label="lab_jnj_Wholesaler2Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wholesaler 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler2Member" xlink:href="jnj-20230101.xsd#jnj_Wholesaler2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_Wholesaler2Member" xlink:to="lab_jnj_Wholesaler2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8d90329b-e312-472e-9ef8-12f31c0dc262_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding beginning of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_e9dcf88d-e7cb-4e02-996f-05a9ae301f25_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding end of period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_0a3bd7a6-539b-4f0a-9438-ed900873c6b4_terseLabel_en-US" xlink:label="lab_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</link:label>
    <link:label id="lab_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_label_en-US" xlink:label="lab_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</link:label>
    <link:label id="lab_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_documentation_en-US" xlink:label="lab_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:href="jnj-20230101.xsd#jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:to="lab_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AsrMember_fa4eabcd-609e-4d2a-b02c-1fb18c11a7f3_terseLabel_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR</link:label>
    <link:label id="lab_jnj_AsrMember_label_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR [Member]</link:label>
    <link:label id="lab_jnj_AsrMember_documentation_en-US" xlink:label="lab_jnj_AsrMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASR.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember" xlink:href="jnj-20230101.xsd#jnj_AsrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AsrMember" xlink:to="lab_jnj_AsrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_b66023e8-7d10-4c17-aaed-416583765e87_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Investment Not Readily Marketable [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:to="lab_us-gaap_OtherInvestmentNotReadilyMarketableLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityOther_040cd329-3e52-42ac-9f17-2614993c0348_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther" xlink:to="lab_us-gaap_StockholdersEquityOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_ffcc72f2-068c-45d7-9e16-59056305f132_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Components of Deferred Tax Assets and Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_9e3bb691-3693-44d8-89b6-fc1d6cae8781_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_decd55d2-9b4e-45ae-b4a8-4c6c9c062cb0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Securities:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_ce339f77-7107-4bbd-b060-e624bc527745_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, plant and equipment, net (Notes&#160;1 and 4)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_d9eb2d2f-5eba-4ede-820e-c87082e8351b_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total property, plant and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_149c0f9f-addd-4c07-85eb-76eb48d9b2d8_terseLabel_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserve established</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_label_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established within Trust</link:label>
    <link:label id="lab_jnj_LossContingencyReserveEstablishedWithinTrust_documentation_en-US" xlink:label="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Reserve Established within Trust</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:href="jnj-20230101.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:to="lab_jnj_LossContingencyReserveEstablishedWithinTrust" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_3b4906b9-0413-49ce-800a-9878308ecd92_negatedTerseLabel_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effect of exchange rates</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_label_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss), pension and other, effects of exchange rate net of tax</link:label>
    <link:label id="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_documentation_en-US" xlink:label="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">other comprehensive income loss, pension and other , effects of exchange rate net of tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:href="jnj-20230101.xsd#jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:to="lab_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_1faf5212-714b-48c3-a0ee-c17ac7ac190c_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) recognized in AOCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_50a85c17-3bcb-4a29-9ca7-e74c7217637d_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Divestitures&#160;&amp; acquisitions</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:to="lab_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_3d5f4b13-7424-4ba7-a191-bebcec90315b_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_113d405f-3860-4270-bee0-613c885a825a_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_e469af88-d808-4282-8a5b-59da48674c05_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other (income) expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_776a7a9a-d090-4baa-91aa-261916bc88b9_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_97639790-a041-4e31-b0ab-3944bc8d90c3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of stock (in USD per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_4dbdd067-8001-433b-b443-c14d0c2aefa6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DebtInstrumentConvertibleAmountOfLoanConverted_b70956e5-6772-4c42-a353-5a0104991a48_terseLabel_en-US" xlink:label="lab_jnj_DebtInstrumentConvertibleAmountOfLoanConverted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Convertible debt, amount of loan converted</link:label>
    <link:label id="lab_jnj_DebtInstrumentConvertibleAmountOfLoanConverted_label_en-US" xlink:label="lab_jnj_DebtInstrumentConvertibleAmountOfLoanConverted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Amount of Loan Converted</link:label>
    <link:label id="lab_jnj_DebtInstrumentConvertibleAmountOfLoanConverted_documentation_en-US" xlink:label="lab_jnj_DebtInstrumentConvertibleAmountOfLoanConverted" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument, Convertible, Amount of Loan Converted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DebtInstrumentConvertibleAmountOfLoanConverted" xlink:href="jnj-20230101.xsd#jnj_DebtInstrumentConvertibleAmountOfLoanConverted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DebtInstrumentConvertibleAmountOfLoanConverted" xlink:to="lab_jnj_DebtInstrumentConvertibleAmountOfLoanConverted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_41f3c96b-f9e7-4ee8-997f-5cd18a7f0bb0_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:to="lab_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_c5e96e55-d01d-4c87-a038-9b45954464b3_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income (loss) (Note&#160;13)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_afc9fc05-47fc-4b36-aefe-8814cf9309af_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized net transition obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Transition Asset (Obligation), before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_7bc462d8-2b0c-48c6-bcf1-7fd011504cb6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected long-term rate of return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_3e1f4a12-2678-4fe7-9ded-c66e4f1be3e1_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_9bdc85c3-b7e0-4ecd-be44-e0f82b0573f3_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for legal settlements</link:label>
    <link:label id="lab_us-gaap_PaymentsForLegalSettlements_label_en-US" xlink:label="lab_us-gaap_PaymentsForLegalSettlements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments for Legal Settlements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForLegalSettlements" xlink:to="lab_us-gaap_PaymentsForLegalSettlements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SettledLitigationMember_fbde077e-5dc3-466e-be1d-7e5c96927aac_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember" xlink:to="lab_us-gaap_SettledLitigationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_b4920d9a-941f-4e1b-81b6-264dd547e822_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ClassIRecommendationForImpellaMember_d03f63dd-924f-412e-90b3-a7a7d92edbcf_terseLabel_en-US" xlink:label="lab_jnj_ClassIRecommendationForImpellaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class I Recommendation For Impella</link:label>
    <link:label id="lab_jnj_ClassIRecommendationForImpellaMember_label_en-US" xlink:label="lab_jnj_ClassIRecommendationForImpellaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class I Recommendation For Impella [Member]</link:label>
    <link:label id="lab_jnj_ClassIRecommendationForImpellaMember_documentation_en-US" xlink:label="lab_jnj_ClassIRecommendationForImpellaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class I Recommendation For Impella</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ClassIRecommendationForImpellaMember" xlink:href="jnj-20230101.xsd#jnj_ClassIRecommendationForImpellaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ClassIRecommendationForImpellaMember" xlink:to="lab_jnj_ClassIRecommendationForImpellaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_00ae6187-5814-4020-a75d-d28d27e4e560_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash dividend (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_9f1c2c6d-99af-41b4-b1df-94f738e0f020_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite lived intangible assets net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_f54f8911-a9a5-4179-96fb-19e64255e3af_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_29d19087-b7e9-44de-8bed-5580cfbc8238_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total compensation cost not yet recognized for option</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_59313af8-bbc0-4088-a454-02b7825e81f4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise of options, tax benefit</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_427a308a-ea77-41eb-bae5-7729d4974dca_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Outstanding Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_2fe3ea1e-f8a2-4fd1-a2b9-e7dcf35cb7ba_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.05Notesdue2023Member_2416c9b9-48cf-4ca4-8790-0eb2d1d46766_terseLabel_en-US" xlink:label="lab_jnj_A2.05Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.05% Notes due 2023</link:label>
    <link:label id="lab_jnj_A2.05Notesdue2023Member_label_en-US" xlink:label="lab_jnj_A2.05Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.05% Notes due 2023 [Member]</link:label>
    <link:label id="lab_jnj_A2.05Notesdue2023Member_documentation_en-US" xlink:label="lab_jnj_A2.05Notesdue2023Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.05% Notes due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.05Notesdue2023Member" xlink:href="jnj-20230101.xsd#jnj_A2.05Notesdue2023Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.05Notesdue2023Member" xlink:to="lab_jnj_A2.05Notesdue2023Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskLineItems_2f4497b0-60dd-4239-a26a-491834a43feb_terseLabel_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk [Line Items]</link:label>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskLineItems_label_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of Credit Risk [Line Items]</link:label>
    <link:label id="lab_jnj_ConcentrationOfCreditRiskLineItems_documentation_en-US" xlink:label="lab_jnj_ConcentrationOfCreditRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration of credit risk.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskLineItems" xlink:href="jnj-20230101.xsd#jnj_ConcentrationOfCreditRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems" xlink:to="lab_jnj_ConcentrationOfCreditRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock_a0d95163-b4da-4938-9733-e37bd1af5119_terseLabel_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling</link:label>
    <link:label id="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shipping and Handling Cost, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:to="lab_us-gaap_ShippingAndHandlingCostPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_71fec3d0-45f1-4747-9474-859c73da2f8a_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Marketable securities assumed</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_8d79a2dd-616c-438e-a872-a8ef3ef21af2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_AurisHealthMember_28e96164-5d2d-4957-a323-3ea317917917_terseLabel_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:label id="lab_jnj_AurisHealthMember_label_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health [Member]</link:label>
    <link:label id="lab_jnj_AurisHealthMember_documentation_en-US" xlink:label="lab_jnj_AurisHealthMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auris Health</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember" xlink:href="jnj-20230101.xsd#jnj_AurisHealthMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_AurisHealthMember" xlink:to="lab_jnj_AurisHealthMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_16633cfe-2939-4b49-8aca-5252de19bc48_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_e1d0b178-9bf7-4dc8-a35e-2ad502fa6523_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_7b5b5a23-b1de-44d5-99a2-968cad769551_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_135d864c-be1a-46ee-9869-114850f20a83_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_34bb8279-8203-4f2d-804d-5583191d72a8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination and Asset Acquisition [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:to="lab_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_324d5678-b7f6-408b-bbfc-c2ddd5262a48_terseLabel_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Sales by Segment of Business</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_label_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales By Segment Of Business [Table Text Block]</link:label>
    <link:label id="lab_jnj_SalesBySegmentOfBusinessTableTextBlock_documentation_en-US" xlink:label="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:href="jnj-20230101.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:to="lab_jnj_SalesBySegmentOfBusinessTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_78a83b73-b265-4751-8895-d3e5a2009eb9_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Gov't Agencies</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_d90ae56d-5ca6-4608-8db4-bb9320198b2b_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_2389f497-5d8d-44b7-9582-6eeb8ad9d012_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rate to which the cost trend rate is assumed to decline (ultimate trend)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Ultimate Health Care Cost Trend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:to="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_23566456-00d5-4a20-8a91-f56fbdd34107_verboseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_367e84e9-c9fb-4d5e-87b7-cf00441d7008_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain/(Loss) Recognized In Income on Derivative</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_30f3bfbe-a27e-4b02-9a3e-6b5e09accae0_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsegmentsDomain_bec122d3-78cc-462e-862d-2e6d9ef00d09_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain" xlink:to="lab_us-gaap_SubsegmentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_9efc23b8-6afd-4d3a-8e73-6afc67f418f9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted, average exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_7c1de8a6-97de-4502-8ffb-41972a4cea2b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Benefits paid from plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9487b3fb-5915-45da-af56-a173627ec04d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Carrying Amount, available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProductLiabilityPolicyTextBlock_e70c6824-a3d5-4879-b0ff-d71742e408a1_terseLabel_en-US" xlink:label="lab_jnj_ProductLiabilityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability</link:label>
    <link:label id="lab_jnj_ProductLiabilityPolicyTextBlock_label_en-US" xlink:label="lab_jnj_ProductLiabilityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product Liability [Policy Text Block]</link:label>
    <link:label id="lab_jnj_ProductLiabilityPolicyTextBlock_documentation_en-US" xlink:label="lab_jnj_ProductLiabilityPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product liability.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityPolicyTextBlock" xlink:href="jnj-20230101.xsd#jnj_ProductLiabilityPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProductLiabilityPolicyTextBlock" xlink:to="lab_jnj_ProductLiabilityPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_d5b32cae-6f27-4ad1-99be-efefaf857c1e_terseLabel_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_label_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:label id="lab_jnj_A3.70Notesdue2046Member_documentation_en-US" xlink:label="lab_jnj_A3.70Notesdue2046Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.70% Notes due 2046 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member" xlink:href="jnj-20230101.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.70Notesdue2046Member" xlink:to="lab_jnj_A3.70Notesdue2046Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_81754643-4b82-4b13-9b29-b0e1ae2aacbe_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reserves&#160;&amp; liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices_7f0ff872-eea4-4afb-9f6b-7511354d57b9_terseLabel_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, fair value adjustment, change in observable prices</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices_label_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Change in Observable Prices</link:label>
    <link:label id="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices_documentation_en-US" xlink:label="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Fair Value Adjustment, Change in Observable Prices</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:href="jnj-20230101.xsd#jnj_EquityFairValueAdjustmentChangeinObservablePrices"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:to="lab_jnj_EquityFairValueAdjustmentChangeinObservablePrices" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_f4f6d398-138e-47c8-8b0a-9719da1a36a5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxAssetsOtherDomestic_ab80c5e7-523f-42ad-9775-85727605733d_terseLabel_en-US" xlink:label="lab_jnj_DeferredTaxAssetsOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous U.S.&#160;</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsOtherDomestic_label_en-US" xlink:label="lab_jnj_DeferredTaxAssetsOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets Other Domestic</link:label>
    <link:label id="lab_jnj_DeferredTaxAssetsOtherDomestic_documentation_en-US" xlink:label="lab_jnj_DeferredTaxAssetsOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets other domestic.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsOtherDomestic" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxAssetsOtherDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxAssetsOtherDomestic" xlink:to="lab_jnj_DeferredTaxAssetsOtherDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ConcentrationRiskThresholdPercentage_7d73118c-1f47-483d-9735-b7beae8748dc_terseLabel_en-US" xlink:label="lab_jnj_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration risk, threshold percentage (as a percent)</link:label>
    <link:label id="lab_jnj_ConcentrationRiskThresholdPercentage_label_en-US" xlink:label="lab_jnj_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Threshold Percentage</link:label>
    <link:label id="lab_jnj_ConcentrationRiskThresholdPercentage_documentation_en-US" xlink:label="lab_jnj_ConcentrationRiskThresholdPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Threshold Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationRiskThresholdPercentage" xlink:href="jnj-20230101.xsd#jnj_ConcentrationRiskThresholdPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ConcentrationRiskThresholdPercentage" xlink:to="lab_jnj_ConcentrationRiskThresholdPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_a973a0b0-788b-4d77-b435-a5192db1d795_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring (Note 20)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_492cb0ea-d544-4e03-9023-34d5b4a18fcb_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_58434567-f3f2-49b9-a393-515c10934829_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Decrease/(Increase) in other current and non-current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_c42380d4-d9f5-40cc-a9ba-e79e87e905ca_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Maturity, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_a22f3d39-2f08-405d-87ce-5e5d10248f8c_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain" xlink:to="lab_us-gaap_HedgingRelationshipDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_182770ed-ffa7-4aa1-9834-e66759b7bc8e_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis" xlink:to="lab_us-gaap_HedgingDesignationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_d81fbbd6-b85a-46b6-8452-33bd11451dce_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_f17d2ca9-c4b9-4f92-8445-243cfd272a16_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_c15652b1-3b2a-4100-aa25-46c110a2f37e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_10ffed5e-a57d-46d0-9db7-96730cfcd3bc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Support Agreement (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetFairValueGrossLiability_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, Liability Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:to="lab_us-gaap_DerivativeAssetFairValueGrossLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_3c3c5633-fd4b-47f7-9112-958af1ca524d_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_9429a52d-1c90-444a-9e90-be0dd3719046_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. taxes</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_cf09cf4f-c761-4a2e-a41b-abb39041c2ae_verboseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Plans</link:label>
    <link:label id="lab_country_US_7d718539-aa64-4ef0-b946-ab831c59856b_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_6e707730-284f-4dbb-a128-c402ccda9b4c_terseLabel_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_label_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:label id="lab_jnj_PatentsAndTrademarksMember_documentation_en-US" xlink:label="lab_jnj_PatentsAndTrademarksMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Patents And Trademarks [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember" xlink:href="jnj-20230101.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PatentsAndTrademarksMember" xlink:to="lab_jnj_PatentsAndTrademarksMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_449e195d-2b12-4f6a-b8b8-cd3e508e6386_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation cost charged for Long term incentive plan</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_e206b020-d9b8-4281-bd10-58464c99cf68_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_93b9ca9b-be5e-40ed-9cba-8798e6a75b93_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies (Note 19)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MedTechMember_e302fcfd-4118-4418-8887-2733552d5f53_terseLabel_en-US" xlink:label="lab_jnj_MedTechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices</link:label>
    <link:label id="lab_jnj_MedTechMember_4961063a-f564-4d6c-909f-be2a7629cba6_verboseLabel_en-US" xlink:label="lab_jnj_MedTechMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Medical Devices</link:label>
    <link:label id="lab_jnj_MedTechMember_label_en-US" xlink:label="lab_jnj_MedTechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MedTech [Member]</link:label>
    <link:label id="lab_jnj_MedTechMember_documentation_en-US" xlink:label="lab_jnj_MedTechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">MedTech [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember" xlink:href="jnj-20230101.xsd#jnj_MedTechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MedTechMember" xlink:to="lab_jnj_MedTechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_14ad5eba-cf0d-4c87-b1dd-e6370eb4a8d3_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2c35f777-ba6d-4b4d-a8b8-46b5b0badc21_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercise price beginning of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f380b329-1c4c-4f03-8ee7-9e0b5cda1509_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options exercise price end of period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_ce7d00e2-871a-42f8-85e7-d6e3474b0411_terseLabel_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A3.625Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A3.625Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">3.625% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member" xlink:href="jnj-20230101.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A3.625Notesdue2037Member" xlink:to="lab_jnj_A3.625Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset_25f91f85-cd2b-4e20-8b7a-e7d16859d3ee_terseLabel_en-US" xlink:label="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of company's common stock to plan asset</link:label>
    <link:label id="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset_label_en-US" xlink:label="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Of Company's Common Stock To Plan Asset</link:label>
    <link:label id="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset_documentation_en-US" xlink:label="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage of the company's common stock to the total plan asset.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:href="jnj-20230101.xsd#jnj_PercentageOfCompanysCommonStockToPlanAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:to="lab_jnj_PercentageOfCompanysCommonStockToPlanAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_8cb97dcc-f5c7-46bd-afa8-7908ff2930e5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherImmunologyMember_08231ac4-f5af-442b-ab5e-3ef10b10b6fc_terseLabel_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_label_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:label id="lab_jnj_OtherImmunologyMember_documentation_en-US" xlink:label="lab_jnj_OtherImmunologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Immunology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember" xlink:href="jnj-20230101.xsd#jnj_OtherImmunologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherImmunologyMember" xlink:to="lab_jnj_OtherImmunologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_a64dbb2a-4e85-4858-8b30-90ad21bdd36f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications to earnings</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_8236f268-1584-4fce-a210-56cdb7a9548a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amount of gain or (loss) reclassified from AOCI into income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_FiscalPeriodPolicyTextBlock_60d2ab20-dace-4c46-a7dd-9e4533e70af8_terseLabel_en-US" xlink:label="lab_jnj_FiscalPeriodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Annual Closing Date</link:label>
    <link:label id="lab_jnj_FiscalPeriodPolicyTextBlock_label_en-US" xlink:label="lab_jnj_FiscalPeriodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period [Policy Text Block]</link:label>
    <link:label id="lab_jnj_FiscalPeriodPolicyTextBlock_documentation_en-US" xlink:label="lab_jnj_FiscalPeriodPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal period policy.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiscalPeriodPolicyTextBlock" xlink:href="jnj-20230101.xsd#jnj_FiscalPeriodPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_FiscalPeriodPolicyTextBlock" xlink:to="lab_jnj_FiscalPeriodPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CommingledFundsMember_989fb961-acbe-45fa-82d2-637befe5b2cc_terseLabel_en-US" xlink:label="lab_jnj_CommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commingled funds</link:label>
    <link:label id="lab_jnj_CommingledFundsMember_label_en-US" xlink:label="lab_jnj_CommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commingled Funds [Member]</link:label>
    <link:label id="lab_jnj_CommingledFundsMember_documentation_en-US" xlink:label="lab_jnj_CommingledFundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commingled funds.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember" xlink:href="jnj-20230101.xsd#jnj_CommingledFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CommingledFundsMember" xlink:to="lab_jnj_CommingledFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_1a39e321-c468-4c19-9174-293af7e7865c_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_fb1930a0-00b9-4c71-85c8-24db02997010_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales to Customers</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_9683a7ce-abf9-43f9-88a3-16e883b6d85f_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity before Treasury Stock</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityBeforeTreasuryStock_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity before Treasury Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:to="lab_us-gaap_StockholdersEquityBeforeTreasuryStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_cb0eacdd-ab1b-4779-aa2f-515dc7fdaf55_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_18ca419e-afb1-49fb-b821-f75cd286406d_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_57a4c923-3090-4a3f-bfbc-4eaa4a379783_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_EvraAndDoxilMember_f036d2ac-5ad4-4cbf-9ea0-c0ad9712962f_terseLabel_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil</link:label>
    <link:label id="lab_jnj_EvraAndDoxilMember_label_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil [Member]</link:label>
    <link:label id="lab_jnj_EvraAndDoxilMember_documentation_en-US" xlink:label="lab_jnj_EvraAndDoxilMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Evra and Doxil</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember" xlink:href="jnj-20230101.xsd#jnj_EvraAndDoxilMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_EvraAndDoxilMember" xlink:to="lab_jnj_EvraAndDoxilMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_a3d413c8-9f97-4386-876a-c6290180a1c7_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover page.</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_1a2c13df-b64f-4323-b6af-998b32ccbe46_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense capitalized</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized" xlink:to="lab_us-gaap_InterestCostsCapitalized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_11eccbe6-b9fa-4a45-b9db-98a4226f3e8a_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_c8144c7d-6f89-4f2a-95d4-3c2a55e8515b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_70a9ec29-1249-4475-bc5c-54e502348342_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_a41c4ffa-52a9-40ed-b5b0-441a263dc0af_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Change in Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_3ccdf988-a3c1-4f9e-b78a-d0ce928dd143_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income reported for tax purposes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterventionalSolutionsMember_95d72070-f28d-4117-b3bb-b7220f4596a1_terseLabel_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_label_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:label id="lab_jnj_InterventionalSolutionsMember_documentation_en-US" xlink:label="lab_jnj_InterventionalSolutionsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interventional Solutions [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember" xlink:href="jnj-20230101.xsd#jnj_InterventionalSolutionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterventionalSolutionsMember" xlink:to="lab_jnj_InterventionalSolutionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_31a54728-77e0-4be6-b451-a03fc93e9a34_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_55850073-e81a-40fc-a61e-57abc571dddf_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent" xlink:to="lab_us-gaap_DerivativeAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_RevenuesContingentConsideration_e562a71f-092d-43bd-9741-1b96ccebdb2d_terseLabel_en-US" xlink:label="lab_jnj_RevenuesContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Contingent Consideration</link:label>
    <link:label id="lab_jnj_RevenuesContingentConsideration_label_en-US" xlink:label="lab_jnj_RevenuesContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Contingent Consideration</link:label>
    <link:label id="lab_jnj_RevenuesContingentConsideration_documentation_en-US" xlink:label="lab_jnj_RevenuesContingentConsideration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues, Contingent Consideration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RevenuesContingentConsideration" xlink:href="jnj-20230101.xsd#jnj_RevenuesContingentConsideration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_RevenuesContingentConsideration" xlink:to="lab_jnj_RevenuesContingentConsideration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_b25d8c06-bb50-420d-91f0-f1976a55774f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_753ffd0e-e0c6-40a9-a276-c0db2284c6f1_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_6c0098eb-1556-4c5a-8557-49ae30bc3aac_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_dccd3015-f67a-40ae-af9d-a60085190eda_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_e610d634-c40b-4aac-b618-ef5bbdb3871c_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recognized actuarial losses (gains)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_6b684842-10b9-4cb0-aab4-db198f95e052_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_4346079d-dcbd-4836-8933-25b2685b0e9e_verboseLabel_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_label_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:label id="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_documentation_en-US" xlink:label="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:href="jnj-20230101.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:to="lab_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_87a1fafd-0e79-4447-a9b3-826717fef3e5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_f647b48e-d8a7-49e1-97df-c674d366ee00_terseLabel_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">TJCA , provisional liability, non-current</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_label_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent</link:label>
    <link:label id="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_documentation_en-US" xlink:label="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:href="jnj-20230101.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:to="lab_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_a930fccc-e214-4a00-b114-d84ca7efff19_terseLabel_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages from Product Defects</link:label>
    <link:label id="lab_us-gaap_DamagesFromProductDefectsMember_label_en-US" xlink:label="lab_us-gaap_DamagesFromProductDefectsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Damages from Product Defects [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DamagesFromProductDefectsMember" xlink:to="lab_us-gaap_DamagesFromProductDefectsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonUsMember_8b32698c-d697-4493-8197-16a655daf0c4_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US</link:label>
    <link:label id="lab_us-gaap_NonUsMember_label_en-US" xlink:label="lab_us-gaap_NonUsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember" xlink:to="lab_us-gaap_NonUsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesMember_ba15e513-3920-432e-9e25-f16e798ffdd9_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales</link:label>
    <link:label id="lab_us-gaap_SalesMember_label_en-US" xlink:label="lab_us-gaap_SalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember" xlink:to="lab_us-gaap_SalesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NondesignatedMember_e39f2c71-ce7b-4b80-8dfe-52901a41dc44_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember" xlink:to="lab_us-gaap_NondesignatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_091f8083-9cd1-4805-be95-8748c5973e61_terseLabel_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_label_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:label id="lab_jnj_A2.95Notesdue2027Member_documentation_en-US" xlink:label="lab_jnj_A2.95Notesdue2027Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.95% Notes due 2027 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member" xlink:href="jnj-20230101.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.95Notesdue2027Member" xlink:to="lab_jnj_A2.95Notesdue2027Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_59eb1b09-cb57-4c35-ae53-77185d3e0811_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_055ea75d-16fa-475a-b4d2-bc1b3794eac3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost Basis</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_c9344888-b5ec-4564-a79c-42b9247ab47c_terseLabel_en-US" xlink:label="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees</link:label>
    <link:label id="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_label_en-US" xlink:label="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number Of Employees Engaged In Company Activities Worldwide</link:label>
    <link:label id="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_documentation_en-US" xlink:label="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of employees engaged in company activities worldwide.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:href="jnj-20230101.xsd#jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:to="lab_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6fb7b5ac-f9b6-4982-8cb9-545e36107625_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_cba60a3f-3f0f-4880-a778-4cf3ee835a51_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted net earnings per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OpioidMember_951def64-b123-4c6c-9cb2-068cf6ef8758_terseLabel_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid</link:label>
    <link:label id="lab_jnj_OpioidMember_label_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">opioid [Member]</link:label>
    <link:label id="lab_jnj_OpioidMember_documentation_en-US" xlink:label="lab_jnj_OpioidMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Opioid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember" xlink:href="jnj-20230101.xsd#jnj_OpioidMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OpioidMember" xlink:to="lab_jnj_OpioidMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_19e65c3c-858c-4b0d-9080-4c18ff542aba_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_23d7e0b8-90c7-445c-b6ef-ac9d718b9452_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2450NotesDue2060Member_42a0db12-bc62-4aa1-9aa4-f974d182df74_terseLabel_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_label_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060 [Member]</link:label>
    <link:label id="lab_jnj_A2450NotesDue2060Member_documentation_en-US" xlink:label="lab_jnj_A2450NotesDue2060Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.450% Notes due 2060</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member" xlink:href="jnj-20230101.xsd#jnj_A2450NotesDue2060Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2450NotesDue2060Member" xlink:to="lab_jnj_A2450NotesDue2060Member" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ConsolidationItemsAxis_df69eb17-f3f4-45bb-9bc5-be10ed17d1eb_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis" xlink:to="lab_srt_ConsolidationItemsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_7f5a1a96-68e4-4fbb-92fb-3cb811cc6243_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="lab_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherMember_6575c704-00d2-48e2-aaea-96f31cf81c0e_terseLabel_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_jnj_OtherMember_label_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:label id="lab_jnj_OtherMember_documentation_en-US" xlink:label="lab_jnj_OtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember" xlink:href="jnj-20230101.xsd#jnj_OtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherMember" xlink:to="lab_jnj_OtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_a454c333-5087-4387-8f9d-4a6ab1cd80ef_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_us-gaap_DeferredTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_f52e6abf-69cf-4dd5-865b-f8366e2fafa3_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_2a669129-2482-4e20-a316-aa011e64102e_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_682cdfe9-5ca7-4ac8-ae69-73285d0d3289_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">End of year</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_67b5d9b7-adcd-450b-bfc5-6a8f1aa6186a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill and intangibles</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_35274fe9-abb2-4ed7-95f2-4f286599bd21_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_51a679cf-acbf-44b2-a932-2580af6b5017_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember" xlink:to="lab_us-gaap_EquitySecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_d25f03d2-317e-450b-a83b-703cf23d66e5_terseLabel_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest (Income) Expense</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_label_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member</link:label>
    <link:label id="lab_jnj_InterestIncomeExpenseNetMember_documentation_en-US" xlink:label="lab_jnj_InterestIncomeExpenseNetMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income Expense Net Member.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember" xlink:href="jnj-20230101.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InterestIncomeExpenseNetMember" xlink:to="lab_jnj_InterestIncomeExpenseNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_CashPaidDuringTheYearAbstract_37ad8ade-cc42-42d2-952e-955c16473a7b_terseLabel_en-US" xlink:label="lab_jnj_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash paid during the year for:</link:label>
    <link:label id="lab_jnj_CashPaidDuringTheYearAbstract_label_en-US" xlink:label="lab_jnj_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During The Year [Abstract]</link:label>
    <link:label id="lab_jnj_CashPaidDuringTheYearAbstract_documentation_en-US" xlink:label="lab_jnj_CashPaidDuringTheYearAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash Paid During The Year [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashPaidDuringTheYearAbstract" xlink:href="jnj-20230101.xsd#jnj_CashPaidDuringTheYearAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_CashPaidDuringTheYearAbstract" xlink:to="lab_jnj_CashPaidDuringTheYearAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_9152f90d-d2c6-49e0-8a86-849d53953538_terseLabel_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Measured at Net Asset Value</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_label_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets</link:label>
    <link:label id="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_documentation_en-US" xlink:label="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:to="lab_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_fcb0d648-6596-4c94-a87e-5f5ce026c77b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_d9a87d73-761a-4066-85a7-7514f12559a9_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.&#160;</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_2a97c882-d429-4026-b585-35465f320fe6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:label id="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_label_en-US" xlink:label="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:to="lab_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_471dc7e8-9cf9-4d9f-8e09-a2785a51ab51_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate debt securities</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_fa943f30-e514-4d3a-8c52-5a7c416448e9_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Canceled/forfeited/adjusted (in shares)</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:to="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_b6c6d16f-7d76-4583-9e45-0b6e9a8dff2a_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service cost discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_ac812258-095f-4695-a6b1-1ce0bfc0df90_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Credit Support Agreement (CSA)</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Subject to Master Netting Arrangement, Asset Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:to="lab_us-gaap_DerivativeLiabilityFairValueGrossAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_c76128ac-777a-4a63-bff2-4e53d073dbf9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_48315562-1aee-41fb-8869-bd903f3e52b1_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total Gross Assets</link:label>
    <link:label id="lab_us-gaap_DerivativeFairValueOfDerivativeAsset_label_en-US" xlink:label="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Asset, Subject to Master Netting Arrangement, before Offset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:to="lab_us-gaap_DerivativeFairValueOfDerivativeAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_18ffcd97-5978-43f0-b0de-98c182edc0e0_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_9141df1d-8dc7-46d4-b1cf-8af2592333c3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities [Abstract]</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee-related Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OncologyMember_124021d1-0df6-4e45-a5c7-b61a78ccace6_terseLabel_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology</link:label>
    <link:label id="lab_jnj_OncologyMember_label_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_jnj_OncologyMember_documentation_en-US" xlink:label="lab_jnj_OncologyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Oncology [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember" xlink:href="jnj-20230101.xsd#jnj_OncologyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OncologyMember" xlink:to="lab_jnj_OncologyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_519f9dec-de15-4bc5-9f9c-97ffd3b684e5_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_79f3051d-222f-4f61-8a62-9dd06427bf75_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_035e16e2-daf1-4551-baa3-71c120a12c52_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_52a77b7c-4380-4014-a5a9-f9aecc48a816_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_f153f9a4-9b9e-4313-bd26-1cf440d0fe06_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_QualifiedPlansMember_0c6a1c12-a061-4c58-bd44-c214980f43ba_terseLabel_en-US" xlink:label="lab_jnj_QualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified Plans</link:label>
    <link:label id="lab_jnj_QualifiedPlansMember_label_en-US" xlink:label="lab_jnj_QualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified Plans [Member]</link:label>
    <link:label id="lab_jnj_QualifiedPlansMember_documentation_en-US" xlink:label="lab_jnj_QualifiedPlansMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Qualified plans.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_QualifiedPlansMember" xlink:href="jnj-20230101.xsd#jnj_QualifiedPlansMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_QualifiedPlansMember" xlink:to="lab_jnj_QualifiedPlansMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpense_a5b0bbf2-8207-4751-8868-e7b714ea6922_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest expense, net of portion capitalized (Note&#160;4)</link:label>
    <link:label id="lab_us-gaap_InterestExpense_label_en-US" xlink:label="lab_us-gaap_InterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense" xlink:to="lab_us-gaap_InterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_629d2052-041e-4cc8-a65b-51b2d771b661_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_us-gaap_RetirementPlanTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_437377cd-0917-44e6-8a57-3ca01c658d72_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardTable_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Tax Credit Carryforward [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_us-gaap_TaxCreditCarryforwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SavingsPlanAbstract_272d536c-6b15-467d-9e5e-f92800bed3d7_terseLabel_en-US" xlink:label="lab_jnj_SavingsPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan [Abstract]</link:label>
    <link:label id="lab_jnj_SavingsPlanAbstract_label_en-US" xlink:label="lab_jnj_SavingsPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan [Abstract]</link:label>
    <link:label id="lab_jnj_SavingsPlanAbstract_documentation_en-US" xlink:label="lab_jnj_SavingsPlanAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Savings Plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanAbstract" xlink:href="jnj-20230101.xsd#jnj_SavingsPlanAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SavingsPlanAbstract" xlink:to="lab_jnj_SavingsPlanAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_e11c9c79-6898-44de-b861-ff9714fcee72_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_4401f91a-95a0-4905-8c6a-cafeb0e03b23_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_7302515e-9094-4795-ae8e-ee14e5284792_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and equipment</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember" xlink:to="lab_us-gaap_MachineryAndEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_b981f2f6-c1e6-4728-8947-acae27a0ecfd_terseLabel_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95%&#160;Notes due 2037</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_label_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:label id="lab_jnj_A5.95Notesdue2037Member_documentation_en-US" xlink:label="lab_jnj_A5.95Notesdue2037Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">5.95% Notes due 2037 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member" xlink:href="jnj-20230101.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A5.95Notesdue2037Member" xlink:to="lab_jnj_A5.95Notesdue2037Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_4074acfb-b02f-47f0-9aec-7bb367b41ec0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_eaf964b4-5df0-418e-a335-68815dc5c69a_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Funded status - end of year</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_422c89b0-0e43-4e22-986b-c7c1aa1a91e6_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected Benefit Obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_35c43db9-30de-4e05-947b-9de0cf5f06a2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityNameDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Authority, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_d1e51f7f-e0f1-46b4-b8a5-01fe2f2bda09_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_030481ba-7a17-4438-ae9e-8080343c2b7f_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A210NotesDue2040Member_8051d328-3e8d-4880-825d-e3bc52a68517_terseLabel_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_label_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040 [Member]</link:label>
    <link:label id="lab_jnj_A210NotesDue2040Member_documentation_en-US" xlink:label="lab_jnj_A210NotesDue2040Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.10% Notes due 2040</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member" xlink:href="jnj-20230101.xsd#jnj_A210NotesDue2040Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A210NotesDue2040Member" xlink:to="lab_jnj_A210NotesDue2040Member" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_SURGICALMember_0571765d-91b1-4569-9013-4bcd773dfe6b_terseLabel_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL</link:label>
    <link:label id="lab_jnj_SURGICALMember_label_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:label id="lab_jnj_SURGICALMember_documentation_en-US" xlink:label="lab_jnj_SURGICALMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SURGICAL [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember" xlink:href="jnj-20230101.xsd#jnj_SURGICALMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_SURGICALMember" xlink:to="lab_jnj_SURGICALMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_e7323041-7948-4d7f-9962-ac4fce9413f4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Plan participant contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Plan Participant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_e4d712e4-7154-4393-b902-cded0022b552_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_4fc385c7-89bf-4ce4-86d2-09aa6728cbc8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Summary of Severance Charges and Associated Spending</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_d17a1f66-2344-4727-83b3-059e2d7222ce_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, and Short-Term Investments [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_8968fd8c-be20-452e-811f-f39db1d6bb8f_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Periodic Benefit Cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_f3d0c557-e341-427c-83e0-3e3cb0730bfc_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_d632fa96-c692-47c1-b30d-3028c1d68d77_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finite-Lived Intangible Asset, Expected Amortization, Year Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_InfectiousDiseasesMember_f255ba97-f782-4d1d-82f4-6bdfa74502a0_terseLabel_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_InfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_InfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember" xlink:href="jnj-20230101.xsd#jnj_InfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_InfectiousDiseasesMember" xlink:to="lab_jnj_InfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_04cfaf12-b9cb-4ce3-9763-35305fee69cd_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Projected benefit obligation, unfunded plans</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards_16c8ac6e-d107-4f43-a446-888030ec7940_terseLabel_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares subject to full value awards (in shares)</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards_label_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards</link:label>
    <link:label id="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards_documentation_en-US" xlink:label="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" xlink:to="lab_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_ceb15f0d-6c8a-4338-ad9a-ffd48dd3d652_terseLabel_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_label_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:label id="lab_jnj_PulmonaryHypertensionMember_documentation_en-US" xlink:label="lab_jnj_PulmonaryHypertensionMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Pulmonary Hypertension [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember" xlink:href="jnj-20230101.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PulmonaryHypertensionMember" xlink:to="lab_jnj_PulmonaryHypertensionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_09d9c44a-ff27-41c9-b754-0b115ff86388_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_532c6201-8eae-4312-8a2c-b1ed22a0492b_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_6ce16613-0c55-4b08-af4d-f548c6f5f412_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_0c9a8591-bf42-46e6-beaa-4ed86c0d35a6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Exercisable, Average Exercise Price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="lab_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_dafe2a6c-76e7-4d22-8f6c-cde561fa6147_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total before tax effects</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4afd2411-d277-44a8-885a-a1dc698d218e_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of intangible assets, excluding goodwill</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_MomentaMember_44c6c441-98ec-4070-81a2-2f6393b4e56f_terseLabel_en-US" xlink:label="lab_jnj_MomentaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Momenta</link:label>
    <link:label id="lab_jnj_MomentaMember_label_en-US" xlink:label="lab_jnj_MomentaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Momenta [Member]</link:label>
    <link:label id="lab_jnj_MomentaMember_documentation_en-US" xlink:label="lab_jnj_MomentaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Momenta</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MomentaMember" xlink:href="jnj-20230101.xsd#jnj_MomentaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_MomentaMember" xlink:to="lab_jnj_MomentaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_caf55db9-4672-4531-b631-edd3f343c4a3_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_9185546e-a737-40b0-9aed-12469792e0b0_terseLabel_en-US" xlink:label="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Treasury Stock Shares Outstanding [Roll Forward]</link:label>
    <link:label id="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_label_en-US" xlink:label="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Treasury Stock Shares Outstanding [Roll Forward]</link:label>
    <link:label id="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_documentation_en-US" xlink:label="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in Treasury Stock Shares Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:href="jnj-20230101.xsd#jnj_ChangesinTreasuryStockSharesOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:to="lab_jnj_ChangesinTreasuryStockSharesOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_3a524521-2b1c-4fbc-ac1e-982614b264c7_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_a0db3c2a-51f6-4928-850a-9ecd2f930c8d_terseLabel_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_OtherDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Debt Obligations [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherDebtSecuritiesMember" xlink:to="lab_us-gaap_OtherDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DeferredTaxLiabilitiesOtherDomestic_13699a3b-fe28-46fc-8921-fe5027d3f06a_negatedTerseLabel_en-US" xlink:label="lab_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Miscellaneous U.S.&#160;</link:label>
    <link:label id="lab_jnj_DeferredTaxLiabilitiesOtherDomestic_label_en-US" xlink:label="lab_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other Domestic</link:label>
    <link:label id="lab_jnj_DeferredTaxLiabilitiesOtherDomestic_documentation_en-US" xlink:label="lab_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Tax Liabilities, Other Domestic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxLiabilitiesOtherDomestic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:to="lab_jnj_DeferredTaxLiabilitiesOtherDomestic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_bdd6a7cc-4ddd-4b10-81d8-521912825f3b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_8860d7ac-402a-46d0-bcfc-a1577d1efa3c_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividends to shareholders</link:label>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_label_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments of Ordinary Dividends</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfOrdinaryDividends" xlink:to="lab_us-gaap_PaymentsOfOrdinaryDividends" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_274290bb-ec8f-4a44-b250-cc88d74da9f4_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_f823632e-7305-4a54-b0c7-d73f69ce9662_terseLabel_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_label_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage Change In Sales By Segment Of Business</link:label>
    <link:label id="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness_documentation_en-US" xlink:label="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percentage change in sales by segment of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:href="jnj-20230101.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:to="lab_jnj_PercentageChangeInSalesBySegmentOfBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_f03e72f7-28b2-4e53-a492-7e5dac6cdcf2_terseLabel_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625% Notes due 2025</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_label_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:label id="lab_jnj_A2.625Notesdue2025Member_documentation_en-US" xlink:label="lab_jnj_A2.625Notesdue2025Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">2.625 Notes due 2025 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member" xlink:href="jnj-20230101.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_A2.625Notesdue2025Member" xlink:to="lab_jnj_A2.625Notesdue2025Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_bcc75375-61a4-49de-b83d-a60a97697815_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_70a6eb97-2ab5-40ca-b6b1-29c6325f7290_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development (Note 5)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_9ac3e7f0-3b8b-49b2-b57a-1fdf35b4810f_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">In-process research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentInProcess_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development in Process</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentInProcess" xlink:to="lab_us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_e47fd18d-5ee5-4e93-ac04-a89fc337cc5d_terseLabel_en-US" xlink:label="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract</link:label>
    <link:label id="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_label_en-US" xlink:label="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract</link:label>
    <link:label id="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_documentation_en-US" xlink:label="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comparison of income tax expense at the Statutory rate and Company's tax rate.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:href="jnj-20230101.xsd#jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:to="lab_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_7729b54a-c9c7-49d7-bec2-727908003070_terseLabel_en-US" xlink:label="lab_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:label id="lab_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_label_en-US" xlink:label="lab_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:label id="lab_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_documentation_en-US" xlink:label="lab_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:href="jnj-20230101.xsd#jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:to="lab_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_UPTRAVIMember_673d6b5a-ab1c-49ad-9ca1-716ecdca374f_terseLabel_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_label_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:label id="lab_jnj_UPTRAVIMember_documentation_en-US" xlink:label="lab_jnj_UPTRAVIMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UPTRAVI [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember" xlink:href="jnj-20230101.xsd#jnj_UPTRAVIMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_UPTRAVIMember" xlink:to="lab_jnj_UPTRAVIMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_3d38f9d5-11dc-4658-80bb-14689ff95c37_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_WoundCareandOtherMember_5dd01c4f-9670-4098-984b-f7b12ae08742_terseLabel_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_label_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:label id="lab_jnj_WoundCareandOtherMember_documentation_en-US" xlink:label="lab_jnj_WoundCareandOtherMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Wound Care and Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember" xlink:href="jnj-20230101.xsd#jnj_WoundCareandOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_WoundCareandOtherMember" xlink:to="lab_jnj_WoundCareandOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_a975e90c-4388-4775-8c59-9ba49371bbd4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset write-downs</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_4669a3e6-1c17-40ff-9e9f-df3760c8cef1_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">R&amp;D Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock_ae67205d-e5a0-44c6-9236-10a136e14231_terseLabel_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Related Obligations</link:label>
    <link:label id="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock_label_en-US" xlink:label="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Compensation Related Costs, General [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:to="lab_us-gaap_CompensationRelatedCostsGeneralTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_bc52c60c-8070-4c93-86ed-6b793f317a65_terseLabel_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_label_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:label id="lab_jnj_OtherInfectiousDiseasesMember_documentation_en-US" xlink:label="lab_jnj_OtherInfectiousDiseasesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Infectious Diseases [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember" xlink:href="jnj-20230101.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_jnj_OtherInfectiousDiseasesMember" xlink:to="lab_jnj_OtherInfectiousDiseasesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_940a0f2a-980c-402f-b202-e3d3fc2354fc_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign currency translation</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfSalesMember_9b199623-6063-460d-92b8-3c1de2beb46f_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Products Sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_051803a1-f30a-4365-b17e-bec4f61537f6_verboseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember" xlink:to="lab_us-gaap_CostOfSalesMember" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>jnj-20230101_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2023 Workiva-->
<!--r:18208529-7e82-4728-be6a-fd0bc0acc451,g:1f111954-4d05-432b-a89f-49b08039c9af-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.jnj.com/role/CoverPage" xlink:type="simple" xlink:href="jnj-20230101.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_fb846622-d27a-454f-9f8c-a88d1854375b" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationTable_30a618b0-b925-4acf-969d-ce7f6473a2a9" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_fb846622-d27a-454f-9f8c-a88d1854375b" xlink:to="loc_dei_DocumentInformationTable_30a618b0-b925-4acf-969d-ce7f6473a2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_455e14f9-038c-48a3-83cd-fe9f3566989d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_30a618b0-b925-4acf-969d-ce7f6473a2a9" xlink:to="loc_us-gaap_StatementClassOfStockAxis_455e14f9-038c-48a3-83cd-fe9f3566989d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_31a8f509-efa9-4637-9795-bf339968387e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_455e14f9-038c-48a3-83cd-fe9f3566989d" xlink:to="loc_us-gaap_ClassOfStockDomain_31a8f509-efa9-4637-9795-bf339968387e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_9b217a2f-a2b3-406a-b80e-1a86b84481c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_31a8f509-efa9-4637-9795-bf339968387e" xlink:to="loc_us-gaap_CommonStockMember_9b217a2f-a2b3-406a-b80e-1a86b84481c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_6d58c0ce-ac37-434d-8610-936d55fe59ae" xlink:href="jnj-20230101.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_31a8f509-efa9-4637-9795-bf339968387e" xlink:to="loc_jnj_A0.650NotesDue2024Member_6d58c0ce-ac37-434d-8610-936d55fe59ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_ac0f9aab-34d5-49a1-81fe-36cb70fbd57c" xlink:href="jnj-20230101.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_31a8f509-efa9-4637-9795-bf339968387e" xlink:to="loc_jnj_A5.50NotesDue2024Member_ac0f9aab-34d5-49a1-81fe-36cb70fbd57c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_5e997ce5-39d5-4187-8e70-e62b69f7addf" xlink:href="jnj-20230101.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_31a8f509-efa9-4637-9795-bf339968387e" xlink:to="loc_jnj_A1.150NotesDue2028Member_5e997ce5-39d5-4187-8e70-e62b69f7addf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_2367d4fc-2227-40c5-b46c-373fd3cbf5ee" xlink:href="jnj-20230101.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_31a8f509-efa9-4637-9795-bf339968387e" xlink:to="loc_jnj_A1.650NotesDue2035Member_2367d4fc-2227-40c5-b46c-373fd3cbf5ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationTable_30a618b0-b925-4acf-969d-ce7f6473a2a9" xlink:to="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_1c2a87ac-9dec-4d3d-a592-c2a6de1dcb8f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_DocumentType_1c2a87ac-9dec-4d3d-a592-c2a6de1dcb8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_878c34fd-478f-4c4a-add4-1bf45f6c62b1" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_DocumentAnnualReport_878c34fd-478f-4c4a-add4-1bf45f6c62b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_82ab7898-d4c3-439e-8b35-3a612ac0e332" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_DocumentPeriodEndDate_82ab7898-d4c3-439e-8b35-3a612ac0e332" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_acdc3a42-2e2f-4ebe-ba55-d906d85d423d" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_DocumentTransitionReport_acdc3a42-2e2f-4ebe-ba55-d906d85d423d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_b81426be-94f8-4c46-8aff-6760116c4562" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityFileNumber_b81426be-94f8-4c46-8aff-6760116c4562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_7ed6f628-b52e-4907-a5cb-2214dd0d0804" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityRegistrantName_7ed6f628-b52e-4907-a5cb-2214dd0d0804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_114f740e-8704-446a-98d4-033464733e5c" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityIncorporationStateCountryCode_114f740e-8704-446a-98d4-033464733e5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_97385b16-09e4-4ee2-b9a8-8456bb837e6f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityTaxIdentificationNumber_97385b16-09e4-4ee2-b9a8-8456bb837e6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_77b6df96-d26d-4286-ae3b-8ea8b334aca0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityAddressAddressLine1_77b6df96-d26d-4286-ae3b-8ea8b334aca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_0395fc7e-fe52-41a8-a2b4-84e2ea88a2ac" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityAddressCityOrTown_0395fc7e-fe52-41a8-a2b4-84e2ea88a2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_5cbddc8a-e4a7-486a-8a26-ea4c94b9d641" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityAddressStateOrProvince_5cbddc8a-e4a7-486a-8a26-ea4c94b9d641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_3e537705-f18f-45d3-9cac-3e7c8a30427e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityAddressPostalZipCode_3e537705-f18f-45d3-9cac-3e7c8a30427e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_fa406ecc-4f45-4318-b0ee-434d591981db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_CityAreaCode_fa406ecc-4f45-4318-b0ee-434d591981db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_80e4d4ba-59ff-40dc-a238-e6a1234aae57" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_LocalPhoneNumber_80e4d4ba-59ff-40dc-a238-e6a1234aae57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_dd0c0cdc-8e85-497e-924b-77ff386ff915" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_Security12bTitle_dd0c0cdc-8e85-497e-924b-77ff386ff915" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_ac537387-1352-4f2b-8cc1-000e8dda823a" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_TradingSymbol_ac537387-1352-4f2b-8cc1-000e8dda823a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_9f72fcc7-9530-4400-a58b-62920024d2a0" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_SecurityExchangeName_9f72fcc7-9530-4400-a58b-62920024d2a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_f5ce46dc-33e7-40d8-adaa-0891450b6f0e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_f5ce46dc-33e7-40d8-adaa-0891450b6f0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_72c01f63-a768-4fbc-966f-cb93213e0841" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityVoluntaryFilers_72c01f63-a768-4fbc-966f-cb93213e0841" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_74bcb2d2-8899-4ccf-b0bd-5334a6f3ad64" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityCurrentReportingStatus_74bcb2d2-8899-4ccf-b0bd-5334a6f3ad64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_4a9f3401-cad9-46c0-89d3-af2f5189fd7f" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityInteractiveDataCurrent_4a9f3401-cad9-46c0-89d3-af2f5189fd7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_26cab73a-5351-4fad-beef-dbdc5eb55107" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityFilerCategory_26cab73a-5351-4fad-beef-dbdc5eb55107" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_35c089ae-2d8c-4f37-9e2f-34482cc78584" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityEmergingGrowthCompany_35c089ae-2d8c-4f37-9e2f-34482cc78584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_5bba94c2-823c-4bff-afe4-e105d0c2c199" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntitySmallBusiness_5bba94c2-823c-4bff-afe4-e105d0c2c199" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_045f09fd-a367-4141-9563-96dd657de860" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_IcfrAuditorAttestationFlag_045f09fd-a367-4141-9563-96dd657de860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_a6c4ff5a-a330-4264-a1e1-123e1d354cb6" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityShellCompany_a6c4ff5a-a330-4264-a1e1-123e1d354cb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_f7a9db68-147a-4309-9af5-4fada9c9803e" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityPublicFloat_f7a9db68-147a-4309-9af5-4fada9c9803e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_f3a545ee-769e-4a2f-b121-49d5bebce051" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_f3a545ee-769e-4a2f-b121-49d5bebce051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_7dca2e04-38de-4ee6-b841-3fc8c4a4c464" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_EntityCentralIndexKey_7dca2e04-38de-4ee6-b841-3fc8c4a4c464" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_ab96a725-9b2a-4538-9e3b-ed5e7c929097" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_CurrentFiscalYearEndDate_ab96a725-9b2a-4538-9e3b-ed5e7c929097" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_dc3d1a5a-5505-488b-b460-3a2152268da5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_DocumentFiscalYearFocus_dc3d1a5a-5505-488b-b460-3a2152268da5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_be092b5d-8d84-49ce-a8d7-e3d9d83917bd" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_DocumentFiscalPeriodFocus_be092b5d-8d84-49ce-a8d7-e3d9d83917bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_e58761e5-c210-4369-8212-cf94b78e3b91" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_DocumentInformationLineItems_c2ee2eeb-0628-4bb8-bdf8-2eb599e6bb13" xlink:to="loc_dei_AmendmentFlag_e58761e5-c210-4369-8212-cf94b78e3b91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AuditInformation" xlink:type="simple" xlink:href="jnj-20230101.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AuditorInformationAbstract_c0c869b6-d332-41ed-bb81-0042537e1dbb" xlink:href="jnj-20230101.xsd#jnj_AuditorInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_add2fb64-8b63-4ac6-b584-622a4ac823db" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_AuditorInformationAbstract_c0c869b6-d332-41ed-bb81-0042537e1dbb" xlink:to="loc_dei_AuditorName_add2fb64-8b63-4ac6-b584-622a4ac823db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_8356e38e-7f48-484a-95a0-6df006faa321" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_AuditorInformationAbstract_c0c869b6-d332-41ed-bb81-0042537e1dbb" xlink:to="loc_dei_AuditorLocation_8356e38e-7f48-484a-95a0-6df006faa321" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_53a4693e-cacd-4068-95d1-2cac33a007b5" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_AuditorInformationAbstract_c0c869b6-d332-41ed-bb81-0042537e1dbb" xlink:to="loc_dei_AuditorFirmId_53a4693e-cacd-4068-95d1-2cac33a007b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="jnj-20230101.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c71a66a3-f496-4e14-9c42-29ea89741296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_73e796d3-4ffe-4db1-960a-af856e3527e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c71a66a3-f496-4e14-9c42-29ea89741296" xlink:to="loc_us-gaap_AssetsAbstract_73e796d3-4ffe-4db1-960a-af856e3527e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_c26ca1d3-c580-471b-b487-29f9cd711995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73e796d3-4ffe-4db1-960a-af856e3527e3" xlink:to="loc_us-gaap_AssetsCurrentAbstract_c26ca1d3-c580-471b-b487-29f9cd711995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8cefa5e3-a873-4644-b46e-fbf0493db8ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c26ca1d3-c580-471b-b487-29f9cd711995" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8cefa5e3-a873-4644-b46e-fbf0493db8ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_bb3adcd4-79d0-4124-9e78-2ab729e0f73f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c26ca1d3-c580-471b-b487-29f9cd711995" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_bb3adcd4-79d0-4124-9e78-2ab729e0f73f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_7acd5fe7-8d4d-4a2d-9693-f04aec3e9545" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c26ca1d3-c580-471b-b487-29f9cd711995" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_7acd5fe7-8d4d-4a2d-9693-f04aec3e9545" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_5555391f-681b-44f6-be46-3277d33339f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c26ca1d3-c580-471b-b487-29f9cd711995" xlink:to="loc_us-gaap_InventoryNet_5555391f-681b-44f6-be46-3277d33339f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73f8ac1d-6926-4e09-b4ca-0ea7dd71ee31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c26ca1d3-c580-471b-b487-29f9cd711995" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_73f8ac1d-6926-4e09-b4ca-0ea7dd71ee31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_3594c799-35e8-4f0b-ad91-24cacec89bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_c26ca1d3-c580-471b-b487-29f9cd711995" xlink:to="loc_us-gaap_AssetsCurrent_3594c799-35e8-4f0b-ad91-24cacec89bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_d06ea10a-7218-46d9-ac80-23e1b771fad0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73e796d3-4ffe-4db1-960a-af856e3527e3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_d06ea10a-7218-46d9-ac80-23e1b771fad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a11276b6-a779-497c-8175-173b782ca0df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73e796d3-4ffe-4db1-960a-af856e3527e3" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_a11276b6-a779-497c-8175-173b782ca0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_f2b9a8f7-15aa-425e-9295-d626dd1e251a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73e796d3-4ffe-4db1-960a-af856e3527e3" xlink:to="loc_us-gaap_Goodwill_f2b9a8f7-15aa-425e-9295-d626dd1e251a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_6e4429ed-c150-45e5-809c-e596d7418b9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73e796d3-4ffe-4db1-960a-af856e3527e3" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_6e4429ed-c150-45e5-809c-e596d7418b9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_a7c98a87-53a3-4e59-91d8-73a39bdf26e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73e796d3-4ffe-4db1-960a-af856e3527e3" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_a7c98a87-53a3-4e59-91d8-73a39bdf26e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_f8bbe063-430a-463e-aa81-2ef8ac22c753" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_73e796d3-4ffe-4db1-960a-af856e3527e3" xlink:to="loc_us-gaap_Assets_f8bbe063-430a-463e-aa81-2ef8ac22c753" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e447a329-2998-4f57-b5bf-14133f22c2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c71a66a3-f496-4e14-9c42-29ea89741296" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e447a329-2998-4f57-b5bf-14133f22c2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_8edbca1f-5c18-4c33-8f6d-02e53ad594d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e447a329-2998-4f57-b5bf-14133f22c2e4" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_8edbca1f-5c18-4c33-8f6d-02e53ad594d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_ced7b36e-ad4f-48d6-a0b0-141cd7e5882a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8edbca1f-5c18-4c33-8f6d-02e53ad594d5" xlink:to="loc_us-gaap_ShortTermBorrowings_ced7b36e-ad4f-48d6-a0b0-141cd7e5882a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_31c0fddf-e295-4248-9a79-d26b96f829cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8edbca1f-5c18-4c33-8f6d-02e53ad594d5" xlink:to="loc_us-gaap_AccountsPayableCurrent_31c0fddf-e295-4248-9a79-d26b96f829cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_d70aabac-bc73-46cf-9ae0-9aabf161b49f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8edbca1f-5c18-4c33-8f6d-02e53ad594d5" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_d70aabac-bc73-46cf-9ae0-9aabf161b49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_720af814-1e5a-408e-901f-2df88add54f6" xlink:href="jnj-20230101.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8edbca1f-5c18-4c33-8f6d-02e53ad594d5" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_720af814-1e5a-408e-901f-2df88add54f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9edc7082-ecc5-42c2-8916-5788b5ab37dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8edbca1f-5c18-4c33-8f6d-02e53ad594d5" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9edc7082-ecc5-42c2-8916-5788b5ab37dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_7787ef48-ff9f-47cc-8dca-857bba0cc4cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8edbca1f-5c18-4c33-8f6d-02e53ad594d5" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_7787ef48-ff9f-47cc-8dca-857bba0cc4cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_c8914805-688d-4503-9b94-1cbea6c1940d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_8edbca1f-5c18-4c33-8f6d-02e53ad594d5" xlink:to="loc_us-gaap_LiabilitiesCurrent_c8914805-688d-4503-9b94-1cbea6c1940d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_07fe04bd-df07-412a-96eb-211812c5220e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e447a329-2998-4f57-b5bf-14133f22c2e4" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_07fe04bd-df07-412a-96eb-211812c5220e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f8c57f7d-0635-4137-9bff-cf764adbe92f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e447a329-2998-4f57-b5bf-14133f22c2e4" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_f8c57f7d-0635-4137-9bff-cf764adbe92f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_9f96d7d4-0dff-4747-b0e3-71d5976fb24a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e447a329-2998-4f57-b5bf-14133f22c2e4" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_9f96d7d4-0dff-4747-b0e3-71d5976fb24a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesNoncurrent_8014b0c5-44ac-4f8e-9730-d5fdda5ba7a0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedIncomeTaxesNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e447a329-2998-4f57-b5bf-14133f22c2e4" xlink:to="loc_us-gaap_AccruedIncomeTaxesNoncurrent_8014b0c5-44ac-4f8e-9730-d5fdda5ba7a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_c5b25ae7-cd71-42c4-a966-c6f162e0af0e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e447a329-2998-4f57-b5bf-14133f22c2e4" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_c5b25ae7-cd71-42c4-a966-c6f162e0af0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_e75e9cb0-9c0d-4bf2-a5dc-1eb3296c6ca5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e447a329-2998-4f57-b5bf-14133f22c2e4" xlink:to="loc_us-gaap_Liabilities_e75e9cb0-9c0d-4bf2-a5dc-1eb3296c6ca5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ad40402c-bccd-4d9d-a605-959599312f47" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e447a329-2998-4f57-b5bf-14133f22c2e4" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ad40402c-bccd-4d9d-a605-959599312f47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_25288471-0036-4525-9b44-8b98faf7e2f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e447a329-2998-4f57-b5bf-14133f22c2e4" xlink:to="loc_us-gaap_StockholdersEquityAbstract_25288471-0036-4525-9b44-8b98faf7e2f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_4fe04113-18c8-47ce-8b86-2ebb7b6841e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25288471-0036-4525-9b44-8b98faf7e2f4" xlink:to="loc_us-gaap_PreferredStockValue_4fe04113-18c8-47ce-8b86-2ebb7b6841e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_2c6bd715-88cd-42a6-b6c2-e92d4e95b164" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25288471-0036-4525-9b44-8b98faf7e2f4" xlink:to="loc_us-gaap_CommonStockValue_2c6bd715-88cd-42a6-b6c2-e92d4e95b164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_18539325-14d9-4ad2-85c2-dd11a366ae78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25288471-0036-4525-9b44-8b98faf7e2f4" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_18539325-14d9-4ad2-85c2-dd11a366ae78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_475f4db9-862a-4110-a018-a52c7f25579b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25288471-0036-4525-9b44-8b98faf7e2f4" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_475f4db9-862a-4110-a018-a52c7f25579b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_16fa89aa-468c-47e9-af8a-16e37d22750a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityBeforeTreasuryStock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25288471-0036-4525-9b44-8b98faf7e2f4" xlink:to="loc_us-gaap_StockholdersEquityBeforeTreasuryStock_16fa89aa-468c-47e9-af8a-16e37d22750a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_0c7ea1a4-15fd-466f-aa4f-628f1bc0ec24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25288471-0036-4525-9b44-8b98faf7e2f4" xlink:to="loc_us-gaap_TreasuryStockValue_0c7ea1a4-15fd-466f-aa4f-628f1bc0ec24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b9e0afd5-f661-4495-8405-84ce56b9af11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_25288471-0036-4525-9b44-8b98faf7e2f4" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_b9e0afd5-f661-4495-8405-84ce56b9af11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_f552731e-4ac4-4e88-95f2-c15aefd633e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_e447a329-2998-4f57-b5bf-14133f22c2e4" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_f552731e-4ac4-4e88-95f2-c15aefd633e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="jnj-20230101.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_558662e9-fedb-4478-ad04-754131216ee4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_44e16bc9-fb08-43c0-bbeb-948c753ce797" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_558662e9-fedb-4478-ad04-754131216ee4" xlink:to="loc_us-gaap_AssetsCurrentAbstract_44e16bc9-fb08-43c0-bbeb-948c753ce797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_9e4aa8a9-6d8e-46e6-b10a-2ef73ef7f447" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_44e16bc9-fb08-43c0-bbeb-948c753ce797" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_9e4aa8a9-6d8e-46e6-b10a-2ef73ef7f447" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_ce997143-ed93-4321-be23-865e45b00d95" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_558662e9-fedb-4478-ad04-754131216ee4" xlink:to="loc_us-gaap_StockholdersEquityAbstract_ce997143-ed93-4321-be23-865e45b00d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_716f85d1-995b-4122-8041-2b0f5354c888" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ce997143-ed93-4321-be23-865e45b00d95" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_716f85d1-995b-4122-8041-2b0f5354c888" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_d4042d4a-1d16-40c6-b2ea-6fc57d386daf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ce997143-ed93-4321-be23-865e45b00d95" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_d4042d4a-1d16-40c6-b2ea-6fc57d386daf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_dd57cc86-25d2-4010-a532-6468edcdba1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ce997143-ed93-4321-be23-865e45b00d95" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_dd57cc86-25d2-4010-a532-6468edcdba1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_02df99fd-e8a8-4e3c-a0f3-bd35328dc17b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ce997143-ed93-4321-be23-865e45b00d95" xlink:to="loc_us-gaap_CommonStockSharesIssued_02df99fd-e8a8-4e3c-a0f3-bd35328dc17b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_4ade8f3a-00d6-4214-a490-c154a5bc554e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_ce997143-ed93-4321-be23-865e45b00d95" xlink:to="loc_us-gaap_TreasuryStockShares_4ade8f3a-00d6-4214-a490-c154a5bc554e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="simple" xlink:href="jnj-20230101.xsd#ConsolidatedStatementsofEarnings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEarnings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_7e1d7666-483d-4cee-b8f4-c77a3f284eb5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_538425d7-d46a-4486-ac18-2dfca6dba98e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7e1d7666-483d-4cee-b8f4-c77a3f284eb5" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_538425d7-d46a-4486-ac18-2dfca6dba98e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_c7056ae3-5565-4638-b6d1-99d338d21e5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7e1d7666-483d-4cee-b8f4-c77a3f284eb5" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_c7056ae3-5565-4638-b6d1-99d338d21e5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_dd1ad94f-4757-465e-a131-cfdb0ab27756" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7e1d7666-483d-4cee-b8f4-c77a3f284eb5" xlink:to="loc_us-gaap_GrossProfit_dd1ad94f-4757-465e-a131-cfdb0ab27756" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_61361de8-45da-4a79-a7d1-cca4c8c57df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7e1d7666-483d-4cee-b8f4-c77a3f284eb5" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_61361de8-45da-4a79-a7d1-cca4c8c57df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_48f677e0-871e-4e73-adf9-558ca1f98caf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7e1d7666-483d-4cee-b8f4-c77a3f284eb5" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_48f677e0-871e-4e73-adf9-558ca1f98caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_c0efabcc-5063-41c1-b923-75a5e829ff5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7e1d7666-483d-4cee-b8f4-c77a3f284eb5" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_c0efabcc-5063-41c1-b923-75a5e829ff5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_211852f0-5f62-43c8-a16e-6cabab517bbe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7e1d7666-483d-4cee-b8f4-c77a3f284eb5" xlink:to="loc_us-gaap_InvestmentIncomeInterest_211852f0-5f62-43c8-a16e-6cabab517bbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpense_594a45e0-94bf-4324-8942-721d4d522a1a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestExpense"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7e1d7666-483d-4cee-b8f4-c77a3f284eb5" xlink:to="loc_us-gaap_InterestExpense_594a45e0-94bf-4324-8942-721d4d522a1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_115e29e5-9662-4f4d-96b3-83dc396c777c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7e1d7666-483d-4cee-b8f4-c77a3f284eb5" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_115e29e5-9662-4f4d-96b3-83dc396c777c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_85c88b12-4b85-4d99-b778-ac6bed7b3d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7e1d7666-483d-4cee-b8f4-c77a3f284eb5" xlink:to="loc_us-gaap_RestructuringCharges_85c88b12-4b85-4d99-b778-ac6bed7b3d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12163b41-9a8f-4d46-b197-95ea83d7822f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7e1d7666-483d-4cee-b8f4-c77a3f284eb5" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_12163b41-9a8f-4d46-b197-95ea83d7822f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_2c618fc6-232d-4a4b-9702-bbc8ad10f876" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7e1d7666-483d-4cee-b8f4-c77a3f284eb5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_2c618fc6-232d-4a4b-9702-bbc8ad10f876" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bfd24696-399b-4b2c-9308-19414ef09ec9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7e1d7666-483d-4cee-b8f4-c77a3f284eb5" xlink:to="loc_us-gaap_NetIncomeLoss_bfd24696-399b-4b2c-9308-19414ef09ec9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_cdea8da1-71a1-44ea-8558-af5d75fc79cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7e1d7666-483d-4cee-b8f4-c77a3f284eb5" xlink:to="loc_us-gaap_EarningsPerShareAbstract_cdea8da1-71a1-44ea-8558-af5d75fc79cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d666a986-8c86-463d-8491-49f2066dc71e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cdea8da1-71a1-44ea-8558-af5d75fc79cb" xlink:to="loc_us-gaap_EarningsPerShareBasic_d666a986-8c86-463d-8491-49f2066dc71e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_0cc84820-6758-4c84-a75b-44b274df3e10" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_cdea8da1-71a1-44ea-8558-af5d75fc79cb" xlink:to="loc_us-gaap_EarningsPerShareDiluted_0cc84820-6758-4c84-a75b-44b274df3e10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e38c6add-7f49-4b0c-b5fc-0229bb7d3ff3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_7e1d7666-483d-4cee-b8f4-c77a3f284eb5" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e38c6add-7f49-4b0c-b5fc-0229bb7d3ff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_836dca7b-1694-442c-a7a7-4bf645b4589f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e38c6add-7f49-4b0c-b5fc-0229bb7d3ff3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_836dca7b-1694-442c-a7a7-4bf645b4589f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_862bdb91-9dbd-460e-a598-23bba4b9616d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_e38c6add-7f49-4b0c-b5fc-0229bb7d3ff3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_862bdb91-9dbd-460e-a598-23bba4b9616d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="jnj-20230101.xsd#ConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bccd56fa-0a34-4241-b279-54657356e957" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_319c7496-ef94-48a0-a1e1-5dd0d895e800" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bccd56fa-0a34-4241-b279-54657356e957" xlink:to="loc_us-gaap_NetIncomeLoss_319c7496-ef94-48a0-a1e1-5dd0d895e800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1d79a611-8bb5-47ea-9866-b17be26de3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bccd56fa-0a34-4241-b279-54657356e957" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1d79a611-8bb5-47ea-9866-b17be26de3e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_df6b0297-c241-4630-9ae9-16b970641861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1d79a611-8bb5-47ea-9866-b17be26de3e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_df6b0297-c241-4630-9ae9-16b970641861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_5123b9d3-02e6-491b-9ef4-b6405625ea53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1d79a611-8bb5-47ea-9866-b17be26de3e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_5123b9d3-02e6-491b-9ef4-b6405625ea53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_af1da962-5503-4332-8e4b-b5c3d868d794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_5123b9d3-02e6-491b-9ef4-b6405625ea53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_af1da962-5503-4332-8e4b-b5c3d868d794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_b933cead-29e2-4f6a-934f-432a74a95aee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_5123b9d3-02e6-491b-9ef4-b6405625ea53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_b933cead-29e2-4f6a-934f-432a74a95aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5dcf720b-0d4b-4d58-a453-bb1372982963" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract_5123b9d3-02e6-491b-9ef4-b6405625ea53" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_5dcf720b-0d4b-4d58-a453-bb1372982963" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_bf23c2aa-29c4-43ad-82b8-d1826fd60bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1d79a611-8bb5-47ea-9866-b17be26de3e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_bf23c2aa-29c4-43ad-82b8-d1826fd60bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_94a489bc-b1a2-4343-86cd-3e5451bbe280" xlink:href="jnj-20230101.xsd#jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_bf23c2aa-29c4-43ad-82b8-d1826fd60bb7" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax_94a489bc-b1a2-4343-86cd-3e5451bbe280" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_230ec1fc-9f8e-4115-84c1-d6dcf08c352d" xlink:href="jnj-20230101.xsd#jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_bf23c2aa-29c4-43ad-82b8-d1826fd60bb7" xlink:to="loc_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax_230ec1fc-9f8e-4115-84c1-d6dcf08c352d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_589de188-7e0b-41a3-a045-426a73ecdd78" xlink:href="jnj-20230101.xsd#jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_bf23c2aa-29c4-43ad-82b8-d1826fd60bb7" xlink:to="loc_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax_589de188-7e0b-41a3-a045-426a73ecdd78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_53044e5d-502a-44bc-9281-6e42f21a126f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract_bf23c2aa-29c4-43ad-82b8-d1826fd60bb7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax_53044e5d-502a-44bc-9281-6e42f21a126f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_0a677f6e-510c-4646-99ea-233539d8d495" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_1d79a611-8bb5-47ea-9866-b17be26de3e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_0a677f6e-510c-4646-99ea-233539d8d495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_df2f9b80-d75e-4c4c-b41c-ba5170a47f38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_0a677f6e-510c-4646-99ea-233539d8d495" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_df2f9b80-d75e-4c4c-b41c-ba5170a47f38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_ca1717cd-c843-4547-babc-2b4e91c4969f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_0a677f6e-510c-4646-99ea-233539d8d495" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_ca1717cd-c843-4547-babc-2b4e91c4969f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_b8f9ca7d-6dcd-49c6-8591-0df81ad947e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract_0a677f6e-510c-4646-99ea-233539d8d495" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax_b8f9ca7d-6dcd-49c6-8591-0df81ad947e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4361842e-4e63-4b0c-92fc-94bc863fdb0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bccd56fa-0a34-4241-b279-54657356e957" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_4361842e-4e63-4b0c-92fc-94bc863fdb0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4f3a04a0-31af-4cf2-bc96-e09da5e460a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bccd56fa-0a34-4241-b279-54657356e957" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_4f3a04a0-31af-4cf2-bc96-e09da5e460a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="jnj-20230101.xsd#ConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9bfde877-7195-48c5-88ca-588c53df1dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_51faaebf-c733-44f1-ae67-a9e8475ab8be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9bfde877-7195-48c5-88ca-588c53df1dc6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_51faaebf-c733-44f1-ae67-a9e8475ab8be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_8330bdae-ccdb-4b3e-9d4f-52172caf6ce0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9bfde877-7195-48c5-88ca-588c53df1dc6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_8330bdae-ccdb-4b3e-9d4f-52172caf6ce0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_9901d708-a415-4164-bf02-438003108022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9bfde877-7195-48c5-88ca-588c53df1dc6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax_9901d708-a415-4164-bf02-438003108022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_3118a348-dfcb-42ca-9905-5b46062ab2c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9bfde877-7195-48c5-88ca-588c53df1dc6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_3118a348-dfcb-42ca-9905-5b46062ab2c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="simple" xlink:href="jnj-20230101.xsd#ConsolidatedStatementsofEquity"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_4a07301a-dd3e-4a98-b16d-d603ff312c37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f0d2860d-76ef-4aba-a040-41444a1ec918" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_4a07301a-dd3e-4a98-b16d-d603ff312c37" xlink:to="loc_us-gaap_StatementTable_f0d2860d-76ef-4aba-a040-41444a1ec918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6b9769d9-a1db-4aaf-821e-0faf86a174c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f0d2860d-76ef-4aba-a040-41444a1ec918" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6b9769d9-a1db-4aaf-821e-0faf86a174c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_4b8439f6-3ecc-41cc-9fbe-4cd712e1c59c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6b9769d9-a1db-4aaf-821e-0faf86a174c9" xlink:to="loc_us-gaap_EquityComponentDomain_4b8439f6-3ecc-41cc-9fbe-4cd712e1c59c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_d9e898ad-081b-46a5-9a20-aa178fd1405b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4b8439f6-3ecc-41cc-9fbe-4cd712e1c59c" xlink:to="loc_us-gaap_RetainedEarningsMember_d9e898ad-081b-46a5-9a20-aa178fd1405b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ec09a25-2f86-4618-809e-5c1ca7ca269e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4b8439f6-3ecc-41cc-9fbe-4cd712e1c59c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9ec09a25-2f86-4618-809e-5c1ca7ca269e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_09cdeffc-2098-42d0-a9e0-0ea17ca5141b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4b8439f6-3ecc-41cc-9fbe-4cd712e1c59c" xlink:to="loc_us-gaap_CommonStockMember_09cdeffc-2098-42d0-a9e0-0ea17ca5141b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_2189413b-c8b9-4572-9648-785278cd6bc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4b8439f6-3ecc-41cc-9fbe-4cd712e1c59c" xlink:to="loc_us-gaap_TreasuryStockMember_2189413b-c8b9-4572-9648-785278cd6bc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f0d2860d-76ef-4aba-a040-41444a1ec918" xlink:to="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_35bd789e-8b39-4ff0-b217-1d1b1f768165" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_35bd789e-8b39-4ff0-b217-1d1b1f768165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2615de94-ef3c-45d0-a326-d2a952461dc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:to="loc_us-gaap_NetIncomeLoss_2615de94-ef3c-45d0-a326-d2a952461dc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsCommonStockCash_2e7b6073-b62a-4930-8ebd-5e630a9c11ba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsCommonStockCash"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:to="loc_us-gaap_DividendsCommonStockCash_2e7b6073-b62a-4930-8ebd-5e630a9c11ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0f86c791-5e0d-4309-bc97-e7d9c0cb68cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0f86c791-5e0d-4309-bc97-e7d9c0cb68cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0c11ca3d-6a45-4fba-ac49-83132cd3ca64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_0c11ca3d-6a45-4fba-ac49-83132cd3ca64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityOther_2c1d2193-85d3-4e8f-b589-7d5b0dacf530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:to="loc_us-gaap_StockholdersEquityOther_2c1d2193-85d3-4e8f-b589-7d5b0dacf530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c3ff3e37-fe54-48b0-8ab1-bb5d176d329a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_c3ff3e37-fe54-48b0-8ab1-bb5d176d329a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49caeff5-13f3-4e43-bf82-a18d22b8e075" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_c6e3e1ec-690a-4b17-9083-9cd5e68feca6" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_49caeff5-13f3-4e43-bf82-a18d22b8e075" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="simple" xlink:href="jnj-20230101.xsd#ConsolidatedStatementsofEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_38077321-c919-49f1-8499-ecf6bf46ae5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_0c979524-3e1c-412f-9bc6-0361f89eb515" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_38077321-c919-49f1-8499-ecf6bf46ae5a" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_0c979524-3e1c-412f-9bc6-0361f89eb515" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="jnj-20230101.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_e13b0630-50dd-4a8c-9552-3323ab21aa40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9f61d98e-4599-4ae3-b0f5-2169451296d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e13b0630-50dd-4a8c-9552-3323ab21aa40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9f61d98e-4599-4ae3-b0f5-2169451296d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_2fb4f83d-2432-4f67-9c95-77e416d85dd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9f61d98e-4599-4ae3-b0f5-2169451296d0" xlink:to="loc_us-gaap_NetIncomeLoss_2fb4f83d-2432-4f67-9c95-77e416d85dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1579b24-b53a-4afd-a524-787614d81a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9f61d98e-4599-4ae3-b0f5-2169451296d0" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1579b24-b53a-4afd-a524-787614d81a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_88b11771-29b5-4ada-8c2d-aca4c994461e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1579b24-b53a-4afd-a524-787614d81a9c" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_88b11771-29b5-4ada-8c2d-aca4c994461e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_3f386775-246e-4c46-99d6-298c23c31539" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1579b24-b53a-4afd-a524-787614d81a9c" xlink:to="loc_us-gaap_ShareBasedCompensation_3f386775-246e-4c46-99d6-298c23c31539" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_2f80e16c-07d0-4c59-9a58-c62948354aa0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1579b24-b53a-4afd-a524-787614d81a9c" xlink:to="loc_us-gaap_AssetImpairmentCharges_2f80e16c-07d0-4c59-9a58-c62948354aa0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3f0d0023-2b78-4a7c-a3ba-51302e9d8bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1579b24-b53a-4afd-a524-787614d81a9c" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_3f0d0023-2b78-4a7c-a3ba-51302e9d8bfd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_7207155d-960d-46c0-bea5-13302d1a528a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1579b24-b53a-4afd-a524-787614d81a9c" xlink:to="loc_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges_7207155d-960d-46c0-bea5-13302d1a528a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5b0cbb5c-addc-47a8-8cb8-a93cb8467f53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1579b24-b53a-4afd-a524-787614d81a9c" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_5b0cbb5c-addc-47a8-8cb8-a93cb8467f53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProvisionForDoubtfulAccounts_e609c281-a581-4e2b-b5c2-4e0107e641c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProvisionForDoubtfulAccounts"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_f1579b24-b53a-4afd-a524-787614d81a9c" xlink:to="loc_us-gaap_ProvisionForDoubtfulAccounts_e609c281-a581-4e2b-b5c2-4e0107e641c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4319ee77-aa03-4373-9be4-6ea16987fdc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_9f61d98e-4599-4ae3-b0f5-2169451296d0" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4319ee77-aa03-4373-9be4-6ea16987fdc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_61b24420-94d5-4b95-a197-81ceddf2cacb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4319ee77-aa03-4373-9be4-6ea16987fdc8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_61b24420-94d5-4b95-a197-81ceddf2cacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_0f506573-d51a-498f-ad36-cfcc8cc9a623" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4319ee77-aa03-4373-9be4-6ea16987fdc8" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_0f506573-d51a-498f-ad36-cfcc8cc9a623" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_00c173a0-6529-462e-a8a0-06c12a941301" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4319ee77-aa03-4373-9be4-6ea16987fdc8" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_00c173a0-6529-462e-a8a0-06c12a941301" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d9a05f14-01c5-4510-ae23-ad45ab195639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4319ee77-aa03-4373-9be4-6ea16987fdc8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_d9a05f14-01c5-4510-ae23-ad45ab195639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_b9e8dc0a-f8dd-4e06-9d6b-328de192f639" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4319ee77-aa03-4373-9be4-6ea16987fdc8" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_b9e8dc0a-f8dd-4e06-9d6b-328de192f639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_23b4d1ad-6848-47b9-9fd4-b0aa2163284c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4319ee77-aa03-4373-9be4-6ea16987fdc8" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_23b4d1ad-6848-47b9-9fd4-b0aa2163284c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_89ee69c3-0c96-41f3-8e67-e952f6c5153d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e13b0630-50dd-4a8c-9552-3323ab21aa40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_89ee69c3-0c96-41f3-8e67-e952f6c5153d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a11ae777-3ddd-4e12-8c8f-1924a186bfc3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_89ee69c3-0c96-41f3-8e67-e952f6c5153d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a11ae777-3ddd-4e12-8c8f-1924a186bfc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_ef0fa57b-0718-4d7c-b25a-1de6f649e8c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfProductiveAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_89ee69c3-0c96-41f3-8e67-e952f6c5153d" xlink:to="loc_us-gaap_ProceedsFromSaleOfProductiveAssets_ef0fa57b-0718-4d7c-b25a-1de6f649e8c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d3c349fe-bc81-4bef-8472-57c81a370eb4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_89ee69c3-0c96-41f3-8e67-e952f6c5153d" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_d3c349fe-bc81-4bef-8472-57c81a370eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_b1100473-a6c1-4184-94c5-3faa19120d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_89ee69c3-0c96-41f3-8e67-e952f6c5153d" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_b1100473-a6c1-4184-94c5-3faa19120d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_f8475227-08e0-4a23-b40a-43959ef8c3f8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_89ee69c3-0c96-41f3-8e67-e952f6c5153d" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_f8475227-08e0-4a23-b40a-43959ef8c3f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_ecfa5111-2c9f-41c1-b516-6b18a17b4b1f" xlink:href="jnj-20230101.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_89ee69c3-0c96-41f3-8e67-e952f6c5153d" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities_ecfa5111-2c9f-41c1-b516-6b18a17b4b1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_83baf5e8-69a5-463c-b968-41c12110bd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_89ee69c3-0c96-41f3-8e67-e952f6c5153d" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_83baf5e8-69a5-463c-b968-41c12110bd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_64a9f463-62c0-461d-9b69-ae8f59d79a0a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_89ee69c3-0c96-41f3-8e67-e952f6c5153d" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_64a9f463-62c0-461d-9b69-ae8f59d79a0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abf07aed-d4f9-4111-a5cb-ae9a41494e35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e13b0630-50dd-4a8c-9552-3323ab21aa40" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abf07aed-d4f9-4111-a5cb-ae9a41494e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_055d0a33-a7db-40b0-abaa-c129480877fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfOrdinaryDividends"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abf07aed-d4f9-4111-a5cb-ae9a41494e35" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_055d0a33-a7db-40b0-abaa-c129480877fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5b9e6116-5739-434e-877f-048cf8079f2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abf07aed-d4f9-4111-a5cb-ae9a41494e35" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_5b9e6116-5739-434e-877f-048cf8079f2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_f3243e3f-8ae9-4d9c-b279-ce9b2785b43e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromShortTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abf07aed-d4f9-4111-a5cb-ae9a41494e35" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_f3243e3f-8ae9-4d9c-b279-ce9b2785b43e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_613bcc81-ebf2-4001-a76a-15c24fbca7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfShortTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abf07aed-d4f9-4111-a5cb-ae9a41494e35" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_613bcc81-ebf2-4001-a76a-15c24fbca7bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_aa60fc11-0c94-4dbd-954f-7e0a44889dde" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abf07aed-d4f9-4111-a5cb-ae9a41494e35" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_aa60fc11-0c94-4dbd-954f-7e0a44889dde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_b9fec15d-28af-4fc6-8c81-7f755216561a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abf07aed-d4f9-4111-a5cb-ae9a41494e35" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_b9fec15d-28af-4fc6-8c81-7f755216561a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_02493164-5c2d-43d0-b65a-1dcd1e5f1d96" xlink:href="jnj-20230101.xsd#jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abf07aed-d4f9-4111-a5cb-ae9a41494e35" xlink:to="loc_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits_02493164-5c2d-43d0-b65a-1dcd1e5f1d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_864d0d33-24d5-4475-acd2-80289d0d3eb1" xlink:href="jnj-20230101.xsd#jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abf07aed-d4f9-4111-a5cb-ae9a41494e35" xlink:to="loc_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities_864d0d33-24d5-4475-acd2-80289d0d3eb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_003ed34d-e66a-47b2-a33f-a77e70cb8eea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abf07aed-d4f9-4111-a5cb-ae9a41494e35" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_003ed34d-e66a-47b2-a33f-a77e70cb8eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c70f372-e6e7-4046-a0ce-6e70b1a8e71d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_abf07aed-d4f9-4111-a5cb-ae9a41494e35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_9c70f372-e6e7-4046-a0ce-6e70b1a8e71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a3eb6dc3-859e-48bc-9d2e-561fec436024" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e13b0630-50dd-4a8c-9552-3323ab21aa40" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_a3eb6dc3-859e-48bc-9d2e-561fec436024" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2d379743-5fb7-4972-be34-cadf6e6c5887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e13b0630-50dd-4a8c-9552-3323ab21aa40" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2d379743-5fb7-4972-be34-cadf6e6c5887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_72ca54a9-8a70-4d56-ac93-57c7afe1e3fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e13b0630-50dd-4a8c-9552-3323ab21aa40" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_72ca54a9-8a70-4d56-ac93-57c7afe1e3fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32149d06-6c8e-4f38-9e37-1eeeb6a6bd5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e13b0630-50dd-4a8c-9552-3323ab21aa40" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_32149d06-6c8e-4f38-9e37-1eeeb6a6bd5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_b7dd5813-2d8e-45e3-9665-be4f594a8d5d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e13b0630-50dd-4a8c-9552-3323ab21aa40" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_b7dd5813-2d8e-45e3-9665-be4f594a8d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CashPaidDuringTheYearAbstract_78f661c8-9de1-4a7c-a5ad-a64b76fdb909" xlink:href="jnj-20230101.xsd#jnj_CashPaidDuringTheYearAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_b7dd5813-2d8e-45e3-9665-be4f594a8d5d" xlink:to="loc_jnj_CashPaidDuringTheYearAbstract_78f661c8-9de1-4a7c-a5ad-a64b76fdb909" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaid_10024d45-2cd1-488b-a7f0-fbf05f32366d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CashPaidDuringTheYearAbstract_78f661c8-9de1-4a7c-a5ad-a64b76fdb909" xlink:to="loc_us-gaap_InterestPaid_10024d45-2cd1-488b-a7f0-fbf05f32366d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_8d2ca1b6-3c72-4d91-97c1-716946d4cec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CashPaidDuringTheYearAbstract_78f661c8-9de1-4a7c-a5ad-a64b76fdb909" xlink:to="loc_us-gaap_InterestPaidNet_8d2ca1b6-3c72-4d91-97c1-716946d4cec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaid_52bc7129-09ec-46ac-8e73-9a94bf061e36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxesPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_CashPaidDuringTheYearAbstract_78f661c8-9de1-4a7c-a5ad-a64b76fdb909" xlink:to="loc_us-gaap_IncomeTaxesPaid_52bc7129-09ec-46ac-8e73-9a94bf061e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ce73c8ff-b3cd-40d0-ac5c-f2688b2ad1f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e13b0630-50dd-4a8c-9552-3323ab21aa40" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ce73c8ff-b3cd-40d0-ac5c-f2688b2ad1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_8be02e4d-8dcd-4be4-9927-7c303b07be0a" xlink:href="jnj-20230101.xsd#jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ce73c8ff-b3cd-40d0-ac5c-f2688b2ad1f9" xlink:to="loc_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds_8be02e4d-8dcd-4be4-9927-7c303b07be0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0f85c879-7f05-4fe4-84a3-eb7e9385503c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_ce73c8ff-b3cd-40d0-ac5c-f2688b2ad1f9" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_0f85c879-7f05-4fe4-84a3-eb7e9385503c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_8aacabf0-34d8-46b5-84d3-178c58c8543c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_e13b0630-50dd-4a8c-9552-3323ab21aa40" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_8aacabf0-34d8-46b5-84d3-178c58c8543c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_b5724978-df83-4eb6-bff2-6d6d626548b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_8aacabf0-34d8-46b5-84d3-178c58c8543c" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1_b5724978-df83-4eb6-bff2-6d6d626548b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_aa02f6d7-a756-4a0a-86b7-fe388b326a79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_8aacabf0-34d8-46b5-84d3-178c58c8543c" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_aa02f6d7-a756-4a0a-86b7-fe388b326a79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_60364816-e9c3-4f4e-8b43-eff04a0ee98f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract_8aacabf0-34d8-46b5-84d3-178c58c8543c" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1_60364816-e9c3-4f4e-8b43-eff04a0ee98f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="jnj-20230101.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d9a69bf7-0211-4f65-bc19-dce1b7d0290c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_45c71b0e-ae13-4a87-9df6-4895ea7695cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d9a69bf7-0211-4f65-bc19-dce1b7d0290c" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_45c71b0e-ae13-4a87-9df6-4895ea7695cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities" xlink:type="simple" xlink:href="jnj-20230101.xsd#CashCashEquivalentsandCurrentMarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0f78fb14-b058-4be6-95f2-44314b80543b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_452071d6-160d-499c-ac2b-5ce67969476e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0f78fb14-b058-4be6-95f2-44314b80543b" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_452071d6-160d-499c-ac2b-5ce67969476e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Inventories" xlink:type="simple" xlink:href="jnj-20230101.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_4bd80a19-159c-4c7b-8a0b-c1d9ca777b38" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_dfbac94f-1802-4515-9298-ac0a4a956e08" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_4bd80a19-159c-4c7b-8a0b-c1d9ca777b38" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_dfbac94f-1802-4515-9298-ac0a4a956e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipment" xlink:type="simple" xlink:href="jnj-20230101.xsd#PropertyPlantandEquipment"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipment" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_91721b15-9cff-45d8-84f0-b55af2696801" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5b38941c-203f-44c6-bc3c-20ece9a7e730" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_91721b15-9cff-45d8-84f0-b55af2696801" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_5b38941c-203f-44c6-bc3c-20ece9a7e730" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="simple" xlink:href="jnj-20230101.xsd#IntangibleAssetsandGoodwill"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f61b56fd-9f1f-43d4-bc8a-d31f7e756db7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_840f5cc5-9893-4566-8039-4db71d73cd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_f61b56fd-9f1f-43d4-bc8a-d31f7e756db7" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_840f5cc5-9893-4566-8039-4db71d73cd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_14120f94-fc91-43a9-9462-6838e579a52d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_980ae18c-e2d6-4f40-974e-003847d00622" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_14120f94-fc91-43a9-9462-6838e579a52d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_980ae18c-e2d6-4f40-974e-003847d00622" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Borrowings" xlink:type="simple" xlink:href="jnj-20230101.xsd#Borrowings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Borrowings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_944747f8-c49e-4f98-a144-79673bc11213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_e7eb92b4-d7f5-4480-8f65-18de31a74c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_944747f8-c49e-4f98-a144-79673bc11213" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_e7eb92b4-d7f5-4480-8f65-18de31a74c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxes" xlink:type="simple" xlink:href="jnj-20230101.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_f4bb59f9-591d-452b-b940-96528357c305" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_d09824f2-7300-4ce2-8184-6edb09f5eab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_f4bb59f9-591d-452b-b940-96528357c305" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_d09824f2-7300-4ce2-8184-6edb09f5eab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligations" xlink:type="simple" xlink:href="jnj-20230101.xsd#EmployeeRelatedObligations"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligations" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_94baf11a-6809-4d63-ae1a-6dc97dcfe335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsGeneralTextBlock_8f3066e6-3eb5-4324-b5c7-e82d47fb0481" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsGeneralTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_94baf11a-6809-4d63-ae1a-6dc97dcfe335" xlink:to="loc_us-gaap_CompensationRelatedCostsGeneralTextBlock_8f3066e6-3eb5-4324-b5c7-e82d47fb0481" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlans"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlans" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_031cacbe-5023-4630-b15e-c09f86b8bc37" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_363d4994-082b-4542-b0bd-8eb4245af926" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_031cacbe-5023-4630-b15e-c09f86b8bc37" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_363d4994-082b-4542-b0bd-8eb4245af926" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SavingsPlan" xlink:type="simple" xlink:href="jnj-20230101.xsd#SavingsPlan"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SavingsPlan" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanAbstract_293b0ec5-1218-4cfa-be2b-f0834170be89" xlink:href="jnj-20230101.xsd#jnj_SavingsPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanTextBlock_7b73e18c-86c5-434a-abf3-c05ae2a95027" xlink:href="jnj-20230101.xsd#jnj_SavingsPlanTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_SavingsPlanAbstract_293b0ec5-1218-4cfa-be2b-f0834170be89" xlink:to="loc_jnj_SavingsPlanTextBlock_7b73e18c-86c5-434a-abf3-c05ae2a95027" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStock" xlink:type="simple" xlink:href="jnj-20230101.xsd#CapitalandTreasuryStock"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStock" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_bfd8ad22-6a7f-4259-9af4-af0537f60831" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockTextBlock_ee40c650-10df-49f3-a6ed-de5c17d617f2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_bfd8ad22-6a7f-4259-9af4-af0537f60831" xlink:to="loc_us-gaap_TreasuryStockTextBlock_ee40c650-10df-49f3-a6ed-de5c17d617f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="simple" xlink:href="jnj-20230101.xsd#AccumulatedOtherComprehensiveIncomeLoss"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_1c7bb332-a3e9-44dc-a6bb-931a37b225ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_08a54cb4-f16b-47b9-8ca4-4bca2777895e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_1c7bb332-a3e9-44dc-a6bb-931a37b225ee" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_08a54cb4-f16b-47b9-8ca4-4bca2777895e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InternationalCurrencyTranslation" xlink:type="simple" xlink:href="jnj-20230101.xsd#InternationalCurrencyTranslation"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InternationalCurrencyTranslation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTranslationAbstract_85caa745-0ef6-4bdc-91df-097aa8497b51" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTranslationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDisclosureTextBlock_5f04eefc-c394-4e93-8949-cda79e385794" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCurrencyTranslationAbstract_85caa745-0ef6-4bdc-91df-097aa8497b51" xlink:to="loc_us-gaap_ForeignCurrencyDisclosureTextBlock_5f04eefc-c394-4e93-8949-cda79e385794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShare" xlink:type="simple" xlink:href="jnj-20230101.xsd#EarningsPerShare"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_f9c596b4-1056-412b-a46c-2936f237faba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_6382f680-ff47-4b61-91a4-ff6fb28b72b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_f9c596b4-1056-412b-a46c-2936f237faba" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_6382f680-ff47-4b61-91a4-ff6fb28b72b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements" xlink:type="simple" xlink:href="jnj-20230101.xsd#CommonStockStockOptionPlansandStockCompensationAgreements"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5d1d9c3-1e91-4571-a248-5366381d3513" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_03e0e473-e3bb-480c-ac47-e4f57177e834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5d1d9c3-1e91-4571-a248-5366381d3513" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_03e0e473-e3bb-480c-ac47-e4f57177e834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="simple" xlink:href="jnj-20230101.xsd#SegmentsofBusinessandGeographicAreas"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_34ba0ee7-e094-4200-a782-01aa8ecf1136" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_d384b5da-cd41-4eb7-af10-d58fd9cdeeab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_34ba0ee7-e094-4200-a782-01aa8ecf1136" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_d384b5da-cd41-4eb7-af10-d58fd9cdeeab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="simple" xlink:href="jnj-20230101.xsd#AcquisitionsandDivestitures"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestitures" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e0dbc65b-bca4-48bd-80f0-28f30f11966f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_394e1570-ba68-489f-b515-7a1bf5b3d978" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_e0dbc65b-bca4-48bd-80f0-28f30f11966f" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_394e1570-ba68-489f-b515-7a1bf5b3d978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedings" xlink:type="simple" xlink:href="jnj-20230101.xsd#LegalProceedings"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedings" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_46398073-fb80-437a-beb1-7448a36e5875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LegalMattersAndContingenciesTextBlock_9eaf3414-0e87-423a-b6b5-2adfc36dc29f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LegalMattersAndContingenciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_46398073-fb80-437a-beb1-7448a36e5875" xlink:to="loc_us-gaap_LegalMattersAndContingenciesTextBlock_9eaf3414-0e87-423a-b6b5-2adfc36dc29f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/Restructuring" xlink:type="simple" xlink:href="jnj-20230101.xsd#Restructuring"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/Restructuring" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d0c44026-3312-4d3d-82d2-5b3eeb4506f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f6b29e60-632e-4105-8c00-c70b2a4e3763" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_d0c44026-3312-4d3d-82d2-5b3eeb4506f5" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_f6b29e60-632e-4105-8c00-c70b2a4e3763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="jnj-20230101.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_d9009912-ac0e-43b7-bbdb-62a699e88939" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_d9009912-ac0e-43b7-bbdb-62a699e88939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9d3eb9ac-258d-4849-8e17-7703eb872e44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_9d3eb9ac-258d-4849-8e17-7703eb872e44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f0fa8a7e-3ca6-492c-a7ce-6b28dfcb2fd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_f0fa8a7e-3ca6-492c-a7ce-6b28dfcb2fd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b87e4300-10a9-4769-88c9-0af39fbbfd14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_b87e4300-10a9-4769-88c9-0af39fbbfd14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_5db03e84-322a-4ea2-9d98-d774486aa26d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentPolicyTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_5db03e84-322a-4ea2-9d98-d774486aa26d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_afdb46ee-ebac-42e1-9e34-cf577556fffe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_afdb46ee-ebac-42e1-9e34-cf577556fffe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_924db98b-7588-4760-a237-9c80c1c873bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_924db98b-7588-4760-a237-9c80c1c873bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_d3ff7d94-34c0-4be0-881d-a92c1af27177" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingCostPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_ShippingAndHandlingCostPolicyTextBlock_d3ff7d94-34c0-4be0-881d-a92c1af27177" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_bc404292-cf95-4e34-b410-95ad7e3ae2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_bc404292-cf95-4e34-b410-95ad7e3ae2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_9bd01bc9-d185-4a22-9042-93ede6888db0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_9bd01bc9-d185-4a22-9042-93ede6888db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_49022023-814c-4f0a-b92e-4998c2778992" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_49022023-814c-4f0a-b92e-4998c2778992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_202a4446-4438-46a4-8832-475b015ee238" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_202a4446-4438-46a4-8832-475b015ee238" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityPolicyTextBlock_850cb03c-56a3-42b3-8eac-520cbbf70d32" xlink:href="jnj-20230101.xsd#jnj_ProductLiabilityPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_jnj_ProductLiabilityPolicyTextBlock_850cb03c-56a3-42b3-8eac-520cbbf70d32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_73fa08de-34d5-4db6-9911-c8a3ec672ff7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_73fa08de-34d5-4db6-9911-c8a3ec672ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_23d4cc11-d68c-4fa7-a27c-b2001125a14e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_23d4cc11-d68c-4fa7-a27c-b2001125a14e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_df4c5c4a-d251-4cd6-aca0-4af38a8e63a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_df4c5c4a-d251-4cd6-aca0-4af38a8e63a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_62cb4d0c-fb0f-46f3-bb6f-a17c18b64edf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_62cb4d0c-fb0f-46f3-bb6f-a17c18b64edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_f3a14bad-4cc5-4381-9df6-0132db486c9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_UseOfEstimates_f3a14bad-4cc5-4381-9df6-0132db486c9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiscalPeriodPolicyTextBlock_2e9822bb-0ef2-4c36-b383-f24cfc693263" xlink:href="jnj-20230101.xsd#jnj_FiscalPeriodPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_jnj_FiscalPeriodPolicyTextBlock_2e9822bb-0ef2-4c36-b383-f24cfc693263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_a7c1de9a-5992-44d2-989a-94cb9f8745ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bb4618c6-d675-4ca6-8155-e6fece33f2b6" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_a7c1de9a-5992-44d2-989a-94cb9f8745ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="jnj-20230101.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_62845e14-1af3-4a82-8035-fe40464f9edf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_4a04494d-f8fa-4bc3-9f45-c5d0063c4d56" xlink:href="jnj-20230101.xsd#jnj_EstimatedUsefulLivesOfAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_62845e14-1af3-4a82-8035-fe40464f9edf" xlink:to="loc_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock_4a04494d-f8fa-4bc3-9f45-c5d0063c4d56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables" xlink:type="simple" xlink:href="jnj-20230101.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_49421f98-4739-4719-99d4-565c4ea0742b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2ee3bd85-ba0d-4813-8315-23bf72c80c18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_49421f98-4739-4719-99d4-565c4ea0742b" xlink:to="loc_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_2ee3bd85-ba0d-4813-8315-23bf72c80c18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_72529001-5b63-467b-a560-47022a54ce12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_49421f98-4739-4719-99d4-565c4ea0742b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_72529001-5b63-467b-a560-47022a54ce12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesTables" xlink:type="simple" xlink:href="jnj-20230101.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_1fbe229e-a928-4c3b-aefa-bd5afe7d26aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1ebbbb9b-d300-4a02-bc1a-1f38cd7d8997" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_1fbe229e-a928-4c3b-aefa-bd5afe7d26aa" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_1ebbbb9b-d300-4a02-bc1a-1f38cd7d8997" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentTables" xlink:type="simple" xlink:href="jnj-20230101.xsd#PropertyPlantandEquipmentTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_49440449-3581-432c-839d-a97a68c66fa7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_a3a8a14f-a174-4d56-90d4-3d7711581162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_49440449-3581-432c-839d-a97a68c66fa7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_a3a8a14f-a174-4d56-90d4-3d7711581162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="simple" xlink:href="jnj-20230101.xsd#IntangibleAssetsandGoodwillTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_25f1ae6d-aba1-4353-8000-a9cff95add74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_cd9d2a81-45be-42e5-8f54-17b5c3a34450" xlink:href="jnj-20230101.xsd#jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_25f1ae6d-aba1-4353-8000-a9cff95add74" xlink:to="loc_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock_cd9d2a81-45be-42e5-8f54-17b5c3a34450" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_6309abd6-ac50-4cb0-9168-caefb15a03a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_25f1ae6d-aba1-4353-8000-a9cff95add74" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_6309abd6-ac50-4cb0-9168-caefb15a03a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_72321c47-5bdf-4baf-96f1-e83ad08160ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_25f1ae6d-aba1-4353-8000-a9cff95add74" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock_72321c47-5bdf-4baf-96f1-e83ad08160ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_50970dc7-9970-4c45-b727-38e8ab1165af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_b2b1d6b6-ddd9-4546-bf1b-ec3a731e054c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_50970dc7-9970-4c45-b727-38e8ab1165af" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_b2b1d6b6-ddd9-4546-bf1b-ec3a731e054c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_750206df-4426-482e-873d-06805703bfb6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_50970dc7-9970-4c45-b727-38e8ab1165af" xlink:to="loc_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_750206df-4426-482e-873d-06805703bfb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_bb92e56e-2cc6-432d-9aa6-024f60575ba0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_50970dc7-9970-4c45-b727-38e8ab1165af" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock_bb92e56e-2cc6-432d-9aa6-024f60575ba0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_e63ec19d-1294-4c80-956b-92c443fee88b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_50970dc7-9970-4c45-b727-38e8ab1165af" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_e63ec19d-1294-4c80-956b-92c443fee88b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_f8d90edb-43a3-4171-a94e-7552e00138c9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_50970dc7-9970-4c45-b727-38e8ab1165af" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock_f8d90edb-43a3-4171-a94e-7552e00138c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsTables" xlink:type="simple" xlink:href="jnj-20230101.xsd#BorrowingsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BorrowingsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7f9f65db-1633-41bc-a375-875051fb857f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_2db52826-299e-4113-abd2-46986d00a096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f9f65db-1633-41bc-a375-875051fb857f" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_2db52826-299e-4113-abd2-46986d00a096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_640060e3-3f98-40c3-8a2b-b2ea1cc44bb7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7f9f65db-1633-41bc-a375-875051fb857f" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_640060e3-3f98-40c3-8a2b-b2ea1cc44bb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="jnj-20230101.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_3c3f4a0f-6638-402e-b7bf-c07e534b8a31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_cf915a29-ae4c-4084-a766-8ddcf6ce1641" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3c3f4a0f-6638-402e-b7bf-c07e534b8a31" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_cf915a29-ae4c-4084-a766-8ddcf6ce1641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6d2217e5-8e38-4747-9c47-005826814aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3c3f4a0f-6638-402e-b7bf-c07e534b8a31" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_6d2217e5-8e38-4747-9c47-005826814aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_670711d3-97c9-4e62-aa18-39c42f2ce818" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3c3f4a0f-6638-402e-b7bf-c07e534b8a31" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_670711d3-97c9-4e62-aa18-39c42f2ce818" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_33c1320e-9609-4501-85d0-b9a365111580" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SummaryOfIncomeTaxContingenciesTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_3c3f4a0f-6638-402e-b7bf-c07e534b8a31" xlink:to="loc_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock_33c1320e-9609-4501-85d0-b9a365111580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsTables" xlink:type="simple" xlink:href="jnj-20230101.xsd#EmployeeRelatedObligationsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_df6be80b-8fcd-4e7f-b232-e1736aa796fa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeRelatedObligationsTableTextBlock_dabfad58-56e2-4569-8c0f-1f608ff98de4" xlink:href="jnj-20230101.xsd#jnj_EmployeeRelatedObligationsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_df6be80b-8fcd-4e7f-b232-e1736aa796fa" xlink:to="loc_jnj_EmployeeRelatedObligationsTableTextBlock_dabfad58-56e2-4569-8c0f-1f608ff98de4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_892aaced-ecf4-43a6-b5b4-ad317aafb8db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_30540cda-9ae9-4fe1-983f-78f3c4bb9ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetBenefitCostsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_892aaced-ecf4-43a6-b5b4-ad317aafb8db" xlink:to="loc_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock_30540cda-9ae9-4fe1-983f-78f3c4bb9ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_b60a6ca3-881b-4d2d-803c-3e98b1ff8637" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_892aaced-ecf4-43a6-b5b4-ad317aafb8db" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_b60a6ca3-881b-4d2d-803c-3e98b1ff8637" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_50ac1fee-5154-4b85-aebe-923bb939af3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_892aaced-ecf4-43a6-b5b4-ad317aafb8db" xlink:to="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_50ac1fee-5154-4b85-aebe-923bb939af3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_b6f696ed-ed7c-4588-999c-7b0557e2b984" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfNetFundedStatusTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_892aaced-ecf4-43a6-b5b4-ad317aafb8db" xlink:to="loc_us-gaap_ScheduleOfNetFundedStatusTableTextBlock_b6f696ed-ed7c-4588-999c-7b0557e2b984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_b9f74a3a-8495-4bdc-9395-cadd3b7ac5a6" xlink:href="jnj-20230101.xsd#jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_892aaced-ecf4-43a6-b5b4-ad317aafb8db" xlink:to="loc_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock_b9f74a3a-8495-4bdc-9395-cadd3b7ac5a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_868953ad-08c7-4291-bd01-8f60099bc1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_892aaced-ecf4-43a6-b5b4-ad317aafb8db" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_868953ad-08c7-4291-bd01-8f60099bc1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_33f6ff92-1f4b-49d7-b970-123b381dcf0e" xlink:href="jnj-20230101.xsd#jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_892aaced-ecf4-43a6-b5b4-ad317aafb8db" xlink:to="loc_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock_33f6ff92-1f4b-49d7-b970-123b381dcf0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_8c755db6-ce9c-4ead-afc2-6c6eade74723" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_892aaced-ecf4-43a6-b5b4-ad317aafb8db" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_8c755db6-ce9c-4ead-afc2-6c6eade74723" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_5e0ba877-ee9c-4541-99d7-33007ef298b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_892aaced-ecf4-43a6-b5b4-ad317aafb8db" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock_5e0ba877-ee9c-4541-99d7-33007ef298b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockTables" xlink:type="simple" xlink:href="jnj-20230101.xsd#CapitalandTreasuryStockTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_2d47104b-9acb-4d04-acdb-c280d010f133" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockTableTextBlock_713b11db-21fc-493d-b326-19396624b95c" xlink:href="jnj-20230101.xsd#jnj_ChangesInTreasuryStockTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_2d47104b-9acb-4d04-acdb-c280d010f133" xlink:to="loc_jnj_ChangesInTreasuryStockTableTextBlock_713b11db-21fc-493d-b326-19396624b95c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="simple" xlink:href="jnj-20230101.xsd#AccumulatedOtherComprehensiveIncomeLossTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_472e5ce5-2b03-4c89-8b17-fb8d5b47da09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8b14c79b-3032-4be0-9318-b3b286c60ae0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_472e5ce5-2b03-4c89-8b17-fb8d5b47da09" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_8b14c79b-3032-4be0-9318-b3b286c60ae0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="simple" xlink:href="jnj-20230101.xsd#EarningsPerShareTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_3b10510e-3685-423d-9c47-45875bed47f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_97e79dd2-150c-4ded-9ee1-578a8bf96503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_3b10510e-3685-423d-9c47-45875bed47f4" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_97e79dd2-150c-4ded-9ee1-578a8bf96503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables" xlink:type="simple" xlink:href="jnj-20230101.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d76884a7-b31a-40ee-a3c6-d4ae1b09fc66" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ef023314-db98-4269-9097-394efd9082d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d76884a7-b31a-40ee-a3c6-d4ae1b09fc66" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_ef023314-db98-4269-9097-394efd9082d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_cb868090-8b2d-44f8-81e7-6b50a094b951" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d76884a7-b31a-40ee-a3c6-d4ae1b09fc66" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_cb868090-8b2d-44f8-81e7-6b50a094b951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_bbf76ea6-a837-48fa-a0db-8adee354e3f1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d76884a7-b31a-40ee-a3c6-d4ae1b09fc66" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_bbf76ea6-a837-48fa-a0db-8adee354e3f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_5cfe28eb-70df-45bf-86f6-cf62c32e972b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_d76884a7-b31a-40ee-a3c6-d4ae1b09fc66" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock_5cfe28eb-70df-45bf-86f6-cf62c32e972b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="simple" xlink:href="jnj-20230101.xsd#SegmentsofBusinessandGeographicAreasTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_4e36d9ee-1540-446e-b6fa-f8098c1a07c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_a8d825fe-0485-41cc-9f29-57a823682f4e" xlink:href="jnj-20230101.xsd#jnj_SalesBySegmentOfBusinessTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4e36d9ee-1540-446e-b6fa-f8098c1a07c7" xlink:to="loc_jnj_SalesBySegmentOfBusinessTableTextBlock_a8d825fe-0485-41cc-9f29-57a823682f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_340da7b2-b122-45c0-946d-cc32c6d02700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4e36d9ee-1540-446e-b6fa-f8098c1a07c7" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_340da7b2-b122-45c0-946d-cc32c6d02700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_03a73867-7baf-499e-a747-3e58efacce4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4e36d9ee-1540-446e-b6fa-f8098c1a07c7" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_03a73867-7baf-499e-a747-3e58efacce4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringTables" xlink:type="simple" xlink:href="jnj-20230101.xsd#RestructuringTables"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4052a90b-8624-4e74-bbd7-8da04cbf2c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_b24c5292-93aa-479b-8fa0-455b80351bc1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_4052a90b-8624-4e74-bbd7-8da04cbf2c93" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_b24c5292-93aa-479b-8fa0-455b80351bc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_050db04e-6f51-416b-8171-51ca84048ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:href="jnj-20230101.xsd#jnj_ConcentrationOfCreditRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_050db04e-6f51-416b-8171-51ca84048ab7" xlink:to="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_d41237f0-30d9-46d7-85e0-6be344969c7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_d41237f0-30d9-46d7-85e0-6be344969c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_70ea591e-8560-44e5-9bb1-129c5eae8fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_d41237f0-30d9-46d7-85e0-6be344969c7d" xlink:to="loc_us-gaap_SegmentDomain_70ea591e-8560-44e5-9bb1-129c5eae8fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_efefe774-853f-403c-bb6d-0ceee17313eb" xlink:href="jnj-20230101.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_70ea591e-8560-44e5-9bb1-129c5eae8fc6" xlink:to="loc_jnj_PharmaceuticalMember_efefe774-853f-403c-bb6d-0ceee17313eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_991886a8-4eae-46af-9764-e8d649662b1b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:to="loc_srt_ProductOrServiceAxis_991886a8-4eae-46af-9764-e8d649662b1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b7ec4102-29db-4a15-bb29-3064aa67520c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_991886a8-4eae-46af-9764-e8d649662b1b" xlink:to="loc_srt_ProductsAndServicesDomain_b7ec4102-29db-4a15-bb29-3064aa67520c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShippingAndHandlingMember_ea5f11fd-7803-4225-bdfc-6edaec4747c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShippingAndHandlingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b7ec4102-29db-4a15-bb29-3064aa67520c" xlink:to="loc_us-gaap_ShippingAndHandlingMember_ea5f11fd-7803-4225-bdfc-6edaec4747c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2f0a3cc-5bc2-41ce-953e-9971a5b85c4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2f0a3cc-5bc2-41ce-953e-9971a5b85c4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d4039c51-91e4-44e6-bb54-4a252ac87d8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_d2f0a3cc-5bc2-41ce-953e-9971a5b85c4d" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d4039c51-91e4-44e6-bb54-4a252ac87d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a9a73753-babf-4501-bae9-dbf5d56d4f98" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_d4039c51-91e4-44e6-bb54-4a252ac87d8f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_a9a73753-babf-4501-bae9-dbf5d56d4f98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_4230f33c-0c27-4682-9c2e-5254f230ccba" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:to="loc_srt_RangeAxis_4230f33c-0c27-4682-9c2e-5254f230ccba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e1611e23-d1bc-4c47-90e7-af9a241c7334" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_4230f33c-0c27-4682-9c2e-5254f230ccba" xlink:to="loc_srt_RangeMember_e1611e23-d1bc-4c47-90e7-af9a241c7334" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3a6d7335-6ea0-4b31-8f7b-e3d8c225c0a7" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e1611e23-d1bc-4c47-90e7-af9a241c7334" xlink:to="loc_srt_MinimumMember_3a6d7335-6ea0-4b31-8f7b-e3d8c225c0a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_70a61bbb-8b9d-4443-889f-ec9b4b084c39" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e1611e23-d1bc-4c47-90e7-af9a241c7334" xlink:to="loc_srt_MaximumMember_70a61bbb-8b9d-4443-889f-ec9b4b084c39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c534bf6-5187-44ff-9d71-9959346fe84c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c534bf6-5187-44ff-9d71-9959346fe84c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b04490d3-7a84-4898-b108-58b6bd12cbfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_8c534bf6-5187-44ff-9d71-9959346fe84c" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b04490d3-7a84-4898-b108-58b6bd12cbfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SoftwareDevelopmentMember_df29fa94-9629-4d33-80b4-44f86f557df6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SoftwareDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b04490d3-7a84-4898-b108-58b6bd12cbfa" xlink:to="loc_us-gaap_SoftwareDevelopmentMember_df29fa94-9629-4d33-80b4-44f86f557df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_d3fc33a2-de56-4402-baf7-12411230d149" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_d3fc33a2-de56-4402-baf7-12411230d149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_c43551d4-5787-4c84-933f-493dc3865a9b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_d3fc33a2-de56-4402-baf7-12411230d149" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_c43551d4-5787-4c84-933f-493dc3865a9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_e58b9799-3219-4f06-b7d8-07aec978156e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProductConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_c43551d4-5787-4c84-933f-493dc3865a9b" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_e58b9799-3219-4f06-b7d8-07aec978156e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:href="jnj-20230101.xsd#jnj_ConcentrationOfCreditRiskLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskTable_9d333ce5-666f-4df4-8bc1-67c9029e901d" xlink:to="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_1e735507-6b3b-4954-ba54-7a8c6b52ae66" xlink:href="jnj-20230101.xsd#jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide_1e735507-6b3b-4954-ba54-7a8c6b52ae66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_21117138-608b-4918-8c75-0760be97bc84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_NumberOfReportableSegments_21117138-608b-4918-8c75-0760be97bc84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_bf88671a-0863-439a-af51-6553ce5e9e86" xlink:href="jnj-20230101.xsd#jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement_bf88671a-0863-439a-af51-6553ce5e9e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c8526352-e002-4ad1-b42c-053633f3a5e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_c8526352-e002-4ad1-b42c-053633f3a5e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AccruedRebatesReturnsAndPromotions_b245901b-810e-4393-9d68-4dbf443e670d" xlink:href="jnj-20230101.xsd#jnj_AccruedRebatesReturnsAndPromotions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_AccruedRebatesReturnsAndPromotions_b245901b-810e-4393-9d68-4dbf443e670d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SalesReturnReserve_92892d8b-eea2-49b8-b199-a45d63b9f163" xlink:href="jnj-20230101.xsd#jnj_SalesReturnReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_SalesReturnReserve_92892d8b-eea2-49b8-b199-a45d63b9f163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProfitLossPercentToSales_94cfcc28-35e2-4eb6-adef-1a2d0c179f92" xlink:href="jnj-20230101.xsd#jnj_ProfitLossPercentToSales"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_ProfitLossPercentToSales_94cfcc28-35e2-4eb6-adef-1a2d0c179f92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_9f7cfada-ac76-45f9-a7f5-8cbb25fd06a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_9f7cfada-ac76-45f9-a7f5-8cbb25fd06a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShippingandHandlingCostsasaPercentofSales_458d1d4e-b508-4d51-8dc2-494c72b95666" xlink:href="jnj-20230101.xsd#jnj_ShippingandHandlingCostsasaPercentofSales"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_ShippingandHandlingCostsasaPercentofSales_458d1d4e-b508-4d51-8dc2-494c72b95666" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_450602bd-ee38-4209-a245-7eb9a52c2dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList_450602bd-ee38-4209-a245-7eb9a52c2dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_960b0da1-2363-460d-8e02-0e63b68b9d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_960b0da1-2363-460d-8e02-0e63b68b9d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_6d66a91c-b388-4318-858c-10887a16cf28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList_6d66a91c-b388-4318-858c-10887a16cf28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_19dcf999-c10c-451d-a27c-f4b9192d3772" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_19dcf999-c10c-451d-a27c-f4b9192d3772" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_dd65b6c5-d89c-40ba-9ab0-591d1f95c7a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_OperatingLeaseLiability_dd65b6c5-d89c-40ba-9ab0-591d1f95c7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_78df5c50-3045-401e-af31-19c9be10d6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_OperatingLeaseCost_78df5c50-3045-401e-af31-19c9be10d6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_5e6777ce-4024-4d71-854f-e379c02954f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_OperatingLeasePayments_5e6777ce-4024-4d71-854f-e379c02954f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConcentrationRiskThresholdPercentage_e0c2e58d-7a1e-4ab3-8d45-4261ad3df887" xlink:href="jnj-20230101.xsd#jnj_ConcentrationRiskThresholdPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_ConcentrationRiskThresholdPercentage_e0c2e58d-7a1e-4ab3-8d45-4261ad3df887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_bfae84e7-ec6c-4911-9da5-114edc30e096" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_AdvertisingExpense_bfae84e7-ec6c-4911-9da5-114edc30e096" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_081251a9-1857-4e80-8db1-d7bacc665af7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_081251a9-1857-4e80-8db1-d7bacc665af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_418ed7db-6fa2-44bc-ad8a-272e3212b50b" xlink:href="jnj-20230101.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent_418ed7db-6fa2-44bc-ad8a-272e3212b50b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_3d89f955-a380-479f-aa70-190aa42980eb" xlink:href="jnj-20230101.xsd#jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent_3d89f955-a380-479f-aa70-190aa42980eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_32d8da64-0697-47e0-8e77-19d57e2edcd8" xlink:href="jnj-20230101.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability_32d8da64-0697-47e0-8e77-19d57e2edcd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_780da594-9ea1-4f6b-b349-fb7a8a493b8d" xlink:href="jnj-20230101.xsd#jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent_780da594-9ea1-4f6b-b349-fb7a8a493b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_eca12767-8264-4e40-b04d-32f7bda384a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ConcentrationOfCreditRiskLineItems_e0f4c9bc-b37e-4b3b-a707-1f0b34ac6e3d" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_eca12767-8264-4e40-b04d-32f7bda384a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_6d37ce6e-b984-409a-addb-7b56ac6baace" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a28a172-b1ef-44bf-9001-a60fda827bfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_6d37ce6e-b984-409a-addb-7b56ac6baace" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a28a172-b1ef-44bf-9001-a60fda827bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_592443d6-a809-4721-9205-3228dce3618d" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a28a172-b1ef-44bf-9001-a60fda827bfa" xlink:to="loc_srt_RangeAxis_592443d6-a809-4721-9205-3228dce3618d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cbed1495-e8ce-4992-9a76-f6879374e9c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_592443d6-a809-4721-9205-3228dce3618d" xlink:to="loc_srt_RangeMember_cbed1495-e8ce-4992-9a76-f6879374e9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_7ec69327-ef60-4357-8f5e-c0bf1ca17f63" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cbed1495-e8ce-4992-9a76-f6879374e9c4" xlink:to="loc_srt_MinimumMember_7ec69327-ef60-4357-8f5e-c0bf1ca17f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_5c2d00e7-3738-410f-bec6-ac37eb6baceb" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cbed1495-e8ce-4992-9a76-f6879374e9c4" xlink:to="loc_srt_MaximumMember_5c2d00e7-3738-410f-bec6-ac37eb6baceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08d04065-c632-4e9e-8c62-b180aef3a5d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a28a172-b1ef-44bf-9001-a60fda827bfa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08d04065-c632-4e9e-8c62-b180aef3a5d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e97abd9d-22e6-49c2-acb9-dd2b6365278d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_08d04065-c632-4e9e-8c62-b180aef3a5d4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e97abd9d-22e6-49c2-acb9-dd2b6365278d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_ada6a193-1114-4107-abb7-15b7240e992a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e97abd9d-22e6-49c2-acb9-dd2b6365278d" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_ada6a193-1114-4107-abb7-15b7240e992a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember_383dc888-2895-4408-b7bd-66a3e4d9cd8c" xlink:href="jnj-20230101.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e97abd9d-22e6-49c2-acb9-dd2b6365278d" xlink:to="loc_jnj_LandAndLeaseholdImprovementsMember_383dc888-2895-4408-b7bd-66a3e4d9cd8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_2a3f1b31-e085-4cde-9598-db25adca84ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e97abd9d-22e6-49c2-acb9-dd2b6365278d" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_2a3f1b31-e085-4cde-9598-db25adca84ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0275639-aed6-4685-b823-c5e5eef8b903" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_7a28a172-b1ef-44bf-9001-a60fda827bfa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0275639-aed6-4685-b823-c5e5eef8b903" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_34ec15c5-f1c3-4418-8c85-48f2d490490f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_a0275639-aed6-4685-b823-c5e5eef8b903" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_34ec15c5-f1c3-4418-8c85-48f2d490490f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_9ec63d64-749f-4d98-91ac-dbe288022c67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4e155fee-6f4f-4096-b4df-d1bc5d0b2381" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_9ec63d64-749f-4d98-91ac-dbe288022c67" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4e155fee-6f4f-4096-b4df-d1bc5d0b2381" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_f9197bcd-e6f2-4ea1-a553-005901c079d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4e155fee-6f4f-4096-b4df-d1bc5d0b2381" xlink:to="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_f9197bcd-e6f2-4ea1-a553-005901c079d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_1793976d-3168-4e2e-969a-139c3860534d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InformationByCategoryOfDebtSecurityAxis_f9197bcd-e6f2-4ea1-a553-005901c079d4" xlink:to="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_1793976d-3168-4e2e-969a-139c3860534d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldtomaturitySecuritiesMember_30181078-fabd-4a86-9703-ce468376604a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldtomaturitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_1793976d-3168-4e2e-969a-139c3860534d" xlink:to="loc_us-gaap_HeldtomaturitySecuritiesMember_30181078-fabd-4a86-9703-ce468376604a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableforsaleSecuritiesMember_9a74f441-faf2-4526-978d-0cf89bdd0a52" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableforsaleSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_1793976d-3168-4e2e-969a-139c3860534d" xlink:to="loc_us-gaap_AvailableforsaleSecuritiesMember_9a74f441-faf2-4526-978d-0cf89bdd0a52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_7dcfb641-2605-4540-b5ee-b423b2484b01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4e155fee-6f4f-4096-b4df-d1bc5d0b2381" xlink:to="loc_us-gaap_FinancialInstrumentAxis_7dcfb641-2605-4540-b5ee-b423b2484b01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_7dcfb641-2605-4540-b5ee-b423b2484b01" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_2fb54bfc-6399-4bd4-8a71-a4155917cf3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:to="loc_us-gaap_CashMember_2fb54bfc-6399-4bd4-8a71-a4155917cf3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SovereignDebtSecuritiesMember_54ef8211-69f5-438b-9ad5-c174937d2856" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SovereignDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:to="loc_us-gaap_SovereignDebtSecuritiesMember_54ef8211-69f5-438b-9ad5-c174937d2856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepurchaseAgreementsMember_244dde98-b425-4863-b8c7-e1d8c49833d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepurchaseAgreementsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:to="loc_us-gaap_RepurchaseAgreementsMember_244dde98-b425-4863-b8c7-e1d8c49833d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8d832643-2535-4454-a1d9-d6b93b00d8e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8d832643-2535-4454-a1d9-d6b93b00d8e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_de1da924-705f-4b3c-93e2-770edfdb3365" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:to="loc_us-gaap_MoneyMarketFundsMember_de1da924-705f-4b3c-93e2-770edfdb3365" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BankTimeDepositsMember_ceb3164d-ffe7-4003-a3c7-b3dfbe898168" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BankTimeDepositsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:to="loc_us-gaap_BankTimeDepositsMember_ceb3164d-ffe7-4003-a3c7-b3dfbe898168" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_89922868-7520-48cf-b5fd-d4e32e8e614f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_89922868-7520-48cf-b5fd-d4e32e8e614f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0cfe74b9-6991-4d49-a4a9-34c31366388f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ebf1f09c-dcce-49fc-ae4e-39fcad7c7e54" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_0cfe74b9-6991-4d49-a4a9-34c31366388f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsLineItems_993791f0-0c62-44bf-85c7-5b8625414928" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTable_4e155fee-6f4f-4096-b4df-d1bc5d0b2381" xlink:to="loc_us-gaap_CashAndCashEquivalentsLineItems_993791f0-0c62-44bf-85c7-5b8625414928" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsLineItems_993791f0-0c62-44bf-85c7-5b8625414928" xlink:to="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecurities_196b7e64-d4ad-420f-8553-49011cae5d1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:to="loc_us-gaap_HeldToMaturitySecurities_196b7e64-d4ad-420f-8553-49011cae5d1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_59abe047-ef0b-44a1-9dae-5db70c2f1799" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_59abe047-ef0b-44a1-9dae-5db70c2f1799" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_a24d37a8-ff7a-43be-9216-ef2bdd68a69f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_a24d37a8-ff7a-43be-9216-ef2bdd68a69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b9cf88b-4004-470d-89b7-413d39eacfd7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1b9cf88b-4004-470d-89b7-413d39eacfd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e1f78f02-71e3-4db2-956e-a7190ec4640a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e1f78f02-71e3-4db2-956e-a7190ec4640a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_2fbfceb6-3979-4693-bd03-74b4f0105529" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_2fbfceb6-3979-4693-bd03-74b4f0105529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_f50beb50-362d-4dae-bf56-37e74056a793" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_f50beb50-362d-4dae-bf56-37e74056a793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3cf0e53c-4991-45ce-811f-f0a956e4cc30" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract_1c8dd498-ea51-4475-b899-eac942ac6dbd" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3cf0e53c-4991-45ce-811f-f0a956e4cc30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_d341cdb3-c0a4-4d73-8e5a-e59e37ab1e04" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_15191385-7bd1-4544-a22c-bcd41825082c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_d341cdb3-c0a4-4d73-8e5a-e59e37ab1e04" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_15191385-7bd1-4544-a22c-bcd41825082c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_e4a9fbdb-b5a5-4cf4-83a3-bad757e1cb75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_15191385-7bd1-4544-a22c-bcd41825082c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_e4a9fbdb-b5a5-4cf4-83a3-bad757e1cb75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_eb727d33-b3a7-4a09-8511-c0ffa3ad3444" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_15191385-7bd1-4544-a22c-bcd41825082c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost_eb727d33-b3a7-4a09-8511-c0ffa3ad3444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_27d45303-366b-4460-aed6-c94fe4b2c966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_15191385-7bd1-4544-a22c-bcd41825082c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost_27d45303-366b-4460-aed6-c94fe4b2c966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_634d2438-8bf5-4a69-8861-09b3f92241d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract_15191385-7bd1-4544-a22c-bcd41825082c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_634d2438-8bf5-4a69-8861-09b3f92241d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8dfa0eca-e8c2-4ea2-a377-9bb6cae1df5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_d341cdb3-c0a4-4d73-8e5a-e59e37ab1e04" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8dfa0eca-e8c2-4ea2-a377-9bb6cae1df5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ae3ed675-d885-4386-bfbc-6c2b49c049e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8dfa0eca-e8c2-4ea2-a377-9bb6cae1df5b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ae3ed675-d885-4386-bfbc-6c2b49c049e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_815f3718-0710-4e74-b901-e9a912d393de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8dfa0eca-e8c2-4ea2-a377-9bb6cae1df5b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_815f3718-0710-4e74-b901-e9a912d393de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_02d4af08-4137-4815-abc0-412655057eac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8dfa0eca-e8c2-4ea2-a377-9bb6cae1df5b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_02d4af08-4137-4815-abc0-412655057eac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_7081f9da-d8a9-4fda-9b69-1243d6c6f5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract_8dfa0eca-e8c2-4ea2-a377-9bb6cae1df5b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_7081f9da-d8a9-4fda-9b69-1243d6c6f5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InventoriesDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_bac1f048-9935-484a-9bae-fd3eabb92358" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNetAbstract_866a337f-99ae-4e1b-8489-1905d4064ac4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_bac1f048-9935-484a-9bae-fd3eabb92358" xlink:to="loc_us-gaap_InventoryNetAbstract_866a337f-99ae-4e1b-8489-1905d4064ac4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_917326af-d26c-46c0-826a-55509245c879" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_866a337f-99ae-4e1b-8489-1905d4064ac4" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_917326af-d26c-46c0-826a-55509245c879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_e88216f1-e0fa-4996-9f4e-f8920527c6b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_866a337f-99ae-4e1b-8489-1905d4064ac4" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_e88216f1-e0fa-4996-9f4e-f8920527c6b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_220a6e97-d72e-4244-80ee-829043ec3408" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_866a337f-99ae-4e1b-8489-1905d4064ac4" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_220a6e97-d72e-4244-80ee-829043ec3408" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_7b98f18d-c53e-4791-bef5-7d1bdad75687" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryNetAbstract_866a337f-99ae-4e1b-8489-1905d4064ac4" xlink:to="loc_us-gaap_InventoryNet_7b98f18d-c53e-4791-bef5-7d1bdad75687" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2589aa46-8594-4605-bad0-f852bf66b55e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_67df00d5-50a7-415c-8abb-41715f99ec03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_2589aa46-8594-4605-bad0-f852bf66b55e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_67df00d5-50a7-415c-8abb-41715f99ec03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b56fb25e-6585-459e-88b3-f5d76b340f63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_67df00d5-50a7-415c-8abb-41715f99ec03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b56fb25e-6585-459e-88b3-f5d76b340f63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d38bfc60-d02b-4ada-8a5f-acf9d1941bee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b56fb25e-6585-459e-88b3-f5d76b340f63" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d38bfc60-d02b-4ada-8a5f-acf9d1941bee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LandAndLeaseholdImprovementsMember_e34b0cd3-ae9e-43f8-a513-c02e57874c1d" xlink:href="jnj-20230101.xsd#jnj_LandAndLeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d38bfc60-d02b-4ada-8a5f-acf9d1941bee" xlink:to="loc_jnj_LandAndLeaseholdImprovementsMember_e34b0cd3-ae9e-43f8-a513-c02e57874c1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BuildingAndBuildingImprovementsMember_f47a2a7a-4802-4fdb-b4f8-f18739f42c5e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BuildingAndBuildingImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d38bfc60-d02b-4ada-8a5f-acf9d1941bee" xlink:to="loc_us-gaap_BuildingAndBuildingImprovementsMember_f47a2a7a-4802-4fdb-b4f8-f18739f42c5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_53b720b3-97a2-45ad-a006-9bdfbd91ea4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MachineryAndEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d38bfc60-d02b-4ada-8a5f-acf9d1941bee" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_53b720b3-97a2-45ad-a006-9bdfbd91ea4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConstructionInProgressMember_6d63eb65-ee51-490f-946c-e3322784f581" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d38bfc60-d02b-4ada-8a5f-acf9d1941bee" xlink:to="loc_us-gaap_ConstructionInProgressMember_6d63eb65-ee51-490f-946c-e3322784f581" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b16b79-fa16-445d-91a6-aedb51df4c29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_67df00d5-50a7-415c-8abb-41715f99ec03" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b16b79-fa16-445d-91a6-aedb51df4c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_93df4320-89b5-4dc4-80d3-a69f39aeeaeb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b16b79-fa16-445d-91a6-aedb51df4c29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_93df4320-89b5-4dc4-80d3-a69f39aeeaeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4cba74d7-abc5-455d-b04e-0d96c72aa786" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b16b79-fa16-445d-91a6-aedb51df4c29" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_4cba74d7-abc5-455d-b04e-0d96c72aa786" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4f8f6446-9568-4005-aa2c-4fa7c69088c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_67b16b79-fa16-445d-91a6-aedb51df4c29" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4f8f6446-9568-4005-aa2c-4fa7c69088c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PropertyPlantandEquipmentNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a9b3d7cf-e6a9-4e80-9159-3fbdadb11503" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestCostsCapitalized_4ce99033-ba0b-47a8-802b-439911f25f2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestCostsCapitalized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a9b3d7cf-e6a9-4e80-9159-3fbdadb11503" xlink:to="loc_us-gaap_InterestCostsCapitalized_4ce99033-ba0b-47a8-802b-439911f25f2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_3b38dc35-98b9-4de8-beb9-7e428a4eca17" xlink:href="jnj-20230101.xsd#jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_a9b3d7cf-e6a9-4e80-9159-3fbdadb11503" xlink:to="loc_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest_3b38dc35-98b9-4de8-beb9-7e428a4eca17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bb2d62ef-aaeb-46c1-b72d-aecd0c0f8bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_92e5048f-7145-4a67-bb76-27cfe10182ca" xlink:href="jnj-20230101.xsd#jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_bb2d62ef-aaeb-46c1-b72d-aecd0c0f8bbb" xlink:to="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_92e5048f-7145-4a67-bb76-27cfe10182ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2f54ef7c-8735-4225-8f65-0628fcead7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_92e5048f-7145-4a67-bb76-27cfe10182ca" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2f54ef7c-8735-4225-8f65-0628fcead7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2da97125-0c9b-4753-9379-d5b4ca1724cc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2f54ef7c-8735-4225-8f65-0628fcead7f3" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2da97125-0c9b-4753-9379-d5b4ca1724cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember_d90048f8-b334-4b1e-a13f-07c42434ecba" xlink:href="jnj-20230101.xsd#jnj_AbiomedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2da97125-0c9b-4753-9379-d5b4ca1724cc" xlink:to="loc_jnj_AbiomedMember_d90048f8-b334-4b1e-a13f-07c42434ecba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_58b339c4-8bfd-42c6-9a76-ac4fabd43fd3" xlink:href="jnj-20230101.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2da97125-0c9b-4753-9379-d5b4ca1724cc" xlink:to="loc_jnj_BermekimabMember_58b339c4-8bfd-42c6-9a76-ac4fabd43fd3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bfeff74b-de72-4554-8f99-c31fba3b4502" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_92e5048f-7145-4a67-bb76-27cfe10182ca" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bfeff74b-de72-4554-8f99-c31fba3b4502" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e163f01-1bc3-48e2-ac76-b9e28ee48e6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_bfeff74b-de72-4554-8f99-c31fba3b4502" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e163f01-1bc3-48e2-ac76-b9e28ee48e6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_0701570e-e045-4662-b66c-e4fc50d75647" xlink:href="jnj-20230101.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e163f01-1bc3-48e2-ac76-b9e28ee48e6a" xlink:to="loc_jnj_PatentsAndTrademarksMember_0701570e-e045-4662-b66c-e4fc50d75647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_9b73bdc2-981e-49ef-b9dd-1f34b7f97dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e163f01-1bc3-48e2-ac76-b9e28ee48e6a" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_9b73bdc2-981e-49ef-b9dd-1f34b7f97dbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_29b3cf78-f036-4234-8a1d-b9e12f7b48c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2e163f01-1bc3-48e2-ac76-b9e28ee48e6a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_29b3cf78-f036-4234-8a1d-b9e12f7b48c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_18c7258f-680d-467a-938d-03ea39607e64" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_92e5048f-7145-4a67-bb76-27cfe10182ca" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_18c7258f-680d-467a-938d-03ea39607e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f309f60-f854-4b59-9ad4-c303e993c249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_18c7258f-680d-467a-938d-03ea39607e64" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f309f60-f854-4b59-9ad4-c303e993c249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TrademarksMember_3e52a8db-e5b2-49d8-9e4d-5ccf41545944" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f309f60-f854-4b59-9ad4-c303e993c249" xlink:to="loc_us-gaap_TrademarksMember_3e52a8db-e5b2-49d8-9e4d-5ccf41545944" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_25c3d735-d927-4126-a3df-0fc41a060d28" xlink:href="jnj-20230101.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f309f60-f854-4b59-9ad4-c303e993c249" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_25c3d735-d927-4126-a3df-0fc41a060d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_e93a0eba-af9f-4de3-b431-fcb61b84791e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0f309f60-f854-4b59-9ad4-c303e993c249" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_e93a0eba-af9f-4de3-b431-fcb61b84791e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_b8f23a29-f426-4e5e-aa80-3052f28391f2" xlink:href="jnj-20230101.xsd#jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable_92e5048f-7145-4a67-bb76-27cfe10182ca" xlink:to="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_b8f23a29-f426-4e5e-aa80-3052f28391f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cb26ad3d-baf7-4e54-bced-e4bb88378f31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_b8f23a29-f426-4e5e-aa80-3052f28391f2" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cb26ad3d-baf7-4e54-bced-e4bb88378f31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cf8ea545-52b9-4561-aea1-d539fb357ada" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cb26ad3d-baf7-4e54-bced-e4bb88378f31" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cf8ea545-52b9-4561-aea1-d539fb357ada" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5d28c50f-2b93-429f-ad9f-9ce59edd2700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cf8ea545-52b9-4561-aea1-d539fb357ada" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_5d28c50f-2b93-429f-ad9f-9ce59edd2700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2203ee26-6f2f-4fb5-91d9-350b15540bc8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cf8ea545-52b9-4561-aea1-d539fb357ada" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_2203ee26-6f2f-4fb5-91d9-350b15540bc8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_87f22fde-d525-4704-af01-18ddaff7ad3d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNetAbstract_cf8ea545-52b9-4561-aea1-d539fb357ada" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_87f22fde-d525-4704-af01-18ddaff7ad3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_51ae2426-42e3-4fda-b6f6-cc9b1885dc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract_cb26ad3d-baf7-4e54-bced-e4bb88378f31" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_51ae2426-42e3-4fda-b6f6-cc9b1885dc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2a332a20-baba-41b6-80d2-eb67d8aa0157" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_51ae2426-42e3-4fda-b6f6-cc9b1885dc8a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_2a332a20-baba-41b6-80d2-eb67d8aa0157" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b407a0fb-2b29-46d4-ae94-5714e2b9d255" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract_51ae2426-42e3-4fda-b6f6-cc9b1885dc8a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_b407a0fb-2b29-46d4-ae94-5714e2b9d255" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4a38f201-de61-4e90-a71f-ba7b76df40d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_b8f23a29-f426-4e5e-aa80-3052f28391f2" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_4a38f201-de61-4e90-a71f-ba7b76df40d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_4e924eb6-79f3-4392-9982-df41345062fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_b8f23a29-f426-4e5e-aa80-3052f28391f2" xlink:to="loc_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent_4e924eb6-79f3-4392-9982-df41345062fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_eabbb843-359d-4ba4-81ca-4c4ec31a9183" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems_b8f23a29-f426-4e5e-aa80-3052f28391f2" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_eabbb843-359d-4ba4-81ca-4c4ec31a9183" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IntangibleAssetsandGoodwillGoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ebca7512-5ce8-4ccb-8949-03ebc505bbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_22a73c53-af1c-4540-ae05-4a99324e95be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfGoodwillTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_ebca7512-5ce8-4ccb-8949-03ebc505bbc6" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_22a73c53-af1c-4540-ae05-4a99324e95be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_f37c9b48-7dae-4ab6-9b75-0aef263323bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_22a73c53-af1c-4540-ae05-4a99324e95be" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_f37c9b48-7dae-4ab6-9b75-0aef263323bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_185bd64c-9770-4ae2-885b-3587db88975f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_f37c9b48-7dae-4ab6-9b75-0aef263323bd" xlink:to="loc_us-gaap_SegmentDomain_185bd64c-9770-4ae2-885b-3587db88975f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_75a1543e-8ea4-4126-bdb7-e0a30330dbcc" xlink:href="jnj-20230101.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_185bd64c-9770-4ae2-885b-3587db88975f" xlink:to="loc_jnj_ConsumerMember_75a1543e-8ea4-4126-bdb7-e0a30330dbcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_1406eee3-8fc7-4a18-a9b0-dd5831568112" xlink:href="jnj-20230101.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_185bd64c-9770-4ae2-885b-3587db88975f" xlink:to="loc_jnj_PharmaceuticalMember_1406eee3-8fc7-4a18-a9b0-dd5831568112" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_ae8c3901-38c8-43ee-87ec-d6723ae3f3d7" xlink:href="jnj-20230101.xsd#jnj_MedTechMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_185bd64c-9770-4ae2-885b-3587db88975f" xlink:to="loc_jnj_MedTechMember_ae8c3901-38c8-43ee-87ec-d6723ae3f3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillLineItems_9e85730b-3172-4964-9090-f0c8633a05d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_22a73c53-af1c-4540-ae05-4a99324e95be" xlink:to="loc_us-gaap_GoodwillLineItems_9e85730b-3172-4964-9090-f0c8633a05d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillRollForward_ab1812c5-d835-4881-847e-befa67688091" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_9e85730b-3172-4964-9090-f0c8633a05d2" xlink:to="loc_us-gaap_GoodwillRollForward_ab1812c5-d835-4881-847e-befa67688091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_bfeffd3c-8963-4d84-836a-943a597b5212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ab1812c5-d835-4881-847e-befa67688091" xlink:to="loc_us-gaap_Goodwill_bfeffd3c-8963-4d84-836a-943a597b5212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_c40e02d9-6bfc-44b8-bff2-f5d4f0d469c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ab1812c5-d835-4881-847e-befa67688091" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_c40e02d9-6bfc-44b8-bff2-f5d4f0d469c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_aad307f2-64de-49db-8132-9f117428a7ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ab1812c5-d835-4881-847e-befa67688091" xlink:to="loc_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit_aad307f2-64de-49db-8132-9f117428a7ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_3b620cb1-98f1-4062-a81a-b1c26b17d7a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillOtherIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ab1812c5-d835-4881-847e-befa67688091" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_3b620cb1-98f1-4062-a81a-b1c26b17d7a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_445e5fe1-ec8e-4bfc-a833-5db9db4bea97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_ab1812c5-d835-4881-847e-befa67688091" xlink:to="loc_us-gaap_Goodwill_445e5fe1-ec8e-4bfc-a833-5db9db4bea97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IntangibleAssetsandGoodwillNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d33ab6d5-eb8a-4f2a-973e-1b542f4ef807" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ee0c61ae-4751-4bd1-9f0b-422e26a9955f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_d33ab6d5-eb8a-4f2a-973e-1b542f4ef807" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ee0c61ae-4751-4bd1-9f0b-422e26a9955f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9d0097c9-c104-4f4d-8595-916c70dea8c2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ee0c61ae-4751-4bd1-9f0b-422e26a9955f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9d0097c9-c104-4f4d-8595-916c70dea8c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1ffd8af4-9c42-46c1-92cf-e8585c26bcbc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_9d0097c9-c104-4f4d-8595-916c70dea8c2" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1ffd8af4-9c42-46c1-92cf-e8585c26bcbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PatentsAndTrademarksMember_0daf7cbb-d9be-4bb0-8ed6-349b298fe05b" xlink:href="jnj-20230101.xsd#jnj_PatentsAndTrademarksMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1ffd8af4-9c42-46c1-92cf-e8585c26bcbc" xlink:to="loc_jnj_PatentsAndTrademarksMember_0daf7cbb-d9be-4bb0-8ed6-349b298fe05b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_ce24ae55-35b6-4627-a24b-875a911fc9d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1ffd8af4-9c42-46c1-92cf-e8585c26bcbc" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_ce24ae55-35b6-4627-a24b-875a911fc9d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_26ffcac8-10d9-4b4a-b5bb-60dce7278f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_1ffd8af4-9c42-46c1-92cf-e8585c26bcbc" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_26ffcac8-10d9-4b4a-b5bb-60dce7278f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_76d14b55-5367-436f-9e46-16b2a27482e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ee0c61ae-4751-4bd1-9f0b-422e26a9955f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_76d14b55-5367-436f-9e46-16b2a27482e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bfad5321-47ed-44bd-bdec-e54393ff5404" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_76d14b55-5367-436f-9e46-16b2a27482e0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bfad5321-47ed-44bd-bdec-e54393ff5404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_a862d7e8-4731-4f32-ae9a-24e31e50d04e" xlink:href="jnj-20230101.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_bfad5321-47ed-44bd-bdec-e54393ff5404" xlink:to="loc_jnj_BermekimabMember_a862d7e8-4731-4f32-ae9a-24e31e50d04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aecc7d0e-393d-4ba7-9aad-6da250ecf425" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_ee0c61ae-4751-4bd1-9f0b-422e26a9955f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aecc7d0e-393d-4ba7-9aad-6da250ecf425" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f95a1070-1fbd-446e-941d-59e4ab93d9f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aecc7d0e-393d-4ba7-9aad-6da250ecf425" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_f95a1070-1fbd-446e-941d-59e4ab93d9f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_1edbbe0b-ea16-4a47-b207-06e5f81e7d5c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmortizationOfIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aecc7d0e-393d-4ba7-9aad-6da250ecf425" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_1edbbe0b-ea16-4a47-b207-06e5f81e7d5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9e705082-8c6f-4d3b-aa49-7121fb9de552" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_aecc7d0e-393d-4ba7-9aad-6da250ecf425" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_9e705082-8c6f-4d3b-aa49-7121fb9de552" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bb695c2-f4a3-43bb-882b-9b811125b8dd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_05ba594c-ba69-4437-b2f2-82c22412eb3e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bb695c2-f4a3-43bb-882b-9b811125b8dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_05ba594c-ba69-4437-b2f2-82c22412eb3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_080fe727-34f0-4011-9c2e-6a57a6de7853" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bb695c2-f4a3-43bb-882b-9b811125b8dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_080fe727-34f0-4011-9c2e-6a57a6de7853" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_54b28f4d-0397-43ca-bb1d-f8fb85257baa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bb695c2-f4a3-43bb-882b-9b811125b8dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_54b28f4d-0397-43ca-bb1d-f8fb85257baa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bb25ef95-0005-4c0b-97c5-f280df5f73be" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bb695c2-f4a3-43bb-882b-9b811125b8dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_bb25ef95-0005-4c0b-97c5-f280df5f73be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2179296d-90fb-4f1d-9778-3383d4b0e89c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_4bb695c2-f4a3-43bb-882b-9b811125b8dd" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_2179296d-90fb-4f1d-9778-3383d4b0e89c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_26f4fef1-b007-4e13-94a3-7268f3b3c916" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTable_374bb587-1cf7-444b-ad31-eddf3b57357a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_26f4fef1-b007-4e13-94a3-7268f3b3c916" xlink:to="loc_us-gaap_DerivativeTable_374bb587-1cf7-444b-ad31-eddf3b57357a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_e6c46cf6-b252-459a-a7e9-d40bed5e5732" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_374bb587-1cf7-444b-ad31-eddf3b57357a" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_e6c46cf6-b252-459a-a7e9-d40bed5e5732" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_701b19e5-15e1-4770-85e9-91ddfbb4d48f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_e6c46cf6-b252-459a-a7e9-d40bed5e5732" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_701b19e5-15e1-4770-85e9-91ddfbb4d48f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_7c923cab-582a-4274-bca4-430c6c115d92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_701b19e5-15e1-4770-85e9-91ddfbb4d48f" xlink:to="loc_us-gaap_EquitySecuritiesMember_7c923cab-582a-4274-bca4-430c6c115d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_3313af3e-c7a7-4c34-8122-43a00aed0adf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_374bb587-1cf7-444b-ad31-eddf3b57357a" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_3313af3e-c7a7-4c34-8122-43a00aed0adf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_1b22ec9b-65fc-4e54-8462-cd962b15dbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_3313af3e-c7a7-4c34-8122-43a00aed0adf" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_1b22ec9b-65fc-4e54-8462-cd962b15dbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_b3119ae7-0363-4608-92a0-b66e25ba93fc" xlink:href="jnj-20230101.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_1b22ec9b-65fc-4e54-8462-cd962b15dbbd" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_b3119ae7-0363-4608-92a0-b66e25ba93fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_3f7cde78-52c0-4d83-98d3-9fd3fc8c29c1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_374bb587-1cf7-444b-ad31-eddf3b57357a" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_3f7cde78-52c0-4d83-98d3-9fd3fc8c29c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_f0c1abc1-03cd-4eeb-a506-ce8ce41d077a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_3f7cde78-52c0-4d83-98d3-9fd3fc8c29c1" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_f0c1abc1-03cd-4eeb-a506-ce8ce41d077a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_d42e88d3-8255-40f4-9007-f6bf0bfe4e20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f0c1abc1-03cd-4eeb-a506-ce8ce41d077a" xlink:to="loc_us-gaap_ForeignExchangeContractMember_d42e88d3-8255-40f4-9007-f6bf0bfe4e20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_825a5bb4-7bf4-4065-9c18-9832585152b5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f0c1abc1-03cd-4eeb-a506-ce8ce41d077a" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_825a5bb4-7bf4-4065-9c18-9832585152b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_1661017a-808b-4bcd-a23c-5c7b1481b30a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_f0c1abc1-03cd-4eeb-a506-ce8ce41d077a" xlink:to="loc_us-gaap_InterestRateSwapMember_1661017a-808b-4bcd-a23c-5c7b1481b30a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_ac7cafe5-19f3-4bb8-8900-43a47886bc09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_374bb587-1cf7-444b-ad31-eddf3b57357a" xlink:to="loc_us-gaap_HedgingDesignationAxis_ac7cafe5-19f3-4bb8-8900-43a47886bc09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_bb670ec4-590e-4267-aed9-adb3f63728af" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_ac7cafe5-19f3-4bb8-8900-43a47886bc09" xlink:to="loc_us-gaap_HedgingDesignationDomain_bb670ec4-590e-4267-aed9-adb3f63728af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3312eebb-b5fa-4478-88c4-baf132863f8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_bb670ec4-590e-4267-aed9-adb3f63728af" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3312eebb-b5fa-4478-88c4-baf132863f8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_374bb587-1cf7-444b-ad31-eddf3b57357a" xlink:to="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_eb2e5618-ee76-4ef2-99c1-375d0faa73e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_eb2e5618-ee76-4ef2-99c1-375d0faa73e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_ce0139d2-864e-4ac3-a12c-856b055aee74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_us-gaap_DerivativeNotionalAmount_ce0139d2-864e-4ac3-a12c-856b055aee74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_78a29257-6414-47e2-aa48-892d6599b809" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax_78a29257-6414-47e2-aa48-892d6599b809" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_cd2e8530-09e1-425b-813d-296cf36e2283" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss_cd2e8530-09e1-425b-813d-296cf36e2283" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_919537f0-e106-4fb7-8a8d-8c069cf01e49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge_919537f0-e106-4fb7-8a8d-8c069cf01e49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_65da9c0a-762e-4899-aad4-728a08bc0082" xlink:href="jnj-20230101.xsd#jnj_EquityFairValueAdjustmentImpairmentLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_jnj_EquityFairValueAdjustmentImpairmentLoss_65da9c0a-762e-4899-aad4-728a08bc0082" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices_e41f6848-6dca-40a9-a15f-82442e1bc2dd" xlink:href="jnj-20230101.xsd#jnj_EquityFairValueAdjustmentChangeinObservablePrices"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_jnj_EquityFairValueAdjustmentChangeinObservablePrices_e41f6848-6dca-40a9-a15f-82442e1bc2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_74b0c844-32a7-49b9-a85e-8f798c6a8c57" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_74b0c844-32a7-49b9-a85e-8f798c6a8c57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_1914cd98-9125-44a8-a6f4-a4ef203b800b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetsCurrent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_1914cd98-9125-44a8-a6f4-a4ef203b800b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_48923a18-c9dc-48e2-abf6-bd882b4ee7ff" xlink:href="jnj-20230101.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_9d01fba7-a08f-4d6b-9f10-a6226e6a7562" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_48923a18-c9dc-48e2-abf6-bd882b4ee7ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurementsSummaryofDerivativeActivityDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_38aa8e91-1e05-48bc-a9d5-44aa74057d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fb11cee8-c82d-4197-bb8d-5403629121a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_38aa8e91-1e05-48bc-a9d5-44aa74057d4d" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fb11cee8-c82d-4197-bb8d-5403629121a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_cbf0e817-9778-4130-a6a8-870dbbe3e4d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fb11cee8-c82d-4197-bb8d-5403629121a6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_cbf0e817-9778-4130-a6a8-870dbbe3e4d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_9b9049b5-a184-4198-8e8c-021be6c2e66f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_cbf0e817-9778-4130-a6a8-870dbbe3e4d1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_9b9049b5-a184-4198-8e8c-021be6c2e66f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesMember_5e70453a-80a6-4272-b282-374e9025ff49" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b9049b5-a184-4198-8e8c-021be6c2e66f" xlink:to="loc_us-gaap_SalesMember_5e70453a-80a6-4272-b282-374e9025ff49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_b07c1134-011d-4209-9264-f74a5a93cf16" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b9049b5-a184-4198-8e8c-021be6c2e66f" xlink:to="loc_us-gaap_CostOfSalesMember_b07c1134-011d-4209-9264-f74a5a93cf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cb2bd923-6d11-4c30-ac69-70fea55b173e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b9049b5-a184-4198-8e8c-021be6c2e66f" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_cb2bd923-6d11-4c30-ac69-70fea55b173e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterestIncomeExpenseNetMember_45433e34-83ca-4a86-9ffa-b9dd49c21630" xlink:href="jnj-20230101.xsd#jnj_InterestIncomeExpenseNetMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b9049b5-a184-4198-8e8c-021be6c2e66f" xlink:to="loc_jnj_InterestIncomeExpenseNetMember_45433e34-83ca-4a86-9ffa-b9dd49c21630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_1605fe08-c76d-4f04-8622-1f48226000e2" xlink:href="jnj-20230101.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_9b9049b5-a184-4198-8e8c-021be6c2e66f" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_1605fe08-c76d-4f04-8622-1f48226000e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_381f783b-a5dd-42e5-9c9a-cb8e2cdbce74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fb11cee8-c82d-4197-bb8d-5403629121a6" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_381f783b-a5dd-42e5-9c9a-cb8e2cdbce74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_9bff47f9-1cdd-4bc9-a646-ece924396adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_381f783b-a5dd-42e5-9c9a-cb8e2cdbce74" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_9bff47f9-1cdd-4bc9-a646-ece924396adc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateSwapMember_44782bd1-adbb-4c01-8f90-8d986f25edb2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateSwapMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9bff47f9-1cdd-4bc9-a646-ece924396adc" xlink:to="loc_us-gaap_InterestRateSwapMember_44782bd1-adbb-4c01-8f90-8d986f25edb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_6732e39e-12bd-4325-b835-1a03f04d1fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9bff47f9-1cdd-4bc9-a646-ece924396adc" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_6732e39e-12bd-4325-b835-1a03f04d1fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_94b17330-1858-4283-9fd6-25d801903171" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_9bff47f9-1cdd-4bc9-a646-ece924396adc" xlink:to="loc_us-gaap_ForeignExchangeContractMember_94b17330-1858-4283-9fd6-25d801903171" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_97140366-19b3-4e6a-97a0-93c418ac58e8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fb11cee8-c82d-4197-bb8d-5403629121a6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_97140366-19b3-4e6a-97a0-93c418ac58e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingRelationshipDomain_d52b99d6-57c3-4e6e-b216-b70c555bd1c3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingRelationshipDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_97140366-19b3-4e6a-97a0-93c418ac58e8" xlink:to="loc_us-gaap_HedgingRelationshipDomain_d52b99d6-57c3-4e6e-b216-b70c555bd1c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueHedgingMember_22a69ecf-1b0b-4220-a7dd-bd278f438433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueHedgingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d52b99d6-57c3-4e6e-b216-b70c555bd1c3" xlink:to="loc_us-gaap_FairValueHedgingMember_22a69ecf-1b0b-4220-a7dd-bd278f438433" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashFlowHedgingMember_22c50a73-7e4b-4176-ba3a-83b311b8d48c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashFlowHedgingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_d52b99d6-57c3-4e6e-b216-b70c555bd1c3" xlink:to="loc_us-gaap_CashFlowHedgingMember_22c50a73-7e4b-4176-ba3a-83b311b8d48c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_63b4e30c-e34f-4d16-a1f5-9dfcad9dd29b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_fb11cee8-c82d-4197-bb8d-5403629121a6" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_63b4e30c-e34f-4d16-a1f5-9dfcad9dd29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_0f6d0db0-74d3-432e-8972-fe8803fc519e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_63b4e30c-e34f-4d16-a1f5-9dfcad9dd29b" xlink:to="loc_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings_0f6d0db0-74d3-432e-8972-fe8803fc519e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_e3c2ce3f-e24d-48e9-a6c3-1a2bae12e61a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_63b4e30c-e34f-4d16-a1f5-9dfcad9dd29b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax_e3c2ce3f-e24d-48e9-a6c3-1a2bae12e61a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_33b0096c-8496-4981-ab71-016508c893cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_63b4e30c-e34f-4d16-a1f5-9dfcad9dd29b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax_33b0096c-8496-4981-ab71-016508c893cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_6a3f55a0-c4f3-4a55-b174-df512d208242" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_63b4e30c-e34f-4d16-a1f5-9dfcad9dd29b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax_6a3f55a0-c4f3-4a55-b174-df512d208242" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_e15d6a7f-ab6c-419e-95d8-77b6089b836b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a22c8aa3-7aa5-435e-bad9-a49554c4416e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_e15d6a7f-ab6c-419e-95d8-77b6089b836b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a22c8aa3-7aa5-435e-bad9-a49554c4416e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_d06fafcc-5262-4f4b-b649-78554f44d6a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a22c8aa3-7aa5-435e-bad9-a49554c4416e" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_d06fafcc-5262-4f4b-b649-78554f44d6a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_f3415f7e-d453-49af-9f9e-7f4ee35e460f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_d06fafcc-5262-4f4b-b649-78554f44d6a1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_f3415f7e-d453-49af-9f9e-7f4ee35e460f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMember_0277632b-a020-4d01-94b1-a2c78c3e35a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_f3415f7e-d453-49af-9f9e-7f4ee35e460f" xlink:to="loc_us-gaap_LongTermDebtMember_0277632b-a020-4d01-94b1-a2c78c3e35a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_690dd601-138a-432f-97a2-6fa17afcfe7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a22c8aa3-7aa5-435e-bad9-a49554c4416e" xlink:to="loc_us-gaap_HedgingDesignationAxis_690dd601-138a-432f-97a2-6fa17afcfe7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_6cf747fc-d749-489d-a04f-6a16c46acf34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_690dd601-138a-432f-97a2-6fa17afcfe7b" xlink:to="loc_us-gaap_HedgingDesignationDomain_6cf747fc-d749-489d-a04f-6a16c46acf34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f1dc54c6-b5be-4e7c-96eb-e3fa5dfd6a88" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DesignatedAsHedgingInstrumentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_6cf747fc-d749-489d-a04f-6a16c46acf34" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_f1dc54c6-b5be-4e7c-96eb-e3fa5dfd6a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a8d68d26-1021-4326-8419-f8f36f8da1ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_a22c8aa3-7aa5-435e-bad9-a49554c4416e" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a8d68d26-1021-4326-8419-f8f36f8da1ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a011a2a5-d322-46b2-ae4c-5450621b8c02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a8d68d26-1021-4326-8419-f8f36f8da1ec" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_a011a2a5-d322-46b2-ae4c-5450621b8c02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_95db6146-3421-4e18-8b56-4515ce6cd6bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_a8d68d26-1021-4326-8419-f8f36f8da1ec" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_95db6146-3421-4e18-8b56-4515ce6cd6bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_031a2f88-4bcc-4c55-93e0-7a89bb61f3ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f9026de9-1e32-4534-9645-ec996600521b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_031a2f88-4bcc-4c55-93e0-7a89bb61f3ce" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f9026de9-1e32-4534-9645-ec996600521b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_73682a79-63ae-47af-a442-7597b9c47fd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f9026de9-1e32-4534-9645-ec996600521b" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_73682a79-63ae-47af-a442-7597b9c47fd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_14b5ed0b-6df5-4aa8-bc85-400a8baa49d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_73682a79-63ae-47af-a442-7597b9c47fd2" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_14b5ed0b-6df5-4aa8-bc85-400a8baa49d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_58c3f246-52cd-4c07-b37b-1c7304e86abd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_14b5ed0b-6df5-4aa8-bc85-400a8baa49d1" xlink:to="loc_us-gaap_ForeignExchangeContractMember_58c3f246-52cd-4c07-b37b-1c7304e86abd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_85cf6ef3-e6e8-4e4c-938a-0fe1529c2bba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f9026de9-1e32-4534-9645-ec996600521b" xlink:to="loc_us-gaap_HedgingDesignationAxis_85cf6ef3-e6e8-4e4c-938a-0fe1529c2bba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_193f8b46-2304-4e2b-8c2b-2211b17d4be8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_85cf6ef3-e6e8-4e4c-938a-0fe1529c2bba" xlink:to="loc_us-gaap_HedgingDesignationDomain_193f8b46-2304-4e2b-8c2b-2211b17d4be8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_bc4eb59e-c366-4e59-919f-8dbf37a8360c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_193f8b46-2304-4e2b-8c2b-2211b17d4be8" xlink:to="loc_us-gaap_NondesignatedMember_bc4eb59e-c366-4e59-919f-8dbf37a8360c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_da9dab34-2840-4e83-b544-de947e3b73d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f9026de9-1e32-4534-9645-ec996600521b" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_da9dab34-2840-4e83-b544-de947e3b73d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_eb7e69d1-6e4e-4840-888c-d4412a0b5838" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_da9dab34-2840-4e83-b544-de947e3b73d3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_eb7e69d1-6e4e-4840-888c-d4412a0b5838" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_4908befe-eb55-4cb8-9921-37634e73d711" xlink:href="jnj-20230101.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_eb7e69d1-6e4e-4840-888c-d4412a0b5838" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_4908befe-eb55-4cb8-9921-37634e73d711" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_40f93da8-a3de-4f8e-832a-c1bdff10e97e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_f9026de9-1e32-4534-9645-ec996600521b" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_40f93da8-a3de-4f8e-832a-c1bdff10e97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c95b0324-b37b-4832-834d-5814ce72ce93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_40f93da8-a3de-4f8e-832a-c1bdff10e97e" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_c95b0324-b37b-4832-834d-5814ce72ce93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_b791e512-7161-4a8b-ba30-409dc424c276" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_40f93da8-a3de-4f8e-832a-c1bdff10e97e" xlink:to="loc_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_b791e512-7161-4a8b-ba30-409dc424c276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_d377d5b1-e5df-47cf-8f4a-8d69c96e9a23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_65fe016f-a166-4ab3-ac4d-fa7257a66cf0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_d377d5b1-e5df-47cf-8f4a-8d69c96e9a23" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_65fe016f-a166-4ab3-ac4d-fa7257a66cf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_f5c6d026-eeb2-4a7e-b5a7-b6793b6b53d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_65fe016f-a166-4ab3-ac4d-fa7257a66cf0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_f5c6d026-eeb2-4a7e-b5a7-b6793b6b53d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_815141e2-178b-408e-aefb-571b58a5949c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_f5c6d026-eeb2-4a7e-b5a7-b6793b6b53d7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_815141e2-178b-408e-aefb-571b58a5949c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_8c0144fc-2ad6-43c8-9a76-bfc9285763fd" xlink:href="jnj-20230101.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_815141e2-178b-408e-aefb-571b58a5949c" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_8c0144fc-2ad6-43c8-9a76-bfc9285763fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_204846f8-395b-4d4a-873b-7220b86a1e84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_65fe016f-a166-4ab3-ac4d-fa7257a66cf0" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_204846f8-395b-4d4a-873b-7220b86a1e84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_39c568d7-51b2-4c42-aff5-3a66c2b66b53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_204846f8-395b-4d4a-873b-7220b86a1e84" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_39c568d7-51b2-4c42-aff5-3a66c2b66b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CrossCurrencyInterestRateContractMember_c397ab86-0ba5-40ab-9b5e-5b631a3e9b63" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CrossCurrencyInterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_39c568d7-51b2-4c42-aff5-3a66c2b66b53" xlink:to="loc_us-gaap_CrossCurrencyInterestRateContractMember_c397ab86-0ba5-40ab-9b5e-5b631a3e9b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0c422a98-5e75-4c68-bc30-4f9a06d15068" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_65fe016f-a166-4ab3-ac4d-fa7257a66cf0" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0c422a98-5e75-4c68-bc30-4f9a06d15068" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_ada891ac-b42c-4100-a496-859f21bf9212" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0c422a98-5e75-4c68-bc30-4f9a06d15068" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_ada891ac-b42c-4100-a496-859f21bf9212" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_9045706c-d91e-4ce9-a13b-dd8e1710c1aa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_0c422a98-5e75-4c68-bc30-4f9a06d15068" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred_9045706c-d91e-4ce9-a13b-dd8e1710c1aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_34e3e296-638c-472c-b828-5f34e1bd4ce3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_c9053dfe-520f-420d-be58-cfca24051ec8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_34e3e296-638c-472c-b828-5f34e1bd4ce3" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_c9053dfe-520f-420d-be58-cfca24051ec8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByAssetClassAxis_ffb1681a-f9de-48ec-95f2-6aa7847a6f84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByAssetClassAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_c9053dfe-520f-420d-be58-cfca24051ec8" xlink:to="loc_us-gaap_FairValueByAssetClassAxis_ffb1681a-f9de-48ec-95f2-6aa7847a6f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8130aac5-d60e-4305-af12-dbc380064ae1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByAssetClassAxis_ffb1681a-f9de-48ec-95f2-6aa7847a6f84" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8130aac5-d60e-4305-af12-dbc380064ae1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_3be3485a-a694-4c7c-8a40-3d49a063e254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_8130aac5-d60e-4305-af12-dbc380064ae1" xlink:to="loc_us-gaap_EquitySecuritiesMember_3be3485a-a694-4c7c-8a40-3d49a063e254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_265f05b1-9855-4d92-9d8c-bbefa351a454" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_c9053dfe-520f-420d-be58-cfca24051ec8" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_265f05b1-9855-4d92-9d8c-bbefa351a454" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9ab5a8d7-7052-443a-bb4c-52e5ae718bd4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableAxis_265f05b1-9855-4d92-9d8c-bbefa351a454" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9ab5a8d7-7052-443a-bb4c-52e5ae718bd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_49599187-1587-4618-8bb2-a9dc605c0d5d" xlink:href="jnj-20230101.xsd#jnj_EquityInvestmentswithReadilyDeterminableValueMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9ab5a8d7-7052-443a-bb4c-52e5ae718bd4" xlink:to="loc_jnj_EquityInvestmentswithReadilyDeterminableValueMember_49599187-1587-4618-8bb2-a9dc605c0d5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_dbc5719b-fea0-4339-b50a-95ef188b51a1" xlink:href="jnj-20230101.xsd#jnj_EquityInvestmentswithoutReadilyDeterminableValueMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableNameDomain_9ab5a8d7-7052-443a-bb4c-52e5ae718bd4" xlink:to="loc_jnj_EquityInvestmentswithoutReadilyDeterminableValueMember_dbc5719b-fea0-4339-b50a-95ef188b51a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_00f6aa1c-423c-4b2e-9232-3053924d49e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherInvestmentNotReadilyMarketableLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableTable_c9053dfe-520f-420d-be58-cfca24051ec8" xlink:to="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_00f6aa1c-423c-4b2e-9232-3053924d49e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentRollForward_00effc79-05fa-439d-9be8-6ba50f89bfff" xlink:href="jnj-20230101.xsd#jnj_EquityInvestmentRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherInvestmentNotReadilyMarketableLineItems_00f6aa1c-423c-4b2e-9232-3053924d49e1" xlink:to="loc_jnj_EquityInvestmentRollForward_00effc79-05fa-439d-9be8-6ba50f89bfff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesNoncurrent_5d5dd93f-de42-4e0d-987d-5a7d3bc182ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_00effc79-05fa-439d-9be8-6ba50f89bfff" xlink:to="loc_us-gaap_MarketableSecuritiesNoncurrent_5d5dd93f-de42-4e0d-987d-5a7d3bc182ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityFairValueAdjustment_311d3dca-6ba7-49ee-aed9-a09f07a0641c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityFairValueAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_00effc79-05fa-439d-9be8-6ba50f89bfff" xlink:to="loc_us-gaap_EquityFairValueAdjustment_311d3dca-6ba7-49ee-aed9-a09f07a0641c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_bce1eb4e-2e3f-4ccb-8665-80addd79c1e3" xlink:href="jnj-20230101.xsd#jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_00effc79-05fa-439d-9be8-6ba50f89bfff" xlink:to="loc_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod_bce1eb4e-2e3f-4ccb-8665-80addd79c1e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_33fa821d-5478-473f-9c31-0392658a6e18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_00effc79-05fa-439d-9be8-6ba50f89bfff" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_33fa821d-5478-473f-9c31-0392658a6e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b44d27dd-e2ea-4496-89ff-e1c771617887" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_EquityInvestmentRollForward_00effc79-05fa-439d-9be8-6ba50f89bfff" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount_b44d27dd-e2ea-4496-89ff-e1c771617887" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3c2e1e85-00a7-46a0-9f65-f095f915d3a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3c2e1e85-00a7-46a0-9f65-f095f915d3a4" xlink:to="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationAxis_c3816fe7-a434-4c1f-b4d1-b7ad494ddbc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:to="loc_us-gaap_HedgingDesignationAxis_c3816fe7-a434-4c1f-b4d1-b7ad494ddbc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_HedgingDesignationDomain_7ad9509f-3388-4783-b2c0-8ff6c925e313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_HedgingDesignationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_c3816fe7-a434-4c1f-b4d1-b7ad494ddbc6" xlink:to="loc_us-gaap_HedgingDesignationDomain_7ad9509f-3388-4783-b2c0-8ff6c925e313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NondesignatedMember_178af82c-809d-417f-ae26-175f26c95427" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NondesignatedMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_7ad9509f-3388-4783-b2c0-8ff6c925e313" xlink:to="loc_us-gaap_NondesignatedMember_178af82c-809d-417f-ae26-175f26c95427" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_c5f4c1da-5851-4d01-8701-8fa2449db5cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_c5f4c1da-5851-4d01-8701-8fa2449db5cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7b488b8a-c258-4e8e-a861-a036e5953fbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_c5f4c1da-5851-4d01-8701-8fa2449db5cb" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7b488b8a-c258-4e8e-a861-a036e5953fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestRateContractMember_9e8ce47f-4429-44db-8a23-1737847c21f7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestRateContractMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7b488b8a-c258-4e8e-a861-a036e5953fbf" xlink:to="loc_us-gaap_InterestRateContractMember_9e8ce47f-4429-44db-8a23-1737847c21f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeContractMember_ae4f3eef-8055-4fe6-bcef-24b9223cd7fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignExchangeContractMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7b488b8a-c258-4e8e-a861-a036e5953fbf" xlink:to="loc_us-gaap_ForeignExchangeContractMember_ae4f3eef-8055-4fe6-bcef-24b9223cd7fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b68ccf99-ecef-432b-b3f7-816378ab0c87" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b68ccf99-ecef-432b-b3f7-816378ab0c87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc176a0b-8d97-4087-9963-415e4aa15f9f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_b68ccf99-ecef-432b-b3f7-816378ab0c87" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc176a0b-8d97-4087-9963-415e4aa15f9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5ddb59cb-1d1e-4ec0-9096-42138f95ee92" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc176a0b-8d97-4087-9963-415e4aa15f9f" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5ddb59cb-1d1e-4ec0-9096-42138f95ee92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_fa8bfe10-0212-49ff-8f62-92443c74f8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc176a0b-8d97-4087-9963-415e4aa15f9f" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_fa8bfe10-0212-49ff-8f62-92443c74f8b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_ad4079df-a55d-4714-bd73-932015c584ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_fc176a0b-8d97-4087-9963-415e4aa15f9f" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_ad4079df-a55d-4714-bd73-932015c584ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeAxis_9d086630-32cd-4695-a9ef-11252526c8b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:to="loc_us-gaap_InvestmentTypeAxis_9d086630-32cd-4695-a9ef-11252526c8b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_639f9eea-e7aa-4a7a-9b8f-38999d0a651f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentTypeCategorizationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_9d086630-32cd-4695-a9ef-11252526c8b1" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_639f9eea-e7aa-4a7a-9b8f-38999d0a651f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_c85165fb-36a8-4f06-9a26-430f7aa8434b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_639f9eea-e7aa-4a7a-9b8f-38999d0a651f" xlink:to="loc_us-gaap_EquitySecuritiesMember_c85165fb-36a8-4f06-9a26-430f7aa8434b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_e950cac3-f87b-4986-b15a-37d980b05ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_e950cac3-f87b-4986-b15a-37d980b05ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65e57abb-6478-48fb-bb07-9d4846373f9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_e950cac3-f87b-4986-b15a-37d980b05ad9" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65e57abb-6478-48fb-bb07-9d4846373f9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_f705fe2c-182a-47df-82fd-9b6ad4e70384" xlink:href="jnj-20230101.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65e57abb-6478-48fb-bb07-9d4846373f9c" xlink:to="loc_jnj_AurisHealthMember_f705fe2c-182a-47df-82fd-9b6ad4e70384" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember_f6628e36-9564-4f1c-a700-3a85a9438531" xlink:href="jnj-20230101.xsd#jnj_AbiomedMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_65e57abb-6478-48fb-bb07-9d4846373f9c" xlink:to="loc_jnj_AbiomedMember_f6628e36-9564-4f1c-a700-3a85a9438531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_fb86a40a-cee0-4611-a7a0-dd14b75e6e75" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_fb86a40a-cee0-4611-a7a0-dd14b75e6e75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_b218d6e4-9c8b-4058-ac33-881be0e34f35" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_fb86a40a-cee0-4611-a7a0-dd14b75e6e75" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_b218d6e4-9c8b-4058-ac33-881be0e34f35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_14984517-f67a-4bf9-922f-24190fc08d28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNoncurrentLiabilitiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b218d6e4-9c8b-4058-ac33-881be0e34f35" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_14984517-f67a-4bf9-922f-24190fc08d28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_9c6e972e-b361-4f5a-8908-ef3f2a33a655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherCurrentLiabilitiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_b218d6e4-9c8b-4058-ac33-881be0e34f35" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_9c6e972e-b361-4f5a-8908-ef3f2a33a655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativesFairValueLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable_8f026090-482e-4b22-b048-8d1e6ac79f36" xlink:to="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentDetailAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_931f837c-7b3d-45e1-9ef7-c163d187e802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue_931f837c-7b3d-45e1-9ef7-c163d187e802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_acae41c2-7ee8-4849-901f-fce0e177c825" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:to="loc_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue_acae41c2-7ee8-4849-901f-fce0e177c825" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_556b6676-0d67-4fef-bec5-5bc6d05e4162" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue_556b6676-0d67-4fef-bec5-5bc6d05e4162" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_185128a6-83e9-42aa-aea3-cbe9cfee2f9e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:to="loc_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue_185128a6-83e9-42aa-aea3-cbe9cfee2f9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_81d72d47-dc8b-4c57-a5d9-413297804f6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesFvNi"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_81d72d47-dc8b-4c57-a5d9-413297804f6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_39f1fc69-7cea-4c36-9991-aacbc446f43d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_39f1fc69-7cea-4c36-9991-aacbc446f43d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_80ad288b-6e5b-4b56-b5cd-1a94f81725b7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentDetailAbstract_39ace056-febd-4779-b442-e41c58364d09" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_80ad288b-6e5b-4b56-b5cd-1a94f81725b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c31b72b3-0fb5-453a-ad5c-ecfa3eeffc54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeAsset"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeAsset_c31b72b3-0fb5-453a-ad5c-ecfa3eeffc54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssetFairValueGrossLiability_bbf01e3c-b126-4d61-a23a-bb490b9fc770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssetFairValueGrossLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_DerivativeAssetFairValueGrossLiability_bbf01e3c-b126-4d61-a23a-bb490b9fc770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_32a59a92-1556-4d9e-ae55-fe1084fa6739" xlink:href="jnj-20230101.xsd#jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_32a59a92-1556-4d9e-ae55-fe1084fa6739" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeAssets_9a54a764-34fd-4017-bb02-c75482b45abf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_DerivativeAssets_9a54a764-34fd-4017-bb02-c75482b45abf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_5b0a2a29-4f47-48b9-ae6a-848fbbd6befe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_DerivativeFairValueOfDerivativeLiability_5b0a2a29-4f47-48b9-ae6a-848fbbd6befe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_740b3331-7a27-46c8-b99c-48855ce0c627" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilityFairValueGrossAsset"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_DerivativeLiabilityFairValueGrossAsset_740b3331-7a27-46c8-b99c-48855ce0c627" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_bfdc534b-acf4-4007-90f6-d0a6385feb32" xlink:href="jnj-20230101.xsd#jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag_bfdc534b-acf4-4007-90f6-d0a6385feb32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeLiabilities_8bfeb71b-a26e-45b0-bbea-7dc2a603ac0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DerivativeLiabilities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_DerivativeLiabilities_8bfeb71b-a26e-45b0-bbea-7dc2a603ac0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eea3a443-f555-4dad-9161-92bf42b0ff4a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_eea3a443-f555-4dad-9161-92bf42b0ff4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_46cecd93-6782-4079-b34e-77b4734b524a" xlink:href="jnj-20230101.xsd#jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue_46cecd93-6782-4079-b34e-77b4734b524a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_e37ff994-f8fa-4df0-9ab9-24c31a7a8492" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred_e37ff994-f8fa-4df0-9ab9-24c31a7a8492" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_5fced0ab-6678-477c-b3e1-5408cf662b59" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements_5fced0ab-6678-477c-b3e1-5408cf662b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_30abd258-108d-45bf-9d48-8f6320e85d55" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_30abd258-108d-45bf-9d48-8f6320e85d55" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_092ce934-1b31-4cdb-abb0-580da17269a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativesFairValueLineItems_09aecbbe-a5b4-448e-b4c2-bc9ffe2e1867" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_092ce934-1b31-4cdb-abb0-580da17269a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#BorrowingsScheduleofLongtermDebtInstrumentsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_1c13cca2-b777-4748-9457-0574c7c99653" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b679b360-ca73-44f0-b07a-292c715698a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_1c13cca2-b777-4748-9457-0574c7c99653" xlink:to="loc_us-gaap_DebtInstrumentTable_b679b360-ca73-44f0-b07a-292c715698a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_af1a7cfd-bcf7-4215-9f17-fc21fd7c72a4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b679b360-ca73-44f0-b07a-292c715698a6" xlink:to="loc_us-gaap_DebtInstrumentAxis_af1a7cfd-bcf7-4215-9f17-fc21fd7c72a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_af1a7cfd-bcf7-4215-9f17-fc21fd7c72a4" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.250NotesDue2022Member_737f17cf-4a91-4dc0-be3e-08ad5611370a" xlink:href="jnj-20230101.xsd#jnj_A0.250NotesDue2022Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A0.250NotesDue2022Member_737f17cf-4a91-4dc0-be3e-08ad5611370a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.25Notesdue2022Member_c2177346-3ec1-4906-98dd-426460955348" xlink:href="jnj-20230101.xsd#jnj_A2.25Notesdue2022Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A2.25Notesdue2022Member_c2177346-3ec1-4906-98dd-426460955348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.73Debenturesdue2023Member_f9bdcca4-823f-42df-baad-868f50709c8e" xlink:href="jnj-20230101.xsd#jnj_A6.73Debenturesdue2023Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A6.73Debenturesdue2023Member_f9bdcca4-823f-42df-baad-868f50709c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.375Notesdue2023Member_c674763a-6f1f-40ac-91a1-64662625cadd" xlink:href="jnj-20230101.xsd#jnj_A3.375Notesdue2023Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A3.375Notesdue2023Member_c674763a-6f1f-40ac-91a1-64662625cadd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.05Notesdue2023Member_5737bab4-6607-4e74-a001-6031f80a5d9b" xlink:href="jnj-20230101.xsd#jnj_A2.05Notesdue2023Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A2.05Notesdue2023Member_5737bab4-6607-4e74-a001-6031f80a5d9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A0.650NotesDue2024Member_d7c6dfed-5ffa-4075-aef1-1bee8aa0c374" xlink:href="jnj-20230101.xsd#jnj_A0.650NotesDue2024Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A0.650NotesDue2024Member_d7c6dfed-5ffa-4075-aef1-1bee8aa0c374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.50NotesDue2024Member_077f1244-cc83-4e1e-b848-307c285bdf8e" xlink:href="jnj-20230101.xsd#jnj_A5.50NotesDue2024Member"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A5.50NotesDue2024Member_077f1244-cc83-4e1e-b848-307c285bdf8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.625Notesdue2025Member_a64f26c1-d470-4fbe-bc1d-75380eb59d7a" xlink:href="jnj-20230101.xsd#jnj_A2.625Notesdue2025Member"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A2.625Notesdue2025Member_a64f26c1-d470-4fbe-bc1d-75380eb59d7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A055NotesDue2025Member_9ed8d169-2ade-4f22-8010-417bc77f094e" xlink:href="jnj-20230101.xsd#jnj_A055NotesDue2025Member"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A055NotesDue2025Member_9ed8d169-2ade-4f22-8010-417bc77f094e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.45Notesdue2026Member_e3988c1d-233c-4c8f-96f1-aa246c311480" xlink:href="jnj-20230101.xsd#jnj_A2.45Notesdue2026Member"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A2.45Notesdue2026Member_e3988c1d-233c-4c8f-96f1-aa246c311480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.95Notesdue2027Member_84f917fa-12eb-45cf-998f-518130444c9e" xlink:href="jnj-20230101.xsd#jnj_A2.95Notesdue2027Member"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A2.95Notesdue2027Member_84f917fa-12eb-45cf-998f-518130444c9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A095NotesDue2027Member_ae844c93-e644-4a07-9e42-38d37d9c0180" xlink:href="jnj-20230101.xsd#jnj_A095NotesDue2027Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A095NotesDue2027Member_ae844c93-e644-4a07-9e42-38d37d9c0180" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.150NotesDue2028Member_1dd7c475-892e-4ab6-8e74-2c342fdcba05" xlink:href="jnj-20230101.xsd#jnj_A1.150NotesDue2028Member"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A1.150NotesDue2028Member_1dd7c475-892e-4ab6-8e74-2c342fdcba05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2.900Notesdue2028Member_1d5d8c4b-9ef5-42aa-9a6b-1103294a4974" xlink:href="jnj-20230101.xsd#jnj_A2.900Notesdue2028Member"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A2.900Notesdue2028Member_1d5d8c4b-9ef5-42aa-9a6b-1103294a4974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A6.95Notesdue2029Member_dcba9a06-3e50-4ae8-99bc-3dbbb94c628e" xlink:href="jnj-20230101.xsd#jnj_A6.95Notesdue2029Member"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A6.95Notesdue2029Member_dcba9a06-3e50-4ae8-99bc-3dbbb94c628e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A130NotesDue2030Member_15e5228c-213f-4796-b16d-ef35ba3b57f3" xlink:href="jnj-20230101.xsd#jnj_A130NotesDue2030Member"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A130NotesDue2030Member_15e5228c-213f-4796-b16d-ef35ba3b57f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.95Debenturesdue2033Member_83f09009-90f0-4cdc-a4fa-242b0ce7bfcf" xlink:href="jnj-20230101.xsd#jnj_A4.95Debenturesdue2033Member"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A4.95Debenturesdue2033Member_83f09009-90f0-4cdc-a4fa-242b0ce7bfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.375Notesdue2033Member_3d2e6078-02a9-4f08-9ec2-5aa86382ed7b" xlink:href="jnj-20230101.xsd#jnj_A4.375Notesdue2033Member"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A4.375Notesdue2033Member_3d2e6078-02a9-4f08-9ec2-5aa86382ed7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A1.650NotesDue2035Member_67b66885-36c3-4924-87ee-d311699b1970" xlink:href="jnj-20230101.xsd#jnj_A1.650NotesDue2035Member"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A1.650NotesDue2035Member_67b66885-36c3-4924-87ee-d311699b1970" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.55Notesdue2036Member_5c63101d-2e53-43c0-a5e4-7098416c83a0" xlink:href="jnj-20230101.xsd#jnj_A3.55Notesdue2036Member"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A3.55Notesdue2036Member_5c63101d-2e53-43c0-a5e4-7098416c83a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.95Notesdue2037Member_84067f9c-d1dc-44c8-869b-2ee1efe4ce97" xlink:href="jnj-20230101.xsd#jnj_A5.95Notesdue2037Member"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A5.95Notesdue2037Member_84067f9c-d1dc-44c8-869b-2ee1efe4ce97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.625Notesdue2037Member_d6f2dce2-54cc-4720-9f19-4f71ba1b1416" xlink:href="jnj-20230101.xsd#jnj_A3.625Notesdue2037Member"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A3.625Notesdue2037Member_d6f2dce2-54cc-4720-9f19-4f71ba1b1416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A5.85Debenturesdue2038Member_6ceb943e-1340-42d6-bde6-9da8216cf575" xlink:href="jnj-20230101.xsd#jnj_A5.85Debenturesdue2038Member"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A5.85Debenturesdue2038Member_6ceb943e-1340-42d6-bde6-9da8216cf575" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.400Notesdue2038Member_a8e9ba37-fa2c-4904-b758-5e863ae2b5c0" xlink:href="jnj-20230101.xsd#jnj_A3.400Notesdue2038Member"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A3.400Notesdue2038Member_a8e9ba37-fa2c-4904-b758-5e863ae2b5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Debenturesdue2040Member_c2f0a571-58dd-4a19-86c1-9691d536d87e" xlink:href="jnj-20230101.xsd#jnj_A4.50Debenturesdue2040Member"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A4.50Debenturesdue2040Member_c2f0a571-58dd-4a19-86c1-9691d536d87e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A210NotesDue2040Member_c3f739b3-c205-4a2f-b93c-b0eddbb5b2e8" xlink:href="jnj-20230101.xsd#jnj_A210NotesDue2040Member"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A210NotesDue2040Member_c3f739b3-c205-4a2f-b93c-b0eddbb5b2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.85Notesdue2041Member_a56b16ff-1521-48da-acba-7d141ce5015d" xlink:href="jnj-20230101.xsd#jnj_A4.85Notesdue2041Member"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A4.85Notesdue2041Member_a56b16ff-1521-48da-acba-7d141ce5015d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A4.50Notesdue2043Member_d466be21-24b5-4022-a529-a0c0fb47335c" xlink:href="jnj-20230101.xsd#jnj_A4.50Notesdue2043Member"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A4.50Notesdue2043Member_d466be21-24b5-4022-a529-a0c0fb47335c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.70Notesdue2046Member_ac2deefc-62e3-4d2e-a04f-5e939a38aac3" xlink:href="jnj-20230101.xsd#jnj_A3.70Notesdue2046Member"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A3.70Notesdue2046Member_ac2deefc-62e3-4d2e-a04f-5e939a38aac3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.75Notesdue2047Member_31421ec8-6431-4f35-a307-db45e02095fe" xlink:href="jnj-20230101.xsd#jnj_A3.75Notesdue2047Member"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A3.75Notesdue2047Member_31421ec8-6431-4f35-a307-db45e02095fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A3.500Notesdue2048Member_ee95960b-594b-4981-826c-65874f158899" xlink:href="jnj-20230101.xsd#jnj_A3.500Notesdue2048Member"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A3.500Notesdue2048Member_ee95960b-594b-4981-826c-65874f158899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2250NotesDue2050Member_4221ecb8-10a0-41ca-828f-fe97fc6bfc7d" xlink:href="jnj-20230101.xsd#jnj_A2250NotesDue2050Member"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A2250NotesDue2050Member_4221ecb8-10a0-41ca-828f-fe97fc6bfc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2450NotesDue2060Member_d306935b-42be-4049-b2c9-6fb48ef17e1e" xlink:href="jnj-20230101.xsd#jnj_A2450NotesDue2060Member"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_jnj_A2450NotesDue2060Member_d306935b-42be-4049-b2c9-6fb48ef17e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherDebtSecuritiesMember_f799c57e-c254-4521-a715-f2c45a6df194" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherDebtSecuritiesMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e8be3e95-7881-463d-abc3-539d599155e6" xlink:to="loc_us-gaap_OtherDebtSecuritiesMember_f799c57e-c254-4521-a715-f2c45a6df194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b679b360-ca73-44f0-b07a-292c715698a6" xlink:to="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_41097a8c-1fdd-4f83-a62f-9b7f1b179ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_41097a8c-1fdd-4f83-a62f-9b7f1b179ef9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_276d8990-2346-423d-b6e9-f0dc7ea7cf22" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_us-gaap_LongTermDebt_276d8990-2346-423d-b6e9-f0dc7ea7cf22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_922ea187-bec2-4922-abf2-9f49279c124b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_us-gaap_LongTermDebtCurrent_922ea187-bec2-4922-abf2-9f49279c124b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_d8872255-b700-4b23-9d50-44199b3a98e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_d8872255-b700-4b23-9d50-44199b3a98e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6b4b99a2-c9a2-4796-b21b-124494cdff40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6b4b99a2-c9a2-4796-b21b-124494cdff40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_29840a2a-9a75-49c2-a573-019920084d4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_29840a2a-9a75-49c2-a573-019920084d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_e1810638-e891-423e-b591-86f667c2a1d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyExchangeRateTranslation1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_us-gaap_ForeignCurrencyExchangeRateTranslation1_e1810638-e891-423e-b591-86f667c2a1d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt_ec3cd8cb-a21f-4166-846c-3af703b60f62" xlink:href="jnj-20230101.xsd#jnj_ExcessOfCarryingValueOverFairValueOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_jnj_ExcessOfCarryingValueOverFairValueOfDebt_ec3cd8cb-a21f-4166-846c-3af703b60f62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_f10ff941-1d04-457b-8dac-9bd25994e8a7" xlink:href="jnj-20230101.xsd#jnj_ExcessOfFairValueOverCarryingValueOfDebt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_d44fdd08-4eec-4c20-97be-84aa28e34bf1" xlink:to="loc_jnj_ExcessOfFairValueOverCarryingValueOfDebt_f10ff941-1d04-457b-8dac-9bd25994e8a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#BorrowingsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BorrowingsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_fc6dfc17-b9ad-4f07-b262-db4f5cee2810" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d913ddd2-8949-4898-a12e-af80b757128d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fc6dfc17-b9ad-4f07-b262-db4f5cee2810" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_d913ddd2-8949-4898-a12e-af80b757128d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtCurrent_5a568db6-2cc6-48ce-8a06-012bc234cfcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fc6dfc17-b9ad-4f07-b262-db4f5cee2810" xlink:to="loc_us-gaap_DebtCurrent_5a568db6-2cc6-48ce-8a06-012bc234cfcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermCommercialPaperCurrent_2627afc3-cefc-4016-8db4-022b8639b940" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermCommercialPaperCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fc6dfc17-b9ad-4f07-b262-db4f5cee2810" xlink:to="loc_us-gaap_LongTermCommercialPaperCurrent_2627afc3-cefc-4016-8db4-022b8639b940" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_873535e8-c014-45c0-9320-6dca2ac465a2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fc6dfc17-b9ad-4f07-b262-db4f5cee2810" xlink:to="loc_us-gaap_LongTermDebtCurrent_873535e8-c014-45c0-9320-6dca2ac465a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_3cd99ebc-5874-47e3-bd27-e803bed8657a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fc6dfc17-b9ad-4f07-b262-db4f5cee2810" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_3cd99ebc-5874-47e3-bd27-e803bed8657a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_00ef36eb-fbf1-4ace-a1b1-3946b2145601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fc6dfc17-b9ad-4f07-b262-db4f5cee2810" xlink:to="loc_us-gaap_DebtInstrumentTerm_00ef36eb-fbf1-4ace-a1b1-3946b2145601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_aa893b33-1042-451a-93c3-3640abfbeb72" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShortTermDebtTable"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_fc6dfc17-b9ad-4f07-b262-db4f5cee2810" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_aa893b33-1042-451a-93c3-3640abfbeb72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_c442091f-d510-4fc2-a824-d6b32349136e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_aa893b33-1042-451a-93c3-3640abfbeb72" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_c442091f-d510-4fc2-a824-d6b32349136e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_183291b2-0670-4b1b-9ebe-25c86b6899a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_c442091f-d510-4fc2-a824-d6b32349136e" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_183291b2-0670-4b1b-9ebe-25c86b6899a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_7192c043-1863-4d9d-9434-4b0992c436c7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_183291b2-0670-4b1b-9ebe-25c86b6899a9" xlink:to="loc_us-gaap_CommercialPaperMember_7192c043-1863-4d9d-9434-4b0992c436c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermDebtLineItems_5c0bd090-67e8-43a3-bce4-d532621b9ee9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermDebtLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_aa893b33-1042-451a-93c3-3640abfbeb72" xlink:to="loc_us-gaap_ShortTermDebtLineItems_5c0bd090-67e8-43a3-bce4-d532621b9ee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermBorrowings_d89c4231-1572-4a3b-a15c-95354cf71f09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShortTermBorrowings"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_5c0bd090-67e8-43a3-bce4-d532621b9ee9" xlink:to="loc_us-gaap_ShortTermBorrowings_d89c4231-1572-4a3b-a15c-95354cf71f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_c849b727-c3ae-498c-83d9-86ed6e73316b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtWeightedAverageInterestRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_5c0bd090-67e8-43a3-bce4-d532621b9ee9" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_c849b727-c3ae-498c-83d9-86ed6e73316b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTerm_7b5a8274-154d-4b06-9246-a00fc9f73523" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentTerm"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_5c0bd090-67e8-43a3-bce4-d532621b9ee9" xlink:to="loc_us-gaap_DebtInstrumentTerm_7b5a8274-154d-4b06-9246-a00fc9f73523" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#BorrowingsAggregateMaturitiesofLongTermObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_6bcdb4ea-2e3a-49cf-9ac3-18dec4be50c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtByMaturityAbstract_9312be15-c364-4b9d-96e1-c229d6717629" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtByMaturityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_6bcdb4ea-2e3a-49cf-9ac3-18dec4be50c5" xlink:to="loc_us-gaap_LongTermDebtByMaturityAbstract_9312be15-c364-4b9d-96e1-c229d6717629" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4f17d30b-43b8-4358-91e9-35c7749831ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_9312be15-c364-4b9d-96e1-c229d6717629" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_4f17d30b-43b8-4358-91e9-35c7749831ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8d56e318-b2f9-46ce-81ef-6954b10e96a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_9312be15-c364-4b9d-96e1-c229d6717629" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_8d56e318-b2f9-46ce-81ef-6954b10e96a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a642ce31-9dcd-4265-94b2-f8b5effedf4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_9312be15-c364-4b9d-96e1-c229d6717629" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_a642ce31-9dcd-4265-94b2-f8b5effedf4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_07befa74-2220-425b-9c56-df59b4c4d9d6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_9312be15-c364-4b9d-96e1-c229d6717629" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour_07befa74-2220-425b-9c56-df59b4c4d9d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_02ab9686-df68-4b6a-ade7-101ff76b611e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_9312be15-c364-4b9d-96e1-c229d6717629" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive_02ab9686-df68-4b6a-ade7-101ff76b611e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6138903d-142b-460e-ac61-f5804568f0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermDebtByMaturityAbstract_9312be15-c364-4b9d-96e1-c229d6717629" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive_6138903d-142b-460e-ac61-f5804568f0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IncomeTaxesProvisionforIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ef1bc21b-1c74-4225-bed6-a6da7d502adc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7f1fdd95-3519-4036-83a7-cb38f89ba403" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef1bc21b-1c74-4225-bed6-a6da7d502adc" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7f1fdd95-3519-4036-83a7-cb38f89ba403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_83f17090-ae86-4b31-b23d-561cc427761d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7f1fdd95-3519-4036-83a7-cb38f89ba403" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_83f17090-ae86-4b31-b23d-561cc427761d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b53cd4a5-bbc4-4b81-9d70-64e855e1d69c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7f1fdd95-3519-4036-83a7-cb38f89ba403" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_b53cd4a5-bbc4-4b81-9d70-64e855e1d69c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_66115903-0b78-4d45-8e8b-5eeb5aa548e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_7f1fdd95-3519-4036-83a7-cb38f89ba403" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_66115903-0b78-4d45-8e8b-5eeb5aa548e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c9e96d79-b776-4c10-ae0d-c59be39f879e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef1bc21b-1c74-4225-bed6-a6da7d502adc" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c9e96d79-b776-4c10-ae0d-c59be39f879e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1441e1f1-b797-40ca-833d-0d56c1578ea3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c9e96d79-b776-4c10-ae0d-c59be39f879e" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_1441e1f1-b797-40ca-833d-0d56c1578ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_10347ac2-e568-415d-90f7-3ca8fe89f269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c9e96d79-b776-4c10-ae0d-c59be39f879e" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_10347ac2-e568-415d-90f7-3ca8fe89f269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_128502b3-9500-41e1-a826-b04fd4e2f9fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_c9e96d79-b776-4c10-ae0d-c59be39f879e" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_128502b3-9500-41e1-a826-b04fd4e2f9fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_f7029155-5571-4fcb-a1ef-25668b117966" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ef1bc21b-1c74-4225-bed6-a6da7d502adc" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_f7029155-5571-4fcb-a1ef-25668b117966" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_803640ef-58e3-469f-ad83-49cfe7ea6ea8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_c0d0a83b-2c42-401f-a221-7db2e0e24506" xlink:href="jnj-20230101.xsd#jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_803640ef-58e3-469f-ad83-49cfe7ea6ea8" xlink:to="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_c0d0a83b-2c42-401f-a221-7db2e0e24506" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2069281e-f489-458e-8f6b-674fa9ee1dda" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_c0d0a83b-2c42-401f-a221-7db2e0e24506" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2069281e-f489-458e-8f6b-674fa9ee1dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9c4ad26e-ebe9-4b48-91e8-8bef06df2671" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_c0d0a83b-2c42-401f-a221-7db2e0e24506" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_9c4ad26e-ebe9-4b48-91e8-8bef06df2671" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3b1271f6-530e-49c9-aae3-5d0e0355b24c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_c0d0a83b-2c42-401f-a221-7db2e0e24506" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_3b1271f6-530e-49c9-aae3-5d0e0355b24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_89ef0373-5984-419e-8b7e-27dd052ec2bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract_c0d0a83b-2c42-401f-a221-7db2e0e24506" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_89ef0373-5984-419e-8b7e-27dd052ec2bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f900136b-ec27-4d1c-ba5f-f9699d26703d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_89ef0373-5984-419e-8b7e-27dd052ec2bd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_f900136b-ec27-4d1c-ba5f-f9699d26703d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_a4ca68e5-a01a-4b0a-ade2-50fb8c28c209" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_89ef0373-5984-419e-8b7e-27dd052ec2bd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_a4ca68e5-a01a-4b0a-ade2-50fb8c28c209" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation_d4b662c0-9e3f-40a8-b9ba-01b879273a69" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_89ef0373-5984-419e-8b7e-27dd052ec2bd" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation_d4b662c0-9e3f-40a8-b9ba-01b879273a69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_60899e75-6c70-4c1d-ab7f-79c023597ad8" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_89ef0373-5984-419e-8b7e-27dd052ec2bd" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome_60899e75-6c70-4c1d-ab7f-79c023597ad8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_da9d5aac-4aac-41b1-b33a-17a92d68c142" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_89ef0373-5984-419e-8b7e-27dd052ec2bd" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_da9d5aac-4aac-41b1-b33a-17a92d68c142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_56c25899-75ba-4be1-ace0-3f1e7037e0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_89ef0373-5984-419e-8b7e-27dd052ec2bd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther_56c25899-75ba-4be1-ace0-3f1e7037e0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0e451a03-b723-4525-8e86-6cb6c4ca7dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_89ef0373-5984-419e-8b7e-27dd052ec2bd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0e451a03-b723-4525-8e86-6cb6c4ca7dcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8ed6ec3-7c65-4eda-a8cc-7d01a405a6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_89ef0373-5984-419e-8b7e-27dd052ec2bd" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_e8ed6ec3-7c65-4eda-a8cc-7d01a405a6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IncomeTaxesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_6aa16e3e-c586-45a9-bbf0-cb760faa8bcb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_6aa16e3e-c586-45a9-bbf0-cb760faa8bcb" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_25c8fa88-f356-45c5-aa8f-1ab48fb88348" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:to="loc_srt_LitigationCaseAxis_25c8fa88-f356-45c5-aa8f-1ab48fb88348" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_4f2b6fc1-d425-4df8-b073-62e62a8bc38e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_25c8fa88-f356-45c5-aa8f-1ab48fb88348" xlink:to="loc_srt_LitigationCaseTypeDomain_4f2b6fc1-d425-4df8-b073-62e62a8bc38e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_60a894b5-1eb5-418e-8dfc-a40cbe1611e2" xlink:href="jnj-20230101.xsd#jnj_TalcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4f2b6fc1-d425-4df8-b073-62e62a8bc38e" xlink:to="loc_jnj_TalcMember_60a894b5-1eb5-418e-8dfc-a40cbe1611e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_6c5b724e-355f-4fe3-86ca-c6f132f71d95" xlink:href="jnj-20230101.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4f2b6fc1-d425-4df8-b073-62e62a8bc38e" xlink:to="loc_jnj_RisperdalMember_6c5b724e-355f-4fe3-86ca-c6f132f71d95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpiodsMember_7f069afa-02be-4a1d-9039-1e345b79af25" xlink:href="jnj-20230101.xsd#jnj_OpiodsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_4f2b6fc1-d425-4df8-b073-62e62a8bc38e" xlink:to="loc_jnj_OpiodsMember_7f069afa-02be-4a1d-9039-1e345b79af25" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_dc47bc4e-9687-4277-b0df-112824dbfa6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_dc47bc4e-9687-4277-b0df-112824dbfa6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_c69d1c2f-dc8b-4ad4-a8eb-b79b59e09122" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_dc47bc4e-9687-4277-b0df-112824dbfa6b" xlink:to="loc_us-gaap_SegmentDomain_c69d1c2f-dc8b-4ad4-a8eb-b79b59e09122" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_a47e0e7f-874c-4403-959d-8712a5b941c2" xlink:href="jnj-20230101.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c69d1c2f-dc8b-4ad4-a8eb-b79b59e09122" xlink:to="loc_jnj_ConsumerMember_a47e0e7f-874c-4403-959d-8712a5b941c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_ea4bd3b8-86b0-47ff-99d4-66444dc4b5f8" xlink:href="jnj-20230101.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_c69d1c2f-dc8b-4ad4-a8eb-b79b59e09122" xlink:to="loc_jnj_PharmaceuticalMember_ea4bd3b8-86b0-47ff-99d4-66444dc4b5f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameAxis_88e910b2-b6fd-46f5-9375-c4953e6dfa1b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameAxis_88e910b2-b6fd-46f5-9375-c4953e6dfa1b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityNameDomain_16ae5d92-505a-43b7-880b-583433eb0ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameAxis_88e910b2-b6fd-46f5-9375-c4953e6dfa1b" xlink:to="loc_us-gaap_IncomeTaxAuthorityNameDomain_16ae5d92-505a-43b7-880b-583433eb0ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_cd52743c-4203-4073-93e0-5a060bdcb63e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityNameDomain_16ae5d92-505a-43b7-880b-583433eb0ac0" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_cd52743c-4203-4073-93e0-5a060bdcb63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_7ec69d83-c96a-4baf-abaf-b6b9021afe14" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_7ec69d83-c96a-4baf-abaf-b6b9021afe14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e4c2fcf-0608-455b-a950-8a345b213f9a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_7ec69d83-c96a-4baf-abaf-b6b9021afe14" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e4c2fcf-0608-455b-a950-8a345b213f9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_dc505705-43be-4d6f-bcb4-d73fd45b2ef1" xlink:href="jnj-20230101.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1e4c2fcf-0608-455b-a950-8a345b213f9a" xlink:to="loc_jnj_AurisHealthMember_dc505705-43be-4d6f-bcb4-d73fd45b2ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1a589da6-01ac-469c-a124-cabb05632598" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1a589da6-01ac-469c-a124-cabb05632598" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6f6dee2-de0a-4c9a-82f4-8e8e38fc4099" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_1a589da6-01ac-469c-a124-cabb05632598" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6f6dee2-de0a-4c9a-82f4-8e8e38fc4099" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_cb81de51-2d23-4133-9854-cca5a3c0b503" xlink:href="jnj-20230101.xsd#jnj_PurchasedInProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_d6f6dee2-de0a-4c9a-82f4-8e8e38fc4099" xlink:to="loc_jnj_PurchasedInProcessResearchAndDevelopmentMember_cb81de51-2d23-4133-9854-cca5a3c0b503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_db39327b-06f0-46af-aa15-50e0cc96f03c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_db39327b-06f0-46af-aa15-50e0cc96f03c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f77e018e-329d-4eda-a37f-ca4311ab9e7f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_db39327b-06f0-46af-aa15-50e0cc96f03c" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f77e018e-329d-4eda-a37f-ca4311ab9e7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_ab8ff02d-5a98-4b8c-80bf-02e9b5f62f69" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_f77e018e-329d-4eda-a37f-ca4311ab9e7f" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_ab8ff02d-5a98-4b8c-80bf-02e9b5f62f69" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c7f687a8-90b2-47db-8b47-2d2421e2df0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:to="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c7f687a8-90b2-47db-8b47-2d2421e2df0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RelatedPartyDomain_153259ad-81f2-4505-98cd-8b57e8d391cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_c7f687a8-90b2-47db-8b47-2d2421e2df0b" xlink:to="loc_us-gaap_RelatedPartyDomain_153259ad-81f2-4505-98cd-8b57e8d391cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerHealthMember_dc8a87e5-bd90-4ef2-a939-d7fd475daa85" xlink:href="jnj-20230101.xsd#jnj_ConsumerHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RelatedPartyDomain_153259ad-81f2-4505-98cd-8b57e8d391cb" xlink:to="loc_jnj_ConsumerHealthMember_dc8a87e5-bd90-4ef2-a939-d7fd475daa85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxCreditCarryforwardLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_493928bc-8bcd-4b39-88d8-7b75d6a871fb" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_c8fe616a-ee22-4c6d-a939-1b03f8433b31" xlink:href="jnj-20230101.xsd#jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent_c8fe616a-ee22-4c6d-a939-1b03f8433b31" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e9dfbb90-8bc6-4476-a3ba-95ce6c1f58a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_e9dfbb90-8bc6-4476-a3ba-95ce6c1f58a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_194e3e9b-b84b-4baf-b3b7-d298eaad1dd4" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_194e3e9b-b84b-4baf-b3b7-d298eaad1dd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_d8acb2da-4924-4d83-8b1d-04ec1f6206d7" xlink:href="jnj-20230101.xsd#jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI_d8acb2da-4924-4d83-8b1d-04ec1f6206d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_cbae67f9-7594-43b5-9eb4-84d59ed66603" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss_cbae67f9-7594-43b5-9eb4-84d59ed66603" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_d0fb2cbf-84a9-40d7-8e8d-37399928e022" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_LitigationSettlementExpense_d0fb2cbf-84a9-40d7-8e8d-37399928e022" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_65c9361f-5afd-42b8-9b7f-09f61af89465" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent_65c9361f-5afd-42b8-9b7f-09f61af89465" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_dbe9686b-3592-491f-9634-7b2cf962c116" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_dbe9686b-3592-491f-9634-7b2cf962c116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_22d9d827-bf1c-4091-a492-adb9acc55d0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses_22d9d827-bf1c-4091-a492-adb9acc55d0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_cf524ae1-50a0-43e3-8ea5-24dbdfdd5f07" xlink:href="jnj-20230101.xsd#jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit_cf524ae1-50a0-43e3-8ea5-24dbdfdd5f07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_6b007861-b5dc-4e4e-8bc6-2a17c3d9a2c6" xlink:href="jnj-20230101.xsd#jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent_6b007861-b5dc-4e4e-8bc6-2a17c3d9a2c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_17a7fe5f-646a-464f-aaf1-b1d3f333777d" xlink:href="jnj-20230101.xsd#jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit_17a7fe5f-646a-464f-aaf1-b1d3f333777d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_ac313925-6074-4de2-b3cc-2771a0cd332b" xlink:href="jnj-20230101.xsd#jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset_ac313925-6074-4de2-b3cc-2771a0cd332b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_679904b6-9708-4914-b3cf-be170a57c8ab" xlink:href="jnj-20230101.xsd#jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit_679904b6-9708-4914-b3cf-be170a57c8ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_8642deb4-b0bf-4979-bdc1-7d60cc4ec370" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDeductions"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions_8642deb4-b0bf-4979-bdc1-7d60cc4ec370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_f6249fb5-82ee-4588-b3b2-1cbfb1ae024d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_f6249fb5-82ee-4588-b3b2-1cbfb1ae024d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment_0ca195fa-2db8-48b5-8f7c-990121ee454e" xlink:href="jnj-20230101.xsd#jnj_UnrecognizedTaxBenefitLiabilityPayment"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_UnrecognizedTaxBenefitLiabilityPayment_0ca195fa-2db8-48b5-8f7c-990121ee454e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_92b9e78b-3a1c-4cc2-8109-c5e69209f1e0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_92b9e78b-3a1c-4cc2-8109-c5e69209f1e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_56ee3136-d78e-4ff8-a4aa-c942dea1f7d5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_56ee3136-d78e-4ff8-a4aa-c942dea1f7d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_a6538431-5f44-4c1e-823a-8ec2a0934923" xlink:href="jnj-20230101.xsd#jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent_a6538431-5f44-4c1e-823a-8ec2a0934923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5a7ee8de-3fd9-47ad-8fb4-4af51d6ba6a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_e9164467-2dd8-41be-8f83-463721ea47d2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5a7ee8de-3fd9-47ad-8fb4-4af51d6ba6a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_4cbafe7b-d564-4626-95f2-1f0009b8b64c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_69cd6fe4-b457-4f25-9b1e-539f62149f7d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_4cbafe7b-d564-4626-95f2-1f0009b8b64c" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_69cd6fe4-b457-4f25-9b1e-539f62149f7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e074841-ba9a-4cf1-94e7-9e60bad9eacb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_69cd6fe4-b457-4f25-9b1e-539f62149f7d" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e074841-ba9a-4cf1-94e7-9e60bad9eacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_aa7d3bef-569f-4107-9610-189d10c1f5ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e074841-ba9a-4cf1-94e7-9e60bad9eacb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_aa7d3bef-569f-4107-9610-189d10c1f5ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_938234c0-b1bd-43c5-a1f9-bdb55ed901ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e074841-ba9a-4cf1-94e7-9e60bad9eacb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_938234c0-b1bd-43c5-a1f9-bdb55ed901ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_4288414a-7b91-4d96-a399-3aa3b7831da2" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e074841-ba9a-4cf1-94e7-9e60bad9eacb" xlink:to="loc_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized_4288414a-7b91-4d96-a399-3aa3b7831da2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_da5f39f1-424c-4dd1-a81c-f5c480634b62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e074841-ba9a-4cf1-94e7-9e60bad9eacb" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_da5f39f1-424c-4dd1-a81c-f5c480634b62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_de5dc595-fbc6-4afe-b4ef-375e126bb51c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e074841-ba9a-4cf1-94e7-9e60bad9eacb" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_de5dc595-fbc6-4afe-b4ef-375e126bb51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_332f6a50-41b7-45f5-a8e4-c73baa736cca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e074841-ba9a-4cf1-94e7-9e60bad9eacb" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_332f6a50-41b7-45f5-a8e4-c73baa736cca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings_40f9b343-7462-4990-84d1-1846b52835aa" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxAssetsUndistributedForeignEarnings"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e074841-ba9a-4cf1-94e7-9e60bad9eacb" xlink:to="loc_jnj_DeferredTaxAssetsUndistributedForeignEarnings_40f9b343-7462-4990-84d1-1846b52835aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_2f67bd80-6baa-434f-b118-5495c7a1e3d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e074841-ba9a-4cf1-94e7-9e60bad9eacb" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_2f67bd80-6baa-434f-b118-5495c7a1e3d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsOtherDomestic_a42379fb-467e-49cd-a0db-9e760b438c7c" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxAssetsOtherDomestic"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e074841-ba9a-4cf1-94e7-9e60bad9eacb" xlink:to="loc_jnj_DeferredTaxAssetsOtherDomestic_a42379fb-467e-49cd-a0db-9e760b438c7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_daf1d9a3-7e90-43b9-8816-a489e4fa02a6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_0e074841-ba9a-4cf1-94e7-9e60bad9eacb" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_daf1d9a3-7e90-43b9-8816-a489e4fa02a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_3f2184d5-76c4-4991-ba63-c435f6350886" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_69cd6fe4-b457-4f25-9b1e-539f62149f7d" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_3f2184d5-76c4-4991-ba63-c435f6350886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8bbb7437-ec92-4555-aa48-3f3b72820da6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_3f2184d5-76c4-4991-ba63-c435f6350886" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_8bbb7437-ec92-4555-aa48-3f3b72820da6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_39f5d22d-f9c5-437b-b6a6-a59c3184be02" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_3f2184d5-76c4-4991-ba63-c435f6350886" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_39f5d22d-f9c5-437b-b6a6-a59c3184be02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_924c2a0a-b870-46a7-9879-327729fbed76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_3f2184d5-76c4-4991-ba63-c435f6350886" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_924c2a0a-b870-46a7-9879-327729fbed76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_e54c19ac-80a3-4608-aef9-1473b6964b36" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_3f2184d5-76c4-4991-ba63-c435f6350886" xlink:to="loc_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome_e54c19ac-80a3-4608-aef9-1473b6964b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_65b9cbc6-eb65-4d1f-aefc-e1ccf1120b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesOther"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_3f2184d5-76c4-4991-ba63-c435f6350886" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_65b9cbc6-eb65-4d1f-aefc-e1ccf1120b5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxLiabilitiesOtherDomestic_edb03821-905e-492c-81e9-8298669f6b09" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxLiabilitiesOtherDomestic"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_3f2184d5-76c4-4991-ba63-c435f6350886" xlink:to="loc_jnj_DeferredTaxLiabilitiesOtherDomestic_edb03821-905e-492c-81e9-8298669f6b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_36603965-b12d-4587-b685-645102e5c38b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_3f2184d5-76c4-4991-ba63-c435f6350886" xlink:to="loc_us-gaap_DeferredTaxLiabilities_36603965-b12d-4587-b685-645102e5c38b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_345762f0-1950-4532-ae30-35eb3c8e102e" xlink:href="jnj-20230101.xsd#jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_69cd6fe4-b457-4f25-9b1e-539f62149f7d" xlink:to="loc_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization_345762f0-1950-4532-ae30-35eb3c8e102e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_91eee0c3-de7d-45da-9264-7736f9924e1c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_69cd6fe4-b457-4f25-9b1e-539f62149f7d" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_91eee0c3-de7d-45da-9264-7736f9924e1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_2dad2269-3453-46bd-a64e-1a5885b160bf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_69cd6fe4-b457-4f25-9b1e-539f62149f7d" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_2dad2269-3453-46bd-a64e-1a5885b160bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_64b60082-8396-4dcf-8c13-37394d1b2f96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e24d7798-3ec3-4724-809a-086066f5aceb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64b60082-8396-4dcf-8c13-37394d1b2f96" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e24d7798-3ec3-4724-809a-086066f5aceb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_b16da34c-a892-4dd2-bae3-71782e25294b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e24d7798-3ec3-4724-809a-086066f5aceb" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_b16da34c-a892-4dd2-bae3-71782e25294b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_d9bc1f52-c1f9-49a1-a886-9cd610329d6a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e24d7798-3ec3-4724-809a-086066f5aceb" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_d9bc1f52-c1f9-49a1-a886-9cd610329d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1badb714-6594-499c-8651-5b6c3b728b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e24d7798-3ec3-4724-809a-086066f5aceb" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_1badb714-6594-499c-8651-5b6c3b728b2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2a726748-97be-49f7-9888-5783c6f64d24" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e24d7798-3ec3-4724-809a-086066f5aceb" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2a726748-97be-49f7-9888-5783c6f64d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_4c8ebfbd-f39e-4681-a349-5a98a6144c56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e24d7798-3ec3-4724-809a-086066f5aceb" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_4c8ebfbd-f39e-4681-a349-5a98a6144c56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_123c5138-aec8-4458-9d8a-0494e1b385a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e24d7798-3ec3-4724-809a-086066f5aceb" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_123c5138-aec8-4458-9d8a-0494e1b385a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_16e162e6-e835-4f9a-b522-b5dc64f07ea9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_e24d7798-3ec3-4724-809a-086066f5aceb" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_16e162e6-e835-4f9a-b522-b5dc64f07ea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_1475d17c-5712-4d65-91f4-19051d882c6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_065f970a-dc5e-44cc-b1ed-041b6c13095a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_1475d17c-5712-4d65-91f4-19051d882c6f" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_065f970a-dc5e-44cc-b1ed-041b6c13095a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_716e92a1-3f9c-4ff5-b605-6b73c96cbc13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_065f970a-dc5e-44cc-b1ed-041b6c13095a" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities_716e92a1-3f9c-4ff5-b605-6b73c96cbc13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_60063c1e-56f4-4ccd-894c-acf8dea96cd1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_065f970a-dc5e-44cc-b1ed-041b6c13095a" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent_60063c1e-56f4-4ccd-894c-acf8dea96cd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_d7c4761c-432d-4abb-9642-adabb118b6c5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_065f970a-dc5e-44cc-b1ed-041b6c13095a" xlink:to="loc_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent_d7c4761c-432d-4abb-9642-adabb118b6c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_8bd64721-2cad-48cb-ae0f-e72bd1ced75e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_065f970a-dc5e-44cc-b1ed-041b6c13095a" xlink:to="loc_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent_8bd64721-2cad-48cb-ae0f-e72bd1ced75e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeObligations_affe5f9c-7321-42d3-916c-2b6ca8e97ae5" xlink:href="jnj-20230101.xsd#jnj_EmployeeObligations"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_065f970a-dc5e-44cc-b1ed-041b6c13095a" xlink:to="loc_jnj_EmployeeObligations_affe5f9c-7321-42d3-916c-2b6ca8e97ae5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_1137fe8b-c81e-4ba5-8bde-793319109489" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_065f970a-dc5e-44cc-b1ed-041b6c13095a" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_1137fe8b-c81e-4ba5-8bde-793319109489" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_63747774-8f43-412d-823d-3d1fd4a5dafe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract_065f970a-dc5e-44cc-b1ed-041b6c13095a" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_63747774-8f43-412d-823d-3d1fd4a5dafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1" xlink:type="simple" xlink:href="jnj-20230101.xsd#EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#EmployeeRelatedObligationsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationRelatedCostsAbstract_42dee5d1-c622-420a-ab7e-844decfd14e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationRelatedCostsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_bfc067af-49a2-4131-90dd-3cacc693a0f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationRelatedCostsAbstract_42dee5d1-c622-420a-ab7e-844decfd14e3" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_bfc067af-49a2-4131-90dd-3cacc693a0f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_12186e3d-dd3f-40a8-b59f-17ecd3d8eb31" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca652616-b751-4e30-855b-7efcbb4ce337" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_12186e3d-dd3f-40a8-b59f-17ecd3d8eb31" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca652616-b751-4e30-855b-7efcbb4ce337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_fd355bfe-61c8-4fcb-99cc-8b538dfba370" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca652616-b751-4e30-855b-7efcbb4ce337" xlink:to="loc_srt_RangeAxis_fd355bfe-61c8-4fcb-99cc-8b538dfba370" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_cb5e02fd-1f73-412f-91fe-801d4aeb1165" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_fd355bfe-61c8-4fcb-99cc-8b538dfba370" xlink:to="loc_srt_RangeMember_cb5e02fd-1f73-412f-91fe-801d4aeb1165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3f23d7d4-4efa-401e-8ddb-688fca0964c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_cb5e02fd-1f73-412f-91fe-801d4aeb1165" xlink:to="loc_srt_MaximumMember_3f23d7d4-4efa-401e-8ddb-688fca0964c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_aa3fc720-f9af-401e-aeb6-94fefd461e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca652616-b751-4e30-855b-7efcbb4ce337" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_aa3fc720-f9af-401e-aeb6-94fefd461e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_16d04e1b-34d6-4300-8220-6b1ef2adca56" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_aa3fc720-f9af-401e-aeb6-94fefd461e23" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_16d04e1b-34d6-4300-8220-6b1ef2adca56" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember_e9771496-5bb6-4fd5-b83d-3f799f457b59" xlink:href="jnj-20230101.xsd#jnj_CommingledFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_16d04e1b-34d6-4300-8220-6b1ef2adca56" xlink:to="loc_jnj_CommingledFundsMember_e9771496-5bb6-4fd5-b83d-3f799f457b59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d983be8f-c7cf-4442-8e73-615c223ea3a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca652616-b751-4e30-855b-7efcbb4ce337" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d983be8f-c7cf-4442-8e73-615c223ea3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63d863c9-c4d0-4cf2-81b8-b7d3f4231cdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_d983be8f-c7cf-4442-8e73-615c223ea3a9" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63d863c9-c4d0-4cf2-81b8-b7d3f4231cdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_d8cd30ea-5e35-46c6-8246-c425c4b49fcf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_63d863c9-c4d0-4cf2-81b8-b7d3f4231cdf" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_d8cd30ea-5e35-46c6-8246-c425c4b49fcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_2a27d34c-4ecf-4143-b389-1b365561d499" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca652616-b751-4e30-855b-7efcbb4ce337" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_2a27d34c-4ecf-4143-b389-1b365561d499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_e882928b-be1b-4ea3-8154-cb30478c7534" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_2a27d34c-4ecf-4143-b389-1b365561d499" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_e882928b-be1b-4ea3-8154-cb30478c7534" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_f543377e-f119-437b-8f95-e7f2827d6b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_e882928b-be1b-4ea3-8154-cb30478c7534" xlink:to="loc_us-gaap_DomesticPlanMember_f543377e-f119-437b-8f95-e7f2827d6b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_84f88194-f9c0-4ccc-a45f-70183f51a025" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_f543377e-f119-437b-8f95-e7f2827d6b8d" xlink:to="loc_country_US_84f88194-f9c0-4ccc-a45f-70183f51a025" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_0070fb4e-9485-47b1-b12e-41599d36d9a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_e882928b-be1b-4ea3-8154-cb30478c7534" xlink:to="loc_us-gaap_ForeignPlanMember_0070fb4e-9485-47b1-b12e-41599d36d9a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2bf3a819-a4e6-4f73-8726-501c111395ec" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca652616-b751-4e30-855b-7efcbb4ce337" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2bf3a819-a4e6-4f73-8726-501c111395ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_fecee48c-86b7-4e9e-aa0a-5f463f6ff3cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2bf3a819-a4e6-4f73-8726-501c111395ec" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_fecee48c-86b7-4e9e-aa0a-5f463f6ff3cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_c33dd345-7df1-407a-8f39-21dcd284af86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_fecee48c-86b7-4e9e-aa0a-5f463f6ff3cd" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_c33dd345-7df1-407a-8f39-21dcd284af86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c7e701a6-d553-4dc4-a8f6-d52eb50e1178" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_fecee48c-86b7-4e9e-aa0a-5f463f6ff3cd" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c7e701a6-d553-4dc4-a8f6-d52eb50e1178" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_ca652616-b751-4e30-855b-7efcbb4ce337" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EmployeeCompensationPeriod_e3198abe-2cc4-484f-8e7f-d25f98d54ab8" xlink:href="jnj-20230101.xsd#jnj_EmployeeCompensationPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_jnj_EmployeeCompensationPeriod_e3198abe-2cc4-484f-8e7f-d25f98d54ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_da55f905-8fff-48ba-b5a6-a023c6ec31a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_da55f905-8fff-48ba-b5a6-a023c6ec31a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_d418bba9-354b-48b8-93ee-4ee28befbdd1" xlink:href="jnj-20230101.xsd#jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets_d418bba9-354b-48b8-93ee-4ee28befbdd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_cdacb069-2f46-41d7-8abb-1f610c3cfc01" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_us-gaap_PensionContributions_cdacb069-2f46-41d7-8abb-1f610c3cfc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_b53e2857-7873-40e6-abbe-a054c0b15e81" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_b53e2857-7873-40e6-abbe-a054c0b15e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_7b11de74-7ff9-4bd2-b41c-6249de1657d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation_7b11de74-7ff9-4bd2-b41c-6249de1657d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_e413f3f5-3623-4e73-845b-0ff6b9d78802" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_e413f3f5-3623-4e73-845b-0ff6b9d78802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e04ddf86-52c6-4600-b120-e30f0598fff9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_e04ddf86-52c6-4600-b120-e30f0598fff9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_4d37f946-0b2f-45b7-90bd-aa61cba0ec8d" xlink:href="jnj-20230101.xsd#jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets_4d37f946-0b2f-45b7-90bd-aa61cba0ec8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset_cd7c761d-ef71-4b1d-828a-459ff6db76fa" xlink:href="jnj-20230101.xsd#jnj_PercentageOfCompanysCommonStockToPlanAsset"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_94d18d8b-0474-4f82-b141-13f9b60e7693" xlink:to="loc_jnj_PercentageOfCompanysCommonStockToPlanAsset_cd7c761d-ef71-4b1d-828a-459ff6db76fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_21a731f2-e020-4775-a5c3-a7861d7ffed6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9072b58a-dea6-4a42-b7c3-15ff0d31461c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_21a731f2-e020-4775-a5c3-a7861d7ffed6" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9072b58a-dea6-4a42-b7c3-15ff0d31461c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_f2526f0e-c13e-4b2a-98da-e2f18f6c483a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9072b58a-dea6-4a42-b7c3-15ff0d31461c" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_f2526f0e-c13e-4b2a-98da-e2f18f6c483a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_389a6bad-4dfb-4525-ac5b-f06050b712ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_f2526f0e-c13e-4b2a-98da-e2f18f6c483a" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_389a6bad-4dfb-4525-ac5b-f06050b712ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_af4a44a8-e4b9-4a73-91c3-000af497f5b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_389a6bad-4dfb-4525-ac5b-f06050b712ad" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_af4a44a8-e4b9-4a73-91c3-000af497f5b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_9f2fd408-dac4-478e-8c07-b2b427904b44" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_389a6bad-4dfb-4525-ac5b-f06050b712ad" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_9f2fd408-dac4-478e-8c07-b2b427904b44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_9072b58a-dea6-4a42-b7c3-15ff0d31461c" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_856df280-a4bd-4d31-94d4-1ff4caab6aa3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_856df280-a4bd-4d31-94d4-1ff4caab6aa3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_cc70943e-1735-4381-89cb-d80621d7d254" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_cc70943e-1735-4381-89cb-d80621d7d254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2dc00d48-ea4c-44b7-8346-fc7f9603f9fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_2dc00d48-ea4c-44b7-8346-fc7f9603f9fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_c52a8d9e-57b5-45a0-8348-156097a707e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_c52a8d9e-57b5-45a0-8348-156097a707e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_e461ff3b-e721-49c8-8201-ce76ff1ba58e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_e461ff3b-e721-49c8-8201-ce76ff1ba58e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_c36f4e28-8f1a-4ae5-aa92-ca85258cd192" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1_c36f4e28-8f1a-4ae5-aa92-ca85258cd192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_145972cb-a7c8-44c3-82d0-bc4e059d16dc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_a1e806dd-ebcf-4a09-ba7e-3d6edd2f4ac2" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_145972cb-a7c8-44c3-82d0-bc4e059d16dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_00ce2842-8819-49ee-96a0-40da4647417c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55ec1611-2562-4113-9068-19bc4e2a5b54" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_00ce2842-8819-49ee-96a0-40da4647417c" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55ec1611-2562-4113-9068-19bc4e2a5b54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_f19d6696-3404-4ac4-b0b0-ebc2f622afe8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55ec1611-2562-4113-9068-19bc4e2a5b54" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_f19d6696-3404-4ac4-b0b0-ebc2f622afe8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_d7581e0c-5b15-4e73-bef9-e76d8e95980e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_f19d6696-3404-4ac4-b0b0-ebc2f622afe8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_d7581e0c-5b15-4e73-bef9-e76d8e95980e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_12b92fa6-9ed1-4fc8-bb96-770216fbe5ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d7581e0c-5b15-4e73-bef9-e76d8e95980e" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_12b92fa6-9ed1-4fc8-bb96-770216fbe5ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c3b5f30d-3ee9-453e-93f7-cbdef45454a7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_d7581e0c-5b15-4e73-bef9-e76d8e95980e" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_c3b5f30d-3ee9-453e-93f7-cbdef45454a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7ab8d90a-b471-44e5-b10a-8e246d5d0f74" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_55ec1611-2562-4113-9068-19bc4e2a5b54" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7ab8d90a-b471-44e5-b10a-8e246d5d0f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_bcb0ed63-444f-4859-b84a-acfcbb01140c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7ab8d90a-b471-44e5-b10a-8e246d5d0f74" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_bcb0ed63-444f-4859-b84a-acfcbb01140c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_a8a6ca34-3bfe-480f-aa1c-fb523cc6e49a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_bcb0ed63-444f-4859-b84a-acfcbb01140c" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_a8a6ca34-3bfe-480f-aa1c-fb523cc6e49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_c503f281-baeb-4e6b-8767-351c2fae3a7f" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_bcb0ed63-444f-4859-b84a-acfcbb01140c" xlink:to="loc_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate_c503f281-baeb-4e6b-8767-351c2fae3a7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_49f69806-016e-4c9f-849c-37a302d7f298" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_bcb0ed63-444f-4859-b84a-acfcbb01140c" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_49f69806-016e-4c9f-849c-37a302d7f298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_469b8860-406d-4ac0-b5f5-9896505709da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_bcb0ed63-444f-4859-b84a-acfcbb01140c" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_469b8860-406d-4ac0-b5f5-9896505709da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_ba90e794-aae0-469a-ae7c-1ee51023a269" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_7ab8d90a-b471-44e5-b10a-8e246d5d0f74" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_ba90e794-aae0-469a-ae7c-1ee51023a269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_1dfa9f82-e61b-4dcd-abfc-5a3be3c97995" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_ba90e794-aae0-469a-ae7c-1ee51023a269" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_1dfa9f82-e61b-4dcd-abfc-5a3be3c97995" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_18bf83c7-246a-47b1-b126-e689fe7bcef6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_ba90e794-aae0-469a-ae7c-1ee51023a269" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_18bf83c7-246a-47b1-b126-e689fe7bcef6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a5dd040e-be0b-413e-9504-2b4cc2fe4e2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_83839080-eb5f-47a4-9b66-6fe04644053c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a5dd040e-be0b-413e-9504-2b4cc2fe4e2e" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_83839080-eb5f-47a4-9b66-6fe04644053c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_ac4a56f0-765d-4e3e-a235-a6b16ca74e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_83839080-eb5f-47a4-9b66-6fe04644053c" xlink:to="loc_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear_ac4a56f0-765d-4e3e-a235-a6b16ca74e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_fb3dd90f-85dc-48fa-9d55-dcf6db048e58" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_83839080-eb5f-47a4-9b66-6fe04644053c" xlink:to="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_fb3dd90f-85dc-48fa-9d55-dcf6db048e58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_0fcc1de5-5baa-47de-b643-dc7e154f2ee2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract_83839080-eb5f-47a4-9b66-6fe04644053c" xlink:to="loc_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate_0fcc1de5-5baa-47de-b643-dc7e154f2ee2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_65cac556-c752-4fc4-87e8-6735aa0c0d7b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1b8becba-aa95-4340-b5a2-6af8d95b51df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_65cac556-c752-4fc4-87e8-6735aa0c0d7b" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1b8becba-aa95-4340-b5a2-6af8d95b51df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_7609a063-d273-485a-b2de-38ec77231642" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1b8becba-aa95-4340-b5a2-6af8d95b51df" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_7609a063-d273-485a-b2de-38ec77231642" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2fb80f33-c8d5-4d26-8710-b277ad31f2b8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_7609a063-d273-485a-b2de-38ec77231642" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2fb80f33-c8d5-4d26-8710-b277ad31f2b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_d8605ec8-d993-4cbb-8aa9-5dfdedbe1508" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2fb80f33-c8d5-4d26-8710-b277ad31f2b8" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_d8605ec8-d993-4cbb-8aa9-5dfdedbe1508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_78852f48-fca4-452c-83f0-789d08cc0d8c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2fb80f33-c8d5-4d26-8710-b277ad31f2b8" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_78852f48-fca4-452c-83f0-789d08cc0d8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9bce677d-3f9b-4280-a8ae-36a87b71bc93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1b8becba-aa95-4340-b5a2-6af8d95b51df" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9bce677d-3f9b-4280-a8ae-36a87b71bc93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9bce677d-3f9b-4280-a8ae-36a87b71bc93" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_36be6cc5-38b2-4968-becc-bc24f20f5549" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_36be6cc5-38b2-4968-becc-bc24f20f5549" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_bba03bc9-ccf8-4103-8d0e-6974d37aaa85" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanServiceCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_bba03bc9-ccf8-4103-8d0e-6974d37aaa85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_233953f0-227f-41ae-bf8b-8f10782babb0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanInterestCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_233953f0-227f-41ae-bf8b-8f10782babb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_564c8a0b-2ce0-414b-989e-cbedc4030146" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_564c8a0b-2ce0-414b-989e-cbedc4030146" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_5d179322-4b19-4b50-8d25-6d8b107ffee0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAmendments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_5d179322-4b19-4b50-8d25-6d8b107ffee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_b3e50a68-05f3-49ae-84e2-75b6a853910d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_b3e50a68-05f3-49ae-84e2-75b6a853910d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_57c81944-8c2c-4ff5-8235-9b379aaaef41" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease_57c81944-8c2c-4ff5-8235-9b379aaaef41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CurtailmentsAndSettlementsAndRestructuring_a50f095b-3496-4d8c-b1e0-263284451d54" xlink:href="jnj-20230101.xsd#jnj_CurtailmentsAndSettlementsAndRestructuring"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_jnj_CurtailmentsAndSettlementsAndRestructuring_a50f095b-3496-4d8c-b1e0-263284451d54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_7f2939e8-abc3-4c90-bf64-c4e4c89afa40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_7f2939e8-abc3-4c90-bf64-c4e4c89afa40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_8aabc484-2e1a-45ea-b00f-1e52540efc62" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_8aabc484-2e1a-45ea-b00f-1e52540efc62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_eb65a370-f9ce-434c-b158-198880851fc6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_710bd198-182b-418e-93a9-fd411ae8110f" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_eb65a370-f9ce-434c-b158-198880851fc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9bce677d-3f9b-4280-a8ae-36a87b71bc93" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_762d5855-8620-498e-8580-6238bcf8f911" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_762d5855-8620-498e-8580-6238bcf8f911" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_c967cfd3-0a43-4471-9a31-24a3a9cab67d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_c967cfd3-0a43-4471-9a31-24a3a9cab67d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_f932fc3e-0802-4705-927b-df4d5a0ebb28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_f932fc3e-0802-4705-927b-df4d5a0ebb28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_eb2696f2-f4aa-4141-8aec-13690121ae73" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_eb2696f2-f4aa-4141-8aec-13690121ae73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_7bf0d331-3fb4-4a22-bf0a-50e9c8bf0a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_7bf0d331-3fb4-4a22-bf0a-50e9c8bf0a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_0f8cb6f6-ca7e-4b30-8b2e-99fd25380308" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease_0f8cb6f6-ca7e-4b30-8b2e-99fd25380308" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_85647183-2024-40bd-83b1-db135028b97f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_85647183-2024-40bd-83b1-db135028b97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_3573c4f0-36ec-4202-a65e-90695bddb2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_3573c4f0-36ec-4202-a65e-90695bddb2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_81ad63ad-98ce-41e6-bae8-34a016d4f375" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_81ad63ad-98ce-41e6-bae8-34a016d4f375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ef02e84e-6e07-44ba-a16d-5dc1c6380535" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_f49f3846-186d-4622-9da7-1db7676053f0" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ef02e84e-6e07-44ba-a16d-5dc1c6380535" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3f682c99-0d26-42c1-8d37-ca5002b12267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9bce677d-3f9b-4280-a8ae-36a87b71bc93" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3f682c99-0d26-42c1-8d37-ca5002b12267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1cb0d623-34dd-49bd-b0dd-c9459a426dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3f682c99-0d26-42c1-8d37-ca5002b12267" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_1cb0d623-34dd-49bd-b0dd-c9459a426dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_ca59a72b-27c1-438b-872b-dea35671784b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3f682c99-0d26-42c1-8d37-ca5002b12267" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_ca59a72b-27c1-438b-872b-dea35671784b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3d46fa9d-bcd5-4ebe-b951-9a755c14df50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3f682c99-0d26-42c1-8d37-ca5002b12267" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_3d46fa9d-bcd5-4ebe-b951-9a755c14df50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_a13408e6-4c07-4971-b4b7-acd302473092" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract_3f682c99-0d26-42c1-8d37-ca5002b12267" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_a13408e6-4c07-4971-b4b7-acd302473092" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f5ddfbd6-8428-4169-b44e-4f26c1507c93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9bce677d-3f9b-4280-a8ae-36a87b71bc93" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f5ddfbd6-8428-4169-b44e-4f26c1507c93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_14e6edbb-0b56-41aa-8639-526b2a8427ee" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f5ddfbd6-8428-4169-b44e-4f26c1507c93" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_14e6edbb-0b56-41aa-8639-526b2a8427ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_d0af8dcf-8995-4311-88e8-1cfd4b3108cf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f5ddfbd6-8428-4169-b44e-4f26c1507c93" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_d0af8dcf-8995-4311-88e8-1cfd4b3108cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_9b25548d-a854-473d-9bc7-279b4af2f9ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f5ddfbd6-8428-4169-b44e-4f26c1507c93" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax_9b25548d-a854-473d-9bc7-279b4af2f9ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_4b87e8f5-b7d4-427e-a335-3e027aece428" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f5ddfbd6-8428-4169-b44e-4f26c1507c93" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_4b87e8f5-b7d4-427e-a335-3e027aece428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_bdafbf4f-d76d-4bd3-886f-776a33131a96" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f5ddfbd6-8428-4169-b44e-4f26c1507c93" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_bdafbf4f-d76d-4bd3-886f-776a33131a96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionContributions_e0997dcf-c5a5-49bd-8961-afde638d3ec7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionContributions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract_f5ddfbd6-8428-4169-b44e-4f26c1507c93" xlink:to="loc_us-gaap_PensionContributions_e0997dcf-c5a5-49bd-8961-afde638d3ec7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9bce677d-3f9b-4280-a8ae-36a87b71bc93" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_73444d59-53a9-4cb1-84df-c53a84640b13" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_73444d59-53a9-4cb1-84df-c53a84640b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_1aae0649-4982-4661-9b3d-a6a21a2557d1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_1aae0649-4982-4661-9b3d-a6a21a2557d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_9181b254-adf4-417e-a784-9144b91cd01f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_9181b254-adf4-417e-a784-9144b91cd01f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_687485ae-0339-476a-a290-bd69102ef655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_687485ae-0339-476a-a290-bd69102ef655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_8555cfc6-e4d7-4833-90c0-804127df4fc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_8555cfc6-e4d7-4833-90c0-804127df4fc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EffectOfExchangeRates_706ca5cb-6aab-429a-b094-eeb717a9efd7" xlink:href="jnj-20230101.xsd#jnj_EffectOfExchangeRates"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:to="loc_jnj_EffectOfExchangeRates_706ca5cb-6aab-429a-b094-eeb717a9efd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_0a617405-c7d0-4de8-bf9e-046bd696d8d3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_0a617405-c7d0-4de8-bf9e-046bd696d8d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_6196e424-4ce6-4254-9178-79de34417c83" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract_7a99dab9-b73d-446f-845a-bb1510ced217" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_6196e424-4ce6-4254-9178-79de34417c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c9a5fc6f-44ce-4be3-86d1-4beddf9f4433" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3b46d2ac-4e87-43b2-b5c9-c58ab8f9fa1d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_c9a5fc6f-44ce-4be3-86d1-4beddf9f4433" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3b46d2ac-4e87-43b2-b5c9-c58ab8f9fa1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d9bc16ad-b5a1-467f-b1b5-aa5e91308de0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3b46d2ac-4e87-43b2-b5c9-c58ab8f9fa1d" xlink:to="loc_us-gaap_PlanNameAxis_d9bc16ad-b5a1-467f-b1b5-aa5e91308de0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_845d2178-6f5d-4f33-a6a0-bd111044cad2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d9bc16ad-b5a1-467f-b1b5-aa5e91308de0" xlink:to="loc_us-gaap_PlanNameDomain_845d2178-6f5d-4f33-a6a0-bd111044cad2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_QualifiedPlansMember_5d449316-60c9-487d-8797-565d0ced2952" xlink:href="jnj-20230101.xsd#jnj_QualifiedPlansMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_845d2178-6f5d-4f33-a6a0-bd111044cad2" xlink:to="loc_jnj_QualifiedPlansMember_5d449316-60c9-487d-8797-565d0ced2952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonQualifiedPlansMember_971dcba0-a340-4979-9942-d8f8bc025c66" xlink:href="jnj-20230101.xsd#jnj_NonQualifiedPlansMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_845d2178-6f5d-4f33-a6a0-bd111044cad2" xlink:to="loc_jnj_NonQualifiedPlansMember_971dcba0-a340-4979-9942-d8f8bc025c66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_FundedPlansMember_7c2c8b8e-877c-4d26-9c39-7b3b09664e95" xlink:href="jnj-20230101.xsd#jnj_FundedPlansMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_845d2178-6f5d-4f33-a6a0-bd111044cad2" xlink:to="loc_jnj_FundedPlansMember_7c2c8b8e-877c-4d26-9c39-7b3b09664e95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UnfundedPlansMember_ae9d5da0-f030-4887-8905-467c9445bb42" xlink:href="jnj-20230101.xsd#jnj_UnfundedPlansMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_845d2178-6f5d-4f33-a6a0-bd111044cad2" xlink:to="loc_jnj_UnfundedPlansMember_ae9d5da0-f030-4887-8905-467c9445bb42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_4649c967-9e3d-4704-8b71-583d353c15ea" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3b46d2ac-4e87-43b2-b5c9-c58ab8f9fa1d" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_4649c967-9e3d-4704-8b71-583d353c15ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_46c0b21f-9989-447e-bba2-ac2a52796ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanSponsorLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_4649c967-9e3d-4704-8b71-583d353c15ea" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_46c0b21f-9989-447e-bba2-ac2a52796ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticPlanMember_e5b5bc43-39e6-4b76-9ade-506489f087ab" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DomesticPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_46c0b21f-9989-447e-bba2-ac2a52796ee1" xlink:to="loc_us-gaap_DomesticPlanMember_e5b5bc43-39e6-4b76-9ade-506489f087ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_c13eca65-3ef4-4bb4-afdf-a06bf945f7c8" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_e5b5bc43-39e6-4b76-9ade-506489f087ab" xlink:to="loc_country_US_c13eca65-3ef4-4bb4-afdf-a06bf945f7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignPlanMember_783c63ff-c606-4a99-8f32-cbffdc4bd249" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignPlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_46c0b21f-9989-447e-bba2-ac2a52796ee1" xlink:to="loc_us-gaap_ForeignPlanMember_783c63ff-c606-4a99-8f32-cbffdc4bd249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71ea8b86-0170-45c8-8507-607966badfa4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_3b46d2ac-4e87-43b2-b5c9-c58ab8f9fa1d" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71ea8b86-0170-45c8-8507-607966badfa4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_340ed514-a32f-4d42-9d8a-0007f5b5ad8d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71ea8b86-0170-45c8-8507-607966badfa4" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_340ed514-a32f-4d42-9d8a-0007f5b5ad8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_c23be965-cfe1-457a-b985-45b43e6d28ae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanBenefitObligation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71ea8b86-0170-45c8-8507-607966badfa4" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_c23be965-cfe1-457a-b985-45b43e6d28ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_46628085-1bb7-4f7c-ba83-20468269bb34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71ea8b86-0170-45c8-8507-607966badfa4" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_46628085-1bb7-4f7c-ba83-20468269bb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_77d91d8d-9454-45db-927d-b13145ae3ce9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71ea8b86-0170-45c8-8507-607966badfa4" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_77d91d8d-9454-45db-927d-b13145ae3ce9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_c7dd94e4-b22e-4ae0-b383-87742440e8b3" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanOverUnderFundedStatusABO"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_71ea8b86-0170-45c8-8507-607966badfa4" xlink:to="loc_jnj_DefinedBenefitPlanOverUnderFundedStatusABO_c7dd94e4-b22e-4ae0-b383-87742440e8b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_89b24649-e622-49aa-8db5-ae276acaf61b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1c3e66bb-e915-4567-8ff7-14f2321e56c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_89b24649-e622-49aa-8db5-ae276acaf61b" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1c3e66bb-e915-4567-8ff7-14f2321e56c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_82340b60-311c-4742-afb5-dfcac585cf06" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1c3e66bb-e915-4567-8ff7-14f2321e56c8" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_82340b60-311c-4742-afb5-dfcac585cf06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_e8417f82-1415-4801-b8b2-ec6733f58c00" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_82340b60-311c-4742-afb5-dfcac585cf06" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_e8417f82-1415-4801-b8b2-ec6733f58c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_fd3fa528-d303-4b12-8f1c-048dcd2c62b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e8417f82-1415-4801-b8b2-ec6733f58c00" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_fd3fa528-d303-4b12-8f1c-048dcd2c62b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_d232b011-2d8d-4817-9a63-b172cf539a0d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_e8417f82-1415-4801-b8b2-ec6733f58c00" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_d232b011-2d8d-4817-9a63-b172cf539a0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_040dcd8a-0f3d-44c1-9380-27d9a5ff2d50" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_1c3e66bb-e915-4567-8ff7-14f2321e56c8" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_040dcd8a-0f3d-44c1-9380-27d9a5ff2d50" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_1aedf611-b9dd-4bd4-96fc-2d4ad9ea4251" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_040dcd8a-0f3d-44c1-9380-27d9a5ff2d50" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_1aedf611-b9dd-4bd4-96fc-2d4ad9ea4251" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_44c25ece-ca04-46b8-bbb2-06ed6fb927fd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_040dcd8a-0f3d-44c1-9380-27d9a5ff2d50" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_44c25ece-ca04-46b8-bbb2-06ed6fb927fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_10f41a82-fb8a-4d96-9a24-486653820703" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_040dcd8a-0f3d-44c1-9380-27d9a5ff2d50" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_10f41a82-fb8a-4d96-9a24-486653820703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_2608c413-f8a3-43fe-952e-859f07fdab7c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_040dcd8a-0f3d-44c1-9380-27d9a5ff2d50" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_2608c413-f8a3-43fe-952e-859f07fdab7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_c0c2a5f5-4793-4c99-a26d-06fd890f6e99" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_040dcd8a-0f3d-44c1-9380-27d9a5ff2d50" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_c0c2a5f5-4793-4c99-a26d-06fd890f6e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_5108275e-956a-44d8-91d8-7bedd8599df1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_040dcd8a-0f3d-44c1-9380-27d9a5ff2d50" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_5108275e-956a-44d8-91d8-7bedd8599df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a7cff385-fc43-458f-a5b1-a614dcb2ae6b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_62028163-668b-4794-a5f0-7f4557c91c73" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a7cff385-fc43-458f-a5b1-a614dcb2ae6b" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne_62028163-668b-4794-a5f0-7f4557c91c73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_4beabb4f-0012-4a72-a878-b4ca6b4a1503" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a7cff385-fc43-458f-a5b1-a614dcb2ae6b" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo_4beabb4f-0012-4a72-a878-b4ca6b4a1503" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_46c38340-0bc2-4d93-bbe3-373de2558b7f" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a7cff385-fc43-458f-a5b1-a614dcb2ae6b" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree_46c38340-0bc2-4d93-bbe3-373de2558b7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_08b32e8d-2a4d-47a3-ba3b-51c063a31dc3" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a7cff385-fc43-458f-a5b1-a614dcb2ae6b" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour_08b32e8d-2a4d-47a3-ba3b-51c063a31dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_6da56e31-f520-4a41-93d8-60ffc48b0ea2" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a7cff385-fc43-458f-a5b1-a614dcb2ae6b" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive_6da56e31-f520-4a41-93d8-60ffc48b0ea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_c2d6629c-8e70-462b-be6d-a05ba769b618" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_a7cff385-fc43-458f-a5b1-a614dcb2ae6b" xlink:to="loc_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter_c2d6629c-8e70-462b-be6d-a05ba769b618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0b83a036-2f73-4447-ad0b-5d4f9ef93b89" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_13a9ede5-5753-4bee-b501-741764005662" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0b83a036-2f73-4447-ad0b-5d4f9ef93b89" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_13a9ede5-5753-4bee-b501-741764005662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_db430c24-f714-4ad0-94a3-4669a632fad3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_13a9ede5-5753-4bee-b501-741764005662" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_db430c24-f714-4ad0-94a3-4669a632fad3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_c8a93fad-bae9-4f5e-8e83-ffee97c8fe5b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_db430c24-f714-4ad0-94a3-4669a632fad3" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_c8a93fad-bae9-4f5e-8e83-ffee97c8fe5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_3b46ab9d-2b11-4358-94a9-440fa8ef8b4e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c8a93fad-bae9-4f5e-8e83-ffee97c8fe5b" xlink:to="loc_us-gaap_EquitySecuritiesMember_3b46ab9d-2b11-4358-94a9-440fa8ef8b4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_27681674-f903-4515-ae8f-9bdf9f368e23" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_c8a93fad-bae9-4f5e-8e83-ffee97c8fe5b" xlink:to="loc_us-gaap_DebtSecuritiesMember_27681674-f903-4515-ae8f-9bdf9f368e23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74c79cb8-dd6a-4418-8de3-15d6c5eed4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_13a9ede5-5753-4bee-b501-741764005662" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74c79cb8-dd6a-4418-8de3-15d6c5eed4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_b082b41a-0367-43fc-9f8a-fa02a3346db1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74c79cb8-dd6a-4418-8de3-15d6c5eed4ef" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_b082b41a-0367-43fc-9f8a-fa02a3346db1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_7111b77e-dbbb-41a6-ad72-a3c96da1a1bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_74c79cb8-dd6a-4418-8de3-15d6c5eed4ef" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_7111b77e-dbbb-41a6-ad72-a3c96da1a1bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_52246109-6192-4bdc-b7a6-1776ba193330" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bfbb30fc-a5c4-4b3d-bba6-22b4c1e3e96a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_52246109-6192-4bdc-b7a6-1776ba193330" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bfbb30fc-a5c4-4b3d-bba6-22b4c1e3e96a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b3b0bc9a-0570-442a-bdcd-0fd46b301033" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bfbb30fc-a5c4-4b3d-bba6-22b4c1e3e96a" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b3b0bc9a-0570-442a-bdcd-0fd46b301033" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3a8aff8a-b4c6-4453-a402-0ca2a47d0cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_b3b0bc9a-0570-442a-bdcd-0fd46b301033" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3a8aff8a-b4c6-4453-a402-0ca2a47d0cf1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_0ec4d7df-1b3f-4589-968a-a8761c5a6cd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3a8aff8a-b4c6-4453-a402-0ca2a47d0cf1" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_0ec4d7df-1b3f-4589-968a-a8761c5a6cd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2d1809ab-24e7-445a-9890-b7cef46c83fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bfbb30fc-a5c4-4b3d-bba6-22b4c1e3e96a" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2d1809ab-24e7-445a-9890-b7cef46c83fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2ea1333d-4578-4666-8605-0e620293d50d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetirementPlanTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2d1809ab-24e7-445a-9890-b7cef46c83fc" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2ea1333d-4578-4666-8605-0e620293d50d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_5bcb84fb-2ae9-4922-9761-1895daed358e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionPlansDefinedBenefitMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2ea1333d-4578-4666-8605-0e620293d50d" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_5bcb84fb-2ae9-4922-9761-1895daed358e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_c38c089f-a394-48b6-8b20-ce8a7d460819" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bfbb30fc-a5c4-4b3d-bba6-22b4c1e3e96a" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_c38c089f-a394-48b6-8b20-ce8a7d460819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_53f3d9a3-9a53-49a7-89ac-379018b55999" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanAssetCategoriesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_c38c089f-a394-48b6-8b20-ce8a7d460819" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_53f3d9a3-9a53-49a7-89ac-379018b55999" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShortTermInvestmentFundsMember_e4d968b6-8946-434f-8e76-64c7d6181057" xlink:href="jnj-20230101.xsd#jnj_ShortTermInvestmentFundsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_53f3d9a3-9a53-49a7-89ac-379018b55999" xlink:to="loc_jnj_ShortTermInvestmentFundsMember_e4d968b6-8946-434f-8e76-64c7d6181057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_83f36528-bee8-4979-bf9d-18cb67311292" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_53f3d9a3-9a53-49a7-89ac-379018b55999" xlink:to="loc_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_83f36528-bee8-4979-bf9d-18cb67311292" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesMember_4062d9c8-46cb-400f-806e-ed79be0d5067" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_53f3d9a3-9a53-49a7-89ac-379018b55999" xlink:to="loc_us-gaap_DebtSecuritiesMember_4062d9c8-46cb-400f-806e-ed79be0d5067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquitySecuritiesMember_023a5423-a12d-45eb-82b1-e6288a671055" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquitySecuritiesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_53f3d9a3-9a53-49a7-89ac-379018b55999" xlink:to="loc_us-gaap_EquitySecuritiesMember_023a5423-a12d-45eb-82b1-e6288a671055" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CommingledFundsMember_5a06b3fa-f766-44cf-89fd-4d9dc81e5d24" xlink:href="jnj-20230101.xsd#jnj_CommingledFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_53f3d9a3-9a53-49a7-89ac-379018b55999" xlink:to="loc_jnj_CommingledFundsMember_5a06b3fa-f766-44cf-89fd-4d9dc81e5d24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsMember_3e54d382-dee5-4994-a010-d877ad1ac5f4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_53f3d9a3-9a53-49a7-89ac-379018b55999" xlink:to="loc_us-gaap_OtherAssetsMember_3e54d382-dee5-4994-a010-d877ad1ac5f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5967e5d-512c-4e1f-8e5d-b66cff3e7d36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bfbb30fc-a5c4-4b3d-bba6-22b4c1e3e96a" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5967e5d-512c-4e1f-8e5d-b66cff3e7d36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1be73a7-cf0a-47fc-99fc-b630eaf3494b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_a5967e5d-512c-4e1f-8e5d-b66cff3e7d36" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1be73a7-cf0a-47fc-99fc-b630eaf3494b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_259e6c83-5aa5-4852-9aa0-2021af0e37ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1be73a7-cf0a-47fc-99fc-b630eaf3494b" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_259e6c83-5aa5-4852-9aa0-2021af0e37ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_784f288f-c577-4b40-94ed-dca129966770" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1be73a7-cf0a-47fc-99fc-b630eaf3494b" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_784f288f-c577-4b40-94ed-dca129966770" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_c11a2bb4-f962-4034-b86b-877197cfc6ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_d1be73a7-cf0a-47fc-99fc-b630eaf3494b" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_c11a2bb4-f962-4034-b86b-877197cfc6ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4beb6fbe-f65b-4469-817e-da38801f3a19" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_bfbb30fc-a5c4-4b3d-bba6-22b4c1e3e96a" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4beb6fbe-f65b-4469-817e-da38801f3a19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_07b836aa-0d0b-479b-9882-bf71114b8af9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4beb6fbe-f65b-4469-817e-da38801f3a19" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_07b836aa-0d0b-479b-9882-bf71114b8af9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_8509e7f3-a82a-4b87-a560-07faeae1ce3f" xlink:href="jnj-20230101.xsd#jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_4beb6fbe-f65b-4469-817e-da38801f3a19" xlink:to="loc_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets_8509e7f3-a82a-4b87-a560-07faeae1ce3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SavingsPlanNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#SavingsPlanNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SavingsPlanNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SavingsPlanAbstract_8e1630fa-dac0-4ad3-8f81-1626981108f0" xlink:href="jnj-20230101.xsd#jnj_SavingsPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_b706315a-65a3-4901-a524-fa4282ec3f33" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_SavingsPlanAbstract_8e1630fa-dac0-4ad3-8f81-1626981108f0" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_b706315a-65a3-4901-a524-fa4282ec3f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#CapitalandTreasuryStockChangesinTreasuryStockDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_b779fb1a-0fd1-4046-8560-44e993dd7dc4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_2d0ff6b9-a46c-4aeb-8ae9-751b8a04575e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_b779fb1a-0fd1-4046-8560-44e993dd7dc4" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_2d0ff6b9-a46c-4aeb-8ae9-751b8a04575e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_9252d6c4-448e-4f47-9204-781d15b3f6a9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_2d0ff6b9-a46c-4aeb-8ae9-751b8a04575e" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_9252d6c4-448e-4f47-9204-781d15b3f6a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_76f66cc5-e601-4cfc-9515-f716d722e2fe" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_9252d6c4-448e-4f47-9204-781d15b3f6a9" xlink:to="loc_us-gaap_EquityComponentDomain_76f66cc5-e601-4cfc-9515-f716d722e2fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockMember_92e47fcc-f2be-4ff6-9f60-afe59adc2e97" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_76f66cc5-e601-4cfc-9515-f716d722e2fe" xlink:to="loc_us-gaap_TreasuryStockMember_92e47fcc-f2be-4ff6-9f60-afe59adc2e97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cab602a6-98f5-46a7-a98e-d74766a6bb3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_2d0ff6b9-a46c-4aeb-8ae9-751b8a04575e" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cab602a6-98f5-46a7-a98e-d74766a6bb3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_7dc39afc-8947-4e99-849c-353f7a4166c3" xlink:href="jnj-20230101.xsd#jnj_ChangesinTreasuryStockSharesOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cab602a6-98f5-46a7-a98e-d74766a6bb3f" xlink:to="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_7dc39afc-8947-4e99-849c-353f7a4166c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_732bebf0-7661-4b68-a0c6-3ace2a7d1e12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_7dc39afc-8947-4e99-849c-353f7a4166c3" xlink:to="loc_us-gaap_TreasuryStockShares_732bebf0-7661-4b68-a0c6-3ace2a7d1e12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_c8b89725-1462-4ebc-941b-3bae1b937a84" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_7dc39afc-8947-4e99-849c-353f7a4166c3" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_c8b89725-1462-4ebc-941b-3bae1b937a84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_7af4139f-d079-4bf0-9451-9b5aeb43a043" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_7dc39afc-8947-4e99-849c-353f7a4166c3" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_7af4139f-d079-4bf0-9451-9b5aeb43a043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockShares_5158792b-9af2-428a-bb47-e19f7104001b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockShares"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesinTreasuryStockSharesOutstandingRollForward_7dc39afc-8947-4e99-849c-353f7a4166c3" xlink:to="loc_us-gaap_TreasuryStockShares_5158792b-9af2-428a-bb47-e19f7104001b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ChangesInTreasuryStockRollForward_33ccd548-07be-4cb6-a507-04d53f483746" xlink:href="jnj-20230101.xsd#jnj_ChangesInTreasuryStockRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_cab602a6-98f5-46a7-a98e-d74766a6bb3f" xlink:to="loc_jnj_ChangesInTreasuryStockRollForward_33ccd548-07be-4cb6-a507-04d53f483746" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_c58cf7dd-79e4-4bee-b0b5-4c440e10eee3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_33ccd548-07be-4cb6-a507-04d53f483746" xlink:to="loc_us-gaap_TreasuryStockValue_c58cf7dd-79e4-4bee-b0b5-4c440e10eee3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_1e2a6774-a056-4e17-b500-f8d9e1202ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_33ccd548-07be-4cb6-a507-04d53f483746" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_1e2a6774-a056-4e17-b500-f8d9e1202ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6aca0fb3-59dd-4c96-8203-45acf878b11a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_33ccd548-07be-4cb6-a507-04d53f483746" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_6aca0fb3-59dd-4c96-8203-45acf878b11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValue_b833177d-7bda-4da4-a469-92d4927f7b32" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TreasuryStockValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ChangesInTreasuryStockRollForward_33ccd548-07be-4cb6-a507-04d53f483746" xlink:to="loc_us-gaap_TreasuryStockValue_b833177d-7bda-4da4-a469-92d4927f7b32" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#CapitalandTreasuryStockNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_f4a5bbb4-26c7-448c-b696-ef5d83fc655f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_9136b0a0-d030-43f1-b7d1-0cbfc339a6b1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfTreasuryStockTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_f4a5bbb4-26c7-448c-b696-ef5d83fc655f" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_9136b0a0-d030-43f1-b7d1-0cbfc339a6b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_1f47d28e-b6d0-4460-9c07-074d13c5946c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_9136b0a0-d030-43f1-b7d1-0cbfc339a6b1" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_1f47d28e-b6d0-4460-9c07-074d13c5946c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_098d2a83-fde6-4773-918a-731501f9e193" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_1f47d28e-b6d0-4460-9c07-074d13c5946c" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_098d2a83-fde6-4773-918a-731501f9e193" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_December172018ShareRepurchaseProgramMember_847cd10a-cfd1-429b-8289-744dfacfe705" xlink:href="jnj-20230101.xsd#jnj_December172018ShareRepurchaseProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_098d2a83-fde6-4773-918a-731501f9e193" xlink:to="loc_jnj_December172018ShareRepurchaseProgramMember_847cd10a-cfd1-429b-8289-744dfacfe705" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_a5da3614-7adb-44b2-af98-daa8a3cfaf2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_9136b0a0-d030-43f1-b7d1-0cbfc339a6b1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_a5da3614-7adb-44b2-af98-daa8a3cfaf2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_7b28188a-9954-4ff6-9169-962888090200" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_a5da3614-7adb-44b2-af98-daa8a3cfaf2b" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_7b28188a-9954-4ff6-9169-962888090200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsequentEventMember_d184cc0c-4fe3-4573-85c8-9f2d63c75159" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_7b28188a-9954-4ff6-9169-962888090200" xlink:to="loc_us-gaap_SubsequentEventMember_d184cc0c-4fe3-4573-85c8-9f2d63c75159" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7f78a0-e6e7-4c29-9949-38501db32296" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityClassOfTreasuryStockLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_9136b0a0-d030-43f1-b7d1-0cbfc339a6b1" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7f78a0-e6e7-4c29-9949-38501db32296" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_23697ae0-e9ff-44a8-9dd7-a13366657c8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7f78a0-e6e7-4c29-9949-38501db32296" xlink:to="loc_us-gaap_CommonStockSharesIssued_23697ae0-e9ff-44a8-9dd7-a13366657c8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareCashPaid_c7605ffd-4ae6-4d5f-b010-97ee6a26656d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareCashPaid"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7f78a0-e6e7-4c29-9949-38501db32296" xlink:to="loc_us-gaap_CommonStockDividendsPerShareCashPaid_c7605ffd-4ae6-4d5f-b010-97ee6a26656d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_e1180111-d0fa-4513-9aa0-062bbd00c213" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7f78a0-e6e7-4c29-9949-38501db32296" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_e1180111-d0fa-4513-9aa0-062bbd00c213" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_50d6499b-6035-4744-a478-496fc4bb81ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7f78a0-e6e7-4c29-9949-38501db32296" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_50d6499b-6035-4744-a478-496fc4bb81ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockRepurchasedDuringPeriodValue_5833d589-70c4-4132-b274-a383d6148c91" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockRepurchasedDuringPeriodValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_7a7f78a0-e6e7-4c29-9949-38501db32296" xlink:to="loc_us-gaap_StockRepurchasedDuringPeriodValue_5833d589-70c4-4132-b274-a383d6148c91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#AccumulatedOtherComprehensiveIncomeLossDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_728b5abf-e6f1-49a6-bf69-a0ba8baa6b94" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_fe838da1-a083-450e-82bd-fef42a04bfbb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_728b5abf-e6f1-49a6-bf69-a0ba8baa6b94" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_fe838da1-a083-450e-82bd-fef42a04bfbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_d36d2c64-c756-4d97-8e89-63c32d8c5191" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_fe838da1-a083-450e-82bd-fef42a04bfbb" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_d36d2c64-c756-4d97-8e89-63c32d8c5191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5050efc3-07cf-4bab-b047-26e614891655" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_d36d2c64-c756-4d97-8e89-63c32d8c5191" xlink:to="loc_us-gaap_EquityComponentDomain_5050efc3-07cf-4bab-b047-26e614891655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5a049ee5-4913-4101-b597-a48eaba6beaa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5050efc3-07cf-4bab-b047-26e614891655" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_5a049ee5-4913-4101-b597-a48eaba6beaa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_9917f636-89cb-43d5-bbf6-c858252c8f20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5050efc3-07cf-4bab-b047-26e614891655" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_9917f636-89cb-43d5-bbf6-c858252c8f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_31f2a1cc-06d8-4b99-be21-df15d96074ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5050efc3-07cf-4bab-b047-26e614891655" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember_31f2a1cc-06d8-4b99-be21-df15d96074ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_95c9f36a-ec96-4e89-a728-3e5e3cb62fdf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5050efc3-07cf-4bab-b047-26e614891655" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_95c9f36a-ec96-4e89-a728-3e5e3cb62fdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_16cc3eef-55da-4f09-867f-599627e227f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5050efc3-07cf-4bab-b047-26e614891655" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_16cc3eef-55da-4f09-867f-599627e227f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ccdc28c2-dc5c-4f96-bbf9-3a36bed51bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_fe838da1-a083-450e-82bd-fef42a04bfbb" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ccdc28c2-dc5c-4f96-bbf9-3a36bed51bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3789822d-4077-4c9a-b8b3-a70694f832a5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_ccdc28c2-dc5c-4f96-bbf9-3a36bed51bc5" xlink:to="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3789822d-4077-4c9a-b8b3-a70694f832a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_805c9314-6693-4db9-8e5f-b21505006c86" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3789822d-4077-4c9a-b8b3-a70694f832a5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_805c9314-6693-4db9-8e5f-b21505006c86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6901308a-020a-4dbf-8e2a-4e29bf25ee29" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3789822d-4077-4c9a-b8b3-a70694f832a5" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_6901308a-020a-4dbf-8e2a-4e29bf25ee29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7114ff28-4962-49d3-928b-f2599daefcd0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract_3789822d-4077-4c9a-b8b3-a70694f832a5" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_7114ff28-4962-49d3-928b-f2599daefcd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#InternationalCurrencyTranslationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTranslationAbstract_67882efc-730b-437c-8378-b20c470e604d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTranslationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1fb15678-d3e3-4b80-a2a7-fcf737a8e3cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ForeignCurrencyTranslationAbstract_67882efc-730b-437c-8378-b20c470e604d" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_1fb15678-d3e3-4b80-a2a7-fcf737a8e3cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8812922a-274e-49f0-b120-ca5ab71aa37b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_9654dcf2-3a31-46c4-b06c-22a772f481d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8812922a-274e-49f0-b120-ca5ab71aa37b" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_9654dcf2-3a31-46c4-b06c-22a772f481d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c5968d3b-9278-46de-b950-50262ac838d0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9654dcf2-3a31-46c4-b06c-22a772f481d0" xlink:to="loc_us-gaap_EarningsPerShareBasic_c5968d3b-9278-46de-b950-50262ac838d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cc8aae68-cee3-45eb-b064-703aa2d9702f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9654dcf2-3a31-46c4-b06c-22a772f481d0" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_cc8aae68-cee3-45eb-b064-703aa2d9702f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans_dff63ec6-44d8-4fe8-b3c9-2cd33d41a12a" xlink:href="jnj-20230101.xsd#jnj_PotentialSharesExercisableUnderStockOptionPlans"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9654dcf2-3a31-46c4-b06c-22a772f481d0" xlink:to="loc_jnj_PotentialSharesExercisableUnderStockOptionPlans_dff63ec6-44d8-4fe8-b3c9-2cd33d41a12a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_a7a24c94-4f30-4c3f-92ff-65231ea998bd" xlink:href="jnj-20230101.xsd#jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9654dcf2-3a31-46c4-b06c-22a772f481d0" xlink:to="loc_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod_a7a24c94-4f30-4c3f-92ff-65231ea998bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_27d681c3-2bc4-4b17-a5c3-57df0d08b3fc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9654dcf2-3a31-46c4-b06c-22a772f481d0" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_27d681c3-2bc4-4b17-a5c3-57df0d08b3fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_68e4c805-622c-4b72-9f1c-80a06e04adf3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_9654dcf2-3a31-46c4-b06c-22a772f481d0" xlink:to="loc_us-gaap_EarningsPerShareDiluted_68e4c805-622c-4b72-9f1c-80a06e04adf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/EarningsPerShareNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#EarningsPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/EarningsPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_c8fa901a-c096-4b19-8f11-2f2546c40a1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6917dea6-a336-4381-8703-23e44327d6db" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_c8fa901a-c096-4b19-8f11-2f2546c40a1e" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_6917dea6-a336-4381-8703-23e44327d6db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eff83355-dc4e-46db-a492-16d106b07aed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b134651a-bb00-4c58-8731-2d658ff6d0ac" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_eff83355-dc4e-46db-a492-16d106b07aed" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b134651a-bb00-4c58-8731-2d658ff6d0ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_56af3790-db74-4792-9d0c-2879cffe843f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b134651a-bb00-4c58-8731-2d658ff6d0ac" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_56af3790-db74-4792-9d0c-2879cffe843f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_45ecc114-56d6-46bb-ab14-0d044ad200b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareRepurchaseProgramDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_56af3790-db74-4792-9d0c-2879cffe843f" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_45ecc114-56d6-46bb-ab14-0d044ad200b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2022LongTermIncentivePlanMember_88086dfd-b9e1-43ac-8bad-93ad221e0c2a" xlink:href="jnj-20230101.xsd#jnj_A2022LongTermIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_45ecc114-56d6-46bb-ab14-0d044ad200b2" xlink:to="loc_jnj_A2022LongTermIncentivePlanMember_88086dfd-b9e1-43ac-8bad-93ad221e0c2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_02046bfc-f628-4bca-8f28-04be11b3860a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b134651a-bb00-4c58-8731-2d658ff6d0ac" xlink:to="loc_srt_RangeAxis_02046bfc-f628-4bca-8f28-04be11b3860a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_e5eaed84-7887-480f-b3ad-e22baef3b2dd" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_02046bfc-f628-4bca-8f28-04be11b3860a" xlink:to="loc_srt_RangeMember_e5eaed84-7887-480f-b3ad-e22baef3b2dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_9ada5123-635a-47c1-b23f-7bcf37003e46" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e5eaed84-7887-480f-b3ad-e22baef3b2dd" xlink:to="loc_srt_MinimumMember_9ada5123-635a-47c1-b23f-7bcf37003e46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e668cc6e-1519-4cc4-85aa-2a254b82f787" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_e5eaed84-7887-480f-b3ad-e22baef3b2dd" xlink:to="loc_srt_MaximumMember_e668cc6e-1519-4cc4-85aa-2a254b82f787" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5c1bf716-a176-407d-986c-4942608e9823" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b134651a-bb00-4c58-8731-2d658ff6d0ac" xlink:to="loc_us-gaap_AwardTypeAxis_5c1bf716-a176-407d-986c-4942608e9823" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e4e3ff4-8766-4fb3-b317-9dd57d74f1f0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5c1bf716-a176-407d-986c-4942608e9823" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e4e3ff4-8766-4fb3-b317-9dd57d74f1f0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_f1fb1373-39a7-4281-99cf-db6f95a48e78" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e4e3ff4-8766-4fb3-b317-9dd57d74f1f0" xlink:to="loc_us-gaap_EmployeeStockOptionMember_f1fb1373-39a7-4281-99cf-db6f95a48e78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3b78da55-c20e-45ee-91a8-ef16adb4d17c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e4e3ff4-8766-4fb3-b317-9dd57d74f1f0" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3b78da55-c20e-45ee-91a8-ef16adb4d17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_8eba68e7-56bc-45d8-ad6e-d7c81a7e2759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9e4e3ff4-8766-4fb3-b317-9dd57d74f1f0" xlink:to="loc_us-gaap_PerformanceSharesMember_8eba68e7-56bc-45d8-ad6e-d7c81a7e2759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_b134651a-bb00-4c58-8731-2d658ff6d0ac" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NumberOfStockBasedCompensationPlans_a658ecdc-ff4b-4cc3-8e8e-58c9bbbe11a7" xlink:href="jnj-20230101.xsd#jnj_NumberOfStockBasedCompensationPlans"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_jnj_NumberOfStockBasedCompensationPlans_a658ecdc-ff4b-4cc3-8e8e-58c9bbbe11a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a1a497be-9d57-476f-be56-2f10a9a3d18d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_a1a497be-9d57-476f-be56-2f10a9a3d18d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4765f961-8290-46f6-b638-1c838bfc19a8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_4765f961-8290-46f6-b638-1c838bfc19a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bd0dcf08-a76d-4208-9043-38b74e4eb94f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bd0dcf08-a76d-4208-9043-38b74e4eb94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_bc30e831-f23d-4b5e-8674-1d785758dd0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_bc30e831-f23d-4b5e-8674-1d785758dd0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_dfcb28d1-37bf-4b47-91ca-91589724c3d8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_dfcb28d1-37bf-4b47-91ca-91589724c3d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f2d22e36-b51c-4930-a633-c6fc4b33d952" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f2d22e36-b51c-4930-a633-c6fc4b33d952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ea7b3d59-0e3e-4f87-bb34-212ff2a4f127" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_ea7b3d59-0e3e-4f87-bb34-212ff2a4f127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a08af434-5734-45dc-b913-b3a0e75693fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_a08af434-5734-45dc-b913-b3a0e75693fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_91859087-df85-4972-84e2-e26369ac37e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_91859087-df85-4972-84e2-e26369ac37e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fb4a41fd-8c40-4598-932e-4d8a6d5fa7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_fb4a41fd-8c40-4598-932e-4d8a6d5fa7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_558bb20e-599e-46c1-8e3a-6c0e087c0715" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_558bb20e-599e-46c1-8e3a-6c0e087c0715" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_580fc611-faf2-4630-a63c-b6f6669c754c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_580fc611-faf2-4630-a63c-b6f6669c754c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_fb009c72-f3dc-4ba8-96f6-b2848ca3ebaf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_fb009c72-f3dc-4ba8-96f6-b2848ca3ebaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0bb65baf-2b8b-47d6-9e2d-d95697a29613" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_0bb65baf-2b8b-47d6-9e2d-d95697a29613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c3e326fb-5302-4a61-94da-b97a00e62335" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_c3e326fb-5302-4a61-94da-b97a00e62335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cc83a16b-fe7b-4317-a8eb-3dc8115f087b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_cc83a16b-fe7b-4317-a8eb-3dc8115f087b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3d1122ee-afe8-42ac-bab1-7ba292235ed2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_3d1122ee-afe8-42ac-bab1-7ba292235ed2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_bdb69806-604b-4775-8919-ad8bd4cf501e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_bdb69806-604b-4775-8919-ad8bd4cf501e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights_b0fdad7d-44bb-407e-abe6-02424036a020" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights_b0fdad7d-44bb-407e-abe6-02424036a020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards_f2368f15-b906-48ca-a35e-a327a4c86fae" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards_f2368f15-b906-48ca-a35e-a327a4c86fae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess_be3422c6-a8fc-4e46-8e1c-54153cc12d49" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e69d1f27-1b65-4d91-9586-cb1841b5cfaf" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess_be3422c6-a8fc-4e46-8e1c-54153cc12d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ef8f8b3-b49c-4f38-b352-d996b8687601" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_007e1af2-3e28-4d44-afca-be796561fb34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ef8f8b3-b49c-4f38-b352-d996b8687601" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_007e1af2-3e28-4d44-afca-be796561fb34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_aa5463fa-182b-4d05-ae57-5ea27cdd099b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_007e1af2-3e28-4d44-afca-be796561fb34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_aa5463fa-182b-4d05-ae57-5ea27cdd099b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ebf697d5-3fa0-4552-ba60-5cf8cc605b76" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_007e1af2-3e28-4d44-afca-be796561fb34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ebf697d5-3fa0-4552-ba60-5cf8cc605b76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_10f163d5-d2ac-4336-bbba-6966189066bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_007e1af2-3e28-4d44-afca-be796561fb34" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_10f163d5-d2ac-4336-bbba-6966189066bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_26e2acbe-3858-4f78-a614-ca82f23f6ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_007e1af2-3e28-4d44-afca-be796561fb34" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_26e2acbe-3858-4f78-a614-ca82f23f6ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5e4409e9-3693-4b07-aa4f-00d3bf10db1e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_63589eb1-b74a-49f7-8eb1-608ffc5a620e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_5e4409e9-3693-4b07-aa4f-00d3bf10db1e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_63589eb1-b74a-49f7-8eb1-608ffc5a620e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ae07c85-c6a5-4f1f-90c4-89116a53d7f5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_63589eb1-b74a-49f7-8eb1-608ffc5a620e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ae07c85-c6a5-4f1f-90c4-89116a53d7f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2e58f68b-2017-4531-8156-e37eb6cd8c28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ae07c85-c6a5-4f1f-90c4-89116a53d7f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2e58f68b-2017-4531-8156-e37eb6cd8c28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_23fc4773-19ec-491a-999b-9cb8c698a54f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ae07c85-c6a5-4f1f-90c4-89116a53d7f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_23fc4773-19ec-491a-999b-9cb8c698a54f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e5c615b6-8ba5-47d9-b1b5-886ac0ccf8f3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ae07c85-c6a5-4f1f-90c4-89116a53d7f5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_e5c615b6-8ba5-47d9-b1b5-886ac0ccf8f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_22b5ce6d-c6fd-445b-af4d-f11ad12eac45" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ae07c85-c6a5-4f1f-90c4-89116a53d7f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_22b5ce6d-c6fd-445b-af4d-f11ad12eac45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4ce15fad-654d-415f-89ca-edb95b1b8e93" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1ae07c85-c6a5-4f1f-90c4-89116a53d7f5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4ce15fad-654d-415f-89ca-edb95b1b8e93" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3997d9fd-5257-401f-aa55-bef9f85d11e5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_63589eb1-b74a-49f7-8eb1-608ffc5a620e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3997d9fd-5257-401f-aa55-bef9f85d11e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f8b46239-3c45-4b9b-9d65-e0d5a778767c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3997d9fd-5257-401f-aa55-bef9f85d11e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f8b46239-3c45-4b9b-9d65-e0d5a778767c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fbaca3bb-8482-4141-9732-f5784a9e0a18" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3997d9fd-5257-401f-aa55-bef9f85d11e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_fbaca3bb-8482-4141-9732-f5784a9e0a18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ee0e5530-2bd1-4953-a9d1-2da50df6988f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3997d9fd-5257-401f-aa55-bef9f85d11e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ee0e5530-2bd1-4953-a9d1-2da50df6988f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b934c05a-9740-4b17-a7be-910b9e2ad780" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3997d9fd-5257-401f-aa55-bef9f85d11e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_b934c05a-9740-4b17-a7be-910b9e2ad780" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b12c3d24-e35d-4984-b315-2d1022d65e67" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3997d9fd-5257-401f-aa55-bef9f85d11e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_b12c3d24-e35d-4984-b315-2d1022d65e67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20ef1908-960b-442b-9520-cacb804266f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_3997d9fd-5257-401f-aa55-bef9f85d11e5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_20ef1908-960b-442b-9520-cacb804266f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99d24976-3393-43ec-80c6-b92edd67c950" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_d731bf1f-f340-4253-8786-9510dcb69010" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_99d24976-3393-43ec-80c6-b92edd67c950" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_d731bf1f-f340-4253-8786-9510dcb69010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1e3ed78f-4984-4dd2-bc3c-3a34a8b06700" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_d731bf1f-f340-4253-8786-9510dcb69010" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1e3ed78f-4984-4dd2-bc3c-3a34a8b06700" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_dd24c06c-8193-4193-b207-9f9166de2267" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_1e3ed78f-4984-4dd2-bc3c-3a34a8b06700" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_dd24c06c-8193-4193-b207-9f9166de2267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeOneMember_cc4cc786-7ae6-4700-96de-e398120ba002" xlink:href="jnj-20230101.xsd#jnj_ExercisePriceRangeOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_dd24c06c-8193-4193-b207-9f9166de2267" xlink:to="loc_jnj_ExercisePriceRangeOneMember_cc4cc786-7ae6-4700-96de-e398120ba002" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeTwoMember_1cdfd2ca-fb7c-4197-9f07-7adc4b839c0d" xlink:href="jnj-20230101.xsd#jnj_ExercisePriceRangeTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_dd24c06c-8193-4193-b207-9f9166de2267" xlink:to="loc_jnj_ExercisePriceRangeTwoMember_1cdfd2ca-fb7c-4197-9f07-7adc4b839c0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeThreeMember_85a8fd4c-e718-43ec-9b3a-f1a23e54c904" xlink:href="jnj-20230101.xsd#jnj_ExercisePriceRangeThreeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_dd24c06c-8193-4193-b207-9f9166de2267" xlink:to="loc_jnj_ExercisePriceRangeThreeMember_85a8fd4c-e718-43ec-9b3a-f1a23e54c904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFourMember_b22632ab-c7d2-4153-a985-82e49ae0fb11" xlink:href="jnj-20230101.xsd#jnj_ExercisePriceRangeFourMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_dd24c06c-8193-4193-b207-9f9166de2267" xlink:to="loc_jnj_ExercisePriceRangeFourMember_b22632ab-c7d2-4153-a985-82e49ae0fb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExercisePriceRangeFiveMember_22d66dd5-3baa-4726-932d-bbb87b5b287b" xlink:href="jnj-20230101.xsd#jnj_ExercisePriceRangeFiveMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_dd24c06c-8193-4193-b207-9f9166de2267" xlink:to="loc_jnj_ExercisePriceRangeFiveMember_22d66dd5-3baa-4726-932d-bbb87b5b287b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_be72d516-4b2c-485f-9016-0e7e013c6f05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_d731bf1f-f340-4253-8786-9510dcb69010" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_be72d516-4b2c-485f-9016-0e7e013c6f05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_be72d516-4b2c-485f-9016-0e7e013c6f05" xlink:to="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_9fc199c2-4af7-41cc-a871-76aac837cead" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_9fc199c2-4af7-41cc-a871-76aac837cead" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_20b4843e-5ac0-4ff5-a491-80f6b66fb750" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_20b4843e-5ac0-4ff5-a491-80f6b66fb750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c5f90280-8df3-4943-9dca-e191a3cb89d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_c5f90280-8df3-4943-9dca-e191a3cb89d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_15576e39-76bc-4b1e-be89-633b4d638861" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_15576e39-76bc-4b1e-be89-633b4d638861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_da94d42d-17b2-4703-8a5b-935540cc15e1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1_da94d42d-17b2-4703-8a5b-935540cc15e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_abff9a6d-e7fe-460e-b06c-692ce3c744c4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:to="loc_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_abff9a6d-e7fe-460e-b06c-692ce3c744c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_8c65dcb4-2477-407b-91bc-7a6ab2bd6f34" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract_4eec64a3-7b04-4019-a93b-4a474eecf974" xlink:to="loc_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_8c65dcb4-2477-407b-91bc-7a6ab2bd6f34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da0e7264-a80d-4eb1-92bc-4cb8845fa5d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2133c436-9511-4a4b-b0af-d411603698c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_da0e7264-a80d-4eb1-92bc-4cb8845fa5d9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2133c436-9511-4a4b-b0af-d411603698c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_075cd106-1344-4f11-b43f-1f64b8a11f77" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2133c436-9511-4a4b-b0af-d411603698c0" xlink:to="loc_us-gaap_AwardTypeAxis_075cd106-1344-4f11-b43f-1f64b8a11f77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c136687d-1e51-4e7e-ac5a-62c4213e05bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_075cd106-1344-4f11-b43f-1f64b8a11f77" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c136687d-1e51-4e7e-ac5a-62c4213e05bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8065cd5f-d3ec-49c3-af44-e02d06d05398" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c136687d-1e51-4e7e-ac5a-62c4213e05bb" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8065cd5f-d3ec-49c3-af44-e02d06d05398" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_91a75989-fe78-404b-93ae-287e9b755c2d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_c136687d-1e51-4e7e-ac5a-62c4213e05bb" xlink:to="loc_us-gaap_PerformanceSharesMember_91a75989-fe78-404b-93ae-287e9b755c2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc4e0c83-5570-4520-8448-ffc09c6f66e7" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2133c436-9511-4a4b-b0af-d411603698c0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc4e0c83-5570-4520-8448-ffc09c6f66e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_110a498d-ad82-47cb-8b92-c6757e21cd2f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_cc4e0c83-5570-4520-8448-ffc09c6f66e7" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_110a498d-ad82-47cb-8b92-c6757e21cd2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_eb673aee-dbb5-41da-bb2f-171907215cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract_110a498d-ad82-47cb-8b92-c6757e21cd2f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_eb673aee-dbb5-41da-bb2f-171907215cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_15027bd0-bd12-4a91-bd44-56cff746aa28" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_eb673aee-dbb5-41da-bb2f-171907215cd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_15027bd0-bd12-4a91-bd44-56cff746aa28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_910117ed-d57d-4eb2-9b5b-896fa5028436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_eb673aee-dbb5-41da-bb2f-171907215cd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_910117ed-d57d-4eb2-9b5b-896fa5028436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_64ff2ce4-925a-497d-9f7b-753c2151d742" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_eb673aee-dbb5-41da-bb2f-171907215cd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_64ff2ce4-925a-497d-9f7b-753c2151d742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_1ff4a39a-0878-4c71-b337-c2a77f0c4d6e" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_eb673aee-dbb5-41da-bb2f-171907215cd2" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod_1ff4a39a-0878-4c71-b337-c2a77f0c4d6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c8d62c6a-adb7-4d7a-8e36-e9294f9af4e2" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward_eb673aee-dbb5-41da-bb2f-171907215cd2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_c8d62c6a-adb7-4d7a-8e36-e9294f9af4e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6bf0ead5-8c40-43f3-9670-258561449a3f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6bf0ead5-8c40-43f3-9670-258561449a3f" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2df5f751-73a8-4890-a6ea-7d63ff4d5049" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2df5f751-73a8-4890-a6ea-7d63ff4d5049" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc2ae324-1a68-4848-a2b0-60e581adb359" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2df5f751-73a8-4890-a6ea-7d63ff4d5049" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc2ae324-1a68-4848-a2b0-60e581adb359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_522a9ba1-70d4-4d32-9eba-5a2d2ea034ac" xlink:href="jnj-20230101.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_fc2ae324-1a68-4848-a2b0-60e581adb359" xlink:to="loc_jnj_AurisHealthMember_522a9ba1-70d4-4d32-9eba-5a2d2ea034ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_38d24875-a347-4e31-9cf1-0dfcbd017b19" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:to="loc_srt_StatementGeographicalAxis_38d24875-a347-4e31-9cf1-0dfcbd017b19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b0227ebd-c8ed-445e-9397-969d11386c4e" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_38d24875-a347-4e31-9cf1-0dfcbd017b19" xlink:to="loc_srt_SegmentGeographicalDomain_b0227ebd-c8ed-445e-9397-969d11386c4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_af760f8a-c0f1-4380-9e0c-51b35583bb51" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b0227ebd-c8ed-445e-9397-969d11386c4e" xlink:to="loc_country_US_af760f8a-c0f1-4380-9e0c-51b35583bb51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonUsMember_ad3ab2a0-7ad8-4cab-8863-71fee3f13422" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NonUsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b0227ebd-c8ed-445e-9397-969d11386c4e" xlink:to="loc_us-gaap_NonUsMember_ad3ab2a0-7ad8-4cab-8863-71fee3f13422" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UNITEDSTATESExportsMember_6c359b75-4535-4dff-bec6-e7e17a8c6cc4" xlink:href="jnj-20230101.xsd#jnj_UNITEDSTATESExportsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b0227ebd-c8ed-445e-9397-969d11386c4e" xlink:to="loc_jnj_UNITEDSTATESExportsMember_6c359b75-4535-4dff-bec6-e7e17a8c6cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_CN_f774ff9d-5188-4e44-b8b4-c503222295d3" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_CN"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_b0227ebd-c8ed-445e-9397-969d11386c4e" xlink:to="loc_country_CN_f774ff9d-5188-4e44-b8b4-c503222295d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0232b9ca-a64e-403d-a361-869887e3dbaf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:to="loc_srt_ProductOrServiceAxis_0232b9ca-a64e-403d-a361-869887e3dbaf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0232b9ca-a64e-403d-a361-869887e3dbaf" xlink:to="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTCMember_214f34bb-2c87-4598-9248-71568cebe4c4" xlink:href="jnj-20230101.xsd#jnj_OTCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_OTCMember_214f34bb-2c87-4598-9248-71568cebe4c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SkinHealthBeautyMember_f32f9723-5029-4740-a496-4cf77a3b288f" xlink:href="jnj-20230101.xsd#jnj_SkinHealthBeautyMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_SkinHealthBeautyMember_f32f9723-5029-4740-a496-4cf77a3b288f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OralCareMember_3e8c48a4-777b-4f3f-ad2d-fff1dcb70891" xlink:href="jnj-20230101.xsd#jnj_OralCareMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_OralCareMember_3e8c48a4-777b-4f3f-ad2d-fff1dcb70891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyCareMember_4896157e-1051-470e-83d8-9322954d3ecf" xlink:href="jnj-20230101.xsd#jnj_BabyCareMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_BabyCareMember_4896157e-1051-470e-83d8-9322954d3ecf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WomensHealthMember_f6fcc7a7-4fd7-4311-b65b-0f256fef1d01" xlink:href="jnj-20230101.xsd#jnj_WomensHealthMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_WomensHealthMember_f6fcc7a7-4fd7-4311-b65b-0f256fef1d01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WoundCareandOtherMember_24e418e4-f4c9-4927-877f-58cbd365faa5" xlink:href="jnj-20230101.xsd#jnj_WoundCareandOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_WoundCareandOtherMember_24e418e4-f4c9-4927-877f-58cbd365faa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RemicadeMember_d46dacde-45ef-4021-b9f5-65bd01c1181e" xlink:href="jnj-20230101.xsd#jnj_RemicadeMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_RemicadeMember_d46dacde-45ef-4021-b9f5-65bd01c1181e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SimponiSimponiAriaMember_a23c30c3-f883-407a-b7a8-3b2469d5bd10" xlink:href="jnj-20230101.xsd#jnj_SimponiSimponiAriaMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_SimponiSimponiAriaMember_a23c30c3-f883-407a-b7a8-3b2469d5bd10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_StelaraMember_546f08bc-1790-419e-85a2-c4ba61081981" xlink:href="jnj-20230101.xsd#jnj_StelaraMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_StelaraMember_546f08bc-1790-419e-85a2-c4ba61081981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TremfyaMember_674e274d-dbff-48d1-a01f-74d085a73458" xlink:href="jnj-20230101.xsd#jnj_TremfyaMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_TremfyaMember_674e274d-dbff-48d1-a01f-74d085a73458" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherImmunologyMember_f3236e6f-0d7c-4829-93f0-fa7472eadf16" xlink:href="jnj-20230101.xsd#jnj_OtherImmunologyMember"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_OtherImmunologyMember_f3236e6f-0d7c-4829-93f0-fa7472eadf16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_COVID19Member_e060c45a-ca34-4d1b-8ecb-a612f41e7d4c" xlink:href="jnj-20230101.xsd#jnj_COVID19Member"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_COVID19Member_e060c45a-ca34-4d1b-8ecb-a612f41e7d4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EDURANTrilpivirineMember_c76a6659-c0c9-4fa4-b2fb-b736c84244a8" xlink:href="jnj-20230101.xsd#jnj_EDURANTrilpivirineMember"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_EDURANTrilpivirineMember_c76a6659-c0c9-4fa4-b2fb-b736c84244a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_b25eba9b-db2c-4754-8c8f-b284f83ad7fd" xlink:href="jnj-20230101.xsd#jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember_b25eba9b-db2c-4754-8c8f-b284f83ad7fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherInfectiousDiseasesMember_0d68ee1d-f0a1-4d17-a6b7-3d9bb9932b09" xlink:href="jnj-20230101.xsd#jnj_OtherInfectiousDiseasesMember"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_OtherInfectiousDiseasesMember_0d68ee1d-f0a1-4d17-a6b7-3d9bb9932b09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONCERTAMethylphenidateMember_7c6d5167-8c72-47ea-9839-0484fbf11ff6" xlink:href="jnj-20230101.xsd#jnj_CONCERTAMethylphenidateMember"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_CONCERTAMethylphenidateMember_7c6d5167-8c72-47ea-9839-0484fbf11ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_b0b00b7e-9c6c-4ee3-a60d-3b71176538f4" xlink:href="jnj-20230101.xsd#jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember_b0b00b7e-9c6c-4ee3-a60d-3b71176538f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RISPERDALCONSTAMember_78c97495-3a6a-40e4-8c56-8affd2373c7d" xlink:href="jnj-20230101.xsd#jnj_RISPERDALCONSTAMember"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_RISPERDALCONSTAMember_78c97495-3a6a-40e4-8c56-8affd2373c7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OTHERNEUROSCIENCEMember_dff5df5a-da85-4d06-8b3a-5e27765fdd4b" xlink:href="jnj-20230101.xsd#jnj_OTHERNEUROSCIENCEMember"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_OTHERNEUROSCIENCEMember_dff5df5a-da85-4d06-8b3a-5e27765fdd4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DARZALEXMember_db124e4a-4a88-49ed-b7b4-7c8c7a611ffb" xlink:href="jnj-20230101.xsd#jnj_DARZALEXMember"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_DARZALEXMember_db124e4a-4a88-49ed-b7b4-7c8c7a611ffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ErleadaMember_79496b3b-be81-4d9a-a012-7fae91bf5a0b" xlink:href="jnj-20230101.xsd#jnj_ErleadaMember"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_ErleadaMember_79496b3b-be81-4d9a-a012-7fae91bf5a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IMBRUVICAMember_9536616a-ba8e-4323-bd54-aa6b0c62e918" xlink:href="jnj-20230101.xsd#jnj_IMBRUVICAMember"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_IMBRUVICAMember_9536616a-ba8e-4323-bd54-aa6b0c62e918" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ZYTIGAMember_52ed6fa1-0a29-4a40-bd29-f224271aca68" xlink:href="jnj-20230101.xsd#jnj_ZYTIGAMember"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_ZYTIGAMember_52ed6fa1-0a29-4a40-bd29-f224271aca68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherOncologyMember_98edd5f2-a5d7-402e-8d02-561e2d80cb46" xlink:href="jnj-20230101.xsd#jnj_OtherOncologyMember"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_OtherOncologyMember_98edd5f2-a5d7-402e-8d02-561e2d80cb46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OPSUMITMember_cb1b726e-aa2a-4496-9c47-38fe11e98a4d" xlink:href="jnj-20230101.xsd#jnj_OPSUMITMember"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_OPSUMITMember_cb1b726e-aa2a-4496-9c47-38fe11e98a4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_UPTRAVIMember_0010f04d-a3d7-4aa1-adcf-479cedee549e" xlink:href="jnj-20230101.xsd#jnj_UPTRAVIMember"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_UPTRAVIMember_0010f04d-a3d7-4aa1-adcf-479cedee549e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherMember_73bbe2f9-85a1-4936-b9c8-0c488d81db33" xlink:href="jnj-20230101.xsd#jnj_OtherMember"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_OtherMember_73bbe2f9-85a1-4936-b9c8-0c488d81db33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_XareltoMember_a2712902-95d2-44fd-99d7-a79639626e7c" xlink:href="jnj-20230101.xsd#jnj_XareltoMember"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_XareltoMember_a2712902-95d2-44fd-99d7-a79639626e7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_INVOKANAINVOKAMETMember_93ffcb97-6a92-4ffc-8941-f9d775aec5fd" xlink:href="jnj-20230101.xsd#jnj_INVOKANAINVOKAMETMember"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_INVOKANAINVOKAMETMember_93ffcb97-6a92-4ffc-8941-f9d775aec5fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_HIPSMember_6dc9820e-86ad-4a97-b4c0-5c0f4f4c6495" xlink:href="jnj-20230101.xsd#jnj_HIPSMember"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_HIPSMember_6dc9820e-86ad-4a97-b4c0-5c0f4f4c6495" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_KNEESMember_7ac11a0a-fa16-44b4-8f1d-658d226b5b90" xlink:href="jnj-20230101.xsd#jnj_KNEESMember"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_KNEESMember_7ac11a0a-fa16-44b4-8f1d-658d226b5b90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TRAUMAMember_6ff8d5d0-116c-4ca9-b35f-947304c660da" xlink:href="jnj-20230101.xsd#jnj_TRAUMAMember"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_TRAUMAMember_6ff8d5d0-116c-4ca9-b35f-947304c660da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SPINESPORTSOTHERMember_496cb117-3d3c-43f0-88bb-7cd8dac2a418" xlink:href="jnj-20230101.xsd#jnj_SPINESPORTSOTHERMember"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_SPINESPORTSOTHERMember_496cb117-3d3c-43f0-88bb-7cd8dac2a418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ADVANCEDMember_dc08e367-95ec-4012-91b6-4b07788ccc3a" xlink:href="jnj-20230101.xsd#jnj_ADVANCEDMember"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_ADVANCEDMember_dc08e367-95ec-4012-91b6-4b07788ccc3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GENERALMember_da1a01db-08b1-4e76-8778-14542fac3105" xlink:href="jnj-20230101.xsd#jnj_GENERALMember"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_GENERALMember_da1a01db-08b1-4e76-8778-14542fac3105" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONTACTLENSESOTHERMember_a028ec00-19bf-40d5-bede-f2cbf0371227" xlink:href="jnj-20230101.xsd#jnj_CONTACTLENSESOTHERMember"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_CONTACTLENSESOTHERMember_a028ec00-19bf-40d5-bede-f2cbf0371227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SURGICALMember_cef1bb3c-4476-4590-9b75-324952708862" xlink:href="jnj-20230101.xsd#jnj_SURGICALMember"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_dc8b9bcc-0d0c-440a-b81f-06efc731f76f" xlink:to="loc_jnj_SURGICALMember_cef1bb3c-4476-4590-9b75-324952708862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_e780fb6c-67da-4c28-88e0-ad9b0e092efc" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:to="loc_srt_ConsolidationItemsAxis_e780fb6c-67da-4c28-88e0-ad9b0e092efc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_c87f5ff9-ba39-4e20-8466-13cf1b990dc3" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_e780fb6c-67da-4c28-88e0-ad9b0e092efc" xlink:to="loc_srt_ConsolidationItemsDomain_c87f5ff9-ba39-4e20-8466-13cf1b990dc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_a0dd469c-d307-4c8f-8baa-5fe8a17be051" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_a0dd469c-d307-4c8f-8baa-5fe8a17be051" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_a59366cf-191b-4cd9-837d-0a416930bca1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_a0dd469c-d307-4c8f-8baa-5fe8a17be051" xlink:to="loc_us-gaap_SegmentDomain_a59366cf-191b-4cd9-837d-0a416930bca1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_7517bae9-bfae-4e91-a9a2-88584dd853e6" xlink:href="jnj-20230101.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a59366cf-191b-4cd9-837d-0a416930bca1" xlink:to="loc_jnj_ConsumerMember_7517bae9-bfae-4e91-a9a2-88584dd853e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_03cfa8cf-57d7-4e07-b92d-ee7f403f8716" xlink:href="jnj-20230101.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a59366cf-191b-4cd9-837d-0a416930bca1" xlink:to="loc_jnj_PharmaceuticalMember_03cfa8cf-57d7-4e07-b92d-ee7f403f8716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_f4554c81-2382-4bfa-8a7e-a04309ab72a8" xlink:href="jnj-20230101.xsd#jnj_MedTechMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a59366cf-191b-4cd9-837d-0a416930bca1" xlink:to="loc_jnj_MedTechMember_f4554c81-2382-4bfa-8a7e-a04309ab72a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_6d767617-ee5e-466a-a36c-676bef0b31bd" xlink:href="jnj-20230101.xsd#jnj_CONSUMERHEALTHAndPHARMACEUTICALMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_a59366cf-191b-4cd9-837d-0a416930bca1" xlink:to="loc_jnj_CONSUMERHEALTHAndPHARMACEUTICALMember_6d767617-ee5e-466a-a36c-676bef0b31bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_c0831582-0c4c-468b-a655-b9181225daae" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:to="loc_us-gaap_SubsegmentsAxis_c0831582-0c4c-468b-a655-b9181225daae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_c0831582-0c4c-468b-a655-b9181225daae" xlink:to="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_705d4ad7-68fa-4fb7-8489-763caa50d5a9" xlink:href="jnj-20230101.xsd#jnj_ImmunologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_ImmunologyMember_705d4ad7-68fa-4fb7-8489-763caa50d5a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InfectiousDiseasesMember_22970320-431c-4c51-8fd0-1cf016a2e28a" xlink:href="jnj-20230101.xsd#jnj_InfectiousDiseasesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_InfectiousDiseasesMember_22970320-431c-4c51-8fd0-1cf016a2e28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NeuroscienceMember_100903c6-a25f-4663-b60c-c3ba86a2f51c" xlink:href="jnj-20230101.xsd#jnj_NeuroscienceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_NeuroscienceMember_100903c6-a25f-4663-b60c-c3ba86a2f51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OncologyMember_356494d4-c82a-409c-a795-5b525b87e412" xlink:href="jnj-20230101.xsd#jnj_OncologyMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_OncologyMember_356494d4-c82a-409c-a795-5b525b87e412" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PulmonaryHypertensionMember_5a271c4b-2415-43f8-baa0-0fcd5c0ec56e" xlink:href="jnj-20230101.xsd#jnj_PulmonaryHypertensionMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_PulmonaryHypertensionMember_5a271c4b-2415-43f8-baa0-0fcd5c0ec56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_CardiovascularMetabolismOtherMember_cfc8de4a-77c7-4880-a760-092bfa60841a" xlink:href="jnj-20230101.xsd#jnj_CardiovascularMetabolismOtherMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_CardiovascularMetabolismOtherMember_cfc8de4a-77c7-4880-a760-092bfa60841a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_InterventionalSolutionsMember_8732ff32-3efc-45f5-8ae7-795d3a4c9d0d" xlink:href="jnj-20230101.xsd#jnj_InterventionalSolutionsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_InterventionalSolutionsMember_8732ff32-3efc-45f5-8ae7-795d3a4c9d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OrthopaedicsMember_2e4e2859-7d31-40e1-beb8-885d9494e6e9" xlink:href="jnj-20230101.xsd#jnj_OrthopaedicsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_OrthopaedicsMember_2e4e2859-7d31-40e1-beb8-885d9494e6e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgeryMember_e2e0797e-27ac-46fd-8a38-537cb7b0748f" xlink:href="jnj-20230101.xsd#jnj_SurgeryMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_SurgeryMember_e2e0797e-27ac-46fd-8a38-537cb7b0748f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VisionMember_cd8aeb84-ac19-4b48-ab97-a3f33ed7eb81" xlink:href="jnj-20230101.xsd#jnj_VisionMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_5d6117b2-4556-4112-bdd0-32c9b3c86aad" xlink:to="loc_jnj_VisionMember_cd8aeb84-ac19-4b48-ab97-a3f33ed7eb81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_d86a8ef5-d973-43b2-80e4-5e87be6bbbf6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0699ec3e-23f2-499c-8a04-d305a1de7e79" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_d86a8ef5-d973-43b2-80e4-5e87be6bbbf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a195b86-105a-4005-b34b-8148a4521834" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d86a8ef5-d973-43b2-80e4-5e87be6bbbf6" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_3a195b86-105a-4005-b34b-8148a4521834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_3e836788-b229-4a9c-a6f1-41855e62159d" xlink:href="jnj-20230101.xsd#jnj_PercentageChangeInSalesBySegmentOfBusiness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_d86a8ef5-d973-43b2-80e4-5e87be6bbbf6" xlink:to="loc_jnj_PercentageChangeInSalesBySegmentOfBusiness_3e836788-b229-4a9c-a6f1-41855e62159d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ebfd7e2b-604f-4ec5-a975-f4ab686ad832" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ebfd7e2b-604f-4ec5-a975-f4ab686ad832" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsAxis_e802a13b-7e7e-4300-8812-123e6928b9ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_SubsegmentsAxis_e802a13b-7e7e-4300-8812-123e6928b9ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsegmentsDomain_6ffc3b7c-9667-4541-91c4-54302364a00e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsegmentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_e802a13b-7e7e-4300-8812-123e6928b9ad" xlink:to="loc_us-gaap_SubsegmentsDomain_6ffc3b7c-9667-4541-91c4-54302364a00e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImmunologyMember_fa059485-52cf-4c13-b840-9bd5300a1acd" xlink:href="jnj-20230101.xsd#jnj_ImmunologyMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_6ffc3b7c-9667-4541-91c4-54302364a00e" xlink:to="loc_jnj_ImmunologyMember_fa059485-52cf-4c13-b840-9bd5300a1acd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsAxis_d9f838e5-0099-4f2f-bcb5-c3145c71af8b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_srt_ConsolidationItemsAxis_d9f838e5-0099-4f2f-bcb5-c3145c71af8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ConsolidationItemsDomain_b04c5d07-f40c-4023-8f41-88f0fb0e6c16" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ConsolidationItemsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_d9f838e5-0099-4f2f-bcb5-c3145c71af8b" xlink:to="loc_srt_ConsolidationItemsDomain_b04c5d07-f40c-4023-8f41-88f0fb0e6c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateNonSegmentMember_74935910-a41c-4492-8e00-d60eb8f22d8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateNonSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_b04c5d07-f40c-4023-8f41-88f0fb0e6c16" xlink:to="loc_us-gaap_CorporateNonSegmentMember_74935910-a41c-4492-8e00-d60eb8f22d8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingSegmentsMember_2d117469-1373-405e-aaf8-afe1e97ae11c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingSegmentsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_b04c5d07-f40c-4023-8f41-88f0fb0e6c16" xlink:to="loc_us-gaap_OperatingSegmentsMember_2d117469-1373-405e-aaf8-afe1e97ae11c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8127abc2-fff1-461d-8eab-e9047fc687da" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8127abc2-fff1-461d-8eab-e9047fc687da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_36ceea9b-0b08-41c7-88e0-a2cb4f783416" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8127abc2-fff1-461d-8eab-e9047fc687da" xlink:to="loc_us-gaap_SegmentDomain_36ceea9b-0b08-41c7-88e0-a2cb4f783416" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GeneralCorporateMember_4da0e986-36a3-4aac-a125-cd89168391a9" xlink:href="jnj-20230101.xsd#jnj_GeneralCorporateMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_36ceea9b-0b08-41c7-88e0-a2cb4f783416" xlink:to="loc_jnj_GeneralCorporateMember_4da0e986-36a3-4aac-a125-cd89168391a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerMember_ad613a21-e44d-458a-8b8a-079d09b03d27" xlink:href="jnj-20230101.xsd#jnj_ConsumerMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_36ceea9b-0b08-41c7-88e0-a2cb4f783416" xlink:to="loc_jnj_ConsumerMember_ad613a21-e44d-458a-8b8a-079d09b03d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PharmaceuticalMember_1d187781-b323-461a-8b38-485cfebd9ce3" xlink:href="jnj-20230101.xsd#jnj_PharmaceuticalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_36ceea9b-0b08-41c7-88e0-a2cb4f783416" xlink:to="loc_jnj_PharmaceuticalMember_1d187781-b323-461a-8b38-485cfebd9ce3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MedTechMember_f3602a31-3f72-492b-a2a0-5d1302377dc1" xlink:href="jnj-20230101.xsd#jnj_MedTechMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_36ceea9b-0b08-41c7-88e0-a2cb4f783416" xlink:to="loc_jnj_MedTechMember_f3602a31-3f72-492b-a2a0-5d1302377dc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SegmentsTotalMember_eaf64d3f-e26e-4233-8119-bf2bcd0daf39" xlink:href="jnj-20230101.xsd#jnj_SegmentsTotalMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_36ceea9b-0b08-41c7-88e0-a2cb4f783416" xlink:to="loc_jnj_SegmentsTotalMember_eaf64d3f-e26e-4233-8119-bf2bcd0daf39" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerHealthMember_c6144439-d8ce-4a02-ac0d-201aa75aad10" xlink:href="jnj-20230101.xsd#jnj_ConsumerHealthMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_36ceea9b-0b08-41c7-88e0-a2cb4f783416" xlink:to="loc_jnj_ConsumerHealthMember_c6144439-d8ce-4a02-ac0d-201aa75aad10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_3df16a30-257a-44b9-a755-d5ce9c3d950b" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_srt_StatementGeographicalAxis_3df16a30-257a-44b9-a755-d5ce9c3d950b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_954b5720-7f3c-441d-9234-db81de5ac32c" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_3df16a30-257a-44b9-a755-d5ce9c3d950b" xlink:to="loc_srt_SegmentGeographicalDomain_954b5720-7f3c-441d-9234-db81de5ac32c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7c43068f-80a1-43d0-a704-f7ab55b796d4" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_954b5720-7f3c-441d-9234-db81de5ac32c" xlink:to="loc_country_US_7c43068f-80a1-43d0-a704-f7ab55b796d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_883d0321-4ed0-40c0-a13e-3d8685186894" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_954b5720-7f3c-441d-9234-db81de5ac32c" xlink:to="loc_srt_EuropeMember_883d0321-4ed0-40c0-a13e-3d8685186894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WesternHemisphereExcludingUSMember_d4ee9d8d-b249-48e2-96ee-934e59dd0b18" xlink:href="jnj-20230101.xsd#jnj_WesternHemisphereExcludingUSMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_954b5720-7f3c-441d-9234-db81de5ac32c" xlink:to="loc_jnj_WesternHemisphereExcludingUSMember_d4ee9d8d-b249-48e2-96ee-934e59dd0b18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsiaPacificAfricaMember_f14c9613-09b1-443c-a2a5-5b8b3b7113aa" xlink:href="jnj-20230101.xsd#jnj_AsiaPacificAfricaMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_954b5720-7f3c-441d-9234-db81de5ac32c" xlink:to="loc_jnj_AsiaPacificAfricaMember_f14c9613-09b1-443c-a2a5-5b8b3b7113aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_cae81cbe-df20-4998-aaac-e0cd92bf007a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_srt_MajorCustomersAxis_cae81cbe-df20-4998-aaac-e0cd92bf007a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_e8146009-4087-4fc8-82a1-6243e4671566" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_cae81cbe-df20-4998-aaac-e0cd92bf007a" xlink:to="loc_srt_NameOfMajorCustomerDomain_e8146009-4087-4fc8-82a1-6243e4671566" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler1Member_e7bc6e37-a2ce-42c1-b223-4041e80680ab" xlink:href="jnj-20230101.xsd#jnj_Wholesaler1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8146009-4087-4fc8-82a1-6243e4671566" xlink:to="loc_jnj_Wholesaler1Member_e7bc6e37-a2ce-42c1-b223-4041e80680ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler2Member_507e1ae7-6257-428a-bc28-24b1f39d0470" xlink:href="jnj-20230101.xsd#jnj_Wholesaler2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8146009-4087-4fc8-82a1-6243e4671566" xlink:to="loc_jnj_Wholesaler2Member_507e1ae7-6257-428a-bc28-24b1f39d0470" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Wholesaler3Member_87195715-2c95-469e-bc12-0365816f3be4" xlink:href="jnj-20230101.xsd#jnj_Wholesaler3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_e8146009-4087-4fc8-82a1-6243e4671566" xlink:to="loc_jnj_Wholesaler3Member_87195715-2c95-469e-bc12-0365816f3be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0982be30-bc5f-4ecd-95d7-3b647fb662f6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0982be30-bc5f-4ecd-95d7-3b647fb662f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca8e3f82-44a6-4e69-a806-ca3f47fcfbed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_0982be30-bc5f-4ecd-95d7-3b647fb662f6" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca8e3f82-44a6-4e69-a806-ca3f47fcfbed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_4177e4b1-6752-4bd6-8534-f29f0fe12436" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ca8e3f82-44a6-4e69-a806-ca3f47fcfbed" xlink:to="loc_us-gaap_SalesRevenueNetMember_4177e4b1-6752-4bd6-8534-f29f0fe12436" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_f4b814b5-c018-4da6-8a48-44bbf3ca6dc0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_f4b814b5-c018-4da6-8a48-44bbf3ca6dc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e946d1fa-2556-411a-b40d-97b59fe6ab03" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_f4b814b5-c018-4da6-8a48-44bbf3ca6dc0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e946d1fa-2556-411a-b40d-97b59fe6ab03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AurisHealthMember_2e8b5cb5-25b2-4880-85a5-adcf03d9a010" xlink:href="jnj-20230101.xsd#jnj_AurisHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e946d1fa-2556-411a-b40d-97b59fe6ab03" xlink:to="loc_jnj_AurisHealthMember_2e8b5cb5-25b2-4880-85a5-adcf03d9a010" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_c347eeaf-48df-411a-8900-750c5a602b4c" xlink:href="jnj-20230101.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_e946d1fa-2556-411a-b40d-97b59fe6ab03" xlink:to="loc_jnj_BermekimabMember_c347eeaf-48df-411a-8900-750c5a602b4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_e8391998-c4bb-406e-aded-d5642eaa7ee6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_e8391998-c4bb-406e-aded-d5642eaa7ee6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_d204b2b1-363f-40de-9ae7-bdc6ace1a744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_e8391998-c4bb-406e-aded-d5642eaa7ee6" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_d204b2b1-363f-40de-9ae7-bdc6ace1a744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIncomeMember_468f03d8-7f35-424e-8a43-77cb55e34b3c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_d204b2b1-363f-40de-9ae7-bdc6ace1a744" xlink:to="loc_us-gaap_OtherIncomeMember_468f03d8-7f35-424e-8a43-77cb55e34b3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4a43417-2988-41a0-b728-4688778e4b36" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4a43417-2988-41a0-b728-4688778e4b36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_611097a4-85da-4345-af56-1c345fb55057" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4a43417-2988-41a0-b728-4688778e4b36" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_611097a4-85da-4345-af56-1c345fb55057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_553aece3-283f-43ce-a9ab-6cb4fa2679b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_611097a4-85da-4345-af56-1c345fb55057" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_553aece3-283f-43ce-a9ab-6cb4fa2679b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherIntangibleAssetsMember_55cf1193-9c6f-4275-8228-6c670d98dbbf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherIntangibleAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_611097a4-85da-4345-af56-1c345fb55057" xlink:to="loc_us-gaap_OtherIntangibleAssetsMember_55cf1193-9c6f-4275-8228-6c670d98dbbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_95237b8a-f260-48d1-9a69-57019329f21e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_95237b8a-f260-48d1-9a69-57019329f21e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1d6c7118-1699-4b2a-967f-9c18459f8d2b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_95237b8a-f260-48d1-9a69-57019329f21e" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1d6c7118-1699-4b2a-967f-9c18459f8d2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConsumerHealthMember_8a7ce98e-90ac-48e8-b805-f07c4dd01bfa" xlink:href="jnj-20230101.xsd#jnj_ConsumerHealthMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_1d6c7118-1699-4b2a-967f-9c18459f8d2b" xlink:to="loc_jnj_ConsumerHealthMember_8a7ce98e-90ac-48e8-b805-f07c4dd01bfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_2858d4c7-6e25-43b1-8665-160cd7bb045b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_2858d4c7-6e25-43b1-8665-160cd7bb045b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_e96f715e-5fad-49d7-897e-46fc6723bd20" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_2858d4c7-6e25-43b1-8665-160cd7bb045b" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_e96f715e-5fad-49d7-897e-46fc6723bd20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_WholesalerConcentrationRiskMember_a09787a5-52ef-439b-97a0-ce80af68c38c" xlink:href="jnj-20230101.xsd#jnj_WholesalerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_e96f715e-5fad-49d7-897e-46fc6723bd20" xlink:to="loc_jnj_WholesalerConcentrationRiskMember_a09787a5-52ef-439b-97a0-ce80af68c38c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ff0cd47c-3256-43e4-885a-f335cc08489f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ff0cd47c-3256-43e4-885a-f335cc08489f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40c0fe78-8a17-4a33-8e1a-9a164eb4913a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_ff0cd47c-3256-43e4-885a-f335cc08489f" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40c0fe78-8a17-4a33-8e1a-9a164eb4913a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_2bf36dbf-d2bf-4b82-9ddd-14fe1342007e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_40c0fe78-8a17-4a33-8e1a-9a164eb4913a" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_2bf36dbf-d2bf-4b82-9ddd-14fe1342007e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_bd4bf543-1bd3-43a8-84d8-616b8d1f4f5f" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_346b48f0-81c7-4b92-876a-972d44be40fb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_346b48f0-81c7-4b92-876a-972d44be40fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ExpenseNotAllocatedToSegments_e166291d-3a55-462c-9816-4355349aa397" xlink:href="jnj-20230101.xsd#jnj_ExpenseNotAllocatedToSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_jnj_ExpenseNotAllocatedToSegments_e166291d-3a55-462c-9816-4355349aa397" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_856a075f-013f-41f0-b0fb-1f0f7e230dfa" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_Assets_856a075f-013f-41f0-b0fb-1f0f7e230dfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes_8768330b-2aee-4276-8046-e5d3389557e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes_8768330b-2aee-4276-8046-e5d3389557e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAdditions_fceb0ed2-8021-42dd-b2f8-f5e613264d90" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAdditions"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentAdditions_fceb0ed2-8021-42dd-b2f8-f5e613264d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_971ad391-3283-4eb7-a0f7-459796370ea6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_971ad391-3283-4eb7-a0f7-459796370ea6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4221784c-81c6-4c1f-aca4-9a74e83a7610" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4221784c-81c6-4c1f-aca4-9a74e83a7610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_03e7ee68-e1a4-438c-849e-801db78cf563" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_NoncurrentAssets_03e7ee68-e1a4-438c-849e-801db78cf563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherNonLongLivedAssets_4cce7ae2-c3b9-4f1e-a496-1605d6775d89" xlink:href="jnj-20230101.xsd#jnj_OtherNonLongLivedAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_jnj_OtherNonLongLivedAssets_4cce7ae2-c3b9-4f1e-a496-1605d6775d89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_4e96df6b-8724-48f8-8088-e0899408b7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_4e96df6b-8724-48f8-8088-e0899408b7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_d25371fe-2f55-41ba-a347-1e138b2ae35f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_NumberOfOperatingSegments_d25371fe-2f55-41ba-a347-1e138b2ae35f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationSettlementExpense_261c4bf4-471f-44e7-9e96-e2c0ff41ff4c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_LitigationSettlementExpense_261c4bf4-471f-44e7-9e96-e2c0ff41ff4c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_fe8509b6-b631-452b-b981-dfb891e4dade" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_RestructuringCharges_fe8509b6-b631-452b-b981-dfb891e4dade" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfBusiness_3dd3ff05-1320-45f8-9dba-9cdf16b42744" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfBusiness"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_GainLossOnSaleOfBusiness_3dd3ff05-1320-45f8-9dba-9cdf16b42744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_01f60312-bb7b-4c76-8392-b7f8d6b2be46" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesRealizedGainLoss"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_MarketableSecuritiesRealizedGainLoss_01f60312-bb7b-4c76-8392-b7f8d6b2be46" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_ddfe10c8-7382-4edf-a871-46dda8192e53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_ddfe10c8-7382-4edf-a871-46dda8192e53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RegulationCharge_bbbe1843-0ed8-47ab-8188-cb2a233c42d1" xlink:href="jnj-20230101.xsd#jnj_RegulationCharge"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_jnj_RegulationCharge_bbbe1843-0ed8-47ab-8188-cb2a233c42d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_cb719da8-70bf-41ff-ae23-87ef8fe4fcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLoss"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLoss_cb719da8-70bf-41ff-ae23-87ef8fe4fcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9eb74955-0dc6-46ca-9915-b50c436451df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_9eb74955-0dc6-46ca-9915-b50c436451df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_22276695-1814-4f26-9c1e-48cffb9dc679" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_22276695-1814-4f26-9c1e-48cffb9dc679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SuppliesExpense_470502e4-84d8-4fe6-9f15-da51c9e59938" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SuppliesExpense"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_SuppliesExpense_470502e4-84d8-4fe6-9f15-da51c9e59938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AcquisitionCosts_f362cd9a-418d-4d03-93c7-f459ea5a96ed" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AcquisitionCosts"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_4350cdcd-597c-4629-98df-1a13d105b959" xlink:to="loc_us-gaap_AcquisitionCosts_f362cd9a-418d-4d03-93c7-f459ea5a96ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#AcquisitionsandDivestituresNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f623cb26-c214-4e55-be2b-ddc78219343c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAndAssetAcquisitionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract_f623cb26-c214-4e55-be2b-ddc78219343c" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a4acad78-f486-4ced-bfa7-e223252d870f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a4acad78-f486-4ced-bfa7-e223252d870f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_671020f9-04b1-4057-9cc6-63366f142df9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_a4acad78-f486-4ced-bfa7-e223252d870f" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_671020f9-04b1-4057-9cc6-63366f142df9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_EvraAndDoxilMember_36ca6b91-6e13-4e61-937f-914466dcc13c" xlink:href="jnj-20230101.xsd#jnj_EvraAndDoxilMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_671020f9-04b1-4057-9cc6-63366f142df9" xlink:to="loc_jnj_EvraAndDoxilMember_36ca6b91-6e13-4e61-937f-914466dcc13c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_5ec027b3-08ee-43be-a2ff-6add3d60cc8a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_5ec027b3-08ee-43be-a2ff-6add3d60cc8a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_e22cbb4e-8800-4fa1-8cf6-efcaadd04c09" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_5ec027b3-08ee-43be-a2ff-6add3d60cc8a" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_e22cbb4e-8800-4fa1-8cf6-efcaadd04c09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConvertibleDebtMember_8536a024-cb9d-4368-9748-c940ac200958" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConvertibleDebtMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_e22cbb4e-8800-4fa1-8cf6-efcaadd04c09" xlink:to="loc_us-gaap_ConvertibleDebtMember_8536a024-cb9d-4368-9748-c940ac200958" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_7d01e691-4373-4bf5-8ef3-4ae11455a877" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:to="loc_srt_RangeAxis_7d01e691-4373-4bf5-8ef3-4ae11455a877" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_7afb1f0f-87c4-482c-8a31-145ed3fe5aae" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7d01e691-4373-4bf5-8ef3-4ae11455a877" xlink:to="loc_srt_RangeMember_7afb1f0f-87c4-482c-8a31-145ed3fe5aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_7b51f41b-169b-405c-9883-238ac0edf3f5" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7afb1f0f-87c4-482c-8a31-145ed3fe5aae" xlink:to="loc_srt_MaximumMember_7b51f41b-169b-405c-9883-238ac0edf3f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_a4e525ee-d204-4dca-86f5-8c334e36d0c4" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_7afb1f0f-87c4-482c-8a31-145ed3fe5aae" xlink:to="loc_srt_MinimumMember_a4e525ee-d204-4dca-86f5-8c334e36d0c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_88f6d291-6fb7-419c-b9f1-ad823f732284" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_88f6d291-6fb7-419c-b9f1-ad823f732284" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2719f4e4-bf8e-452b-9813-347c4a67891f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_88f6d291-6fb7-419c-b9f1-ad823f732284" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2719f4e4-bf8e-452b-9813-347c4a67891f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_IdorsiaMember_a1fe0ec4-75fc-4cc9-91e1-d0961f0ae56d" xlink:href="jnj-20230101.xsd#jnj_IdorsiaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2719f4e4-bf8e-452b-9813-347c4a67891f" xlink:to="loc_jnj_IdorsiaMember_a1fe0ec4-75fc-4cc9-91e1-d0961f0ae56d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_MomentaMember_436faffa-a3d4-48e2-b2de-db9d6dee2785" xlink:href="jnj-20230101.xsd#jnj_MomentaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2719f4e4-bf8e-452b-9813-347c4a67891f" xlink:to="loc_jnj_MomentaMember_436faffa-a3d4-48e2-b2de-db9d6dee2785" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_A2020AcquisitionsMember_00f7e64e-11ea-485e-93a9-8e1b5f6e2d6a" xlink:href="jnj-20230101.xsd#jnj_A2020AcquisitionsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2719f4e4-bf8e-452b-9813-347c4a67891f" xlink:to="loc_jnj_A2020AcquisitionsMember_00f7e64e-11ea-485e-93a9-8e1b5f6e2d6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BermekimabMember_67ab77ea-e178-4da1-a7a7-8b191c2308d6" xlink:href="jnj-20230101.xsd#jnj_BermekimabMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2719f4e4-bf8e-452b-9813-347c4a67891f" xlink:to="loc_jnj_BermekimabMember_67ab77ea-e178-4da1-a7a7-8b191c2308d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_VerbSurgicalIncMember_6483c453-040b-40fb-9265-ea64c10699d6" xlink:href="jnj-20230101.xsd#jnj_VerbSurgicalIncMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2719f4e4-bf8e-452b-9813-347c4a67891f" xlink:to="loc_jnj_VerbSurgicalIncMember_6483c453-040b-40fb-9265-ea64c10699d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AbiomedMember_ac943bea-3f3f-4718-b75a-8e7d4e396b23" xlink:href="jnj-20230101.xsd#jnj_AbiomedMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_2719f4e4-bf8e-452b-9813-347c4a67891f" xlink:to="loc_jnj_AbiomedMember_ac943bea-3f3f-4718-b75a-8e7d4e396b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f69bf16c-5521-45ad-af63-b696f3017313" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f69bf16c-5521-45ad-af63-b696f3017313" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54b8e481-f660-4f64-bf46-cdc5ed2e5c11" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_f69bf16c-5521-45ad-af63-b696f3017313" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54b8e481-f660-4f64-bf46-cdc5ed2e5c11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_28fb66ec-e924-4295-9bc6-67e259203a40" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54b8e481-f660-4f64-bf46-cdc5ed2e5c11" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_28fb66ec-e924-4295-9bc6-67e259203a40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_fc07c793-1019-48f6-8b5d-4dc0fa9775b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:to="loc_us-gaap_AwardTypeAxis_fc07c793-1019-48f6-8b5d-4dc0fa9775b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7741fb02-c80d-4643-8bfc-c87600bc56d9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_fc07c793-1019-48f6-8b5d-4dc0fa9775b0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7741fb02-c80d-4643-8bfc-c87600bc56d9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_NonTradeableContingentValueRightMember_43971272-33f0-41b0-a2d9-589f0e7b039a" xlink:href="jnj-20230101.xsd#jnj_NonTradeableContingentValueRightMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7741fb02-c80d-4643-8bfc-c87600bc56d9" xlink:to="loc_jnj_NonTradeableContingentValueRightMember_43971272-33f0-41b0-a2d9-589f0e7b039a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_97aebeb3-4d5c-4774-b463-d0ac6aae1ba9" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:to="loc_srt_ProductOrServiceAxis_97aebeb3-4d5c-4774-b463-d0ac6aae1ba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_315fe530-1a0a-4b1a-8049-325e34a316cf" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_97aebeb3-4d5c-4774-b463-d0ac6aae1ba9" xlink:to="loc_srt_ProductsAndServicesDomain_315fe530-1a0a-4b1a-8049-325e34a316cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ImpellaMember_9f3c1277-d085-4ac6-a2de-a596a4cdf810" xlink:href="jnj-20230101.xsd#jnj_ImpellaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_315fe530-1a0a-4b1a-8049-325e34a316cf" xlink:to="loc_jnj_ImpellaMember_9f3c1277-d085-4ac6-a2de-a596a4cdf810" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ClassIRecommendationForImpellaMember_cf22d9dd-bcc9-4972-ba80-d7ca010a5f20" xlink:href="jnj-20230101.xsd#jnj_ClassIRecommendationForImpellaMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_315fe530-1a0a-4b1a-8049-325e34a316cf" xlink:to="loc_jnj_ClassIRecommendationForImpellaMember_cf22d9dd-bcc9-4972-ba80-d7ca010a5f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionLineItems"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_69af1dd7-7a4e-44b1-b330-72962dd4fc2e" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d6473a96-326e-4816-bf31-16e950eef2de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_d6473a96-326e-4816-bf31-16e950eef2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_65a40597-898d-4932-94dd-2477ce72603e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities_65a40597-898d-4932-94dd-2477ce72603e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_23e7fd02-6b6e-468a-8eee-7da3260138df" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IntangibleAssetsNetIncludingGoodwill"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_IntangibleAssetsNetIncludingGoodwill_23e7fd02-6b6e-468a-8eee-7da3260138df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_460755f7-b795-4f54-b73d-7e58c4b84d7e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_460755f7-b795-4f54-b73d-7e58c4b84d7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_8dea54ba-6e23-46db-8c14-e867a06499d0" xlink:href="jnj-20230101.xsd#jnj_BusinessCombinationProbabilityOfSuccessFactor"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_jnj_BusinessCombinationProbabilityOfSuccessFactor_8dea54ba-6e23-46db-8c14-e867a06499d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessAcquisitionDiscountRate_49c411e6-8b8f-4dfb-8e11-52bce6f8739a" xlink:href="jnj-20230101.xsd#jnj_BusinessAcquisitionDiscountRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_jnj_BusinessAcquisitionDiscountRate_49c411e6-8b8f-4dfb-8e11-52bce6f8739a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_455d2f1f-ee5c-4e08-802b-ac9daf27904e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_Goodwill_455d2f1f-ee5c-4e08-802b-ac9daf27904e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a22398fe-f9a5-444c-9974-a4224d546fa1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets_a22398fe-f9a5-444c-9974-a4224d546fa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_2249d130-ed7a-42ca-bac8-a2315bb1bebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_2249d130-ed7a-42ca-bac8-a2315bb1bebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_49bc09bc-90bd-49fe-a23c-35b1fe1d3007" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities_49bc09bc-90bd-49fe-a23c-35b1fe1d3007" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_dc089da9-89a5-4272-bcd2-d7384774f1ca" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_dc089da9-89a5-4272-bcd2-d7384774f1ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_357f9e85-a383-4587-b8ab-31634ee863e3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_357f9e85-a383-4587-b8ab-31634ee863e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_f73178da-b983-4ffb-9be7-4dd1fa544cba" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction_f73178da-b983-4ffb-9be7-4dd1fa544cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_3123e5cb-bff5-4d94-a701-f68b948eb35d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleOfInterestInCorporateUnit"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit_3123e5cb-bff5-4d94-a701-f68b948eb35d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_bae7cd20-01bf-4615-b5f6-9046d7a6471e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_bae7cd20-01bf-4615-b5f6-9046d7a6471e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares_f22f1656-92bf-4b27-9d67-260df90a5a8c" xlink:href="jnj-20230101.xsd#jnj_ConvertibleNoteEquityInterestNumberOfShares"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_jnj_ConvertibleNoteEquityInterestNumberOfShares_f22f1656-92bf-4b27-9d67-260df90a5a8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_654404e2-0e9b-4c41-a130-cf39ad278226" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_LongTermDebt_654404e2-0e9b-4c41-a130-cf39ad278226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DebtInstrumentConvertibleAmountOfLoanConverted_2d6dad7b-1fcd-4ffd-aff7-d83394ce74fa" xlink:href="jnj-20230101.xsd#jnj_DebtInstrumentConvertibleAmountOfLoanConverted"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_jnj_DebtInstrumentConvertibleAmountOfLoanConverted_2d6dad7b-1fcd-4ffd-aff7-d83394ce74fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_38532a72-e800-4b9c-ac31-e07cbba5ae0b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments_38532a72-e800-4b9c-ac31-e07cbba5ae0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_3b2310bd-9265-4427-a6b0-baa5ed859cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_AssetImpairmentCharges_3b2310bd-9265-4427-a6b0-baa5ed859cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_ec9cdbd5-12ae-4c7b-a01f-65619585caa5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireBusinessesGross"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_ec9cdbd5-12ae-4c7b-a01f-65619585caa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b039e380-1faa-4fb2-969e-9b9e2d1020b0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities_b039e380-1faa-4fb2-969e-9b9e2d1020b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_d7d80e1e-4e20-4ebf-abbb-b31aac11104c" xlink:href="jnj-20230101.xsd#jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets_d7d80e1e-4e20-4ebf-abbb-b31aac11104c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_29fc984c-447a-4ee2-bc41-989b0b431665" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessAcquisitionSharePrice"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_29fc984c-447a-4ee2-bc41-989b0b431665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a901492a-4661-41b4-8b42-1081f2e060d4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_a901492a-4661-41b4-8b42-1081f2e060d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6b9c3e48-f075-4348-96ed-cdd24de999a1" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_6b9c3e48-f075-4348-96ed-cdd24de999a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_270bb43e-248a-4693-94bc-086159856205" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_270bb43e-248a-4693-94bc-086159856205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_155f454a-3c01-47d8-baa8-5dc4a9f36360" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight_155f454a-3c01-47d8-baa8-5dc4a9f36360" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_e84dba83-c9a5-4880-8d32-84a41115972e" xlink:href="jnj-20230101.xsd#jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight_e84dba83-c9a5-4880-8d32-84a41115972e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DividendsPayableAmountPerShare_c0a1e9c7-610b-44a1-b1c2-ffbd8a9e47c0" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DividendsPayableAmountPerShare"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_DividendsPayableAmountPerShare_c0a1e9c7-610b-44a1-b1c2-ffbd8a9e47c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RevenuesContingentConsideration_752a1886-aea8-402b-b96e-7d99ba22fe49" xlink:href="jnj-20230101.xsd#jnj_RevenuesContingentConsideration"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_jnj_RevenuesContingentConsideration_752a1886-aea8-402b-b96e-7d99ba22fe49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3cb77ff3-a867-4eeb-af18-c8845268411d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_3cb77ff3-a867-4eeb-af18-c8845268411d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1f623cbd-40d1-429c-8cb7-ae65ebcbe76f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_1f623cbd-40d1-429c-8cb7-ae65ebcbe76f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_155dee59-023b-4f03-ade6-414e14583859" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAcquiredFromAcquisition"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_155dee59-023b-4f03-ade6-414e14583859" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_aad3c229-8755-47a9-ba77-770ef940aa53" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAcquiredDuringPeriod"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_aad3c229-8755-47a9-ba77-770ef940aa53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_61313219-ff13-4db6-a76b-da586eb8d7de" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinitelivedIntangibleAssetsAcquired1"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_FinitelivedIntangibleAssetsAcquired1_61313219-ff13-4db6-a76b-da586eb8d7de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentInProcess_7e1b8061-ce6e-4e30-8362-9b5a5bd199c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentInProcess"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_ResearchAndDevelopmentInProcess_7e1b8061-ce6e-4e30-8362-9b5a5bd199c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c07375b6-85f0-437c-bd46-ebe4a2a08ebf" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:presentationArc order="38" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_21879cc4-3e2e-41a7-bc51-61737bf9b79e" xlink:to="loc_us-gaap_BusinessCombinationAcquisitionRelatedCosts_c07375b6-85f0-437c-bd46-ebe4a2a08ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#LegalProceedingsDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/LegalProceedingsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4dcde18-6058-46b1-a807-195fc48d1ef4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_c4dcde18-6058-46b1-a807-195fc48d1ef4" xlink:to="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_9707f016-4e14-42cd-b72a-ccdffb661ece" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:to="loc_srt_LitigationCaseAxis_9707f016-4e14-42cd-b72a-ccdffb661ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_ae1bdcb2-7731-45cd-bb21-25af84e010fe" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_9707f016-4e14-42cd-b72a-ccdffb661ece" xlink:to="loc_srt_LitigationCaseTypeDomain_ae1bdcb2-7731-45cd-bb21-25af84e010fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_DePuyASRU.S.Member_33375db1-f835-4cf2-b6dd-079396a98b13" xlink:href="jnj-20230101.xsd#jnj_DePuyASRU.S.Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ae1bdcb2-7731-45cd-bb21-25af84e010fe" xlink:to="loc_jnj_DePuyASRU.S.Member_33375db1-f835-4cf2-b6dd-079396a98b13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_1cbfa188-8467-454b-b192-57286729a281" xlink:href="jnj-20230101.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ae1bdcb2-7731-45cd-bb21-25af84e010fe" xlink:to="loc_jnj_RisperdalMember_1cbfa188-8467-454b-b192-57286729a281" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_BabyPowderMember_40336d9b-2196-49bc-813c-c7ad93236f10" xlink:href="jnj-20230101.xsd#jnj_BabyPowderMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ae1bdcb2-7731-45cd-bb21-25af84e010fe" xlink:to="loc_jnj_BabyPowderMember_40336d9b-2196-49bc-813c-c7ad93236f10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_f7e76b0f-2df1-4133-9d87-e02a3884625a" xlink:href="jnj-20230101.xsd#jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ae1bdcb2-7731-45cd-bb21-25af84e010fe" xlink:to="loc_jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember_f7e76b0f-2df1-4133-9d87-e02a3884625a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SurgicalMeshProductsMarketingMember_3ce420ca-c0be-47f6-aab4-4fc03b4ea5c0" xlink:href="jnj-20230101.xsd#jnj_SurgicalMeshProductsMarketingMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_ae1bdcb2-7731-45cd-bb21-25af84e010fe" xlink:to="loc_jnj_SurgicalMeshProductsMarketingMember_3ce420ca-c0be-47f6-aab4-4fc03b4ea5c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusAxis_e7c0b3d9-be6f-42b7-b5da-ee2e16bf07bd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:to="loc_us-gaap_LitigationStatusAxis_e7c0b3d9-be6f-42b7-b5da-ee2e16bf07bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LitigationStatusDomain_3a04dd4c-996c-4616-ab44-3e7cb1e60e05" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LitigationStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_e7c0b3d9-be6f-42b7-b5da-ee2e16bf07bd" xlink:to="loc_us-gaap_LitigationStatusDomain_3a04dd4c-996c-4616-ab44-3e7cb1e60e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SettledLitigationMember_811e5807-9106-4177-93b6-3436dfca45cd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SettledLitigationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_3a04dd4c-996c-4616-ab44-3e7cb1e60e05" xlink:to="loc_us-gaap_SettledLitigationMember_811e5807-9106-4177-93b6-3436dfca45cd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_JudicialRulingMember_0b16ef48-7595-46c5-abed-c1410582ee6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_JudicialRulingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_3a04dd4c-996c-4616-ab44-3e7cb1e60e05" xlink:to="loc_us-gaap_JudicialRulingMember_0b16ef48-7595-46c5-abed-c1410582ee6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PendingLitigationMember_c83a2d8e-3bc5-4308-8f8d-a5aa222fb4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PendingLitigationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_3a04dd4c-996c-4616-ab44-3e7cb1e60e05" xlink:to="loc_us-gaap_PendingLitigationMember_c83a2d8e-3bc5-4308-8f8d-a5aa222fb4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_73bedc8a-a0b4-40db-bfda-a96fac579b15" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:to="loc_srt_ProductOrServiceAxis_73bedc8a-a0b4-40db-bfda-a96fac579b15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_73bedc8a-a0b4-40db-bfda-a96fac579b15" xlink:to="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AsrMember_bbacd058-69a0-45c8-812d-7f5f799a5e72" xlink:href="jnj-20230101.xsd#jnj_AsrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:to="loc_jnj_AsrMember_bbacd058-69a0-45c8-812d-7f5f799a5e72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PinnacleAcetabularCupSystemMember_dc050cc3-88b5-479e-9e53-de9f448049b4" xlink:href="jnj-20230101.xsd#jnj_PinnacleAcetabularCupSystemMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:to="loc_jnj_PinnacleAcetabularCupSystemMember_dc050cc3-88b5-479e-9e53-de9f448049b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PelvicMeshesMember_22892aa6-0608-46e1-896f-c2220548f9f1" xlink:href="jnj-20230101.xsd#jnj_PelvicMeshesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:to="loc_jnj_PelvicMeshesMember_22892aa6-0608-46e1-896f-c2220548f9f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_32dd6b55-9bc9-4de3-8869-8fbbbeac13e8" xlink:href="jnj-20230101.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:to="loc_jnj_RisperdalMember_32dd6b55-9bc9-4de3-8869-8fbbbeac13e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_TalcMember_dd770e2f-c792-4c49-9882-6b3fabbe33a4" xlink:href="jnj-20230101.xsd#jnj_TalcMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:to="loc_jnj_TalcMember_dd770e2f-c792-4c49-9882-6b3fabbe33a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_PhysiomeshMember_5c0274a1-fe55-4bca-9dcf-e8a437f1e6d7" xlink:href="jnj-20230101.xsd#jnj_PhysiomeshMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:to="loc_jnj_PhysiomeshMember_5c0274a1-fe55-4bca-9dcf-e8a437f1e6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OpioidMember_3631cd22-5786-42b8-b199-837a6018401b" xlink:href="jnj-20230101.xsd#jnj_OpioidMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:to="loc_jnj_OpioidMember_3631cd22-5786-42b8-b199-837a6018401b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ElmironMember_587a0fb8-3287-4c62-b5e8-a50af757d1a2" xlink:href="jnj-20230101.xsd#jnj_ElmironMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_78a85148-7b1a-4d4c-a438-cb3f15bc3645" xlink:to="loc_jnj_ElmironMember_587a0fb8-3287-4c62-b5e8-a50af757d1a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesAxis_54ebbb46-40e0-4d31-973b-bb77eb07fc95" xlink:href="jnj-20230101.xsd#jnj_LitigationSettlementByCompaniesAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:to="loc_jnj_LitigationSettlementByCompaniesAxis_54ebbb46-40e0-4d31-973b-bb77eb07fc95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LitigationSettlementByCompaniesDomain_dd7191bd-794c-4aa0-a5a2-0bfc0307ec30" xlink:href="jnj-20230101.xsd#jnj_LitigationSettlementByCompaniesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesAxis_54ebbb46-40e0-4d31-973b-bb77eb07fc95" xlink:to="loc_jnj_LitigationSettlementByCompaniesDomain_dd7191bd-794c-4aa0-a5a2-0bfc0307ec30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RisperdalMember_70ffc84d-36ac-40cd-a963-8959417197ad" xlink:href="jnj-20230101.xsd#jnj_RisperdalMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LitigationSettlementByCompaniesDomain_dd7191bd-794c-4aa0-a5a2-0bfc0307ec30" xlink:to="loc_jnj_RisperdalMember_70ffc84d-36ac-40cd-a963-8959417197ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_7c6b5e8e-1b1f-4ed5-80b3-2e68a353c30d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_7c6b5e8e-1b1f-4ed5-80b3-2e68a353c30d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyNatureDomain_c375ad84-12c9-47d6-a7f6-c76edc5417eb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyNatureDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_7c6b5e8e-1b1f-4ed5-80b3-2e68a353c30d" xlink:to="loc_us-gaap_LossContingencyNatureDomain_c375ad84-12c9-47d6-a7f6-c76edc5417eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DamagesFromProductDefectsMember_fc0c43ba-0ca8-45b4-ad19-d19cf222980e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DamagesFromProductDefectsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_c375ad84-12c9-47d6-a7f6-c76edc5417eb" xlink:to="loc_us-gaap_DamagesFromProductDefectsMember_fc0c43ba-0ca8-45b4-ad19-d19cf222980e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_26b573f6-3d42-4eb7-985b-fe6f4c77608a" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:to="loc_srt_CounterpartyNameAxis_26b573f6-3d42-4eb7-985b-fe6f4c77608a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b6506c2-460c-47c0-a3fb-d0d166f85c51" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_26b573f6-3d42-4eb7-985b-fe6f4c77608a" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b6506c2-460c-47c0-a3fb-d0d166f85c51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_RasmussenInstrumentsLLCMember_761c193d-183e-4cb3-8b6b-1cb35f8a517b" xlink:href="jnj-20230101.xsd#jnj_RasmussenInstrumentsLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_9b6506c2-460c-47c0-a3fb-d0d166f85c51" xlink:to="loc_jnj_RasmussenInstrumentsLLCMember_761c193d-183e-4cb3-8b6b-1cb35f8a517b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingenciesLineItems_c9da4494-085f-4879-859d-d46310bb0678" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingenciesLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_b9b81122-0ed9-4f4d-b8e4-7395cc41a89f" xlink:to="loc_us-gaap_LossContingenciesLineItems_c9da4494-085f-4879-859d-d46310bb0678" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:href="jnj-20230101.xsd#jnj_LegalProceedingTextualsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c9da4494-085f-4879-859d-d46310bb0678" xlink:to="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyPendingClaimsNumber_b32d2906-9215-4b8a-9433-280d1a8c5309" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyPendingClaimsNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_us-gaap_LossContingencyPendingClaimsNumber_b32d2906-9215-4b8a-9433-280d1a8c5309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_4dbb30ad-34f1-4f39-994c-28967e472947" xlink:href="jnj-20230101.xsd#jnj_ProductLiabilityContingencyNumberOfClaimant"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_jnj_ProductLiabilityContingencyNumberOfClaimant_4dbb30ad-34f1-4f39-994c-28967e472947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_577855a4-ceb7-4777-b6a1-6f2e6aff3c29" xlink:href="jnj-20230101.xsd#jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement_577855a4-ceb7-4777-b6a1-6f2e6aff3c29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_Numberofpatientsinsettlement_d69b115d-7bde-4e80-95d5-0961bd6557bf" xlink:href="jnj-20230101.xsd#jnj_Numberofpatientsinsettlement"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_jnj_Numberofpatientsinsettlement_d69b115d-7bde-4e80-95d5-0961bd6557bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesAwardedValue_84a6de1e-2417-4444-9775-632ca7d05110" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesAwardedValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_us-gaap_LossContingencyDamagesAwardedValue_84a6de1e-2417-4444-9775-632ca7d05110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyDamagesSoughtValue_8623d0a3-759d-45f5-98e9-1643e66cc79e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyDamagesSoughtValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_us-gaap_LossContingencyDamagesSoughtValue_8623d0a3-759d-45f5-98e9-1643e66cc79e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForLegalSettlements_66710e12-e7a9-4284-be68-875fa4977085" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsForLegalSettlements"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_us-gaap_PaymentsForLegalSettlements_66710e12-e7a9-4284-be68-875fa4977085" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyReserveEstablishedWithinTrust_3b2fc1f9-1d98-44a0-921e-e1eca63737db" xlink:href="jnj-20230101.xsd#jnj_LossContingencyReserveEstablishedWithinTrust"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_jnj_LossContingencyReserveEstablishedWithinTrust_3b2fc1f9-1d98-44a0-921e-e1eca63737db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_c7903c1f-af0b-43ba-8683-5a2e3995d530" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_c7903c1f-af0b-43ba-8683-5a2e3995d530" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_182c3d4e-10bd-46de-b8eb-e5bcc24c42bc" xlink:href="jnj-20230101.xsd#jnj_LossContingencyEstimateOfAdditionalPossibleLoss"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_jnj_LegalProceedingTextualsAbstract_98cd147b-8599-4713-80a9-65ac7bff2854" xlink:to="loc_jnj_LossContingencyEstimateOfAdditionalPossibleLoss_182c3d4e-10bd-46de-b8eb-e5bcc24c42bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyPendingClaimsNumberAdditional_76fa3f1a-35a2-4f79-8495-48c2c46394c3" xlink:href="jnj-20230101.xsd#jnj_LossContingencyPendingClaimsNumberAdditional"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c9da4494-085f-4879-859d-d46310bb0678" xlink:to="loc_jnj_LossContingencyPendingClaimsNumberAdditional_76fa3f1a-35a2-4f79-8495-48c2c46394c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_de8f8f7f-9739-4424-9455-6d784da034bb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LossContingencyClaimsDismissedNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c9da4494-085f-4879-859d-d46310bb0678" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_de8f8f7f-9739-4424-9455-6d784da034bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_LossContingencyPendingClaimsNumberRemaining_12462377-806d-4f22-ae76-9cb7ebc260ab" xlink:href="jnj-20230101.xsd#jnj_LossContingencyPendingClaimsNumberRemaining"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_c9da4494-085f-4879-859d-d46310bb0678" xlink:to="loc_jnj_LossContingencyPendingClaimsNumberRemaining_12462377-806d-4f22-ae76-9cb7ebc260ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#RestructuringNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7330e5b8-91fa-4fdc-8986-c0b44fc2abc5" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_627d8565-6397-4823-b2b8-ffbd385b7fcd" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_7330e5b8-91fa-4fdc-8986-c0b44fc2abc5" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_627d8565-6397-4823-b2b8-ffbd385b7fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_a86d33d5-c22a-40b2-80a4-bc3920565985" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_627d8565-6397-4823-b2b8-ffbd385b7fcd" xlink:to="loc_us-gaap_RestructuringPlanAxis_a86d33d5-c22a-40b2-80a4-bc3920565985" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_11ca8db0-75af-4ffc-9314-2cdcfa3469ad" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_a86d33d5-c22a-40b2-80a4-bc3920565985" xlink:to="loc_us-gaap_RestructuringPlanDomain_11ca8db0-75af-4ffc-9314-2cdcfa3469ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_a34193ec-d973-4175-bebd-3efe9316cf5e" xlink:href="jnj-20230101.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_11ca8db0-75af-4ffc-9314-2cdcfa3469ad" xlink:to="loc_jnj_SupplyChainMember_a34193ec-d973-4175-bebd-3efe9316cf5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_05e47c64-d585-4ee6-a43d-2809187790a6" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_627d8565-6397-4823-b2b8-ffbd385b7fcd" xlink:to="loc_srt_RangeAxis_05e47c64-d585-4ee6-a43d-2809187790a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_82905f87-1213-479a-ae5a-de774a273d08" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_05e47c64-d585-4ee6-a43d-2809187790a6" xlink:to="loc_srt_RangeMember_82905f87-1213-479a-ae5a-de774a273d08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5a135c43-52df-4220-82b5-fc9b56a5f745" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_82905f87-1213-479a-ae5a-de774a273d08" xlink:to="loc_srt_MinimumMember_5a135c43-52df-4220-82b5-fc9b56a5f745" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_936e6a3a-8f82-4ea8-8003-9091a3a69917" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_82905f87-1213-479a-ae5a-de774a273d08" xlink:to="loc_srt_MaximumMember_936e6a3a-8f82-4ea8-8003-9091a3a69917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_83ee8897-1f8f-46a3-821c-adad257806ce" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_627d8565-6397-4823-b2b8-ffbd385b7fcd" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_83ee8897-1f8f-46a3-821c-adad257806ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_03ed1080-7be9-4232-951e-488b2139fd12" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_83ee8897-1f8f-46a3-821c-adad257806ce" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_03ed1080-7be9-4232-951e-488b2139fd12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringChargesMember_1d132cd0-7469-4904-8815-0637fc6e19e4" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringChargesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_03ed1080-7be9-4232-951e-488b2139fd12" xlink:to="loc_us-gaap_RestructuringChargesMember_1d132cd0-7469-4904-8815-0637fc6e19e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfSalesMember_04a75dda-7987-4ab6-99bc-9f6623b0fa8f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CostOfSalesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_03ed1080-7be9-4232-951e-488b2139fd12" xlink:to="loc_us-gaap_CostOfSalesMember_04a75dda-7987-4ab6-99bc-9f6623b0fa8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_OtherIncomeExpenseNetMember_e7f965c1-e536-447d-a911-2fc33168658d" xlink:href="jnj-20230101.xsd#jnj_OtherIncomeExpenseNetMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_03ed1080-7be9-4232-951e-488b2139fd12" xlink:to="loc_jnj_OtherIncomeExpenseNetMember_e7f965c1-e536-447d-a911-2fc33168658d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_29d6113c-95ec-499b-a15e-50c3c59dd94a" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_627d8565-6397-4823-b2b8-ffbd385b7fcd" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_29d6113c-95ec-499b-a15e-50c3c59dd94a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_5e34b431-e695-4f86-9e2c-22e5f4b1694f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_29d6113c-95ec-499b-a15e-50c3c59dd94a" xlink:to="loc_us-gaap_RestructuringCharges_5e34b431-e695-4f86-9e2c-22e5f4b1694f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_4b7a0a69-ae39-4a63-905d-8f548085d29d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_29d6113c-95ec-499b-a15e-50c3c59dd94a" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_4b7a0a69-ae39-4a63-905d-8f548085d29d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" xlink:type="simple" xlink:href="jnj-20230101.xsd#RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"/>
  <link:presentationLink xlink:role="http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_73ce04bb-decd-40ed-8b89-c75f3f20647b" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fffac13-fca0-40ce-bc1b-a4693c9f595c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_73ce04bb-decd-40ed-8b89-c75f3f20647b" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fffac13-fca0-40ce-bc1b-a4693c9f595c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_8b18abc2-d217-4a26-8ec5-72e65fb1be9c" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fffac13-fca0-40ce-bc1b-a4693c9f595c" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_8b18abc2-d217-4a26-8ec5-72e65fb1be9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_4626811b-11dd-490b-b56c-a0eeb9598046" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_8b18abc2-d217-4a26-8ec5-72e65fb1be9c" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_4626811b-11dd-490b-b56c-a0eeb9598046" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_2d2c6922-276c-4b6c-bd63-990cb4e340f9" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4626811b-11dd-490b-b56c-a0eeb9598046" xlink:to="loc_us-gaap_EmployeeSeveranceMember_2d2c6922-276c-4b6c-bd63-990cb4e340f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_AssetWriteoffMember_652874ab-78d1-4a01-bdb7-0e71963b20d0" xlink:href="jnj-20230101.xsd#jnj_AssetWriteoffMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4626811b-11dd-490b-b56c-a0eeb9598046" xlink:to="loc_jnj_AssetWriteoffMember_652874ab-78d1-4a01-bdb7-0e71963b20d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherRestructuringMember_833d6591-c79b-4450-b2cf-22ba4f7834cb" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherRestructuringMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_4626811b-11dd-490b-b56c-a0eeb9598046" xlink:to="loc_us-gaap_OtherRestructuringMember_833d6591-c79b-4450-b2cf-22ba4f7834cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanAxis_59855e0b-dfb2-4d41-9dbc-87551349f274" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fffac13-fca0-40ce-bc1b-a4693c9f595c" xlink:to="loc_us-gaap_RestructuringPlanAxis_59855e0b-dfb2-4d41-9dbc-87551349f274" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringPlanDomain_7b088fc0-0f79-41db-b52d-b259d79349c6" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringPlanDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_59855e0b-dfb2-4d41-9dbc-87551349f274" xlink:to="loc_us-gaap_RestructuringPlanDomain_7b088fc0-0f79-41db-b52d-b259d79349c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_55e787c0-6a08-4846-9fd9-e7332d9422de" xlink:href="jnj-20230101.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_7b088fc0-0f79-41db-b52d-b259d79349c6" xlink:to="loc_jnj_SupplyChainMember_55e787c0-6a08-4846-9fd9-e7332d9422de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_42fc314b-9593-4d86-8fae-0014d60e290e" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fffac13-fca0-40ce-bc1b-a4693c9f595c" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_42fc314b-9593-4d86-8fae-0014d60e290e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_06950da0-3142-41e6-abce-4696d132cd6f" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_42fc314b-9593-4d86-8fae-0014d60e290e" xlink:to="loc_us-gaap_SegmentDomain_06950da0-3142-41e6-abce-4696d132cd6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_SupplyChainMember_73b5ce3d-5968-41e9-9ad2-cdf96c1a750f" xlink:href="jnj-20230101.xsd#jnj_SupplyChainMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_06950da0-3142-41e6-abce-4696d132cd6f" xlink:to="loc_jnj_SupplyChainMember_73b5ce3d-5968-41e9-9ad2-cdf96c1a750f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_d9e21e12-5cff-431a-b0f5-013095380759" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_9fffac13-fca0-40ce-bc1b-a4693c9f595c" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_d9e21e12-5cff-431a-b0f5-013095380759" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveRollForward_b1cfce26-5d75-43f3-b4ef-e3575b146d6d" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_d9e21e12-5cff-431a-b0f5-013095380759" xlink:to="loc_us-gaap_RestructuringReserveRollForward_b1cfce26-5d75-43f3-b4ef-e3575b146d6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_75368aee-7ab7-4d82-abba-3bad70843867" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b1cfce26-5d75-43f3-b4ef-e3575b146d6d" xlink:to="loc_us-gaap_RestructuringReserve_75368aee-7ab7-4d82-abba-3bad70843867" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_8e988aa4-f452-400e-b153-d098e48d8875" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReservePeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b1cfce26-5d75-43f3-b4ef-e3575b146d6d" xlink:to="loc_us-gaap_RestructuringReservePeriodIncreaseDecrease_8e988aa4-f452-400e-b153-d098e48d8875" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_aacc6973-9fba-4cfb-9e7e-730751243368" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b1cfce26-5d75-43f3-b4ef-e3575b146d6d" xlink:to="loc_us-gaap_RestructuringCharges_aacc6973-9fba-4cfb-9e7e-730751243368" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_a5c505ac-a6f4-4fc8-b41c-eb6c59136337" xlink:href="jnj-20230101.xsd#jnj_GainOnSaleOfAnAssetPaymentForRestructuring"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b1cfce26-5d75-43f3-b4ef-e3575b146d6d" xlink:to="loc_jnj_GainOnSaleOfAnAssetPaymentForRestructuring_a5c505ac-a6f4-4fc8-b41c-eb6c59136337" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserveSettledWithoutCash2_5750faf2-d33b-491f-bb6f-fcfaa41cd936" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserveSettledWithoutCash2"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b1cfce26-5d75-43f3-b4ef-e3575b146d6d" xlink:to="loc_us-gaap_RestructuringReserveSettledWithoutCash2_5750faf2-d33b-491f-bb6f-fcfaa41cd936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_263abcb1-c25a-4e30-a520-df5c038d0ff8" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_b1cfce26-5d75-43f3-b4ef-e3575b146d6d" xlink:to="loc_us-gaap_RestructuringReserve_263abcb1-c25a-4e30-a520-df5c038d0ff8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>jnj-20230101_g1.jpg
<TEXT>
begin 644 jnj-20230101_g1.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@Q^P;^R/JNE_#WX77-UX3\':%<WEYH>GQK/=7\2J7N'?S2!-(R[F;<<$#'
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M3>Z1J'?^\0.34E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M\Q8[[4[ZZMMV<_\ 'O-.\)'^R4Q[5]'T4 ,M;6VLK:.RLK=(884"111(%5%
MP% '  '&*?110 4444 %<E\,_@9\*_@_JWB37OAYX46QO_%^M/JOB2^EO)KB
M>^NF&-S23.[!5&0L:D1H"0JKDUUM% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWJ?8@&NZKAKX?$8:I[.M!QEV::?W,[Z->AB:?/1FI1[IIK[T%%%%8FH4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M4L9]OX9KM-;_ 'Z27DT%%%%?*'TX4444 %%%% !1110 4444 %%%% !1110
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M> -1EO-$URR2\TJ[FL9K9IX'&4D\N=$D4,.1N49!!'!!KXHM/"WQ*\4?LW_
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^8OV]-7,WB[0-!W_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M+7Q3\2_&ML-UKITMMO6.PBE'#S/ND4A<X;;U\J3: >V_M._MY>'/@-\3-'^
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M#,5_HDN@7L]CXKT'Q#;BWO=$NX1F6*X3)VX'(;.",]&5E'DG@S_@IYJ.O_\
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MQ?9K@@?[<0V_B4)]Z]B\+_\ !6;X0WR(OB_X;^(=.D8?-]B>&Z13]6:,D?\
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M<EXAUR<LHZY +5])4J.\;!T8JP.00<$54*DZ4N:&_P"?]?@:0G96>Q\#45]
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MCLO[VO0EHHHK^;3^A0HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7B/[0O
M[*%CXU:?QG\.H8[75VR]U89"Q7A[D=DD/Y,>N#DGVZBN_+<SQF58E5\/*SZ]
MFNS75?TM3S\SRO!9MA70Q,;KIW3[I]'_ $]#\[M3TS4=&U";2M7L9;:Y@<I-
M;SQE71AV(/(J"ON#XP_ 3P3\8K'=JL'V34XTQ;:K;H/,7T5A_P M%]CT[$9K
MY0^*WP.\>?"*^,?B'3_-LG?%OJ=L"T,GH"?X&_V6P?3(YK]FR+BG 9S%0;Y*
MO\KZ_P"%]?3?RZGXIGW"F89))S2YZ7\RZ?XET]=O/H<=112J 6PTBH.[NV%4
M>I)Z#WKZ<^6.+^-OB0:7X<C\/0.!-J3;I1W6!#GN/XG  (_YYN.]>35L>//$
MQ\6^*;K5XRP@+>7:(PQMB7A>,G!(^8XXW,3WK'K] RS"_4\'&#W>K]7_ );?
M(_/,UQ?US&RFMEHO1?Y[_,****] \X**** "BBB@ HHHH **** "BBB@ HHJ
M?3-+U/6]0ATC1M.GN[NXD$=O;6T1DDE<]%55!+$^@I-J*N]AJ+DTDKMD%>N_
MLO?L??$3]I365NK2)],\-P2[;_79XOEXZQP@X\V3Z<+_ !$< ^U?LO?\$R[Z
M_>V\;?M%@V]OQ)!X7@EQ))W'VAU/R#_84[N>67!%?:>BZ)H_AS2;?0O#^EV]
ME96D0CMK2UA$<<2#HJJO %?CW&/BCA<#&6$RAJ=79SWC'_#_ #/S^%>>Q^S\
M&>%6*Q\HXS.$Z=+=4]IR_P 7\J\OB?EN87PB^#W@'X'^#8/ WP\T9;2TB^:6
M1CNEN9,8,LK_ ,;G'7H!@    =/117\]XC$5\56E6K2<IR=VV[MONV?T5A\/
M0PE"-&C%1A%622LDNR04445B;!1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M/+BJ,*B_O14OS3/FO7_^"67[-^JEI-)U3Q+I;'[JVVHQR(/PEB8G\ZY74?\
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M>R_M:_M??MJ_#+QE\8M6M]JW'_"<:>;#PQ;L#_H5@GG87 8JT@&3E@OWG:0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M7"8W!9A1]MA:L:D-KQDI*Z\TV@HHHKF.H**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **Q?'?Q
M#\'?#32(]=\;:Q]BM);D01R_9Y),R%68+B-6/1&.<8XKD_\ AK/]G[_H?_\
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MD?F/BY_R1T_\</S/F&BBBOZB/Y5/I[_@D_\ \G$ZU_V)5S_Z5V=?H-7Y\_\
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MJD6@SPR_$?0_A[<B2XO1&V[4'O;AXS"OF@R$9*J/EVD<'Z\_X)#>+?$7C?\
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MQ_>_ "/X3^#_  ?#H/B>UM(FT[XD6T;OJT&H)AA>-)YBM)EP6,>Y5P<+LPI
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MG?$?5_VH_P!EO3/A#XBL=)\3S^*]831-2U.V\ZWMK@C3]KR)@[E'IB@#M_\
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M/A_Q,LI/F?:[554.^>=TD)BD/^T[#M0!]&4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5^?/\
MP5@_Y.)T7_L2K;_TKO*_0:LG7?''A?PS>+8:WJGD2O&)%3R';*DD9RJD=0:^
MHX0SVIPYG*QD*+JM1:Y4[;];\LMO0^5XRR"GQ)DCP4ZRI)RB^9J^W2W-'?U/
MQQHK]@?^%M?#[_H8/_)27_XBC_A;7P^_Z&#_ ,E)?_B*_6/^(NXW_H5R_P#
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M/V O&GC3_@F]X=_8R^!"Z8^HZ -)02ZA<F"&<VYW3S%MI^9W+OC')8]*O?\
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M_@W4O"GA7QSJ-GJ_]CVMY>E[/27BN)H;62Y+!V* (C.^S#<D* 0M>!?\$O\
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M_B?]M[X5_M5?$2QT6!- ^$TFB^+X[34-[#5I#*TGDKL&^(L^0W& >G%?4%%
M'S[\4OV:_B3XO_X*)?"_]IS2%L/^$9\(^%-5T_5S+=;;CSKB.98]D>WYAEUR
M<C%+\:/V;/B3X[_X* ?!G]I+0EL/^$;\"Z3KEMKIFNBL^^[LY(HO+3;\XW.,
M\C KZ!HH ^/9OV<_VQ?V/OV@/'7Q3_8Z\,^&?''@SXDZJVLZWX(U_63IUUIN
MJMDRS6\Y4QF-V8D@\XVKM^0,>]_93^%/[8]S\8?$G[1?[6_Q$AL6U?3X]/\
M#OPO\-:S//I.C0*RL9Y-Q"2W3;<;U!X9^<%4C^A:* /GS_@FG^S5\2?V5/V=
M[OX9?%1; :G-XNU+44_LVZ,T?DSNI3YBH^; .1CBN9^"7["GB.*W_:3\%_&Y
M+0:!\9?&>H7FEOIMWYDT=E<+(%D8%0(Y5+JP'(!4=:^J:* /BOP%X._X*T_
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M!;?V[JGPON]!M1+-MA^UR:<]NN7QPF]A\V.G.*]0HH \S_8T^%'BOX&?LK^
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>jnj-20230101_g10.jpg
<TEXT>
begin 644 jnj-20230101_g10.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1$017AI9@  34T *@    @ ! $[  (
M   7   (2H=I  0    !   (8IR=  $    N   0VNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=U>FUA;BP@
M06YD<F5A(%M*2D-54UT    %D ,  @   !0  !"PD 0  @   !0  !#$DI$
M @    ,R-   DI(  @    ,R-   ZAP !P  " P   BD     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( /P"TP,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M ,[S]:_Z!]A_X'/_ /&://UK_H'V'_@<_P#\9K1HH SO/UK_ *!]A_X'/_\
M&://UK_H'V'_ ('/_P#&:T:* ,[S]:_Z!]A_X'/_ /&://UK_H'V'_@<_P#\
M9K1HH SO/UK_ *!]A_X'/_\ &://UK_H'V'_ ('/_P#&:T:* ,[S]:_Z!]A_
MX'/_ /&://UK_H'V'_@<_P#\9K1HH SO/UK_ *!]A_X'/_\ &://UK_H'V'_
M ('/_P#&:T:* ,[S]:_Z!]A_X'/_ /&://UK_H'V'_@<_P#\9K1HH SO/UK_
M *!]A_X'/_\ &://UK_H'V'_ ('/_P#&:T:* ,[S]:_Z!]A_X'/_ /&://UK
M_H'V'_@<_P#\9K1HH SO/UK_ *!]A_X'/_\ &://UK_H'V'_ ('/_P#&:T:*
M ,[S]:_Z!]A_X'/_ /&://UK_H'V'_@<_P#\9K1HH SO/UK_ *!]A_X'/_\
M&://UK_H'V'_ ('/_P#&:T:* ,[S]:_Z!]A_X'/_ /&://UK_H'V'_@<_P#\
M9K1HH SO/UK_ *!]A_X'/_\ &://UK_H'V'_ ('/_P#&:T:* ,[S]:_Z!]A_
MX'/_ /&://UK_H'V'_@<_P#\9K1HH SO/UK_ *!]A_X'/_\ &://UK_H'V'_
M ('/_P#&:T:* ,[S]:_Z!]A_X'/_ /&://UK_H'V'_@<_P#\9K1HH SO/UK_
M *!]A_X'/_\ &://UK_H'V'_ ('/_P#&:T:* ,[S]:_Z!]A_X'/_ /&://UK
M_H'V'_@<_P#\9K1HH SO/UK_ *!]A_X'/_\ &://UK_H'V'_ ('/_P#&:T:*
M ,[S]:_Z!]A_X'/_ /&://UK_H'V'_@<_P#\9K1HH SO/UK_ *!]A_X'/_\
M&://UK_H'V'_ ('/_P#&:T:IZOJ]AH.DSZEJ]RMK9VX!EF<'"@D =/<B@"+S
M]:_Z!]A_X'/_ /&:R=7\47^E?:(4TVTO]1AMOM0TRSORUS)%NV[E0QC(SQFK
MWG:W?:AB&!=,MK2]*2_: LIO8/+^]&5;Y/F(Z\_*>*LZ1HEIHUC;V]OYLS6\
M7E+<7,AEF*YS@R-\QY]Z ,CS_'(NB_V/0#:_:0VS[3.)!;[.5_U9!DW]^F.V
M>:GTK7M2U>R@N(=-M;=YHA,+:ZNY(ID4D@%HS#E>0>M=!61JWA^*_>:ZLIFT
MS5)8XX?[2MXD:98DDW^6"P(VGD8Q_%0!-Y^M?] ^P_\  Y__ (S1Y^M?] ^P
M_P# Y_\ XS5:VUV6'4TT_7+9;2YN[FX6P$)>99H8P&$CL%Q&2#]UC]":VJ ,
M[S]:_P"@?8?^!S__ !FCS]:_Z!]A_P"!S_\ QFM&B@#.\_6O^@?8?^!S_P#Q
MFCS]:_Z!]A_X'/\ _&:T:* ,[S]:_P"@?8?^!S__ !FCS]:_Z!]A_P"!S_\
MQFM&B@#.\_6O^@?8?^!S_P#QFCS]:_Z!]A_X'/\ _&:T:* *MI)?NS?;K:WA
M7'RF&X:0D^X*+BK5%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %9VN?\@^+_ *_+7_T?'6C6=KG_
M "#XO^ORU_\ 1\= &C1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%:-% &=_;EI_SRO_ /P77'_Q%']N6G_/*_\ _!=<?_$5HT4 9W]N6G_/*_\
M_!=<?_$4?VY:?\\K_P#\%UQ_\16C10!G?VY:?\\K_P#\%UQ_\11_;EI_SRO_
M /P77'_Q%:-% &=_;EI_SRO_ /P77'_Q%']N6G_/*_\ _!=<?_$5HT4 9W]N
M6G_/*_\ _!=<?_$4?VY:?\\K_P#\%UQ_\16C10!G?VY:?\\K_P#\%UQ_\11_
M;EI_SRO_ /P77'_Q%:-% &=_;EI_SRO_ /P77'_Q%']N6G_/*_\ _!=<?_$5
MHT4 9W]N6G_/*_\ _!=<?_$4?VY:?\\K_P#\%UQ_\16C10!G?VY:?\\K_P#\
M%UQ_\11_;EI_SRO_ /P77'_Q%:-% &=_;EI_SRO_ /P77'_Q%']N6G_/*_\
M_!=<?_$5HT4 9W]N6G_/*_\ _!=<?_$4?VY:?\\K_P#\%UQ_\16C10!G?VY:
M?\\K_P#\%UQ_\11_;EI_SRO_ /P77'_Q%:-% &=_;EI_SRO_ /P77'_Q%']N
M6G_/*_\ _!=<?_$5HT4 9W]N6G_/*_\ _!=<?_$4?VY:?\\K_P#\%UQ_\16C
M10!G?VY:?\\K_P#\%UQ_\11_;EI_SRO_ /P77'_Q%:-% &=_;EI_SRO_ /P7
M7'_Q%']N6G_/*_\ _!=<?_$5=N+B*TM9;BX;9%"A=VQG"@9)_*L(ZIJ6OP'_
M (1LQVUI-!;75IJ\JB6*=7;+IY>0P.P=3C[P]* )+WQCI%A/!;3M=B[N@_V6
MV-E,LEP47<RH"HR0.?:LF34KSQ';LMV-5T?3KJU@D1+>RN(KZWF#[G5G563;
M@*./]H=#726&BV>G/.\*R2/-=271:>5I2COPVPL3L7'\(P!D\5?H Q[6_P!)
MLO.^Q6%S;^?*TTWE:5,GF2'J[8CY8X&2>>*G_MRT_P">5_\ ^"ZX_P#B*T:*
M ,[^W+3_ )Y7_P#X+KC_ .(H_MRT_P">5_\ ^"ZX_P#B*T:* ,[^W+3_ )Y7
M_P#X+KC_ .(J&Z\4:98P&:\:ZMX@<%Y;&=1GZE*;K7B2WTEUM88VO=1E_P!5
M9P\L?<_W1[FJ=CX<N+Z\74_%,BW5RIW0VB_ZFW^@_B/N: *'_";:HUYY\/AZ
M\DTO. P@D\UEZ[QQMQ[9_&MFR\7:1J*%K*2YF*_?6.SF<H?0X4UMUAZKX6MK
MZY^W6,KZ=J0^[=6_!;_>'1A0!;_MRT_YY7__ (+KC_XBC^W+3_GE?_\ @NN/
M_B*R(_$E[HLBVWBVW$:$[4U&W4F%_3<.JFNEBECGB66"19(V&5=&R"/8B@"C
M_;EI_P \K_\ \%UQ_P#$5%/J>G7.SSK6]<QDM&QTV?<AP1E3LX."1D>M:U%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5G:Y_R#XO^ORU_P#1\=:-9VN?\@^+_K\M?_1\= &C1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%8UUXGLX[R:SL8YM3N[6Y@M[RWLP&>U\WE7<
M$C"@')(SQVH V&944LY"JHR23@ 5BWGB"1[J>QT&T_M"^M_L\DB2,T,7DR-@
MNLI4JQ"AC@>E1II.IZK(DGB*XCCBC>YA>PLVWV]Y!)\J>:'7=N"]@0,D]16S
M:6EO864-I90I!;P1K'%%&,*B@8  [  4 9EKX>!U"&_UFZ;4KRTN9Y;&9D$7
MV:.48\L!>& 7C+9-;(&!@444 %%%% !115/4]5LM'LVNM0G6*,=,]6/H!W-
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M%H%NX]S0N<F-@2K+GOA@1GOC-1^(=3L8+>.">]MXYA=6SF-Y5#!1,A)P3G&
M3GVJ3PMX?B\+>%K#18)FG6TCVM,XP9&)+,V.V6)..V<5+KG_ "#XO^ORU_\
M1\= !_PD6B_]!BP_\"D_QH_X2+1?^@Q8?^!2?XUHT4 9W_"1:+_T&+#_ ,"D
M_P :/^$BT7_H,6'_ (%)_C6C10!G?\)%HO\ T&+#_P "D_QH_P"$BT7_ *#%
MA_X%)_C6C10!G?\ "1:+_P!!BP_\"D_QH_X2+1?^@Q8?^!2?XUHT4 9W_"1:
M+_T&+#_P*3_&C_A(M%_Z#%A_X%)_C6C10!G?\)%HO_08L/\ P*3_ !H_X2+1
M?^@Q8?\ @4G^-:-% &=_PD6B_P#08L/_  *3_&C_ (2+1?\ H,6'_@4G^-:-
M% &=_P )%HO_ $&+#_P*3_&C_A(M%_Z#%A_X%)_C6C10!G?\)%HO_08L/_ I
M/\:/^$BT7_H,6'_@4G^-:-% &=_PD6B_]!BP_P# I/\ &C_A(M%_Z#%A_P"!
M2?XUHT4 9W_"1:+_ -!BP_\  I/\:/\ A(M%_P"@Q8?^!2?XUHT4 9W_  D6
MB_\ 08L/_ I/\:/^$BT7_H,6'_@4G^-:-% &=_PD6B_]!BP_\"D_QH_X2+1?
M^@Q8?^!2?XUHT4 9W_"1:+_T&+#_ ,"D_P :/^$BT7_H,6'_ (%)_C6C10!G
M?\)%HO\ T&+#_P "D_QH_P"$BT7_ *#%A_X%)_C6C10!G?\ "1:+_P!!BP_\
M"D_QH_X2+1?^@Q8?^!2?XUH,ZJ5#, 6.%!/4XS@?@#^5<['XFFURSCD\(VXN
MH;RSFEM=3G4BV69&V*DBY$F"<]!T'% &B?$6B#KK&GC_ +>D_P :R3\0-"FN
MX(-.O8;Q7NI;6>>.9 EJZ*22^Y@<9  (SDFK3^&4U-9&\1S-?K.+:1K,G_1X
M)HOFWQ# 89;!Y)Z"M[% '% V6MV(3QAK^ES)=:>;2_TNTNU^R.Y;)D5CB3..
M.HX/KS701:WH,$82+5=/4*H4?Z2G0# YS6K10!G?\)%HO_08L/\ P*3_ !H_
MX2+1?^@Q8?\ @4G^-:-% &=_PD6B_P#08L/_  *3_&C_ (2+1?\ H,6'_@4G
M^-:-% &=_P )%HO_ $&+#_P*3_&C_A(M%_Z#%A_X%)_C5^21(HVDE=411EF8
MX 'J37+RZQJ'B:9K7PR3;6*L5FU-UZ^HB'<^] $FM>.--T]4AT^>WOKN;B-4
MG41K[N^< 52TM-(-XNJ>(M>T^^U''R#[2GE6_LBY_6NBT;0[+0[4Q649+N<R
MS.<R2GU8]ZT: ,[_ (2+1?\ H,6'_@4G^-'_  D6B_\ 08L/_ I/\:T:* ,[
M_A(M%_Z#%A_X%)_C1_PD6B_]!BP_\"D_QK1JK>ZA#9;%D#O))]R.-<LU-)MV
M0FTE=D'_  D6B_\ 08L/_ I/\:5-?T>1@J:M8LQZ 7*$_P Z>(+V2[=YKA8[
M?!5(HUYP1U)/0_2B'2;:.-TDWW <@L9VWY(Z55DMV*[>R(+KQ)I-H#OO8G*]
M5C8,1]?3\:K?\)78->+''=V/D<;IGO8QQCTSFMN.-(HPD2*B#HJC %.I7CT0
M6EU9SZ:S:2K*+OQ'IR!UPHMYT!7GKDFG+>>&_(6*?5[.Y"MO!GO$8Y_.MZBC
MG?0.5'(ZG;>&;V5;JQUNSTV_C&$N;:Y1?P9<X85#9>.4L+I;+Q!<6DV>$O[*
M59(V_P!Y1RI_2NTILD:2QM'*BNC##*PR"/<5)10'B+1#TUBP_P# E/\ &C_A
M(M%_Z#%A_P"!2?XUDS>&;O2)FNO"5R+?)W26$Q)@D^G=3]/TJSI?BJWNKH6&
MIPOIFI#@V\_1_P#<;HPH N_\)%HO_08L/_ I/\:H:K=>'=6M6BEUNWMW8QDS
MVE^L4OR.' WJ<XSVZ8)]:Z"B@#!T36Y;J_DLKJYL[Z1VGFBFT[F.*%741I(2
MQ(D(?MP=K>G.]110 4444 %%%% !1110 4444 %8'CO4[O1OA[K^IZ;+Y-Y9
MZ=/-!)M#;'5"0<$$'D="*WZJZIIMIK.DW6F:E%YUG>0M#/'N*[T88(R"".#U
M!H \X'Q;N[)F6[T19[2SN[&QN[T7FV1GN8D<.L7EX(!<@C<.V,Y(%%OBSJL&
MIV.LZII_V+0)O#USJT=K!.L\DX#Q^66)12CX;[H)7YAR<<=Z? 7AIA*#IN1-
M<V]VX,\GS2P*JQ-][^$(HQT..0:K6GPQ\(V4CO#I)8/:R67ES74TL:P2$%HE
M1W*JF1PH  YQC)H YZZ^+EYI?A.\U_6?"=Y:VMA=0QW)W2QAHI0 )(O/AB:0
MAR%9=HQU!(KO=#OKK4] L;[4+1+*YN8%EDMHYQ,(BPSMW@ -C/4#'IGK61#\
M._"\,4<;::UPL=R+K_2KJ6<R2*GEJ7,CGS-J#"ALA>P%;.C:/9>']&MM*TJ-
MXK*T3RX8WE>4HO8;G); Z#)X& .!0!=HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH *SM<_P"0?%_U^6O_ */CK1K.US_D'Q?]?EK_ .CXZ -&BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HK/U?7=.T.QN+O4)]J6T8DE2)&ED52VT'8@+$9]!522XU^\O6CL[6'3X+:^
MC#RW1$OVRVV9<H%(*-N.!N_NGB@#3O+^UL(9);N98UCB>9AU;8HRQ"CDX]A6
M.=8U36+=SX;M8XXI+>WNK+4KT9@G5VRR^6") 0GJ!RP].;&G>&;&QEMKB=IM
M1O;0S>1>WS"2>-96W,@? ^7H /0 5L4 8Z>&K-[PW.HR3:DZ7QOK7[6P;[&Y
M39MCP!A0,X!S]XUL444 %%%% !1110 4444 %9^KZW9:':B:^DP6.(XD&7D/
MHH[UGZKXE9+QM+T"#[?J?\0'^K@]W;^E/TCPTMK=G4M6F_M#5'ZSN/EB_P!E
M%["@"C'I.H^*)%N/$8:TT]6W1:8AY?T,I_I_*NHBBC@B6*%%CC085$& !Z 4
M^B@ HHHH *CFGBMU#3R+&"< L<9-5#J/VL31Z7MDECQ\[@^7G/KW-/BT]&\J
M6^VW-S&"/,*X'7/ Z?C5\MOB(YK_  C/,N[V2:(1/:0@%5F)^<G/4#TZU8M+
M..SA$<>YL$DLYRQ)ZG-3T4G+HAJ/5A1114E!1110 4444 %%%% !5+5-(L=9
MM?L^I6ZS)_"3U0^H/4&KM% '*>7KWA?)@,FMZ6O_ "S8_P"DPCV/\8_7Z5MZ
M3KEAK=N9=/G#E>'C;AT/H5ZBM"L35O"]IJ5P+RV=[#4%^[=V_P K?\"'1A]:
M -NBL31KG6TO'L-<MD?9&7COX#\DN"!@K_"W.?P-;= !1110 4444 %%%07O
MVK^S[C^SO)-YY3>1YY/E^9CY=V.=N<9QSB@">BL&?_A+OLTOV;^Q//\ [.3R
MC)YNW[;SNSCGR>F,?-UI]V?%.R]^PKI!;RX/L?G-*!OS^^\S Z8^YCOUH VZ
M*QKD^)_.NOL8TGR_M4/V;S3+N-O\OG;\#B3[VW''3/>K5H=2$=^=7^S!!._V
M4V8<MY&!MW _\M,[ON\=,4 7Z*^;;2ZTW2_!_B70])%EJWVS38H9=>T^>6VQ
M%+-Y>=00AA',IDE9F(+,BD$*!4%GK=O<?!7QEX;2"W>>RN;>XDD@EC-G=&6]
MV'[,L:A1 !$O3/S.P(R,D ^F:*XSP'X1O/#>J:]>3VFF:5:ZE) T&DZ5(SV]
MOY<>UG!,<8W.<9P@X1>2:\K\)?VS;Z/\,+@SVEU;BXU!K.TCM624.(;CAI#(
M0V3Z(O6@#Z'HKP;2OB3XG/A>_P!1U/Q!:,7M[3S!;A';3+B6?84D<P)';KU4
MB0S/'@,0X.&X]_$6M^(8?%=]>:R_VJTLK6WDO+1X_P![;KJ;J=S"-5*^6V=P
M1 P49&"P(!]4T5X/)K.JZ)XL\1ZSX?UJ2ZBEU[2;4Q!('BODE@B4NS!,Y(((
M*%1SG!'%7;7XB7T?@F?4IO&+W.HRV]I]LM!80J-&N))BC*TVT)"N24_?"1EV
M[\.,J0#VNBO%?!_C'Q1XEUOP[IMSXB:..6?5%N9[2*WD-RL$D?E?.8@N-KXW
M*B;EYP"<C3\#^+_$^M?$*:TU34K%8A+>I/HX8M-:I'(%B?:L ,>1CF25@X<E
M0,8 !ZO1110 4444 %<?XB^(MEH'C'3O#BZ9J&HW=WL>8V<6_P"S1MO"N5^\
M_*,2%!(56/H#V%>9_$OP)KWBSQ-H=SHRZ=;):S*?[55GBO+(#?N((_UB'(PG
MR_-UX)*@'21_$/0)O$FL:+;7#SW&BVANKV2, QQ@$ADW9Y<8Y'0="<@@0I\0
M(SHMC?R^'M8A?4Y8XM/LY#;>==ET+@J!,54!5).]EQCUXJKJ_@6XOO%>M:A:
MBP2RU'P^=,$,GF#,S32R.SB/:=K>9R5<,23]:Y[3_ACK6FWZ:QI]MHNG3VVH
MP75OHEI<2"RPEN\,C>9Y0*N_F9)\L_ZM02<D@ ])T'6K/Q'H-GJ^FLQMKN,2
M('7:R^JL.S Y!'J#2:Y_R#XO^ORU_P#1\=4_!7A^3PMX,TW1[B99Y[:,^;(@
M(4NS%FVYYVY8XSSC%/\ $.GPS6\<SO<!C=6RX2YD5<&9!]T,!GGKC/?K0!M4
M5G?V':?\]K__ ,&-Q_\ %T?V':?\]K__ ,&-Q_\ %T :-%9W]AVG_/:__P#!
MC<?_ !=']AVG_/:__P#!C<?_ != &C16=_8=I_SVO_\ P8W'_P 71_8=I_SV
MO_\ P8W'_P 70!HT5G?V':?\]K__ ,&-Q_\ %T?V':?\]K__ ,&-Q_\ %T :
M-%9W]AVG_/:__P#!C<?_ !=']AVG_/:__P#!C<?_ != &C16=_8=I_SVO_\
MP8W'_P 71_8=I_SVO_\ P8W'_P 70!HT5G?V':?\]K__ ,&-Q_\ %T?V':?\
M]K__ ,&-Q_\ %T :-%9W]AVG_/:__P#!C<?_ !=']AVG_/:__P#!C<?_ !=
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M'_Q=']AVG_/:_P#_  8W'_Q= &C16=_8=I_SVO\ _P &-Q_\71_8=I_SVO\
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MOQ5*+:N2Y).QJW5\L$;>2AN)5(!BB.2">F?0>]1"TGNY8;BZEDA"@,;9&X#
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M8ZN@ HHHH **** "BBB@ K.US_D'Q?\ 7Y:_^CXZT:SM<_Y!\7_7Y:_^CXZ
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M:\EFNVMK:!\!3NN&&%4XXP/XJ8+"2^A0ZOM9E<L(HR0N.P/KBKX 50%& !@
M=JK1>9.K\BK:6'DI_I,K74A;?NEYVG_9':K=%%2VV]2DDEH%%%%(84444 %%
M%% !13)9HH$WSR)&O]YV 'ZUDW7C#P[9Y^T:U9 CJJS!R/P&351C*6RN3*48
M[LV:*Y0_$?09&*V'VW4&]+6T=OY@4G_"7ZM<_P#(,\'ZI)Z?:V6W_GFM/85.
MJMZZ?F9^WI]'?TU_(ZRBN3^V>.[O_4:5I-@#_P _-PTI'_?%']C>,KK_ (^O
M$]O: ]5M+%6_5CD4>R2WDE^/Y7#VM]HO\OSL=94<UQ#;)ON)HXE]78*/UKE_
M^$&>XYU/Q+K=UZHMSY:'_@(%2P_#GPQ$^^33OM$G=[B9W)_,XHY:2WE]R_S:
M#FJO:/XERZ\9^'+//GZU9Y'4)*'(_!<UGGXCZ'*<:='?ZB?2TLW;/Y@5M6OA
M_1[+'V32K*$CNENH/YXK1 P,#@47HKHW\_\ @!:J^J7R_P""<G_PENM7/_(-
M\':B^>GVN1+?^>:/M7CN[_U.GZ/IX/\ S\3O*1_WSQ7644>TBMHK\?\ ,/9R
M>\G^'^1B:+9>(H;QYM=U:VN8C&56WM[;8%;(^;<>3P",>];=%%9RDY.YI&/*
MK!1114E!1110 4444 %%<I_PL[PA_P!!?_R6E_\ B*/^%G>$/^@O_P"2TO\
M\16WU>M_(_N9C[>E_,OO1U=%<I_PL[PA_P!!?_R6E_\ B*/^%G>$/^@O_P"2
MTO\ \11]7K?R/[F'MZ7\R^]'5T5RG_"SO"'_ $%__):7_P"(H_X6=X0_Z"__
M )+2_P#Q%'U>M_(_N8>WI?S+[T=717*?\+.\(?\ 07_\EI?_ (BC_A9WA#_H
M+_\ DM+_ /$4?5ZW\C^YA[>E_,OO1U=%<I_PL[PA_P!!?_R6E_\ B*/^%G>$
M/^@O_P"2TO\ \11]7K?R/[F'MZ7\R^]'5T5RG_"SO"'_ $%__):7_P"(H_X6
M=X0_Z"__ )+2_P#Q%'U>M_(_N8>WI?S+[T=717*?\+.\(?\ 07_\EI?_ (BC
M_A9WA#_H+_\ DM+_ /$4?5ZW\C^YA[>E_,OO1U=%<I_PL[PA_P!!?_R6E_\
MB*/^%G>$/^@O_P"2TO\ \11]7K?R/[F'MZ7\R^]'5T5DZ'XGT?Q'Y_\ 8UW]
MI^S[?,_=.FW=G'W@,]#6M6<HRB[25F:QDI*\7<*S-2\2:+I&I6&GZIJEK:7F
MHR>5:02RA6F;T ^O'N2!U(%:=>+?%O3KA?B+H.H:+I%W?:K,T4 AN+);BPO$
M7S2$8\F-UW$EFV@ [N=I(D9["^H6<=X]H]W MRD/GO"90'6/)&\KG(7((STX
MJBOBSPZ^C/JZ:_I;:9&_EO>B\C,*MQ\I?.T'D<9[BN'7PTNC?%KQ)J/]D7^K
M6.H>'_,NA(GG"[E:>7= I<A#B,(@CR!M"^N3A16=ZGB5=>MM$U3^PX/$$%V[
MR:=,ETZ_8WC_ ./8(&*1,T:*43ID_-AG(![1#-%<V\<]O(DL,JAXY(V#*ZD9
M!!'4$=ZHZY_R#XO^ORU_]'QUC?#/3;S2/AKHMEJ<#V]Q' 28).&B5F9E0CL0
MI QVQCM6AXACOVMXS!<VZ0_:K8!'MV9@WG)@[@XXS@XQ[9[T ;5%9WD:U_T$
M+#_P!?\ ^/4>1K7_ $$+#_P!?_X]0!HT5G>1K7_00L/_  !?_P"/4>1K7_00
ML/\ P!?_ ./4 :-%9WD:U_T$+#_P!?\ ^/4>1K7_ $$+#_P!?_X]0!HT5G>1
MK7_00L/_  !?_P"/4>1K7_00L/\ P!?_ ./4 :-%9WD:U_T$+#_P!?\ ^/4>
M1K7_ $$+#_P!?_X]0!HT5G>1K7_00L/_  !?_P"/4>1K7_00L/\ P!?_ ./4
M :-%9WD:U_T$+#_P!?\ ^/4>1K7_ $$+#_P!?_X]0!HT5G>1K7_00L/_  !?
M_P"/5!>3:AIUG)=ZAK.E6MM$,R33VC(B#U+&; H V*S]6UJTT>RN+BY,DK6\
M)G:WMT,LS(#C*QK\QY/85C+?>*;Z\>'339Q1VMX(;F6^T^6-9(C'N\R B4B3
MDJ.<#AO2G:5X7U#3/L\\NIVFH:C! ;;^T[S3]US)&7W[6=9!QGL !Q0!<,.M
MZC?!GN!I=M:WJ2PF B0WL'E\I(KIF/YF/3GY:O:1H^GZ#I4.FZ/:QVEG!GRX
M8Q\JY8L?S))_&H_(UK_H(6'_ ( O_P#'J/(UK_H(6'_@"_\ \>H T:*SO(UK
M_H(6'_@"_P#\>H\C6O\ H(6'_@"__P >H T:*SO(UK_H(6'_ ( O_P#'J/(U
MK_H(6'_@"_\ \>H T:*RY%U>&-I)M3TZ-%&69K)P!^/G5S]QXLOWF-OH=Q;Z
MQ<#@BVT]_+7ZN9< >_- ':5FZIX@TO1A_P 3"\CC?M$/F=OHHYK$?2_%VM6N
M-1U6WTA6'^JLHBS'ZMNR/P-2:=X8.B;I;>YTM9@-SW$UD[2?4L9N* '?VSX@
MUCC1-+%C >EWJ/!(]1&.?SXI\7@V*YE6?Q%?7&KS Y"RG9$I]D'%32:A>QP>
M;_:^GNF[9F.PD;G&<<2TV2\US;$UN\$XD7<"-.=0.>^9N*KDEV)YX]S<@@AM
MH5BMHDAC7HD:A0/P%25C+_PD9N3&SZ>(@>)O(;D?[OF?UJ8VVLR(0U_;PD]T
M@+$?3+#'ZT<O=AS>1ITQY8XR!)(JD]-S8S6)+HNK30B.36(G4,6RUL^?IQ*.
M*=_8E\6C9KC3G:-0JLUBY( Z=9J=H]PO+L:7]IV?V@P"=6E7.44$GCK42:J)
MH))+:TN)"F, IMW9],U&MIJZL66]TX,>I%@_/_D6G>1K7_00L/\ P!?_ ./4
MKQ[!:7<5X[W4(HR[O8+D[T0@N?3##I5V."*%G,4:H7.6(&"Q]35'R-:_Z"%A
M_P" +_\ QZCR-:_Z"%A_X O_ /'J')O0%&QHT5G>1K7_ $$+#_P!?_X]1Y&M
M?]!"P_\  %__ (]4E&C16)>WEYIL>_4-=TBU7&<S6K)G\YJY^7QYND,6EWR:
MM,.-ECI$K\_4R@5I&G.?PHB52$?B9W=%<1;:I\0;]OW.DZ;9Q'I)>!E/_?*N
MQ%2W/A;Q5J<?^G^+VML]8K*UV ?\"#!C5^R2^*27X_D1[5OX8M_A^9U5W?V=
MA%YE]=0VR?WII @_6N?G^(>@K*8;"2XU2<?\LK"W:0_GP/UJC:?#BWMI/-E:
MPO9^\M[:2S%OJ#-C]*Z""PU2UB$5M=:9#&.B1Z<R@?@):/W,>[_#_,/WK[+\
M?\C(_MWQ9J/_ ""O#26:'I-J=QC\XU^:C_A'O$^H_P#(7\4-;(>L.F0"/'TD
M/S5N>1K7_00L/_ %_P#X]1Y&M?\ 00L/_ %__CU'MK?#%+\?SN'LK_$V_P /
MR,>'X=>'5?S+RWFU";O+>7#R,?U _2M>U\.:+98^R:391$?Q+;KG\\9I?(UK
M_H(6'_@"_P#\>H\C6O\ H(6'_@"__P >J)5:DMY,J-*$=DC0 "J H  Z 4M9
MWD:U_P!!"P_\ 7_^/4>1K7_00L/_  !?_P"/5F:&C16=Y&M?]!"P_P# %_\
MX]1Y&M?]!"P_\ 7_ /CU &C16=Y&M?\ 00L/_ %__CU'D:U_T$+#_P  7_\
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M]%9RG*?Q.Y<81C\*L%%%%06%%%% !1110 4444 %%%% !1110 4444 %%%%
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M]=BY\:7FG7E['.]O)(D2RLJ*R,#$I:,?*I'' XS0![76=KG_ "#XO^ORU_\
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M#S:')O<:BEL9T'A'[7.MUXGO'U6=3E83\L$?T3O]3UKHT1(XU2-51%& JC
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M\-6\GF2:?]KE[R74C2D_4$X_2M3^T[O_ * =_P#]_+?_ ..T?VG=_P#0#O\
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MDN<F6XS*Q/KEL\_2MY5"J%4  #  '2EHK*4Y2=Y.YI&,8JT58****DH****
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M9Z:[W \R:[B>TCBAVC<")6!+;SY:L#M8@D# Q4I)Z+^OZ_X.[N&N_P#7]?\
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M-%9W]N6G_/*__P#!?/\ _$4?VY:?\\K_ /\ !?/_ /$4 :-%9W]N6G_/*_\
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M )Y7_P#X+Y__ (B@#1HK._MRT_YY7_\ X+Y__B*/[<M/^>5__P""^?\ ^(H
MT:*SO[<M/^>5_P#^"^?_ .(H_MRT_P">5_\ ^"^?_P"(H T:*SO[<M/^>5__
M ."^?_XBC^W+3_GE?_\ @OG_ /B* -&BL[^W+3_GE?\ _@OG_P#B*/[<M/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
)HH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>jnj-20230101_g11.jpg
<TEXT>
begin 644 jnj-20230101_g11.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1$017AI9@  34T *@    @ ! $[  (
M   7   (2H=I  0    !   (8IR=  $    N   0VNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $=U>FUA;BP@
M06YD<F5A(%M*2D-54UT    %D ,  @   !0  !"PD 0  @   !0  !#$DI$
M @    ,P,@  DI(  @    ,P,@  ZAP !P  " P   BD     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( /\"V ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6C10!G?\(]HO_0(L/_ 9/\*/^$>T7_H$6'_@,G^%:-% &=_PCVB_] BP_P#
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MOS$DG)S],9K7TK2Y(Y9+_49)GNKHQS-:RS":*RD$85EA.T$*><GN23QG%:M
M''+X?T_PY?QPKHMO>:7=20VUI;6NF1XTX!&WO+(3ED) YQQTYS6^F@Z'(BO'
MI6GLK#*LMLA!'KTJ_-#'<020SHLD4BE'1AD,I&"#6#;1R^&+R*SBBDFT>=H[
M>QMK.T54TQ$C.XR/NY0E>#C@D#WH T/^$>T7_H$6'_@,G^%'_"/:+_T"+#_P
M&3_"M!'61%>-@RL,JRG((]:6@#._X1[1?^@18?\ @,G^%'_"/:+_ - BP_\
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MX@_^-4?V9=?]!N__ .^(/_C5 &C16=_9EU_T&[__ +X@_P#C5']F77_0;O\
M_OB#_P"-4 :-%9W]F77_ $&[_P#[X@_^-5B:JVK32G3- UG4!>S0221:A):0
MS6D+HZJ4D*H#N.3A?8^F* -76]4N+9ETW250ZO=P2O9FYAD-L&0#_6N@^4?,
M/<]JGTK2ET[[3,TDKSWDOVB</,\B))M"D1AONKQT%4=,\*II NO[/U6_B^V7
M+W<_^J;?*^-S<QG&<#@<"KO]F77_ $&[_P#[X@_^-4 :-%9W]F77_0;O_P#O
MB#_XU1_9EU_T&[__ +X@_P#C5 &C4=Q;PW=K+;74:RPS(8Y(W&0ZD8((]"*I
M?V9=?]!N_P#^^(/_ (U1_9EU_P!!N_\ ^^(/_C5 &?:K/X;OHK$))/I$[)#9
M16MHJ1Z7%'#R)'W<J2O!QP2!TYKH%974,A#*PR"#D$5E76A/?6<UI>:M>3V]
MQ&T4L3QP%71A@J1Y7((.*QH+#4O#]];V#:IJ4^FSMY5F+2QMDBTV*.+.)7*_
M=.T@$#N!CO0!U]%9PTVZ8 C7+X@\@A(.?_(5']F77_0;O_\ OB#_ .-4 :-%
M(H*J 6+$#!)ZFEH **** "BBB@ HHK%U+4]<M;UHM.\/?;H  1-]M2/)[C:1
MF@#:HKF_[;\3_P#0H_\ E3B_PH_MOQ/_ -"C_P"5.+_"@#I**P;/5_$,UY%'
M=^&?LT+, \WV^-]@]=H&37%_$B^N]*\51:Q+JEXVBZ=:1/>6NE:H(+FP/FLP
MN6@/RSQOM6,JV>-VT$YH ]2HKPE?&M[9?&5-3U"^U=/#U[J<NGV*99X[J93'
M;&#RA+LB57+2AV4.P5OH;VD)XGUGQAJ4NDMK;267B]TEO9=5/V*.R3:9(/LY
ME.202!B+@L/F&. #VBBO+/B'J][IGB]]1E6:YT31].BENK6SUZ2SFWR7&W>(
M8CNE(50 'VJ<D D].7U/Q9X@TZ"]UFRU*\:_N!X@2>!YGDB@6U.(66$DK&4V
MKR ,[SNSD4 >]T5PGP\N+B/6_$6E?;KN]L;,V;V\EW<O<.K2VRLZ^8Y)(SAL
M9XW\8! KSW0?B7XLT_P%:M;S6=V;#PPFLSSZDDL\UPWVB6,IN$BXR$!#'.,=
M#G@ ]]HKQB?QWK^KZYX=OVN+>TTY_$-W:?V=:&1;AU@BE!$K;\."5#;=@VY3
MKFI-.^*GBN[\*:GKEU8Z19PQZ0-7L_M$B#Y Y!B*I</(^Y?E60K'\X(*'.*
M/8Z*YGX?^(KWQ9X0AUK44M89+J64I;6X;-L@<J(I"W)D7&&.%&<X'KTU !11
M10 4444 %%%% !1110 5G:'_ ,@^7_K\NO\ T?)6C6=H?_(/E_Z_+K_T?)0!
MHT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !14-U=1VEO)-+N(C1G*HI9F"C)P!R3["L-)-3\2*LEM++IFER1VUU:74)
MVW$ASN>.2*1/E!&!Z\F@!UUJ=UK;M9>&[GR8I(?-36X!%<0(Z2A7AV[N6(##
MVYYR,5K:?I=CI4,L6FVD5K'-,\\BQ+M#2.<LQ]R:DM+*UL+?R+&VAMH=S-Y<
M,81<L<DX'&222?<U-0 4444 %%%% !1110 5!>V5MJ-A<65]"L]M<QM%-$XR
MKHPP0?8@U/10!S]M)<>'M0BT^=9;C3KEV%HUO:+'!I<,<0PDK;NA*G:<=\>]
M= "& (.0>01WJO?V-KJ>GSV.H0)<6MQ&8IHI!E74C!!K(MI[K0M0%E?&2YL;
MEY'MIH+58H--@C1<1RMN[\X;'/3C% &_1110 4444 %%%% !1110 4444 %9
MVH>'M%U:]M[S5-(L+VZM2#;SW-LDCPD'.59@2O(SQ6C10!CS^#_#5U?S7UUX
M=TF:[G(,MQ)8QM)(001N8KDX*J>?0>E:-K8VEEYWV*UAM_M$IFF\J,)YDAQE
MVQU8X&2>>*GHH S[W0-'U._MK[4M)L;N[LV#6UQ/;))) 0<@HQ&5.0#QWIT6
MAZ3!J=SJ,&EV4=]=KLN+I+=!+,O'#N!EAP.">PJ]10!3TO1],T.S^R:+IUII
MUMN+^3:0+$FX]3M4 9X'-5T\+Z!';M;IH>FK"UM]D:,6D84P;BWE8QC9DD[>
MF236I10!E)X6\/QZK_:::%IJZAN#_:Q9QB7<!M!WXSD D9STI(O"GAV 3B'0
M-+C%S,L\X2SC'FR*2RNW'+ DD$\@G-:U% %>TT^RT_S_ +!9P6OVF9IY_)B5
M/-E;&YVP/F8X&2>3BK%%% !1110 4444 <W\0%O9/ ]_%I>K0:1>2>6D5U/<
M>0N3(H*>9U0N,H&'(+ CG%>&CQQJUO\ L_PZ?X=;7[2>"%UN]2ECDN!9B..-
MQ%%-&ORA]Z[2Y&Q=XS\JBOI"[L[;4+.6TO[>*ZMIE*2PS('1U/4%3P1]:HV7
MAK1-.\.)H%II=JFDI'Y7V(Q!HV4]0P.=V>I)R222<F@#REO$NJW'BD:E;7VH
M"6#6M-T^WLW>:-'MIK4/)OMV(!8EW;<R[AL'("UH_"S6-2O-:TUKK4+N\75O
M#PU*]6XN'E6.Y^T%?D#$B($,Z[%P/W8X^4UZ4VA:2VKPZJVEV1U&"/RHKPVZ
M>=&F"-JOC('S'@'N?6G6&BZ5I5Q=3Z7IEG937C^9<R6]NL;3MDG<Y4#<<D\G
MU- %BY:X6'-I%%+)G[LLA08^H5OY5BZ/-JPL9/*LK)A]JN,EKQQSYSY'^J/&
M<\]_;I6_6=H?_(/E_P"ORZ_]'R4 'G:U_P ^%A_X'/\ _&J/.UK_ )\+#_P.
M?_XU6C10!G>=K7_/A8?^!S__ !JCSM:_Y\+#_P #G_\ C5:-% &=YVM?\^%A
M_P"!S_\ QJCSM:_Y\+#_ ,#G_P#C5:-% &=YVM?\^%A_X'/_ /&J/.UK_GPL
M/_ Y_P#XU6C10!G>=K7_ #X6'_@<_P#\:H\[6O\ GPL/_ Y__C5:-% &=YVM
M?\^%A_X'/_\ &J/.UK_GPL/_  .?_P"-5HT4 9WG:U_SX6'_ ('/_P#&J/.U
MK_GPL/\ P.?_ .-5HT4 9WG:U_SX6'_@<_\ \:H\[6O^?"P_\#G_ /C5:-%
M&=YVM?\ /A8?^!S_ /QJCSM:_P"?"P_\#G_^-5HT4 9WG:U_SX6'_@<__P :
MH\[6O^?"P_\  Y__ (U6C10!G>=K7_/A8?\ @<__ ,:H\[6O^?"P_P# Y_\
MXU6C10!G>=K7_/A8?^!S_P#QJCSM:_Y\+#_P.?\ ^-5HT4 9WG:U_P ^%A_X
M'/\ _&J/.UK_ )\+#_P.?_XU6C10!G>=K7_/A8?^!S__ !JCSM:_Y\+#_P #
MG_\ C5:-% &=YVM?\^%A_P"!S_\ QJCSM:_Y\+#_ ,#G_P#C5:-% &=YVM?\
M^%A_X'/_ /&J/.UK_GPL/_ Y_P#XU6C10!G>=K7_ #X6'_@<_P#\:H\[6O\
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M@'IM%>8^$OB3JVOZ5ID>D:))JUR=/AOKYKJ_CBE5))GC 3;$J2.!&[$8C7
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MG_\ B*/[<M?^>-__ ."^?_XB@#1HK._MRU_YXW__ (+Y_P#XBC^W+7_GC?\
M_@OG_P#B* -&BL[^W+7_ )XW_P#X+Y__ (BC^W+7_GC?_P#@OG_^(H T:*SO
M[<M?^>-__P""^?\ ^(H_MRU_YXW_ /X+Y_\ XB@#1HK._MRU_P">-_\ ^"^?
M_P"(H_MRU_YXW_\ X+Y__B* -&BL[^W+7_GC?_\ @OG_ /B*/[<M?^>-_P#^
M"^?_ .(H T:*SO[<M?\ GC?_ /@OG_\ B*/[<M?^>-__ ."^?_XB@#1HK._M
MRU_YXW__ (+Y_P#XBC^W+7_GC?\ _@OG_P#B* -&BL[^W+7_ )XW_P#X+Y__
M (BC^W+7_GC?_P#@OG_^(H T:*SO[<M?^>-__P""^?\ ^(H_MRU_YXW_ /X+
MY_\ XB@#1HK._MRU_P">-_\ ^"^?_P"(H_MRU_YXW_\ X+Y__B* -&BL[^W+
M7_GC?_\ @OG_ /B*/[<M?^>-_P#^"^?_ .(H T:*SO[<M?\ GC?_ /@OG_\
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MP:Z:O&]9TC7Y/B1JQLH=8MK+4/$NFB>>R\V(2VHT]ED/F)@[ V 6!X;'((%
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MNO2V]RNDZ)&+G5IAD*?NP+_?<]OI_DV-!T"+187=Y#<WUP=US=/]Z1OZ#T%
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M?V':?\];[_P83_\ Q= &C16=_8=I_P ];[_P83__ !=']AVG_/6^_P#!A/\
M_%T :-%9W]AVG_/6^_\ !A/_ /%T?V':?\];[_P83_\ Q= &C16=_8=I_P ]
M;[_P83__ !=']AVG_/6^_P#!A/\ _%T :-%9W]AVG_/6^_\ !A/_ /%T?V':
M?\];[_P83_\ Q= &C16=_8=I_P ];[_P83__ !=']AVG_/6^_P#!A/\ _%T
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M?\];[_P83_\ Q= &C16=_8=I_P ];[_P83__ !=']AVG_/6^_P#!A/\ _%T
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M*:9--;62O?:/#J,H@:>$K(=1@M\*R2A@NUV.,\D8)*Y4@'J-[X2^V>-)=?\
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M8H;F2=?+W/A' E=-S!P>#M!%4[OX,S7VKZC?7/B"*22\M]0MQ.^GEK@I=(4
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M!_\ '*/[2N_^@)??]_(/_CE &C12*2R@E2I(R0>HI: "BBB@ HHHH *JWYQ
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MDM#!*J/.5&,3$E-N[(V_> !;I78>'=1CU2TM;J&\M;P.OS36<@>(L!AMI!/
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M;(>7H4:G[.OW8L[?N#)^7I5W^VX%.?\ A.-3)P!\E@J\#H*]7HI>WGY?<O\
M(/8P\_O?^9Y,=<M?XO&6O-_NVZBF'6K#^+Q7XG;_ '0HKURBCV]3^D@]C#^F
MSR$ZQI7\7B/Q@W^[,@IGVC0+U@)O[=UG'2/5M22*,?CD5[#11[>IT8>PI]CS
MK3KF2V7&E?\ "+:&G=A.LDOY@X/XU?\ )AN_^0KX]\P'JEI/%;CZ<$UVU%9-
MMN[-4DE9''6^C^!X9/,ENK&ZE[R7-Z)"?P+8_2MJVU3PY9IML[[2X%](I8U'
MZ&M>BD,SO^$AT;_H+V/_ ($I_C1_PD.C?]!>Q_\  E/\:T:* ,[_ (2'1O\
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M\:T:* ,[_A(=&_Z"]C_X$I_C1_PD.C?]!>Q_\"4_QK1HH SO^$AT;_H+V/\
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MC2/N7(*X!V+C@#!'2NDTGQ7?7^O3VMS%86\,;RJ;=Y7BN4"9P^' 5U.,Y3@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M09("'Y@S.05'S9)%>A4 9W]AVG_/6_\ _!A/_P#%T?V':?\ /6__ /!A/_\
M%UHU5U03G2;L6EY'83^2WEW4L8D6 X^^5) ('7!(Z4 0?V':?\];_P#\&$__
M ,745MH,:1$7-U?2/YCD,+^<84L2H^_V7 _"O,=%\8^(==OK+2].U^[DTS5-
M9GM;'7WM(!--##:-)(47R_+*^<C*&V= 1UY%C3O'OBW5!\.KMH[2UTW6BB7T
MJX:2YE,4I*JI'R(/+#$YR2P X!R >E_V':?\];__ ,&$_P#\71_8=I_SUO\
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MRT_P]8:G91:,GVJTGC,L9EGNHPO4'YE4%MJ]-Q5^H KU6@#._L.T_P">M_\
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M(?80H4>3AAN9CD "O7: ,[^P[3_GK?\ _@PG_P#BZ/[#M/\ GK?_ /@PG_\
MBZT:* ,[^P[3_GK?_P#@PG_^+J)M!C-Y&ZW5\(!&X>/[?/EF)7:<[^P#?G7"
M>)_%VLZ!X^>UT[6&U<QV]S?7FE):QK!86J6Y,9>0 R>8TH');!#?='!-72_%
MOC%-*U.VMKF'6-0&B66JQ7%ZJ0K;F9)/,&V-1N1?+RJ\MS@L>H /2O[#M/\
MGK?_ /@PG_\ BZ/[#M/^>M__ .#"?_XNO.+O6O$FH_#_ ,%W>F^)[RSU_P 0
M0VL"+';6K0M(R>9-.ZM$6^5 QPK*,A1QFO5T4K&JLQ<@ %FQEO<XXH S_P"P
M[3_GK?\ _@PG_P#BZ/[#M/\ GK?_ /@PG_\ BZT:* ,[^P[3_GK?_P#@PG_^
M+J*;08VE@,-U?(BR$RJ;^<[UVL,??X^8J?PKD_%FO:MI?Q&T+3M+UR2XN-1N
M8?\ B1PVD96.S!(GN)I""X_V2"HRN,-\QK%\(>-?%FJ/:O%)'JESKFAR:K:V
MESLABLI!<K&$#H@8QA)03NW,?+X.6H ]+_L.T_YZW_\ X,)__BZ/[#M/^>M_
M_P"#"?\ ^+KR,^-_%U[\/?#%S!JT@U:_34I;C[%;0^;(("X5@)$,:Q(=F[^,
MC&W)SGUOPY?MJOA?2]0DG@N7NK.*9IK8,(Y"R EE# $*2> 0#CK0 O\ 8=I_
MSUO_ /P83_\ Q=']AVG_ #UO_P#P83__ !=:-% &=_8=I_SUO_\ P83_ /Q=
M17.@QO$!;75]&_F(2QOYSE0P+#[_ '7(_&N3^(FO:MHFM:3'HNN.+^_N((++
M0X;2-_M1\T&9Y78%A&(L\KLVD9)/;*T3QMXDN=<M;A9/[135FU=+?2F\N)(F
MM)-L*K*%W?, 0Q<L,MD  8H ]&_L.T_YZW__ (,)_P#XNC^P[3_GK?\ _@PG
M_P#BZ\RTSQ1XTU#PC!/?7<XF7Q#=V6IWFC:>+A[:&,N%\J(HY9=X5<E&;:<G
MGFNZ^'FNWGB;X?:1JVJ($O+B#]^ NW+JQ4G';.W./>@#3_L.T_YZW_\ X,)_
M_BZ/[#M/^>M__P"#"?\ ^+K1HH SO[#M/^>M_P#^#"?_ .+J*YT&-XE%M=7T
M;^8A+&_G.5# L/O]UR/QKE_BKKFH^'M)AN])UZ2RO) T%AIEO:1S2ZC=L5$:
M?.&.P<[@H!^;.X8 .3:^,?$4OB^%YKQ4MIO$,FA-IWDH8HPMIYOFA\;RWF \
M;MI4XP#\U 'H?]AVG_/6_P#_  83_P#Q=']AVG_/6_\ _!A/_P#%UY1#XU\1
M&\O-.T_Q%+J]FVI:?I7]N&S@C$=S)(1<" *NU@J[<;M^TMR6&,^@_#_6;W6O
M#4K:I+]HNK/4+JQ:XVJIF$,SHKE5  )4#. !G. .@ -;^P[3_GK?_P#@PG_^
M+H_L.T_YZW__ (,)_P#XNM&B@#._L.T_YZW_ /X,)_\ XNHKK08Y+.9+6ZOH
MIVC81R&_G(1L<'&_G!K"^)^L3Z!X7_M.+Q%+HJQ,RI';6L<\]],RD10QB0,,
MEN2 I) ZJ 37*1^-O%0URWEU&?[*;/4-(TN\TM(H_*D>[A1IG+%2X97F&T*P
M'[L9!R: /3?[#M/^>M__ .#"?_XNC^P[3_GK?_\ @PG_ /BZX'2?$?B>7QGK
M^DZ+J2^*?L%H1-)-#';6MK?-, L"N@W%5C)+@EV!3&=Q(KH_A?K6I>(OASIN
MJ:Y.MQ?S-.)9$0(#MF=1@#@ !0/PH V_[#M/^>M__P"#"?\ ^+H_L.T_YZW_
M /X,)_\ XNM&B@#._L.T_P">M_\ ^#"?_P"+H_L.T_YZW_\ X,)__BZS?'6H
M#2/"\NHS>(3X?M;5Q)<W:01RR-& ?W<8<%0[': 2K>@&2"/-#X]\91Z*M[J%
MS)976D:387MS:M;1C[<T]RR$3 J3&3&@.$*X9CV 6@#V>RBE@T^WAN9?.FCB
M59)#_&P&"?Q-3UYL==UQOBE<Z#IGB7[<!:7,UZK6$?V;1PP'V7)&':3(.Y6?
MY@2<)QB]\,M?O]>_MMI-4GUO2;:[6&PU6>WCB-R0@$VWRU56C$@.UL=R,G%
M'=T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M( *X'85-H_@W0M!L;JSTRS:.&[C6&827$DI,:KM6,,[$JBJ2%4$!<G %;E%
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..+CMZ"M>B@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>jnj-20230101_g2.jpg
<TEXT>
begin 644 jnj-20230101_g2.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
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MY[CRI#%(ID$4;E4( 8C&Y<U\(Z=_P4H_:@_X*-?\%0OC/_P3]_8D^,L/PO\
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MY;"SUO2K:\A60.L5U LBAAT;# C([&K- !1110 4444 %%%% !1110 4444
M%%%% 'X@_P#![S_R:S\#_P#LH&H_^D(HH_X/>?\ DUGX'_\ 90-1_P#2$44
M>?\ _!IM_P I3/VN_P#MX_\ 3Y/7[_5^ /\ P:;?\I3/VN_^WC_T^3U^_P!0
M 4444 %%%% !1110 4444 %%%% '+:G\<?@KHNHSZ1K'Q@\+6EW;2M%<VMSX
M@MHY(G4X*LK."I!X(/(J]X7^)?PY\;SO:^"_'^B:O+$NZ6/2]5AN&0>I$;$@
M5_/[_P 'POA#PKI/Q$_9V\6:5X;L;;5-4TOQ1%J>HP6B)-=I#)I9B61P,N$,
MTI7)./,;'4U]E?MP?\$@/V5OCG_P1TTSXS_!+X*>'O 7QA\#?!JQ\6>#_'G@
M728M)U.2^M-+CNGAEGM51IA.$>/,A;:\HD!##- 'ZIT5^2G_  :H_P#!7GXQ
M?\% ?@CXM_9L_:B\6S^(?'GPO2TGT[Q3?/NN]:T><NBFX;K+/!)'L:9OFD6:
M(MN<.[?6'Q+_ ."VO[$OPYOO'E[8R>,O%?A;X4ZM!IGQ3^('@WPM)J&A^%;N
M601^5<3JP>=D8CS?LL<_E9&_:>* /KNBOEC]LO\ X+(_L._L)_#SP5\8_CEX
MNUV7P7\0[-+CPCXR\,>')]4TN_#Q^:B"> ,JN\7[Q5.-R9*YVMCI/$'_  4L
M_9X\-?L0:=_P4+U#1O&3?#34[&VO[>]M_"TLEXMC<$""\:U4F40N6CP0"W[U
M"5 )( /H.H[R\M-.M)=0U"ZC@MX(VDGGF<*D:*,LS,>   22>E>)_M&?\%"?
MV</V4/A1X4^*'QVU+6=$N?'>H6VF^"_!3:)++XAUK4;@J(K&"P0&1I\NBL#A
M8RZAV7(J']FC_@H)^SS^U=\4O&O[-VDVFN>&OB1X"2)O&7PT\<Z4MIJMG:SH
MC17(17DAN+=UEC_>0R2*/,3=MWIN /6?"_Q0^&?CB^DTSP5\1-"UBYBB,LMO
MI>KPW#HF0-Q6-B0,D#/3)'K6[7\^W_!MQHVD^'?^#BO]L'P_H&F065A86GC.
MWLK.UB$<4$*>+K-4C15X554  #@  5^LWQ3_ ."NG[+O@+X^>*?V8_A]X<\=
M?%'QKX#T9M5\?:/\+_#']ICPW;+@G[5*TD<?FX/_ ![Q-)-D%?+W<4 ?4=%>
M&?"?_@HQ^RK^T#^R)??MN_L]^-KKQUX&TRTFGU!O#.F2S:A;&$*T\,EFP69)
MHT8.T3*'*890P9=WSKX2_P"#E/\ X)F?$SX6^(OBC\&[[XD^-QX75IM8T#PE
M\,]0O-1M[1$WRWTD00+!:1KC?<3/'&"P&XGB@#[]HKPW]C__ (*)_LO?MZ?L
MW7'[4/[*7BR\\6Z%9F:*_P!+L]/9-4M+N) [V<EJ^&6?:RE5SM<.I5F5@3\]
M?#C_ (.3?^"7GQ?T;Q1=_"_Q?XZU_5O"L"RW/A+2OAUJ,^L7H/FE_L]HD9>1
M8EA=I9#MCB&TR.NY<@'WO17PO\*?^#BK_@F7\:_V=[_]H+X:^.?%6KS:;=30
M7/P]TSP?<W?B<-%%YTD@L+<2$VZQ'>UUN^SIT>56^6O9_P#@G7_P4W_9-_X*
MC?"*_P#C#^RGXKO[NUT?4OL&NZ3K6GFTO]-N"@=%EBRPVNAW*Z,R-A@&W*P
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M+2O@Q\%_AYI'AGPIH=G]ETK0-'LEAMK>+)) 11@EB69F.2S,S,222?SVTO\
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MQS6EK!'OMWBB9&:)B=@$GF D$ \V_P"#;?\ Y0D? 3_L!:E_Z>+ZON*OF/\
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M!5B@ HHHH **** "BBB@#\0?^#WG_DUGX'_]E U'_P!(111_P>\_\FL_ _\
M[*!J/_I"** //_\ @TV_Y2F?M=_]O'_I\GK]_J_ '_@TV_Y2F?M=_P#;Q_Z?
M)Z_?Z@ HHHH **** "BBB@ HHHH **** "H[R"6ZLY;:"\DMGDC94N(0I>(D
M8#*'#+D=1N!''((XJ2B@#Y[_ &</^";_ ,(OV7/VAO'?[3GPY^)WCZY\3_$^
M]@N_B$=:UJ"YMM<F@CE2!GB^S@0^4)6V>1Y6!A>5^6OH2BB@#RG]F_\ 8T^"
M?[*OC'XE^.?A)8ZC#?\ Q9\<3^+/&#7VH-.LFI3 !VB4@>4F!P@X%9O[('[!
M_P #OV)$^(<?P=NO$5ROQ-\?7WB_Q(OB/7'O@M_=[?-2$,!LB^7@'<Y_B=L#
M'M%% 'S-H_\ P2C_ &;/#G@G6?@=X;\2^--/^$6OZM-J.J?!6TUR-/#CR33>
M?/ B^3]K@M)92SR6,5REJ_F.IA*.RGZ4L;&QTNQATS3+.*VMK>)8K>W@C")$
MBC"JJCA0   !P *EHH **** "BBB@ HHHH **** "BBB@ KB]>_9O_9W\5:S
M<>(O%'P$\%ZEJ%Y(9+N^O_"UI--.YZL[O&68^Y-=I10 BJJJ%50 !@ #I6?-
MX/\ "5QXHA\<3^%].?6K>T-K!K#V49NHX"VXQ+*1O"$G)4'&><5HT4 8_P#P
MKOX?_P#">_\ "U/^$&T?_A*/[+_LS_A)/[,B^W_8O,\S[-]HV^9Y._Y_+W;=
MW.,\U)JW@?P5KWB72?&FN>#]+O=8T#S_ .PM6N]/CDN=.\]!'-Y$K*7A\Q %
M?81N48.16I10 4444 %%%% !1110 4444 ?B#_P>\_\ )K/P/_[*!J/_ *0B
MBC_@]Y_Y-9^!_P#V4#4?_2$44 >?_P#!IM_RE,_:[_[>/_3Y/7[_ %?@#_P:
M;?\ *4S]KO\ [>/_ $^3U^_U !1110 4444 %%%% !1110 5\<?\%#/VJ/VH
MOA+^T1X*^#/[/7BS0=)BU[PS>:C>SZUHPN@7AE"@#D$<&OL>O@?_ (*2?\G\
M_"__ +)_JO\ Z/6O2R?#TL7FE&C55XRDD_1L\S.<36P>55Z])VE&+:]4CG/^
M&GO^"G/_ $7+P!_X1I_^*H_X:>_X*<_]%R\ ?^$:?_BJ?17Z]_J3P]_S[?\
MX%+_ #/QS_7GB/\ Y^K_ ,!C_D,_X:>_X*<_]%R\ ?\ A&G_ .*H_P"&GO\
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M?^GR>OW^H **** "BJ^JZKI>A:9<:UK>I6]G9VD+375W=S+'%#&HRSNS$!5
M!)). !3-!\0:#XJT:V\1>%];M-2T^\B$EI?V%RLT,Z'HR.A*L/<'% %NBBB@
M HHHH *^!_\ @I)_R?S\+_\ LG^J_P#H]:^^*^!_^"DG_)_/PO\ ^R?ZK_Z/
M6O9X>_Y'F&_QQ_,\7B/_ )$.)_P2_(Y^BBBOZ#/YU"BBB@ HHHH **** "O-
MOVG?^19\,?\ 90-%_P#2M:])KS;]IW_D6?#'_90-%_\ 2M:\?B'_ )$>)_P2
M_(]GAW_D?8;_ !Q_,_6&BBBOY[/Z+"BBB@ HHHH ^3?^"SO_ "9[:?\ 90-#
M_P#2BO&:]F_X+._\F>VG_90-#_\ 2BO&:_4_#K^!B/6/Y,_*/$G^/AO27YQ"
MBBBOTD_,@HHHH **** "BBB@#(^('_(AZW_V"+G_ -%-7UO_ ,$P?^3 ?A7_
M -BM'_Z,>ODCX@?\B'K?_8(N?_135];_ /!,'_DP'X5_]BM'_P"C'K\M\1OX
MV&])?^VGZOX;?P,3ZQ_)GO%%%%?FI^FA1110!^(/_![S_P FL_ __LH&H_\
MI"**/^#WG_DUGX'_ /90-1_](110!Y__ ,&FW_*4S]KO_MX_]/D]?O\ 5^ /
M_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %%%% 'YF?M _\$U?V@/VA?B9_P ,E2_L
MTZ-X6^"OB7XPZKX_^//Q,TGQ'9B]^)%E_:-SJ&G: ((V6Z )G@BF:;9'&+;]
MU(1C?]6_\$[_ (8M\)O#'Q(\+:1^S?9?"+PU_P +-FD\'?#RPO-->/2]/_LK
M3$,GDZ;/-;V;7%PES=&!6!'VC>PW2%F_-SX@^//^",WB?]J/XV:-_P %)?\
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M_1ZU[/#W_(\PW^./YGB\1_\ (AQ/^"7Y'/T445_09_.H4444 %%%% !1110
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M_P!(111_P>\_\FL_ _\ [*!J/_I"** //_\ @TV_Y2F?M=_]O'_I\GK]_J_
M'_@TV_Y2F?M=_P#;Q_Z?)Z_?Z@ KP/\ ;<_:5_:B_9[O_!=E^S%^P7J7QQOO
M$=U?07D6G>.=/T+^QS#"DJ,\M\OE,)5\X#YU(,. &W#'OE>!?MN_!C]N3XQZ
MCX+LOV,_VW;?X+PVMU?#QA=3?#[3O$+ZC"T*&W\N*]QL,<D; E'7*SDD-M7
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MO?'.\N=$E;2)K#S)FT31FOI?L\Z))&9+XW<AW*"S2%OXLT ?6M%%% !1110
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M ()@_P#)@/PK_P"Q6C_]&/7R1\0/^1#UO_L$7/\ Z*:OK?\ X)@_\F _"O\
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M &1\0/\ D0];_P"P1<_^BFKZW_X)@_\ )@/PK_[%:/\ ]&/7R1\0/^1#UO\
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M% 'G_P#P:;?\I3/VN_\ MX_]/D]?O]7X _\ !IM_RE,_:[_[>/\ T^3U^_U
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M#]H"BBB@ HHHH ^3?^"SO_)GMI_V4#0__2BO&:^O_P!L[]EW_AKOX/1?"?\
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MG[7?_;Q_Z?)Z_?ZOP!_X--O^4IG[7?\ V\?^GR>OW^H **** "BBB@ HHHH
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MM[B?2O#EDK".)([>##7=[.YD\M"PC1+:5I#S&K_/'[!O[?'[?/@__@HGKO\
MP2K_ ."F_ASP7J?BN7P,?&7PY^)7P]M)K:QUW3%G\F2.>"0DQRAO,&0$"F!U
M(<-'(_W]K.LZ/X<T>[\0^(=5MK"PL+:2XOKZ\G6*&WA12SR.[$*B*H)+$@
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MEXY;>:/"[6E8!UD.1@%1C)^M:** "BBB@ HHHH **** /Q!_X/>?^36?@?\
M]E U'_TA%%'_  >\_P#)K/P/_P"R@:C_ .D(HH \_P#^#3;_ )2F?M=_]O'_
M *?)Z_?ZOY/?^"7?_!87X;?\$>_^"@?[17Q(^)'P=USQC!XQUR_TVVMM#OX8
M'MWBU:>4NQE&""#C K]!/^(WG]EG_HQ[X@?^%%8_X4 ?M]17X@_\1O/[+/\
MT8]\0/\ PHK'_"C_ (C>?V6?^C'OB!_X45C_ (4 ?M]17X@_\1O/[+/_ $8]
M\0/_  HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^(/\ Q&\_LL_]&/?$#_PH
MK'_"C_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\ $;S^RS_T8]\0/_"BL?\
M"C_B-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_ -&/?$#_ ,**Q_PH_P"(
MWG]EG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&/?$#_P **Q_PH_XC>?V6
M?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\ HQ[X
M@?\ A16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_  H_XC>?V6?^C'OB!_X4
M5C_A0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A16/\
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M>?V6?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\**Q_PH_XC>?V6?\
MHQ[X@?\ A16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_  H_XC>?V6?^C'OB
M!_X45C_A0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\ B-Y_99_Z,>^('_A1
M6/\ A0 ?\'O/_)K/P/\ ^R@:C_Z0BBO@/_@OI_P7T^$7_!83X1> /AO\-_@#
@XD\'3^#O$EUJ5S<ZYJ=O.EPDMN(@BB(9!!&<FB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>jnj-20230101_g3.jpg
<TEXT>
begin 644 jnj-20230101_g3.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
MB$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-
MO^"IG_27;_RH:Y_\>K]_J* /Y/?^"PO_  2[_P""@?\ P1[^&W@[XD?$C_@H
MIKGC&#QCKD^FVUMH>OZK ]N\4(E+L99L$$'&!17Z"?\ ![S_ ,FL_ __ +*!
MJ/\ Z0BB@#S_ /X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z
M?)Z_?Z@ HHHH **** "BBB@ HHK#^)WQ(\&?!SX;^(/BW\1M;BTWP_X7T6ZU
M;7-1F/R6UI;Q-++(?941C^% 'C6O_P#!1_X ^'?^"D.@?\$Q[W4?^*YU_P"'
MEUXI@F\]?*0Q2@1V.T DSR0)=7.,C;';9P?,6OH&OY<O^"R_@']LK]@C]N7X
M%_\ !;#Q)=:BGB?XIW<?BZ\TB^;"^';^WG#P^'9"H^6)-(DL;1@23(T-V1QP
M/Z7/V>OCGX!_::^!7A#]H?X6ZE]J\.^-/#MIK.D3$C<(;B)9 C@?===VUEZJ
MRL#R* .QHK\A_AC_ ,%0?V^_^"L[?M7_ !!_X)U?%C_A!O#?P'TH6_PDT71?
M">G:K?\ C[5 MW(KW;7\,P2*=;/9%# L3C[5'ND)C8-Z%I'_  6W_:*_9I_X
M(=+_ ,%"?^"@?[,UYX7^*T6J2^'='\%ZEI<^D?\ "0ZD9&2UN3;SCS;6)XTD
MFD4]5MI6CP'C% 'Z;45^/GQ=_P""AG_!4S]EW_@CWX'_ ."R?B_]H'1/%.L^
M)Y-.U36_@_J/@FQM_#=MI&JNR626LUNB:BL\8EMI"\MW*K LNP8W'T9_^"D'
M[9FK_P#!MK:?\%/M-^)>FVGQ5M?#T^O75RWANVDL+L#6IK7[*UN5 6,0E0K*
M0^Z)"S/E]X!^GM>7?MK_ +3NG?L7_LG>/_VJM7\#:GXEM_ GANXU:70M(P)[
MP1C[@8@B-<D%Y""$0,^#MP?RXTO_ (+'?M_>)?\ @V\U#_@JM;?$;0+/XF^'
M?&)M+B./PI;OI^H6CZW;Z:(WA;)1E6<.'1ADI@@@\>K>"?\ @I-^V3\4?^#:
MI/\ @IX?'^CZ?\4['P[K&L7<T7AJWDTZ_6TUN\LA;R6T@(5&@C3E&5MZALD%
ME8 ^K?\ @DS_ ,%&=._X*G?L::3^UOIWP:U/P)_:&K7NG3Z%J-^+Q!);R!6D
M@N1%%]HB.0-_EIAUD3'R9/TK7XX_ ?\ X+B_M5^'O^#<'Q7_ ,%*?$WA/PUJ
MOQ!T?Q5-X>T"WTW01::58B2]MK2&>6WA(&R(3LVT$!W"*<!LUZ[_ ,$P_P!M
M+]I_]LL? WXU?!/]ONP^,W@?5+R:U_:)\)ZQX'TK3->\'WS:'?20!!9QQ>58
M_P!HQPQC>DDCXB*7$D;2@ 'I>J?\%MO#FF?\%J;;_@CH?V8/$TEU<:6LY^(:
MWX\@3-I?]H@BT\G+6HC_ '1N/-&)0R^7@;J^M?B?\?/A5\'?$W@SP9\0/%<-
MEJWQ \1_V'X2T[[TVH7@MYKEU51SM2&"1V<_*N "<LH/Y9Z9_P %2?VTO"O_
M  <]6O\ P2[U_P 8^&];^'DDDD2ZE<^#[6'6/L<OA=]92W-U$%^5+@J.% 94
M!(R2:^5OVS]4_;:\>_\ !V)\/O@;J?[7T U?0;Q&^'6KOX)$FF>%K:[TB:Z:
M&/3&N\3MM.R29I@\K!6. B1J ?J'_P %E/\ @M?X>_X) W_PLL-;_9D\1_$,
M_$O6+NU,FC:DMHMA#;&W$FPM#)]HN6^TKY=O\F_8V9%XS]P6TPN;>.X$;H)$
M#!)$*LN1G!!Z'VK\9?\ @X@_X*5_\%%?^"2EK\!+'P/\<O"7C2^\9V6K/K]W
MKWPTLTA34=-:Q"WEK%O=K?>M\<H9)"I3*L VT>]?\%U?^"P_Q3_8?^)_PB_8
M;_9+CTF+XM?&C6[2WC\0ZW8_:X/#>G7%ZEE'<BW)"S323-($#Y11;R;E8E:
M/TCHK\K_ (T_\%2_VE?^"6W_  5O^%G["?[57QJ/Q:^%_P 9]%T\Z=XQUOP[
MI^F:SX;U2YO9K)0QTZ&"VGM/.CC+;H@Z)-G>?*/F\1_P5Z_X*W?\%'/V(O\
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M!K6C:?IGA+Q!!X>N-1#@60>WAN'0%EG:WB9_G W;'/4&@#ZPHKXJD_X. _\
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MV;O&%WX?G\479'G^*-&ANIK6"^D_OS(T.R1_XUD@=BSNYH _16BBB@ HHHH
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MD_LDJSQP2R1CRUB4ABS*S?-0!9_X)+_L:_LOZ?\ \$W?V5_%^H_ 7PAJ6O\
MA[X4Z'K^A>(=2\.6T]]INHZAI\%U=W-O.Z&2%WEE8EE()PO]T8_*K_@AG\0_
MVE/''_!<K]L'P?X?^/'A/P7\1/$6O:U<7;>.O L^NO=QV6MRQR6END>I6)B,
M0EC^7<_[N(851&37[M?LJ?L\:5^R=^SYX3_9O\-_$3Q'XGT?P7H=KHVA:AXK
M:S:]CL+:%(+>!VL[:WC<)'&JAC'O.,LS'FOCC]M+_@W-_97_ &J?VOHOV[OA
M?\</B1\%OB?)=)<ZGX@^&6K16OVNY">6;H!HRT%PR?*[QNJN,ED9F9F /A__
M (*#_P#!,OQA_P $=O\ @A!^TI\&/AY^UC+\0+?QKXW\-:QXBL+7PZNEMH5K
M<7\,$I\I;NX81W#0P1;B5!6$K\PSCK?A3#X8F_X,G[Y-&AMVA_X5[J[7 50?
M]*'BBX+D_P"T)!GUX'M7ZD^#?^">/[.V@_LL>)?V2?'=OKWC_0O'-K.GC_6_
M'^N2ZEK'B::6)(FN;N\;#F94CB6,Q[!"L,0B$8C4#Y!\'?\ !LA\ ?"'[-GC
M']C4?MK_ !POOA/XDO)+S2O EWKEF++2+MY$<W6([93<R+Y8*))^Y$G[TQ-*
MJNH!%_P:-_\ *&/PS_V.^O\ _I57RU_P2F?6$_X.XOVJT\,;_P"SVT+Q'_;
MCSLV_P!H:5RW;/G[?Q)K])_V1_V0?V2/^"%/['?B'1=$^-GC _#O1Y7U:\F\
M=ZS!=O#<. K+:I!;PYEG?8JP1J3)(45%W-\WC'_!!C_@GS\3_A!XA^,G_!2K
M]J?P5/X>^*/[2/C&\UR+PK?J!<^%]"FNY;J"SF'6.>1I5:2,\HL,"MM=74 '
MZ-T444 %%%% !1110 4444 ?B#_P>\_\FL_ _P#[*!J/_I"**/\ @]Y_Y-9^
M!_\ V4#4?_2$44 >?_\ !IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\
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M6?@?_P!E U'_ -(111_P>\_\FL_ _P#[*!J/_I"** //_P#@TV_Y2F?M=_\
M;Q_Z?)Z_?ZOP!_X--O\ E*9^UW_V\?\ I\GK]_J "BBB@ HHHH **** "BBB
M@ HHHH ***CO();JSEMH+R2V>2-E2XA"EXB1@,H<,N1U&X$<<@CB@#\\?^"4
M7_*7[_@HC_V/'@?_ --%U7W]XX\9^&OAQX+UCXA^,]4CL='T'2[C4=6O93\E
MO;01M++(WLJ*Q/TKP_\ 9P_X)O\ PB_9<_:&\=_M.?#GXG>/KGQ/\3[V"[^(
M1UK6H+FVUR:".5(&>+[.!#Y0E;9Y'E8&%Y7Y:](_:>_9[\(?M7_L_P#BS]F[
MX@ZYK.G:!XTT>32]<N/#]XEO=O9RX$T*2.CA1)'NB;Y2=DC $$@@ \2_X(Z>
M"?$MO^QQ%^T7\1-+DM/%OQZ\4:E\3O$=O,/GMQJTHDL+8]QY&FI80;3T\DBO
MJFH-+TO3M#TRVT71[&*UM+.!(+6V@0*D4:*%5% X    '8"O(/V//V$_@E^P
M^?B"?@Q?>(Y_^%E_$"^\8>(O^$AUU[W9J%UM\Q8=P&R/Y1@'<Y_B=L# !Y1^
MVXG_  T7^WW^SK^QE:_OM*\.:I=_%_Q_$O\ #:Z/MMM'B?/!$FJW<4P7J?[.
M8]J^O:\\\(?LS_#_ ,'?M*>-/VJ[>^U2]\5>-] TC1+PZA<1O!IVGZ<;EX;>
MT4(&B1Y;N>:0,S;W8'@* /0Z "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** /Q!_P"#WG_DUGX'_P#90-1_](111_P>
M\_\ )K/P/_[*!J/_ *0BB@#S_P#X--O^4IG[7?\ V\?^GR>OW^K\ ?\ @TV_
MY2F?M=_]O'_I\GK]_J "BBB@ HHHH **** "BBB@ HHK\C_VY_\ @LE^V9^S
M]^UCXX^#_@/6- 31M"UM[;3DN=!2218PJG#,3\QR3S7?EN68[-\6L+@X<]1W
MLE9;*[W:6QP9GFF R?!RQ6,GR4U:[=WN[+9-[GZX45^&W_#_ '_;Y_Z#?AG_
M ,)N/_XJC_A_O^WS_P!!OPS_ .$W'_\ %5]+_P 0\XS_ .@1_P#@4/\ Y(^8
M_P"(C<%?]!D?_ 9__(G[DT5^&W_#_?\ ;Y_Z#?AG_P )N/\ ^*H_X?[_ +?/
M_0;\,_\ A-Q__%4?\0\XS_Z!'_X%#_Y(/^(C<%?]!D?_  &?_P B?N317X;?
M\/\ ?]OG_H-^&?\ PFX__BJ/^'^_[?/_ $&_#/\ X3<?_P 51_Q#SC/_ *!'
M_P"!0_\ D@_XB-P5_P!!D?\ P&?_ ,B?N317X;?\/]_V^?\ H-^&?_";C_\
MBJ/^'^_[?/\ T&_#/_A-Q_\ Q5'_ !#SC/\ Z!'_ .!0_P#D@_XB-P5_T&1_
M\!G_ /(G[DT5^&W_  _W_;Y_Z#?AG_PFX_\ XJC_ (?[_M\_]!OPS_X3<?\
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M)7]#U?SP_P#!5G_E('\4/^QGD_\ 0$K]#\+?^2SH_P"&?_I#/SGQ5_Y(JO\
MXH?^EH^>:***_JD_DT**** "BBB@ HHHH **** /V%_X-OO^2$?$/_L9[3_T
MF-?H_7YP?\&WW_)"/B'_ -C/:?\ I,:_1^OXIS__ )'N*_Z^3_\ 2F?W!P]_
MR(,)_P!>J?\ Z0@HHHKR3V HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*** "BBB@ HHHH **** "BBB@#\0?^#WG_DUGX'_ /90-1_](111_P 'O/\
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M)WK*LA^:0B@#W.BBB@ HHHH *_GA_P""K/\ RD#^*'_8SR?^@)7]#U?SP_\
M!5G_ )2!_%#_ +&>3_T!*_0_"W_DLZ/^&?\ Z0S\Y\5?^2*K_P"*'_I:/GFB
MBBOZI/Y-"BBB@ HHHH **** "BBB@#]A?^#;[_DA'Q#_ .QGM/\ TF-?H_7Y
MP?\ !M]_R0CXA_\ 8SVG_I,:_1^OXIS_ /Y'N*_Z^3_]*9_<'#W_ "(,)_UZ
MI_\ I""BBBO)/8"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* /Q!_X/>?\ DUGX'_\ 90-1_P#2$44?\'O/_)K/P/\ ^R@:C_Z0BB@#S_\
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MT/5_/#_P59_Y2!_%#_L9Y/\ T!*_0_"W_DLZ/^&?_I#/SGQ5_P"2*K_XH?\
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MU^C]?Q3G_P#R/<5_U\G_ .E,_N#A[_D083_KU3_](04445Y)[ 4444 %%%%
M!7E'[>/PH\1_'C]AWXR_ [P=$9-7\9?"GQ%H>E1J<%KF[TVXMXA^+R+7J]%
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MX$^)_$\W@O26D.A:)XBU..\73/-GEGF$,OE++M>69V*N[@'[H7)R >QT444
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M* /Q!_X/>?\ DUGX'_\ 90-1_P#2$44?\'O/_)K/P/\ ^R@:C_Z0BB@#S_\
MX--O^4IG[7?_ &\?^GR>OW^K\ ?^#3;_ )2F?M=_]O'_ *?)Z_?Z@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#\0?^#WG_DUGX'_
M /90-1_](111_P 'O/\ R:S\#_\ LH&H_P#I"** //\ _@TV_P"4IG[7?_;Q
M_P"GR>OW^K\ ?^#3;_E*9^UW_P!O'_I\GK]_J "BBB@ HHHH **** "BBB@
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M'X4>&-1\,_ ^9UYUR]OV5=6\01'_ )]&BCCL[9N1.BSSKF*2!V *W[4.M_\
M!83XY?$#Q%I/_!/W7/A1\./"/A.X:PL]>^)VDWE_>^+=1CC!G,,<0V6=C'(Q
MM_-97EDDAE95$80O/_P1P_X*)_%?]OOX,^-='_:5^%%GX,^+7PB\?WO@OXDZ
M-I+LUB]_;8S/;;F<JC99=I=\-&2&*LIKZ*_:#^.OA7]G;X97?Q$\26-WJ-QY
MJ6>@^'M+027VNZE*=MMI]I&2-\\KX49PJC<[E41V7RS_ ()J_L=Z[^R1\&?$
M&I_$^>RN/B5\5?'6J>/?BC=::Y>V36M1D$CVENQ +6]M&L5NA.-WE-)A3(5
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M#'&CN[86.)!EF8D@DG)KZTK\[?\ @U6_Y0D?"_\ [#7B3_T^7M?HE0 4444
M%%%% !1110!^(/\ P>\_\FL_ _\ [*!J/_I"**/^#WG_ )-9^!__ &4#4?\
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M0[^&![=XM6GE+L91@@@XP*_03_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\
M$;S^RS_T8]\0/_"BL?\ "C_B-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_
M -&/?$#_ ,**Q_PH_P"(WG]EG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&
M/?$#_P **Q_PH_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\
M**Q_PH_XC>?V6?\ HQ[X@?\ A16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_
M  H_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\
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G#X;_  W^ /B3P=/X.\276I7-SKFIV\Z7"2VXB"*(AD$$9R:* /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>jnj-20230101_g4.jpg
<TEXT>
begin 644 jnj-20230101_g4.jpg
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M#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _
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M_P#'J/\ B$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\
MQZC_ (A-O^"IG_27;_RH:Y_\>K]_J* /P!_XA-O^"IG_ $EV_P#*AKG_ ,>H
M_P"(3;_@J9_TEV_\J&N?_'J_?ZB@#\ ?^(3;_@J9_P!)=O\ RH:Y_P#'J/\
MB$V_X*F?])=O_*AKG_QZOW^HH _ '_B$V_X*F?\ 27;_ ,J&N?\ QZC_ (A-
MO^"IG_27;_RH:Y_\>K]_J* /YK?VW?\ @W=_X*6_L1_LG^.OVL/%/_!4R\US
M3_ NAMJ5WI.GZOK,<UTBNJ[$9YMH/S=3Z5^2G_#6'[4W_1ROQ _\+*^_^.U_
M7]_P7X_Y0V?M"?\ 9/YO_1T5?QA4 ?O]_P &FW_*4S]KO_MX_P#3Y/7[_5^
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M_LG\W_HZ*OXPJ /W^_X--O\ E*9^UW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\
M;Q_Z?)Z_?Z@ HHHH **** "BBB@ HHHH POB1\4?AI\'/"=QX\^+7Q!T7PQH
MEK_Q\ZOK^J16=M&2"0#)*RJ"<' SDXK^9#_@UQ_:5^!?[+W_  5&^*7Q._:*
M^(]AX+\/>(?AOJUGH^L^(MUM;W-P^LZ=.D(=A@.T44C!3@G80.>*_J,HH _
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M %?@#_P:;?\ *4S]KO\ [>/_ $^3U^_U !1110 4444 %%%% !1110 4444
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M&\R2(,Z*;F.)[<%U_>_,"0#[)HJ'3M1T_6-/@U;2;^&ZM+J%9K6ZMI0\<T;
M,KJRY#*0001P0:FH **** "BBB@ HHHH **** "BBB@ HHHH ^0/^"_'_*&S
M]H3_ +)_-_Z.BK^,*O[/?^"_'_*&S]H3_LG\W_HZ*OXPJ /W^_X--O\ E*9^
MUW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@
MHHHH **** "BBB@ K^9?]BWX/Z'\=/\ @[-^,?PY\1>*_%>BVEW\0_'[R7_@
MOQ9>Z)?KL:Z8!+NRECF13C#!6 8<'BOZ6_$6EWVMZ)<Z5IOB2]TB>>(K%J>G
M1P-/;G^^@GCDC)_WT8>U? GP6_X-S/V:?@'^V_>?\%#_  !^U]\>%^*6I:WJ
M>JZKK%[JGAR6"\GU#S?M8>W.B",(_G/\JA0F1LVE1@ ^AOV0/^"6'[!/["/B
MC5O'_P"S+^SW8:-XGUXR?VUXMU/4KO5=7O/,?S)0U[?S33A7?#.JN%9@"02
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MK7FC66DZ7K_@W5K:."SLK>/:;>6TN8)K>]BE?#2).CCY$V;&4/0!^#?[</\
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M>/?VE_C%IOQ#\)7FFS^%4T+4=#CT_2Q8SF>WB2&;296D02,['S7D+;R"2,
M%W_@L-\(O GP(_X)H?M0?'?]G'X.>'/#GC[Q#\++R#Q%XI\.>'[>TU*_M%C\
MN1IKB)%DD\JV>8J68[ N1C%?G#_P16_8V^*'_!5;_@@#J7[$VB?M>>"_"7@B
M7QA=Z?XHTF+X4S:AK=C=0ZI!JT4AO/[8AC._]P03;#$>4!)7=7[PZWX2T/Q7
MX/N_ OC2QBUO3-2TV2PU:VU."-TOX)(S'*DJ!0C!U+!E"A2&(P!Q7YO_  4_
MX-@OV9_V:/C=K7Q"_9L_;._:!^'_ (1\22@Z_P##SP?X].GVM_ &9ELY+J&-
M;AH%W,JDL9E5F F#,6H ^V?V$_@BG[-/['OP[_9XA^,*>/HO WABWT&#Q<EN
ML(OXK0&!#L664(45%C(WM@Q]<\#UFLWP=X/\+_#WPEI?@+P/H-KI6BZ+I\-C
MI.F640CAM+:)!''$BCA55%"@=@*TJ "BBB@ HHHH **** "BBB@ HHHH ***
M* /D#_@OQ_RAL_:$_P"R?S?^CHJ_C"K^SW_@OQ_RAL_:$_[)_-_Z.BK^,*@#
M]_O^#3;_ )2F?M=_]O'_ *?)Z_?ZOP!_X--O^4IG[7?_ &\?^GR>OW^H ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^0/^"_'_*&S
M]H3_ +)_-_Z.BK^,*O[/?^"_'_*&S]H3_LG\W_HZ*OXPJ /W^_X--O\ E*9^
MUW_V\?\ I\GK]_J_ '_@TV_Y2F?M=_\ ;Q_Z?)Z_?Z@ HHHH **** "BBB@
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M[7?_ &\?^GR>OW^H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:<)^KMB2;*$DY)B7)/TH EHKA_VBOCSX3_9M^$NI?%7Q797=^;9HK71]#TQ
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M5 '[_?\ !IM_RE,_:[_[>/\ T^3U^_U?@#_P:;?\I3/VN_\ MX_]/D]?O]0
M4444 9>N^.?!/A?1=1\2>)O&&E:=IVD0--JU_?:A'#!91KG<\SNP6-1@Y+$
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M%I7B/Q#JOB&_TY_V;_#M[-+<7<C2R>;=7$CS3$+LB5F8[(XHXT"I&B* 7O\
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MA5_9[_P7X_Y0V?M"?]D_F_\ 1T5?QA4 ?O\ ?\&FW_*4S]KO_MX_]/D]?O\
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MK?PY_P!!"^Z7^1^C=%?G)_PT]_P4Y_Z+EX _\(T__%4?\-/?\%.?^BY> /\
MPC3_ /%4?ZI\0_\ 0._OC_F'^M_#G_00ONE_D?HW17YR?\-/?\%.?^BY> /_
M  C3_P#%4?\ #3W_  4Y_P"BY> /_"-/_P 51_JGQ#_T#O[X_P"8?ZW\.?\
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M^BE^/_\ PM;O_P"*KTFBC_5[(_\ H&A_X"@_UBS[_H)G_P"!,\V_X9A\,?\
M12_'_P#X6MW_ /%4?\,P^&/^BE^/_P#PM;O_ .*KTFBC_5[(_P#H&A_X"@_U
MBS[_ *"9_P#@3/-O^&8?#'_12_'_ /X6MW_\51_PS#X8_P"BE^/_ /PM;O\
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MN_\ MX_]/D]?O]0 5'=75K8VLE]?7,<,,,9>::5PJHH&2Q)X  Y)-25\L_\
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MW_*4S]KO_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %?.O[?\
M_P $\/#/_!01O ND>,OC1X\\$6'@O5KS5$U+X;>)&TG59KB6V-LL0N51RD)2
M24N!@L0@S@M7T510!\ ?\0\GP)_Z2"?M?_\ A_;K_P",U]$?L ?L,Z)^P)\.
M_%?PK\-?%?Q?XSL->\<3>(+;6O'FMG4M7(EL;*W:.XN2B&;:]JVPD9$9C4DE
M2:\9U?\ X*4_\% OB+\0O&FE_L9_\$D[GXA>#_!OC;4_"K>,O$_QMTOPS_:5
M_IUR]K>-!:2VT\ODK/&ZK(Q7> & Z@>[?L2?&/\ :I^-7@CQ/KO[7G[-%O\
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M+PIXQ_;'N_CEJD/Q(D:]\9ZA!;13Q,=(TO%G(EJ! IC7:<1@#$@R-VZO*/\
MB&]_X(E?]&$>'_\ PH-6_P#DNO?_ -C#]AO]GG]@/P!KOPC_ &7_  8OASPG
MJ_BB37+?0(KF::*QFDM+6"54>>1W*LUMYO+<&5@  !0![!1110 4444 %?D]
M^S#_ ,BQXE_['_6O_2MZ_6&OR>_9A_Y%CQ+_ -C_ *U_Z5O7VW /_(\?^"7Y
MQ/AO$'_D0K_''\I'I-%%%?LQ^*!1110 4444 %%%% !1110!T'_!-K_D_CXH
M_P#8@:5_Z/:OOBO@?_@FU_R?Q\4?^Q TK_T>U??%?SYQ#_R/,3_CE^9_17#O
M_(APW^"/Y!1117C'M!1110!\#_\ !23_ )/Y^%__ &3_ %7_ -'K7/UT'_!2
M3_D_GX7_ /9/]5_]'K7/U^S\!?\ (C?^.7Y(_$_$#_D?+_!'\V%%%%?:GPX4
M444 %%%% !1110 5YM^T[_R+/AC_ +*!HO\ Z5K7I->;?M._\BSX8_[*!HO_
M *5K7C\0_P#(CQ/^"7Y'L\._\C[#?XX_F?K#1117\]G]%A1110!\@?\ !?C_
M )0V?M"?]D_F_P#1T5?QA5_9[_P7X_Y0V?M"?]D_F_\ 1T5?QA4 ?O\ ?\&F
MW_*4S]KO_MX_]/D]?O\ 5^ /_!IM_P I3/VN_P#MX_\ 3Y/7[_4 %%%% !11
M10 4444 %%%% !7Y/?LP_P#(L>)?^Q_UK_TK>OUAK\GOV8?^18\2_P#8_P"M
M?^E;U]MP#_R/'_@E^<3X;Q!_Y$*_QQ_*1Z31117[,?B@4444 %%%% !1110
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M>,=<O]-MK;0[^&![=XM6GE+L91@@@XP*_03_ (C>?V6?^C'OB!_X45C_ (4
M?M]17X@_\1O/[+/_ $8]\0/_  HK'_"C_B-Y_99_Z,>^('_A16/^% '[?45^
M(/\ Q&\_LL_]&/?$#_PHK'_"C_B-Y_99_P"C'OB!_P"%%8_X4 ?M]17X@_\
M$;S^RS_T8]\0/_"BL?\ "C_B-Y_99_Z,>^('_A16/^% '[?45^(/_$;S^RS_
M -&/?$#_ ,**Q_PH_P"(WG]EG_HQ[X@?^%%8_P"% '[?45^(/_$;S^RS_P!&
M/?$#_P **Q_PH_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_ ,1O/[+/_1CWQ _\
M**Q_PH_XC>?V6?\ HQ[X@?\ A16/^% '[?45^(/_ !&\_LL_]&/?$#_PHK'_
M  H_XC>?V6?^C'OB!_X45C_A0!^WU%?B#_Q&\_LL_P#1CWQ _P#"BL?\*/\
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%PMH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>jnj-20230101_g5.jpg
<TEXT>
begin 644 jnj-20230101_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_M%>,/B/8W.D?$OXC_#;7O$6I:4P*3Z#:OI3V]K;N.JSQQ&2=QP4>781F,Y
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M*R?L-I_P4>_8"^('['UOXP@T#4O%%G;2:#JMUDPPZA:W45W;"4+DF)Y(%1\
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MSI\8/"WCZ(_ CX>Z7J6D)8ZSHR7-M%,J636\MQJ,<:/,TEY)(T+L\6S8JLC
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M!K]DKX*Z_P#M"?'_ ,;VWA[PIX:L_M&IZE< L>6"I%&B@M++([*B1J"SNRJ
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M.?%&HZ:^FV$&FZ<-,CDL3;74KZ@\T7F2(J*%!V!V0$LO[=T4 ?CO_P %Y_\
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M.!H(W4\AT<5]IT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;[2BX_FD?4X3,,!F$.?"U8U%WC)2_)LFHHHKD.P**** "BBB@ HHHH ****
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M "BBB@ HHHH *[+X4?M$?'CX%7HO_@W\8O$GAE]^YTT;6)H(Y#_MQJP20>S
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M.)K#4M.G,<L3?4=01D%3D,"0002*_/>+/#S*>(XRK44J5?\ F2TD_P"^NO\
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MBGPY\*K+4/#_ ,0_"PM!&=7NM9UJ]N;"VLY=X.\BXA;SAM,#(7'^KS7ZQ?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MM7O910M%U7Z+]3YG/L3>4:"Z:O\ 0****]H^="BBB@ K@OVB/V:?@_\ M2>
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MX:D5+TNM5ZIW3\T%%%%>>>B%%%% !1110 4444 %%%% !1110 4444 %%%%
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M]I=SH>N:;;WME>0/#=V=W"LD4\3 JR.C AE()!!&"#5BBFFT[H32:LS\7_\
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MOPU"NEK3J+[I)I_CRGZUX.8UX?B:>';TJ4W]\6FOPYC[VHHHK^:3^G@HHHH
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MOCAIGB'XI?#[1KC4?$7@734E-VB0JIDBC=D$4TJET5HXW9T9L.%P< 'X4?\
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MUV5<+\5Y,ZI:Q>EN3^;'_"N_+%?&1^?Y'F9Q*V7R\[?FCE:***^I/B@HHHH
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M4444 %%%% !1110 5^JO_!M)XHS!\7O!<LGW7T6]MTSZB\CD/Z1U^55?H_\
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M:N\KA?BM'C5+67^];D?DQ_QKT<K_ -\7HSRLZ_W"7JOS.5HHHKZ<^,"BBB@
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MA":M.I^\EZRM;[H\J?F@HHHKXD^X"BBB@ HHHH **** "BBB@ HHHH ****
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MV\,R6\;\$+-=)* <F(=*]FU75+#1-+N=:U6Y6&UL[=Y[F9LXCC12S,<>@!-
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M P% '  '  KQG]@?]C/P?^P[^SUIOPBT!XKO59C]L\4:RB8.H7[J [#/(C4
M(B]E4$_,6)]JK^3./.*9<3YRY4W^YIWC!=^\O63_  26Y_7? '"D>%LE4:J_
M?U+2F^W:/I%?BV]@HHHKX@^Z"BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ KX]_X+D?\ !,O6?^"K?["&H?LX^#/&UOH/BG2M
M?MO$?A&\ORWV274+>*>)8+@H"RQ217$R;U!*,4?:VW:?L*O"_P!OK6_VP?!_
MPY\*?$3]BSX9-XW\0^'/']C?>(O!2:];:<VN:$8;B&]MTEN72+S LR21AV \
MR)#SMQ0!^'W_  3T_P""PWQ*_8!_:8^)G_!.S_@O1\+]3O9/B#-IVC^,O&6L
MRQW$EI"FF0Z? ;U8LK>6<EHL)-W&[28S(?-+%E]'_P""W/Q#^)W[</\ P<1_
ML\?\$]?"NM:)_P ([X+.FZS8:9XGMIKO1[S594EU*2>[@@DC:YB-O;VT7EAU
M)7S5#H)6-=9^W?\ L8_%_P#X+0_%+XM_ [P+^QOXC\%ZW>?&'PCJM_\ $#XD
MIIEJW@;3H_#-I#>1E;>[FENIIP$VP6^^%PJ/)+&44CV'_@I+_P $C/CWX$_X
M*.?L\_\ !5+]B3P-<>.'^%L>CZ+\1/ L&HV\&JW^E6>Z#[;:-</'%/.;.66)
MHRZ$F*$J&W/M .K_ .">/_!9?]J/Q;_P58^(G_!'_P#X*"^ O!,/CGPVMQ<>
M$O&'P]L[NTL]4BCMX[Q4EMKJ>9E:2SE6X5@X"A&1@Q(>OTVK\R/V2_\ @FE\
M;OB7_P %T_BI_P %F?C+\.;OP-X=N-$@TGX6^%-?N8#JM],ND6NFS:A=1V\D
MJVT12"<)&S>:1.I94V8;T_\ X(W>./\ @M9XC3XOW'_!7/X>:-8+8Z_#_P *
MV@T2/3HY)T_T@W4,/V:3:]JN+40RSL)&+ON=@,J ? ?C4 ?\'QGA8@==%;/_
M (05W7[R5^,'B?\ 84_X*1:G_P ',ND?\%6++]@OQ0WPITW;8M(WC?PL-1>(
M^&I=):X%O_:WW1/*7V[MQC7.-QV5^S=I-)<VD5Q-:26[R1JSP3%2\9(R5;:2
MN1T."1QP3UH DHHHH *\9_:M_9__ .%@:4WCWPE9YUJQA_TB"->;V%>V.[J.
MG<CY>?EKV:BN[+<QQ.5XR.(H.S7W-=4_)_UJ<&9Y=ALUP<L-76C^]/HUYK_@
M;'YSD$'!&".HHKZ-_:K_ &:WE>X^*/P^T[).9-8TZ%>3W,Z ?FP'^]ZU\Y5^
M]91FV%SC!JO1?JNJ?9_IW/Y_SC*,7DN,>'KKT?22[K]5T84CO'%&\T\JQQQH
M7DD<X5% R6)[ #FG(CR.(XU+,QPJ@<DUY9\6OB0-9D?PKX?N0;&-_P#2IXVX
MNG!R #WC4CCLQ&[G"X^@P."JXZNJ<=NK[+^MCY['8VE@*'M)[]%W?];O_@&;
M\3/B%-XROQ96!:/3+9S]GC/!E;H97]ST _A''4L6Y>BBOOJ%"EAJ2ITU9(_/
M<17JXFJZE1W;"BBBMC$**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH *Y3XM?!_PM\8-#&G:XGV>]MT(T[5(DS);Y).TCC?&2<E">I)!!))Z
MNBIE%25F5&3@[H^'/B!\./%GPT\3/X5\4Z?LN!AK>6++1749)"R1-CYE.".Q
M!!5@&! _8_\ X(M_\$S)/V9O!R?M*?&W0C'X^\16.W2M-NH_GT&P< [2#]VX
ME&"_=$PG!,@.U^PU_P $_=#\0/HWQ[^/WA&WNFTZZ74/!ND:A;@M!+@;;QP>
MG12B'@E5<C*IC[>K\!\2>.OK"ED^!G>*TJ377^XO+^;N]-KW_H3PRX"^K..<
MX^%I/6G!_9O]M^?\JZ+7>UBBBBOQ,_<@HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "OG3]I3]E1G:X^(/POT_).9-1T>%?Q,D('YE/R]*^BZ*]/*<VQF38I
M5J#]5T:[/_/H>7F^3X/.L(Z&(7H^L7W7^6S/RJ^+_P 1&TY)O!>A7&)W!34Y
MT/,8/!@![$]'_P"^#_$*\PK]"OVP/^"?F@?%\W/Q$^$<-MI7B=LR7=D<1VVI
MMW)[1RG^_P#=8_>P26'P-XK\)>)O WB"Y\*^,-#N=.U&SDV7-I=Q%'0_0]01
MR".""",BOZFX+XAR7.\N7U25JB^.+^)/OYQ[-:='9W1_*/&W#N=Y%F3^N1O3
M>D)KX6NWE+NGK?575F9U%%%?9GQ(4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#V<6FOO1^*XS!8S+\0Z&)IN$UNI)I_<PHHHKI.4**** "BBB@ HHHH ****
M"BBB@ HHHH **] ^#/[+WQL^/%T@\ >"YWLF?;)K%X##9Q^N9&'S$=U3<WM7
MV=^S_P#\$T_A5\-)(/$7Q0N5\5ZO'AEMYHMMA"WM$>9<>K_*?[@-?(<0\<</
M\.1<:]3FJ?R1UE\^D?FUY)GV/#O G$/$LE*A3Y*3^W+2/RZR_P"W4_-H^3_V
M<OV+_B[^T3<QZCIM@=(\/[\3:]J$1$;#N(4X,S=>F%!&"PK] OV?OV8?A9^S
MEH7]G>"-)\V_FC O];O &N;D^A;'R)GHBX''.3R?0H((;:%+:VA6..-0L<:*
M JJ!@  = *=7\]<4\>YSQ.W2D_9T>D(O?_$_M?@NRN?T9PIX?Y+PLE5BO:5^
MLY+;_"MHK[WW=M HHHKX<^["BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@!ES;6]Y;O:7=NDL4BE9(I$#*ZGJ"#P17AGQ?
M_P""=_[.OQ2:34=*T*3PQJ+Y/VG0=L<3-_M0$&/'^Z$)]:]VHKT<MS?,\HK>
MUP5:5.7D[7]5L_1IGFYGD^5YS1]EC:,:D?[RO;T>Z]4T?GC\4/\ @EW\>/"+
MR77P_P!0T[Q3:+DHL,HM;G'O'*=GY2$GTKP7QK\,OB)\.+PV'CWP/JNCR[L*
M-0L7B#_[K,,,/<$BOV(J.\L[/4+9[*_M8YX9%Q)%-&&5AZ$'@U^FY7XPYWAD
MHXVE&LNZ]R7X7C]T4?E^:^#61XIN6!K2HOL_?C^+4OODS\7Z*_5;QE^QI^S#
MX[9Y=<^#>D1RR<M-ID;6;9]<P%,GZYSWKS'Q+_P2I_9_U4M+X>\2^)=*<_=1
M;N*:)?P>/<?^^J^YP?B]PU725>%2F_-*2^]._P"!\'C?!SB?#MNA.G47DW%_
M<U;_ ,F/SWHK[1UC_@D0V6?P_P#'4?[,5YX?_FRS_P#LM<]>_P#!)7XLQ@_V
M=\4/#LOIY\4\?\D:O?I>(W!E9:8M+UC-?G$^>K>&W&U%ZX1OTE!_E(^3Z*^I
M/^'3GQX_Z'WPC_X$W7_QBKMI_P $E?BN[ 7_ ,4O#T2YY,,,[G'XJM;2X_X.
MBKO&1_\ )G^2,(^'O&<G98.7WQ7YL^3J*^TM&_X)$?.LGB#XZ_+_ !16?A_D
M_1VG_P#9:[?PS_P2K_9]TEUF\0^(_$FK,/O1O>10Q-^"1[O_ !ZO,Q/BCP=0
M7NUI3_PPE_[<HK\3U,-X4\:8A^_1C#_%./\ [:Y/\#\]JW?!/PP^(WQ)N_L7
M@'P-JNL2!L-_9]B\JI_O,HPH]R0*_3KP9^QO^S%X"=)M!^#>D22IRLVI1M>L
M#Z@W!?!^F*](MK:QTNS6VM+>&VMX4^6.- B(H] . *^3S#QGPL4U@<*WYS:7
MX1YK_P#@2/KLN\$\5)IX_%I+M!-_^32Y;?\ @+/SW^%__!+OX[^+S'>?$#4M
M.\+6K8W)-(+JYQZB.([/SD!]J^E_A#_P3O\ V=/A<8M0U709/$^HQX/VK7B)
M(@W^S  (\?[P8CUKD?$__!9W_@G%X1\;1^$=5_:$22Q?3[V[D\9V&@7]UX=B
M2TNK>UGW:K#"UH DUS$C.)#&C$*[HS(K>G?'3]N+]DG]FW]G'_AKCXQ_'WP[
MIGPXDMH9['Q7!>B\MM168;H1:?9_,:[:0 E%A#LP!(! )'YSG'B'Q3G*<)UO
M9P?V:?NK[_B?HY6/TO)?#GA3)6IPH>TFOM5/>?W?"O51N>IV]O;VENEK:0)%
M%&@6..-0JHHX  ' %/KY@_8(_P""QO\ P3T_X*6:WJOA#]DSX[QZQX@T6V-U
M?^'-4TJYT^^%MN"_:(XKA$\Z(,RAFC+;"ZA]I9<K^WM_P6+_ .">G_!-35M-
M\*_M8_'F'2/$&KVXN;#PUI6F7&HZ@UN6*B=X;=',,1*L \A4.48+N*D#XAMM
MW9]RDDK(^GJ*\Z_97_:Q_9Z_;8^"VF?M"?LP?$VQ\6>$M6+I;:E9I)&T<J'#
MPRQ2JLD$JG&8Y%5AD'&""?1: "BO(OVD/VY_V:/V4/B+\-/A)\:?'ZV'B7XN
M^+8?#O@31;>V>>XOKN1D3>50'RX5:2)6E;"J94&>:]=H **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2XU6]8F:]DCC5&GD)))=R"QR2<L>3UH U**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@#$N?AQX&O/B-9?%VY\-6S^)=.T2ZT>RUAE/G0V-Q-;S3P YQL
M>2UMW/'6):VZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ JEXE\1:/X0\.W_BSQ%>?9]/TNREN[ZX\MG\J&-"[MM4%FPJ
MDX ).. :NUQ?[27_ ";MX^_[$K5?_226NG!48XG&4Z4MI22=O-I'+C:\\-@J
MM:.\8R:OM=)LXK_AX;^Q[_T5_P#\M_4/_D>C_AX;^Q[_ -%?_P#+?U#_ .1Z
M_,2BOZ+_ .(.<,?\_JW_ (%#_P"5G\W?\1HXI_Y\T?\ P&?_ ,L/V7\-^(M'
M\7^';#Q9X=O/M&GZI917=C<>6R>;#(@=&VL RY5@<$ C/(%7:XO]FW_DW;P#
M_P!B5I7_ *215VE?SIC:,</C*E*.T9-*_DVC^D<%7GB<%2K2WE&+=MKM)A11
M17,=0445^9_PHU#X'Z;_ ,%;_P!L[PA\;?!?C'Q!H.@Q?#^Z\,:)X=\'Z]KE
MMI37&ASS7IAM],@F6V::0([+M4RN"0&(8@ _3"BOE/X9_M0?#+]G#X;?LX^$
M/!GP]\2W'A?]H#7I%\+3:MK#2WF@SZG:WNOI;W"7&9##'$)84 8M&$CCVX&1
MF?&;_@KAX:^"7PH^.WQ,U[]G?Q+J3_ 3Q[IWA?Q-8Z-J5K(+EKV&QFAO(FD9
M&,(74( RK&TH8D"-@": /K^BOG.P_;H^(,GC;1O@CXG_ &5=6\,?$CQAK>L+
MX*\)>(O%=@T=YH>G06TLNN75S8M<BSMRUU%;^5LEG\]PH0INE7@_%G_!8_X?
M>"OA?J7BO6_V>O&4GB7PM\:=-^&7C[P;8SV<MQH.JWUS!#;W 8RJ;NTF2YBE
M@DA1FE#@,D1#A #[(HKY"\-?\%<_!OACQU\5?A;^UY^S]XH^#OB3X8>!X_&W
M]E:WJ=AJ0UWP[),;=+NTFLIGB:7[2%MVA+_++(BAVR2O6? 7_@HSX4^+W[5,
MW[)&O>#[&QUVX\%?\)3H.K^&?%MMKNF7=HLX@FM)KB!5%M?1,\;- 0Z,C%HY
M9 IH ^D:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0W4M_=R:<QX9CI<2%L"@#ZCHKX\O/^"P_P )? WC#QUX0^+O@=;<^#OA%?\
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MQP7QAI7@7_A(KRWT :*NGWFEKI<>I+IYG$OD7(N#.UH5$QD01^6$QY1\6_\
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MWEOUUSP5JMU#%%?O:P00M!J,+M$LT<4DL 5V96;;EG]=_P""D_[*6J_MH?\
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H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>jnj-20230101_g6.jpg
<TEXT>
begin 644 jnj-20230101_g6.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M165Q>2137<UK974-QLMSLA>S59 6*2$1OCZFK\.?^"6/_!R9K?[0O[1/@_\
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M#\?_ +1GB[XEW-[%!=V^K>,;/2X9[*%K:%1:1C3;.UC,2E68%T:3,C9<C:
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M)6*2B ;'D_+3X[_\%D_&'AK_ (+._&/]C/\ ;"_:]\=_L\>'-'CLM,^"&O\
MA_2].?1K&[:%9/[0UE+NUE-W#<F2)E9R(8T#*QC)\Y/L_P#X*$?"SQU\2/\
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MXO[OX4_#BSU:WDC\$V43WLFGV1N8V-LMWB\=049H(C'#A\!\?$7Q0_X(W?\
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MJGPY^%^D>'(/$U[)XO\ #=O=%X=4O;VY$4$NIJS^5'=HAZ!GC<(67:[?K/\
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MUJ%[<6T5U+MMI&=X00);CRT#QQB9OBW]O;_@E%_P4]_:%_X(<?LO_L)?#O\
M8JU>3X@_#76IKCQC977CCPW%;V<<4-W"A68ZGME\W[2K*$R0$;?L.T-^\U%
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M.D+Y&D7OBBZCN+V&S4 16\DZHC7 C4;%EEW3,H!D>1]SL ?D;_P7=_X)R?\
M!1/]OO\ X)]_LS? /]GC]C?6KSQ/X&TZ&;QG9:CXQ\.VJ:5+%I\=GY!D?4MD
MSLZ,X:(NFS&6#$H+?_!5+]@/_@HG^U/_ ,%//V1?VL_@Y^Q+XAOO"GP:3PO?
M>-#<^,_#4%Q');:O%?7-M%')J@\V2.-"NX'RV?A69?FK]EJ* &02/- DLD#Q
M,R M%(060D=#M)&1[$CWK\A_"G["7[</[/7_  </?%3_ (*K3?LTZKXG^%.N
M/_8-NGAO5;&36)8I=&LH_P"T(;.6>,R6Z7-OY+C<)?F++&ZJ37Z]T4 ?E_\
M\$N?^"9OQ_\ #?\ P4Q_: _X+'?M1?"VZ\+ZIX^GO[/X8_#:;4+2?58--DDB
M(N;MHIFMX+F2&U@C6+SB%,LV]EPIKSG_ ((-?L)_\%"?V"_VPOVGOCE^T?\
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MZ%9+.XO[A[E+=U/*R10O#$Z]GC:OLVBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;3)V']YM_GHQ]@J ^W6OK;X#?\%W/V%/B^8=-\:>(-5\ ZE)A3#XGL";8O\
M[-S 70+_ +4GEU\9F7A[Q;EB<IX9SBNL+3_!>]]Z/M<L\1>$,U:C#$J$GTFG
M#\7[OW-GV?161X(^(/@/XEZ%'XI^'/C72=?TR;_5:AHNHQ74#_1XF93^=:]?
M&SA.G)QDK-=&?:PG"I%2@[I]4%%%%24%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 445Q_QQ^/WP=_9N\!W'Q+^-OCZP\/Z/;\?:+R3YYGQD1Q1KEYI#@X1
M 6."<8!K2C1JXBJJ=*+E)Z))7;?9);F=:M1P]*56K)1BM6V[)+NV]CL*\?\
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M6AZ-#8MT>3J#/R%_@RWSI[F0</9GQ)CEA<'&[ZM_#%=Y/^F^B/"X@XBROAG
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MHHKQ#W0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ H) &2:*_,/_@MC_P5-F\)QZC^QE^SKXDVZE+&T'CWQ!92
M\VB,,-IT+CI(1Q*P^Z#Y?WBX7W.'L@QW$F9QP>%6KU;Z1CU;_3N[(\+B+B'
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M;+07'V$LIQ+>D90@]_*'[S(.5?R<C#5]-UG\4_)?F:?!#S?Y!1116AF%%%%
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M-;U?R16HU</5E2J*THMII[IK1I^A_8-&M2Q%&-6D[QDDTULT]4UZH****S-
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MG(**** "BBB@ HHHH **** "BBB@ HHKI/AK\&_BW\9=7_L'X2?#+7_$UX"
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MKXM:O:D/,'M-$WJ00G2:89'?_5!@<8\Y2.E>\TE[TK]OZ?\ D-^["W5_TO\
M/[@HHHK0S"BBB@ HHHH **** "BBB@#ZM_X)C?M%2>$/&TOP)\2WN-,U^0RZ
M.TC<07H7E!Z"11C_ 'U4#EC7WO7XQ:7J>H:+J=OK.DWDEO=6DZ36T\38:.16
M#*P/8@@'\*_6+]FOXR6?QY^#.C?$:$HMU<0>5JD$?2&[C^65<=@2-P']UEK^
M>/%OAM83&PS:A'W:ONS\II:/_MY+[U?=G]'>#_$SQF"GE%>5Y4O>AYP;U7_;
MK?W.VR.[HHHK\:/VH**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M[2I5(5J<:D'=-)I^3V/XBJTYT:LJ<U9Q;379K<****L@**** "BBB@ HHHH
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MQK^T,OA'XJ_#F+X3V3?"A]2DU*?QT;Y/M">(1'811Z;Y/F;C&UJTDWF>7C*
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M%%% !1110!^9W_!1CPI'X8_:LURX@CV1ZM:VM\B@=VB".?Q>-S^->&5]2_\
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M*_G\_H<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MNZ?]-/1A1117MGA!1110 4444 %%%% !2HCR.(XU+,QPJ@9)-)7<_LQ^$?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA%1BK)'O%%?!WA7_ (+^?LR?$_\ X*B>$O\ @EM\)/A7XXO_ !+K=UJ$6O\
MB/Q'HD^AVVD_9M)N=179;7D:W5PSBW51NCA3;,LBO(, _1'_  4(_;7\#_\
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M]WONGOKZ)I-]S;R.,I#&-H(7Y<XR23\@_P##['_@IQ_T<Q_Y9FB__(=>J_\
M!QM_R>[X6_[)58_^G+4Z^ :_JC@SA[(,5PMA*M;"4I3E!-MTX-O5[MJ[/Y/X
MVXCXAPG%>+HT,95A",VDHU)I)66R3LC]9_\ @BM_P4/_ &P_VM?VIM?^''[0
M?Q?_ .$@T6R\ 76I6MG_ ,(_I]ILNDOK&)9-]M;QN<)-(-I)7YLXR 1^GM?B
MS_P;D_\ )[OBG_LE5]_Z<M,K]IJ_%_$S!8/ <4RI8:G&G#DB[12BMNR21^V>
M%^-QN8<*1K8JK*I/GFKRDY.R?=ML****_/S]$"O$O^"A/[9UC_P3]_9=UO\
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MEJMKX?30K;4[3PC91W$.E*@1;!9%B#+;!0%$(.P 8VXK<^&?PH^%OP6\)0>
M/@Y\-= \):#;2.]MHGAG1H+"TB9VW.RPP*J*6))) Y/)K?HH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
00 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>jnj-20230101_g7.jpg
<TEXT>
begin 644 jnj-20230101_g7.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ>%?A5XB\.75]?>(-&M)(5O+B[U*.\C%O.5ED,:PPE%:W*MY@8-0!^N=>/\
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MUY^S=H/C>]\+L_\ 8=[J#3136Z.06B+P2(TD1(!\IRR9YVY)H _G9_X*(/\
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M_@DG\>OAU\,;"XN];N? -Q<VEG:*6EN5MGCNI844<LSQ0N@4<L6 ')K\B?\
M@V.\/_\ !,+]KC]BSQC^RC^V+XCNXO%FAZ]=W%SX;U/XPZWHVGZQH-S'&PD6
MS@U""VF"2B=90(R0#$SD[Q7]$-?&7C3_ (-ZO^"-?Q!^-$OQ\\4_L*^&I?$%
MQ?&\NHK;4M0M]-GG+;B[Z=#<+:-DY)4Q;6W'<#0!ZU_P3K^%W[''PA_9BL/"
M7[!'@X:-\+QK&H2: (+ZZN;:^;[0Z37=M+=2R22V\DB.T<@;RY%Q)'E'5FSO
M^"MDD<7_  2M_:5:1PH/P$\7@$GN=&NP!^9KWS2-(TGP_I-KH.@Z7;V-C8VZ
M6]E96<"Q16\2*%2-$4 (JJ  H    %<-^T9^RW\$/VL_!+_#7]H#PM>:]X=G
MB>.]T%?$-_:6=\CE"4N8;:>-+E044@2APIR5QDY /Q1_X,:Y(SX8_:6B#C<M
M_P"$B5SR 4UC!_0_E7[WU\Z?LW_\$F_^"??['WC%_'O[+G[/<7@+59O*%Y<>
M&/$NJ6JWJ1MN2.XC2YV7,8;)\N563DY'-?19&1@]_0T ?SF_L]6FG:G_ ,'M
M&L?:XXY1#XT\1R1!L$"1/"=W@_4'GV(SVK]?O^"Z_P $/B-^T5_P2.^.GPG^
M$VGW%YK]WX/%[8V-FA::[%G=07LL$:CEWDBMW15'+%@!DFM71?\ @C-_P36\
M.?&<?M&Z#^S3%:?$$:G)J/\ PG$'BO5UU<W<@823F[%WYQD<,P9BV6#,#G)K
MZ?H _"G_ (($^./#.C_\&O7[3-]/J,*'1(/B -05I "CMX<MW0$>K!T ]2<"
MNH_X,G?@E\1/!O[(GQ;^.'B33;FUT#QMXTL;3PT;A"JW7V""9;B>,'[R;[E8
MMXX+P.O5#C]!_'/_  14_P"":'Q \0>)]=U;]G*6PA\;7L5YXUT#PUXVUK1]
M&\03QR>8DM]IEA>0V5TP<E\RPMEB2<DFOI#P!\/_  +\*O!6F?#?X9>#],\/
M^']%LTM-(T31K)+:ULH$&%CBBC 5% [ 4 ?SF?M-? O]J7_@D3_P<HI#^PMX
M=C"_M$PW:>"+.5"+)!K>^*X64*,"*QU)1>>6,!8K>'.U6S7[E_&7X,^#OV</
M^"7WC7X%>!%D71O"/P0U?3+*6Y?=+,D.DS*9I6_CE<@R.YY9W9CDDUZ1XY_9
MR^"GQ*^,?@?X_P#CCX?V>H>,/AO_ &C_ ,(5KDQ;S=+^WP+!=[ " ?,B4*=P
M.,9&#S6A\9?@W\._V@/AMJOPA^+.BSZGX<URV:VUC3(=3N;1;R!AAX9&MY(W
M:)P2KQEMKJ2K @D4 ?@[_P &=GB/PAX2_8Z_:\\4^/?#9UO0]+M--O-;T58D
MD-]9QZ?JCRP;'(5O,173#$ YP3BOG_\ X*4_\$H/&O\ P2KT_P ,?\%G/^"0
M?[3=W/\ "#4[NRU'0-1L-3QJ/AQ+TCR(BYRM]9.S"$K("XWB*9)/GD/] /[/
MO_!*'_@GW^RG%XCMOV<_V<[/P?;^+](?3/%%IHNN:A'!JEJR.FR>+[04D*K+
M($8C<GF,4*DDUS-K_P $0/\ @E[9QZ5I5O\ LP(- T;4H]1L?!#^+]8;PV+R
M,86Y?1FO#I\LO7+O Q8L2VXG- 'Y=_\ !U%\6O&OQY_X(R?LF_&[XF>'5T?Q
M)XRU'2=<UW24C*"UN[KP^\\T85N5"O(0 >0, \UR'_!>#X)?$3QY_P &X_[$
M/QI\)V%Q>:%X%\!^%T\4+;*66U2]\/VD4-S)C[J+-$(=QZ/<H/XJ_;+]J_\
MX)P_L5?MR7>DW/[67P,M/&Z:#"T>C6>K:M>BULMQ^9H[>*98D=A@-(%WLJJI
M)"J!U'P\_9&_9R^%WP!?]E?PI\++)_AS)8R6+>#=9N)M2L!9R+M:U$5X\H6
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M (F_&_X2_:?%WA//_",>-O#^NW^B:YI8.X[8-1TV>"Z1,NYV"3;EVX^8YO\
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M&DFG-I[>#-<GFU*R%F0,6ZI=O(5B7 VQ@A4(!4*10!^8?[(/PG_X((_MU?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !17G
M?[57[4GPA_8U^!^K_M ?&[5[FVT326@A6#3[4W%W?W<\J0VUG;0KS+/++(D:
M+P,MEBJAF'@/AK_@J#\3-!\>^(M-_:$_8A\;>%_#-A\5M&\$0>(-+U+3-4.B
MWFIZ?H\]HNK16]VS1!Y]5CC,UL)X4\R-68$%B ?85%?-_P"VE_P40;]ESQ=9
M?"'X1_LK?$CXV?$"[TE=6N?"7PXTM)!I.G-(\4=U?7,S+%;+*\4R1)EGE:"3
M"X1F%7_@FU_P5.^!?_!2OP]XKMO OA#Q1X*\;_#[55TSXA?#?QSIPM-6T&Y8
MN%\Q 2&C9HI5#<,#$P94(Q0!]-45^?O[0W_!?;PS\"AJ7Q0T?_@G[\=_&/P6
MT&_:VUGXVZ!X;A&CLB2&*2\M$ED62ZLU<%1<GRXG()1F4JS?;7P3^,_PS_:*
M^$?ASXZ_!OQ5!K?A;Q9I$.IZ%JMN"%N+>50RDJP#(PSAD8!E8%6 ((H ZBBO
M*_VJ_P!K;P%^RCH7AM_$.A:KX@\1^./%%OX;\">#] 6(WVN:I,KNL2&:2.**
M-(XY)99I76...-B2255N;\,_MMOI'[2/A?\ 90_:+^#][X!\7>/=)O[_ , 3
MC68-2TW7_L*))>VL5Q%M>.ZAB=96CDB56CRR.^UPH![Q1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%5](U?2?$&DVNO:#J=O>V-[;I<65[
M:3K+%<1.H9)$=20ZLI!# D$$$58H **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]M:?\) KJK+H]O-+*K);.&(NI5 =U#0)M#O(.]_8Z_;>_:T^-OC>[\*^-O\
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MA>)_"5YH%S>V-Q8O#!H<4%]%#<W9::9I&?RS!#'YX$F^78P!]T4444 %%%%
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MN)F;S)Y!(RO$"@3YA_X(WZ[^UK_P3E_:$_9I_8D\3?&>\^)7P2_:9^"S>+?
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M;PW_ ,^/_)I__)!_KKQ-_P __P#R6'_R)]&?\-_?]4F_\KW_ -HH_P"&_O\
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MX>_\CR7_ %[E^<3U"BBBOQH_:@HHHH **** "BBB@ HHHH **** /B/]IO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?9'['?_ "0G3O\
MK[N?_1K5\;U]D?L=_P#)"=._Z^[G_P!&M7Q''_\ R)(_XU^4C[KP]_Y'DO\
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M***] \X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH _0[0O^0'9_P#7I'_Z"*M55T+_ ) =G_UZ
M1_\ H(JU7\S5/XC]3^H:?\->@4445!84444 %?-/[?'_ "'/#?\ UZ7/_H4=
M?2U?-/[?'_(<\-_]>ES_ .A1U]5P7_R45+TE_P"DL^3XW_Y)NMZQ_P#2D?/M
M%%%?N1^#A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !7V1^QW_ ,D)T[_K[N?_ $:U?&]?9'['
M?_)"=._Z^[G_ -&M7Q''_P#R)(_XU^4C[KP]_P"1Y+_KW+\XGJ%%%%?C1^U!
M1110 4444 %%%% !1110 4444 ?$?[3?_)=O$7_7VG_HI*X.N\_:;_Y+MXB_
MZ^T_]%)7!U_1F4?\BG#_ ."'_I*/YLSC_D;XC_KY/_TIA1117H'G!1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% 'Z':%_R [/\ Z](__015JJNA?\@.S_Z](_\ T$5:K^9JG\1^
MI_4-/^&O0****@L**** "OFG]OC_ )#GAO\ Z]+G_P!"CKZ6KYI_;X_Y#GAO
M_KTN?_0HZ^JX+_Y**EZ2_P#26?)\;_\ )-UO6/\ Z4CY]HHHK]R/P<**** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH *^R/V._P#DA.G?]?=S_P"C6KXWK[(_8[_Y(3IW_7W<_P#H
MUJ^(X_\ ^1)'_&ORD?=>'O\ R/)?]>Y?G$]0HHHK\:/VH**** "BBB@ HHHH
M **** "BBB@#XC_:;_Y+MXB_Z^T_]%)7!UWG[3?_ "7;Q%_U]I_Z*2N#K^C,
MH_Y%.'_P0_\ 24?S9G'_ "-\1_U\G_Z4PHHHKT#S@HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M#]#M"_Y =G_UZ1_^@BK55="_Y =G_P!>D?\ Z"*M5_,U3^(_4_J&G_#7H%%%
M%06%%%% !7S3^WQ_R'/#?_7I<_\ H4=?2U?-/[?'_(<\-_\ 7I<_^A1U]5P7
M_P E%2])?^DL^3XW_P"2;K>L?_2D?/M%%%?N1^#A1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M7V1^QW_R0G3O^ONY_P#1K5\;U]D?L=_\D)T[_K[N?_1K5\1Q_P#\B2/^-?E(
M^Z\/?^1Y+_KW+\XGJ%%%%?C1^U!1110 4444 %%%% !1110 4444 ?$?[3?_
M "7;Q%_U]I_Z*2N#KO/VF_\ DNWB+_K[3_T4E<'7]&91_P BG#_X(?\ I*/Y
MLSC_ )&^(_Z^3_\ 2F%%%%>@><%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?H=H7_ " [/_KT
MC_\ 015JJNA?\@.S_P"O2/\ ]!%6J_F:I_$?J?U#3_AKT"BBBH+"BBB@ KYI
M_;X_Y#GAO_KTN?\ T*.OI:OFG]OC_D.>&_\ KTN?_0HZ^JX+_P"2BI>DO_26
M?)\;_P#)-UO6/_I2/GVBBBOW(_!PHHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[(_8[_Y(3IW
M_7W<_P#HUJ^-Z^R/V._^2$Z=_P!?=S_Z-:OB./\ _D21_P :_*1]UX>_\CR7
M_7N7YQ/4****_&C]J"BBB@ HHHH **** "BBB@ HHHH ^(_VF_\ DNWB+_K[
M3_T4E<'7>?M-_P#)=O$7_7VG_HI*X.OZ,RC_ )%.'_P0_P#24?S9G'_(WQ'_
M %\G_P"E,****] \X**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M117H'G!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% 'Z':%_R [/_KTC_P#015JJNA?\@.S_ .O2
M/_T$5:K^9JG\1^I_4-/^&O0****@L**** "OFG]OC_D.>&_^O2Y_]"CKZ6KY
MI_;X_P"0YX;_ .O2Y_\ 0HZ^JX+_ .2BI>DO_26?)\;_ /)-UO6/_I2/GVBB
MBOW(_!PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ K[(_8[_Y(3IW_ %]W/_HUJ^-Z^R/V._\
MDA.G?]?=S_Z-:OB./_\ D21_QK\I'W7A[_R/)?\ 7N7YQ/4****_&C]J"BBB
M@ HHHH **** "BBB@ HHHH ^(_VF_P#DNWB+_K[3_P!%)7!UWG[3?_)=O$7_
M %]I_P"BDK@Z_HS*/^13A_\ !#_TE'\V9Q_R-\1_U\G_ .E,****] \X****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH _0[0O^0'9_\ 7I'_ .@BK55="_Y =G_UZ1_^@BK5?S-4
M_B/U/ZAI_P ->@4445!84444 %?-/[?'_(<\-_\ 7I<_^A1U]+5\T_M\?\AS
MPW_UZ7/_ *%'7U7!?_)14O27_I+/D^-_^2;K>L?_ $I'S[1117[D?@X4444
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M_P#0HZ^JX+_Y**EZ2_\ 26?)\;_\DW6]8_\ I2/GVBBBOW(_!PHHHH ****
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M_)14O27_ *2SY/C?_DFZWK'_ -*1\^T445^Y'X.%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M?9'['?\ R0G3O^ONY_\ 1K5\;U]D?L=_\D)T[_K[N?\ T:U?$<?_ /(DC_C7
MY2/NO#W_ )'DO^O<OSB>H4445^-'[4%%%% !1110 4444 %%%% !1110!\1_
MM-_\EV\1?]?:?^BDK@Z[S]IO_DNWB+_K[3_T4E<'7]&91_R*</\ X(?^DH_F
MS./^1OB/^OD__2F%%%%>@><%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?H=H7_(#L_P#KTC_]
M!%6JJZ%_R [/_KTC_P#015JOYFJ?Q'ZG]0T_X:] HHHJ"PHHHH *^:?V^/\
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MS_Z%'7U7!?\ R45+TE_Z2SY/C?\ Y)NMZQ_]*1\^T445^Y'X.%%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %?9'['?_)"=._Z^[G_T:U?&]?9'['?_ "0G3O\ K[N?_1K5\1Q_
M_P B2/\ C7Y2/NO#W_D>2_Z]R_.)ZA1117XT?M04444 %%%% !1110 4444
M%%%% 'Q'^TW_ ,EV\1?]?:?^BDK@Z[S]IO\ Y+MXB_Z^T_\ 125P=?T9E'_(
MIP_^"'_I*/YLSC_D;XC_ *^3_P#2F%%%%>@><%%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?H=
MH7_(#L_^O2/_ -!%6JJZ%_R [/\ Z](__015JOYFJ?Q'ZG]0T_X:] HHHJ"P
MHHHH *^:?V^/^0YX;_Z]+G_T*.OI:OFG]OC_ )#GAO\ Z]+G_P!"CKZK@O\
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M ,E%2])?^DL^3XW_ .2;K>L?_2D?/M%%%?N1^#A1110 4444 %%%% !1110
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MO$5C8Z7X@^'.@WUMID/E:;;WFD0RQVD>%&R)64B-<*HPN!\H]!4&C_!GX/\
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MB]--7Y]5XM_P3+_8RF_8@_9=L?AIXAN;2Y\4ZSJ,VN>,KJQ15@;4;@*&CB
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MT3C9*JL,.C#D#.,C((-:7A[PUX<\):5'H7A30++3+&)F,5GI]JD,2%F+,0B
M 9))/'))-7$1(U"(H50,  8 H ^8/VT_B)\??BM^QP_CS]F/0M6TVWO3./$=
MEJ.GR6NLQV".\;F*/DKDH6;'S&-@5ZFOR?K^@"OS_P#^"DG_  3;_P"/_P#:
M&_9YT#^]<>)O#-G%^+W5N@_$O&/=E[B@#\_Z^@/^";?_  T?_P -'V'_  SS
M_L_\)-]LW?8/L&[Y_M&/QV8^;=C;WKS_ /9M_9M^(_[4/Q'M_AY\/+#TDU/4
MYE/D:?!G!ED(_(*.6/ [D?L!^S;^S;\./V7OAQ;_  \^'EAZ2:GJ<RCS]0GQ
M@RR$?D%'"C@=R0#T"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K[(_8[
M_P"2$Z=_U]W/_HUJ^-Z^R/V._P#DA.G?]?=S_P"C6KXCC_\ Y$D?\:_*1]UX
M>_\ (\E_U[E^<3U"BBBOQH_:@HHHH **** "BBB@ HHHH **** /B/\ :;_Y
M+MXB_P"OM/\ T4E<'7>?M-_\EV\1?]?:?^BDK@Z_HS*/^13A_P#!#_TE'\V9
MQ_R-\1_U\G_Z4PHHHKT#S@HHHH **** "BBB@ HHHH **** "BBL_P 5^*_#
M?@;PW>^+_%^M6^G:9IUNT][>W4@6.&-1R2?Z=2< <F@ \5^*_#?@;PW>^+_%
M^M6^G:9IUNT][>W4@6.&-1R2?Z=2< <FCPIXK\-^.?#=EXO\(:U;ZCIFHVZS
MV5[:R!HYHV'!!_IU!R#R*_)_]OG]OGQ)^U7XD;PAX0EN-.\"Z=<9LK)B5DU&
M13Q<3C_T"/HHY/S'@_8&_;Y\2?LJ>)%\(>+Y;C4? NHW&;VR4EI-.D8\W$ _
M]#CZ,.1\PY /UPHK/\*>*_#?CGPW9>+_  AK5OJ.F:C;K/97MK(&CFC8<$'^
MG4'(/(K0H **** "BH+/5-,U&2>'3]1@G>UE,5RD,RL8GP#L8 _*V".#SS5+
MP[XU\(^+KK4K+POXDLM0ET>_:RU6.TN%<VERH!:*3'W7 (RIY&: -2BN?\$?
M%'P-\1[[7--\&ZW]LF\-ZQ)I6M(;:6/[/=H%+1_O%7?@,/F7*G/!-'@;XAV7
MCR[URSM/#FLZ>="UJ739GU;3S MVR!29H"2?-A.[ <8R0>* .@HKG_ OB_Q#
MXJN=<@U[P#?:&NEZW-96$M[*C#4H$"[;N/;]U&)( //R^]'@35_B'JL^N)X^
M\'VNDQVNN30Z$]KJ G-[8*%\NX? 'ENQW93M@4 =!17/^ T^**2ZW_PLV;0G
M1M=G/AS^PUF!73/E\D7'F];C[V\I\G(Q1X"T+Q]H;ZV?'GCR+75O->N+G15C
MTM+;^SK!MOE6A*$^<4PW[UL,V[GH* .@HKG_  #X+U7P8=:_M7QWJNN_VKKU
MQJ-M_:CJW]GQ2;=MI#@#$*;?E!R?F/-'@#X<:/\ #E=971]3U.Y&N:]<ZM<_
MVG?-/Y4TVW='%N_U<0VC;&.%Y]: -V&XM[C=Y$Z/L?:^Q@=K>AQT/(_.J>@>
M*O#'BI+J7POXCL-26QO9+.]:PO$F%O<)C?"^PG9(N1E#@C(R*H^!?AIX'^&<
M>K1>!M 33UUS6[C5]45)G?S[V<@RR_.QV[MH^5<*,< 5<\.^$/"GA!+R/PIX
M:L-,&HZA+?Z@+"S2'[3=2$&2>3:!OD; RYR3@9/% 'WK\#/C;\+/C?X:U"]^
M%7C"#6(O#6M3^']<:"*1/LFI6JH)[9MZKED+KDC(YX)I_P &?CAX1^.>GZ]J
M7@_3=9M8_#OBF]T"_76M)DM&>ZM2JR/$''[R$EAMD'RM@XZ5T'A33--TO0;=
M-,T^"W$T:S3"")4$DC*"SM@<L3U)Y-:-?S76='VD^5/?2[V[WTU_ _IRC&M[
M.'-);:V6_:VKM^)QWP8^*NL_%G2]<U'6OA-XD\(-H_B>\TF"V\36JQ2:A% R
MA;Z$*Q#6\N24;.2 >!1\%O&7Q=\:Z1K-Y\8_@PO@B[LO$MY9:19)XB@U,:CI
MT; 07^^%0(O.&6\EAOCQAN:[&BHE.#YK12OZZ>FO7SOY%QIS7+>;=M]M?73I
MY6\[G'?!6Z^/5WHNKO\ M!:7X7M-07Q'>)H:>%)YY(I-)##[*\WG<K<%<EU7
M* XQWH^"F@_&SP]H.JVWQT\?:5XBU";Q%>3Z1=:1I7V1+?36<&VMW7)WR(N0
MS_Q$UV-%$JKES:)7\MO3J@C24>7WF[>>_KT9QWP3^'?COX:^'M2TCX@_&/4?
M&UU>^(+R_M-1U.QBMWL[:5]T5FJQ<,D0^4,>2.M?-'[1?P:L_@A;:5X:LOB%
MXK\2KJ&IZIJCWOC#6C?W,+7$L;FWCD*J5@3I&G.T<9-?9%?-/[?'_(<\-_\
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MW6"RLK6,+'#&HX ']>I.2>36A10 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% 'Z':%_R [/_KTC_P#015JJNA?\@.S_ .O2/_T$5:K^9JG\1^I_
M4-/^&O0****@L**** "OFG]OC_D.>&_^O2Y_]"CKZ6KYI_;X_P"0YX;_ .O2
MY_\ 0HZ^JX+_ .2BI>DO_26?)\;_ /)-UO6/_I2/GVBBBOW(_!PHHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K[(_8[_Y(3IW_ %]W/_HUJ^-Z^R/V._\ DA.G?]?=S_Z-:OB.
M/_\ D21_QK\I'W7A[_R/)?\ 7N7YQ/4****_&C]J"BBB@ HHHH **** "BBB
M@ HHHH ^(_VF_P#DNWB+_K[3_P!%)7!UWG[3?_)=O$7_ %]I_P"BDK@Z_HS*
M/^13A_\ !#_TE'\V9Q_R-\1_U\G_ .E,****] \X**** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M_0[0O^0'9_\ 7I'_ .@BK55="_Y =G_UZ1_^@BK5?S-4_B/U/ZAI_P ->@44
M45!84444 %?-/[?'_(<\-_\ 7I<_^A1U]+5\T_M\?\ASPW_UZ7/_ *%'7U7!
M?_)14O27_I+/D^-_^2;K>L?_ $I'S[1117[D?@X4444 %%%% !1110 4444
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M2_\ 26?)\;_\DW6]8_\ I2/GVBBBOW(_!PHHHH **** "BBB@ HHHH ****
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M_P#DFOTRHK3_ %RXD_Y__P#DL/\ Y$S_ -2N&?\ GQ_Y-/\ ^2/S-V?M,_\
M1C7Q3_\ !?9?_)-&S]IG_HQKXI_^"^R_^2:_3*BC_7+B3_G_ /\ DL/_ )$/
M]2N&?^?'_DT__DC\S=G[3/\ T8U\4_\ P7V7_P DT;/VF?\ HQKXI_\ @OLO
M_DFOTRHH_P!<N)/^?_\ Y+#_ .1#_4KAG_GQ_P"33_\ DC\S=G[3/_1C7Q3_
M /!?9?\ R31L_:9_Z,:^*?\ X+[+_P"2:_3*BC_7+B3_ )__ /DL/_D0_P!2
MN&?^?'_DT_\ Y(_,W9^TS_T8U\4__!?9?_)-&S]IG_HQKXI_^"^R_P#DFOTR
MHH_URXD_Y_\ _DL/_D0_U*X9_P"?'_DT_P#Y(_,W9^TS_P!&-?%/_P %]E_\
MDT;/VF?^C&OBG_X+[+_Y)K],J*/]<N)/^?\ _P"2P_\ D0_U*X9_Y\?^33_^
M2/S-V?M,_P#1C7Q3_P#!?9?_ "31L_:9_P"C&OBG_P""^R_^2:_3*BC_ %RX
MD_Y__P#DL/\ Y$/]2N&?^?'_ )-/_P"2/S-V?M,_]&-?%/\ \%]E_P#)-&S]
MIG_HQKXI_P#@OLO_ ))K],J*/]<N)/\ G_\ ^2P_^1#_ %*X9_Y\?^33_P#D
MC\S=G[3/_1C7Q3_\%]E_\DT;/VF?^C&OBG_X+[+_ .2:_3*BC_7+B3_G_P#^
M2P_^1#_4KAG_ )\?^33_ /DC\S=G[3/_ $8U\4__  7V7_R31L_:9_Z,:^*?
M_@OLO_DFOTRHH_URXD_Y_P#_ )+#_P"1#_4KAG_GQ_Y-/_Y(_,W9^TS_ -&-
M?%/_ ,%]E_\ )-&S]IG_ *,:^*?_ (+[+_Y)K],J*/\ 7+B3_G__ .2P_P#D
M0_U*X9_Y\?\ DT__ )(_,W9^TS_T8U\4_P#P7V7_ ,DT;/VF?^C&OBG_ ."^
MR_\ DFOTRHH_URXD_P"?_P#Y+#_Y$/\ 4KAG_GQ_Y-/_ .2/S-V?M,_]&-?%
M/_P7V7_R31L_:9_Z,:^*?_@OLO\ Y)K],J*/]<N)/^?_ /Y+#_Y$/]2N&?\
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MF;L_:9_Z,:^*?_@OLO\ Y)HV?M,_]&-?%/\ \%]E_P#)-?IE11_KEQ)_S_\
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M1^9NS]IG_HQKXI_^"^R_^2:-G[3/_1C7Q3_\%]E_\DU^F5%'^N7$G_/_ /\
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MRGF 'ZAT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!117C_[='P__ &O/BK^SOJWPY_8F^+WASP#XTUDBV_X3#Q%837/]F6C*PEDM
MHXO^7G[H1VRJ99L%@M 'D'[2GPQLO^"C/[6?P^^%%O MS\+O@!X_@\9>.]7
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ML8M,T^#389II$MX5B22YG:61@H !9W)9VXY8DDGDFIJ "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ KYK_X*1ZQXO^+?PFU']@;X%W<9\??&+0KG1[N\*;X_"WARX!M]
M2UNY ^ZJ0O)%;H2#-=21HORK*\?T%XQ_X2__ (1+5!\/SIO]O?V?-_8IUGS/
ML@N]A\HS^7\YBW[=P7YMN<8-?G-\.?V#_P#@O]\,->\3>+O#W_!0OX$3ZUXP
MU=M0\0:UJ/PLNI[JY89$,&]I/DMX(SY<,*X2-<D#<\C, <)_P7N^!OA/]GC]
MG_\ 86^"7P_TR2T^''@3]ISP5HC02-N$=O!!)# TK8&YC%'/ER.69B>6KK?^
M#M-=1N_^"5=EHOAU7;6]2^+_ (<MM 6+_6->EYS&$QSNPK8QS7T5\0?^";_B
MW]JW_@G)=?L=_MS?'NY\7>.M7E;5+[XEZ18K;-INMI=M<V=W86XVK!';$11K
M$NW?&CACF5V-7Q?^PY^T3^UY\1?A'K/[>GBKP/<^&O@QXD@\46.@>"([IU\6
M^);>%XK34[P7*(+*&#S)95LH_/S)(-TY1-C 'TI\7OBWX%^!7PWU/XJ?$K5S
M::3I,"M,T,#2S3R,PCBMX(D!>>>61DBBA0%Y))$1068 ^%?\$YOV5?%WPFO?
MBA^UE\;]!CTWXH?'_P 7Q^(_%>DI,LIT+3[> 6VDZ,TB$K+):V@ ED7*M/--
MM)0(3YE^VM^QY_P5O^.?[5^E_&C]GW]J_P"$'A?PAX0B;_A!_"GBCP5=ZF;6
M\>/9+J<_SB.2\VM)'&^,0Q.ZIAI)7?TC]B3X$?\ !3/P7\4=8^(/[?\ ^V-X
M4\=V":$+#PMX9\!^%&TFRMYI)EDN+NY#9:>4+%$D>20BO-@ N20#PS_@J%_R
MFW_X)S?]AKXE_P#ICL:_1*OC7]M3]AC]JC]HW_@H!^S_ /MA?#[Q'X TW2/V
M?[[79].T/6+R]:YU\:K:06TXDDC@VVFQ(?DVB;D[CG[H^Q[9KA[>-KR)(Y2@
M,J1R%U5L<@,0"1GO@9]!0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
&HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>jnj-20230101_g8.jpg
<TEXT>
begin 644 jnj-20230101_g8.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M=]X?EL;'2KR^FNK/4;=S]K8-;10M \4$J?: [* %$GV!7(_$#X(?#SXF^/?
MGQ,\5Z09=9^'&OW6K^%KR,A6@GN--O--F5CC)C:WO9<ID LL;'[@K\X/ ?\
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MG6:4 QQE4+;_ )RN["YP #S+_@J9_P %!O%W_!,K]G#4_P!K.^_9\B\<>"M
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M^"[G^R)=:^+'Q'72K>_U#3HET][Z'3]/@NDDMUE>(0%IIHY0!<KA,QL&H?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^#%I^V"^I'XBIX(MO^$A_MLM]N498VZW6_Y_M MO($N_Y_,#[OFS7E7[=O\
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M'F;7P=A5L88$_P!"FG:1I.D))'I.EV]JLLADE6W@5 [GJQV@9)]:L4 ?S_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV@?^A_\ _*5:?_&J\YHH_L3)?^@:G_X!'_(/[<SO_H*J?^!R_P ST;_AK/\
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M'_(/[<SO_H*J?^!R_P ST;_AK/\ :!_Z'_\ \I5I_P#&J/\ AK/]H'_H?_\
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^<_P!O[_F4O^W_ /\
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MY*:O_P!N_P#I$0HHHKZ<^6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH *^C/V ?^9M_[</_ &XKYSKZ,_8!_P"9M_[</_;BOF.,O^2;K_\ ;O\
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MHH **** "BBB@ HHHH *^<_V_O\ F4O^W_\ ]MZ^C*^<_P!O[_F4O^W_ /\
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M_P#_ &WKYSK]UX-_Y)NA_P!O?^ER/P3C7_DIJ_\ V[_Z1$****^G/E@HHHH
M**** "BBB@#\_P#_ (*2?\$V_P#C_P#VAOV>= _O7'B;PS9Q?B]U;H/Q+QCW
M9>XH_P"";?\ P3;_ ./#]H;]H;0/[MQX9\,WD7XI=7"'\"D9]F;L*_0"B@ H
MHHH **** "BBB@ HHHH *^C/V ?^9M_[</\ VXKYSKZ,_8!_YFW_ +</_;BO
MF.,O^2;K_P#;O_I<3ZG@K_DIJ'_;W_I$CZ,HHHK\*/WL**** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ KYS_;^_YE+_M__P#;>OHROG/]O[_F4O\
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MS(&$+*\9;*_.,D!2  6W+WM%14@JM-Q;:OV=G\F72J.E44TD[=U=?-'B5O\
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M:'_;W_I<@HHHKY@^I"BBB@ HHHH **** "BBB@ HHHH ^<_V_O\ F4O^W_\
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M9ZM\)/%GB'5['1=>L9K'6HM&N(X9+RTEC:.6!I&C9E1E8@["K8XS@D&#X ?
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MO?\ I<@HHHKY@^I"BBB@ HHHH **** "BBB@ HHHH ^<_P!O[_F4O^W_ /\
M;>OG.OHS]O[_ )E+_M__ /;>OG.OW7@W_DFZ'_;W_I<C\$XU_P"2FK_]N_\
MI$0HHHKZ<^6"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *^C/V
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M /VWKZ,KYS_;^_YE+_M__P#;>OI^#?\ DI*'_;W_ *1(^6XU_P"29K_]N_\
MI<3YSHHHK]U/P0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ^C/V ?^9M_[</_ &XKZ,KYS_8!_P"9M_[</_;BOHROPKC+_DI*_P#V[_Z1
M$_>^"O\ DF:'_;W_ *7(****^8/J0HHHH **** "BBB@ HHHH **** /G/\
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MZD**** "BBB@ HHHH **** "BBB@#YS_ &_O^92_[?\ _P!MZ^<Z^C/V_O\
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M** "BBB@ HHHH *^C/V ?^9M_P"W#_VXKYSKZ,_8!_YFW_MP_P#;BOF.,O\
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M=_%K0;'[=]D^R_\ $P27?L\[=_JRV,;UZXZU[3_PW/\ LC_]%ZT'_O\ /_\
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MT+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+_P %$/\
M\36[10!A?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1#_\ $UNT4 87
M_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q-;M% &%_PJ[X9_\
M1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 36[10!A?\*N^&?_1.]"_\%$/_
M ,31_P *N^&?_1.]"_\ !1#_ /$UNT4 87_"KOAG_P!$[T+_ ,%$/_Q-'_"K
MOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\ Q-'_  J[X9_]$[T+
M_P %$/\ \36[10!A?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0O_!1#_\
M$UNT4 87_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q-;M% &%_
MPJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 36[10!A?\*N^&?_1.
M]"_\%$/_ ,31_P *N^&?_1.]"_\ !1#_ /$UNT4 87_"KOAG_P!$[T+_ ,%$
M/_Q-'_"KOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\ Q-'_  J[
MX9_]$[T+_P %$/\ \36[10!A?\*N^&?_ $3O0O\ P40__$T?\*N^&?\ T3O0
MO_!1#_\ $UNT4 87_"KOAG_T3O0O_!1#_P#$T?\ "KOAG_T3O0O_  40_P#Q
M-;M% &%_PJ[X9_\ 1.]"_P#!1#_\31_PJ[X9_P#1.]"_\%$/_P 36[10!A?\
M*N^&?_1.]"_\%$/_ ,31_P *N^&?_1.]"_\ !1#_ /$UNT4 87_"KOAG_P!$
M[T+_ ,%$/_Q-'_"KOAG_ -$[T+_P40__ !-;M% &%_PJ[X9_]$[T+_P40_\
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MR[A\%8'*_<] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
H !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>jnj-20230101_g9.jpg
<TEXT>
begin 644 jnj-20230101_g9.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MTGC*TNKCPI'=2")M6C359IW-N'P92(F$A"Y(0%L8!(_H5I'#E"(V ;'READ
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M\8>%;7P_X0^$%[XN_MJ\M$$L4]U?7DZ3W$4;M+"@CACN+@(K2_O &"  ]O\
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ME_"7QUI?B6Y7POJ&HS6^A7B73PVKVFFPI+((B3&&EAGC&[&7@E7K&P']&M%
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M(VT9\NR# $?:X?WPW9'2@#]HIXWE@>**=HF9"%E0 E"1U&01D>X(KXT^//\
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M$?\ (/[<SO\ Z"JG_@<O\ST;_AK/]H'_ *'_ /\ *5:?_&J/^&L_V@?^A_\
M_*5:?_&J\YHH_L3)?^@:G_X!'_(/[<SO_H*J?^!R_P ST;_AK/\ :!_Z'_\
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M*7?L\G;_ *Q&QC>W3'6O%O\ AK/]H'_H?_\ RE6G_P :KT;]O[_F4O\ M_\
M_;>OG.OV;A/*\LQ/#]&I5H0E)\UVXQ;?OR6[1^)\79KFF&XAK4Z-><8KELE*
M22]R+V3MN>C?\-9_M _]#_\ ^4JT_P#C5'_#6?[0/_0__P#E*M/_ (U7G-%?
M1_V)DO\ T#4__ (_Y'S?]N9W_P!!53_P.7^9Z-_PUG^T#_T/_P#Y2K3_ .-4
M?\-9_M _]#__ .4JT_\ C5><T4?V)DO_ $#4_P#P"/\ D']N9W_T%5/_  .7
M^9Z-_P -9_M _P#0_P#_ )2K3_XU1_PUG^T#_P!#_P#^4JT_^-5YS11_8F2_
M] U/_P  C_D']N9W_P!!53_P.7^9Z-_PUG^T#_T/_P#Y2K3_ .-4?\-9_M _
M]#__ .4JT_\ C5><T4?V)DO_ $#4_P#P"/\ D']N9W_T%5/_  .7^9Z-_P -
M9_M _P#0_P#_ )2K3_XU1_PUG^T#_P!#_P#^4JT_^-5YS11_8F2_] U/_P
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MY;-1BFO?BMTCZ3A'-<TQ/$-&G6KSE%\UTY2:?N2>S=MSZ,HHHK\9/VP****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KYS_;^_P"92_[?_P#VWKZ,
MKYS_ &_O^92_[?\ _P!MZ^GX-_Y*2A_V]_Z1(^6XU_Y)FO\ ]N_^EQ/G.BBB
MOW4_! HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#Z,_8!_
MYFW_ +</_;BOHROG/]@'_F;?^W#_ -N*^C*_"N,O^2DK_P#;O_I$3][X*_Y)
MFA_V]_Z7(****^8/J0HHHH **** "BBB@ HHHH **** /G/]O[_F4O\ M_\
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M+_DI*_\ V[_Z1$_>^"O^29H?]O?^ER"BBBOF#ZD**** "BBB@ HHHH ****
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M*_Y)FA_V]_Z7(****^8/J0HHHH **** "BBB@ HHHH **** /G/]O[_F4O\
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MUIUOF]LE(6/48U'-Q /_ $./JIY'RGCZ0K\'_A5_PL?_ (6/HO\ PJ#^T/\
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M^$1N?^&DO^$-_M[^V;O['_P@_P!K^R?V?YA^S;_M7S^?Y>/,Q\F[[O%'P/\
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M .EQ/J>"O^2FH?\ ;W_I$CZ,HHHK\*/WL**** "BBB@ HHHH **** "BBB@
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MO^2;K_\ ;O\ Z7$^IX*_Y*:A_P!O?^D2/HRBBBOPH_>PHHHH **** "BBB@
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MG^PNZ+ #L:*1N"&.?U3LK*RTRRAT[3K2*WM[>)8X(((PB1HHPJJHX     X
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MCXC\,>.?&'B*YM%^%?\ 8%_!=WAU!KB+,D+1EFBB6/S#.YPJ1!R^,5]<Z?\
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M%%%>H>4%%%% !7T9^P#_ ,S;_P!N'_MQ7SG7T9^P#_S-O_;A_P"W%?,<9?\
M)-U_^W?_ $N)]3P5_P E-0_[>_\ 2)'T91117X4?O84444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !7SG^W]_S*7_ &__ /MO7T97SG^W]_S*7_;_
M /\ MO7T_!O_ "4E#_M[_P!(D?+<:_\ ),U_^W?_ $N)\YT445^ZGX(%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?1G[ /_,V_P#;A_[<
M5]&5\Y_L _\ ,V_]N'_MQ7T97X5QE_R4E?\ [=_](B?O?!7_ "3-#_M[_P!+
MD%%%%?,'U(4444 %%%% !1110 4444 %%%% 'SG^W]_S*7_;_P#^V]?.=?1G
M[?W_ #*7_;__ .V]?.=?NO!O_)-T/^WO_2Y'X)QK_P E-7_[=_\ 2(A1117T
MY\L%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5]&?L _P#,V_\
M;A_[<5\YU]&?L _\S;_VX?\ MQ7S'&7_ "3=?_MW_P!+B?4\%?\ )34/^WO_
M $B1]&4445^%'[V%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5\
MY_M_?\RE_P!O_P#[;U]&5\Y_M_?\RE_V_P#_ +;U]/P;_P E)0_[>_\ 2)'R
MW&O_ "3-?_MW_P!+B?.=%%%?NI^"!1110 4444 %%%% !1110 4444 %%%%
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MQ7T97X5QE_R4E?\ [=_](B?O?!7_ "3-#_M[_P!+D%%%%?,'U(4444 %%%%
M!1110 4444 %%%% 'SG^W]_S*7_;_P#^V]?.=?1G[?W_ #*7_;__ .V]?.=?
MNO!O_)-T/^WO_2Y'X)QK_P E-7_[=_\ 2(A1117TY\L%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5]&?L _P#,V_\ ;A_[<5\YU]&?L _\S;_V
MX?\ MQ7S'&7_ "3=?_MW_P!+B?4\%?\ )34/^WO_ $B1]&4445^%'[V%%%%
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M(Y.BL79^TS_T8U\4_P#P7V7_ ,DT;/VF?^C&OBG_ ."^R_\ DFOUC_7+AO\
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M[3/_ $C!^*?_ ('67_Q5'_#??[3/_2,'XI_^!UE_\50!]345\L_\-]_M,_\
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M8NS]IG_HQKXI_P#@OLO_ ))HV?M,_P#1C7Q3_P#!?9?_ "31_KEPW_S_ /\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQ/,Z&"W0N(_,#-)E4V/#\"?VROB3X)_X*!Z[_P $S/VH]=TS6?$4W@.#QO\
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M#70KS3KWPEJEXS?9R%G=C-!@.V6WLZPN,QN4\SZ<_;/_ &W/'G@O]K'X2_\
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M\&P>$?">C:&TS:3X3T*&5[C['%<2HLMU+/<N99KDQ1<;42)0&+_.FE_L,_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
)BB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428785422560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Feb. 10, 2023</div></th>
<th class="th"><div>Jul. 03, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jan.  01,  2023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3215<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">JOHNSON & JOHNSON<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">22-1024240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">One Johnson & Johnson Plaza<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Brunswick<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">08933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">732<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">524-0400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 472<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,604,286,303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000200406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--01-01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock, Par Value $1.00</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes Due May 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.650% Notes Due May 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24C<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member', window );">5.50% Notes Due November 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">5.50% Notes Due November 2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ24BP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes Due November 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.150% Notes Due November 2028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes Due May 2035</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.650% Notes Due May 2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">JNJ35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428785392256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_AuditorInformationAbstract', window );"><strong>Auditor Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">PricewaterhouseCoopers LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Florham Park, New Jersey<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">238<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AuditorInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Auditor Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AuditorInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428785474912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents (Notes&#160;1 and 2)</a></td>
<td class="nump">$ 14,127<span></span>
</td>
<td class="nump">$ 14,487<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities (Notes&#160;1 and 2)</a></td>
<td class="nump">9,392<span></span>
</td>
<td class="nump">17,121<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable trade, less allowances for doubtful accounts $203 (2021, $230)</a></td>
<td class="nump">16,160<span></span>
</td>
<td class="nump">15,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories (Notes&#160;1 and 3)</a></td>
<td class="nump">12,483<span></span>
</td>
<td class="nump">10,387<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">3,132<span></span>
</td>
<td class="nump">3,701<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">55,294<span></span>
</td>
<td class="nump">60,979<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net (Notes&#160;1 and 4)</a></td>
<td class="nump">19,803<span></span>
</td>
<td class="nump">18,962<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net (Notes&#160;1 and 5)</a></td>
<td class="nump">48,325<span></span>
</td>
<td class="nump">46,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Notes&#160;1 and 5)</a></td>
<td class="nump">45,231<span></span>
</td>
<td class="nump">35,246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred taxes on income (Note&#160;8)</a></td>
<td class="nump">9,123<span></span>
</td>
<td class="nump">10,223<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">9,602<span></span>
</td>
<td class="nump">10,216<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">187,378<span></span>
</td>
<td class="nump">182,018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loans and notes payable (Note&#160;7)</a></td>
<td class="nump">12,771<span></span>
</td>
<td class="nump">3,766<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,703<span></span>
</td>
<td class="nump">11,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">11,456<span></span>
</td>
<td class="nump">13,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued rebates, returns and promotions</a></td>
<td class="nump">14,417<span></span>
</td>
<td class="nump">12,095<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and employee related obligations</a></td>
<td class="nump">3,328<span></span>
</td>
<td class="nump">3,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Accrued taxes on income (Note 8)</a></td>
<td class="nump">2,127<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">55,802<span></span>
</td>
<td class="nump">45,226<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt (Note&#160;7)</a></td>
<td class="nump">26,888<span></span>
</td>
<td class="nump">29,985<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred taxes on income (Note 8)</a></td>
<td class="nump">6,374<span></span>
</td>
<td class="nump">7,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Employee related obligations (Notes&#160;9 and 10)</a></td>
<td class="nump">6,767<span></span>
</td>
<td class="nump">8,898<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesNoncurrent', window );">Long-term taxes payable (Note 1)</a></td>
<td class="nump">4,306<span></span>
</td>
<td class="nump">5,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">10,437<span></span>
</td>
<td class="nump">10,686<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">110,574<span></span>
</td>
<td class="nump">107,995<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 19)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock&#160;&#8212; without par value (authorized and unissued 2,000,000&#160;shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock&#160;&#8212; par value $1.00 per share (Note&#160;12) (authorized 4,320,000,000&#160;shares; issued 3,119,843,000&#160;shares)</a></td>
<td class="nump">3,120<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss) (Note&#160;13)</a></td>
<td class="num">(12,967)<span></span>
</td>
<td class="num">(13,058)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">128,345<span></span>
</td>
<td class="nump">123,060<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityBeforeTreasuryStock', window );">Stockholders' Equity before Treasury Stock</a></td>
<td class="nump">118,498<span></span>
</td>
<td class="nump">113,122<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Less: common stock held in treasury, at cost (Note&#160;12) (506,246,000&#160;shares and 490,878,000&#160;shares)</a></td>
<td class="nump">41,694<span></span>
</td>
<td class="nump">39,099<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">76,804<span></span>
</td>
<td class="nump">74,023<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 187,378<span></span>
</td>
<td class="nump">$ 182,018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AccruedRebatesReturnsAndPromotions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AccruedRebatesReturnsAndPromotions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15)(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityBeforeTreasuryStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityBeforeTreasuryStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428782075936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Allowances for doubtful accounts</a></td>
<td class="nump">$ 203<span></span>
</td>
<td class="nump">$ 230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares)</a></td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share (in dollars per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">4,320,000,000<span></span>
</td>
<td class="nump">4,320,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">3,119,843,000<span></span>
</td>
<td class="nump">3,119,843,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares</a></td>
<td class="nump">506,246,000<span></span>
</td>
<td class="nump">490,878,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5074-111524<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428783416848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Earnings - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to customers</a></td>
<td class="nump">$ 94,943<span></span>
</td>
<td class="nump">$ 93,775<span></span>
</td>
<td class="nump">$ 82,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">31,089<span></span>
</td>
<td class="nump">29,855<span></span>
</td>
<td class="nump">28,427<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">63,854<span></span>
</td>
<td class="nump">63,920<span></span>
</td>
<td class="nump">54,157<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, marketing and administrative expenses</a></td>
<td class="nump">24,765<span></span>
</td>
<td class="nump">24,659<span></span>
</td>
<td class="nump">22,084<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expense</a></td>
<td class="nump">14,603<span></span>
</td>
<td class="nump">14,714<span></span>
</td>
<td class="nump">12,159<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development (Note 5)</a></td>
<td class="nump">783<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="num">(490)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense, net of portion capitalized (Note&#160;4)</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">183<span></span>
</td>
<td class="nump">201<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income) expense, net</a></td>
<td class="nump">1,871<span></span>
</td>
<td class="nump">489<span></span>
</td>
<td class="nump">2,899<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring (Note 20)</a></td>
<td class="nump">321<span></span>
</td>
<td class="nump">252<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">21,725<span></span>
</td>
<td class="nump">22,776<span></span>
</td>
<td class="nump">16,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income (Note&#160;8)</a></td>
<td class="nump">3,784<span></span>
</td>
<td class="nump">1,898<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 17,941<span></span>
</td>
<td class="nump">$ 20,878<span></span>
</td>
<td class="nump">$ 14,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net earnings per share (Notes 1 and 15)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 6.83<span></span>
</td>
<td class="nump">$ 7.93<span></span>
</td>
<td class="nump">$ 5.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 6.73<span></span>
</td>
<td class="nump">$ 7.81<span></span>
</td>
<td class="nump">$ 5.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Average shares outstanding (Notes 1 and 15)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">2,625.2<span></span>
</td>
<td class="nump">2,632.1<span></span>
</td>
<td class="nump">2,632.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">2,663.9<span></span>
</td>
<td class="nump">2,674.0<span></span>
</td>
<td class="nump">2,670.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 18: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1,2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428785227344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 17,941<span></span>
</td>
<td class="nump">$ 20,878<span></span>
</td>
<td class="nump">$ 14,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss), net of tax</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation</a></td>
<td class="num">(1,796)<span></span>
</td>
<td class="num">(1,079)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Securities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized holding gain (loss) arising during period</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax', window );">Reclassifications to earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax', window );">Net change</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Employee benefit plans:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax', window );">Prior service credit (cost), net of amortization</a></td>
<td class="num">(160)<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="nump">1,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax', window );">Gain (loss), net of amortization</a></td>
<td class="nump">1,854<span></span>
</td>
<td class="nump">4,318<span></span>
</td>
<td class="num">(1,135)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax', window );">Effect of exchange rates</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="num">(229)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax', window );">Net change</a></td>
<td class="nump">1,805<span></span>
</td>
<td class="nump">4,255<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Derivatives &amp; hedges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Unrealized gain (loss) arising during period</a></td>
<td class="nump">454<span></span>
</td>
<td class="num">(199)<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Reclassifications to earnings</a></td>
<td class="num">(348)<span></span>
</td>
<td class="num">(789)<span></span>
</td>
<td class="num">(53)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax', window );">Net change</a></td>
<td class="nump">106<span></span>
</td>
<td class="num">(988)<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss)</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">649<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income</a></td>
<td class="nump">$ 18,032<span></span>
</td>
<td class="nump">$ 23,062<span></span>
</td>
<td class="nump">$ 15,363<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>other comprehensive income loss, pension and other , effects of exchange rate net of tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28129-110885<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30304-110892<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428785415744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation</a></td>
<td class="num">$ (460)<span></span>
</td>
<td class="num">$ (346)<span></span>
</td>
<td class="nump">$ 536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Securities</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax', window );">Employee benefits</a></td>
<td class="nump">461<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
<td class="num">(21)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Derivatives &amp; hedges</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="num">$ (263)<span></span>
</td>
<td class="num">$ (252)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32262-110900<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30755-110894<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428783243120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Retained Earnings</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Common Stock Issued Amount</div></th>
<th class="th"><div>Treasury Stock Amount</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance at Dec. 29, 2019</a></td>
<td class="nump">$ 59,471<span></span>
</td>
<td class="nump">$ 110,659<span></span>
</td>
<td class="num">$ (15,891)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (38,417)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">14,714<span></span>
</td>
<td class="nump">14,714<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(10,481)<span></span>
</td>
<td class="num">(10,481)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee compensation and stock option plans</a></td>
<td class="nump">2,217<span></span>
</td>
<td class="num">(931)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(3,221)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(71)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">649<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jan. 03, 2021</a></td>
<td class="nump">63,278<span></span>
</td>
<td class="nump">113,890<span></span>
</td>
<td class="num">(15,242)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(38,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">20,878<span></span>
</td>
<td class="nump">20,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(11,032)<span></span>
</td>
<td class="num">(11,032)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee compensation and stock option plans</a></td>
<td class="nump">2,171<span></span>
</td>
<td class="num">(676)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(3,456)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,456)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">2,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jan. 02, 2022</a></td>
<td class="nump">74,023<span></span>
</td>
<td class="nump">123,060<span></span>
</td>
<td class="num">(13,058)<span></span>
</td>
<td class="nump">3,120<span></span>
</td>
<td class="num">(39,099)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">17,941<span></span>
</td>
<td class="nump">17,941<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Cash dividends paid</a></td>
<td class="num">(11,682)<span></span>
</td>
<td class="num">(11,682)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Employee compensation and stock option plans</a></td>
<td class="nump">2,466<span></span>
</td>
<td class="num">(974)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,440<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="num">(6,035)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,035)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income (loss), net of tax</a></td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance at Jan. 01, 2023</a></td>
<td class="nump">$ 76,804<span></span>
</td>
<td class="nump">$ 128,345<span></span>
</td>
<td class="num">$ (12,967)<span></span>
</td>
<td class="nump">$ 3,120<span></span>
</td>
<td class="num">$ (41,694)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428788851984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Equity (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid (in dollars per share)</a></td>
<td class="nump">$ 4.45<span></span>
</td>
<td class="nump">$ 4.19<span></span>
</td>
<td class="nump">$ 3.98<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428782564768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net earnings</a></td>
<td class="nump">$ 17,941<span></span>
</td>
<td class="nump">$ 20,878<span></span>
</td>
<td class="nump">$ 14,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net earnings to cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization of property and intangibles</a></td>
<td class="nump">6,970<span></span>
</td>
<td class="nump">7,390<span></span>
</td>
<td class="nump">7,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock based compensation</a></td>
<td class="nump">1,138<span></span>
</td>
<td class="nump">1,135<span></span>
</td>
<td class="nump">1,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset write-downs</a></td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">989<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges', window );">Net gain on sale of assets/businesses</a></td>
<td class="num">(380)<span></span>
</td>
<td class="num">(617)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred tax provision</a></td>
<td class="num">(1,663)<span></span>
</td>
<td class="num">(2,079)<span></span>
</td>
<td class="num">(1,141)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProvisionForDoubtfulAccounts', window );">Credit losses and accounts receivable allowances</a></td>
<td class="num">(17)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="nump">63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in assets and liabilities, net of effects from acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">(Increase)/Decrease in accounts receivable</a></td>
<td class="num">(1,290)<span></span>
</td>
<td class="num">(2,402)<span></span>
</td>
<td class="nump">774<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Increase in inventories</a></td>
<td class="num">(2,527)<span></span>
</td>
<td class="num">(1,248)<span></span>
</td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Increase in accounts payable and accrued liabilities</a></td>
<td class="nump">1,098<span></span>
</td>
<td class="nump">2,437<span></span>
</td>
<td class="nump">5,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Decrease/(Increase) in other current and non-current assets</a></td>
<td class="nump">687<span></span>
</td>
<td class="num">(1,964)<span></span>
</td>
<td class="num">(3,704)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">(Decrease)/Increase in other current and non-current liabilities</a></td>
<td class="num">(1,979)<span></span>
</td>
<td class="num">(1,061)<span></span>
</td>
<td class="nump">744<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash flows from operating activities</a></td>
<td class="nump">21,194<span></span>
</td>
<td class="nump">23,410<span></span>
</td>
<td class="nump">23,536<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Additions to property, plant and equipment</a></td>
<td class="num">(4,009)<span></span>
</td>
<td class="num">(3,652)<span></span>
</td>
<td class="num">(3,347)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfProductiveAssets', window );">Proceeds from the disposal of assets/businesses, net</a></td>
<td class="nump">543<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions, net of cash acquired (Note&#160;18)</a></td>
<td class="num">(17,652)<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="num">(7,323)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(32,384)<span></span>
</td>
<td class="num">(30,394)<span></span>
</td>
<td class="num">(21,089)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Sales of investments</a></td>
<td class="nump">41,609<span></span>
</td>
<td class="nump">25,006<span></span>
</td>
<td class="nump">12,137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities', window );">Credit support agreements activity, net</a></td>
<td class="num">(249)<span></span>
</td>
<td class="nump">214<span></span>
</td>
<td class="num">(987)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other (primarily licenses and milestones)</a></td>
<td class="num">(229)<span></span>
</td>
<td class="num">(508)<span></span>
</td>
<td class="num">(521)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used by investing activities</a></td>
<td class="num">(12,371)<span></span>
</td>
<td class="num">(8,683)<span></span>
</td>
<td class="num">(20,825)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Dividends to shareholders</a></td>
<td class="num">(11,682)<span></span>
</td>
<td class="num">(11,032)<span></span>
</td>
<td class="num">(10,481)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common stock</a></td>
<td class="num">(6,035)<span></span>
</td>
<td class="num">(3,456)<span></span>
</td>
<td class="num">(3,221)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term debt</a></td>
<td class="nump">16,134<span></span>
</td>
<td class="nump">1,997<span></span>
</td>
<td class="nump">3,391<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Repayment of short-term debt</a></td>
<td class="num">(6,550)<span></span>
</td>
<td class="num">(1,190)<span></span>
</td>
<td class="num">(2,663)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from long-term debt, net of issuance costs</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">7,431<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayment of long-term debt</a></td>
<td class="num">(2,134)<span></span>
</td>
<td class="num">(1,802)<span></span>
</td>
<td class="num">(1,064)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits', window );">Proceeds from the exercise of stock options/employee withholding tax on stock awards, net</a></td>
<td class="nump">1,329<span></span>
</td>
<td class="nump">1,036<span></span>
</td>
<td class="nump">1,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities', window );">Credit support agreements activity, net</a></td>
<td class="num">(28)<span></span>
</td>
<td class="nump">281<span></span>
</td>
<td class="num">(333)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other</a></td>
<td class="nump">93<span></span>
</td>
<td class="nump">114<span></span>
</td>
<td class="num">(294)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used by financing activities</a></td>
<td class="num">(8,871)<span></span>
</td>
<td class="num">(14,047)<span></span>
</td>
<td class="num">(6,120)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(312)<span></span>
</td>
<td class="num">(178)<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">(Decrease)/Increase in cash and cash equivalents</a></td>
<td class="num">(360)<span></span>
</td>
<td class="nump">502<span></span>
</td>
<td class="num">(3,320)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, beginning of year (Note&#160;1)</a></td>
<td class="nump">14,487<span></span>
</td>
<td class="nump">13,985<span></span>
</td>
<td class="nump">17,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents, end of year (Note&#160;1)</a></td>
<td class="nump">14,127<span></span>
</td>
<td class="nump">14,487<span></span>
</td>
<td class="nump">13,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_CashPaidDuringTheYearAbstract', window );"><strong>Cash paid during the year for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest</a></td>
<td class="nump">982<span></span>
</td>
<td class="nump">990<span></span>
</td>
<td class="nump">904<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest, net of amount capitalized</a></td>
<td class="nump">933<span></span>
</td>
<td class="nump">941<span></span>
</td>
<td class="nump">841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Income taxes</a></td>
<td class="nump">5,223<span></span>
</td>
<td class="nump">4,768<span></span>
</td>
<td class="nump">4,619<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental schedule of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds', window );">Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards</a></td>
<td class="nump">2,114<span></span>
</td>
<td class="nump">1,811<span></span>
</td>
<td class="nump">1,937<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">27<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract', window );"><strong>Acquisitions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1', window );">Fair value of assets acquired</a></td>
<td class="nump">18,710<span></span>
</td>
<td class="nump">61<span></span>
</td>
<td class="nump">7,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Fair value of liabilities assumed</a></td>
<td class="num">(1,058)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(432)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1', window );">Net cash paid for acquisitions (Note 18)</a></td>
<td class="nump">$ 17,652<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 7,323<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CashPaidDuringTheYearAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash Paid During The Year [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CashPaidDuringTheYearAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From The Exercise Of Stock Options And Excess Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury stock issued for employee compensation and stock option plans, net of cash proceeds.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProvisionForDoubtfulAccounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for expected credit loss on accounts receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919249-210447<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProvisionForDoubtfulAccounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428868494112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies<div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Johnson&#160;&amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of the Company and Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately 152,700&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is organized into three business segments: Consumer Health, Pharmaceutical and MedTech. The Consumer Health segment includes a broad range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-Counter pharmaceutical, Women&#8217;s Health and Wound Care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on the following therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2021, the Company announced its intention to separate the Company&#8217;s Consumer Health business (Kenvue as the name for the planned New Consumer Health Company), with the intention to create a new, publicly traded company by the end of the fiscal year 2023.</span></div><div style="margin-top:3pt"><span><br/></span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in fiscal 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Adopted as of January 1, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50) &#8211; Disclosure of Supplier Finance Program Obligations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This update requires that a buyer in a supplier finance program disclose additional information about the program to allow financial statement users to better understand the effect of the programs on an entity&#8217;s working capital, liquidity, and cash flows. This update will be effective for the Company for fiscal years beginning after December 15, 2022, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently assessing the impact of this update on its disclosures and will adopt this standard in the fiscal first quarter of 2023.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.  The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value.  The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and </span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.&#160;</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment and Depreciation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:86.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;- 20&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;- 13&#160;years</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Managed Care, Medicare and Medicaid programs, which amounted to $9.6 billion and $7.7 billion as of January&#160;1, 2023 and January&#160;2, 2022, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years&#160;2022,&#160;2021&#160;and&#160;2020.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in fiscal year 2022 and less than 3.0% of the total revenues in fiscal years 2021 and 2020 and are included in sales to customers.</span></div><div style="margin-bottom:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred were $1.1 billion, $1.1 billion and $1.0 billion in fiscal years 2022, 2021 and 2020, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 1.0% of sales to customers for all periods presented.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2022 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset. If warranted the purchased in-process research and development could be written off or partially impaired depending on the underlying program.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions.  See Note&#160;5 for further details on Intangible Assets and Goodwill.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#8217;s impact on the Company&#8217;s financial performance; (2)&#160;protect the Company&#8217;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODEw_97635a41-161e-48cc-9741-d517f85ec4b3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODEw_df08f0e2-160d-4a75-87a1-87cfb24da89c">Other assets</span></span>, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzMx_e32a30e6-d584-47b7-845d-23d4e433bc41"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzQ4_870a3311-5ffc-4b2b-8721-b5d7ead81c4b">Accrued liabilities</span></span>, and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzU3_21dc535a-a5b3-4717-bcb6-281e2bef1694"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzU3_b32467a4-74d9-403d-8502-48e5120b86ad">Other liabilities</span></span> on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $1.1&#160;billion and $0.9&#160;billion in fiscal years 2022 and 2021, respectively. The lease liability was $1.3&#160;billion and $1.0&#160;billion in fiscal years 2022 and 2021, respectively. The operating lease costs were $0.3&#160;billion in fiscal years 2022, 2021 and 2020, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3&#160;billion in fiscal years 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product Liability</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development.  Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product.  Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#8217;s operations. In general, the income statement presentation for these collaborations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:48.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Collaboration</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Earnings Presentation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third-party sale of product &amp; profit share payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties/milestones paid to collaborative partner (post-regulatory approval)*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties received from collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payments&#160;&amp; milestones paid to collaborative partner (pre-regulatory approval)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments to collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments received from collaborative partner or government entity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"/><td style="width:1.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG and IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.1 billion, $2.7 billion and $2.1 billion in fiscal years 2022, 2021 and 2020, respectively.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of  15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2022 was approximately  $6.1&#160;billion, of which $4.6&#160;billion is classified as noncurrent and reflected as &#8220;Long-term taxes payable&#8221; on the Company&#8217;s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder&#8217;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#8220;period cost&#8221;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., &#8220;deferred method&#8221;). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">See Note 8 to the Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">for further information regarding income taxes.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Earnings Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Closing Date</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428790397776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Current Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Cash, Cash Equivalents and Current Marketable Securities</a></td>
<td class="text">Cash, Cash Equivalents and Current Marketable Securities<div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the fiscal year 2022 and 2021, cash, cash equivalents and current marketable securities were comprised of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.615%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.690%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Loss</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't Agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and other debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,392</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.615%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.690%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Loss</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and other debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,487</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale debt securities at January&#160;1, 2023 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"/><td style="width:43.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,487&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-indent:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428786945712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2022 and 2021, inventories were comprised of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"/><td style="width:66.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428897325200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text">Property, Plant and Equipment<div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2022 and 2021, property, plant and equipment at cost and accumulated depreciation were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:67.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,803</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,962</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2022, 2021 and 2020 was $49 million, $49 million and $63 million, respectively.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation expense, including the amortization of capitalized interest in fiscal years 2022, 2021 and 2020 was $2.7 billion, $2.7 billion and $2.6 billion, respectively. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428788840416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text">Intangible Assets and Goodwill<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2022 and 2021, the gross and net amounts of intangible assets were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,266)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,746</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,987&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,011&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,086</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,086</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,493</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,822</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets&#160;&#8212; net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48,325</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,392</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change was primarily related to the intangible assets acquired with the acquisition of Abiomed, Inc. which was partially offset by amortization expense of previously existing intangible assets and the result of currency translation effects.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority is comprised of customer relationships</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The reduction was primarily related to an intangible asset impairment charge of approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">$0.8&#160;billion recorded in the fiscal year 2022 related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS. An additional reduction of $0.7&#160;billion was driven by Monarch assets that reached commercialization and are now classified as having definite lives. This was partially offset by approximately $1.1&#160;billion of IPR&amp;D acquired with Abiomed, Inc. </span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of January&#160;1, 2023 and January&#160;2, 2022, as allocated by segment of business, was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:33.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MedTech</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to divestitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to divestitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(626)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,071)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,863</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,231</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable assets included in Cost of products sold was $4.3 billion, $4.7 billion and $4.7 billion before tax, for the fiscal years ended January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI https://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428788840416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the Company primarily uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"> In the fiscal fourth quarter of 2022, the Company entered into forward starting interest rate swaps with notional amounts totaling $2.4&#160;billion in contemplation of hedging interest rate risk associated with long-term financing for the Consumer Health segment separation. These forward starting interest rate swaps are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings. At the end of the fiscal year 2022, the changes in fair value was not material and therefore not included in the table below.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of January&#160;1, 2023, the total amount of cash collateral paid by the Company under the CSA amounted to $0.8 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of January&#160;1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $43.3 billion, $36.2 billion and $12.4 billion, respectively. As of January&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8 billion,  $37.4 billion and $10.0 billion, respectively.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings.&#160;Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted through the currency translation account within accumulated other comprehensive income.&#160;The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of January&#160;1, 2023, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $230 million&#160;after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note&#160;13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022, net of tax:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January&#160;1, 2023 and January&#160;2, 2022, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:30.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:37.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.532%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItMi0xLTEtMTA5MzI3_baf92b4c-2473-4ad1-9202-3d7157cbead6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItMi0xLTEtMTA5MzI3_d20882e0-6ef3-4436-8245-6610c60bdc82">Other (income) expense</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of net investment hedges for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:20.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.621%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)           Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense<br/></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"> </span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:25.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(538)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:25.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.505%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022 for equity investments without readily determinable market values, $51 million and $28 million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were offsetting impacts of $142 million and $422 million, respectively, of changes in the fair value reflected in net income due to changes in observable prices and gains on the disposal of investments. The impact in fiscal year 2021, was driven by the gain on disposal of the Grail investment. In fiscal year 2022, the Company sold all of its equity investments in argenx SE for proceeds of $0.6&#160;billion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability.  In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S.&#160;Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#8217;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level&#160;1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following three levels of inputs are used to measure fair value:</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;1&#160;&#8212; Quoted prices in active markets for identical assets and liabilities.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;2&#160;&#8212; Significant other observable inputs.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level&#160;3&#160;&#8212; Significant unobservable inputs.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of the fiscal year ended January&#160;1, 2023 and January&#160;2, 2022 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.218%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,289</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,289</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,860</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Available For Sale Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.409%"><tr><td style="width:1.0%"/><td style="width:53.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.695%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2021 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $1,884 million, which are classified as Level&#160;1 and contingent consideration of $533 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes cross currency interest rate swaps and interest rate swaps.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as non-current other assets.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes $1,116 million, $520 million and $594 million, classified as non-current other liabilities as of January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, respectively. Includes $4 million, $13&#160;million and $39&#160;million classified as current liabilities as of January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, respectively.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt">Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense.  The Company recorded a contingent consideration reversal of $1,148&#160;million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt">In fiscal year 2022, the Company recorded $704&#160;million of contingent consideration related to Abiomed.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Notes&#160;2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428867716160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Borrowings</a></td>
<td class="text">Borrowings<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term debt are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.289%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.250% Notes due 2022                                                        (1B Euro 1.1311)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73%&#160;Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05% Notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(750MM Euro 1.0651)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(750MM Euro 1.1311)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50%&#160;Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(500MM 1.2037 GBP )</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(500MM GBP 1.3485)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028                                                (750MM Euro 1.0651)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(750MM Euro 1.1311)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95%&#160;Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95%&#160;Debentures due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035                                                     (1.5B Euro 1.0651)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(1.5B Euro 1.1311)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95%&#160;Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85%&#160;Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.400%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%&#160;Debentures due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.500% Notes due 2048</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250% Notes due 2050</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.450% Notes due 2060</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,439</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,116</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Weighted average effective rate.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at January&#160;1, 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at January&#160;2, 2022.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The excess of the carrying value over the fair value of debt was $1.6 billion at the end of fiscal year 2022 and the excess of the fair value over the carrying value of debt was $3.2 billion at the end of fiscal year 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has access to substantial sources of funds at numerous banks worldwide. In September 2022, the Company secured a new 364-day Credit Facility of  $10 billion, which expires on September&#160;7, 2023. In November 2022, the Company secured an additional 364-day Credit Facility of $10&#160;billion, which expires on November 21, 2023. Interest charged on borrowings under the credit line agreement is based on either the Term SOFR Reference Rate or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreements are not material.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Throughout fiscal years 2022 and 2021, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $12.8 billion and $3.8 billion</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> at the end of fiscal years 2022 and 2021, respectively. The current portion of the long term debt was $1.6 billion and $2.1 billion in 2022 and 2021, respectively, and the remainder is commercial paper and local borrowing by international subsi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">diaries. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The current debt balance as of January&#160;1, 2023 includes $11.2&#160;billion of commercial paper which has a weighted average interest rate of 4.23% and a weighted average maturity of approximately two months.</span></div><div style="text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate maturities of long-term debt obligations commencing in 2023 are:</span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"/><td style="width:15.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.879%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">After 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,551</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,562</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428867656112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 03, 2021</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for taxes on income consists of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"/><td style="width:50.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.003%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currently payable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total currently payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,447&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,065)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,663)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,079)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Provision for taxes on income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,784</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,783</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A comparison of income tax expense at the U.S.&#160;statutory rate of 21% in fiscal years 2022, 2021 and 2020, to the Company&#8217;s effective tax rate is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:48.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,369&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,312&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes on income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,725&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,776&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rates:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer health separation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes on international income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits from loss on capital assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits on share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)       </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflect the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2021 amounts include the reorganization of international subsidiaries; the 2020 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. The 2022 amount includes the impact of certain provisions of the 2017 TCJA that became effective in fiscal 2022. The 2021 amounts include the reorganization of international subsidiaries; the 2020 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">    Certain prior year amounts have been reclassified to conform to current year presentation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The fiscal year 2022 effective tax rate increased 9.1% as compared to the fiscal year 2021 effective tax rate. As part of the planned separation of the Company&#8217;s Consumer Health business, the Company has recognized approximately $0.5&#160;billion in net incremental tax costs in fiscal year 2022, which increased the 2022 effective tax rate by approximately 2.2%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Additionally, the Company recorded certain non-recurring favorable tax items in fiscal year 2021 which resulted in an unfavorable impact to the Company&#8217;s fiscal 2022 effective tax rate when compared to the prior fiscal year. These items are described below. The Company&#8217;s 2022 tax rate also benefited from certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in fiscal 2022, the impairment of bermekimab for AD and HS IPR&amp;D (for further information see Note 5 of the 2022 10-K Consolidated Financial Statements) and changes in the fair value of securities in the Company&#8217;s investment portfolio, both recorded at the U.S. statutory rate. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fiscal year 2021 tax rate decreased by 2.5% compared to the fiscal year 2020 tax rate, which was primarily driven by the following items. In fiscal year 2021, the Company reorganized the ownership structure of certain wholly-owned international subsidiaries. As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with applicable local regulations. The net impact of this restructuring was approximately $0.6&#160;billion net benefit or 2.7% benefit to the Company&#8217;s annual effective tax rate, comprised of the following items: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $2.3&#160;billion of local deferred tax assets to record the remeasurement of the tax basis of these assets to fair value, this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $1.7&#160;billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of these deferred tax assets. This expense has been reflected as &#8220;U.S. tax on international income&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Also, in the fiscal fourth quarter of 2021, the Company recognized a loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2021 tax rate by approximately 1.3% which is reflected as a &#8220;Tax benefits from loss on capital assets&#8221; on the effective tax rate reconciliation. Additionally other fiscal 2021 impacts to the rate were primarily driven by litigation and acquisition related items as follows:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company accrued additional legal expenses, of approximately $1.6&#160;billion for talc at an effective tax rate of 23.5% and $0.8&#160;billion for Risperdal Gynecomastia settlements at an effective tax rate of 16.4% (See Note 19 to the Consolidated Financial Statements for more details).</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the Company recorded a partial IPR&amp;D charge of $0.9&#160;billion for the Ottava intangible asset (acquired with the Auris Health acquisition in 2019) at an effective rate of 22.4%.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In fiscal year 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF) and became effective for fiscal year 2020. The Federal transitional provisions of TRAF allow companies, under certain conditions, to adjust the tax basis in certain assets to fair value (i.e., &#8220;step-up&#8221;) to be depreciated and amortized resulting in an incremental Swiss tax deduction over the transitional period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">TRAF also provides for parameters which enable the Swiss cantons to establish localized tax rates and regulations for companies. The new cantonal tax parameters include favorable tax benefits for patents and additional research and development tax deductions. The cantonal transitional provisions of TRAF allowed companies to elect either 1) tax basis step-up similar to the Federal transition benefit or 2) alternative statutory tax rate for a period not to exceed 5 years. The Company has operations located in various Swiss cantons. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">During the fiscal year 2020, the final canton where the Company maintains significant operations enacted TRAF legislation. Additionally, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company revising its estimate on the tax basis adjustment (i.e., &#8220;step-up&#8221;) for its assets and as a result, the Company recorded additional deferred tax benefits in 2020. The Company recognized a net benefit in the fiscal year 2020 for Swiss Tax Reform of approximately $0.4&#160;billion or 2.6% benefit to the Company&#8217;s annual effective tax rate, comprised of the following items: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $0.3 billion tax benefit relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred in the fiscal year 2020; this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation. </span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a $450 million deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company&#8217;s Swiss subsidiaries&#8217; assets as described above; this benefit has been reflected as &#8220;International Operations&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approximately $0.3 billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities in the fiscal year 2020. This benefit has been reflected as &#8220;U.S. tax on international income&#8221; on the Company&#8217;s effective tax rate reconciliation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company does not expect to receive future rulings regarding the transitional provisions of TRAF. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Also, in the fiscal year 2020, the Company recognized a capital loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2020 tax rate by approximately 1.2% which is reflected as a &#8220;Tax benefits from loss on capital assets&#8221; on the effective tax rate reconciliation. In addition, in the fiscal year 2020, the Company had lower income in higher tax jurisdictions, primarily driven by:       </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of the accrual of litigation costs related to talc for $4.0&#160;billion which reduced the U.S. earnings before taxes at an effective tax rate of 23.5%;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the accrual of additional legal costs, including an additional $1.0&#160;billion associated with a revised agreement in principle to settle opioid litigation at an effective tax rate of 21.4% </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Company also reduced the contingent consideration liability related to the Auris Health acquisition in 2019 and reversed some of its unrecognized tax benefits due to the completion of several years of tax examinations in certain jurisdictions during the fiscal year 2020. </span></div><div style="margin-bottom:9.9pt;margin-top:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Temporary differences and carryforwards at the end of fiscal years 2022 and 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.729%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 Deferred Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Deferred Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation of property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,659)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D capitalized for tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves&#160;&amp; liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income reported for tax purposes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realizable operating loss carryforwards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undistributed foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,547)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,853)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous international</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,183</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,434)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,904)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Amount is inclusive of the $2.3&#160;billion deferred tax asset established as part of the reorganized ownership structure of   certain wholly-owned international subsidiaries, as previously described. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Amount is inclusive of the $1.8&#160;billion deferred tax liability due to the acquisition of Abiomed.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Net of valuation allowances of $0.9&#160;billion in both 2022 and 2021. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to utilize these deferred tax assets. However, in certain jurisdictions, valuation allowances have been recorded against deferred tax assets for loss carryforwards that are not more likely than not to be realized. </span></div><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to unrecognized tax benefits:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"/><td style="width:50.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to prior period tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to prior period tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,829</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,323</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The unrecognized tax benefits of $3.8 billion at January&#160;1, 2023, if recognized, would affect the Company&#8217;s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. In the fiscal year 2020, the Company made its final payments for approximately $0.7 billion to the U.S. Treasury related to the final settlement of 2010-2012 tax audit liability.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:96%">In other major jurisdictions where the Company conducts business, the years that remain open to tax audits go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions, including in the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments or change in uncertain tax positions, if any. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $139 million, $44 million and $32 million in fiscal years 2022, 2021 and 2020, respectively. The total amount of accrued interest was $651&#160;million and $512 million in fiscal years 2022 and 2021, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784134368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Related Obligations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsGeneralTextBlock', window );">Employee Related Obligations</a></td>
<td class="text">Employee Related Obligations<div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal 2022 and fiscal 2021, employee related obligations recorded on the Consolidated Balance Sheets were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postemployment benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total employee obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current benefits payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations&#160;&#8212; non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,767</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prepaid employee related obligations of $4,581 million and $4,436 million for 2022 and 2021, respectively, are included in Other assets on the Consolidated Balance Sheets.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsGeneralTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items. Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -URI https://asc.fasb.org/topic&amp;trid=2127225<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 710<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6409950&amp;loc=d3e20396-108366<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsGeneralTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784413792">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pensions and Other Benefit Plans</a></td>
<td class="text">Pensions and Other Benefit Plans<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily healthcare, to all eligible U.S.&#160;retired employees and their dependents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S, non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee&#8217;s compensation during the last five years before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula).</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees,</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accrued under the Final Average Pay formula for service before January 1, 2026. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not fund retiree healthcare benefits in advance and has the right to modify these plans in the future.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022 and 2021 the Company used December 31, 2022 and December 31, 2021, respectively, as the measurement date for all U.S.&#160;and international retirement and other benefit plans.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans for 2022, 2021 and 2020 include the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">623</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">524</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unrecognized gains and losses for the U.S.&#160;pension plans are amortized over the average remaining future service for each plan.  For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S.&#160;benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior service costs/benefits for the U.S.&#160;pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S.&#160;benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average actuarial assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:39.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Periodic Benefit Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.01&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the assumed healthcare cost trend rates, for all individuals:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"/><td style="width:71.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.946%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Healthcare Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare cost trend rate assumed for next year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline (ultimate trend)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year the rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2047&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2046&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2022 and 2021 for the Company&#8217;s defined benefit retirement plans and other post-retirement plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,582&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains) losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(704)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments, settlements&#160;&amp; restructuring</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,631</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,582</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,878</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,195&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return (loss) on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,665)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(574)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,514</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,930</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status &#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,119)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,776)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(461)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,658)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,119)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,776)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,948&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net transition obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,929</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligations&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The actuarial gain for retirement plans in 2022 and 2021 was primarily related to increases in discount rates.</span></div></td></tr></table><div style="margin-top:3pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">623</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (gain) loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(793)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,927)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(655)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (cost) credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total loss/(income) recognized in other comprehensive income, before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,398)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,134)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(868)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(319)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,445)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,511)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(335)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company contributed $119 million and $151 million to its U.S.&#160;and international pension plans, respectively.</span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the funded status of the Company's U.S. Qualified &amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2022 and December&#160;31, 2021, respectively:</span></div><div style="margin-top:7pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:25.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unfunded Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,937&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over (Under) Funded Status</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,937)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,703)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $2.9 billion, $2.9 billion and $0.3 billion, respectively, at the end of 2022, and $3.9 billion, $4.2 billion and $0.3 billion, respectively, at the end of 2021.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future benefit payments from the Company&#8217;s retirement and other benefit plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2028-2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future benefit payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other benefit plans&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future minimum contributions to the unfunded retirement plans.  These amounts do not include any discretionary contributions that the Company may elect to make in the future.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2028-2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company&#8217;s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s retirement plan asset allocation at the end of 2022 and 2021 and target allocations for 2023 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:58.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.755%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent of<br/>Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Target<br/>Allocation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Determination of Fair Value of Plan Assets</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Plan has an established and well-documented process for determining fair values.  Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation Hierarchy</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A financial instrument&#8217;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</span></div><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following is a description of the valuation methodologies used for the investments measured at fair value.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Short-term investment funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level&#160;2.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Government and agency securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level&#160;1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level&#160;2.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Debt instruments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level&#160;1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level&#160;2. Level&#160;3 debt instruments are priced based on unobservable inputs.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Equity securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level&#160;1 of the valuation hierarchy.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commingled funds</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level&#160;2 category have a quoted market price.</span></div><div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other assets</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#8212; Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level&#160;1, while inactively traded assets are classified as Level&#160;2. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2022 and December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:18.235%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.161%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government and agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,879</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,954</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,086</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,612</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,515</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,514</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,930</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The activity for the Level 3 assets is not significant for all years presented.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's Other Benefit Plans are unfunded except for U.S.&#160;commingled funds (Level 2) of $78 million and $102 million at December&#160;31, 2022 and December&#160;31, 2021, respectively. </span></div>The fair value of Johnson&#160;&amp; Johnson Common Stock directly held in plan assets was $21 million (0.1% of total plan assets) at December&#160;31, 2022 and $385 million (0.9% of total plan assets) at December&#160;31, 2021.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784284672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Savings Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SavingsPlanAbstract', window );"><strong>Savings Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SavingsPlanTextBlock', window );">Savings Plan</a></td>
<td class="text">Savings PlanThe Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee&#8217;s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $275 million, $256 million and $243 million in fiscal years 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SavingsPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Savings Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SavingsPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SavingsPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Savings Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SavingsPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428785353296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital and Treasury Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockTextBlock', window );">Capital and Treasury Stock</a></td>
<td class="text">Capital and Treasury Stock<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in treasury stock were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in Millions Except Treasury Stock Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,490&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,847)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,007)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,694&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate shares of common stock issued were approximately 3,119,843,000&#160;shares at the end of fiscal years 2022, 2021 and 2020.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash dividends paid were $4.45 per share in fiscal year 2022, compared with dividends of $4.19 per share in fiscal year 2021, and $3.98 per share in fiscal year 2020. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2023, the Board of Directors declared a regular cash dividend of $1.13 per share, payable on March 7, 2023 to shareholders of record as of February 21, 2023.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. Share repurchases may be made at management&#8217;s discretion from time to time on the open market or through privately negotiated transactions.  The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Through January&#160;1, 2023, approximately $2.5&#160;billion has been repurchased under the program.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -URI https://asc.fasb.org/subtopic&amp;trid=2208821<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784553408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">Accumulated Other Comprehensive Income (Loss)<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>Currency Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss) On Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/<br/>(Loss) On<br/>Derivatives &amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,705)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2020 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,938)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,957)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,242)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2021 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,017)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,702)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,058)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2022 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,796)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,813)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(897)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,967)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Details on reclassifications out of Accumulated Other Comprehensive Income:</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details.</span></div><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gain/(Loss) On Derivatives &amp; Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction.  See Note 6 for additional details.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI https://asc.fasb.org/topic&amp;trid=2134417<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784284672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>International Currency Translation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTranslationAbstract', window );"><strong>Foreign Currency Translation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDisclosureTextBlock', window );">International Currency Transalation</a></td>
<td class="text">International Currency Translation<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For translation of its subsidiaries operating in non-U.S.&#160;Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non-current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies, (Argentina and Venezuela). Beginning in the fiscal second quarter of 2022, the Company also accounted for operations in Turkey as highly inflationary. The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A rollforward of the changes during fiscal years 2022, 2021 and 2020 for foreign currency translation adjustments is included in Note&#160;13. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net currency transaction gains and losses included in Other (income) expense were losses of $328 million, $236 million and $209 million in fiscal years 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30885-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -URI https://asc.fasb.org/topic&amp;trid=2175825<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTranslationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTranslationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784279888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share</a></td>
<td class="text">Earnings Per Share<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions Except Per Share Amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding&#160;&#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted average shares outstanding&#160;&#8212; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.81&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The diluted net earnings per share calculation for the fiscal years 2022 and 2021 included all shares related to stock options, as the exercise price of these options was less than the average market value of the Company's stock. </span></div>The diluted net earnings per share calculation for fiscal year 2020 excluded 18 million shares related to stock options, as the exercise price of these options was greater than the average market value of the Company's stock.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784098224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Common Stock, Stock Option Plans and Stock Compensation Agreements</a></td>
<td class="text">Common Stock, Stock Option Plans and Stock Compensation Agreements<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At January&#160;1, 2023, the Company had one stock-based compensation plan. The shares outstanding are for contracts under the Company's 2012 Long-Term Incentive Plan and the 2022 Long-Term Incentive Plan. The 2012 Long-Term Incentive Plan expired on April 26, 2022. All awards (stock options, restricted shares units and performance share units) granted subsequent to that date were under the 2022 Long-Term Incentive Plan. Under the 2022 Long-Term Incentive Plan, the Company may issue up to 150&#160;million shares of common stock, of which up to 110&#160;million shares of common stock may be issued subject to stock options or stock appreciation rights and up to 40&#160;million shares of common stock may be issued subject to full value awards. Awards will generally be counted on a 1-for-1 basis against the share reserve, provided that if more than 40&#160;million full value awards are granted, each full value award in excess of 40&#160;million will be counted on a 5-for-1 basis against the share reserve. Shares available for future grants under the 2022 Long-Term Incentive Plan were 150 million at the end of fiscal year 2022.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The compensation cost that has been charged against income for these plans was $1,138 million, $1,135 million and $1,005 million for fiscal years 2022, 2021 and 2020, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $196 million, $218 million and $210 million for fiscal years 2022, 2021 and 2020, respectively. The Company also recognized additional income tax benefits of $282&#160;million, $223&#160;million and $248&#160;million for fiscal years 2022, 2021 and 2020, respectively, for which options were exercised or restricted shares were vested. The total unrecognized compensation cost was $939 million, $862 million and $804 million for fiscal years 2022, 2021 and 2020, respectively.  The weighted average period for this cost to be recognized was 1.80&#160;years, 1.78&#160;years and 1.76&#160;years for fiscal years 2022, 2021, and 2020, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock Options</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options expire 10&#160;years from the date of grant and vest over service periods that range from 6 months to 4 years.  All options are granted at the average of the high and low prices of the Company&#8217;s Common Stock on the New York Stock Exchange on the date of grant. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2022, 2021, and 2020 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson&#160;&amp; Johnson options with a life of 2&#160;years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S.&#160;Treasury yield curve in effect at the time of grant.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average fair value of options granted was $23.23, $20.86 and $16.42, in fiscal years 2022, 2021 and 2020, respectively.  The fair value was estimated based on the weighted average assumptions of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:56.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Plan as of January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, and changes during the years ending on those dates is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:47.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(Dollars in Millions) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134.95</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,949</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The total intrinsic value of options exercised was $1,228 million, $919 million and $1,021 million in fiscal years 2022, 2021 and 2020, respectively.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock options outstanding and exercisable at January&#160;1, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:29.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.168%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price Range</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$72.54-$100.48</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$93.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$93.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$101.87-$115.67</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$108.78</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$108.78</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$129.51-$141.06</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130.88</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130.85</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$151.41-$164.62</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$157.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$156.21</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$164.63-$165.89</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$165.89</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$165.89</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$134.95</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63,661</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$113.06</span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Average contractual life remaining in years.</span></div><div style="margin-top:7pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options outstanding at January&#160;2, 2022 and January&#160;3, 2021 were 117,361 and an average life of 5.8 years and 114,250 and an average life of 6.0&#160;years, respectively. Stock options exercisable at January&#160;2, 2022 and January&#160;3, 2021 were 62,742 at an average price of $104.42 and 61,289 at an average price of $96.97, respectively. </span></div><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Share Units and Performance Share Units</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company grants restricted share units which vest over service periods that range from 6 months to 3 years. The Company also grants performance share units, which are paid in shares of Johnson &amp; Johnson Common Stock after the end of a three-year performance period. Performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The number of shares actually earned at the end of the three-year period will vary, based only on actual performance, from 0% to 200% of the target number of performance share units granted</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%">. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted share units and performance share units activity under the Plans as of January&#160;1, 2023 is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"/><td style="width:55.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.611%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Performance Share Units</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,866)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited/adjusted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(794)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,616&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average fair value of the restricted share units granted was $153.67, $152.62 and $139.58 in fiscal years 2022, 2021 and 2020, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $591 million, $611 million and $650 million in 2022, 2021 and 2020, respectively.</span></div><div style="text-indent:13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average fair value of the performance share units granted was $170.46, $179.35 and $160.54 in fiscal years 2022, 2021 and 2020, calculated using the weighted average fair market value for each of the component goals at the date of grant.&#160; </span></div>The fair values for the sales and earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period.&#160;The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model.&#160;The fair value of performance share units issued was $94 million, $83 million and $91 million in fiscal years 2022, 2021 and 2020, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784238288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segments of Business and Geographic Areas</a></td>
<td class="text">Segments of Business* and Geographic Areas<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;22 vs. &#8217;21</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;21 vs. &#8217;20</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSUMER HEALTH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:189pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT / rilpivirine</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA / PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> /                                              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA / methylphenidate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* *</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA/ INVOKAMET</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:113pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MEDTECH*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Approximately $0.4&#160;billion in both the fiscal 2021 and 2020, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pr</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">eviously referred to as Medical Devices</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (Loss) Before Tax*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,915&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,829&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,776</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,497</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">187,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182,018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*Income before tax of approximately $0.2&#160;billion and $0.2&#160;billion in the fiscal years 2021 and 2020, respectively, has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions to Property,<br/>Plant &amp; Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation and<br/>Amortization</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,817&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,647&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,074&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,652</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,347</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,390</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,231</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-Lived Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere excluding U.S.&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non long-lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94,943</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93,775</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">187,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182,018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;1 for a description of the segments in which the Company operates. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Export sales are not significant. In fiscal year 2022, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.5%, 13.0% and 12.0% of the total consolidated revenues. In fiscal year 2021, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0%, and 12.0% of the total consolidated revenues. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">General corporate includes cash, cash equivalents and marketable securities.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.2&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.44pt">One-time COVID-19 Vaccine manufacturing exit related costs of $1.5&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An intangible asset impairment charge of approximately $0.8&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation expense of $0.1&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of $0.7&#160;billion related to the change in the fair value of securities </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $0.1&#160;billion </span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MedTech includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation expense of $0.6&#160;billion primarily for pelvic mesh related costs</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquisition and integration related costs of $0.3&#160;billion primarily related to the acquisition of Abiomed</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Medical Device Regulation charge of $0.3&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $1.6&#160;billion, primarily talc related costs</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.6&#160;billion, primarily related to Risperdal Gynecomastia</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Divestiture gains of $0.6&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Gains of  $0.5&#160;billion related to the change in the fair value of securities</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1&#160;billion </span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MedTech includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $0.9&#160;billion related to Ottava</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A Medical Device Regulation charge of $0.2&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.1&#160;billion </span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $3.9&#160;billion, primarily talc related costs and certain settlements.</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.8&#160;billion, primarily related to the agreement in principle to settle opioid litigation </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $0.5&#160;billion related to the change in the fair value of securities</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MedTech includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A contingent consideration reversal of $1.1&#160;billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $0.2&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A Medical Device Regulation charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Long-lived assets include property, plant and equipment, net for fiscal years 2022, and 2021 of $19,803 and $18,962, respectively, and intangible assets and goodwill, net for fiscal years 2022 and 2021 of $93,556 and $81,638, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 34<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8981-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 26<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8844-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8657-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8721-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI https://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784165488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 02, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract', window );"><strong>Business Combination and Asset Acquisition [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions and Divestitures</a></td>
<td class="text">Acquisitions and Divestitures<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the fiscal year 2022, certain businesses were acquired for $17.7&#160;billion in cash and $1.1&#160;billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.   </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">       The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $17.3&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fiscal year 2022 acquisitions primarily included Abiomed, Inc. (Abiomed). The remaining acquisitions were not material.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Company&#8217;s position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcare&#8217;s largest areas of unmet need. The transaction was accounted for as a business combination and the results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $380.00 per share in cash, amounting to $17.1&#160;billion, net of cash acquired, as well as a non-tradeable contingent value right (&#8220;CVR&#8221;) entitling the holder to receive up to $35.00 per share in cash (which with respect to the CVRs total approximately $1.6&#160;billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $16.5&#160;billion includes cash, cash equivalents and marketable securities acquired. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The milestones of the CVR consist of:</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">$17.50 per share, payable if net sales for Abiomed products exceeds $3.7&#160;billion during Johnson &amp; Johnson&#8217;s fiscal second quarter of 2027 through fiscal first quarter of 2028, or if this threshold is not met during this period and is subsequently met during any rolling four quarter period up to the end of Johnson &amp; Johnson&#8217;s fiscal first quarter of 2029, $8.75 per share;</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt">$7.50 per share payable upon FDA premarket application approval of the use of Impella</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> products in ST-elevated myocardial infarction (STEMI) patients without cardiogenic shock by January 1, 2028; and</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt">$10.00 per share payable upon the first publication of a Class I recommendation for the use of Impella</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> products in high risk PCI or STEMI with or without cardiogenic shock within four years from their respective clinical endpoint publication dates, but in all cases no later than December 31, 2029.</span></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The fair value of the acquisition was allocated to assets acquired of $19.9&#160;billion (net of $0.3&#160;billion cash acquired), primarily to goodwill for $10.9&#160;billion, amortizable intangible assets for $6.6&#160;billion, IPR&amp;D for $1.1&#160;billion, marketable </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">securities of $0.6&#160;billion and liabilities assumed of $2.8&#160;billion, which includes the fair value of the contingent consideration mentioned above for $0.7&#160;billion and deferred taxes of $1.8&#160;billion. The goodwill is primarily attributable to the commercial acceleration and expansion of the portfolio and is not expected to be deductible for tax purposes. The contingent consideration was recorded in Other Liabilities on the Consolidated Balance Sheet.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As the acquisition occurred in December 2022, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. To assist management in the allocation, the Company engaged valuation specialists to prepare appraisals. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The amortizable intangible assets were primarily comprised of already in-market products of the Impella</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> platform with an average weighted life of 14 years. The IPR&amp;D assets were valued for technology programs for unapproved products. The value of the IPR&amp;D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from 52% to 70%. The discount rate applied was 9.5%.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In 2022, the Company recorded acquisition related costs before tax of approximately $0.3&#160;billion, which was recorded in Other (income)/expense. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During fiscal year 2021, the Company did not make any material acquisitions. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During fiscal year 2020, certain businesses were acquired for $7.3&#160;billion in cash and $0.4&#160;billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $7.5&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fiscal year 2020 acquisitions primarily included: all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc. (XBiotech), Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases and the outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8&#160;billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $0.8&#160;billion applying a probability of success factor that ranged from 20% to 60% to reflect inherent development, regulatory and commercial risk for the different indications. The discount rate applied was approximately 16%. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. In fiscal 2022, the Company recorded an intangible asset impairment charge of approximately $0.8&#160;billion related to this in-process research and development asset.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, in the fiscal first quarter of 2020, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the MedTech segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;D, for $0.4&#160;billion, goodwill for $0.2&#160;billion, other assets of $0.2&#160;billion and liabilities assumed of $0.3&#160;billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4&#160;billion. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">On October 1, 2020, the Company completed the acquisition of Momenta for a purchase price of approximately $6.1&#160;billion, net of cash acquired. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets (IPR&amp;D) of $6.0&#160;billion, goodwill of $1.2&#160;billion, other assets of $0.5&#160;billion and liabilities of $1.6&#160;billion. The assets acquired are intended to address substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Depending on the asset, probability of success factors ranging from 20% to 77% were used in the fair value calculation to reflect inherent development and regulatory risk of the IPR&amp;D. The discount rate applied was approximately 13%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. The transaction was accounted for as a business combination and included in the Pharmaceutical segment.                   </span></div><div style="text-align:justify;text-indent:18pt"><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In accordance with U.S.&#160;GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2022, 2021 and 2020 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company&#8217;s results of operations.</span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Divestitures</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During fiscal year 2022, the Company did not make any material divestitures. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">During fiscal year 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6&#160;billion. </span></div>During fiscal year 2020, the Company sold 11.8&#160;million shares of Idorsia LTD (Idorsia), or its 8.3% ownership in the company at that time. The transaction resulted in gross proceeds of approximately CHF 337&#160;million ($357&#160;million) based on a sales price of CHF 28.55/share and resulted in an immaterial net loss. At the end of fiscal 2020, the Company had rights to approximately 38.7&#160;million shares through a convertible loan with a principal amount of CHF 445&#160;million (due June 2027). During fiscal year 2021, the Company converted CHF 110&#160;million ($120&#160;million) of this loan into approximately 9.6&#160;million shares of Idorsia which were reflected at fair value as of January 2, 2022. During the fiscal third quarter of 2021, the Company's undrawn credit facility with Idorsia was terminated.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAndAssetAcquisitionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAndAssetAcquisitionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI https://asc.fasb.org/topic&amp;trid=2303972<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4946-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784295168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LegalMattersAndContingenciesTextBlock', window );">Legal Proceedings</a></td>
<td class="text">Legal Proceedings<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Johnson &amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of January 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the Company&#8217;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#8217;s balance sheet, is not expected to have a material adverse effect on the Company&#8217;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#8217;s results of operations and cash flows for that period.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PRODUCT LIABILITY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The most significant of these cases include: the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; the PINNACLE Acetabular Cup System; pelvic meshes; RISPERDAL; body powders containing talc, primarily JOHNSON'S Baby Powder; ETHICON PHYSIOMESH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Flexible Composite Mesh; ELMIRON; and TYLENOL. As of January&#160;1, 2023, in the United States there were approximately 170 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; 1,400 with respect to the PINNACLE Acetabular Cup System; 9,000 with respect to pelvic meshes; 1,100 with respect to RISPERDAL; 40,300 with respect to body powders containing talc;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,100 with respect to ETHICON PHYSIOMESH Flexible Composite Mesh; 2,000 with respect to ELMIRON; and 170 with respect to TYLENOL. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. Prior to 2019, several adverse verdicts had been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon&#8217;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#8217;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#8217;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia, Canada and South Africa. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In September 2022, after exhausting its appeals, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia, pending Federal Court approval. In November 2022, the application for approval of the settlement was filed, and a hearing on the settlement has been scheduled for the end of February 2023. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicon&#8217;s pelvic mesh products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 2,236 have been dismissed with prejudice. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of January 2023, there are approximately 208 active cases subject to these orders which are being reviewed and evaluated. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products.  All litigation activities in the two New Jersey MCLs are stayed pending resolution of the proposed settlement.  Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury arising out of the use of XARELTO, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); the Company; and JPI&#8217;s collaboration partner for XARELTO, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases were filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and the Company announced an agreement in principle to settle the XARELTO cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp; Johnson Consumer Inc. and the Company arising out of the use of body powders containing talc, primarily JOHNSON&#8217;S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7&#160;billion in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ingham v. Johnson &amp; Johnson, et al., </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No. ED 207476 (Mo. App.), reducing the overall award to $2.1&#160;billion. An application for transfer of the case to the Missouri Supreme Court </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ingham </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5&#160;billion. The facts and circumstances, including the terms of the award, were unique to the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Ingham</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#8217;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Johnson &amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#8217;s direct parent, Johnson &amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#8217;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#8217; compensation statute or act (the Talc-Related Liabilities). </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, notwithstanding the Company&#8217;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the North Carolina Bankruptcy Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties). The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court extended the PI through the end of February 2022. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions by order issued in March 2022. The New Jersey Bankruptcy Court simultaneously issued another order extending the stay as to the Protected Parties. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss and the extension of the stay. In May 2022, the Third Circuit Court of Appeals granted the petitions to appeal. The briefing and oral argument on the appeal were completed in September 2022. On January 30, 2023, the Third Circuit reversed the Bankruptcy Court&#8217;s ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy.  LTL filed a petition for rehearing on the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While the New Jersey Bankruptcy Court&#8217;s order effectively stays all of the Company&#8217;s talc-related personal injury litigation, LTL has agreed to lift the stay on a small number of appeals where appeal bonds have been filed.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $2&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2&#160;billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action). The Edley Class Action asserts, among other things, that the Company fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by the Company&#8217;s then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter. The Company removed the Edley Class Action to federal court in the District of New Jersey. In July 2022, Imerys filed a motion in the Imerys Bankruptcy to stay the Edley Class Action, which was denied in August 2022.  In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2019, the Company&#8217;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#8217;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds.  In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#8217; Committee (TCC), and the Future Claimants&#8217; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#8217;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, certain of Imerys&#8217;s insurers, and certain parties in the Cyprus Mines chapter 11 case (described below) (collectively the Mediation Parties) agreed to engage in mediation. The most recent term of the mediation ended on December 31, 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys Adversary Proceeding). The Imerys Adversary Proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#8217;s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys Adversary Proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2020, Cyprus Mines Corporation and its parent, Cyprus Amax Minerals Company (CAMC) (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus Adversary Proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain protected parties. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus Adversary Proceeding. In June 2022, Cyprus commenced an Adversary Proceeding in its chapter 11 case seeking an order enforcing the automatic stay by enjoining parties from commencing or continuing &#8220;talc-related claims&#8221; against CAMC. In June 2022, the court entered a preliminary injunction order enjoining claimants from pursuing talc-related claims against CAMC through January 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2021, several of the Company&#8217;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action. In March 2022, the New Jersey Bankruptcy Court ruled that the LTL automatic stay applied to the Coverage Action.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#8217;S Baby Powder, and that purchasers of the Company&#8217;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiff&#8217;s motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff&#8217;s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. In April 2022, Defendants filed a second motion to supplement the class certification record.  In May 2022, the New Jersey Bankruptcy Court entered an order staying the securities class action. Plaintiff has appealed the Bankruptcy Court&#8217;s order.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#8217;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#8217;S Baby Powder. In that lawsuit, the plaintiffs allege that the Company violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#8217;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. In October 2021, Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit. A bankruptcy stay was imposed in December 2021, and the Court held the reply deadline in abeyance. In February 2022, the Bankruptcy Court issued an order extending the stay. The appeal continues to be held in abeyance, with the Company being required to file periodic status updates. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of INVOKANA, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company&#8217;s accruals.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against a number of Johnson &amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Claims for personal injury have been made against Johnson and Johnson Consumer Inc. (JJCI), arising out of the use of TYLENOL, an over-the-counter pain medication, alleging that prenatal exposure to acetaminophen is associated with the development of autism spectrum disorder and/or attention-deficit/hyperactivity disorder. In October 2022, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the Southern District of New York.  In addition, lawsuits have been filed in Canada.  Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with TYLENOL related product liability litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">INTELLECTUAL PROPERTY</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#8217;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">MedTech</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos.  6,522,906 (&#8217;906); 6,800,056 (&#8217;056); 8,142,447 (&#8217;447); and 9,452,276 (&#8217;276) based on Auris&#8217; MONARCH Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the &#8217;056, &#8217;447, &#8217;276 and &#8217;906 patents.  In December 2019, the USPTO denied review of the &#8217;056 patent. In February and March 2020, the USPTO instituted review of the &#8217;447, and &#8217;906 patents and denied review of the &#8217;276 patent. In March 2021, the USPTO ruled that the challenged claims of the &#8217;447 and &#8217;906 patents are not invalid. Auris appealed, and in April 2022, the United States Court of Appeals for the Federal Circuit vacated the decision that the &#8217;447 patent was not invalid and remanded the decision to the USPTO for further review.  In May 2022, the United States Court of Appeals for the Federal Circuit confirmed the ruling that claim 53 of the &#8217;906 patent was not invalid, vacated the decision that the remaining claims of the &#8217;906 patent were not invalid and remanded the decision to the USPTO for further review. Auris filed a request for reexamination of the &#8217;276 patent in November 2021, and in January 2022, the USPTO granted the reexamination request. Trial is scheduled to begin in September 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in the United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of U.S. Patent Nos. 6,984,234 (&#8217;234) and 9,713,537 (&#8217;537) by one or more of the following products:  ZERO-P-VA Spacer, ZERO-P Spacer, ZERO-P NATURAL Plate, SYNFIX LR Spacer and SYNFIX Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. In June 2022, DePuy filed potentially dispositive summary judgment motions that the &#8217;234 patent is invalid as anticipated and the &#8217;537 patent is not infringed.  In November 2022, the Court granted DePuy&#8217;s summary judgment motion that the &#8217;234 patent is invalid as anticipated and denied DePuy&#8217;s motion that the &#8217;537 patent is not infringed.  In December 2022, the Court conducted a jury trial on the &#8217;537 patent where the jury found that the &#8217;537 patent was not literally infringed, but that DePuy infringed under the doctrine of equivalents (DOE).  The jury awarded RSB $12 million in damages subject to post-trial motions and appeals.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Rasmussen Instruments, LLC (Rasmussen) filed a patent infringement suit against DePuy Synthes Products, Inc., DePuy Synthes Sales, Inc. and Medical Device Business Services, Inc. (collectively, DePuy) in the United States District Court for the District of Massachusetts. Rasmussen alleges that DePuy willfully infringes U.S. Patent Nos. 9,492,180 (&#8217;180) and 10,517,583 (&#8217;583) by making and selling the Attune Balanced Sizer. In April 2021, Rasmussen sought permission to amend its infringement contentions to allege that DePuy also willfully infringes the &#8217;583 patent by making and selling the Attune Balancing Blocks. Rasmussen seeks treble damages for willful infringement. Trial concluded in March 2022, with the jury returning a verdict in favor of Rasmussen, finding willful infringement of the &#8217;180 patent, and awarding damages in the amount of $20&#160;million. DePuy challenged the verdict in its post-trial motions. In July 2022, a hearing was held on the post-trial motions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Pharmaceutical</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following summarizes lawsuits the Company&#8217;s subsidiaries have brought against generic companies that have filed ANDAs with the U.S. FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents. In the event the Company&#8217;s subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the U.S. FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#8217;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ZYTIGA </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in January 2019, Janssen Inc., Janssen Oncology, Inc., and BTG International Ltd. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy&#8217;s Laboratories Ltd. and Dr. Reddy&#8217;s Laboratories, Inc. (collectively, DRL) in response to those parties&#8217; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA before the expiration of the Canadian Patent No. 2,661,422 (&#8217;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#8217;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision. The appeal hearing took place in September 2022. In November 2022, Janssen's appeal was dismissed.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2021, July 2021 and April 2022, respectively, Apotex, DRL and Pharmascience initiated Statements of Claim under Section 8 of the Patented Medicines (Notice of Compliance) Regulations against Janssen seeking damages in respect of those parties generic Zytiga tablets.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Trials against Apotex and DRL are scheduled for June 2023. A trial date for the Pharmascience action has not been set.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">XARELTO</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO (2.5 mg) before expiration of U.S. Patent No. 10,828,310 (&#8217;310). The following generic drug companies are named defendants:  Dr. Reddy&#8217;s Laboratories, Inc. and Dr. Reddy&#8217;s Laboratories, Ltd.; Lupin Limited and Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc.; and Teva Pharmaceuticals USA, Inc. In October 2021, the court consolidated the Delaware lawsuits for all purposes, including trial. Trial for the consolidated Delaware lawsuits is scheduled to begin in May 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan) which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#8217;310 patent. In August 2021, JPI and Bayer filed a motion before the United States Judicial Panel on Multidistrict Litigation (the MDL panel) to transfer this lawsuit to the United States District Court for the District of Delaware for coordinated and consolidated pretrial proceedings. In December 2021, the MDL panel granted the motion. In August 2022, after receiving a second notice letter from Mylan regarding the same ANDA, JPI and Bayer filed a second patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan. In September 2022, Mylan moved to dismiss the second lawsuit. In September 2022, the MDL panel transferred the second lawsuit to the District of Delaware. No trial date has been set for these two lawsuits. In October 2022, Mylan voluntarily withdrew its motion to dismiss.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent. In January 2023, the court issued an order staying the lawsuits until after a final written decision is issued in the Inter Partes Review proceedings on the &#8217;310 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Mylan Pharmaceuticals Inc. filed a Petition for Inter Partes Review (IPR) with the United States Patent and Trademark Office (USPTO), seeking to invalidate the &#8217;310 patent. In August 2022, the Patent Trial and Appeal Board (PTAB) issued a decision instituting IPR.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, InvaGen Pharmaceuticals, Inc. filed a Petition for IPR with the USPTO seeking to invalidate the &#8217;310 patent. Also in September 2022, Teva Pharmaceuticals USA, Inc. filed a Petition for IPR with the USPTO seeking to invalidate the &#8217;310 patent. In October 2022, the PTAB issued decisions instituting IPR in both proceedings and joining them with the earlier IPR proceeding filed by Mylan Pharmaceuticals Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, JPI, Bayer, and Bayer Intellectual Property GmbH (BIP) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against USV Private Limited (USV), who filed an ANDA seeking approval to market generic versions of XARELTO (2.5 mg, 10 mg, 15 mg, and 20 mg) before the expiration of the '310 patent and U.S. Patent No. 9,539,218 (&#8217;218). JPI, Bayer, and BIP are seeking an order enjoining USV from marketing its generic version of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent, and its generic versions of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#8217;218 patent. In November 2022, the MDL panel transferred this lawsuit to the United States District Court for the District of Delaware.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2022, JPI, Bayer AG, and BIP </span><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mankind Pharma Limited (Mankind), who filed an ANDA seeking approval to market generic versions of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#8217;218 patent. JPI, Bayer AG, and BIP are seeking an order enjoining Mankind from marketing its generic versions of XARELTO before the expiration of the &#8217;218 patent.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, JPI, Bayer, and BIP initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Epic Pharma, LLC (Epic), who filed an ANDA seeking approval to market generic versions of XARELTO (2.5 mg, 10 mg, 15 mg, and 20 mg) before the expiration of the &#8217;310 patent and the &#8217;218 patent. JPI, Bayer, and BIP are seeking an order enjoining Epic from marketing its generic version of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent, and its generic versions of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#8217;218 patent. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2022, JPI and Bayer initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Apotex Inc. and Apotex Corp. (collectively, Apotex), who filed an ANDA seeking approval to market generic versions of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent. JPI and Bayer are seeking an order enjoining Apotex from marketing its generic version of XARELTO (2.5 mg) before the expiration of the &#8217;310 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">OPSUMIT</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen Inc. (Janssen) and Actelion Pharmaceuticals Ltd (Actelion) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of Canadian Patent No. 2,659,770 (&#8217;770). Sandoz stipulated to infringement of the &#8217;770 patent.  Trial against Sandoz on the issue of validity concluded in February 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Sandoz appealed the decision. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 mg,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before the expiration of the &#8217;770 patent. Apotex stipulated to validity of the &#8217;770 patent.  Trial against Apotex on the issue of infringement concluded in March 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Apotex appealed the decision.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#404a52;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Generic Medical Partners Inc. (GMP) in Canada in response to GMP&#8217;s filing of an ANDS seeking approval to market a generic version of OPSUMIT 10 mg, before the expiration of Canadian Patent Nos. 2,659,770 and 2,621,273.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2023, Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. (collectively, Actelion) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Sun Pharmaceutical Industries Limited and Sun Pharmaceutical Industries, Inc. (collectively, Sun) who filed an ANDA seeking approval to market a generic version of OPSUMIT before the expiration of U.S. Patent Nos. 7,094,781 (&#8217;781) and 10,946,015 (&#8217;015).  Actelion is seeking an order enjoining Sun from marketing their generic versions of OPSUMIT before the expiration of the &#8217;781 and &#8217;015 patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA SUSTENNA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of U.S. Patent No. 9,439,906 (&#8217;906). Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen&#8217;s favor. Teva has appealed the decision.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent. Pursuant to an agreement by the parties, judgment in favor of Janssen was entered in December 2021. Mylan appealed. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Tolmar, Inc., Tolmar Therapeutics, Inc., Tolmar Pharmaceuticals, Inc. and Tolmar Holding, Inc. (collectively, Tolmar), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent. A trial is scheduled to begin in October 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Accord Healthcare, Inc., Accord Healthcare, Ltd. and Intas Pharmaceuticals, Ltd. (collectively, Accord), who filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;906 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of Canadian Patent Nos. 2,309,629 (&#8217;629) and 2,655,335 (&#8217;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#8217;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#8217;s generic version of INVEGA SUSTENNA, if approved, would infringe certain claims of the &#8217;335 patent and that the claims of the &#8217;335 patent are not invalid. Teva Canada appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.&#8217;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in November 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Pharmascience filed an appeal. In March 2022, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience in response to Pharmascience&#8217;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. The action has been consolidated with the November 2020 action for trial, which took place in July 2022. In August 2022, the Court issued a decision finding the claims of the&#8217;335 patent are not invalid. Pharmascience appealed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex&#8217;s filing of an ANDS (original ANDS) seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A summary trial on the issue of infringement took place in December 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Apotex appealed. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Janssen Canada initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex in response to Apotex&#8217;s Notice of Allegation of invalidity with respect to the original ANDS and in response to Apotex&#8217;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#8217;335 patent. A trial is scheduled to begin in March 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVEGA TRINZA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp; Development, LLC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (546 mg) before expiration of U.S. Patent No. 10,143,693 (&#8217;693) relating to INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(546 mg).  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(819 mg) before expiration of the &#8217;693 patent.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (273 mg and 410 mg) before expiration of the &#8217;693 patent.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2022, the court consolidated the three cases into the case filed in September 2020. In each of these consolidated cases, Janssen is seeking an order enjoining Mylan from marketing its generic versions of INVEGA TRINZA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">before expiration of the &#8217;693 patent. Trial was conducted in November and December 2022, and post-trial briefing is proceeding. Closing arguments will be held in March 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IMBRUVICA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2019, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA tablets, asserting infringement of U.S. Patent Nos. 7,514,444; 8,003,309; 8,476,284; 8,497,277; 8,697,711; 8,753,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of U.S. Patent No. 10,213,386. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Trial against Alvogen took place in October 2020. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. In November 2022, the United States Court of Appeals for the Federal Circuit affirmed the District Court&#8217;s decision.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#8217;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capsules before the expiration of Canadian Patent Nos. 2,663,116 (&#8217;116); 2,928,721 (&#8217;721); 2,800,913 (&#8217;913); 3,007,787 (&#8217;787); 3,007,788 (&#8217;788); 2,875,986 (&#8217;986); and 3,022,256 (&#8217;256). In this lawsuit, Pharmacyclics and Janssen Canada are seeking an order enjoining Natco from marketing its generic version of IMBRUVICA before the expiration of the relevant patents. Trial is scheduled to begin in July 2023.  </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Pharmacyclics and Janssen Canada initiated a second Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco in response to Natco&#8217;s filing of an ANDS seeking approval to market a generic version of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capsules before the expiration of the &#8217;116, &#8217;721, &#8217;913, &#8217;787, and &#8217;788 patents and Canadian Patent No. 2,851,808. In this lawsuit, Pharmacyclics and Janssen Canada are seeking an order enjoining Natco from marketing its generic version of IMBRUVICA capsules before the expiration of the relevant patents. Trial in this second action is scheduled to begin in August 2024. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2023, Pharmacyclics and Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in response to Sandoz&#8217;s filing of an ANDS seeking approval to market a generic version of IMBRUVICA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">capsules before the expiration of the &#8217;116, &#8217;913, &#8217;787, and &#8217;788 patents. Also in February 2023, Pharmacyclics and Janssen initiated a Statement of Claim under Section 8.2 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz asserting the &#8217;721 and &#8217;256 patents, which are also listed in Health Canada&#8217;s Patent Register for IMBRUVICA. In these lawsuits, Pharmacyclics and Janssen Canada are seeking an order enjoining Sandoz from marketing its generic version of IMBRUVICA capsules before the expiration of the relevant patents. A trial date for these actions has not been set. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SYMTUZA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited, Lupin Pharmaceuticals, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., and MSN Pharmaceuticals Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of SYMTUZA before the expiration of U.S. Patent Nos. 10,039,718 (&#8217;718) and 10,786,518 (&#8217;518). The trial is scheduled to begin in October 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Apotex Inc. and Apotex Corp. (collectively, Apotex), which filed an ANDA seeking approval to market a generic version of SYMTUZA before the expiration of the &#8217;718 and &#8217;518 patents. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of SYMTUZA before the expiration of the relevant patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ERLEADA</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. (collectively, Janssen) and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of U.S. Patent No. 9,481,663 (&#8217;663). In August 2022, Janssen and SKI filed a first amended complaint against Lupin adding U.S. Patent Nos. 9,884,054 (&#8217;054), 10,052,314 (&#8217;314), 10,702,508 (&#8217;508) and 10,849,888 (&#8217;888) to the suit. Janssen and SKI are seeking an order enjoining Lupin from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents. In August 2022, Janssen and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Janssen and SKI initiated a patent infringement lawsuit in United States District Court for the District of New Jersey against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA), Inc., and Zydus Lifesciences Limited (collectively, Zydus), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents. Janssen and SKI are seeking an order enjoining Zydus from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Janssen, The Regents of the University of California (UC), and SKI initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Sandoz Inc. (Sandoz), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663 patent and U.S. Patent Nos. 8,445,507 (&#8217;507), 8,802,689 (&#8217;689), 9,338,159 (&#8217;159), and 9,987,261 (&#8217;261).  In August 2022, Janssen, UC, and SKI filed a first amended complaint against Sandoz adding the &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents to the suit. In August 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint.  In December 2022, Janssen, UC, and SKI filed a second amended complaint against Sandoz withdrawing the &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents from the suit without prejudice.  Janssen, UC, and SKI are seeking an order enjoining Sandoz from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507, &#8217;689, &#8217;159, and &#8217;261 patents.  The New Jersey action is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Janssen, UC, and SKI initiated patent infringement lawsuits in United States  District Court for the Districts of New Jersey and Delaware against Eugia Pharma Specialities Limited, Aurobindo Pharma USA, Inc., and Auromedics Pharma LLC (collectively, Eugia), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of  the &#8217;663, &#8217;507, &#8217;689, &#8217;159 and &#8217;261 patents. In September 2022, Janssen, UC, and SKI filed a first amended complaint against Eugia adding U.S. Patent Nos. 9,884,054 (&#8217;054), 10,052,314 (&#8217;314), 10,702,508 (&#8217;508) and 10,849,888 (&#8217;888) to the suit. In September 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint. Janssen, UC, and SKI are seeking an order enjoining Eugia from marketing its generic version of ERLEADA before the expiration of the &#8217;663,&#8217;507, &#8217;689, &#8217;159, &#8217;261, &#8217;054, &#8217;314, &#8217;508, and &#8217;888 patents. The New Jersey action is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2022, Janssen, UC, and SKI initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Hetero Labs Limited Unit V and Hetero USA, Inc. (collectively, Hetero), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507,&#8217;054, &#8217;314,&#8217;508, and &#8217;888 patents. Janssen, UC, and SKI are seeking an order enjoining Hetero from marketing its generic version of ERLEADA before the expiration of the &#8217;663, &#8217;507, &#8217;054, &#8217;314, &#8217;508 and &#8217;888 patents.  In August 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">UPTRAVI </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2022, Actelion Pharmaceuticals Ltd, and Janssen Inc. (collectively, Janssen) and Nippon Shinyaku Co. (Nippon Shinyaku) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. in response to Sandoz&#8217;s filing of an ANDS seeking approval to market generic versions of UPTRAVI tablets before the expiration of Canadian Patent Nos. 2,731,370 and 2,764,475. In this lawsuit, Janssen and Nippon Shinyaku are seeking an order enjoining Sandoz from marketing its generic version of UPTRAVI before the expiration of the relevant patents. A trial is scheduled to begin in May 2024.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2022, Actelion Pharmaceuticals US Inc. and Actelion Pharmaceuticals Ltd (collectively, Actelion) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals Inc. (collectively, Alembic) who filed an </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ANDA seeking approval to market generic versions of UPTRAVI </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">injection for intravenous use before expiration of U.S. Patent Nos. 8,791,122 (&#8217;122) and 9,284,280 (&#8217;280) relating to UPTRAVI. In this lawsuit, Actelion and Nippon Shinyaku are seeking an order enjoining Alembic from marketing a generic version of UPTRAVI before the expiration of the relevant patents. A trial date has not been set. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In February 2023, Actelion and Nippon Shinyaku initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Ltd. and Lupin Pharmaceuticals, Inc. (collectively, Lupin) who filed an ANDA seeking approval to market generic versions of UPTRAVI</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">injection for intravenous use before expiration of the &#8217;122 and &#8217;280 patents relating to UPTRAVI. In this lawsuit, Actelion and Nippon Shinyaku are seeking an order enjoining Lupin from marketing a generic version of UPTRAVI before the expiration of the relevant patents. A trial date has not been set.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other Litigation</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, Janssen Pharmaceutica N.V. (Janssen) provided to Alkermes Pharma Ireland Limited, Elan Pharma International Limited, and Elan Drug Delivery, Inc. three-months&#8217; notice of termination of a License Agreement by and among Elan Pharmaceutical Research Corp., d/b/a Nanosystems, Elan Pharma International Limited and Janssen, executed in March, 1999. In November 2021, Janssen also provided to Alkermes Pharma Ireland Limited three-months&#8217; notice of termination of a License Agreement between Elan Pharma International Limited and Janssen executed in July 2003. In April 2022, in response to these notices, Alkermes Pharma Ireland Limited (Alkermes) initiated arbitration in the International Institute for Conflict Prevention and Resolution. The parties exchanged opening briefs in July 2022 and responsive briefs in September 2022.  In December 2022, the Arbitration Tribunal issued an Interim Decision finding that Janssen may terminate the agreements, but it may not continue to sell products developed during the term of the agreements without continuing to pay royalties to Alkermes.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GOVERNMENT PROCEEDINGS</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Like other companies in the pharmaceutical, consumer health and medical devices industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Average Wholesale Price (AWP) Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and several of its pharmaceutical subsidiaries (the J&amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;J AWP Defendants were ultimately dismissed. The J&amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), the Company and ALZA Corporation. All other cases have been resolved.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Opioid Litigation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including the Company and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in every state but Alaska. The Government of Puerto Rico filed suit in Superior Court of San Juan. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company, JPI and other pharmaceutical companies had also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, the Company and JPI were contacted by the Texas and Colorado Attorney General&#8217;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2019, the trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against the Company and JPI in the amount of $465&#160;million. The Company and JPI appealed the judgment, and in November 2021, the Oklahoma Supreme Court reversed the trial court&#8217;s judgment and directed entry of judgment for Defendants. In October 2019 the Company and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against the Company and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021, and in December 2021, the Court entered a final trial judgment in favor of Defendants on all claims. In February 2022, Plaintiffs&#8217; motion to set aside and vacate the judgment was denied. Plaintiffs appealed the judgment, but later filed a request to dismiss the appeal after electing to participate in the national settlement agreement. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4&#160;billion as settlement of these matters that had not been tried or settled. In October 2020, the Company agreed to contribute up to an additional $1&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $5&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately half of the all-in settlement was expected to be paid by the end of fiscal year 2022, depending upon the level of participation by the states and their subdivisions. The terms provided a period of time for states to elect to participate in the agreement and, thereafter, a period for the subdivisions of the participating states to opt-in. Based on expected participation, the Company committed in advance to proceed with the settlement in five of the participating states (New York, Texas, Florida, Nevada, and New Mexico) and with tribal governments. By late February 2022, 45 states, five territories, the District of Columbia, and the vast majority of eligible subdivisions had elected to participate in the settlement, and the Company confirmed that the level of participation was sufficient to proceed with the agreement as to all participants. The agreement was effective in April 2022. Also in April 2022, the Company entered into settlement agreements with the states of Alabama and West Virginia and their participating subdivisions. In July 2022, the Company reached a settlement agreement with all litigating Oklahoma subdivisions, and in September 2022, the Company settled with the State of New Hampshire and its participating subdivisions. Consequently, by the end of the fiscal year 2022, the Company had settled the opioid claims advanced by all states except Washington.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are approximately 60 cases remaining post-settlement in various state courts. There are approximately 570 remaining federal cases against the Company and JPI coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio, and approximately 20 additional cases pending against the Company and JPI in other federal courts. In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an antitrust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2019, the Company received a grand jury subpoena from the United States Attorney&#8217;s Office for the Eastern District of New York for documents related to the Company&#8217;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#8217; and distributors&#8217; monitoring programs and reporting under the Controlled Substances Act. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From June 2017 through December 2019, the Company&#8217;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#8217;s report.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, one of the shareholders who sent a demand filed a derivative complaint against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020. By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted the Company&#8217;s motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state court&#8217;s dismissal order.   </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Other</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#8217;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#8217; motion to dismiss with prejudice, unsealed the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> complaint, and denied the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relators&#8217; request for leave to file a further amended complaint. The </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">qui tam</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#8217;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#8217; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#8217; second amended complaint; the District Court denied DePuy&#8217;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#8217;s July 2021 ruling. In November 2021, the District Court granted DePuy&#8217;s motion for reconsideration and dismissed the case with prejudice. The District Court&#8217;s order was unsealed in December 2021. The relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration, which the District Court denied. Following the District Court&#8217;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#8217; fees and costs, which the District Court denied except as to costs. The Relators have appealed the District Court&#8217;s dismissal of the case to the First Circuit. The briefing on the appeal is complete, the First Circuit held oral argument on December 6, 2022, and the First Circuit&#8217;s decision remains pending.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2012, the Company was contacted by the California Attorney General&#8217;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by the Company&#8217;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against the Company, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, the Company and Ethicon settled the Washington case. In October 2019, the Company and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon. In November 2020, the Company settled with the Attorney General of Mississippi. Trial in the Kentucky matter is scheduled for June 2023. The California case started trial in July 2019 and concluded in September 2019. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company&#8217;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $344&#160;million, but denied the Attorney General&#8217;s request for injunctive relief. The Company appealed the penalty judgment. In April 2022, the Court of Appeals reduced the judgment to $302&#160;million, but otherwise denied the appeal. In July 2022, the Supreme Court of California denied the Company&#8217;s petition to review the Court of Appeals decision, and the Company recorded a charge to reflect the judgment in the second quarter of 2022. In November 2022, the Company petitioned the United States Supreme Court for review.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against the Company and Johnson &amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#8217; use of talc contained in JOHNSON&#8217;S Baby Powder and JOHNSON&#8217;S Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. The Company and JJCI moved for summary judgment on the grounds that the State&#8217;s claim was barred by preemption, which the trial court denied. The Mississippi Supreme Court granted the Company and JJCI&#8217;s request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing and oral argument were completed. Thereafter, the Court </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rejected the interlocutory appeal in April 2021 and remanded the matter to the trial court. In August 2021, JJCI filed a Petition for Writ of Certiorari in the United States Supreme Court as to the Mississippi Supreme Court&#8217;s ruling of April 2021. In December 2021 the United States Supreme Court denied the Petition for Writ of Certiorari. After the Mississippi Supreme Court remanded the matter to the trial court, the State moved for a trial setting. JJCI objected to any trial setting as barred by the stay arising from the LTL Bankruptcy Case, referenced above, while the State argued that the stay did not apply. In January 2022, the Court granted the State&#8217;s motion for trial setting and directed the parties to consult with the Court administrator to secure a trial date. In February 2022, the trial court set the case for trial to begin in February 2023. However, given the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a temporary stay of discovery until May 2022. The temporary stay expired in May 2022. LTL thereafter moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. The State filed an appeal to the Third Circuit concerning the stay order.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. In March 2022, the New Mexico court denied the Company&#8217;s motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Company&#8217;s request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexico&#8217;s discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. In December 2022, the State filed an appeal to the Third Circuit concerning the stay order. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexico&#8217;s discovery obligations. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forty-two states and the District of Columbia have commenced a joint investigation into the Company&#8217;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states (including Mississippi and New Mexico) agreed to mediation of their claims in the LTL Bankruptcy Case. In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court. LTL moved the New Jersey Bankruptcy Court for an order staying further proceedings in those two actions, which the Bankruptcy Court granted in October 2022.  In December 2022, the Bankruptcy Court allowed New Mexico and Mississippi to file a direct appeal of its stay.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April and September 2017, the Company received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX, OLYSIO, REMICADE, SIMPONI, STELARA and ZYTIGA. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2017, the Company received a subpoena from the United States Attorney&#8217;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. (DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals.  The Company and DePuy fully cooperated with the government&#8217;s investigation. In January 2023, the Company, DePuy Synthes, Inc., and DePuy Synthes Sales Inc. entered into a settlement agreement with the United States resolving the matter for an immaterial amount.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp; Johnson do Brasil Ind&#250;stria e Com&#233;rcio de Produtos para Sa&#250;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp; Johnson to cooperate with these inquiries by producing the requested information.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">GENERAL LITIGATION</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE against the Company and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The cases were consolidated for pre-trial purposes as</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> In re REMICADE Antitrust Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in United States District Court for the Eastern District of Pennsylvania. This case was settled in February 2022.  The final approval hearing is scheduled for February 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#8217;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands.  Janssen is in ongoing discussions with the FTC staff regarding the inquiry. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc. seeking milestones and an extended royalty term for Darzalex FASPRO. Janssen filed its Notice of Defense in July 2022. Genmab and Janssen have cross-moved for early disposition of the arbitration.  Argument was had in January 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#8217;s decision. In February 2022, defendants petitioned for rehearing en banc. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In October 2019, the Court granted Actelion&#8217;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2019, a class action antitrust complaint was filed against Janssen R&amp;D Ireland (Janssen) and Johnson &amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#8217; motions to dismiss. Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint. In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. In December 2021, several insurance companies and other payers filed individual &#8220;Opt-Out&#8221; complaints containing allegations similar to the original complaint. In September 2022, the Court granted in part and denied in part plaintiff&#8217;s motion for class certification. In January 2023, the Court granted in part and denied in part defendants&#8217; motion for summary judgment.  Trial is scheduled for May 2023.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#8217;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#8217;s motion to dismiss. In December 2021, BWI filed a motion for summary judgment. In March 2022, the Court granted BWI&#8217;s motion for summary judgment. In April 2022, Innovative appealed this ruling to the United States Court of Appeals for the Ninth Circuit.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2019, the Company received a demand for indemnification from Pfizer Inc. (Pfizer), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp; Johnson Inc. received notice reserving rights to claim indemnification from Sanofi Consumer Health, Inc. (Sanofi), pursuant to the 2016 Asset Purchase Agreement between Johnson &amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim), pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. In November 2022, Johnson &amp; Johnson received a demand for indemnification from GlaxoSmithKline LLC (GSK), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer, and certain 1993, 1998, and 2002 agreements between Glaxo Wellcome and Warner-Lambert entities. The notices seek indemnification for legal claims related to over-the-counter ZANTAC (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief. The Company and Johnson &amp; Johnson Inc. have also been named in putative class actions filed in Canada with similar allegations regarding ZANTAC or ranitidine use. Johnson &amp; Johnson Inc. was also named as a defendant along with other manufacturers in various personal injury actions in Canada related to ZANTAC products. Johnson &amp; Johnson Inc. has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Asset Purchase Agreement related to the class actions and personal injury actions.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#8217;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#8217; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for January 2024.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Emergent Biosolutions Inc. et al (&#8220;EBSI&#8221;) with the American Arbitration Association, alleging that EBSI breached the parties&#8217; Manufacturing Services Agreement for the Company&#8217;s COVID-19 vaccine.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In July 2022, Emergent filed its answering statement and counterclaims.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Merck Sharp &amp; Dohme Corp. with the American Arbitration Association pursuant to the Parties&#8217; agreements relating to production of drug substance and drug product for the Company&#8217;s COVID-19 vaccine. Also in October 2022, Merck filed its answer and counterclaims.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beginning in May 2021, multiple putative class actions were filed in state and federal courts (California, Florida, New York, and New Jersey) against various Johnson &amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products and the affirmative promotion of those products as &#8220;safe&#8221;; and, in at least one case, alleging a strict liability manufacturing defect and failure to warn claims, asserting that the named plaintiffs suffered unspecified injuries as a result of alleged exposure to benzene. The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. In December 2021, </span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">plaintiffs in the consolidated actions filed a motion for preliminary approval of a nationwide class settlement. The settlement was preliminarily approved by the court in March 2022.</span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company (subsequently substituted by Johnson &amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. </span></div><div><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalMattersAndContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalMattersAndContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784295168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring</a></td>
<td class="text">Restructuring<div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fiscal second quarter of 2018, the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In fiscal year 2022, the Company recorded a pre-tax charge of $0.5 billion, which is included on the following lines of the Consolidated Statement of Earnings, $0.3 billion in restructuring, $0.1 billion in other (income) expense and $0.1 billion in cost of products sold. Total project costs of approximately $2.2 billion have been recorded since the restructuring was announced. The program was completed in the fiscal fourth quarter of 2022. </span></div><div style="text-indent:18pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2022: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:31.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.173%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.481%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;3, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;2, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(432)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;1, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Although the restructuring program has been completed in the fiscal year 2022, the Company expects that severance charges will continue beyond that date. The reserve balance as of January 1, 2023 is recorded in the Employee Related Obligation account in the Consolidated Balance Sheet.   </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents gain on sale of assets</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(e))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI https://asc.fasb.org/topic&amp;trid=2175745<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428782294800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Principles of Consolidation</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The consolidated financial statements include the accounts of Johnson&#160;&amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Description of the Company And Business Segments</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Description of the Company and Business Segments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has approximately 152,700&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is organized into three business segments: Consumer Health, Pharmaceutical and MedTech. The Consumer Health segment includes a broad range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-Counter pharmaceutical, Women&#8217;s Health and Wound Care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on the following therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In November 2021, the Company announced its intention to separate the Company&#8217;s Consumer Health business (Kenvue as the name for the planned New Consumer Health Company), with the intention to create a new, publicly traded company by the end of the fiscal year 2023.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Standards</a></td>
<td class="text"><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Standards</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new material accounting standards adopted in fiscal 2022.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Issued Accounting Standards</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Adopted as of January 1, 2023</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50) &#8211; Disclosure of Supplier Finance Program Obligations</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">This update requires that a buyer in a supplier finance program disclose additional information about the program to allow financial statement users to better understand the effect of the programs on an entity&#8217;s working capital, liquidity, and cash flows. This update will be effective for the Company for fiscal years beginning after December 15, 2022, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently assessing the impact of this update on its disclosures and will adopt this standard in the fiscal first quarter of 2023.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash Equivalents</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.  The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).</span></div><div style="text-align:justify;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value.  The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Investments</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and </span></div>losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment and Depreciation</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Plant and Equipment and Depreciation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:86.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;- 20&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;- 13&#160;years</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#8217;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">t</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he Managed Care, Medicare and Medicaid programs, which amounted to $9.6 billion and $7.7 billion as of January&#160;1, 2023 and January&#160;2, 2022, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#8217;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#8217;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years&#160;2022,&#160;2021&#160;and&#160;2020.</span></div><div style="margin-bottom:10pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in fiscal year 2022 and less than 3.0% of the total revenues in fiscal years 2021 and 2020 and are included in sales to customers.</span></div>See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock', window );">Shipping and Handling</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Shipping and Handling</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shipping and handling costs incurred were $1.1 billion, $1.1 billion and $1.0 billion in fiscal years 2022, 2021 and 2020, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 1.0% of sales to customers for all periods presented.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Inventories</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intangible Assets and Goodwill</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2022 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset. If warranted the purchased in-process research and development could be written off or partially impaired depending on the underlying program.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions.  See Note&#160;5 for further details on Intangible Assets and Goodwill.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Financial Instruments</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Instruments</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#8217;s impact on the Company&#8217;s financial performance; (2)&#160;protect the Company&#8217;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Leases </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODEw_97635a41-161e-48cc-9741-d517f85ec4b3"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODEw_df08f0e2-160d-4a75-87a1-87cfb24da89c">Other assets</span></span>, <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzMx_e32a30e6-d584-47b7-845d-23d4e433bc41"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzQ4_870a3311-5ffc-4b2b-8721-b5d7ead81c4b">Accrued liabilities</span></span>, and <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzU3_21dc535a-a5b3-4717-bcb6-281e2bef1694"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzU3_b32467a4-74d9-403d-8502-48e5120b86ad">Other liabilities</span></span> on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $1.1&#160;billion and $0.9&#160;billion in fiscal years 2022 and 2021, respectively. The lease liability was $1.3&#160;billion and $1.0&#160;billion in fiscal years 2022 and 2021, respectively. The operating lease costs were $0.3&#160;billion in fiscal years 2022, 2021 and 2020, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3&#160;billion in fiscal years 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityPolicyTextBlock', window );">Product Liability</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Product Liability</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company </span></div>accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development.  Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product.  Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#8217;s operations. In general, the income statement presentation for these collaborations is as follows:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:48.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.535%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nature/Type of Collaboration</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Statement of Earnings Presentation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Third-party sale of product &amp; profit share payments received</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales to customers</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties/milestones paid to collaborative partner (post-regulatory approval)*</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of products sold</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalties received from collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Upfront payments&#160;&amp; milestones paid to collaborative partner (pre-regulatory approval)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments to collaborative partner</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expense</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development payments received from collaborative partner or government entity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reduction of Research and development expense</span></td></tr></table></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:0.1%"/><td style="width:1.706%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:96.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">*</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG and IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company.</span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Advertising</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.1 billion, $2.7 billion and $2.1 billion in fiscal years 2022, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of  15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2022 was approximately  $6.1&#160;billion, of which $4.6&#160;billion is classified as noncurrent and reflected as &#8220;Long-term taxes payable&#8221; on the Company&#8217;s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder&#8217;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#8220;period cost&#8221;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., &#8220;deferred method&#8221;). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.  </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">See Note 8 to the Consolidated Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">for further information regarding income taxes.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Earnings Per Share</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Earnings Per Share</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. </span></div><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_FiscalPeriodPolicyTextBlock', window );">Annual Closing Date</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Annual Closing Date</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassification</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FiscalPeriodPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period policy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FiscalPeriodPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProductLiabilityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProductLiabilityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI https://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126900757&amp;loc=d3e543-108305<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShippingAndHandlingCostPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShippingAndHandlingCostPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784359840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock', window );">Estimated Useful Lives of Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"><tr><td style="width:1.0%"/><td style="width:86.011%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.789%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Building and building equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and leasehold improvements</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;- 20&#160;years</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;- 13&#160;years</span></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EstimatedUsefulLivesOfAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Estimated useful lives of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EstimatedUsefulLivesOfAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428785205168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Current Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash and Cash Equivalent Composition</a></td>
<td class="text"><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of the fiscal year 2022 and 2021, cash, cash equivalents and current marketable securities were comprised of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.615%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.690%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Loss</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">872&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,032&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">873&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't Securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,931&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,922&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,009&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't Agencies</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and other debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">351&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,521&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(34)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,968&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,127</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,392</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.615%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.056%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:11.690%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.219%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.382%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.526%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Carrying Amount</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized Loss</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Estimated Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash &amp; Cash Equivalents</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current Marketable Securities</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,936&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-U.S. Sovereign Securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,006&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Reverse repurchase agreements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,659&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Time deposits</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;Subtotal </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,881&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Gov't Securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,481&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate and other debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">246&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">230&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;Subtotal available for sale</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,731&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total cash, cash equivalents and current marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,487</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,121</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Contractual Maturities of Available for Sale Securities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The contractual maturities of the available for sale debt securities at January&#160;1, 2023 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"><tr><td style="width:1.0%"/><td style="width:43.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.117%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.377%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.119%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost Basis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due within one year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,430&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,399&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after one year through five years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Due after five years through ten years</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,521&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,487&#160;</span></td><td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784125408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Summary of Inventories</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2022 and 2021, inventories were comprised of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"><tr><td style="width:1.0%"/><td style="width:66.000%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.614%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.069%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.645%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.072%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,070&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,592&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goods in process</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,700&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,713&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,483</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,387</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784359840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment at Cost and Accumulated Depreciation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2022 and 2021, property, plant and equipment at cost and accumulated depreciation were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"><tr><td style="width:1.0%"/><td style="width:67.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.570%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.305%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.443%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.307%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Land and land improvements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">859&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Buildings and building equipment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Machinery and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,431&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,774&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Construction in progress</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,253&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,679&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated depreciation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,717&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total property, plant and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19,803</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,962</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784489328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock', window );">Schedule of Intangible Assets and Goodwill</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal years 2022 and 2021, the gross and net amounts of intangible assets were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with definite lives:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44,012&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,572&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22,266)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,088)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Patents and trademarks&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,746</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">18,484</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; gross</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,987&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,011&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less accumulated amortization</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,901)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,925)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Customer relationships and other intangibles&#160;&#8212; net</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,086</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">11,086</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Intangible assets with indefinite lives:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trademarks</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,807&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchased in-process research and development</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,686&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,837&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets with indefinite lives</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,493</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,822</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total intangible assets&#160;&#8212; net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">48,325</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">46,392</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The change was primarily related to the intangible assets acquired with the acquisition of Abiomed, Inc. which was partially offset by amortization expense of previously existing intangible assets and the result of currency translation effects.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The majority is comprised of customer relationships</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%">The reduction was primarily related to an intangible asset impairment charge of approximately</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span>$0.8&#160;billion recorded in the fiscal year 2022 related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS. An additional reduction of $0.7&#160;billion was driven by Monarch assets that reached commercialization and are now classified as having definite lives. This was partially offset by approximately $1.1&#160;billion of IPR&amp;D acquired with Abiomed, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Goodwill as of January&#160;1, 2023 and January&#160;2, 2022, as allocated by segment of business, was as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"><tr><td style="width:1.0%"/><td style="width:33.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.253%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.777%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.407%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.249%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Consumer Health</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">MedTech</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,009&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,048&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to divestitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(517)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(429)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(192)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,138)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,810&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,856&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,246&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,056&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill, related to divestitures</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Currency translation/other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(626)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(396)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(49)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,071)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">9,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">25,863</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">45,231</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock', window );">Intangible Asset Amortization Expense</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"><tr><td style="width:1.0%"/><td style="width:18.528%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.114%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.833%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.910%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$4,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,400</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,600</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,000</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400</span></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=SL108378252-109267<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428785432688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Summary of Derivative Activity</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022, net of tax:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.771%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.940%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.356%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.087%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.648%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.525%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.239%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Sales</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of Products Sold</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (Income) Expense</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other (Income) Expense</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">The effects of fair value, net investment and cash flow hedging:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on fair value hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Hedged items</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,098)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;Derivatives designated as hedging instruments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,098&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on net investment hedging relationship:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain (Loss) on cash flow hedging relationship:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Forward foreign exchange contracts:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(72)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(113)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(94)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(557)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Cross currency interest rate swaps contracts:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">425&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">402&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January&#160;1, 2023 and January&#160;2, 2022, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"><tr><td style="width:1.0%"/><td style="width:30.328%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.852%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Line item in the Consolidated Balance Sheet in which the hedged item is included</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Carrying Amount of the Hedged Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term Debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,665&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,435)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(142)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Effect of Derivatives not Designated as Hedging Instruments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"><tr><td style="width:1.0%"/><td style="width:37.594%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.510%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.425%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.012%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.469%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.532%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Location of Gain /(Loss) Recognized in Income on Derivative</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Income on Derivative</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Derivatives Not Designated as Hedging Instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Foreign Exchange Contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItMi0xLTEtMTA5MzI3_baf92b4c-2473-4ad1-9202-3d7157cbead6"><span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItMi0xLTEtMTA5MzI3_d20882e0-6ef3-4436-8245-6610c60bdc82">Other (income) expense</span></span></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(70)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Effect of Net Investment Hedges</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%">The following table is the effect of net investment hedges for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:20.422%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:28.621%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.027%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)<br/>Recognized In<br/>Accumulated OCI</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss)           Reclassified From<br/>Accumulated OCI<br/>Into Income</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">197&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">387&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense<br/></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cross Currency interest rate swaps</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">766&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest (income) expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Summary of Activity Related to Equity Investments</a></td>
<td class="text"><div style="margin-bottom:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table is a summary of the activity related to equity investments for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:25.772%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.504%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 1, 2023</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(538)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(770)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">107&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:25.478%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.143%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.827%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.318%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.505%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">January 2, 2022</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in Fair Value Reflected in Net Income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sales/ Purchases/Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Carrying Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non Current Other Assets</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments with readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,481&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">198&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">205&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity Investments without readily determinable value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(632)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Recorded in Other Income/Expense</span></div><div style="padding-left:36pt;text-indent:-36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Other includes impact of currency</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock', window );">Financial Assets and Liabilities at Fair Value</a></td>
<td class="text"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s significant financial assets and liabilities measured at fair value as of the fiscal year ended January&#160;1, 2023 and January&#160;2, 2022 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:42.218%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives designated as hedging instruments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">629&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">796&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,163</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,336</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest rate contracts </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,778&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">979&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,289</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,289</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,860</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Derivatives not designated as hedging instruments:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forward foreign exchange contracts</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Available For Sale Other Investments:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity investments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">576&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,884&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,487&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,727&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Liabilities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent Consideration</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.409%"><tr><td style="width:1.0%"/><td style="width:53.627%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.527%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.356%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross to Net Derivative Reconciliation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,201&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,176)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,285)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Asset</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Gross Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Credit Support Agreement (CSA)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,023)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total Net Liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">334&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Summarized information about changes in liabilities for contingent consideration is as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"><tr><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.691%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.695%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,715&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in estimated fair value </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(194)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(52)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,089)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additions </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(48)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(99)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ending Balance</span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,120&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">533&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">633&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">2021 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $1,884 million, which are classified as Level&#160;1 and contingent consideration of $533 million, classified as Level 3.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes cross currency interest rate swaps and interest rate swaps.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as non-current other assets.  </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Classified as cash equivalents and current marketable securities.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Includes $1,116 million, $520 million and $594 million, classified as non-current other liabilities as of January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, respectively. Includes $4 million, $13&#160;million and $39&#160;million classified as current liabilities as of January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, respectively.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt">Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense.  The Company recorded a contingent consideration reversal of $1,148&#160;million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(7)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt">In fiscal year 2022, the Company recorded $704&#160;million of contingent consideration related to Abiomed.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998890-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428783518352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of long-term debt are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.122%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.572%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.280%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.285%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.426%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.289%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective Rate %</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.250% Notes due 2022                                                        (1B Euro 1.1311)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,131&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.26&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.25% Notes due 2022</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73%&#160;Debentures due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">250&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.375% Notes due 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">801&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">802&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.18&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.05% Notes due 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.650% Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(750MM Euro 1.0651)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(750MM Euro 1.1311)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">792&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">847&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.68&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.50%&#160;Notes due 2024 </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(500MM 1.2037 GBP )</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(500MM GBP 1.3485)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.625% Notes due 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.63&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.55% Notes due 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.57&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.45% Notes due 2026</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,995&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.47&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">877&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">978&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.96&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.95% Notes due 2027</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.96&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.150% Notes due 2028                                                (750MM Euro 1.0651)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(750MM Euro 1.1311)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.90%&#160;Notes due 2028</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,495&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.95%&#160;Notes due 2029</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30% Notes due 2030</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,607&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.30&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95%&#160;Debentures due 2033</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">498&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.95&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.375% Notes due 2033</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.650% Notes due 2035                                                     (1.5B Euro 1.0651)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/(1.5B Euro 1.1311)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,591&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.68&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.55% Notes due 2036</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">842&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.95%&#160;Notes due 2037</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">993&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.625% Notes due 2037</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,336&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,475&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.64&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85%&#160;Debentures due 2038</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">697&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.85&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.400%&#160;Notes due 2038</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">992&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50%&#160;Debentures due 2040</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">540&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.63&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.10% Notes due 2040</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">974&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.85% Notes due 2041</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.89&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.50% Notes due 2043</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">496&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.52&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.70% Notes due 2046</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,976&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,975&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.75% Notes due 2047</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">812&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">971&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.76&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.500% Notes due 2048</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.52&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.250% Notes due 2050</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.29&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.450% Notes due 2060</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,222&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Subtotal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,439</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.04</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32,116</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2.89</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current portion</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,551&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">26,888</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,985</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Weighted average effective rate.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at January&#160;1, 2023.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Translation rate at January&#160;2, 2022.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">The excess of the carrying value over the fair value of debt was $1.6 billion at the end of fiscal year 2022 and the excess of the fair value over the carrying value of debt was $3.2 billion at the end of fiscal year 2021.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Aggregate Maturities of Long Term Obligations</a></td>
<td class="text"><div style="text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Aggregate maturities of long-term debt obligations commencing in 2023 are:</span></div><div style="text-indent:18pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"><tr><td style="width:1.0%"/><td style="width:15.223%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.879%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.707%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.659%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.882%"/><td style="width:0.1%"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:13pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline">After 2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$1,551</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,392</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,667</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,996</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,271</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,562</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21538-112644<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123599511&amp;loc=d3e64711-112823<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428788824400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Provision for Income Taxes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for taxes on income consists of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"><tr><td style="width:1.0%"/><td style="width:50.115%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.000%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.141%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.003%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Currently payable:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,378&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,026&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,069&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total currently payable</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,447&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,977&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,924&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,081)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,662)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,065)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,663)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,079)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,141)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Provision for taxes on income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,784</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,783</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate</a></td>
<td class="text"><div style="margin-top:4pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A comparison of income tax expense at the U.S.&#160;statutory rate of 21% in fiscal years 2022, 2021 and 2020, to the Company&#8217;s effective tax rate is as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:48.820%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.597%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.089%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.297%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:1.933%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,369&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,110&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,312&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,356&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,666&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Earnings before taxes on income:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,725&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,776&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,497&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax rates:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. statutory rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International operations </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer health separation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. taxes on international income </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits from loss on capital assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax benefits on share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">All other </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effective Rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.8&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt"><span><br/></span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)       </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflect the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2021 amounts include the reorganization of international subsidiaries; the 2020 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. The 2022 amount includes the impact of certain provisions of the 2017 TCJA that became effective in fiscal 2022. The 2021 amounts include the reorganization of international subsidiaries; the 2020 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">    Certain prior year amounts have been reclassified to conform to current year presentation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Temporary Differences and Carryforwards</a></td>
<td class="text"><div style="margin-bottom:9.9pt;margin-top:9pt;padding-right:4.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Temporary differences and carryforwards at the end of fiscal years 2022 and 2021 were as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:38.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.554%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.408%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.729%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 Deferred Tax</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 Deferred Tax</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Asset</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Liability</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">725&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,244&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation of property, plant and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(858)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(876)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill and intangibles</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,271)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,659)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">R&amp;D capitalized for tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,611&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,664&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserves&#160;&amp; liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income reported for tax purposes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,045&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net realizable operating loss carryforwards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,260&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,720&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Undistributed foreign earnings</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,693)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Global intangible low-taxed income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,547)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,853)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous international</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,053&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(65)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(39)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Miscellaneous U.S.&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">476&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total deferred income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,183</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(10,434)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">12,640</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(9,904)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)     </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified to conform to current year presentation.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  Amount is inclusive of the $2.3&#160;billion deferred tax asset established as part of the reorganized ownership structure of   certain wholly-owned international subsidiaries, as previously described. </span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   Amount is inclusive of the $1.8&#160;billion deferred tax liability due to the acquisition of Abiomed.</span></div>(4)    Net of valuation allowances of $0.9&#160;billion in both 2022 and 2021.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock', window );">Summary of Activity Related to Unrecognized Tax Benefits</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to unrecognized tax benefits:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"><tr><td style="width:1.0%"/><td style="width:50.775%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.456%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.025%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.556%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.495%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Beginning of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,373&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to current year tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">523&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">242&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases related to prior period tax positions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">668&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Decreases related to prior period tax positions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(128)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(551)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(187)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(839)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Lapse of statute of limitations</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">End of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,829</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,323</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,373</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfIncomeTaxContingenciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfIncomeTaxContingenciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784165488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Related Obligations (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EmployeeRelatedObligationsTableTextBlock', window );">Employee Related Obligations</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the end of fiscal 2022 and fiscal 2021, employee related obligations recorded on the Consolidated Balance Sheets were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pension benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,698&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,088&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postretirement benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,069&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Postemployment benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total employee obligations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,455&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less current benefits payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">557&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee related obligations&#160;&#8212; non-current</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,767</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,898</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EmployeeRelatedObligationsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee related obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EmployeeRelatedObligationsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428785573040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock', window );">Components of Net Periodic Benefit Cost</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net periodic benefit costs for the Company&#8217;s defined benefit retirement plans and other benefit plans for 2022, 2021 and 2020 include the following components:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,380&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,757)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,645)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,461)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service cost </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(184)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Recognized actuarial losses (gains)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,257&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments and settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">623</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">790</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">524</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the weighted-average actuarial assumptions:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"><tr><td style="width:1.0%"/><td style="width:39.358%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.060%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.563%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.064%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net Periodic Benefit Cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.46&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.82&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.59&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.09&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.04&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost discount rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.80&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.33&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.08&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.02&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected long-term rate of return on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.71&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discount rate</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.01&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.49&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.14&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.42&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.68&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.23&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate of increase in compensation levels</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.00&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.27&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock', window );">Assumed Health Care Cost Trend Rates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the assumed healthcare cost trend rates, for all individuals:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"><tr><td style="width:1.0%"/><td style="width:71.313%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.943%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.549%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.946%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Healthcare Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Healthcare cost trend rate assumed for next year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.99&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rate to which the cost trend rate is assumed to decline (ultimate trend)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.01&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.73&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Year the rate reaches the ultimate trend rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2047&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2046&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfNetFundedStatusTableTextBlock', window );">Schedule of Net Funded Status</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2022 and 2021 for the Company&#8217;s defined benefit retirement plans and other post-retirement plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Benefit Obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,582&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,300&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,878&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,028&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Service cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,327&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest cost</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">911&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">770&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amendments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actuarial (gains) losses</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,213)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,132)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(704)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(188)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Curtailments, settlements&#160;&amp; restructuring</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(815)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(683)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected benefit obligation&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">29,631</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,582</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,197</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,878</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change in Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; beginning of year</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,930&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,195&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Actual return (loss) on plan assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,665)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Company contributions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">270&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">386&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan participant contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Divestitures&#160;&amp; acquisitions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Benefits paid from plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,228)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,157)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(393)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(574)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan assets at fair value&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,514</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,930</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">78</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">102</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Funded status &#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,119)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,776)</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,581&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,436&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(132)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(115)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(461)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(438)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,566)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,973)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,658)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,338)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,883</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">348</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,119)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,776)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial loss</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,948&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,539&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">239&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,113&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,417)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,610)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unrecognized net transition obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total before tax effects</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2,531</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,929</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">232</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">1,100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Accumulated Benefit Obligations&#160;&#8212; end of year</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">28,023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">39,049</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">The actuarial gain for retirement plans in 2022 and 2021 was primarily related to increases in discount rates.</span></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:43.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.139%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.619%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.624%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Retirement Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Benefit Plans</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net periodic benefit cost (credit)</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(47)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">623</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">533</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">503</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net actuarial (gain) loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(793)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,927)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(751)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(199)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of net actuarial loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(655)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,257)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(151)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior service cost (credit)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of prior service (cost) credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Effect of exchange rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(140)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(136)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total loss/(income) recognized in other comprehensive income, before tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,398)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(5,134)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(868)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(319)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total recognized in net periodic benefit cost and other comprehensive income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(1,445)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(4,511)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(335)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">184</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock', window );">Information Related to the Benefit Obligation and the Fair Value of Plan Assets</a></td>
<td class="text"><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the funded status of the Company's U.S. Qualified &amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2022 and December&#160;31, 2021, respectively:</span></div><div style="margin-top:7pt"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:25.879%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.697%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.551%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.844%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.430%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.137%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.288%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">U.S. Plans</span></td><td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">International Plans</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Qualified Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Funded Plans</span></td><td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unfunded Plans</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Plan Assets</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,937&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,944&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,577&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,986&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,041&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,937&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,703&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">410&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,696&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,985&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,872&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,479&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,212&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">253&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Over (Under) Funded Status</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Projected Benefit Obligation</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,543&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,903&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,937)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,703)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,553&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">558&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(276)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(410)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated Benefit Obligation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,241&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,959&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,872)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,479)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,375&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(373)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future benefit payments from the Company&#8217;s retirement and other benefit plans:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2028-2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future benefit payments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retirement plans</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,445&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,457&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,609&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,708&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other benefit plans&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">471&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">433&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">462&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,539&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock', window );">Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table displays the projected future minimum contributions to the unfunded retirement plans.  These amounts do not include any discretionary contributions that the Company may elect to make in the future.</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:35.089%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.796%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.803%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2026</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2027</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2028-2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Projected future contributions</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">123&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">136&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">816&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Company' Retirement Plan Asset Allocation and Target Allocations</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s retirement plan asset allocation at the end of 2022 and 2021 and target allocations for 2023 are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"><tr><td style="width:1.0%"/><td style="width:58.131%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.750%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.538%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.755%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent of<br/>Plan Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Target<br/>Allocation</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Worldwide Retirement Plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total plan assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">100</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock', window );">Schedule of Defined Benefit Plans Disclosures</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2022 and December&#160;31, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"><tr><td style="width:1.0%"/><td style="width:18.235%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.754%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.555%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.161%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Quoted Prices<br/>in Active<br/>Markets for<br/>Identical Assets</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant<br/>Other<br/>Observable<br/>Inputs</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Significant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unobservable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inputs</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investments Measured at Net Asset Value</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 1)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 2)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Level 3)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investment funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">102&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,033&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,135&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government and agency securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,016&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt instruments</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,681&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Equity securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,107&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,848&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,109&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commingled funds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,496&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,106&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,524&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,309&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,506&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,552&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Investments at fair value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,879</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14,209</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">13,954</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">17,086</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">69</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">120</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">8,612</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10,515</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31,514</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">41,930</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The activity for the Level 3 assets is not significant for all years presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Information related to the benefit obligation and the fair value of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Schedule of estimated future employer contributions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2439-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2410-114920<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetBenefitCostsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetBenefitCostsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetFundedStatusTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetFundedStatusTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784134080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital and Treasury Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ChangesInTreasuryStockTableTextBlock', window );">Changes in Treasury Stock</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in treasury stock were:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:71.960%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.639%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Treasury Stock</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Amounts in Millions Except Treasury Stock Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,336&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,417&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21,765)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,148)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 3, 2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487,331&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,490&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(17,399)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,847)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,946&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">490,878&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,099&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Employee compensation and stock option plans</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20,007)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,440)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Repurchase of common stock</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,375&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at January 1, 2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">506,246&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,694&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ChangesInTreasuryStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ChangesInTreasuryStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784279888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Components of Accumulated Other Comprehensive Income</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Components of other comprehensive income (loss) consist of the following:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:35.117%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.897%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.457%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.292%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.630%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.392%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Foreign<br/>Currency Translation</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/(Loss) On Securities</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Employee Benefit Plans</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gain/<br/>(Loss) On<br/>Derivatives &amp; Hedges</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Accumulated<br/>Other<br/>Comprehensive Income (Loss)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,705)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(295)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,891)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2020 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(233)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(66)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">947&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">649&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,938)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6,957)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">652&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15,242)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2021 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,079)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(988)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,017)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,702)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(336)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,058)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net 2022 changes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,796)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(24)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,805&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">106&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">91&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,813)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(27)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(897)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(230)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12,967)</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784134080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:58.490%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.640%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(In Millions Except Per Share Amounts)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic net earnings per share</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.93&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Average shares outstanding&#160;&#8212; basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,625.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,632.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Potential shares exercisable under stock option plans</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">140.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: shares repurchased under treasury stock method</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(96.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted average shares outstanding&#160;&#8212; diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,663.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,674.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,670.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted net earnings per share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.73&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.81&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.51&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428782049696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule Valuation Assumptions</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The average fair value of options granted was $23.23, $20.86 and $16.42, in fiscal years 2022, 2021 and 2020, respectively.  The fair value was estimated based on the weighted average assumptions of:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"><tr><td style="width:1.0%"/><td style="width:56.819%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.409%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.576%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.411%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Risk-free rate</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.98&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.83&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.47&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.00&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.59&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected life (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.0</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.70&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.50&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.60&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of option activity under the Plan as of January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, and changes during the years ending on those dates is presented below:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"><tr><td style="width:1.0%"/><td style="width:47.322%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.672%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.588%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.570%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Outstanding Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted<br/>Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic<br/>Value<br/>(Dollars in Millions) </span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at December 29, 2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">111,637&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105.63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,478&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,275)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86.05&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,835)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 3, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,250&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">116.22&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,703&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,525&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">164.62&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13,248)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.48&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,361&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">125.36&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,364&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,809&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">165.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16,310)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Options canceled/forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2,188)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160.56&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">134.95</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,949</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Options Outstanding</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes stock options outstanding and exercisable at January&#160;1, 2023:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"><tr><td style="width:1.0%"/><td style="width:29.132%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.163%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.628%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.217%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.575%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.168%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exercisable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise Price Range</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Average Life</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted Average Exercise Price</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$72.54-$100.48</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$93.07</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$93.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$101.87-$115.67</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$108.78</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,039&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$108.78</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$129.51-$141.06</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,870&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130.88</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$130.85</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$151.41-$164.62</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,465&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$157.75</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$156.21</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$164.63-$165.89</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,077&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$165.89</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$165.89</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">118,672</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">5.8</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$134.95</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">63,661</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$113.06</span></td></tr></table></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Average contractual life remaining in years.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock', window );">Summary of Restricted Share Units</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the restricted share units and performance share units activity under the Plans as of January&#160;1, 2023 is presented below:</span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"><tr><td style="width:1.0%"/><td style="width:55.231%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.611%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.445%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.032%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Shares in Thousands)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Restricted Share Units</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding Performance Share Units</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 2, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,122&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,312&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,154&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">753&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issued</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4,866)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Canceled/forfeited/adjusted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(794)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(71)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Shares at January 1, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,616&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,357&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428785224672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas (Tables)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SalesBySegmentOfBusinessTableTextBlock', window );">Schedule of Sales by Segment of Business</a></td>
<td class="text"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">% Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;22 vs. &#8217;21</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#8217;21 vs. &#8217;20</span></td></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">CONSUMER HEALTH</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">OTC</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,782&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,594&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,034&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,031&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,627&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,221&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Skin Health/Beauty</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,400&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,015&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,352&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,541&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oral Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">635&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">637&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">871&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,505&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Baby Care</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,188&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,461&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,566&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,517&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Women's Health</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">891&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">905&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">888&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">917&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">901&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Wound Care/Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">475&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">739&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">720&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL CONSUMER HEALTH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,599&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,516&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,362&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,354&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,519&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,088&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,953&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,450&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:189pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"><div><span><br/></span></div><div><span><br/></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">PHARMACEUTICAL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Immunology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,175&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,899&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,907&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,880&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;REMICADE</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S. Exports</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">236&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(31.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">722&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">893&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,343&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,190&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,747&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SIMPONI / SIMPONI ARIA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,166&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,155&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,017&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,148&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,276&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,243&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">STELARA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,388&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,240&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,467&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,723&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,707&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TREMFYA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,844&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,503&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">926&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">421&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,668&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,127&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER IMMUNOLOGY</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(73.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Infectious Diseases</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,735&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,769&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,576&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,808&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,449&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,825&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">COVID-19 VACCINE</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(81.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,179&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,385&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">EDURANT / rilpivirine</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">972&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">920&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">964&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-13.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">PREZISTA / PREZCOBIX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"> /                                              </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"> REZOLSTA / SYMTUZA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,494&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,508&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">575&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">597&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(21.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,083&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,184&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER INFECTIOUS DISEASES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(55.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(36.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">297&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">396&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Neuroscience</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,570&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,641&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,435&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,893&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,988&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,526&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONCERTA / methylphenidate</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">151&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">172&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">183&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">493&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">495&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">439&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">644&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">667&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,714&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,550&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,314&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,426&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,472&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,339&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,140&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,653&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;RISPERDAL CONSTA</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">296&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">228&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">305&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">346&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">485&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">642&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(18.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER NEUROSCIENCE</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">447&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,312&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(14.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,623&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,706&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Oncology</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,930&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,958&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,092&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,052&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,983&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,367&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">DARZALEX</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,210&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,854&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,958&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,023&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">32.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ERLEADA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">968&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">813&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">583&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39.3</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">478&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">* *</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,881&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">760&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">IMBRUVICA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,390&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,747&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,394&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,622&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,307&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,369&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ZYTIGA</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">/</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">abiraterone acetate</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(68.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,696&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,178&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,770&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,297&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,470&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER ONCOLOGY</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">**</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">283&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">458&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(38.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">821&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(30.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Pulmonary Hypertension</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,346&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,365&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,071&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,085&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,417&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,450&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,148&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OPSUMIT</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,132&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,147&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">651&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">672&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">631&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,783&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,639&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">&#160;UPTRAVI</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,056&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">955&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">218&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,237&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,093&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER </span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">163&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(32.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">395&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">416&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cardiovascular / Metabolism / Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,042&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,509&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">845&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">927&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,887&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,534&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">XARELTO</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,473&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,438&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,345&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">INVOKANA/ INVOKAMET</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">193&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">564&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(45.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">255&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">231&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">795&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(29.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">OTHER</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">376&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">446&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(25.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">590&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">673&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">794&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(15.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,119&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(19.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL PHARMACEUTICAL</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,604&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,735&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,726&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,680&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr style="height:113pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">MEDTECH*</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Interventional Solutions</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,169&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,836&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,452&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,131&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,135&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,971&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,046&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Orthopaedics</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,321&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,126&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,267&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,984&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,588&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,763&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">HIPS</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">943&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">878&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">793&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">571&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">602&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">487&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,514&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,480&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">KNEES</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">851&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">787&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">508&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">538&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">427&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,359&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,325&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,170&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">TRAUMA</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,882&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,648&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">966&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,871&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,885&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SPINE, SPORTS &amp; OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,642&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,595&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,256&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,104&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,898&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,699&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Surgery</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,897&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,249&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,793&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,945&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,983&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,690&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,812&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,232&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">ADVANCED</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,784&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,761&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,535&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,785&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,861&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,304&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,569&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,622&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,839&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">GENERAL</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,113&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,105&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,714&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,008&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,085&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,679&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,121&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,857&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,557&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,859&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,831&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,849&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,688&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,919&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">CONTACT LENSES / OTHER</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,522&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,398&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,213&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,022&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,781&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,543&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,994&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"><tr><td style="width:1.0%"/><td style="width:34.374%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.285%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.979%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.564%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.290%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">SURGICAL</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">468&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">344&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">837&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">788&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">581&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,248&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">TOTAL MEDTECH</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,377&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,686&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,036&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,050&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,923&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,427&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,060&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,959&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:9pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">WORLDWIDE</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,580&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,156&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,133&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;International</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,363&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,619&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,451&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;Worldwide  </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,943&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,775&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,584&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">*Certain prior year amounts have been reclassified to conform to current year presentation</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">**Percentage greater than 100% or not meaningful</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Approximately $0.4&#160;billion in both the fiscal 2021 and 2020, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Inclusive of  PROCRIT / EPREX</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">which was previously disclosed separately</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"> (3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pr</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">eviously referred to as Medical Devices</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information</a></td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.295%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.446%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income (Loss) Before Tax*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Identifiable Assets</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,930&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(852)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,068&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,081&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,901&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,969&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,250&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,436&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64,376&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,607&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,044&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70,956&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">53,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,438&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,915&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,442&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">153,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,829&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Expense not allocated to segments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">624&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,072&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">945&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: Consumer Health separation costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,089&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,918&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,189&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21,725</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">22,776</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">16,497</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">187,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182,018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">*Income before tax of approximately $0.2&#160;billion and $0.2&#160;billion in the fiscal years 2021 and 2020, respectively, has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Additions to Property,<br/>Plant &amp; Equipment</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Depreciation and<br/>Amortization</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consumer Health</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">658&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">759&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">785&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pharmaceutical</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,374&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,198&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">863&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,687&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,029&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,006&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">MedTech</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,120&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,933&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,980&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,302&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,286&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,140&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,817&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,462&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,091&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,647&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,074&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">192&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">190&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">256&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">323&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">300&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4,009</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,652</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3,347</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">6,970</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,390</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">7,231</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:44.580%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.824%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.441%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.300%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Sales to Customers </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Long-Lived Assets </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2021</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">United States</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,580&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,156&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,133&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,283&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,449&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,594&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,980&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,774&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43,257&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Western Hemisphere excluding U.S.&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,125&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,750&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,737&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,708&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Asia-Pacific, Africa</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,789&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,136&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,035&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Segments total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">94,943&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">93,775&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,584&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112,225&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">99,586&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General corporate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,134&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,014&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other non long-lived assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,019&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,418&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Worldwide total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">94,943</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">93,775</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">82,584</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">187,378</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">182,018</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Note&#160;1 for a description of the segments in which the Company operates. </span></div><div style="margin-top:3pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Export sales are not significant. In fiscal year 2022, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.5%, 13.0% and 12.0% of the total consolidated revenues. In fiscal year 2021, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0%, and 12.0% of the total consolidated revenues. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. </span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">General corporate includes cash, cash equivalents and marketable securities.</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt">Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.2&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.44pt">One-time COVID-19 Vaccine manufacturing exit related costs of $1.5&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">An intangible asset impairment charge of approximately $0.8&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation expense of $0.1&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Loss of $0.7&#160;billion related to the change in the fair value of securities </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $0.1&#160;billion </span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MedTech includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Litigation expense of $0.6&#160;billion primarily for pelvic mesh related costs</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A restructuring related charge of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Acquisition and integration related costs of $0.3&#160;billion primarily related to the acquisition of Abiomed</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">A Medical Device Regulation charge of $0.3&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $1.6&#160;billion, primarily talc related costs</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.6&#160;billion, primarily related to Risperdal Gynecomastia</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Divestiture gains of $0.6&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Gains of  $0.5&#160;billion related to the change in the fair value of securities</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1&#160;billion </span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MedTech includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $0.9&#160;billion related to Ottava</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A Medical Device Regulation charge of $0.2&#160;billion</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.1&#160;billion </span></div><div style="margin-top:3pt;text-indent:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">        </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Consumer Health includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $3.9&#160;billion, primarily talc related costs and certain settlements.</span></div><div style="margin-top:3pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.8&#160;billion, primarily related to the agreement in principle to settle opioid litigation </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A gain of $0.5&#160;billion related to the change in the fair value of securities</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MedTech includes:</span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A contingent consideration reversal of $1.1&#160;billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">Litigation expense of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring related charge of $0.3&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">An in-process research and development expense of $0.2&#160;billion </span></div><div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">A Medical Device Regulation charge of $0.1&#160;billion</span></div><div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Long-lived assets include property, plant and equipment, net for fiscal years 2022, and 2021 of $19,803 and $18,962, respectively, and intangible assets and goodwill, net for fiscal years 2022 and 2021 of $93,556 and $81,638, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesBySegmentOfBusinessTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesBySegmentOfBusinessTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784139856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Summary of Severance Charges and Associated Spending</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2022: </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"><tr><td style="width:1.0%"/><td style="width:31.986%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.173%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.885%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.767%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.481%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Dollars in Millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Severance</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Asset Write-offs/Sales </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;3, 2021</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">135&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2021 activity</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(23)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;2, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">112&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">137&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current year activity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Charges  </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">448&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">463&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Cash settlements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(37)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%">(3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(439)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(432)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;Settled non cash </span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(59)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Reserve balance, January&#160;1, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">34&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">109&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Although the restructuring program has been completed in the fiscal year 2022, the Company expects that severance charges will continue beyond that date. The reserve balance as of January 1, 2023 is recorded in the Employee Related Obligation account in the Consolidated Balance Sheet.   </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline">(3) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Represents gain on sale of assets</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428778558192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($) </div>
<div>Segment </div>
<div>Employee</div>
</th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Dec. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide', window );">Number of employees | Employee</a></td>
<td class="nump">152,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of business segments | Segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement', window );">Minimum reverse repurchase agreement collateral (as a percent)</a></td>
<td class="nump">102.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued Rebates Returns And Promotions</a></td>
<td class="nump">$ 14,417<span></span>
</td>
<td class="nump">$ 12,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SalesReturnReserve', window );">Sales return reserve (as a percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProfitLossPercentToSales', window );">Percentage of profit share payments (less than)</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">$ 31,089<span></span>
</td>
<td class="nump">$ 29,855<span></span>
</td>
<td class="nump">$ 28,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShippingandHandlingCostsasaPercentofSales', window );">Shipping and handling costs as a percent of sales</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other assets, noncurrent<span></span>
</td>
<td class="text">Other assets, noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
<td class="text">Accrued Liabilities, Current<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">Other Liabilities, Noncurrent<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right-of-use asset</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Cash paid for operating leases</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent', window );">TCJA, undistributed foreign earnings percent related to cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent', window );">TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability', window );">TCJA, provisional liability</a></td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent', window );">TJCA , provisional liability, non-current</a></td>
<td class="nump">4,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings', window );">Repatriation of foreign earnings amount</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Software Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Software Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Project Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationRiskThresholdPercentage', window );">Concentration risk, threshold percentage (as a percent)</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="nump">0.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember', window );">Shipping and Handling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConcentrationOfCreditRiskLineItems', window );"><strong>Concentration of Credit Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_AccruedRebatesReturnsAndPromotions', window );">Accrued Rebates Returns And Promotions</a></td>
<td class="nump">$ 9,600<span></span>
</td>
<td class="nump">$ 7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_AccruedRebatesReturnsAndPromotions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_AccruedRebatesReturnsAndPromotions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ConcentrationOfCreditRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration of credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ConcentrationOfCreditRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ConcentrationRiskThresholdPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Threshold Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ConcentrationRiskThresholdPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Minimum Collateral Value as a Percent, Reverse Repurchase Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of employees engaged in company activities worldwide.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProfitLossPercentToSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Profit loss percent to sales.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProfitLossPercentToSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SalesReturnReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sales return reserve</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SalesReturnReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShippingandHandlingCostsasaPercentofSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Shipping and Handling Costs as a Percent of Sales</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShippingandHandlingCostsasaPercentofSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes noncurrent operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ShippingAndHandlingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428778800208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Jan. 01, 2023</div></th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Land and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Building and building equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">30 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Land and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of the assets</a></td>
<td class="text">13 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428779676752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale</a></td>
<td class="nump">$ 10,487<span></span>
</td>
<td class="nump">$ 19,727<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">14,127<span></span>
</td>
<td class="nump">14,487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">9,392<span></span>
</td>
<td class="nump">17,121<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">13,032<span></span>
</td>
<td class="nump">11,881<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">13,031<span></span>
</td>
<td class="nump">11,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">12,159<span></span>
</td>
<td class="nump">7,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">873<span></span>
</td>
<td class="nump">4,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">4,926<span></span>
</td>
<td class="nump">2,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">4,926<span></span>
</td>
<td class="nump">2,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">4,926<span></span>
</td>
<td class="nump">2,936<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Non-U.S. Sovereign Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">916<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | U.S. Reverse repurchase agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">1,419<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">1,419<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">1,419<span></span>
</td>
<td class="nump">1,659<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">873<span></span>
</td>
<td class="nump">3,479<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">872<span></span>
</td>
<td class="nump">3,478<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">873<span></span>
</td>
<td class="nump">3,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">5,368<span></span>
</td>
<td class="nump">1,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">5,368<span></span>
</td>
<td class="nump">1,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">5,368<span></span>
</td>
<td class="nump">1,901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember', window );">Held-to-maturity Securities | Time deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Carrying Amount, held-to-maturity</a></td>
<td class="nump">446<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Fair value, held-to-maturity</a></td>
<td class="nump">446<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">446<span></span>
</td>
<td class="nump">900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity, unrecognized loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="nump">10,521<span></span>
</td>
<td class="nump">19,731<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale</a></td>
<td class="nump">10,487<span></span>
</td>
<td class="nump">19,727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">1,968<span></span>
</td>
<td class="nump">6,801<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">8,519<span></span>
</td>
<td class="nump">12,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, unrecognized loss</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | Corporate debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="nump">352<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale</a></td>
<td class="nump">351<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">16<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">305<span></span>
</td>
<td class="nump">230<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, unrecognized loss</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | U.S. Gov't Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="nump">9,959<span></span>
</td>
<td class="nump">19,485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale</a></td>
<td class="nump">9,931<span></span>
</td>
<td class="nump">19,481<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">1,922<span></span>
</td>
<td class="nump">6,785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">8,009<span></span>
</td>
<td class="nump">12,696<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, unrecognized loss</a></td>
<td class="num">(28)<span></span>
</td>
<td class="num">$ (4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale Securities | U.S. Gov't Agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract', window );"><strong>Cash, Cash Equivalents, and Short-term Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Carrying Amount, available-for-sale</a></td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair value, available-for-sale</a></td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Current Marketable Securities</a></td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale, unrecognized loss</a></td>
<td class="num">$ (5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124255206&amp;loc=SL82895884-210446<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=124255953&amp;loc=SL82919253-210447<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7A<br> -URI https://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=SL6953401-111524<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27232-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=SL120269820-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_HeldtomaturitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_SovereignDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_RepurchaseAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_RepurchaseAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428785294160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract', window );"><strong>Cost Basis</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Due within one year</a></td>
<td class="nump">$ 10,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost', window );">Due after one year through five years</a></td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total debt securities</a></td>
<td class="nump">10,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Due within one year</a></td>
<td class="nump">10,399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Due after one year through five years</a></td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">Due after five years through ten years</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total debt securities</a></td>
<td class="nump">$ 10,487<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428782861568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNetAbstract', window );"><strong>Summary of Inventories</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 2,070<span></span>
</td>
<td class="nump">$ 1,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Goods in process</a></td>
<td class="nump">1,700<span></span>
</td>
<td class="nump">2,287<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">8,713<span></span>
</td>
<td class="nump">6,508<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Total inventories</a></td>
<td class="nump">$ 12,483<span></span>
</td>
<td class="nump">$ 10,387<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI https://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428779484592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">$ 49,253<span></span>
</td>
<td class="nump">$ 47,679<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation</a></td>
<td class="nump">29,450<span></span>
</td>
<td class="nump">28,717<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property, plant and equipment, net</a></td>
<td class="nump">19,803<span></span>
</td>
<td class="nump">18,962<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember', window );">Land and leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">859<span></span>
</td>
<td class="nump">884<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember', window );">Building and building equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">12,989<span></span>
</td>
<td class="nump">12,882<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">30,431<span></span>
</td>
<td class="nump">29,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment, gross</a></td>
<td class="nump">$ 4,974<span></span>
</td>
<td class="nump">$ 4,139<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=jnj_LandAndLeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingAndBuildingImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428782729152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest expense capitalized</a></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 63<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest', window );">Depreciation expense, including the amortization of capitalized interest</a></td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Depreciation expense including the amortization of capitalized interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428785091504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,493<span></span>
</td>
<td class="nump">$ 16,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Total intangible assets - net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">48,325<span></span>
</td>
<td class="nump">46,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">783<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember', window );">Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,807<span></span>
</td>
<td class="nump">6,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember', window );">Purchased in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Indefinite lived intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,686<span></span>
</td>
<td class="nump">9,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent', window );">Reduction in intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite lived intangible assets gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,012<span></span>
</td>
<td class="nump">38,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(22,266)<span></span>
</td>
<td class="num">(20,088)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,746<span></span>
</td>
<td class="nump">18,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract', window );"><strong>Intangible assets with definite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite lived intangible assets gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,987<span></span>
</td>
<td class="nump">23,011<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Less accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,901)<span></span>
</td>
<td class="num">(11,925)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite lived intangible assets net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,086<span></span>
</td>
<td class="nump">$ 11,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">Abiomed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">Abiomed | Purchased in-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember', window );">bermekimab | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract', window );"><strong>Intangible assets with indefinite lives:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 926<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=120154696&amp;loc=d3e54445-107959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in intangible assets (for example patents and licenses).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428779105024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill beginning of period</a></td>
<td class="nump">$ 35,246<span></span>
</td>
<td class="nump">$ 36,393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">11,056<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, related to divestitures</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/other</a></td>
<td class="num">(1,071)<span></span>
</td>
<td class="num">(1,138)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill end of period</a></td>
<td class="nump">45,231<span></span>
</td>
<td class="nump">35,246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill beginning of period</a></td>
<td class="nump">9,810<span></span>
</td>
<td class="nump">10,336<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, related to divestitures</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/other</a></td>
<td class="num">(626)<span></span>
</td>
<td class="num">(517)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill end of period</a></td>
<td class="nump">9,184<span></span>
</td>
<td class="nump">9,810<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill beginning of period</a></td>
<td class="nump">10,580<span></span>
</td>
<td class="nump">11,009<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, related to divestitures</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/other</a></td>
<td class="num">(396)<span></span>
</td>
<td class="num">(429)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill end of period</a></td>
<td class="nump">10,184<span></span>
</td>
<td class="nump">10,580<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill beginning of period</a></td>
<td class="nump">14,856<span></span>
</td>
<td class="nump">15,048<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">11,056<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit', window );">Goodwill, related to divestitures</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Currency translation/other</a></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill end of period</a></td>
<td class="nump">$ 25,863<span></span>
</td>
<td class="nump">$ 14,856<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428782055600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Narrative (Details) - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2022</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense of amortizable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="nump">$ 4.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember', window );">Patents And Trademarks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember', window );">Customer relationships and other intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Intangible assets useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">21 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development | bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets, excluding goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PatentsAndTrademarksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428783506304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Intangible Assets and Goodwill - Estimated Amortization of Intangible Assets (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 4,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2024</a></td>
<td class="nump">4,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2025</a></td>
<td class="nump">3,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2026</a></td>
<td class="nump">3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2027</a></td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428782915904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax', window );">Deferred net losses (gains) on derivatives included in accumulated other comprehensive income</a></td>
<td class="num">$ (230)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss', window );">Description of reclassification of cash flow hedge gain (loss)</a></td>
<td class="text">next 12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge', window );">Maximum length of time for hedging transaction exposure</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total Gross Assets</a></td>
<td class="nump">$ 2,201<span></span>
</td>
<td class="nump">$ 1,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Equity investments, increase (decrease) from acquisition (sale) during period</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral paid</a></td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">43,300<span></span>
</td>
<td class="nump">45,800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">36,200<span></span>
</td>
<td class="nump">37,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">12,400<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember', window );">Interest Rate Swap | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Derivative Asset, Current</a></td>
<td class="nump">2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities | Equity Investments without readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityFairValueAdjustmentImpairmentLoss', window );">Equity, fair value adjustment, impairment loss</a></td>
<td class="num">(51)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityFairValueAdjustmentChangeinObservablePrices', window );">Equity, fair value adjustment, change in observable prices</a></td>
<td class="nump">142<span></span>
</td>
<td class="nump">422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Equity investments, increase (decrease) from acquisition (sale) during period</a></td>
<td class="nump">$ 107<span></span>
</td>
<td class="num">$ (632)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityFairValueAdjustmentChangeinObservablePrices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity, Fair Value Adjustment, Change in Observable Prices</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityFairValueAdjustmentChangeinObservablePrices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityFairValueAdjustmentImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity, Fair Value Adjustment, Impairment Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityFairValueAdjustmentImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428778385376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Derivative Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">$ 348<span></span>
</td>
<td class="nump">$ 789<span></span>
</td>
<td class="nump">$ 53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">454<span></span>
</td>
<td class="num">(199)<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Sales | Interest Rate Swap | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Sales | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Sales | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember', window );">Sales | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(72)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(94)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Products Sold | Interest Rate Swap | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Products Sold | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Products Sold | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Products Sold | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(271)<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">319<span></span>
</td>
<td class="num">(557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Interest Rate Swap | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">R&amp;D Expense | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">149<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember', window );">Interest (Income) Expense | Interest Rate Swap | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="num">(1,098)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">1,098<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember', window );">Interest (Income) Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember', window );">Interest (Income) Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">425<span></span>
</td>
<td class="nump">402<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember', window );">Interest (Income) Expense | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Interest Rate Swap | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Cross currency interest rate swaps contracts: | Fair Value Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings', window );">Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Cross currency interest rate swaps contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Forward foreign exchange contracts: | Cash Flow Hedging</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax', window );">Amount of gain or (loss) reclassified from AOCI into income</a></td>
<td class="num">(23)<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax', window );">Amount of gain or (loss) recognized in AOCI</a></td>
<td class="num">$ (113)<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061172-113977<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateSwapMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_FairValueHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_InterestIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428788417856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Carrying Amount of the Hedged Liability</a></td>
<td class="nump">$ 3,357<span></span>
</td>
<td class="nump">$ 1,888<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember', window );">Long-term Debt | Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Carrying Amount of the Hedged Liability</a></td>
<td class="nump">8,665<span></span>
</td>
<td class="nump">9,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability</a></td>
<td class="num">$ (1,435)<span></span>
</td>
<td class="num">$ (142)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428786948912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">Other Nonoperating Income (Expense)<span></span>
</td>
<td class="text">Other Nonoperating Income (Expense)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Forward foreign exchange contracts: | Not Designated as Hedging Instrument</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Gain/(Loss) Recognized In Income on Derivative</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="num">$ (70)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428782221280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197<span></span>
</td>
<td class="nump">$ 387<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember', window );">Cross currency interest rate swaps contracts:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Gain/(Loss) Recognized In Accumulated OCI</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 766<span></span>
</td>
<td class="nump">$ 548<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Gain/(Loss) Reclassified From Accumulated OCI Into Income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember', window );">Other (Income) Expense | Cross currency interest rate swaps contracts:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred', window );">Gain/(Loss) Reclassified From Accumulated OCI Into Income</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121549185&amp;loc=d3e80845-113994<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=121577181&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_CrossCurrencyInterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428782935456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Equity investments, increase (decrease) from acquisition (sale) during period</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">9,602<span></span>
</td>
<td class="nump">$ 10,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities | Equity Investments with readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesNoncurrent', window );">Marketable securities, noncurrent</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
<td class="nump">$ 1,481<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Equity, fair value adjustment</a></td>
<td class="num">(538)<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Equity investments, increase (decrease) from acquisition (sale) during period</a></td>
<td class="num">(770)<span></span>
</td>
<td class="nump">205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities | Equity Investments without readily determinable value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentRollForward', window );"><strong>Equity Investment [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityFairValueAdjustment', window );">Equity, fair value adjustment</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod', window );">Equity investments, increase (decrease) from acquisition (sale) during period</a></td>
<td class="nump">107<span></span>
</td>
<td class="num">(632)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets, noncurrent</a></td>
<td class="nump">698<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount', window );">Equity securities without readily determinable fair value, amount</a></td>
<td class="nump">$ 698<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 738<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Investment [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityFairValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityFairValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980263&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherInvestmentNotReadilyMarketableAxis=jnj_EquityInvestmentswithoutReadilyDeterminableValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428777369200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 22, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">$ 2,163<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">3,289<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Investments</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">$ 1,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">10,487<span></span>
</td>
<td class="nump">19,727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeAsset', window );">Total Gross Assets</a></td>
<td class="nump">2,201<span></span>
</td>
<td class="nump">1,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssetFairValueGrossLiability', window );">Credit Support Agreement (CSA)</a></td>
<td class="num">$ (2,176)<span></span>
</td>
<td class="num">$ (1,285)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag', window );">Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</a></td>
<td class="text">Total Net Asset<span></span>
</td>
<td class="text">Total Net Asset<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Total Net Asset</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Total Gross Liabilities</a></td>
<td class="nump">3,357<span></span>
</td>
<td class="nump">1,888<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilityFairValueGrossAsset', window );">Credit Support Agreement (CSA)</a></td>
<td class="num">$ (3,023)<span></span>
</td>
<td class="num">$ (1,855)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag', window );">Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</a></td>
<td class="text">Total Net Liabilities<span></span>
</td>
<td class="text">Total Net Liabilities<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total Net Liabilities</a></td>
<td class="nump">$ 334<span></span>
</td>
<td class="nump">$ 33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning Balance</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="nump">$ 1,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue', window );">Changes in estimated fair value</a></td>
<td class="num">(194)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="num">(1,089)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred', window );">Additions (7)</a></td>
<td class="nump">792<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements', window );">Payments</a></td>
<td class="num">(11)<span></span>
</td>
<td class="num">(48)<span></span>
</td>
<td class="num">(99)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending Balance</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="nump">633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">1,116<span></span>
</td>
<td class="nump">520<span></span>
</td>
<td class="nump">594<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="num">(1,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">Abiomed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Investments</a></td>
<td class="nump">576<span></span>
</td>
<td class="nump">1,884<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">2,163<span></span>
</td>
<td class="nump">1,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">3,289<span></span>
</td>
<td class="nump">1,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">10,487<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity Investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swaps contracts:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">1,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">2,778<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swaps contracts: | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swaps contracts: | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">1,534<span></span>
</td>
<td class="nump">796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">2,778<span></span>
</td>
<td class="nump">979<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate swaps contracts: | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">629<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">881<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">68<span></span>
</td>
<td class="nump">$ 28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentDetailAbstract', window );"><strong>Financial assets and liabilities at fair value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue', window );">Derivatives designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue', window );">Derivatives designated as hedging instruments : Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue', window );">Derivatives not designated as hedging instruments : Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue', window );">Derivatives not designated as hedging instruments : Liabilities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6405-128476<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetFairValueGrossLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetFairValueGrossLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentDetailAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentDetailAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13433-108611<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226052-175313<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilityFairValueGrossAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226038-175313<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226003-175313<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilityFairValueGrossAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI https://asc.fasb.org/extlink&amp;oid=123594786&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428773846384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Schedule of Long-term Debt Instruments (Details)<br> &#8364; in Millions, &#163; in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.04%<span></span>
</td>
<td class="nump">2.89%<span></span>
</td>
<td class="nump">3.04%<span></span>
</td>
<td class="nump">3.04%<span></span>
</td>
<td class="nump">2.89%<span></span>
</td>
<td class="nump">2.89%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 28,439<span></span>
</td>
<td class="nump">$ 32,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="nump">1,551<span></span>
</td>
<td class="nump">2,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">26,888<span></span>
</td>
<td class="nump">29,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ExcessOfCarryingValueOverFairValueOfDebt', window );">Excess of carrying value over fair value of debt</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt', window );">Excess of fair value over carrying value of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.250NotesDue2022Member', window );">0.250% Notes due 2022 (1B Euro 1.1311)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
<td class="nump">0.26%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.1311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.25Notesdue2022Member', window );">2.25% Notes due 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
<td class="nump">2.31%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member', window );">6.73%&#160;Debentures due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="nump">6.73%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member', window );">3.375% Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.17%<span></span>
</td>
<td class="nump">3.18%<span></span>
</td>
<td class="nump">3.17%<span></span>
</td>
<td class="nump">3.17%<span></span>
</td>
<td class="nump">3.18%<span></span>
</td>
<td class="nump">3.18%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 801<span></span>
</td>
<td class="nump">$ 802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="nump">3.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member', window );">2.05% Notes due 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 499<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.05%<span></span>
</td>
<td class="nump">2.05%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member', window );">0.650% Notes due 2024 (750MM Euro 1.0651)(2)/(750MM Euro 1.1311)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 792<span></span>
</td>
<td class="nump">$ 847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="nump">0.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.0651<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.0651<span></span>
</td>
<td class="nump">1.0651<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member', window );">5.50%&#160;Notes due 2024 (500MM 1.2037 GBP )(2)/(500MM GBP 1.3485)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 600<span></span>
</td>
<td class="nump">$ 672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.2037<span></span>
</td>
<td class="nump">1.3485<span></span>
</td>
<td class="nump">1.2037<span></span>
</td>
<td class="nump">1.2037<span></span>
</td>
<td class="nump">1.3485<span></span>
</td>
<td class="nump">1.3485<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member', window );">2.625% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
<td class="nump">2.63%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 749<span></span>
</td>
<td class="nump">$ 749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.625%<span></span>
</td>
<td class="nump">2.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A055NotesDue2025Member', window );">0.55% Notes due 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
<td class="nump">0.57%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 918<span></span>
</td>
<td class="nump">$ 983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member', window );">2.45% Notes due 2026</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
<td class="nump">2.47%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,996<span></span>
</td>
<td class="nump">$ 1,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member', window );">2.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
<td class="nump">2.96%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 877<span></span>
</td>
<td class="nump">$ 978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member', window );">0.95% Notes due 2027</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
<td class="nump">0.96%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,394<span></span>
</td>
<td class="nump">$ 1,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">0.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="nump">0.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member', window );">1.150% Notes due 2028 (750MM Euro 1.0651)(2)/(750MM Euro 1.1311)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
<td class="nump">1.21%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 794<span></span>
</td>
<td class="nump">$ 843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="nump">1.15%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.0651<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.0651<span></span>
</td>
<td class="nump">1.0651<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member', window );">2.90%&#160;Notes due 2028</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
<td class="nump">2.91%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,496<span></span>
</td>
<td class="nump">$ 1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member', window );">6.95%&#160;Notes due 2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
<td class="nump">7.14%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 298<span></span>
</td>
<td class="nump">$ 298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.95%<span></span>
</td>
<td class="nump">6.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A130NotesDue2030Member', window );">1.30% Notes due 2030</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,607<span></span>
</td>
<td class="nump">$ 1,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member', window );">4.95%&#160;Debentures due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 498<span></span>
</td>
<td class="nump">$ 498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="nump">4.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member', window );">4.375% Notes due 2033</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
<td class="nump">4.24%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 854<span></span>
</td>
<td class="nump">$ 854<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="nump">4.375%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member', window );">1.650% Notes due 2035 (1.5B Euro 1.0651)(2)/(1.5B Euro 1.1311)(3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
<td class="nump">1.68%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,591<span></span>
</td>
<td class="nump">$ 1,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="nump">1.65%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyExchangeRateTranslation1', window );">Foreign currency exchange rate, translation</a></td>
<td class="nump">1.0651<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.0651<span></span>
</td>
<td class="nump">1.0651<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
<td class="nump">1.1311<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member', window );">3.55% Notes due 2036</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
<td class="nump">3.59%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 842<span></span>
</td>
<td class="nump">$ 974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="nump">3.55%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member', window );">5.95%&#160;Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.99%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">$ 993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="nump">5.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member', window );">3.625% Notes due 2037</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
<td class="nump">3.64%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,336<span></span>
</td>
<td class="nump">$ 1,475<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="nump">3.625%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member', window );">5.85%&#160;Debentures due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 697<span></span>
</td>
<td class="nump">$ 696<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="nump">5.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member', window );">3.400%&#160;Notes due 2038</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
<td class="nump">3.42%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="nump">$ 992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member', window );">4.50%&#160;Debentures due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
<td class="nump">4.63%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 540<span></span>
</td>
<td class="nump">$ 540<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member', window );">2.10% Notes due 2040</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 828<span></span>
</td>
<td class="nump">$ 974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member', window );">4.85% Notes due 2041</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
<td class="nump">4.89%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
<td class="nump">4.85%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member', window );">4.50% Notes due 2043</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
<td class="nump">4.52%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="nump">$ 496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member', window );">3.70% Notes due 2046</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
<td class="nump">3.74%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,976<span></span>
</td>
<td class="nump">$ 1,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member', window );">3.75% Notes due 2047</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
<td class="nump">3.76%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 812<span></span>
</td>
<td class="nump">$ 971<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member', window );">3.500% Notes due 2048</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
<td class="nump">3.52%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 743<span></span>
</td>
<td class="nump">$ 743<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member', window );">2.250% Notes due 2050</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
<td class="nump">2.29%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 808<span></span>
</td>
<td class="nump">$ 983<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member', window );">2.450% Notes due 2060</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 1,055<span></span>
</td>
<td class="nump">$ 1,222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Stated interest rate (as a percent)</a></td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="nump">2.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=us-gaap_OtherDebtSecuritiesMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">$ 9<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExcessOfCarryingValueOverFairValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excess Of Carrying Value Over Fair Value Of Debt</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExcessOfCarryingValueOverFairValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExcessOfFairValueOverCarryingValueOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Excess of fair value over carrying value of debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExcessOfFairValueOverCarryingValueOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyExchangeRateTranslation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section S99<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6897108&amp;loc=SL6897125-166521<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32618-110901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyExchangeRateTranslation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0.250NotesDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0.250NotesDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.25Notesdue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.25Notesdue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.73Debenturesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.375Notesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.05Notesdue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A0.650NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.50NotesDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.625Notesdue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A055NotesDue2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A055NotesDue2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.45Notesdue2026Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.95Notesdue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A095NotesDue2027Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.150NotesDue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2.900Notesdue2028Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A6.95Notesdue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A130NotesDue2030Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A130NotesDue2030Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.95Debenturesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.375Notesdue2033Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A1.650NotesDue2035Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.55Notesdue2036Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.95Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.625Notesdue2037Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A5.85Debenturesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.400Notesdue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Debenturesdue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A210NotesDue2040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.85Notesdue2041Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A4.50Notesdue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.70Notesdue2046Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.75Notesdue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A3.500Notesdue2048Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2250NotesDue2050Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=jnj_A2450NotesDue2060Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=us-gaap_OtherDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=us-gaap_OtherDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428785255376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Borrowings - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Nov. 30, 2022</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Sep. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Borrowing capacity under credit facility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings and the current portion of long-term debt</a></td>
<td class="nump">$ 12,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermCommercialPaperCurrent', window );">Borrowed under the commercial paper program</a></td>
<td class="nump">1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long term debt</a></td>
<td class="nump">1,551<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loans and notes payable</a></td>
<td class="nump">$ 12,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,766<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Debt, weighted average interest rate</a></td>
<td class="nump">4.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShortTermBorrowings', window );">Loans and notes payable</a></td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Debt, weighted average interest rate</a></td>
<td class="nump">4.23%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">2 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of debt and lease obligation, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermCommercialPaperCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the current portion of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermCommercialPaperCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428786882144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Borrowings - Aggregate Maturities of Long Term Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtByMaturityAbstract', window );"><strong>Aggregate maturities of long-term obligations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,551<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2024</a></td>
<td class="nump">1,392<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2025</a></td>
<td class="nump">1,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour', window );">2026</a></td>
<td class="nump">1,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive', window );">2027</a></td>
<td class="nump">2,271<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive', window );">After 2026</a></td>
<td class="nump">$ 19,562<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtByMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtByMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24072-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428788391120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Provision for Income Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Currently payable:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">U.S. taxes</a></td>
<td class="nump">$ 2,378<span></span>
</td>
<td class="nump">$ 1,525<span></span>
</td>
<td class="nump">$ 1,026<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">International taxes</a></td>
<td class="nump">3,069<span></span>
</td>
<td class="nump">2,452<span></span>
</td>
<td class="nump">1,898<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total currently payable</a></td>
<td class="nump">5,447<span></span>
</td>
<td class="nump">3,977<span></span>
</td>
<td class="nump">2,924<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. taxes</a></td>
<td class="num">(2,081)<span></span>
</td>
<td class="nump">583<span></span>
</td>
<td class="num">(76)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">International taxes</a></td>
<td class="nump">418<span></span>
</td>
<td class="num">(2,662)<span></span>
</td>
<td class="num">(1,065)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(1,663)<span></span>
</td>
<td class="num">(2,079)<span></span>
</td>
<td class="num">(1,141)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for taxes on income</a></td>
<td class="nump">$ 3,784<span></span>
</td>
<td class="nump">$ 1,898<span></span>
</td>
<td class="nump">$ 1,783<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428779683312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract', window );"><strong>Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">U.S.&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,369<span></span>
</td>
<td class="nump">$ 6,110<span></span>
</td>
<td class="nump">$ 4,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">International</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,356<span></span>
</td>
<td class="nump">16,666<span></span>
</td>
<td class="nump">12,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,725<span></span>
</td>
<td class="nump">$ 22,776<span></span>
</td>
<td class="nump">$ 16,497<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Tax rates:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">International operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4.50%)<span></span>
</td>
<td class="num">(16.40%)<span></span>
</td>
<td class="num">(9.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation', window );">Consumer health separation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome', window );">U.S. taxes on international income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.90%)<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss', window );">Tax benefits from loss on capital assets</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther', window );">Tax benefits on share-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1.30%)<span></span>
</td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(1.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">All other (3)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.40%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="nump">10.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Comparison of income tax expense at the Statutory rate and Company's tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Capital Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Consumer Health Separation</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation related to domestic tax on international income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428779534528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent', window );">Effective tax rate reconciliation, net increase (decrease) in tax rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization', window );">Deferred tax assets, tax basis increase of certain assets due to reorganization</a></td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI', window );">Increase (decrease) in deferred tax liabilities, global intangible low-taxed income (GILTI)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss', window );">Tax benefits from loss on capital assets</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit', window );">Income tax expense recorded related to TRAF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent', window );">TRAF effect on tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit', window );">Income tax expense related to change in tax rate from TRAF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset', window );">Deferred tax asset recorded related to TRAF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">450<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit', window );">Deferred tax expense related to TRAF</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions', window );">Effective income tax rate reconciliation, deduction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 3,323<span></span>
</td>
<td class="nump">$ 3,829<span></span>
</td>
<td class="nump">$ 3,323<span></span>
</td>
<td class="nump">$ 3,373<span></span>
</td>
<td class="nump">$ 3,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Unrecognized tax benefits, interest on income tax expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139<span></span>
</td>
<td class="nump">44<span></span>
</td>
<td class="nump">32<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized tax benefits, interest on income taxes accrued</a></td>
<td class="nump">512<span></span>
</td>
<td class="nump">$ 651<span></span>
</td>
<td class="nump">512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent', window );">Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Incremental tax costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,784<span></span>
</td>
<td class="nump">$ 1,898<span></span>
</td>
<td class="nump">1,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=jnj_ConsumerHealthMember', window );">Consumer Health Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent', window );">Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Incremental tax costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent', window );">Effective tax rate reconciliation, net increase (decrease) in tax rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Deferred tax assets, net</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health | Purchased in-process research and development(1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets, excluding goodwill</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses', window );">Effective income tax rate reconciliation, nondeductible expense, impairment losses, percent</a></td>
<td class="nump">22.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Internal Revenue Service (IRS)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_UnrecognizedTaxBenefitLiabilityPayment', window );">Payment on unrecognized tax benefit liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_TalcMember', window );">Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent', window );">Effective income tax rate reconciliation, litigation settlement, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_TalcMember', window );">Talc | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent', window );">Effective income tax rate reconciliation, litigation settlement, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_RisperdalMember', window );">Risperdal | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent', window );">Effective income tax rate reconciliation, litigation settlement, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.164<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_OpiodsMember', window );">Opiods</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent', window );">Effective income tax rate reconciliation, litigation settlement, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_OpiodsMember', window );">Opiods | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Tax Credit Carryforward [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Capital Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Litigation Settlement, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Federal Act On Tax Reform And AHV Financing, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, Change In Tax Rate, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Federal Act On Tax Reform And AHV Financing, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_UnrecognizedTaxBenefitLiabilityPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefit Liability, Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_UnrecognizedTaxBenefitLiabilityPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=jnj_ConsumerHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=jnj_ConsumerHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=jnj_PurchasedInProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityNameAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_RisperdalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_RisperdalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_OpiodsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_OpiodsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428788329504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Temporary Differences and Carryforwards (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits', window );">Employee related obligations</a></td>
<td class="nump">$ 725<span></span>
</td>
<td class="nump">$ 1,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">687<span></span>
</td>
<td class="nump">679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized', window );">R&amp;D capitalized for tax</a></td>
<td class="nump">2,611<span></span>
</td>
<td class="nump">1,664<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves&#160;&amp; liabilities</a></td>
<td class="nump">2,761<span></span>
</td>
<td class="nump">2,882<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Income reported for tax purposes</a></td>
<td class="nump">2,045<span></span>
</td>
<td class="nump">2,566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Net realizable operating loss carryforwards(4)</a></td>
<td class="nump">1,260<span></span>
</td>
<td class="nump">1,720<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DeferredTaxAssetsUndistributedForeignEarnings', window );">Undistributed foreign earnings</a></td>
<td class="nump">1,565<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Miscellaneous international</a></td>
<td class="nump">1,053<span></span>
</td>
<td class="nump">870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DeferredTaxAssetsOtherDomestic', window );">Miscellaneous U.S.&#160;</a></td>
<td class="nump">476<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred income taxes</a></td>
<td class="nump">13,183<span></span>
</td>
<td class="nump">12,640<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Liability</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Depreciation of property, plant and equipment</a></td>
<td class="num">(858)<span></span>
</td>
<td class="num">(876)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Goodwill and intangibles</a></td>
<td class="num">(4,271)<span></span>
</td>
<td class="num">(2,659)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Undistributed foreign earnings</a></td>
<td class="num">(1,693)<span></span>
</td>
<td class="num">(1,461)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome', window );">Global intangible low-taxed income</a></td>
<td class="num">(3,547)<span></span>
</td>
<td class="num">(4,853)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">Miscellaneous international</a></td>
<td class="num">(65)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DeferredTaxLiabilitiesOtherDomestic', window );">Miscellaneous U.S.&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Total deferred income taxes</a></td>
<td class="num">(10,434)<span></span>
</td>
<td class="num">(9,904)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization', window );">Deferred tax assets, tax basis increase of certain assets due to reorganization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability, acquisition</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Operating Loss Carryforwards, Valuation Allowance</a></td>
<td class="nump">$ 900<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets international research and development capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsOtherDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets other domestic.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsOtherDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxAssetsUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Undistributed Foreign Earnings</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxAssetsUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxLiabilitiesOtherDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Other Domestic</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxLiabilitiesOtherDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liability, Global Intangible Low-Taxed Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428789517008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Summary of unrecognized tax benefits</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning of year</a></td>
<td class="nump">$ 3,323<span></span>
</td>
<td class="nump">$ 3,373<span></span>
</td>
<td class="nump">$ 3,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases related to current year tax positions</a></td>
<td class="nump">523<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="nump">265<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases related to prior period tax positions</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">23<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases related to prior period tax positions</a></td>
<td class="num">(148)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="num">(551)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(187)<span></span>
</td>
<td class="num">(839)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Lapse of statute of limitations</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">End of year</a></td>
<td class="nump">$ 3,829<span></span>
</td>
<td class="nump">$ 3,323<span></span>
</td>
<td class="nump">$ 3,373<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428788508384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Related Obligations - Employee Related Obligations (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Employee-related Liabilities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities', window );">Pension benefits</a></td>
<td class="nump">$ 2,698<span></span>
</td>
<td class="nump">$ 4,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent', window );">Postretirement benefits</a></td>
<td class="nump">1,734<span></span>
</td>
<td class="nump">2,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent', window );">Postemployment benefits</a></td>
<td class="nump">2,832<span></span>
</td>
<td class="nump">3,117<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent', window );">Deferred compensation</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EmployeeObligations', window );">Total employee obligations</a></td>
<td class="nump">7,364<span></span>
</td>
<td class="nump">9,455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Less current benefits payable</a></td>
<td class="nump">597<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Employee related obligations&#160;&#8212; non-current</a></td>
<td class="nump">$ 6,767<span></span>
</td>
<td class="nump">$ 8,898<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EmployeeObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total employee obligations current and non current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EmployeeObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan. Excludes pension plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount as of the balance sheet date of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79691-111665<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 712<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=6410138&amp;loc=d3e79708-111665<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428784302400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Employee Related Obligations - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationRelatedCostsAbstract', window );"><strong>Compensation Related Costs [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Prepaid employee related obligations</a></td>
<td class="nump">$ 4,581<span></span>
</td>
<td class="nump">$ 4,436<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationRelatedCostsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationRelatedCostsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428778288992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets', window );">Percentage of corridor of greater of market value of assets</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">Accumulated benefit obligation unfunded plans</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation', window );">Projected benefit obligation, unfunded plans</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Plan with accumulated benefit obligation in excess of plan assets, plan assets</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets', window );">Fair value of company's common stock directly held in plan assets</a></td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 385<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageOfCompanysCommonStockToPlanAsset', window );">Percentage of company's common stock to plan asset</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="nump">$ 7<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">31,514<span></span>
</td>
<td class="nump">41,930<span></span>
</td>
<td class="nump">$ 38,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US', window );">U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">International Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionContributions', window );">Contribution to pension plans</a></td>
<td class="nump">151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember', window );">Commingled funds | Level 2 | Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">$ 78<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EmployeeCompensationPeriod', window );">Retirement plan benefits Employee compensation Period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EmployeeCompensationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Employee Compensation Period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EmployeeCompensationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of company's common stock directly held in plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageOfCompanysCommonStockToPlanAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the company's common stock to the total plan asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageOfCompanysCommonStockToPlanAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of corridor of greater of market value of assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionContributions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionContributions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428779220592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 1,327<span></span>
</td>
<td class="nump">$ 1,421<span></span>
</td>
<td class="nump">$ 1,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">911<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="nump">955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(2,757)<span></span>
</td>
<td class="num">(2,645)<span></span>
</td>
<td class="num">(2,461)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="num">(184)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses (gains)</a></td>
<td class="nump">655<span></span>
</td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">891<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="num">(47)<span></span>
</td>
<td class="nump">623<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(8)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service cost</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Recognized actuarial losses (gains)</a></td>
<td class="nump">121<span></span>
</td>
<td class="nump">151<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1', window );">Curtailments and settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="nump">$ 533<span></span>
</td>
<td class="nump">$ 503<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428782906752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net Periodic Benefit Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Service cost discount rate</a></td>
<td class="nump">2.46%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
<td class="nump">2.82%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate', window );">Interest cost discount rate</a></td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.34%<span></span>
</td>
<td class="nump">3.13%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of increase in compensation levels</a></td>
<td class="nump">4.02%<span></span>
</td>
<td class="nump">4.01%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Expected long-term rate of return on plan assets</a></td>
<td class="nump">7.25%<span></span>
</td>
<td class="nump">7.71%<span></span>
</td>
<td class="nump">8.12%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.01%<span></span>
</td>
<td class="nump">2.49%<span></span>
</td>
<td class="nump">2.14%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of increase in compensation levels</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="nump">4.01%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Net Periodic Benefit Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Service cost discount rate</a></td>
<td class="nump">2.59%<span></span>
</td>
<td class="nump">2.09%<span></span>
</td>
<td class="nump">3.04%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate', window );">Interest cost discount rate</a></td>
<td class="nump">2.64%<span></span>
</td>
<td class="nump">2.33%<span></span>
</td>
<td class="nump">3.08%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Rate of increase in compensation levels</a></td>
<td class="nump">4.21%<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
<td class="nump">4.25%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Discount rate</a></td>
<td class="nump">5.42%<span></span>
</td>
<td class="nump">2.68%<span></span>
</td>
<td class="nump">2.23%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Rate of increase in compensation levels</a></td>
<td class="nump">4.21%<span></span>
</td>
<td class="nump">4.21%<span></span>
</td>
<td class="nump">4.27%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2919-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428782561472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract', window );"><strong>Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear', window );">Healthcare cost trend rate assumed for next year</a></td>
<td class="nump">5.99%<span></span>
</td>
<td class="nump">5.33%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1', window );">Rate to which the cost trend rate is assumed to decline (ultimate trend)</a></td>
<td class="nump">4.01%<span></span>
</td>
<td class="nump">3.73%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate', window );">Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate</a></td>
<td class="text">2047<span></span>
</td>
<td class="text">2046<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ultimate trend rate for health care cost for defined benefit postretirement plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Year ultimate health care cost trend rate is expected to be reached, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428778983232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">$ 4,581<span></span>
</td>
<td class="nump">$ 4,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(597)<span></span>
</td>
<td class="num">(557)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(6,767)<span></span>
</td>
<td class="num">(8,898)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation - beginning of year</a></td>
<td class="nump">41,582<span></span>
</td>
<td class="nump">43,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">1,327<span></span>
</td>
<td class="nump">1,421<span></span>
</td>
<td class="nump">$ 1,380<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">911<span></span>
</td>
<td class="nump">770<span></span>
</td>
<td class="nump">955<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses(1)</a></td>
<td class="num">(12,213)<span></span>
</td>
<td class="num">(2,132)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease', window );">Divestitures&#160;&amp; acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_CurtailmentsAndSettlementsAndRestructuring', window );">Curtailments, settlements&#160;&amp; restructuring</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid from plan</a></td>
<td class="num">(1,228)<span></span>
</td>
<td class="num">(1,157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effect of exchange rates</a></td>
<td class="num">(815)<span></span>
</td>
<td class="num">(683)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation - end of year</a></td>
<td class="nump">29,631<span></span>
</td>
<td class="nump">41,582<span></span>
</td>
<td class="nump">43,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value&#160;&#8212; beginning of year</a></td>
<td class="nump">41,930<span></span>
</td>
<td class="nump">38,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="num">(8,665)<span></span>
</td>
<td class="nump">4,439<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">67<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease', window );">Divestitures&#160;&amp; acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid from plan assets</a></td>
<td class="num">(1,228)<span></span>
</td>
<td class="num">(1,157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effect of exchange rates</a></td>
<td class="num">(855)<span></span>
</td>
<td class="num">(574)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value&#160;- End of year</a></td>
<td class="nump">31,514<span></span>
</td>
<td class="nump">41,930<span></span>
</td>
<td class="nump">38,195<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status - end of year</a></td>
<td class="nump">1,883<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">4,581<span></span>
</td>
<td class="nump">4,436<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(132)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(2,566)<span></span>
</td>
<td class="num">(3,973)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</a></td>
<td class="nump">1,883<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract', window );"><strong>Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Net actuarial loss</a></td>
<td class="nump">3,948<span></span>
</td>
<td class="nump">5,539<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service cost (credit)(1)</a></td>
<td class="num">(1,417)<span></span>
</td>
<td class="num">(1,610)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax', window );">Unrecognized net transition obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Total before tax effects</a></td>
<td class="nump">2,531<span></span>
</td>
<td class="nump">3,929<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">28,023<span></span>
</td>
<td class="nump">39,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract', window );"><strong>Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="num">(47)<span></span>
</td>
<td class="nump">623<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net actuarial (gain) loss</a></td>
<td class="num">(793)<span></span>
</td>
<td class="num">(3,927)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Amortization of net actuarial loss</a></td>
<td class="num">(655)<span></span>
</td>
<td class="num">(1,257)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service cost (credit)</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service (cost) credit</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectOfExchangeRates', window );">Effect of exchange rates</a></td>
<td class="num">(140)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total loss/(income) recognized in other comprehensive income, before tax</a></td>
<td class="num">(1,398)<span></span>
</td>
<td class="num">(5,134)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax', window );">Total recognized in net periodic benefit cost and other comprehensive income</a></td>
<td class="num">(1,445)<span></span>
</td>
<td class="num">(4,511)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in Benefit Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation - beginning of year</a></td>
<td class="nump">4,878<span></span>
</td>
<td class="nump">5,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">320<span></span>
</td>
<td class="nump">309<span></span>
</td>
<td class="nump">287<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">81<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Actuarial (gains) losses(1)</a></td>
<td class="num">(704)<span></span>
</td>
<td class="num">(188)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease', window );">Divestitures&#160;&amp; acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_CurtailmentsAndSettlementsAndRestructuring', window );">Curtailments, settlements&#160;&amp; restructuring</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid from plan</a></td>
<td class="num">(393)<span></span>
</td>
<td class="num">(348)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Effect of exchange rates</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected benefit obligation - end of year</a></td>
<td class="nump">4,197<span></span>
</td>
<td class="nump">4,878<span></span>
</td>
<td class="nump">5,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value&#160;&#8212; beginning of year</a></td>
<td class="nump">102<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual return on plan assets</a></td>
<td class="num">(17)<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">386<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Plan participant contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease', window );">Divestitures&#160;&amp; acquisitions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid from plan assets</a></td>
<td class="num">(393)<span></span>
</td>
<td class="num">(348)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Effect of exchange rates</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan assets at fair value&#160;- End of year</a></td>
<td class="nump">78<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status - end of year</a></td>
<td class="num">(4,119)<span></span>
</td>
<td class="num">(4,776)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract', window );"><strong>Amounts Recognized in the Company&#8217;s Balance Sheet consist of the following:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Non-current assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(461)<span></span>
</td>
<td class="num">(438)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Non-current liabilities</a></td>
<td class="num">(3,658)<span></span>
</td>
<td class="num">(4,338)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Total recognized in the consolidated balance sheet&#160;&#8212; end of year</a></td>
<td class="num">(4,119)<span></span>
</td>
<td class="num">(4,776)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract', window );"><strong>Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Net actuarial loss</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service cost (credit)(1)</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax', window );">Unrecognized net transition obligation</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Total before tax effects</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract', window );"><strong>Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit cost (credit)</a></td>
<td class="nump">533<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="nump">$ 524<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Net actuarial (gain) loss</a></td>
<td class="num">(751)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Amortization of net actuarial loss</a></td>
<td class="num">(121)<span></span>
</td>
<td class="num">(151)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Prior service cost (credit)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Amortization of prior service (cost) credit</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_EffectOfExchangeRates', window );">Effect of exchange rates</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">Total loss/(income) recognized in other comprehensive income, before tax</a></td>
<td class="num">(868)<span></span>
</td>
<td class="num">(319)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax', window );">Total recognized in net periodic benefit cost and other comprehensive income</a></td>
<td class="num">$ (335)<span></span>
</td>
<td class="nump">$ 184<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_CurtailmentsAndSettlementsAndRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase or decrease related to curtailments, settlements and restructuring.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_CurtailmentsAndSettlementsAndRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_EffectOfExchangeRates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effect Of Exchange Rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_EffectOfExchangeRates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increase benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=SL108413299-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4587-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1731-114919<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428782759504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jnj_QualifiedPlansMember', window );">Qualified Plans | U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">$ 20,937<span></span>
</td>
<td class="nump">$ 27,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected Benefit Obligation</a></td>
<td class="nump">18,394<span></span>
</td>
<td class="nump">25,041<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">17,696<span></span>
</td>
<td class="nump">23,985<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Projected Benefit Obligation</a></td>
<td class="nump">2,543<span></span>
</td>
<td class="nump">2,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">3,241<span></span>
</td>
<td class="nump">3,959<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jnj_NonQualifiedPlansMember', window );">Non-Qualified Plans | U.S. Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected Benefit Obligation</a></td>
<td class="nump">1,937<span></span>
</td>
<td class="nump">2,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">1,872<span></span>
</td>
<td class="nump">2,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Projected Benefit Obligation</a></td>
<td class="num">(1,937)<span></span>
</td>
<td class="num">(2,703)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO', window );">Accumulated Benefit Obligation</a></td>
<td class="num">(1,872)<span></span>
</td>
<td class="num">(2,479)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jnj_FundedPlansMember', window );">Funded Plans | International Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">10,577<span></span>
</td>
<td class="nump">13,986<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected Benefit Obligation</a></td>
<td class="nump">9,024<span></span>
</td>
<td class="nump">13,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">8,202<span></span>
</td>
<td class="nump">12,212<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Projected Benefit Obligation</a></td>
<td class="nump">1,553<span></span>
</td>
<td class="nump">558<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">2,375<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=jnj_UnfundedPlansMember', window );">Unfunded Plans | International Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Projected Benefit Obligation</a></td>
<td class="nump">276<span></span>
</td>
<td class="nump">410<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Accumulated Benefit Obligation</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Projected Benefit Obligation</a></td>
<td class="num">(276)<span></span>
</td>
<td class="num">(410)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO', window );">Accumulated Benefit Obligation</a></td>
<td class="num">$ (253)<span></span>
</td>
<td class="num">$ (373)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanOverUnderFundedStatusABO">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan over (under) funded status ABO</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanOverUnderFundedStatusABO</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123453770&amp;loc=d3e1703-114919<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jnj_QualifiedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jnj_QualifiedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jnj_NonQualifiedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jnj_NonQualifiedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jnj_FundedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jnj_FundedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=jnj_UnfundedPlansMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=jnj_UnfundedPlansMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428779193936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Retirement plans</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">1,457<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">1,532<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">1,609<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">1,708<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027-2031</a></td>
<td class="nump">10,034<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Other benefit plans&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2022</a></td>
<td class="nump">471<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2023</a></td>
<td class="nump">485<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2024</a></td>
<td class="nump">433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2025</a></td>
<td class="nump">447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2026</a></td>
<td class="nump">462<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2027-2031</a></td>
<td class="nump">$ 2,539<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428782118640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne', window );">2022</a></td>
<td class="nump">$ 123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo', window );">2023</a></td>
<td class="nump">128<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree', window );">2024</a></td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour', window );">2025</a></td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive', window );">2026</a></td>
<td class="nump">146<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter', window );">2027-2031</a></td>
<td class="nump">$ 816<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year five.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year four.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year three.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined benefit plan expected future benefit contribution in year two.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428788307296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)<br></strong></div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Percent of Plan Assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember', window );">Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Percent of Plan Assets</a></td>
<td class="nump">62.00%<span></span>
</td>
<td class="nump">65.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">61.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Percent of Plan Assets</a></td>
<td class="nump">38.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Target Allocation</a></td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428779566976">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details) - Retirement plans - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">$ 31,514<span></span>
</td>
<td class="nump">$ 41,930<span></span>
</td>
<td class="nump">$ 38,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">31,514<span></span>
</td>
<td class="nump">41,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets', window );">Investments Measured at Net Asset Value</a></td>
<td class="nump">8,612<span></span>
</td>
<td class="nump">10,515<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">8,879<span></span>
</td>
<td class="nump">14,209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">13,954<span></span>
</td>
<td class="nump">17,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term investment funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">46<span></span>
</td>
<td class="nump">1,135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term investment funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term investment funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">1,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Short-term investment funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government and agency securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">5,863<span></span>
</td>
<td class="nump">7,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government and agency securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government and agency securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">5,863<span></span>
</td>
<td class="nump">7,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Government and agency securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Debt instruments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">3,681<span></span>
</td>
<td class="nump">3,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Debt instruments | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Debt instruments | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">3,681<span></span>
</td>
<td class="nump">3,505<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Debt instruments | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">8,848<span></span>
</td>
<td class="nump">14,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Equity securities | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">8,846<span></span>
</td>
<td class="nump">14,107<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Equity securities | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Equity securities | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commingled funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">10,524<span></span>
</td>
<td class="nump">14,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets', window );">Investments Measured at Net Asset Value</a></td>
<td class="nump">6,106<span></span>
</td>
<td class="nump">8,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commingled funds | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commingled funds | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">4,362<span></span>
</td>
<td class="nump">5,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Commingled funds | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">2,552<span></span>
</td>
<td class="nump">1,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets', window );">Investments Measured at Net Asset Value</a></td>
<td class="nump">2,506<span></span>
</td>
<td class="nump">1,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Other assets | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Other assets | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value, Measurements, Recurring | Other assets | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Plan Assets</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_ShortTermInvestmentFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_ShortTermInvestmentFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=jnj_CommingledFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428867550240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Savings Plan - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SavingsPlanAbstract', window );"><strong>Savings Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Matching contributions</a></td>
<td class="nump">$ 275<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SavingsPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Savings Plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SavingsPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428788260112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital and Treasury Stock - Changes in Treasury Stock (Details) - USD ($)<br> shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ChangesinTreasuryStockSharesOutstandingRollForward', window );"><strong>Changes in Treasury Stock Shares Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, beginning balance (shares)</a></td>
<td class="nump">490,878<span></span>
</td>
<td class="nump">487,331<span></span>
</td>
<td class="nump">487,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Employee compensation and stock option plans (shares)</a></td>
<td class="num">(20,007)<span></span>
</td>
<td class="num">(17,399)<span></span>
</td>
<td class="num">(21,765)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury Stock, ending balance (shares)</a></td>
<td class="nump">506,246<span></span>
</td>
<td class="nump">490,878<span></span>
</td>
<td class="nump">487,331<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ChangesInTreasuryStockRollForward', window );"><strong>Changes in treasury stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Balance</a></td>
<td class="nump">$ 39,099<span></span>
</td>
<td class="nump">$ 38,490<span></span>
</td>
<td class="nump">$ 38,417<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Employee compensation and stock option plans</a></td>
<td class="num">(3,440)<span></span>
</td>
<td class="num">(2,847)<span></span>
</td>
<td class="num">(3,148)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="nump">6,035<span></span>
</td>
<td class="nump">3,456<span></span>
</td>
<td class="nump">3,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury Stock, Ending Balance</a></td>
<td class="nump">$ 41,694<span></span>
</td>
<td class="nump">$ 39,099<span></span>
</td>
<td class="nump">$ 38,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember', window );">Treasury Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ChangesinTreasuryStockSharesOutstandingRollForward', window );"><strong>Changes in Treasury Stock Shares Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Repurchase of common stock (shares)</a></td>
<td class="nump">35,375<span></span>
</td>
<td class="nump">20,946<span></span>
</td>
<td class="nump">21,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ChangesInTreasuryStockRollForward', window );"><strong>Changes in treasury stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Repurchase of common stock</a></td>
<td class="nump">$ 6,035<span></span>
</td>
<td class="nump">$ 3,456<span></span>
</td>
<td class="nump">$ 3,221<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ChangesInTreasuryStockRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ChangesInTreasuryStockRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ChangesinTreasuryStockSharesOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Changes in Treasury Stock Shares Outstanding [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ChangesinTreasuryStockSharesOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_TreasuryStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428778299920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital and Treasury Stock - Narrative (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Billions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 03, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Sep. 14, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,119,843<span></span>
</td>
<td class="nump">3,119,843<span></span>
</td>
<td class="nump">3,119,843<span></span>
</td>
<td class="nump">3,119,843<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareCashPaid', window );">Cash dividends paid (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.45<span></span>
</td>
<td class="nump">$ 4.19<span></span>
</td>
<td class="nump">$ 3.98<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchasedDuringPeriodValue', window );">Stocks repurchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividend (in dollars per share)</a></td>
<td class="nump">$ 1.13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=jnj_December172018ShareRepurchaseProgramMember', window );">December 17, 2018 Share Repurchase Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Stock repurchase program, authorized amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareCashPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends paid during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareCashPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchasedDuringPeriodValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchasedDuringPeriodValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=jnj_December172018ShareRepurchaseProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=jnj_December172018ShareRepurchaseProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428779709520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Income (Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="nump">$ 74,023<span></span>
</td>
<td class="nump">$ 63,278<span></span>
</td>
<td class="nump">$ 59,471<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">649<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="nump">76,804<span></span>
</td>
<td class="nump">74,023<span></span>
</td>
<td class="nump">63,278<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(10,017)<span></span>
</td>
<td class="num">(8,938)<span></span>
</td>
<td class="num">(8,705)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(1,796)<span></span>
</td>
<td class="num">(1,079)<span></span>
</td>
<td class="num">(233)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(11,813)<span></span>
</td>
<td class="num">(10,017)<span></span>
</td>
<td class="num">(8,938)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Gain/(Loss) On Securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(27)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember', window );">Employee Benefit Plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(2,702)<span></span>
</td>
<td class="num">(6,957)<span></span>
</td>
<td class="num">(6,891)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">1,805<span></span>
</td>
<td class="nump">4,255<span></span>
</td>
<td class="num">(66)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(897)<span></span>
</td>
<td class="num">(2,702)<span></span>
</td>
<td class="num">(6,957)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Gain/ (Loss) On Derivatives &amp; Hedges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(336)<span></span>
</td>
<td class="nump">652<span></span>
</td>
<td class="num">(295)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">106<span></span>
</td>
<td class="num">(988)<span></span>
</td>
<td class="nump">947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">(230)<span></span>
</td>
<td class="num">(336)<span></span>
</td>
<td class="nump">652<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract', window );"><strong>AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning Balance</a></td>
<td class="num">(13,058)<span></span>
</td>
<td class="num">(15,242)<span></span>
</td>
<td class="num">(15,891)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Net change</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
<td class="nump">649<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending Balance</a></td>
<td class="num">$ (12,967)<span></span>
</td>
<td class="num">$ (13,058)<span></span>
</td>
<td class="num">$ (15,242)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126987489&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 848<br> -SubTopic 10<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (a)(3)(iii)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=125980421&amp;loc=SL125981372-237846<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126983759&amp;loc=SL121830611-158277<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 22: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 25: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4568447-111683<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128097895&amp;loc=SL121327923-165333<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428783695072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>International Currency Translation - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTranslationAbstract', window );"><strong>Foreign Currency Translation [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency transaction gain (loss), before tax</a></td>
<td class="num">$ (328)<span></span>
</td>
<td class="num">$ (236)<span></span>
</td>
<td class="num">$ (209)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=125521441&amp;loc=d3e30690-110894<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123602790&amp;loc=d3e30226-110892<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=126980362&amp;loc=d3e28228-110885<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124440516&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTranslationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTranslationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428788539520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details) - $ / shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Reconciliation of basic net earnings per share to diluted net earnings per share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic net earnings per share (in dollars per share)</a></td>
<td class="nump">$ 6.83<span></span>
</td>
<td class="nump">$ 7.93<span></span>
</td>
<td class="nump">$ 5.59<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Average shares outstanding&#160;&#8212; basic (in shares)</a></td>
<td class="nump">2,625.2<span></span>
</td>
<td class="nump">2,632.1<span></span>
</td>
<td class="nump">2,632.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PotentialSharesExercisableUnderStockOptionPlans', window );">Potential shares exercisable under stock option plans (in shares)</a></td>
<td class="nump">140.1<span></span>
</td>
<td class="nump">138.0<span></span>
</td>
<td class="nump">118.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod', window );">Less: shares repurchased under treasury stock method (in shares)</a></td>
<td class="num">(101.4)<span></span>
</td>
<td class="num">(96.1)<span></span>
</td>
<td class="num">(80.4)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Average shares outstanding - diluted (in shares)</a></td>
<td class="nump">2,663.9<span></span>
</td>
<td class="nump">2,674.0<span></span>
</td>
<td class="nump">2,670.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted net earnings per share (in dollars per share)</a></td>
<td class="nump">$ 6.73<span></span>
</td>
<td class="nump">$ 7.81<span></span>
</td>
<td class="nump">$ 5.51<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PotentialSharesExercisableUnderStockOptionPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Potential Shares Exercisable Under Stock Option Plans</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PotentialSharesExercisableUnderStockOptionPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428867608304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Share - Narrative (Details)<br> shares in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 03, 2021 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</a></td>
<td class="nump">18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428779458288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($) </div>
<div>StockBasedCompensationPlans </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_NumberOfStockBasedCompensationPlans', window );">Number of stock-based compensation plans | StockBasedCompensationPlans</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation cost charged for Long term incentive plan | $</a></td>
<td class="nump">$ 1,138<span></span>
</td>
<td class="nump">$ 1,135<span></span>
</td>
<td class="nump">$ 1,005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Total income tax benefit recognized | $</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">218<span></span>
</td>
<td class="nump">210<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Exercise of options, tax benefit | $</a></td>
<td class="nump">282<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost not yet recognized for option | $</a></td>
<td class="nump">$ 939<span></span>
</td>
<td class="nump">$ 862<span></span>
</td>
<td class="nump">$ 804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted average period for total compensation cost not yet recognized</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 10 days<span></span>
</td>
<td class="text">1 year 9 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Average fair value of option granted (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 23.23<span></span>
</td>
<td class="nump">$ 20.86<span></span>
</td>
<td class="nump">$ 16.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Total intrinsic value of options exercised | $</a></td>
<td class="nump">$ 1,228<span></span>
</td>
<td class="nump">$ 919<span></span>
</td>
<td class="nump">$ 1,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Stock options outstanding (in shares) | shares</a></td>
<td class="nump">118,672<span></span>
</td>
<td class="nump">117,361<span></span>
</td>
<td class="nump">114,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Stock option average life</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Stock options exercisable | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,742<span></span>
</td>
<td class="nump">61,289<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Stock options average price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 104.42<span></span>
</td>
<td class="nump">$ 96.97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock options expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Average fair value of RSU's and PSU's granted | $ / shares</a></td>
<td class="nump">$ 153.67<span></span>
</td>
<td class="nump">$ 152.62<span></span>
</td>
<td class="nump">$ 139.58<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair Value of RSU or PSU units settled | $</a></td>
<td class="nump">$ 591<span></span>
</td>
<td class="nump">$ 611<span></span>
</td>
<td class="nump">$ 650<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Average fair value of RSU's and PSU's granted | $ / shares</a></td>
<td class="nump">$ 170.46<span></span>
</td>
<td class="nump">$ 179.35<span></span>
</td>
<td class="nump">$ 160.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Fair Value of RSU or PSU units settled | $</a></td>
<td class="nump">$ 94<span></span>
</td>
<td class="nump">$ 83<span></span>
</td>
<td class="nump">$ 91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=jnj_A2022LongTermIncentivePlanMember', window );">2022 Long-Term Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized for issuance under long-term incentive plan | shares</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants under long-term incentive plan | shares</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights', window );">Shares issued subject to stock options or stock appreciation rights (in shares) | shares</a></td>
<td class="nump">110,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards', window );">Shares subject to full value awards (in shares) | shares</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess', window );">Shares subject to full value award, excess (in shares) | shares</a></td>
<td class="nump">40,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_NumberOfStockBasedCompensationPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of stock-based compensation plans.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_NumberOfStockBasedCompensationPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards, Excess</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Stock Options Or Stock Appreciation Rights</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=jnj_A2022LongTermIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=jnj_A2022LongTermIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428782743936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Weighted average assumptions of fair value of options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free rate</a></td>
<td class="nump">1.98%<span></span>
</td>
<td class="nump">0.83%<span></span>
</td>
<td class="nump">1.47%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="nump">18.59%<span></span>
</td>
<td class="nump">15.33%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (in years)</a></td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">2.70%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428785628544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
<th class="th"><div>Dec. 29, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Outstanding Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding beginning of period</a></td>
<td class="nump">117,361<span></span>
</td>
<td class="nump">114,250<span></span>
</td>
<td class="nump">111,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod', window );">Options granted</a></td>
<td class="nump">19,809<span></span>
</td>
<td class="nump">18,525<span></span>
</td>
<td class="nump">20,723<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised</a></td>
<td class="num">(16,310)<span></span>
</td>
<td class="num">(13,248)<span></span>
</td>
<td class="num">(16,275)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled/forfeited</a></td>
<td class="num">(2,188)<span></span>
</td>
<td class="num">(2,166)<span></span>
</td>
<td class="num">(1,835)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding end of period</a></td>
<td class="nump">118,672<span></span>
</td>
<td class="nump">117,361<span></span>
</td>
<td class="nump">114,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options exercise price beginning of period (in dollars per share)</a></td>
<td class="nump">$ 125.36<span></span>
</td>
<td class="nump">$ 116.22<span></span>
</td>
<td class="nump">$ 105.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, average exercise price (in dollars per share)</a></td>
<td class="nump">165.89<span></span>
</td>
<td class="nump">164.62<span></span>
</td>
<td class="nump">151.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, average exercise price (in dollars per share)</a></td>
<td class="nump">100.15<span></span>
</td>
<td class="nump">97.48<span></span>
</td>
<td class="nump">86.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options canceled/forfeited, average exercise price (in dollars per share)</a></td>
<td class="nump">160.56<span></span>
</td>
<td class="nump">149.75<span></span>
</td>
<td class="nump">137.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options exercise price end of period (in dollars per share)</a></td>
<td class="nump">$ 134.95<span></span>
</td>
<td class="nump">$ 125.36<span></span>
</td>
<td class="nump">$ 116.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate intrinsic value</a></td>
<td class="nump">$ 4,949<span></span>
</td>
<td class="nump">$ 5,364<span></span>
</td>
<td class="nump">$ 4,703<span></span>
</td>
<td class="nump">$ 4,478<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Net number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428777270704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details) - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">118,672<span></span>
</td>
<td class="nump">117,361<span></span>
</td>
<td class="nump">114,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 134.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">63,661<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 113.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeOneMember', window );">$72.54-$100.48</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">72.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 100.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">17,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 93.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">17,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 93.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeTwoMember', window );">$101.87-$115.67</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">101.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 115.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">22,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 108.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">22,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 108.78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeThreeMember', window );">$129.51-$141.06</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">129.51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 141.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">24,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 130.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">24,228<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 130.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFourMember', window );">$151.41-$164.62</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">151.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 164.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">35,465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 157.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 156.21<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFiveMember', window );">$164.63-$165.89</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract', window );"><strong>Stock options outstanding and exercisable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Price Range, Minimum (in dollars per share)</a></td>
<td class="nump">164.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Price Range, Maximum (in dollars per share)</a></td>
<td class="nump">$ 165.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Outstanding number of Options (in shares)</a></td>
<td class="nump">19,077<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Outstanding, Average Life</a></td>
<td class="text">9 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1', window );">Outstanding Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 165.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Exercisable number of Options (in shares)</a></td>
<td class="nump">23<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Exercisable, Average Exercise Price (in dollars per share)</a></td>
<td class="nump">$ 165.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share based compensation shares authorized under stock option plans by exercise price range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=jnj_ExercisePriceRangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428782038560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jan. 01, 2023 </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">14,122<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">5,154<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Issued (in shares)</a></td>
<td class="num">(4,866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod', window );">Canceled/forfeited/adjusted (in shares)</a></td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">13,616<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Issued (in shares)</a></td>
<td class="num">(637)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod', window );">Canceled/forfeited/adjusted (in shares)</a></td>
<td class="num">(71)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">2,357<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428762194544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Sales by Segment of Business (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 94,943<span></span>
</td>
<td class="nump">$ 93,775<span></span>
</td>
<td class="nump">$ 82,584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">13.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 14,953<span></span>
</td>
<td class="nump">$ 15,035<span></span>
</td>
<td class="nump">14,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 52,563<span></span>
</td>
<td class="nump">$ 51,680<span></span>
</td>
<td class="nump">45,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">14.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 16,935<span></span>
</td>
<td class="nump">$ 16,750<span></span>
</td>
<td class="nump">15,055<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">11.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,449<span></span>
</td>
<td class="nump">$ 5,825<span></span>
</td>
<td class="nump">3,543<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(6.50%)<span></span>
</td>
<td class="nump">64.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 6,893<span></span>
</td>
<td class="nump">$ 6,988<span></span>
</td>
<td class="nump">6,526<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.40%)<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 15,983<span></span>
</td>
<td class="nump">$ 14,548<span></span>
</td>
<td class="nump">12,367<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">9.90%<span></span>
</td>
<td class="nump">17.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,417<span></span>
</td>
<td class="nump">$ 3,450<span></span>
</td>
<td class="nump">3,148<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">9.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,887<span></span>
</td>
<td class="nump">$ 4,119<span></span>
</td>
<td class="nump">4,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(5.60%)<span></span>
</td>
<td class="num">(9.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 27,427<span></span>
</td>
<td class="nump">$ 27,060<span></span>
</td>
<td class="nump">22,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">17.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">Medical Devices | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="nump">$ 3,971<span></span>
</td>
<td class="nump">3,046<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.30%<span></span>
</td>
<td class="nump">30.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 8,587<span></span>
</td>
<td class="nump">$ 8,588<span></span>
</td>
<td class="nump">7,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">10.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 9,690<span></span>
</td>
<td class="nump">$ 9,812<span></span>
</td>
<td class="nump">8,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.20%)<span></span>
</td>
<td class="nump">19.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,849<span></span>
</td>
<td class="nump">$ 4,688<span></span>
</td>
<td class="nump">3,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">19.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OTCMember', window );">OTC | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 6,031<span></span>
</td>
<td class="nump">$ 5,627<span></span>
</td>
<td class="nump">5,221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.20%<span></span>
</td>
<td class="nump">7.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_SkinHealthBeautyMember', window );">Skin health/Beauty | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,352<span></span>
</td>
<td class="nump">$ 4,541<span></span>
</td>
<td class="nump">4,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(4.20%)<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OralCareMember', window );">Oral Care | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,505<span></span>
</td>
<td class="nump">$ 1,645<span></span>
</td>
<td class="nump">1,641<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(8.50%)<span></span>
</td>
<td class="nump">0.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_BabyCareMember', window );">Baby Care | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,461<span></span>
</td>
<td class="nump">$ 1,566<span></span>
</td>
<td class="nump">1,517<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(6.70%)<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_WomensHealthMember', window );">Women's Health | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 904<span></span>
</td>
<td class="nump">$ 917<span></span>
</td>
<td class="nump">901<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember', window );">Wound Care and Other | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 739<span></span>
</td>
<td class="nump">720<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(5.30%)<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RemicadeMember', window );">Remicade | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,343<span></span>
</td>
<td class="nump">$ 3,190<span></span>
</td>
<td class="nump">3,747<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(26.60%)<span></span>
</td>
<td class="num">(14.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember', window );">Simponi/Simponi Aria | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,184<span></span>
</td>
<td class="nump">$ 2,276<span></span>
</td>
<td class="nump">2,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_StelaraMember', window );">Stelara | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 9,723<span></span>
</td>
<td class="nump">$ 9,134<span></span>
</td>
<td class="nump">7,707<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">18.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TremfyaMember', window );">Tremfya | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,668<span></span>
</td>
<td class="nump">$ 2,127<span></span>
</td>
<td class="nump">1,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">25.40%<span></span>
</td>
<td class="nump">57.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherImmunologyMember', window );">Other Immunology | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(28.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_COVID19Member', window );">COVID-19 | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,179<span></span>
</td>
<td class="nump">2,385<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(8.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember', window );">EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,008<span></span>
</td>
<td class="nump">$ 994<span></span>
</td>
<td class="nump">964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember', window );">PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,943<span></span>
</td>
<td class="nump">$ 2,083<span></span>
</td>
<td class="nump">2,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(6.70%)<span></span>
</td>
<td class="num">(4.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember', window );">Other Infectious Diseases | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 318<span></span>
</td>
<td class="nump">$ 363<span></span>
</td>
<td class="nump">396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(12.30%)<span></span>
</td>
<td class="num">(8.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember', window );">CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 644<span></span>
</td>
<td class="nump">$ 667<span></span>
</td>
<td class="nump">622<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(3.50%)<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember', window );">INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,140<span></span>
</td>
<td class="nump">$ 4,022<span></span>
</td>
<td class="nump">3,653<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">10.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember', window );">RISPERDAL CONSTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 485<span></span>
</td>
<td class="nump">$ 592<span></span>
</td>
<td class="nump">642<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(18.10%)<span></span>
</td>
<td class="num">(7.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember', window );">OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,623<span></span>
</td>
<td class="nump">$ 1,706<span></span>
</td>
<td class="nump">1,610<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(4.90%)<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_DARZALEXMember', window );">DARZALEX | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 7,977<span></span>
</td>
<td class="nump">$ 6,023<span></span>
</td>
<td class="nump">4,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">32.40%<span></span>
</td>
<td class="nump">43.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ErleadaMember', window );">ERLEADA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,881<span></span>
</td>
<td class="nump">$ 1,291<span></span>
</td>
<td class="nump">760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">45.70%<span></span>
</td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_IMBRUVICAMember', window );">IMBRUVICA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,784<span></span>
</td>
<td class="nump">$ 4,369<span></span>
</td>
<td class="nump">4,128<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(13.40%)<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ZYTIGAMember', window );">ZYTIGA/abiraterone acetate | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,770<span></span>
</td>
<td class="nump">$ 2,297<span></span>
</td>
<td class="nump">2,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(22.90%)<span></span>
</td>
<td class="num">(7.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherOncologyMember', window );">Other Oncology | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 571<span></span>
</td>
<td class="nump">$ 568<span></span>
</td>
<td class="nump">821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.60%<span></span>
</td>
<td class="num">(30.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OPSUMITMember', window );">OPSUMIT | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,783<span></span>
</td>
<td class="nump">$ 1,819<span></span>
</td>
<td class="nump">1,639<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_UPTRAVIMember', window );">UPTRAVI | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,322<span></span>
</td>
<td class="nump">$ 1,237<span></span>
</td>
<td class="nump">1,093<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">13.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherMember', window );">Other | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">$ 395<span></span>
</td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(20.80%)<span></span>
</td>
<td class="num">(5.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OtherMember', window );">Other | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 966<span></span>
</td>
<td class="nump">$ 1,119<span></span>
</td>
<td class="nump">1,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(13.60%)<span></span>
</td>
<td class="num">(19.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_XareltoMember', window );">XARELTO | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,473<span></span>
</td>
<td class="nump">$ 2,438<span></span>
</td>
<td class="nump">2,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember', window );">INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 448<span></span>
</td>
<td class="nump">$ 563<span></span>
</td>
<td class="nump">795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(20.40%)<span></span>
</td>
<td class="num">(29.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_HIPSMember', window );">HIPS | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,514<span></span>
</td>
<td class="nump">$ 1,480<span></span>
</td>
<td class="nump">1,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">15.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_KNEESMember', window );">KNEES | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,359<span></span>
</td>
<td class="nump">$ 1,325<span></span>
</td>
<td class="nump">1,170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">13.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TRAUMAMember', window );">TRAUMA | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,871<span></span>
</td>
<td class="nump">$ 2,885<span></span>
</td>
<td class="nump">2,614<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_SPINESPORTSOTHERMember', window );">SPINE,SPORTS &amp; OTHER | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,843<span></span>
</td>
<td class="nump">$ 2,898<span></span>
</td>
<td class="nump">2,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="nump">7.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ADVANCEDMember', window );">ADVANCED | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,569<span></span>
</td>
<td class="nump">$ 4,622<span></span>
</td>
<td class="nump">3,839<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.10%)<span></span>
</td>
<td class="nump">20.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_GENERALMember', window );">GENERAL | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,121<span></span>
</td>
<td class="nump">$ 5,190<span></span>
</td>
<td class="nump">4,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="nump">18.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember', window );">CONTACT LENSES/OTHER | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,543<span></span>
</td>
<td class="nump">$ 3,440<span></span>
</td>
<td class="nump">2,994<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">14.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_SURGICALMember', window );">SURGICAL | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,306<span></span>
</td>
<td class="nump">$ 1,248<span></span>
</td>
<td class="nump">925<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">34.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 48,580<span></span>
</td>
<td class="nump">$ 47,156<span></span>
</td>
<td class="nump">43,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="nump">9.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 6,599<span></span>
</td>
<td class="nump">$ 6,516<span></span>
</td>
<td class="nump">6,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">2.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 28,604<span></span>
</td>
<td class="nump">$ 27,954<span></span>
</td>
<td class="nump">25,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">8.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 11,036<span></span>
</td>
<td class="nump">$ 10,843<span></span>
</td>
<td class="nump">10,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,680<span></span>
</td>
<td class="nump">$ 2,249<span></span>
</td>
<td class="nump">1,735<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(25.30%)<span></span>
</td>
<td class="nump">29.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,570<span></span>
</td>
<td class="nump">$ 3,347<span></span>
</td>
<td class="nump">3,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">6.70%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 6,930<span></span>
</td>
<td class="nump">$ 5,958<span></span>
</td>
<td class="nump">5,092<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">16.30%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,346<span></span>
</td>
<td class="nump">$ 2,365<span></span>
</td>
<td class="nump">2,133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(0.80%)<span></span>
</td>
<td class="nump">10.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,042<span></span>
</td>
<td class="nump">$ 3,192<span></span>
</td>
<td class="nump">3,509<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(4.70%)<span></span>
</td>
<td class="num">(9.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 13,377<span></span>
</td>
<td class="nump">$ 12,686<span></span>
</td>
<td class="nump">11,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">14.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,169<span></span>
</td>
<td class="nump">$ 1,836<span></span>
</td>
<td class="nump">1,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">18.20%<span></span>
</td>
<td class="nump">26.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,321<span></span>
</td>
<td class="nump">$ 5,126<span></span>
</td>
<td class="nump">4,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">7.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,897<span></span>
</td>
<td class="nump">$ 3,867<span></span>
</td>
<td class="nump">3,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,990<span></span>
</td>
<td class="nump">$ 1,857<span></span>
</td>
<td class="nump">1,557<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.20%<span></span>
</td>
<td class="nump">19.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | OTC | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,782<span></span>
</td>
<td class="nump">$ 2,594<span></span>
</td>
<td class="nump">2,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="nump">5.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Skin health/Beauty | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,337<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">2,350<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(2.60%)<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Oral Care | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 635<span></span>
</td>
<td class="nump">$ 637<span></span>
</td>
<td class="nump">683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(6.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Baby Care | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">$ 378<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(5.50%)<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Women's Health | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="num">(1.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Wound Care and Other | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 475<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
<td class="nump">480<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(4.00%)<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Remicade | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,417<span></span>
</td>
<td class="nump">$ 2,019<span></span>
</td>
<td class="nump">2,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(29.80%)<span></span>
</td>
<td class="num">(19.50%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Simponi/Simponi Aria | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,166<span></span>
</td>
<td class="nump">$ 1,127<span></span>
</td>
<td class="nump">1,155<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="num">(2.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Stelara | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 6,388<span></span>
</td>
<td class="nump">$ 5,938<span></span>
</td>
<td class="nump">5,240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.60%<span></span>
</td>
<td class="nump">13.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Tremfya | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,844<span></span>
</td>
<td class="nump">$ 1,503<span></span>
</td>
<td class="nump">926<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">22.70%<span></span>
</td>
<td class="nump">62.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other Immunology | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(18.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | COVID-19 | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(81.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">44<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(10.80%)<span></span>
</td>
<td class="num">(7.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,494<span></span>
</td>
<td class="nump">$ 1,508<span></span>
</td>
<td class="nump">1,587<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="num">(4.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other Infectious Diseases | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
<td class="nump">104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(55.50%)<span></span>
</td>
<td class="num">(36.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 151<span></span>
</td>
<td class="nump">$ 172<span></span>
</td>
<td class="nump">183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(12.50%)<span></span>
</td>
<td class="num">(5.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,714<span></span>
</td>
<td class="nump">$ 2,550<span></span>
</td>
<td class="nump">2,314<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">10.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | RISPERDAL CONSTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 257<span></span>
</td>
<td class="nump">$ 287<span></span>
</td>
<td class="nump">296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(10.40%)<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 447<span></span>
</td>
<td class="nump">$ 338<span></span>
</td>
<td class="nump">298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">32.40%<span></span>
</td>
<td class="nump">13.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | DARZALEX | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 4,210<span></span>
</td>
<td class="nump">$ 3,169<span></span>
</td>
<td class="nump">2,232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">32.80%<span></span>
</td>
<td class="nump">42.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | ERLEADA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 968<span></span>
</td>
<td class="nump">$ 813<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">19.20%<span></span>
</td>
<td class="nump">39.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | IMBRUVICA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,390<span></span>
</td>
<td class="nump">$ 1,747<span></span>
</td>
<td class="nump">1,821<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(20.40%)<span></span>
</td>
<td class="num">(4.00%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | ZYTIGA/abiraterone acetate | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 74<span></span>
</td>
<td class="nump">$ 119<span></span>
</td>
<td class="nump">373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(37.80%)<span></span>
</td>
<td class="num">(68.10%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other Oncology | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | OPSUMIT | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,132<span></span>
</td>
<td class="nump">$ 1,147<span></span>
</td>
<td class="nump">1,008<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="nump">13.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | UPTRAVI | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,104<span></span>
</td>
<td class="nump">$ 1,056<span></span>
</td>
<td class="nump">955<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 110<span></span>
</td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(32.30%)<span></span>
</td>
<td class="num">(3.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | Other | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 376<span></span>
</td>
<td class="nump">$ 446<span></span>
</td>
<td class="nump">600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(15.50%)<span></span>
</td>
<td class="num">(25.70%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | XARELTO | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,473<span></span>
</td>
<td class="nump">$ 2,438<span></span>
</td>
<td class="nump">2,345<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 193<span></span>
</td>
<td class="nump">$ 308<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(37.40%)<span></span>
</td>
<td class="num">(45.40%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | HIPS | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 943<span></span>
</td>
<td class="nump">$ 878<span></span>
</td>
<td class="nump">793<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="nump">10.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | KNEES | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 851<span></span>
</td>
<td class="nump">$ 787<span></span>
</td>
<td class="nump">743<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.20%<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | TRAUMA | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,882<span></span>
</td>
<td class="nump">$ 1,819<span></span>
</td>
<td class="nump">1,648<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | SPINE,SPORTS &amp; OTHER | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,645<span></span>
</td>
<td class="nump">$ 1,642<span></span>
</td>
<td class="nump">1,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">2.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | ADVANCED | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,784<span></span>
</td>
<td class="nump">$ 1,761<span></span>
</td>
<td class="nump">1,535<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">14.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | GENERAL | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,113<span></span>
</td>
<td class="nump">$ 2,105<span></span>
</td>
<td class="nump">1,714<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">22.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | CONTACT LENSES/OTHER | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,522<span></span>
</td>
<td class="nump">$ 1,398<span></span>
</td>
<td class="nump">1,213<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">8.90%<span></span>
</td>
<td class="nump">15.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States | SURGICAL | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">33.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 46,363<span></span>
</td>
<td class="nump">$ 46,619<span></span>
</td>
<td class="nump">39,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(0.60%)<span></span>
</td>
<td class="nump">18.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 8,354<span></span>
</td>
<td class="nump">$ 8,519<span></span>
</td>
<td class="nump">8,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="nump">5.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 23,959<span></span>
</td>
<td class="nump">$ 23,726<span></span>
</td>
<td class="nump">19,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">22.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,899<span></span>
</td>
<td class="nump">$ 5,907<span></span>
</td>
<td class="nump">4,880<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,769<span></span>
</td>
<td class="nump">$ 3,576<span></span>
</td>
<td class="nump">1,808<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">97.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,323<span></span>
</td>
<td class="nump">$ 3,641<span></span>
</td>
<td class="nump">3,435<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(8.70%)<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 9,052<span></span>
</td>
<td class="nump">$ 8,590<span></span>
</td>
<td class="nump">7,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">5.40%<span></span>
</td>
<td class="nump">18.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,071<span></span>
</td>
<td class="nump">$ 1,085<span></span>
</td>
<td class="nump">1,015<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.30%)<span></span>
</td>
<td class="nump">6.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 845<span></span>
</td>
<td class="nump">$ 927<span></span>
</td>
<td class="nump">1,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(8.90%)<span></span>
</td>
<td class="num">(9.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 14,050<span></span>
</td>
<td class="nump">$ 14,374<span></span>
</td>
<td class="nump">11,923<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(2.30%)<span></span>
</td>
<td class="nump">20.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices | Interventional Solutions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,131<span></span>
</td>
<td class="nump">$ 2,135<span></span>
</td>
<td class="nump">1,594<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(0.20%)<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,267<span></span>
</td>
<td class="nump">$ 3,462<span></span>
</td>
<td class="nump">2,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(5.60%)<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 5,793<span></span>
</td>
<td class="nump">$ 5,945<span></span>
</td>
<td class="nump">4,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(2.60%)<span></span>
</td>
<td class="nump">19.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,859<span></span>
</td>
<td class="nump">$ 2,831<span></span>
</td>
<td class="nump">2,362<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">19.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | OTC | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,249<span></span>
</td>
<td class="nump">$ 3,034<span></span>
</td>
<td class="nump">2,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">7.10%<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Skin health/Beauty | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,015<span></span>
</td>
<td class="nump">$ 2,141<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(5.90%)<span></span>
</td>
<td class="nump">1.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Oral Care | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 871<span></span>
</td>
<td class="nump">$ 1,008<span></span>
</td>
<td class="nump">958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(13.60%)<span></span>
</td>
<td class="nump">5.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Baby Care | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,104<span></span>
</td>
<td class="nump">$ 1,188<span></span>
</td>
<td class="nump">1,141<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(7.10%)<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Women's Health | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 891<span></span>
</td>
<td class="nump">$ 905<span></span>
</td>
<td class="nump">888<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="nump">1.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Wound Care and Other | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 224<span></span>
</td>
<td class="nump">$ 243<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(8.00%)<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Remicade | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 722<span></span>
</td>
<td class="nump">$ 935<span></span>
</td>
<td class="nump">893<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(22.80%)<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Simponi/Simponi Aria | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,017<span></span>
</td>
<td class="nump">$ 1,148<span></span>
</td>
<td class="nump">1,088<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(11.40%)<span></span>
</td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Stelara | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,335<span></span>
</td>
<td class="nump">$ 3,196<span></span>
</td>
<td class="nump">2,467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">29.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Tremfya | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 824<span></span>
</td>
<td class="nump">$ 624<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">48.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other Immunology | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73.30%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | COVID-19 | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,059<span></span>
</td>
<td class="nump">$ 1,751<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">17.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | EDURANT/rilpivirine | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 972<span></span>
</td>
<td class="nump">$ 953<span></span>
</td>
<td class="nump">920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 449<span></span>
</td>
<td class="nump">$ 575<span></span>
</td>
<td class="nump">597<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(21.90%)<span></span>
</td>
<td class="num">(3.60%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other Infectious Diseases | Pharmaceutical | Infectious Diseases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 289<span></span>
</td>
<td class="nump">$ 297<span></span>
</td>
<td class="nump">292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(2.60%)<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | CONCERTA/Methylphenidate | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 493<span></span>
</td>
<td class="nump">$ 495<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,426<span></span>
</td>
<td class="nump">$ 1,472<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(3.10%)<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | RISPERDAL CONSTA | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 228<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(25.30%)<span></span>
</td>
<td class="num">(11.80%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | OTHER NEUROSCIENCE | Pharmaceutical | Neuroscience</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,176<span></span>
</td>
<td class="nump">$ 1,368<span></span>
</td>
<td class="nump">1,312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(14.10%)<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | DARZALEX | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,767<span></span>
</td>
<td class="nump">$ 2,854<span></span>
</td>
<td class="nump">1,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">45.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | ERLEADA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 913<span></span>
</td>
<td class="nump">$ 478<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | IMBRUVICA | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,394<span></span>
</td>
<td class="nump">$ 2,622<span></span>
</td>
<td class="nump">2,307<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(8.70%)<span></span>
</td>
<td class="nump">13.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | ZYTIGA/abiraterone acetate | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,696<span></span>
</td>
<td class="nump">$ 2,178<span></span>
</td>
<td class="nump">2,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(22.10%)<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other Oncology | Pharmaceutical | Oncology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 283<span></span>
</td>
<td class="nump">$ 458<span></span>
</td>
<td class="nump">738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(38.30%)<span></span>
</td>
<td class="num">(37.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | OPSUMIT | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 651<span></span>
</td>
<td class="nump">$ 672<span></span>
</td>
<td class="nump">631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(3.20%)<span></span>
</td>
<td class="nump">6.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | UPTRAVI | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 218<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
<td class="nump">138<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">20.40%<span></span>
</td>
<td class="nump">31.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other | Pharmaceutical | Pulmonary Hypertension</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 202<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(12.80%)<span></span>
</td>
<td class="num">(5.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | Other | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 590<span></span>
</td>
<td class="nump">$ 673<span></span>
</td>
<td class="nump">794<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(12.30%)<span></span>
</td>
<td class="num">(15.20%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | XARELTO | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | INVOKANA/INVOKAMET | Pharmaceutical | Cardiovascular/Metabolism/Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 255<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
<td class="nump">231<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | HIPS | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 571<span></span>
</td>
<td class="nump">$ 602<span></span>
</td>
<td class="nump">487<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(5.10%)<span></span>
</td>
<td class="nump">23.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | KNEES | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 508<span></span>
</td>
<td class="nump">$ 538<span></span>
</td>
<td class="nump">427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(5.70%)<span></span>
</td>
<td class="nump">26.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | TRAUMA | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 989<span></span>
</td>
<td class="nump">$ 1,066<span></span>
</td>
<td class="nump">966<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(7.20%)<span></span>
</td>
<td class="nump">10.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | SPINE,SPORTS &amp; OTHER | Medical Devices | Orthopaedics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 1,198<span></span>
</td>
<td class="nump">$ 1,256<span></span>
</td>
<td class="nump">1,104<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(4.60%)<span></span>
</td>
<td class="nump">13.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | ADVANCED | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,785<span></span>
</td>
<td class="nump">$ 2,861<span></span>
</td>
<td class="nump">2,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(2.60%)<span></span>
</td>
<td class="nump">24.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | GENERAL | Medical Devices | Surgery</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 3,008<span></span>
</td>
<td class="nump">$ 3,085<span></span>
</td>
<td class="nump">2,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(2.50%)<span></span>
</td>
<td class="nump">15.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | CONTACT LENSES/OTHER | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 2,022<span></span>
</td>
<td class="nump">$ 2,043<span></span>
</td>
<td class="nump">1,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">14.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember', window );">Non-US | SURGICAL | Medical Devices | Vision</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 837<span></span>
</td>
<td class="nump">$ 788<span></span>
</td>
<td class="nump">581<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="nump">6.20%<span></span>
</td>
<td class="nump">35.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember', window );">UNITED STATES Exports | Remicade | Pharmaceutical | Immunology</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 204<span></span>
</td>
<td class="nump">$ 236<span></span>
</td>
<td class="nump">346<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_PercentageChangeInSalesBySegmentOfBusiness', window );">Percentage Change In Sales By Segment Of Business</a></td>
<td class="num">(13.60%)<span></span>
</td>
<td class="num">(31.90%)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_CN', window );">CHINA | OTC | CONSUMER HEALTH and PHARMACEUTICAL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_PercentageChangeInSalesBySegmentOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage change in sales by segment of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_PercentageChangeInSalesBySegmentOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_NeuroscienceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_PulmonaryHypertensionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_CardiovascularMetabolismOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_InterventionalSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_OrthopaedicsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_SurgeryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_SurgeryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_VisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_VisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SkinHealthBeautyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SkinHealthBeautyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OralCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OralCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_BabyCareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_BabyCareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WomensHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WomensHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_WoundCareandOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RemicadeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RemicadeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SimponiSimponiAriaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_StelaraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_StelaraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TremfyaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TremfyaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_EDURANTrilpivirineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherInfectiousDiseasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONCERTAMethylphenidateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RISPERDALCONSTAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OTHERNEUROSCIENCEMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_DARZALEXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_DARZALEXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ErleadaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ErleadaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_IMBRUVICAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_IMBRUVICAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ZYTIGAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ZYTIGAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherOncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherOncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OPSUMITMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OPSUMITMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_UPTRAVIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_UPTRAVIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_XareltoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_XareltoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_INVOKANAINVOKAMETMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_HIPSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_HIPSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_KNEESMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_KNEESMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TRAUMAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TRAUMAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SPINESPORTSOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SPINESPORTSOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ADVANCEDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ADVANCEDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_GENERALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_GENERALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_CONTACTLENSESOTHERMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_SURGICALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_SURGICALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_UNITEDSTATESExportsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_CONSUMERHEALTHAndPHARMACEUTICALMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_CONSUMERHEALTHAndPHARMACEUTICALMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428772593344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">$ 21,725<span></span>
</td>
<td class="nump">$ 22,776<span></span>
</td>
<td class="nump">$ 16,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">187,378<span></span>
</td>
<td class="nump">182,018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes', window );">Results of Operations, Income before Income Taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">4,009<span></span>
</td>
<td class="nump">3,652<span></span>
</td>
<td class="nump">3,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">6,970<span></span>
</td>
<td class="nump">7,390<span></span>
</td>
<td class="nump">7,231<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 94,943<span></span>
</td>
<td class="nump">$ 93,775<span></span>
</td>
<td class="nump">$ 82,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of segments | Segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">783<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">$ (1,148)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, Plant and Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">19,803<span></span>
</td>
<td class="nump">18,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherIntangibleAssetsMember', window );">Other Intangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">93,556<span></span>
</td>
<td class="nump">$ 81,638<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember', window );">Auris Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="num">(1,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember', window );">bermekimab | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment of intangible assets, excluding goodwill</a></td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=jnj_Wholesaler1Member', window );">Wholesaler 1 | Sales Revenue, Net | Wholesaler Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">16.50%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=jnj_Wholesaler2Member', window );">Wholesaler 2 | Sales Revenue, Net | Wholesaler Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=jnj_Wholesaler3Member', window );">Wholesaler 3 | Sales Revenue, Net | Wholesaler Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk (as a percent)</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 48,580<span></span>
</td>
<td class="nump">$ 47,156<span></span>
</td>
<td class="nump">$ 43,133<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">14,953<span></span>
</td>
<td class="nump">15,035<span></span>
</td>
<td class="nump">14,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
<td class="nump">3,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember', window );">Consumer Health | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">6,599<span></span>
</td>
<td class="nump">6,516<span></span>
</td>
<td class="nump">6,362<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">52,563<span></span>
</td>
<td class="nump">51,680<span></span>
</td>
<td class="nump">45,175<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfBusiness', window );">Gain (loss) on divestiture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesRealizedGainLoss', window );">Marketable securities, realized gain (loss)</a></td>
<td class="num">(700)<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember', window );">Pharmaceutical | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">28,604<span></span>
</td>
<td class="nump">27,954<span></span>
</td>
<td class="nump">25,735<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">27,427<span></span>
</td>
<td class="nump">27,060<span></span>
</td>
<td class="nump">22,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">600<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_RegulationCharge', window );">Regulation charge</a></td>
<td class="nump">300<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AcquisitionCosts', window );">Acquisition Costs, Period Cost</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">Medical Devices | Auris Health | Other Income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Contingent consideration reversal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,100)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember', window );">Medical Devices | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">13,377<span></span>
</td>
<td class="nump">12,686<span></span>
</td>
<td class="nump">11,036<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_SegmentsTotalMember', window );">Segments Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">153,460<span></span>
</td>
<td class="nump">142,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">3,817<span></span>
</td>
<td class="nump">3,462<span></span>
</td>
<td class="nump">3,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">6,647<span></span>
</td>
<td class="nump">7,074<span></span>
</td>
<td class="nump">6,931<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerHealthMember', window );">Consumer Health Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation expense</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ExpenseNotAllocatedToSegments', window );">Less: Expense not allocated to segments</a></td>
<td class="nump">624<span></span>
</td>
<td class="nump">1,072<span></span>
</td>
<td class="nump">945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_OtherNonLongLivedAssets', window );">Other Non Long Lived Assets</a></td>
<td class="nump">74,019<span></span>
</td>
<td class="nump">81,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment | Consumer Health Business</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ExpenseNotAllocatedToSegments', window );">Less: Expense not allocated to segments</a></td>
<td class="nump">1,089<span></span>
</td>
<td class="nump">67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate, Non-Segment | General Corporate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">33,918<span></span>
</td>
<td class="nump">39,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">192<span></span>
</td>
<td class="nump">190<span></span>
</td>
<td class="nump">256<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">316<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">1,134<span></span>
</td>
<td class="nump">1,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">23,438<span></span>
</td>
<td class="nump">23,915<span></span>
</td>
<td class="nump">17,442<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">94,943<span></span>
</td>
<td class="nump">93,775<span></span>
</td>
<td class="nump">82,584<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">112,225<span></span>
</td>
<td class="nump">99,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">48,580<span></span>
</td>
<td class="nump">47,156<span></span>
</td>
<td class="nump">43,133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">66,283<span></span>
</td>
<td class="nump">48,586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">23,449<span></span>
</td>
<td class="nump">23,594<span></span>
</td>
<td class="nump">18,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">38,774<span></span>
</td>
<td class="nump">43,257<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Western Hemisphere excluding U.S.&#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">6,125<span></span>
</td>
<td class="nump">5,750<span></span>
</td>
<td class="nump">5,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">2,737<span></span>
</td>
<td class="nump">2,708<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Asia-Pacific, Africa</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">16,789<span></span>
</td>
<td class="nump">17,275<span></span>
</td>
<td class="nump">15,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-Lived Assets</a></td>
<td class="nump">4,431<span></span>
</td>
<td class="nump">5,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Consumer Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">2,930<span></span>
</td>
<td class="nump">1,573<span></span>
</td>
<td class="num">(852)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">24,068<span></span>
</td>
<td class="nump">25,081<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">323<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">658<span></span>
</td>
<td class="nump">759<span></span>
</td>
<td class="nump">785<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">15,901<span></span>
</td>
<td class="nump">17,969<span></span>
</td>
<td class="nump">15,250<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">58,436<span></span>
</td>
<td class="nump">64,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">1,374<span></span>
</td>
<td class="nump">1,198<span></span>
</td>
<td class="nump">863<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">3,687<span></span>
</td>
<td class="nump">4,029<span></span>
</td>
<td class="nump">4,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss', window );">Unrealized gain (loss) on securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SuppliesExpense', window );">Supplies Expense</a></td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments | Medical Devices</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings before provision for taxes on income</a></td>
<td class="nump">4,607<span></span>
</td>
<td class="nump">4,373<span></span>
</td>
<td class="nump">3,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Identifiable Assets</a></td>
<td class="nump">70,956<span></span>
</td>
<td class="nump">53,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAdditions', window );">Additions to Property, Plant &amp; Equipment</a></td>
<td class="nump">2,120<span></span>
</td>
<td class="nump">1,933<span></span>
</td>
<td class="nump">1,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">2,302<span></span>
</td>
<td class="nump">2,286<span></span>
</td>
<td class="nump">2,140<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember', window );">Immunology | Pharmaceutical</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">16,935<span></span>
</td>
<td class="nump">16,750<span></span>
</td>
<td class="nump">15,055<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember', window );">Immunology | Pharmaceutical | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Sales to Customers</a></td>
<td class="nump">$ 11,036<span></span>
</td>
<td class="nump">$ 10,843<span></span>
</td>
<td class="nump">$ 10,175<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ExpenseNotAllocatedToSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expense not allocated to segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ExpenseNotAllocatedToSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_OtherNonLongLivedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other non long lived assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_OtherNonLongLivedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RegulationCharge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Regulation charge</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RegulationCharge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquisitionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(7)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126954596&amp;loc=d3e511914-122862<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10(c)(3)(ii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126954596&amp;loc=d3e511914-122862<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquisitionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941158&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income before income taxes for oil and gas producing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 235<br> -Section 50<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=126939881&amp;loc=d3e62136-109447<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126920106&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI https://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SuppliesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense associated with supplies that were used during the current accounting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.14)<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SuppliesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OtherIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AurisHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=jnj_Wholesaler1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=jnj_Wholesaler1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=jnj_WholesalerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=jnj_WholesalerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=jnj_Wholesaler2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=jnj_Wholesaler2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=jnj_Wholesaler3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=jnj_Wholesaler3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_PharmaceuticalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_MedTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_SegmentsTotalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_SegmentsTotalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_ConsumerHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_ConsumerHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_ConsumerHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_GeneralCorporateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_WesternHemisphereExcludingUSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=jnj_AsiaPacificAfricaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=jnj_ImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=jnj_ImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428776382864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions and Divestitures - Narrative (Details)<br> $ / shares in Units, shares in Millions, SFr in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="5">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 22, 2022 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Oct. 01, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 04, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 02, 2022 </div>
<div>CHF (SFr) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>CHF (SFr) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 03, 2021 </div>
<div>CHF (SFr)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Notes&#160;1 and 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,231<span></span>
</td>
<td class="nump">35,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,393<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,439<span></span>
</td>
<td class="nump">32,116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset write-downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,216<span></span>
</td>
<td class="nump">989<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to Acquire Businesses, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-Lived Intangible Asset, Useful Life</a></td>
<td class="text">14 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">533<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability, acquisition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,056<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">783<span></span>
</td>
<td class="nump">900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts', window );">Acquisition related costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=jnj_NonTradeableContingentValueRightMember', window );">Non-Tradeable Contingent Value Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends Payable, Amount Per Share | $ / shares</a></td>
<td class="nump">$ 8.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=jnj_NonTradeableContingentValueRightMember', window );">Non-Tradeable Contingent Value Right | Class I Recommendation For Impella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends Payable, Amount Per Share | $ / shares</a></td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_IdorsiaMember', window );">Idorsia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Sale of stock, number of shares issued in transaction (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="nump">11.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction', window );">Sale of stock, percentage of ownership before transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="nump">8.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit', window );">Proceeds from sale of equity interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 357<span></span>
</td>
<td class="nump">SFr 337.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock (in USD per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ConvertibleNoteEquityInterestNumberOfShares', window );">Convertible note, equity Interest (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
<td class="nump">38.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember', window );">Momenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessAcquisitionDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Notes&#160;1 and 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Other assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember', window );">Momenta | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_A2020AcquisitionsMember', window );">2020 Acquisitions | In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetIncludingGoodwill', window );">Purchase price over fair value of assets acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember', window );">bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessAcquisitionDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset write-downs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalIncMember', window );">Verb Surgical Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities', window );">Liabilities assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill (Notes&#160;1 and 5)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Other assets assumed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Equity method investments, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">Abiomed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessAcquisitionDiscountRate', window );">Discount rate</a></td>
<td class="nump">9.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets', window );">Other assets assumed</a></td>
<td class="nump">$ 19,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities', window );">Marketable securities assumed</a></td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities</a></td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Acquisition price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 380.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Business Combination, Consideration Transferred, Equity Interests Issued and Issuable</a></td>
<td class="nump">$ 17,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</a></td>
<td class="nump">16,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 704<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability, acquisition</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash Acquired from Acquisition</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Goodwill, related to acquisitions</a></td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinitelivedIntangibleAssetsAcquired1', window );">Finite-lived Intangible Assets Acquired</a></td>
<td class="nump">6,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">In-process research and development</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">Abiomed | Non-Tradeable Contingent Value Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right</a></td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight', window );">Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right | $ / shares</a></td>
<td class="nump">$ 35.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends Payable, Amount Per Share | $ / shares</a></td>
<td class="nump">$ 17.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_RevenuesContingentConsideration', window );">Revenues, Contingent Consideration</a></td>
<td class="nump">$ 3,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember', window );">Abiomed | Non-Tradeable Contingent Value Right | Impella</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DividendsPayableAmountPerShare', window );">Dividends Payable, Amount Per Share | $ / shares</a></td>
<td class="nump">$ 7.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Momenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum | Abiomed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="nump">70.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Momenta</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | bermekimab</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum | Abiomed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_BusinessCombinationProbabilityOfSuccessFactor', window );">Probability of success factor</a></td>
<td class="nump">52.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember', window );">Convertible Debt | Idorsia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt | SFr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">SFr 445.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_DebtInstrumentConvertibleAmountOfLoanConverted', window );">Convertible debt, amount of loan converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
<td class="nump">SFr 110.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Convertible Debt, number of equity instruments (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="nump">9.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember', window );">Evra and Doxil</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Proceeds from divestiture of brands</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_BusinessAcquisitionDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Acquisition, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_BusinessAcquisitionDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_BusinessCombinationProbabilityOfSuccessFactor">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Probability Of Success Factor</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_BusinessCombinationProbabilityOfSuccessFactor</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ConvertibleNoteEquityInterestNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Convertible Note, Equity Interest, number of shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ConvertibleNoteEquityInterestNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_DebtInstrumentConvertibleAmountOfLoanConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Convertible, Amount of Loan Converted</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_DebtInstrumentConvertibleAmountOfLoanConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_RevenuesContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenues, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_RevenuesContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 25<br> -Paragraph 23<br> -URI https://asc.fasb.org/extlink&amp;oid=123586518&amp;loc=d3e1043-128460<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126966197&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126966325&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of assets acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=128092470&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21521-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21506-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableAmountPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The per share amount of a dividend declared, but not paid, as of the financial reporting date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableAmountPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126960272&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinitelivedIntangibleAssetsAcquired1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinitelivedIntangibleAssetsAcquired1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 55<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=122137925&amp;loc=d3e14258-109268<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetIncludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetIncludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=126975305&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfInterestInCorporateUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow resulting from the sale of an interest in a corporate unit during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfInterestInCorporateUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=jnj_NonTradeableContingentValueRightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=jnj_NonTradeableContingentValueRightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ClassIRecommendationForImpellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ClassIRecommendationForImpellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_IdorsiaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_IdorsiaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_MomentaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_A2020AcquisitionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_A2020AcquisitionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_BermekimabMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_VerbSurgicalIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=jnj_AbiomedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ImpellaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ImpellaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=jnj_EvraAndDoxilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428776409200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Legal Proceedings (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 30, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 22, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>cases</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 27, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2023 </div>
<div>claimant </div>
<div>claim </div>
<div>cases</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>cases </div>
<div>claimant</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyPendingClaimsNumberAdditional', window );">Loss Contingency Pending Claims, Number, Additional | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyPendingClaimsNumberRemaining', window );">Loss Contingency, Pending Claims, Number, Remaining | claim</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=jnj_RasmussenInstrumentsLLCMember', window );">Rasmussen Instruments, LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_AsrMember', window );">ASR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember', window );">Pinnacle Acetabular Cup System</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember', window );">Pelvic Meshes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_RisperdalMember', window );">Risperdal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_TalcMember', window );">Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember', window );">Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_OpioidMember', window );">Opioid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ProductOrServiceAxis=jnj_ElmironMember', window );">Elmiron</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember', window );">Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.8<span></span>
</td>
<td class="nump">$ 8,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Loss contingency, estimate of possible loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyEstimateOfAdditionalPossibleLoss', window );">Loss contingency, estimate of additional possible loss | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Pending Litigation | Physiomesh</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyPendingClaimsNumber', window );">Number of pending claims | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="nump">3,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_ProductLiabilityContingencyNumberOfClaimant', window );">Product liability contingency, number of claimants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement', window );">Number of claims within settlement agreement | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,729<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Loss Contingency, Claims Dismissed, Number | cases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,236<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member', window );">DePuy ASR U.S. | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_Numberofpatientsinsettlement', window );">Number of patients in settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Talc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LossContingencyReserveEstablishedWithinTrust', window );">Reserve established | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_BabyPowderMember', window );">Baby Powder | Judicial Ruling | Damages from Product Defects</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesSoughtValue', window );">Litigation contingency | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,700.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForLegalSettlements', window );">Payments for legal settlements | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember', window );">Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI | Settled Litigation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember', window );">Surgical Mesh Products Marketing | Judicial Ruling</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_LegalProceedingTextualsAbstract', window );"><strong>Legal Proceeding (Textuals)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyDamagesAwardedValue', window );">Damages awarded | $</a></td>
<td class="nump">$ 302.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 344.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LegalProceedingTextualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Legal Proceeding Textuals Abstract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LegalProceedingTextualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyEstimateOfAdditionalPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Estimate of Additional Possible Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyEstimateOfAdditionalPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number of Claims within Settlement Agreement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyPendingClaimsNumberAdditional">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency Pending Claims, Number, Additional</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyPendingClaimsNumberAdditional</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyPendingClaimsNumberRemaining">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Pending Claims, Number, Remaining</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyPendingClaimsNumberRemaining</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_LossContingencyReserveEstablishedWithinTrust">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Reserve Established within Trust</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_LossContingencyReserveEstablishedWithinTrust</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_Numberofpatientsinsettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patients in settlement</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_Numberofpatientsinsettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_ProductLiabilityContingencyNumberOfClaimant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Product liability contingency number of claimant.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_ProductLiabilityContingencyNumberOfClaimant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesAwardedValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of damages awarded to the plaintiff in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesAwardedValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyDamagesSoughtValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value (monetary amount) of the award the plaintiff seeks in the legal matter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyDamagesSoughtValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124440162&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPendingClaimsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of pending claims pertaining to a loss contingency.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14435-108349<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14557-108349<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPendingClaimsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for the settlement of litigation or for other legal issues during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=jnj_RasmussenInstrumentsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=jnj_RasmussenInstrumentsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_AsrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_AsrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PinnacleAcetabularCupSystemMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PelvicMeshesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PelvicMeshesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_RisperdalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_RisperdalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_TalcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_TalcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_PhysiomeshMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_PhysiomeshMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_OpioidMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_OpioidMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=jnj_ElmironMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=jnj_ElmironMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_DePuyASRU.S.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_BabyPowderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_BabyPowderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=us-gaap_DamagesFromProductDefectsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=jnj_SurgicalMeshProductsMarketingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428785625744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring costs incurred since announced</a></td>
<td class="nump">2,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Restructuring Charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Cost of products sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Other Income Expense Net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_RestructuringChargesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=jnj_OtherIncomeExpenseNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140428772198960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring - Summary of Severance Charges and Associated Spending (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2023</div></th>
<th class="th"><div>Jan. 02, 2022</div></th>
<th class="th"><div>Jan. 03, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">$ 321<span></span>
</td>
<td class="nump">$ 252<span></span>
</td>
<td class="nump">$ 247<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Activity during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_GainOnSaleOfAnAssetPaymentForRestructuring', window );">Cash settlements</a></td>
<td class="num">(432)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember', window );">Supply Chain | Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance | Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">135<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Activity during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_GainOnSaleOfAnAssetPaymentForRestructuring', window );">Cash settlements</a></td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Severance | Supply Chain | Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember', window );">Asset Write-offs/Sales | Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Activity during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_GainOnSaleOfAnAssetPaymentForRestructuring', window );">Cash settlements</a></td>
<td class="nump">44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="num">(59)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember', window );">Asset Write-offs/Sales | Supply Chain | Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other | Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance beginning</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReservePeriodIncreaseDecrease', window );">Activity during the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Charges</a></td>
<td class="nump">448<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_jnj_GainOnSaleOfAnAssetPaymentForRestructuring', window );">Cash settlements</a></td>
<td class="num">(439)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveSettledWithoutCash2', window );">Settled non cash</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Other | Supply Chain | Supply Chain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Reserve balance ending</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_jnj_GainOnSaleOfAnAssetPaymentForRestructuring">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain on Sale of an Asset (Payment) for Restructuring</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">jnj_GainOnSaleOfAnAssetPaymentForRestructuring</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>jnj_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReservePeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the accrual for restructuring costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReservePeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveSettledWithoutCash2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in the reserve for full or partial settlement through consideration other than cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveSettledWithoutCash2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=jnj_SupplyChainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=jnj_SupplyChainMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=jnj_SupplyChainMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=jnj_AssetWriteoffMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>jnj-20230101_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2022"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:jnj="http://www.jnj.com/20230101"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="jnj-20230101.xsd" xlink:type="simple"/>
    <context id="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i0c37a522bee54a7797e1e6cb838f251b_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i24117e0479bb43b39fee8a31afe69358_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i88ae5583fd7b47fd87a649c4e0bfef49_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i1602ec71af1c48e8a8514b07a9371e2d_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ibfdad04f19eb4b2788c13457aacbc7d5_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i2a6f74ddd04b42a7beb1b698b449e828_I20220703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-07-03</instant>
        </period>
    </context>
    <context id="id42e890d27894b429fe640211353b83a_I20230210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2023-02-10</instant>
        </period>
    </context>
    <context id="i5b376816a5e84e09b89d79bed596a4a7_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ibe67d998d2674637a9c218fa218dce7d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic330177c89fd42f9a9a64f7236279ef9_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ie0d81a2faf2847ea921dc2fc7b6a23ce_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ie9807f0aec4641a1ac4bec134b355aad_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i86826cf58c434c3ea3d165935690175b_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i6c5dd290ffc74ea1be26c69d111518e6_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="if2730b868c9a489d915184459e52ff91_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib7e50ef6296740dda9036c6c59bae7a8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9a2bd92352194bcdb8a871945d2b04b6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ie485eb6b64444292b2444b1661ce61de_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i81bc749533a9432f82631e2ec08fb7c4_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i011816d4a7074b90ad92edd54a14570a_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i22968ecd8b144767bf02c951d4deb7ae_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i646e87c85036437b9c9703c88ff78a63_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ica40f5d5420a42c4baf327e28f3ff166_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ieade5efd55fc4e7f9b55b76ad9b270a0_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iec1f1ce9d602483b960c5f739d33f211_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="icec2276dbd2e4d76878d45adc66f315e_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i3ef1d9f1b2874c9dadea9df7caa69641_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ia2339bc2da5948afb7331d7646e12408_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i9b341fec469b4745a481f3935cfdc814_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i0bd8a9ce6ebc4c33ba835359ee340f7a_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ifb64fb4e20f1404cbc6e31613ca7eef9_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="id693fb46504d40baa0ff184c359c60c3_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ia8ed0029b3204669a3f2d23dad442d8e_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i9e876c735af9409796c44f0d4a41a05a_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i4b74a9312aa14cef802c651c6aca0f51_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i4f6dd96b61df4014b63f77ec38d4f931_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="icc105f8c066041479b85014a44b4f246_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="if67355a8e31e4d4e89a2d4cc2404fd2a_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i1a7641e1bba746ceacabd5c374aae1d9_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i5bd05c5ccad24c3e9251efadcad9b101_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i1c19938fb98647cb9ab6821478e99ec4_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ibe54a493eb1a41b6b7d5520bdcfdcbf9_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i6f076cad0e094616a814262376cb5191_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ia4852527980040579d16cf952b6a58ff_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ic46c5718fa2f417e8d7f7298244c427b_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i6908986b3f7946f8bf4a62d5cf5b646c_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i220866b1cfb44cf7905eb75b0089e1a7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ShippingAndHandlingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i02fac9589cc2476b800ec305e2b17a61_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i2cdccdf73d6c4a2d8ad6277d9b89cbc6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibd8fd68737c9443dac923965cbcebb07_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i2ba832f9031d440b8709fc80396eb47d_D20170102-20171231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2017-01-02</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="i6f986503ddc443e8b150a30eb4915336_D20180101-20181230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-30</endDate>
        </period>
    </context>
    <context id="ibf53a7687af04964921188585c336575_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i85c32c30caff4e45bdfc303e877e94fe_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i6bca58ccfae247149a00663f0e2670b1_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="id6f10e7ae95e4d70a2beba21fbda5a78_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i8467c8ec68cf4654bf1cfcdfa1fe2c5a_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i67038bc29ba6469cb0cb5ca65068f855_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i632070131d164fd8a05baaff80e0d485_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="icacfc2ccbd7d4914be4e26893f91b754_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ib93e73399a1d41008b08bfb56335dc30_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i00843ad11c494c3fb53ae75e01995264_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i519faf5a8e3a4305a459c43d43018179_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ic073077c7dc4462981e17199faf38094_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:SovereignDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i82c0433d6c4941c9b80bb52a13ddf638_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:RepurchaseAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i1a78016e63d142e2be872b5982def0bd_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i257e8511898a47d39e8a99ec93263f31_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="id9c9e2118e3a44a88a2ba07a0b756864_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib4c98dc571d344a8a06b677c3e8a1699_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:HeldtomaturitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="if181e914ddc64a03888d0ef1285d38d7_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i3ce066abcfe8429094c975b988b24365_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i75b15a0f49774cf698bedb20449bca68_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i29a1acc3c1844b598aadafb03da80979_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="if115c6f434d64fca899b4e6a5f072637_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">jnj:LandAndLeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ifedc4ec86cd34c35b9afcab55baa12c2_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i8b40c1d088ec4a9789ae9b2483d16368_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingAndBuildingImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="id891cac7e84b467ea4fcc3186ec8542e_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ib504a49900c149668603de87c85be222_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ibacac16e36314568b61aff5d3e80baea_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i01d8e5a2c62c4ce184e8d87099bffb41_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie9e0ee8b5a704aaca8a9274822576332_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ib9408b29849f4c0b9380a8d9f61c6f3e_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i282196aad12c47c99220e44da280b8d8_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i247541d8f154426a91d3065202f7ea83_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ifdfd1b47f49946eca78fbf8f06e72987_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i626b5e4c6aef4b478b14fa53c5ad89bf_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i406e87a2fe59450390cb44ac1a234e33_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i4d2228f7987c44149e5a689a665fe7f0_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i0e228c02951e4d53a756f82e5d074c5e_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ib43d5a9a7c574ba0a893b62c4b1938a6_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ie439be9218914ee6b4279a8133fe851b_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ib42b110678ca4863806a1d2bf6bd1bcc_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5629ac5f2c33469584439760fbeaa46e_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i7f72a14eea6547cebb097d81ee48e0d6_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i2c6099acc42a42639c659499eeee550a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib4784eb1517047d9af150653b71eabfe_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i85328680ec914e0d9a276b4db4c66dcd_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ia324deef03f5433486883e8775658b95_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ie72473fe7392450db0865cca43131db3_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i0fe95ef042a2429798d99a69cf874da9_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i1379957dc92040fdaa4530fe7c7b94a4_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PatentsAndTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ie385825a1c3f41b6b5d0e02f82243bb4_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ie7a29114e911461faec7fe4e8a9d1d04_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ie9ea9658839544de90b002aa4a145255_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ibc88406d872445a3ad6785a8573a5a24_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i5e54799bc7f7459f8e4524bc93b31c2b_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="iab47b85ba2e7444aa7e1fb2845fe47bd_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i6c2143b059d34074a2a1c452daf27abc_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ia2bd3f4828754f62ad5a5f11c2503d8f_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ife931fffad564c719966395e598010a2_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i8ab96c6a2a554d78b428a02174937f21_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i3e6a3d10477946979e7db7037955a625_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i8b66c56f1d944b9798daa8b8b05d751a_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="id306832042b14bc3bb6e213608544feb_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ie74a64d7fcd74669819570ee01cfe012_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iead1aa87d38f45fead8c4b6118f2e9cd_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i6e3bf19e86414044b7432eb058f5401e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i862297e326264912a68191b181c4f8ba_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i328303dfcaed4235be1c6fb645ddafa7_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateSwapMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i639b622f74424cdebe2c37fde791f0dd_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i1fc528ec58784d3da8a3590dbabf6c70_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="if363846d56154bcfaaaf3101bca3794f_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i28d922839a92453babec3a62e5dd77d0_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i73a1657c370b446a9a91aeb39ed80cb3_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i9b9d25facfe14e558d8538281e17e27f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7eda7450d4d9456b9e83912cf600f6da_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i98e6ade62ef44067805f023366e22a49_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i81d9971dcb124172ad9892da8f77ed8f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i0c15d323b29d4f51a3b0277a6efe9fcb_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:FairValueHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i260cec3db7e141a7bab9fbc38d51513a_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i5af51b0799c94e2f99fb3ffe042cf726_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i82dcae20ab7f46d58205e38411c02bc4_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ic45912abb9de446ab846fa3d96ef734b_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i56073f5e045041e085b3b01d323734e9_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ib6e64db864e94433959e07e907b7df1d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic55999a6bc9a460e938066f5c6f50247_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i4b7dae6e9bb14eb495b8a03281389def_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i44cb3ddc5bc04bb699e468e1eb79f066_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i5e4545ac2dc1439cbf7c13f15c6f32af_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i3dc946cef90d46caaddb4f18c8fd5893_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="iaa09240ffe5c45a493822e57c2dc3858_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ieb9f80f9c820492780c7f8c91535919c_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i14cee3a2fdc941089f344ca72308f0f0_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i59a01ed372cd4e95abefcdf0e51356aa_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i8143a538b2e94972a97a82b7e6ec6c68_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i1b5eb91944ab42f6bd12eae5c9d5ae5d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ifb690af5f3694f69b7b889d872aeaf05_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic136e45ed1b94c44a821b42b608d5c9d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:InterestIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id7980b23189f4bc7b2e93c0103862863_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i8ef91f5dac5a431b8628840f5ad90267_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ia55d14fcbb70445388964f5f5d173a93_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i237858b83a9d4cf297ac85f26bb8ae97_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="iab7309c98649499d9713793656af22d7_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i83f081c66b1b450a84f5571770ed1022_D20221003-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i12f4dde8b4404aef8dca3c97bf241db1_D20211004-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i2e7e250084ad46a6a9cbab407dbeb7ab_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i8c81dca775704665a78c37783de6d091_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia8d53c59ceef44b389961dad508f831b_D20221003-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-10-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i4ae9179932924168b60062ab11671493_D20211004-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:CrossCurrencyInterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i6534a66bb873492c8df03d6fc07250d9_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i828e3ede8e3549dc9f5058a9b4b0483e_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i8bb50a86cda447408f1cd7369b0d9418_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ia3e4435e5d9a4e60aa7205751e72f33b_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i1f2f9ac2b4014e1fbb1ff7315cbbb47a_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i5db883efd7e1433a90d82a1129bb778b_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i3133d52c339b4153b25eed2e42d701a3_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib0a9dbd90e4e4b16b09008c309918698_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9771bb6b36dc4c2eb9a95f16e382664c_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5daa381fed7742f0a17f958e3f55f3d0_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:OtherInvestmentNotReadilyMarketableAxis">jnj:EquityInvestmentswithoutReadilyDeterminableValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7375a9453abe472696f28e9901817945_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="id2864e7cf41c41f3a7a0337f807e5568_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i3bc84e4de9ae423e8fd3d6a2ad33e500_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i14578454fa464922b37380e635487d56_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i0310802ba8b84af0ab17442fe8266124_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ia39659278be5497eb0de37bcacef7e1c_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ic3d82bd1550d4cf091ae15cb452ce838_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i7c9291dfb5a14a27898df7a62b8d588a_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i29258a2318d3469e9984174d5a29a387_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie48b117336c44afdb375a11b9255f3b1_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i5ef2c7f6b53641888829b0aa74f1baba_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i10c2690afca047d8a831e4a7983bda38_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="iff70c34dd9b948dca087b12faaa08430_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i38d00501bab6464fa7c7be34c6d914c9_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="id7cd5b6c455d48de8f7bf42de3895a90_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i1fa9b7b2390c4ef88b1b4a20e07ca293_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i853d7b4b73e148b18f6b3d77f487972d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i4535c102f78246f28d354501ec8be219_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i9da5b69b8f28444dbde29713e7b26de9_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i141ff0a4da5940ae95c9e2df4dd982b2_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i33c7604b66f44fbc8b00fe1f4ef4b6eb_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ia68fbb4c6ced466380b79a6a0e444ecc_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i3935ca62623944f3a9d651e98ee70890_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="idd838f2728344154a7eaa225122dffc9_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ib4be09c6f2a742c2872a7b5200cf5855_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.250NotesDue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie1be16c858d742f980612d02fd786f2f_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.25Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i4adc99f2fb284c778be3f71c61bc0de9_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.25Notesdue2022Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i5ed0d053a547493695781065ce302590_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i2c69578754b841ad8feb98ac1c3242b2_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.73Debenturesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i9b6971f2c45b4b4bbe271ae191423bff_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ie38e52b1bfe842649d2000136af597c5_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.375Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i5182d9f822204a00a480cc34f4ec92a0_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i8fe3adfe765241a28bf93429cd742b69_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.05Notesdue2023Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i34b79ae775034104a023060dd2d5ec9f_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ie437d7bfb45f4c6995ab0a136f5c1320_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A0.650NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i5971a213eabf4160b6e3f25559619b06_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i12619cfbbd3b4411975c686625cd4ee8_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.50NotesDue2024Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="id160170994a44083bc75890cadbe9623_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="id4b486d1b1024bb589a658274877269a_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.625Notesdue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie9afa533d623446aaad16fd946291ca1_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ic5bb2d0484d64d079887869bc2c1d3d7_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A055NotesDue2025Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ia73e0d2b294240f09389800e85e374d4_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="id09ef46ccfc64f829b503e8d23112272_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.45Notesdue2026Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i8e41ec0707864b1b9019a8e24ae75a97_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i168bd65ad6a0451d816d411b7f64f62d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.95Notesdue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ibeb93d53afa248caa20093bc023648b7_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i22bff2ba3f0e400a90a0044c29f13928_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A095NotesDue2027Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ia496b34d6cb74a168adcb5bf7122133e_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i92f030712061450fa2980a5ce6c8142a_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.150NotesDue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i7258a1e04b8c4f889adafc8d5386fd96_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i602d89dbe75f4f748c2295cd5de57aec_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2.900Notesdue2028Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i423501f49ac54505aa65ac29a7fd6d80_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i26d49418e0d74c1189e8912cc7d7675f_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A6.95Notesdue2029Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="iaa0326f0db384917ad2a786fa145a98a_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="iaf8bfdbb53ca42e3af2e559cf8fb62c2_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A130NotesDue2030Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie15d3b834f6345ec822ccb7085d7c0ff_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i8db5ee980d1342e793d3791eedfbef40_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.95Debenturesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i65b796c75e3b43b6bda7c9efb4daa55f_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="iad65bba4399943f9b1454685a4155820_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.375Notesdue2033Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i0dd231a0bb104e1684521862f1414b9f_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="idfedf7be284043c98fd18f790c2086ec_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A1.650NotesDue2035Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="idd6fe30488d441739d3babad588015ad_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i8a23940668d946ea8954481965daba62_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.55Notesdue2036Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i6ba6c50490e34f12bda5adb99407a82b_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ibd4cdb4f57b84232a93db6b02e61c82d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.95Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="if509cd02d4494abc9bae248548e9fe2b_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ie8dfee6b2b9f486783bc9cb6cab9a4dd_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.625Notesdue2037Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i26b8da89821f4ac284bd3d5d3cabf51e_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i1cf6df4972c749909f6092392e43369e_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A5.85Debenturesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i696b5a358a7a4568935c7e93c24e7f41_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="idd634615b6a848fa8f9569f674e894e6_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.400Notesdue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ia7967ec234e94809b83f6d22fbf9ce9d_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ia97fbaf7b43e485e95cf7e8916d74a96_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Debenturesdue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="if61dc0cc1b304eaa99917f19dad110d2_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i83fdb88fdea44eacb07ca88b7b8ca7dd_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A210NotesDue2040Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib9293aa9d30342248d3d85c512c81764_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i565be597706647e888d0c0ea676ef094_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.85Notesdue2041Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i26f202863bc94082a97d142a46e8d1b2_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="if67ac9c2c837491fa49ff3662e87bfe1_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A4.50Notesdue2043Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib10ffb3abaf54da0b43cea2e2ceb7e08_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i1902162eea4549f78cee91e0c0156868_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.70Notesdue2046Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i91feec6def3047ae92ab21665e29fbe4_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="iefcd48741e0b49cebaf892a4bad31d22_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.75Notesdue2047Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i4f24fb8b890841428b85dac4bce5953f_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i86d445ff094d4648b596d34b86e80355_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A3.500Notesdue2048Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i1fad250982dc47abbb5a254928d9895f_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i0e53361c290b43718ffeb7cd8f9afc2d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2250NotesDue2050Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i46a29376f79d4b30a03d32aff4ccdfe8_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="id01a95b64b3942d1a96051a89d5e3413_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">jnj:A2450NotesDue2060Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i80f90c4157e04d8cb1fd3fca5f4ecb65_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ifbebb1875a3d44ca9658f3fde18446f9_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">us-gaap:OtherDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="iac989accfda349e1b99a6c9cdcdcaa17_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="i4f53b7ce48b043d2944b5ea32ee20998_I20221130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <instant>2022-11-30</instant>
        </period>
    </context>
    <context id="i608e0e39b1eb42ac87ce9ad42b7316e9_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i9d8b8a1c1b90452cb498943d7fbd6cdd_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="id2821f9be6044964b18bd8dd41179df6_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">jnj:ConsumerHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i93cff80013cb4ca0867d9c8d85521e22_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ic658f5e90fb74521b314a6664d0b97c5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i5117957d990a4c01bf764aa9f770ef81_D20211004-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9fb809688a744a4ea19a1ad0f2b4bf9c_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ifaf8a0dc444a439691c1ba9c0fc72e52_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:RisperdalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9abf5a6f4dd843c6bdff0c9b78680b08_D20211004-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">jnj:PurchasedInProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic88fac17377d4247a40066aad9de7fc4_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id39169ea988c4eadb476790566c83233_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic89e3ab0d07149d68abf9f2332bddb1e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OpiodsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id40d1a3a2e954c59984259c6a56987f8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OpiodsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6823d2e54e284392b4c4cc465f125c28_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityNameAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie38c867d387040219eb10b7ae2cf8194_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="iacf23778894f4cb882f12ee101a37225_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i381b1781da63498caf01563beb9220f8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i160fee01a45e4e15969651172a1b8a52_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i703d5232b81a4b55936dd90e0dad0606_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i8c7ef14eeaff45dba385c284096876e5_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="iee7e142ff6024167983180ffabb98005_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="idfb66bf1fb1c43f6b51ba191f9fdbc89_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i568e2ee4449d4f8280ec25b22561b13b_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="idf25c935e9904a50a945cc29fc06d712_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i1330068050ee43c89fd0edf712d3cd33_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i89994b04ef5a4989828cbb2641ea63d2_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:QualifiedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i02d251447a4644728a4ec4ab07eeee7e_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i2f5c5ef2ccbe491e8eae45d4c1b715f8_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:NonQualifiedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ifbef14fca11e481c8e30ad28994f26d9_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i4ee98d3d2af347e6aa674a643b6056df_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:FundedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie6f2b519c9234298b0417a7077818079_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i2c2557ba884340dcb35175f91b95b324_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">jnj:UnfundedPlansMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib9ef98128abe4aedb0a5007195b08de1_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i92a0708b59e24d4ea0866aa54072a7da_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i2c0a56ded60c4a9bb35be25cde1c1637_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ie6a1005463744b0db3476c6fa293b2a7_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i8b5854265567407d8c334a909d643d48_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i22e0ddcdbf4c44c2a8e38032719cfecb_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i065c9f2a0f964ee285c2b8a25d0a06ec_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i2b6a8806889b4e03a0a58daf7c2e8756_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i9dd0d8c6503a45b587ecfb92769cc43c_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i74650ae05ec94371b9d6bc18a602bdba_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="id57112356ae147f6acddb2fa2ef3c2c2_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i91b00037a81c40799e88359b6a3d230a_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:ShortTermInvestmentFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="id4e0173b76424c5f8b69bc8e9ad909f3_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i11c5835ef6d041e0a21935aa096c3e34_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i89fe4d1a68ff41478d904f10e0e0ae0e_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ic6e4971765ee45178f66de2094bb223b_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib2558baea70f43d6a6cf9affe1cb228c_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="iaaa2fb24fe7f4913b81bd9b6e6a69211_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ia65b35d656b7404cad2cded1a7f84257_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i13253a658c83423ba8e9c1af10e40f9f_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="idfffbb437b674ebbad4375b66a624388_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ia30472b13c2c42c698c7f0512ec7426c_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i6f96d2d3087247fea72a69f7464a8ffe_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ic562463a901d4f7d98741278df63a71e_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i040ae04cd8d34049b557c7754b4d1903_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i0a4136d235304b9ca96dc52ca2bae31f_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i3aca2e86db254efcb60046d3b1959e83_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i629d668c721f43fa9a69ae248da4c767_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i27927d8dc21840e0886a91b302a75133_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i72431f66c0344014974314a2d6fcebee_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i6053a0abc1f746509f25b60b89e316da_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ie1c3b856e495487fb9397d837ce7430d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i6a93ad27dcc346cb8ed7ba5d19476117_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i34cf66c98020432c86dbfab2c8bc0591_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i907758fcc942478385fb4e997c7b28e4_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="if460c561b88c46f197e086c2eb780175_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="if667a81b90034bb89345e0e86dc1c837_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ie873bd0c000344438fb4154226263234_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i14706b8e4e9b45fa8ad2b00f7b025b13_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i08e5d2a42732496faba5e2998478e99f_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i4c63ed9d635548eda5b40167be502d34_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i5c17edc19d844447920bcf55fcb965c9_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i9464afb4525c4171b9f7c85f564ca383_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i678ae776bb3e4394807bdb4118962522_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="idbdd72723de74d5ab22897210e1d235d_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="id16f7d3ae47a40419613a4e6ebcdf931_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i94f0cc6d1b0143a7ad0de6a6b7171527_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i1489b8c66a064c22a4d320bbc28a949e_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i5684bd25916640ce8a21cd76052a6a5c_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="id5175417cdaa471eb56e2f0adbf22f49_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i4522e617517843a2883f058c7048bf98_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i7f898d8c94c649a4bcd40d0903b33a8b_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i6d78a014cb7b4600b9b987e0c8d3ef4e_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="if9eedf365257482e9a59a6c5f27d0a37_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i409919d7e88f41b790a753d01b52083e_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i5db77b85a6024162854cd564cb20a41d_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i9e09026399524065bc97affeb43c546d_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i199aa9d6185f445c8a0e845551e8cd3b_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i44bda01bf133404387afaead8b97a718_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="iccce90dd21004e5daf45ef5005ed0551_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="idd19fe4f42064eab8bbfb528aac6c080_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i74f4b70efeba4325a8712247faf7b3ff_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">jnj:CommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ifc3e95d2480f4b09a43e8526cb530ec0_D20230103-20230103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-03</startDate>
            <endDate>2023-01-03</endDate>
        </period>
    </context>
    <context id="i3aaa8d30ebdd4b799164c6d64da029ec_I20220914">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">jnj:December172018ShareRepurchaseProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-09-14</instant>
        </period>
    </context>
    <context id="ie95b18f0bb224ce39159e2cece26a7de_D20220914-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2022-09-14</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i998292a4720542fb97323e8a21027018_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i11d2f866128a4c0bbd34f29e255e2e5e_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="ic2e5b348e871404cb444f06edd6e8a44_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i72f9f2cb97f549a783317a29d6bcb3a6_I20191229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-29</instant>
        </period>
    </context>
    <context id="i4bdd796b17934806b83c05e06ce34090_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibdc62ce8bcb249e58d2e978447347cbf_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="idd018d59093549458cb4f3761ccbb821_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i7b330b391c664593bf5ce01ca6a9e387_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib1263a8933f94cd2b1db256f5159e8c1_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i86541415a18745ad9fad6d5a9da21dab_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i56cfe48a1389431abade9bcff2c63177_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5a4b14144c8b45d7b5c9ed3c00162124_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ic08350f7471944cfb12cf9ffa56a221c_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i503c1b32967d4343a8eb327c8c6be661_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i602c299adc484e92a89fdcbd8f6fc8cc_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ief3f111fd6524bf78a21c828a283c3d5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id0b83f8ef9bf4d359fa8bb52b6dc3fcf_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="iaba6b6f0ecea42ebb8ac410bf2612423_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="id1d1b96425db42a181eb410f603a9c9c_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i43fcad8870384544ab9df6081f406c7f_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i71c7679daebf4d0db0b277193d8ac50e_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i76d61a4fb2f4474181a28e27ff866f5d_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i1fd635367c6c4ca58981a78d2275f2cb_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i4d00a4d2722e40608c24963350b6de0a_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="icf4d10f59ddd4ab8bd56434bad43ae20_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i5800e1082b6146cea9073bcfbb7f02fd_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i6e067c6346f74a20b1c0fe95515d8e9c_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="if4ddbcdadcf848e69b32b80c8a7d34f4_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i4a0e319fb645457cbe71977be1f29fdb_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">jnj:A2022LongTermIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i33dbc6eb904844ee90275f3f8b7ed3ab_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i8ef74a38473e44019ba37eeec97c7385_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i847f3b4e40ed4892b6cd1c9603a89184_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i14d568c675ed410f94bed5ff0929c46a_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i1a71324ab9d241068eb20d3f9cd41ba3_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="iad9b5fbc5ef141b588c3ee79455a9741_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i07803580a3e146b98a24a385beff349a_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i34afa7b8b8a04ccb830c793de735eb10_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i1b1e92a43acd42e993eb03a79e248489_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i215808acd76647669f725a762f3598d8_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i354df684ca7745c6aa4c8a3b46276a9b_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i4c10dbb3a1594a2d8da6daba7890426e_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="idf5256f81d8e4f98b3cca09bfe121aef_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">jnj:ExercisePriceRangeFiveMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ife13ff98e4674d7694f59286307e1d2d_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i3bc3aa29768f417584ae7a6a6eda8f3f_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ie2cad4d651314028b720522ec64631ba_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ifb399cca07bf4bf1a81d45b257cf9c08_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i71da035cf1914f3b9868aecc174233de_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i6bc0d59a1f134f84a89b363a070d1183_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="iec99756e458a459cb8bef3fdab17c001_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ib1ec1e614eeb4b98a73fb86f9046cd7d_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="iab9745c050214279b0fa340682e40433_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i69db6ec00d174b129e0e5cb215633ec0_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ibf40cc2fafb74f6c9d2be93eeff661c6_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iec1fd52e3482447ea1b11486ef26a9be_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2198f462491444aca0da61923b632a27_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i6ce09bf2900145f1a937004d1c00046f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9f84b91d4aae4af0a05f5090f62c6609_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i58914e95bbb84bc5a9ea2cb7385bd869_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia8a784927c1c4189af0712f9727df3f0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id4e29289044343a48f06844e7131ac18_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="id3ee2aa1541c4993ab5a6731b5086c7d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id2433209091f4b3d9ccc6502e13af23d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5735f3b990b141e4a4be776a1cc02da1_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i62fff57daefb4ad48862e19671a6dc9a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i439805017432405eb34a20668de55a4a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ifcef65e498e74c66bbc548320bf01eda_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i56cc8799267a4d1bb446fc871370346d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id06a8fbb2c854362baef8d48b3e539ec_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i305f2baf4f5040bfa89c742f613cb693_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i1bcd6c0066854e439a15990c5325aea0_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ife8ad7f9de9f40939e7def44ca83e3cb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i575246cb13cb4e958a9cd5c6a9682cc2_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ia568e79890ed43dca885e271433dca1d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i6438bc69468141788dc7dd15c2e6f0b1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SkinHealthBeautyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i740d75bd86104d0c94afefc9b87d51ef_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i8aff1a3d834643a8840f76c325a3a99f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9b07581a92b746fc9cdb03ab06449ec2_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id6514fba7e78484d8e9d6a382b648d8f_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ieef3ea0559af465c8780f85fc9c95f1d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i187c9f9d5d5349338afe50224cc27c1e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iaf17bd3c525a4b3bb0011ec89a64ff51_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i193f625c1b214c7793df54d141c36d73_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i042187f7809d42bc81ee957ee586ef6b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OralCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib5671c06ac22418998bf233fa3ac24ff_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ie1f0e48a118f4e0f8d62b1d1fbf833aa_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i2cebe4ddd2e04f1cb5a741a9533d0a67_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4fb8ac4e52c9497b82e8cd22bd29d272_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i015e212fa198442b8d18e922914d6075_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i81bd67b3b0634ce4b563b42531da6b02_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i001c88dc32694c0aa767413204814f97_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="icb68778688b84eec8b98dc05b1c73823_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i3ee93092fc834bb3890c0d900445063e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:BabyCareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3aa6061cdfda45b48d4a19e23fa32015_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i1c2531fa73d44239a380b2362f5e121d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i8578159027f24dcf86568156693183a5_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id93ba1dabe3f4b5da204b1077b4518d0_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i3bfbe7c9fccc4c64b09c41d52ad70175_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i263452e9213e47c886650ce7cb371065_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i9d7ed3b7665e416388b6a9aa612a4869_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ib4896b102e9542ca93ed851ae014915e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i1269622a495a4e64ad8c2c22a7e91280_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WomensHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1fb3b41722c44fb497e08d86ff98bf18_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ib1082a9661ae476683c756bbaca58883_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="if02a3937e37448db80bbb8a99ffff4dc_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2292a22d2f6a4e18acba13c92c14b1c3_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ib87733bbde604e8f9bd05fb51223e407_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i34a442a0814740f1a1e5b57d6e051977_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3285a500e83d4e938ed7a18bb07f562d_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="id3c3b87812e3421384238aff93cefacf_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="icc2c65b893a44bd3a5dff496a5a117bc_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:WoundCareandOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id1ee80a6d40c46f0b266441ca6963f33_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i43d7081e6eac4175b0632049d45aea0b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ifb2956c17ea2404b80a4eb00815a6af4_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i88289ceda63741c295f461bebbc818d7_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ie47ee78762394fc48eeb03bbee8192b3_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id69b428176aa4a3cbe479f87f86f7bbd_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ieabc073d9ebf4111b8a8d92bdd0b8b7d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5e88cbad6cbe49bd8e825a7ed41c9c3a_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i4e22bab2b8ce4579a43a60a12cd1a9c5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iec93cf328ce84ef3a066a9fa498ab413_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i986b4a68a2bf4fb0ab3a4d6b014ad0b4_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="if74c6a56a65d42e393222e70b8ee3b45_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7849117524e141089fc6dba149013836_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i397c0bcfffa744e1afc241f015ce8b04_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="if478f7362b5f45038c0ff48e4dd32d76_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i002e689e81af4469875bf4167de1a9f3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i12bc3574823a42a18c54341c7e48ccfd_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i72281ed8b429494f9436d47de34888bf_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i39cd91fc937e48888264b49955721321_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i912cb26a60ad460497cb59430e03bcd6_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ie4af108e7bc8424987da6ec7762b48a7_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ibe204b8f9621439b9d7201393c46acc4_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:UNITEDSTATESExportsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3b9e7de8698c4e4b8582e62338b3a308_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i1893a467cc624e79a62e62fec246d121_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i50aef40f53704f639eeb4ead4f673ed0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i150c9d621d58436592cfc84eadbbd8de_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i1cd61c709b4f4822b6b0abb800e70ce2_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i07927d37d35247c4ab9e64a048a34675_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RemicadeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="idce1aa757100453fbf226e404cf449c5_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="iad404b1e843448c5a861fc281c54f700_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i00d6f86395074f92b284bee5e41b9c56_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie59a2dae302645e09d149c7d7a174a78_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="iafa5cf4ed7ac4030baf40b5dbd7736bf_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i692eee4c082846c498f4462756e57681_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic3834f86e6904624bfc14ea56990f87f_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i203194712a9c4ff294ad81780e8d8a52_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i0bc9b8fea3634731bf270a2f122b7d2d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SimponiSimponiAriaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia865193fbf2a4050bbe5db56a5edfd29_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i4ab664701a68493eb072fd6ca439c0a5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i16dc654ea1db4b339475642249680907_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i80dcf3087ead4df5aeb6e738124670d9_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="id3d161ddece944bf8ad540a6a199f574_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib6fdb567ab044e4fa2b02db9f1115bc1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibaf99c2470714a549d4827198b5e4306_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i42f4fa8e366c4d2b8cfaed938a637eae_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i61655eb3ec9a40bf900bfa9966b2388f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:StelaraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i75ed4bc48a164740854aa44ff42c7c43_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i6d721f0119c44c98b11f757b023c30a6_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic03f559a7b2b4eb3ad1bd1999053ca64_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i476d6bdc170f480880b6f349fe1d02a4_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i655fec7a57304dc5b69e3c08e261ce49_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie6870ec4af934c098b1c08e0fcc5d5ea_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5ebfb3cbb91849ffa928740c09fb6845_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i7187388ca7ef477bb2a513ddc7d152a5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib767315f9702455d885f117ae21d3c8b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TremfyaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iedf85e7c05384372a344804b1789a29f_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="iacae22ebe7674dd6b631866883fc36a3_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ide93fb67d26b41bcba491ed0c9028795_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib5952a4c02d1407ab7d93feadb356126_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i0d48aee7697b440ebfe16cb49fadabe5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i68ae8a2a744646ef8a4dd8027eff0ee1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6cf92bdfac4a45ff8d99efa6eaed94c6_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i3a36def101eb47b484d4ee34dde2f395_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i111650d10ac748e7a9e029ffdde290cd_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:ImmunologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i735de00a843942b69ff5f4e4395b0611_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i494446ad1b9140cebb18afa776b08b68_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib33427d3662a40198bb45dcf433c1468_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if823818df08f47e38c8e54ee1da81441_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="id9098882055048acb56f0a7daff7b6cc_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9abfdce0d16e405883d49726c32f1acb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iddcc1f0bfd31441da630d17bcd07bdd5_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i2117a45f239d496da7c89c744b4799cf_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic396314e70cc4e8aa30c901f000516c6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ice5729f779d5409483631d4dc721f7d2_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i7789339e6baa4ad0abaa2c19f511a483_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i92e52543ccad4142906214832c2a1522_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i133db46d59e84bdab73a70f71326e38f_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i2853f108a89e46679d84a145dc7f721b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i739fdbf5c9b249b5bb242066485fd13b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5e252aba7cdd4ec2a540688ab64830b1_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i2d36aaa849d34410912a18791f8c1fdc_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i65e91319a96348ee87ae160ca65edaff_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:COVID19Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i681b21f0446d4385936cb77eb4b9dca1_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ib410879725f24ae8ba0999c6d06366a5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ifeb843593c464cb18a4c3dacc904ae00_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i35f94389fa524ab289f01a52a921cf7c_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="iffe39ec345a94ec18338abc237e01452_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie433d85e7b6448d19d8075af0de26e2d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6bc2c48e4eca4c58b9de0abae4adff22_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ib44093e5c3a0432f8560133ae4395d30_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ibf0b6c7689e44b268e1b721f04f9848b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:EDURANTrilpivirineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5b87d067ef004f5aafaed64f58162f4d_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i41fb3351d90d4979bd4aade9045ceba1_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i19991ad08c1340cb8a9f12dfc8fbf112_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i186ad1cd9a1e4945a51acd1fbe039a6c_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i2534504edb8d464f8ee62a5593a78d54_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i20f893fb187e464aa1a397a82dad33e8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iffa2c64baab1439f89e0e380d54cb895_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i33b8737e36dc40e891fd7257c424ab9b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="if08b714b754d43ffa7a441ceafdc12db_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PREZISTAPREZCOBIXREZOLSTASYMTUZAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iafa49f8cb28444c08b3e7691d9289fd0_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i5b32cf9f39464d33a7bac9a57081607b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ifce1d8aac6f64a9e8d3edf11466fbeb0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6a6257c648ce4c319ca04351b1ac19ca_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ifd0f4a707d5c4611ba64f2bd6e1a1cbb_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iae286eb23a9649dab05aa0c949e37a1e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3d8e4c1f3ded4e2683fd1b1d3d7f2f3c_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i4a46b60d378740ab9a53a2c913e6fa9b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i6008938b9b8142ec828a603dc31c9ad2_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherInfectiousDiseasesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InfectiousDiseasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2cd9ba3232ba45e7b1a6b4629a8020a2_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i531f3041cd70490aa0a614493a0966a5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i0c2c03afbcdc4c75bc0ae9b17f75089b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i402fca2f518340d8af0930c93c070ab6_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i0e268daebe694083b67a5bd25ccebbaf_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9ed046d3cd9f404a967c40585336ae5e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i6d6c31d76c79411d9f1e91f496118539_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i89359ce197324e7d8e9b12c16f4d715a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie38900d6ebb345d29c6d1b684d8bc793_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ief7ad9c3131d41be987d8486d4ad049b_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="idcc6f1927b774f8d96f04fe0a712fb86_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="if22f8c6bf53748f190098078cc426ff1_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic6610d754863471e9d5a6fed947d250a_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i388399bd3edd4e449f4d93d8915eb54c_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia806a9dc2927417fa00d06260663112c_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie4a41b434b5643ac9706b30fd05f05cc_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i7c01b12144ba4292808074086604f6b9_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="icfaa8480658d47aeb19114550474ae8e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONCERTAMethylphenidateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0e93fc3771554eaea942a7d80a2a5191_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ie5235c523a314775ab067969dfd06501_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib3d7ae90ffe640d1b0883b71099f3c5c_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i03c54db2a9f24834a5cd8e9430746ef9_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ia1925b3bd72f49578ec926bb8b286ea4_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ifec5634cbb6c4bc397afe138e65efc43_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i26dc3482b6c144828d2d9c88adc29ae9_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ia24bd46b2fd04893b597d1d6c0898eb7_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic7228601370344a3b7c098e83bbcb756_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVEGASUSTENNAXEPLIONTRINZATREVICTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8cc6bf38d4874b188bd7a4fbd673a97a_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i6698df7c52e241f69da5dfaf96df667e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie8692c4c3b564eeaabf2e1b6e509764f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ifb475dbd9dd64c05bd7d3314c41d69fe_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ibe678f07567c458196735fc6dbe00d17_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i605fa23baf2f4ea78746871328fb7ead_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iae81ec5366b14326a0b7f0c13fb74817_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ic9404055d94a45daba90f61bf0fb4da5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i6f2a17cebf7348ba8a85d601ef95950d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RISPERDALCONSTAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0b4e7b35d9e54a27b148b95717e09f65_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i46565c94f13f45f4b15ef2dfc93ac248_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i269786122e034c9a8fd09281eddd8ce6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie53f9949f4d84aa5a52762670bfefd4b_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i324b80e3c3ce440d9637c080549788f0_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i84e21a76b60c423bb70648b1c526109e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i531753cbd8df46a191a33e3a9070c38f_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i26f47936bebf4e8e931a42d37ff16544_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iff8d6fee31d84079a124b85f43dd7a5d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTHERNEUROSCIENCEMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:NeuroscienceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i258d249f5434470bb702dca877dce7cc_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i1bf95a45f3b7410cb1201a2856109d72_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i262b23b4cfa3413ea822c90957dc8c6b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i24b8ea85287e48b5ab16ce511107e30d_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i0d14d3af658b449da07dc0be4f9a9b0d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7520de6a9d0449ffb1547564cab682ed_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i68e64b453d6c408381dbb9d6a4335a90_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i5c85d4146adf40d590c1b983de215889_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iab4f46984eb74afe9365b8352076078e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i42467f46f4f94427ab2e63069eef5ae8_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i6ffac75e48304352a8dfea6d5c6ab3f6_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i646423bb9a524219bf440e4800663ed3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if600a19a06ac46f1afe1fb53208669c2_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="iddfa392c8b99451a919767258d532fe5_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic353f059b15e42808dfe31fbfa26b20b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i56d81c1fa8cd49908a0537e36e44cae0_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ic0bfc95e5f50496095f0e7adbac02fae_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i081324fa191f4ecfb64d5fd21e4897f8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:DARZALEXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ic5a747f1894746c18acebe55fcee36be_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ia9952f78ff604ce98857b34e7d2d4ee4_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i56304f6c91134b9ea995c8c26f92fcf8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1170f44e3e784c13a897d1f33b657d36_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i1aab7e608c8647bfae8078c104427a5e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i98cb0d95137a4c3e932962b28dfea7fd_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia7df5c5bd36f4c42bc5a42a86e4787fd_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ib995e35deab1419bb10080c3e8bbe15f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i008fe96bbc464d418ec59e61164bd16f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ErleadaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3e40224a7adc43c8a51c165cb1091d51_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="id0e1bf9204c548b1a2ba79c5c9f86b69_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i1d65c31f1e1e4231a4590f52e12e147f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib8696093b3c14612a5e87f253f041390_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i013ed648148d4e64a510c4039f176525_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="if0ee4b03f8ff435d8d7e8b5936462ff2_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie1bef826f6694533ac45bf2390d238f4_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i9d1ab414424746e7be5d469d0581e83d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i98d58d05f93b4a88bda30ee75b9bd330_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:IMBRUVICAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="idf89a91e03874addb0a5a3f057b8bf3b_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ic89356ecf07b40f0a9a2da3ade617700_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="idea1ec1749cd4cabbe3791c077d397a5_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iee811815defd442b9a2cc33fcd46a0d9_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ie657f643b4d84751a89bb88a4ad2046b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i0fc87b939f80405381cdf5826af23b5e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i7b389620244e4707b32be2326487bc32_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="iefecdd362bfa4d2db19e395e947a0d65_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id84af39344ca4fa5a66b03352afc5e18_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ZYTIGAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8b76b01e302941c287997d97c3f61777_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i6936c2410a964df4898165a8dde602da_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie7bd843dd374433190aa473e3d8f6192_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i76995ebc9d3b42ce851ae92a54711982_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i36a27cd0e7ed41e68d19c477b421f3c0_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7001035b825b4a55830f9093152ea514_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iba577ca1802747c39cfd14db4de2c73e_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i59a17dd172ff4c2481abf0f956446b82_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9d1cfe8125bf4f15bb0a5e1a59589712_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherOncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OncologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1fe446820d2747f094272bcdc9f800bf_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i7b8757a22a8743e3ac6b47bb33abf088_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="if6d1cb780cac40c392f1b55b06665d46_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0a13564b2ced4d028a7c3601115a89a0_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i8e26b9b503db42389ed14ff2087d196d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i374baaf3b488452d89425765aac44db0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i77a7e09f6f90410eb6663244cbe7e73d_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i2cfc4b069b214a88b076bd5e9211de36_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="idf16b29572b6423cbbce71268561dc2f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5463962cffff4346b6f757fb352376bf_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i4508e19a81e14913a4c1c511d2086478_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id0255ba511594a8bbe1f7b35cf65502f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i22de2e9856b44e04a06ccf411d64efe4_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i0dc14570d9244e2aa7a97f84bbea32ad_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="icce2f7bceb104ba68129e1d88ba12479_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id6137d6c2ae845578e96f2f9558e743f_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i9b1ade7237d24dd7ab77638d8c40a4e7_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i95b5c4f0629a4cc4aecab891a4bc05f0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OPSUMITMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="icb55d931932c4dbfabf0ea3d29fbb324_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i5becc7177bbb4f019eb9d2832933f156_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic28b731dc2294261b6dbf518da9544b6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2b6cf0ef3640429391dcd90960832aa6_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i0a56ab7b9ca24f89852d9e93dffafe9f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia8e2a5ed832e47a9b4b8c86beaaf4733_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5eb95d7922c64ca28dea90d41bac3081_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="if85629f30c724cee9d887e6dd896ce8d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i3b8655d882ea44638ed3ff1d03bd0dbe_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:UPTRAVIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i30916c73190f498bb12adcd4eee7e812_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i7b7c39109744471db0921f5a010a74fd_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i3cf850e2559a44ccb6fb87628e4893d5_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib6c76de98f2c417a87e983700d3295da_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ib5500ee09e8148309c05055c79c1eab2_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iccddf880ad6748c5b0f867362c1aac4d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i799adb7b649a470ab60c3ff073dc1386_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i9059956b7ebd4ef9aa0ca0715ffea91e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i36786c954f1b44aabdb08b417155a2f2_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:PulmonaryHypertensionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib8f249bd22be4ccc99f79b41ee68c3cb_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="iaea127e21314435ea7a422bda430700d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i79f7eca78939441fa15ec6298a45d1ef_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i32cf8ca571194576b3812f9911ec7c96_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i2c3d4326ed9749e08f9f55e523f5ee30_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ibb734ded22cc4f09a1e7aa403217a9eb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i475da8e727be45c3b387f78b1fea2e7e_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i8b6d20e6fbcf404989fa7f5435ba4ba6_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic976412b06ed475dbb01665551f97bd7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib2de02b1a13d4d139855d845acf40789_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="if5e8976d4e1a4b71a27811336c8ab1f8_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id7c26f3cd65d4c5d8f2b5bd56c02ed3d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3f077fb9d5034effb52f4a2b5f9eef57_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i33a26b2938054f1184c11ed6cf4b88f0_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i6a88b4bdd8c94764a0107e43c486dc09_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie8d8278156114626afb74c2ac5266a22_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i5bd8ff0a20174e8aa35746d67cdc6c5a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i4cddddd8de4b47ea9ad8c08d1dbcfde7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:XareltoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8ea11b9899164f17b368e2e8e1fd6646_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i13c3371fdeb14d998c863d3e43e1fc97_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ieafb2d92ce5b42eba36f9dd9ad33d3a5_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ieaf051fa36294b75bbdb2a6a108964d0_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="id73e900fdc57444dbbceb802f1d0608b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib07d526f34e8412e9d6ac51ac9f427f2_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i81eec297555347958006226c1ad5a577_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="iafbedc70de804139afe4d7945d4cb53d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ifcc31dc5500e46db949b0cb3ef157084_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:INVOKANAINVOKAMETMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i5a2ef424a8a8474cac5b9126f26ba070_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i2d05b9c8081748e2a9f6313aa40cc11b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="if79c42dff8224bcd8bda45cfd70678a7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2555de19982c4c1c919234a3b7833ea2_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i1e55884aa128493da77727ae7c6d1253_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i23a8d86b9d8a4084b1e6ddcc45ead16a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i76a0c1c8ef9849838870a39529fcdb16_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ie5e0a45bdcbf45c7b2fdde90c75f5932_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i50af60fd4c5f4255ac6d02be0a13ae03_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:CardiovascularMetabolismOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i45a0926568d6467b9669368002f75388_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i17d037573a5d4222b17c5284accac4ec_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i0f866a6e7b4747ab9df0359131844149_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3ac1d092bd684cfe97e775dae9a43281_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i3b6d9f05d93342c9ac54a0fd0e292ec8_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i1ddc948c59f44ab9aeceef6ea85eea1b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i45c63832601e43b1ad4c8f083610e7c3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i850b26f85bd14a8598514f4059d09199_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="id55db4e038a84957890427287eb9ab56_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i92374c3d2722492fa34458de0e14064c_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i599608cf1f684eed8b209bd530f295e9_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i422216cc59db4c0c941301f559702000_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i20e19e67050949db82566d3868c92ad7_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if9afb09ccee54d4abc14d8bb45e5e1bb_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ia20a5ce5890e4d60b4948961eba84c76_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i00419766ad6e4ea89e37292413d0efab_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:InterventionalSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iaa1c27da4bbd4f5bb7644fd70f60b7ff_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i6abe4cf6499f44b8864302dc6a141046_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib44237838e71484c841e5e53a3a8c7bb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4be2e62190a748c1a9f9858019ad5f2c_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i7280243f94ec4714a8ecd07ad5de6b9b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7bb69c6ba5614a0da3881621e639aaba_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ie95a799c54a94247a4f4738e17ef6bdd_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i78fa9c5783f54e208617e980cb82b18c_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i8c722ac2a4a64faa8604869f789d2250_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2c379bb07b1f423494b9602d42fcbda1_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i599b25cf3d4a4566a4fb6560ac142a99_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iaa4a315b27d540e6a99eb9f14f0a2b22_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iba96a050bfaa4084a8d2900a2e3a04d5_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i74464a7622714b598ec7ac59bb92daa9_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ia431b44bdbc04745b1da9bc7e6129763_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1c3fa299f6ba45c4b222ae1e49bcebb9_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i386d38aa8c394c4f935a4311fd4ef278_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib5940e0037084662b3d6936dc73b3ee8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:HIPSMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i16a080af195245c883230bee9c30e225_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ia55cc74e40ab4d0592d91514f04f2608_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i91aa6b32077b4d2497b10c0c7a56e179_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ib6a9e1c6f9634d72a1c5c2e943619a42_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i97e2595ac4db46c4bddda29dbd79cb53_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="icacd0f9bc97a476d9227cb9d73c43f17_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i555d0de63ee2467baa26c01abdb6a217_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="if0158c50e3f843b98737f71038b73b04_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i7ad2240e53ec400db99843a0627fa101_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:KNEESMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id93d92b03daf447eb4bf22985d9d8c14_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i523f9716669b47d5b297828fd6724f6a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id3648561601548a8b97f7f711182c5f0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2a8043dcb8a040d7adcd300412045ab4_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i223e6d03e08f4f5a90b7a1f6a8ac3d0a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i346d453f53cc4ecea306f279831549f3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if03efae791104d9aa1b01944645a6b01_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i0e3094a2457647888f8c0f56ba3fed56_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9250e1cbda2047ae9863cef248995cf3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TRAUMAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4122251b77234594bcddabafeb5af123_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ie544b42a603147f09a40781c6c42143e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ibd6437ba34c148db8aeccaa67fa06cf2_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ida0bc11d3c5748e98275291ec923ccc5_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i9347c56f2a1444a78a4fc62e6b386a5a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i01517169bf524cb6924cf818325d7fdc_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2160f5b0fbab41038676a89c226cb367_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i23c7667c458748c8904119e1c5445a7e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id5c1850237ad45cda71fcf02b4cf082e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SPINESPORTSOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:OrthopaedicsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3e62ffa3592b449586bbb8ca2c4d6213_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ib476cbca912b416981dd09c3a83db02e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i1dc2f5c56a204d2d8e644eb8886f841e_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i28c6713f2ac548cc8106299c4be563a8_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="id895d721db2044efbb2aef35407c5f24_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9db4f8d31fdc492993044895704613be_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i96bb599ebb2d4c758610207a98846d97_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i2c19ae7f1d1548cf9a2a61003b3d3900_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i1b8a7dbc6dbd43db9aab7933e394d7d5_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0b2a0ef2af13440cbfde1878f560a53e_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i8a93418c3f9348089a17785066c9ecc3_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i3e5b37a473aa4e9684ab211e4fae10e6_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i96d0bb9e034b4b778811c7e9a7a32561_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i660f2a9622b542f29df16b4d0065c995_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i31bd9ea308664465abdeee40896776b0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i69a0f6c8007a466aa040c51aae63e17b_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ib47ac25eee8d470cb19fc3f3bad77acb_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i4ee222c80d4f45629294aa4cee852d97_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ADVANCEDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i92b401eaaab44d8a91db95e7fd4cfaea_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i7c79a9ae4055493892121d39b7f040e9_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i5659d078f59d475b8e7b8881e5f8c8cc_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0e13a27025ab49258fc3f28523703d4b_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i0797cce295e84999983ff7d4951ae7d4_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib8ad838c4d37450791faf447300dcf25_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i882f781054b24565afcf9d67c24e9a56_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i5ce0c967e6d044a2b3a5bc24c3067d09_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i4f2fdf8254144adc9c79f0edf1186108_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:GENERALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:SurgeryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0bc0508a06e84d47a8eff2b1d5c74e86_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i728978b4bbb44796bdeddaa130466c9e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i8ae8b4447dde420f8505681fa323ea4a_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i2f8b318c15894833b1cf92df3f7a9fb5_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i8df5c7b107134f5abf47b44faecc645b_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i5419094e757b46019b8bd5f8d7e871b4_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i0940ba1ce2fb4e058d1eb84ccb6c5e03_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i06e2030e683e436aa4324bd6a5a14b69_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic1d0785d36d044d6b08df217279ef868_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i488b67a47d294aabab33cbdf59e13a0e_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ic31b2338c66b49679900818d0ee6a39c_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i656cbb2cc38042e38ca323806c588d5d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="if2f17244bd1447cf9c736ae386f8dee8_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i8e7770d83fdd4f678c448c98a7ec4ec9_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i3fe4b910600f4a8d98db1f5f0c7b5c53_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibf869d6b3a56497f82172be314aa1d7a_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i7cb2f6bb944c47db8946085e687244f3_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ifb6de0174c394ad7878f8b8ab48c1760_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:CONTACTLENSESOTHERMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i69e5be1f408d42a6a28f913328b3aa23_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i6a6d1bdd3da5427197bae916d67ef765_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id0aac6fcbd0b4218a1df93bffd709deb_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i780835081b4f4f33ad0a3bec79b6575e_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i20f1c099cf014d2396f6e27e3f282b73_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i3240822529b343708c19d857074c3efe_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="icd9e83bd141f43718f07eebf8ae9d726_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i686d5e925e204bfb9c56b7dc9949c828_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i94d99e94b59a4dc786f934bdf8f8ad28_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:SURGICALMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">jnj:VisionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i02394e8a5d34408f80dba10b20b2294e_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="id12b26c88eb041a5b128765f1710cfff_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i0c5ab80c014e4ab6bf12909c673b5286_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ice2505dd78c947788c029470885cbb84_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i26073ee7b24f444ea78dd572e1428c7f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie04e4e86c1b24d1889b9660122ff5c0b_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia05a6854e4e147f5a99bd5f6979dc765_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i3420461825204a15b06642c0e8effdc3_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ic25e0a35046d4798afe7f6c61ccd2212_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iddce33c475c74ebcb63073bdefd18fc8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8f735f0bd8754f549f6a3d8505541990_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ia7f7ca8fc4824ad1b05a99c0f85ecbd9_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i21ae89a5e6e44a19bda3cea2a2a46a91_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i11096dc41162493598fbde3c3328208f_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:CONSUMERHEALTHAndPHARMACEUTICALMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i44f421d84e9d4a00bd90e95f56e2755d_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OTCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:CONSUMERHEALTHAndPHARMACEUTICALMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i65f83a7c98be45a5b6124322b7bd487f_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="if7d4fcfbaed948f7b96ddd9e7c955350_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i0db9c12fbc594fa39ecdd6ab21950596_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i41b31e63f2ca46a3845da852aec0b900_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i716a54942efa46028603ae4da3c07d56_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ia03e77d7325e4d73b78a0c69bf6f9c96_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ie279ec7ee04446a18580684b9417ccef_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ifeb973b453fb448c977acc62f23cfbf9_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ia41cb8ba083c40d8bb8e8e5a75a886d3_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i56d29c41cf14436b8bd0387c90fdcc9c_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:PharmaceuticalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i1a7ed898049b448889443be8ec36feff_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i2b06ba1df96b4a3e9332405eed4144c7_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ife9ff28d3f5c4f9f823666db103add14_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i44bfea2a30414fd2acc71a28c1a9338c_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i2bd8eb466f7641b58a738548f55f05ca_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i765d240ac3504d22b02095e7b50f9664_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i3c6e97913c1e42e8a73e24fdcddbb0f0_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ic546e27439c549a5930ca85efae9f793_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibaa94ed145ab44e893b1141cd2f4b6d2_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i2194cc52a1204b8bb062f0829cc720a3_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ia637975db75f4d6ca976d19b81d5d23b_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i5a13137501ef420499797d78d356afa9_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i50227f06e5f04961b0e6a7aea3926827_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="iea8f7496466a454890b32615eb14ec08_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:ConsumerHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i3d62e4d77ba942f7bd7bc31625c7c643_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:ConsumerHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="iec21bae1ba8f4a4b9e8a25cbda75c2c4_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i12f90c84177a4ab0ac0f09d5f702e4e9_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i3baea8052de54dbf99a582b503fe5ae9_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i365b842e2df647adb11480f7f5a63d9f_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i44e23d74806e4408bdef269ad289b155_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SegmentsTotalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i35f2772fa1fb464686fdad7eba530bc2_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="iad4ae67402be4d30bf0509f57bdf82a4_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i4662aafc35c84c71a32e5811a0481ac0_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:GeneralCorporateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="ibf6f3d4d30c44652ac9e77a021f74bc7_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i901d71842aaf4089b7b7a4d97fdc8942_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="id907daafbe5d44ec927b1cf4e8fcfb0d_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8bd1a077b7d6414e8935bd70e97c8cf2_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i68257c001b354a5a98508e8a0ac0e82a_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i96a3daea3f49408e971870669b0f5512_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i9fa7b3a6c25c4eada02b8646ac415062_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i1cdb9152618c42eea5013297dbf2e4c3_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i200f93e3b77244a583b1ad4b7a71d3a1_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ib112e058fb6b447dbc3310478fc97587_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="icafa0a8044c04de497b6f3dfe30d2a58_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i43130bad99db457ba44ec22f2c697510_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i9c2fc3c8e9594706a561854ef8052a58_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="id2d96b411f4d40debdac91b9aabb935f_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i01fde314497149c6b70e4d076fa6dd4f_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:WesternHemisphereExcludingUSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i20c9f4592a754d2cb500873c6ed0be54_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="if1a5151945ca4ac086f58deeeb720914_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i44509d3ef3cb4581b00a5c4862521e64_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i8ebf98b5fa324cbaa9bfaebdca053ff4_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i29d342791cfc4b03a1713eb39bf942d5_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">jnj:AsiaPacificAfricaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i8d276957b87d4834ba1ee537b68aa89e_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i0daf7a509a1742c0af022ecd6a711956_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i3fea49b8326e4a0bbb7c8f8cfee7b454_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ibb0265bad6f240a28a737ed052560826_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="ie500d8c896d44983b9c33f2ac1ef9710_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i3ae4ff8713334360a336393c7dac68d5_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="if853701b34c2430d8f37795599100d52_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ic1cb58176e324fddab800e715c7039c3_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i40efe68b209843249746ea7032375b47_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i196d06199bcb47afb512e58c6c6cce33_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib97ee1e8d98d45f78eea6e86d0d96a02_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i4dc7c4601c144f7091a2700b230221f8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i648dd03c46344752a321bbba8fc97340_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">jnj:Wholesaler3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">jnj:WholesalerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1a210155919049c2bd43c936b49f1ee6_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:ConsumerHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i0675e6e915374fb5b095d7fd0834c9be_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AurisHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherIncomeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:MedTechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i903579018dfc4744b7b1bc7085ee9dea_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i6272b36311854ffb8459a6a826a10495_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i4498e185f42a4d2c931df62d565c61fc_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ic6bb87c09ab1449d8ac694d344eae356_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="ib9836117d3a94830a8233450377a1deb_D20221222-20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="i92d127c3ca8d4ec2976b3e3c568fecc2_D20221222-20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="i81a39d36d1174514a434b80d6c743dc6_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="i8b185cbc0eed49e1bf2b12aead1c396f_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="i84406520b58240c49988945086079984_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ImpellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="i7342e69dce654189845f736621bb11ac_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ClassIRecommendationForImpellaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">jnj:NonTradeableContingentValueRightMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="i4f147e1dd45545d3abb1795f5f7086da_D20221222-20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
        </entity>
        <period>
            <startDate>2022-12-22</startDate>
            <endDate>2022-12-22</endDate>
        </period>
    </context>
    <context id="i3ea49ac2e6aa4de69e5169b63d21cc06_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="i1690230576734ba492365e566a8b6b5e_I20221222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:AbiomedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-22</instant>
        </period>
    </context>
    <context id="i3fbf2d6d15164f949f7d00b550a2d80f_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:A2020AcquisitionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i6c96d667b7284485a85bb50fece53ad0_D20210104-20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2021-04-04</endDate>
        </period>
    </context>
    <context id="ia24eda47473543d58b1d6c2d349bdfc5_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="idf3a369e46f249199404ae4a686a3719_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i829e1cea7f8840eabf95f9902ac2836e_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="ic25eb0c4ceda4b8ca2e1719553bd3d9f_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:BermekimabMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="icc8a7af544c348f792fe38f31e341481_I20210404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:VerbSurgicalIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-04</instant>
        </period>
    </context>
    <context id="i96285e2125c044239562f06c5a49708f_D20201001-20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-01</endDate>
        </period>
    </context>
    <context id="i3825927182464ac79b6e43df181cccf8_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i27aa2a498bdb4d7fb75719ee6d31b90f_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="if2ea1b03a3be4ff59976cf8545ab6d21_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i6535353e93a14112b8d587f589b7bd9f_I20201001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:MomentaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-01</instant>
        </period>
    </context>
    <context id="i07c8b24309d443688602562848d8298e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">jnj:EvraAndDoxilMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ie3dd034235f641b9a1484d7974551ed8_D20191230-20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2021-01-03</endDate>
        </period>
    </context>
    <context id="i1aee0cedf1f94f5a8d36040886e87e0f_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i5282653c940b42ef862b668ed6921a2d_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i0e37979e6ad844279246c3dd8ff74a38_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">jnj:IdorsiaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i647eea070e4240cca28f6b76979c3a28_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:AsrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i34154fc7f1e24a8cb5c558996d6b6896_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PinnacleAcetabularCupSystemMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i255cda4840fb4aa88fa64590ce872e72_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PelvicMeshesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ie6cf165cbbd74fdfbb1fa0b952e8bff6_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:RisperdalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i2c9a481d368148b0929cadc2b0a5af97_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ie47bff957cb84bb49f3b161a5860618a_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ibc66bcf7171d418a86ecd62a2404c17e_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:ElmironMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i03778e924ff348b5a3f45913272ec65a_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:DePuyASRU.S.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="iddc88969213c48ea97060082ffa73825_I20210531">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="ia897c0714e5c4774b0c045831789f7f2_I20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="iaf6a73a559664e0ebb512a48d328ad5e_D20210901-20210930">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="iac21980ceda94b21a50b291a322d153b_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:PhysiomeshMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i3682b642e54048a5b5181c77d2d45dd4_D20191001-20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-10-01</startDate>
            <endDate>2019-10-31</endDate>
        </period>
    </context>
    <context id="i5dcee1a6065d4ba0abd1619dd17fb039_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i595e23088c2c4b02bebb9612c8ab2a93_D20180701-20180731">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="i33aa324aaa9d42f4a185c9928408a20c_D20200601-20200630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="i748cd779f212410081567ad7ca01f948_D20210601-20210630">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">us-gaap:DamagesFromProductDefectsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="i2391578fa34543b695b3fb891576fdee_D20211001-20211031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:BabyPowderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:TalcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="if6878b220b444ed8b48a88bc1bfe70dc_D20220301-20220322">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">jnj:RasmussenInstrumentsLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-01</startDate>
            <endDate>2022-03-22</endDate>
        </period>
    </context>
    <context id="ibe39ec7be3e24f578dd104058f18f8a3_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">jnj:OpioidMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i8fe1e7bec0cc453594ea48b53c12aae3_D20191230-20200927">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2020-09-27</endDate>
        </period>
    </context>
    <context id="i78a211fb9da44857b52720a3523178e1_I20191031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-10-31</instant>
        </period>
    </context>
    <context id="ibd40d3a12acb4dcfbf80471e318ded84_I20201031">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-10-31</instant>
        </period>
    </context>
    <context id="ie97127abe6644e81b414d38b27b36e32_D20200101-20200131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="i3b4964f990444943801868a6dd79fc6b_D20220401-20220430">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">jnj:SurgicalMeshProductsMarketingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-04-01</startDate>
            <endDate>2022-04-30</endDate>
        </period>
    </context>
    <context id="i2474e48849f1407492b006d664c27c42_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ie567e5eb9dcb41d0a398be109e77b0d9_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:RestructuringChargesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="iaa15521dd2654667b094254ebe535fc4_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">jnj:OtherIncomeExpenseNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i49c2401f8f3d4163afe6adbe4293302d_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i95e5b2037fbd445ea91d492ad3152fe5_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i32d057f69df94f2280959b742aaf5e0b_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i628034b976194b3c95eee1d092e53459_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="i31117717375a483aba04eca1e392ee44_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="if41a7f60706e4d6c8d7278663011a8e6_I20210103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-03</instant>
        </period>
    </context>
    <context id="ib3e13d3f1dcb4123ab1494c07d04692a_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="ib8895b2c96ae49d9ab87668b6e4d972e_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="icbf00d9c7c2c47b2a38a0e33043c8e05_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i3dbe54c0baea4b92b0175ecdc2c32d60_D20210104-20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-04</startDate>
            <endDate>2022-01-02</endDate>
        </period>
    </context>
    <context id="i346e675961384d10af15a172a233f844_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i224a56e9b03f475f8ef466ec18c2e508_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i9413ac0768844d14a4e88ef98209b2be_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i7ccc395680a1473f92468bceaec711ec_I20220102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-02</instant>
        </period>
    </context>
    <context id="i78a5f0207ed948bbab5f326ccad7f02d_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i0a124d2841f84a198ab499b74262070b_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="ia22ff0765200405d8456d1b39ac5257f_D20220103-20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-03</startDate>
            <endDate>2023-01-01</endDate>
        </period>
    </context>
    <context id="i105785393ea04c2ba49bcb40429c6955_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i6235e13b21004a43a0daa993991daa3a_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">jnj:AssetWriteoffMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="ic2ba4d95af9e4e4fa22e3ffb45143679_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <context id="i1f013b59c3b14695b75acec1bdb16def_I20230101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000200406</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">jnj:SupplyChainMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-01-01</instant>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="employee">
        <measure>jnj:Employee</measure>
    </unit>
    <unit id="segment">
        <measure>jnj:Segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="stockbasedcompensationplans">
        <measure>jnj:StockBasedCompensationPlans</measure>
    </unit>
    <unit id="chf">
        <measure>iso4217:CHF</measure>
    </unit>
    <unit id="claimant">
        <measure>jnj:claimant</measure>
    </unit>
    <unit id="cases">
        <measure>jnj:cases</measure>
    </unit>
    <unit id="claim">
        <measure>jnj:claim</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y180L2ZyYWc6ZDYzNDRlYTJkNzExNDU3Nzg3YzU1Y2MzY2E0YzI2Y2IvdGFibGU6Yjk3Y2Q3MTVmOWRjNDljOWE3YTQ2NjhlYWFiNWRjZmIvdGFibGVyYW5nZTpiOTdjZDcxNWY5ZGM0OWM5YTdhNDY2OGVhYWI1ZGNmYl8yLTEtMS0xLTg0NDQ0_17befa4f-030d-4ecb-b014-bbf7de1eb8f9">0000200406</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y180L2ZyYWc6ZDYzNDRlYTJkNzExNDU3Nzg3YzU1Y2MzY2E0YzI2Y2IvdGFibGU6Yjk3Y2Q3MTVmOWRjNDljOWE3YTQ2NjhlYWFiNWRjZmIvdGFibGVyYW5nZTpiOTdjZDcxNWY5ZGM0OWM5YTdhNDY2OGVhYWI1ZGNmYl8zLTEtMS0xLTg0NDQ0_68d7cae4-aa1d-45b2-b405-6d97b9d102f6">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y180L2ZyYWc6ZDYzNDRlYTJkNzExNDU3Nzg3YzU1Y2MzY2E0YzI2Y2IvdGFibGU6Yjk3Y2Q3MTVmOWRjNDljOWE3YTQ2NjhlYWFiNWRjZmIvdGFibGVyYW5nZTpiOTdjZDcxNWY5ZGM0OWM5YTdhNDY2OGVhYWI1ZGNmYl80LTEtMS0xLTg0NDQ0_1d1b238f-90d9-4557-abde-158d499f82a2">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y180L2ZyYWc6ZDYzNDRlYTJkNzExNDU3Nzg3YzU1Y2MzY2E0YzI2Y2IvdGFibGU6Yjk3Y2Q3MTVmOWRjNDljOWE3YTQ2NjhlYWFiNWRjZmIvdGFibGVyYW5nZTpiOTdjZDcxNWY5ZGM0OWM5YTdhNDY2OGVhYWI1ZGNmYl81LTEtMS0xLTg0NDQ0_fc0e1e1a-a073-4c14-acda-c3e356741cec">false</dei:AmendmentFlag>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODEw_97635a41-161e-48cc-9741-d517f85ec4b3">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODEw_df08f0e2-160d-4a75-87a1-87cfb24da89c">http://fasb.org/us-gaap/2022#OtherAssetsNoncurrent</us-gaap:OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzMx_e32a30e6-d584-47b7-845d-23d4e433bc41">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzQ4_870a3311-5ffc-4b2b-8721-b5d7ead81c4b">http://fasb.org/us-gaap/2022#AccruedLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzU3_21dc535a-a5b3-4717-bcb6-281e2bef1694">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzU3_b32467a4-74d9-403d-8502-48e5120b86ad">http://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrent</us-gaap:OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItMi0xLTEtMTA5MzI3_baf92b4c-2473-4ad1-9202-3d7157cbead6">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItMi0xLTEtMTA5MzI3_d20882e0-6ef3-4436-8245-6610c60bdc82">http://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpense</us-gaap:DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dei:DocumentType
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQw_9949bbd9-7111-445c-9b3f-53a295ce3443">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6ZGNjYTdhYjJiM2FjNGJiMWFiNjljODA4NzU5NDUxZWIvdGFibGVyYW5nZTpkY2NhN2FiMmIzYWM0YmIxYWI2OWM4MDg3NTk0NTFlYl8wLTAtMS0xLTg0NDQ0_aa8f2684-2fd7-438a-aaf8-1a1e9ce820fe">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18xMTU_cb4d87b1-bc35-4b0a-8c42-434fda7d3ecc">2023-01-01</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18xMTU_d1f5c0f5-0bed-4037-b2ca-22f4c365a3f6">--01-01</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6ZjQ0MjdjY2Y3NTA4NDkzNTlmNDc3OWJhYmM4M2FmNTYvdGFibGVyYW5nZTpmNDQyN2NjZjc1MDg0OTM1OWY0Nzc5YmFiYzgzYWY1Nl8wLTAtMS0xLTg0NDQ0_629ff729-23ca-4b63-9b7f-e5b5598de3b3">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQ1_a7ae1332-5acd-47f3-94bc-26ecc3cb1391">1-3215</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODM1_73f3365b-77c6-430e-8e1b-c79664f016eb">JOHNSON &amp; JOHNSON</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6MDIyYjYyOWMyNDhmNGI3NTk0OTkxYjE0OTViNWViNTQvdGFibGVyYW5nZTowMjJiNjI5YzI0OGY0Yjc1OTQ5OTFiMTQ5NWI1ZWI1NF8wLTAtMS0xLTg0NDQ0_bd7d6b1d-3947-448b-89f9-48dc8203ed2c">NJ</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6MDIyYjYyOWMyNDhmNGI3NTk0OTkxYjE0OTViNWViNTQvdGFibGVyYW5nZTowMjJiNjI5YzI0OGY0Yjc1OTQ5OTFiMTQ5NWI1ZWI1NF8wLTItMS0xLTg0NDQ0_54fa01ce-f990-4251-bda1-1541f00663e4">22-1024240</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQx_71473352-8f9e-4394-b885-d2115cf41532">One Johnson &amp; Johnson Plaza</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQ2_1ffa9611-7495-4a24-8109-fde340590413">New Brunswick</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQ3_dcc810bb-8f27-4b09-ac3f-82f974e6d6c5">NJ</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQ4_0eb9468c-88be-4ab8-9279-7355217f7406">08933</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODM2_09942029-5ac3-4317-bc05-06b4faf58e73">732</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODM4_13e57c8a-ca62-4535-824a-6cfc1492bd75">524-0400</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i0c37a522bee54a7797e1e6cb838f251b_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8xLTAtMS0xLTg0NDQ0_428a1a85-5515-4987-98c3-e16062a40f65">Common Stock, Par Value $1.00</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i0c37a522bee54a7797e1e6cb838f251b_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8xLTEtMS0xLTg0NDQ0_085d79b4-2e69-46c4-87a3-52479fbfa5a2">JNJ</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i0c37a522bee54a7797e1e6cb838f251b_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8xLTItMS0xLTg0NDQ0_07af4003-d65c-48b1-b77e-73e8686c8d99">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i24117e0479bb43b39fee8a31afe69358_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8yLTAtMS0xLTg0NDQ0_38e5ee08-a0ed-47b1-b622-1da79992e7e6">0.650% Notes Due May 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i24117e0479bb43b39fee8a31afe69358_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8yLTEtMS0xLTg0NDQ0_5c943417-0fbd-44ad-8b93-7c6faffb5b96">JNJ24C</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i24117e0479bb43b39fee8a31afe69358_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8yLTItMS0xLTg0NDQ0_2a78b9b8-5975-4b1e-b472-b850886e85d7">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i88ae5583fd7b47fd87a649c4e0bfef49_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8zLTAtMS0xLTg0NDQ0_cb024ad3-bf93-4d1e-a3a8-9de1e8083be7">5.50% Notes Due November 2024</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i88ae5583fd7b47fd87a649c4e0bfef49_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8zLTEtMS0xLTg0NDQ0_c2787abf-a444-4133-956d-67a5190e1848">JNJ24BP</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i88ae5583fd7b47fd87a649c4e0bfef49_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl8zLTItMS0xLTg0NDQ0_a249bfb0-588c-469f-a89a-5755b832918c">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="i1602ec71af1c48e8a8514b07a9371e2d_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl80LTAtMS0xLTg0NDQ0_6af65028-0c27-4739-87ae-6a7c4f1ea34c">1.150% Notes Due November 2028</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i1602ec71af1c48e8a8514b07a9371e2d_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl80LTEtMS0xLTg0NDQ0_aa9f70ac-5251-476f-8e98-2483ca34ef95">JNJ28</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i1602ec71af1c48e8a8514b07a9371e2d_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl80LTItMS0xLTg0NDQ0_5138aadf-a382-4ae6-85db-11c816bf2f8b">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="ibfdad04f19eb4b2788c13457aacbc7d5_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl81LTAtMS0xLTg0NDQ0_8b4793d1-70da-4b58-8f22-312e2c55c80b">1.650% Notes Due May 2035</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="ibfdad04f19eb4b2788c13457aacbc7d5_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl81LTEtMS0xLTg0NDQ0_ffcf771e-419e-436c-aea0-deeaafb84dea">JNJ35</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="ibfdad04f19eb4b2788c13457aacbc7d5_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6NzlkNTQxOTEyM2E0NDY1ZDlkMjQ0ZDJlNjI1MzJmZjIvdGFibGVyYW5nZTo3OWQ1NDE5MTIzYTQ0NjVkOWQyNDRkMmU2MjUzMmZmMl81LTItMS0xLTg0NDQ0_bdbb616d-ee28-43af-8d7b-b154c5148b90">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQy_37390e7e-cbb0-430f-b60b-87b571fbbce0">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQz_e21c011b-c911-4eba-8153-10744f65c878">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODM3_9cb0a540-ad17-4f71-8d0c-acaf1792fb55">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODM5_1ea012d7-7096-433e-9226-7893b1329853">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6Zjk2NThlYmUyM2U0NDBmYzg1ZWY2YzMxNjFhNDExZjMvdGFibGVyYW5nZTpmOTY1OGViZTIzZTQ0MGZjODVlZjZjMzE2MWE0MTFmM18wLTEtMS0xLTg0NDQ0_a4e4afa7-7b6b-47aa-b9b7-56b609005fbb">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6Zjk2NThlYmUyM2U0NDBmYzg1ZWY2YzMxNjFhNDExZjMvdGFibGVyYW5nZTpmOTY1OGViZTIzZTQ0MGZjODVlZjZjMzE2MWE0MTFmM18xLTQtMS0xLTg0NDQ0_462983a6-90e0-4584-987e-ccbbff784a83">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGFibGU6Zjk2NThlYmUyM2U0NDBmYzg1ZWY2YzMxNjFhNDExZjMvdGFibGVyYW5nZTpmOTY1OGViZTIzZTQ0MGZjODVlZjZjMzE2MWE0MTFmM18yLTItMS0xLTg0NDQ0_70314669-7ffe-4e33-bb7c-677d9588fa46">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQ5_d9c64b2d-aa40-4476-acc5-982ac5a9ed44">true</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yODQ0_67fd5f98-8a3f-43ce-a9a1-bf49eda4c42d">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="i2a6f74ddd04b42a7beb1b698b449e828_I20220703"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yNzIz_5ca87861-6b3a-4381-b87a-822fa68bbd91"
      unitRef="usd">472000000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="id42e890d27894b429fe640211353b83a_I20230210"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xL2ZyYWc6ZDU3Zjc3MTE3NGE0NDU0ZjhmYTJmYjk3ZTA2N2YxZTMvdGV4dHJlZ2lvbjpkNTdmNzcxMTc0YTQ0NTRmOGZhMmZiOTdlMDY3ZjFlM18yNzYw_431770ac-0da1-42d5-9a06-1e9489b00817"
      unitRef="shares">2604286303</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMDkvZnJhZzpjMDc4YjM4ODIyYjY0NWZkYTEzNzYwYzgyNmVjZDcyNy90YWJsZTplMTgzMzdjMWU4ZjE0NDdkYjA2NDI2OTE0NjE4YzIzYy90YWJsZXJhbmdlOmUxODMzN2MxZThmMTQ0N2RiMDY0MjY5MTQ2MThjMjNjXzctMS0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo0Y2RiNjVjZTYyZGU0YmE5YTUxYzUxMThjZTYzNzVkYV83MA_83c125e3-a9c4-4922-b790-50c61591bdbc">238</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMtMS0xLTEtODQ0NDQ_fbb64bd0-345f-4c50-96e8-3167148fce33"
      unitRef="usd">14127000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMtMy0xLTEtODQ0NDQ_b5d750f8-4cc1-465c-9333-2b72ad4b11c5"
      unitRef="usd">14487000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzQtMS0xLTEtODQ0NDQ_acc91843-d42c-402a-8d32-2f04154db5c3"
      unitRef="usd">9392000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzQtMy0xLTEtODQ0NDQ_9e2ddf38-29a3-40d8-966a-58c3a67c47bf"
      unitRef="usd">17121000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzUtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjowYjIxZTU2YjgyOWU0MWEyYWJiMDQ1OWIxZmFmZTQxNF83MA_475e2fb9-fa05-43e0-8691-34c258a1ef15"
      unitRef="usd">203000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzUtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjowYjIxZTU2YjgyOWU0MWEyYWJiMDQ1OWIxZmFmZTQxNF84MQ_2a0de18e-f69d-442d-81bc-1b845ebe34a0"
      unitRef="usd">230000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzUtMS0xLTEtODQ0NDQ_611614be-82fe-4313-bf7d-ec2cdfff4ba4"
      unitRef="usd">16160000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzUtMy0xLTEtODQ0NDQ_54aa754c-416f-401a-b2a4-ffd075fcf297"
      unitRef="usd">15283000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzYtMS0xLTEtODQ0NDQ_08087429-322f-4665-acfc-1d2bab78fc78"
      unitRef="usd">12483000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzYtMy0xLTEtODQ0NDQ_b17f26b2-5252-4fb3-9bd6-7b2575a520a0"
      unitRef="usd">10387000000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzgtMS0xLTEtODQ0NDQ_49003c05-6be9-4791-a616-9e46b58e79b3"
      unitRef="usd">3132000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzgtMy0xLTEtODQ0NDQ_e792b737-d139-42ce-9570-6712330d2599"
      unitRef="usd">3701000000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzktMS0xLTEtODQ0NDQ_ac4372f8-1958-47aa-9087-2e0f1599ffbe"
      unitRef="usd">55294000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzktMy0xLTEtODQ0NDQ_4647ed63-5ee0-4d38-bf9d-ceb4b1889243"
      unitRef="usd">60979000000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzEwLTEtMS0xLTg0NDQ0_9bbe30e9-4067-48bf-a02e-7eba8d11f771"
      unitRef="usd">19803000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzEwLTMtMS0xLTg0NDQ0_2c29a255-5506-4dcb-9aad-d40e610c23dd"
      unitRef="usd">18962000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzExLTEtMS0xLTg0NDQ0_035eed1a-a10c-4142-a3ab-8bbff1434e1b"
      unitRef="usd">48325000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzExLTMtMS0xLTg0NDQ0_6d03a377-b6c4-4605-9798-2b046af9a2af"
      unitRef="usd">46392000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzEyLTEtMS0xLTg0NDQ0_8ed7a150-1cce-496f-895f-853d53c8e356"
      unitRef="usd">45231000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzEyLTMtMS0xLTg0NDQ0_61b9abc2-f8f7-4bf6-be38-877fbe7e52f8"
      unitRef="usd">35246000000</us-gaap:Goodwill>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzEzLTEtMS0xLTg0NDQ0_f4655cf3-9a1a-4af2-98a6-2bd196ea8f40"
      unitRef="usd">9123000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzEzLTMtMS0xLTg0NDQ0_6905f6d7-4652-42ca-8f50-f15ba0b2f7c8"
      unitRef="usd">10223000000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzE0LTEtMS0xLTg0NDQ0_e88f1c4a-f46b-4b9d-88e2-edda2f5513cf"
      unitRef="usd">9602000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzE0LTMtMS0xLTg0NDQ0_1aa8c73b-9033-4f2b-8e22-f26c07b14cec"
      unitRef="usd">10216000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzE1LTEtMS0xLTg0NDQ0_79d810e3-4696-4b98-8b05-2b57b3ea958c"
      unitRef="usd">187378000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzE1LTMtMS0xLTg0NDQ0_84c47b87-1f9b-4883-8244-cfa07452e409"
      unitRef="usd">182018000000</us-gaap:Assets>
    <us-gaap:ShortTermBorrowings
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzE4LTEtMS0xLTg0NDQ0_da816bf0-5649-4e65-8df7-f8acec8d2977"
      unitRef="usd">12771000000</us-gaap:ShortTermBorrowings>
    <us-gaap:ShortTermBorrowings
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzE4LTMtMS0xLTg0NDQ0_cb3e0c53-9745-4728-8f4c-6d29ce89433e"
      unitRef="usd">3766000000</us-gaap:ShortTermBorrowings>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzE5LTEtMS0xLTg0NDQ0_f72b003b-4d64-426f-843a-5bfdaf6aff7c"
      unitRef="usd">11703000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzE5LTMtMS0xLTg0NDQ0_e0c9f3ff-8bca-4c50-aa6d-ec9cca1ac61e"
      unitRef="usd">11055000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzIwLTEtMS0xLTg0NDQ0_d40e8934-2062-4af1-85fd-9c5d597c668f"
      unitRef="usd">11456000000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzIwLTMtMS0xLTg0NDQ0_63f8ca0d-b9f7-43aa-be0b-10d4a58e8a63"
      unitRef="usd">13612000000</us-gaap:AccruedLiabilitiesCurrent>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzIxLTEtMS0xLTg0NDQ0_6e05c87c-a513-42d9-ab7f-e846bbec21c1"
      unitRef="usd">14417000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzIxLTMtMS0xLTg0NDQ0_ac9cfa13-8ca1-4258-8f28-f7d7fb77f41a"
      unitRef="usd">12095000000</jnj:AccruedRebatesReturnsAndPromotions>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzIyLTEtMS0xLTg0NDQ0_665dcdda-6ccc-4e3f-9d3c-c57fe0c60f88"
      unitRef="usd">3328000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzIyLTMtMS0xLTg0NDQ0_840e3ffc-0468-400e-9a08-af76f12e0fb9"
      unitRef="usd">3586000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzIzLTEtMS0xLTg0NDQ0_084e2e62-e993-4adc-b16c-129e5acbf34a"
      unitRef="usd">2127000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzIzLTMtMS0xLTg0NDQ0_82960655-5cad-4e2f-94b6-096be981085c"
      unitRef="usd">1112000000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI0LTEtMS0xLTg0NDQ0_ac329c67-118e-4ca0-8c5a-13000c4107ff"
      unitRef="usd">55802000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI0LTMtMS0xLTg0NDQ0_fab8d9be-85bc-4bb4-811a-dd7351cb424c"
      unitRef="usd">45226000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI1LTEtMS0xLTg0NDQ0_87616c63-c216-454e-a400-b7b540f2b7fd"
      unitRef="usd">26888000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI1LTMtMS0xLTg0NDQ0_6b189b11-12f6-4ca1-99fc-ab93a5b2dfd7"
      unitRef="usd">29985000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI2LTEtMS0xLTg0NDQ0_afe517dd-9ca5-43a8-a90e-d1fe2ff5eab9"
      unitRef="usd">6374000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI2LTMtMS0xLTg0NDQ0_dc5bbe40-128a-4718-80af-f458d556d1bd"
      unitRef="usd">7487000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI3LTEtMS0xLTg0NDQ0_211f4918-49bd-49ba-806c-dcc2a6fa3b15"
      unitRef="usd">6767000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI3LTMtMS0xLTg0NDQ0_7396a5d0-ab9b-4116-9dc5-a408f894cd3e"
      unitRef="usd">8898000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI4LTEtMS0xLTg0NDQ0_41dec7f4-26e8-429a-a695-0b2635a8bfdc"
      unitRef="usd">4306000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:AccruedIncomeTaxesNoncurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI4LTMtMS0xLTg0NDQ0_a350672e-3656-48dc-a73e-cab5cb7d584a"
      unitRef="usd">5713000000</us-gaap:AccruedIncomeTaxesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI5LTEtMS0xLTg0NDQ0_246082cf-8762-42d6-8582-72cf58f523ee"
      unitRef="usd">10437000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzI5LTMtMS0xLTg0NDQ0_ab962a5a-6a74-4a15-9d8a-a5902d85a0c7"
      unitRef="usd">10686000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMwLTEtMS0xLTg0NDQ0_7dff3486-d453-47f0-b1fe-872d3b8c9a99"
      unitRef="usd">110574000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMwLTMtMS0xLTg0NDQ0_6378e7e8-ff5a-4c28-aac9-27f9417bbb3e"
      unitRef="usd">107995000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMxLTEtMS0xLTg0NDQ0_4ae2fa2d-9b96-4a02-b658-7a1bfe9a0419"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMxLTMtMS0xLTg0NDQ0_02bb4b34-1f2b-4873-8c1e-22b8faa085f2"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMzLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NzIyNjZmMzZiMDdiNDI4ODg2ZmEwYWRiNTYyYWVjZjZfNjU_ab223652-d8ce-47d2-a3d3-60afacb5a996"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMzLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NzIyNjZmMzZiMDdiNDI4ODg2ZmEwYWRiNTYyYWVjZjZfNjU_e20be93d-274c-45b0-9ba4-36f9e8a809f3"
      unitRef="shares">2000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockValue
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMzLTEtMS0xLTg0NDQ0_c7df43d0-0984-4c83-b204-dbfdffdda2e2"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzMzLTMtMS0xLTg0NDQ0_2ca4dea6-acc7-4120-9c40-80fdfa02c452"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NTM0OTI3MWU5YTU2NDYyNmE0ODVlODc1MWJkZmVlOWJfMzA_fb3d4939-df3c-47fe-b850-5057ef934006"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NTM0OTI3MWU5YTU2NDYyNmE0ODVlODc1MWJkZmVlOWJfMzA_fcac3872-bbbb-43ae-b27c-ce457c448013"
      unitRef="usdPerShare">1.00</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NTM0OTI3MWU5YTU2NDYyNmE0ODVlODc1MWJkZmVlOWJfNjU_1815a034-c23f-4e82-8184-633d10f8e5db"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NTM0OTI3MWU5YTU2NDYyNmE0ODVlODc1MWJkZmVlOWJfNjU_47d9e290-db1e-46b8-9cac-50ff762f844d"
      unitRef="shares">4320000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NTM0OTI3MWU5YTU2NDYyNmE0ODVlODc1MWJkZmVlOWJfODM_7c271d0b-847a-4583-83c4-316855b74c13"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NTM0OTI3MWU5YTU2NDYyNmE0ODVlODc1MWJkZmVlOWJfODM_f9298fb7-cb87-4553-87f0-c262c307c708"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM0LTEtMS0xLTg0NDQ0_503a2d89-633d-446c-9638-36b81fbb8957"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM0LTMtMS0xLTg0NDQ0_a0590f76-a4a4-4eae-9318-15b7aa7b81b1"
      unitRef="usd">3120000000</us-gaap:CommonStockValue>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM1LTEtMS0xLTg0NDQ0_4a1955bc-bbd9-4b38-af7f-ba5cd336bf8f"
      unitRef="usd">-12967000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM1LTMtMS0xLTg0NDQ0_db7a0226-191e-477b-b98d-b2cae5346fd2"
      unitRef="usd">-13058000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM2LTEtMS0xLTg0NDQ0_7838f67b-d499-4603-8fa7-ec0fa2efed54"
      unitRef="usd">128345000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM2LTMtMS0xLTg0NDQ0_257bbb45-86d7-4506-87c2-9d988e6e1a1f"
      unitRef="usd">123060000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM3LTEtMS0xLTg0NDQ0_f7dabcb2-61da-43a8-9945-e64695105940"
      unitRef="usd">118498000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:StockholdersEquityBeforeTreasuryStock
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM3LTMtMS0xLTg0NDQ0_5541dc06-7ddc-44f0-ad17-edbf2947c8e8"
      unitRef="usd">113122000000</us-gaap:StockholdersEquityBeforeTreasuryStock>
    <us-gaap:TreasuryStockShares
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM4LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MzNhZjEzOWMzYmU5NDM1MjlmZmE4ZTA0NzFlNjA2ZGFfNjA_2fa090bf-3c4c-46ea-8b14-871f558c871b"
      unitRef="shares">506246000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM4LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MzNhZjEzOWMzYmU5NDM1MjlmZmE4ZTA0NzFlNjA2ZGFfNzQ_7c9222b0-aac5-4656-89f0-285667cb1028"
      unitRef="shares">490878000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM4LTEtMS0xLTg0NDQ0_dd44f222-690f-4ce1-adce-31a819de9678"
      unitRef="usd">41694000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM4LTMtMS0xLTg0NDQ0_c40ab317-163c-4c94-a708-f5bd4fffcdf8"
      unitRef="usd">39099000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM5LTEtMS0xLTg0NDQ0_6fbb84d7-8e89-405a-beea-4718e9169de2"
      unitRef="usd">76804000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzM5LTMtMS0xLTg0NDQ0_f0d3d781-180e-40c1-9e7f-dda6672ba577"
      unitRef="usd">74023000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzQwLTEtMS0xLTg0NDQ0_16ca264a-6ef8-448b-8701-4f0bf4532b0f"
      unitRef="usd">187378000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMTUvZnJhZzplZTU5MTE5NTQxYWY0N2VmOTNmNjBmZmY4NGQ4MWI4OS90YWJsZTo4ODY4NGNmOTFlMzU0ZWU2YWM1MGY2YzliZWZjZTIxYy90YWJsZXJhbmdlOjg4Njg0Y2Y5MWUzNTRlZTZhYzUwZjZjOWJlZmNlMjFjXzQwLTMtMS0xLTg0NDQ0_d272ebb9-8f17-4f82-8554-fe6d312af002"
      unitRef="usd">182018000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEtMS0xLTEtODQ0NDQ_1b298ec4-2b9f-42ba-bf0c-ad96c91f21bf"
      unitRef="usd">94943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEtMy0xLTEtODQ0NDQ_b4485073-b6b3-4159-be94-3bc7f54ff08a"
      unitRef="usd">93775000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEtNS0xLTEtODQ0NDQ_5452f4f1-f02e-41ad-9276-35352577008f"
      unitRef="usd">82584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzItMS0xLTEtODQ0NDQ_3bca784a-1bef-49b6-8a94-0fa429cc20e3"
      unitRef="usd">31089000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzItMy0xLTEtODQ0NDQ_51a64f33-0125-43e8-97c8-77f1a0b75d07"
      unitRef="usd">29855000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzItNS0xLTEtODQ0NDQ_7c09199d-eb8d-48fe-832e-6c4583fc187f"
      unitRef="usd">28427000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzMtMS0xLTEtODQ0NDQ_4d11d416-abc6-4c0b-8f24-1547e40070ca"
      unitRef="usd">63854000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzMtMy0xLTEtODQ0NDQ_4e286ffe-788b-4357-aee8-3ea60e970cab"
      unitRef="usd">63920000000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzMtNS0xLTEtODQ0NDQ_dec2ceaa-4ea5-41a2-b300-1865209ae488"
      unitRef="usd">54157000000</us-gaap:GrossProfit>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzQtMS0xLTEtODQ0NDQ_84f5489a-0de4-464f-a03c-3b861b52970c"
      unitRef="usd">24765000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzQtMy0xLTEtODQ0NDQ_7384e88b-afad-499e-b17b-c57f0fc75ed3"
      unitRef="usd">24659000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzQtNS0xLTEtODQ0NDQ_62f10b71-b69a-4cd2-a1b0-565415949998"
      unitRef="usd">22084000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzUtMS0xLTEtODQ0NDQ_78e74110-8485-4890-8d18-2c6dd6f721fd"
      unitRef="usd">14603000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzUtMy0xLTEtODQ0NDQ_384d48a4-b5bd-41e9-978b-76ca273e55cc"
      unitRef="usd">14714000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzUtNS0xLTEtODQ0NDQ_ede4a6f5-a0ea-4b8a-837b-1545876f432c"
      unitRef="usd">12159000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzYtMS0xLTEtODQ0NDQ_7876b10f-86ea-43bc-82c7-621e28ca12de"
      unitRef="usd">783000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzYtMy0xLTEtODQ0NDQ_1f53a315-68d1-4abd-a9f7-72ad763db397"
      unitRef="usd">900000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzYtNS0xLTEtODQ0NDQ_98812f38-2f8c-4044-bf56-bf51ea6c4395"
      unitRef="usd">181000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzctMS0xLTEtODQ0NDQ_877b3759-d97a-46fd-b2b9-af8743e3a1b7"
      unitRef="usd">490000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzctMy0xLTEtODQ0NDQ_ddae7bfd-48f8-4b10-b39c-52bfe719eb0c"
      unitRef="usd">53000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzctNS0xLTEtODQ0NDQ_f26241eb-18a7-4ae4-bff1-884efeed5d25"
      unitRef="usd">111000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzgtMS0xLTEtODQ0NDQ_18a94d2b-997b-4860-be8f-b34e40ebd21d"
      unitRef="usd">276000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzgtMy0xLTEtODQ0NDQ_d9c42465-fa41-461a-9ad4-ff2ac8ea2740"
      unitRef="usd">183000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzgtNS0xLTEtODQ0NDQ_ffa12976-7e19-4016-b172-552f689c17ad"
      unitRef="usd">201000000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzktMS0xLTEtODQ0NDQ_9256bf28-c31b-49b1-ae81-5c1d03116217"
      unitRef="usd">-1871000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzktMy0xLTEtODQ0NDQ_4bfbeb90-f378-43dd-84bb-4595d5726e27"
      unitRef="usd">-489000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzktNS0xLTEtODQ0NDQ_ee3d9dbb-3b17-4970-b6c0-7e736cd34c93"
      unitRef="usd">-2899000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:RestructuringCharges
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEwLTEtMS0xLTg0NDQ0_c0d2ea83-d513-4e39-8ea5-4e22f476783a"
      unitRef="usd">321000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEwLTMtMS0xLTg0NDQ0_973d996d-5011-47b4-ae2b-588ba3fb8e7f"
      unitRef="usd">252000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEwLTUtMS0xLTg0NDQ0_b49187b8-a3e4-40e1-8c36-50ffc89900e9"
      unitRef="usd">247000000</us-gaap:RestructuringCharges>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzExLTEtMS0xLTg0NDQ0_90e86feb-8571-4591-89a1-006d16e3dbbb"
      unitRef="usd">21725000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzExLTMtMS0xLTg0NDQ0_98d83c3f-3246-436f-a96a-cd635eb53e2e"
      unitRef="usd">22776000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzExLTUtMS0xLTg0NDQ0_f36ce766-4be4-4eca-bbb5-a7b5eadeec25"
      unitRef="usd">16497000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEyLTEtMS0xLTg0NDQ0_78b1e5bc-9e1d-4cd7-be27-3f622f2598f9"
      unitRef="usd">3784000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEyLTMtMS0xLTg0NDQ0_acd8b251-0ad5-4d87-b047-bff723e19629"
      unitRef="usd">1898000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEyLTUtMS0xLTg0NDQ0_a1d70552-7f10-41af-9c69-5748551e94c3"
      unitRef="usd">1783000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEzLTEtMS0xLTg0NDQ0_68cdabd3-ae47-43d1-9e64-fb9c05c4cc05"
      unitRef="usd">17941000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEzLTMtMS0xLTg0NDQ0_5ae68e1e-a4d4-490b-81cb-324255e5e3eb"
      unitRef="usd">20878000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzEzLTUtMS0xLTg0NDQ0_0822c701-4635-47aa-b99d-95ff548a27b5"
      unitRef="usd">14714000000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE2LTEtMS0xLTg0NDQ0_db19d8bb-a87b-4a30-9ef7-09df8adbfbaa"
      unitRef="usdPerShare">6.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE2LTMtMS0xLTg0NDQ0_0cc0e8a6-d0fe-42e5-a23c-4a50a071e8ae"
      unitRef="usdPerShare">7.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE2LTUtMS0xLTg0NDQ0_67877b5b-ad4f-426c-b4ff-8351e0696267"
      unitRef="usdPerShare">5.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE3LTEtMS0xLTg0NDQ0_77082265-00f3-4ec6-83d4-985bb8d48649"
      unitRef="usdPerShare">6.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE3LTMtMS0xLTg0NDQ0_966b2012-44af-41ed-9006-a834bbed5abc"
      unitRef="usdPerShare">7.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE3LTUtMS0xLTg0NDQ0_05e51390-9a55-497a-91b8-a5db15881660"
      unitRef="usdPerShare">5.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE5LTEtMS0xLTg0NDQ0_0556ff91-622a-4e0b-aff5-3c07992b1715"
      unitRef="shares">2625200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE5LTMtMS0xLTg0NDQ0_516c2766-7ca6-41cf-9d09-c2aba174d3ee"
      unitRef="shares">2632100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzE5LTUtMS0xLTg0NDQ0_f907dc28-2dac-435c-a00b-a9bb38b615bd"
      unitRef="shares">2632800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzIwLTEtMS0xLTg0NDQ0_e3fc8241-28c0-4a49-af63-98b64d562a23"
      unitRef="shares">2663900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzIwLTMtMS0xLTg0NDQ0_09917441-094c-40df-bef6-a268f83c7101"
      unitRef="shares">2674000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjEvZnJhZzo4M2MwMWZhMWMyNTU0ZDg5OTliYzhjZDUyMjVlZDZlYy90YWJsZTpiMjU3ZTJiNjgzOTk0ODM5ODVmZDQyMDcxODZiZjA4Ny90YWJsZXJhbmdlOmIyNTdlMmI2ODM5OTQ4Mzk4NWZkNDIwNzE4NmJmMDg3XzIwLTUtMS0xLTg0NDQ0_aefc54e2-fde0-4794-8761-85d3c52f24eb"
      unitRef="shares">2670700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEtMS0xLTEtODQ0NDQ_08afc636-efd6-40e1-810e-ca59ea9b698a"
      unitRef="usd">17941000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEtMy0xLTEtODQ0NDQ_7d3b46aa-c7c7-41df-83ed-1ffc85fd4100"
      unitRef="usd">20878000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEtNS0xLTEtODQ0NDQ_3806501f-f373-4fc1-8a6e-583c19c62eca"
      unitRef="usd">14714000000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzQtMS0xLTEtODQ0NDQ_5128ca8e-954a-4dcb-8c3b-445c62e4a91e"
      unitRef="usd">-1796000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzQtMy0xLTEtODQ0NDQ_78169503-a001-484c-afe9-fef89058116e"
      unitRef="usd">-1079000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzQtNS0xLTEtODQ0NDQ_07f9fde7-174d-4245-8d6c-dcaa88a2a4f7"
      unitRef="usd">-233000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzctMS0xLTEtODQ0NDQ_ab54c967-c02c-421d-a6bc-41e5f0c818ce"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzctMy0xLTEtODQ0NDQ_c734ee8c-11e4-4e37-91e7-93309ed28381"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzctNS0xLTEtODQ0NDQ_d00c6dc1-ef75-47bb-8aa6-89f0362b4fc3"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzgtMS0xLTEtODQ0NDQ_e08ca63e-74e2-4201-9215-30b65f8b0a3e"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzgtMy0xLTEtODQ0NDQ_ed7dae72-2640-4211-bd5c-feb7e87f31d5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzgtNS0xLTEtODQ0NDQ_d8cfbce6-994f-4846-9d7e-e996e6e5364a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzktMS0xLTEtODQ0NDQ_c84ddeaa-27fc-4a67-944e-058dc87a42c2"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzktMy0xLTEtODQ0NDQ_f9953042-fcd0-432a-9c71-c04e25d45024"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzktNS0xLTEtODQ0NDQ_cdeee152-ad69-46dc-8be5-60303d5f3cd0"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEyLTEtMS0xLTg0NDQ0_903e26f2-ea6b-4aa8-b538-4092cce4cf92"
      unitRef="usd">160000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEyLTMtMS0xLTg0NDQ0_04501413-bb7d-4208-932b-a5cb5c253d72"
      unitRef="usd">169000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEyLTUtMS0xLTg0NDQ0_368607ca-29b5-412c-837f-38a23def5582"
      unitRef="usd">-1298000000</jnj:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEzLTEtMS0xLTg0NDQ0_da1230e9-a721-46e4-97f6-2d6c6ccd6af8"
      unitRef="usd">-1854000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEzLTMtMS0xLTg0NDQ0_ab994eb5-2dd4-42ef-806e-29cef6b51621"
      unitRef="usd">-4318000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzEzLTUtMS0xLTg0NDQ0_60f0e16c-74c3-4076-938b-8677e5f97d8f"
      unitRef="usd">1135000000</jnj:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax>
    <jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE0LTEtMS0xLTg0NDQ0_6f9d74ae-598e-4964-b5ad-18a9cba6d959"
      unitRef="usd">-111000000</jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE0LTMtMS0xLTg0NDQ0_6c76037d-3c76-41c6-b67f-5e2244bb218b"
      unitRef="usd">-106000000</jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax>
    <jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE0LTUtMS0xLTg0NDQ0_3acba7e7-8117-41fa-85aa-9e84a1657abc"
      unitRef="usd">229000000</jnj:OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE1LTEtMS0xLTg0NDQ0_24220a1b-ac82-4351-b41d-6c3d824fcc66"
      unitRef="usd">-1805000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE1LTMtMS0xLTg0NDQ0_24246945-816b-40db-8744-e95f838d912a"
      unitRef="usd">-4255000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE1LTUtMS0xLTg0NDQ0_04bd9213-51f0-4343-9ae5-edd8ab4cca6b"
      unitRef="usd">66000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE4LTEtMS0xLTg0NDQ0_d3136d1f-f94c-48f5-b7b9-74a605aece51"
      unitRef="usd">454000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE4LTMtMS0xLTg0NDQ0_1087d1c6-2eb5-4cd8-84ac-e489f9cdb765"
      unitRef="usd">-199000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE4LTUtMS0xLTg0NDQ0_1f235593-635a-4448-8b23-3298f165b3d9"
      unitRef="usd">1000000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE5LTEtMS0xLTg0NDQ0_d3e6190a-9834-4e50-bb95-4889b5208578"
      unitRef="usd">348000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE5LTMtMS0xLTg0NDQ0_5fa88afe-d6c3-48ef-9f60-b6d3eb350a3c"
      unitRef="usd">789000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzE5LTUtMS0xLTg0NDQ0_800d03fe-83eb-44b8-be80-8bc4bdb6c858"
      unitRef="usd">53000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzIwLTEtMS0xLTg0NDQ0_93de580e-ce59-45da-969f-59c04a01de0b"
      unitRef="usd">106000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzIwLTMtMS0xLTg0NDQ0_29775933-51ff-4ef8-862b-4498ec83643f"
      unitRef="usd">-988000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzIwLTUtMS0xLTg0NDQ0_3ca3e296-e76c-4419-ae34-723891b5a44e"
      unitRef="usd">947000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzIyLTEtMS0xLTg0NDQ0_257512ec-f5fb-4af3-8709-1aaa97c0ccb8"
      unitRef="usd">91000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzIyLTMtMS0xLTg0NDQ0_3af5b411-9072-4fe8-96f0-3d46f08d0754"
      unitRef="usd">2184000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzIyLTUtMS0xLTg0NDQ0_d90c20c8-48cd-4f6e-bd6b-cf766f7bfb68"
      unitRef="usd">649000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzI0LTEtMS0xLTg0NDQ0_ed661d29-dd99-4615-a2b0-7e33c174f4a3"
      unitRef="usd">18032000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzI0LTMtMS0xLTg0NDQ0_facc923f-7944-4e35-8cc5-fe160f7eacc6"
      unitRef="usd">23062000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTpiNTljY2VmNmExNGE0NWY2YjhkMzk4ZGUxZTBhNTU0MC90YWJsZXJhbmdlOmI1OWNjZWY2YTE0YTQ1ZjZiOGQzOThkZTFlMGE1NTQwXzI0LTUtMS0xLTg0NDQ0_d1f94148-b8d6-4146-9fd5-55cabdf5b832"
      unitRef="usd">15363000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8xMzY_a6850446-75bc-4486-a8f6-2587a4602a91"
      unitRef="usd">-460000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8xNDk_9bf6e8c8-53ed-4ba0-8498-3cfdebe4d201"
      unitRef="usd">-346000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8xNjU_d98b6f68-9af2-4a6f-ae36-eb7fa71c98ac"
      unitRef="usd">536000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8xOTA_69d20e77-c7d0-4171-bd76-d593fe0a5d3b"
      unitRef="usd">-6000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF82NTk3MDY5NzY3MDI0_3d176449-85ee-479e-93e1-7e066f0626b9"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8yMzU_b717d770-a409-465c-a8b0-d8dbc6b530a6"
      unitRef="usd">-461000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8yNDg_278b4007-f759-4aa3-837c-dd713a0ae745"
      unitRef="usd">-1198000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8yNjQ_81985f53-da51-42cb-a81f-c8a086751dda"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8yOTk_5988ba7b-ceec-4356-b0eb-f6b47debfdba"
      unitRef="usd">30000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8zMTI_1fe4c543-d307-48b5-852c-595b48f75963"
      unitRef="usd">-263000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMjQvZnJhZzo1ZmUzZThlNjlmOWE0OGFkYTFjMzBmOTJmZGIyOWVhMy90YWJsZTplNGVlZGIwOWU5YWI0OTVkODIxNTEzYzA1Zjk1YmNhZi90YWJsZXJhbmdlOmU0ZWVkYjA5ZTlhYjQ5NWQ4MjE1MTNjMDVmOTViY2FmXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NTRlYjI3MzBhMTE0ZmMzOTViMmM1MDllNjcwOTZjNF8zMjg_a40397d9-59b8-4fb8-a505-5bc055fe01ac"
      unitRef="usd">-252000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEtMS0xLTEtODQ0NDQ_88abda68-2597-4e79-895a-137e3ba5897c"
      unitRef="usd">59471000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie0d81a2faf2847ea921dc2fc7b6a23ce_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEtMy0xLTEtODQ0NDQ_4f64efc2-d16a-4be2-bf1b-fc39156ab48a"
      unitRef="usd">110659000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie9807f0aec4641a1ac4bec134b355aad_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEtNS0xLTEtODQ0NDQ_a989a7ee-24cb-4c1d-a5fe-f3302c8c4aa8"
      unitRef="usd">-15891000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86826cf58c434c3ea3d165935690175b_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEtNy0xLTEtODQ0NDQ_11e458bd-962a-47e9-a9e6-72c4be702067"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6c5dd290ffc74ea1be26c69d111518e6_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEtOS0xLTEtODQ0NDQ_1332b001-e7a5-4fce-a05d-605f39785d2e"
      unitRef="usd">-38417000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzMtMS0xLTEtODQ0NDQ_8804d56f-d7c3-4337-bb78-86c8db98c162"
      unitRef="usd">14714000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="if2730b868c9a489d915184459e52ff91_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzMtMy0xLTEtODQ0NDQ_d052d1c4-bbb7-4a56-9732-54b56881412e"
      unitRef="usd">14714000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzQtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjowM2QyZTMxN2E2ZjM0YzIwODhkMmUyYTQyN2FjNjAzYl8yNg_bf8e3695-1c6a-4336-ba4f-fa350303dd19"
      unitRef="usdPerShare">3.98</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzQtMS0xLTEtODQ0NDQ_3743828c-ff96-4acc-b0b5-a6564fd59b9f"
      unitRef="usd">10481000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="if2730b868c9a489d915184459e52ff91_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzQtMy0xLTEtODQ0NDQ_96e0900c-c3d8-4152-834f-ed1a22f48d43"
      unitRef="usd">10481000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzUtMS0xLTEtODQ0NDQ_b5745ccf-7799-4f7f-beda-d55b2efbf613"
      unitRef="usd">2217000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="if2730b868c9a489d915184459e52ff91_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzUtMy0xLTEtODQ0NDQ_207be59a-2b32-4934-8049-e86d68caeb76"
      unitRef="usd">-931000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ib7e50ef6296740dda9036c6c59bae7a8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzUtOS0xLTEtODQ0NDQ_8f7bd354-f7f6-4e8f-847b-0567dd10573b"
      unitRef="usd">3148000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzYtMS0xLTEtODQ0NDQ_0384a122-85bb-4930-b370-69c3ecef7748"
      unitRef="usd">3221000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib7e50ef6296740dda9036c6c59bae7a8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzYtOS0xLTEtODQ0NDQ_a7b5fc9f-d502-4d4c-977c-d0be063d8091"
      unitRef="usd">3221000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockholdersEquityOther
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzctMS0xLTEtODQ0NDQ_e510074a-9dea-4d67-a78e-413de1e5a297"
      unitRef="usd">71000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="if2730b868c9a489d915184459e52ff91_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzctMy0xLTEtODQ0NDQ_3a9396f3-5739-4656-b2cf-89290de23598"
      unitRef="usd">71000000</us-gaap:StockholdersEquityOther>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzgtMS0xLTEtODQ0NDQ_45ca41a5-46c6-431a-b206-c95cf0f6509b"
      unitRef="usd">649000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9a2bd92352194bcdb8a871945d2b04b6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzgtNS0xLTEtODQ0NDQ_c1e647f2-9957-492e-9405-864fa71e5086"
      unitRef="usd">649000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzktMS0xLTEtODQ0NDQ_da3d3f47-da31-4021-8818-b05ab1e62002"
      unitRef="usd">63278000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie485eb6b64444292b2444b1661ce61de_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzktMy0xLTEtODQ0NDQ_a5a66e46-6dce-4c7b-90fd-8dd0a897a93c"
      unitRef="usd">113890000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81bc749533a9432f82631e2ec08fb7c4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzktNS0xLTEtODQ0NDQ_cb288cbb-5ba9-41e6-9d72-ee860936bb73"
      unitRef="usd">-15242000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i011816d4a7074b90ad92edd54a14570a_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzktNy0xLTEtODQ0NDQ_74c97513-4360-4908-841e-bf8d4bc0204c"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i22968ecd8b144767bf02c951d4deb7ae_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzktOS0xLTEtODQ0NDQ_04b69fc3-2040-4e75-bd2f-cb55dc2d52ca"
      unitRef="usd">-38490000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzExLTEtMS0xLTg0NDQ0_ec95f51b-7793-475b-ba73-951a2eaa4500"
      unitRef="usd">20878000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i646e87c85036437b9c9703c88ff78a63_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzExLTMtMS0xLTg0NDQ0_3fe8842c-4d38-4a18-aaea-26f49dc2a27e"
      unitRef="usd">20878000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEyLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246M2ExZmQ5NmU3MTU2NDZkODkyMTM3NzllOTJmOTNhNDVfMjY_45ff67a9-b8cf-4525-93b6-12af065f781e"
      unitRef="usdPerShare">4.19</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEyLTEtMS0xLTg0NDQ0_4cc5c305-2bec-4afe-be1c-eea6789f8920"
      unitRef="usd">11032000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i646e87c85036437b9c9703c88ff78a63_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEyLTMtMS0xLTg0NDQ0_58e31ad0-1619-47b0-a5d2-6a9495ca0ced"
      unitRef="usd">11032000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEzLTEtMS0xLTg0NDQ0_a0d08a00-d3c4-455c-b26e-70bf90e713df"
      unitRef="usd">2171000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i646e87c85036437b9c9703c88ff78a63_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEzLTMtMS0xLTg0NDQ0_075224d2-d77f-42b4-9ab7-3913a0b9e5cc"
      unitRef="usd">-676000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="ica40f5d5420a42c4baf327e28f3ff166_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzEzLTktMS0xLTg0NDQ0_8f00cd52-b66e-4141-b556-fc0b993fa27d"
      unitRef="usd">2847000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE0LTEtMS0xLTg0NDQ0_35ff5675-4503-4ff7-9ec8-df6a6b4b3cc8"
      unitRef="usd">3456000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ica40f5d5420a42c4baf327e28f3ff166_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE0LTktMS0xLTg0NDQ0_7781383f-475c-4336-afe8-be8447d5f5a8"
      unitRef="usd">3456000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE2LTEtMS0xLTg0NDQ0_1c66e6f3-6f87-4fe3-85d8-ea142057c213"
      unitRef="usd">2184000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ieade5efd55fc4e7f9b55b76ad9b270a0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE2LTUtMS0xLTg0NDQ0_b5181394-fc58-4f98-b472-399dc833e5ee"
      unitRef="usd">2184000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE3LTEtMS0xLTg0NDQ0_cade66b0-2049-4878-8076-3cc56a939d17"
      unitRef="usd">74023000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iec1f1ce9d602483b960c5f739d33f211_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE3LTMtMS0xLTg0NDQ0_5dabeb4e-3195-41e3-af24-6e095aedd727"
      unitRef="usd">123060000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icec2276dbd2e4d76878d45adc66f315e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE3LTUtMS0xLTg0NDQ0_19c6bf87-baba-400f-a487-f1ff29fbbcb9"
      unitRef="usd">-13058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i3ef1d9f1b2874c9dadea9df7caa69641_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE3LTctMS0xLTg0NDQ0_f76c8f1c-6ee3-4de5-a64f-1c08c9e0c438"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia2339bc2da5948afb7331d7646e12408_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE3LTktMS0xLTg0NDQ0_4b2c8c81-32e2-450d-ab57-6e4033ace196"
      unitRef="usd">-39099000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE5LTEtMS0xLTg0NDQ0_5ed4e766-29e4-4a6e-a05e-8f1aca9d592f"
      unitRef="usd">17941000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i9b341fec469b4745a481f3935cfdc814_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzE5LTMtMS0xLTg0NDQ0_8d8c7eb2-3f82-40e8-b7c9-6bef70d7e1c1"
      unitRef="usd">17941000000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzIwLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MzkzYWQ2ZmYyNTBjNGIxMGIxOThkNjY2Yzg3NTc2MDZfMjY_39d44a4d-3db0-4969-b3a1-4e6ac2fcaf17"
      unitRef="usdPerShare">4.45</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:DividendsCommonStockCash
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzIwLTEtMS0xLTg0NDQ0_630e5431-0a39-4641-b7f8-5d5d68dae3ef"
      unitRef="usd">11682000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="i9b341fec469b4745a481f3935cfdc814_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzIwLTMtMS0xLTg0NDQ0_6a723d08-e7cd-49ef-a390-94822b1aaf69"
      unitRef="usd">11682000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzIxLTEtMS0xLTg0NDQ0_632fad99-8672-48e0-a386-1d2497492aa4"
      unitRef="usd">2466000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9b341fec469b4745a481f3935cfdc814_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzIxLTMtMS0xLTg0NDQ0_92bec0cc-8d30-4559-8eb5-c3ac0abb042d"
      unitRef="usd">-974000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i0bd8a9ce6ebc4c33ba835359ee340f7a_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzIxLTktMS0xLTg0NDQ0_69fe56e3-786c-4435-8ead-d1882fc89ca9"
      unitRef="usd">3440000000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzIyLTEtMS0xLTg0NDQ0_9d81d158-5178-4ac1-9680-7789607d8734"
      unitRef="usd">6035000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0bd8a9ce6ebc4c33ba835359ee340f7a_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzIyLTktMS0xLTg0NDQ0_064b54e4-b7e3-4172-b1ec-f8807e86a574"
      unitRef="usd">6035000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzI0LTEtMS0xLTg0NDQ0_ff842e70-f846-47bc-9fbc-e71fadb950df"
      unitRef="usd">91000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifb64fb4e20f1404cbc6e31613ca7eef9_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzI0LTUtMS0xLTg0NDQ0_82a43447-1e9f-431f-a8b5-56a6e925a866"
      unitRef="usd">91000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzI1LTEtMS0xLTg0NDQ0_6c6e583f-36bc-4f11-bfb5-0d618a0770f0"
      unitRef="usd">76804000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id693fb46504d40baa0ff184c359c60c3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzI1LTMtMS0xLTg0NDQ0_08ac406f-f86a-446e-90eb-e86ef4004d5d"
      unitRef="usd">128345000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia8ed0029b3204669a3f2d23dad442d8e_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzI1LTUtMS0xLTg0NDQ0_89f76fcd-76ed-4428-993d-85c8c64f99e6"
      unitRef="usd">-12967000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i9e876c735af9409796c44f0d4a41a05a_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzI1LTctMS0xLTg0NDQ0_ba21c56b-4b47-4245-b1f9-387db5b0a0b6"
      unitRef="usd">3120000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i4b74a9312aa14cef802c651c6aca0f51_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzAvZnJhZzpjNmY0ZDY4YWE3OTU0N2FmYTg4MGZmMDZmYTk5MTZjNS90YWJsZTplM2NlYzE3MTc2ZGM0NzRiOTNkYmQyNjI1OTZmMTc5Yy90YWJsZXJhbmdlOmUzY2VjMTcxNzZkYzQ3NGI5M2RiZDI2MjU5NmYxNzljXzI1LTktMS0xLTg0NDQ0_16bf592d-aac7-4919-be3b-2fd387af6147"
      unitRef="usd">-41694000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzItMS0xLTEtODQ0NDQ_af3b81ad-0f72-445e-baaf-1b58c7c97da1"
      unitRef="usd">17941000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzItMy0xLTEtODQ0NDQ_ec824388-ea80-4c05-becd-935b34e3136e"
      unitRef="usd">20878000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzItNS0xLTEtODQ0NDQ_b2d5df67-58df-4b48-ae2d-84ab73bb0b30"
      unitRef="usd">14714000000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQtMS0xLTEtODQ0NDQ_016787ff-b5b7-450d-9b40-8af9d649aa35"
      unitRef="usd">6970000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQtMy0xLTEtODQ0NDQ_f7e5c810-ff12-4833-bbb7-bd4e49ad5390"
      unitRef="usd">7390000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQtNS0xLTEtODQ0NDQ_e5942dbc-3e06-41ac-bc7a-51d7ee104878"
      unitRef="usd">7231000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUtMS0xLTEtODQ0NDQ_79c71fe3-b701-4c7a-bd30-b4aa58ea2da4"
      unitRef="usd">1138000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUtMy0xLTEtODQ0NDQ_ca8acb0b-4198-4da6-a14a-dde9e22ac0f5"
      unitRef="usd">1135000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUtNS0xLTEtODQ0NDQ_33117aa5-a50b-4b29-bb9f-d258aa4ef36f"
      unitRef="usd">1005000000</us-gaap:ShareBasedCompensation>
    <us-gaap:AssetImpairmentCharges
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzctMS0xLTEtODQ0NDQ_2c27add5-ed58-42e2-abbe-d3c7f03dcae0"
      unitRef="usd">1216000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzctMy0xLTEtODQ0NDQ_30bcf894-f624-4637-acac-db648232d8b6"
      unitRef="usd">989000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzctNS0xLTEtODQ0NDQ_472a20e1-e5f6-4b14-846f-bdd3150fb3af"
      unitRef="usd">233000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzgtMS0xLTEtODQ0NDQ_7d93c7ca-2da0-46e4-b570-02cc7ba33e55"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzgtMy0xLTEtODQ0NDQ_28276b36-c5c2-4075-88be-3f1343e449bb"
      unitRef="usd">0</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzgtNS0xLTEtODQ0NDQ_b1ef7937-ae57-4781-84a3-2b106caa7dfd"
      unitRef="usd">-1148000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzktMS0xLTEtODQ0NDQ_b866d479-06d5-4ff2-9fd1-d02760095e46"
      unitRef="usd">380000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzktMy0xLTEtODQ0NDQ_2ddb6564-551c-4b5a-bf6f-14538c87c070"
      unitRef="usd">617000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzktNS0xLTEtODQ0NDQ_236ace0e-0954-4ac8-9c50-07acabe4f768"
      unitRef="usd">111000000</us-gaap:GainLossOnSalesOfAssetsAndAssetImpairmentCharges>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzExLTEtMS0xLTg0NDQ0_5d8e0994-a5e6-4f1d-95c0-6502e0fc8d5d"
      unitRef="usd">-1663000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzExLTMtMS0xLTg0NDQ0_3eccca0e-c076-4eb8-8128-30b63e9fab73"
      unitRef="usd">-2079000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzExLTUtMS0xLTg0NDQ0_acd67ad8-d7cf-4495-ac17-46a0edb6d2fd"
      unitRef="usd">-1141000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzEyLTEtMS0xLTg0NDQ0_d2aa60f4-cae3-49d4-91d7-29452aa9f4c6"
      unitRef="usd">-17000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzEyLTMtMS0xLTg0NDQ0_1d700ff5-e09b-479e-bc44-643b95310621"
      unitRef="usd">-48000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:ProvisionForDoubtfulAccounts
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzEyLTUtMS0xLTg0NDQ0_19cea028-b168-42a2-9fe9-d51715c2da2b"
      unitRef="usd">63000000</us-gaap:ProvisionForDoubtfulAccounts>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE0LTEtMS0xLTg0NDQ0_e02a946d-53d4-48e1-8cef-bfe9aeaaae46"
      unitRef="usd">1290000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE0LTMtMS0xLTg0NDQ0_fa883095-5b78-4123-8658-272e80825ab9"
      unitRef="usd">2402000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE0LTUtMS0xLTg0NDQ0_0e06b377-813b-4e9d-80bc-3f22005b8a06"
      unitRef="usd">-774000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE1LTEtMS0xLTg0NDQ0_30e8ac7f-68df-46cc-8850-de5258c71474"
      unitRef="usd">2527000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE1LTMtMS0xLTg0NDQ0_54465125-c7d4-4cf7-82a2-6acdc9f6a58b"
      unitRef="usd">1248000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE1LTUtMS0xLTg0NDQ0_1e586a51-efa0-4a56-9b50-f18b5fb43b2b"
      unitRef="usd">265000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE2LTEtMS0xLTg0NDQ0_543333d8-a69f-451e-9aab-036326019440"
      unitRef="usd">1098000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE2LTMtMS0xLTg0NDQ0_5250da0b-59b7-43a2-a821-62314090e185"
      unitRef="usd">2437000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE2LTUtMS0xLTg0NDQ0_d36fbbd0-e475-4d47-b2a0-403b655ebabe"
      unitRef="usd">5141000000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE3LTEtMS0xLTg0NDQ0_122f6f6b-d1b3-48ca-8ab5-71652b6fdcdb"
      unitRef="usd">-687000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE3LTMtMS0xLTg0NDQ0_180395c1-8736-4fc0-960e-e09a515ed1b9"
      unitRef="usd">1964000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE3LTUtMS0xLTg0NDQ0_d62de0ef-a0a8-460e-a2d5-123067624bcd"
      unitRef="usd">3704000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE4LTEtMS0xLTg0NDQ0_d29288cd-a453-4370-b4e5-0d7fb9c7464b"
      unitRef="usd">-1979000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE4LTMtMS0xLTg0NDQ0_dbb1d6a1-144f-4f95-849f-b26b75e75746"
      unitRef="usd">-1061000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE4LTUtMS0xLTg0NDQ0_b1192422-d33e-4b6f-b88a-52b1bb812e72"
      unitRef="usd">744000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE5LTEtMS0xLTg0NDQ0_1a932995-2730-4ca2-b2da-ebc92ee773f6"
      unitRef="usd">21194000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE5LTMtMS0xLTg0NDQ0_f2ce4fb8-1236-4535-b76a-ab82fc7dda31"
      unitRef="usd">23410000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzE5LTUtMS0xLTg0NDQ0_f0751f94-3226-463d-bef4-d874df6b639c"
      unitRef="usd">23536000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIxLTEtMS0xLTg0NDQ0_24733dd6-ac4d-4201-b439-dcd73e197221"
      unitRef="usd">4009000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIxLTMtMS0xLTg0NDQ0_3fa00997-3260-4a0e-8ecf-008200c7182d"
      unitRef="usd">3652000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIxLTUtMS0xLTg0NDQ0_5ba10700-a899-4998-be05-25f4fec6cf37"
      unitRef="usd">3347000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIyLTEtMS0xLTg0NDQ0_02f87a88-baae-4786-9544-0f9faee6c3ef"
      unitRef="usd">543000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIyLTMtMS0xLTg0NDQ0_4868e587-f7b5-4fe3-bcbd-5bfab688e3a0"
      unitRef="usd">711000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:ProceedsFromSaleOfProductiveAssets
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIyLTUtMS0xLTg0NDQ0_208b51e4-6530-4935-9c64-26093fb4e8c2"
      unitRef="usd">305000000</us-gaap:ProceedsFromSaleOfProductiveAssets>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIzLTEtMS0xLTg0NDQ0_e9b6d926-ffaa-4d56-b638-428064461517"
      unitRef="usd">17652000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIzLTMtMS0xLTg0NDQ0_71f0a3ba-7654-4142-ace5-22b299e9c6ff"
      unitRef="usd">60000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzIzLTUtMS0xLTg0NDQ0_122bb212-2a85-4311-97db-808544a3c276"
      unitRef="usd">7323000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI0LTEtMS0xLTg0NDQ0_770aec0b-fd54-4b9e-923c-ae03ed44b2c0"
      unitRef="usd">32384000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI0LTMtMS0xLTg0NDQ0_82664ef9-04f6-442a-85a1-e0db6f677d8e"
      unitRef="usd">30394000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI0LTUtMS0xLTg0NDQ0_7bbfa543-8ef1-4347-b8aa-97d04cc7053d"
      unitRef="usd">21089000000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI1LTEtMS0xLTg0NDQ0_b4b635d3-9c98-4c18-930e-1dac8f22f9aa"
      unitRef="usd">41609000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI1LTMtMS0xLTg0NDQ0_7585a807-f2a1-4ef2-8e38-f29d6fd80019"
      unitRef="usd">25006000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI1LTUtMS0xLTg0NDQ0_203b629b-1f89-43be-ba8b-8cb16b9f5441"
      unitRef="usd">12137000000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI2LTEtMS0xLTg0NDQ0_4c683fd0-7706-4085-b4fa-665ee3ffc3c8"
      unitRef="usd">-249000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI2LTMtMS0xLTg0NDQ0_1fc483e0-cf1a-4af3-93f0-d5ff83d9dfab"
      unitRef="usd">214000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI2LTUtMS0xLTg0NDQ0_d7f74caf-1921-479b-b891-446fb16fae21"
      unitRef="usd">-987000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI3LTEtMS0xLTg0NDQ0_12f19723-787b-4658-bf79-c1c638e5b16a"
      unitRef="usd">229000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI3LTMtMS0xLTg0NDQ0_1bae97ff-e3dc-4d7b-8d7f-6f562e869ed0"
      unitRef="usd">508000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI3LTUtMS0xLTg0NDQ0_cb13b61e-c3d8-4290-a4a6-53b949e29c7c"
      unitRef="usd">521000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI4LTEtMS0xLTg0NDQ0_23927a9a-8ce4-40c2-9a9c-2b0d0b93a962"
      unitRef="usd">-12371000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI4LTMtMS0xLTg0NDQ0_a39eddb2-aff0-4fc0-84bf-df368eae132d"
      unitRef="usd">-8683000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzI4LTUtMS0xLTg0NDQ0_c004f2f6-a245-4424-bdbe-a8af50503b10"
      unitRef="usd">-20825000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMwLTEtMS0xLTg0NDQ0_11a5ca8c-27a3-491f-8022-a4da73f658a4"
      unitRef="usd">11682000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMwLTMtMS0xLTg0NDQ0_40e860ec-d2d7-45cc-b576-445fac9f8268"
      unitRef="usd">11032000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMwLTUtMS0xLTg0NDQ0_038a966c-cbed-4c1e-ac1a-474591f01b1f"
      unitRef="usd">10481000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMxLTEtMS0xLTg0NDQ0_e13e4702-c2b8-4457-805a-0b232f8845cf"
      unitRef="usd">6035000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMxLTMtMS0xLTg0NDQ0_55d48d78-ee86-482d-a2c4-0422fc12f8db"
      unitRef="usd">3456000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMxLTUtMS0xLTg0NDQ0_5c14527f-941e-4b27-a05e-0b02c423247f"
      unitRef="usd">3221000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMyLTEtMS0xLTg0NDQ0_fa3a1180-d7be-44f3-a26a-0c02a9a8e401"
      unitRef="usd">16134000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMyLTMtMS0xLTg0NDQ0_08ce970c-6b54-4073-b696-cde5fbea35d4"
      unitRef="usd">1997000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMyLTUtMS0xLTg0NDQ0_339f9e47-9402-4fd1-88d3-e8a815dcdc0c"
      unitRef="usd">3391000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMzLTEtMS0xLTg0NDQ0_51b92db4-86e4-4172-92a9-d03928a31c9d"
      unitRef="usd">6550000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMzLTMtMS0xLTg0NDQ0_690569fe-efcb-4d7b-b09e-67cd6ebe9736"
      unitRef="usd">1190000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzMzLTUtMS0xLTg0NDQ0_78d6ebce-92b0-4a06-9efb-29200b8c1379"
      unitRef="usd">2663000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM0LTEtMS0xLTg0NDQ0_4b11f41d-c4a4-4ac6-8638-828db8dca99f"
      unitRef="usd">2000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM0LTMtMS0xLTg0NDQ0_fce24748-c94d-4bbc-9f6d-77d0ed45045d"
      unitRef="usd">5000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM0LTUtMS0xLTg0NDQ0_322fb33a-0d06-4121-9a7d-1966a3624d6e"
      unitRef="usd">7431000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM1LTEtMS0xLTg0NDQ0_8f02e467-994e-46f4-bd7a-6cc3ff889425"
      unitRef="usd">2134000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM1LTMtMS0xLTg0NDQ0_eaf33c37-f5d8-4108-af0b-5f36f33f4f24"
      unitRef="usd">1802000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM1LTUtMS0xLTg0NDQ0_c971e27f-75e6-4423-bc7b-5761247ad77a"
      unitRef="usd">1064000000</us-gaap:RepaymentsOfLongTermDebt>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM2LTEtMS0xLTg0NDQ0_380a5b3f-8731-4e8c-bb4d-46090787e6f0"
      unitRef="usd">1329000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM2LTMtMS0xLTg0NDQ0_95e5e173-84a7-49ba-aaba-66d78cef6cf7"
      unitRef="usd">1036000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM2LTUtMS0xLTg0NDQ0_2da6dfa9-3790-4515-b2a3-164b2a8c34cd"
      unitRef="usd">1114000000</jnj:ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM3LTEtMS0xLTg0NDQ0_98e578aa-3858-490b-addf-99f72f0bb2b4"
      unitRef="usd">-28000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM3LTMtMS0xLTg0NDQ0_e9bb7116-19ca-48c3-b506-b07ae0788103"
      unitRef="usd">281000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM3LTUtMS0xLTg0NDQ0_3cffb60a-a19b-46ac-8100-3a7af5a21670"
      unitRef="usd">-333000000</jnj:ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM4LTEtMS0xLTg0NDQ0_9b1b449a-5de0-4227-9b21-9cbd6b9fcc3e"
      unitRef="usd">93000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM4LTMtMS0xLTg0NDQ0_83bb0594-7d9f-4e72-84f0-7c504d063c4c"
      unitRef="usd">114000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM4LTUtMS0xLTg0NDQ0_dabe8505-6a27-463a-8f61-5d0e00d440b6"
      unitRef="usd">-294000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM5LTEtMS0xLTg0NDQ0_b2c13166-c384-46dc-a4c4-84bd953a2fd8"
      unitRef="usd">-8871000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM5LTMtMS0xLTg0NDQ0_fa67e404-2a7f-474f-a63f-a0364010ca30"
      unitRef="usd">-14047000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzM5LTUtMS0xLTg0NDQ0_95210754-3e2a-4e7a-9f24-0b3b83fb179f"
      unitRef="usd">-6120000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQwLTEtMS0xLTg0NDQ0_11efbafe-03d2-49ba-8cc1-f3cbc3bb192e"
      unitRef="usd">-312000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQwLTMtMS0xLTg0NDQ0_98d815dc-01b6-4a0b-a366-d1521e997aab"
      unitRef="usd">-178000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQwLTUtMS0xLTg0NDQ0_7002d7db-14a5-4781-8b37-834872991802"
      unitRef="usd">89000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQxLTEtMS0xLTg0NDQ0_47406562-397f-40c3-99b5-e4a4f3c2b439"
      unitRef="usd">-360000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQxLTMtMS0xLTg0NDQ0_b6565be4-ca33-49b8-9b83-ae3b70e5aea1"
      unitRef="usd">502000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQxLTUtMS0xLTg0NDQ0_355e2df3-02b3-4b88-9e32-3528b3148a80"
      unitRef="usd">-3320000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQyLTEtMS0xLTg0NDQ0_3e63211e-ef39-4b45-9dde-adc00461b835"
      unitRef="usd">14487000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQyLTMtMS0xLTg0NDQ0_033c4b90-1e6d-4211-a864-ece19ae3bc72"
      unitRef="usd">13985000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQyLTUtMS0xLTg0NDQ0_cb281bd8-eca0-4702-9afd-339c8b5e6740"
      unitRef="usd">17305000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQzLTEtMS0xLTg0NDQ0_ad4b4d4f-a0ec-4d25-917d-e89eb6de74b2"
      unitRef="usd">14127000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQzLTMtMS0xLTg0NDQ0_d997b868-b35b-4a93-a10c-0dec55ab94ea"
      unitRef="usd">14487000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQzLTUtMS0xLTg0NDQ0_abd7b143-c476-44ce-a83b-5ffc4cad3524"
      unitRef="usd">13985000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaid
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ3LTEtMS0xLTg0NDQ0_3368bd88-a47b-492a-b3cd-64207ae302a9"
      unitRef="usd">982000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ3LTMtMS0xLTg0NDQ0_1fd22f11-5634-44de-86e0-f550ca56dc72"
      unitRef="usd">990000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaid
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ3LTUtMS0xLTg0NDQ0_5568dbab-eea7-478a-a09a-377eb0840a6b"
      unitRef="usd">904000000</us-gaap:InterestPaid>
    <us-gaap:InterestPaidNet
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ4LTEtMS0xLTg0NDQ0_273b7357-7de4-43ba-bd35-810c8f14e8ae"
      unitRef="usd">933000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ4LTMtMS0xLTg0NDQ0_0da598b5-1423-4d63-a925-5d43dd12a6cf"
      unitRef="usd">941000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ4LTUtMS0xLTg0NDQ0_e42ff6e0-2e2b-4e3b-8c46-dde7be2f00ca"
      unitRef="usd">841000000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaid
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ5LTEtMS0xLTg0NDQ0_c1fb193f-f83e-4827-8cb9-d8b9e63d2166"
      unitRef="usd">5223000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ5LTMtMS0xLTg0NDQ0_3b61e12d-a926-4b80-84fc-ee4a606846de"
      unitRef="usd">4768000000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzQ5LTUtMS0xLTg0NDQ0_71285da1-2af9-4c12-a2ac-28458df2f3a2"
      unitRef="usd">4619000000</us-gaap:IncomeTaxesPaid>
    <jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUyLTEtMS0xLTg0NDQ0_5102e0c2-f56b-43fa-aa1b-c7952e9c6720"
      unitRef="usd">2114000000</jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds>
    <jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUyLTMtMS0xLTg0NDQ0_2125c33f-fd82-4f17-800f-3fedef65eb97"
      unitRef="usd">1811000000</jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds>
    <jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUyLTUtMS0xLTg0NDQ0_9ce20aa2-b677-4579-b372-c38cdbb54b58"
      unitRef="usd">1937000000</jnj:TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUzLTEtMS0xLTg0NDQ0_836ef4a5-3e02-46eb-8a04-6ffd1bb7e70a"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUzLTMtMS0xLTg0NDQ0_96a9a66c-dd04-4df0-a7e3-b2c4814821ff"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzUzLTUtMS0xLTg0NDQ0_d73787c0-ebf2-4e89-918e-dd4592b36b05"
      unitRef="usd">27000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU2LTEtMS0xLTg0NDQ0_baf3eb62-cc58-432e-81fe-864c2fe0e66e"
      unitRef="usd">18710000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU2LTMtMS0xLTg0NDQ0_a518cd3d-d56b-4c44-85f9-4bd6e4bc9d25"
      unitRef="usd">61000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU2LTUtMS0xLTg0NDQ0_c1ea5787-64b9-4eca-8bd2-37643f7c058d"
      unitRef="usd">7755000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU3LTEtMS0xLTg0NDQ0_12a46762-8d1d-4b65-8777-a238bf2f6d2e"
      unitRef="usd">1058000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU3LTMtMS0xLTg0NDQ0_8d968fde-fe64-47b5-ac91-59b210526969"
      unitRef="usd">1000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU3LTUtMS0xLTg0NDQ0_644865bc-c604-4c28-a795-4cc75387763f"
      unitRef="usd">432000000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU4LTEtMS0xLTg0NDQ0_dc6b50af-fe6d-4c4e-ac3f-eceb70054e0f"
      unitRef="usd">17652000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU4LTMtMS0xLTg0NDQ0_36c906a3-f3ea-4e81-95c5-27cb52a7f914"
      unitRef="usd">60000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xMzYvZnJhZzo4ZTdlZDVlMWRmNWE0NWZhYjVjY2E0ZDYxNmI1ZTllZS90YWJsZTplNDEyNDJlYzdjYTQ0MzFmODllMWQ0ZmYwOTUyZjI2ZC90YWJsZXJhbmdlOmU0MTI0MmVjN2NhNDQzMWY4OWUxZDRmZjA5NTJmMjZkXzU4LTUtMS0xLTg0NDQ0_84c20786-e239-4d50-b67c-e1fb22fba43a"
      unitRef="usd">7323000000</us-gaap:NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzQ5_1b3ddae5-8081-4199-b8c8-9d489c5b3388">Summary of Significant Accounting Policies&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Johnson&#160;&amp;amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description of the Company and Business Segments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has approximately 152,700&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is organized into three business segments: Consumer Health, Pharmaceutical and MedTech. The Consumer Health segment includes a broad range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-Counter pharmaceutical, Women&#x2019;s Health and Wound Care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on the following therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In November 2021, the Company announced its intention to separate the Company&#x2019;s Consumer Health business (Kenvue as the name for the planned New Consumer Health Company), with the intention to create a new, publicly traded company by the end of the fiscal year 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in fiscal 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Not Adopted as of January 1, 2023&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50) &#x2013; Disclosure of Supplier Finance Program Obligations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;This update requires that a buyer in a supplier finance program disclose additional information about the program to allow financial statement users to better understand the effect of the programs on an entity&#x2019;s working capital, liquidity, and cash flows. This update will be effective for the Company for fiscal years beginning after December 15, 2022, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently assessing the impact of this update on its disclosures and will adopt this standard in the fiscal first quarter of 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.  The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value.  The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment and Depreciation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;- 20&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;- 13&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#x2019;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Managed Care, Medicare and Medicaid programs, which amounted to $9.6 billion and $7.7 billion as of January&#160;1, 2023 and January&#160;2, 2022, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#x2019;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#x2019;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years&#160;2022,&#160;2021&#160;and&#160;2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in fiscal year 2022 and less than 3.0% of the total revenues in fiscal years 2021 and 2020 and are included in sales to customers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shipping and Handling&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling costs incurred were $1.1 billion, $1.1 billion and $1.0 billion in fiscal years 2022, 2021 and 2020, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 1.0% of sales to customers for all periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2022 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset. If warranted the purchased in-process research and development could be written off or partially impaired depending on the underlying program.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions.  See Note&#160;5 for further details on Intangible Assets and Goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#x2019;s impact on the Company&#x2019;s financial performance; (2)&#160;protect the Company&#x2019;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODEw_97635a41-161e-48cc-9741-d517f85ec4b3"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODEw_df08f0e2-160d-4a75-87a1-87cfb24da89c"&gt;Other assets&lt;/span&gt;&lt;/span&gt;, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzMx_e32a30e6-d584-47b7-845d-23d4e433bc41"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzQ4_870a3311-5ffc-4b2b-8721-b5d7ead81c4b"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;, and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzU3_21dc535a-a5b3-4717-bcb6-281e2bef1694"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzU3_b32467a4-74d9-403d-8502-48e5120b86ad"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt; on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $1.1&#160;billion and $0.9&#160;billion in fiscal years 2022 and 2021, respectively. The lease liability was $1.3&#160;billion and $1.0&#160;billion in fiscal years 2022 and 2021, respectively. The operating lease costs were $0.3&#160;billion in fiscal years 2022, 2021 and 2020, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3&#160;billion in fiscal years 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development.  Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product.  Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#x2019;s operations. In general, the income statement presentation for these collaborations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nature/Type of Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Earnings Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third-party sale of product &amp;amp; profit share payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales to customers&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties/milestones paid to collaborative partner (post-regulatory approval)*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties received from collaborative partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront payments&#160;&amp;amp; milestones paid to collaborative partner (pre-regulatory approval)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development payments to collaborative partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development payments received from collaborative partner or government entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:96.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG and IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.1 billion, $2.7 billion and $2.1 billion in fiscal years 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of  15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2022 was approximately  $6.1&#160;billion, of which $4.6&#160;billion is classified as noncurrent and reflected as &#x201c;Long-term taxes payable&#x201d; on the Company&#x2019;s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder&#x2019;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#x201c;period cost&#x201d;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., &#x201c;deferred method&#x201d;). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;See Note 8 to the Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;for further information regarding income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Annual Closing Date&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzIy_5416d2a9-aa54-43f8-a6b4-0a395bde0263">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Principles of Consolidation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The consolidated financial statements include the accounts of Johnson&#160;&amp;amp; Johnson and its subsidiaries (the Company). Intercompany accounts and transactions are eliminated. Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures.&lt;/span&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODIz_5dd2d0b6-1db0-4906-951c-a64feffe8f60">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Description of the Company and Business Segments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has approximately 152,700&#160;employees worldwide engaged in the research and development, manufacture and sale of a broad range of products in the healthcare field. The Company conducts business in virtually all countries of the world and its primary focus is on products related to human health and well-being.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is organized into three business segments: Consumer Health, Pharmaceutical and MedTech. The Consumer Health segment includes a broad range of products used in the Baby Care, Oral Care, Skin Health/Beauty, Over-the-Counter pharmaceutical, Women&#x2019;s Health and Wound Care markets. These products are marketed to the general public and sold online (eCommerce) and to retail outlets and distributors throughout the world. The Pharmaceutical segment is focused on the following therapeutic areas, including Immunology, Infectious diseases, Neuroscience, Oncology, Pulmonary Hypertension, and Cardiovascular and Metabolic diseases. Products in this segment are distributed directly to retailers, wholesalers, distributors, hospitals and healthcare professionals for prescription use. The MedTech segment includes a broad portfolio of products used in the Orthopaedic, Surgery, Interventional Solutions (cardiovascular and neurovascular) and Vision fields. These products are distributed to wholesalers, hospitals and retailers, and used principally in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In November 2021, the Company announced its intention to separate the Company&#x2019;s Consumer Health business (Kenvue as the name for the planned New Consumer Health Company), with the intention to create a new, publicly traded company by the end of the fiscal year 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzQ1NA_1998cb8f-ed43-4ba5-988b-0e64e8921d69"
      unitRef="employee">152700</jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide>
    <us-gaap:NumberOfReportableSegments
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzc3MA_984d5d56-ff3f-4a84-8cd3-907a6e3a561d"
      unitRef="segment">3</us-gaap:NumberOfReportableSegments>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODMy_029588fb-92af-470e-a50a-79e6de8e8335">&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new material accounting standards adopted in fiscal 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Standards&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Not Adopted as of January 1, 2023&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;ASU 2022-04: Liabilities-Supplier Finance Programs (Topic 405-50) &#x2013; Disclosure of Supplier Finance Program Obligations&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;This update requires that a buyer in a supplier finance program disclose additional information about the program to allow financial statement users to better understand the effect of the programs on an entity&#x2019;s working capital, liquidity, and cash flows. This update will be effective for the Company for fiscal years beginning after December 15, 2022, except for the amendment on roll forward information, which is effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company is currently assessing the impact of this update on its disclosures and will adopt this standard in the fiscal first quarter of 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzMw_41e68ad7-9f96-40ca-9646-196d9b3e11db">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash Equivalents&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies all highly liquid investments with stated maturities of three months or less from date of purchase as cash equivalents and all highly liquid investments with stated maturities of greater than three months from the date of purchase as current marketable securities. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.  The Company invests its cash primarily in government securities and obligations, corporate debt securities, money market funds and reverse repurchase agreements (RRAs).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;RRAs are collateralized by deposits in the form of Government Securities and Obligations for an amount not less than 102% of their value.  The Company does not record an asset or liability as the Company is not permitted to sell or repledge the associated collateral. The Company has a policy that the collateral has at least an A (or equivalent) credit rating. The Company utilizes a third party custodian to manage the exchange of funds and ensure that collateral received is maintained at 102% of the value of the RRAs on a daily basis. RRAs with stated maturities of greater than three months from the date of purchase are classified as marketable securities.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzUwMzE_a2e3d338-4f68-4763-9a5e-322e411115eb"
      unitRef="number">1.02</jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement>
    <jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzU0MDQ_73427cfe-7912-42d5-b9a3-1b96e443e4cd"
      unitRef="number">1.02</jnj:MinimumCollateralValueasaPercentReverseRepurchaseAgreement>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODI1_52bebfe5-a4ab-4e70-853f-41bdf44d7c58">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Investments classified as held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. Investments classified as available-for-sale debt securities are carried at estimated fair value with unrealized gains and &lt;/span&gt;&lt;/div&gt;losses recorded as a component of accumulated other comprehensive income. Available-for-sale securities available for current operations are classified as current assets otherwise, they are classified as long term. Management determines the appropriate classification of its investment in debt and equity securities at the time of purchase and re-evaluates such determination at each balance sheet date. The Company reviews its investments for impairment and adjusts these investments to fair value through earnings, as required.</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODM4_475c8eec-e420-4339-b657-2eee5d336d83">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Plant and Equipment and Depreciation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;- 20&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;- 13&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes certain computer software and development costs, included in machinery and equipment, when incurred in connection with developing or obtaining computer software for internal use. Capitalized software costs are amortized over the estimated useful lives of the software, which generally range from 3 to 8&#160;years.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reviews long-lived assets to assess recoverability using undiscounted cash flows. When certain events or changes in operating or economic conditions occur, an impairment assessment may be performed on the recoverability of the carrying value of these assets. If the asset is determined to be impaired, the loss is measured based on the difference between the asset&#x2019;s fair value and its carrying value. If quoted market prices are not available, the Company will estimate fair value using a discounted value of estimated future cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <jnj:EstimatedUsefulLivesOfAssetsTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2Nzg5_fb2fbb56-aad0-4a08-b1fe-5d41be05c63f">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, plant and equipment are stated at cost. The Company utilizes the straight-line method of depreciation over the estimated useful lives of the assets:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.684%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:86.011%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.789%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Building and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;- 20&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;- 13&#160;years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</jnj:EstimatedUsefulLivesOfAssetsTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i4f6dd96b61df4014b63f77ec38d4f931_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90YWJsZTowOTZkMjk2YTNkNDk0YTRlYWFkY2QxYTlhNTVhZWIwZS90YWJsZXJhbmdlOjA5NmQyOTZhM2Q0OTRhNGVhYWRjZDFhOWE1NWFlYjBlXzAtMS0xLTEtODQ0NDQvdGV4dHJlZ2lvbjphMmYxMWJlNWRjZDQ0NDFlOGI5ZTk5MmZhZWM5YjkxMV85_53fab3cb-7b8e-46b1-8a03-94cffffec916">P30Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="icc105f8c066041479b85014a44b4f246_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90YWJsZTowOTZkMjk2YTNkNDk0YTRlYWFkY2QxYTlhNTVhZWIwZS90YWJsZXJhbmdlOjA5NmQyOTZhM2Q0OTRhNGVhYWRjZDFhOWE1NWFlYjBlXzEtMS0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo4YTk1MWUyMGQ1Y2M0ZGQzOWUwZTBlYzJhMzIwYWRiMF80_1423d52b-4061-468d-89cf-a607c6597426">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="if67355a8e31e4d4e89a2d4cc2404fd2a_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90YWJsZTowOTZkMjk2YTNkNDk0YTRlYWFkY2QxYTlhNTVhZWIwZS90YWJsZXJhbmdlOjA5NmQyOTZhM2Q0OTRhNGVhYWRjZDFhOWE1NWFlYjBlXzEtMS0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo4YTk1MWUyMGQ1Y2M0ZGQzOWUwZTBlYzJhMzIwYWRiMF85_93b365a0-8c77-4cf0-99bf-d77505600d38">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1a7641e1bba746ceacabd5c374aae1d9_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90YWJsZTowOTZkMjk2YTNkNDk0YTRlYWFkY2QxYTlhNTVhZWIwZS90YWJsZXJhbmdlOjA5NmQyOTZhM2Q0OTRhNGVhYWRjZDFhOWE1NWFlYjBlXzItMS0xLTEtODQ0NDQvdGV4dHJlZ2lvbjoxOWQ2NGI3NGI1NzM0ODJiODkxYmI3M2JlZTIzMzRiNF80_48f0b324-1e12-4fe2-ab0f-5b1b41d6efdc">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i5bd05c5ccad24c3e9251efadcad9b101_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90YWJsZTowOTZkMjk2YTNkNDk0YTRlYWFkY2QxYTlhNTVhZWIwZS90YWJsZXJhbmdlOjA5NmQyOTZhM2Q0OTRhNGVhYWRjZDFhOWE1NWFlYjBlXzItMS0xLTEtODQ0NDQvdGV4dHJlZ2lvbjoxOWQ2NGI3NGI1NzM0ODJiODkxYmI3M2JlZTIzMzRiNF85_7a6dc7a3-2ea3-4434-b86a-d48789071cba">P13Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="i1c19938fb98647cb9ab6821478e99ec4_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzY5MDk_ce2f2f7e-7a76-4d39-bf05-7fca535f7645">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="ibe54a493eb1a41b6b7d5520bdcfdcbf9_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzY5MTU_9cdd1959-3e8c-413d-be77-d849a2f5181c">P8Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODA4_50268a46-9e56-4b07-a637-f77562c5677e">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue from product sales when obligations under the terms of a contract with the customer are satisfied; generally, this occurs with the transfer of control of the goods to customers. The Company's global payment terms are typically between 30 to 90 days. Provisions for certain rebates, sales incentives, trade promotions, coupons, product returns, discounts to customers and governmental clawback provisions are accounted for as variable consideration and recorded as a reduction in sales. The liability is recognized within Accrued Rebates, Returns, and Promotions on the consolidated balance sheet.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Product discounts granted are based on the terms of arrangements with direct, indirect and other market participants, as well as market conditions, including consideration of competitor pricing. Rebates are estimated based on contractual terms, historical experience, patient outcomes, trend analysis and projected market conditions in the various markets served. A significant portion of the liability related to rebates is from the sale of the Company's pharmaceutical products within the U.S., primarily &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he Managed Care, Medicare and Medicaid programs, which amounted to $9.6 billion and $7.7 billion as of January&#160;1, 2023 and January&#160;2, 2022, respectively. The Company evaluates market conditions for products or groups of products primarily through the analysis of wholesaler and other third-party sell-through and market research data, as well as internally generated information.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales returns are estimated and recorded based on historical sales and returns information. Products that exhibit unusual sales or return patterns due to dating, competition or other marketing matters are specifically investigated and analyzed as part of the accounting for sales return accruals.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Sales returns allowances represent a reserve for products that may be returned due to expiration, destruction in the field, or in specific areas, product recall. The sales returns reserve is based on historical return trends by product and by market as a percent to gross sales. In accordance with the Company&#x2019;s accounting policies, the Company generally issues credit to customers for returned goods. The Company&#x2019;s sales returns reserves are accounted for in accordance with the U.S.&#160;GAAP guidance for revenue recognition when right of return exists. Sales returns reserves are recorded at full sales value. Sales returns in the Consumer Health and Pharmaceutical segments are almost exclusively not resalable. Sales returns for certain franchises in the MedTech segment are typically resalable but are not material. The Company infrequently exchanges products from inventory for returned products. The sales returns reserve for the total Company has been approximately 1.0% of annual net trade sales during each of the fiscal years&#160;2022,&#160;2021&#160;and&#160;2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:10pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Promotional programs, such as product listing allowances and cooperative advertising arrangements, are recorded in the same period as related sales. Continuing promotional programs include coupons and volume-based sales incentive programs. The redemption cost of consumer coupons is based on historical redemption experience by product and value. Volume-based incentive programs are based on the estimated sales volumes for the incentive period and are recorded as products are sold. These arrangements are evaluated to determine the appropriate amounts to be deferred or recorded as a reduction of revenue. The Company also earns profit-share payments through collaborative arrangements for certain products, which are included in sales to customers. Profit-share payments were less than 2.0% of the total revenues in fiscal year 2022 and less than 3.0% of the total revenues in fiscal years 2021 and 2020 and are included in sales to customers.&lt;/span&gt;&lt;/div&gt;See Note 17 to the Consolidated Financial Statements for further disaggregation of revenue.</us-gaap:RevenueRecognitionPolicyTextBlock>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="i6f076cad0e094616a814262376cb5191_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzg3MDE_44f08c75-971d-487b-a099-8cd58213dcb7"
      unitRef="usd">9600000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:AccruedRebatesReturnsAndPromotions
      contextRef="ia4852527980040579d16cf952b6a58ff_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzg3MDg_ded2507c-cf02-4670-8fcd-493ef50cb447"
      unitRef="usd">7700000000</jnj:AccruedRebatesReturnsAndPromotions>
    <jnj:SalesReturnReserve
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzEwMjQ0_85a86da4-3fce-4582-bdf8-a81b2624303b"
      unitRef="number">0.010</jnj:SalesReturnReserve>
    <jnj:SalesReturnReserve
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzEwMjQ0_b9bd6ce9-d1b2-431d-b543-30e0cc4aef60"
      unitRef="number">0.010</jnj:SalesReturnReserve>
    <jnj:SalesReturnReserve
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzEwMjQ0_cbccea22-199e-4236-8177-92762fcb8f51"
      unitRef="number">0.010</jnj:SalesReturnReserve>
    <jnj:ProfitLossPercentToSales
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzc2OTY1ODE0NDA0Mjk_be2f80f9-c7c2-4b7c-b616-62b8baf3d567"
      unitRef="number">0.020</jnj:ProfitLossPercentToSales>
    <jnj:ProfitLossPercentToSales
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzExMTM0_b9c0af23-98cf-4eb0-8341-68bc993b5b33"
      unitRef="number">0.030</jnj:ProfitLossPercentToSales>
    <jnj:ProfitLossPercentToSales
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzExMTM0_f41214bf-f36d-4c69-b211-fd47920dd550"
      unitRef="number">0.030</jnj:ProfitLossPercentToSales>
    <us-gaap:ShippingAndHandlingCostPolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODIy_6de65b11-9c14-4e63-b18c-94994eb87ceb">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Shipping and Handling&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Shipping and handling costs incurred were $1.1 billion, $1.1 billion and $1.0 billion in fiscal years 2022, 2021 and 2020, respectively, and are included in selling, marketing and administrative expense. The amount of revenue received for shipping and handling is less than 1.0% of sales to customers for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShippingAndHandlingCostPolicyTextBlock>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="ic46c5718fa2f417e8d7f7298244c427b_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzExMzU1_54005ab2-b8ec-4c05-94a7-1edb708e9be9"
      unitRef="usd">1100000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i6908986b3f7946f8bf4a62d5cf5b646c_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzExMzU5_29a518c7-1112-4683-8509-7433a86eab61"
      unitRef="usd">1100000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i220866b1cfb44cf7905eb75b0089e1a7_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzExMzY2_53f41cce-f9f5-4e5a-90da-8b6711abd614"
      unitRef="usd">1000000000</us-gaap:CostOfGoodsAndServicesSold>
    <jnj:ShippingandHandlingCostsasaPercentofSales
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzExNTUx_a9f7f5e8-d00c-4cfd-854d-21bf6c0745e0"
      unitRef="number">0.010</jnj:ShippingandHandlingCostsasaPercentofSales>
    <jnj:ShippingandHandlingCostsasaPercentofSales
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzExNTUx_f5df1a23-3d2d-4ced-b55c-018e5c086f01"
      unitRef="number">0.010</jnj:ShippingandHandlingCostsasaPercentofSales>
    <jnj:ShippingandHandlingCostsasaPercentofSales
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzExNTUx_ff78cca8-9d0f-4217-ab0d-49b057275be9"
      unitRef="number">0.010</jnj:ShippingandHandlingCostsasaPercentofSales>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzI0_7ccfe0fc-5401-4b35-9f72-386f7a48b2d5">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventories are stated at the lower of cost or net realizable value determined by the first-in, first-out method.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2Nzc0_cbf214d3-043e-45bb-8fa9-d0b5ecf10d34">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Intangible Assets and Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative literature on U.S.&#160;GAAP requires that goodwill and intangible assets with indefinite lives be assessed annually for impairment. The Company completed its annual impairment test for 2022 in the fiscal fourth quarter. Future impairment tests will be performed annually in the fiscal fourth quarter, or sooner if warranted. Purchased in-process research and development is accounted for as an indefinite lived intangible asset until the underlying project is completed, at which point the intangible asset will be accounted for as a definite lived intangible asset. If warranted the purchased in-process research and development could be written off or partially impaired depending on the underlying program.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Intangible assets that have finite useful lives continue to be amortized over their useful lives, and are reviewed for impairment when warranted by economic conditions.  See Note&#160;5 for further details on Intangible Assets and Goodwill.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2Nzgz_80f6b297-a071-41ce-a2f7-c4ec6a7b8f41">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As required by U.S.&#160;GAAP, all derivative instruments are recorded on the balance sheet at fair value.  Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability. The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value, with Level&#160;1 having the highest priority and Level&#160;3 having the lowest. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company documents all relationships between hedged items and derivatives. The overall risk management strategy includes reasons for undertaking hedge transactions and entering into derivatives. The objectives of this strategy are: (1)&#160;minimize foreign currency exposure&#x2019;s impact on the Company&#x2019;s financial performance; (2)&#160;protect the Company&#x2019;s cash flow from adverse movements in foreign exchange rates; (3)&#160;ensure the appropriateness of financial instruments; and (4)&#160;manage the enterprise risk associated with financial institutions. See Note&#160;6 for additional information on Financial Instruments.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODUx_21d1634e-b22b-4d68-80ad-53bd90baa086">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Leases &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines whether an arrangement is a lease at contract inception by establishing if the contract conveys the right to control the use of identified property, plant, or equipment for a period of time in exchange for consideration. Right of Use (ROU) Assets and Lease Liabilities for operating leases are included in &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODEw_97635a41-161e-48cc-9741-d517f85ec4b3"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODEw_df08f0e2-160d-4a75-87a1-87cfb24da89c"&gt;Other assets&lt;/span&gt;&lt;/span&gt;, &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzMx_e32a30e6-d584-47b7-845d-23d4e433bc41"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzQ4_870a3311-5ffc-4b2b-8721-b5d7ead81c4b"&gt;Accrued liabilities&lt;/span&gt;&lt;/span&gt;, and &lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzU3_21dc535a-a5b3-4717-bcb6-281e2bef1694"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzU3_b32467a4-74d9-403d-8502-48e5120b86ad"&gt;Other liabilities&lt;/span&gt;&lt;/span&gt; on the consolidated balance sheet. The ROU Assets represent the right to use an underlying asset for the lease term and lease liabilities represent an obligation to make lease payments arising from the lease. Commitments under finance leases are not significant, and are included in Property, plant and equipment, Loans and notes payable, and Long-term debt on the consolidated balance sheet.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ROU Assets and Lease Liabilities are recognized at the lease commencement date based on the present value of all minimum lease payments over the lease term. The Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments, when the implicit rate is not readily determinable. Lease terms may include options to extend or terminate the lease. These options are included in the lease term when it is reasonably certain that the Company will exercise that option. Operating lease expense is recognized on a straight-line basis over the lease term. The Company has elected the following policy elections on adoption: use of portfolio approach on leases of assets under master service agreements, exclusion of short term leases on the balance sheet, and not separating lease and non-lease components. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company primarily has operating lease for space, vehicles, manufacturing equipment and data processing equipment. The ROU asset pertaining to operating leases was $1.1&#160;billion and $0.9&#160;billion in fiscal years 2022 and 2021, respectively. The lease liability was $1.3&#160;billion and $1.0&#160;billion in fiscal years 2022 and 2021, respectively. The operating lease costs were $0.3&#160;billion in fiscal years 2022, 2021 and 2020, respectively. Cash paid for amounts included in the measurement of lease liabilities were $0.3&#160;billion in fiscal years 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE1OTE4_3e6756b6-df97-489d-8636-84c53b29c29c"
      unitRef="usd">1100000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE1OTI1_fdc19ce4-e1b5-419e-adc0-0227cd93c0a7"
      unitRef="usd">900000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE1OTg0_c61fbfd4-da1b-481a-9341-e4a1c4c9cf34"
      unitRef="usd">1300000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE1OTkx_06fa972d-d5ce-417e-8482-735c51e8996a"
      unitRef="usd">1000000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE2MDU2_1800c38e-d585-4bf6-adeb-334729d72991"
      unitRef="usd">300000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE2MDU2_1bb5cf57-f774-4d1d-afe6-6184e32bc66f"
      unitRef="usd">300000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE2MDU2_2c6dba9f-3e20-4722-b654-4349d4e51f77"
      unitRef="usd">300000000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeasePayments
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE2MTg0_8ae55af8-ed15-4229-8e1f-4dd14aa65066"
      unitRef="usd">300000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE2MTg0_9a16dd4a-58b8-4e03-b034-c8408f2d1f32"
      unitRef="usd">300000000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE2MTg0_cad53d10-4498-4614-b1c9-bea4f31dcb01"
      unitRef="usd">300000000</us-gaap:OperatingLeasePayments>
    <jnj:ProductLiabilityPolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzM4_00addaf2-e1bb-4c67-a49a-e7f4ce7ba901">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%"&gt;Product Liability&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accruals for product liability claims are recorded, on an undiscounted basis, when it is probable that a liability has been incurred and the amount of the liability can be reasonably estimated based on existing information and actuarially determined estimates where applicable. The accruals are adjusted periodically as additional information becomes available. The Company &lt;/span&gt;&lt;/div&gt;accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. To the extent adverse verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated. The Company has self insurance through a wholly-owned captive insurance company. In addition to accruals in the self insurance program, claims that exceed the insurance coverage are accrued when losses are probable and amounts can be reasonably estimated.</jnj:ProductLiabilityPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzM5_44835a2d-ba73-4ccb-8288-b92d47080401">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses are expensed as incurred in accordance with ASC 730, Research&#160;and Development.  Upfront and milestone payments made to third parties in connection with research and development collaborations are expensed as incurred up to the point of regulatory approval. Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product.  Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into collaborative arrangements, typically with other pharmaceutical or biotechnology companies, to develop and commercialize drug candidates or intellectual property. These arrangements typically involve two (or more) parties who are active participants in the collaboration and are exposed to significant risks and rewards dependent on the commercial success of the activities. These collaborations usually involve various activities by one or more parties, including research and development, marketing and selling and distribution. Often, these collaborations require upfront, milestone and royalty or profit share payments, contingent upon the occurrence of certain future events linked to the success of the asset in development. Amounts due from collaborative partners related to development activities are generally reflected as a reduction of research and development expense because the performance of contract development services is not central to the Company&#x2019;s operations. In general, the income statement presentation for these collaborations is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.535%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nature/Type of Collaboration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Statement of Earnings Presentation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Third-party sale of product &amp;amp; profit share payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales to customers&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties/milestones paid to collaborative partner (post-regulatory approval)*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalties received from collaborative partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Upfront payments&#160;&amp;amp; milestones paid to collaborative partner (pre-regulatory approval)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development payments to collaborative partner&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development payments received from collaborative partner or government entity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reduction of Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.706%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:96.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Milestones are capitalized as intangible assets and amortized to cost of products sold over the useful life.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all years presented, there was no individual project that represented greater than 5% of the total annual consolidated research and development expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a number of products and compounds developed in collaboration with strategic partners including XARELTO, co-developed with Bayer HealthCare AG and IMBRUVICA, developed in collaboration and co-marketed with Pharmacyclics LLC, an AbbVie company.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Separately, the Company has a number of licensing arrangements for products and compounds including DARZALEX, licensed from Genmab A/S.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <jnj:ConcentrationRiskThresholdPercentage
      contextRef="i02fac9589cc2476b800ec305e2b17a61_D20210104-20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE4OTY1_65028e99-b8d8-4433-974a-852337309754"
      unitRef="number">0.05</jnj:ConcentrationRiskThresholdPercentage>
    <jnj:ConcentrationRiskThresholdPercentage
      contextRef="i2cdccdf73d6c4a2d8ad6277d9b89cbc6_D20191230-20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE4OTY1_99303881-54aa-4f50-aec7-61170a0d1bf1"
      unitRef="number">0.05</jnj:ConcentrationRiskThresholdPercentage>
    <jnj:ConcentrationRiskThresholdPercentage
      contextRef="ibd8fd68737c9443dac923965cbcebb07_D20220103-20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE4OTY1_fcedf5fb-409c-45b0-b941-bf52e1225b71"
      unitRef="number">0.05</jnj:ConcentrationRiskThresholdPercentage>
    <us-gaap:AdvertisingCostsPolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODUy_43d90c53-5feb-4a54-9494-19665bb26947">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Advertising&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Costs associated with advertising are expensed in the year incurred and are included in selling, marketing and administrative expenses. Advertising expenses worldwide, which comprised television, radio, print media and Internet advertising, were $2.1 billion, $2.7 billion and $2.1 billion in fiscal years 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE5Njk0_d0dbae8e-c60d-4e03-9e2d-e40814d497b7"
      unitRef="usd">2100000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE5Njk4_6397eb0b-568f-483a-85a4-6f948ed27452"
      unitRef="usd">2700000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzE5NzA1_1bed4461-dece-483e-b122-8d6da25e1d97"
      unitRef="usd">2100000000</us-gaap:AdvertisingExpense>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2Nzg2_442747ab-9e0a-4e78-a714-3c20172caaa8">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Income taxes are recorded based on amounts refundable or payable for the current year and include the results of any difference between U.S. GAAP accounting and tax reporting, recorded as deferred tax assets or liabilities. The Company estimates deferred tax assets and liabilities based on enacted tax regulations and rates. Future changes in tax laws and rates may affect recorded deferred tax assets and liabilities in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company has unrecognized tax benefits for uncertain tax positions. The Company follows U.S. GAAP which prescribes a recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. Management believes that changes in these estimates would not have a material effect on the Company's results of operations, cash flows or financial position. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;In 2017, the United States enacted into law new U.S. tax legislation, the U.S. Tax Cuts and Jobs Act (TCJA). This law included provisions for a comprehensive overhaul of the corporate income tax code, including a reduction of the statutory corporate tax rate from 35% to 21%, effective on January 1, 2018. The TCJA included a provision for a tax on all previously &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;undistributed earnings of U.S. companies located in foreign jurisdictions. Undistributed earnings in the form of cash and cash equivalents were taxed at a rate of  15.5% and all other earnings were taxed at a rate of 8.0%. This tax is payable over 8 years and will not accrue interest. These payments began in 2018 and will continue through 2025. The remaining balance at the end of the 2022 was approximately  $6.1&#160;billion, of which $4.6&#160;billion is classified as noncurrent and reflected as &#x201c;Long-term taxes payable&#x201d; on the Company&#x2019;s balance sheet. The balance of this account is related to receivables from tax authorities not expected to be received in the next 12 months. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The TCJA also includes provisions for a tax on global intangible low-taxed income (GILTI). GILTI is described as the excess of a U.S. shareholder&#x2019;s total net foreign income over a deemed return on tangible assets, as provided by the TCJA. In January 2018, the FASB issued guidance that allows companies to elect as an accounting policy whether to record the tax effects of GILTI in the period the tax liability is generated (i.e., &#x201c;period cost&#x201d;) or provide for deferred tax assets and liabilities related to basis differences that exist and are expected to effect the amount of GILTI inclusion in future years upon reversal (i.e., &#x201c;deferred method&#x201d;). The Company has elected to account for GILTI under the deferred method. The deferred tax amounts recorded are based on the evaluation of temporary differences that are expected to reverse as GILTI is incurred in future periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company has recorded deferred tax liabilities on all undistributed earnings prior to December 31, 2017 from its international subsidiaries. The Company has not provided deferred taxes on the undistributed earnings subsequent to January 1, 2018 from certain international subsidiaries where the earnings are considered to be indefinitely reinvested. The Company intends to continue to reinvest these earnings in those international operations. If the Company decides at a later date to repatriate these earnings to the U.S., the Company would be required to provide for the net tax effects on these amounts. The Company estimates that the tax effect of this repatriation would be approximately $0.5 billion under currently enacted tax laws and regulations and at current currency exchange rates. This amount does not include the possible benefit of U.S. foreign tax credits, which may substantially offset this cost.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;See Note 8 to the Consolidated Financial Statements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;for further information regarding income taxes.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i2ba832f9031d440b8709fc80396eb47d_D20170102-20171231"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzIwOTEz_79a91e8b-f0dc-499f-8bc9-8ca2cb403f88"
      unitRef="number">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i6f986503ddc443e8b150a30eb4915336_D20180101-20181230"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzIwOTE5_121092f0-a92b-4f18-9602-f63255262445"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent
      contextRef="i6f986503ddc443e8b150a30eb4915336_D20180101-20181230"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzIxMTc0_8782142f-cb7e-4157-8e45-9bfa3c35692a"
      unitRef="number">0.155</jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent>
    <jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent
      contextRef="i6f986503ddc443e8b150a30eb4915336_D20180101-20181230"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzIxMjI0_d9901cc1-0c19-4279-a43b-3cbee39fcb13"
      unitRef="number">0.080</jnj:TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent>
    <jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzIxNDE1_cc342a71-2932-4539-b013-c7c885324210"
      unitRef="usd">6100000000</jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability>
    <jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzIxNDI4_b3be4dc6-a65a-4e14-ad48-2653d5998f95"
      unitRef="usd">4600000000</jnj:TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzIzMjM5_f1dd7fab-239a-4ee5-9428-ed624e4cb54e"
      unitRef="usd">500000000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzMz_1f7cbd27-4680-4167-a0f7-40f9c10ef8de">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Earnings Per Share&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic earnings per share is computed by dividing net earnings available to common shareholders by the weighted average number of common shares outstanding for the period. Diluted earnings per share reflects the potential dilution that could occur if securities were exercised or converted into common stock using the treasury stock method.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODA0_04e4f102-ab76-42d8-89ec-a4ca641aafa5">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the U.S.&#160;requires management to make estimates and assumptions that affect the amounts reported. Estimates are used when accounting for sales discounts, rebates, allowances and incentives, product liabilities, income taxes, withholding taxes, depreciation, amortization, employee benefits, contingencies and intangible asset and liability valuations. Actual results may or may not differ from those estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the provisions of U.S.&#160;GAAP when recording litigation related contingencies. A liability is recorded when a loss is probable and can be reasonably estimated. The best estimate of a loss within a range is accrued; however, if no estimate in the range is better than any other, the minimum amount is accrued.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <jnj:FiscalPeriodPolicyTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2ODIx_e3f53a12-b473-4981-8265-53939c69157a">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Annual Closing Date&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the concept of a fiscal year, which ends on the Sunday nearest to the end of the month of December. Normally each fiscal year consists of 52&#160;weeks, but every five or six years the fiscal year consists of 53&#160;weeks, and therefore includes additional shipping days, as was the case in fiscal year 2020, and will be the case again in fiscal year 2026.&lt;/span&gt;&lt;/div&gt;</jnj:FiscalPeriodPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDIvZnJhZzpmNmZlODU2NDkxNGE0ZWU4OGFjNWVjYmEwMmIyNGViMC90ZXh0cmVnaW9uOmY2ZmU4NTY0OTE0YTRlZTg4YWM1ZWNiYTAyYjI0ZWIwXzI2NzIx_71cf50c0-ed51-4efd-926c-4a4d73a883bb">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassification&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90ZXh0cmVnaW9uOjkxNjM1MTczMDllMTQzOTc4ZWQ2ZTU5NWRiNWE2Mjk2XzEwMDY_d0c5f1a0-af13-4621-bfad-57989186b0b1">Cash, Cash Equivalents and Current Marketable Securities&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of the fiscal year 2022 and 2021, cash, cash equivalents and current marketable securities were comprised of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate and other debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,392&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. Sovereign Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate and other debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of government securities and obligations and corporate debt securities were estimated using quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale debt securities at January&#160;1, 2023 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company invests its excess cash in both deposits with major banks throughout the world and other high-quality money market instruments. The Company has a policy of making investments only with commercial institutions that have at least an investment grade credit rating.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90ZXh0cmVnaW9uOjkxNjM1MTczMDllMTQzOTc4ZWQ2ZTU5NWRiNWE2Mjk2XzEwMDE_5e68d9b9-3784-4a04-a8bc-c8c0f4214637">&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of the fiscal year 2022 and 2021, cash, cash equivalents and current marketable securities were comprised of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,032&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;873&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,922&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't Agencies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate and other debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;351&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(34)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,127&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,392&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.615%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.056%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.690%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.219%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.382%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.526%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Carrying Amount&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized Loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Estimated Fair Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash &amp;amp; Cash Equivalents&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current Marketable Securities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,936&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-U.S. Sovereign Securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Reverse repurchase agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,659&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;200&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Time deposits&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;900&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;Subtotal &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Gov't Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate and other debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;230&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;Subtotal available for sale&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,731&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total cash, cash equivalents and current marketable securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,487&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,121&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Held to maturity investments are reported at amortized cost and realized gains or losses are reported in earnings. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Available for sale debt securities are reported at fair value with unrealized gains and losses reported net of taxes in other comprehensive income.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ibf53a7687af04964921188585c336575_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzItMi0xLTEtODQ0NDQ_68fbae21-e639-46be-ba22-785c28f04c85"
      unitRef="usd">4926000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ibf53a7687af04964921188585c336575_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzItNi0xLTEtODQ0NDQ_947b79cd-08bf-4335-9f55-a1514e9b884b"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ibf53a7687af04964921188585c336575_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzItOC0xLTEtODQ0NDQ_f9611d0e-be26-4a72-9915-f705cde46e03"
      unitRef="usd">4926000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibf53a7687af04964921188585c336575_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzItMTAtMS0xLTg0NDQ0_1be685ad-9615-464a-9671-9382b56cd34c"
      unitRef="usd">4926000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ibf53a7687af04964921188585c336575_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzItMTItMS0xLTg0NDQ0_c5318322-497b-4161-9bdf-e3356c102ee0"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i85c32c30caff4e45bdfc303e877e94fe_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzUtMi0xLTEtODQ0NDQ_d87f6e62-6c32-49b9-be3a-3fc974b98eb1"
      unitRef="usd">1419000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i85c32c30caff4e45bdfc303e877e94fe_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzUtNi0xLTEtODQ0NDQ_725941c8-2ebc-481b-a719-c8fc90cc9daa"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i85c32c30caff4e45bdfc303e877e94fe_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzUtOC0xLTEtODQ0NDQ_444a6f72-2029-4c72-a758-5587999bf280"
      unitRef="usd">1419000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i85c32c30caff4e45bdfc303e877e94fe_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzUtMTAtMS0xLTg0NDQ0_8ae07efd-9f92-4a0f-8e00-3603cea7a7c7"
      unitRef="usd">1419000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i85c32c30caff4e45bdfc303e877e94fe_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzUtMTItMS0xLTg0NDQ0_aeab5d5e-3512-4495-ab7a-ecc144666ceb"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i6bca58ccfae247149a00663f0e2670b1_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzctMi0xLTEtODQ0NDQ_4820c970-d9b2-48a0-ae52-73a92c33fe6b"
      unitRef="usd">873000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i6bca58ccfae247149a00663f0e2670b1_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzctNi0xLTEtODQ0NDQ_3699a4b8-48ac-45ea-a7e2-3505f8888397"
      unitRef="usd">1000000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i6bca58ccfae247149a00663f0e2670b1_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzctOC0xLTEtODQ0NDQ_eb97a084-56c9-49be-a0ca-5a0d9ce4196d"
      unitRef="usd">872000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i6bca58ccfae247149a00663f0e2670b1_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzctMTAtMS0xLTg0NDQ0_942d9843-b351-4c86-986d-9028b5cca91d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i6bca58ccfae247149a00663f0e2670b1_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzctMTItMS0xLTg0NDQ0_8e641af2-3f55-44ec-922e-15b7d9a602c2"
      unitRef="usd">873000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="id6f10e7ae95e4d70a2beba21fbda5a78_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzgtMi0xLTEtODQ0NDQ_eecd84e0-9bc2-460f-adad-5650a4a63598"
      unitRef="usd">5368000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="id6f10e7ae95e4d70a2beba21fbda5a78_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzgtNi0xLTEtODQ0NDQ_6b284023-8386-4fa1-b8a0-b84c00277a09"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="id6f10e7ae95e4d70a2beba21fbda5a78_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzgtOC0xLTEtODQ0NDQ_bd89853f-bbba-4834-9257-15e7192ca002"
      unitRef="usd">5368000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id6f10e7ae95e4d70a2beba21fbda5a78_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzgtMTAtMS0xLTg0NDQ0_83804ae8-5c99-42b1-a999-9db575fca0dc"
      unitRef="usd">5368000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id6f10e7ae95e4d70a2beba21fbda5a78_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzgtMTItMS0xLTg0NDQ0_73be0bee-d169-47ed-9f45-08871db51f92"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i8467c8ec68cf4654bf1cfcdfa1fe2c5a_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzktMi0xLTEtODQ0NDQ_9c48d46a-721e-4218-b2bf-581ed260e58e"
      unitRef="usd">446000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i8467c8ec68cf4654bf1cfcdfa1fe2c5a_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzktNi0xLTEtODQ0NDQ_bfb0e769-1d6c-41c3-9389-20df0f81c52a"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i8467c8ec68cf4654bf1cfcdfa1fe2c5a_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzktOC0xLTEtODQ0NDQ_f0818cf1-6f23-40be-8fdc-3c9653afa98a"
      unitRef="usd">446000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i8467c8ec68cf4654bf1cfcdfa1fe2c5a_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzktMTAtMS0xLTg0NDQ0_f2b69077-c7b8-43ed-b20f-6c720e4b0f1a"
      unitRef="usd">446000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i8467c8ec68cf4654bf1cfcdfa1fe2c5a_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzktMTItMS0xLTg0NDQ0_8e872f27-a338-4201-b19b-b948ecf80261"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i67038bc29ba6469cb0cb5ca65068f855_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEwLTItMS0xLTg0NDQ0_0e23ac88-9b2e-48d4-97ac-24fc5b4baf49"
      unitRef="usd">13032000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i67038bc29ba6469cb0cb5ca65068f855_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEwLTYtMS0xLTg0NDQ0_58d1b27c-cc94-4225-a3a2-c53e38b2b0bc"
      unitRef="usd">1000000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i67038bc29ba6469cb0cb5ca65068f855_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEwLTgtMS0xLTg0NDQ0_fb584749-4976-4ec0-b8d9-e98dd4eef6bf"
      unitRef="usd">13031000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i67038bc29ba6469cb0cb5ca65068f855_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEwLTEwLTEtMS04NDQ0NA_56c181fa-32c5-462e-a99f-f366d1fb71d5"
      unitRef="usd">12159000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i67038bc29ba6469cb0cb5ca65068f855_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEwLTEyLTEtMS04NDQ0NA_d80ea656-2a5f-4317-b20e-70b8f9900117"
      unitRef="usd">873000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i632070131d164fd8a05baaff80e0d485_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEyLTItMS0xLTg0NDQ0_5f40b467-fa5e-4563-90dd-895935d82034"
      unitRef="usd">9959000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i632070131d164fd8a05baaff80e0d485_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEyLTYtMS0xLTg0NDQ0_8036673c-69a3-43b1-aca1-53c88404aca9"
      unitRef="usd">28000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i632070131d164fd8a05baaff80e0d485_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEyLTgtMS0xLTg0NDQ0_be36f0c8-498f-43ec-a8f5-a1c2512d5fd4"
      unitRef="usd">9931000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i632070131d164fd8a05baaff80e0d485_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEyLTEwLTEtMS04NDQ0NA_020ff0ee-1861-429a-9e4d-e1b343785a14"
      unitRef="usd">1922000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i632070131d164fd8a05baaff80e0d485_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEyLTEyLTEtMS04NDQ0NA_f31b4930-87aa-41b9-8102-63d0e19ad5da"
      unitRef="usd">8009000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="icacfc2ccbd7d4914be4e26893f91b754_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEzLTItMS0xLTk4MDY3_993a7799-2d2c-40d5-b82f-afe6e986c088"
      unitRef="usd">210000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="icacfc2ccbd7d4914be4e26893f91b754_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEzLTYtMS0xLTk4MDc2_43199ffb-2a31-495a-ae57-bc12059b2c8d"
      unitRef="usd">5000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icacfc2ccbd7d4914be4e26893f91b754_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEzLTgtMS0xLTk4MDg0_4c4933e3-ebf8-4737-82e9-a62c9762a6e5"
      unitRef="usd">205000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="icacfc2ccbd7d4914be4e26893f91b754_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEzLTEwLTEtMS05ODA5NA_40fc1437-9c7a-4941-af06-9383d8296e23"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="icacfc2ccbd7d4914be4e26893f91b754_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzEzLTEyLTEtMS05ODEwMg_51a90182-06ea-4ad7-9024-b78e983e9277"
      unitRef="usd">205000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib93e73399a1d41008b08bfb56335dc30_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE0LTItMS0xLTg0NDQ0_2dde3af0-a33e-42b4-8418-c63bf66b83f2"
      unitRef="usd">352000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib93e73399a1d41008b08bfb56335dc30_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE0LTYtMS0xLTg0NDQ0_d29e8b1f-be76-4627-8e43-3511953bb5e6"
      unitRef="usd">1000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib93e73399a1d41008b08bfb56335dc30_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE0LTgtMS0xLTg0NDQ0_db830a19-772b-4f94-9ac4-3395030a4e67"
      unitRef="usd">351000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib93e73399a1d41008b08bfb56335dc30_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE0LTEwLTEtMS04NDQ0NA_b9f73cdb-dc52-4a6b-b5a4-4f5ca6988821"
      unitRef="usd">46000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ib93e73399a1d41008b08bfb56335dc30_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE0LTEyLTEtMS04NDQ0NA_24a8eb2b-2f7d-49df-a2c2-ecc69d8e7edf"
      unitRef="usd">305000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i00843ad11c494c3fb53ae75e01995264_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE2LTItMS0xLTg0NDQ0_89f070df-3b9f-4ff8-b38f-af771e1577a4"
      unitRef="usd">10521000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i00843ad11c494c3fb53ae75e01995264_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE2LTYtMS0xLTg0NDQ0_9b253df2-a977-4871-8c6d-1aa06133682e"
      unitRef="usd">34000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i00843ad11c494c3fb53ae75e01995264_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE2LTgtMS0xLTg0NDQ0_b1ed767f-7d73-4828-8b7f-e4a3c54baa03"
      unitRef="usd">10487000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i00843ad11c494c3fb53ae75e01995264_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE2LTEwLTEtMS04NDQ0NA_1f9776c7-9b22-42b2-ae8f-b330c20f3577"
      unitRef="usd">1968000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i00843ad11c494c3fb53ae75e01995264_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE2LTEyLTEtMS04NDQ0NA_00aa0b71-1668-4bbc-bd00-b5975c577391"
      unitRef="usd">8519000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE4LTEwLTEtMS04NDQ0NA_26a6523a-494f-4a60-801d-49356c843fa4"
      unitRef="usd">14127000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZToxMTMyYzllZjdiNDg0NWJmYTg3M2YwODUxYjhhMzA3MS90YWJsZXJhbmdlOjExMzJjOWVmN2I0ODQ1YmZhODczZjA4NTFiOGEzMDcxXzE4LTEyLTEtMS04NDQ0NA_66f77046-fa89-4487-891d-12db7efa8926"
      unitRef="usd">9392000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i519faf5a8e3a4305a459c43d43018179_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzItMi0xLTEtOTg5Mjg_42605bfe-59b0-4c0c-bf89-6e2d0fec36e9"
      unitRef="usd">2936000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i519faf5a8e3a4305a459c43d43018179_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzItNi0xLTEtOTkwMTI_71daab92-f62a-41b2-bd42-69d691a43bca"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i519faf5a8e3a4305a459c43d43018179_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzItOC0xLTEtOTk0NjE_713b4913-cf57-4cde-93e9-b0cb2d01fb6b"
      unitRef="usd">2936000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i519faf5a8e3a4305a459c43d43018179_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzItMTAtMS0xLTk5NDk3_4c528feb-904a-4855-a71a-1893e37a0fcb"
      unitRef="usd">2936000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i519faf5a8e3a4305a459c43d43018179_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzItMTItMS0xLTk5NTAz_0421abca-15c0-4c8f-a028-b64422f92a76"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ic073077c7dc4462981e17199faf38094_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzQtMi0xLTEtOTg5Njk_8e374d35-caf3-4090-be45-88e15f17278a"
      unitRef="usd">1006000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ic073077c7dc4462981e17199faf38094_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzQtNi0xLTEtOTk0MDE_3dc28bfb-3d4d-44ab-a6b9-5637890aed44"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ic073077c7dc4462981e17199faf38094_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzQtOC0xLTEtOTk0Njc_238b6a2f-3d1c-4fa2-8ff5-ab4043cd23f1"
      unitRef="usd">1006000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ic073077c7dc4462981e17199faf38094_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzQtMTAtMS0xLTk5NTA5_ddcc6370-fa8a-4e4a-8e48-f7972b303717"
      unitRef="usd">90000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ic073077c7dc4462981e17199faf38094_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzQtMTItMS0xLTk5NTE1_5b2799c6-027b-40e3-a5fe-9337b4055ea2"
      unitRef="usd">916000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i82c0433d6c4941c9b80bb52a13ddf638_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzUtMi0xLTEtOTg5Njk_9b2d4f46-2cb9-4123-b7b1-2b22dbd26648"
      unitRef="usd">1659000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i82c0433d6c4941c9b80bb52a13ddf638_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzUtNi0xLTEtOTk0MDE_de0fde40-0033-45b8-86df-391d6c499fd0"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i82c0433d6c4941c9b80bb52a13ddf638_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzUtOC0xLTEtOTk0Njc_dd2562dc-4eaa-4fad-a69e-76dd5868c6a5"
      unitRef="usd">1659000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i82c0433d6c4941c9b80bb52a13ddf638_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzUtMTAtMS0xLTk5NTA5_e83900a2-ac2e-4225-b244-7a395ce425e0"
      unitRef="usd">1659000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i82c0433d6c4941c9b80bb52a13ddf638_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzUtMTItMS0xLTk5NTE1_9f06815c-337a-45f3-9015-0a0b9fb5efe6"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i1a78016e63d142e2be872b5982def0bd_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzctMi0xLTEtOTg5NzU_d18ce3e2-bdfd-4212-a118-b9be7b919048"
      unitRef="usd">3479000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i1a78016e63d142e2be872b5982def0bd_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzctNi0xLTEtOTk0MTA_13054dc6-bd87-4f70-90c8-a14295367481"
      unitRef="usd">1000000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i1a78016e63d142e2be872b5982def0bd_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzctOC0xLTEtOTk0NzM_e861e908-0394-4bce-8336-592a483000ea"
      unitRef="usd">3478000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i1a78016e63d142e2be872b5982def0bd_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzctMTAtMS0xLTk5NTIx_820080d0-1f16-4383-9159-5ec91d7991c3"
      unitRef="usd">200000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i1a78016e63d142e2be872b5982def0bd_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzctMTItMS0xLTk5NTI3_cd8a1086-c60e-40d5-883f-28ef81af72e6"
      unitRef="usd">3279000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="i257e8511898a47d39e8a99ec93263f31_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzgtMi0xLTEtOTg5NzU_957deda2-49db-4229-be16-2aa8524bedd0"
      unitRef="usd">1901000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="i257e8511898a47d39e8a99ec93263f31_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzgtNi0xLTEtOTk0MTA_45bd5cd5-64c2-45a7-a8b9-6a497031ca92"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="i257e8511898a47d39e8a99ec93263f31_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzgtOC0xLTEtOTk0NzM_aab4d988-9125-488c-9a3b-cc4b34b0694b"
      unitRef="usd">1901000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i257e8511898a47d39e8a99ec93263f31_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzgtMTAtMS0xLTk5NTIx_d5b37d0d-7873-45a3-8ce0-508542e1a154"
      unitRef="usd">1901000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i257e8511898a47d39e8a99ec93263f31_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzgtMTItMS0xLTk5NTI3_5fc903d1-4e47-485f-8941-ac4a32e09e8a"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="id9c9e2118e3a44a88a2ba07a0b756864_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzktMi0xLTEtOTg5NzU_dcadd982-9edb-42ea-94eb-13843e306ca0"
      unitRef="usd">900000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="id9c9e2118e3a44a88a2ba07a0b756864_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzktNi0xLTEtOTk0MTA_77ae4946-c19c-4bce-ba13-f0134c915a44"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="id9c9e2118e3a44a88a2ba07a0b756864_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzktOC0xLTEtOTk0NzM_d497b89e-db7e-4180-9a83-815412899458"
      unitRef="usd">900000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="id9c9e2118e3a44a88a2ba07a0b756864_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzktMTAtMS0xLTk5NTIx_f7b157db-8d36-4080-a150-e9a6990c4b43"
      unitRef="usd">900000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="id9c9e2118e3a44a88a2ba07a0b756864_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzktMTItMS0xLTk5NTI3_2b994915-0ab0-4cd2-8e65-1a2d0d91ef07"
      unitRef="usd">0</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecurities
      contextRef="ib4c98dc571d344a8a06b677c3e8a1699_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEwLTItMS0xLTk4OTc1_f923a00b-0a7a-43dc-9018-15e813680b08"
      unitRef="usd">11881000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="ib4c98dc571d344a8a06b677c3e8a1699_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEwLTYtMS0xLTk5NDMy_0be38d9c-30d6-4807-8e11-85f3ccc10a34"
      unitRef="usd">1000000</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="ib4c98dc571d344a8a06b677c3e8a1699_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEwLTgtMS0xLTk5NDcz_34e9e09f-6f34-41c1-a29b-d0d753c2ef45"
      unitRef="usd">11880000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ib4c98dc571d344a8a06b677c3e8a1699_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEwLTEwLTEtMS05OTUyMQ_1c612221-f233-4715-9389-19932e433ccd"
      unitRef="usd">7686000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ib4c98dc571d344a8a06b677c3e8a1699_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEwLTEyLTEtMS05OTUyNw_77830cf1-d121-4b68-899d-a4090fd961d6"
      unitRef="usd">4195000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="if181e914ddc64a03888d0ef1285d38d7_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEyLTItMS0xLTk4OTg2_4b6a8345-8ed8-4f03-bc9f-f9f64da739e1"
      unitRef="usd">19485000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="if181e914ddc64a03888d0ef1285d38d7_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEyLTYtMS0xLTk5NDM4_81f12a75-b7b0-4bdb-a008-fa56718be431"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if181e914ddc64a03888d0ef1285d38d7_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEyLTgtMS0xLTk5NDc5_7bfd1165-9dab-4adf-973c-2402e8311d5a"
      unitRef="usd">19481000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="if181e914ddc64a03888d0ef1285d38d7_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEyLTEwLTEtMS05OTUzMw_1e304218-d434-409d-87b1-dd98c3abd575"
      unitRef="usd">6785000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="if181e914ddc64a03888d0ef1285d38d7_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzEyLTEyLTEtMS05OTU1MQ_7e4b6059-7638-4842-8a1f-71409525d0f6"
      unitRef="usd">12696000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i3ce066abcfe8429094c975b988b24365_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE0LTItMS0xLTk4OTk0_7d63b8a0-aa1d-40ec-b715-eeff4a9b9dd4"
      unitRef="usd">246000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i3ce066abcfe8429094c975b988b24365_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE0LTYtMS0xLTk5NDQ5_3df11e1d-b321-4983-97af-90942e42cc90"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3ce066abcfe8429094c975b988b24365_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE0LTgtMS0xLTk5NDg1_faa7d0f7-9528-405f-9f05-71e1269f4e01"
      unitRef="usd">246000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i3ce066abcfe8429094c975b988b24365_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE0LTEwLTEtMS05OTUzOQ_29a9cc83-ea55-42a5-997a-c914ee0cc03f"
      unitRef="usd">16000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i3ce066abcfe8429094c975b988b24365_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE0LTEyLTEtMS05OTU1Nw_d62ddd23-b164-48fb-aeb9-c75c42e09436"
      unitRef="usd">230000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i75b15a0f49774cf698bedb20449bca68_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE2LTItMS0xLTk5MDAx_8e5f4799-4672-408c-b910-d224c0155ed7"
      unitRef="usd">19731000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i75b15a0f49774cf698bedb20449bca68_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE2LTYtMS0xLTk5NDU1_833a9cd1-aef5-4585-94c2-fdbe3074bb00"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i75b15a0f49774cf698bedb20449bca68_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE2LTgtMS0xLTk5NDkx_bca6f088-731c-47fa-9be6-7413788f44c0"
      unitRef="usd">19727000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i75b15a0f49774cf698bedb20449bca68_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE2LTEwLTEtMS05OTU0NQ_bbe0ccb1-cec6-4886-9074-3816edb3083d"
      unitRef="usd">6801000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="i75b15a0f49774cf698bedb20449bca68_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE2LTEyLTEtMS05OTU2Mw_60629a9d-ef05-4356-816c-85e971482719"
      unitRef="usd">12926000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE4LTEwLTEtMS05OTU2OQ_e00b8151-5864-4a33-8831-d303660ae63d"
      unitRef="usd">14487000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTphOWRmYmNkYTliNzA0MDZmODg4YTU1M2FjMWI5MzVkNy90YWJsZXJhbmdlOmE5ZGZiY2RhOWI3MDQwNmY4ODhhNTUzYWMxYjkzNWQ3XzE4LTEyLTEtMS05OTU3NQ_55d36fc2-3c35-462f-b6ca-858a01f7e89b"
      unitRef="usd">17121000000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90ZXh0cmVnaW9uOjkxNjM1MTczMDllMTQzOTc4ZWQ2ZTU5NWRiNWE2Mjk2XzEwMDM_a2bdde92-1092-48a4-9803-1031107425c2">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The contractual maturities of the available for sale debt securities at January&#160;1, 2023 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:88.157%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.377%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:22.119%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost Basis&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due within one year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,430&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,399&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Due after five years through ten years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,521&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTpiZjExYzhmN2FiZTc0MjE0YjdmNTM2YTkxYmRiZmU2NS90YWJsZXJhbmdlOmJmMTFjOGY3YWJlNzQyMTRiN2Y1MzZhOTFiZGJmZTY1XzEtMi0xLTEtODQ0NDQ_694b5c29-ac51-4787-8d7b-e7ac902a06e4"
      unitRef="usd">10430000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTpiZjExYzhmN2FiZTc0MjE0YjdmNTM2YTkxYmRiZmU2NS90YWJsZXJhbmdlOmJmMTFjOGY3YWJlNzQyMTRiN2Y1MzZhOTFiZGJmZTY1XzEtNC0xLTEtODQ0NDQ_add7a15e-f1a7-4b17-9839-26037caccffc"
      unitRef="usd">10399000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTpiZjExYzhmN2FiZTc0MjE0YjdmNTM2YTkxYmRiZmU2NS90YWJsZXJhbmdlOmJmMTFjOGY3YWJlNzQyMTRiN2Y1MzZhOTFiZGJmZTY1XzItMi0xLTEtODQ0NDQ_c57e72cc-6733-499b-9449-06037e2c9a3c"
      unitRef="usd">91000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTpiZjExYzhmN2FiZTc0MjE0YjdmNTM2YTkxYmRiZmU2NS90YWJsZXJhbmdlOmJmMTFjOGY3YWJlNzQyMTRiN2Y1MzZhOTFiZGJmZTY1XzItNC0xLTEtODQ0NDQ_0222e6e1-ab06-49c5-b84e-bc75f4d9539e"
      unitRef="usd">88000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTpiZjExYzhmN2FiZTc0MjE0YjdmNTM2YTkxYmRiZmU2NS90YWJsZXJhbmdlOmJmMTFjOGY3YWJlNzQyMTRiN2Y1MzZhOTFiZGJmZTY1XzMtMi0xLTEtODQ0NDQ_1549dc78-69ba-4ce6-a9d7-039d1b03ee5a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTpiZjExYzhmN2FiZTc0MjE0YjdmNTM2YTkxYmRiZmU2NS90YWJsZXJhbmdlOmJmMTFjOGY3YWJlNzQyMTRiN2Y1MzZhOTFiZGJmZTY1XzMtNC0xLTEtODQ0NDQ_47500c47-df51-451a-bfbf-1cab32d92618"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTpiZjExYzhmN2FiZTc0MjE0YjdmNTM2YTkxYmRiZmU2NS90YWJsZXJhbmdlOmJmMTFjOGY3YWJlNzQyMTRiN2Y1MzZhOTFiZGJmZTY1XzQtMi0xLTEtODQ0NDQ_883eb41a-3097-4330-8717-ae07f8116efb"
      unitRef="usd">10521000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNDgvZnJhZzo5MTYzNTE3MzA5ZTE0Mzk3OGVkNmU1OTVkYjVhNjI5Ni90YWJsZTpiZjExYzhmN2FiZTc0MjE0YjdmNTM2YTkxYmRiZmU2NS90YWJsZXJhbmdlOmJmMTFjOGY3YWJlNzQyMTRiN2Y1MzZhOTFiZGJmZTY1XzQtNC0xLTEtODQ0NDQ_61e5873e-d5d8-4d5e-b6bb-96c64f385a4b"
      unitRef="usd">10487000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90ZXh0cmVnaW9uOjdiNWVkMzUyMmVmMzQ2NWZhNmM1NzA0NGJkOTJmMDE3Xzk1_b0c0635c-fe4c-47b6-aaec-6ed593a8187d">Inventories&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2022 and 2021, inventories were comprised of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,483&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90ZXh0cmVnaW9uOjdiNWVkMzUyMmVmMzQ2NWZhNmM1NzA0NGJkOTJmMDE3Xzk5_000d8ee5-e246-484e-96a4-1eeef7ece73e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2022 and 2021, inventories were comprised of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:89.766%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:66.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.614%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.069%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.645%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.072%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,070&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goods in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total inventories&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,483&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,387&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90YWJsZTo5MTVmYTA3MjY0NmE0OGJmOGNiMzQ2ZmNjYjljZDliNy90YWJsZXJhbmdlOjkxNWZhMDcyNjQ2YTQ4YmY4Y2IzNDZmY2NiOWNkOWI3XzEtMi0xLTEtODQ0NDQ_ff41ea3f-a3f4-4ea5-b28c-6f1b6858d7fc"
      unitRef="usd">2070000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90YWJsZTo5MTVmYTA3MjY0NmE0OGJmOGNiMzQ2ZmNjYjljZDliNy90YWJsZXJhbmdlOjkxNWZhMDcyNjQ2YTQ4YmY4Y2IzNDZmY2NiOWNkOWI3XzEtNC0xLTEtODQ0NDQ_bc4b03f1-12cc-4774-b428-3796956c594a"
      unitRef="usd">1592000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90YWJsZTo5MTVmYTA3MjY0NmE0OGJmOGNiMzQ2ZmNjYjljZDliNy90YWJsZXJhbmdlOjkxNWZhMDcyNjQ2YTQ4YmY4Y2IzNDZmY2NiOWNkOWI3XzItMi0xLTEtODQ0NDQ_869dc377-04d3-4652-995d-2d8de9b47e97"
      unitRef="usd">1700000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90YWJsZTo5MTVmYTA3MjY0NmE0OGJmOGNiMzQ2ZmNjYjljZDliNy90YWJsZXJhbmdlOjkxNWZhMDcyNjQ2YTQ4YmY4Y2IzNDZmY2NiOWNkOWI3XzItNC0xLTEtODQ0NDQ_f345314b-d4ee-405c-b827-3f49a193d98d"
      unitRef="usd">2287000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90YWJsZTo5MTVmYTA3MjY0NmE0OGJmOGNiMzQ2ZmNjYjljZDliNy90YWJsZXJhbmdlOjkxNWZhMDcyNjQ2YTQ4YmY4Y2IzNDZmY2NiOWNkOWI3XzMtMi0xLTEtODQ0NDQ_6151129a-6267-4948-ab25-e5737db15f55"
      unitRef="usd">8713000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90YWJsZTo5MTVmYTA3MjY0NmE0OGJmOGNiMzQ2ZmNjYjljZDliNy90YWJsZXJhbmdlOjkxNWZhMDcyNjQ2YTQ4YmY4Y2IzNDZmY2NiOWNkOWI3XzMtNC0xLTEtODQ0NDQ_45ba55fa-0d7d-4cee-9940-65b022e3b11b"
      unitRef="usd">6508000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90YWJsZTo5MTVmYTA3MjY0NmE0OGJmOGNiMzQ2ZmNjYjljZDliNy90YWJsZXJhbmdlOjkxNWZhMDcyNjQ2YTQ4YmY4Y2IzNDZmY2NiOWNkOWI3XzQtMi0xLTEtODQ0NDQ_aaeae968-d4e6-469f-bd95-65430398b902"
      unitRef="usd">12483000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTEvZnJhZzo3YjVlZDM1MjJlZjM0NjVmYTZjNTcwNDRiZDkyZjAxNy90YWJsZTo5MTVmYTA3MjY0NmE0OGJmOGNiMzQ2ZmNjYjljZDliNy90YWJsZXJhbmdlOjkxNWZhMDcyNjQ2YTQ4YmY4Y2IzNDZmY2NiOWNkOWI3XzQtNC0xLTEtODQ0NDQ_33104ebe-68da-4846-8288-a7eba38b66f1"
      unitRef="usd">10387000000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90ZXh0cmVnaW9uOjI5ZTBlM2JiMWE5ZTQyYWJhOGU5MmM5OTJhMzY1YzIzXzgxMQ_ca1d3323-45e2-4345-87b3-e26b7a39aee5">Property, Plant and Equipment&lt;div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2022 and 2021, property, plant and equipment at cost and accumulated depreciation were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,803&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,962&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes interest expense as part of the cost of construction of facilities and equipment. Interest expense capitalized in fiscal years 2022, 2021 and 2020 was $49 million, $49 million and $63 million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation expense, including the amortization of capitalized interest in fiscal years 2022, 2021 and 2020 was $2.7 billion, $2.7 billion and $2.6 billion, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon retirement or other disposal of property, plant and equipment, the costs and related amounts of accumulated depreciation or amortization are eliminated from the asset and accumulated depreciation accounts, respectively. The difference, if any, between the net asset value and the proceeds are recorded in earnings.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90ZXh0cmVnaW9uOjI5ZTBlM2JiMWE5ZTQyYWJhOGU5MmM5OTJhMzY1YzIzXzgxNA_5396a86d-766d-408e-b6cd-af6f1d7ee508">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2022 and 2021, property, plant and equipment at cost and accumulated depreciation were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.883%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:67.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.305%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.443%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.307%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Land and land improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Buildings and building equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Machinery and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Construction in progress&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;49,253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,717&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total property, plant and equipment, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;19,803&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,962&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i29a1acc3c1844b598aadafb03da80979_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzEtMi0xLTEtODQ0NDQ_7dfe818e-43bf-4254-9d87-128710e678e2"
      unitRef="usd">859000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="if115c6f434d64fca899b4e6a5f072637_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzEtNC0xLTEtODQ0NDQ_2eb31cf1-bc3b-43d2-be1b-76bc2ba7fe19"
      unitRef="usd">884000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ifedc4ec86cd34c35b9afcab55baa12c2_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzItMi0xLTEtODQ0NDQ_095ab3b9-7891-49bd-96e3-dac66b53506c"
      unitRef="usd">12989000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i8b40c1d088ec4a9789ae9b2483d16368_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzItNC0xLTEtODQ0NDQ_c51c485d-2269-429c-a96a-1519d1bc9d57"
      unitRef="usd">12882000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="id891cac7e84b467ea4fcc3186ec8542e_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzMtMi0xLTEtODQ0NDQ_c74d150e-691f-4226-8519-cd4c31fd7f79"
      unitRef="usd">30431000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ib504a49900c149668603de87c85be222_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzMtNC0xLTEtODQ0NDQ_5413b41b-91df-486a-bb4e-d977bef121df"
      unitRef="usd">29774000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibacac16e36314568b61aff5d3e80baea_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzQtMi0xLTEtODQ0NDQ_f6dfa518-6eaa-46a7-a08a-4d23cf443965"
      unitRef="usd">4974000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i01d8e5a2c62c4ce184e8d87099bffb41_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzQtNC0xLTEtODQ0NDQ_9b7beb1b-593e-4308-84a2-0637803dd37c"
      unitRef="usd">4139000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzUtMi0xLTEtODQ0NDQ_f7c92d7f-7e52-4ed8-8945-4b9ab68175c1"
      unitRef="usd">49253000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzUtNC0xLTEtODQ0NDQ_02364566-85d9-490c-9607-ed2dd423388f"
      unitRef="usd">47679000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzYtMi0xLTEtODQ0NDQ_e6565b91-2ae1-4fca-9a27-730d58f5dac2"
      unitRef="usd">29450000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzYtNC0xLTEtODQ0NDQ_5216a3e0-a459-4b15-9be8-dd60911d378b"
      unitRef="usd">28717000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzctMi0xLTEtODQ0NDQ_49b0abd6-bd2e-40a3-b939-97946248c017"
      unitRef="usd">19803000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90YWJsZTo3OTRhZjFiNzU2NjY0M2NkYmNjMGVjMDYyNDdlZjFiOC90YWJsZXJhbmdlOjc5NGFmMWI3NTY2NjQzY2RiY2MwZWMwNjI0N2VmMWI4XzctNC0xLTEtODQ0NDQ_4505ea5e-5c3f-4057-8cbe-9ad1b0bb2f41"
      unitRef="usd">18962000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:InterestCostsCapitalized
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90ZXh0cmVnaW9uOjI5ZTBlM2JiMWE5ZTQyYWJhOGU5MmM5OTJhMzY1YzIzXzMxOA_2dbb07b2-22cf-4958-80e7-a41c56c5cdd7"
      unitRef="usd">49000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90ZXh0cmVnaW9uOjI5ZTBlM2JiMWE5ZTQyYWJhOGU5MmM5OTJhMzY1YzIzXzMyMg_e94874d7-d3d2-4fed-ad35-d34f4fa190a6"
      unitRef="usd">49000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90ZXh0cmVnaW9uOjI5ZTBlM2JiMWE5ZTQyYWJhOGU5MmM5OTJhMzY1YzIzXzMyOQ_2474af8c-140e-4235-9699-c4ee03dc5f2b"
      unitRef="usd">63000000</us-gaap:InterestCostsCapitalized>
    <jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90ZXh0cmVnaW9uOjI5ZTBlM2JiMWE5ZTQyYWJhOGU5MmM5OTJhMzY1YzIzXzQ1NA_5c3546d7-9fd8-451d-a057-fb2f35f13fc3"
      unitRef="usd">2700000000</jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest>
    <jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90ZXh0cmVnaW9uOjI5ZTBlM2JiMWE5ZTQyYWJhOGU5MmM5OTJhMzY1YzIzXzQ1OA_d2be2fae-b09b-42e1-a3c5-cf4c68086d23"
      unitRef="usd">2700000000</jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest>
    <jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTQvZnJhZzoyOWUwZTNiYjFhOWU0MmFiYThlOTJjOTkyYTM2NWMyMy90ZXh0cmVnaW9uOjI5ZTBlM2JiMWE5ZTQyYWJhOGU5MmM5OTJhMzY1YzIzXzQ2NQ_c859cbae-58ce-4e94-b853-42703c8d70f7"
      unitRef="usd">2600000000</jnj:DepreciationExpenseIncludingAmortizationOfCapitalizedInterest>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzE1NDA_1ce80390-acca-4e87-a524-10aec8c8acab">Intangible Assets and Goodwill&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2022 and 2021, the gross and net amounts of intangible assets were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks&#160;&#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks&#160;&#x2014; net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,484&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,086&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,086&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&#160;&#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;48,325&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46,392&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The change was primarily related to the intangible assets acquired with the acquisition of Abiomed, Inc. which was partially offset by amortization expense of previously existing intangible assets and the result of currency translation effects.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The reduction was primarily related to an intangible asset impairment charge of approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;$0.8&#160;billion recorded in the fiscal year 2022 related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS. An additional reduction of $0.7&#160;billion was driven by Monarch assets that reached commercialization and are now classified as having definite lives. This was partially offset by approximately $1.1&#160;billion of IPR&amp;amp;D acquired with Abiomed, Inc. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of January&#160;1, 2023 and January&#160;2, 2022, as allocated by segment of business, was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,863&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;45,231&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average amortization period for patents and trademarks is 12 years. The weighted average amortization period for customer relationships and other intangible assets is 21 years. The amortization expense of amortizable assets included in Cost of products sold was $4.3 billion, $4.7 billion and $4.7 billion before tax, for the fiscal years ended January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, respectively. Intangible asset write-downs are included in Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,400&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note 18 to the Consolidated Financial Statements for additional details related to acquisitions and divestitures.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzE1NDk_f88f5b53-9294-47e1-a5f2-6e755959691a">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal years 2022 and 2021, the gross and net amounts of intangible assets were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets with definite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks&#160;&#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,572&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22,266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,088)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Patents and trademarks&#160;&#x2014; net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,746&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;18,484&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; gross&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,987&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,011&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less accumulated amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,901)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,925)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Customer relationships and other intangibles&#160;&#x2014; net&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,086&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;11,086&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Intangible assets with indefinite lives:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Trademarks&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Purchased in-process research and development&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets with indefinite lives&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,493&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,822&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total intangible assets&#160;&#x2014; net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;48,325&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;46,392&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The change was primarily related to the intangible assets acquired with the acquisition of Abiomed, Inc. which was partially offset by amortization expense of previously existing intangible assets and the result of currency translation effects.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The majority is comprised of customer relationships&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:115%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:115%"&gt;The reduction was primarily related to an intangible asset impairment charge of approximately&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &lt;/span&gt;$0.8&#160;billion recorded in the fiscal year 2022 related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS. An additional reduction of $0.7&#160;billion was driven by Monarch assets that reached commercialization and are now classified as having definite lives. This was partially offset by approximately $1.1&#160;billion of IPR&amp;amp;D acquired with Abiomed, Inc.</jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ie9e0ee8b5a704aaca8a9274822576332_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzItMi0xLTEtODQ0NDQ_99432cf7-4b0f-4bf5-9951-4fde42a9dd29"
      unitRef="usd">44012000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="ib9408b29849f4c0b9380a8d9f61c6f3e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzItNC0xLTEtODQ0NDQ_e49a20f8-06ee-4b50-96ae-f47c130a444d"
      unitRef="usd">38572000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ie9e0ee8b5a704aaca8a9274822576332_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzMtMi0xLTEtODQ0NDQ_b9de4925-d6f3-4eec-ba5c-2c7e3d291a2c"
      unitRef="usd">22266000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="ib9408b29849f4c0b9380a8d9f61c6f3e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzMtNC0xLTEtODQ0NDQ_58144203-232b-405e-85d5-f516933c50d6"
      unitRef="usd">20088000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ie9e0ee8b5a704aaca8a9274822576332_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzQtMi0xLTEtODQ0NDQ_7c6e2929-5dd5-4285-bb2e-6b0606c512dc"
      unitRef="usd">21746000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="ib9408b29849f4c0b9380a8d9f61c6f3e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzQtNC0xLTEtODQ0NDQ_8632a54c-0f44-42b6-b1da-10b6b0e27f70"
      unitRef="usd">18484000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i282196aad12c47c99220e44da280b8d8_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzUtMi0xLTEtODQ0NDQ_862f2a39-4c0e-4f9d-86e9-8643167d1173"
      unitRef="usd">22987000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="i247541d8f154426a91d3065202f7ea83_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzUtNC0xLTEtODQ0NDQ_d3ef6fd2-d339-4219-aba8-f6df66972073"
      unitRef="usd">23011000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i282196aad12c47c99220e44da280b8d8_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzYtMi0xLTEtODQ0NDQ_81a260a6-82a5-4abb-abcb-cc69753ad149"
      unitRef="usd">12901000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="i247541d8f154426a91d3065202f7ea83_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzYtNC0xLTEtODQ0NDQ_35a59f00-5907-4d21-9521-db6629086898"
      unitRef="usd">11925000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i282196aad12c47c99220e44da280b8d8_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzctMi0xLTEtODQ0NDQ_dadbe387-c190-475e-9b0e-d2f7c233ebac"
      unitRef="usd">10086000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="i247541d8f154426a91d3065202f7ea83_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzctNC0xLTEtODQ0NDQ_c2703bd5-c998-4fa1-8fd9-26efda698d92"
      unitRef="usd">11086000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ifdfd1b47f49946eca78fbf8f06e72987_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzktMi0xLTEtODQ0NDQ_a0aa6607-e812-4491-bb4a-045dc0ad2751"
      unitRef="usd">6807000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i626b5e4c6aef4b478b14fa53c5ad89bf_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzktNC0xLTEtODQ0NDQ_7297e42c-9049-4c34-b37b-60ce3a657e90"
      unitRef="usd">6985000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i406e87a2fe59450390cb44ac1a234e33_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzEwLTItMS0xLTg0NDQ0_d4595ae1-cba5-4882-b192-fc439d815c73"
      unitRef="usd">9686000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i4d2228f7987c44149e5a689a665fe7f0_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzEwLTQtMS0xLTg0NDQ0_d32cf866-09da-4d8b-aa9f-f932f11c781a"
      unitRef="usd">9837000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzExLTItMS0xLTg0NDQ0_29ee15fc-9488-4460-8580-8907197b44a2"
      unitRef="usd">16493000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzExLTQtMS0xLTg0NDQ0_6db4381f-23af-46c7-8d05-695095965fcb"
      unitRef="usd">16822000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzEyLTItMS0xLTg0NDQ0_fed66578-27ce-4c56-b7db-0e54a4a8e713"
      unitRef="usd">48325000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpiOWU3ZmYwZGZhZWE0YjgzODk1OWJiMDFjZjczMmQ2Mi90YWJsZXJhbmdlOmI5ZTdmZjBkZmFlYTRiODM4OTU5YmIwMWNmNzMyZDYyXzEyLTQtMS0xLTg0NDQ0_c7b62a74-1931-4732-89e8-d540081833e8"
      unitRef="usd">46392000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i0e228c02951e4d53a756f82e5d074c5e_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzU0OTc1NTgxNjIwMQ_2882df41-158a-4433-89ce-bcd63dee8b7a"
      unitRef="usd">800000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent
      contextRef="ib43d5a9a7c574ba0a893b62c4b1938a6_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzU0OTc1NTgxOTQxNg_23248519-ac76-4891-8ede-59098c19ac52"
      unitRef="usd">-700000000</us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ie439be9218914ee6b4279a8133fe851b_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzU0OTc1NTgxOTIyNA_de3ff367-555c-4baf-a65c-6168057d5427"
      unitRef="usd">1100000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzE1NTY_184cd824-292a-4a9a-9afc-52c14b844419">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Goodwill as of January&#160;1, 2023 and January&#160;2, 2022, as allocated by segment of business, was as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.321%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:33.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.253%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.777%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.407%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.249%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,009&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,048&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,393&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(517)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(429)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(192)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,138)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,810&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill, related to divestitures&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Currency translation/other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(626)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(396)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(49)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,071)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;9,184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;25,863&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;45,231&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="ib42b110678ca4863806a1d2bf6bd1bcc_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzEtMi0xLTEtODQ0NDQ_8094be31-5206-4aa8-a0f6-cf9f8486750e"
      unitRef="usd">10336000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5629ac5f2c33469584439760fbeaa46e_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzEtNC0xLTEtODQ0NDQ_14c549e1-a341-4c0b-ac76-53ad1e6c1bfb"
      unitRef="usd">11009000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7f72a14eea6547cebb097d81ee48e0d6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzEtNi0xLTEtODQ0NDQ_665aa453-2dd6-4177-823e-f668b9f02f52"
      unitRef="usd">15048000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzEtOC0xLTEtODQ0NDQ_182cfff9-8683-431d-a245-420d392bfad5"
      unitRef="usd">36393000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i2c6099acc42a42639c659499eeee550a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzItMi0xLTEtODQ0NDQ_06b3b81f-af67-46ba-b0ad-40b9bef4e6ef"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzItNC0xLTEtODQ0NDQ_a7b3bffd-e0f8-4c99-9ea2-28138374fd88"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzItNi0xLTEtODQ0NDQ_7022917c-5b64-4087-829c-396a95104ca0"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzItOC0xLTEtODQ0NDQ_bb35d41c-c598-4699-911b-ec005e695c19"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i2c6099acc42a42639c659499eeee550a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzMtMi0xLTEtODQ0NDQ_b6b91360-c977-4e4b-9072-dcc64f97915e"
      unitRef="usd">9000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzMtNC0xLTEtODQ0NDQ_b483e00d-435b-47c1-ba60-8f30ef3ac65f"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzMtNi0xLTEtODQ0NDQ_2cac1594-d399-4eee-9873-95f4eb5d81e3"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzMtOC0xLTEtOTg0MTA_5c0d2173-2060-465c-acad-d8b7a1c8dc9a"
      unitRef="usd">9000000</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i2c6099acc42a42639c659499eeee550a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzQtMi0xLTEtODQ0NDQ_a830a442-2c23-46de-9c95-eb6e03d7e3df"
      unitRef="usd">-517000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzQtNC0xLTEtODQ0NDQ_1bd1ac77-eef5-4382-a1d6-59b6fd5afc7e"
      unitRef="usd">-429000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzQtNi0xLTEtODQ0NDQ_176d454a-9c06-42f1-8427-7c3d98c5ab3c"
      unitRef="usd">-192000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzQtOC0xLTEtODQ0NDQ_0aadde63-4dfc-46ca-a043-178a5278ec9b"
      unitRef="usd">-1138000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="ib4784eb1517047d9af150653b71eabfe_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzUtMi0xLTEtODQ0NDQ_66dc7731-a12a-4ba6-aece-53d2bfa0b17b"
      unitRef="usd">9810000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ia4852527980040579d16cf952b6a58ff_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzUtNC0xLTEtODQ0NDQ_14d1a187-a278-4db8-a188-9a7e87897177"
      unitRef="usd">10580000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i85328680ec914e0d9a276b4db4c66dcd_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzUtNi0xLTEtODQ0NDQ_4b962222-0e07-43c9-a1f8-825af5547c52"
      unitRef="usd">14856000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzUtOC0xLTEtODQ0NDQ_685f0010-1949-4f8c-9ff8-e50420cb9512"
      unitRef="usd">35246000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ia324deef03f5433486883e8775658b95_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzYtMi0xLTEtODQ0NDQ_b877f7d6-9ac3-4d54-9f1e-9fd124e3a082"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzYtNC0xLTEtODQ0NDQ_e100d89f-0957-4a7e-bce0-efda661ddcaa"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzYtNi0xLTEtODQ0NDQ_512ddead-5f4e-4141-82e6-d472dc0d4ab1"
      unitRef="usd">11056000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzYtOC0xLTEtODQ0NDQ_78c706ef-e675-4d49-acbd-a2d443cc03b8"
      unitRef="usd">11056000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="ia324deef03f5433486883e8775658b95_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzctMi0xLTEtODQ0NDQ_1987ee81-4357-49e0-ade4-d7b614ca4a61"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzctNC0xLTEtODQ0NDQ_dbfe6472-ceb5-4b7b-aa08-81cb979c295c"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzctNi0xLTEtODQ0NDQ_7a36c5bd-4285-4fed-9f99-660676b7a699"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzctOC0xLTEtODQ0NDQ_4639be48-6814-461c-af5a-c96a52efaa4d"
      unitRef="usd">0</us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="ia324deef03f5433486883e8775658b95_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzgtMi0xLTEtODQ0NDQ_c7d1030a-809e-4e62-b8d3-a916901ad36a"
      unitRef="usd">-626000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzgtNC0xLTEtODQ0NDQ_dd66a7c3-4565-4a41-bd3c-684eedeb72b0"
      unitRef="usd">-396000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzgtNi0xLTEtODQ0NDQ_ab692542-7ebb-4c5a-a797-4a8b4f4b0e5e"
      unitRef="usd">-49000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzgtOC0xLTEtODQ0NDQ_7430df1c-00f5-4128-8020-8f8b6a675506"
      unitRef="usd">-1071000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="ie72473fe7392450db0865cca43131db3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzktMi0xLTEtODQ0NDQ_e20f965f-ecf3-420a-a94c-24b7e99a2044"
      unitRef="usd">9184000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i6f076cad0e094616a814262376cb5191_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzktNC0xLTEtODQ0NDQ_4d338f33-5701-432c-a31a-5a055ac6c488"
      unitRef="usd">10184000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i0fe95ef042a2429798d99a69cf874da9_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzktNi0xLTEtODQ0NDQ_6bca1791-ff3c-4f47-ad39-aa14b86bc29b"
      unitRef="usd">25863000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTpkYzEwNGIwMzYwMDU0YTBiOGIyOTA0MjE4ZjcyNjg2OS90YWJsZXJhbmdlOmRjMTA0YjAzNjAwNTRhMGI4YjI5MDQyMThmNzI2ODY5XzktOC0xLTEtODQ0NDQ_78657f7b-c1b2-43c2-bd96-62db328bac18"
      unitRef="usd">45231000000</us-gaap:Goodwill>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i1379957dc92040fdaa4530fe7c7b94a4_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1Xzk1Mg_07ee9421-929c-42c2-8dc7-990a0f8597fb">P12Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="ie385825a1c3f41b6b5d0e02f82243bb4_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzEwNTU_90fe0214-4828-4620-a0ad-0b76134da38f">P21Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzExNDQ_128ffcf8-ba72-42f5-8864-f0a287bf9d1e"
      unitRef="usd">4300000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzExNDg_5e03a6cc-d5f7-461e-a905-9d57628cfe9c"
      unitRef="usd">4700000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzExNTU_09b8107d-a064-4ccd-be1f-43ba52e4ca74"
      unitRef="usd">4700000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90ZXh0cmVnaW9uOmIwZjkwNDVhZmNiOTQ4MTJhYzhjNWZmYTliNWE2ODc1XzE1NDY_4aa70e5a-53c6-444a-bfc4-2e4895b449e8">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The estimated amortization expense for approved products, before tax, for the five succeeding years is approximately:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:70.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.528%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.114%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.908%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.833%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.910%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$4,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,400&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,600&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,000&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,400&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTplMzJlMmY3Yzk2NjU0ODBhYmUyYmVlOWM5NWM0M2YyMC90YWJsZXJhbmdlOmUzMmUyZjdjOTY2NTQ4MGFiZTJiZWU5Yzk1YzQzZjIwXzItMC0xLTEtODQ0NDQ_1cc549be-3749-450f-9afd-58a313deaae0"
      unitRef="usd">4600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTplMzJlMmY3Yzk2NjU0ODBhYmUyYmVlOWM5NWM0M2YyMC90YWJsZXJhbmdlOmUzMmUyZjdjOTY2NTQ4MGFiZTJiZWU5Yzk1YzQzZjIwXzItMi0xLTEtODQ0NDQ_9cf3b78f-3974-48a9-b98b-31e7d709f980"
      unitRef="usd">4400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTplMzJlMmY3Yzk2NjU0ODBhYmUyYmVlOWM5NWM0M2YyMC90YWJsZXJhbmdlOmUzMmUyZjdjOTY2NTQ4MGFiZTJiZWU5Yzk1YzQzZjIwXzItNC0xLTEtODQ0NDQ_07b4cb90-8fbd-43f4-9edd-cacde1e27d14"
      unitRef="usd">3600000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTplMzJlMmY3Yzk2NjU0ODBhYmUyYmVlOWM5NWM0M2YyMC90YWJsZXJhbmdlOmUzMmUyZjdjOTY2NTQ4MGFiZTJiZWU5Yzk1YzQzZjIwXzItNi0xLTEtODQ0NDQ_8eb2a7d3-b411-46df-b43b-8d8eb120994c"
      unitRef="usd">3000000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNTcvZnJhZzpiMGY5MDQ1YWZjYjk0ODEyYWM4YzVmZmE5YjVhNjg3NS90YWJsZTplMzJlMmY3Yzk2NjU0ODBhYmUyYmVlOWM5NWM0M2YyMC90YWJsZXJhbmdlOmUzMmUyZjdjOTY2NTQ4MGFiZTJiZWU5Yzk1YzQzZjIwXzItOC0xLTEtODQ0NDQ_ced8b47a-e889-4ce2-9dc1-4f6faee74b53"
      unitRef="usd">2400000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzEwMDE4_c47775dc-1f50-4781-acf8-c7b57ce44629">Fair Value Measurements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company uses forward foreign exchange contracts to manage its exposure to the variability of cash flows, primarily related to the foreign exchange rate changes of future intercompany products and third-party purchases of materials denominated in a foreign currency. The Company uses cross currency interest rate swaps to manage currency risk primarily related to borrowings. Both types of derivatives are designated as cash flow hedges.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, the Company primarily uses interest rate swaps as an instrument to manage interest rate risk related to fixed rate borrowings. These derivatives are designated as fair value hedges. The Company uses cross currency interest rate swaps and forward foreign exchange contracts designated as net investment hedges. Additionally, the Company uses forward foreign exchange contracts to offset its exposure to certain foreign currency assets and liabilities. These forward foreign exchange contracts are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings, thereby offsetting the current earnings effect of the related foreign currency assets and liabilities. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt; In the fiscal fourth quarter of 2022, the Company entered into forward starting interest rate swaps with notional amounts totaling $2.4&#160;billion in contemplation of hedging interest rate risk associated with long-term financing for the Consumer Health segment separation. These forward starting interest rate swaps are not designated as hedges and therefore, changes in the fair values of these derivatives are recognized in earnings. At the end of the fiscal year 2022, the changes in fair value was not material and therefore not included in the table below.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company does not enter into derivative financial instruments for trading or speculative purposes, or that contain credit risk related contingent features. The Company maintains credit support agreements (CSA) with certain derivative counterparties establishing collateral thresholds based on respective credit ratings and netting agreements. As of January&#160;1, 2023, the total amount of cash collateral paid by the Company under the CSA amounted to $0.8 billion net, related to net investment and cash flow hedges. On an ongoing basis, the Company monitors counter-party credit ratings. The Company considers credit non-performance risk to be low, because the Company primarily enters into agreements with commercial institutions that have at least an investment grade credit rating. Refer to the table on significant financial assets and liabilities measured at fair value contained in this footnote for receivables and payables with these commercial institutions. As of January&#160;1, 2023, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $43.3 billion, $36.2 billion and $12.4 billion, respectively. As of January&#160;2, 2022, the Company had notional amounts outstanding for forward foreign exchange contracts, cross currency interest rate swaps and interest rate swaps of $45.8 billion,  $37.4 billion and $10.0 billion, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All derivative instruments are recorded on the balance sheet at fair value. Changes in the fair value of derivatives are recorded each period in current earnings or other comprehensive income, depending on whether the derivative is designated as part of a hedge transaction, and if so, the type of hedge transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The designation as a cash flow hedge is made at the entrance date of the derivative contract. At inception, all derivatives are expected to be highly effective. Foreign exchange contracts designated as cash flow hedges are accounted for under the forward method and all gains/losses associated with these contracts will be recognized in the income statement when the hedged item impacts earnings.&#160;Changes in the fair value of these derivatives are recorded in accumulated other comprehensive income until the underlying transaction affects earnings, and are then reclassified to earnings in the same account as the hedged transaction.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gains and losses associated with interest rate swaps and changes in fair value of hedged debt attributable to changes in interest rates are recorded to interest expense in the period in which they occur. Gains and losses on net investment hedges are accounted through the currency translation account within accumulated other comprehensive income.&#160;The portion excluded from effectiveness testing is recorded through interest (income) expense using the spot method. On an ongoing basis, the Company assesses whether each derivative continues to be highly effective in offsetting changes of hedged items. If and when a derivative is no longer expected to be highly effective, hedge accounting is discontinued.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company designated its Euro denominated notes issued in May 2016 with due dates ranging from 2022 to 2035 as a net investment hedge of the Company's investments in certain of its international subsidiaries that use the Euro as their functional currency in order to reduce the volatility caused by changes in exchange rates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; As of January&#160;1, 2023, the balance of deferred net loss on derivatives included in accumulated other comprehensive income was $230 million&#160;after-tax. For additional information, see the Consolidated Statements of Comprehensive Income and Note&#160;13. The Company expects that substantially all of the amounts related to forward foreign exchange contracts will be reclassified into earnings over the next 12 months as a result of transactions that are expected to occur over that period. The maximum length of time over which the Company is hedging transaction exposure is 18 months, excluding interest rate contracts and net investment hedges. The amount ultimately realized in earnings may differ as foreign exchange rates change. Realized gains and losses are ultimately determined by actual exchange rates at maturity of the derivative.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022, net of tax:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of January&#160;1, 2023 and January&#160;2, 2022, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Line item in the Consolidated Balance Sheet in which the hedged item is included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItMi0xLTEtMTA5MzI3_baf92b4c-2473-4ad1-9202-3d7157cbead6"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItMi0xLTEtMTA5MzI3_d20882e0-6ef3-4436-8245-6610c60bdc82"&gt;Other (income) expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;The following table is the effect of net investment hedges for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)           Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company holds equity investments with readily determinable fair values and equity investments without readily determinable fair values. The Company measures equity investments that do not have readily determinable fair values at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.505%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022 for equity investments without readily determinable market values, $51 million and $28 million, respectively, of the changes in fair value reflected in net income were the result of impairments. There were offsetting impacts of $142 million and $422 million, respectively, of changes in the fair value reflected in net income due to changes in observable prices and gains on the disposal of investments. The impact in fiscal year 2021, was driven by the gain on disposal of the Grail investment. In fiscal year 2022, the Company sold all of its equity investments in argenx SE for proceeds of $0.6&#160;billion.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Fair value is the exit price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement determined using assumptions that market participants would use in pricing an asset or liability.  In accordance with ASC 820, a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of a derivative financial instrument (i.e., forward foreign exchange contracts, interest rate contracts) is the aggregation by currency of all future cash flows discounted to its present value at the prevailing market interest rates and subsequently converted to the U.S.&#160;Dollar at the current spot foreign exchange rate. The Company does not believe that fair values of these derivative instruments materially differ from the amounts that could be realized upon settlement or maturity, or that the changes in fair value will have a material effect on the Company&#x2019;s results of operations, cash flows or financial position. The Company also holds equity investments which are classified as Level&#160;1 and debt securities which are classified as Level 2. The Company holds acquisition related contingent liabilities based upon certain regulatory and commercial events, which are classified as Level 3, whose values are determined using discounted cash flow methodologies or similar techniques for which the determination of fair value requires significant judgment or estimations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following three levels of inputs are used to measure fair value:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;1&#160;&#x2014; Quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;2&#160;&#x2014; Significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level&#160;3&#160;&#x2014; Significant unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of the fiscal year ended January&#160;1, 2023 and January&#160;2, 2022 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,860&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Available For Sale Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.409%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2021 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $1,884 million, which are classified as Level&#160;1 and contingent consideration of $533 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Classified as non-current other assets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Classified as cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Includes $1,116 million, $520 million and $594 million, classified as non-current other liabilities as of January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, respectively. Includes $4 million, $13&#160;million and $39&#160;million classified as current liabilities as of January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt"&gt;Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense.  The Company recorded a contingent consideration reversal of $1,148&#160;million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt"&gt;In fiscal year 2022, the Company recorded $704&#160;million of contingent consideration related to Abiomed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Notes&#160;2 and 7 for financial assets and liabilities held at carrying amount on the Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="ie7a29114e911461faec7fe4e8a9d1d04_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzI3NDg3NzkwODMxOTI_ed244edc-c0b3-4f37-9dba-4dfe4d185535"
      unitRef="usd">2400000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="ie9ea9658839544de90b002aa4a145255_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzE2NDE_a6104cee-dd5a-4b48-9a8e-c4f5d73e0b48"
      unitRef="usd">800000000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ie9ea9658839544de90b002aa4a145255_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzIzMDU_99a5308d-9804-4fd2-bf36-39df5ac2ce84"
      unitRef="usd">43300000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ibc88406d872445a3ad6785a8573a5a24_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzIzMDk_afb7ef2e-4e57-4041-9d43-6039c6a2e1dd"
      unitRef="usd">36200000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i5e54799bc7f7459f8e4524bc93b31c2b_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzIzMTY_5141a324-4fac-4c74-ad74-1f4d052653f5"
      unitRef="usd">12400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="iab47b85ba2e7444aa7e1fb2845fe47bd_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzY1OTcwNjk3NzY4MjE_3982c205-0cbb-464d-b47a-e2e4247e01c0"
      unitRef="usd">45800000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="i6c2143b059d34074a2a1c452daf27abc_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzY1OTcwNjk3NzY4MjU_04ff72d4-d9f4-4874-a10d-a9a93f870350"
      unitRef="usd">37400000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ia2bd3f4828754f62ad5a5f11c2503d8f_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzY1OTcwNjk3NzY4MTU_4d586e5b-6677-48f8-91bb-3826b5e707f8"
      unitRef="usd">10000000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzQ2MDA_3d192573-2862-464a-a3c2-7f1121dbd730"
      unitRef="usd">-230000000</us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax>
    <us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzQ4NTk_1231d22c-5da6-480e-a867-0e8c1d25835d">next 12 months</us-gaap:DescriptionOfReclassificationOfCashFlowHedgeGainLoss>
    <us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzUwMjA_dfaa8e5e-15ac-4cb8-8622-d9c5dea6dea6">P18M</us-gaap:MaximumLengthOfTimeForeignCurrencyCashFlowHedge>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzEwMDQ0_6202a4c3-4703-4ff6-813e-a04939d2d0b9">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to derivatives and hedges for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022, net of tax:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.344%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.771%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.940%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.087%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.648%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.525%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.239%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Sales&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cost of Products Sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other (Income) Expense&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;The effects of fair value, net investment and cash flow hedging:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on fair value hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Hedged items&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,098)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;Derivatives designated as hedging instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,098&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on net investment hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain (Loss) on cash flow hedging relationship:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Forward foreign exchange contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(72)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(113)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(94)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(557)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Cross currency interest rate swaps contracts:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) reclassified from AOCI into income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;425&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;402&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Amount of gain or (loss) recognized in AOCI&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of January&#160;1, 2023 and January&#160;2, 2022, the following amounts were recorded on the consolidated balance sheet related to cumulative basis adjustment for fair value hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.222%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:30.328%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.852%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.994%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Line item in the Consolidated Balance Sheet in which the hedged item is included&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,665&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,435)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(142)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ife931fffad564c719966395e598010a2_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtMS0xLTEtODQ0NDQ_f83e71e5-fb26-4e9c-97cf-32e38daaec9a"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i8ab96c6a2a554d78b428a02174937f21_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtMi0xLTEtODQ0NDQ_c6db5343-4517-4a06-8674-ecc2b48af2cd"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i3e6a3d10477946979e7db7037955a625_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtMy0xLTEtODQ0NDQ_3b18bd2a-fef3-480a-be66-9555f8495567"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i8b66c56f1d944b9798daa8b8b05d751a_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtNC0xLTEtODQ0NDQ_fee8e747-b21b-4db2-8cb2-4015f2fb8b57"
      unitRef="usd">-1098000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="id306832042b14bc3bb6e213608544feb_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtNS0xLTEtODQ0NDQ_1c7a3e46-dd9f-4dd9-bb0d-a8a372dde4f0"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="ie74a64d7fcd74669819570ee01cfe012_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtNi0xLTEtODQ0NDQ_60209cea-57a7-4fae-9c03-b8d2d26b73d2"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="iead1aa87d38f45fead8c4b6118f2e9cd_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtNy0xLTEtODQ0NDQ_e1b8ff90-0db0-4c2f-9965-a7e3d94007c9"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i6e3bf19e86414044b7432eb058f5401e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtOC0xLTEtODQ0NDQ_efb54f59-0fca-431a-8e2c-ac896864bcad"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i862297e326264912a68191b181c4f8ba_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtOS0xLTEtODQ0NDQ_11097348-6f50-4fbf-8c28-31d03e82edb8"
      unitRef="usd">-109000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i328303dfcaed4235be1c6fb645ddafa7_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzgtMTAtMS0xLTg0NDQ0_f27294ca-3aeb-4ab8-b72d-5d59d27c7829"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ife931fffad564c719966395e598010a2_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktMS0xLTEtODQ0NDQ_e977f7e7-cfe8-4339-ae0d-8adbda281a43"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i8ab96c6a2a554d78b428a02174937f21_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktMi0xLTEtODQ0NDQ_b9141de6-507a-4440-8357-2d63ecd6bb7b"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i3e6a3d10477946979e7db7037955a625_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktMy0xLTEtODQ0NDQ_3f55f406-faf4-4d79-a1d0-54557249a8cf"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i8b66c56f1d944b9798daa8b8b05d751a_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktNC0xLTEtODQ0NDQ_f4ad432c-ab25-470d-a2b1-29ac4dcf4151"
      unitRef="usd">1098000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="id306832042b14bc3bb6e213608544feb_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktNS0xLTEtODQ0NDQ_6a58cf5b-13c3-43ec-92f4-7a45c3e599fa"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="ie74a64d7fcd74669819570ee01cfe012_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktNi0xLTEtODQ0NDQ_a5ad898f-dba3-48f1-97b6-0479a0721080"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="iead1aa87d38f45fead8c4b6118f2e9cd_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktNy0xLTEtODQ0NDQ_89cb9e2b-13fb-491e-9212-476034747238"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i6e3bf19e86414044b7432eb058f5401e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktOC0xLTEtODQ0NDQ_0b6ddb64-1d3b-4731-ac7a-a429c268b7a1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i862297e326264912a68191b181c4f8ba_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktOS0xLTEtODQ0NDQ_674104a2-1fbf-4c28-b066-86501cdd1f88"
      unitRef="usd">109000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i328303dfcaed4235be1c6fb645ddafa7_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzktMTAtMS0xLTg0NDQ0_5ed23394-1c06-48ff-bb51-5f95101a65ac"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i639b622f74424cdebe2c37fde791f0dd_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTEtMS0xLTg0NDQ0_0acdc26d-81cb-48f3-b156-b7d80b515cb4"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i1fc528ec58784d3da8a3590dbabf6c70_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTItMS0xLTg0NDQ0_bf94295c-e25b-4607-ae48-13b03552df6f"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="if363846d56154bcfaaaf3101bca3794f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTMtMS0xLTg0NDQ0_07a80547-caa6-4cbd-aff1-a2a479977a23"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i28d922839a92453babec3a62e5dd77d0_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTQtMS0xLTg0NDQ0_fa34d219-8778-4432-8c05-e490cc5ec3c0"
      unitRef="usd">140000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i73a1657c370b446a9a91aeb39ed80cb3_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTUtMS0xLTg0NDQ0_2f9e73fd-18ba-4b8e-a0cb-85a41cc43f07"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i9b9d25facfe14e558d8538281e17e27f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTYtMS0xLTg0NDQ0_d887727a-ddf3-44bb-9f2e-ce700c3da9db"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i7eda7450d4d9456b9e83912cf600f6da_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTctMS0xLTg0NDQ0_a4bc68a5-064e-4b5e-aa8a-12b6761d882f"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i98e6ade62ef44067805f023366e22a49_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTgtMS0xLTg0NDQ0_2422e571-8ec4-4a9e-8dde-56bca7e7dc85"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i81d9971dcb124172ad9892da8f77ed8f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTktMS0xLTg0NDQ0_b8aa7f23-4098-4135-abfd-44f51ca6383b"
      unitRef="usd">174000000</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings
      contextRef="i0c15d323b29d4f51a3b0277a6efe9fcb_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzEzLTEwLTEtMS04NDQ0NA_e3a70196-bb1f-4045-b423-28541b6897a6"
      unitRef="usd">0</us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i639b622f74424cdebe2c37fde791f0dd_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTEtMS0xLTg0NDQ0_331b01ec-77a7-4fdf-b9c4-90c719c0e618"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i1fc528ec58784d3da8a3590dbabf6c70_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTItMS0xLTg0NDQ0_2354e08d-d995-4ef9-b332-4a3ff8e8a5ca"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="if363846d56154bcfaaaf3101bca3794f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTMtMS0xLTg0NDQ0_e0295132-7712-46cd-9c5b-16be5923aab8"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i28d922839a92453babec3a62e5dd77d0_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTQtMS0xLTg0NDQ0_7bb23438-43d5-4a8b-84a8-b14a1ab14ca7"
      unitRef="usd">140000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i73a1657c370b446a9a91aeb39ed80cb3_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTUtMS0xLTg0NDQ0_c3c5ec18-e515-4ad1-abad-09f3ddee4f83"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i9b9d25facfe14e558d8538281e17e27f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTYtMS0xLTg0NDQ0_77566fa5-5278-4b71-b996-8368c8d2b1e6"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i7eda7450d4d9456b9e83912cf600f6da_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTctMS0xLTg0NDQ0_21c4be7d-f69d-4804-b005-886ae101040f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i98e6ade62ef44067805f023366e22a49_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTgtMS0xLTg0NDQ0_07845ae5-b197-4cb0-9e0f-90db3c22b863"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i81d9971dcb124172ad9892da8f77ed8f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTktMS0xLTg0NDQ0_cf9d1c03-c1dd-44bd-b3ff-503a5db83cb8"
      unitRef="usd">174000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax
      contextRef="i0c15d323b29d4f51a3b0277a6efe9fcb_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE0LTEwLTEtMS04NDQ0NA_6f6f3226-3237-4585-a955-a4ef1883a9a7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i260cec3db7e141a7bab9fbc38d51513a_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTEtMS0xLTg0NDQ0_5c64c76c-cdd6-43bb-b558-69874be6eec2"
      unitRef="usd">-72000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i5af51b0799c94e2f99fb3ffe042cf726_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTItMS0xLTg0NDQ0_39afad0c-c6c6-4305-9e87-4dc0931bdec5"
      unitRef="usd">-271000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i82dcae20ab7f46d58205e38411c02bc4_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTMtMS0xLTg0NDQ0_cb7bd621-2d2c-4fb9-9267-ef7c3a005b42"
      unitRef="usd">149000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ic45912abb9de446ab846fa3d96ef734b_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTQtMS0xLTg0NDQ0_4fd70dff-73a8-4457-9374-955fd05291e2"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i56073f5e045041e085b3b01d323734e9_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTUtMS0xLTg0NDQ0_6a623588-e80d-416f-9d19-3ffef361d7e8"
      unitRef="usd">-23000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ib6e64db864e94433959e07e907b7df1d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTYtMS0xLTg0NDQ0_6f658a9c-66a2-44cc-ba86-011e1e051c5a"
      unitRef="usd">17000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ic55999a6bc9a460e938066f5c6f50247_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTctMS0xLTg0NDQ0_4e168105-087c-4c6f-9e33-0a25c2df0760"
      unitRef="usd">119000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i4b7dae6e9bb14eb495b8a03281389def_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTgtMS0xLTg0NDQ0_5d6765a6-372b-4cd8-bbba-768d5057284c"
      unitRef="usd">30000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i44cb3ddc5bc04bb699e468e1eb79f066_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTktMS0xLTg0NDQ0_a6ca2d4d-549d-4be4-9343-7beb759defd1"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i5e4545ac2dc1439cbf7c13f15c6f32af_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzE4LTEwLTEtMS04NDQ0NA_0368cae0-f144-473c-ad41-b970a6256356"
      unitRef="usd">47000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i260cec3db7e141a7bab9fbc38d51513a_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTEtMS0xLTg0NDQ0_5981181a-9f62-4549-97ca-6180958b16e0"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i5af51b0799c94e2f99fb3ffe042cf726_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTItMS0xLTg0NDQ0_d11cbbdb-ddb4-43a2-8136-8626764e1ac1"
      unitRef="usd">319000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i82dcae20ab7f46d58205e38411c02bc4_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTMtMS0xLTg0NDQ0_12485b3e-4b46-4705-91f6-130bed3bc93c"
      unitRef="usd">61000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ic45912abb9de446ab846fa3d96ef734b_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTQtMS0xLTg0NDQ0_229effad-9df1-471f-8290-7425b444ea67"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i56073f5e045041e085b3b01d323734e9_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTUtMS0xLTg0NDQ0_ac4c5b3a-cd67-4698-a1b6-3a5ec5e8d0a8"
      unitRef="usd">-113000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ib6e64db864e94433959e07e907b7df1d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTYtMS0xLTg0NDQ0_e2636f0f-46a0-4211-8806-520ffc1c6c0a"
      unitRef="usd">-94000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ic55999a6bc9a460e938066f5c6f50247_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTctMS0xLTg0NDQ0_f4682aac-89a9-4cdc-b758-0e527d6af345"
      unitRef="usd">-557000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i4b7dae6e9bb14eb495b8a03281389def_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTgtMS0xLTg0NDQ0_d70104c8-5c17-4ddc-9d0b-d6e22a721803"
      unitRef="usd">123000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i44cb3ddc5bc04bb699e468e1eb79f066_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTktMS0xLTg0NDQ0_5d2de4f3-282f-4c01-8fe1-b8686398651d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i5e4545ac2dc1439cbf7c13f15c6f32af_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzIyLTEwLTEtMS04NDQ0NA_b1c4cae4-d0c1-4b7c-b13e-ef810aacd063"
      unitRef="usd">146000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i3dc946cef90d46caaddb4f18c8fd5893_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTEtMS0xLTg0NDQ0_cb669226-8079-4383-a162-4ad48454e9ce"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="iaa09240ffe5c45a493822e57c2dc3858_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTItMS0xLTg0NDQ0_29e744fd-0edc-4311-8c8f-dc6788a35e28"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ieb9f80f9c820492780c7f8c91535919c_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTMtMS0xLTg0NDQ0_0a73b410-3bc2-4840-a5c4-b6596b6cf887"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i14cee3a2fdc941089f344ca72308f0f0_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTQtMS0xLTg0NDQ0_2bcfca5d-4ddb-41d6-97c2-d3bb1d74fad1"
      unitRef="usd">425000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i59a01ed372cd4e95abefcdf0e51356aa_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTUtMS0xLTg0NDQ0_79cb5dfb-76e5-4a27-a15d-479fe0f001b3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i8143a538b2e94972a97a82b7e6ec6c68_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTYtMS0xLTg0NDQ0_667caa4c-5c08-4fa3-81e9-50f2bea3b253"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="i1b5eb91944ab42f6bd12eae5c9d5ae5d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTctMS0xLTg0NDQ0_c293291d-e506-4e8a-b874-bcbf3b7302da"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ifb690af5f3694f69b7b889d872aeaf05_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTgtMS0xLTg0NDQ0_24f0d79a-04b6-4ff3-835e-83fbd10702a5"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="ic136e45ed1b94c44a821b42b608d5c9d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTktMS0xLTg0NDQ0_710077b6-b347-4e06-9637-8258ecc96459"
      unitRef="usd">402000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax
      contextRef="id7980b23189f4bc7b2e93c0103862863_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI1LTEwLTEtMS04NDQ0NA_33c0bdc9-8b4b-4a73-a777-be61422a8f2f"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i3dc946cef90d46caaddb4f18c8fd5893_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTEtMS0xLTg0NDQ0_a58d06fa-5b1d-4569-ab33-40376dfc5396"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="iaa09240ffe5c45a493822e57c2dc3858_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTItMS0xLTg0NDQ0_50d25e97-f7e0-44d1-968b-537c7cd9f25a"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ieb9f80f9c820492780c7f8c91535919c_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTMtMS0xLTg0NDQ0_7d155e11-fdca-4810-83a0-82413bdfd98d"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i14cee3a2fdc941089f344ca72308f0f0_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTQtMS0xLTg0NDQ0_b388d642-fadf-4f7a-8171-dcce0d5dcf1a"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i59a01ed372cd4e95abefcdf0e51356aa_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTUtMS0xLTg0NDQ0_21601079-01c9-408c-ac46-d43b98a07c76"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i8143a538b2e94972a97a82b7e6ec6c68_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTYtMS0xLTg0NDQ0_5d0b328e-5b6a-4874-9445-8e01202b2ac3"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="i1b5eb91944ab42f6bd12eae5c9d5ae5d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTctMS0xLTg0NDQ0_1d08c458-343e-460e-9bb3-af1df0616bf4"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ifb690af5f3694f69b7b889d872aeaf05_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTgtMS0xLTg0NDQ0_cc5af963-231e-49b9-97e1-b81771daddab"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="ic136e45ed1b94c44a821b42b608d5c9d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTktMS0xLTg0NDQ0_316d66b9-9e29-40ec-a353-b30e26b64628"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax
      contextRef="id7980b23189f4bc7b2e93c0103862863_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpkZmNkYWQxMDQ4ODg0MTRkYTVmMjhkMDRiZjYwMTk5ZS90YWJsZXJhbmdlOmRmY2RhZDEwNDg4ODQxNGRhNWYyOGQwNGJmNjAxOTllXzI3LTEwLTEtMS04NDQ0NA_19367c50-65fb-4a32-863a-27c4389c97eb"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i8ef91f5dac5a431b8628840f5ad90267_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpiYmY5MjgzM2E3ZTA0MTVlYWRjZmE3ZjE0Mjc5MThkZS90YWJsZXJhbmdlOmJiZjkyODMzYTdlMDQxNWVhZGNmYTdmMTQyNzkxOGRlXzQtMi0xLTEtODQ0NDQ_eece80f5-224f-4816-be5a-7a0f3e0431a6"
      unitRef="usd">8665000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ia55d14fcbb70445388964f5f5d173a93_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpiYmY5MjgzM2E3ZTA0MTVlYWRjZmE3ZjE0Mjc5MThkZS90YWJsZXJhbmdlOmJiZjkyODMzYTdlMDQxNWVhZGNmYTdmMTQyNzkxOGRlXzQtNC0xLTEtODQ0NDQ_c3b4159c-fb00-4b0c-b9c6-e4f1b0237673"
      unitRef="usd">9793000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="i8ef91f5dac5a431b8628840f5ad90267_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpiYmY5MjgzM2E3ZTA0MTVlYWRjZmE3ZjE0Mjc5MThkZS90YWJsZXJhbmdlOmJiZjkyODMzYTdlMDQxNWVhZGNmYTdmMTQyNzkxOGRlXzQtNi0xLTEtODQ0NDQ_663cad9f-992b-4389-b694-e9409a693a5b"
      unitRef="usd">-1435000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="ia55d14fcbb70445388964f5f5d173a93_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpiYmY5MjgzM2E3ZTA0MTVlYWRjZmE3ZjE0Mjc5MThkZS90YWJsZXJhbmdlOmJiZjkyODMzYTdlMDQxNWVhZGNmYTdmMTQyNzkxOGRlXzQtOC0xLTEtODQ0NDQ_b35885cb-f179-400a-9ada-42ae59c70a09"
      unitRef="usd">-142000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzEwMDQy_8e4819b1-5f9c-4361-aac3-a711d20f3dea">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;The following table is the effect of derivatives not designated as hedging instrument for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.345%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:37.594%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.558%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:21.510%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:5.425%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.012%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.469%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Location of Gain /(Loss) Recognized in Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Income on Derivative&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Derivatives Not Designated as Hedging Instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Foreign Exchange Contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItMi0xLTEtMTA5MzI3_baf92b4c-2473-4ad1-9202-3d7157cbead6"&gt;&lt;span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItMi0xLTEtMTA5MzI3_d20882e0-6ef3-4436-8245-6610c60bdc82"&gt;Other (income) expense&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(70)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="i237858b83a9d4cf297ac85f26bb8ae97_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItNC0xLTEtODQ0NDQ_79c28af2-4837-4157-a751-4fff3c15c517"
      unitRef="usd">94000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="iab7309c98649499d9713793656af22d7_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmNGYxMmExOGUwMjQ0YmY5OTE0MzEwZjJlODM1ZjdkNS90YWJsZXJhbmdlOmY0ZjEyYTE4ZTAyNDRiZjk5MTQzMTBmMmU4MzVmN2Q1XzItNi0xLTEtODQ0NDQ_f2b5789b-ac41-4271-9261-6e3516691de8"
      unitRef="usd">-70000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzEwMDU3_142aa5f1-8e87-4492-add4-c150fb08b382">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:174%"&gt;The following table is the effect of net investment hedges for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:20.422%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:28.621%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.027%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)&lt;br/&gt;Recognized In&lt;br/&gt;Accumulated OCI&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Location of Gain or (Loss) Reclassified from Accumulated Other Comprehensive Income Into Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss)           Reclassified From&lt;br/&gt;Accumulated OCI&lt;br/&gt;Into Income&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;197&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;387&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;br/&gt;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cross Currency interest rate swaps&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;766&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest (income) expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo5YmVmMzM0YTRjNWU0MmM1YTg0YWIwNDA0NTQ4MTM1MS90YWJsZXJhbmdlOjliZWYzMzRhNGM1ZTQyYzVhODRhYjA0MDQ1NDgxMzUxXzItMi0xLTEtODQ0NDQ_46f185f6-b149-4cd3-9ab5-6098db1bc908"
      unitRef="usd">197000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo5YmVmMzM0YTRjNWU0MmM1YTg0YWIwNDA0NTQ4MTM1MS90YWJsZXJhbmdlOjliZWYzMzRhNGM1ZTQyYzVhODRhYjA0MDQ1NDgxMzUxXzItNC0xLTEtODQ0NDQ_e73c6666-2560-4e62-b308-852a2e0e3c2a"
      unitRef="usd">387000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i83f081c66b1b450a84f5571770ed1022_D20221003-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo5YmVmMzM0YTRjNWU0MmM1YTg0YWIwNDA0NTQ4MTM1MS90YWJsZXJhbmdlOjliZWYzMzRhNGM1ZTQyYzVhODRhYjA0MDQ1NDgxMzUxXzItOC0xLTEtODQ0NDQ_7ebe2411-e224-47fc-8ceb-72d77500159a"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i12f4dde8b4404aef8dca3c97bf241db1_D20211004-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo5YmVmMzM0YTRjNWU0MmM1YTg0YWIwNDA0NTQ4MTM1MS90YWJsZXJhbmdlOjliZWYzMzRhNGM1ZTQyYzVhODRhYjA0MDQ1NDgxMzUxXzItMTAtMS0xLTg0NDQ0_312fe63a-67b2-47d2-aa41-fa3cbfb3e706"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i2e7e250084ad46a6a9cbab407dbeb7ab_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo5YmVmMzM0YTRjNWU0MmM1YTg0YWIwNDA0NTQ4MTM1MS90YWJsZXJhbmdlOjliZWYzMzRhNGM1ZTQyYzVhODRhYjA0MDQ1NDgxMzUxXzMtMi0xLTEtODQ0NDQ_ad07dc5f-68f0-4dcf-8401-18cb401be35f"
      unitRef="usd">766000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="i8c81dca775704665a78c37783de6d091_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo5YmVmMzM0YTRjNWU0MmM1YTg0YWIwNDA0NTQ4MTM1MS90YWJsZXJhbmdlOjliZWYzMzRhNGM1ZTQyYzVhODRhYjA0MDQ1NDgxMzUxXzMtNC0xLTEtODQ0NDQ_79ab5c2e-19ef-4455-aba6-c6990f27043a"
      unitRef="usd">548000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="ia8d53c59ceef44b389961dad508f831b_D20221003-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo5YmVmMzM0YTRjNWU0MmM1YTg0YWIwNDA0NTQ4MTM1MS90YWJsZXJhbmdlOjliZWYzMzRhNGM1ZTQyYzVhODRhYjA0MDQ1NDgxMzUxXzMtOC0xLTEtODQ0NDQ_f5a082db-99e8-40c8-9531-b01d807185e9"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred
      contextRef="i4ae9179932924168b60062ab11671493_D20211004-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo5YmVmMzM0YTRjNWU0MmM1YTg0YWIwNDA0NTQ4MTM1MS90YWJsZXJhbmdlOjliZWYzMzRhNGM1ZTQyYzVhODRhYjA0MDQ1NDgxMzUxXzMtMTAtMS0xLTg0NDQ0_25e779f1-6ddf-4e3c-a557-d6439cfdd554"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzEwMDI0_a7b2a79b-a5ac-41a7-85f3-a2ec23631714">&lt;div style="margin-bottom:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table is a summary of the activity related to equity investments for the fiscal years ended January&#160;1, 2023 and January&#160;2, 2022:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.772%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.504%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(538)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(770)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.478%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.143%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.827%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.675%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.318%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.505%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Changes in Fair Value Reflected in Net Income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sales/ Purchases/Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Carrying Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non Current Other Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments with readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,481&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;205&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity Investments without readily determinable value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(632)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Recorded in Other Income/Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Other includes impact of currency&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i6534a66bb873492c8df03d6fc07250d9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzItMi0xLTEtODQ0NDQ_3ca6ec34-a233-42fa-8647-22eb5bfbf515"
      unitRef="usd">1884000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:EquityFairValueAdjustment
      contextRef="i828e3ede8e3549dc9f5058a9b4b0483e_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzItNC0xLTEtODQ0NDQ_89f3afe0-1229-45fd-b020-ed0f68e18281"
      unitRef="usd">-538000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="i828e3ede8e3549dc9f5058a9b4b0483e_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzItNi0xLTEtODQ0NDQ_a1404d0a-bfaa-4ae0-86c1-1a47744209a3"
      unitRef="usd">-770000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i8bb50a86cda447408f1cd7369b0d9418_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzItOC0xLTEtODQ0NDQ_5b02cf3e-6452-4a32-9ba7-7caeb3753e4d"
      unitRef="usd">576000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i8bb50a86cda447408f1cd7369b0d9418_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzItMTAtMS0xLTg0NDQ0_dcc4f92a-a6d9-464c-8b76-0bb8308ee7cd"
      unitRef="usd">576000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ia3e4435e5d9a4e60aa7205751e72f33b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzQtMi0xLTEtODQ0NDQ_8ed5774c-c346-4a29-ae27-79cbfdb943ca"
      unitRef="usd">500000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityFairValueAdjustment
      contextRef="i1f2f9ac2b4014e1fbb1ff7315cbbb47a_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzQtNC0xLTEtODQ0NDQ_1c0cd83b-f2d6-4613-8d9e-2433b63297a9"
      unitRef="usd">91000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="i1f2f9ac2b4014e1fbb1ff7315cbbb47a_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzQtNi0xLTEtODQ0NDQ_af48782a-e305-4378-9d62-925126485418"
      unitRef="usd">107000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i5db883efd7e1433a90d82a1129bb778b_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzQtOC0xLTEtODQ0NDQ_28334f8e-3b49-4c20-90fd-730e6a4b9873"
      unitRef="usd">698000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5db883efd7e1433a90d82a1129bb778b_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZToyMjRkYWI5OGNmOGE0NmU2YjIwZDZhMmNjYTY4YzczZC90YWJsZXJhbmdlOjIyNGRhYjk4Y2Y4YTQ2ZTZiMjBkNmEyY2NhNjhjNzNkXzQtMTAtMS0xLTg0NDQ0_817cb85b-fd9a-4c79-a6e3-bb63be076957"
      unitRef="usd">698000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i3133d52c339b4153b25eed2e42d701a3_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzItMi0xLTEtODQ0NDQ_4108960d-450e-4518-b2d6-00581b819f3a"
      unitRef="usd">1481000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:EquityFairValueAdjustment
      contextRef="ib0a9dbd90e4e4b16b09008c309918698_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzItNC0xLTEtODQ0NDQ_ea61684f-f915-4a6d-a7db-47f430baf4e4"
      unitRef="usd">198000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="ib0a9dbd90e4e4b16b09008c309918698_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzItNi0xLTEtODQ0NDQ_28ddfa38-afe4-424e-89c6-68ee7ef9586b"
      unitRef="usd">205000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:MarketableSecuritiesNoncurrent
      contextRef="i6534a66bb873492c8df03d6fc07250d9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzItOC0xLTEtODQ0NDQ_129ff40b-6dce-49a6-be2c-b70416cc551b"
      unitRef="usd">1884000000</us-gaap:MarketableSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i6534a66bb873492c8df03d6fc07250d9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzItMTAtMS0xLTg0NDQ0_67dcfd84-9bcc-42a4-a4ad-139bbd5f9117"
      unitRef="usd">1884000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="i9771bb6b36dc4c2eb9a95f16e382664c_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzQtMi0xLTEtODQ0NDQ_ba7aca6f-814a-4d17-ba03-a192e411cb86"
      unitRef="usd">738000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:EquityFairValueAdjustment
      contextRef="i5daa381fed7742f0a17f958e3f55f3d0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzQtNC0xLTEtODQ0NDQ_d9165270-1f1d-4825-9019-56bb0ee22ff3"
      unitRef="usd">394000000</us-gaap:EquityFairValueAdjustment>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="i5daa381fed7742f0a17f958e3f55f3d0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzQtNi0xLTEtODQ0NDQ_a00372d2-cb20-4626-92ed-9d71b2813021"
      unitRef="usd">-632000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount
      contextRef="ia3e4435e5d9a4e60aa7205751e72f33b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzQtOC0xLTEtODQ0NDQ_eae32a8a-3b88-4a5c-b394-baf8d083c69b"
      unitRef="usd">500000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="ia3e4435e5d9a4e60aa7205751e72f33b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo3NzZkYzIwNGFlZWI0MzczYThmYjVhZjkwNGU5MDFiOS90YWJsZXJhbmdlOjc3NmRjMjA0YWVlYjQzNzNhOGZiNWFmOTA0ZTkwMWI5XzQtMTAtMS0xLTg0NDQ0_a90c1e15-e787-43a1-9c91-ebd2be7e4a0b"
      unitRef="usd">500000000</us-gaap:OtherAssetsNoncurrent>
    <jnj:EquityFairValueAdjustmentImpairmentLoss
      contextRef="i1f2f9ac2b4014e1fbb1ff7315cbbb47a_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzY1NDE_7cf3e3cc-cc3b-45d0-8ef2-fd8983876118"
      unitRef="usd">-51000000</jnj:EquityFairValueAdjustmentImpairmentLoss>
    <jnj:EquityFairValueAdjustmentImpairmentLoss
      contextRef="i5daa381fed7742f0a17f958e3f55f3d0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzY1NDg_dc0d566b-394e-4834-816b-0ad94fa292d9"
      unitRef="usd">-28000000</jnj:EquityFairValueAdjustmentImpairmentLoss>
    <jnj:EquityFairValueAdjustmentChangeinObservablePrices
      contextRef="i1f2f9ac2b4014e1fbb1ff7315cbbb47a_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzY1OTcwNjk3ODA4OTE_bf43b4a9-44d8-4062-9835-3485511ddc9d"
      unitRef="usd">142000000</jnj:EquityFairValueAdjustmentChangeinObservablePrices>
    <jnj:EquityFairValueAdjustmentChangeinObservablePrices
      contextRef="i5daa381fed7742f0a17f958e3f55f3d0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzY2OTI_8ba2f27b-8b26-4046-a9be-1d27a92b5ae9"
      unitRef="usd">422000000</jnj:EquityFairValueAdjustmentChangeinObservablePrices>
    <jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzc2OTY1ODE0MDc5NTk_911183bb-ee83-4af3-a98f-0e653369100e"
      unitRef="usd">600000000</jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod>
    <us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzEwMDQz_768f8d21-d317-4495-9ddf-48f0f69d6a8b">&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s significant financial assets and liabilities measured at fair value as of the fiscal year ended January&#160;1, 2023 and January&#160;2, 2022 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:42.218%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.472%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.534%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;629&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;796&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,163&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,336&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest rate contracts &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;979&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,289&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,860&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forward foreign exchange contracts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Available For Sale Other Investments:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity investments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,884&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:80.409%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:53.627%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.263%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.527%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.356%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross to Net Derivative Reconciliation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,201&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,360&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,176)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,285)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Gross Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Credit Support Agreement (CSA)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,023)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total Net Liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Summarized information about changes in liabilities for contingent consideration is as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.245%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.691%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.695%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,715&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Changes in estimated fair value &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(194)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(52)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,089)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Additions &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(48)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(99)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ending Balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;633&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="6" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;2021 assets and liabilities are all classified as Level&#160;2 with the exception of equity investments of $1,884 million, which are classified as Level&#160;1 and contingent consideration of $533 million, classified as Level 3.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Includes cross currency interest rate swaps and interest rate swaps.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Classified as non-current other assets.  &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Classified as cash equivalents and current marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Includes $1,116 million, $520 million and $594 million, classified as non-current other liabilities as of January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, respectively. Includes $4 million, $13&#160;million and $39&#160;million classified as current liabilities as of January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt"&gt;Ongoing fair value adjustment amounts are recorded primarily in Research and Development expense.  The Company recorded a contingent consideration reversal of $1,148&#160;million in 2020 related to the timing of certain developmental milestones associated with the Auris Health acquisition. The reversal of the contingent consideration was recorded in Other income and expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(7)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:10.43pt"&gt;In fiscal year 2022, the Company recorded $704&#160;million of contingent consideration related to Abiomed.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i7375a9453abe472696f28e9901817945_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzQtMi0xLTEtODQ0NDQ_452c6678-2337-49cc-bb67-5c17f9202b92"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="id2864e7cf41c41f3a7a0337f807e5568_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzQtNC0xLTEtODQ0NDQ_db3a4862-bbf0-4914-bcc1-1d074308e3e9"
      unitRef="usd">629000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i3bc84e4de9ae423e8fd3d6a2ad33e500_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzQtNi0xLTEtODQ0NDQ_6f778ff4-18f4-4eb1-98d0-3d04f85c5e6b"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ie9ea9658839544de90b002aa4a145255_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzQtOC0xLTEtODQ0NDQ_1ce1dbaf-a313-4dbe-8f88-3f401f46f41a"
      unitRef="usd">629000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i14578454fa464922b37380e635487d56_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzQtMTAtMS0xLTg0NDQ0_3da23963-1bc6-4383-a2f6-09a2e7ea9172"
      unitRef="usd">540000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i0310802ba8b84af0ab17442fe8266124_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzUtMi0xLTEtODQ0NDQ_e8392417-2c1b-4636-94e6-1ecf9d8d7ccb"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ia39659278be5497eb0de37bcacef7e1c_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzUtNC0xLTEtODQ0NDQ_a7023a3c-e8d0-46f6-a7e1-3fff7cdc1201"
      unitRef="usd">1534000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ic3d82bd1550d4cf091ae15cb452ce838_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzUtNi0xLTEtODQ0NDQ_7177f208-7b4d-4031-bafa-5845bbf40263"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i7c9291dfb5a14a27898df7a62b8d588a_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzUtOC0xLTEtODQ0NDQ_ad38a963-fdd2-4554-97f9-82d7fa9810f5"
      unitRef="usd">1534000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i29258a2318d3469e9984174d5a29a387_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzUtMTAtMS0xLTg0NDQ0_5ad82e16-ef8b-4f1a-8fc2-c0e9b636d04d"
      unitRef="usd">796000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="ie48b117336c44afdb375a11b9255f3b1_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzctMi0xLTEtODQ0NDQ_73464291-cdad-4160-bc9f-e4cdbcc0c8b4"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i5ef2c7f6b53641888829b0aa74f1baba_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzctNC0xLTEtODQ0NDQ_7b90899a-b627-4f85-979f-a3b71a80243c"
      unitRef="usd">2163000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i10c2690afca047d8a831e4a7983bda38_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzctNi0xLTEtODQ0NDQ_02b7c543-ef2e-466f-9c80-d290490ce722"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzctOC0xLTEtODQ0NDQ_6384f838-e67b-422d-b494-745e033ff48d"
      unitRef="usd">2163000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue
      contextRef="iff70c34dd9b948dca087b12faaa08430_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzctMTAtMS0xLTg0NDQ0_526a6312-e7a4-44cd-8b98-0ae89a46e9ce"
      unitRef="usd">1336000000</us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i7375a9453abe472696f28e9901817945_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzktMi0xLTEtODQ0NDQ_78482d42-15e4-4f01-ab48-e1ac3779bb9f"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="id2864e7cf41c41f3a7a0337f807e5568_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzktNC0xLTEtODQ0NDQ_af0a996c-3904-4258-93f4-6443405bc782"
      unitRef="usd">511000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i3bc84e4de9ae423e8fd3d6a2ad33e500_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzktNi0xLTEtODQ0NDQ_dc54ef1c-7794-4178-a7bf-b3e0ef2e7a1c"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ie9ea9658839544de90b002aa4a145255_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzktOC0xLTEtODQ0NDQ_6f87f1d7-c541-4bd2-82b8-cb22c4d4a630"
      unitRef="usd">511000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i14578454fa464922b37380e635487d56_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzktMTAtMS0xLTg0NDQ0_558430e6-1c22-4684-8dce-daa9873c972f"
      unitRef="usd">881000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i0310802ba8b84af0ab17442fe8266124_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEwLTItMS0xLTg0NDQ0_3ba87914-1e94-43c3-a844-0184d3a3c767"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ia39659278be5497eb0de37bcacef7e1c_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEwLTQtMS0xLTg0NDQ0_bce477ac-cfce-4d7b-84ac-78a1cc59eee0"
      unitRef="usd">2778000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ic3d82bd1550d4cf091ae15cb452ce838_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEwLTYtMS0xLTg0NDQ0_0b1dc01f-93a1-49fb-859d-a9fe48455648"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i7c9291dfb5a14a27898df7a62b8d588a_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEwLTgtMS0xLTg0NDQ0_72cf72d8-4f14-4625-9879-cf76e4237488"
      unitRef="usd">2778000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i29258a2318d3469e9984174d5a29a387_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEwLTEwLTEtMS04NDQ0NA_abe8caef-f1a8-4dc6-8a7a-711ba6283e46"
      unitRef="usd">979000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="ie48b117336c44afdb375a11b9255f3b1_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEzLTItMS0xLTg0NDQ0_1f0107a6-3fe5-437e-a2b4-63e3b09f7cc6"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i5ef2c7f6b53641888829b0aa74f1baba_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEzLTQtMS0xLTg0NDQ0_37a162b7-422b-4e0b-b6b5-4dca2e5367cf"
      unitRef="usd">3289000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i10c2690afca047d8a831e4a7983bda38_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEzLTYtMS0xLTg0NDQ0_e6023c90-dc2b-412d-b5cc-1f9c919bafb8"
      unitRef="usd">0</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEzLTgtMS0xLTg0NDQ0_92e31ca6-8abf-4581-8ca7-ecdf7fe570cd"
      unitRef="usd">3289000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue
      contextRef="iff70c34dd9b948dca087b12faaa08430_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzEzLTEwLTEtMS04NDQ0NA_3b50f329-1afc-4b5c-b39e-6830dfc437de"
      unitRef="usd">1860000000</us-gaap:DerivativeInstrumentsInHedgesLiabilitiesAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i7375a9453abe472696f28e9901817945_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE2LTItMS0xLTg0NDQ0_50c44b9f-3ba1-4451-8074-13e43184ea6a"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="id2864e7cf41c41f3a7a0337f807e5568_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE2LTQtMS0xLTg0NDQ0_78dd48f7-abcc-47ec-b022-9c6473090e51"
      unitRef="usd">38000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i3bc84e4de9ae423e8fd3d6a2ad33e500_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE2LTYtMS0xLTg0NDQ0_0dbd67d1-eca7-4691-85ed-87178ed610fb"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="ie9ea9658839544de90b002aa4a145255_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE2LTgtMS0xLTg0NDQ0_7020e0eb-0bf9-41ca-9d09-15d2383a87aa"
      unitRef="usd">38000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue
      contextRef="i14578454fa464922b37380e635487d56_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE2LTEwLTEtMS04NDQ0NA_b6153214-f96b-4481-a9be-b72abdff992e"
      unitRef="usd">24000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i7375a9453abe472696f28e9901817945_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE4LTItMS0xLTg0NDQ0_d6bc396c-cee8-41d7-90a9-5a2e6f1b5985"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="id2864e7cf41c41f3a7a0337f807e5568_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE4LTQtMS0xLTg0NDQ0_a78d9401-c28c-4720-bb91-ea1caae150bc"
      unitRef="usd">68000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i3bc84e4de9ae423e8fd3d6a2ad33e500_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE4LTYtMS0xLTg0NDQ0_8924b5bd-8624-4146-a55e-56ee59e87c66"
      unitRef="usd">0</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="ie9ea9658839544de90b002aa4a145255_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE4LTgtMS0xLTg0NDQ0_8d54d460-d112-43ac-b4bf-624f84c15b8e"
      unitRef="usd">68000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue
      contextRef="i14578454fa464922b37380e635487d56_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzE4LTEwLTEtMS04NDQ0NA_651456d6-2fe9-4f8f-90f2-093c02930e26"
      unitRef="usd">28000000</us-gaap:ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ie48b117336c44afdb375a11b9255f3b1_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIwLTItMS0xLTg0NDQ0_35b6d3be-2971-4a3b-8708-c2526549b2f7"
      unitRef="usd">576000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5ef2c7f6b53641888829b0aa74f1baba_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIwLTQtMS0xLTg0NDQ0_0dd33ea2-eeba-443b-8f22-560b1e446b97"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i10c2690afca047d8a831e4a7983bda38_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIwLTYtMS0xLTg0NDQ0_b9f8854c-a49b-4aa1-88be-7ff7e5b4eb1c"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIwLTgtMS0xLTg0NDQ0_e934dd01-599c-4a7a-ba40-60694316a5ac"
      unitRef="usd">576000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIwLTEwLTEtMS04NDQ0NA_b415d7a6-2f95-4b09-af1e-78c21a4d19e0"
      unitRef="usd">1884000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ie48b117336c44afdb375a11b9255f3b1_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIxLTItMS0xLTg0NDQ0_b4677d29-b342-4315-9f4c-a287c01a9da7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5ef2c7f6b53641888829b0aa74f1baba_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIxLTQtMS0xLTg0NDQ0_f89fb4fd-9c5a-47bf-8081-03794034ac27"
      unitRef="usd">10487000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i10c2690afca047d8a831e4a7983bda38_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIxLTYtMS0xLTg0NDQ0_82d31a22-1c92-45b4-aa4c-6e7efdbf56c1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIxLTgtMS0xLTg0NDQ0_cf773796-4525-40f4-9c6f-3fd6a21a086c"
      unitRef="usd">10487000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIxLTEwLTEtMS04NDQ0NA_cfb6828d-279f-4e83-a647-5645d0624682"
      unitRef="usd">19727000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i10c2690afca047d8a831e4a7983bda38_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIzLTYtMS0xLTg0NDQ0_431a76bd-566b-47f6-9b9e-a4115ab0b9a9"
      unitRef="usd">1120000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIzLTgtMS0xLTg0NDQ0_f9f7cb14-9117-4579-aaef-570832fc89df"
      unitRef="usd">1120000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NjkyMTg5NzQxODk0MGE1OGI5M2YzN2RmMDI0MjI4NS90YWJsZXJhbmdlOjQ2OTIxODk3NDE4OTQwYTU4YjkzZjM3ZGYwMjQyMjg1XzIzLTEwLTEtMS04NDQ0NA_d000a022-c727-412e-ad22-664012a0743e"
      unitRef="usd">533000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzItMi0xLTEtODQ0NDQ_3c4522a5-9def-4ebe-acef-38565579d522"
      unitRef="usd">2201000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeFairValueOfDerivativeAsset
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzItNC0xLTEtODQ0NDQ_6a97bbc5-5d5a-409f-9c7b-21c219441e27"
      unitRef="usd">1360000000</us-gaap:DerivativeFairValueOfDerivativeAsset>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzMtMi0xLTEtODQ0NDQ_67a9023e-bc8d-4d92-b3c0-ef58e6adf2c5"
      unitRef="usd">2176000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <us-gaap:DerivativeAssetFairValueGrossLiability
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzMtNC0xLTEtODQ0NDQ_56845f4c-cb45-4a5b-b0cd-3f2f65cb896a"
      unitRef="usd">1285000000</us-gaap:DerivativeAssetFairValueGrossLiability>
    <jnj:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzQtMC0xLTEtODQ0NDQ_4966d4e1-530d-4c61-924d-57de650e9cb3">Total Net Asset</jnj:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <jnj:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzQtMC0xLTEtODQ0NDQ_9607f038-69b7-42a6-bd6e-71e943c248fb">Total Net Asset</jnj:DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:DerivativeAssets
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzQtMi0xLTEtODQ0NDQ_6f485f54-a8c4-4dcd-be02-2b632460f93c"
      unitRef="usd">25000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeAssets
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzQtNC0xLTEtODQ0NDQ_0fc0dd44-ae06-448c-9c43-1482893a65d0"
      unitRef="usd">75000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzYtMi0xLTEtODQ0NDQ_97a59b83-ca51-4002-aceb-7fef51d19906"
      unitRef="usd">3357000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzYtNC0xLTEtODQ0NDQ_f393dccf-7fac-42b0-a35d-9d974aca2a9d"
      unitRef="usd">1888000000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzctMi0xLTEtODQ0NDQ_21e70c65-a27b-496b-8ef7-6fde7a5f67bb"
      unitRef="usd">3023000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <us-gaap:DerivativeLiabilityFairValueGrossAsset
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzctNC0xLTEtODQ0NDQ_59d3de29-a9c7-4d13-9a18-eb43e38b319a"
      unitRef="usd">1855000000</us-gaap:DerivativeLiabilityFairValueGrossAsset>
    <jnj:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzgtMC0xLTEtODQ0NDQ_3e8d0ab9-c9f2-4465-beaa-3506b5e362e8">Total Net Liabilities</jnj:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <jnj:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzgtMC0xLTEtODQ0NDQ_ddba4376-7665-4b75-b536-8046a2692df3">Total Net Liabilities</jnj:DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag>
    <us-gaap:DerivativeLiabilities
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzgtMi0xLTEtODQ0NDQ_c2970802-c0be-4b82-937d-ca7a0e427033"
      unitRef="usd">334000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTo0NmQxYmM3NDQ0NjI0MWQ3YmFhMGE3YzZmYWViOTllMi90YWJsZXJhbmdlOjQ2ZDFiYzc0NDQ2MjQxZDdiYWEwYTdjNmZhZWI5OWUyXzgtNC0xLTEtODQ0NDQ_8e617ebb-cb18-4459-add6-3bc8671d13f0"
      unitRef="usd">33000000</us-gaap:DerivativeLiabilities>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzItMy0xLTEtODQ0NDQ_cf3a30b0-fd6e-4ad6-84fb-4117c6b59651"
      unitRef="usd">533000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzItNC0xLTEtODQ0NDQ_3c841210-a1df-4d4e-960f-7440e80ba827"
      unitRef="usd">633000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzItNS0xLTEtODQ0NDQ_51757283-9e5e-4881-8533-82910823e943"
      unitRef="usd">1715000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzMtMy0xLTEtODQ0NDQ_b13c6da7-c80d-4bad-b916-1a14da9a898a"
      unitRef="usd">-194000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzMtNC0xLTEtODQ0NDQ_f803537b-5abf-46c3-b3dc-3de9c4b4aad1"
      unitRef="usd">-52000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzMtNS0xLTEtODQ0NDQ_0399cf00-0e50-45a2-aacd-4f22f6feb065"
      unitRef="usd">-1089000000</jnj:FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzQtMy0xLTEtODQ0NDQ_af2136f2-29de-43e6-a95a-ce6ecdf5567f"
      unitRef="usd">792000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzQtNC0xLTEtODQ0NDQ_4f13c8ac-3df6-4f33-8a58-297e30c033ce"
      unitRef="usd">0</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzQtNS0xLTEtODQ0NDQ_ebe8bf44-d439-4e9c-8700-24515c30f08f"
      unitRef="usd">106000000</us-gaap:BusinessCombinationConsiderationTransferredLiabilitiesIncurred>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzUtMy0xLTEtODQ0NDQ_7aab4537-3fa5-4842-a4e5-6a4ba58054c2"
      unitRef="usd">11000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzUtNC0xLTEtODQ0NDQ_07fff26c-da0c-4fd6-80ff-1fd4fea65d10"
      unitRef="usd">48000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzUtNS0xLTEtODQ0NDQ_6d477839-ea21-40bf-befb-b84a19f56663"
      unitRef="usd">99000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzYtMy0xLTEtODQ0NDQ_c5748e11-e129-416d-87a8-32fe98271d52"
      unitRef="usd">1120000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzYtNC0xLTEtODQ0NDQ_0d3dc1fc-0aba-45a2-9a88-6ff5a076f18d"
      unitRef="usd">533000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90YWJsZTpmMmU0N2U0ODIyNzA0M2NlYjQ3MDc4ZmVjNDZkNWM2OS90YWJsZXJhbmdlOmYyZTQ3ZTQ4MjI3MDQzY2ViNDcwNzhmZWM0NmQ1YzY5XzYtNS0xLTEtODQ0NDQ_f8ce9779-0ac3-4b2a-be95-fe22e0126657"
      unitRef="usd">633000000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="i38d00501bab6464fa7c7be34c6d914c9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzkwNzQ_545636f0-90f9-43a2-89cb-61672c0b3e27"
      unitRef="usd">1884000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="id7cd5b6c455d48de8f7bf42de3895a90_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzkxNDI_a3f69d02-2538-4629-bbfe-7c4bb04f3f97"
      unitRef="usd">533000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i1fa9b7b2390c4ef88b1b4a20e07ca293_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzkzNTU_7befa2b4-bf19-4c5d-bffc-2d6bc2061418"
      unitRef="usd">1116000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i853d7b4b73e148b18f6b3d77f487972d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzkzNTk_d8f4c5f3-0b38-4957-9a15-7bcf43bc751b"
      unitRef="usd">520000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i4535c102f78246f28d354501ec8be219_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzkzNjY_6fdcef03-c744-4488-83ea-ed48e29d0fec"
      unitRef="usd">594000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i9da5b69b8f28444dbde29713e7b26de9_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzk0NTg_e5f17ccd-bb46-4465-84b9-673ccfea8b87"
      unitRef="usd">4000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i141ff0a4da5940ae95c9e2df4dd982b2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzk0NjI_eebcfce3-65b4-4985-9380-e80bb6fbc73d"
      unitRef="usd">13000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i33c7604b66f44fbc8b00fe1f4ef4b6eb_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzk0Njk_c242b62d-afc6-40bc-b0da-0c80aa4949bb"
      unitRef="usd">39000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="ia68fbb4c6ced466380b79a6a0e444ecc_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzk3MDA_f3bfa59d-14f4-4d43-9ff5-dfd9879b9f88"
      unitRef="usd">-1148000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i3935ca62623944f3a9d651e98ee70890_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjAvZnJhZzo3ODZkMmU5ZjYxYTI0ZGIyYThmYWY4NDIzMjU5YWVmYS90ZXh0cmVnaW9uOjc4NmQyZTlmNjFhMjRkYjJhOGZhZjg0MjMyNTlhZWZhXzc2OTY1ODE0MDc3ODk_8acf27d5-d199-4bdb-88a7-f64616fadad9"
      unitRef="usd">704000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzE2Njc_1dd1466d-25c6-458b-b3bd-99fc4b966a70">Borrowings&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of long-term debt are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective Rate %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective Rate %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.250% Notes due 2022                                                        (1B Euro 1.1311)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73%&#160;Debentures due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(750MM Euro 1.0651)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(750MM Euro 1.1311)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50%&#160;Notes due 2024 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(500MM 1.2037 GBP )&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(500MM GBP 1.3485)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028                                                (750MM Euro 1.0651)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(750MM Euro 1.1311)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95%&#160;Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95%&#160;Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035                                                     (1.5B Euro 1.0651)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(1.5B Euro 1.1311)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95%&#160;Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85%&#160;Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.400%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&#160;Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.500% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.250% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.450% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28,439&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.04&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Weighted average effective rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Translation rate at January&#160;1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Translation rate at January&#160;2, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The excess of the carrying value over the fair value of debt was $1.6 billion at the end of fiscal year 2022 and the excess of the fair value over the carrying value of debt was $3.2 billion at the end of fiscal year 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value of the long-term debt was estimated using market prices, which were corroborated by quoted broker prices and significant other observable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company has access to substantial sources of funds at numerous banks worldwide. In September 2022, the Company secured a new 364-day Credit Facility of  $10 billion, which expires on September&#160;7, 2023. In November 2022, the Company secured an additional 364-day Credit Facility of $10&#160;billion, which expires on November 21, 2023. Interest charged on borrowings under the credit line agreement is based on either the Term SOFR Reference Rate or other applicable market rates as allowed under the terms of the agreement, plus applicable margins. Commitment fees under the agreements are not material.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Throughout fiscal years 2022 and 2021, the Company continued to have access to liquidity through the commercial paper market. Short-term borrowings and the current portion of long-term debt amounted to approximately $12.8 billion and $3.8 billion&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; at the end of fiscal years 2022 and 2021, respectively. The current portion of the long term debt was $1.6 billion and $2.1 billion in 2022 and 2021, respectively, and the remainder is commercial paper and local borrowing by international subsi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;diaries. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The current debt balance as of January&#160;1, 2023 includes $11.2&#160;billion of commercial paper which has a weighted average interest rate of 4.23% and a weighted average maturity of approximately two months.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate maturities of long-term debt obligations commencing in 2023 are:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;After 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1,551&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,996&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,562&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzE2NzA_3bb23fcb-18ce-4014-a949-dfe42e94945f">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of long-term debt are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:46.122%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.572%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.280%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.426%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.289%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective Rate %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective Rate %&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.250% Notes due 2022                                                        (1B Euro 1.1311)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.26&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.25% Notes due 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73%&#160;Debentures due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.375% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;801&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;802&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.18&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.05% Notes due 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;500&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.650% Notes due 2024 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(750MM Euro 1.0651)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(750MM Euro 1.1311)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;847&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.50%&#160;Notes due 2024 &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(500MM 1.2037 GBP )&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(500MM GBP 1.3485)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.625% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.55% Notes due 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.57&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.45% Notes due 2026&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,996&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,995&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;877&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;978&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.95% Notes due 2027&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.96&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.150% Notes due 2028                                                (750MM Euro 1.0651)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(750MM Euro 1.1311)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.90%&#160;Notes due 2028&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.95%&#160;Notes due 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30% Notes due 2030&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95%&#160;Debentures due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;498&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.95&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.375% Notes due 2033&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.650% Notes due 2035                                                     (1.5B Euro 1.0651)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;/(1.5B Euro 1.1311)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,591&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.55% Notes due 2036&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.95%&#160;Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;993&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.625% Notes due 2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85%&#160;Debentures due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.85&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.400%&#160;Notes due 2038&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50%&#160;Debentures due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;540&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.10% Notes due 2040&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;974&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.85% Notes due 2041&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.50% Notes due 2043&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.70% Notes due 2046&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,976&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,975&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.75% Notes due 2047&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.76&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.500% Notes due 2048&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.52&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.250% Notes due 2050&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.450% Notes due 2060&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,222&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Subtotal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28,439&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3.04&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;32,116&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2.89&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current portion&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,551&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;26,888&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,985&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Weighted average effective rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Translation rate at January&#160;1, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Translation rate at January&#160;2, 2022.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;The excess of the carrying value over the fair value of debt was $1.6 billion at the end of fiscal year 2022 and the excess of the fair value over the carrying value of debt was $3.2 billion at the end of fiscal year 2021.&lt;/span&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idd838f2728344154a7eaa225122dffc9_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo0Njg1M2VhODY0ZTA0NTVmOWQ2NDhkNjc1YWVjZTgzN180_945193cf-7328-4e64-ba17-ef666b363763"
      unitRef="number">0.00250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="idd838f2728344154a7eaa225122dffc9_I20230101"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo0Njg1M2VhODY0ZTA0NTVmOWQ2NDhkNjc1YWVjZTgzN183OA_239c6220-1dd6-4636-96ee-048cbc47ca7b"
      unitRef="eur">1000000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="idd838f2728344154a7eaa225122dffc9_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo0Njg1M2VhODY0ZTA0NTVmOWQ2NDhkNjc1YWVjZTgzN184Nw_361feba9-8fea-4792-b092-b0ff27540597"
      unitRef="number">1.1311</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt
      contextRef="idd838f2728344154a7eaa225122dffc9_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQtMi0xLTEtODQ0NDQ_cb1970f9-0758-47c3-9b5c-a54ae512ffe4"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="idd838f2728344154a7eaa225122dffc9_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQtNC0xLTEtODQ0NDQ_95f4c482-0ebb-4271-85ae-e8d9d1204555"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ib4be09c6f2a742c2872a7b5200cf5855_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQtNi0xLTEtODQ0NDQ_486d1b92-5a66-4d5a-9206-7ac88693231a"
      unitRef="usd">1131000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib4be09c6f2a742c2872a7b5200cf5855_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQtOC0xLTEtODQ0NDQ_63dc0f15-6522-4038-90de-a5e62e8205bc"
      unitRef="number">0.0026</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie1be16c858d742f980612d02fd786f2f_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzUtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo5OWM0YzUzMTI1NDg0YzMwODgwMGRlOWFjZDk3YmYxNF80_057c1f7a-72bd-43e8-ab1d-46ec8e033209"
      unitRef="number">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie1be16c858d742f980612d02fd786f2f_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzUtMi0xLTEtODQ0NDQ_cfad07e2-a530-4361-8cc0-2bb23fc8f070"
      unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie1be16c858d742f980612d02fd786f2f_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzUtNC0xLTEtODQ0NDQ_f3492b31-fbaf-4751-9330-55a93fc185ee"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i4adc99f2fb284c778be3f71c61bc0de9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzUtNi0xLTEtODQ0NDQ_37af4b58-8a6b-44b0-847a-51914d54e304"
      unitRef="usd">1000000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i4adc99f2fb284c778be3f71c61bc0de9_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzUtOC0xLTEtODQ0NDQ_ad0ca292-64bc-43a8-8d12-6bbd4aa7f4cd"
      unitRef="number">0.0231</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5ed0d053a547493695781065ce302590_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzYtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjpiNjk4MmVkY2QyY2E0ZmY1YmE1YWRjN2IwMWM1NTdhMV80_9eb47f47-97ea-4cad-9cb4-84ce88b0664b"
      unitRef="number">0.0673</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i5ed0d053a547493695781065ce302590_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzYtMi0xLTEtODQ0NDQ_5aaae5e7-0311-4bb1-9f29-37e14d9868b7"
      unitRef="usd">250000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i5ed0d053a547493695781065ce302590_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzYtNC0xLTEtODQ0NDQ_63b1b986-f70a-4604-95f9-0b4df0d572a8"
      unitRef="number">0.0673</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i2c69578754b841ad8feb98ac1c3242b2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzYtNi0xLTEtODQ0NDQ_43cb3f7b-abe4-4103-9c54-81d714f338c2"
      unitRef="usd">250000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i2c69578754b841ad8feb98ac1c3242b2_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzYtOC0xLTEtODQ0NDQ_4fdcf679-ea90-44b6-9c97-f66ba573c034"
      unitRef="number">0.0673</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i9b6971f2c45b4b4bbe271ae191423bff_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzctMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo2NDc5ZmZhNGFjYjI0ODFmODY2YzgzZjcwMThiZWExMV80_14c9ad3f-da41-400c-b9fc-96b2be35a829"
      unitRef="number">0.03375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i9b6971f2c45b4b4bbe271ae191423bff_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzctMi0xLTEtODQ0NDQ_b13724ab-2763-4abd-b421-18088391c5bb"
      unitRef="usd">801000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i9b6971f2c45b4b4bbe271ae191423bff_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzctNC0xLTEtODQ0NDQ_b0d0f685-91c3-4364-8269-f5fc7b54492a"
      unitRef="number">0.0317</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ie38e52b1bfe842649d2000136af597c5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzctNi0xLTEtODQ0NDQ_26d04231-a4d7-484e-8324-c8cac8157c8c"
      unitRef="usd">802000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie38e52b1bfe842649d2000136af597c5_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzctOC0xLTEtODQ0NDQ_9aa40caa-6287-4abf-b359-833a61aa027e"
      unitRef="number">0.0318</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5182d9f822204a00a480cc34f4ec92a0_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzgtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjphOTBkNzUwMDczMzQ0NjYwYTU4ODcxODdmY2Q4NzBlM180_bacf4d4a-79c1-4093-acc0-80e4bc89317d"
      unitRef="number">0.0205</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i5182d9f822204a00a480cc34f4ec92a0_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzgtMi0xLTEtODQ0NDQ_6be8af63-2f04-4582-8102-f97fa3d7b2fa"
      unitRef="usd">500000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i5182d9f822204a00a480cc34f4ec92a0_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzgtNC0xLTEtODQ0NDQ_4f65a715-f9e4-4f61-8df4-d63cdf6b502c"
      unitRef="number">0.0209</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i8fe3adfe765241a28bf93429cd742b69_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzgtNi0xLTEtODQ0NDQ_eff9bc60-3031-4fd5-a088-61bf68e54fd2"
      unitRef="usd">499000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i8fe3adfe765241a28bf93429cd742b69_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzgtOC0xLTEtODQ0NDQ_34929271-12b3-428e-bc01-cb147178f2c8"
      unitRef="number">0.0209</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i34b79ae775034104a023060dd2d5ec9f_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjpiYzA4NWRhODJiZGY0MzRhODNlMzQxZThmODEzZWUyM180_49e21be1-b0d7-404a-82ff-01154eb3f309"
      unitRef="number">0.00650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i34b79ae775034104a023060dd2d5ec9f_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjpiYzA4NWRhODJiZGY0MzRhODNlMzQxZThmODEzZWUyM18yNA_30082295-5fef-4751-8cf2-ecff0a7e967c"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i34b79ae775034104a023060dd2d5ec9f_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjpiYzA4NWRhODJiZGY0MzRhODNlMzQxZThmODEzZWUyM18zNA_ba897b28-4c1c-4f0b-b125-e9946e173e19"
      unitRef="number">1.0651</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ie437d7bfb45f4c6995ab0a136f5c1320_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjpiYzA4NWRhODJiZGY0MzRhODNlMzQxZThmODEzZWUyM180Mg_9d1e3ba4-9096-400f-9282-6ce549af2af9"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="ie437d7bfb45f4c6995ab0a136f5c1320_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjpiYzA4NWRhODJiZGY0MzRhODNlMzQxZThmODEzZWUyM181Mg_14e2c310-4a6e-41a5-99fe-fb82eecbbe2c"
      unitRef="number">1.1311</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt
      contextRef="i34b79ae775034104a023060dd2d5ec9f_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktMi0xLTEtODQ0NDQ_560659b7-f206-44c6-bfcd-14a0471264a5"
      unitRef="usd">792000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i34b79ae775034104a023060dd2d5ec9f_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktNC0xLTEtODQ0NDQ_bdcc4f3e-51bc-4a61-a303-6b0acf1eae64"
      unitRef="number">0.0068</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ie437d7bfb45f4c6995ab0a136f5c1320_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktNi0xLTEtODQ0NDQ_1c04a905-9f61-4776-b3f8-30a83c4c55f0"
      unitRef="usd">847000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie437d7bfb45f4c6995ab0a136f5c1320_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzktOC0xLTEtODQ0NDQ_1b3a8222-ef2f-48df-ae09-d2055a8e44ef"
      unitRef="number">0.0068</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i5971a213eabf4160b6e3f25559619b06_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246Y2IwZmU2Y2ZhOWI0NGY1NDk1ODJjMTQ3MGQwZWU0NzhfNA_ff0519a3-a5f9-4f13-8521-5b1e46fb0983"
      unitRef="number">0.0550</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i5971a213eabf4160b6e3f25559619b06_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246Y2IwZmU2Y2ZhOWI0NGY1NDk1ODJjMTQ3MGQwZWU0NzhfMjQ_1757cdbe-d2ff-4067-9a39-0cd17029004b"
      unitRef="gbp">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i5971a213eabf4160b6e3f25559619b06_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246Y2IwZmU2Y2ZhOWI0NGY1NDk1ODJjMTQ3MGQwZWU0NzhfMjk_34c31510-f544-4120-b290-f5bbc0a75617"
      unitRef="number">1.2037</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i12619cfbbd3b4411975c686625cd4ee8_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246Y2IwZmU2Y2ZhOWI0NGY1NDk1ODJjMTQ3MGQwZWU0NzhfNDI_3bebcc29-3d70-4c43-859f-b1a53034971f"
      unitRef="gbp">500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i12619cfbbd3b4411975c686625cd4ee8_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246Y2IwZmU2Y2ZhOWI0NGY1NDk1ODJjMTQ3MGQwZWU0NzhfNTE_422f3de6-b96d-4ebe-ad22-1c13dcb56732"
      unitRef="number">1.3485</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt
      contextRef="i5971a213eabf4160b6e3f25559619b06_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTItMS0xLTg0NDQ0_163d0cee-a7ae-4c0a-a1d2-5e8512a001d3"
      unitRef="usd">600000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i5971a213eabf4160b6e3f25559619b06_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTQtMS0xLTg0NDQ0_f6f25d1a-589f-41fb-8559-a0526164e1c1"
      unitRef="number">0.0675</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i12619cfbbd3b4411975c686625cd4ee8_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTYtMS0xLTg0NDQ0_d82a7dbe-18dc-40cc-a35c-134fc0ec9d5b"
      unitRef="usd">672000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i12619cfbbd3b4411975c686625cd4ee8_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEwLTgtMS0xLTg0NDQ0_47a0c2e0-8868-4072-8257-09e749293aac"
      unitRef="number">0.0675</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="id160170994a44083bc75890cadbe9623_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzExLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246YTJiYzg1MjI4ODY3NDQzODljYzA3YmU4YzYwMzA2YTRfNA_9eaeb031-cb00-41ad-b814-ac042a6940ed"
      unitRef="number">0.02625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="id160170994a44083bc75890cadbe9623_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzExLTItMS0xLTg0NDQ0_dccc3302-1a0d-4311-9c1a-7bd8f35fcc14"
      unitRef="usd">749000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id160170994a44083bc75890cadbe9623_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzExLTQtMS0xLTg0NDQ0_5c2e6d0a-2f2a-4ff1-adad-a9cfc34cb5b1"
      unitRef="number">0.0263</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="id4b486d1b1024bb589a658274877269a_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzExLTYtMS0xLTg0NDQ0_dd4b8c97-35d5-4cca-9dd6-8c52c4754319"
      unitRef="usd">749000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id4b486d1b1024bb589a658274877269a_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzExLTgtMS0xLTg0NDQ0_dd79acb2-99ef-4cb5-87d4-38ab9a091b4f"
      unitRef="number">0.0263</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie9afa533d623446aaad16fd946291ca1_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEyLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ODZkMjlkMGI2NjY3NDY1MWE3ODFiYTgyMDI0NTU2MjJfNA_ee458ea3-01a8-4dcb-846e-3a0330403589"
      unitRef="number">0.0055</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie9afa533d623446aaad16fd946291ca1_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEyLTItMS0xLTg0NDQ0_6a9d0c04-aa7e-4283-9023-08fd1817c553"
      unitRef="usd">918000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie9afa533d623446aaad16fd946291ca1_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEyLTQtMS0xLTg0NDQ0_8352e70b-6c67-414d-973d-6baad2924cba"
      unitRef="number">0.0057</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ic5bb2d0484d64d079887869bc2c1d3d7_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEyLTYtMS0xLTg0NDQ0_9fbb72f1-9e8d-4872-bb41-69af977000d4"
      unitRef="usd">983000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ic5bb2d0484d64d079887869bc2c1d3d7_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEyLTgtMS0xLTg0NDQ0_44d28ab5-f9a6-4e2d-8fd1-66ba4669b5fc"
      unitRef="number">0.0057</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia73e0d2b294240f09389800e85e374d4_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEzLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ZjAxNjZmNjc1MDE3NGU2OThhMzAyMWQ5NDQ5ZThkYTRfNA_6827772a-3fec-406d-a9cc-8163709ce9bb"
      unitRef="number">0.0245</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ia73e0d2b294240f09389800e85e374d4_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEzLTItMS0xLTg0NDQ0_e2c664b2-533c-4082-917d-9969224a2beb"
      unitRef="usd">1996000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ia73e0d2b294240f09389800e85e374d4_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEzLTQtMS0xLTg0NDQ0_2533045f-dc8c-440a-be0b-9126278f8268"
      unitRef="number">0.0247</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="id09ef46ccfc64f829b503e8d23112272_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEzLTYtMS0xLTg0NDQ0_0a53983f-ff22-46a4-a3f2-8092c37c9a42"
      unitRef="usd">1995000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id09ef46ccfc64f829b503e8d23112272_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzEzLTgtMS0xLTg0NDQ0_55c7f7ff-b17f-43b5-ab46-9c5a13575aff"
      unitRef="number">0.0247</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i8e41ec0707864b1b9019a8e24ae75a97_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246Mzc3MWZlZGFkNjEwNDFhODliODNjMWFlMmI2MDViYWFfNA_6955e516-e8b7-46db-bab8-386ba157c8bc"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i8e41ec0707864b1b9019a8e24ae75a97_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE0LTItMS0xLTg0NDQ0_42c7ce90-12f9-4e3c-bddf-8b4f556a2292"
      unitRef="usd">877000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i8e41ec0707864b1b9019a8e24ae75a97_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE0LTQtMS0xLTg0NDQ0_88f2808f-d0e4-4f3e-9f2a-2f9718688f96"
      unitRef="number">0.0296</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i168bd65ad6a0451d816d411b7f64f62d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE0LTYtMS0xLTg0NDQ0_0880bb30-7a96-4976-9d49-195974131ba0"
      unitRef="usd">978000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i168bd65ad6a0451d816d411b7f64f62d_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE0LTgtMS0xLTg0NDQ0_ea504ce1-c8e9-4f68-bd65-0bd3b4d76c3f"
      unitRef="number">0.0296</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ibeb93d53afa248caa20093bc023648b7_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE1LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NzE4NDIyNjE5MWRmNDM3Y2I1Mjc4MWUwNzhkMzdhMWZfNA_08b5c632-c6bf-4cec-97bd-8d2b2b856805"
      unitRef="number">0.0095</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ibeb93d53afa248caa20093bc023648b7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE1LTItMS0xLTg0NDQ0_73f29ec7-e95e-48f0-a590-d4beee737111"
      unitRef="usd">1394000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ibeb93d53afa248caa20093bc023648b7_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE1LTQtMS0xLTg0NDQ0_1ac40928-405d-4893-a5e3-1307867d02d9"
      unitRef="number">0.0096</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i22bff2ba3f0e400a90a0044c29f13928_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE1LTYtMS0xLTg0NDQ0_bb463b05-a560-4155-be59-1ea23f8d5f12"
      unitRef="usd">1478000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i22bff2ba3f0e400a90a0044c29f13928_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE1LTgtMS0xLTg0NDQ0_c1455b2c-cec2-4b74-8a0b-1b2df93c638f"
      unitRef="number">0.0096</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia496b34d6cb74a168adcb5bf7122133e_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ZDcwOWM0NmMzY2M0NDExNTlhOWRmMzQ1NGJkZjhiNzdfNA_8fec346a-65eb-4230-a862-2c8a88038d3d"
      unitRef="number">0.01150</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="ia496b34d6cb74a168adcb5bf7122133e_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ZDcwOWM0NmMzY2M0NDExNTlhOWRmMzQ1NGJkZjhiNzdfNzA_7ba510e5-c49d-4c76-b479-63ea66b68764"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="ia496b34d6cb74a168adcb5bf7122133e_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ZDcwOWM0NmMzY2M0NDExNTlhOWRmMzQ1NGJkZjhiNzdfODA_9021ab78-9f44-4fd5-b5c1-34f16b8d32d2"
      unitRef="number">1.0651</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i92f030712061450fa2980a5ce6c8142a_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ZDcwOWM0NmMzY2M0NDExNTlhOWRmMzQ1NGJkZjhiNzdfODg_18b6551d-485d-4aea-800c-1a99b9321dce"
      unitRef="eur">750000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i92f030712061450fa2980a5ce6c8142a_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ZDcwOWM0NmMzY2M0NDExNTlhOWRmMzQ1NGJkZjhiNzdfOTg_e3cfcaaf-62b2-442b-a539-98d77495d0c5"
      unitRef="number">1.1311</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt
      contextRef="ia496b34d6cb74a168adcb5bf7122133e_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTItMS0xLTg0NDQ0_9d8075ab-0717-447a-9077-40044326f5bf"
      unitRef="usd">794000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ia496b34d6cb74a168adcb5bf7122133e_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTQtMS0xLTg0NDQ0_e0edbe5a-f9c8-4761-a6d2-571b05a82a87"
      unitRef="number">0.0121</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i92f030712061450fa2980a5ce6c8142a_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTYtMS0xLTg0NDQ0_587b8e49-5f29-4e99-860f-23520c021fd8"
      unitRef="usd">843000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i92f030712061450fa2980a5ce6c8142a_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE2LTgtMS0xLTg0NDQ0_dddff9ab-147f-4277-baf4-62191d083b4f"
      unitRef="number">0.0121</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i7258a1e04b8c4f889adafc8d5386fd96_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE3LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ZTc4OWM3NTY0YWZjNGYyMTkxNTdlNjYwODQ2NjMzN2ZfNA_02f88a26-3e05-4ae5-900c-fd3c04bf4242"
      unitRef="number">0.0290</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i7258a1e04b8c4f889adafc8d5386fd96_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE3LTItMS0xLTg0NDQ0_bf8ab000-b687-4a84-98e5-693571c164ea"
      unitRef="usd">1496000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i7258a1e04b8c4f889adafc8d5386fd96_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE3LTQtMS0xLTg0NDQ0_15e4a8bd-cd93-495b-861f-022b27ec8686"
      unitRef="number">0.0291</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i602d89dbe75f4f748c2295cd5de57aec_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE3LTYtMS0xLTg0NDQ0_a7c82e0a-483a-436b-a3c5-9002efd04370"
      unitRef="usd">1495000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i602d89dbe75f4f748c2295cd5de57aec_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE3LTgtMS0xLTg0NDQ0_9b439ab1-5f93-4ea0-9140-6c614f586196"
      unitRef="number">0.0291</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i423501f49ac54505aa65ac29a7fd6d80_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE4LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MDc0NjVkNDBiZjk0NGRkYjllMTAzYmYyNGE0YzU4ZmZfNA_0cc7ee77-931e-4334-b2de-9dc09c9b3af4"
      unitRef="number">0.0695</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i423501f49ac54505aa65ac29a7fd6d80_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE4LTItMS0xLTg0NDQ0_f6484ec9-cd7d-4c30-b001-3cf8e29d95f2"
      unitRef="usd">298000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i423501f49ac54505aa65ac29a7fd6d80_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE4LTQtMS0xLTg0NDQ0_7f2016b7-0a41-454d-ba54-734910aed7b7"
      unitRef="number">0.0714</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i26d49418e0d74c1189e8912cc7d7675f_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE4LTYtMS0xLTg0NDQ0_def57efb-8248-460f-9d0f-22577e12d1fc"
      unitRef="usd">298000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i26d49418e0d74c1189e8912cc7d7675f_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE4LTgtMS0xLTg0NDQ0_be5346c8-d48d-4e52-9a32-d0b9cfb7c5f0"
      unitRef="number">0.0714</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="iaa0326f0db384917ad2a786fa145a98a_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE5LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NDM2YTQ5MDI2YmEyNDExOGIxNTgwOWYzMzg1MzAwNWRfNA_fc688e87-5af9-4b47-968a-7807495325e3"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="iaa0326f0db384917ad2a786fa145a98a_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE5LTItMS0xLTg0NDQ0_51dfb279-eac9-473a-8077-9dc40ef483a1"
      unitRef="usd">1607000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iaa0326f0db384917ad2a786fa145a98a_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE5LTQtMS0xLTg0NDQ0_f61cc5ad-0111-4629-a289-52192022bfef"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="iaf8bfdbb53ca42e3af2e559cf8fb62c2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE5LTYtMS0xLTg0NDQ0_ec83439f-895f-4b4b-8cad-d2a1354ed41b"
      unitRef="usd">1723000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iaf8bfdbb53ca42e3af2e559cf8fb62c2_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzE5LTgtMS0xLTg0NDQ0_1c08db45-2091-4ebe-88f3-0571f97d729b"
      unitRef="number">0.0130</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ie15d3b834f6345ec822ccb7085d7c0ff_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIwLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246Nzc5MTc3OWYxZTY4NDgwNjgzNzQwOTczNGE2YTczZmZfNA_df556ff2-6ba4-47bf-a4f1-49c7674857c0"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ie15d3b834f6345ec822ccb7085d7c0ff_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIwLTItMS0xLTg0NDQ0_c113fe5b-c7b0-422e-99ef-ec6a78b54dab"
      unitRef="usd">498000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie15d3b834f6345ec822ccb7085d7c0ff_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIwLTQtMS0xLTg0NDQ0_a16a6c2d-5b90-492c-b9ed-1e6a32cf0b6d"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i8db5ee980d1342e793d3791eedfbef40_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIwLTYtMS0xLTg0NDQ0_74e716a4-315e-4e3a-bb02-301ff52bc581"
      unitRef="usd">498000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i8db5ee980d1342e793d3791eedfbef40_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIwLTgtMS0xLTg0NDQ0_faefc765-3dfd-42f0-aedc-7623865b2c6d"
      unitRef="number">0.0495</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i65b796c75e3b43b6bda7c9efb4daa55f_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIxLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NWE4NDlhYTZhMGNkNGVhN2ExYjZjYWMwNTBkYTQ2NjZfNA_af05148e-624b-475a-b270-69dae07d242f"
      unitRef="number">0.04375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i65b796c75e3b43b6bda7c9efb4daa55f_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIxLTItMS0xLTg0NDQ0_63464434-5b69-431f-8a3d-2951e3c1e8d0"
      unitRef="usd">854000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i65b796c75e3b43b6bda7c9efb4daa55f_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIxLTQtMS0xLTg0NDQ0_3633f65d-f3e3-4d29-a1db-b7082373e497"
      unitRef="number">0.0424</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="iad65bba4399943f9b1454685a4155820_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIxLTYtMS0xLTg0NDQ0_78cb5108-d801-46dd-8879-a68644cb5e9e"
      unitRef="usd">854000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iad65bba4399943f9b1454685a4155820_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIxLTgtMS0xLTg0NDQ0_7ef98e9f-1876-42fa-9669-0dae1f64cb21"
      unitRef="number">0.0424</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i0dd231a0bb104e1684521862f1414b9f_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NDY1NTE3YjllNGMwNDhlZjhiN2RhZWE3ZWI0NzA1NTJfNA_5cdc1b32-474c-4e7b-bdf9-b147416dbfd4"
      unitRef="number">0.01650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i0dd231a0bb104e1684521862f1414b9f_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NDY1NTE3YjllNGMwNDhlZjhiN2RhZWE3ZWI0NzA1NTJfNzU_465fb86f-79c4-426f-bbe1-ae4c609fb920"
      unitRef="eur">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="i0dd231a0bb104e1684521862f1414b9f_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NDY1NTE3YjllNGMwNDhlZjhiN2RhZWE3ZWI0NzA1NTJfODQ_ea7becfc-bc5c-4648-85c4-8f8f4b18653c"
      unitRef="number">1.0651</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="idfedf7be284043c98fd18f790c2086ec_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NDY1NTE3YjllNGMwNDhlZjhiN2RhZWE3ZWI0NzA1NTJfOTI_d26ae8df-20d0-428a-a4b5-42add9f25fd5"
      unitRef="eur">1500000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:ForeignCurrencyExchangeRateTranslation1
      contextRef="idfedf7be284043c98fd18f790c2086ec_I20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NDY1NTE3YjllNGMwNDhlZjhiN2RhZWE3ZWI0NzA1NTJfMTAx_78fad006-3cde-46ff-98e7-c076c6ef5acd"
      unitRef="number">1.1311</us-gaap:ForeignCurrencyExchangeRateTranslation1>
    <us-gaap:LongTermDebt
      contextRef="i0dd231a0bb104e1684521862f1414b9f_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTItMS0xLTg0NDQ0_d1b54bd1-2afd-44c6-b579-e1994cea960e"
      unitRef="usd">1591000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i0dd231a0bb104e1684521862f1414b9f_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTQtMS0xLTg0NDQ0_46bb21a6-2a0b-49f5-95dd-1034cdb08e16"
      unitRef="number">0.0168</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="idfedf7be284043c98fd18f790c2086ec_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTYtMS0xLTg0NDQ0_48e665ed-a902-402d-9df0-85c6687614a4"
      unitRef="usd">1683000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="idfedf7be284043c98fd18f790c2086ec_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIyLTgtMS0xLTg0NDQ0_1f94b952-1eec-4501-8357-6cf3e38257ad"
      unitRef="number">0.0168</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="idd6fe30488d441739d3babad588015ad_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIzLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MTM2ZGQ3ZDBlZTY4NDM0OTkzZmIzYjVjOGFmNzkyZDhfNA_e6c3c0da-ede1-40b1-be74-449e6ab4ec15"
      unitRef="number">0.0355</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="idd6fe30488d441739d3babad588015ad_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIzLTItMS0xLTg0NDQ0_0fd60ea9-f3ae-4c2c-ac56-293bb36702c8"
      unitRef="usd">842000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="idd6fe30488d441739d3babad588015ad_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIzLTQtMS0xLTg0NDQ0_e4998880-d510-4d87-9726-52069af8ee93"
      unitRef="number">0.0359</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i8a23940668d946ea8954481965daba62_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIzLTYtMS0xLTg0NDQ0_d30f84e0-9944-4387-9504-fb8a6424849c"
      unitRef="usd">974000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i8a23940668d946ea8954481965daba62_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzIzLTgtMS0xLTg0NDQ0_45a52b6b-3648-4aed-b5be-5b561b3fe047"
      unitRef="number">0.0359</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i6ba6c50490e34f12bda5adb99407a82b_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246N2Q4YzUzZTRkZTVjNDhiZThkYmE0ZDEzMWNmYzEyYjRfNA_f29d0058-5aca-4b6d-843c-defa7af3dc86"
      unitRef="number">0.0595</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i6ba6c50490e34f12bda5adb99407a82b_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI0LTItMS0xLTg0NDQ0_8d821269-a4ac-4cb2-8fa3-1ac0e19d1615"
      unitRef="usd">993000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i6ba6c50490e34f12bda5adb99407a82b_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI0LTQtMS0xLTg0NDQ0_e34fddf3-94c2-477f-8afb-5d17b4617997"
      unitRef="number">0.0599</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ibd4cdb4f57b84232a93db6b02e61c82d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI0LTYtMS0xLTg0NDQ0_e2dc2d75-cb42-454d-a777-75058c5fcbfc"
      unitRef="usd">993000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ibd4cdb4f57b84232a93db6b02e61c82d_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI0LTgtMS0xLTg0NDQ0_877254ed-3ef0-4fed-ae89-c3b2b97ffe01"
      unitRef="number">0.0599</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if509cd02d4494abc9bae248548e9fe2b_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI1LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246OGU3ODBiMTkwZGYyNDkwYTg3OTdkZjY0YzNlN2RhNTFfNA_66b91aaf-c625-4058-a04b-8733443f582b"
      unitRef="number">0.03625</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if509cd02d4494abc9bae248548e9fe2b_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI1LTItMS0xLTg0NDQ0_e2a61a6a-b38c-4aef-a79a-b346f62d4fb6"
      unitRef="usd">1336000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="if509cd02d4494abc9bae248548e9fe2b_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI1LTQtMS0xLTg0NDQ0_24837d1c-2bb0-4442-84fd-de9abfe26581"
      unitRef="number">0.0364</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ie8dfee6b2b9f486783bc9cb6cab9a4dd_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI1LTYtMS0xLTg0NDQ0_900ff0bd-d680-4624-8bc7-3dd2f6fda9eb"
      unitRef="usd">1475000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ie8dfee6b2b9f486783bc9cb6cab9a4dd_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI1LTgtMS0xLTg0NDQ0_d1ed4b4a-45d9-41c2-a9b7-fb1d0b3061d5"
      unitRef="number">0.0364</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i26b8da89821f4ac284bd3d5d3cabf51e_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI2LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MmUwOWU1Yzg4NDExNDM3Mjg2OTczZDRmZjQ3NjA0OTlfNA_ef07f509-2c79-417a-94c1-5d8c5c1d4b02"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i26b8da89821f4ac284bd3d5d3cabf51e_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI2LTItMS0xLTg0NDQ0_a544a9b4-dfdd-43bf-b6d3-9b4c89e9ec70"
      unitRef="usd">697000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i26b8da89821f4ac284bd3d5d3cabf51e_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI2LTQtMS0xLTg0NDQ0_7f663e27-ecba-4d1a-94ae-cea4870e41c5"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i1cf6df4972c749909f6092392e43369e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI2LTYtMS0xLTg0NDQ0_ffb84435-c39f-45cb-b1ca-62272657d599"
      unitRef="usd">696000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i1cf6df4972c749909f6092392e43369e_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI2LTgtMS0xLTg0NDQ0_0af0ec13-f501-4c94-9643-335e6abef016"
      unitRef="number">0.0585</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i696b5a358a7a4568935c7e93c24e7f41_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI3LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MTI5NDhmZTJhNmVmNDY4YzliYmJiMmFmNjQwNTc5YWRfNA_ce3ca7a4-96c9-4e20-a95e-976af0d3f75a"
      unitRef="number">0.03400</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i696b5a358a7a4568935c7e93c24e7f41_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI3LTItMS0xLTg0NDQ0_483e69ed-6e02-4ccf-8428-4bafc8486266"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i696b5a358a7a4568935c7e93c24e7f41_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI3LTQtMS0xLTg0NDQ0_85f82136-60b3-4976-a0a0-8a309500f360"
      unitRef="number">0.0342</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="idd634615b6a848fa8f9569f674e894e6_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI3LTYtMS0xLTg0NDQ0_fbd35910-df61-4e14-b6ff-9611090d89e9"
      unitRef="usd">992000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="idd634615b6a848fa8f9569f674e894e6_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI3LTgtMS0xLTg0NDQ0_88523ae7-87c2-4b5a-bd65-539b4c08237f"
      unitRef="number">0.0342</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ia7967ec234e94809b83f6d22fbf9ce9d_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI4LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246YzQ3OTZiMDE2MDdkNGMzNDk3MmMyYzI4NWI3NmI2YzlfNA_c12a7184-6489-4e01-bd79-766ebd5cb122"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ia7967ec234e94809b83f6d22fbf9ce9d_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI4LTItMS0xLTg0NDQ0_8e74deaa-a46c-4829-9edf-c12e2a1f1612"
      unitRef="usd">540000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ia7967ec234e94809b83f6d22fbf9ce9d_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI4LTQtMS0xLTg0NDQ0_0542055a-c5bf-43a8-95e0-e434cc962715"
      unitRef="number">0.0463</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ia97fbaf7b43e485e95cf7e8916d74a96_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI4LTYtMS0xLTg0NDQ0_be92f16f-df49-4ff6-80d4-c6fac4bcde62"
      unitRef="usd">540000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ia97fbaf7b43e485e95cf7e8916d74a96_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI4LTgtMS0xLTg0NDQ0_683e2317-71f8-4513-822b-e6ed9c3974b5"
      unitRef="number">0.0463</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="if61dc0cc1b304eaa99917f19dad110d2_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI5LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NTk5NTk1MjMwMzdjNDRjYzg4Mzc2OGE2NDQxODY1NjNfNA_86cc87e9-fc19-48b9-8e1f-825eb4ed887f"
      unitRef="number">0.0210</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="if61dc0cc1b304eaa99917f19dad110d2_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI5LTItMS0xLTg0NDQ0_10453bc5-eed9-4333-ab65-f6af7a4e0736"
      unitRef="usd">828000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="if61dc0cc1b304eaa99917f19dad110d2_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI5LTQtMS0xLTg0NDQ0_bb0b245b-8f1f-4f5f-ba38-8f13a2dbf5e6"
      unitRef="number">0.0214</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i83fdb88fdea44eacb07ca88b7b8ca7dd_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI5LTYtMS0xLTg0NDQ0_007dc76e-bb45-4a71-b858-a2f3384c92ba"
      unitRef="usd">974000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i83fdb88fdea44eacb07ca88b7b8ca7dd_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzI5LTgtMS0xLTg0NDQ0_43ae8cb8-d109-4978-8d1d-ec173b44915f"
      unitRef="number">0.0214</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib9293aa9d30342248d3d85c512c81764_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMwLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246NTc5ZGQ4NThhNzJkNGNhMWFlYTJiYzBmOTZhNmM3ZjhfNA_1d7865a8-4770-4d64-946f-7ae302afd0bf"
      unitRef="number">0.0485</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ib9293aa9d30342248d3d85c512c81764_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMwLTItMS0xLTg0NDQ0_ba4dacb2-42a6-4eb8-9d25-1e79cb067661"
      unitRef="usd">297000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib9293aa9d30342248d3d85c512c81764_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMwLTQtMS0xLTg0NDQ0_1911ceec-aa8a-446a-b9aa-3d25be06518a"
      unitRef="number">0.0489</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i565be597706647e888d0c0ea676ef094_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMwLTYtMS0xLTg0NDQ0_74066004-564c-454c-a443-c097a5b31def"
      unitRef="usd">297000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i565be597706647e888d0c0ea676ef094_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMwLTgtMS0xLTg0NDQ0_2fb4f5ca-7289-4d6d-a7ae-e5ad9f1352d3"
      unitRef="number">0.0489</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i26f202863bc94082a97d142a46e8d1b2_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMxLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246YmNlMjgwNTFhYWY0NDZhMGI5MmFlZDNmMjVhZThmODdfNA_554e582a-59cb-4b07-baac-b12f50e96c87"
      unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i26f202863bc94082a97d142a46e8d1b2_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMxLTItMS0xLTg0NDQ0_acd9b273-d138-4b80-890c-07ce0b22db97"
      unitRef="usd">496000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i26f202863bc94082a97d142a46e8d1b2_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMxLTQtMS0xLTg0NDQ0_af6ab844-3d6a-4ebb-909c-b3d56e6147ff"
      unitRef="number">0.0452</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="if67ac9c2c837491fa49ff3662e87bfe1_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMxLTYtMS0xLTg0NDQ0_03835f07-1753-4aa9-a2ab-4d16caaf7327"
      unitRef="usd">496000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="if67ac9c2c837491fa49ff3662e87bfe1_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMxLTgtMS0xLTg0NDQ0_10f72c59-bcc3-413d-a1a0-e9649b533427"
      unitRef="number">0.0452</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="ib10ffb3abaf54da0b43cea2e2ceb7e08_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMyLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246YTNhMDZiYjhiOWU2NDQwZGFlN2VlZjE5Y2ZmM2ExODBfNA_e4a89cd7-e214-433c-993f-65393786f08c"
      unitRef="number">0.0370</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="ib10ffb3abaf54da0b43cea2e2ceb7e08_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMyLTItMS0xLTg0NDQ0_4846ef3b-0d82-4fbc-a7a1-b7c6de382ead"
      unitRef="usd">1976000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ib10ffb3abaf54da0b43cea2e2ceb7e08_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMyLTQtMS0xLTg0NDQ0_072549ba-23a8-4088-bf9b-8323c9bb1301"
      unitRef="number">0.0374</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i1902162eea4549f78cee91e0c0156868_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMyLTYtMS0xLTg0NDQ0_91352346-84cf-42d4-a509-7cbbe362b1b1"
      unitRef="usd">1975000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i1902162eea4549f78cee91e0c0156868_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMyLTgtMS0xLTg0NDQ0_40353370-979d-43d1-beaa-a49f811e0171"
      unitRef="number">0.0374</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i91feec6def3047ae92ab21665e29fbe4_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMzLTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MmRiZWQxZjBiY2UwNDYzMTlkMzI0MWU2YjBiZWE3ZGRfNA_ddae6e8f-2943-4a4a-aa0f-9612062d78fc"
      unitRef="number">0.0375</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i91feec6def3047ae92ab21665e29fbe4_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMzLTItMS0xLTg0NDQ0_83afa388-2bcb-4e63-841f-0448e80472f4"
      unitRef="usd">812000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i91feec6def3047ae92ab21665e29fbe4_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMzLTQtMS0xLTg0NDQ0_436a964f-d8e6-418c-9388-2e7f395c7f18"
      unitRef="number">0.0376</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="iefcd48741e0b49cebaf892a4bad31d22_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMzLTYtMS0xLTg0NDQ0_c1d99e9a-faaf-491d-8eec-9d999d579e67"
      unitRef="usd">971000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="iefcd48741e0b49cebaf892a4bad31d22_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzMzLTgtMS0xLTg0NDQ0_708a3906-dbc1-4962-b2b8-7cb3790d62bd"
      unitRef="number">0.0376</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i4f24fb8b890841428b85dac4bce5953f_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM0LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246MThiYTMwZDUzNmU0NDNkZTljY2FlMmVmMDZmYTNhMGRfNA_b87c49cf-ecb4-4403-9251-ba7c80505701"
      unitRef="number">0.03500</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i4f24fb8b890841428b85dac4bce5953f_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM0LTItMS0xLTg0NDQ0_d973d1e9-6093-4363-b949-5a1776ac7e4e"
      unitRef="usd">743000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i4f24fb8b890841428b85dac4bce5953f_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM0LTQtMS0xLTg0NDQ0_726083da-a24a-41ff-9ec3-f914dce5a005"
      unitRef="number">0.0352</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i86d445ff094d4648b596d34b86e80355_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM0LTYtMS0xLTg0NDQ0_cf5dd344-0b2b-4493-86e6-a5c40625e262"
      unitRef="usd">743000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i86d445ff094d4648b596d34b86e80355_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM0LTgtMS0xLTg0NDQ0_1ad2c13a-1739-40e0-adfe-b7f4f9bf68ff"
      unitRef="number">0.0352</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i1fad250982dc47abbb5a254928d9895f_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM1LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246ZGY0YmRmMmVmMjdhNGIzMDk3Mzk4ZGJkYTRlZTc5ZDhfNA_f2e787ba-0780-4abe-863f-6a05285ae268"
      unitRef="number">0.02250</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i1fad250982dc47abbb5a254928d9895f_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM1LTItMS0xLTg0NDQ0_c65c65ce-4df0-474d-94c0-ef0505fb02a8"
      unitRef="usd">808000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i1fad250982dc47abbb5a254928d9895f_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM1LTQtMS0xLTg0NDQ0_b9406cc4-9b22-43b5-8dc7-6fe0a10514be"
      unitRef="number">0.0229</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i0e53361c290b43718ffeb7cd8f9afc2d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM1LTYtMS0xLTg0NDQ0_17b7b9a2-6edf-41c7-b090-50877dd5b786"
      unitRef="usd">983000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i0e53361c290b43718ffeb7cd8f9afc2d_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM1LTgtMS0xLTg0NDQ0_a0b697f8-dc94-4897-8a8d-c99ef2be2db4"
      unitRef="number">0.0229</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="i46a29376f79d4b30a03d32aff4ccdfe8_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM2LTAtMS0xLTg0NDQ0L3RleHRyZWdpb246Y2M1YTIzM2VhYmZhNDc5YjgwMWJkNmVkMDkyNDI3NDZfNA_df355b8e-3e98-4a0a-89a5-8e2d2e405fc0"
      unitRef="number">0.02450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt
      contextRef="i46a29376f79d4b30a03d32aff4ccdfe8_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM2LTItMS0xLTg0NDQ0_adddfdfa-77a6-4a46-be07-6735cead4b9e"
      unitRef="usd">1055000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i46a29376f79d4b30a03d32aff4ccdfe8_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM2LTQtMS0xLTg0NDQ0_77c47578-a94f-4ec4-8b42-b6ecd084d215"
      unitRef="number">0.0249</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="id01a95b64b3942d1a96051a89d5e3413_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM2LTYtMS0xLTg0NDQ0_124f4583-03cc-4667-ae50-98f2de591e6c"
      unitRef="usd">1222000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="id01a95b64b3942d1a96051a89d5e3413_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM2LTgtMS0xLTg0NDQ0_af01f2aa-b81c-4649-b025-9414cb87d853"
      unitRef="number">0.0249</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i80f90c4157e04d8cb1fd3fca5f4ecb65_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM3LTItMS0xLTg0NDQ0_42ef7f83-5828-488c-824b-c54c3d9e2f65"
      unitRef="usd">9000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i80f90c4157e04d8cb1fd3fca5f4ecb65_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM3LTQtMS0xLTg0NDQ0_3d4cf62b-de02-4e0d-ae6c-13ca32acb759"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ifbebb1875a3d44ca9658f3fde18446f9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM3LTYtMS0xLTg0NDQ0_4102d121-6d00-4c17-becf-889bc1f25272"
      unitRef="usd">7000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ifbebb1875a3d44ca9658f3fde18446f9_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM3LTgtMS0xLTg0NDQ0_66330cbd-3c36-41ca-92fb-df62b6e79abd"
      unitRef="number">0</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM4LTItMS0xLTg0NDQ0_e63d9247-def1-49d3-91a3-f3a449905212"
      unitRef="usd">28439000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM4LTQtMS0xLTg0NDQ0_cc84c5e1-b436-4e88-95d6-97363b70c9b2"
      unitRef="number">0.0304</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebt
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM4LTYtMS0xLTg0NDQ0_cac23772-cb1e-4020-8d94-107be2ea324c"
      unitRef="usd">32116000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM4LTgtMS0xLTg0NDQ0_fc1f2bc0-6144-4705-a0c7-3cf9a827a9a9"
      unitRef="number">0.0289</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LongTermDebtCurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM5LTItMS0xLTg0NDQ0_2daf5732-8db6-4790-95ee-75bbb8984ed6"
      unitRef="usd">1551000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzM5LTYtMS0xLTg0NDQ0_1fa9a09a-67e6-42eb-a4bb-3e0b8691fbb2"
      unitRef="usd">2131000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQwLTItMS0xLTg0NDQ0_e0faf598-4a64-476e-b2b2-24c8e51df88c"
      unitRef="usd">26888000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo3YWUyNTc0NDE2OTI0ZjAwYWFlY2ZmNDgxMzg3YjM0ZC90YWJsZXJhbmdlOjdhZTI1NzQ0MTY5MjRmMDBhYWVjZmY0ODEzODdiMzRkXzQwLTYtMS0xLTg0NDQ0_b88aac3b-782c-4dd5-8ce4-779546dba489"
      unitRef="usd">29985000000</us-gaap:LongTermDebtNoncurrent>
    <jnj:ExcessOfCarryingValueOverFairValueOfDebt
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzIxNQ_86b1a0c4-15d8-445c-bd80-2b6ae889cead"
      unitRef="usd">1600000000</jnj:ExcessOfCarryingValueOverFairValueOfDebt>
    <jnj:ExcessOfFairValueOverCarryingValueOfDebt
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzI1MQ_fa78d064-3621-4e9d-8573-9e36c93dd12e"
      unitRef="usd">3200000000</jnj:ExcessOfFairValueOverCarryingValueOfDebt>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="iac989accfda349e1b99a6c9cdcdcaa17_I20210930"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzYzNQ_d35f0301-52e6-468f-b029-9600d9bebbf0"
      unitRef="usd">10000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="i4f53b7ce48b043d2944b5ea32ee20998_I20221130"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzU0OTc1NTgxNzAxNg_828cd0a6-6ce9-4325-a613-fdf8daac0990"
      unitRef="usd">10000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:DebtCurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzExNjA_36734269-07c7-4f59-91a5-8efffeb58550"
      unitRef="usd">12800000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzExNjc_b22698c9-7d86-44d6-994f-d51e2d6d6744"
      unitRef="usd">3800000000</us-gaap:DebtCurrent>
    <us-gaap:LongTermCommercialPaperCurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzEyNzA_27a4e649-0e09-49f2-a402-5180662ef49b"
      unitRef="usd">1600000000</us-gaap:LongTermCommercialPaperCurrent>
    <us-gaap:LongTermCommercialPaperCurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzEyNzc_f0042990-16dc-4565-a82b-e8ed453fb693"
      unitRef="usd">2100000000</us-gaap:LongTermCommercialPaperCurrent>
    <us-gaap:ShortTermBorrowings
      contextRef="i608e0e39b1eb42ac87ce9ad42b7316e9_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzE0NDU_9fcd704a-322e-4737-948a-8190ff956e94"
      unitRef="usd">11200000000</us-gaap:ShortTermBorrowings>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="i608e0e39b1eb42ac87ce9ad42b7316e9_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzE1MTQ_cf781839-7f8b-47fc-a79f-30798bbaa179"
      unitRef="number">0.0423</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentTerm
      contextRef="i9d8b8a1c1b90452cb498943d7fbd6cdd_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzE1NjY_8b923cc9-9405-4011-9796-c47810b851f4">P2M</us-gaap:DebtInstrumentTerm>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90ZXh0cmVnaW9uOjU0NTdkNTEzYTgwYzQ0MDQ4OGU2OGI4MThhYjA3ZDRkXzE2NDk_1dcc12f1-abac-4258-9529-f8d9cfa3ffac">&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate maturities of long-term debt obligations commencing in 2023 are:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:85.087%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.223%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.707%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.659%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.882%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"&gt;After 2026&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$1,551&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,392&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,667&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,996&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,271&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,562&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo1YzBlMTgyMjJkN2U0NDM3OTEzODJhMzQ1NmZlMjczNi90YWJsZXJhbmdlOjVjMGUxODIyMmQ3ZTQ0Mzc5MTM4MmEzNDU2ZmUyNzM2XzItMC0xLTEtODQ0NDQ_86459d6b-d9f8-4973-936f-b72cb1976b88"
      unitRef="usd">1551000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo1YzBlMTgyMjJkN2U0NDM3OTEzODJhMzQ1NmZlMjczNi90YWJsZXJhbmdlOjVjMGUxODIyMmQ3ZTQ0Mzc5MTM4MmEzNDU2ZmUyNzM2XzItMi0xLTEtODQ0NDQ_77f38e95-c234-47dd-b8f1-a2d2195741ea"
      unitRef="usd">1392000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo1YzBlMTgyMjJkN2U0NDM3OTEzODJhMzQ1NmZlMjczNi90YWJsZXJhbmdlOjVjMGUxODIyMmQ3ZTQ0Mzc5MTM4MmEzNDU2ZmUyNzM2XzItNC0xLTEtODQ0NDQ_031225dd-a770-4420-8d24-33d827678a84"
      unitRef="usd">1667000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo1YzBlMTgyMjJkN2U0NDM3OTEzODJhMzQ1NmZlMjczNi90YWJsZXJhbmdlOjVjMGUxODIyMmQ3ZTQ0Mzc5MTM4MmEzNDU2ZmUyNzM2XzItNi0xLTEtODQ0NDQ_df6c3ab6-93d8-4472-b50d-c9e931f2e9be"
      unitRef="usd">1996000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo1YzBlMTgyMjJkN2U0NDM3OTEzODJhMzQ1NmZlMjczNi90YWJsZXJhbmdlOjVjMGUxODIyMmQ3ZTQ0Mzc5MTM4MmEzNDU2ZmUyNzM2XzItOC0xLTEtODQ0NDQ_2792054b-5fe7-42b3-b994-075d9f9fa436"
      unitRef="usd">2271000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNjYvZnJhZzo1NDU3ZDUxM2E4MGM0NDA0ODhlNjhiODE4YWIwN2Q0ZC90YWJsZTo1YzBlMTgyMjJkN2U0NDM3OTEzODJhMzQ1NmZlMjczNi90YWJsZXJhbmdlOjVjMGUxODIyMmQ3ZTQ0Mzc5MTM4MmEzNDU2ZmUyNzM2XzItMTAtMS0xLTg0NDQ0_03c94055-f171-428a-bee3-513c95c34ab7"
      unitRef="usd">19562000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMzY2_e4249d3f-6bba-4103-b3e2-3d2815624f70">Income Taxes&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for taxes on income consists of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.003%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Currently payable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total currently payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Provision for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,784&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A comparison of income tax expense at the U.S.&#160;statutory rate of 21% in fiscal years 2022, 2021 and 2020, to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings before taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax rates:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer health separation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes on international income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefits from loss on capital assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefits on share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)       &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflect the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2021 amounts include the reorganization of international subsidiaries; the 2020 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)     &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. The 2022 amount includes the impact of certain provisions of the 2017 TCJA that became effective in fiscal 2022. The 2021 amounts include the reorganization of international subsidiaries; the 2020 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;    Certain prior year amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The fiscal year 2022 effective tax rate increased 9.1% as compared to the fiscal year 2021 effective tax rate. As part of the planned separation of the Company&#x2019;s Consumer Health business, the Company has recognized approximately $0.5&#160;billion in net incremental tax costs in fiscal year 2022, which increased the 2022 effective tax rate by approximately 2.2%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Additionally, the Company recorded certain non-recurring favorable tax items in fiscal year 2021 which resulted in an unfavorable impact to the Company&#x2019;s fiscal 2022 effective tax rate when compared to the prior fiscal year. These items are described below. The Company&#x2019;s 2022 tax rate also benefited from certain provisions of the Tax Cuts and Jobs Act of 2017 that became effective in fiscal 2022, the impairment of bermekimab for AD and HS IPR&amp;amp;D (for further information see Note 5 of the 2022 10-K Consolidated Financial Statements) and changes in the fair value of securities in the Company&#x2019;s investment portfolio, both recorded at the U.S. statutory rate. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fiscal year 2021 tax rate decreased by 2.5% compared to the fiscal year 2020 tax rate, which was primarily driven by the following items. In fiscal year 2021, the Company reorganized the ownership structure of certain wholly-owned international subsidiaries. As part of this reorganization, the Company increased the tax basis of certain assets to fair value in accordance with applicable local regulations. The net impact of this restructuring was approximately $0.6&#160;billion net benefit or 2.7% benefit to the Company&#x2019;s annual effective tax rate, comprised of the following items: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;approximately $2.3&#160;billion of local deferred tax assets to record the remeasurement of the tax basis of these assets to fair value, this benefit has been reflected as &#x201c;International Operations&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;approximately $1.7&#160;billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of these deferred tax assets. This expense has been reflected as &#x201c;U.S. tax on international income&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Also, in the fiscal fourth quarter of 2021, the Company recognized a loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2021 tax rate by approximately 1.3% which is reflected as a &#x201c;Tax benefits from loss on capital assets&#x201d; on the effective tax rate reconciliation. Additionally other fiscal 2021 impacts to the rate were primarily driven by litigation and acquisition related items as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the Company accrued additional legal expenses, of approximately $1.6&#160;billion for talc at an effective tax rate of 23.5% and $0.8&#160;billion for Risperdal Gynecomastia settlements at an effective tax rate of 16.4% (See Note 19 to the Consolidated Financial Statements for more details).&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the Company recorded a partial IPR&amp;amp;D charge of $0.9&#160;billion for the Ottava intangible asset (acquired with the Auris Health acquisition in 2019) at an effective rate of 22.4%.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In fiscal year 2019, Switzerland enacted the Federal Act on Tax Reform and AHV Financing (TRAF) and became effective for fiscal year 2020. The Federal transitional provisions of TRAF allow companies, under certain conditions, to adjust the tax basis in certain assets to fair value (i.e., &#x201c;step-up&#x201d;) to be depreciated and amortized resulting in an incremental Swiss tax deduction over the transitional period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;TRAF also provides for parameters which enable the Swiss cantons to establish localized tax rates and regulations for companies. The new cantonal tax parameters include favorable tax benefits for patents and additional research and development tax deductions. The cantonal transitional provisions of TRAF allowed companies to elect either 1) tax basis step-up similar to the Federal transition benefit or 2) alternative statutory tax rate for a period not to exceed 5 years. The Company has operations located in various Swiss cantons. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;During the fiscal year 2020, the final canton where the Company maintains significant operations enacted TRAF legislation. Additionally, the Company received rulings from the Swiss Federal and cantonal tax authorities in the remaining jurisdictions where it has significant operations. These rulings resulted in the Company revising its estimate on the tax basis adjustment (i.e., &#x201c;step-up&#x201d;) for its assets and as a result, the Company recorded additional deferred tax benefits in 2020. The Company recognized a net benefit in the fiscal year 2020 for Swiss Tax Reform of approximately $0.4&#160;billion or 2.6% benefit to the Company&#x2019;s annual effective tax rate, comprised of the following items: &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;approximately $0.3 billion tax benefit relating to the remeasurement of Swiss deferred tax assets and liabilities for the change in the Federal and cantonal tax rates, where enactment occurred in the fiscal year 2020; this benefit has been reflected as &#x201c;International Operations&#x201d; on the Company&#x2019;s effective tax rate reconciliation. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;a $450 million deferred tax asset related to the estimated value of a Federal tax basis step-up of the Company&#x2019;s Swiss subsidiaries&#x2019; assets as described above; this benefit has been reflected as &#x201c;International Operations&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;approximately $0.3 billion of U.S. deferred tax expense relating to the GILTI deferred tax liability resulting from the remeasurement of the Swiss deferred tax assets and liabilities in the fiscal year 2020. This benefit has been reflected as &#x201c;U.S. tax on international income&#x201d; on the Company&#x2019;s effective tax rate reconciliation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company does not expect to receive future rulings regarding the transitional provisions of TRAF. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;Also, in the fiscal year 2020, the Company recognized a capital loss on certain U.S. affiliates related to the previously impaired book value of certain intangibles, which reduced the 2020 tax rate by approximately 1.2% which is reflected as a &#x201c;Tax benefits from loss on capital assets&#x201d; on the effective tax rate reconciliation. In addition, in the fiscal year 2020, the Company had lower income in higher tax jurisdictions, primarily driven by:       &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the impact of the accrual of litigation costs related to talc for $4.0&#160;billion which reduced the U.S. earnings before taxes at an effective tax rate of 23.5%;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;the accrual of additional legal costs, including an additional $1.0&#160;billion associated with a revised agreement in principle to settle opioid litigation at an effective tax rate of 21.4% &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The Company also reduced the contingent consideration liability related to the Auris Health acquisition in 2019 and reversed some of its unrecognized tax benefits due to the completion of several years of tax examinations in certain jurisdictions during the fiscal year 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9.9pt;margin-top:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Temporary differences and carryforwards at the end of fiscal years 2022 and 2021 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.729%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022 Deferred Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021 Deferred Tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee related obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D capitalized for tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves&#160;&amp;amp; liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income reported for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realizable operating loss carryforwards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undistributed foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global intangible low-taxed income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Miscellaneous international&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Miscellaneous U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,183&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)     &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Amount is inclusive of the $2.3&#160;billion deferred tax asset established as part of the reorganized ownership structure of   certain wholly-owned international subsidiaries, as previously described. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   Amount is inclusive of the $1.8&#160;billion deferred tax liability due to the acquisition of Abiomed.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   Net of valuation allowances of $0.9&#160;billion in both 2022 and 2021. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has wholly-owned international subsidiaries that have cumulative net losses. The Company believes that it is more likely than not that these subsidiaries will generate future taxable income sufficient to utilize these deferred tax assets. However, in certain jurisdictions, valuation allowances have been recorded against deferred tax assets for loss carryforwards that are not more likely than not to be realized. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to unrecognized tax benefits:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,829&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,323&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The unrecognized tax benefits of $3.8 billion at January&#160;1, 2023, if recognized, would affect the Company&#x2019;s annual effective tax rate. The Company conducts business and files tax returns in numerous countries and currently has tax audits in progress with a number of tax authorities. With respect to the United States, the IRS has completed its audit for the tax years through 2012 and is currently auditing tax years 2013 through 2016. In the fiscal year 2020, the Company made its final payments for approximately $0.7 billion to the U.S. Treasury related to the final settlement of 2010-2012 tax audit liability.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:96%"&gt;In other major jurisdictions where the Company conducts business, the years that remain open to tax audits go back to the year 2008. The Company believes it is possible that some tax audits may be completed over the next twelve months by taxing authorities in some jurisdictions, including in the United States. However, the Company is not able to provide a reasonably reliable estimate of the timing of any other future tax payments or change in uncertain tax positions, if any. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company classifies liabilities for unrecognized tax benefits and related interest and penalties as long-term liabilities. Interest expense and penalties related to unrecognized tax benefits are classified as income tax expense. The Company recognized after tax interest expense of $139 million, $44 million and $32 million in fiscal years 2022, 2021 and 2020, respectively. The total amount of accrued interest was $651&#160;million and $512 million in fiscal years 2022 and 2021, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMzc2_56b35758-bfe4-4507-b465-82aa56e613f1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The provision for taxes on income consists of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.204%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.115%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.000%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.141%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.003%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Currently payable:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,026&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total currently payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,924&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,081)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,662)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,065)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,663)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,141)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Provision for taxes on income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,784&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,783&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzItMS0xLTEtODQ0NDQ_0f1fb76e-da8a-4070-ab5c-78613c859d8d"
      unitRef="usd">2378000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzItMy0xLTEtODQ0NDQ_8fe232d7-6742-42a7-b6aa-46e509e5930d"
      unitRef="usd">1525000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzItNS0xLTEtODQ0NDQ_6bc490ca-7c29-465d-b2b0-786241fb45bf"
      unitRef="usd">1026000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzQtMS0xLTEtODQ0NDQ_198d561b-7edc-4de7-b5e1-dfe950cdb66d"
      unitRef="usd">3069000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzQtMy0xLTEtODQ0NDQ_c6a7b41d-b005-4784-84a6-6a5d305ef2fd"
      unitRef="usd">2452000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzQtNS0xLTEtODQ0NDQ_f26f5a20-0d95-46ee-b7bd-b1a7005ab887"
      unitRef="usd">1898000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzUtMS0xLTEtODQ0NDQ_f45f0ea8-2c17-4171-933f-b07d43b0b24e"
      unitRef="usd">5447000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzUtMy0xLTEtODQ0NDQ_152284e6-8305-4f59-af14-0840ad25dd68"
      unitRef="usd">3977000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzUtNS0xLTEtODQ0NDQ_e8a99b89-a611-4cd5-b318-db861174f08a"
      unitRef="usd">2924000000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzctMS0xLTEtODQ0NDQ_dba8d283-b116-4551-99b2-a0c223725cfc"
      unitRef="usd">-2081000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzctMy0xLTEtODQ0NDQ_39ff6f73-5481-4ada-b02c-2f7d7ed8827c"
      unitRef="usd">583000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzctNS0xLTEtODQ0NDQ_cb1b6299-ecef-4af0-a401-9c4c20218948"
      unitRef="usd">-76000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzktMS0xLTEtODQ0NDQ_cf0bdacc-5d60-4b90-ae41-9a9ca530fad7"
      unitRef="usd">418000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzktMy0xLTEtODQ0NDQ_05684e9a-155f-46f0-8f07-405b46188875"
      unitRef="usd">-2662000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzktNS0xLTEtODQ0NDQ_3cc20fe1-0d97-4c90-a609-b25dea3c6735"
      unitRef="usd">-1065000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzEwLTEtMS0xLTg0NDQ0_32008ec0-acde-418d-a824-80fb2c7c2e58"
      unitRef="usd">-1663000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzEwLTMtMS0xLTg0NDQ0_06ca2a0c-6ad9-4325-86cc-8a5bf12ecbfe"
      unitRef="usd">-2079000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzEwLTUtMS0xLTg0NDQ0_53a2f968-0aa4-4bcc-9956-0bebfda73394"
      unitRef="usd">-1141000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzExLTEtMS0xLTg0NDQ0_4ad3a14e-c50f-402b-97cc-581b6b39c953"
      unitRef="usd">3784000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzExLTMtMS0xLTg0NDQ0_4d7babb7-2c1b-4f6e-ae5d-843374cdbf7c"
      unitRef="usd">1898000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo1MjBkZTlhYzVmOTk0YTc0OWZlYTU4YjY4MTY0ZjQzZi90YWJsZXJhbmdlOjUyMGRlOWFjNWY5OTRhNzQ5ZmVhNThiNjgxNjRmNDNmXzExLTUtMS0xLTg0NDQ0_a662c53d-f24d-4f96-8c4b-a7138c89440a"
      unitRef="usd">1783000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMzc3_8f9a3abc-494b-47ca-b743-fef89b716c2a">&lt;div style="margin-top:4pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A comparison of income tax expense at the U.S.&#160;statutory rate of 21% in fiscal years 2022, 2021 and 2020, to the Company&#x2019;s effective tax rate is as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:48.820%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.597%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.930%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.297%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:1.933%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,356&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,185&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Earnings before taxes on income:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,776&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,497&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax rates:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. statutory rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International operations &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer health separation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. taxes on international income &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefits from loss on capital assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax benefits on share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;All other &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effective Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)       &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For all periods presented the Company has subsidiaries operating in Puerto Rico under various tax incentives. International operations reflect the impacts of operations in jurisdictions with statutory tax rates different than the U.S., particularly Ireland, Switzerland and Puerto Rico, which is a favorable impact on the effective tax rate as compared with the U.S. statutory rate. The 2021 amounts include the reorganization of international subsidiaries; the 2020 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)     &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Includes the impact of the GILTI tax, the Foreign-Derived Intangible Income deduction and other foreign income that is taxable under the U.S. tax code. The 2022 amount includes the impact of certain provisions of the 2017 TCJA that became effective in fiscal 2022. The 2021 amounts include the reorganization of international subsidiaries; the 2020 amounts include the impact of the new tax legislation enactment in Switzerland, both of which are further described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:107%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;    Certain prior year amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzNA_31a5ec66-7be6-4e2a-95d0-a40353b082ee"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzNA_91efaa80-119a-4a1b-80e9-dd322df5f681"
      unitRef="number">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEtMi0xLTEtODQ0NDQ_8003a496-dc1c-4357-812d-efae47b62f28"
      unitRef="usd">5369000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEtNC0xLTEtODQ0NDQ_1f8fbf23-321e-4020-aa19-3c8ac7e71255"
      unitRef="usd">6110000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEtNi0xLTEtODQ0NDQ_40493403-c35e-4dd1-8dc0-8ffc9e38ca2b"
      unitRef="usd">4312000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzItMi0xLTEtODQ0NDQ_576ea995-5068-4bb9-95f6-05b92a5d4f3d"
      unitRef="usd">16356000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzItNC0xLTEtODQ0NDQ_81560cce-533f-4915-862f-41951a4c1400"
      unitRef="usd">16666000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzItNi0xLTEtODQ0NDQ_72a68e0f-1c96-45c8-9715-c8eba28c9a56"
      unitRef="usd">12185000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzMtMi0xLTEtODQ0NDQ_191e5964-0883-4d37-9eb8-3502fce6459e"
      unitRef="usd">21725000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzMtNC0xLTEtODQ0NDQ_6b46b956-eeb6-4f9f-979d-aa6bd8f497e7"
      unitRef="usd">22776000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzMtNi0xLTEtODQ0NDQ_935c0b38-5d1e-4544-abdd-8cdf67a8637e"
      unitRef="usd">16497000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzUtMi0xLTEtODQ0NDQ_ae08110f-1221-4a93-82d3-c378b7774d80"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzUtNC0xLTEtODQ0NDQ_216226ed-5ad1-4be3-ab8f-c90cd0f30746"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzUtNi0xLTEtODQ0NDQ_38bcfa87-2a93-4760-b1a6-a2f9c84da09d"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzYtMi0xLTEtODQ0NDQ_c23e7645-ecdc-4c5d-8051-b36e587e321c"
      unitRef="number">-0.045</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzYtNC0xLTEtODQ0NDQ_eafbb6e7-82f5-46e5-abb5-714a37e71c57"
      unitRef="number">-0.164</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzYtNi0xLTEtODQ0NDQ_67c9f892-ba60-4f29-b018-45cb01dfc41b"
      unitRef="number">-0.099</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEwLTItMS0xLTEwNTUzNw_5be77885-1907-4a5e-ab54-5307d686f4c4"
      unitRef="number">0.022</jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation>
    <jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEwLTQtMS0xLTEwNTU0NQ_ab5806ea-ee5d-4aee-82a9-42483ae114a8"
      unitRef="number">0</jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation>
    <jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEwLTYtMS0xLTEwNTU1Mw_246d267d-35c4-40db-9e03-aa278be7093d"
      unitRef="number">0</jnj:EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation>
    <jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEwLTItMS0xLTg0NDQ0_8936d546-3dc8-4fe7-be9f-5838e8a1a0b7"
      unitRef="number">-0.019</jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome>
    <jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEwLTQtMS0xLTg0NDQ0_13a35a59-755d-4452-ae58-10f5ef34b929"
      unitRef="number">0.067</jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome>
    <jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEwLTYtMS0xLTg0NDQ0_27c8514d-8e35-4ffa-b986-46935f12e62e"
      unitRef="number">0.027</jnj:EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome>
    <jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzExLTQtMS0xLTg0NDQ0_8c3adabc-9893-46b8-99e0-653250f541c4"
      unitRef="number">-0.013</jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss>
    <jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzExLTYtMS0xLTg0NDQ0_26dc73fc-9e4a-452a-9858-0e78946aaeb2"
      unitRef="number">-0.012</jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEyLTItMS0xLTg0NDQ0_35f8d486-cdf0-4e5e-8e09-f6aa43de1635"
      unitRef="number">0.013</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEyLTQtMS0xLTg0NDQ0_7f280d3e-8f2e-4d71-b05c-1e737f4be0c3"
      unitRef="number">0.010</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzEyLTYtMS0xLTg0NDQ0_45cf084e-68e8-47b2-8174-7c140e70f137"
      unitRef="number">0.015</us-gaap:EffectiveIncomeTaxRateReconciliationDeductionsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzE1LTItMS0xLTg0NDQ0_db66c510-a148-454a-9bb1-cbb714f1cfda"
      unitRef="number">0.019</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzE1LTQtMS0xLTg0NDQ0_49edad65-1fcc-4a7a-a78a-c0a73f8360a3"
      unitRef="number">-0.007</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzE1LTYtMS0xLTg0NDQ0_5f5fe9af-b141-49a6-881d-9b231870e200"
      unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzE2LTItMS0xLTg0NDQ0_382e0dca-bc10-4cda-8df9-e8608bde2581"
      unitRef="number">0.174</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzE2LTQtMS0xLTg0NDQ0_65dd7090-92b3-4a41-b0c9-4ac83a304ad7"
      unitRef="number">0.083</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo5NzVlNTUxZjExOWQ0N2EyODY4ZWYwZGY0NmY4NTljZi90YWJsZXJhbmdlOjk3NWU1NTFmMTE5ZDQ3YTI4NjhlZjBkZjQ2Zjg1OWNmXzE2LTYtMS0xLTg0NDQ0_96180031-56e8-4e50-97ae-1b668c237c40"
      unitRef="number">0.108</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3Xzk4OTU2MDQ2ODk4NjM_33ffa58c-8945-4bb6-b467-bac515c2530e"
      unitRef="number">0.091</jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="id2821f9be6044964b18bd8dd41179df6_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3Xzk4OTU2MDQ2ODk4NjU_7fd90379-45a4-4c41-b6ea-9ea087e2dbeb"
      unitRef="usd">500000000</us-gaap:IncomeTaxExpenseBenefit>
    <jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent
      contextRef="id2821f9be6044964b18bd8dd41179df6_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3Xzk4OTU2MDQ2ODk4Nzk_f5912c20-66ad-4af7-b77d-d0dc47cbcdab"
      unitRef="number">0.022</jnj:EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent>
    <jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzOTg_fbcfcd53-ba80-4e48-bfdd-130e2628484a"
      unitRef="number">-0.025</jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i93cff80013cb4ca0867d9c8d85521e22_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzE4MjA_374969b1-2296-403d-bea3-46cd472a3c18"
      unitRef="usd">600000000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent
      contextRef="ic658f5e90fb74521b314a6664d0b97c5_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzE4Mzg_d3165753-ed07-466a-8814-72ab6a81974b"
      unitRef="number">0.027</jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent>
    <jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzE5NDM_66e7ba35-1f69-45f3-8e6c-960379a353bb"
      unitRef="usd">2300000000</jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization>
    <jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzIxNzk_2994f492-fff5-4649-b5a4-a4542b219e45"
      unitRef="usd">1700000000</jnj:IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI>
    <jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss
      contextRef="i5117957d990a4c01bf764aa9f770ef81_D20211004-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzI2NjI_8e56c7af-48ba-4194-bb08-a964fcee7db0"
      unitRef="number">-0.013</jnj:EffectiveIncomeTaxRateReconciliationCapitalLoss>
    <us-gaap:LitigationSettlementExpense
      contextRef="i9fb809688a744a4ea19a1ad0f2b4bf9c_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzI5Njg_f6187d15-0d44-48cb-bdeb-cef1a45ccf7e"
      unitRef="usd">1600000000</us-gaap:LitigationSettlementExpense>
    <jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent
      contextRef="i9fb809688a744a4ea19a1ad0f2b4bf9c_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzMwMDg_28930f4c-5ee9-41cf-84da-05bd6b16b9ec"
      unitRef="number">0.235</jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent>
    <us-gaap:LitigationSettlementExpense
      contextRef="ifaf8a0dc444a439691c1ba9c0fc72e52_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzMwMTU_c090f77b-47f1-4448-b004-65539f5e3b42"
      unitRef="usd">800000000</us-gaap:LitigationSettlementExpense>
    <jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent
      contextRef="ifaf8a0dc444a439691c1ba9c0fc72e52_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzMwNzI_0039b848-deb8-4de8-a640-ead197a5afb1"
      unitRef="number">0.164</jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i9abf5a6f4dd843c6bdff0c9b78680b08_D20211004-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzMxOTU_b510ed0f-0cd9-4713-894f-3c807732273b"
      unitRef="usd">900000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="i9abf5a6f4dd843c6bdff0c9b78680b08_D20211004-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzMzMDc_117ab197-5c82-4361-9391-f8446b1fb3d8"
      unitRef="number">0.224</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses>
    <jnj:FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzUyMjU_96240a7c-969f-4454-9d6f-328bc10c3dca"
      unitRef="usd">400000000</jnj:FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit>
    <jnj:EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzUyMzE_b8caecbd-f9e4-4b58-a786-90c27ecdaa47"
      unitRef="number">0.026</jnj:EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent>
    <jnj:FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzUzMzc_48b6b268-67ce-403b-a37d-0723f68c76b8"
      unitRef="usd">300000000</jnj:FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit>
    <jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzU2NDg_a8f3dd67-4424-49e4-be13-5b295cd54d3e"
      unitRef="usd">450000000</jnj:FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset>
    <jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzU5MjU_2093399a-eea8-4e5b-ac4f-188ca06f510a"
      unitRef="usd">300000000</jnj:FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDeductions
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzY1NTA_48598cf7-eed9-4c09-95b7-621c73207379"
      unitRef="number">0.012</us-gaap:EffectiveIncomeTaxRateReconciliationDeductions>
    <us-gaap:LitigationSettlementExpense
      contextRef="ic88fac17377d4247a40066aad9de7fc4_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzY4NTM_c1c9d7e6-e52a-4709-86f7-f253150c4600"
      unitRef="usd">4000000000</us-gaap:LitigationSettlementExpense>
    <jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent
      contextRef="id39169ea988c4eadb476790566c83233_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzY5Mjk_6564f0ca-7698-46e0-a406-2c1118a21d09"
      unitRef="number">0.235</jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent>
    <us-gaap:LitigationSettlementExpense
      contextRef="ic89e3ab0d07149d68abf9f2332bddb1e_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzY5OTY_696ec326-fa63-4615-9860-9e9cc8241a4e"
      unitRef="usd">1000000000</us-gaap:LitigationSettlementExpense>
    <jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent
      contextRef="id40d1a3a2e954c59984259c6a56987f8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzcxMDQ_e8baf793-e3cd-48cd-a6f3-fafa685140a4"
      unitRef="number">0.214</jnj:EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMzY4_1e24750f-91fe-42cb-8c23-22969651236b">&lt;div style="margin-bottom:9.9pt;margin-top:9pt;padding-right:4.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Temporary differences and carryforwards at the end of fiscal years 2022 and 2021 were as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:38.519%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.554%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.180%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.723%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.408%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.729%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022 Deferred Tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021 Deferred Tax&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Liability&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee related obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;725&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Depreciation of property, plant and equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(858)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(876)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Goodwill and intangibles&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,271)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,659)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;R&amp;amp;D capitalized for tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,611&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,664&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserves&#160;&amp;amp; liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Income reported for tax purposes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,045&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net realizable operating loss carryforwards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,260&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Undistributed foreign earnings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,693)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Global intangible low-taxed income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,547)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,853)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Miscellaneous international&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,053&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(65)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(39)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Miscellaneous U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;476&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total deferred income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,183&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(10,434)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;12,640&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(9,904)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)     &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts have been reclassified to conform to current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  Amount is inclusive of the $2.3&#160;billion deferred tax asset established as part of the reorganized ownership structure of   certain wholly-owned international subsidiaries, as previously described. &lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;   Amount is inclusive of the $1.8&#160;billion deferred tax liability due to the acquisition of Abiomed.&lt;/span&gt;&lt;/div&gt;(4)    Net of valuation allowances of $0.9&#160;billion in both 2022 and 2021.</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzItMi0xLTEtODQ0NDQ_378c9874-8b00-48d9-9000-9bebeb11f55d"
      unitRef="usd">725000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzItNi0xLTEtODQ0NDQ_d1807e94-0069-4f88-b560-e508070b83f6"
      unitRef="usd">1244000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzMtMi0xLTEtODQ0NDQ_3f267a27-b770-4f51-a9f0-97a6dbd8ad30"
      unitRef="usd">687000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzMtNi0xLTEtODQ0NDQ_bbc5c9ce-9307-4b17-9bb5-d348b1fa8eeb"
      unitRef="usd">679000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzQtNC0xLTEtODQ0NDQ_b8560e39-770e-46ef-bf4e-e25a2f88cf91"
      unitRef="usd">858000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzQtOC0xLTEtODQ0NDQ_908088f9-ec4a-49e3-b836-88209ef9ca62"
      unitRef="usd">876000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzUtNC0xLTEtODQ0NDQ_babc1ad4-9cdb-4d1a-a7fd-2c0728e968f4"
      unitRef="usd">4271000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzUtOC0xLTEtODQ0NDQ_53ab1509-41d3-447a-8803-7b88bafd8b4e"
      unitRef="usd">2659000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzYtMi0xLTEtODQ0NDQ_26e92178-0680-45d1-bcb6-bd22eb12ece0"
      unitRef="usd">2611000000</jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized>
    <jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzYtNi0xLTEtODQ0NDQ_91481e24-0cce-44fc-953f-1f78fd77a56f"
      unitRef="usd">1664000000</jnj:DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzctMi0xLTEtODQ0NDQ_d0da2357-c241-419d-bda1-a03c95a73930"
      unitRef="usd">2761000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzctNi0xLTEtODQ0NDQ_b4410a80-987f-445e-83fb-652869ebf5a9"
      unitRef="usd">2882000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzgtMi0xLTEtODQ0NDQ_955ea45b-b7f6-4e0b-9f9f-93364dc2fb63"
      unitRef="usd">2045000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzgtNi0xLTEtODQ0NDQ_85e7e6e1-c93e-4e45-bfe5-49fc449266fc"
      unitRef="usd">2566000000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzktMi0xLTEtODQ0NDQ_53804d7c-7090-466c-a777-db7e68bace00"
      unitRef="usd">1260000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzktNi0xLTEtODQ0NDQ_ef5462da-61eb-4432-9b81-7db29ea4a424"
      unitRef="usd">1720000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <jnj:DeferredTaxAssetsUndistributedForeignEarnings
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEwLTItMS0xLTg0NDQ0_6b60edad-d993-4d20-a52f-5a8f9444ae17"
      unitRef="usd">1565000000</jnj:DeferredTaxAssetsUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEwLTQtMS0xLTg0NDQ0_f78639a5-cd98-42c4-bb18-b24c7a973b00"
      unitRef="usd">1693000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <jnj:DeferredTaxAssetsUndistributedForeignEarnings
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEwLTYtMS0xLTg0NDQ0_e2aa4cf7-c7b6-4f3e-a6f3-1b70cdf69939"
      unitRef="usd">1015000000</jnj:DeferredTaxAssetsUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEwLTgtMS0xLTg0NDQ0_101b0e3d-722a-48c8-acbf-1d6eb28c09d9"
      unitRef="usd">1461000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzExLTQtMS0xLTg0NDQ0_9cf7e67c-6ca8-4fd4-961b-c9ad4ffc12bd"
      unitRef="usd">3547000000</jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome>
    <jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzExLTgtMS0xLTg0NDQ0_d9ce67b0-4f3f-4496-956a-7a8536d0661d"
      unitRef="usd">4853000000</jnj:DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEyLTItMS0xLTg0NDQ0_a59d5897-903a-4288-ad91-937abb3f654c"
      unitRef="usd">1053000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEyLTQtMS0xLTg0NDQ0_71cae9d9-eaaa-45d1-bc1f-fa5e36cb79c3"
      unitRef="usd">65000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEyLTYtMS0xLTg0NDQ0_1febcad7-ea69-4167-bd7c-8b8e677147a9"
      unitRef="usd">870000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEyLTgtMS0xLTg0NDQ0_d91260a9-5233-41d7-80dc-9449da349e03"
      unitRef="usd">39000000</us-gaap:DeferredTaxLiabilitiesOther>
    <jnj:DeferredTaxAssetsOtherDomestic
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEzLTItMS0xLTg0NDQ0_cecf4a6c-d93c-459c-a50f-b0e784f71b25"
      unitRef="usd">476000000</jnj:DeferredTaxAssetsOtherDomestic>
    <jnj:DeferredTaxLiabilitiesOtherDomestic
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzEzLTgtMS0xLTg0NDQ0_1a8437fc-9b46-40fc-b0b1-b82a1bd2223b"
      unitRef="usd">16000000</jnj:DeferredTaxLiabilitiesOtherDomestic>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzE0LTItMS0xLTg0NDQ0_0ead31e5-4744-4ea9-a9d4-4ed659275a30"
      unitRef="usd">13183000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzE0LTQtMS0xLTg0NDQ0_0624d3eb-fa52-40ec-a122-74ceff1808ab"
      unitRef="usd">10434000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzE0LTYtMS0xLTg0NDQ0_ee3fccc6-6464-4f7a-8b43-72574f2632e5"
      unitRef="usd">12640000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilities
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTpiMmQwMmM4YjIyMGM0MWMwODhiODllMGZlMDI0NTIzMy90YWJsZXJhbmdlOmIyZDAyYzhiMjIwYzQxYzA4OGI4OWUwZmUwMjQ1MjMzXzE0LTgtMS0xLTg0NDQ0_2635d7a0-0a25-4aca-93d7-08ca9acefb1d"
      unitRef="usd">9904000000</us-gaap:DeferredTaxLiabilities>
    <jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzExMDc2_c6885af5-7729-4ee9-96c9-6410360eeaf1"
      unitRef="usd">2300000000</jnj:DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzU0OTc1NTg2Nzg2Mw_3f9fa05b-da68-4501-9353-891bf1aa998a"
      unitRef="usd">1800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzU0OTc1NTg2Nzg3Nw_057d0b09-c1ab-41e8-9a91-e6df45d2e967"
      unitRef="usd">900000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzU0OTc1NTg2Nzg3Nw_34560cbe-986f-49cb-bc2d-5965cd583676"
      unitRef="usd">900000000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:SummaryOfIncomeTaxContingenciesTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMzg2_9770f9cd-ea7c-41ee-9bf6-476f611c2e1e">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to unrecognized tax benefits:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.567%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:50.775%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.581%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.456%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.025%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.556%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:2.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to current year tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;523&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Decreases related to prior period tax positions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(551)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(187)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(839)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Lapse of statute of limitations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;End of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,829&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,323&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,373&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:SummaryOfIncomeTaxContingenciesTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzEtMi0xLTEtODQ0NDQ_0fc4c6f0-b714-404d-9888-18805d98bd92"
      unitRef="usd">3323000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzEtNC0xLTEtODQ0NDQ_2cb499c6-228d-475a-84c0-ed157b8f657f"
      unitRef="usd">3373000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzEtNi0xLTEtODQ0NDQ_24f8da13-fd22-4e54-9c5e-5bebf976fa81"
      unitRef="usd">3853000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzItMi0xLTEtODQ0NDQ_2813d89b-cb6a-4684-a280-9e968208c3f1"
      unitRef="usd">523000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzItNC0xLTEtODQ0NDQ_7b9917f2-05f9-417a-a623-f0dd68ab7648"
      unitRef="usd">242000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzItNi0xLTEtODQ0NDQ_5ad27aeb-2f57-4214-86a1-fa475ec8adef"
      unitRef="usd">265000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzMtMi0xLTEtODQ0NDQ_6f46bfbe-2171-489b-a467-d3b95b189752"
      unitRef="usd">143000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzMtNC0xLTEtODQ0NDQ_2fa6178b-89f6-4bbc-b1ee-25dc3ba4b9ff"
      unitRef="usd">23000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzMtNi0xLTEtODQ0NDQ_643c0ca1-c62a-4bf1-8477-742305890dbd"
      unitRef="usd">668000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzQtMi0xLTEtODQ0NDQ_a891de05-c987-4e87-b797-1e4d78ddd035"
      unitRef="usd">148000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzQtNC0xLTEtODQ0NDQ_3b1eba04-0cc7-4d41-9939-85e2e8e8473c"
      unitRef="usd">128000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzQtNi0xLTEtODQ0NDQ_56776f10-53b5-4cb2-95b5-a6470cea82b6"
      unitRef="usd">551000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzUtMi0xLTEtODQ0NDQ_8018b02b-7326-4728-b36e-e32b341e65d6"
      unitRef="usd">1000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzUtNC0xLTEtODQ0NDQ_2cee6463-5c74-4c52-acd7-c350afd8abd3"
      unitRef="usd">187000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzUtNi0xLTEtODQ0NDQ_29079255-8872-48e0-8f83-fecac31989bb"
      unitRef="usd">839000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzYtMi0xLTEtODQ0NDQ_e746887d-9570-42e7-85bb-651eb8592633"
      unitRef="usd">11000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzYtNC0xLTEtODQ0NDQ_06ff4a77-eb45-446f-9a51-5367b4d6957e"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzYtNi0xLTEtODQ0NDQ_fd9934b7-5436-417c-b740-7e7a11053683"
      unitRef="usd">23000000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzctMi0xLTEtODQ0NDQ_7131898b-b813-4296-807f-95617a5fb43d"
      unitRef="usd">3829000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzctNC0xLTEtODQ0NDQ_d9508fb4-920b-45f2-82fb-4e833b6b4e7d"
      unitRef="usd">3323000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90YWJsZTo4ZDY3ZGU0YWJjZDc0MzE3OGI2MmRkMTUyMjdkZmRmZS90YWJsZXJhbmdlOjhkNjdkZTRhYmNkNzQzMTc4YjYyZGQxNTIyN2RmZGZlXzctNi0xLTEtODQ0NDQ_dc0d67aa-a2d3-4a10-8097-6848a05408a3"
      unitRef="usd">3373000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzExODI1_e603bbb3-7900-4be4-9622-ade6038ccd91"
      unitRef="usd">3800000000</us-gaap:UnrecognizedTaxBenefits>
    <jnj:UnrecognizedTaxBenefitLiabilityPayment
      contextRef="i6823d2e54e284392b4c4cc465f125c28_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEyMjg0_4f2ad854-a7da-4097-a997-5edb4de2d5f6"
      unitRef="usd">700000000</jnj:UnrecognizedTaxBenefitLiabilityPayment>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMjEx_d7c3c32f-c789-4c11-a293-4e4e0e029a4d"
      unitRef="usd">139000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMjE1_4d38134f-87b4-4102-b962-c822da867b4d"
      unitRef="usd">44000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMjIy_fc98546e-30ea-4e2f-9378-8401e5f050af"
      unitRef="usd">32000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMzEx_47896a03-45ce-4a62-a248-967cedcfaad3"
      unitRef="usd">651000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzIvZnJhZzo5ZDVlNWE2Mjg0YjU0YzNkODZiOTg0MWZmZGI5YTk5Ny90ZXh0cmVnaW9uOjlkNWU1YTYyODRiNTRjM2Q4NmI5ODQxZmZkYjlhOTk3XzEzMzE4_b1f10098-c3a3-4bb8-aef9-b2b7e706e1bb"
      unitRef="usd">512000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:CompensationRelatedCostsGeneralTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90ZXh0cmVnaW9uOjdiMGNjNzI1M2Y5YzRkYzRhYmIxODU3NjdlYzA1OGE3XzMwNA_26a9fe4c-5531-433b-a46e-b2cfee088fbc">Employee Related Obligations&lt;div style="margin-top:7pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal 2022 and fiscal 2021, employee related obligations recorded on the Consolidated Balance Sheets were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Postretirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Postemployment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total employee obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current benefits payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee related obligations&#160;&#x2014; non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,767&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prepaid employee related obligations of $4,581 million and $4,436 million for 2022 and 2021, respectively, are included in Other assets on the Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:CompensationRelatedCostsGeneralTextBlock>
    <jnj:EmployeeRelatedObligationsTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90ZXh0cmVnaW9uOjdiMGNjNzI1M2Y5YzRkYzRhYmIxODU3NjdlYzA1OGE3XzMwMg_76d43370-3e4b-4441-927f-6960f5b27064">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At the end of fiscal 2022 and fiscal 2021, employee related obligations recorded on the Consolidated Balance Sheets were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pension benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Postretirement benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,069&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Postemployment benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total employee obligations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,455&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less current benefits payable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee related obligations&#160;&#x2014; non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,767&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,898&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</jnj:EmployeeRelatedObligationsTableTextBlock>
    <us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzEtMi0xLTEtODQ0NDQ_508a7d7a-508d-4c7b-aa64-a97a5344c1f5"
      unitRef="usd">2698000000</us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities>
    <us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzEtNC0xLTEtODQ0NDQ_bfb36b2a-163c-4023-9276-fd3a1f76349b"
      unitRef="usd">4088000000</us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzItMi0xLTEtODQ0NDQ_20857b36-4f45-4dd9-ae38-69d51488d120"
      unitRef="usd">1734000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzItNC0xLTEtODQ0NDQ_f1821273-ec0e-4e12-839f-435bd52aa265"
      unitRef="usd">2069000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzMtMi0xLTEtODQ0NDQ_b6640edc-b3f5-4c94-8aff-05fd02f151f0"
      unitRef="usd">2832000000</us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent>
    <us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzMtNC0xLTEtODQ0NDQ_753a44f5-cbed-45d5-9994-193ea6dbc4ac"
      unitRef="usd">3117000000</us-gaap:PostemploymentBenefitsLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzQtMi0xLTEtODQ0NDQ_cfdd2c69-0c61-40fa-9fb0-c9ee79467a23"
      unitRef="usd">100000000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzQtNC0xLTEtODQ0NDQ_cbdf6f1d-c7a7-4fbd-bde8-23a503bacb5b"
      unitRef="usd">181000000</us-gaap:DeferredCompensationLiabilityCurrentAndNoncurrent>
    <jnj:EmployeeObligations
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzUtMi0xLTEtODQ0NDQ_68262424-fdc7-42af-9fc1-b1df31474131"
      unitRef="usd">7364000000</jnj:EmployeeObligations>
    <jnj:EmployeeObligations
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzUtNC0xLTEtODQ0NDQ_5fd627e5-049d-4aa3-a2f6-c92c8c59f2fc"
      unitRef="usd">9455000000</jnj:EmployeeObligations>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzYtMi0xLTEtODQ0NDQ_88717380-3f4d-4557-b9af-f07b2d06b911"
      unitRef="usd">597000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzYtNC0xLTEtODQ0NDQ_6989d24c-942a-4e79-84f3-f43afee4eb6a"
      unitRef="usd">557000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzctMi0xLTEtODQ0NDQ_bb10e6d6-6016-4761-8c79-8435f160b380"
      unitRef="usd">6767000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90YWJsZToxMDEwODYyNDMyYzQ0Yjc4OGFhYjk5OTUzMjhjZGVjMy90YWJsZXJhbmdlOjEwMTA4NjI0MzJjNDRiNzg4YWFiOTk5NTMyOGNkZWMzXzctNC0xLTEtODQ0NDQ_d4cfbddb-455c-47b0-9112-7cc01874ac15"
      unitRef="usd">8898000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90ZXh0cmVnaW9uOjdiMGNjNzI1M2Y5YzRkYzRhYmIxODU3NjdlYzA1OGE3XzE5NA_8625080b-4ef9-49f2-bb0e-34d84b71113b"
      unitRef="usd">4581000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xNzgvZnJhZzo3YjBjYzcyNTNmOWM0ZGM0YWJiMTg1NzY3ZWMwNThhNy90ZXh0cmVnaW9uOjdiMGNjNzI1M2Y5YzRkYzRhYmIxODU3NjdlYzA1OGE3XzIwMQ_b08d4049-49aa-4049-9547-95b1c23f7ef4"
      unitRef="usd">4436000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjU2_4cd59238-8340-4efc-9edc-251bdc468340">Pensions and Other Benefit Plans&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sponsors various retirement and pension plans, including defined benefit, defined contribution and termination indemnity plans, which cover most employees worldwide. The Company also provides post-retirement benefits, primarily healthcare, to all eligible U.S.&#160;retired employees and their dependents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Many international employees are covered by government-sponsored programs and the cost to the Company is not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the U.S, non-union pension benefits for employees hired before January 1, 2015 are primarily based on the employee&#x2019;s compensation during the last five years before retirement and the number of years of service (the Final Average Pay formula). U.S. pension benefits for employees hired after 2014, are calculated using a different formula based on employee compensation over total years of service (the Retirement Value formula).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, the Company announced that, effective on January 1, 2026, all eligible U.S. non-union employees,&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;regardless of hire date, will earn benefits under the Retirement Value formula. This amendment does not affect the benefits&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;accrued under the Final Average Pay formula for service before January 1, 2026. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;International subsidiaries have plans under which funds are deposited with trustees, annuities are purchased under group contracts, or reserves are provided. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not fund retiree healthcare benefits in advance and has the right to modify these plans in the future.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022 and 2021 the Company used December 31, 2022 and December 31, 2021, respectively, as the measurement date for all U.S.&#160;and international retirement and other benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans for 2022, 2021 and 2020 include the following components:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses (gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;623&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;533&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;524&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The service cost component of net periodic benefit cost is presented in the same line items on the Consolidated Statement of Earnings where other employee compensation costs are reported, including Cost of products sold, Research and development expense, and Selling, marketing and administrative expenses. All other components of net periodic benefit cost are presented as part of Other (income) expense, net on the Consolidated Statement of Earnings.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Unrecognized gains and losses for the U.S.&#160;pension plans are amortized over the average remaining future service for each plan.  For plans with no active employees, they are amortized over the average life expectancy. The amortization of gains and losses for the other U.S.&#160;benefit plans is determined by using a 10% corridor of the greater of the market value of assets or the accumulated postretirement benefit obligation. Total unamortized gains and losses in excess of the corridor are amortized over the average remaining future service.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior service costs/benefits for the U.S.&#160;pension plans are amortized over the average remaining future service of plan participants at the time of the plan amendment. Prior service cost/benefit for the other U.S.&#160;benefit plans is amortized over the average remaining service to full eligibility age of plan participants at the time of the plan amendment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the weighted-average actuarial assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Worldwide Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Periodic Benefit Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of increase in compensation levels&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected long-term rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of increase in compensation levels&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s discount rates are determined by considering current yield curves representing high quality, long-term fixed income instruments. The resulting discount rates are consistent with the duration of plan liabilities. The Company's methodology in determining service and interest cost uses duration specific spot rates along that yield curve to the plans' liability cash flows.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The expected rates of return on plan asset assumptions represent the Company's assessment of long-term returns on diversified investment portfolios globally. The assessment is determined using projections from external financial sources, long-term historical averages, actual returns by asset class and the various asset class allocations by market. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the assumed healthcare cost trend rates, for all individuals:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Healthcare Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare cost trend rate assumed for next year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate to which the cost trend rate is assumed to decline (ultimate trend)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year the rate reaches the ultimate trend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2022 and 2021 for the Company&#x2019;s defined benefit retirement plans and other post-retirement plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&#160;&#x2014; beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gains) losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&#160;&amp;amp; acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments, settlements&#160;&amp;amp; restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid from plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,631&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,582&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,878&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&#160;&#x2014; beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return (loss) on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&#160;&amp;amp; acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid from plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31,514&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,930&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funded status &#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,883&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in the Company&#x2019;s Balance Sheet consist of the following:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in the consolidated balance sheet&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,883&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized net transition obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,531&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,929&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Benefit Obligations&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28,023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The actuarial gain for retirement plans in 2022 and 2021 was primarily related to increases in discount rates.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:3pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;623&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;533&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,927)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (cost) credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total loss/(income) recognized in other comprehensive income, before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in net periodic benefit cost and other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company plans to continue to fund its U.S. Qualified Plans to comply with the Pension Protection Act of 2006. International Plans are funded in accordance with local regulations. Additional discretionary contributions are made when deemed appropriate to meet the long-term obligations of the plans. For certain plans, funding is not a common practice, as funding provides no economic benefit. Consequently, the Company has several pension plans that are not funded. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, the Company contributed $119 million and $151 million to its U.S.&#160;and international pension plans, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the funded status of the Company's U.S. Qualified &amp;amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2022 and December&#160;31, 2021, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Qualified Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-Qualified Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Funded Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unfunded Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over (Under) Funded Status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Plans with accumulated benefit obligations in excess of plan assets have an accumulated benefit obligation, projected benefit obligation and plan assets of $2.9 billion, $2.9 billion and $0.3 billion, respectively, at the end of 2022, and $3.9 billion, $4.2 billion and $0.3 billion, respectively, at the end of 2021.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the projected future benefit payments from the Company&#x2019;s retirement and other benefit plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2028-2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Projected future benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other benefit plans&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the projected future minimum contributions to the unfunded retirement plans.  These amounts do not include any discretionary contributions that the Company may elect to make in the future.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2028-2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Projected future contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Each pension plan is overseen by a local committee or board that is responsible for the overall administration and investment of the pension plans. In determining investment policies, strategies and goals, each committee or board considers factors including, local pension rules and regulations; local tax regulations; availability of investment vehicles (separate accounts, commingled accounts, insurance funds, etc.); funded status of the plans; ratio of actives to retirees; duration of liabilities; and other relevant factors including: diversification, liquidity of local markets and liquidity of base currency. A majority of the Company&#x2019;s pension funds are open to new entrants and are expected to be on-going plans. Permitted investments are primarily liquid and/or listed, with little reliance on illiquid and non-traditional investments such as hedge funds.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s retirement plan asset allocation at the end of 2022 and 2021 and target allocations for 2023 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.131%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Percent of&lt;br/&gt;Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Target&lt;br/&gt;Allocation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Worldwide Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Determination of Fair Value of Plan Assets&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Plan has an established and well-documented process for determining fair values.  Fair value is based upon quoted market prices, where available. If listed prices or quotes are not available, fair value is based upon models that primarily use, as inputs, market-based or independently sourced market parameters, including yield curves, interest rates, volatilities, equity or debt prices, foreign exchange rates and credit curves.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the Plan believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in a different estimate of fair value at the reporting date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The authoritative literature establishes a three-level hierarchy to prioritize the inputs used in measuring fair value. The levels within the hierarchy are described in the table below with Level&#160;1 having the highest priority and Level&#160;3 having the lowest.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;       The Net Asset Value (NAV) is based on the value of the underlying assets owned by the fund, minus its liabilities, and then divided by the number of shares outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A financial instrument&#x2019;s categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following is a description of the valuation methodologies used for the investments measured at fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Short-term investment funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Cash and quoted short-term instruments are valued at the closing price or the amount held on deposit by the custodian bank. Other investments are through investment vehicles valued using the NAV provided by the administrator of the fund. The NAV is a quoted price in a market that is not active and classified as Level&#160;2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Government and agency securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified within Level&#160;1 of the valuation hierarchy. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows. When quoted market prices for a security are not available in an active market, they are classified as Level&#160;2.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Debt instruments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; A limited number of these investments are valued at the closing price reported on the major market on which the individual securities are traded. Where quoted prices are available in an active market, the investments are classified as Level&#160;1. If quoted market prices are not available for the specific security, then fair values are estimated by using pricing models, quoted prices of securities with similar characteristics or discounted cash flows and are classified as Level&#160;2. Level&#160;3 debt instruments are priced based on unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Equity securities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Equity securities are valued at the closing price reported on the major market on which the individual securities are traded. Substantially all equity securities are classified within Level&#160;1 of the valuation hierarchy.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Commingled funds&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; These investment vehicles are valued using the NAV provided by the fund administrator. Assets in the Level&#160;2 category have a quoted market price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Other assets&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#x2014; Other assets are represented primarily by limited partnerships. These investment vehicles are valued using the NAV provided by the fund administrator. Other assets that are exchange listed and actively traded are classified as Level&#160;1, while inactively traded assets are classified as Level&#160;2. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Investments at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,954&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,086&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;69&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,612&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,515&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31,514&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,930&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The activity for the Level 3 assets is not significant for all years presented.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's Other Benefit Plans are unfunded except for U.S.&#160;commingled funds (Level 2) of $78 million and $102 million at December&#160;31, 2022 and December&#160;31, 2021, respectively. &lt;/span&gt;&lt;/div&gt;The fair value of Johnson&#160;&amp;amp; Johnson Common Stock directly held in plan assets was $21 million (0.1% of total plan assets) at December&#160;31, 2022 and $385 million (0.9% of total plan assets) at December&#160;31, 2021.</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <jnj:EmployeeCompensationPeriod
      contextRef="ie38c867d387040219eb10b7ae2cf8194_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzYyNg_9b638475-05d3-4e43-92c6-f61682b1a06e">P5Y</jnj:EmployeeCompensationPeriod>
    <us-gaap:ScheduleOfNetBenefitCostsTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjE4_588446bc-3dc1-46c7-abcc-08a4a1766bf4">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net periodic benefit costs for the Company&#x2019;s defined benefit retirement plans and other benefit plans for 2022, 2021 and 2020 include the following components:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,757)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,645)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service cost &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(184)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Recognized actuarial losses (gains)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments and settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;623&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;790&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;533&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;524&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetBenefitCostsTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzItMi0xLTEtODQ0NDQ_71622c25-f2b6-4bbd-9919-8e6b0167f126"
      unitRef="usd">1327000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzItNC0xLTEtODQ0NDQ_1fa6a2fb-02ac-4cb5-9b1e-e50032045e43"
      unitRef="usd">1421000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzItNi0xLTEtODQ0NDQ_052b5d96-c4ab-433e-9292-0142242de20e"
      unitRef="usd">1380000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzItOC0xLTEtODQ0NDQ_8124ecc0-e2ce-4b1d-9ac0-c8dd99dfad8b"
      unitRef="usd">320000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzItMTAtMS0xLTg0NDQ0_fc240bc1-d6d9-4e13-9117-8eb2c35eb402"
      unitRef="usd">309000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzItMTItMS0xLTg0NDQ0_170c6f62-8d10-4539-bd27-0a8c56659d27"
      unitRef="usd">287000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzMtMi0xLTEtODQ0NDQ_bd03cea6-bf6e-46db-8974-292b2b91d383"
      unitRef="usd">911000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzMtNC0xLTEtODQ0NDQ_55b2aeab-e326-4d5e-82a0-c3906bec2711"
      unitRef="usd">770000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzMtNi0xLTEtODQ0NDQ_c6e7f197-3966-490a-8ef0-e1b0f986cb98"
      unitRef="usd">955000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzMtOC0xLTEtODQ0NDQ_dc3d5346-d5db-465b-ba66-c298c5d5a8c6"
      unitRef="usd">105000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzMtMTAtMS0xLTg0NDQ0_6dd00e56-789b-460a-8f7a-b71d3de5d129"
      unitRef="usd">81000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzMtMTItMS0xLTg0NDQ0_ba82ebbb-e7a2-47fc-8c09-5d3ace475b77"
      unitRef="usd">133000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzQtMi0xLTEtODQ0NDQ_c3b97161-d546-44dc-96d4-372a4696e6ae"
      unitRef="usd">2757000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzQtNC0xLTEtODQ0NDQ_87c36c2e-ab62-48f7-babd-53c03956638f"
      unitRef="usd">2645000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzQtNi0xLTEtODQ0NDQ_af21a01e-b27a-40f7-918a-3ddc7a6ab3fd"
      unitRef="usd">2461000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzQtOC0xLTEtODQ0NDQ_5f97b2ca-2bb0-485a-aae9-9c3cd2b78b48"
      unitRef="usd">8000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzQtMTAtMS0xLTg0NDQ0_1074cba2-735b-4867-8ca7-107e01273095"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzQtMTItMS0xLTg0NDQ0_e6639802-f90b-4023-9897-c61259bfaca8"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzUtMi0xLTEtODQ0NDQ_3d8de1cb-22c8-4436-9c3b-53b24be8db17"
      unitRef="usd">-184000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzUtNC0xLTEtODQ0NDQ_afe355ac-fd17-48c1-ac6f-50028122db09"
      unitRef="usd">-181000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzUtNi0xLTEtODQ0NDQ_9b3bc58c-0ce6-42cb-889b-030aad39b2bb"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzUtOC0xLTEtODQ0NDQ_8bf2f11e-c17a-430d-a438-b2f3a4b92e48"
      unitRef="usd">-5000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzUtMTAtMS0xLTg0NDQ0_be960196-996a-4d97-9761-337b921b3c23"
      unitRef="usd">-31000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzUtMTItMS0xLTg0NDQ0_428bbde3-41b1-4488-8953-5054cefdd526"
      unitRef="usd">-31000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzctMi0xLTEtODQ0NDQ_cb95e8b4-682c-431f-8e07-f7bba83bb280"
      unitRef="usd">-655000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzctNC0xLTEtODQ0NDQ_092ab5b9-3e08-445e-8db6-c68fa2e00b4e"
      unitRef="usd">-1257000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzctNi0xLTEtODQ0NDQ_de08670e-8e0d-41fb-8fb0-a0760b2d28da"
      unitRef="usd">-891000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzctOC0xLTEtODQ0NDQ_8b40ded8-b522-4c4a-b920-13018dfd7eb9"
      unitRef="usd">-121000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzctMTAtMS0xLTg0NDQ0_2ae2ddaf-e87a-4fac-8249-04be52df6139"
      unitRef="usd">-151000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzctMTItMS0xLTg0NDQ0_a27aea24-f6ba-4447-bace-27df78198766"
      unitRef="usd">-142000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzgtMi0xLTEtODQ0NDQ_72637888-744a-4b56-8114-27f867a228bb"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzgtNC0xLTEtODQ0NDQ_62774e59-36ef-4c8b-b7c6-6fd4017a5ebe"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzgtNi0xLTEtODQ0NDQ_1f32c764-5887-4874-8354-b3d6927aa567"
      unitRef="usd">-23000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzgtOC0xLTEtODQ0NDQ_f857cc0b-9373-4831-9476-fa4864d88ce1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzgtMTAtMS0xLTg0NDQ0_9b618248-3bcb-40b5-b133-fbc5bc0694a8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1
      contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzgtMTItMS0xLTg0NDQ0_42d7b879-af67-4ab1-ad8b-abd36837ca9a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzktMi0xLTEtODQ0NDQ_2886fb44-dae0-4b0b-a1bd-792c1c7d2369"
      unitRef="usd">-47000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzktNC0xLTEtODQ0NDQ_2a90762a-2037-4e82-a9cb-e0976d40e883"
      unitRef="usd">623000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzktNi0xLTEtODQ0NDQ_97b04d75-1b34-4879-a9d1-ab310be9b31d"
      unitRef="usd">790000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzktOC0xLTEtODQ0NDQ_6f10f85e-de75-4aa7-b797-f748d58404e9"
      unitRef="usd">533000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzktMTAtMS0xLTg0NDQ0_298aab2f-b342-40ce-a0ab-eaae913359b8"
      unitRef="usd">503000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTo5ZTRhNjQ4NjgwMWY0YmQ2YWYzNzc3Yzg3ZGY0ZmViZS90YWJsZXJhbmdlOjllNGE2NDg2ODAxZjRiZDZhZjM3NzdjODdkZjRmZWJlXzktMTItMS0xLTg0NDQ0_f5aed802-eced-4a56-8063-4c147b7e26f6"
      unitRef="usd">524000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzI3NjY_06422818-403c-4363-9092-69cdea2ff041"
      unitRef="number">0.10</jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjY0_fcf199be-ac51-4b27-966d-2be39ac17672">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table represents the weighted-average actuarial assumptions:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.760%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.358%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.060%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.563%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.064%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Worldwide Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net Periodic Benefit Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.82&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.09&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.04&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.80&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.64&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.08&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of increase in compensation levels&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.02&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected long-term rate of return on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.71&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discount rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.42&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.68&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate of increase in compensation levels&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.27&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzMtMi0xLTEtODQ0NDQ_a877bcc0-e4bb-4a1e-b325-1b616d173681"
      unitRef="number">0.0246</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzMtNC0xLTEtODQ0NDQ_f9971243-3b25-4a43-b527-5f983573ce13"
      unitRef="number">0.0214</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzMtNi0xLTEtODQ0NDQ_730bb690-4fcd-4c69-9bd2-71bcb8ba0445"
      unitRef="number">0.0282</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzMtOC0xLTEtODQ0NDQ_9b6663f0-7759-45e5-bdce-009ddfa87d30"
      unitRef="number">0.0259</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzMtMTAtMS0xLTg0NDQ0_4eb966fe-c8df-4bdd-8499-ceed20722b84"
      unitRef="number">0.0209</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzMtMTItMS0xLTg0NDQ0_b80cd946-fe89-4a3b-8f2b-39296efe3688"
      unitRef="number">0.0304</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzQtMi0xLTEtODQ0NDQ_54618d1b-78b3-43fe-a56d-96601d0b0f9c"
      unitRef="number">0.0280</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzQtNC0xLTEtODQ0NDQ_25d6581b-e820-4531-94ac-236f3ab609e0"
      unitRef="number">0.0234</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzQtNi0xLTEtODQ0NDQ_b9f86773-a601-4cf4-8329-b16c499d63d8"
      unitRef="number">0.0313</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzQtOC0xLTEtODQ0NDQ_ed7006d6-8572-46ab-b43c-dbe223ed3696"
      unitRef="number">0.0264</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzQtMTAtMS0xLTg0NDQ0_6a79b2b5-794a-425a-a062-24d5313871a0"
      unitRef="number">0.0233</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate
      contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzQtMTItMS0xLTg0NDQ0_d0b268fd-2532-4b42-bc8e-56021144ce41"
      unitRef="number">0.0308</jnj:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzUtMi0xLTEtODQ0NDQ_4e739540-adbc-45ae-a9c2-5e07a8c048e6"
      unitRef="number">0.0402</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzUtNC0xLTEtODQ0NDQ_8baf55b4-587b-43dc-b8ea-edc87479ea16"
      unitRef="number">0.0401</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzUtNi0xLTEtODQ0NDQ_a57c065e-bf0a-425e-a4b6-9af8f7f83f94"
      unitRef="number">0.0400</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzUtOC0xLTEtODQ0NDQ_6661685e-86a2-4721-8ae5-473f16007cb2"
      unitRef="number">0.0421</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzUtMTAtMS0xLTg0NDQ0_42e5ce49-a9ff-4713-8968-d00992d07700"
      unitRef="number">0.0425</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="i381b1781da63498caf01563beb9220f8_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzUtMTItMS0xLTg0NDQ0_1c18aaaa-66e9-4ab5-8cb8-6abf9ed36971"
      unitRef="number">0.0425</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzYtMi0xLTEtODQ0NDQ_23080b2b-f808-4fb7-96fe-dcc96c0b6d92"
      unitRef="number">0.0725</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzYtNC0xLTEtODQ0NDQ_3e73f179-aa9f-46b3-b4d1-9977390db12d"
      unitRef="number">0.0771</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="i9ea0a2640c8b4efe89347d32e854f5e1_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzYtNi0xLTEtODQ0NDQ_207bece0-5ebf-4f6a-9e24-28aef5bd8f7a"
      unitRef="number">0.0812</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzktMi0xLTEtODQ0NDQ_459fa37c-b30c-411e-94fe-68a0c20aeac4"
      unitRef="number">0.0501</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzktNC0xLTEtODQ0NDQ_c31d3457-4e6c-4aa1-9531-e438a57023c7"
      unitRef="number">0.0249</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i703d5232b81a4b55936dd90e0dad0606_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzktNi0xLTEtODQ0NDQ_894c9b21-84ab-4917-a3d1-f8555b8eacc0"
      unitRef="number">0.0214</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzktOC0xLTEtODQ0NDQ_83519883-997d-4a10-b8cd-1cfc6280bdc6"
      unitRef="number">0.0542</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="iee7e142ff6024167983180ffabb98005_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzktMTAtMS0xLTg0NDQ0_56d5f7b6-f8a2-46f1-bc7c-bf8a8e9ae322"
      unitRef="number">0.0268</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="idfb66bf1fb1c43f6b51ba191f9fdbc89_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzktMTItMS0xLTg0NDQ0_31b0aa02-f531-4368-8388-d4dd765b5cef"
      unitRef="number">0.0223</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzEwLTItMS0xLTg0NDQ0_6f360d03-bda0-4c93-8c8c-237e19e81938"
      unitRef="number">0.0400</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzEwLTQtMS0xLTg0NDQ0_4610460b-88f7-4eeb-9702-7fc96b0a4de3"
      unitRef="number">0.0401</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i703d5232b81a4b55936dd90e0dad0606_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzEwLTYtMS0xLTg0NDQ0_b437de13-a233-4d09-bf60-2d980001d9db"
      unitRef="number">0.0400</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzEwLTgtMS0xLTg0NDQ0_9236066e-9c87-4ce1-8547-239bada51ced"
      unitRef="number">0.0421</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="iee7e142ff6024167983180ffabb98005_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzEwLTEwLTEtMS04NDQ0NA_3bf739b9-96cb-42dc-8b82-4e4be2122243"
      unitRef="number">0.0421</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="idfb66bf1fb1c43f6b51ba191f9fdbc89_I20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmMmZmZWJmZWZkZGI0ZWI2YTZmMzE4OGU3OGM4OGMwZi90YWJsZXJhbmdlOmYyZmZlYmZlZmRkYjRlYjZhNmYzMTg4ZTc4Yzg4YzBmXzEwLTEyLTEtMS04NDQ0NA_e7f2a4a5-03ed-4148-93f2-98af958f7f04"
      unitRef="number">0.0427</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjMz_38447870-eb47-4093-a0de-24021beaa3eb">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the assumed healthcare cost trend rates, for all individuals:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:97.514%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.313%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.943%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.549%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.946%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Healthcare Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Healthcare cost trend rate assumed for next year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.99&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Rate to which the cost trend rate is assumed to decline (ultimate trend)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.01&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Year the rate reaches the ultimate trend rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2047&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyMjFhY2FjZTI1ZTc0MDMxOGMxMmE4MjAwYzFlMjdhZS90YWJsZXJhbmdlOjIyMWFjYWNlMjVlNzQwMzE4YzEyYTgyMDBjMWUyN2FlXzEtMi0xLTEtODQ0NDQ_9008992f-47d3-42e4-851c-cd35a8cb3421"
      unitRef="number">0.0599</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyMjFhY2FjZTI1ZTc0MDMxOGMxMmE4MjAwYzFlMjdhZS90YWJsZXJhbmdlOjIyMWFjYWNlMjVlNzQwMzE4YzEyYTgyMDBjMWUyN2FlXzEtNC0xLTEtODQ0NDQ_dabac546-6dfe-4fdf-94f2-8aa81aab420c"
      unitRef="number">0.0533</us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyMjFhY2FjZTI1ZTc0MDMxOGMxMmE4MjAwYzFlMjdhZS90YWJsZXJhbmdlOjIyMWFjYWNlMjVlNzQwMzE4YzEyYTgyMDBjMWUyN2FlXzItMi0xLTEtODQ0NDQ_bd65d97c-0359-40c1-8cdf-09e21e807f5b"
      unitRef="number">0.0401</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyMjFhY2FjZTI1ZTc0MDMxOGMxMmE4MjAwYzFlMjdhZS90YWJsZXJhbmdlOjIyMWFjYWNlMjVlNzQwMzE4YzEyYTgyMDBjMWUyN2FlXzItNC0xLTEtODQ0NDQ_619076a9-af8b-4a54-ab27-a3a647b6420d"
      unitRef="number">0.0373</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyMjFhY2FjZTI1ZTc0MDMxOGMxMmE4MjAwYzFlMjdhZS90YWJsZXJhbmdlOjIyMWFjYWNlMjVlNzQwMzE4YzEyYTgyMDBjMWUyN2FlXzMtMi0xLTEtODQ0NDQ_90d0329a-d75e-44fc-9575-4604b0995995">2047</us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
    <us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyMjFhY2FjZTI1ZTc0MDMxOGMxMmE4MjAwYzFlMjdhZS90YWJsZXJhbmdlOjIyMWFjYWNlMjVlNzQwMzE4YzEyYTgyMDBjMWUyN2FlXzMtNC0xLTEtODQ0NDQ_a2c57b40-585b-4c07-8f62-32c7913ea8ce">2046</us-gaap:DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate>
    <us-gaap:ScheduleOfNetFundedStatusTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjQ1_9615c4aa-ec94-4f8a-94b8-358a414a580b">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth information related to the benefit obligation and the fair value of plan assets at fiscal year-end 2022 and 2021 for the Company&#x2019;s defined benefit retirement plans and other post-retirement plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&#160;&#x2014; beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,582&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Service cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Interest cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;911&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amendments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actuarial (gains) losses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,213)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(704)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&#160;&amp;amp; acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Curtailments, settlements&#160;&amp;amp; restructuring&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid from plan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(815)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(683)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected benefit obligation&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;29,631&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,582&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,197&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,878&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Change in Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&#160;&#x2014; beginning of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Actual return (loss) on plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,665)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Company contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;270&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;386&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan participant contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Divestitures&#160;&amp;amp; acquisitions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Benefits paid from plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,228)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,157)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(393)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(348)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(574)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan assets at fair value&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31,514&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,930&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;78&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;102&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Funded status &#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,883&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in the Company&#x2019;s Balance Sheet consist of the following:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(132)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(461)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(438)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Non-current liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,566)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,973)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,658)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,338)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in the consolidated balance sheet&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,883&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;348&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,119)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,776)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in Accumulated Other Comprehensive Income consist of the following:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,417)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,610)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Unrecognized net transition obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total before tax effects&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2,531&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,929&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;232&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;1,100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Accumulated Benefit Obligations&#160;&#x2014; end of year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;28,023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;39,049&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:12pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;The actuarial gain for retirement plans in 2022 and 2021 was primarily related to increases in discount rates.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:43.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.139%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.619%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.530%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.624%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Amounts Recognized in Net Periodic Benefit Cost and Other Comprehensive Income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net periodic benefit cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(47)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;623&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;533&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;503&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net actuarial (gain) loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(793)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,927)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(751)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(199)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of net actuarial loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(655)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,257)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(151)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior service cost (credit)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Amortization of prior service (cost) credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Effect of exchange rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(140)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(136)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total loss/(income) recognized in other comprehensive income, before tax&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,398)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(5,134)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(868)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(319)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total recognized in net periodic benefit cost and other comprehensive income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(1,445)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(4,511)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;(335)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;184&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfNetFundedStatusTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMtMi0xLTEtODQ0NDQ_473fb4b3-8261-4683-8c3a-018cdc8df9d5"
      unitRef="usd">41582000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i703d5232b81a4b55936dd90e0dad0606_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMtNC0xLTEtODQ0NDQ_d200d84c-ea79-4641-bd93-f3b63f619aa4"
      unitRef="usd">43300000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="iee7e142ff6024167983180ffabb98005_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMtNi0xLTEtODQ0NDQ_a79afbd4-816d-4cef-a8e9-98887acd6c77"
      unitRef="usd">4878000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="idfb66bf1fb1c43f6b51ba191f9fdbc89_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMtOC0xLTEtODQ0NDQ_f48bb8a9-4460-44fc-b0e6-40f96babd94a"
      unitRef="usd">5028000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQtMi0xLTEtODQ0NDQ_fabeff50-4c1d-4e28-951d-6e56aeff9a7c"
      unitRef="usd">1327000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQtNC0xLTEtODQ0NDQ_cb3d091e-4463-43d6-afe5-b422099eb240"
      unitRef="usd">1421000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQtNi0xLTEtODQ0NDQ_bfd33933-2311-456e-a104-fe97e5bd18f0"
      unitRef="usd">320000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQtOC0xLTEtODQ0NDQ_8e105a2e-97c7-44e6-ad90-bab5521200ca"
      unitRef="usd">309000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzUtMi0xLTEtODQ0NDQ_8cafe36a-91ec-4330-ae3e-ae41c7782b8d"
      unitRef="usd">911000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzUtNC0xLTEtODQ0NDQ_e8ea4e98-a2ab-47cc-940e-44ffe67a1ef0"
      unitRef="usd">770000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzUtNi0xLTEtODQ0NDQ_dbdbf72b-2023-43e3-aaec-0308926dc8d4"
      unitRef="usd">105000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzUtOC0xLTEtODQ0NDQ_e85eb711-c505-42b7-b3d7-7eeb3be3593d"
      unitRef="usd">81000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzYtMi0xLTEtODQ0NDQ_ff42f78c-0758-43ee-8430-d3e8b67f3dc9"
      unitRef="usd">67000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzYtNC0xLTEtODQ0NDQ_3e14a544-6abe-468b-8d18-91a4de95f1ce"
      unitRef="usd">67000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzYtNi0xLTEtODQ0NDQ_fe397b96-1402-4a8c-a231-6ff106e972a1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzYtOC0xLTEtODQ0NDQ_9971b4df-809e-4999-a7bc-f06e2e548924"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzctMi0xLTEtODQ0NDQ_3db19da7-7d1e-42ad-ae2f-e3a1651b97a7"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzctNC0xLTEtODQ0NDQ_200a24df-e686-4260-8122-c6178edd7143"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzctNi0xLTEtODQ0NDQ_33748b03-f53e-452c-a2e5-18f788fdf92b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzctOC0xLTEtODQ0NDQ_82eb406b-d290-4787-ab84-d566b0f091a5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzgtMi0xLTEtODQ0NDQ_6893ac25-915a-4c16-ac33-9e9ded51d1cb"
      unitRef="usd">12213000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzgtNC0xLTEtODQ0NDQ_37ce9db6-b131-4b73-a01d-3cf897bf94ab"
      unitRef="usd">2132000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzgtNi0xLTEtODQ0NDQ_d04a5468-fa3a-40f1-8066-684ee972aeaf"
      unitRef="usd">704000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzgtOC0xLTEtODQ0NDQ_e9d41afb-4b1c-44d2-acf3-8bafd0837375"
      unitRef="usd">188000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzktMi0xLTEtODQ0NDQ_acd773b7-ab1a-4d80-b8a5-4421f2291e8f"
      unitRef="usd">0</jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzktNC0xLTEtODQ0NDQ_5aad43dc-031d-4b7e-a9d1-0f3d538630d4"
      unitRef="usd">-2000000</jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzktNi0xLTEtODQ0NDQ_5f50ea22-99a4-4342-87e0-487ba6719adf"
      unitRef="usd">0</jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzktOC0xLTEtODQ0NDQ_482a21b5-c1d8-441e-a8de-e914c058c3af"
      unitRef="usd">0</jnj:DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:CurtailmentsAndSettlementsAndRestructuring
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEwLTItMS0xLTg0NDQ0_030d98dd-70e4-430f-b397-d71b295b39ad"
      unitRef="usd">7000000</jnj:CurtailmentsAndSettlementsAndRestructuring>
    <jnj:CurtailmentsAndSettlementsAndRestructuring
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEwLTQtMS0xLTg0NDQ0_fcd8ffbc-8b79-4456-ac03-294ade0b4935"
      unitRef="usd">7000000</jnj:CurtailmentsAndSettlementsAndRestructuring>
    <jnj:CurtailmentsAndSettlementsAndRestructuring
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEwLTYtMS0xLTg0NDQ0_b0e8cbd1-4485-4df6-b704-09b537179384"
      unitRef="usd">0</jnj:CurtailmentsAndSettlementsAndRestructuring>
    <jnj:CurtailmentsAndSettlementsAndRestructuring
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEwLTgtMS0xLTg0NDQ0_77270dd1-011f-4d64-98a9-063a5277a1aa"
      unitRef="usd">0</jnj:CurtailmentsAndSettlementsAndRestructuring>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzExLTItMS0xLTg0NDQ0_64fa331e-1e92-4900-acdc-da76023a1c46"
      unitRef="usd">1228000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzExLTQtMS0xLTg0NDQ0_4bfc11b8-83ff-49d4-b75a-b02355910cb4"
      unitRef="usd">1157000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzExLTYtMS0xLTg0NDQ0_1eaba255-75cc-4d04-b5da-4398e8f62b3c"
      unitRef="usd">393000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzExLTgtMS0xLTg0NDQ0_6de93f95-9c6d-44e2-b8e8-a944b8146575"
      unitRef="usd">348000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEyLTItMS0xLTg0NDQ0_725f2ab8-d81e-45d9-94b5-099203d2801d"
      unitRef="usd">815000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEyLTQtMS0xLTg0NDQ0_394cf338-3a5f-4132-8e1f-d5476174dc6b"
      unitRef="usd">683000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEyLTYtMS0xLTg0NDQ0_72a03404-21ee-4124-8f2a-3f270533f245"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEyLTgtMS0xLTg0NDQ0_c8ec18c6-e46b-4228-95b3-d1ef959e9661"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEzLTItMS0xLTg0NDQ0_da503f03-315f-471d-aa15-eba2e06f0c9a"
      unitRef="usd">29631000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEzLTQtMS0xLTg0NDQ0_3ad0312e-8fb8-4192-9912-cbb3636b58aa"
      unitRef="usd">41582000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEzLTYtMS0xLTg0NDQ0_2101129e-b151-499b-a823-93b731fe1ba7"
      unitRef="usd">4197000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="iee7e142ff6024167983180ffabb98005_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzEzLTgtMS0xLTg0NDQ0_70cee68c-c15f-4be3-93da-2a648077a2ee"
      unitRef="usd">4878000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE1LTItMS0xLTg0NDQ0_0e4de76c-742f-47a7-a561-9876bbcebf81"
      unitRef="usd">41930000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i703d5232b81a4b55936dd90e0dad0606_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE1LTQtMS0xLTg0NDQ0_c11e0fcf-5c7c-425c-856d-b30f77aa1d3d"
      unitRef="usd">38195000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iee7e142ff6024167983180ffabb98005_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE1LTYtMS0xLTg0NDQ0_c03cecef-9eba-4b39-b20a-f390194ac763"
      unitRef="usd">102000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idfb66bf1fb1c43f6b51ba191f9fdbc89_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE1LTgtMS0xLTg0NDQ0_9081cde1-321b-48cd-a7f8-6a0cb8498d2b"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE2LTItMS0xLTg0NDQ0_f8022463-d023-4067-870b-36bbb623377d"
      unitRef="usd">-8665000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE2LTQtMS0xLTg0NDQ0_0f62e600-0360-40d1-a82c-506c480f779a"
      unitRef="usd">4439000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE2LTYtMS0xLTg0NDQ0_9f213db9-72be-4200-9bca-b00bfbf1fd2e"
      unitRef="usd">-17000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE2LTgtMS0xLTg0NDQ0_2c6a1fdd-f52f-406b-baf0-6905223feee8"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE3LTItMS0xLTg0NDQ0_50ef24b8-4aee-4611-b532-a01ed5ed3f2d"
      unitRef="usd">270000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE3LTQtMS0xLTg0NDQ0_694f947b-cb7b-4dfc-af88-d4e9b437deea"
      unitRef="usd">969000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE3LTYtMS0xLTg0NDQ0_d3272346-8e14-4dd7-ab6c-fad1f8aeb3d2"
      unitRef="usd">386000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE3LTgtMS0xLTg0NDQ0_236b3ada-57c3-4c7c-b411-19a3692b851b"
      unitRef="usd">343000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE4LTItMS0xLTg0NDQ0_d243b9cb-8025-487f-8d5c-8aaa4aba4cc9"
      unitRef="usd">67000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE4LTQtMS0xLTg0NDQ0_f496987b-dac6-400b-81c0-067e486fa3ab"
      unitRef="usd">67000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE4LTYtMS0xLTg0NDQ0_0483e35b-8503-4e31-ae67-e4e75e85bafb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE4LTgtMS0xLTg0NDQ0_9bef777e-88ad-4967-9ff4-4962a8940e2c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE5LTItMS0xLTg0NDQ0_e527d8e7-23b2-452a-bbf5-60a8fbba2f8f"
      unitRef="usd">5000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE5LTQtMS0xLTg0NDQ0_c927f081-02fb-4868-91e9-1aeab89581df"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE5LTYtMS0xLTg0NDQ0_90e3f8b8-cd20-4201-b740-0d4d21ecff04"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzE5LTgtMS0xLTg0NDQ0_a393a0b2-dfba-421d-83a3-f35d053c910f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIwLTItMS0xLTg0NDQ0_17304df4-4ace-49d4-92c8-370c51f0105e"
      unitRef="usd">0</jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIwLTQtMS0xLTg0NDQ0_80ffb3f2-7bfe-4b9f-83dd-10dc5f88965d"
      unitRef="usd">-2000000</jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIwLTYtMS0xLTg0NDQ0_2cc510ec-f616-4b66-8dd8-8a43dfb50a4b"
      unitRef="usd">0</jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease>
    <jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIwLTgtMS0xLTg0NDQ0_60b85f68-e295-49db-a3de-4c7640c36933"
      unitRef="usd">0</jnj:DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIxLTItMS0xLTg0NDQ0_19483fb0-1281-4ad1-a952-588941088ef1"
      unitRef="usd">1228000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIxLTQtMS0xLTg0NDQ0_8a3807ed-9bee-490a-b4ba-0c2122940f54"
      unitRef="usd">1157000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIxLTYtMS0xLTg0NDQ0_02fd5247-ec43-4833-b5af-b02b6cd9b825"
      unitRef="usd">393000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIxLTgtMS0xLTg0NDQ0_597484f6-26ac-4581-8f5b-6de973919008"
      unitRef="usd">348000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIyLTItMS0xLTg0NDQ0_5164f845-65be-44a8-9e2a-48999dae4cfd"
      unitRef="usd">-855000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIyLTQtMS0xLTg0NDQ0_6512028d-2c96-48ee-a460-14e9c947b6c5"
      unitRef="usd">-574000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIyLTYtMS0xLTg0NDQ0_f9746164-e961-448f-822b-50074b52081a"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIyLTgtMS0xLTg0NDQ0_35681fd2-85fc-4a13-8246-3839e8f32720"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIzLTItMS0xLTg0NDQ0_d46f5020-9ab7-4ffd-8d63-393ae31c9ead"
      unitRef="usd">31514000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIzLTQtMS0xLTg0NDQ0_8a8be5b5-9388-4769-9e69-852e95e33eb9"
      unitRef="usd">41930000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIzLTYtMS0xLTg0NDQ0_fbfc3426-9072-4db3-b379-e7ea94da90d0"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iee7e142ff6024167983180ffabb98005_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzIzLTgtMS0xLTg0NDQ0_96aa787c-7275-473d-adb1-02fabc5bba88"
      unitRef="usd">102000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI0LTItMS0xLTg0NDQ0_8bfd7b61-3ca5-4cd8-a4ae-2b662509cb4f"
      unitRef="usd">1883000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI0LTQtMS0xLTg0NDQ0_6e8dcd7f-09f3-49fc-b793-c6dba46574e0"
      unitRef="usd">348000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI0LTYtMS0xLTg0NDQ0_8ecca1a7-5ba5-4043-a772-d1d32f4e83f9"
      unitRef="usd">-4119000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="iee7e142ff6024167983180ffabb98005_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI0LTgtMS0xLTg0NDQ0_eb549ccc-6b3a-4692-9f16-6e53166bc7cf"
      unitRef="usd">-4776000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI2LTItMS0xLTg0NDQ0_2cba5de2-8cec-4648-8a77-11f17a47eae7"
      unitRef="usd">4581000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI2LTQtMS0xLTg0NDQ0_84def377-7a75-4e71-a477-3bbb9ece7ce2"
      unitRef="usd">4436000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI2LTYtMS0xLTg0NDQ0_41cc7eed-5922-4e6f-99ba-cf8339974ecd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="iee7e142ff6024167983180ffabb98005_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI2LTgtMS0xLTg0NDQ0_1439e151-247b-42d7-9d76-52ea48456502"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI3LTItMS0xLTg0NDQ0_f7d39b59-e820-43ff-8996-4448c31cd82b"
      unitRef="usd">132000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI3LTQtMS0xLTg0NDQ0_8744a260-e155-43ec-8da8-837aebc1bb80"
      unitRef="usd">115000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI3LTYtMS0xLTg0NDQ0_bf0adca3-fd2d-463b-b875-509380422f2f"
      unitRef="usd">461000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="iee7e142ff6024167983180ffabb98005_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI3LTgtMS0xLTg0NDQ0_ba5ab444-39b2-4186-b858-84dd2b78b536"
      unitRef="usd">438000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI4LTItMS0xLTg0NDQ0_8a4278c7-8ffe-4d92-820e-b8e82241f959"
      unitRef="usd">2566000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI4LTQtMS0xLTg0NDQ0_532f4dd7-2d76-4123-bf93-e00402420831"
      unitRef="usd">3973000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI4LTYtMS0xLTg0NDQ0_4eef1581-eb0f-461b-b589-75ca829f0eca"
      unitRef="usd">3658000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="iee7e142ff6024167983180ffabb98005_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI4LTgtMS0xLTg0NDQ0_f61c72e5-157b-4d27-b250-493780c1f4b1"
      unitRef="usd">4338000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI5LTItMS0xLTg0NDQ0_6b80510c-492c-4b99-a3ea-2856512751ad"
      unitRef="usd">1883000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI5LTQtMS0xLTg0NDQ0_a14c2683-b5e4-4acc-a79a-f041091b7c28"
      unitRef="usd">348000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI5LTYtMS0xLTg0NDQ0_ee75baa3-33d7-4fe8-8160-2f98d1067bf5"
      unitRef="usd">-4119000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="iee7e142ff6024167983180ffabb98005_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzI5LTgtMS0xLTg0NDQ0_a6c901c6-20bb-4326-8482-cf9d262dbb4e"
      unitRef="usd">-4776000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMxLTItMS0xLTg0NDQ0_ef9fbcfa-e8c7-4563-834c-105759729bf1"
      unitRef="usd">-3948000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMxLTQtMS0xLTg0NDQ0_b219de41-b15e-43ba-8906-2427bba70bf3"
      unitRef="usd">-5539000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMxLTYtMS0xLTg0NDQ0_1e92bb08-3192-4c76-aff8-7abff1da1c6e"
      unitRef="usd">-239000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="iee7e142ff6024167983180ffabb98005_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMxLTgtMS0xLTg0NDQ0_286198e9-30b5-46b8-a10b-46e1399b77b6"
      unitRef="usd">-1113000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMyLTItMS0xLTg0NDQ0_2f83077b-e655-491e-99bd-470f207b5ec3"
      unitRef="usd">-1417000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMyLTQtMS0xLTg0NDQ0_91021db7-b8bf-4882-b805-773a9e078da4"
      unitRef="usd">-1610000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMyLTYtMS0xLTg0NDQ0_3dc26ee4-8ab8-431d-bd87-8db36ad1ae85"
      unitRef="usd">-7000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="iee7e142ff6024167983180ffabb98005_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMyLTgtMS0xLTg0NDQ0_0aed8263-5bbe-4068-93ad-23b08231be9c"
      unitRef="usd">-13000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMzLTItMS0xLTg0NDQ0_6a483cf1-130a-4aeb-b799-be63060ad9b8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax
      contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMzLTQtMS0xLTg0NDQ0_15c208e6-40e8-4546-9502-ab35cca94dcd"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMzLTYtMS0xLTg0NDQ0_f10b57a2-5419-43bf-a611-d3727a4f8416"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax
      contextRef="iee7e142ff6024167983180ffabb98005_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzMzLTgtMS0xLTg0NDQ0_d98c8feb-3158-4b45-b7ff-c0d5ee72027b"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzM0LTItMS0xLTg0NDQ0_16c161f0-e727-4996-bb9d-272942ce4715"
      unitRef="usd">2531000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzM0LTQtMS0xLTg0NDQ0_e8f48450-e17a-4f7e-a7cc-70020110d155"
      unitRef="usd">3929000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzM0LTYtMS0xLTg0NDQ0_f4ef3d23-555b-4c93-813a-535b3f74b3e3"
      unitRef="usd">232000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="iee7e142ff6024167983180ffabb98005_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzM0LTgtMS0xLTg0NDQ0_ac4c8aeb-0a56-48e3-a2e1-94e9465a5449"
      unitRef="usd">1100000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzM2LTItMS0xLTg0NDQ0_bcd8ad07-60d7-41ae-a034-254f8e949d07"
      unitRef="usd">28023000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i160fee01a45e4e15969651172a1b8a52_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzM2LTQtMS0xLTg0NDQ0_3ea98c33-d0c2-498c-8951-77af297d2320"
      unitRef="usd">39049000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQyLTItMS0xLTg0NDQ0_506cbb4a-b798-4c26-afe3-d89d4341e562"
      unitRef="usd">-47000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQyLTQtMS0xLTg0NDQ0_35353d8f-121f-4617-a40e-cd1591f49a1d"
      unitRef="usd">623000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQyLTYtMS0xLTg0NDQ0_bb9c4d74-4707-4c2f-8d05-fa1ca306c48f"
      unitRef="usd">533000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQyLTgtMS0xLTg0NDQ0_94735e95-fe61-4811-a28c-967746a602a9"
      unitRef="usd">503000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQzLTItMS0xLTg0NDQ0_4e9fda09-d32c-4000-a429-5862661c1938"
      unitRef="usd">793000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQzLTQtMS0xLTg0NDQ0_387b4320-cb0f-4f35-9647-d02116e5a465"
      unitRef="usd">3927000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQzLTYtMS0xLTg0NDQ0_a2d0d0e1-0d03-4eb0-828d-cdd46079a7d9"
      unitRef="usd">751000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQzLTgtMS0xLTg0NDQ0_25b676cf-717a-4213-a899-9062fcd331df"
      unitRef="usd">199000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ0LTItMS0xLTg0NDQ0_7528022e-de86-415d-8463-23d95d3dd1f4"
      unitRef="usd">-655000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ0LTQtMS0xLTg0NDQ0_621252c5-1f16-409a-833f-682815563d25"
      unitRef="usd">-1257000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ0LTYtMS0xLTg0NDQ0_50a56dc5-2dbb-4c24-b6e9-ee172fdc56a6"
      unitRef="usd">-121000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ0LTgtMS0xLTg0NDQ0_58aaa291-916e-4dde-9097-ff2f9573c000"
      unitRef="usd">-151000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ1LTItMS0xLTg0NDQ0_2047fe58-a89b-4aea-a6a1-b928148cb314"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ1LTQtMS0xLTg0NDQ0_b0e4ebca-720e-4abb-86d5-66e580a73d45"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ1LTYtMS0xLTg0NDQ0_c63bdead-84cb-4802-ad15-6739f492fbab"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ1LTgtMS0xLTg0NDQ0_7ddb9b93-b9bb-4502-a15f-775a006e161c"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ2LTItMS0xLTg0NDQ0_f1ea9fb3-affe-4234-a0ba-8519c0a394c3"
      unitRef="usd">-183000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ2LTQtMS0xLTg0NDQ0_12794e4e-7d3f-4827-9b0a-181724ebd10c"
      unitRef="usd">-181000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ2LTYtMS0xLTg0NDQ0_a73af249-db78-41f5-989d-ef3883e6c3de"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ2LTgtMS0xLTg0NDQ0_5570b72b-7d48-4a67-ad6b-3c0c2ee5be3e"
      unitRef="usd">-31000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <jnj:EffectOfExchangeRates
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ3LTItMS0xLTg0NDQ0_caf51e98-7333-4378-9cab-614f4c05bedd"
      unitRef="usd">-140000000</jnj:EffectOfExchangeRates>
    <jnj:EffectOfExchangeRates
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ3LTQtMS0xLTg0NDQ0_e73b5455-67bc-4f6e-8ef6-d47bccaae451"
      unitRef="usd">-136000000</jnj:EffectOfExchangeRates>
    <jnj:EffectOfExchangeRates
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ3LTYtMS0xLTg0NDQ0_94bb3bce-2f89-495e-8768-1b2419b7afdc"
      unitRef="usd">-1000000</jnj:EffectOfExchangeRates>
    <jnj:EffectOfExchangeRates
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ3LTgtMS0xLTg0NDQ0_90c3ff4e-4511-4322-a21e-e2d0b8e6a58d"
      unitRef="usd">0</jnj:EffectOfExchangeRates>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ4LTItMS0xLTg0NDQ0_619f115c-b509-432b-af34-57b16d66837c"
      unitRef="usd">-1398000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ4LTQtMS0xLTg0NDQ0_00fbbc63-96aa-42d7-a997-4eb84756b299"
      unitRef="usd">-5134000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ4LTYtMS0xLTg0NDQ0_c096e5cd-0c18-4f2c-9587-ed9793a02a27"
      unitRef="usd">-868000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ4LTgtMS0xLTg0NDQ0_3b03e9de-29e3-42a4-95cf-3161e2897a3f"
      unitRef="usd">-319000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="iacf23778894f4cb882f12ee101a37225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ5LTItMS0xLTg0NDQ0_6ac2ca5e-ea50-4e36-80ca-4c047531555e"
      unitRef="usd">-1445000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="i6cf65dde0dca4f0b9bf1b12ec8b0da52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ5LTQtMS0xLTg0NDQ0_7cdd785a-5ae3-46eb-a480-4131243f1932"
      unitRef="usd">-4511000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="i29e611bdfcda46d58f1b3be4df924599_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ5LTYtMS0xLTg0NDQ0_9b4afbfa-a917-4095-8495-42e9ca9d6dad"
      unitRef="usd">-335000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="i7beff5786be445b5b63a3aa52c71238d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpmZDY1M2M5NjVjYzE0N2YwOTI3ZjUyNzA0MjI2ZGUzOS90YWJsZXJhbmdlOmZkNjUzYzk2NWNjMTQ3ZjA5MjdmNTI3MDQyMjZkZTM5XzQ5LTgtMS0xLTg0NDQ0_ed98e8e6-6872-4500-9f69-1fa2ffb57ae7"
      unitRef="usd">184000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:PensionContributions
      contextRef="i568e2ee4449d4f8280ec25b22561b13b_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzQ5OTQ_8fd56f20-6389-4938-ae3a-8818d5bfd3f1"
      unitRef="usd">119000000</us-gaap:PensionContributions>
    <us-gaap:PensionContributions
      contextRef="idf25c935e9904a50a945cc29fc06d712_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzUwMDE_9ec8dad8-9351-4b0d-9981-0e0c7e8ef4c5"
      unitRef="usd">151000000</us-gaap:PensionContributions>
    <jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjI4_b719f076-7e24-4e75-b022-083579a1b429">&lt;div style="margin-top:7pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the funded status of the Company's U.S. Qualified &amp;amp; Non-Qualified pension plans and international funded and unfunded pension plans at December&#160;31, 2022 and December&#160;31, 2021, respectively:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:25.879%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.697%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.551%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.844%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.430%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.137%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.288%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;U.S. Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="12" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;International Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Qualified Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Non-Qualified Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Funded Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="6" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unfunded Plans&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,986&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,041&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,937&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;410&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,985&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,872&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,212&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;253&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Over (Under) Funded Status&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Projected Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,903&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,937)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,703)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,553&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;558&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(410)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accumulated Benefit Obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,241&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,872)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,479)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(373)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1330068050ee43c89fd0edf712d3cd33_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzMtMS0xLTEtODQ0NDQ_bcd532e0-4ab7-4310-a4b6-72e9d2228413"
      unitRef="usd">20937000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i89994b04ef5a4989828cbb2641ea63d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzMtMi0xLTEtODQ0NDQ_f35e5879-4d70-4dc4-96cc-2d4274c4d26c"
      unitRef="usd">27944000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i02d251447a4644728a4ec4ab07eeee7e_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzMtMy0xLTEtODQ0NDQ_0fdbe8a5-302f-4875-965a-ac3b5d4d2a9c"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2f5c5ef2ccbe491e8eae45d4c1b715f8_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzMtNC0xLTEtODQ0NDQ_e074b952-070d-410a-8346-796bd46cb8cb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ifbef14fca11e481c8e30ad28994f26d9_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzMtNS0xLTEtODQ0NDQ_9d3ded6f-4189-4c4e-adbc-789204b19560"
      unitRef="usd">10577000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4ee98d3d2af347e6aa674a643b6056df_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzMtNi0xLTEtODQ0NDQ_493728d3-4db8-411a-b4c4-8ab641dd9916"
      unitRef="usd">13986000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie6f2b519c9234298b0417a7077818079_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzMtNy0xLTEtODQ0NDQ_d3673580-fa4a-4df0-91dd-695598127dcb"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2c2557ba884340dcb35175f91b95b324_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzMtOC0xLTEtODQ0NDQ_fd54bc80-5fb0-4b7e-b9ae-efe43e882bfe"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i1330068050ee43c89fd0edf712d3cd33_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzQtMS0xLTEtODQ0NDQ_27f0f5ea-1ef6-4f8a-8577-7ace7fcf64cc"
      unitRef="usd">18394000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i89994b04ef5a4989828cbb2641ea63d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzQtMi0xLTEtODQ0NDQ_a34216a5-c441-44e1-9c2f-1bd6f6a55163"
      unitRef="usd">25041000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i02d251447a4644728a4ec4ab07eeee7e_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzQtMy0xLTEtODQ0NDQ_5f2f0af0-20b4-4b61-92d1-226e1185ca64"
      unitRef="usd">1937000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i2f5c5ef2ccbe491e8eae45d4c1b715f8_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzQtNC0xLTEtODQ0NDQ_f1d1aec0-3434-4876-aa5b-a5e4a6c95c85"
      unitRef="usd">2703000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ifbef14fca11e481c8e30ad28994f26d9_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzQtNS0xLTEtODQ0NDQ_34c011fa-5dc5-419a-b11d-032c01eb5efe"
      unitRef="usd">9024000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i4ee98d3d2af347e6aa674a643b6056df_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzQtNi0xLTEtODQ0NDQ_4e183134-3bf9-45c1-9c38-f28804e6b0cf"
      unitRef="usd">13428000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="ie6f2b519c9234298b0417a7077818079_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzQtNy0xLTEtODQ0NDQ_521045fd-4694-4b82-aee6-694cfe12064d"
      unitRef="usd">276000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="i2c2557ba884340dcb35175f91b95b324_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzQtOC0xLTEtODQ0NDQ_5447bb2f-180e-4c94-bb49-78eefeaff34e"
      unitRef="usd">410000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i1330068050ee43c89fd0edf712d3cd33_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzUtMS0xLTEtODQ0NDQ_893896b9-6fe6-4c5b-8a97-6c583d483ad8"
      unitRef="usd">17696000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i89994b04ef5a4989828cbb2641ea63d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzUtMi0xLTEtODQ0NDQ_359e6a13-e227-4d84-99d8-d4c0515f80cd"
      unitRef="usd">23985000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i02d251447a4644728a4ec4ab07eeee7e_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzUtMy0xLTEtODQ0NDQ_151c9e1d-6e2c-4781-88b5-4d24f9530a9a"
      unitRef="usd">1872000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i2f5c5ef2ccbe491e8eae45d4c1b715f8_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzUtNC0xLTEtODQ0NDQ_7f663e1a-546a-4bc2-900f-c631138652f4"
      unitRef="usd">2479000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="ifbef14fca11e481c8e30ad28994f26d9_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzUtNS0xLTEtODQ0NDQ_b36b4a44-165c-48fb-84a4-4de069df82aa"
      unitRef="usd">8202000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i4ee98d3d2af347e6aa674a643b6056df_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzUtNi0xLTEtODQ0NDQ_c094d172-a698-4e60-a409-03b89f9f0afe"
      unitRef="usd">12212000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="ie6f2b519c9234298b0417a7077818079_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzUtNy0xLTEtODQ0NDQ_a4d28b6b-5872-43fe-8517-0adaa8480b41"
      unitRef="usd">253000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="i2c2557ba884340dcb35175f91b95b324_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzUtOC0xLTEtODQ0NDQ_6020afd8-8bf1-4458-b4d4-d4ac7214605f"
      unitRef="usd">373000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i1330068050ee43c89fd0edf712d3cd33_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzctMS0xLTEtODQ0NDQ_3e2d4f0a-2c04-4fac-b81c-439ae64f3eaf"
      unitRef="usd">2543000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i89994b04ef5a4989828cbb2641ea63d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzctMi0xLTEtODQ0NDQ_97baa712-211a-4c35-8690-8b8acdfb3bb0"
      unitRef="usd">2903000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i02d251447a4644728a4ec4ab07eeee7e_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzctMy0xLTEtODQ0NDQ_8a161a5f-b68a-4179-8dc1-b0e66a91dad0"
      unitRef="usd">-1937000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i2f5c5ef2ccbe491e8eae45d4c1b715f8_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzctNC0xLTEtODQ0NDQ_13c036c8-ca30-4a9e-be9a-a68309e05165"
      unitRef="usd">-2703000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ifbef14fca11e481c8e30ad28994f26d9_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzctNS0xLTEtODQ0NDQ_adf03891-ec7c-453a-9baa-12feeb6610ba"
      unitRef="usd">1553000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i4ee98d3d2af347e6aa674a643b6056df_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzctNi0xLTEtODQ0NDQ_5c718eb2-90ef-4862-a00f-f99c536f5d9a"
      unitRef="usd">558000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="ie6f2b519c9234298b0417a7077818079_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzctNy0xLTEtODQ0NDQ_b50c968c-a513-4121-af69-85793fd2e17f"
      unitRef="usd">-276000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="i2c2557ba884340dcb35175f91b95b324_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzctOC0xLTEtODQ0NDQ_f3e4a854-7c79-456b-bfeb-a175caa2a087"
      unitRef="usd">-410000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="i1330068050ee43c89fd0edf712d3cd33_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzgtMS0xLTEtODQ0NDQ_41bcc91e-f65e-4311-bf33-15eff4ca3ceb"
      unitRef="usd">3241000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="i89994b04ef5a4989828cbb2641ea63d2_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzgtMi0xLTEtODQ0NDQ_41706110-4652-4352-84fd-11612901fe68"
      unitRef="usd">3959000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="i02d251447a4644728a4ec4ab07eeee7e_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzgtMy0xLTEtODQ0NDQ_3a0c9e5d-0c90-47d2-bf3b-536a89c6764f"
      unitRef="usd">-1872000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="i2f5c5ef2ccbe491e8eae45d4c1b715f8_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzgtNC0xLTEtODQ0NDQ_87ab44c8-d093-4544-9379-a3dffae64868"
      unitRef="usd">-2479000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="ifbef14fca11e481c8e30ad28994f26d9_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzgtNS0xLTEtODQ0NDQ_182f199d-c8e4-4c73-ad8d-aff5f688fc44"
      unitRef="usd">2375000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="i4ee98d3d2af347e6aa674a643b6056df_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzgtNi0xLTEtODQ0NDQ_fc224df2-f958-4dad-9a46-25b3e0d59a08"
      unitRef="usd">1774000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="ie6f2b519c9234298b0417a7077818079_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzgtNy0xLTEtODQ0NDQ_73d32c74-1be7-43ed-ab77-e1492e99fc2b"
      unitRef="usd">-253000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <jnj:DefinedBenefitPlanOverUnderFundedStatusABO
      contextRef="i2c2557ba884340dcb35175f91b95b324_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpkZmFlYzllOThmMGM0ZGY0YWQ5ZDExNTRkNDVhYWI4YS90YWJsZXJhbmdlOmRmYWVjOWU5OGYwYzRkZjRhZDlkMTE1NGQ0NWFhYjhhXzgtOC0xLTEtODQ0NDQ_eb6477f3-b223-4410-9021-4cfb25a66f6c"
      unitRef="usd">-373000000</jnj:DefinedBenefitPlanOverUnderFundedStatusABO>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzU0NDA_497e7bb0-a07c-4373-be99-b67e8416d924"
      unitRef="usd">2900000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzU0NDQ_51a1de96-e9ca-4b12-bd9a-7e6ff81eaa24"
      unitRef="usd">2900000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzU0NTE_84e76f5d-2176-45c1-8a32-fd9af1a58647"
      unitRef="usd">300000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzU0OTE_ccd38d6b-d478-4d21-85b2-435c6706cd1d"
      unitRef="usd">3900000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzU0OTU_0075cb8c-588e-4a6e-8fac-a2e532af4160"
      unitRef="usd">4200000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzU1MDI_5510a48f-81fa-44b7-88bb-575fc4cfe6c3"
      unitRef="usd">300000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjI5_eda555a2-ce6d-4f55-8f8c-bd9311b045b7">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the projected future benefit payments from the Company&#x2019;s retirement and other benefit plans:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2028-2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Projected future benefit payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Retirement plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,457&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,609&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other benefit plans&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;471&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,539&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzItMi0xLTEtODQ0NDQ_abe6750d-e525-43c3-aca0-2d86136814ac"
      unitRef="usd">1445000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzItNC0xLTEtODQ0NDQ_a1882bf1-808f-4fa1-986a-c52a62009e7a"
      unitRef="usd">1457000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzItNi0xLTEtODQ0NDQ_b2c8f2da-41f0-48ab-8158-a5e795c25788"
      unitRef="usd">1532000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzItOC0xLTEtODQ0NDQ_2129db0c-96e9-423f-966a-6814478d93e5"
      unitRef="usd">1609000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzItMTAtMS0xLTg0NDQ0_de7d5b6d-ca49-4146-8204-93dc4bbfb93d"
      unitRef="usd">1708000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzItMTItMS0xLTg0NDQ0_b60f0020-98a0-4cb7-90ca-3a6bcc7d8017"
      unitRef="usd">10034000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzUtMi0xLTEtODQ0NDQ_6c32a70f-a528-4add-a729-aac5ade21638"
      unitRef="usd">471000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzUtNC0xLTEtODQ0NDQ_a38613c8-38f8-4730-970b-39f4cac0a0e1"
      unitRef="usd">485000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzUtNi0xLTEtODQ0NDQ_ac786eae-4519-4227-8f37-f0bac2c9057a"
      unitRef="usd">433000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzUtOC0xLTEtODQ0NDQ_58a133c7-eae3-4319-8558-7c2dac71e3f9"
      unitRef="usd">447000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzUtMTAtMS0xLTg0NDQ0_e082cee5-aa74-4315-be87-6d6b004b33d0"
      unitRef="usd">462000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="i8c7ef14eeaff45dba385c284096876e5_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyODg3NTZkZTNmYjk0ZDc4YTVmMzc5ZGI1NzEzMzlkYS90YWJsZXJhbmdlOjI4ODc1NmRlM2ZiOTRkNzhhNWYzNzlkYjU3MTMzOWRhXzUtMTItMS0xLTg0NDQ0_f682f2db-ace3-4062-abcb-39c3387f7455"
      unitRef="usd">2539000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjA1_10f88ae5-84aa-4c97-9562-066bbb7d3773">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table displays the projected future minimum contributions to the unfunded retirement plans.  These amounts do not include any discretionary contributions that the Company may elect to make in the future.&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.089%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.796%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.803%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2028-2032&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Projected future contributions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;123&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;816&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyZDViYjk3MzlhNmI0ZmVmOGJlNjk1MzlmOTY2OGQzOC90YWJsZXJhbmdlOjJkNWJiOTczOWE2YjRmZWY4YmU2OTUzOWY5NjY4ZDM4XzEtMi0xLTEtODQ0NDQ_e1dedf8f-0216-4501-8c56-c91efd53d996"
      unitRef="usd">123000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyZDViYjk3MzlhNmI0ZmVmOGJlNjk1MzlmOTY2OGQzOC90YWJsZXJhbmdlOjJkNWJiOTczOWE2YjRmZWY4YmU2OTUzOWY5NjY4ZDM4XzEtNC0xLTEtODQ0NDQ_870e2661-bca7-4705-9ea4-b6c63db2521c"
      unitRef="usd">128000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyZDViYjk3MzlhNmI0ZmVmOGJlNjk1MzlmOTY2OGQzOC90YWJsZXJhbmdlOjJkNWJiOTczOWE2YjRmZWY4YmU2OTUzOWY5NjY4ZDM4XzEtNi0xLTEtODQ0NDQ_d76f16c4-768a-4d60-8c67-57dba918b793"
      unitRef="usd">136000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyZDViYjk3MzlhNmI0ZmVmOGJlNjk1MzlmOTY2OGQzOC90YWJsZXJhbmdlOjJkNWJiOTczOWE2YjRmZWY4YmU2OTUzOWY5NjY4ZDM4XzEtOC0xLTEtODQ0NDQ_c8517aed-a98b-4fd1-8e56-9f5a34f95291"
      unitRef="usd">141000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyZDViYjk3MzlhNmI0ZmVmOGJlNjk1MzlmOTY2OGQzOC90YWJsZXJhbmdlOjJkNWJiOTczOWE2YjRmZWY4YmU2OTUzOWY5NjY4ZDM4XzEtMTAtMS0xLTg0NDQ0_b0487641-1cad-49d9-8ac9-58f73efb25a9"
      unitRef="usd">146000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive>
    <jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZToyZDViYjk3MzlhNmI0ZmVmOGJlNjk1MzlmOTY2OGQzOC90YWJsZXJhbmdlOjJkNWJiOTczOWE2YjRmZWY4YmU2OTUzOWY5NjY4ZDM4XzEtMTItMS0xLTg0NDQ0_860cf11d-ebef-4dfb-aecb-34f582938c9b"
      unitRef="usd">816000000</jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjQ5_ec0ed06a-2af5-4cc5-acd1-7552b2b8604d">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s retirement plan asset allocation at the end of 2022 and 2021 and target allocations for 2023 are as follows:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.976%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.131%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.750%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.538%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.755%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Percent of&lt;br/&gt;Plan Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Target&lt;br/&gt;Allocation&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Worldwide Retirement Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total plan assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;100&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="ib9ef98128abe4aedb0a5007195b08de1_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzMtMi0xLTEtODQ0NDQ_b6341672-0c17-454a-8948-ff50977501e2"
      unitRef="number">0.62</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="i92a0708b59e24d4ea0866aa54072a7da_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzMtNC0xLTEtODQ0NDQ_ad4d9ac4-0145-4347-81c7-6eb1d24d723e"
      unitRef="number">0.65</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="ib9ef98128abe4aedb0a5007195b08de1_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzMtNi0xLTEtODQ0NDQ_2dde57c4-f493-46be-9edb-11550014dce6"
      unitRef="number">0.61</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="i2c0a56ded60c4a9bb35be25cde1c1637_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzQtMi0xLTEtODQ0NDQ_1e971be1-6611-4eb5-a426-23c40623d49f"
      unitRef="number">0.38</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="ie6a1005463744b0db3476c6fa293b2a7_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzQtNC0xLTEtODQ0NDQ_77877b65-4d34-4da6-a276-f56023b11577"
      unitRef="number">0.35</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i2c0a56ded60c4a9bb35be25cde1c1637_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzQtNi0xLTEtODQ0NDQ_4cc155c3-bc3e-4b06-b275-4cd08938d943"
      unitRef="number">0.39</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzUtMi0xLTEtODQ0NDQ_9062ed3f-5749-4c60-a11e-7d57fc36bc42"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzUtNC0xLTEtODQ0NDQ_d7d6c3c2-cfe3-437b-9c82-c24bd0e69663"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTpiYTc5YWRmOGJlZTE0YTAzOTAyMWNhZjkyOGZjNGEyNC90YWJsZXJhbmdlOmJhNzlhZGY4YmVlMTRhMDM5MDIxY2FmOTI4ZmM0YTI0XzUtNi0xLTEtODQ0NDQ_3ef4c765-f0f8-4fdc-9a44-eb2d2d0a1541"
      unitRef="number">1</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMjA4_bcd46648-514b-4ab6-826c-cd660c1d8a30">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table sets forth the Retirement Plans' investments measured at fair value as of December&#160;31, 2022 and December&#160;31, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.783%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:18.235%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.754%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.150%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.555%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:6.161%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Quoted Prices&lt;br/&gt;in Active&lt;br/&gt;Markets for&lt;br/&gt;Identical Assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;br/&gt;Other&lt;br/&gt;Observable&lt;br/&gt;Inputs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Significant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unobservable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Inputs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Investments Measured at Net Asset Value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 1)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 2)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;(Level 3)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Short-term investment funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;102&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,033&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government and agency securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,016&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt instruments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,681&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Equity securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,848&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commingled funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,496&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,524&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,309&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,506&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,552&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Investments at fair value&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,879&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;14,209&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;13,954&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;17,086&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;69&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;120&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;8,612&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;10,515&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;31,514&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;41,930&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;The activity for the Level 3 assets is not significant for all years presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i8b5854265567407d8c334a909d643d48_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzMtMi0xLTEtODQ0NDQ_e750d0eb-ce6a-48ca-b291-38f0de585aa4"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i22e0ddcdbf4c44c2a8e38032719cfecb_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzMtNC0xLTEtODQ0NDQ_22cec668-1119-4e2a-89b2-3c4f944e1d41"
      unitRef="usd">102000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i065c9f2a0f964ee285c2b8a25d0a06ec_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzMtNi0xLTEtODQ0NDQ_ed881a45-bf3f-4abe-9cdc-98c24ed69159"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i2b6a8806889b4e03a0a58daf7c2e8756_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzMtOC0xLTEtODQ0NDQ_80cc0b21-89bd-4608-8e65-ea7b9920cf6f"
      unitRef="usd">1033000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9dd0d8c6503a45b587ecfb92769cc43c_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzMtMTAtMS0xLTg0NDQ0_1fded3ae-b93b-4663-bc49-6fdbc1bfdbfe"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i74650ae05ec94371b9d6bc18a602bdba_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzMtMTItMS0xLTg0NDQ0_d21049aa-833a-4047-9e9f-2dec2915a2e9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id57112356ae147f6acddb2fa2ef3c2c2_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzMtMTgtMS0xLTg0NDQ0_abaf0b66-a93c-4708-a856-92a881be54cc"
      unitRef="usd">46000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i91b00037a81c40799e88359b6a3d230a_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzMtMjAtMS0xLTg0NDQ0_8bdaa25a-5b74-48c0-b117-9f8480b82896"
      unitRef="usd">1135000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id4e0173b76424c5f8b69bc8e9ad909f3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzQtMi0xLTEtODQ0NDQ_ac8d7813-307c-4e46-97b1-93a6bbdab43e"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i11c5835ef6d041e0a21935aa096c3e34_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzQtNC0xLTEtODQ0NDQ_d2b4f154-ff0f-4dba-8b03-18f0e7f17a72"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i89fe4d1a68ff41478d904f10e0e0ae0e_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzQtNi0xLTEtODQ0NDQ_1240c4af-ae62-4a24-89f2-68fe14b60d7c"
      unitRef="usd">5863000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic6e4971765ee45178f66de2094bb223b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzQtOC0xLTEtODQ0NDQ_d5d9772b-5ec6-4cb4-bdb0-fb4cd10a5578"
      unitRef="usd">7016000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ib2558baea70f43d6a6cf9affe1cb228c_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzQtMTAtMS0xLTg0NDQ0_1a8b8981-5b28-499c-8dcf-8a589d1b36c4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iaaa2fb24fe7f4913b81bd9b6e6a69211_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzQtMTItMS0xLTg0NDQ0_600ab1f2-3434-4de4-9a71-62cffa097383"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia65b35d656b7404cad2cded1a7f84257_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzQtMTgtMS0xLTg0NDQ0_90c284dd-87c4-4e83-bbcc-024ea209546a"
      unitRef="usd">5863000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i13253a658c83423ba8e9c1af10e40f9f_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzQtMjAtMS0xLTg0NDQ0_87496e5c-001b-49a6-b041-8df906131700"
      unitRef="usd">7016000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idfffbb437b674ebbad4375b66a624388_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzUtMi0xLTEtODQ0NDQ_833e7ee0-11f8-4373-ac87-8c1e26cabe4f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ia30472b13c2c42c698c7f0512ec7426c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzUtNC0xLTEtODQ0NDQ_6300aa8c-a4e1-4458-918f-3bbb5f358a14"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6f96d2d3087247fea72a69f7464a8ffe_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzUtNi0xLTEtODQ0NDQ_d667c75f-fd5f-4bf0-9115-71ddb5685731"
      unitRef="usd">3681000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ic562463a901d4f7d98741278df63a71e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzUtOC0xLTEtODQ0NDQ_16df4ac7-82cb-423e-b983-e8059e606bdc"
      unitRef="usd">3505000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i040ae04cd8d34049b557c7754b4d1903_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzUtMTAtMS0xLTg0NDQ0_64251114-991e-487f-b779-18695c0c9d1d"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i0a4136d235304b9ca96dc52ca2bae31f_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzUtMTItMS0xLTg0NDQ0_00d0adc0-086c-482f-ace6-6b99e1d997f1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i3aca2e86db254efcb60046d3b1959e83_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzUtMTgtMS0xLTg0NDQ0_c3e233ee-8582-46cd-88d3-52497c3286d3"
      unitRef="usd">3681000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i629d668c721f43fa9a69ae248da4c767_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzUtMjAtMS0xLTg0NDQ0_8bcbc8aa-da2a-43a2-83b1-ff799f8eaf83"
      unitRef="usd">3505000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i27927d8dc21840e0886a91b302a75133_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzYtMi0xLTEtODQ0NDQ_32f6d034-e3b3-4e2f-a3c0-e229bea47bdb"
      unitRef="usd">8846000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i72431f66c0344014974314a2d6fcebee_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzYtNC0xLTEtODQ0NDQ_a1183dce-dc6e-44f8-963f-c1ade03e0a27"
      unitRef="usd">14107000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6053a0abc1f746509f25b60b89e316da_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzYtNi0xLTEtODQ0NDQ_6def09bc-1233-4b37-9548-a61fed4d5bd8"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie1c3b856e495487fb9397d837ce7430d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzYtOC0xLTEtODQ0NDQ_58a07694-8065-499f-b26b-985b822413ba"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6a93ad27dcc346cb8ed7ba5d19476117_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzYtMTAtMS0xLTg0NDQ0_600a34ae-c1a3-4d00-8fdd-0da3a36fa3c0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i34cf66c98020432c86dbfab2c8bc0591_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzYtMTItMS0xLTg0NDQ0_26a9cb00-141a-4d21-9aa0-018179f18f60"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i907758fcc942478385fb4e997c7b28e4_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzYtMTgtMS0xLTg0NDQ0_883481ad-2253-4453-b902-018e16e29339"
      unitRef="usd">8848000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if460c561b88c46f197e086c2eb780175_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzYtMjAtMS0xLTg0NDQ0_584fdc73-f20f-4e7f-b9f9-d1313a6d7d03"
      unitRef="usd">14109000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if667a81b90034bb89345e0e86dc1c837_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctMi0xLTEtODQ0NDQ_3be200a1-5aaf-4c48-b97c-10b984299b7f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="ie873bd0c000344438fb4154226263234_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctNC0xLTEtODQ0NDQ_242ed8e5-c76c-4fd9-942a-f7b96e678650"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i14706b8e4e9b45fa8ad2b00f7b025b13_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctNi0xLTEtODQ0NDQ_1a54c188-cda6-4afa-9257-3dd4381761f1"
      unitRef="usd">4362000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i08e5d2a42732496faba5e2998478e99f_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctOC0xLTEtODQ0NDQ_ebcd1984-fa8c-4ec2-b5a9-f7439e8edc66"
      unitRef="usd">5496000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4c63ed9d635548eda5b40167be502d34_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctMTAtMS0xLTg0NDQ0_441cd29d-f2c7-4b4f-a7b0-cc29fabebd6a"
      unitRef="usd">56000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5c17edc19d844447920bcf55fcb965c9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctMTItMS0xLTg0NDQ0_5ceb9aaf-a160-4e96-bc91-a51daf219035"
      unitRef="usd">105000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="i9464afb4525c4171b9f7c85f564ca383_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctMTQtMS0xLTg0NDQ0_cad97ca6-5809-425c-9a1a-182010682bff"
      unitRef="usd">6106000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="i678ae776bb3e4394807bdb4118962522_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctMTYtMS0xLTg0NDQ0_204bfa7c-d958-4db9-a7fc-9c1605105c06"
      unitRef="usd">8708000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9464afb4525c4171b9f7c85f564ca383_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctMTgtMS0xLTg0NDQ0_2edc7f6d-cf32-411d-9823-c05bb917ae8e"
      unitRef="usd">10524000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i678ae776bb3e4394807bdb4118962522_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzctMjAtMS0xLTg0NDQ0_709047d5-6f16-4ed8-b898-bcf62f1845e4"
      unitRef="usd">14309000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idbdd72723de74d5ab22897210e1d235d_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktMi0xLTEtODQ0NDQ_0d68204f-de37-43d4-968e-759953e9040f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id16f7d3ae47a40419613a4e6ebcdf931_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktNC0xLTEtODQ0NDQ_3f267763-1321-4e58-9a46-0ab2016cfe2f"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i94f0cc6d1b0143a7ad0de6a6b7171527_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktNi0xLTEtODQ0NDQ_cb8de841-220c-49dd-99f0-0c85ffe851e4"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i1489b8c66a064c22a4d320bbc28a949e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktOC0xLTEtODQ0NDQ_33c24f34-857f-4b46-8ff7-f18395ea1fe1"
      unitRef="usd">34000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5684bd25916640ce8a21cd76052a6a5c_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktMTAtMS0xLTg0NDQ0_9307cf0c-32c0-48ea-a821-f8a7876c18c3"
      unitRef="usd">13000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="id5175417cdaa471eb56e2f0adbf22f49_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktMTItMS0xLTg0NDQ0_8642e849-fbb7-4775-b06f-03de0f8ef39d"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="i4522e617517843a2883f058c7048bf98_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktMTQtMS0xLTg0NDQ0_e2a12272-e58b-427e-b9bc-a1f2836c283f"
      unitRef="usd">2506000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="i7f898d8c94c649a4bcd40d0903b33a8b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktMTYtMS0xLTg0NDQ0_77772839-dea1-4a2c-a247-b4c47d1a7674"
      unitRef="usd">1807000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i4522e617517843a2883f058c7048bf98_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktMTgtMS0xLTg0NDQ0_29d980e5-ea2a-4e86-bac5-0efc97139be8"
      unitRef="usd">2552000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i7f898d8c94c649a4bcd40d0903b33a8b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzktMjAtMS0xLTg0NDQ0_0273064f-4092-42b6-bb7d-981fb0d46593"
      unitRef="usd">1856000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i6d78a014cb7b4600b9b987e0c8d3ef4e_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTItMS0xLTg0NDQ0_ecb42b98-34c3-42f0-a22b-7acef3a0aab0"
      unitRef="usd">8879000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="if9eedf365257482e9a59a6c5f27d0a37_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTQtMS0xLTg0NDQ0_7ef7b07c-6c32-41dd-8349-1428646c5914"
      unitRef="usd">14209000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i409919d7e88f41b790a753d01b52083e_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTYtMS0xLTg0NDQ0_3da7c555-36ce-49a6-a537-3ce57c63926d"
      unitRef="usd">13954000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i5db77b85a6024162854cd564cb20a41d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTgtMS0xLTg0NDQ0_9789bd71-2ff4-490a-a9db-402d3c85c327"
      unitRef="usd">17086000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i9e09026399524065bc97affeb43c546d_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTEwLTEtMS04NDQ0NA_079de2c8-b218-4413-9f28-2a3b5d143e60"
      unitRef="usd">69000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i199aa9d6185f445c8a0e845551e8cd3b_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTEyLTEtMS04NDQ0NA_1d89b92a-91d1-4d65-bfa7-e36fa45796cb"
      unitRef="usd">120000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="i44bda01bf133404387afaead8b97a718_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTE0LTEtMS04NDQ0NA_026a9a6f-423d-42ab-84de-686143ff4d8c"
      unitRef="usd">8612000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets
      contextRef="iccce90dd21004e5daf45ef5005ed0551_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTE2LTEtMS04NDQ0NA_0e8771c9-9535-4655-947e-6c41a153fe18"
      unitRef="usd">10515000000</jnj:DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i44bda01bf133404387afaead8b97a718_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTE4LTEtMS04NDQ0NA_aae97caf-955f-4827-b48c-cdb04e0c4358"
      unitRef="usd">31514000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="iccce90dd21004e5daf45ef5005ed0551_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90YWJsZTphN2NkNGJiZWEyNGU0YTVmODQ5ZTA3ODI0NTM1YjViNi90YWJsZXJhbmdlOmE3Y2Q0YmJlYTI0ZTRhNWY4NDllMDc4MjQ1MzViNWI2XzEwLTIwLTEtMS04NDQ0NA_eafc2abf-142d-4540-8873-6e85ad30a51d"
      unitRef="usd">41930000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="idd19fe4f42064eab8bbfb528aac6c080_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzEwOTQ4_03794fb3-2bd0-4e95-91e4-b1443b4e1409"
      unitRef="usd">78000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="i74f4b70efeba4325a8712247faf7b3ff_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzEwOTU1_434c2041-1dc6-4986-9bc4-617f8e6d0795"
      unitRef="usd">102000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMDk5_72c091d2-763c-4a97-9f63-40df7860704d"
      unitRef="usd">21000000</jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets>
    <jnj:PercentageOfCompanysCommonStockToPlanAsset
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMTAz_f80fd5c9-7a6e-4d4f-891d-bc689f50138b"
      unitRef="number">0.001</jnj:PercentageOfCompanysCommonStockToPlanAsset>
    <jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMTUz_262c5fb2-5042-4bf1-b667-5da8f60084fa"
      unitRef="usd">385000000</jnj:FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets>
    <jnj:PercentageOfCompanysCommonStockToPlanAsset
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODEvZnJhZzpmOWJlMTk5M2Q4YzM0ODNjOWY3N2QxYmQzNGNlODk1My90ZXh0cmVnaW9uOmY5YmUxOTkzZDhjMzQ4M2M5Zjc3ZDFiZDM0Y2U4OTUzXzExMTU3_b115e194-2b7d-4399-96fa-93dc2a91009f"
      unitRef="number">0.009</jnj:PercentageOfCompanysCommonStockToPlanAsset>
    <jnj:SavingsPlanTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODcvZnJhZzplOTk1MWU2OTkzODY0ZmRlOTI5ZjFjYmY3YWYwMjhkZS90ZXh0cmVnaW9uOmU5OTUxZTY5OTM4NjRmZGU5MjlmMWNiZjdhZjAyOGRlXzQwNA_a287b6b3-9408-4287-b3c2-66833f750c50">Savings PlanThe Company has voluntary 401(k) savings plans designed to enhance the existing retirement programs covering eligible employees. The Company matches a percentage of each employee&#x2019;s contributions consistent with the provisions of the plan for which he/she is eligible. Total Company matching contributions to the plans were $275 million, $256 million and $243 million in fiscal years 2022, 2021 and 2020, respectively.</jnj:SavingsPlanTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODcvZnJhZzplOTk1MWU2OTkzODY0ZmRlOTI5ZjFjYmY3YWYwMjhkZS90ZXh0cmVnaW9uOmU5OTUxZTY5OTM4NjRmZGU5MjlmMWNiZjdhZjAyOGRlXzM0Mg_75a5fef2-9caf-4876-b404-f4d8e5c6ac89"
      unitRef="usd">275000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODcvZnJhZzplOTk1MWU2OTkzODY0ZmRlOTI5ZjFjYmY3YWYwMjhkZS90ZXh0cmVnaW9uOmU5OTUxZTY5OTM4NjRmZGU5MjlmMWNiZjdhZjAyOGRlXzM0Ng_0cfdf53a-6785-45e8-8dcf-00296e6deeec"
      unitRef="usd">256000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xODcvZnJhZzplOTk1MWU2OTkzODY0ZmRlOTI5ZjFjYmY3YWYwMjhkZS90ZXh0cmVnaW9uOmU5OTUxZTY5OTM4NjRmZGU5MjlmMWNiZjdhZjAyOGRlXzM1Mw_e1b05ede-3880-4a98-9754-50605141d6c2"
      unitRef="usd">243000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:TreasuryStockTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzc2OA_0a3b1cbc-2bfc-4b99-a19d-dfdfb1a0c7ba">Capital and Treasury Stock&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in treasury stock were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts in Millions Except Treasury Stock Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Aggregate shares of common stock issued were approximately 3,119,843,000&#160;shares at the end of fiscal years 2022, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash dividends paid were $4.45 per share in fiscal year 2022, compared with dividends of $4.19 per share in fiscal year 2021, and $3.98 per share in fiscal year 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 3, 2023, the Board of Directors declared a regular cash dividend of $1.13 per share, payable on March 7, 2023 to shareholders of record as of February 21, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 14, 2022, the Company announced that its Board of Directors approved a share repurchase program, authorizing the Company to purchase up to $5.0 billion of the Company's shares of common stock. Share repurchases may be made at management&#x2019;s discretion from time to time on the open market or through privately negotiated transactions.  The repurchase program has no time limit and may be suspended for periods or discontinued at any time. Through January&#160;1, 2023, approximately $2.5&#160;billion has been repurchased under the program.&lt;/span&gt;&lt;/div&gt;</us-gaap:TreasuryStockTextBlock>
    <jnj:ChangesInTreasuryStockTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzc3Nw_75e793c2-c7f0-4695-940d-e89278050573">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in treasury stock were:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:71.960%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.639%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Treasury Stock&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Amounts in Millions Except Treasury Stock Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,336&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21,765)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,148)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(17,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,847)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;490,878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,099&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Employee compensation and stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20,007)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3,440)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Repurchase of common stock&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,375&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;506,246&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,694&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</jnj:ChangesInTreasuryStockTableTextBlock>
    <us-gaap:TreasuryStockShares
      contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzItMi0xLTEtODQ0NDQ_4f11a4b3-3e4f-4c73-8056-a8c6d135fd34"
      unitRef="shares">487336000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzItNC0xLTEtODQ0NDQ_b8ac3f15-2811-4c6f-8f18-7dd949921567"
      unitRef="usd">38417000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzMtMi0xLTEtODQ0NDQ_582a3cb6-2ea7-4810-bcf7-bf01c7ccae09"
      unitRef="shares">21765000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzMtNC0xLTEtODQ0NDQ_c53264ee-4e0f-4792-a601-b6740746037a"
      unitRef="usd">3148000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ib7e50ef6296740dda9036c6c59bae7a8_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzQtMi0xLTEtODQ0NDQ_9894848f-2ce8-429d-8503-86627bdd8728"
      unitRef="shares">21760000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ib7e50ef6296740dda9036c6c59bae7a8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzQtNC0xLTEtODQ0NDQ_339f841f-382f-427c-941a-87663b66bea8"
      unitRef="usd">3221000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockShares
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzUtMi0xLTEtODQ0NDQ_2ba6b19f-dfd9-482e-83dc-6b2b1cc82723"
      unitRef="shares">487331000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzUtNC0xLTEtODQ0NDQ_723a8553-082f-49e5-9f33-4dcff5d7cc77"
      unitRef="usd">38490000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzYtMi0xLTEtODQ0NDQ_a51057e8-3e60-4c69-b01c-2cfe08ada420"
      unitRef="shares">17399000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzYtNC0xLTEtODQ0NDQ_4ff786ed-86f6-459f-91bc-e81701bd1bfa"
      unitRef="usd">2847000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="ica40f5d5420a42c4baf327e28f3ff166_D20210104-20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzctMi0xLTEtODQ0NDQ_7b665ec7-61be-4d87-a183-8ef402f8f1e8"
      unitRef="shares">20946000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="ica40f5d5420a42c4baf327e28f3ff166_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzctNC0xLTEtODQ0NDQ_4763b800-a994-41e9-886c-4c006522b782"
      unitRef="usd">3456000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockShares
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzgtMi0xLTEtODQ0NDQ_bd6d0365-ac6d-4264-ba9c-848595f9b2d0"
      unitRef="shares">490878000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzgtNC0xLTEtODQ0NDQ_7aa15b59-da1f-4c62-9d65-77faa3b5cb03"
      unitRef="usd">39099000000</us-gaap:TreasuryStockValue>
    <us-gaap:StockIssuedDuringPeriodSharesOther
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzktMi0xLTEtODQ0NDQ_02f1ec4b-58ae-4179-9737-08cab7325a53"
      unitRef="shares">20007000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzktNC0xLTEtODQ0NDQ_95213481-6046-4aae-8bc3-0e8b15b3f263"
      unitRef="usd">3440000000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="i0bd8a9ce6ebc4c33ba835359ee340f7a_D20220103-20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzEwLTItMS0xLTg0NDQ0_3c873471-51b5-43a3-92f6-d2fddf2ca2e2"
      unitRef="shares">35375000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="i0bd8a9ce6ebc4c33ba835359ee340f7a_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzEwLTQtMS0xLTg0NDQ0_3246bb94-9849-421a-908d-519e749a45d0"
      unitRef="usd">6035000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockShares
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzExLTItMS0xLTg0NDQ0_caea7d19-3783-40a7-8262-1ffd908276ae"
      unitRef="shares">506246000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockValue
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90YWJsZTozODkxZTEzNGY4NWQ0OWI4YTkxNDg4ZWE4NDJmNWY3NC90YWJsZXJhbmdlOjM4OTFlMTM0Zjg1ZDQ5YjhhOTE0ODhlYTg0MmY1Zjc0XzExLTQtMS0xLTg0NDQ0_f502b170-db08-4e00-9d4c-9957bd52587c"
      unitRef="usd">41694000000</us-gaap:TreasuryStockValue>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzEyNg_1a6b39b0-e1b5-43a7-a747-6f9056da7e0d"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzEyNg_7a6beb44-33cb-4032-a105-12f8c2616393"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzEyNg_e532dde2-e844-443e-9dfb-38d899294517"
      unitRef="shares">3119843000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzIwNA_bab0f4cb-8b84-42d5-b47d-83d9d4e0f30b"
      unitRef="usdPerShare">4.45</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzI2Mw_26dfeab5-c715-4bf2-9f65-83e5f76b87a9"
      unitRef="usdPerShare">4.19</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareCashPaid
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzI5OQ_849c079b-c3a5-4805-80c1-4d8cfe3049b3"
      unitRef="usdPerShare">3.98</us-gaap:CommonStockDividendsPerShareCashPaid>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="ifc3e95d2480f4b09a43e8526cb530ec0_D20230103-20230103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzQxMQ_0d55da42-59de-48bc-a264-5045b4341029"
      unitRef="usdPerShare">1.13</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="i3aaa8d30ebdd4b799164c6d64da029ec_I20220914"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzY1Mg_da55cd89-e37b-4711-8587-c9e69072cc6f"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchasedDuringPeriodValue
      contextRef="ie95b18f0bb224ce39159e2cece26a7de_D20220914-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTAvZnJhZzozYjg4ZGE0NTVmMGE0NGViYWFlZjhlY2QxYTFiNmI4YS90ZXh0cmVnaW9uOjNiODhkYTQ1NWYwYTQ0ZWJhYWVmOGVjZDFhMWI2YjhhXzU0OTc1NTgxNjMyOQ_6c28ce5e-f07e-4217-85aa-ef2499566470"
      unitRef="usd">2500000000</us-gaap:StockRepurchasedDuringPeriodValue>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90ZXh0cmVnaW9uOjZhNTQwMDFhMjBiODQwYTk4Y2Y0MzkzZjhjMTVmZjNkXzkxNw_cfcd7135-8be5-406e-9e2a-05050c4011b7">Accumulated Other Comprehensive Income (Loss)&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss) On Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/&lt;br/&gt;(Loss) On&lt;br/&gt;Derivatives &amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2020 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2021 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2022 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts in accumulated other comprehensive income are presented net of the related tax impact. Foreign currency translation is not adjusted for income taxes where it relates to permanent investments in international subsidiaries. For additional details on comprehensive income see the Consolidated Statements of Comprehensive Income. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Details on reclassifications out of Accumulated Other Comprehensive Income:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Securities - reclassifications released to Other (income) expense, net.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Employee Benefit Plans - reclassifications are included in net periodic benefit cost. See Note 10 for additional details.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Gain/(Loss) On Derivatives &amp;amp; Hedges - reclassifications to earnings are recorded in the same account as the hedged transaction.  See Note 6 for additional details.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90ZXh0cmVnaW9uOjZhNTQwMDFhMjBiODQwYTk4Y2Y0MzkzZjhjMTVmZjNkXzkyNA_8f95d921-8ab4-459c-9b1e-630310e54785">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Components of other comprehensive income (loss) consist of the following:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.117%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.897%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.457%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.292%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.483%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.630%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.533%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.392%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Foreign&lt;br/&gt;Currency Translation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/(Loss) On Securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Employee Benefit Plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gain/&lt;br/&gt;(Loss) On&lt;br/&gt;Derivatives &amp;amp; Hedges&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;br/&gt;Accumulated&lt;br/&gt;Other&lt;br/&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,705)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(295)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,891)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2020 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(233)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(66)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;649&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8,938)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6,957)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;652&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15,242)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2021 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(988)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10,017)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,702)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(336)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,058)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net 2022 changes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,796)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(24)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,805&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;106&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;91&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,813)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(27)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(897)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(230)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12,967)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i998292a4720542fb97323e8a21027018_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEtMi0xLTEtODQ0NDQ_a62906d5-10f6-46e5-aa2d-dd57574af9f3"
      unitRef="usd">-8705000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i11d2f866128a4c0bbd34f29e255e2e5e_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEtNC0xLTEtODQ0NDQ_acd3f84d-0b61-4eaa-972b-c84e40d05e5a"
      unitRef="usd">0</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ic2e5b348e871404cb444f06edd6e8a44_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEtNi0xLTEtODQ0NDQ_3414eb07-904e-4a1c-a1b3-d864532ea869"
      unitRef="usd">-6891000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i72f9f2cb97f549a783317a29d6bcb3a6_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEtOC0xLTEtODQ0NDQ_f1b53d91-c8a2-4457-a566-3bac32e07256"
      unitRef="usd">-295000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ie9807f0aec4641a1ac4bec134b355aad_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEtMTAtMS0xLTg0NDQ0_a43e5291-3007-4f96-9a7e-2c4b7da9da85"
      unitRef="usd">-15891000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4bdd796b17934806b83c05e06ce34090_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzMtMi0xLTEtODQ0NDQ_c25bda50-c63c-4089-b1bd-1b9f6ae2d1e8"
      unitRef="usd">-233000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ibdc62ce8bcb249e58d2e978447347cbf_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzMtNC0xLTEtODQ0NDQ_bc85cd39-b42f-4108-b18f-f6064034dfce"
      unitRef="usd">1000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="idd018d59093549458cb4f3761ccbb821_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzMtNi0xLTEtODQ0NDQ_9cf754da-7e7c-4195-a23b-115444a7567c"
      unitRef="usd">-66000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i7b330b391c664593bf5ce01ca6a9e387_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzMtOC0xLTEtODQ0NDQ_4c3a0cc4-100e-4fbb-ab8b-a4fa240bfcae"
      unitRef="usd">947000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i9a2bd92352194bcdb8a871945d2b04b6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzMtMTAtMS0xLTg0NDQ0_b65bd112-1e46-4f62-bd78-c9e6c096571a"
      unitRef="usd">649000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ib1263a8933f94cd2b1db256f5159e8c1_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzQtMi0xLTEtODQ0NDQ_6fa8430a-0757-4af2-a0a8-aa8a9e640cc6"
      unitRef="usd">-8938000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i86541415a18745ad9fad6d5a9da21dab_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzQtNC0xLTEtODQ0NDQ_285ea4c6-f9b1-4323-8a52-8bfaf854ddf9"
      unitRef="usd">1000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i56cfe48a1389431abade9bcff2c63177_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzQtNi0xLTEtODQ0NDQ_a9cc2f7e-2a40-4898-a5ae-b395bd6b5460"
      unitRef="usd">-6957000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5a4b14144c8b45d7b5c9ed3c00162124_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzQtOC0xLTEtODQ0NDQ_e62695b7-5ed0-44d6-9eca-ad9fe54da408"
      unitRef="usd">652000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i81bc749533a9432f82631e2ec08fb7c4_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzQtMTAtMS0xLTg0NDQ0_9ab6fa3c-5c4f-48ec-88bf-057ace4c6843"
      unitRef="usd">-15242000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ic08350f7471944cfb12cf9ffa56a221c_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzYtMi0xLTEtODQ0NDQ_aba72bab-04c8-4a3f-a741-3e7e048829f7"
      unitRef="usd">-1079000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i503c1b32967d4343a8eb327c8c6be661_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzYtNC0xLTEtODQ0NDQ_26ccbe58-f7ee-42d7-9cb6-5872914751a8"
      unitRef="usd">-4000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i602c299adc484e92a89fdcbd8f6fc8cc_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzYtNi0xLTEtODQ0NDQ_b232ae5c-00e2-4aec-9f29-db0bbe75996f"
      unitRef="usd">4255000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ief3f111fd6524bf78a21c828a283c3d5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzYtOC0xLTEtODQ0NDQ_e95ab340-c0ec-46b3-89fc-9728c20b33c0"
      unitRef="usd">-988000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ieade5efd55fc4e7f9b55b76ad9b270a0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzYtMTAtMS0xLTg0NDQ0_f5b4fbe3-9d94-488c-a376-48e107046bfb"
      unitRef="usd">2184000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id0b83f8ef9bf4d359fa8bb52b6dc3fcf_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzctMi0xLTEtODQ0NDQ_0f8988d7-d838-4d9a-bbea-5a4623981f27"
      unitRef="usd">-10017000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="iaba6b6f0ecea42ebb8ac410bf2612423_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzctNC0xLTEtODQ0NDQ_9b6cc221-e7c5-4a86-98a3-bfd9aa54452b"
      unitRef="usd">-3000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="id1d1b96425db42a181eb410f603a9c9c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzctNi0xLTEtODQ0NDQ_81ea932e-7d22-4b9f-a8bc-1572967718ac"
      unitRef="usd">-2702000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i43fcad8870384544ab9df6081f406c7f_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzctOC0xLTEtODQ0NDQ_25a3ab19-09dc-4345-822f-38bc4fde56cc"
      unitRef="usd">-336000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icec2276dbd2e4d76878d45adc66f315e_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzctMTAtMS0xLTg0NDQ0_9b67f811-456a-497a-a822-7fc8c3e2ae7d"
      unitRef="usd">-13058000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i71c7679daebf4d0db0b277193d8ac50e_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzktMi0xLTEtODQ0NDQ_7ce15834-790b-4750-ab7e-f5d93aabb8d6"
      unitRef="usd">-1796000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i76d61a4fb2f4474181a28e27ff866f5d_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzktNC0xLTEtODQ0NDQ_6122157d-6d24-4979-a0bd-b6ddd27962ca"
      unitRef="usd">-24000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i1fd635367c6c4ca58981a78d2275f2cb_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzktNi0xLTEtODQ0NDQ_9389ea23-9779-4ed0-a2e4-be2a611f2f33"
      unitRef="usd">1805000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="i4d00a4d2722e40608c24963350b6de0a_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzktOC0xLTEtODQ0NDQ_00e1e7d4-95a3-4f9c-bdd0-4426c1614252"
      unitRef="usd">106000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="ifb64fb4e20f1404cbc6e31613ca7eef9_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzktMTAtMS0xLTg0NDQ0_9da12b8c-1619-4bae-8794-241c082c8f8b"
      unitRef="usd">91000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="icf4d10f59ddd4ab8bd56434bad43ae20_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEwLTItMS0xLTg0NDQ0_8738afe9-c28f-457a-a266-4e78aaa389d1"
      unitRef="usd">-11813000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i5800e1082b6146cea9073bcfbb7f02fd_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEwLTQtMS0xLTg0NDQ0_bd1b8735-142e-42f3-bad7-46dc272f9e30"
      unitRef="usd">-27000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i6e067c6346f74a20b1c0fe95515d8e9c_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEwLTYtMS0xLTg0NDQ0_06631886-0d21-4248-9388-42740ac2fdbf"
      unitRef="usd">-897000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="if4ddbcdadcf848e69b32b80c8a7d34f4_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEwLTgtMS0xLTg0NDQ0_fb188f46-5588-483d-bfeb-7cff5ef6e3c8"
      unitRef="usd">-230000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="ia8ed0029b3204669a3f2d23dad442d8e_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTYvZnJhZzo2YTU0MDAxYTIwYjg0MGE5OGNmNDM5M2Y4YzE1ZmYzZC90YWJsZTowZjVhZDAzMGNiYjM0YjMxOGI3ODVhY2U3NGI1NDc5Ny90YWJsZXJhbmdlOjBmNWFkMDMwY2JiMzRiMzE4Yjc4NWFjZTc0YjU0Nzk3XzEwLTEwLTEtMS04NDQ0NA_498cc8fc-de11-4225-97b1-20d0a830e399"
      unitRef="usd">-12967000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ForeignCurrencyDisclosureTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTkvZnJhZzowNjg5MTMxZTY5ZmQ0MTk3YTUzNTIxMGUwMGYxMTJmNC90ZXh0cmVnaW9uOjA2ODkxMzFlNjlmZDQxOTdhNTM1MjEwZTAwZjExMmY0XzE1MTg_00044bef-a82d-446f-84b6-d1341b0dfcf1">International Currency Translation&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For translation of its subsidiaries operating in non-U.S.&#160;Dollar currencies, the Company has determined that the local currencies of its international subsidiaries are the functional currencies except those in highly inflationary economies, which are defined as those which have had compound cumulative rates of inflation of 100% or more during the past three years, or where a substantial portion of its cash flows are not in the local currency. For the majority of the Company's subsidiaries the local currency is the functional currency. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In consolidating international subsidiaries, balance sheet currency effects are recorded as a component of accumulated other comprehensive income. The other current and non-current assets line within the Statement of Cash flows includes the impact of foreign currency translation. This equity account includes the results of translating certain balance sheet assets and liabilities at current exchange rates and some accounts at historical rates, except for those located in highly inflationary economies, (Argentina and Venezuela). Beginning in the fiscal second quarter of 2022, the Company also accounted for operations in Turkey as highly inflationary. The translation of balance sheet accounts for highly inflationary economies are reflected in the operating results.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A rollforward of the changes during fiscal years 2022, 2021 and 2020 for foreign currency translation adjustments is included in Note&#160;13. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net currency transaction gains and losses included in Other (income) expense were losses of $328 million, $236 million and $209 million in fiscal years 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyDisclosureTextBlock>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTkvZnJhZzowNjg5MTMxZTY5ZmQ0MTk3YTUzNTIxMGUwMGYxMTJmNC90ZXh0cmVnaW9uOjA2ODkxMzFlNjlmZDQxOTdhNTM1MjEwZTAwZjExMmY0XzE0NTc_a155dc93-d560-4e78-8bed-79c570b6e46a"
      unitRef="usd">-328000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTkvZnJhZzowNjg5MTMxZTY5ZmQ0MTk3YTUzNTIxMGUwMGYxMTJmNC90ZXh0cmVnaW9uOjA2ODkxMzFlNjlmZDQxOTdhNTM1MjEwZTAwZjExMmY0XzE0NjE_dcf5189c-11ee-41b1-ba91-a72529c44411"
      unitRef="usd">-236000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18xOTkvZnJhZzowNjg5MTMxZTY5ZmQ0MTk3YTUzNTIxMGUwMGYxMTJmNC90ZXh0cmVnaW9uOjA2ODkxMzFlNjlmZDQxOTdhNTM1MjEwZTAwZjExMmY0XzE0Njg_98c0ff48-bc7c-4f5c-95c5-7339f69cae79"
      unitRef="usd">-209000000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90ZXh0cmVnaW9uOjA5NGYyNjc5NzAxOTRiNGE5ZTNlYTNjNmIxYzFiNTgwXzExODI_f56d8c3f-4b9f-46f8-8ab8-c02a10c324f6">Earnings Per Share&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In Millions Except Per Share Amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding&#160;&#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,625.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted average shares outstanding&#160;&#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,663.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,670.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The diluted net earnings per share calculation for the fiscal years 2022 and 2021 included all shares related to stock options, as the exercise price of these options was less than the average market value of the Company's stock. &lt;/span&gt;&lt;/div&gt;The diluted net earnings per share calculation for fiscal year 2020 excluded 18 million shares related to stock options, as the exercise price of these options was greater than the average market value of the Company's stock.</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90ZXh0cmVnaW9uOjA5NGYyNjc5NzAxOTRiNGE5ZTNlYTNjNmIxYzFiNTgwXzExODQ_eb651b23-f055-44fe-ade2-27167ca212ad">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a reconciliation of basic net earnings per share to diluted net earnings per share for the fiscal years ended January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:58.490%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.637%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.640%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(In Millions Except Per Share Amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Basic net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.93&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Average shares outstanding&#160;&#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,625.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,632.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Potential shares exercisable under stock option plans&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;140.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;118.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: shares repurchased under treasury stock method&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(101.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(96.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Adjusted average shares outstanding&#160;&#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,663.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,674.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,670.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Diluted net earnings per share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.73&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.51&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:EarningsPerShareBasic
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzEtMi0xLTEtODQ0NDQ_4e536b8c-faf2-49ce-9709-969fdd59d4ae"
      unitRef="usdPerShare">6.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzEtNC0xLTEtODQ0NDQ_7bb2998e-ed2f-40a6-83a0-35faf1faa3d4"
      unitRef="usdPerShare">7.93</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzEtNi0xLTEtODQ0NDQ_2bb151d4-33e1-4512-babc-a6e81cda7062"
      unitRef="usdPerShare">5.59</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzItMi0xLTEtODQ0NDQ_ac37d4e3-53fc-498c-88ea-684d0a93876c"
      unitRef="shares">2625200000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzItNC0xLTEtODQ0NDQ_40576d52-970d-4fdf-a7cb-c95382347c47"
      unitRef="shares">2632100000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzItNi0xLTEtODQ0NDQ_19fb08bf-a159-47f1-9f6e-79449ff2db0f"
      unitRef="shares">2632800000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <jnj:PotentialSharesExercisableUnderStockOptionPlans
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzMtMi0xLTEtODQ0NDQ_ea67103c-5070-4751-8175-314e00178a6d"
      unitRef="shares">140100000</jnj:PotentialSharesExercisableUnderStockOptionPlans>
    <jnj:PotentialSharesExercisableUnderStockOptionPlans
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzMtNC0xLTEtODQ0NDQ_b0f3975f-cba2-41f8-b3ca-3f6ec9a4f161"
      unitRef="shares">138000000.0</jnj:PotentialSharesExercisableUnderStockOptionPlans>
    <jnj:PotentialSharesExercisableUnderStockOptionPlans
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzMtNi0xLTEtODQ0NDQ_749717a5-2c95-4618-91d7-8096bc913707"
      unitRef="shares">118300000</jnj:PotentialSharesExercisableUnderStockOptionPlans>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzQtMi0xLTEtODQ0NDQ_215cc636-a158-45fd-812e-80081b690a73"
      unitRef="shares">101400000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzQtNC0xLTEtODQ0NDQ_61af70a7-45e0-48a7-b9bd-4a790100d200"
      unitRef="shares">96100000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzQtNi0xLTEtODQ0NDQ_b8d3aaba-de18-469d-930b-3b4d485ffef4"
      unitRef="shares">80400000</jnj:SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzYtMi0xLTEtODQ0NDQ_241f081f-e948-4865-9858-e02b19d43d49"
      unitRef="shares">2663900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzYtNC0xLTEtODQ0NDQ_54825b19-492c-4987-ab15-62d568b9db71"
      unitRef="shares">2674000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzYtNi0xLTEtODQ0NDQ_f72b67f2-14b0-4d66-a23d-9e53b9ee35ba"
      unitRef="shares">2670700000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzctMi0xLTEtODQ0NDQ_b41fa438-ab51-4a43-b03b-f12842cab51c"
      unitRef="usdPerShare">6.73</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzctNC0xLTEtODQ0NDQ_dbcd3206-a584-410e-8fd5-921924d0ab32"
      unitRef="usdPerShare">7.81</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90YWJsZTo2YmQyZTVjY2NkZmY0NTkyODZhNzIyNWU3YTc2MjM3NC90YWJsZXJhbmdlOjZiZDJlNWNjY2RmZjQ1OTI4NmE3MjI1ZTdhNzYyMzc0XzctNi0xLTEtODQ0NDQ_0bb5b024-6345-427e-ba59-d8c93ca69c3b"
      unitRef="usdPerShare">5.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDIvZnJhZzowOTRmMjY3OTcwMTk0YjRhOWUzZWEzYzZiMWMxYjU4MC90ZXh0cmVnaW9uOjA5NGYyNjc5NzAxOTRiNGE5ZTNlYTNjNmIxYzFiNTgwXzUzMA_79a4c7a8-234f-42a8-b708-f8f393f974a0"
      unitRef="shares">18000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzYwMzc_2f21aba2-60b7-4cdd-8185-9e038a40c431">Common Stock, Stock Option Plans and Stock Compensation Agreements&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;At January&#160;1, 2023, the Company had one stock-based compensation plan. The shares outstanding are for contracts under the Company's 2012 Long-Term Incentive Plan and the 2022 Long-Term Incentive Plan. The 2012 Long-Term Incentive Plan expired on April 26, 2022. All awards (stock options, restricted shares units and performance share units) granted subsequent to that date were under the 2022 Long-Term Incentive Plan. Under the 2022 Long-Term Incentive Plan, the Company may issue up to 150&#160;million shares of common stock, of which up to 110&#160;million shares of common stock may be issued subject to stock options or stock appreciation rights and up to 40&#160;million shares of common stock may be issued subject to full value awards. Awards will generally be counted on a 1-for-1 basis against the share reserve, provided that if more than 40&#160;million full value awards are granted, each full value award in excess of 40&#160;million will be counted on a 5-for-1 basis against the share reserve. Shares available for future grants under the 2022 Long-Term Incentive Plan were 150 million at the end of fiscal year 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The compensation cost that has been charged against income for these plans was $1,138 million, $1,135 million and $1,005 million for fiscal years 2022, 2021 and 2020, respectively. The total income tax benefit recognized in the income statement for share-based compensation costs was $196 million, $218 million and $210 million for fiscal years 2022, 2021 and 2020, respectively. The Company also recognized additional income tax benefits of $282&#160;million, $223&#160;million and $248&#160;million for fiscal years 2022, 2021 and 2020, respectively, for which options were exercised or restricted shares were vested. The total unrecognized compensation cost was $939 million, $862 million and $804 million for fiscal years 2022, 2021 and 2020, respectively.  The weighted average period for this cost to be recognized was 1.80&#160;years, 1.78&#160;years and 1.76&#160;years for fiscal years 2022, 2021, and 2020, respectively. Share-based compensation costs capitalized as part of inventory were insignificant in all periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company settles employee benefit equity issuances with treasury shares. Treasury shares are replenished through market purchases throughout the year for the number of shares used to settle employee benefit equity issuances. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options expire 10&#160;years from the date of grant and vest over service periods that range from 6 months to 4 years.  All options are granted at the average of the high and low prices of the Company&#x2019;s Common Stock on the New York Stock Exchange on the date of grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of each option award was estimated on the date of grant using the Black-Scholes option valuation model that uses the assumptions noted in the following table. For 2022, 2021, and 2020 grants, expected volatility represents a blended rate of 10-year weekly historical overall volatility rate, and a 5-week average implied volatility rate based on at-the-money traded Johnson&#160;&amp;amp; Johnson options with a life of 2&#160;years. For all grants, historical data is used to determine the expected life of the option. The risk-free rate was based on the U.S.&#160;Treasury yield curve in effect at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average fair value of options granted was $23.23, $20.86 and $16.42, in fiscal years 2022, 2021 and 2020, respectively.  The fair value was estimated based on the weighted average assumptions of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of option activity under the Plan as of January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, and changes during the years ending on those dates is presented below:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Outstanding Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(Dollars in Millions) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;118,672&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;134.95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,949&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The total intrinsic value of options exercised was $1,228 million, $919 million and $1,021 million in fiscal years 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock options outstanding and exercisable at January&#160;1, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$72.54-$100.48&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$93.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$93.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$101.87-$115.67&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$108.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$108.78&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$129.51-$141.06&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$130.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$130.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$151.41-$164.62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$157.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$156.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$164.63-$165.89&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$165.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$165.89&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;118,672&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$134.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63,661&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$113.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Average contractual life remaining in years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:7pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options outstanding at January&#160;2, 2022 and January&#160;3, 2021 were 117,361 and an average life of 5.8 years and 114,250 and an average life of 6.0&#160;years, respectively. Stock options exercisable at January&#160;2, 2022 and January&#160;3, 2021 were 62,742 at an average price of $104.42 and 61,289 at an average price of $96.97, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:13pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Share Units and Performance Share Units&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The Company grants restricted share units which vest over service periods that range from 6 months to 3 years. The Company also grants performance share units, which are paid in shares of Johnson &amp;amp; Johnson Common Stock after the end of a three-year performance period. Performance shares were granted with two equally-weighted goals that directly align with or help drive long-term total shareholder return: adjusted operational earnings per share and relative total shareholder return. The number of shares actually earned at the end of the three-year period will vary, based only on actual performance, from 0% to 200% of the target number of performance share units granted&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:107%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the restricted share units and performance share units activity under the Plans as of January&#160;1, 2023 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Performance Share Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited/adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average fair value of the restricted share units granted was $153.67, $152.62 and $139.58 in fiscal years 2022, 2021 and 2020, respectively, using the fair market value at the date of grant. The fair value of restricted share units was discounted for dividends, which are not paid on the restricted share units during the vesting period. The fair value of restricted share units issued was $591 million, $611 million and $650 million in 2022, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average fair value of the performance share units granted was $170.46, $179.35 and $160.54 in fiscal years 2022, 2021 and 2020, calculated using the weighted average fair market value for each of the component goals at the date of grant.&#160; &lt;/span&gt;&lt;/div&gt;The fair values for the sales and earnings per share goals of each performance share unit were estimated on the date of grant using the fair market value of the shares at the time of the award discounted for dividends, which are not paid on the performance share units during the vesting period.&#160;The fair value for the relative total shareholder return goal of each performance share unit was estimated on the date of grant using the Monte Carlo valuation model.&#160;The fair value of performance share units issued was $94 million, $83 million and $91 million in fiscal years 2022, 2021 and 2020, respectively.</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <jnj:NumberOfStockBasedCompensationPlans
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzk2_87aeba63-70b7-480e-85b5-a88776562c03"
      unitRef="stockbasedcompensationplans">1</jnj:NumberOfStockBasedCompensationPlans>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i4a0e319fb645457cbe71977be1f29fdb_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzU0OTc1NTgyMzI4OA_c3338055-e699-4474-afc5-0949d64f636c"
      unitRef="shares">150000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights
      contextRef="i4a0e319fb645457cbe71977be1f29fdb_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzU0OTc1NTgyMzgwMg_3015beef-ae9a-438b-96b6-01ea192e02af"
      unitRef="shares">110000000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards
      contextRef="i4a0e319fb645457cbe71977be1f29fdb_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzU0OTc1NTgyMzgxNQ_6ee4045e-71a1-43ca-92a1-e6a3726f2055"
      unitRef="shares">40000000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards
      contextRef="i4a0e319fb645457cbe71977be1f29fdb_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzU0OTc1NTgyMzgyNw_7866b8af-795f-4c40-959d-66c0a32a2513"
      unitRef="shares">40000000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess
      contextRef="i4a0e319fb645457cbe71977be1f29fdb_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzU0OTc1NTgyMzgzOQ_e40005fc-76da-4613-918f-7464e0215e7b"
      unitRef="shares">40000000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i4a0e319fb645457cbe71977be1f29fdb_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzczNg_ba9f3780-8f75-4d7b-a262-c8cbb6b6fbac"
      unitRef="shares">150000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzg0OA_84ba1cfe-1ad3-434e-b682-afb017a73802"
      unitRef="usd">1138000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzg1Mg_26d2eda3-9456-4f09-99e1-c1585ae77ea5"
      unitRef="usd">1135000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzg1OQ_1e0fac7c-83a7-4c8e-ac47-85f0e884bbfb"
      unitRef="usd">1005000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzEwMTE_3bc68a22-321b-41a9-8602-900821bb4e12"
      unitRef="usd">196000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzEwMTU_4ca13973-ec45-440b-85d1-cf2b288d2737"
      unitRef="usd">218000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzEwMjI_edacefcf-751e-4592-acc9-8b0d84febf59"
      unitRef="usd">210000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzExMzM_a4c1773f-33f6-46b0-9cc6-6d911498daaf"
      unitRef="usd">282000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzExMzc_e13beef7-b55f-4388-bc23-4538a3b2567d"
      unitRef="usd">223000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzExNDQ_ba0cab5b-96ac-44b6-81ff-7fb1b670e3d9"
      unitRef="usd">248000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzEzMTE_de7219fd-4149-4912-b8e4-0fc928ecac32"
      unitRef="usd">939000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzEzMTU_b208b91f-27fe-48fe-bb9f-1f812cbebdcc"
      unitRef="usd">862000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzEzMjI_01592390-78e7-425b-a929-3bae987885b0"
      unitRef="usd">804000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzE0MzU_44613f99-33e4-49b2-bfca-4b6105aceca4">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzE0NDU_f5a7c330-1b84-4462-945c-0d20cdeda391">P1Y9M10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzE0NTg_0077ef56-fc12-4935-841b-3c3f30b002d6">P1Y9M3D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="i33dbc6eb904844ee90275f3f8b7ed3ab_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzE4Nzc_07d50dcf-1b06-4481-90dc-8896c92f0322">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i8ef74a38473e44019ba37eeec97c7385_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzE5NTU_7da6a409-13b5-43cc-a9bd-f682d8ec81dd">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i847f3b4e40ed4892b6cd1c9603a89184_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzE5NjE_a417d36e-d982-4529-91d6-ea6ee0e68148">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzYwNTI_6c61339c-8e84-4350-b3b8-7fe595ac47c5">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The average fair value of options granted was $23.23, $20.86 and $16.42, in fiscal years 2022, 2021 and 2020, respectively.  The fair value was estimated based on the weighted average assumptions of:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.152%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:56.819%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.409%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.576%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.411%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Risk-free rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.98&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.47&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.00&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.33&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected life (in years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.0&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.70&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.50&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzI3NzM_a891d4d2-cb18-4bae-a97b-625ba50c3598"
      unitRef="usdPerShare">23.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzI3Nzc_a7f06c1a-8cda-44bf-898f-8436dcf7c163"
      unitRef="usdPerShare">20.86</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzI3ODQ_d2fe85e9-9c1f-446d-a79f-dbb154a6094a"
      unitRef="usdPerShare">16.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzEtMS0xLTEtODQ0NDQ_89f28300-8865-4a2f-b0a1-5d09a71663e1"
      unitRef="number">0.0198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzEtMy0xLTEtODQ0NDQ_76cf1fac-d55c-4c5a-b268-969bd3d6aafb"
      unitRef="number">0.0083</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzEtNS0xLTEtODQ0NDQ_0bfc741c-c3a6-4c5e-86cb-eaf09cf21c1a"
      unitRef="number">0.0147</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzItMS0xLTEtODQ0NDQ_18abb125-9c14-4404-8085-791f4620b130"
      unitRef="number">0.1800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzItMy0xLTEtODQ0NDQ_d06a2da0-7862-4133-9596-f916c4bae56f"
      unitRef="number">0.1859</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzItNS0xLTEtODQ0NDQ_43b16a54-6f16-4d3c-8926-9432301fac4c"
      unitRef="number">0.1533</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzMtMS0xLTEtODQ0NDQ_ae4e84ac-9d22-4835-a593-21718f511e8f">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzMtMy0xLTEtODQ0NDQ_6a688712-12dd-4c91-beef-cd5bfb7ccae8">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzMtNS0xLTEtODQ0NDQ_9993da22-2a9d-431d-8e31-efe9a1d5621a">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzQtMS0xLTEtODQ0NDQ_8ea7c69c-efe9-4c67-a5fe-60d80ef7695b"
      unitRef="number">0.0270</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzQtMy0xLTEtODQ0NDQ_6222c96a-6bdd-4a8a-9e76-97e56bdb96b3"
      unitRef="number">0.0250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZToyMTBkNDI5ZTIyZGM0MGY2ODE3NTg5ZjFiMTAwMjgzMy90YWJsZXJhbmdlOjIxMGQ0MjllMjJkYzQwZjY4MTc1ODlmMWIxMDAyODMzXzQtNS0xLTEtODQ0NDQ_d6740b70-3726-48bf-9a42-634c0200bec3"
      unitRef="number">0.0260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzYwNTU_eb16a124-ee68-482d-90a4-c9b3777009a1">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of option activity under the Plan as of January&#160;1, 2023, January&#160;2, 2022 and January&#160;3, 2021, and changes during the years ending on those dates is presented below:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:92.690%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:47.322%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.672%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.588%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:16.570%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Outstanding Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted&lt;br/&gt;Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;br/&gt;(Dollars in Millions) &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at December 29, 2019&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;111,637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;105.63&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,275)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;86.05&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 3, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;116.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,703&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,525&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;164.62&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13,248)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.48&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;149.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;117,361&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;125.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,364&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,809&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;165.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16,310)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Options canceled/forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2,188)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;160.56&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;118,672&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;134.95&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,949&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEtMi0xLTEtODQ0NDQ_6a80bb3c-3ffe-46fc-82f2-33c3024bb786"
      unitRef="shares">111637000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEtNC0xLTEtODQ0NDQ_4fb26731-23ee-44f1-8117-a620c6b0180a"
      unitRef="usdPerShare">105.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ic330177c89fd42f9a9a64f7236279ef9_I20191229"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEtNi0xLTEtODQ0NDQ_db9c2102-09f1-4169-a02d-1986b5277f92"
      unitRef="usd">4478000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzItMi0xLTEtODQ0NDQ_35eb7cad-53b0-4db8-9d68-12c0f259e92f"
      unitRef="shares">20723000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzItNC0xLTEtODQ0NDQ_6e855043-ec09-4828-9411-a5e7a6d01d93"
      unitRef="usdPerShare">151.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzMtMi0xLTEtODQ0NDQ_8b4596cd-40ac-4a79-b2e0-ba0665072374"
      unitRef="shares">16275000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzMtNC0xLTEtODQ0NDQ_52e57a84-d22e-4373-b4bb-cb7488aa0e1c"
      unitRef="usdPerShare">86.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzQtMi0xLTEtODQ0NDQ_348a5dcb-4452-468e-b36d-5495191970a6"
      unitRef="shares">1835000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzQtNC0xLTEtODQ0NDQ_00d6618f-7f32-4934-9ed0-de521438ac63"
      unitRef="usdPerShare">137.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzUtMi0xLTEtODQ0NDQ_7d4fcec3-892a-4991-9916-6f0b949d5e86"
      unitRef="shares">114250000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzUtNC0xLTEtODQ0NDQ_da9849e8-98b1-4738-b1b0-c6ddc923901d"
      unitRef="usdPerShare">116.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzUtNi0xLTEtODQ0NDQ_f2e03809-161a-463e-9b70-3d931015bb98"
      unitRef="usd">4703000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzYtMi0xLTEtODQ0NDQ_9196606e-b327-40b4-998f-f6db351cb85e"
      unitRef="shares">18525000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzYtNC0xLTEtODQ0NDQ_aa875bcb-bc7a-4007-a038-006e09578147"
      unitRef="usdPerShare">164.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzctMi0xLTEtODQ0NDQ_f55ef7b7-de0f-4aec-a366-7d77d7974b30"
      unitRef="shares">13248000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzctNC0xLTEtODQ0NDQ_7008a009-b9b2-468c-877c-9875fde72138"
      unitRef="usdPerShare">97.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzgtMi0xLTEtODQ0NDQ_c02947f6-84b8-45de-bbc3-689450deaaa4"
      unitRef="shares">2166000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzgtNC0xLTEtODQ0NDQ_351d5c19-2854-459b-83bd-e29cbbb5164d"
      unitRef="usdPerShare">149.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzktMi0xLTEtODQ0NDQ_7adc014b-498d-495e-91f9-dd9b5fa3a05b"
      unitRef="shares">117361000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzktNC0xLTEtODQ0NDQ_dde023aa-0334-4ba9-9e54-f9fe6aa4d727"
      unitRef="usdPerShare">125.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzktNi0xLTEtODQ0NDQ_f23dd7c2-7543-4a85-8601-59380293da2e"
      unitRef="usd">5364000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEwLTItMS0xLTg0NDQ0_2daca3db-bac1-44a8-acc9-d6daf4534888"
      unitRef="shares">19809000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEwLTQtMS0xLTg0NDQ0_da56fa10-156a-4a46-9312-d8e34ba246cb"
      unitRef="usdPerShare">165.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzExLTItMS0xLTg0NDQ0_9442366d-51a3-4c99-992d-537cb1571e17"
      unitRef="shares">16310000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzExLTQtMS0xLTg0NDQ0_f3d875ab-fdff-45df-bd32-fb8b9c36fc2f"
      unitRef="usdPerShare">100.15</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEyLTItMS0xLTg0NDQ0_9733e1e7-19f1-4f3a-a2ac-7a149f1f0793"
      unitRef="shares">2188000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEyLTQtMS0xLTg0NDQ0_8f74c00e-1848-4dc5-ba5f-8ff1e218648f"
      unitRef="usdPerShare">160.56</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEzLTItMS0xLTg0NDQ0_5b2b5743-f6c0-4784-8548-b39db0ca89c4"
      unitRef="shares">118672000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEzLTQtMS0xLTg0NDQ0_ed0d89f0-9853-48b5-806d-d69910f2d9d9"
      unitRef="usdPerShare">134.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1MTg5ZTYwNTFmZWY0ZmQ2YjdiZDQ5ODA3MTg1NjI3Yi90YWJsZXJhbmdlOjUxODllNjA1MWZlZjRmZDZiN2JkNDk4MDcxODU2MjdiXzEzLTYtMS0xLTg0NDQ0_25673495-9e82-4829-a602-47affa3a8cf3"
      unitRef="usd">4949000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzMxMDA_0f43d1f4-ed6c-4a5f-8002-f35fde716e13"
      unitRef="usd">1228000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzMxMDQ_746fbe1b-faae-4e53-bf33-13a2b1b8826b"
      unitRef="usd">919000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzMxMTE_92d54ce2-aebc-4c31-a31e-c87117fb77a1"
      unitRef="usd">1021000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzYwNjA_55d6a1e9-b5a5-4b60-a06d-5f504d342aa5">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes stock options outstanding and exercisable at January&#160;1, 2023:&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.298%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:29.132%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.163%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.628%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.217%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.575%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.168%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Exercisable&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Exercise Price Range&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Average Life&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Weighted Average Exercise Price&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$72.54-$100.48&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$93.07&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$93.07&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$101.87-$115.67&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$108.78&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$108.78&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$129.51-$141.06&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$130.88&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$130.85&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$151.41-$164.62&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,465&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$157.75&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$156.21&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$164.63-$165.89&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,077&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$165.89&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$165.89&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;118,672&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;5.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$134.95&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;63,661&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-bottom:3pt double #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$113.06&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Average contractual life remaining in years.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i14d568c675ed410f94bed5ff0929c46a_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo0YjZiNzExZDc0OTc0Mjg0YTJkYTU5MDAxYjYxOWFhZl81_e9d6ad9d-3f7f-4d77-a257-5e76074c26e3"
      unitRef="usdPerShare">72.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i14d568c675ed410f94bed5ff0929c46a_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzItMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjo0YjZiNzExZDc0OTc0Mjg0YTJkYTU5MDAxYjYxOWFhZl85_d0c0ccc9-c164-4402-9bb7-17fca80440ff"
      unitRef="usdPerShare">100.48</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i1a71324ab9d241068eb20d3f9cd41ba3_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzItMi0xLTEtODQ0NDQ_d644cc65-8b09-4d00-84ce-2c97242ceeea"
      unitRef="shares">17221000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i14d568c675ed410f94bed5ff0929c46a_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzItNC0xLTEtODQ0NDQ_75d27d1f-421a-4618-b242-4956ee014c10">P1Y6M</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i1a71324ab9d241068eb20d3f9cd41ba3_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzItNi0xLTEtODQ0NDQ_088700f0-45df-4d9e-a8b1-90486187fe72"
      unitRef="usdPerShare">93.07</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i1a71324ab9d241068eb20d3f9cd41ba3_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzItOC0xLTEtODQ0NDQ_39fd4c40-9c77-404a-b16e-7e50d05b8dca"
      unitRef="shares">17221000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i1a71324ab9d241068eb20d3f9cd41ba3_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzItMTAtMS0xLTg0NDQ0_aed5bd22-c2da-4b3d-b878-bd04f8f28db7"
      unitRef="usdPerShare">93.07</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="iad9b5fbc5ef141b588c3ee79455a9741_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzMtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjozZjQ0MGNhOTQ0MDg0NjA0OGYxYjc5YmJkYzhhMWJjN181_c7b171dc-536d-4af2-b2fb-38913e719685"
      unitRef="usdPerShare">101.87</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="iad9b5fbc5ef141b588c3ee79455a9741_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzMtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjozZjQ0MGNhOTQ0MDg0NjA0OGYxYjc5YmJkYzhhMWJjN185_720a495d-6a09-40c8-a61d-e49b6b2df7e3"
      unitRef="usdPerShare">115.67</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i07803580a3e146b98a24a385beff349a_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzMtMi0xLTEtODQ0NDQ_0dc2d6fd-822f-434d-bd8e-f044e5bfacb6"
      unitRef="shares">22039000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="iad9b5fbc5ef141b588c3ee79455a9741_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzMtNC0xLTEtODQ0NDQ_518385b5-acad-466b-9e04-981cfb7d3882">P3Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i07803580a3e146b98a24a385beff349a_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzMtNi0xLTEtODQ0NDQ_84d23636-d2b3-4e6e-8958-4d40240e48fa"
      unitRef="usdPerShare">108.78</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i07803580a3e146b98a24a385beff349a_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzMtOC0xLTEtODQ0NDQ_99574068-5b90-492d-a10f-1fbe7238197a"
      unitRef="shares">22039000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i07803580a3e146b98a24a385beff349a_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzMtMTAtMS0xLTg0NDQ0_2a5d3630-181a-4d1c-be1b-60d8ba408e63"
      unitRef="usdPerShare">108.78</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i34afa7b8b8a04ccb830c793de735eb10_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzQtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjowY2VhODJjNTRiYzE0MWQ4YmQzYWViMmEwZThkNmNlYV81_39c1f36e-5244-4187-b6a0-fd06f0a1b48a"
      unitRef="usdPerShare">129.51</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i34afa7b8b8a04ccb830c793de735eb10_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzQtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjowY2VhODJjNTRiYzE0MWQ4YmQzYWViMmEwZThkNmNlYV85_cc47d449-47b9-4618-b18a-af684cac84ca"
      unitRef="usdPerShare">141.06</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i1b1e92a43acd42e993eb03a79e248489_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzQtMi0xLTEtODQ0NDQ_7bdc8977-7a4d-4588-bce9-26deea76b5e1"
      unitRef="shares">24870000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i34afa7b8b8a04ccb830c793de735eb10_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzQtNC0xLTEtODQ0NDQ_371f7608-5ca2-4877-bdaf-924b7001ad6c">P5Y8M12D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i1b1e92a43acd42e993eb03a79e248489_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzQtNi0xLTEtODQ0NDQ_5153c216-3850-446a-99f9-1d4b258b29d8"
      unitRef="usdPerShare">130.88</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i1b1e92a43acd42e993eb03a79e248489_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzQtOC0xLTEtODQ0NDQ_72f524d9-f36c-439e-a6bd-f2a219f564d6"
      unitRef="shares">24228000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i1b1e92a43acd42e993eb03a79e248489_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzQtMTAtMS0xLTg0NDQ0_a3452764-cd47-4e38-b7b3-44d673ac43fe"
      unitRef="usdPerShare">130.85</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i215808acd76647669f725a762f3598d8_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzUtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjpmNDBlOTc3ZWY3YTc0MDQ3YTBjMTY3OGRjNzg5NjZmOF81_9538f3c7-a6d6-4bb1-84e7-c6fb51ae3304"
      unitRef="usdPerShare">151.41</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i215808acd76647669f725a762f3598d8_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzUtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjpmNDBlOTc3ZWY3YTc0MDQ3YTBjMTY3OGRjNzg5NjZmOF85_a430832c-5280-435a-9d69-e3f60504d008"
      unitRef="usdPerShare">164.62</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i354df684ca7745c6aa4c8a3b46276a9b_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzUtMi0xLTEtODQ0NDQ_2b55c592-eaef-413a-8d7b-ef280994930a"
      unitRef="shares">35465000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i215808acd76647669f725a762f3598d8_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzUtNC0xLTEtODQ0NDQ_c7e56f0a-53d3-4216-880e-e793a6abdbd1">P7Y7M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i354df684ca7745c6aa4c8a3b46276a9b_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzUtNi0xLTEtODQ0NDQ_c46bff0b-73be-47ea-b648-899ab97535c8"
      unitRef="usdPerShare">157.75</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i354df684ca7745c6aa4c8a3b46276a9b_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzUtOC0xLTEtODQ0NDQ_4eae8ff0-7e39-4745-9839-9e3aec9af1c9"
      unitRef="shares">150000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i354df684ca7745c6aa4c8a3b46276a9b_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzUtMTAtMS0xLTg0NDQ0_667295c3-025f-4193-8a6d-965f94e1c350"
      unitRef="usdPerShare">156.21</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="i4c10dbb3a1594a2d8da6daba7890426e_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzYtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjowNDI4MWI1YWRmZGQ0M2I3OWE2MTVjMWE4Y2MyMzQ5M181_cd5048eb-31bd-4c6c-a356-fe3130695b93"
      unitRef="usdPerShare">164.63</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="i4c10dbb3a1594a2d8da6daba7890426e_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzYtMC0xLTEtODQ0NDQvdGV4dHJlZ2lvbjowNDI4MWI1YWRmZGQ0M2I3OWE2MTVjMWE4Y2MyMzQ5M185_da30de7b-898f-4d02-8ae1-0798dda183dd"
      unitRef="usdPerShare">165.89</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="idf5256f81d8e4f98b3cca09bfe121aef_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzYtMi0xLTEtODQ0NDQ_5020bc68-2337-4c71-9a51-8271498e8f93"
      unitRef="shares">19077000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i4c10dbb3a1594a2d8da6daba7890426e_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzYtNC0xLTEtODQ0NDQ_d0fe8b5d-6664-4d03-924d-1e488f223a5d">P9Y1M6D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="idf5256f81d8e4f98b3cca09bfe121aef_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzYtNi0xLTEtODQ0NDQ_f113e5f2-b01c-415a-a04b-1d4c26da1473"
      unitRef="usdPerShare">165.89</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="idf5256f81d8e4f98b3cca09bfe121aef_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzYtOC0xLTEtODQ0NDQ_4a2f38a7-6a75-4bf0-926b-69606f0ce6ee"
      unitRef="shares">23000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="idf5256f81d8e4f98b3cca09bfe121aef_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzYtMTAtMS0xLTg0NDQ0_c51e2d2c-477c-4c78-a94d-58c763d20552"
      unitRef="usdPerShare">165.89</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzctMi0xLTEtODQ0NDQ_72eb277a-21d1-41ac-a203-f66312e144bc"
      unitRef="shares">118672000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzctNC0xLTEtODQ0NDQ_9ca0a8c8-abcc-4f6b-9d92-25bcff8a994a">P5Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzctNi0xLTEtODQ0NDQ_71fe86e4-ee6b-43bc-8583-87a349011769"
      unitRef="usdPerShare">134.95</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzctOC0xLTEtODQ0NDQ_5e61ab88-df33-468a-a0b8-bc0512c5c561"
      unitRef="shares">63661000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTpkZjVmMTJlZTNiMGE0OGI3ODc2MWVkZjcxMTMzY2ZlMy90YWJsZXJhbmdlOmRmNWYxMmVlM2IwYTQ4Yjc4NzYxZWRmNzExMzNjZmUzXzctMTAtMS0xLTg0NDQ0_8f3ac40f-5b50-4dc4-ae5f-c35da5eb121f"
      unitRef="usdPerShare">113.06</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzMzMzY_14d19325-9ed2-4d2e-b3ee-2007f00d5623"
      unitRef="shares">117361000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzMzNjI_97a3bdd6-64c0-4eab-8675-4d67d35850fe">P5Y9M18D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzMzNzU_26f737eb-4a12-485a-b87a-c9d7f8e01deb"
      unitRef="shares">114250000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
    <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzM0MDE_7d88842a-6496-442e-91fc-c0bbd70f07fc">P6Y</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzM0Njk_bf653133-fa8f-4cbd-aca9-361bc807dbd2"
      unitRef="shares">62742000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzM0OTU_37c37134-9cc6-4a93-95ab-f2e4db656f00"
      unitRef="usdPerShare">104.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzM1MDI_59a0d134-201c-46af-bfdf-db64f1749519"
      unitRef="shares">61289000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzM1Mjg_19c07c21-3531-4aa7-9205-631023bcdb6a"
      unitRef="usdPerShare">96.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ife13ff98e4674d7694f59286307e1d2d_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzM2ODg_4bee08f0-83e8-4358-adc3-9b49c4ff1ade">P6M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="i3bc3aa29768f417584ae7a6a6eda8f3f_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzM2OTQ_bf5d98e1-445f-49aa-97f6-0afe6f322127">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie2cad4d651314028b720522ec64631ba_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzYwMzk_5e156df5-82bc-496f-8d2b-5c043fa0c366">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="ie2cad4d651314028b720522ec64631ba_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzYwMzU_3ea33c25-79f8-4750-b6a8-6434268c3a24">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="ifb399cca07bf4bf1a81d45b257cf9c08_D20220103-20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzQ2MTA_7630b589-27da-4a90-80fa-396870e8208b"
      unitRef="number">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i71da035cf1914f3b9868aecc174233de_D20220103-20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzQ2MTY_ed34259b-8437-4aa9-a357-d577fcc24d5f"
      unitRef="number">2</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzYwMzA_c3ba136d-e442-4550-8458-41c719742d43">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the restricted share units and performance share units activity under the Plans as of January&#160;1, 2023 is presented below:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.058%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:55.231%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.611%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:17.081%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:3.445%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:19.032%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Shares in Thousands)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Restricted Share Units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding Performance Share Units&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 2, 2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,122&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;753&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4,866)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Canceled/forfeited/adjusted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(794)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(71)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Shares at January 1, 2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,616&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i6bc0d59a1f134f84a89b363a070d1183_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzktMi0xLTEtODQ0NDQ_bf926f7c-a410-4e23-b4f0-7ee4ed522fd2"
      unitRef="shares">14122000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iec99756e458a459cb8bef3fdab17c001_I20220102"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzktNC0xLTEtODQ0NDQ_9091b28a-1d9a-4c12-af34-f4c0ab078716"
      unitRef="shares">2312000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ib1ec1e614eeb4b98a73fb86f9046cd7d_D20220103-20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzEwLTItMS0xLTg0NDQ0_0c3a2aee-e34d-47d1-8334-bfc94201ee95"
      unitRef="shares">5154000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ie2cad4d651314028b720522ec64631ba_D20220103-20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzEwLTQtMS0xLTg0NDQ0_3982665a-a380-4a10-887e-489f4740f768"
      unitRef="shares">753000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ib1ec1e614eeb4b98a73fb86f9046cd7d_D20220103-20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzExLTItMS0xLTg0NDQ0_35fad04f-af0e-416a-8e2a-07cafde36123"
      unitRef="shares">4866000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="ie2cad4d651314028b720522ec64631ba_D20220103-20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzExLTQtMS0xLTg0NDQ0_1f6ad5d8-55d6-414f-bacb-6d985a7ee755"
      unitRef="shares">637000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod
      contextRef="ib1ec1e614eeb4b98a73fb86f9046cd7d_D20220103-20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzEyLTItMS0xLTg0NDQ0_d6703de9-f989-4b93-b6f9-70b33c765e4d"
      unitRef="shares">794000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod
      contextRef="ie2cad4d651314028b720522ec64631ba_D20220103-20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzEyLTQtMS0xLTg0NDQ0_916302fe-1262-4b84-8b4e-c3b57885dc21"
      unitRef="shares">-71000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="iab9745c050214279b0fa340682e40433_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzEzLTItMS0xLTg0NDQ0_1d8f4745-3c53-42e2-ad03-28c94c849b97"
      unitRef="shares">13616000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i69db6ec00d174b129e0e5cb215633ec0_I20230101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90YWJsZTo1YjM2NTIzYTYzMWQ0NDdiODhlYTU4MDk4Zjc3ZDBmMS90YWJsZXJhbmdlOjViMzY1MjNhNjMxZDQ0N2I4OGVhNTgwOThmNzdkMGYxXzEzLTQtMS0xLTg0NDQ0_562ef4a6-5e67-4d27-95b1-d6e76cda1c4c"
      unitRef="shares">2357000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ib1ec1e614eeb4b98a73fb86f9046cd7d_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzQ4Njc_0ea79a1f-a61f-472a-9721-d5ef45aadc99"
      unitRef="usdPerShare">153.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ibf40cc2fafb74f6c9d2be93eeff661c6_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzQ4NzE_ccc6982a-b5bf-474e-99d3-051d475e901f"
      unitRef="usdPerShare">152.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="iec1fd52e3482447ea1b11486ef26a9be_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzQ4Nzg_34b6bcd3-16c8-4041-a91b-0fc158b49ec2"
      unitRef="usdPerShare">139.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ib1ec1e614eeb4b98a73fb86f9046cd7d_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzUxNzU_36700c93-6a9d-434b-aea7-fbd901e93659"
      unitRef="usd">591000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ibf40cc2fafb74f6c9d2be93eeff661c6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzUxNzk_44e87d8d-e147-42f8-8acc-9873a5843c2e"
      unitRef="usd">611000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="iec1fd52e3482447ea1b11486ef26a9be_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzUxODY_c182ffd0-71a1-4822-9c50-669c40ea5ed9"
      unitRef="usd">650000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ie2cad4d651314028b720522ec64631ba_D20220103-20230101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzUyOTY_e5836cce-df5f-4406-9138-eb54d536244b"
      unitRef="usdPerShare">170.46</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i2198f462491444aca0da61923b632a27_D20210104-20220102"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzUzMDA_6076a895-db6e-485a-864e-36dc66cbd441"
      unitRef="usdPerShare">179.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i6ce09bf2900145f1a937004d1c00046f_D20191230-20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzUzMDc_c5d6c04e-9585-4cf9-9eb2-1f5a8b839c0f"
      unitRef="usdPerShare">160.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="ie2cad4d651314028b720522ec64631ba_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzU5Njk_a70dd030-fbac-4686-99d3-3632905dff84"
      unitRef="usd">94000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i2198f462491444aca0da61923b632a27_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzU5NzM_98ff4035-83cf-4ae5-9e30-d3d4cf9ffe54"
      unitRef="usd">83000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="i6ce09bf2900145f1a937004d1c00046f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMDgvZnJhZzplNTFhMWU0MDAwZTk0MWZlODM5N2YxMTA2YzQ4NGU3Zi90ZXh0cmVnaW9uOmU1MWExZTQwMDBlOTQxZmU4Mzk3ZjExMDZjNDg0ZTdmXzU5ODA_bbd98027-4105-4649-8bd4-a85e42381460"
      unitRef="usd">91000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzMyMjM_2a1bbaba-a801-460a-8126-ed52b985d596">Segments of Business* and Geographic Areas&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2019;22 vs. &#x2019;21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2019;21 vs. &#x2019;20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;CONSUMER HEALTH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women's Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:189pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;REMICADE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;COVID-19 VACCINE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA / PREZCOBIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; /                                              &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; REZOLSTA / SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;RISPERDAL CONSTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;* *&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;/&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVOKANA/ INVOKAMET&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:113pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;MEDTECH*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDTECH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Certain prior year amounts have been reclassified to conform to current year presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;**Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Approximately $0.4&#160;billion in both the fiscal 2021 and 2020, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inclusive of  PROCRIT / EPREX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;which was previously disclosed separately&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pr&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;eviously referred to as Medical Devices&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income (Loss) Before Tax*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Consumer Health separation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,725&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,776&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;187,378&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;182,018&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*Income before tax of approximately $0.2&#160;billion and $0.2&#160;billion in the fiscal years 2021 and 2020, respectively, has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions to Property,&lt;br/&gt;Plant &amp;amp; Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Depreciation and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segments total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,970&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,390&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,231&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-Lived Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere excluding U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segments total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;94,943&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;93,775&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;82,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;187,378&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;182,018&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note&#160;1 for a description of the segments in which the Company operates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Export sales are not significant. In fiscal year 2022, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.5%, 13.0% and 12.0% of the total consolidated revenues. In fiscal year 2021, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0%, and 12.0% of the total consolidated revenues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;General corporate includes cash, cash equivalents and marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.2&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.44pt"&gt;One-time COVID-19 Vaccine manufacturing exit related costs of $1.5&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;An intangible asset impairment charge of approximately $0.8&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Litigation expense of $0.1&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Loss of $0.7&#160;billion related to the change in the fair value of securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.1&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MedTech includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Litigation expense of $0.6&#160;billion primarily for pelvic mesh related costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Acquisition and integration related costs of $0.3&#160;billion primarily related to the acquisition of Abiomed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A Medical Device Regulation charge of $0.3&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $1.6&#160;billion, primarily talc related costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.6&#160;billion, primarily related to Risperdal Gynecomastia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Divestiture gains of $0.6&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Gains of  $0.5&#160;billion related to the change in the fair value of securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MedTech includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An in-process research and development expense of $0.9&#160;billion related to Ottava&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A Medical Device Regulation charge of $0.2&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.1&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;        &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $3.9&#160;billion, primarily talc related costs and certain settlements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.8&#160;billion, primarily related to the agreement in principle to settle opioid litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A gain of $0.5&#160;billion related to the change in the fair value of securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MedTech includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A contingent consideration reversal of $1.1&#160;billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An in-process research and development expense of $0.2&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A Medical Device Regulation charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Long-lived assets include property, plant and equipment, net for fiscal years 2022, and 2021 of $19,803 and $18,962, respectively, and intangible assets and goodwill, net for fiscal years 2022 and 2021 of $93,556 and $81,638, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <jnj:SalesBySegmentOfBusinessTableTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzMyMzc_38a642dc-e217-4226-9862-adaeb09ecba1">&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;% Change&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2019;22 vs. &#x2019;21&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#x2019;21 vs. &#x2019;20&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:5pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;CONSUMER HEALTH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;OTC&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,034&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,031&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,627&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,221&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Skin Health/Beauty&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,400&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,350&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,100&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,352&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,541&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oral Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;635&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;637&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,505&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Baby Care&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;357&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,188&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,566&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,517&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Women's Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;888&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;904&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Wound Care/Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;475&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;224&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;739&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;720&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL CONSUMER HEALTH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,516&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,354&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,519&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:189pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;PHARMACEUTICAL&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Immunology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,907&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,880&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,055&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;REMICADE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S. Exports&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(31.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;722&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,343&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SIMPONI / SIMPONI ARIA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,166&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,155&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,017&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,276&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,243&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;STELARA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,240&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,467&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,707&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TREMFYA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,503&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;926&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;421&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,668&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,127&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER IMMUNOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(73.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Infectious Diseases&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;29.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,769&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,576&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,808&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;COVID-19 VACCINE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(81.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,059&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,179&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,385&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;EDURANT / rilpivirine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;972&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;920&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-13.5pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;PREZISTA / PREZCOBIX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt; /                                              &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt; REZOLSTA / SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,494&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(21.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,083&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,184&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER INFECTIOUS DISEASES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(55.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(36.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;292&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Neuroscience&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,570&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,641&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,435&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,893&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,988&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,526&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONCERTA / methylphenidate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;172&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;493&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;495&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;439&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;644&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:13.5pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVEGA SUSTENNA / XEPLION / INVEGA TRINZA / TREVICTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,550&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,426&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,472&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,339&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,653&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;RISPERDAL CONSTA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;296&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(10.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;228&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;305&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;485&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;592&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(18.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER NEUROSCIENCE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;447&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;338&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,312&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(14.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,623&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Oncology&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,548&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,367&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;DARZALEX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,854&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,958&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,977&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;32.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ERLEADA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;968&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;813&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;583&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39.3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;* *&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,881&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;IMBRUVICA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,390&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,747&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,307&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,369&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,128&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ZYTIGA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;/&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;abiraterone acetate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(68.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,696&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,178&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,770&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,297&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,470&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER ONCOLOGY&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 13pt 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;**&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;458&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(38.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(30.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Pulmonary Hypertension&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,346&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,365&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,071&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,417&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,450&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,148&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OPSUMIT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,132&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;672&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;631&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,639&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;&#160;UPTRAVI&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,056&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;955&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;138&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,237&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,093&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;110&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;163&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(32.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(3.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;202&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;395&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;416&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cardiovascular / Metabolism / Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,509&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;845&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;927&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(8.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,887&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,534&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;XARELTO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,473&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,345&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;INVOKANA/ INVOKAMET&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;193&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;308&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;564&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(45.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;255&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;254&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;795&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(29.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;OTHER&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;446&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;600&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(25.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;590&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;673&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;794&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(15.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,119&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(19.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL PHARMACEUTICAL&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,604&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,735&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,726&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;45,175&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr style="height:113pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;MEDTECH*&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Interventional Solutions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,836&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,452&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,131&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,971&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,046&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Orthopaedics&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,321&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,126&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,267&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,984&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,588&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,763&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;HIPS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;878&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;571&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;602&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;487&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,514&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,480&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,280&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;KNEES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;851&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;787&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;508&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;538&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(5.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,359&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,325&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,170&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;TRAUMA&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,648&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,871&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,885&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SPINE, SPORTS &amp;amp; OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,642&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,595&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,104&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,699&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Surgery&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,867&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,793&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,983&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;ADVANCED&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,535&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,861&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,304&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,569&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,622&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;GENERAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,105&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,714&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,008&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,085&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,679&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.5)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,857&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,859&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,831&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,849&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,919&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;CONTACT LENSES / OTHER&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,522&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,213&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,022&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,043&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,781&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,543&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,440&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,994&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.614%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:34.374%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.285%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.979%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.564%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.290%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;&#160;&#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline"&gt;SURGICAL&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;468&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;459&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;344&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;837&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;788&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;581&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;TOTAL MEDTECH&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,377&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,686&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,050&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,427&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,060&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,959&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:9pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;WORLDWIDE&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;International&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,363&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,619&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,451&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;Worldwide  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;*Certain prior year amounts have been reclassified to conform to current year presentation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;**Percentage greater than 100% or not meaningful&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Approximately $0.4&#160;billion in both the fiscal 2021 and 2020, of certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Inclusive of  PROCRIT / EPREX&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;which was previously disclosed separately&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; (3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pr&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;eviously referred to as Medical Devices&lt;/span&gt;&lt;/div&gt;</jnj:SalesBySegmentOfBusinessTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9f84b91d4aae4af0a05f5090f62c6609_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUtMi0xLTEtODQ0NDQ_c799dec2-f446-4b32-82fb-8b250f6126aa"
      unitRef="usd">2782000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i58914e95bbb84bc5a9ea2cb7385bd869_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUtNC0xLTEtODQ0NDQ_f4c0a499-897f-4be3-9b08-48a477a3024e"
      unitRef="usd">2594000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8a784927c1c4189af0712f9727df3f0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUtNi0xLTEtODQ0NDQ_a43ed9d4-1511-43c6-bc41-268b35af2d5b"
      unitRef="usd">2460000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9f84b91d4aae4af0a05f5090f62c6609_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUtOC0xLTEtODQ0NDQ_da3fb9bc-aa5c-4525-adc3-2d0f4bd634cb"
      unitRef="number">0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i58914e95bbb84bc5a9ea2cb7385bd869_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUtMTAtMS0xLTg0NDQ0_b8550b55-7d48-412c-91c9-553b6a55d0a8"
      unitRef="number">0.054</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id4e29289044343a48f06844e7131ac18_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYtMi0xLTEtODQ0NDQ_bb4864bf-d7a1-47b2-bce8-56c9dc500a20"
      unitRef="usd">3249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3ee2aa1541c4993ab5a6731b5086c7d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYtNC0xLTEtODQ0NDQ_d46c0e62-bdbc-4d09-816a-8ac82e660f4c"
      unitRef="usd">3034000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id2433209091f4b3d9ccc6502e13af23d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYtNi0xLTEtODQ0NDQ_182d8a10-3920-4349-9bcc-b1cbf65602d6"
      unitRef="usd">2761000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id4e29289044343a48f06844e7131ac18_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYtOC0xLTEtODQ0NDQ_f3bc3a88-65b6-4c02-8a81-c68957f1c846"
      unitRef="number">0.071</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id3ee2aa1541c4993ab5a6731b5086c7d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYtMTAtMS0xLTg0NDQ0_bbaf4b0a-deba-4443-a17e-3b1a415370c7"
      unitRef="number">0.099</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5735f3b990b141e4a4be776a1cc02da1_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzctMi0xLTEtODQ0NDQ_e132d1c4-ea68-43c9-be45-8932831d882d"
      unitRef="usd">6031000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i62fff57daefb4ad48862e19671a6dc9a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzctNC0xLTEtODQ0NDQ_5ef430cc-90fd-4814-9197-a5b58acf8ce9"
      unitRef="usd">5627000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i439805017432405eb34a20668de55a4a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzctNi0xLTEtODQ0NDQ_fdaae01d-5dd3-4388-acf6-fcf7ec12472a"
      unitRef="usd">5221000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5735f3b990b141e4a4be776a1cc02da1_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzctOC0xLTEtODQ0NDQ_b172b4ae-1505-45a4-b0cc-785e0562e0d3"
      unitRef="number">0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i62fff57daefb4ad48862e19671a6dc9a_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzctMTAtMS0xLTg0NDQ0_b004f7bc-e16d-4b70-9edb-524877bc7fe7"
      unitRef="number">0.078</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcef65e498e74c66bbc548320bf01eda_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzktMi0xLTEtODQ0NDQ_5291e177-bf92-43c5-bf01-572a48b7414d"
      unitRef="usd">2337000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56cc8799267a4d1bb446fc871370346d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzktNC0xLTEtODQ0NDQ_0f407ba5-d101-42a2-827a-d4ff30072642"
      unitRef="usd">2400000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id06a8fbb2c854362baef8d48b3e539ec_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzktNi0xLTEtODQ0NDQ_ed3c668b-9efa-4a49-b55f-9ebdfc28aff0"
      unitRef="usd">2350000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifcef65e498e74c66bbc548320bf01eda_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzktOC0xLTEtODQ0NDQ_08b535c7-de9b-4842-972e-6485f130db27"
      unitRef="number">-0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i56cc8799267a4d1bb446fc871370346d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzktMTAtMS0xLTg0NDQ0_69fd76e7-c299-4abe-90ec-87fa80770fc9"
      unitRef="number">0.021</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i305f2baf4f5040bfa89c742f613cb693_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwLTItMS0xLTg0NDQ0_45fb07f9-03f7-44b3-9ae8-11ba21b3fbd7"
      unitRef="usd">2015000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bcd6c0066854e439a15990c5325aea0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwLTQtMS0xLTg0NDQ0_193eb547-a63f-4caa-8fe1-231684bb69c1"
      unitRef="usd">2141000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ife8ad7f9de9f40939e7def44ca83e3cb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwLTYtMS0xLTg0NDQ0_91327612-de4a-4622-8c97-5248af9c6b15"
      unitRef="usd">2100000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i305f2baf4f5040bfa89c742f613cb693_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwLTgtMS0xLTg0NDQ0_04f95bc7-8684-49a7-b545-e7b57b185831"
      unitRef="number">-0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1bcd6c0066854e439a15990c5325aea0_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwLTEwLTEtMS04NDQ0NA_a018f781-f4aa-401a-b98e-0dfb00bdbac8"
      unitRef="number">0.019</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i575246cb13cb4e958a9cd5c6a9682cc2_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExLTItMS0xLTg0NDQ0_55e53e5c-7d0e-4e01-ae7b-dc8f97533222"
      unitRef="usd">4352000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia568e79890ed43dca885e271433dca1d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExLTQtMS0xLTg0NDQ0_78baf9fa-8d7f-4418-b52f-0d794acca6cc"
      unitRef="usd">4541000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6438bc69468141788dc7dd15c2e6f0b1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExLTYtMS0xLTg0NDQ0_ab49690a-5a63-4f6d-a6ea-3717b0692828"
      unitRef="usd">4450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i575246cb13cb4e958a9cd5c6a9682cc2_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExLTgtMS0xLTg0NDQ0_76a882e5-c7b1-479f-a0b2-310117b19809"
      unitRef="number">-0.042</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia568e79890ed43dca885e271433dca1d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExLTEwLTEtMS04NDQ0NA_85797f68-c7cb-4d3c-a169-1be9f1d948e4"
      unitRef="number">0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i740d75bd86104d0c94afefc9b87d51ef_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzLTItMS0xLTg0NDQ0_32ed8c8a-e85b-44e9-8da0-1feeb3c8e8b0"
      unitRef="usd">635000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8aff1a3d834643a8840f76c325a3a99f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzLTQtMS0xLTg0NDQ0_87c072dd-acc4-40ee-8b54-ca2c6e0c4eb7"
      unitRef="usd">637000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b07581a92b746fc9cdb03ab06449ec2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzLTYtMS0xLTg0NDQ0_6008b6d7-4bbb-49be-b1d8-dcfc945d1005"
      unitRef="usd">683000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i740d75bd86104d0c94afefc9b87d51ef_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzLTgtMS0xLTg0NDQ0_f67a8c98-a9eb-44bc-b576-3eff9726d128"
      unitRef="number">-0.003</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8aff1a3d834643a8840f76c325a3a99f_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzLTEwLTEtMS04NDQ0NA_f08edfe4-9c09-42ef-a60b-3872964997a7"
      unitRef="number">-0.067</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6514fba7e78484d8e9d6a382b648d8f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0LTItMS0xLTg0NDQ0_a859fe83-ef29-46c9-afd9-b4bc34b204d8"
      unitRef="usd">871000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieef3ea0559af465c8780f85fc9c95f1d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0LTQtMS0xLTg0NDQ0_008ac16d-63d1-418d-974a-b35ad2c62e06"
      unitRef="usd">1008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i187c9f9d5d5349338afe50224cc27c1e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0LTYtMS0xLTg0NDQ0_a8e0213e-adfd-4efb-b0d0-bec30618e7a2"
      unitRef="usd">958000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id6514fba7e78484d8e9d6a382b648d8f_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0LTgtMS0xLTg0NDQ0_42062e6f-1b7e-49a9-a589-a82082770bba"
      unitRef="number">-0.136</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ieef3ea0559af465c8780f85fc9c95f1d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0LTEwLTEtMS04NDQ0NA_c7887a4b-696d-4663-97c3-a5779a6b6f96"
      unitRef="number">0.051</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaf17bd3c525a4b3bb0011ec89a64ff51_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1LTItMS0xLTg0NDQ0_f6d74e7a-d974-485d-a118-33f36ac40c4f"
      unitRef="usd">1505000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i193f625c1b214c7793df54d141c36d73_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1LTQtMS0xLTg0NDQ0_8da7b9a6-91b0-4245-a19a-1f6e926e8066"
      unitRef="usd">1645000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i042187f7809d42bc81ee957ee586ef6b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1LTYtMS0xLTg0NDQ0_87f78c28-b51b-4c41-95be-216e363e8150"
      unitRef="usd">1641000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaf17bd3c525a4b3bb0011ec89a64ff51_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1LTgtMS0xLTg0NDQ0_3ca3e163-59da-4ed3-9768-d4727c466427"
      unitRef="number">-0.085</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i193f625c1b214c7793df54d141c36d73_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1LTEwLTEtMS04NDQ0NA_30ca8492-f254-4259-a070-9d29dd4438c1"
      unitRef="number">0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5671c06ac22418998bf233fa3ac24ff_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3LTItMS0xLTg0NDQ0_e39e2d7f-f3c1-4578-a93b-073c551201c9"
      unitRef="usd">357000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1f0e48a118f4e0f8d62b1d1fbf833aa_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3LTQtMS0xLTg0NDQ0_ebd99454-b6d8-44a7-bc72-176346ff59a6"
      unitRef="usd">378000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cebe4ddd2e04f1cb5a741a9533d0a67_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3LTYtMS0xLTg0NDQ0_a66c728c-b8c4-4b0a-b265-66d73f306b8a"
      unitRef="usd">376000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib5671c06ac22418998bf233fa3ac24ff_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3LTgtMS0xLTg0NDQ0_d22acd7f-a13d-49cf-9cf1-19121d2cc21f"
      unitRef="number">-0.055</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie1f0e48a118f4e0f8d62b1d1fbf833aa_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3LTEwLTEtMS04NDQ0NA_a3b770e0-eb43-47e4-96e3-288a139a6bf3"
      unitRef="number">0.005</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4fb8ac4e52c9497b82e8cd22bd29d272_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4LTItMS0xLTg0NDQ0_18abe64d-dbf3-4cf9-a276-f7f29c762db5"
      unitRef="usd">1104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i015e212fa198442b8d18e922914d6075_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4LTQtMS0xLTg0NDQ0_bd693f2f-c1ec-47ac-ae11-a0b55a58561a"
      unitRef="usd">1188000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81bd67b3b0634ce4b563b42531da6b02_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4LTYtMS0xLTg0NDQ0_eec68993-5704-43bd-a5c6-fea9db4e3b11"
      unitRef="usd">1141000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4fb8ac4e52c9497b82e8cd22bd29d272_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4LTgtMS0xLTg0NDQ0_2056ba2d-ef6d-4655-81af-2b6faff09842"
      unitRef="number">-0.071</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i015e212fa198442b8d18e922914d6075_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4LTEwLTEtMS04NDQ0NA_d2122229-b709-4112-ac6e-96451ef90717"
      unitRef="number">0.041</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i001c88dc32694c0aa767413204814f97_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5LTItMS0xLTg0NDQ0_aa327ad3-cfd8-4373-8b63-3c6d7c889c40"
      unitRef="usd">1461000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb68778688b84eec8b98dc05b1c73823_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5LTQtMS0xLTg0NDQ0_8d533fa3-e449-410d-8895-b9a82720cc14"
      unitRef="usd">1566000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ee93092fc834bb3890c0d900445063e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5LTYtMS0xLTg0NDQ0_33e395be-d974-498d-9f6f-e1bfc2501e26"
      unitRef="usd">1517000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i001c88dc32694c0aa767413204814f97_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5LTgtMS0xLTg0NDQ0_5e98a1e8-43d6-4390-b758-1e716e612d44"
      unitRef="number">-0.067</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icb68778688b84eec8b98dc05b1c73823_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5LTEwLTEtMS04NDQ0NA_d69f9036-7a4f-4536-88bf-08564a799306"
      unitRef="number">0.032</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3aa6061cdfda45b48d4a19e23fa32015_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxLTItMS0xLTg0NDQ0_2a698b92-a89f-4fcf-bccf-0c2eb5d3aaf6"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c2531fa73d44239a380b2362f5e121d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxLTQtMS0xLTg0NDQ0_726067d5-2825-44f4-96c9-639839008688"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8578159027f24dcf86568156693183a5_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxLTYtMS0xLTg0NDQ0_8a23477e-1263-4f55-bffa-0295409dd4c7"
      unitRef="usd">13000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3aa6061cdfda45b48d4a19e23fa32015_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxLTgtMS0xLTg0NDQ0_26a30e2f-0dc0-4e30-ad53-d1bab96fd926"
      unitRef="number">0.017</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1c2531fa73d44239a380b2362f5e121d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxLTEwLTEtMS04NDQ0NA_ff9177f4-5d41-4468-bfc9-7c74c695376d"
      unitRef="number">-0.016</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id93ba1dabe3f4b5da204b1077b4518d0_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyLTItMS0xLTg0NDQ0_ad45c121-ea21-4251-a838-51ff053a0d7f"
      unitRef="usd">891000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3bfbe7c9fccc4c64b09c41d52ad70175_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyLTQtMS0xLTg0NDQ0_5ec4d758-4cb6-4848-a1ee-66a1ec6dd7aa"
      unitRef="usd">905000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i263452e9213e47c886650ce7cb371065_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyLTYtMS0xLTg0NDQ0_136ea39e-a15f-4bfe-8398-f5ef1ed3571d"
      unitRef="usd">888000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id93ba1dabe3f4b5da204b1077b4518d0_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyLTgtMS0xLTg0NDQ0_ead46394-7870-4f5b-98ff-4538a521a775"
      unitRef="number">-0.015</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3bfbe7c9fccc4c64b09c41d52ad70175_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyLTEwLTEtMS04NDQ0NA_5f682e06-ec83-4a4f-9435-a4f8c1e024a1"
      unitRef="number">0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d7ed3b7665e416388b6a9aa612a4869_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzLTItMS0xLTg0NDQ0_ad3fb3b7-3005-46dc-8f50-4dba76a89d32"
      unitRef="usd">904000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4896b102e9542ca93ed851ae014915e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzLTQtMS0xLTg0NDQ0_6ef0940b-b8e5-461a-9254-216c7e6f9b01"
      unitRef="usd">917000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1269622a495a4e64ad8c2c22a7e91280_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzLTYtMS0xLTg0NDQ0_050e4ebc-67fc-40a1-9825-a299aa3affc9"
      unitRef="usd">901000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9d7ed3b7665e416388b6a9aa612a4869_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzLTgtMS0xLTg0NDQ0_e9f37236-ce24-47a9-987c-0d96d261a8d0"
      unitRef="number">-0.015</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib4896b102e9542ca93ed851ae014915e_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzLTEwLTEtMS04NDQ0NA_68549e81-36e1-4d95-96ae-84c0b580458e"
      unitRef="number">0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fb3b41722c44fb497e08d86ff98bf18_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI1LTItMS0xLTg0NDQ0_5c39e375-d3d7-416e-8b29-e03c46e9b063"
      unitRef="usd">475000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib1082a9661ae476683c756bbaca58883_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI1LTQtMS0xLTg0NDQ0_f2d67a5f-9a94-4827-954a-103708ff66a4"
      unitRef="usd">495000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if02a3937e37448db80bbb8a99ffff4dc_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI1LTYtMS0xLTg0NDQ0_161fe8cf-195d-4203-a300-f08fc3123776"
      unitRef="usd">480000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1fb3b41722c44fb497e08d86ff98bf18_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI1LTgtMS0xLTg0NDQ0_10b6faa0-f7da-4437-9446-b323e4f244f0"
      unitRef="number">-0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib1082a9661ae476683c756bbaca58883_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI1LTEwLTEtMS04NDQ0NA_a52212d9-0378-4c5d-8275-ef219725d0b3"
      unitRef="number">0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2292a22d2f6a4e18acba13c92c14b1c3_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI2LTItMS0xLTg0NDQ0_1b371e03-de4e-44c5-b9ef-08df7f63e371"
      unitRef="usd">224000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib87733bbde604e8f9bd05fb51223e407_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI2LTQtMS0xLTg0NDQ0_1f71554f-00ea-4d93-af39-50c9e8249eff"
      unitRef="usd">243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34a442a0814740f1a1e5b57d6e051977_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI2LTYtMS0xLTg0NDQ0_9b8049c8-9824-4a2e-8bd6-c4a470186801"
      unitRef="usd">240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2292a22d2f6a4e18acba13c92c14b1c3_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI2LTgtMS0xLTg0NDQ0_e31a41b3-1a30-4b88-8e7c-0de0ef1f359d"
      unitRef="number">-0.080</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib87733bbde604e8f9bd05fb51223e407_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI2LTEwLTEtMS04NDQ0NA_1ec5c1ef-7cf2-4813-b6c1-fb64722c10fe"
      unitRef="number">0.017</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3285a500e83d4e938ed7a18bb07f562d_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI3LTItMS0xLTg0NDQ0_a3986bf0-4553-401f-8aed-9dad9afc14cb"
      unitRef="usd">700000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3c3b87812e3421384238aff93cefacf_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI3LTQtMS0xLTg0NDQ0_a8760383-9aea-4998-926e-5eaf70fe335d"
      unitRef="usd">739000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icc2c65b893a44bd3a5dff496a5a117bc_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI3LTYtMS0xLTg0NDQ0_5659ac13-3fdb-4238-8628-48dc71a66784"
      unitRef="usd">720000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3285a500e83d4e938ed7a18bb07f562d_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI3LTgtMS0xLTg0NDQ0_807ae26c-5ed5-4915-b866-41bb6ad63eb9"
      unitRef="number">-0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id3c3b87812e3421384238aff93cefacf_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI3LTEwLTEtMS04NDQ0NA_16bc79bb-194d-4a81-9c3b-4e2de27696d3"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id1ee80a6d40c46f0b266441ca6963f33_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI5LTItMS0xLTg0NDQ0_d055f133-9048-476f-9a93-c12cba364c8f"
      unitRef="usd">6599000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43d7081e6eac4175b0632049d45aea0b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI5LTQtMS0xLTg0NDQ0_3f24d8a0-026c-472c-a5d0-f90854aa3a00"
      unitRef="usd">6516000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb2956c17ea2404b80a4eb00815a6af4_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI5LTYtMS0xLTg0NDQ0_28370584-c663-4583-8aab-92537ef3d282"
      unitRef="usd">6362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id1ee80a6d40c46f0b266441ca6963f33_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI5LTgtMS0xLTg0NDQ0_2f8b1f86-fb1f-4cb3-99fc-9d60c687fcf5"
      unitRef="number">0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i43d7081e6eac4175b0632049d45aea0b_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI5LTEwLTEtMS04NDQ0NA_cce948b3-e05c-45ad-b3f9-6f850a236307"
      unitRef="number">0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88289ceda63741c295f461bebbc818d7_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMwLTItMS0xLTg0NDQ0_580b388b-b870-491c-bf9e-8f3010bd1761"
      unitRef="usd">8354000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie47ee78762394fc48eeb03bbee8192b3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMwLTQtMS0xLTg0NDQ0_d17e8718-e9c0-472a-83a2-09bb0fe46378"
      unitRef="usd">8519000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id69b428176aa4a3cbe479f87f86f7bbd_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMwLTYtMS0xLTg0NDQ0_04059dd4-26ef-4688-a0ce-b4a337301250"
      unitRef="usd">8088000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i88289ceda63741c295f461bebbc818d7_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMwLTgtMS0xLTg0NDQ0_e6f457cc-caa3-4586-900a-9c23312ed35b"
      unitRef="number">-0.019</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie47ee78762394fc48eeb03bbee8192b3_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMwLTEwLTEtMS04NDQ0NA_90f13b97-7e8a-4b8b-833e-0f32e4156048"
      unitRef="number">0.053</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia324deef03f5433486883e8775658b95_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMxLTItMS0xLTg0NDQ0_93ce1f95-5376-4880-a0ed-f96d24b43a9f"
      unitRef="usd">14953000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c6099acc42a42639c659499eeee550a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMxLTQtMS0xLTg0NDQ0_0c9d231e-2486-4017-ac68-93974d4fbf8e"
      unitRef="usd">15035000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieabc073d9ebf4111b8a8d92bdd0b8b7d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMxLTYtMS0xLTg0NDQ0_99f2ca6e-125a-4831-8df9-79bc05123355"
      unitRef="usd">14450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia324deef03f5433486883e8775658b95_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMxLTgtMS0xLTg0NDQ0_430ea938-5a2b-4742-a2a9-9111c44adba6"
      unitRef="number">-0.005</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2c6099acc42a42639c659499eeee550a_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzMxLTEwLTEtMS04NDQ0NA_48d27c13-8499-4aad-ba88-9f93b0dbb550"
      unitRef="number">0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e88cbad6cbe49bd8e825a7ed41c9c3a_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM1LTItMS0xLTg0NDQ0_4013b410-89d4-412a-9656-7ff119b49bf4"
      unitRef="usd">11036000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4e22bab2b8ce4579a43a60a12cd1a9c5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM1LTQtMS0xLTg0NDQ0_205c5753-67f7-432f-b2b1-03e17b320726"
      unitRef="usd">10843000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iec93cf328ce84ef3a066a9fa498ab413_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM1LTYtMS0xLTg0NDQ0_017e0967-f36c-4f9d-8022-5885098ce6b3"
      unitRef="usd">10175000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5e88cbad6cbe49bd8e825a7ed41c9c3a_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM1LTgtMS0xLTg0NDQ0_8eb1f59a-b407-4ff7-b835-6557a2325ad5"
      unitRef="number">0.018</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4e22bab2b8ce4579a43a60a12cd1a9c5_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM1LTEwLTEtMS04NDQ0NA_b6b4e428-a87a-4f51-9dae-4fb068f09636"
      unitRef="number">0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i986b4a68a2bf4fb0ab3a4d6b014ad0b4_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM2LTItMS0xLTg0NDQ0_912790d5-6943-4f1f-83cc-6128fbf6ec5b"
      unitRef="usd">5899000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if74c6a56a65d42e393222e70b8ee3b45_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM2LTQtMS0xLTg0NDQ0_bfade3eb-a9fa-49ed-8842-ddd5423889b8"
      unitRef="usd">5907000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7849117524e141089fc6dba149013836_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM2LTYtMS0xLTg0NDQ0_30f801dd-3777-47a8-87e6-1ff5d5d39bba"
      unitRef="usd">4880000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i986b4a68a2bf4fb0ab3a4d6b014ad0b4_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM2LTgtMS0xLTg0NDQ0_f601dffb-7284-4bc4-acc3-f77fab2b378d"
      unitRef="number">-0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if74c6a56a65d42e393222e70b8ee3b45_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM2LTEwLTEtMS04NDQ0NA_306f79be-5903-4155-bb0c-235c5b874b10"
      unitRef="number">0.210</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i397c0bcfffa744e1afc241f015ce8b04_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM3LTItMS0xLTg0NDQ0_fb1404ab-c9da-4571-9151-e248df8bcba8"
      unitRef="usd">16935000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if478f7362b5f45038c0ff48e4dd32d76_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM3LTQtMS0xLTg0NDQ0_3405e8bc-60b2-4b4a-8bef-e25732b25428"
      unitRef="usd">16750000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i002e689e81af4469875bf4167de1a9f3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM3LTYtMS0xLTg0NDQ0_7db6a9dc-a72c-4b98-a655-94178c6497b1"
      unitRef="usd">15055000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i397c0bcfffa744e1afc241f015ce8b04_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM3LTgtMS0xLTg0NDQ0_bcfaa126-0e3a-4661-ab73-405642a1ebb4"
      unitRef="number">0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if478f7362b5f45038c0ff48e4dd32d76_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM3LTEwLTEtMS04NDQ0NA_cb3d00fa-6e84-4ed0-8046-f39941b37a0e"
      unitRef="number">0.113</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i12bc3574823a42a18c54341c7e48ccfd_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM5LTItMS0xLTg0NDQ0_5e496427-d3a9-4384-8c19-1dd6d96da496"
      unitRef="usd">1417000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i72281ed8b429494f9436d47de34888bf_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM5LTQtMS0xLTg0NDQ0_c4476c8b-1dac-48dc-be84-a7680626156f"
      unitRef="usd">2019000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i39cd91fc937e48888264b49955721321_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM5LTYtMS0xLTg0NDQ0_a7fde4f2-73cc-4c44-bf7a-adb064cb71da"
      unitRef="usd">2508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i12bc3574823a42a18c54341c7e48ccfd_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM5LTgtMS0xLTg0NDQ0_fb3f96e0-795b-4ac7-ac79-a69df347a5b1"
      unitRef="number">-0.298</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i72281ed8b429494f9436d47de34888bf_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzM5LTEwLTEtMS04NDQ0NA_d4acf813-b693-4730-a9c0-9bbfeb336bb0"
      unitRef="number">-0.195</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i912cb26a60ad460497cb59430e03bcd6_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQwLTItMS0xLTg0NDQ0_a9dcdbff-637d-4056-991c-ad0c4fb04c87"
      unitRef="usd">204000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4af108e7bc8424987da6ec7762b48a7_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQwLTQtMS0xLTg0NDQ0_1b90b0c9-0ae3-41d8-86ce-97166ebb0413"
      unitRef="usd">236000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe204b8f9621439b9d7201393c46acc4_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQwLTYtMS0xLTg0NDQ0_0588613e-25d1-4791-82a4-fab1a8ad54a8"
      unitRef="usd">346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i912cb26a60ad460497cb59430e03bcd6_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQwLTgtMS0xLTg0NDQ0_2f439b93-0de2-4727-b82a-36005e8a6e55"
      unitRef="number">-0.136</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie4af108e7bc8424987da6ec7762b48a7_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQwLTEwLTEtMS04NDQ0NA_9156d077-384a-426b-8342-291a94757282"
      unitRef="number">-0.319</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b9e7de8698c4e4b8582e62338b3a308_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQxLTItMS0xLTg0NDQ0_3469d887-c0eb-4771-842f-ab21cf631c97"
      unitRef="usd">722000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1893a467cc624e79a62e62fec246d121_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQxLTQtMS0xLTg0NDQ0_f05aeaa4-4e2c-41bd-ae2a-37bb63043f2e"
      unitRef="usd">935000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50aef40f53704f639eeb4ead4f673ed0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQxLTYtMS0xLTg0NDQ0_df37f8c4-8866-4de1-867e-f61fecad30ca"
      unitRef="usd">893000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3b9e7de8698c4e4b8582e62338b3a308_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQxLTgtMS0xLTg0NDQ0_232e9a9c-d5bd-48ae-9a7c-948e4cfd1cb3"
      unitRef="number">-0.228</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1893a467cc624e79a62e62fec246d121_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQxLTEwLTEtMS04NDQ0NA_d7eb8900-3cb5-48e1-bbae-508eab946c06"
      unitRef="number">0.048</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i150c9d621d58436592cfc84eadbbd8de_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQyLTItMS0xLTg0NDQ0_d9a3e7ad-f292-4f95-b896-96ea12885cf5"
      unitRef="usd">2343000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cd61c709b4f4822b6b0abb800e70ce2_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQyLTQtMS0xLTg0NDQ0_5a91d3ff-eed8-4380-adf3-e78b8369a32f"
      unitRef="usd">3190000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i07927d37d35247c4ab9e64a048a34675_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQyLTYtMS0xLTg0NDQ0_b921a57a-155c-46bf-911c-cefc1af70f63"
      unitRef="usd">3747000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i150c9d621d58436592cfc84eadbbd8de_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQyLTgtMS0xLTg0NDQ0_3ae462f4-1727-4114-84ac-f7cebdb17fcb"
      unitRef="number">-0.266</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1cd61c709b4f4822b6b0abb800e70ce2_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQyLTEwLTEtMS04NDQ0NA_4b58653b-b986-482b-b872-e89b82d48aeb"
      unitRef="number">-0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idce1aa757100453fbf226e404cf449c5_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ0LTItMS0xLTg0NDQ0_5f308e02-5aab-494e-8eca-5be7b05441ef"
      unitRef="usd">1166000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iad404b1e843448c5a861fc281c54f700_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ0LTQtMS0xLTg0NDQ0_274a5a3e-cbd5-4f97-85d3-53f17dd4053b"
      unitRef="usd">1127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00d6f86395074f92b284bee5e41b9c56_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ0LTYtMS0xLTg0NDQ0_e9eafd0e-888a-46f0-89de-89484ec8da50"
      unitRef="usd">1155000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idce1aa757100453fbf226e404cf449c5_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ0LTgtMS0xLTg0NDQ0_e56d13b3-679e-4954-895b-c20db3fc93dd"
      unitRef="number">0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iad404b1e843448c5a861fc281c54f700_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ0LTEwLTEtMS04NDQ0NA_3a313eaf-f5a2-4d23-9ec3-b755ac04ad09"
      unitRef="number">-0.024</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie59a2dae302645e09d149c7d7a174a78_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ1LTItMS0xLTg0NDQ0_730a83df-500b-4893-b673-b2551bc5693e"
      unitRef="usd">1017000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafa5cf4ed7ac4030baf40b5dbd7736bf_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ1LTQtMS0xLTg0NDQ0_96d81bb3-3971-4629-9570-4f9fb3a5f05d"
      unitRef="usd">1148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i692eee4c082846c498f4462756e57681_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ1LTYtMS0xLTg0NDQ0_67e7d022-045c-4464-b5b7-c8f10f42d821"
      unitRef="usd">1088000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie59a2dae302645e09d149c7d7a174a78_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ1LTgtMS0xLTg0NDQ0_58baacc8-b627-4299-a430-789e55bd8229"
      unitRef="number">-0.114</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iafa5cf4ed7ac4030baf40b5dbd7736bf_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ1LTEwLTEtMS04NDQ0NA_d8a9b14e-0d63-4728-b862-a56fa1e2568c"
      unitRef="number">0.055</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic3834f86e6904624bfc14ea56990f87f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ2LTItMS0xLTg0NDQ0_662b8181-0eb2-4bc8-98cf-4a79ec3906b0"
      unitRef="usd">2184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i203194712a9c4ff294ad81780e8d8a52_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ2LTQtMS0xLTg0NDQ0_2070d55c-755f-4ac4-9543-4afe39354cfc"
      unitRef="usd">2276000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bc9b8fea3634731bf270a2f122b7d2d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ2LTYtMS0xLTg0NDQ0_ffde87e1-1f6b-4ace-bb6c-7e80f1cb2b21"
      unitRef="usd">2243000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic3834f86e6904624bfc14ea56990f87f_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ2LTgtMS0xLTg0NDQ0_87dd9c18-8f92-4efe-96b8-d5e1268371ab"
      unitRef="number">-0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i203194712a9c4ff294ad81780e8d8a52_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ2LTEwLTEtMS04NDQ0NA_633ae063-a28e-4cc8-b299-92320e86e284"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia865193fbf2a4050bbe5db56a5edfd29_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ4LTItMS0xLTg0NDQ0_565cf582-1f34-43bf-b11a-93ed533cff3d"
      unitRef="usd">6388000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ab664701a68493eb072fd6ca439c0a5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ4LTQtMS0xLTg0NDQ0_18255d32-fa4e-40d2-9fd1-6039a8839da4"
      unitRef="usd">5938000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16dc654ea1db4b339475642249680907_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ4LTYtMS0xLTg0NDQ0_1a99264e-96ef-405c-8de3-a0a1f9c2bba8"
      unitRef="usd">5240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia865193fbf2a4050bbe5db56a5edfd29_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ4LTgtMS0xLTg0NDQ0_1b02d0ce-58e2-4d6e-a00f-5df852d5911c"
      unitRef="number">0.076</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4ab664701a68493eb072fd6ca439c0a5_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ4LTEwLTEtMS04NDQ0NA_7c779d89-81b4-4214-8a68-0f875529f2f1"
      unitRef="number">0.133</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i80dcf3087ead4df5aeb6e738124670d9_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ5LTItMS0xLTg0NDQ0_15183c46-63df-4dc4-ae92-8e46510465c0"
      unitRef="usd">3335000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3d161ddece944bf8ad540a6a199f574_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ5LTQtMS0xLTg0NDQ0_7c52724b-d22b-4006-917c-27b49a74b2ab"
      unitRef="usd">3196000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6fdb567ab044e4fa2b02db9f1115bc1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ5LTYtMS0xLTg0NDQ0_ef5bf8ef-a842-4470-861e-7774a183e7a1"
      unitRef="usd">2467000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i80dcf3087ead4df5aeb6e738124670d9_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ5LTgtMS0xLTg0NDQ0_dee6d34b-1775-46a4-aa2b-10ec99b2f019"
      unitRef="number">0.044</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id3d161ddece944bf8ad540a6a199f574_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzQ5LTEwLTEtMS04NDQ0NA_d49073a2-8eef-4535-9eae-da5660fcbcf2"
      unitRef="number">0.296</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibaf99c2470714a549d4827198b5e4306_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUwLTItMS0xLTg0NDQ0_7173492d-03e5-4c5f-87b7-f9b4728a116b"
      unitRef="usd">9723000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42f4fa8e366c4d2b8cfaed938a637eae_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUwLTQtMS0xLTg0NDQ0_2e8e1773-1e9d-44ca-a4c7-7f19387cee39"
      unitRef="usd">9134000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i61655eb3ec9a40bf900bfa9966b2388f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUwLTYtMS0xLTg0NDQ0_21560dcd-5ddb-483a-b8cc-f82d2adeecd2"
      unitRef="usd">7707000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibaf99c2470714a549d4827198b5e4306_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUwLTgtMS0xLTg0NDQ0_25423867-5fbb-4005-b586-8cf0564665f8"
      unitRef="number">0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i42f4fa8e366c4d2b8cfaed938a637eae_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUwLTEwLTEtMS04NDQ0NA_4caeae10-d638-40b7-9b5a-3368519f57f5"
      unitRef="number">0.185</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i75ed4bc48a164740854aa44ff42c7c43_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUyLTItMS0xLTg0NDQ0_99b1428d-8a27-4093-97b8-53606308d956"
      unitRef="usd">1844000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d721f0119c44c98b11f757b023c30a6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUyLTQtMS0xLTg0NDQ0_8df390f2-f3d4-4e27-a14d-b3a00c99c3df"
      unitRef="usd">1503000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic03f559a7b2b4eb3ad1bd1999053ca64_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUyLTYtMS0xLTg0NDQ0_5945470a-4164-484d-aa35-31c38029f52c"
      unitRef="usd">926000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i75ed4bc48a164740854aa44ff42c7c43_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUyLTgtMS0xLTg0NDQ0_acdb1250-566e-46c5-bf54-63be6fac7676"
      unitRef="number">0.227</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6d721f0119c44c98b11f757b023c30a6_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUyLTEwLTEtMS04NDQ0NA_dfd851ff-f344-4508-bc71-c3024d4f8a03"
      unitRef="number">0.623</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i476d6bdc170f480880b6f349fe1d02a4_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUzLTItMS0xLTg0NDQ0_e631ae5a-e14c-4059-8be0-99b79f94448c"
      unitRef="usd">824000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i655fec7a57304dc5b69e3c08e261ce49_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUzLTQtMS0xLTg0NDQ0_eabda62f-7b83-43f9-b505-309f2246cd29"
      unitRef="usd">624000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie6870ec4af934c098b1c08e0fcc5d5ea_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUzLTYtMS0xLTg0NDQ0_698d46e5-1427-4186-bb8e-10560b9e5510"
      unitRef="usd">421000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i476d6bdc170f480880b6f349fe1d02a4_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUzLTgtMS0xLTg0NDQ0_fe0cb30c-ffb1-468f-a69f-a545a3617c3f"
      unitRef="number">0.320</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i655fec7a57304dc5b69e3c08e261ce49_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzUzLTEwLTEtMS04NDQ0NA_e092783d-9c57-46d4-af97-17c8d08a335a"
      unitRef="number">0.482</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ebfb3cbb91849ffa928740c09fb6845_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU0LTItMS0xLTg0NDQ0_4a4566bb-7cb3-4ab0-806c-def7e0b98a03"
      unitRef="usd">2668000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7187388ca7ef477bb2a513ddc7d152a5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU0LTQtMS0xLTg0NDQ0_d0159c11-31db-4714-a96f-715942fa376b"
      unitRef="usd">2127000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib767315f9702455d885f117ae21d3c8b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU0LTYtMS0xLTg0NDQ0_01e3c06d-87fa-4085-af73-2dccfefbae47"
      unitRef="usd">1347000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5ebfb3cbb91849ffa928740c09fb6845_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU0LTgtMS0xLTg0NDQ0_e0a65009-0d29-4882-98b0-6304e081d68f"
      unitRef="number">0.254</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7187388ca7ef477bb2a513ddc7d152a5_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU0LTEwLTEtMS04NDQ0NA_2846118c-243e-4013-9162-003628c203e5"
      unitRef="number">0.579</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iedf85e7c05384372a344804b1789a29f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU2LTItMS0xLTg0NDQ0_aa02cb44-29cb-4369-b7e1-0f25a45fa1be"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iacae22ebe7674dd6b631866883fc36a3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU2LTQtMS0xLTg0NDQ0_b7bb4936-aead-487d-be1f-f1baccdeffc7"
      unitRef="usd">21000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide93fb67d26b41bcba491ed0c9028795_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU2LTYtMS0xLTg0NDQ0_aaa288a5-91a7-492d-bea9-c765beed40a9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iedf85e7c05384372a344804b1789a29f_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU2LTgtMS0xLTg0NDQ0_c4a22b17-31d3-4e6a-8af6-b7225d68eb76"
      unitRef="number">-0.184</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5952a4c02d1407ab7d93feadb356126_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU3LTItMS0xLTg0NDQ0_48accda8-6b4c-4fbc-b624-eae09fbccb4d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d48aee7697b440ebfe16cb49fadabe5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU3LTQtMS0xLTg0NDQ0_38fcc9ea-5935-445a-862e-c48c26b70b4d"
      unitRef="usd">3000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68ae8a2a744646ef8a4dd8027eff0ee1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU3LTYtMS0xLTg0NDQ0_0f9b34cc-7e6b-41ac-a4ac-adf10c4ab693"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0d48aee7697b440ebfe16cb49fadabe5_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU3LTEwLTEtMS04NDQ0NA_8d7ba171-732d-44c3-b6e7-d9d0be83ee4b"
      unitRef="number">-0.733</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cf92bdfac4a45ff8d99efa6eaed94c6_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU4LTItMS0xLTg0NDQ0_d4617a7a-38b6-4ed1-8c8c-98416af42651"
      unitRef="usd">17000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3a36def101eb47b484d4ee34dde2f395_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU4LTQtMS0xLTg0NDQ0_d434091e-5dd5-434b-a2ba-e3214c818d89"
      unitRef="usd">24000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i111650d10ac748e7a9e029ffdde290cd_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU4LTYtMS0xLTg0NDQ0_8622ba87-df5e-4586-84b1-7272ebecef8c"
      unitRef="usd">11000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6cf92bdfac4a45ff8d99efa6eaed94c6_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzU4LTgtMS0xLTg0NDQ0_acb3394c-6c89-4dd1-a46c-0e561be5e7c2"
      unitRef="number">-0.282</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i735de00a843942b69ff5f4e4395b0611_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYxLTItMS0xLTg0NDQ0_c0cd2425-9caf-4931-a940-81df1290fc4c"
      unitRef="usd">1680000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i494446ad1b9140cebb18afa776b08b68_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYxLTQtMS0xLTg0NDQ0_51de5e17-9f14-4c95-86b8-5652db77aac9"
      unitRef="usd">2249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib33427d3662a40198bb45dcf433c1468_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYxLTYtMS0xLTg0NDQ0_25e4d5c3-dbc1-48a5-9ee4-384afd71242b"
      unitRef="usd">1735000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i735de00a843942b69ff5f4e4395b0611_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYxLTgtMS0xLTg0NDQ0_2f4109d9-6981-4364-8e85-03d5b0548a61"
      unitRef="number">-0.253</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i494446ad1b9140cebb18afa776b08b68_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYxLTEwLTEtMS04NDQ0NA_a21f66cd-0830-4d04-b07e-475c08683a13"
      unitRef="number">0.297</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if823818df08f47e38c8e54ee1da81441_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYyLTItMS0xLTg0NDQ0_e7b5f17e-3c9a-4483-a542-1b104c7f7cf9"
      unitRef="usd">3769000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id9098882055048acb56f0a7daff7b6cc_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYyLTQtMS0xLTg0NDQ0_c48599cf-fc3f-48bd-8754-f4fde25c6e12"
      unitRef="usd">3576000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9abfdce0d16e405883d49726c32f1acb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYyLTYtMS0xLTg0NDQ0_42e941e5-1b65-46ca-9510-afa5509f9677"
      unitRef="usd">1808000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if823818df08f47e38c8e54ee1da81441_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYyLTgtMS0xLTg0NDQ0_0ff22930-22aa-444c-b7f6-55166406258e"
      unitRef="number">0.054</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id9098882055048acb56f0a7daff7b6cc_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYyLTEwLTEtMS04NDQ0NA_fa302353-b478-4b4f-bba2-02f24de462cc"
      unitRef="number">0.978</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddcc1f0bfd31441da630d17bcd07bdd5_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYzLTItMS0xLTg0NDQ0_9642a27c-2971-49ad-9db0-6ff2036de3e1"
      unitRef="usd">5449000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2117a45f239d496da7c89c744b4799cf_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYzLTQtMS0xLTg0NDQ0_70279e3c-b6d0-4d5f-b94f-954ba3eacb9e"
      unitRef="usd">5825000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic396314e70cc4e8aa30c901f000516c6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYzLTYtMS0xLTg0NDQ0_b1b3a21b-ed0f-4119-9aeb-76e986106304"
      unitRef="usd">3543000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iddcc1f0bfd31441da630d17bcd07bdd5_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYzLTgtMS0xLTg0NDQ0_a123dac6-769b-4b5f-928b-9073b482c058"
      unitRef="number">-0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2117a45f239d496da7c89c744b4799cf_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzYzLTEwLTEtMS04NDQ0NA_f4429d3a-35dc-43da-95e7-1b24fe919f02"
      unitRef="number">0.644</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice5729f779d5409483631d4dc721f7d2_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY1LTItMS0xLTg0NDQ0_93b4999d-2263-46e2-8bf6-a4e710c3e79b"
      unitRef="usd">120000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7789339e6baa4ad0abaa2c19f511a483_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY1LTQtMS0xLTg0NDQ0_431168b8-00a2-4918-9cb4-e7e80fa7d653"
      unitRef="usd">634000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92e52543ccad4142906214832c2a1522_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY1LTYtMS0xLTg0NDQ0_b48f4c95-d134-4c64-b4a2-5b43ce58b69a"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ice5729f779d5409483631d4dc721f7d2_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY1LTgtMS0xLTg0NDQ0_cd963629-ee3a-408d-aa7e-17a6146062c5"
      unitRef="number">-0.811</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i133db46d59e84bdab73a70f71326e38f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY2LTItMS0xLTg0NDQ0_e81944e9-a2e2-4fb1-b43d-586b92baa8b3"
      unitRef="usd">2059000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2853f108a89e46679d84a145dc7f721b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY2LTQtMS0xLTg0NDQ0_5eda7096-7bf6-4e9a-a5e0-ebcd0238b5ec"
      unitRef="usd">1751000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i739fdbf5c9b249b5bb242066485fd13b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY2LTYtMS0xLTg0NDQ0_c764f554-41a2-4e5d-806b-1b11f24330f7"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i133db46d59e84bdab73a70f71326e38f_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY2LTgtMS0xLTg0NDQ0_cbb15647-4a5a-43e9-90e8-e97985f0096a"
      unitRef="number">0.176</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5e252aba7cdd4ec2a540688ab64830b1_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY3LTItMS0xLTg0NDQ0_a0f89d1e-1e51-46bb-9a4a-d8ec73bbc2c1"
      unitRef="usd">2179000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d36aaa849d34410912a18791f8c1fdc_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY3LTQtMS0xLTg0NDQ0_c0a17d12-b9d2-456d-8789-6b78b89e5c0f"
      unitRef="usd">2385000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i65e91319a96348ee87ae160ca65edaff_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY3LTYtMS0xLTg0NDQ0_222d3939-fb16-47da-9654-01acbea90d0e"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5e252aba7cdd4ec2a540688ab64830b1_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY3LTgtMS0xLTg0NDQ0_7de9e680-cf46-4eca-a1dc-592ff3a5f8fa"
      unitRef="number">-0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i681b21f0446d4385936cb77eb4b9dca1_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY5LTItMS0xLTg0NDQ0_4e237308-5ad7-46fb-8ca7-5499c9268a1e"
      unitRef="usd">36000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib410879725f24ae8ba0999c6d06366a5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY5LTQtMS0xLTg0NDQ0_81d58d74-812a-47f4-90ef-adf3f727f4be"
      unitRef="usd">41000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifeb843593c464cb18a4c3dacc904ae00_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY5LTYtMS0xLTg0NDQ0_7d2d2aee-dd39-4ea7-bcbf-334b2be67c72"
      unitRef="usd">44000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i681b21f0446d4385936cb77eb4b9dca1_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY5LTgtMS0xLTg0NDQ0_84091358-cff6-4122-84f9-91b9d8ce259d"
      unitRef="number">-0.108</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib410879725f24ae8ba0999c6d06366a5_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzY5LTEwLTEtMS04NDQ0NA_9cfcf6e1-3664-446d-8ea6-a3045ead845b"
      unitRef="number">-0.076</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i35f94389fa524ab289f01a52a921cf7c_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcwLTItMS0xLTg0NDQ0_02c23b90-7f78-4d8f-843b-980e577c8e53"
      unitRef="usd">972000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffe39ec345a94ec18338abc237e01452_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcwLTQtMS0xLTg0NDQ0_0eae857a-6328-427c-8123-64d3addae8d7"
      unitRef="usd">953000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie433d85e7b6448d19d8075af0de26e2d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcwLTYtMS0xLTg0NDQ0_7269cd01-90c5-4fa1-84bb-106f4e0ae472"
      unitRef="usd">920000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i35f94389fa524ab289f01a52a921cf7c_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcwLTgtMS0xLTg0NDQ0_55b8572d-d7ab-4198-9583-1bdba662fe79"
      unitRef="number">0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iffe39ec345a94ec18338abc237e01452_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcwLTEwLTEtMS04NDQ0NA_4f6c6006-8fcb-4586-aacd-616dd414f87d"
      unitRef="number">0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6bc2c48e4eca4c58b9de0abae4adff22_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcxLTItMS0xLTg0NDQ0_af9867da-728b-4555-b7f7-08bfd28e343f"
      unitRef="usd">1008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib44093e5c3a0432f8560133ae4395d30_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcxLTQtMS0xLTg0NDQ0_ca5e1efd-824a-4a3c-9961-e7d4a47ff321"
      unitRef="usd">994000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf0b6c7689e44b268e1b721f04f9848b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcxLTYtMS0xLTg0NDQ0_04a6563d-dad1-4607-9480-1ac5cfa476b3"
      unitRef="usd">964000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6bc2c48e4eca4c58b9de0abae4adff22_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcxLTgtMS0xLTg0NDQ0_2b929410-2aed-4506-8825-6993ff68b807"
      unitRef="number">0.015</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib44093e5c3a0432f8560133ae4395d30_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzcxLTEwLTEtMS04NDQ0NA_e60a16db-22b8-49ea-bdf4-1326321aae4d"
      unitRef="number">0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b87d067ef004f5aafaed64f58162f4d_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzczLTItMS0xLTg0NDQ0_915ee996-cf8d-4283-84a0-fbd6d9346d04"
      unitRef="usd">1494000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i41fb3351d90d4979bd4aade9045ceba1_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzczLTQtMS0xLTg0NDQ0_4f4ad68b-ec7c-485d-ac02-56db9082c5a4"
      unitRef="usd">1508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i19991ad08c1340cb8a9f12dfc8fbf112_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzczLTYtMS0xLTg0NDQ0_a3e05de0-d668-4625-b28e-e4af42cdd3b0"
      unitRef="usd">1587000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5b87d067ef004f5aafaed64f58162f4d_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzczLTgtMS0xLTg0NDQ0_ce05a81c-8006-458d-8dd0-aa0d3498e4f0"
      unitRef="number">-0.010</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i41fb3351d90d4979bd4aade9045ceba1_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzczLTEwLTEtMS04NDQ0NA_a848bfe6-3045-465a-a795-b7fc64f3e2f8"
      unitRef="number">-0.049</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i186ad1cd9a1e4945a51acd1fbe039a6c_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc0LTItMS0xLTg0NDQ0_0e62432f-4040-4af0-b472-6b291507bc0b"
      unitRef="usd">449000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2534504edb8d464f8ee62a5593a78d54_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc0LTQtMS0xLTg0NDQ0_cbbc3cbb-8f5e-42df-a495-b903a2a934b2"
      unitRef="usd">575000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20f893fb187e464aa1a397a82dad33e8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc0LTYtMS0xLTg0NDQ0_4bce929a-d034-4b3a-aa46-5663102bdd89"
      unitRef="usd">597000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i186ad1cd9a1e4945a51acd1fbe039a6c_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc0LTgtMS0xLTg0NDQ0_1fa04e00-f85f-4290-914a-9bbc7e40657f"
      unitRef="number">-0.219</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2534504edb8d464f8ee62a5593a78d54_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc0LTEwLTEtMS04NDQ0NA_3cba7695-e644-4e9d-b70e-729d015e7b98"
      unitRef="number">-0.036</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iffa2c64baab1439f89e0e380d54cb895_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc1LTItMS0xLTg0NDQ0_4388de6c-43e3-4053-b7f5-8ffae6c2829d"
      unitRef="usd">1943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33b8737e36dc40e891fd7257c424ab9b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc1LTQtMS0xLTg0NDQ0_fa8e3043-82e4-47a4-93e3-1aa37d8c9352"
      unitRef="usd">2083000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if08b714b754d43ffa7a441ceafdc12db_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc1LTYtMS0xLTg0NDQ0_330b3816-5276-42f7-b306-de5da2340794"
      unitRef="usd">2184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iffa2c64baab1439f89e0e380d54cb895_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc1LTgtMS0xLTg0NDQ0_1a2c9c3d-df99-409c-b6d9-49333853adb3"
      unitRef="number">-0.067</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i33b8737e36dc40e891fd7257c424ab9b_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc1LTEwLTEtMS04NDQ0NA_7dcc1cb7-ad9c-4bd6-a4ca-b2a7c61e907d"
      unitRef="number">-0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafa49f8cb28444c08b3e7691d9289fd0_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc3LTItMS0xLTg0NDQ0_9ab52602-16a9-40ec-bbcd-20fd4ae7091a"
      unitRef="usd">30000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b32cf9f39464d33a7bac9a57081607b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc3LTQtMS0xLTg0NDQ0_80a059b4-18a6-4c01-b452-c8b0be075178"
      unitRef="usd">66000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifce1d8aac6f64a9e8d3edf11466fbeb0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc3LTYtMS0xLTg0NDQ0_391c5337-097b-4ef8-a7e3-abf58a7973b2"
      unitRef="usd">104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iafa49f8cb28444c08b3e7691d9289fd0_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc3LTgtMS0xLTg0NDQ0_28eeb197-935f-4da7-92be-07bf03a0f46a"
      unitRef="number">-0.555</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5b32cf9f39464d33a7bac9a57081607b_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc3LTEwLTEtMS04NDQ0NA_83c11b7d-8239-4deb-8673-f0f95036f026"
      unitRef="number">-0.360</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a6257c648ce4c319ca04351b1ac19ca_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc4LTItMS0xLTg0NDQ0_f7bd6155-92d8-4ec3-8d26-6a8a3b329b88"
      unitRef="usd">289000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd0f4a707d5c4611ba64f2bd6e1a1cbb_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc4LTQtMS0xLTg0NDQ0_fdb664c0-450d-4b4a-84c6-ba191bedb3de"
      unitRef="usd">297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae286eb23a9649dab05aa0c949e37a1e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc4LTYtMS0xLTg0NDQ0_b68e6432-a59a-40c3-93da-98b80254e718"
      unitRef="usd">292000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6a6257c648ce4c319ca04351b1ac19ca_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc4LTgtMS0xLTg0NDQ0_21a2ca65-ff1c-4b44-995f-52a5a696838c"
      unitRef="number">-0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifd0f4a707d5c4611ba64f2bd6e1a1cbb_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc4LTEwLTEtMS04NDQ0NA_0a3035d4-da05-40de-8ad6-83b963d77e99"
      unitRef="number">0.017</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3d8e4c1f3ded4e2683fd1b1d3d7f2f3c_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc5LTItMS0xLTg0NDQ0_e25c31a3-4b30-478d-bd58-d983a43b32d4"
      unitRef="usd">318000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4a46b60d378740ab9a53a2c913e6fa9b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc5LTQtMS0xLTg0NDQ0_3c1a7391-37fb-469c-a19d-a9da1a1883e1"
      unitRef="usd">363000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6008938b9b8142ec828a603dc31c9ad2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc5LTYtMS0xLTg0NDQ0_902a9cc5-ffd5-4c74-a219-8943bdedf8e7"
      unitRef="usd">396000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3d8e4c1f3ded4e2683fd1b1d3d7f2f3c_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc5LTgtMS0xLTg0NDQ0_a4e8e268-bd20-4a49-ac8b-8ae40656ded7"
      unitRef="number">-0.123</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4a46b60d378740ab9a53a2c913e6fa9b_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzc5LTEwLTEtMS04NDQ0NA_af8b414f-2621-4efa-87c8-9c75e2de175b"
      unitRef="number">-0.083</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cd9ba3232ba45e7b1a6b4629a8020a2_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgyLTItMS0xLTg0NDQ0_7e1745e2-45df-446d-a2ab-b616c1fb5f90"
      unitRef="usd">3570000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i531f3041cd70490aa0a614493a0966a5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgyLTQtMS0xLTg0NDQ0_1c60584b-00dc-4d2a-a751-48d12be6a031"
      unitRef="usd">3347000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c2c03afbcdc4c75bc0ae9b17f75089b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgyLTYtMS0xLTg0NDQ0_562383ac-1328-402c-a6a9-01084a3c39a6"
      unitRef="usd">3091000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2cd9ba3232ba45e7b1a6b4629a8020a2_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgyLTgtMS0xLTg0NDQ0_3d623e2a-1796-4532-926d-2b5b51d3ac67"
      unitRef="number">0.067</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i531f3041cd70490aa0a614493a0966a5_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgyLTEwLTEtMS04NDQ0NA_441eaa8b-92d2-4dc4-9967-70a73205c5e3"
      unitRef="number">0.083</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i402fca2f518340d8af0930c93c070ab6_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgzLTItMS0xLTg0NDQ0_61de4603-fb5b-4932-9c4c-3dad3240734b"
      unitRef="usd">3323000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e268daebe694083b67a5bd25ccebbaf_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgzLTQtMS0xLTg0NDQ0_f9093954-066a-44d0-bc5d-3b21faed7d79"
      unitRef="usd">3641000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9ed046d3cd9f404a967c40585336ae5e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgzLTYtMS0xLTg0NDQ0_3f640f08-d5f9-4977-98b8-a02ac881d494"
      unitRef="usd">3435000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i402fca2f518340d8af0930c93c070ab6_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgzLTgtMS0xLTg0NDQ0_af745640-cefa-4b62-92e2-3865f295a5eb"
      unitRef="number">-0.087</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0e268daebe694083b67a5bd25ccebbaf_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzgzLTEwLTEtMS04NDQ0NA_1601398b-8820-41b0-87b4-f86d9c12036c"
      unitRef="number">0.060</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6d6c31d76c79411d9f1e91f496118539_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg0LTItMS0xLTg0NDQ0_6eb1ef24-6311-40d2-93ce-e126854f6390"
      unitRef="usd">6893000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i89359ce197324e7d8e9b12c16f4d715a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg0LTQtMS0xLTg0NDQ0_5456c2d9-9ed9-4bee-b036-1fba14d822db"
      unitRef="usd">6988000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie38900d6ebb345d29c6d1b684d8bc793_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg0LTYtMS0xLTg0NDQ0_6d9804e6-397c-4e81-846c-6e1f659e56bc"
      unitRef="usd">6526000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6d6c31d76c79411d9f1e91f496118539_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg0LTgtMS0xLTg0NDQ0_00c4fd6e-89d6-4f9c-80b5-e3410fffe461"
      unitRef="number">-0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i89359ce197324e7d8e9b12c16f4d715a_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg0LTEwLTEtMS04NDQ0NA_394cc3ec-b1bc-4ab3-b7ec-c33f4e31b1a4"
      unitRef="number">0.071</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ief7ad9c3131d41be987d8486d4ad049b_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg2LTItMS0xLTg0NDQ0_220cba1f-719d-4f11-88d2-55b2be95d434"
      unitRef="usd">151000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idcc6f1927b774f8d96f04fe0a712fb86_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg2LTQtMS0xLTg0NDQ0_19b2a137-d700-43e4-ba78-abb899ee129c"
      unitRef="usd">172000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if22f8c6bf53748f190098078cc426ff1_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg2LTYtMS0xLTg0NDQ0_67b593be-b742-4afb-808d-28e4e76b6bb6"
      unitRef="usd">183000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ief7ad9c3131d41be987d8486d4ad049b_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg2LTgtMS0xLTg0NDQ0_0701af91-bc97-400c-834d-2647fa9e247b"
      unitRef="number">-0.125</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idcc6f1927b774f8d96f04fe0a712fb86_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg2LTEwLTEtMS04NDQ0NA_27c979fd-925c-41dc-83fc-b914d497f799"
      unitRef="number">-0.058</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6610d754863471e9d5a6fed947d250a_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg3LTItMS0xLTg0NDQ0_06ec4ced-dffe-4fd5-8769-dd8e283b54b6"
      unitRef="usd">493000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i388399bd3edd4e449f4d93d8915eb54c_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg3LTQtMS0xLTg0NDQ0_c4852a38-0c9a-4223-a66d-86ceda91ba78"
      unitRef="usd">495000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia806a9dc2927417fa00d06260663112c_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg3LTYtMS0xLTg0NDQ0_8046c0d0-a914-4162-9ed7-849c90e01232"
      unitRef="usd">439000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic6610d754863471e9d5a6fed947d250a_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg3LTgtMS0xLTg0NDQ0_71eff16f-00cb-4f9b-9562-4203337d460e"
      unitRef="number">-0.004</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i388399bd3edd4e449f4d93d8915eb54c_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg3LTEwLTEtMS04NDQ0NA_308b3cfe-894c-4413-b4fc-4df026285862"
      unitRef="number">0.128</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie4a41b434b5643ac9706b30fd05f05cc_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg4LTItMS0xLTg0NDQ0_63444b59-9ea4-4d6a-883f-c26db710028b"
      unitRef="usd">644000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c01b12144ba4292808074086604f6b9_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg4LTQtMS0xLTg0NDQ0_188a75f4-e700-4dc7-8f34-ad8d67f924ad"
      unitRef="usd">667000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icfaa8480658d47aeb19114550474ae8e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg4LTYtMS0xLTg0NDQ0_8ef9cfe5-2656-4938-8c46-f43f2b52d03f"
      unitRef="usd">622000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie4a41b434b5643ac9706b30fd05f05cc_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg4LTgtMS0xLTg0NDQ0_6b3125c0-002a-4cd1-a412-21bfc2ebbc75"
      unitRef="number">-0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7c01b12144ba4292808074086604f6b9_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzg4LTEwLTEtMS04NDQ0NA_b41a817f-ca47-405d-ac46-94ad0fa42695"
      unitRef="number">0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e93fc3771554eaea942a7d80a2a5191_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkwLTItMS0xLTg0NDQ0_ce55caaf-74ef-4f04-b1cd-59f828e0382a"
      unitRef="usd">2714000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5235c523a314775ab067969dfd06501_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkwLTQtMS0xLTg0NDQ0_de191f51-ca21-43e3-b18d-b10119ebeac3"
      unitRef="usd">2550000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib3d7ae90ffe640d1b0883b71099f3c5c_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkwLTYtMS0xLTg0NDQ0_4eeea559-706f-4c9b-947a-755e9bb014eb"
      unitRef="usd">2314000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0e93fc3771554eaea942a7d80a2a5191_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkwLTgtMS0xLTg0NDQ0_34d03487-ef26-44e3-89c8-d153c34a7c46"
      unitRef="number">0.065</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie5235c523a314775ab067969dfd06501_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkwLTEwLTEtMS04NDQ0NA_8ef11315-85ea-4b21-ace3-f9e0497d0efa"
      unitRef="number">0.102</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i03c54db2a9f24834a5cd8e9430746ef9_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkxLTItMS0xLTg0NDQ0_fa2901ba-c79b-4f5d-acc5-aa0b66ed50ce"
      unitRef="usd">1426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia1925b3bd72f49578ec926bb8b286ea4_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkxLTQtMS0xLTg0NDQ0_2528f8a0-518e-4466-86bb-b5fb0b2b5753"
      unitRef="usd">1472000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifec5634cbb6c4bc397afe138e65efc43_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkxLTYtMS0xLTg0NDQ0_e90e66fb-3541-41d7-8236-5b45091ca667"
      unitRef="usd">1339000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i03c54db2a9f24834a5cd8e9430746ef9_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkxLTgtMS0xLTg0NDQ0_3c5c541e-b4b1-4e0b-915a-f392b8ab8a58"
      unitRef="number">-0.031</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia1925b3bd72f49578ec926bb8b286ea4_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkxLTEwLTEtMS04NDQ0NA_bc6526f5-2233-42c4-903f-14dc76139b8f"
      unitRef="number">0.100</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26dc3482b6c144828d2d9c88adc29ae9_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkyLTItMS0xLTg0NDQ0_d6cc3c18-277c-480e-936c-c78d573d4ef0"
      unitRef="usd">4140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia24bd46b2fd04893b597d1d6c0898eb7_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkyLTQtMS0xLTg0NDQ0_837fd93c-c1af-43ad-8db6-2f1ab3a0f637"
      unitRef="usd">4022000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic7228601370344a3b7c098e83bbcb756_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkyLTYtMS0xLTg0NDQ0_79915ddb-c699-409a-bd86-648e29d71f54"
      unitRef="usd">3653000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i26dc3482b6c144828d2d9c88adc29ae9_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkyLTgtMS0xLTg0NDQ0_9b742b5d-19e2-494a-adbd-1058501eacd5"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia24bd46b2fd04893b597d1d6c0898eb7_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzkyLTEwLTEtMS04NDQ0NA_b1dd6d8e-957a-476f-add8-a0710e24f0da"
      unitRef="number">0.101</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8cc6bf38d4874b188bd7a4fbd673a97a_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk0LTItMS0xLTg0NDQ0_e7b2e066-24a4-4ec1-868d-b218572004f1"
      unitRef="usd">257000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6698df7c52e241f69da5dfaf96df667e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk0LTQtMS0xLTg0NDQ0_6bd96698-ac94-4a69-b3eb-7014a24384d4"
      unitRef="usd">287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8692c4c3b564eeaabf2e1b6e509764f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk0LTYtMS0xLTg0NDQ0_86442588-6cc1-47b4-829f-35b9df1b9312"
      unitRef="usd">296000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8cc6bf38d4874b188bd7a4fbd673a97a_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk0LTgtMS0xLTg0NDQ0_b6927beb-4c55-4105-9e5b-d06af961ddb4"
      unitRef="number">-0.104</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6698df7c52e241f69da5dfaf96df667e_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk0LTEwLTEtMS04NDQ0NA_a5e87fa5-e0ef-47b2-95f7-c2e7283f1e27"
      unitRef="number">-0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb475dbd9dd64c05bd7d3314c41d69fe_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk1LTItMS0xLTg0NDQ0_fb937fbe-d899-4c0a-ba94-7566757ce4a4"
      unitRef="usd">228000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibe678f07567c458196735fc6dbe00d17_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk1LTQtMS0xLTg0NDQ0_37a5f5e9-ac40-4922-8f14-9ec57c010c14"
      unitRef="usd">305000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i605fa23baf2f4ea78746871328fb7ead_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk1LTYtMS0xLTg0NDQ0_31239aef-05db-4c2d-a1f8-be8a1d93c99a"
      unitRef="usd">346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ifb475dbd9dd64c05bd7d3314c41d69fe_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk1LTgtMS0xLTg0NDQ0_fbbfcaeb-6773-48bf-8d59-bf36b0a029e7"
      unitRef="number">-0.253</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibe678f07567c458196735fc6dbe00d17_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk1LTEwLTEtMS04NDQ0NA_bba8d681-ff42-4368-ba2e-4eccafc934c8"
      unitRef="number">-0.118</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iae81ec5366b14326a0b7f0c13fb74817_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk2LTItMS0xLTg0NDQ0_86189178-6c72-49e6-a901-98de9a3c85bc"
      unitRef="usd">485000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9404055d94a45daba90f61bf0fb4da5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk2LTQtMS0xLTg0NDQ0_ff4a030c-f2bf-4455-882c-c93dbe5db8f4"
      unitRef="usd">592000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6f2a17cebf7348ba8a85d601ef95950d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk2LTYtMS0xLTg0NDQ0_ff2fbf26-9281-4230-8619-3a3788b45e0f"
      unitRef="usd">642000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iae81ec5366b14326a0b7f0c13fb74817_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk2LTgtMS0xLTg0NDQ0_bf6e09bc-8f7a-4b90-af8b-387dcb79dcb7"
      unitRef="number">-0.181</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic9404055d94a45daba90f61bf0fb4da5_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk2LTEwLTEtMS04NDQ0NA_802b0e41-d5d3-4bff-8626-1067f6da762a"
      unitRef="number">-0.077</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b4e7b35d9e54a27b148b95717e09f65_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk4LTItMS0xLTg0NDQ0_f1a84b94-3e7a-4800-a798-19beda89564f"
      unitRef="usd">447000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i46565c94f13f45f4b15ef2dfc93ac248_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk4LTQtMS0xLTg0NDQ0_724836aa-9e4c-4745-81f2-48575b4c510d"
      unitRef="usd">338000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i269786122e034c9a8fd09281eddd8ce6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk4LTYtMS0xLTg0NDQ0_d0972c94-97f4-4e43-a6c8-b69f054e53b8"
      unitRef="usd">298000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0b4e7b35d9e54a27b148b95717e09f65_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk4LTgtMS0xLTg0NDQ0_769ae52c-6444-43c6-a3bf-346c71815bf0"
      unitRef="number">0.324</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i46565c94f13f45f4b15ef2dfc93ac248_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk4LTEwLTEtMS04NDQ0NA_3a84efb3-e8b7-4813-ab90-8be30a068b71"
      unitRef="number">0.133</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie53f9949f4d84aa5a52762670bfefd4b_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk5LTItMS0xLTg0NDQ0_0810b9ae-6968-4711-bf50-0710f4079ae6"
      unitRef="usd">1176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i324b80e3c3ce440d9637c080549788f0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk5LTQtMS0xLTg0NDQ0_247cfedb-9f77-4ee8-be5b-3a228dd560fa"
      unitRef="usd">1368000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i84e21a76b60c423bb70648b1c526109e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk5LTYtMS0xLTg0NDQ0_80c22b0c-a691-407d-9be2-1996df98c5d6"
      unitRef="usd">1312000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie53f9949f4d84aa5a52762670bfefd4b_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk5LTgtMS0xLTg0NDQ0_54e2a233-a1d7-4371-b124-4a2def17fadf"
      unitRef="number">-0.141</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i324b80e3c3ce440d9637c080549788f0_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzk5LTEwLTEtMS04NDQ0NA_ed7138d7-89b3-448c-a8e0-d22dd748e6b6"
      unitRef="number">0.043</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i531753cbd8df46a191a33e3a9070c38f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMC0yLTEtMS04NDQ0NA_38639408-e9f5-4118-bab3-cbb4b777a86a"
      unitRef="usd">1623000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26f47936bebf4e8e931a42d37ff16544_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMC00LTEtMS04NDQ0NA_98ea4761-fb2e-4edc-91c7-367ddf812850"
      unitRef="usd">1706000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iff8d6fee31d84079a124b85f43dd7a5d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMC02LTEtMS04NDQ0NA_342efb66-fde1-4042-9d13-a73f335b52b9"
      unitRef="usd">1610000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i531753cbd8df46a191a33e3a9070c38f_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMC04LTEtMS04NDQ0NA_7be8f142-04a0-41a5-a08c-2eb672b9c697"
      unitRef="number">-0.049</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i26f47936bebf4e8e931a42d37ff16544_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMC0xMC0xLTEtODQ0NDQ_ed617c49-4ad7-4c65-895b-54762a60a313"
      unitRef="number">0.060</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i258d249f5434470bb702dca877dce7cc_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMy0yLTEtMS04NDQ0NA_79fd5d2e-b687-49f7-8957-3e09928572e3"
      unitRef="usd">6930000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1bf95a45f3b7410cb1201a2856109d72_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMy00LTEtMS04NDQ0NA_af26c20a-c505-4dab-aa2d-0810f1a4c81d"
      unitRef="usd">5958000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i262b23b4cfa3413ea822c90957dc8c6b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMy02LTEtMS04NDQ0NA_f8a66ede-c8d8-495a-a183-afdccdf6da0b"
      unitRef="usd">5092000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i258d249f5434470bb702dca877dce7cc_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMy04LTEtMS04NDQ0NA_5b4e397e-54ad-4f55-b18f-d417d6cf5674"
      unitRef="number">0.163</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1bf95a45f3b7410cb1201a2856109d72_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwMy0xMC0xLTEtODQ0NDQ_b024d80b-a7f9-4c2d-996c-cbd6152d50b4"
      unitRef="number">0.170</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i24b8ea85287e48b5ab16ce511107e30d_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNC0yLTEtMS04NDQ0NA_a443a8ff-e613-4855-b5eb-fe57871b9699"
      unitRef="usd">9052000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0d14d3af658b449da07dc0be4f9a9b0d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNC00LTEtMS04NDQ0NA_e77719be-0642-4e8f-9fd5-d7276d1a22eb"
      unitRef="usd">8590000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7520de6a9d0449ffb1547564cab682ed_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNC02LTEtMS04NDQ0NA_45cabbb7-2727-4a79-a7e1-8767b4dafbf1"
      unitRef="usd">7275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i24b8ea85287e48b5ab16ce511107e30d_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNC04LTEtMS04NDQ0NA_bef3e543-0a9c-4873-b24b-232259d4a0ce"
      unitRef="number">0.054</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0d14d3af658b449da07dc0be4f9a9b0d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNC0xMC0xLTEtODQ0NDQ_a7cde4b8-bb6a-4ce7-8e22-f9ae84a02667"
      unitRef="number">0.181</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i68e64b453d6c408381dbb9d6a4335a90_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNS0yLTEtMS04NDQ0NA_cad25694-a5d7-4981-86e9-550671d4aed7"
      unitRef="usd">15983000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5c85d4146adf40d590c1b983de215889_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNS00LTEtMS04NDQ0NA_906b86ca-0802-4197-bb99-f5546526c3e7"
      unitRef="usd">14548000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iab4f46984eb74afe9365b8352076078e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNS02LTEtMS04NDQ0NA_a6d971f6-d426-4503-8b4a-b6c2fa782a36"
      unitRef="usd">12367000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i68e64b453d6c408381dbb9d6a4335a90_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNS04LTEtMS04NDQ0NA_a65f318f-b141-464f-a14e-bfc70332beba"
      unitRef="number">0.099</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5c85d4146adf40d590c1b983de215889_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNS0xMC0xLTEtODQ0NDQ_4a6f3b75-25a1-48ad-a362-09afec6d20dc"
      unitRef="number">0.176</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i42467f46f4f94427ab2e63069eef5ae8_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNy0yLTEtMS04NDQ0NA_104e9a46-9db8-4997-a773-16684f35bce7"
      unitRef="usd">4210000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6ffac75e48304352a8dfea6d5c6ab3f6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNy00LTEtMS04NDQ0NA_e7a201cb-2dfb-4f38-ba60-ccab2351b1fd"
      unitRef="usd">3169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i646423bb9a524219bf440e4800663ed3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNy02LTEtMS04NDQ0NA_54eec778-21e6-4061-9631-b7073a5def35"
      unitRef="usd">2232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i42467f46f4f94427ab2e63069eef5ae8_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNy04LTEtMS04NDQ0NA_bb2b83e5-2365-46bb-97f4-f6211455faa9"
      unitRef="number">0.328</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6ffac75e48304352a8dfea6d5c6ab3f6_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwNy0xMC0xLTEtODQ0NDQ_dab98830-b831-44e4-8417-48ffb927071f"
      unitRef="number">0.420</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if600a19a06ac46f1afe1fb53208669c2_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOC0yLTEtMS04NDQ0NA_3038d85e-7f65-416d-9c28-d9462cd763f7"
      unitRef="usd">3767000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddfa392c8b99451a919767258d532fe5_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOC00LTEtMS04NDQ0NA_147d5390-5404-4e77-99a6-d8195db3efff"
      unitRef="usd">2854000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic353f059b15e42808dfe31fbfa26b20b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOC02LTEtMS04NDQ0NA_879bab56-035d-4d87-ae71-0ee02a42d047"
      unitRef="usd">1958000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if600a19a06ac46f1afe1fb53208669c2_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOC04LTEtMS04NDQ0NA_e9170898-ebcb-4a0d-9979-10bfcbd0eb23"
      unitRef="number">0.320</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iddfa392c8b99451a919767258d532fe5_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOC0xMC0xLTEtODQ0NDQ_e9194080-00a6-4a4c-9931-1e78284ebb0f"
      unitRef="number">0.458</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56d81c1fa8cd49908a0537e36e44cae0_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOS0yLTEtMS04NDQ0NA_714ce710-e75d-49c3-ad35-6e7fedcba5d8"
      unitRef="usd">7977000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic0bfc95e5f50496095f0e7adbac02fae_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOS00LTEtMS04NDQ0NA_4b05fd5d-0e8e-4e58-9204-8689670454f8"
      unitRef="usd">6023000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i081324fa191f4ecfb64d5fd21e4897f8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOS02LTEtMS04NDQ0NA_d2512c5c-6e02-4c0e-908d-aa5c03a44958"
      unitRef="usd">4190000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i56d81c1fa8cd49908a0537e36e44cae0_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOS04LTEtMS04NDQ0NA_ea997b4e-c34f-44cc-8184-9b5096dfaf5a"
      unitRef="number">0.324</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic0bfc95e5f50496095f0e7adbac02fae_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEwOS0xMC0xLTEtODQ0NDQ_cb7f77ca-2cb6-478d-b9f4-b53c9684f19d"
      unitRef="number">0.438</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic5a747f1894746c18acebe55fcee36be_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMS0yLTEtMS04NDQ0NA_7a932d7b-7559-4d2c-907c-c5f5efc2b80a"
      unitRef="usd">968000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia9952f78ff604ce98857b34e7d2d4ee4_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMS00LTEtMS04NDQ0NA_a5f9528b-141d-4daf-bb82-d7e15aae2ac2"
      unitRef="usd">813000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i56304f6c91134b9ea995c8c26f92fcf8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMS02LTEtMS04NDQ0NA_08dffd3b-c886-4123-bcb4-c4220845d7eb"
      unitRef="usd">583000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic5a747f1894746c18acebe55fcee36be_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMS04LTEtMS04NDQ0NA_a52ecf38-ada1-41ae-93a7-75cf54d09ca1"
      unitRef="number">0.192</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia9952f78ff604ce98857b34e7d2d4ee4_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMS0xMC0xLTEtODQ0NDQ_1ba7ec8a-b0f3-4b52-8856-7044f2f152d6"
      unitRef="number">0.393</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1170f44e3e784c13a897d1f33b657d36_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMi0yLTEtMS04NDQ0NA_db11ec2b-92bf-41ed-bac7-543501f967c0"
      unitRef="usd">913000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1aab7e608c8647bfae8078c104427a5e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMi00LTEtMS04NDQ0NA_e90d1e6d-13cd-4fec-9b06-d810c03a0613"
      unitRef="usd">478000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98cb0d95137a4c3e932962b28dfea7fd_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMi02LTEtMS04NDQ0NA_da3c2120-0386-43d5-9530-e6e58e895d48"
      unitRef="usd">176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7df5c5bd36f4c42bc5a42a86e4787fd_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMy0yLTEtMS04NDQ0NA_73bcde1e-0fcb-4e26-8a5c-26f1d831bef7"
      unitRef="usd">1881000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib995e35deab1419bb10080c3e8bbe15f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMy00LTEtMS04NDQ0NA_1ebe85ab-6613-424d-aa1a-75e021e90d53"
      unitRef="usd">1291000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i008fe96bbc464d418ec59e61164bd16f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMy02LTEtMS04NDQ0NA_c6d46e71-10d9-4e49-b5db-f021b9b6c4d7"
      unitRef="usd">760000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia7df5c5bd36f4c42bc5a42a86e4787fd_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMy04LTEtMS04NDQ0NA_509efd45-513c-4f33-bbf2-ccf14cef038c"
      unitRef="number">0.457</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib995e35deab1419bb10080c3e8bbe15f_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExMy0xMC0xLTEtODQ0NDQ_66d22a5a-40c7-45a6-95b6-f919a032a966"
      unitRef="number">0.700</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e40224a7adc43c8a51c165cb1091d51_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNS0yLTEtMS04NDQ0NA_1ebdb71e-5dbf-448a-a875-1d76ea6e7d5c"
      unitRef="usd">1390000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0e1bf9204c548b1a2ba79c5c9f86b69_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNS00LTEtMS04NDQ0NA_e01eb4bb-4911-4343-9f2f-e296a76b3401"
      unitRef="usd">1747000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1d65c31f1e1e4231a4590f52e12e147f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNS02LTEtMS04NDQ0NA_81a5c4b0-0802-47a7-bbda-c68d48515992"
      unitRef="usd">1821000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3e40224a7adc43c8a51c165cb1091d51_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNS04LTEtMS04NDQ0NA_3c61eacb-667d-4d4c-a343-805fe5822a3d"
      unitRef="number">-0.204</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id0e1bf9204c548b1a2ba79c5c9f86b69_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNS0xMC0xLTEtODQ0NDQ_6e747843-46d1-42fe-92d5-6018abf55b2b"
      unitRef="number">-0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8696093b3c14612a5e87f253f041390_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNi0yLTEtMS04NDQ0NA_14bd3573-caad-465d-8eda-c1b71aa351fb"
      unitRef="usd">2394000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i013ed648148d4e64a510c4039f176525_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNi00LTEtMS04NDQ0NA_a51927a5-839b-4d21-a66c-e61761400339"
      unitRef="usd">2622000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0ee4b03f8ff435d8d7e8b5936462ff2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNi02LTEtMS04NDQ0NA_4fa878d5-4f24-44fd-a97d-5c2b9d77f664"
      unitRef="usd">2307000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib8696093b3c14612a5e87f253f041390_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNi04LTEtMS04NDQ0NA_b5d020c8-8bcc-44e2-bbc4-78ca799d8410"
      unitRef="number">-0.087</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i013ed648148d4e64a510c4039f176525_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNi0xMC0xLTEtODQ0NDQ_414a996d-ebd9-4422-b048-f14e8cb29354"
      unitRef="number">0.136</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1bef826f6694533ac45bf2390d238f4_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNy0yLTEtMS04NDQ0NA_d9a6e5ec-bf54-44f3-90e9-59be854e063f"
      unitRef="usd">3784000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d1ab414424746e7be5d469d0581e83d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNy00LTEtMS04NDQ0NA_a03e2b5f-dd8b-4049-8e40-aaf26d041b3f"
      unitRef="usd">4369000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i98d58d05f93b4a88bda30ee75b9bd330_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNy02LTEtMS04NDQ0NA_a38e5ec3-c2c5-4d8b-b570-138f20711a33"
      unitRef="usd">4128000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie1bef826f6694533ac45bf2390d238f4_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNy04LTEtMS04NDQ0NA_02ab001c-4a25-42b3-8f11-fb54d3b501c2"
      unitRef="number">-0.134</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9d1ab414424746e7be5d469d0581e83d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzExNy0xMC0xLTEtODQ0NDQ_bc8d7465-462e-4c1e-bf96-cc6fdb58fe5f"
      unitRef="number">0.058</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf89a91e03874addb0a5a3f057b8bf3b_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyMy0yLTEtMS04NDQ0NA_51e13b43-9881-4af2-97fb-75f5469cba76"
      unitRef="usd">74000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic89356ecf07b40f0a9a2da3ade617700_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyMy00LTEtMS04NDQ0NA_cac887a0-73a2-4278-b67c-1b0c0e72120c"
      unitRef="usd">119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idea1ec1749cd4cabbe3791c077d397a5_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyMy02LTEtMS04NDQ0NA_d144c198-f73c-4209-8c94-44c29df81a42"
      unitRef="usd">373000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="idf89a91e03874addb0a5a3f057b8bf3b_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyMy04LTEtMS04NDQ0NA_9b62340f-5851-44cb-9847-e6b4c7719328"
      unitRef="number">-0.378</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic89356ecf07b40f0a9a2da3ade617700_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyMy0xMC0xLTEtODQ0NDQ_acc2462d-7af6-4450-a0dc-1fe2cae0debc"
      unitRef="number">-0.681</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee811815defd442b9a2cc33fcd46a0d9_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNC0yLTEtMS04NDQ0NA_8042428b-cc42-4dd3-9df6-5731cac153b4"
      unitRef="usd">1696000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie657f643b4d84751a89bb88a4ad2046b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNC00LTEtMS04NDQ0NA_0de79e64-ab03-4fe7-89c1-6b05b38ced6f"
      unitRef="usd">2178000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0fc87b939f80405381cdf5826af23b5e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNC02LTEtMS04NDQ0NA_601cb9be-6e1b-4456-a6e0-e0afa2f9c32f"
      unitRef="usd">2097000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iee811815defd442b9a2cc33fcd46a0d9_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNC04LTEtMS04NDQ0NA_ef2bddf9-f871-4cd9-853d-161156d93fdf"
      unitRef="number">-0.221</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie657f643b4d84751a89bb88a4ad2046b_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNC0xMC0xLTEtODQ0NDQ_b9b9f531-4c8e-4600-9b63-5962b1e6cb99"
      unitRef="number">0.039</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b389620244e4707b32be2326487bc32_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNS0yLTEtMS04NDQ0NA_20b0bf9e-98c7-4960-b898-6977f72f75cd"
      unitRef="usd">1770000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iefecdd362bfa4d2db19e395e947a0d65_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNS00LTEtMS04NDQ0NA_a1371306-98de-4f8a-86eb-9eb02383d3c9"
      unitRef="usd">2297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id84af39344ca4fa5a66b03352afc5e18_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNS02LTEtMS04NDQ0NA_3566838f-071c-44b3-b252-390f1240942f"
      unitRef="usd">2470000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7b389620244e4707b32be2326487bc32_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNS04LTEtMS04NDQ0NA_6369267a-dece-46d8-9b0d-8dd74a55ab3c"
      unitRef="number">-0.229</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iefecdd362bfa4d2db19e395e947a0d65_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNS0xMC0xLTEtODQ0NDQ_b71be8da-8cb6-49a2-8e0e-d23a5b6410eb"
      unitRef="number">-0.070</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b76b01e302941c287997d97c3f61777_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNy0yLTEtMS04NDQ0NA_a62e8176-d320-4b03-be4e-393fa7cdc1f9"
      unitRef="usd">289000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6936c2410a964df4898165a8dde602da_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNy00LTEtMS04NDQ0NA_9e7a7717-4a58-4dff-b250-ca3e42b1ab02"
      unitRef="usd">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie7bd843dd374433190aa473e3d8f6192_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNy02LTEtMS04NDQ0NA_ae9ecf81-4ec1-4df3-8e97-bb0316b80a8e"
      unitRef="usd">83000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6936c2410a964df4898165a8dde602da_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyNy0xMC0xLTEtODQ0NDQ_c29020e7-780f-4086-ba61-c58f74e11445"
      unitRef="number">0.317</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76995ebc9d3b42ce851ae92a54711982_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOC0yLTEtMS04NDQ0NA_fe7d90a8-1741-4552-8204-051d1b4afd59"
      unitRef="usd">283000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36a27cd0e7ed41e68d19c477b421f3c0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOC00LTEtMS04NDQ0NA_75b03d09-3624-49c9-a0c0-9632a26be54d"
      unitRef="usd">458000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7001035b825b4a55830f9093152ea514_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOC02LTEtMS04NDQ0NA_e9077542-8f76-4846-a7c9-442f5401e8c3"
      unitRef="usd">738000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i76995ebc9d3b42ce851ae92a54711982_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOC04LTEtMS04NDQ0NA_f3d1b03d-858e-4a9a-aaa9-7db535e26821"
      unitRef="number">-0.383</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i36a27cd0e7ed41e68d19c477b421f3c0_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOC0xMC0xLTEtODQ0NDQ_6fd61b5f-f60e-4045-bb63-f19097223434"
      unitRef="number">-0.379</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba577ca1802747c39cfd14db4de2c73e_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOS0yLTEtMS04NDQ0NA_927c786e-1028-4965-85f5-e68a89b1347d"
      unitRef="usd">571000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i59a17dd172ff4c2481abf0f956446b82_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOS00LTEtMS04NDQ0NA_8adcfc51-2ad3-4821-b74e-82ebfe4b33c7"
      unitRef="usd">568000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9d1cfe8125bf4f15bb0a5e1a59589712_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOS02LTEtMS04NDQ0NA_43da5e3a-4386-4808-9246-65e194753206"
      unitRef="usd">821000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iba577ca1802747c39cfd14db4de2c73e_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOS04LTEtMS04NDQ0NA_82d8eff2-d704-4d09-8cc9-b61c710df0a1"
      unitRef="number">0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i59a17dd172ff4c2481abf0f956446b82_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEyOS0xMC0xLTEtODQ0NDQ_1443ca14-04ee-4b4b-93ee-e48c3e717990"
      unitRef="number">-0.308</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1fe446820d2747f094272bcdc9f800bf_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMi0yLTEtMS04NDQ0NA_26d0e450-da64-46d9-a657-60b7da539834"
      unitRef="usd">2346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b8757a22a8743e3ac6b47bb33abf088_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMi00LTEtMS04NDQ0NA_3fdf9c51-88da-4379-b0d3-aa8372cf9ea1"
      unitRef="usd">2365000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if6d1cb780cac40c392f1b55b06665d46_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMi02LTEtMS04NDQ0NA_6c35d249-7fdc-4096-97d9-e6719afaf6ee"
      unitRef="usd">2133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1fe446820d2747f094272bcdc9f800bf_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMi04LTEtMS04NDQ0NA_3ba4df86-2f30-45c6-8bfa-b354011ea18c"
      unitRef="number">-0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7b8757a22a8743e3ac6b47bb33abf088_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMi0xMC0xLTEtODQ0NDQ_d57f1648-e67d-49eb-bb9e-c191149ab4fc"
      unitRef="number">0.109</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a13564b2ced4d028a7c3601115a89a0_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMy0yLTEtMS04NDQ0NA_6b8640d2-1660-4f03-95f2-7f79549fcfe6"
      unitRef="usd">1071000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e26b9b503db42389ed14ff2087d196d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMy00LTEtMS04NDQ0NA_1e337c30-94b2-406c-9f04-eebbef8bcd28"
      unitRef="usd">1085000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i374baaf3b488452d89425765aac44db0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMy02LTEtMS04NDQ0NA_99c51a07-19de-42b7-bf8e-74d0884593d5"
      unitRef="usd">1015000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0a13564b2ced4d028a7c3601115a89a0_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMy04LTEtMS04NDQ0NA_1ef24e3a-c3da-48a5-ae5b-d91fe296124a"
      unitRef="number">-0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8e26b9b503db42389ed14ff2087d196d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzMy0xMC0xLTEtODQ0NDQ_8acc573e-af48-4632-90a8-7abf83f4dda9"
      unitRef="number">0.069</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77a7e09f6f90410eb6663244cbe7e73d_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNC0yLTEtMS04NDQ0NA_b6f68b10-eaae-4178-8899-65262c504d63"
      unitRef="usd">3417000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2cfc4b069b214a88b076bd5e9211de36_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNC00LTEtMS04NDQ0NA_74925cf0-73ac-49f2-bbc4-09812b1c3a03"
      unitRef="usd">3450000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="idf16b29572b6423cbbce71268561dc2f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNC02LTEtMS04NDQ0NA_f0ae5502-e09d-46ed-b767-a2e5ce38f045"
      unitRef="usd">3148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i77a7e09f6f90410eb6663244cbe7e73d_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNC04LTEtMS04NDQ0NA_8b8a010d-0da7-476e-b722-94c0325938cf"
      unitRef="number">-0.010</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2cfc4b069b214a88b076bd5e9211de36_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNC0xMC0xLTEtODQ0NDQ_bea8d3a2-4910-4b28-82c3-f64639db4c2e"
      unitRef="number">0.096</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5463962cffff4346b6f757fb352376bf_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNi0yLTEtMS04NDQ0NA_8ca30ed2-f3c5-417b-b83c-7e2580649855"
      unitRef="usd">1132000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4508e19a81e14913a4c1c511d2086478_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNi00LTEtMS04NDQ0NA_20975fa5-1d7f-4bf4-9b98-dc4692df1cfa"
      unitRef="usd">1147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0255ba511594a8bbe1f7b35cf65502f_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNi02LTEtMS04NDQ0NA_cda0b04f-b91f-4ee3-8fcd-b1c41462b3f5"
      unitRef="usd">1008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5463962cffff4346b6f757fb352376bf_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNi04LTEtMS04NDQ0NA_330fe26a-1362-4665-aa90-24e65b8808ea"
      unitRef="number">-0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4508e19a81e14913a4c1c511d2086478_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNi0xMC0xLTEtODQ0NDQ_71d5f01a-316b-44f3-9458-151936489b05"
      unitRef="number">0.137</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i22de2e9856b44e04a06ccf411d64efe4_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNy0yLTEtMS04NDQ0NA_5591949e-7866-49e7-b2bd-ff96e4fd376f"
      unitRef="usd">651000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0dc14570d9244e2aa7a97f84bbea32ad_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNy00LTEtMS04NDQ0NA_44124c28-3f0b-43fc-9776-75b4515375f3"
      unitRef="usd">672000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icce2f7bceb104ba68129e1d88ba12479_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNy02LTEtMS04NDQ0NA_39518a41-4b4e-46fc-a3ed-828c894386cc"
      unitRef="usd">631000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i22de2e9856b44e04a06ccf411d64efe4_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNy04LTEtMS04NDQ0NA_ca300d1c-4a9a-41c4-83af-8a4fa742b8ac"
      unitRef="number">-0.032</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0dc14570d9244e2aa7a97f84bbea32ad_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzNy0xMC0xLTEtODQ0NDQ_9ba69358-7572-43a9-98e9-a78b49323a04"
      unitRef="number">0.066</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id6137d6c2ae845578e96f2f9558e743f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzOC0yLTEtMS04NDQ0NA_e0d85bda-0013-44f3-9f05-50210ff5a87f"
      unitRef="usd">1783000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9b1ade7237d24dd7ab77638d8c40a4e7_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzOC00LTEtMS04NDQ0NA_15c5f165-2e95-4d1d-8132-0f82aaaa5c9e"
      unitRef="usd">1819000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i95b5c4f0629a4cc4aecab891a4bc05f0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzOC02LTEtMS04NDQ0NA_17ac631d-cf39-499a-9da3-f16cdc51b303"
      unitRef="usd">1639000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id6137d6c2ae845578e96f2f9558e743f_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzOC04LTEtMS04NDQ0NA_8190bb9a-5fb3-45d0-8427-1f50d061897e"
      unitRef="number">-0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9b1ade7237d24dd7ab77638d8c40a4e7_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzEzOC0xMC0xLTEtODQ0NDQ_158f9e70-b652-45b7-ac3f-cec62f1efd4d"
      unitRef="number">0.110</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb55d931932c4dbfabf0ea3d29fbb324_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MC0yLTEtMS04NDQ0NA_e21022b2-0dfa-4355-b042-cfa2a99dd9b6"
      unitRef="usd">1104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5becc7177bbb4f019eb9d2832933f156_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MC00LTEtMS04NDQ0NA_785078ca-4c88-475c-b786-78c3b8890275"
      unitRef="usd">1056000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic28b731dc2294261b6dbf518da9544b6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MC02LTEtMS04NDQ0NA_02463ff0-e786-43f8-a9db-cca5b7470bad"
      unitRef="usd">955000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icb55d931932c4dbfabf0ea3d29fbb324_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MC04LTEtMS04NDQ0NA_8877ae78-3b7c-47d7-8178-1d3fe9a357ce"
      unitRef="number">0.045</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5becc7177bbb4f019eb9d2832933f156_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MC0xMC0xLTEtODQ0NDQ_0bc20a98-766a-4284-b5bc-2154a3ee383e"
      unitRef="number">0.105</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b6cf0ef3640429391dcd90960832aa6_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MS0yLTEtMS04NDQ0NA_e0d493d8-0da4-4dc2-9576-a84665fb5182"
      unitRef="usd">218000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0a56ab7b9ca24f89852d9e93dffafe9f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MS00LTEtMS04NDQ0NA_31270250-b7dc-4f36-9ff1-6dadb2be6976"
      unitRef="usd">181000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia8e2a5ed832e47a9b4b8c86beaaf4733_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MS02LTEtMS04NDQ0NA_a8bbfe2e-7ded-45e0-a149-f9bb1f9445bf"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2b6cf0ef3640429391dcd90960832aa6_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MS04LTEtMS04NDQ0NA_077fb067-193d-4698-8b5b-ab71ce7d46d6"
      unitRef="number">0.204</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0a56ab7b9ca24f89852d9e93dffafe9f_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0MS0xMC0xLTEtODQ0NDQ_b6b7db2f-41d6-4aaa-a240-3a514cd370f3"
      unitRef="number">0.311</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5eb95d7922c64ca28dea90d41bac3081_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Mi0yLTEtMS04NDQ0NA_a5e12cb3-8ce3-4b05-a0ef-ae89c92afc30"
      unitRef="usd">1322000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if85629f30c724cee9d887e6dd896ce8d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Mi00LTEtMS04NDQ0NA_dc3faf20-801f-457a-8c9c-5ae62e7ba6ff"
      unitRef="usd">1237000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b8655d882ea44638ed3ff1d03bd0dbe_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Mi02LTEtMS04NDQ0NA_a0dcca4a-f0bd-4838-be15-c39cff7750fd"
      unitRef="usd">1093000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5eb95d7922c64ca28dea90d41bac3081_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Mi04LTEtMS04NDQ0NA_b31948ce-e753-469f-ab93-8719364fb8d6"
      unitRef="number">0.069</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if85629f30c724cee9d887e6dd896ce8d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Mi0xMC0xLTEtODQ0NDQ_63828be5-c95f-403f-aaca-d90b194a0cf7"
      unitRef="number">0.131</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i30916c73190f498bb12adcd4eee7e812_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NC0yLTEtMS04NDQ0NA_283e7928-80e9-4028-8db1-8e82e2fc0526"
      unitRef="usd">110000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7b7c39109744471db0921f5a010a74fd_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NC00LTEtMS04NDQ0NA_301ad34c-152a-4d36-bad5-8f6f288d4cbe"
      unitRef="usd">163000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3cf850e2559a44ccb6fb87628e4893d5_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NC02LTEtMS04NDQ0NA_d02a0dc8-4230-400c-a3b0-da988b8b829a"
      unitRef="usd">169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i30916c73190f498bb12adcd4eee7e812_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NC04LTEtMS04NDQ0NA_d34f8360-3378-4e22-ad1e-5f9ca7612da5"
      unitRef="number">-0.323</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7b7c39109744471db0921f5a010a74fd_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NC0xMC0xLTEtODQ0NDQ_4ca31234-328c-45e7-86e9-7b40056192ab"
      unitRef="number">-0.037</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6c76de98f2c417a87e983700d3295da_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NS0yLTEtMS04NDQ0NA_9a0c23d1-5bca-45e8-be1c-53363aa6d858"
      unitRef="usd">202000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5500ee09e8148309c05055c79c1eab2_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NS00LTEtMS04NDQ0NA_bd50f67f-a905-4abe-ae43-559a2a8f7312"
      unitRef="usd">232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iccddf880ad6748c5b0f867362c1aac4d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NS02LTEtMS04NDQ0NA_cec4a48c-8301-4ffc-80f9-60bb816ecc0c"
      unitRef="usd">247000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib6c76de98f2c417a87e983700d3295da_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NS04LTEtMS04NDQ0NA_f3dd1cb4-123d-43a2-a1b2-a2340de43522"
      unitRef="number">-0.128</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib5500ee09e8148309c05055c79c1eab2_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0NS0xMC0xLTEtODQ0NDQ_2fad40e6-3faa-4a6c-b7e3-b6e78bdc57fb"
      unitRef="number">-0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i799adb7b649a470ab60c3ff073dc1386_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Ni0yLTEtMS04NDQ0NA_6235179b-ce9c-48c6-b080-7b180d360f60"
      unitRef="usd">313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9059956b7ebd4ef9aa0ca0715ffea91e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Ni00LTEtMS04NDQ0NA_f171e29f-8913-4f8e-a8fc-09d85bc8c99e"
      unitRef="usd">395000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36786c954f1b44aabdb08b417155a2f2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Ni02LTEtMS04NDQ0NA_9eb86da5-8067-44c6-8658-cfef73c7763c"
      unitRef="usd">416000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i799adb7b649a470ab60c3ff073dc1386_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Ni04LTEtMS04NDQ0NA_cb665933-83d2-4575-acc4-7cc2fd634c5a"
      unitRef="number">-0.208</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9059956b7ebd4ef9aa0ca0715ffea91e_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0Ni0xMC0xLTEtODQ0NDQ_11bcacba-31bd-4cce-8b68-4de5bf997174"
      unitRef="number">-0.050</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8f249bd22be4ccc99f79b41ee68c3cb_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0OS0yLTEtMS04NDQ0NA_245374d7-8b88-417b-aca9-a7cbdec2c604"
      unitRef="usd">3042000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaea127e21314435ea7a422bda430700d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0OS00LTEtMS04NDQ0NA_b0f51bc9-3e1d-4988-96b2-4c721d878236"
      unitRef="usd">3192000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i79f7eca78939441fa15ec6298a45d1ef_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0OS02LTEtMS04NDQ0NA_7c390970-08c7-4250-b4bf-408e8ff16e03"
      unitRef="usd">3509000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib8f249bd22be4ccc99f79b41ee68c3cb_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0OS04LTEtMS04NDQ0NA_00eb1ffe-bb65-46b2-8c7f-a088f6ce7440"
      unitRef="number">-0.047</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaea127e21314435ea7a422bda430700d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE0OS0xMC0xLTEtODQ0NDQ_e77384d1-2a10-4eb5-bc37-9947380dd856"
      unitRef="number">-0.090</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i32cf8ca571194576b3812f9911ec7c96_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MC0yLTEtMS04NDQ0NA_dff5179d-ed01-46ef-a20d-5d6c37601bbc"
      unitRef="usd">845000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c3d4326ed9749e08f9f55e523f5ee30_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MC00LTEtMS04NDQ0NA_dbb3c444-d5df-4ec7-87af-2c44433ffdae"
      unitRef="usd">927000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibb734ded22cc4f09a1e7aa403217a9eb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MC02LTEtMS04NDQ0NA_6e2ab469-5dae-477e-a6f0-3ffcb5786c45"
      unitRef="usd">1025000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i32cf8ca571194576b3812f9911ec7c96_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MC04LTEtMS04NDQ0NA_bae208d2-7aba-428a-9a02-feff8083ce4f"
      unitRef="number">-0.089</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2c3d4326ed9749e08f9f55e523f5ee30_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MC0xMC0xLTEtODQ0NDQ_0ecfdb3f-e2e8-466b-8b14-54c586ecb045"
      unitRef="number">-0.096</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i475da8e727be45c3b387f78b1fea2e7e_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MS0yLTEtMS04NDQ0NA_8af61a32-5430-42ee-8564-dd3796e53134"
      unitRef="usd">3887000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b6d20e6fbcf404989fa7f5435ba4ba6_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MS00LTEtMS04NDQ0NA_da936132-f6f1-478d-8fc3-28de2bf15279"
      unitRef="usd">4119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic976412b06ed475dbb01665551f97bd7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MS02LTEtMS04NDQ0NA_2e27a1ab-454d-4cb8-8349-e44b94103610"
      unitRef="usd">4534000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i475da8e727be45c3b387f78b1fea2e7e_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MS04LTEtMS04NDQ0NA_f0b2e58b-9655-43c1-bd6b-11506c394cc6"
      unitRef="number">-0.056</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8b6d20e6fbcf404989fa7f5435ba4ba6_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1MS0xMC0xLTEtODQ0NDQ_b97b66e4-481b-49a4-8b85-9ef74e8511e5"
      unitRef="number">-0.092</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib2de02b1a13d4d139855d845acf40789_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1My0yLTEtMS04NDQ0NA_9807407f-30d6-4f33-ae29-b7a50e828a00"
      unitRef="usd">2473000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if5e8976d4e1a4b71a27811336c8ab1f8_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1My00LTEtMS04NDQ0NA_9112c67c-b03d-4e44-9d56-083f1b7ef987"
      unitRef="usd">2438000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id7c26f3cd65d4c5d8f2b5bd56c02ed3d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1My02LTEtMS04NDQ0NA_f59791c2-2f0c-4fb2-8f1a-53310b84fa5e"
      unitRef="usd">2345000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib2de02b1a13d4d139855d845acf40789_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1My04LTEtMS04NDQ0NA_0ff73d2b-17f2-4b5c-8825-8ed603c656f7"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if5e8976d4e1a4b71a27811336c8ab1f8_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1My0xMC0xLTEtODQ0NDQ_7c1b6520-a0ee-4759-9178-7f6de8bdc240"
      unitRef="number">0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3f077fb9d5034effb52f4a2b5f9eef57_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NC0yLTEtMS04NDQ0NA_b46552ea-4ca1-4ba8-83e5-bcde695cbf72"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i33a26b2938054f1184c11ed6cf4b88f0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NC00LTEtMS04NDQ0NA_c0a2aab6-40c9-4b92-b495-a2dfe0fbd064"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a88b4bdd8c94764a0107e43c486dc09_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NC02LTEtMS04NDQ0NA_0c63a432-b9ac-4460-a14e-8d6e32055c9d"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3f077fb9d5034effb52f4a2b5f9eef57_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NC04LTEtMS04NDQ0NA_a3570819-9a9d-4082-b8cf-6e47165ef665"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i33a26b2938054f1184c11ed6cf4b88f0_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NC0xMC0xLTEtODQ0NDQ_0b84643d-4eb9-4de8-922f-479dcf4a95ce"
      unitRef="number">0</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie8d8278156114626afb74c2ac5266a22_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NS0yLTEtMS04NDQ0NA_208332fb-2c33-4806-b5ae-f6b85402f11d"
      unitRef="usd">2473000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5bd8ff0a20174e8aa35746d67cdc6c5a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NS00LTEtMS04NDQ0NA_7e7fe6bf-d72f-4157-be50-ae8173f3b440"
      unitRef="usd">2438000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4cddddd8de4b47ea9ad8c08d1dbcfde7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NS02LTEtMS04NDQ0NA_bac875d4-a244-4690-857d-74d576453761"
      unitRef="usd">2345000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie8d8278156114626afb74c2ac5266a22_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NS04LTEtMS04NDQ0NA_6e5dc74b-5c31-4703-8e7f-c671ab51aec7"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5bd8ff0a20174e8aa35746d67cdc6c5a_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1NS0xMC0xLTEtODQ0NDQ_4786b29b-b3e3-43f3-be77-dc37939ce06d"
      unitRef="number">0.040</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ea11b9899164f17b368e2e8e1fd6646_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1Ny0yLTEtMS04NDQ0NA_ea4b8949-69a9-42f7-90a9-58d32ea5f50a"
      unitRef="usd">193000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i13c3371fdeb14d998c863d3e43e1fc97_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1Ny00LTEtMS04NDQ0NA_b00d006e-f4b6-4dfb-9853-8167894c3710"
      unitRef="usd">308000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieafb2d92ce5b42eba36f9dd9ad33d3a5_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1Ny02LTEtMS04NDQ0NA_76ecff55-3733-43f2-8d05-4d3c509a5e11"
      unitRef="usd">564000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8ea11b9899164f17b368e2e8e1fd6646_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1Ny04LTEtMS04NDQ0NA_7e2e21eb-0c6d-4ee7-a059-65743b4e1955"
      unitRef="number">-0.374</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i13c3371fdeb14d998c863d3e43e1fc97_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1Ny0xMC0xLTEtODQ0NDQ_bf0eb0bb-4ca0-4b24-87a5-b58633ac7774"
      unitRef="number">-0.454</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieaf051fa36294b75bbdb2a6a108964d0_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OC0yLTEtMS04NDQ0NA_5efdf70e-7e58-49b6-912a-631d0d4ccf22"
      unitRef="usd">255000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id73e900fdc57444dbbceb802f1d0608b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OC00LTEtMS04NDQ0NA_9eaa1907-0520-4b2b-b889-0c334fc226af"
      unitRef="usd">254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib07d526f34e8412e9d6ac51ac9f427f2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OC02LTEtMS04NDQ0NA_bf6f4743-0f71-4ed6-84d3-791693839565"
      unitRef="usd">231000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ieaf051fa36294b75bbdb2a6a108964d0_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OC04LTEtMS04NDQ0NA_909ce4b1-bf13-40ab-93b1-95f1ef71d009"
      unitRef="number">0.001</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id73e900fdc57444dbbceb802f1d0608b_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OC0xMC0xLTEtODQ0NDQ_d81b1336-ecf2-4774-94d8-22b2b1990936"
      unitRef="number">0.099</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i81eec297555347958006226c1ad5a577_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OS0yLTEtMS04NDQ0NA_1cef35c1-ac0d-4929-a428-95002a4fc130"
      unitRef="usd">448000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iafbedc70de804139afe4d7945d4cb53d_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OS00LTEtMS04NDQ0NA_d7b87782-f3c7-439c-8cfd-1d7270805881"
      unitRef="usd">563000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcc31dc5500e46db949b0cb3ef157084_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OS02LTEtMS04NDQ0NA_052f55b3-e105-4c03-b40a-470a09fbf6cf"
      unitRef="usd">795000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i81eec297555347958006226c1ad5a577_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OS04LTEtMS04NDQ0NA_409856e1-0ac9-4dfa-809b-6c7b387238cf"
      unitRef="number">-0.204</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iafbedc70de804139afe4d7945d4cb53d_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE1OS0xMC0xLTEtODQ0NDQ_638c9114-d813-4229-8662-e583f2fc42c2"
      unitRef="number">-0.293</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5a2ef424a8a8474cac5b9126f26ba070_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2NS0yLTEtMS04NDQ0NA_93811f87-c1c8-4d9e-91ea-1d431d7208e1"
      unitRef="usd">376000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2d05b9c8081748e2a9f6313aa40cc11b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2NS00LTEtMS04NDQ0NA_02a3f7c4-525e-429b-9f66-d9b41337c2bd"
      unitRef="usd">446000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if79c42dff8224bcd8bda45cfd70678a7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2NS02LTEtMS04NDQ0NA_592fcfb1-01ae-48ca-be14-01814e86a540"
      unitRef="usd">600000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5a2ef424a8a8474cac5b9126f26ba070_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2NS04LTEtMS04NDQ0NA_f1f2f06d-1b70-473f-8f45-69d6ecf1e6cd"
      unitRef="number">-0.155</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2d05b9c8081748e2a9f6313aa40cc11b_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2NS0xMC0xLTEtODQ0NDQ_5eedeaaf-2501-4d24-b4be-e52e770be5b6"
      unitRef="number">-0.257</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2555de19982c4c1c919234a3b7833ea2_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ni0yLTEtMS04NDQ0NA_57f6fdd1-f6ac-456b-865f-ef977266e37d"
      unitRef="usd">590000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e55884aa128493da77727ae7c6d1253_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ni00LTEtMS04NDQ0NA_6968b2fe-769c-46ef-bb7a-8ca7e8b6806f"
      unitRef="usd">673000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23a8d86b9d8a4084b1e6ddcc45ead16a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ni02LTEtMS04NDQ0NA_7b74bd8a-12b2-44e0-8c32-2ed6888f2c03"
      unitRef="usd">794000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2555de19982c4c1c919234a3b7833ea2_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ni04LTEtMS04NDQ0NA_13a927f4-591b-49c0-b96c-43a4ee8f30cc"
      unitRef="number">-0.123</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1e55884aa128493da77727ae7c6d1253_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ni0xMC0xLTEtODQ0NDQ_105296fe-69bc-4f2a-a6c1-ca608cf90832"
      unitRef="number">-0.152</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i76a0c1c8ef9849838870a39529fcdb16_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ny0yLTEtMS04NDQ0NA_3b0ec23c-b791-460d-ab4f-071614128d87"
      unitRef="usd">966000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie5e0a45bdcbf45c7b2fdde90c75f5932_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ny00LTEtMS04NDQ0NA_968b25c7-b492-42e1-93ca-42aed2ba730e"
      unitRef="usd">1119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i50af60fd4c5f4255ac6d02be0a13ae03_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ny02LTEtMS04NDQ0NA_bb46e887-9906-416d-9229-2d20fb306fa2"
      unitRef="usd">1394000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i76a0c1c8ef9849838870a39529fcdb16_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ny04LTEtMS04NDQ0NA_b60f65ea-4b29-40ca-b34d-80eb1cef0c0a"
      unitRef="number">-0.136</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie5e0a45bdcbf45c7b2fdde90c75f5932_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE2Ny0xMC0xLTEtODQ0NDQ_8135cd9a-8b2b-4d0c-93eb-16e5f997f318"
      unitRef="number">-0.197</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45a0926568d6467b9669368002f75388_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MC0yLTEtMS04NDQ0NA_23339909-4c7d-4409-810f-3b64853d808d"
      unitRef="usd">28604000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i17d037573a5d4222b17c5284accac4ec_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MC00LTEtMS04NDQ0NA_68e275fe-9f71-4439-a8cc-e205f2ac5670"
      unitRef="usd">27954000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0f866a6e7b4747ab9df0359131844149_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MC02LTEtMS04NDQ0NA_f57129bf-36fc-4f27-90f6-a2f2c48d96c5"
      unitRef="usd">25735000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i45a0926568d6467b9669368002f75388_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MC04LTEtMS04NDQ0NA_1734561e-5340-437c-91e4-88b9e625f46e"
      unitRef="number">0.023</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i17d037573a5d4222b17c5284accac4ec_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MC0xMC0xLTEtODQ0NDQ_a442a951-1aef-4b2d-911b-e500f08ac416"
      unitRef="number">0.086</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3ac1d092bd684cfe97e775dae9a43281_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MS0yLTEtMS04NDQ0NA_a569ae20-23ee-44c0-a84b-09a07d409d26"
      unitRef="usd">23959000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3b6d9f05d93342c9ac54a0fd0e292ec8_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MS00LTEtMS04NDQ0NA_e833255f-1fdf-4cbe-8802-628dc7354bb2"
      unitRef="usd">23726000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1ddc948c59f44ab9aeceef6ea85eea1b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MS02LTEtMS04NDQ0NA_01b88777-4e28-4ab2-a2e1-01d7c00ba65c"
      unitRef="usd">19440000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3ac1d092bd684cfe97e775dae9a43281_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MS04LTEtMS04NDQ0NA_b97f7aec-42fe-4ae0-9323-fc9c2965d43c"
      unitRef="number">0.010</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3b6d9f05d93342c9ac54a0fd0e292ec8_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3MS0xMC0xLTEtODQ0NDQ_43dbea11-b987-450e-a4d3-3081032b3051"
      unitRef="number">0.220</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3Mi0yLTEtMS04NDQ0NA_54840670-469c-4bf7-b296-4693cdee9f23"
      unitRef="usd">52563000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3Mi00LTEtMS04NDQ0NA_7d4135db-78aa-4ffe-a64e-41e32c220730"
      unitRef="usd">51680000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i45c63832601e43b1ad4c8f083610e7c3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3Mi02LTEtMS04NDQ0NA_8962a27f-fbd4-496c-a501-394a28c5ea5e"
      unitRef="usd">45175000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3Mi04LTEtMS04NDQ0NA_a73df45e-5638-49a3-904f-10a2342add11"
      unitRef="number">0.017</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE3Mi0xMC0xLTEtODQ0NDQ_85a185d4-0bea-4f1e-858a-c1b9197ce52d"
      unitRef="number">0.144</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i850b26f85bd14a8598514f4059d09199_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4NS0yLTEtMS04NDQ0NA_61e39050-ab60-4cf1-9759-681827e32319"
      unitRef="usd">2169000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id55db4e038a84957890427287eb9ab56_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4NS00LTEtMS04NDQ0NA_d1064d66-d585-428e-bdbc-6754ab8483bb"
      unitRef="usd">1836000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92374c3d2722492fa34458de0e14064c_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4NS02LTEtMS04NDQ0NA_535b2d07-3f33-4ffa-a82a-811fcb1c8e74"
      unitRef="usd">1452000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i850b26f85bd14a8598514f4059d09199_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4NS04LTEtMS04NDQ0NA_b430fe0a-6b87-4675-8806-a10b4c7e5cef"
      unitRef="number">0.182</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id55db4e038a84957890427287eb9ab56_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4NS0xMC0xLTEtODQ0NDQ_a398320b-f908-4d1a-a06f-5598c35e1fc8"
      unitRef="number">0.264</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i599608cf1f684eed8b209bd530f295e9_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ni0yLTEtMS04NDQ0NA_71fa344a-f286-4c13-80c3-4f6575a86c18"
      unitRef="usd">2131000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i422216cc59db4c0c941301f559702000_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ni00LTEtMS04NDQ0NA_180b8cf9-3887-43e5-984d-2c107f6cd24b"
      unitRef="usd">2135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20e19e67050949db82566d3868c92ad7_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ni02LTEtMS04NDQ0NA_2fbd5417-c189-4dae-9bdc-38045be0c53f"
      unitRef="usd">1594000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i599608cf1f684eed8b209bd530f295e9_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ni04LTEtMS04NDQ0NA_3c8408ae-d0ab-4f24-8d10-798937321a37"
      unitRef="number">-0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i422216cc59db4c0c941301f559702000_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ni0xMC0xLTEtODQ0NDQ_89c485dc-a0dd-4b86-b40c-11c9bc6f6d10"
      unitRef="number">0.340</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if9afb09ccee54d4abc14d8bb45e5e1bb_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ny0yLTEtMS04NDQ0NA_be2aabd7-56ca-46e2-bc45-c65116899d89"
      unitRef="usd">4300000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia20a5ce5890e4d60b4948961eba84c76_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ny00LTEtMS04NDQ0NA_e6db09ce-2995-459f-ac3f-28cd2796713a"
      unitRef="usd">3971000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i00419766ad6e4ea89e37292413d0efab_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ny02LTEtMS04NDQ0NA_9c2d9b33-c5d3-4118-baac-b8409737f349"
      unitRef="usd">3046000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if9afb09ccee54d4abc14d8bb45e5e1bb_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ny04LTEtMS04NDQ0NA_5d9db4c7-c44a-4362-a2f1-4cecf3879b7d"
      unitRef="number">0.083</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia20a5ce5890e4d60b4948961eba84c76_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4Ny0xMC0xLTEtODQ0NDQ_8cee9330-3e9c-4746-9732-a18d981e62a6"
      unitRef="number">0.304</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa1c27da4bbd4f5bb7644fd70f60b7ff_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4OS0yLTEtMS04NDQ0NA_e24b69b1-a0c8-4ad2-968c-521e1dd8182c"
      unitRef="usd">5321000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6abe4cf6499f44b8864302dc6a141046_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4OS00LTEtMS04NDQ0NA_2e3226a9-64be-41d8-ac1a-7bb6b1be2ad8"
      unitRef="usd">5126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib44237838e71484c841e5e53a3a8c7bb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4OS02LTEtMS04NDQ0NA_50f9f73f-7e24-41f3-a7c2-40a06a0e12a7"
      unitRef="usd">4779000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iaa1c27da4bbd4f5bb7644fd70f60b7ff_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4OS04LTEtMS04NDQ0NA_b4bd5942-57ba-473e-9265-4843cc3052db"
      unitRef="number">0.038</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6abe4cf6499f44b8864302dc6a141046_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE4OS0xMC0xLTEtODQ0NDQ_75aa0996-cf11-4094-be8b-f8477acde8a5"
      unitRef="number">0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4be2e62190a748c1a9f9858019ad5f2c_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MC0yLTEtMS04NDQ0NA_47815d2b-e874-4f11-b84b-3d47674b8d4a"
      unitRef="usd">3267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7280243f94ec4714a8ecd07ad5de6b9b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MC00LTEtMS04NDQ0NA_52a04285-8623-4dfa-971d-9c44a268d6b3"
      unitRef="usd">3462000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7bb69c6ba5614a0da3881621e639aaba_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MC02LTEtMS04NDQ0NA_2e06a221-a1e6-4e76-ae72-1b977bcfaa96"
      unitRef="usd">2984000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4be2e62190a748c1a9f9858019ad5f2c_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MC04LTEtMS04NDQ0NA_1ae22274-4a6c-42a1-a7b7-23b80d540b61"
      unitRef="number">-0.056</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7280243f94ec4714a8ecd07ad5de6b9b_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MC0xMC0xLTEtODQ0NDQ_5f967af4-7644-4a46-ab9a-9d452ba98629"
      unitRef="number">0.160</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie95a799c54a94247a4f4738e17ef6bdd_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MS0yLTEtMS04NDQ0NA_1337eb46-02df-46a3-82cc-b53ecb3c925a"
      unitRef="usd">8587000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78fa9c5783f54e208617e980cb82b18c_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MS00LTEtMS04NDQ0NA_7144e5b5-b66e-4aee-9a71-27e40e750550"
      unitRef="usd">8588000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c722ac2a4a64faa8604869f789d2250_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MS02LTEtMS04NDQ0NA_fe495f6c-2826-44b8-9550-eba8c7482b21"
      unitRef="usd">7763000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie95a799c54a94247a4f4738e17ef6bdd_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MS04LTEtMS04NDQ0NA_354f665b-1ddf-44af-af61-1ad849306d6f"
      unitRef="number">0.000</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i78fa9c5783f54e208617e980cb82b18c_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5MS0xMC0xLTEtODQ0NDQ_9684fa8a-65b8-4393-b1cd-208c902bf3cd"
      unitRef="number">0.106</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c379bb07b1f423494b9602d42fcbda1_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5My0yLTEtMS04NDQ0NA_c8ec4e9b-0fe0-4feb-b561-fff9995079b5"
      unitRef="usd">943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i599b25cf3d4a4566a4fb6560ac142a99_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5My00LTEtMS04NDQ0NA_038e74dc-9d3e-4e04-a87c-7aee0c254605"
      unitRef="usd">878000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iaa4a315b27d540e6a99eb9f14f0a2b22_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5My02LTEtMS04NDQ0NA_688a4d70-b2e5-49f3-b841-cc1c4d5ac8bd"
      unitRef="usd">793000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2c379bb07b1f423494b9602d42fcbda1_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5My04LTEtMS04NDQ0NA_14e2c9fc-5a52-4bc4-80d6-6d20cd9fb794"
      unitRef="number">0.073</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i599b25cf3d4a4566a4fb6560ac142a99_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5My0xMC0xLTEtODQ0NDQ_0349cf47-f4d4-42fd-992f-c4edfdbcc3e6"
      unitRef="number">0.107</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba96a050bfaa4084a8d2900a2e3a04d5_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NC0yLTEtMS04NDQ0NA_97884a8b-d9a4-48a7-996d-8e87690913f9"
      unitRef="usd">571000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i74464a7622714b598ec7ac59bb92daa9_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NC00LTEtMS04NDQ0NA_d50d3019-c886-4785-830e-e4cf4cf6683a"
      unitRef="usd">602000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia431b44bdbc04745b1da9bc7e6129763_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NC02LTEtMS04NDQ0NA_a6217f37-10b6-4c8e-a3d5-98b9a9a88f2e"
      unitRef="usd">487000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="iba96a050bfaa4084a8d2900a2e3a04d5_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NC04LTEtMS04NDQ0NA_cadad67e-71c3-44a0-b6a5-17a4b4042193"
      unitRef="number">-0.051</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i74464a7622714b598ec7ac59bb92daa9_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NC0xMC0xLTEtODQ0NDQ_b2b7039c-a3d3-49ec-90ef-e905ef85b6f7"
      unitRef="number">0.236</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1c3fa299f6ba45c4b222ae1e49bcebb9_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NS0yLTEtMS04NDQ0NA_a8987f88-be62-43f8-a2ed-211cfc620aee"
      unitRef="usd">1514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i386d38aa8c394c4f935a4311fd4ef278_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NS00LTEtMS04NDQ0NA_206141f7-1566-4452-bec8-23d82f78108a"
      unitRef="usd">1480000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib5940e0037084662b3d6936dc73b3ee8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NS02LTEtMS04NDQ0NA_3cbd4b5b-e693-4fcb-9134-81e95a3e111a"
      unitRef="usd">1280000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i1c3fa299f6ba45c4b222ae1e49bcebb9_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NS04LTEtMS04NDQ0NA_56be5386-d91f-4ae6-b9a7-8a7b50164134"
      unitRef="number">0.023</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i386d38aa8c394c4f935a4311fd4ef278_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5NS0xMC0xLTEtODQ0NDQ_7e7c5df7-5ba5-48bf-afc1-c89e48fba77b"
      unitRef="number">0.156</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i16a080af195245c883230bee9c30e225_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5Ny0yLTEtMS04NDQ0NA_7b32d3f4-cfd7-4532-b370-b982e42b59da"
      unitRef="usd">851000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia55cc74e40ab4d0592d91514f04f2608_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5Ny00LTEtMS04NDQ0NA_6c12aafd-a5dd-4fdc-95a8-af52cb718690"
      unitRef="usd">787000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91aa6b32077b4d2497b10c0c7a56e179_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5Ny02LTEtMS04NDQ0NA_1644790f-b1da-4cae-ab8d-076990d42cd9"
      unitRef="usd">743000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i16a080af195245c883230bee9c30e225_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5Ny04LTEtMS04NDQ0NA_19afbd8c-d3c1-48c3-b6f0-0bac8216b5a1"
      unitRef="number">0.082</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia55cc74e40ab4d0592d91514f04f2608_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5Ny0xMC0xLTEtODQ0NDQ_eb989772-6654-4750-9470-582881321e85"
      unitRef="number">0.059</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib6a9e1c6f9634d72a1c5c2e943619a42_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OC0yLTEtMS04NDQ0NA_f118f3e4-b93e-480f-a588-b9c76746b089"
      unitRef="usd">508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i97e2595ac4db46c4bddda29dbd79cb53_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OC00LTEtMS04NDQ0NA_cc2e8f8f-2256-483a-ad48-377f8c9bb991"
      unitRef="usd">538000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icacd0f9bc97a476d9227cb9d73c43f17_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OC02LTEtMS04NDQ0NA_0bc457ba-8d80-420d-b7d9-6009e1c62f98"
      unitRef="usd">427000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib6a9e1c6f9634d72a1c5c2e943619a42_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OC04LTEtMS04NDQ0NA_17cd93e8-8490-47b8-b58a-be258059956b"
      unitRef="number">-0.057</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i97e2595ac4db46c4bddda29dbd79cb53_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OC0xMC0xLTEtODQ0NDQ_03769658-a1a0-4fc9-baf4-8e60790d3b88"
      unitRef="number">0.261</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i555d0de63ee2467baa26c01abdb6a217_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OS0yLTEtMS04NDQ0NA_be5e423e-6382-4be7-8fca-f6942ef50684"
      unitRef="usd">1359000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0158c50e3f843b98737f71038b73b04_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OS00LTEtMS04NDQ0NA_21600fe1-2166-4ecf-855f-b3e89f906fc1"
      unitRef="usd">1325000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7ad2240e53ec400db99843a0627fa101_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OS02LTEtMS04NDQ0NA_87d22911-6319-4af0-9115-40ee166118af"
      unitRef="usd">1170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i555d0de63ee2467baa26c01abdb6a217_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OS04LTEtMS04NDQ0NA_edf7fe50-2df5-449e-9c6e-b966ad4f1431"
      unitRef="number">0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if0158c50e3f843b98737f71038b73b04_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzE5OS0xMC0xLTEtODQ0NDQ_c91a9552-f8e1-4a4c-bdb1-b8881669127a"
      unitRef="number">0.133</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id93d92b03daf447eb4bf22985d9d8c14_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMS0yLTEtMS04NDQ0NA_6998b8e7-09b5-4c24-9fbe-3a3fb22d1b9d"
      unitRef="usd">1882000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i523f9716669b47d5b297828fd6724f6a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMS00LTEtMS04NDQ0NA_c3108c91-a056-4f4d-ae2e-8ca3530880b8"
      unitRef="usd">1819000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id3648561601548a8b97f7f711182c5f0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMS02LTEtMS04NDQ0NA_9e9458ff-b7d2-462a-b1a9-bd5e70f895fd"
      unitRef="usd">1648000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id93d92b03daf447eb4bf22985d9d8c14_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMS04LTEtMS04NDQ0NA_a50c179e-645d-49a7-84f7-ef306da79f76"
      unitRef="number">0.035</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i523f9716669b47d5b297828fd6724f6a_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMS0xMC0xLTEtODQ0NDQ_81fd7d5c-db13-4e37-bda7-6ca11e09a162"
      unitRef="number">0.104</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2a8043dcb8a040d7adcd300412045ab4_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMi0yLTEtMS04NDQ0NA_189c94d2-484a-448b-9a58-fc6f1647cb3e"
      unitRef="usd">989000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i223e6d03e08f4f5a90b7a1f6a8ac3d0a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMi00LTEtMS04NDQ0NA_39c16baa-282f-4d9f-a670-bf295f048096"
      unitRef="usd">1066000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i346d453f53cc4ecea306f279831549f3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMi02LTEtMS04NDQ0NA_4d3ab4cb-a3a0-4fc1-b61d-69a827422093"
      unitRef="usd">966000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2a8043dcb8a040d7adcd300412045ab4_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMi04LTEtMS04NDQ0NA_cb51fa86-fda5-4721-a6e8-b6a449f240d4"
      unitRef="number">-0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i223e6d03e08f4f5a90b7a1f6a8ac3d0a_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMi0xMC0xLTEtODQ0NDQ_c8b01806-41f1-4bc2-8ea1-afdb18d6b5ff"
      unitRef="number">0.104</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if03efae791104d9aa1b01944645a6b01_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMy0yLTEtMS04NDQ0NA_f6e7c514-f05e-47d2-9f48-1343a9ede93b"
      unitRef="usd">2871000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e3094a2457647888f8c0f56ba3fed56_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMy00LTEtMS04NDQ0NA_12c749d4-a6ea-4e72-aa7c-cb1a3d7cc343"
      unitRef="usd">2885000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9250e1cbda2047ae9863cef248995cf3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMy02LTEtMS04NDQ0NA_e519df2e-ef10-453c-b417-954b43f5de16"
      unitRef="usd">2614000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if03efae791104d9aa1b01944645a6b01_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMy04LTEtMS04NDQ0NA_1f997a77-cc4b-4425-9d56-44847794f7ec"
      unitRef="number">-0.005</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0e3094a2457647888f8c0f56ba3fed56_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwMy0xMC0xLTEtODQ0NDQ_d51761e9-b120-4481-b8f6-d7315a90944d"
      unitRef="number">0.104</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4122251b77234594bcddabafeb5af123_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNS0yLTEtMS04NDQ0NA_76a102ef-7e12-4101-bb7a-0fef426c12a0"
      unitRef="usd">1645000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie544b42a603147f09a40781c6c42143e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNS00LTEtMS04NDQ0NA_18927996-6f27-4d3f-843f-97d44b166cfd"
      unitRef="usd">1642000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibd6437ba34c148db8aeccaa67fa06cf2_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNS02LTEtMS04NDQ0NA_74597f9b-227a-48fd-a330-503802a20e42"
      unitRef="usd">1595000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i4122251b77234594bcddabafeb5af123_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNS04LTEtMS04NDQ0NA_d3f10c6e-2038-444c-a6f2-cac144c870d3"
      unitRef="number">0.002</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ie544b42a603147f09a40781c6c42143e_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNS0xMC0xLTEtODQ0NDQ_0ffa1d1d-babf-4336-ac5f-9c9d2d7150d3"
      unitRef="number">0.029</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida0bc11d3c5748e98275291ec923ccc5_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNi0yLTEtMS04NDQ0NA_795a3c5f-7067-4ccb-97e5-21d6f374026b"
      unitRef="usd">1198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9347c56f2a1444a78a4fc62e6b386a5a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNi00LTEtMS04NDQ0NA_03dd6511-f1bb-4bbb-af8a-7c9377ca8551"
      unitRef="usd">1256000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i01517169bf524cb6924cf818325d7fdc_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNi02LTEtMS04NDQ0NA_03eb7935-5987-4d94-8203-9836b5433122"
      unitRef="usd">1104000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ida0bc11d3c5748e98275291ec923ccc5_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNi04LTEtMS04NDQ0NA_1804fdbe-b85a-4380-b209-1a2fd3d72dcc"
      unitRef="number">-0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i9347c56f2a1444a78a4fc62e6b386a5a_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNi0xMC0xLTEtODQ0NDQ_a47318d6-82ad-41dd-99f4-b21fb82be0e7"
      unitRef="number">0.138</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2160f5b0fbab41038676a89c226cb367_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNy0yLTEtMS04NDQ0NA_763f3480-8d28-4b8f-95fe-7add5442bc4b"
      unitRef="usd">2843000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23c7667c458748c8904119e1c5445a7e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNy00LTEtMS04NDQ0NA_9f218403-b52f-453f-9c48-6bd29d9848c7"
      unitRef="usd">2898000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id5c1850237ad45cda71fcf02b4cf082e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNy02LTEtMS04NDQ0NA_1cb81f1d-d797-4401-bda0-76e046c585ff"
      unitRef="usd">2699000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2160f5b0fbab41038676a89c226cb367_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNy04LTEtMS04NDQ0NA_6ae95150-ec75-4e9d-a361-3aa4a9772ca4"
      unitRef="number">-0.019</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i23c7667c458748c8904119e1c5445a7e_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwNy0xMC0xLTEtODQ0NDQ_52e565f8-432b-499e-a1cc-6abd7a7b23a9"
      unitRef="number">0.074</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e62ffa3592b449586bbb8ca2c4d6213_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwOS0yLTEtMS04NDQ0NA_5ce57618-fd5d-47f3-8896-e5d461c58134"
      unitRef="usd">3897000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib476cbca912b416981dd09c3a83db02e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwOS00LTEtMS04NDQ0NA_e7dcc98a-a220-4a22-b7b0-8d8cb65e3104"
      unitRef="usd">3867000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1dc2f5c56a204d2d8e644eb8886f841e_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwOS02LTEtMS04NDQ0NA_8ced3489-eb56-453c-ad9f-4d4cc9ed5d3e"
      unitRef="usd">3249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3e62ffa3592b449586bbb8ca2c4d6213_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwOS04LTEtMS04NDQ0NA_bf44df96-11f2-4efd-aa56-c05fa9264166"
      unitRef="number">0.008</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib476cbca912b416981dd09c3a83db02e_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIwOS0xMC0xLTEtODQ0NDQ_0878421b-6cfb-40e3-9138-32cb5a157cef"
      unitRef="number">0.190</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i28c6713f2ac548cc8106299c4be563a8_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMC0yLTEtMS04NDQ0NA_d01068b1-bce1-400c-8899-a988ad7e76bd"
      unitRef="usd">5793000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id895d721db2044efbb2aef35407c5f24_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMC00LTEtMS04NDQ0NA_b670afee-388c-475f-afeb-7d2a447cc83a"
      unitRef="usd">5945000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9db4f8d31fdc492993044895704613be_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMC02LTEtMS04NDQ0NA_5d56b4b2-b564-44f2-819c-4b9f50dda634"
      unitRef="usd">4983000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i28c6713f2ac548cc8106299c4be563a8_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMC04LTEtMS04NDQ0NA_c6970919-0b43-4048-b3c2-9d41b6d0a132"
      unitRef="number">-0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id895d721db2044efbb2aef35407c5f24_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMC0xMC0xLTEtODQ0NDQ_02322258-e637-411a-b125-cfc18cd8ba23"
      unitRef="number">0.193</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96bb599ebb2d4c758610207a98846d97_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMS0yLTEtMS04NDQ0NA_ab7feb22-f4b0-4060-8a30-13ccb0e4a5e4"
      unitRef="usd">9690000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2c19ae7f1d1548cf9a2a61003b3d3900_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMS00LTEtMS04NDQ0NA_7e9a51dd-62b7-42e0-8689-19751a636990"
      unitRef="usd">9812000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1b8a7dbc6dbd43db9aab7933e394d7d5_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMS02LTEtMS04NDQ0NA_f01129b7-1a03-497e-844b-609abfe05726"
      unitRef="usd">8232000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i96bb599ebb2d4c758610207a98846d97_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMS04LTEtMS04NDQ0NA_23fa031e-c987-48f1-9e66-8273a6128ca3"
      unitRef="number">-0.012</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2c19ae7f1d1548cf9a2a61003b3d3900_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMS0xMC0xLTEtODQ0NDQ_8abb8fb2-e66f-4237-9243-104f956e3e68"
      unitRef="number">0.192</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0b2a0ef2af13440cbfde1878f560a53e_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMy0yLTEtMS04NDQ0NA_7b4749ef-c175-4571-b0bc-d1da7f0f6067"
      unitRef="usd">1784000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8a93418c3f9348089a17785066c9ecc3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMy00LTEtMS04NDQ0NA_c77f1a0b-7df0-4766-880b-0d2483ca8669"
      unitRef="usd">1761000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e5b37a473aa4e9684ab211e4fae10e6_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMy02LTEtMS04NDQ0NA_8bb4c8d8-2f24-49a6-8b19-481b0949e4cd"
      unitRef="usd">1535000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0b2a0ef2af13440cbfde1878f560a53e_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMy04LTEtMS04NDQ0NA_7e927bc0-98ca-45a0-9e8c-5fe37c65c36b"
      unitRef="number">0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8a93418c3f9348089a17785066c9ecc3_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxMy0xMC0xLTEtODQ0NDQ_f117d601-4fe4-4e11-8d44-11c79306a8ac"
      unitRef="number">0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96d0bb9e034b4b778811c7e9a7a32561_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNC0yLTEtMS04NDQ0NA_cfd30496-6abf-4451-a633-6ceb8da5e30d"
      unitRef="usd">2785000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i660f2a9622b542f29df16b4d0065c995_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNC00LTEtMS04NDQ0NA_cce05a1d-8e73-4a94-aaab-55f2ee443f94"
      unitRef="usd">2861000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i31bd9ea308664465abdeee40896776b0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNC02LTEtMS04NDQ0NA_a5bf8ef5-b735-4d48-8435-a344560810ba"
      unitRef="usd">2304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i96d0bb9e034b4b778811c7e9a7a32561_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNC04LTEtMS04NDQ0NA_37225464-5769-4f83-ac17-389ae33033e8"
      unitRef="number">-0.026</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i660f2a9622b542f29df16b4d0065c995_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNC0xMC0xLTEtODQ0NDQ_d330f37b-5d47-4eca-b064-fc7fe39e6599"
      unitRef="number">0.241</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69a0f6c8007a466aa040c51aae63e17b_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNS0yLTEtMS04NDQ0NA_fad3962b-e186-4cab-b2c8-0c04902a5b29"
      unitRef="usd">4569000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib47ac25eee8d470cb19fc3f3bad77acb_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNS00LTEtMS04NDQ0NA_dc5877c1-4fd9-4359-9fbb-70afdbe14efd"
      unitRef="usd">4622000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4ee222c80d4f45629294aa4cee852d97_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNS02LTEtMS04NDQ0NA_fdeaaa9f-fdbf-448b-bdab-c35f3e068415"
      unitRef="usd">3839000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i69a0f6c8007a466aa040c51aae63e17b_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNS04LTEtMS04NDQ0NA_f62307fe-f6cb-40a7-a103-f789ce947d90"
      unitRef="number">-0.011</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ib47ac25eee8d470cb19fc3f3bad77acb_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNS0xMC0xLTEtODQ0NDQ_e1da4e61-f49b-4758-ad4d-d9e9926f4685"
      unitRef="number">0.204</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i92b401eaaab44d8a91db95e7fd4cfaea_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNy0yLTEtMS04NDQ0NA_34ae1b15-d841-44a1-9e2a-da21a45e8942"
      unitRef="usd">2113000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c79a9ae4055493892121d39b7f040e9_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNy00LTEtMS04NDQ0NA_a92d6e88-0b78-4bcf-9494-8c7ba95056f5"
      unitRef="usd">2105000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5659d078f59d475b8e7b8881e5f8c8cc_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNy02LTEtMS04NDQ0NA_a6120208-bbf0-42bc-b8e6-656a94cb82c2"
      unitRef="usd">1714000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i92b401eaaab44d8a91db95e7fd4cfaea_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNy04LTEtMS04NDQ0NA_121d42f0-911b-4693-8127-3f96c8a4974b"
      unitRef="number">0.004</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7c79a9ae4055493892121d39b7f040e9_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxNy0xMC0xLTEtODQ0NDQ_56005955-7426-4d48-82cd-1a3406ca6c47"
      unitRef="number">0.227</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e13a27025ab49258fc3f28523703d4b_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOC0yLTEtMS04NDQ0NA_9a2ed0a5-c9ae-4142-8fff-970beefa1e61"
      unitRef="usd">3008000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0797cce295e84999983ff7d4951ae7d4_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOC00LTEtMS04NDQ0NA_defd3451-c48d-43d3-bde1-a0d42dd5431a"
      unitRef="usd">3085000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib8ad838c4d37450791faf447300dcf25_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOC02LTEtMS04NDQ0NA_346c6635-04bd-4b5f-98ae-a649b873e26d"
      unitRef="usd">2679000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0e13a27025ab49258fc3f28523703d4b_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOC04LTEtMS04NDQ0NA_c9656e7a-0429-4593-a423-d8625a588a29"
      unitRef="number">-0.025</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0797cce295e84999983ff7d4951ae7d4_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOC0xMC0xLTEtODQ0NDQ_8887f6e1-0bec-4a3a-abaf-ea59f1a4774a"
      unitRef="number">0.152</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i882f781054b24565afcf9d67c24e9a56_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOS0yLTEtMS04NDQ0NA_55523554-ea3d-46c6-a8d9-36e70aa66264"
      unitRef="usd">5121000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5ce0c967e6d044a2b3a5bc24c3067d09_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOS00LTEtMS04NDQ0NA_0ac9607c-8a8e-4082-90de-6d9b150709c3"
      unitRef="usd">5190000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f2fdf8254144adc9c79f0edf1186108_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOS02LTEtMS04NDQ0NA_a3a68850-ff89-405c-af07-35d5650e90b0"
      unitRef="usd">4392000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i882f781054b24565afcf9d67c24e9a56_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOS04LTEtMS04NDQ0NA_4e425760-6e94-4d5b-b7b5-4d98e0ef7357"
      unitRef="number">-0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i5ce0c967e6d044a2b3a5bc24c3067d09_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIxOS0xMC0xLTEtODQ0NDQ_05c9e961-edc5-44d2-8905-67104c6809ee"
      unitRef="number">0.181</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0bc0508a06e84d47a8eff2b1d5c74e86_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMS0yLTEtMS04NDQ0NA_262f87a6-c9f3-4be7-a02a-64f99c07f19f"
      unitRef="usd">1990000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i728978b4bbb44796bdeddaa130466c9e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMS00LTEtMS04NDQ0NA_5c5364a5-2b31-4630-8a4b-3578412ccbef"
      unitRef="usd">1857000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8ae8b4447dde420f8505681fa323ea4a_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMS02LTEtMS04NDQ0NA_c54428b8-8086-47e9-b4bd-85094812040c"
      unitRef="usd">1557000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0bc0508a06e84d47a8eff2b1d5c74e86_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMS04LTEtMS04NDQ0NA_169d3446-0ba5-45dd-b51f-1c347d7c6904"
      unitRef="number">0.072</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i728978b4bbb44796bdeddaa130466c9e_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMS0xMC0xLTEtODQ0NDQ_34338550-e50d-4fb8-8fe1-c21cc7b0ad5e"
      unitRef="number">0.193</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2f8b318c15894833b1cf92df3f7a9fb5_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMi0yLTEtMS04NDQ0NA_b144bbfe-8b01-4aaa-bde9-7e0dfcfd29a2"
      unitRef="usd">2859000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8df5c7b107134f5abf47b44faecc645b_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMi00LTEtMS04NDQ0NA_f0fe4286-7718-4bce-9f02-b93ba21290b6"
      unitRef="usd">2831000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5419094e757b46019b8bd5f8d7e871b4_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMi02LTEtMS04NDQ0NA_f55e155a-30c7-4574-8395-33f77ca2a652"
      unitRef="usd">2362000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i2f8b318c15894833b1cf92df3f7a9fb5_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMi04LTEtMS04NDQ0NA_d2e90a63-41d7-4843-ae75-85f79a6b4217"
      unitRef="number">0.010</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8df5c7b107134f5abf47b44faecc645b_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMi0xMC0xLTEtODQ0NDQ_94490e01-2285-46a3-90ac-fee5db6f6c82"
      unitRef="number">0.198</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0940ba1ce2fb4e058d1eb84ccb6c5e03_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMy0yLTEtMS04NDQ0NA_5baa8d6a-d7fc-4b12-8c7a-335234889ae5"
      unitRef="usd">4849000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i06e2030e683e436aa4324bd6a5a14b69_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMy00LTEtMS04NDQ0NA_af034a50-e8f2-44ea-8193-605df3d4addc"
      unitRef="usd">4688000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic1d0785d36d044d6b08df217279ef868_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMy02LTEtMS04NDQ0NA_0da17c34-1904-4a2b-a65e-21067d4114cf"
      unitRef="usd">3919000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0940ba1ce2fb4e058d1eb84ccb6c5e03_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMy04LTEtMS04NDQ0NA_f22138dc-dd7e-41f1-ab35-1dd549ad871e"
      unitRef="number">0.034</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i06e2030e683e436aa4324bd6a5a14b69_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyMy0xMC0xLTEtODQ0NDQ_748b9479-ce02-4a5b-a2bb-acb9954aa789"
      unitRef="number">0.196</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i488b67a47d294aabab33cbdf59e13a0e_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNS0yLTEtMS04NDQ0NA_dff164cc-03e5-4989-a6ea-ab453c1b68f1"
      unitRef="usd">1522000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic31b2338c66b49679900818d0ee6a39c_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNS00LTEtMS04NDQ0NA_0f71eed9-ea8a-4541-a864-4bfe9bc71cd9"
      unitRef="usd">1398000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i656cbb2cc38042e38ca323806c588d5d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNS02LTEtMS04NDQ0NA_163d51e9-b4d5-48f5-aff0-ea5bd995b8c9"
      unitRef="usd">1213000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i488b67a47d294aabab33cbdf59e13a0e_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNS04LTEtMS04NDQ0NA_7196707b-e630-4d1b-bd1e-c09cbf013f91"
      unitRef="number">0.089</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic31b2338c66b49679900818d0ee6a39c_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNS0xMC0xLTEtODQ0NDQ_77423263-83d4-4747-9d15-b40e7cbd7b10"
      unitRef="number">0.152</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if2f17244bd1447cf9c736ae386f8dee8_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNi0yLTEtMS04NDQ0NA_b3f3f6f3-44a9-4db5-b2a9-c6f4dea69512"
      unitRef="usd">2022000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8e7770d83fdd4f678c448c98a7ec4ec9_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNi00LTEtMS04NDQ0NA_4efe6ee1-fb27-4455-ac89-934d368d0833"
      unitRef="usd">2043000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3fe4b910600f4a8d98db1f5f0c7b5c53_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNi02LTEtMS04NDQ0NA_b46235d9-a85d-4ad8-bb36-28f7659442cb"
      unitRef="usd">1781000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="if2f17244bd1447cf9c736ae386f8dee8_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNi04LTEtMS04NDQ0NA_66223b31-58d2-48ba-b2c1-5ffb3c7d7ef1"
      unitRef="number">-0.010</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8e7770d83fdd4f678c448c98a7ec4ec9_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNi0xMC0xLTEtODQ0NDQ_db6cdf90-7614-46c9-ba99-6daddeddf01e"
      unitRef="number">0.147</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf869d6b3a56497f82172be314aa1d7a_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNy0yLTEtMS04NDQ0NA_6bda994e-bf4d-4943-a5a1-cdc88052d5b3"
      unitRef="usd">3543000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7cb2f6bb944c47db8946085e687244f3_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNy00LTEtMS04NDQ0NA_b0c82ba7-c6fb-4867-a6dc-1dcc22a80926"
      unitRef="usd">3440000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifb6de0174c394ad7878f8b8ab48c1760_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNy02LTEtMS04NDQ0NA_0e86d2f3-2891-405f-8242-565a59a12bbe"
      unitRef="usd">2994000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ibf869d6b3a56497f82172be314aa1d7a_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNy04LTEtMS04NDQ0NA_b34e22e7-cc20-4341-ba3c-e340d4ca9384"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7cb2f6bb944c47db8946085e687244f3_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIyNy0xMC0xLTEtODQ0NDQ_fa964d2f-184f-44c1-824d-232e95619d0d"
      unitRef="number">0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i69e5be1f408d42a6a28f913328b3aa23_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMC0yLTEtMS04NDQ0NA_fcc0f317-c7d7-44ae-a247-1d0cc02109d2"
      unitRef="usd">468000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6a6d1bdd3da5427197bae916d67ef765_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMC00LTEtMS04NDQ0NA_6ae34435-74f8-4e66-8f5d-fb4ecfdaec3a"
      unitRef="usd">459000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id0aac6fcbd0b4218a1df93bffd709deb_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMC02LTEtMS04NDQ0NA_9e7848ef-f03e-4da1-8e87-566304c51e48"
      unitRef="usd">344000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i69e5be1f408d42a6a28f913328b3aa23_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMC04LTEtMS04NDQ0NA_643571a0-4124-4d68-a014-c6943fe37615"
      unitRef="number">0.020</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6a6d1bdd3da5427197bae916d67ef765_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMC0xMC0xLTEtODQ0NDQ_8ac8496d-a157-44f0-9d63-b38d749ea448"
      unitRef="number">0.335</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i780835081b4f4f33ad0a3bec79b6575e_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMS0yLTEtMS04NDQ0NA_8e3723aa-236e-47d1-8447-9b9d8a44f902"
      unitRef="usd">837000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20f1c099cf014d2396f6e27e3f282b73_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMS00LTEtMS04NDQ0NA_82467810-36af-4ea5-a205-ab64b6ccefe1"
      unitRef="usd">788000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3240822529b343708c19d857074c3efe_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMS02LTEtMS04NDQ0NA_47282e41-0e7e-4b4d-aafa-f215d78043bb"
      unitRef="usd">581000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i780835081b4f4f33ad0a3bec79b6575e_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMS04LTEtMS04NDQ0NA_d65723cb-7827-4bb1-a2e7-5a868fad9d03"
      unitRef="number">0.062</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i20f1c099cf014d2396f6e27e3f282b73_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMS0xMC0xLTEtODQ0NDQ_0c9fb1a6-2908-40ac-a712-97c984b22719"
      unitRef="number">0.357</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icd9e83bd141f43718f07eebf8ae9d726_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMi0yLTEtMS04NDQ0NA_3a642a0e-d6c8-4c72-8e84-e3947f08a184"
      unitRef="usd">1306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i686d5e925e204bfb9c56b7dc9949c828_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMi00LTEtMS04NDQ0NA_db3fceb8-6639-4cd4-8576-f690238d2f01"
      unitRef="usd">1248000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i94d99e94b59a4dc786f934bdf8f8ad28_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMi02LTEtMS04NDQ0NA_bcfe3ffa-503b-4ac2-a036-f0b185259e8d"
      unitRef="usd">925000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="icd9e83bd141f43718f07eebf8ae9d726_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMi04LTEtMS04NDQ0NA_52e3bca4-7da3-4e96-bf75-221f84894da7"
      unitRef="number">0.046</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i686d5e925e204bfb9c56b7dc9949c828_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzMi0xMC0xLTEtODQ0NDQ_e879d0cc-6e25-4b5b-8ce8-bd5a8498f84e"
      unitRef="number">0.349</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i02394e8a5d34408f80dba10b20b2294e_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNS0yLTEtMS04NDQ0NA_52ec605f-b297-4be9-9864-668f022d653a"
      unitRef="usd">13377000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id12b26c88eb041a5b128765f1710cfff_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNS00LTEtMS04NDQ0NA_0a42de61-f292-4e30-bdfb-baf3f92f3d2f"
      unitRef="usd">12686000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c5ab80c014e4ab6bf12909c673b5286_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNS02LTEtMS04NDQ0NA_0ad6cbac-ea76-4272-b1ea-441a08b21697"
      unitRef="usd">11036000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i02394e8a5d34408f80dba10b20b2294e_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNS04LTEtMS04NDQ0NA_e1825e82-3a41-4c47-bd6b-690c4c155a2e"
      unitRef="number">0.054</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="id12b26c88eb041a5b128765f1710cfff_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNS0xMC0xLTEtODQ0NDQ_2a655e25-8e4a-48df-bee3-4400d2338e6c"
      unitRef="number">0.149</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ice2505dd78c947788c029470885cbb84_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNi0yLTEtMS04NDQ0NA_de48a12c-b7f0-4ef6-bce2-e39c0a024353"
      unitRef="usd">14050000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i26073ee7b24f444ea78dd572e1428c7f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNi00LTEtMS04NDQ0NA_8360f75c-86b4-4b5b-83b9-38b0daa9259d"
      unitRef="usd">14374000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie04e4e86c1b24d1889b9660122ff5c0b_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNi02LTEtMS04NDQ0NA_1f758417-1689-4489-836b-3b775b35bbe9"
      unitRef="usd">11923000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ice2505dd78c947788c029470885cbb84_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNi04LTEtMS04NDQ0NA_27db489b-36bf-4a72-92ef-2d72cce1a935"
      unitRef="number">-0.023</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i26073ee7b24f444ea78dd572e1428c7f_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNi0xMC0xLTEtODQ0NDQ_f3b802c9-a611-4619-8e10-6cb6482c6048"
      unitRef="number">0.206</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNy0yLTEtMS04NDQ0NA_1c501217-18f2-4593-a420-e4160507b08b"
      unitRef="usd">27427000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNy00LTEtMS04NDQ0NA_533e59f0-e2a8-4764-9de5-7c15946b7089"
      unitRef="usd">27060000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia05a6854e4e147f5a99bd5f6979dc765_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNy02LTEtMS04NDQ0NA_825a0fd0-c464-4dfc-9c2a-c7192be9a11e"
      unitRef="usd">22959000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNy04LTEtMS04NDQ0NA_94e13d1e-23c2-484a-af3f-11962f37cd3d"
      unitRef="number">0.014</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzIzNy0xMC0xLTEtODQ0NDQ_9f1924b7-be02-4c0b-97ef-4fc755fc9ab1"
      unitRef="number">0.179</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3420461825204a15b06642c0e8effdc3_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MC0yLTEtMS04NDQ0NA_5bac1b71-c105-486f-84ed-4de11e9c417f"
      unitRef="usd">48580000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic25e0a35046d4798afe7f6c61ccd2212_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MC00LTEtMS04NDQ0NA_da966ee3-e3c9-4779-8407-a8466b3f81d4"
      unitRef="usd">47156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iddce33c475c74ebcb63073bdefd18fc8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MC02LTEtMS04NDQ0NA_c765e07f-b76e-4860-88ed-ee8955a10b68"
      unitRef="usd">43133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i3420461825204a15b06642c0e8effdc3_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MC04LTEtMS04NDQ0NA_c9b69034-5fd5-4f8d-bf42-c17ecc50835d"
      unitRef="number">0.030</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ic25e0a35046d4798afe7f6c61ccd2212_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MC0xMC0xLTEtODQ0NDQ_633510bf-daca-49da-98cc-17e0d578e1de"
      unitRef="number">0.093</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8f735f0bd8754f549f6a3d8505541990_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MS0yLTEtMS04NDQ0NA_b2ba0d29-2970-4d6d-ac59-71cfc86dc6fa"
      unitRef="usd">46363000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia7f7ca8fc4824ad1b05a99c0f85ecbd9_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MS00LTEtMS04NDQ0NA_34050583-3d6a-434d-a8f4-970dee85cc49"
      unitRef="usd">46619000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i21ae89a5e6e44a19bda3cea2a2a46a91_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MS02LTEtMS04NDQ0NA_3cb3fa4d-d74a-46dc-a819-677ed3bc888a"
      unitRef="usd">39451000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i8f735f0bd8754f549f6a3d8505541990_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MS04LTEtMS04NDQ0NA_43f277a8-9310-4a44-8219-028fcbc7c9ca"
      unitRef="number">-0.006</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="ia7f7ca8fc4824ad1b05a99c0f85ecbd9_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0MS0xMC0xLTEtODQ0NDQ_6cb3571c-1514-4616-b6e6-a0a7bb167b08"
      unitRef="number">0.182</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0Mi0yLTEtMS04NDQ0NA_75b37740-e530-459e-a13f-6a898e4b4d66"
      unitRef="usd">94943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0Mi00LTEtMS04NDQ0NA_a9ae6546-e476-42f6-8219-818c02bad5f1"
      unitRef="usd">93775000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0Mi02LTEtMS04NDQ0NA_66827f79-0677-49a8-bc8e-cd30430a0424"
      unitRef="usd">82584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0Mi04LTEtMS04NDQ0NA_42358740-24b3-42c0-b612-644d45e18bc5"
      unitRef="number">0.013</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <jnj:PercentageChangeInSalesBySegmentOfBusiness
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTowYTVhNGQzZTE1Y2M0Zjg2OWNhMTk0MTg3ODI5ZGZlMy90YWJsZXJhbmdlOjBhNWE0ZDNlMTVjYzRmODY5Y2ExOTQxODc4MjlkZmUzXzI0Mi0xMC0xLTEtODQ0NDQ_1f8c611b-cf49-4bc9-839e-4131867f2347"
      unitRef="number">0.136</jnj:PercentageChangeInSalesBySegmentOfBusiness>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i11096dc41162493598fbde3c3328208f_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgxNzUyOQ_2f328ba7-6e69-4cfb-96af-8c5cc71a29a4"
      unitRef="usd">400000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44f421d84e9d4a00bd90e95f56e2755d_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgxNzUyOQ_e7487fca-74d7-4d4c-8d72-3b3e90e966c9"
      unitRef="usd">400000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzMyMTk_f72ef568-7372-4392-9ac3-5fff81a92df3">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.295%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.446%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income (Loss) Before Tax*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Identifiable Assets&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020 &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,573&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(852)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,068&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,969&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,250&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;58,436&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;64,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,607&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70,956&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;53,372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,442&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;153,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142,829&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Expense not allocated to segments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;624&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,072&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;945&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less: Consumer Health separation costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,089&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,189&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;21,725&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;22,776&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;16,497&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;187,378&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;182,018&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;*Income before tax of approximately $0.2&#160;billion and $0.2&#160;billion in the fiscal years 2021 and 2020, respectively, has been reclassified as certain international OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:35.649%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.714%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Additions to Property,&lt;br/&gt;Plant &amp;amp; Equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Depreciation and&lt;br/&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Consumer Health&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;658&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;759&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;785&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pharmaceutical&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,374&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;863&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,687&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,029&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,006&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;MedTech&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,933&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,302&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,286&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,140&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segments total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,817&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,091&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,647&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,074&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;192&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;256&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;323&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;300&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;4,009&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,652&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;3,347&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;6,970&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,390&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;7,231&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i65f83a7c98be45a5b6124322b7bd487f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzItMi0xLTEtODQ0NDQ_d796984a-8027-4354-9dce-1b2221716290"
      unitRef="usd">2930000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="if7d4fcfbaed948f7b96ddd9e7c955350_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzItNC0xLTEtODQ0NDQ_ac018646-49d3-44a6-a7cd-31978d92f349"
      unitRef="usd">1573000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0db9c12fbc594fa39ecdd6ab21950596_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzItNi0xLTEtODQ0NDQ_82e507bc-0ad5-48fe-84f2-bccaa1e3c420"
      unitRef="usd">-852000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets
      contextRef="i41b31e63f2ca46a3845da852aec0b900_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzItOC0xLTEtODQ0NDQ_099c0e3a-ba1a-4842-8374-ac99009b200d"
      unitRef="usd">24068000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i716a54942efa46028603ae4da3c07d56_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzItMTAtMS0xLTg0NDQ0_018bc0e7-7d05-45ed-a0fa-af902563bc5e"
      unitRef="usd">25081000000</us-gaap:Assets>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ia03e77d7325e4d73b78a0c69bf6f9c96_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzMtMi0xLTEtODQ0NDQ_21824062-c6a3-49de-8bd6-461a7dd35058"
      unitRef="usd">15901000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie279ec7ee04446a18580684b9417ccef_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzMtNC0xLTEtODQ0NDQ_dbec410d-a185-4da8-8a78-0eb832c273df"
      unitRef="usd">17969000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ifeb973b453fb448c977acc62f23cfbf9_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzMtNi0xLTEtODQ0NDQ_e7bea324-4703-4fe2-894d-5bac1c7ecfe2"
      unitRef="usd">15250000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets
      contextRef="ia41cb8ba083c40d8bb8e8e5a75a886d3_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzMtOC0xLTEtODQ0NDQ_4b6fbdba-a13b-4a83-a74c-655cbddd3c92"
      unitRef="usd">58436000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i56d29c41cf14436b8bd0387c90fdcc9c_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzMtMTAtMS0xLTg0NDQ0_e49a58ce-f130-4fac-9dfd-a0d3c5c86bb3"
      unitRef="usd">64376000000</us-gaap:Assets>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i1a7ed898049b448889443be8ec36feff_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzQtMi0xLTEtODQ0NDQ_1ad6fbac-975d-4566-8e09-a223acedc9ec"
      unitRef="usd">4607000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i2b06ba1df96b4a3e9332405eed4144c7_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzQtNC0xLTEtODQ0NDQ_6ee06c95-3847-46bd-a448-abf4cd3c0362"
      unitRef="usd">4373000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ife9ff28d3f5c4f9f823666db103add14_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzQtNi0xLTEtODQ0NDQ_2445347e-9fac-43d2-a86d-b99a0ec462e1"
      unitRef="usd">3044000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets
      contextRef="i44bfea2a30414fd2acc71a28c1a9338c_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzQtOC0xLTEtODQ0NDQ_ebd9563d-2519-4821-9acf-7a5518a769ea"
      unitRef="usd">70956000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2bd8eb466f7641b58a738548f55f05ca_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzQtMTAtMS0xLTg0NDQ0_57fc0a5f-3d6b-4ca1-b62b-34dee7101cb4"
      unitRef="usd">53372000000</us-gaap:Assets>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i765d240ac3504d22b02095e7b50f9664_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzUtMi0xLTEtODQ0NDQ_2634c5b7-e85f-4a74-9e3f-c3d9f6025a88"
      unitRef="usd">23438000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i3c6e97913c1e42e8a73e24fdcddbb0f0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzUtNC0xLTEtODQ0NDQ_2b72659d-0d5f-4505-b91a-37cc0c9b486e"
      unitRef="usd">23915000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ic546e27439c549a5930ca85efae9f793_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzUtNi0xLTEtODQ0NDQ_47eff7f1-1a6c-410e-a84a-2c57b14ba550"
      unitRef="usd">17442000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets
      contextRef="ibaa94ed145ab44e893b1141cd2f4b6d2_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzUtOC0xLTEtODQ0NDQ_5a0fd95f-835a-4959-904c-a191bb49f5a5"
      unitRef="usd">153460000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i2194cc52a1204b8bb062f0829cc720a3_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzUtMTAtMS0xLTg0NDQ0_b419f039-f833-4472-a676-0cc7941bb165"
      unitRef="usd">142829000000</us-gaap:Assets>
    <jnj:ExpenseNotAllocatedToSegments
      contextRef="ia637975db75f4d6ca976d19b81d5d23b_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzYtMi0xLTEtODQ0NDQ_3f5a4241-e0d8-401d-bc3b-017b0f813692"
      unitRef="usd">624000000</jnj:ExpenseNotAllocatedToSegments>
    <jnj:ExpenseNotAllocatedToSegments
      contextRef="i5a13137501ef420499797d78d356afa9_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzYtNC0xLTEtODQ0NDQ_c239e753-a44c-46c8-a8b5-431490831812"
      unitRef="usd">1072000000</jnj:ExpenseNotAllocatedToSegments>
    <jnj:ExpenseNotAllocatedToSegments
      contextRef="i50227f06e5f04961b0e6a7aea3926827_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzYtNi0xLTEtODQ0NDQ_48709f4c-0269-4b5c-8322-39ddd2413368"
      unitRef="usd">945000000</jnj:ExpenseNotAllocatedToSegments>
    <jnj:ExpenseNotAllocatedToSegments
      contextRef="iea8f7496466a454890b32615eb14ec08_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzctMi0xLTEtOTQxMDk_ac50867b-a4f5-4cb5-b146-41c6af48d8ef"
      unitRef="usd">1089000000</jnj:ExpenseNotAllocatedToSegments>
    <jnj:ExpenseNotAllocatedToSegments
      contextRef="i3d62e4d77ba942f7bd7bc31625c7c643_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzctNC0xLTEtOTQxMjI_d552beaa-ca05-48aa-970a-be4478e313fb"
      unitRef="usd">67000000</jnj:ExpenseNotAllocatedToSegments>
    <us-gaap:Assets
      contextRef="iec21bae1ba8f4a4b9e8a25cbda75c2c4_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzctOC0xLTEtODQ0NDQ_4f21aef0-6af4-442e-b2be-98ec86847797"
      unitRef="usd">33918000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i12f90c84177a4ab0ac0f09d5f702e4e9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzctMTAtMS0xLTg0NDQ0_d7395fd4-fee0-4f9e-99ba-dc9fd28a8257"
      unitRef="usd">39189000000</us-gaap:Assets>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzgtMi0xLTEtODQ0NDQ_a309fd21-80ae-4a32-bf3f-99796f4c66b4"
      unitRef="usd">21725000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzgtNC0xLTEtODQ0NDQ_d0355860-028f-458e-8ffc-464a24ecbd20"
      unitRef="usd">22776000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzgtNi0xLTEtODQ0NDQ_41f982be-355b-46ce-a8ee-bdcabe29c5e0"
      unitRef="usd">16497000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:Assets
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzgtOC0xLTEtODQ0NDQ_5fd3964e-1a32-4bd5-ac3c-52159632ab3d"
      unitRef="usd">187378000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpmZTRkMTFmZTc4YmU0MjRjYmNhMThhNzU0ZjEwYzU1Ni90YWJsZXJhbmdlOmZlNGQxMWZlNzhiZTQyNGNiY2ExOGE3NTRmMTBjNTU2XzgtMTAtMS0xLTg0NDQ0_075947f6-cef0-427b-a024-e5ef6c85bfb4"
      unitRef="usd">182018000000</us-gaap:Assets>
    <us-gaap:ResultsOfOperationsIncomeBeforeIncomeTaxes
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzI3NDg3NzkwODI1Njc_dba99a4b-0c3e-429c-ab3c-8526b8295591"
      unitRef="usd">200000000</us-gaap:ResultsOfOperationsIncomeBeforeIncomeTaxes>
    <us-gaap:ResultsOfOperationsIncomeBeforeIncomeTaxes
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzI3NDg3NzkwODI1ODE_e6ddfb62-89eb-4d1d-bfc6-d12cc0e4b5bb"
      unitRef="usd">200000000</us-gaap:ResultsOfOperationsIncomeBeforeIncomeTaxes>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i65f83a7c98be45a5b6124322b7bd487f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzItMi0xLTEtODQ0NDQ_29ecb0e6-b4f6-40c3-9e43-94a61a6eddb0"
      unitRef="usd">323000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="if7d4fcfbaed948f7b96ddd9e7c955350_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzItNC0xLTEtODQ0NDQ_e40a1fb1-6eb5-4e7c-96e5-89dcb4fa52c7"
      unitRef="usd">331000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i0db9c12fbc594fa39ecdd6ab21950596_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzItNi0xLTEtODQ0NDQ_7ec2072c-969c-4ec8-9976-a86e77682c20"
      unitRef="usd">248000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i65f83a7c98be45a5b6124322b7bd487f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzItOC0xLTEtODQ0NDQ_938554c7-f98e-4f9f-8140-2b801b9db78e"
      unitRef="usd">658000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="if7d4fcfbaed948f7b96ddd9e7c955350_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzItMTAtMS0xLTg0NDQ0_c38700e9-8109-4227-bcf2-08ac5402f977"
      unitRef="usd">759000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0db9c12fbc594fa39ecdd6ab21950596_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzItMTItMS0xLTg0NDQ0_a32f538f-9898-4846-8d90-c6d0b34fa51d"
      unitRef="usd">785000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="ia03e77d7325e4d73b78a0c69bf6f9c96_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzMtMi0xLTEtODQ0NDQ_63877649-9799-423f-851a-3e224572c9d0"
      unitRef="usd">1374000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="ie279ec7ee04446a18580684b9417ccef_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzMtNC0xLTEtODQ0NDQ_e42451c6-afb0-449a-9601-9ea06978d8b1"
      unitRef="usd">1198000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="ifeb973b453fb448c977acc62f23cfbf9_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzMtNi0xLTEtODQ0NDQ_f92e8ef6-e67b-40b6-a467-1371948ab3f3"
      unitRef="usd">863000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ia03e77d7325e4d73b78a0c69bf6f9c96_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzMtOC0xLTEtODQ0NDQ_82d2c800-8133-475d-89df-e1a45c104067"
      unitRef="usd">3687000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie279ec7ee04446a18580684b9417ccef_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzMtMTAtMS0xLTg0NDQ0_8928811e-f753-4035-a2b5-5499b8e86165"
      unitRef="usd">4029000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ifeb973b453fb448c977acc62f23cfbf9_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzMtMTItMS0xLTg0NDQ0_281057bb-95c2-4855-be15-ca91464868fb"
      unitRef="usd">4006000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i1a7ed898049b448889443be8ec36feff_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzQtMi0xLTEtODQ0NDQ_ae188a31-dc09-457e-8294-c9f8886b59be"
      unitRef="usd">2120000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i2b06ba1df96b4a3e9332405eed4144c7_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzQtNC0xLTEtODQ0NDQ_008b3470-f9c0-4a06-8d5d-9476197c65ac"
      unitRef="usd">1933000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="ife9ff28d3f5c4f9f823666db103add14_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzQtNi0xLTEtODQ0NDQ_07ad01ba-4904-4d70-96ac-45b8396830e6"
      unitRef="usd">1980000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i1a7ed898049b448889443be8ec36feff_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzQtOC0xLTEtODQ0NDQ_20dc46d1-a300-419d-b8db-4ea5ec09dc8f"
      unitRef="usd">2302000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i2b06ba1df96b4a3e9332405eed4144c7_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzQtMTAtMS0xLTg0NDQ0_0490ec09-c792-4845-8ad8-17eed307aaa1"
      unitRef="usd">2286000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ife9ff28d3f5c4f9f823666db103add14_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzQtMTItMS0xLTg0NDQ0_4ace5a95-3371-4f63-8e7a-4c0426df04b0"
      unitRef="usd">2140000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i3baea8052de54dbf99a582b503fe5ae9_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzUtMi0xLTEtODQ0NDQ_49794c68-3475-43aa-936a-48722d55a40e"
      unitRef="usd">3817000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i365b842e2df647adb11480f7f5a63d9f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzUtNC0xLTEtODQ0NDQ_5fbb879f-8e3c-4d49-b5c4-e60f3056e961"
      unitRef="usd">3462000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i44e23d74806e4408bdef269ad289b155_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzUtNi0xLTEtODQ0NDQ_4381830a-652e-4b5b-8b10-4fa717c6610c"
      unitRef="usd">3091000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i3baea8052de54dbf99a582b503fe5ae9_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzUtOC0xLTEtODQ0NDQ_577f5bff-adf5-4781-acdd-2120f6ab6d88"
      unitRef="usd">6647000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i365b842e2df647adb11480f7f5a63d9f_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzUtMTAtMS0xLTg0NDQ0_b675d0fc-6731-4c40-9b91-1171e4d3dcb4"
      unitRef="usd">7074000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i44e23d74806e4408bdef269ad289b155_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzUtMTItMS0xLTg0NDQ0_be59271d-d144-455b-a97c-c75d7d15a247"
      unitRef="usd">6931000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i35f2772fa1fb464686fdad7eba530bc2_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzYtMi0xLTEtODQ0NDQ_7f7662e5-eba2-41e6-8d3b-a8f7b8451f3d"
      unitRef="usd">192000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="iad4ae67402be4d30bf0509f57bdf82a4_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzYtNC0xLTEtODQ0NDQ_d4cb0541-02dc-4e8b-a42f-82c5d99eb16c"
      unitRef="usd">190000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i4662aafc35c84c71a32e5811a0481ac0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzYtNi0xLTEtODQ0NDQ_31f6e966-90c6-4105-b7cf-389f1ada6c91"
      unitRef="usd">256000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i35f2772fa1fb464686fdad7eba530bc2_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzYtOC0xLTEtODQ0NDQ_a8fce9c8-9d25-4149-aac7-523196ccb5f6"
      unitRef="usd">323000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="iad4ae67402be4d30bf0509f57bdf82a4_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzYtMTAtMS0xLTg0NDQ0_44fe23f1-7e96-4294-9e08-82be664a2257"
      unitRef="usd">316000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i4662aafc35c84c71a32e5811a0481ac0_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzYtMTItMS0xLTg0NDQ0_48441730-526b-40ce-92cc-5801db5462ab"
      unitRef="usd">300000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzctMi0xLTEtODQ0NDQ_664b08f9-0cee-4035-a058-81de5527d181"
      unitRef="usd">4009000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzctNC0xLTEtODQ0NDQ_7d9b26f0-8bcb-4d5e-9a5b-0fb4e6082a4a"
      unitRef="usd">3652000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:PropertyPlantAndEquipmentAdditions
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzctNi0xLTEtODQ0NDQ_e985fc6b-61d1-4ab0-a718-89a6a6570dc6"
      unitRef="usd">3347000000</us-gaap:PropertyPlantAndEquipmentAdditions>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzctOC0xLTEtODQ0NDQ_d5492a74-9996-4080-afe4-691f066be96a"
      unitRef="usd">6970000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzctMTAtMS0xLTg0NDQ0_cd8e2a0f-5744-484a-bebf-d8bca23a61fe"
      unitRef="usd">7390000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTo5MWIyMzhhMjFhOTc0MzUzYmJmOGYwMzY4OTY0NzVmMS90YWJsZXJhbmdlOjkxYjIzOGEyMWE5NzQzNTNiYmY4ZjAzNjg5NjQ3NWYxXzctMTItMS0xLTg0NDQ0_5abc732f-ddcd-4d1b-9b0f-b72474c73c7f"
      unitRef="usd">7231000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzMyMTI_bc503088-12ee-4670-b6c2-d7b0bd1c181b">&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:44.580%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:8.709%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.824%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.441%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.532%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:9.300%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Sales to Customers &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Long-Lived Assets &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;United States&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,580&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,156&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,133&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,283&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;48,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,449&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23,594&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,980&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,774&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43,257&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Western Hemisphere excluding U.S.&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,750&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,335&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,737&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,708&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Asia-Pacific, Africa&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,789&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,275&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,431&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Segments total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;94,943&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;93,775&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,584&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112,225&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;99,586&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;General corporate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,134&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,014&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other non long-lived assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;74,019&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,418&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Worldwide total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;94,943&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;93,775&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;82,584&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;187,378&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;182,018&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"/&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See Note&#160;1 for a description of the segments in which the Company operates. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Export sales are not significant. In fiscal year 2022, the Company utilized three wholesalers distributing products for all three segments that represented approximately 16.5%, 13.0% and 12.0% of the total consolidated revenues. In fiscal year 2021, the Company had three wholesalers distributing products for all three segments that represented approximately 14.0%, 11.0% and 11.0% of the total consolidated revenues. In fiscal year 2020, the Company had three wholesalers distributing products for all three segments that represented approximately 16.0%, 12.0%, and 12.0% of the total consolidated revenues. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Amounts not allocated to segments include interest (income) expense and general corporate (income) expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;General corporate includes cash, cash equivalents and marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.43pt"&gt;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.2&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.15pt;font-weight:400;line-height:120%;position:relative;top:-3.85pt;vertical-align:baseline"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.44pt"&gt;One-time COVID-19 Vaccine manufacturing exit related costs of $1.5&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;An intangible asset impairment charge of approximately $0.8&#160;billion related to an in-process research and development asset, bermekimab (JnJ-77474462), an investigational drug for the treatment of Atopic Dermatitis (AD) and Hidradenitis Suppurativa (HS) acquired with the acquisition of XBiotech, Inc. in the fiscal year 2020. Additional information regarding efficacy of the AD and HS indications became available which led the Company to the decision to terminate the development of bermekimab for AD and HS&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Litigation expense of $0.1&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Loss of $0.7&#160;billion related to the change in the fair value of securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.1&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MedTech includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Litigation expense of $0.6&#160;billion primarily for pelvic mesh related costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A restructuring related charge of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Acquisition and integration related costs of $0.3&#160;billion primarily related to the acquisition of Abiomed&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;A Medical Device Regulation charge of $0.3&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(4)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $1.6&#160;billion, primarily talc related costs&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.6&#160;billion, primarily related to Risperdal Gynecomastia&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Divestiture gains of $0.6&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Gains of  $0.5&#160;billion related to the change in the fair value of securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MedTech includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An in-process research and development expense of $0.9&#160;billion related to Ottava&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A Medical Device Regulation charge of $0.2&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.1&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;        &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(5)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Consumer Health includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $3.9&#160;billion, primarily talc related costs and certain settlements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pharmaceutical includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.8&#160;billion, primarily related to the agreement in principle to settle opioid litigation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A gain of $0.5&#160;billion related to the change in the fair value of securities&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;MedTech includes:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A contingent consideration reversal of $1.1&#160;billion related to the timing of certain developmental milestones associated with the Auris Health acquisition. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;Litigation expense of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A restructuring related charge of $0.3&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;An in-process research and development expense of $0.2&#160;billion &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:54pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt"&gt;A Medical Device Regulation charge of $0.1&#160;billion&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(6)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Long-lived assets include property, plant and equipment, net for fiscal years 2022, and 2021 of $19,803 and $18,962, respectively, and intangible assets and goodwill, net for fiscal years 2022 and 2021 of $93,556 and $81,638, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf6f3d4d30c44652ac9e77a021f74bc7_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzItMi0xLTEtODQ0NDQ_1d15abc5-2edb-4723-be47-9eaccf4f3ef3"
      unitRef="usd">48580000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i901d71842aaf4089b7b7a4d97fdc8942_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzItNC0xLTEtODQ0NDQ_4c3c1179-c99a-48d8-8ce2-7b3cc1af9605"
      unitRef="usd">47156000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id907daafbe5d44ec927b1cf4e8fcfb0d_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzItNi0xLTEtODQ0NDQ_36058287-d252-45ae-81dc-ff1c323cbc3f"
      unitRef="usd">43133000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets
      contextRef="i8bd1a077b7d6414e8935bd70e97c8cf2_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzItOC0xLTEtODQ0NDQ_6e8bfbfe-bda0-44f5-8d54-bf3dcdae9385"
      unitRef="usd">66283000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i68257c001b354a5a98508e8a0ac0e82a_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzItMTAtMS0xLTg0NDQ0_e8491590-3bb8-46ed-af1c-9e8f1b7ac79b"
      unitRef="usd">48586000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96a3daea3f49408e971870669b0f5512_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzMtMi0xLTEtODQ0NDQ_31149c12-9f9f-4aeb-abc9-926d9c9d813a"
      unitRef="usd">23449000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fa7b3a6c25c4eada02b8646ac415062_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzMtNC0xLTEtODQ0NDQ_a10cd7a2-e0a0-49f0-a527-b82a3b455647"
      unitRef="usd">23594000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1cdb9152618c42eea5013297dbf2e4c3_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzMtNi0xLTEtODQ0NDQ_cb7f2309-88e4-46cf-b667-e029447d5eba"
      unitRef="usd">18980000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets
      contextRef="i200f93e3b77244a583b1ad4b7a71d3a1_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzMtOC0xLTEtODQ0NDQ_7be39930-b862-47f1-a502-d015bbb2c9cc"
      unitRef="usd">38774000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ib112e058fb6b447dbc3310478fc97587_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzMtMTAtMS0xLTg0NDQ0_ee4ee891-93f7-426f-8e53-5456b8695d74"
      unitRef="usd">43257000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icafa0a8044c04de497b6f3dfe30d2a58_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzQtMi0xLTEtODQ0NDQ_464fecdf-17ab-46d9-89c8-72e1fc1acb29"
      unitRef="usd">6125000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i43130bad99db457ba44ec22f2c697510_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzQtNC0xLTEtODQ0NDQ_126fb0b1-05d5-4d77-88ae-9672d2948677"
      unitRef="usd">5750000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9c2fc3c8e9594706a561854ef8052a58_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzQtNi0xLTEtODQ0NDQ_dc08f969-8f6d-4a05-8a6b-ba5ce1b441a3"
      unitRef="usd">5335000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets
      contextRef="id2d96b411f4d40debdac91b9aabb935f_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzQtOC0xLTEtODQ0NDQ_58bb6367-c91e-4b72-a0b3-b69183a6a6f6"
      unitRef="usd">2737000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i01fde314497149c6b70e4d076fa6dd4f_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzQtMTAtMS0xLTg0NDQ0_1d4fdc36-2c97-4ff2-b741-19d6d8aaf4e7"
      unitRef="usd">2708000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i20c9f4592a754d2cb500873c6ed0be54_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzUtMi0xLTEtODQ0NDQ_5a4c9140-88db-4bf8-893c-c524f5864479"
      unitRef="usd">16789000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if1a5151945ca4ac086f58deeeb720914_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzUtNC0xLTEtODQ0NDQ_84bc0e01-aa84-4236-87d4-6067b3ae60a6"
      unitRef="usd">17275000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i44509d3ef3cb4581b00a5c4862521e64_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzUtNi0xLTEtODQ0NDQ_ee4f73ab-1c6e-4b05-af8b-1c243e935ad7"
      unitRef="usd">15136000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets
      contextRef="i8ebf98b5fa324cbaa9bfaebdca053ff4_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzUtOC0xLTEtODQ0NDQ_c8e0f2ea-9266-46be-b53d-f405069ba74d"
      unitRef="usd">4431000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i29d342791cfc4b03a1713eb39bf942d5_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzUtMTAtMS0xLTg0NDQ0_4dac11c4-5caa-4241-b6b5-6ff73f6ce569"
      unitRef="usd">5035000000</us-gaap:NoncurrentAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i765d240ac3504d22b02095e7b50f9664_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzYtMi0xLTEtODQ0NDQ_c042694e-25e4-4b3d-b191-44902ca45501"
      unitRef="usd">94943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3c6e97913c1e42e8a73e24fdcddbb0f0_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzYtNC0xLTEtODQ0NDQ_42aa22d8-2506-4348-ad69-69f6b185c116"
      unitRef="usd">93775000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic546e27439c549a5930ca85efae9f793_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzYtNi0xLTEtODQ0NDQ_d8e3a81b-eb02-4cb0-8cf2-71c43687a330"
      unitRef="usd">82584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:NoncurrentAssets
      contextRef="i8d276957b87d4834ba1ee537b68aa89e_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzYtOC0xLTEtODQ0NDQ_17509e78-1f01-4bf6-a520-34d91c61ee2a"
      unitRef="usd">112225000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i0daf7a509a1742c0af022ecd6a711956_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzYtMTAtMS0xLTg0NDQ0_93b352cb-daa8-4b10-b97c-10a028835893"
      unitRef="usd">99586000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="iec21bae1ba8f4a4b9e8a25cbda75c2c4_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzctOC0xLTEtODQ0NDQ_4761d5c2-0d5e-4061-b16a-a9f2586c64fd"
      unitRef="usd">1134000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i12f90c84177a4ab0ac0f09d5f702e4e9_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzctMTAtMS0xLTg0NDQ0_7df4d23d-69c9-4007-a225-aaaf9918b145"
      unitRef="usd">1014000000</us-gaap:NoncurrentAssets>
    <jnj:OtherNonLongLivedAssets
      contextRef="i3fea49b8326e4a0bbb7c8f8cfee7b454_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzgtOC0xLTEtODQ0NDQ_1cc90142-8dcd-4e1b-a624-91151bcd3350"
      unitRef="usd">74019000000</jnj:OtherNonLongLivedAssets>
    <jnj:OtherNonLongLivedAssets
      contextRef="ibb0265bad6f240a28a737ed052560826_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzgtMTAtMS0xLTg0NDQ0_2464a274-baaf-4c5f-9132-f6f38ee1df3f"
      unitRef="usd">81418000000</jnj:OtherNonLongLivedAssets>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzktMi0xLTEtODQ0NDQ_243ab64f-e9c1-4417-8a37-3da4f51ab7ac"
      unitRef="usd">94943000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzktNC0xLTEtODQ0NDQ_ba8eb4e9-5f81-4978-9155-e20ee30118b7"
      unitRef="usd">93775000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzktNi0xLTEtODQ0NDQ_49e191b3-6c86-4a82-87d8-aa1706428776"
      unitRef="usd">82584000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Assets
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzktOC0xLTEtODQ0NDQ_02962e6d-5ffb-4566-b23a-5504769a7bde"
      unitRef="usd">187378000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90YWJsZTpiMTkzN2E3ZDk1MWE0YTA4YmQ2NTlhNTkxZmE3MDMxMS90YWJsZXJhbmdlOmIxOTM3YTdkOTUxYTRhMDhiZDY1OWE1OTFmYTcwMzExXzktMTAtMS0xLTg0NDQ0_e5428880-e941-4181-bb24-c038d54e456a"
      unitRef="usd">182018000000</us-gaap:Assets>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNzE3NA_1c0d91f1-8489-4b7f-9d29-88f8f704f776"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNzE3NA_535e325a-ca53-47f4-8162-979275a2add7"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ie500d8c896d44983b9c33f2ac1ef9710_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzQ0Mw_5e95631e-7eef-4ad4-8365-e07756b67fa6"
      unitRef="number">0.165</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3ae4ff8713334360a336393c7dac68d5_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzQ0Nw_0420bd06-8d3c-445c-9a66-921d13dc684b"
      unitRef="number">0.130</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if853701b34c2430d8f37795599100d52_D20220103-20230101"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzQ1NA_d75d0cfd-d075-48e6-8fb2-282ccaaccd83"
      unitRef="number">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU3Ng_e6189f47-5ac8-4658-8019-c4730028a7bd"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic1cb58176e324fddab800e715c7039c3_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzYxOQ_fc198ae2-be92-4988-8cdd-81624d24cc09"
      unitRef="number">0.140</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i40efe68b209843249746ea7032375b47_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzYyMw_491165c1-b574-42b1-919b-57cd41222901"
      unitRef="number">0.110</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i196d06199bcb47afb512e58c6c6cce33_D20210104-20220102"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzYzMA_033efe1b-d498-4a21-a692-5c078219525a"
      unitRef="number">0.110</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:NumberOfOperatingSegments
      contextRef="ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc1Mg_b861c310-b3a7-46e6-aeba-5ff1b786132b"
      unitRef="segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib97ee1e8d98d45f78eea6e86d0d96a02_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc5NQ_bc5638b0-319f-47ee-b9ae-469cd49ec4a3"
      unitRef="number">0.160</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i4dc7c4601c144f7091a2700b230221f8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc5OQ_b79a6f03-088b-4d77-87a4-82a1ef47b6e8"
      unitRef="number">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i648dd03c46344752a321bbba8fc97340_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzgwNw_3a73cae3-df02-4e88-a430-93fb6ffdd8b0"
      unitRef="number">0.120</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LitigationSettlementExpense
      contextRef="i1a210155919049c2bd43c936b49f1ee6_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzI3NDg3NzkwODI1OTc_cbec6075-caef-46c9-a5ed-b02868a8b282"
      unitRef="usd">200000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:RestructuringCharges
      contextRef="i1a210155919049c2bd43c936b49f1ee6_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzI3NDg3NzkwODI2MTE_ce5b5c77-2f1b-4bf8-8c4b-f2c106ae3144"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:SuppliesExpense
      contextRef="ia03e77d7325e4d73b78a0c69bf6f9c96_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNDk1Mg_91a87a8b-4580-46c8-8184-568a3e25d6f1"
      unitRef="usd">1500000000</us-gaap:SuppliesExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="i0e228c02951e4d53a756f82e5d074c5e_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyMzY1NQ_495b4d72-a1ed-4788-97fe-3de143358cce"
      unitRef="usd">800000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:LitigationSettlementExpense
      contextRef="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNDk4NQ_4111f69e-4e21-40a6-ac9e-7b1fa55a2590"
      unitRef="usd">100000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="i379137abaff142e485faca5b8e6eff8f_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNDk3MA_65c2ffd9-8c52-4f6b-b6d3-fa75b61a179a"
      unitRef="usd">-700000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:RestructuringCharges
      contextRef="ia324deef03f5433486883e8775658b95_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNTAxNA_e528c0f7-616e-4ec2-af76-9ffcf0e23896"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:LitigationSettlementExpense
      contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNTQyNA_86956e80-43e5-4cde-860f-6548d1021f20"
      unitRef="usd">600000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:RestructuringCharges
      contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNTQxMA_0712a165-020f-4e1b-9d6c-ed23ffa1fc4f"
      unitRef="usd">300000000</us-gaap:RestructuringCharges>
    <us-gaap:AcquisitionCosts
      contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNTQzNw_b684bc3a-848d-4fd1-b19c-47d15d43e749"
      unitRef="usd">300000000</us-gaap:AcquisitionCosts>
    <jnj:RegulationCharge
      contextRef="i7d7b06e25e534f789c632c936cc3156d_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzU0OTc1NTgyNTQzOQ_fe18afde-62d3-454c-8898-f5324bad3ef8"
      unitRef="usd">300000000</jnj:RegulationCharge>
    <us-gaap:LitigationSettlementExpense
      contextRef="i2c6099acc42a42639c659499eeee550a_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc4NDI_8e63eb00-cbdc-4e7f-b814-db28b9186f67"
      unitRef="usd">1600000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:RestructuringCharges
      contextRef="i2c6099acc42a42639c659499eeee550a_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc4NTA_828e4506-d979-4409-9d92-f1fb479c31f5"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:LitigationSettlementExpense
      contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc4NTg_19ecf231-292f-4fc2-9d4c-63c1bd5b9abd"
      unitRef="usd">600000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:GainLossOnSaleOfBusiness
      contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc4NjY_b35d3649-c159-4fbc-bc98-4fbd6f9e380f"
      unitRef="usd">600000000</us-gaap:GainLossOnSaleOfBusiness>
    <us-gaap:MarketableSecuritiesRealizedGainLoss
      contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc4NzQ_71e7e4f1-3293-4cfa-82a0-d168a72dd199"
      unitRef="usd">500000000</us-gaap:MarketableSecuritiesRealizedGainLoss>
    <us-gaap:RestructuringCharges
      contextRef="ic55dfbbdcc9e47c9a8ad4ed24173300b_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc4ODI_e9676f98-13bc-48f7-88b7-931d67c5429a"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc4OTA_0f0da4c8-d213-4536-9dc6-3608d789e3e0"
      unitRef="usd">300000000</us-gaap:RestructuringCharges>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc4OTg_7e7ebf0c-5b47-403a-9ad0-6f172d338073"
      unitRef="usd">900000000</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:RegulationCharge
      contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc5MDY_cabf04e2-c48b-4ad0-aff0-286bab0886a3"
      unitRef="usd">200000000</jnj:RegulationCharge>
    <us-gaap:LitigationSettlementExpense
      contextRef="ia80090ee1971490c96d43d82b91d9f03_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzc5MTQ_0d16b5eb-0f05-4488-b5e1-7dee6f2f7a8a"
      unitRef="usd">100000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="ieabc073d9ebf4111b8a8d92bdd0b8b7d_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzE1NzM_483f918c-7c9c-45ed-b6f7-d191b95d70c7"
      unitRef="usd">3900000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="i45c63832601e43b1ad4c8f083610e7c3_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzE2ODE_231d7335-6fe6-4260-abc5-329212658b49"
      unitRef="usd">800000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:MarketableSecuritiesUnrealizedGainLoss
      contextRef="ifeb973b453fb448c977acc62f23cfbf9_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzE3OTg_af435078-49d4-43f2-8015-2db2756d1b88"
      unitRef="usd">500000000</us-gaap:MarketableSecuritiesUnrealizedGainLoss>
    <us-gaap:RestructuringCharges
      contextRef="i45c63832601e43b1ad4c8f083610e7c3_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzE4MzY_d3fb99b2-4d02-45aa-b64f-19a9adf46bf4"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="i0675e6e915374fb5b095d7fd0834c9be_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzE5MDQ_33446bab-3e37-4355-abb4-679ee4e80a18"
      unitRef="usd">-1100000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <us-gaap:LitigationSettlementExpense
      contextRef="ia05a6854e4e147f5a99bd5f6979dc765_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzIwMzQ_a816c650-57ba-40af-9f9d-9d8f72fc649e"
      unitRef="usd">300000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:RestructuringCharges
      contextRef="ia05a6854e4e147f5a99bd5f6979dc765_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzIwNzI_9fc419cd-e8ef-4413-bdfa-a6f32c500c93"
      unitRef="usd">300000000</us-gaap:RestructuringCharges>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ia05a6854e4e147f5a99bd5f6979dc765_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzIxMjY_867abdd1-ea82-4287-a445-a8cc11f8e9df"
      unitRef="usd">200000000</us-gaap:ResearchAndDevelopmentInProcess>
    <jnj:RegulationCharge
      contextRef="ia05a6854e4e147f5a99bd5f6979dc765_D20191230-20210103"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzIxNjg_3969a44b-69b9-4a81-bbbc-ffa19a2a1531"
      unitRef="usd">100000000</jnj:RegulationCharge>
    <us-gaap:NoncurrentAssets
      contextRef="i903579018dfc4744b7b1bc7085ee9dea_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzMwODM_a4923c20-9570-49c3-8d9c-6411537dfba3"
      unitRef="usd">19803000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i6272b36311854ffb8459a6a826a10495_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzMwOTA_39da22e7-422e-4d37-be2f-0ab37ca2d0b3"
      unitRef="usd">18962000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="i4498e185f42a4d2c931df62d565c61fc_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzMxNzg_682a3b37-3d78-48ac-bd79-8f4596babecc"
      unitRef="usd">93556000000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets
      contextRef="ic6bb87c09ab1449d8ac694d344eae356_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTQvZnJhZzpkNmM3NmVmYmU5ODM0YWQ3YmE0YzNhZmVkOGJiZTMxZC90ZXh0cmVnaW9uOmQ2Yzc2ZWZiZTk4MzRhZDdiYTRjM2FmZWQ4YmJlMzFkXzMxODU_c1dca1da-ef09-47b3-984b-ea2cc64e2d9d"
      unitRef="usd">81638000000</us-gaap:NoncurrentAssets>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzEwMDI5_fc0ac1b7-99e4-4eeb-864d-e427fb683d45">Acquisitions and Divestitures&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During the fiscal year 2022, certain businesses were acquired for $17.7&#160;billion in cash and $1.1&#160;billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;       The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $17.3&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fiscal year 2022 acquisitions primarily included Abiomed, Inc. (Abiomed). The remaining acquisitions were not material.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; On December 22, 2022, the Company completed the acquisition of Abiomed, a leading, first-to-market provider of cardiovascular medical technology with a first-in-kind portfolio for the treatment of coronary artery disease and heart failure which also has an extensive innovation pipeline of life-saving technologies. The transaction broadens the Company&#x2019;s position as a growing cardiovascular innovator, advancing the standard of care in heart failure and recovery, one of healthcare&#x2019;s largest areas of unmet need. The transaction was accounted for as a business combination and the results of operations were included in the MedTech segment as of the date of the acquisition. The acquisition was completed through a tender offer for all outstanding shares. The consideration paid in the acquisition consisted of an upfront payment of $380.00 per share in cash, amounting to $17.1&#160;billion, net of cash acquired, as well as a non-tradeable contingent value right (&#x201c;CVR&#x201d;) entitling the holder to receive up to $35.00 per share in cash (which with respect to the CVRs total approximately $1.6&#160;billion in the aggregate) if certain commercial and clinical milestones are achieved. The corresponding enterprise value (without taking into account the CVRs) of approximately $16.5&#160;billion includes cash, cash equivalents and marketable securities acquired. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The milestones of the CVR consist of:&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt"&gt;$17.50 per share, payable if net sales for Abiomed products exceeds $3.7&#160;billion during Johnson &amp;amp; Johnson&#x2019;s fiscal second quarter of 2027 through fiscal first quarter of 2028, or if this threshold is not met during this period and is subsequently met during any rolling four quarter period up to the end of Johnson &amp;amp; Johnson&#x2019;s fiscal first quarter of 2029, $8.75 per share;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:10.5pt"&gt;$7.50 per share payable upon FDA premarket application approval of the use of Impella&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; products in ST-elevated myocardial infarction (STEMI) patients without cardiogenic shock by January 1, 2028; and&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;c.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:11.07pt"&gt;$10.00 per share payable upon the first publication of a Class I recommendation for the use of Impella&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; products in high risk PCI or STEMI with or without cardiogenic shock within four years from their respective clinical endpoint publication dates, but in all cases no later than December 31, 2029.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The fair value of the acquisition was allocated to assets acquired of $19.9&#160;billion (net of $0.3&#160;billion cash acquired), primarily to goodwill for $10.9&#160;billion, amortizable intangible assets for $6.6&#160;billion, IPR&amp;amp;D for $1.1&#160;billion, marketable &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;securities of $0.6&#160;billion and liabilities assumed of $2.8&#160;billion, which includes the fair value of the contingent consideration mentioned above for $0.7&#160;billion and deferred taxes of $1.8&#160;billion. The goodwill is primarily attributable to the commercial acceleration and expansion of the portfolio and is not expected to be deductible for tax purposes. The contingent consideration was recorded in Other Liabilities on the Consolidated Balance Sheet.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As the acquisition occurred in December 2022, the Company is still finalizing the allocation of the purchase price to the individual assets acquired and liabilities assumed. The allocation of the purchase price included in the current period balance sheet is based on the best estimate of management and is preliminary and subject to change. To assist management in the allocation, the Company engaged valuation specialists to prepare appraisals. The Company will finalize the amounts recognized as the information necessary to complete the analysis is obtained. The Company expects to finalize these amounts as soon as possible but no later than one year from the acquisition date.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The amortizable intangible assets were primarily comprised of already in-market products of the Impella&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;&#xae;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; platform with an average weighted life of 14 years. The IPR&amp;amp;D assets were valued for technology programs for unapproved products. The value of the IPR&amp;amp;D was calculated using probability-adjusted cash flow projections discounted for the risk inherent in such projects. The probability of success factor ranged from 52% to 70%. The discount rate applied was 9.5%.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In 2022, the Company recorded acquisition related costs before tax of approximately $0.3&#160;billion, which was recorded in Other (income)/expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During fiscal year 2021, the Company did not make any material acquisitions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During fiscal year 2020, certain businesses were acquired for $7.3&#160;billion in cash and $0.4&#160;billion of liabilities assumed. These acquisitions were accounted for using the acquisition method and, accordingly, results of operations have been included in the financial statements from their respective dates of acquisition.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess of purchase price over the estimated fair value of tangible assets acquired amounted to $7.5&#160;billion and has been assigned to identifiable intangible assets, with any residual recorded to goodwill. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fiscal year 2020 acquisitions primarily included: all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc. (XBiotech), Momenta Pharmaceuticals, Inc. (Momenta), a company that discovers and develops novel therapies for immune-mediated diseases and the outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During the fiscal first quarter of 2020, the Company completed the acquisition of all rights to the investigational compound bermekimab, which has multiple dermatological indications, along with certain employees from XBiotech Inc., for a purchase price of $0.8&#160;billion. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;amp;D, for $0.8&#160;billion applying a probability of success factor that ranged from 20% to 60% to reflect inherent development, regulatory and commercial risk for the different indications. The discount rate applied was approximately 16%. The transaction was accounted for as a business combination and included in the Pharmaceutical segment. In fiscal 2022, the Company recorded an intangible asset impairment charge of approximately $0.8&#160;billion related to this in-process research and development asset.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Additionally, in the fiscal first quarter of 2020, the Company completed the acquisition of all outstanding shares in Verb Surgical Inc., a company with significant robotics and data science capabilities, including those shares previously held by Verily. The transaction was accounted for as a business combination and included in the MedTech segment. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets, primarily IPR&amp;amp;D, for $0.4&#160;billion, goodwill for $0.2&#160;billion, other assets of $0.2&#160;billion and liabilities assumed of $0.3&#160;billion. The fair value of the Company's previously held equity investment in Verb Surgical Inc. was $0.4&#160;billion. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;On October 1, 2020, the Company completed the acquisition of Momenta for a purchase price of approximately $6.1&#160;billion, net of cash acquired. The fair value of the acquisition was allocated primarily to non-amortizable intangible assets (IPR&amp;amp;D) of $6.0&#160;billion, goodwill of $1.2&#160;billion, other assets of $0.5&#160;billion and liabilities of $1.6&#160;billion. The assets acquired are intended to address substantial unmet medical need in maternal-fetal disorders, neuro-inflammatory disorders, rheumatology, dermatology and autoimmune hematology. Depending on the asset, probability of success factors ranging from 20% to 77% were used in the fair value calculation to reflect inherent development and regulatory risk of the IPR&amp;amp;D. The discount rate applied was approximately 13%. The goodwill is primarily attributable to synergies expected to arise from the business acquisition and is not expected to be deductible for tax purposes. The transaction was accounted for as a business combination and included in the Pharmaceutical segment.                   &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify;text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;In accordance with U.S.&#160;GAAP standards related to business combinations, and goodwill and other intangible assets, supplemental pro forma information for fiscal years 2022, 2021 and 2020 is not provided, as the impact of the aforementioned acquisitions did not have a material effect on the Company&#x2019;s results of operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Divestitures&lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;During fiscal year 2022, the Company did not make any material divestitures. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;During fiscal year 2021, in separate transactions, the Company divested two brands outside the U.S. within the Pharmaceutical segment. The Company recognized a pre-tax gain recorded in Other (income) expense, net, of approximately $0.6&#160;billion. &lt;/span&gt;&lt;/div&gt;During fiscal year 2020, the Company sold 11.8&#160;million shares of Idorsia LTD (Idorsia), or its 8.3% ownership in the company at that time. The transaction resulted in gross proceeds of approximately CHF 337&#160;million ($357&#160;million) based on a sales price of CHF 28.55/share and resulted in an immaterial net loss. At the end of fiscal 2020, the Company had rights to approximately 38.7&#160;million shares through a convertible loan with a principal amount of CHF 445&#160;million (due June 2027). During fiscal year 2021, the Company converted CHF 110&#160;million ($120&#160;million) of this loan into approximately 9.6&#160;million shares of Idorsia which were reflected at fair value as of January 2, 2022. During the fiscal third quarter of 2021, the Company's undrawn credit facility with Idorsia was terminated.</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTEzMzQ_e4886f35-056d-43f5-b480-54b9764c88ea"
      unitRef="usd">17700000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTEzNDk_883728b1-d1f8-41d1-93db-971cb8aced83"
      unitRef="usd">1100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <jnj:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTEzNjM_d392a9e6-085d-4ed2-83b5-421d2544f37e"
      unitRef="usd">17300000000</jnj:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTEzNzg_bcc39731-8a29-4aae-96a6-af6f275dd9a6"
      unitRef="usdPerShare">380.00</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable
      contextRef="ib9836117d3a94830a8233450377a1deb_D20221222-20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTE0MjY_eea4b5e3-0daf-427d-be49-9b398e99eff1"
      unitRef="usd">17100000000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight
      contextRef="i92d127c3ca8d4ec2976b3e3c568fecc2_D20221222-20221222"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1ODg1MQ_c50a31fd-fdd1-4d12-80e9-0b1ee37a434c"
      unitRef="usdPerShare">35.00</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight>
    <jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight
      contextRef="i92d127c3ca8d4ec2976b3e3c568fecc2_D20221222-20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1OTIxMQ_1e1fa0a7-12c9-47bc-8da2-987d4ffb39b4"
      unitRef="usd">1600000000</jnj:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1OTE5Ng_a41d9bb9-4a2b-4fc5-9365-858c98b5cdf0"
      unitRef="usd">16500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="i81a39d36d1174514a434b80d6c743dc6_I20221222"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTE0NDE_c290a436-d1dc-41d2-b448-ad0c9871a06c"
      unitRef="usdPerShare">17.50</us-gaap:DividendsPayableAmountPerShare>
    <jnj:RevenuesContingentConsideration
      contextRef="i92d127c3ca8d4ec2976b3e3c568fecc2_D20221222-20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTE0NDk_ee953fee-594d-4d25-84fe-590a8a1ccd53"
      unitRef="usd">3700000000</jnj:RevenuesContingentConsideration>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="i8b185cbc0eed49e1bf2b12aead1c396f_I20221222"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTE0NjM_59d51420-de2f-4c26-b250-100b3674e481"
      unitRef="usdPerShare">8.75</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="i84406520b58240c49988945086079984_I20221222"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTE0NzA_86de3f4f-6ff3-4458-ac76-b954a5236040"
      unitRef="usdPerShare">7.50</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:DividendsPayableAmountPerShare
      contextRef="i7342e69dce654189845f736621bb11ac_I20221222"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTE0Nzc_f5216cc3-d4a9-49d0-b575-819e270fc243"
      unitRef="usdPerShare">10.00</us-gaap:DividendsPayableAmountPerShare>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTQ0MA_2ff4b549-e0e5-49e7-b593-696b7d0e06b2"
      unitRef="usd">19900000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="ib9836117d3a94830a8233450377a1deb_D20221222-20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTQ4Mw_72ebd972-bca6-40cd-8fb7-e3b55fc51eba"
      unitRef="usd">300000000</us-gaap:CashAcquiredFromAcquisition>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="ib9836117d3a94830a8233450377a1deb_D20221222-20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTQ5Nw_486bdf73-5d73-429c-a77b-4d040a201f5d"
      unitRef="usd">10900000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:FinitelivedIntangibleAssetsAcquired1
      contextRef="ib9836117d3a94830a8233450377a1deb_D20221222-20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTQ1NQ_106216e6-f173-4731-a39c-4a13a4385f30"
      unitRef="usd">6600000000</us-gaap:FinitelivedIntangibleAssetsAcquired1>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="ib9836117d3a94830a8233450377a1deb_D20221222-20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTQ2OQ_a6171530-2763-43b9-89bd-dab3387102d9"
      unitRef="usd">1100000000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities
      contextRef="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTUxMg_02934db0-dec2-4ef0-9244-1258d7a0c6de"
      unitRef="usd">600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities
      contextRef="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTUyNg_9ccd5d10-e080-4eae-898b-6cea20c499a8"
      unitRef="usd">2800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTU0MA_70bc7e38-e294-4cda-8503-831d8ab69b8d"
      unitRef="usd">700000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTU1NA_24fb1034-7509-4c34-a852-3320ba17fb68"
      unitRef="usd">1800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="i4f147e1dd45545d3abb1795f5f7086da_D20221222-20221222"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzI3NDg3NzkxMTE0OTU_8074e455-424a-4da1-8766-50c21f0a1f51">P14Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="i3ea49ac2e6aa4de69e5169b63d21cc06_I20221222"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTM4OA_a97a93f5-6862-453d-ae31-410ec965e932"
      unitRef="number">0.52</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="i1690230576734ba492365e566a8b6b5e_I20221222"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTM5Mw_ec870e86-1468-4a2a-9349-d0eca9ff6f34"
      unitRef="number">0.70</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessAcquisitionDiscountRate
      contextRef="i2c916c6b3cde41e3b67ac92e1405bfdd_I20221222"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MTM5OA_df460b60-5108-4c04-8c88-94ea740e6092"
      unitRef="number">0.095</jnj:BusinessAcquisitionDiscountRate>
    <us-gaap:BusinessCombinationAcquisitionRelatedCosts
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg0NDk1NQ_0d7ea0fd-32a3-4f96-b4b0-01accbc59a08"
      unitRef="usd">300000000</us-gaap:BusinessCombinationAcquisitionRelatedCosts>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzE3Nw_bd60ff1d-6f53-415f-a128-6efbc189c7db"
      unitRef="usd">7300000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="ibe67d998d2674637a9c218fa218dce7d_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzE5Mg_d3b81c88-7e06-4f81-b452-0be1ec8adb7c"
      unitRef="usd">400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:IntangibleAssetsNetIncludingGoodwill
      contextRef="i3fbf2d6d15164f949f7d00b550a2d80f_I20220102"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzUxNg_c67651e9-4df5-42d4-ba6d-d66be6c9312e"
      unitRef="usd">7500000000</us-gaap:IntangibleAssetsNetIncludingGoodwill>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i6c96d667b7284485a85bb50fece53ad0_D20210104-20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzEzMzI_a179da65-5826-4ce3-aa92-e9afa81fa345"
      unitRef="usd">800000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="ia24eda47473543d58b1d6c2d349bdfc5_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzE0NTM_00bcb283-61c1-4925-a4cb-0e0ca7f28e13"
      unitRef="usd">800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="idf3a369e46f249199404ae4a686a3719_I20210404"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzE1MTQ_72817e28-2d80-4b66-a412-262dc370a84e"
      unitRef="number">0.20</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="i829e1cea7f8840eabf95f9902ac2836e_I20210404"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzE1MjE_f2391e20-2f89-4c45-a1be-20a72e39135b"
      unitRef="number">0.60</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessAcquisitionDiscountRate
      contextRef="ia24eda47473543d58b1d6c2d349bdfc5_I20210404"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzE2NjM_25813adb-7611-4dd4-a33c-e535a729eef7"
      unitRef="number">0.16</jnj:BusinessAcquisitionDiscountRate>
    <us-gaap:AssetImpairmentCharges
      contextRef="ic25eb0c4ceda4b8ca2e1719553bd3d9f_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzU0OTc1NTg1MjIzNQ_d7731409-5f97-44cb-b252-ec414a94bea2"
      unitRef="usd">800000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="icc8a7af544c348f792fe38f31e341481_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzMwODk_2f770c3b-384e-43cb-a2da-78e6fd87b1a1"
      unitRef="usd">400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="icc8a7af544c348f792fe38f31e341481_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzMxMDY_41dfde46-995f-4ee4-b951-3d82d8faf1b4"
      unitRef="usd">200000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="icc8a7af544c348f792fe38f31e341481_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzMxMjY_8a9eb47c-acf6-4962-b156-3a29bbed7c92"
      unitRef="usd">200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="icc8a7af544c348f792fe38f31e341481_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzMxNTY_b4829f98-2141-4f49-a7c3-711a34ca8d68"
      unitRef="usd">300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="icc8a7af544c348f792fe38f31e341481_I20210404"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzMyNTI_792e1123-736e-438b-855d-f11f61c2f7d2"
      unitRef="usd">400000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="i96285e2125c044239562f06c5a49708f_D20201001-20201001"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzMzNjQ_83c38976-f99c-4b43-98d9-891a1423e9dd"
      unitRef="usd">6100000000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="i3825927182464ac79b6e43df181cccf8_I20201001"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzM0OTY_e236552c-02d3-4f2f-acc2-7d72df00bd42"
      unitRef="usd">6000000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="i27aa2a498bdb4d7fb75719ee6d31b90f_I20201001"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzM1MTI_42a6f067-e961-485d-a0b2-22312b123daa"
      unitRef="usd">1200000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets
      contextRef="i27aa2a498bdb4d7fb75719ee6d31b90f_I20201001"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzM1MzI_2287dcb5-bba5-4269-a67f-c35eeea40876"
      unitRef="usd">500000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities
      contextRef="i27aa2a498bdb4d7fb75719ee6d31b90f_I20201001"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzM1NTQ_0f600db2-448b-4dbc-a002-fdbff7e36ee8"
      unitRef="usd">1600000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="if2ea1b03a3be4ff59976cf8545ab6d21_I20201001"
      decimals="1"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzM4MTM_086b0705-bcfb-4fcb-acc5-bff75d7e002b"
      unitRef="number">0.20</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessCombinationProbabilityOfSuccessFactor
      contextRef="i6535353e93a14112b8d587f589b7bd9f_I20201001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzM4MTk_cf9b3513-97ca-4f91-ae09-fbc88c2a236d"
      unitRef="number">0.77</jnj:BusinessCombinationProbabilityOfSuccessFactor>
    <jnj:BusinessAcquisitionDiscountRate
      contextRef="i27aa2a498bdb4d7fb75719ee6d31b90f_I20201001"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzM5NzI_92f7accb-6f8f-4274-8bc5-19d6ac5d2e85"
      unitRef="number">0.13</jnj:BusinessAcquisitionDiscountRate>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="i07c8b24309d443688602562848d8298e_D20210104-20220102"
      decimals="-7"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzkwMDk_c4c7ffb4-a5ce-4c2c-82aa-1c64531b6d8d"
      unitRef="usd">600000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="ie3dd034235f641b9a1484d7974551ed8_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzkwNTY_6be3daa8-92cc-4893-a48e-b1c34ea3bb7a"
      unitRef="shares">11800000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction
      contextRef="ie3dd034235f641b9a1484d7974551ed8_D20191230-20210103"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzkwOTk_5831718d-23e4-461d-b035-49b2ed52179d"
      unitRef="number">0.083</us-gaap:SaleOfStockPercentageOfOwnershipBeforeTransaction>
    <us-gaap:ProceedsFromSaleOfInterestInCorporateUnit
      contextRef="ie3dd034235f641b9a1484d7974551ed8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzkyMDU_75630753-54fb-428c-9070-ad0e4970f2b5"
      unitRef="chf">337000000</us-gaap:ProceedsFromSaleOfInterestInCorporateUnit>
    <us-gaap:ProceedsFromSaleOfInterestInCorporateUnit
      contextRef="ie3dd034235f641b9a1484d7974551ed8_D20191230-20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzkyMDk_955cc9ce-ec87-4945-8639-6418850653e9"
      unitRef="usd">357000000</us-gaap:ProceedsFromSaleOfInterestInCorporateUnit>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="i1aee0cedf1f94f5a8d36040886e87e0f_I20210103"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzkyNDM_e1a86d60-0eca-4db4-9f26-a91cfc2bc62e"
      unitRef="usdPerShare">28.55</us-gaap:SaleOfStockPricePerShare>
    <jnj:ConvertibleNoteEquityInterestNumberOfShares
      contextRef="ie3dd034235f641b9a1484d7974551ed8_D20191230-20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzkzNTk_13ef837d-c996-4a5c-a9a2-c8f6ae095b3c"
      unitRef="shares">38700000</jnj:ConvertibleNoteEquityInterestNumberOfShares>
    <us-gaap:LongTermDebt
      contextRef="i5282653c940b42ef862b668ed6921a2d_I20210103"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzk0Mjc_be39fed6-3518-4e60-b4ca-2644fca3bf78"
      unitRef="chf">445000000</us-gaap:LongTermDebt>
    <jnj:DebtInstrumentConvertibleAmountOfLoanConverted
      contextRef="i0e37979e6ad844279246c3dd8ff74a38_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzk0OTg_13fdacf4-0570-42e4-8f1d-3f655bab357b"
      unitRef="chf">110000000</jnj:DebtInstrumentConvertibleAmountOfLoanConverted>
    <jnj:DebtInstrumentConvertibleAmountOfLoanConverted
      contextRef="i0e37979e6ad844279246c3dd8ff74a38_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzk1MDI_677bdbec-877c-4677-963e-3fd8612ac533"
      unitRef="usd">120000000</jnj:DebtInstrumentConvertibleAmountOfLoanConverted>
    <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments
      contextRef="i0e37979e6ad844279246c3dd8ff74a38_D20210104-20220102"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMTcvZnJhZzo2ZjE5MmZjOGNlNmY0ZjRkYjI5MzMyOTE3MmUxNTE2MC90ZXh0cmVnaW9uOjZmMTkyZmM4Y2U2ZjRmNGRiMjkzMzI5MTcyZTE1MTYwXzk1Mzg_d6328b62-9dde-475d-8ac6-21bd45368111"
      unitRef="shares">9600000</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
    <us-gaap:LegalMattersAndContingenciesTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzI3NDg3NzkzNzc1ODE_96d1f226-4d4a-4278-b9bb-3e4036e94804">Legal Proceedings&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Johnson &amp;amp; Johnson and certain of its subsidiaries are involved in various lawsuits and claims regarding product liability; intellectual property; commercial; indemnification and other matters; governmental investigations; and other legal proceedings that arise from time to time in the ordinary course of their business.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records accruals for loss contingencies associated with these legal matters when it is probable that a liability will be incurred, and the amount of the loss can be reasonably estimated. As of January 1, 2023, the Company has determined that the liabilities associated with certain litigation matters are probable and can be reasonably estimated. The Company has accrued for these matters and will continue to monitor each related legal issue and adjust accruals as might be warranted based on new information and further developments in accordance with ASC 450-20-25. For these and other litigation and regulatory matters discussed below for which a loss is probable or reasonably possible, the Company is unable to estimate the possible loss or range of loss beyond the amounts accrued. Amounts accrued for legal contingencies often result from a complex series of judgments about future events and uncertainties that rely heavily on estimates and assumptions including timing of related payments. The ability to make such estimates and judgments can be affected by various factors including, among other things, whether damages sought in the proceedings are unsubstantiated or indeterminate; scientific and legal discovery has not commenced or is not complete; proceedings are in early stages; matters present legal uncertainties; there are significant facts in dispute; procedural or jurisdictional issues; the uncertainty and unpredictability of the number of potential claims; ability to achieve comprehensive multi-party settlements; complexity of related cross-claims and counterclaims; and/or there are numerous parties involved. To the extent adverse awards, judgments or verdicts have been rendered against the Company, the Company does not record an accrual until a loss is determined to be probable and can be reasonably estimated.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the Company&#x2019;s opinion, based on its examination of these matters, its experience to date and discussions with counsel, the ultimate outcome of legal proceedings, net of liabilities accrued in the Company&#x2019;s balance sheet, is not expected to have a material adverse effect on the Company&#x2019;s financial position. However, the resolution of, or increase in accruals for, one or more of these matters in any reporting period may have a material adverse effect on the Company&#x2019;s results of operations and cash flows for that period.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;PRODUCT LIABILITY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and certain of its subsidiaries are involved in numerous product liability claims and lawsuits involving multiple products. Claimants in these cases seek substantial compensatory and, where available, punitive damages. While the Company believes it has substantial defenses, it is not feasible to predict the ultimate outcome of litigation. From time to time, even if it has substantial defenses, the Company considers isolated settlements based on a variety of circumstances. The Company has established accruals for product liability claims and lawsuits in compliance with ASC 450-20 based on currently available information, which in some cases may be limited. The Company accrues an estimate of the legal defense costs needed to defend each matter when those costs are probable and can be reasonably estimated. For certain of these matters, the Company has accrued additional amounts such as estimated costs associated with settlements, damages and other losses. Product liability accruals can represent projected product liability for thousands of claims around the world, each in different litigation environments and with different fact patterns. Changes to the accruals may be required in the future as additional information becomes available.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The most significant of these cases include: the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; the PINNACLE Acetabular Cup System; pelvic meshes; RISPERDAL; body powders containing talc, primarily JOHNSON'S Baby Powder; ETHICON PHYSIOMESH&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Flexible Composite Mesh; ELMIRON; and TYLENOL. As of January&#160;1, 2023, in the United States there were approximately 170 plaintiffs with direct claims in pending lawsuits regarding injuries allegedly due to the DePuy ASR XL Acetabular System and DePuy ASR Hip Resurfacing System; 1,400 with respect to the PINNACLE Acetabular Cup System; 9,000 with respect to pelvic meshes; 1,100 with respect to RISPERDAL; 40,300 with respect to body powders containing talc;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2,100 with respect to ETHICON PHYSIOMESH Flexible Composite Mesh; 2,000 with respect to ELMIRON; and 170 with respect to TYLENOL. The number of pending lawsuits is expected to fluctuate as certain lawsuits are settled or dismissed and additional lawsuits are filed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2010, DePuy Orthopaedics, Inc. (DePuy) announced a worldwide voluntary recall of its ASR XL Acetabular System and DePuy ASR Hip Resurfacing System (ASR Hip) used in hip replacement surgery. Claims for personal injury have been made against DePuy and the Company. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Ohio. Litigation has also been filed in countries outside of the United States, primarily in the United Kingdom, Canada, Australia, Ireland, Germany, India and Italy. In November 2013, DePuy reached an agreement with a Court-appointed committee of lawyers representing ASR Hip plaintiffs to establish a program to settle claims with eligible ASR Hip patients in the United States who had surgery to replace their ASR Hips, known as revision surgery, as of August 2013. DePuy reached additional agreements in February 2015 and March 2017, which further extended the settlement program to include ASR Hip patients who had revision surgeries after August 2013 and prior to February 15, 2017. This settlement program has resolved more than 10,000 claims, thereby bringing to resolution significant ASR Hip litigation activity in the United States. However, lawsuits in the United States remain, and the settlement program does not address litigation outside of the United States. In Australia, a class action settlement was reached that resolved the claims of the majority of ASR Hip patients in that country. In Canada, the Company has reached agreements to settle the class actions filed in that country. The Company continues to receive information with respect to potential additional costs associated with this recall on a worldwide basis. The Company has established accruals for the costs associated with the United States settlement program and ASR Hip-related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have also been made against DePuy Orthopaedics, Inc. and the Company (collectively, DePuy) relating to the PINNACLE Acetabular Cup System used in hip replacement surgery. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. Most cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Northern District of Texas (Texas MDL). Beginning on June 1, 2022, the Judicial Panel on Multidistrict Litigation ceased transfer of new cases into the Texas MDL, and there are now cases pending in federal court outside the Texas MDL. Litigation also has been filed in state courts and in countries outside of the United States. Prior to 2019, several adverse verdicts had been rendered against DePuy, one of which was reversed on appeal and remanded for retrial. During the first quarter of 2019, DePuy established a United States settlement program to resolve these cases. As part of the settlement program, adverse verdicts have been settled. The Company has established an accrual for product liability litigation associated with the PINNACLE Acetabular Cup System and the related settlement program.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company arising out of Ethicon&#x2019;s pelvic mesh devices used to treat stress urinary incontinence and pelvic organ prolapse. The Company continues to receive information with respect to potential costs and additional cases. Cases filed in federal courts in the United States had been organized as a multi-district litigation (MDL) in the United States District Court for the Southern District of West Virginia. In March 2021, the MDL Court entered an order closing the MDL. The MDL Court has remanded cases for trial to the jurisdictions where the case was originally filed and additional pelvic mesh lawsuits have been filed, and remain, outside of the MDL. The Company has settled or otherwise resolved the majority of the United States cases and the estimated costs associated with these settlements and the remaining cases are reflected in the Company&#x2019;s accruals. In addition, class actions and individual personal injury cases or claims seeking damages for alleged injury resulting from Ethicon&#x2019;s pelvic mesh devices have been commenced in various countries outside of the United States, including claims and cases in the United Kingdom, the Netherlands, Belgium, France, Ireland, Italy, Spain and Slovenia and class actions in Israel, Australia, Canada and South Africa. In November 2019, the Federal Court of Australia issued a judgment regarding its findings with respect to liability in relation to the three Lead Applicants and generally in relation to the design, manufacture, pre and post-market assessments and testing, and supply and promotion of the devices in Australia used to treat stress urinary incontinence and pelvic organ prolapse. In September 2022, after exhausting its appeals, the Company reached an in-principle agreement to resolve the two pelvic mesh class actions in Australia, pending Federal Court approval. In November 2022, the application for approval of the settlement was filed, and a hearing on the settlement has been scheduled for the end of February 2023. The class actions in Canada were discontinued in 2020 as a result of a settlement of a group of cases and an agreement to resolve the Israeli class action was reached in May 2021. The parties in the Israeli class action are currently finalizing the terms of the settlement. A motion to approve the settlement was filed with the Court. The Company has established accruals with respect to product liability litigation associated with Ethicon&#x2019;s pelvic mesh products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Following a June 2016 worldwide market withdrawal of ETHICON PHYSIOMESH Flexible Composite Mesh (Physiomesh), claims for personal injury have been made against Ethicon, Inc. (Ethicon) and the Company alleging personal injury arising out of the use of this hernia mesh device. Cases filed in federal courts in the United States have been organized as a multi-district litigation (MDL) in the United States District Court for the Northern District of Georgia. A multi-county litigation (MCL) also has been formed in New Jersey state court and assigned to Atlantic County for cases pending in New Jersey. In addition to the matters in the MDL and MCL, there are additional lawsuits pending in the United States District Court for the Southern District &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;of Ohio, which are part of the MDL for polypropylene mesh devices manufactured by C.R. Bard, Inc., and lawsuits pending in two New Jersey MCLs formed for Proceed/Proceed Ventral Patch and Prolene Hernia systems, and lawsuits pending outside the United States. In May 2021, Ethicon and lead counsel for the plaintiffs entered into a term sheet to resolve approximately 3,600 Physiomesh cases (covering approximately 4,300 plaintiffs) pending in the MDL and MCL at that time. A master settlement agreement (MSA) was entered into in September 2021 and includes 3,729 cases in the MDL and MCL. All deadlines and trial settings in those proceedings are currently stayed pending the completion of the settlement agreement. Of the cases subject to the MSA, 2,236 have been dismissed with prejudice. Post-settlement cases in the Physiomesh MDL and MCL are subject to docket control orders requiring early expert reports and discovery requirements. As of January 2023, there are approximately 208 active cases subject to these orders which are being reviewed and evaluated. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims have also been filed against Ethicon and the Company alleging personal injuries arising from the PROCEED Mesh and PROCEED Ventral Patch hernia mesh products. In March 2019, the New Jersey Supreme Court entered an order consolidating these cases pending in New Jersey as an MCL in Atlantic County Superior Court. Additional cases have been filed in various federal and state courts in the United States, and in jurisdictions outside the United States. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ethicon and the Company also have been subject to claims for personal injuries arising from the PROLENE Polypropylene Hernia System. In January 2020, the New Jersey Supreme Court created an MCL in Atlantic County Superior Court to handle such cases. Cases involving this product have also been filed in other federal and state courts in the United States. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, an agreement in principle, subject to various conditions, was reached to settle the majority of the pending cases involving Proceed, Proceed Ventral Patch, Prolene Hernia System and related multi-layered mesh products.  All litigation activities in the two New Jersey MCLs are stayed pending resolution of the proposed settlement.  Future cases that are filed in the New Jersey MCLs will be subject to docket control orders requiring early expert reports and discovery requirements.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has established accruals with respect to product liability litigation associated with ETHICON PHYSIOMESH Flexible Composite Mesh, PROCEED Mesh and PROCEED Ventral Patch, and PROLENE Polypropylene Hernia System products.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have been made against Janssen Pharmaceuticals, Inc. and the Company arising out of the use of RISPERDAL, and related compounds, indicated for the treatment of schizophrenia, acute manic or mixed episodes associated with bipolar I disorder and irritability associated with autism. Lawsuits primarily have been filed in state courts in Pennsylvania, California, and Missouri. Other actions are pending in various courts in the United States and Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has successfully defended a number of these cases but there have been verdicts against the Company, including a verdict in October 2019 of $8.0&#160;billion of punitive damages related to one plaintiff, which the trial judge reduced to $6.8&#160;million in January 2020. In September 2021, the Company entered into a settlement in principle with the counsel representing plaintiffs in this matter and in substantially all of the outstanding cases in the United States. The costs associated with this and other settlements are reflected in the Company&#x2019;s accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury arising out of the use of XARELTO, an oral anticoagulant, have been made against Janssen Pharmaceuticals, Inc. (JPI); the Company; and JPI&#x2019;s collaboration partner for XARELTO, Bayer Healthcare AG, and certain of its affiliates. Cases filed in federal courts in the United States have been organized as a multi-district litigation in the United States District Court for the Eastern District of Louisiana. In addition, cases were filed in state courts across the United States. Many of these cases were consolidated into a state mass tort litigation in Philadelphia, Pennsylvania and in a coordinated proceeding in Los Angeles, California. Class action lawsuits also have been filed in Canada. In March 2019, JPI and the Company announced an agreement in principle to settle the XARELTO cases in the United States; the settlement agreement was executed in May 2019, the settlement became final in December 2019, and the settlement was funded in January 2020. This resolved the majority of cases pending in the United States. The Company has established accruals for its costs associated with the United States settlement program and XARELTO related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A significant number of personal injury claims alleging that talc causes cancer were made against Johnson &amp;amp; Johnson Consumer Inc. and the Company arising out of the use of body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder. The number of these personal injury lawsuits, filed in state and federal courts in the United States as well as outside of the United States, continued to increase. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In talc cases that previously have gone to trial, the Company has obtained a number of defense verdicts, but there also have been verdicts against the Company, many of which have been reversed on appeal. In June 2020, the Missouri Court of Appeals reversed in part and affirmed in part a July 2018 verdict of $4.7&#160;billion in &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ingham v. Johnson &amp;amp; Johnson, et al., &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No. ED 207476 (Mo. App.), reducing the overall award to $2.1&#160;billion. An application for transfer of the case to the Missouri Supreme Court &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;was subsequently denied and in June 2021, a petition for certiorari, seeking a review of the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ingham &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;decision by the United States Supreme Court, was denied. In June 2021, the Company paid the award, which, including interest, totaled approximately $2.5&#160;billion. The facts and circumstances, including the terms of the award, were unique to the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Ingham&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; decision and not representative of other claims brought against the Company.  The Company continues to believe that it has strong legal grounds to contest the other talc verdicts that it has appealed. Notwithstanding the Company&#x2019;s confidence in the safety of its talc products, in certain circumstances the Company has settled cases. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, Johnson &amp;amp; Johnson Consumer Inc. (Old JJCI) implemented a corporate restructuring (the 2021 Corporate Restructuring). As a result of that restructuring, Old JJCI ceased to exist and three new entities were created: (a) LTL Management LLC, a North Carolina limited liability company (LTL or Debtor); (b) Royalty A&amp;amp;M LLC, a North Carolina limited liability company and a direct subsidiary of LTL (RAM); and (c) the Debtor&#x2019;s direct parent, Johnson &amp;amp; Johnson Consumer Inc., a New Jersey company (New JJCI). The Debtor received certain of Old JJCI&#x2019;s assets and became solely responsible for the talc-related liabilities of Old JJCI, including all liabilities related in any way to injury or damage, or alleged injury or damage, sustained or incurred in the purchase or use of, or exposure to, talc, including talc contained in any product, or to the risk of, or responsibility for, any such damage or injury, except for any liabilities for which the exclusive remedy is provided under a workers&#x2019; compensation statute or act (the Talc-Related Liabilities). &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, notwithstanding the Company&#x2019;s confidence in the safety of its talc products, the Debtor filed a voluntary petition with the United States Bankruptcy Court for the Western District of North Carolina, Charlotte Division, seeking relief under chapter 11 of the Bankruptcy Code (the LTL Bankruptcy Case). As a result of the LTL Bankruptcy Case, the North Carolina Bankruptcy Court entered a temporary restraining order staying all litigation against LTL and Old JJCI. On November 15, 2021, the North Carolina Bankruptcy Court confirmed the scope of the stay, issuing a Preliminary Injunction (PI) prohibiting and enjoining the commencement and prosecution of talc-related claims against LTL, Old JJCI, New JJCI, the Company, other of their corporate affiliates, identified retailers, insurance companies, and certain other parties (the Protected Parties). The LTL Bankruptcy Case was transferred to the United States Bankruptcy Court for the District of New Jersey in November 2021, and that court extended the PI through the end of February 2022. Claimants filed motions to dismiss the LTL Bankruptcy Case and, following a multiple day hearing, the New Jersey Bankruptcy Court denied those motions by order issued in March 2022. The New Jersey Bankruptcy Court simultaneously issued another order extending the stay as to the Protected Parties. The claimants subsequently filed notices of appeal as to the denial of the motions to dismiss and the extension of the stay. In May 2022, the Third Circuit Court of Appeals granted the petitions to appeal. The briefing and oral argument on the appeal were completed in September 2022. On January 30, 2023, the Third Circuit reversed the Bankruptcy Court&#x2019;s ruling and remanded to the Bankruptcy Court to dismiss the LTL bankruptcy.  LTL filed a petition for rehearing on the decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;While the New Jersey Bankruptcy Court&#x2019;s order effectively stays all of the Company&#x2019;s talc-related personal injury litigation, LTL has agreed to lift the stay on a small number of appeals where appeal bonds have been filed.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has agreed to provide funding to LTL for the payment of amounts the New Jersey Bankruptcy Court determines are owed by LTL and the establishment of a $2&#160;billion trust in furtherance of this purpose. The Company has established a reserve for approximately $2&#160;billion in connection with the aforementioned trust. After and as a result of the filing of the LTL Bankruptcy Case, the Company de-consolidated LTL, which is a related party. The impact of the de-consolidation is not material to the Company. The parties have not yet reached a resolution of all talc matters in the LTL Bankruptcy Case, and the Company is unable to estimate the possible loss or range of loss beyond the amount accrued.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A class action advancing claims relating to industrial talc was filed against the Company and others in New Jersey state court in May 2022 (the Edley Class Action). The Edley Class Action asserts, among other things, that the Company fraudulently defended past asbestos personal injury lawsuits arising from exposure to industrial talc mined, milled, and manufactured before January 6, 1989 by the Company&#x2019;s then wholly owned subsidiary, Windsor Minerals, Inc., which is currently a debtor in the Imerys Bankruptcy described hereafter. The Company removed the Edley Class Action to federal court in the District of New Jersey. In July 2022, Imerys filed a motion in the Imerys Bankruptcy to stay the Edley Class Action, which was denied in August 2022.  In October 2022, the Company filed motions to dismiss and to deny certification of a class to pursue the Edley Class Action in the New Jersey District Court. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2019, the Company&#x2019;s talc supplier, Imerys Talc America, Inc. and two of its affiliates, Imerys Talc Vermont, Inc. and Imerys Talc Canada, Inc. (collectively, Imerys) filed a voluntary petition under chapter 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the District of Delaware (Imerys Bankruptcy). The Imerys Bankruptcy relates to Imerys&#x2019;s potential liability for personal injury from exposure to talcum powder sold by Imerys. In its bankruptcy, Imerys alleges it has claims against the Company for indemnification and rights to joint insurance proceeds.  In May 2020, Imerys, its parent Imerys S.A., the Tort Claimants&#x2019; Committee (TCC), and the Future Claimants&#x2019; Representative (FCR) (collectively, the Plan Proponents) filed their Plan of Reorganization (the Plan) and the Disclosure Statement related &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;thereto. The Plan Proponents have since filed numerous amendments to the Plan and Disclosure Statement. A hearing on the Plan Proponent&#x2019;s Disclosure Statement was held in January 2021, and the Court entered an order approving the Disclosure Statement, allowing Imerys to proceed with soliciting votes on the Plan. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, the Company voted to reject the Plan and opted out of the consensual releases in the Plan. In April 2021, the Plan Proponents announced the Plan had received the requisite number of accepting votes to confirm the Plan. The Company challenged certain improprieties with respect to portions of the vote and sought to disqualify those votes. In October 2021, the Bankruptcy Court issued a ruling deeming thousands of votes as withdrawn. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, Imerys cancelled the confirmation hearing on the Plan. Imerys, the TCC, the FCR, certain of Imerys&#x2019;s insurers, and certain parties in the Cyprus Mines chapter 11 case (described below) (collectively the Mediation Parties) agreed to engage in mediation. The most recent term of the mediation ended on December 31, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, Imerys commenced an adversary proceeding against the Company in the Imerys Bankruptcy (the Imerys Adversary Proceeding). The Imerys Adversary Proceeding sought, among other things, certain declarations with respect to the indemnification obligations allegedly owed by the Company to Imerys. The TCC and FCR simultaneously filed a motion for temporary restraining order and preliminary injunction seeking to enjoin the Company from undergoing a corporate restructuring that would separate the Company&#x2019;s talc liabilities from its other assets. The Bankruptcy Court denied the motion. The Company thereafter filed a motion to dismiss the adversary proceeding. The Bankruptcy Court has not yet decided the motion to dismiss. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Imerys Adversary Proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2020, Cyprus Mines Corporation and its parent, Cyprus Amax Minerals Company (CAMC) (together, Cyprus), which had owned certain Imerys talc mines, filed an adversary proceeding against the Company and Imerys in the Imerys Bankruptcy seeking a declaration of indemnity rights under certain contractual agreements (the Cyprus Adversary Proceeding). The Company denies such indemnification is owed, and filed a motion to dismiss the adversary complaint. In February 2021, Cyprus filed a voluntary petition for relief under chapter 11 of the Bankruptcy Code and filed its Disclosure Statement and Plan (the Cyprus Plan). The Cyprus Plan contemplates a settlement with Imerys and talc claimants where Cyprus would make a monetary contribution to a trust established under the Imerys Plan in exchange for an injunction against talc claims asserted against it and certain protected parties. Cyprus has not yet sought approval of its Disclosure Statement and Plan. Cyprus, along with the TCC and FCR appointed in the Cyprus chapter 11 case, have agreed to participate in the mediation with the Mediation Parties. In October 2021, the Company filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Cyprus Adversary Proceeding. In June 2022, Cyprus commenced an Adversary Proceeding in its chapter 11 case seeking an order enforcing the automatic stay by enjoining parties from commencing or continuing &#x201c;talc-related claims&#x201d; against CAMC. In June 2022, the court entered a preliminary injunction order enjoining claimants from pursuing talc-related claims against CAMC through January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2021, several of the Company&#x2019;s insurers involved in coverage litigation in New Jersey State Court (the Coverage Action) filed a motion in the Imerys Bankruptcy Court proceeding seeking a determination that the automatic stay does not apply to the Coverage Action and, in the alternative, seeking relief from the automatic stay to allow them to continue to litigate their claims in the Coverage Action. In March 2021, the Company filed a limited response and reservation of rights with respect to the motion. The Court entered an agreed order modifying the stay to allow the litigation in the Coverage Action to continue. In October 2021, LTL filed a Notice of Bankruptcy Filing and Stay of Proceedings clarifying that the automatic stay arising upon the filing of the LTL Bankruptcy Case should apply to the Coverage Action. In March 2022, the New Jersey Bankruptcy Court ruled that the LTL automatic stay applied to the Coverage Action.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, a securities class action lawsuit was filed against the Company and certain named officers in the United States District Court for the District of New Jersey, alleging that the Company violated the federal securities laws by failing to disclose alleged asbestos contamination in body powders containing talc, primarily JOHNSON&#x2019;S Baby Powder, and that purchasers of the Company&#x2019;s shares suffered losses as a result. Plaintiff is seeking damages. In April 2019, the Company moved to dismiss the complaint and briefing on the motion was complete as of August 2019. In December 2019, the Court denied, in part, the motion to dismiss. In March 2020, the Company answered the complaint. In April 2021, briefing on Plaintiff&#x2019;s motion for class certification was completed. In July 2021, the Company filed a notice of supplemental authority in opposition to Plaintiff&#x2019;s motion for class certification, and Plaintiff filed a response. In December 2021, the Company filed a motion to supplement the class certification record, and in January 2022, Plaintiff responded. In March 2022, LTL asked the New Jersey Bankruptcy Court to stay the securities class action. In April 2022, Defendants filed a second motion to supplement the class certification record.  In May 2022, the New Jersey Bankruptcy Court entered an order staying the securities class action. Plaintiff has appealed the Bankruptcy Court&#x2019;s order.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A lawsuit was brought against the Company in the Superior Court of California for the County of San Diego alleging violations of California&#x2019;s Consumer Legal Remedies Act (CLRA) relating to JOHNSON&#x2019;S Baby Powder. In that lawsuit, the plaintiffs allege that the Company violated the CLRA by failing to provide required Proposition 65 warnings. In July 2019, the Company filed a notice of removal to the United States District Court for the Southern District of California and plaintiffs filed a second amended complaint shortly thereafter. In October 2019, the Company moved to dismiss the second amended complaint for failure to state a claim upon which relief may be granted. In response to those motions, plaintiffs filed a third amended complaint. In December 2019, the Company moved to dismiss the third amended complaint for failure to state a claim upon which relief may be granted. In April 2020, the Court granted the motion to dismiss but granted leave to amend. In May 2020, plaintiffs filed a Fourth Amended Complaint but indicated that they would be filing a motion for leave to file a fifth amended complaint. Plaintiffs filed a Fifth Amended Complaint in August 2020. The Company moved to dismiss the Fifth Amended Complaint for failure to state a claim upon which relief may be granted. In January 2021, the Court issued an Order and opinion ruling in the Company&#x2019;s favor and granting the motion to dismiss with prejudice. In February 2021, Plaintiffs filed a Notice of Appeal with the Ninth Circuit. Plaintiffs filed their opening brief in July 2021. The company filed its responsive brief in October 2021. In October 2021, Notice of Suggestion of Bankruptcy was filed with the Ninth Circuit. A bankruptcy stay was imposed in December 2021, and the Court held the reply deadline in abeyance. In February 2022, the Bankruptcy Court issued an order extending the stay. The appeal continues to be held in abeyance, with the Company being required to file periodic status updates. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, the Company has received inquiries, subpoenas, and requests to produce documents regarding talc matters and the LTL Bankruptcy Case from various governmental authorities. The Company has produced documents and responded to inquiries, and will continue to cooperate with government inquiries.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of INVOKANA, a prescription medication indicated to improve glycemic control in adults with Type 2 diabetes. In December 2016, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the District of New Jersey. Cases have also been filed in state courts. Class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has settled or otherwise resolved many of the cases and claims in the United States and the costs associated with these settlements are reflected in the Company&#x2019;s accruals.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have been made against a number of Johnson &amp;amp; Johnson companies, including Janssen Pharmaceuticals, Inc. and the Company, arising out of the use of ELMIRON, a prescription medication indicated for the relief of bladder pain or discomfort associated with interstitial cystitis. These lawsuits, which allege that ELMIRON&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;contributes to the development of permanent retinal injury and vision loss, have been filed in both state and federal courts across the United States. In December 2020, lawsuits filed in federal courts in the United States, including putative class action cases seeking medical monitoring, were organized as a multi-district litigation in the United States District Court for the District of New Jersey. In addition, cases have been filed in various state courts of New Jersey, which have been coordinated in a multi-county litigation in Bergen County, as well as the Court of Common Pleas in Philadelphia, which have been coordinated and granted mass tort designation. In addition, three class action lawsuits have been filed in Canada. Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense and indemnity costs associated with ELMIRON related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Claims for personal injury have been made against Johnson and Johnson Consumer Inc. (JJCI), arising out of the use of TYLENOL, an over-the-counter pain medication, alleging that prenatal exposure to acetaminophen is associated with the development of autism spectrum disorder and/or attention-deficit/hyperactivity disorder. In October 2022, lawsuits filed in federal courts in the United States were organized as a multi-district litigation in the United States District Court for the Southern District of New York.  In addition, lawsuits have been filed in Canada.  Product liability lawsuits continue to be filed, and the Company continues to receive information with respect to potential costs and the anticipated number of cases. The Company has established accruals for defense costs associated with TYLENOL related product liability litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;INTELLECTUAL PROPERTY&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain subsidiaries of the Company are subject, from time to time, to legal proceedings and claims related to patent, trademark and other intellectual property matters arising out of their businesses. Many of these matters involve challenges to the coverage and/or validity of the patents on various products and allegations that certain of the Company&#x2019;s products infringe the patents of third parties. Although these subsidiaries believe that they have substantial defenses to these challenges and allegations with respect to all significant patents, there can be no assurance as to the outcome of these matters. A loss in any of these cases could adversely affect the ability of these subsidiaries to sell their products, result in loss of sales due to loss of market exclusivity, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;require the payment of past damages and future royalties, and may result in a non-cash impairment charge for any associated intangible asset. Significant matters are described below.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;MedTech&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2018, Intuitive Surgical, Inc. and Intuitive Surgical Operations, Inc. (collectively, Intuitive) filed a patent infringement suit against Auris Health, Inc. (Auris) in United States District Court for the District of Delaware. In the suit, Intuitive alleges willful infringement of U.S. Patent Nos.  6,522,906 (&#x2019;906); 6,800,056 (&#x2019;056); 8,142,447 (&#x2019;447); and 9,452,276 (&#x2019;276) based on Auris&#x2019; MONARCH Platform. Auris filed IPR Petitions with the U.S. Patent and Trademark Office (USPTO) regarding the &#x2019;056, &#x2019;447, &#x2019;276 and &#x2019;906 patents.  In December 2019, the USPTO denied review of the &#x2019;056 patent. In February and March 2020, the USPTO instituted review of the &#x2019;447, and &#x2019;906 patents and denied review of the &#x2019;276 patent. In March 2021, the USPTO ruled that the challenged claims of the &#x2019;447 and &#x2019;906 patents are not invalid. Auris appealed, and in April 2022, the United States Court of Appeals for the Federal Circuit vacated the decision that the &#x2019;447 patent was not invalid and remanded the decision to the USPTO for further review.  In May 2022, the United States Court of Appeals for the Federal Circuit confirmed the ruling that claim 53 of the &#x2019;906 patent was not invalid, vacated the decision that the remaining claims of the &#x2019;906 patent were not invalid and remanded the decision to the USPTO for further review. Auris filed a request for reexamination of the &#x2019;276 patent in November 2021, and in January 2022, the USPTO granted the reexamination request. Trial is scheduled to begin in September 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, RSB Spine LLC (RSB Spine) filed a patent infringement suit against DePuy Synthes, Inc. in the United States District Court for the District of Delaware. In October 2019, RSB Spine amended the complaint to change the named defendants to DePuy Synthes Sales, Inc. and DePuy Synthes Products, Inc. In the suit, RSB Spine alleges willful infringement of U.S. Patent Nos. 6,984,234 (&#x2019;234) and 9,713,537 (&#x2019;537) by one or more of the following products:  ZERO-P-VA Spacer, ZERO-P Spacer, ZERO-P NATURAL Plate, SYNFIX LR Spacer and SYNFIX Evolution System. RSB Spine seeks monetary damages and injunctive relief. In November 2019, the suit was consolidated for pre-trial purposes with other patent infringement suits brought by RSB Spine in the United States District Court for the District of Delaware against Life Spine, Inc., Medacta USA, Inc., and Precision Spine, Inc. In June 2022, DePuy filed potentially dispositive summary judgment motions that the &#x2019;234 patent is invalid as anticipated and the &#x2019;537 patent is not infringed.  In November 2022, the Court granted DePuy&#x2019;s summary judgment motion that the &#x2019;234 patent is invalid as anticipated and denied DePuy&#x2019;s motion that the &#x2019;537 patent is not infringed.  In December 2022, the Court conducted a jury trial on the &#x2019;537 patent where the jury found that the &#x2019;537 patent was not literally infringed, but that DePuy infringed under the doctrine of equivalents (DOE).  The jury awarded RSB $12 million in damages subject to post-trial motions and appeals.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, Rasmussen Instruments, LLC (Rasmussen) filed a patent infringement suit against DePuy Synthes Products, Inc., DePuy Synthes Sales, Inc. and Medical Device Business Services, Inc. (collectively, DePuy) in the United States District Court for the District of Massachusetts. Rasmussen alleges that DePuy willfully infringes U.S. Patent Nos. 9,492,180 (&#x2019;180) and 10,517,583 (&#x2019;583) by making and selling the Attune Balanced Sizer. In April 2021, Rasmussen sought permission to amend its infringement contentions to allege that DePuy also willfully infringes the &#x2019;583 patent by making and selling the Attune Balancing Blocks. Rasmussen seeks treble damages for willful infringement. Trial concluded in March 2022, with the jury returning a verdict in favor of Rasmussen, finding willful infringement of the &#x2019;180 patent, and awarding damages in the amount of $20&#160;million. DePuy challenged the verdict in its post-trial motions. In July 2022, a hearing was held on the post-trial motions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Pharmaceutical&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Litigation Against Filers of Abbreviated New Drug Applications (ANDAs)&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following summarizes lawsuits the Company&#x2019;s subsidiaries have brought against generic companies that have filed ANDAs with the U.S. FDA or undertaken similar regulatory processes outside of the United States, seeking to market generic forms of products sold by various subsidiaries of the Company prior to expiration of the applicable patents covering those products. These ANDAs typically include allegations of non-infringement and invalidity of the applicable patents. The Inter Partes Review (IPR) process with the USPTO, created under the 2011 America Invents Act, is also being used at times by generic companies in conjunction with ANDAs and lawsuits, to challenge the applicable patents. In the event the Company&#x2019;s subsidiaries are not successful in an action, or the automatic statutory stay of the ANDAs expires before the United States District Court rulings are obtained, the generic companies involved would have the ability, upon approval of the U.S. FDA, to introduce generic versions of their products to the market, resulting in the potential for substantial market share and revenue losses for the applicable products, and which may result in a non-cash impairment charge in any associated intangible asset. In addition, from time to time, the Company&#x2019;s subsidiaries may settle these types of actions and such settlements can involve the introduction of generic versions of the products at issue to the market prior to the expiration of the relevant patents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ZYTIGA &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in January 2019, Janssen Inc., Janssen Oncology, Inc., and BTG International Ltd. (collectively, Janssen) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations in Canada against Apotex Inc. (Apotex), Pharmascience Inc. (Pharmascience) and Dr. Reddy&#x2019;s Laboratories Ltd. and Dr. Reddy&#x2019;s Laboratories, Inc. (collectively, DRL) in response to those parties&#x2019; filing of Abbreviated New Drug Submissions (ANDS) seeking approval to market generic versions of ZYTIGA before the expiration of the Canadian Patent No. 2,661,422 (&#x2019;422). The trial in these actions concluded in November 2020, and the Court issued a decision holding the &#x2019;422 patent invalid in January 2021. In February 2021, Janssen appealed the decision. The appeal hearing took place in September 2022. In November 2022, Janssen's appeal was dismissed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2021, July 2021 and April 2022, respectively, Apotex, DRL and Pharmascience initiated Statements of Claim under Section 8 of the Patented Medicines (Notice of Compliance) Regulations against Janssen seeking damages in respect of those parties generic Zytiga tablets.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Trials against Apotex and DRL are scheduled for June 2023. A trial date for the Pharmascience action has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;XARELTO&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in March 2021, Janssen Pharmaceuticals, Inc. (JPI) and Bayer Pharma AG and Bayer AG (collectively, Bayer) filed patent infringement lawsuits in the United States District Court for the District of Delaware against a number of generic companies who filed ANDAs seeking approval to market generic versions of XARELTO (2.5 mg) before expiration of U.S. Patent No. 10,828,310 (&#x2019;310). The following generic drug companies are named defendants:  Dr. Reddy&#x2019;s Laboratories, Inc. and Dr. Reddy&#x2019;s Laboratories, Ltd.; Lupin Limited and Lupin Pharmaceuticals, Inc.; Taro Pharmaceutical Industries Ltd. and Taro Pharmaceuticals U.S.A., Inc.; and Teva Pharmaceuticals USA, Inc. In October 2021, the court consolidated the Delaware lawsuits for all purposes, including trial. Trial for the consolidated Delaware lawsuits is scheduled to begin in May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, JPI and Bayer filed a patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan Pharmaceuticals Inc. and Mylan Inc. (collectively, Mylan) which filed an ANDA seeking approval to market a generic version of XARELTO (2.5 mg) before expiration of the &#x2019;310 patent. In August 2021, JPI and Bayer filed a motion before the United States Judicial Panel on Multidistrict Litigation (the MDL panel) to transfer this lawsuit to the United States District Court for the District of Delaware for coordinated and consolidated pretrial proceedings. In December 2021, the MDL panel granted the motion. In August 2022, after receiving a second notice letter from Mylan regarding the same ANDA, JPI and Bayer filed a second patent infringement lawsuit in the United States District Court for the Northern District of West Virginia against Mylan. In September 2022, Mylan moved to dismiss the second lawsuit. In September 2022, the MDL panel transferred the second lawsuit to the District of Delaware. No trial date has been set for these two lawsuits. In October 2022, Mylan voluntarily withdrew its motion to dismiss.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these lawsuits, JPI and Bayer are seeking an order enjoining defendants from marketing their generic version of XARELTO (2.5 mg) before the expiration of the &#x2019;310 patent. In January 2023, the court issued an order staying the lawsuits until after a final written decision is issued in the Inter Partes Review proceedings on the &#x2019;310 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, Mylan Pharmaceuticals Inc. filed a Petition for Inter Partes Review (IPR) with the United States Patent and Trademark Office (USPTO), seeking to invalidate the &#x2019;310 patent. In August 2022, the Patent Trial and Appeal Board (PTAB) issued a decision instituting IPR.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, InvaGen Pharmaceuticals, Inc. filed a Petition for IPR with the USPTO seeking to invalidate the &#x2019;310 patent. Also in September 2022, Teva Pharmaceuticals USA, Inc. filed a Petition for IPR with the USPTO seeking to invalidate the &#x2019;310 patent. In October 2022, the PTAB issued decisions instituting IPR in both proceedings and joining them with the earlier IPR proceeding filed by Mylan Pharmaceuticals Inc.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, JPI, Bayer, and Bayer Intellectual Property GmbH (BIP) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against USV Private Limited (USV), who filed an ANDA seeking approval to market generic versions of XARELTO (2.5 mg, 10 mg, 15 mg, and 20 mg) before the expiration of the '310 patent and U.S. Patent No. 9,539,218 (&#x2019;218). JPI, Bayer, and BIP are seeking an order enjoining USV from marketing its generic version of XARELTO (2.5 mg) before the expiration of the &#x2019;310 patent, and its generic versions of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#x2019;218 patent. In November 2022, the MDL panel transferred this lawsuit to the United States District Court for the District of Delaware.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2022, JPI, Bayer AG, and BIP &lt;/span&gt;&lt;span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mankind Pharma Limited (Mankind), who filed an ANDA seeking approval to market generic versions of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#x2019;218 patent. JPI, Bayer AG, and BIP are seeking an order enjoining Mankind from marketing its generic versions of XARELTO before the expiration of the &#x2019;218 patent.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, JPI, Bayer, and BIP initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Epic Pharma, LLC (Epic), who filed an ANDA seeking approval to market generic versions of XARELTO (2.5 mg, 10 mg, 15 mg, and 20 mg) before the expiration of the &#x2019;310 patent and the &#x2019;218 patent. JPI, Bayer, and BIP are seeking an order enjoining Epic from marketing its generic version of XARELTO (2.5 mg) before the expiration of the &#x2019;310 patent, and its generic versions of XARELTO (10 mg, 15 mg, and 20 mg) before the expiration of the &#x2019;218 patent. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2022, JPI and Bayer initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Apotex Inc. and Apotex Corp. (collectively, Apotex), who filed an ANDA seeking approval to market generic versions of XARELTO (2.5 mg) before the expiration of the &#x2019;310 patent. JPI and Bayer are seeking an order enjoining Apotex from marketing its generic version of XARELTO (2.5 mg) before the expiration of the &#x2019;310 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;OPSUMIT&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, Janssen Inc. (Janssen) and Actelion Pharmaceuticals Ltd (Actelion) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in Canada in response to Sandoz&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10 mg,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before the expiration of Canadian Patent No. 2,659,770 (&#x2019;770). Sandoz stipulated to infringement of the &#x2019;770 patent.  Trial against Sandoz on the issue of validity concluded in February 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Sandoz appealed the decision. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2020, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in Canada in response to Apotex&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10 mg,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before the expiration of the &#x2019;770 patent. Apotex stipulated to validity of the &#x2019;770 patent.  Trial against Apotex on the issue of infringement concluded in March 2022, and in May 2022, the Court issued a decision in favor of Janssen and Actelion.  In June 2022, Apotex appealed the decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#404a52;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, Janssen and Actelion initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Generic Medical Partners Inc. (GMP) in Canada in response to GMP&#x2019;s filing of an ANDS seeking approval to market a generic version of OPSUMIT 10 mg, before the expiration of Canadian Patent Nos. 2,659,770 and 2,621,273.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian actions, Janssen and Actelion are seeking an order enjoining the defendants from marketing their generic versions of OPSUMIT before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2023, Actelion Pharmaceuticals Ltd and Actelion Pharmaceuticals US, Inc. (collectively, Actelion) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Sun Pharmaceutical Industries Limited and Sun Pharmaceutical Industries, Inc. (collectively, Sun) who filed an ANDA seeking approval to market a generic version of OPSUMIT before the expiration of U.S. Patent Nos. 7,094,781 (&#x2019;781) and 10,946,015 (&#x2019;015).  Actelion is seeking an order enjoining Sun from marketing their generic versions of OPSUMIT before the expiration of the &#x2019;781 and &#x2019;015 patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVEGA SUSTENNA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2018, Janssen Pharmaceutica NV and Janssen Pharmaceuticals, Inc. (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. (Teva), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of U.S. Patent No. 9,439,906 (&#x2019;906). Trial concluded in October 2020. In October 2021, the court issued a decision in Janssen&#x2019;s favor. Teva has appealed the decision.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited (Mylan), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;906 patent. Pursuant to an agreement by the parties, judgment in favor of Janssen was entered in December 2021. Mylan appealed. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2019, Janssen initiated a patent infringement lawsuit in the United States District Courts for the Districts of New Jersey and Delaware against Pharmascience Inc., Mallinckrodt PLC and Specgx LLC (collectively, Pharmascience), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;906 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Tolmar, Inc., Tolmar Therapeutics, Inc., Tolmar Pharmaceuticals, Inc. and Tolmar Holding, Inc. (collectively, Tolmar), which filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;906 patent. A trial is scheduled to begin in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Accord Healthcare, Inc., Accord Healthcare, Ltd. and Intas Pharmaceuticals, Ltd. (collectively, Accord), who filed an ANDA seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;906 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2018, Janssen Inc. and Janssen Pharmaceutica NV (collectively, Janssen Canada) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Teva Canada Limited (Teva Canada) in response to Teva&#x2019;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of Canadian Patent Nos. 2,309,629 (&#x2019;629) and 2,655,335 (&#x2019;335). Janssen subsequently discontinued the portion of the lawsuit relating to the &#x2019;629 patent. In May 2020, the Canadian Federal Court issued a Public Judgment and Reasons declaring that Teva Canada&#x2019;s generic version of INVEGA SUSTENNA, if approved, would infringe certain claims of the &#x2019;335 patent and that the claims of the &#x2019;335 patent are not invalid. Teva Canada appealed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2020, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience Inc. in response to Pharmascience Inc.&#x2019;s filing of an ANDS seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;335 patent. A summary trial on the issue of infringement took place in November 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Pharmascience filed an appeal. In March 2022, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Pharmascience in response to Pharmascience&#x2019;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#x2019;335 patent. The action has been consolidated with the November 2020 action for trial, which took place in July 2022. In August 2022, the Court issued a decision finding the claims of the&#x2019;335 patent are not invalid. Pharmascience appealed.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex Inc. (Apotex) in response to Apotex&#x2019;s filing of an ANDS (original ANDS) seeking approval to market a generic version of INVEGA SUSTENNA before the expiration of the &#x2019;335 patent. A summary trial on the issue of infringement took place in December 2021. In January 2022, the Court issued a decision in favor of Janssen on the issue of infringement. Apotex appealed. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, Janssen Canada initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Apotex in response to Apotex&#x2019;s Notice of Allegation of invalidity with respect to the original ANDS and in response to Apotex&#x2019;s filing of an ANDS seeking approval to market a generic version of an additional strength of INVEGA SUSTENNA before the expiration of the &#x2019;335 patent. A trial is scheduled to begin in March 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these Canadian lawsuits, Janssen Canada is seeking an order enjoining the defendant from marketing a generic version of INVEGA SUSTENNA before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;INVEGA TRINZA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2020, Janssen Pharmaceuticals, Inc., Janssen Pharmaceutica NV, and Janssen Research &amp;amp; Development, LLC (collectively, Janssen) initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan Laboratories Limited, Mylan Pharmaceuticals Inc., and Mylan Institutional LLC (collectively, Mylan). Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (546 mg) before expiration of U.S. Patent No. 10,143,693 (&#x2019;693) relating to INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(546 mg).  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(819 mg) before expiration of the &#x2019;693 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2021, Janssen initiated a patent infringement lawsuit in the United States District Court for the District of New Jersey against Mylan. Mylan filed an ANDA seeking approval to market generic versions of INVEGA TRINZA (273 mg and 410 mg) before expiration of the &#x2019;693 patent.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2022, the court consolidated the three cases into the case filed in September 2020. In each of these consolidated cases, Janssen is seeking an order enjoining Mylan from marketing its generic versions of INVEGA TRINZA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;before expiration of the &#x2019;693 patent. Trial was conducted in November and December 2022, and post-trial briefing is proceeding. Closing arguments will be held in March 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;IMBRUVICA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2019, Pharmacyclics LLC (Pharmacyclics) and Janssen Biotech, Inc. (JBI) filed a patent infringement lawsuit in the United States District Court for the District of Delaware against Alvogen Pine Brook LLC and Natco Pharma Ltd. (collectively, Alvogen), which filed an ANDA seeking approval to market generic versions of IMBRUVICA tablets, asserting infringement of U.S. Patent Nos. 7,514,444; 8,003,309; 8,476,284; 8,497,277; 8,697,711; 8,753,403; 8,754,090; 8,754,091; 8,952,015; 8,957,079; 9,181,257; 9,296,753; 9,655,857; 9,725,455; 10,010,507; 10,106,548; and 10,125,140. In June 2019, Pharmacyclics and JBI amended their complaint against Alvogen to further allege infringement of U.S. Patent No. 10,213,386. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Trial against Alvogen took place in October 2020. In August 2021, the District Court issued a decision in favor of Pharmacyclics and Janssen finding the asserted claims against Alvogen to be infringed and not invalid. In November 2022, the United States Court of Appeals for the Federal Circuit affirmed the District Court&#x2019;s decision.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2021, Pharmacyclics and Janssen Inc. (Janssen Canada) initiated Statements of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco Pharma (Canada) Inc. (Natco) in response to Natco&#x2019;s filing of two ANDSs seeking approval to market generic versions of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;capsules before the expiration of Canadian Patent Nos. 2,663,116 (&#x2019;116); 2,928,721 (&#x2019;721); 2,800,913 (&#x2019;913); 3,007,787 (&#x2019;787); 3,007,788 (&#x2019;788); 2,875,986 (&#x2019;986); and 3,022,256 (&#x2019;256). In this lawsuit, Pharmacyclics and Janssen Canada are seeking an order enjoining Natco from marketing its generic version of IMBRUVICA before the expiration of the relevant patents. Trial is scheduled to begin in July 2023.  &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, Pharmacyclics and Janssen Canada initiated a second Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Natco in response to Natco&#x2019;s filing of an ANDS seeking approval to market a generic version of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;capsules before the expiration of the &#x2019;116, &#x2019;721, &#x2019;913, &#x2019;787, and &#x2019;788 patents and Canadian Patent No. 2,851,808. In this lawsuit, Pharmacyclics and Janssen Canada are seeking an order enjoining Natco from marketing its generic version of IMBRUVICA capsules before the expiration of the relevant patents. Trial in this second action is scheduled to begin in August 2024. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2023, Pharmacyclics and Janssen Canada initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. (Sandoz) in response to Sandoz&#x2019;s filing of an ANDS seeking approval to market a generic version of IMBRUVICA&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:120%;position:relative;top:-3.48pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;capsules before the expiration of the &#x2019;116, &#x2019;913, &#x2019;787, and &#x2019;788 patents. Also in February 2023, Pharmacyclics and Janssen initiated a Statement of Claim under Section 8.2 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz asserting the &#x2019;721 and &#x2019;256 patents, which are also listed in Health Canada&#x2019;s Patent Register for IMBRUVICA. In these lawsuits, Pharmacyclics and Janssen Canada are seeking an order enjoining Sandoz from marketing its generic version of IMBRUVICA capsules before the expiration of the relevant patents. A trial date for these actions has not been set. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;SYMTUZA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Limited, Lupin Pharmaceuticals, Inc., MSN Laboratories Private Ltd., MSN Life Sciences Private Ltd., and MSN Pharmaceuticals Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of SYMTUZA before the expiration of U.S. Patent Nos. 10,039,718 (&#x2019;718) and 10,786,518 (&#x2019;518). The trial is scheduled to begin in October 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, Janssen Products, L.P. and Janssen Sciences Ireland Unlimited Company (collectively, Janssen) and Gilead Sciences, Inc. and Gilead Sciences Ireland UC (collectively, Gilead) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Apotex Inc. and Apotex Corp. (collectively, Apotex), which filed an ANDA seeking approval to market a generic version of SYMTUZA before the expiration of the &#x2019;718 and &#x2019;518 patents. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In each of these U.S. lawsuits, Janssen is seeking an order enjoining the defendant from marketing a generic version of SYMTUZA before the expiration of the relevant patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ERLEADA&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Aragon Pharmaceuticals, Inc. and Janssen Biotech, Inc. (collectively, Janssen) and Sloan Kettering Institute for Cancer Research (SKI) initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, Lupin), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of U.S. Patent No. 9,481,663 (&#x2019;663). In August 2022, Janssen and SKI filed a first amended complaint against Lupin adding U.S. Patent Nos. 9,884,054 (&#x2019;054), 10,052,314 (&#x2019;314), 10,702,508 (&#x2019;508) and 10,849,888 (&#x2019;888) to the suit. Janssen and SKI are seeking an order enjoining Lupin from marketing its generic version of ERLEADA before the expiration of the &#x2019;663, &#x2019;054, &#x2019;314, &#x2019;508, and &#x2019;888 patents. In August 2022, Janssen and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Janssen and SKI initiated a patent infringement lawsuit in United States District Court for the District of New Jersey against Zydus Worldwide DMCC, Zydus Pharmaceuticals (USA), Inc., and Zydus Lifesciences Limited (collectively, Zydus), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#x2019;663, &#x2019;054, &#x2019;314, &#x2019;508, and &#x2019;888 patents. Janssen and SKI are seeking an order enjoining Zydus from marketing its generic version of ERLEADA before the expiration of the &#x2019;663, &#x2019;054, &#x2019;314, &#x2019;508, and &#x2019;888 patents.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Janssen, The Regents of the University of California (UC), and SKI initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Sandoz Inc. (Sandoz), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#x2019;663 patent and U.S. Patent Nos. 8,445,507 (&#x2019;507), 8,802,689 (&#x2019;689), 9,338,159 (&#x2019;159), and 9,987,261 (&#x2019;261).  In August 2022, Janssen, UC, and SKI filed a first amended complaint against Sandoz adding the &#x2019;054, &#x2019;314, &#x2019;508, and &#x2019;888 patents to the suit. In August 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint.  In December 2022, Janssen, UC, and SKI filed a second amended complaint against Sandoz withdrawing the &#x2019;054, &#x2019;314, &#x2019;508, and &#x2019;888 patents from the suit without prejudice.  Janssen, UC, and SKI are seeking an order enjoining Sandoz from marketing its generic version of ERLEADA before the expiration of the &#x2019;663, &#x2019;507, &#x2019;689, &#x2019;159, and &#x2019;261 patents.  The New Jersey action is proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Janssen, UC, and SKI initiated patent infringement lawsuits in United States  District Court for the Districts of New Jersey and Delaware against Eugia Pharma Specialities Limited, Aurobindo Pharma USA, Inc., and Auromedics Pharma LLC (collectively, Eugia), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of  the &#x2019;663, &#x2019;507, &#x2019;689, &#x2019;159 and &#x2019;261 patents. In September 2022, Janssen, UC, and SKI filed a first amended complaint against Eugia adding U.S. Patent Nos. 9,884,054 (&#x2019;054), 10,052,314 (&#x2019;314), 10,702,508 (&#x2019;508) and 10,849,888 (&#x2019;888) to the suit. In September 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint. Janssen, UC, and SKI are seeking an order enjoining Eugia from marketing its generic version of ERLEADA before the expiration of the &#x2019;663,&#x2019;507, &#x2019;689, &#x2019;159, &#x2019;261, &#x2019;054, &#x2019;314, &#x2019;508, and &#x2019;888 patents. The New Jersey action is proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2022, Janssen, UC, and SKI initiated patent infringement lawsuits in United States District Court for the Districts of New Jersey and Delaware against Hetero Labs Limited Unit V and Hetero USA, Inc. (collectively, Hetero), which filed an ANDA seeking approval to market a generic version of ERLEADA before the expiration of the &#x2019;663, &#x2019;507,&#x2019;054, &#x2019;314,&#x2019;508, and &#x2019;888 patents. Janssen, UC, and SKI are seeking an order enjoining Hetero from marketing its generic version of ERLEADA before the expiration of the &#x2019;663, &#x2019;507, &#x2019;054, &#x2019;314, &#x2019;508 and &#x2019;888 patents.  In August 2022, Janssen, UC, and SKI voluntarily dismissed the Delaware complaint. The New Jersey action is proceeding.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;UPTRAVI &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2022, Actelion Pharmaceuticals Ltd, and Janssen Inc. (collectively, Janssen) and Nippon Shinyaku Co. (Nippon Shinyaku) initiated a Statement of Claim under Section 6 of the Patented Medicines (Notice of Compliance) Regulations against Sandoz Canada Inc. in response to Sandoz&#x2019;s filing of an ANDS seeking approval to market generic versions of UPTRAVI tablets before the expiration of Canadian Patent Nos. 2,731,370 and 2,764,475. In this lawsuit, Janssen and Nippon Shinyaku are seeking an order enjoining Sandoz from marketing its generic version of UPTRAVI before the expiration of the relevant patents. A trial is scheduled to begin in May 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2022, Actelion Pharmaceuticals US Inc. and Actelion Pharmaceuticals Ltd (collectively, Actelion) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Alembic Pharmaceuticals Limited and Alembic Pharmaceuticals Inc. (collectively, Alembic) who filed an &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ANDA seeking approval to market generic versions of UPTRAVI &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;injection for intravenous use before expiration of U.S. Patent Nos. 8,791,122 (&#x2019;122) and 9,284,280 (&#x2019;280) relating to UPTRAVI. In this lawsuit, Actelion and Nippon Shinyaku are seeking an order enjoining Alembic from marketing a generic version of UPTRAVI before the expiration of the relevant patents. A trial date has not been set. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In February 2023, Actelion and Nippon Shinyaku initiated a patent infringement lawsuit in the United States District Court for the District of Delaware against Lupin Ltd. and Lupin Pharmaceuticals, Inc. (collectively, Lupin) who filed an ANDA seeking approval to market generic versions of UPTRAVI&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:112%;position:relative;top:-3.48pt;vertical-align:baseline"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;injection for intravenous use before expiration of the &#x2019;122 and &#x2019;280 patents relating to UPTRAVI. In this lawsuit, Actelion and Nippon Shinyaku are seeking an order enjoining Lupin from marketing a generic version of UPTRAVI before the expiration of the relevant patents. A trial date has not been set.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, Janssen Pharmaceutica N.V. (Janssen) provided to Alkermes Pharma Ireland Limited, Elan Pharma International Limited, and Elan Drug Delivery, Inc. three-months&#x2019; notice of termination of a License Agreement by and among Elan Pharmaceutical Research Corp., d/b/a Nanosystems, Elan Pharma International Limited and Janssen, executed in March, 1999. In November 2021, Janssen also provided to Alkermes Pharma Ireland Limited three-months&#x2019; notice of termination of a License Agreement between Elan Pharma International Limited and Janssen executed in July 2003. In April 2022, in response to these notices, Alkermes Pharma Ireland Limited (Alkermes) initiated arbitration in the International Institute for Conflict Prevention and Resolution. The parties exchanged opening briefs in July 2022 and responsive briefs in September 2022.  In December 2022, the Arbitration Tribunal issued an Interim Decision finding that Janssen may terminate the agreements, but it may not continue to sell products developed during the term of the agreements without continuing to pay royalties to Alkermes.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;GOVERNMENT PROCEEDINGS&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Like other companies in the pharmaceutical, consumer health and medical devices industries, the Company and certain of its subsidiaries are subject to extensive regulation by national, state and local government agencies in the United States and other countries in which they operate. Such regulation has been the basis of government investigations and litigations. The most significant litigation brought by, and investigations conducted by, government agencies are listed below. It is possible that criminal charges and substantial fines and/or civil penalties or damages could result from government investigations or litigation.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Average Wholesale Price (AWP) Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and several of its pharmaceutical subsidiaries (the J&amp;amp;J AWP Defendants), along with numerous other pharmaceutical companies, were named as defendants in a series of lawsuits in state and federal courts involving allegations that the pricing and marketing of certain pharmaceutical products amounted to fraudulent and otherwise actionable conduct because, among other things, the companies allegedly reported an inflated Average Wholesale Price (AWP) for the drugs at issue. Payors alleged that they used those AWPs in calculating provider reimbursement levels. The plaintiffs in these cases included three classes of private persons or entities that paid for any portion of the purchase of the drugs at issue based on AWP, and state government entities that made Medicaid payments for the drugs at issue based on AWP. Many of these cases, both federal actions and state actions removed to federal court, were consolidated for pre-trial purposes in a multi-district litigation in the United States District Court for the District of Massachusetts, where all claims against the J&amp;amp;J AWP Defendants were ultimately dismissed. The J&amp;amp;J AWP Defendants also prevailed in a case brought by the Commonwealth of Pennsylvania. Other AWP cases have been resolved through court order or settlement. The case brought by Illinois was settled after trial. In New Jersey, a putative class action based upon AWP allegations is pending against Centocor, Inc. and Ortho Biotech Inc. (both now Janssen Biotech, Inc.), the Company and ALZA Corporation. All other cases have been resolved.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Opioid Litigation&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in 2014 and continuing to the present, the Company and Janssen Pharmaceuticals, Inc. (JPI), along with other pharmaceutical companies, have been named in close to 3,500 lawsuits related to the marketing of opioids, including DURAGESIC, NUCYNTA and NUCYNTA ER. The suits also raise allegations related to previously owned active pharmaceutical ingredient supplier subsidiaries, Tasmanian Alkaloids Pty, Ltd. and Noramco, Inc. (both subsidiaries were divested in 2016). The majority of the cases have been filed by state and local governments. Similar lawsuits have also been filed by private plaintiffs and organizations, including but not limited to the following: individual plaintiffs on behalf of children born with Neonatal Abstinence Syndrome; hospitals; and health insurers/payors. To date, complaints against pharmaceutical manufacturers, including the Company and JPI, have been filed by the state Attorneys General in Arkansas, Florida, Idaho, Illinois, Kentucky, Louisiana, Mississippi, Missouri, Nevada, New Hampshire, New Jersey, New Mexico, New York, Ohio, Oklahoma, South Dakota, Texas, Washington and West Virginia. Complaints against the manufacturers also have been filed in state or federal court by city, county and local government agencies in every state but Alaska. The Government of Puerto Rico filed suit in Superior Court of San Juan. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company, JPI and other pharmaceutical companies had also received subpoenas or requests for information related to opioids marketing practices from the following state Attorneys General: Alaska, Indiana, Montana, New Hampshire, South Carolina, Tennessee, Texas and Washington. In September 2017, the Company and JPI were contacted by the Texas and Colorado Attorney General&#x2019;s Offices on behalf of approximately 38 states regarding a multi-state Attorney General investigation. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2019, the trial in the matter filed by the Oklahoma Attorney General resulted in a judgment against the Company and JPI in the amount of $465&#160;million. The Company and JPI appealed the judgment, and in November 2021, the Oklahoma Supreme Court reversed the trial court&#x2019;s judgment and directed entry of judgment for Defendants. In October 2019 the Company and JPI announced a settlement of the first case set for trial in the MDL with two counties in Ohio. In April 2021, three California counties and the City of Oakland commenced a trial in California state court against the Company and JPI, and other affiliates, as well as three other pharmaceutical manufacturers. The trial concluded in October 2021, and in December 2021, the Court entered a final trial judgment in favor of Defendants on all claims. In February 2022, Plaintiffs&#x2019; motion to set aside and vacate the judgment was denied. Plaintiffs appealed the judgment, but later filed a request to dismiss the appeal after electing to participate in the national settlement agreement. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, the Company announced a proposed agreement in principle that would include the Company paying $4&#160;billion as settlement of these matters that had not been tried or settled. In October 2020, the Company agreed to contribute up to an additional $1&#160;billion to an all-in settlement amount that would resolve opioid lawsuits filed and future claims by states, cities, counties and tribal governments, for a total of $5&#160;billion which has been accrued, subject to various conditions and an agreement being finalized. This agreement is not an admission of liability or wrong-doing. In July 2021, the Company announced that the terms of the agreement to settle the state and subdivision claims had been finalized and approximately half of the all-in settlement was expected to be paid by the end of fiscal year 2022, depending upon the level of participation by the states and their subdivisions. The terms provided a period of time for states to elect to participate in the agreement and, thereafter, a period for the subdivisions of the participating states to opt-in. Based on expected participation, the Company committed in advance to proceed with the settlement in five of the participating states (New York, Texas, Florida, Nevada, and New Mexico) and with tribal governments. By late February 2022, 45 states, five territories, the District of Columbia, and the vast majority of eligible subdivisions had elected to participate in the settlement, and the Company confirmed that the level of participation was sufficient to proceed with the agreement as to all participants. The agreement was effective in April 2022. Also in April 2022, the Company entered into settlement agreements with the states of Alabama and West Virginia and their participating subdivisions. In July 2022, the Company reached a settlement agreement with all litigating Oklahoma subdivisions, and in September 2022, the Company settled with the State of New Hampshire and its participating subdivisions. Consequently, by the end of the fiscal year 2022, the Company had settled the opioid claims advanced by all states except Washington.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There are approximately 60 cases remaining post-settlement in various state courts. There are approximately 570 remaining federal cases against the Company and JPI coordinated in a federal Multi-District Litigation (MDL) pending in the U.S. District Court for the Northern District of Ohio, and approximately 20 additional cases pending against the Company and JPI in other federal courts. In addition, the Province of British Columbia filed suit against the Company and its Canadian affiliate Janssen Inc., and many other industry members, in Canada, and is seeking to have that action certified as an opt in class action on behalf of other provincial/territorial and the federal governments in Canada. Additional proposed class actions have been filed in Canada against the Company and Janssen Inc., and many other industry members, by and on behalf of people who used opioids (for personal injuries), municipalities and First Nations bands. In October 2019, an antitrust complaint was filed by private plaintiffs in federal court in Tennessee and is pending transfer to the MDL. These actions allege a variety of claims related to opioid marketing practices, including false advertising, unfair competition, public nuisance, consumer fraud violations, deceptive acts and practices, false claims and unjust enrichment. The suits generally seek penalties and/or injunctive and monetary relief and, in some of the suits, the plaintiffs are seeking joint and several liability among the defendants. An adverse judgment in any of these lawsuits could result in the imposition of large monetary penalties and significant damages including, punitive damages, cost of abatement, substantial fines, equitable remedies and other sanctions. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2019, the Company received a grand jury subpoena from the United States Attorney&#x2019;s Office for the Eastern District of New York for documents related to the Company&#x2019;s anti-diversion policies and procedures and distribution of its opioid medications, in what the Company understands to be part of a broader investigation into manufacturers&#x2019; and distributors&#x2019; monitoring programs and reporting under the Controlled Substances Act. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From June 2017 through December 2019, the Company&#x2019;s Board of Directors received a series of shareholder demand letters alleging breaches of fiduciary duties related to the marketing of opioids. The Board retained independent counsel to investigate the allegations in the demands, and in April 2020, independent counsel delivered a report to the Board recommending that the &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Company reject the shareholder demands and take the steps that are necessary or appropriate to secure dismissal of related derivative litigation. The Board unanimously adopted the recommendations of the independent counsel&#x2019;s report.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, one of the shareholders who sent a demand filed a derivative complaint against the Company as the nominal defendant and certain current and former directors and officers as defendants in the Superior Court of New Jersey. The complaint alleges breaches of fiduciary duties related to the marketing of opioids, and that the Company has suffered damages as a result of those alleged breaches. A series of additional derivative complaints making similar allegations against the same and similar defendants were filed in New Jersey state and federal courts in 2019 and 2020. By 2022, all but two state court cases had been voluntarily dismissed. In February 2022, the state court granted the Company&#x2019;s motion to dismiss one of the two cases, and the shareholder that brought the second case filed a notice of dismissal. The shareholder whose complaint was dismissed filed a motion for reconsideration. In May 2022, the state court held oral argument on the motion for reconsideration and subsequently denied the motion. The shareholder has appealed the state court&#x2019;s dismissal order.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2012, DePuy Orthopaedics, Inc., DePuy, Inc. (now known as DePuy Synthes, Inc.), and Johnson &amp;amp; Johnson Services, Inc. (collectively DePuy) received an informal request from the United States Attorney&#x2019;s Office for the District of Massachusetts and the Civil Division of the United States Department of Justice (the United States) for the production of materials relating to the DePuy ASR XL Hip device. In July 2014, the United States notified the United States District Court for the District of Massachusetts that it had declined to intervene in a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; case filed pursuant to the False Claims Act against the companies concerning the hip devices. In February 2016, the District Court granted the companies&#x2019; motion to dismiss with prejudice, unsealed the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; complaint, and denied the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; relators&#x2019; request for leave to file a further amended complaint. The &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;qui tam&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; relators appealed the case to the United States Court of Appeals for the First Circuit. In July 2017, the First Circuit affirmed the District Court&#x2019;s dismissal in part, reversed in part, and affirmed the decision to deny the relators&#x2019; request to file a third amended complaint. In March 2021, DePuy filed its motion to strike and dismiss the relators&#x2019; second amended complaint; the District Court denied DePuy&#x2019;s motion to strike and dismiss in July 2021. DePuy filed a motion for reconsideration of the District Court&#x2019;s July 2021 ruling. In November 2021, the District Court granted DePuy&#x2019;s motion for reconsideration and dismissed the case with prejudice. The District Court&#x2019;s order was unsealed in December 2021. The relators filed several post-dismissal motions, including a January 2022 omnibus motion for reconsideration, which the District Court denied. Following the District Court&#x2019;s order dismissing the case with prejudice, DePuy filed a December 2021 motion seeking the recovery of attorneys&#x2019; fees and costs, which the District Court denied except as to costs. The Relators have appealed the District Court&#x2019;s dismissal of the case to the First Circuit. The briefing on the appeal is complete, the First Circuit held oral argument on December 6, 2022, and the First Circuit&#x2019;s decision remains pending.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2012, the Company was contacted by the California Attorney General&#x2019;s office regarding a multi-state Attorney General investigation of the marketing of surgical mesh products for hernia and urogynecological purposes by the Company&#x2019;s subsidiary, Ethicon, Inc. (Ethicon). In May 2016, California and Washington filed civil complaints against the Company, Ethicon and Ethicon US, LLC alleging violations of their consumer protection statutes. Similar complaints were filed against the companies by the following states:  Kentucky, Mississippi, West Virginia and Oregon. In April 2019, the Company and Ethicon settled the Washington case. In October 2019, the Company and Ethicon settled the multi-state investigation with 41 other states and the District of Columbia. In April 2020, the Company settled the West Virginia case. In October 2020, the Company settled with the Attorney General of Oregon. In November 2020, the Company settled with the Attorney General of Mississippi. Trial in the Kentucky matter is scheduled for June 2023. The California case started trial in July 2019 and concluded in September 2019. In January 2020, the Court in California issued a statement of decision, finding in favor of the State of California, and awarded civil penalties in the amount of $344&#160;million. In April 2020, the Court in California denied the Company&#x2019;s motion for a new trial. In August 2020, the Court entered judgment with respect to the penalties of $344&#160;million, but denied the Attorney General&#x2019;s request for injunctive relief. The Company appealed the penalty judgment. In April 2022, the Court of Appeals reduced the judgment to $302&#160;million, but otherwise denied the appeal. In July 2022, the Supreme Court of California denied the Company&#x2019;s petition to review the Court of Appeals decision, and the Company recorded a charge to reflect the judgment in the second quarter of 2022. In November 2022, the Company petitioned the United States Supreme Court for review.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2014, the Mississippi Attorney General filed a complaint in Chancery Court of The First Judicial District of Hinds County, Mississippi against the Company and Johnson &amp;amp; Johnson Consumer Companies, Inc. (now known as Johnson &amp;amp; Johnson Consumer Inc.) (collectively, JJCI). The complaint alleges that JJCI violated the Mississippi Consumer Protection Act by failing to disclose alleged health risks associated with female consumers&#x2019; use of talc contained in JOHNSON&#x2019;S Baby Powder and JOHNSON&#x2019;S Shower to Shower (a product divested in 2012) and seeks injunctive and monetary relief. The Company and JJCI moved for summary judgment on the grounds that the State&#x2019;s claim was barred by preemption, which the trial court denied. The Mississippi Supreme Court granted the Company and JJCI&#x2019;s request to file an interlocutory appeal of the denial of the motion for summary judgment in late 2019. Briefing and oral argument were completed. Thereafter, the Court &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;rejected the interlocutory appeal in April 2021 and remanded the matter to the trial court. In August 2021, JJCI filed a Petition for Writ of Certiorari in the United States Supreme Court as to the Mississippi Supreme Court&#x2019;s ruling of April 2021. In December 2021 the United States Supreme Court denied the Petition for Writ of Certiorari. After the Mississippi Supreme Court remanded the matter to the trial court, the State moved for a trial setting. JJCI objected to any trial setting as barred by the stay arising from the LTL Bankruptcy Case, referenced above, while the State argued that the stay did not apply. In January 2022, the Court granted the State&#x2019;s motion for trial setting and directed the parties to consult with the Court administrator to secure a trial date. In February 2022, the trial court set the case for trial to begin in February 2023. However, given the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a temporary stay of discovery until May 2022. The temporary stay expired in May 2022. LTL thereafter moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. The State filed an appeal to the Third Circuit concerning the stay order.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2020, the State of New Mexico filed a consumer protection case alleging that the Company deceptively marketed and sold its talcum powder products by making misrepresentations about the safety of the products and the presence of carcinogens, including asbestos. The State of New Mexico filed an Amended Complaint in March 2020. The Company moved to dismiss certain of the claims in the Amended Complaint, which was granted. The Company then filed a motion for partial judgment on the pleadings in December 2020, which was denied. In March 2022, the New Mexico court denied the Company&#x2019;s motion to compel the State of New Mexico to engage in discovery of state agencies and denied the Company&#x2019;s request for interlocutory appeal of that decision. The Company then filed a Petition for Writ of Superintending Control and a Request for a Stay to the New Mexico Supreme Court on the issue of the State of New Mexico&#x2019;s discovery obligations. In April 2022, in view of the efforts to resolve talc-related claims in the LTL Bankruptcy Case, the Company and the State agreed to a 60-day stay of all matters except for the pending writ before the New Mexico Supreme Court, which expired in June 2022. Thereafter, the Company moved to enjoin prosecution of the case in the LTL Bankruptcy Case. In October 2022, the bankruptcy court issued an order staying the case. In December 2022, the State filed an appeal to the Third Circuit concerning the stay order. Separately, in September 2022, the New Mexico Supreme Court granted the Company's request for a stay pending further briefing on the scope of the State of New Mexico&#x2019;s discovery obligations. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Forty-two states and the District of Columbia have commenced a joint investigation into the Company&#x2019;s marketing of its talcum powder products. At this time, the multi-state group has not asserted any claims against the Company. Five states have issued Civil Investigative Demands seeking documents and other information. The Company has produced documents to Arizona, North Carolina, Texas, and Washington and entered into confidentiality agreements. The Company has not received any follow up requests from those states. In March 2022, each of the forty-two states (including Mississippi and New Mexico) agreed to mediation of their claims in the LTL Bankruptcy Case. In July 2022, New Mexico and Mississippi indicated they would no longer voluntarily submit to further mediation in the LTL Bankruptcy and would proceed with their respective cases in state court. LTL moved the New Jersey Bankruptcy Court for an order staying further proceedings in those two actions, which the Bankruptcy Court granted in October 2022.  In December 2022, the Bankruptcy Court allowed New Mexico and Mississippi to file a direct appeal of its stay.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2016, the Company and Janssen Products, LP were served with a qui tam complaint pursuant to the False Claims Act filed in the United States District Court for the District of New Jersey alleging the off-label promotion of two HIV products, PREZISTA and INTELENCE, and anti-kickback violations in connection with the promotion of these products. The complaint was filed under seal in December 2012. The federal and state governments have declined to intervene, and the lawsuit is being prosecuted by the relators. The Court denied summary judgment on all claims in December 2021. Daubert motions were granted in part and denied in part in January 2022, and the case is proceeding to trial. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2017, Janssen Biotech, Inc. (JBI) received a Civil Investigative Demand from the United States Department of Justice regarding a False Claims Act investigation concerning management and advisory services provided to rheumatology and gastroenterology practices that purchased REMICADE or SIMPONI ARIA. In August 2019, the United States Department of Justice notified JBI that it was closing the investigation. Subsequently, the United States District Court for the District of Massachusetts unsealed a qui tam False Claims Act complaint, which was served on the Company. The Department of Justice had declined to intervene in the qui tam lawsuit in August 2019. The Company filed a motion to dismiss, which was granted in part and denied in part. Discovery is underway. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April and September 2017, the Company received subpoenas from the United States Attorney for the District of Massachusetts seeking documents broadly relating to pharmaceutical copayment support programs for DARZALEX, OLYSIO, REMICADE, SIMPONI, STELARA and ZYTIGA. The subpoenas also seek documents relating to Average Manufacturer Price and Best Price reporting to the Center for Medicare and Medicaid Services related to those products, as well as rebate payments to state Medicaid agencies. The Company has provided documents in response to the subpoenas. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2017, the Company received a subpoena from the United States Attorney&#x2019;s Office for the District of Massachusetts seeking information regarding practices pertaining to the sterilization of DePuy Synthes, Inc. (DePuy) spinal implants at three hospitals in Boston as well as interactions of employees of Company subsidiaries with physicians at these hospitals.  The Company and DePuy fully cooperated with the government&#x2019;s investigation. In January 2023, the Company, DePuy Synthes, Inc., and DePuy Synthes Sales Inc. entered into a settlement agreement with the United States resolving the matter for an immaterial amount.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2018, the Public Prosecution Service in Rio de Janeiro and representatives from the Brazilian antitrust authority CADE inspected the offices of more than 30 companies including Johnson &amp;amp; Johnson do Brasil Ind&#xfa;stria e Com&#xe9;rcio de Produtos para Sa&#xfa;de Ltda. The authorities appear to be investigating allegations of possible anti-competitive behavior and possible improper payments in the medical device industry. The Company continues to respond to inquiries regarding the Foreign Corrupt Practices Act from the United States Department of Justice and the United States Securities and Exchange Commission.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company has received requests from a variety of United States Congressional Committees to produce information relevant to ongoing congressional inquiries. It is the policy of Johnson &amp;amp; Johnson to cooperate with these inquiries by producing the requested information.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline"&gt;GENERAL LITIGATION&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in September 2017, multiple purported class actions were filed on behalf of indirect purchasers of REMICADE against the Company and Janssen Biotech, Inc. (collectively, Janssen) alleging that Janssen has violated federal antitrust laws through its contracting strategies for REMICADE. The cases were consolidated for pre-trial purposes as&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; In re REMICADE Antitrust Litigation &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;in United States District Court for the Eastern District of Pennsylvania. This case was settled in February 2022.  The final approval hearing is scheduled for February 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the United States Federal Trade Commission (FTC) issued a Civil Investigative Demand to the Company and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether Janssen&#x2019;s REMICADE contracting practices violate federal antitrust laws. The Company has produced documents and information responsive to the Civil Investigative Demand. Janssen is in ongoing discussions with the FTC staff regarding its inquiry.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In February 2022, the United States Federal Trade Commission (FTC) issued Civil Investigative Demands to Johnson &amp;amp; Johnson and Janssen Biotech, Inc. (collectively, Janssen) in connection with its investigation of whether advertising practices for REMICADE violate federal law. Janssen has produced documents and information responsive to the Civil Investigative Demands.  Janssen is in ongoing discussions with the FTC staff regarding the inquiry. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, Genmab A/S filed a Notice for Arbitration with International Institute for Conflict Prevention and Resolution (CPR) against Janssen Biotech, Inc. seeking milestones and an extended royalty term for Darzalex FASPRO. Janssen filed its Notice of Defense in July 2022. Genmab and Janssen have cross-moved for early disposition of the arbitration.  Argument was had in January 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2017, certain United States service members and their families brought a complaint against a number of pharmaceutical and medical devices companies, including Johnson &amp;amp; Johnson and certain of its subsidiaries in United States District Court for the District of Columbia, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court dismissed the complaint. In January 2022, the United States Court of Appeals for the District of Columbia Circuit reversed the District Court&#x2019;s decision. In February 2022, defendants petitioned for rehearing en banc. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2018, two separate putative class actions were filed against Actelion Pharmaceutical Ltd., Actelion Pharmaceuticals U.S., Inc., and Actelion Clinical Research, Inc. (collectively Actelion) in United States District Court for the District of Maryland and United States District Court for the District of Columbia. The complaints allege that Actelion violated state and federal antitrust and unfair competition laws by allegedly refusing to supply generic pharmaceutical manufacturers with samples of TRACLEER. TRACLEER is subject to a Risk Evaluation and Mitigation Strategy required by the Food and Drug Administration, which imposes restrictions on distribution of the product. In January 2019, the plaintiffs dismissed the District of Columbia case and filed a consolidated complaint in the United States District Court for the District of Maryland. In October 2019, the Court granted Actelion&#x2019;s motion to dismiss the amended complaint. In April 2021, the United States Court of Appeals for the Fourth Circuit reversed and remanded. Discovery is ongoing.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2019, a class action antitrust complaint was filed against Janssen R&amp;amp;D Ireland (Janssen) and Johnson &amp;amp; Johnson in the United States District Court for the Northern District of California. The complaint alleges that Janssen violated federal and state &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;antitrust and consumer protection laws by agreeing to exclusivity provisions in its agreements with Gilead concerning the development and marketing of combination antiretroviral therapies (cART) to treat HIV. The complaint also alleges that Gilead entered into similar agreements with Bristol-Myers Squibb and Japan Tobacco. In March 2020, the Court granted in part and denied in part defendants&#x2019; motions to dismiss. Plaintiffs filed an amended complaint in April 2020. Defendants moved to dismiss the amended complaint. In July 2020, the Court granted in part and denied in part the renewed motion to dismiss. In December 2021, several insurance companies and other payers filed individual &#x201c;Opt-Out&#x201d; complaints containing allegations similar to the original complaint. In September 2022, the Court granted in part and denied in part plaintiff&#x2019;s motion for class certification. In January 2023, the Court granted in part and denied in part defendants&#x2019; motion for summary judgment.  Trial is scheduled for May 2023.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2019, Innovative Health, LLC filed a complaint against Biosense Webster, Inc. (BWI) in the United States District Court for the Middle District of California. The complaint alleges that certain of BWI&#x2019;s business practices and contractual terms violate the antitrust laws of the United States and the State of California by restricting competition in the sale of High Density Mapping Catheters and Ultrasound Catheters. In January 2020, BWI filed a motion to dismiss the complaint. In August 2020, the Court granted in part and denied in part BWI&#x2019;s motion to dismiss. In December 2021, BWI filed a motion for summary judgment. In March 2022, the Court granted BWI&#x2019;s motion for summary judgment. In April 2022, Innovative appealed this ruling to the United States Court of Appeals for the Ninth Circuit.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2019, the Company received a demand for indemnification from Pfizer Inc. (Pfizer), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer. Also in November 2019, Johnson &amp;amp; Johnson Inc. received notice reserving rights to claim indemnification from Sanofi Consumer Health, Inc. (Sanofi), pursuant to the 2016 Asset Purchase Agreement between Johnson &amp;amp; Johnson Inc. and Sanofi. In January 2020, Johnson &amp;amp; Johnson received a demand for indemnification from Boehringer Ingelheim Pharmaceuticals, Inc. (Boehringer Ingelheim), pursuant to the 2006 Asset Purchase Agreement among the Company, Pfizer, and Boehringer Ingelheim. In November 2022, Johnson &amp;amp; Johnson received a demand for indemnification from GlaxoSmithKline LLC (GSK), pursuant to the 2006 Stock and Asset Purchase Agreement between the Company and Pfizer, and certain 1993, 1998, and 2002 agreements between Glaxo Wellcome and Warner-Lambert entities. The notices seek indemnification for legal claims related to over-the-counter ZANTAC (ranitidine) products. Plaintiffs in the underlying actions allege that ZANTAC and other over-the-counter ranitidine medications contain unsafe levels of NDMA (N-nitrosodimethylamine) and can cause and/or have caused various cancers in patients using the products, and seek injunctive and monetary relief. The Company and Johnson &amp;amp; Johnson Inc. have also been named in putative class actions filed in Canada with similar allegations regarding ZANTAC or ranitidine use. Johnson &amp;amp; Johnson Inc. was also named as a defendant along with other manufacturers in various personal injury actions in Canada related to ZANTAC products. Johnson &amp;amp; Johnson Inc. has provided Sanofi notice reserving rights to claim indemnification pursuant to the 2016 Asset Purchase Agreement related to the class actions and personal injury actions.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2020, Fortis Advisors LLC (Fortis), in its capacity as representative of the former stockholders of Auris Health Inc. (Auris), filed a complaint against the Company, Ethicon Inc., and certain named officers and employees (collectively, Ethicon) in the Court of Chancery of the State of Delaware. The complaint alleges breach of contract, fraud, and other causes of action against Ethicon in connection with Ethicon&#x2019;s acquisition of Auris in 2019. The complaint seeks damages and other relief. In December 2021, the Court granted in part and denied in part defendants&#x2019; motion to dismiss certain causes of action. All claims against the individual defendants were dismissed. The trial is scheduled for January 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Emergent Biosolutions Inc. et al (&#x201c;EBSI&#x201d;) with the American Arbitration Association, alleging that EBSI breached the parties&#x2019; Manufacturing Services Agreement for the Company&#x2019;s COVID-19 vaccine.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In July 2022, Emergent filed its answering statement and counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2022, Janssen Pharmaceuticals, Inc. filed a Demand for Arbitration against Merck Sharp &amp;amp; Dohme Corp. with the American Arbitration Association pursuant to the Parties&#x2019; agreements relating to production of drug substance and drug product for the Company&#x2019;s COVID-19 vaccine. Also in October 2022, Merck filed its answer and counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Beginning in May 2021, multiple putative class actions were filed in state and federal courts (California, Florida, New York, and New Jersey) against various Johnson &amp;amp; Johnson entities alleging violations of state consumer fraud statutes based on nondisclosure of alleged benzene contamination of certain Neutrogena and Aveeno sunscreen products and the affirmative promotion of those products as &#x201c;safe&#x201d;; and, in at least one case, alleging a strict liability manufacturing defect and failure to warn claims, asserting that the named plaintiffs suffered unspecified injuries as a result of alleged exposure to benzene. The Judicial Panel on Multi-District Litigation has consolidated all pending actions, except one product liability case and one case pending in New Jersey state court, in the United States District Court for the Southern District of Florida, Fort Lauderdale Division. In October 2021, the Company reached an agreement in principle for the settlement of a nationwide class, encompassing the claims of the consolidated actions, subject to approval by the Florida federal Court. In December 2021, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;plaintiffs in the consolidated actions filed a motion for preliminary approval of a nationwide class settlement. The settlement was preliminarily approved by the court in March 2022.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company (subsequently substituted by Johnson &amp;amp; Johnson Consumer Inc. (JJCI)) along with more than 120 other companies, is a defendant in a cost recovery and contribution action brought by Occidental Chemical Corporation in June 2018 in the United States District Court for the District of New Jersey, related to the clean-up of a section of the Lower Passaic River in New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company or its subsidiaries are also parties to various proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act, commonly known as Superfund, and comparable state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.&lt;/span&gt;&lt;/div&gt;</us-gaap:LegalMattersAndContingenciesTextBlock>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i647eea070e4240cca28f6b76979c3a28_I20230101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzQ1OTY_735aa8dd-694f-425a-9591-d002dd074005"
      unitRef="claimant">170</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i34154fc7f1e24a8cb5c558996d6b6896_I20230101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzQ3NjA_d54c13c2-c98d-4ed5-bc8c-fbce7e656888"
      unitRef="claimant">1400</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i255cda4840fb4aa88fa64590ce872e72_I20230101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzQ4MTY_b09239b2-4f72-45d6-a0dc-ad9d3a7621db"
      unitRef="claimant">9000</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ie6cf165cbbd74fdfbb1fa0b952e8bff6_I20230101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzQ4NTA_bef6c590-24f4-4dda-8bd0-95a31b187b8e"
      unitRef="claimant">1100</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="i2c9a481d368148b0929cadc2b0a5af97_I20230101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzQ5MTA_c1131f39-c051-438c-b27f-29f9a0f53ee4"
      unitRef="claimant">40300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ie47bff957cb84bb49f3b161a5860618a_I20230101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzQ5OTM_041cc840-8ead-4e53-981f-f9dc6930ceca"
      unitRef="claimant">2100</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ibc66bcf7171d418a86ecd62a2404c17e_I20230101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTkwOTAyMg_b3b4e0cb-9e47-41af-a97c-72bf87ec7ae6"
      unitRef="claimant">2000</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:Numberofpatientsinsettlement
      contextRef="i03778e924ff348b5a3f45913272ec65a_I20230101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTkyMjE1MQ_c8d59fd7-79b1-4c0f-9417-b57e3f17c612"
      unitRef="claimant">10000</jnj:Numberofpatientsinsettlement>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="iddc88969213c48ea97060082ffa73825_I20210531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTk0OTMzOQ_aea7c0c9-3aff-4dd9-8265-c088606ac9f0"
      unitRef="cases">3600</us-gaap:LossContingencyPendingClaimsNumber>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="iddc88969213c48ea97060082ffa73825_I20210531"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTk0OTM0NQ_44dc0025-e45c-4362-92a4-8d4a91b03dd5"
      unitRef="claimant">4300</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement
      contextRef="ia897c0714e5c4774b0c045831789f7f2_I20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTk0OTM0Nw_4e9df01c-bdcc-4d6f-b452-82bab96c8176"
      unitRef="cases">3729</jnj:LossContingencyNumberOfClaimsWithinSettlementAgreement>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="iaf6a73a559664e0ebb512a48d328ad5e_D20210901-20210930"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTk0OTM1NA_910bcd34-e37c-4177-802b-b058792e49fb"
      unitRef="cases">2236</us-gaap:LossContingencyClaimsDismissedNumber>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="iac21980ceda94b21a50b291a322d153b_I20230101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTk0OTM2MQ_a8899a5f-ef0f-479b-beaa-68cc30942e8a"
      unitRef="cases">208</us-gaap:LossContingencyPendingClaimsNumber>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i3682b642e54048a5b5181c77d2d45dd4_D20191001-20191031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTk1MDM2OA_9629d525-2217-463a-8d0f-dd4a5031e717"
      unitRef="usd">8000000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i5dcee1a6065d4ba0abd1619dd17fb039_D20200101-20200131"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NTk1MDM4Mg_6cbad731-80fc-4966-a24e-07987fa849a3"
      unitRef="usd">6800000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i595e23088c2c4b02bebb9612c8ab2a93_D20180701-20180731"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyODkyNg_aec7027a-096b-4c12-81e1-1c2fce9cf5e7"
      unitRef="usd">4700000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:LossContingencyDamagesSoughtValue
      contextRef="i33aa324aaa9d42f4a185c9928408a20c_D20200601-20200630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyODk0MA_1f97808c-d690-4fdb-b66a-370467e5422b"
      unitRef="usd">2100000000</us-gaap:LossContingencyDamagesSoughtValue>
    <us-gaap:PaymentsForLegalSettlements
      contextRef="i748cd779f212410081567ad7ca01f948_D20210601-20210630"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyODk1NA_614af2d9-4419-45e0-a93d-1e20e4bab885"
      unitRef="usd">2500000000</us-gaap:PaymentsForLegalSettlements>
    <jnj:LossContingencyReserveEstablishedWithinTrust
      contextRef="i2391578fa34543b695b3fb891576fdee_D20211001-20211031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyODk2OA_489d0efd-5782-400e-89fd-7d1ef9be368e"
      unitRef="usd">2000000000</jnj:LossContingencyReserveEstablishedWithinTrust>
    <jnj:LossContingencyReserveEstablishedWithinTrust
      contextRef="i2391578fa34543b695b3fb891576fdee_D20211001-20211031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyODk4MA_b19facd9-58b2-4e5a-b110-40a0487c8d91"
      unitRef="usd">2000000000</jnj:LossContingencyReserveEstablishedWithinTrust>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="if6878b220b444ed8b48a88bc1bfe70dc_D20220301-20220322"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyODk5Mg_7f531309-b384-47a0-b236-4da7cb731b86"
      unitRef="usd">20000000</us-gaap:LossContingencyDamagesAwardedValue>
    <jnj:ProductLiabilityContingencyNumberOfClaimant
      contextRef="ibe39ec7be3e24f578dd104058f18f8a3_I20230101"
      decimals="0"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTAwNQ_52b02c02-df32-452c-8148-6f8a47f6b752"
      unitRef="claimant">3500</jnj:ProductLiabilityContingencyNumberOfClaimant>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i8fe1e7bec0cc453594ea48b53c12aae3_D20191230-20200927"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTAxNA_6d06a682-c2fc-40bb-83ca-43b72c072992"
      unitRef="usd">465000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="i78a211fb9da44857b52720a3523178e1_I20191031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTAyOA_f227ef1c-14e5-4fed-9ab9-ca91c0262f09"
      unitRef="usd">4000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <jnj:LossContingencyEstimateOfAdditionalPossibleLoss
      contextRef="ibd40d3a12acb4dcfbf80471e318ded84_I20201031"
      decimals="-9"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTA0MA_7d71b7b4-9b45-4d4d-b435-c29ce87f0cae"
      unitRef="usd">1000000000</jnj:LossContingencyEstimateOfAdditionalPossibleLoss>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="ibd40d3a12acb4dcfbf80471e318ded84_I20201031"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTA1Mg_44a29709-efce-46e7-b2b5-9dc28ae97d88"
      unitRef="usd">5000000000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LossContingencyPendingClaimsNumber
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTA2OA_daaefb99-6737-4031-b805-a04223ae5075"
      unitRef="claim">60</us-gaap:LossContingencyPendingClaimsNumber>
    <jnj:LossContingencyPendingClaimsNumberRemaining
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTA2NA_5fe8c546-21fc-4edd-9179-2351eb590d82"
      unitRef="claim">570</jnj:LossContingencyPendingClaimsNumberRemaining>
    <jnj:LossContingencyPendingClaimsNumberAdditional
      contextRef="i5b376816a5e84e09b89d79bed596a4a7_I20230101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTA3MA_96afde91-32a8-4c2a-98d2-79d0641c0504"
      unitRef="claim">20</jnj:LossContingencyPendingClaimsNumberAdditional>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ie97127abe6644e81b414d38b27b36e32_D20200101-20200131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTA3NQ_b5a5f870-4d12-47ca-896b-dfaafb02fd9c"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="ie97127abe6644e81b414d38b27b36e32_D20200101-20200131"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTA4OQ_9fa41753-cd17-4a82-bc24-0d88a3785aaa"
      unitRef="usd">344000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:LossContingencyDamagesAwardedValue
      contextRef="i3b4964f990444943801868a6dd79fc6b_D20220401-20220430"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjAvZnJhZzozZjZkNTJkZDljNWM0MDg2YjJkNTYxZjZjMjIzMzc3MC90ZXh0cmVnaW9uOjNmNmQ1MmRkOWM1YzQwODZiMmQ1NjFmNmMyMjMzNzcwXzU0OTc1NjAyOTEwMw_4c44fa84-f6a0-4c24-99aa-20e5c6790100"
      unitRef="usd">302000000</us-gaap:LossContingencyDamagesAwardedValue>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90ZXh0cmVnaW9uOmVkOWRkOWM2NzhjMDRhNmU4ZDZiMTUzZjYxMGFlYTY2XzIzODc_1a170e40-7f85-4017-849e-5d2c535f4b27">Restructuring&lt;div style="text-indent:18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the fiscal second quarter of 2018, the Company announced plans to implement a series of actions across its Global Supply Chain that are intended to focus resources and increase investments in the critical capabilities, technologies and solutions necessary to manufacture and supply its product portfolio, enhance agility and drive growth. The Global Supply Chain actions include expanding the use of strategic collaborations and bolstering initiatives to reduce complexity, improve cost-competitiveness, enhance capabilities and optimize the Supply Chain network. In fiscal year 2022, the Company recorded a pre-tax charge of $0.5 billion, which is included on the following lines of the Consolidated Statement of Earnings, $0.3 billion in restructuring, $0.1 billion in other (income) expense and $0.1 billion in cost of products sold. Total project costs of approximately $2.2 billion have been recorded since the restructuring was announced. The program was completed in the fiscal fourth quarter of 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-indent:18pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2022: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Write-offs/Sales &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January&#160;3, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January&#160;2, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Charges  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cash settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Settled non cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January&#160;1, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Although the restructuring program has been completed in the fiscal year 2022, the Company expects that severance charges will continue beyond that date. The reserve balance as of January 1, 2023 is recorded in the Employee Related Obligation account in the Consolidated Balance Sheet.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Represents gain on sale of assets&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringCharges
      contextRef="i2474e48849f1407492b006d664c27c42_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90ZXh0cmVnaW9uOmVkOWRkOWM2NzhjMDRhNmU4ZDZiMTUzZjYxMGFlYTY2XzY1Mg_bcdcf1df-9a28-47c2-b485-2a21b23af93e"
      unitRef="usd">500000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ie567e5eb9dcb41d0a398be109e77b0d9_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90ZXh0cmVnaW9uOmVkOWRkOWM2NzhjMDRhNmU4ZDZiMTUzZjYxMGFlYTY2Xzc0MA_ce0bb41b-a749-47b7-9f5e-128dfec927ca"
      unitRef="usd">300000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="iaa15521dd2654667b094254ebe535fc4_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90ZXh0cmVnaW9uOmVkOWRkOWM2NzhjMDRhNmU4ZDZiMTUzZjYxMGFlYTY2Xzc2MQ_d7875348-8284-49b3-9b5a-14d4d3ebf597"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i49c2401f8f3d4163afe6adbe4293302d_D20220103-20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90ZXh0cmVnaW9uOmVkOWRkOWM2NzhjMDRhNmU4ZDZiMTUzZjYxMGFlYTY2Xzc5NA_e68c18f2-8461-429f-ab6a-adc7b719c354"
      unitRef="usd">100000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="i95e5b2037fbd445ea91d492ad3152fe5_I20230101"
      decimals="-8"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90ZXh0cmVnaW9uOmVkOWRkOWM2NzhjMDRhNmU4ZDZiMTUzZjYxMGFlYTY2Xzg2MA_48f009a7-8742-4879-a057-11ae4bed0749"
      unitRef="usd">2200000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90ZXh0cmVnaW9uOmVkOWRkOWM2NzhjMDRhNmU4ZDZiMTUzZjYxMGFlYTY2XzIzOTE_c89ded33-5cb5-4844-bf16-14e9e8d6494d">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the severance charges and the associated spending under these initiatives through the fiscal year ended 2022: &lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.538%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:31.986%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.291%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.517%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.173%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.885%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:2.767%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:14.481%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;(Dollars in Millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Severance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Asset Write-offs/Sales &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Other&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:700;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January&#160;3, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;135&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2021 activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(23)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January&#160;2, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;137&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current year activity:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Charges  &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;448&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;463&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Cash settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(37)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6pt;font-weight:400;line-height:100%"&gt;(3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(432)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;Settled non cash &lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(59)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Reserve balance, January&#160;1, 2023&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;109&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:6pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Although the restructuring program has been completed in the fiscal year 2022, the Company expects that severance charges will continue beyond that date. The reserve balance as of January 1, 2023 is recorded in the Employee Related Obligation account in the Consolidated Balance Sheet.   &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt; Other includes project expense such as salaries for employees supporting these initiatives and consulting expenses.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:120%;position:relative;top:-3.15pt;vertical-align:baseline"&gt;(3) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;Represents gain on sale of assets&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="i32d057f69df94f2280959b742aaf5e0b_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzE4LTEtMS0xLTg0NDQ0_55c94eb8-6a50-4b64-a2b1-43060f5a3e06"
      unitRef="usd">135000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i628034b976194b3c95eee1d092e53459_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzE4LTItMS0xLTg0NDQ0_3ef16716-a872-427e-9e45-05228915c070"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i31117717375a483aba04eca1e392ee44_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzE4LTQtMS0xLTg0NDQ0_6295348a-2235-4849-9947-90f87672d39f"
      unitRef="usd">9000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="if41a7f60706e4d6c8d7278663011a8e6_I20210103"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzE4LTYtMS0xLTg0NDQ0_a0b8a96f-22df-4c9e-81ee-45905883b733"
      unitRef="usd">144000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="ib3e13d3f1dcb4123ab1494c07d04692a_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzIwLTEtMS0xLTg0NDQ0_14518385-1910-4c53-8eda-024456f5b685"
      unitRef="usd">-23000000</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="ib8895b2c96ae49d9ab87668b6e4d972e_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzIwLTItMS0xLTg0NDQ0_279761ac-dc1c-4e74-aeae-56125d368fb5"
      unitRef="usd">0</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="icbf00d9c7c2c47b2a38a0e33043c8e05_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzIwLTQtMS0xLTg0NDQ0_2b348a05-6cbf-4882-8ed5-0a7ec81b696f"
      unitRef="usd">16000000</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReservePeriodIncreaseDecrease
      contextRef="i3dbe54c0baea4b92b0175ecdc2c32d60_D20210104-20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzIwLTYtMS0xLTg0NDQ0_e6289b84-43ff-4d80-981d-0c6cac2abf62"
      unitRef="usd">-7000000</us-gaap:RestructuringReservePeriodIncreaseDecrease>
    <us-gaap:RestructuringReserve
      contextRef="i346e675961384d10af15a172a233f844_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzIyLTEtMS0xLTg0NDQ0_38a76f27-384d-4e5e-88c4-5b3f58ec51e7"
      unitRef="usd">112000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i224a56e9b03f475f8ef466ec18c2e508_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzIyLTItMS0xLTg0NDQ0_5149a2d9-fe68-47d4-b499-417acee0630f"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i9413ac0768844d14a4e88ef98209b2be_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzIyLTQtMS0xLTg0NDQ0_fe95750b-9286-4f36-aa34-b61e0250e04c"
      unitRef="usd">25000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i7ccc395680a1473f92468bceaec711ec_I20220102"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzIyLTYtMS0xLTg0NDQ0_5b0653a0-b02e-4761-ba3c-ee2b795fac37"
      unitRef="usd">137000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="i78a5f0207ed948bbab5f326ccad7f02d_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI1LTEtMS0xLTg0NDQ0_6a631f60-0690-409c-b19e-0fcaa2cf76e3"
      unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i0a124d2841f84a198ab499b74262070b_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI1LTItMS0xLTg0NDQ0_9dde2058-31f6-4e0f-a4c7-fe32c85019d9"
      unitRef="usd">15000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="ia22ff0765200405d8456d1b39ac5257f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI1LTQtMS0xLTg0NDQ0_e9d17736-2092-4cd9-b8f8-e5289db0ae6d"
      unitRef="usd">448000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="i2474e48849f1407492b006d664c27c42_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI1LTYtMS0xLTg0NDQ0_517b7285-140a-418b-969c-31541d31e985"
      unitRef="usd">463000000</us-gaap:RestructuringCharges>
    <jnj:GainOnSaleOfAnAssetPaymentForRestructuring
      contextRef="i78a5f0207ed948bbab5f326ccad7f02d_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI2LTEtMS0xLTg0NDQ0_22df7135-76f1-4dd0-b5a4-a3fe5067d30a"
      unitRef="usd">37000000</jnj:GainOnSaleOfAnAssetPaymentForRestructuring>
    <jnj:GainOnSaleOfAnAssetPaymentForRestructuring
      contextRef="i0a124d2841f84a198ab499b74262070b_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI2LTItMS0xLTg0NDQ0_27988681-bee6-4861-a189-cc63d05d8f02"
      unitRef="usd">-44000000</jnj:GainOnSaleOfAnAssetPaymentForRestructuring>
    <jnj:GainOnSaleOfAnAssetPaymentForRestructuring
      contextRef="ia22ff0765200405d8456d1b39ac5257f_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI2LTQtMS0xLTg0NDQ0_b075f12b-38bd-457c-980c-e5edc5771b65"
      unitRef="usd">439000000</jnj:GainOnSaleOfAnAssetPaymentForRestructuring>
    <jnj:GainOnSaleOfAnAssetPaymentForRestructuring
      contextRef="i2474e48849f1407492b006d664c27c42_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI2LTYtMS0xLTg0NDQ0_3e7f90aa-42ef-474b-9c0f-2944e3e3ba9e"
      unitRef="usd">432000000</jnj:GainOnSaleOfAnAssetPaymentForRestructuring>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i78a5f0207ed948bbab5f326ccad7f02d_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI3LTEtMS0xLTg0NDQ0_ea545280-0579-479a-a26f-08e455e75001"
      unitRef="usd">0</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i0a124d2841f84a198ab499b74262070b_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI3LTItMS0xLTg0NDQ0_77d90328-2ab2-44c7-add1-526c76703952"
      unitRef="usd">59000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="ia22ff0765200405d8456d1b39ac5257f_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI3LTQtMS0xLTg0NDQ0_b21a97b5-b54c-4277-b725-7d0c12373218"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:RestructuringReserveSettledWithoutCash2
      contextRef="i2474e48849f1407492b006d664c27c42_D20220103-20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI3LTYtMS0xLTg0NDQ0_13c02774-5656-4b4a-997d-65d4a614aeb6"
      unitRef="usd">59000000</us-gaap:RestructuringReserveSettledWithoutCash2>
    <us-gaap:RestructuringReserve
      contextRef="i105785393ea04c2ba49bcb40429c6955_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI4LTEtMS0xLTg0NDQ0_4b4e6748-5823-48ce-84f0-d7223dcaf9ae"
      unitRef="usd">75000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i6235e13b21004a43a0daa993991daa3a_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI4LTItMS0xLTg0NDQ0_f1d3d77e-d799-4fc0-ab6e-449e610a4b1f"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="ic2ba4d95af9e4e4fa22e3ffb45143679_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI4LTQtMS0xLTg0NDQ0_043ccaaa-7b50-499a-bdaf-51d4cf2d795b"
      unitRef="usd">34000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="i1f013b59c3b14695b75acec1bdb16def_I20230101"
      decimals="-6"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMjMvZnJhZzplZDlkZDljNjc4YzA0YTZlOGQ2YjE1M2Y2MTBhZWE2Ni90YWJsZTo0Y2Y4NDUwNjI0ZTQ0ZDhkOGVlMjNhOTI3YzY1OWI0Mi90YWJsZXJhbmdlOjRjZjg0NTA2MjRlNDRkOGQ4ZWUyM2E5MjdjNjU5YjQyXzI4LTYtMS0xLTg0NDQ0_8717f772-c8fe-4995-8650-8cb451a77cf3"
      unitRef="usd">109000000</us-gaap:RestructuringReserve>
    <dei:AuditorName
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMzIvZnJhZzplOWU3ZDg2NWZlMDU0NjBlYTIzZmEwYThmOTBhZGVjZS90ZXh0cmVnaW9uOmU5ZTdkODY1ZmUwNTQ2MGVhMjNmYTBhOGY5MGFkZWNlXzE4Njcx_661c3e2d-1c2f-446f-bee3-102e56adc6c9">PricewaterhouseCoopers LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101"
      id="id3VybDovL2RvY3MudjEvZG9jOjUxYTQ2MTY3ZWYzNjQ5NTFiZjcwYWU5ZDY0OTM3NzZjL3NlYzo1MWE0NjE2N2VmMzY0OTUxYmY3MGFlOWQ2NDkzNzc2Y18yMzIvZnJhZzplOWU3ZDg2NWZlMDU0NjBlYTIzZmEwYThmOTBhZGVjZS90ZXh0cmVnaW9uOmU5ZTdkODY1ZmUwNTQ2MGVhMjNmYTBhOGY5MGFkZWNlXzE4Njcz_e103e102-1da4-4d77-bcd8-d86779038e5a">Florham Park, New Jersey</dei:AuditorLocation>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>129
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( #6 4%8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    "  U@%!6\D?"X>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)TEQ#Z';B^))07!!\1:2V=U@\X=DI-VWMZV[740?P&-F?OGF
M&YC6)&5BQN<<$V9R6&Y&WX>B3-JR(U%2 ,4<T>M23XDP-?<Q>TW3,Q\@:?.A
M#PB2\PUX)&TU:9B!55J)K&NM42:CIIC/>&M6?/K,_0*S!K!'CX$*B%H Z^:)
MZ33V+5P!,XPP^_)=0+L2E^J?V*4#[)P<BUM3PS#40[/DIAT$O#T]OBSK5BX4
MTL'@]*LX1:>$6W:9_-K<W>\>6">Y;"HN*['92:&X4.+V?7;]X7<5]M&ZO?O'
MQA?!KH5?=]%] 5!+ P04    "  U@%!6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M #6 4%:E,$WWX @  *1(   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MM9QM;]LX%D;_"N'M#F: )M9KDG:2 (F<[#C3ND:<Z:"[V ^,Q-A")-%+47G9
M7[^4[)AFA[JRMM>#8F([OL?6"2G>QY)U^LS%8[E@3)*7/"O*L\%"RN7'X;",
M%RRGY2%?LD+]YH&+G$IU5\R'Y5(PFC1%>3;T'.=HF-.T&)R?-H]-Q?DIKV26
M%FPJ2%GE.16OERSCSV<#=_#VP&TZ7\CZ@>'YZ9+.V8S)/Y93H>X--Y0DS5E1
MIKP@@CV<#2[<CZ/PI"YHGO$U9<_EUFU2;\H]YX_UG7%R-G#J=\0R%LL:0=6/
M)Q:Q+*M)ZGW\9PT=;%ZS+MR^_4:_;C9>;<P]+5G$LS_31"[.!B<#DK '6F7R
MEC__QM8;%-:\F&=E\W_RO'IN$ Q(7)62Y^MB]0[RM%C]I"]K$5L%OMM2X*T+
MO.\*W+97\-<%_JX%P;H@:,RL-J7Q,**2GI\*_DQ$_6Q%JV\T,IMJM?EI4?_=
M9U*HWZ:J3IY'_(D),E5_8G) _IB-R,_O?B'O2%J0RS3+U%^F/!U*]3KULX?Q
MFGFY8GHM3-<CGWDA%R6Y*A*6F("A>H.;=^F]O<M+#R3>T.*0..Y[XCF>;WE#
M$5Q^S>X/B>NTEH\Z7KW*U*O[3;D';(V_<>XW/+^%-^)QI::.).-B-7'K"?"O
M3^I99"Q97O[;IGR%#.S(>N_PL5S2F)T-U/0OF7AB@_.?_N8>.;_:=&'"1D@P
M0V6P41E =*WR[G7);-K@<M<Y^-WF!ZSJZP<)9O@)-W["W?Q<%$5%,W++EEQ(
MFRB8(T5ETQN!57U%(<$,44<;44>[B9HRD?*DWG,1M4.UCBF8U.RKFIU5Z]X*
M!/2UA@0SK!UOK!WO./T$5:U LR-K'V(PZX%FI76,@65];2'!#%LG&ULGX!9>
M%3*5K^0ZS1B95/D]$S9+,,,]\#TWM&D"Z_IJ0H(9FCYL-'W81=,MFZ>E5.-*
MD@G-K1,1YMQ\^6TR^S(A/]%\^2M9W[.9 S%]S2'!#'.NH[LY9Q=WXR+F0DW#
MIK5X3V92[<D(%R3B52'%J_J96(5VT"<W-GUP45]_6#13X%8[[.XB\(Z^D'&B
M]FSI0QJO&K3V&=N!]+P#U_$"+W"L]L#BWO:0:*8]3]OS=K%WD22*7KY_NT&:
MWO9+81]S,%)5D1N^*$KU)UC/Y/6]:4;_2ZU*06)OI4@T4ZG."B[8/_]%:53?
M4U/YCC\75ITP;J*2^*6HBO(YC1^M\E"S 1;-E*?3@0OW]]_+V^P(IX(_I45L
M'Y PLV4GB!H9L&BF-AT:7+C;_U[;E)=2A8=_ILOVE0,F.B<??&LK#-?U]K:/
M".'J#.'"K7\S-R\$H^V:8,"Q[UDEH08&+)HI24<&%^[S/_%8C:7I@A=0%]P!
M";W@P D<^XJ*&ABP:*8M'1G<G3+#GRS+#AX+M<\G,T;5ZL<2,B[+JD4>S/S&
M;!_J17!5;V_[B!"NSA#N3B'B*\]4QTO%*G4)^X>9,&G"K;)00P,6S?QP5:<&
M;Z?4$%5"U&%^E>#38MZLEY556@>Q98C!57VM8=%,:SHJ>#M%A7$AF5@=OJ@_
M,:)O&JW68&*;-=2(@$4SK>F(X.T4$9KI2"+5CLVY>+6Z@CF?J)@S<A''3($4
M)EDAK?Y0\P 6S?2G\X"W4QZXRIF8UU/T'XH@%ZKAR)>TL(N$@:V?N\%UO;7M
M(PEX.@EX.R6!64ZSC%Q6I?IU:=^QP9QV6Z@! (MFVM(!P(/;]7%T?4LNJB25
M*BM=2,E4_]]\"'*=T;G5VO]W^  NZRUM']V_I[M_#V[>WX;80O5JX'R$,>TC
M##4%8-%,63H%>' #OY8UK>ZS-%;#BE/[@HG9RT>HM-&:%C:T^OR*I_/@6.6W
M)YL8W?![.S7\:OSD:K[-)(\?WZLQ1=4;(E\JJ29BD:C]OE469@,?K6E'6YOG
M'3F!=W+D._YF*]<J]M'L>[K9]W9J]B/5=0F5+<=%PE[([\P^^V"4H_[S'!4M
MCZQ.4+M^+)IY$H+N^GVX1W]K]Z_3LD[DWQ@5X&'/#MS!@>.J?];3#5#;?BR:
MJ4VW_3[<I&^.>6Y[NU8/6MN)#MA?SRA9&T-M^;%HIC'=\OMPJ_Z]L?4A]G9G
M,.[ZF]48:I./13.-;9T@!/?D%TI7LE+6TG!U %J;"+BNMZ9]-/6^;NI]N!DW
M%\FIFH=?:58Q\LX]M'XT> GS>I]%A=KR8]%,E[KE]\,]G)2&V;]'J+01%LWT
MJ=. #[?Q=ZG,&.$/Q/5^OO^%S%A<"=6D6"UV'%7H.<HCF-?;XSZ"@J^#@@\'
MA3M!D^:CR-?\GF=6?3#@QG[ #J[J+6D?1PE\'1I\.#2\C2YR]1(O:#%GK:?,
M=( FWV975ENHQP:P:*8M'1?\CA[_\"AT_DXF7*I,-5(SZ3-]K<_5"ZS",%O^
M")4VPJ*9I][J !$X^$M&@)D%(E3:"(MF^M3)(H##0(\EHX/49X1',*NWPWUD
MC4!GC0 .!]W+10= +1=>$%D]H28,+)KI22>,  X(NZ\8':"V%0,NZVUK+U\R
MV/J6 1PTPD-S.DWX$ZO/7&A=-6!>[[T<:M# HIDN== (]A T M2@@4H;8=%,
MGSIH!&A!HX/4=Y1',*^WQWT$C4 'C>!'@T8'H%DY+J=64:AA XMFBM)A(\ *
M&QV@UJ4#-6Q@T4Q;.FP$<-AP#]WV675BM8::.%!I(RR:^64VG3C"/22.$#5Q
MH-)&6#33ITX<(5KBZ"#U'N81#.PM<A^Q(]2Q(_S1V-$!J!</NR;4U(%%,S7I
MU!%BI8X.4-O2 9?UMK6/U!'JU!'"J<.UIWC?]O6_2YC5>R^'FCBP:*;'K>]
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MU8VV5/E^FE.K!70.M+_5VAX-=T#;O)._4$L#!!0    ( #6 4%;CGF-@9P<
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M4-T;WN[&R%W[DG0EC9%5>[D5W))W /O]K;3EUM^X]Z[[]^S+_P-02P,$%
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M!=($X/Q2"/W2,1_M]HX6_0-02P,$%     @ -8!05HY[U 9^!0  CA8  !@
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MB#6'G\V-H+OZ./"1"D'+^G)+<$:8$LC_KZF,IO9&O: [@E[^#U!+ P04
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MX8<,APM&=NV#]V^$,5*V;[<XR7#=!/#O[PEA/R^:9_G]STE6_P-02P,$%
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MJB]OJT[_#9Y&;;@(\GW7M_58&*Z@+IOA?_9C;(BC B1V%*!C 6H6X(X";"S
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M970Q,2YX;6RM76V3V\:1_BLHQ<E)*2[W3;(<R7;5:B7;\DFV:E>R4W=U'X;
MD(0% C0&V!7SZZ_[Z9XWD+NV$U>EG"4)S/3T].O3/:,O;[O^HUM;.Q2?-DWK
MOGJP'H;ML^-C5Z[MQKAYM[4M_;+L^HT9Z&._.G;;WIH*+VV:X[.3D\^/-Z9N
M'WS]);Y[UW_]93<.3=W:=WWAQLW&]+L7MNENOWIP^L!_<56OU@-_<?SUEUNS
MLM=V^+!]U].GXS!*56]LZ^JN+7J[_.K!Q>FS%X_Y>3SP4VUO7?)WP2M9=-U'
M_O"Z^NK!"1-D&UL./(*A_[NQE[9I>" BXU<=\T&8DE],__:C?X.UTUH6QMG+
MKOFYKH;U5P^^>%!4=FG&9KCJ;K^SNIXG/%[9-0[_+6[EV<?G#XIR=$.WT9>)
M@DW=RO^;3\J'Y(4O3NYXX4Q?. /=,A&H?&D&\_67?7=;]/PTC<9_8*EXFXBK
M6]Z4ZZ&G7VMZ;_CZ6C:CZ);%=;UJZV5=FG8H+LJR&]NA;E?%NZZIR]JZ+X\'
MFH_?.BYU[!<R]MD=8Y^>%6^[=EB[XE5;V2H?X)@(#=2>>6I?G-T[XO>FG1<G
MI[/B[.3L_)[QSL/JSS'>^1WC'5AF\;\7"S?T)"W_=VC%,M[CP^.Q!CUS6U/:
MKQZ0BCC;W]@'7__M+Z>?GSR_A]K'@=K']XW^'^[5GS5V\:ZOV[+>-O0G/7W9
MM8Y^J0R4[/W:%F7XQE;%LFX-/6V:P@WT!:GSX IZOQDK6PSTM)$9,-;WW9I>
M;8N_F<WV>?ADVJJHZ0$W+EQ=U:9G(A[RNY?=9FO:W:-Y\;H=;%_*QS@DOTE;
MV3H#$T!?]+:P34UZQ,3-:8!FW+3R(&V&(^4;UG5;#&;!R]N87=%V0V&JJJA&
MHK>CI\:V(G;,BW<T(:V&+)<KUN;&%@MKVZ(T33DV6/KHF&TT]6B:&8W3'N%E
M,&4UDGC,BY?6E7V]!>MH_<F:0-(+'L(Z5US;E7#N??+$VA#AVVW??:K).MEF
M5YP^.9L]/3DI[&;;=#M+A)%);"JR*+3L=D6D$B=;3,/2:?IRC7DJ>T/6><M3
MS&C1[;ADJHE7_*,SC67B3+'H.T-\,NT*7]#,U5AB.S'DVIIF6)?,XV5M&V)O
M2BU)A3R]\(NBUV[JGKE#I--_"NP:=E=Y >K#_F_[&B*Z[,@N%C4]U48:>BM,
MIRU:C[0$I08OWY+-/UI8[%I*$@_1KTQ;_PM\H5>'=6]MI- IVY]!RL>-[8OO
M,.RL>+<VY!-*.PZD* VF>6NK][9<^SFR%_Q07O3=/>P<7=RF%V:Q*RZ)I;/B
MQY[FD3^O/]+/,O#Q"VO&84<_W]C^B%XYNF0NTL3;C,)9\7-'!/SM+U^<G3Y]
M[CQ93/?/+)48F?:^_VC)R?,2G(TDQ=^$Q4S:RK:62=J."S(,(BH=;5<'VU(\
M)$>YV;"./!(])-VQ@ZF;@D,#J]I9U61KZ\4X=+UC[G?C:DV_Q]T7;DZX'9CI
M1!@LSXIWEEU#80;K'7WJS19O,/G&S93W_./KS69LNZ9;$>->MTM$""131 T]
M:.G1'^S8=X[,75LRZ]M2'WXW-INN92G\;K>U_2#1R0QK(0Y6=7=C'!N 7D6"
M+ G;S3 TV8U,;>H@96!RX(=EWO1$&.E&8)WMB;3;=4>VR<B'E'^S8MVY;3V8
M1GB;Z"-MY)($FDCE'RF4*]@]!=-#'!0^JPC?+:W;KA^(QW5WI\3^V _K;FML
M59<DJ&._LCV8/+ S; >04%R3W16+_+#<YUK+S/??B/3\5",*A%TY+)XIYXAA
M&9=ROB2\Y(\@?BL^#:9(%Y+R3"<N2!FWZYTC/TA.A6SZV$-:POBSPN[( >ZS
MG"<J22_JTK&S*G[H;NQF05I*@0R%,[GA;TDA2RM&C\R2<(T7Y>S6]&3FTN>#
M1D\M3K!B#__;MC?DO8S#>ZW96(@ %MG0=#35#Q0^3P?PWG4&KXC',VI*TBJB
MQ=!^W<[4#+"T]H9]G'?&Q#)^TQ(#U*HO:\=*O"/_@SANCMF32.-Z(':16+CB
MRK*+I4$OJF[+.WOP*9(&8O@M_Z?MF)J"_6'/08>)S[OPO-'!ZM;30F2<S>-L
MKYT;[YKL!XH'/#5&HA9RF&P1-"PM+JX_8,"CD\?/BC>U6=1-/9!7.[H>M]NF
M)@9_@Z#(LBE8]69#6_2^VY*1>'SRY.C)R:,">WKZO'A)U#6=8T_,<=D=KQ<_
M$N=71O3I/5N4<<O!%PGZKR/9$-YV,[ *CSMZFU9M*);2L98ZUE;'JF1*RS%/
MK=I:MY+\(8M:>//LWR!),&QT#X5ZK%QLV#L*C@9V2AS_]-@)D8HEVUXO&%O/
M#@1]!4O:$.6;LSO>BM) UV9%4]/RB,B=Z'%IW+I8$B&P#Y$+MS6%%@L_%Z6
M0?B]QO'G1"A)S>VJ;EM$;TNF^B4)!K3U] GV^(ST_%-IMT,8BG2JK;!BSE7)
M"?$OMR0P*?/8=M=D78FVG)@_-#GIRRO3<\C$4LA[0N.1+]K4 V+:2813CGTO
M4FV<8X,DOK&HZ0G/^L@L'FUP7@HX2)4(BGF(^=1EJ3IX6ZD+6-:TM\6OI U,
M. TMY%[RSKRBS;HA>SR-8LN&Z*)T@V>B2=:411.MLK<T_(UU@X2^,$*0K(KU
M>^RA5+( CMHVDFH2.QNV>LN^(VG&FLA3C13J&@<;"#FQ"36\P']WZA5L(,N
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MV2,VL@,[F$.OA;*-),C(#1VW?=R$TRF!M-"TPHMP-/;YH]BRDJ4BZ+3EUI9
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MW%C1]6D54Q>#@//LY/2I&-D/W I2243H@J0AYR3IP74WV!2($WD3UV@??.C
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M#?Y<6T-NCA^@WY<=.1[]P!.$?ZWFZ_\'4$L#!!0    ( #6 4%:KBY)C\P4
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M/'[N[+M)H\VC+1$=/%52V6E4.E>/X]CF)5;<GNL:%>VLM*FX(].L8UL;Y$4
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M)\^I5%FYH;CHW1/9PSC,A@FD13B99'!#2JQNNU.$U!'SFO)K( L+FL["9%C
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ML:IHB8&@D&5SY8^M'?8($O\$0=@2A YW(\BAO.667UUHM6&:3H,;W3A5'37
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M4>*-)B'[AR"L:5H7=0[ZC/!J*__'7<TX"T,O'(_[N/$]/TGZKPDAC<^"/L3
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M!=U-]O;G#\SR@<PDR,!HYI%!Q58_TTT4YOYF@/+#\+[&SO1YX[/7 O46!Z;
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MQI3Y307SHBJW]#L&#V55E1MZNA8<>(0+X'/\-I)[@0?X'[9X_3]02P,$%
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M$#$3)02'0[;,:0PK2JO*$V&0#YQ/Z:S(PMO;G?]AGK'_\3E-GF_L U-4L6.
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M09&>7\9N]GL[.SHR.XS$+WE6;HSX/DM4TB5P"59J?B+/S_OH28H_R6P@AJ-
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M:JP9,TJU1V"=7ROX5Z)C^^!!DRYK6_%F;T2BL6T"%E"36>UT 5"F*'5<P0D
M.3>%2N%5@;@#H;^K@KZPF[5V$XB'C8XW[$EB)>_S@E'*,DB:(MH]G@=I63B
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M)<-9 ^XVWV_7-!"OL?V@IJ;/[UVEWMTY=Z(&?L](OUD65*F3#*D^VRJ@JW$
M!65Q/0(Z=I%89B7)#>PB#\%+;38VGMNDK&X4$?>M=(;)U^+UR<V#H^?JLM;R
MO@;OUD0-)#*SI77,K ,<5/C*@@IN/$_4/8J1'4>_CGP<"\WR+[$/US+D+; $
MN*VF-*-H>-ZR!:==8?16IS!(AP:'UMC)SF#=J8NF,.K#]AMO6SHEHGCD'$Y]
MBQ48F]B^=J?LXBC>:O.1GES%Z)N(':T.Q$>;5?:E]H%[2@*RXZE4+%0'I>CH
MDCP $M"(PRM-(]LL>.]GH;;:*,^4S8I[6$65<@^\3F\L]UZJ7$^U[4E6Y2;O
M%E#P&;!'>]QK>/)67*+8S[LO>3T7[0*\RRX9#^?$AIR$ Y:/T(V)6 QARWP:
M&4CI1,J!"IL[I0IV_2,=AI9#=)*]VH,8SSU*]J9/[=JAFXDUY1[Q9I70PN[#
M4#T<C)M\E\J0Z>]2A@Q;94A+& =9]D'6;+?85["0-GP&KAV*$@E;UWNY';50
MQLK 65_32<QC;N8EQ^1^]=]5W(C3\60HMDZRAV+:S[2]4R1-:BT;;#P T2/-
M0JN4=B'O7M6Z,:VFE%PB(OZ7R>VX=?Z?%X7_A(D?L4E70+Y(MO_Y K*-:DD.
MKBE:D@!M7]2%%+&JN&?40/I:%HF/@,_D!/U5ZEZ\[$567\/]C@7J\,D"-?H=
M"U04$#YXO5"V&PD#1796^&,KS-KH-25EM$HGT =]A6RW*.T>^7!I2N>IJW:Y
M:T\0VOJAXI/ _W0\&-9N?"AZ5K'J/<Q_MG2]ZK#98NR@;&;V I=$DSG+K#WH
M-&SQ"#WEKN*P34F;P)"^UX52_F0+8H.6=I2(YZXN1FZD<YUTV@!/[2&D(KGM
MF%R M*4#2R"HHB7Y/DWB0+>#9QV?>*Y>=74(BB':D2'KH.- **_*6C[928V2
M2GGRE&JDRA]9&:)3WR A V%4EEN=-0?IW@>[^65R/+$&6*GM#E4.,GU_O!Z[
M"BJ61?$(&WD +!G?R5<99SX'UUG\19;0=FS:31=^[:_[<*[&XSI/^(9'[SV6
M:P[B/]<ZV/_^/824/RI5*R='7;AV(CD5,[[ %(W'XJ[,XZ^BY_+%=#X3T]D"
M#+GZUTD<L(3 6Z(@H$/$DG>HH&1;T9W-)W/P/*=;2C_F>?( CGE("__$V3B(
M9K0U>Q=I.J&[2"BUZMZ)Q2LV W<C26!8& JZP#1&4LOWTA"[:'PG$D;!;!KB
M<SZ/_*%ZH>@<ID5J5Q6[W/#@X7B"S\ET*O[$.1$MRJ5M<^&#0;2K]+/Q.4EO
M.J3;4'2+*$NT*9'45&X9/K"O(27$ A.^?+6@2RO!,.1OXRE$\&.:+SG&UGT@
M6,<%H4]2W[X9!9,QW7$9!_,)"/P"(U,PB4Q1M=B-U2 ^&8DSNOLUGPTQ=;$_
MGM%N/)O2G:&#"V+--2Z^[A:.@I"NG(7#8#RB/4,)8U!=!(LA73<*_Z,GY&01
MU^[N@NL^& (P%P4Z)Q@]"6[="[%ALGWZW3ZS^O><5P6\1),,U$FNO4?PU#;"
M5M_S2,+80K\VGH+"]5)#8;0*]$$FC&>4>CCH)ZB1C%S[?4ALC8\D.R!UV*EX
MX?;M42\K/*ZVW&"ZMR=EY#UJKP6R5*E6]WZ69KEPNS757RG9X6M,W$K96'A%
M@MU9C4$%(4G9#HQ-&/V%&&?#ID+2%FON,N6B*C7!R5-G+9^0KB"6!$<#1M O
MV8Z9NTI_3?V6LC=U)Q#J@13>*IW9T[[[A<'=2 M1I/$OG2J[Y+W;N^=X;YRQ
M0 ][$?IHC'WAC<GW:JTS[M; I-AKZ7[H*!K1YXP^ 5($O7PBVTG(.K[.0)Q;
M2S9B@OG1&.L *'OG6GQQ;;;NW'",N2,QG<X1J_ZYJ6?AF*)5&-'G9 (\NVL=
M+W#T#><$O7,"TI_ESMA+ -P&5#8!W>JROH^)"?6%QX@N)-JTH!;3/%ITA$4Z
M/)[TD,^.6N@ "_E)9A4E)2'?DQW!6%>M.@:%15ZE"=4K_G+ABWLX71>EYGI%
MAT[^N@]C!*H@99O:A8+/V>0JH]M!%%EBPCCV3TZ3ZLO.A".V]9>X+A=2".2Q
MQOCL%B26]OAPKT4X$'_3?&_"^"J1$_:,[Z;P@8V[AW1S>\?KN.203[F,7;'N
M_Q!MFYF5&S"\)O ++?@!@!I^>9;UJ6]U*A>.VK.F7!,]7P9M9:*8$]NCW<G'
MYH#IH-70G#_[?5*H_E)P8^ @R[84F],P=^MF>,&;JN7=1!%FV9XN;N6O8*"O
MVUH^90-V;UZ$LG2=6\J5+,^-DM< *XF\TC'KQ#.<'PD$-@; +XVV9QL@;OR%
M<D=R*VE"2\/U<4JFOL$V'E0*<][:WVLLN4//95:WX<Q4]V"]J<E<;=LQL%9D
MZ-PYL?T+>PY2G]EPJ29-3F<TK#+- YJ6L[LP =2P"$JDW)%O'<8:.Z$#FKIK
M664^+'5 C#$ 9/8<V"=<YJ 7>AQP;&'F3HDIV(-O?@@%HYICUZ8CBVQ]@9?;
M-F5WUYDFU#\ Z$Q\20CB -A*%:7I^6'!\?;XJG3M!;W/"B%I.%KX?F@@3E'Y
M^.8HGSZ/HOK[BWZ6X" )")HZR9><2KO+MJ19=X!>,T/W@DZGD["[\"1\>N4Z
M.=M;L^_'.)>M'TH!E-?\<S 'S/8W4_73^A=GU_:'5LUP^W.U7V2QIC.C5*TP
M%> T.1&%_0F8_5+F._[9%;+(,M_ROQL%N"MH -ZO\KST7VB!^G=X[_X!4$L#
M!!0    ( #6 4%;K:C"C' ,  !\'   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$Y+GAM;)U576_3,!3]*U=A0B"%Y;-M-MI*:S<$B(EJX^,!\> F-ZV%8P?;
M7=F_Y]IILR)M1?"2V#?W'I_C8]^,MTK_,&M$"[\:(<TD6%O;GD>1*=?8,'.J
M6I3TI5:Z89:F>A695B.K?%$CHC2.AU'#N RF8Q];Z.E8;:S@$A<:S*9IF+Z?
MH5#;29 $^\ -7ZVM"T33<<M6>(OV<[O0-(MZE(HW* U7$C36D^ B.9_E+M\G
M?.&X-0=C<$J62OUPDW?5)(@=(1186H? Z'6'<Q3" 1&-GSO,H%_2%1Z.]^AO
MO';2LF0&YTI\Y95=3X(B@ IKMA'V1FW?XD[/P.&52AC_A&V7FU%RN3%6-;MB
M8M!PV;W9K]T^'!04\1,%Z:X@];R[A3S+2V;9=*S5%K3+)C0W\%)]-9'CTIER
M:S5]Y51GIU=-*]0](MR@8!8K^+@4?,7<CIEQ9&D%EQ>5.[19AY8^@9:D<*VD
M71NXDA56?P)$1*WGE^[YS=*CB.^9/(4X"2&-T^P(7M;KS3Q>]@3>7#5TGHT7
MV&N>*V,-?+M8&JOIF'Q_3'@'FS\.ZZ[.N6E9B9. [H9!?8?!]/FS9!B_/D(Z
M[TGGQ]#_V:3_1X,+"W:-@+("54/-3<F$V_L4&(4>YN0([G'T#D<=X&@LE:Y<
M4'K .065X)5/G#'!9(EPZXZM@2UJ/(<7ETH(I@UP"==<" ?SLEO:K0>+72=8
MHL2:4]D)I.'PK( \C(L"%N2A1LLU4LNP#UE).,IRRHR'9SZG8_UG3AH660I9
MF"0CN,0:M2:2Y>%)2>(8DB*!3\J2_E[YH>)1F US. OSP0 ^H#%T>PGG<)F6
MW;.E0!B<C6 P&,'5L0U\_JQ(D_0U2"5?[9%.8!B.AB,HPH)T+S2VC%?'?2 3
M3_)P0-2;;D^]CQ3*LV$?HM[^X'%G+AWB%GW'%/<A,(UD2RDVSE'RYR-9JH$9
MX^S[N\.GC]V!Z*!I-:A7OC73KJF-M%W_ZJ-]][_HFMY#>O?KN&9ZQ4FLP)I*
MX]/1( #=M>-N8E7K6^!266JH?KBF/QAJET#?:Z7L?N(6Z/^)T]]02P,$%
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M6Y5LL><>6.Z*JA9RM\^*@Y05&8$LA0[)V0#C.*L*L2^+>]RIQ!Y[+BV<#3J
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M8.2@QWOAS6FO'V"QZ^-31%#@@+!W*3[0(K 4!A!JAQ!/Y4.SGY'1KD0PFWN
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M!74*$, %P4($D<=1]NH+6$@E\5VS&WE64]7K#.PXG.;#JKB9Q_%K6K"#:B=
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M<3QBPK+BF8[6!_#^RABW-WR"_E]B]A=02P,$%     @ -8!05IT[=(RU!
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M#8U,[K.D&165%:#SM91FM[ &]E/OXC]02P,$%     @ -8!05MH6T$Y5!
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M,M1.@+ZO%-%O-\Y ]\I;_ 502P,$%     @ -8!05@R, <&E!   1 L  !D
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M]/^(_E/PG7S9,HMW6OXI2E<MHFD$)>Y8*]U7??@9>W_&'H]K:<,7#IUND4;
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M+R8G]!6' =@%@1^>5QB %9 @S (_S8X LQX)8(67Y1$9,T[\2:J-.4DF.R,
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M*Q&"_SKKZ;1\EMY;#4"PMI%'TB2490A)NRIHU#V*.!<C@A:O*M'(8\1T6 5
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M0K/37GA3\R_J4#IY4_+'F9*@45J ^Q.#IB1>T '=3RPO_@-02P,$%     @
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M_WQ!JU\'JV^7JH7%F$8G\[I:)2T8FZ2M^%]8%[R65$@\&"L@JJOA0> '?&S
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M'L L SJ5QU#[H9O)-MJ,P3%/$2'JL@5CY;8GA'NI0"T8K4'>\9:C5LP0$D/
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MP%6+]05!_V:EZB^Z17$'2QT(-NH#=4*4&-W#E%N):ZM5%=1^G9B8(&K[?;P
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M*'D';IH%-(W[%4*JP4\$G(8E-W8/<$II[GXJ_R8_@?6H*?/0(J$P*'Q#Y/S
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M>$+9/#DK2+RTO59\2QW-)Y>TW*_G<GD7%P:J#7>E6;=&PF\3>K[G]@\3EXB
MZ*.AK*B<=B;K;7LC 2-B1?J>)&$B=Z;ZYN0@; XS'N @2[G2UT$8!2^1,X-/
MD4E(#N"$N:VSJ"%B0"_$U_OMQ0_N*C3]393M)B\H%P#QX/:.P+J5J!EB/I6Y
M^:(!:"E\0-G=G25J% 7>UL>1=.#36]WZYO)>]1]EC9!@KS]R=&W]A.3O=_-C
M</%CKSTZO\,KR_P9C/"TJRES[' G1N :?,OS2%;"%[6:/:VGOH=[PB#A0U[
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M@DRQ<.S"'YMV.7/7SQS<GIT=>A\FW6V#%Z[CM/?!Q[/KP[YX4411J!+#BC6
M!WC=RAI'KO0E=E)I*>'+80C[HC]#$MPC3R(DI^^D>04M7UNQ3/0F9/<./B"S
MM7EW.Z6"07)WT8<CEBYM&ID.?6X//,=S.5$;)1:-VE(7_0KQ20@71MN ^=R2
M#=C&QDY1UC@:E>UF)$N]E7Q#($"CC!,6=Q7J1[" T6/'5C3QZ9P[I[A3,>12
MM:;KCWV9%4$8A'%XHA7V1D<MZG:FZ;HV13!3?[]\5X#[EJ_GD00P)2^QTY&Z
M"P/\GV%6TJ^0*R.8[@GFCPHN2]30<A$DE0%5 B%X4R:E[@>-8;7T,O-J<1[N
MO^42#SN<7SKLG=A*8$^TC&0F1X,Z=[Y4(L%<ZQ7O>W#?(J].->Z\5SDRO(@!
ME=4+T3?+#KE):RC)1\Y^D)TX.Y,#L6?7:9AV[]E5,DJ46PK32+TC?6?;-80-
M!'B:T)E0/?/ 0QBZ:KUG1[C8J0$[$>$V!Q4$;;")F**&N5;VL> ^1Y0</*6(
MAV%L(L*-QF"R"IH\GLG](A'2"5CJ3DJK4JZ8('_I>VG&+/Q.0'00?#QUH_G?
MD8@=W=@3(GWC8-IN!T3YA;*7 8]=8]AW/Q7$C@M[>;"[5M$&K^'2G*=E2D%L
M2!! :OKIJ!Y())>_)R_,J5.?A34^"VO3WK3WZ!M[ 0-X<,(MBXHS=+MJ@A1K
M;*JNP([NM:IM6#:*V*(Z!TZ!7I;9S84G9L#N1)]-@,5FJ'6PO<^@7HYG3-AV
M3&DOF,>(%A,\>31_,/ .RQ0#:JPC8HH/M2>8ZJ-QZ:H;RLK,H]\_08$#.^C;
M?7 )75NA_<DD[RC!6;<6*W1OWB!IEK1;BDZMV\K\;N7H-X]$=LC6@2W<\JC)
M/3A=J:\N3//W2YU-/YV!E6JK!5UB8!\_3%T_2RYAGU5 ZY=MJ.DZ@QYC10)H
MO].@^,Z-0.<I@F -!]0KL%*0O:W8X\$#Q3\7$]R =A!8[SWVR6=RL*+ A<.^
M28&X%NT'^XF'BCIE7['+MQ]<H:@*77NB%TYY/JHVYJE#>1B%<G1( 8%)R!W"
MJ\(-_PEW9^ :R&M'38-HAFVL@!"02K<NT\YY3!F*;13]% ;RK-0M,P?OYYAU
M[H2[Y K#W!\O.Y 5H@HV7'_-Z%)EJ>.&YM7)GJ.HD9Q-D#(R;>SP7>5@;2L'
M0GMHC 0IA?<CW,ME.Q"B7/1P+C$9NAI_D6:,.'I80QJC@WPO$LM=_?9-#P[<
M3 /T\?_";NY1Z\AN3IRF1>!G%(P8#H?[$,]9)1O4:#R X1KC>NN;;8.2JD62
MY'*%  8)MF4*_T)7/3D^':FMTC<GITYNT7;WE\?H."Y9[X >EGQ+GE=8(I R
M2+818U>5%TEP-<KP^.R8D;,7NNTHJECXG80_P$ 'PA 2QPWBX7%&RN4R6F K
M9E^1Y.V#4WH\1N"Y0@]D?Q.'#-0.:?;7B4;"&=/#55<A0A78+$&)AT$+A#OU
MV9L%S2,&R?C=RK;-V=-#PB9[LZV_=7R$DKWALF6:[;22SAHM13TLPCB'+&YX
M#(W'.+&7%1#CQ8*XJG)G+/1PI2.''_J,#5@Q8M7"0N*_N37;MTV3^^OQ=<=Q
MLA!)];D>H92QS?=-&&9_7Z7D[S,(-<B 92/G*!Y0BK$.ME38MU+- 4\%]:<'
M'6493^6G_7[\,.UC*I=:<^6!8"U(/IKIN>*]8OR&/ER[;C=7G*%V-&<&@/#?
MH0T_: &Q;7)UL\M&-DM ]8A*Z=<E<OE!C+!P>81(@\^2)69PW5J4M^IE]1,I
MKL0 UL%6;D:T#0<BX&)2<>]M=\'@HNS7-&GOZ(G/$G)0F=J.]G1/>.>4X#CM
M"5>S(79$! ]R="'QCDF.M4$LS_(=EU?")>;]C,J8X2R=C:$"B9:?G@1-7/*9
M&<Q!K>W/,N%2'TM3:H&E;+>=V9KJ/M]W4>J9[2EE5H[P@7_CRUV-$/A\L$R>
M%J8A%U:%UHO,4?-%=FN?'0M+;#NL3[S'$[R:%:NJ03L4&2XL/?^*58YT[>RC
M=Y#OMOV >Q?@>1:VM8^F5>.6%<SBA\9W3W^^M;&]JQQ -OWQ.&=CY=H'^/)&
M81^G7E3>OK(YM;EC_[8CS75&\^_(7F.[+"YZBEVO9Q?7T_CZZKWGD\X%:LDJ
M>0>"H[)LG^^Q^3AGS\#;UACW8SN4M!=%?/D"?\03K7@3JGG?6 [5G*K3OD/C
MU]\:%>P)90[]@GLB364?G0<V&N!$W19A*JZ'A!YD\W<.CV0C'Z6>* ?!&&4R
MZN&LD2!8^4TC:64C2AR,)"X%#8/IV#I;ZCT;T+';H>Q9U(ZQ?H<U.?MS'/JU
ML(%OF!O"PV;VB4)C)(]@%XGK%4)'N/(1QU]BA9V6<N:6@H/ZBQJL6FPEYS)S
M>#1*7+O9<7CX:F[F>+_"D.=7(Y30LT-"HEZ'XSBQ-KHYNP;Z[9L3%RC]]KB.
MTN32Y>CEMR1MT6K'>?>YNJOX>9K'&OCA'O<OOAI&Q",L]:')5%HW;>KF,SRZ
MM(V8(]O!$5^UUH1 ">SP,;DBO*$RB^P7__P4GYFXT_ZE,'0:B:4\D3?=8H%]
M8!P(!@YKY#+*W@*F0:L!.WI\QZSX7AHS@"YQ<9D*T"U54-?43<57H]$YD9G>
M8KEPP/')/=7*<F=CL?R6+^]([WR;JX7;>=/P_DW[4XP<V(N_L=K&/UK)45G;
M-2#1N;ODR)_)#P?BJ["E@&Q*NE,'4_!--UM7NE2-O<'E%Z"OM>5SO.D"[^7I
M.!7N[_J-&@$M@\?B5$I&V!M/HM]2MX#6C!WPEKGS8'+)'S ZY/XUMPK\;O";
MW%G%/_\I=VCXR?V;O^;NG/ P\/@AK^!<@3^6]*@K=](])[C//_]T^>?IYVG*
M&3JL&]./2U/6UA8:O#&ON*2/IYV++>B%R=P-2RAZ.?U4*C'H=KO6R02L$,BC
M%:;06;X,?CCG4==44!/Y/^6&BET=>F?^/K>1Z\/">REV7>ZPYUZ'\?MXWCQM
MW[YY:AKXGPS^OZXV\+]T\^1[U:JW;P#:+O29+@JY5?S[)R=/@D_QNI3OGTQ/
MOIM.GCR%-_WC;]^L(0*'2 AP= ->=PZO'A]]^^()I\_L'VVUQB&36=6VU8K^
M<PFV3=?X 'P_KZK6_H$3X*$S(N_M_P%02P,$%     @ -8!05BX@6720!0
M;PP  !D   !X;"]W;W)K<VAE971S+W-H965T,S N>&ULE5=M;]LV$/XK![<H
M$B#UB^R\-$T")&FW=4#1(MG6#\,^T-+9XBJ1*DG%\7[]GB-EQ>Z2;/MB2>2]
M/O?<D3Y;6??5E\R![NO*^/-!&4)S.AKYO.1:^:%MV&!G85VM C[=<N0;QZJ(
M2G4URL;CHU&MM!E<G,6US^[BS+:ATH8_._)M72NWON+*KLX'D\%FX48ORR +
MHXNS1BWYEL.OS6>'KU%OI= U&Z^M(<>+\\'EY/1J)O)1X#?-*[_U3I+)W-JO
M\O&A.!^,)2"N. ]B0>%QQ]=<56((87SK; YZEZ*X_;ZQ_D/,';G,E>=K6WW1
M12C/!R<#*GBAVBK<V-5/W.5S*/9R6_GX2ZLD.X-PWOI@ZTX9$=3:I*>Z[W#8
M4C@9/Z&0=0I9C#LYBE&^4T%=G#F[(B?2L"8O,=6HC>"TD:+<!H==#;UP<<,^
MN#8/K=-F>38*,"D;H[Q3OTKJV1/JDXP^6A-*3^]-P<6N@1%BZ0/*-@%=9<]:
M_%F9(8TG!Y2-L^DS]J9]@M-H;_I?$B1E"KKA2@4NZ%((H8-F3[]?SB$%AOSQ
M& 3)P>QQ!](UI[Y1.9\/T!:>W1T/+EZ]F!R-WSX3_JP/?_:<]7^OS_]0IP^&
M0LFTT#Y7%7G.+>#XUBH7V)%= /+)R4$4N;9UH\P:>!G;FAQH-94RGH(E73<5
MHRT#*9AP A]456PRCZ>SWI,.GGZL[!QN;MNFJ=9T76)"P+:"GF/2)K P1BPN
M+(B.#O>V=3G,29&TR3%CO C>(0?Q!ZLI_MRA:I)!KAHUUU6L(>+FO#2VLDO=
MV?"V:E-4AF'78^B(NUJ9=J$$$TYB*4 )N7&V %K46!<6MM+V@-B4"@"06HJC
M==0H'"8)+5'*4 [I%X3T6*X;2)!*U19,? ]("ZF#)-$B-^ FM N\U#FADRLU
MM_A,0,+/',V-THB*-LA2R02+17",.(&$E6+<(ZX#J8NS=[+FPVO9X*!%WB#S
MAS2V(8L^;!-TK?_B&-1._(:#3-2AT*:CS)J5D\;,=EGBP"0GQ51 D%\'=4]Y
MJ=PR9OAR/#PDN 2:YH!6I<Y+TCTJ"* C)=*W*TE5.!PYE5P8E%$7L6-O QZ1
M>MA]KYR!.'*#A^G&@W#$;9,^;D^VMRWL.MI# +;F?2D+SIA$A>]%!4OQU?'"
M"Z4*5-P&@('%/W&V1*'4 PV6[C6."@:(+[-AUMLJ%2HS9S8/6'DM]9 <=^*E
ME?(/;9?8!;-+I^JXE4HN:.B=;EZ@>4*YV\U9EO0?L UJ7G%W J/H/EKP?,<N
ML2-6+1%#=I3W-M<1>P^4(GE;M*V3W=B<6ZPLG6V7Y79,D2ZIS2684]I[)R1W
ML9,_)FC\/MWV_B^]QSWD"_J;7]O%PH]N5073GU+%LOT.^9LT9G$<5Z)V0#@T
M6NGN:3PV)O22)M-#>O7B))MD;^D-36:SM*'2S%_#V'2_%Y@<T=[Q_M-FLV@V
MHPF.NXU.=@@?QW3=.B>$C*ENK)]*!T4@>P^'-)N=T.QH2M?*EX \A#1%/>U-
MX1L![B&BO=GT3?S-!!:1*<B /[DH;8SM'8J,_#P9<7=^TMYD'V </V QG=%D
M_":N7U:A["NVR\$-X4H0+K+V*=8],1"DIZ1=XKC_)[U6*#U,FJ!-*VVQMI%O
MD)4^3YQUNZF!BL+I[_/3_J&ANLC>(U*[9N[/^4_S2B]5=P?,T5=A([HS7*XZ
M1[=REQI&MB7>=9/*]PV_F1B^Q2A#7!Z:\1S$'9FX<^_CN8)SI!OXWW6+=!@0
M\+@\BD!GT@\C"VXXWB2$'$N9Q(@</N(T5=(A_K&+Q6CK$E@S<):KKLP+))SN
M@_UJ?YN^3)?(!_%T%?^(,FF<014OH#H>'A\.R*7K;?H(MHE7RKD-N*#&UQ+_
M"-B) /87UH;-ASCH_V-<_ U02P,$%     @ -8!05I)L09/Y(@  46P  !D
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&ULK3UK<]M&DG]ERIO=L[8HBJ0L
MV[$35\ER'L[9L4NRDZV[N@]#8$A.# ((!I#,_?77KWD !.G'IBJQ^,#T]/3T
MNWN&W]U5S0>W,:95'[=%Z;Z_MVG;^LG9F<LV9JO=M*I-"=^LJF:K6WC;K,]<
MW1B=TZ!M<;:8S1Z>;;4M[SW[CCY[VSS[KNK:PI;F;:-<M]WJ9O?<%-7=]_?F
M]_P'UW:]:?&#LV??U7IM;DS[OG[;P+NS "6W6U,Z6Y6J,:OO[UW.GSQ?G.,
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MF_\'K##JLD352X2'^X_%#:GM*')\\RD$-R[I,D 7-*E"QCU/"FO"X51V\=&
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MX=@ZA@_^"+\HT_@#,HU)$B;L15-BBFKA27H^K>N/+OHL^96GK6G6]%M6CG_
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M?S9FF,EB(W7&,W JYO-6IP9,BH!D5ZXLN<IT(G)X0*&XW+[U2015/[%8XE_
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MV451M'4KF,42KI&D%)RYJW JH[.<IS-:6+ 5 A*3VL"&FX()>$"FC=NBN)-
M ]JQ9I#<#)+Q6')QD,R.))='DF&'&B_A^;42PA%P"3=<"%HQ+WHVQP3O.PQZ
MA'OQFHCOT9$8> K9*(<L2V'9<E%RN36=YWIO'0F*8C_/<O?),CK&K*BH'/KA
M#]E)Z*=)!''N3R8I%5W2>6G[5D/JB'E+E3*0^CDMIWZ4Y/!!62K1V6KXL-7*
M.+EI[L>C!-*)/Y[D\-YA/5H=$I&.0H@S?Q)-_HU&4L-_"E'N9V$"4>;GXQA.
MG<[@J+?4J+==!S6T8ZVT?9L99H<FO>A[TR_WOL/?,+WETH# #86&%Y.1![KO
MFKUA5=-UJK6RU/>Z844_&M3.@=8W2MF#X0B&7]?\)U!+ P04    "  U@%!6
ML=H 680%   F#@  &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6R=5VMO
MVS84_2N$5Q0QH,5Z6TX3 T[:K1T6(&BS[<.P#[1$VUPET26I.-FOW[F47VED
M!1M@4!+->WG.?1Q*EQNEOYJ5$)8]5F5MK@8K:]<7HY')5Z+BYERM18U_%DI7
MW.)1+T=FK04OG%%5CD+?3T<5E_5@>NGF[O3T4C6VE+6XT\PT5<7UT[4HU>9J
M$ QV$Y_E<F5I8C2]7/.E^"+L;^L[C:?1WDLA*U$;J6JFQ>)J, LNKE-:[Q;\
M+L7&'-TS8C)7ZBL]?"JN!CX!$J7(+7G@N#R(&U&6Y @POFU]#O9;DN'Q_<[[
M3XX[N,RY$3>J_$,6=G4UR :L$ O>E/:SVGP46SX)^<M5:=S(-NW:)!JPO#%6
M55MC(*ADW5[YXS8.1P:9?\(@W!J$#G>[D4/YGEL^O=1JPS2MAC>Z<52=-<#)
MFI+RQ6K\*V%GIY]JR^NEG)>"S8P1UC!>%^QGI8J-+$MV=L_QEQE>CBPV(Y-1
MOG5\W3H.3S@.0G:K:KLR[$-=B.*Y@Q%0[J&&.ZC78:_'7WA]SOS 8Z$?1CW^
MHCWUR/F+3OC;DR3&+^/P7IJ\5*;1@OTYFQNK44!_=<6AW27NWH6:ZL*L>2ZN
M!N@:(_2#&$S?_A"D_KL>#O&>0]SG??H%35HT *T6'12.4]F%O-=W-_*9978E
MF(!G;+E C'C)G@37AM(2NBUQ@RS1LJ56IH510U]XI9H:L& H#UAYBW4CM+A@
M9^]569(S6;-;H$;CFF'KF;P><]S92;NB-I2UM(*5:'%SP>ZX%?4V $A< 2&#
MR+&W/V1A$+[;PGK#XMCS4:=1YB7CD/TJ"&N>-U53PKX@O-K*?[B3C[,P],(T
M'>+&]_PL&[ZV"3$^"X;8!M$8QRD+,B_.8G;CFEIH2%KI7)N57+=>%&*FCV+S
M$C% 3+(Q"R, #UY#'&"Q#P1G0>!-PF3X_[9V/$+B$1!Q\ C<Y40J9/U],NX/
ML7G#4B_SQQ@G6<+N&IVOH*@%C'Y<:Y43':HTCGF'JA /.#;6. 2 (1JRB9=B
MYXF716-VKRQ*KZ.0NE 0^M2+)Q%=,E33*>MCUBB0S(O"A,6I%TU"E\U[5#5
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MH%G[[G]8WGY!W4(C)0JR% N8^N=CR)=NOTK:!ZO6[DM@KBSDVMVN\"$G-"W
M_PNE[.Z!-MA_&D[_!5!+ P04    "  U@%!6^O(85"(*  !C(@  &0   'AL
M+W=O<FMS:&5E=',O<VAE970S-RYX;6S56EMOV[@2_BN$-RALP!OK8EWL)@$<
M)]EZD;9!TMU].#@/C$3;.I5$KTC'R?GU9X:D+KZ[[?;A (DM4>3,<"[?S-"Z
M6/'BJY@S)LEKEN;BLC67<C'L]40T9QD5YWS!<G@RY45&)=P6LYY8%(S&:E&6
M]AS+\GL93?+6U84:>RBN+OA2IDG.'@HBEEE&B[=KEO+59<MNE0./R6PN<:!W
M=;&@,_;$Y!^+AP+N>A65.,E8+A*>DX)-+ULC>W@=XGPUX<^$K43CFN!.GCG_
MBC>3^+)EH4 L99%$"A2^7MB8I2D2 C'^-C1;%4M<V+PNJ=^IO<->GJE@8Y[^
ME<1R?MD*6R1F4[I,Y2-??6!F/Q[2BW@JU"=9Z;F!TR+14DB>F<4@09;D^IN^
M&CTT%H36G@6.6> HN34C)>4-E?3JHN K4N!LH(87:JMJ-0B7Y&B4)UG TP36
MR:L[FA3D3YHN&?G(J%@6##0N!6E_H<\I$YV+G@0N.+<7&8K7FJ*SAZ+MD(\\
MEW-!;O.8Q>L$>B!>):-3RGCM'*3X.\W/B65WB6,Y[@%Z;K5G5]%SC^_Y)A%1
MRG';@OQK]"QD 6[R[UV;UB3[NTEBZ S%@D;LL@6Q(5CQPEI7[WZQ?>O] 8'[
ME<#]0]2OGG3$$#XE-ZQ(7BAZ,AFA0R?R;9>TA^E]F3,RY2D$9)+/B$1+DT00
M6H8F,I(PAQH.$'TIE2PFDH/'EP+ @CPF<Q;/X!+@02V9@D)I2MX8+01AZ  $
MS+=$HL: :E4YYJ@Q^,P!?Y K?1UN+=B83-HW(#O23W+R,4E3B&[1(4\4_)6,
MN5"$'@H>+R-PY">>QN3Q'<T6[V_([2N F6!DDDL&9I*D/<DCGK%.]>0S;*+8
M'OZIQ-$<;#IE2!&H3]$]7] ]M5J2''0M,2R5ZB(JYF0*ME.J!P,.R6\ OJ1]
MSP6H 9"N)E!.T09$/<V3Q;"6L "K$K&B"T$BB%ET?C$D']"D,4DDRP0Y(^]^
M"1W;>;_UW;:[UB#L['U>S[,&]:R;AO_$3"2S7'D6%96L20YAN-0PM(^F8GV4
M,S"NKC=TM*'8W7H:%S =4+@H6!Z]P?R#:AME?)DK_Y@A+PB(=JK8%2SBLSSY
M+^HTAS^T/LI0AQ*A>BU[C=(EQLRTX)GQ"7B<,Q!# F<4<;]![+YU7"5!O[H^
M4>#1Y_'D'^.Y888M9]ZP &3>%2UBA!?(KSDJ:$[S&3M5[RD5(IDFI4;55L",
MO+1".W ZI.T$=@=V4CM+VW%A(""V/2!NO<%^\$TZ\X@+ZWV[$0DVT&T/^O#A
M>0&P '2K->G_@PYW;./[;-5WO*/V[%O.=_G0?L_M.T>9UL89*90\*:O(M42G
M@TR0%2A5R5=@J($7XC30J^!I$BLT>J8IS2-0N:J+&]DO6F;+5(<LU(*8,^/_
M+ V&8 K<@%[ N'O(O0I*40W(:-QD=&T8/2E&,&,U3Z*YFC>O41B3,]A-0\.8
M%L4;;J=6/4XWH'V?T.<DQ9P]KD6M9S9*GP\FX$;U#B8ECU+4$UGM3LC'TOBQ
MY_<\G_T* 9!!SGB6X#UAU_<]^!YT@X$+WY" ^J[745=]IW.@T/*J0LL[7&A!
MSQ,OH1J"G=XJ]%VON03)N83[9MHJ]3BIT]:NBNPPXST5F:PJ Y0CWI#C6/K\
MP:)LN,>N]SQ2"(TB*3CO&3Q_7 OY297G&C4KSB^G-]7ZZ12U'O68.Y,E;LLL
M,2[!LBR]$E-Z,5-Z@3/U(0E8AYS'KYS'_P[G^<0PKJI"0\7.3@<Y2'QW@W&2
MU^RH='ZX7A^N&7++(3 +5"ZQF8DB@Z$PH(TRYAEL:8Z-_@LKW6:"N<I<-WFM
M$;Q#@C\'? SDV(. N&'0J.DW/6@S3^D4/CZ4PL](X/O$ZX??0/: ?P:5?P:G
M=I%EZPCJK%+;[=]+'*E]=:>7'F;Q(XTET_QK5_UQ)SUF]-VN4V4]G2?'"DK4
MG$;V?&13/%C24*=C7!>4MNE$>^1A60 ,";@TX.-LT?X$0:-=19I@& G!8.?;
MQB"K1,X)GKLEZ1M /R;&)%<:UO4&.&LW# '-/!>:LG8 H$:\P%?_>\CQI3Q,
MT;,L,K"ACPJ(#_T6_I<Z=)4.[1.;\_]CG?9#4 !LW+$\HV']^;TZ#=R0N)AU
M?!>$1PWC/^[QL2Q)8?M:<JV 7GE0@+O5#TPU"!K,("DHG"^[A@-($59($1X,
MXSL0.8\2"#FC.HRNLMQ+\.!'-NRV"R8.T_^BRF"0/']3^!:\%P1S/Z!Z1+%N
MJ?C3FG_:X)_IH\H8!6F4W%24 -- C-,!0S<&5!@(@PY+C2HWWU,*L1>6$MM\
M.^;;)5^X!.[Z$RW[38<>0Z/U4[K?1D_E.X.U:P\Z\_6#GGH5.E)]E.*Y_8V[
M8. ;Z6OZ3M?VW8T[N^NZ?M,S3I*YI.'9]MIU")%VBL1.-PC"C;M!,-B2V.TZ
MX6#C#F+7M[8J^I]E$S=L7CK][U:5'S8OG9",7FB2*EP!*@H=*\BH\&A88E0S
MI[9=G18V"PP<T\"F2A_! $]TL+7[#6>Q  ^#S5L;.C(G, (T<0+K;] D0C&V
MO0ET,+I2;*NVS>[:CF4^/=<EOZG:"6H!!/]&UX# "'@ "* 6'XM*[0>:F &P
M,W 3Q[+18<'\8X".1)*GY6+!"TE&LX*IGSU(>_PTPO.@KAWX'>POG= KZ:%,
MBAIQ/!)X:UR:>W:[KA<H589'&;E="T^:@%'HK3%J$CPC+H0DJ$<7<*:_TK_'
MJ1^VGC'G1'5*;2(EEE!1;85HS0I8FNU$._BP]BCWFD%LY!@>Y=G%F;*=[R(<
M!+;73.YX9)FIL&J@=%NI5A^".6KS5CCHD%$,JD(>4+MT (&<AI?YY(&^&?^U
M 4_;?2QQ!K#J-H_79:F]"25"\%4[VI-(* )^FI)&4P$:*>%<E0>JFWJ-V*)L
M<784JC!ZIH,GTXKJFH,<I+^+MJV/\O<9!NGA%BIJNVBXYPH5)V4I$!T_/$2F
M.\;/%2J,UWCD//\U,F445X&M57BN\&!]KCK%1;6 @94^U.;,8G#9KTRW C6H
MG"L$J$0'Y=FV7V_WS ,;FCM%[,P;]/=I8UO2-0OO.BWL;J7^9CE@2MLNU'%B
MH4_@T[?SAK0-4<YL=UU0=U#=KXM9BOASA,.@^IS/. 9#LR*J#_?*TT_://Q<
M% E"2HKN C KH%Y"KP5^-^AC?*&6FJ;TG#0*MYH&W>_'!1 I!&":#A ;6MY2
M.4FN4:;1 6*D 5[@%K">987$PX2X%@0(P7+P79XKY0D.12(NK@)U!/Z%9T<T
MA0$:@4L*!2I:]*8XYLQWM]PK,$RQ58V;HW/43J41Q*I)OE9OUD?/6ZHZ"ZS*
M=]0>]RNNTLKH.0&N\?FNNK[7^.$_8\5,O=Z OQ& I?4[ -5H]0;%2+\X4$_7
MKU]\I 4 NR IF\)2ZSSP6J30KS3H&\D7ZC6"9RXES]3E'/H<5N $>#[E7)8W
MR*!ZK^3J?U!+ P04    "  U@%!6S5:E),@%  "L#@  &0   'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6R=5VUO&S<,_BN$FQ0)X)U/+_>6)@;BM=LZ-&O0
M9.N'81]D6[8//9\\G9RT_WZD9)\=GVL4^V(_)U*/2(J4J.MG8[\T"ZT=?%U6
M=7/36SBWNAH,FLE"+U43F96N43(S=JD<?MKYH%E9K:9^TK(:\#A.!TM5UKWA
MM1^[M\-KLW956>M["\UZN53VVTA7YOFFQWK;@4_E?.%H8#"\7JFY?M#NS]6]
MQ:]!RS(ME[IN2E.#U;.;WBV[&B6D[Q7^*O5SLX>!/!D;\X4^WD]O>C$9I"L]
M<<2@\.])_ZRKBHC0C'\WG+UV29JXC[?LOWC?T9>Q:O3/IOI<3MWBII?W8*IG
M:EVY3^;Y-[WQQQLX,57C?^$YZ,JT!Y-UX\QR,QDM6)9U^%=?-W'8FY#'WYG
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MF0?G<]U^<VQOK%J[[WQ@.%95[B_.?^"&M #OETK9W0T9Z#_\7OP;4$L#!!0
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MXT,F*K:.&A1MN'*+!Z+8\^3LC3PQ^>8Y\?!PDHY/\[ P3S,Z-AUEQWBXY^%
M$.%D/($D#UF>O_7[L)"QL?\^:<I.\B2C,!F/( M9,CK&,UQ'&+$LY*G+6!J'
M69["L?J/#GI4C7KC.[&A ZD@^G:U7]TW^ZN^Q_TT[_\4=T)O*HI%XII<V<5X
M%(#NNV\_L:KU'6^I+/5//RSIAX7:&=#^6BF[F[@#]K_ ^?]02P,$%     @
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MH/$&]'VKM7N<>('QK[7Z%U!+ P04    "  U@%!6ET#C C8#  !5!P  &0
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M)8+C"$S7Q+N)TTUHG%OMJ V'WXK>/33>@/9WFNZKG_@#AI=T^0]02P,$%
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M(75!>@V1UWS!1RJVO3!F@D]IDF!(B#V$=Y"G"Y)==(>_=2_[O[3Z.D8S''1
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M@)8-:']KC#]^<(#^'\G\7U!+ P04    "  U@%!61*IFV4$)   P2   &0
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M;#H^3#RV8M-1<)#%8G?C^T8:BF:&>F_E[;O3RIIN-GJ%C56.5SUYF>HW"R6
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MF9\)E':!F4^%T-N.K6_U[TG\#U!+ P04    "  U@%!6;[6A-WH"  #,!@
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M!?J,'I?7Z/SL ITARM$]9<S47*6^-EM:H)^W]%<-/3Y"_X/P2Q2$GQ .<#0
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MIG<V@1:5:S\KH4TS<\.M^=V M EF?2V$?@EL1^M^8-D_4$L#!!0    ( #6
M4%:9#O%SJ@,  - 1   9    >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;+58
M76^;,!3]*Q:KIDWJ"H8D0)<@K>FF;5JEJ-W'P[0'%YS$FL',-DG[[V<#(9"Z
M:%W)0Q)L[CTYY_C&N6:Z9?RW6&,LP5U*,S&SUE+FY[8MXC5.D3AC.<[4G27C
M*9)JR%>VR#E&29F44MMUG(F=(I)9T;2<6_!HR@I)2887'(@B31&_O\"4;6<6
MM'83UV2UEGK"CJ8Y6N$;++_E"ZY&=H.2D!1G@K ,<+R<6>_@^1SZ.J&,^$[P
M5K2N@99RR]AO/?B4S"Q',\(4QU)#(/6QP7-,J492//[4H%;SG3JQ?;U#_U"*
M5V)ND<!S1G^01*YG5F"!!"]10>4UVW[$M:"QQHL9%>4[V-:QC@7B0DB6ULF*
M04JRZA/=U4:T$N#HD02W3G#_-<&K$[Q2:,6LE'6))(JFG&T!U]$*35^4WI39
M2@W)]#+>2*[N$I4GHP57%<'E_2E84)1)@+($O/]3D%PME01O0/]]),&<B6KV
M71P7:4&1Q FXQ*JF8H+*E7IUB24B5+Q6<-]N+L&KD]?@!) ,7!%*58"8VE(I
MT7SLN&9]4;%V'V']&65GP(&GP'5<SY ^_Y=TMTQWN^FV\J\QT6U,=$L\[[],
M_/E%A8-/$J?BETEJA3TR8^N?\;G(48QGEO)48+[!5O3R!9PX;TW"!P+KV. U
M-GA]Z-%7)A$%>6-&WIB!=V:<@A5GPKCB%?:XQ-:;SR8:A>Y8K>ZFK<\0Y4_\
ML(GJ$!\UQ$>]Q+]@(=2&LJ_?I%6_)JX5W*3%P@U'8^> JR$J\*%OYCINN(Z?
M;W*&I8GV^ $A& ;.H<6&J""<N&;:DX;VI-]BS5"_*%:;[IK1!)!4J=A@S=A8
M$+V 3_U=# 36T>XWVOTC;@_^D#8,!-:Q(6AL"(ZX/00/JC(8AP>5:X@)1N:Z
M#1O282_IBX+0A&2KDN?M;M 0-C'M!7SJ@@T$UM$.G7USX!RQ<FOP@9P8"JUK
M1:M/@D>LWAJ\LZFZ87!8P,:P('AD[X7[_@3V_N]'5RA>JRE^WR5L9#IH.S(4
M6E?WOB&!WC'KM[?=>;(5 Z%UK=BW.+"_QWEF_3[L93QGY,'#^C4U1K[_R!X,
M]ST/[&]ZYNJ4('E1G?S4R4')6"F3S%1[H9Z\:@.A=87ONR8X.68!#]I"#876
MM6+?1,'>YN2Y!>P;CA>MPJPE&J*@=WBZL%O';?VLXPKQ%<F$:FV7*LTY\U4^
MKQX?5 /)\O($?LND.L^7EVN,$LQU@+J_9$SN!OI0WSS$B?X"4$L#!!0    (
M #6 4%8%?Q[MO0(  *$'   9    >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM
M;*U584_;,!#]*U:&)I 829.V;*R-!(1I3&*J0&P?IGUPDVMCX=C!=EO@U^]L
MIUDII:LFOB2V\][SO7-\-UA(=:=+ $,>*B[T,"B-J4_"4.<E5%0?R1H$?IE(
M55&#4S4-=:V %HY4\3".HGY842:"=.#61BH=R)GA3,!($3VK*JH>SX#+Q3#H
M!,N%:S8MC5T(TT%-IW #YK8>*9R%K4K!*A":24$43(;!:><DZUF\ _Q@L- K
M8V*=C*6\LY/+8AA$-B#@D!NK0/$UAW/@W IA&/>-9M!N:8FKXZ7Z%^<=O8RI
MAG/)?[+"E,/@8T *F- 9-]=R\14:/R[ 7'+MGF3AL<?]@.0S;635D#&"B@G_
MI@]-'E8(G=<(<4.(UPG=5PA)0TAV)70;0M=EQEMQ><BHH>E R051%HUJ=N"2
MZ=AHGPE[[#=&X5>&/)..%/Y!RCP>DA&GPA J"G)Q/V,U'JTA'\AWJA2U1T/V
M,S"4<7V J[<W&=G?.R![A ERQ3C'(]2#T&! 5C;,F\W/_.;Q*YMW8G(EA2DU
MN1 %%,\%0G32VHF7=L[BK8K?J#@B4>>0Q%&<; CH?!=Z[.CQ!GJV"SUQ],X6
M-TE[.(G32_[K<'Z=CK51>'%^;\J\5^YN5K;%Y$37-(=A@-5"@YI#D+Y_U^E'
MGS=E[2W%LC<2>Y;1;IO1[C;U]%(80%5#X $+IP:2TYH9RMG3^N_GL^C5>D[-
M5M!YVOTT".>KN?DW)'L)Z2<MY)F/7NNCM]5'!IB<G%%7.QLOAW@9<SXKF)@2
M4P*AE52&/7F,G*Q:1:3/PR;/O1?1QL=1M.9Z%U"V =1? 7GGX4KQJD!-71/0
M))<S8?S%;U?;/G/JRNO:^AGV']\N_LKXYG5%U90)33A,4#(Z.L:0E&\(?F)D
M[4KD6!HLN&Y88@\%90'X?2*E64[L!FU73O\ 4$L#!!0    ( #6 4%;7%R1&
M3@8  )\Q   9    >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;+6;[V^C-AC'
M_Q4K.TUWTK7!)B&D:R/UBF^[:2=5[6Y[[00W00<XPT[33?OC9WX48J!NZ)Z\
M:1/BYX/Y/O#87PR7>Y%]EQO.%7I*XE1>C39*;2_&8[G:\(3)<['EJ?[E060)
M4_IKMA[+;<996 0E\9@XCC=.6)2.%I?%MMML<2EV*HY2?ILAN4L2EOW]B<=B
M?S7"H^<-=]%ZH_(-X\7EEJWY/5??MK>9_C:N*6&4\%1&(D49?[@:7>,+ZI(\
MH&CQ1\3W\N SR@]E*<3W_,N7\&KDY#WB,5^I','TOT=^P^,X)^E^_%5!1_4^
M\\##S\_TS\7!ZX-9,LEO1/QG%*K-U<@?H9 _L%VL[L3^%UX=T#3GK40LB[]H
M7[5U1FBUDTHD5;#N01*EY7_V5 EQ$( G+P20*H"T [P7 MPJP#UV#Y,J8')L
MP+0** Y]7!Y[(5S %%M<9F*/LKRUIN4?"O6+:*U7E.8GRKW*]*^1CE.++ZEB
MZ3I:QAQ=2\F51"P-T<]"A/LHCM$9NM>G9KC3/XL']$KC]P%7+(KE!QWV[3Y
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M6JW[0YGSW\9\7#G]&,4Y^3-*=HQ\8E&QRQE?U+(@E^1A_TD@V9)0EL>/4;5
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MN(5X59S/Q<3(F3OB1M+@@>F&4_RE 64#\/U82K.<V%.S^DF*_P)02P,$%
M  @ -8!05H&5+9@V P  F D  !D   !X;"]W;W)K<VAE971S+W-H965T-C(N
M>&ULM5913]LP$/XKIPQ-( %)4V@WUE:"4D8GV! 5[ 'MP237Q%IB=[;3=M-^
M_,Y.&MJM=$SJ7EK;\7W^[O/=^3HSJ;[J%-' /,^$[GJI,9,3W]=1BCG3AW*"
M@KZ,I<J9H:E*?#U1R&)GE&=^& 0M/V=<>+V.6[M1O8XL3,8%WBC019XS]?T,
M,SGK>@UOL7#+D]38!;_7F; $1VCN)C>*9GZ-$O,<A>92@,)QUSMMG/3;=K_;
M<,]QII?&8#UYE/*KG0SCKA=80IAA9"P"H[\I]C'++!#1^%9A>O61UG!YO$"_
M<+Z3+X],8U]FGWELTJ[WQH,8QZS(S*V<76+ES['%BV2FW2_,JKV!!U&AC<PK
M8V*0<U'^LWFEPY)!L_6,05@9A"\U:%8&3>=HR<RY=<X,ZW64G(&RNPG-#IPV
MSIJ\X<+>XL@H^LK)SO0N&%=PS[("X1J9+A32%1D-!S"B@(F+#$&.83 >D^QV
M=(Z*3YF57H.0AN::)X(9C(%IN,0XX2*!H=!&%272[CD:QC.]1YAWHW/8W=F#
M'> "KGF6T4WJCF_($4O'CRK29R7I\!G2C1"NI3"IAH&(,5X%\$F!6H9P(<-9
MN!'Q Q.'$#3V(0S"YAI"_9>8A\X\W$"G6=]*T^$UG\%[4GE9RGUX3VD)NU=2
MDYH/5V0$0X.Y_K).PO*$H_4GV.)PHB<LPJY'V:]13='KO7[5: 7OUKF_); 5
M,8YJ,8XVH2^)L2+ /HP,Q9U5Q@;F4$0RIV!5T)<YL4AMI7'ZN?6'P=S8E4<*
MZ($@/16S962M<IOI?#(I*O@H!552"^+"W9VQ.YA3<=6XMT[!+8.N*'E<*WF\
M\10J?#.F8J#B3^5- ,ZCE(D$(:)L4E11]0G\)!9_3^MULFT\^U\#;DM@*S*U
M:IE:_SW[6ML48TM@*V*T:S':&V/&.NU73M]B)!/!?U!4#$6=<6+I45@G18E_
M[/!M4S'MO3WJ^--E!__<<M .ZCTE;W_ID:/T3=S;KRET"V'*0E^OUNW%J7M5
M?UL_H[:C[!*>8,J>Y9HIBG,-&8X),CAL$R-5]@'EQ,B)>TH?I:&'V0U3:IU0
MV0WT?2RE64SL 74SUOL%4$L#!!0    ( #6 4%;B =7+ 00  &06   9
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M&H#O%XS)QX8*4%\L>]\ 4$L#!!0    ( #6 4%;@[ ;A8 0  +,5   9
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MYN'=9.&YKX2'773+8[61Z%,<0E@%L#77@K#[0OC&[43\C<27R,'GR'7<04M
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MQXT6$(0QT+^O.%<O+V:"XIYV_B]02P,$%     @ -8!05OEKS67>#   LHL
M !D   !X;"]W;W)K<VAE971S+W-H965T-C4N>&ULO9UM;]LX%H7_BN =+%J@
MK:UW.9L$2"QVIHOI3#'=F?VLV$PL5)8RDIRTP/[XE6S7-$7F2DR/\J5-'/+X
MZAZ)Y*-+V>>/1?FE6G->6U\W65Y=3-9U?7\VG5;+-=\DU;OBGN?-7VZ+<I/4
MS:_EW;2Z+WFRVG7:9%-G-@NFFR3-)Y?GN]<^E9?GQ;;.TIQ_*JUJN]DDY;=K
MGA6/%Q-[\OV%/]*[==V^,+T\OT_N^&=>_WG_J6Q^FQY55NF&YU5:Y%;);R\F
M5_89F[MMAUV+OU+^6)W\;+6'<E,47]I?/JPN)K,V(I[Q9=U*),U_#WS!LZQ5
M:N+X^R Z.;YGV_'TY^_J[W<'WQS,35+Q19']-UW5ZXM)-+%6_#;99O4?Q>,O
M_'! ?JNW++)J]Z_U>&@[FUC+;547FT/G)H)-FN__3[X>$G'2P7&>Z. <.CA#
M.[B'#FZG@^T]T<$[=/"&=O /'7:'/MT?^RYQ<5(GE^=E\6B5;>M&K?UAE_U=
M[R9?:=Z>*)_KLOEKVO2K+]\G:6G]E61;;GWD2;4M>7,6U)7UUGJ?YDF^3)/,
MNJHJWKR4Y"OKUS2Y2;.T3GGS>VV=]'X5\SI)L^IUT_7/S['UZJ?7UD]6FEL?
MTRQK3HGJ?%HW\;;O.ET>8KO>Q^8\$9OM6!^+O%Y7%LM7?"4+3)L#/1ZM\_UH
MKQU2\=])_LZ:V6\L9^:XFH 60[H[N^Z.IGL\I+N[ZVYKNC.Z>\R7[RQ'^^Y2
M,MRC]>Y.SWW*^J/!B3 XDPV^;0U^: W6V;?7]_3Z[1!W5MTG2WXQ:<:PBI</
M?'+YSW_8P>Q?NM0CQ6*D& .)229Y1Y,\2KTQO4P?DG8PK9KQKTKO\J3FJ\8Q
M:\U7=VE^UUQB55UN]U?MV>%:U9FU?Q]_]S[M]/%PZ=A!<Q$\G)I !F-J E*,
M@<0D$_RC"3[4A)-14N?$_LV"$R=<)YIWG" C,G4"*<9 8I(3P=&)@'2"_;U-
MZV_6A[RQHMZE6Y?@0$FP'P:=_ ;*Y6!'D2<WBLE@3/,&$I/R%A[S%O:<P3>U
M5?'EMGSRK R5I-DS+PH[:=.TFH=.IU5,!F.:-Y"8E+?HF+>(S-NB67\TUW=S
MHEG+9@V3KGB9[!:XW^?);[I41FJ2;&?6R:3:R'<[PW%,!F>:1Y"8E,?Y,8]S
M,H__*>IFG?%S6505,47-E90XSLSNY$UM9+M!)[DQ&8UIXD!B4N+LF5B@S^A3
ML.2KM+8^;^_OB[*VKNY*OENC6Z\6GZ]>:U?5,V5L>^O8R@BH:V8[D=]))1V>
M:2Y1:G(R3VC''CB3[T_#-];GNIG+=_G\_?:$>3X55=I>Z&\L]K5NN?@FXPV&
M-%/\?@!X8_U6U%:<5LNLJ)JUP/LLN=-Z0<>SORY^X_4^'-VZ^(<58EK!V$&0
MFNR@(QQT?O!XKP\*TE+7[Y[\:IM0.?/)2(SS!E*3\R9@SR8Q11J!>]:G!R5I
M@>KZW96 IE6S@HJZ.822&$I-SJ%@,9N&L6<,Q2IUO75W]Q[D7&J:V9&OG)!0
MHD*IR<D43&4/A:KC^?AM_.&8CDD,+O0EL@#IQ+2.L:-CH)DMV,RFX6SH45_;
M*GRYKM>])G2-NA<$%-!0:G+Z!*+9-*-=\[LTS]N["==)UISWVEMNM@I@"C8L
M-(T"-7>A2L"AW1ER&!WS<W,B\,ONX:]UTM!7U=Y';H _W>SNN] W)6T5K-[:
M<^7LTK3RG6Z*=%*S[JT:1A_#<W,DT,JFV>IJM=J-C97U*M1/0BHRA7.GFQ"U
M41>J-$WL6=!-QABTY A:<FA:^I1\>_*VT*&K;&<7+W6-O.ZJ1M=HWCTMZ$B?
MFPF!.@X-!BQ?]8PE!X&>^Q2:5NJ-"DTC9<1A=,#/38@@!X<FAR?OY93\@9=5
MDFESY/1=%HO^)K&F27/F=4\K1A_ <Q,D$,&A$>'W>LW+9B&5+[=EV::I9QJG
MY4SK/U"U&*K&4&JR,8(['&_D2IV#)(<%5"V&JC&4FFR5H!J'7OD_[X:QHY:$
M;-ONWK#3M/*[PW6L:]1=_3#Z()Z;) $*#@T*^X%F,7"40:[Q%U"U&*K&4&JR
M*X(_G'#L4099]UE U6*H&D.IR58)+'+&*$LY*LYTL4C3Q%;6>I$*YLK:=PPD
M<@02.3U(M"W3ROJ%)UF]UF8"61]:0-5BJ!I#J<D[C 2.N;.1QQ0767Y:0-5B
MJ!I#J<E6"5YT:5Y\%AZY*O=IP&9!O[5QVJ'U+)2:G'9!I2Y-I5<W:;'I;FX\
M)!=9?UI U6*H&D.IR1Z<;(0<?2<D=BLD=B\D=C/D&"CL"A1V>TIPSUKY'$2E
M.Z"S[MJ'?F?CK$.IUE4+A.%,H)^<3 &K+@VKOS8C>V;IMB)?TSV-3VCH;D:H
M&D.IR1X(%G:#L<<>*"!#U6*H&D.IR58)0';[-E&B]F*[:H&N>U>9CL78!RC]
MHM1D'P3]NC3]@K=CNRKS*F8@-V+&4#6&4I/-$*CMTJ@];$>VJY8.U2W9FD::
M/=ET/,;9&X.//<'''EVN'+ OVU-KC=W3DWX3X\<VH%2+4I,3+*C6HZEVO\31
M/:QU3?<TG3>A:C%4C:'49 \$XGK.R$L<#TK"4+48JL90:K)5@H0]N@0,?-Q,
MW1ZJ>]Y,LXG4=3L30TP';9SB49[G.WF@CR98\.K%4]%6\S29II4=*4]-T)$;
MYWF,2JPGX-:CX7;8PL13RZ7*[ J%5Z@:0ZG).1;PZM&%W"'+%_5A/-US9?0;
M&2<9BITH-3G) CL]&COW2QC=X^K7=$_C>1&*G% UAE*3/1#(Z45C+V&0T+>
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M/T,(,L\$_=!-!V1L!A2Z46JR&0*Z QJZ!TXRV@T M+3IR 55BZ%J#*4FFR3
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M7=Q?3)I+_J:HZV*S^W'-DQ4OVP;-WV^+HO[^2_L&CT7Y91?VY?\!4$L#!!0
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MJM9I1=RGE=--E'L/%:P>4C5=0&D"2I-0FH+2"$6S!XN6=$6/O5]":J@+*$U
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M'&75L4AU(VBIO_LOJ! TUY=K( DPU4$^7U*9N>H;1= <3LW^!5!+ P04
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MG)-$78HJ?(VI-!#/-X3P]X9\07' //D.4$L#!!0    ( #6 4%;LO5=QF H
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M,CNDM[A0Q\OKFFQ.U_(RI/(ZEWD,53)=#&5E>78KZWX1%4N!7U=)'!DO5NV
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M0S]#1=7%5EY48-^7M!FLY6,@[]Y*MY-Z:P>UGZ T"J4Q%$U7>.=7HX^S/RF
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M@,1]A7*9D2@<T7W<"2J>5M2G5T\\%,LYCI:#/> R"XZ4]Q2X4U4\+:OOA-S
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MF5>7MXQF3%D#^'TKI7F\L=]]VN]\Z_\ 4$L#!!0    ( #6 4%;P-ILA; ,
M *(+   9    >&PO=V]R:W-H965T<R]S:&5E=#<S+GAM;*U6[V_;-A#]5PBM
M&%I@C7[+<FH+B*,-Z[  0;*LGQGI;!.E2(VDXV1__4A*41R9UE*T7RR2>N_I
MWIUUNL6>BZ]R"Z#08T.97'I;I=ISWY?5%AHLSW@+3-]9<]%@I;=BX\M6 *XM
MJ:%^% 29WV#"O&)ASZY%L> [10F#:X'DKFFP>%H!Y?NE%WK/!S=DLU7FP"\6
M+=[ +:B[]EKHG3^HU*0!)@EG2,!ZZ5V$YV48&()%_$U@+P_6R%BYY_RKV7RN
MEUY@(@(*E3(26%\>X!(H-4HZCG]Z46]XIB$>KI_5?[/FM9E[+.&2TR^D5MNE
MEWNHAC7>477#][]#;R@U>A6GTOZB?8\-/%3MI.)-3]81-(1U5_S8)^* $&8G
M"%%/B,:$Y 0A[@GQ6PE)3TAL9CHK-@\E5KA8"+Y'PJ"UFEG89%JVMD^8J?NM
M$OHNT3Q5?&85;P#]A1]!HH_HMBL_XFMT82I"U!.Z 8H5U$AQ=,<$5'S#R+]Z
MKSEH!0S61$GTO@2%"94?M,C=;8G>O_N WB'"T!6A5!=8+GREPS4/]:L^M%47
M6G0BM#!"5YRIK42_LAKJUP*^]CF8C9[-KJ))Q3\P.T-!^ N*@BAV!'3Y%GID
MZ9&#7KZ%'EMZ..$F'DH76[WXA-Y!K7:'=5&Z+O=]75Q9[U03MZKI,^>RQ14L
M/=U()(@'\(J??PJSX),K8S]2K/Q!8J^RF0S93*;4BQ5L"&.$;4P^GP +5^HZ
MB=1*F([Z4,2Q^2<]'*;$!9J-0*4#E*<OH%<6TL%".FE!O\NZ]4O](HN75[;:
M"0%,64OVK]%R2=2I-[)[0'805GKD[Q@3)='(G@.3I6YWV> N^W9WK2!<H!;T
MI?Y_=]E15&$R=G>,&2>@/(9D6>XV-QO,S2;-E?#=YF9'47T,DWSDS@6*1J#2
M 4K3T&TP'PSFDP;U *$HZ('!W9-R1URCT%V0?#8*W0'*X[D[]/D0^GPR]#]Q
M*\%T!:FPVBF[I*0A>G>J%G-'K&,_QYA@9,:A$IUH$6'P\KT/)MWH;^E4A^O9
MKQM3-!_%[D(=-<+2B9J-'?@'PTL#8F.'0(DJOF.J^[0/I\.@>6''J]'YR@R@
M=BAZD>FFURLL='.7B,):2P9G,QV2Z ;";J-X:T>D>Z[TP&676SU$@S  ?7_-
MN7K>F <,8WGQ'U!+ P04    "  U@%!6P,JFEP0#   D"0  &0   'AL+W=O
M<FMS:&5E=',O<VAE970W-"YX;6RMEFU/VS 0Q[^*E2$$TB!/S1.TD:!LVB;0
M*AC;BVDOG/;:6CAQ9KLM?/O93AI*$P(O]J:UX_N??W>.[S+<,/X@E@ 2/>:T
M$"-K*65Y9MMBNH0<BU-60J%6YHSG6*HI7]BBY(!G1I13VW.<T,XQ*:QT:)Y-
M>#ID*TE) 1..Q"K/,7^Z!,HV(\NUM@]NR6(I]0,['99X 7<@[\L)5S.[\3(C
M.12"L )QF(^L"_=LG&A[8_"3P$;LC)&.)&/L04^^SD:6HX& PE1J#UC]K6$,
ME&I'"N-O[=-JMM3"W?'6^V<3NXHEPP+&C/XB,[D<6;&%9C#'*RIOV>8+U/$$
MVM^446%^T::V=2PT70G)\EJL"')25/_XL<[#CL =O"+P:H'W7H%?"WP3:$5F
MPKK"$J=#SC:(:VOE30],;HQ:14,*?8IWDJM5HG0R_927E#T!H%N@6,(,?<\H
M66"=8H%.4._RT15(3*@X5H;W=U?HZ. 8'2!2H!M"J;88VE(AZHWL:8US6>%X
MK^!\P\4I<MR/R',\OT,^?H_<,W+OI=Q6B6FRXS79\8P__XWLG/ Z_&N",T*)
M)"#0[XM,2*[>PS]=<5:.!]V.]=T\$R6>PLA2ET\ 7X.5'GYP0^>\*^K_Y.Q%
M#OPF!WZ?]W127]D,"I@3V7FHE8? >-!U8YUZ81(/[?5N$&VC@1,_&[V &S1P
M@WXXIHX ).&@*HOL9:P<A3O;NY$_V&-L&WE.F'0S!@UC\"8CF!?I3<:@O7WL
M>WN,;2/?=:-NQK!A#'L9KV .G*L7?,IRU2"$N>%=A&$[BXZS!]AA$[O=?%'#
M%_7R_6 24P3;:L2>JU 79-0"B/QP_ZC;1LD@"+HQXP8S[L6\!B%4U5:9W#EH
M5.(GG%'H(HU;$$$2[8%VV 2O''?2<":]G$U9W]:UG816A>/P0^RYWCDJ6'%2
M!]3%G[3N=!B%^P&TC>(XV;_X]DX/T]\/-Y@OB&HR%.9*YIQ&2L^KGEQ-)"M-
M6\N85$W2#)?J,P:X-E#K<\;D=J([9?-AE/X#4$L#!!0    ( #6 4%9RHB]5
M.0(  "H%   9    >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;*U476_3,!3]
M*Y:9T"9!G8^V3"6)M+4@0!I4K08/B <WN6VLV7&PW6;[]]A.&CHI17O@I?&U
M[SF^Y_1>)XU4#[H$,.A1\$JGN#2FGA&B\Q($U2-90V5/ME():FRH=D37"FCA
M08*3* BF1%!6X2SQ>TN5)7)O.*M@J9#>"T'5TRUPV:0XQ,>-%=N5QFV0+*GI
M#M9@[NNELA'I60HFH-),5DC!-L4WX6P>NWR?\)U!HT_6R"G92/G@@L]%B@-7
M$'#(C6.@]G. .7#NB&P9OSM.W%_I@*?K(_M'K]UJV5 -<\E_L,*4*;[&J( M
MW7.SDLTGZ/1,'%\NN?:_J&ESWTTPRO?:2-&!;06"5>V7/G8^G #"\1E U &B
MEP+B#N"=(VUE7M:"&IHE2C9(N6S+YA;>&X^V:ECE_L6U4?:469S)/HB:RR<
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M   9    >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM;+5:VV[C-A#]%<)=M+M
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M)8NSRQ5&$>;:0'V_8$R^WN@&RL- T_\!4$L#!!0    ( #6 4%8!C+WAKP0
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MD\NF(QW+B2DVZ:<")WY'E1'4G6)]D&L6-*T$34_LUA'=9.2;'"5I=W:($90
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MYLGGX=D(C@ /NL4W;^XQV>*QV+H%/#E)/&PE7S<%=F,WB?J&V $DTWE_-3B
MQ&'Z\<D>XD$']5V+?G'IHK\0&#N!LYY,_^QHJP"^,T>$ IEIJ<]YVM'V&/*]
M.7SKC=_HXTES9':BJ<\V/U&^RTJA]&\597 U4WV'U\>%]8UDE3E >V!2LL)<
M[H&FP#5 /=\R)I]O]!^TA[;K_P!02P,$%     @ -8!05AL$YJW; @  Y <
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M7,C*8BX!6/68JR]04U+@.12EQVG:#D:J\VW2-*8W,9:W?MHUW 4XW(W9M!U
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MWA6EG5=[33CMP]@89?WO(=JF+F:K4<G24PY>4M!-"A2:2K<4(=Z\75,>5&!
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MB??>(R6LZ(:;6[G[ ET_(\M72*[=D^S:V-$'CQ0;;63=@;&"FHGV31^Z.1P
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M2+6*UQI&-DX#EM*@HKAEA3\)4#8 ]U=2FKUA$_2_G>P?4$L#!!0    ( #6
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M=1\(EVAUSU(-."G5S<.:<$YR]9A@%&,J >+]AA!^&,@/-+==B_\ 4$L#!!0
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MDY/+*-JDFX1(.@<W<D4%F/%474&KO+5;"JY8Q%,*/OS!L^PC^("I)'&BML[
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MJ'H: Y>;D1=ZV\ =6Y;&!OPTJ>D29F#NZZG"F=^Q%*P"H9D41,%BY%V'5]G
MYKN$GPPV>F=,;"=S*1_LY*88>8$M"#CDQC)0?*UA IQ;(BSC;\OI=5M:X.YX
MR_[%]8Z]S*F&B>2_6&'*D7?ID0(6=,7-G=Q\A;:?"\N72Z[=DVS:W, C^4H;
M6;5@K*!BHGG3QU:''4 X/ "(6D#T'# X (A;0/Q:P* %.*G]IA6G0T8-31,E
M-T39;&2S R>F0V/[3-ACGQF%JPQQ)KT1!I2@]@PH)Y.54B#R)_)#4:&Y"Y,S
M\ITJ1>WYD.,,#&5<GV#T?I:1XZ,3<D28(+>,<TS6B6^P*LOMYVT%XZ:"Z$ %
M841NI3"E)I]% <4^@8_M=#U%VY[&T8N,WZ@X)T%X2J(@BGL*FKP&'CEXU //
M7@./'3Q\H9NX.Z'8\<4'^/#SQH]7])_-[^NY-@HOSY\^X1OB03^Q-90K7=,<
M1AXZA@:U!B]]_RX<!I_Z1'M+LNR-R/8$'72"#EYB[P3-MX(:*RAM?&B)3DF.
MN=3ZY)3, 7T5B*&/?>HVNURX7:R[KM.S.+I,_/6N:CU)43S<3\KZDH*/75+3
MI;]SR2M02V>6FN1R)4QS-[IHY\?7SH:>Q<?HTXVM_J=I3/Z6JB43FG!8(&5P
M_@%+4HUQ-A,C:V<E<VG0F-RPQ'\-*)N ZPLIS79B-^C^7ND_4$L#!!0    (
M #6 4%:M >O,J0,  /(+   9    >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM
M;*V6;8_:.!#'OXJ5GJI6:O,(2=@"T@(]7:O;$]I5[UZ;9"#6.G;.-K#]]K6=
MD,N&P&Y/Y05)G/F/_9MQQC,]<O$H"P"%GDK*Y,PIE*IN/$]F!918NKP"IM]L
MN2BQTH]BY\E* ,ZMJ*1>Z/NQ5V+"G/G4CJW%?,KWBA(&:X'DOBRQ^+X RH\S
M)W!. _=D5R@SX,VG%=[! ZAOU5KH)Z_UDI,2F"2<(0';F7,;W*PFQMX:_$W@
M*#OWR)!L.'\T#U_RF>.;!0&%3!D/6%\.L 1*C2.]C'\;GTX[I1%V[T_>?[?L
MFF6#)2PY_8?DJI@YJ8-RV.(]5??\^ <T/&/C+^-4VG]T;&Q]!V5[J7C9B/4*
M2L+J*WYJXM 1!/$%0=@(PKY@=$$0-8+HM8)1(QC9R-0H-@XKK/!\*O@1"6.M
MO9D;&TRKUOB$F;0_**'?$JU3\\]8,,)V$JU!H(<""T ?T3UDG&6$$FQSP[=H
M@27)T%]Z&[:"JA4HCE:$[A7DERS>K4!A0N5[[?PWY"%I1N7I0ABZ(Y3JJ>34
M4QK*+,W+&H!%#1!>  A"=,>9*B3ZS'+(GSOP=#3:D(2GD"S"JQZ_8N8B/_B
M0C^,!A:T?(T\M/)P0+YZC3RR\N *3=0F.++^H@O^SG.YL;ED.E/0S90\Y3)O
M<CEL,92A>@6CX168PG4C*YS!S-&528(X@#-_^R:(_4]#T?V5SE:_R-FSR(_:
MR(^N>9\OKL7YG=[T.:<4B\[H^Z'@UI,D=A)3Q _SV$WUOCQT@W9NE+B3GM'J
MW&CLCB>MT3/(<0LYO@IY>P"ACX?3IZP/%JDPRS5M'<>W;](P"#\UF\Y0UY:#
MJ/54:6>!81R.W; '.V06A6[0P[U@E@X#QRUP?!5XS14P13 ](<,3B(Q(O*&
M]KH$Z5PJGCTB7MD/KJ*8R9? X[.E!B._#[2LK>*N593VH <\!:D;#3,G+7-R
ME?E/D/+FQ"N@VHNLT&=MWO JW6_(O?C>@)>@"IZ_A)R<+?1CX ?NJ,<\8#:)
M77_2_?5","!)?7?D=W[!<#S2-A[I_]ST^GP[E<\7^-.!W1E';@]FF9[E/(R3
M7I!60[X2WTV&*2<MY>0JY>KJ.? 3%6PR4,&2?@4[-TK<M/])GQOI"M9/IM?I
MADH0.]M52I3Q/5-U%]".MHWKK>W7>N,+W=#6_>=_;NIN^ Z+'=&?-86M=JDC
MK6N-J#O,^D'QRO9<&ZYT!V=O"]V4@S &^OV6ZS+2/)@)VC9__@-02P,$%
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M(UY^10/^^[HHV,L7,4#S&HF+_P-02P,$%     @ -8!05ORRT($+ P  =PD
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M!">$%P#U?L&8_&@4'VCN8,?_ U!+ P04    "  U@%!687B39=D'  "U0P
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MVMR).?KNE8E$IDIN=6N>*S;/T/9>[Y/CJCDYOIC?+JYG'[?EVY''M#4+'_L
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M/C)AB:)8.0^38XXE:7M6JJC"8D6Q<AXFQ[Q+<GT(6E1)U- R.!5",K.FX)L
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M7-41:FJPUCQF6&UB-OT37'^6/)G 5G4"MMH<IS:_F-S>/BZCYXTFY(]^K+!
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M 6UB&98IC)7S,#EV(TBMD94I;+!,8:R<A\DQ[Y):!,(4-A(NF*\@'4E6)CP
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M;I*@< M*7-FP#K8W)CYVZ]M,$N<$(S8>I5(<V(3R\0\0MG&>A0-K"0?69N7
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MLEK<W"\^+U;;!^P[PAL6QHJ5\S YYG920F2%L3HLC!4KYV%RS+ND$H' 6)U
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M:'W722J>0-5^BV!7YY<7P_>3[XQ@*,;LSH_8!3A9"+B.$'#=,Q$V5P3#O@G
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M>7:"2DMI%9?#T67O[?AT.IZ>Q.O&]XO8\OO$7,<_9-"F/4R.^9I4 2IGT[[
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MR?L3SWF9KIQG = ,J(0=%2W!0E,-*PE[-&7,183J$4=%2[#05,.V<B?;&?]
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MXIMWYO9.6P(X-'!&M0C58E03J"913:&:IC2G^"<V<)[X ^<X7=?WVB_3N_K
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M9J7EJWCE@4IVQ<MI3XE2R;;XN)%^(-.\@/Y^G23J]2"OH'HA<O$_4$L#!!0
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MAFG&,^DHO1UH*3Y8BN\&]DT/=HK*3\I$)LO8)H+YG52W;P'K'@ADG-<"8=<
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MC5?([CK YG17A6 CQ2L1&RF>:T#L>0-&%-EG&XL##&P6L-J!^/8X4%-V3A#
MK&+:L!6,(U&$(5"+]AH-0R0[(7SM\X.MDB"((CL"F%U!$& (K$8<P12 !@P)
M@O(YN/4\\M;/*:_Y]\KH+U!+ P04    "  U@%!6EXJ[',     3 @  "P
M %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=
MOZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'
MTD!$VV-#L%HL/D N&6:WO606IW.D5XA<UYVE/=LO3T%O@*\Z3'%":4A+,P[P
MS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T
M>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0    ( #6 4%;W,N8+"@<
M ,I#   /    >&PO=V]R:V)O;VLN>&ULQ9Q;;]LX$$;_BN"G+M"L+=FZ%4V!
M7-IN@+0)FJ"O!2/3-E&)]%)2TO37+RDGZ3"7#_LRT9-C29:/29%GAI>\OS'V
MYY4Q/Z-?3:W;_<FFZ[;OIM.VVLA&M'^;K=3NS,K81G3NK5U/VZV58MENI.R:
M>IK,9MFT$4I//KR_O]>YG=(WII-5IXQV!_V![TK>M'_.^[?1M6K5E:I5=[L_
M&?ZNY21JE%:-^BV7^Y/9)&HWYN8?8]5OHSM17U36U/7^)-Z=^"YMIZHGAR\\
MY*6X:H<CG;CZ)AS(_B2;N1NNE&V[X8KA_L(Q7DMW\>Y=WYE/JNZD/1:=_&Q-
MOU5Z[6_C?L64_(RA'.Y?=X7XSOZ?8C2KE:KDL:GZ1NIN5XY6UAY0MQNU;2>1
M%HW<GQR9:VFC<[&6_D>Y;SE9[GY@Y\A(<=EWRIVP)\N!D8_GH%^J+CK1NP^[
MLP0K 5@)+]:1>V]JM73?OHP.12UT):.A>EL". > \]$ HS?G@D N .3B%2$O
M/(3_0!N95?116%K5*8!,1X,\,LV60&8 ,AL1\D="(', F8]7W?_VBD 6 +(8
M$3(HR1) EN-5MV@WM.N>H;Y[QHMYT3>-L+<>ZT*MM7(?$[J+#JK*]+JC%1Y#
MQ3 [QA?9VZ'@AN?P6M1#80J]C(YZ:RDF4D[,[)P3?>TN<$&)I(Z)D61B9LNX
M<&OK@J';M]%Y[6O6%YDOPJW_'(5$DHF9+7/B0CB]]E\:';2MO*O9S\8L;U1=
M4TIDF9A9,Y^$LM%W4?<R^B)%V]M=DZ9XR"\QLV .C;7FQD6E 1&22<QLDQ-=
MF49&E^)7V!Z0.V)F>7QLMK6YE3+ZYL^ZOOGLJE;KW764$:DC9G;'N=2M/S:T
M@K-NX\+]0ZGERH79OA'3^!JY(^%VA[CV3]L3)B2*A%T46^72P:'D+NW02F^=
M?DWUDQ+"M(39$4ZM?=/?/7M#W?H8U<J-K_1KFM,ER!L)LS=<ERRM'HZ[XO22
ME;JZ=64J=.LNIYC(' FS.7P2LGL(74%>;(0-"A#9(F%/2IK&Z-VS]W;W$IUM
M_65/&@RR1L)LC0NY?@A,#_M6:=G>V5>:M:59:()4DC"KY*!R,4NKNH=N\=BU
ME;93G;,P[;<3Y):$V2VG<NW:BHNX*BF7CT2<(*$DS$+YYHK*]I4K+$=%1S^0
M/N9CIAY!&C='1IDS&P5CSBDFTLJ<>[@+94AA:<(Q+W:M/&1(T9M+X;Z\_8NR
M(9?,F5T"4Z7H#<5$8IDSBP4G2Q'%1&*9,XOEA6SIOM8I)A++G%DL?[*F9Y]'
MI),YLTYH^O0L'%+*G%DI*(]RL'3T&DEFP2P9F$H%W>("268Q6MHR5#S%1))9
MC)F[A*6))+-@ELS3I."YYK. TRKL\RH@.PA+$KEFP>P:F!V$F,@U"V;7!/'M
MLW6-%+-@5@R.(!<4$^EFP:P;C)E23"2>!??$"@QT:3R>(O&DS.+!F+324R2>
ME%D\03Q^+#NAZJ#AI$@W*;-N<$"^1S&1;M(QIUB"3C)%RDG'G&0),>%<_ICI
M3=B^D7)29N5@S*!](_>D[%,P")-VZBER3\KLGI>2Q;WHJ[#!*&2*W),RN^=E
MS$&>=*$)<D_&[!Z Z>Z^I)C(/1FS>R!FT"%ER$(9LX4P)NV0,F2AC-E"\-D,
M2Q-9*&.VT,N8GY0.ID4R9*&,V4)D6.BNU?2N"W6A\:G1ZSTZ_97!-66O-N=_
MWU7Z1:L/D1S%1!;*7F^0;2\Z6*^M7#N2Z(OP&5NPRBA#%LI><\!MST_D> :7
MDKN[12?!LXDLE#%;Z!&F'X(15K6.TSV? 6:.+)0S6^@1YN.GDV(B"^7L&5"
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M*D==BD##XA)9J!QS/740%I?(0B7[-D^$2</B$EFHY%Z3 !=V!$T(6:CD7I,
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MJ=X.H+=3O1U ;Z=Z.X#>KGI8 M#;J=X.H+=3O1U ;Z=Z.X#>3O5V +V=ZNT
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M/MO?OO^Z_+I8WS!7IMO[C/'I+U!+ P04    "  U@%!6A'6;AV,"  !A.@
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MI3<_ 5!+ 0(4 Q0    ( #6 4%8'04UB@0   +$    0              "
M 0    !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ -8!05O)'PN'N
M*P(  !$              ( !KP   &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#
M%     @ -8!05IE<G",0!@  G"<  !,              ( !S $  'AL+W1H
M96UE+W1H96UE,2YX;6Q02P$"% ,4    "  U@%!6I3!-]^ (  "D2   &
M            @($-"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L! A0#
M%     @ -8!05LKJ$<)" @  R 4  !@              ("!(Q$  'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( #6 4%;CGF-@9P<  ',?
M   8              " @9L3  !X;"]W;W)K<VAE971S+W-H965T,RYX;6Q0
M2P$"% ,4    "  U@%!6RV* Z@P#  "O"0  &               @($X&P
M>&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ -8!05HY[U 9^
M!0  CA8  !@              ("!>AX  'AL+W=O<FMS:&5E=',O<VAE970U
M+GAM;%!+ 0(4 Q0    ( #6 4%;EB; &!@4  $\6   8              "
M@2XD  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4    "  U@%!6
MU2!&"@4#   C"0  &               @(%J*0  >&PO=V]R:W-H965T<R]S
M:&5E=#<N>&UL4$L! A0#%     @ -8!05FG@,J^^!0  6B(  !@
M     ("!I2P  'AL+W=O<FMS:&5E=',O<VAE970X+GAM;%!+ 0(4 Q0    (
M #6 4%:TW&D=CP(  +(&   8              " @9DR  !X;"]W;W)K<VAE
M971S+W-H965T.2YX;6Q02P$"% ,4    "  U@%!6%G(@F;\*  ")-0  &0
M            @(%>-0  >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4
M Q0    ( #6 4%8Q4<T<WB(  +EF   9              " @51   !X;"]W
M;W)K<VAE971S+W-H965T,3$N>&UL4$L! A0#%     @ -8!05JN+DF/S!0
M>0\  !D              ("!:6,  'AL+W=O<FMS:&5E=',O<VAE970Q,BYX
M;6Q02P$"% ,4    "  U@%!6QW\7J(H"  "1!0  &0              @(&3
M:0  >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    ( #6 4%9$
MA>3SY@,  ',)   9              " @51L  !X;"]W;W)K<VAE971S+W-H
M965T,30N>&UL4$L! A0#%     @ -8!05ANNO^ Z!P  .!(  !D
M     ("!<7   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"% ,4
M"  U@%!6ZBLJ;9\3  #D0@  &0              @('B=P  >&PO=V]R:W-H
M965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( #6 4%9818K_UP<  *@3   9
M              " @;B+  !X;"]W;W)K<VAE971S+W-H965T,3<N>&UL4$L!
M A0#%     @ -8!05E'$!%?P$0  DS<  !D              ("!QI,  'AL
M+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    "  U@%!6ZVHPHQP#
M   ?!P  &0              @('MI0  >&PO=V]R:W-H965T<R]S:&5E=#$Y
M+GAM;%!+ 0(4 Q0    ( #6 4%9.#8AB$1<  .)&   9              "
M@4"I  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%     @ -8!0
M5FB%61/0 @  ,08  !D              ("!B,   'AL+W=O<FMS:&5E=',O
M<VAE970R,2YX;6Q02P$"% ,4    "  U@%!6G3MTC+4$   !"P  &0
M        @(&/PP  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+ 0(4 Q0
M   ( #6 4%;:%M!.500  /$)   9              " @7O(  !X;"]W;W)K
M<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ -8!05@R, <&E!   1 L
M !D              ("!!\T  'AL+W=O<FMS:&5E=',O<VAE970R-"YX;6Q0
M2P$"% ,4    "  U@%!6M)U VW@#   '"   &0              @('CT0
M>&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( #6 4%8!(D5K
MK@L  ,,A   9              " @9+5  !X;"]W;W)K<VAE971S+W-H965T
M,C8N>&UL4$L! A0#%     @ -8!05FL!!^:F%0  NC8  !D
M ("!=^$  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4    "  U
M@%!68![0G*$-  !N*0  &0              @(%4]P  >&PO=V]R:W-H965T
M<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( #6 4%8K-EXT2B<  *.%   9
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M970S,RYX;6Q02P$"% ,4    "  U@%!6-X);?Y<"  "9!0  &0
M    @($=7@$ >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    (
M #6 4%8TY;QJ\@(  ,8&   9              " @>M@ 0!X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL4$L! A0#%     @ -8!05K': %F$!0  )@X  !D
M             ("!%&0! 'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6Q02P$"
M% ,4    "  U@%!6^O(85"(*  !C(@  &0              @('/:0$ >&PO
M=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( #6 4%;-5J4DR 4
M *P.   9              " @2AT 0!X;"]W;W)K<VAE971S+W-H965T,S@N
M>&UL4$L! A0#%     @ -8!05N7@O\NN"   !!8  !D              ("!
M)WH! 'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4    "  U@%!6
MX&FL].@"  !U!@  &0              @($,@P$ >&PO=V]R:W-H965T<R]S
M:&5E=#0P+GAM;%!+ 0(4 Q0    ( #6 4%:[&*IAZ0P  *8G   9
M      " @2N& 0!X;"]W;W)K<VAE971S+W-H965T-#$N>&UL4$L! A0#%
M  @ -8!05L2*@$<) P  #@<  !D              ("!2Y,! 'AL+W=O<FMS
M:&5E=',O<VAE970T,BYX;6Q02P$"% ,4    "  U@%!69*H5J#H#  #!!@
M&0              @(&+E@$ >&PO=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+
M 0(4 Q0    ( #6 4%:70.,"-@,  %4'   9              " @?R9 0!X
M;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ -8!05IP0%4OS
M!0  \@X  !D              ("!:9T! 'AL+W=O<FMS:&5E=',O<VAE970T
M-2YX;6Q02P$"% ,4    "  U@%!63"\=<#H6  #_.0  &0
M@(&3HP$ >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0    ( #6
M4%8?7,>E]P,  )T(   9              " @02Z 0!X;"]W;W)K<VAE971S
M+W-H965T-#<N>&UL4$L! A0#%     @ -8!05D2J9ME!"0  ,$@  !D
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M=#4R+GAM;%!+ 0(4 Q0    ( #6 4%:9#O%SJ@,  - 1   9
M  " @0G: 0!X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#%     @
M-8!05@5_'NV] @  H0<  !D              ("!ZMT! 'AL+W=O<FMS:&5E
M=',O<VAE970U-"YX;6Q02P$"% ,4    "  U@%!6UQ<D1DX&  "?,0  &0
M            @('>X $ >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4
M Q0    ( #6 4%9S$LRSM 0  "48   9              " @6/G 0!X;"]W
M;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ -8!05MRJVI(8!
MNQ<  !D              ("!3NP! 'AL+W=O<FMS:&5E=',O<VAE970U-RYX
M;6Q02P$"% ,4    "  U@%!6.K2+KU<"   )!@  &0              @(&=
M\ $ >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    ( #6 4%:G
M8*[0E 4  -D9   9              " @2OS 0!X;"]W;W)K<VAE971S+W-H
M965T-3DN>&UL4$L! A0#%     @ -8!05I;/?*SW"0  A6P  !D
M     ("!]O@! 'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( #6 4%;Y:\UEW@P  +*+   9              "
M@982 @!X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%     @ -8!0
M5M!A"\J9&0  RF0! !D              ("!JQ\" 'AL+W=O<FMS:&5E=',O
M<VAE970V-BYX;6Q02P$"% ,4    "  U@%!6&HA 9HT$  "H&@  &0
M        @(%[.0( >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+ 0(4 Q0
M   ( #6 4%8IK$^>:0(  &,&   9              " @3\^ @!X;"]W;W)K
M<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ -8!05H71CL]F P  9 P
M !D              ("!WT " 'AL+W=O<FMS:&5E=',O<VAE970V.2YX;6Q0
M2P$"% ,4    "  U@%!686W$%48%  !L'@  &0              @(%\1 (
M>&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( #6 4%;LO5=Q
MF H  %UG   9              " @?E) @!X;"]W;W)K<VAE971S+W-H965T
M-S$N>&UL4$L! A0#%     @ -8!05H: X4DF!0  \Q,  !D
M ("!R%0" 'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4    "  U
M@%!6\#:;(6P#  "B"P  &0              @($E6@( >&PO=V]R:W-H965T
M<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( #6 4%; RJ:7! ,  "0)   9
M          " @<A= @!X;"]W;W)K<VAE971S+W-H965T-S0N>&UL4$L! A0#
M%     @ -8!05G*B+U4Y @  *@4  !D              ("! V$" 'AL+W=O
M<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    "  U@%!6Q*G&=L8%   8
M)   &0              @(%S8P( >&PO=V]R:W-H965T<R]S:&5E=#<V+GAM
M;%!+ 0(4 Q0    ( #6 4%8!C+WAKP0   D5   9              " @7!I
M @!X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @ -8!05BL1
M!YE=!   P!4  !D              ("!5FX" 'AL+W=O<FMS:&5E=',O<VAE
M970W."YX;6Q02P$"% ,4    "  U@%!6&P3FK=L"  #D!P  &0
M    @('J<@( >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4 Q0    (
M #6 4%9<)%!D5@T  "AC   9              " @?QU @!X;"]W;W)K<VAE
M971S+W-H965T.# N>&UL4$L! A0#%     @ -8!05M/HN\6U!   *1D  !D
M             ("!B8," 'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6Q02P$"
M% ,4    "  U@%!6+],4 "D#  !8"P  &0              @(%UB ( >&PO
M=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( #6 4%83P^3>E (
M )T&   9              " @=6+ @!X;"]W;W)K<VAE971S+W-H965T.#,N
M>&UL4$L! A0#%     @ -8!05LI/ D7Y @  S@P  !D              ("!
MH(X" 'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4    "  U@%!6
MK0WM*! *  !J<   &0              @('0D0( >&PO=V]R:W-H965T<R]S
M:&5E=#@U+GAM;%!+ 0(4 Q0    ( #6 4%8CPC7W;@(  ((&   9
M      " @1>< @!X;"]W;W)K<VAE971S+W-H965T.#8N>&UL4$L! A0#%
M  @ -8!05F#?;3@T!   ^1(  !D              ("!O)X" 'AL+W=O<FMS
M:&5E=',O<VAE970X-RYX;6Q02P$"% ,4    "  U@%!6IEVTM5\$  #P&@
M&0              @($GHP( >&PO=V]R:W-H965T<R]S:&5E=#@X+GAM;%!+
M 0(4 Q0    ( #6 4%9X W.BF 4   $B   9              " @;VG @!X
M;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ -8!05GGA=L&0
M @  R08  !D              ("!C*T" 'AL+W=O<FMS:&5E=',O<VAE970Y
M,"YX;6Q02P$"% ,4    "  U@%!6K0'KS*D#  #R"P  &0
M@(%3L ( >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0    ( #6
M4%9: LK81P(  .X$   9              " @3.T @!X;"]W;W)K<VAE971S
M+W-H965T.3(N>&UL4$L! A0#%     @ -8!05HIH9R M"0  4D(  !D
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M=#DW+GAM;%!+ 0(4 Q0    ( #6 4%9@TE*K43\  "WI @ 9
M  " @3/4 @!X;"]W;W)K<VAE971S+W-H965T.3@N>&UL4$L! A0#%     @
M-8!05C(JZQ"P$0  99H  !D              ("!NQ,# 'AL+W=O<FMS:&5E
M=',O<VAE970Y.2YX;6Q02P$"% ,4    "  U@%!6&+"^+)H6  !O0P$ &@
M            @(&B)0, >&PO=V]R:W-H965T<R]S:&5E=#$P,"YX;6Q02P$"
M% ,4    "  U@%!6;,W+AJ4/  #*"0$ &@              @(%T/ , >&PO
M=V]R:W-H965T<R]S:&5E=#$P,2YX;6Q02P$"% ,4    "  U@%!651S;2M4#
M  !V%@  &@              @(%13 , >&PO=V]R:W-H965T<R]S:&5E=#$P
M,BYX;6Q02P$"% ,4    "  U@%!6W,!4Z;X&   <.0  &@
M@(%>4 , >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4    "  U
M@%!6/*& *YP#  !K&0  #0              @ %45P, >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( #6 4%:7BKL<P    !,"   +              "  1M;
M P!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( #6 4%;W,N8+"@<  ,I#   /
M          "  01< P!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  U@%!6
M"DA2;NL"  "&/   &@              @ $[8P, >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    "  U@%!6A'6;AV,"  !A.@  $P
M        @ %>9@, 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     ;P!O (0>
(  #R: ,    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1040</ContextCount>
  <ElementCount>602</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>235</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>13</UnitCount>
  <MyReports>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>0000003 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>0000004 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>0000005 - Statement - Consolidated Statements of Earnings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEarnings</Role>
      <ShortName>Consolidated Statements of Earnings</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>0000006 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>0000007 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>0000008 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>0000009 - Statement - Consolidated Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>0000010 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>0000011 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>0000012 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities</Role>
      <ShortName>Cash, Cash Equivalents and Current Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>0000013 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>0000014 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PropertyPlantandEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>0000015 - Disclosure - Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwill</Role>
      <ShortName>Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>0000016 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>0000017 - Disclosure - Borrowings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Borrowings</Role>
      <ShortName>Borrowings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>0000018 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>0000019 - Disclosure - Employee Related Obligations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EmployeeRelatedObligations</Role>
      <ShortName>Employee Related Obligations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>0000020 - Disclosure - Pensions and Other Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlans</Role>
      <ShortName>Pensions and Other Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>0000021 - Disclosure - Savings Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SavingsPlan</Role>
      <ShortName>Savings Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>0000022 - Disclosure - Capital and Treasury Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CapitalandTreasuryStock</Role>
      <ShortName>Capital and Treasury Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>0000023 - Disclosure - Accumulated Other Comprehensive Income (Loss)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>0000024 - Disclosure - International Currency Translation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InternationalCurrencyTranslation</Role>
      <ShortName>International Currency Translation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>0000025 - Disclosure - Earnings Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShare</Role>
      <ShortName>Earnings Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>0000026 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>0000027 - Disclosure - Segments of Business and Geographic Areas</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</Role>
      <ShortName>Segments of Business and Geographic Areas</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>0000028 - Disclosure - Acquisitions and Divestitures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestitures</Role>
      <ShortName>Acquisitions and Divestitures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>0000029 - Disclosure - Legal Proceedings</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedings</Role>
      <ShortName>Legal Proceedings</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>0000030 - Disclosure - Restructuring</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/Restructuring</Role>
      <ShortName>Restructuring</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>0000031 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>0000032 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>0000033 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables</Role>
      <ShortName>Cash, Cash Equivalents and Current Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>0000034 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Inventories</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>0000035 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PropertyPlantandEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PropertyPlantandEquipment</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>0000036 - Disclosure - Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillTables</Role>
      <ShortName>Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IntangibleAssetsandGoodwill</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>0000037 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/FairValueMeasurements</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>0000038 - Disclosure - Borrowings (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/BorrowingsTables</Role>
      <ShortName>Borrowings (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Borrowings</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>0000039 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/IncomeTaxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>0000040 - Disclosure - Employee Related Obligations (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EmployeeRelatedObligationsTables</Role>
      <ShortName>Employee Related Obligations (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EmployeeRelatedObligations</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>0000041 - Disclosure - Pensions and Other Benefit Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansTables</Role>
      <ShortName>Pensions and Other Benefit Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/PensionsandOtherBenefitPlans</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>0000042 - Disclosure - Capital and Treasury Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CapitalandTreasuryStockTables</Role>
      <ShortName>Capital and Treasury Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/CapitalandTreasuryStock</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>0000043 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>0000044 - Disclosure - Earnings Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareTables</Role>
      <ShortName>Earnings Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/EarningsPerShare</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>0000045 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>0000046 - Disclosure - Segments of Business and Geographic Areas (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables</Role>
      <ShortName>Segments of Business and Geographic Areas (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>0000047 - Disclosure - Restructuring (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringTables</Role>
      <ShortName>Restructuring (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.jnj.com/role/Restructuring</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>0000048 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>0000049 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>0000050 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails</Role>
      <ShortName>Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>0000051 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails</Role>
      <ShortName>Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>0000052 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/InventoriesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>0000053 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails</Role>
      <ShortName>Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>0000054 - Disclosure - Property, Plant and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails</Role>
      <ShortName>Property, Plant and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>0000055 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>0000056 - Disclosure - Intangible Assets and Goodwill - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>0000057 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>0000058 - Disclosure - Intangible Assets and Goodwill - Estimated Amortization of Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails</Role>
      <ShortName>Intangible Assets and Goodwill - Estimated Amortization of Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>0000059 - Disclosure - Fair Value Measurements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails</Role>
      <ShortName>Fair Value Measurements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>0000060 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Derivative Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>0000061 - Disclosure - Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>0000062 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>0000063 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>0000064 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>0000065 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>0000066 - Disclosure - Borrowings - Schedule of Long-term Debt Instruments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails</Role>
      <ShortName>Borrowings - Schedule of Long-term Debt Instruments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>0000067 - Disclosure - Borrowings - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/BorrowingsNarrativeDetails</Role>
      <ShortName>Borrowings - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>0000068 - Disclosure - Borrowings - Aggregate Maturities of Long Term Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails</Role>
      <ShortName>Borrowings - Aggregate Maturities of Long Term Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>0000069 - Disclosure - Income Taxes - Provision for Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Provision for Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>0000070 - Disclosure - Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails</Role>
      <ShortName>Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>0000071 - Disclosure - Income Taxes - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesNarrativeDetails</Role>
      <ShortName>Income Taxes - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>0000072 - Disclosure - Income Taxes - Temporary Differences and Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails</Role>
      <ShortName>Income Taxes - Temporary Differences and Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>0000073 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>0000074 - Disclosure - Employee Related Obligations - Employee Related Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails</Role>
      <ShortName>Employee Related Obligations - Employee Related Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>0000075 - Disclosure - Employee Related Obligations - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails</Role>
      <ShortName>Employee Related Obligations - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>0000076 - Disclosure - Pensions and Other Benefit Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>0000077 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>0000078 - Disclosure - Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>0000079 - Disclosure - Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>0000080 - Disclosure - Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>0000081 - Disclosure - Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>0000082 - Disclosure - Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>0000083 - Disclosure - Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>0000084 - Disclosure - Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>0000085 - Disclosure - Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails</Role>
      <ShortName>Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>0000086 - Disclosure - Savings Plan - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SavingsPlanNarrativeDetails</Role>
      <ShortName>Savings Plan - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>0000087 - Disclosure - Capital and Treasury Stock - Changes in Treasury Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails</Role>
      <ShortName>Capital and Treasury Stock - Changes in Treasury Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>87</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>0000088 - Disclosure - Capital and Treasury Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails</Role>
      <ShortName>Capital and Treasury Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>88</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>0000089 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Accumulated Other Comprehensive Income (Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables</ParentRole>
      <Position>89</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>0000090 - Disclosure - International Currency Translation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails</Role>
      <ShortName>International Currency Translation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>0000091 - Disclosure - Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails</Role>
      <ShortName>Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>0000092 - Disclosure - Earnings Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/EarningsPerShareNarrativeDetails</Role>
      <ShortName>Earnings Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>0000093 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables</ParentRole>
      <Position>93</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>0000094 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>0000095 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>0000096 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>0000097 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails</Role>
      <ShortName>Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>0000098 - Disclosure - Segments of Business and Geographic Areas - Sales by Segment of Business (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Sales by Segment of Business (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>0000099 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails</Role>
      <ShortName>Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>0000100 - Disclosure - Acquisitions and Divestitures - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails</Role>
      <ShortName>Acquisitions and Divestitures - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>0000101 - Disclosure - Legal Proceedings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/LegalProceedingsDetails</Role>
      <ShortName>Legal Proceedings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.jnj.com/role/LegalProceedings</ParentRole>
      <Position>101</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>0000102 - Disclosure - Restructuring - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringNarrativeDetails</Role>
      <ShortName>Restructuring - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="jnj-20230101.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>0000103 - Disclosure - Restructuring - Summary of Severance Charges and Associated Spending (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails</Role>
      <ShortName>Restructuring - Summary of Severance Charges and Associated Spending (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="jnj-20230101.htm">jnj-20230101.htm</File>
    <File>ex101-jjexcessplanx2022res.htm</File>
    <File>ex21-subsidiariesxform10xk.htm</File>
    <File>ex23-pwcconsentxform10xkx2.htm</File>
    <File>ex311-302certofceoxform10x.htm</File>
    <File>ex312-302certofcfoxform10x.htm</File>
    <File>ex321-906certofceoxform10x.htm</File>
    <File>ex322-906certofcfoxform10x.htm</File>
    <File>jnj-20230101.xsd</File>
    <File>jnj-20230101_cal.xml</File>
    <File>jnj-20230101_def.xml</File>
    <File>jnj-20230101_lab.xml</File>
    <File>jnj-20230101_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>jnj-20230101_g1.jpg</File>
    <File>jnj-20230101_g10.jpg</File>
    <File>jnj-20230101_g11.jpg</File>
    <File>jnj-20230101_g2.jpg</File>
    <File>jnj-20230101_g3.jpg</File>
    <File>jnj-20230101_g4.jpg</File>
    <File>jnj-20230101_g5.jpg</File>
    <File>jnj-20230101_g6.jpg</File>
    <File>jnj-20230101_g7.jpg</File>
    <File>jnj-20230101_g8.jpg</File>
    <File>jnj-20230101_g9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="2460">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="48">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>134
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "jnj-20230101.htm": {
   "axisCustom": 0,
   "axisStandard": 47,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 2460,
    "http://xbrl.sec.gov/dei/2022": 48
   },
   "contextCount": 1040,
   "dts": {
    "calculationLink": {
     "local": [
      "jnj-20230101_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "jnj-20230101_def.xml"
     ]
    },
    "inline": {
     "local": [
      "jnj-20230101.htm"
     ]
    },
    "labelLink": {
     "local": [
      "jnj-20230101_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "jnj-20230101_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "jnj-20230101.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 1055,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 8,
    "http://xbrl.sec.gov/dei/2022": 4,
    "total": 12
   },
   "keyCustom": 101,
   "keyStandard": 501,
   "memberCustom": 141,
   "memberStandard": 79,
   "nsprefix": "jnj",
   "nsuri": "http://www.jnj.com/20230101",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0000001 - Document - Cover Page",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.jnj.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000010 - Statement - Consolidated Statements of Cash Flows",
     "menuCat": "Statements",
     "order": "10",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000100 - Disclosure - Acquisitions and Divestitures - Narrative (Details)",
     "menuCat": "Details",
     "order": "100",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
     "shortName": "Acquisitions and Divestitures - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationConsiderationTransferred1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000101 - Disclosure - Legal Proceedings (Details)",
     "menuCat": "Details",
     "order": "101",
     "role": "http://www.jnj.com/role/LegalProceedingsDetails",
     "shortName": "Legal Proceedings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LossContingencyPendingClaimsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "claim",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000102 - Disclosure - Restructuring - Narrative (Details)",
     "menuCat": "Details",
     "order": "102",
     "role": "http://www.jnj.com/role/RestructuringNarrativeDetails",
     "shortName": "Restructuring - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i95e5b2037fbd445ea91d492ad3152fe5_I20230101",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedCostCostIncurredToDate1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000103 - Disclosure - Restructuring - Summary of Severance Charges and Associated Spending (Details)",
     "menuCat": "Details",
     "order": "103",
     "role": "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails",
     "shortName": "Restructuring - Summary of Severance Charges and Associated Spending (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i3dbe54c0baea4b92b0175ecdc2c32d60_D20210104-20220102",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReservePeriodIncreaseDecrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000011 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000012 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities",
     "shortName": "Cash, Cash Equivalents and Current Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000013 - Disclosure - Inventories",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.jnj.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000014 - Disclosure - Property, Plant and Equipment",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.jnj.com/role/PropertyPlantandEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000015 - Disclosure - Intangible Assets and Goodwill",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwill",
     "shortName": "Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000016 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.jnj.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000017 - Disclosure - Borrowings",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.jnj.com/role/Borrowings",
     "shortName": "Borrowings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000018 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.jnj.com/role/IncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000019 - Disclosure - Employee Related Obligations",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.jnj.com/role/EmployeeRelatedObligations",
     "shortName": "Employee Related Obligations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CompensationRelatedCostsGeneralTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "false",
     "longName": "0000002 - Document - Audit Information",
     "menuCat": "Cover",
     "order": "2",
     "role": "http://www.jnj.com/role/AuditInformation",
     "shortName": "Audit Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:AuditorName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000020 - Disclosure - Pensions and Other Benefit Plans",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlans",
     "shortName": "Pensions and Other Benefit Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SavingsPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000021 - Disclosure - Savings Plan",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.jnj.com/role/SavingsPlan",
     "shortName": "Savings Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SavingsPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000022 - Disclosure - Capital and Treasury Stock",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.jnj.com/role/CapitalandTreasuryStock",
     "shortName": "Capital and Treasury Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000023 - Disclosure - Accumulated Other Comprehensive Income (Loss)",
     "menuCat": "Notes",
     "order": "23",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss",
     "shortName": "Accumulated Other Comprehensive Income (Loss)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000024 - Disclosure - International Currency Translation",
     "menuCat": "Notes",
     "order": "24",
     "role": "http://www.jnj.com/role/InternationalCurrencyTranslation",
     "shortName": "International Currency Translation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000025 - Disclosure - Earnings Per Share",
     "menuCat": "Notes",
     "order": "25",
     "role": "http://www.jnj.com/role/EarningsPerShare",
     "shortName": "Earnings Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000026 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements",
     "menuCat": "Notes",
     "order": "26",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000027 - Disclosure - Segments of Business and Geographic Areas",
     "menuCat": "Notes",
     "order": "27",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas",
     "shortName": "Segments of Business and Geographic Areas",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000028 - Disclosure - Acquisitions and Divestitures",
     "menuCat": "Notes",
     "order": "28",
     "role": "http://www.jnj.com/role/AcquisitionsandDivestitures",
     "shortName": "Acquisitions and Divestitures",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000029 - Disclosure - Legal Proceedings",
     "menuCat": "Notes",
     "order": "29",
     "role": "http://www.jnj.com/role/LegalProceedings",
     "shortName": "Legal Proceedings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LegalMattersAndContingenciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000003 - Statement - Consolidated Balance Sheets",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000030 - Disclosure - Restructuring",
     "menuCat": "Notes",
     "order": "30",
     "role": "http://www.jnj.com/role/Restructuring",
     "shortName": "Restructuring",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000031 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "31",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000032 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000033 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "33",
     "role": "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables",
     "shortName": "Cash, Cash Equivalents and Current Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000034 - Disclosure - Inventories (Tables)",
     "menuCat": "Tables",
     "order": "34",
     "role": "http://www.jnj.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000035 - Disclosure - Property, Plant and Equipment (Tables)",
     "menuCat": "Tables",
     "order": "35",
     "role": "http://www.jnj.com/role/PropertyPlantandEquipmentTables",
     "shortName": "Property, Plant and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000036 - Disclosure - Intangible Assets and Goodwill (Tables)",
     "menuCat": "Tables",
     "order": "36",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables",
     "shortName": "Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000037 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "37",
     "role": "http://www.jnj.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000038 - Disclosure - Borrowings (Tables)",
     "menuCat": "Tables",
     "order": "38",
     "role": "http://www.jnj.com/role/BorrowingsTables",
     "shortName": "Borrowings (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000039 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "39",
     "role": "http://www.jnj.com/role/IncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000004 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:EmployeeRelatedObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000040 - Disclosure - Employee Related Obligations (Tables)",
     "menuCat": "Tables",
     "order": "40",
     "role": "http://www.jnj.com/role/EmployeeRelatedObligationsTables",
     "shortName": "Employee Related Obligations (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:EmployeeRelatedObligationsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000041 - Disclosure - Pensions and Other Benefit Plans (Tables)",
     "menuCat": "Tables",
     "order": "41",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables",
     "shortName": "Pensions and Other Benefit Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ChangesInTreasuryStockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000042 - Disclosure - Capital and Treasury Stock (Tables)",
     "menuCat": "Tables",
     "order": "42",
     "role": "http://www.jnj.com/role/CapitalandTreasuryStockTables",
     "shortName": "Capital and Treasury Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:ChangesInTreasuryStockTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000043 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Tables)",
     "menuCat": "Tables",
     "order": "43",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000044 - Disclosure - Earnings Per Share (Tables)",
     "menuCat": "Tables",
     "order": "44",
     "role": "http://www.jnj.com/role/EarningsPerShareTables",
     "shortName": "Earnings Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000045 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)",
     "menuCat": "Tables",
     "order": "45",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000046 - Disclosure - Segments of Business and Geographic Areas (Tables)",
     "menuCat": "Tables",
     "order": "46",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables",
     "shortName": "Segments of Business and Geographic Areas (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "jnj:SalesBySegmentOfBusinessTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000047 - Disclosure - Restructuring (Tables)",
     "menuCat": "Tables",
     "order": "47",
     "role": "http://www.jnj.com/role/RestructuringTables",
     "shortName": "Restructuring (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000048 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-2",
      "first": true,
      "lang": "en-US",
      "name": "jnj:NumberOfEmployeesEngagedInCompanyActivitiesWorldwide",
      "reportCount": 1,
      "unique": true,
      "unitRef": "employee",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "icc105f8c066041479b85014a44b4f246_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000049 - Disclosure - Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
     "shortName": "Summary of Significant Accounting Policies - Estimated Useful Lives of Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "jnj:EstimatedUsefulLivesOfAssetsTableTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "icc105f8c066041479b85014a44b4f246_D20220103-20230101",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000005 - Statement - Consolidated Statements of Earnings",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
     "shortName": "Consolidated Statements of Earnings",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GrossProfit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000050 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails",
     "shortName": "Cash, Cash Equivalents and Current Marketable Securities - Cash and Cash Equivalent Composition (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i67038bc29ba6469cb0cb5ca65068f855_I20230101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:HeldToMaturitySecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000051 - Disclosure - Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails",
     "shortName": "Cash, Cash Equivalents and Current Marketable Securities - Contractual Maturities of Available for Sale Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000052 - Disclosure - Inventories (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.jnj.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000053 - Disclosure - Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
     "shortName": "Property, Plant and Equipment - Property, Plant and Equipment at Cost and Accumulated Depreciation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000054 - Disclosure - Property, Plant and Equipment - Narrative (Details)",
     "menuCat": "Details",
     "order": "54",
     "role": "http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails",
     "shortName": "Property, Plant and Equipment - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000055 - Disclosure - Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details)",
     "menuCat": "Details",
     "order": "55",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill - Schedule of Intangible Assets and Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "ibe67d998d2674637a9c218fa218dce7d_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000056 - Disclosure - Intangible Assets and Goodwill - Goodwill (Details)",
     "menuCat": "Details",
     "order": "56",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
     "shortName": "Intangible Assets and Goodwill - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i4f147e1dd45545d3abb1795f5f7086da_D20221222-20221222",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000057 - Disclosure - Intangible Assets and Goodwill - Narrative (Details)",
     "menuCat": "Details",
     "order": "57",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
     "shortName": "Intangible Assets and Goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000058 - Disclosure - Intangible Assets and Goodwill - Estimated Amortization of Intangible Assets (Details)",
     "menuCat": "Details",
     "order": "58",
     "role": "http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails",
     "shortName": "Intangible Assets and Goodwill - Estimated Amortization of Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000059 - Disclosure - Fair Value Measurements - Narrative (Details)",
     "menuCat": "Details",
     "order": "59",
     "role": "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
     "shortName": "Fair Value Measurements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AociLossCashFlowHedgeCumulativeGainLossAfterTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000006 - Statement - Consolidated Statements of Comprehensive Income",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000060 - Disclosure - Fair Value Measurements - Summary of Derivative Activity (Details)",
     "menuCat": "Details",
     "order": "60",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
     "shortName": "Fair Value Measurements - Summary of Derivative Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "ife931fffad564c719966395e598010a2_D20220103-20230101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeExcludedComponentGainLossRecognizedInEarnings",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000061 - Disclosure - Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)",
     "menuCat": "Details",
     "order": "61",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails",
     "shortName": "Fair Value Measurements - Schedule of Derivatives Recorded in Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i8ef91f5dac5a431b8628840f5ad90267_I20230101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DerivativeFairValueOfDerivativeLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i237858b83a9d4cf297ac85f26bb8ae97_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000062 - Disclosure - Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "menuCat": "Details",
     "order": "62",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Derivatives not Designated as Hedging Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i237858b83a9d4cf297ac85f26bb8ae97_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeGainLossOnDerivativeNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000063 - Disclosure - Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "menuCat": "Details",
     "order": "63",
     "role": "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
     "shortName": "Fair Value Measurements - Schedule of Effect of Net Investment Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "jnj:EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000064 - Disclosure - Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "menuCat": "Details",
     "order": "64",
     "role": "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
     "shortName": "Fair Value Measurements - Summary of Activity Related to Equity Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i8bb50a86cda447408f1cd7369b0d9418_I20230101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000065 - Disclosure - Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "menuCat": "Details",
     "order": "65",
     "role": "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
     "shortName": "Fair Value Measurements - Financial Assets and Liabilities at Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeInstrumentsInHedgesAssetsAtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtInstrumentInterestRateEffectivePercentage",
      "reportCount": 1,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000066 - Disclosure - Borrowings - Schedule of Long-term Debt Instruments (Details)",
     "menuCat": "Details",
     "order": "66",
     "role": "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
     "shortName": "Borrowings - Schedule of Long-term Debt Instruments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-8",
      "lang": "en-US",
      "name": "jnj:ExcessOfCarryingValueOverFairValueOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i4f53b7ce48b043d2944b5ea32ee20998_I20221130",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000067 - Disclosure - Borrowings - Narrative (Details)",
     "menuCat": "Details",
     "order": "67",
     "role": "http://www.jnj.com/role/BorrowingsNarrativeDetails",
     "shortName": "Borrowings - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i4f53b7ce48b043d2944b5ea32ee20998_I20221130",
      "decimals": "-9",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000068 - Disclosure - Borrowings - Aggregate Maturities of Long Term Obligations (Details)",
     "menuCat": "Details",
     "order": "68",
     "role": "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails",
     "shortName": "Borrowings - Aggregate Maturities of Long Term Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000069 - Disclosure - Income Taxes - Provision for Income Taxes (Details)",
     "menuCat": "Details",
     "order": "69",
     "role": "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails",
     "shortName": "Income Taxes - Provision for Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000007 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000070 - Disclosure - Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)",
     "menuCat": "Details",
     "order": "70",
     "role": "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails",
     "shortName": "Income Taxes - Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000071 - Disclosure - Income Taxes - Narrative (Details)",
     "menuCat": "Details",
     "order": "71",
     "role": "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
     "shortName": "Income Taxes - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "jnj:EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000072 - Disclosure - Income Taxes - Temporary Differences and Carryforwards (Details)",
     "menuCat": "Details",
     "order": "72",
     "role": "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails",
     "shortName": "Income Taxes - Temporary Differences and Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "ibe67d998d2674637a9c218fa218dce7d_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000073 - Disclosure - Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "menuCat": "Details",
     "order": "73",
     "role": "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails",
     "shortName": "Income Taxes - Summary of Activity Related to Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:SummaryOfIncomeTaxContingenciesTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "jnj:EmployeeRelatedObligationsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000074 - Disclosure - Employee Related Obligations - Employee Related Obligations (Details)",
     "menuCat": "Details",
     "order": "74",
     "role": "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails",
     "shortName": "Employee Related Obligations - Employee Related Obligations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "jnj:EmployeeRelatedObligationsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000075 - Disclosure - Employee Related Obligations - Narrative (Details)",
     "menuCat": "Details",
     "order": "75",
     "role": "http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails",
     "shortName": "Employee Related Obligations - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000076 - Disclosure - Pensions and Other Benefit Plans - Narrative (Details)",
     "menuCat": "Details",
     "order": "76",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
     "shortName": "Pensions and Other Benefit Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "jnj:PercentageOfCorridorOfGreaterOfMarketValueOfAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetFundedStatusTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "iacf23778894f4cb882f12ee101a37225_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000077 - Disclosure - Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "menuCat": "Details",
     "order": "77",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
     "shortName": "Pensions and Other Benefit Plans - Components of Net Periodic Benefit Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetBenefitCostsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "iacf23778894f4cb882f12ee101a37225_D20220103-20230101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "iacf23778894f4cb882f12ee101a37225_D20220103-20230101",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000078 - Disclosure - Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)",
     "menuCat": "Details",
     "order": "78",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
     "shortName": "Pensions and Other Benefit Plans - Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "iacf23778894f4cb882f12ee101a37225_D20220103-20230101",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000079 - Disclosure - Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)",
     "menuCat": "Details",
     "order": "79",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails",
     "shortName": "Pensions and Other Benefit Plans - Assumed Health Care Cost Trend Rates (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "ic330177c89fd42f9a9a64f7236279ef9_I20191229",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000008 - Statement - Consolidated Statements of Equity",
     "menuCat": "Statements",
     "order": "8",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "ie0d81a2faf2847ea921dc2fc7b6a23ce_I20191229",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000080 - Disclosure - Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details)",
     "menuCat": "Details",
     "order": "80",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails",
     "shortName": "Pensions and Other Benefit Plans - Schedule of Net Funded Status (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetFundedStatusTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "iacf23778894f4cb882f12ee101a37225_D20220103-20230101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i1330068050ee43c89fd0edf712d3cd33_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000081 - Disclosure - Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)",
     "menuCat": "Details",
     "order": "81",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
     "shortName": "Pensions and Other Benefit Plans - Information Related to the Benefit Obligation and the Fair Value of Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "jnj:InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i1330068050ee43c89fd0edf712d3cd33_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000082 - Disclosure - Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)",
     "menuCat": "Details",
     "order": "82",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
     "shortName": "Pensions and Other Benefit Plans - Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000083 - Disclosure - Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)",
     "menuCat": "Details",
     "order": "83",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails",
     "shortName": "Pensions and Other Benefit Plans - Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "jnj:ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "jnj:DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000084 - Disclosure - Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)",
     "menuCat": "Details",
     "order": "84",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
     "shortName": "Pensions and Other Benefit Plans - Company' Retirement Plan Asset Allocation and Target Allocations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNetFundedStatusTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i1a8e9e2a78a24252baa5c99c0cb8f5d6_I20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000085 - Disclosure - Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details)",
     "menuCat": "Details",
     "order": "85",
     "role": "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
     "shortName": "Pensions and Other Benefit Plans - Schedule of Defined Benefit Plans Disclosures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i44bda01bf133404387afaead8b97a718_I20230101",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000086 - Disclosure - Savings Plan - Narrative (Details)",
     "menuCat": "Details",
     "order": "86",
     "role": "http://www.jnj.com/role/SavingsPlanNarrativeDetails",
     "shortName": "Savings Plan - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "ibe67d998d2674637a9c218fa218dce7d_I20220102",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockShares",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000087 - Disclosure - Capital and Treasury Stock - Changes in Treasury Stock (Details)",
     "menuCat": "Details",
     "order": "87",
     "role": "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
     "shortName": "Capital and Treasury Stock - Changes in Treasury Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "jnj:ChangesInTreasuryStockTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "ic330177c89fd42f9a9a64f7236279ef9_I20191229",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:TreasuryStockShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000088 - Disclosure - Capital and Treasury Stock - Narrative (Details)",
     "menuCat": "Details",
     "order": "88",
     "role": "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
     "shortName": "Capital and Treasury Stock - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesIssued",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "ib5daa03d1e6943aea8f1c79f2a1c4a43_I20210103",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "ibe67d998d2674637a9c218fa218dce7d_I20220102",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000089 - Disclosure - Accumulated Other Comprehensive Income (Loss) (Details)",
     "menuCat": "Details",
     "order": "89",
     "role": "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
     "shortName": "Accumulated Other Comprehensive Income (Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i998292a4720542fb97323e8a21027018_I20191229",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockDividendsPerShareCashPaid",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "0000009 - Statement - Consolidated Statements of Equity (Parenthetical)",
     "menuCat": "Statements",
     "order": "9",
     "role": "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical",
     "shortName": "Consolidated Statements of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000090 - Disclosure - International Currency Translation - Narrative (Details)",
     "menuCat": "Details",
     "order": "90",
     "role": "http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails",
     "shortName": "International Currency Translation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyTransactionGainLossBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareBasic",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000091 - Disclosure - Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)",
     "menuCat": "Details",
     "order": "91",
     "role": "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails",
     "shortName": "Earnings Per Share - Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-5",
      "lang": "en-US",
      "name": "jnj:PotentialSharesExercisableUnderStockOptionPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000092 - Disclosure - Earnings Per Share - Narrative (Details)",
     "menuCat": "Details",
     "order": "92",
     "role": "http://www.jnj.com/role/EarningsPerShareNarrativeDetails",
     "shortName": "Earnings Per Share - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "ie81818c16c5a49bd9fa96f84fb849ab8_D20191230-20210103",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "jnj:NumberOfStockBasedCompensationPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "stockbasedcompensationplans",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000093 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)",
     "menuCat": "Details",
     "order": "93",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "0",
      "first": true,
      "lang": "en-US",
      "name": "jnj:NumberOfStockBasedCompensationPlans",
      "reportCount": 1,
      "unique": true,
      "unitRef": "stockbasedcompensationplans",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000094 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)",
     "menuCat": "Details",
     "order": "94",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements - Schedule Valuation Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "4",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "ibe67d998d2674637a9c218fa218dce7d_I20220102",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000095 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details)",
     "menuCat": "Details",
     "order": "95",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "ic330177c89fd42f9a9a64f7236279ef9_I20191229",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000096 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details)",
     "menuCat": "Details",
     "order": "96",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Options Outstanding (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i5b376816a5e84e09b89d79bed596a4a7_I20230101",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i6bc0d59a1f134f84a89b363a070d1183_I20220102",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000097 - Disclosure - Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)",
     "menuCat": "Details",
     "order": "97",
     "role": "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails",
     "shortName": "Common Stock, Stock Option Plans and Stock Compensation Agreements - Summary of Restricted Share Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i6bc0d59a1f134f84a89b363a070d1183_I20220102",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000098 - Disclosure - Segments of Business and Geographic Areas - Sales by Segment of Business (Details)",
     "menuCat": "Details",
     "order": "98",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
     "shortName": "Segments of Business and Geographic Areas - Sales by Segment of Business (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "3",
      "lang": "en-US",
      "name": "jnj:PercentageChangeInSalesBySegmentOfBusiness",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i0535b75a91b0440fba341aa27ca7ca13_D20220103-20230101",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "0000099 - Disclosure - Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)",
     "menuCat": "Details",
     "order": "99",
     "role": "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
     "shortName": "Segments of Business and Geographic Areas - Schedule of Segment Reporting Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "jnj-20230101.htm",
      "contextRef": "i6cf17b4823de48eea6f3c3ee4a75cc88_D20210104-20220102",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:ResultsOfOperationsIncomeBeforeIncomeTaxes",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 235,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "CHINA"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States",
        "verboseLabel": "U.S. Plans"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r936",
      "r937",
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r936",
      "r937",
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r936",
      "r937",
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r936",
      "r937",
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]",
        "terseLabel": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]",
        "terseLabel": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r939"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r940"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r934"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r941"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r936",
      "r937",
      "r938"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r933"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r935"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "jnj_A0.250NotesDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.250% Notes Due 2022 [Member]",
        "label": "0.250% Notes Due 2022 [Member]",
        "terseLabel": "0.250% Notes due 2022 (1B Euro 1.1311)(3)"
       }
      }
     },
     "localname": "A0.250NotesDue2022Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A0.650NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.650% Notes Due 2024 [Member]",
        "label": "0.650% Notes Due 2024 [Member]",
        "terseLabel": "0.650% Notes due 2024 (750MM Euro 1.0651)(2)/(750MM Euro 1.1311)(3)",
        "verboseLabel": "0.650% Notes Due May 2024"
       }
      }
     },
     "localname": "A0.650NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A055NotesDue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.55% Notes due 2025",
        "label": "0.55% Notes due 2025 [Member]",
        "terseLabel": "0.55% Notes due 2025"
       }
      }
     },
     "localname": "A055NotesDue2025Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A095NotesDue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "0.95% Notes due 2027",
        "label": "0.95% Notes due 2027 [Member]",
        "terseLabel": "0.95% Notes due 2027"
       }
      }
     },
     "localname": "A095NotesDue2027Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.150NotesDue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.150% Notes Due 2028 [Member]",
        "label": "1.150% Notes Due 2028 [Member]",
        "terseLabel": "1.150% Notes due 2028 (750MM Euro 1.0651)(2)/(750MM Euro 1.1311)(3)",
        "verboseLabel": "1.150% Notes Due November 2028"
       }
      }
     },
     "localname": "A1.150NotesDue2028Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A1.650NotesDue2035Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.650% Notes Due 2035 [Member]",
        "label": "1.650% Notes Due 2035 [Member]",
        "terseLabel": "1.650% Notes due 2035 (1.5B Euro 1.0651)(2)/(1.5B Euro 1.1311)(3)",
        "verboseLabel": "1.650% Notes Due May 2035"
       }
      }
     },
     "localname": "A1.650NotesDue2035Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A130NotesDue2030Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1.30% Notes due 2030",
        "label": "1.30% Notes due 2030 [Member]",
        "terseLabel": "1.30% Notes due 2030"
       }
      }
     },
     "localname": "A130NotesDue2030Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.05Notesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.05% Notes due 2023 [Member]",
        "label": "2.05% Notes due 2023 [Member]",
        "terseLabel": "2.05% Notes due 2023"
       }
      }
     },
     "localname": "A2.05Notesdue2023Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.25Notesdue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.25% Notes due 2022 [Member]",
        "label": "2.25% Notes due 2022 [Member]",
        "terseLabel": "2.25% Notes due 2022"
       }
      }
     },
     "localname": "A2.25Notesdue2022Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.45Notesdue2026Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.45% Notes due 2026 [Member]",
        "label": "2.45% Notes due 2026 [Member]",
        "terseLabel": "2.45% Notes due 2026"
       }
      }
     },
     "localname": "A2.45Notesdue2026Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.625Notesdue2025Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.625 Notes due 2025 [Member]",
        "label": "2.625 Notes due 2025 [Member]",
        "terseLabel": "2.625% Notes due 2025"
       }
      }
     },
     "localname": "A2.625Notesdue2025Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.900Notesdue2028Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.900% Notes due 2028 [Member]",
        "label": "2.900% Notes due 2028 [Member]",
        "terseLabel": "2.90%\u00a0Notes due 2028"
       }
      }
     },
     "localname": "A2.900Notesdue2028Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2.95Notesdue2027Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.95% Notes due 2027 [Member]",
        "label": "2.95% Notes due 2027 [Member]",
        "terseLabel": "2.95% Notes due 2027"
       }
      }
     },
     "localname": "A2.95Notesdue2027Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2020AcquisitionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2020 Acquisitions",
        "label": "2020 Acquisitions [Member]",
        "terseLabel": "2020 Acquisitions"
       }
      }
     },
     "localname": "A2020AcquisitionsMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2022LongTermIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2022 Long-Term Incentive Plan",
        "label": "2022 Long-Term Incentive Plan [Member]",
        "terseLabel": "2022 Long-Term Incentive Plan"
       }
      }
     },
     "localname": "A2022LongTermIncentivePlanMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A210NotesDue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.10% Notes due 2040",
        "label": "2.10% Notes due 2040 [Member]",
        "terseLabel": "2.10% Notes due 2040"
       }
      }
     },
     "localname": "A210NotesDue2040Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2250NotesDue2050Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.250% Notes due 2050",
        "label": "2.250% Notes due 2050 [Member]",
        "terseLabel": "2.250% Notes due 2050"
       }
      }
     },
     "localname": "A2250NotesDue2050Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A2450NotesDue2060Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2.450% Notes due 2060",
        "label": "2.450% Notes due 2060 [Member]",
        "terseLabel": "2.450% Notes due 2060"
       }
      }
     },
     "localname": "A2450NotesDue2060Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.375Notesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.375% Notes due 2023 [Member]",
        "label": "3.375% Notes due 2023 [Member]",
        "terseLabel": "3.375% Notes due 2023"
       }
      }
     },
     "localname": "A3.375Notesdue2023Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.400Notesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.400% Notes due 2038 [Member]",
        "label": "3.400% Notes due 2038 [Member]",
        "terseLabel": "3.400%\u00a0Notes due 2038"
       }
      }
     },
     "localname": "A3.400Notesdue2038Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.500Notesdue2048Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.500% Notes due 2048 [Member]",
        "label": "3.500% Notes due 2048 [Member]",
        "terseLabel": "3.500% Notes due 2048"
       }
      }
     },
     "localname": "A3.500Notesdue2048Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.55Notesdue2036Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.55% Notes due 2036 [Member]",
        "label": "3.55% Notes due 2036 [Member]",
        "terseLabel": "3.55% Notes due 2036"
       }
      }
     },
     "localname": "A3.55Notesdue2036Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.625Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.625% Notes due 2037 [Member]",
        "label": "3.625% Notes due 2037 [Member]",
        "terseLabel": "3.625% Notes due 2037"
       }
      }
     },
     "localname": "A3.625Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.70Notesdue2046Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.70% Notes due 2046 [Member]",
        "label": "3.70% Notes due 2046 [Member]",
        "terseLabel": "3.70% Notes due 2046"
       }
      }
     },
     "localname": "A3.70Notesdue2046Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A3.75Notesdue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "3.75% Notes due 2047 [Member]",
        "label": "3.75% Notes due 2047 [Member]",
        "terseLabel": "3.75% Notes due 2047"
       }
      }
     },
     "localname": "A3.75Notesdue2047Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.375Notesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.375% Notes due 2033 [Member]",
        "label": "4.375% Notes due 2033 [Member]",
        "terseLabel": "4.375% Notes due 2033"
       }
      }
     },
     "localname": "A4.375Notesdue2033Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Debenturesdue2040Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Debentures due 2040 [Member]",
        "label": "4.50% Debentures due 2040 [Member]",
        "terseLabel": "4.50%\u00a0Debentures due 2040"
       }
      }
     },
     "localname": "A4.50Debenturesdue2040Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.50Notesdue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.50% Notes due 2043 [Member]",
        "label": "4.50% Notes due 2043 [Member]",
        "terseLabel": "4.50% Notes due 2043"
       }
      }
     },
     "localname": "A4.50Notesdue2043Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.85Notesdue2041Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.85% Notes due 2041 [Member]",
        "label": "4.85% Notes due 2041 [Member]",
        "terseLabel": "4.85% Notes due 2041"
       }
      }
     },
     "localname": "A4.85Notesdue2041Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A4.95Debenturesdue2033Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "4.95% Debentures due 2033 [Member]",
        "label": "4.95% Debentures due 2033 [Member]",
        "terseLabel": "4.95%\u00a0Debentures due 2033"
       }
      }
     },
     "localname": "A4.95Debenturesdue2033Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.50NotesDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.50% Notes Due 2024 [Member]",
        "label": "5.50% Notes Due 2024 [Member]",
        "terseLabel": "5.50%\u00a0Notes due 2024 (500MM 1.2037 GBP )(2)/(500MM GBP 1.3485)(3)",
        "verboseLabel": "5.50% Notes Due November 2024"
       }
      }
     },
     "localname": "A5.50NotesDue2024Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.85Debenturesdue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.85% Debentures due 2038 [Member]",
        "label": "5.85% Debentures due 2038 [Member]",
        "terseLabel": "5.85%\u00a0Debentures due 2038"
       }
      }
     },
     "localname": "A5.85Debenturesdue2038Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A5.95Notesdue2037Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "5.95% Notes due 2037 [Member]",
        "label": "5.95% Notes due 2037 [Member]",
        "terseLabel": "5.95%\u00a0Notes due 2037"
       }
      }
     },
     "localname": "A5.95Notesdue2037Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.73Debenturesdue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.73% Debentures due 2023 [Member]",
        "label": "6.73% Debentures due 2023 [Member]",
        "terseLabel": "6.73%\u00a0Debentures due 2023"
       }
      }
     },
     "localname": "A6.73Debenturesdue2023Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_A6.95Notesdue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "6.95% Notes due 2029 [Member]",
        "label": "6.95% Notes due 2029 [Member]",
        "terseLabel": "6.95%\u00a0Notes due 2029"
       }
      }
     },
     "localname": "A6.95Notesdue2029Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ADVANCEDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ADVANCED [Member]",
        "label": "ADVANCED [Member]",
        "terseLabel": "ADVANCED"
       }
      }
     },
     "localname": "ADVANCEDMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AbiomedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Abiomed",
        "label": "Abiomed [Member]",
        "terseLabel": "Abiomed"
       }
      }
     },
     "localname": "AbiomedMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AccruedRebatesReturnsAndPromotions": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated obligations due within one year for rebates, returns and promotions. Reserves include such items related to Medicaid rebates, product returns due to expiration, product recalls, current portion of coupons and volume-based sales incentives programs.",
        "label": "Accrued Rebates Returns And Promotions",
        "terseLabel": "Accrued Rebates Returns And Promotions",
        "verboseLabel": "Accrued rebates, returns and promotions"
       }
      }
     },
     "localname": "AccruedRebatesReturnsAndPromotions",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_AsiaPacificAfricaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asia-Pacific, Africa [Member]",
        "label": "Asia-Pacific, Africa [Member]",
        "terseLabel": "Asia-Pacific, Africa"
       }
      }
     },
     "localname": "AsiaPacificAfricaMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AsrMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ASR.",
        "label": "ASR [Member]",
        "terseLabel": "ASR"
       }
      }
     },
     "localname": "AsrMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AssetWriteoffMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Write-off [Member]",
        "label": "Asset Write-off [Member]",
        "terseLabel": "Asset Write-offs/Sales"
       }
      }
     },
     "localname": "AssetWriteoffMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_AuditorInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auditor Information",
        "label": "Auditor Information [Abstract]"
       }
      }
     },
     "localname": "AuditorInformationAbstract",
     "nsuri": "http://www.jnj.com/20230101",
     "xbrltype": "stringItemType"
    },
    "jnj_AurisHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Auris Health",
        "label": "Auris Health [Member]",
        "terseLabel": "Auris Health"
       }
      }
     },
     "localname": "AurisHealthMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Care [Member]",
        "label": "Baby Care [Member]",
        "terseLabel": "Baby Care"
       }
      }
     },
     "localname": "BabyCareMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BabyPowderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Baby Powder [Member]",
        "label": "Baby Powder [Member]",
        "terseLabel": "Baby Powder"
       }
      }
     },
     "localname": "BabyPowderMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BermekimabMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "bermekimab",
        "label": "bermekimab [Member]",
        "terseLabel": "bermekimab"
       }
      }
     },
     "localname": "BermekimabMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_BusinessAcquisitionDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Acquisition, Discount Rate",
        "label": "Business Acquisition, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "BusinessAcquisitionDiscountRate",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_BusinessCombinationProbabilityOfSuccessFactor": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Probability Of Success Factor",
        "label": "Business Combination, Probability Of Success Factor",
        "terseLabel": "Probability of success factor"
       }
      }
     },
     "localname": "BusinessCombinationProbabilityOfSuccessFactor",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Tangible Assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTangibleAssets",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_CONCERTAMethylphenidateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONCERTA/Methylphenidate [Member]",
        "label": "CONCERTA/Methylphenidate [Member]",
        "terseLabel": "CONCERTA/Methylphenidate"
       }
      }
     },
     "localname": "CONCERTAMethylphenidateMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONSUMERHEALTHAndPHARMACEUTICALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONSUMER HEALTH and PHARMACEUTICAL",
        "label": "CONSUMER HEALTH and PHARMACEUTICAL [Member]",
        "terseLabel": "CONSUMER HEALTH and PHARMACEUTICAL"
       }
      }
     },
     "localname": "CONSUMERHEALTHAndPHARMACEUTICALMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CONTACTLENSESOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "CONTACT LENSES/OTHER [Member]",
        "label": "CONTACT LENSES/OTHER [Member]",
        "terseLabel": "CONTACT LENSES/OTHER"
       }
      }
     },
     "localname": "CONTACTLENSESOTHERMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID-19",
        "label": "COVID-19 [Member]",
        "terseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CardiovascularMetabolismOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cardiovascular/Metabolism/Other [Member]",
        "label": "Cardiovascular/Metabolism/Other [Member]",
        "terseLabel": "Cardiovascular/Metabolism/Other"
       }
      }
     },
     "localname": "CardiovascularMetabolismOtherMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CashPaidDuringTheYearAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash Paid During The Year [Abstract]",
        "label": "Cash Paid During The Year [Abstract]",
        "terseLabel": "Cash paid during the year for:"
       }
      }
     },
     "localname": "CashPaidDuringTheYearAbstract",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_ChangesInTreasuryStockRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in treasury stock.",
        "label": "Changes In Treasury Stock [Roll Forward]",
        "terseLabel": "Changes in treasury stock"
       }
      }
     },
     "localname": "ChangesInTreasuryStockRollForward",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_ChangesInTreasuryStockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in treasury stock.",
        "label": "Changes In Treasury Stock [Table Text Block]",
        "terseLabel": "Changes in Treasury Stock"
       }
      }
     },
     "localname": "ChangesInTreasuryStockTableTextBlock",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ChangesinTreasuryStockSharesOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Changes in Treasury Stock Shares Outstanding [Roll Forward]",
        "label": "Changes in Treasury Stock Shares Outstanding [Roll Forward]",
        "terseLabel": "Changes in Treasury Stock Shares Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ChangesinTreasuryStockSharesOutstandingRollForward",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_ClassIRecommendationForImpellaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class I Recommendation For Impella",
        "label": "Class I Recommendation For Impella [Member]",
        "terseLabel": "Class I Recommendation For Impella"
       }
      }
     },
     "localname": "ClassIRecommendationForImpellaMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_CommingledFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commingled funds.",
        "label": "Commingled Funds [Member]",
        "terseLabel": "Commingled funds"
       }
      }
     },
     "localname": "CommingledFundsMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Comparison of income tax expense at the Statutory rate and Company's tax rate.",
        "label": "Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract",
        "terseLabel": "Comparison Of Income Tax Expense At Statutory Rate And Company's Tax Rate Abstract"
       }
      }
     },
     "localname": "ComparisonOfIncomeTaxExpenseAtStatutoryRateAndCompanysTaxRateAbstract",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_ConcentrationOfCreditRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration of credit risk.",
        "label": "Concentration of Credit Risk [Line Items]",
        "terseLabel": "Concentration of Credit Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskLineItems",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_ConcentrationOfCreditRiskTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration of Credit Risk [Table]",
        "label": "Concentration of Credit Risk [Table]",
        "terseLabel": "Concentration of Credit Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskTable",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_ConcentrationRiskThresholdPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration Risk, Threshold Percentage",
        "label": "Concentration Risk, Threshold Percentage",
        "terseLabel": "Concentration risk, threshold percentage (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskThresholdPercentage",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "jnj_ConsumerHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer Health",
        "label": "Consumer Health [Member]",
        "terseLabel": "Consumer Health Business"
       }
      }
     },
     "localname": "ConsumerHealthMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ConsumerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Consumer.",
        "label": "Consumer [Member]",
        "terseLabel": "Consumer Health"
       }
      }
     },
     "localname": "ConsumerMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ConvertibleNoteEquityInterestNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Convertible Note, Equity Interest, number of shares",
        "label": "Convertible Note, Equity Interest, number of shares",
        "terseLabel": "Convertible note, equity Interest (in shares)"
       }
      }
     },
     "localname": "ConvertibleNoteEquityInterestNumberOfShares",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_CurtailmentsAndSettlementsAndRestructuring": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase or decrease related to curtailments, settlements and restructuring.",
        "label": "Curtailments And Settlements And Restructuring",
        "negatedTerseLabel": "Curtailments, settlements\u00a0&amp; restructuring"
       }
      }
     },
     "localname": "CurtailmentsAndSettlementsAndRestructuring",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DARZALEXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DARZALEX [Member]",
        "label": "DARZALEX [Member]",
        "terseLabel": "DARZALEX"
       }
      }
     },
     "localname": "DARZALEXMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DePuyASRU.S.Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "DePuy ASR U.S. [Member]",
        "label": "DePuy ASR U.S. [Member]",
        "terseLabel": "DePuy ASR U.S."
       }
      }
     },
     "localname": "DePuyASRU.S.Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DebtInstrumentConvertibleAmountOfLoanConverted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt Instrument, Convertible, Amount of Loan Converted",
        "label": "Debt Instrument, Convertible, Amount of Loan Converted",
        "terseLabel": "Convertible debt, amount of loan converted"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleAmountOfLoanConverted",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_December172018ShareRepurchaseProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "December 17, 2018 Share Repurchase Program [Member]",
        "label": "December 17, 2018 Share Repurchase Program [Member]",
        "terseLabel": "December 17, 2018 Share Repurchase Program"
       }
      }
     },
     "localname": "December172018ShareRepurchaseProgramMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets international research and development capitalized.",
        "label": "Deferred Tax Assets International Research And Development Capitalized",
        "terseLabel": "R&amp;D capitalized for tax"
       }
      }
     },
     "localname": "DeferredTaxAssetsInternationalResearchAndDevelopmentCapitalized",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DeferredTaxAssetsOtherDomestic": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax assets other domestic.",
        "label": "Deferred Tax Assets Other Domestic",
        "terseLabel": "Miscellaneous U.S."
       }
      }
     },
     "localname": "DeferredTaxAssetsOtherDomestic",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization",
        "label": "Deferred Tax Assets, Tax Basis Increase of Certain Assets due to Reorganization",
        "terseLabel": "Deferred tax assets, tax basis increase of certain assets due to reorganization"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxBasisIncreaseOfCertainAssetsDueToReorganization",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DeferredTaxAssetsUndistributedForeignEarnings": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets, Undistributed Foreign Earnings",
        "label": "Deferred Tax Assets, Undistributed Foreign Earnings",
        "terseLabel": "Undistributed foreign earnings"
       }
      }
     },
     "localname": "DeferredTaxAssetsUndistributedForeignEarnings",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DeferredTaxLiabilitiesOtherDomestic": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Other Domestic",
        "label": "Deferred Tax Liabilities, Other Domestic",
        "negatedTerseLabel": "Miscellaneous U.S."
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOtherDomestic",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Liability, Global Intangible Low-Taxed Income",
        "label": "Deferred Tax Liability, Global Intangible Low-Taxed Income",
        "negatedTerseLabel": "Global intangible low-taxed income"
       }
      }
     },
     "localname": "DeferredTaxLiabilityGlobalIntangibleLowTaxedIncome",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets",
        "label": "Defined Benefit Plan, Alternative Investments, Fair Value of Plan Assets",
        "terseLabel": "Investments Measured at Net Asset Value"
       }
      }
     },
     "localname": "DefinedBenefitPlanAlternativeInvestmentsFairValueofPlanAssets",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Interest Cost, Discount Rate",
        "terseLabel": "Interest cost discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostInterestCostDiscountRate",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)",
        "label": "Defined Benefit Plan, Benefit Obligation, Business Combination and Divestiture, Increase (Decrease)",
        "terseLabel": "Divestitures\u00a0&amp; acquisitions"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBusinessCombinationandDivestitureIncreaseDecrease",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in five fiscal years thereafter.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Five Fiscal Years Thereafter",
        "terseLabel": "2027-2031"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInFiveFiscalYearsThereafter",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in year five.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearFive",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in year four.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearFour",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in year one.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearOne",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in year three.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearThree",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan expected future benefit contribution in year two.",
        "label": "Defined Benefit Plan Expected Future Benefit Contribution In Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitContributionInYearTwo",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureMinimumContributionstotheCompanysUSandInternationalUnfundedRetirementPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanOverUnderFundedStatusABO": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan over (under) funded status ABO",
        "label": "Defined Benefit Plan Over (Under) Funded Status ABO",
        "terseLabel": "Accumulated Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanOverUnderFundedStatusABO",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)",
        "label": "Defined Benefit Plan, Plan Assets, Business Combination and Divestiture, Increase (Decrease)",
        "terseLabel": "Divestitures\u00a0&amp; acquisitions"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBusinessCombinationandDivestitureIncreaseDecrease",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DepreciationExpenseIncludingAmortizationOfCapitalizedInterest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Depreciation expense including the amortization of capitalized interest.",
        "label": "Depreciation Expense Including Amortization Of Capitalized Interest",
        "terseLabel": "Depreciation expense, including the amortization of capitalized interest"
       }
      }
     },
     "localname": "DepreciationExpenseIncludingAmortizationOfCapitalizedInterest",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag",
        "label": "Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag",
        "terseLabel": "Derivative Asset, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag"
       }
      }
     },
     "localname": "DerivativeAssetStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag",
        "label": "Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag",
        "terseLabel": "Derivative Liability, Statement Of Financial Position, Extensible Enumeration, Not Disclosed Flag"
       }
      }
     },
     "localname": "DerivativeLiabilityStatementOfFinancialPositionExtensibleEnumerationNotDisclosedFlag",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_EDURANTrilpivirineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "EDURANT/rilpivirine [Member]",
        "label": "EDURANT/rilpivirine [Member]",
        "terseLabel": "EDURANT/rilpivirine"
       }
      }
     },
     "localname": "EDURANTrilpivirineMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EffectOfExchangeRates": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effect Of Exchange Rates.",
        "label": "Effect Of Exchange Rates",
        "terseLabel": "Effect of exchange rates"
       }
      }
     },
     "localname": "EffectOfExchangeRates",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationCapitalLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Capital Loss",
        "label": "Effective Income Tax Rate Reconciliation, Capital Loss",
        "negatedTerseLabel": "Tax benefits from loss on capital assets",
        "terseLabel": "Tax benefits from loss on capital assets"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationCapitalLoss",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Consumer Health Separation",
        "label": "Effective Income Tax Rate Reconciliation, Consumer Health Separation",
        "terseLabel": "Consumer health separation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationConsumerHealthSeparation",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent",
        "label": "Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Increase (Decrease), Percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationIncreaseDecreasePercent",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Litigation Settlement, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Litigation Settlement, Percent",
        "terseLabel": "Effective income tax rate reconciliation, litigation settlement, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationLitigationSettlementPercent",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "jnj_EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation related to domestic tax on international income.",
        "label": "Effective Income Tax Rate Reconciliation Related To Domestic Tax On International Income",
        "terseLabel": "U.S. taxes on international income"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationRelatedToDomesticTaxOnInternationalIncome",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, Federal Act On Tax Reform And AHV Financing, Percent",
        "label": "Effective Tax Rate Reconciliation, Federal Act On Tax Reform And AHV Financing, Percent",
        "terseLabel": "TRAF effect on tax rate"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationFederalActOnTaxReformAndAHVFinancingPercent",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent",
        "label": "Effective Tax Rate Reconciliation, Net Increase (Decrease) In Tax Rate, Percent",
        "terseLabel": "Effective tax rate reconciliation, net increase (decrease) in tax rate, percent"
       }
      }
     },
     "localname": "EffectiveTaxRateReconciliationNetIncreaseDecreaseInTaxRatePercent",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ElmironMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Elmiron",
        "label": "Elmiron [Member]",
        "terseLabel": "Elmiron"
       }
      }
     },
     "localname": "ElmironMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EmployeeCompensationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Compensation Period.",
        "label": "Employee Compensation Period",
        "terseLabel": "Retirement plan benefits Employee compensation Period"
       }
      }
     },
     "localname": "EmployeeCompensationPeriod",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "jnj_EmployeeObligations": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total employee obligations current and non current.",
        "label": "Employee Obligations",
        "totalLabel": "Total employee obligations"
       }
      }
     },
     "localname": "EmployeeObligations",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EmployeeRelatedObligationsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee related obligations.",
        "label": "Employee Related Obligations [Table Text Block]",
        "terseLabel": "Employee Related Obligations"
       }
      }
     },
     "localname": "EmployeeRelatedObligationsTableTextBlock",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_EquityFairValueAdjustmentChangeinObservablePrices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity, Fair Value Adjustment, Change in Observable Prices",
        "label": "Equity, Fair Value Adjustment, Change in Observable Prices",
        "terseLabel": "Equity, fair value adjustment, change in observable prices"
       }
      }
     },
     "localname": "EquityFairValueAdjustmentChangeinObservablePrices",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityFairValueAdjustmentImpairmentLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity, Fair Value Adjustment, Impairment Loss",
        "label": "Equity, Fair Value Adjustment, Impairment Loss",
        "terseLabel": "Equity, fair value adjustment, impairment loss"
       }
      }
     },
     "localname": "EquityFairValueAdjustmentImpairmentLoss",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investment [Roll Forward]",
        "label": "Equity Investment [Roll Forward]",
        "terseLabel": "Equity Investment [Roll Forward]"
       }
      }
     },
     "localname": "EquityInvestmentRollForward",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "label": "Equity Investments, Increase (Decrease) from Acquisition (Sale) During Period",
        "terseLabel": "Equity investments, increase (decrease) from acquisition (sale) during period"
       }
      }
     },
     "localname": "EquityInvestmentsIncreaseDecreasefromAcquisitionSaleDuringPeriod",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_EquityInvestmentswithReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments with Readily Determinable Value [Member]",
        "label": "Equity Investments with Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments with readily determinable value"
       }
      }
     },
     "localname": "EquityInvestmentswithReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EquityInvestmentswithoutReadilyDeterminableValueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity Investments without Readily Determinable Value [Member]",
        "label": "Equity Investments without Readily Determinable Value [Member]",
        "terseLabel": "Equity Investments without readily determinable value"
       }
      }
     },
     "localname": "EquityInvestmentswithoutReadilyDeterminableValueMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ErleadaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Erleada",
        "label": "Erleada [Member]",
        "terseLabel": "ERLEADA"
       }
      }
     },
     "localname": "ErleadaMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_EstimatedUsefulLivesOfAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated useful lives of the assets.",
        "label": "Estimated Useful Lives Of Assets [Table Text Block]",
        "terseLabel": "Estimated Useful Lives of Assets"
       }
      }
     },
     "localname": "EstimatedUsefulLivesOfAssetsTableTextBlock",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_EvraAndDoxilMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Evra and Doxil",
        "label": "Evra and Doxil [Member]",
        "terseLabel": "Evra and Doxil"
       }
      }
     },
     "localname": "EvraAndDoxilMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExcessOfCarryingValueOverFairValueOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess Of Carrying Value Over Fair Value Of Debt",
        "label": "Excess Of Carrying Value Over Fair Value Of Debt",
        "terseLabel": "Excess of carrying value over fair value of debt"
       }
      }
     },
     "localname": "ExcessOfCarryingValueOverFairValueOfDebt",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ExcessOfFairValueOverCarryingValueOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of fair value over carrying value of debt.",
        "label": "Excess Of Fair Value Over Carrying Value Of Debt",
        "terseLabel": "Excess of fair value over carrying value of debt"
       }
      }
     },
     "localname": "ExcessOfFairValueOverCarryingValueOfDebt",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ExercisePriceRangeFiveMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range.",
        "label": "Exercise Price Range Five [Member]",
        "terseLabel": "$164.63-$165.89"
       }
      }
     },
     "localname": "ExercisePriceRangeFiveMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExercisePriceRangeFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range.",
        "label": "Exercise Price Range Four [Member]",
        "terseLabel": "$151.41-$164.62"
       }
      }
     },
     "localname": "ExercisePriceRangeFourMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExercisePriceRangeOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price range.",
        "label": "Exercise Price Range One Member",
        "terseLabel": "$72.54-$100.48"
       }
      }
     },
     "localname": "ExercisePriceRangeOneMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExercisePriceRangeThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range.",
        "label": "Exercise Price Range Three [Member]",
        "terseLabel": "$129.51-$141.06"
       }
      }
     },
     "localname": "ExercisePriceRangeThreeMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExercisePriceRangeTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise Price Range.",
        "label": "Exercise Price Range Two [Member]",
        "terseLabel": "$101.87-$115.67"
       }
      }
     },
     "localname": "ExercisePriceRangeTwoMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ExpenseNotAllocatedToSegments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expense not allocated to segments.",
        "label": "Expense Not Allocated To Segments",
        "terseLabel": "Less: Expense not allocated to segments"
       }
      }
     },
     "localname": "ExpenseNotAllocatedToSegments",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Change In Estimated Fair Value",
        "terseLabel": "Changes in estimated fair value"
       }
      }
     },
     "localname": "FairValueMeasurementwithUnobservableInputsReconciliationRecurringBasisChangeInEstimatedFairValue",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of company's common stock directly held in plan assets.",
        "label": "Fair Value Of Company's Common Stock Directly Held In Plan Assets",
        "terseLabel": "Fair value of company's common stock directly held in plan assets"
       }
      }
     },
     "localname": "FairValueOfCompanysCommonStockDirectlyHeldInPlanAssets",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, Change In Tax Rate, Income Tax Expense (Benefit)",
        "label": "Federal Act On Tax Reform And AHV Financing, Change In Tax Rate, Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense related to change in tax rate from TRAF"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingChangeInTaxRateIncomeTaxExpenseBenefit",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset",
        "label": "Federal Act On Tax Reform And AHV Financing, Deferred Tax Asset",
        "terseLabel": "Deferred tax asset recorded related to TRAF"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingDeferredTaxAsset",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)",
        "label": "Federal Act On Tax Reform And AHV Financing, GILTI Remeasurement, Income Tax Expense (Benefit)",
        "terseLabel": "Deferred tax expense related to TRAF"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingGILTIRemeasurementIncomeTaxExpenseBenefit",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal Act On Tax Reform And AHV Financing, Income Tax Expense (Benefit)",
        "label": "Federal Act On Tax Reform And AHV Financing, Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense recorded related to TRAF"
       }
      }
     },
     "localname": "FederalActOnTaxReformAndAHVFinancingIncomeTaxExpenseBenefit",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "label": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived And Indefinite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_FiscalPeriodPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period policy.",
        "label": "Fiscal Period [Policy Text Block]",
        "terseLabel": "Annual Closing Date"
       }
      }
     },
     "localname": "FiscalPeriodPolicyTextBlock",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_FundedPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Funded plans.",
        "label": "Funded Plans [Member]",
        "terseLabel": "Funded Plans"
       }
      }
     },
     "localname": "FundedPlansMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_GENERALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GENERAL [Member]",
        "label": "GENERAL [Member]",
        "terseLabel": "GENERAL"
       }
      }
     },
     "localname": "GENERALMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_GainOnSaleOfAnAssetPaymentForRestructuring": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on Sale of an Asset (Payment) for Restructuring",
        "label": "Gain on Sale of an Asset (Payment) for Restructuring",
        "negatedTerseLabel": "Cash settlements"
       }
      }
     },
     "localname": "GainOnSaleOfAnAssetPaymentForRestructuring",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_GeneralCorporateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General corporate member.",
        "label": "General Corporate [Member]",
        "terseLabel": "General Corporate"
       }
      }
     },
     "localname": "GeneralCorporateMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_HIPSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HIPS [Member]",
        "label": "HIPS [Member]",
        "terseLabel": "HIPS"
       }
      }
     },
     "localname": "HIPSMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IMBRUVICAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "IMBRUVICA [Member]",
        "label": "IMBRUVICA [Member]",
        "terseLabel": "IMBRUVICA"
       }
      }
     },
     "localname": "IMBRUVICAMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVEGASUSTENNAXEPLIONTRINZATREVICTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "label": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA [Member]",
        "terseLabel": "INVEGA SUSTENNA/XEPLION/TRINZA/TREVICTA"
       }
      }
     },
     "localname": "INVEGASUSTENNAXEPLIONTRINZATREVICTAMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_INVOKANAINVOKAMETMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "INVOKANA/INVOKAMET [Member]",
        "label": "INVOKANA/INVOKAMET [Member]",
        "terseLabel": "INVOKANA/INVOKAMET"
       }
      }
     },
     "localname": "INVOKANAINVOKAMETMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IdorsiaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Idorsia [Member]",
        "label": "Idorsia [Member]",
        "terseLabel": "Idorsia"
       }
      }
     },
     "localname": "IdorsiaMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Immunology [Member]",
        "label": "Immunology [Member]",
        "terseLabel": "Immunology"
       }
      }
     },
     "localname": "ImmunologyMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ImpellaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impella",
        "label": "Impella [Member]",
        "terseLabel": "Impella"
       }
      }
     },
     "localname": "ImpellaMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)",
        "label": "Increase (Decrease) in Deferred Tax Liabilities, Global Intangible Low-Taxed Income (GILTI)",
        "terseLabel": "Increase (decrease) in deferred tax liabilities, global intangible low-taxed income (GILTI)"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredTaxLiabilitiesGlobalIntangibleLowTaxedIncomeGILTI",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_InfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Infectious Diseases [Member]",
        "label": "Infectious Diseases [Member]",
        "terseLabel": "Infectious Diseases"
       }
      }
     },
     "localname": "InfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the benefit obligation and the fair value of plan assets.",
        "label": "Information Related To Benefit Obligation And Fair Value Of Plan Assets [Table Text Block]",
        "terseLabel": "Information Related to the Benefit Obligation and the Fair Value of Plan Assets"
       }
      }
     },
     "localname": "InformationRelatedToBenefitObligationAndFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_InterestIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest Income Expense Net Member.",
        "label": "Interest Income Expense Net Member",
        "terseLabel": "Interest (Income) Expense"
       }
      }
     },
     "localname": "InterestIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_InterventionalSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interventional Solutions [Member]",
        "label": "Interventional Solutions [Member]",
        "terseLabel": "Interventional Solutions"
       }
      }
     },
     "localname": "InterventionalSolutionsMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_KNEESMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "KNEES [Member]",
        "label": "KNEES [Member]",
        "terseLabel": "KNEES"
       }
      }
     },
     "localname": "KNEESMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LandAndLeaseholdImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Land and leasehold improvements.",
        "label": "Land And Leasehold Improvements [Member]",
        "terseLabel": "Land and leasehold improvements"
       }
      }
     },
     "localname": "LandAndLeaseholdImprovementsMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LegalProceedingTextualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Legal Proceeding Textuals Abstract.",
        "label": "Legal Proceeding (Textuals) [Abstract]",
        "terseLabel": "Legal Proceeding (Textuals)"
       }
      }
     },
     "localname": "LegalProceedingTextualsAbstract",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LitigationSettlementByCompaniesAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement by companies.",
        "label": "Litigation Settlement By Companies [Axis]",
        "terseLabel": "Litigation Settlement By Companies"
       }
      }
     },
     "localname": "LitigationSettlementByCompaniesAxis",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_LitigationSettlementByCompaniesDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation settlement by companies.",
        "label": "Litigation Settlement By Companies [Domain]",
        "terseLabel": "Litigation Settlement By Companies"
       }
      }
     },
     "localname": "LitigationSettlementByCompaniesDomain",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_LossContingencyEstimateOfAdditionalPossibleLoss": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Estimate of Additional Possible Loss",
        "label": "Loss Contingency, Estimate of Additional Possible Loss",
        "terseLabel": "Loss contingency, estimate of additional possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfAdditionalPossibleLoss",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_LossContingencyNumberOfClaimsWithinSettlementAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Number of Claims within Settlement Agreement",
        "label": "Loss Contingency, Number of Claims within Settlement Agreement",
        "terseLabel": "Number of claims within settlement agreement"
       }
      }
     },
     "localname": "LossContingencyNumberOfClaimsWithinSettlementAgreement",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_LossContingencyPendingClaimsNumberAdditional": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency Pending Claims, Number, Additional",
        "label": "Loss Contingency Pending Claims, Number, Additional",
        "terseLabel": "Loss Contingency Pending Claims, Number, Additional"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumberAdditional",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_LossContingencyPendingClaimsNumberRemaining": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Pending Claims, Number, Remaining",
        "label": "Loss Contingency, Pending Claims, Number, Remaining",
        "terseLabel": "Loss Contingency, Pending Claims, Number, Remaining"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumberRemaining",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_LossContingencyReserveEstablishedWithinTrust": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loss Contingency, Reserve Established within Trust",
        "label": "Loss Contingency, Reserve Established within Trust",
        "terseLabel": "Reserve established"
       }
      }
     },
     "localname": "LossContingencyReserveEstablishedWithinTrust",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_MedTechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MedTech [Member]",
        "label": "MedTech [Member]",
        "terseLabel": "Medical Devices",
        "verboseLabel": "Medical Devices"
       }
      }
     },
     "localname": "MedTechMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_MinimumCollateralValueasaPercentReverseRepurchaseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum Collateral Value as a Percent, Reverse Repurchase Agreement",
        "label": "Minimum Collateral Value as a Percent, Reverse Repurchase Agreement",
        "terseLabel": "Minimum reverse repurchase agreement collateral (as a percent)"
       }
      }
     },
     "localname": "MinimumCollateralValueasaPercentReverseRepurchaseAgreement",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_MomentaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Momenta",
        "label": "Momenta [Member]",
        "terseLabel": "Momenta"
       }
      }
     },
     "localname": "MomentaMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NeuroscienceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Neuroscience [Member]",
        "label": "Neuroscience [Member]",
        "terseLabel": "Neuroscience"
       }
      }
     },
     "localname": "NeuroscienceMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NonQualifiedPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non qualified plans.",
        "label": "Non Qualified Plans [Member]",
        "terseLabel": "Non-Qualified Plans"
       }
      }
     },
     "localname": "NonQualifiedPlansMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NonTradeableContingentValueRightMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non-Tradeable Contingent Value Right",
        "label": "Non-Tradeable Contingent Value Right [Member]",
        "terseLabel": "Non-Tradeable Contingent Value Right"
       }
      }
     },
     "localname": "NonTradeableContingentValueRightMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_NumberOfEmployeesEngagedInCompanyActivitiesWorldwide": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of employees engaged in company activities worldwide.",
        "label": "Number Of Employees Engaged In Company Activities Worldwide",
        "terseLabel": "Number of employees"
       }
      }
     },
     "localname": "NumberOfEmployeesEngagedInCompanyActivitiesWorldwide",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_NumberOfStockBasedCompensationPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of stock-based compensation plans.",
        "label": "Number Of Stock Based Compensation Plans",
        "terseLabel": "Number of stock-based compensation plans"
       }
      }
     },
     "localname": "NumberOfStockBasedCompensationPlans",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_Numberofpatientsinsettlement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of patients in settlement",
        "label": "Number of patients in settlement",
        "terseLabel": "Number of patients in settlement"
       }
      }
     },
     "localname": "Numberofpatientsinsettlement",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_OPSUMITMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OPSUMIT [Member]",
        "label": "OPSUMIT [Member]",
        "terseLabel": "OPSUMIT"
       }
      }
     },
     "localname": "OPSUMITMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTC [Member]",
        "label": "OTC [Member]",
        "terseLabel": "OTC"
       }
      }
     },
     "localname": "OTCMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OTHERNEUROSCIENCEMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "OTHER NEUROSCIENCE [Member]",
        "label": "OTHER NEUROSCIENCE [Member]",
        "terseLabel": "OTHER NEUROSCIENCE"
       }
      }
     },
     "localname": "OTHERNEUROSCIENCEMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "label": "Oklahoma Attorney General VS. Johnson And Johnson And JPI [Member]",
        "terseLabel": "Oklahoma Attorney General vs. Johnson &amp; Johnson and JPI"
       }
      }
     },
     "localname": "OklahomaAttorneyGeneralVS.JohnsonAndJohnsonAndJPIMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oncology [Member]",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OpiodsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opiods [Member]",
        "label": "Opiods [Member]",
        "terseLabel": "Opiods"
       }
      }
     },
     "localname": "OpiodsMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OpioidMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Opioid",
        "label": "opioid [Member]",
        "terseLabel": "Opioid"
       }
      }
     },
     "localname": "OpioidMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OralCareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Oral Care [Member]",
        "label": "Oral Care [Member]",
        "terseLabel": "Oral Care"
       }
      }
     },
     "localname": "OralCareMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OrthopaedicsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Orthopaedics [Member]",
        "label": "Orthopaedics [Member]",
        "terseLabel": "Orthopaedics"
       }
      }
     },
     "localname": "OrthopaedicsMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "other comprehensive income loss, pension and other , effects of exchange rate net of tax",
        "label": "Other comprehensive income (loss), pension and other, effects of exchange rate net of tax",
        "negatedTerseLabel": "Effect of exchange rates"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherEffectsOfExchangeRateNetOfTax",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Net Prior Service Cost (Credit), Net of Amortization, Arising During Period, Net of Tax",
        "negatedTerseLabel": "Prior service credit (cost), net of amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansNetPriorServiceCostCreditNetofAmortizationArisingDuringPeriodNetofTax",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "label": "Other Comprehensive (Income) Loss, Reclassification Adjustment from AOCI Pension and Other Postretirement Benefit Plans for Net Gain Loss, Net of Amortization, Net of Tax",
        "negatedTerseLabel": "Gain (loss), net of amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetGainLossNetofAmortizationNetofTax",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Immunology [Member]",
        "label": "Other Immunology [Member]",
        "terseLabel": "Other Immunology"
       }
      }
     },
     "localname": "OtherImmunologyMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherIncomeExpenseNetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Income Expense Net [Member]",
        "label": "Other Income Expense Net [Member]",
        "terseLabel": "Other (Income) Expense",
        "verboseLabel": "Other Income Expense Net"
       }
      }
     },
     "localname": "OtherIncomeExpenseNetMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherInfectiousDiseasesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Infectious Diseases [Member]",
        "label": "Other Infectious Diseases [Member]",
        "terseLabel": "Other Infectious Diseases"
       }
      }
     },
     "localname": "OtherInfectiousDiseasesMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other [Member]",
        "label": "Other [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_OtherNonLongLivedAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other non long lived assets.",
        "label": "Other Non Long Lived Assets",
        "terseLabel": "Other Non Long Lived Assets"
       }
      }
     },
     "localname": "OtherNonLongLivedAssets",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_OtherOncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Oncology [Member]",
        "label": "Other Oncology [Member]",
        "terseLabel": "Other Oncology"
       }
      }
     },
     "localname": "OtherOncologyMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PREZISTAPREZCOBIXREZOLSTASYMTUZAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "label": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA [Member]",
        "terseLabel": "PREZISTA/PREZCOBIX/REZOLSTA/SYMTUZA"
       }
      }
     },
     "localname": "PREZISTAPREZCOBIXREZOLSTASYMTUZAMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PatentsAndTrademarksMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Patents And Trademarks [Member]",
        "label": "Patents And Trademarks [Member]",
        "terseLabel": "Patents And Trademarks"
       }
      }
     },
     "localname": "PatentsAndTrademarksMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PelvicMeshesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pelvic meshes.",
        "label": "Pelvic Meshes [Member]",
        "terseLabel": "Pelvic Meshes"
       }
      }
     },
     "localname": "PelvicMeshesMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PercentageChangeInSalesBySegmentOfBusiness": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage change in sales by segment of business.",
        "label": "Percentage Change In Sales By Segment Of Business",
        "terseLabel": "Percentage Change In Sales By Segment Of Business"
       }
      }
     },
     "localname": "PercentageChangeInSalesBySegmentOfBusiness",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageOfCompanysCommonStockToPlanAsset": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the company's common stock to the total plan asset.",
        "label": "Percentage Of Company's Common Stock To Plan Asset",
        "terseLabel": "Percentage of company's common stock to plan asset"
       }
      }
     },
     "localname": "PercentageOfCompanysCommonStockToPlanAsset",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PercentageOfCorridorOfGreaterOfMarketValueOfAssets": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of corridor of greater of market value of assets.",
        "label": "Percentage Of Corridor Of Greater Of Market Value Of Assets",
        "terseLabel": "Percentage of corridor of greater of market value of assets"
       }
      }
     },
     "localname": "PercentageOfCorridorOfGreaterOfMarketValueOfAssets",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PharmaceuticalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pharmaceutical.",
        "label": "Pharmaceutical [Member]",
        "terseLabel": "Pharmaceutical",
        "verboseLabel": "Pharmaceutical"
       }
      }
     },
     "localname": "PharmaceuticalMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PhysiomeshMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physiomesh [Member]",
        "label": "Physiomesh [Member]",
        "terseLabel": "Physiomesh"
       }
      }
     },
     "localname": "PhysiomeshMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PinnacleAcetabularCupSystemMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pinnacle Acetabular cup system.",
        "label": "Pinnacle Acetabular Cup System [Member]",
        "terseLabel": "Pinnacle Acetabular Cup System"
       }
      }
     },
     "localname": "PinnacleAcetabularCupSystemMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PotentialSharesExercisableUnderStockOptionPlans": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Potential Shares Exercisable Under Stock Option Plans",
        "label": "Potential Shares Exercisable Under Stock Option Plans",
        "terseLabel": "Potential shares exercisable under stock option plans (in shares)"
       }
      }
     },
     "localname": "PotentialSharesExercisableUnderStockOptionPlans",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "label": "Proceeds From The Exercise Of Stock Options And Excess Tax Benefits",
        "verboseLabel": "Proceeds from the exercise of stock options/employee withholding tax on stock awards, net"
       }
      }
     },
     "localname": "ProceedsFromExerciseOfStockOptionsAndExcessTaxBenefits",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Financing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsFinancingActivities",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "label": "Proceeds (Payments) from (to) Credit Support Agreements, Investing Activities",
        "terseLabel": "Credit support agreements activity, net"
       }
      }
     },
     "localname": "ProceedsPaymentsFromToCreditSupportAgreementsInvestingActivities",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ProductLiabilityContingencyNumberOfClaimant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product liability contingency number of claimant.",
        "label": "Product Liability Contingency Number Of Claimant",
        "terseLabel": "Product liability contingency, number of claimants"
       }
      }
     },
     "localname": "ProductLiabilityContingencyNumberOfClaimant",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "jnj_ProductLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product liability.",
        "label": "Product Liability [Policy Text Block]",
        "terseLabel": "Product Liability"
       }
      }
     },
     "localname": "ProductLiabilityPolicyTextBlock",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ProfitLossPercentToSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit loss percent to sales.",
        "label": "Profit Loss Percent To Sales",
        "terseLabel": "Percentage of profit share payments (less than)"
       }
      }
     },
     "localname": "ProfitLossPercentToSales",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_PulmonaryHypertensionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pulmonary Hypertension [Member]",
        "label": "Pulmonary Hypertension [Member]",
        "terseLabel": "Pulmonary Hypertension"
       }
      }
     },
     "localname": "PulmonaryHypertensionMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_PurchasedInProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased In-Process Research And Development [Member]",
        "label": "Purchased In-Process Research And Development [Member]",
        "terseLabel": "Purchased in-process research and development(1)",
        "verboseLabel": "Purchased in-process research and development"
       }
      }
     },
     "localname": "PurchasedInProcessResearchAndDevelopmentMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_QualifiedPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qualified plans.",
        "label": "Qualified Plans [Member]",
        "terseLabel": "Qualified Plans"
       }
      }
     },
     "localname": "QualifiedPlansMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RISPERDALCONSTAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RISPERDAL CONSTA [Member]",
        "label": "RISPERDAL CONSTA [Member]",
        "terseLabel": "RISPERDAL CONSTA"
       }
      }
     },
     "localname": "RISPERDALCONSTAMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RasmussenInstrumentsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rasmussen Instruments, LLC",
        "label": "Rasmussen Instruments, LLC [Member]",
        "terseLabel": "Rasmussen Instruments, LLC"
       }
      }
     },
     "localname": "RasmussenInstrumentsLLCMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RegulationCharge": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulation charge",
        "label": "Regulation charge",
        "terseLabel": "Regulation charge"
       }
      }
     },
     "localname": "RegulationCharge",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_RemicadeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remicade [Member]",
        "label": "Remicade [Member]",
        "terseLabel": "Remicade"
       }
      }
     },
     "localname": "RemicadeMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_RevenuesContingentConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenues, Contingent Consideration",
        "label": "Revenues, Contingent Consideration",
        "terseLabel": "Revenues, Contingent Consideration"
       }
      }
     },
     "localname": "RevenuesContingentConsideration",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_RisperdalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risperdal.",
        "label": "Risperdal [Member]",
        "terseLabel": "Risperdal"
       }
      }
     },
     "localname": "RisperdalMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SPINESPORTSOTHERMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SPINE &amp; OTHER [Member]",
        "label": "SPINE, SPORTS &amp; OTHER [Member]",
        "terseLabel": "SPINE,SPORTS &amp; OTHER"
       }
      }
     },
     "localname": "SPINESPORTSOTHERMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SURGICALMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SURGICAL [Member]",
        "label": "SURGICAL [Member]",
        "terseLabel": "SURGICAL"
       }
      }
     },
     "localname": "SURGICALMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SalesBySegmentOfBusinessTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales by segment of business.",
        "label": "Sales By Segment Of Business [Table Text Block]",
        "terseLabel": "Schedule of Sales by Segment of Business"
       }
      }
     },
     "localname": "SalesBySegmentOfBusinessTableTextBlock",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_SalesReturnReserve": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales return reserve",
        "label": "Sales Return Reserve",
        "terseLabel": "Sales return reserve (as a percent)"
       }
      }
     },
     "localname": "SalesReturnReserve",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_SavingsPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Savings Plan.",
        "label": "Savings Plan [Abstract]",
        "terseLabel": "Savings Plan [Abstract]"
       }
      }
     },
     "localname": "SavingsPlanAbstract",
     "nsuri": "http://www.jnj.com/20230101",
     "xbrltype": "stringItemType"
    },
    "jnj_SavingsPlanTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Savings Plan.",
        "label": "Savings Plan [Text Block]",
        "terseLabel": "Savings Plan"
       }
      }
     },
     "localname": "SavingsPlanTextBlock",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SavingsPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of estimated future employer contributions.",
        "label": "Schedule Of Estimated Future Employer Contributions [Table Text Block]",
        "terseLabel": "Projected Future Minimum Contributions to the Company's U.S. and International Unfunded Retirement Plans"
       }
      }
     },
     "localname": "ScheduleOfEstimatedFutureEmployerContributionsTableTextBlock",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "label": "Schedule of Finite and Indefinite-Lived Intangible Assets Excluding Goodwill by Major Class [Table Text Block]",
        "verboseLabel": "Schedule of Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "ScheduleOfFiniteAndIndefiniteLivedIntangibleAssetsExcludingGoodwillByMajorClassTableTextBlock",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "jnj_ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "label": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]",
        "terseLabel": "Schedule of Finite-Lived And Indefinite-Lived Intangible Assets By Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedAndIndefiniteLivedIntangibleAssetsByMajorClassTable",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_SegmentsTotalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Segments Total",
        "label": "Segments Total [Member]",
        "terseLabel": "Segments Total"
       }
      }
     },
     "localname": "SegmentsTotalMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Equity Instruments Other Than Options, Canceled, Forfeited and Adjusted During the Period",
        "terseLabel": "Canceled/forfeited/adjusted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsCanceledForfeitedandAdjustedDuringthePeriod",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Tradeable Contingent Value Right"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonTradeableContingentValueRight",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards",
        "terseLabel": "Shares subject to full value awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwards",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards, Excess",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Full Value Awards, Excess",
        "terseLabel": "Shares subject to full value award, excess (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToFullValueAwardsExcess",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Stock Options Or Stock Appreciation Rights",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number, May Be Issued Subject To Stock Options Or Stock Appreciation Rights",
        "terseLabel": "Shares issued subject to stock options or stock appreciation rights (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumberMayBeIssuedSubjectToStockOptionsOrStockAppreciationRights",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right",
        "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares, Non-Tradeable Contingent Value Right"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesNonTradeableContingentValueRight",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "jnj_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation shares authorized under stock option plans by exercise price range.",
        "label": "Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Abstract]",
        "terseLabel": "Stock options outstanding and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAbstract",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "jnj_SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock assumed to be purchased using the proceeds that could be obtained upon exercise of potential shares exercisable under stock option plans, at the average market price during the period.",
        "label": "Shares Which Could Be Repurchased Under Treasury Stock Method",
        "negatedTerseLabel": "Less: shares repurchased under treasury stock method (in shares)"
       }
      }
     },
     "localname": "SharesWhichCouldBeRepurchasedUnderTreasuryStockMethod",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "jnj_ShippingandHandlingCostsasaPercentofSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shipping and Handling Costs as a Percent of Sales",
        "label": "Shipping and Handling Costs as a Percent of Sales",
        "terseLabel": "Shipping and handling costs as a percent of sales"
       }
      }
     },
     "localname": "ShippingandHandlingCostsasaPercentofSales",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_ShortTermInvestmentFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short term investment funds.",
        "label": "Short Term Investment Funds [Member]",
        "terseLabel": "Short-term investment funds"
       }
      }
     },
     "localname": "ShortTermInvestmentFundsMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SimponiSimponiAriaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Simponi/Simponi Aria [Member]",
        "label": "Simponi/Simponi Aria [Member]",
        "terseLabel": "Simponi/Simponi Aria"
       }
      }
     },
     "localname": "SimponiSimponiAriaMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SkinHealthBeautyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Skin health/Beauty",
        "label": "Skin health/Beauty [Member]",
        "terseLabel": "Skin health/Beauty"
       }
      }
     },
     "localname": "SkinHealthBeautyMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_StelaraMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stelara [Member]",
        "label": "Stelara [Member]",
        "terseLabel": "Stelara"
       }
      }
     },
     "localname": "StelaraMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SupplyChainMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supply Chain",
        "label": "Supply Chain [Member]",
        "terseLabel": "Supply Chain"
       }
      }
     },
     "localname": "SupplyChainMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SurgeryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgery [Member]",
        "label": "Surgery [Member]",
        "terseLabel": "Surgery"
       }
      }
     },
     "localname": "SurgeryMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_SurgicalMeshProductsMarketingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Surgical Mesh Products Marketing",
        "label": "Surgical Mesh Products Marketing [Member]",
        "terseLabel": "Surgical Mesh Products Marketing"
       }
      }
     },
     "localname": "SurgicalMeshProductsMarketingMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TRAUMAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TRAUMA [Member]",
        "label": "TRAUMA [Member]",
        "terseLabel": "TRAUMA"
       }
      }
     },
     "localname": "TRAUMAMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TalcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Talc [Member]",
        "label": "Talc [Member]",
        "terseLabel": "Talc"
       }
      }
     },
     "localname": "TalcMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability",
        "label": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability",
        "terseLabel": "TCJA, provisional liability"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiability",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent",
        "label": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Provisional Liability, Noncurrent",
        "terseLabel": "TJCA , provisional liability, non-current"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingProvisionalLiabilityNoncurrent",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent",
        "label": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Cash And Cash Equivalents, Tax Rate, Percent",
        "terseLabel": "TCJA, undistributed foreign earnings percent related to cash and cash equivalents"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017UndistributedForeignEarningsCashAndCashEquivalentsTaxRatePercent",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent",
        "label": "Tax Cuts And Jobs Act Of 2017, Undistributed Foreign Earnings, Other Than Cash And Cash Equivalents, Tax Rate, Percent",
        "terseLabel": "TCJA, undistributed foreign earnings percent related to earnings other than cash and cash equivalents"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017UndistributedForeignEarningsOtherThanCashAndCashEquivalentsTaxRatePercent",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "jnj_TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Treasury stock issued for employee compensation and stock option plans, net of cash proceeds.",
        "label": "Treasury Stock Issued For Employee Compensation And Stock Option Plans Net Of Cash Proceeds",
        "terseLabel": "Treasury stock issued for employee compensation and stock option plans, net of cash proceeds/ employee withholding tax on stock awards"
       }
      }
     },
     "localname": "TreasuryStockIssuedForEmployeeCompensationAndStockOptionPlansNetOfCashProceeds",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_TremfyaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tremfaya",
        "label": "Tremfya [Member]",
        "terseLabel": "Tremfya"
       }
      }
     },
     "localname": "TremfyaMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UNITEDSTATESExportsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UNITED STATES Exports [Member]",
        "label": "UNITED STATES Exports [Member]",
        "terseLabel": "UNITED STATES Exports"
       }
      }
     },
     "localname": "UNITEDSTATESExportsMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UPTRAVIMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "UPTRAVI [Member]",
        "label": "UPTRAVI [Member]",
        "terseLabel": "UPTRAVI"
       }
      }
     },
     "localname": "UPTRAVIMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UnfundedPlansMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unfunded plans.",
        "label": "Unfunded Plans [Member]",
        "terseLabel": "Unfunded Plans"
       }
      }
     },
     "localname": "UnfundedPlansMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_UnrecognizedTaxBenefitLiabilityPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unrecognized Tax Benefit Liability, Payment",
        "label": "Unrecognized Tax Benefit Liability, Payment",
        "terseLabel": "Payment on unrecognized tax benefit liability"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitLiabilityPayment",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "jnj_VerbSurgicalIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Verb Surgical Inc.",
        "label": "Verb Surgical Inc. [Member]",
        "terseLabel": "Verb Surgical Inc."
       }
      }
     },
     "localname": "VerbSurgicalIncMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_VisionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vision[Member]",
        "label": "Vision [Member]",
        "terseLabel": "Vision"
       }
      }
     },
     "localname": "VisionMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WesternHemisphereExcludingUSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Western Hemisphere, excluding U.S. [Member]",
        "label": "Western Hemisphere, excluding U.S. [Member]",
        "terseLabel": "Western Hemisphere excluding U.S."
       }
      }
     },
     "localname": "WesternHemisphereExcludingUSMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_Wholesaler1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesaler 1 [Member]",
        "label": "Wholesaler 1 [Member]",
        "terseLabel": "Wholesaler 1"
       }
      }
     },
     "localname": "Wholesaler1Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_Wholesaler2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesaler 2 [Member]",
        "label": "Wholesaler 2 [Member]",
        "terseLabel": "Wholesaler 2"
       }
      }
     },
     "localname": "Wholesaler2Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_Wholesaler3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesaler 3 [Member]",
        "label": "Wholesaler 3 [Member]",
        "terseLabel": "Wholesaler 3"
       }
      }
     },
     "localname": "Wholesaler3Member",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WholesalerConcentrationRiskMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wholesaler Concentration Risk",
        "label": "Wholesaler Concentration Risk [Member]",
        "terseLabel": "Wholesaler Concentration Risk"
       }
      }
     },
     "localname": "WholesalerConcentrationRiskMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WomensHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Women's Health [Member]",
        "label": "Women's Health [Member]",
        "terseLabel": "Women's Health"
       }
      }
     },
     "localname": "WomensHealthMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_WoundCareandOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Wound Care and Other [Member]",
        "label": "Wound Care and Other [Member]",
        "terseLabel": "Wound Care and Other"
       }
      }
     },
     "localname": "WoundCareandOtherMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_XareltoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xarelto [Member]",
        "label": "Xarelto [Member]",
        "terseLabel": "XARELTO"
       }
      }
     },
     "localname": "XareltoMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "jnj_ZYTIGAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ZYTIGA [Member]",
        "label": "ZYTIGA [Member]",
        "terseLabel": "ZYTIGA/abiraterone acetate"
       }
      }
     },
     "localname": "ZYTIGAMember",
     "nsuri": "http://www.jnj.com/20230101",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r351",
      "r390",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r418",
      "r498",
      "r499",
      "r500",
      "r501",
      "r503",
      "r504",
      "r506",
      "r508",
      "r509",
      "r998",
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [
      "r351",
      "r390",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r414",
      "r418",
      "r498",
      "r499",
      "r500",
      "r501",
      "r503",
      "r504",
      "r506",
      "r508",
      "r509",
      "r998",
      "r999"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r348",
      "r349",
      "r514",
      "r542",
      "r881",
      "r884"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case Type [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r424",
      "r908",
      "r1002",
      "r1077"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r496",
      "r630",
      "r803",
      "r836",
      "r873",
      "r874",
      "r905",
      "r919",
      "r929",
      "r1000",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r496",
      "r630",
      "r803",
      "r836",
      "r873",
      "r874",
      "r905",
      "r919",
      "r929",
      "r1000",
      "r1066",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r424",
      "r908",
      "r1002",
      "r1077"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r420",
      "r805",
      "r906",
      "r927",
      "r996",
      "r997",
      "r1002",
      "r1076"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r420",
      "r805",
      "r906",
      "r927",
      "r996",
      "r997",
      "r1002",
      "r1076"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/LegalProceedingsDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r496",
      "r576",
      "r630",
      "r659",
      "r660",
      "r661",
      "r779",
      "r803",
      "r836",
      "r873",
      "r874",
      "r905",
      "r919",
      "r929",
      "r991",
      "r1000",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r496",
      "r576",
      "r630",
      "r659",
      "r660",
      "r661",
      "r779",
      "r803",
      "r836",
      "r873",
      "r874",
      "r905",
      "r919",
      "r929",
      "r991",
      "r1000",
      "r1067",
      "r1068",
      "r1069",
      "r1070",
      "r1071"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r348",
      "r349",
      "r514",
      "r542",
      "r883",
      "r884"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r421",
      "r422",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r907",
      "r928",
      "r1002"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r421",
      "r422",
      "r859",
      "r864",
      "r865",
      "r866",
      "r867",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r907",
      "r928",
      "r1002"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]",
        "terseLabel": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r13",
      "r926"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r426",
      "r427"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "verboseLabel": "Accounts receivable trade, less allowances for doubtful accounts $203 (2021, $230)"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "auth_ref": [
      "r3",
      "r259",
      "r275"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.",
        "label": "Accrued Income Taxes, Current",
        "verboseLabel": "Accrued taxes on income (Note 8)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedIncomeTaxesNoncurrent": {
     "auth_ref": [
      "r5",
      "r259",
      "r275"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all domestic and foreign income tax obligations due beyond one year or the operating cycle, whichever is longer. Alternate captions include income taxes payable, noncurrent.",
        "label": "Accrued Income Taxes, Noncurrent",
        "terseLabel": "Long-term taxes payable (Note 1)"
       }
      }
     },
     "localname": "AccruedIncomeTaxesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Liabilities, Current",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentMember": {
     "auth_ref": [
      "r33",
      "r41",
      "r207",
      "r947",
      "r948",
      "r949"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]",
        "terseLabel": "Employee Benefit Plans"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r122",
      "r295"
     ],
     "calculation": {
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r321",
      "r331",
      "r332",
      "r716",
      "r885",
      "r947"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Gain/ (Loss) On Derivatives &amp; Hedges"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r316",
      "r317",
      "r318",
      "r321",
      "r331",
      "r332",
      "r947"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "terseLabel": "Gain/(Loss) On Securities"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r38",
      "r40",
      "r41",
      "r306",
      "r831",
      "r841",
      "r842"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive income (loss) (Note\u00a013)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [
      "r330",
      "r331",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r756"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r37",
      "r41",
      "r207",
      "r769",
      "r837",
      "r838",
      "r947",
      "r948",
      "r949",
      "r962",
      "r963",
      "r964"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r31",
      "r41",
      "r207",
      "r331",
      "r332",
      "r750",
      "r751",
      "r752",
      "r753",
      "r756",
      "r947"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquisitionCosts": {
     "auth_ref": [
      "r251",
      "r252"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The capitalized costs incurred during the period (excluded from amortization) to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.",
        "label": "Acquisition Costs, Period Cost",
        "terseLabel": "Acquisition Costs, Period Cost"
       }
      }
     },
     "localname": "AcquisitionCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r176",
      "r177",
      "r634"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Employee compensation and stock option plans"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Adjustments to reconcile net earnings to cash flows from operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "auth_ref": [
      "r673"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for advertising cost.",
        "label": "Advertising Cost [Policy Text Block]",
        "terseLabel": "Advertising"
       }
      }
     },
     "localname": "AdvertisingCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r674"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r663"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-Based Payment Arrangement, Expense",
        "terseLabel": "Compensation cost charged for Long term incentive plan"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r307",
      "r428",
      "r444"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "verboseLabel": "Allowances for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r69",
      "r108",
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "verboseLabel": "Amortization expense of amortizable intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r911"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss.",
        "label": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax",
        "terseLabel": "Total recognized in net periodic benefit cost and other comprehensive income"
       }
      }
     },
     "localname": "AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]",
        "terseLabel": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax [Abstract]"
       }
      }
     },
     "localname": "AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AociLossCashFlowHedgeCumulativeGainLossAfterTax": {
     "auth_ref": [
      "r319"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of accumulated gain (loss) on derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "AOCI, Cash Flow Hedge, Cumulative Gain (Loss), after Tax",
        "terseLabel": "Deferred net losses (gains) on derivatives included in accumulated other comprehensive income"
       }
      }
     },
     "localname": "AociLossCashFlowHedgeCumulativeGainLossAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r69",
      "r120"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Asset write-downs"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r257",
      "r274",
      "r299",
      "r344",
      "r398",
      "r410",
      "r416",
      "r442",
      "r498",
      "r499",
      "r501",
      "r502",
      "r503",
      "r505",
      "r507",
      "r509",
      "r510",
      "r714",
      "r718",
      "r739",
      "r926",
      "r998",
      "r999",
      "r1064"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets",
        "verboseLabel": "Identifiable Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "verboseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r290",
      "r310",
      "r344",
      "r442",
      "r498",
      "r499",
      "r501",
      "r502",
      "r503",
      "r505",
      "r507",
      "r509",
      "r510",
      "r714",
      "r718",
      "r739",
      "r926",
      "r998",
      "r999",
      "r1064"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "verboseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Available-for-sale, unrecognized loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r431",
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "terseLabel": "Carrying Amount, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost": {
     "auth_ref": [
      "r97"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "auth_ref": [
      "r94",
      "r434",
      "r829"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "terseLabel": "Due after five years through ten years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost": {
     "auth_ref": [
      "r96"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r94",
      "r433",
      "r828"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Due after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Fair Value, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r970",
      "r971",
      "r1074"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "terseLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r970",
      "r971",
      "r1073"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "terseLabel": "Total debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-Sale, Maturity, Allocated and Single Maturity Date, Amortized Cost [Abstract]",
        "terseLabel": "Cost Basis"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r94",
      "r432",
      "r827"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Due within one year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesContractualMaturitiesofAvailableforSaleSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r92",
      "r430",
      "r451",
      "r821"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale",
        "terseLabel": "Debt securities",
        "verboseLabel": "Fair value, available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableforsaleSecuritiesMember": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Available-for-Sale Securities [Member]",
        "terseLabel": "Available-for-sale Securities"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r217",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BuildingAndBuildingImprovementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing.",
        "label": "Building and Building Improvements [Member]",
        "terseLabel": "Building and building equipment"
       }
      }
     },
     "localname": "BuildingAndBuildingImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r708",
      "r913",
      "r916"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r192",
      "r193",
      "r708",
      "r913",
      "r916"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Acquisition price (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Acquisition related costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination and Asset Acquisition [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationAndAssetAcquisitionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r198",
      "r199",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable": {
     "auth_ref": [
      "r198",
      "r199"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.",
        "label": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable",
        "terseLabel": "Business Combination, Consideration Transferred, Equity Interests Issued and Issuable"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferredLiabilitiesIncurred": {
     "auth_ref": [
      "r196",
      "r198",
      "r199",
      "r711"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred by the acquirer as part of consideration transferred in a business combination.",
        "label": "Business Combination, Consideration Transferred, Liabilities Incurred",
        "terseLabel": "Additions (7)"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredLiabilitiesIncurred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r713",
      "r954"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration reversal"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r197",
      "r200",
      "r712"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration liability"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r202",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "verboseLabel": "Acquisitions and Divestitures"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestitures"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets",
        "terseLabel": "Other assets assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments in debt and equity securities, including, but not limited to, held-to-maturity, trading and available-for-sale expected to be converted to cash, sold or exchanged within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Marketable Securities",
        "terseLabel": "Marketable securities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities",
        "terseLabel": "Liabilities assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Deferred tax liability, acquisition"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets assumed"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities",
        "terseLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash Acquired from Acquisition"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r71",
      "r293",
      "r876"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and Cash Equivalents, at Carrying Value",
        "verboseLabel": "Cash and cash equivalents (Notes\u00a01 and 2)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Cash and Cash Equivalents [Line Items]",
        "terseLabel": "Cash and Cash Equivalents [Line Items]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "terseLabel": "Cash, Cash Equivalents and Current Marketable Securities"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, and Short-Term Investments [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, and Short-term Investments [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r64",
      "r71",
      "r77"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents, end of year (Note\u00a01)",
        "periodStartLabel": "Cash and cash equivalents, beginning of year (Note\u00a01)"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r64",
      "r244"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "(Decrease)/Increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r214"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental schedule of non-cash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r344",
      "r367",
      "r368",
      "r370",
      "r372",
      "r380",
      "r381",
      "r442",
      "r498",
      "r501",
      "r502",
      "r503",
      "r509",
      "r510",
      "r540",
      "r541",
      "r543",
      "r544",
      "r546",
      "r739",
      "r875",
      "r942",
      "r957",
      "r965"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r145",
      "r146",
      "r147",
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "auth_ref": [
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.",
        "label": "Collateral Already Posted, Aggregate Fair Value",
        "terseLabel": "Collateral paid"
       }
      }
     },
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r133"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r24",
      "r264",
      "r282"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies (Note 19)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockDividendsPerShareCashPaid": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends paid during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Cash Paid",
        "terseLabel": "Cash dividends paid (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareCashPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquityParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividend (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r962",
      "r963",
      "r1058"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock Issued Amount",
        "verboseLabel": "Common Stock, Par Value $1.00"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity",
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Common stock, par value per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7",
      "r926"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "verboseLabel": "Common stock\u00a0\u2014 par value $1.00 per share (Note\u00a012) (authorized 4,320,000,000\u00a0shares; issued 3,119,843,000\u00a0shares)"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retirement Benefits [Abstract]",
        "terseLabel": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Related Costs [Abstract]",
        "terseLabel": "Compensation Related Costs [Abstract]"
       }
      }
     },
     "localname": "CompensationRelatedCostsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CompensationRelatedCostsGeneralTextBlock": {
     "auth_ref": [
      "r550",
      "r551"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for compensation costs, including compensated absences accruals, compensated absences liability, deferred compensation arrangements and income statement compensation items. Deferred compensation arrangements may include a description of an arrangement with an individual employee, which is generally an employment contract between the entity and a selected officer or key employee containing a promise by the employer to pay certain amounts at designated future dates, usually including a period after retirement, upon compliance with stipulated requirements. This type of arrangement is distinguished from broader based employee benefit plans as it is usually tailored to the employee. Disclosure also typically includes the amount of related compensation expense recognized during the reporting period, the number of shares (units) issued during the period under such arrangements, and the carrying amount as of the balance sheet date of the related liability.",
        "label": "Compensation Related Costs, General [Text Block]",
        "terseLabel": "Employee Related Obligations"
       }
      }
     },
     "localname": "CompensationRelatedCostsGeneralTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligations"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Components of Deferred Tax Assets and Liabilities [Abstract]"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r205",
      "r209",
      "r326",
      "r328",
      "r335",
      "r823",
      "r833"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r53",
      "r334",
      "r822",
      "r832"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "verboseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLoss"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r82",
      "r83",
      "r242",
      "r243",
      "r424",
      "r860"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r82",
      "r83",
      "r242",
      "r243",
      "r424",
      "r843",
      "r860"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r82",
      "r83",
      "r242",
      "r243",
      "r424",
      "r860",
      "r1079"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r82",
      "r83",
      "r242",
      "r243",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Concentration risk (as a percent)"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r82",
      "r83",
      "r242",
      "r243",
      "r424",
      "r860"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r206",
      "r886"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertibleDebtMember": {
     "auth_ref": [
      "r136",
      "r511",
      "r512",
      "r523",
      "r524",
      "r525",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock.",
        "label": "Convertible Debt [Member]",
        "terseLabel": "Convertible Debt"
       }
      }
     },
     "localname": "ConvertibleDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r909",
      "r911",
      "r1078"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r90",
      "r409",
      "r410",
      "r411",
      "r412",
      "r418",
      "r969"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "terseLabel": "Corporate, Non-Segment"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r49",
      "r805"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Products Sold",
        "verboseLabel": "Cost of products sold"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CrossCurrencyInterestRateContractMember": {
     "auth_ref": [
      "r1008",
      "r1057"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to interest rates and foreign exchange rates.",
        "label": "Cross Currency Interest Rate Contract [Member]",
        "terseLabel": "Cross currency interest rate swaps contracts:",
        "verboseLabel": "Cross currency interest rate swaps"
       }
      }
     },
     "localname": "CrossCurrencyInterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r960",
      "r1048",
      "r1050"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "U.S. taxes"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r960",
      "r1048"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "International taxes"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r190",
      "r692",
      "r700",
      "r960"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total currently payable"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Currently payable:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DamagesFromProductDefectsMember": {
     "auth_ref": [
      "r993"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk of loss arises with respect to product defects and recalls, or improperly performed services which actually or allegedly resulted in damages suffered by the injured party, excluding major product liability matters.",
        "label": "Damages from Product Defects [Member]",
        "terseLabel": "Damages from Product Defects"
       }
      }
     },
     "localname": "DamagesFromProductDefectsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r74",
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of debt"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of debt and lease obligation, classified as current.",
        "label": "Debt, Current",
        "terseLabel": "Short-term borrowings and the current portion of long-term debt"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Disclosure [Abstract]",
        "terseLabel": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r137",
      "r343",
      "r516",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521",
      "r522",
      "r527",
      "r534",
      "r535",
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Borrowings"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/Borrowings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r258",
      "r261",
      "r271",
      "r351",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r761",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r958"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments": {
     "auth_ref": [
      "r21",
      "r139",
      "r140",
      "r142",
      "r513"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.",
        "label": "Debt Instrument, Convertible, Number of Equity Instruments",
        "terseLabel": "Convertible Debt, number of equity instruments (in shares)"
       }
      }
     },
     "localname": "DebtInstrumentConvertibleNumberOfEquityInstruments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r247",
      "r249",
      "r511",
      "r761",
      "r901",
      "r902"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r20",
      "r247",
      "r539",
      "r761"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "terseLabel": "Effective interest rate"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r20",
      "r512"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Stated interest rate (as a percent)"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r22",
      "r351",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r761",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r958"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r22",
      "r139",
      "r141",
      "r142",
      "r143",
      "r246",
      "r247",
      "r249",
      "r270",
      "r351",
      "r511",
      "r512",
      "r513",
      "r514",
      "r515",
      "r517",
      "r523",
      "r524",
      "r525",
      "r526",
      "r528",
      "r529",
      "r530",
      "r531",
      "r532",
      "r533",
      "r536",
      "r761",
      "r900",
      "r901",
      "r902",
      "r903",
      "r904",
      "r958"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Debt Instrument, Term",
        "terseLabel": "Debt instrument, term"
       }
      }
     },
     "localname": "DebtInstrumentTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "auth_ref": [
      "r973"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "terseLabel": "Contractual Maturities of Available for Sale Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Debt securities",
        "verboseLabel": "Debt instruments"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Debt, weighted average interest rate"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeferredCompensationLiabilityCurrentAndNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1": {
       "order": 4.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate carrying value as of the balance sheet date of the liabilities for all deferred compensation arrangements. Represents currently earned compensation under compensation arrangements that is not actually paid until a later date.",
        "label": "Deferred Compensation Liability, Current and Noncurrent",
        "terseLabel": "Deferred compensation"
       }
      }
     },
     "localname": "DeferredCompensationLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r960",
      "r1049",
      "r1050"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "U.S. taxes"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r190",
      "r960",
      "r1049"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "International taxes"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r678",
      "r679"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "verboseLabel": "Deferred taxes on income (Note\u00a08)"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r69",
      "r190",
      "r693",
      "r699",
      "r700",
      "r960"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred",
        "verboseLabel": "Deferred tax provision"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r678",
      "r679"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "verboseLabel": "Deferred taxes on income (Note 8)"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r188",
      "r1047"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Income reported for tax purposes"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r1046"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r1046"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred income taxes"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": {
     "auth_ref": [
      "r188",
      "r1047"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign",
        "terseLabel": "Net realizable operating loss carryforwards(4)"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r188",
      "r1047"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "Miscellaneous international"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
     "auth_ref": [
      "r188",
      "r1047"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "terseLabel": "Employee related obligations"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r188",
      "r1047"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r188",
      "r1047"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Reserves\u00a0&amp; liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r179",
      "r1046"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Total deferred income taxes"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r188",
      "r1047"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedTerseLabel": "Goodwill and intangibles"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r188",
      "r1047"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedTerseLabel": "Miscellaneous international"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r188",
      "r1047"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedTerseLabel": "Depreciation of property, plant and equipment"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": {
     "auth_ref": [
      "r1047"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.",
        "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "negatedTerseLabel": "Undistributed foreign earnings"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities": {
     "auth_ref": [
      "r152",
      "r153",
      "r260",
      "r276"
     ],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1": {
       "order": 1.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan. Excludes other postretirement benefit plan.",
        "label": "Liability, Defined Benefit Pension Plan",
        "terseLabel": "Pension benefits"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlanCurrentAndNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "auth_ref": [
      "r585"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": {
     "auth_ref": [
      "r34",
      "r41",
      "r1011"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax",
        "totalLabel": "Total before tax effects"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": {
     "auth_ref": [
      "r41",
      "r597"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax",
        "negatedLabel": "Net actuarial loss"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r41",
      "r597"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax",
        "terseLabel": "Prior service cost (credit)(1)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax": {
     "auth_ref": [
      "r36",
      "r41",
      "r597"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for transition asset (obligation) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Transition Asset (Obligation), before Tax",
        "terseLabel": "Unrecognized net transition obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetTransitionAssetsObligationsBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r567",
      "r911"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Actual return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r560"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedTerseLabel": "Actuarial (gains) losses(1)"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r554",
      "r592",
      "r618",
      "r911",
      "r912"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Recognized actuarial losses (gains)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r554",
      "r593",
      "r619",
      "r911",
      "r912"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "verboseLabel": "Amortization of prior service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": {
     "auth_ref": [
      "r152",
      "r153"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position",
        "totalLabel": "Total recognized in the consolidated balance sheet\u00a0\u2014 end of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position [Abstract]",
        "terseLabel": "Amounts Recognized in the Company\u2019s Balance Sheet consist of the following:"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]",
        "terseLabel": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss) [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r256",
      "r273",
      "r552",
      "r553",
      "r575",
      "r911"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Non-current assets",
        "verboseLabel": "Prepaid employee related obligations"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]",
        "terseLabel": "Defined Benefit Plan, Assumed Health Care Cost Trend Rates [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumedHealthCareCostTrendRatesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Rate of increase in compensation levels"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r599"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Service cost discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r601",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-Term Rate of Return on Plan Assets",
        "terseLabel": "Expected long-term rate of return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "auth_ref": [
      "r600"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "terseLabel": "Rate of increase in compensation levels"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r555"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "periodEndLabel": "Projected benefit obligation - end of year",
        "periodStartLabel": "Projected benefit obligation - beginning of year",
        "terseLabel": "Projected Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r562",
      "r626"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedTerseLabel": "Benefits paid from plan"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": {
     "auth_ref": [
      "r559"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.",
        "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant",
        "terseLabel": "Plan participant contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r604",
      "r909",
      "r910",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "verboseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Change in Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r569",
      "r579",
      "r622",
      "r909",
      "r910",
      "r911",
      "r912"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Company contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r586"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, after Year Five for Next Five Years",
        "terseLabel": "2027-2031"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r586"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in next fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year One",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r586"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fifth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r586"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in fourth fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r586"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in third fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r586"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of benefit for defined benefit plan expected to be paid in second fiscal year following current fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r554",
      "r591",
      "r617",
      "r911",
      "r912"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r566",
      "r577",
      "r579",
      "r580",
      "r909",
      "r910",
      "r911"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "periodEndLabel": "Plan assets at fair value\u00a0- End of year",
        "periodStartLabel": "Plan assets at fair value\u00a0\u2014 beginning of year",
        "verboseLabel": "Plan Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "auth_ref": [
      "r561"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Effect of exchange rates"
       }
      }
     },
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r552",
      "r575",
      "r911"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "terseLabel": "Projected Benefit Obligation",
        "totalLabel": "Funded status - end of year"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assumed rate, for next fiscal year, based on annual change in cost of health care cost benefits used to measure expected cost of benefits covered by defined benefit postretirement plan. Factors include, but are not limited to, estimate of health care inflation, change in health care utilization or delivery pattern, technological advances, and change in health status of participant. Excludes factors for change in composition of plan population by age and dependency status.",
        "label": "Defined Benefit Plan, Health Care Cost Trend Rate Assumed, Next Fiscal Year",
        "terseLabel": "Healthcare cost trend rate assumed for next year"
       }
      }
     },
     "localname": "DefinedBenefitPlanHealthCareCostTrendRateAssumedNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r554",
      "r558",
      "r590",
      "r616",
      "r911",
      "r912"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost",
        "verboseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r588",
      "r614",
      "r911",
      "r912"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "terseLabel": "Net periodic benefit cost (credit)",
        "totalLabel": "Net periodic benefit cost (credit)"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "auth_ref": [
      "r611",
      "r612",
      "r911"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "terseLabel": "Accumulated benefit obligation unfunded plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "auth_ref": [
      "r611",
      "r612",
      "r911"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "terseLabel": "Plan with accumulated benefit obligation in excess of plan assets, plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation": {
     "auth_ref": [
      "r1012"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "terseLabel": "Projected benefit obligation, unfunded plans"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateProjectedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAmendments": {
     "auth_ref": [
      "r563"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment",
        "terseLabel": "Amendments"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAmendments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r571",
      "r1014"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedTerseLabel": "Benefits paid from plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": {
     "auth_ref": [
      "r570"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant",
        "terseLabel": "Plan participant contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r568"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Effect of exchange rates"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r576",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Target Allocation"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1": {
     "auth_ref": [
      "r1006",
      "r1009",
      "r1013"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from settlement and curtailment.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement and Curtailment",
        "negatedTerseLabel": "Curtailments and settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlementsAndCurtailments1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r556",
      "r589",
      "r615",
      "r911",
      "r912"
     ],
     "calculation": {
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost",
        "verboseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan.",
        "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate",
        "terseLabel": "Rate to which the cost trend rate is assumed to decline (ultimate trend)"
       }
      }
     },
     "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations": {
     "auth_ref": [
      "r1007"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage",
        "terseLabel": "Percent of Plan Assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]",
        "terseLabel": "Benefit Obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]",
        "terseLabel": "Net Periodic Benefit Cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate": {
     "auth_ref": [
      "r603"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Year ultimate health care cost trend rate is expected to be reached, in YYYY format.",
        "label": "Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate",
        "terseLabel": "Defined Benefit Plan, Year Health Care Cost Trend Rate Reaches Ultimate Trend Rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanYearHealthCareCostTrendRateReachesUltimateTrendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansAssumedHealthCareCostTrendRatesDetails"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r627"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Matching contributions"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SavingsPlanNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r69",
      "r393"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and Amortization",
        "verboseLabel": "Depreciation and amortization of property and intangibles"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetFairValueGrossLiability": {
     "auth_ref": [
      "r27",
      "r29",
      "r219"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of liability associated with financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, Liability Offset",
        "negatedTerseLabel": "Credit Support Agreement (CSA)"
       }
      }
     },
     "localname": "DerivativeAssetFairValueGrossLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r312",
      "r313",
      "r738",
      "r884"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "totalLabel": "Total Net Asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r312"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Derivative Asset, Current"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeExcludedComponentGainLossRecognizedInEarnings": {
     "auth_ref": [
      "r724",
      "r1055"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from excluded component of derivative hedge, recognized in earnings. Excludes recognition under systematic and rational method.",
        "label": "Derivative, Excluded Component, Gain (Loss), Recognized in Earnings",
        "terseLabel": "Amount of gain or (loss) recognized in income on derivative amount excluded from effectiveness testing"
       }
      }
     },
     "localname": "DerivativeExcludedComponentGainLossRecognizedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeAsset": {
     "auth_ref": [
      "r28",
      "r219",
      "r250",
      "r311",
      "r884"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets elected not to be offset. Excludes assets not subject to a master netting arrangement.",
        "label": "Derivative Asset, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Total Gross Assets"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r28",
      "r219",
      "r250",
      "r311",
      "r884"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, before Offset",
        "terseLabel": "Carrying Amount of the Hedged Liability",
        "verboseLabel": "Total Gross Liabilities"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r1054"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Gain/(Loss) Recognized In Income on Derivative"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "auth_ref": [
      "r1054"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of income or comprehensive income that includes gain (loss) from derivative.",
        "label": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "terseLabel": "Derivative, Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]"
       }
      }
     },
     "localname": "DerivativeGainLossStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_DerivativeInstrumentDetailAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Derivative Instrument Detail [Abstract]",
        "verboseLabel": "Financial assets and liabilities at fair value"
       }
      }
     },
     "localname": "DerivativeInstrumentDetailAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r218",
      "r220",
      "r226",
      "r228",
      "r884"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r215",
      "r218",
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r215",
      "r218",
      "r226",
      "r228",
      "r234",
      "r235",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred": {
     "auth_ref": [
      "r726"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated value of gains (losses), net anticipated to be transferred in the future from accumulated other comprehensive income into earnings.",
        "label": "Derivative Instruments, Gain (Loss) Reclassification from Accumulated OCI to Income, Estimated Net Amount to be Transferred",
        "terseLabel": "Gain/(Loss) Reclassified From Accumulated OCI Into Income"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossReclassificationFromAccumulatedOCIToIncomeEstimatedNetAmountToBeTransferred",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesAssetsAtFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative assets designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Assets, at Fair Value",
        "terseLabel": "Derivatives designated as hedging instruments : Assets"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesAssetsAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentsInHedgesLiabilitiesAtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate fair value of all derivative liabilities designated as hedging instruments. Includes instruments designated as cash flow hedges, fair value hedges, and hedges of net investments in foreign operations.",
        "label": "Derivative Instruments in Hedges, Liabilities, at Fair Value",
        "terseLabel": "Derivatives designated as hedging instruments : Liabilities"
       }
      }
     },
     "localname": "DerivativeInstrumentsInHedgesLiabilitiesAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r312",
      "r313",
      "r738",
      "r884"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "totalLabel": "Total Net Liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilityFairValueGrossAsset": {
     "auth_ref": [
      "r27",
      "r29",
      "r219",
      "r882"
     ],
     "calculation": {
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of asset associated with financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Liability, Subject to Master Netting Arrangement, Asset Offset",
        "negatedTerseLabel": "Credit Support Agreement (CSA)"
       }
      }
     },
     "localname": "DerivativeLiabilityFairValueGrossAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r1052",
      "r1053"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r215",
      "r216",
      "r223",
      "r226",
      "r231",
      "r233",
      "r235",
      "r727"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesFairValueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivatives, Fair Value [Line Items]",
        "terseLabel": "Derivatives, Fair Value [Line Items]"
       }
      }
     },
     "localname": "DerivativesFairValueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r210",
      "r211",
      "r215",
      "r216",
      "r232",
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DescriptionOfReclassificationOfCashFlowHedgeGainLoss": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the transactions or other events that will result in the reclassification into earnings of gains or losses reported in accumulated other comprehensive income. May include the time period over which gains or losses will be reclassified to earnings.",
        "label": "Description of Reclassification of Cash Flow Hedge Gain (Loss)",
        "terseLabel": "Description of reclassification of cash flow hedge gain (loss)"
       }
      }
     },
     "localname": "DescriptionOfReclassificationOfCashFlowHedgeGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r636",
      "r664",
      "r665",
      "r667",
      "r672",
      "r920"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "terseLabel": "Common Stock, Stock Option Plans and Stock Compensation Agreements"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Payment Arrangement [Abstract]",
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [
      "r913",
      "r916"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedTerseLabel": "Cash dividends paid"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableAmountPerShare": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The per share amount of a dividend declared, but not paid, as of the financial reporting date.",
        "label": "Dividends Payable, Amount Per Share",
        "terseLabel": "Dividends Payable, Amount Per Share"
       }
      }
     },
     "localname": "DividendsPayableAmountPerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r1015",
      "r1016",
      "r1017"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Earnings Per Share [Abstract]",
        "verboseLabel": "Net earnings per share (Notes 1 and 15)"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r336",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r365",
      "r367",
      "r370",
      "r371",
      "r372",
      "r376",
      "r729",
      "r730",
      "r824",
      "r834",
      "r891"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Basic net earnings per share (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r336",
      "r357",
      "r358",
      "r359",
      "r360",
      "r361",
      "r367",
      "r370",
      "r371",
      "r372",
      "r376",
      "r729",
      "r730",
      "r824",
      "r834",
      "r891"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted net earnings per share (in dollars per share)",
        "verboseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r79",
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "verboseLabel": "Reconciliation of basic net earnings per share to diluted net earnings per share"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r373",
      "r374",
      "r375",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "verboseLabel": "Earnings Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r747"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "verboseLabel": "Effect of exchange rate changes on cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r681"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective Rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]",
        "terseLabel": "Tax rates:"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r346",
      "r681",
      "r702"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductions": {
     "auth_ref": [
      "r1044",
      "r1051"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Percent",
        "terseLabel": "Effective income tax rate reconciliation, deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDeductionsOther": {
     "auth_ref": [
      "r1044",
      "r1051"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other deductions.",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Other, Percent",
        "negatedTerseLabel": "Tax benefits on share-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionsOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r1044",
      "r1051"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "International operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r1044",
      "r1051"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent",
        "terseLabel": "Effective income tax rate reconciliation, nondeductible expense, impairment losses, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r1044",
      "r1051"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "All other (3)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "verboseLabel": "Accrued compensation and employee related obligations"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee-related Liabilities [Abstract]",
        "terseLabel": "Employee-related Liabilities [Abstract]"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r666"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total compensation cost not yet recognized for option"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r666"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Weighted average period for total compensation cost not yet recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r663"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Expense, Tax Benefit",
        "terseLabel": "Total income tax benefit recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r668"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Exercise of options, tax benefit"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Severance"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "terseLabel": "Employee Stock Option"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]",
        "terseLabel": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r138",
      "r286",
      "r330",
      "r331",
      "r332",
      "r352",
      "r353",
      "r354",
      "r356",
      "r362",
      "r364",
      "r379",
      "r443",
      "r547",
      "r669",
      "r670",
      "r671",
      "r695",
      "r696",
      "r728",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r756",
      "r769",
      "r837",
      "r838",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which an instrument classified in shareholders' equity could be incurred (settled) in a current transaction between willing parties.",
        "label": "Equity, Fair Value Adjustment",
        "terseLabel": "Equity, fair value adjustment"
       }
      }
     },
     "localname": "EquityFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Equity method investments, fair value"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r300",
      "r737",
      "r878"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI), classified as current.",
        "label": "Equity Securities, FV-NI, Current",
        "terseLabel": "Equity Investments"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r103",
      "r272",
      "r930",
      "r931",
      "r932"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "terseLabel": "Equity securities",
        "verboseLabel": "Equity Securities"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": {
     "auth_ref": [
      "r440"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Amount",
        "terseLabel": "Equity securities without readily determinable fair value, amount"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]",
        "terseLabel": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r238",
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]",
        "terseLabel": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r525",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r732",
      "r776",
      "r777",
      "r778",
      "r901",
      "r902",
      "r909",
      "r910",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "verboseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r731",
      "r732",
      "r733",
      "r734",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r735"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "verboseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueHedgingMember": {
     "auth_ref": [
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A hedge of the exposure to changes in the fair value of a recognized asset or liability, or of an unrecognized firm commitment, that are attributable to a particular risk.",
        "label": "Fair Value Hedging [Member]",
        "terseLabel": "Fair Value Hedging"
       }
      }
     },
     "localname": "FairValueHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r525",
      "r579",
      "r584",
      "r732",
      "r776",
      "r909",
      "r910",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "verboseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r525",
      "r579",
      "r584",
      "r732",
      "r777",
      "r901",
      "r902",
      "r909",
      "r910",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "verboseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r525",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r732",
      "r778",
      "r901",
      "r902",
      "r909",
      "r910",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "verboseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Fair Value, Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": {
     "auth_ref": [
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements",
        "negatedTerseLabel": "Payments"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r239"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r525",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r776",
      "r777",
      "r778",
      "r901",
      "r902",
      "r909",
      "r910",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "verboseLabel": "Fair Value, Measurements, Fair Value Hierarchy [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r735",
      "r736"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value, Measurements, Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable": {
     "auth_ref": [
      "r217",
      "r223",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule that discloses the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]",
        "terseLabel": "Fair Values Derivatives, Balance Sheet Location, by Derivative Contract Type [Table]"
       }
      }
     },
     "localname": "FairValuesDerivativesBalanceSheetLocationByDerivativeContractTypeByHedgingDesignationTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r435",
      "r438",
      "r445",
      "r447",
      "r448",
      "r449",
      "r450",
      "r452",
      "r453",
      "r454",
      "r536",
      "r545",
      "r727",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r894",
      "r974",
      "r975",
      "r976",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-Lived Intangible Asset, Useful Life",
        "verboseLabel": "Intangible assets useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r297",
      "r474"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Less accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]",
        "terseLabel": "Intangible Asset Amortization Expense"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r116"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillEstimatedAmortizationofIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r470",
      "r473",
      "r474",
      "r476",
      "r806",
      "r807"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r114",
      "r807"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "verboseLabel": "Finite lived intangible assets gross"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r109",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r114",
      "r806"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "totalLabel": "Finite lived intangible assets net"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finite-Lived Intangible Assets, Net [Abstract]",
        "verboseLabel": "Intangible assets with definite lives:"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinitelivedIntangibleAssetsAcquired1": {
     "auth_ref": [
      "r471"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in assets, excluding financial assets, lacking physical substance with a definite life, from an acquisition.",
        "label": "Finite-Lived Intangible Assets Acquired",
        "terseLabel": "Finite-lived Intangible Assets Acquired"
       }
      }
     },
     "localname": "FinitelivedIntangibleAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative assets not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Asset at Fair Value",
        "terseLabel": "Derivatives not designated as hedging instruments : Assets"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsAssetAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue": {
     "auth_ref": [
      "r221"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of all foreign currency derivative liabilities not designated as hedging instruments.",
        "label": "Foreign Currency Derivative Instruments Not Designated as Hedging Instruments, Liability at Fair Value",
        "terseLabel": "Derivatives not designated as hedging instruments : Liabilities"
       }
      }
     },
     "localname": "ForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstrumentsLiabilityAtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyDisclosureTextBlock": {
     "auth_ref": [
      "r758",
      "r759",
      "r943"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for foreign currency transactions and translation. This may include description of foreign currency transactions, foreign currency gains and losses, explanation of change in cumulative translation adjustment, description of effect of subsequent foreign currency exchange rate change, cumulative translation adjustment movement, foreign currency translation adjustment by component movement, translation adjustment for net investment hedge movement, adjustment for long-term intercompany transactions, schedule of long-term intercompany balances and any other foreign currency transactions and translation related items.",
        "label": "Foreign Currency Disclosure [Text Block]",
        "terseLabel": "International Currency Transalation"
       }
      }
     },
     "localname": "ForeignCurrencyDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InternationalCurrencyTranslation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignCurrencyExchangeRateTranslation1": {
     "auth_ref": [
      "r757",
      "r758"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange rate used to translate amounts denominated in functional currency to reporting currency.",
        "label": "Foreign Currency Exchange Rate, Translation",
        "terseLabel": "Foreign currency exchange rate, translation"
       }
      }
     },
     "localname": "ForeignCurrencyExchangeRateTranslation1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": {
     "auth_ref": [
      "r740",
      "r742",
      "r744",
      "r746"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.",
        "label": "Foreign Currency Transaction Gain (Loss), before Tax",
        "terseLabel": "Foreign currency transaction gain (loss), before tax"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InternationalCurrencyTranslationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTranslationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Foreign Currency Translation [Abstract]",
        "terseLabel": "Foreign Currency Translation [Abstract]"
       }
      }
     },
     "localname": "ForeignCurrencyTranslationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r884",
      "r909",
      "r924"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign exchange contracts",
        "verboseLabel": "Forward foreign exchange contracts:"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r1015",
      "r1016",
      "r1017"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "International Plans"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfBusiness": {
     "auth_ref": [
      "r717",
      "r955"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from sale and disposal of integrated set of activities and assets capable of being conducted and managed for purpose of providing return in form of dividend, lower cost, or other economic benefit to investor, owner, member and participant.",
        "label": "Gain (Loss) on Disposition of Business",
        "terseLabel": "Gain (loss) on divestiture"
       }
      }
     },
     "localname": "GainLossOnSaleOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSalesOfAssetsAndAssetImpairmentCharges": {
     "auth_ref": [
      "r955"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) from the difference between the sale price or salvage price and the book value of an asset that was sold or retired, and gain (loss) from the write down of assets from their carrying value to fair value.",
        "label": "Gain (Loss) on Sale of Assets and Asset Impairment Charges",
        "negatedTerseLabel": "Net gain on sale of assets/businesses"
       }
      }
     },
     "localname": "GainLossOnSalesOfAssetsAndAssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r296",
      "r458",
      "r820",
      "r895",
      "r926",
      "r980",
      "r987"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill end of period",
        "periodStartLabel": "Goodwill beginning of period",
        "terseLabel": "Goodwill (Notes\u00a01 and 5)"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r460",
      "r895"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Goodwill, related to acquisitions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "verboseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r465"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Currency translation/other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillWrittenOffRelatedToSaleOfBusinessUnit": {
     "auth_ref": [
      "r462",
      "r895"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of divestiture of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Written off Related to Sale of Business Unit",
        "negatedTerseLabel": "Goodwill, related to divestitures"
       }
      }
     },
     "localname": "GoodwillWrittenOffRelatedToSaleOfBusinessUnit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrossProfit": {
     "auth_ref": [
      "r48",
      "r344",
      "r398",
      "r409",
      "r415",
      "r418",
      "r442",
      "r498",
      "r499",
      "r501",
      "r502",
      "r503",
      "r505",
      "r507",
      "r509",
      "r510",
      "r739",
      "r893",
      "r998"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.",
        "label": "Gross Profit",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "GrossProfit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r723"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Included in the Carrying Amount of the Hedged Liability"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r215",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r98",
      "r429",
      "r448",
      "r978"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Amortized Cost, before Allowance for Credit Loss",
        "terseLabel": "Carrying Amount, held-to-maturity"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r100",
      "r437"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Accumulated Unrecognized Loss",
        "negatedTerseLabel": "Held-to-maturity, unrecognized loss"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r99",
      "r436",
      "r821"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-Maturity, Fair Value",
        "terseLabel": "Fair value, held-to-maturity"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldtomaturitySecuritiesMember": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as held-to-maturity.",
        "label": "Held-to-Maturity Securities [Member]",
        "terseLabel": "Held-to-maturity Securities"
       }
      }
     },
     "localname": "HeldtomaturitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r69",
      "r118"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Impairment of intangible assets, excluding goodwill"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r345",
      "r701"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r44",
      "r254",
      "r265",
      "r285",
      "r398",
      "r409",
      "r415",
      "r418",
      "r825",
      "r893"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      },
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Earnings before provision for taxes on income",
        "totalLabel": "Earnings before provision for taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r345",
      "r701"
     ],
     "calculation": {
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "International"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesComparisonofIncomeTaxesatStatutoryRateandCompanysEffectiveTaxRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [
      "r913",
      "r916"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r477",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameAxis": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of taxing authority.",
        "label": "Income Tax Authority, Name [Axis]",
        "terseLabel": "Income Tax Authority, Name [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named agency, division or body that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority, Name [Domain]",
        "terseLabel": "Income Tax Authority, Name [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r346",
      "r682",
      "r688",
      "r691",
      "r697",
      "r703",
      "r705",
      "r706",
      "r707"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "verboseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r347",
      "r363",
      "r364",
      "r396",
      "r680",
      "r698",
      "r704",
      "r835"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for taxes on income (Note\u00a08)",
        "totalLabel": "Provision for taxes on income",
        "verboseLabel": "Incremental tax costs"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IncomeTaxesProvisionforIncomeTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r329",
      "r676",
      "r677",
      "r688",
      "r689",
      "r690",
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": {
     "auth_ref": [
      "r1044"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount",
        "terseLabel": "Repatriation of foreign earnings amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r65",
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "verboseLabel": "Increase in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "(Increase)/Decrease in accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInIntangibleAssetsCurrent": {
     "auth_ref": [
      "r68"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in intangible assets (for example patents and licenses).",
        "label": "Increase (Decrease) in Intangible Assets, Current",
        "negatedTerseLabel": "Reduction in intangible assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInIntangibleAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedLabel": "Increase in inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "verboseLabel": "Changes in assets and liabilities, net of effects from acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedLabel": "Decrease/(Increase) in other current and non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "verboseLabel": "(Decrease)/Increase in other current and non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r472",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets [Axis]",
        "verboseLabel": "Indefinite-lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r117"
     ],
     "calculation": {
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill)",
        "verboseLabel": "Indefinite lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Indefinite-Lived Intangible Assets (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets with indefinite lives:"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r110",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InformationByCategoryOfDebtSecurityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by category of debt security, either available-for-sale or held-to-maturity.",
        "label": "Debt Security Category [Axis]",
        "terseLabel": "Debt Security Category [Axis]"
       }
      }
     },
     "localname": "InformationByCategoryOfDebtSecurityAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r107",
      "r112"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Total intangible assets - net",
        "verboseLabel": "Intangible assets, net (Notes\u00a01 and 5)"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwillAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible Assets, Net (Excluding Goodwill) [Abstract]",
        "verboseLabel": "Intangible assets and Goodwill"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwillAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IntangibleAssetsNetIncludingGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.",
        "label": "Intangible Assets, Net (Including Goodwill)",
        "terseLabel": "Purchase price over fair value of assets acquired"
       }
      }
     },
     "localname": "IntangibleAssetsNetIncludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r245"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Interest expense capitalized"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r248",
      "r268",
      "r333",
      "r392",
      "r760"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense, net of portion capitalized (Note\u00a04)"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaid": {
     "auth_ref": [
      "r956"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, including, but not limited to, capitalized interest and payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount; classified as operating and investing activities.",
        "label": "Interest Paid, Including Capitalized Interest, Operating and Investing Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaid",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r338",
      "r340",
      "r341"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest, net of amount capitalized"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r884",
      "r909",
      "r923"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest rate swaps contracts:"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRateSwapMember": {
     "auth_ref": [
      "r923"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Forward based contracts in which two parties agree to swap periodic payments that are fixed at the outset of the swap contract with variable payments based on a market interest rate (index rate) over a specified period.",
        "label": "Interest Rate Swap [Member]",
        "terseLabel": "Interest Rate Swap"
       }
      }
     },
     "localname": "InterestRateSwapMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InternalRevenueServiceIRSMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.",
        "label": "Internal Revenue Service (IRS) [Member]",
        "terseLabel": "Internal Revenue Service (IRS)"
       }
      }
     },
     "localname": "InternalRevenueServiceIRSMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "verboseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r105",
      "r879"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "verboseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r309",
      "r877",
      "r926"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "totalLabel": "Total inventories",
        "verboseLabel": "Inventories (Notes\u00a01 and 3)"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory, Net [Abstract]",
        "verboseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "InventoryNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r292",
      "r308",
      "r378",
      "r455",
      "r456",
      "r457",
      "r804",
      "r887"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r105",
      "r945"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "verboseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r105",
      "r880"
     ],
     "calculation": {
      "http://www.jnj.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "verboseLabel": "Goods in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r51",
      "r391"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedTerseLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r441",
      "r1075"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r844",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r854",
      "r855",
      "r856",
      "r857",
      "r858"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_JudicialRulingMember": {
     "auth_ref": [
      "r993"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Litigation outcome that occurs as a result of judicial intervention, supervision, or approval.",
        "label": "Judicial Ruling [Member]",
        "terseLabel": "Judicial Ruling"
       }
      }
     },
     "localname": "JudicialRulingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalMattersAndContingenciesTextBlock": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for legal proceedings, legal contingencies, litigation, regulatory and environmental matters and other contingencies.",
        "label": "Legal Matters and Contingencies [Text Block]",
        "verboseLabel": "Legal Proceedings"
       }
      }
     },
     "localname": "LegalMattersAndContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedings"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r766"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r17",
      "r344",
      "r442",
      "r498",
      "r499",
      "r501",
      "r502",
      "r503",
      "r505",
      "r507",
      "r509",
      "r510",
      "r715",
      "r718",
      "r719",
      "r739",
      "r892",
      "r998",
      "r1064",
      "r1065"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r9",
      "r262",
      "r280",
      "r926",
      "r959",
      "r977",
      "r1060"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and shareholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "verboseLabel": "Liabilities and Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r19",
      "r291",
      "r344",
      "r442",
      "r498",
      "r499",
      "r501",
      "r502",
      "r503",
      "r505",
      "r507",
      "r509",
      "r510",
      "r715",
      "r718",
      "r719",
      "r739",
      "r926",
      "r998",
      "r1064",
      "r1065"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "verboseLabel": "Current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r14"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Borrowing capacity under credit facility"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [
      "r993"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [
      "r993"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermCommercialPaperCurrent": {
     "auth_ref": [
      "r16"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the current portion of long-term unsecured obligations issued by corporations and other borrowers to investors (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Long-Term Commercial Paper, Current",
        "terseLabel": "Borrowed under the commercial paper program"
       }
      }
     },
     "localname": "LongTermCommercialPaperCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r4",
      "r261",
      "r278",
      "r524",
      "r538",
      "r901",
      "r902"
     ],
     "calculation": {
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-Term Debt",
        "terseLabel": "Long-term debt",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtByMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Long-Term Debt, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Aggregate maturities of long-term obligations"
       }
      }
     },
     "localname": "LongTermDebtByMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-Term Debt, Current Maturities",
        "terseLabel": "Less current portion",
        "verboseLabel": "Current portion of long term debt"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails",
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive": {
     "auth_ref": [
      "r134",
      "r351",
      "r1001"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, after Year Five",
        "terseLabel": "After 2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "auth_ref": [
      "r134",
      "r351",
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive": {
     "auth_ref": [
      "r134",
      "r351",
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour": {
     "auth_ref": [
      "r134",
      "r351",
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "auth_ref": [
      "r134",
      "r351",
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "auth_ref": [
      "r134",
      "r351",
      "r529"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Long-Term Debt, Maturity, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsAggregateMaturitiesofLongTermObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-Term Debt [Member]",
        "terseLabel": "Long-term Debt"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofDerivativesRecordedinConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt (Note\u00a07)",
        "verboseLabel": "Total long-term debt"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r22"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-Term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r22",
      "r135"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-Term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r131",
      "r132",
      "r492",
      "r493",
      "r494",
      "r994",
      "r995"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r131",
      "r132",
      "r492",
      "r493",
      "r494",
      "r994",
      "r995"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "verboseLabel": "Product Liability Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [
      "r994",
      "r995"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Loss Contingency, Claims Dismissed, Number"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyDamagesAwardedValue": {
     "auth_ref": [
      "r993",
      "r994",
      "r995"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of damages awarded to the plaintiff in the legal matter.",
        "label": "Loss Contingency, Damages Awarded, Value",
        "terseLabel": "Damages awarded"
       }
      }
     },
     "localname": "LossContingencyDamagesAwardedValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyDamagesSoughtValue": {
     "auth_ref": [
      "r993",
      "r994",
      "r995"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value (monetary amount) of the award the plaintiff seeks in the legal matter.",
        "label": "Loss Contingency, Damages Sought, Value",
        "terseLabel": "Litigation contingency"
       }
      }
     },
     "localname": "LossContingencyDamagesSoughtValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r493",
      "r494",
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Loss contingency, estimate of possible loss"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r131",
      "r132",
      "r492",
      "r493",
      "r494",
      "r994",
      "r995"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPendingClaimsNumber": {
     "auth_ref": [
      "r994",
      "r995"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of pending claims pertaining to a loss contingency.",
        "label": "Loss Contingency, Pending Claims, Number",
        "terseLabel": "Number of pending claims"
       }
      }
     },
     "localname": "LossContingencyPendingClaimsNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities, Current",
        "terseLabel": "Current Marketable Securities",
        "verboseLabel": "Marketable securities (Notes\u00a01 and 2)"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as noncurrent.",
        "label": "Marketable Securities, Noncurrent",
        "terseLabel": "Marketable securities, noncurrent"
       }
      }
     },
     "localname": "MarketableSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in marketable security, including other-than-temporary impairment (OTTI).",
        "label": "Marketable Securities, Realized Gain (Loss)",
        "terseLabel": "Marketable securities, realized gain (loss)"
       }
      }
     },
     "localname": "MarketableSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesUnrealizedGainLoss": {
     "auth_ref": [
      "r46"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in marketable security.",
        "label": "Marketable Securities, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gain (loss) on securities"
       }
      }
     },
     "localname": "MarketableSecuritiesUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MaximumLengthOfTimeForeignCurrencyCashFlowHedge": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum period of time the entity is hedging its exposure to variability in future cash flows for forecasted transactions, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Excludes forecasted transactions related to payment of variable interest on existing financial instruments.",
        "label": "Maximum Length of Time, Foreign Currency Cash Flow Hedge",
        "terseLabel": "Maximum length of time for hedging transaction exposure"
       }
      }
     },
     "localname": "MaximumLengthOfTimeForeignCurrencyCashFlowHedge",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r1008"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r339"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "verboseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r339"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash used by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "verboseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r64",
      "r67",
      "r70"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "verboseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r45",
      "r70",
      "r266",
      "r284",
      "r289",
      "r324",
      "r327",
      "r332",
      "r344",
      "r355",
      "r357",
      "r358",
      "r359",
      "r360",
      "r363",
      "r364",
      "r369",
      "r398",
      "r409",
      "r415",
      "r418",
      "r442",
      "r498",
      "r499",
      "r501",
      "r502",
      "r503",
      "r505",
      "r507",
      "r509",
      "r510",
      "r730",
      "r739",
      "r893",
      "r998"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net earnings",
        "totalLabel": "Net earnings",
        "verboseLabel": "Net earnings"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "New Accounting Standards"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonUsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Countries excluding the United States of America (US).",
        "label": "Non-US [Member]",
        "terseLabel": "Non-US"
       }
      }
     },
     "localname": "NonUsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net book value of a nonmonetary asset transferred or exchanged in connection with the acquisition of a business or asset in a noncash transaction. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Nonmonetary assets and liabilities are assets and liabilities that will not result in cash receipts or cash payments in the future.",
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed)",
        "totalLabel": "Net cash paid for acquisitions (Note 18)"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash or Part Noncash Acquisition, Net Nonmonetary Assets Acquired (Liabilities Assumed) [Abstract]",
        "verboseLabel": "Acquisitions"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of an asset or business acquired in a noncash (or part noncash) acquisition. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Assets Acquired",
        "verboseLabel": "Fair value of assets acquired"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1": {
     "auth_ref": [
      "r74",
      "r75",
      "r76"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Noncash or Part Noncash Acquisition, Value of Liabilities Assumed",
        "negatedLabel": "Fair value of liabilities assumed"
       }
      }
     },
     "localname": "NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncurrentAssets": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.",
        "label": "Long-Lived Assets",
        "terseLabel": "Long-Lived Assets"
       }
      }
     },
     "localname": "NoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails",
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofDerivativesnotDesignatedasHedgingInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r968"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r968"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r767",
      "r925"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r763"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes noncurrent operating lease liability.",
        "label": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r765",
      "r768"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Cash paid for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r762"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease, right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r764"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes operating lease right-of-use asset.",
        "label": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]",
        "terseLabel": "Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "terseLabel": "Operating Loss Carryforwards, Valuation Allowance"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTemporaryDifferencesandCarryforwardsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r217",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r298"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets, noncurrent",
        "verboseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Securities:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r35",
      "r38",
      "r596"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "terseLabel": "Prior service cost (credit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax and Reclassification Adjustment, Attributable to Parent [Abstract]",
        "terseLabel": "Employee benefit plans:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansAdjustmentNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax, Parent [Abstract]",
        "terseLabel": "Derivatives &amp; hedges:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDerivativesQualifyingAsHedgesNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r30",
      "r38",
      "r741",
      "r743",
      "r748"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r38",
      "r42",
      "r323",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "negatedLabel": "Amortization of prior service (cost) credit"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": {
     "auth_ref": [
      "r316",
      "r317",
      "r319"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax": {
     "auth_ref": [
      "r314",
      "r319"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification and Tax",
        "totalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r320"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "terseLabel": "Derivatives &amp; hedges"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax": {
     "auth_ref": [
      "r314",
      "r319"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before reclassification, of gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, after Tax",
        "terseLabel": "Amount of gain or (loss) recognized in AOCI",
        "verboseLabel": "Unrealized gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax": {
     "auth_ref": [
      "r319",
      "r322"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationAndTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax",
        "negatedTerseLabel": "Reclassifications to earnings",
        "terseLabel": "Amount of gain or (loss) reclassified from AOCI into income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax": {
     "auth_ref": [
      "r315",
      "r319",
      "r720",
      "r725"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments, after Tax",
        "terseLabel": "Amount of gain or (loss) recognized in AOCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAfterTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r315",
      "r319",
      "r720",
      "r721",
      "r725"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Gain/(Loss) Recognized In Accumulated OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsScheduleofEffectofNetInvestmentHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r30",
      "r39",
      "r745",
      "r755"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign currency translation"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r43",
      "r138",
      "r325",
      "r328",
      "r334",
      "r749",
      "r754",
      "r756",
      "r822",
      "r832",
      "r947",
      "r948"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Net change",
        "totalLabel": "Other comprehensive income (loss)",
        "verboseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]",
        "terseLabel": "Other comprehensive income (loss), net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": {
     "auth_ref": [
      "r34",
      "r38",
      "r911",
      "r1010"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax",
        "terseLabel": "Total loss/(income) recognized in other comprehensive income, before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax": {
     "auth_ref": [
      "r34",
      "r38"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, after Tax",
        "negatedTotalLabel": "Net change"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r32",
      "r38",
      "r157"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "negatedLabel": "Net actuarial (gain) loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax": {
     "auth_ref": [
      "r34",
      "r39",
      "r205"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after reclassification adjustment, of tax (expense) benefit for (increase) decrease in accumulated other comprehensive income of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax",
        "negatedTerseLabel": "Employee benefits"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": {
     "auth_ref": [
      "r38",
      "r42",
      "r102",
      "r323"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax",
        "negatedTerseLabel": "Reclassifications to earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": {
     "auth_ref": [
      "r38",
      "r42",
      "r323",
      "r596"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax",
        "terseLabel": "Amortization of net actuarial loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r316",
      "r319"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized holding gain (loss) arising during period"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r39",
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "negatedTerseLabel": "Securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other Current Liabilities"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherDebtSecuritiesMember": {
     "auth_ref": [
      "r972",
      "r979",
      "r1008",
      "r1059"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments in debt securities classified as other.",
        "label": "Other Debt Obligations [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsScheduleofLongtermDebtInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeMember": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other revenue.",
        "label": "Other Income [Member]",
        "terseLabel": "Other Income"
       }
      }
     },
     "localname": "OtherIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible assets classified as other.",
        "label": "Other Intangible Assets [Member]",
        "terseLabel": "Other Intangible Assets",
        "verboseLabel": "Customer relationships and other intangible assets"
       }
      }
     },
     "localname": "OtherIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableAxis": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Group of items that represent other investments not readily marketable, including description of investment, fair value, and value as measured by quoted value method.",
        "label": "Other Investment Not Readily Marketable [Axis]",
        "terseLabel": "Other Investment Not Readily Marketable [Axis]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Other Investment Not Readily Marketable [Line Items]",
        "terseLabel": "Other Investment Not Readily Marketable [Line Items]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableNameDomain": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the investment category or actual investment title.",
        "label": "Other Investment Not Readily Marketable, Name [Domain]",
        "terseLabel": "Other Investment Not Readily Marketable, Name [Domain]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsNarrativeDetails",
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherInvestmentNotReadilyMarketableTable": {
     "auth_ref": [
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the information about other investments not readily marketable, including, but not limited to, description of investment, fair value and value as measured by quoted price.",
        "label": "Other Investment Not Readily Marketable [Table]",
        "terseLabel": "Other Investment Not Readily Marketable [Table]"
       }
      }
     },
     "localname": "OtherInvestmentNotReadilyMarketableTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofActivityRelatedtoEquityInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "verboseLabel": "Other liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsFinancialAssetsandLiabilitiesatFairValueDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedTerseLabel": "Other (income) expense, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r151",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r601",
      "r602",
      "r604",
      "r607",
      "r610",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r627",
      "r628",
      "r629",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Other benefit plans",
        "verboseLabel": "Other Benefit Plans"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r152",
      "r153",
      "r260",
      "r276"
     ],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1": {
       "order": 2.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan. Excludes pension plan.",
        "label": "Liability, Other Postretirement Defined Benefit Plan",
        "terseLabel": "Postretirement benefits"
       }
      }
     },
     "localname": "OtherPostretirementDefinedBenefitPlanLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [
      "r896",
      "r897",
      "r898",
      "r899"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Provides the categories of debt securities, available-for-sale or held-to-maturity, on which an entity may recognize other than temporary impairments (OTTI) for which a portion related to credit losses has been recognized in earnings and a portion related to all other factors has been recognized in other comprehensive income.",
        "label": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]",
        "terseLabel": "Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments [Domain]"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentsForLegalSettlements": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for the settlement of litigation or for other legal issues during the period.",
        "label": "Payments for Legal Settlements",
        "terseLabel": "Payments for legal settlements"
       }
      }
     },
     "localname": "PaymentsForLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r950",
      "r951"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other (primarily licenses and milestones)"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "auth_ref": [
      "r62"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.",
        "label": "Payments of Ordinary Dividends",
        "negatedLabel": "Dividends to shareholders"
       }
      }
     },
     "localname": "PaymentsOfOrdinaryDividends",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r57",
      "r710"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "terseLabel": "Payments to Acquire Businesses, Gross"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions, net of cash acquired (Note\u00a018)"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r59"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r58"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Additions to property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [
      "r993"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r576",
      "r578",
      "r584",
      "r603",
      "r605",
      "r606",
      "r607",
      "r608",
      "r609",
      "r624",
      "r625",
      "r627",
      "r632",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]",
        "verboseLabel": "Pensions and Other Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r3",
      "r552",
      "r553",
      "r575",
      "r911"
     ],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails": {
       "order": 1.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      },
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Liability, Defined Benefit Plan, Current",
        "negatedLabel": "Current liabilities",
        "terseLabel": "Less current benefits payable"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r5",
      "r552",
      "r553",
      "r575",
      "r911"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails": {
       "order": 2.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      },
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "negatedLabel": "Non-current liabilities",
        "terseLabel": "Employee related obligations\u00a0\u2014 non-current",
        "verboseLabel": "Employee related obligations (Notes\u00a09 and 10)"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionContributions": {
     "auth_ref": [
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for pension benefit. Includes, but is not limited to, employer contribution to fund plan asset and payment to retiree. Excludes other postretirement benefit.",
        "label": "Payment for Pension Benefits",
        "terseLabel": "Contribution to pension plans"
       }
      }
     },
     "localname": "PensionContributions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r150",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r601",
      "r602",
      "r604",
      "r607",
      "r610",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r627",
      "r628",
      "r631",
      "r911",
      "r912",
      "r916",
      "r917",
      "r918"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Retirement plans",
        "verboseLabel": "Retirement Plans"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r604",
      "r909",
      "r910",
      "r911"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r1018",
      "r1019",
      "r1020",
      "r1021",
      "r1022",
      "r1023",
      "r1024",
      "r1025",
      "r1026",
      "r1027",
      "r1028",
      "r1029",
      "r1030",
      "r1031",
      "r1032",
      "r1033",
      "r1034",
      "r1035",
      "r1036",
      "r1037",
      "r1038",
      "r1039",
      "r1040",
      "r1041",
      "r1042",
      "r1043"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PostemploymentBenefitsLiabilityCurrentAndNoncurrent": {
     "auth_ref": [
      "r263",
      "r283",
      "r1004",
      "r1005"
     ],
     "calculation": {
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails_1": {
       "order": 3.0,
       "parentTag": "jnj_EmployeeObligations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The carrying amount as of the balance sheet date of the obligations recognized for the various benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement.",
        "label": "Postemployment Benefits Liability",
        "terseLabel": "Postemployment benefits"
       }
      }
     },
     "localname": "PostemploymentBenefitsLiabilityCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EmployeeRelatedObligationsEmployeeRelatedObligationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r6",
      "r926"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock\u00a0\u2014 without par value (authorized and unissued 2,000,000\u00a0shares)"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r946"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other receivables"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r944"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassification"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Proceeds from divestiture of brands"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "verboseLabel": "Proceeds from long-term debt, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r952",
      "r953"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r56"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "verboseLabel": "Sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfInterestInCorporateUnit": {
     "auth_ref": [
      "r60"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow resulting from the sale of an interest in a corporate unit during the period.",
        "label": "Proceeds from Sale of Interest in Corporate Unit",
        "terseLabel": "Proceeds from sale of equity interests"
       }
      }
     },
     "localname": "ProceedsFromSaleOfInterestInCorporateUnit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfProductiveAssets": {
     "auth_ref": [
      "r55"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Proceeds from Sale of Productive Assets",
        "verboseLabel": "Proceeds from the disposal of assets/businesses, net"
       }
      }
     },
     "localname": "ProceedsFromSaleOfProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r61"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-Term Debt",
        "verboseLabel": "Proceeds from short-term debt"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Project Concentration Risk"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]",
        "terseLabel": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAdditions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of acquisition of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Additions",
        "terseLabel": "Additions to Property, Plant &amp; Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAdditions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r861",
      "r862",
      "r863"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r121",
      "r294"
     ],
     "calculation": {
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property, plant and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment [Member]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r123",
      "r281",
      "r830",
      "r926"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "totalLabel": "Total property, plant and equipment, net",
        "verboseLabel": "Property, plant and equipment, net (Notes\u00a01 and 4)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r123",
      "r861",
      "r862"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment and Depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Property, Plant and Equipment at Cost and Accumulated Depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Estimated useful lives of the assets"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ProvisionForDoubtfulAccounts": {
     "auth_ref": [
      "r337",
      "r446"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable.",
        "label": "Accounts Receivable, Credit Loss Expense (Reversal)",
        "verboseLabel": "Credit losses and accounts receivable allowances"
       }
      }
     },
     "localname": "ProvisionForDoubtfulAccounts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]",
        "terseLabel": "AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]"
       }
      }
     },
     "localname": "ReclassificationFromAccumulatedOtherComprehensiveIncomeCurrentPeriodNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Summary of unrecognized tax benefits"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r604",
      "r770",
      "r771"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party [Domain]"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r604",
      "r770",
      "r808",
      "r809",
      "r810",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r1063"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party [Axis]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-Term Debt",
        "negatedLabel": "Repayment of long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-Term Debt",
        "negatedLabel": "Repayment of short-term debt"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepurchaseAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investments represented by an agreement between the entity and another party for the sale and repurchase of identical or substantially the same securities at a date certain for a specified price. Such agreements are generally short-term in nature.",
        "label": "Repurchase Agreements [Member]",
        "terseLabel": "U.S. Reverse repurchase agreements"
       }
      }
     },
     "localname": "RepurchaseAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r178"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "R&amp;D Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r178"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Research and Development in Process",
        "terseLabel": "In-process research and development",
        "verboseLabel": "In-process research and development (Note 5)"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]",
        "terseLabel": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r479",
      "r481",
      "r484",
      "r490",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/Restructuring"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r480",
      "r483",
      "r487",
      "r489"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring costs incurred since announced"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r69",
      "r485",
      "r487",
      "r992"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring (Note 20)",
        "verboseLabel": "Charges"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesMember": {
     "auth_ref": [
      "r126",
      "r129"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about restructuring charges have been included.",
        "label": "Restructuring Charges [Member]",
        "terseLabel": "Restructuring Charges"
       }
      }
     },
     "localname": "RestructuringChargesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [
      "r480",
      "r481",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r481",
      "r486"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Reserve balance ending",
        "periodStartLabel": "Reserve balance beginning"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReservePeriodIncreaseDecrease": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the accrual for restructuring costs.",
        "label": "Restructuring Reserve, Period Increase (Decrease)",
        "terseLabel": "Activity during the period"
       }
      }
     },
     "localname": "RestructuringReservePeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringReserveSettledWithoutCash2": {
     "auth_ref": [
      "r481",
      "r488"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in the reserve for full or partial settlement through consideration other than cash.",
        "label": "Restructuring Reserve, Settled without Cash",
        "negatedTerseLabel": "Settled non cash"
       }
      }
     },
     "localname": "RestructuringReserveSettledWithoutCash2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResultsOfOperationsIncomeBeforeIncomeTaxes": {
     "auth_ref": [
      "r253"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income before income taxes for oil and gas producing activities.",
        "label": "Results of Operations, Income before Income Taxes",
        "terseLabel": "Results of Operations, Income before Income Taxes"
       }
      }
     },
     "localname": "ResultsOfOperationsIncomeBeforeIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r8",
      "r144",
      "r279",
      "r840",
      "r842",
      "r926"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityBeforeTreasuryStock",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "verboseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r286",
      "r352",
      "r353",
      "r354",
      "r356",
      "r362",
      "r364",
      "r443",
      "r669",
      "r670",
      "r671",
      "r695",
      "r696",
      "r728",
      "r837",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r604",
      "r607",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r1015",
      "r1016",
      "r1017"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r600",
      "r601",
      "r602",
      "r604",
      "r607",
      "r611",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r1015",
      "r1016",
      "r1017"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r150",
      "r151",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r601",
      "r602",
      "r604",
      "r607",
      "r610",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r627",
      "r628",
      "r629",
      "r631",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r150",
      "r151",
      "r552",
      "r555",
      "r556",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r567",
      "r568",
      "r569",
      "r570",
      "r571",
      "r572",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r599",
      "r601",
      "r602",
      "r604",
      "r607",
      "r610",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623",
      "r627",
      "r628",
      "r629",
      "r631",
      "r911",
      "r912",
      "r913",
      "r914",
      "r915",
      "r916",
      "r917",
      "r918"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r389",
      "r390",
      "r408",
      "r413",
      "r414",
      "r420",
      "r421",
      "r424",
      "r548",
      "r549",
      "r805"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 1.0,
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Sales to Customers",
        "verboseLabel": "Sales to customers"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r888",
      "r889"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Sale of stock, number of shares issued in transaction (in shares)"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPercentageOfOwnershipBeforeTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company before stock transaction.",
        "label": "Sale of Stock, Percentage of Ownership before Transaction",
        "terseLabel": "Sale of stock, percentage of ownership before transaction"
       }
      }
     },
     "localname": "SaleOfStockPercentageOfOwnershipBeforeTransaction",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Sale of stock (in USD per share)"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Sales"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsSummaryofDerivativeActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r424",
      "r967"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]",
        "terseLabel": "Sales Revenue, Net"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r41",
      "r1061",
      "r1062"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "verboseLabel": "Components of Accumulated Other Comprehensive Income"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r154"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans. This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Company' Retirement Plan Asset Allocation and Target Allocations"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r598"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Rates Used to Develop Actuarial Present Value of Projected Benefit Obligation"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Equity Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r192",
      "r193",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.",
        "label": "Schedule of Cash and Cash Equivalents [Table]",
        "terseLabel": "Schedule of Cash and Cash Equivalents [Table]"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Cash and Cash Equivalent Composition"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Provision for Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r22",
      "r139",
      "r141",
      "r142",
      "r143",
      "r246",
      "r247",
      "r249",
      "r270",
      "r901",
      "r903",
      "r961"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r186"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Temporary Differences and Carryforwards"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansCompanyRetirementPlanAssetAllocationandTargetAllocationsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansComponentsofNetPeriodicBenefitCostDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansInformationRelatedtotheBenefitObligationandtheFairValueofPlanAssetsDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansNarrativeDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansProjectedFutureBenefitPaymentsfromCompanysRetirementandOtherBenefitPlansDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansRatesUsedtoDevelopActuarialPresentValueofProjectedBenefitObligationDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails",
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofNetFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTextBlock": {
     "auth_ref": [
      "r159",
      "r160",
      "r161",
      "r162",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of one or more of the entity's defined benefit pension plans or one or more other defined benefit postretirement plans, separately for pension plans and other postretirement benefit plans including the entity's schedule of fair value of plan assets for defined benefit or other postretirement plans.",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table Text Block]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r224"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the effective portion of the gains and losses on derivative instruments designated (and non-derivative instruments) designated and qualifying in cash flow hedges and net investment hedges that was recognized in other comprehensive income (loss) during the current period.",
        "label": "Schedule of Derivative Instruments, Effect on Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Effect of Net Investment Hedges"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsEffectOnOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r218",
      "r226",
      "r722"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "verboseLabel": "Summary of Derivative Activity"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock": {
     "auth_ref": [
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the location and fair value amounts of derivative instruments (and nonderivative instruments that are designated and qualify as hedging instruments) reported in the statement of financial position.",
        "label": "Schedule of Derivative Instruments in Statement of Financial Position, Fair Value [Table Text Block]",
        "verboseLabel": "Financial Assets and Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsInStatementOfFinancialPositionFairValueTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r966"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "verboseLabel": "Reconciliation of Basic Net Earnings per Share to Diluted Net Earnings per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/EarningsPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Comparison of Income Taxes at Statutory Rate and Company's Effective Tax Rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r155"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Projected Future Benefit Payments from Company's Retirement and Other Benefit Plans"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r109",
      "r113",
      "r806"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets by Major Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r895"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r895",
      "r980",
      "r981",
      "r982",
      "r983",
      "r984",
      "r985",
      "r986",
      "r987",
      "r988",
      "r989",
      "r990"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "verboseLabel": "Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock": {
     "auth_ref": [
      "r158"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.",
        "label": "Schedule of Health Care Cost Trend Rates [Table Text Block]",
        "terseLabel": "Assumed Health Care Cost Trend Rates"
       }
      }
     },
     "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r0",
      "r10",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "verboseLabel": "Summary of Inventories"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "terseLabel": "Aggregate Maturities of Long Term Obligations"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetBenefitCostsTableTextBlock": {
     "auth_ref": [
      "r156"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net benefit costs for pension plans and/or other employee benefit plans including service cost, interest cost, expected return on plan assets, gain (loss), prior service cost or credit, transition asset or obligation, and gain (loss) recognized due to settlements or curtailments.",
        "label": "Schedule of Net Benefit Costs [Table Text Block]",
        "verboseLabel": "Components of Net Periodic Benefit Cost"
       }
      }
     },
     "localname": "ScheduleOfNetBenefitCostsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetFundedStatusTableTextBlock": {
     "auth_ref": [
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of net funded status of pension plans and/or other employee benefit plans.",
        "label": "Schedule of Net Funded Status [Table Text Block]",
        "terseLabel": "Schedule of Net Funded Status"
       }
      }
     },
     "localname": "ScheduleOfNetFundedStatusTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r225",
      "r1056"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of derivative instrument not designated or qualifying as hedging instrument.",
        "label": "Derivatives Not Designated as Hedging Instruments [Table Text Block]",
        "terseLabel": "Schedule of Effect of Derivatives not Designated as Hedging Instruments"
       }
      }
     },
     "localname": "ScheduleOfOtherDerivativesNotDesignatedAsHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PropertyPlantandEquipmentPropertyPlantandEquipmentatCostandAccumulatedDepreciationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesEstimatedUsefulLivesofAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r480",
      "r481",
      "r482",
      "r483",
      "r487",
      "r488",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringNarrativeDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r125",
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Summary of Severance Charges and Associated Spending"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock": {
     "auth_ref": [
      "r47",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material. An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "auth_ref": [
      "r87",
      "r88",
      "r89",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "verboseLabel": "Schedule of Segment Reporting Information"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": {
     "auth_ref": [
      "r167",
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Share Units"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r633",
      "r635",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]",
        "terseLabel": "Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]",
        "terseLabel": "Summary of Options Outstanding"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r164",
      "r169",
      "r170"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-Term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r424",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r483",
      "r489",
      "r895",
      "r1076"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]",
        "terseLabel": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r386",
      "r387",
      "r388",
      "r398",
      "r401",
      "r412",
      "r416",
      "r417",
      "r418",
      "r419",
      "r420",
      "r423",
      "r424",
      "r425"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "verboseLabel": "Segments of Business and Geographic Areas"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreas"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Description of the Company And Business Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, marketing and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [
      "r993"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/LegalProceedingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "verboseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r920"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "verboseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r651"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Average fair value of RSU's and PSU's granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r648",
      "r649"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r652"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Issued (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r655"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Fair Value of RSU or PSU units settled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Weighted average assumptions of fair value of options"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r660"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r659"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r661"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r922"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares authorized for issuance under long-term incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for future grants under long-term incentive plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Summary of option activity under the Plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Stock options exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r642"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Stock options average price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r655"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Total intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "negatedTerseLabel": "Options canceled/forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r1025"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r654"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Average fair value of option granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r640",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Options outstanding end of period",
        "periodStartLabel": "Options outstanding beginning of period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Outstanding Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r640",
      "r641"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Options exercise price end of period (in dollars per share)",
        "periodStartLabel": "Options exercise price beginning of period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r642",
      "r643",
      "r644",
      "r645",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AcquisitionsandDivestituresNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofRestrictedShareUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Options exercised, average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r646"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Options canceled/forfeited, average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Options granted, average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]",
        "terseLabel": "Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit",
        "terseLabel": "Price Range, Minimum (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": {
     "auth_ref": [
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable",
        "terseLabel": "Exercisable number of Options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Outstanding",
        "terseLabel": "Outstanding number of Options (in shares)",
        "verboseLabel": "Stock options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit",
        "terseLabel": "Price Range, Maximum (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r1018"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r921"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "verboseLabel": "Stock options expiration period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r658"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected life (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsScheduleValuationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1": {
     "auth_ref": [
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average price as of the balance sheet date at which grantees could acquire the underlying shares with respect to all outstanding stock options which are in the customized range of exercise prices.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Outstanding Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageExercisePriceBeginningBalance1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, Average Life",
        "verboseLabel": "Stock option average life"
       }
      }
     },
     "localname": "SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsNarrativeDetails",
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofOptionsOutstandingDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShippingAndHandlingCostPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the classification of shipping and handling costs, including whether the costs are included in cost of sales or included in other income statement accounts. If shipping and handling fees are significant and are not included in cost of sales, disclosure includes both the amounts of such costs and the line item on the income statement which includes such costs.",
        "label": "Shipping and Handling Cost, Policy [Policy Text Block]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingCostPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShippingAndHandlingMember": {
     "auth_ref": [
      "r1003"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Packing and transport of product.",
        "label": "Shipping and Handling [Member]",
        "terseLabel": "Shipping and Handling"
       }
      }
     },
     "localname": "ShippingAndHandlingMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermBorrowings": {
     "auth_ref": [
      "r1",
      "r258",
      "r277",
      "r926"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.",
        "label": "Short-Term Debt",
        "terseLabel": "Loans and notes payable (Note\u00a07)",
        "verboseLabel": "Loans and notes payable"
       }
      }
     },
     "localname": "ShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-Term Debt [Line Items]",
        "terseLabel": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-Term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-Term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/BorrowingsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r78",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Internally developed software for sale, licensing or long-term internal use.",
        "label": "Software Development [Member]",
        "terseLabel": "Software Development"
       }
      }
     },
     "localname": "SoftwareDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SovereignDebtSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt security issued by foreign government (not within the country of domicile of the entity).",
        "label": "Sovereign Debt Securities [Member]",
        "terseLabel": "Non-U.S. Sovereign Securities"
       }
      }
     },
     "localname": "SovereignDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State and Local Jurisdiction"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r288",
      "r386",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414",
      "r415",
      "r416",
      "r418",
      "r424",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r478",
      "r483",
      "r489",
      "r895",
      "r1076"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]",
        "verboseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillGoodwillDetails",
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails",
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r303",
      "r304",
      "r305",
      "r344",
      "r367",
      "r368",
      "r370",
      "r372",
      "r380",
      "r381",
      "r442",
      "r498",
      "r501",
      "r502",
      "r503",
      "r509",
      "r510",
      "r540",
      "r541",
      "r543",
      "r544",
      "r546",
      "r739",
      "r875",
      "r942",
      "r957",
      "r965"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r26",
      "r138",
      "r286",
      "r330",
      "r331",
      "r332",
      "r352",
      "r353",
      "r354",
      "r356",
      "r362",
      "r364",
      "r379",
      "r443",
      "r547",
      "r669",
      "r670",
      "r671",
      "r695",
      "r696",
      "r728",
      "r749",
      "r750",
      "r751",
      "r752",
      "r753",
      "r756",
      "r769",
      "r837",
      "r838",
      "r839"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]",
        "verboseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r352",
      "r353",
      "r354",
      "r379",
      "r805"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Shares, Other",
        "negatedLabel": "Employee compensation and stock option plans (shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r7",
      "r138",
      "r144",
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "negatedTerseLabel": "Options exercised"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CommonStockStockOptionPlansandStockCompensationAgreementsSummaryofStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of shares of stock issued attributable to transactions classified as other.",
        "label": "Stock Issued During Period, Value, Other",
        "negatedLabel": "Employee compensation and stock option plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Stock repurchase program, authorized amount"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchasedDuringPeriodValue": {
     "auth_ref": [
      "r6",
      "r7",
      "r138",
      "r144"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of stock that has been repurchased during the period and has not been retired and is not held in treasury. Some state laws may mandate the circumstances under which an entity may acquire its own stock and prescribe the accounting treatment therefore. This element is used when state law does not recognize treasury stock.",
        "label": "Stock Repurchased During Period, Value",
        "terseLabel": "Stocks repurchased"
       }
      }
     },
     "localname": "StockRepurchasedDuringPeriodValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "verboseLabel": "Shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityBeforeTreasuryStock": {
     "auth_ref": [],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total amount of stockholders' equity (deficit) items including stock value, paid in capital, retained earnings and including equity attributable to noncontrolling interests and before deducting the carrying value of treasury stock.",
        "label": "Stockholders' Equity before Treasury Stock",
        "totalLabel": "Stockholders' Equity before Treasury Stock"
       }
      }
     },
     "localname": "StockholdersEquityBeforeTreasuryStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r203",
      "r204",
      "r208",
      "r286",
      "r287",
      "r331",
      "r352",
      "r353",
      "r354",
      "r356",
      "r362",
      "r443",
      "r547",
      "r669",
      "r670",
      "r671",
      "r695",
      "r696",
      "r728",
      "r749",
      "r750",
      "r756",
      "r769",
      "r838",
      "r839",
      "r959",
      "r977",
      "r1060"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending Balance",
        "periodStartLabel": "Beginning Balance",
        "totalLabel": "Total shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/AccumulatedOtherComprehensiveIncomeLossDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasSalesbySegmentofBusinessDetails",
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r757",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r757",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r757",
      "r772"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SummaryOfIncomeTaxContingenciesTextBlock": {
     "auth_ref": [
      "r181",
      "r183",
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Summary of Income Tax Contingencies [Table Text Block]",
        "terseLabel": "Summary of Activity Related to Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "SummaryOfIncomeTaxContingenciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow data"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SuppliesExpense": {
     "auth_ref": [
      "r267"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense associated with supplies that were used during the current accounting period.",
        "label": "Supplies Expense",
        "terseLabel": "Supplies Expense"
       }
      }
     },
     "localname": "SuppliesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SegmentsofBusinessandGeographicAreasScheduleofSegmentReportingInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Tax Credit Carryforward [Line Items]",
        "terseLabel": "Tax Credit Carryforward [Line Items]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardTable": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A listing of tax credit carryforwards available to reduce future taxable income including descriptions, amounts, expiration dates, limitations on use and the related deferred tax assets and valuation allowances.",
        "label": "Tax Credit Carryforward [Table]",
        "terseLabel": "Tax Credit Carryforward [Table]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TrademarksMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or style.",
        "label": "Trademarks [Member]",
        "terseLabel": "Trademarks"
       }
      }
     },
     "localname": "TrademarksMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IntangibleAssetsandGoodwillScheduleofIntangibleAssetsandGoodwillDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r435",
      "r438",
      "r536",
      "r545",
      "r727",
      "r773",
      "r774",
      "r775",
      "r776",
      "r777",
      "r778",
      "r779",
      "r780",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r800",
      "r801",
      "r802",
      "r974",
      "r975",
      "r976",
      "r1080",
      "r1081",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r25",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock Amount",
        "verboseLabel": "Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r25",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "periodEndLabel": "Treasury Stock, ending balance (shares)",
        "periodStartLabel": "Treasury Stock, beginning balance (shares)",
        "verboseLabel": "Treasury stock, shares"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r7",
      "r138",
      "r144"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "verboseLabel": "Repurchase of common stock (shares)"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Treasury Stock [Text Block]",
        "terseLabel": "Capital and Treasury Stock"
       }
      }
     },
     "localname": "TreasuryStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r25",
      "r145",
      "r148"
     ],
     "calculation": {
      "http://www.jnj.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "periodEndLabel": "Treasury Stock, Ending Balance",
        "periodStartLabel": "Treasury Stock, Balance",
        "verboseLabel": "Less: common stock held in treasury, at cost (Note\u00a012) (506,246,000\u00a0shares and 490,878,000\u00a0shares)"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r138",
      "r144",
      "r145"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedTerseLabel": "Repurchase of common stock",
        "terseLabel": "Repurchase of common stock"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CapitalandTreasuryStockChangesinTreasuryStockDetails",
      "http://www.jnj.com/role/ConsolidatedStatementsofEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [
      "r480",
      "r481",
      "r487",
      "r488"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/RestructuringSummaryofSeveranceChargesandAssociatedSpendingDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r890",
      "r909",
      "r1072"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "U.S. Gov't Agencies"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r1072"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Government Corporations and Agencies Securities [Member]",
        "terseLabel": "Government and agency securities"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/PensionsandOtherBenefitPlansScheduleofDefinedBenefitPlansDisclosuresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r826",
      "r909",
      "r1078"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Gov't Securities"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/CashCashEquivalentsandCurrentMarketableSecuritiesCashandCashEquivalentCompositionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r675",
      "r683"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "End of year",
        "periodStartLabel": "Beginning of year",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails",
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r684"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedTerseLabel": "Decreases related to prior period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r686"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r685"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "terseLabel": "Increases related to current year tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r684"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "terseLabel": "Increases related to prior period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "auth_ref": [
      "r1045"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "terseLabel": "Unrecognized tax benefits, interest on income taxes accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "auth_ref": [
      "r1045"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest expense for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense",
        "terseLabel": "Unrecognized tax benefits, interest on income tax expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "auth_ref": [
      "r687"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "negatedTerseLabel": "Lapse of statute of limitations"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/IncomeTaxesSummaryofActivityRelatedtoUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r84",
      "r85",
      "r86",
      "r382",
      "r383",
      "r384",
      "r385"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r366",
      "r372"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Average shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "verboseLabel": "Average shares outstanding (Notes 1 and 15)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r365",
      "r372"
     ],
     "calculation": {
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Average shares outstanding\u00a0\u2014 basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.jnj.com/role/ConsolidatedStatementsofEarnings",
      "http://www.jnj.com/role/EarningsPerShareReconciliationofBasicNetEarningsperSharetoDilutedNetEarningsperShareDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 13
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1000": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1001": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1002": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1003": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1004": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410138&loc=d3e79691-111665",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1005": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410138&loc=d3e79708-111665",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1006": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1007": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1008": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1009": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27340-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1010": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1011": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1012": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1013": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1014": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1015": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1016": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1017": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1018": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1019": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1020": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1021": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1022": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1023": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1024": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1025": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1026": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1027": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1028": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1029": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1030": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1031": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1032": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1033": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1034": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1035": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1036": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1037": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1038": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1039": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=126960272&loc=d3e32014-111567",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1040": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1041": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1042": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1043": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1044": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1045": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1046": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1047": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1048": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1049": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1050": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1051": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1052": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1053": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1054": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1055": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1056": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998890-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1057": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(6)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1058": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1059": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1060": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1061": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1062": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1063": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1064": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1065": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1066": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1067": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1068": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1069": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1070": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1071": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1072": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1073": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1074": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1075": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1076": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1077": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1078": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1079": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1080": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1081": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1082": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1083": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1084": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1085": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r1086": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "https://asc.fasb.org/topic&trid=2144416",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2420-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(c))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12053-110248",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466302&loc=d3e4852-112606",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21506-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21521-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21538-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "https://asc.fasb.org/subtopic&trid=2208821",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "https://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=123410050&loc=d3e5263-128473",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6405-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6578-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966197&loc=d3e6613-128477",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126966325&loc=d3e6819-128478",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "https://asc.fasb.org/topic&trid=2303972",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(5))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(i)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624186-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624258-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41641-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=d3e41678-113959",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=127000641&loc=SL5629052-113961",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577467&loc=d3e76258-113986",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80748-113994",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(3)(ii)(A))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10(c)(7)(ii))",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126954596&loc=d3e511914-122862",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62136-109447",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "820",
   "Topic": "940",
   "URI": "https://asc.fasb.org/extlink&oid=35710923&loc=d3e45360-110995",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.14)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123398031&loc=d3e60009-112784",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=123599511&loc=d3e64711-112823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15)(b)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(15))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226003-175313",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(15))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(16))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(21))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL34724391-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i),(j),(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(22))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(5))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(k)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "https://asc.fasb.org/extlink&oid=126900757&loc=d3e543-108305",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "34",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e689-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "https://asc.fasb.org/topic&trid=2134510",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=d3e5074-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=123577603&loc=SL6953401-111524",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL6284393-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "https://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "https://asc.fasb.org/topic&trid=2126998",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(7)(c))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1,2)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(e))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "https://asc.fasb.org/topic&trid=2175745",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "https://asc.fasb.org/extlink&oid=124440162&loc=d3e12021-110248",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "https://asc.fasb.org/topic&trid=2134417",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "710",
   "URI": "https://asc.fasb.org/extlink&oid=6409950&loc=d3e20396-108366",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "710",
   "URI": "https://asc.fasb.org/topic&trid=2127225",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1703-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=d3e1731-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123453770&loc=SL108413299-114919",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(9)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2709-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2919-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=29639808&loc=d3e29008-114946",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450691-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e7008-128479",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109998896-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624181-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL109999712-113959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061172-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121577181&loc=SL110061190-113977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=121549185&loc=d3e80845-113994",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594786&loc=SL75136599-209740",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28228-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=126980362&loc=d3e28129-110885",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30226-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123602790&loc=d3e30304-110892",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30690-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30840-110895",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6897108&loc=SL6897125-166521",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "830",
   "URI": "https://asc.fasb.org/topic&trid=2175825",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r804": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r805": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r806": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r807": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r808": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r809": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r810": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r811": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r812": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r813": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r814": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r815": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r816": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r817": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r818": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r819": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r820": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r821": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r822": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r823": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(24))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r824": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r825": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r826": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r827": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r828": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r829": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(c)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r830": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r831": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r832": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r833": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(20))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r834": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r835": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r836": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r837": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r838": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r839": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r840": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r841": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r842": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r843": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r844": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r845": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r846": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r847": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r848": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r849": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r850": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r851": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r852": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r853": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r854": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r855": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r856": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r857": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r858": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r859": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r860": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=126942805&loc=d3e3115-115594",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r861": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r862": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r863": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r864": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r865": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r866": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r867": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r868": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r869": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r870": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r871": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r872": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r873": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r874": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r875": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r876": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r877": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r878": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r879": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r880": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r881": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r882": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226038-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r883": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r884": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r885": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r886": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r887": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r888": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r889": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r890": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r891": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r892": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r893": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r894": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r895": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r896": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r897": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r898": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r899": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8475-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r900": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r901": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r902": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r903": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r904": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r905": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r906": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r907": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r908": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r909": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r910": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r911": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r912": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4587-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r913": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r914": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r915": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r916": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r917": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r918": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r919": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r920": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r921": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r922": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r923": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r924": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r925": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r926": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r927": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r928": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r929": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r930": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r931": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r932": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "https://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r933": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r934": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r935": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r936": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r937": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r938": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r939": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r940": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r941": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r942": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r943": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=124440516&loc=d3e30885-110895",
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef"
  },
  "r944": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r945": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r946": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r947": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r948": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r949": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r950": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r951": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r952": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r953": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r954": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r955": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r956": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r957": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r958": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r959": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r960": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r961": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r962": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r963": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r964": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r965": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e2626-109256",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r966": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r967": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r968": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r969": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r970": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r971": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r972": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27290-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r973": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r974": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r975": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r976": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r977": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r978": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255206&loc=SL82895884-210446",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r979": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r980": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r981": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r982": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r983": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r984": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r985": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r986": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r987": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r988": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r989": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=SL108378252-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r990": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r991": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r992": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r993": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r994": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r995": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r996": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r997": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r998": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r999": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>135
<FILENAME>0000200406-23-000016-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000200406-23-000016-xbrl.zip
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MPQ(0AQ9J>0_3Y##I=NVJW*.LS>FOE./]S27Q6LLY_YJ!O+L&@9:G0%M D3(
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M].%5F;&W!=2? #L(;^N%@#%FEH.D;N/%P+_P3*3\\>\&[%Z[KD.]$%? OX6
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M4XYUU0EG5\$?.)U5+!9A,*'^=$J%,$7W*[H0N%R_LI6)Q!4H[PBUZ,-QS"'
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M_%/O:/=U]7\/ND?%I;=+YHXTF;]39'[.9+Y>R?L=[DE;-+*MWG9[;X>Z#-X
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M%8'TV[S=(LQ_,2/+"%WB\XI,-'Y&X,0D?<1X-+D;E(*A7689U2?.YT@(NJV
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M'L(=%XQB<$R_:4P)#HC?8.=TDW&'S@A.5 R*X5!G\@9AY)8*U*#<!G(^<@?
M<FWL+HG,8%#+I**/-.D)K,B]3QZQ!$=VRB5ADJ!O9""UW4&1O:H8SCVL-TS*
M3.RWVR%0O$F8XB&W$WK"AW;7%4[8WB.,R4DRQ@!9/K7\-9$$BS N;KO-I58
M\@#58<$]'C2)((R/LW5B.O>DAKLIU^2QMO@C*J)Z4#P'.]-S)K.4"-0G4IEU
M'%43M-5O!7W4N[GN704M='79^6.["O*O=V70/4PUN3FWIH^>1P!X=-T*9LZP
M ,V74+>_FH)+><UQ)%'K40F2&L\93*0BZ1JK)??TT-<1,I&2P*-\4._#NC7V
M#<M8#U5M<AV%94ZNETU0ERIR#XG;72PE#N-,$J7 [7/G-K\2*N8C;)9$L.;U
M-HLH9N VP'*K]P2/LE#!.LVJQ.+N 3VW>##2;T#:Y;Z**8=)[F#"5*R?V692
M496I-<SNH@I@+M#G35^!?W=1!3!7ZO.FMQ?(0,WK/HHOC>_I#H'NF0KC::T^
M/[-O.L-;S<YOD )WJ+QNJ9B&G*$6B_AND(DA$>N4X'1/ >NOV-P#^V*C>[)#
M(;N?OJ$PW%1@A,/K)3<']FQ=_M]?]P%XT6%CQ/,6(Y^%1HVB8_*JY\9467EM
M__WGC^"!Y$FFEG]D65>+I0T\\C]C43Y@A(=D=R (OM_%=_KSGW'R@"?RS=_7
M-\2W2?B1;1)^9F?[@]HDN*:2*MLDN.>-BSD(U/80W#SG,_U1PLHT9VWSF?9
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M;Z%^.S)_%=1:-1\Z /89SW5X_6H"KA?(Q-#.'+=4TK4ZK;BG$7\\.8N$&S'
MII@C(P\:#G4I>4BQ(M([!I".(?<'=M<)E%-8&B/Z%H"^!:![+0!_9D?\@UH
MNJ:2*EL NN>/SZ^Z+\K*5[%P<4\/4(/5"\+&&8&T1(6ZN]WI=TP%81V@ "LQ
M><E%?K[+]7O@2DAWPTM"D^?LR!<]1/0;4(@/=PE:8"#/= A-H@,<]D.=V N;
M=^K^X+H2?B/[]_X"!=C75*^CF/J\^^GU$OD'HZ#5UO-^MP>I903<HZB"]9>9
M$C3/6 #5)09J;#^?GX :F:1Y?BO$I7R;110##/3_.D<%;H-8[QAR4,QWG( 3
M$8!=!9 A/IDP,LU@>VXA"6C+[T;A&![SF>("];!03(?",1V5Y5)0DZ=:X EJ
M0UH3P/4 %@=]\HAU!-#S<SX4YN<6[]1Z4.)^X S_QD42/=!H]<U=]T0'2W%;
M_DB21Y-(F(GBDGL^JW=H2A6)@)#^EHA4_Q(XSG-SB(M?GN:!BNJADO^2\$ )
MK*U?4![4[A[46?Z2J)@(TTU*OES(>;YO.-^S;W@\W<+Q;(? =CZF J.^ICP>
MV=G=;]=#H'JFXUGLF0Z(Z5?=<Q_% Z3Z52KH(VI0/JK,^.XI 2SIA8JY,7["
MA^9DWL_L&T_WTN**A/%T >>/WS:=Z3VLA#;ZZRD>#N5[A#$Y2<:847"U8;3L
ME,DL6;!3Z[F_\=PG(J1CB@%Q'>KT/A*D6;\^:==]^ Z!V(*RD"A3%!(/S$UZ
M+BBP0D]0B=X37-)H@GTI)Q!$SQ*)!;K%,M0QG/ ,!\#P:S(D+)Q46[#+/37
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M&HIJ*T> [NFA*3A6W@$4YL=,!X -@C/]UX)<\\W5AT^LGT'!R64--<Y.H+B
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MW7-TQA,S7$B+=\A$3P5]1 W*1W/EW26D^KYM*3 !=Z5VJ>4O;X'0OD&2(<W
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M0/9YIZA=L<,U=O-V,'00<A:0\V47>.D.F3\(>,.HNC%IH]FKV3[WX5=RGNA
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M'!VL?A!)7@4[M=3??_O^AEW:;M32=C"TM/QY*6%8E@ODY1E%GJ'S2AAS,8?
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MKW+D6<=4&J10%>/6)+X7N?OW<TIA2J5 OG5)[('-SQ"V7C@'P980^3/FRZ9
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M5*K F!M ZD-[-!B;JA/E%D'0TE\7)]VW_G(A6>F1>BTD1QA:M4@B(HF#1?F
MC9 FO28XG#M)($VEL.4TQ9A]#312W^*Q=TM\:\-.W.NDUZA<*B(KC"1Y'"Y9
M<B_40*)C%UL,W#O4VKI.69$$>!N1/!4;:<XS)<F&!D%H]B"[Y!FI)8W@XY1M
MY#(166&'(=?'H:P^F42'AE5\;[%73J,1M^0T31LY=\+:N.">UN/%E$XH-#4H
MXK$DCI9[53.4A#WVIAX!<I]H-^YUX;+"V?=JZ177VAM'(/5"Q+E2;?8OLR^O
MSB6DZ"X:EX\; ?OZM!?=2O19BI;7J,D ![$% I"D'(.:WR-Z557R?M-&(.QY
MOYH1R [5:23Q*A"XHHT&<8,@)?H\A?-=[STY7!S=U\7!L,'[+Y_I>?.\>GAP
MH(LZX_T?V<9E(BZ3&@JRKZ--'J10!<Q4C:&E2\NUM0D=2+EN?)9K/Y:RA;%F
MED2S Z#1_!"E81N]]BR;[WE"8-[5?1N$]J,-V\O["YXON8XS*I??O7S[F3>I
MY%5[SF+F8GO/'*58>\=Q H\9:66'N32JV#"EX'4*1=<;\WIXH/?YQ97C([/5
MV1E^KPWXR(;FRKR-@W_W_SE.D&VS$]0GDN;4D6XF)=>EC'VT$CUPSJ-SLIR<
MF'0MG!Z_#'L[J/Z:Y9V>Q P?8GGOX/H)EI>&^TQF;>08JO/22P9FZJ4X[>A/
M<?7N$G']^''S[M+'C;J@HXS(!8!!V1-[;JX'@;'N=@+VL%P<?7/3I-;CDY/(
MK_)2WX2<^[Q?_X3N'YZ[#'L:G^GL7.9[IQ]Q^=L(MXT6UKDCNU9A\"12II&0
M,E77:PF:P@28LGHD/XF<=V=+&__&^]M(%QH;P3AW: TAUBRM=U=)"F9TXG -
M#OFOTN6/SV$?@?6#,MH/?K_O9_/9D=Z</==V8VZ)SN.9[.N5Y5*/++6^Q4\/
M%U?W>?D667\\7M0G1BV[_,?%8;6/>E>7RO9+"__7]+GN'SX;W_G">;:& %81
M.U=?8BD- A0&YW)F;M2T] J#9YZ\*:F]5_XI;AK//KL YFG/A[=*5G_$%']>
MQWV*\H[D,RD38K5$IPF47,BEG"O&$./V,V62L%4DC2RNN>*!6D8++-0-KR"M
MB=<)P/81!OCC$UX<<-7CHUG]T\3@D_ARYYDA< &S$^MG3 /7/$<.2@EJ(D((
MB6KFE E+QPDPYO,$+F.(S;0$C,9:D4R"5J@5<NH^I!JF -SO%V=N\\$[U6Y+
M[G0QY_V[EJ'-C_6>+I[/JMZX>V\;L=6(=91#(Q8;Z^!)Q3LIK*%V] 23JGL?
MS18G?OS'?9[_=A;CQ],7C">7U[2;IV_?Z=Q^^+,$_(/<PET3!*_><#R\Q2]F
M!\<'VUA-YVIAOA1$@@Y5$(/Y 55C!L<20MI19J+ YMIS:DU=JPS="4GW8M!6
MM#2/)U5*VEA@UU/T478<,CA#$K0K4@1S^4$Q04_J)Q3 -Q78]43O0)J]E]9K
M8\@MH1EL%(76*8!EV%ODBD^6</UXN#Q:O+[P%;"?B7<NHKVG@MGPA21)<C0Q
M96ZY%K-<;%ODG3<)Z[4X[(@6> OZQCD"8>4^ME#&<?2@(3L)J3Q!K-?CPSVC
MDHX36SA 2$',IBM1=99:]]0F< [8)L7DB]G8G%U7-7T#24%]HDQYK&P([ 5'
M8KSQZX<V%*(5GJ;G8DLA!D%#25*BF%LC9UJ&F\LNOUHG/6%'N2:(WG%TG[+U
MHQ;M'E3'CJC4A"..ZB&,=2XEZP2V?FQX++N8#>M:U$/H/;L /A?"Z-'USB*$
MSDU@+^YT4%OAL0M=<I;NN_@*L6=)7M@RQDZ]246:OCO<'-16YR%31@UJ\@ZH
M0<> 3FM($D+*I@>B3%;.WWMV.%\>+L:2US?+=.KA\?QH\?*;!_>V2ZBW'BR!
MCTF)''!R3)#J.(V\NMQ,JV\7BJ]71QTN=/;X)#W9QNJ+C]&YC"XYL\]H'K0W
M-PX;\J'%VF*<6O+R5RWR@]]NO,F;N=4Q0?ZO8]X?WZ&=..B)I#\X#EP3!]H3
MC_U=YI2K2,C@E7-LDY-^VXW["D]W"RTD#V/A8K8_ S)H!1975$=*O/GV_EL@
M;A_./PJ+S0_V%V+RH:>:M(\38A7(*RJKZ56H7HI/?0)M[#XSZ%?8O5M&A:)7
M]EX!?46-CENP(  ]Y#:!G=:_A?[[XWF[?- O)2V\$/.'<2)QL]#./4+1S)P+
M<!X'X;J4VP3.M_]<.;#"\\)S#Y(\50H1 HW.$[YP<:6@1U<FZ0<>S/MGP8(5
M)@(UI%2$$2&":U5B\B5U\D))8IA 7_3/EP6K/*] .Z$W!6#I(&L3Q\FYXHT#
M#IM.XI2HMVNA8^B_>SG^/-F[=I6/]/'A8J;+\T!=_^^Q?8?)];&BP*ZXT3%4
M S30T>S!0G@"5P*7QIMOLYN/U@K/.:AF3-G<478FKDG,PXJ&5,VLJL^Q;*EM
M3;)#G&7"WKD$!@N N":6'>>:^^AY*69;6VI9D^P:9_X/$X2<DFD75QK6&,V^
M'#73,0TFT(GT>YXM_LW[Q_K=R]<__L/N.'9/O[PY]DZ_DU><771C_NSX:'ER
MQ9^=]O(7\YO+W%GRGN&XI;P\/OTTWR_TO\<ZKR]_9RS>NG1Y=W!X,9L_7M5'
M^BAK&JGGZR9C-^;/=7ET\@4L%YV*_PM!76NU28<*4 .C1G0Q6"98NU;9?/^W
MLZF=36U6G'(Y5>J6LG?*H!K&@C!!#JDY=EGKYL>IC:+Q7[;JL+.I[8E3X^QD
M=!F1!-1%-HF%C7NIXZRR-(&#87<VM;.IS8I3U)HS$963F=/8>X5%:Q<*)5.M
M$'=Q:D?CC?$[4SE1LX"9$ZM+6FF<7R/4LE2/G%V0)A.HU.YL:F=3FQ6G6BK>
MAY@RJX?2,]?6)'0.VF,-=0+G!N]L:K+IU@HG\;P8N6)A]!5<(5+$F,B$36Q&
MWUUHV-%X$M[8Y+<O44J& #5UE$Q2<9S=0H[Z!/8,["K&6V539R]Z<.^'P^>Z
MF(^/=/5P\>QP<;)29WEEWJX\MF]B+YC<]+3W-5F0T)Z;&Z<K<_ 4$[.C7*/&
M"2S6VAG;SM@F$MF0ND+SG+%W,*6!%M"@>Z?VKTGZ">R.V2A^[VK,VV=LJXML
M-2M0\24G54B^8,^YC;,/022$.(&%!SMCVQG;1"*;A)106+FX#K%ESG6<I][5
M5S,VW,WT[/C]E_A]J9YJ*E- S!RZ!.A:.I"/@EX:258S.PK>[R+;SM@^<V-;
MX4GB.4E,+:<L!1Q4;J$V-1%7^CB(8P)[+7;&MHG&MBG!Q,>0HI$<*T8P633:
MJE;/HRH!KM,$]FWO^+U]_%YE2[_>12 6R054A)O]G"1;KA0@XFY/SZ[ O1YC
MF^1N1HX.2A _EL5 J)FPEN[2..VD0,AU\Z/%SIIVUK0IL2EWRBVTZ+ $*%VY
M!%/PO4 &QMYW\T&[$O766],*)WR2970Y,CG?H)=&6,"'@JW;+XO7S8]-.VO:
M6=.FQ";C-JN#VK!%<$"24JFE)!!HGMP$5N%ME#5]/@2^5%\SE2D;Q^"CY7HQ
MF8 2JFR)7TVA<A#6Z'=5MITU;;TUK2XV13;#4<Q-0@+M5;+1/;<HGA(I[F+3
MSIHV.QSD0"UGK"7X#K$SF>QG#8"-H98\@:9@.P)/D, K[$!8*!23!C5X!*<.
M,3-YB2YP27X*YWKLZL!;:4T3[;]: I@*R+FZ". \4+''P*'E7E5T K6KG3WM
M[&ESXE-V:71PDNK[2<,,ZB&92A D4]OY53_CC8Y/&T7A72UXDO:TPB[&OD;!
M-+;4),#2A2)9_A=+58M4KFU^?-K9T\Z>-B@^,45N)J%JC9"KH+8BG)HG*-G[
MW:KB'84WPM],97XE0AWJB="8#C'441ON+/:#5)=HMR5F9T^?@3VML'.G*R5A
MKY4@0,&(J0LH4:E% BKLXM/.GC8\)'3(KHX3X!$KY.ZIJ,-<@TI!YTO:A80=
MA3?<"UM*,YKY"3D7000I0E(W)KZKKSB%<YYV5>&MLJ?17?#JX<&!O?^^MBGU
MQE0L49JKHT$F $2T?,8G""&'',.NS]G.E+;<E%87E3P4E\5$@)) ZHS<@CC7
MB[B0Q$]@[G^CV+NK!4_-E%:X+!@UM< 02@Q N;-PTD"$IKE-;>^6!>],:;M-
M:751"6J.VJCEF!*@-DX"SN<BFEQH<5>QVK%WW5YF*I,IJ?JBK7IJ:%()"@4G
MM:?4J] X>7 7E7:FM-6FM,)YE+&5OYM,"JF"'Z<U]5(Q]92A<MSM5-F9TB8'
M@ER0M90L$A4B ;HB3<![I!Q2"+M L&/OYOK>)JV54$)L6J E'HV(J03OU(^-
MN&WS?>^NY/OI4W]WCI[HXN2*BTA@+MBD-R40-)][:9$5"H,#3]E'!LTJM76*
M$UA>M3.EG2EM1%0BZ*[6W+PX#Y$+-]=&XVXI)@]2F,"<_HZ]GWGI>5.BD@<D
MP9HS.Y/3(3"T&)Q(#<@$-(%-DSM3VIG21D2EE!&DA40^9W!5D8.OK627 F=.
MN_-;IFE*FU)QV/R2[PJU4O(E@2^U,4/Q*BEKZ(Z;]! Z[&9/=J:TW::TPCG]
M%()F,R=?T+120(S=):S% 4JG"?3NWYG2U'*J%?9TZ4C8L!+4#,0@M8%KCER4
M&!EW!U#NV+O!OC>W@NP\5"D"V3DA(2SJ*K:H'2;0FWY7\ITDA5>X Y!46X\Y
MA50 @Q(GXEQ3#Z4YCA/HLKBC\"0IO,(,V!%Y:D41.W@IY+BDV)R7%!S&"7CA
MC6+-KK2XAM6D34H13)Q= )\#)JAMK'^3,+JB[UI'[2B\Z5Z8U%1;R)$H!>-6
MDDIE'&XN$&N"/(&51!M%X5TI;0USI43,U++'U %2-6VG""DEKUA;W!4C=A3>
M="\,((TM\^T^CA.)(IH/9N6&8MZX^%TU>*,HO"F.K]:JY%H+WN#4U+A#TIZ<
M2]J<N;^=X]L>UJQP[7CSU!4Z!)=!65"DF^1&YIJK0[?YOF:C),.?4?BD8O_C
MX?)H\?K"MTK^FS"W,-U-/,58+,6IR16&&!)C\6$<-\N]2.P3Z#&PH_*DJ;S"
M?F@U*J46 )UQVI'Q63&%7"5%I]7]Y]HKKQSWSG[85$[?.Y;E2?@\NO[<_O@M
MC]ZY8/4(&0J+HVO&C3?N)KZ^S^OG7H]>^YU+SY[Y"W!&9L9FR$EKYJ*(?(::
M6P9+\P/IV6'RY&%C47S""[VKSX[-$_%2?UP</E[PP1LSNZ;UY+6^F(/%]U]]
MT;9'>QY68'MF>.*Q.Q$+'E4C^40:JGW!D+DT/;&]$[#V+BLU^EB2OS,8?TYR
MOP*2$V&@P& ,2!"Z:=48XLGZ6A>*.U6MGBPBT\:2_,B^^GC-:1=-"QW/#N<C
MJ3_OL*[4>GQPO&_7MOL+BW3VD]WF2GMZO#PZN! /]H;GWG ->X%642CS+73,
MV5NR#]7HWB)T\T8A)0V:=!OQNJU'#^8+Y?W9K]INS)_K*6(_\&Q^\W!YH=G!
M"I&K!H]$0+4$%QQ4 8#NLK:6S=X MA&YWR9^R\E97 F=>JCF&7L"XH(Q^L+C
MA$RI$CEO(VYGIG5[I.?+)]_O'_[R#VV/]4?+$"8#'(P-]I3%%S*S&STA8W5)
M7;;T !R=I.,#N.A&2N W.AW?U!CW=@)S"EUT'Y+ ^)5EZ=)JMCP/S1@#D"9L
M0:D@0(E0JO2M1OG2(^/Z\6[-LM*6R%$T=PP)+9#V6+*O502#WVJ\+SF>KA_M
M(C$Z,357<X9$47JJZGSES*01RU:C?=E1>/UPBP\Y,E*,G:"V(+Y)2+FGH>:Q
MGLZ&;1G*EZY&W\7K$U(LS D\^,0>"R1NU+GEEI@:!]]8MA&O-:K1%2*7<NT*
MR#XB0?0LW)2D=E,ZV?1-V4;DUJ9&5XD;@YC% 5042*U(JJ3-A(WS.?@ VXC;
M^M3H"H&K#F-RO4#Q9.AU"W6U4^^<,H?@ZTF!>@!W4J#>Z G/C8UQY\KII]!]
M4#G]G2G 3TA@DHO52PR42X,(ELNH/2H5:Q;-V6\URFM5H^O!.[M0 Q&W"@A*
MP7+7WJHT[+D;Z-MMU6M4H^M!6WOLWOO><@H@O9RTH<%@?V&LL:6M1GN=:G0]
M<#<G&#MJ)^G08C)U@R(I2&XU]CJ!I4D;&ZDO9/V-B9@LN3NMRA!4!+F"=])#
MMLPXQ&W$:YUJ=(7K67WS0AE":@*!/7H50ZYG%YDJU6U$;GUJ=(5['LP-<D,L
M+B(D !9J!AKZ;L-;RU9ZR#6JT=4!5WPMN5!C':'--7$2BBG3V,QG)G>V7.JM
MI8H;NY)\8V/<NXN[/FX%XRH6=Y7<LF?H$CI  7.KEJEJ*'VL(.JI;37*ZU6C
M:\%[*).88BXU5ZB<D SQ@BV$DL82EJW&>YUJ="UHF]]V#"V4$-1&WV$=AS3&
MF)P)%'6\U6BO58VN!>YJ@=I2XD2M-1A;OD:7B@C"#2)KF,">KXV-U!?36 2=
M4^\P2/:039*2*U%J%RG=A3Z!K@P3B+D7<ZZ4NA%"(^1>@(,37UU72LFGADH3
MZ#:]\='S8AJJ06M2&[?:$5 S20R"KB*7L4I^ F>L;GX<7!5PQ_/9*6K+H\/Z
ML_!26[5O:P-RXNV?#0*^1NG@=*OVR9ZE>^/Z[\;U5]^Z_H2P9V]U=OG9X_%>
M[\^@V&GTU"5#@E2JJ$G@4D1]#]2;3( P?[+#Z\K(5FX>SA_?U\7!C7D=[_A<
MQVAM+C7.;\*+9M)9A1P@@"JYH65B1RG:(D])TESYA1?MMSLIKQ\\VS]\J7I"
M[#O/!INW,7U%'<$T(I2H ,Z3<"RJ6JG4$C%]CD#^Z3LN%T??W.7YXU?O-![>
MFLUG!\<7L"US R@"I4<!$[/: ,D2Y]I\I3$)@.01=A3Y0(KPBVVEB =3O5AS
M24814\,$HBWU[BA0A3RIFL<(W;])9$Y^N[QR?/3D<#%$U(-YT\5;=#E)=+Y[
M>?V%+NIL!/Q9U;?@'S'_M\_=F>M6DH&+C^%DTBD8&3*J!-=BIVK<L/ RD?1M
MPARXD)2/&TGJ4I-V;S@FQ!I5"T%*3 7\SL;?A^_]7PZWT<9=01<3.H[J(0LA
MAY%%)M'>(Q#O;/RB.7 QL@ZX<Q$49 >U"D97"XVCL&-2\6YGX^_%]\E"MS.2
MBQ^+9R&RA>Z@1%'%LOY"&DSV(^VL_.)9<"%V'KSY;N1Q5F,&^Y]Z"8E+#CVF
M<?K0SL[?A_#WA\>+;33SF*#UC%"Y%$@U,T-%-LF?0\E,4ZFW3ID$%V+E4+UK
M(I%](N#0L'%N+%R0'(0\J=5DEPCP[/E6!O/6T]BSC;ZA0B>46"L[DJX^>-:^
ML_(+)\'%3*^JC]WP5,@%+* 3]$0!<W1%?0M36DWX.^79N[H\,F2.M)W ^F ^
M.UK>O?=@5\7_J" O-3('*GF<"542 FOAS%D;8X]]1Y-=)7_LI0N5&[2<?/3@
M LKH0!F"U@PY>IE2)?]W:/*C+OKAXH#G54]#QS;"V"42C?A>I(-TSQ;V(4E(
MI7:J;DH";T4P[L+!.SM-&KN8:O?DH4<AS,A:JR\08FQ3T@;K),CV!H(LU;5$
M[+N/T"U;0)*8HWD4U[S'">S:7&F:\&G9_NIVB&DE*BDK)&1(5 5E;'\W6>_+
MZ#8S65@N(2Q?""#BM7K-'E0%QD18B5TP=W*0:RN?K?R:I--CH5$!=<D%#Z&0
MN,[11AG'5AZ($UBZL&X,+V;E/S7):NZM67HB/I Z356"3SG&<8+'5&&Y7*>W
M.D!,5+A:0^<N!?K_8^_=ENPZCBS!?YDOB(N'7_H-HF 2K2521H#JZGH9\UL4
M,4,",I L:_W]Q":IGNFI*JI:(+'/WB<@$">1"0&9N=>*M?P2[N@2S5)ZYIR(
MU?%"$U?.)LSY\U26?LT8+3MP Z#4:K4"8\YV5'_R0L-<'^EAGC.JM57A"=A@
MA74 ZEI"L4KKAKUIH^LS\V/G;\X98.9YE&::+$L/8U:53NL;''6)X#*65QJ?
M_AB/\1PVR@J<36J :H+.HF7,4:1,;(Y8Y +!P9'F^-/[=_&]?_?Y^U?Y_E_?
M^/^G<O;YZT]^B;3*_[Q@][L\;DK]Y:LWKC^MY_-WW[_][OU?_\N7K_[Q?^+?
MW./[S???OGF;WW[[ZL=OP_^RXN[MM]]_D[?L\QB\1.'8R&6V8.E#);6Y'==\
M+!CE MJPT7@;B5-68I!&7ATJRSH>J;8IU"AFGU?8 [/1>!NE#L@F[6B,^F$^
M,/ L>-QLI=JK>KU"P>Q71^,O#Y4/)<#?/J//WKW]\I9UW.B93;4.6(>D2%<;
MBM2KC<+H/V67GURRGQN6YXS@;=![6X&,U G60]P=1VE9N\[68VOWD\/R'!$?
MU,?1RR#E6,:Q(FZP)$*M[J6%7N&*X@5A>4EAQ3;G'!2:TT #F'&=7H)4%<-%
MM[ ^(E1.$3OHPF642M ;E)'6C^ECB!PYAH)NL7M J)PC0--SXD@03@)'-/,!
MO)R2S5(SKM ]^_-0>?5_OWG[^]2OO_OJ-ZG??_?7G>"XBN -=&<2:4@*4<T
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MQNJ0H[F D'%+]FC-HDDTNG[WT2\%R:=.<IRT[;..;+5-K<*PHA".RBFM287
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M7;/T;3DV6!_&!L#0(@T'<B @F2!*1UY@FC26*;B2#;A>GN^28EPI2J=!74=
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M$85"7!T=6H6>%[$+FP*WH, YUWX#H=/RQ^ 5.(PUW561IA;T>96I:)L"=Z#
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M=^3N[(YT2$P-DW$=2^_JQ'),/8RHJ9L.,6/#<%V;D[6WEJ6;AD4L8MRX(U=
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M0:=;MO!3L)DS?>$7Y0A$*SREJ,$22)L1+,)T'<$IX#I<L3/MK,@OJV']W08
M62XF)CQ\HEF/J%F$]7PL>,=KIB>^-M_4EUVY0'V_7E]P_>3JD1"KJHNOF6M]
MI?)!@B0/=6NAT?\X93P"?\,(@E_KV18$UW_[J]4V;++AF/[]%_'8\-U?:W]Q
MXV2##=^__XHCWH9%;K<$MPP6,/ 4:^U7C[R6KJSL;VD\56R"8#C+B^F" R]Q
MD1 93%VTTF=?7\Z_6OLGP_1T]'&Z9WV$>]Z-3K^?F3!/Z_3[WK?]\YWA_M;V
MMR_G>W-G7^/1P<FI>?#^4_+E9/?[%T \>^^_G!]L?4J_G,/5W[<M?(>]DYT1
M()[+J_%@A!,:4T _H1OJQ*-4#X/0TQTW=(W ,)PX#-?>?E@LSJ^O\_1H7'Z_
M?1R;]M&/_5KWNGD'5^GXV._W &0C;WXEJ.N)R>G]1:CO:6Y3\M2VZ?%UV/?Q
MWW-ENN5*,"%6\MVDA">7Y6S?[CCYQB-XK[1<Y?C%WP0? #;\-5<FRK4"WZ:N
M'AC<T(GC$SWP,8Z A6$<>SZA_BU;Y#Y/^;R]V&3M=_A/[O!Z'=^+9=R4J]CO
M]%_>Z5=+ 7B&;1+7#70OCKE.N&WK8>@QW?6\*'!\/Z;$O8]FV#^QP6<N7<E0
MNQC===>XK;  ]BU#8O#,1)R4 ,+#V)@JUR:E=,_!BW)XSVA14^V\$,]*I_CP
MRP0>#8_5,GBW'%''15(*Q)C1C*$P !R)G2SQXK*B642+J-2P:4 2S9VRJ$-N
MS;1?T,7A-3];Q_O!'</J,F)M>.BT&^=RK5X7'$^'+GA;<A?%6>=&Y>DSVEMH
M6.;II+IZR_4EVKO_#HN6S\^X'A:<?M5I7/'B-4TOZ;1<>S7+VL#7<[/_V0<O
M_T;YZ2-$%9&AP#/67$5',:TJCKTND#F!3['7,,P-EAFC%_ZWU&A9 D+$/VJN
MY2#MQ"E9IHKRXST)'IYEL"50D15YJN6@;3L[I47L$UBZ)N9,(P;!NM%U["LM
M0@K#Z@??4CX5 1\O3$?[N'&\L;FA>9:+1:9?XBNW[X?%8F&KA2EHT<Y^C)-B
M)(\=Q_!LBA?!%A9QN)&8,9U$2:7FM:&U 6T/IY=W65P,\*EY,6A7?2>E9XO4
M<E5,5E,KWRFXR_D["IA+0BO2*26 GXGGHKGN (BV*(.UYQ$A'3?4H@/(_@CN
MGE1QV<:BPPZ:W7 +=)O5V<JP=Z]5UUTAU8H(T7%'QDSE5T-<1><+&38O;U.1
M5G$J K#@(Y87A9I)+E%$46#L58X2X"+))V4ZK07 HJ<NGP9>4KZXF:@(F 3]
M<L!;D@0M96H^ZM!:R.@F#@35$\M%3 MHH71:)J5J#XOG&Q>@_"E", 1I/"NE
MVL* %/A*!!,V3^]R3]-19;YI3%%V(UL V/ +9+9F"@H6=ID=)8CWQB+&AFEL
MZ29P?,\W#W:D7PYYFM;H7WMQ7?;,M<?7+Y<I:/WA?7JX6D_2T+\3I##^=KTX
M<N+ UWUJQSJQ&==I0$T]C G "4H8L:(?&NI]1-$3"&@_ 0%!S\Y SJ @0OG#
M*^U"%.A7XJ-;OU^##26TBH@4BA%S4,PW1X$TJ:3" 00"@ C4$RH'&1\)B@7,
M*M71XLJ8&/:88BPXF,01)@2J!XO/0N61UR)ZDQX;Y:704K":@&F$QX+C? "O
MY1FBFY(!M/GOA(H83'PB'8^+_%L"$H'#'?]/R:(=$>\(4YMDB91$DS):FZM)
M2MW8(U$4&20D%O5"'IJA&_@A@<WC6_[?NT(T>8:]!M*9P2/2\O_6]."J?#H4
M1MI.FM-J5CQEDY$>Y96N;E_3</IP:_#,A-7^]]WO?SN,^I[OFKH;VA2$E0]R
MRO>H[EM63%T_#*/ 7'M+O*;M5TW$MUJ8I"G\LK%BF_(@TW9X6 "W3C736,>"
M4/8ZLCY Q4O\YUIN+8< )\LYAHV(Q?W B"S/#Y!E@YB[Q+!,TW;LT+>I8%@;
M/C"Z#+N[O[,@:4)L7+%OC\6C#B:5</2!^+P="QO/CH5/+__&7G6BHI(1@98%
MY0K6.S5<W>0!\8/0,'S36WMKK;L&6;=\=]TV[*O,+&F+0G!&?.8M!7Z.SY>@
MI=K6P>;'O>W]DV-M=W_SX.CPX&APLKVEO3O5CK9WMH^V]S>W'RW>TK=_J6N:
MN^&1^X^W#.!+]W;#_GIEHD5G@H]6X_"08HK<KG#)[N[NOK[_XT[Y:HWK^W>_
M'WI_54#T D"#X&3:^F+$00PZ:5%2PYID$X S(\Z%9Q=&$+)A"/@)+7CIU\;#
MF@1]4)T,.TV<$4CG4(KNB.L1E8),4TX+[05>HP*H#\7$CNN)J<!I3 @$O91D
M+"_&N8PCNHH%D[+C:]\!90':3?\W#@_?J/%E/EX][)Q$N^$4[U:];9?G! ?'
M%GK0,2EQ3=?CL>V2P#%#++W'@PC^L#W/97][:X][ZO/;16^PX3OVKXA>9\,,
M[K]?I>=OF$9P_VTP[0T[<!]!HC]FL\-=$!JK4]AI_IVN"RSLNAQ6[ZT64^J0
M8MFBJ[%7<Y+4E-$5=^AS]JNQ'/?UR(6;*[@SIJCO_PFD'<</@[2!GG+:8(JA
M:D;M)<Z<\2J8#EV:N6C# @W6?_Q8*9HVL.C@Z$1NOMU_O:+SZFLEH/ M0^/,
MQP"_]\0"B][HL=CQ)^?R$^SHKKVM8X>OX<7[U=V+)4R!;_7@ N;94-1\XF+E
M/I#+K92@NE_'B]%!XMSD6>VY]">X-%A[^YYGO*!I+W:>"D%[L=.+G>7F4LM:
M>WO,SYK0M![Z/#7J]C*HET%+SJ4.0I_\K*#C8<*T0<%I+W^>#&6M7O[T\F>Y
MN=1?>WM$+[4]6G',@^V%SY,A:R]\>N&SW%QJFWA"5Z']U8N=IT+0.XJ=^Z]Z
MT>_GWT9^LO86FXUQ#,#OM_33H*FW]M;ND40O>9:>2V5O*UCY:MJ+GJ="U%[T
M]*)GN;F4&&MO,3F75R*BNA<]3X6HO>CI1<^2<ZF]]G8[NTB*/,-#[%[T/!6B
M]J*G%SU+SJ7NVMNVH50O>9X*3>\H>7KO[0J3/\ BS>,TGW*L"Y=%VA\3F)>V
M2<=)15-MKRD?V6_WIT)OIP<:O51::BYUK+6W@PN:I")[>S>3Q5EZS/&$R.L]
M<2%D#C8>4 +U;'@?;.B .9.47[4=RJJ\Z,^NGPQ5_:<N7-[UPF79V=!?>_LQ
M*WB9IUC-^+BBL2Q^U@>^/242F^X3%S56+VB6FPM=C*<M\C&N,>\ERY.AZ9.7
M+'8O69:<"\G:VP_\C*8:R!?&N:@SW@N8IT+:)R]@2"]@EIP+O;6W>W"+=DQC
M7DVUK:3$TJZ3HL<Q3X? 3U[,//AQ4\^*]\"*GK'V=KOI&'50=XQ21:2/FB+2
MO>!Y*M0V?^J(Z9?+ICYJ?^T%LJ<O"KN*16&]V:*P3[TJK-.KRR47H"Y <]E1
M"]LW'%UMLJ :N6S_=Y)4TW6X(A6=$T1C%]G- >N+5*AD11\,[-59:(>3@@UI
M*7O!R'NQY:AJ3-HKWZ?".Y;QQ"68VTNP)>?"8.WMBR,.$[C@T<M>LCP5FCYY
MR>+UDF6YN=!W$!O5<?$-($+OY:0LL:<A IY!I^,UB*%)*NO-'HRY?+2$13M-
M[_+-/(OZ9.(GQ2364R]%Z_5!KLO.AZ8!:/PO;'B?5*)/G! [\$%:_]TY==$&
M83ZI-&7X86QL+XR>#!/8P1.71GXOBY:=#0&_MXBG:<0IH=#Q9#Q.Q=_8.WJ+
M5K07/D^&ZD]>^ 2]\%EN-K0(67N[.:39&4PKD38:0!]Z5G EA#XGU5 ;,)9/
M0 2)]B!9_2>V*IXUUUK4U$NI)\,>IO'4,X>"WF);?D[TL+A<5A5 &"%U1/AM
MU(?%/2D*/P-9TV<I+CTG.L;:VX-JR(N^RL*3I.WODC*/&@47;/:"9NF9T5Y[
MV_4T'_$S6B ]M)V\@(=EVI^3(BFCA,G#L9,AK0#X\ LPS4 VE6,NO^AETY-A
MAY^437V$;A^A^X@1NI;CSH;H/O487=/HE>JR2]$ E6K!1?FB=6U!?@NZ#S;S
M8HR/X=K['.B!'LS>:?ET&.#I.Q),LY=$2\Z(KM5-KQ.M,;*R=R8\+0*;QE,_
MQ37[<D=+SX@.=OT2&4-3[> R Y0S3,886KL)ZTZ33'O',P[P!T]IY?<"!;41
MN^+/&_*5>HGU9!CE&4BLOHS2TC.BO_:VEDU"[* ?$V16.2.(3@J8)I5.SG45
MG2(M.VT7G@IX*N*]X?:4>.(9"*>^!-.R,Z(GRD<F&4O&@)?:Z#=MIVX(<LR+
MBX3UL2=/B. _*7GZDY?^Y.4Q3UX\,G/R\NFI:\V^.LK2"U$/W9W#)$RJ^3S>
M)JM%.V9#'DW27G,^(:*;YE,O/V#VE4V6G1%]8^WM3EZ,--/0_ZT=3T8C6DQ[
M(?-D:/OTA4Q?,W4UF-%>>WL,ZTJK/OGD21'5-)]Z:9)>PJP&,[J-(:6L>QCE
M6R]IG@QQ3?/&[N*O*FSQ6G_>(8F:#+%$6]TWX[P4Q;%>%^( [8*_N4RB:J@V
M>_=&2=_71GL+#<L\G517;Y%4?ONOL'@U/\'.O\.BY;0SKH<%IU]U&E>\>$W3
M2SHMUU[-3&"49/K<['_VP3=>@H]*HO];NTWEA;4%*_L37LI[DM!7/(,6+L3F
MX./)[L'^X.A4VS\XV=:.MM\/CK9V]]]K.P='G^%7_</!P;_Q[^.3P<GVWO;^
MR;%V=2E^\%;7K6#WM@2/5F%:_DW]FQ]*6XFU.!DFI3;(L@E-M2,^SHL*BP^T
M-EX]_P5SLTS\[P/.#=U;?^;#K(09_9..QF_JOYK*=[E((!Q/PC1AZ52C3>?F
M*&<365N!P6/P_!OOL7 EBTM:1'J:YU\Q!ZAL2L&("\PWVF52#>%Z+,X_XC3#
MBU2M_I+&7!O2(LSAF45^D90B84A]^S%+9%@/#%AJAT5R@8'/;8EA[0/\.!-"
M#58:4QZU :OP;C,(G(WY,*&"CP'Y8DT:%#KB*0O70ER,SL!R$I9)E- "G_4"
M9X3!D#2;OM1H6N;:B$ZUN,A'6@4TTJI<_AS1KUR[?E$V;F* !V?.G6OG!036
MLKS2A% &RE1%PBK@ '@M8.@J+U#O:D G6/T"ES2F3#E,08FD'!9^=+60(BW+
MR6BL B$N$GX)/\8IQ;_R\!SSP"[4T220_USEA6E4E"[#!8\G:*YL:#?,&ZD0
M<A"C\%<2)\ PX53<.RDYTO@R+R*D)1O";&JFE7.H&51]R+]A9MJ5CR^3-)W_
M#&NPX3$K,.:544I@ _RB_AS?3FXK.1684YD ;6G1; ?8';"KSB>96 "Q8=8U
M.LIQIX@[<0.=E:^UJ"E,*<:1RZ/E32'*-YI\"5@%]2$,4:B2E3B1N'%NP]<B
M2SAC_(V6 %_+K8,KD\'ME/UWDDBM*^^$1]=JN&QNP"_@==66A@=5Q83!G.1+
MP<5RKZW#'RR=B!Q!8(D<)H!39'E9@0RXP'?K+%,H@OXJ> J2L9Y0R<=4OF4M
M']1N[)0QSX#;8( _.$VKH19.2M@ I1IG_FJL@5[QLZDHBGY6Y)?5\ UR800O
MH$7\@J?Y6,H.Y%(A<-[ &YY-8'_D!8C&,4HL$ 1O@ 5%D;UZ><2K(!VP"BA:
MVQM7=-8J*;1WG%'<2]?+-(T"$X:T1*[+&@$1\C3A,=!>LF2G4FI'*N"*JN11
MQ<PB313N II-Q< @AE$RH"2"#2*#KY :ZUJ1E%_EB$P5 ZHPU11OBA),FP&V
MQ]M [F,RJK@2EF,JQ,(P08F NV=2@9CGUW$5JKLB3S>TW0PX&;-SM'*83U*4
M>P!2OG/YT"36)+">*B9OWA#9!.131AFL#"S9.DK1KUE^F>$ODTS^*M]%?-!Y
M1PTE29&(YZPOG!YP)R*-Q7N<U85HX3><\0668ZN'3)7VND*>KBB&+V%H0=D"
M-WV* A;$%>K'FY1<NUBXQ+BM44%S#5@)!X9!4-D ;4#?3)%KX)(;>6Q#U+"4
M$YQ=(BE:8'G"B:0]CIR"4$(14^6O?V[S/=@>$R.^3BJ@);L%I)9O6T<4PD(=
M*M&TU8JF];J\Y_&$,:"22A$;C7FER@]?(UF4G:VC4?W:=FM+6\D:_>>$S0"9
MZ;K7MVXE8H2J=-\\'C)Z,[,BIKTA5F!S"+N$"\&RB.V0J4'.X6[(,E %C>SO
M:@^0*AG,4&#*D1 %4:UEY*@59\,,7O(,!T7E+P33=9(HR28P@%17XO92D5Z&
ME785;3M=(? 8O+/$<).*Y2.4G_C..&GXD'9*7/-O /APA.:6B%84$1N.)A'%
M536XK@VEVD6%#7.] /AQ)DO4 F0!.QX4,Q5SE2&Q$AZD\H+FS1BV52^$\%)O
M]D!<<3O&U*ZW4OL]]+-[""VD11HL3%), (&O)8?52JA"K4\C_M\)6B0(MI4E
M)V$B,#9/T?! _3>6;;.GFG#Z"=W4[+N&GZ_?=\H\G;4X.X\:H1V/H902ZK5,
MV;/%K['%":QVQ^B0M 6PD2A#!L#.=(RR!U%*GJ;Y96O8)0C(D)#*%F!2XP&!
MS\!R $,5H$"2US86,()R:G2I+_&2E&4 ."=<@4.A3LLAPH@T!]S34_JNE-[-
M& !EL,3.T)]T=H9PLJY='A>PN9'R[(=20K)(B3R@Z"W19;U' 95S+C C#)!2
M4'[#7V*,1$Z7(XLP/A:FG]2?^:10=LF\9ZJ53"<%R"OD(I6VWY$A$6?"O24<
M1(5X3^&4:%]]'2Q('$EB\Y9#03@A+^(D%(/R;Z#D2SDUP<UTG"#L0(6-^P.,
MZI1+(8C3!8S-+U!ZU>9MF0,$Q^^ 16J'0<_H=]5T+?!&$J"OD19L^%.(<!U_
M0]3#KRJI=04-&<T4<^!C:I(JG2FP8(ZG)+QDF&34D_4>R2KL58HTK4L-"U\=
MNN<*6'Y:",L MQW,.*6A.G);!W,4B($R<'W6M=3H'.$T:.L7QWEQ/5KI27J/
M)&W=5GE9Z3R.I5,Z$W9*O;DZOM+U#BG0-*+1!7ZL/"=*2=$*<:Q$+!UM)7S!
M/?'N1KP!:,LSY:T2GK>%:*'>.TD6HS.:2U=R39[;V1#"(=C9V(T %KXT(#RH
M<?1>4<$T/[)MX-)4SJ*=FP;HIVS<!@B&DJ*>ZK16%B/0U5,PP4>T=D0H3VF1
M3\'@3J[W+R^Q%^M#HI9FO7N*)Y-H&]_"0'K>I_V6N=N6J1>=(R:E;(K0%X]>
M*Y1.Z"7*!&]SL270<,ZK5BZ6+)$G:TSC%XE(7+X!J-82$]5B5-!+X1@") U7
MBE]:OY$RWS+%[D6U^-AW)\\CF4)=3,ZT031*,M&^5MS](I=;N,BH\F.)G$=>
MX'CERW4%B84G&1$QSF \J>J+Y9Y:[V#^M.5%<8!32@0O#<)Q@8A>6JV]#KXW
M!T#79SE'K_K<_BK)Q"'J689LB89-AVYXFB=JHS6'=RA8I+">,RZ[3ZX9-ZT%
MD\92FHS4@55'YQ2M,!L#6XPHXQ,1E-9!<N,"GUNC G&"A!^( PUQZG@CBGON
M\5+]3KJ#*XVVS'X^B<XDB  R\JI*VU@8W 32L\JFZN0>F^O.<#>R?"IM2HY/
MG3G%5QZ[=M^M7]U!ZXB;2[%MD^Q\4M1;:AUFT\3PP$=EJ37%,CI;-Q%'B&IX
M/$8>C=-\.IIU E^99"^8[\=?AQ$7K #))H_+D6'D^0Y#50B+-@%1-D4#IRMM
MSP >)$KLB;-;-(7R @!L*7UPS5&UP@NS1*Z]&*6H/I=G'9]'44CG+YZ3STM_
M!BA1'205&(PBHELRB8T[3"M/B&=/AQ$BA"#%1403GH9WWJ:-'^EYZFX\M4.3
M%"T6D"HCSBMA$X.8 "BIY6':4%^$037?=-PAPLG24J:<5_**[68-M-9'UN45
M>#4I:WI!<5>KHK8!VNB;'(^#P3(4$:,IO:P!G$#]<H-+!PML_JMG;;-(O@UJ
MZ^H=B8&$E_]U<_9<NU1KR_I-ZV_KN&646?^F RWAAE%>'R-UQ%L[D#RQ%H)"
MODHR"B>@7!LUA$:!B%[*B_5%0TA1J.JNO-%X=I$4N6!;J;<J&6DCPP3+?%*P
M.IB.7C:A.CVSWH?+3\D5(4S2G E5U.%,6'_!LL*IA%&E(IPQ^;%G!R8\P6A8
M$8I92$</QD=U'3W-$8PZ0)[E:>'WD9(-QA,R<"KG.<+(-;1[.#(0VD)Y475"
M,)JI2S@T,U0=\XK3WYZ@<PMH =NN$^Z]IX;?$L.7M?,%&;+GN#L'/M3]"2,,
MMP%[<(&4J^BWA8*R<4H(&09\4K5P#(_!X38ZJ8:Y0M&TR"<*UE_F11K5(:BJ
M0P<*YC;61SQ3@72\N>O,2=#Q(0^1.H% M7G0.[#ORUXKRXF$/U)SY;AU+Y)2
M!%XW;2H!06<1Q9AQ%?G0EB;I-+,\;JYZE\./*RI7W=O)F\ KMK])K8V";92(
MD/(5<B,ODLC'RK7"M-UNY/D?K4Y6T9(G!<^BLK&##U6 ^?%/!YB_4P9"OR/N
MZI^6&$J$&@N!U=J(,L%&4JS*,3BXB[)$!H%*2)(1L:U:10IV PNS,D^32!TT
MB-R*6;B&SNUN1$D3UH^G/YCL(</29Z8B4UXBM$]5?'8Y3.*J_KIKLB3=.)B0
M@Y*O)PD0$JM^X)D/3F 6BBHW-#I-.E8,R@R.7D4%&>;,<P4RNB$Q!0<L(A=,
MOF/'?JK771Z#(L\G4FE<Y"F6$"P2X>:?&T"YPY6[H(>H=]T%1PINHN=%Y(Y(
M-QNB!<$4L%X)\.B$ILCEH)BK21.\VR4GVA5@1@R!*%>X::%5HD4389H#3V;
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MZV0<B8S8;'K]FK6R.T3T%_&K'0;:4AWB-%>!!I5(T(4EL'HS-;5%#%8;[[?
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M"8R&''%Q.*0\E%$G'EZ^)-;(R1)A@LVN,A:7U#YN'&]<7S)A9A.*'#(L6;J
M.DFA8>N1SLRP+5(3DA/1*7"P#C]F KAB90@TS]C0MO$!C>R;=CVL5U8;&$G)
MC+H*"R8<USVBZH2Z4*3?"_#?$%**BBG"7U&>F^$V7; ';Z<.+6MIU>%QO53P
MXM?FF"Z?3*G-(!'4?0:L\5U(49'>=/>-MZ$-VA3VKIG3>!G$'H*')PC@DCEI
MCCP#+!FJ38ME#.O$JPR3CJJZ)GE%PPF6!^]8V[)G5TV4SL%EI[F6,/E>UTW
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M!%RHE.N\=]6TJ! '%7B#Y)/.,T+>IK\GS514_I (;TS:PFYU]C4&GDRX@$1
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M1&?#%@"L<E$ B'\;)[/-7SKE?&HJ"^>+/!?(.U;RAG;<80ZI\ 2=>"2<"])
MI<FHE-7V+NJCA7:.:L5:UD']FZ);:B('0Y?P5)KCW6H[F,:FF<%Z#2D_B(<?
MM@\75+)N*@]E,?SO@Z*DSJL<JE?YK>EXO_V]#>\&6;<DTYM-&CD6W>.O*>N7
MXA%!6=4,OWYM]*ILWZM./>8L=6/#^I\%R>MY)?2Q['X@[E,)')9A61NB(S!F
MPI_):ICM7BRZ;7/;H@F+Q%\C^Y3 ZZ.B^JBH/BIJ9:*BK)6.BGIP.=[4$WFT
M.'2<Q9]P+QB0VKL$0?@0TZO8!N)F/"Y(ISJ :QYUBVFT95EFST#6$8>7C9@O
MQYP)9"4MSK94M=1 /_G*AU3 \%S[ /_@6?\OU]X4+_VSU;1N^W@/:VC^\/G7
MI2N0#>O&=(5'Y1,T()"(@"8$Y$8H/%NE';U>G8XH(]$KN@;(XA[I7I.YG8O&
MVYX@R%0.M%L.16Y9G--V;ULW\)J[?O>"WPCL9&3557R'JEZ&C,"N6QP[*&R5
M7PP.O $F^AMD25!B*U??\PS?9_#J6,JFZC*OF4B0;.ZDM5X4>0BZ4#!J0RQR
MB95FP98I94R+<#C(APOC<O8!DM,7/1DT]U Q\^*V!Y+!@\5[I7%T-)MFT?8
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MVTA-"Z;$&8?,4\N)O6S8^LQ8;W[A/6%P\A"YX-@7J)ZC82VE?(.V4GG\:;[
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M,9.H%JVG**W:=/X03//!RX/#AZGCB@;VE&&_:2 M'] N*C0U/NKBT]L4-E!
MGPZ?7SBQT018=E@U%,PB='!HP9GFQ& R6W2D,Q-T*QO@YP..Z.2D[$6BK*_#
MQO ?F2*\NPL6#XJ3E1"2*Z[7VX>/1%2E:6=1G+3YF%M!T:>[;QVC4AHS:\/T
M+")0[U>5\\X0W>;<O;NPBY3AI<JYC7\*37>==IKM/8-+&@;P(!EI"[XF+>VI
M_?RTG'%GOH?ZG#DQACEZ=9F/H$-H[KRK_9)I,E_H\MP7P@Q^R]OR,S S-,)@
M<QG%=,[,9U*=<LR700+">GNA-(K;@.JGINRDCHD2@#JA,*\B B " :[?%EP'
M86,//LO4ZH7GD-9YL;[--#O-D8;H&ZM;7]ZY?>93\ Q(6PK;05"^"&UB1['E
M-B><5U[M@>!VCL\EVBI!\]*)N3A[XUAK=.HFUFYCW&FBP2=!."M[+.-6U()D
M334FF)JS?&L1!QKVERP-+UQ(=/# >H%EJ5R@7TXW(<(\5D<@2A,&ECUC(5EY
MA\":4(M"\N1)0%3#/17Y@H(F.U/>QAS3NRN-#2D-@.:&/K6]NYY+;985)ZT]
M#VZF5'7%A_C:C9^]Q_$-?.>^)^"^)^"^)V"-EBCMFIV[TA.PYM'#+U5YUC #
M^<M NV;=@]SW9426-C.9JQJY5NK =7?]U"D<+/1;5RU1;SGRQ4 8SUTUX]19
MD+2QOUU(\N RP17O7Y"O/^3*"K4OJAI*0ALH^5B49S,S/N$0KOY(W>K$?>,(
MON0[2TZ.]2K.E-0?<R=CD%?H6S44?40:IV$($VD5:3LZIX"MLZ<<6L[INOW&
M19IXRM$[*45,TFP6EDO?1Q%?28THU"A/X^7R&C,1B7$)#IHWN)\UHK>%8;$Z
MSB6XD,R._-^MD;%%Z#B5% .:%X6UI"J'F.]%OJ HAOK?.<T'IBW[NU-4RHK>
MD&^IP, \V.![I/Y,E9$B35KW;G'7YMA@+!!]B:-++1-X&; QH1X1JU3E0F6*
M4*0L3+I,5\[9F7/)'$7K*_E@%T=AS@,O^_'N@/ULOP'LHA0^,^'10UGW0SE,
M0+!Z4HI\):1_QLE<%,WJY($O:K0+4F-Q<E9$=XF"!FNV2#OQ0_N&Y4?0=F9%
M U87$,;P8\8;9WB.V]!TL>L_:0MMIN80X!PW<'FAVIPP#Q>U3#_PY?SH%6E#
MK](<+*N3K!"ZM/IA=YF>6J^P(%X7NQ8+-+0SM0_"BV?_N',9J9<^1WA .4*N
M+!W&2<*U/V)B(1_D>/)&:FBH9#/)GLN'<D.Y3Z12CQW;&]:?P<K'TF0Z"F=X
ML%-Z$JG!CNK5NP_E/OI,B6$APH1:FA85A&R6IJ4S*[XPR,$MR'-/[*(%38 ]
M9NR<D?C&3$0=^NX:Q/QS8YKX/"YL].\DQ<.466B^)'T4V$J$WF_;BOBR.)=
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MK_68V6^-;ON<I.6Y?H/TQ_L_/$-*X,'=]G"M@= 7/<=?AJ2"N$U?3K-:A!.
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MT'2"KXJKXP,\/*[3("TFU05P$N8(DL!C (YVEJ*?"%*R-HT0':+Q[PP/VKD
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MHN=@"+**69)I92ME<OQ:H2Z-+MCN$I\!X.I-U12\'V!LX34M>0"\=;2HU\7
M7+CDC^@$D7))QW+B;; -5#GGPHW L^06@A+;Q-\WP34XZ N.8:\B2:/LUB72
MH)PPF]OC$0&K73O91;PPO5D4@)WG>4/P,$\^RX4FO"G2$04>)/5%#U0\1U.]
M3;QP?!9)XMKPU1STVI5/[,HC)&A)!8NB+,"?<9;-KG/Q1K:7%&M<WDG ('@1
ML@<8X-8NQ-=E94K:9/F$P2%LK5;O*1@5<@M!%)[-,T;D>?^2\A8@V5'<*]4
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MC@6,;<]4+931900=]]100=X9*WM>P^5B:Z:;Z\JF;(5SV=M:X^8H&-T4F!V
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M)<=:<4_QTN'J@\WGR52;E,-1MR,U(^:X#.XYQM@&AQ2(+KC!P@6K(V4Z]9Z
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MTUS8$TIPI#BGQL!P#,1R]"U4'W(,B;>P63E]UTIB;FX]#Z ^WS##>3?=A?T
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MQL\9I;%?Q&P%73O"I5/?B6A[#&AD8K^L=_RNF@Z6ID\.&="JD(H.;[R4SM?
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M4=-A3*AXOV&^?$;4B8:=8N>Z72!U24)>[B $BL.I)56&-&F5!(!S?KIW2-B
MP=/WD_-EDW-B2C\_%!]'8:#=0RVJ"N.\SFK69E-Y11QW= ZQ;RM(YC/(,H*:
MGJS>Q'HB:#PW555:(S>WL[W(QX9*@*B5V1FD'SXSENS)VWQHZR:?G-]<YN8S
M<:FOLGS6LAJQ@Q=D-@YO\IJ[!<Y!W0 :/*E[<U2_5/PL6SCIUD5@NHU1ML C
M. X74$;9L3WC*ZB"B]/X=9^765H7H.A?1HN;(&_5\0GZ/D[(VXU&2++SK\MR
M[&WU(7T%O1?'W,=+[W_<V/^" HN9@]Z69>6^\4XN)I^'9 I/@-,E\*Q+ I6
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M:6LCOL-B-$@>_,0__O10F,V6%TPNKR5RC7^W=OU-SKG,U&2?-B:5D>[_S(O
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MZ*]+/#)#DX9>.3?WB7+0ZKE:<LJBN)\^(EL Y[%=EE4FQ >>RX*[41)";=M
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M<I>0"E!'2!P-=GQ^_=N[JC2!P B#**#R(7$,*E7M>>_: P-%GEA 7?-TICJ
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MJXWN]'%V]9;>XU@Q$WST:H R74F+9$T7LIX+2LNV?&OBN6,O^(_K9Y3 \$]
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MFV?]*/::<B37.(<U!.7IE=/%>$<'],'[!VNELK+!!0Y5>'!C'.V2-> '!HY
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M)B.A\B\! [AUQ\4(!;5+HSFQXTQ9.RD<&Z B8R-KO'@;<PAOX!+4_,2G5V8
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M-6E^5/AJA*76C^ ^D@LG> 3CJ:(.FZ5W8_XHS9RS?N0)IBJM::"-9&%%;#I
M:Z%PU>A-6I# SV'#TVY,>]+RWUBVS68>P?X)N+=HAN'HHT>,3,C;VPH#Q-#:
M,CK?'+RM4A]S6N#CLSY;E%7Y_STWJ^:4BF0)AFVM+Q7)0>F6UYNLH%XFK*6P
M7;;*:]^22('[8L+U2[V.,@-A;CTQZX!9#6&"U4VYV%6>)]\<B&D@!YB K =W
MU3>E4*>&2$<;R.R<P_-%T7#V\ZZ?:UEB0UDBLP:V']-\BED#6V0Z[PXVS:K1
M<\T:R,K^%J]4-L@2J+@]LVEW:Q%;B]Q4Y."F78%>889T=NN?5M:5.RG2',DQ
M;%5>(<DK)'F%=*I*_8BT<\N4D<%&#7*>L$6;P<VQH42(/>"P?1\+L6#"%FWC
M(D."%45(?:TOW<<&J37O]BDC?54A:EETW#3,06;"@9R(N1JL@50T#R++J[Q!
MI!>-4I0N@7$HRX\/4BK'^NOC$)R\7:Z4K%7E9(8T2QN,X+ <"]X44+$F(>%5
M!CS0\20%Z2XH50K1E\*;-V+.8VJ>:^<Y3]EHQ>CU"TLAY:6&O-18YXENTPY#
M7F@<B9#Y7&IJ@,F2FW7?.(8:R%\J^C-D=QB#PN2A9ZXP#E4%)^\PQ&,K>8<A
MND0[Z3L,7:\3%I;>XDL!3AMG$]]A,Y>G5DBF@0<GVR2?[OP<Q%Z=&S;I(+X4
MWB&9)Z$]M9A%@V.RL<($BUEDG*VB6DO>8!PB#%R^Q8BF-.CF.XH7X.0!$LX4
MAXQDN*TJN5Z6%Q[VRHV*4H6-U(@4\H.$M@L^X1LRFWO!$V$C,] >H$,TK!]*
M*GX5Z]$*G6=NY&0\3L;C]M[U4X;CCDL +8?C-FLRNJMDX])CRP-IF@0'3O2Y
MC):G+'5*_<S^.U+\ &=T%>N?T+:XR&P+&M9S?6P?2:)L$DBMKF'*FHV@D4-?
MD[;XHN][I?>*G='*<U5B-JD$L$N[H]%N//FW%P;:+TRH9[/J<(7B@&)8@L\M
M5G'&H8;GS8=9T4F7][1$'?;)^]I5S7^A.^\,M?ZJG;_J=,IC4UEG-VSA!GXR
M'1.)!3=^S &)HU9X&N!B&SHLS;E(1V(Y=*IKWJ'<3EL7,:QXV: @T-!CEZ/9
M"0C%/O()B0C^\JDT4*PX23!TH^_E^5SP#==VYW3"&QT+4_5ZMFM61D?']886
MV #*./%3*P$X!4<4>NG,&54!412R6:TXQM;&!_DW71981U?-C>ED:G8;/89O
M%8;=6C:E5(YG_#::'CA3U8(M<M!&8'YX7FF"(9_&IT3)&"#@(AKR$<8XU3BA
MDW334_IHZI0'@17Y"D!GN=C\(Z,86&($E&NYV5C:[/J<QD=('&-[@[D;N$YQ
MDCKMW[<X_;5 8SZ;/IC-!4QGV-+!/(;6SKX9ATD4\Y%=GIT-^"K6.;;2+H.*
M/GQIA\'7=*!O=1]%\+7=. A9QZP)F[!L\PE6*8+HV>#O2<"@&+D,ORRARYTQ
M5L9_<18EHZQTC<<I\9>9B$["&UL/08@B2E.NLY%T(S)Q?8JMTL1*/@_RFW:G
MX114Y2KA@N[W8*1<LKZZ1EOO*ZW[J]\O7P-(@=-"$BT.Q'8(G41-UV%U=,7!
MG,A^5FBS1II.84 C;=,!>T]"/B.2]L9(0I"5F!R$PQB[N+S>I:*04F,4$\MA
MB4.,_GD9=J&A)!7(%F]4IE:>.-T[[B $5L#1X8LU@FSD,YL+A?NRGA@U+ \K
MU@O#BJT1[!OP@Q(#K^@?$6V/0>(YI3G&G,,Y"0+@E'M\<Q(^E<40()>?T$M'
M1>/92MU$1L0G8Y=3?C;_N]3&).67E:AHW=+)91]>+^&![8=C/F7F=.XS?TJA
M.I0/< 4R3GS6BYD9*90L?KV\_)KC-F5J/MV02B<V^SI=,7V#RX2X14DY'0GJ
M1GD+%:UB_&!JB11&Z0U3V^[P=LL77[DC\YA/9C75"KK,!]I3W8/J[WT 7B/B
MD0U<1>&2#:JT6/19*<3\^#QF5;&2>!J$;#CZ MMF7T[F5'UW"\(T&Y*;"OPK
M%D&\0Q=64^X6WA=1(35"6>50XP&@9$THO61#8W'X8DB8S%^2<5QE@/[)!!LE
M9W #)E,T<1X8L_ED$N @>01-"$C(AJMS,ET$ +4E?/X2SP6^R\;[CE 71BB"
M.*%FHS79H$BN.QT\#H48+ &R!<T(/'W$;"PD>:IK83GK 10#-0]EL]C\IETV
MBVU@6=DL]D7-8HUC:19;K=H.I,E0:/)QWT ?H-OI[(6RY9 />(_3JU(6M6"3
MCE<IKDSTYS(533%<D_V>N]N\77CJ<R\Y$OGT>%0$W/I*7^: I>*0D+O<]+W+
M/< K(&X> N+9&--Q@#W>6%B9RM)DAO[_?\IV>:9V$1:A:S%G, 1]B69M *[4
MA/?[Y<:8"T[.!#RV">(0'LHZO1>C&R5POU7NP:^#5:(Q;7*'5XWYNF6+IH#^
M)"+<ARY7R5=9<DWKBP'80(/^-OK"&&C&8+7P7B?8UW_6ZPYWKBYT4QOTMUOV
MF5>VC3/?;%<SC,YA-[MA*Z8]??/0I-W5AOIFZ8W/Y"$*<34P6% +2U/(RRF%
MKJ]\JI%2N!MCC]T=B 0/#&9])!,W\ECX@\6OSA@@'S"V_R57SF<,BAO<$(EB
M)?"IH;U?T#0H>,\(A_=!;'EUFA8^=Z6\?#-\;)?#:)!ODD3^7";;(JGL#("G
MG52RP?G%3AW1U:[QL@9U&_%0@VDBZ_>S4B1NGORZ)<T+B?ONELUZ1<.]1.\R
M>@?#NLFBQXI<4>PN29YU@N_JL-<3E$!KFY75:=9"FSQ@.9I;68X+9]V IH^0
M.@VU;:R?+K4_07C:D-75SG"]Q7F 8H47">@*YC\27 S,XZDG.6(KX+R)S%2-
MGGDX,MLV1'1DNKR[CRA0'?OT""G34+N=+4U0$=V@TT22KO9Z=6=A220UC*3^
MX'A&L1ZQ(7'>1&:JPV<\A[V2V9D$!7HR*+ *.C2YSG@GPP)[4?/#X7I;3$2?
M\S0]MKYY0']-A@7.@\@,M6^V95A@S]J\+\,">U'S1^70G"::#-7H'\^LX3-%
M4O^4 FSBFA+G360=M=T^8(CP' (#EUCAJ,CP@ P/'"@\,%2[/9DV( 8R!FJ_
M?SP#M(Y8K9\WF1D#M=.1F0,[@O&F)37-%I#P*NT.H,@)$JSY3L]\M!4FU8!^
M8=O2%P%(%#:OADQ/;0^R,-5A[+87)"'O #^BN+>;)Z'OBVO%(T[0069G**E3
M4J>(U*D;8(E+V2D =8KK0S3%7R]I,B\>9YE]M=/NG!AG[;FM^S$, =2[ -I?
M>+/3F17'!!O,1KP_,(/Y8.,>P=JF34B;I^+%:8>^HWQB#39OW>C[X1&1]35+
M6X4EV$YTG $9>_Z&">N]"^A@C46+W6.#,>WQ#62(7=QIXUF%-J)C/]-.RWG/
M;DVYM+&-+L#">UKH!HQM+K"'#O:H"T(<T[&\<MI%+>(]M6-BLU;IV*R<S5H"
MUK!</WN4-?"UGQ0KBDB<]BS/FU+3_FN!,B7.)&O>N_1LL=EIH>-[VN2:[85V
M8;:#".GQ5]@";67J!5'$@,!:M.4'P,Y[P7@,FV)M=8DRJ7R(=<GSGFC+N5+3
MU4M%;_],F^X1P%6QTS V_65,Q%H3\9:O\$E5)[FTY6M(^ZVS=LE9,V:V _C9
M X)R<CA7-;M+T98?$D[VJEWLGX_,#-(K(HA^BQ[ (?LX@$-V>0#VNNP4-T"2
M+IT!'=G$!V((U R#*0)3]"VNR?<WJL+^XK/5J%?3IH$A04I5BQVN_2!C3#_K
M19UUTW<48H78B9S1?8$O!1XWL22B**^R=HODQSR(\(PH-+P$VRLR)G4+W%N2
M2Y&:-[6G;:VI@.)"8X6,J! G*J*-BBS6UQW>G[TO>K3F.0E1/OV9B\.T<7H$
M)&\A$<2/V!0S)W?:@YZ_RTU[)3&ZYC2Q2+.E;X$*];%!,5!"M0QGI,*)-V-R
M[+F\#;^43XH@66K.WE?6<@UM5DV[73ZM9J'2:P[+/T?*,MD\#DJR7,E6$@CM
M0!]:=.@$_!C-B9VPYMB%UK*_)"&";WENB*7,P5(#'@"""7QOB44R4L'Y7,K<
M"BE_T3;K%/SPKP=4&+-Y #CMFC:]GX38V)Q/Y& C,EA_6QML;WA!ME!0J69G
MUI_YN!Y^7C=.2@U80][MOC2E! < $%PIU4V9O*'[QU.#*UC<Q9,&]EW:?!V(
MU'/) Y=5..8$UZ $ZM(A'F"_E/OT4G 1AT.+G3=*YG,ZFB\=Z!$IK:N[R]=L
M#ZGHPA$O#PQ/"T#)9G>X=+Z)AS8+]@R.IR V<$9:A/,O"!T< K^9\ZD5)6@S
M,/DD9M/'LYUHREW)9N^]=*X'E<:KSGU4+,?(ERH/\,] :+@_ !142%,A[P5L
MU O]32;$N7XN3#A2'J>N#7BVPO")#I] <+ 9'$7!GP_1&5MN.H@FE]Z%MQ>6
MYHWX+8>;9%SVP3?Y,",+UZ5:JZR,5-P5N+/E4RRLS&QB AP=T0D5 4X< #6(
MXR8<E[[&'2]JN;'E>5QEML #YZ-9Y@%\+7I=T*)<@]94BKE,>8DJK!Q/E<Y"
MJ1Q3A4J*@H&>OVP2'Q-14QF?C4"*DA'(%M".^8@E2FMT A.(<A]T2A@D*%_\
M[PCPT',>78=04R"?PK$\@8,"CH[6\.$,G9YYX0 ]73&Y\ N;R$1US"N]73+-
M5<XM(*?IJ)R@\![VQ3YS&>@6/@</S^[ +PJI="<A>0B\!Z3[ZCTI"]NA8//9
MKC)=DK]=S_?$R1;H/)PPD9R-K(H*_=*YB$1D%08]N05)SNGZCI_C"W"XCTA5
M\F#$+?)&Z^[++[>OE5N<:8.C>-AO@0OH !VTYT"?4VHN.%G8EMS"/NBP\MQ+
MHH6O35QT3Z_H*"VZL3$AQ=WG.T;MC&9)VB9=? F/%_5%G%2,:D-I@,/7E$>T
M*NC0MA*1TB_0<6T+M)MK7^]I8=2<6R($' :WZ;BY&Y^3=S8-KT7EU[,RBST!
MZ^%#K_/1>>6S%$?096]8&)N73Z-CX*/?"='MC]#@<92.J8&\1R>#?IX.VFH5
MQ[ISV4[E;OS$XS;I:J_Y*QCP.[K6J5@NV\7=ZF5QB!N;BK!J!I\QU#K#TK%?
M&0--[^$#. #K@G#T"T_+EWQX 95:!>H"TQ>M@C'&M1%HN7G7WSPD6R\B^\S,
M2SFW1\[MD7-[!")1EN_?*3/LJMNGLYW;4WT;],'%2:!@(@MX^Y/:&VSHJ\-W
MFBG7=,AAKQU/F4:P01& Q4"=*S;^\0J-B_3)B(TD98:0J9G=@H(M:FSX3!\N
M?:97.$=BW6-2 '[QL_'#G>+XX8JA@>!:>A;S;$(R2?!FPR["B_D/FM[)8:%F
M\Y/!D/I$YT=R'X:Z8 53!A]F4RKYV*!?R"BDV\H\C/4F"1,II6'4C:N]Y1VZ
MSO_^Y'9UR^SIO3X9@P\V[.JC<;]MD:$#_^GT^SW[__1VYZ<&*:&:M;]0G^G&
M!SZ943^O<0JMWM<56O0XA!5O7Q.?1FR^8J VO0&]CF(:LQ=%)GVJ'F"91%'J
M/\$7O"<,#5&BQV&S],=\H!6+LF6F:3:HE_J<F9M<%3RRB\9MOD*4QR[S@#6=
M:0:.#',&\ J)WF_3"6LL1IQ#?!Z">'7G'H")SVWSGF@T91ZS9\LWGRV<VOJ:
M^8'L#<4KTHA4;ZTP);@T"!1^_$[G.#,\,QA&X #,&;3HU]F@5^93SG#;N!X&
M8?F,SI \$#]!UY!/B,7;-'IGIBY=JK/X07I%CMCS:.B<Y@#0,6@IVC!6&(3T
M'XP%."[L(K_QC0J[+@?+"]%U[JS1$ .&I-CU19X-\)T\E3!1I/T"3$)\%_JD
M[)8 'IG"&_")64"U4D1#*#0Z7T4Y^0#O]&PKB)!-3(6CK=H8F_Q-4HA3N3[Q
M^;#K-)9J_4 $>&0"2^.+(N*-P:\$*%/Z8S-4@=1LZLVS>>Z<@KS GUQX+IU?
MRQ%8I(8D8JZM0T 5S##*5*8)I/%L;JL?9?S&D$YF<R]X(B0;C@Q>B9_-3T_/
MB@]'.-"6<Z.%U^2;.8Z=U?.$#V095,O=6XZ]VQQ[;P^4S&;DR6Q%'N)TA>,+
M4U*CC)?FLT261Z\@0,H5IQ;FL3RD#S:6NW!#BX*/S0<'!,\PC C<PV85NL1Y
MEXL_E<V3#FP[":/\.7I9BT( 61A7#;ST"GH2!&R08;IV62C\=Y1.?.<CP_D&
M<0/QTQR5H/>4W;MWVKC2L*TXX'EHRM=TK#6[G4J%1TA&[,Z# <.E=X+ .CAD
MD5Y, K!F 1^[".0]IS^D$ Q)G(3X"SK5..&)5-GN*5=,<-RZC]M%(>%9CYA8
MF$_99MOGK,/9#BR\!RMTV6Q.^ J8CUP_X((9AUIL&#ONA ?BZ"&$CTU]Y=#+
M@38!FL##+ZGOG +#$&^'^.T.TI)##6\4F.RG@HSBT6QZ28J7^SX3@>"J>![^
MRS_/)':D<IG,;E&+ *=$.IN3V(U1'H:N3>^G;QG9<*W"=(R3;[TX$)0>056
M%6 %:JBA?@U=#,BC_0]*%2@Y2&*4^Y3L2-$$PE,!L?S)AK0O[3PU+9!>\#:&
M?2$"=1&"_%^X@&9:@E0 @$E[AA>:IH:9KW,*^>RW>6Y<.D&6ZHV"K?8(S@I!
M&@P+R  A$#H7]/X<E9AWD<V?];/S8+"8>C]@EUDE5-'+/I\R-A,LS)S*C'#A
MB?V.RA4N*!;HI<3-&?$4*(4))?8UMD#QZ,K7%#742"(_INX(%'+B)U&2/4PM
M.WP620UAF=TN.-2:43/ZIN0>EEB(6D<L@Y>)^3FQ:?X$XH/=MZ+:X$>AI/ ?
M)I@0WZE87[0+"A#!S\"-]<076@MXQ LR-,2B_*Z#"F/*=V5NXL8ZO8UGS^=W
M\/FM(>@0@IDZF2RG^84N\1P5L4)OQ1GP$1-620G9]%X=63TJ[3+=3O'NL$!=
M' 54X-!;['1%1";\ES,G2_TAH4TU;H"B(8JXJL$;J$6OJ,IXKC"#RW>RN=/D
M@JD*9^"WH"5U.LZ(F3C,6"@)N#QUK0H*58JVPJ<K^VGHIBF3Q&5?*+A)1:.=
MF5 T6LL\5@I6\L.EZ<)WJS>3:_)8&2=>RK(T%V'Q0=?/+F?PYEWYC5A>S(3H
MUZD%(L$F"8L#1&3"U"0]KS<+,/7D!ZBWB%X^4C\L1#&-]L7B:XJVT1A=#: 7
MDKW]$W'N"8AI_HH%RRM;5!DE%=>_"T/+Q^C-PB)>GL09Y4Q##564,.".A4]E
MS*=?6D?R:323W1(64QRH5U].9<1[!&ID^#X*3KSJ9,8?6]M):)8;8\@(08S1
MT(A1"+M_I5?"_&ZX+;(LH]/EOZ8V+9K2;#H[6L )8-;*< !.?\0RPG)91^^5
M ^X)/_#D(K#\Z=<*%II:)N\T,=8"QQ9-GX"JB#1\P"7)%?5H$Q9,6=Y?YC5S
M(YSNY2'P@!DNF'!;L."S)QF9@#@AS .F>?S<^V"\E"ZY4DYFC^:FVZ*\Y$S[
M1W%'RWM9MG!S:X S/UT@R@BXL :'G.\L"(\"VU E'7C,\(M(V6RFQ@>W :LB
M ,@38.31')!9YLV UG(P@01C8)0+J[T/*OBH:"PS.NCV@&:^T5V.7:!4>@O
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M@LI@GW4,P/7JC]N:OO*S0RRK:P-SLV4KHQ^]S+JHT<+C!1TKQ"%1YHAT*[I
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M+OQ1P$8E?@[]>(JI@.)N"X*<E+_ Z?V6E]8E$/M)!&2%!0)&*Y!8P^(!Y5=
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M#*7*"D0S@9%,<8J$I:EBW,*F)ANOD@9.[ARIKMTKZ\O/R]*&:GZ^;WZ>49*
M88G*D@P9G  _$VV18%F,T@R3)(D-84)X?L[B.P>L:R?+K6IX#GO^Z!Q]LTJ>
MQVZ>+5Z"AXC<U-"S&NCYNB#IC289<1QAP3BH$E(B$?,,$1L[#+#CG (;@[$&
M$70.>QZR45CMU7DRL+&T,%$-&RN#C1F-A:8TLR9-$+,V1M0D'"DG@&RMH@IS
M+@@%"R2-&R(3-6S<R4/S".NAKW+?^'-U!Q>-Z+SM3PGTWAM?NGGN&XD59Q;/
MQ['HK\6QYM<N@;7SJ81MNW#QU@Y5U\C;4VS;>[]I8!SN5%M6^\Z7"K([WSW
M%OK9B0?9^(M0RB:Q=_'$:88H5P[)F%B4626YP=AE&=YXA46#+TAE_#7#\.8<
M\XC<0,\9!I;G)*IAX+Y@8&\:!H@F0A+&$&-Q"LJ65DA(:9"AL4UQK$EB#,
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MLBK&UD8;6G[FU'.$@J5;3#44W!,4S!A&#,N4NB1!,28,T<1R)#+-498Y+&-
M>Q-G&Z^(:'"VK#:B-10\*2A8NF%40\']0,&L_9/I6& A#+**&T2YLX@G8 FE
MVI]QYS3F&=@_A#<HF3^_8$VAX&F%Q1;SZKN\U^][ \>U!L^SH'S]+)NP)^_#
MEM2@M3S0VILS9:C!V%"<(JETBJCVQW(Z0A%F-+- %UFLY<:K- ']Y=$X;6K'
M[J,V96K>7Q7OS]@NU!*>.E!3,LX5V"XL0]*" 9/ 'L96>-97@??%W4^0JWG_
M*?+^TFV7FO=7Q/NSQ@JL(]%62G]N)//!&H)4$L<(\Y216$B <K[QBM$&9G<V
M5M8]6/.8C)4#&QJ2-**.S+_: ;P,V>C2=%K=5G^0A_*HR/XXM]V^K0]RNC^+
MI=R8=[9K<]G>ZIJMJ2W9*7:D!K7E@=J'.6,&! ^C7$@4@RJ*:$H=DG&B4:)X
MBA4C7J79>$5H(TOK,YV>,',OW22IF?L!F'O&6LD23JTW5*23!E$A+%*PRTBS
MS,5.9\R:)#!WRM:I36?-W.MN<]3,??_,/6N.I,3A6&48J13$-]6&( F:&6(I
M\\FFP.T"S!%"&O'=<\?J'KRW/!VV;V6N3X.=8>PWV^Z=^^X-E9'QS ZL?]C2
MF6(K *.VQQM1 M0XX57_=]C*K=GMOL][VO;[/B!<P]?RX.O3G.&1<9M1C&/$
M*6<(3!!X93!'1*?&I"XCV)F-5QATDWA9)32/U%GZM#E^!84P-<>O!\?/6"-@
MC!C*)46**;!&L!5(9&"<9+[G7Y98!OL=.#[#RXJ;UAR_AAR_@K*6FN/7@N-G
M310+D YXSI",??=\Q27B2:9\I@3C6>IH0CS'DP:^N_]AB1S_'((BNUUT7K!!
ME%]EK806/!'[O0Z)/+"Y,H*L&I%NA4A'"ZR.+%4X=HC[8R%IHC3B1&<H)=@2
M#EM&C-UXE?$[FQRU.W1]N?:>3(Z::W^9:V<L!^Q8(A/,4,H-1E2"^2"%RU!&
MI,G2Q*A$9!NOQ)7G:=9<^P2X]I[,AIIK?Y5K9[5_P3DF+N&(.*X1!04)*<=2
M_P,#YFJ:".8[8.,UXMKG$)VH3F:*6EW=ZSRW8,35I\C?@WJ_V_T&"U_ C%_[
M\2%9-=;< FOT?!I3EJDD8P(9D8%>GSJ#%%$"2<<SFMA$8I6%D[?GL&;.NJU]
MBH^159>NT]>LNBQ6G5'FC9$V4RZ4>W)$P1I'H+]KQ(AR-L/"*I]QR.8M\)I3
MGP2G+EV/KSEU29PZJ\ [DA**K4*8RPS,;NL5>(<1Y]0Z:PTSQ"OP>%Z!?Q!6
M?1YN^U)W+S.)&E'7%LVFBA-9(RW/P\DSE]9,MM"GM1/_/K7\8I-&:9 U#MT"
MAT[FN^WZ3E&&*"1$ID!M2$%CL-R!VD MC:TR!)N-5R1+U\B14+O_UMUI7W/I
M';ET5J\7FA*:,J 4BL$$QQ():2ARCDC-+> IC;V[KPZM/6$N78%R7W/I7;AT
M3J=W$A.1I2BS6" :X]27!!'$&'$I%QIGTLO2N';*WR^/[0].;1[]5KCD?Y]2
M[Y^9@_Y^-?<^S!=>S<).V(YFK]L[M[ZDJ7M2N!;JPJ:E0]37.75?$)8J1SC2
M"5:^52Q&$N0*8AJ;.,$X)3@#1:+!LSN#5.TH7%_F7H+"_XO,7?/O[?AWMD>2
M<LHJ$2.79!S1Q!C$J0).9H(9EI'4$A^+NWN?YYI[UY=[EV (U*+YP5E[+J'?
M)D88X.5$^4/M118CE>H8C(DL2;5)J!:^H4"#BW5B[N<0&/@(-G(^U(-A[OL;
M%9G[)*Z]_O>:NC_>@3>G,C^Q=0[A+0_(^>[!IK '3CS@Q%]T;(B5/$&&X011
MFPC$0_LU2XBC69KQ1&Z\2L@Z^2MJK^+ZF0(UKZZ 5_>F>55DH!V(U" 68XPH
M[!@8[D0AQCF@*VA^-G1S9Z3FU:?+JZM(TZ]Y]>Z\^FF:5Q45F&>*(YGXOG^Q
MQ8CK) 76=4Z#^A['5OC68,LZ=J&. ]R,TW9DWH6Q]B-EP9"U_HR%;ZV^YSGX
M,QK('_ H^./NJ?M7MI9]XOBT@FP?OQ5_]_K]ZES-5G<(Z[=?^"=ZW?[KL)7%
M]P[]#N[\&.02UK_5E?G%[L!V^LU>UX\R[X6^:N,,QMJ9L30,_#%G6XC8\M19
MA3C+L'=/ @8*B5$<IP:G-C%**<! W,C(RD_H?:Q>S.<*(RM(1ZIAY)' R*S9
MPPV'O7<H(31%-$D= I57(FW2A%G%$DML:,28W3U#L8:1IP4C*\B7JF'DD<#(
MC$7FDE3;+ 4$4=XBLUHBT#\8DIEB5AIK=:BV2!M4K/QXB3KL<D-6?W^=>399
M@,'K4,Q]FV0 ;F50^+7MVOIXG.4"V,6<.95QA2U3&@F+C6](G2%E2882EQ+B
M"!/<B8U722-;JW[4M0/X<5A&-3>OF)MGK!JI#5>$811+PQ U'+@YIIFO ,U(
M8K%(B0A9F(+7W/QTN7E%!DK-S2OFYAGC0F*3Q8P1E#D<^[/K'!(Z%8AEE#.&
MK: Z\=R\7IT/GU; )UO(BTT[B&P9]%G9\8 +<6GMEN)?JYO_NN#QXHD_I*T$
M]#?V&=4HO$04OIRSD%*NC50F0=*")D43@\%62BER2NB8::KA)Z!PUA!T/I^M
M8HZ'4!C6]/32=7)4K[VO^L[0LW3#KH:>%4+/C#G'I$VYQ19):BBB(E:(8ZU\
MS(HP9IE-K(]UQPV>S=MS-?34T/.@T+-T*[2&GA5"SXSM&7-"=!;[GB )0S23
M$BDA#!+,^;.'07=5[,IS?VKHN<HJK@92#9D&8+FE ^Q&@[T2M&[W@ 0>8'I#
MU;9+?4(]RFM&^=P\*-&Y!<8XE7D9?.U'.!QK@Z\YQ689XKN^QU.+]R^FM4(D
MS/]\+?LM?1<7Z5/ST"V:XN-51]_;_,"#RG*=<616*ZV2_ZO'!:H:*:!QK8#>
M1 $E<VXWH[ P7"DDN>\?*<%*$-9E*!;&<6D4[)O<>)5N+HA]/"+ULXZBKC]@
MW-&%5@/&B@!CQED6:QU;+E-D8F<1)98A21(-T,%B&6<8/O.GQ&V*&C!JP%@I
M8-S1\54#QHH 8\;%E6;^ !H&&H:A#@ CU4A1YQ!/&+9Q*E*29ANOV.:"8VZ?
M)V \![_$5;;B=JL]'%@3W:45TE,S%Q=-\<F!^:K-Q9*P:CB_'9PG\YGLF8]9
MI S%L?--AW0*2&XH$IPIQ0WE*17>8,P>M?Y7MT]<?\A8M<%80\:O0L9L$7":
M*EA^@BB5H %B:Y"(XQ1)GE"EK&%2:6\R+CCMM(:,&C(>D<E80\:O0L9L7@2S
M#"<B1D(RYINI2@2:(4>2&849YSA-XV TUI#Q? *,6S 8>6*+&'8_Z@T'_8'L
MFE%3U[L&M)>8CO#D[_$\G10+0]G/5<P6;+CD&@PV*V(_A[%84S)_<]A1-M]W
M0=SV]\<04'IKZVS%I4EE-F?[QXRES@F,4D(DV/ZQ0M(YAA(=9T(0A3/,?(OS
ME+#-^4:FSU,PU[K\\D'FKM46-<BL$\C,5F. =49\KQ^0%RFB6#LD3"R0)E))
MG%$#&QU )B&;M?9?@\RJ0.:N=14UR*P3R,PV%!-Q9C3AB!BI$4V81C+VZHQ0
M*N$JQ4R9"F2>0LW70[H8RM3\XF8_K_MX9"9AZ?*[2P>SVRS0DX3:^S(:R[V:
M0]P:;)<'MKOSY]38Q&E.*$:$ZQA1D*9@-J8)$@"TU+"42!).QDK39/,I) '=
M$O >2U;ALX>I^S([:YBZ'YB:S6P6 LQ+@*E84- )8^.0LBY%DJ3<\41G7NQX
MF,KH9ES#5 U3:PI3]V6XUC!U/S UVZ[..LVH)<@9"]I4)BCB68H19R;1C#A"
M0[<2@*EX<[X9=@U35YJV?PRD:EOX;5K?7OT[_"A&JO(_1NLV^K :=T?F)ZUN
MT24@":"UHJ4-=WS1&L#X]?6+3?QB'U@;%4'Q02]ZT^N&19,^M_IMJRN[NB7;
MT<$ WNC8[J _-[UKYWZCA2E'0\EFQF .Y[U^RU/@B]RVY:#US;[\WC*#TPKA
M)BXL=SH>7R(5C!ZPYLI+9G?[_GN'AC6/PK]J10(YC2<5J!A&TI;G??NB>O'2
MM/KG;7GQHM4-]PL7O2R)JEP)OWPSY!LF7'Q<+HK@FR)+_;J4+IKRP>62;88E
MF^&YXK.$;-+DZH_C37SE9P]Q6[S)Z<UNN]!AE8XTB%OD1ORJBVJM2#1PC6^>
M-\FP5\'?Y$\_BR"K&98TQ6EF79)2P;!R62RM,/!'DF6I_H()W:BN.LW'JW=B
MD<JM_ IV_\#F+V3[N[SH;_PQ#:1 \#.8,<ON5^/.'/I,++>V_I".^U?= B3\
MM?]G\V"_&?V/[)R_C*J_MIK;T<&GUP>[V[M;'W=W#JX$T769QIM]&/??N]M;
MASLP\D/XM;?3/#R(]M]&;_;WWG_<^7.G>;#[STZTVX2_=Z*UG]!OVQZ \W[4
MZD9[K7;;G_[R^^2A%/CW6\WAGL$^WA0)^Q6P9^DF$6SIJ(SQ9AK_&MA?_T@N
MEB]"8+"@,#^FP=)?EW?S0NQN\JZ@^+4RC[VS[08)GT]Y_OB9SS^>FO_32H9>
MK,A-=?;Z19OZ\35'7[P6MVZ]]/B:HZ_?05*/LDWHA\KGAX\[GRZ/#T_;S;-V
M9Q_NL?_N[=>CP[=G>Y>O._N'?W6.W^U>['_^YW1OPN?7/&R?'<%SFIV='\UW
M\-S/1^3H[/2K]]\=O_OTX_CP]:GW'^Z]F?/YX?W/S;-C__W#G1CFB(_/CEO[
M[SY<[A^>?CT^?-O>>[>#FX<?OO_GLHJ>[@SVMS]XG]^7F$NGTR1%UIFT/) <
MQQ9IR8250J6"RRM[H]_)Z_;P38*7'QEXA$V"U^_@J9K[5\?]%]/<GYE$T51*
MI#.=(8J-[YUB#<+.:<Z<H4 -5[8GK[F_YOZZ1?@CXO[FC.Q/>)RR&#ODDBQ!
MU&F0_3*UB/%$8Z%38K6\LD/XFG+_%5VZV:VZ=#^&MK]/Z1[/P:C>'YS:'&;7
M.<_MJ>WV6]_LZ+SB-D#=[XVH"W9WS_GCC.L:X[K&>$DY$=?_?-O+X9)NI(=Y
M;KOZ(AKD\,1V.++^R18C+UZNW^[7X]&'"<.K6?4GP,2;290HM*%RH]Z4^W3H
MMZD8YU;7'(XW[9UL=;WF]-J"YF0_6MV6_7[+P2)7WY4_:JUJ>5K5ASF/"L.$
M:\DM$HQ*1(U6B.M$(4J95ZDH$(T-9WZ*=$ZIFFLN45?X/49X6()+I(:'IP(/
MLRX7CE/!0##(V)_-Q*E&TEF!G'5<Q(QCG 9XB+/Y>I4:'IX$/"S!9_*@\% C
MP*T08-;M$F=..&,SY#L.($HH0]RD&ADM)>>22.JRC5<DF>]R^B#\OQ2/RF.P
M"9_2/6K[MOAY8,&R;0U:MO^B/HBL]N+="\U=]?-3-[<PA4MKHM->._06/ %Y
M6[K_(IFW^OX] P0+O\YA@+T[U?X_<2WJ_GTPXPW\L]B_2EW:[XYQ9JO8QNVP
MB^_#)C;M8-_5FM-M-2<]YUJ1BE$MT@SIF&C0G+!!,E7:]WUF+M9>J?;]F^:#
M53=7G.K3>=:8Y>_?KU*S_'VS_(R[1&<)M99KA+&EB-HD0P*#[222)!;6$)YP
MO/&JYOA'Q/$/F5U2\_F:\/FL4\3$L4Z-QLBZS)]6KQ3B4J:("Q<G*5'4Z63C
MU;)24.NSM%9O[LQZ#T.U>%56\,QBRP^93'\5Y'ETF_/PFK-A?^#+]M_FO<[6
M_IO=M[W\ (!MWXUA<(QYDW$BU_IA#;JT>:_&PEMAX<F<F6-CKF6:6)3Y7AP4
M-AL)@AE*8I4RQU4L$^MYDQ-,7MX5$>M(T?IBP=)3ZVLL6'LLF+%_K,F,M!E!
M)*6Q=WE@I S3R%F569ZY!!M68\$SP()[,X5J+%@7+)BSD;AV2ML4">&/.^84
M7IG,(BM$:E/+DI3*=<2".C!T_4]?;ZU/9??$+J'5\Y,I0EKO6)!'R:UOLM7V
M?59*,)SP%(WPLG80_1+X?9TSBC2GQE@I$<F<1E2F&1*46A0S;C3/)"6:+"?V
M4U<H/BUPN/^H40T.JP:'&2O)"<&2F!+DM $K*2$2"9UAI&-J"3.4Q;Y[7(T-
MSP(;UM6HJA%AA8@P:RMI8ZW%C"!I4H%H:C3BRC*4QDF<& 82P,3+BR?59<WU
M/>J$R*M^[G3.V[T+:R-EN]:U!M%Y&Y[X:PFYCR'Y>EWN44>HK__Y/F_U %)M
M_JVE;:1S:X V?].]_F!<C"\[/9CL95T0?4]1Z[/NV;5*U'O_1J\KNR9\ZSUL
M5FX'K3STFG]=X,M[#R^@287]/2BV]PU\\4W88?B@Y[8FMG5Q6D^O5L-NWV+F
M8NZ +A$GEJ2.(#"[%:)2<J18PA&-!0'LHMH) GI8.G_J35WL^"2086DQ[!H9
M'CDRS)Z)15F,*4Z04IDO@XPY$@E12#*MF"8L,5E AKH,^A$APX-60:\;0M1M
M%)8)'S-G524I3V/0+1$1BB&*B48\R1Q*N/2BQC'&/7PTB+ASY\HZ%'YO)MF[
M<4'D\DRP9U$JL?P0^,_@].HD(5<F"=T8< $I 3:KFHLYE*TA=060>CEGJQGI
MI:T52&8$(YI:BD3F4D1,JE.M32H=]Y#*V;+:@3[2B-G31I+EQ\MK)'GJ2#)C
MVTDE!+6@EQ%C*-AVUB$>IQ9T-6U=JAA.B:_:;"1X66W%:R191^?/TN+K-8(\
M=029,>_2V,46Z 9E5">(QEF*1,(5XFF66>9$9KCSN@A.V'K4?M?!MI\$@9VS
M.MAS]D>1[!SE<F#K2M ULNA*C-PJ,;+8LOZ^VREW["-L6)VA]&L0%\^96ZD3
M)J/2(B:X152D%"DF#<)<"JUD:@03 ''XSDE*M1=\?9G\_HVMFLE7RN0SEE"J
MLS1.,H,2>($HUBE2:>80LX10JA3!7 &3Q_.]P&LF7V\F7TL[J&;NE3+W; Q*
M@IS.;(8XQO[X-"<19U(B83F5.&695'KC%2%K$L*N@T]U'>8CLUAN4E<Q@WE7
M>W86E5G43IREX2.>LW (A=V66"&I.4$T81@IB@U*=6(XH4[K- T!I7C>B;.F
MA1AU?=;CMHYJ0'E4@+(W!R@T%?[ !.RSB6.C$,\H158PQQ-N0(66/JY$6 TH
MSP=0'L026SF0U%AQ2ZSX-)M?#+M+<((8=KXFG"9(2,N0-89+1;66J=IXE=[E
M$+:Z^K.^1UW]^1.K>AMN_4T. !C[T?_(SOG+Z-2:DU\]D.4QU%VNRSWJD/2-
M#V19S4$LC]>YO:X-B]_(_NG;=N_[GQY"?G):G1O8O-:D;JU)T?F\X 0GJ<$.
M.4$UHMPQI#(E4$9E&C-IM64^F^_N6<%U#&N-+:>'\<74#'\?##_C9L$QSXP/
M51.?PTNUX8A3J1'LNW!"&Y6E;.,5%FL2UZIY??U*,U?,X;67=9GL/^,YP8XD
MC(D$I0F3B%(*[*](@A(BN,,I4XD1X8CJ>+YK0UU:N:[6SO+/8WD>-0P/;]_4
MBLYRD(XML&QLBD4LD>")/UV.Q4@I 2H/YT(Q$G.6\8U7"9VO4JK/EWL2S'VO
M)ZS4S+U:YIZQ8IB3G$MGD4E]"1&W#@F7 H>GP/8J8;%,],:KC-_%BJF9>XV9
M^^'-F)JYE\;<,S8*CV,3)\#<''@9;!3%D;(\!D-%4V54JCD#R<V2]>#M.A*S
MTLS;<K6>6E[+HS)2 K3-X5W7U&AW6[3;_3[?11/44\9CB[1E E%FP&))A4-,
MZ)C*&!L;+[6*:&VRWI;HLGUJZ/!(8S<U3BP3)V;S8T66,9&$G#>'J'4<\91X
M_4APJWF2TL1MO!+\+OZ,&B(>#40\*ENI!H9E L-LI:*6B24B139+-< !%DC:
MA**,)!QT1MAS:@$8:/98%(BEI,0^AB2^IW2/YV &!]R#V4T 7]0*R%?F%]86
M[OI;N'45QJ\)GOGS'PC+&"96(\></__!)8AGL4"P=5)D.M9:<1 \R^IQ4VNE
M3XKI[S4\5]=PK@81]F:;9CBF*,9(Q!E!U%F.P-*(46(H_.(FSAC=>$4:F"\K
MG[@&A2<%"O=JJM::P"_S_8P):D2L2:PYHEP;X/O4(F52A;3+TM1ERJD4-(&4
MSH?CUY3K:Q/T$=[C.9B@;Q89GRMCGX4"9NW6Y%^KF_^3$:Q+-[$7R-1*GL)?
M[:%?P_>^M7:ONS48Y"TU'/CSL0][S5[7CRSOM6%")[LPQMSV![5BOD0!/=^/
MUIHTQ88(9(SP1V9CAB11,<ILDFB<44=ELO$*\T:<D,<BHVO-_%&;ZS6 K#6
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M+T*YU'+-$4NL053)&'$J.$JT,U99:H @?!^(^?JJBAH#GMZ&(.\UBZ&FPT=
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MG%1"+@:+@A".QN22))E9;)->4J7Q?0'V-H;0GR0HW+,S<46MUMW#0T6 FR'
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MM8N8TT=/J9+!!1IY4!+T;.#"!B]E8D3$JZ&J$G,^(LQ:"$H0XZ7+L5EGG44
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M>X^]KG7=7CFZE#W)T^/O9*A]M&F9']KO.OU^OD;;S1)59%LELBWWJR#4<JG
M?=*!!#"'I$!:*84L9=HEFF2@V7W:!(1;0K8?:P;V"8CZ [DXEXIZE>8;2O."
MFZ.#D3J%B%*4'''E!++>$"2,@R445!II0)JK)#])27X@5Z1*\BHD><'CD)QK
M*9Q'7N8"*4\ULLH(^,DKP4!%2Y8VMCA;[B/U(+)\RT35=:FIVNQM[,7QY)1Q
M[D.:#RK;N<Q]YX>]P3AVB+[^\EPZ19<TQWZL>:W+RQV^-Z^UBOEIB2:X?&):
M[+W!UH<7CP?].+;#LXNAJ>K2W:WJ6&Y>$KQT MN4C<"08]T1C$"64/31P=82
M/&)0'41M2K&L/:;2UX[ZAWL5_T?4TN&.=<)CQK[[=F=OC'T5WFX(;XLDR](;
M+"U#B46;ZXX),L(+!-K-"6I5,H1O;,GE9'^%M@IMCQK:[MN_KV;=@^+>0D1
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MJHS&F&.A3"#2)R.HDU;HE,JR+_=%K<N^LF4_? >F !58>>03IHC+?.8P>=@
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MF5SORV6LJ:&""47(&&<KR>UH!@!EEC/1QMOE.89Q"6T)$V1F@RE:HZ?*CJD
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MW5./HRYI#1+P9MNU]6"AS'VH"_T\EOCI9YJP=5_R)+. GG,9Y7+\MZS87OY
M)7=#/C+5A?,87U2C[0+MNC ::2=#.Q7Q,OY>N_?=#POX[*D72O=)?>1YJJ]R
MZ?OCCU?%TIF\1X+MGGV^&02], NL'5V<I.L+1HP\*.=RP2W=Y$3'12K9YJ=O
M4P+U):T]VS!?U&JS1<R8BOE=IU5181U'LUJPJOF60GA9Y\*8G'[RY;$M'S]K
MGI&HGF(V>GG4;MA)X6>F0O1IZKEWPUQ87CNEESBE%\VC)FL%Y)P(V@!,5')*
M/0.*XL3.QC'UU!I&?2)X6LSFC!OI"A-1>J )(7RJWV72PC+7^)+:%4J?M<3X
M/$_.3.Y@J+IB<I!?&L,Q=OUT6]!)/WK!R4\I6T+&V<_*S\G%\BA![=&P:@M/
M731)U40?9U20Q_1#2"BA6022![#96'OS\=G[QDX_ZA0YP?N<&O=Z-V[+&&/E
MC?O%5OJXZEI/V[B7>U]SJ9+"#*>#$K!H0N43#Z0>N()8:-+"MJ3'<[9.>;]=
MGI72^ML//B='OF[VW+EH7K10$-8X+ #E$@**$K48#/&O,"B+H _2^;5OWMR)
M.F:"5AE/8][AQV_CS _W1PQ7[)0[&1^O (1L%]%:]O%,<M2C%Y*$)OD?$]>L
MHL,J7*QN#-FG ]%A%3,6CY "@Y*/8C(5./VMZ,V<CI*"SG>J/)["M]]L;+<[
M<[[O^&'+S,>P- Z).24I09>^4;3U);.3'9L,+=UHA\;0QQ^F&&7]CP32G6.6
M09+O5*&M6L*JAQQ%66R<YOFC[$H-<GO?>?F+,CYZS&[Q+T._&]Y63M\+5!N[
MVUNP!:,#$U)'FC:" XJ=!%)Y"S2UFJ<E#9JMO=J(6YEQ;JO-7!.%D:*+DT$Q
M\EN&\S,3YTNZ8BL>BF2#4SZFF!Z<RO@,HB5NGZ2<X013/?[>GXPF6<'DWA7I
MT#(Z2GW1XW[8**-=?3S=^)I]S>'PM'M2^)Y%=F$^US(L6\13Y/AV\MU!QGDI
MJ7*FGC03161(UXHK<9@ZRTWZUD:1Y-(YEU'VL2<]]#W]:IZ)L8+H'_L?&WE5
MDMK,RJ7X)Y> 6&R[[#R=9I?8:/CN2:=_[L<N\#22OFV/'V$VHS>3N#IOC),R
M:;:R(%FHNG^3MYPX!>+_)>>[R-.4*=T<(X]7>JUS+@L8 E5'>#84DPQM&3\4
M!ZQL%,\46RD[DW8D[=E!Y4 6R;Z9Y8X+.)MQ'"=VBC,T)MBZ 1%8RKJG-,4T
M(UEYH718<G]X'J1O%/GXQ.[T>^.P?Y9R9AO)QO7ZDR^7<C3^@O&C,;!/6IE<
MFB\2$FG\MGO:K4*PR=4?C7KW71[8^CM[ K5OO+O]X4?+D\"(1A@8FKB>E$1
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MAKK^Y'UEJ.\X'_ H5*MY2* _2#PUHT1W8T93<_KW MS"$PC+E4^U!%PK3:<
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M\N*0K\9#>-TXJ).(,K>IW3FMS?DZ*^F*%+BP_>'%]6284^-DF:WCQ3=E^-X
M+(MR^N'=* J+SDAK Z&>*V\,:*+(>;!48Z>#+GO+RZ>>9OLR:$D3M<P@L"\B
MXLD$I&4T\(,S(E4@1+$J0FOT#U<?O3-85BB(^X,B<+4E 5>"DZ 3$9Q3:0T)
M#$L!\$\J6LW*OO0R2H*FH1I83#(%B@++X@"$.[+.:I0;[DEI%,65)&#KF"RJ
M[>_#2X)GSQM<_*[URZ;CW&5GZQ$LH+*S]>"2<+8/@R:62FPETN"Y(VZ= TGH
M'?(>Q*!@,-_<@,L.-A&>E82WW]DJ5+MEQO;#VS0%VX^ [::5PX05)F&,A,$J
M-PTFR CX$9R4U& MM=& ;;)NJ%@.;#]JP.O)=JWO'_5:S;UL^B-[V2^UA>IB
MFT.\I+WL1S!5RT[20E77;/>'8(.+3"ODB<$([).(C,,1!3!)/&4LPH('U94)
M5RN]EUW:MRZA1?WC$NCA#>HB@18L@9K&L\\E(%T0"!2(1KE>-M(I&$1E3,%*
MHX.AE?%<)-!+BT[>J1)!I[>(6@2W#6;<XAIW"D0OBTA>>#&",J /58U@U3@H
M!Y>\\:>@DRRS"[H@PLA2>ID_O!&<0@K$<96X,5Q&;Y5.+NF$9534Z%MW&+QK
M<;UB]2W.ZOLTXW=:;*V46*&H"46<&X*<XQ9A+H+'-E ER-JF7-=X40R1%?7N
MEMJ!^V%P2RJ=B-Q+&Q,'D&M'P ,0S L;M''IM@Y< ?=3@KOITH%<5I%3CPSF
MF03&.'),.22QC\Q*H:+!&=Q&SVZ'/!VX7T@FWWC@VW98E=M'51W^X3!7]H\6
M/J^V1D+\'+O]J@7!"NZ!L ?,YWOF6]EWD-L<K"^M+$U1&"YRX6?O.+>>6,IX
M9*P89<LOMU^?_?M@9[3[+LONHRRW\<? A1$V$N1=)JEH39$CAJ+D.3-!$^$S
M7<^LRSFAN%(3ZOF@.U!*=5+@77G."3=16*D-&.PB195PL<I6 ]UO&NC.!=^T
ME B;8!$/VB%K34+),)H(\4H3F]&MV0_[7*M*57F2N%A_9+OSJK+/BVH_<296
MH7:\#&J' ']-:B*MB)I';)PV01D7@S#2<EN";JN@ ;[,V'?4Q$A$ L<<;#O$
MN<1("PT_#%;$J&S"Y[U6N<[-;-?:LM>Z#/' %\SV<%&J8(P.5"HNF;+&4Z*3
MA1_!1Q6*6;H:0JEAELK@.-,D(<IL0EQZA73  DDC<.[9 _+*54))T]G:I44H
M/6<"R)T,YAL9W$]0TFO2 FD.36%URQHLMNC70D;HV:BVQ=G;,^S%HLX>4IV=
MS]C8*08IA=*(JMSJV@N)G H.X2@X3*6.BK"U3:[7V9QDH!529XN'\PK%?Q]:
MS*^T,%N<G5Z$V6,+LX9M[I63U"J.B&$$<<4HTB9J% 3($$TT8U&#,)/KS*RT
M;;X\PFQ.H^O%<P7$AO[N'CS]UAX\N6U1W84^MKE5F]2#=FSY-DB.V#JSP];I
M $3! .Y29X'&T!KUJP:ILQ%WZ_]OW!G &57H/9]3?5*/06Z=NN4Z_9,8UEL[
M/;_1.FMW?+N^AX61L%VX1S\EN%3+G5^KF=&*7TYC;QCS-4X'\7.G/Q["R?%+
M9SB"!3/O47*A97B 01R.NZ/\/3\>#&+/G^?ZR[UA=W+=E*(?#3>N<QY6;\'0
MIUXP)[F1<F=TWNH,09F=P*+)%)EJV.?E$#<X)HW.TS=WG/Y^L^'KS8F=)T9A
M!<<9X8IHEPOG1)=88 IKXQ=M#-QFGHFX_SRS)YIG>.9ZG@'=X]J N5$VP',U
M\=CJG)S:SB!3HK)H&1Q52+:GIX/^%[C"*';/GTC952_6NER.C47W),,\?^5_
M?R7_SQU,3!PIU1Y3(TCD03"KA$R:1A&P I<KSNV]/F5KZAE;\W*"]]." L)F
M18W.^S=A_QN>QY.]@Z,O>\=@7+[Y2+6F(7&"B- 6<<X8F(_@%3L?) NY#KJR
M:YMX8[:70VV_N;H1,Z#39\,K<Q8KK3C5^[QN?=Z$[W>9C36NUULNPJ1_@GES
MK9_^ZOV%E.**<TE_7J\O]#F"ACZJUC'<, S&1WGNJX<8#:(=5=?*E@'(OXYO
M;<>\+D T#EL_;6W_7-WU7YV0,U]ZU:?OQJ>GXT$6F;;UT[_>_?Q]F^._OW?Z
MH^C;$Z-C_@C@C=86V)Z3Q^STZO59#]V1'>3%FVT%$,H^VRC5);:VZ\=[ETD&
M<*12;C @'H#1LI]MIUMU@J^MG&ZL[9%7H!MM[_S"ALIK?IAOD_\-[][IP31,
MCER--=QP:ISS^%W>&YZ[U[)7CWXEG^%+=Y$(CK,@K+'*"\6=Q58;!KZ+YPY<
M%VWE+23"$)05_#;KAGJ8Z6'<CO7?.[VF@'A5F6:WS!-^R6(!SONR=_21,LJU
MR+4 O9*(:T.0CB'F\CE&@YZP7M L%FZB(5V(A:S"PP"LCUXVN'=A 55(KRWH
M4=N.8#E9WXXYMG,"MID'&_W"(L_+SPYBJ]<_:_DN?*>3.KG2W;#5MI\S7*[S
M;C9:!VV [XW&_K0I<*=U&SDS+AI*8!1XC-)QJHS5A+$488S<G379VXG$V^J%
M[2L,[O3^4TO$LDB_OTAWSO>V/H;(4F)2(2&$1R!2$K(2?I-$:BQ4$#!1:YMD
MXZ:ZE1>+%.38SG_>_C][<OK;=D/:7W,G9XVWU@U>W>;_NL$OFW<]>,U':5A3
M@@FG0'H2ASG'R5G&B;44'!+XC["Y:_#ZJGN783;NQOUT820=P.5_[_;]IQ>W
ME%[#,CK\2#3W05..J*%@^X!J0L8FCP3UA#O-.2> L@B .X5Q' W&\?&W4ROW
M]V+"LNR#Q?J7A?4W.*\7,5G/U@6KI.6U [0Z #_A2R +^[XROT 2#N/1I<X?
M#^%FP^%Z)3;AO]2',\^N,O.K*-=E4*X.K<%;=^WI,/YZ\<MOH3,\[=KS7SN]
MZMFK+_T&;ML1F'F32-T<I[.*NM6'?SOKA%'[5R,V&"7909ELCD]N7!\E&U64
MNQ$IK(\QMJ%JUV;N8;Q![GE,2'FO;W[K80DXX9(M_&'I!A7WN^J3/"S'ZB$>
M5JG[7?8)'A8FC)M;7?8[A)$[\D(>9I=*WVJ3ZJ?M+#0&P^PE[=;Z=SA37_$;
MKWB+ZA3?& T/<B\.'F<\FJ&8^>/Q"MX_*_S6OZ+MCMHO>"3^T[9@]?HXKA[H
M!0_$;@P'T;_DI5#1QYZB],J3IG]=67FC"TNNQ2HCCI2<DB=M[K,B.24_G%7H
M.'6$8*FTMUQ+IK&T)%"7I O$>5_10DCV,K]-"WE1U(]/AU]?G^W]N7,&]SG;
MW?X;'Q[\WMG_<^=\_V +[QZ_YO"<Y_ =NO^N2?UX>[P+YQP>;\$[;9WM';QM
M[_ZYPP^/=_(SG.\>M$_VONZ RWHHP&6=K5>/#7>1$?!7L03WU6ID<9+()Y,T
M3)\2.%:%01G[X5S@DJZQA#2P'\:[D#1'<A/UC'%IA.:<&25Q<M%:+F/!^U/B
MO5FSA7 ON(D$Y=A?;MSEZNA\U9HB2D]<<G493FP*W@O>9_&NDJ(V[V%8*;CR
MT3EL5- D1JXC#K+@_4GQWM#O4@J0PH(A&@+H=Z(4TI1%E*34SB1,4]Z#(V(=
M\YMVYPO>7S3>G0C68I:U@^',1JL3\<HD$ *>6\X*WI\2[_M-_:ZI3RGE)IR:
M(<Y(0);RW+X>!V; "[-!K&VRS.2>3?U>4KP_4J;C4L1MUJ]QG*XH0O>K"++X
M5)B7* &IE]B C^,YM9Q*9KP4AAL3X8\0V%;[YED"<G2[C)>+R=Z:T 2VQP,8
MO?_ B_3#=?&8.E]B0%_CH%\DXYTDX\Y,I -+QUS./[=)*L2EL\AA&Q#'SKB8
M>)0QY822*J]X0861EL84*H)@$8+ "Q&2<\%[$W,G)*MMX#%0,*L9P]@50;",
M@J 9 K$*!$%* 46<-.+>&&2BI8AJPC13/ 6MBR H@N ;@L!JC V.D1A%N,'>
MR,!9T-09$L"I9D40+*4@:%@$"J;&$.61<)*#':!S;,1XQ(RT1L#D>8N+("B"
MX%N%[7TBRG%-6<CASVAE8I[%R*T2WFM=!,$R"H)FT,0Y)@(G'GF1>Y/);!$0
MXE#T&(LHC?#$K)P@>$ELEVM1D]"ILKE&X\'#U%&]2]QX!:7?G3J=/U1DY/V@
M,QK%WGY*;^N)/>B_LSGMX/<)V?QO>*@B]^XD]W9G0B).@L'*)$;>*(5XY X9
MK"@"!U?R9)0A(JYMSNX#W[Z7>6G*L[RVRX-%,VX)WF+,+ 34S? &6*,L8AP0
M9\(AF%B"G,T5@!/#,3$+(GIQ<<Z"[^7%]X,%*0J^'Q7?#:5-O?4$K"P4&/@I
M'"PM9+1BR(C$HQ.9B<,*OE<5WW>QOA\L^%"L[X< \F74X> (P_<^"H\#!5L+
M)@?4,\])Y];;@$(NET*\#F"2+8WU_1(X&*_FE%[[I3]JQ\%3DR^>N2!;0!CA
MAJ(N%Q)M/\]BL\)+D6!WDF!O9KO[:H8MYQ113QE(L "FB#<"12<C9D%%%L#5
M$&2VP,OM95AI(+?$P%U "*$ ]Q& .Y,%X@*Q7BD$]H% G&F*+ D2">-D"L(F
MK^+:)J<_8GP4X"XQ<!<0&RC ?0S@-C0N43!1@EO0LSE=DR:"-*<**<^"T5Y8
MQ_S:)IE3I;L ]UD =P$^__V 6Y(V%H?J)O\ 6UBT48()'9+/K;$LLI@S1)2V
M@BH=O<E)F>N$S>9H/0FN7Q*W8+J2QJ0<6JFD42II/$HE#:5Y= 0<:,Q5,#81
M@:5@3I%H78JW;;!2,N\6+\3_G@F&2!G HV($/*E<"-)9B6ST$0F6BY]8[$!O
M5VVW"5Z5Q+N2:/NH^[5<"PKJWH!OQK%0)A"P]HR@3EJA4RIP?TJXSQ;2",02
MK9 % PT,-Z<!^%HC8U742H-?K515.$?H@O>"]SEXUX)1+34&ZY[PB$&_4R4=
MK"3NLRZY=?^T@O<'P7M#O7-G)(4_"$>L$&?> -Z31IH*FT2NA%(5TN#K6I1"
M607O#]@OL>#](?#>C,E(+1*&R4#$<(-XTAZ9!'B/ G.*O3." -Z96*=\9?#^
M$D@<I9#&\DI RR@/L-0Q2X(SQL'ZT0RL926DT("H[S5!*=ERCR\9#V>S1F#"
MD@H27!V?0]:"@V0D$7X$0GED%FNZ<MER11 \IB!@RA P@)Q-B7 :.>A:ZZUP
M.A=A23H50;",@J 9 HDP[T&;A+ 1X!)9E3O^18QB"E9*$H*WM@B"(@B^54PT
M*(=EI"(*QI/2QDM&O6'2>T:$# \H"(K#](/2H&$6@#\40K0!Y3P4Q DG2-,H
M4>"*!H\#MX[4E85_/$!2A,%S% ;WZD]7A,$R"(-F]$1IKT"N)Q2E$N C\-P$
MU.5:I(%SYCUF3J^:,'A)I)=24.-Y!4A*RN[C24,_$S$A1JL8-<DI^> H&?"1
M;(@<@?$K"?>66TE*RNX+P/>#Q3T*OA\3W\U 2' I2G!SD(\.K!VG'+(6:Z2)
M=T893XWP!=\O -\/%LXH^'Y4?#<+A5J800'N"Z<:\)U@7$TR!DF)I9).66D6
M5Q^PX'MY\?U@$8J"[\?$=S-:P24S#JPQ)#7AB$OBD4W"(F^D%30F:WE81GR_
M!#Y'*<KQ5"G"/QZ+*"G"#R[,CF:"#5X%F!-LD<8F(AXE14X'AD!I28.)#4S:
MM4U)9^.N)47X60!W 4&& MQ' .Y,%"%("68D0QPD+.*6$^0"\V"4\!A#=(HZ
MO+;)3 'N,P7N J('!;B/ =QF&2PG#16<(A6=0]R#YV"5R8PH[7CB#L=<1IN7
M8CK/%+<+B J4FAQ/#>H9!@-G."3B$<:Y1!:A&@QJFLMH:R>M5$)@F6MR8$66
M ]<OB9XP79.#5#4YV!/6Y*B'Y%<&$Q?Z8]>-E[23E2W:H19:M&,1 [0LZF+^
MR-Q!6T1%N6(I*F8H%S@XK*7PWG)&& FN[J=]A]!Q40.+4P.?9J(ID>)DI$@H
M^L1R%VVP[0SWB'*GHC&6@L;/53V(YC-JX (M3R$I?R@#<0%X7:$MJP>6XBLM
MK&3"2GH;<,2&2R*M)IQ*RN!#)X@A15@]I;!J1I!X8$PGQI!0.)/-J$>6$8N$
MQ4)8+SW/G6T)+M*J2*OG**UPBD;$A#FUE%.CC Z@HJ7Q22L>K"G2ZDFE5;-@
MFO.6*$-02LPCGKA"-C"#K"7<:3A*<]5+*M:U9$5:%6GUW*25<&!&:;"I1-0<
M["NG35#&Q2",M-RJ(JV>4EK-9C1)H9)RR!-'<_TGBEPP$DD*/CO5@  "MA47
MZY3-!@2+M+IG//.7D86;;EX,Z-[X! ;!P[]#Y_/F_U8_ZO=R@U\N1_DN!Q]Q
M-FB>C8-V;-4GQ-"R, #V*+;L21\&XFO%;6J=5NF)&<NM4SN*O=&P97LATY]"
M/+&#3\-69]CZWVOC<5VN$*:,$2IX0S''*5C+!0/32'GE#+=\[G;$=9'R1P?$
M5OQWYW,,.[V1[1UU8!:VAL,X^GL8T[C[[TZZOOT P^%_#>/!>;2#%14P'_[;
MQO[DGYY];\;[)SMG'XX_G>UM_]/^<++7V3]XPW</_FH??FT?[[W_<')XT.WL
MO7\-PL(3$!9D]^@C5C$:3@DRU( U0T$^Z. 5,@9;G+0P*N4:WK2YE%MYR(8;
MK3LM##\> E+BH,[2RU6-VIW3>IU4U+A6YW+66C9/VW<7361:Y%)VQ+/$B9-.
M9)^?)DTI9\Z51;/H10-:[.#OCP9PB6DFG6J:.\]3C"RV 6&G)&'@LX _#S8P
M^=:JN;9(XI?3V!O&5C]=?CZ]"'J^.PZPP#J]UJO^<)1/.QWTP]C#01#AH75F
MAZW_><2]3]U<15M3;[.?&@MI>#L;Q[R\U?2ERC.D.B5P=I&SBN;N( )I+3E*
MV%*M7#*!9"+"QJP[U7)@0,(OZW>:_!]M1E$F?V&3?_111,RL]!X%D50FL4=D
M#1;(!*$DU3Y%X_/DSS9CNYC\2G_<9?ZC)O _3Z07EALPAY,U,FF>G.;&NFK^
MB2$ >S19"*S,_X/,/ZB2[$ 2K (H$( \]SX@%TD"5\7E) 8. IE_9_Y=A &.
MK9']LEZ9&6!*M%(GCVNM;UJQEY7'9.>]=BPFV^_KUS^=-,JH5M2U ZPZ0')]
M@>%IA/M_CMWSC=9.PUYIG0W EH#Y/>N!60//-*VY*C9,ZR?X"&R@GR]4WGJK
M%T<;=_,!+JS_*<_D&$RK3CJ_].3G6DOWTGJWM9:&TRAX7;_<0=;B!W#_W[M]
M_^GEK7"RMWWXD5NK<!06">8EXIQ;Y)('W0+*QPC'N8D@42*LU],\IX-Q?'R:
MRJ63ERMFG%05-.;:9QE>]A1L+YC_2Q-L_08$?HZMX3@[YMFIGD 1[/GJ^U^J
MN\ K7"SNRF.^].]K+QU>O&M/A_'7BU]^"YWA:=>>_]KI58]??>DW<"^/.KT+
MIU^<SGCH%4[JP[^==<*H_:O"&TI6@:\)]6ARX_HHV:@.-8(.DV-Z0U!]XV&\
M0>YY3#-VKV]^YV$)X:ORL&K#X)49V55[6'+SX>G+SJ7CF<N(^7U9=U-*:X+6
M*@+'J@C]0F6=OE6\^Z?M+%&R/.JU=FLS8OCS=3W[C;V'[VXQ/*-3O\//_,:"
M\!%,C\$2;7/4#P>&=W]0:;5?QV 7#O)9:YNWY&+>8S2?P<CP,C(WC(PH(W/#
MR,@R,C>,C+HV,@_ ?W_2 ;FI;^+C;S#?S57=@_L?G,7NY[@+#].^9=1FQ;>E
MN[M?_^KNPK4/OWZB>\=_PW=^;Q^>_'U^>/(/W&M7[+W?Q;OT\'SW57-;^N^O
MNW#>A^-PO']P2/>R'_PGO-?!7YT/\%YP/7+X]0V\U<[9?[_NC':;;<B\%QSF
M%#&5VY0(G)"Q*2"A+2,L1&LC7MODZQ+/=B%[T%J.SPYY2P^\PV@'!V?]@K>%
MXJU!6C,^,:=T0LRHO&MG#7)&.\1(5$%ADXRN\,8+WEX$WMJ#^#(2,1\-<4U2
M.U:.>V=RYF6NP,821R8&6-O6AT@B58'PM4U6--S+0-P?_?&@ &ZA@&NH.!T=
MM2HPY#@AB,N0X#?FD YPA%!L#/<9<+@ [D4 #LXM@%LDX)K48A^#=EQ9%+4&
M'\Y'BDSP +TDDXU1<2?8VB;]ODVY,,KL8V^8OHNQM=<?Q1;1N>% WO5\U>]5
MG.)J"Q56K>WYCNVVWHW@@Y.*%5MMH0+<\SC D1!'MM,=WM3VL:(B3'<R:% %
M\G!EQ'5Z8UN/[-16R^1A.=U0>5?TM%]?]->:?ODY3C9#)ZB>^N)D*Q5??<4Z
M>*WQZ.:O-%G23[2'W:K^/,VFLM$;1LG[;"HSNL'9[3;HEN&R9$/S']A.E L.
M -]VY_'IEVB%&L'F;#1>EX'UYU,_VX.K<3B*R VB_81L LO@5]L]L^?#M5^N
M;[+"TFV@OPG<F^7I+4E(E=(4Q.8$:Q43D]P(XI+"-IH _V!*2?^12+PVA[HT
MF4Z4Y^Y7HB_W@;_#>%K4U^KET^D%$,F_HJD+/>).026OY,;C)-G,N_MOUX<%
M;XAJ&!Z80&8[@W]L=QRW.T/?[0^S3EL:AMCQUL02Z[/][0^?P#H28(?!/7?P
MAS]WS@\/VB>'[P_YWO;.U]UCL)#>_W-RV&2('7N^=_+F_,-!]V3O^(_V[O';
M3X?'?[7W__S0_G!\A'>/=\_W#KKM#^\_M#.=?G?[-?_HN5)*!(]($AAQI0FR
MF1#ME1/*1\XE-;5E#7H^AJULT8)D9Y[SE!1+7 ?O<@=;'8*2Q&J*0Y-2E@>^
M58U\:S?:/.Z5/3)K<$UCJ&%=U-/S_3LWGM3YD 4"B 3*%;=&8))"9,%J0J@A
M:T^<V/2J?P)W/F^-A[$RS\[LH,I7@?,R\\VWP=^(U3ME\W68332X;TYTZ<"_
MXI?3:A5?6("?[:!C7:?;&9WG/ 5OA^U6ZO;/ANNMTP$X'@-XB6EKK^+*-6\V
M@*.M^O=AODH:9^,OY\?$@9\\[F4&1)5GU>X, CJU [CKZ7@ 7QW6W\PT.W@@
ML#!!UO5!+U3W[?1:]O*N?E*KNL[+N#8:?M ?#B]/J.\/IFC]?,,S,)^F1N/R
MM$%G^&G^RX(--NB?@<P9;K1^[X_:K='Y:?V<8)IU/E=6:<V<#3$7EZN9B,.K
M46RU8X QV;BR\>:S8B>B_5$D^_R5M75IXW?/UR>^P<7$78Q,-<;S!M7F684C
M0\!NANGTFKMV>C744P-<E=>O#TV/-4SL,'YGC%,6$)\K 7$QR/=9#WDUW@)$
MU^_=BR.X6/9RJK>]N/_-8W@'K/93RM3L)E8]&(P6<-!$P47247Z/[@3)G7@Y
MAK>X9Q[:7G_4>,7ZG29@A5'+%UB_Q#@\2"4(+N>@ L5H[K0-HN\?]6 I5CB.
M=M#+D[Q>7]:=3UYXE$FW^9KUBXTN3VS%E*(?3:Y_N7AN/0Y+##RLL@NXTYM.
M 4C]\0 $S?^-03;&07[K;*-<7TU5C*T:S@RAR0P/1_"-/(CS5OE9!ZX)DUP[
M\?:D/^Y5JVT$_@5\Y4[I*,J"$B0\YA^2)!N]2I%';4T@ ?,;8F0S62C;E\ND
M#HS5+0A&*Y)^\NBFUP[;VSZ"Y_UTMK^]^V7_8.=C#)3S"%:8QXXAGIA")CB+
M>(#I"$0+L'[7-L&GOJ&7QD4^"H"RFN"3TSK+-:^YC/[9M51);\!9WW<J#%:K
MJML'DQS..H$57,6/X&L7I/H<7LJ&6NM?T7;AW&$\J@3F,(+JKV[6E%/?7,5/
M(ZE KH^J:\2<^)N:^3I3^)RZYY1VRLF>^:DO3)OK3UH=FLZ[R1>J T$N@@6Q
MW*8#$0VC-/1C_;:5C*HEU-4P7RP1&(0K8Z&.,>;,^SSO\&M.61K7(;]L'((.
MC* NJB5E1]5:S8K0@P3LC*Y;%+4A?Y276(JV#D!>LPI.;*?Z]O#BZ\/QZ6E_
M,&K9HT&<1#Q_>O5NZ^=Z;5\HW:DW\%ETQD$V74&]Y 04F*O.L)V?O0K1P4%X
MO5$;[MWN=\.PY<"VA873FTK&NGQX.ZI47%X1O8D.O'H26'C58IV?"5:MDRS
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MT A'0560-C$NUC:%F.5@%)P^M=?Z](SC@LX%H[/!.PXJSY[72'B2JT8 .DW
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M'8Y@)\>U$H8!+SP!6J' ,>Y D<?$<A:B%+FT(MT\&=@-K]-N2#H%P+:&I',
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MKQ:+L&H^X/P2 D276.R='=#[XW7PZ5BX"6B%3!EMSEX7&66N54XJ1FL_K=9
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M-6D>P)1<%$_<.::75N0KJ1Y\_KM9>O,+ZADES1NH'P74P^9AD4ZF& NAV$=
M$1AXJ1*XY SZZ(5W:="HMHU.:XGS%Y-IF[[E\H//KF?;6FW0E"DNCM@M@F?#
MHE;@A0F 3@>PN1C0)64R:8HV(52[A39T/C)M#<[SGSAO<)X5G$<2YR[)E(4#
MVD0#F+@$Y[F%'%!F:8/DKI\XMZHESN<B<3ZUA.D/S+6DZ2R@MSV2-)79)N:#
M@^B* $32J2%[#U(Q'5266F0[HR**)@M/+ LI!8]D)(/1NDXX,20+2FJP#+47
MVHE4Y,\)]&M!U]FGT=NAK'8HZYZF7;^I:#/6[L<20[Y7%,XPRP1$%C*QA!7@
MI"')],:SC,(P22PAY3VG(+6(\7."Z.-Y7PVB]X?HL#]EL^8FAP QD!>%J,BS
M2DF##-%JP\F_*JQ"=(X0V@H$GJ! X'Z->F9.2J*2TN]G!P?^F-Z0.KN'@R!,
MY28?CLY..W'''V[G?DN(_2O^J+&:/EU=-JF-/[>HZNR>='Q]R?[^T?G)+W/<
MCLC998%JDG9$W"YK-UD7GT>Z[%__SN)<W>Q3759-WN9(SZCA]1-WQ[EC5_5[
M=@=Z-@_%%_&AV.V-C/0S20.W1D8SK&8<I;SG$.+Y-9,9<$AWV_G5[_O#F!_0
MQ6S,XS_O.-=BAK.FY2O_2$MVLS\Y.^Y'R#_NGNY\.#P*]!1_5CMS[?#+V>G)
M]3:!]=NSXV-:V%_]R>[58>#^M1;$U_YR0*]G/?&!K:^N?>M=O&9=0?>P]UYV
M5R-N'?RQUZ-K]CYVQ?IPH]:#S6];&^\E_8?=O35Z_?N+3?'';F\UGO<N=@ZV
M/G:K'\\W+S95O^_0MZ%P6)%>LL"@U+-FZ,G-ME@"(.<FZJ"<5GR"+JW3CGJ)
ML6RY@($IE;QG,O&L'4J?O2T\&E>$YQ$]RC[8:C9*-K#-/]B& ULRDJM(VP>>
MIP*8,(/3K(!!9-FRX&WM":0;V&8#MB@EX\9$ZTI"49QW7F,Q0FIA7"ZN@HT[
M+H1[$K M?LG.#)'X^U#)#C?*""O!945JSUH.EI0<6.$XLT+6(]>U9,?P>QY#
M>[3RG$=T(I]N$M=5_#.?G))@G^;4*82FSI\5 IUG.)%+SV(B5RN?G*B"ZSJ'
MG] #TU<_%_.,(_+S.Q#Y=1X?2/7:X9OO(OWCLHVV[T7;W1%O)7 9=?(&HJV]
M4H)/$!S7P#W'1.K;.ELK+=UH\O[)RZ8;9B>JM&N8?6Z8'3G/99E4T@10/I#3
MHZ.$(%,$D@(7,:#WJ4881(/L_$$V6T[_1*ZC\NA"<L4[76J R*+SH0_9ZB%)
M!C?%)9X$LLUUFB*>AUPG)IV+A3%@63% Y05X'TD;%R&*+CDPK:KKQ*R;#T@_
M4OKER;RFUW2__?#!<_2/S-W]HWNX0<^0AF?K[-QE(MY5D='&,3U8R<?'.?U4
MU[AV6.DWI\:@]V+0]R->C"^"2UT$")<RH,P:O%,>8M8YIJ*4-F5IQ;A1DZB%
M@1\!7E/P2Z8+KY^ME[+[-2>XR,='#7;WA-VP(X*%RVA]]3R*)G.EAGN]LH1"
MDR6+3,I(&NK__1\KN/A[@]XLH#<%_Z)IMJ>$V)!OD$.VH2!"0ND R<$':\A5
M$*BXBI(59NOD9C8Z#V#ADBI/@;Q_^V_5EYZLAUQ+/CR9/3YI OF&_/'O^?1T
MOW^113F+-"M&^S!BJQOO RII0!:O "T*\)@5:(^!C >F, IBM-&A;"UZ^>0X
MG;IAWW Z-S@=:2IL2BE"1TB>13+N:QTC*P5X25AR[2G,V=(*CK:,:SA]<IQ.
MW0MH.)T?G YY"#JA,9:<@^Q%;=D:"H1< M!6>^Z*TEK+I16WV*F#IP#DF\/4
MCFV\H&,;T^I"THI;YYQC-T?/="A#YB[GD+EP@%PGL,9;D*)D9X7A256?Y147
M]QP]V\*<[0A5@]N(ZY%DBKQ$8#[X04&$\]:"+D5Y9G2A76Y'J-H1J@:V2<#V
M^W U8<S.&$=@BQ(P"$_^@U-0LA"9<:&U>JHC5.-[ '$UT@1H5MTN9O#2"?KP
M#%T/JI_P"[??&6CW,!'0?H'ZDVF3S1U*F\3DI4W\OQZE'NM.C8;^?GTUV3+*
MNGR5Z3J^/[:LXP_3M2Y#_CAW_/Y^)^[3"W;+;DZUL="_\I]Y?P 5T:E%F9W3
MG=S)7V/^TB?>H]+)_WM&=-;9/?PSGYSVHR+UI__W'A0M;6),,1Y\T*BQ>!--
MR!*C3HYC='>UA][T[^3WRK?]9WK[9V]WL5V+K?_98?'@CT/_T9VM[T4DJB0Z
MW3_H[;W=Z>[]]GES[Y\[Z^^V=K;VMEEWK_NMM[&_L_5Q:^=_+CX3O;[_I%!I
MJ0L#QPJY!I)L%>MB ,VU$9$%F>L)U#I<8_0(1>=@T.WC5>=\9S?N] 7H1N'A
M?7F[L8O5/04FF9A4T!&52FA3ML6$@B)E:9WRCMU58,:7!US>XK5"@1<R[.4!
M\O25KO7)RZ)=JI,UE;2 FOS-$$H&$S$$AD469\;;OE?2-$:&.G+YY>@-,7]Z
M8^TP[I\E^I#8'T_7KXXYC)7S3_,QL7Z'0)([)^?^RT"OC/GYT :.:[ \8(>S
M/MZN;?'E#:)8-G7I1M?ULNO8P#7XZ8V7_>G8U5M\.#G:/SN]^2W#-M[L'9Q^
MG\!._\_W-9MYISYG]"2=^J0@@;GYUY.VDWNLR_)EBW>[[/2[U$UPO&!^1+2/
M&F7'E.Z/<0!^_GOG^&H=MC.$X^P_@R_$%K_X_7/_[63I;]<>]8!$=PC]P\"]
MV;D8_#U$+ .];)2)RI.J4CZA3]S6R@"N!6FHQ'4,2S>\+SIO=%0VD\&*HJ0@
M.)=&"Q6+%>2&+BVV:I+SIYK^<<U:()4" ^UTVCDB3^7XTMM9ON+2Q3<@<-YW
M*?J3G;[;^"<9RX>7ONCW;2.%]3E?*KP?GMP+,O_4_.W>#_/O/CX:+]X%$X1T
M+&(NU@8>T N6F8E>.'G7A&/ST:;GHUWT-CY\,B$7+P)"*)Q\_J@2?54BB*1#
M%$QSY+:?#N2C9=E77MI]1,$JF4S 8&3F2')@BP[T$U/0&F?$G?-=312F*@J?
M/R5;:/^+!!:JN^Z4J9/*%)@0"\H0C>*AGL4?S0M_%X0^==]'%E!)%6FGB[$"
M=1$V286*\1QMR(*[NZ9CFBQ,4Q;V-C_IDF(N3$(TB(!H+5B9/>2$-@N76,F1
M9&%,+Y6;0C>CQMBU>',_3/Q/3_;U\;?+(.&K3M4)KZ[_5/1_*OJ2=NT7LO\+
M>M-Q/OF28U6Q^]^6.Q-I*Y>\"MH%2Q*)B"G4 7Z&RTP:3*?LFK::O5BRWL;V
MIZS(-8N1=%1 /9CH9C$XT$;&6+*WP9JEE;\2RGL9+<A+81Y)&APRGYV*+HM4
M,"5G11!-4SV%&.RM?<J95%+,$K0BRP6=5>"D95#;9 9=2%7).@7\IC3OI-I*
MRF@TPZ!U0:1/L8$1#_)"!BW],(>FK9Y$'CY_B@)%T"*!+U'7NN$(@24/+%KF
M/3IT_9')HW7#U^7ANL+ZKJQFH::>F4/+U11:(,[8H>W?\UB'=OUP^ZA6/__4
M6]*GO;-!^KKC#X[.^E&)XTQ[%FNX/76^'._6P3W[->G1^2V?9']<<YZTV:LU
M0W7TI?_6_/5+/CS)RYW.QD[N$-KIB;]=7<3?G $]IJL<G_C]^Z9"O;:%5&/4
MD0PUK8D3@W%>U]EUB#G&^W<^O#]GO3X^KKV7^KG_[VV87O<7<;W<1G.\\=P-
M/">[JZ\_%1D*V2().!:L+:(EN%(4I$(&B7'!%3MPUL<<9;I.=22V=3Q)IP]>
MDL73HWXIQ^GN044"25TD!'MZ5;J29Q)'>GL^.3TZ[%/AR5'<[;_Y1R7(Z[/C
MW9/.?V>_3S_P\7_/=@<<L=P'P,]"75]]H_2?$\W^0 G=PWK?7=@]C$<'N0^R
M[\!Z.;1IYH\VUPX[9;<"LO.-Z*^O[E[U]W6$Z.YE8SFIHM=""^G(R)+>):UX
M=C9GP^QE,4=SO6;)/5&L;VSR]=4WK+L:Z3,_?[(^%F$2$0]W#C"D -9Z T6C
MYKKXY)-;6C'LIC&IWUFH\LS-*O ',[T.NX3\-*9HX,8B@;L3P'P-!,RYTSLZ
MS2??B^PJVYG^S+_R?5KX325[.WF?; I:1G]\_*VR^,!RZ=!:#E!Y>'*TOYOZ
MBWIYT*OS^T[.IW=9USL5;;;*C%:9T2HSYDA$!Y49[OZ5&?4I^EI.<5\IW>0B
M-3K%0S$U$);H&VF,CI^XUDM/6,_QM#;?[8, ^R1AEF=CO(W[]!'C;7#BX%K!
MW10:V Q/O@ZGJV0;[A_5LS$;=.E?]X_BYR>WG#:_6TZ\M_I!;JU^^-H5;[#[
MKLMZJZ_9^NK.?F]O9Y<L'=S\N';>$^_9UC^&+:</K+>1/O<VWEQL;FR?;UZ\
M)ZOH/:Z_^R#6WZUA=V-G9W/O-5W[M\__<T'WM4<028F3,YY J!J=4C9 D"&!
M<R5B<%I[PY8N#:&SG%Y7 S0Y6FR6I'6>]H!I6G?%4"0?O#(<B:<RV:-?*LL<
MGY&#\.O1\?'1.>WSR6@QY<^H&5O'=/N'7;^Y4%Q@LA2=1$9.KS<Z156B,+GF
M1^RCR]?O<2>GL_V\7JJDK1V>T"+TXPTO6M0N7G^2(0A98B"VBQF0<03OT$$J
M&46FKU"5X=VDK4A9688\2%2*7E.3L)&GR'-A0@V+VM-9QQO]H,'!EZ/#[^=*
M]H^(V4B_') O&$X'IU9&YU_/UBPCY;7,!@KLOG89ZF4NQ",,H5:/8):Y966F
M?Z]B6=B[S8J^W[T*.]D*/,6]HM O_E[=Y/;^PXWXJ9+;\.#D\<.B)QV<W.:<
MSTN#_D=MC3]T/OFNW?&?QU:_*660">W\5D\(_4?;]A>Q[34/WK;Z16SU Q ^
MVE'@9GT_K3[-M%]/.</EQG39X=E!R,?#QY^3E;:(.K 4D2OT)I,W+11Y$JF4
M>$.QXEKO[;BHS94OO79Y:K-NV.^G-6OP[WQ<1<MO7S4J ?%,'>U!IY(C2??P
MK;<1Z;5OQ'K-H.V]IOMZN[\IM@YZJ]M?NQ?;<G.O>_6>[YU*]M+.UL8:[U6G
M?&-3=?=^.^BN_KJS^?&/O:T#NN?5-Q?KJVFW>U&=\_>GW>MM@?Y,[_[ ]-__
MW-\2^W^&O2-ZWFW>%7_LK--Z;&V\)L?_CX/!L^Y\[NU%WK_NQO9%CUOVB;QX
M[F0L8*2P@%DC!,\-Y**U#E)+4]LDLF6A1DNU_V.07^JDLSRH4)KPS\TM///9
M="04W%\+Z%L?\Z"NY(<XNB:-LY9&N?[ZDY N:B$8\)0TH)8:G,X9&-H8(M;
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M9&,1D&,IS)OLM"'7T8R1[FYWDA%44V/0-H)J[N7K@N0K>.M,J*/V(H_D_[
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MVJ!5M/-+*_@7E7RTV;279\=7H2K9ROD>WV">#*PM.SUE,*X-3UK@LF05()K
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M9<-W(GRH1=*4,(DD=@R!,R.1Q18C;1DV N/$)"XT88G?M<'OS.*UC$LBG+1
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M\3NM6H6$Q18&S" IN8I:ZX ]CA;8.R9L>!EB6@HV)T),BL-R8,R1D-SGOJB
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M^OVL=O[G677G[*JVL\MJ.X?%4;G$A' Z(A:-1MQBB[2Q8&,#^FGDX"![G#F
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MDA>X&//8;.(MSO+T_55\(X:*A6';XUB)PU2Q2MMVX];;61RZ>HNSWX8[YG<
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MJY"3%N MH\ F"L-P*%)1Z70_KQ+4:P/JN;9 2E"O"*AK$YI:.L\-]A8I3PU
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M[;J#MW2QT;K<>CO8I;^\.'(!3,7Z=F8L\.==\)SS$F\6?QT4 $<[\*3OL%H
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M&YW6\+@R7%>4T;G;F<EGFS_V@%6R8_5[RW4J'_H^1.'E/,3!V;QQ/NKMPK>
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M!%>$ZEPZT[/@;79%[JJ3>9.=]-B,]T65-+L_X_TALE,&F;(\7'\Z<MK;Z%U
MR42.N!,Z5XN7R&!/5?3!6JYR;NST3D:9^;X&0:F7HWO]6+K_6)PMO3F[4K+_
MX]!^7;WV1UP[Z:C42"H?\]DGARQ3 6%%69+:*^GT[#KRE2'QC]@B4UFH4UFE
M?0MC5KI\-H8:MUG'-Z&M_@GBH=ERIX%8N%.; ^/OMKI2RQ>5=\)=9L_[54BM
MG^:VDK[FI:_5ME G3_8\C)SDVR,G>/[QD=6)A2 56*443)%LC[A(&!*.&N&#
MX('%C6TNIGO:5LX'Y#3--).9TD.W+MRF1MO;",14J.*.>D-]7AL]U#SXZ(;>
M.B,5)*QK?8\K03TE\[Q!PZDX&_)U5#67MM/CZ$EDSYEBPY@Q%L5HB[+.8#MY
MG@ ;X$)AF03!]A[;:>E'>AYA@-UA,0V._SR(MM[Z\9^;8HG#J%QHP7US1#JO
M<;^$T2 D6DF]HGK&;4CRV+;#,()[3]S]=42D9YV#FHA)SXQ>#H^.O. 1*+RP
M(U OVZ/]+8>W#DAM_P,XO,)HGQ20=LZ\\-@@(YQ"DA*O&,6**9,3=6=49WNY
MPT^[S9M=@ <"Z,0"F;<NBX)>15%FN.H$L)@W9.$I8SLFF[,.2;V;*#E?AMV>
M/1=LO&IT<78@U[Y/H^?5^G4G1YDN)XOG6,EC+$ZO=;*>@*RK *Z5LC!0*:T-
M)D25/'^PQ5DF!L]/1[RV7SWRQ)N@HD114(NX CK2$M@I4<&(P)[+W,>1;TV[
MN..[+]-:J]".0 [-PIQPV0\H&"8N,CTX,$.DB=: R<NC#8XKJ0P64GK-*&-S
M[>&4Z<&/EB7P1\Z.I) \86^1D@;\$1DQ F!+1#TA1%M* C9WG2UX7U+Y(JE\
MA+RGSGX5%+XY2-W)!KYMCG[I<3QN(K,.!ZP(-T%JZY))@#OJ0G DECR^#.SM
M[1\<22.C9U2"F,E<.8X(9+3$R$3CO::<6%Z<_[J/Q\%"; UR[_H5"OLY*-G2
M/&['..P8 08;D.)%SO=J#4Y^5%H7]58]C!UN7QS/<QR(999&([@7QFA.A?'2
M"J :E>;;JR]Y_K&RYG]4=[X<1>UL4H:AR'S(9PT#RH6 0/1 ^+0@'%L./$]F
M'@-9\4 !$1,1DR+[<M2NZ1]F/LY @!\[]3"(A8_%PL8" ?=EO ^2,+_'=L99
M)WM+N?D+V-F]YD@@8BSG*O3B\/8Y=:$1A\T(.OD^ [^L7]:KB.C!-#5O^U,-
M P_CB6OA[HR]R0#/X^M//,IM:_<7IZ_/RJH6956+LJK%JZQJP5YO58L'5*D8
M:Y6T@ 9"XZ;P'_X$M$XC[J6I<IP?FF&D/MY^GLI]>/2OC98_>W,VR:=K&!,_
M(I%R)7!"AJ2(./4.Y=:F14UE(P68AM)-5B*!3Y0B)/JD!5<JV: B@S4*6DEA
M&'@G$=3@1094NQ?'(3;.FF;+@. -?I=;BN6_WJW-EJTK]N/Y1:MMVU<W+2?]
MX.R'M^WV%3A6E[8=.L-6!K%9I$&.& &#SA+YBGZ+C)SE-*,ZU7+5$$!\"_=A
M_F@]I+<$,7,IC)]_)IY!#1&R)9]AL&1+"/X<@R5ZOCGXV6? [92]GIGE6+^6
MP>:9?=A=9]HXTX;+(VR<.[]J'F(.97<\MI?35=U,$*V::?$4+#G4U_D@RV3G
M[&>;BSE,P_[TO=A$D9D3]<Q=06>-9OZVV#/,VT>L\0/A]-C%7N@,Z@>MYC]V
MLFHOSH-6JOU(8N>718C^2%_WOC&1%R8WC"_*AMS53GZU.:*PX1\P.0]ZXS<U
M<T.GYZH4K5*T5DRT[B%S9_W9<;O5:P8T>"/O8TSI_;Q3.$L%P$U>*-+SZ?RB
MT;J*\2;TW7*-P09*YR'R>-?LW"6+"YM57'E1]?K Z?W;Y!PN[OW?3\8*5^K%
M'[$7+1Q34A-I1=0\8N.T"<JX&(21EEM5-+Z9[GQ\?RLS^&'XN\%6=-X;@O\O
MQ/M#,PR2U3M#$ S__NK/SQS\]7OG</^B7CW_<ED]K_*#T]VKZN<J?*]ZN;=S
M4M_;:32JGP\;U9U=7-O?O:X.K_G/[R?N/#3VSG>O#G<^7!U<G]2KI[N7!]=?
M?AQ<?^![GW?YWE_?+@_/OUU63[^0ZFGU^C_7N]UJ'?_XU_ZG[M[.%US;^7+$
ME/9&*XZTPQAQ'0PR(&\(5A7^)20)$3:V%;VKA_*SH29_^DCT+)+]%JY?GO*
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M/SF9-1="^^#/UZ=@>I #>B2.OK_]#'].CLY>?3M\\8&]/@W0KN?D\,^78"[
M/9Y_HM*:%+E'0C"".&-5I7C )O4I1JQU<GYL^<&*'L/S;'1)<%T8PY( ?W)
M@]:*I"2PML9@P\$KC& [G&?(@;FVL__R[+S3NXBQ->G^UJ$#^IJ>G:UO*5_'
M8<V8&(_03[_^)H>,5\"\XZVR]7 O8#[.C,R[1=.^F'3%M9YXGUGS*<_&@^-/
M2@:8@@HC%KE#G.=R?U0E)(W$23@*UBNOSZZU&&C/QYO#<7SN86(K7UK)5[^#
ML1RGLW\:A.Y=C7D5009[#E[L3C8ANE5.1O7!WVS'=GULO3N)<3AH?06'Z-F:
M;$*SIP5[B$VHR!Z,W8.,MQ^_)QA=NDE(R!YXLIO46/-P^W5QHW2IP-/WRC/\
MY46>VOUJQ^]@[*P.9HZ%_> 1%S/1?<Q1B48E7F;.>>+/3VX\_T//VLV3RM?<
M@WAOP-+-AM)T4W.-I_$V[[#=[5WZT,-V&W26;N'R#<O:'G@!D[8;PR0(/)G,
M;\ *FL@L/N^&U[WN)-/LKZL$@$V)"#_,J)XD?7\[>/'RZ^&+HXO7+PXNCK[_
MC8]./3_\\X^3H]// K[W^\'IR>G'/_]]>G!13_I^^?7@_7/^^O05/OC^WZ>O
M<R3Y^S$_^N>/]F&..K\_N#C\\_5G^,[O6;V^?M@NNU8J*(O@AX"X5^ C6LF1
M-<H*QKDG20 3[TJS+&F2IN55+_%,R 8>^5B8'I:U5U3HH0GT4#_/YI)CTE&+
MB&0><2#Z[+1+E *S)"G)N'$[^WP7ZXVAAZVO:/>F-QCVX[#='Z?!+F0N/NWR
M-FNPD@YS6NG-$:PQ(U#B-?J[C1T+)2Z/$E_-6$P4:Z%<KFZ3<D6K$ RRD6DD
M31"$:QT(Q3O[9%>QV82P4L]J:P"_++NG +YI@*_;0(GDXG2*H>AQ1#P2BC0S
M"7$F7!#46BHK%PG+V9S@]0%^Z^M29<R,]U\6-W.>=H7S-9@Y-P=OFAAX>;"N
MD-SCDMRLJKR3DN,8/'(L9=4FPY&V*2$L4L T$4$2SB2G;\EHWFR)VH+O1[!J
M"K[7C.^Z$:,$LYP#M#V0->(B"&0,@)P8%JT,SG/K<W$/0F:/X:X/WUL?JP%3
M/\+L#]4)V6DF6XG4;((),QVZZSF(/R&XPF%S<-BL#K1/(5 O#<)>$L1QLL@D
MAY$W,2K#I;(TZPA@W" WK,"WH19*@>]CP[=N@G@7DDP$IJNR"O'D G(A:D29
M%9C!=';"976TNTZSE2C*(R#O?76:]#*/M7<]>WN]@90GO*>^J(ER/1G]6A9Z
M\;"61V^STJY24TDYY2B%+&=/;0+KQ!/D2$B,<,4)(SO[:I?)A?>%2B;--J)^
M4<NFH'X%J*\;-2(%2544"',3$+>6(4N3!)^$>NV%233YG7VSRX78%-1O?=#E
MKUQ=<6+57Y6(.K<7^0A-";XTV;*YC"^/\P/!0;O7_OETU_Q&WF!AOCF8;U;5
M,1_-5$QCQ!+/$66AD#-@]"2L' U8.D/ WA%FX7ARB<8T%\]+VR\J>%XUGNN6
MC#3 Q91[9,!W03PJ@S1/#"7.;(J11R<MX%DT"<];'YYY^8,#QN-NGTAGMF!
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MT0\<VO$=EJYO!_")3TQSKK3"*#IP/3DV#%D<(J(<S! 7K671[;0BF 7GT+O
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MJ]$O+#<7RQW-;OHG3I/28(LHH;-I$I'F#*/ HG92)1:\V=F79<=_BV&]@AA
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MH6"]1# W -K$8X2EBES+!*:G*X#>;D"O(&1P?T 7X> E ;T66\!<L\@$P%O
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M[<>'I_WX\FD_OGK:CZ^?]N,;]!$%/S<'"Z^DO:3':R^>DS]^Y"G=J"I]JR?
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M!/%!)((,K(CGNF1-1FJL,-&"0!0O79WWQ6:_+)<3L3,8E]3VD^S/N?;!%AC
MF29Y"ERW.#@L*:/'<_%P(SP7[\Y?CP)O=I2SVC!WS7ZS'5\M>AHIBDRD!HN<
MIRAQC"6BH]0Y".4#\)5UE(D9^CN&Y'WPPUR1I06 >.E"3Q>#>*Z@>*7-6Z=-
MGY2.UIK(E2[^G[.!,X.>'S,Q)!VKZ[<LM-EV_:*.*HC 2<A-9S_MB0T&_^3@
M(TW**B4J;5;:K+3YD*S-ZG#?"G>V3$Z1,@2M),FT-"C/,1#K $CR//)('9/
M*G<^"NZ\6D.ZD[H'DY.492[LP>T7>)AY #[9OYR<X#\Y?_Z;ZPX[?[O>82I_
M772DZ_S!Z/LX0MN,:L^50^:=-"KSW1WMI<F)[R^IUR-Q$ Y+@CV^=C <A#2:
M'(D]6ZX@E^?\7)ZSG/K^[>2O4BFAG(F/G<,#G)%_'P[*52;'Y\N9]%#*&GPI
M-92.JPKTTEKG59Z>2Y]^I-0T:+XZ.<M>.K:=?'KUS+U;=]L?Q-2;-FT[/?]^
M.,+ON'+D_^"P%""8#(9,OH<WZO9C.DCXHS_&3X\&ATC>IT-V0U0#^-Q-Y8)I
MS8#.43?U8CGV_SDUK^/[.)&E3$'Y^_.@5$Z8%"%8[:1)EG8S?_YT#G!"<5UP
M ;Z&/=?_D"9?;M8@#%/LCJ>77YL1G',U3KK-N)\Q<P<0N%BBWNYUD:'&QW+E
M4Z^;2HF&[GC4+-($&CB'>X-IP0-W@%*%\] 4B^A/ZU;@ZO?'DZH$DY(-IPN
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MG0>:U_NX >T$!<T]*VGYP(.R)NA,)>,I:$!)J+&YY01T.\U%"4J=,X$X2(P
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MRE%K6\F!*NF#U2[GY$$$"6KQYVXK85V3L)K_+Z0%A;"V7KRGVL;$@R&>,T,
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M["G:>X'T4XA<_9D.#H=ASXV:_-XP.4<YFHF9WT/<Z@&RV_6,%J^3I"DK;@L
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M&DY>!YP\!$TL=Z!W<.ZUXR(H)\#$#\QC3"0EE-=ZQT+CQ+C/-4HJ 1$4$C$
M3O @D8G>HJQ0QAQ!X5@#3@A::QXU5#Q4\]#$><6-8,R"YD&3IJ!P1!H]ULDI
M?P=6U)K'TB#*A"O86">391X)SQ.H'M$C#68,PD)9'\'&T;ER'A&KE$^BRN+I
M'G6R[JO\Y!M*UB5ULN[S''#%F@F<%,_Q2NZ3(]0GDY(5TE)*_$\:P#PZ9ZB6
M:O.2:KN3-3*<5=19AS 8/HA;EG(;/8)85!%SK:E)"H3:*E:3$<XZI^A5L+?
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M7#OEM]YI)WR(?UWM<X%W.]4N%[C7*O:XAKP'0=[G"0.$$M N)9/9WZ(1%RF
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M(]F<TIRU!IX:>-Y2#*4&GL< S[@)%:3BV"F,F*(2<>T2,I93)!GWF&+LHB^
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MX%[%X>+V>":#QLXQCUC*+0!E\DC31!%CGF'*G5,Z=[PA9%6R93BL-T_P>%K
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M^KX005H2#7+""L2=Q,AF/[)( O/ .+56K#0B2,R3S)?]T[CRPO9K F'0.P.
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MC"&CQ%BMT/%9/%T2S3^L;9-WD69OC]:>)ZOS-_)HCE&\R1*H0O/LB2U @"!
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M/C7 14)Y30,42F@#!<,R-$!F,NRQF=BD)^4J(42M-E+@">7#A7(IOF#,Q$$
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MZ[H=$$7FTDTOH1N@/.:+1# =>FT^%FS.#Z3'A!/IAXMTEMQK:;8Z;& C4:C
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MVQ>D)&6FGY.$D(@ZE3#_-7E/F#+-3&6&JEMJO+E%\'RD9@H>?&@'E36O7',
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M:POFLX6$#?/UPNR!6UG>K-@%8^K:R&J)5G5@XI&V*GB=,)]T( \:R)@A#(Z
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MI3 ?ET>*IE&'1PC1)LQ2#;Q'G'^4B%W(RC)EIW!-_I ;Y@^@JIX9:F]5]2/
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M<8;=Z:H@WKV,YUIZ[$+*NVH/K#&SN8T1,764,JQ:<>DTW\TRMM!X<ZO@,Q[
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MU]DY79.@\X;YCF&N5EL8ZE79D*EI2EQ=&^>*>43>2N!UPGRL! :O6-@-I$D
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MF_>77^I-ZV_6G?_:OOVN?_KC)S]OK[_[]FO[TZ>O_W"XWN&'?OY[>_.OK_\
M/]R)9WQ6#K_PVR__<%-4'I5IW9<?BB0__,,_W++'PRT[6DK??BVG1\Q__<OA
M,?[5KWV,R\9'P7>[[+,E(_HS$"]@YPS7GNMYBQZH87W&S^8_P_[V[__#Q]^]
M^<M]^-<._J;;_P8;W_<WG]K7_VY_^N[A9__I5_W]?.L>T7\,[MM?_NE_^)OY
MH__Y!1T^'BTO;Z.P,'. 3G%4P82U-,?<0TTE>1L]>'X;/,Z?Z>VS[P]1&\XP
M0P9SFCE?$&DIK BRSJ6PV9+WG_]W"&MK&LM2$!!UN/5&@]3B_$%)_<=?X<*
MET>*^#<!CH^9\6\B\;_^VLRKWSO?,3XF*;?R8L-<='6_V _R8HGSK;S8^9[5
M,_:D#]C&L'WC/KQOW&__^3?_\Q]_\=FOSG"*>U=1:%]C7^-#7&,?Y?R;G>)V
MU^B[.LIH+][CP" -DY$E&1IS3N+9+%UH6LZNL+Y$V?V_O_[%2>?4J#6,'!E6
MI_<ZJ=G!$C+$%N974@S:TL,3TC4-!=LPOV^8C5KTUG*S@HFC\LR2-5(C[NM,
MSV7ZIC;,+X7YN#5J';U!S 48AP!V(I!1&JQ)"'4TZS7;A+F<7:39,%\OS"V8
M51K56UAS6<5B&YI]C,9S,>]^F<:H#?-+83[N?=+.@M('C) [8+,(TH6A$.6
MM<2.\O T>=\PWPO,S[9-G!EI[[:)RR%\<K1R[L4<+0#&A!-A$K 0$2HIYM$S
M4RP/3VF/S;YWA,^+KS?"ET/XI/-)K HJ-;!85H(\ FBC#)ZE,6HW/&S#^;%<
M$<3[?.7Y9FZ[M?-=3UU)D%R"1,>!(V>;&4CV7EF="I<+#8W8"<?+EKK3N1 R
M Y(T0TI(F6;"P6TF'+B\*UV;S&5NZ-R6GB2??9!\]VE?+\PIC%B#:ATS4&TI
M*PWJB7L>29+SA8Y0;IA?"O.Q%"@)B24&R&0#L%L!2V%^<$*G^58>/3X\\1Y]
M?<\PYX1!4BI)/6/F(#7.I;QP6*<FYSM@2X'7"?.Q%(@\%]^.$4)?@W$=9S9B
MPV"D6-H,OS"[/SR5\_W6-LS7 O/S)ZC.B[2WCG YA(^EP#8?4,K5@649I+K'
MN1]WAF)",JQIFVOO$UV5)?Q&^/TC?&9\O1&^',(G4F"H.CP:0=(@@,$J&,<$
MRE4%/2UE]^$IE_.MUO9<ARNR6MN5CG>=*-FT2UY>L'',="/*"-R[#[&NC1-M
MJ[6;6P5/ISID(TP6.C2J<Q&LG%9; D+/BCR"6%QN#O%5#G1%!9'-^OMN&11J
MI6LJ/07TX5H+.;>JBEHER;9:NT'6CT7$YGG4[@)$62?K#4$*$PS2N7Y+2S.(
M/4R4Q-T>?,>L*S;5KNA%#5MEH:$9O0V96WM[R_J6$:\/YY/!#77,/',8E) =
MT&H""WGB'#Q*265&;^WA::[I&^9[@?GYV9+GQ>E;@[@<PL<R8DD]>S4$;I8!
MNQ+XX (IQ2$H<Z4V?GC"QQU[WS?"9X;?&^'+(7PB(W9A7:?K@'HJ,*,J!ZE=
MP%LQ09U!%?;5V'^^E]K[[RC\\=_ZX:VK+[)2NX6ST_L:^QIW>[;^V!N#G]V)
MOOKRJ\]^]<FO/_^'KS[_Q2\_J&)^*_?M166(?<=N]8Y=RS7VDSO?[?(G??CA
M;[8_V9T<[RB)AI05NUAI&3',D#TTMQ@\S?^E^95=ZKRU3.V+TP,1)?5*:^:$
M)UT]6UU!A1"(9,RGVZ@L.X687V6^IHZ/#?O[=E2(R1-5D>X!HQ6/29C*B!Q#
MG=O0KG7>(.S'M<Y@F%JG""-I NPY@+?AX#;RT#1R2V/"GEZ1G"VN;MBO%_90
MB[F$&B)V-"<?,6G02IR])*$]5^H&83^9*V7M8!P-W9@ $R?PV UP+N]!/$52
MGK#'5R%OV.\&]F<K*6=&\KN2<CF*CXNA/4HJ71)DPPAKJ-#<LLF!-%2LL11;
M]N[E<<^&NV^$SXS/-\*70_BD&)J,2EEU4)G1%J"TF6WWGN=.'$)+.4NG>JV#
MI7X" N^'LU?9W1[O>JIBTA%*:RQ5D5FDAAF7<! IU5UP2XTWMPZ>GJIH'<5B
MJN \ F ?!#X?_#I548.%A+GDM0R^"F6;Q=TQ[(D"Y][9$PY$G.FIM%8X]8A)
M*F^I\19A/_%FR10&EPI"CC\T@&57R.*AF6DJ>ABF^2KS-G>]8]A[P(Y=J,:)
M>XLBZDH48DICE!HNY-2\87^OL!]+C7&2+A@9(HG.M&9^F/P[9&<NGHM[UX/4
MJ"EOV&\,]K][X<&+\T+Y]1SFKSS)WXK%Q7@^%AT3-Y\03X#)!Z!Q DU]0&J<
M:NW1-!\\G4]A_OO-\;5R_$(/E_."]*TW7H[>TT'VV26DJF 4(ZR1LB ]!J#J
MA)(JA67GG,)5G:#:'8WG>KCL<LJ[FCDW_O_9>_>FMHYE??BKJ'C/^55R2D/F
MTG.S=U'E;3LY[-K@V"';L?^AYM(#LH7$D81OG_[M60)L2Q $"!!XQ0X&=%MK
M9IZGG^[IZ8Z\'DQ"K:!8YY-1!!=E4E)"F]Q&&^\="WZ>BS:*I,G+K#Z)*Y*!
M]HH%D)PA$-8TIQ7@(I&@[8)L$QL?,-B#X]QS1.&M ,^3-QE4=C)ZD7WAMU3L
MN07[4L$^&VW42J&FV60H@V-@#3"?43.;A/9@(KF?O@$[-]?>6FC!OL)@YSH8
MIVO(48 M.G@?LR[&6Y_3<1.:-MIXS\ ^&VUT4@=>,F<)3.TX51+S20:6K/ R
MH@]"((%==OWUFT"V8%\5L)]=+/IZ2KZ-4MP>BF=CC)XH6F6!3*I$^MQ!8/44
M A/"&UF435G5#<(VL?&!0_B:^KR%\.U!>"[0Z M97(B61>2$X<0C\Q8+@Y*L
MUB7Y$&OM1+N*B8W7JO*RHH?JV_=HW^/'*"&P6)67UR]>_?O9Z\UGSV\TGGY?
MQNSFJUZT(]:.V#T<L95\C_;\Q94KO+1Y'HOVS@/)P=03AO1O$#IR8T FCHZ6
M94ZJW0B]9UX:)P]MKL(++6X1K6!)<,W F<(<8&:040CT"80M:QO@NMJUQRX>
M,-B3U,B#TH3X#-:[4- 6DXQ(*4LI9+L1>@_!/M?-(GACZME25,DSL-83V+EE
MP8$Q414G,A#8;5?H54K^:L&^[')..:%2":Q.%C"F:!2W*F8L6;B2;JF=10OV
MI8)]=B.T[F@CMX5%6YO9.\.9<V39$9W7NA;X,([ KKI"M<<N'@S8S]Q%N::2
M;W=1;@_%LQNAR4?CN0*F2R9]7EQFL8 DN6XQ)5V[(>>U#;7>BO.'#>%KZO,6
MPK<'X;F-4*.4)G-;6 XI,/ Y,.]28@1AGK5U*#*N;?@S#DRU!R[N<X&7-M%C
M07_$%:MTX3$[JZ%H\,4$E9WF6H/PGK>1QGM'@_.UI*.,@6?IF?26,\@FLY"T
M9U8D<CE-3J8$\D=,5YEK$V&;U;6Z8 ^VV!1<2> DA"PBKXG8B1>G,<7LVTCC
M/03[;*11 2?V=HJI;$CR*""PNP*,H)\1G4X)? -V(U8I^ZL%^[*K.8F S@>-
M!@&"\#$'E3!(^@,F>-%&&N\AV&<CC2I%50)!/-M:P9),.8%=>&:LQ:QB<LZ1
M95>^"UJT8+]G8+]D@9=K2OFVP,L=X'DVY@BJ2&N#8UX)4NH!@#E)>.:25%M,
M-OE$>#ZK0,3B!5Y:'*^*T3[[W,7U1'H;;KP]],Z'&\D<:_*JF= ":H$7PZ)!
MPP(/-D9A:G&#M0WAUN4*&>,VH?&Z!5XNV$VY]@[*R@WG?UTG+GZ)];E2;'U&
MNQZM=+1$ST32 +S$H$"$((F_Z:]HTS3O'ZG/5\>NA3*M!<Y0DZL,VB.CJ2W,
M!.<=0H1LS-J&AZZ'5=I%:G>"EPQVDXJPD429JO72$8,I*BE$"%8G<K3;X.D]
M!/ML\#3X@$:#80A-;ZYBIOZ7$[5<:@Q9%T%@5UUK=0OVAPMVI FG*1<FZ0">
MO*X2O"D.2G3@0VS3-.\CV&>#I\8X2<ZV9]Q8RVA>'8O)(4M9<5 \<)"PMN%D
M5[NV%/Z# ?O9C?BNI^3;H,OMH7@N9"J5=E6?2XB*U=Q:%HV0S !DT"A<3+K6
MJUD1<7X76/CO]K3F#?/'-9V#EC]NCS_F@K:BN&2$B"P5\ QBJDTRR,L'H80S
MMD@%M1^O6KVJW+],0NPC_9M['S;^T7RYT6(><TB1%2G_\Y0N-/0&G<-1;SCJ
M?,8PZH0#NN_)N+,?/F G(@XZ(TS],![W2@]S9S*L\*GRMOGV:#2B=3U]Y>$(
MQW7UU_$]'=B[O;__^8K(SMX(PP1'G0E!LU.9HD.W/!A..@<8!C2IY:A_TU=M
MUO4"U_WX<#CNU4%\-,(^C>8'?#P9'CYBJGGU[-H*8ZQOL+;QDSC=2+R#H7YR
M>#@:?B)2G&#_<^>_+N&P"<&]R0F$,!*\TMZ5F)$X6$DGN2L7.6SNUAPV?T^I
M^NU?^SP=_&<07ONC%P<OY1MZO[>OW]+C[V'KRZO]M\]R[\W.JW=;\M>#MZ]?
MPIN#?_6WOOSZ_J\O?]+U)+&]L_=I^\N?GU^\W)6%9B4&RPP:8MQ4(O,F%.82
M&4LK@O0!+N6N Q20(CM GR%P3@X[1Z^+-BBMUOFBV%P[^[<X^VC!V9("LY#)
M[<Z0F,M6,A45UFDS)OF:XS#O<Y]C?V.OWZ\+A$P0&<E]XF;LE%X=\$Z=]DX8
MY/H-[W:&I9..C57OVS,&G1<[3\GR#/-1FHR[U9 =A!&Q6WW+I_N]0>AV/N((
MOS=BA19'\UF_[P>:^(1'#:5VQE.95BU;?936S_B(UDSG?S'TZ>I.'JZ<FSMT
MV<-#')U<1VH4W_A^FQ!Y,R9$K[OK7;7XV\ONW*'=VQP0GXSI4NL*[?S^ZL73
M5YL[G5\ZSW]_]?RO=C O-Y@?]WMIO_,QC*N6_- ;'HT)R)GXH#^LB!OC81@U
M N->HZSSD_KY9D;Y8@>Y&>;?1W<XQZ?S.L*"Y#TT+@7-^!;FAH.?T1/2+(]6
MZU%E0V]P%*;VY'3.-_X11[]L?/_TJ:W9KMS=2TL(%WZO,/Y(^YB/^OBB'+OU
MK_!P2',]V-L<3(4$7>&IS[]#'_W/_C"]_^'DPQ9]YOO=8B62FG/,*E(*H+QD
M/B3%-/G33@0O<R$]CV3S#VF,)Z,C0LAT=AL7^=0E'XXRCJH[W@^'8WQT\LUC
MHH?#?OC\J#=HUEKSHL>D ?9Z S9UO!^=@<;&99\^_/AC+T_V'WE/O*IJ^.@X
MH>KX@Z>/BO4FLC03)Y@^!K"NW?D/\W5QQ<>TDE=ZY=]=K%NWW+?7>F^NU4E8
M^K7Z=>GU/1E7OPY@%GK7"Y(A_R;GL4:(<'0[,6RWW&*>%X;XA5ZU$9@3*6<7
M&B9A3?YZYZ=_#\?CGSO_1+*LV"%G_7^6,2K^O@Y*IFLB'[:QC#6",1E_-QQ7
MQ\#M):K.(N#L._WI637PHW'UX[>F48+QW$&)JTS]-_MF4TE1)7N-Y8^'_5[N
MG-S858>*E,O)^\\MI;NIV%WU[,VX&V=XHF==PE4]47*39KR :\YENR:^61/B
M?JX):-?$S:T)?C_7A%Y\3=S"M-^F;%C< BR21W+'>%G)@1.7T5?G'O:Z$0JY
MB]R:F2V1FZCPM+2Q?&@'LBY]__<T3>N, QRZ.!5L\BXBZ*!KEB H*:.-N>Y(
M7OJTUM2YK*[ER3YQ;W!$X_;B9$-O/'4XI\\CKQ/'SS]-1H&&OC<(H\^;$SP8
M;P\']2I'Y*@TL5\B+QQ/?H3<[\.#MSNOWF_M_$K_)J#7\:UWK]Z].:A97_O[
MVU_^Y&_?/?_XYLN?8KLWD_5U\+:__=O+3UNOZ=\O^_2^+S]O_[;=:[*^?GNN
MMG=>'6SM_//=]LZ?\J\OFY.:]?5MQE>VWOC:V-!Q:1DH7;L2)V0B2BF%%49Z
M3KS=]6I938DO0]WWY23^]2CT7E-)L1E**C%@]N"*C=[DG#T2N6BM-+_T6;"6
M2NX)E6S/)(^&Q(4S8&IM4<4 @F%D8C)3PEN7O2RJ5ML276V755FOI9+5IY+S
M*_><<8@\1Y^$+#%I#R4HCREG$Z(47G/MS0)'S6;J]MP*J;2\<3G>F)$@3J+F
M-B;&0RTN[@HR!T6RF%(( E4"21+$Z?E"(9<N]'-?"*-UV5J7;3:O5T0ET*@B
M4RU:J!SH' @4 1./GO/=S<4\M>DF5ZN$ELEH+V:4$*]%JE %%H,(M6^\9$Y9
M8"%YFBD?)>>9G"KH<N-:*?3#2*%+H)T<[Z#!@\1":.?2&:X"0JU;RFW6ID'[
M LY4B_8;"*'L/*F';@GQ>Q7M?)?7@[4<+;.Y=B_4F%G@);!0/)?:*)*S2'#7
M7>Z657GTQN'^(U1"^_ZP0GLP^"8)+7"%UF:KI"8:LRI:%W@R/A93?)JZ=FW$
M^>'1Y=9<Q%D*)X$;R1*IV!HK(G<O9E-+1 :;LZH5V]<VA.YZ?FVV;$N-K"XC
MH+0>DT7D .30"*<=R6&('H0E*U?:P/%#9839P'&.F$!P4DVT"!B)7,=<L(YQ
MC$[))*W*A1C!=KVY=IN&EA%6EQ$*1D_* +0J$< E;VU(R<@B52JQ^$M7&FL9
MX;XPPHQ&0!LQ* D,+ E"*"B9\Y!9TR>>;$:BWS0:0>JVY>0#9H0 (D47 W<J
M <\N1H<.=; Z.&>R:H.>=X?9V: G1%-BCJ&6!(X,@E,L6$C,:)UB)F&?/&%6
MNRZH5:H>U&)VR9C5)DM/>BX5 335!-_,E;/)\Y)3\JD-7=ZA+SX;ND3P0;N$
MK(A:T;N$Q'PN-7Y)>-7)F1C5VH:!KK*K!-H?H2_L%N8=3#>2$7R939B'358B
M6,S..PZ^NAR.5":H2!HC*5/H]MNPY,.DPI=S84D1,NF7RG]69P;:&.:0>Q:D
M5"%A3A[3V@9T#;<KU+"F)81EMXJ,W,0@<O$F0E#H%;FA7"-F(#F3;!N5?*B$
M,!N5-(C<)*^9<F 9F$BJB$P$"[% (G7$E9&5$-32TEE;0EA!0BCH2Y$NJZ(3
M%%^<5,:8'$D2T'T+:(.2#Y809C<N ;0"B\Q7-PE4EBPXDUGT/G!,8"2*M0W5
MY7#M%@DM(:PN(0#$4GM'*TZ*H&09IG5:71*!Q()+;4SR[B [&Y/$F+TV*C.I
MA6?@I*BUT@JS06OA@C4>P]J&Y5UZ5HO9AXM9&;/#",84:T!$35.OG 97M"Y<
MI]#&)._0$9^-26I;$@^Z,)5-9)""8-'(R!1D1$N\FB*L;6A%RKOM'7N[D-L9
M3NX^4?)'3@LW.DO@(2G-(4L9N>1>HXV:%V\,M.'*A\F2?\YG41H%24?+T!%3
M0K# /*K"DLJ^&"[K!OG:AE1=4-<^8G)9W-VCK=@?F$M4,NBM%RH)!(E5$J$D
MAR;E'",O[<']!\LELY%.&:TTVF?&<^42S36+7@2F;$H\^0C.8,,E7BRKTVO+
M)0^*2Y*&VEX&E*?O?-!>\12<QA+0%^M5&R1]L%PRHTO DC]EBV BF,1 <&2A
MEA>22=LH( :M>9/+#7!MYZWEDH?()3$$#Y@%Z! !T'D5A0"1LBP0399M?/7N
MT#X;7]6!E^Q)-#BE P.O/?,<$@M$]C&"+SK4AK.:W!"SK$3M%NX/"NY2>$A)
MRR DA^C(]3"R<"=]2E;RH-K0[!T&'69#LQ&$+UQY5IRJ);ZL9,%8PSA-E@>"
MO# 5[R"[-('W!>^WG4RZ_.Y:"Z+RWS@>/^H\_W2(@S$VG5I#OS],83+M&77<
MC6]\,S6K%^@ ]K<EJQ=MU7IQ%?-V&^W*QW&,LC4],EI=()L4O#59^.A$UEFJ
MN'#XN?;V/EZ'V\/)DY-5N#,\[O$U;JGZ4E3]9BX^K$AZ@03!D&?'@(O,8E*1
M<6$C+TXH4T_C&-FFJCQ@O.H@E%!6<X$%2%YY3_#-UF6E32C!+QSB70"OK>Y:
M'IAG [1)*H]6JYJ FAB8Y%AP43-0 CQW2CA1C\-V^4IMB+=P7C:<":.V<(.Z
M$):-B!Q-L &#\M(X:1>.LK;F=^F(G0V#.LM](;!R6=NZ1YV84U(RY7/.9):5
M,FYMP\.U]U-6&*_W_3U^A(2>J4LXWY>]Z0M=Z2@-QS,M\=H#T\LNA!1<L<3G
M8$P #<[SJ*01&J, 3-PMTZMJ5=JR.#]]=;EVZ#7/WN^&I+DS-I)**Z3-$@DT
MFD'#0"12V^"RP]*H--=6,7K <%;9R%KBT,;@018;LR7/6QBIDTT&U#*=KA:Q
MET+LJ5]5$?MN<S=K+2.&P%*HA5L=?><M#RPB@'5(OG.):QOFV@=^5QBN[7LL
MYSU^F$V$WW" H]"GFQP=#DDDXJVUN+S<?L$%+2[E;6P8M.^QFN_QPT>2,$D1
M ]+_KD" Z-$%6<MT!:N33-#FV-R=2)FKJU:D"%@XJTX$ Y#((JD6YATF9QQ8
MZ^W:AJK9N<MJ)K&*T:0?'K-"%L^3 V%M@!!Y2+QPGW6QG/P-]&VBS!V& F83
M9;)57I<,K"#6NFJ>\.IC8#GYDJ4+3NH*6M\5UP\&M&<8+P6YU\-1/W_L9>Q,
M;NHTXX(I3=-A>*1HLO+P*/;Q-*WIWO;W.KOM]^+]O98_0*O"_V>/S&6:(VJE
MH]7!B\@!>(E!@0A!VA3HKU#MV<^':5WVYG)[@N+5B@CF>$ &04D6BRJLIG>8
M LF8>D!>BJZ5\_N+-^*M+TB]UTH 70(9K$K0;?&,\)LR$?>:"4TJPD9P4F4$
MAQA,44DA0O5>DW/MR=6'RH1SG4.XTMH9SKAT]>2J0^9*J2E2$"1@BKFVCI6R
M:\\H7]PR8<N$]YP)T0GZDX1).H"/V9= "L!!B0Y\B*X]=_M@F7 VX4P4[VI8
MD @QUA31>NX6D<6<0D3ID\9Z[M9TP<]O9[9,>&=,V(8*VE#!TLV"CLH:5UL(
MHP/D/CJ?K8^8M3>!5'*[O7-WQ#UWA+IDY0T@$]6/AY@U"TDEIJ6@V5(R1)6)
MN)WM*CN_O],R=ZMA[SE9130V>^^R-!:,LL$G*5P)]"4GM+G=U[K#R.-<JW.K
M/=AB6*H[TB!KMBN7P%!C,<GI6&KH43C9Y6?L1K=L=<4MN5\F@3[T)%=I^;E?
M"QS.EE<^G/T_4V>Q$QO/L3,)GSK#T@F'AZ/A)T+E!/N?._]UB^$_-\L<KW!\
MU)^,7Y2O7N[TDN=\W<78Q=]3=GG[USY/!_\9A-?^Z,7!2_F&WN_MZ[?T^'O8
M^O)J_^VSW'NS\^K=EB3F>?V2F.=?_:TOO[[_Z\NFVGZV1]?[_N.+9YMB^UW:
MS3%X'R R3E-#1.$3(R63F-/21">]UEZL;?#U\PXLQEZ_7]=!&.1++8[K1D3:
MQ7'#B^/%L^>[:'(NT=2FKA@9Y'HXO23#LI I<82H8UQD<?0&G<D^=DJOCFWG
M,X;1N%-GM5DU] WO=D8X/L14N:K_N=O9#V.B(1S0KU,_C,>]TL/<H5\F(J_0
MJ^\XP=&@F69ZQQ<[3SO$4ODH3<9=^HXF<D2L6C_WZ7YO$+J=CTB,]MV;E='P
MH+FJW_<#K8:$1PTKGE37J(4VZJ/S1ZZF#U?:S!VZM^')<JNYMOMAL(?C[S-6
M3ZW QC_BZ)>-,QYLC,:IB9L:*C(5_7 XQD<GWSS.O?%A/WQ^U!LT?-^\Z#'=
MZ%YO<&+WSJ#WQHA-'W[\L9<G^X^\7W=:5>UWG$!R_,'31\5Z(PMG[.[T,:77
M#?AS'^;KXHJ/:26O],J_NUBW;GE[K>VUMM=Z(]<J8*%WO2!1[1)9Y!<^5>BY
MYY[A@B>LEF.E?/ G=+&-7JDVY_=1-2B3S]W&6/S>#V1K_E\X.'S<>?Y_1[W#
M:GL6R(1[N(/U# _)C/>FAYY)/C3#].1@2%?XI?GE=Z.SX/*[TX"[6^B^?WI6
M=0#I)M(T6U-9-?YY&2OAF\C:)5SDNUHE?J'!JN[D(OFBB]SPCS9PHAVXJPT<
M;]'8HK%%XXH,'+^,#CCWK,95AV3E#E/,A#%NHEG]TL9RU1(@SA[1Q1,@+GW_
MJ[)E>.VC<$87IX)-WD4$'70T0H*2,MJ8P=ERZ:,0)]Y1XQ<]&>13G^C4AWH@
M6X=#O?5Z\_/6E_W]K7>_[K_827SKRY]?WAS\Z^#%;V\^TF?#BYTW?/L+7<<?
M,UN'[]Y_>O-N\\N+WYY_INO5VU]>?MG>V>[1=<+;=T_H/O<TW:O:?OWFTU]?
M-N<;5GE,M6 =BU , YX4\PCT!8(1P6#.D:]M*+FL9MHKDT:PQ .N]S=+X/IM
MN&V&DDH,F#VX8J,W.6>/1 ):*WWY;E4MY)<.^=GL? 0>1(F"&:S%2FFNF#>H
MF?,Y$0L$+5-S<EVTD&\A?\:!QQQ]$K+$I#VM%D4&)&<3HA1><^W-I9/;6\@O
M'_(S5MYBDMS*"G2?"/+)U5.)A@5GT%KC9&H.Y,"R*E7<%\BW3DSKQ-RT$_/M
M%@9]W\?Z#='<M[L8+<%=DN!FT[6]<EI#LJQXA[6P1V%. %F@Z+B(/D?K<&W#
MZ!^-X%I-<S=N3 OZFXA=S*8])^4LY^@)Z]PSD-*RF(IDW(6D@<OB+7DR5B^K
MED^+^@>%^J5[,BWJ;P3UF]^C/BA9M'*%>><= P>&N>PY2R;SJ&H 0V1"O5M6
M$X?5ZW1W#\M[?9]VVW8NN$E>"UR15Y^MDKI6/%<D?@-/QL=BBD]37EOZ/LS#
M/]]U6Y2W-;=)8TCG6 .>>>NKSE'DW6@1F$(I05N9?*Y5!+K*7KMOW K71/_A
M<8W2DD2QB!P 3!!..VX<1 _"DJTJ-[+9TN)Z>;B>WXDA^(ID6"B1,P ?F#=<
M,(^!&V]==E%47 M_[;A%B^O5Q77!Z,E*@U8E KA$7FM(R<@B52JQ^'9'906@
M.V.2BY?HL!B&M;40\$@@!F.94%9X<"&JHM8VG+EVWD0+W-4%[M*%]F(!A-8D
M+P_7LQL)3F:9'.?,":486)UK7D1A* +H1-**FYH<T37N(;<?^N&1O72IW2+[
MUIWHV=T"YZ5S0B KM6<S<*59D%$S#=Y'A\X(H]<VH,MEVPCP 4-[Z6J[A?;M
M0WMF2T ZP;6-D7F=) .G-8LH-$O!"S#@C*L= PG:?+[>\-U!^[:;T]T%,+<P
M[V"ZD1,HE]GE?-B4)H+%[+SCX"NE.><!5"3_-"E3Z/;;@/]*$]K+^582*)P+
M2K"<:F*#MLB<],"2+S2[)FH?<6U#=D4]^+8R;8I:7"\9US)R$X/(Q9L(0:%7
M2@+7B!D$0+)MP'_%<3T;\.?<1066L^(39Q!X35W0F7FP1GB;C ZI!OQIHEM<
M/UQ<%_2E2)=5T:GFJCJIC#$YDH&F^Q9P(P'_%M=+Q/6,O>8V9"YB8.")BR$3
MPKT)B2QW=,H;ISB:!M>NM=</&-=+U^%M:.&VD3V['R!Y3F"R8$%QLMC"9Q9=
MC@PP:"1QGI,K58DK?EY5S!;9#P#92U?B+;)OW<>>*YI.QKI"F"7K:] 0-',A
M.R8L3:LBDQZ"J-"6[MI!PQ;:JPOMI8OQ%MJW#^V9_0 ("77PFBEE!8-B%'-H
M29XG#M+DPJ%6-9%= :NDQW^$<P!_3 MJCV^NR_=E=CI_X,-/*@8,CFN944..
MQ?N@G8R:JT+00=_N&:PTZ?TYMV< WGI(QC$%5C-0(3"O#'&>LU)FK0-PK)E+
M3BPK<VEECD.VC+ 41C Z.I H<S%@ RD@ 8X76W0P*OOV>,&J,\+L;H,N,3I;
M2R&@2@PR>!9)XS(TO"BN#7HC*B. N7;LHF6$A\@( "A5ML0"!@&XBQF+-#YD
MZ7P46K?[%*O."+,:03GA% _,:(FL-O1ACAQ=\I""%389(WBJC,#]M8N_M8SP
M$!EAZ5Y#&RRY;4Z8ZW1K2>'%4EC(A?P&ZP0+*6<FA>3%A&BR<VL;IDN:L.6$
MEA-NP6]H.>'68PFS>R/16)UY2<Q8)1@DX,Q'+Y@05B!D52O%KFW8+E]:Q8&6
M%!X4*2S==6A)X?9)8697):+VTHK,L@!@H,E["-XFEH@K;!8Z2+!5*?CKEXZ^
M+5+X$8Y@_(8#'-5VI</1X7 4)M@>QKA1.:2+M%:66F,=#!AG2@[98@Q:\9AD
MVP7CKJGMS=S>B2W6&(F:T2Q)!@)K7K8B>JNU0!UH451>VQ"^S?%ZP, -&0(:
M"US&*G%Y+%QS7[2-N3@9H.UE<?? G=WBR) BUR 8E[D6MG>$69"%.9ET]AZC
M,/5 A5^E-(\6N,OV-8B[0RA)Z>0@61$44;D3(G!P(B3>UD]: >#.6%PE2MU_
M-,SS9,CB<LVB384IYXL(.9CD:_*E;E,O'S!PERZ5VP+,-P#=V0T#$L4)?6TA
MDZ4FZ()G(23+M%3"FY2B+F:9+>-:Z*X@=)<NEEOHWH2?.QO7!R@H51',DO%E
M4&L*>.2.]')$8R!(J6MY,]&:W0>,W:7KY1:[-X+=V4,-#D!8FA0M32TYFI!Y
MF1+3CHL<-="D1L(N7R5?]T<XTO!Z..KGC[V,-W>F8<%]DNDP/%(T67EX%/MX
MNE=R;QO9G=WQ??%&=LL?H%4Q V>/S&7:WVBEH]7!B\@!>(E!@0A!VA3HKU#M
M"9"5MA!IODV$@<A=\8Q, QX7N.2:Q)W(J+6T63@QK8(W7^#R!%!W0:#7VAM>
M J3O7T;)31']O>8SDXJP$9Q4&<$A!E-44H@0K$[)N?;\RHKSV>SFCLT^2E,X
M<S&1X,V:!&_0D9&I C2\AAE"4XM;S^_+MGS6\MD]YS-T9*]=$B;I #YF7X(W
MQ4&)#GR(KCU]L^I\-J//T#M=$OGN1F3!($3.@A6DSWPPP6C+<ZJ!\ZXZ(].^
MY;,[X[/6^6Z=[]5WOMO\Z-NF]]E]T:S!RV"!>5_W5K@C>B\(S'A1N#$1O0E-
M>K2=C]"V]-[*U7O.:$MWOUM&N_6 XNQV<<H.9>"%:5M/?#@(+&(L+)-''J0*
M1A2LQ\#4&0F6+:6UE';/*6WI'GA+:;=/:3.[Z#K$9)4D#LLI,\@B,A^)X:*5
M8($>2K942I-G'&)K*>V*&0"_3 )]*/V;>Q\V3H9U^^B AB)-?ZZXZPV.PG2<
MZ6DGMW8\""#7K::!.AR.FU#5HQ'VZ<D?\/''7I[LGV#[FQ<>WS/_^I(0Z?:.
M)N>_9/;.;C^A0-9+ZC3_G4QU,W1?;ZJ9+KJ2?C@<XZ.3;Q[GWOBP'SX_Z@V:
M]VM>]/@@C/9Z@Y/9K\,W,U7-#4\?/AX4[]:]-75<CK,VCC_X>,C6FR&;67W3
MQY1<!W7^PWQ=G/O87;RM6'>PV-N>F<-B3BWKA498S3WULE&>E5JB#6IJ'X-C
M)II"^CRH?_-U?_1U'/:0Q1&&]^0A3W#T*/0_AL_CM5^^N]4#6KHSZ)\%[O3F
M-_X11[]LS%Q0\W6&6$Y,)ACA7;%6"@C<N2RY\V 2L6@.44U% +T&\Y-JA3.J
MG+&@BHZ#K0FO&;@)SO+(E2_B5%(<$]H2W*+O5<,?:1_S41]?E%?X >FZQK^.
MA@?//]'(#4+_Z=&85@F.QJ0C_CT<[/V;2#$_&8]Q,O[GY]]PN#<*A_MU53VA
M 1_OU-G9H:O[9W^8WM]3$?'VKWV>#OXS"*_]T8N#E_(-O=_;UV_I\?>P]>75
M_MMGN?=FY]6[+?GKP=O7+X&$17_KRZ_O__JR19^YN1N3YHHFG@E9$R6,Y2R:
M)%FVD<<L$JF^.+L*P"O%B_/(/4+F*F89!)(V#$)Q5'ZM@R3-#BM$1T=XLCQO
MF;S]NM/J*N0-L*[=U5CV[Q_32BZ=N]VZY;Z]UGMSK4["TJ_5KP-<]7IN>US]
MNN+7D!H+Z8>$9'-&M^-HNVLX+']S5^<***%7;006##7\0:YZK73>.;71G66,
MA[^Y_.FSE>9T:.]H$*NF88VHZ4Q53>=&W'"SKA>XG#/\S^HZ,[5^AH&.88SU
M#=8V?C(_GZ>7KX3VV]L3GL7ZV7/TT[,J96AY]P:=K5Z_7W-)?E[&4O\F"'J)
M0,5=T8)?:+"JS%_DD, B-_RC#9QH!^YJ \=;-+9HO%DT7K66VE6'9.4.@OTY
MZ$U(I?PQ"1,<WT21M:6-Y*HEFIT]GHLGFEWZ_E=EB_+:9WEC,47E>@(_ 1@M
M0_)H;2!L%@OQN#'A9?+(CD.,-<+XE#ZH7L+KWF3_Q(-Y_BGUC^HX5BU.?_-.
M^/0C[%@>]K9VZ+WD<_7VV?OF<]_L/($W!_09._W][9WWG]X>/%=;S[8^S>U8
M'FQ^JM?]9B>_;ZYOY]7^UK/]'MV/>/'ZN7BQ\^O!FYWT<>O+\T]_?=F<.]4E
M:F7-F#236/N.6JE81+#,8TBI0%%8U-H&N*Y>6G/AE<ES6.*1_ON;QG!MCO!<
M9"L<U$/_P)V/-MH V=N2D_,@+YV9U7+$'7/$[$DI2"H)83U+WM>.7]DQEU R
M&U5*(A1ON":.L%VQM():+4<\*([(GMM,_!!19P!,7MHHR+R@*ZE$GB^=ZM1R
MQ%USQ&S%/>( )YUE66K)0 >L!\,3*T4D)56*217B"-45:EF5N^X+1[1^5>M7
MS?"ABUD$;DDI90.":- K';/EZ&URJ<C=S<7<J>WA(!V-1O609;-YT7+<,CEN
M]@B.01=++,AB#IP!%,U<UL B^<@I!_3*D0XRIBO=C\9QK0Y:[!2+D]HFSD54
M&H(.WFGNT 4>$D<G0X/[!5RD%O<W&B.9/:B"#KS0GC,5HV-@,+- NH9YTJ^"
MO-UD?3P.DMP;!^A'J)WV_*C6)+CK-O /F]*\"8IL7U %/!"9>2N<Y<;48P]:
MB\M766Y=NSNEOZVY$+$2 GP2DOGB"X. D868///29)]\=D*%M0VIN@#SE;^N
M=K#DGIYV>^!(+\%&%4R2.@$&TL R.@,F)!":FS;0>^^0/AOH#8*G;(-DR*N#
MXPMG04O+(DE3%4%K4UNP$=*U7U9CQA;I*XATD7(DP2N-< DD8M!<*.EMCD4B
M)-6&:^\=TF=L>HJVT/1YYAP">32IL&B,)>!+#V"SQD@V7;BNO_ZV;XOTU46Z
MY+QXA2I:*P&"=BJ*D(%\6BNR"J(-1*X">F<#D3:B\I[8E_279&"+(#O-)<M<
MZ!BC3#ZEM0WENG9I#91;]*X@>J,0$KEV)9I863LFI4A^6U>2M]K9-IRX"NB=
M#R<B(#HOF%?%,I"F,(=:,0W:$**]SA::O5*IYTLUWAU\?X1NQJ]Q7,\]=_X7
M#WKCPWT<80=/Q&GGS_4_UA<^=]9VD+DRK:50 @^. R0.&<';6--0"RJ>)6F4
M-J1XORCPY5Q($0P43+DP84,D]R.3(U)[OEF)HB014I2^%C,44J]0NYD6Z,MN
M%:6$XC%D[W,$;6.HN6%2%ID,Z1?!VXCB?0/Z;$11D+B)/ K&==8,LK7,N8#,
M&RNS].",M6L;NFOU*O65:H&^[*V#)$M2R:'7'BPW01OA-&!Q7)]8]#:@>*^
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M5XOGM[A; '?#\:4=AR4@K1[_HN]F(;=U&O3_XS3F_PI#<_;KM] ;U*MML;<
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MLUWFN9&?N]9W/P;K$ O&Z/3J'06=WSR_@/Q#&,J>53:<RW_=LL .;1\9JL(
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MIW#!9W$Y?'&ZZ '5JFVP=^(E3O =]J&N-9L/BV<1VF-E(6=6GIFNPUS3R^/
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M//#5F>U%X,''H>?[-L^(P\F.;0=;PHG3UNT<LG[_D+V&$_(ROYZ5Z8<+"A7
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M7H+_0FO"L5X-P'KI&_M5([>HN_NO)WR,+EIZB76DAJ^&UVY8&B!EKU2=PC*
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MJYPTKX(W;?N-J6WQ)/,#21.8Z.2!FZ?C[>&KO,BQ3=CBG%\-C(2N71Q(IRC
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M?==VK=A,W,@SO9!99N*X@>EE+$R3T+63*/CN1\=:T@A)'C-'<I=I@0$4%TU
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MN-+Y7.F=_G8]7-$V[+!^HV3!];P_T [T78/0K[QR^,W@)X?;!9!6[O*ETK5
M.A8:5NP9862W?D9D-Z1CL1<8ENVWY-.VCT1XK5*M5^T1G(<ONS':(>J4QSC"
MG=HI%[^__?EX=/W;]<W;BXOCG1ARIY8W6E(V-+KX730\6UU3M+:*]YOMZ37
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M,BF^;[AN&V"%O[$X33%'S9,:6V1-9J);36-D"A>\K'1)5?I2>+FBS%-3#CB
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MVK4Z,)*L3] K>F$8Z!(]H@[Z0V6ROK[J&$39?#O%\<+U!IYS9*YE/"W%F_Y
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M5<)+ ]3.60;?5J*OKG0?@,A;E" _?YN1T@KP*\B;/VA21AL5I'//<(6+%%"
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MJ--B@@!+0'/'A' N@HDD#T0;#/+O5,*IFRQ T -N)POB';>H+Q&<5^RHY%C
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M]!HYO:K8M+\,5,^<7B*_MB:C*:CP'C#9ZHE<++G(*K3"*EDHV_2<1YODE"]
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M9 &X0<Y(S!)2V@M<= +,=8(R6M6NU0=0?MI3 *FFZ=,> 7AJ*YJ>HY*(Q3'
M3,&H%KRC'Z ]04WTDDUGXH(TOK+&_;O+XB0IM9"S1*GZXF]U(_(:59Z!L -S
MZ9TD4:K6( U4QNKOJHF2V*MX;_Z#BG_WIN/5ENQWH4P]:;U^$YGX742EC =,
M!I%LO*8CXO4]QVL%UP<HL1"$&%,'_$0;1J-)EK=2U.IWU/$^(5" '<!A)]D7
M :VLA"MF)9&Z:.0D;P3882S.>0_,'[3U*N(V:/D MUD6=0WWZ"%4\6V+,HFU
M"!*7:\43EL&;9G 9,E*AT*'S@(A8+<68]1ML\1D,W<C?IF27@6"HYK"O*TU!
MU%B. %<N4+AU_&Y"I=P8*TMTG1!ZZW$!\LR7"J'[[I6LG)X8<OW](S5XW@&.
MR:KV32J[/0%P9YJ5<\PF\4-AG3UF3 5V#-ZC'7Z%.8.Q/H8*.C  PCRP;"O9
M64#! QA+ 0O-5?+KA)\0_9&1W"JD 8 -A/V342HUD$%$EH?,+&HT=&I@0+FN
MY+1)FL14TI5KE9YV _".M,C55:.= B<31\> +*JG":;>PBJ7F)$Y:/P:Y.V
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ML5C,C4D&YR#8#%;^Z&$!EL5R=*$$8EQ,IXL<&/]<O+UO*!^0$.@W4YK@+$"
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MH@Y_DB<S'(Y]]SZ>3-\9!J[[S5V.MC7T@N!>RU[_G>\ZWV.S@7T_&/SXS3H
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M YEOP5/C5; <NM3B8@$M?\U\@63@L#Z<1CUOY'XHEU]?7R58I_1LOY1;CCZ
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M_]E<(EL;&63FDO.MO8^P#5NDL"9R5Z^9GA1%%54 OG" ;R+@&_7RI*[)524
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M:TF;)I4J4WX6JHW*Y"*DB=:DW!1RZPY1?VSG7Q&1CQB!&&^A(&%((#-F&Q=
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MO%VIG4_5X 9T1?H%!S-^J!6YC>(!>X47L01MZ%(V)LL5]4G\PV9$E:Q5"V^
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M(Q0L(S[:?E;T,;B_5WBO%$@&=$NH3I_Z]]2?RW=0FV=:+;R92A>G:;6KU*A
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M^H&C'(H!2K'] WP_Z N\Z@=$7_UP_=,I'ZC 6?"#SR]_^3]02P,$%     @
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MZ_I5H54^D5Z5)#)GV>A$.EZ1D*'W\;A3TIAH>&@=0^T'<4Q1U@.P\U:4-J"
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M2Z$?VP4=#\G,G:%(2YDV,Y+7]^FC<% L!E8H.JI;=XIYE)YEYT*2A>O 6Y_
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MIE1T!,]7IS!H)J5PQEJ>BQ&'^%C'[@B=JG)B6(^JV=2?4GUM+SI]VE^#V5W
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M&5V]'2#KFTU:=A+HH(>/ZF;;4_%H>#'=,QC8O%[_B?3LO_SA_P%02P,$%
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M:YF&PNNUCLX2? H))%H"*YD2=LG]^[:<WWKVL3&^O6"7\+W3A5G=:T[&&&9
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M8[V&6*3TWCCI'DS-?\KLW^I*=$#R-Q%Q%Z1?WPW]@O-BORBXK== 040)BID
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M]S&AK8L(@[J$BOT%EM&XC@GJR508:EF'VGJ2G4X(CO,"A86ZZZJ49.L6ODV
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M3:A<0SUVY^$P"I.#MYS@U0)L4%9+J)-D(.NH4N!6J-3: #^0HCR2YWT@/=E
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MA,HGP8V\D]R[M)SHX:<< ]V-9=GPYJ8BNRR36@J+&Z8+,G*)K*%=JC ":(0
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M@F?%0&;!2*?)$Y5B(\NF';9CT*XGP5NGOON-6&3/17JNY01*&"0G,;*:)AO
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M_.5/?0Q7R^+ZZ8?1KW^79\&/>7X(SFE]<7DY@<L2\WOBOQP$)9#DRA!C34G
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M"C2.5>1<@!>^>IN&3LC.W[AHH*$&V4.WT'X'7Q8^3X!\C'=5#-P!;*LF,[L
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MJ#&?7HS2NYM)<5_F?V2#*'26P!%\9A[%!0J]<,=)]%9Q96-BKKU_L1?TUT'
M]EKMI3?99D=ZP*1RAJ/1Z$VI!Y91X"9*E(0H@2J7F$ZU7^>Z8GL=]*J@EP8-
MO'9[LW34\*"L)PF\1HE(3H)!Q$SE3-%QQ8.Z-HE><.^40_C33B_'[IWRS/M7
MYHKK3(%$A@ZO#-P39Y,GP#.S64=IA:],L9><1;"3YKME$>RB@5X?C#O@>LU9
M!#OIK?/+\1Y"[Y,4PCJO@R]QTQS0R>1H?D452*::*AH,X_XU9A$TX<(NLCY&
M%H''&U5*;PG(X/ L-((XAF<AI13_R9FL'HZ(>4U9!#MI;]<L@EU$?R)9!"[S
MG"2U)/DR!,=8(#920P(/DAM'99"U'S9>=A;!(01JK:"C9A'\Z6<P_0L-Y]EX
M.4G^(LYN_&3HKSZAH89KG1<'CO/V%N=MT@PJ FN7A]!*>@\2%2"9I 0-2B&;
MM/2.J6BL9R8;%E5V3R8J5,381R:#\<$F1ST)LO1CE67L(,,_6N!2)Y5H-NW?
M;'O)9/@7#"^_HK@OOL/$7\+%='IS_6W>2[UHZ\/HG;^*I=OZ<'2Y.?YR$?!,
M\G$V"#%02%J4:O$RZTJALVZEQR.NI&-3QB1M'Q^KMIQ3#:GMPLSG0VK'T7XO
M.1@/UO+L2HJP2V50.:D&WGH=O9!$E :0TM+YT/M(<E!<Q*A!NMHQE+HK. 7Z
M'HE<S[^3]<6,RDVW#E_)>D[,O55%147FEI'@H517Z4"LT88(Q2+/'H0W^1DS
MJBW"-SZ?$ /ZR6K9<65E%8L^^ZM9K1]&<0)^"@/ILG:6:D*9QCT;7296NDB$
M\8+R9#)W[:>AUEO/VUXX.=;TDWVSX]I6.6R_C4>77V!RO<IE6TTAT2Y8JRF1
M5"<B?:0DJ%Q&M#NMJ#+4I=.S<9Y>T]O..$GV]))2M(/<'X46[D3N'07C)-IT
M@$O3#J4-)A(&H!A:.Y[K]E.V:JSD%';"2;FO=73>2V[X]IWZ.":V;L*QE+TK
M\V5 EQ8)*2;B0XY$>1% 1&><ZS2=H=&!_B3X4^!K_VPZX-"N1X53X_03)AFS
M(5L1#<'#PM^V[="X2NLRF! AUZYR;K24-[Z?"$T:^+*[Y1\I!9%IQ@A7FA/)
MF"".:DN8*PF,W*M0O3SL!6<$'F(_M-/+J6<$,I>T=IH(266QU24)--"25<FS
MYMQGJ!W_>,D9@3MIOF-&X X:Z#4CL .N5YT1N(O>.F<$[B'T/DF1C+(,*%J+
M@:G%1.P V1$P.EEPREE:NY;K160$MN#"+K(^1D8@X\'Q[#5QD%@9@F=)""@#
M8RAG.@=0U;-#7U!&X$[:VS4C<!?1GTA&8!1!94$3$0".2"6 .)$-B0'5)!7^
M7_7VE2\[(_ 0 K56T%$S E<6V[RM39F6!.GSS,]NIFWR_)[]NG;9>[NM]$%.
M7O(2HK+*:DHEM\+:;!A%5F7->)+ZR9R\9[^YCTP[M*E!&U/&7;E Y+R+B_5
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M8#VQ6CBBN [<XP(-U.YL5A/_*9"T.84ZY/;THO^>$LNZK.739#B>K-7_OYM
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MI@QM '7^WDQ=O30(SCX)<+E/ND#L)05Q([Q3R$8\6+&[T.8 K33/4=P&-=+
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MGS9=A-$1]-5-J7G]-)[,E3>;38;A9E:\EB_C/\:C$I9&'>$G7GX8S6 "T]G
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MF[/WOY_^>G+QZ>+R]/W[D_\X_?CV[,/[R_.S]_\ZN3P__?WL]>7-ZD(#I<$
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MM;.--F$Z=JNY$VXZ*$K_&-\2W>(M:8*OHR3%3=B>)V^Q+J,;U:4"'9W<?-B
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M&KA"FR0P8K56.&T:DPF!2E5[V7D"SH]BS=5B9,5R4#\'_(X3U@3;OFX-/'?
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M)GG*M<-A+TIS7T8WY.=0W&V8K]S(\/3;R!=O;OA7K[_H_B)T]#HX-,^@>/B
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MX-QRQ&^-IC1$I5/M9.'#T=L-AMH+5]MMJ*T<\=]4'O3F3,(95AJZ"U'*!K!
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MJ\42-=!N?L+QVU&6Q,R5,%>;\I<U)\W?B0?-')RU%:!U/E!+8F5A#(.OCQJ
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MJG!S\=5\)%U?W6XN=J9LX&YB:^@Q>67N[Q\9I('!.4&T.X8#>9)>A@RG.OM
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MM=5*?,.EX5ZGFN^]:X@%-LTR-MD?;.NT(]7HJ4S ;RX55HV.1YVJ)\XM6/&
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M5D98DOP(F"0H-\V1M-PMS&-9;4,:JPXLG6*?$!HTEW5'5[5*NOTX*4G70)X
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M%S_QK2E:\B)AK5K/Q_R<Y-%9Y9=IYT=>L4OM:&QG]7%#.@XP5"$(3CZ5HO6
MG#DG1]R(*'.".[4.W[D=]V1*RKHA?G-P_DN:$?<VKR[KCW/GX8XD1QQZK9N4
M0BXC>JPK^#P60I,T13;@?.+3UR;!Q%=3AMGD8?L951F.DSIB7TZ;33O^X <9
M[HS!83@?A:Y; ).F]PBE+C=,/_82\&H//J]<UN>FYB=Z6)-[)D9DL0RN 23A
M>!/:#XT@%()9;V1N7YD\F[9]M26[CYFD[*+F^DW#LE;=J4TF%]D>743'*^LK
MDY1ZP;7(#B0@?Z11;O9#"UZ%T\$+)OCB9=P.\IA#3>UTDWB_[,@S&^_$L!HC
M$Z6-;UJ6HSL^NEC3D8<%#?5U8:<:&L(.%=XHX2QY^P@$ K$;G3[T_#_,+/UO
MM05#;:"<?GPHLIG<GK:6JKX7/QOVVT)AXP?]6 ==<'PR#O&++D5A[_;1ZR:U
M@ZW&+Y\?LB.8*#! DFYH6YFN"E__2PE37V##7@P0VS,=LO)\@-=NYI]S<VAC
MH Y>RA0[.SI4_+]?O70&=_F!G*G7@;#B8-V?-45?IYHS3 \^V2X^/5AGE_S-
MLYOQ?(RXXV[SONY>CM^7DS_>V0HXJ)>6#UC*ML[%DM$_,?,]?RI)?C![/G%U
M!\LF60X01+U"+S'QM$&G[X#W<G/$M=&SZCZ:6+.1=1LN;SL;I6"K1['O0;QO
M!0V0AAXZ10\)Y_.E0PSXUYI5MK<A!35.9<F66=W<T,#RT(7QOS/93$!:R/^/
MLSLL2]AZX;5QX@RY'E"J@/,![XKCS@9J/_8.CCTV'3H2L>#4!36]A$CD4ARH
M9M^?H;UO!P%[9!@PBH;S .GN"U[/!5=BO\9?";)"92O%;H_+7JK2>_%36RJ,
MICJYA*(*[Y'U&X LXO5!<B4Q.J/%F6@RXQS<@]+XGG[V];&0]&/?19[+CJ3O
M&2,P. 7AL2^U49GWY"CQ&P,,T/WWPQITE:C]K?:8!4E%8I'^C.*SC*/T@_@6
M^HYN,1T<]\PY$"*V7!!/KX2\#O^W&W;:EQF@" 3]@OF\RHP+ 9<WCG.$B@??
M7QR74H[R;GGH;(*](1[$"<%J$-N>P]8\29I^$:CZF&YTG/^O_1LKAA<^IJUO
M)\ZH_TE'$P2TJ=X=^-SZ^U2=A,X9^RX;!HC?-H5^+77CT?<[6U5277ATH8<8
M$^];+(@/Z:^8ZH7.#VG@/4VK98 \6]!3[//ND_T7B0-[O9H.ON]\A"H][SX]
M%6)A#W-U2KNQ5=++(@(.T0$)N%@P\5\(0%&$J!=I84R:KB(47-SE\"VS'O=F
MD1@Z)M"IW-M70D15M[4;(M4M:I_J6/-B%HXI_:FTN#8:6*D;"K8;G6^I:XYZ
MUUS?%&LN/OSQ5&I&V+%"?J9H\NZC@IE13*!%PP\32NBR )3L2JS_4,W=D3^-
MK!:5:7PE'A,O['KB&J]405+AH0MA1N +4XC/**(5*A%YC 'R@,4>F";!3]12
M#8G6]3/!07BKMM#F;G8^YV\G+J3+5COF//I@\BM-*=<M+1B9X*! /=$. 10]
MND(@)X(G<6RHXX7$Z"KXA6?N[B7<9Y1NG)@+_F0#.__9A-9BHFKBO4-O6K?%
M:77[/,9K9I"";(G.4?UQ.Q;F/D^2?.TN?JJ+MNJZ8K(FHG;(8/E051/I<0>2
MQZ]597XS'G/\B:5*C^%I?^]">\NGTKIYT[$]<;Y5088GKQ#0W]OKMR'4$[QD
M\@25@P2Y1DO >#!S&_#NSM>>7&<[V$MJM2^[['T79R'$%L?Q*BHD$_9&(/=0
MC+>PR$%0'P-TI%V0:D[2BFGU( RQK$Q7E>/T^IJ)L[3U3\_45UZ_\Y2&=/7T
M@R%KG(1V&7HWI(:W=U-TCGH%R*/H![LZ36H(B+:/:TCHFZLOR-B-/I;\=,5:
M<N TZQ #=!=[C/G[VN1X0PFJ#*VP50*/%07RMX=(PK%RI*B\.31>C]#TYN?9
MBM]N37:3>@'F9WOSVB-(C8GZ:L2]KI/%*52/TE[WPN5L^.1TTAKVZ5%IDZ#'
M.U;>WZA<E,.(/LPQJO-= A:$^$87'-'(.X?4@XY5U/U(F_D2KJ6X]@BZY%S<
M!XE \=(-X?KM@#7)PCS+ZD>@9NP?(3Z8A>\Y(1TA8Y,';^S>N3E5/>JX$\YQ
M@H68U>MSB\ > YE'P821\V^%;[DLNV@!F,?%&AE=%X0EQ8FU<Y>]/0[Q#6A-
MN3^SGV1_@DL657-F@"+;^0%6LN[?XX5P6<"1<OY+B#L."P:4'/S$'A#LLC>X
MPCPY+;Q+M5-_<N1?NO5-Y!<':^G03Q=Y(C12WQW'-00*+N^VL3V0?^<V$91M
M_:VYCK]CL*[OELA,\H7I3^ 7J&J_M6&*ZJH60A90(PZKSUXE?WNX,.:[:U&^
M,C)^?:$AV:+4[<$[-M:%=]8#X1<[WO+>_$^]GNXUQL_2Z1M^G?4BEAE9TT]J
MUW>V96<8H+KRE>E]=O)H.P76]T7J.^);T4SOSO<E!FAJ=2U8**T4U0<;%(6,
M[AJJI9QIAAN<9H#4"S!B])BT86-!BCWPZ-_BL^T(\F-*.+\RQ Z(><P[=#:\
M;SAVN8SU,R+R=3^5;?);!K.NKTWB=HA+G;R\T['$22&8U^-DNZ]]1DAY5B(Z
MD5#A]G%*I39AHC!M7QGV.^LKQ?=0IZE ?HB]LF(O)F<8X4--7F3*[]Z4F?!_
MLNOQ4 W\V3R:AWJ5:%)-W.R=D%ZZ.OFD:8=V]1<#-&@FG_0^D&J=Y'W#FN-[
M[AA^;:*4[/:=KY1=5*GXO>DV'RD'E]Q(M,4OQ;7S!2>"&X,]G)M'?46J6.M4
MZT+Z:P\?XWUD_-B:K$ 5ML6] O,R0^M@L=K39^$R_AL7=.*&4<=95\WOW:MR
MM=5[\NUZZ,USX*^8!E5]38W-FWSINY[.\+PA_-D]%?J7[_XBAJ^63J.O[%#&
MF:- W]GZU[%DV*=&O#]^\;/43F'!"TBQ2IB+5CK>HQ-\A&KVIAL2JZ]4['6]
MNRE_6L>< >I?+4-S,*/U'I#Z=TL6&P,$6):9];QNE?#Q2%_QR_$_,'99AW4\
M:Q"]L^UD(A$:]QWR)!O2%-!ZN7?AE1*F\>C@9CQ3L-CF!T7]KUS \/^WP5TI
MSN88PD8=YE?R&/)WG<?!Y-0X*64]4'(HI7D4B="[Q0"E#:>LP )QNYB&8@;(
M!4O/$)BG7L&092&K> 9HQ.U9Y8D;L&IPPK_K)R(,.#G\4%_@_<^W7=U%CGWL
M'Y.,$0C;97!8U00#U*EKL"5>,6W=^H(B,C:Y2)?>#CD&\1[<,EW)%PN@N0K,
M#5.GRIF#7_!8_9]-+[+_9J>*1[V_S+[.2MSN.8-J;28^G%B;*Q><^0C>%Z$'
M[O?"WJ.( 4*US))3)]P]Q%N.V)KLK'4ZOV/O.VM*CX-D(/PGR:CH5NP?3:Z<
M?1@]2PG!3F* 8G,QJQ_4LO:SZ.EB]%/,/OQ""?U;8H8T A--!C?7P8!\8[=8
M^..&T9L)=&#\W"@#Y(XN5EJ$ #*!Q4SRE<T ';O;I^7@I8K$/B^:03H<!& B
M/U5A5Z\;SH1X80Z<4M81PIB#^O!V>A^*GGJ\(%ZIP^#'_]$;,%\B??3 -?"'
M:7#7=0?G5HR3+Y26UM[^#^B1ZF9"C\L4 P36??+1=W?K]RP#5._-1)BR8E0?
MY)NHRN0.$V$4=7,-%)%G"Q@@,41Q^(U_@C!,Q*J%Q0KT(-GT(4]D!QVG0C/Z
MGMWB$NF@O@+WM4NA"YDU"RQ6V(RH)FXM^N4K'MXM2!^W8WL9RL*' OC^0HQX
MM8Y*7?Q$;OJ^ 7@1]9D),7W]W/DAB@9GC-'9XPA+^- [)BVBVOUCT0OT/S8F
MR!!@O'!-)LB0>'L;"V:N_JAK2;I\\Q-DZ_M15T\)S.%;UD>O%XY)5\W%/4O7
MZ<L5+US+K$3%8(C.?G&/J!?_GN#WSM:H[,\1CMQ1AIC8L,L\2IS5!ILV!QK.
M3_8'CL(]@+Q*N!?0A/=+:)?^W$;2; LL_77JX;Z/>J5\Y]J[\!2CPX\U: O=
M^WYD$]/H3H.5K@N(4B5,3A/5.'\1/#WU749TI'!!;GD.%?"1:<,U2:O_;L(S
MY6J'K6737X!6C<##*E0!L6XD,1[9":$+>+IK[K?S-+3VT^#W"9"4G.P]KP7$
M84"$>AZ0F]^,KLB!QK0J%:]$A>HG/&#FY912&7I>?X:_^DV5S/'V7TLJ[9:H
M7TTN$CC5@1/@GY&N>\92S) ;TNOZ9T#]_['Q2M$JD ]1+/0!F^8CJ26 HP,)
M&D]UAD\@^(E^T961C<VORHZ002_YU7^UY.[\.L^KC=,_S&2H(IA& (/;#$?5
M@]=Z\>C( U2B@B:=?TPC83!D%G+CT^=#V/7CXJ9J0E;'(P9!9K^:R&W(>94N
MV GJO1\(B#?]N 5*./A>7X@!EYUW4UA=M'M@QI6[/1X!+<=JTH?8_&$R]'%)
MC7JF0\/I3-#A968H[$6LAB4OSB-9&7Z+I-+7T!U8E:?<L)O<I6C*J[:1:N:$
M:]C=*IQF6<?4;:XOX(9>8 74D2\@O'3!50:(KUW&._/^UF27X<F?'Z;'^/4I
M;U +81PVG5([7Z:/R@^M$2B^3*EPTE#&"\Q"EX.?GJ2+48U'U7?'9(E9<=?\
MR(.J,XAA3W\^17\1OU>IX3S!I^Q26,<,3P<+D_7^WF$#,,L&MBZS()LGC&31
M^?PA@HOTM##2OF?BXTRO_X-1UX?VP0FY+X_(*"?]@6J1)LFE@">IF,Y92='S
MPH T>B;/JGM_LS4?U[<N*O46^W+.IX^BO=0W]?7&R_6Z&O2T<.X.B,:'SJ:?
M1G9>UN"&$"1;B'ID;]H;ZBV2JQWQQ46"6"7G!I>%\AE3M@2DH:\<"K1X7C><
M1<Y.922#U$_E4Z K0&K!"0@96-)!<3Q"R=LAN3R VII6'8=P'=M1D*R /C:2
M7*!<H$]BN9!>*M$G8WJ0QWJ1!19O789<\6WL/9KXN;TK+9'W[:H$%'S93]6&
MJPUGO'JF$ &9+\Y.QC! 1QM[, +TK\U],<2L?DD%9ZXN+)_"Y/KO-/O?&?AP
M[P10@<4#V2=W9,_]G$\-5QND'B,N5$Y2!67(A8"6G]+,\IP2T3<A$'E,G"W?
M0@3_#$0G4:Y40 /&OP,A9!M:#?46$8*;7),@\<Z3LPH!VPX7E=JV"<3IR_B$
M9SZ[SJH#N*4XY8HQ6H'.[\.W]U^<>26;JP4"6].',75(ZNGU6YTNG$1L!!(G
M1[)-@4,ET]\N*Y70LO:NZ@^V3,EN_5;B;I5J>1F96T)X:EH\V<L \2 ?@".:
M&WNQ)Y@5SY0. 19GS(AN6G[S?A%'\*+RWBUV19"'[8W1<D'9%CF1[C?C6HU9
MV.,/TN>'^B&1F#J5\$F\<"=*W'YUVL+)H.77=+1-M%O?<E&R$?I$A-2K0!N6
ML+ZC;WEJ_B9AJP5YB<@ S=!/KLQ)):D>/"T33-8UE3X/ ;:*0GP"4.)P)0:(
MH[C+.:1[17)?=G3.,;!?WHX!"HX@N;.2T+8RO6>%_"[53IG#AID1?.29#IF/
M4..U8[-Q;J[<&BB$R_V3*0K!8:H\B8;M!L>>#$KTB5!UM$PH><4 54:UV\*J
M1OPW6-:=%@0SGJN33KA?+6AUR_;^DOT#;<OMH.'9<E59G3I10N,;U=#C]K!L
M'-]I*<J>_B.8R?'RM^[YSS)_N*$P+3I3-XGC&Z:(";VV8=:Y>3S/Q%[T++Q5
M^/4;W233'']P"8-ZG%O6#DW)E/PPT[OG#-[?1PWKR/M<UATDQ!:WCS@7C2/_
M99)"\N-_7,VP7<JB"E/(70V -_%Z/_DF,;GD2!,AM-&!& _-GC&/OQ:E_5OT
M@]'[\5.OP*U*:YCI!'(&X$.1@PN-TS6I-\:NV.@^U*ZO-3WD<VDE;*OR+GMY
MD\B.E6BRH#GX^]*Z!(G2CZEG[\M#$E)Z<CKE2ZOF1*]=2%^8[@+951+8"TS"
MK(*Z?O].@Z[2^1]%72-HV^<%T_$1S9CIDGIS9 P> 2\OW3>-A]M"%0=<'"_!
MVBLJ&* 6'C1]#K#-P%Z.9>+V01W]WK^;H-K!_!S%P;&B#) 7 Q2#/.8:\37%
MAA2:&)20B)^Z;YM7C>530G6UCOQC+@-IR TE;,XX$/"AO1]650X!OHO+UTPN
MS?Y*J>G!W!+[=9X!J@J<][_N5I,LWDM0\> ,: 2RZQ#[ZB&Y:EFMD['G/UDX
M7_?' +=:,5NWAV:NGB[ 1*:LO_A/(BJL.!2@A%K7(:5T.VS&0-P9H&A#<=)L
M?A1>R;T5B"#PL@4'.,[\5)]()5 DRKE+:K63!OG_7'HE(1J&7*NE/$%\P;*T
M*K^#LP!@B@C5Y\>3*17I1F%A&.^E_='/ ]&+?_STL^X]LO_^Z B(\YWIKR=6
M[ .H^LUU[E*J&+#IAT-/H\BA-22/CE#81?N'@:N0(^U5!RX?4[;EUMP^O^/T
M/3TH M%F?3HIDP#(O-=:3Z5X C*$XFZ_"%LZ#W"!Z&T\)D.,\')@)SNL/J_\
M\RS W,>G_FI'[(G-CGV\Q,\H"B(>M.W'B1ANF#M#^Z!_@Z*IT,TK8#^(2Y*?
MVZ?>"KHC;('A+^1>N'@.$0338W.-$#NP'8" #%6GD9UGJ:XD8?(S&G-L^-=4
MF3)@8KL'Q@-W+ A&A% L!ATKW]2X<J+./1@X/6TJEYM7_K%Q;L>*_1^W<;/
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M#TV)YJJ3:<16H'(\R+;LO_EP%>&9O.O46Z&+>Y2Z^"TSIC/V+Z_\WP"70R4
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M>6LSIC-/6AB^L%,?(H."[3PU@DZT78I?Z[JO$PT[]U#9\Q9R-CWE]W!OXF#
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M.X)>P HR0+_1*.#4/GC<A8\!^B+!2QK:9CH6HP&YSDE"S3! Y,QF6CK&'2I
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M(A17&YX7QTF%<FO,FEYOW'K;U"S\DD,VZ;QFZ<.7Y\^?6>H\#*Z%4D\P0"Y
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M_I,+GI/1"V?K7M].L&.+LGTI_HX5N)N2/K-RYC1K-V3^/;@F;VD]B:+DC>2
MZ\FU&DI'!VNH<#G/7KTAA0FK:;K#84FJJ][H/W0IQ!85C,:AJ2=RNG6QW0S0
M-"\.&U>7%^123;SV7*''+^I@*.Y#PM6Q<Z_"IZ/>ART4K@UPW+>R-OGA^#AB
MM^@$RQ:D"SW52"X QBE>P=[D$5JI/A\.RLK+]D#8 1D#5\-]L_HCG!7PRU06
M*C?[V?KRR<*A:EMM@QBY)IH8G:.7]+@'5LN[+D$4ZT5(CZHG#,5C! )YCP/W
MZ-,K14E2WK'GE"="RSB//#BDS1)KHST[TOZ3B<;:1$P49+XX7P40]J"<^0/C
M-)2 &]3$=)>^_0,^K@R_,HE=]@:%%=9^C!-V*S)<3C-Z^YOT0FD,PRRU+ AY
M^E=P-3:*S@IW;/AHZ=H]>3*\-=M]"76L^EN(P<#Y>V7/+>O"(=%M$_&@_2$Z
M9RA%A0JE52(]DO1P65WNH]^+O0G*D%M9E.MKW>#4HZ\,193@6.V.?@UFQ%NQ
MOT+\@M0V%%/L$ /M%P"6@N!D WE*C] %+K&5B&>>ZEI\3B8U/E_X:J_PQ;)%
MW3,RX(T-?MR%)-["G(1SU=,RZJ%18)YV27MCW-B/0#!X&HA#,T _)EA8S3WN
M\I_[<C44JVI4%A#<(4C6.,%",@U#SN> ^?7_/A.)(>ZM/29IN7S\H>\S3[L?
MZMBM2\X)\/591V<>+"[.W7M:.GUS >^KVG2618H5TN-W!-EI@_$<BBFE:%&O
M$+/"]%F*8:W' 33>) QO[ZO0U)!L[,F=45;6JFK^,73KB$AB58#A#Z;I?8<Q
M;FC)8&\ZI]Q;Q(^#*YE;P4I7 $5PI&O:Y@U/E>P_>HVI%H=4"8-*6<II4W@T
M_3.D%M:#"D?6L??[Q1EJ"+%: C&$TQH0WM"TY2\*+^/.&WJMBXF=:W7;0[\M
M><N;@.!&=JI1;Y3]/=:K;TLY"0\<JZBC09U(RN32#W\<;F,]+70<GF1/NUS:
MZ);BR76W )D$\ H S ZMD[1P;-@:;)R^ G'/5#<ZCY9:"7>N):G7J$^XPYL\
MXK]*I?I*ZF\]3?IJQM$)JRMYRX/$F7:OJD0R24(=;[3#4W1(R>6W*T)D163)
M=[=/S5OOC[JGQLFV'+>CI#L?_I\<'$Y S"*WS'8V*2(XIK -B=^_U#Y%>P_Q
M H<A:SS"E1$RB!^&VO2.873@[5$?-*3V7-7>K/[-@>JUAGA343,WO5BN+8*.
M%%B8 8J90':J8I87,%O?)C#[/!A+W,-^PV[W,R+7&BJ#G2FDFUXTFY=IHV/4
M_OB W'31'-W7%7UY'%,A-?Z8JMJ$R1_$/\MT7N07)V(C+?$IY, J8P5+/!@"
MY&UIXHUT^V8F?3HU@6:&3!6S#$/!<2Y:P^WB@ (YDN);B^>VP5J.G&7R%8'Q
M]]L;Q1GWX@VV',Z<6W(7>QTE^D7JL<NB@A;^S=T/Q>D3\;4M_GEI#0Q0]W+P
M:Z>8Z'=QD>]SAM,M[16X&D,Q<6,'5_]Q9G_ZTM^CG*\P\^^1M:;K&J1T?%8G
M.A%2*_D&E_/M%NY#8XF7FF-P =WL3NIOH?:;J2*_NO=4<@5EDI^5P8@Y3._[
M0OY;>5<:#64;]T>4;$EH;)D66]:2)>N4'H2GIN1))48I8D)1C$PS5,@Z:2&>
MF(I"ELDR1I89&DR4%&4ML]G7N<6XF<4[WH_O^^4]YSWG_?)^N,^Y/]S7.==]
M_K_K___][OM__:[)-,PF\4U%@9A4E,Z\,Y <)0[1F-)SF?Q+&Q)I&7F?H=0(
M9W;9L5V*2H?=>;FFK\RG2J6LD_=FZC0P;J9'N*XT&6YX'4?R', ._E\80^[)
M2KX]RLHVJ!4A&>)<T^0T/_OQ7A_[9_D\>YL*DSR//^FD-$)Y*\;Y7\(*N+^9
M!KI7)-/$8@Q\9CI-X8LG)=V.FKZ*\$^,#(M&' PM&H\V!>FZ>/<F<1W6$.;"
M@[O3<*H4><$5X?,:JOQ("$%^.=WU5.YP&W3QF!3>H&8Q7BG]"SQBM<7S\$3N
M6JTXP4!%RCC0A"Y4PL<A0<L?.'#94PR>(,5A%.\[^ ^7SD+2TQ5;[C@_1L^&
M$%3W<,>+K#--\\)W+YHPSUO7I$TN'KH:YWV\NW?VCH%$I;/6P;(#[<4/7YU6
M\3?8!=E5.HX8+.4AP ]\*]$OG*H@AD7JU60A6U]IEV65WG'NRJC:&KPU-6R3
MG5N$F_2KAP%CQ*)K_[NFU<8"#E&0WL?@*2"$ZKIWFF)<Z<A5S7+JK 9AS=R=
M%P%;53-S07\0QR25\.[P.X/7E%_@&1*HN@[9=[M;>!^Y#G%Q]2/ZG>8:B5QF
M"/PM5%%:1I,?99_C.B3S_I+KKU'8HIE?V<:6$?QUH_'N>$(-N2U\H__1%6N)
M[1K9^]/D"I=X[U:H-N<(*:-CQ[G".A+YL6>/Q(?%'BN)J=RUDQ1389:X?ILS
M:LC"5*QX9(^<.X3O\AX3 "!8231R"ORA6+'ODBE2C[^==UGNS.ZOCLB#V?9
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M\V^Z8!YW32&ZC6+#S:.45X 3IYZ-_V@3CLK9G=":'<[^'+/EVP$UO8L' [_
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M9S8H6/\#>"?<\B H(8><=IYP\OK)W+I(8.^VDUBVG"2HB&>1BZO*$%=$J7Y
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M)+' @!@NO+(.*4*N6@LDQ33B+&YJ02064\/:_T5?IQBUTMFBAH>\QMI>%$.
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ML4LS>.XB[PG?6O1-I"\D4U1%/Y%*QK?.*1\!3^BELL$Y2X59RV#Y<OW'#5O
M5,=C-^/NW$2>.GT$YBCP%.:*=$"J2%:72^6]Z-E)$RD1MH)G_NE=CC3I&\;;
MLFVR'#+G5A-](R(.>@ %O.O@$PX5-)!N(0QY./DH@BX"N<*9K*&IW,DR_OSL
M:(J9B96 $YFV>,!H4L- DC-(#8(/0WF.PI?VMP$$SY;;G8BYR>Q.MBU%V3+N
M60JO3/5?"'LW:-X5;G-&/7TP>?>?]%+RJ'PL8Q#!0LSA(X&D5D(-<BX<V*&Y
M\^<2N"3F]@(S;E^U_=K)]$U5E?DG6G7()\B:/[355UN\\),7#"0GNC=2T4]
MG^<ES)L7J6.\?"1*NMAS'J<1L\,%%MB_Y]\X7BX8;[918W\@W$.^+WK()@L+
M!5#@@\F6>""[_4[">-9:*"/'(LI;;O=Y-=5--E[U[[7BO&X3WUU[J9@BV,Q<
M (T0S83[?8RJHGOVZMR95JLAESQA)@N7XHW=^WA@<.#=Z@U[GK-<3:5KG-68
M2UMWSCV?0W1QYCZ)P!-D+>!Q(C@HS0Z%TRG&H/E*5\D4Q8KZ^#"IO7'/F\?[
MD=&//PTJ)<(-RX)TZ$G\?#%277E-PA=49B&!;!UO$06X/FB48_H@Y<#'W=Z]
M&&7IAR-K'*\/Z2DYIF9G=3-TCH^<>)@RG),QGXJ,*CBT.]"I,.V9?A')Y+^?
MX\$U$V@AUR%Z'JQPOF$6?"WTQPP012WI-%K^J@ @A)X=9Y'+<%2P^\61WFQL
MUFCV.-:[C:*^#BFWH=&%X8,C^R/XCJ&-JYQ5V.===PBS9NL0?1(W6M19E$1=
M&@M']IQ073I'U:*0'I0<XSO^ FY224/3_2(E)LL>NE9AF!=.9&2Y#0^&!^%6
M0973SMA-V-&-?@$,P#\G^D)5=C07_61 ' ^"EK?^% BL^Y91Q!V:I=5:%-_6
MJ%+8TX:3?YXC]^W3NM,?S??#?M'>(GSON&D&)RF(N&=!3>WJ6=ZC/64Q,RI%
MB\B?IDMMLMYG.R&/ZC5XJ9B*NQ0.ZINU(B"B5JHR_"INB'RJ.G^"/J)+;?CW
M5(_EEOK0)T,7VLEVO[URSE[[.^Z ?;&^S=X\IH*B2':*:\;ZAS#;RX)#!%:
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MQ>YCB+@+N=O8VY@Z&U*[V[RU=1)R%Z7YHW<A>/[G90X:,1%'$S,AY6<R?^&
MET1I_C(6-S<W=C<>=CM'<PXN04%!#DYN#FYN-C@'FY.'K;.A.YNM$^U?.GAF
MZF3L:&GO;&EG2_VS;&ADY^(L2N/B8FDB9&9HQF=D8L+'9F3(8\+&Q65BR&9H
MPL/%9L+#8\+/QR7 ;<9E1/,7\2;&?Y5N[^+X]@_9)L8<IF]-;4QMG9W@L\'%
M0</Q?U8F?(K^*O0?3C]<1SB/D!0<63J;/H,GL9]&9^/D8N/F5?UGH[-S\_")
M</P=GPC'WPWT?V"VQ$1,C(6,?X[)SO&?Q*N8.OSGK/W64NP? ^Y_TA=>_4\9
MN""X%]Z[=T^$X\]C^-\GA>,O3@C/_=5EX2VI_QOHMY#?0GX+^2WDMY#?0GX+
M^;]+R-]@KZDM'.NZP4$M# +'S6@H**@HR&BH**CH:&CH&+B8<(R!08"-@X5+
M3$!*0DQ 3$1&R?B(C(*>@HB8AIV&GNDQ"RL+*34'#P<S-R,S"_//3A#0T-$Q
M[F'@8V+B,Y,3DS/_?R;8%P 7'8 B3B AT "(N A(N BP3H * !!0$/Z@?XX:
M$!"1D%%0T=#O86#"&>IP $0$)"1$9"04%&1D>*T/O!Y QD5Y^(A+$A7OM2$:
MC0,^MW]L-CKMTZJO!,ICAW0\1HX!]S (B8A)2.D9&)D>,_/R/>$7$!22>B8M
M(RLG_UQ%54U=0U-+V]C$U,S<PM+*R=G%U<W=P_/=^\"@X)#0L+CX#PF)21^3
M4W)R\_(+"HN*2ZIK:NOJ&QJ;FK]U='9U]_3V]8]/3$Y-S\S.@9=75M?6-S:W
MMG>.CD].S\XO+J^N?^J% " A_#/]0[UPX7HA(B,C(:/]U L!T>TG RXRRB,N
MU(>2K]$,'?!HN/W1\9_&9E=]O4?+HWQ(8.0XAD%(Q[M,?_13M3\T^_<I%O ?
MTNROBOU-+S" A80 -QX2+B .7,N$,64A_KL2LR#[HS"YW$15V>2PSK(O1-2$
MU \V@0QA)(F'KZ7Q 36;I]ME>W%JK[H*PUBI9&-?94*]^,QJZD:NT+I@@$%B
M^[68$#"6$\8$_$^G B6.6#NZ%DHE-H6W$::I2 )(385C$N2%4,;,,^;+5!B
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MIB/"FJ+ME* /*=[GKM,S%L;-)]-RA>HL\56NG\"2Y-%/K<O*AL0[FO63BI5
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M:U"^3P[^A W'&;%-VR3O@/#Q#+=TB^VZ%''O"$GIHFN#3Y$1,=&+^MK/CSG
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M3KX4)TH4/M[DJ@"5GWB"4]5EBHWCL* (K2U[=FM-BH[>2Q>:.3.9V6*:-?D
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MWUA<D:=.Y#%W-OT\ZSM85?0:P.5X 1W^$A$1@UU@4<'SQ1>W]7"QN%)?R;+
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M"!\0>N=^)3XL&A7:E_IHSN>ZNB">[,^>-;P6L\E0/S0-H*!5R)X02IHXV !
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MF$U]=<J9T3)R7DZ"+6P4VOR1XQ4P^+/:1YC:%@9/('HVS&FKG]Q-&V&D+PC
MS<-M,/C7&,*Z6JVLGA?OOH&,.NL[ ;[G&NG>3/NOKGRAL7S$@GMT>CN&[.1Q
MH(_!5#]#W[2(#$+Y/D=<7AM'N+(/O>]*&7H]32)R.EAI 8YD.;V;YO^*.8T
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M!NX]D5>2!Q 0$ !S^!\ 6\&_)^<-L@4 %16 #0  =  9011 A-=(X =/PD
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M!^#L6P.M[@^4BFPP54,6X>TS<RY7H2]H-%$2HDI.^2.5Y%;>UJ^4NF[5?,<
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M</\(_Z7[PTT*=[PF#V@H609?*\]!Y%?O\S2;\ K$KSQ1K*@(?WXVD1N^'(\
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MB?G$A=!"FH%G.[Q"GLO=@U^/QVMU<*4]C=1]J"1Y9@?+H,>S1E@WEG4>]^'
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MG%\ 6B-+*+7$RSRQ;-K42DM,<=&80:V$G'S4.#LLRL%AYE\Y\IY!CEC^/CW
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MIHN3?E+3TR-#"JG:?KO2*H4NY!G']N0P ,C/2AX>X?FL/-@4QXJ]14;P0J)
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M3(E?F%WCY;(U@;;$-BX@)!R\,:-E\_)E=^&9U&6O=03CL'.5>CS:Y[0EDMY
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M?FZDHV:YX'Y55XZU MYH;LJA[-5=;X6 P+&4RTW:);O?M5@_$FN@()J.#W,
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MIF:@4.)D81T5@R-0ZF)&]ER:#:$.SLP?$7]S(>;+L%(+'#7 J]QF 1&;,P%
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MD7]QEN(T+/:K<Y>?D971R);69^9R<JLET39E842?M8=0:M9^MJ=*/S!WJ+7
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M2P8@D&1Z):/ZGW2U^IO+_FV]@-\<>?X )<)C %7&$E+^$UUIWCH,_7#KS*
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M)<GE;2[,H'AAXZME. ^KY4^QS1GJ<4.9E[YFI8729G3X4OJ_9VT>\,OIMSQ
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MP<'&)'YZ7\:6$!M)"$K&;2:]Q_)_YT)>V '/>BS]N-WZ;U=Z^ZB@Z%O%EN[
M^_5O;@QW?^'[(<[-Z[- O,U4"E527$GG[*T*!4]S*)V&ZV>-5LY4LCS8;IP'
MV'.42!?=$.)&^B:;/1KU;L84>F_7=_]"J9-J289A578&E^K]O(IG'C[0:U*]
M%=L@_<J&M06N.53ER1AG.B,I(WOV#W\&R4"A>BWRE?7&=!L2].B4P;4>5"U\
MPL_/K=\YP,!(UDY;3^CQYXW[MXZ,2#8/PW2_L+3T'!\N5!$4$<,K)FG!PA'N
M^>X[PWI[^=[Y[V;PCE!J:@!;0MY_-P794LB6QKN6K>%$:-1SUO:W12R7WA#V
M"?FV=B#\6V7 F+V \4PH"P_77 2[?<=HE\9,,LNCB6XS@JWQ39#H!UQ8@FA(
MIUI22BGT?-DCJ]MO.']W-=[R;)] LGI?XL$-00PTA>C0B6ZNI7]G.2 RZ03X
M.$.Q_VZ[3I7=4SO/<RW'9KS5PH7(T/",L'['Y<7"^S">&KX.1W>@*'GAZ'8/
MC?A?T8TB1AYJU5$PAB<OAFCMMI9D-M:^OVXX./8!;Q"]]G19[*L9XW4LE/)(
M+ DL,A*NH#: &$EA2SUXBRFO;/154NBI2U/O6BQ[64;G/*CQYG-<SFJNVMX0
M_[WWQ(C9W?-J(=9-A05:\Y7H&D>0P=6(@&,5]41A%Y9NX#*._<V#_[>P['\P
M;7Z6!=J H3O/1E(K0)4]HT&_P6Q =!Y]6[X@!79=S&1W(2(\?P1]4WK9O/2)
MIPBSJ</GPP[Y7I/'6O*@Z".U[<48DAK(I94S71D6H[Z%R&;9&6,:'&U5YRCN
M?=TXHDJ'!D\W*[]MO$#QF=]PX4&4I]Z6T@.N/N8RUR)^(ZY0FY!3*R<.0$UW
M)1@5\J2WCL(1VM6K?>UR)UX&Q,RNF\1)?ZN6I:197RP[,:SI]UV]SX3)H)I\
M*-$X.7#@G?Z/,&D>1NM,(TN8U&VZ@W./*,92 %%K8JI%$*0EW#39G=T_\7(F
M(:K,]]5XY\*'8_$[#"B#NT:ZNE8_;]+9]3#VFDG>)K$:'$@X(MZR];J"]2Q+
M$A60WB\(/F-J78\+%XJH5B+N#-K*LJ^HX(PY6N^6&GL[IV:SP38K8^A^K3AI
M#!1RJS@98/UBB/:/.OR ).!CR<@>ECMQW:>K049"94!$FE(/FS_P"7S:^86*
M<V=I&.O<1+G''Z+3RD=D8HO@*YRP:L!U:\Q,E7W0S8P$D%]83LB-D4V9N?7>
MOK0@W9HTQ5V'[S]V;?QJ,">7T&PPO[M!Y(5?C/"M?OF:Y2V_)BI+(JAP(&LS
M7&..]05\7P2Q8CIR'I$4";MK%(XQ)I75VXB>M+P"ZRJ+0,52"_[WJMIX3WF)
MIK'U4>=P0P(6O=ZD9FII GN=Y<!H:X3)<=9YTA!9K!PP/Z\2._]<@A-M-AAS
M\'G7=Y,(&\+X\\LG]B;MN),H/+M]2\68=L[T4TW>+SCD+#Z66IHS<XFAQ<SG
M1"UB! U@^>E\W(A82!5^3U?!XUU=J2;V4T;)+O5:%PF/M?8\,9?2TXH:O?"U
M\*UNK\BHTS3,DD-&:1'3<8R8VO%1ISJ\U*2I)B.@'B?W[6+W#]*&SO/4@%R1
M'?>+)'[[?>_'=\'B+Y+'J8M9TCQ+.?12IBC@ C>KA8F&";2$6BR(U3?_S]9:
M7?6Y='JE_:'5W;-OK]XY8\_US6>M=^[8.<DM4RZR7#Q-Y?G2VL_9#]=WV?/O
M8W^YC_N#WO;L1_TBF5*B:WNBSO=\U5PL_OFXT+'OY4:N,GWGCDA*.DC/F+BS
M>$=920#[R?@/;ODW@A^W_Q$._V9RR3ZYO]M._\/ZSK4VYK7UQ4M^]!\^7RPR
MG>G=N^CI?=&5BP^]S8Q@C^1S8PSLF;\6;>,/I<,CD^__4 56_^(/M_\1?/^/
MB_VW:XW'CXD?RF,^]L@97M?_<CL[E^^?A-S=1U>73]DMZ<:A\)AIOZ/](_/Y
MP&S04_V(_9](F/U#!_GM5\(?\?]Q^_Q;!S3X"!H:.M1U_(_&?X:.>_6I\W\9
MON^0_Q$8 >PN,-3=#XSOL/\H??[-9M XYD=@"<2E+?]A\3_ERK_3ZE\<WZ=0
M_] U^9\(X^]:5]!I*4?R[3>=_ROQ_0C_'XTU]8?Z?_0":R'0$ 5H@*)5M/]'
M /O;KZ*@8E!PS[_3]E^2[PO8?UBT$6CJJ"M'73G<7(DQ0*_]P/Z'_O(_XI<?
MB@,;\0_%&^RD_YC_8'[DS^[_X+U0;%:XN=6SY?E6,2K;'BET*4FR",Z9I<'\
M_R8 4$L#!!0    ( #: 4%9_[_2(=$<  ,I<   3    :FYJ+3(P,C,P,3 Q
M7V<S+FIP9^RZ!U137;<VNI'>!*0)*$% 00%1:2I(4*2)B*AT-:(H38B-)B$;
M07H3$%!X-=($%8A(59'0$1 1D(ZD@")*21#"AB0[=_O>__SG^[[W'>.>_][_
MW'/O&&<S%B6LM?:<<\WYS&>NM;@C7 H@><S2QA+@V< #7$"^ .X"L/&P)_;B
M9> R@#P\W'' '-C \_OY_7W#[X>/]_=W?CX^7CX!?@&!/YN@L!#2! 4$A$2%
MA$5^/\AO8J(B8K__^#W)_SET S\O+[^(H("@R/_RPVT$I(1XKO%X\_*H AND
M>'BE>+BM  J1D?]/\7B __'P;.#EXQ<01,0013I42R+B\_(B0O,C$B/_#4?^
M#_!)\6_:MO>P@+2#AZ#J=9E]=]+RA-2.5#3)GNJCJ^M=O!$I+"(GOUE!<?L.
M#<V=N_0-#(WV'SAH?M3"TLK:YMCI,XY.SBZN;I<\+U_Q\O;QO7DK,"@X)/1V
MU-WHF-BX^(3TC/N96=D/'N;D%Q06/2TN>?;\5655=4UMW>LWS2VM;>T=[SN[
M^@<^#PX-CXR.46E3TU^_S7R?_<%8^K6\PER%UM9_Z\4#\/+\V_.W>DDA>FWX
MO0:"O_7BV1#\NX,4'_^VO0*;#CL(>ER75MUW1TCF2%I>19.PFMXINNS%&WTB
M<NKZU.V,WZK]J=E_3+'(_UN:_4_%_EVO,4",EP=9/%XI  U JTP4)Y8+!-A#
M6L3Y3@:9:M6<.OZV55F("]Q5:U6,9C64T<1/N!3%KQS(<REPN:P4-#6;HC4G
M =T=AT4><@&;("[0%?.:"W24<($H.]+7G81J,J<>G%VZS8&?2#2B_K9CG!V)
M\HRPG(UEE_@1V+=)8,E_=_WOKO_=]3^KZ_0J+"K*!?C><H'(.UR@21E6"C&F
M6;6F0II/7T]M-KE4;O]TW-W[-OR"=[S^9+QM1=95R</M_++KPEQ L)X+=):R
M);C JSO(]+-"^1$F7  6-^0"]Y_BAT$F@PL4=_Y<72<!(&4 NW;,:SZ8"V!1
MZ[C'R+N!_ 3-?V@MT".&6A-!T%0)BJ*16_T#=(Q:8/F^@&K_FPX/V%E#60S]
M5^_#,Z52J6;*!D1$4BL8@()A$?,G8-/>Q4 45![(!6*SS^^,Q!["%>X]QA=D
M;*;>JRX<>#,IN6+<2_"#V[H *5L7TB9%@%>)(VK,KY \%^!_R=@^E/]8 RH.
M1B42]1._-4-!\.0U.A1TI.!KO'Z\MO_F3<>3Q4>W7$,7]8[^G")$@#[$.^<E
M.7FPW ^,+WTQV<38IW16>I.14("JZX;]J,#AH*'SS[L:ES1Y*_))V^#-B*0G
M02P)TC+&#W(!29#R"".'I@K0R8WAFNYL];Y;&.'9L3(ND%IM5GM#ZTLU6X\O
M(;!R5&:/]@G30>59X>2HVW)IB*"UG'S2%0*TK1^9\ A(>0)6&LQ$PUH6SVVI
M7U!-M[.R39%>PAL+/3VK7QO^2C4<TDA6S[$XY#3FE,HS)<.S[F^!-\6=0U8Y
M!FPZC;Y,AM3(R'I37N%U.4]NV<O\--7(.#%H0(I:3XV\ZL\V\B_T+>_TS*IT
MS_?5,KGH[B/:';SKI?9; 2.4)0CM%)Q_^ *1HZ:&0#\];T0[G^O#<!IN&?@Y
M[*Q#?>NCO;MQZ&DU2\L]D^>29*9(E_E"O*C>U]4(_./A;/P8%ZA:>,22ASLG
MT9SGU2"O+WY[+5TC9L' YY:.VH:PILVL.W&J!IW\TRIWS7JC:@67IFP1J3OP
MY,GM2![!&DA NZIK6_TW]-*PL;B+_KO54INS%HM_R*66C<_F&T6_<LCTVKAU
ML^=3(17&CTG$2R,S\*-H&9 R5HC\_AB%^KX.MAFC-OY4;)OH"_&=M#O(\3=X
MV[T-N[TJ(MHR4O^K@OOMF$[^S A39%$BCR-:6MY:A'8%S_D4PD/KP4UE]HV$
M,<7JA4>FT27DQ-9-[N]E"R.G+>3'5 _P@ED/ M/V+GERM# I:![$NG6D:DPL
MB3*!DD7F.8:SHZ+%?4F2MT!9.^K\!K+=)XNGF1?5W]54Q83Z4U6NQIWHJ9+<
MVKRS\>IP.=)_#Q?PUQT#F=TH7KP!3IK3,&>J%X(Z4Y\SS(RG/ZZ@A&L='ZY'
MX<:V+M_CD[O>]M6%"WAWB%VZ;:-&4\W>9-D?P3-[NY@M-]Z2X\66>SH."WT'
MKTA(VP1>+RJ=H2F24U6.CV&8<:H#G=UN<5S@5H!)7[RY;O:=-PW5$('QB^K<
M1)8.T6LB2)HXBV>5,7A;P1'\IH&&Y;%H2FW.U\$S-ZNW15IYH7=1-MSHDOCZ
M& $;?AM.5;T6@@N'W!#Q=Z]P@<T0UAT*54\_^B:S-VK>8\BT0S>:[&I[,U 2
MD[E;)$5&X Q?4KK?5^PX^@RGICX,&7H19PHI/8.'/XEC#M=;0H$O2)%'<[RB
MR\J7X\MS-B^WOVV=KYI+O_+ I%0V98.Z+\\Z0E'X[R,K-0R%P<*\(/U5BSOG
MH8D50XQM.[1[_GB.86%-HH=X1>VFJSIB!._7V"IB-G8).S*:%M([(3<@FANR
MP!<0>51LT]%=W6E_2-Y&^;(O(VX6AZ84@70'#*1>1&RT1?&R;]"SDW7KO2Z_
M,"4%$W'ZE=:G'0;<6G6^EKI_*5LM8W0IJ.\ZO:O1L&\10S^'@;31;>@1D 8V
MZXY@F;:I-HFTX?;D@/Y)M.3/(+1?5,OMP+8?KE8W=#I%]?N/]_-)W'? [OAZ
MT2D";?V=V,4%DM'T,Z0Q9UC8'U$."[FRA.%!C&)J&S&:"R@LGS.9G=P[Q#8N
MGLWIC5FQS1TMO;]W("]R+,S^X/[N@+B#ZJ.3N()O#!3=F0AI!;-E;C)5$?MT
MX[9RXM!7R'+0:7=Z;YMUO5XP-B_DA7F":H:OXI>/.4Q+IKKN%AWF!=R7%,9:
MZ366F0KJY;+SU&__?0;23V-'=>&- G026]J/60W]HNK&-PA!T>)/[NCK BWY
M.U)6:_IMA&O&ECX>/=WQE6 :6MN6M;8E^9W1_#M$AQ<,^Q8N .E$=["EP0ZP
MV@_^R 7$EW6%W?0QDMOH3Q^5U%321+O#_%[<>I/K$.-=IL_8,J]PR\+TZG'%
M,\Y?) 5_!JJ]L8RQV;*KI%MO"W#(KPU]X9TMLZ8!.O1\#!Z=5.TS(,F.AO2>
MCK)C2,14M54-5(<K?9 H_C+>7LYRF/\BS#\1.UF4&^ WC4AQ\";S/2-[+@K)
M>G\P^ DMCR[ZH\]"!)HHAM_]A]Q')W<_]P<!NW45K&<;QH:\]3Z'KFU64036
M24P7Q$?56%XA!:UNI#D.U6<%&X/?6E_7GP\1=&@=7D3?3\>>Z1_T/&Q[;JP5
MUQK6W-=^V2Q-N'TU==SO*PAID)J->R-!NI7]78(X+/.31$_QO0TV<G8OC)^)
M[-K9>O#^V.USO0<2+#2I"YYI#ZVGC6](?$#K(BB2@Z8[$R"=5+;,#-.&D]^@
M$N(UU=MBSW^>K4J?<!LD)2A1U\]]Z:+UKU-<#E_]J'+8:/0$Z]G=AI..HKS9
MVA&H=S+.W[S8DFA85(^!8GY"G,$+9\DI(?ESCG6P3E,^%B#)N]F19J=UPO9Z
MB4_6^FT,I^A)ZE6_?7D/1=IE[;/N B[#=R$,+*K "H/[2'0[5"(70$0"X$^F
M2O3-=*ND'#02AAL(1P:PVH$Z<F-^C@36,9HW3-;YD&CR(,RGK.^X@I Y.P)5
MB==DH&-QTM0RJ_;SNL,ZMWHT;"JR5L]\)A:[/*FJC1?MU$YIY;-PU':A SM>
M-4C@'.E>'=B[>#F(3*?!ML2-4'=+UL%O48'ZXM(]EX,#LB6-U8#WQV_LW!6J
MT$1L(4'[B<Q?4!_+%6P2QPOC1\A\L$XG53>6O-G@K8Y:.TE"6W]NXOQYI? C
MKK1LAU^'P[QWZ\_$F;TLN<]>:.5/!FU(E#@RPF>\D50*-J%-)?U("J!WCUZ[
MJ?(@+ *98ODA?'=CVNRID*!QUBXY2=L;M?MRI[[6[_PFD_C UG^-_@1UH<]"
M!G#X]\8#1?T=4TJ%#LW =EX4D'-?W(H+6",=9Q"C^M2RB_28"!FK3>68VF-(
M@Q O%Q#(!;M.H_U(K! N,#"]PN*8\<LX_'O#@PC:.H%7P5$]FFZ'?0PRS3%[
M!-&KY#*>N"%#6G>LTE;60Z*OQJ3EC[A7+RO>&O:X[]H+!FXM/%;ZXYN$4>ID
M&VEY0P+ 1GABY!PRF2[Z"F$+\G,?.ZP,(C%S&<T_)E$#F/,0B&XE)(VEY'F8
M$OWX*HOJ]Y#/5IVROQY0NT?E)&:UE7B,+@'IJ\$B.GE0%#-T&$U!LH(RSIZ3
M60:!#CFKU,+;]4^_5.L8SE5.C(QGMZ]YU.T[+HEKVQU_TFF'VJI< @ CEJ?<
M0U4?&F8K>2# (0V]8RDADAQE&Q&_GQ=E$-)DLQ/];]DLY&7.72',';R_M[7T
MUU@O_X>\I&U?,-U.9H[-X0.(O65P!R$D?_,[(AH9:K2#HRV4VJ2":KISJQ]&
M=E;1L#J_V^^YW[J,D[/AJQ]2(_NEFU_7^SAL=\Q\<J=PA"]!:Z6<9=U?;:.2
M?6I 9T%YS$&GTE[D=7R'Y2FKKO .@XL1Z$?8<5M8Y#1K#[Z/0/<3C *O(.S3
M5.OMY_HP*EH,0A]F>,665OEE'Q3UR78:ZCDTEX_>-7G@N/!7.=S[ <V3UN$$
M!QP?9#NUF(*A>^FCQ1HVA_@NN@YC&Z1^9/BL.][=8;.0W%!]_5I?>V+W:^L'
MNS2U.X -UK++]NPMCBP]_"=2=2I;.@K#R00][4<[SC!BX]GN-'%#1DI&Z--1
M=[>RZFGG33;7MW_Y<."*<'60H/I*HP+"*6 A.WKP5/'<%P3[6B _EB'<A[A7
M()8/(C7)!0<=?$IX-CEZMI"U6.YEXY'^D7;9<^>N<%JIDMH6SPC\9IP^IZ)!
M^B>*[FO?*C%RLSD'C%LAQ-WV2J;4,7;G/H4"9N>7M3086Y,_.P<';^?33-_C
M(L5;5:9%SSUE95]&\N("22C16T1(3\V);EG,X+6N':+0.^)N"=_R(4ZY5P_N
M-C$/N\Y/2#_!!0Y:;[WBPJAK#[Y3)8UYXW0[B% L+$"X)*9\ZZEK_8/(Q9N#
M*0<S?H0^*^&E9\!"#UD6<"]!$*1,$*5]",JP\FC(KY:QX#;OJM1X+B Q-EA.
MO-1O\.A\<\<\RM.>K,=?MZ^M:L,BCU!PN7,G^C)VQ(\Z,_>;P,#03B0\F^1)
MOJU0&GVFK<+F!;30<GC("3&=U"'>Z^[=XD[>-AB=SWAJP(;CE>J^79Y'$=I=
M8.,1$RAL<NS'YCT;7ROP2>*?1%C5E93I]Q@V^RQHZW]72?]FO^\K-?I,%]3^
M3077L<7SD^"O#AHQ"2TR $O854&?R)*W4B%SRJ#'P!6&_?@4_-&6"!TQ;?8P
M4EA:%:UDWC"ZON/DTEYW)+1/O:CEI*$I2)A&$ZI)'1RMTY_@K7Y[9['%(<6L
M'33:)*4\32<J/U1H;DF=96[YY$VLDYK?!O#),4W>-81[1_7@M4*P4W8S<RV"
M=W6P!8.ER]A-OK=),=BR^G>G;6K>P1U^YJ&^PF%.F1[W2V_P7Z^(TKQ\X=!I
M>*,!)/SB)UC#!>:0ZHO_,>2NR]Z!$JK?&T[]B5: 8EM<&VKZ2TL#VS]?;+BY
M<7'".MM(R!.UJWY7J?G!*%:!=5=ID>MAO@N1!S\)4LAL67EJ.($M9P^+,ECH
M$"_F;L;Y1U.]_+B#](;$$K8-8_'N8CK+ID]GP*FN(5WC[=VJ\V'N<?5U+9MZ
M#V[LJ446-9(+X&SI@NRC?2R=D!X33'%#&D6#+H/7_SSUVBGJ:(B):VCPOB_[
MC3V\Y[^F7-EX^$S@I0B_=>F!6X]T+6M8<JE/Q\?,ZVLS_47:WZ:J4\T4_HQI
M,J1);EN,GH(WCD,6#&-8>EX=\FL)AC=7#K./ZMX;F1UX;OMN1UUOMG*O@9'<
M!6FTX1Z_63*D8]2X"&TGLV4N39%;":/=S!;H81Y.!'I+[SWV,H-*;-<)F-4N
M-7AG.G4B96YDHON 2T"27N<!PZ:A6\G]UC;B^P@C;F5A!3Z*]S>Y_3CH6-UZ
MVOJ5[1:ZUHNZ]LV1>ZS'Z@Z]/*3)^\L*%M_;C_8]IP0+6_CXL:RWGO6Q:L_N
MH3<<\O?<1(RMS_6/V:8BII/<.S:F8K9FH[4D4RH!F6A1)!+P"(MHTBB#MX6<
MML^:@F5K6\.-S@_);9]P:K8.N+J5?J"Y.Y17>M1<NE$=_P( &F53&:)4Q,8-
MVB$2;A"&H=;BE-,;6V]1U/OTYVV+Y3!J?56.88K+N; 7:GO0;@ =-6H[9=7R
MGD1)0XF;&D'9;6/X;&0\=%)19W[A&1B4=OAJL=7=/<$7-]Q;.R[]:"*0V+((
M&3K3P!;R7=)+P?G1?/9)1@J!^K.;$,-<=<K*Z>D?M[TI/V+@Y]^G?E<!!*_[
MR\E(?SM[A'#[J"#S%RS<P5)CGT4$Q(<<^\D\F(B):@.%]'>6+YK*A:0L0,D8
MJZJ<J9Z#.LL6U_?'%Z7EO4UN\&Y*GHK+5S#-?2(Q0X+%HR%'B7D-! 7O<8C@
M11VCUIH<;+))H%_)N,]M_V7:SK3=RYA7YK?Z" \:=PLY7=MS<).P+,)@FWA(
M_IB1**9@/RX8&;R B%")[Y;\CA3V^F3%SF!J_ KY[BF_-\F?!ZQD= O73KKU
M7B=]N&LC+'+IWEE3A6M(8B],(.Y.*^Q]9E':6S3^;EJHDW^\\:G+YQ7'JYZ\
M$[QFJ!0T_995$S$.(T.BQ$[R#3?(X;N=E3=6T$EM[KI2/Y4%^Y:A6NBF=7JO
M<_R5NIA1OFN=#0NCQ4<G*FQ-$AO,8IQ87K!0,,L.MX^31Z+D@@++V.AGI>?&
M(2VJ8/2M0WXN;_J\JBO]3Y&/ITS^^"B\P]%(@K>)U9&DCWF7I)T4_#P\S *0
M<?CGAE=!5%]$+_FA$38R]\07O7Y$LP"6".4"&:X0B@M<YG7@ OU2%@#R"5L1
M*5IV'N<@V69^B@O89PPOKN !9/Q3\M+]WK%%>!*]O'8(SP5.\EC(_$.3_97=
M@8%V:<R-TMV9&=6<Y%M;==L(4GCMGH*:LF Z%Z VQ!B(SALVG3$:VSUIHQHY
M>NR5K.OVC<W6].(/=HTHR^%M#'?F'4B4KBIJ2TQ!*=5OHXP0)XJ2'FLQ=,K_
MJ!7;FZ90EV;TV(KWD$4H::X)P3 5)'M>)=PQ58=660<@XAG&=F)4U@^T#'1^
MP.PU3![834G^,E<X<"S\R<2CI&>*+T)+#=O/#E/1<UC&BQ:D.I2 ]BLQG]#1
M\QX4+I"PS@5B&C1#C%LQ&ZN2C4[0 _+'B-&W.@._&/9_GAB/<UUV*:.:SW0?
M5+_6J;8V\;XI EUX3N)LGXE=@1N4V'*[K3ROF&R6,8IQF=!^.7&T14OUX*;R
M0LG#?)'B;D0=3B+:4Q>)%:^Y3BIFU(CB^:;UL1P]NHKAD^XWECJV0/Y8ET6S
M3+=[+KSOPXS(\^="(D\ K8^@#PCM0E:LEF6 .\F0:/Q6P<"FFOA1%@5[:$3%
M$'=J^QU.T4WJO**ZL]_;(:^4S7A+)Y>DQS<%3E7<Z[(6')!QCL3W(K4?8221
MF<.YMT@*2(T!M^H/0GX%%M<FU88-(H:\+-+YG7)$ZZ9Y\C/-\\:CZJVCC6*/
M3!HS1&%1%DL4IY+:J*P#-2%H$-\@0Q=L$T^F8!(>J]!EAM8%BJ6?U]\,32)[
M)QA9N<H6W=%3(*\>OL##G+<*#/2[Y+=]9>7#M1:QR]]RG$5*GGA6:$0 TQGG
M#[ NP)-<H#)[SIS^"PE)2=.]4,+2;/UEXI@W7O"3B=[%L9@BFMVQZ535L:[-
MO8NNKS;2' 6<M44U]=%>Y/%?E([YG8S<\YR'I?7"4P2QD)\MCY4271D:=]FA
M5(5;L_Y7BQ_FQ4=5> <X63JUC-=7L$M%!?B]>8=PN@QS:G&*KN< 3I8A?61H
M]\7$GBRR[2"U[M;Q.W6E5ZT55+R>6I>-P5?1E'A"57%CZD@8+)K&N@"UT%2_
MC,XB%(*>[?-X"YT<7:5 7%P1SFB3K IR,C0LZ3].TSQ7DS]O30N^6)+4PD2X
MAC )<4]73BJ:\MR4;QCGS]H)59[*P8B2K?QHAW@Q W:/\XKU\S[HJH<]/'Y#
M:'KL^P?AY*:6G0#OK(CF[%"#'E2-C!_D). 5<$8,JPZT^'>,)#N<_K-)>=M!
MC213]1#>IOGPO%GGO"DKR]?IUNQEIQR5RQ&VF_=I3M@\D:C4+!>E8.</TR68
M:1S",F$LFT)NG==SIF^L+C(M\J)A]%LVC'?4'>M?RSLNL,-&SN+>SN2""XVR
M!DNU"2"%2H8TK"*7R1MQY@SEXJE<I$C68=@-Q]8;,U+L!8Z;Z(6# 6U77&9T
M9JI\FSK^4%E*S=RV\>A5,\&)S\XI^!%T[?!< 4L8)Q\UU3N_G7%^P/I3H/!4
M[2>+/^Q# \O.6K_-C^P2XCW4_7+Z*O\1]@?'&X,TL@R:\H9<(3^W%H3399WR
M>8R&W&G=N<9:[P2;E(WH42W/?MX[]^%"C.U>WFXQ0OVI\K)=5>HH_1V:O'-=
M6M\D($TT6W:*>0 !\PL_\%LK..4KNC+>3'A7C->G:CNCY@&RVT3]=MQ(_?O#
MXZJ"R0DOM^Q7,YE28B+4.7(,WXRLJST7D JQ;2%7?:ND]2C!TF7; U$BF#'(
M\MN/\9-WXU;YTE7,;OVZ-!G+'TS<K/))<  M9;J+K0N9%YC3T(GH3?H2HK/#
M\FEC[F0HT26R2R$ 9;S-^6&FFV53<U1&U!UW2N2^C8>_6^ =P:;>V\YL:2^:
M1DMO#'HCFE* DH,U<8=>50^7&^B*0!E-RIL/1I?]7+MH_,+&U.JPIKW._9?\
M-]/JY-W6LYD(4XU\"+=AZ+;$T0(J(0EOZ&NZYQ5=H+K 9]WK;OUAP=AR TF*
MJV!M#/63G.O8Y [P#_'Q+2L"$:8O\QMV9< ;$?2/O&+#.LK>Q<G6QR:Z/7Y&
M(R<.W=[>?@?[]/NI3CD"ARBFY].'0:.\LBX_1GV)Z$$]>&J68.[\E'T+&9H+
M?R3SP\;GX.Z<C<FTQ3C2IEM$<1L:2C)$C5H>::#U1?Z86>R\T>7"%,U@8<G"
M[>Q9D]91)2P"[D>=G!-P@10"KWM;\!1V\ZR;R>G7UML' X7*ABQYU7>F16AL
MC0[M:-0=)S)/<IZ"EULYE0U2;*]^K.F6W;DWPTH05F#NI_QPZYNLU^[5#[3<
M30[;!%[; P2<B03UD(*S'$-W)HUX,=<0(8_AK@W FR&)CMNIL6-M561!MBU#
MHL6X!&=<\E-RHDDEIG_]J*H"O;#XCY=9:A?3IW<"G.NOH$SZS*E7+S]7+:*^
M9\NMEZU5]"]L&_2X5?]F9''Z:%.%>NZEM)K=[D(=FP5J?B[YP>(9D"R=Q,Q$
MWB?@PI:#VJAQU><$SS*P<:JO[\"NVZX'/UC8=@_WJ5<Z.OW R=CD/E=K%<45
M"4BEERVC2R.TSYO35MG2!&8Y(REGM8TP^K9='H\BM,E[AL*:?7EO<H9$9]&D
M??K&ZN"4JTJ0]L*W"+2%=WX"H/D/C7T8J08FP>DAO" 7&#7[#"[?=;!B*__B
M CLJZ6BX2Z  (2NJ"0#R :0_#I]ZR#K'!<8[8((&D?R#S?,W9[H;$C3_O9$V
MD"B3.K8=I@C+BDH%K]IOPET(S6WS*PYY*MKV5@-WK$'CE;W.S7Y]%YH%;T1"
MQ/4$S@HQPW0GV*0.;_8EU;0AJMHR_:$F&N8N6JXZ?(.=?%L.*>9J*58;9WZ%
MMA?.]@KCBQO8&3D1+_GTN)#+ 84G$MTDR.B2&Z.:Q-[BP?*&PIK+]M##)_.F
M%%:\+[VO91T]KYU\]<%4,G7[&V&XVR;!BRU9"3N5<EZA?Q):41S;Y1\<+TX$
M2,DB51+8TMF-IMJ?3 5^W.;,)-2'EW0^"YFBV<<%J+P>6DF<V;?GX7BG9$GR
MU[3^;?)9HA67;WQP[R9=_KU"<ZNLK?#$>43MR"C<7DYQP[Y)MAFC>JC * FL
MQ2XK7 T,)+VS'2\IC-%1U=MDPBC ?RVX+!I]689G=3L> )OJ4 IS]9<1_,[A
MO(+%X(%D&7@/E&'Z,F N,.K7.24[-YIQMZ12N5H=%SAST"I@A.=T*GF=3>?4
MD2CCY%$UYCM.:0&GSA2%\X02Z7ZTL]GQP<_]N(#8BG>9W9?^\MZ:W=^[Q[_(
M OH5!V.^/G1]^"#"EF4/-AT@45))='LBI ZV8T=G:,K9I9 &):7ZIMR[J4N%
M(0FT&>>P;Z^K6:C1QT&924_#W%WRD^\D)^ H46JH#@*DU4ZD$63!)G'TE2]A
MU-X[&4VD#?ZX\.!+],06O.KG7$>&W4I^2SCIS*#NR:)Z'>W(4UG7CC@97,#U
M&^;#B[C?1SR&<!=I,]H#E,8W@YO8#E-D21]X[]O:SR9V#%$,XS09*CCUF>*=
MH[1&#)!M>1^YN>_2WC4MQ3F7P1#B8P,B9(""A0>(\/LWV+F\%S@;J#J8DUHN
M;F_%B%Y-VA3VY4!<1D]-36V(W:/J^ABG8.LGSL%GO((T"__DK+*78.$TA@8L
M@MB=KY6374;RTDV0R_%JQ\02-I::6%! B4E?\J5P/,]3GWS&A5RUKKJ4PU<8
M7=:.5\8^W&&WSI H7Q"J!<XKL"S@H0953@P"S5Q ., #6J1/-0X[Y8 I*W:'
MY@W\DO<IO3UMFONL+4(]\QPUYP"3_?.;]"]C$]*MGV2Z#0:PIW=3B!$FXJQ3
M[ OTH2*Z0H!2D[)^)4-?_G9]NNW5K-9SA[[6?^H5O/]6O/;^R_O;-CR/T')F
M>B#F\\"9<@@D'U0<6%.;V+ [)*,#5&C8/KMG]F!OZDJNEJCSRP%JBB:MYE5U
M3:WUMI,Z\Z.)I=%C?-K6[U50Z4@2"["(3NYE;_%B79R<<+50'T(^RE$*/;_'
M3752IT:\ZK&S6E1*?C$2S(?50]!8I,ALEQL7WH/:&7*V_,5M^=0+';^(?9@1
M,BRDQCH$MZ"K,<GHJZ1(4K5N>SP.R]C0XEC#</SX&GQRUOU+-:?Q39;'IN_?
M-UF\MOYF5W?RO6QF@:[2>40++-@D3+K2"VV?Z="59M^&>!A<@#9440)]['G"
M.)$[M=7>ZG7E9^',(M?-[K/WCJ6\TMNS]WW!-Y68+2<%1Y7W*2N:2@Y:)>_.
MB[*">P@LM[#$*+'KXZ'^WRJMA4;RC#:-;MXR?9'T2,L(VH"FW"/78"/0E/0Q
MN4H?EJFW<YK=E 2*?>;S&!=P9%@67JYQF:M*W._$][(ZQ2"Y9_!]NH]4GYA[
M"D3*[U4*,6HA2.$47K!-&2DYNOK)P;9U ]7NED$.AZH853?:C]VSG+ZBP*?L
M]RN* K(5'R%N]072I:#BT&)/&<-M1*GO!$EMS^I<NR$3WXIQG]AO2P$7:VLB
M-;W>Q 9=ROJZ0\ALV^&/9J9RD#2-%&\JAUA]9WUP.'WRVP_CAX'CW5N/N)\*
M[G@Z$9(UJ56]&1:(L9%B74WKI#7\/K/<B^_&O/SMU+VP. 0=9AW$]RF+V4OY
MX'D8_&RW+(+'\QZOZT4_Y5:'4XC?W-^\>:B#=>S*B''_8TI%:F5Q3A:1-8CS
M@ M<Z!W5;257Q*32")O91^CV29N^Z80=@^++=+Y4ND]HE=;0QX^D'0Y(4;_Q
M(4X]Z&KEHQ+I&>+H "P>PLE&:D)BHEM'@JD8/ I6R451PF]?6Y]I.21*$_6I
M4:Q2VU]5G].GED.;$+@%O,RX).EYX&(C2@9LPAFH1\&B')8$OM?H>E%M,U&<
MP(O:.)M_A&G#WQ%_7'YW8;K0'C=WRQ,VXR+20XBV3;231TFU@G-Y-RKNJ'6$
ME(Y,WWDV<@_-F%H;_J'+EBF&A8BL;4@WVP;E$+UF_ $[]\:QX9;P9TA!V8;?
MD*YE_$Z.7^J.;T+?*X.ZI?Q=#_C%+K1W9GV!$'(G:(CO>4.<^\)RP7<[F1IR
M"NJ#&>:M;@DG K&R$.MT]#=OVF?M+$UJ;4V*5IAW]JW8Z23C2KFTZ?TJO-\E
M(%/9S6Q)#J%0Y)J)8WGD]4^Y?O9TXDYD(1M<W5O BOUBPES@KKTS.J9'A.0)
M4IZ1Z,=Z$>.)]-$W=5.".^;-7?LQ%H/MSZB]4E"0=_^O$Z^7Q@P;T[:J)_<E
MU%\]T'S/,=,%U\,@P>+^G!2TSZ)@B/PQ3@':EPN,\;8I;Z/O?K >2$A<P/EX
MK@;+Y7I(CMVOJ\C1O!#5M4,__N2W4#?+S-QKP!H)E@A#JG@/2($+7/J&1'>A
MS0E$QA>DK[Q@)9&3.BG#!3YC'(GOT)1"D'Z4?(=$=T0+0VI-F&I[I(ZZ/F<B
M*ET=&1+TR[S2:/B&:F%VK?JL_9LKCD I_JSYHXIGZH@?^=M#JD:-Y/&?3%<H
MF*4"?R)4#;>Q4D5P1NG"59VW7LR+3"XZU$5.VKIHO,U@J;\PN6:K?JG;Y7Z,
M=E?/KY/\!$B=-.?'TIU% ,F./(II6T]MQ CYNG&!V :9[[?A:-I6VY:L ;+/
MFY2\XJ; X)M8X[QT^=#+%UVM-40Y?:E=1&@;H14]=KH#13]+'!=L@E$0@XKF
M9Q]ER+TK.WNN-J5>U/3-ZO51OQL=VXO>6#US>9!TQ 4^U\NJBY$]ZCF\,#SW
MC&7B@WD5/+=&18^26D I$RM:.*KI]M;RY#Q?92T_PW<IS6,RD9."?L9^(1/J
MUY_'[%W<WZVG[#>5.FX+B_=P$)[G2QA;UQU_2P4[).)1_ T:G;>R#Q+B3!5\
M^]PXY=,:60$1WMV'KW4NO6W_4;[/5>'APPA3U&\&\><IC,?OD$3^DL3W$P1,
ME?%#^]AFM0QB,MN@-"2A>;CE15%-M-]U4&P386? PF:K:Y^:Y&AG9.\2/^BE
MU%*/FV[.A<4(#7:*2D&QL.Q"^3#/&=1R'BTQ<IH+5*DKK%#"G'_81X&4Q^C*
MFBB6=D@VTX;QI>'=%$>TP["R.'6%A/J9_L.M(_YIEGI\><"BTL8K9U*V)W6\
M//*R554J[K/$/=Q6+B#P'L=#CYT;G4*-?/Y]QV.+;H,TE+YDVZ/5F'W[ZX-7
M_;LGC]X,C)N_/_&^P44S'3]MPQJ0/O;\!X\\6]&("VA>HO=R4M:1TC?3N1M#
M/^8U) UOI'&>#[0H(;7^^!$&BMF8:FS(!;Q]SM9>76.!F_R6"4PKSCW0,Q7:
M9C\73-LJ?Q0:G>*E+UIEKOAUU@>7-@71)_:+=/O><V]YZ!6>\-*RL'.;A<4$
M&:%A30)H"@$M#4N&Q$YIL&5>,(OI9V!EJ(!E#;7_.IO87/N#OS=Z>6?YUS>1
M'SV&#DS[.!8F+26*B8R?.V<F^/W+/QZ^(0T!=7I8+SNGMY$+L#054^%["9I_
MI=9FRN#?G.1A(M!_.?/[_(_'A__0#C]SZP6+S[J,_3@]:JN_,6W2?9>"RD6A
M32IIKJ([IP.<SJ8<WG*2;]EY!L/>Q.L&56 1#KF'\Q8OQSX&,:906\=";-O/
M;ZJE<WJ3 L&JSLO^AS(Y33'J%M87S/HO>3KDLY],F0P3X7$T_3@7B,/49K?G
M8N1"WC(94!^]N G>VB?7W3*Y!5*:NI1O'QZH]G W%OO-V]/UADE)P5V-A59M
MV$-/QDRBS)O88P_M(,Y=)^(0[2.);%=Z[UVT/X)+TK3@.PVRN(/]MQZY#4])
MM"E4/W!O4ZPT^"E48$U-Y*!.)(P\^OY!Z>1'2P&T&6SHC=F$.TU/;<7+08=H
M8><D6M>?IAD\CB>>M^RW*NK=]:#M6]LWI]CKF9>ZXA7W1'_:>XWGLP/F'KFV
M@RW%[&#J<A)P6);Y*-CD3@HXA&T=D[O[$O*SQ:8:7Q@,_/E0K6I@OK["IUZ]
MMK(QVGQ!I$,\+8=SD).)EP[)IEC-#5!TH_ &C*%GM&1LR_E-+P=62)O\W.[7
M9KL5S5U3G3C;J?_AX[SZ6[)VB)B@&3\0O/P_=DIE*5Q F41Y@/F])S"6T>'/
M,&8F<>[7;Y\Z%UX@5?Z"9KSC3=;^CFV2;Z449S1\*9X921GG&1: %W2Z>4P^
MTL3H,A4EYI+KCSY1ZZ(]_Z%7(UN1+G\SO4-Y>BA:YI]V3/FW^C7#B@SU(7EE
M5?I\,COGW-+D;&J8=WJN<::5Q6/5QK4;?&F?#U(C@A2:#&[_TU6[/QLO0_!O
M=G!1?_%DWEZD0/[7RWLOZ()_<\TO0D0S_V]:R:)*UH^/[MZZZC6A:I=MXXYD
MQZ5%=&W9-QVH=&?+#2%:!-H$I-S'+&4O0IJIG%1EQ&L&+ ;#.5.I"I ?M2-R
M)34.KS>H5M&WO'7WE,,@\3)Z^[LJJ:I7[R>[$EHY6BU<P$L"VL$%FG5';S)C
M&.3Y _096G!J.<Z>8<H4)<59N0T]>5TSO"/RP"F!D(:/?*8G,VM"E9T$Y#/7
M_/J1S#FZV(RJ!N<0GMD[^I:V\77I[)A@LGZH_KL;4RVK\=@@Y@V*G8CU=^K1
MM(7XAE-!UHV2UBJ\K21*RF-AA@YI[KK\O#Q#VC9]H(VD7._P#'>"L;6^9:96
ML2K?5O321*BBK\OAJN4E:^)S7W%=VX&J0_O&+?KF+E975=Y1J:ZYLZ'0(3_Z
MS,G]  !LC2"J<%+1'NA(S,LU*!(OA@E) 2%74%*WWH.F"UD'#K\;+3GG_TMN
M:^/5U*^;!6\2:$&-C8+W\>/Q7$!<GA4.?R159!(7JX@;?;-!>3:X"?FX/+5F
MW"K^5],FW]KKQ^6?P1\OC36\(YH@4-V+4* F<E5Q,MKW;=C\J=6V\T:?]),W
MT7_(2]4K!A&*E;)C)ON.",0KN[_^=D_/</5"B BP?/"?MA#^(^T_>9OASZ:U
MA&;.(%C3B1\E5*[.7YI*C8)YA_3Y^JIT_.>KIE]_.F4CM^?YM0_V'V[8&Y"S
MOCZ8(\N]K-M_\W/P*R=WK7=C[EL4'OM$=-)OM%W2Z+1SF_^R,%=CMX"O<\#$
MD!$K@>,S<!0>84C- 6AX5RH$DN81:0^3Q+@ U0@)'ED,4KY*_DKB M^ED& Y
MR06F4Q'>$Y?<A%E60+$%0'8\*\,"KP2V<) ((JR+0UY(;8C4[]!S-!5&<+^7
M(\#60^C@!,AV1#$D]O?"=U POP1LC::I77/F"%AQ 1X"%U#%3_?]!R6R8IM_
M1&9\@HR\8\X%TB6@N F$V!].XP*-R,O?$U[K.U-KV6CR[SVO)^08D)Z;R@42
M"F#4(@O'!3YA6]"070?"D1W^5;,H6-6('_SD"=*1UR]I+-C)0@BV2ZQR&L#O
M1E0">\<4$D@E"#ECP63TLA*]%Y:^S@489\!6DRGT.A\(R:#75/YBG#^/TX(X
MU7@C_!A9#(>AD9.'QVZMNIG6\E?'#U2MU(HJ-9^- ?[X8Y58H36MU?<BIFR7
MHVR1W,"YG""_1=/VZ-LN.5)E-I/[;(J_&-R"*?D)6FHG\_^*>O\E* B'@)07
MZ*5[Z 044Z\3L?=VT'R03?_SULY7%5 &/>>5P07,CG$DFLEKVM^Y0 RX;HX^
MP'"&K9\CQHR%LU(?>^<GP,_0&4?^Q?<E1C"0(0NVMFI%LQ3FT<L/AK]S\-?
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MOU?$BUCH[^8EG3?<[:EWWCMQRT'9#STBNAN%YS=#J6ULFHRI-,&'F96=P;X
MIS?U.SUWN/1.,<<Y9H.[W%E@R\'1?2S7M6&4*3P?V!H-%2'M]6B[]1C6[-$
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MT>DQN<B1(FX;J#A=XA&/2"/)*^],&)UGI[9H.5PT5\-+_;Q=X"IWS+%:;M/
M"WMS0.H?!G&Y08'1JKB;](G,MOW.![J['5F1N,$9KNPH8C?(.0 .8C/Y@(4Y
MKE4:(/$!L.$Q;?9N%W4&&<'.+^Y#_\>1+LZ5#^0#VX[R7O"!Z5$^8)LZ,//[
M3TO]VW#H-\C"-%$]J?V49T.G!X>V<N)KV_LU\G .WLH:"UM?DV%?VQO@O(L)
M&N&1VB5\8-.+%[\^]MI5I;Q'^O<R[AWI6/-.SD4I)Z)!FHOVB0U&)$&N!*N:
MJQC-\J!W)=:O@W%.T%5XABFJ'AER?<7(#YN3!Z_8FU?$= N=6#C\=<<JW3@
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MP/9K<9!PE+/=U/O/KO^(Y_8.54P> XN*_XXW12=">WCZT3D\[(U9 W9;L_@
M(E,-+H/=!].-*%2FH]G%U0Y")WTVGZ'Q'\)'\,YU47YN!6%)DR%$+KH),W^<
M"_*!R&(:"JLNU2WBD:.,;5!7O(DZ2Z?U\4]XR*K:JX[EU5=:<<E5^>S)JG7F
MU^Z%54\O.[$K"CN5XTM9<JC\YO- R?:@>LGQK-5/-:HRCHQ_^5VFM;"WY"%C
MO*_9IN7CMD)U[Q>DE]WFTO!-SI/_PN;W9*BC0]7N,AS.I6W-SE8WOX(+S^)6
M66\@ .NL#+80RY<W:&'4&)4C65 36V7 Q..I[\@Z.'7T@6US[J.1RLJ/13GC
M2R&?QVK.';FU2[OE_9DVU6W"[7-FG#Z!O_$'#?5F\97<H,^DE2AD[:+0G^)*
ME:H+"4G-"POL[$UP6XG;%B3^"<W5*C@4[Q?V^-A9BD--MI]JW*$S$NW?@NXH
M2R_H3!ES#+DG>%FF&_U_H#YJ[8>C60JM]5M2FTDFK*-7_0>=K(GL_OY8H:PR
MEE"%3-653RHI9^H>J1)[=FY:A4;AR@-HN!^:Q*YU9M@,<"6+&/I7/9RN9TY?
MR1:OCC@ADA DG^"_HPFUDJWAE;!./"KG[CI%)BZ<(D(\P=D*1[11D^("D76$
M7Z.-B-) 92;9B'U=;NIYI8V10BSV6WX:.^.N3 %D>/W^)L]/PI_F_S77I1?W
M<7;R@7>E3!P'\[N$IWF5YU[2/C,8C9@G;> #7_A ,3CN/#!T09R;A(&W+#;#
M> EP[ "E#?/>(A_U.T<7SOG'%W ^@0V[*6.(*>J0+S<+P)_LDGI-.@AO'>"2
MVUHP' G]$I[2YX46T/0B.JDN=C3].VA^888;<X%&3QI#A2*T5?R-LHJC;E7C
M ZF+, X-&SYP"B6MDRX\%)Z.VRYBR9%\@&W[&\=3JNP:F.(*H8%KB.PE67)M
MF\47,3J0Q1Q:J1VIY'5_#VW2WVD5,]SXY4PJNYG'!\:=!O(',DF]E%DM-#7?
MKXKG P4!;E@)U"))DBA<6I0W469-F\#;V =+3>AT<X,\F?]B.BT]5S+-1ROG
M2@CJXDJMKQ/+)W2,6B29K'>GOW&:.VECS:B.5;#Z[/TJ[<N0UH%O]N\/'+>R
MOAG>K/Q1S+'[I)WP6PQ+7/TM><E2?1K-_VCV)!](&.C&O!2>TLLCO26OXSI"
M)4TX:2YNU'CMM39)0OB0$^M[58BV2^SY\\54X_B4&&\JN_AE<K)<HM46JQ*Y
MSR@>%6 A.YT8BD2=7P'2"D)6QN08-W$(GUB)%:U.J+-E55M#7>Q[2-8E=G6B
M4'Y5;\?8<U;-\P1'@L"-">%:4C,9M;<_.=%M-<NTEN-&ZI1!.]DZJT)"PY26
MB6H \WY(A;. N]?V8SJYM_?\,FS7;]L>7ZYT1NZ I7!Y][\&EN/8PA0:_2IM
ML> 4V$^9+Y[\'451IWAC%F5,K/F !X*6IP(\+O M=M8$K>H_)!EU*&](%N4#
MF\!M2JFH[Z;:F#?_D>2@EZRDHB$&PX_XP+E5]_C (VH]7()ZEYZ)FP4Q4N"4
M60]E_IHC39J[V(Q.W<P';N,>\*31L-C<!(9C[]B;2X\J?5H.>PC+E4I%;'\P
M0%XJSQ'U?7'P;S05K+!C"$F6#PQB/X/S5P>PN')(EAM#0VNF*@LK@1TC4AHP
MG9%2]CA_XIZ_SR3'/X5EJEL@YQ@:F>6,)(Z&O YRKYC 10NPBHDMFIA*7>O0
M4YRUR![$9W(M.EV7S_SI_T)$=C0>Q<1CUZ&M:(0%-'";Z%$X+FO$!ZBKDGD%
M5^YLZ6A\UB6O=T=L.K#!8HO]QYV/:[:SQ(<L$)%OG.57L/9/F^@R*%0:H\]M
M!S03B7^!G[HL%M\1HY(R:WE+4V]?7>GK0;F[0FKAGBMG\VZ8!O13W&VINSBC
MALWX6-(J%"B9A.BW-8Z))@'!S\<1.6@DFC%8/$5/V9.V9_"%LE:/2N$]2AJ!
M&5.NY_UF!A'II.ML0&FV3[..**&-W58+?WMVD*5R^ TK.U>HXD1SFV4/RT?%
MZ>:*^P-^S6?76.XR#"I!P2L&#])C<?/N2B@#:(QPX -C-0LHI#6Q%7C9X%DL
M$$!9S0>\4(OI1)NH%\%Y-I=H9G'?_?)*,ZRM3V\Y&386NKTS\/OL5[G3 " E
M,"7U%^3^#X7<?R3 ?WGH+P_]Y:'_ @^EUF\$&]!NCN'B=S4;74>L;9I"->+]
M*J0@Z\DZ'9Q#CVUU,'[GIS\:7LQ^)?W;1/4^O:SN<W^+=9I)L5OG9,B@X:=%
M-]V.BZ]?''_"<._<X3E]N<)JP2_$Y%S<DAZR41AYUH78@9SK&.@M]K<#.!O!
M!X8FY[M^=T3Q@1]H)V6-10YQ:WE'F/A%M+%*18MGBFEP7GT"VNL)\(%G:!]Q
M%X/0++@[Q7FGR-P<U%-+V($="GR S <6T;JUB%KX^*M,A B.?4++0=+#GR6/
ML(P;X,1S/O!-&*V.W6B+B+;:I] >4 /+JT_ZP\K8OA=;T:DPB_K81=4?1IH_
MN^"SF*4B["+*0J;GP2:4]'T^PP?>HP&$?\2[Q* L+O/ E"Z4QHC_UHRE_&A#
M;,01R\6/_^_*_N0#+J_P"$K\QE!EQ@[^0543VW_2Q+L)<W:3FFA0%PYC8L]J
M0V1 -H6K5B/T^ $OG1?/!LO#=CA_F#/Y0:O=,U3AT3=0[SCZX*/*;1V#8J?4
M.J^MO4.'N;^QONT7?K]\8"-J<*I@8WX_VR_,%PV!L,+'_ZM\N+Z78[6\\"<R
MAJCS+PM;<%5)F)I>;!D?*"5ULY/V-BUF^SS,U$T(I 9/:&+_3F=29J/)P=1O
M82<>Q19U[/">[E!_9%WFRZU-V!.\MS/8RUG,.L/D*2Y#\R3MRH.Y+.EYGS^X
M].\]-M 'OG QY -H2S^+&G]6_3T?>.IBPP=,L;.^X*S%Q\N.W>0_6O@/L;+T
MK0F<6_;3%C1&5# 3CI)@5Q(W \--_E^OVXV\OD#C+G^Q'0V6=]%+]YII<Z/+
M+_3Q 37B#_/K<O\02G^(E3^(O!DIN&C(1=.Z/1<=F+U_0@:</Q_X0W2]"&""
MW W+6PNF#Q[[T: Z4@LODRFF;0MR54U]'K###F6[F?:\&DX(^J%X(:#S(Z%H
M<\NW4T]ZBL..:&_I,"ARNU@Z/E:GWKSQ*#72OR)P8_ONQ9RIU-E[7<]]\^*X
M%W@YRQOABX*(&!IZ&N=YN=@I<B=*K?-*1D4IY;1_\J@'P$/^_*=>2MYB8/TA
MY/@#CBMJ^#:$K%Y"FP#^_D;Q_ZGQWRBJYF@2-=H99;"-Q$OP3::V.B+">4'4
M@"\R,")?#2*SW[",K>HH;UA!CS:=_>A^>W/9Q]:]&X<6GY=HI1S4W![3*,M1
M>D6FBH^61((^^"A'<+V)E4?HDZ]A3WURX&O6^[>P:Y\>N3+DQTY.,>S29!R^
M\,S0^-ZA*W;B]T'Z/0QT$I1%^G'EZLTT&62P7J"W7I%K!@LSWS@V438&/E>[
MTGLVK5%5:^".C(^F3$NJYAOHW+F-1=H7E=;QWH!X\00:9/L&1$094,]0DXRI
MQ,NR/JXUPS8\X_:-SI BV-$VPUYSV-]:US=$;IJ>P=39KK?F6F[BH_MI5]_!
MWSBRQ .\-) >!59ZM<7D5]7 Q2Q<([*+M=!BG*@8_]9@WX$1JZ#GT_=O=.+Q
M_GF#X@K-1SDGWYV\@GO)6XBZS =@0_&&FK@ZW& _ZHV*,K?LW>$U6H^)?.!M
M\P.NKV"?21@'1\3S\BG>,U$DP^6WHGR5%/LJR0E&\I-.AG%$4FHBIDG^2)-D
M5W"88NG<UAK';(7+%0['>VK+=UJJE0CRT((41(.W64RA*"ZT$P*YD@&(:(@/
M'2,[R'7]9*!HS7!LP40[>;*W;>F\)7XQQ"L4OTTY\/:N2SF!.K*=RG<674.Y
M"E@?YEIU9'4PM!4K,V/%!\H-GC[22UE==3W4GK#.%EK4EE.L8M:*1X)B@6 @
M"&LHI2^_A-Y7?) @S+"(,L"LX8H_&$ ;:=Z]$+S$(?!'=]YM8V/OL6/Q)I/W
M\V]^65$]?; 8;:#<3?<2S5@RRP](\P9,I8A[H*1;O^0;N]S@K/P1W A<;7][
MI\_.-HE!'X]-"8'<?L<TJ\WW[AUR%T.KR<H+J'%BN8Z\>F0-/&#!*R!)G8'U
MF .-.I@16(=Y+#&_UB">-N2A-Q3DLSTQS;6 ME9N<UQ9QI(F.P*>9. &AQCW
M:,VV&TX/3Q@J^9_Y::K4\\GJ^HN)XUE5U.OYGHES[V'[A]L3/WZS5TSOP-(S
M**4CM1PUHAQK52'+])IF4BQ.FACRC+# 3.S/^#:=ZM3GN6%?0:V$F//0X5+G
MW#W#W_3OG]AL)S!O\V][W'\WE$(Y]L2C\%.(PM#^^ C",.J4M%D?GX:M2F>L
M78>,%T^-L*]0U6L?2&=HGE;=X'+TO=A]NI>9ZQW,#5,MTE<<=!HE=#K3@E")
M"VJ#6R-<53@=\F&VW9[B;G[B3UM[6;/3:*'1J6#4</#=F>&$3V>-O:K+G^_0
M4[@[A[6;'!.GGF DIG.E?-CE\'4H;T3H->P*";9!A(ZVJZ_DXAU87OG':H)B
M!2_?<9:C3D"SS\SK-M4>40&^\-!R$=BE1-!AE\+6J =F>!EDJWBF8\MI?.5U
MVV;Y;ZFN5-BV*<V^UI;4/Z[FS0S+6B/ST\7B^RJ_74]+&; DQXMH!=ERI<1=
M__:Z7]_57P^>PW%X@891,,K4L+>"\A)LW)\O-T*=Z)GX:GPXO6JNM4U7HJRQ
M@?OJ_>Z9ASK/?XOA86/O]Y,M[K<,L65BF#7ZC\)7/6_XO*])+,7LMVG%S-"6
M$&,TR8QTV&95$'2N'[/:Q#FX) QL\F0[/;PHVP8M<H NA5(S1=RT(LL8$9MF
MHH$;0*XLF8HMY&[\9*)8X&S[%#[(P,17!$P6@\U73YK56(5=>)X\Y.IRJ/Z<
M4ZZMEF5RN_(=7<P1L,$ #%(T1D3U.*L)DNP.J#J"4EK(NG+O0M!ES<R\X_T(
M]7N =<RA7!'?.EB-RKED]U3S83&.]ZI>%QYH ,7&8&-(OD?1FMG5[&R=I<[X
ME:Z*V='O8);JOW!HA4=IV1F9,!?>Z+<##]((R57@.=M!0\;"E#9''99D'X%=
MU5)^C@A_\G@9-^LIMF7J6X9S?*%]8UUON]8'88%\Y8MF2@*<U:2OM,K0-CR\
M#3^]CZ-(ZB;)0F[)A<2-Y5 1X=)0P^S7KXOQSYRZ")X9$PS[0G!;SHDJC7M'
M=HJ26)PC%&/P+&;Q-):]7-Q?ZC2)\RR*YH_\X2DY4S/4BUSPO0+6UY:C/@?^
M_%D$-Y9,+?RS*G0#"U+^]&QC$23\3YZ"_"=/XZ$#%F/'\Q*P]'+:>LIY-/BH
MMO2%Z43(>7_W_)>MO8@2(10'27\OX-WT'HOU.?Y1=CKU\>>T"WHOPRP==C4@
M/%1:?UXBU@<_5'0HOG4 !QW7H>(;^8!44LQSY9YYO#C!&?UM,&-?Y.U!TN?O
M9H.&&SYZGO*^4]47LWUZ'7UQF="LK.45(!BDU8@/<#=T,<BM?&#=&:)$/]F^
M]_*,[(AV7_VV;J(.:)(R[%OZUF[HJW59V/1H?5BZY['75<EW?&9$-01'R4-)
M;"G><^)%SDX8PS9 #4@@.D#B31B $&I3V1LRA)'T'0CM>CJ>]G33!3^P)J2E
MZ-GZBRE.(<8;I\(<CF+"*65=7)D>G3@W\7AV H^"R'9 -/-^[1<H)18G&L&7
MEES9N8&!G'?/4ZZHMT>.6::995J;O]&+4N:UHRQ6B&..M&*@,S,QM*HM* =3
MAZZQ6V'MG)]+YR7]T!E,C$M@T;GCR-OR2X?*G_J(L=M[_3OVR'TQR=>4.XO\
MX(@1)5&1PXDFG[DG1C%#*!\L@1::;2SLXWH&&I=P$2:[+V?I658G?? ;T\5D
M^'T/39"]-"0C+5*A%S%_2NH?_\C5WQI6E"U66S2A#IUCEDS-%!'W\F+K=0C!
M;TWU^RVK^,"MIF8'213FO)UVO4RS]D73-9U<LWYH^P/OAK.5:,@TS7RQ1L0^
MT\6C,WP:;%>##8=,10B.C547M._CQ8CJ=W!.0^7>?NXIC/RUEX:R/I1%>R=W
MO/;>DC0N)"4PAY]VYXA,@%*F^MRMO!+2"CBOPP(NAORMBP+E)YN]_9YS#SYR
M,SM;UU,R=L!+H"]6]55SXIH.BF?F_8WU0DCSR.Y>,*!$%BUD:&/BFXAK6BIL
ML0EM>$FP:+RZ.ZIW=RICGZB<V^C419<C\=I]Y5]?IP6D2KD$'HHU.\<'K+O-
M,)DUN"D]%( @B ^T8C<2\9^P>/!&]R1I9XVMZ35:E&&ZC;O[>JQ/;V"&E55<
MO_;'1MV%_!0KE[H4/?)+[#E*)%CIV A&A#J0J]3;AG1BL1*_78/0?MC^\_P;
M0P[V:%7,,W.\GU^0\*]SEGD'OF[H:=?,:BF['A<'P+WL$[PHT)\2CH6.=]T&
MJW&WN0<A9,X2G@S,<9XP5>C!X^N[<[>F>FHK^WY/^:K=?7GE*Z_XM'?*:PNG
M:C1R5L3]QQ"_@_W3$\Y%G'W_!!QRQ&DS?V:8B"U(3P>AT[@H&F1!@34PT](L
M5:9%PW!PZTY"FPNE-["XPA@^>RTTWB'[^)371N6(!%'>2CX0,P)ZD9=T9V(P
ML/UI/A )D&CVN!@L2Z%K"BU4A_>QT,9#5!,#/4)4PU#.]K.M7AEDF'L@4@*<
MZ^8D93[0C,>6=?$V+C2+<S6>@XU)<.(/-MI</%*";Z+322?!=L+3OZ5AM&%:
M7X=T8.<]:!)8**\4G17+-"0/^B )UYC"B)0#EF&&J>YS9(IS#\\M;PQW)Q%1
M:&R,:^-J_"7E7U+^WR;E EK__KS11AH'&RRP]&F=P5'V5UXT:0NI'9'AI9CX
MY4XH&4%#XU495;DOG*S6%I4_PH?L?Y64GO.[I)$*\ ?_'U!+ P04    "  V
M@%!6)<@>%["9  #4K0  $P   &IN:BTR,#(S,#$P,5]G-2YJ<&?LO'=4$V'X
M+AA$I$OO8E1 I(E2+4AL@(A(DRY$I!,A-B1(2!2D-P$!!246BH@8J9$:0A41
M$1!I0D(0D1*8B(3!%';XW;V[^\>><_=W]^S=/7ON<+X)G&1FWO*]S_L\7V;8
M'-VDP23/6UI;POBV\<&N0#^PS678SE-^Z*O^,'\8M/%M3L#.P+;Q;6U;^VU;
MVW;^K;W ]NW\VW<([-CQ'T-06 @:@CMV"(D*"8ML;=!O8J(B8EM_;)WDOQRZ
M38"?7T!$<(>@R']ZVVR%20EM4][VD9]O'VR;%!^_%-]F!PP.V2CP'^;QP?[7
MC6\;_W:!'8*0&:+0!VHE(?/Y^2&C!2"+H7>CH?=AVZ4$I/<>/K5#QL%'<-\-
M68/[F2^$U$Y74N0<!P!UPZLW8X1%Y!44E90U]FL>T-(V,C8Q/7+TV)FS%I96
MYZS/.UUR=G%U<_?P]?,/" P*#KEU._Q.!";R;NR#N/B$Q*3DK.Q'.;EYCY_D
MOWQ55%Q2^KKL355U36T=Z4-]0UM[1V=7]\>>3X-#WX:_CXR.C4_39W[._IK[
M/;_ _+/Z=XVU#F[\V_*+#\;/]U^W_U._I""_MFWE0'#++[YM$5L?D-HNL/?P
M#NE3#H(^-V3V&=P7DCV=^:*2(JQFZ C(7;TY("*O;C2MP=QR[3\\^[_F6,Q_
MEV?_FV/_NU_C,#%^/BAY_%(P!(S+>9E\ /;_D\&_VLL3>;4)$^!^Q=.>%1H.
M\^!8;6X*)YI9N$H!**8=T>B3[M?^ZHM$#A15GHIXK5?;ID=)/C=[.,=96->O
MQ9/_!YF6AP"<]<<6>2)E[$-];&OL'E+35WSERL\ACM<TXZY;QS^]<<NJ]Y&R
M2UGR:<.#/O=ZG\;YW_9N9,V!98 IRXJ;U**#18(IS^=-IG;5 %]*;[T)3@E6
M+JF.O)VF/"'++]T7;E:F</3@JM@:\;/=J"E/F,TLY0G[;,)V?.<->!\",WQO
M%6%MP Q@PILI7UQ\2,L\-N2?T\3XQ(>%ZFZIK(A=LI%WI!Y_.6F>^0U!F[;C
M]^+ F'F,.9K$6+G]R"8L8(4/:YG0IKP)ZW!KNOA^44':K.[K,\O^<ZBKU:-)
M833[/UZ=ANB/"?'\OPGCFS">2#!@QW+GYG&.LL]C7-O-]X%%/$3\9(L":#7]
M)4^#5TSO*J0R#M?6G"M^L$]BJD?K\KX[ 7Z6G#/<ISY)"-JG35CZM9,;O/TG
MNQ<W8<([8@3_R/V#,K!C\ <Y T%+H59OPC(XOD43/Q;S7>*(O_\%E-\*J[@A
M$(,:N9[H^S"M1\4J,$0DAC^ZT.#4^ <8?1-&R\4#-_%M$N !-,,NDBW+<>4^
MP5H#@727@YNPRMNV49<4DJ(UWAAEC]>CHB+UWN4:9=EIT?>\M5N-Y_-\O@F+
M>;T)H^!OPT'-P-0U? )5A'QU$P;'!C8!V$.V3+CG5WG/$Z)MA;>#=>V]%D1#
MKZ=<OYIU](*_\VD;)?W<5J;$6 ;K7#6W$4'[V9^$!"[I"P0?/@60:!^18L&X
M?3&']C$#DWT&-V'5RTTOC^0>=]#]^"?F5- 5_NMZI+^(_XY)\'RG*T_8$YJR
M5J HM/?C%D@P! $KVV]&D7\9MC5D60S2[4!83<'LV6P?O^/^29G#6<ZM5\[M
M=?=2&":'D,?QM$W8D@_;#$-D/0?7B"T%TPC!X/A5YP_Q^@:NO6]OG)'V0^>Z
M>Q_)O,D7*2O-]Q',XXFG0U$*XEA"^]M0K!#>,S.%>0<+9LA)_SZ!&1Y?YQRK
M@E@MIRV" [59C_<$^PD**-]24DJ=^[T) W4TETP(@,/*J"A=<"D:/2-D)&[3
M*7]G,.A8Q?<+AQ;D20Y>$\*G?SXN/"<'A[VWNOK\H0#LQCB"(ZO#(J>P,-7<
M2H[7)FS[[#.>"A)S]P3NA&$;0IH^;.:_(T?]].T/>>>R/DU](V6Y6,:HG@X^
MJ7&Z.JWVK^E2/[/Z K>8'"B1L FK"4MY:5LR!D*6*]LEZ1DM)CW(\NB,#I0;
M[/@,$_ND(7(.)FV([(<OS4+AA#X?TXZGM+1H#2!\J:"6YM+:&PQI.C>GKOWD
M,9*"Y&AWG$/10D^#RD>'0V>E5PZ\4)L,VR&XH,"(8OOR!DAPP'KE 54108O%
M"QQL0A9A"KUT; 8M,U&B4YC ]H$SZ@<K3X7_LJQNUVCP,#Q?;<4O&.@J^@&&
M2QQI]]:!+OTM> H&O;2 >)ZPT@QBK(JEA^Y8"#,B*(]B2HZ^'1]X^^X@/9,6
M)#7\::+**'*OYZMC][I_2HCC*?8\$ZS8)BPV%K>+U[$)$\)?BW:=$:10D^ZJ
M-IGO&^+8E+F%D$?_M6LLG*_+^_[PN;C8]\J$LX$9^D9^.YS_;.B/DWBN%B!D
MP]4<,N^)L0>,._"2O'<-#FIOPI(0US) ;04&/_N -^[[W7X*/AY*R6V;/HGV
MFYB+WQ$,\8C.PU]"BYKKGS#F? 6:!KZ47VOT?2CTN>"/2U,!?86C8,,3L4)!
MQX@"FS"&S3N0WPL@=DSHI^9.;0>?T#]@#]6Y.@1?'9U4=1P7?:RL$ADF5\%H
M&E(YFVU6(.?6]8:/_<K;@7T#-SA.6+K!UL9,L(JJP#LMVG7 _@3SZO*@5VYL
ML6KWDW&_#I^[FGGA_JF]B@>N27W8%?@+":IK,A EN%&<]C>>*:^?0+)*Y.E@
M]WX _"L:P./=Y5<*U0#SEH-*):3F0Z=DJXL&#AWNW?LH8,H^JR&'Z RE JK<
M3^J;L* 5MEK^.B_3^J0R$K"Q P\$QI-IKY%5\CGLRQB;Z8KU!V]K;3W^48R\
MK.QMGOBB@E,M4A/?"%TUV'&$^+)\8Q0Z4]1O:EUW&QDT27'BUD"XJS]1VFG.
M_PVGN)C?17R!.7[V:TW7X(I/BH-#!(M53\J-*E/R./TXZ\BE?65Q/<$2WQ#2
M>-I+.."@/X'DB2\/D&FEU,JYK@(J#.L(R"ID8RT&C/0$[1HKOS.6WHDIK.I&
MY*XJ)I].N=NH=)KX3$GBC\$]7+L#,@_"Q 1&)[.1)R(#)20?%*6C'U!KR<E&
M&:DM)F"2_S1:#I,[9#>H\2%^83"P<43L_8ELSR+\F,F(8>MV5&UIC<M5MWCN
ML:%0]:&_BU'"Q%\-F+WGQA=^$I\<AFU;J=%>/M+3RJ]Y[YB]X"<X8 \A@*[I
MTB(;AEEL(U>O8GR]P0QF1C=)DD(C/^ )IQ\U5NG*M]/6"LRR=&/L#10X4Z][
MI_*2OY5.Z5O>=P3@@(QOV8Y.WH3)DVE/_GG]2D.%A-6>X)_&=_F-<&Q0(C']
M=5US-I5U]9F7\&]B_EA>/53PA8^#A*)]$2RXS"W%TQC$)()LB_'G=8_^A";K
MF3N#>YN/ISVO-IC/_;Z@PL.,JZ;,S\Z])E+QXPA6!_<)WD]5>@*JGQIJEYX.
MY9CSSY<ZT9[>!F>"!G?1$<>#4X]2VN3%3JKO/, OPQ/>8 =C#'DB"FQ-,(+5
M"$9,J]J=^=KD]'I1<O[8G1I7!DH@O2*RM"A;V]\W4H"8#U5&]?Z^?M(-5@B'
MR7V'I[V%$KBD#V7A-7.=80.]LKXWF<X</W&\(\(!O*JG59QGC9=<O%O<^6-Y
M4$SGI=V-B)M 5SL?MG(VWM$<!71S9-=9KT#X.UXW7L$,SK;!=,\\PBL\KR%Q
MBSAZIO&.J!/R-G^KLHY/2(4&PD<MRB__V..,/GB)Y#5S0_\DO.:2ZZQI#)[V
MG+J;3"M& E[D)#QP$9& 5VFR!JC3FA2$8,BMD&IP;T7%&E)RT85TQ\6QAN1T
M1L="[-;4.>D#K'CVH<!)<@@3 =CU@_I6# W]I5?L*Q@D*[:Z%KS/-&0YU7U[
M9Z2'"9Z'2E_XQ"-#+T\KC9\N% </I8KA8DQ;6+)#JU_@%8G1?SJ ?@<2L$>
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MUJHBY.'#77TG9OL^>-[>Z6&<+M1N(#3V;%4S1R$7NG@H3YJ#Y[["TPJHTN0
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MKTI:"GQV%)2*&QS5M:W]1GQM-A"9M>]EG."5.R=M]!F34%16H/DW!QWNCYM
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MI$;?^HZ=W%8OHK-VN3KAIEF^UI7WS-CEG-G5["9"'R$[X*E5X9PC6B7QZ4@
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M_"'*=*>BU,TV<UU^ TPNIYQ!H7F>OU$/'8>Q=<!J*(?Q+;K_U/98O<#QE1]
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MK)M$!%5  CGAC5(:[ 6P*1.704*DP48C)A_-&1!N4MWG+S>V6*U P7T@K^K
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M_F-[;!8*M3)U_F7]FLS\[G$&5ZW<'ZJ;=@_]6\%\KW=BI>,$$&9,0.)COYP
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MN[E3<.Z?(G546'Z$'KXV<P(PJ4^<#V"V=EJ\UG,@$?^H'PQ^_]OFNOQ2!G_
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MX/" /.NNG^O<3#)[-P->>7>Q6V\;)08Y6T_D'7+-N).2P+75<RLW<X9M-IU
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MMHT<LT3Z%,(F6V"L=6A9ZNMCA.1\>%$ER2CS6-M3P?W1?7G=B4D_9'%^TPG
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M)24OSNQS<F*MJ:R2KKL".]H4B)H MR"+>UM<6$*%^ B(H-,"AC,WJX;+*DX
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MG>^U/%IU1_^U-L'.1:BKISVT0 J2__?2Z"86@S5Q6G "V%;!$ME0O0 Y_CV
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MA3'$=W0%B<$\T0"0$7#FG%,FDK<BLN;7WE:=G(_SQXT*>.$525AT>.ZJ>MC
MKF?96P:9>G?W?3PZ94OE>2PSR9S>'@\RJ1'\RB/]4'9QQ3\$$WY0NOHMJUJE
M+\I?'S:-42O"AI"W:"WINLZQ\5=2^VZ]O9SL\H'AR:$"^MCKQ#V$;52V3[<'
M\P9G+EUT8D9_V$H(SFBM:;N$6[(6NK0*O1^.S>=B0K0<#>\T:X<JAMZA)BHQ
MFL2/Z,'(39(!EH[=+LFPOTS\0O$4)/ 86TJ&E&<T!?A%U)A517A-P%2,$\.<
MHFF>3XR>WP)-JGH:3MKKL/^;7\\W<P9%.R.D((,V-E:H[PW_'3VZ,*LE1LFJ
M:_1?B_K+<.:XH&S(3E<R2-T"9^\:ODR3PY1-!Y$Z'<J9EUO=%K[Z'Z'8*+_H
M=-><DD/F:[[>1;@A!2F>7/.*( TW2$&?YHJDH)40TIDK**6/&D&03J_JS%+-
M'GG+>0>KI],VL20#?HMBE"(L@X][<G[^G4H^NN<1,[P_]'[>/)T7Z2$J6,X@
M+=Y'DK[VGZAEAHLZ92\V)OT[L EC0=FX1%?&?V4#@PYC"7*X,N;,VL"FEUL3
M%S2]C^2.J_S9Y[A[RAY)T7P#DA2,<R1[+U[!2PSOG[-R&4W5.\L9S9T>"1,W
M=(H@-C"VRW"WU_V#WP>8GE%QV ;76ZJ>2"JU:"/!00K:K+H1">C;9'[3!R'
M62*5E;989QG,GA[?0'482**?0RSI"P^)],75Q(U OB *6&#?>0J<[I8U(@QD
M3VA6QC<?5^71E&RG.UY.47VMQHKWY-;.&#L=;5D,Y'Y)V_"FM%L+MII7<^&L
MYS=74.+#']C;0>J\WFP[9:"\(\AF'.DVC",K(OW"?S^*QZSW]^^/Y/?OO__\
M=M$!Z^^=7(/2!(_4M:.JRH.0&S(2EP5MDH*ZJ&DSVKQI\>,E<BK!#4)>A_1
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MV]AW: %4+[Q-9.WW#H17!'D)]'^U/=/P1X\ZX%P'8PAWQ" N-^2[%6A&AFJ
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M3]0'C&4><78M+M0A!4-S=2# ./S*],[%H0Q+M1B3MWYNDUW2=3&+KOE.DUO
MVF^[T.#/=0&JLZIM75E/^#4:_S'>NS#+Y&6 V2 1-D /Y0CPTS8Y B^8NJS+
MC32]03WNNZ'5-C7?L GE0*7#4;OKG[Z6.PVHZ+.+8GW%JTW>*^^UM+HZCL9;
MPDB/?&3861Q+EC>[R5(IA@&58?D 7^I&XBEAX2.VQL8'+Q=_"/0^/KBOP%WJ
MT)R)K4KF>.PQ,>EP/MZI+7!&2])S6-+1BX6L(_ 9<R?:_?NKA54QZZZMGZ_R
M$4WOB$?<(/YZF#("^ST3-SW[!0#G#B\4Z9[OS7YN(4CSG:*UX%*0>KH5$0?;
M!"-BS<Z+LLD*KZ%7U=NQS;1M'7>,%/F%ZB_\)HYYZ_(.)-\=*DK1#=SH.=#_
M46^A: G.8#;M0(;#QSX>T2C%U8DLDOX'MM@%3H\L',VNG_V*=1[3[#"D(X%)
M*5+X[@T[_XQ/\5#7F?=0S^ QX@F%E,*/*D.CL'KBVC/*[JLW#S[U\ (H6QVJ
MKK^)SZ')Q?/LI N9288+Q?6G#UG(JIR,,<-^:R./]8WQ(M5H:OFT"3+C_O[B
MTN#;HK/?6X_J2FD\N"+BY. T]-]JO*5:Q,.-\THCM)LM<>G46K)P,U7S6F%
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MG\ZN]NNF8=A8FZ!Y]_7;Z*/ "_R-=PVAQ_#6DT<Z#5OO;4\T!W2L_6IM-/4
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MD[C<XK,+BAN%A/2:&6!L<"UU_SY$%[ :, 3LFUW0D]4APRL ^8NA4E-&:>A
MHY@]HGQYQS/X\->-T0!)U=HX-?G7L"Y$ RX<?10H&=>3F7!J6'XI:6PPH"A3
MW:/\"*I8I!UX5#M06T@W^\ Q+FEBO#6]C<4US/;;JZ:#L,96N@[J9?\GE-X
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M@G#%NZ!:W';*+HA<515]M:%,9.LEXJ/?Z?0/E$,SIP]K21PUL<U;Y<3\3,O
M_-4 ,X4):;"4?J/[<;:#.TJ'1H^7#Z(O[S70^FHGH+R<YD,5F21%[(*<((,P
M,LI.J[\&\J-:'SJP:8NA*USI4I;'MF--X>F!$_#(CM-YT8+GM:\5I%K).'+[
M#Q'UV;<55D*L6WU#(H0MQ5.?49^S3EFC>_2EJ<E]T8O+W_O5E*Q<TPO[4H_\
M+OQ95.SV,-B>^Z\L-VAG<ARZ?' "')FB0LUJ((HRA 9T1?( Z;4_8VM*U@MC
M2'6U[T%_C*O./'(4L(Z3%/I[G3X9:Z<UR#V0:=E,HMS'#=TV#27QHL0?CY,$
MVQV^D!@8BF4(6AV(O)EXXV@T>;BM?H"OS5=*_X]$$M)AB#P9RA8N\HE1*#BM
MA!(6SCK,ZL&4&M8IO]9.R2>OAE26+]W-!=I@G2CUW)$'UH!'D_#6W;K'ODXT
MIZN/MNX8>,P8"C=^_JOZ_0GD!>>\E]!V&%T5>85$!B_+L.,)DTH*0ME,F"Z;
M1F+V;T8BPGL6]$]75]GZ*C'4,\>&?8M,%*[7W!I.A"K=.^%]YT+35;K,"-!6
M2Q1"J5+$:3C *A/(O4==K0?S&U&(M&  DZ<[A&@Z<C'NSXYQM&-[;2+)XD'_
MD$5R5+BURT>1.\,W.!>$A+;5Z;HH>U<8S6\O\Q]@O\")D0$I:>JIG+*:DU7O
M&L\-O"(4 T_OK<=-;2>M\+E-1OHD?%?\^DK]!5$4Q95HR1"HHA&!75 6PXA:
M";21H<OPO/(&/%_[Y.AMEPV.0_CT5*[JUD'8UDM=UYDPQ>"3<A:70$Q<*E$-
MZFQ/)2Y9T#U0K@3FVW->ZSD+D,*6<)3KH4B_@K%GQ"'TF9Y-&:$/=$,OV4SC
MJ%MW)A,.]5V<*(?:*X?!]K.T@([Q7=#R&8H/;;6KX#D#1B&9]50;DR%ABWYP
MS*1S9I&5R5C^"W6KV8B=7YZR)"&C?JM$SK>B9I<XYY*1T/!=D*L?'KQWFH,:
M^"\?FJ]#GXUR^VR1S<--//G20U<SAVT-X2K5CE#5Y?U6=Y^!S(+VV]M=HF"!
M$Y#:7= AXM(^2A"MLF^3)+ (.Z8+HY2--31JKU1,2E[9//?(.-OA&EVM1!PY
M*/Y:^GHQ7Y7'!1^E!+HA4J=17X<M?U[7B,[I"P,-$^ #H_BE_(G#M_/)2?X:
M-O&7\0^"^&RO=R\H17^.DP&_/_Y(<_^^C?M8.GST&9%RQ]62=9A!XIH-N]N-
MEKP\Z5)]QRM=(\[%8ZS5@3_O"?M6#SGC+KP]=O;=C-2^K0C&! 4=1)4G:S)$
M+"=2!U$F5,Y&!+\-NI&F6:DV=IK0\_1[G!?UX'9HYZDD%Q>^J])1CBK;[Z=_
M#HE\9@;@69+H3K:R2L*XZ6G2-BG,^.C4'AKJ:I>G)+]' ?"+!>=@YF; S<K2
M9&[U]Q@JCC,_*14/AX4\"3X; .[EZ,E ;=*U,767&&>H<')Y$SX"(H*2$6EH
MUR'+-]G:U%F7Q@\-C>4W?H0YFKW(BSW%6_PP1_:LY)NA?8ITPP8,.S0U8;F'
M67V0(F@3- 3#YQC9 !5Z3%V$(<,:QT['( 20B[=9[175H5MVQ_)>A-I\>]^P
M;SU*_ IG='E]==BR#!ER")G+.IQ+?[* 5NS.+PB-W#N.,&*F'QXZT974R!(+
MM-K7\0OU)O.*GT+YK4[.>>\DNBUI=.\4 @+X[^TMLLVP7%8]DN'N,K&>+Y/?
M:_*-&;94_]?P_<F&(@]Y@X=G1C_0<AC;U/*E>8K"I!-#V*N&!QE:#R<>:J)+
MY8%3YZ5.5!!"'Z4HI*A*8%W/&DFGK6SS?#CZ);9"$)^/J0,S_":5WV H-TT#
M:Q2INZ"(54*[1?4%N?2=@BS/GI&'<H3IIM+K1L<_>O/5!Q3)?K:/<^98^/7O
M"_[.$\<)4,J=O>1 VDUF=BDX#%(RV[0+ @PW;$@@ZP7+^Q@*=G[+;R5E9^?4
M.__VZAB5M\T:@2+3?U2,H"=V00U+F/$LR(8'9-O1F<@(L\O=!7&*8UI7 !M6
MJP66]9F@#1PBYFBIAA7S6O(\/MM?;_Y^^L"PY_APW\I0%?0=,!P.A!UN0E:J
M7?CPF*L]/<W<1<ZA^/9/)AN@ A4P=5=W0<^A0P.TS &6!+H3P\8E\HFNY]7[
MO+*M]U@X-&OH>:7QXO&/)K1^:D6]R8DA(UB2UL\#Z)2!B0Z&^+M=D'S5!(XN
M9TG:>=FC0$LDBE!5#P;5NM_*?IS=_/FB]+)@:ME2G.%RBLBD>T48]_6RLWDY
MIBG/UMZ]*_8?WNMJQV PCRDT$L>_0LN\L R!+9IM_R[H&8D/I5%-O?V&W)9[
MG."O8]PK$[BD-+HD;*9VQ:R(JM[H]]JA?BJZ\1'=%<5V5<X3E7OGX3@"U1U:
MX?[X^O$;-[9-&;)#EKK42U+Q[ <]*(HU8J850)_B(G E*S_(T#?E-8<JJ::O
M-ZI&[?Y,FE M,BH4=.\/=%9QS;X)6Y5)5#MY?O$'O'.OH54H>-B&=@WPIUL.
M 6<8%T6PJ(M'\Z7"3GTYE]AJ_T=&)7R2_QBG;>Y AOL%5IVV.*NWA;8 ]%$]
MK*CX:%V=<3_24>!<_\2OH;9;%&9RL]W,C4<AFD8>&AK5Q3<:G'[EI!*AT,?@
M_?-03J(C$3B%:2'NA^\LX]^@GN);R C^4>B;<V-CNR!#7,-0=7-3?N)=4(A<
MV>NN^Q?*KI&V!A,"H/:G\:U'C">A@2V-N,%9VF= DWH.64H29@WNS$1B)K%"
M0 +G&UW#3!5X)\EJI$&L^>..06E9IP$"<2;VH]:RK((;26%'?BF,KH32 "HF
M\$,]$Y!&B!CJ"K&O1IS5K:](H%C4 MD%5X:NF0,V1E;[C^.%<-+DEE6>@VN3
M@^4.(/2'+A@6NA\M^J!\::_!P C0C#N&<A5YPY+K<"+C).'G@75S(T*T]&Q]
M9?3O,O,G*$6T:ZEBQOY*+14%Q:B'FV4L>0!!A[I "."E\ESD8G.B4Z BYAGQ
M !+#5H"AI3 !%>'O?7FE.N5=8VN45IK)N07RC(@N^5'BN'0)].,X)%?-<K*%
M39;8A%^"U38&81;KRJ4B:6V7*%DA^GHH[4B['A9D456/&(32S+:9BYS0Z.$:
MEOMNIC8O&RMK]["[]6PZ.*"&3'<#(L<Q2T%T;88K\ROQ\2XH9HLJZ=0P=JR*
M"@ME".3(K;PA)_,1(OV,E[W[>93P+E[Z27K#"4\3Q!X_<;PB)?P6A([L@L7#
M2G'UIF$IQYG)4!=L#+2$N!Q-CO8P'=@%.1Q!6!8"OI0LT[@C9SO,B\H_PJ&"
M5Z6?B< <?CQBW7%FE+A/;>-T:I=M^_#1*.5)"'#:<"F,?) Z9=G/TF!^0IG)
M1ZK]52]NR[ONZ@DM;GO!I@(_Y.RKUZ8>W1:SS<H'^4=.0&*L.R+TP494*.T^
MQ36LL2J$*MJ=VC-)E7CU7&5;++MG4_3@[]A*7(FOI6GIF763FB9$LO4/,:(P
M2Q()JR6"B>.C8&X@C1R3[_X%3H.*;"#*V'% ;X(GTO""9F-S3Z,/W]6S8>&U
M/8TRL3<ETR=?VOLK34($&%S,;_\X;ZV'9L<DL%1P!T>1FB:=X :3ZPB^E@Q;
M).(2SC""O+DL[1+SLR#^CA]>8UFPV/>\P<G3.<$<&]K5EK;,@M52R#"] 5>X
M/%#?LJ9K1&F[1_7*BH*663K3CTQ_R!UBOK_^( YA4=T@/>FXO^RE_CYV#$M"
M7:= PVN$T;W66PVP-Z]8V1/X$,P^E*HGZS255443QW*._4ANI^'.A1TP,U!Y
M9IF1YI?=5J^97_U,[B]%OI."S 2+8NJ>ZH. !/5/RBETFCG5OL3V\MGBUC-]
M&T<8>-&QX\>TCQD^ ]%#_[-*(1<NAJ&5Q7IE^([!AEQ3E%7=O%?,56.8S]K=
M,:7QC*1R+''I9A]F(\YZOJ[;B^HY+^]T1LY_V0?^=Z:Y[P%*\F:^[76E8?B@
M)CR!2/D"77#=!;6"68.&C-/@G23,&CMVEUE.'Q%B<NR"CE6I[H*^XEAFV%W0
M*0P[*#9:M$'G+'=!'Z9W03\A):_T<<QWZ=;S=CX)-+A]Y._AZ.%[O)/E-TL>
MPI:&V9<LCT/H_*5XIFQ$U4T6NMG<\X+7F7(?475_O!/\+RN\SL*"XKF0X7 Z
MRW79,[E T,S 0_+D0W S=-"&YLS\ZJ6G^A"8I_#4L<[UJMF2_NY@PW7U$%X>
M3\17N1QB>1K%OYOO6TU<S27C@W9!Y5LM>"XVB,-0'O2#K,Z!2M?5 /71?M)!
MU.W*E\.C;;F#SD-V^=DN/DI2_)9TC7R)HL)[OZP+I]]\ 1<*C+?4 2Q18XJ9
MOB#2&:GA=T9QAO*V,W\75");_C:.0BCH.-W<].F#0M"[V':'.6@)>(E$QH3M
M9-5CP0P.BFM6J/K/8.O9L E*W[>2WK<G+I4?6QK4XLH)T'HD=&4#9/F+?7L#
MR]O423)F>98"IAD ^]PS!YWMSE-'"[!4PT8?ZU<C'7!:FTUNKHV.WG:T_-IS
MIX]7%L:L.YR';WRL^0!DT1^SVJ$<!#(9'PD1>:[FDE9=6D*LK@J]ZY3UT%;(
MY@'>K>O(C\C?5BC"=^3OI-#.EZ<Y;K;08,Q$M1^&]3O-270=0'ALM>[8<5T1
M+\[@O#B3_=+GS5N#K0CF6M)*J?%DIZ46NA;J2)4Q*7 7M$]7G'SF26E<_R'*
M0&C^<]0GR7[#4*B<2%MTLL6@"/?OK^&RCM4#+.Y]],> )LV7B6/)9H6RSE_^
M@EQM((&5O=H.IW;)]@X82I]!MWF\BA1O@A\HN=:5'B\G\Q(?Z*VA"VLD2A 1
M.AC@U#7VQ)0EL5G0U6)7 =J]0FJ>F#V+N_S[.ZN!U$ZY7KS\]Q=S15<54VYR
MI5X;+KMR5/1*@+\\N>.O#DV:@O[*S"5#!SG('Y,\=D&'(0Q9*7_LZ^?2B&77
M&!SB5R.T>W^K]!LTP*]UP.UB=Q)-EQEW#G4F#S@Z26/KLU-A$WIWZ::-VJJ
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M6IEP@O&-E5B!.R4JI\W<P0G[%-/<1_:-8\83H10S4@BD%+&T33&L@PIBG$W
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M@^AEH@_YOJ@(I9AAT/";\Q%"!-_%A 8AUBMC%9)%'PD6==N[P1G:]16'5!Y
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M+ N>DMV^G]=]^.*7+3?\IC< ICI\)@\TV6R$9,JM,DX2;5\VQ1V/I@!]4GE
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MHH!(@:GX*0=X,]B"C322F2NFX(<9MD@18T/11WF0A&T?6JLR7[XE,[^Z.N/
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M5#V:RK!WW4^1:0:W3S?U.GP+./\6M8]K9^Z51'N19FX)WG-*L+;U2ZTS&,?
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M+LF1]@[54D5F)0YVY,HTC+RXM).;5E0R>(@7\.09KIWW,C:Q8?YBN3=N8FU
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M5^U#U@._+;7C'*VX+9LWYH_9"R;//ID=Z WV=A[=WUCJ@1^M(MA2#1N)T9G
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M7 <8F!RK*^;-P\T"V3\V-;F.[L";:J_5<2TV@!7/_OCJG=@WN?<BH@O(!;/
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M-V*XW*D# ,,F8T1)0=] +;YX;\[)+G++6"-W9[/33&9]'O?@_CXSG:V.L1F
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MT,V[#"D.W9(/\%9;C<\1<!H>GJ)HM=7N64;FZ_J::&S:<DXU_#S'G/>FX0
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M!OE=OCWTS9.5]>1OQUAN GK+P__1*C0J!@\ 9+DEJBJ">@/Q\Q4,N75LY@
MI#+RMB7Z"%V\M0N<)X#$M[)#O7MT15L(,?&_;$,-3$8],1Q3LD4=!JH>%P\C
M'/+FDO0 <-8AL"$<"_J@$0MR-N/58/@T@>Z".7O]>4&K4@XCE&%/?- @/4Q:
M7PSXT@_^"?M[WJ-67H;A!@MTY\S9:\T+U;UG[RWZC,J&<M-CI/7$N%\2F#:
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M&,\6FD1LF8J"&*0H5<0AR H,4A:R:,IO& IF5Y]&9[B&A0^,87( &"T_<0!
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M.=-1<4@V(IS'\YAGN8T!7V5)I/G-@Y$ZUR-Z3I:6&!?K4&(.(+(WGRUW]]5
MP"K> Q[. L#2M^DK4PS)3>++B?KE5I.R/*T@-9M&6;:9T)KXW)S?[^QD-EZ[
MIM<^E^)Z2BHKT^R-U&FEW0(FAB*;\3/8$6@SEF3$/](VP]_2,[) 67S2!.54
M6?%;[^%''AY@2CO^3'L3616\XW2.9W5$ZL'+/=B.F$-I?;,7^9J%ONO=S27-
M482H<B0\I8\:10M%>-.:,3.8F+0]+[,1";R?@V;[+TUV:B;(<!;MBX]M?7[B
M@%2+T6:2'Q):!&EDA$VWQI$K9N"QM>9DC687T2IM _[4U@V;'@_B9N<2S?A-
M?+8H)2[@T?W +V6-X4;MKQZ?TM=C\C$9T?4RJ$8(Z3P_-_T$==A'JR*!;OUN
M$E'36F[+OM<!!BO^<+_-R_6^<I_AJ/$MG1WU _\;M812"]YG)0XF@!)#-X([
M8I=\M$$39:6,D<?8JQBRN H6R/DFK=H5YX)P7K@7+ "^LOD4O\0"C>*[,%]Y
MX>%^2P&K')LC5LCA\X>Q5?(E!O"XO.&F6^O>3V_,R'6YIY\/(SL6!.O/,25Z
M*&"Z>[T]4M$&2_?&4'V@HUS,*)"TO'% D]^OI2E1T(OG4IGW<\&$*\@"9,C0
MI4\KS/#WZ*G;+$"C%T_,!]D 9 O" E:3O5A ZSL6$%G">(6>1[. 3NL<L#+&
MG<C$_#W$ >9X-PN8/Y+#Y%)=.RGY;\B@P&SN0,]+8)ELD%7^/Z?_/V5Z QSC
M,4H9I"!9+(";GRZ/.D +^8KJH,!^F66.X+LGF 5B)[[6!?35O:T/8-Q#?_=E
M 17\C$I<EA(YX>AK4[YFD=R^V$>VRDGF<LO&BY@Q'9,ZI"6_5:[#A4O(8=]R
M EZN9OAJ9JS2G&4VCT+FO7]H2MTH*!T4]:$XXPD+$$ZEY%!RL"Q E6F:/!N*
M_O5YP^,3I57O>^T<4Y+&S-5FVN)IQF&5*N+=:[LU_??=<?J2O+B96>Y[4M(R
M$+%O4KY]=?'*!VKL>$E\8=6-#?."*PXC6!,KV DP0J+1@X=!E6R ZLKZ.[ @
M=&ZM.0LP@*YZHE=-5;<6FJ!KVY:0 Z4X=%?<&#G' O@8+.!*.@M0(C R,53X
MRE8V8=.%!2P)__U80V8UJ8>^/;3#@P6T_XMI(3_A>]$]&'H:A/X875BKP0*@
MH 7MP2;?^]2V&TTB$-;-\:M@^3&J %J4R0+>GV<!R2O,7M.M]&;LV@P+. PZ
MB"QD ;>;!6P_%TI!TV-^N8FL8>G:&XQ+<#H.38F%$O'XGT_0LV%@R6#%?$N6
MIU-!\4!/Z^#Z<Z%_6VB=Y!17&PN@NJ!'"61SM!L+<-N$K+* N<UZ^',6<*[?
M3Q^/G"M72I5L.C$)BTR1$;1($2PC:+HLR67Z+G?GBPE]"TTXHH,\Z>?527$J
M=CP\6:AX$V,".GWC2=*_>EOR'S)'YV8/!53"<PLF@050)NNQ#]#?LL&%P-$_
M]AHXQJ._/<>Q #\6\,/?( "<8N,RZ=2_\T;F?,]7+J8[@78+K#IBM]3_N)E)
MA6!IGY2$9]2P@.PSC)5P_+?G?YGT-KA-ZZ]N/?YGH'/0,1K3394&[M^Q.YO=
M]8\8>/SW2R H"V!4X%XL;+CP@:A^40S0NF_:Z4*@]&__*KW@-NR+S:O_4C]9
MT*N0S73T4A,X3FE.=TN#P@9JIX(Y#J5,U[L^PG]+_Y_ZR &E?OLW53T"E4/*
MVOCP_[P!>LBP6)#WP?DFJ?B6K<'ZEV^]AI9.+BT-W'>-U-J?A,ZY=(OK\#U-
M!3!P\R!P3:@3I(G4./K! L>?NNY9?B4C+J/M$B>RKC5P;05Q'5A5,OJ'H&GP
MZ/?&FX/^SK9XGAG5344E\ :_=<9RDJK$-$^#4#:8J0= <;_SY_ZS.&P0\ ?3
MS??\SK3XH"G"YN%Y]!AARPG3H#/,/.L-*F>%F2@ 8O[H2?FGL?WOV^_M%O![
MLW[7Z6*:5_\&F"KT$Z$$HF\+G"@SWZF0B>>!AOU+^#_8[-$?K?J#JLT\>_8O
MH+.5PZ!&_CK;G"XX0Q"4X^_1-.BVTW@^JF132+TJ&54&S_%*"ZJQ# L+.F!'
MC#>5Q?X8>,'6@>L -3-'V23++]E.FY"B(N0J^VMY<YS<.SMB[+7$A<G^.BS@
MB\Q\UI,U::B=OBW1DH\Z!R(*D%%Q\'<_TN)K#,/<@O9Y?H^/.H!9&-@OV/Y7
MQ)UD^<7<:1,R.N)0Y0"2]]WX]<[U^UZ:/_:1X6"8_2([W_1@;<\I_J^2VW.#
M/8U)47&S?^GI3NDPW^ZYY@\N^LO,?%/BVAZT+5)J!LI--R1-X.+H@M.2YVW/
MU46;^X2Y'4LZ(8RQ^K+UH%U?@ ]EA?I(^* = _7&[U6-H\-$6E]..>O.B%6\
MY^EXUYZ3CN!G1LD;[^=_1M["DKJ(MDV$!RXBEAQT-5*MA$'R_IXC]HX:(GOF
MCHY<OV Y=$^[8+F@<&:M0&7OE7&3^?%C[3HR,E_Z&W:S*W((-HA$@?4Y$1=N
M(.I9@@C[J,MQ)^CI1K^+!<?MFL@,FPF9V:\9ECH_ELY1_4DU'_'<FB?H6J0-
M(XF[R:VO3_[ZPOO<;<)?8R5Q349-W/4%^_VO/  ALPK,'"Q@M[X8*=4PO<F%
MLU^VK 1[,8-B-UN3=-W]^4;[6+;[ :$Q':E[6<2*)E5NNL(7=Q+A@>_RH;+M
M;L95M4G!&N=HX\NWS<3G=?<,L'VQ<MI.:9'U$E3;5Y^)/3QEQ JPY^KINW?6
M\.E*RTB-)*.YS%_L;R!\]9+S4-Y \5H]XL)G(X3\@'QMR  N;=I0%E=US_V;
MPDFQ5\)_@XO2M6SBVPGG]QPMSPT3'HW8\%7!H8;W1B5OJ$?Z&;$WXJZU0/B8
MTO9(#5 \1E3T^LM+)\JXE^F,@(O:&@>3-_8-1N][)+2*NW8*8H/Z"%T[#CI,
M%'/<MC=Y%4O?._>1ET0P)*>$9Z@/KS>HO(8'JM!-WS'>(^AM57 YF&>S^8:5
M_^K]1VD;>)!N[EHQX*4:S36FXD5J;6?$*H=45EIS9Z0N.D^<.?RXLL*4IS)2
M?\FXK3-+7(OJL>]=_<'FX^L;FF" D-F$U-YR3")^TK6P1+M,TO$:19F5*R B
M3Q#ZP:1 %:F\C.S17*^>-F-74^]LVV(;=_*3N>;#H1'[*VS"5T%(($@3R4^%
M3:M&9 A4DGIBF"H^3,U*K%U-W7G'YMLREL(!9LZ^J5?9NQXAW^M.!<"T%2X[
M#24OE6-@4&K #Z(N)H5<-E1=H%_+-'4U]B>P,R40-43;"!7DB1G+N*V>^,(Y
M<"TR@^OM,_:9L?:\<L71'Z6=7&==J/M[25#B< )J']5HIHD@@%+S1NG4I]O5
MU,39#MZ<#C>[FF+4.\:)"4]4[>2_Q*5Y5L!I*"EX["YR"/LR7"-7Q;$AKR"X
MOV-A$^;ZVXJ9;%0,::913(*KA?_1,$IW0&Y(9?G5D&K@LYN3DEXWE$4*VR\,
M"2J.[J=_ CY#V.E"9->/+@*5O0;J2&^XM'>2CUB(Z&@7(ICO6).'[,-7I:NO
MY&"=Y^334!ZM,P_.Y#;J#Z4%WX'CTOK72@9D+MV>K96H'O;5SZA#%I8.+@9K
MVDJ1H(W0??IB4[1X^1EXRSS2)Z\CW[D'GF?XROAMO@WFH*=R[;L8&[6W8I_D
M51^E&7!176=4(VHA_F^1 =37'M-+U];CJ@K6]:0$C^[5TW[\3/F3IYFRQ#6+
M]>OJGLDZ;6G]%WIZ8%J!I>LEJ[L&GE;!=Q;6EJX&PV$6!=IZ$DH)5 AQ)=Y
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M,>A6%$E1G.*^J/1KQS]Y?/E[/^C^O9L\ VN$PPN_2>=DF0NN7_'=]OK/8++
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M2RUWQ6$/_5/I3Y/!]$Q@'))?08JP -G/_+0P%F#QV,I89(UKX.$_>PGI!)-
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M<T1]8@$EZ)99'V?^%@.IH76TE)?NW:XV'U G=P)OEB>T?^S@N-2^NGDF^;;
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M-*_^[>!4AG1A6_JTOQZ/@[!; ;/A_U(]?QK@3P/\:8 _#?"G ?XTP)\&^-,
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M"?5N;I]?%NXT9N$46'7H:P-O6YW%;_;]R^K_O_ZZ(BU-_A-02P,$%     @
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M#+'-;@3%&I$$IYS'3W6?PSM0]KE_-3Y /93Z7&/#>_*3A8.UH7/>OOG/+M-
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M,BU>-9:-_3;ME&<336@PLU'0%Y13\>BUN!3#JQ2#.'^PN@L&JI@S)-@ 2\"
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MJ]- ?]AD-B07&*X>U 15E1F[=:H@-RNSM$Y0\(N3:RK/ C.\_".FT_,7;/G
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MJ'M_CWX8E=?I@%;LR-X_J1=(-?S*)[\X_:#E[DG\I99#"=D[1I<NG&H1W\.
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ML#\Y,IWEF+*N;W_W76@O9VMYT+7VY"_\PGQ4^+072_ ;,Y/@CXV7PO)CK\!
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MVQM.J)^;\_*TN3=K*M=0\SA=^MNA'6I6]%?2>P :U&4.(3IQTSRT!(B6+2,
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M-"-#X;T+3U=G R.-:,3VI-;/!M*<HI!(I ]2/C^_U727A>C!0I/GR=P[8HX
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MC=>A[35?!($;XDX(ROS6@B,K3I<HH>MQJ-M>-GYUIZ'I@)68&S=S+&LV46U
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MSNN)2?O$HASN&VDE.-YV>-5KKL?SNNJWE/6Y<*EC=:M(EJ?O48H;;8*9M?T
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M"Z:J_]???/MOO367W_M?4$L#!!0    ( #: 4%9=/+5SF0H" ,-/%0 4
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MY]_>;73KC^M\++3FTP-JR;;$F6MG89D_AV')3&'8?(.%TJ#"0)*"5DHTCU"
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M:J$<!\KA$"GD*25$L0SR$V[#*,>'G!JIU%*!I02/M;" 5=+:,8L!U&;DXA;
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MGC>:"]A+S:Y_V.\!]I/ Q7)1J!=NO1R)4Y02YL-$)(D.K*8P]6@(24JY3[V
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M/G9D.(K)S;AT:H8<F(HK=<&6OFV5]7KOZ@RT9FY5!QW=*_+N:-_=]3H#M,(
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M_)G<8[_;\+=[)7>AB"G?.F/39VO- HTF/I)Q@"%E2'?^]CU(B&0P3%"01H'
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MZ4>4"YA6QSY!$$.U?&8P1J$4(6>^;QZ9?ZHP4YM0FA2_HA8=D+7L@#2-]<[
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MH-:A(O1BS,/4]PBR\Q,-1YZ>FZAE [5P=CQABC7"L2=HC""-$P*1C".($X]
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M&9/$,OIX#ZQQRI!08L  8[U:Q @2I'Z4DE**(\%0&-LUES\=V'%ZR;=GN5V
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M] >. L%)DL)8Z'YQOA? U*<2JO4J35,<!(A2&T]J_U!3\Y\VDH)6U-YY$@<
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MGXKEKH()_&9,XQC2@2FGQ;)M7ZZAK).7U]4C7*?%60#DB&Y,1AR5=RP@>$Y
M-K?:+R-?+GGU0&S=K:3Y0[<8Q8?%?PN2W_Z^G(64XYBE%,:)U)'*GJ8GQ*'/
M!/<HBZG'C)K)GBK(U):>VJ,V7QN=9(+C*\^Q@'V%'4?0:M(VLVK_V%4&?%@
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M0NWG>N0J5[&>U7)"%*6FZ)GG<Q1X,E33/4LA\K":^ .1PB!%*4&Q6H2EQ.Y
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MQ"RO*T*H!DF0 &<^R5NUX[ILAZ7JOG/K0P96F=.I3$TN+JM__06X9%+*3";
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ME@K/LKXNPTZ-H?92MR.ZG^[Q?K?2@U)\SV,YQZEPV[&'!WAP-W$@;'O$//E
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M/O/[8K5<U"NHR#A/&(EAFBB[4U$*YI()&#.>Y4F.N11.Q7 .GCPUVJB%\_!
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M2,D55*FM%(13#BG&"&8\2C!*1,+-\[QLEO.#3L^ :60&JA;:V_E^#F=G[WM
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M&;9U6X7YZ&62PE2E6G*2D Q[=;FX1)@)DL23H%70U@#4*GC2QB5SY<@P(\W
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M/]+I,35N;#0LW /3E!&^:LK<B&^C<%Y9#4"Q^ GLE ![+08I"-0?Q$!,UD.
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MT7 )1 -_M3W1\;8(3D$0:*T_>/RHJ_@IY9ZOSR>OZ_=IOZ["^&Z^*;7Y:&?
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M_!=&/(ZI$EF4Q5XIA%V#36V1:,MJNUT\U-)ZEF;M@M>-GT.!-C#)/L>K$72
M8!071$(51.T::MQZIPY*'Y0S=;GG0M?;XGD,W/IML1;SY7J[VB<0(:QRI"F%
ML4AL<1JE(14QA2F5*%&4QV:?W<L7YS+ZU)BE$;ZT+)['?*[!7@'O'+!^D^/I
MP L-^4@>O2!H]_?R^: 6VNWG-/;+^ %]8#GI&/1ZR,OOX-\JK5;FE[?LQY/.
ML3R/!6$93&@D(8X38HPMJB!#G",=4:*%5S67X46>&K$V4MKCZUWUP,>K]L''
MRVW,3\SZ^'OTR^?RS[E=W[T=1O'I[]V[9VF"V_@3 O]I=_3=$S#DYO[,R!<$
MJ%6#?S)@5D4J9YF,,(DPA1IG'&(J,\@HS2#.*<D()RB-=(_(J.?C3#44JDH<
M[!&(<P"D2@BF5$E(&2809UC#7)K%&[%,2)$G2E"_ /U+81SE++$%XA58[.0,
M :C;NG@Q3$,?.I8(-9U1/YU'J%^8TBD$0L8E'8PQ?B#2*36/1AZ=O#BXO^/+
M<EZ(QUOU8_/:B/R/&<5$J$AR*%!$;+DU"G,M"419)"3&L<;8RVOJ/O34".)P
MNVVMLT:?8#Z-YQ-PL4/C EA?U)MQ!2K)P>_UGU8%4.HPCD_C!'##.S2>#SP5
M;\8)0#Q<&:>>T(_&CE>;N5Z5=8=LS,GKQ_TE7]BC_='U'VPEJ[(SZVLIBZJ9
MTM[%LMYY$M,L9S))..3<NC"2&,$\-?]$6DLAF4JD5C[,-ZBT4R/+F^W]/5N5
M-<OK(E%&R.*[+?9<%9 RJUI9,\R/-X>=<3>JG<P\#LS.I1+P2#VXEJJVZ%?[
MNEI=4.I[5=>&,TR^U[GEHUX/XJ0>97H"K0'#RCKJLC$*[,]7FG$&?9G%Z=V^
M/N:G;7G"G@L2Z<08X!$5 F)M2Y!&B8!,211)\SVGF=>V/+B$DUN$GA0@]2XX
M.MQ,CK/07#0_?Z+%I:7G%:@TG<YR<G(2)K*$',KWIUHV3L(;>JDX/9!_ML8U
M^CE^TLT^KF.HB" )11Q!+6@,<91C2$D6P5@P1)G2-.72-7'CU"!3(^E2S'\#
MI:! ;A6PHH)7T6OP;KM:@NCG*(FBGUXECKG4G?AV\VXHU :FSB> O6T \\\$
M.8F2>U)("+1&R@_IB9I7ML@Y.#H21T[>.EH.R3GAV^DD9Z_M9S*_50\K)8JJ
M$8!ZF*N2HA?R^GZYVA3_K-['**+4C(AAID@.,<LHI%@G4"M)$%.<LU3YG?*Y
M##N]0[^VU*4#E;7$M7Z7A]7R0:TVC^4OBYTCSO.$T&E.J(IS@@2'*:$*XMQ6
M\E/F/RK&0A*N6*Z\#@E"S\@X\3K/YJ,M[ "8N^TA0B,Y\-K6%M<&N=0"N^/I
M;=_[ !3(9'<:<E0KW >$YX:UU[T];.7XYQQ52XTLEQK:=$1G+"$\H5#D-((X
M80CF240@HLJ2CA!9PIUMY1.#3(UCK)C_]N__$F7H/Y_8R]3#ZCN%IX-M' "E
M@?FCE/#99H+VL8U/H>1A&P= :R3;N"=J?K;Q&3BZ;.-3MXYG&Y\1_HEM?.Y:
M?P[\[=.'VW=O;VZO;]_=O/OQ8'BU2;IBBFI&DP3&/-(0BTA"GN(8ICF.$ZDR
MEC'G2@\G1YD:"U:"@DI24(OJ_FV?1O,\!0;!:& ./ I/#PX\C9,["0;!:R06
M[(F;%PN>Q:.#!D_?.QH/GA6_383G+_9CPO5J,WNSW"X,Q3PPLZ_]9.:RK)8:
M81KC# LHT@1!G!$,#?U1F'#**$,\E9E3KLFI :;&?VT9@172J^SL21B[V2\$
M. ,3GS<NSI_N.>6[-H;FWM:FT/QKOR$\^=A1/NAS2C7?\MGK_ V:=UHK&PY4
M%]&[93^^LHVR.08+4<R+.N.@K/5VNWQKKEAO"F&N^KSX8,6H4A+8O+I[QA'!
MB%,%193:)D(J@5SE!#+"DD3(C(O4^=0DJ&13(X[??K[YV::3&2N_3&MO"5R7
M3G6W#L).X7G+Z\4F9F#2VNG5E &U"5U6-?!4-U K!VZ7H%&OO/;S CS1L'[.
M2\VDNVWX8C,ZDCVYG]FZ++%-Y%S9F5T]G=E654O9S*R]]L0W&JBAYB#P=YBO
M8<<;S>0=!*:VF3S, /T.X*Z%^3*VY5A=!6]O;13$3%)%I3)VMLPDA9BR''*9
M*JB5-@:.692U6R_-/H-/;65MR0[.EG@&OY<Z>);!\)H;M\.AH1 ?>,D,"[;W
MB5$?U *=''D-/>H)4A]0GI\D]7I&W^8U3_-2/JF-&6"^M=WIF_2561KG@MH8
M+)WA#&(9"<@I2F'.8RD%)2B/O6INNPPZ-6+[8A[TC>TZ>B^_FZ]-VQYMW\L>
M;4O=]"ME=1*X;^\;AWEP([/0Z Y,8D?2W6SA_U<[F7>9A:<#WWHTS7''*%@;
M'8<A1VZLXP["8:L=CWO]FY6_6VR*S:.ENM7#<E7U3C?;%%6Z7U:/;Y92S40L
M%4I3PT4:8XAQ$D&:$P:EP#SE<29S['3N[3C>U BI$AD\D?D*E%(;F$$M.;"B
MNW<]=\&]FX4&0'-HQT, (+W:IWO TZNINLOS1VNU[J%LNP&[SVT]W*X_A%JO
M/^M=H\_/9CE_PU:K1T-?U0_T6\4W,T:C5.4"04UM1R.=,$B)0C!569;F)(HD
MCIT]JHZ#3HYH2KFMA=.V=ZS](VKA]S:0-/)[.-Q<I\'!*SH N$/S3H7K9PU:
MO7ZMV*"1N_F9!F^'P=7#1SD OF.Y'SW?WU!N14_$NCR&KH\:SQGHJ=P3/Y_O
MO2.GG7Y:+JI4IW=F(V?7(%MLU_YV_7F[61NSU]JX7Y?S^?OEREX_BZ24.!(4
M1HRE9I&@&K)$8DCB1"!,D6"YT[';Z))/;:6I<ARY8RXD/Y8+:2" %0:@ @&T
M4+@"+1S [Q8)4$/AZ8,<[^5RV_-/\I49>/T,D#D;_FT9+ZVV[\R]=+JMM]Q_
MCC3<OM,1+#VWMP ].TRP];?KA;1_V &-!66'VE60R7&>DL@6GLPU@SAFAJ\3
M9/Y)4I8AS6DFO<H>=P\WM87,BEFFZI1_:0G<N_;[&;C=5HEP( Y,[1?AY]]X
MP@F64*TGN@<;M_F$D^('[2?<[NI9T/9!66_/XNZC,@17\]MZAE*529Y)2#"V
M/:8S!7.289BHC(L\S5.6./EANH>9)(T\L$("O5R!92,SF%NA?0O<'@?6C3@N
MAVM@PM@)"$H)KQI#+V 9\&X,0M5D/3[(N$59.Q4]J,K:?74_%OBJ'NH'?=8?
MEXN[6[6Z+QU6$4E1GIF]=2RR&&(N$L@49Y#(1/*$9SK1T6RA[NS1N1L3G!K*
MZ>7.JY>[/>!P[_A.4NNHFAM1H>&@>P^7ZUETW<C@(L3&H8.]B!8K*R2T4G:[
M4;T9X1P0@3CAY#"CLL(Y99_SPMGK>V1 XY_SU#S#/-26IRN3"I.D:6HG<J54
MFD,1H01BQ!+(!8E@G&=<1PS'*&/.6= = TW-1K"BUIG0>XGKW-4D\4CT[0+W
M_/E+*,@&)H82+7 $J#ZIT5V(>:1'!T)NI-.4"Q#T2Y-V@*4K5;KK]O'2I1V4
M>)(R[7*]/W'^KT_OWMW4+Z:6B,=81E!A;"PHH@ED>8*@)$F6Y1PG>1:Y\F3K
MN5.CQ5(T]V^YC=!YLNNI]\#<5DK5@\?:NKO35D\,1F(I1RR\&.F(QAT$U+YZ
M-+XY(F*;7H[]NM\&[=W]PWSYJ%196+9R.]=O$$\)BJ2D4,@DA3A-"*2:,8BE
M,+RF,178JS;OR9&FQCB-H* JMEN)ZK<Q.XVJV\XL"%8CGMKM3N/VIQM--=L!
M^@N?12?0?NWT.*-NV,ZJ^WS'=OZ&OL4,=;%0\K5:F+]L;*N#OZOB[MM&R>OO
M:L7N5-D@K2HN^YMY+3XLWK"YL.D/Q>*NONLSGQ=WU4G8KBM%E"B:)@RFD= V
MZD)"BDD"29SE,A-Y$HO<K]3>$&).C:5J0<%>4M^*?(-,IAN_O?P4#4R.M8*@
MF26KXA5HE 2UEJ"E)K!ZVL;L+4W!X20/<FXV['0$JS$XB) C5R4<$NC#.H:#
MCM9S$:GS?:TXS4X6<26C+(?"[)$A1IC!G"(%,Y8F6$<R%\BK^_SA$%,C[UVY
M _]^04?P<^3<BU 9FB_;@ Q@,IY6/A0['0XP+K.<5/" %4Y?V>^+OETIMMZN
M'DMSLPS[G6692A(:2ZC-=PTQE]S6K^(0\31-$(WRA*1^%:T/!_%Y>\>I7_U1
MK=?_ <3R_MZLT^MR\_A-S<M%?5.+?P78QERQWH!7MIYBY>Z/XI_ JQ1E5S'.
MKA!"U4_7=G]5=63$.;JBA#[_G6/_@(YYBFTG3))SJ%)B]OA**4B91C!.$L*S
ME"9)PF</:E4LY<V&K39CS-7SX8:;KT;.:J-_!5XS\VOAV4KG"*J,ZHQEB8 (
MV3J^-(T@D[&M:(DR;- 6,B$UJN\6CJ?;(3!M!AL/T7=5R&TH8-T6NLN@&GBA
M>XY0*5^X=>ZT[H'6N2,#C+K.G5;P^3K7<66_=:Y]^%U;7HDF,1))#K7&&F(F
M,62,<T@)1D*3B)+$Z0SF]!!3LUP_[L)5W#/9.@!T^Z(O@V7@+_II4,H MNMI
M[0-]TT<&&/6;/JW@\V^ZX\J>4:H=55F^V!^4A?_+J[X8JVVE-L6J"M[?;ZK7
MU_*_M^N-_>DGM?FL;]F/&<USB11*(,=20)SE!.9(8\BE)BGGD6(X:<+;;I<;
M-G?CAX'$=?J:GH;([84>[LNRU4/$-WN@X!DA.]"DNI'52\[12#&Z1RI4O:J4
M_ E8-6V?DV/^3Z;-RF&K0,[9>EWH0M1I7CMEFTN,O@'C?8>=D% !PP-).6[$
M\;!0'X0L#SS<R/G*NSSJEE_VW8\')0S?_FUIW;+S8O-H:RG.(IJGC&8(I@D3
M=5:6S!C4*A*)D@IE@HR2J>PN\]0LV49*\'TGYDBIPQ[S[+;D3&SV1@P\Z)DN
MW*K3T=+<]MVMWXF]\F7EX@ED"?M/U4OG!WM(_.?(#/:?@F YP3V&[AOCL2J^
MLZIX[R[O^,/BKTK>J755(>YZLY-F1CFCD<P(U)%MDRAR!GF:HM+1+WD<I8H[
ME6[K-_S4EI2]]&L@U;JX6Y057=D:?#,*6$]HL=<*_$==)M$W;L-K@ESC,8:"
M?? XBT;P=L$'>^)2R7ZU*T7)-BW6#QDZT0>Y8"$17H./'.K0!YC#$(9>3^E9
M*WP^7_YA#RK>+U=OEUN^T=OYM1"V4-W:;%J5D83/U9OM:F6DF$7:$!UB.618
M4^O[99!RQ*#,E2 JBC5'V.^,TVO\Z1U_[L1?EUG.LM8 L%H%S^+@7I/A1G.#
M 3PPRS4R@KV0AM@:94JTWZR4+#:U]Z76(&"!\#[ A:H0[C7VN"7"^\!R4".\
MUT/\<X<.H\%LN;;?%N;N]UOS7WODOMFNKU]_GD4L4A'7!"8DP1#'QJIC(M=0
M2,K3.*8(*^=&M.[#3LV::Q?E[QMMZPE\-XT-!^?@5MJA-[@JD/FJE/PG4,D.
M*N&!D7X0>-V3HH:!>:2<J09N7L/]8.$NZV2^VE9PZPKN]7FXO1*K_%'KR+OR
M>-AH:5G^"K:SMGK<'?Y4\_H[*^9V13'+S0V;JQLEMJMB4ZAC)UYQ1&1,(P$3
MLQ!!C(R-R[B((2(T4B+*<L+1;!/F_-)',*^EXD]Z4NDU49<?30X%_]!GD6\^
M7%6!%WN!C6W<* .-;0RM.E?@%U8LZ@XZS3'C7K,RS'*T4\<^6(]PS.@EUF3.
M%?N Z7.0V.OY/4LQEJ'#9<!:Z09>7V\WWY:KXI]*SJ1$.HT-]\H\R2#.8@&I
M$!2F$K$D2Z-,44]W0\=HTW,NO&E%55^!)C9Z)S!X93[N7E'179B[L6H@' <F
MRAK .NRT$A3L)0U8A/$\'*$J,':,-&[YQ?,J']1>=+BE9_B![:YA2>FSKDC,
MEG@\I+9=QF:&$TI3'$.JI888DQCR-%>0D$1)EJ$$)5X%7CW'G]JN?R>^+3AV
MM M?W\JOOA/C>/8_'-Q#G^.'0-K_ +X?7J$.TSU''_=@O!\T!X?</1_3N\'K
M:FMS5^M6LVK=G G0A$<L-DR&%3(64RQCF$N50ZTP8XP23:3T/* Y-=;T[*5:
MU'9O]*J%J$T[ ]332#H-LN/!2PC@AC]D*1';-RU7@QREG(,B7&/5$^.,W46U
M6]TC+5//W.#'$^O59O8K^U'<;^_KG).81AG-(PF)MH73&.4PSQ(-=9)AA#!B
MDC@9/ =/GIHI4POG]JD?XM3]:5^D_<"?<BU7P%R<D]IV?:WFIM:7:OZU_TH/
MGS?*5WE2C>8K/'U!S\V(^*;D=JX^Z]?;=;%0Z_6U[:J[+LH(MM>/K7]5;;ZS
M%*4HBB*8YA1!3(BT&<DY%%F<"BZ3&"._P&9/ :;V#3?R6QNYT0"T5;BRH:ZM
M'_1KQ>X]3XZ;DP'1'WIW$AQX_ZU*3_1"[55\AQ]WL](3G(/=2M_G7$J(I<^Y
M%3%J#/.WNYC1Z_5?JXC15MC;;E]E6^X5"[80!9M_42N]7-W;^!&SS=K_>%F)
M_'%9Y5B5HM^J'YO7!L-_S'*I)4F$@B32'&))*,Q9(F!$E> ",XPRK]J.D]!J
MRM3]3FLE2D='.T9XL=R MT_BA&M\_B]U;];=.(ZEB_X5K-6G^T:N961R $G@
MU)-CRO+IR'#<"&?5[9,/6A@=K)(EER@[P_WK+\!!HB8*H$":_5"5=I@$]OY
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M5U@':Z]L+<@K]UEV!>Q\PV7G$?O&-@@S=;Z6G_+GDM3UM#F;5QV>BP\_ZL_
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MFB.>+$@BC-RB<8[/,[57NQ83;.5T]"*<@-/2=7 Y2$/["P[P\7AZ80F#+Z_
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M.[J6^EHL.Z(<=@D&YLF#*G@M^?6&=[,2E0ZM*SW67ND/X""E]*P$>,52>RX
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MJ[%,(<L0@Y*1C,<R2Q!FLV>Y8DO;+>3N!"[/77N:X1Z_2CZW/>$>:':[OOY
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M'^=;J=WX>(@5MB/IUUJP<9B[HQ+^1D.PT;",MP&;A=UJ";YMU_B3Q1H[L_V
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M'6N!'X74CH:] #7:F<]&2O#]%%KN=<%/(>&K1OC1<<:M%WY*W;W:X2=OZ)'
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M(4DCJU+,)\:9&C%\7*Y6RS],MWGWKIV'8+3=D)X-SN#[3;8&6Q'![X-UW.S
MP6-SS4.CC-Y'LT/50RTSNRYW+V!XLUH*;=85)F] &W,YET7MU,58<8%4"''
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MZ<WIW^'7ZPMP517@]>@M[$#"EZ?PT!#C>@D[E-SS$'9=V^^+OU[HSTF_X\:
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M:]V5X7(A3/QMT\<E9)RI5$):]G%!Q&3%4@(11512A-,PL'(\G"'#U'AY5P7
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MP,.]G+?;0CREU([]?4]!G' A$QY*2$200DPIUW]+"90!3O2F6'-;9M6[8@B
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M8*QY"&)",21*<<@3DH29)#RPLU4LQYL:)6U%!EN9P<=7L)':H6B"!=S=%#0
MB .3SVG\P.]&9(?,.1L8'4I.^(5SK$H36UB++:SL%?!&<$_%U!S@Z2HH8?&4
M\>I(V*NT4S["X;8S0D JWW^=%<8"P7B"0LAB%4(<(@YI2 BD*E!)P%(6A4[Q
M=7LC3(UNJU" /F=Z^^#967-G03(P>59H5,(-D#5W5'6?,0D[SQ\_L."0>@>C
M PY>Z&Y2W3S0U:.>S>=USNF\^8Q5$&&J8IB%*H(XB!BDF#"( I1&*J5):.L-
M/C;$]%S NU+:K^X' 40LHTG  YA$TKC320(9$Q+&)!%)0E(B[?J/^8!O#!KT
M"MYID_)<2 :FP5WQ>M1:. B+O8EX+CPCV82[8GJR_[IT[S#X#MXVFH77)73;
MI.N\KF?4Q;9D^O[NO=@&_#>=C11"&$FB$93:P&-8:=N.(I@E!'.B8IG0V"G2
MPFGXJ='>ICATVU7E&E[A-@%V1N)PL Y,G2W!P2$_8-'.07G;7^*&KLJ&B=X-
MSWYP^HJ4<!M\W.B(7L#L143T>TK?L\T7_:CEZO5F.<_YZ_;$GJ9I)"(L( ]P
M #$-A"GGH)E."8;,?R)VHK9C TV-Q!HYG0/#CB)I>[QY/CZ#GW/6(EZ 2DCP
M>_W_0<(>3B'B[4CSR# CGVUV*[M_R'GB^GYT<&6D7:Q7I:U[FQ?_N-//^;1\
MI/EB)A*6<9%QF'%328ID"A(D,IA1(8(XRX(XD2Z,T#'6U$AA1U1@9 5&6/![
M):[C:687R'9DX0FZ@?FB-VK.5&&!AR>VZ!II5,*P4/DM9]C<XD8;Q6H]NY5/
M^H5YH(6\O%_)TJ]^9>*#Y.J)KM:OIL%L_6ZGE,>!U#:$"9_2!)*DD/)4F$@)
M0F@L"<ZLZG ZC3H]*ME*6;8J=B01-\B[Z60P( <G%F<,K2FE%R9=Y*(?V"(6
M_=.65-S&&H5>>JG?$$V_F_M9*G<F:_MY]5I6P6M\@J'@$<<1#!0U[AB&((LT
MWR NI2(HD %Q2GPY,,;4Z*01L2[46)6;<#-'#B$9IG'*@@3!-(PU50<J,"&N
M' 9!IE2F JDX<0N /Q/+<4X]=M$\'T8[:^Y,: 8FVS=OF']W4H?ZGHRV0R.,
M:JQUJ/C62.NZM&]]X#U&;L[8"6=,H"2!2"82XBS$VB*35+-FDJHD42E%5M7+
M3@\U-=[\[>?O/X-;^6*& JN-V(!NY'8M#WP49#L2\ /=P%RP%1)LI1RD(/ I
M,+Q5 SXZT,BE@$\IO%\'^.0=[N$/W^E+OK@OC*.YE0P7DR B5&_;<*)M <8Q
MS*BV!8C"B"$I4A)8^7V.#3 U:JAE+ ]8[ ^I#T+7_>G[ &3@#[Z-!?B]5P/=
M@\#8G]Z?"]!(I_=MH#R=W7=IWG%V?_"VT<[NNX1NG]UW7M<[4T>N5F7GF2H:
MK P,FX610"Q(%4S-&1866,$,2P$C2E3$$,6,.MDXAX>9&HG]FA=<SO4_R>5S
M80JNR-6"NK0)/(&JG5%S/E8#\ULC8-FRJA+Q I1">DVEZ0#!7^[,H4'&3I;I
M4/1 =DS7U3V,EYOKKY^_WWR[O?O^[>YOGV^;Z,TXH@F3!&;"='^*(FV^D"B#
M2*49#QBF :?6YLO!(:;V[9=27E1B@C_1QZ?_!*6T#FOV82@MS)FS 1K:H"FQ
M ?O@](A+/(*2@VUS-EIC63=&4#>TW$R=3B"ZC)W#-XYG[G0*OF/P=%_9LX8)
M-?4.2E=1U0)5__! ]<Q?%\6S%->+NQ5=%)27;Z+( HX3TY T0'H?EP0(DH $
M4 02R2S4=!@Y9:.X##XYBJ15_8["2'\!%J7\Y3^4&H"\5*&LYKQ5 GS0/U<7
M.#:/<IHG.]-J*/0'WU!6P'^O@/^Z ;X2'EQO@&_)[[&42@_4?-56<1EZW&(K
M/4#9J[[2YQG]2.]+OLC7\I?\Q3QVM^9>*W2R79QOED0$\2#5VS]I(@\P$]H:
MQ (F21;1*-'#H&2VD/?F1COR<Q?"ZB/,JH^P+<IPW^(OLB@ ;848TY:X;@37
M8T[L:&X@G,<ANTIX6$J_7[?S K3#NR]ML'?FN_[P>6*]'@*,RGW] 7K+@&<\
MJ4\?HL><4R&;XWK$E<14P)!G2MMW<0!IB,I&'@D5*5,BL>YPO/OHJ1ENC70N
M'7=VH#J]A^T/P."G;Y5@/;:J;T!P:3K4%XS16@[9@N+8<NB0WIT-AW9N&+'=
MT"%!=YL-';S"O_'5HK;/5>'O_Y9T=:=!DS/*8QR1)"QWFQ!':0 S&2MMAO%4
M,"JIHDX%LGK*,34ZTZ]1[,_2ZIJ \\TM3["^I\UEBO,]2?[6WKH 1A-0JC*.
M[66!Y0@&6)<4D['"+*!R,<5L'N>W!= GN<I?RIY#Q?_W3.>Y,HW!+HNR847Q
M5:Z_J3OZX\:(M5RT<SCOEE4&YR4KUBN]<YY)1I)4A@R&69) G-$ ,AH8!UX0
M90D2(D;<N9S,@ )/C6Q;>M6^[(=2I;_XZ1SD;9[MJ'I*LS<PIP_<8>ABDRK=
MZ.Z[2L\(TS1P(R)OXDZB.9%O\&T;%GD?M]]*]<MR<7\G5X^[%?9OY1-]+>,(
MOZF;5;[@^1.=7R_,\OA%2SP+,5)8A@D,36(%IDD$">49C'@B,DY"1&*K*CYG
M23&U-45_0*G;\M$/?+LU87!(!R9Z(S\T"@"C0;M#2&F@&VG],?-98'FBVWXR
MC,JA9\'TEAC/>U@_MON5_L@?GQ]_D8O[]8-FV/S1]!J1^?WBZGFE696_[O20
MFW&NTC#-$AA3DQ21&#-;* )Q*I(L%8'$5+GPG./X4V.X6GPP+^4O.QEK#8!:
MKDKSV=2Q;Y^1RQ]/98%C-U)TG2,[.AP0^8&)L ']EPWH1O@+4(L/&OG?VKW^
MV+$G=IYXT77T41FQ)S1ON;#O8]Q/B^Y6\E&]TJ8:8X9PEB;:A%-,0,PR!C.$
M--TA&<11+.,HM:[&N//DJ3%7+9S]*<DN3J=/BGIK/S![U'+U."?:1<#^F*@W
M$B.=$I7RT8YWP>EPZ*"V'6=#N]>/=C1T4,SVR=#A"_IFF:ZIJ57VF:X6)K.C
M?H72(,!9%H<P0%(;4U)FVIAB$4R%9B&4I2S#R"W#]- P4V.>1DK0B.F:3'H0
M2SNCYWR$!C_&?@/.( FD72!X2QX].,C(B:-=BNXGC79>W3,(6=X;!M>;...X
M6MQ?+_3>X+$D]%\VO7DB$L18(0%5'&K+@P0*9E(P&"*B(J1-DC E3L''%H-.
MC15JF<%&:-"2^HSN2%838$<>OF$=F$H\(.H>0NP D:_089LAQPT9=@!A+U38
MY=Z>J:#Y2R[D0A17R\?'Y:(,2S:;J5D411S%5&KR,=' *A.01HI D68)CV(<
MJ) U@<!W#CFA1\:S^E1V8W[OQJA!9IP&HI$9/-'<L8/C47SM6.8LN$9*#&U$
MO "5D$W&@I'38V[H"21\98<>&V;<_- 3RNYEB)ZZOF^-T\W3:L,:JX2&5)LD
M8:0T*\0XAA2Q (9Q%LJ RUBAQ*W:U=X8+J_V.+6N=E_K&UHW5P?_'OX<!*X%
M3=\B&F+$(QIG,$ZH\9QKFR^+.8-1&":<$;WKHTYGA6?A.4Y9QRV:31)3GV)L
M^U#:4>I9  W,I3O8^-_K'57=6\G7M\\?N=#K$?7VR[L>N]#=8_Q5/J^6!<^E
M%K%Q&R=9)!A.8:("O8/C00R9Z7H1)=JD4AGE(;&JHW'X\5/[GML2VKM/#\!V
MVHM\'A@#?[MMX7KXDP\ 8N]4/@^8D3S+;@ YN9F/Z]_A:SYPTV@.Y^,"M[W.
M'5?U,^B:A--J1VGBI>HM9C%C24S*.K!A)%*]WZ,I)$(2F*0)"D1(42"=BO\<
M'VIR!+;)K&;/A=Y6%P4H:E'=+)(.=.U,$S^8#<US&[BV8H+OIP!SME5.8^')
M:.D8:%3KY;3";\T8BSMZ^JE-/OI'6DAA(C/EHBA7ALO52K\'=3O8[24W54#2
MY1]T)783VB]?:#XW8GU9KOZJ[UW/DL0TUY9ZLR-##''(-<D$H8"4"*40";,D
M<RH[/92@4Z.HNN0#;>0L8XK4\]ITM;\W A?@>:'G%\Q-6.#:A 7F90<#$__]
M9%V=<?#YMW2M3V!6AW;'&PEAJ0!H*PE:6IHNU^WK:DU!J>J!@B"7.V]'J;%'
M7_[ <^++_S^4F..>&0P,]MXYP]#C]5N&/M;FF!:*Y55-QJOEPAR$E*T2%D6N
MGU6?AE"6S_/UZRQA"95)2&$88 4Q%ADDB$>0D%C&,6(DT0,XK# ]9)C:XK&5
M%_"VP&#>2.RV.O29%COB'QCL@3F]D1ZTQ#=G(AOT=S2X +^<A-^9I<\ T!,!
M]Y%@5&X] Z*WM'G.H_J&CKW(Q;.\E7QYO\C-D]^V4!1!)#!2&:14<8@3%D$J
M(P$S0AD3*<&QLJIO8CWBU-BN%ABT)'8-*3N%L1V9>45N8.IJ0!NT2Z4U(-Z"
MSDZ--W+\F:7Z^Z%HMC?VW.VOZ;JT\NZ,[3;#@>24"@F5,,TK0QQ"HG@(N<1,
M216B.+"J GSX\5.CBXUTX/=2/M> LEWL+/>WO1$9>E=J#8;[_O&@SKYV?;L/
M'W>O=E"QO1W6X:O<CQL__Y KGA?R9I5S>6OV9V5!CN;$*,*$TXB83.,88D(S
MR))80!(E@21A)A-E5??BY$A3^XS_/8RRG^,0_KNFJY^#Q/[8K1O/TT>2WE :
M^--NY 2EH*"4M"KCT^.L\L1+:'ULZ0V\D4XP#X'HJ86)%10=AYG=]X]VKFFE
M1ON(T^X&=Y[\(LW>:W[)U]\6=_3'K321LY<+<?FWOW_1>[4%U[NTJP<SWG7Y
M>TW/5>$)_4-=[>BC7$B5KV=A%L=1%F@S2+(48I%)2!,60Y:B("5)BGADY5+R
M*];4&+BN,K.F/TQBLQ$4K&15L'6]!+S4J:P2KB_0FV()S(L#[FXOO]CSCL=)
M/<WL[S-5 R\#M5) :P6^+<I>+I5B0&L&M&I@H]L%J+0#U_5U6L&+IIB0^8=:
M2?"A5M.RTKOGB;1?;=YG0D=:FMYG8IV6./_X=ZR''@<;;?'T#U![I1W@Z7V[
MC['U]:)8K\KOXMHTW)+%VHSW62G)S9GUC38*S#=S+V>"R  %*()I0@3$(0TA
MPWI+DW*9)J$47&216U,RA]&GMLAN1*SZE&G!R[74M4^9"_YV+HW!4!UX/31R
M@ZW@A@9K7"M6W *^%=]GO[,>J'EK@^8R]LC=T7K LM\TK<]#>O=3-+G"YO"G
M+$1G7+3Z-;M:Z@$KK^V_I)@E,3%)_!@JPAC$2#"3.Y-"%<:(96$:,N&4Z6$U
MZM08[%>ZY@\F_92WQ':,L[2#VY:X/(,X.&&5\H*VP&4K57/27'@,^'$"QE]K
M1HLQQ^[4: _#@<:-#C?W< 8W3+8QU R_F4=K:VZ>-R?2A:; U=\DG:\?OLLG
M6AU)SQ"AJ8@B"EEJNCU*0J'F):K_%G),62RSU*K>R+F"3(VA&CG!0RDH*#:2
M.CA(SYD8"Z?S2' /[9/>&%>MS:?1!.RJ4@;15'-2:0.^CSTG#C[MD>9F+)?W
MD'/DYB'W &R7 _V<QX_G7_< PH[[W<?S_#8!,(7(M]6?/__@\V=1!:8N%Z4E
MSU>2%O*3K/[_T?@QY*7XG^=B7>8^7"Y,H^09BQA!-*00):&$.$A#F*F80J'B
M5)(LC"AV"@0=5MRI+8*F)OR?JYKP8&NJ&(]ANQ/;MZMK/PT!/,VYG<D_G9D<
M>'VU: :PU=<T?*DT!AN52Z]PJ2SXT*BM;V*EYJ"E>M,?8/AF 'XG:>!6 )Z$
MG40C +_ V[8!\#RJVTI5K-:S\DCZ\D=>S%(2IIQ0#C%C!.(D49 $,H%"!@%G
M""%I%Q>W\]2I\7X5%_*[$<TR'F07I&X&[JWZP$1IHK/R8IUS.@>_ZO?H>55'
MP77C8$UJ!_7NXAY]0XMW]$];SME]UBC4<%#\Y@L^_,M^)N'=J@3_M:S,4><4
M\7\^YRLI9B%%/(YE!HG$H2F/&D&2, ;#" <XI1@)D;E5'NH8S>7='*<&T:U\
MTH]Z,$OQ4@%>U8DI>[*##[T:K7=A;6='><)OX&^[D;(IWU0):CH*5Z+Z,UDL
M\/!D;W2--*JQ8*'RVY7>YI9^['&]$,;?>JR?764\Y(O[ORZ7XH]\/I_A$/&0
MIPB&L5[,<<;T%C%0FE=$)A".1$+UBNY$*:XB3(]GMAJ >=D8,M\VAJ2E$FXT
MXSPI=MPS)- #$])6]&/MSL&'C?R@4<!##,ZYV'DB+^?A1V6TON"\I;G>SQGF
M%.B7?)W?EW_[+M?K>6G>UL??LXC*)#6NL2@54N]NPA0R3!/]-TXD9T$4)JG/
M@Z .6::V'6K'VVS"6\OHU=4;[_=\HQ0H-EI=@*=*+[^G%%V3Z>?PR-,43>;\
M:*L/^-Z:G9NQ9\?O,9*G69K<25+/V?)^FF2![YD'2ETC3.I,R0(*UV,EFT>Z
M+X:_ZC7W\?GQ:CDW1Q0K.B]+]=*"UH\VR;1ZW=ANIR_O5[(<>T:3. @BJ2!7
M@D-,!8$T(:G)I,=*,11'U+IL9W\QIK8$UIKH!:^46/]_XXB@C<R ;_0$'V@!
M:+/N.:0$G#%QI]>\<:9CX.6NF8FM%G4=ZA+Q6I,+4.L"6AZCC3:C3(?](C?.
MM(RTO@TY/4Y+V_FH=JQJ9SQ\M 7M? #::YF'I_7U9YFU<Y,Y_I'JUXW+[P]2
MKDW:AA!E+0@Z_Y07?%YV$BT^ONH?GI8%G?]UM7Q^*O0CJFVFN:8L3?,LQ;>G
MNBI-41[9B"S 4J4(8A%1B)5 D.J?(1<"4<0(24*GL.1QQ)[:,MDH $H-P%=]
MJ=,QVLB3;NMEF]I4#KS$]IC%'NZW,4'UYK0;1>B177UC3L2^@W#4T?LM09><
MF\8<A=ZYR?S%E"[Y*M=5S]WU+.116G:H)#B2$,>17C@"0B!!,9%IS.(8!6['
M)UW#3>^HI)'6^ )K<4U_;R$OP-R4 :3S^?(/,ZE%69!5+)_96CW/ 6WN^_<H
M0."#_M;""_UW%#B>X'9.CAW!^P)\8%K>(+V5\P)0I==U<-F 7&)\M9+ZNP$F
M:NBB[OSM,27&!BU/?-LYU*@L::/T6VZSNJ<?(_WVO3E UBSYUZ7^TA>&/IL>
MNI+'88 R*)5F(YR9^N(9%YJ7! NB@&J3UJGZ8>=H4S-!?_OY^\] "_F_UN"[
MY,\KO8!(Q]/:;G3M.,4;9@.3RF_?P28VQ(2O;D4=H/.2%2B>N*-[K%')PTKM
MM^QA=].9M0X___,Y7[]N DFK71&60<SCC,&$R1!BG&%(PS"%(HTR1-,4,>G4
M@KMSM*G11R7C-OB[Z+5_/0&P0EF2QB%D:4JUR2AC2)*$0$X81S1$B8J5F\GH
M#>)Q;,8Q0+:C:6_ #7W(ZXI8_]*474CXKE1Y<*SW*5S9I?;1.I:=-[F'V6\/
M Z]H(>_T SXM'VF^F(D@U#NJ,($T,R[*+%*0Q$$*4QK((,E(0I"TC;H_-LC4
MF+AU_FT$!492\'LEJT-4_E%,NPG"%U(#\\);D$[BXQ2M?PJ ,X+WCSYZM%C^
M4\JU0_M/7MO3#GO3V;RJ:/VVT+HD7*4B"" *90HQTY8"4V$,$R(EQVF* [?M
MG-6H4V.#3[+@J_RI?-.7"JP?9+D8TL7K_R7O39OCQK%TX;^"B!LSXXH0JDD"
M7##S2=YZ-.&R')8\'1/U(0.KS*Y4IBZ9<EGSZU^ 2^[)!)@@Q;IO1+=+EDGB
MG ?D@X.#LU2EW=9=)\ZV8+M@(BQ-"M_P#DPAC;Q@+? 5:.K?#UH'WPDF7W:'
MU9CCVA\N,!S8(4XWNX<173^+7,_BS<(4R:N[(;%R55!N$VUR^N8)O?R-D&!+
M2FU9-W(ZU(+N0,H^$,0/8B,%>AQ!SD_@QGD4.@(S.FX>+?#BO +;@1465U_H
MY/FD5\8;_6,YPW$:RHB&4&8QA5CP!!(5AE#% 4$DI%% ^S6U6 \Q-;-AJY>#
MD1%40O;U,VR ='0N]()GZ&7?#9G^_H0#Y7T[$38#O([GX$#!D^Z"PRO[?=JF
M+HDYW;M=W-&Y+&]5G4YC3LS-#S?:+LX+,^"[[[1XD.5,A)F*D! PS!*3W((Y
MI#B.(!5Q@I@(.!5TMI /II[)O?WW[RJ'U>M/ZM?_0)KA/H7/<@4>M"K I*UH
M1<P&H\[R^UO;"]OU",EYANP891# Q^$;(WI3<,7@?-?@W.3ZF:.GZD>PT0$T
M2OCCI+[P>6(LY^%'Y;.^X.RS7>_GC-REN_;=;HKCEE7UE?OO='%;N1G*S\O%
M#UEJ#JK[N\Y"'"J$&(("AP3B@#%S+I; E''$@Y@QKN+9DRSRI=",7ZPL;:BQ
MY'?A@GTMAJ.%M_(A7RQ,CB^K8[_ &\T3O6HYC/<F9#B( ARED!*IWP26"LCB
M)($R3B5.I K"5#9OPH>%^,N_!ZT. QYO+<1?[!6PW %,<5*'WEA<WM2].>W<
M4A_45=Q6&@#0(' %UABT;> GT.B][\2]=N=W9[G_&JW@^TZ'M][PO07H9PU]
M/%ULX>^%-LIF*@S") AC*"5%$.,TA5FB&(QI2*1$:1;(U"WVY-R0TPL_^=A9
MV04\&*G=UIVSL-LM%SZA')CE/W;6;KD"?^\$T9F/;9'Q1*-GAQN5_6R5WR<M
MZ_OZGE[/YZ9VBUQ4'95,NL:C'M$XK^LRE56W),TX,1$L"2$3)IPPS6*8A7H7
M%8=)&&59$,C8*G;%;=C).:)KJ:_ (RW^D.:PKO)YT!W9VYZ!SJ?75A-A>WSM
M&][!SZ\;9!N1:U_2+JZ-U#Y/KUU0\G9\;37HR.?7+D <'F [W=V/I]K8$&VY
ML7S1%G,WGZ!Q0FD3+!=-LMB6/5>V3>"N'TT2QZTZ<<NGG+)\KDV\<!8($H0!
M26"<$)-"+&/(>)Q"'*>,\BB,@]CI=&TDN:?&E!N!37>DC<1-[0TZ=R/'L6;?
MCETG.*<#T_,Z,FM+Y:I-1CO).RIL.PG*=8O.7/^^4MV<&)RZU51,:O3WQ_,C
MSY>GA6(LJ4==:4:>BOVE:NSA^ZUU-B6GWDOQS"O?PRS)B$PB%$%%:: 7JD!!
M%B8,!BS#,6$R#1/NLF2Y#3^UE<>^SJ%H=7!;BQQGQVY)&0[S@5<&^U)X:_$]
MEK^[##Y/1.TX^*A\VP^8?=KL^92>A1I^T'QN$JT_+@MS^&RZGVZ2@+=Z]E3N
MCV^+0M*YZ>ACCJOKIAFF?T[*DHCQ1,& ! AB*IL6%UR$3"#$8IZ*'L$R7H2;
M: 3-6C>HY80FAN8*/"^*3<NDN;-+U<]<VE'H>%,S8C_GC0)78'=^[JKYV6YA
M5>D%-HHUM2.:%D=>6QIYQ=I7G0DO,HU;D,(GC >5*[P^O&=CO+J"S^+ADVEI
M]#5_^*[-YV]E[;^>17&(4$2UX:J7%XB%)FHBC<.%$9'A#.$XRISZVG6--C4[
M=2TLF!MIKT!AY(5+!9_+YA3+L2%=)]9V'.H-P8&Y<0/>IQJ\KRUXW\KF^,IC
M_S8;4'RU7^L<:]SN:39J'S0_L[JI;R[$DO^QJ4TIWFLJ6SQ\J:*;JD*6,YQI
MTRY1%-*82X@S'$$:1AS&)(FR*$&,14X[X;,C3HU4*H'+K<+&IWL"]838\OS)
M)W!#'SU5G:>VA 6UM* 6]ZHN?>LSI\(2&V\I%N?&&SGCPE+]PP0,VQM[%PAL
M+:)3+1R;XE&95$&JA(04(06Q9!AFH= T$\=9P%&$B'+JQVL]\M3H9J>![KD.
MK<X5 2UGPW)W. 3& S/3]>V[&W"]6A4Y>U[5-1F7X LMAJGKY8R0O_J EN..
M72S0#8XCE0,='] CMQO]&@?!Y^5*EN)91@'.FH\B#B0A<<QA(#F%6#,2)#$/
M(*$HB&C,0A(3VP80IP:9&AM58OX+J 0%6E)@1'7(_CZ%93?!^$)H8"XY"LYY
M%K%'R2%#W@-:(^7']T3-+57^#!Q=B?*G;ATO3?Z,\#M)\N>N[6>W'>%5,\:F
MXHM(D HRBF":DK *Y(%9G*40\XAS%+!,2L?BSN>&='F31ROP/)2E=A9_.P/-
M)Z8#<VD'=!55@-\'*;9CBY GN^SL<*.:8[;*[UMAUO>YD8^0>5OTXV->/-Z(
M&8J(3)#>"BIF<C*H9AE"TP &61I$+$T$8J&-Q77PY*F966W-&",=N'EO1Q:'
M>'6SPD4H#+TMLP3 ^@,_J>R1+[F4_->'Y8^_Z7OJCUC_L/EV#Y\TRD=Z4H'V
M:SQ]08\>L54RUD>:%Y77YUK\\[E<&5MPDY1NJ'B&,B10*$)HOCZ(51!"@A+]
M049Z^R-Q@/4W:=T+UF[,J7VJM=A70&D9P8^Z@]=:]"N0;ZHTV!_MNTS!^9W3
M , ._/6WF!J9FZYHUUN8;E6^^#0(I@Y]5_UC.U9_53\8NW51=4.KJUNJY9/&
MZXKJIMI.]U/'6_MMX4PMUEOU59K\6KZJ_/IMS63.:299 .- Q1"'2$$:H10B
MH<(T1$01Y.1J/SG2U*B[*I2\5&!'5,?*R>?AM=N:>0%M8%KNB9?S)NPL%IYV
M7Z?'&77;=5;=_?W6^1O<-UKOFU7GOJ!Z&V>6GKI8ZBP)."/85$$DIFU7R"+(
M4AS"F"@:)2(A*+8*(.H:9&K$T,H)-H(V57_M=V(G 3V_*?,!T\!4T ,AIZW:
M.0AZ[=I./G2T#=PYM;;W<F>O[6<'O)<J7TCQ5B[T#ZLO>E9-\BA?2?'Q67.)
M;/^A+LU1_H^DQ?V?RUF %<EP&,"$,TT#A$8P4P+#-,1*<P()>>@4]M-/C*D1
MA;%+W>R$GO#;&1'#@SHTK=0*@$908%2X JT2H-9B\Z^U'E? * *T)OY,D,N0
M]&2?]!1B5./E,J#V+9L+G^9N]GS2;\+\R_?E0C;ERE(>I#26&$:(&IY#D=X,
M92E421+Q4"F.XMC6W-E_^-38JY(/5 *>JPMV'KCS9LTE< S,.PY(.)DQIU3N
M9;X</&PTL^64&MOFRLEKW+W/-V)9E#EM@AX2_<DI+!G,JAJ2(4L@Y;&"*8^Q
M( PAQ%);'_/.DZ?V.3;"V;LS=W$Z[PCNK?W 7U\C5X](F5T$[-VVO9$8R3EK
MC8B3^_6HUAU.UMWK1W.E'A5SVV%Z_(*>"0_\NQ3/<WFKCE<NK"*BFPJ$UR8_
M-U^]W)LXT4WL!4D"+!."(4E09ORG :1QJNT&GD@A$J9X[-8&]&*1IL9L=\^/
MC[1X,;[#.A.@EAZTTCLF4%P^97;;J7$G8F"2/5I%=E. XZJ9DZOUI(#?*UT&
M:FKE#5I?&1R7"S1NBH<W  ]R0/P]N6^A^OSI*5\\7"_$?]*%T%<^M*:@1$E"
MXA1*%F&3>R8TTT8<\A"%A*5(H-C*%#P[TN0(M!&T*MG7BNI:\?L4JI9DZ .K
MP3GN"$P#I'&<Q<);D>I3XXQ<5/J,NH=%H,_=T+-H\[*0^</BW7-1R 5_>2^+
M_ >M:Z:LRT9_7J[>RU)?9>)PK\O_E.)!#[]UP;J$U/5J?>8^DRB(DB 04*5I
M +%*]'8SQ!F,*>82I1$1W*EUZ&"23HV9-IJ58+%< ;'6"- 2?*]U OE6@?I_
M7Y>?RUWKMPXW_W8<.(E9'9A#&QU!JR38:+G39T#K"=[O3':CZO956Z4& 5UM
MQ1IY+'@]])SXJI0]F)SCEM@>&NZ#VMR##]AO+?HL_[SFW!0K-!G2Q7*A?^1U
M+</C39%10&)!H@R2.$PA%IF +"028IS$421Q3+F3F\!5@*FM'%I^L%$ W*VT
MI4 +X;@D.$^#'=,/">[ !+Z'ZZ[PX[2L[HN>)ZIU'GY4!NT+SCXQ]GZ.^X&,
MY;&LJ=E:Y='GR\7-XJ/FZ(]YR>G<'-.6]]]E(:G2S#)#"!$FI((H3,TVG@<P
MPX&$5'$4!DIAE%J%E/D7;6H<J5_M5+_?*+0_$O$\5^=/E5YO!@8FTF/!*"=C
M4;;5TQ8P, J"6L,J/*4$&QU?;3+M#\A>;U)'.F%K)Y<U\_=D)E>VDZOJR6W_
MD6]/;KX RDRNJB?WI9K<U5K77_V<U0TS 1V'?9X''.VT<!B@MH\;!QKA@F;U
MUPM1A5O\UW.1ER*O2@*W+G+%TB3E&*J,Z%T&DQ%D<<!A$N.,Q32*N%O=I#/C
M36W!K,2MW+]U2,^VQ#V:V7< ;>DU]P??T+[S#N2&<*'; >.M/EOW:"-79[-2
M_; VF]UM?</"6[]*VY:Z&L^LQ+>JSNF_/59>Z<//E?DKF\L/"[UNUUT:9BB*
M9)8P"F6&"<3$Q&Q%(85*\Y%IK$BQ6TJ95^FFQED;Y:[ 5O/W*[#6T01.-"4P
MEB>JBOR^415LZ>J8Q>;W+;"CR%>;V\&W#Z\QK3TBW0> WUL O$_91HZ+'P#6
MPW#Y(0;I68;\1/T](]57R>>T+'.5\[KQSSK%^:,&SI1@_&)NT?^PJ.OX?5F6
MJT*N\J)N&;RQO,N/R^*S7+7J;OH7)%11F1$.)<THQ#(4D(0)@AE!"<:*F$;T
M3G7.7U6=J2U1UX_+8I7_;]UY3+/60JX Y:MG6N3:5'3O6?'*+XO=PO37>04&
M7LG.%C,SC8>.)6[M+'O[D&V5FP"&/X%!;9A6&M.825_EZU]7F7'KXT]BX@X*
M\$]#*O=SG'Z"JUW!Z5G!U8[@^L>EVEY JE\8&B8HPC&+4B@#LTN,DPAF68QA
M*IDBJ20DH<2A?]3T-+3B\/&;4-6T/*]IV2SE>D6G6^+;GT],"VZ+PZII"3SQ
M-?Y-C<TO39,KJP4<-!A5GL3ZH;LP[9@()=!( 0U';2K4XWRNW\AMP-:_[#(+
MIOYVVI^^34OP"9[>_3_PMCJ=!D[SA>@X39R8P*.=1DY,[R.GF1.5L&<_F;6
MY?VR[94J]<,W.MTOW]'R^Y=B^2,74KQ]^59*<;-8]]!J,IA,MSZF=:%\-:.$
MDRC$,922QQ!'<0II@ 5,F IP1+&2/'2K93Z$F"ZL/%+]\XV6IHE*VPI:5B:F
MI,5"ZU']"]>: C5?_EG63+Q<=YJC:S7_W;&5S1 O@IV;Z+4G=V##<&]6UPI6
M:]QN77;]ST9/T"H*V MX8W0%^>(7L.DGN-$7_-YJ[+/)SH 3XJL?SQ BCMNZ
M9T"0#[K\##E6OX7G[\NE^#.?SZ\7>IB5_E[,84K5@+%\GY=<[ZV?BZU\<ZX4
MIHE0D"0\A)AC K.8*YAPC)*,2,X$<EM2W 28WF*Q$;IN)5I6)GBKE1OY.TZ&
M':T/!_# A-T*7@%Z"/-&^(%::/0#SA.Q.@X^*F7V V:?#'L^I4</ -,QVIPM
M:S/]*UW)EGCSRH#_*/53Z%P3Z^W"7&"\TX]:INO__.^/N=X?\+IO)->D/4LS
M%8<4<1AR)4PTD()9J!*8"L4E1QG&E%IW"? EU=2.6.^_7G\$LM(.+!=@17\"
MO7:=3I0<<+[.NU%?918&YLVU3L9M XQ68%>M*] H9@Q8<+NHKZN4 UH[H-4#
M:_VN0*/A:TR@0_^"UYC(L3H<C#RA;JT0? /?U2S!VUCCM5/P#<].PP7O#^^W
MB=#;%;U!6;T8A]E*CV :03R9#V,_9S6.@S1A(M K)F804\%-FQT)<1PC%DN2
M8&)5E-1UX*FMD:W<5Y4[?E59N&O9J[^]ET^%Y+G#,:;S9-AM'X: >. %L!/=
M<1*'75'SM&NP'G;4_8(K&/L[!>?[>[,8EU*4)K[E[ONR6-W+XO&]9*M9+!0)
M*<$0*:P@3M+ .-+U-H 0SJ1,588<FX*>'&MZ#HY6U-K%71IAH>;(1R"TN,[4
M= )A:RZZ'+7AR6<+KDI*:,0$[[O@ZD,PW5#X8Y03XXQ-(=WJ'N&,,S?T(XG:
M4[N.3E\?L:0L"W"648@":5K,A!S26&E#AT:()"IE@CBUE3@QSM0,F>;<9),)
M8G$.XH2K'3%X0&M@6N@#E#,IG('!$R6<&F540CBCZCX=G+N\=PL:6112-#NM
M>A"]U3)IU8NRS:>>818IF0:9-AJ$Y@9LZBJGFB#B)-5L@0B/J%5S4;=AIT85
MWWZ]^]5X UUKY5F";$<4_J$;F#=:@=<>GH9(C(>G$1J\:<0^W8N]3]L8!YS\
MM8FQ&73LMC .0!QI ^-R=_]N=W6%AB^RR)?BH_Y=.4M5G#'&!4P1B37I* DS
M%3 8Q$G$8RIB0JQ;C)\<96H<L^[FUA2LJ44%E:SN'>\.0>TF&6]0#<TI?5#J
MU?7N) H7M;T[?.KH?>].*G:L\=WIB_O6%3]6SGRK!O[;E\TE38G\ZS]I(9IB
MYQ]^RH+GI2QO%K50]\N5(:=5D2_*G->%9"D24<I%H@G#Y+1(06#&(P4UKR#]
M0Q ER(H_QA1Z:G14B0CR5L:FJ_I2@66M$Y"-4L*U!/H(+X"=036U:1V8.K>;
M3VPKO-V!PD0+'FU28=1NVU.4IAM@H[JIQ%4K?P76FOLN+SSF1'FK&C^"R",7
MH!]O$@YKV8\X]J6U>S[E"WFC]^KE+ A1%(1ZWYPAJNW8 )GV1"&&B@O)8Q:H
M-'%JE7%DC*DM&UN%RG\W0H)*RMX5<#98VNZ1+T)H\ VQ&S@7U)$Y4-][-9C-
M"*]4T^5 Q=.560XO[?>1_T/F#]]->?,?>DO\T#19O%7O\_FS_FU%0>7M\ZHT
M9;3SQ<,LH81&.!8PEEQ"C$)MB(8$0X89$1G-@AA)%P)P'']RY%#+"=YHHZ&L
MA#WM]O&"/Q418C@4, Q-(UFD%*0FGRC6Z!-) Q&C:+8R:\'KX[^68CC\&[$;
M[,%R(RF 0(P].7:,/B#D [-]*SEH8:]EKQKPU1.P)?<5:#3RMQCT1,[30N$Z
M^JB+2$]H]A>8OH_IM_B8%!M3WU8_R33A^$Q-W=OWRT>:+V:"R31.45C'I>%0
MFYN4":*G14JE4A6E3+DL-!UC36U1,:*"+5FO0"TM^+V6U]'V[$+9CK$\83<P
M._6'S9F(+ #Q1#I=(XU*,!8J[Y.)S2V7MM>]6?S0.^-E\5)W\EGM=63-5!!B
MD20PD41!G%$%"1*F>'6&2(2$RF+'I&O;H:<7.K;5+K<5W;E5FC7PEO[* < <
MVN?8B+P-HZ::1NR1NMO:H>6]A^V985^I4ZT=&*?[T5K>?\'I$#OOYV/[?KYU
M0['KLGQ^;)U^=8, $ST7SCBAC,H8PTB9,R&4,$B%D) IEH7Z#T4#['PF-(BH
M4S.PUMU6YKF2U?:P:K?AN#L<<&H=3GM>?<*F?\:SZ0\)MA2^VC3=,3I[/ML9
M=%I\GN@,(^CXYSB# G[T]&;8$?N>V92\R*OGWJK]NDNWRE2S^#A?_FE:6:Z+
M>\^B, L(BI#>:H?F4"=,8*:87DU()E H9*:(8T2DNQ!36R*V=#"67K%?]DW_
M;EUOJ.I'+,'#IOZEZ^%0CTFS/3T:=BH&/U[:F86#XGOZ=U5I(*-#U2A8;A>'
M]GD*U1]&;\=4/408^1RK/TB'!UT7/*L?=;Y]SN>B[B[?_GCS^%0L?]3-+YO^
M3"+E,LN"$*9QHHWN4"+(&)&0F',QEF(2NQV 6XTZ-7)L):UR.5G[%]DF KJQ
MGQWN=G3G'<V!^6T'R/5?MD4>H$>6$TB>V,MNS%'IR@F&?7YRN_E2)^?U#YK/
MC5?BX[*XHW-Y)_ES4=4=VZTQL.>#$SQB@0D:C=,D@3B1$M(D%#"EB0@RD2D1
MN06-7BC0U&ALRR':5')[T2;&W-1+-T4'36*S_HUQ#S5EXOKZ2GO.GZL/=?A9
M&=&WNE8&JF4!C3I@H\]>Q961O*Z7X>O=&]M3G%?RTEX&WFGO[87/[4?->M?_
MN%S<K?23WN>F-N1"E%]D4>WYJXJ1-!>S( XRG&021B2B$".105.3$1))0AR0
M*)3<*0G99M"I46RU.Q.MM.!)BUCY6\5R/C<-CI]D48?F.&Z9K2; CC]]PSHP
M1];B@DI>$V+32%S5D:J=H%=-N5PMMS\6=$')$]-9#3DJF[F L,]83O>ZIQ[>
M<%5</XM<S^+U:J4-EKKHU)P^S%(J**FVK-BX]Y1*(!%9 #.581R%3$5V6];N
M8:;&/#?O/GX%C:A@2U9@A+7//NS M9M>_*$U,*'T \HI ?$\#KTR$#L>.UH*
MXGG5MG,0+:YVKZC:%E=ISAFJ(BOWRW>%U./</3\]+8O5]4,AZYWINM;<IG;U
M3"2829'$,&21@CCE'&:!3"%+0TZ#A*,XRVP+J5XJS-1HI)8<E+7H@*YE;YL*
MO%2]KNS+<5X\6]VT,_8<#$Q.Z_I-;UIE?JE+.;U9+7\!S>0T.H&-4E>; IM;
M;0%&G"3[4JEC3M9(%5+'F32GNJB^4.XHAWKQ$*-50?4%QG;Q4V_/=%__KL-?
MPSCXO-3KZ?MGJ><E:\X,9,8IXRR$+*$)Q$*&,&,8P2B+0\6$1%@D=L&?7<-,
M+]"S$O1?0"4JT++JGWY4H@(CM3T+G@0V2]-$)2;KBW,-+(DI) 1C2,)("1H+
MFJ16CF5?L(YA".R *C2H1E3P)HV#WWX#'YZ+)0A_#9(X_.5-],O?=G\=HE#_
M&EFZ.#J1/[_X^\!SX$7]X/VLH#Q[T&6/DOWJZP.MD5;5GJ@Y+9/GX.A8_D[>
M.MJR=D[X[>7J[+5]8PC*?"%-UL,CTVN<>2&,%_IAD?^O%#="OR2YRNFZL\8U
M_[_/N5XBKQ?BD_YU/J]["9G0,"F::.2M?YAE.*:!R6%@L29?'&>:<E4J3/*M
M7N<D5H$(W((/AA1W:@R^)1J@M="ND0J#SJZ=NWHZ<S;P*M$J"K8TK?JO-KJ"
M;67;-D2MNE5 Q?:$-QIO$C6V_M%G:,48D^,M)F-084<.YA@#^,,HD%%&';DN
M61WW<+,H5T5EUY153];[[W31U)[YNW[$:EUX9B]EN/K']W0EUZ'.,X0CKF0L
M(555$EY$]'8AT7\HR:,4150Q-DKQ,M^:36V%:]/RE4EX6)<W^WKW[=_J/GA?
MJI\>C!ZC%3GS_C;9+9.3D7="*ZJ'5)IU3-0:GJ:_^4H#M"FF5F.T74GMH'1$
M=0DP4&WEYTR@P-I0\__:5=B\Z_77*-4VU'1ZJ^<VF(!]K8:M[@R?UK7*B,(B
MDDD(N<0AQ '1J[?0ZS@/XY"@-"1<.-8?/3;,U-;3NTU[%2/G!?7?3L!JNY9=
M"M;@"\M.7Y6!2L%UP^"-7X\.,C+9=2EZR#R=5_?HT/K^V]?KS_=%/G_*?^2%
M?F+C5D4H9C2A"$I$&<3<U!X36,)4)H2C.,5$)M8-5T\,,C4*:.3\VY:@#JTW
M3R%YWHWO Y^!O_HCT/1PXI_$R*';J >LQFH>V@<SMPZ@9\#H:NAYZM;Q^G.>
M$7ZGW>:Y:_N&=B^T:;4R[:\-H;8O(\IXS"2"-$QC4XT,018F".(T59P%49 E
M3K4VCHXR->[;$K*[7YH#D'86S\7P#$Q]^\@,D*77"8&W".MC8XP<4MVAYF$,
M==?%_;[WVR>]D3(ERN[DPW;"J:(\(0EF4*$T@3CC$211DD"1)2&FDF"6.27Z
MGAAG:M_\6DS0RNGVU9^"T^Z[]P#2P%_^(3X#?/MG8/#T]9\:9=3O_XRJ^PQP
M[G+WW<Y>D<(/Y2I_I"N36"9$;HQ!.O^B+S&<4]7=X"B-% LR*!A/(492PBSA
M 0SB.,-<)(Q):KL)<AQ[:EQ1%=SDVP4W9:.!.7:@:QW 4Z,$,,51[+<&KE-S
M?E<U(. #\\YA<=,/6UAOQ >M_.#3H%C;[\X&Q'RD39MG[)VV<SW1Z]CEN3YQ
MM,U?3U6W]X1]']&W17G34+#*ZJN+8U\_K[XO"W/^/PLY%SP,(BC"2%N0$=)[
M1A5A*!%*E!1)DF:QBP79/=S4%H>UM*"L4U6;$OUT+7'_NOQG@+>S-?W!.3#U
M;Y!LDGZ;6OL;87TV,K<!Q5LW\\[!1FYI;J/X85]SJ[OZTLM2///5.Z/ 8E74
MX45Y^4<;A"\1HX0C&"*3W1 3!@FG*50D(UD0B%B%3IU8NH>;'KTL_RGY"NR(
M"XR\KE32";(ME?B";G JJ00]@MH NU@[5+QQ2>=@(W.)C>*'7&)U5X_S/*6D
MR;.2ZX;'7[5-M%L=1?]3(6DIW\OZOU]D8:28Q3@4+$XE)+'D$ <FTR<..&1Q
M1%" HE@(*QOF0CFFQCYK5;8;@!MM]@H3F0Z2M2+@3:O2+U6I#FY=)^_2*;0X
M:QQG8H8^COP+S8G#V>8X<S/6\>>P<^1V4'HYLEUGJ1<\?;SCULLAV#F1]? X
M]^5-#_/N>55>+\1_+5EYS5>W*@K"]-M"Y.6JR)EI7/5Q6<C\8?&!%HM\\; )
ML3.%=_2-YC\F#N\'G1N?<B-X^[$B1$SX.H<4*=-R#W%(PH#!!&&B,IZI)+$R
MM,<0=FH+Y?V[_[J^ L_;Z@%5ZP=DHZ I F9D!\6F]N+ZWY:;Z.*JWK8)8Z]^
MD!L([#E[\'?E_&([I3=@X!79D+O1%6B9@='6E'4 MPH8A:_ CLJ@T1FT2E\U
M@>5&[[J@F7E*]<.6[E?K%:3'"C[XVV"_S$_IK1C)%IC8V^%D.XPU71T&QN B
MC&:%C 7FMJDRVIB]77]5-1531>6F+)^I!O%6?5HN'MI WQFG4BD3D!+'H8G(
MCQ-(PRB#*""("Y7A+ O<.MN=']2%1<8I=;(N-535%YIK6>MP?:&EK0ISF1.Z
MO%$&\&7I&L]B,1/6/D*/Z [O)]R"M1778&D$WD3Z>W466L+CSV%X;L"QG8:6
M !QQ'-K>V3-$SC!?O:=KW.)Z)X1"&0@8IB2".$4)9&F0PI!BE60I83)QZAAT
M,,+4]C&UM5%+Z!@0=P">'5]<!,G ]+"-QA#A;Z=4]Q7X=O#\<4/>3JEW$.QV
M\L*+JY;71Y6&+:2881I'VI0(8)P(4R!8FQ(DY@*2) Y(FDFD&'4S)4Z,-#W[
MH:FFO1NBD%?"]@]/.(6SW8?O ;N!/__=$N2UD%>@%G.0BN/'</!?9'QGE->J
M*WY,U8Y2XD<O=_>AWOSV]NNW_[YY=]VFNX@DI1Q3TTN60"P9@HP*!-- IF$8
MR2C!R-;EN??LJ:WL:_'L_4;[:)UW^EV P<#?\EJR'JE[!V^-M;OK CQ&\DXY
MX.+D.3JA>8>C9_^.T?PR)T3==J.<NN2"?88IGU#([W)1K@^2JJC.8QW_KI5F
MB/WN@/?TYRP22*4I9U 2KODKC23,L.(P3:. 8Y0E0>04&^5-LJFQWWM9Y#^H
M.;,KP;_2QZ?_J'N9NB;]>)LXA[W1V-,QRIYJ1ZEVAU5W,[W:;W5ZM=WK] I0
MH^-!B]3*!>YY:^83>9];.B]RC;\5] GGT2VDUP%ZU.>.HNU2JW'0F LX(6&B
M4 0%-E6D$3(%I%$ I2"QWI%&F#/K3*H38TR-;J-?H_TBTG'@4/#X!)+G#5 /
M^ S,?T>AZ5,4^@1&#C6A+\=J)"/5[75RJP3=#4)7(>@3=XY7![I;])TRT&<N
M[6?'-@>'=45/_G)?T$5INL4L%RW+OI4F",88/(QF22P"4T0'91 S%$/*5 B3
ME(6,R!BCP&JGW6/LJ9%C>\;/&]G!:B,\>*A,G7EMZK!*!;#JL&PNGA@[2W0@
MN ?FVA;I5FRP)?>N4=D@[=6&[(&9)RO19>11[< >D.Q;>GT>X:W(?579N,SK
M LA5$-\[<]0^XY(0Q;F$,1>:W9*$P8Q*!JD*XE31*.;DTH+U)X:>&KEMB;F.
M<^P1CN" O1V!#8/HP/QUO#3\-L1M&^]WG1#[J.]^!JWA:K6?&OBUZZZ? <2B
MAOJY)_0\_=S:[N:+AW9;0+*$HDA &E*E[:\@@PPAJ3>A*J2QXDK9E?/H'&5J
M9+3K2-)B.IYO'D72\G3S4GR&/MO<AV:(TEY=&/@ZUSPZQKBGFEUJ'IQI=E[<
M[XO_+%=59^5B:?HMB[<OWTHI;A8WBQ^F3LU.OT;"&0IP%,$892'$>D\&B4@C
M*"*6L"!*B:#Q;+5<T;D=#=@/[<0-:P&&^P"TY'6"Q;,I_\Y>0-[*W'8\M>ZD
MV6,>[$AD&'0'9A8#;-V8O1';@/O&2*XA_@6LA??:^[(_8IYXR&'@4<G)'9!]
MQNKQA'XT]KZI,:%W;G4?&?U#^[L//TVM>;E3<WXAWLJ%5/FJ_/#X-%^^2-G^
M?:8(S>(DDA!K<T=;.W%H: [!* K21"B)H]2IJ*$_T:9F(K7RK3=K2S;/'RHM
M'-G/X_39L>/K3,K [-DJ4&7TU&K5V3WK?VA4N]IM;6+R!5MUKL!Z5MM?^6-8
M_ZA[8F"/@HW*T/X!W6?P 4;HR_!LM>D \E%_ =>/R^?%:A;$4A$6IS"((PXQ
M82&D&28P0R1!C 1<$:<X^U,#38U]JYK*&T&O@!$5U+*ZLN\):&VY]'+ !F?&
M'ECUH+=N(+R1U8EA1J:>;F4/B>3,]?UHX6:AO[4%G7^5/^3B6=[)XD?.Y<W7
MN\;C$DN*J$@8) '1)IV4&!(2:&M.,4)3DL@H(R[L<&:\J9%$*RYHY 6-P."-
M%MDQ9/\<U'9LX1' @4FC&[L!?%Z6T'BBD7.CC<HFEJKODXKM;?VXI6X[]IM<
M?5^*>LM:E=->MQ%[GY=\OBR?"SF+6,0%QJFV.A(,<4(H9!AS$[851H2RD HG
M(\1^Z*DQ3M/]\+$2O7&,/=:%!C8M-]V(QV$>[#AH&'0'IJ,&V%IJ<+,-[*8Y
M)-B([H^7W.'R1%$. X_*5NZ [!-7CR?TM8_:AW]9SG/^<B]_KMYJ7?Z819G,
M8HP%1#'1E"7" &89XC".!0U$PA.",C?+Z,1(4V.H+;Q=#:!36-J:/AX0&MSH
M:66\ K64X/?FOT9<4,GKU>8Y@XDW:^?4."/;.6?4/;1PSMW@'FQ^6]#Y.UJT
MN?9Q%H0!X0E,)-=;)(%22#@*8(SCB$=A*JA=H8+#1T_MRS?2 2.>?:CT'E;=
M'_IE" S\9:^5[Q$POH>"?9QX?S1&"@]W0,4I-ORXXATAX7LWC!8)?ES0[0#P
M$U>X\4Y9K&:?\E5S//2.EO+Z9U[. B04B54 ):,4XH@A2)",8( P"U&$8LFM
M:B<??_S4^&<CH3GEUJ^<$=+R,SP!8#<A70[+P*3DB(CU)]BM>)=-H>_<LB?T
MWS:VQ(F'CO*I=BO4?JYGKG(W%>[X=RF>Y_)6?<P7^4I^RG](<;W0>Q8AU>8W
M-YJG%P^F94Q]2/3VY3?ZSV7QSF3(W5/]ZQF7$HE(2"B),$?KA,.,\ @*GJ69
M3 D+";<U,GP)-35Z:/4R-<1JS6"E2%6W<:-<\\N->LU9+WC[ BH-0:4B^+U2
MTF&5]S;9YZVDUYC"@:GL_YG9L[?N7F,61[(+1YY-)]O2-^P=5JFWH4:S9WV#
MLVT)>W]V/Y_>1HRFP^=7^;0L3#S=S4(MB\?JTWC[TOSCQDN5)$)@04*(0[W'
MQRSAD C]1Q"CF(111@A3;C7,>DKB\KV/4^-L^W-OI 5K7<"6,FX>P[XS9>=/
M' ']$=?,3MBO3"!P>T5-IL/X(R_$U).WLJ\4H_HR+X1JW]-YZ>/\UU/Z8GY1
MQ;155WU9EJM"KO)"&@&:L+8O^GTV,7$SRB*%5:I@$,D,8I$0F"680YJ&B=[=
M)%RE;+:0#R90]MY/5247^:P^>E)_] =2#GBHV0:;LG/!IL/.GAWACCH9KU=2
MZ4VMU2]5B]XK$SV<+^0Z1!@8+4Z54@+7XI_/[?G1:%65^F _0E$E)[$F4U.I
M#Y@N)95Z/=^-W(7,9Q\6JWSU4J?Z;Y:2.[UO?"YG01(E)%4""I1%VAQF F9*
MV\3:.$YY$&$>!8F--^K<0%/S,-6R-C4MMDVM6EP[\CV+;C>9^L1L8'+L"Y<U
MN=EB<82L2LE_?5C^^)M^1,U3^H<-/9U]\"AT8ZM>2Q_6U_>S];;+_9L]^>JY
MT$-=,TU E*]FDG&.:1)")A""F&#3QY,'$,>1"E2JS;O0*8:O>[BI4</UPT-1
MV7W@L98TEZ79EFWZA?3.[CJ#NYWMY0_-H8^T=KI_7(&/><GI'/R/I 5HQ0:_
MMX)[W+K:(>3)[CDSV*C6C)WB^S:*Y5V7NN@^R]7'YX4P[<\-A56NBXVC!V6(
M4\I"F' 3-XQ"#AD1%*HDHRP@ 4.*N7".Y;A3(Y]M/Y#) :\E=[)*7)%W=;%Y
MPW-$E]H!E".YSJRP\NXJZQ[UE5QC5E"<=H79W=ZSV$]A"MPVM="J3 I9KDQ_
MMG?+1<6!3;17%*2,J@Q#+A-M#9% ;Y9(A&$B$X8"R3E#TK'UB=W(TSLFJ 3?
M%%_,&]%!8>RF\D_ZY$A6ME,@XPAE(4XATG.AEXD@AEF04AB%+$KUA&2(6>U7
M!YR 46HRG84?\$:!\M^'F0F[96, ? =>-FIHU\4N6YGKQN.MU$/4>7)#RE?E
M)\M1QZT%Y0;%074HQ]M[YL0U#OL[J1G7=-%KO@LF:18%/(.1Y)$Y_I!Z&\UC
MF 9<"$(#P8E5(.>9<:;&2&OQ'#/:3J!HQRX>L!G:<=8>ZZQ%'( ZSL#@*P?M
MQ"CC)IQUJWJ077;F\IZ?OE+2U&MJ?/E-,]^OTNB0S_.Z_L?JH]1/I//*7M7S
M][)S\2SA&N $(;W?#0C$QJ2A">>0,LQ)D* D2I4335PNT]0HY=NO=[^"LA6U
MLFT<R<7#/%D2T;CH#TU:K39M3YFV,3K8U>@*4+VMKI4":ZWV;_+837T N'V1
MHP>)QB52?Q >D*['1_<LD92;*GL+47ZA+\914!=8T:]AU0%Q)G&0I4)2&#*2
M0:QD!#7E*A@3ICCF**"Q$_=V#S<U6EU+"QIQKYKZ/^8[K1MT.E9-ZD;;CD']
M83@P.5X"GWLA)2M4?)53ZAYLW*)*5HH?E%:RNZM'5RH3OOR/(E_)I5)M[F>2
MH#@+J"80E.B-GC#%P+4M%R<IEV&2IF&*K3M2'3Y_:K11B0@J&:$6LOS;'9W;
MUO8]!6$W-7@ 9F NV,.D3P.J8R^6??.IR] 9*8/$&26WWE.G,>CJ.W7DKO%Z
M3IT6>:??5,=E/1(8#06^I:7IC[!5IK+0V^*'.N+L97.)YD_SJ^L_:2%NGZI(
MA]OGE=Z++42^>/C\;&3YC;Z\E74SZ;MG]D]M\MTO/S[/YU79ENK.\L-/+LMR
M%N@MKHQCI*<AU/86TI878SR",E6"IZ&@06K=N^_UU)@:(=?=O$%9"PU62Z"T
MV'59*4"-X%= 5I*[-Z=_Y1?F_+KPUW@-AC[A-AK"2L7=.L9;.%3I(EO7-5B
MZ_H%:>#0/VP N0(U)%= @P+>2E## AI<P/T2&&2:.ELU-E>@1N<O\7HYY'7^
M)5ZSL3)!_T*OFUL:Z:O/<E?BZ>L)-UZJZJM/P$YRZ^M+T[<R>-N?O2DU$:"
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M)@I)J/^($FT\)4Q; 8RX6 "G!IJ:-=#("2I!02LI^-W(ZIC4?!);._+P@=C
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MIWSJ>:-\PF>4:3_=<Y>YQX._F^N-Z,U7R9>/V@(0%0]HP^#F\4G.Y[19<$2
M5(*$@"3"^AL.(PE)P!"D*4T%B:1@W.K<TG; J7W4E<S@!NQ*#;38H)';/A+9
M"O#N3WX(& ?F@/,(GE_Z>[Z[UJ'<OB$=*8#[@I?3*5C;!9Z.$&VKQXP6F.VB
MU'8XMM-]O;O!/RX751+D^_Q'+O0P99L(^5[RN?Z/F 4!E4F8I3#.0@QQ$ 6:
ME&,!192)*)58QHE3C+7-H)-C9]-G5C325BG.8JDGH2A[ISE;06^W"_,-Z- \
M78G;9C^O);[:I$";HKNUV%X[M5N#Y*\U^_DAQ^[%;@W"D>;K]O?VHZ./^2)?
MR4_Y#REN])JV>*B23RI_L^F41E3((YYH$Y%08R(R#%DHE-[UJ11E,E":FEQ.
M<KJ'F]K13BTMF!MQ0;Z6MSGD<2_C= 9L.^KQ!^' I%,+"BM)P4;4=:U.KYWI
M[%#QQ#)G!AN57^P4WV<6R[MZ^HOSAT6N<FY:WW%N\MCRQ<.7Y3SGN2PWZ?\J
MQBHC80@IH;'FEI1 DB@&0R(3',6Q1&YALW;#3LW,N7M^?*3%2U6<9*, V&@
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M. [W@$$6)P;L<2RIEZJR[KG4'DAFDNAE <-81 )B$J>0H@A!)"D*4U+]S_I
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M#Z-(()AFG$.<1-KN2B(!(YD((K7Q)0*W(JS[(TR-P+8$[)D:=0BB'5E=!,W
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M(Z2#U8NUE>.5"\@ZPG6^HJSK _L1[KLZ(.RCU+?0N=Y(-I4G&D%F!$=$<Z>
M(2<!Q!A32*3^B<E ")2&),!.WJ$SXTV-/$TVGLF2<@VQ/0>K'<]Y!&M@-FLD
M!8VHE7NH$1:\:<0];4<[LY4E,)XXZ=QHHS*/I>K[_&)[FQN+<%-5N7B9?;N;
M<140KK""/$U"T]99;S!QR"!E#&F2"'E$I5T$_N:A+B_X./'V%1\8=K;D@RV
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M68KKA3 _4#:7,\X"2;D0FL!"TUPI-57L(P7C,!8\58*JV"G0TJ-L4S/G6M7
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MP$KP7TK>V'/2#ZMR4U2.N?<:^@Q8Y[7T'+A&7U/[D1IGQ3T%2KB5]]D(4Z_
MIU0\LA*?O-1_E_LR_CDG9EY5*;?*X)(VKVN4(YU%60)S(1'$640@5SF!68HS
M0?(T4=2Y0N&),>;& U;*/X!*3F $!592][W*4T#V;QT'@&?D[_X8,@/J$)Z"
MR'US-@!4$VVU#H/,:\.T!XR.[<]3=TZVF=DC>GMKLN_28:9/DW!<7JV;QARM
MFG#7)%<<\2B'@MM,4I$0R!1)8)JBC,A$11E"?@'[7<,YO;R31NA_-@^Z938>
M?ZW!XB"IGQ'4";&;-70V;!.%?#5B@LUZUW0'?'" S=L0<L$CD$74.=2DII&+
MTD]M)*=[AC''Y3U;F-^7ZOVZL*[85R6V114S:^,.?F6;YK>OQBQ>JN;WA[?F
MLVV"]VU!A'+SFI6+<M]3)B)$L91(B*CMUY<2!CF6,>0"\23-L6+"J\C\&$+.
MS5RS H)*0C]>&F4"W?CLI:=E[$,6HP0XZ'0!]OI"O2Z@U?@"[+0R_[JL&,\Z
MDBL):IWW_PRLUOOLI:KNC9GN,1H4C3DI@<AX%!$G)?$Q07Y*_J..Y>]A?]Q:
M>_63?M=$XI?O5C?LQK88L(5QV.KA4FP6]Y5$?UL72_G[0JIKD2<89UD&.5$"
M8D(Q9&EN?HIY'N.4<9PZE349*L#<R+[6P=JCNX0&CRCY03/0[[>/C>O8FWDU
MI)\TV"L &@V,]0H:'<!!";#78F3HW?<#QIZ"B38+CKS=0#53L5@!T4P%.TS%
M[SMM?@ZSEW .D!T;#8,>.]DNQ#E*M[<HSGK.,"_D'2M69ODJ/ZNBJJ+V=K'<
M&DOJFFJ><L($U#FG$.=9##/!<T@P40E%44ICXE>I[,1(/E_11%7):L' *_/%
MR/5RR8H2W)FOJDK2]2PI< I>P1F-6*)AHB,-S0(=F64YS2 6.E$J2P@C3KOB
M <&=IH1.#>U*;8!J1#Y@.RKB;HY5 !Q'7FUW$@(C8EVGT]:TJ:0,Y\KTP!#(
M&SDURJ0.18^J3WV"OLO]S?I/=XOU8G>XFQ,DE39&.D=Q8MB "I@+'L.(9D)3
MI;.49*[F>OO!<R."6C9W\^\12/T6]5#51_YVUY58 PZ\'JGO;M4.A6$B:[7G
M)?"R.X^IVF%//KI\,COQF)!M^^_HOP>K*R7,I-J*5ON_'@I:7:-<42(2 3.2
M"8BYK80>&:,$"Y1I37#,^+E% #N&GQL[M60%X7LU=TZ$FYDR'KRC[^P>+2TU
M#.\0U:4<8!NOP%37X"]=8\H!&(<R4RY/F;@[1/6?OZJRRD%2Q6(MT76<R%1%
M/#.D)VPH/[&5]92&3.0R11G/,8G]O-V0XLW/1:Z$!/>UE-95,V).U/WAV/2Y
MD>9+3<G(E!J@IT,]G8V&X'/W=$[7N*$#]Y?NT7!,M'^-=@P=H ;KO- UQI#(
M4DRB*G#KK0W<HE'C!QFC-)+&3X9<T-B60T4P9PQ#G:=8HBR6.G6*,.\88VZ&
M:?RS$?-Q-""-?.(FCR/9[U 'P&=D&CP*S:#8TN,8^<26GHW59+&E/J^39TQI
M)PB=,:7'[YPPIK13],<QI=V7^I%=66RN;0.U]7(AJYG_L%'?ZS884E,;2YI"
MG6@,,>$<YES84'H4*8E2B11WX;K30\R-ZAY)"2HQO8I#=8#937=A(!J9[0:@
MX_SY]@/097V9NUN6E_GM8'5U/'B2C[M?L=VW[7!E2*^U^FMYN=W<VB[52GY;
MF2>VRM!95[K<%:C[7"R$^F)-L+KC^'6J"4,LIY!FRG"#MMP0:PX3P3.$A#&.
ML%?,YP@RSHU<:E^(/_.9+FHOJ00'/<'6*OJHL&.U:U5>' H_5NJ"2M_^/O"3
MO1?G>,63S?;8IZ6#IBB0BQL$Q%$]W?,DG('#&P1B-[\WS% #SH<WMZIHG!!*
M4B+2",,HDL;ES50,&5,,YE0G2.@,B4@Y'P\?GCLW>JY$\S@=;2'D<#8\3.^1
MB:J2:LC)<$MWCX/A81A,=2[LAH7?^?!SC;N.AUM73W<Z_%S$1X?#1_YY\-FP
M*@HEK]B/NL_@1[6Y9IA@D20))%&60IR8_V2V#1QFE'$D9!8I[=.8X]@@7CPS
M63,.V4@*%K9*G;)%[7T+K!Q%U/DH]RR<QC^PK<&Q)1]W72F-B#;&V#;7;8X:
MELOU[\R\X4'/:D_B$NY$]OD04Y^[GE3RR.GJZ6N'$<&W5;'OH=4NZZ])K,Q7
MKR'-A8982@(S2CC4F2TR'&NFF9='>6*<N9D=;3&KUA;<JX]"'ZHQHS1'<0YC
MG!GC3<419 FBQH*+$%(4HRA6U_59ZM<-*S:38?MTS/$0?JUN%BL;/VGIXT$Q
M1R.O#UF:Q4)JE4,B;%UL)C+(%,UAFL09D9$T_Y<WR+Y;.6;:!\-U-^*(3NY*
MAL73;>4*@-#(B]>C#SIL!PY'$ *M5*=&F72QZE'UZ7K5=_G9MFNKR]1?UFOY
M^V*YO%S)#\8]6=TL^%+5J^33WZ]IRHG,>0J9%,:\)1&'7 L"*<LT8HRBC+)=
M48XKKXC'\P1S^FX>E^^XFF!1W&E0Y58O]C(/-Y '3INW-3WB++R Z=W2QM97
MWPG=F.2CF-WG 1C>1A\HSTL9].?!UV']G_G@@7F"5>.^0P9\L^64D#C%UO)B
MG%N;5J8P)]K\I&/C,>0YE[%?'MO18>;F*-12@G(OIF>*VG$L"6(TM0X7$\;U
MPM@ RO(DAC')(J8I)Q%*/5,NST9SFG#2!L^O8?%T6S'.QVCL(ZRGX(Q0&+,;
MA%#I?L<'F3;;KU/19\E^W5?[G^484E;FW=A4_3#4NQ_V<$E]5)O=!GY,=)3(
M&"8H5;5IRK*$PS1*A(X32:E;%[C^H>;&J#MIP:M:WI] (['[24@/MOT'0^$0
M&YD1]F#5DNZ@JK9E:V&#H>9^I!0.O8E.F?I1#%02PPV9CM.HG@=,=D#EIDC[
MS,KQ#G\B?</*V\]L(=\:9E[=7-VJORM6[(NH)2F3&9,*"H&-+1H;1LV);0E
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M*CA:4+6)V6U! ^JB!A:<IHJ0,<QW^%R /4)5FLT.HUT\A8WBZ:G*.M.WS_V
M<Q;RSO"@]%_R;?0Z?)W5S'<<XLY#SLD.@^>A[I%#Y7D)%JP]1UENO]=B?+.J
ML:6PA?/-F!_5IAYS(9KK;5?1MXM2K+>KS1=C\%YS*JA$5,-4IA1BDB4P5YC
MB%.5LTQJ'9_;ON,,\>9FZ7U5Q;VM!B=L)V#9" JLYW!V:X]S)M'-2WZYJ7F9
MV*V#<N!;M08>U*OBZ78*[N^S*MJ6:,VT?NF:UA =1 *@/UZ'D7.$>^D.) &
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M\>@8:N+MCWZEG^^%.-PSL'F>N%5RNZPRH?FF53+Q\'IC'"&=(P9SPB*(\XC
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M,3=VL%+^H3Z0K80%1EI@Q77?ESB%9O^&30",1N:#"A[P&)D!X2BG('+?O@D
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M.-E)Q%ZPL<\,-NW$/@H4?0[?WV62U+1,SPM^+NRDM]+IR TPC\0(28S"_>#
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MB*F^*V(^!XW*L-"Z=5%C%H:>_O5T>!Y2]R,?<__ V]"6@^\?M=03OG_=P>-
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MG?F^T._DLRI O'"%L; 2M(W +">KGVV"*'0 GM$4H\@YZ>-FY0&J1EE/W!L
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MC_+[T=,H/1K:[2?3.M&W2Z;1UO_+8I'_F,YF!WDX]W_M>(]G3TH;V:C+CQ,
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MDD:(@)K#?4U1ZVS1I4+>?*_OBO"<MXF5)3"7L0XAUW5^B0'O.8?D@L1DK*
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MVX1\>-IV-%*.S>*>1D:-DKK;2P3OTG4>R:W-1H%5OH[4I@?8\Y#H%4;A'%T
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M#U1.SWA[L  ^2Q=+,@PR$R2HD .)3!<(J?C,O>(13W:_WY/5Z>UV*!2&0NU
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MM3]%;'$TU741\4[+.ECY1[SY[\_SIRR^N5XNUX.JT M%5SQ87V2=VR' >R>
M6.)2:69$:=V9.)BXZ8J_)HEUCZ&R8[WL#\T@N3W#>9< O:A+':-3$J3V&50,
M"AQ/9(@DA4GRX+EKW93]'9*FRPM. +^6ZCFO,2NC3E(YX;"4_N:A8$S!:BY
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M9UF=C2Q1Y=8M'R^0TTM&M2\$/2M[;*/.?I%Y6UM##ALCKTT#64.J"HGX0)>
M"1[1)('&M"Y$>I&@:='93.W#X'2 #CH 5+6F-SWP&BU36M8ZX&!J#[R *)P
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MJ.4[$$2R+DEB(K1VPIY3T1]H#M'OHJFP.X#+CE4?QK.<#='.I0LU=EUJG8,
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M#=TIEJ2W@00#+-9&6Q8B^*@1=#22!XF>_ML862V7O4U3([H7%@Y<]K:/8CK
MV\  +"-9B> =:+0U"VIJ=6T->Q8?F,E<,W/215S[Y0O_#I4TK=_;(Y7< 71'
MFXX^SW62;LC!>1X21"7JV$?&ZA0# T[[(G@L7O!3#D\^GJ->+N9V&#S5N/S]
M ='!\7A1X$_G1[\E?;U*Z::='//[-S]_6-PZCZNKV>?Z9^0^OOJ\N)Y??5B\
MQ@_+,%_=L'7AF=*6F039<R25U24"G$RWG!URRUGBH75?P:EXZ]B;:W-DN@3)
MV>1-KS]_#LMOB_(JD01G5]_6#SWFJ\5/_^^:?GN?3&R>/=W_F\?)H1XI@5-D
M4J5"B8+N:2,=7=N6[N[H!)V60G_#8R8LGE,F]3:NMY'KKXNKWS'DV>6W7\+R
MWR1CLA5O#,;DF9:YD.<A6 $E6(:(VD$J*0C%-,?4VF0?2EO'6<Q]T++5_FBM
MF@XLB3N!O?[V:K7"JS?U5;C)793(C>,!BJ]U.0X3>%T$F!"L4^25E.;!UYW$
M3 NJ<72_:PWI48KH"5%K-E:W3TI^/R>3XWJY))_Y=5C-5O^<+^(*EU^KX'Z>
M?[F^JHLMYFEV.;MUF>^E<)<MD2R$I"$;1G*03$,H7$ FB\@Q9E3 YMOI1^*E
MDTOR.*CM O"4>N\ _S?6T1^5Z=G5#%>WL4,942JG P3C%1G)-H$+BH',JIKR
M]##IUM?I=DHZP=ZD*%DT5UD'P!OP3-VD8XPNK!9S>5>[7K(7X#,91#%B"5+S
MH)HC<2!IT[KD)WGFQU#2>6#OU_!YDZOQ(>I0<S66:0%*R4!\U4F; G5 RQW9
MXJ='X#V!W9N;^T-D?Q@>J*^)BXV>Q2;^G%U]NN7M1Z3O^#R;5^YNPQVW;8#:
M>^XL<$V_*+,>IUFGO_J<#-.)93VD".F K^X>:(>"8'$ZC?0(N,7UU7<X)+-$
M6^XC% R,S!7I(6H6R-S&PIV+='R'-/,>]NW=O[-CP:ZM7L[CW7V03&"%'#F>
MR&21]$L4"%Y( 60K2R\46;7-'>A]Z)LVW=^+]7>8NCJ[!']?7%Z^72S_#,M,
M;& IR7I@NM0=*CZ#C^C Q*!9<3Z64@ZXZ1Y\1?>OZ($Z?>$V.U3 '5Q9]V*Y
M=[A_)=]^77YU=:'I:<]>%LBHZ+Y'.E[>V0PZV"QCXDZ$ULT%+U,T#;J:*GTQ
MF@8ZP-.-E.[C2G>U'1>2\RQS"E4H9$5ZK.7U=6$)\X79P(SBK:&TDYAI3*XQ
M4=1&[IT]7*NG!4-E71=!_VHUJ\KZ(USBC]<U3/D;+F>+?!$3<HP*02"=&)52
M!&>,!L="SMGZQ)]FH(?9\7O2,8WM- :\3JZ5#JZPM0EQ$Q!_< ]+68(3G"Y>
M91TH2YSX)#DPLA2,=L$@'R7)_Y20:<;VC'EU'2_O#D#S-&GQKYW^[?T=O2[?
MNHA*96%S!A1(HEO7.?I2 'FR=?2%=:YU;_'!Q X"GSXG\)U&;^=29_>66)VG
M6;B\.8YA?K<.B403KN[K>=H6V>W[M:-4V!W%^TG*ZY*@=]1I8*P:<B8P\(6>
MT<*\+I[K+,-H)4 CE-?=??:#BO'5MOW5#_LU'K8:W75]/!C/>Q,4<H4)PSP#
MY<BE)[]>0&3*@<L<3:";HLC6DZ+&XZ:3"H%C$;FS0&5:]7=@.NR82YZDXZ:@
MA:!DK7?@!:+*'*(-67F5<TRM07S$$H'Q 3@Q3H8M#=A':5U"[S;/0^1ZS7P!
M*>O.+5O'_XK$P)5BDA<:)6]=RGU62P/VTO/0I0'["+T#\&R;8T]6;RA.)/+M
MR0I7W!8(6-=Q6ET$,:&5:.W,G,_2@+WT.V!IP#["[@ O+TXE2+K0*<H!M-,<
M5&8<G*V_E"#(M\I1IU/L5>QCN$BG;UXS!78%QBW3"VQ4SD47( E=5\+424#.
M< A,&M1>R])\*?.9#A/92^O[#!/91P4=P.F%,14>74)%=[-2PM,O.8(+0M(M
M+6L5?Q*\M)\=>(8C0_;2^+/I;$W$WP&07EZ0%U 5B5CHQ:]%I@4-Q$2_%2IZ
M(63*MC3?VWSTEL(3=&TWAE,[)?2 J/O^HON5]C-<$E&?OKW#KWBYOLFC<2D5
M[P$K+TJ*"%$6"^3GT$$)D:7F:8AAE$U;B-:I*3:"4KM8J+D],O^,P]LS7A*W
M)C"ZT;.W=6*C!>^-)%=(HPJ!Z^);VVE[$=A)Y*PA1G;!L+FZ^D+CNNEMM989
MW^RJS63<^A2!YSIF \F/]\P;4()+5[Q&]*V'%KU 3B=(:P^#78 [4B/=PDO<
M,E."BP4Y R:X %43RZX8 9[<*IFL*B[Z$\!+]&#G30NO0S32+;SDQH;-BEF?
M"P2M,RC+%<1L)7@I&-=).X7-'8G=Y'1BXDT"KT,TT@6\[FMQJIF[-B5\9LX8
MR4"N][<;KR%X,BHX%YK^SR076[>T/*=BVKUVG?H+1RJK S?V,0=OPA5^7"QG
M_[.6S^T1,M(7CQ@ ;0AUOG\ 'UT!Z;PG;H/1O+4[\'VJIIYX?YS>7X31T4KH
M %8[ADTDI[G1)8(TP8$JS( /HD[P9X7X<DJJUNFH'N>#M-;WL$D?^PB_BZ?P
M]?5J-L?5ZD$1_/JHH=<LA22AN+JNT3L#D>L TF;O6&0ZY-9&_ Y2IBG<[?Q1
M;*&V#JZP;6S4'Y>XB84;C=J&&,&L:^D=':T8&1FNN:X"D%:6YBN"ODO4M!=;
M$]4/@-/A>IBX%>L57<FK_\)P>?5IX_]:I@N*!+7ED!P4<E6<*+74WI#O@I;)
MIQ,(M_96/?O@_H!PA-(6K20XM?KC;/'YKM"H&",<2GJ&M5'T(/,$P3*R((/3
MP2OIM!PR'N/1ATX;4AI1[0=+KH>G9,N;?#.*L&Z&42Q 0F1U! PG/@*#G+F*
M5J-!JUN_(#MH&00<\Y]FRK107*< O#V047"7#2KP:;V>33N@AUJ"<SPB0ZF*
M/ 4$N[!>FFA[ (0.$'T'(%HWE-ZWDCYHX]H4SI)AIS2W4 RYJRH6#UZ(6L'!
M/2N)N2Q&Z>5]@:;^ '6([K=U]K921"_ >K.+&9\,>DM7=Y1U87TAM\%YY@"+
M+")(&8QN?4&]2-#$%M:(D&JB@@[P],"$N+,KWMU/)_(!4XP(04>R'94CME0B
MHR#Y0FX$<F=:5V2]2- @/-G_,,.KG0J[PN-]J?=-N_-]RZ</"9DV4##6-*7U
MQ)$2@(HG[:11F;4.:7Z?JEZJFH^&P("&BR/TT46L?.L>I)_G]6SBZJ;U_M5]
ML_V%E[PX:1/8*(D_C1P\%@N)&YFYL^A8ZS*K_2CL!7MM$#)D:54;975ZW=UQ
M]\"X>,AB2*$*3H!%K&$A118KXP4*R1BYM<F)UD;> 63V4I=_>E V4%L'R+QM
M0-@LP=W*\:^+JQ_O.D)?K6Z-FP?_8'T^'PI!:Q.-L098-K8V+A2(F#3HF$QF
MF@1DFI>LCL%(?YMH&Z)[>M7_7?"_N0J^/10$=YH+%PPXB1Z4" $"!@DIHD\%
M410_4@=5>V:FK70[AW-P- 0Z. M/BV3>?OUU=N%XMB(K"WD=0DG:DG^1B1LN
MA;>.J6)R8QAOHV/:LI*1$7BTX#L SZNO)(WU]+K%LL[EO.?F1XQ7][\C015>
MDO%@4YUFEVK*TGL.(:28E#)%R=: &DK;M F_D4$VBH(Z -XFP?YF\3G.;H)M
M-1A'US/)CWY:S4AMX69JW^T=?5'GP0I'Q\J@IK,52:)1IPP\>%4<MT+'U@'/
M \B<-@PZ,AS'5EL'R+R7X)U)\+[<_^':=+Y(DD<KH@16H@:E)=D(62? 5$+M
M_2ZI^5:V(73UXM>/%^ALI).N<+8F_XZQ?RS7.^4WIR?&PCC*!)'7$N=<1Q2(
MF[4ZGD5?DK5L-*2]1%DO7O9X6&NFE_W1YF_0-L>/U77YT*1F[PEC?Y"RUKUL
M[\O=:-O?%C>U;C_5<;6K&9D=/\WI";FYT:LW=3/D$_/;R_#Q0HJ@?? "N-95
M!+YN#M ::A>D4R48*Y_D>K:6_;6FJQ>WMQ4P)]==?Y?EZL('K8(U"J0J9,0P
M;FOYI8!DM7(B*AU&',%U0T,OSNW(%^!^LCX<*XNK<'D* ^[^"M>1!1'JU*="
M#KMRT=,9, %<K>:-V41L/BUI*&V]^+0G-N0.TTUG>>L[)AZ;#C=&JE4L2BDY
MV"#J2.SD('J?B$.G-;EER30?@#J,LE[<UO$0UTPOO9ES=XP=;Q;$DI.6*D)(
MA23-:D,#*P9JHZ9TNF"48B^3KAUM@P#JS@>@7>BP*]/N06[^HLY2B983$\(@
M.?.1U4W9 6Q.(A@F0V+CS?M]0,@@U/GS05T[J7=@Z6V;S%(7]/QSOH@K7'ZM
M<?.;42J_8UK04;J<K557?WN]K!O(7H?5[-ZIO\G_(089E))0]'I3>\C@.;GW
M7L2B1&2EJ- Z!3P&(\,JS]CY87=ZM1^,_2_KC7=TQR^OCC8 MHGASP%B>"R%
M-^L1IC_/?UI=S3Y7Z^0^$4Y6$*;L)1CK!-3Q0Q"E0K V*DL/C!9/#\)68V!L
M.H?A_(S*>[M3;@=6PO;$TWVZZ<,RS%>WE-T_:#_?M!;E"Y2V%.\5%%=7P.7"
MP ?R*85*D@<;G&H^C?$XBH>!^@Q3.2=49 >P/?2IVO%2_8%75Y<W ^@N=$E(
M)GT$8]8+,&VB XP<M&(NU;[RJ$>; -F<FV%P/\-L4B< F#YD,:[Q)DD.N0YR
MY\S5SH)8UH,8Z@1.*1@ZG9OW5DYHLY]1\JH?M1]IL_\TSR<N?'JU7%;K;7W8
M-X;<S6[9]^5[13><E"42>JF 1\E!I4Q.?21_7CN6 [?"^#!=L=11K T[(V>8
M>.L1&AUN)GZ]6"X7?Q*+JS_2)\S7E[@H[Q;SCW45<RV*?%#???@>X@.^Y-BM
MP\?RU6C'</VJ^V6N=U6#/'&94B D6VO)VJ!;UBMM@6FKDDW>&]UZX^-V2HZ/
M-S\4Y4V'=S361VD8I& EG5KR*B*S 02=%,NU\2ZTWJ6ZA8RI6T6/UOOS(/-Q
MHN[ @7O,PGJ(3BCD:*:2Z4XOMFX/T.!+G5%2=T5EFZQHOF?[.1738^4HQ;X(
ME+VEW!U.?@V?-W/BT$64Z#58Y^BQ-3+38YLD:.FS]IYKC>->+?>T](29_77\
M(F0.%/C44Q39#T*S7Q=7N/KQ&JL>;^?46&E)#JF "KZN34QTEH@I8"YD;3B7
ME@V)O._Z_)Z <*CF%HW%.#44!/&P9B$_8H%.@K52&9"8B 5?9UV[3+ZN,,HP
MK[54;@@2MG_\U/T"K8'00(A3X\#\8"4)A@1"5M@M'YL=(,7'3+:8 B<D@5KD
M C&$#,ZXHIEE/KGO^37?^XZIJ_I;(Z*5.*>&A?Q!VH?0WO"0C%76R "F<.*!
MA02>!PX$;".,T"GD/ 02.SY_ZEKZUG!H(<:IH2!^8-M8T/3:Q1 5&,/(F$*K
M(#!&++ Z=8?5+N0X[*78]O%3%[NW?RF.%N+4.& _F$=6C[KE@0QGDPMFT*6F
M2)G5$+!PX!'1A<"2M(,&L>_X_*E+T]L;C\>+<6HHZ!^VLL LV;]"*4C)D4N.
M'"$ZY4 RFX33,9=A]L+VCY^Z8KPU$!H(<6H<B!_,(P-8;Y;'&56$(=LW*\M
ME4@\))[!:ND81NVS'>1/[OC\J4NSVS\.QXMQ:B@PK1^ ><.!Q^PR-QY$R$@<
M" &.5 R*VY@(Z,RK03?"UD^?NE:Z^<MPM BG!H'X03W$L;EE :5WK@)72)E
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M$I(WM5@G% CUEVBB9X*'@EPUQM,3I(Q;P#K0*]="[)VBI_YV@;='#159D:D
MH=^!TCI"\)J!"S6&)+@LOO6PA1>)&O=F:J+Z'>!TN!Y&=KM>72VFR^NF@LV=
MFA-=U);I>E4CJ&Q(*BDJR%:67,G'\F#"P5:?Z]$']P>$(Y0V;R7!#NZ5-]/9
M=(6_3[_5 7*K,/L\I0OWU7*)JV7=G_+/^>+U15A>!Y]XT,[G8(#Q6A5M?(+
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M(/!BLQX1EALR=X/E.29*AM99+X'I9\S0AX5K-Z'-8+1T2G+01:FZHY;$*F0
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M=_%BLZ]Z^?2_')Y).N;;CLT@->.T4>;H_M"NS3?7V5UW25&NK,[<)K*B>8U
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M7:)I$\='I[@M3I LJF@<XQ!=%(#)6"F+=HFUK@5_BI:>LJ.'Z?E%Z!P@] [
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M^P/0Y@K-W*F46"+ZL0:GZ)9V.CGP160CD]5<-R_[WT9(=\ Y1,G/0^< B7<
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MC7U"S#XJL!E%_3T4FCT]T%^;4*3U#'*TY-)9$J7/C(Q[9WTJ!9V2S=?1=;I
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M5#X@*Y'SG3!U_8XQGJF.!5([:F)\B)I\WZR,>@1D<FVJ%T.@W5M0""=%KIW
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M(,L-BD3HC;0,0^OZ^"YTC:*/?7]@:ZZ:$<!MW=MA$YW,0UK^8[+\NNFD=-5
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MEN2ZH"81\, "D$!"';SDZP1CE"I("L<ZG=-WP\Y] H:K"-M?I_<!LJ> ASZ
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M(=@1[-G7EE+K+ HO@%C3Y<CJC$X1(22?0Q'6,]5Z.]UJI^OMY*FWG6XGT8X
M$BUWZ/5@X2"$]*X@%!]H&U8J@?=605!"J*R5*:%U:65[+H9-2!Z$0[:#ND<
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MMW'@>YM?_N(._#92W].!?S/-7:X$K']0/T1R\/['?_M_4$L! A0#%     @
M-H!05F*F$$H_+P  FV(! !X              ( !     &5X,3 Q+6IJ97AC
M97-S<&QA;G@R,#(R<F5S+FAT;5!+ 0(4 Q0    ( #: 4%;#L74)>"4  !0Q
M!  >              "  7LO  !E>#(Q+7-U8G-I9&EA<FEE<WAF;W)M,3!X
M:RYH=&U02P$"% ,4    "  V@%!6(&)EG!L#  !K"   '@
M@ $O50  97@R,RUP=V-C;VYS96YT>&9O<FTQ,'AK>#(N:'1M4$L! A0#%
M  @ -H!05DDSLFPW"   BR8  !X              ( !AE@  &5X,S$Q+3,P
M,F-E<G1O9F-E;WAF;W)M,3!X+FAT;5!+ 0(4 Q0    ( #: 4%8]J)<+,P@
M (DF   >              "  ?E@  !E>#,Q,BTS,#)C97)T;V9C9F]X9F]R
M;3$P>"YH=&U02P$"% ,4    "  V@%!6&CLA4VD%  !R&P  '@
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M:BTR,#(S,#$P,2YX<V102P$"% ,4    "  V@%!6D/J.H?XL  "2Q $ %
M            @ %T$0< :FYJ+3(P,C,P,3 Q7V-A;"YX;6Q02P$"% ,4
M"  V@%!6PM(A"^/>   ML@D %               @ &D/@< :FYJ+3(P,C,P
M,3 Q7V1E9BYX;6Q02P$"% ,4    "  V@%!6$7H\1ON<  "OK@  $P
M        @ &Y'0@ :FYJ+3(P,C,P,3 Q7V<Q+FIP9U!+ 0(4 Q0    ( #:
M4%86WW1??UH  "*,   4              "  >6Z" !J;FHM,C R,S Q,#%?
M9S$P+FIP9U!+ 0(4 Q0    ( #: 4%;3:\CH?EX  )>4   4
M  "  985"0!J;FHM,C R,S Q,#%?9S$Q+FIP9U!+ 0(4 Q0    ( #: 4%9L
MK4D'(T4   ]<   3              "  49T"0!J;FHM,C R,S Q,#%?9S(N
M:G!G4$L! A0#%     @ -H!05G_O](AT1P  REP  !,              ( !
MFKD) &IN:BTR,#(S,#$P,5]G,RYJ<&=02P$"% ,4    "  V@%!6'$G"$ M!
M  #I5P  $P              @ $_ 0H :FYJ+3(P,C,P,3 Q7V<T+FIP9U!+
M 0(4 Q0    ( #: 4%8ER!X7L)D  -2M   3              "  7M""@!J
M;FHM,C R,S Q,#%?9S4N:G!G4$L! A0#%     @ -H!05G7]U"@8@   R9$
M !,              ( !7-P* &IN:BTR,#(S,#$P,5]G-BYJ<&=02P$"% ,4
M    "  V@%!6C#J?#_9G  #TF   $P              @ &E7 L :FYJ+3(P
M,C,P,3 Q7V<W+FIP9U!+ 0(4 Q0    ( #: 4%8=\D#Y^DL  &UO   3
M          "  <S$"P!J;FHM,C R,S Q,#%?9S@N:G!G4$L! A0#%     @
M-H!05@1_W1R.60  87H  !,              ( !]Q , &IN:BTR,#(S,#$P
M,5]G.2YJ<&=02P$"% ,4    "  V@%!673RU<YD* @##3Q4 %
M    @ &V:@P :FYJ+3(P,C,P,3 Q7VQA8BYX;6Q02P$"% ,4    "  V@%!6
MEM;"@J Y 0 A+0X %               @ &!=0X :FYJ+3(P,C,P,3 Q7W!R
;92YX;6Q02P4&     !@ & !E!@  4Z\/

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
